FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Masingue, M
   Rucheton, B
   Bris, C
   Romero, NB
   Procaccio, V
   Eymard, B
AF Masingue, M.
   Rucheton, B.
   Bris, C.
   Romero, N. B.
   Procaccio, V.
   Eymard, B.
TI Highly asymmetrical distribution of muscle wasting correlates to the
   heteroplasmy in a patient carrying a large-scale mitochondrial DNA
   deletion: a novel pathophysiological mechanism for explaining asymmetry
   in mitochondrial myopathies
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE Mitochondrial DNA deletion; Asymmetrical genetic myopathy; eKLIPse
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; DUCHENNE MUSCULAR-DYSTROPHY;
   CARRIERS; MTDNA; PHENOTYPES; MUTATIONS; SPECTRUM; WEAKNESS; DISEASE
AB Mitochondrial diseases are a heterogeneous group of pathologies, caused by missense mutations, sporadic large-scale deletions of mitochondrial DNA (mtDNA) or mutations of nuclear maintenance genes. We report the case of a patient in whom extended muscle pathology, biochemical and genetic mtDNA analyses have proven to be essential to elucidate a unique asymmetrical myopathic presentation. From the age of 34 years on, the patient has presented with oculomotor disorders, right facial peripheral palsy and predominantly left upper limb muscle weakness and atrophy. By contrast, he displayed no motor weakness on the right hemi-body, and no sensory symptoms, cerebellar syndrome, hypoacusis, or parkinsonism. Cardiac function was normal. CK levels were elevated (671 UI/L). Electroneuromyography (ENMG) and muscle MRI showed diffuse myogenic alterations, more pronounced on the left side muscles. Biopsy of the left deltoid muscle showed multiple mitochondrial defects, whereas in the right deltoid, mitochondrial defects were much less marked. Extended mitochondrial biochemical and molecular workup revealed a unique mtDNA deletion, with a 63.4% heteroplasmy load in the left deltoid, versus 8.1% in the right one. This case demonstrates that, in mitochondrial myopathies, heteroplasmy levels may drastically vary for the same type of muscle, rising the hypothesis of a new pathophysiological mechanism explaining asymmetry in hereditary myopathies.(c) 2022 Elsevier B.V. All rights reserved.
C1 [Masingue, M.; Eymard, B.] CHU Pitie Salpetriere, Inst Myol, Reference Ctr Neuromuscular Disorders Nord Est Ile, Neuromuscular Morphol Unit, Paris, France.
   [Rucheton, B.] Serv Biochim Metab, UF Biochim Malad neuromet abol neurodegenerat t, AP HP, Paris, France.
   [Bris, C.; Procaccio, V.] Angers Hosp, Dept Genet, Angers, France.
   [Bris, C.; Procaccio, V.] Univ Angers, Inst MitoVasc, MitoLab Team, UMR CNRS 6015 INSERM U1083, Angers, France.
   [Romero, N. B.] Univ Sorbonne, Ctr Res Myol, INSERM UMRS974, CNRS FRE3617,UPMC Paris 06, Paris, France.
   [Masingue, M.; Eymard, B.] CHU Pitie Salpetriere, APHP, Ctr Reference Pathol Neuromusculaire, F-75013 Paris, France.
C3 Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Pitie-Salpetriere - APHP; Sorbonne Universite; Assistance Publique
   Hopitaux Paris (APHP); Universite d'Angers; Centre Hospitalier
   Universitaire d'Angers; Universite d'Angers; Institut National de la
   Sante et de la Recherche Medicale (Inserm); Sorbonne Universite;
   Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Pitie-Salpetriere - APHP; Universite Paris Cite; Hopital Universitaire
   Hotel-Dieu - APHP; Sorbonne Universite
RP Masingue, M; Eymard, B (corresponding author), CHU Pitie Salpetriere, APHP, Ctr Reference Pathol Neuromusculaire, F-75013 Paris, France.
EM marion.masingue@aphp.fr; brunoeymard@aphp.fr
RI Procaccio, Vincent/M-2596-2015
CR [Anonymous], 1985, N Engl J Med, V312, P171
   Auré K, 2006, BRAIN, V129, P1249, DOI 10.1093/brain/awl061
   Auré K, 2007, BRAIN, V130, P1516, DOI 10.1093/brain/awm067
   Bevilacqua JA, 2009, ACTA NEUROPATHOL, V117, P283, DOI 10.1007/s00401-008-0472-1
   Biancalana V, 2017, ACTA NEUROPATHOL, V134, P889, DOI 10.1007/s00401-017-1748-0
   Boucret L, 2017, HUM REPROD, V32, P2101, DOI 10.1093/humrep/dex268
   BROCKINGTON M, 1995, J NEUROL SCI, V131, P78, DOI 10.1016/0022-510X(95)00091-F
   Chinnery PF, 2004, LANCET, V364, P592, DOI 10.1016/S0140-6736(04)16851-7
   Cocanougher BT, 2019, NEUROLOGY, V93, pE1535, DOI 10.1212/WNL.0000000000008316
   Cui H, 2013, GENET MED, V15, P388, DOI 10.1038/gim.2012.144
   DiMauro S, 2013, NAT REV NEUROL, V9, P429, DOI 10.1038/nrneurol.2013.126
   Goldstein A, 2003, MITOCHONDRIAL DNA DE
   Goudenège D, 2019, GENET MED, V21, P1407, DOI 10.1038/s41436-018-0350-8
   Guglieri M, 2008, HUM MUTAT, V29, P258, DOI 10.1002/humu.20642
   Helderman-van den Enden ATJM, 2003, NEUROMUSCULAR DISORD, V13, P317, DOI 10.1016/S0960-8966(02)00285-7
   HOLT IJ, 1989, ANN NEUROL, V26, P699, DOI 10.1002/ana.410260603
   Hoogerwaard EM, 1999, LANCET, V353, P2116, DOI 10.1016/S0140-6736(98)10028-4
   Kim Y, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/3165396
   López-Gallardo E, 2009, MITOCHONDRION, V9, P314, DOI 10.1016/j.mito.2009.04.005
   MATTHEWS PM, 1995, NEUROMUSCULAR DISORD, V5, P209, DOI 10.1016/0960-8966(94)00057-G
   Medja F, 2009, MITOCHONDRION, V9, P331, DOI 10.1016/j.mito.2009.05.001
   Mercier S, 2013, EUR J HUM GENET, V21, P855, DOI 10.1038/ejhg.2012.269
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Paradas C, 2010, NEUROLOGY, V75, P316, DOI 10.1212/WNL.0b013e3181ea1564
   Pitceathly RDS, 2012, NEUROMUSCULAR DISORD, V22, P577, DOI 10.1016/j.nmd.2012.03.009
   Rijken NHM, 2014, NEUROMUSCULAR DISORD, V24, P1087, DOI 10.1016/j.nmd.2014.05.012
   Sarkozy A, 2012, NEUROMUSCULAR DISORD, V22, pS122, DOI 10.1016/j.nmd.2012.05.012
   Savarese M, 2016, NEUROMUSCULAR DISORD, V26, P292, DOI 10.1016/j.nmd.2016.02.004
   Sharma NK, 2002, J NEUROL NEUROSUR PS, V73, P95, DOI 10.1136/jnnp.73.1.95
   TATUCH Y, 1992, AM J HUM GENET, V50, P852
   Vissing J, 2016, CURR OPIN NEUROL, V29, P635, DOI 10.1097/WCO.0000000000000375
   Wallace DC, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a021220
   Wang LH, 2016, CURR NEUROL NEUROSCI, V16, DOI 10.1007/s11910-016-0667-0
   Wei W, 2020, J INTERN MED, V287, P634, DOI 10.1111/joim.13047
   Yamashita S, 2008, J HUM GENET, V53, P598, DOI 10.1007/s10038-008-0289-8
NR 35
TC 1
Z9 1
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD DEC
PY 2022
VL 32
IS 11-12
BP 923
EP 930
DI 10.1016/j.nmd.2022.10.006
PG 8
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 7K0FU
UT WOS:000904962000001
PM 36428163
DA 2024-11-01
ER

PT J
AU Manini, A
   Meneri, M
   Rodolico, C
   Corti, S
   Toscano, A
   Comi, GP
   Musumeci, O
   Ronchi, D
AF Manini, Arianna
   Meneri, Megi
   Rodolico, Carmelo
   Corti, Stefania
   Toscano, Antonio
   Comi, Giacomo Pietro
   Musumeci, Olimpia
   Ronchi, Dario
TI Case Report: Thymidine Kinase 2 (TK2) Deficiency: A Novel Mutation
   Associated With Childhood-Onset Mitochondrial Myopathy and Atypical
   Progression
SO FRONTIERS IN NEUROLOGY
LA English
DT Article
DE thymidine kinase 2; TK2; mitochondrial DNA; mtDNA maintenance defects;
   myopathy; deoxynucleosides
ID EXTERNAL OPHTHALMOPLEGIA; DNA DEPLETION; GENE
AB The nuclear gene TK2 encodes the mitochondrial thymidine kinase, an enzyme involved in the phosphorylation of deoxycytidine and deoxythymidine nucleosides. Biallelic TK2 mutations are associated with a spectrum of clinical presentations mainly affecting skeletal muscle and featuring muscle mitochondrial DNA (mtDNA) instability. Current classification includes infantile- ( <= 1 year), childhood- (1-12 years), and late-onset (>= 12 years) forms. In addition to age at onset, these forms differ for progression, life expectancy, and signs of mtDNA instability (mtDNA depletion vs. accumulation of multiple mtDNA deletions). Childhood-onset TK2 deficiency typically causes a rapidly progressive proximal myopathy, which leads to wheelchair-bound status within 10 years of disease onset, and severe respiratory impairment. Muscle biopsy usually reveals a combination of mitochondrial myopathy and dystrophic features with reduced mtDNA content. Here we report the case of an Italian patient presenting childhood-onset, slowly progressive mitochondrial myopathy, ptosis, hypoacusis, dysphonia, and dysphagia, harboring the TK2 variants c.278A>G and c.543del, the latter unreported so far. Compared to other childhood-onset TK2-patients, our case displays atypical features, including slowly progressive muscle weakness and absence of respiratory failure, which are usually observed in late-onset forms. This report extends the genetic background of TK2-related myopathy, highlighting the clinical overlap among different forms.
C1 [Manini, Arianna; Meneri, Megi; Corti, Stefania; Comi, Giacomo Pietro; Ronchi, Dario] Univ Milan, Dino Ferrari Ctr, Dept Pathophysiol & Transplantat, Neurosci Sect, Milan, Italy.
   [Meneri, Megi; Corti, Stefania] IRCCS Fdn CaGranda Osped Maggiore Policlin, Neurol Unit, Milan, Italy.
   [Rodolico, Carmelo; Toscano, Antonio; Musumeci, Olimpia] Univ Messina, Dept Clin & Expt Med, Unit Neurol & Neuromuscular Disorders, Messina, Italy.
   [Comi, Giacomo Pietro] Fdn IRCCS CaGranda Osped Maggiore Policlin, Dept Neurosci, Neuromuscular & Rare Dis Unit, Milan, Italy.
C3 University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico;
   University of Messina; IRCCS Ca Granda Ospedale Maggiore Policlinico
RP Ronchi, D (corresponding author), Univ Milan, Dino Ferrari Ctr, Dept Pathophysiol & Transplantat, Neurosci Sect, Milan, Italy.; Musumeci, O (corresponding author), Univ Messina, Dept Clin & Expt Med, Unit Neurol & Neuromuscular Disorders, Messina, Italy.
EM olimpia.musumeci@unime.it; dario.ronchi@unimi.it
RI MANINI, ARIANNA/AGF-1957-2022; Corti, Stefania/K-6034-2016; Comi,
   Giacomo/K-5702-2016; Toscano, Antonio/AHE-4657-2022; Musumeci,
   Olimpia/AHE-3041-2022; Ronchi, Dario/K-8011-2016
OI MENERI, MEGI/0000-0002-3429-1809
FU Italian Ministry Fundation IRCCS Ca Granda Ospedale Maggiore Policlinico
   Ricerca Corrente 2020
FX This study was funded by Italian Ministry Fundation IRCCS Ca Granda
   Ospedale Maggiore Policlinico Ricerca Corrente 2020 to GC. This work was
   promoted within the European Reference Network (ERN) for Neuromuscular
   Diseases.
CR Alston CL, 2013, NEUROLOGY, V81, P2051, DOI 10.1212/01.wnl.0000436931.94291.e6
   Collins J, 2009, NEUROMUSCULAR DISORD, V19, P784, DOI 10.1016/j.nmd.2009.08.002
   Domínguez-González C, 2019, ANN NEUROL, V86, P293, DOI 10.1002/ana.25506
   Domínguez-González C, 2019, ORPHANET J RARE DIS, V14, DOI 10.1186/s13023-019-1071-z
   Fasullo M, 2015, INT J MOL SCI, V16, P9431, DOI 10.3390/ijms16059431
   Galbiati S, 2006, PEDIATR NEUROL, V34, P177, DOI 10.1016/j.pediatrneurol.2005.07.013
   Garone C, 2018, J MED GENET, V55, P515, DOI 10.1136/jmedgenet-2017-105012
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Oskoui M, 2006, ARCH NEUROL-CHICAGO, V63, P1122, DOI 10.1001/archneur.63.8.1122
   Ronchi D, 2019, ANN CLIN TRANSL NEUR, V6, P1893, DOI 10.1002/acn3.50888
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Tyynismaa H, 2012, HUM MOL GENET, V21, P66, DOI 10.1093/hmg/ddr438
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Vilà MR, 2003, NEUROLOGY, V60, P1203, DOI 10.1212/01.WNL.0000055928.58122.47
   Wang JL, 2018, MOL GENET METAB, V124, P124, DOI 10.1016/j.ymgme.2018.04.012
NR 17
TC 0
Z9 0
U1 0
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2295
J9 FRONT NEUROL
JI Front. Neurol.
PD FEB 25
PY 2022
VL 13
AR 857279
DI 10.3389/fneur.2022.857279
PG 6
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA ZV8MR
UT WOS:000770778400001
PM 35280287
OA gold, Green Published
DA 2024-11-01
ER

PT J
AU Stringer, HAJ
   Sohi, GK
   Maguire, JA
   Côté, HCF
AF Stringer, Henry A. J.
   Sohi, Gurmeet K.
   Maguire, John A.
   Cote, Helene C. F.
TI Decreased skeletal muscle mitochondrial DNA in patients with
   statin-induced myopathy
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE Statin; Statin-induced myopathy; Mitochondrial DNA; Mitochondria;
   HMG-CoA reductase inhibitors; Skeletal muscle
ID HIGH-DOSE SIMVASTATIN; SLCO1B1 POLYMORPHISM; DELETION MUTATIONS;
   CREATINE-KINASE; MELAS-SYNDROME; PHARMACOKINETICS; TOXICITY;
   RHABDOMYOLYSIS; PRAVASTATIN; METABOLISM
AB Statins are widely used to treat hyperlipidemia and lower cardiovascular disease risk. While statins are generally well tolerated, some patients experience statin-induced myopathy (SIM). Statin treatment has been associated with mitochondrial dysfunction and mitochondrial DNA (mtDNA) depletion. In this retrospective study, skeletal muscle biopsies from patients diagnosed with SIM were studied. These were compared with biopsies from patients clinically assessed as having statin-unrelated myopathy but whose biopsy showed no or negligible pathology. For each biopsy sample, mtDNA was quantified relative to nuclear DNA (mtDNA content) by qPCR, mtDNA deletions were investigated by long-template PCR followed by gel densitometty, and mtDNA oxidative damage was quantified using a qPCR-based assay. For a subset of matched samples, mtDNA heteroplasmy and mutations were investigated by cloning/sequencing. Skeletal muscle mtDNA content was significantly lower in SIM patients (N=23, mean +/- SD, 2036 +/- 1146) than in comparators (N=24, 3220 +/- 1594), p=0.006. There was no difference in mtDNA deletion score or oxidative mtDNA damage between the two groups, and no evidence of increased mtDNA heteroplasmy or somatic mutations was detected. The significant difference in skeletal muscle mtDNA suggests that SIM or statin treatments are associated with depletion of skeletal muscle mtDNA or that patients with an underlying predisposition to SIM have lower mtDNA levels. If statins induce mtDNA depletion, this would likely reflect decreased mitochondria biogenesis and/or increased mitochondria autophagy. Further work is necessary to distinguish between the lower mtDNA as a predisposition to SIM or an effect of SIM or statin treatment. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Stringer, Henry A. J.; Sohi, Gurmeet K.; Cote, Helene C. F.] Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V6T 2B5, Canada.
   [Maguire, John A.] Univ British Columbia, Vancouver Gen Hosp, Dept Pathol & Lab Med, Dept Anat Pathol, Vancouver, BC V5Z 4E3, Canada.
C3 University of British Columbia; University of British Columbia
RP Côté, HCF (corresponding author), Univ British Columbia, Dept Pathol & Lab Med, G227-2211 Wesbrook Mall, Vancouver, BC V6T 2B5, Canada.
EM hstring@interchange.ubc.ca; gurmeet.sohi@gmail.com; john.maguire@vch.ca;
   helene.cote@ubc.ca
RI Cote, Helene/K-7896-2012
FU Michael Smith Foundation; Canadian Foundation
FX This research was partially supported by a Michael Smith Foundation for
   Health Research Establishment Fund and by Canadian Foundation for
   Innovation Funding to HCFC.
CR Armitage J, 2007, LANCET, V370, P1781, DOI 10.1016/S0140-6736(07)60716-8
   Bouitbir J, 2011, EUR HEART J
   Bua E, 2006, AM J HUM GENET, V79, P469, DOI 10.1086/507132
   Camerino GM, 2011, BIOCHEM PHARMACOL, V81, P1054, DOI 10.1016/j.bcp.2011.01.022
   CHARIOT P, 1993, AM J MED, V94, P109, DOI 10.1016/0002-9343(93)90129-D
   Coté HCF, 2002, NEW ENGL J MED, V346, P811, DOI 10.1056/NEJMoa012035
   de Mendoza C, 2004, AIDS REV, V6, P169
   Diaczok BJ, 2003, SOUTH MED J, V96, P318, DOI 10.1097/01.SMJ.0000061501.81880.83
   Echaniz-Laguna A, 2010, NEW ENGL J MED, V362, P564, DOI 10.1056/NEJMc0908215
   Egan A, 2011, NEW ENGL J MED, V365, P285, DOI 10.1056/NEJMp1106689
   ENGLAND JDF, 1995, AUST NZ J MED, V25, P374, DOI 10.1111/j.1445-5994.1995.tb01912.x
   Fernandez Genaro, 2011, Cleve Clin J Med, V78, P393, DOI 10.3949/ccjm.78a.10073
   Gambelli S., 2004, Journal of Submicroscopic Cytology and Pathology, V36, P85
   Golomb BA, 2008, AM J CARDIOVASC DRUG, V8, P373, DOI 10.2165/0129784-200808060-00004
   Graham DJ, 2004, JAMA-J AM MED ASSOC, V292, P2585, DOI 10.1001/jama.292.21.2585
   Guis S, 2006, ARTHRIT RHEUM-ARTHR, V55, P551, DOI 10.1002/art.22100
   Herbst A, 2007, J GERONTOL A-BIOL, V62, P235, DOI 10.1093/gerona/62.3.235
   Jacobson TA, 2008, MAYO CLIN PROC, V83, P687, DOI 10.4065/83.6.687
   Jitratkosol MHJ, 2012, AIDS, V26, P675, DOI 10.1097/QAD.0b013e32835142eb
   Joy TR, 2009, ANN INTERN MED, V150, P858, DOI 10.7326/0003-4819-150-12-200906160-00009
   Kashani A, 2006, CIRCULATION, V114, P2788, DOI 10.1161/CIRCULATIONAHA.106.624890
   Knauer MJ, 2010, CIRC RES, V106, P297, DOI 10.1161/CIRCRESAHA.109.203596
   Link E, 2008, NEW ENGL J MED, V359, P789, DOI 10.1056/NEJMoa0801936
   Miller Nancy Houston, 1997, American Journal of Medicine, V102, P43, DOI 10.1016/S0002-9343(97)00467-1
   Mohaupt MG, 2009, CAN MED ASSOC J, V181, pE11, DOI 10.1503/cmaj.081785
   Neale R, 2004, J CLIN PATHOL, V57, P989, DOI 10.1136/jcp.2004.015958
   Niemi M, 2006, CLIN PHARMACOL THER, V80, P356, DOI 10.1016/j.clpt.2006.06.010
   Päivä H, 2005, CLIN PHARMACOL THER, V78, P60, DOI 10.1016/j.clpt.2005.03.006
   Pasanen MK, 2007, CLIN PHARMACOL THER, V82, P726, DOI 10.1038/sj.clpt.6100220
   Pasanen MK, 2006, PHARMACOGENET GENOM, V16, P873, DOI 10.1097/01.fpc.0000230416.82349.90
   Phillips PS, 2002, ANN INTERN MED, V137, P581, DOI 10.7326/0003-4819-137-7-200210010-00009
   Romaine SPR, 2010, PHARMACOGENOMICS J, V10, P1, DOI 10.1038/tpj.2009.54
   Santos Janine H, 2002, Methods Mol Biol, V197, P159, DOI 10.1385/1-59259-284-8:159
   Schick BA, 2007, CLIN PHARMACOL THER, V81, P650, DOI 10.1038/sj.clpt.6100124
   Thomas JE, 2007, EUR NEUROL, V57, P232, DOI 10.1159/000101287
   Westermeyer C, 2007, FEMS YEAST RES, V7, P436, DOI 10.1111/j.1567-1364.2006.00194.x
   Wikhe K, 2007, BIOCHEM SOC T, V35, P1529, DOI 10.1042/BST0351529
NR 37
TC 58
Z9 62
U1 0
U2 22
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD FEB 15
PY 2013
VL 325
IS 1-2
BP 142
EP 147
DI 10.1016/j.jns.2012.12.023
PG 6
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 095GP
UT WOS:000315323000026
PM 23312852
DA 2024-11-01
ER

PT J
AU Nasca, A
   Legati, A
   Meneri, M
   Ermert, ME
   Frascarelli, C
   Zanetti, N
   Garbellini, M
   Comi, GP
   Catania, A
   Lamperti, C
   Ronchi, D
   Ghezzi, D
AF Nasca, Alessia
   Legati, Andrea
   Meneri, Megi
   Ermert, Melisa Emel
   Frascarelli, Chiara
   Zanetti, Nadia
   Garbellini, Manuela
   Comi, Giacomo Pietro
   Catania, Alessia
   Lamperti, Costanza
   Ronchi, Dario
   Ghezzi, Daniele
TI Biallelic Variants in <i>ENDOG</i> Associated with Mitochondrial
   Myopathy and Multiple mtDNA Deletions
SO CELLS
LA English
DT Article
DE endonuclease G; ENDOG; mitochondrial DNA; mitochondrial myopathy;
   multiple mtDNA deletions
ID ENDONUCLEASE-G; DNA DELETIONS; MUTATIONS; REPLICATION; GENERATION;
   MECHANISMS
AB Endonuclease G (ENDOG) is a nuclear-encoded mitochondrial-localized nuclease. Although its precise biological function remains unclear, its proximity to mitochondrial DNA (mtDNA) makes it an excellent candidate to participate in mtDNA replication, metabolism and maintenance. Indeed, several roles for ENDOG have been hypothesized, including maturation of RNA primers during mtDNA replication, splicing of polycistronic transcripts and mtDNA repair. To date, ENDOG has been deemed as a determinant of cardiac hypertrophy, but no pathogenic variants or genetically defined patients linked to this gene have been described. Here, we report biallelic ENDOG variants identified by NGS in a patient with progressive external ophthalmoplegia, mitochondrial myopathy and multiple mtDNA deletions in muscle. The absence of the ENDOG protein in the patient's muscle and fibroblasts indicates that the identified variants are pathogenic. The presence of multiple mtDNA deletions supports the role of ENDOG in mtDNA maintenance; moreover, the patient's clinical presentation is very similar to mitochondrial diseases caused by mutations in other genes involved in mtDNA homeostasis. Although the patient's fibroblasts did not present multiple mtDNA deletions or delay in the replication process, interestingly, we detected an accumulation of low-level heteroplasmy mtDNA point mutations compared with age-matched controls. This may indicate a possible role of ENDOG in mtDNA replication or repair. Our report provides evidence of the association of ENDOG variants with mitochondrial myopathy.
C1 [Nasca, Alessia; Legati, Andrea; Ermert, Melisa Emel; Frascarelli, Chiara; Zanetti, Nadia; Catania, Alessia; Lamperti, Costanza; Ghezzi, Daniele] Fdn IRCCS Ist Neurol Carlo Besta, Unit Med Genet & Neurogenet, I-20126 Milan, Italy.
   [Meneri, Megi; Garbellini, Manuela; Ronchi, Dario] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Neurol Unit, I-20122 Milan, Italy.
   [Meneri, Megi; Ermert, Melisa Emel; Comi, Giacomo Pietro; Ronchi, Dario; Ghezzi, Daniele] Univ Milan, Dept Pathophysiol & Transplantat DEPT, I-20122 Milan, Italy.
   [Comi, Giacomo Pietro] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Neuromuscular & Rare Dis Unit, I-20122 Milan, Italy.
C3 Fondazione IRCCS Istituto Neurologico Carlo Besta; IRCCS Ca Granda
   Ospedale Maggiore Policlinico; University of Milan; IRCCS Ca Granda
   Ospedale Maggiore Policlinico
RP Ghezzi, D (corresponding author), Fdn IRCCS Ist Neurol Carlo Besta, Unit Med Genet & Neurogenet, I-20126 Milan, Italy.; Ghezzi, D (corresponding author), Univ Milan, Dept Pathophysiol & Transplantat DEPT, I-20122 Milan, Italy.
EM alessia.nasca@istituto-besta.it; andrea.legati@istituto-besta.it;
   megimeneri@gmail.com; melisaemel.ermert@studenti.unimi.it;
   chiara.frascarelli@istituto-besta.it; nadia.zanetti@istituto-besta.it;
   manuela.garbellini@polidinico.mi.it; giacomo.comi@unimi.it;
   alessia.catania@istituto-besta.it; costanza.lamperti@istituto-besta.it;
   dario.ronchi@unimi.it; daniele.ghezzi@unimi.it
RI Comi, Giacomo/K-5702-2016; Catania, Alessia/HLX-6398-2023; Ronchi,
   Dario/K-8011-2016; Legati, Andrea/ABA-6968-2021; Nasca,
   Alessia/K-2227-2016; zanetti, nadia/AAK-4682-2021; Ghezzi,
   Daniele/J-7873-2016
OI Nasca, Alessia/0000-0002-0640-9929; zanetti, nadia/0000-0003-1485-8983;
   Ghezzi, Daniele/0000-0002-6564-3766; Ermert, Melisa
   Emel/0000-0001-6296-3417; MENERI, MEGI/0000-0002-3429-1809
FU ERA PerMed project PerMiM [J49C2000019000-RE15]; European Joint
   Programme on Rare Diseases [J42F19000030006-RE17]; Italian Ministry
   Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico Ricerca
   Corrente 2020 - Mariani Foundation; Dino Ferrari Center at the
   University of Milan
FX This research was funded by the ERA PerMed project PerMiM
   (J49C2000019000-RE15) and the European Joint Programme on Rare Diseases
   (EJP RD) project GENOMIT (J42F19000030006-RE17), and by the Italian
   Ministry Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico
   Ricerca Corrente 2020 to G.P.C. This project was carried out at the
   Center for the Study of Mitochondrial Pediatric Diseases funded by the
   Mariani Foundation, in collaboration with the Dino Ferrari Center at the
   University of Milan.
CR Bugiani M, 2004, BBA-BIOENERGETICS, V1659, P136, DOI 10.1016/j.bbabio.2004.09.006
   Campbell G, 2014, HUM MOL GENET, V23, P4612, DOI 10.1093/hmg/ddu176
   da Costa CK, 2007, J NEUROL SCI, V263, P139, DOI 10.1016/j.jns.2007.07.006
   Diener T, 2010, EXP GERONTOL, V45, P638, DOI 10.1016/j.exger.2010.03.002
   El-Hattab AW, 2017, BBA-MOL BASIS DIS, V1863, P1539, DOI 10.1016/j.bbadis.2017.02.017
   Fontana GA, 2020, NUCLEIC ACIDS RES, V48, P11244, DOI 10.1093/nar/gkaa804
   Irvine RA, 2005, MOL CELL BIOL, V25, P294, DOI 10.1128/MCB.25.1.294-302.2005
   Itsara LS, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1003974
   Jang DS, 2015, DNA CELL BIOL, V34, P92, DOI 10.1089/dna.2014.2530
   Kennedy SR, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003794
   Kujoth GC, 2007, PLOS GENET, V3, P161, DOI 10.1371/journal.pgen.0030024
   Legati A, 2021, J MOL DIAGN, V23, P732, DOI 10.1016/j.jmoldx.2021.03.002
   Legati A, 2016, BBA-BIOENERGETICS, V1857, P1326, DOI 10.1016/j.bbabio.2016.02.022
   Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620
   Marchet S, 2020, HUM MUTAT, V41, P1745, DOI 10.1002/humu.24081
   McDermott-Roe C, 2011, NATURE, V478, P114, DOI 10.1038/nature10490
   Park CB, 2011, J CELL BIOL, V193, P809, DOI 10.1083/jcb.201010024
   Parrish J, 2001, NATURE, V412, P90, DOI 10.1038/35083608
   Reyes A, 2015, AM J HUM GENET, V97, P186, DOI 10.1016/j.ajhg.2015.05.013
   Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30
   Ronchi D, 2013, AM J HUM GENET, V92, P293, DOI 10.1016/j.ajhg.2012.12.014
   Rong ZY, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.669379
   SHANSKE S, 1990, NEUROLOGY, V40, P24, DOI 10.1212/WNL.40.1.24
   Sharma P, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8020100
   Wiehe Rahel Stefanie, 2018, Oncotarget, V9, P18309, DOI 10.18632/oncotarget.24822
   Wu SL, 2009, J BIOMED SCI, V16, DOI 10.1186/1423-0127-16-6
   Yan CJ, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8040379
   Yu-Wai-Man P, 2010, INVEST OPHTH VIS SCI, V51, P3347, DOI 10.1167/iovs.09-4660
   ZASSENHAUS HP, 1994, CURR GENET, V25, P142, DOI 10.1007/BF00309540
NR 29
TC 6
Z9 6
U1 0
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD MAR
PY 2022
VL 11
IS 6
AR 974
DI 10.3390/cells11060974
PG 10
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 0D0NB
UT WOS:000775699200001
PM 35326425
OA Green Published, gold
DA 2024-11-01
ER

PT J
AU Marchet, S
   Legati, A
   Nasca, A
   Di Meo, I
   Spagnolo, M
   Zanetti, N
   Lamantea, E
   Catania, A
   Lamperti, C
   Ghezzi, D
AF Marchet, Silvia
   Legati, Andrea
   Nasca, Alessia
   Di Meo, Ivano
   Spagnolo, Manuela
   Zanetti, Nadia
   Lamantea, Eleonora
   Catania, Alessia
   Lamperti, Costanza
   Ghezzi, Daniele
TI Homozygous mutations in <i>C1QBP</i> as cause of progressive external
   ophthalmoplegia (PEO) and mitochondrial myopathy with multiple mtDNA
   deletions
SO HUMAN MUTATION
LA English
DT Article
DE C1QBP; mitochondrial DNA; primary mitochondrial myopathy; progressive
   external ophthalmoplegia
ID DNA DELETIONS; CHILDREN; DEFECTS
AB Biallelic mutations in theC1QBPgene have been associated with mitochondrial cardiomyopathy and combined respiratory-chain deficiencies, with variable onset (including intrauterine or neonatal forms), phenotypes, and severity. We studied two unrelated adult patients from consanguineous families, presenting with progressive external ophthalmoplegia (PEO), mitochondrial myopathy, and without any heart involvement. Muscle biopsies from both patients showed typical mitochondrial alterations and the presence of multiple mitochondrial DNA deletions, whereas biochemical defects of the respiratory chain were present only in one subject. Using next-generation sequencing approaches, we identified homozygous mutations inC1QBP. Immunoblot analyses in patients' muscle samples revealed a strong reduction in the amount of the C1QBP protein and varied impairment of respiratory chain complexes, correlating with disease severity. Despite the original study indicatedC1QBPmutations as causative for mitochondrial cardiomyopathy, our data indicate that mutations inC1QBPhave to be considered in subjects with PEO phenotype or primary mitochondrial myopathy and without cardiomyopathy.
C1 [Marchet, Silvia; Legati, Andrea; Nasca, Alessia; Di Meo, Ivano; Spagnolo, Manuela; Zanetti, Nadia; Lamantea, Eleonora; Catania, Alessia; Lamperti, Costanza; Ghezzi, Daniele] Fdn IRCCS Ist Neurol Carlo Besta, Unit Med Genet & Neurogenet, Via Temolo, I-20126 Milan, Italy.
   [Ghezzi, Daniele] Univ Milan, Dipartimento Fisiopatol Med Chirurg & Trapianti, Milan, Italy.
C3 Fondazione IRCCS Istituto Neurologico Carlo Besta; University of Milan
RP Ghezzi, D (corresponding author), Fdn IRCCS Ist Neurol Carlo Besta, Unit Med Genet & Neurogenet, Via Temolo, I-20126 Milan, Italy.; Ghezzi, D (corresponding author), Univ Milan;, Dept Pathophysiol & Transplantat, Lab Neurogenet & Mitochondrial Disorders, Via Temolo 4, I-20126 Milan, Italy.
EM daniele.ghezzi@istituto-besta.it
RI CATANIA, ALESSIA/AAH-8810-2021; lamperti, costanza/J-8801-2016; Nasca,
   Alessia/K-2227-2016; Legati, Andrea/K-2181-2016; MARCHET,
   SILVIA/AAF-5898-2021; Spagnolo, Manuela/AAL-1503-2021; zanetti,
   nadia/AAK-4682-2021; Ghezzi, Daniele/J-7873-2016; Lamantea,
   Eleonora/J-8339-2016; Di Meo, Ivano/H-7840-2014
OI Legati, Andrea/0000-0002-8178-6126; MARCHET, SILVIA/0000-0002-7858-3256;
   Spagnolo, Manuela/0000-0003-1262-8447; zanetti,
   nadia/0000-0003-1485-8983; Ghezzi, Daniele/0000-0002-6564-3766;
   Lamantea, Eleonora/0000-0001-5090-6028; Di Meo,
   Ivano/0000-0002-4616-5623
FU Fondazione Pierfranco e Luisa Mariani-Center for the Study of
   Mitochondrial Diseases [CM23]; Ministero della Salute [RF-2016-02361495,
   RF-2016-02361241]
FX Fondazione Pierfranco e Luisa Mariani-Center for the Study of
   Mitochondrial Diseases: CM23; Ministero della Salute, Grant/Award
   Numbers: RF-2016-02361495, RF-2016-02361241
CR Adzhubei Ivan, 2013, Curr Protoc Hum Genet, VChapter 7, DOI 10.1002/0471142905.hg0720s76
   Bamshad MJ, 2011, NAT REV GENET, V12, P745, DOI 10.1038/nrg3031
   Bugiani M, 2004, BBA-BIOENERGETICS, V1659, P136, DOI 10.1016/j.bbabio.2004.09.006
   Calvaruso MA, 2008, METHODS, V46, P281, DOI 10.1016/j.ymeth.2008.09.023
   Constantinides VC, 2018, IN VIVO, V32, P1647, DOI 10.21873/invivo.11427
   Feichtinger RG, 2017, AM J HUM GENET, V101, P525, DOI 10.1016/j.ajhg.2017.08.015
   Heighton JN, 2019, MITOCHONDRION, V49, P227, DOI 10.1016/j.mito.2019.09.002
   Hillman GA, 2019, J BIOL CHEM, V294, P9813, DOI 10.1074/jbc.RA119.008476
   Legati A, 2017, J MED GENET, V54, P815, DOI 10.1136/jmedgenet-2017-104822
   Legati A, 2016, BBA-BIOENERGETICS, V1857, P1326, DOI 10.1016/j.bbabio.2016.02.022
   Mancuso M, 2017, NEUROMUSCULAR DISORD, V27, P1126, DOI 10.1016/j.nmd.2017.08.006
   McClelland C, 2016, CURR NEUROL NEUROSCI, V16, DOI 10.1007/s11910-016-0652-7
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Rehm HL, 2013, NAT REV GENET, V14, P295, DOI 10.1038/nrg3463
   Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30
   Sadikovic B, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188610
   Saha SK, 2019, J CLIN MED, V8, DOI 10.3390/jcm8040513
   Sciacco M, 1996, Methods Enzymol, V264, P509, DOI 10.1016/S0076-6879(96)64045-2
   Tengan CH, 1996, BIOCHEM MOL MED, V58, P130, DOI 10.1006/bmme.1996.0040
   Theunissen TEJ, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00400
   Vaser R, 2016, NAT PROTOC, V11, P1, DOI 10.1038/nprot.2015.123
   Viscomi C, 2017, J INHERIT METAB DIS, V40, P587, DOI 10.1007/s10545-017-0027-5
   Xue Y, 2015, GENET MED, V17, P444, DOI 10.1038/gim.2014.122
   ZEVIANI M, 1990, ANN NEUROL, V28, P94, DOI 10.1002/ana.410280118
NR 24
TC 14
Z9 14
U1 1
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1059-7794
EI 1098-1004
J9 HUM MUTAT
JI Hum. Mutat.
PD OCT
PY 2020
VL 41
IS 10
BP 1745
EP 1750
DI 10.1002/humu.24081
EA JUL 2020
PG 6
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA NT6FA
UT WOS:000550806100001
PM 32652806
OA gold
DA 2024-11-01
ER

PT J
AU Manini, A
   Caporali, L
   Meneri, M
   Zanotti, S
   Piga, D
   Arena, IG
   Corti, S
   Toscano, A
   Comi, GP
   Musumeci, O
   Carelli, V
   Ronchi, D
AF Manini, Arianna
   Caporali, Leonardo
   Meneri, Megi
   Zanotti, Simona
   Piga, Daniela
   Arena, Ignazio Giuseppe
   Corti, Stefania
   Toscano, Antonio
   Comi, Giacomo Pietro
   Musumeci, Olimpia
   Carelli, Valerio
   Ronchi, Dario
TI Case Report: Rare Homozygous <i>RNASEH1</i> Mutations Associated With
   Adult-Onset Mitochondrial Encephalomyopathy and Multiple Mitochondrial
   DNA Deletions
SO FRONTIERS IN GENETICS
LA English
DT Article
DE RNASEH1; ribonuclease H1; mitochondrial DNA; mtDNA maintenance
   disorders; myopathy; CPEO
ID IMPAIR MTDNA REPLICATION
AB Mitochondrial DNA (mtDNA) maintenance disorders embrace a broad range of clinical syndromes distinguished by the evidence of mtDNA depletion and/or deletions in affected tissues. Among the nuclear genes associated with mtDNA maintenance disorders, RNASEH1 mutations produce a homogeneous phenotype, with progressive external ophthalmoplegia (PEO), ptosis, limb weakness, cerebellar ataxia, and dysphagia. The encoded enzyme, ribonuclease H1, is involved in mtDNA replication, whose impairment leads to an increase in replication intermediates resulting from mtDNA replication slowdown. Here, we describe two unrelated Italian probands (Patient 1 and Patient 2) affected by chronic PEO, ptosis, and muscle weakness. Cerebellar features and severe dysphagia requiring enteral feeding were observed in one patient. In both cases, muscle biopsy revealed diffuse mitochondrial abnormalities and multiple mtDNA deletions. A targeted next-generation sequencing analysis revealed the homozygous RNASEH1 mutations c.129-3C>G and c.424G>A in patients 1 and 2, respectively. The c.129-3C>G substitution has never been described as disease-related and resulted in the loss of exon 2 in Patient 1 muscle RNASEH1 transcript. Overall, we recommend implementing the use of high-throughput sequencing approaches in the clinical setting to reach genetic diagnosis in case of suspected presentations with impaired mtDNA homeostasis.
C1 [Manini, Arianna; Meneri, Megi; Corti, Stefania; Comi, Giacomo Pietro; Ronchi, Dario] Univ Milan, Dino Ferrari Ctr, Dept Pathophysiol & Transplantat, Milan, Italy.
   [Caporali, Leonardo; Carelli, Valerio] Ist Sci Neurolog Bologna, Programma Neurogenet, Bologna, Italy.
   [Meneri, Megi; Piga, Daniela; Corti, Stefania; Ronchi, Dario] Fdn IRCCS CaGranda Osped Maggiore Policlin, Dept Neurosci, Neurol Unit, Milan, Italy.
   [Zanotti, Simona; Comi, Giacomo Pietro] Fdn IRCCS CaGranda Osped Maggiore Policlin, Dept Neurosci, Neuromuscular & Rare Dis Unit, Milan, Italy.
   [Arena, Ignazio Giuseppe; Toscano, Antonio; Musumeci, Olimpia] Univ Messina, Dept Clin & Expt Med, Unit Neurol & Neuromuscular disorders, Messina, Italy.
   [Carelli, Valerio] Univ Bologna, Dipartimento Sci Biomed & Neuromotorie DIBINEM, Bologna, Italy.
C3 University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico;
   IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Messina;
   University of Bologna
RP Ronchi, D (corresponding author), Univ Milan, Dino Ferrari Ctr, Dept Pathophysiol & Transplantat, Milan, Italy.; Carelli, V (corresponding author), Ist Sci Neurolog Bologna, Programma Neurogenet, Bologna, Italy.; Ronchi, D (corresponding author), Fdn IRCCS CaGranda Osped Maggiore Policlin, Dept Neurosci, Neurol Unit, Milan, Italy.; Musumeci, O (corresponding author), Univ Messina, Dept Clin & Expt Med, Unit Neurol & Neuromuscular disorders, Messina, Italy.; Carelli, V (corresponding author), Univ Bologna, Dipartimento Sci Biomed & Neuromotorie DIBINEM, Bologna, Italy.
EM dario.ronchi@unimi.it; valerio.carelli@unibo.it;
   olimpia.musumeci@unime.it
RI Musumeci, Olimpia/AHE-3041-2022; Comi, Giacomo/K-5702-2016; Corti,
   Stefania/K-6034-2016; MANINI, ARIANNA/AGF-1957-2022; Toscano,
   Antonio/ABG-8813-2020; zanotti, simone/AAS-7160-2020; Ronchi,
   Dario/K-8011-2016; Caporali, Leonardo/J-7398-2016
OI Arena, Ignazio Giuseppe/0000-0003-0882-7865; MENERI,
   MEGI/0000-0002-3429-1809; Caporali, Leonardo/0000-0002-0666-4380;
   Zanotti, Simona/0000-0003-4520-4966
FU Italian Ministry of Health (Ministero della Salute); Foundation IRCCS Ca
   Granda Ospedale Maggiore Policlinico Grant Ricerca Corrente 2020; IRCCS
   Istituto delle Scienze Neurologiche di Bologna Grant Ricerca Corrente
   2020
FX This work was partially supported by the Italian Ministry of Health
   (Ministero della Salute), Foundation IRCCS Ca' Granda Ospedale Maggiore
   Policlinico Grant Ricerca Corrente 2020 to GPC, and IRCCS Istituto delle
   Scienze Neurologiche di Bologna Grant Ricerca Corrente 2020 to LC and
   VC. This work was promoted within the European Reference Network (ERN)
   for Neuromuscular Diseases.
CR Ahmed N, 2015, INT J MOL SCI, V16, P18054, DOI 10.3390/ijms160818054
   Bugiardini E, 2017, NEUROL-GENET, V3, DOI 10.1212/NXG.0000000000000149
   Carreño-Gago L, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00576
   Cerritelli SM, 1998, GENOMICS, V53, P300, DOI 10.1006/geno.1998.5497
   Cerritelli SM, 2003, MOL CELL, V11, P807, DOI 10.1016/S1097-2765(03)00088-1
   Holt IJ, 2019, DNA REPAIR, V84, DOI 10.1016/j.dnarep.2019.06.001
   Kornblum C, 2013, NAT GENET, V45, P214, DOI 10.1038/ng.2501
   Lieber DS, 2013, NEUROLOGY, V80, P1762, DOI 10.1212/WNL.0b013e3182918c40
   Lima WF, 2016, NUCLEIC ACIDS RES, V44, P5299, DOI 10.1093/nar/gkw350
   Manini A, 2022, AGEING RES REV, V76, DOI 10.1016/j.arr.2022.101578
   Reyes A, 2015, AM J HUM GENET, V97, P186, DOI 10.1016/j.ajhg.2015.05.013
   Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30
   Ronchi D, 2012, BRAIN, V135, P3404, DOI 10.1093/brain/aws258
   Sachdev A, 2018, CAN J OPHTHALMOL, V53, pE203, DOI 10.1016/j.jcjo.2018.01.005
   Viscomi C, 2017, J INHERIT METAB DIS, V40, P587, DOI 10.1007/s10545-017-0027-5
NR 15
TC 3
Z9 3
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1664-8021
J9 FRONT GENET
JI Front. Genet.
PD MAY 31
PY 2022
VL 13
AR 906667
DI 10.3389/fgene.2022.906667
PG 8
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 2C6BH
UT WOS:000810951000001
PM 35711919
OA gold, Green Published
DA 2024-11-01
ER

PT J
AU Rajakulendran, S
   Pitceathly, RDS
   Taanman, JW
   Costello, H
   Sweeney, MG
   Woodward, CE
   Jaunmuktane, Z
   Holton, JL
   Jacques, TS
   Harding, BN
   Fratter, C
   Hanna, MG
   Rahman, S
AF Rajakulendran, Sanjeev
   Pitceathly, Robert D. S.
   Taanman, Jan-Willem
   Costello, Harry
   Sweeney, Mary G.
   Woodward, Cathy E.
   Jaunmuktane, Zane
   Holton, Janice L.
   Jacques, Thomas S.
   Harding, Brian N.
   Fratter, Carl
   Hanna, Michael G.
   Rahman, Shamima
TI A Clinical, Neuropathological and Genetic Study of Homozygous A467T
   <i>POLG</i>-Related Mitochondrial Disease
SO PLOS ONE
LA English
DT Article
ID DNA-POLYMERASE-GAMMA; PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; MUTATIONS;
   PHENOTYPE; SPECTRUM; FEATURES; ENCEPHALOMYOPATHY; DOMINANT; EPILEPSY;
   MYOPATHY
AB Mutations in the nuclear gene POLG (encoding the catalytic subunit of DNA polymerase gamma) are an important cause of mitochondrial disease. The most common POLG mutation, A467T, appears to exhibit considerable phenotypic heterogeneity. The mechanism by which this single genetic defect results in such clinical diversity remains unclear. In this study we evaluate the clinical, neuropathological and mitochondrial genetic features of four unrelated patients with homozygous A467T mutations. One patient presented with the severe and lethal Alpers-Huttenlocher syndrome, which was confirmed on neuropathology, and was found to have a depletion of mitochondrial DNA (mtDNA). Of the remaining three patients, one presented with mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS), one with a phenotype in the Myoclonic Epilepsy, Myopathy and Sensory Ataxia (MEMSA) spectrum and one with Sensory Ataxic Neuropathy, Dysarthria and Ophthalmoplegia (SANDO). All three had secondary accumulation of multiple mtDNA deletions. Complete sequence analysis of muscle mtDNA using the MitoChip resequencing chip in all four cases demonstrated significant variation in mtDNA, including a pathogenic MT-ND5 mutation in one patient. These data highlight the variable and overlapping clinical and neuropathological phenotypes and downstream molecular defects caused by the A467T mutation, which may result from factors such as the mtDNA genetic background, nuclear genetic modifiers and environmental stressors.
C1 [Rajakulendran, Sanjeev; Pitceathly, Robert D. S.; Hanna, Michael G.] UCL Inst Neurol, London WC1N 3BG, England.
   [Rajakulendran, Sanjeev; Pitceathly, Robert D. S.; Hanna, Michael G.] Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England.
   [Rajakulendran, Sanjeev; Hanna, Michael G.] MRC Ctr Neuromuscular Dis, London WC1N 3BG, England.
   [Pitceathly, Robert D. S.] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Basic & Clin Neuroscince, London SE5 8AF, England.
   [Taanman, Jan-Willem] UCL Inst Neurol, Dept Clin Neurosci, London NW3 2PF, England.
   [Costello, Harry; Rahman, Shamima] UCL Inst Child Hlth, Mitochondrial Res Grp, Genet & Genom Med, London WC1N 1EH, England.
   [Sweeney, Mary G.; Woodward, Cathy E.] UCL Inst Neurol, Dept Neurogenet, London WC1N 3BG, England.
   [Sweeney, Mary G.; Woodward, Cathy E.; Jaunmuktane, Zane; Holton, Janice L.] Natl Hosp Neurol, London WC1N 3BG, England.
   [Jaunmuktane, Zane; Holton, Janice L.] UCL Inst Neurol, Div Neuropathol, London WC1N 3BG, England.
   [Jacques, Thomas S.] UCL Inst Child Hlth, Dev Biol & Canc Programme, London WC1N 1EH, England.
   [Jacques, Thomas S.] Great Ormond St Hosp Children Fdn Trust, Dept Histopathol, London WC1N 1EH, England.
   [Harding, Brian N.] Childrens Hosp Philadelphia, Div Neuropathol, Philadelphia, PA 19104 USA.
   [Fratter, Carl] Churchill Hosp, Oxford Univ Hosp NHS Trust, Oxford Med Genet Labs, Oxford OX3 7LE, England.
   [Rahman, Shamima] Great Ormond St Hosp Sick Children, Metab Unit, London WC1N 3JH, England.
C3 University of London; University College London; University of London;
   University College London; UCL Medical School; University College London
   Hospitals NHS Foundation Trust; University of London; University College
   London; University of London; King's College London; University of
   London; University College London; University of London; University
   College London; University of London; University College London;
   University of London; University College London; UCL Medical School;
   University College London Hospitals NHS Foundation Trust; University of
   London; University College London; University of London; University
   College London; University of London; University College London; Great
   Ormond Street Hospital for Children NHS Foundation Trust; University of
   Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia;
   Oxford University Hospitals NHS Foundation Trust; University of Oxford;
   University of London; University College London; Great Ormond Street
   Hospital for Children NHS Foundation Trust
RP Rahman, S (corresponding author), UCL Inst Child Hlth, Mitochondrial Res Grp, Genet & Genom Med, London WC1N 1EH, England.
EM shamima.rahman@ucl.ac.uk
RI Jaunmuktane, Zane/ABC-9039-2020; Rahman, Shamima/C-5232-2008; Jacques,
   Thomas/C-2209-2008; Holton, Janice/F-6831-2011; Taanman,
   Jan-Willem/A-5379-2011
OI Pitceathly, Robert/0000-0002-6123-4551; Taanman,
   Jan-Willem/0000-0002-5476-9785; Jaunmuktane, Zane/0000-0001-7738-8881;
   Hanna, Michael/0000-0003-0825-4075
FU Wellcome Trust Clinical Research Training Fellowship; Myositis UK;
   National Institute for Health Research Biomedical Research Centres at
   Great Ormond Street Hospital; University College London Hospitals, an
   MRC Centre for Neuromuscular Diseases grant [G0601943]; UK NHS
   Specialised Service for Rare Mitochondrial Diseases of Adults and
   Children; MRC [MR/K000608/1, G0200335, G0601943] Funding Source: UKRI
FX S. Rajakulendran was supported by a Wellcome Trust Clinical Research
   Training Fellowship. JLH is supported by Myositis UK. S. Rahman is the
   Great Ormond Street Children's Charity Professor of Paediatric Metabolic
   Medicine. This research was supported in part by the National Institute
   for Health Research Biomedical Research Centres at Great Ormond Street
   Hospital and University College London Hospitals, an MRC Centre for
   Neuromuscular Diseases grant (G0601943) and the UK NHS Specialised
   Service for Rare Mitochondrial Diseases of Adults and Children.
CR Blok MJ, 2009, J MED GENET, V46, P776, DOI 10.1136/jmg.2009.067686
   Blümcke I, 2013, EPILEPSIA, V54, P1315, DOI 10.1111/epi.12220
   Chan SSL, 2005, J BIOL CHEM, V280, P31341, DOI 10.1074/jbc.M506762200
   Engelsen BA, 2008, BRAIN, V131, P818, DOI 10.1093/brain/awn007
   Euro L, 2011, NUCLEIC ACIDS RES, V39, P9072, DOI 10.1093/nar/gkr618
   Graziewicz MA, 2006, CHEM REV, V106, P383, DOI 10.1021/cr040463d
   Hargreaves IP, 2002, J INHERIT METAB DIS, V25, P673, DOI 10.1023/A:1022881231253
   Herrnstadt C, 2002, AM J HUM GENET, V70, P1152, DOI 10.1086/339933
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Lee YS, 2009, CELL, V139, P312, DOI 10.1016/j.cell.2009.07.050
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Luoma PT, 2005, HUM MOL GENET, V14, P1907, DOI 10.1093/hmg/ddi196
   McHugh JC, 2010, MUSCLE NERVE, V41, P265, DOI 10.1002/mus.21494
   McKenzie M, 2007, J BIOL CHEM, V282, P36845, DOI 10.1074/jbc.M704158200
   Neeve VCM, 2012, BRAIN, V135, P3614, DOI 10.1093/brain/aws298
   Nguyen KV, 2005, NEUROLOGY, V65, P1493, DOI 10.1212/01.wnl.0000182814.55361.70
   Pagnamenta AT, 2006, HUM REPROD, V21, P2467, DOI 10.1093/humrep/del076
   Pitceathly RDS, 2013, J NEUROL NEUROSUR PS, V84, P107, DOI 10.1136/jnnp-2012-303232
   Rahman S, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000411
   Rovio AT, 2001, NAT GENET, V29, P261, DOI 10.1038/ng759
   Schulte C, 2009, NEUROLOGY, V73, P898, DOI 10.1212/WNL.0b013e3181b78488
   Spinazzola A, 2009, J INHERIT METAB DIS, V32, P143, DOI 10.1007/s10545-008-1038-z
   Stumpf JD, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a011395
   Tang S, 2012, J NEUROL, V259, P862, DOI 10.1007/s00415-011-6268-6
   Tang S, 2011, J MED GENET, V48, P669, DOI 10.1136/jmedgenet-2011-100222
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, NEUROLOGY, V61, P1811, DOI 10.1212/01.WNL.0000098997.23471.65
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   Xie HBM, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-402
   Zhadanov SI, 2005, BIOCHEM BIOPH RES CO, V332, P1115, DOI 10.1016/j.bbrc.2005.05.059
NR 32
TC 33
Z9 34
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 6
PY 2016
VL 11
IS 1
AR e0145500
DI 10.1371/journal.pone.0145500
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA DA4XE
UT WOS:000367805100027
PM 26735972
OA gold, Green Published, Green Submitted
DA 2024-11-01
ER

PT J
AU Filosto, M
   Tonin, P
   Scarpelli, M
   Savio, C
   Greco, F
   Mancuso, M
   Vattemi, G
   Govoni, V
   Rizzuto, N
   Tupler, R
   Tornelleri, G
AF Filosto, Massimiliano
   Tonin, Paola
   Scarpelli, Mauro
   Savio, Chiara
   Greco, Francesca
   Mancuso, Michelangelo
   Vattemi, Gaetano
   Govoni, Vittorio
   Rizzuto, Nicolo
   Tupler, Rossella
   Tornelleri, Giuliano
TI Novel mitochondrial tRNA<SUP>Leu(CUN)</SUP> transition and D4Z4 partial
   deletion in a patient with a facioscapulohumeral phenotype
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE mtDNA; mitochondrial myopathy; FSHD
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; MTDNA POINT MUTATION; TRANSFER-RNA
   GENES; MUSCULAR-DYSTROPHY; SKELETAL-MUSCLE; SPORADIC PATIENT; MYOPATHY;
   DNA; ENCEPHALOMYOPATHY; DEFICIENCY
AB Point mutations in mtDNA-encoded tRNA genes frequently cause isolated myopathies but rarely cause the facioscapulohumeral phenotype.
   We report on a patient affected with chronic progressive weakness of facioscapulolmmeral/peroneal muscles whose muscle biopsy showed a mitochondrial myopathy. mtDNA direct sequencing and RFLP analysis revealed a heteroplasmic transition T12313C which disrupts a conserved site in the TTC stem of the tRNA(Leu(CUN)) gene and fulfills the accepted criteria of pathogenicity.
   A partial deletion of the nuclear DNA D4Z4 region with residual repeat sizes of 25 kb was also found in the patient and in her mother.
   This is the first reported case of mitochondrial myopathy/facioscapulohumeral muscular dystrophy (FSHD) "double trouble". (C) 2007 Elsevier B.V. All rights reserved.
C1 [Filosto, Massimiliano; Tonin, Paola; Scarpelli, Mauro; Savio, Chiara; Vattemi, Gaetano; Rizzuto, Nicolo; Tornelleri, Giuliano] Univ Verona, Sect Clin Neurol, Dept Neurol Sci & Vis, I-37100 Verona, Italy.
   [Filosto, Massimiliano] Univ Hosp Spedali Civili, Brescia, Italy.
   [Greco, Francesca; Tupler, Rossella] Univ Modena & Reggio Emilia, Dept Biomed Sci, Modena, Italy.
   [Mancuso, Michelangelo] Univ Pisa, Dept Neurosci, I-56100 Pisa, Italy.
   [Govoni, Vittorio] Univ Ferrara, Inst Clin Neurol, I-44100 Ferrara, Italy.
C3 University of Verona; Hospital Spedali Civili Brescia; Universita di
   Modena e Reggio Emilia; University of Pisa; University of Ferrara
RP Tornelleri, G (corresponding author), Univ Verona, Sect Clin Neurol, Dept Neurol Sci & Vis, I-37100 Verona, Italy.
EM giuliano.tomelleri@univr.it
RI Vattemi, Gaetano/AAC-4668-2022; Filosto, Massimiliano/S-9446-2019;
   Tonin, Paola/AAC-5052-2022; Mancuso, Michelangelo/K-4170-2016; Tupler,
   Rossella/C-9500-2015
OI Tupler, Rossella/0000-0002-3797-1789; Vattemi,
   Gaetano/0000-0003-3412-8339; Filosto, Massimiliano/0000-0002-2852-7512
CR ANDREU AL, 2002, METHODS MOL BIOL NEU, V217, P185
   BANCROFT JD, 1984, MANUAL HIST TECHNIQU
   Bauer MKA, 1999, J CELL BIOL, V147, P1493, DOI 10.1083/jcb.147.7.1493
   Bushby KMD, 1998, NEUROMUSCULAR DISORD, V8, P574, DOI 10.1016/S0960-8966(98)00088-1
   Cardaioli E, 2005, BIOCHEM BIOPH RES CO, V327, P675, DOI 10.1016/j.bbrc.2004.11.170
   Chuenkongkaew WL, 2005, EUR J NEUROL, V12, P388, DOI 10.1111/j.1468-1331.2004.01060.x
   DiMauro S, 2005, CURR OPIN NEUROL, V18, P538, DOI 10.1097/01.wco.0000179761.63486.1a
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   *EM U CTR MOL MED, MIT HUM MIT GEN DAT
   Fu K, 1996, HUM MOL GENET, V5, P1835, DOI 10.1093/hmg/5.11.1835
   Gabellini D, 2006, NATURE, V439, P973, DOI 10.1038/nature04422
   Gabellini D, 2002, CELL, V110, P339, DOI 10.1016/S0092-8674(02)00826-7
   Gattermann N, 1996, BRIT J HAEMATOL, V93, P845, DOI 10.1046/j.1365-2141.1996.d01-1724.x
   Grasso M, 2001, EUR J HUM GENET, V9, P311, DOI 10.1038/sj.ejhg.5200622
   HATTORI Y, 1994, J NEUROL SCI, V125, P50, DOI 10.1016/0022-510X(94)90241-0
   HOUSHMAND M, 1994, BBA-MOL BASIS DIS, V1226, P49, DOI 10.1016/0925-4439(94)90058-2
   HUDGSON P, 1972, J NEUROL SCI, V16, P343, DOI 10.1016/0022-510X(72)90197-9
   Karadimas CL, 2002, NEUROMUSCULAR DISORD, V12, P865, DOI 10.1016/S0960-8966(02)00072-X
   Laoudj-Chenivesse D, 2005, J MOL MED, V83, P216, DOI 10.1007/s00109-004-0583-7
   McFarland R, 2004, ANN NEUROL, V55, P478, DOI 10.1002/ana.20004
   MORAES CT, 1992, AM J HUM GENET, V50, P934
   Padberg G W, 1991, Neuromuscul Disord, V1, P231, DOI 10.1016/0960-8966(91)90094-9
   PADBERG GW, 1995, MUSCLE NERVE, pS73
   Pál E, 1999, EUR NEUROL, V42, P211, DOI 10.1159/000008109
   Pulkes T, 1999, ANN NEUROL, V46, P916, DOI 10.1002/1531-8249(199912)46:6<916::AID-ANA16>3.0.CO;2-R
   Pulkes T, 2003, NEUROLOGY, V61, P1144, DOI 10.1212/01.WNL.0000090465.27024.3D
   ROWLAND LP, 1991, REV NEUROL-FRANCE, V147, P467
   Sacconi S, 2006, NEUROLOGY, V67, P1464, DOI 10.1212/01.wnl.0000240071.62540.6f
   SLIPETZ DM, 1991, AM J HUM GENET, V48, P502
   Vives-Bauza C, 2001, ANN MED, V33, P493, DOI 10.3109/07853890109002099
   Weber K, 1997, AM J HUM GENET, V60, P373
   Zsurka G, 2004, J MED GENET, V41, DOI 10.1136/jmg.2004.022566
NR 32
TC 12
Z9 13
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD MAR
PY 2008
VL 18
IS 3
BP 204
EP 209
DI 10.1016/j.nmd.2007.12.005
PG 6
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 300EX
UT WOS:000255808200003
PM 18343111
DA 2024-11-01
ER

PT J
AU Chen, T
   Pu, CQ
   Shi, Q
   Wang, Q
   Cong, L
   Liu, JX
   Luo, HY
   Fei, LN
   Tang, W
   Yu, SS
AF Chen, Ting
   Pu, Chuanqiang
   Shi, Qiang
   Wang, Qian
   Cong, Lu
   Liu, Jiexiao
   Luo, Hongyu
   Fei, Lingna
   Tang, Wei
   Yu, Shanshan
TI Chronic progressive external ophthalmoplegia with inflammatory myopathy
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE Chronic progressive external ophthalmoplegia; mitochondrial DNA
   deletions; inflammatory myopathy
ID MUSCLE MITOCHONDRIAL-DNA; DELETIONS; MUTATIONS; READS
AB Chronic progressive external ophthalmoplegia is one of mitochondrial disorders, characterized by ptosis, limitation of eye movement, variably severe bulbar muscle weakness and proximal limb weakness. Chronic progressive external ophthalmoplegia complicated with acquired disease is extremely rare. We report a 44 years old male patient with more than 20 years of chronic progressive bilateral ptosis and limitation of eye movements manifested dysarthria, dysphagia and neck muscle weakness for 3 years. The first muscle biopsy showed red-ragged fibers and cytochrome c oxidase negative fibers as well as inflammatory cells infiltration. Electron microscopy revealed paracrystalline inclusions. Mitochondrial genetic analysis demonstrated a large-scale mtDNA deletion of m.8470_13446del4977. The patient was treated with prednisone. In a three-year follow-up study, the second biopsy was performed. Before the treatment, except bilateral ptosis and external ophthalmopelgia, this patient presented bulbar muscle weakness and neck muscle weakness. After treated with prednisone, the symptoms of dysphagia, dysarthria and neck muscle weakness were significantly improved, and the second biopsy showed only mitochondrial myopathy pathology but the inflammations disappeared. Here, we report a patient with chronic progressive external ophthalmoplegia complicated with inflammatory myopathy and after treated with prednisone as myositis, he had a significant therapeutic effect.
C1 [Chen, Ting; Pu, Chuanqiang; Shi, Qiang; Cong, Lu; Liu, Jiexiao] Chinese Peoples Liberat Army Gen Hosp, Dept Neurol, Beijing 100853, Peoples R China.
   [Chen, Ting; Pu, Chuanqiang] Nankai Univ, Sch Med, Tianjin 300071, Peoples R China.
   [Luo, Hongyu; Fei, Lingna; Tang, Wei; Yu, Shanshan] BGI Shenzhen, Shenzhen 518083, Peoples R China.
   [Wang, Qian] Chinese Armed Police Gen Hosp, Dept Emergency, Beijing 100039, Peoples R China.
C3 Chinese People's Liberation Army General Hospital; Nankai University;
   Beijing Genomics Institute (BGI)
RP Pu, CQ (corresponding author), Chinese Peoples Liberat Army Gen Hosp, Dept Neurol, 28 Fu Xing Rd, Beijing 100853, Peoples R China.
EM pucq30128@sina.cn; yushanshan@genomics.cn
RI Tang, Wei/IZQ-1283-2023; Yu, Shanshan/K-6288-2012; chen,
   xia/GYR-3948-2022
FU National Natural Science Foundation of China [81271399]; Natural Science
   Foundation of Beijing [7132216]
FX We thank the patient for his participation in this study. This work was
   supported by the National Natural Science Foundation of China under
   Grant No. 81271399 and the Natural Science Foundation of Beijing under
   Grant No. 7132216.
CR Brandon BR, 2013, J NEUROL, V260, P1931, DOI 10.1007/s00415-013-6975-2
   CHENG S, 1994, NAT GENET, V7, P350, DOI 10.1038/ng0794-350
   Dalakas MC, 2003, LANCET, V362, P971, DOI 10.1016/S0140-6736(03)14368-1
   DiMauro S, 2008, ANNU REV NEUROSCI, V31, P91, DOI 10.1146/annurev.neuro.30.051606.094302
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   HOLT IJ, 1989, NUCLEIC ACIDS RES, V17, P4465, DOI 10.1093/nar/17.12.4465
   Mancuso M, 2013, NEUROMUSCULAR DISORD, V23, P907, DOI 10.1016/j.nmd.2013.07.011
   Marotta R, 2009, J CLIN NEUROSCI, V16, P1223, DOI 10.1016/j.jocn.2008.11.012
   Negro R, 2009, NEUROMUSCULAR DISORD, V19, P423, DOI 10.1016/j.nmd.2009.04.008
   SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184
   Schröder J, 2014, BIOINFORMATICS, V30, P1064, DOI 10.1093/bioinformatics/btt767
   Tengan CH, 1996, BIOCHEM MOL MED, V58, P130, DOI 10.1006/bmme.1996.0040
   Varadhachary AS, 2010, CURR OPIN RHEUMATOL, V22, P651, DOI 10.1097/BOR.0b013e32833f108a
   Ye K, 2009, BIOINFORMATICS, V25, P2865, DOI 10.1093/bioinformatics/btp394
NR 15
TC 7
Z9 7
U1 0
U2 4
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2014
VL 7
IS 12
BP 8887
EP 8892
PG 6
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA AZ6RG
UT WOS:000348345900064
PM 25674260
DA 2024-11-01
ER

PT J
AU McClelland, C
   Manousakis, G
   Lee, MS
AF McClelland, Collin
   Manousakis, Georgios
   Lee, Michael S.
TI Progressive External Ophthalmoplegia
SO CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS
LA English
DT Review
DE Mitochondrial myopathy; Progressive external ophthalmoplegia
ID KEARNS-SAYRE-SYNDROME; MITOCHONDRIAL-DNA DELETIONS; SENSORINEURAL
   HEARING-LOSS; IMPAIR MTDNA REPLICATION; EXTRAOCULAR-MUSCLES; OPTIC
   ATROPHY; CLINICAL-FEATURES; OPA1 MUTATIONS; DIAGNOSIS; DISEASE
AB Progressive external ophthalmoplegia (PEO), marked by progressive bilateral ptosis and diffuse reduction in ocular motility, represents a finding of mitochondrial myopathy rather than a true diagnosis. PEO often occurs with other systemic features of mitochondrial dysfunction that can cause significant morbidity and mortality. Accurate and early recognition of PEO is paramount for the optimal care of these patients. We present an evidence-based review of the presenting neuroophthalmic features, differential diagnosis, diagnostic tools, systemic implications, and treatment options for isolated PEO and other PEO-associated mitochondrial syndromes.
C1 [McClelland, Collin; Lee, Michael S.] Univ Minnesota, Dept Ophthalmol, 420 Delaware St SE MMC 493, Minneapolis, MN 55455 USA.
   [McClelland, Collin; Lee, Michael S.] Univ Minnesota, Dept Visual Neurosci, 420 Delaware St SE MMC 493, Minneapolis, MN 55455 USA.
   [Manousakis, Georgios; Lee, Michael S.] Univ Minnesota, Dept Neurol, Minneapolis, MN 55455 USA.
   [Lee, Michael S.] Univ Minnesota, Dept Neurosurg, Minneapolis, MN 55455 USA.
C3 University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities
RP Lee, MS (corresponding author), Univ Minnesota, Dept Ophthalmol, 420 Delaware St SE MMC 493, Minneapolis, MN 55455 USA.; Lee, MS (corresponding author), Univ Minnesota, Dept Visual Neurosci, 420 Delaware St SE MMC 493, Minneapolis, MN 55455 USA.; Lee, MS (corresponding author), Univ Minnesota, Dept Neurol, Minneapolis, MN 55455 USA.; Lee, MS (corresponding author), Univ Minnesota, Dept Neurosurg, Minneapolis, MN 55455 USA.
EM cmc@umn.edu; gmanousa@umn.edu; mikelee@umn.edu
RI Lee, Michael/GZP-3892-2022
OI McClelland, Collin/0000-0003-2836-4263; Iakovenko,
   Elena/0000-0002-7514-5736; Fedotova, Ekaterina/0000-0001-8070-7644
FU Research to Prevent Blindness (New York, NY)
FX This research was supported by the unrestricted grant from the Research
   to Prevent Blindness (New York, NY).
CR Ahn J, 2008, BRIT J OPHTHALMOL, V92, P1685, DOI 10.1136/bjo.2008.144816
   Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   [Anonymous], 2010, NEUROOPHTHALMOLOGY D
   Assaf AA, 2011, EYE, V25, P1251, DOI 10.1038/eye.2011.38
   de Castro FAA, 2010, OPHTHAL PLAST RECONS, V26, P416, DOI 10.1097/IOP.0b013e3181cb57a7
   Behbehani R, 2007, J NEURO-OPHTHALMOL, V27, P41, DOI 10.1097/WNO.0b013e31803312fa
   Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   Chaudhuri Z, 2013, JAMA OPHTHALMOL, V131, P619, DOI 10.1001/jamaophthalmol.2013.783
   Chu BC, 1999, NEURORADIOLOGY, V41, P759, DOI 10.1007/s002340050838
   Domenis DR, 2011, DIGEST DIS SCI, V56, P2343, DOI 10.1007/s10620-011-1631-0
   DRACHMAN DA, 1968, ARCH NEUROL-CHICAGO, V18, P654, DOI 10.1001/archneur.1968.00470360076008
   Draeger A, 2006, J PATHOL, V210, P94, DOI 10.1002/path.2018
   El-Hattab AW, 2015, MOL GENET METAB, V116, P4, DOI 10.1016/j.ymgme.2015.06.004
   Fraunfelder FW, 2008, OPHTHALMOLOGY, V115, P2282, DOI 10.1016/j.ophtha.2008.08.006
   Gonzalez-Moron D, 2013, BMJ CASE REP, P20
   González-Vioque E, 2006, ARCH NEUROL-CHICAGO, V63, P107, DOI 10.1001/archneur.63.1.107
   Gregoratos Gabriel, 2002, Circulation, V106, P2145, DOI 10.1161/01.CIR.0000035996.46455.09
   Haas RH, 2008, MOL GENET METAB, V94, P16, DOI 10.1016/j.ymgme.2007.11.018
   Hanisch F, 2005, NERVENARZT, V76, P395, DOI 10.1007/s00115-004-1742-3
   Hanisch F, 2015, J NEUROL NEUROSUR PS, V86, P630, DOI 10.1136/jnnp-2013-306748
   Hansen N, 2012, NEUROL SCI, V33, P209, DOI 10.1007/s10072-011-0631-3
   Hirano M, 2001, NEUROLOGY, V57, P2163, DOI 10.1212/WNL.57.12.2163
   HIRANO M, 1994, J CHILD NEUROL, V9, P4, DOI 10.1177/088307389400900102
   Horga A, 2014, BRAIN, V137, P3200, DOI 10.1093/brain/awu279
   Hudson G, 2008, BRAIN, V131, P329, DOI 10.1093/brain/awm272
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   KEARNS TP, 1958, ARCH OPHTHALMOL-CHIC, V60, P280, DOI 10.1001/archopht.1958.00940080296016
   Kornblum C, 2005, J NEUROL, V252, P1101, DOI 10.1007/s00415-005-0827-7
   Kornblum C, 2001, NEUROLOGY, V56, P1409, DOI 10.1212/WNL.56.10.1409
   Kornblum C, 2013, NAT GENET, V45, P214, DOI 10.1038/ng.2501
   KRENDEL DA, 1987, MUSCLE NERVE, V10, P299, DOI 10.1002/mus.880100404
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Lapid O, 2000, PLAST RECONSTR SURG, V106, P1213, DOI 10.1097/00006534-200010000-00046
   Lee Andrew G, 2002, Curr Neurol Neurosci Rep, V2, P413, DOI 10.1007/s11910-002-0067-5
   Liskova P, 2013, ACTA OPHTHALMOL, V91, pE225, DOI 10.1111/aos.12038
   López-Gallardo E, 2009, MITOCHONDRION, V9, P314, DOI 10.1016/j.mito.2009.04.005
   Man CYW, 2006, EYE, V20, P564, DOI 10.1038/sj.eye.6701924
   Mancuso M, 2015, J NEUROL, V262, P1301, DOI 10.1007/s00415-015-7710-y
   MEIRE F, 1985, OPHTHALMIC PAED GEN, V5, P91, DOI 10.3109/13816818509007861
   Miller NR., 2005, WALSH HOYTS CLIN NEU, V1, P237
   Milone M, 2013, MOL GENET METAB, V110, P35, DOI 10.1016/j.ymgme.2013.07.007
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   MULLIE MA, 1985, ARCH OPHTHALMOL-CHIC, V103, P1825, DOI 10.1001/archopht.1985.01050120059020
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Okamoto K, 1996, J NEURO-OPHTHALMOL, V16, P286
   OLSON W, 1972, ARCH NEUROL-CHICAGO, V26, P193, DOI 10.1001/archneur.1972.00490090019001
   Ortube MC, 2006, J AAPOS, V10, P414, DOI 10.1016/j.jaapos.2006.04.012
   OTA I, 1989, Nippon Ganka Gakkai Zasshi, V93, P329
   OTA Y, 1994, RETINA-J RET VIT DIS, V14, P270, DOI 10.1097/00006982-199414030-00015
   Peragallo JH, 2015, J NEURO-OPHTHALMOL, V35, P185, DOI 10.1097/WNO.0000000000000228
   PETTY RKH, 1986, BRAIN, V109, P915, DOI 10.1093/brain/109.5.915
   Pfeffer G, 2009, NEUROLOGY, V73, P71, DOI 10.1212/WNL.0b013e3181aae814
   Pfeffer G, 2013, ANN MED, V45, P4, DOI 10.3109/07853890.2011.605389
   Pfeffer G, 2012, MUSCLE NERVE, V46, P593, DOI 10.1002/mus.23538
   Pfeffer G, 2012, CAN J NEUROL SCI, V39, P520, DOI 10.1017/S0317167100014062
   Pfeffer G, 2011, CAN J NEUROL SCI, V38, P119, DOI 10.1017/S031716710001115X
   Pineles SL, 2012, J AAPOS, V16, P529, DOI 10.1016/j.jaapos.2012.08.005
   Pitceathly RD, 2015, EUR RADIOL
   POLAK PE, 1989, EUR HEART J, V10, P281, DOI 10.1093/oxfordjournals.eurheartj.a059477
   REICHMANN H, 1991, EUR NEUROL, V31, P108, DOI 10.1159/000116656
   RESKENIELSEN E, 1976, ACTA OPHTHALMOL, V54, P553
   Reyes A, 2015, AM J HUM GENET, V97, P186, DOI 10.1016/j.ajhg.2015.05.013
   Richardson C, 2005, EYE, V19, P258, DOI 10.1038/sj.eye.6701488
   Ronchi D, 2013, AM J HUM GENET, V92, P293, DOI 10.1016/j.ajhg.2012.12.014
   Schaefer AM, 2005, MUSCLE NERVE, V32, P104, DOI 10.1002/mus.20319
   Shorr N, 1987, Ophthalmic Plast Reconstr Surg, V3, P141, DOI 10.1097/00002341-198703030-00005
   Sinnathuray AR, 2003, OTOL NEUROTOL, V24, P418, DOI 10.1097/00129492-200305000-00012
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   St Guily J L, 1994, Ear Nose Throat J, V73, P34
   Sundaram C, 2011, J CLIN NEUROSCI, V18, P535, DOI 10.1016/j.jocn.2010.06.014
   SUOMALAINEN A, 1995, NAT GENET, V9, P146, DOI 10.1038/ng0295-146
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   Tinley C, 2010, STRABISMUS, V18, P41, DOI 10.3109/09273971003758388
   TRANCHANT C, 1993, NEUROMUSCULAR DISORD, V3, P561, DOI 10.1016/0960-8966(93)90116-2
   Tyynismaa H, 2009, AM J HUM GENET, V85, P290, DOI 10.1016/j.ajhg.2009.07.009
   Van Goethem G, 2003, NEUROMOL MED, V3, P129, DOI 10.1385/NMM:3:3:129
   Wabbels B, 2008, OPHTHALMOLOGE, V105, P550, DOI 10.1007/s00347-007-1643-5
   Wallace DK, 1997, OPHTHALMOLOGY, V104, P695, DOI 10.1016/S0161-6420(97)30250-4
   Walsh FB, 1969, CLIN NEURO OPHTH, P567
   Wong LJC, 2013, MITOCHONDRION, V13, P379, DOI 10.1016/j.mito.2013.02.001
   Young TJ, 2005, PACE, V28, P454, DOI 10.1111/j.1540-8159.2005.40049.x
   Yu-Wai-Man P, 2010, BRAIN, V133, P771, DOI 10.1093/brain/awq007
NR 82
TC 51
Z9 58
U1 0
U2 12
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1528-4042
EI 1534-6293
J9 CURR NEUROL NEUROSCI
JI Curr. Neurol. Neurosci. Rep.
PD JUN
PY 2016
VL 16
IS 6
AR 53
DI 10.1007/s11910-016-0652-7
PG 10
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA DM3YL
UT WOS:000376282500002
PM 27072953
DA 2024-11-01
ER

PT J
AU Ronchi, D
   Fassone, E
   Bordoni, A
   Sciacco, M
   Lucchini, V
   Di Fonzo, A
   Rizzuti, M
   Colombo, I
   Napoli, L
   Ciscato, P
   Moggio, M
   Cosi, A
   Collotta, M
   Corti, S
   Bresolin, N
   Comi, GP
AF Ronchi, Dario
   Fassone, Elisa
   Bordoni, Andreina
   Sciacco, Monica
   Lucchini, Valeria
   Di Fonzo, Alessio
   Rizzuti, Mafalda
   Colombo, Irene
   Napoli, Laura
   Ciscato, Patrizia
   Moggio, Maurizio
   Cosi, Alessandra
   Collotta, Martina
   Corti, Stefania
   Bresolin, Nereo
   Comi, Giacomo P.
TI Two novel mutations in <i>PEO1</i> (Twinkle) gene associated with
   chronic external ophthalmoplegia
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE Progressive external ophthalmoplegia; PEO1 (C100RF2); Mitochondrial
   myopathy; mtDNA multiple deletions; COX deficiency
ID MITOCHONDRIAL-DNA DEPLETION; MTDNA MAINTENANCE; OPTIC ATROPHY;
   DELETIONS; SPECTRUM; DISORDER; HELICASE; ATAXIA; ADPEO
AB Maintenance and replication of mitochondrial DNA require the concerted action of several factors encoded by nuclear genome. The mitochondrial helicase Twinkle is a key player of replisome machinery. Heterozygous mutations in its coding gene, PEO1, are associated with progressive external ophthalmoplegia (PEO) characterised by ptosis and ophthalmoparesis, with cytochrome c oxidase (COX)-deficient fibres, ragged-red fibres (RRF) and multiple mtDNA deletions in muscle. Here we describe clinical, histological and molecular features of two patients presenting with mitochondrial myopathy associated with PEO. PEO1 sequencing disclosed two novel mutations in exons 1 and 4 of the gene, respectively. Although mutations in PEO1 exon 1 have already been described, this is the first report of mutation occurring in exon 4. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Ronchi, Dario; Fassone, Elisa; Bordoni, Andreina; Sciacco, Monica; Lucchini, Valeria; Di Fonzo, Alessio; Rizzuti, Mafalda; Colombo, Irene; Napoli, Laura; Ciscato, Patrizia; Moggio, Maurizio; Cosi, Alessandra; Collotta, Martina; Corti, Stefania; Bresolin, Nereo; Comi, Giacomo P.] Univ Milan, Dept Neurol Sci, IRCCS Fdn Ca Granda Osped Maggiore Policlin, Dino Ferrari Ctr, I-20122 Milan, Italy.
   [Corti, Stefania; Bresolin, Nereo; Comi, Giacomo P.] Univ Milan, Ctr Excellence Neurodegenerat Dis, I-20122 Milan, Italy.
   [Bresolin, Nereo] IRCCS Eugenio Medea, Bosisio Parini, Lecco, Italy.
C3 IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan;
   University of Milan; IRCCS Eugenio Medea
RP Comi, GP (corresponding author), Univ Milan, Dept Neurol Sci, IRCCS Fdn Ca Granda Osped Maggiore Policlin, Dino Ferrari Ctr, Via Francesco Sforza 35, I-20122 Milan, Italy.
EM giacomo.comi@unimi.it
RI Ronchi, Dario/K-8011-2016; Sciacco, Monica/AAC-6500-2022; Di Fonzo,
   Alessio/A-5702-2013; Rizzuti, Mafalda/AAC-2407-2022; Comi,
   Giacomo/K-5702-2016; corti, stefania/K-6034-2016
OI Di Fonzo, Alessio/0000-0001-6478-026X; Ronchi,
   Dario/0000-0002-6093-9816; Rizzuti, Mafalda/0000-0001-5734-7476;
   Sciacco, Monica/0000-0003-4593-4977; Comi, Giacomo/0000-0002-1383-5248;
   Ripolone, Michela/0000-0001-9293-6823; Bresolin,
   Nereo/0000-0001-6694-3595; corti, stefania/0000-0001-5425-969X; Napoli,
   Laura/0000-0003-4607-8084
FU 'Associazione Amici del Centro Dino Ferrari'; Telethon [GTB07001ER];
   Eurobiobank [QLTR-2001-02769, GUP09004C]
FX Gratitude has to be expressed to the patients for participating in this
   research. We wish to thank especially the 'Associazione Amici del Centro
   Dino Ferrari' for their support. The financial support of the research
   grants of Telethon projects GTB07001ER, Eurobiobank project
   QLTR-2001-02769 and GUP09004C is gratefully acknowledged.
CR Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   Fratter C, 2010, NEUROLOGY, V74, P1619, DOI 10.1212/WNL.0b013e3181df099f
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Hudson G, 2008, BRAIN, V131, P329, DOI 10.1093/brain/awm272
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Lewis S, 2002, J NEUROL SCI, V201, P39, DOI 10.1016/S0022-510X(02)00190-9
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Martin-Negrier ML, 2011, EUR J NEUROL, V18, P436, DOI 10.1111/j.1468-1331.2010.03171.x
   Matsushima Y, 2008, J BIOL CHEM, V283, P23964, DOI 10.1074/jbc.M803674200
   Moraes CT, 2003, J MOL DIAGN, V5, P197, DOI 10.1016/S1525-1578(10)60474-6
   Nikali K, 2005, HUM MOL GENET, V14, P2981, DOI 10.1093/hmg/ddi328
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Rötig A, 2009, BBA-MOL BASIS DIS, V1792, P1103, DOI 10.1016/j.bbadis.2009.06.009
   Sarzi E, 2007, ANN NEUROL, V62, P579, DOI 10.1002/ana.21207
   Sciacco M, 2001, J NEUROL, V248, P778, DOI 10.1007/s004150170094
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Tyynismaa H, 2009, AM J HUM GENET, V85, P290, DOI 10.1016/j.ajhg.2009.07.009
   Virgilio R, 2008, J NEUROL, V255, P1384, DOI 10.1007/s00415-008-0926-3
   Wanrooij S, 2010, BBA-BIOENERGETICS, V1797, P1378, DOI 10.1016/j.bbabio.2010.04.015
NR 20
TC 8
Z9 9
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD SEP 15
PY 2011
VL 308
IS 1-2
BP 173
EP 176
DI 10.1016/j.jns.2011.05.042
PG 4
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 816IO
UT WOS:000294592100037
PM 21689831
OA hybrid, Green Published
DA 2024-11-01
ER

PT J
AU Roos, S
   Lindgren, U
   Ehrstedt, C
   Moslemi, AR
   Oldfors, A
AF Roos, S.
   Lindgren, U.
   Ehrstedt, C.
   Moslemi, A. R.
   Oldfors, A.
TI Mitochondrial DNA depletion in single fibers in a patient with novel
   <i>TK2</i> mutations
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE Mitochondrial DNA depletion syndrome; Myopathy; Thymidine kinase 2; TK2;
   Mitochondrial myopathy
ID MTDNA DEPLETION; THYMIDINE KINASE; COENZYME Q(10); GENE; DELETIONS;
   MYOPATHY; MUSCLE; DEFECTS
AB The mitochondrial DNA (mtDNA) depletion syndrome is a genetically heterogeneous group of diseases caused by nuclear gene mutations and secondary reduction in mtDNA copy number. We describe a patient with progressive muscle weakness and increased creatine kinase and lactate levels. Muscle weakness was first noted at age 1.5 years and he died of respiratory failure and bronchopneumonia at age 3.5 years. The muscle biopsy showed dystrophic features with ragged red fibers and numerous cytochrome c oxidase (COX)-negative fibers. qPCR analysis demonstrated depletion of mtDNA and sequence analysis of the mitochondrial thymidine kinase 2 (TK2) gene revealed two novel heterozygous variants, c.332C > T, p.(T111I) and c.156 + 5G > C. Quantitative analysis of mtDNA in single muscle fibers demonstrated that COX-deficient fibers showed more pronounced depletion of mtDNA when compared with fibers with residual COX activity (P < 0.01, n = 25). There was no evidence of manifestations from other organs than skeletal muscle although there was an apparent reduction of mtDNA copy number also in liver. The patient showed a pronounced, albeit transient, improvement in muscle strength after onset of treatment with coenzyme Q10, asparaginase, and increased energy intake, suggesting that nutritional modulation may be a therapeutic option in myopathic mtDNA depletion syndrome. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Roos, S.; Lindgren, U.; Moslemi, A. R.; Oldfors, A.] Univ Gothenburg, Sahlgrenska Acad, Inst Biomed, Dept Pathol, SE-41345 Gothenburg, Sweden.
   [Ehrstedt, C.] Uppsala Univ, Childrens Hosp, Dept Womens & Childrens Hlth, Uppsala, Sweden.
C3 University of Gothenburg; Uppsala University
RP Roos, S (corresponding author), Univ Gothenburg, Inst Biomed, Dept Pathol, Gula Straket 8, SE-41345 Gothenburg, Sweden.
EM sara.roos@gu.se
RI Lindgren, Ulrika/HJH-0146-2022; Ehrstedt, Christoffer/HSH-7252-2023
OI Ehrstedt, Christoffer/0000-0003-3063-3741
FU Swedish Research Council [07122]; WHI Sequencing Project [HL-102924];
   Broad GO Sequencing Project [HL-102925]; Seattle GO Sequencing Project
   [HL-102926]; Heart GO Sequencing Project [HL-103010]; Lung GO Sequencing
   Project [HL-102923]
FX This work was supported by the Swedish Research Council (grant number
   07122). The authors would like to thank the NHLBI GO Exome Sequencing
   Project and its ongoing studies which produced and provided exome
   variant calls for comparison: the Lung GO Sequencing Project
   (HL-102923), the WHI Sequencing Project (HL-102924), the Broad GO
   Sequencing Project (HL-102925), the Seattle GO Sequencing Project
   (HL-102926) and the Heart GO Sequencing Project (HL-103010).
CR Alberio S, 2007, MITOCHONDRION, V7, P6, DOI 10.1016/j.mito.2006.11.010
   Alston CL, 2013, NEUROLOGY, V81, P2051, DOI 10.1212/01.wnl.0000436931.94291.e6
   Béhin A, 2012, NEUROLOGY, V78, P644, DOI 10.1212/WNL.0b013e318248df2b
   Betts MJ, 2002, BIOINFORMATICS GENET, P289
   Blakely E, 2008, NEUROMUSCULAR DISORD, V18, P557, DOI 10.1016/j.nmd.2008.04.014
   Carrozzo R, 2003, HUM MUTAT, V21, DOI 10.1002/humu.9135
   Collins J, 2009, NEUROMUSCULAR DISORD, V19, P784, DOI 10.1016/j.nmd.2009.08.002
   Copeland WC, 2012, CRIT REV BIOCHEM MOL, V47, P64, DOI 10.3109/10409238.2011.632763
   Dimmock D, 2010, CLIN CHEM, V56, P1119, DOI 10.1373/clinchem.2009.141549
   Durham SE, 2005, NEUROLOGY, V65, P453, DOI 10.1212/01.wnl.0000171861.30277.88
   Fayet G, 2002, NEUROMUSCULAR DISORD, V12, P484, DOI 10.1016/S0960-8966(01)00332-7
   Galbiati S, 2006, PEDIATR NEUROL, V34, P177, DOI 10.1016/j.pediatrneurol.2005.07.013
   Götz A, 2008, BRAIN, V131, P2841, DOI 10.1093/brain/awn236
   Johansson K, 2001, NAT STRUCT BIOL, V8, P616, DOI 10.1038/89661
   Kollberg G, 2009, NEUROMUSCULAR DISORD, V19, P147, DOI 10.1016/j.nmd.2008.11.014
   Lesko N, 2010, NEUROMUSCULAR DISORD, V20, P198, DOI 10.1016/j.nmd.2009.11.013
   Mancuso M, 2003, ARCH NEUROL-CHICAGO, V60, P1007, DOI 10.1001/archneur.60.7.1007
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   MarinGarcia J, 1997, J INHERIT METAB DIS, V20, P674, DOI 10.1023/A:1005322409330
   Martí R, 2010, PEDIATR RES, V68, P151, DOI 10.1203/00006450-201011001-00294
   Montero R, 2013, MITOCHONDRION, V13, P337, DOI 10.1016/j.mito.2013.04.001
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Morava E, 2006, J INHERIT METAB DIS, V29, P589, DOI 10.1007/s10545-006-0227-x
   Murphy JL, 2012, NEUROMUSCULAR DISORD, V22, P690, DOI 10.1016/j.nmd.2012.04.003
   OLDFORS A, 1995, J NEUROPATH EXP NEUR, V54, P581, DOI 10.1097/00005072-199507000-00012
   Oskoui M, 2006, ARCH NEUROL-CHICAGO, V63, P1122, DOI 10.1001/archneur.63.8.1122
   Paradas C, 2013, NEUROLOGY, V80, P504, DOI 10.1212/WNL.0b013e31827f0ff7
   Pohjoismäki JLO, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010426
   Poulton J, 2009, BBA-MOL BASIS DIS, V1792, P1109, DOI 10.1016/j.bbadis.2009.08.016
   Poulton Joanna, 2009, Neuromuscul Disord, V19, P439, DOI 10.1016/j.nmd.2009.04.009
   Roos S, 2013, HUM MOL GENET, V22, P2411, DOI 10.1093/hmg/ddt094
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Saada-Reisch A, 2004, NUCLEOS NUCLEOT NUCL, V23, P1205, DOI 10.1081/NCN-200027480
   Sacconi S, 2010, NEUROMUSCULAR DISORD, V20, P44, DOI 10.1016/j.nmd.2009.10.014
   Santorelli FM, 2002, NEUROMUSCULAR DISORD, V12, P56, DOI 10.1016/S0960-8966(01)00248-6
   Sofou K, 2012, EUR J PAEDIATR NEURO, V16, P379, DOI 10.1016/j.ejpn.2011.12.006
   Stewart JD, 2011, BBA-MOL BASIS DIS, V1812, P321, DOI 10.1016/j.bbadis.2010.11.012
   Suomalainen A, 2010, NEUROMUSCULAR DISORD, V20, P429, DOI 10.1016/j.nmd.2010.03.017
   Tulinius M, 2005, NEUROMUSCULAR DISORD, V15, P412, DOI 10.1016/j.nmd.2005.03.010
   Tyynismaa H, 2012, HUM MOL GENET, V21, P66, DOI 10.1093/hmg/ddr438
   Vilà MR, 2003, NEUROLOGY, V60, P1203, DOI 10.1212/01.WNL.0000055928.58122.47
   Wang LY, 2005, MOL GENET METAB, V84, P75, DOI 10.1016/j.ymgme.2004.09.005
   Zhang SL, 2010, MOL GENET METAB, V99, P53, DOI 10.1016/j.ymgme.2009.09.003
NR 43
TC 10
Z9 14
U1 0
U2 6
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD AUG
PY 2014
VL 24
IS 8
BP 713
EP 720
DI 10.1016/j.nmd.2014.05.009
PG 8
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA AN1BH
UT WOS:000340317200009
PM 24953930
DA 2024-11-01
ER

PT J
AU Blakely, EL
   Butterworth, A
   Hadden, RDM
   Bodi, I
   He, LP
   McFarland, R
   Taylor, RW
AF Blakely, Emma L.
   Butterworth, Anna
   Hadden, Robert D. M.
   Bodi, Istvan
   He, Langping
   McFarland, Robert
   Taylor, Robert W.
TI <i>MPV17</i> mutation causes neuropathy and leukoencephalopathy with
   multiple mtDNA deletions in muscle
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE Mitochondrial DNA; mtDNA maintenance; Multiple mtDNA deletions;
   Neuropathy; COX-deficient fibres
ID MITOCHONDRIAL-DNA DEPLETION; PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA;
   THYMIDINE KINASE; GENE; PROTEIN; MYOPATHY; TWINKLE; DISEASE; CELLS; FORM
AB Disorders of mitochondrial DNA (mtDNA) maintenance are clinically and genetically heterogeneous, embracing recessive mtDNA depletion syndromes affecting children and adult-onset multiple mtDNA deletion disorders. Here we show that mutation of MPV17 - a gene implicated in severe, infantile hepatocerebral mtDNA depletion disorders characterised by a loss of mtDNA - copies can also cause clonally-expanded mtDNA deletion and focal cytochrome c oxidase (COX) deficiency in skeletal muscle associated with an adult presentation of neuropathy and leukoencephalopathy. The mpv17 protein is therefore intimately involved in both the mtDNA replication and repair processes and associated with both quantitative and qualitative mtDNA abnormalities. (c) 2012 Elsevier B.V. All rights reserved.
C1 [Blakely, Emma L.; Butterworth, Anna; He, Langping; McFarland, Robert; Taylor, Robert W.] Newcastle Univ, Sch Med, Inst Ageing & Hlth, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Hadden, Robert D. M.] Kings Coll Hosp, Dept Neurol, London SE5 9RS, England.
C3 Newcastle University - UK; King's College Hospital NHS Foundation Trust;
   King's College Hospital
RP Taylor, RW (corresponding author), Newcastle Univ, Sch Med, Inst Ageing & Hlth, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM robert.taylor@ncl.ac.uk
RI Hadden, Robert/F-4280-2010
OI McFarland, Robert/0000-0002-8833-2688; Bodi, Istvan/0000-0002-2533-4758;
   Hadden, Robert/0000-0002-9702-0256
FU Wellcome Trust Centre for Mitochondrial Research [906919]; UK NHS
   Specialised Services "Rare Mitochondrial Disorders of Adults and
   Children" Diagnostic Service; MRC [G0800674] Funding Source: UKRI
FX This work was supported by The Wellcome Trust Centre for Mitochondrial
   Research (906919), and the UK NHS Specialised Services "Rare
   Mitochondrial Disorders of Adults and Children" Diagnostic Service
   (http://www.mitochondrialncg.nhs.uk). We thank Mr. Gavin Falkous for
   excellent technical assistance.
CR Blakely E, 2008, NEUROMUSCULAR DISORD, V18, P557, DOI 10.1016/j.nmd.2008.04.014
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Copeland WC, 2008, ANNU REV MED, V59, P131, DOI 10.1146/annurev.med.59.053006.104646
   Dallabona C, 2010, HUM MOL GENET, V19, P1098, DOI 10.1093/hmg/ddp581
   El-Hattab AW, 2010, MOL GENET METAB, V99, P300, DOI 10.1016/j.ymgme.2009.10.003
   Karadimas CL, 2006, AM J HUM GENET, V79, P544, DOI 10.1086/506913
   Krishnan KJ, 2007, ANAL BIOCHEM, V370, P127, DOI 10.1016/j.ab.2007.06.024
   McFarland R, 2010, LANCET NEUROL, V9, P829, DOI 10.1016/S1474-4422(10)70116-2
   Navarro-Sastre A, 2008, MOL GENET METAB, V94, P234, DOI 10.1016/j.ymgme.2008.01.012
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Sarzi E, 2007, ANN NEUROL, V62, P579, DOI 10.1002/ana.21207
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Spinazzola A, 2008, ARCH NEUROL-CHICAGO, V65, P1108, DOI 10.1001/archneur.65.8.1108
   Suomalainen A, 2010, NEUROMUSCULAR DISORD, V20, P429, DOI 10.1016/j.nmd.2010.03.017
   Taylor RW, 2003, J CLIN INVEST, V112, P1351, DOI 10.1172/JCI200319435
   Tyynismaa H, 2012, HUM MOL GENET, V21, P66, DOI 10.1093/hmg/ddr438
   Tyynismaa H, 2009, AM J HUM GENET, V85, P290, DOI 10.1016/j.ajhg.2009.07.009
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Viscomi C, 2009, HUM MOL GENET, V18, P12, DOI 10.1093/hmg/ddn309
   Wong LJC, 2007, HEPATOLOGY, V46, P1218, DOI 10.1002/hep.21799
NR 22
TC 48
Z9 50
U1 1
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD JUL
PY 2012
VL 22
IS 7
BP 587
EP 591
DI 10.1016/j.nmd.2012.03.006
PG 5
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 975VH
UT WOS:000306539100002
PM 22508010
OA Green Published, hybrid
DA 2024-11-01
ER

PT J
AU Gervasoni, J
   Primiano, A
   Marini, F
   Sabino, A
   Biancolillo, A
   Calvani, R
   Picca, A
   Marzetti, E
   Persichilli, S
   Urbani, A
   Servidei, S
   Primiano, G
AF Gervasoni, Jacopo
   Primiano, Aniello
   Marini, Federico
   Sabino, Andrea
   Biancolillo, Alessandra
   Calvani, Riccardo
   Picca, Anna
   Marzetti, Emanuele
   Persichilli, Silvia
   Urbani, Andrea
   Servidei, Serenella
   Primiano, Guido
TI Fourier-Transform Infrared Spectroscopy of Skeletal Muscle Tissue:
   Expanding Biomarkers in Primary Mitochondrial Myopathies
SO GENES
LA English
DT Article
DE mitochondrial diseases; FTIR; biomarkers; metabolomics; differential
   diagnosis; mtDNA; oculopharyngeal muscular dystrophy (OPMD); progressive
   external ophthalmoplegia (PEO); personalized medicine
ID DNA; DELETIONS; DISEASE; TOOL
AB Primary mitochondrial myopathies (PMM) are a group of mitochondrial disorders characterized by a predominant skeletal muscle involvement. The aim of this study was to evaluate whether the biochemical profile determined by Fourier-transform infrared (FTIR) spectroscopic technique would allow to distinguish among patients affected by progressive external ophthalmoplegia (PEO), the most common PMM presentation, oculopharyngeal muscular dystrophy (OPMD), and healthy controls. Thirty-four participants were enrolled in the study. FTIR spectroscopy was found to be a sensitive and specific diagnostic marker for PEO. In particular, FTIR spectroscopy was able to distinguish PEO patients from those affected by OPMD, even in the presence of histological findings similar to mitochondrial myopathy. At the same time, FTIR spectroscopy differentiated single mtDNA deletion and mutations in POLG, the most common nuclear gene associated with mitochondrial diseases, with high sensitivity and specificity. In conclusion, our data suggest that FTIR spectroscopy is a valuable biodiagnostic tool for the differential diagnosis of PEO with a high ability to also distinguish between single mtDNA deletion and mutations in POLG gene based on specific metabolic transitions.
C1 [Gervasoni, Jacopo; Primiano, Aniello; Calvani, Riccardo; Picca, Anna; Marzetti, Emanuele; Persichilli, Silvia; Urbani, Andrea; Servidei, Serenella; Primiano, Guido] Fdn Policlin Univ A Gemelli IRCCS, I-00168 Rome, Italy.
   [Primiano, Aniello; Sabino, Andrea; Marzetti, Emanuele; Persichilli, Silvia; Urbani, Andrea; Servidei, Serenella; Primiano, Guido] Univ Cattolica Sacro Cuore, I-00168 Rome, Italy.
   [Marini, Federico] Sapienza Univ Roma, Dept Chem, I-00185 Rome, Italy.
   [Biancolillo, Alessandra] Univ Aquila, Dept Phys & Chem Sci, I-67100 Laquila, Italy.
   [Calvani, Riccardo; Picca, Anna] Karolinska Inst, Dept Neurobiol Care Sci & Soc, Aging Res Ctr, S-17177 Stockholm, Sweden.
   [Calvani, Riccardo; Picca, Anna] Stockholm Univ, S-17177 Stockholm, Sweden.
C3 Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli;
   Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli;
   Sapienza University Rome; University of L'Aquila; Karolinska Institutet;
   Stockholm University
RP Primiano, G (corresponding author), Fdn Policlin Univ A Gemelli IRCCS, I-00168 Rome, Italy.; Primiano, G (corresponding author), Univ Cattolica Sacro Cuore, I-00168 Rome, Italy.
EM jacopo.gervasoni@policlinicogemelli.it; aniello.primiano@unicatt.it;
   federico.marini@uniroma1.it; andrea.sabino@unicatt.it;
   alessandra.biancolilllo@univaq.it;
   riccardo.calvani@guest.policlinicogemelli.it;
   anna.picca@guest.policlinicogemelli.it;
   emanuele.marzetti@policlinicogemelli.it;
   silvia.persichilli@policlinicogemelli.it;
   andrea.urbani@policlinicogemelli.it; serenella.servidei@unicatt.it;
   guidoalessandro.primiano@policlinicogemelli.it
RI Servidei, Serenella/ABC-4262-2021; Gervasoni, Jacopo/K-7251-2016;
   Marini, Federico/I-3384-2012; Primiano, Guido/AAB-7829-2019; Primiano,
   Aniello/AAC-3548-2022; Persichilli, Silvia/AAB-3908-2019; Biancolillo,
   Alessandra/AAN-5781-2020; Urbani, Andrea/AAD-1675-2022; Calvani,
   Riccardo/K-2011-2018; Picca, Anna/K-2305-2018; Marzetti,
   Emanuele/A-9430-2010
OI Persichilli, Silvia/0000-0002-7955-8810; Calvani,
   Riccardo/0000-0001-5472-2365; Picca, Anna/0000-0001-7032-3487; SERVIDEI,
   Serenella/0000-0001-8478-2799; Marzetti, Emanuele/0000-0001-9567-6983;
   Primiano, Aniello/0000-0001-9415-9175; Primiano,
   Guido/0000-0001-7616-7008; Marini, Federico/0000-0001-8266-1117
FU  [870177]
FX G.P. and S.S. are members of the European Reference Network for
   Neuromuscular Diseases-Project ID No 870177.
CR [Anonymous], 2020, J INHERIT METAB 1118
   Cocchi M., 2018, Compr. Anal. Chem, V82, P265, DOI [10.1016/bs.coac.2018.08.006, DOI 10.1016/BS.COAC.2018.08.006]
   De Vries MC, 2020, J INHERIT METAB DIS, V43, P800, DOI 10.1002/jimd.12196
   Fisher RA, 1936, ANN EUGENIC, V7, P179, DOI 10.1111/j.1469-1809.1936.tb02137.x
   Gorman GS, 2016, NAT REV DIS PRIMERS, V2, P1, DOI 10.1038/nrdp.2016.80
   Gorman GS, 2015, ANN NEUROL, V77, P753, DOI 10.1002/ana.24362
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Lightowlers RN, 2015, SCIENCE, V349, P1494, DOI 10.1126/science.aac7516
   Mancuso M, 2017, NEUROMUSCULAR DISORD, V27, P1126, DOI 10.1016/j.nmd.2017.08.006
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Orsucci D, 2017, J NEUROL, V264, P1777, DOI 10.1007/s00415-017-8567-z
   Parikh S, 2017, GENET MED, V19, DOI 10.1038/gim.2017.107
   Primiano A, 2014, DIS MARKERS, V2014, DOI 10.1155/2014/176165
   Roger JM, 2011, CHEMOMETR INTELL LAB, V106, P216, DOI 10.1016/j.chemolab.2010.10.003
   Romanò S, 2020, ANAL CHIM ACTA, V1140, P219, DOI 10.1016/j.aca.2020.09.037
   Schon KR, 2020, TRENDS GENET, V36, P702, DOI 10.1016/j.tig.2020.06.009
   Sjostrom M., 1986, PATTERN RECOGN, P461
   Smit S, 2007, ANAL CHIM ACTA, V592, P210, DOI 10.1016/j.aca.2007.04.043
   Szymanska E, 2012, METABOLOMICS, V8, pS3, DOI 10.1007/s11306-011-0330-3
   Wold S, 2001, CHEMOMETR INTELL LAB, V58, P109, DOI 10.1016/S0169-7439(01)00155-1
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 22
TC 7
Z9 7
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4425
J9 GENES-BASEL
JI Genes
PD DEC
PY 2020
VL 11
IS 12
AR 1522
DI 10.3390/genes11121522
PG 8
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA PJ8HC
UT WOS:000602000400001
PM 33352713
OA Green Published, gold
DA 2024-11-01
ER

PT J
AU Slee, M
   Finkemeyer, J
   Krupa, M
   Raghupathi, R
   Gardner, J
   Blumbergs, P
   Agzarian, M
   Thyagarajan, D
AF Slee, M.
   Finkemeyer, J.
   Krupa, M.
   Raghupathi, R.
   Gardner, J.
   Blumbergs, P.
   Agzarian, M.
   Thyagarajan, D.
TI A novel mitochondrial DNA deletion producing progressive external
   ophthalmoplegia associated with multiple sclerosis
SO JOURNAL OF CLINICAL NEUROSCIENCE
LA English
DT Article
DE Mitochondrial disease; Multiple sclerosis; Progressive external
   ophthalmoplegia
ID HEREDITARY OPTIC NEUROPATHY; KEARNS-SAYRE-SYNDROME; WHITE-MATTER
   DISEASE; PARKINSONS-DISEASE; COMPLEX-I; MUTATIONS; COMBINATION;
   DISORDER; RISK; GENE
AB We report a previously undescribed 7676 base pair mitochondria! (mt)DNA deletion involving genes of complex I, complex IV subunits 2 and 3 (cytochrome oxidase [Cox] II, III), adenosine triphosphatase 8 and 6, cytochrome b and 8 transfer (t)RNA genes producing myopathy and progressive external ophthalmoplegia (PEO) in a 44-year-old right-handed Caucasian man with features of multiple sclerosis (MS). We performed complete mtDNA sequencing and deletion analysis, spectrophotometric analysis of muscle and platelet respiratory chain activity, measurement of platelet mitochondrial membrane potential with the potentiometric dye JC-1 and magnetic resonance spectroscopy (MRS) and MRI studies of normal-appearing and lesional cerebral tissue. The deletion resulted in significant respiratory chain deficiency in muscle and blood and abnormalities of the platelet mitochondrial membrane potential. However, cerebrospinal fluid analysis, magnetic resonance spectroscopy and MRI features suggested inflammatory central nervous system demyelination rather than a primary respiratory chain disorder. We conclude that this novel mtDNA deletion causing myopathy and PEO is associated with severe muscle and platelet cellular energetic abnormalities. Furthermore, clinical and paraclinical features of multiple sclerosis were found. The potential pathomechanistic interaction between mtDNA variation and multiple sclerosis is reviewed. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Slee, M.; Raghupathi, R.; Thyagarajan, D.] Flinders Univ S Australia, Dept Human Physiol, Adelaide, SA, Australia.
   [Slee, M.; Krupa, M.; Thyagarajan, D.] Flinders Med Ctr, Dept Neurol, Bedford Pk, SA 5042, Australia.
   [Finkemeyer, J.] Flinders Univ S Australia, Sch Med, Adelaide, SA, Australia.
   [Blumbergs, P.] Univ Adelaide, Hanson Inst Neurol Dis, Adelaide, SA 5005, Australia.
   [Agzarian, M.] Flinders Med Ctr, Div Med Imaging, Bedford Pk, SA, Australia.
C3 Flinders University South Australia; Flinders Medical Centre; Flinders
   University South Australia; Hanson Institute; University of Adelaide;
   Flinders Medical Centre
RP Slee, M (corresponding author), Flinders Univ S Australia, Dept Human Physiol, Adelaide, SA, Australia.
EM mark.slee@flinders.edu.au
RI Thyagarajan, Dominic/H-6633-2014; Slee, Mark/J-4731-2015
OI Slee, Mark/0000-0003-4323-2453
FU Multiple Sclerosis Research Australia; Flinders University of South
   Australia; Government of Australia
FX This research is supported by grants from Multiple Sclerosis Research
   Australia and Flinders University of South Australia (M. Slee and D.
   Thyagarajan). R. Raghupathi is supported by an Endeavour International
   Postgraduate Research Scholarship from the Government of Australia. The
   authors wish to thank Mr Matthew Le Krupa for assistance with the
   figures.
CR Ban M, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002891
   BET L, 1994, J NEUROL, V241, P511, DOI 10.1007/BF00919714
   Bhatti MT, 1999, J NEURO-OPHTHALMOL, V19, P28
   Buhmann C, 2002, ACTA NEUROL SCAND, V106, P236, DOI 10.1034/j.1600-0404.2002.01323.x
   D'Aguanno S, 2008, J NEUROIMMUNOL, V193, P156, DOI 10.1016/j.jneuroim.2007.10.004
   Ebers GC, 2004, LANCET, V363, P1773, DOI 10.1016/S0140-6736(04)16304-6
   Hoppenbrouwers IA, 2008, ARCH NEUROL-CHICAGO, V65, P345, DOI 10.1001/archneurol.2007.63
   Horváth R, 2000, J NEUROL, V247, P65, DOI 10.1007/s004150050015
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Huoponen K, 2001, NEUROGENETICS, V3, P119, DOI 10.1007/s100480100115
   Hwang JM, 2001, OPHTHALMOLOGICA, V215, P398, DOI 10.1159/000050896
   Jamrozik Zygmunt, 2003, Neurol Neurochir Pol, V37, P713
   Khusnutdinova E, 2008, ANN NY ACAD SCI, V1147, P1, DOI 10.1196/annals.1427.001
   Kovács GG, 2005, BRAIN, V128, P35, DOI 10.1093/brain/awh310
   KRIGE D, 1992, ANN NEUROL, V32, P782, DOI 10.1002/ana.410320612
   Küker W, 2007, EUR J NEUROL, V14, P591, DOI 10.1111/j.1468-1331.2007.01757.x
   Miller DH, 2007, LANCET NEUROL, V6, P903, DOI 10.1016/S1474-4422(07)70243-0
   Mojon DS, 1999, GRAEF ARCH CLIN EXP, V237, P348, DOI 10.1007/s004170050243
   Mojon DS, 1999, OPHTHALMOLOGICA, V213, P171, DOI 10.1159/000027414
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Nicholls DG, 2000, TRENDS NEUROSCI, V23, P166, DOI 10.1016/S0166-2236(99)01534-9
   OLSEN NK, 1995, ACTA NEUROL SCAND, V91, P326, DOI 10.1111/j.1600-0404.1995.tb07016.x
   Parry-Jones A R, 2008, Pract Neurol, V8, P118, DOI 10.1136/jnnp.2007.139360
   Perez F, 2009, CLIN NEUROL NEUROSUR, V111, P83, DOI 10.1016/j.clineuro.2008.06.021
   Porcelli AM, 2009, J BIOL CHEM, V284, P2045, DOI 10.1074/jbc.M807321200
   Saneto RP, 2008, MITOCHONDRION, V8, P396, DOI 10.1016/j.mito.2008.05.003
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   Sheremata WA, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-27
   Tanji K, 2000, J NEUROL SCI, V178, P29, DOI 10.1016/S0022-510X(00)00354-3
   Taylor RW, 1998, BIOCHEM BIOPH RES CO, V243, P47, DOI 10.1006/bbrc.1997.8055
   Thyagarajan D, 2002, INT REV NEUROBIOL, V53, P93
   Tran M, 2001, AM J OPHTHALMOL, V132, P591, DOI 10.1016/S0002-9394(01)01045-5
   TROUNCE I, 1996, MITOCHONDRIAL BIOGEN, P484
   Vanopdenbosch L, 2000, J NEUROL, V247, P535, DOI 10.1007/s004150070153
   Verhoeven AJ, 2005, TRANSFUSION, V45, P82, DOI 10.1111/j.1537-2995.2005.04023.x
   Verny C, 2008, NEUROLOGY, V70, P1152, DOI 10.1212/01.wnl.0000289194.89359.a1
   Vyshkina T, 2005, J NEUROL SCI, V228, P55, DOI 10.1016/j.jns.2004.09.027
   Wallace DC, 2001, MENT RETARD DEV D R, V7, P158, DOI 10.1002/mrdd.1023
   Yu XH, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001530
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
NR 40
TC 15
Z9 17
U1 0
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0967-5868
J9 J CLIN NEUROSCI
JI J. Clin. Neurosci.
PD OCT
PY 2011
VL 18
IS 10
BP 1318
EP 1324
DI 10.1016/j.jocn.2011.02.019
PG 7
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 824FX
UT WOS:000295188900007
PM 21795050
DA 2024-11-01
ER

PT J
AU Montano, V
   Simoncini, C
   Calì, CL
   Legati, A
   Siciliano, G
   Mancuso, M
AF Montano, V.
   Simoncini, C.
   Cali, Cassi L.
   Legati, A.
   Siciliano, G.
   Mancuso, M.
TI CPEO and Mitochondrial Myopathy in a Patient with <i>DGUOK</i> Compound
   Heterozygous Pathogenetic Variant and mtDNA Multiple Deletions
SO CASE REPORTS IN NEUROLOGICAL MEDICINE
LA English
DT Article
ID DNA DEPLETION; OPTIC ATROPHY; MOLECULAR-FEATURES; MUTATIONS;
   INSTABILITY; GENE
AB The classic features of deoxyguanosine kinase (DGUOK) deficiency are infantile onset hepatic failure with nystagmus and hypotonia; mitochondrial DNA studies on affected tissue reveal mitochondrial DNA depletion. Later, it has been shown that the mutations in the same gene may present with adult-onset mitochondrial myopathy and mitochondrial DNA multiple deletions in skeletal muscle. Here we report the case of a 42-year-old Italian woman presenting with a chronic progressive external ophthalmoplegia and myopathy with mtDNA multiple deletions and the compound heterozygous c.462T>A (p.Asn154Lys) and c.707+2T>G pathogenic variants in DGUOK.
C1 [Montano, V.; Simoncini, C.; Siciliano, G.; Mancuso, M.] Univ Pisa, Dept Clin & Expt Med, Neurol Clin, Pisa, Italy.
   [Cali, Cassi L.] Univ Pisa, Dept Hand Surg & Reconstruct Microsurg, Pisa, Italy.
   [Legati, A.] Fdn IRCCS Ist Neurol C Besta, Unit Med Genet & Neurogenet, Milan, Italy.
C3 University of Pisa; University of Pisa; Fondazione IRCCS Istituto
   Neurologico Carlo Besta
RP Mancuso, M (corresponding author), Univ Pisa, Dept Clin & Expt Med, Neurol Clin, Pisa, Italy.
EM v.montano89@gmail.com; costanza.simoncini85@gmail.com;
   lorenzo.cali.cassi@gmail.com; Andrea.Legati@istituto-besta.it;
   g.siciliano@med.unipi.it; mancusomichelangelo@gmail.com
RI Mancuso, Michelangelo/K-4170-2016; Montano, Vincenzo/AAB-8681-2022;
   Legati, Andrea/K-2181-2016
OI Montano, Vincenzo/0000-0002-7548-7699; Legati,
   Andrea/0000-0002-8178-6126
FU Telethon Grant [GUP09004]; Telethon-MITOCON Grant [GSP16001]
FX This work was partially supported by Telethon Grant (GUP09004) and
   Telethon-MITOCON Grant (GSP16001).
CR Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   Buchaklian AH, 2012, MOL GENET METAB, V107, P92, DOI 10.1016/j.ymgme.2012.04.019
   Caporali L, 2018, BRAIN, V141, DOI 10.1093/brain/awx301
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Dimmock DP, 2008, HUM MUTAT, V29, P330, DOI 10.1002/humu.9519
   El-Hattab A, 2013, NEUROTHERAPEUTICS, V10, P186, DOI 10.1007/s13311-013-0177-6
   Gorman GS, 2015, ANN NEUROL, V77, P753, DOI 10.1002/ana.24362
   Hudson G, 2008, BRAIN, V131, P329, DOI 10.1093/brain/awm272
   Krishnan KJ, 2008, NAT GENET, V40, P275, DOI 10.1038/ng.f.94
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Nogueira C, 2014, ITAL J PEDIATR, V40, DOI 10.1186/1824-7288-40-34
   Ronchi D, 2012, BRAIN, V135, P3404, DOI 10.1093/brain/aws258
   Rouzier C, 2012, BRAIN, V135, P23, DOI 10.1093/brain/awr323
   Spinazzola A, 2009, J INHERIT METAB DIS, V32, P143, DOI 10.1007/s10545-008-1038-z
   Vilarinho S, 2016, HEPATOLOGY, V63, P1977, DOI 10.1002/hep.28499
   Yu-Wai-Man P, 2012, BRAIN, V135, P9, DOI 10.1093/brain/awr352
NR 16
TC 4
Z9 4
U1 0
U2 3
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-6668
EI 2090-6676
J9 CASE REP NEUROL MED
JI Case Rep. Neurol. Med.
PY 2019
VL 2019
AR 5918632
DI 10.1155/2019/5918632
PG 4
WC Clinical Neurology
WE Emerging Sources Citation Index (ESCI)
SC Neurosciences & Neurology
GA HP3ZE
UT WOS:000461615400001
PM 30956829
OA gold, Green Published, Green Submitted
DA 2024-11-01
ER

PT J
AU Van Hove, JLK
   Cunningham, V
   Rice, C
   Ringel, SP
   Zhang, Q
   Chou, PC
   Truong, CK
   Wong, LJC
AF Van Hove, Johan L. K.
   Cunningham, Vicki
   Rice, Cathlin
   Ringel, Steven P.
   Zhang, Qing
   Chou, Ping-Chieh
   Truong, Cavatina K.
   Wong, Lee-Jun C.
TI Finding <i>Twinkle</i> in the Eyes of a 71-Year-Old Lady: A Case Report
   and Review of the Genotypic and Phenotypic Spectrum of
   <i>TWINKLE</i>-Related Dominant Disease
SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A
LA English
DT Article
DE twinkle; helicase; opthalmoplegia; genotype; mitochondrial DNA;
   deletions; depletion; phenotypic spectrum
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; DNA-POLYMERASE-GAMMA;
   MITOCHONDRIAL-DNA; MULTIPLE DELETIONS; GENE MUTATION; HELICASE TWINKLE;
   MTDNA DELETIONS; POLG; REPLICATION; DEPLETION
AB Progressive external ophthalmoplegia (PEO) call be caused by a disorder characterized by multiple mitochondrial DNA (mtDNA) deletions due to mutations in the TWINKLE gene, encoding a mtDNA helicase. We describe a 71-year-old woman who had developed PEO at age 55 years. She had cataracts, diabetes, paresthesias, cognitive defects, memory problems, hearing loss, and sensory ataxia. She had muscle weakness with ragged red fibers oil biopsy. MRI showed static white matter changes. A c.908G > A substitution (p.R303Q) in the TWINKLE gene was identified. Multiple mtDNA deletions were detected ill muscle but not blood by a PCR-based method, but not by Southern blot analysis. MtDNA copy number was maintained ill blood and muscle. A systematic literature search was used to identify the genotypic and phenotypic spectrum of dominant disease. Patients were adults with PEO and symptoms including myopathy, neuropathy, dysarthria or dysphagia, sensory ataxia, and parkinsonism. Diabetes, cataract, memory loss, hearing loss, and cardiac problems were infrequent. All reported mutations clustered between amino acids 303 and 508 with no mutations at the N-terminal half of the gene. The TWINKLE gene should be analyzed in adults with PEO even in the absence of mtDNA deletions in muscle oil Southern blot analysis, and of a family history for PEO. The pathogenic mutations identified 5' beyond the linker region suggest a functional role for this part of the protein despite the absence of a primase function in humans. In our patient,the pathogenesis involved multiple mtDNA deletions without reduction in mtDNA copy number. (c) 2009 Wiley-Liss, hic.
C1 [Van Hove, Johan L. K.; Cunningham, Vicki; Rice, Cathlin] Univ Colorado, Dept Pediat, Denver, CO 80202 USA.
   [Ringel, Steven P.] Univ Colorado, Dept Neurol, Denver, CO 80202 USA.
   [Zhang, Qing; Chou, Ping-Chieh; Truong, Cavatina K.; Wong, Lee-Jun C.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
C3 University of Colorado System; University of Colorado Denver; University
   of Colorado System; University of Colorado Denver; Baylor College of
   Medicine
RP Van Hove, JLK (corresponding author), Univ Colorado Denver Fitzsimmons, Dept Pediat, Sect Clin Genet & Metab, Mail Stop 8313,RC-1 N,12800 E 19th Ave,Room P18-4, Aurora, CO 80045 USA.
EM johan.vanhove@ucdenver.edu
RI ZHANG, QING/AGY-7972-2022
FU United Mitochondrial Disease Foundation
FX The authors wish to thank the United Mitochondrial Disease Foundation
   for their Support.
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   Angst J, 1999, J CLIN PSYCHIAT, V60, P5
   Arenas J, 2003, ANN NEUROL, V53, P278, DOI 10.1002/ana.10430
   Bai RK, 2005, J MOL DIAGN, V7, P613, DOI 10.1016/S1525-1578(10)60595-8
   Baloh RH, 2007, ARCH NEUROL-CHICAGO, V64, P998, DOI 10.1001/archneur.64.7.998
   Deschauer M, 2003, NEUROMUSCULAR DISORD, V13, P568, DOI 10.1016/S0960-8966(03)00071-3
   Farge G, 2007, NUCLEIC ACIDS RES, V35, P902, DOI 10.1093/nar/gkl1116
   Garrido N, 2003, MOL BIOL CELL, V14, P1583, DOI 10.1091/mbc.E02-07-0399
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   Hirano M, 2001, NEUROLOGY, V57, P2163, DOI 10.1212/WNL.57.12.2163
   Houshmand M, 2006, NEUROL INDIA, V54, P182
   Hudson G, 2005, NEUROLOGY, V64, P371, DOI 10.1212/01.WNL.0000149767.51152.83
   Jeppesen TD, 2008, NEUROMUSCULAR DISORD, V18, P306, DOI 10.1016/j.nmd.2007.10.007
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kessler RC, 2003, JAMA-J AM MED ASSOC, V289, P3095, DOI 10.1001/jama.289.23.3095
   Kiechl S, 2004, J NEUROL NEUROSUR PS, V75, P1125, DOI 10.1136/jnnp.2003.025890
   Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257
   Korhonen JA, 2003, J BIOL CHEM, V278, P48627, DOI 10.1074/jbc.M306981200
   Lewis S, 2002, J NEUROL SCI, V201, P39, DOI 10.1016/S0022-510X(02)00190-9
   Li FY, 1999, NEUROLOGY, V53, P1265, DOI 10.1212/WNL.53.6.1265
   Liang MH, 1998, AM J MED GENET, V77, P395, DOI 10.1002/(SICI)1096-8628(19980605)77:5<395::AID-AJMG8>3.0.CO;2-M
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Naïmi M, 2006, EUR J HUM GENET, V14, P917, DOI 10.1038/sj.ejhg.5201627
   Nikali K, 2005, HUM MOL GENET, V14, P2981, DOI 10.1093/hmg/ddi328
   Rivera H, 2007, NEUROMUSCULAR DISORD, V17, P677, DOI 10.1016/j.nmd.2007.05.006
   Sarzi E, 2007, ANN NEUROL, V62, P579, DOI 10.1002/ana.21207
   Shutt TE, 2006, J MOL EVOL, V62, P588, DOI 10.1007/s00239-005-0162-8
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
   Tyynismaa H, 2004, HUM MOL GENET, V13, P3219, DOI 10.1093/hmg/ddh342
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, HUM MUTAT, V22, P175, DOI 10.1002/humu.10246
   Virgilio R, 2008, J NEUROL, V255, P1384, DOI 10.1007/s00415-008-0926-3
   Wanrooij S, 2004, NUCLEIC ACIDS RES, V32, P3053, DOI 10.1093/nar/gkh634
   Wanrooij S, 2007, NUCLEIC ACIDS RES, V35, P3238, DOI 10.1093/nar/gkm215
   Wong LJC, 2007, HEPATOLOGY, V46, P1218, DOI 10.1002/hep.21799
   Wong LJC, 2008, HUM MUTAT, V29, pE150, DOI 10.1002/humu.20824
   Wong LJC, 1997, CLIN CHEM, V43, P1857
   Wong LJC, 2005, CLIN CHIM ACTA, V354, P1, DOI 10.1016/j.cccn.2004.11.003
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 42
TC 44
Z9 46
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1552-4825
EI 1552-4833
J9 AM J MED GENET A
JI Am. J. Med. Genet. A
PD MAY
PY 2009
VL 149A
IS 5
BP 861
EP 867
DI 10.1002/ajmg.a.32731
PG 7
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 441YG
UT WOS:000265805900008
PM 19353676
DA 2024-11-01
ER

PT J
AU Lang, T
   Laver, N
   Strominger, MB
   Witking, A
   Pfannl, R
   Alroy, J
AF Lang, Tee
   Laver, Nora
   Strominger, Mitchell B.
   Witking, Andre
   Pfannl, Rolf
   Alroy, Joseph
TI Morphological Findings of Extraocular Myopathy with Chronic Progressive
   External Ophthalmoplegia
SO ULTRASTRUCTURAL PATHOLOGY
LA English
DT Article
DE CPEO; mitochondria; ultrastructure
ID KEARNS-SAYRE-SYNDROME; MITOCHONDRIAL; DIAGNOSIS; MUSCLE; PATHOLOGY;
   BIOPSY
AB Mitochondrial diseases are a large group of disorders resulting from mutations of nuclear DNA (nDNA) and mitochondrial DNA (mtDNA). Patients present clinically with multiple manifestations, including myopathies and multiple system disorders. Establishing a specific diagnosis often requires extensive clinical and laboratory evaluation. In this study of 2 adult patients with presumptive mitochondrial disease, the authors have identified distinctive morphological changes in medial rectus muscle biopsies that confirm the diagnosis of chronic progressive external ophthalmoplegia (CPEO). These findings demonstrate the usefulness of electron microscopy using medial rectus muscle in the diagnosis of adult patients with a slowly progressive course of mild skeletal weakness and CPEO.</.
C1 [Lang, Tee; Laver, Nora; Pfannl, Rolf; Alroy, Joseph] Tufts Univ, Sch Med, Dept Pathol, Boston, MA 02111 USA.
   [Lang, Tee; Laver, Nora; Strominger, Mitchell B.; Witking, Andre; Pfannl, Rolf; Alroy, Joseph] Tufts Med Ctr, Boston, MA USA.
   [Alroy, Joseph] Tufts Univ, Cummings Sch Vet Med, Dept Biomed Sci, Grafton, MA USA.
   [Strominger, Mitchell B.; Witking, Andre] Tufts Univ, Sch Med, New England Eye Ctr, Boston, MA 02111 USA.
C3 Tufts University; Tufts Medical Center; Tufts University; Tufts
   University
RP Alroy, J (corresponding author), Tufts Univ, Sch Med, Dept Pathol, Boston, MA 02111 USA.
EM joseph.alroy@tufts.edu
RI lang, tu/GVU-5255-2022
CR BRIL V, 1984, CAN J NEUROL SCI, V11, P390, DOI 10.1017/S0317167100045789
   Cardaioli E, 2008, J NEUROL SCI, V272, P106, DOI 10.1016/j.jns.2008.05.005
   Carta A, 2000, ARCH OPHTHALMOL-CHIC, V118, P1441
   CHANG TS, 1993, ARCH OPHTHALMOL-CHIC, V111, P1254, DOI 10.1001/archopht.1993.01090090106028
   CHARLES R, 1981, CIRCULATION, V63, P214, DOI 10.1161/01.CIR.63.1.214
   Di Mauro S., 2004, MYOLOGY PHILADELPHIA, P1623
   Fosslien E, 2001, ANN CLIN LAB SCI, V31, P25
   Haas RH, 2008, MOL GENET METAB, V94, P16, DOI 10.1016/j.ymgme.2007.11.018
   Kyriacou K, 1999, ULTRASTRUCT PATHOL, V23, P163
   LINDAL S, 1992, ULTRASTRUCT PATHOL, V16, P263, DOI 10.3109/01913129209061355
   Lloreta-Trull J, 1998, ULTRASTRUCT PATHOL, V22, P357, DOI 10.3109/01913129809103357
   Munnich A., 2001, METABOLIC MOL BASES, P2261
   REICHMANN H, 1993, ACTA NEUROPATHOL, V85, P679, DOI 10.1007/BF00334681
   Scaglia F, 2004, PEDIATRICS, V114, P925, DOI 10.1542/peds.2004-0718
   SCHWARTZKOPFF B, 1988, J AM COLL CARDIOL, V12, P1522, DOI 10.1016/S0735-1097(88)80020-2
   Shoffner JM, 2001, METABOLIC MOL BASES, P2367
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   Vogel H, 2001, J NEUROPATH EXP NEUR, V60, P217, DOI 10.1093/jnen/60.3.217
   Wabbels B, 2008, OPHTHALMOLOGE, V105, P550, DOI 10.1007/s00347-007-1643-5
   Wallace D.C., 2001, The Metabolic and Molecular Basis of Inherited Disease, P2425
   Wredenberg A, 2002, P NATL ACAD SCI USA, V99, P15066, DOI 10.1073/pnas.232591499
NR 21
TC 1
Z9 2
U1 0
U2 1
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0191-3123
EI 1521-0758
J9 ULTRASTRUCT PATHOL
JI Ultrastruct. Pathol.
PD APR
PY 2010
VL 34
IS 2
BP 78
EP 81
DI 10.3109/01913121003624684
PG 4
WC Microscopy; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Microscopy; Pathology
GA 562QF
UT WOS:000275067000005
PM 20192704
DA 2024-11-01
ER

PT J
AU Van Goethem, G
AF Van Goethem, Gert
TI Autosomal disorders of mitochondrial DNA maintenance
SO ACTA NEUROLOGICA BELGICA
LA English
DT Review
DE mitochondrial DNA; depletion; multiple mtDNA deletions; progressive
   external opthalmoplegia; sensory ataxic neuropathy; Alpers' syndrome;
   MNGIE
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; ONSET SPINOCEREBELLAR ATAXIA;
   POLYMERASE-GAMMA MUTATIONS; MULTIPLE DELETIONS; POLG MUTATIONS;
   NEUROGASTROINTESTINAL ENCEPHALOMYOPATHY; DILATED CARDIOMYOPATHY; SENSORY
   NEUROPATHY; GENETIC FEATURES; MTDNA DELETIONS
AB Mitochondrial DNA (mtDNA) is maternally inherited. After birth, secondary mtDNA defects can arise. MONA depletion is a reduction in the amount of mtDNA in particular tissues. Multiple deletions of mtDNA accumulate as somatic mutations in mainly postmitotic tissues. These disorders of mtDNA maintenance frequently show Mendelian inheritance. Positional cloning has identified several genes involved in the control of mtDNA stability.
   Recessive mutations in the genes ECGF1, dGK, TK2, SUCLA2 and POLG cause mtDNA depletion syndromes (MDS). Generally, MDS has infantile onset tissue specific features. Mutations in the genes ECGF1, ANT1, C10orf2 and POLG are associated with multiple mtDNA deletions. The nature of these mutations is dominant in ANTI, C10orf2 and POLG and recessive in ECGF1, C10orf2 and POLG. Mutations in these genes frequently cause progressive external ophthalmoplegia (PEO). However clinical heterogeneity results in different neurological syndromes with considerable overlap. The most common features are PEO, neuropathy, myopathy, ataxia, epilepsy and hepatopathy.
C1 Univ Antwerp Hosp, Div Neurol, Antwerp, Belgium.
   Univ Antwerp Hosp, Neuromuscular Reference Ctr, Antwerp, Belgium.
   Univ Antwerp VIB, Dept Mol Genet, B-2000 Antwerp, Belgium.
C3 University of Antwerp; University of Antwerp; Flanders Institute for
   Biotechnology (VIB); University of Antwerp
RP Van Goethem, G (corresponding author), Univ Antwerp Hosp, Div Neurol, Antwerp, Belgium.
EM gert.vangoethem@ua.ac.be
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   ARNAUDO E, 1991, LANCET, V337, P508, DOI 10.1016/0140-6736(91)91294-5
   Blumenthal DT, 1998, NEUROLOGY, V50, P524, DOI 10.1212/WNL.50.2.524
   Bohlega S, 1996, NEUROLOGY, V46, P1329, DOI 10.1212/WNL.46.5.1329
   Brosh RM, 2000, J BIOL CHEM, V275, P23500, DOI 10.1074/jbc.M001557200
   CORMIER V, 1991, AM J HUM GENET, V48, P643
   Deschauer M, 2003, NEUROMUSCULAR DISORD, V13, P568, DOI 10.1016/S0960-8966(03)00071-3
   Di Fonzo A, 2003, HUM MUTAT, V22, DOI 10.1002/humu.9203
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   HARDING BN, 1990, J CHILD NEUROL, V5, P273, DOI 10.1177/088307389000500402
   HIRANO M, 1994, NEUROLOGY, V44, P721, DOI 10.1212/WNL.44.4.721
   Jacobs HT, 2005, TRENDS GENET, V21, P312, DOI 10.1016/j.tig.2005.04.003
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   KLOPSTOCK T, 1994, NEUROLOGY, V44, P862, DOI 10.1212/WNL.44.5.862
   KOSKINEN T, 1994, J NEUROL SCI, V121, P50, DOI 10.1016/0022-510X(94)90156-2
   KOSKINEN T, 1994, MUSCLE NERVE, V17, P509, DOI 10.1002/mus.880170507
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Lewis S, 2002, J NEUROL SCI, V201, P39, DOI 10.1016/S0022-510X(02)00190-9
   LEWIS W, 1995, NAT MED, V1, P417, DOI 10.1038/nm0595-417
   Li FY, 2001, FEBS LETT, V494, P79, DOI 10.1016/S0014-5793(01)02319-5
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Mancuso M, 2003, ARCH NEUROL-CHICAGO, V60, P1007, DOI 10.1001/archneur.60.7.1007
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Napoli L, 2001, NEUROLOGY, V57, P2295, DOI 10.1212/WNL.57.12.2295
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nikali K, 2005, HUM MOL GENET, V14, P2981, DOI 10.1093/hmg/ddi328
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   OHNO K, 1991, ANN NEUROL, V29, P364, DOI 10.1002/ana.410290406
   OZAWA T, 1990, BIOCHEM BIOPH RES CO, V170, P830, DOI 10.1016/0006-291X(90)92166-W
   Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490
   Rotig A, 1997, NAT GENET, V17, P215, DOI 10.1038/ng1097-215
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Shoubridge EA, 2001, HUM MOL GENET, V10, P2277, DOI 10.1093/hmg/10.20.2277
   Sobreira C, 1997, NEUROLOGY, V48, P1238, DOI 10.1212/WNL.48.5.1238
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spelbrink JN, 2000, J BIOL CHEM, V275, P24818, DOI 10.1074/jbc.M000559200
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   SUOMALAINEN A, 1992, LANCET, V340, P1319, DOI 10.1016/0140-6736(92)92496-3
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, NEUROLOGY, V61, P1811, DOI 10.1212/01.WNL.0000098997.23471.65
   Van Goethem G, 2003, NEUROMOL MED, V3, P129, DOI 10.1385/NMM:3:3:129
   Van Goethem G, 2003, HUM MUTAT, V22, P175, DOI 10.1002/humu.10246
   Van Goethem G, 2003, EUR J HUM GENET, V11, P547, DOI 10.1038/sj.ejhg.5201002
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   VanGoethem G, 1997, EUR J NEUROL, V4, P476
   Vogel RO, 2005, FEBS J, V272, P5317, DOI 10.1111/j.1742-4658.2005.04928.x
   Vu TH, 1998, NEUROLOGY, V50, P1783, DOI 10.1212/WNL.50.6.1783
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
   Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804
NR 55
TC 5
Z9 5
U1 0
U2 3
PU ACTA MEDICA BELGICA
PI BRUSSELS
PA AVENUE CIRCULAIRE 138-A, B-1180 BRUSSELS, BELGIUM
SN 0300-9009
J9 ACTA NEUROL BELG
JI Acta Neurol. Belg.
PD JUN
PY 2006
VL 106
IS 2
BP 66
EP 72
PG 7
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 063ON
UT WOS:000239029200004
PM 16898256
DA 2024-11-01
ER

PT J
AU Santoro, L
   Manganelli, E
   Lanzillo, R
   Tessa, A
   Barbieri, E
   Pierelli, R
   Di Giacinto, G
   Nigro, V
   Santorelli, EM
AF Santoro, L.
   Manganelli, E.
   Lanzillo, R.
   Tessa, A.
   Barbieri, E.
   Pierelli, R.
   Di Giacinto, G.
   Nigro, V.
   Santorelli, E. M.
TI A new <i>POLG1</i> mutation with peo and severe axonal and demyelinating
   sensory-motor neuropathy
SO JOURNAL OF NEUROLOGY
LA English
DT Article
DE POLG1; PEO; neuropathy; mitochondrial disorders
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; DNA-POLYMERASE-GAMMA; MTDNA
   DELETIONS; DISORDER; TWINKLE; ATAXIA; ANT1
AB Background Progressive external ophthalmoplegia (PEO) is a mitochondrial disorder associated with defective enzymatic activities of oxidative phosphorylation (OXPHOS), depletion of mitochondrial DNA (mtDNA) and/or accumulation of mtDNA mutations and deletions. Recent positional cloning studies have linked the disease to four different chromosomal loci. Mutations in POLGI are a frequent cause of this disorder. Methods We describe two first-cousins: the propositus presented with PEO, mitochondrial myopathy and neuropathy, whereas his cousin showed a Charcot-Marie-Tooth phenotype. Neurophysiological studies, peroneal muscle and sural nerve biopsies, and molecular studies of mtDNA maintenance genes (ANT1, Twinkle, POLGI, TP) and non dominant CMT-related genes (GDAP1, LMNA, GJB1) were performed. Results A severe axonal degeneration was found in both patients whereas hypomyelination was observed only in the patient with PEO whose muscle biopsy specimen also showed defective OXPHOS and multiple mtDNA deletions. While no pathogenetic mutations in GDAP1, LMNA, and GJB1 were found, we identified a novel homozygous POLGI mutation (G763R) in the PEO patient. The mutation was heterozygous in his healthy relatives and in his affected cousin. Conclusions A homozygous POLG1 mutation might explain PEO with mitochondrial abnormalities in skeletal muscle in our propositus, and it might have aggravated his axonal and hypomyelinating sensory-motor neuropathy. Most likely, his cousin had an axonal polyneuropathy with CMT phenotype of still unknown etiology.
C1 Univ Naples Federico II, Dipartimento Sci Neurol, I-80131 Naples, Italy.
   Univ Naples Federico II, Dept Neurol Sci, Naples, Italy.
   IRCCS, Childrens Hosp Bambino Gesu, Rome, Italy.
   Univ Roma La Sapienza, Dept Neurol & ORL, Rome, Italy.
   Univ Roma La Sapienza, Dept Neurol & ORL, Rome, Italy.
   IRCCS Neuromed, Pozzilli, Italy.
C3 University of Naples Federico II; University of Naples Federico II;
   IRCCS Bambino Gesu; Sapienza University Rome; Sapienza University Rome;
   IRCCS Neuromed
RP Santoro, L (corresponding author), Univ Naples Federico II, Dipartimento Sci Neurol, Via Sergio Pansini 5, I-80131 Naples, Italy.
EM lusantor@unina.it
RI Nigro, Vincenzo/AAB-2274-2022; Lanzillo, Roberta/AFA-8874-2022;
   MANGANELLI, Fiore/AAC-9096-2019; tessa, alessandra/AAA-4442-2021;
   Santorelli, Filippo M/ABE-5124-2020
OI Santoro, Lucio/0000-0001-9507-2303; Lanzillo,
   Roberta/0000-0001-6388-8180; Nigro, Vincenzo/0000-0002-3378-5006;
   MANGANELLI, Fiore/0000-0002-1442-9604; tessa,
   alessandra/0000-0002-1445-6434; Santorelli, Filippo
   M/0000-0002-1359-9062
FU Telethon [TGM06S01, TGM03Z02] Funding Source: Medline
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Berciano J, 2003, CURR OPIN NEUROL, V16, P613, DOI 10.1097/00019052-200310000-00008
   Chinnery PF, 2004, LANCET, V364, P592, DOI 10.1016/S0140-6736(04)16851-7
   De Sandre-Giovannoli A, 2002, AM J HUM GENET, V70, P726, DOI 10.1086/339274
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Hirano M, 2001, NEUROLOGY, V57, P2163, DOI 10.1212/WNL.57.12.2163
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Longley MJ, 2005, GENE, V354, P125, DOI 10.1016/j.gene.2005.03.029
   Mancuso M, 2004, NEUROLOGY, V62, P316, DOI 10.1212/WNL.62.2.316
   Morocutti C, 2002, NEUROEPIDEMIOLOGY, V21, P241, DOI 10.1159/000065642
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nelis E, 2002, NEUROLOGY, V59, P1865, DOI 10.1212/01.WNL.0000036272.36047.54
   Santorelli FM, 2000, J INHERIT METAB DIS, V23, P155, DOI 10.1023/A:1005617916260
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
NR 17
TC 20
Z9 20
U1 0
U2 1
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-5354
EI 1432-1459
J9 J NEUROL
JI J. Neurol.
PD JUL
PY 2006
VL 253
IS 7
BP 869
EP 874
DI 10.1007/s00415-006-0082-6
PG 6
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 070YO
UT WOS:000239563200006
PM 16715201
DA 2024-11-01
ER

PT J
AU González-Vioque, E
   Blázquez, A
   Fernández-Moreira, D
   Bornstein, B
   Bautista, J
   Arpa, J
   Navarro, C
   Campos, Y
   Fernández-Moreno, MA
   Garesse, R
   Arenas, J
   Martín, MA
AF González-Vioque, E
   Blázquez, A
   Fernández-Moreira, D
   Bornstein, B
   Bautista, J
   Arpa, J
   Navarro, C
   Campos, Y
   Fernández-Moreno, MA
   Garesse, R
   Arenas, J
   Martín, MA
TI Association of novel <i>POLG</i> mutations and multiple mitochondrial
   DNA deletions with variable clinical phenotypes in a Spanish population
SO ARCHIVES OF NEUROLOGY
LA English
DT Article
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; POLYMERASE-GAMMA;
   AUTOSOMAL-DOMINANT; HETEROGENEITY; DEPLETION; MUSCLE; PEO
AB Background: Both dominant and recessive mutations were reported in the gene encoding the mitochondrial (mt) DNA polymerase gamma (POLG) in patients with progressive external oplithalmoplegia (PEO). Phenotypes other than PEO were recently documented in patients with mutations in the POLG gene.
   Objective: To screen patients with mitochondrial disease and multiple mtDNA deletions in muscle for mutations in the coding regions of the POLG, PEO1, and SLC25A4 genes.
   Design: To identify the underlying molecular defect in a group of patients with multiple mtDNA deletions comparing their molecular genetic findings with those of healthy controls.
   Patients: Twenty-four patients (16 men and 8 women) diagnosed with mitochondrial disease and having multiple mtDNA deletions in muscle by Southern blot analysis. Thirteen patients had PEO; 2 had PEO alone, 4 had PEO and myopathy, and 5 had PEO and multisystem involvement. Four patients had multisystem disease without PEO. The remaining 9 patients had isolated myopathy. DNA from 100 healthy individuals was also studied.
   Results: No mutation was identified in the PEO1 or SLC25A4 genes. Nine POLG mutations were observed in 6 of 24 patients. Four novel mutations were detected and mapped in the linker region (M603L) and in the pol domain of the enzyme (R853W; D1184N; R1146C). Five patients with PEO had mutations: 2 were compound heterozygotes, 1 was homozygous, and another showed a mutation in a single allele. The remaining patient also showed a sole mutation and had an unusual phenotype lacking ocular involvement.
   Conclusions: POLG molecular defects were found in 25% of our patients with multiple mtDNA deletions and mitochondrial disease. The uncommon phenotype found in I of these patients stresses the clinical variability of patients harboring POLG mutations. Molecular studies in the POLG gene should be addressed in patients with mitochondrial disease, particularly in those with PEO, and multiple mtDNA deletions.
C1 Univ Madrid, Hosp 12 Octubre, Ctr Invest, Madrid 28041, Spain.
   Univ Madrid, Hosp La Paz, Serv Neurol, Madrid 3, Spain.
   Hosp Virgen Rocio, Serv Neurol, Seville, Spain.
   Hosp Do Meixoeiro, Serv Anat Patol, Vigo, Spain.
   UAM, CSIC, Fac Med, Dept Bioquim,Inst Invest Biomed Alberto Sols, Madrid, Spain.
C3 Hospital Universitario 12 de Octubre; Hospital Universitario La Paz;
   Virgen del Rocio University Hospital; Complexo Hospitalario
   Universitario de Vigo; Consejo Superior de Investigaciones Cientificas
   (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols
   (IIBM); Autonomous University of Madrid
RP Univ Madrid, Hosp 12 Octubre, Ctr Invest, Avda Cordoba S-N, Madrid 28041, Spain.
EM mamcasanueva@h12o.es
RI Garesse, Rafael/F-3836-2012; Fernandez-Moreno, Miguel/K-4425-2017;
   Yolanda, Campos/A-8711-2017; Martin, Miguel/S-2758-2018; Navarro,
   Carmen/A-9210-2012; Blazquez Encinar, Alberto/S-4425-2018; Martin,
   Miguel Angel/B-6261-2017
OI CAMPOS, YOLANDA/0000-0003-4785-9659; Arenas,
   Joaquin/0000-0002-2877-5049; Garesse, Rafael/0000-0002-0338-2281;
   Blazquez Encinar, Alberto/0000-0002-6479-3615; Martin, Miguel
   Angel/0000-0003-4741-772X; Fernandez Moreno, Miguel
   Angel/0000-0002-3461-0726; Gonzalez Vioque, Emiliano/0000-0001-7279-4311
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   [Anonymous], [No title captured]
   Campos Y, 1998, NEUROMUSCULAR DISORD, V8, P568, DOI 10.1016/S0960-8966(98)00080-7
   Di Fonzo A, 2003, HUM MUTAT, V22, DOI 10.1002/humu.9203
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   Lamantea E, 2004, ANN NEUROL, V56, P454, DOI 10.1002/ana.20219
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Martinez B, 2001, J NEUROCHEM, V78, P1054, DOI 10.1046/j.1471-4159.2001.00487.x
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Rovio AT, 2001, NAT GENET, V29, P261, DOI 10.1038/ng759
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, NEUROLOGY, V61, P1811, DOI 10.1212/01.WNL.0000098997.23471.65
   Van Goethem G, 2003, EUR J HUM GENET, V11, P547, DOI 10.1038/sj.ejhg.5201002
NR 16
TC 49
Z9 51
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9942
EI 1538-3687
J9 ARCH NEUROL-CHICAGO
JI Arch. Neurol.
PD JAN
PY 2006
VL 63
IS 1
BP 107
EP 111
DI 10.1001/archneur.63.1.107
PG 5
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 001OT
UT WOS:000234546900013
PM 16401742
DA 2024-11-01
ER

PT J
AU Berardo, A
   Domínguez-González, C
   Engelstad, K
   Hirano, M
AF Berardo, Andres
   Dominguez-Gonzalez, Cristina
   Engelstad, Kristin
   Hirano, Michio
TI Advances in Thymidine Kinase 2 Deficiency: Clinical Aspects,
   Translational Progress, and Emerging Therapies
SO JOURNAL OF NEUROMUSCULAR DISEASES
LA English
DT Review
DE Mitochondrial myopathies; deoxycytidine; thymidine; DNA; mitochondrial;
   mitochondrial diseases
ID MITOCHONDRIAL-DNA DEPLETION; IMPAIR MTDNA REPLICATION; MUTATIONS;
   MYOPATHY; GENE; BIOMARKER; SPECIFICITY; DELETIONS; DEFECTS; RRM2B
AB Defects in the replication, maintenance, and repair of mitochondrial DNA (mtDNA) constitute a growing and genetically heterogeneous group of mitochondrial disorders. Multiple genes participate in these processes, including thymidine kinase 2 (TK2) encoding the mitochondrial matrix protein TK2, a critical component of the mitochondrial nucleotide salvage pathway. TK2 deficiency (TK2d) causes mtDNA depletion, multiple deletions, or both, which manifest predominantly as mitochondrial myopathy. A wide clinical spectrum phenotype includes a severe, rapidly progressive, early onset form (median survival: < 2 years); a less severe childhood-onset form; and a late-onset form with a variably slower rate of progression. Clinical presentation typically includes progressive weakness of limb, neck, facial, oropharyngeal, and respiratory muscle, whereas limb myopathy with ptosis, ophthalmoparesis, and respiratory involvement is more common in the late-onset form. Deoxynucleoside monophosphates and deoxynucleosides that can bypass the TK2 enzyme defect have been assessed in a mouse model, as well as under open-label compassionate use (expanded access) in TK2d patients, indicating clinical efficacy with a favorable side-effect profile. This treatment is currently undergoing testing in clinical trials intended to support approval in the US and European Union (EU). In the early expanded access program, growth differentiation factor 15 (GDF-15) appears to be a useful biomarker that correlates with therapeutic response. With the advent of a specific treatment and given the high morbidity and mortality associated with TK2d, clinicians need to know how to recognize and diagnose this disorder. Here, we summarize translational research about this rare condition emphasizing clinical aspects.
C1 [Berardo, Andres; Engelstad, Kristin; Hirano, Michio] Columbia Univ, Dept Neurol, Irving Med Ctr, 630 West 168th St,P&S 4-423, New York, NY 10032 USA.
   [Dominguez-Gonzalez, Cristina] Univ Hosp 12 Octubre, Res Inst Imas12, Neurol Dept, Neuromuscular Unit,Spanish Network Biomed Res Rar, Madrid, Spain.
C3 Columbia University; NewYork-Presbyterian Hospital; Hospital
   Universitario 12 de Octubre
RP Hirano, M (corresponding author), Columbia Univ, Dept Neurol, Irving Med Ctr, 630 West 168th St,P&S 4-423, New York, NY 10032 USA.
EM mh29@cumc.columbia.edu
OI Dominguez, Cristina/0000-0001-5151-988X; Berardo, Andres
   Ignacio/0000-0003-0702-2117
FU National Institutes of Health [P01 HD32062]; Department of Defense
   [W81XWH2010807]; Muscular Dystrophy Association [577392]; Arturo
   Estopinan TK2 Research Fund; Nicholas Nunno Foundation; JDM Fund for
   Mitochondrial Research; Shuman Mitochondrial Disease Fund; Marriott
   Mitochondrial Disease Clinic Research Fund (MMDCRF) from the J. Willard
   and Alice S. Marriott Foundation; NIH from NINDS [U54 NS078059]; NICHD;
   U.S. Department of Defense (DOD) [W81XWH2010807] Funding Source: U.S.
   Department of Defense (DOD)
FX This work was supported by research grants from the National Institutes
   of Health (P01 HD32062), Department of Defense (W81XWH2010807) and
   Muscular Dystrophy Association (577392). MH is supported by the Arturo
   Estopinan TK2 Research Fund, Nicholas Nunno Foundation, JDM Fund for
   Mitochondrial Research, Shuman Mitochondrial Disease Fund, and the
   Marriott Mitochondrial Disease Clinic Research Fund (MMDCRF) from the J.
   Willard and Alice S. Marriott Foundation. MH also acknowledges support
   from NIH U54 NS078059 from NINDS and NICHD.
CR Akman HO, 2008, HUM MOL GENET, V17, P2433, DOI 10.1093/hmg/ddn143
   ARNAUDO E, 1991, LANCET, V337, P508, DOI 10.1016/0140-6736(91)91294-5
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Carrozzo R, 2003, HUM MUTAT, V21, DOI 10.1002/humu.9135
   Carrozzo R, 2016, J INHERIT METAB DIS, V39, P243, DOI 10.1007/s10545-015-9894-9
   Davis RL, 2013, NEUROLOGY, V81, P1819, DOI 10.1212/01.wnl.0000436068.43384.ef
   Di Noia MA, 2014, J BIOL CHEM, V289, P33137, DOI 10.1074/jbc.M114.610808
   Dominguez-Gonzalez C, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-66940-8
   Domínguez-González C, 2019, ANN NEUROL, V86, P293, DOI 10.1002/ana.25506
   Domínguez-González C, 2019, ORPHANET J RARE DIS, V14, DOI 10.1186/s13023-019-1071-z
   Dorado B, 2011, HUM MOL GENET, V20, P155, DOI 10.1093/hmg/ddq453
   ERIKSSON S, 1991, ADV EXP MED BIOL, V309, P239
   Finsterer J, 2018, NEUROPEDIATRICS, V49, P231, DOI 10.1055/s-0037-1609039
   Franzolin E, 2012, EXP CELL RES, V318, P2226, DOI 10.1016/j.yexcr.2012.05.028
   Garone C, 2018, J MED GENET, V55, P515, DOI 10.1136/jmedgenet-2017-105012
   Garone C, 2014, EMBO MOL MED, V6, P1016, DOI 10.15252/emmm.201404092
   Götz A, 2008, BRAIN, V131, P2841, DOI 10.1093/brain/awn236
   Kalko SG, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-91
   Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279
   Jurkute N, 2019, ANN NEUROL, V86, P368, DOI 10.1002/ana.25550
   Koga Y, 2021, J INHERIT METAB DIS, V44, P358, DOI 10.1002/jimd.12317
   Kornblum C, 2013, NAT GENET, V45, P214, DOI 10.1038/ng.2501
   Kumar D, 2014, GENOMIC MED, P131
   Lehtonen JM, 2021, J INHERIT METAB DIS, V44, P469, DOI 10.1002/jimd.12307
   Lesko N, 2010, NEUROMUSCULAR DISORD, V20, P198, DOI 10.1016/j.nmd.2009.11.013
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Lopez-Gomez C, 232 ENMC INT WORKSH
   Lopez-Gomez C, 2021, ANN NEUROL, V90, P640, DOI 10.1002/ana.26185
   Lopez-Gomez C, 2019, EBIOMEDICINE, V46, P356, DOI 10.1016/j.ebiom.2019.07.037
   Macmillan CJ, 1996, PEDIATR NEUROL, V14, P203, DOI 10.1016/0887-8994(96)00018-5
   Mancuso M, 2003, ARCH NEUROL-CHICAGO, V60, P1007, DOI 10.1001/archneur.60.7.1007
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Mayo Clinic Laboratories, 2021, ROCH 2021 INT HDB 20
   Mazurova S, 2017, CARDIOL YOUNG, V27, P936, DOI 10.1017/S1047951116001876
   Munch-Petersen B, 2010, NUCLEOS NUCLEOT NUCL, V29, P363, DOI 10.1080/15257771003729591
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Oskoui M, 2006, ARCH NEUROL-CHICAGO, V63, P1122, DOI 10.1001/archneur.63.8.1122
   Palmieri F, 2013, MOL ASPECTS MED, V34, P465, DOI 10.1016/j.mam.2012.05.005
   Pons R, 1996, PEDIATR NEUROL, V15, P153, DOI 10.1016/0887-8994(96)00118-X
   Reyes A, 2015, AM J HUM GENET, V97, P186, DOI 10.1016/j.ajhg.2015.05.013
   Rötig A, 2009, BBA-MOL BASIS DIS, V1792, P1103, DOI 10.1016/j.bbadis.2009.06.009
   Saada A, 2003, MOL GENET METAB, V79, P1, DOI 10.1016/S1096-7192(03)00063-5
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Sarzi E, 2007, J PEDIATR-US, V150, P531, DOI 10.1016/j.jpeds.2007.01.044
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2009, J INHERIT METAB DIS, V32, P143, DOI 10.1007/s10545-008-1038-z
   Suomalainen A, 2011, LANCET NEUROL, V10, P806, DOI 10.1016/S1474-4422(11)70155-7
   Tsygankova PG, 2019, J INHERIT METAB DIS, V42, P918, DOI 10.1002/jimd.12142
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Wang JL, 2018, MOL GENET METAB, V124, P124, DOI 10.1016/j.ymgme.2018.04.012
   Wang L, 1999, FEBS LETT, V443, P170, DOI 10.1016/S0014-5793(98)01711-6
   Yatsuga S, 2015, ANN NEUROL, V78, P814, DOI 10.1002/ana.24506
   Zhou XS, 2008, HUM MOL GENET, V17, P2329, DOI 10.1093/hmg/ddn133
NR 54
TC 9
Z9 9
U1 0
U2 3
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 2214-3599
EI 2214-3602
J9 J NEUROMUSCULAR DIS
JI J. Neuromusc. Dis.
PY 2022
VL 9
IS 2
BP 225
EP 235
DI 10.3233/JND-210786
PG 11
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA ZM0BX
UT WOS:000764033400001
PM 35094997
OA Green Published, hybrid
DA 2024-11-01
ER

PT J
AU DiMauro, S
   Gurgel-Giannetti, J
AF DiMauro, S
   Gurgel-Giannetti, J
TI The expanding phenotype of mitochondrial myopathy
SO CURRENT OPINION IN NEUROLOGY
LA English
DT Article
DE coenzyme Q10 deficiency; homoplasmy; mitochondrial DNA; nuclear DNA;
   polymerase gamma
ID POLG MUTATIONS; COMPLEX-I; DNA; ENCEPHALOMYOPATHY; DEFICIENCY; GENE;
   CARDIOLIPIN
AB Purpose of review Our understanding of mitochondrial diseases (defined restrictively as defects in the mitochondrial respiratory chain) continues to progress apace. In this review we provide an update of information regarding disorders that predominantly or exclusively affect skeletal muscle.
   Recent findings Most recently described mitochondrial myopathies are due to defects in nuclear DNA, including coenzyme Q(10) deficiency, and mutations in genes that control mitochondrial DNA (mtDNA) abundance and structure such as POLG and TK2. Barth syndrome, an X-linked recessive mitochondrial myopathy/cardiopathy, is associated with altered lipid composition of the inner mitochondrial membrane, but a putative secondary impairment of the respiratory chain remains to be documented. Concerning the 'other genome', the role played by mutations in protein encoding genes of mtDNA in causing isolated myopathies has been confirmed. It has also been confirmed that mutations in tRNA genes of mtDNA can cause predominantly myopathic syndromes and - contrary to conventional wisdom - these mutations can be homoplasmic.
   Summary Defects in the mitochondrial respiratory chain impair energy production and almost invariably involve skeletal muscle, causing exercise intolerance, myalgia, cramps, or fixed weakness, which often affects extraocular muscles and results in droopy eyelids (ptosis) and progressive external ophthalmoplegia.
C1 Columbia Univ, Med Ctr, Dept Neurol, Coll Phys & Surg, New York, NY 10032 USA.
   Univ Fed Minas Gerais, Dept Pediat, Belo Horizonte, MG, Brazil.
C3 Columbia University; Universidade Federal de Minas Gerais
RP Columbia Univ, Med Ctr, Dept Neurol, Coll Phys & Surg, 630 W 168th St,4-420, New York, NY 10032 USA.
EM sd12@columbia.edu
RI Gurgel-Giannetti, Juliana/AAK-2172-2021
OI Gurgel-Giannetti, Juliana/0000-0003-3335-1491
FU NICHD NIH HHS [HD32062] Funding Source: Medline; NINDS NIH HHS [NS11766]
   Funding Source: Medline
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   Boitier E, 1998, J NEUROL SCI, V156, P41, DOI 10.1016/S0022-510X(98)00006-9
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   Di Giovanni S, 2001, NEUROLOGY, V57, P515, DOI 10.1212/WNL.57.3.515
   DiMauro S, 2004, BBA-BIOENERGETICS, V1659, P107, DOI 10.1016/j.bbabio.2004.08.003
   DiMauro S, 2005, NEUROMUSCULAR DISORD, V15, P276, DOI 10.1016/j.nmd.2004.12.008
   Dimauro S, 2005, ANN MED, V37, P222, DOI 10.1080/07853890510007368
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Hirano M, 2004, TOP CURR GENET, V8, P177
   Horváth R, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.015024
   Kirby DM, 2004, J CLIN INVEST, V114, P837, DOI 10.1172/JCI200420683
   Lalani SR, 2005, ARCH NEUROL-CHICAGO, V62, P317, DOI 10.1001/archneur.62.2.317
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   LAMPERTI C, 2005, IN PRESS ARCH NEUROL
   Mancuso M, 2005, J NEUROL SCI, V228, P93, DOI 10.1016/j.jns.2004.10.018
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   McFarland R, 2004, ANN NEUROL, V55, P478, DOI 10.1002/ana.20004
   McFarland R, 2002, NAT GENET, V30, P145, DOI 10.1038/ng819
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   OGASAHARA S, 1989, P NATL ACAD SCI USA, V86, P2379, DOI 10.1073/pnas.86.7.2379
   Owczarek J, 2005, PHARMACOL REP, V57, P23
   Rahman S, 2001, J PEDIATR-US, V139, P456, DOI 10.1067/mpd.2001.117575
   Rötig A, 2000, LANCET, V356, P391, DOI 10.1016/S0140-6736(00)02531-9
   SALVIATI L, 2005, IN PRESS NEUROLOGY
   Schlame M, 2003, J AM COLL CARDIOL, V42, P1994, DOI 10.1016/j.jacc.2003.06.015
   Schlame M, 2002, ANN NEUROL, V51, P634, DOI 10.1002/ana.10176
   Sobreira C, 1997, NEUROLOGY, V48, P1238, DOI 10.1212/WNL.48.5.1238
   Taylor RW, 2003, J AM COLL CARDIOL, V41, P1786, DOI 10.1016/S0735-1097(03)00300-0
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   Thompson PD, 2003, JAMA-J AM MED ASSOC, V289, P1681, DOI 10.1001/jama.289.13.1681
   Ugalde C, 2004, HUM MOL GENET, V13, P659, DOI 10.1093/hmg/ddh071
   Vreken P, 2000, BIOCHEM BIOPH RES CO, V279, P378, DOI 10.1006/bbrc.2000.3952
NR 34
TC 31
Z9 32
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1350-7540
EI 1473-6551
J9 CURR OPIN NEUROL
JI Curr. Opin. Neurol.
PD OCT
PY 2005
VL 18
IS 5
BP 538
EP 542
DI 10.1097/01.wco.0000179761.63486.1a
PG 5
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 977SP
UT WOS:000232823800008
PM 16155436
DA 2024-11-01
ER

PT J
AU Viscomi, C
   Zeviani, M
AF Viscomi, Carlo
   Zeviani, Massimo
TI MtDNA-maintenance defects: syndromes and genes
SO JOURNAL OF INHERITED METABOLIC DISEASE
LA English
DT Article; Proceedings Paper
CT Annual Symposium of the
   Society-for-the-Study-of-Inborn-Errors-of-Metabolism (SSIEM)
CY SEP 06-09, 2016
CL Rome, ITALY
SP Soc Study Inborn Errors Metab
ID MITOCHONDRIAL NEUROGASTROINTESTINAL ENCEPHALOMYOPATHY; PROGRESSIVE
   EXTERNAL OPHTHALMOPLEGIA; ADENINE-NUCLEOTIDE TRANSLOCATOR; ONSET
   SPINOCEREBELLAR ATAXIA; DOMINANT OPTIC ATROPHY; LOSS-OF-FUNCTION;
   AUTOSOMAL-DOMINANT; DNA-POLYMERASE; POLG MUTATIONS; MULTIPLE DELETIONS
AB A large group of mitochondrial disorders, ranging from early-onset pediatric encephalopathic syndromes to late-onset myopathy with chronic progressive external ophthalmoplegia (CPEOs), are inherited as Mendelian disorders characterized by disturbed mitochondrial DNA (mtDNA) maintenance. These errors of nuclear-mitochondrial intergenomic signaling may lead to mtDNA depletion, accumulation of mtDNA multiple deletions, or both, in critical tissues. The genes involved encode proteins belonging to at least three pathways: mtDNA replication and maintenance, nucleotide supply and balance, and mitochondrial dynamics and quality control. In most cases, allelic mutations in these genes may lead to profoundly different phenotypes associated with either mtDNA depletion or multiple deletions.
C1 [Viscomi, Carlo; Zeviani, Massimo] MRC MBU, MRC Mitochondrial Biol Unit, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 0XY, England.
RP Zeviani, M (corresponding author), MRC MBU, MRC Mitochondrial Biol Unit, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 0XY, England.
EM mdz21@mrc-mbu.cam.ac.uk
RI Zeviani, Massimo/AAU-2632-2021; viscomi, Carlo/R-1940-2016
OI Viscomi, Carlo/0000-0001-6050-0566; Zeviani, Massimo/0000-0002-9067-5508
FU ERC grant [FP7-322424]; CoEN grant [3038]; MRC core grant; MRC
   [MC_UU_00015/5, MC_UP_1002/1] Funding Source: UKRI
FX This work was supported by: ERC FP7-322424 grant (to MZ), CoEN grant
   3038 (to MZ and CV) and the MRC core grant to the Mitochondrial Biology
   Unit.
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Alston CL, 2013, NEUROLOGY, V81, P2051, DOI 10.1212/01.wnl.0000436931.94291.e6
   Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   Bamber L, 2007, P NATL ACAD SCI USA, V104, P10830, DOI 10.1073/pnas.0703969104
   Béhin A, 2012, NEUROLOGY, V78, P644, DOI 10.1212/WNL.0b013e318248df2b
   Besse A, 2015, CELL METAB, V21, P417, DOI 10.1016/j.cmet.2015.02.008
   Blakely EL, 2012, NEUROMUSCULAR DISORD, V22, P587, DOI 10.1016/j.nmd.2012.03.006
   Bonnen PE, 2013, AM J HUM GENET, V93, P773, DOI 10.1016/j.ajhg.2013.09.003
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Cámara Y, 2014, HUM MOL GENET, V23, P2459, DOI 10.1093/hmg/ddt641
   Carelli V, 2015, ANN NEUROL, V78, P21, DOI 10.1002/ana.24410
   Carrozzo R, 2007, BRAIN, V130, P862, DOI 10.1093/brain/awl389
   Carrozzo R, 2016, J INHERIT METAB DIS, V39, P243, DOI 10.1007/s10545-015-9894-9
   Casari G, 1998, CELL, V93, P973, DOI 10.1016/S0092-8674(00)81203-9
   Chen HC, 2010, CELL, V141, P280, DOI 10.1016/j.cell.2010.02.026
   Copeland WC, 2014, DNA REPAIR, V19, P190, DOI 10.1016/j.dnarep.2014.03.010
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   Deschauer M, 2005, NEUROMUSCULAR DISORD, V15, P311, DOI 10.1016/j.nmd.2004.12.004
   Di Fonzo A, 2009, AM J HUM GENET, V84, P594, DOI 10.1016/j.ajhg.2009.04.004
   Echaniz-Laguna A, 2012, J MED GENET, V49, P146, DOI 10.1136/jmedgenet-2011-100504
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Ferraro P, 2005, J BIOL CHEM, V280, P24472, DOI 10.1074/jbc.M502869200
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   Fratter C, 2011, NEUROLOGY, V76, P2032, DOI 10.1212/WNL.0b013e31821e558b
   Gai XW, 2013, AM J HUM GENET, V93, P482, DOI 10.1016/j.ajhg.2013.07.016
   Galbiati S, 2006, PEDIATR NEUROL, V34, P177, DOI 10.1016/j.pediatrneurol.2005.07.013
   Garone C, 2012, NEUROLOGY, V78
   Garone C, 2014, EMBO MOL MED, V6, P1016, DOI 10.15252/emmm.201404092
   Garone C, 2012, ARCH NEUROL-CHICAGO, V69, P1648, DOI 10.1001/archneurol.2012.405
   Gauthier-Villars M, 2001, NEUROPEDIATRICS, V32, P150, DOI 10.1055/s-2001-16614
   Giordano C, 2006, GASTROENTEROLOGY, V130, P893, DOI 10.1053/j.gastro.2006.01.004
   Giordano C, 2008, AM J PATHOL, V173, P1120, DOI 10.2353/ajpath.2008.080252
   Gorman GS, 2015, JAMA NEUROL, V72, P106, DOI 10.1001/jamaneurol.2014.1753
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   HIRANO M, 1994, NEUROLOGY, V44, P721, DOI 10.1212/WNL.44.4.721
   Hirano M, 1998, AM J HUM GENET, V63, P526, DOI 10.1086/301979
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Hudson G, 2008, BRAIN, V131, P329, DOI 10.1093/brain/awm272
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Komaki H, 2002, ANN NEUROL, V51, P645, DOI 10.1002/ana.10172
   Koopman WJH, 2013, EMBO J, V32, P9, DOI 10.1038/emboj.2012.300
   Kornblum C, 2013, NAT GENET, V45, P214, DOI 10.1038/ng.2501
   Körver-Keularts IMLW, 2015, JIMD REP, V22, P39, DOI 10.1007/8904_2015_409
   KOSKINEN T, 1994, MUSCLE NERVE, V17, P509, DOI 10.1002/mus.880170507
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Lodi R, 2011, ARCH NEUROL-CHICAGO, V68, P67, DOI 10.1001/archneurol.2010.228
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Martí R, 2005, ANN NEUROL, V58, P649, DOI 10.1002/ana.20615
   Martí R, 2004, CLIN CHEM, V50, P120, DOI 10.1373/clinchem.2003.026179
   MAZZIOTTA MRM, 1992, J PEDIATR-US, V121, P896, DOI 10.1016/S0022-3476(05)80335-X
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Moslemi AR, 1996, ANN NEUROL, V40, P707, DOI 10.1002/ana.410400506
   Napoli L, 2001, NEUROLOGY, V57, P2295, DOI 10.1212/WNL.57.12.2295
   Naviaux RK, 2005, ANN NEUROL, V58, P491, DOI 10.1002/ana.20544
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Naviaux RK, 1999, ANN NEUROL, V45, P54, DOI 10.1002/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B
   Nikali K, 2005, HUM MOL GENET, V14, P2981, DOI 10.1093/hmg/ddi328
   Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Nolden M, 2005, CELL, V123, P277, DOI 10.1016/j.cell.2005.08.003
   Oskoui M, 2006, ARCH NEUROL-CHICAGO, V63, P1122, DOI 10.1001/archneur.63.8.1122
   Ostergaard E, 2007, AM J HUM GENET, V81, P383, DOI 10.1086/519222
   Ostergaard E, 2007, BRAIN, V130, P853, DOI 10.1093/brain/awl383
   Palmieri L, 2005, HUM MOL GENET, V14, P3079, DOI 10.1093/hmg/ddi341
   Paradas C, 2013, NEUROLOGY, V80, P504, DOI 10.1212/WNL.0b013e31827f0ff7
   Pfeffer G, 2014, BRAIN, V137, P1323, DOI 10.1093/brain/awu060
   Pitceathly RDS, 2012, BRAIN, V135, P3392, DOI 10.1093/brain/aws231
   Pontarin G, 2006, J BIOL CHEM, V281, P22720, DOI 10.1074/jbc.M604498200
   Reyes A, 2015, AM J HUM GENET, V97, P186, DOI 10.1016/j.ajhg.2015.05.013
   Ronchi D, 2012, BRAIN, V135, P3404, DOI 10.1093/brain/aws258
   Rosa ID, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005779
   Rouzier C, 2012, BRAIN, V135, P23, DOI 10.1093/brain/awr323
   Sarzi E, 2007, ANN NEUROL, V62, P579, DOI 10.1002/ana.21207
   Schon EA, 2012, NAT REV GENET, V13, P878, DOI 10.1038/nrg3275
   SERVIDEI S, 1991, NEUROLOGY, V41, P1053, DOI 10.1212/WNL.41.7.1053
   Siciliano G, 2003, NEUROMUSCULAR DISORD, V13, P162, DOI 10.1016/S0960-8966(02)00221-3
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Spinazzola A, 2005, GENE, V354, P162, DOI 10.1016/j.gene.2005.03.025
   Spinazzola A, 2002, J BIOL CHEM, V277, P4128, DOI 10.1074/jbc.M111028200
   Stiles AR, 2016, MOL GENET METAB, V119, P91, DOI 10.1016/j.ymgme.2016.07.001
   Strauss KA, 2013, P NATL ACAD SCI USA, V110, P3453, DOI 10.1073/pnas.1300690110
   Takata A, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-9-r92
   Thompson K, 2016, AM J HUM GENET, V99, P860, DOI 10.1016/j.ajhg.2016.08.014
   TRITSCHLER HJ, 1992, NEUROLOGY, V42, P209, DOI 10.1212/WNL.42.1.209
   Tyynismaa H, 2012, HUM MOL GENET, V21, P66, DOI 10.1093/hmg/ddr438
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Tzoulis C, 2014, ANN NEUROL, V76, P66, DOI 10.1002/ana.24185
   Vafai SB, 2012, NATURE, V491, P374, DOI 10.1038/nature11707
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Vu TH, 2001, HEPATOLOGY, V34, P116, DOI 10.1053/jhep.2001.25921
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Walter MC, 2010, J NEUROL, V257, P1517, DOI 10.1007/s00415-010-5565-9
   Wedding IM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086340
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   Young MJ, 2011, HUM MOL GENET, V20, P3052, DOI 10.1093/hmg/ddr209
   Yu-Wai-Man P, 2010, BRAIN, V133, P771, DOI 10.1093/brain/awq007
   Yu-Wai-Man P, 2012, BRAIN, V135, P9, DOI 10.1093/brain/awr352
   Zeviani M, 2004, BRAIN, V127, P2153, DOI 10.1093/brain/awh259
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
   Zeviani M, 2008, BRAIN, V131, P314, DOI 10.1093/brain/awm339
NR 106
TC 127
Z9 131
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0141-8955
EI 1573-2665
J9 J INHERIT METAB DIS
JI J. Inherit. Metab. Dis.
PD JUL
PY 2017
VL 40
IS 4
BP 587
EP 599
DI 10.1007/s10545-017-0027-5
PG 13
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental
   Medicine
GA EZ9AC
UT WOS:000405020500012
PM 28324239
OA Green Published, Green Submitted, hybrid
DA 2024-11-01
ER

PT J
AU Martin-Negrier, ML
   Sole, G
   Jardel, C
   Vital, C
   Ferrer, X
   Vital, A
AF Martin-Negrier, M. -L.
   Sole, G.
   Jardel, C.
   Vital, C.
   Ferrer, X.
   Vital, A.
TI <i>TWINKLE</i> gene mutation: report of a French family with an
   autosomal dominant progressive external ophthalmoplegia and literature
   review
SO EUROPEAN JOURNAL OF NEUROLOGY
LA English
DT Review
DE mitochondria; myopathy; neuropathy; ophthalmoplegia; Twinkle gene
ID SENSORY ATAXIC NEUROPATHY; MITOCHONDRIAL-DNA; MULTIPLE DELETIONS;
   DISEASE; HELICASE; ANT1; PARKINSONISM; MYOPATHIES; DISORDERS; PHENOTYPE
AB Background: Multiple mitochondrial DNA (mtDNA) deletions usually have a mendelian inheritance secondary to mutation in nuclear genes. One of these is the Twinkle gene whose mutation is responsible for autosomal dominant progressive external ophthalmoplegia (PEO). The number of reported cases with mainly myopathic symptoms and possible nervous system involvement related to Twinkle gene mutation is limited. We present a new French family of whom two members displayed myopathy and neuropathy associated with PEO, and we perform a clinical review in light of other observations reported in the literature.
   Methods: The proband, one son and the daughter have been investigated. Southern blot analysis and long-range PCR assay have been performed from muscle biopsy specimens. Coding exons and flanking intron regions of polymerase gamma (POLG) and DNA helicase (Twinkle) genes were sequenced.
   Results: Multiple mitochondrial DNA deletions have been found and sequencing of the Twinkle gene showed the change p. R374Q.
   Conclusion: Two other families from the literature also had the R374Q mutation. Symptoms reported in association with this mutation were myopathy, peripheral neuropathy, dysarthria and/or dysphagia, respiratory insufficiency and parkinsonism. Respiratory insufficiency caused by chest wall weakness was reported in other families with different Twinkle gene mutations, and one might provide exercise intolerance, dysarthria and/or dysphagia as symptoms in favor of the diagnosis. Occurrence of impressive emaciation was a peculiarity in our family.
C1 [Martin-Negrier, M. -L.; Vital, C.; Vital, A.] Bordeaux Inst Neurosci, CNRS, UMR 5227, Bordeaux, France.
   [Sole, G.; Ferrer, X.] Bordeaux Univ Hosp, Dept Neurol, Bordeaux, France.
   [Jardel, C.] Grp Hosp Pitie Salpetriere, INSERM, UMRS 975, F-75634 Paris, France.
C3 Universite de Bordeaux; Centre National de la Recherche Scientifique
   (CNRS); CHU Bordeaux; Sorbonne Universite; Assistance Publique Hopitaux
   Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Institut
   National de la Sante et de la Recherche Medicale (Inserm)
RP Vital, A (corresponding author), Univ Victor Segalen, BP42,146 Rue Leo Saignat, F-33076 Bordeaux, France.
EM anne.vital@chu-bordeaux.fr
RI Sole, Gabriele/LEM-7147-2024
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Baloh RH, 2007, ARCH NEUROL-CHICAGO, V64, P998, DOI 10.1001/archneur.64.7.998
   Bohlega S, 2009, NEUROMUSCULAR DISORD, V19, P845, DOI 10.1016/j.nmd.2009.10.002
   Bouillot S, 2002, J PERIPHER NERV SYST, V7, P213, DOI 10.1046/j.1529-8027.2002.02027.x
   Deschauer M, 2003, NEUROMUSCULAR DISORD, V13, P568, DOI 10.1016/S0960-8966(03)00071-3
   DIMAURO S, 1985, ANN NEUROL, V17, P521, DOI 10.1002/ana.410170602
   Echaniz-Laguna A, 2010, NEUROGENETICS, V11, P21, DOI 10.1007/s10048-009-0202-4
   Fadic R, 1997, NEUROLOGY, V49, P239, DOI 10.1212/WNL.49.1.239
   Goffart S, 2009, HUM MOL GENET, V18, P328, DOI 10.1093/hmg/ddn359
   HANNA MG, 2005, PERIPHERAL NEUROPATH, P1937
   Hirano M, 2001, NEUROLOGY, V57, P2163, DOI 10.1212/WNL.57.12.2163
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   Hong DJ, 2010, MUSCLE NERVE, V41, P92, DOI 10.1002/mus.21439
   Houshmand M, 2006, NEUROL INDIA, V54, P182
   Hudson G, 2005, NEUROLOGY, V64, P371, DOI 10.1212/01.WNL.0000149767.51152.83
   Jeppesen TD, 2008, NEUROMUSCULAR DISORD, V18, P306, DOI 10.1016/j.nmd.2007.10.007
   Kiechl S, 2004, J NEUROL NEUROSUR PS, V75, P1125, DOI 10.1136/jnnp.2003.025890
   LAMPERTI C, 2009, ACTA MYOL, V23, P2
   Lewis S, 2002, J NEUROL SCI, V201, P39, DOI 10.1016/S0022-510X(02)00190-9
   Li FY, 1999, NEUROLOGY, V53, P1265, DOI 10.1212/WNL.53.6.1265
   Naïmi M, 2006, EUR J HUM GENET, V14, P917, DOI 10.1038/sj.ejhg.5201627
   Nardin RA, 2001, MUSCLE NERVE, V24, P170, DOI 10.1002/1097-4598(200102)24:2<170::AID-MUS30>3.0.CO;2-0
   Negro R, 2009, NEUROMUSCULAR DISORD, V19, P423, DOI 10.1016/j.nmd.2009.04.008
   Orth M, 2001, AM J MED GENET, V106, P27, DOI 10.1002/ajmg.1425
   Rivera H, 2007, NEUROMUSCULAR DISORD, V17, P677, DOI 10.1016/j.nmd.2007.05.006
   Schapira AHV, 2006, LANCET, V368, P70, DOI 10.1016/S0140-6736(06)68970-8
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   Tyynismaa H, 2004, HUM MOL GENET, V13, P3219, DOI 10.1093/hmg/ddh342
   Van Hove JLK, 2009, AM J MED GENET A, V149A, P861, DOI 10.1002/ajmg.a.32731
   Vandenberghe W, 2009, MOVEMENT DISORD, V24, P308, DOI 10.1002/mds.22198
   Virgilio R, 2008, J NEUROL, V255, P1384, DOI 10.1007/s00415-008-0926-3
   Vogel H, 2001, J NEUROPATH EXP NEUR, V60, P217, DOI 10.1093/jnen/60.3.217
NR 33
TC 18
Z9 20
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1351-5101
EI 1468-1331
J9 EUR J NEUROL
JI Eur. J. Neurol.
PD MAR
PY 2011
VL 18
IS 3
BP 436
EP 441
DI 10.1111/j.1468-1331.2010.03171.x
PG 6
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 722RB
UT WOS:000287450900013
PM 20880070
DA 2024-11-01
ER

PT J
AU Giordano, C
   Sebastiani, M
   Plazzi, G
   Travaglini, C
   Sale, P
   Pinti, M
   Tancredi, A
   Liguori, R
   Montagna, P
   Bellan, M
   Valentino, ML
   Cossarizza, A
   Hirano, M
   d'Amati, G
   Carelli, V
AF Giordano, C
   Sebastiani, M
   Plazzi, G
   Travaglini, C
   Sale, P
   Pinti, M
   Tancredi, A
   Liguori, R
   Montagna, P
   Bellan, M
   Valentino, ML
   Cossarizza, A
   Hirano, M
   d'Amati, G
   Carelli, V
TI Mitochondrial Neurogastrointestinal encephalomyopathy: Evidence of
   mitochondrial DNA depletion in the small intestine
SO GASTROENTEROLOGY
LA English
DT Article
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; FAMILIAL VISCERAL MYOPATHY;
   MUTATION; DISORDER; A5814G; MNGIE
AB Background & Aims: Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is an autosomal recessive disease clinically defined by gastrointestinal dysmotility, cachexia, ptosis, ophthalmoparesis, peripheral neuropathy, white-matter changes in brain magnetic resonance imaging, and mitochondrial abnormalities. Loss-of-function mutations in thymidine phosphorylase gene induce pathologic accumulations of thymidine and deoxyuridine that in turn cause mitochondrial DNA (mtDNA) defects (depletion, multiple deletions, and point mutations). Our study is aimed to define the molecular basis of gastrointestinal dysmotility in a case of MNGIE. Methods: By using laser capture microdissection techniques, we correlated histologic features with mtDNA abnormalities in different tissue components of the gastrointestinal wall in a MNGIE patient and ten controls. Results: The patient's small intestine showed marked atrophy and mitochondrial proliferation of the external layer of muscularis propria. Genetic analysis revealed selective depletion of mtDNA in the small intestine compared with esophagus, stomach, and colon, and microdissection analysis revealed that mtDNA depletion was confined to the external layer of muscularis propria. Multiple deletions were detected in the upper esophagus and skeletal muscle. Site-specific somatic point mutations were detected only at low abundance both in the muscle and nervous tissue of the gastrointestinal tract. Analysis of the gastrointestinal tract from 10 controls revealed a non-homogeneous distribution of mtDNA content; the small intestine had the lowest levels of mtDNA. Conclusion: Atrophy, mitochondrial proliferation, and mtDNA depletion in the external layer of muscularis propria of small intestine indicate that visceral myopathy is responsible for gastrointestinal dysmotility in this MNGIE patient.
C1 Univ Roma La Sapienza, Dipartimento Med Sperimentale & Patol, I-00161 Rome, Italy.
   Univ Bologna, Dipartimento Sci Neurol, Bologna, Italy.
   IRCCS San Raffaele, Rome, Italy.
   Univ Modena & Reggio Emilia, Dipartimento Sci Biomed, Sez Patol Gen, Emilia, Italy.
   Univ Roma La Sapienza, Dipartimento Geoecon, Rome, Italy.
   Columbia Univ, Coll Phys & Surg, New York, NY USA.
C3 Sapienza University Rome; University of Bologna; Vita-Salute San
   Raffaele University; IRCCS Ospedale San Raffaele; IRCCS San Raffaele
   Pisana; Universita di Modena e Reggio Emilia; Sapienza University Rome;
   Columbia University
RP Univ Roma La Sapienza, Dipartimento Med Sperimentale & Patol, Viale Regina Elena 324, I-00161 Rome, Italy.
EM carla.giordano@uniroma1.it
RI Liguori, Rocco/AAB-7860-2020; Plazzi, Giuseppe/AAB-9627-2020; d'Amati,
   Giulia/F-1251-2011; Sale, Patrizio/K-8757-2016; Pinti,
   Marcello/C-9351-2015; GIORDANO, Carla/L-5657-2015
OI Sale, Patrizio/0000-0002-4850-3673; VALENTINO, MARIA
   LUCIA/0000-0001-5323-0115; Liguori, Rocco/0000-0002-1815-1013; Pinti,
   Marcello/0000-0001-9118-1262; CARELLI, VALERIO/0000-0003-4923-6404;
   Cossarizza, Andrea/0000-0002-5381-1558; Plazzi,
   Giuseppe/0000-0002-1051-0472; GIORDANO, Carla/0000-0002-3716-4303
CR ANURAS S, 1983, GASTROENTEROLOGY, V84, P346
   ARNAUDO E, 1991, LANCET, V337, P508, DOI 10.1016/0140-6736(91)91294-5
   CAVE DR, 1990, NEW ENGL J MED, V322, P829
   Cossarizza A, 2003, ANTIVIR THER, V8, P315
   FENOGLIOPREISER CM, 1998, GASTROINTESTINAL PAT, P614
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   HIRANO M, 1994, NEUROLOGY, V44, P721, DOI 10.1212/WNL.44.4.721
   IONASESCU V, 1983, J NEUROL SCI, V59, P215, DOI 10.1016/0022-510X(83)90039-4
   Karadimas C, 2001, J CHILD NEUROL, V16, P531, DOI 10.1177/088307380101600715
   Kornblum C, 2001, NEUROLOGY, V56, P1409, DOI 10.1212/WNL.56.10.1409
   Manfredi G, 1996, HUM MUTAT, V7, P158
   Martí R, 2003, BIOCHEM BIOPH RES CO, V303, P14, DOI 10.1016/S0006-291X(03)00294-8
   MCSHANE MA, 1991, AM J HUM GENET, V48, P39
   MONTAGNA P, 1995, J NEUROL NEUROSUR PS, V58, P640, DOI 10.1136/jnnp.58.5.640
   Mueller LA, 1999, GASTROENTEROLOGY, V116, P959, DOI 10.1016/S0016-5085(99)70080-6
   Neuman M I, 1998, J Perinatol, V18, P20
   Nishigaki Y, 2004, HUM MOL GENET, V13, P91, DOI 10.1093/hmg/ddh010
   Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828
   Nishino I, 2000, ANN NEUROL, V47, P792
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Pinhero J., 2000, MIXED EFFECTS MODELS, DOI DOI 10.1007/978-1-4419-0318-1
   Pistilli D, 2003, HUM PATHOL, V34, P1058, DOI 10.1053/S0046-8177(03)00344-7
   Santorelli FM, 1997, NEUROMUSCULAR DISORD, V7, P156, DOI 10.1016/S0960-8966(97)00444-6
   Spinazzola A, 2002, J BIOL CHEM, V277, P4128, DOI 10.1074/jbc.M111028200
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
NR 25
TC 48
Z9 49
U1 0
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0016-5085
EI 1528-0012
J9 GASTROENTEROLOGY
JI Gastroenterology
PD MAR
PY 2006
VL 130
IS 3
BP 893
EP 901
DI 10.1053/j.gastro.2006.01.004
PG 9
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA 024QC
UT WOS:000236210100030
PM 16530527
OA Bronze
DA 2024-11-01
ER

PT J
AU DiMauro, S
AF DiMauro, Salvatore
TI A Brief History of Mitochondrial Pathologies
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE mitochondrial pathologies; mtDNA mutations; mendelian and maternal
   inheritance
ID ONSET SPINOCEREBELLAR ATAXIA; MULTIPLE DELETIONS; DNA-DAMAGE; MUTATIONS;
   GENE; MTDNA; DEPLETION; FAMILY; DEFICIENCY; MYOPATHY
AB The history of "mitochondrial pathologies", namely genetic pathologies affecting mitochondrial metabolism because of mutations in nuclear DNA-encoded genes for proteins active inside mitochondria or mutations in mitochondrial DNA-encoded genes, began in 1988. In that year, two different groups of researchers discovered, respectively, large-scale single deletions of mitochondrial DNA (mtDNA) in muscle biopsies from patients with "mitochondrial myopathies" and a point mutation in the mtDNA gene for subunit 4 of NADH dehydrogenase (MTND4), associated with maternally inherited Leber's hereditary optic neuropathy (LHON). Henceforth, a novel conceptual "mitochondrial genetics", separate from mendelian genetics, arose, based on three features of mtDNA: (1) polyplasmy; (2) maternal inheritance; and (3) mitotic segregation. Diagnosis of mtDNA-related diseases became possible through genetic analysis and experimental approaches involving histochemical staining of muscle or brain sections, single-fiber polymerase chain reaction (PCR) of mtDNA, and the creation of patient-derived "cybrid" (cytoplasmic hybrid) immortal fibroblast cell lines. The availability of the above-mentioned techniques along with the novel sensitivity of clinicians to such disorders led to the characterization of a constantly growing number of pathologies. Here is traced a brief historical perspective on the discovery of autonomous pathogenic mtDNA mutations and on the related mendelian pathology altering mtDNA integrity.
C1 [DiMauro, Salvatore] Columbia Univ, Dept Neurol, Med Ctr, New York, NY 10032 USA.
C3 Columbia University
RP DiMauro, S (corresponding author), Columbia Univ, Dept Neurol, Med Ctr, New York, NY 10032 USA.
EM sd12@cumc.columbia.edu
CR Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   Bornstein B, 2008, NEUROMUSCULAR DISORD, V18, P453, DOI 10.1016/j.nmd.2008.04.006
   Borthwick Gillian M, 2006, Ann Neurol, V59, P570, DOI 10.1002/ana.20758
   Chinnery PF, 2004, LANCET, V364, P592, DOI 10.1016/S0140-6736(04)16851-7
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   DiMauro S, 2013, NAT REV NEUROL, V9, P429, DOI 10.1038/nrneurol.2013.126
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Garone C, 2018, J MED GENET, V55, P515, DOI 10.1136/jmedgenet-2017-105012
   Garone C, 2017, J CHILD NEUROL, V32, P246, DOI 10.1177/0883073816666221
   Garone C, 2012, ARCH NEUROL-CHICAGO, V69, P1648, DOI 10.1001/archneurol.2012.405
   GILES RE, 1980, P NATL ACAD SCI-BIOL, V77, P6715, DOI 10.1073/pnas.77.11.6715
   Hakonen AH, 2008, HUM MOL GENET, V17, P3822, DOI 10.1093/hmg/ddn280
   Halter JP, 2015, BRAIN, V138, P2847, DOI 10.1093/brain/awv226
   Hirano M, 2018, ESSAYS BIOCHEM, V62, P467, DOI 10.1042/EBC20170114
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Hong DJ, 2010, MUSCLE NERVE, V41, P92, DOI 10.1002/mus.21439
   Karadimas CL, 2006, AM J HUM GENET, V79, P544, DOI 10.1086/506913
   Karadimas CL, 2000, NEUROLOGY, V55, P644, DOI 10.1212/WNL.55.5.644
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Lopez-Gomez C, 2017, ANN NEUROL, V81, P641, DOI 10.1002/ana.24922
   Luo SY, 2018, P NATL ACAD SCI USA, V115, P13039, DOI 10.1073/pnas.1810946115
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   MORAES CT, 1993, J CLIN INVEST, V92, P2906, DOI 10.1172/JCI116913
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Nguyen KV, 2005, NEUROLOGY, V65, P1493, DOI 10.1212/01.wnl.0000182814.55361.70
   Nikali K, 2005, HUM MOL GENET, V14, P2981, DOI 10.1093/hmg/ddi328
   Nishigaki Y, 2004, HUM MOL GENET, V13, P91, DOI 10.1093/hmg/ddh010
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Palmieri F, 2014, J INHERIT METAB DIS, V37, P565, DOI 10.1007/s10545-014-9708-5
   Paradas C, 2013, JAMA NEUROL, V70, P1425, DOI 10.1001/jamaneurol.2013.3185
   Paradas C, 2013, NEUROLOGY, V80, P504, DOI 10.1212/WNL.0b013e31827f0ff7
   Pitceathly RDS, 2011, J MED GENET, V48, P610, DOI 10.1136/jmg.2010.088328
   Pons R, 1996, PEDIATR NEUROL, V15, P153, DOI 10.1016/0887-8994(96)00118-X
   Ronchi D, 2012, BRAIN, V135, P3404, DOI 10.1093/brain/aws258
   Sazonova MA, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9090499
   Sazonova MA, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/6934394
   Shaibani A, 2009, ARCH NEUROL-CHICAGO, V66, P1028, DOI 10.1001/archneurol.2009.139
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   Takata A, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-9-r92
   Tanji K, 2007, METHOD CELL BIOL, V80, P135, DOI 10.1016/S0091-679X(06)80006-3
   TRITSCHLER HJ, 1992, NEUROLOGY, V42, P209, DOI 10.1212/WNL.42.1.209
   Uryga A, 2016, ANNU REV PHYSIOL, V78, P45, DOI 10.1146/annurev-physiol-021115-105127
   Van Hove JLK, 2010, PEDIATR RES, V68, P159, DOI 10.1203/00006450-201011001-00310
   Varma H, 2016, EUR J MED GENET, V59, P540, DOI 10.1016/j.ejmg.2016.08.012
   Volobueva A, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9080377
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   Wang JL, 2018, MOL GENET METAB, V124, P124, DOI 10.1016/j.ymgme.2018.04.012
   Wong LJC, 2008, HUM MUTAT, V29, pE150, DOI 10.1002/humu.20824
   Yu EPK, 2016, FREE RADICAL BIO MED, V100, P223, DOI 10.1016/j.freeradbiomed.2016.06.011
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 54
TC 14
Z9 16
U1 0
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD NOV
PY 2019
VL 20
IS 22
AR 5643
DI 10.3390/ijms20225643
PG 11
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA JW0YW
UT WOS:000502786800125
PM 31718067
OA Green Published, gold
DA 2024-11-01
ER

PT J
AU Rusecka, J
   Kaliszewska, M
   Bartnik, E
   Tonska, K
AF Rusecka, Joanna
   Kaliszewska, Magdalena
   Bartnik, Ewa
   Tonska, Katarzyna
TI Nuclear genes involved in mitochondrial diseases caused by instability
   of mitochondrial DNA
SO JOURNAL OF APPLIED GENETICS
LA English
DT Review
DE Mitochondrial diseases; Nuclear genes; Mitochondrial DNA instability;
   Mitochondrial DNA deletions; Depletion
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; MULTIPLE MTDNA DELETIONS;
   TRANSCRIPTION-FACTOR; BINDING-PROTEIN; POLYMERASE-GAMMA; COPY NUMBER;
   AUTOSOMAL-DOMINANT; DEPLETION MYOPATHY; THYMIDINE KINASE; MPV17 ENCODES
AB Mitochondrial diseases are defined by a respiratory chain dysfunction and in most of the cases manifest as multisystem disorders with predominant expression in muscles and nerves and may be caused by mutations in mitochondrial (mtDNA) or nuclear (nDNA) genomes. Most of the proteins involved in respiratory chain function are nuclear encoded, although 13 subunits of respiratory chain complexes (together with 2 rRNAs and 22 tRNAs necessary for their translation) encoded by mtDNA are essential for cell function. nDNA encodes not only respiratory chain subunits but also all the proteins responsible for mtDNA maintenance, especially those involved in replication, as well as other proteins necessary for the transcription and copy number control of this multicopy genome. Mutations in these genes can cause secondary instability of the mitochondrial genome in the form of depletion (decreased number of mtDNA molecules in the cell), vast multiple deletions or accumulation of point mutations which in turn leads to mitochondrial diseases inherited in a Mendelian fashion. The list of genes involved in mitochondrial DNA maintenance is long, and still incomplete.
C1 [Rusecka, Joanna; Kaliszewska, Magdalena; Bartnik, Ewa; Tonska, Katarzyna] Univ Warsaw, Inst Genet & Biotechnol, Fac Biol, Pawinskiego 5a, PL-02106 Warsaw, Poland.
   [Bartnik, Ewa] Polish Acad Sci, Inst Biochem & Biophys, Pawinskiego 5a, PL-02106 Warsaw, Poland.
C3 University of Warsaw; Polish Academy of Sciences; Institute of
   Biochemistry & Biophysics - Polish Academy of Sciences
RP Tonska, K (corresponding author), Univ Warsaw, Inst Genet & Biotechnol, Fac Biol, Pawinskiego 5a, PL-02106 Warsaw, Poland.
EM kaska@igib.uw.edu.pl
OI Kaliszewska, Magdalena/0000-0003-3649-4375; Bartnik,
   Ewa/0000-0003-0489-7102; Rusecka, Joanna/0000-0002-6936-9645; Tonska,
   Katarzyna/0000-0002-1793-6089
FU National Science Center [2014/15/B/NZ5/00434]
FX This work was supported by National Science Center grant
   2014/15/B/NZ5/00434.
CR Ahmed N, 2015, INT J MOL SCI, V16, P18054, DOI 10.3390/ijms160818054
   Antonenkov VD, 2015, J BIOL CHEM, V290, P13840, DOI 10.1074/jbc.M114.608083
   Arpa J, 2003, MUSCLE NERVE, V28, P690, DOI 10.1002/mus.10507
   Béhin A, 2012, NEUROLOGY, V78, P644, DOI 10.1212/WNL.0b013e318248df2b
   Bronckaers A, 2009, MED RES REV, V29, P903, DOI 10.1002/med.20159
   Cámara Y, 2015, NEUROLOGY, V84, P2286, DOI 10.1212/WNL.0000000000001644
   Campbell CT, 2012, BBA-GENE REGUL MECH, V1819, P921, DOI 10.1016/j.bbagrm.2012.03.002
   Capps GJ, 2003, J THEOR BIOL, V221, P565, DOI 10.1006/jtbi.2003.3207
   Capt C, 2016, MITOCHONDRIAL DNA A, V27, P3098, DOI 10.3109/19401736.2014.1003924
   Cerritelli SM, 2003, MOL CELL, V11, P807, DOI 10.1016/S1097-2765(03)00088-1
   Chen HC, 2010, CELL, V141, P280, DOI 10.1016/j.cell.2010.02.026
   Ciesielski GL, 2016, METHODS MOL BIOL, V1351, P211, DOI 10.1007/978-1-4939-3040-1_16
   DeBalsi KL, 2017, AGEING RES REV, V33, P89, DOI 10.1016/j.arr.2016.04.006
   Di Re M, 2009, NUCLEIC ACIDS RES, V37, P5701, DOI 10.1093/nar/gkp614
   Dinwiddie GY, 2013, SOC SCI MED, V80, P67, DOI 10.1016/j.socscimed.2012.11.024
   Ekstrand MI, 2004, HUM MOL GENET, V13, P935, DOI 10.1093/hmg/ddh109
   Elachouri G, 2011, GENOME RES, V21, P12, DOI 10.1101/gr.108696.110
   Fahrner JA, 2016, AM J MED GENET A, V170, P2002, DOI 10.1002/ajmg.a.37721
   Falkenberg M, 2002, NAT GENET, V31, P289, DOI 10.1038/ng909
   Filadi R, 2015, P NATL ACAD SCI USA, V112, pE2174, DOI 10.1073/pnas.1504880112
   Friedman JR, 2011, SCIENCE, V334, P358, DOI 10.1126/science.1207385
   García-Gómez S, 2013, MOL CELL, V52, P541, DOI 10.1016/j.molcel.2013.09.025
   Goffart S, 2009, HUM MOL GENET, V18, P328, DOI 10.1093/hmg/ddn359
   Gorman GS, 2015, ANN NEUROL, V77, P753, DOI 10.1002/ana.24362
   Holt IJ, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a012971
   Holt IJ, 2000, CELL, V100, P515, DOI 10.1016/S0092-8674(00)80688-1
   Hudson G, 2008, BRAIN, V131, P329, DOI 10.1093/brain/awm272
   Hudson G, 2006, HUM MOL GENET, V15, pR244, DOI 10.1093/hmg/ddl233
   Javaid S, 2017, BIOORG CHEM, V70, P44, DOI 10.1016/j.bioorg.2016.11.007
   Johnson AA, 2001, J BIOL CHEM, V276, P40847, DOI 10.1074/jbc.M106743200
   Jüllig M, 2000, EUR J BIOCHEM, V267, P5466, DOI 10.1046/j.1432-1327.2000.01607.x
   Kang D, 2007, MITOCHONDRION, V7, P39, DOI 10.1016/j.mito.2006.11.017
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kawamata H, 2011, HUM MOL GENET, V20, P2964, DOI 10.1093/hmg/ddr200
   Korhonen JA, 2003, J BIOL CHEM, V278, P48627, DOI 10.1074/jbc.M306981200
   Krishnan KJ, 2008, NAT GENET, V40, P275, DOI 10.1038/ng.f.94
   Kühl I, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600963
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Lee YS, 2009, CELL, V139, P312, DOI 10.1016/j.cell.2009.07.050
   Lightowlers RN, 2015, SCIENCE, V349, P1494, DOI 10.1126/science.aac7516
   Linkowska K, 2015, ANN HUM GENET, V79, P320, DOI 10.1111/ahg.12111
   Litonin D, 2010, J BIOL CHEM, V285, P18129, DOI 10.1074/jbc.C110.128918
   Liu YX, 2015, MOL BIOL CELL, V26, P1985, DOI 10.1091/mbc.E15-01-0030
   Lodeiro MF, 2012, P NATL ACAD SCI USA, V109, P6513, DOI 10.1073/pnas.1118710109
   Losón OC, 2013, MOL BIOL CELL, V24, P659, DOI 10.1091/mbc.E12-10-0721
   MacVicar T, 2016, J CELL SCI, V129, P2297, DOI 10.1242/jcs.159186
   Maier D, 2001, MOL BIOL CELL, V12, P821, DOI 10.1091/mbc.12.4.821
   Mancuso M, 2003, ARCH NEUROL-CHICAGO, V60, P1007, DOI 10.1001/archneur.60.7.1007
   Martin-Garcia J, 2013, INTRO MITOCHONDRIA H, P63
   McKinney EA, 2013, GENET MOL BIOL, V36, P308, DOI 10.1590/s1415-47572013000300002
   Milenkovic D, 2013, HUM MOL GENET, V22, P1983, DOI 10.1093/hmg/ddt051
   Minczuk M, 2011, NUCLEIC ACIDS RES, V39, P4284, DOI 10.1093/nar/gkq1224
   Moustafa IM, 2015, BBA-GENE REGUL MECH, V1849, P987, DOI 10.1016/j.bbagrm.2015.05.010
   Naïmi M, 2006, EUR J HUM GENET, V14, P917, DOI 10.1038/sj.ejhg.5201627
   NASS MMK, 1963, J CELL BIOL, V19, P593, DOI 10.1083/jcb.19.3.593
   Nicholls TJ, 2014, HUM MOL GENET, V23, P6147, DOI 10.1093/hmg/ddu336
   Nikkanen J, 2016, CELL METAB, V23, P635, DOI 10.1016/j.cmet.2016.01.019
   Oliveira MT, 2015, GENOME BIOL EVOL, V7, P943, DOI 10.1093/gbe/evv042
   Paradas C, 2013, NEUROLOGY, V80, P504, DOI 10.1212/WNL.0b013e31827f0ff7
   Paramasivam A, 2016, MITOCHONDRION, V26, P81, DOI 10.1016/j.mito.2015.12.006
   Pebay-Peyroula E, 2003, NATURE, V426, P39, DOI 10.1038/nature02056
   Pfeffer G, 2015, NEUROLOGY, V84, P1174, DOI 10.1212/WNL.0000000000001369
   Pfeffer G, 2014, BRAIN, V137, P1323, DOI 10.1093/brain/awu060
   Picca A, 2015, MITOCHONDRION, V25, P67, DOI 10.1016/j.mito.2015.10.001
   Pontarin G, 2012, P NATL ACAD SCI USA, V109, P13302, DOI 10.1073/pnas.1211289109
   Posse V, 2015, NUCLEIC ACIDS RES, V43, P2615, DOI 10.1093/nar/gkv105
   Reyes A, 2015, AM J HUM GENET, V97, P186, DOI 10.1016/j.ajhg.2015.05.013
   Ronchi D, 2013, AM J HUM GENET, V92, P293, DOI 10.1016/j.ajhg.2012.12.014
   Ronchi D, 2012, BRAIN, V135, P3404, DOI 10.1093/brain/aws258
   Ruhanen H, 2010, BBA-MOL CELL RES, V1803, P931, DOI 10.1016/j.bbamcr.2010.04.008
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Sánchez-Ferrero E, 2013, CLIN GENET, V83, P257, DOI 10.1111/j.1399-0004.2012.01896.x
   SCHATZ G, 1963, BIOCHEM BIOPH RES CO, V12, P448, DOI 10.1016/0006-291X(63)90313-9
   Scheibye-Knudsen M, 2015, TRENDS CELL BIOL, V25, P158, DOI 10.1016/j.tcb.2014.11.002
   Shokolenko IN, 2015, BBA-MOL BASIS DIS, V1852, P1805, DOI 10.1016/j.bbadis.2015.05.016
   Skladal D, 2003, BRAIN, V126, P1905, DOI 10.1093/brain/awg170
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Stiles AR, 2016, MOL GENET METAB, V119, P91, DOI 10.1016/j.ymgme.2016.07.001
   Suomalainen A, 2010, NEUROMUSCULAR DISORD, V20, P429, DOI 10.1016/j.nmd.2010.03.017
   Szymanski MR, 2015, EMBO J, V34, P1959, DOI 10.15252/embj.201591520
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
   Tyynismaa H, 2004, HUM MOL GENET, V13, P3219, DOI 10.1093/hmg/ddh342
   Tyynismaa H, 2012, HUM MOL GENET, V21, P66, DOI 10.1093/hmg/ddr438
   Uhler JP, 2016, NUCLEIC ACIDS RES, V44, P5861, DOI 10.1093/nar/gkw468
   VANDYCK E, 1992, EMBO J, V11, P3421, DOI 10.1002/j.1460-2075.1992.tb05421.x
   Vielhaber S, 2013, ACTA NEUROPATHOL, V125, P245, DOI 10.1007/s00401-012-1036-y
   Wang LY, 2003, J BIOL CHEM, V278, P6963, DOI 10.1074/jbc.M206143200
   Wong LJC, 2013, MITOCHONDRION, V13, P379, DOI 10.1016/j.mito.2013.02.001
   Wortmann SB, 2015, J INHERIT METAB DIS, V38, P437, DOI 10.1007/s10545-015-9823-y
   Yoon G, 2016, J PEDIATR-US, V171, P313, DOI 10.1016/j.jpeds.2015.12.060
   Young MJ, 2016, CURR OPIN GENET DEV, V38, P52, DOI 10.1016/j.gde.2016.03.005
   Yu-Wai-Man P, 2010, BRAIN, V133, P771, DOI 10.1093/brain/awq007
NR 92
TC 59
Z9 66
U1 0
U2 14
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1234-1983
EI 2190-3883
J9 J APPL GENET
JI J. Appl. Genetics
PD FEB
PY 2018
VL 59
IS 1
BP 43
EP 57
DI 10.1007/s13353-017-0424-3
PG 15
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA FV1BN
UT WOS:000424296100005
PM 29344903
OA Green Published, hybrid
DA 2024-11-01
ER

PT J
AU Hatakeyama, H
   Katayama, A
   Komaki, H
   Nishino, I
   Goto, Y
AF Hatakeyama, Hideyuki
   Katayama, Ayako
   Komaki, Hirofumi
   Nishino, Ichizo
   Goto, Yu-ichi
TI Molecular pathomechanisms and cell-type-specific disease phenotypes of
   MELAS caused by mutant mitochondrial tRNA<SUP>Trp</SUP>
SO ACTA NEUROPATHOLOGICA COMMUNICATIONS
LA English
DT Article
DE Mitochondrial myopathy; encephalopathy; lactic acidosis; stroke-like
   episodes (MELAS); Mutant mitochondrial tRNA(Trp); Mitochondrial
   respiratory dysfunction; Induced pluripotent stem cells (iPSCs); in
   vitro cellular disease models
ID PLURIPOTENT STEM-CELLS; CYTOCHROME-C-OXIDASE; WOBBLE MODIFICATION
   DEFICIENCY; MTDNA MUTATION; POINT MUTATION; TRANSFER-RNAS; DNA;
   ENCEPHALOPATHY; PATHWAY; GENOME
AB Introduction: Numerous pathogenic mutations responsible for mitochondrial diseases have been identified in mitochondrial DNA (mtDNA)-encoded tRNA genes. In most cases, however, the detailed molecular pathomechanisms and cellular pathophysiology of these mtDNA mutations - how such genetic defects determine the variation and the severity of clinical symptoms in affected individuals-remain unclear. To investigate the molecular pathomechanisms and to realize in vitro recapitulation of mitochondrial diseases, intracellular mutant mtDNA proportions must always be considered.
   Results: We found a disease-causative mutation, m.5541C>T heteroplasmy in MT-TW gene, in a patient exhibiting mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) with multiple organ involvement. We identified the intrinsic molecular pathomechanisms of m.5541C>T. This mutation firstly disturbed the translation machinery of mitochondrial tRNA(Trp) and induced mitochondrial respiratory dysfunction, followed by severely injured mitochondrial homeostasis. We also demonstrated cell-type-specific disease phenotypes using patient-derived induced pluripotent stem cells (iPSCs) carrying similar to 100 % mutant m.5541C>T. Significant loss of terminally differentiated iPSC-derived neurons, but not their stem/progenitor cells, was detected most likely due to serious mitochondrial dysfunction triggered by m.5541C>T; in contrast, m.5541C>T did not apparently affect skeletal muscle development.
   Conclusions: Our iPSC-based disease models would be widely available for understanding the "definite" genotype-phenotype relationship of affected tissues and organs in various mitochondrial diseases caused by heteroplasmic mtDNA mutations, as well as for further drug discovery applications.
C1 [Hatakeyama, Hideyuki; Komaki, Hirofumi; Goto, Yu-ichi] Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Mental Retardat & Birth Defect Res, Kodaira, Tokyo 1878502, Japan.
   [Hatakeyama, Hideyuki; Goto, Yu-ichi] Japan Agcy Med Res & Dev, AMED CREST, Chiyoda Ku, Tokyo, Japan.
   [Katayama, Ayako; Komaki, Hirofumi; Goto, Yu-ichi] Natl Ctr Hosp, Natl Ctr Neurol & Psychiat, Dept Child Neurol, Kodaira, Tokyo 1878551, Japan.
   [Nishino, Ichizo] Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Neuromuscular Res, Kodaira, Tokyo 1878502, Japan.
   [Nishino, Ichizo; Goto, Yu-ichi] Natl Ctr Neurol & Psychiat, Med Genome Ctr, Kodaira, Tokyo 1878551, Japan.
C3 National Center for Neurology & Psychiatry - Japan; National Center for
   Neurology & Psychiatry - Japan; National Center for Neurology &
   Psychiatry - Japan; National Center for Neurology & Psychiatry - Japan
RP Hatakeyama, H (corresponding author), Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Mental Retardat & Birth Defect Res, Kodaira, Tokyo 1878502, Japan.
EM hideyuki@ncnp.go.jp; goto@ncnp.go.jp
RI Nishino, Ichizo/G-2676-2010
FU Ministry of Health, Labour, and Welfare, Japan; AMED-CREST from the
   Japan Agency for Medical Research and Development
FX This study was financially supported in part by Grant-in-Aid for
   Research on Intractable Diseases (Mitochondrial Disorders) from the
   Ministry of Health, Labour, and Welfare, Japan; by AMED-CREST from the
   Japan Agency for Medical Research and Development.
CR Akanuma J, 2000, J HUM GENET, V45, P337, DOI 10.1007/s100380070004
   Armstrong L, 2010, STEM CELLS, V28, P661, DOI 10.1002/stem.307
   Blakely EL, 2013, HUM MUTAT, V34, P1260, DOI 10.1002/humu.22358
   Chambers SM, 2009, NAT BIOTECHNOL, V27, P275, DOI 10.1038/nbt.1529
   Cherry ABC, 2013, STEM CELLS, V31, P1287, DOI 10.1002/stem.1354
   ENRIQUEZ JA, 1995, NAT GENET, V10, P47, DOI 10.1038/ng0595-47
   Folmes CDL, 2013, STEM CELLS, V31, P1298, DOI 10.1002/stem.1389
   Folmes CDL, 2012, CELL STEM CELL, V11, P596, DOI 10.1016/j.stem.2012.10.002
   Folmes CDL, 2011, CELL METAB, V14, P264, DOI 10.1016/j.cmet.2011.06.011
   Fujikura J, 2012, DIABETOLOGIA, V55, P1689, DOI 10.1007/s00125-012-2508-2
   Hämäläinen RH, 2013, P NATL ACAD SCI USA, V110, pE3622, DOI 10.1073/pnas.1311660110
   Hao HL, 1997, MOL CELL BIOL, V17, P6831, DOI 10.1128/MCB.17.12.6831
   Kaufmann P, 1996, ANN NEUROL, V40, P172, DOI 10.1002/ana.410400208
   Kirino Y, 2005, P NATL ACAD SCI USA, V102, P7127, DOI 10.1073/pnas.0500563102
   Kirino Y, 2004, P NATL ACAD SCI USA, V101, P15070, DOI 10.1073/pnas.0405173101
   Kodaira M, 2015, FEBS OPEN BIO, V5, P219, DOI 10.1016/j.fob.2015.03.008
   Maniura-Weber K, 2004, EUR J HUM GENET, V12, P509, DOI 10.1038/sj.ejhg.5201185
   Menendez L, 2011, P NATL ACAD SCI USA, V108, P19240, DOI 10.1073/pnas.1113746108
   Mkaouar-Rebai E, 2009, MOL GENET METAB, V97, P179, DOI 10.1016/j.ymgme.2009.03.003
   NELSON I, 1995, ANN NEUROL, V37, P400, DOI 10.1002/ana.410370317
   Okita K, 2011, NAT METHODS, V8, P409, DOI [10.1038/NMETH.1591, 10.1038/nmeth.1591]
   Prigione A, 2010, STEM CELLS, V28, P721, DOI 10.1002/stem.404
   Sacconi S, 2008, HUM MOL GENET, V17, P1814, DOI 10.1093/hmg/ddn073
   Santorelli FM, 1997, ANN NEUROL, V42, P256, DOI 10.1002/ana.410420220
   Schägger H, 2006, NAT PROTOC, V1, P16, DOI 10.1038/nprot.2006.4
   Shoubridge EA, 2001, AM J MED GENET, V106, P46, DOI 10.1002/ajmg.1378
   Silvestri G, 1998, NEUROMUSCULAR DISORD, V8, P291, DOI 10.1016/S0960-8966(98)00037-6
   Silvestri G, 2000, NEUROLOGY, V54, P1693, DOI 10.1212/WNL.54.8.1693
   Sproule DM, 2008, ANN NY ACAD SCI, V1142, P133, DOI 10.1196/annals.1444.011
   Suzuki T, 2011, ANNU REV GENET, V45, P299, DOI 10.1146/annurev-genet-110410-132531
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Tanaka M, 2004, ANN NY ACAD SCI, V1011, P7, DOI 10.1196/annals.1293.002
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0
   Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136
   Wittig I, 2006, NAT PROTOC, V1, P418, DOI 10.1038/nprot.2006.62
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
NR 37
TC 32
Z9 32
U1 0
U2 9
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2051-5960
J9 ACTA NEUROPATHOL COM
JI Acta Neuropathol. Commun.
PD AUG 22
PY 2015
VL 3
AR 52
DI 10.1186/s40478-015-0227-x
PG 13
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA CP9XE
UT WOS:000360247900001
PM 26297375
OA gold, Green Published
DA 2024-11-01
ER

PT J
AU Béhin, A
   Jardel, C
   Claeys, KG
   Fagart, J
   Louha, M
   Romero, NB
   Laforêt, P
   Eymard, B
   Lombès, A
AF Behin, A.
   Jardel, C.
   Claeys, K. G.
   Fagart, J.
   Louha, M.
   Romero, N. B.
   Laforet, P.
   Eymard, B.
   Lombes, A.
TI Adult cases of mitochondrial DNA depletion due to <i>TK2</i> defect An
   expanding spectrum
SO NEUROLOGY
LA English
DT Article
ID THYMIDINE KINASE-2 GENE; MTDNA DEPLETION; MUTATIONS; MYOPATHY; PATIENT;
   DISEASES
AB Objective: In this study we aim to demonstrate the occurrence of adult forms of TK2 mutations causing progressive mitochondrial myopathy with significant muscle mitochondrial DNA (mtDNA) depletion.
   Methods: Patients' investigations included serum creatine kinase, blood lactate, electromyographic, echocardiographic, and functional respiratory analyses as well as TK2 gene sequencing and TK2 activity measurement. Mitochondrial activities and mtDNA were analyzed in the patients' muscle biopsy.
   Results: The 3 adult patients with TK2 mutations presented with slowly progressive myopathy compatible with a fairly normal life during decades. Apart from its much slower progression, these patients' phenotype closely resembled that of pediatric cases including early onset, absence of CNS symptoms, generalized muscle weakness predominating on axial and proximal muscles but affecting facial, ocular, and respiratory muscles, typical mitochondrial myopathy with a mosaic pattern of COX-negative and ragged-red fibers, combined mtDNA-dependent respiratory complexes deficiency and mtDNA depletion. In accordance with the disease's relatively slow progression, the residual mtDNA content was higher than that observed in pediatric cases. That difference was not explained by the type of the TK2 mutations or by the residual TK2 activity.
   Conclusion: TK2 mutations can cause mitochondrial myopathy with a slow progression. Comparison of patients with similar mutations but different disease progression might address potential mechanisms of mtDNA maintenance modulation. Neurology (R) 2012;78:644-648
C1 [Jardel, C.; Louha, M.; Lombes, A.] GH Pitie Salpetriere, APHP, Unite Cardiogenet & Myogenet Mol & Cellulaire, Paris, France.
   [Behin, A.; Laforet, P.; Eymard, B.] GH Pitie Salpetriere, APHP, Ctr Reference Pathol Neuromusculaire Paris Est, Inst Myol, Paris, France.
   [Claeys, K. G.; Romero, N. B.] GH Pitie Salpetriere, APHP, Lab Pathol Musculaire Risler, Inst Myol, Paris, France.
   [Jardel, C.; Lombes, A.] Hop La Pitie Salpetriere, INSERM, UMRS 975, Paris, France.
   [Jardel, C.; Lombes, A.] Hop La Pitie Salpetriere, CNRS, UMR 7225, Paris, France.
   [Eymard, B.; Lombes, A.] Hop La Pitie Salpetriere, UPMC, Paris, France.
   [Claeys, K. G.] RWTH Univ Hosp Aachen, Inst Neuropathol, Aachen, Germany.
   [Claeys, K. G.] RWTH Univ Hosp Aachen, Neurol Klin, Aachen, Germany.
   [Fagart, J.] Fac Med Paris Sud, INSERM, UMRS 693, Le Kremlin Bicetre, France.
C3 Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite;
   Hopital Universitaire Hotel-Dieu - APHP; Hopital Universitaire
   Ambroise-Pare - APHP; Hopital Universitaire Pitie-Salpetriere - APHP;
   Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP);
   Universite Paris Cite; Hopital Universitaire Hotel-Dieu - APHP; Sorbonne
   Universite; Hopital Universitaire Pitie-Salpetriere - APHP; Hopital
   Universitaire Ambroise-Pare - APHP; Assistance Publique Hopitaux Paris
   (APHP); Universite Paris Cite; Hopital Universitaire Hotel-Dieu - APHP;
   Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire
   Pitie-Salpetriere - APHP; Sorbonne Universite; Sorbonne Universite;
   Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Pitie-Salpetriere - APHP; Institut National de la Sante et de la
   Recherche Medicale (Inserm); Centre National de la Recherche
   Scientifique (CNRS); CNRS - National Institute for Biology (INSB);
   Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital
   Universitaire Pitie-Salpetriere - APHP; Sorbonne Universite; Assistance
   Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere
   - APHP; RWTH Aachen University; RWTH Aachen University Hospital; RWTH
   Aachen University; RWTH Aachen University Hospital; Institut National de
   la Sante et de la Recherche Medicale (Inserm); Universite Paris Saclay
RP Lombès, A (corresponding author), GH Pitie Salpetriere, APHP, Unite Cardiogenet & Myogenet Mol & Cellulaire, Paris, France.
EM anne.lombes@inserm.fr
RI Lombes, Anne/G-4684-2014; Fagart, Jerome/S-4581-2018
OI Fagart, Jerome/0000-0002-7965-0553; Behin, Anthony/0000-0001-7179-5152;
   Claeys, Kristl/0000-0001-9937-443X
FU AFM (Association Francaise contre les Myopathies); Genzyme Corporation;
   INSERM; ANR (Agence Nationale pour la Recherche) [ANR-08-MNPS-020-01]
FX Supported by grants from ANR (Agence Nationale pour la Recherche; ANR
   MNP 2008 Mitopark: ANR-08-MNPS-020-01) and AFM (Association Francaise
   contre les Myopathies) to A.L. Dr. Behin, Dr. Jardel, Dr. Claeys, Dr.
   Fagart, Dr. Louha, and Dr. Romero report no disclosures. Dr. Laforet
   serves on a scientific advisory board for and has received speaker
   honoraria and research support from Genzyme Corporation. Dr. Eymard has
   received speaker honoraria from Servier and receives research support
   from AFM (Association Francaise contre les myopathies). Dr. Lombes has
   received research support from INSERM: recurrent state funding, ANR, and
   AFM.
CR ARNER ESJ, 1995, PHARMACOL THERAPEUT, V67, P155, DOI 10.1016/0163-7258(95)00015-9
   Auré K, 2007, BRAIN, V130, P1516, DOI 10.1093/brain/awm067
   Barthélémy C, 2001, ANN NEUROL, V49, P607, DOI 10.1002/ana.1002.abs
   Blakely E, 2008, NEUROMUSCULAR DISORD, V18, P557, DOI 10.1016/j.nmd.2008.04.014
   Carrozzo R, 2003, HUM MUTAT, V21, DOI 10.1002/humu.9135
   Collins J, 2009, NEUROMUSCULAR DISORD, V19, P784, DOI 10.1016/j.nmd.2009.08.002
   Copeland WC, 2008, ANNU REV MED, V59, P131, DOI 10.1146/annurev.med.59.053006.104646
   Dubowitz V., 1973, MUSCLE BIOPSY MODERN
   Galbiati S, 2006, PEDIATR NEUROL, V34, P177, DOI 10.1016/j.pediatrneurol.2005.07.013
   Götz A, 2008, BRAIN, V131, P2841, DOI 10.1093/brain/awn236
   Hakonen AH, 2008, HUM MOL GENET, V17, P3822, DOI 10.1093/hmg/ddn280
   Kim MJ, 2008, ANTIMICROB AGENTS CH, V52, P1670, DOI 10.1128/AAC.01449-07
   Lesko N, 2010, NEUROMUSCULAR DISORD, V20, P198, DOI 10.1016/j.nmd.2009.11.013
   Mancuso M, 2003, ARCH NEUROL-CHICAGO, V60, P1007, DOI 10.1001/archneur.60.7.1007
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Martí R, 2010, PEDIATR RES, V68, P151, DOI 10.1203/00006450-201011001-00294
   Medja F, 2009, MITOCHONDRION, V9, P331, DOI 10.1016/j.mito.2009.05.001
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Oskoui M, 2006, ARCH NEUROL-CHICAGO, V63, P1122, DOI 10.1001/archneur.63.8.1122
   Poulton J, 2009, BBA-MOL BASIS DIS, V1792, P1109, DOI 10.1016/j.bbadis.2009.08.016
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Spinazzola A, 2009, J INHERIT METAB DIS, V32, P143, DOI 10.1007/s10545-008-1038-z
   Suomalainen A, 2010, NEUROMUSCULAR DISORD, V20, P429, DOI 10.1016/j.nmd.2010.03.017
   Tulinius M, 2005, NEUROMUSCULAR DISORD, V15, P412, DOI 10.1016/j.nmd.2005.03.010
   Vilà MR, 2003, NEUROLOGY, V60, P1203, DOI 10.1212/01.WNL.0000055928.58122.47
   Vu TH, 1998, NEUROLOGY, V51, P1190, DOI 10.1212/WNL.51.4.1190
   Wang LY, 2005, MOL GENET METAB, V84, P75, DOI 10.1016/j.ymgme.2004.09.005
   Zhou XS, 2008, HUM MOL GENET, V17, P2329, DOI 10.1093/hmg/ddn133
NR 28
TC 37
Z9 42
U1 0
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD FEB
PY 2012
VL 78
IS 9
BP 644
EP 648
DI 10.1212/WNL.0b013e318248df2b
PG 5
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 901FP
UT WOS:000300948400014
PM 22345218
DA 2024-11-01
ER

PT J
AU Spinazzola, A
   Zeviani, M
AF Spinazzola, A
   Zeviani, M
TI Disorders of nuclear-mitochondrial intergenomic signaling
SO GENE
LA English
DT Article; Proceedings Paper
CT Meeting on Cross Talk between Nucleus and Organelles
CY SEP 15-18, 2004
CL Stazione Zool Anton Dohrn, Naples, ITALY
HO Stazione Zool Anton Dohrn
DE mitochondrial DNA; multiple deletions; depletion; autosomal
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; POLYMERASE-GAMMA MUTATIONS;
   AUTOSOMAL-DOMINANT; MULTIPLE DELETIONS; DNA DEPLETION; POLG MUTATIONS;
   THYMIDINE KINASE; GENETIC FEATURES; MYOPATHY; INVOLVEMENT
AB Depletion and multiple deletions of mitochondrial DNA (mtDNA) have been associated with a number of autosomal disorders classified as defects of nuclear-mitochondrial intergenomic signaling. The mendelian forms of progressive external ophthalmoplegia (PEO) are clinically and genetically heterogeneous disorders characterized by the accumulation of multiple deletions of mtDNA in postmitotic patient's tissues.
   Most of the autosomal dominant PEO (adPEO) families carry heterozygous mutations in either one of three genes: ANTI, Twinkle, and POLG1. Mutations in POLG1 can also cause autosomal recessive PEO (arPEO) and apparently sporadic cases. In addition, recessive POLG1 mutations are responsible for sensory-atactic neuropathy, dysarthria and ophthalmoplegia (SANDO), juvenile spino-cerebellar ataxia-epilepsy syndrome (SCAE) and Alpers-Huttenlocher hepatopathic poliodystrophy.
   Mutations in thymidine phosphorylase gene (TP) are linked to mitochondrial neurogastrointestinal encephalomyopathy (MNGIE), an autosomal recessive disorder in which PEO is associated with gastrointestinal dysmotility and leukodystrophy.
   Finally, mitochondrial DNA depletion syndromes (MDS), defined by tissue-reduction in mtDNA copy number, have been linked to mutations in two genes involved in deoxyribonucleotide (dNTP) metabolism: thymidine kinase 2 (TK2) and deoxyguanosine kinase (DGUOK). (c) 2005 Elsevier B.V. All rights reserved.
C1 Natl Neurol Inst Carlo Besta, Unit Mol Neurogenet, Pierfranco & Luisa Mariani Ctr Study Childrens Mi, I-20126 Milan, Italy.
C3 Fondazione IRCCS Istituto Neurologico Carlo Besta
RP Zeviani, M (corresponding author), Natl Neurol Inst Carlo Besta, Unit Mol Neurogenet, Pierfranco & Luisa Mariani Ctr Study Childrens Mi, Via Temolo 4, I-20126 Milan, Italy.
EM zeviani@istituto-besta.it
RI Zeviani, Massimo/K-2891-2014; Spinazzola, Antonella/P-5298-2017
OI Zeviani, Massimo/0000-0002-9067-5508; Spinazzola,
   Antonella/0000-0003-4242-8091
FU Telethon [GGP030039] Funding Source: Medline
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   ARNAUDO E, 1991, LANCET, V337, P508, DOI 10.1016/0140-6736(91)91294-5
   Bauer MKA, 1999, J CELL BIOL, V147, P1493, DOI 10.1083/jcb.147.7.1493
   Bohlega S, 1996, NEUROLOGY, V46, P1329, DOI 10.1212/WNL.46.5.1329
   FERRARI G, 2005, UNPUB BRAIN, V21
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   HIRANO M, 1994, NEUROLOGY, V44, P721, DOI 10.1212/WNL.44.4.721
   Holt IJ, 2000, CELL, V100, P515, DOI 10.1016/S0092-8674(00)80688-1
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Mancuso M, 2003, ARCH NEUROL-CHICAGO, V60, P1007, DOI 10.1001/archneur.60.7.1007
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   MAZZIOTTA MRM, 1992, J PEDIATR-US, V121, P896, DOI 10.1016/S0022-3476(05)80335-X
   Melberg A, 1996, MUSCLE NERVE, V19, P751
   MIZUSAWA H, 1988, J NEUROL SCI, V86, P171, DOI 10.1016/0022-510X(88)90096-2
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Moslemi AR, 1996, ANN NEUROL, V40, P707, DOI 10.1002/ana.410400506
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Saada A, 2004, DNA CELL BIOL, V23, P797
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   SERVIDEI S, 1991, NEUROLOGY, V41, P1053, DOI 10.1212/WNL.41.7.1053
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   TRITSCHLER HJ, 1992, NEUROLOGY, V42, P209, DOI 10.1212/WNL.42.1.209
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   YUZAKI M, 1989, BIOCHEM BIOPH RES CO, V164, P1352, DOI 10.1016/0006-291X(89)91818-4
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 37
TC 89
Z9 98
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0378-1119
J9 GENE
JI Gene
PD JUL 18
PY 2005
VL 354
SI SI
BP 162
EP 168
DI 10.1016/j.gene.2005.03.025
PG 7
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)
SC Genetics & Heredity
GA 959DN
UT WOS:000231497200025
PM 15921863
DA 2024-11-01
ER

PT J
AU Milone, M
   Massie, R
AF Milone, Margherita
   Massie, Rami
TI Polymerase Gamma 1 Mutations <i>Clinical Correlations</i>
SO NEUROLOGIST
LA English
DT Review
DE ataxia; Alpers; mitochondrial disease; PEO; POLG
ID MITOCHONDRIAL-DNA POLYMERASE; PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA;
   ALPERS-HUTTENLOCHER-SYNDROME; SENSORY ATAXIC NEUROPATHY;
   MAGNETIC-RESONANCE SPECTROSCOPY; ONSET SPINOCEREBELLAR ATAXIA; DOMINANT
   OPTIC ATROPHY; POLG1 MUTATIONS; NEURONAL DEGENERATION; PHENOTYPIC
   SPECTRUM
AB Background: Mitochondrial disorders result from primary defects in the mitochondrial DNA (mtDNA) or from defects in nuclear genes which cause disease by affecting the mtDNA. POLG1 is a nuclear gene which encodes for the catalytic subunit of the mtDNA polymerase gamma, essential for mtDNA replication. Less than a decade ago, POLG1 mutations were discovered in patients with progressive external ophthalmoplegia. Since then, it has emerged that POLG1 mutations can result in a spectrum of clinical manifestations, resulting in autosomal recessive or dominant mitochondrial diseases.
   Review Summary: Here we summarize the common clinical phenotypes associated with POLG1 mutations. Alpers syndrome, progressive external ophthalmoplegia with or without limb myopathy, ataxia-neuropathy syndrome, and epilepsy are frequent clinical manifestations of the POLG1-related disease. Childhood progressive encephalopathy, Parkinsonism, stroke-like events, and isolated exercise intolerance can occur in association with POLG1 mutations. Muscle biopsy can show signs of mitochondrial dysfunction by histologic and biochemical studies or it can be unrevealing. mtDNA analysis of affected tissues can reveal depletion, multiple deletions or point mutations, but it can be occasionally noninformative by routine analysis.
   Conclusions: POLG1 mutations result in extremely heterogenous phenotypes which often have overlapping clinical findings, making it difficult to categorize patients into syndromes. The lack of signs of mitochondrial dysfunction in the muscle biopsy does not exclude a POLG1-related disease. Analysis of mtDNA of clinically affected tissues is often informative, but not always. Molecular analysis of POLG1 is essential when POLG1-related disease is suspected. Sodium valproate should be avoided because of the risk of liver failure.
C1 [Milone, Margherita; Massie, Rami] Mayo Clin, Dept Neurol, Rochester, MN 55902 USA.
C3 Mayo Clinic
RP Milone, M (corresponding author), Mayo Clin, Dept Neurol, 200 1st St SW, Rochester, MN 55902 USA.
EM milone.margherita@mayo.edu
CR Aknin-Seifer IE, 2005, HUM REPROD, V20, P736, DOI 10.1093/humrep/deh666
   Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   Ashley N, 2008, HUM MOL GENET, V17, P2496, DOI 10.1093/hmg/ddn150
   Baloh RH, 2007, ARCH NEUROL-CHICAGO, V64, P998, DOI 10.1001/archneur.64.7.998
   Brunetti-Pierri N, 2008, NEUROPEDIATRICS, V39, P179, DOI 10.1055/s-0028-1093334
   Chan SSL, 2009, MITOCHONDRION, V9, P340, DOI 10.1016/j.mito.2009.05.002
   CHAN SS, 2008, BIOCHIM BIOPHYS ACTA, V1787, P312
   CHINNERY PF, 2007, NEUROMUSCULAR DISORD, V18, P259
   Copeland WC, 2008, ANNU REV MED, V59, P131, DOI 10.1146/annurev.med.59.053006.104646
   de Laveaucoupet J, 2005, PRENATAL DIAG, V25, P307, DOI 10.1002/pd.1128
   de Vries MC, 2007, EUR J PEDIATR, V166, P229, DOI 10.1007/s00431-006-0234-9
   Del Bo R, 2003, NEUROLOGY, V61, P903, DOI 10.1212/01.WNL.0000092303.13864.BE
   Deschauer M, 2007, NEUROLOGY, V68, P1741, DOI 10.1212/01.wnl.0000261929.92478.3e
   DiMauro S, 2004, BBA-BIOENERGETICS, V1658, P80, DOI 10.1016/j.bbabio.2004.03.014
   Engelsen BA, 2008, BRAIN, V131, P818, DOI 10.1093/brain/awn007
   Fadic R, 1997, NEUROLOGY, V49, P239, DOI 10.1212/WNL.49.1.239
   Farge G, 2007, NUCLEIC ACIDS RES, V35, P902, DOI 10.1093/nar/gkl1116
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Flemming K, 2002, AM J NEURORADIOL, V23, P1421
   Galassi G, 2008, NEUROMUSCULAR DISORD, V18, P465, DOI 10.1016/j.nmd.2008.03.013
   Giordano C, 2009, NEUROLOGY, V72, P1103, DOI 10.1212/01.wnl.0000345002.47396.e1
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Hakonen AH, 2008, HUM MOL GENET, V17, P3822, DOI 10.1093/hmg/ddn280
   Hakonen AH, 2007, EUR J HUM GENET, V15, P779, DOI 10.1038/sj.ejhg.5201831
   HARDING BN, 1990, J CHILD NEUROL, V5, P273, DOI 10.1177/088307389000500402
   Harrower T, 2008, ARCH NEUROL-CHICAGO, V65, P133, DOI 10.1001/archneurol.2007.4
   Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Hudson G, 2005, NEUROLOGY, V64, P371, DOI 10.1212/01.WNL.0000149767.51152.83
   Hudson G, 2008, BRAIN, V131, P329, DOI 10.1093/brain/awm272
   Hudson G, 2006, HUM MOL GENET, V15, pR244, DOI 10.1093/hmg/ddl233
   HUTTENLOCHER PR, 1976, ARCH NEUROL-CHICAGO, V33, P186, DOI 10.1001/archneur.1976.00500030042009
   Invernizzi F, 2008, NEUROMUSCULAR DISORD, V18, P460, DOI 10.1016/j.nmd.2008.04.005
   Johansen KK, 2008, MOVEMENT DISORD, V23, P1624, DOI 10.1002/mds.22178
   Joshi CN, 2009, PEDIATR NEUROL, V40, P314, DOI 10.1016/j.pediatrneurol.2008.10.023
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   Kang HC, 2007, EPILEPSIA, V48, P82, DOI 10.1111/j.1528-1167.2006.00906.x
   Kollberg G, 2006, J NEUROPATH EXP NEUR, V65, P758, DOI 10.1097/01.jnen.0000229987.17548.6e
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Lecrenier N, 1997, GENE, V185, P147, DOI 10.1016/S0378-1119(96)00663-4
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Lönnqvist T, 2009, BRAIN, V132, P1553, DOI 10.1093/brain/awp045
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Luoma PT, 2005, HUM MOL GENET, V14, P1907, DOI 10.1093/hmg/ddi196
   Mancuso M, 2004, ARCH NEUROL-CHICAGO, V61, P1777, DOI 10.1001/archneur.61.11.1777
   MATTHEWS PM, 1991, NEUROLOGY, V41, P114, DOI 10.1212/WNL.41.1.114
   Michalk A, 2008, AM J HUM GENET, V82, P464, DOI 10.1016/j.ajhg.2007.11.006
   Milone M, 2008, NEUROMUSCULAR DISORD, V18, P626, DOI 10.1016/j.nmd.2008.05.009
   Milone M, 2009, MITOCHONDRION, V9, P279, DOI 10.1016/j.mito.2009.03.001
   Naïmi M, 2006, EUR J HUM GENET, V14, P917, DOI 10.1038/sj.ejhg.5201627
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Naviaux RK, 1999, ANN NEUROL, V45, P54, DOI 10.1002/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B
   Nikali K, 2005, HUM MOL GENET, V14, P2981, DOI 10.1093/hmg/ddi328
   Payne M, 2004, AM J OPHTHALMOL, V138, P749, DOI 10.1016/j.ajo.2004.06.011
   Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200
   RANI DS, INT J ANDRO IN PRESS
   Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490
   Rovio AT, 2001, NAT GENET, V29, P261, DOI 10.1038/ng759
   Santoro L, 2006, J NEUROL, V253, P869, DOI 10.1007/s00415-006-0082-6
   Spelbrink JN, 2000, J BIOL CHEM, V275, P24818, DOI 10.1074/jbc.M000559200
   Spinazzola A, 2005, GENE, V354, P162, DOI 10.1016/j.gene.2005.03.025
   Stewart JD, 2009, J MED GENET, V46, P209, DOI 10.1136/jmg.2008.058180
   Tiangyou W, 2006, NEUROLOGY, V67, P1698, DOI 10.1212/01.wnl.0000238963.07425.d5
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Uusimaa J, 2008, EPILEPSIA, V49, P1038, DOI 10.1111/j.1528-1167.2008.01544.x
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Van Hove JLK, 2009, AM J MED GENET A, V149A, P861, DOI 10.1002/ajmg.a.32731
   Vandenberghe W, 2009, MOVEMENT DISORD, V24, P308, DOI 10.1002/mds.22198
   Virgilio R, 2008, J NEUROL, V255, P1384, DOI 10.1007/s00415-008-0926-3
   Wilichowski E, 1999, NEUROPEDIATRICS, V30, P256, DOI 10.1055/s-2007-973500
   Wiltshire E, 2008, ARCH NEUROL-CHICAGO, V65, P121, DOI 10.1001/archneurol.2007.14
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   Wong LJC, 2008, HUM MUTAT, V29, pE150, DOI 10.1002/humu.20824
   Yakubovskaya E, 2006, J BIOL CHEM, V281, P374, DOI 10.1074/jbc.M509730200
NR 77
TC 72
Z9 74
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1074-7931
J9 NEUROLOGIST
JI Neurologist
PD MAR
PY 2010
VL 16
IS 2
BP 84
EP 91
DI 10.1097/NRL.0b013e3181c78a89
PG 8
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 567ZU
UT WOS:000275490500003
PM 20220442
DA 2024-11-01
ER

PT J
AU Kollberg, G
   Moslemi, AR
   Darin, N
   Nennesmo, I
   Bjamadottir, I
   Uvebrant, P
   Holme, E
   Melberg, A
   Tulinius, M
   Oldfors, A
AF Kollberg, Gittan
   Moslemi, Ali-Reza
   Darin, Niklds
   Nennesmo, Inger
   Bjamadottir, Ingibjorg
   Uvebrant, Paul
   Holme, Elisabeth
   Melberg, Atle
   Tulinius, Mar
   Oldfors, Anders
TI POLG1 mutations associated with progressive encephalopathy in childhood
SO JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
LA English
DT Article
DE Alpers-Huttenlocher syndrome; COX deficiency; mitochondrial myopathy;
   MtDNA deletions; MtDNA depletion; polymerase gamma
ID MITOCHONDRIAL-DNA POLYMERASE; EXTERNAL OPHTHALMOPLEGIA; ALPERS-SYNDROME;
   AUTOSOMAL-DOMINANT; MULTIPLE DELETIONS; GAMMA MUTATIONS; VALPROIC ACID;
   KINASE GENE; DEGENERATION; DEPLETION
AB We have identified compound heterozygous missense mutations in POLG1, encoding the mitochondrial DNA polymerase gamma (Pol gamma), in 7 children with progressive encephalopathy from 5 unrelated families. The clinical features in 6 of the children included psychomotor regression, refractory seizures, stroke-like episodes, hepatopathy, and ataxia compatible with Alpers-Huttenlocher syndrome. Three families harbored a previously reported A467T substitution, which was found in compound with the earlier described G848S or the W748S substitution or a novel R574W substitution. Two families harbored the W748S change in compound with either of 2 novel mutations predicted to give an R232H or M1163R substitution. Muscle morphology showed mitochondrial myopathy with cytochrome c oxidase (COX)-deficient fibers in 4 patients. mtDNA analyses in muscle tissue revealed mtDNA depletion in 3 of the children and mtDNA deletions in the 2 sibling pairs. Neuropathologic investigation in 3 children revealed widespread cortical degeneration with gliosis and subcortical neuronal loss, especially in the thalamus, whereas there were only subcortical neurodegenerative findings in another child. The results support the concept that deletions as well as depletion of mtDNA are involved in the pathogenesis of Alpers-Huttenlocher syndrome and add 3 new POLG1 mutations associated with an early-onset neurodegenerative disease.
C1 Sahlgrens Univ Hosp, Dept Pathol, SE-41345 Gothenburg, Sweden.
   Sahlgrens Univ Hosp, Dept Clin Chem, SE-41345 Gothenburg, Sweden.
   Queen Silvia Childrens Hosp, Gothenburg, Sweden.
   Karolinska Univ Hosp, Dept Pathol, Stockholm, Sweden.
   Univ Uppsala Hosp, Dept Neurol, S-75185 Uppsala, Sweden.
   Univ Uppsala Hosp, Dept Neurosci, S-75185 Uppsala, Sweden.
C3 Sahlgrenska University Hospital; Sahlgrenska University Hospital; Queen
   Silvia Children's Hospital; Karolinska Institutet; Karolinska University
   Hospital; Uppsala University; Uppsala University Hospital; Uppsala
   University; Uppsala University Hospital
RP Oldfors, A (corresponding author), Sahlgrens Univ Hosp, Dept Pathol, SE-41345 Gothenburg, Sweden.
EM anders.oldfors@pathology.gu.se
RI Darin, Niklas/AAL-6345-2020
CR Alpers BJ, 1931, ARCH NEURO PSYCHIATR, V25, P469, DOI 10.1001/archneurpsyc.1931.02230030027002
   Andréasson H, 2002, BIOTECHNIQUES, V33, P402, DOI 10.2144/02332rr07
   BECKER CM, 1983, ARCH BIOCHEM BIOPHYS, V223, P381, DOI 10.1016/0003-9861(83)90602-1
   Bryant AE, 1996, NEUROLOGY, V46, P465, DOI 10.1212/WNL.46.2.465
   Chan SSL, 2005, J BIOL CHEM, V280, P31341, DOI 10.1074/jbc.M506762200
   CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6
   COULTER DL, 1991, J CHILD NEUROL, V6, P7, DOI 10.1177/088307389100600102
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   Di Fonzo A, 2003, HUM MUTAT, V22, DOI 10.1002/humu.9203
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   HAAS R, 1981, NEUROLOGY, V31, P1473, DOI 10.1212/WNL.31.11.1473
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   HARDING BN, 1990, J CHILD NEUROL, V5, P273, DOI 10.1177/088307389000500402
   HUTTENLOCHER PR, 1976, ARCH NEUROL-CHICAGO, V33, P186, DOI 10.1001/archneur.1976.00500030042009
   Kayihan N, 2000, Pediatr Transplant, V4, P211, DOI 10.1034/j.1399-3046.2000.00115.x
   Kollberg G, 2005, EUR J HUM GENET, V13, P463, DOI 10.1038/sj.ejhg.5201341
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Longley MJ, 2005, GENE, V354, P125, DOI 10.1016/j.gene.2005.03.029
   Luo NG, 2005, J BIOL CHEM, V280, P2491, DOI 10.1074/jbc.M411447200
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Moslemi AR, 1996, ANN NEUROL, V40, P707, DOI 10.1002/ana.410400506
   Moslemi AR, 1999, NEUROLOGY, V53, P79, DOI 10.1212/WNL.53.1.79
   Naviaux RK, 2005, ANN NEUROL, V58, P491, DOI 10.1002/ana.20544
   Naviaux RK, 1999, ANN NEUROL, V45, P54, DOI 10.1002/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B
   Nguyen KV, 2005, NEUROLOGY, V65, P1493, DOI 10.1212/01.wnl.0000182814.55361.70
   Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, NEUROLOGY, V61, P1811, DOI 10.1212/01.WNL.0000098997.23471.65
   Van Goethem G, 2003, NEUROMOL MED, V3, P129, DOI 10.1385/NMM:3:3:129
   Van Goethem G, 2003, HUM MUTAT, V22, P175, DOI 10.1002/humu.10246
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
NR 36
TC 70
Z9 71
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0022-3069
J9 J NEUROPATH EXP NEUR
JI J. Neuropathol. Exp. Neurol.
PD AUG
PY 2006
VL 65
IS 8
BP 758
EP 768
DI 10.1097/01.jnen.0000229987.17548.6e
PG 11
WC Clinical Neurology; Neurosciences; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pathology
GA 100TR
UT WOS:000241692300003
PM 16896309
OA Bronze
DA 2024-11-01
ER

PT J
AU Carreño-Gago, L
   Blázquez-Bermejo, C
   Díaz-Manera, J
   Cámara, Y
   Gallardo, E
   Martí, R
   Torres-Torronteras, J
   García-Arumí, E
AF Carreno-Gago, Lidia
   Blazquez-Bermejo, Cora
   Diaz-Manera, Jordi
   Camara, Yolanda
   Gallardo, Eduard
   Marti, Ramon
   Torres-Torronteras, Javier
   Garcia-Arumi, Elena
TI Identification and Characterization of New <i>RNASEH1</i> Mutations
   Associated With PEO Syndrome and Multiple Mitochondrial DNA Deletions
SO FRONTIERS IN GENETICS
LA English
DT Article
DE mtDNA; mitochondrial disease; PEO; multiple mtDNA deletions; RNASEH1
ID IMPAIR MTDNA REPLICATION; DISEASES; H1; SEQUENCE
AB Mitochondrial DNA (mtDNA) depletion and deletion syndrome encompasses a group of disorders caused by mutations in genes involved in mtDNA replication and maintenance. The clinical phenotype ranges from fatal infantile hepatocerebral forms to mild adult onset progressive external ophthalmoplegia (PEO). We report the case of a patient with PEO and multiple mtDNA deletions, with two new homozygous mutations in RNASEH1. The first mutation (c.487>C) is located in the same catalytic domain as the four previously reported mutations, and the second (c.258_260del) is located in the connection domain, where no mutations have been reported. In silico study of the mutations predicted only the first mutation as pathogenic, but functional studies showed that both mutations cause loss of ribonuclease H1 activity. mtDNA replication dysfunction was demonstrated in patient fibroblasts, which were unable to recover normal mtDNA copy number after ethidium bromide-induced mtDNA depletion. Our results demonstrate the pathogenicity of two new RNASEH1 variants found in a patient with PEO syndrome, multiple deletions, and mild mitochondrial myopathy.
C1 [Carreno-Gago, Lidia; Blazquez-Bermejo, Cora; Camara, Yolanda; Marti, Ramon; Torres-Torronteras, Javier; Garcia-Arumi, Elena] Univ Autonoma Barcelona, Hosp Univ Vail dHebron, Inst Recerca VHIR, Dept Patol Mitocondnal & Neuromuscular, Barcelona, Spain.
   [Carreno-Gago, Lidia; Blazquez-Bermejo, Cora; Diaz-Manera, Jordi; Camara, Yolanda; Gallardo, Eduard; Marti, Ramon; Torres-Torronteras, Javier; Garcia-Arumi, Elena] Inst Salud Carlos III, CIBERER, Barcelona, Spain.
   [Diaz-Manera, Jordi; Gallardo, Eduard] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Serv Neurol Malalties Neuromusculars, Barcelona, Spain.
   [Diaz-Manera, Jordi; Gallardo, Eduard] Univ Autonoma Barcelona, Inst Recerca, HSCSP, Barcelona, Spain.
   [Garcia-Arumi, Elena] Hosp Univ Vall dHebron, Area Genet Clin & Mol, Barcelona, Spain.
C3 Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron;
   Vall d'Hebron Institut de Recerca (VHIR); CIBER - Centro de
   Investigacion Biomedica en Red; CIBERER; Instituto de Salud Carlos III;
   Autonomous University of Barcelona; Hospital of Santa Creu i Sant Pau;
   Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron;
   Vall d'Hebron Institut de Recerca (VHIR); Hospital Universitari Vall
   d'Hebron
RP Torres-Torronteras, J; García-Arumí, E (corresponding author), Univ Autonoma Barcelona, Hosp Univ Vail dHebron, Inst Recerca VHIR, Dept Patol Mitocondnal & Neuromuscular, Barcelona, Spain.; Torres-Torronteras, J; García-Arumí, E (corresponding author), Inst Salud Carlos III, CIBERER, Barcelona, Spain.; García-Arumí, E (corresponding author), Hosp Univ Vall dHebron, Area Genet Clin & Mol, Barcelona, Spain.
EM javier.torres@vhir.org; elena.garcia@vhir.org
RI Garcia-Arumi, Elena/ABH-4229-2020; Martí, Ramon/Q-3442-2016;
   Torres-Torronteras, Javier/K-4974-2014; Camara, Yolanda/K-4597-2014
OI Torres-Torronteras, Javier/0000-0002-6092-9458; Camara,
   Yolanda/0000-0003-2458-6942; Marti, Ramon/0000-0002-8273-9540;
   Garcia-Arumi, Elena/0000-0003-0096-3336
FU Spanish Instituto de Salud Carlos III, Fondo de Investigaciones
   Sanitarias; ERDF funds [FIS PI15/01428, FIS PI18/01574]; Spanish
   Ministry of Industry, Economy and Competitiveness [SAF2017-87506-R];
   Generalitat de Catalunya (URDCat project PERIS); Generalitat de
   Catalunya (PERIS program) [SLT002/16/00370]
FX This work was supported by the Spanish Instituto de Salud Carlos III,
   Fondo de Investigaciones Sanitarias and cofunded with ERDF funds (Grant
   No. FIS PI15/01428 to EG-A and FIS PI18/01574 to RM), the Spanish
   Ministry of Industry, Economy and Competitiveness (Grant No.
   SAF2017-87506-R to YC), and the Generalitat de Catalunya (a grant from
   the URDCat project PERIS to EG-A and RM). JT-T was funded by a
   fellowship granted by the Generalitat de Catalunya (PERIS program,
   SLT002/16/00370).
CR Al-Behadili A, 2018, NUCLEIC ACIDS RES, V46, P9471, DOI 10.1093/nar/gky708
   Alla NR, 2012, FEBS J, V279, P4492, DOI 10.1111/febs.12035
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andreu AL, 2009, MITOCHONDRION, V9, P242, DOI 10.1016/j.mito.2009.02.006
   Bugiardini E, 2017, NEUROL-GENET, V3, DOI 10.1212/NXG.0000000000000149
   Cerritelli SM, 1998, GENOMICS, V53, P300, DOI 10.1006/geno.1998.5497
   Cerritelli SM, 2003, MOL CELL, V11, P807, DOI 10.1016/S1097-2765(03)00088-1
   Dubowitz C., 2007, MUSCLE BIOPSY PRACTI, V3rd
   El-Hattab AW, 2017, BBA-MOL BASIS DIS, V1863, P1539, DOI 10.1016/j.bbadis.2017.02.017
   Gorman GS, 2016, NAT REV DIS PRIMERS, V2, P1, DOI 10.1038/nrdp.2016.80
   Herrmann JM, 2012, ADV EXP MED BIOL, V748, P41, DOI 10.1007/978-1-4614-3573-0_3
   Holmes JB, 2015, P NATL ACAD SCI USA, V112, P9334, DOI 10.1073/pnas.1503653112
   Kornblum C, 2013, NAT GENET, V45, P214, DOI 10.1038/ng.2501
   Landsverk ML, 2012, GENET MED, V14, P877, DOI 10.1038/gim.2012.58
   Martins Raisa da Silva, 2014, BMC Res Notes, V7, P583, DOI 10.1186/1756-0500-7-583
   Nishigaki Y, 2004, HUM MOL GENET, V13, P91, DOI 10.1093/hmg/ddh010
   Reyes A, 2015, AM J HUM GENET, V97, P186, DOI 10.1016/j.ajhg.2015.05.013
   Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30
   Ronchi D, 2013, AM J HUM GENET, V92, P293, DOI 10.1016/j.ajhg.2012.12.014
   Rosa ID, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005779
   Ruhanen H, 2011, BBA-MOL CELL RES, V1813, P2000, DOI 10.1016/j.bbamcr.2011.08.008
   Rusecka J, 2018, J APPL GENET, V59, P43, DOI 10.1007/s13353-017-0424-3
   Sachdev A, 2018, CAN J OPHTHALMOL, V53, pE203, DOI 10.1016/j.jcjo.2018.01.005
   Schwarz JM, 2014, NAT METHODS, V11, P361, DOI 10.1038/nmeth.2890
   Shibata A, 2015, J DERMATOL SCI, V80, P196, DOI 10.1016/j.jdermsci.2015.10.003
   Stewart JD, 2011, BBA-MOL BASIS DIS, V1812, P321, DOI 10.1016/j.bbadis.2010.11.012
   Suomalainen A, 2001, AM J MED GENET, V106, P53, DOI 10.1002/ajmg.1379
   Uhler JP, 2015, DNA REPAIR, V34, P28, DOI 10.1016/j.dnarep.2015.07.003
   Viscomi C, 2017, J INHERIT METAB DIS, V40, P587, DOI 10.1007/s10545-017-0027-5
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Wu HJ, 2001, J BIOL CHEM, V276, P23547, DOI 10.1074/jbc.M009676200
NR 31
TC 11
Z9 11
U1 0
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-8021
J9 FRONT GENET
JI Front. Genet.
PD JUN 14
PY 2019
VL 10
AR 576
DI 10.3389/fgene.2019.00576
PG 8
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA IE0DP
UT WOS:000472057300001
PM 31258551
OA Green Published, gold
DA 2024-11-01
ER

PT J
AU Beecher, G
   Gavrilova, RH
   Mandrekar, J
   Naddaf, E
AF Beecher, Grayson
   Gavrilova, Ralitza H.
   Mandrekar, Jay
   Naddaf, Elie
TI Mitochondrial myopathies diagnosed in adulthood: clinico-genetic
   spectrum and long-term outcomes
SO BRAIN COMMUNICATIONS
LA English
DT Article
DE mitochondrial myopathies; MELAS; POLG; chronic progressive external
   ophthalmoplegia; inherited myopathies
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; DNA DELETIONS; PERIPHERAL
   NEUROPATHY; EXERCISE INTOLERANCE; MUSCLE INVOLVEMENT; MUTATION; DISEASE;
   FEATURES; SINGLE; COMMON
AB Mitochondrial myopathies are frequently recognized in childhood as part of a broader multisystem disorder and often overlooked in adulthood. Herein, we describe the phenotypic and genotypic spectrum and long-term outcomes of mitochondrial myopathies diagnosed in adulthood, focusing on neuromuscular features, electrodiagnostic and myopathological findings and survival. We performed a retrospective chart review of adult patients diagnosed with mitochondrial myopathy at Mayo Clinic (2005-21). We identified 94 patients. Median time from symptom onset to diagnosis was 11 years (interquartile range 4-21 years). Median age at diagnosis was 48 years (32-63 years). Primary genetic defects were identified in mitochondrial DNA in 48 patients (10 with single large deletion, 38 with point mutations) and nuclear DNA in 29. Five patients had multiple mitochondrial DNA deletions or depletion without nuclear DNA variants. Twelve patients had histopathological features of mitochondrial myopathy without molecular diagnosis. The most common phenotypes included multisystem disorder (n = 30); mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (14); limb myopathy (13); chronic progressive external ophthalmoplegia (12); and chronic progressive external ophthalmoplegia-plus (12). Isolated skeletal muscle manifestations occurred in 27%. Sixty-nine per cent had CNS and 21% had cardiac involvement. Mutations most frequently involved MT-TL1 (27) and POLG (17); however, a wide spectrum of established and novel molecular defects, with overlapping phenotypes, was identified. Electrodiagnostic studies identified myopathy (77%), fibrillation potentials (27%) and axonal peripheral neuropathy (42%, most common with nuclear DNA variants). Among 42 muscle biopsies available, median percentage counts were highest for cytochrome C oxidase negative fibres (5.1%) then ragged blue (1.4%) and ragged red fibres (0.5%). Skeletal muscle weakness was mild and slowly progressive (decline in strength summated score of 0.01/year). Median time to gait assistance was 5.5 years from diagnosis and 17 years from symptom onset. Thirty patients died, with median survival of 33.4 years from symptom onset and 10.9 years from diagnosis. Median age at death was 55 years. Cardiac involvement was associated with increased mortality [hazard ratio 2.36 (1.05, 5.29)]. There was no difference in survival based on genotype or phenotype. Despite the wide phenotypic and genotypic spectrum, mitochondrial myopathies in adults share similar features with slowly progressive limb weakness, contrasting with common multiorgan involvement and high mortality.
   Beecher et al. describe the clinical, genetic, electrodiagnostic and myopathological features and long-term outcomes in 94 patients diagnosed with mitochondrial myopathy in adulthood. They highlight that despite the wide genotypic and phenotypic spectrum, mitochondrial myopathies in adults share slowly progressive limb weakness, contrasting with common multiorgan involvement and high mortality.
   Graphical Abstract
C1 [Beecher, Grayson; Gavrilova, Ralitza H.; Mandrekar, Jay; Naddaf, Elie] Mayo Clin, Dept Neurol, 200 First St Southwest, Rochester, MN 55905 USA.
   [Beecher, Grayson] Univ Alberta, Dept Med, Div Neurol, Edmonton, AB, Canada.
   [Gavrilova, Ralitza H.] Mayo Clin, Dept Clin Genom, Rochester, MN 55905 USA.
C3 Mayo Clinic; University of Alberta; Mayo Clinic
RP Naddaf, E (corresponding author), Mayo Clin, Dept Neurol, 200 First St Southwest, Rochester, MN 55905 USA.
EM Naddaf.elie@mayo.edu
RI Beecher, Grayson/K-1334-2019
OI Naddaf, Elie/0000-0001-6212-1236; Beecher, Grayson/0000-0003-3512-1796
CR Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   Arena IG, 2022, J CLIN MED, V11, DOI 10.3390/jcm11030632
   Barca E, 2020, NEUROL-GENET, V6, DOI 10.1212/NXG.0000000000000402
   Barends M, 2016, JIMD REP, V26, P103, DOI 10.1007/8904_2015_449
   Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   Braz LP, 2021, NEUROL-CLIN PRACT, V11, P97, DOI 10.1212/CPJ.0000000000000795
   Choi BO, 2010, EXP MOL MED, V42, P446, DOI 10.3858/emm.2010.42.6.046
   COLLINS S, 1995, ACTA NEUROL SCAND, V91, P287, DOI 10.1111/j.1600-0404.1995.tb07007.x
   Davis RL, 2022, NEUROLOGY, V99, pE730, DOI 10.1212/WNL.0000000000200745
   DiMauro S, 2005, NEUROMUSCULAR DISORD, V15, P276, DOI 10.1016/j.nmd.2004.12.008
   DiMauro S, 2013, NAT REV NEUROL, V9, P429, DOI 10.1038/nrneurol.2013.126
   Fadic R, 1997, NEUROLOGY, V49, P239, DOI 10.1212/WNL.49.1.239
   Finsterer J, 2018, PEDIATR NEUROL, V80, P8, DOI 10.1016/j.pediatrneurol.2017.12.005
   Girlanda P, 1999, CLIN NEUROPHYSIOL, V110, P1284, DOI 10.1016/S1388-2457(98)00041-8
   GOTO Y, 1990, J NEUROL SCI, V100, P63, DOI 10.1016/0022-510X(90)90014-E
   Grier J, 2018, NEUROL-GENET, V4, DOI 10.1212/NXG.0000000000000230
   Hedermann G, 2017, MITOCHONDRION, V32, P27, DOI 10.1016/j.mito.2016.11.007
   HIRANO M, 1992, NEUROMUSCULAR DISORD, V2, P125, DOI 10.1016/0960-8966(92)90045-8
   Hirano M., 1993, Genereviews((R))
   Hirano M., 2022, Merritt's neurology, P1011
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Horga A, 2014, BRAIN, V137, P3200, DOI 10.1093/brain/awu279
   Howse MLP, 2003, MUSCLE NERVE, V28, P757, DOI 10.1002/mus.10492
   Imai-Okazaki A, 2021, INT J CARDIOL, V341, P48, DOI 10.1016/j.ijcard.2021.06.042
   KAWAI H, 1995, MUSCLE NERVE, V18, P753, DOI 10.1002/mus.880180712
   LAFORET P, 1995, NEUROMUSCULAR DISORD, V5, P399, DOI 10.1016/0960-8966(94)00080-S
   Lu JQ, 2021, MITOCHONDRION, V56, P52, DOI 10.1016/j.mito.2020.11.005
   Lu JQ, 2019, J NEUROPATH EXP NEUR, V78, P508, DOI 10.1093/jnen/nlz029
   Luigetti M, 2016, EUR J NEUROL, V23, P1020, DOI 10.1111/ene.12954
   Mancuso M, 2012, NEUROMUSCULAR DISORD, V22, pS226, DOI 10.1016/j.nmd.2012.10.012
   Mancuso M, 2016, NEUROMUSCULAR DISORD, V26, P272, DOI 10.1016/j.nmd.2016.02.008
   Mancuso M, 2015, J NEUROL, V262, P1301, DOI 10.1007/s00415-015-7710-y
   Mancuso M, 2012, NEUROL SCI, V33, P449, DOI 10.1007/s10072-011-0703-4
   Miller TM, 2008, MUSCLE NERVE, V37, P293, DOI 10.1002/mus.20923
   Montano V, 2022, J NEUROL, V269, P6555, DOI 10.1007/s00415-022-11324-3
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Nardin RA, 2001, MUSCLE NERVE, V24, P170, DOI 10.1002/1097-4598(200102)24:2<170::AID-MUS30>3.0.CO;2-0
   Naue J, 2015, MITOCHONDRION, V20, P82, DOI 10.1016/j.mito.2014.12.002
   Nesbitt V, 2013, J NEUROL NEUROSUR PS, V84, P936, DOI 10.1136/jnnp-2012-303528
   Ng YS, 2021, LANCET NEUROL, V20, P573, DOI 10.1016/S1474-4422(21)00098-3
   Olimpio C, 2021, NEUROMUSCULAR DISORD, V31, P978, DOI 10.1016/j.nmd.2021.08.005
   Orsucci D, 2017, J NEUROL, V264, P1777, DOI 10.1007/s00415-017-8567-z
   Papadopoulos C, 2020, J INHERIT METAB DIS, V43, P459, DOI 10.1002/jimd.12185
   Parikh S, 2015, GENET MED, V17, P689, DOI 10.1038/gim.2014.177
   Paul P, 2020, NEUROLOGY, V95, P933, DOI 10.1212/WNL.0000000000010613
   PETTY RKH, 1986, BRAIN, V109, P915, DOI 10.1093/brain/109.5.915
   Pfeffer G, 2011, CAN J NEUROL SCI, V38, P119, DOI 10.1017/S031716710001115X
   Riley LG, 2010, AM J HUM GENET, V87, P52, DOI 10.1016/j.ajhg.2010.06.001
   Schon EA, 2012, NAT REV GENET, V13, P878, DOI 10.1038/nrg3275
   Sleigh K, 2011, MUSCLE NERVE, V43, P795, DOI 10.1002/mus.21962
   TORBERGSEN T, 1991, MUSCLE NERVE, V14, P35
   VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   Weber K, 1997, AM J HUM GENET, V60, P373
   YAMAMOTO M, 1991, NEUROLOGY, V41, P1822, DOI 10.1212/WNL.41.11.1822
   Zierz CM, 2015, NEUROPATHOLOGY, V35, P130, DOI 10.1111/neup.12173
NR 56
TC 0
Z9 0
U1 1
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
EI 2632-1297
J9 BRAIN COMMUN
JI Brain Commun.
PD MAR 1
PY 2024
VL 6
IS 2
AR fcae041
DI 10.1093/braincomms/fcae041
EA MAR 2024
PG 14
WC Clinical Neurology; Neurosciences
WE Emerging Sources Citation Index (ESCI)
SC Neurosciences & Neurology
GA JW0T8
UT WOS:001176088900001
PM 38434220
OA gold, Green Published
DA 2024-11-01
ER

PT J
AU Montano, V
   Mancuso, M
   Simoncini, C
   Torri, F
   Chico, L
   Ali, G
   Rocchi, A
   Baldinotti, F
   Caligo, MA
   Lattanzi, G
   Mattioli, E
   Cenacchi, G
   Barison, A
   Siciliano, G
   Ricci, G
AF Montano, Vincenzo
   Mancuso, Michelangelo
   Simoncini, Costanza
   Torri, Francesca
   Chico, Lucia
   Ali, Greta
   Rocchi, Anna
   Baldinotti, Fulvia
   Caligo, Maria Adelaide
   Lattanzi, Giovanna
   Mattioli, Elisabetta
   Cenacchi, Giovanna
   Barison, Andrea
   Siciliano, Gabriele
   Ricci, Giulia
TI A Single mtDNA Deletion in Association with a <i>LMNA</i> Gene New
   Frameshift Variant: A Case Report
SO JOURNAL OF NEUROMUSCULAR DISEASES
LA English
DT Article
DE Muscle disorders; myopathies; LMNA-associated diseases; mitochondria
ID MITOCHONDRIAL; ACCUMULATION; CELLS
AB Background: Proximal muscle weakness may be the presenting clinical feature of different types of myopathies, including limb girdle muscular dystrophy and primary mitochondrial myopathy. LGMD1B is caused by LMNA mutation. It is characterized by progressive weakness and wasting leading to proximal weakness, cardiomyopathy, and hearth conduction block.
   Objective: In this article, we describe the case of a patient who presented with limb-girdle weakness and a double trouble scenario - mitochondrial DNA single deletion and a new LMNA mutation.
   Methods: Pathophysiological aspects were investigated with muscle biopsy, Western Blot analysis, NGS nuclear and mtDNA analysis and neuromuscular imaging (muscle and cardiac MRI).
   Results: Although secondary mitochondrial involvement is possible, a "double trouble" syndrome can not be excluded.
   Conclusions: Implication deriving from hypothetical coexistence of two different pathological conditions or the possible secondary mitochondrial involvement are discussed.
C1 [Montano, Vincenzo; Mancuso, Michelangelo; Simoncini, Costanza; Torri, Francesca; Chico, Lucia; Rocchi, Anna; Siciliano, Gabriele; Ricci, Giulia] Univ Pisa, Dept Clin & Expt Med, Neurol Clin, Pisa, Italy.
   [Ali, Greta] Univ Pisa, Dept Surg Pathol Med Mol & Crit Area, Pisa, Italy.
   [Baldinotti, Fulvia; Caligo, Maria Adelaide] Azienda Osped Univ Pisana, Mol Genet, Pisa, Italy.
   [Lattanzi, Giovanna; Mattioli, Elisabetta] CNR, Inst Mol Genet Luigi Luca Cavalli Sforza, Unit Bologna, Bologna, Italy.
   [Lattanzi, Giovanna; Mattioli, Elisabetta] IRCCS Ist Ortoped Rizzoli, Bologna, Italy.
   [Cenacchi, Giovanna] Univ Bologna, Dept Biomed & Neuromotor Sci, Alma Mater, Italy.
   [Barison, Andrea] UOC Fdn G Monasterio CNR Reg Toscana, Pisa, Italy.
C3 University of Pisa; University of Pisa; University of Pisa; Azienda
   Ospedaliero Universitaria Pisana; Consiglio Nazionale delle Ricerche
   (CNR); University of Bologna
RP Ricci, G (corresponding author), Univ Pisa, Neurol Inst, Dept Clin & Expt Med, Pisa, Italy.
EM giulia.ricci@unipi.it
RI Barison, Andrea/J-3609-2016; Montano, Vincenzo/AAB-8681-2022; Lattanzi,
   Giovanna/AAY-3186-2020; Mattioli, Elisabetta/IUQ-5529-2023; ricci,
   giulia/U-6470-2019; Alì, Greta/J-9642-2016; chico, lucia/K-3235-2016
OI TORRI, FRANCESCA/0000-0002-1731-3500; chico, lucia/0000-0001-5832-7098
FU Telethon-MITOCON grant [GSP16001]; EJPRD2019 project GENOMIT; European
   Reference Network for Neuromuscular Diseases (ERN EURO-NMD); AIFA (TREAT
   LMNA project);  [RF-2016-02361495]
FX The authors are grateful to the following supporting and funding
   subjects: European Reference Network for Neuromuscular Diseases (ERN
   EURO-NMD), AIFA (TREAT LMNA project), Telethon-MITOCON grant GSP16001.
   MMwas partially supported by RF-2016-02361495 and the EJPRD2019 project
   GENOMIT. The funder had no role in study design, writing of the report,
   or data collection, analysis, or interpretation.
CR DiMauro S, 2002, MUSCLE NERVE, V26, P597, DOI 10.1002/mus.10194
   Fontana M, 2013, JACC-CARDIOVASC IMAG, V6, P124, DOI 10.1016/j.jcmg.2012.06.013
   Ghaoui R, 2015, JAMA NEUROL, V72, P1424, DOI 10.1001/jamaneurol.2015.2274
   Jungbluth H, 2017, NEUROPATH APPL NEURO, V43, P24, DOI 10.1111/nan.12385
   Li YH, 2016, CURR BIOL, V26, P2052, DOI 10.1016/j.cub.2016.06.007
   Lu D, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015167
   Maggi L, 2016, CELLS-BASEL, V5, DOI 10.3390/cells5030033
   Maggi L, 2014, NEUROLOGY, V83, P1634, DOI 10.1212/WNL.0000000000000934
   Pitceathly RDS, 2012, NEUROMUSCULAR DISORD, V22, P577, DOI 10.1016/j.nmd.2012.03.009
   Sieprath T, 2015, NUCLEUS-PHILA, V6, P236, DOI 10.1080/19491034.2015.1050568
   Straub V, 2018, NEUROMUSCULAR DISORD, V28, P702, DOI 10.1016/j.nmd.2018.05.007
   Suresh E, 2013, POSTGRAD MED J, V89, P470, DOI 10.1136/postgradmedj-2013-131752
   Xu XL, 2019, THERANOSTICS, V9, P2252, DOI 10.7150/thno.30658
NR 13
TC 1
Z9 1
U1 0
U2 1
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 2214-3599
EI 2214-3602
J9 J NEUROMUSCULAR DIS
JI J. Neuromusc. Dis.
PY 2022
VL 9
IS 3
BP 457
EP 462
DI 10.3233/JND-220802
PG 6
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 1H3JG
UT WOS:000796440600010
PM 35466949
DA 2024-11-01
ER

PT J
AU Hedermann, G
   Dahlqvist, JR
   Lokken, N
   Vissing, CR
   Knak, KL
   Andersen, LK
   Thomsen, C
   Vissing, J
AF Hedermann, Gitte
   Dahlqvist, Julia R.
   Lokken, Nicoline
   Vissing, Christoffer R.
   Knak, Kirsten Lykke
   Andersen, Linda Kahr
   Thomsen, Carsten
   Vissing, John
TI Progressive fat replacement of muscle contributes to the disease
   mechanism of patients with single, large-scale deletions of
   mitochondrial DNA
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE Single large-scale deletion; Chronic progressive external
   ophthalmoplegia; CPEO; Mitochondrial myopathy; Mitochondrial DNA
   deletion; Muscle fat fraction; MRI; 3243A > G
ID EXTERNAL OPHTHALMOPLEGIA; MUSCULAR-DYSTROPHY; MYOPATHIES; PHENOTYPES
AB Muscle dysfunction in mitochondrial myopathy is predominantly caused by insufficient generation of energy. We hypothesise that structural changes in muscles could also contribute to their pathophysiology. The aims of this study were to determine fat fractions and strength in selected muscles in patients with chronic progressive external ophthalmoplegia (CPEO), and compare progression of muscle fat fraction with age in individuals with CPEO vs. healthy controls and patients with the m.3243A>G mutation of mitochondrial DNA (mtDNA). Seventeen patients with CPEO and single large-scale deletions of mtDNA, 52 healthy controls, and 12 patients carrying the m.3243A>G mtDNA mutation were included. Muscle fat fractions were measured from cross-sections of paraspinal and leg muscles. Peak muscle strength was assessed from a static dynamometer. There was a direct correlation between age and fat fraction in all muscle groups in CPEO patients and healthy controls (p < 0.05). Analysis of covariance showed a higher progression rate of fat replacement in CPEO patients vs. healthy controls in studied muscle groups (p < 0.05). Patients with the m.3243A>G mutation had slower progression rates of fat replacement. Muscle strength decreased with increasing muscular fat fraction in CPEO patients, no correlation was seen in other groups. This indicates that structural muscle changes contribute to the phenotype of older patients affected by CPEO and large-scale deletions. It should therefore be considered, along with known energy deficiencies, as the cause of exercise intolerance. (C) 2018 Elsevier B.V. All rights reserved.
C1 [Hedermann, Gitte; Dahlqvist, Julia R.; Lokken, Nicoline; Vissing, Christoffer R.; Knak, Kirsten Lykke; Andersen, Linda Kahr; Vissing, John] Univ Copenhagen, Rigshosp, Dept Neurol, Copenhagen Neuromuscular Ctr, Copenhagen, Denmark.
   [Thomsen, Carsten] Univ Copenhagen, Rigshosp, Dept Diagnost Radiol, Copenhagen, Denmark.
C3 University of Copenhagen; Rigshospitalet; Rigshospitalet; University of
   Copenhagen
RP Hedermann, G (corresponding author), Univ Copenhagen, Rigshosp, Copenhagen Neuromuscular Ctr, Sect 3342,Dept Neurol, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.
EM hedermann@gmail.com
RI Vissing, Christoffer/AAX-2530-2020; Christensen, Gitte/GRY-3412-2022;
   Vissing, John/IUN-4271-2023; Andersen, Linda/AAK-3203-2020; Løkken,
   Nicoline/GZL-0909-2022
OI Andersen, Linda Kahr/0000-0002-4780-7739; Vissing,
   Christoffer/0000-0002-0834-206X; Hedermann, Gitte/0000-0001-8853-0986;
   Lokken, Nicoline/0000-0002-5494-8484
FU Genzyme/Sanofi; Ultragenyx Pharmaceuticals
FX Dr. Hedermann reports no disclosures. Dr. Dahlqvist reports no
   disclosures. Dr. Lokken reports no disclosures. Dr. CR Vissing reports
   no disclosures. MSc Knak reports no disclosures. MSc Andersen reports no
   disclosures. Dr. Thomsen reports no disclosures. Dr. J. Vissing reports
   having received research and travel support and speaker honoraria from
   Genzyme/Sanofi and Ultragenyx Pharmaceuticals, and has acted as
   consultant on advisory boards for Genzyme/Sanofi, Lundbeck, Ultragenyx
   Pharmaceuticals, NOVO Nordisk and Alexion Pharmaceuticals within the
   last 3 years.
CR Auré K, 2007, BRAIN, V130, P1516, DOI 10.1093/brain/awm067
   Dahlqvist JR, 2017, MED SCI SPORT EXER, V49, P595, DOI 10.1249/MSS.0000000000001119
   Dahlqvist JR, 2014, NEUROLOGY, V83, P1178, DOI 10.1212/WNL.0000000000000828
   Danneskiold-Samsoe B, 2009, ACTA PHYSIOL, V197, P1, DOI 10.1111/j.1748-1716.2009.02022.x
   Grady JP, 2014, BRAIN, V137, P323, DOI 10.1093/brain/awt321
   Harbo T, 2012, EUR J APPL PHYSIOL, V112, P267, DOI 10.1007/s00421-011-1975-3
   Jeppesen TD, 2006, ARCH NEUROL-CHICAGO, V63, P1701, DOI 10.1001/archneur.63.12.1701
   Kiyomoto BH, 2006, J NEUROL NEUROSUR PS, V77, P541, DOI 10.1136/jnnp.2005.079954
   Krag TO, 2013, MITOCHONDRION, V13, P63, DOI 10.1016/j.mito.2013.01.009
   Lokken N, 2016, ANN NEUROL, V80, P466, DOI 10.1002/ana.24743
   Mancuso M, 2015, J NEUROL, V262, P1301, DOI 10.1007/s00415-015-7710-y
   McClelland C, 2016, CURR NEUROL NEUROSCI, V16, DOI 10.1007/s11910-016-0652-7
   McFarland R, 2010, LANCET NEUROL, V9, P829, DOI 10.1016/S1474-4422(10)70116-2
   Olsen DB, 2003, J NEUROL, V250, P1328, DOI 10.1007/s00415-003-0206-1
   Pitceathly RDS, 2012, NEUROMUSCULAR DISORD, V22, P577, DOI 10.1016/j.nmd.2012.03.009
   Schoser BGH, 2006, STRABISMUS, V14, P107, DOI 10.1080/09273970600701218
   Smits BW, 2011, NEUROMUSCULAR DISORD, V21, P272, DOI 10.1016/j.nmd.2010.12.008
NR 17
TC 8
Z9 8
U1 1
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD MAY
PY 2018
VL 28
IS 5
BP 408
EP 413
DI 10.1016/j.nmd.2018.02.008
PG 6
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA GJ1VP
UT WOS:000435056300004
PM 29567350
DA 2024-11-01
ER

PT J
AU Mkaouar-Rebai, E
   Ben Mahmoud, A
   Chamkha, I
   Chabchoub, I
   Kammoun, T
   Hachicha, M
   Fakhfakh, F
AF Mkaouar-Rebai, Emna
   Ben Mahmoud, Afif
   Chamkha, Imen
   Chabchoub, Imen
   Kammoun, Thouraya
   Hachicha, Mongia
   Fakhfakh, Faiza
TI A novel MT-CO2 m.8249G&gt;A pathogenic variation and the MT-TW
   m.5521G&gt;A mutation in patients with mitochondrial myopathy
SO MITOCHONDRIAL DNA
LA English
DT Article
DE m.5521G.> A; m.8249G > A; mitochondrial mutations; MT-CO2; MT-TW;
   myopathy
ID HEREDITARY OPTIC NEUROPATHY; POINT MUTATION; DISEASE; RNA; DNA; GENE;
   TRNA(ASN); DEAFNESS; IMPACT
AB Mitochondrial DNA (mtDNA) defects were known to be associated with a large spectrum of human diseases and patients might present wide range of clinical features with various combinations. Mutations in mitochondrial tRNAs, rRNAs and protein-coding genes or largescale rearrangements have been implicated in several cytopathies. Mitochondrial myopathies, usually maternally inherited group of neuromuscular diseases caused by mitochondrial dysfunction occurring before the age of 20 years and often begin with exercise intolerance, muscle weakness and neurodevelopmental retardation. We studied the mtDNA in three Tunisian patients with mitochondrial myopathy. The mutational analysis screening revealed the presence of two mitochondrial mutations: the m. 5521G>A mutation in the D-stem region of the tRNA(Trp) gene which could lead to a disruption of the secondary structure of this tRNA and affect the tRNA-ribosome interaction with a consequent decrease in the rate of synthesis of mitochondrial proteins. The second mutation is the m. 8249G>A (p.G222R) variation in the MT-CO2 gene which may affect the electrons transfer from cytochrome c to the bimetallic center of the catalytic subunit I.
C1 [Mkaouar-Rebai, Emna; Ben Mahmoud, Afif; Chamkha, Imen; Fakhfakh, Faiza] Univ Sfax, Fac Med, Lab Human Mol Genet, Sfax, Tunisia.
   [Chabchoub, Imen; Kammoun, Thouraya; Hachicha, Mongia] CHU Habib Bourguiba Sfax, Serv Pediat, Sfax, Tunisia.
C3 Universite de Sfax; Universite de Sfax; Hopital Hedi Chaker; Hopital
   Habib Bourguiba
RP Mkaouar-Rebai, E (corresponding author), Fac Med Sfax, Lab Genet Mol Humaine, Sfax, Tunisia.
EM emna_mkaouar@mail2world.com; faiza.fakhfakh@gmail.com
RI MKAOUAR-REBAI, Emna/AAE-6650-2019
OI Chamkha, Imen/0000-0002-6919-585X; Mkaouar-Rebai,
   Emna/0000-0003-3095-510X
FU Ministry of the Higher Education; Scientific Research in Tunisia
FX We thank the patients and her families for their cooperation in the
   present study. This work was supported by The Ministry of the Higher
   Education and the Scientific Research in Tunisia.
CR Abu-Amero KK, 2008, MOL VIS, V14, P29
   Berardo A, 2010, CURR NEUROL NEUROSCI, V10, P118, DOI 10.1007/s11910-010-0096-4
   BROWN MD, 1994, AM J HUM GENET, V55, P410
   Bruno C, 2011, BIOCHEM BIOPH RES CO, V412, P518, DOI 10.1016/j.bbrc.2011.06.155
   Chomyn A, 2000, J BIOL CHEM, V275, P19198, DOI 10.1074/jbc.M908734199
   Flierl A, 1997, J BIOL CHEM, V272, P27189, DOI 10.1074/jbc.272.43.27189
   Greaves LC, 2012, J PATHOL, V226, P274, DOI 10.1002/path.3028
   Hao HL, 1997, MOL CELL BIOL, V17, P6831, DOI 10.1128/MCB.17.12.6831
   Hofacker IL, 2003, NUCLEIC ACIDS RES, V31, P3429, DOI 10.1093/nar/gkg599
   JOHNS DR, 1993, BIOCHEM BIOPH RES CO, V196, P810, DOI 10.1006/bbrc.1993.2321
   KOGA Y, 1995, MUSCLE NERVE, pS119
   Levinger L, 2001, NUCLEIC ACIDS RES, V29, P4334, DOI 10.1093/nar/29.21.4334
   LEWIN HA, 1992, BIOTECHNIQUES, V13, P522
   McFarland R, 2007, CURR TOP DEV BIOL, V77, P113, DOI 10.1016/S0070-2153(06)77005-3
   MEHTA AB, 1989, ANN HUM GENET, V53, P303, DOI 10.1111/j.1469-1809.1989.tb01799.x
   Olivieri A, 2006, SCIENCE, V314, P1767, DOI 10.1126/science.1135566
   OOSTRA RJ, 1995, AM J HUM GENET, V57, P954
   Pfeffer G, 2013, ANN MED, V45, P4, DOI 10.3109/07853890.2011.605389
   Pinós T, 2013, NEUROMUSCULAR DISORD, V23, P330, DOI 10.1016/j.nmd.2013.01.001
   Rahman S, 1999, AM J HUM GENET, V65, P1030, DOI 10.1086/302590
   Ramensky V, 2002, NUCLEIC ACIDS RES, V30, P3894, DOI 10.1093/nar/gkf493
   Rossmanith W, 1998, FEBS LETT, V433, P269, DOI 10.1016/S0014-5793(98)00928-4
   Scaglia F, 2008, MUSCLE NERVE, V37, P150, DOI 10.1002/mus.20917
   Schaefer AM, 2008, ANN NEUROL, V63, P35, DOI 10.1002/ana.21217
   Silvestri G, 1998, NEUROMUSCULAR DISORD, V8, P291, DOI 10.1016/S0960-8966(98)00037-6
   Sunyaev S, 2001, HUM MOL GENET, V10, P591, DOI 10.1093/hmg/10.6.591
   Wittenhagen LM, 2003, TRENDS BIOCHEM SCI, V28, P605, DOI 10.1016/j.tibs.2003.09.006
   Yasukawa T, 2000, NUCLEIC ACIDS RES, V28, P3779, DOI 10.1093/nar/28.19.3779
   Zheng J, 2012, MITOCHONDRION, V12, P406, DOI 10.1016/j.mito.2012.04.001
NR 29
TC 6
Z9 6
U1 0
U2 3
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1940-1736
EI 1940-1744
J9 MITOCHONDR DNA
JI Mitochondrial DNA
PD OCT
PY 2014
VL 25
IS 5
BP 394
EP 399
DI 10.3109/19401736.2013.803086
PG 6
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA AP3RG
UT WOS:000341994200027
PM 23841600
DA 2024-11-01
ER

PT J
AU Wang, LY
   Limongelli, A
   Vila, MR
   Carrara, F
   Zeviani, M
   Eriksson, S
AF Wang, LY
   Limongelli, A
   Vila, MR
   Carrara, F
   Zeviani, M
   Eriksson, S
TI Molecular insight into mitochondrial DNA depletion syndrome in two
   patients with novel mutations in the deoxyguanosine kinase and thymidine
   kinase 2 genes
SO MOLECULAR GENETICS AND METABOLISM
LA English
DT Article
DE deoxyguanosine kinase; thymidine kinase 2; mitochondrial DNA depletion;
   mitochondrial DNA depletion syndrome; mutation; mutagenesis; enzyme
   kinetic
ID MTDNA DEPLETION; DEOXYRIBONUCLEOSIDE KINASES; SUBSTRATE-SPECIFICITY; TK2
   DEFICIENCY; MYOPATHY; EXPRESSION; DELETIONS
AB Thymidine kinase 2 (TK2) and deoxyguanosine kinase (dGK) are the two key enzymes in mitochondrial DNA (mtDNA) precursor synthesis. Deficiencies in TK2 or dGK activity, due to genetic alteration, have been shown to cause tissue-specific depletion of mtDNA. In the case of TK2 deficiency, affected individuals suffer severe myopathy and, in the case of dGK deficiency, devastating liver or multi-systemic disease. Here, we report clinical and biochemical findings from two patients with mtDNA depletion syndrome. Patient A was a compound heterozygote carrying the previously reported T77M mutation and a novel mutation (R161K) in the TK2 gene. Patient B carried a novel mutation (L250S) in the dGK gene. The clinical symptoms of patient A included muscular weakness and exercise intolerance due to a severe mitochondrial myopathy associated with a 92% reduction in mtDNA. There was minimal involvement of other organs. Patient B suffered from rapidly progressive, early onset fatal liver failure associated with profoundly decreased mtDNA levels in liver and, to a lesser extent, in skeletal muscle. Site-directed mutagenesis was used to introduce the mutations detected in patients A and B into the TK2 and dGK cDNAs, respectively. We then characterized each of these recombinant enzymes. Catalytic activities of the three mutant enzymes were reduced to about 2-4% for TK2 and 0.5% for dGK as compared to the wild-type enzymes. Altered competition between dCyd and dThd was observed for the T77M mutant. The residual activities of the two mitochondrial enzymes correlated directly with disease development. (C) 2004 Elsevier Inc. All rights reserved.
C1 SLU, Biomed Ctr, Sect Vet Med Biochem, Dept Mol Biosci, SE-75123 Uppsala, Sweden.
   Natl Neurol Inst C Besta, Div Mol Neurogenet, I-20126 Milan, Italy.
   Columbia Univ, Dept Neurol, New York, NY 10032 USA.
C3 Swedish University of Agricultural Sciences; Fondazione IRCCS Istituto
   Neurologico Carlo Besta; Columbia University
RP Wang, LY (corresponding author), SLU, Biomed Ctr, Sect Vet Med Biochem, Dept Mol Biosci, POB 575, SE-75123 Uppsala, Sweden.
EM liya.wang@vmk.slu.se
RI Zeviani, Massimo/K-2891-2014
OI Zeviani, Massimo/0000-0002-9067-5508
FU Telethon [GGP030039] Funding Source: Medline
CR ARNER ESJ, 1995, PHARMACOL THERAPEUT, V67, P155, DOI 10.1016/0163-7258(95)00015-9
   Carrozzo R, 2003, HUM MUTAT, V21, DOI 10.1002/humu.9135
   CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324
   Cotter D, 2004, NUCLEIC ACIDS RES, V32, pD463, DOI 10.1093/nar/gkh048
   Darley-Usmar V.M., 1987, MITOCHONDRIA PRACTIC
   Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279
   Johansson K, 2001, NAT STRUCT BIOL, V8, P616, DOI 10.1038/89661
   Mancuso M, 2003, ARCH NEUROL-CHICAGO, V60, P1007, DOI 10.1001/archneur.60.7.1007
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Pontarin G, 2003, P NATL ACAD SCI USA, V100, P12159, DOI 10.1073/pnas.1635259100
   Saada A, 2003, MOL GENET METAB, V79, P1, DOI 10.1016/S1096-7192(03)00063-5
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284
   Sjoberg AH, 1998, MOL PHARMACOL, V53, P270, DOI 10.1124/mol.53.2.270
   Taanman JW, 2002, ANN NEUROL, V52, P237, DOI 10.1002/ana.10247
   Tang YY, 2000, MOL BIOL CELL, V11, P1471, DOI 10.1091/mbc.11.4.1471
   Vilà MR, 2003, NEUROLOGY, V60, P1203, DOI 10.1212/01.WNL.0000055928.58122.47
   Wang LY, 2003, FEBS LETT, V554, P319, DOI 10.1016/S0014-5793(03)01181-5
   Wang LY, 2003, J BIOL CHEM, V278, P6963, DOI 10.1074/jbc.M206143200
   WANG LY, 1993, J BIOL CHEM, V268, P22847
   Wang LY, 1996, FEBS LETT, V390, P39, DOI 10.1016/0014-5793(96)00623-0
NR 23
TC 60
Z9 71
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1096-7192
J9 MOL GENET METAB
JI Mol. Genet. Metab.
PD JAN
PY 2005
VL 84
IS 1
BP 75
EP 82
DI 10.1016/j.ymgme.2004.09.005
PG 8
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental
   Medicine
GA 899VL
UT WOS:000227173700010
PM 15639197
DA 2024-11-01
ER

PT J
AU Levin, BC
   Sekiguchi, K
   Tully, LA
   Chen, TLJ
   Gropman, A
AF Levin, BC
   Sekiguchi, K
   Tully, LA
   Chen, TLJ
   Gropman, A
TI The common deletion found in patient reexamined after 33 years and
   comparison with complete mtDNA sequences of maternal relatives
SO MITOCHONDRION
LA English
DT Article
DE chronic progressive external ophthalmoplegia; CPEO; haplogroup K;
   mitochondrial DNA (mtDNA); mitochondrial disease; ptosis; ragged-red
   fibers
ID HUMAN MITOCHONDRIAL-DNA; MUTATION
AB In 1966, a male (17 years old) was clinically examined at the National Institutes of Health (NIH) and diagnosed with Idiopathic Progressive External Ophthalmoplegia (IPEO). A muscle biopsy showing ragged-red fibers implicated mitochondrial involvement. Since the sequence of human mitochondrial DNA (mtDNA) was not determined until 1981, no genetic confirmation of the disease was possible at that time. In 1999, clinical reexamination and sequencing the entire mtDNA of the patient and living maternal relatives (mother and brother) indicated a progressive mitochondrial myopathy and the presence of the 4977 base pair (bp) deletion (the common deletion) in the patient. Published by Elsevier B.V. on behalf of Mitochondria Research Society.
C1 Natl Inst Stand & Technol, Div Biotechnol, Gaithersburg, MD 20899 USA.
   Natl Res Inst Police Sci, Kashiwa, Chiba, Japan.
   Natl Inst Justice, Invest & Forens Sci Div, Washington, DC USA.
   Penn State Univ, Milton S Hershey Med Ctr, Dept Surg, Hershey, PA 17033 USA.
   Georgetown Univ, Ctr Funct & Mol Imaging, Washington, DC USA.
   NHGRI, NIH, Bethesda, MD 20892 USA.
C3 National Institute of Standards & Technology (NIST) - USA; Pennsylvania
   Commonwealth System of Higher Education (PCSHE); Pennsylvania State
   University; Penn State Health; Georgetown University; National
   Institutes of Health (NIH) - USA; NIH National Human Genome Research
   Institute (NHGRI)
RP Levin, BC (corresponding author), Natl Inst Stand & Technol, Div Biotechnol, 100 Bur Dr,MS 8311, Gaithersburg, MD 20899 USA.
EM barbara.levin@nist.gov
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Herrnstadt C, 2002, AM J HUM GENET, V70, P1152, DOI 10.1086/339933
   LEE HC, 1994, BBA-MOL BASIS DIS, V1226, P37, DOI 10.1016/0925-4439(94)90056-6
   Lee MS, 2002, MITOCHONDRION, V1, P321, DOI 10.1016/S1567-7249(01)00031-9
   Levin BC, 1999, GENOMICS, V55, P135, DOI 10.1006/geno.1998.5513
   OLSON W, 1972, ARCH NEUROL-CHICAGO, V26, P193, DOI 10.1001/archneur.1972.00490090019001
   Ro LS, 2003, MUSCLE NERVE, V28, P737, DOI 10.1002/mus.10504
   Thayer RE, 2003, EXP GERONTOL, V38, P567, DOI 10.1016/S0531-5565(03)00033-0
   WALLACE DC, 1996, EMERY RIMOINS PRINCI, V1, P277
   WEI YH, 1992, MUTAT RES, V275, P145, DOI 10.1016/0921-8734(92)90019-L
   Zullo Steven J, 2002, Methods Mol Biol, V197, P119, DOI 10.1385/1-59259-284-8:119
NR 12
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
J9 MITOCHONDRION
JI Mitochondrion
PD DEC
PY 2005
VL 5
IS 6
BP 403
EP 410
DI 10.1016/j.mito.2005.08.001
PG 8
WC Cell Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Genetics & Heredity
GA 997HL
UT WOS:000234236000003
PM 16172025
DA 2024-11-01
ER

PT J
AU Walter, MC
   Czermin, B
   Muller-Ziermann, S
   Bulst, S
   Stewart, JD
   Hudson, G
   Schneiderat, P
   Abicht, A
   Holinski-Feder, E
   Lochmüller, H
   Chinnery, PF
   Klopstock, T
   Horvath, R
AF Walter, Maggie C.
   Czermin, Birgit
   Muller-Ziermann, Solvig
   Bulst, Stefanie
   Stewart, Joanna D.
   Hudson, Gavin
   Schneiderat, Peter
   Abicht, Angela
   Holinski-Feder, Elke
   Lochmueller, Hanns
   Chinnery, Patrick F.
   Klopstock, Thomas
   Horvath, Rita
TI Late-onset ptosis and myopathy in a patient with a heterozygous
   insertion in POLG2
SO JOURNAL OF NEUROLOGY
LA English
DT Article
DE Ptosis; Mitochondrial myopathy; mtDNA deletions; Polymerase gamma 2
   (POLG2)
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; MITOCHONDRIAL-DNA POLYMERASE;
   MUTATIONS
AB Polymerase gamma 1 (POLG) mutations are a frequent cause of both autosomal dominant and recessive complex neurological phenotypes. In contrast, only a single pathogenic mutation in one patient was reported in POLG2 so far. Here we describe a 62-year-old woman, carrying a novel heterozygous sequence variant in the POLG2 gene. She developed bilateral ptosis at 30 years of age, followed by exercise intolerance, muscle weakness and mild CK increase in her late forties. Muscle histology and respiratory chain activities were normal. Southern blot and long range PCR detected multiple mtDNA deletions, but no depletion in muscle DNA. Sequencing of POLG, PEO1, ANT1, OPA1 and RRM2B showed normal results. A novel heteroallelic 24 bp insertion (c.1207_1208ins24) was detected in POLG2. This 24 bp insertion into exon 7 causes missplicing and loss of exon 7 in myoblast cDNA. We did not detect POLG2 mutations in 62 patients with multiple mtDNA deletions in muscle DNA, suggesting that POLG2 mutations may represent a rare cause of autosomal dominant PEO.
C1 [Stewart, Joanna D.; Hudson, Gavin; Chinnery, Patrick F.; Horvath, Rita] Newcastle Univ, Inst Hlth & Aging, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Walter, Maggie C.; Bulst, Stefanie; Schneiderat, Peter; Abicht, Angela; Klopstock, Thomas; Horvath, Rita] Univ Munich, Dept Neurol, Friedrich Baur Inst, D-8000 Munich, Germany.
   [Czermin, Birgit; Muller-Ziermann, Solvig; Abicht, Angela; Holinski-Feder, Elke; Horvath, Rita] Ctr Med Genet, Munich, Germany.
   [Lochmueller, Hanns] Newcastle Univ, Inst Human Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
C3 Newcastle University - UK; University of Munich; Newcastle University -
   UK
RP Horvath, R (corresponding author), Newcastle Univ, Inst Hlth & Aging, Mitochondrial Res Grp, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM Rita.Horvath@ncl.ac.uk
RI Hudson, Gavin/E-7117-2017; Horvath, Rita/AAY-7042-2020; Stewart, Joanna
   D/H-1614-2012
OI Horvath, Rita/0000-0002-9841-170X; Chinnery,
   Patrick/0000-0002-7065-6617; Stewart, Joanna D/0000-0002-2608-1967;
   Hudson, Gavin/0000-0001-7210-2733; Lochmuller, Hanns/0000-0003-2324-8001
FU Deutsche Forschungsgemeinschaft [HO 2505/2-1]; Academy of Medical
   Sciences [BH090164]; RVI/NGH; Newcastle upon Tyne Hospitals NHS Charity
   [RES0211/7262]; German ministry of education and research (BMBF, Bonn,
   Germany); EC [036825]; MRC Centre for Neuromuscular Disease; MRC
   [G0601943] Funding Source: UKRI
FX The excellent technical assistance of Ira Kaus and Eva Neugebauer is
   gratefully acknowledged. RH is supported by the Deutsche
   Forschungsgemeinschaft HO 2505/2-1, the Academy of Medical Sciences
   (BH090164) and the RVI/NGH and Newcastle upon Tyne Hospitals NHS Charity
   (RES0211/7262). The Muscle Tissue Culture Collection is part of the
   German network on muscular dystrophies (MD-NET, service structure S1,
   01GM0601) funded by the German ministry of education and research (BMBF,
   Bonn, Germany). The Muscle Tissue Culture Collection is a partner of
   EuroBioBank (http://www.eurobiobank.org) and TREAT-NMD (EC, 6th FP,
   proposal # 036825). RH, HL and PFC are supported by the MRC Centre for
   Neuromuscular Disease.
CR Carrodeguas JA, 2000, NUCLEIC ACIDS RES, V28, P1237, DOI 10.1093/nar/28.5.1237
   CHINNERY PF, 2007, NEUROMUSCULAR DISORD, V18, P259
   Copeland WC, 2008, ANNU REV MED, V59, P131, DOI 10.1146/annurev.med.59.053006.104646
   Ferraris S, 2008, ARCH NEUROL-CHICAGO, V65, P125, DOI 10.1001/archneurol.2007.9
   FISCHER JC, 1986, EUR J PEDIATR, V144, P441, DOI 10.1007/BF00441735
   Fuhrmann N, 2009, J MED GENET, V46, P136, DOI 10.1136/jmg.2008.062570
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
NR 11
TC 35
Z9 36
U1 0
U2 38
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-5354
J9 J NEUROL
JI J. Neurol.
PD SEP
PY 2010
VL 257
IS 9
BP 1517
EP 1523
DI 10.1007/s00415-010-5565-9
PG 7
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 642VW
UT WOS:000281250100014
PM 20405137
DA 2024-11-01
ER

PT J
AU Pfeffer, G
   Gorman, GS
   Griffin, H
   Kurzawa-Akanbi, M
   Blakely, EL
   Wilson, I
   Sitarz, K
   Moore, D
   Murphy, JL
   Alston, CL
   Pyle, A
   Coxhead, J
   Payne, B
   Gorrie, GH
   Longman, C
   Hadjivassiliou, M
   McConville, J
   Dick, D
   Imam, I
   Hilton, D
   Norwood, F
   Baker, MR
   Jaiser, SR
   Yu-Wai-Man, P
   Farrell, M
   McCarthy, A
   Lynch, T
   McFarland, R
   Schaefer, AM
   Turnbull, DM
   Horvath, R
   Taylor, RW
   Chinnery, PF
AF Pfeffer, Gerald
   Gorman, Grainne S.
   Griffin, Helen
   Kurzawa-Akanbi, Marzena
   Blakely, Emma L.
   Wilson, Ian
   Sitarz, Kamil
   Moore, David
   Murphy, Julie L.
   Alston, Charlotte L.
   Pyle, Angela
   Coxhead, Jon
   Payne, Brendan
   Gorrie, George H.
   Longman, Cheryl
   Hadjivassiliou, Marios
   McConville, John
   Dick, David
   Imam, Ibrahim
   Hilton, David
   Norwood, Fiona
   Baker, Mark R.
   Jaiser, Stephan R.
   Yu-Wai-Man, Patrick
   Farrell, Michael
   McCarthy, Allan
   Lynch, Timothy
   McFarland, Robert
   Schaefer, Andrew M.
   Turnbull, Douglass M.
   Horvath, Rita
   Taylor, Robert W.
   Chinnery, Patrick F.
TI Mutations in the <i>SPG7</i> gene cause chronic progressive external
   ophthalmoplegia through disordered mitochondrial DNA maintenance
SO BRAIN
LA English
DT Article
DE chronic progressive external ophthalmoplegia; hereditary spastic
   paraplegia; paraplegin; mtDNA maintenance; SPG7
ID DOMINANT OPTIC ATROPHY; HEREDITARY SPASTIC PARAPLEGIA; M-AAA PROTEASE;
   MULTIPLE DELETIONS; CLONAL EXPANSION; DISEASE; DYSFUNCTION; NEUROPATHY;
   MYOPATHY; MUSCLE
AB Progressive external ophthalmoplegia (PEO) is a canonical feature of mitochondrial disease, but in many patients its genetic basis is unknown. Using exome sequencing, Pfeffer et al. identify mutations in SPG7 as an important cause of PEO associated with spasticity and ataxia, and uncover evidence of disordered mtDNA maintenance in patients.Despite being a canonical presenting feature of mitochondrial disease, the genetic basis of progressive external ophthalmoplegia remains unknown in a large proportion of patients. Here we show that mutations in SPG7 are a novel cause of progressive external ophthalmoplegia associated with multiple mitochondrial DNA deletions. After excluding known causes, whole exome sequencing, targeted Sanger sequencing and multiplex ligation-dependent probe amplification analysis were used to study 68 adult patients with progressive external ophthalmoplegia either with or without multiple mitochondrial DNA deletions in skeletal muscle. Nine patients (eight probands) were found to carry compound heterozygous SPG7 mutations, including three novel mutations: two missense mutations c.2221G > A; p.(Glu741Lys), c.2224G > A; p.(Asp742Asn), a truncating mutation c.861dupT; p.Asn288*, and seven previously reported mutations. We identified a further six patients with single heterozygous mutations in SPG7, including two further novel mutations: c.184-3C > T (predicted to remove a splice site before exon 2) and c.1067C > T; p.(Thr356Met). The clinical phenotype typically developed in mid-adult life with either progressive external ophthalmoplegia/ptosis and spastic ataxia, or a progressive ataxic disorder. Dysphagia and proximal myopathy were common, but urinary symptoms were rare, despite the spasticity. Functional studies included transcript analysis, proteomics, mitochondrial network analysis, single fibre mitochondrial DNA analysis and deep re-sequencing of mitochondrial DNA. SPG7 mutations caused increased mitochondrial biogenesis in patient muscle, and mitochondrial fusion in patient fibroblasts associated with the clonal expansion of mitochondrial DNA mutations. In conclusion, the SPG7 gene should be screened in patients in whom a disorder of mitochondrial DNA maintenance is suspected when spastic ataxia is prominent. The complex neurological phenotype is likely a result of the clonal expansion of secondary mitochondrial DNA mutations modulating the phenotype, driven by compensatory mitochondrial biogenesis.
C1 [Pfeffer, Gerald; Gorman, Grainne S.; Griffin, Helen; Kurzawa-Akanbi, Marzena; Blakely, Emma L.; Wilson, Ian; Sitarz, Kamil; Moore, David; Murphy, Julie L.; Alston, Charlotte L.; Pyle, Angela; Coxhead, Jon; Payne, Brendan; Yu-Wai-Man, Patrick; McFarland, Robert; Schaefer, Andrew M.; Turnbull, Douglass M.; Horvath, Rita; Taylor, Robert W.; Chinnery, Patrick F.] Newcastle Univ, Wellcome Ctr Mitochondrial Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Pfeffer, Gerald; Griffin, Helen; Kurzawa-Akanbi, Marzena; Wilson, Ian; Sitarz, Kamil; Moore, David; Pyle, Angela; Coxhead, Jon; Payne, Brendan; Yu-Wai-Man, Patrick; Horvath, Rita; Chinnery, Patrick F.] Newcastle Univ, Inst Med Genet, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.
   [Gorman, Grainne S.; Blakely, Emma L.; Murphy, Julie L.; Alston, Charlotte L.; McFarland, Robert; Schaefer, Andrew M.; Turnbull, Douglass M.; Taylor, Robert W.] Newcastle Univ, Inst Ageing & Hlth, Newcastle Upon Tyne NE4 5PL, Tyne & Wear, England.
   [Gorman, Grainne S.; Blakely, Emma L.; Murphy, Julie L.; Alston, Charlotte L.; McFarland, Robert; Schaefer, Andrew M.; Turnbull, Douglass M.; Taylor, Robert W.] Newcastle Univ, NIHR Biomed Res Ctr Ageing, Newcastle Upon Tyne NE4 5PL, Tyne & Wear, England.
   [Gorrie, George H.; Longman, Cheryl] So Gen Hosp, Inst Neurol Sci, Glasgow G51 4TF, Lanark, Scotland.
   [Hadjivassiliou, Marios] Acad Dept Neurosci, Sheffield S10 2JF, S Yorkshire, England.
   [Hadjivassiliou, Marios] Univ Sheffield, Royal Hallamshire Hosp, Sheffield S10 2JF, S Yorkshire, England.
   [McConville, John] Belfast City Hosp, Belfast BT9 7AD, Antrim, North Ireland.
   [Dick, David] Norfolk & Norwich Univ Hosp, Dept Neurol, Norwich NR4 7UY, Norfolk, England.
   [Imam, Ibrahim; Hilton, David] Torbay Hosp, Dept Neurol, Torquay TQ2 7AA, Devon, England.
   [Norwood, Fiona] Kings Coll Hosp London, Dept Neurol, Ruskin Wing, London, England.
   [Baker, Mark R.; Jaiser, Stephan R.] Newcastle Univ, Inst Neurosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Yu-Wai-Man, Patrick] Royal Victoria Infirm, Newcastle Eye Ctr, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.
   [Farrell, Michael] Beaumont Hosp, Dept Neuropathol, Dublin 9, Ireland.
   [McCarthy, Allan; Lynch, Timothy] Mater Hosp, Dublin Neurol Inst, Dublin, Ireland.
   [McCarthy, Allan; Lynch, Timothy] Univ Coll Dublin, Dublin, Ireland.
C3 Newcastle University - UK; Newcastle University - UK; Newcastle
   University - UK; Newcastle University - UK; University of Glasgow;
   University of Sheffield; Belfast City Hospital; Norfolk & Norwich
   University Hospitals NHS Foundation Trust; Norfolk & Norwich University
   Hospital; King's College Hospital NHS Foundation Trust; King's College
   Hospital; Newcastle University - UK; Newcastle University - UK; Mater
   Misericordiae University Hospital; University College Dublin; University
   College Dublin
RP Chinnery, PF (corresponding author), Inst Med Genet, Cent Pkwy, Newcastle Upon Tyne, Tyne & Wear, England.
EM p.f.chinnery@ncl.ac.uk
RI Lynch, Timothy/M-1316-2019; Alston, Charlotte/ABG-9602-2020; Horvath,
   Rita/AAY-7042-2020; Payne, Brendan/I-1233-2016
OI McFarland, Robert/0000-0002-8833-2688; Pfeffer,
   Gerald/0000-0002-7657-7098; Chinnery, Patrick/0000-0002-7065-6617;
   Schaefer, Andrew/0000-0001-9891-7332; Horvath, Rita/0000-0002-9841-170X;
   Alston, Charlotte/0000-0003-2095-5464; Kurzawa-Akanbi,
   Marzena/0000-0002-2482-2741; Baker, Mark/0000-0001-6916-1329; Gorman,
   Grainne/0000-0002-7585-3409; Moore, David/0000-0002-0161-7390; Griffin,
   Helen R/0000-0002-5288-3322; Turnbull, Doug/0000-0002-8878-9901; Payne,
   Brendan/0000-0002-3101-3512; Jaiser, Stephan/0000-0003-4453-2650
FU Bisby Fellowship from the Canadian Institutes of Health Research;
   Wellcome Trust Centre for Mitochondrial Research [096919Z/11/Z]; Medical
   Research Council (UK) Centre for Translational Muscle Disease research
   [G0601943]; Medical Research Council (UK) Mitochondrial Disease Patient
   Cohort [G0800674]; UK NHS Highly Specialised 'Rare Mitochondrial
   Disorders of Adults and Children' Service; EU FP7 TIRCON; National
   Institute for Health Research (NIHR) Newcastle Biomedical Research
   Centre based at Newcastle upon Tyne Hospitals NHS Foundation Trust;
   Newcastle University; National Institute for Health Research (NIHR)
   [NIHR-HCS-D12-03-04]; NIHR; Wellcome Trust; Academy of Medical Sciences;
   MRC [G0701386, MR/K006312/1, G1002570, G0601943, G0800470, G0800674,
   G1000848, MR/K000608/1] Funding Source: UKRI
FX G.P. is the recipient of a Bisby Fellowship from the Canadian Institutes
   of Health Research. P. F. C. is an Honorary Consultant Neurologist at
   Newcastle upon Tyne Foundation Hospitals NHS Trust, a Wellcome Trust
   Senior Fellow in Clinical Science (084980/Z/08/Z) and a UK NIHR Senior
   Investigator. P. F. C, R. W. T. and D. M. T. receive support from the
   Wellcome Trust Centre for Mitochondrial Research (096919Z/11/Z). P. F.
   C., R. W. T., R. H., R. M., G. S. G., and D. M. T. receive support from
   the Medical Research Council (UK) Centre for Translational Muscle
   Disease research (G0601943). R. W. T., R. M. and D. M. T. are supported
   by the Medical Research Council (UK) Mitochondrial Disease Patient
   Cohort (G0800674) and the UK NHS Highly Specialised 'Rare Mitochondrial
   Disorders of Adults and Children' Service. P. F. C. receives additional
   support from EU FP7 TIRCON, and the National Institute for Health
   Research (NIHR) Newcastle Biomedical Research Centre based at Newcastle
   upon Tyne Hospitals NHS Foundation Trust and Newcastle University. CLA
   is the recipient of a National Institute for Health Research (NIHR)
   doctoral fellowship (NIHR-HCS-D12-03-04). The views expressed are those
   of the author(s) and not necessarily those of the NHS, the NIHR or the
   Department of Health. MRB is funded by the NIHR, Wellcome Trust and
   Academy of Medical Sciences. SRJ is supported the Wellcome Trust.
CR Almajan ER, 2012, J CLIN INVEST, V122, P4048, DOI 10.1172/JCI64604
   Arnoldi A, 2008, HUM MUTAT, V29, P522, DOI 10.1002/humu.20682
   Baker MR, 2011, NEUROLOGY, V77, P1309, DOI 10.1212/WNL.0b013e318230a15a
   Blakely E, 2008, NEUROMUSCULAR DISORD, V18, P557, DOI 10.1016/j.nmd.2008.04.014
   Blakely EL, 2012, NEUROMUSCULAR DISORD, V22, P587, DOI 10.1016/j.nmd.2012.03.006
   Bonn F, 2010, HUM MUTAT, V31, P617, DOI 10.1002/humu.21226
   Brugman F, 2008, NEUROLOGY, V71, P1500, DOI 10.1212/01.wnl.0000319700.11606.21
   Cagnoli C, 2010, HUM MUTAT, V31, P1117, DOI 10.1002/humu.21342
   Casari G, 1998, CELL, V93, P973, DOI 10.1016/S0092-8674(00)81203-9
   Copeland WC, 2008, ANNU REV MED, V59, P131, DOI 10.1146/annurev.med.59.053006.104646
   Duvezin-Caubet S, 2007, MOL BIOL CELL, V18, P3582, DOI 10.1091/mbc.E07-02-0164
   Ehses S, 2009, J CELL BIOL, V187, P1023, DOI 10.1083/jcb.200906084
   Elleuch N, 2006, NEUROLOGY, V66, P654, DOI 10.1212/01.wnl.0000201185.91110.15
   He LP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf067
   Hudson G, 2008, BRAIN, V131, P329, DOI 10.1093/brain/awm272
   Klebe S, 2012, BRAIN, V135, P2980, DOI 10.1093/brain/aws240
   LAFORET P, 1995, NEUROMUSCULAR DISORD, V5, P399, DOI 10.1016/0960-8966(94)00080-S
   Lang N, 2011, CLIN NEUROPHYSIOL, V122, P1417, DOI 10.1016/j.clinph.2010.12.033
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Maltecca F, 2012, HUM MOL GENET, V21, P3858, DOI 10.1093/hmg/dds214
   McDermott CJ, 2001, NEUROLOGY, V56, P467, DOI 10.1212/WNL.56.4.467
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Moslemi AR, 1996, ANN NEUROL, V40, P707, DOI 10.1002/ana.410400506
   Noensie EN, 2001, NAT BIOTECHNOL, V19, P434, DOI 10.1038/88099
   Payne BAI, 2013, HUM MOL GENET, V22, P384, DOI 10.1093/hmg/dds435
   Payne BAI, 2011, NAT GENET, V43, P806, DOI 10.1038/ng.863
   Pitceathly RDS, 2012, BRAIN, V135, P3392, DOI 10.1093/brain/aws231
   Ronchi D, 2013, AM J HUM GENET, V92, P293, DOI 10.1016/j.ajhg.2012.12.014
   Sánchez-Ferrero E, 2013, CLIN GENET, V83, P257, DOI 10.1111/j.1399-0004.2012.01896.x
   Schlipf NA, 2011, CLIN GENET, V80, P148, DOI 10.1111/j.1399-0004.2011.01715.x
   Song ZY, 2007, J CELL BIOL, V178, P749, DOI 10.1083/jcb.200704110
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   Taylor RW, 1997, ORGANELLE DIS
   Tondera D, 2009, EMBO J, V28, P1589, DOI 10.1038/emboj.2009.89
   van Gassen KLI, 2012, BRAIN, V135, P2994, DOI 10.1093/brain/aws224
   Warnecke T, 2010, MOVEMENT DISORD, V25, P413, DOI 10.1002/mds.22949
   Yoneda T, 2004, J CELL SCI, V117, P4055, DOI 10.1242/jcs.01275
   Yu-Wai-Man P, 2010, BRAIN, V133, P771, DOI 10.1093/brain/awq007
   Yu-Wai-Man P, 2009, INVEST OPHTH VIS SCI, V50, P4561, DOI 10.1167/iovs.09-3634
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 40
TC 124
Z9 129
U1 0
U2 10
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 1460-2156
J9 BRAIN
JI Brain
PD MAY
PY 2014
VL 137
BP 1323
EP 1336
DI 10.1093/brain/awu060
PN 5
PG 14
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA AH6PK
UT WOS:000336252800013
PM 24727571
OA Green Submitted, Green Published, hybrid
DA 2024-11-01
ER

PT J
AU Cohen, BH
   Naviaux, RK
AF Cohen, Bruce H.
   Naviaux, Robert K.
TI The clinical diagnosis of POLG disease and other mitochondrial DNA
   depletion disorders
SO METHODS
LA English
DT Review
DE Mitochondrial disease diagnosis; Mitochondrial DNA depletion syndrome;
   Alpers-Huttenlocher syndrome; Ataxia-neuropathy spectrum disorders;
   Progressive external ophthalmoplegia; Childhood myocerebrohepatopathy
   spectrum; Myoclonic epilepsy myopathy sensory ataxia; POLG
ID PROGRESSIVE NEURONAL DEGENERATION; DIFFUSE CEREBRAL DEGENERATION;
   POLIODYSTROPHY ALPERS-DISEASE; RESPIRATORY-CHAIN DEFICIENCY; CITRIC-ACID
   CYCLE; POLYMERASE-GAMMA; INFANTILE POLIODYSTROPHY; EXTERNAL
   OPHTHALMOPLEGIA; ATAXIC NEUROPATHY; MUTATIONS
AB Disorders of oxidative phosphorylation and mitochondrial function can be caused from mutations involving both mitochondrial DNA (mtDNA) or mitochondrial-targeted nuclear DNA genes. Progressive depletion of mtDNA is one mechanism of mitochondrial dysfunction leading to human disease, which is the end result of loss of the sufficient mtDNA-encoded proteins for normal electron transport chain function. Mitochondrial DNA depletion is caused by germline deletions and duplications of segments within the mtDNA as well as germline mutations in the nuclear genes responsible for mtDNA duplication (the polymerase apparatus including POLG, POLG2 and PEO1) and mtDNA maintenance (those genes that regulate the deoxynucleotide triphosphate pools and other functions including TP1, TK2, DGUOK, SUCLA1, SUCLA2, ANT1, RRM2B and MPV17). This review will focus on the most common disorders that result from mutations with POLG, with some discussion of the other nuclear-encoded genes involved in mtDNA maintenance. Mutations in POLG can cause a wide range of disease, which vary in both age of onset and severity. These disorders comprise a continuous spectrum of overlapping symptoms and signs; and range from a rapidly fatal infantile cerebrohepatic disease to a progressive external ophthalmoplegia (PEO) that may not present until the sixth decade of life. Many of the disorders seem to have a more unique and restrictive clinical presentation, at least to date. Since the first disorders linked to mtDNA depletion were described in 2001, the nomenclature, methods of diagnosis, clinical evaluation and treatment of these disorders have been better defined. However, this remains a rapidly evolving field, with additional proteins and genes are being discovered as DNA testing becomes part of the standard of care in everyday medical practice. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Cohen, Bruce H.] Cleveland Clin, Neurol Inst, Brain Tumor & Neurooncol Ctr, Pediat Neurol Ctr, Cleveland, OH USA.
   [Naviaux, Robert K.] Univ Calif San Diego, Sch Med, Mitochondrial & Metab Dis Ctr, San Diego, CA 92103 USA.
C3 Cleveland Clinic Foundation; University of California System; University
   of California San Diego
RP Cohen, BH (corresponding author), Cleveland Clin, Neurol Inst, Brain Tumor & Neurooncol Ctr, Pediat Neurol Ctr, Desk S-63,9500 Euclid Ave, Cleveland, OH USA.
EM brucehcohen@gmail.com
CR Alpers BJ, 1931, ARCH NEURO PSYCHIATR, V25, P469, DOI 10.1001/archneurpsyc.1931.02230030027002
   BICKNESE AR, 1992, ANN NEUROL, V32, P767, DOI 10.1002/ana.410320610
   BLACKWOOD W, 1963, ARCH DIS CHILD, V38, P193, DOI 10.1136/adc.38.199.193
   Bohan TP, 2001, NEUROLOGY, V56, P1405, DOI 10.1212/WNL.56.10.1405
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   BOYD SG, 1986, NEUROPEDIATRICS, V17, P75, DOI 10.1055/s-2008-1052505
   Chan SSL, 2009, METHODS MOL BIOL, V554, P59, DOI 10.1007/978-1-59745-521-3_4
   Chan SSL, 2005, DNA REPAIR, V4, P1381, DOI 10.1016/j.dnarep.2005.08.010
   Cohen B.H., 2010, GENEREVIEWS GENETEST
   Copeland WC, 2008, ANNU REV MED, V59, P131, DOI 10.1146/annurev.med.59.053006.104646
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   Di Fonzo A, 2003, HUM MUTAT, V22, DOI 10.1002/humu.9203
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Fadic R, 1997, NEUROLOGY, V49, P239, DOI 10.1212/WNL.49.1.239
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Ferraris S, 2008, ARCH NEUROL-CHICAGO, V65, P125, DOI 10.1001/archneurol.2007.9
   GABREELS FJM, 1984, ACTA NEUROL SCAND, V70, P145
   Gallagher RC, 2009, ANN NEUROL, V65, P550, DOI 10.1002/ana.21568
   Gauthier-Villars M, 2001, NEUROPEDIATRICS, V32, P150, DOI 10.1055/s-2001-16614
   Gold DR, 2001, SEMIN NEUROL, V21, P309, DOI 10.1055/s-2001-17948
   Graziewicz MA, 2007, HUM MOL GENET, V16, P2729, DOI 10.1093/hmg/ddm227
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   HARDING BN, 1990, J CHILD NEUROL, V5, P273, DOI 10.1177/088307389000500402
   Hasselmann O, 2010, MOL GENET METAB, V99, P58, DOI 10.1016/j.ymgme.2009.08.005
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   HUTTENLOCHER PR, 1976, ARCH NEUROL-CHICAGO, V33, P186, DOI 10.1001/archneur.1976.00500030042009
   JAKOB A, 1930, DTSCH Z NERVENHEILK, V116, P240
   Karadimas CL, 2006, AM J HUM GENET, V79, P544, DOI 10.1086/506913
   Kasiviswanathan R, 2009, J BIOL CHEM, V284, P19501, DOI 10.1074/jbc.M109.011940
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Lecrenier N, 1997, GENE, V185, P147, DOI 10.1016/S0378-1119(96)00663-4
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Longley MJ, 2001, J BIOL CHEM, V276, P38555, DOI 10.1074/jbc.M105230200
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Luoma PT, 2005, HUM MOL GENET, V14, P1907, DOI 10.1093/hmg/ddi196
   Mancuso M, 2004, NEUROLOGY, V62, P316, DOI 10.1212/WNL.62.2.316
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Mochel F, 2005, J CLIN ENDOCR METAB, V90, P3780, DOI 10.1210/jc.2005-0009
   Naviaux RK, 2005, ANN NEUROL, V58, P491, DOI 10.1002/ana.20544
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Naviaux RK, 1999, ANN NEUROL, V45, P54, DOI 10.1002/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B
   Nguyen KV, 2006, J HEPATOL, V45, P108, DOI 10.1016/j.jhep.2005.12.026
   Nguyen KV, 2005, NEUROLOGY, V65, P1493, DOI 10.1212/01.wnl.0000182814.55361.70
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Ostergaard E, 2007, AM J HUM GENET, V81, P383, DOI 10.1086/519222
   Pagnamenta AT, 2006, HUM REPROD, V21, P2467, DOI 10.1093/humrep/del076
   Parikh S, 2009, CURR TREAT OPTION N, V11, P414, DOI 10.1007/s11940-009-0046-0
   Poulton J, 2009, BBA-MOL BASIS DIS, V1792, P1109, DOI 10.1016/j.bbadis.2009.08.016
   PRICK MJJ, 1982, NEUROPEDIATRICS, V13, P108, DOI 10.1055/s-2008-1059608
   PRICK MJJ, 1981, ARCH NEUROL-CHICAGO, V38, P767, DOI 10.1001/archneur.1981.00510120067011
   RICCI E, 1992, BRAIN PATHOL, V2, P141, DOI 10.1111/j.1750-3639.1992.tb00682.x
   Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   SANDBANK U, 1972, J NEUROL NEUROSUR PS, V35, P749, DOI 10.1136/jnnp.35.6.749
   Saneto RP, 2010, SEIZURE-EUR J EPILEP, V19, P140, DOI 10.1016/j.seizure.2010.01.002
   Sarzi E, 2007, J PEDIATR-US, V150, P531, DOI 10.1016/j.jpeds.2007.01.044
   Simonati A, 2003, ACTA NEUROPATHOL, V106, P57, DOI 10.1007/s00401-003-0698-x
   Smith JK, 1996, CLIN IMAG, V20, P235, DOI 10.1016/0899-7071(95)00039-9
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, NEUROLOGY, V61, P1811, DOI 10.1212/01.WNL.0000098997.23471.65
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   Wolf NI, 2009, EPILEPSIA, V50, P1596, DOI 10.1111/j.1528-1167.2008.01877.x
   Wong LJC, 2008, HUM MUTAT, V29, pE150, DOI 10.1002/humu.20824
   Worle H, 1998, CLIN NEUROPATHOL, V17, P63
NR 68
TC 74
Z9 81
U1 0
U2 24
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1046-2023
EI 1095-9130
J9 METHODS
JI Methods
PD AUG
PY 2010
VL 51
IS 4
BP 364
EP 373
DI 10.1016/j.ymeth.2010.05.008
PG 10
WC Biochemical Research Methods; Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 640KK
UT WOS:000281049900002
PM 20558295
DA 2024-11-01
ER

PT J
AU Mkaouar-Rebai, E
   Felhi, R
   Tabebi, M
   Alila-Fersi, O
   Chamkha, I
   Maalej, M
   Ammar, M
   Kammoun, F
   Keskes, L
   Hachicha, M
   Fakhfakh, F
AF Mkaouar-Rebai, Emna
   Felhi, Rahma
   Tabebi, Mouna
   Alila-Fersi, Olfa
   Chamkha, Imen
   Maalej, Marwa
   Ammar, Marwa
   Kammoun, Fatma
   Keskes, Leila
   Hachicha, Mongia
   Fakhfakh, Faiza
TI Mitochondrial DNA triplication and punctual mutations in patients with
   mitochondrial neuromuscular disorders
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Mitochondrial mutations; mtDNA; Mitochondrial duplication; m.9157G > A;
   m.14924T > C; MT-ATP6
ID 9-BP DELETION; D-LOOP; DUPLICATION; SEQUENCE; GENOME
AB Mitochondrial diseases are a heterogeneous group of disorders caused by the impairment of the mitochondrial oxidative phosphorylation system which have been associated with various mutations of the mitochondrial DNA (mtDNA) and nuclear gene mutations. The clinical phenotypes are very diverse and the spectrum is still expanding. As brain and muscle are highly dependent on OXPHOS, consequently, neurological disorders and myopathy are common features of mtDNA mutations. Mutations in mtDNA can be classified into three categories: large-scale rearrangements, point mutations in tRNA or rRNA genes and point mutations in protein coding genes. In the present report, we screened mitochondrial genes of complex I, III, IV and V in 2 patients with mitochondrial neuromuscular disorders. The results showed the presence the pathogenic heteroplasmic m.9157G>A variation (A211T) in the MT-ATP6 gene in the first patient. We also reported the first case of triplication of 9 bp in the mitochondrial NC7 region in Africa and Tunisia, in association with the novel m.14924T>C in the MT-CYB gene in the second patient with mitochondrial neuromuscular disorder. (C) 2016 Elsevier Inc. All rights reserved.
C1 [Mkaouar-Rebai, Emna; Alila-Fersi, Olfa; Chamkha, Imen; Fakhfakh, Faiza] Univ Sfax, Fac Sci Sfax, Dept Sci Vie, Sfax, Tunisia.
   [Felhi, Rahma; Tabebi, Mouna; Maalej, Marwa; Ammar, Marwa; Keskes, Leila] Univ Sfax, Fac Med Sfax, Lab Genet Mol Humaine, Sfax, Tunisia.
   [Kammoun, Fatma; Hachicha, Mongia] CHU Hedi Chaker Sfax, Serv Pediat, Sfax, Tunisia.
C3 Universite de Sfax; Faculty of Sciences Sfax; Universite de Sfax;
   Universite de Sfax; Hopital Hedi Chaker
RP Mkaouar-Rebai, E; Fakhfakh, F (corresponding author), Fac Sci Sfax, Dept Sci Vie, Route Soukra,Km 3, Sfax, Tunisia.
EM emna.mkaouar@gmail.com; faiza.fakhfakh02@gmail.com
RI MKAOUAR-REBAI, Emna/AAE-6650-2019; tabebi, mouna/AAL-2270-2020;
   Abdelhedi, Fatma/AAT-3786-2021
OI kamoun, fatma/0000-0002-5058-7693; Mkaouar-Rebai,
   Emna/0000-0003-3095-510X; tabebi, mouna/0000-0002-2873-161X; Keskes,
   Leila/0000-0002-8420-139X; Maalej, Marwa/0000-0001-5155-0465; Chamkha,
   Imen/0000-0002-6919-585X
FU Ministry of the Higher Education and the Scientific Research in Tunisia
FX We thank patients and their family for their cooperation in the present
   study. This work was supported by The Ministry of the Higher Education
   and the Scientific Research in Tunisia.
CR Amanchy R, 2007, NAT BIOTECHNOL, V25, P285, DOI 10.1038/nbt0307-285
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Attimonelli M, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-S4-S4
   Blum A, 2009, ISR MED ASSOC J, V11, P105
   Brandon M, 2006, ONCOGENE, V25, P4647, DOI 10.1038/sj.onc.1209607
   BROCKINGTON M, 1993, NAT GENET, V4, P67, DOI 10.1038/ng0593-67
   Carling PJ, 2011, MITOCHONDRION, V11, P686, DOI 10.1016/j.mito.2011.05.004
   Chiaratti MR, 2011, MITOCHONDRION, V11, P820, DOI 10.1016/j.mito.2010.11.004
   Choi Y, 2015, BIOINFORMATICS, V31, P2745, DOI 10.1093/bioinformatics/btv195
   Cree LM, 2009, BBA-MOL BASIS DIS, V1792, P1097, DOI 10.1016/j.bbadis.2009.03.002
   Cwerman-Thibault H, 2011, J INHERIT METAB DIS, V34, P327, DOI 10.1007/s10545-010-9131-5
   El-Hattab A.W., 2016, Cell Calcium
   Elango S, 2011, MITOCHONDRION, V11, P878, DOI 10.1016/j.mito.2011.07.002
   Montiel-Sosa JF, 2013, MITOCHONDR DNA, V24, P420, DOI 10.3109/19401736.2012.760550
   Hung WY, 2008, MUTAGENESIS, V23, P137, DOI 10.1093/mutage/gen002
   LEWIN HA, 1992, BIOTECHNIQUES, V13, P522
   LI S, 2000, EUR J HUM GENET, V22, P1040
   Mancuso M, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.012278
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   PASSARINO G, 1993, AM J HUM GENET, V53, P609
   POULTON J, 1993, DEV MED CHILD NEUROL, V35, P833
   POULTON J, 1989, LANCET, V1, P236
   POULTON J, 1992, BIOESSAYS, V14, P763, DOI 10.1002/bies.950141108
   Prasad B.V., 2001, HUM BIOL, P715
   Ramensky V, 2002, NUCLEIC ACIDS RES, V30, P3894, DOI 10.1093/nar/gkf493
   Rubino F, 2012, NUCLEIC ACIDS RES, V40, pD1150, DOI 10.1093/nar/gkr1086
   Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755
   SHIELDS GF, 1992, AM J HUM GENET, V50, P758
   Cardena MMSG, 2013, MITOCHONDR DNA, V24, P46, DOI 10.3109/19401736.2012.717933
   Soodyall H, 1996, AM J HUM GENET, V58, P595
   Sunyaev S, 2001, HUM MOL GENET, V10, P591, DOI 10.1093/hmg/10.6.591
   Tang S, 2013, HUM MUTAT, V34, P882, DOI 10.1002/humu.22307
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Thangaraj K, 2005, HUM GENET, V116, P507, DOI 10.1007/s00439-005-1271-6
   Thangaraj K, 2008, HUM HERED, V66, P1, DOI 10.1159/000114160
   Tucker EJ, 2011, IUBMB LIFE, V63, P669, DOI 10.1002/iub.495
   Zeviani M, 2004, BRAIN, V127, P2153, DOI 10.1093/brain/awh259
NR 37
TC 5
Z9 5
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD APR 29
PY 2016
VL 473
IS 2
BP 578
EP 585
DI 10.1016/j.bbrc.2016.03.126
PG 8
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA DK3IG
UT WOS:000374809700033
PM 27033601
DA 2024-11-01
ER

PT J
AU Kärppä, M
   Mahjneh, I
   Karttunen, A
   Tolonen, U
   Majamaa, K
AF Kärppä, M
   Mahjneh, I
   Karttunen, A
   Tolonen, U
   Majamaa, K
TI Muscle computed tomography patterns in patients with the mitochondrial
   DNA mutation 3243A&gt;G
SO JOURNAL OF NEUROLOGY
LA English
DT Article
DE myopathy; MELAS; muscle CT; myopathic pattern
ID GIRDLE MUSCULAR-DYSTROPHY; STROKE-LIKE EPISODES; NEUROMUSCULAR DISEASE;
   LACTIC-ACIDOSIS; FIBER TYPES; CT; INVOLVEMENT; POPULATION; MYOPATHIES;
   HUMANS
AB Computed tomography provides a sensitive method for investigating skeletal muscle changes in neuromuscular diseases, but this method has not been applied to mitochondrial myopathies. We characterized the pattern of muscle involvement in patients with the 3243A>G mutation in mitochondrial DNA (mtDNA), the common MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes) mutation. Twenty-four patients, age 19-73 years, with 3243A>G were examined. Clinical evaluation included assessment of muscle strength and functional capacity. All the patients underwent muscle computed tomography, and muscle samples from 17 of them were examined for the presence of ragged red fibres and for the 3243A>G heteroplasmy. Venous blood lactate at rest and serum creatine kinase were determined. Clinical myopathy was found in six patients, while nine showed mild muscle weakness and nine had normal muscle function. The upper and lower limbs were equally affected, but the proximal muscles were more severely affected than the distal ones. CT revealed abnormalities in the muscles of 13 patients (54%; 95% confidence interval, 33-76%), including the six with clinical myopathy and seven without clinical myopathy. Myopathic changes were found most frequently in the pelvic muscles, with predominant involvement of the gluteus maximus. These data show that CT reveals frequent abnormal findings in the muscle of patients with the 3243A>G mtDNA mutation.Muscle CT is a useful adjunct to clinical evaluation in these patients.
C1 Univ Oulu, Dept Neurol, Oulu 90014, Finland.
   Univ Oulu, Bioctr, Oulu 90014, Finland.
   Univ Oulu, Dept Radiol, Oulu, Finland.
   Univ Oulu, Dept Neurophysiol, Oulu, Finland.
   Pietarsaari Hosp, Dept Neurol, Pietarsaari, Finland.
C3 University of Oulu; University of Oulu; University of Oulu; University
   of Oulu
RP Univ Oulu, Dept Neurol, POB 5000, Oulu 90014, Finland.
EM kari.majamaa@oulu.fi
RI Majamaa, Kari/A-1344-2012
OI Mahjneh, Ibrahim/0000-0002-0752-9949; Majamaa, Kari/0000-0002-9070-3791
CR BULCKE JA, 1979, NEURORADIOLOGY, V17, P127
   BULCKE JA, 1981, MUSCLE NERVE, V4, P67, DOI 10.1002/mus.880040112
   BULCKE JAL, 1983, RADIOLOGY, V28, P523
   CALO M, 1986, NEURORADIOLOGY, V28, P53, DOI 10.1007/BF00341766
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   Harridge SDR, 1996, PFLUG ARCH EUR J PHY, V432, P913, DOI 10.1007/s004240050215
   Hauschka S., 1994, Myology, V1, P3
   HAWLEY RJ, 1984, ARCH NEUROL-CHICAGO, V41, P383, DOI 10.1001/archneur.1984.04050160045014
   HOWALD H, 1985, PFLUG ARCH EUR J PHY, V403, P369, DOI 10.1007/BF00589248
   JOHNSON MA, 1973, J NEUROL SCI, V18, P111, DOI 10.1016/0022-510X(73)90023-3
   Kärppä M, 2003, J NEUROL, V250, P216, DOI 10.1007/s00415-003-0981-8
   KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5
   Mahjneh I, 2001, NEUROMUSCULAR DISORD, V11, P20, DOI 10.1016/S0960-8966(00)00157-7
   Mahjneh I, 1996, ACTA NEUROL SCAND, V94, P177, DOI 10.1111/j.1600-0404.1996.tb07050.x
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   Marconi G, 2001, ACTA NEUROL SCAND, V104, P156, DOI 10.1034/j.1600-0404.2001.00087.x
   *MED RES COUNC, 1986, 45 MRC
   Mercuri E, 2002, NEUROPEDIATRICS, V33, P10, DOI 10.1055/s-2002-23593
   MORGANHUGHES JA, 1994, MYOLOGY, P1610
   PETTY RKH, 1986, BRAIN, V109, P915, DOI 10.1093/brain/109.5.915
   SCHWARTZ MS, 1988, MUSCLE NERVE, V11, P1240, DOI 10.1002/mus.880111208
   Sciacco M, 2001, J NEUROL, V248, P778, DOI 10.1007/s004150170094
   SWASH M, 1995, MUSCLE NERVE, V18, P708, DOI 10.1002/mus.880180706
   Vissing J, 1998, NEUROLOGY, V50, P1875, DOI 10.1212/WNL.50.6.1875
   Vlak M, 2000, NEUROL SCI, V21, pS975, DOI 10.1007/s100720070013
   VLIET A M V, 1988, Neuroradiology, V30, P421
   WILBOURN AJ, 1993, J CLIN NEUROPHYSIOL, V10, P132, DOI 10.1097/00004691-199304000-00002
   [No title captured]
NR 28
TC 15
Z9 16
U1 0
U2 0
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-5354
EI 1432-1459
J9 J NEUROL
JI J. Neurol.
PD MAY
PY 2004
VL 251
IS 5
BP 556
EP 563
DI 10.1007/s00415-004-0363-x
PG 8
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 824ED
UT WOS:000221667000007
PM 15164188
DA 2024-11-01
ER

PT J
AU Nikkanen, J
   Forsström, S
   Euro, L
   Paetau, I
   Kohnz, RA
   Wang, LY
   Chilov, D
   Viinamäki, J
   Roivainen, A
   Marjamäki, P
   Liljenbäck, H
   Ahola, S
   Buzkova, J
   Terzioglu, M
   Khan, NA
   Pirnes-Karhu, S
   Paetau, A
   Lönnqvist, T
   Sajantila, A
   Isohanni, P
   Tyynismaa, H
   Nomura, DK
   Battersby, BJ
   Velagapudi, V
   Carroll, CJ
   Suomalainen, A
AF Nikkanen, Joni
   Forsstrom, Saara
   Euro, Liliya
   Paetau, Ilse
   Kohnz, Rebecca A.
   Wang, Liya
   Chilov, Dmitri
   Viinamaki, Jenni
   Roivainen, Anne
   Marjamaki, Paivi
   Liljenback, Heidi
   Ahola, Sofia
   Buzkova, Jana
   Terzioglu, Mugen
   Khan, Nahid A.
   Pirnes-Karhu, Sini
   Paetau, Anders
   Lonnqvist, Tuula
   Sajantila, Antti
   Isohanni, Pirjo
   Tyynismaa, Henna
   Nomura, Daniel K.
   Battersby, Brendan J.
   Velagapudi, Vidya
   Carroll, Christopher J.
   Suomalainen, Anu
TI Mitochondrial DNA Replication Defects Disturb Cellular dNTP Pools and
   Remodel One-Carbon Metabolism
SO CELL METABOLISM
LA English
DT Article
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; ONSET SPINOCEREBELLAR ATAXIA;
   MULTIPLE DELETIONS; CRYSTAL-STRUCTURE; RECESSIVE ATAXIA; BACTERIOPHAGE
   T7; MTDNA DEPLETION; HELICASE; MUTATIONS; TWINKLE
AB Mitochondrial dysfunction affects cellular energy metabolism, but less is known about the consequences for cytoplasmic biosynthetic reactions. We report that mtDNA replication disorders caused by TWINKLE mutations-mitochondrial myopathy (MM) and infantile onset spinocerebellar ataxia (IOSCA)-remodel cellular dNTP pools in mice. MM muscle shows tissue-specific induction of the mitochondrial folate cycle, purine metabolism, and imbalanced and increased dNTP pools, consistent with progressive mtDNA mutagenesis. IOSCA-TWINKLE is predicted to hydrolyze dNTPs, consistent with low dNTP pools and mtDNA depletion in the disease. MM muscle also modifies the cytoplasmic one-carbon cycle, transsulfuration, and methylation, as well as increases glucose uptake and its utilization for de novo serine and glutathione biosynthesis. Our evidence indicates that the mitochondrial replication machinery communicates with cytoplasmic dNTP pools and that upregulation of glutathione synthesis through glucose-driven de novo serine biosynthesis contributes to the metabolic stress response. These results are important for disorders with primary or secondary mtDNA instability and offer targets for metabolic therapy.
C1 [Nikkanen, Joni; Forsstrom, Saara; Euro, Liliya; Paetau, Ilse; Chilov, Dmitri; Ahola, Sofia; Buzkova, Jana; Terzioglu, Mugen; Khan, Nahid A.; Pirnes-Karhu, Sini; Isohanni, Pirjo; Tyynismaa, Henna; Battersby, Brendan J.; Carroll, Christopher J.; Suomalainen, Anu] Univ Helsinki, Res Programs Unit, Mol Neurol, FIN-00290 Helsinki, Finland.
   [Kohnz, Rebecca A.; Nomura, Daniel K.] Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.
   [Kohnz, Rebecca A.; Nomura, Daniel K.] Univ Calif Berkeley, Dept Nutr Sci & Toxicol, Berkeley, CA 94720 USA.
   [Wang, Liya] Swedish Univ Agr Sci, Dept Anat Physiol & Biochem, S-75007 Uppsala, Sweden.
   [Viinamaki, Jenni; Sajantila, Antti] Univ Helsinki, Dept Forens Med, Kytosuontie 11, SF-00300 Helsinki, Finland.
   [Roivainen, Anne; Marjamaki, Paivi; Liljenback, Heidi] Univ Turku, Turku PET Ctr, FIN-20520 Turku, Finland.
   [Roivainen, Anne; Liljenback, Heidi] Univ Turku, Inst Biomed, Turku Ctr Dis Modeling, FIN-20520 Turku, Finland.
   [Paetau, Anders] Univ Helsinki, Helsinki Univ Hosp, HUSLAB, FIN-00290 Helsinki, Finland.
   [Paetau, Anders] Univ Helsinki, Helsinki Univ Hosp, Dept Pathol, FIN-00290 Helsinki, Finland.
   [Lonnqvist, Tuula; Isohanni, Pirjo] Univ Helsinki, Helsinki Univ Hosp, Childrens Hosp, Dept Child Neurol, FIN-00290 Helsinki, Finland.
   [Suomalainen, Anu] Univ Helsinki, Helsinki Univ Hosp, Dept Neurol, FIN-00290 Helsinki, Finland.
   [Tyynismaa, Henna] Univ Helsinki, Dept Med & Clin Genet, FIN-00290 Helsinki, Finland.
   [Velagapudi, Vidya] Univ Helsinki, Inst Mol Med Finland, Metabol Unit, FIN-00290 Helsinki, Finland.
   [Suomalainen, Anu] Univ Helsinki, Ctr Neurosci, Helsinki 00790, Finland.
C3 University of Helsinki; University of California System; University of
   California Berkeley; University of California System; University of
   California Berkeley; Swedish University of Agricultural Sciences;
   University of Helsinki; University of Turku; University of Turku;
   University of Helsinki; Helsinki University Central Hospital; University
   of Helsinki; Helsinki University Central Hospital; University of
   Helsinki; Helsinki University Central Hospital; University of Helsinki;
   Helsinki University Central Hospital; University of Helsinki; University
   of Helsinki; University of Helsinki
RP Carroll, CJ; Suomalainen, A (corresponding author), Univ Helsinki, Res Programs Unit, Mol Neurol, FIN-00290 Helsinki, Finland.; Suomalainen, A (corresponding author), Univ Helsinki, Helsinki Univ Hosp, Dept Neurol, FIN-00290 Helsinki, Finland.; Suomalainen, A (corresponding author), Univ Helsinki, Ctr Neurosci, Helsinki 00790, Finland.
EM christopher.carroll@helsinki.fi; anu.wartiovaara@helsinki.fi
RI Carroll, Christopher/AAV-8023-2021; Sajantila, Antti/AAY-9084-2021;
   Nomura, Daniel/GNH-5946-2022; Ahola, Sofia/JEP-4595-2023; Velagapudi,
   Vidya/L-7278-2015; Tyynismaa, Henna/F-1428-2011; Liliya,
   Euro/F-3808-2015
OI Terzioglu, Mugen/0000-0003-0872-3046; Tyynismaa,
   Henna/0000-0002-2493-2422; Khan, Nahid/0000-0002-2835-3655; Liljenback,
   Heidi/0000-0001-9372-1584; Liliya, Euro/0000-0001-9705-3886;
   Suomalainen-Wartiovaara, Anu/0000-0003-4833-5195; Nikkanen,
   Joni/0000-0001-7099-4061; Sajantila, Antti/0000-0003-4117-5248; Carroll,
   Christopher/0000-0002-2814-6955; Forsstrom, Saara/0000-0003-1610-6793;
   Ahola, Sofia/0000-0001-7552-4843; Roivainen, Anne/0000-0002-4006-7977
FU European Research Council; Academy of Finland; Sigrid Juselius
   Foundation; Jane and Aatos Erkko Foundation; University of Helsinki;
   Helsinki University Central Hospital; Helsinki Biomedical Graduate
   School; NIH [R01CA172667]; University of Turku; Turku University
   Hospital; Abo Akademi University
FX The authors wish to thank Anna Hakonen and Ksenia Sevastianova for
   patient sampling; Anu Harju, Markus Innila, and Tuula Manninen for
   technical assistance; Johanna Silvola for technical help with PET
   imaging and data analysis; and Meri Kokkonen and Jatin Nandania for
   technical help with metabolomics analyses. The following funding
   resources are acknowledged: European Research Council, Academy of
   Finland, Sigrid Juselius Foundation, Jane and Aatos Erkko Foundation,
   University of Helsinki and Helsinki University Central Hospital (A.S.),
   Helsinki Biomedical Graduate School (J.N. and S.F.), and NIH R01CA172667
   (D.K.N.). The PET studies were conducted within the Finnish Centre of
   Excellence in Cardiovascular and Metabolic Disease supported by the
   Academy of Finland, the University of Turku, the Turku University
   Hospital, and Abo Akademi University.
CR Arnold K, 2006, BIOINFORMATICS, V22, P195, DOI 10.1093/bioinformatics/bti770
   BALSOM PD, 1994, SPORTS MED, V18, P268, DOI 10.2165/00007256-199418040-00005
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Christensen KE, 2006, BIOESSAYS, V28, P595, DOI 10.1002/bies.20420
   CORTOPASSI GA, 1992, P NATL ACAD SCI USA, V89, P7370, DOI 10.1073/pnas.89.16.7370
   Crampton DJ, 2006, MOL CELL, V21, P165, DOI 10.1016/j.molcel.2005.11.027
   DeNicola GM, 2015, NAT GENET, V47, P1475, DOI 10.1038/ng.3421
   Di Pietro E, 2004, BBA-GEN SUBJECTS, V1674, P78, DOI 10.1016/j.bbagen.2004.06.014
   Field MS, 2006, J BIOL CHEM, V281, P4215, DOI 10.1074/jbc.M510624200
   Garcia-Diaz B, 2014, BRAIN, V137, P1337, DOI 10.1093/brain/awu068
   Goffart S, 2009, HUM MOL GENET, V18, P328, DOI 10.1093/hmg/ddn359
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Hakonen AH, 2008, HUM MOL GENET, V17, P3822, DOI 10.1093/hmg/ddn280
   Hingorani MM, 1996, BIOCHEMISTRY-US, V35, P2218, DOI 10.1021/bi9521497
   Jain M, 2012, SCIENCE, V336, P1040, DOI 10.1126/science.1218595
   Khan NA, 2014, EMBO MOL MED, V6, P721, DOI 10.1002/emmm.201403943
   Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257
   Li Y, 2014, CELL, V158, P213, DOI 10.1016/j.cell.2014.05.034
   Liao JC, 2005, J MOL BIOL, V350, P452, DOI 10.1016/j.jmb.2005.04.051
   Locasale JW, 2011, NAT GENET, V43, P869, DOI 10.1038/ng.890
   Lönnqvist T, 1998, J NEUROL SCI, V161, P57, DOI 10.1016/S0022-510X(98)00249-4
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Martí R, 2012, METHODS MOL BIOL, V837, P135, DOI 10.1007/978-1-61779-504-6_9
   Mehrmohamadi M, 2014, CELL REP, V9, P1507, DOI 10.1016/j.celrep.2014.10.026
   Mudd SH, 2007, AM J CLIN NUTR, V85, P19, DOI 10.1093/ajcn/85.1.19
   Naviaux RK, 1999, ANN NEUROL, V45, P54, DOI 10.1002/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B
   Nikali K, 2005, HUM MOL GENET, V14, P2981, DOI 10.1093/hmg/ddi328
   Nilsson R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4128
   Nunnari J, 2012, CELL, V148, P1145, DOI 10.1016/j.cell.2012.02.035
   Pagliarini DJ, 2008, CELL, V134, P112, DOI 10.1016/j.cell.2008.06.016
   Pagliarini DJ, 2013, GENE DEV, V27, P2615, DOI 10.1101/gad.229724.113
   Pike ST, 2010, J BIOL CHEM, V285, P4612, DOI 10.1074/jbc.M109.079855
   Poli J, 2012, EMBO J, V31, P883, DOI 10.1038/emboj.2011.470
   Sawaya MR, 1999, CELL, V99, P167, DOI 10.1016/S0092-8674(00)81648-7
   SCHIRCH V, 1989, ARCH BIOCHEM BIOPHYS, V269, P371, DOI 10.1016/0003-9861(89)90120-3
   SCOTT JM, 1981, LANCET, V2, P337
   Sengupta Rajib, 2014, World J Biol Chem, V5, P68, DOI 10.4331/wjbc.v5.i1.68
   Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Stockler S, 1996, AM J HUM GENET, V58, P914
   STRONG WB, 1990, J BIOL CHEM, V265, P12149
   Suh JR, 2001, ANNU REV NUTR, V21, P255, DOI 10.1146/annurev.nutr.21.1.255
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   Tibbetts AS, 2010, ANNU REV NUTR, V30, P57, DOI 10.1146/annurev.nutr.012809.104810
   Tufi R, 2014, NAT CELL BIOL, V16, P157, DOI 10.1038/ncb2901
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
   Tyynismaa H, 2004, HUM MOL GENET, V13, P3219, DOI 10.1093/hmg/ddh342
   Tyynismaa H, 2010, HUM MOL GENET, V19, P3948, DOI 10.1093/hmg/ddq310
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 52
TC 201
Z9 213
U1 0
U2 21
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1550-4131
EI 1932-7420
J9 CELL METAB
JI Cell Metab.
PD APR 12
PY 2016
VL 23
IS 4
BP 635
EP 648
DI 10.1016/j.cmet.2016.01.019
PG 14
WC Cell Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Endocrinology & Metabolism
GA DJ3RL
UT WOS:000374123200012
PM 26924217
OA Bronze
DA 2024-11-01
ER

PT J
AU Garone, C
   Taylor, RW
   Nascimento, A
   Poulton, J
   Fratter, C
   Domínguez-González, C
   Evans, JC
   Loos, M
   Isohanni, P
   Suomalainen, A
   Ram, D
   Hughes, MI
   McFarland, R
   Barca, E
   Gomez, CL
   Jayawant, S
   Thomas, ND
   Manzur, AY
   Kleinsteuber, K
   Martin, MA
   Kerr, T
   Gorman, GS
   Sommerville, EW
   Chinnery, PF
   Hofer, M
   Karch, C
   Ralph, J
   Cámara, Y
   Madruga-Garrido, M
   Domínguez-Carral, J
   Ortez, C
   Emperador, S
   Montoya, J
   Chakrapani, A
   Kriger, JF
   Schoenaker, R
   Levin, B
   Thompson, JLP
   Long, YL
   Rahman, S
   Donati, MA
   DiMauro, S
   Hirano, M
AF Garone, Caterina
   Taylor, Robert W.
   Nascimento, Andres
   Poulton, Joanna
   Fratter, Carl
   Dominguez-Gonzalez, Cristina
   Evans, Julie C.
   Loos, Mariana
   Isohanni, Pirjo
   Suomalainen, Anu
   Ram, Dipak
   Hughes, M. Imelda
   McFarland, Robert
   Barca, Emanuele
   Gomez, Carlos Lopez
   Jayawant, Sandeep
   Thomas, Neil D.
   Manzur, Adnan Y.
   Kleinsteuber, Karin
   Martin, Miguel A.
   Kerr, Timothy
   Gorman, Grainne S.
   Sommerville, Ewen W.
   Chinnery, Patrick F.
   Hofer, Monika
   Karch, Christoph
   Ralph, Jeffrey
   Camara, Yolanda
   Madruga-Garrido, Marcos
   Dominguez-Carral, Jana
   Ortez, Carlos
   Emperador, Sonia
   Montoya, Julio
   Chakrapani, Anupam
   Kriger, Joshua F.
   Schoenaker, Robert
   Levin, Bruce
   Thompson, John L. P.
   Long, Yuelin
   Rahman, Shamima
   Donati, Maria Alice
   DiMauro, Salvatore
   Hirano, Michio
TI Retrospective natural history of thymidine kinase 2 deficiency
SO JOURNAL OF MEDICAL GENETICS
LA English
DT Article
ID MITOCHONDRIAL-DNA DEPLETION; SPINAL MUSCULAR-ATROPHY; TK2 GENE; MTDNA
   DEPLETION; MYOPATHIC FORM; MUTATIONS; PATIENT; DELETIONS; SPECTRUM;
   DEFECT
AB Background Thymine kinase 2 (TK2) is a mitochondrial matrix protein encoded in nuclear DNA and phosphorylates the pyrimidine nucleosides: thymidine and deoxycytidine. Autosomal recessive TK2 mutations cause a spectrum of disease from infantile onset to adult onset manifesting primarily as myopathy.
   Objective To perform a retrospective natural history study of a large cohort of patients with TK2 deficiency.
   Methods The study was conducted by 42 investigators across 31 academic medical centres.
   Results We identified 92 patients with genetically confirmed diagnoses of TK2 deficiency: 67 from literature review and 25 unreported cases. Based on clinical and molecular genetics findings, we recognised three phenotypes with divergent survival: (1) infantile-onset myopathy (42.4%) with severe mitochondrial DNA (mtDNA) depletion, frequent neurological involvement and rapid progression to early mortality (median post-onset survival (POS) 1.00, CI 0.58 to 2.33 years); (2) childhood-onset myopathy (40.2%) with mtDNA depletion, moderate-to-severe progression of generalised weakness and median POS at least 13 years; and (3) late-onset myopathy (17.4%) with mild limb weakness at onset and slow progression to respiratory insufficiency with median POS of 23 years. Ophthalmoparesis and facial weakness are frequent in adults. Muscle biopsies show multiple mtDNA deletions often with mtDNA depletion.
   Conclusions In TK2 deficiency, age at onset, rate of weakness progression and POS are important variables that define three clinical subtypes. Nervous system involvement often complicates the clinical course of the infantile-onset form while extraocular muscle and facial involvement are characteristic of the late-onset form. Our observations provide essential information for planning future clinical trials in this disorder.
C1 [Garone, Caterina; Barca, Emanuele; Gomez, Carlos Lopez; Schoenaker, Robert; DiMauro, Salvatore; Hirano, Michio] Columbia Univ, Dept Neurol, Med Ctr, New York, NY 10032 USA.
   [Garone, Caterina; Chinnery, Patrick F.] MRC Mitochondrial Biol Unit, Cambridge Biomed Campus, Cambridge, England.
   [Taylor, Robert W.; McFarland, Robert; Gorman, Grainne S.; Sommerville, Ewen W.] Newcastle Univ, Sch Med, Inst Neurosci, Wellcome Trust Ctr Mitochondrial Res, Newcastle Upon Tyne, Tyne & Wear, England.
   [Nascimento, Andres; Dominguez-Gonzalez, Cristina; Ortez, Carlos] Hosp Univ 12 Octubre, Neuromuscular Unit, Madrid, Spain.
   [Poulton, Joanna] Univ Oxford, Nuffield Dept Obstet & Gynaecol, Oxford, England.
   [Fratter, Carl; Evans, Julie C.] Oxford Univ Hosp NHS Fdn Trust, Oxford Med Genet Labs, Oxford, England.
   [Dominguez-Gonzalez, Cristina; Martin, Miguel A.] Inst Salud Carlos III, Ctr Biomed Network Res Rare Dis CIBERER, Madrid, Spain.
   [Dominguez-Gonzalez, Cristina; Martin, Miguel A.] Hosp Univ 12 Octubre, Inst Invest, Madrid, Spain.
   [Loos, Mariana] Hosp Pediat Prof Dr JP Garrahan, Neurol Dept, Buenos Aires, DF, Argentina.
   [Isohanni, Pirjo; Suomalainen, Anu] Univ Helsinki, Res Programs Unit, Mol Neurol, Biomed Helsinki, Helsinki, Finland.
   [Isohanni, Pirjo] Univ Helsinki, Helsinki Univ Hosp, Childrens Hosp, Dept Child Neurol, Helsinki, Finland.
   [Suomalainen, Anu] Univ Helsinki, Neurosci Ctr, Helsinki, Finland.
   [Suomalainen, Anu] Helsinki Univ Hosp, Dept Neurol, Helsinki, Finland.
   [Ram, Dipak; Hughes, M. Imelda] Royal Manchester Childrens Hosp, Dept Paediat Neurol, Manchester, Lancs, England.
   [Barca, Emanuele] Univ Messina, Dept Clin & Expt Med, UOC Neurol & Neuromuscular Dis, Messina, Italy.
   [Jayawant, Sandeep] Oxford Univ Hosp NHS Fdn Trust, Paediat Neurol, Oxford, England.
   [Thomas, Neil D.] Univ Hosp Southampton NHS Fdn Trust, Paediat Neurol, Southampton, Hants, England.
   [Manzur, Adnan Y.] Great Ormond St Hosp Children NHS Fdn Trust, Dubowitz Neuromuscular Ctr, London, England.
   [Kleinsteuber, Karin] Univ Chile, Fac Med, Pediat Neurol, Clin Los Condes, Santiago, Chile.
   [Kerr, Timothy] St Georges Univ Hosp NHS Fdn Trust, Paediat Neurol, London, England.
   [Chinnery, Patrick F.] Newcastle Univ, Inst Genet Med, Wellcome Trust Ctr Mitochondrial Res, Newcastle Upon Tyne, Tyne & Wear, England.
   [Hofer, Monika] Oxford Univ Hosp NHS Fdn Trust, Dept Neuropathol, Oxford, England.
   [Karch, Christoph; Ralph, Jeffrey] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
   [Camara, Yolanda] Vall dHebron Inst Rec, Res Grp Neuromuscular & Mitochondrial Disorders, Barcelona, Spain.
   [Camara, Yolanda] Inst Salud Carlos III, Ctr Biomed Network Res Rare Dis CIBERER, Barcelona, Spain.
   [Madruga-Garrido, Marcos] Hosp Univ Virgen del Rocio, Inst Biomed Sevilla, Secc Neuropediat, Seville, Spain.
   [Dominguez-Carral, Jana] Univ Barcelona, ISCIII, CIBERER, Hosp Sant Joan de Deu,Dept Neurol,Neuromuscular U, Barcelona, Spain.
   [Emperador, Sonia; Montoya, Julio] Univ Zaragoza, CIBERER Inst Invest Sanitarias Aragon, Dept Biochem & Mol Biol, Zaragoza, Spain.
   [Chakrapani, Anupam; Rahman, Shamima] Great Ormond St Hosp NHS Fdn Trust, Metab Unit, London, England.
   [Kriger, Joshua F.; Levin, Bruce; Thompson, John L. P.; Long, Yuelin] Columbia Univ, Med Ctr, Dept Biostat, Mailman Sch Publ Hlth, New York, NY 10032 USA.
   [Rahman, Shamima] UCL Great Ormond St Inst Child Hlth, Mitochondrial Res Grp, Genet & Genom Med, London, England.
   [Donati, Maria Alice] Meyer Hosp, Metab & Neuromuscular Unit, Florence, Italy.
C3 Columbia University; Newcastle University - UK; Hospital Universitario
   12 de Octubre; University of Oxford; Oxford University Hospitals NHS
   Foundation Trust; Instituto de Salud Carlos III; CIBER - Centro de
   Investigacion Biomedica en Red; CIBERER; Hospital Universitario 12 de
   Octubre; Hospital de Pediatria Doctor Juan Garrahan; University of
   Helsinki; University of Helsinki; Helsinki University Central Hospital;
   University of Helsinki; University of Helsinki; Helsinki University
   Central Hospital; Royal Manchester Children's Hospital; University of
   Messina; Oxford University Hospitals NHS Foundation Trust; University of
   Southampton; University Hospital Southampton NHS Foundation Trust;
   University of London; University College London; Great Ormond Street
   Hospital for Children NHS Foundation Trust; Clinica Las Condes;
   Universidad de Chile; Newcastle University - UK; Oxford University
   Hospitals NHS Foundation Trust; University of California System;
   University of California San Francisco; CIBER - Centro de Investigacion
   Biomedica en Red; CIBERER; Instituto de Salud Carlos III; Virgen del
   Rocio University Hospital; Consejo Superior de Investigaciones
   Cientificas (CSIC); University of Sevilla; CSIC-JA-USE - Instituto de
   Biomedicina de Sevilla (IBIS); CIBER - Centro de Investigacion Biomedica
   en Red; CIBERER; University of Barcelona; Instituto de Salud Carlos III;
   University of Zaragoza; University of London; University College London;
   Great Ormond Street Hospital for Children NHS Foundation Trust; Columbia
   University; University of London; University College London; University
   of Florence; Azienda Ospedaliera Universitaria (AOU) MEYER
RP Hirano, M (corresponding author), Columbia Univ, Dept Neurol, Med Ctr, New York, NY 10032 USA.
EM mh29@columbia.edu
RI López-Gómez, Carlos/C-8938-2009; Martin, Miguel/S-2758-2018; Rahman,
   Shamima/C-5232-2008; Garone, Caterina/AAB-8659-2019; Cámara,
   Yolanda/P-2540-2019; Poulton, Joanna/AAB-4828-2021; Camara,
   Yolanda/K-4597-2014; Martin, Miguel Angel/B-6261-2017
OI Dominguez, Cristina/0000-0001-5151-988X; Gorman,
   Grainne/0000-0002-7585-3409; McFarland, Robert/0000-0002-8833-2688;
   Lopez-Gomez, Carlos/0000-0003-2699-451X; Poulton,
   Joanna/0000-0002-2460-5587; BARCA, EMANUELE/0009-0007-6672-6524; Camara,
   Yolanda/0000-0003-2458-6942; Suomalainen-Wartiovaara,
   Anu/0000-0003-4833-5195; Garone, Caterina/0000-0003-4928-1037; MARIA
   ALICE, DONATI/0000-0003-4769-5025; Martin, Miguel
   Angel/0000-0003-4741-772X; Chinnery, Patrick/0000-0002-7065-6617; Ortez
   Gonzalez, Carlos Ignacio/0000-0001-8187-8103
FU NIH [P01 HD080642]; NINDS, NICHD, ODS [U54 NS078059]; National Center
   for Advancing Translational Science (NCATS); Muscular Dystrophy
   Association (MIH); Associarione Maalattie Metaboliche Congenite eredit
   arie (AMMeC); Arturo Estopinan TK2 Research Fund; Marriott Mitochondrial
   Disease Clinic Research Fund (MMDCRF); Wellcome Trust Strategic Award
   [096919/Z/11/Z]; MRC Centre for Nleuromuscular Diseases [G0601943]; Lily
   Foundation; UK NHS Highly Specialised 'Rare Mitochondrial Disorders of
   Adults and Children' Service; Medical Research Council Project Grant
   [MR/101044811]; Wellcome Trust Project Grant [0948685/Z/10/Z]; Great
   Ormond Street Hospital Children's Charity Research Leadership award
   [V1260]; Wellcome Trust Senior Fellow in Clinical Science
   [101876/Z/13/Z]; K NIHR Senior Investigator; Medical Research Council
   Mitochondrial Biology Unit [MC_UP_150112]; Wellcome Trust Centre for
   Mitochondrial Research [096919Z/11/Z]; Medical Research Council (UK)
   Centre for Translational Muscle Disease research [G0601943]; EU FP7
   TIRCON; National Institute for Health Research (NIHR) Biomedical
   Research Centre based at Cambridge University Hospitals NHS Foundation
   Trust; University of Cambridge; Sigrid Juselius Foundation; Jane and
   Aatos Erkko Foundation; Academy of Finland; European Research Council;
   University of Helsinki; Spanish Instituto Salud Carlos III (ISCIII)
   [FIS-P112/01683]; ISCIII [FIS-P114/00005]; Departamento de Ciencia,
   Tecnologia y Universidad del Gobierno de Aragon (Grupos Consolidados
   B33); European Union; European Union, and CIBERER; ISCIII; 'Biobanc de
   l'Hospital Infantil Sant Joan de Deu per a la Investigacia' integrated
   in the Spanish Biobank Network of ISCIII; Spanish Ministry of Economy
   and Competitiveness [BFU2014-52618-R]; AFM-Telethon [19965]; MRC
   [G0200335, G0800674] Funding Source: UKRI
FX This work was supported by research grants from NIH (P01 HD080642) and
   U54 NS078059 from NINDS, NICHD, ODS and the National Center for
   Advancing Translational Science (NCATS), the Muscular Dystrophy
   Association (MIH) and the Associarione Maalattie Metaboliche Congenite
   eredit arie (AMMeC) (CG) as well as by the Arturo Estopinan TK2 Research
   Fund (MIH) and the Marriott Mitochondrial Disease Clinic Research Fund
   (MMDCRF) (MIN). FONT is funded by a Wellcome Trust Strategic Award
   (096919/Z/11/Z), the MRC Centre for Nleuromuscular Diseases (G0601943),
   the Lily Foundation and the UK NHS Highly Specialised 'Rare
   Mitochondrial Disorders of Adults and Children' Service. JP is funded by
   a Medical Research Council Project Grant (MR/101044811), Wellcome Trust
   Project Grant (0948685/Z/10/Z), and UK NHS Highly Specialised 'Rare
   Mitochondrial Disorders of Adults and Children' Service. SR acknowledges
   support from a Great Ormond Street Hospital Children's Charity Research
   Leadership award (V1260) and the Lily Foundation. PFC is a Wellcome
   Trust Senior Fellow in Clinical Science (101876/Z/13/Z) and a UK NIHR
   Senior Investigator, who receives support from the Medical Research
   Council Mitochondrial Biology Unit (MC_UP_150112), the Wellcome Trust
   Centre for Mitochondrial Research (096919Z/11/Z), the Medical Research
   Council (UK) Centre for Translational Muscle Disease research
   (G0601943), EU FP7 TIRCON and the National Institute for Health Research
   (NIHR) Biomedical Research Centre based at Cambridge University
   Hospitals NHS Foundation Trust and the University of Cambridge. During
   this study, AS has received support from Sigrid Juselius Foundation,
   Jane and Aatos Erkko Foundation, Academy of Finland, European Research
   Council and University of Helsinki. MAM has received funding from the
   Spanish Instituto Salud Carlos III (ISCIII) (FIS-P112/01683). JM has
   received funding from the ISCIII (FIS-P114/00005), Departamento de
   Ciencia, Tecnologia y Universidad del Gobierno de Aragon (Grupos
   Consolidados B33), FEDER Funding Program from the European Union, and
   CIBERER, an initiative of the ISCIII. AN has received funding from
   'Biobanc de l'Hospital Infantil Sant Joan de Deu per a la Investigacia'
   integrated in the Spanish Biobank Network of ISCIII for the sample and
   data procurement. YC has received funding from the Spanish Ministry of
   Economy and Competitiveness (BFU2014-52618-R) and AFM-Telethon (19965).
CR Alston CL, 2013, NEUROLOGY, V81, P2051, DOI 10.1212/01.wnl.0000436931.94291.e6
   Bartesaghi S, 2010, HUM MOL GENET, V19, P1669, DOI 10.1093/hmg/ddq043
   Béhin A, 2012, NEUROLOGY, V78, P644, DOI 10.1212/WNL.0b013e318248df2b
   Blakely E, 2008, NEUROMUSCULAR DISORD, V18, P557, DOI 10.1016/j.nmd.2008.04.014
   Cámara Y, 2015, NEUROLOGY, V84, P2286, DOI 10.1212/WNL.0000000000001644
   Carrozzo R, 2003, HUM MUTAT, V21, DOI 10.1002/humu.9135
   Chanprasert S, 2013, MOL GENET METAB, V110, P153, DOI 10.1016/j.ymgme.2013.07.009
   Collins J, 2009, NEUROMUSCULAR DISORD, V19, P784, DOI 10.1016/j.nmd.2009.08.002
   Galbiati S, 2006, PEDIATR NEUROL, V34, P177, DOI 10.1016/j.pediatrneurol.2005.07.013
   Garone C, 2014, EMBO MOL MED, V6, P1016, DOI 10.15252/emmm.201404092
   Garone C, 2012, ARCH NEUROL-CHICAGO, V69, P1648, DOI 10.1001/archneurol.2012.405
   Götz A, 2008, BRAIN, V131, P2841, DOI 10.1093/brain/awn236
   Knierim E, 2015, MITOCHONDRION, V20, P1, DOI 10.1016/j.mito.2014.10.007
   Leshinsky-Silver E, 2008, EUR J PAEDIATR NEURO, V12, P309, DOI 10.1016/j.ejpn.2007.09.005
   Lesko N, 2010, NEUROMUSCULAR DISORD, V20, P198, DOI 10.1016/j.nmd.2009.11.013
   Lopez-Gomez C, 2017, ANN NEUROL, V81, P641, DOI 10.1002/ana.24922
   Mancuso M, 2003, ARCH NEUROL-CHICAGO, V60, P1007, DOI 10.1001/archneur.60.7.1007
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Martí R, 2010, PEDIATR RES, V68, P151, DOI 10.1203/00006450-201011001-00294
   Oskoui M, 2006, ARCH NEUROL-CHICAGO, V63, P1122, DOI 10.1001/archneur.63.8.1122
   Paradas C, 2013, NEUROLOGY, V80, P504, DOI 10.1212/WNL.0b013e31827f0ff7
   Piepers S, 2008, J NEUROL, V255, P1400, DOI 10.1007/s00415-008-0929-0
   Roos S, 2014, NEUROMUSCULAR DISORD, V24, P713, DOI 10.1016/j.nmd.2014.05.009
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Stewart JD, 2011, BBA-MOL BASIS DIS, V1812, P321, DOI 10.1016/j.bbadis.2010.11.012
   Tawil R, 2015, NEUROLOGY, V85, P357, DOI 10.1212/WNL.0000000000001783
   Taylor RW, 2014, JAMA-J AM MED ASSOC, V312, P68, DOI 10.1001/jama.2014.7184
   Tizzano EF, 2017, NEUROMUSCULAR DISORD, V27, P883, DOI 10.1016/j.nmd.2017.05.011
   Tulinius M, 2005, NEUROMUSCULAR DISORD, V15, P412, DOI 10.1016/j.nmd.2005.03.010
   Tyynismaa H, 2012, HUM MOL GENET, V21, P66, DOI 10.1093/hmg/ddr438
   Vilà MR, 2003, NEUROLOGY, V60, P1203, DOI 10.1212/01.WNL.0000055928.58122.47
   Wang LY, 2005, MOL GENET METAB, V84, P75, DOI 10.1016/j.ymgme.2004.09.005
NR 32
TC 64
Z9 68
U1 0
U2 5
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-2593
EI 1468-6244
J9 J MED GENET
JI J. Med. Genet.
PD AUG
PY 2018
VL 55
IS 8
BP 515
EP 521
DI 10.1136/jmedgenet-2017-105012
PG 7
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA GR2ZW
UT WOS:000442457100002
PM 29602790
OA hybrid, Green Published
DA 2024-11-01
ER

PT J
AU Kärppä, M
   Herva, R
   Moslemi, AR
   Oldfors, A
   Kakko, S
   Majamaa, K
AF Kärppä, M
   Herva, R
   Moslemi, AR
   Oldfors, A
   Kakko, S
   Majamaa, K
TI Spectrum of myopathic findings in 50 patients with the 3243A&gt;G
   mutation in mitochondrial DNA
SO BRAIN
LA English
DT Article
DE mitochondrial myopathies; muscle fibres; ultrastructure; clinical
   laboratory techniques; MELAS
ID TRANSFER RNALEU(UUR) GENE; STROKE-LIKE EPISODES; RAGGED-RED FIBERS;
   MUSCLE-FIBERS; SKELETAL-MUSCLE; HEARING IMPAIRMENT; LACTIC-ACIDOSIS;
   MTDNA MUTATION; POINT MUTATION; MELAS
AB Myopathy is a typical clinical finding among patients with the 3243A > G mutation in mitochondrial DNA (mtDNA), but the variability in such findings has not been properly established. We have previously determined the prevalence of patients with 3243A > G in a defined population in northern Finland and characterized a group of patients who represent a good approximation to a population-based cohort. We report here on examinations performed on patients belonging to this cohort in order to determine the frequency of myopathy and to evaluate the clinical, histological, ultrastructural and single fibre mtDNA variability in muscle involvement. Fifty patients with 3243A > G underwent a thorough structured interview and clinical examination. Muscle histology, ultrastructure and single fibre analysis were examined in a subset of patients. A clinical diagnosis of myopathy was made in 50% of cases [95% confidence interval (CI), 36-64] and abnormalities in muscle histology were found in 72% (95% CI, 55-86). Moderate limb weakness leading to functional impairment was the most common myopathic sign, but mild weakness, ptosis and external ophthalmoplegia could also be found. The presence of intramitochondrial crystals and cytochrome c oxidase (COX)-negative fibres and variation in mitochondrial size and shape were more common in the muscles of the myopathic patients. Longitudinal variations in mutation heteroplasmy were examined in single muscle fibres from two severely affected patients. Although the total variation in mutation heteroplasmy along four ragged red fibres (RRFs) was small, the mutation heteroplasmy in five 10 mu m segments was clearly lower (median 68%, range 64-74%) than that in the neighbouring segments. There were also segments with deviant mutation load in histologically normal fibres in one patient. The highest incidence of myopathy was in the fifth decade of life, but, apart from age, no other clinical variables such as gender, muscle heteroplasmy, physical inactivity or diabetes were associated with an increased risk of myopathy. The clinical presentation of myopathy is highly variable in patients with 3243A > G.
C1 Univ Oulu, Dept Neurol, FIN-90014 Oulu, Finland.
   Oulu Univ Hosp, Clin Res Ctr, Oulu, Finland.
   Oulu Univ Hosp, Dept Pathol, Oulu, Finland.
   Oulu Univ Hosp, Dept Internal Med, Oulu, Finland.
   Sahlgrens Univ Hosp, Dept Pathol, S-41345 Gothenburg, Sweden.
   Univ Turku, Dept Neurol, FIN-20520 Turku, Finland.
C3 University of Oulu; University of Oulu; University of Oulu; University
   of Oulu; Sahlgrenska University Hospital; University of Turku
RP Univ Oulu, Dept Neurol, POB 5000, FIN-90014 Oulu, Finland.
EM kari.majamaa@oulu.fi
RI Majamaa, Kari/A-1344-2012
OI Majamaa, Kari/0000-0002-9070-3791
CR BOFFOLI D, 1994, BBA-MOL BASIS DIS, V1226, P73, DOI 10.1016/0925-4439(94)90061-2
   Brierley EJ, 1996, QJM-MON J ASSOC PHYS, V89, P251
   Brierley EJ, 1997, ANN NEUROL, V41, P114, DOI 10.1002/ana.410410120
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   Chinnery PF, 2003, J NEUROL SCI, V211, P63, DOI 10.1016/S0022-510X(03)00039-X
   Cwik Valerie A., 1996, P359
   Deschauer M, 2001, ARCH NEUROL-CHICAGO, V58, P1885, DOI 10.1001/archneur.58.11.1885
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Ebneth A, 1998, J CELL BIOL, V143, P777, DOI 10.1083/jcb.143.3.777
   Elson JL, 2002, NEUROMUSCULAR DISORD, V12, P858, DOI 10.1016/S0960-8966(02)00047-0
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   HAMMANS SR, 1995, BRAIN, V118, P721, DOI 10.1093/brain/118.3.721
   Kärppä M, 2004, J NEUROL, V251, P556, DOI 10.1007/s00415-004-0363-x
   Kärppä M, 2003, J NEUROL, V250, P216, DOI 10.1007/s00415-003-0981-8
   Katirji B, INNEUROMUSCULAR DISO, P3
   KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5
   Larsson NG, 2001, ACTA PHYSIOL SCAND, V171, P385, DOI 10.1046/j.1365-201x.2001.00842.x
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   MATSUOKA T, 1991, J NEUROL SCI, V106, P193, DOI 10.1016/0022-510X(91)90257-8
   MENDELL JR, 1990, MUSCLE NERVE       S, V13, P16
   MORAES CT, 1993, NEUROMUSCULAR DISORD, V3, P43, DOI 10.1016/0960-8966(93)90040-Q
   MORGANHUGHES JA, 1994, MYOLOGY, P1610
   Moslemi AR, 1998, NEUROMUSCULAR DISORD, V8, P345, DOI 10.1016/S0960-8966(98)00029-7
   OLDFORS A, 1995, J NEUROPATH EXP NEUR, V54, P581, DOI 10.1097/00005072-199507000-00012
   PETRUZZELLA V, 1994, HUM MOL GENET, V3, P449, DOI 10.1093/hmg/3.3.449
   Sciacco M, 2001, J NEUROL, V248, P778, DOI 10.1007/s004150170094
   SCIACCO M, 1994, HUM MOL GENET, V3, P13, DOI 10.1093/hmg/3.1.13
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   STADHOUDERS AM, 1994, P NATL ACAD SCI USA, V91, P5089, DOI 10.1073/pnas.91.11.5089
   Uimonen S, 2001, HUM GENET, V108, P284, DOI 10.1007/s004390100475
   Weber K, 1997, AM J HUM GENET, V60, P373
NR 31
TC 28
Z9 29
U1 0
U2 0
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 1460-2156
J9 BRAIN
JI Brain
PD AUG
PY 2005
VL 128
BP 1861
EP 1869
DI 10.1093/brain/awh515
PN 8
PG 9
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 948OB
UT WOS:000230724500014
PM 15857931
OA Bronze
DA 2024-11-01
ER

PT J
AU Souilem, S
   Chebel, S
   Mancuso, M
   Petrozzi, L
   Siciliano, G
   FrihAyed, M
   Hentati, F
   Amouri, R
AF Souilem, Sihem
   Chebel, Saber
   Mancuso, Michelangelo
   Petrozzi, Lucia
   Siciliano, Gabriele
   FrihAyed, Mahbouba
   Hentati, Faycal
   Amouri, Rim
TI A novel mitochondrial tRNA<SUP>Ile</SUP> point mutation associated with
   chronic progressive external ophthalmoplegia and hyperCKemia
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE Mitochondrial diseases; PEO; mtDNA; tRNA mutation; HyperCKemia
ID TRNA(LEU(UUR)) GENE; A3243G MUTATION; DNA; DEFICIENCY; MYOPATHY; DISEASE
AB We have sequenced the entire mitochondrial DNA (mtDNA) from a 54-year-old man with chronic progressive external ophthalmoplegia (PEO) and hyperCKemia. Muscle biopsy showed ragged red and SDH positive/COX negative fibres, and the biochemistry was suggestive mitochondrial respiratory chain dysfunction. Analysis of mtDNA revealed a heteroplasmic m. 4308G>A mutation in the transfer RNA isoleucine gene (MT-TI gene). Our report expands the genetic heterogeneity of PRO. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Souilem, Sihem] Inst Natl Neurol, Lab Neurobiol Mol & Neuropathol, Dept Mol Neurobiol & Neuropathol, Tunis 1007, Tunisia.
   [Chebel, Saber; FrihAyed, Mahbouba] Univ Hosp Monastir, Dept Neurol, Monastir 5000, Tunisia.
   [Mancuso, Michelangelo; Petrozzi, Lucia; Siciliano, Gabriele] Univ Pisa, Neurol Clin, Dept Neurosci, I-56100 Pisa, Italy.
C3 Universite de Tunis-El-Manar; Institut National de Neurologie;
   Universite de Monastir; Hopital Fattouma Bourguiba; University of Pisa
RP Souilem, S (corresponding author), Inst Natl Neurol, Lab Neurobiol Mol & Neuropathol, Dept Mol Neurobiol & Neuropathol, Tunis 1007, Tunisia.
EM sihemsouilem@yahoo.fr
RI Mancuso, Michelangelo/K-4170-2016; Siciliano, Gabriele/K-7259-2016
OI Siciliano, Gabriele/0000-0002-6142-2384; AMOURI, RIM/0000-0001-5641-5748
CR Berardo A, 2010, NEUROMUSCULAR DISORD, V20, P204, DOI 10.1016/j.nmd.2010.01.006
   Chinnery PF, 1997, NEUROLOGY, V49, P1166, DOI 10.1212/WNL.49.4.1166
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Dimauro S, 2004, ANN NY ACAD SCI, V1011, P217, DOI 10.1196/annals.1293.022
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   FANCESCHINA L, 1998, J NEUROL, V245, P755
   Hadjigeorgiou GM, 1999, J NEUROL SCI, V164, P153, DOI 10.1016/S0022-510X(99)00062-3
   HATTORI Y, 1994, J NEUROL SCI, V125, P50, DOI 10.1016/0022-510X(94)90241-0
   Koga Y, 2000, ARCH DIS CHILD, V82, P407, DOI 10.1136/adc.82.5.407
   Laforêt P, 2000, REV NEUROL-FRANCE, V156, P1136
   Lalani SR, 2005, ARCH NEUROL-CHICAGO, V62, P317, DOI 10.1001/archneur.62.2.317
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   MORAES CT, 1993, NEUROMUSCULAR DISORD, V3, P43, DOI 10.1016/0960-8966(93)90040-Q
   Nishigaki Y, 2002, NEUROLOGY, V58, P1282, DOI 10.1212/WNL.58.8.1282
   Sciacco M, 1996, Methods Enzymol, V264, P509, DOI 10.1016/S0076-6879(96)64045-2
   Silvestri G, 1996, BIOCHEM BIOPH RES CO, V220, P623, DOI 10.1006/bbrc.1996.0453
   Taylor RW, 1998, BIOCHEM BIOPH RES CO, V243, P47, DOI 10.1006/bbrc.1997.8055
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
NR 18
TC 7
Z9 9
U1 0
U2 4
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD JAN 15
PY 2011
VL 300
IS 1-2
BP 187
EP 190
DI 10.1016/j.jns.2010.08.065
PG 4
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 714ZT
UT WOS:000286850900040
PM 20884012
DA 2024-11-01
ER

PT J
AU Bartsakoulia, M
   Pyle, A
   Troncoso-Chandía, D
   Vial-Brizzi, J
   Paz-Fiblas, MV
   Duff, J
   Griffin, H
   Boczonadi, V
   Lochmüller, H
   Kleinle, S
   Chinnery, PF
   Grünert, S
   Kirschner, J
   Eisner, V
   Horvath, R
AF Bartsakoulia, Marina
   Pyle, Angela
   Troncoso-Chandia, Diego
   Vial-Brizzi, Josefa
   Paz-Fiblas, Marysol V.
   Duff, Jennifer
   Griffin, Helen
   Boczonadi, Veronika
   Lochmueller, Hanns
   Kleinle, Stephanie
   Chinnery, Patrick F.
   Gruenert, Sarah
   Kirschner, Janbernd
   Eisner, Veronica
   Horvath, Rita
TI A novel mechanism causing imbalance of mitochondrial fusion and fission
   in human myopathies
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID DOMINANT OPTIC ATROPHY; SKELETAL-MUSCLE; FUNCTIONAL-ANALYSIS; DRP1
   RECRUITMENT; MAMMALIAN-CELLS; OPA1 MUTATIONS; PROTEIN DRP1; DYNAMICS;
   MID51; DISEASE
AB Mitochondrial dynamics play an important role in cellular homeostasis and a variety of human diseases are linked to its dysregulated function. Here, we describe a 15-year-old boy with a novel disease caused by altered mitochondrial dynamics. The patient was the second child of consanguineous Jewish parents. He developed progressive muscle weakness and exercise intolerance at 6 years of age. His muscle biopsy revealed mitochondrial myopathy with numerous ragged red and cytochrome c oxidase (COX) negative fibers and combined respiratory chain complex I and IV deficiency. MtDNA copy number was elevated and no deletions of the mtDNA were detected in muscle DNA. Whole exome sequencing identified a homozygous nonsense mutation (p.Q92*) in the MIEF2 gene encoding the mitochondrial dynamics protein of 49 kDa (MID49). Immunoblotting revealed increased levels of proteins promoting mitochondrial fusion (MFN2, OPA1) and decreased levels of the fission protein DRP1. Fibroblasts of the patient showed elongated mitochondria, and significantly higher frequency of fusion events, mtDNA abundance and aberrant mitochondrial cristae ultrastructure, compared with controls. Thus, our data suggest that mutations in MIEF2 result in imbalanced mitochondrial dynamics and a combined respiratory chain enzyme defect in skeletal muscle, leading to mitochondrial myopathy.
C1 [Bartsakoulia, Marina; Pyle, Angela; Duff, Jennifer; Griffin, Helen; Boczonadi, Veronika; Lochmueller, Hanns; Horvath, Rita] Newcastle Univ, Inst Genet Med, Wellcome Ctr Mitochondrial Res, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.
   [Troncoso-Chandia, Diego; Vial-Brizzi, Josefa; Paz-Fiblas, Marysol V.; Eisner, Veronica] Pontificia Univ Catolica Chile, Sch Biol Sci, Dept Cellular & Mol Biol, Santiago 8330025, Chile.
   [Kleinle, Stephanie] Med Genet Ctr, Munich, Germany.
   [Chinnery, Patrick F.] Univ Cambridge, MRC Mitochondrial Biol Unit, Cambridge Biomed Campus, Cambridge CB2 0QQ, England.
   [Chinnery, Patrick F.] Univ Cambridge, Dept Clin Neurosci, Cambridge Biomed Campus, Cambridge CB2 0QQ, England.
   [Gruenert, Sarah] Univ Freiburg, Fac Med, Med Ctr, Dept Gen Pediat Adolescent Med & Neonatol, Freiburg, Germany.
   [Kirschner, Janbernd] Univ Freiburg, Fac Med, Med Ctr, Dept Neuropediat & Muscle Disorders, Freiburg, Germany.
C3 Newcastle University - UK; Pontificia Universidad Catolica de Chile;
   University of Cambridge; University of Cambridge; University of
   Freiburg; University of Freiburg
RP Eisner, V (corresponding author), Pontificia Univ Catolica Chile, Sch Biol Sci, Dept Cellular & Mol Biol, Santiago 8330025, Chile.; Horvath, R (corresponding author), Newcastle Univ, Inst Med Genet, Cent Pkwy, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.
EM veisner@bio.puc.cl; rita.horvath@ncl.ac.uk
RI Horvath, Rita/AAY-7042-2020; Kirschner, Janbernd/Q-1493-2019; Kirschner,
   Janbernd/H-7418-2016
OI Chinnery, Patrick/0000-0002-7065-6617; Kirschner,
   Janbernd/0000-0003-1618-7386; Eisner, Veronica/0000-0002-9458-7150;
   Grunert, Sarah Catharina/0000-0001-5986-0468; Horvath,
   Rita/0000-0002-9841-170X; Griffin, Helen R/0000-0002-5288-3322
FU Wellcome Trust [109915/Z/15/Z, 101876/Z/13/Z]; Wellcome Centre for
   Mitochondrial Research [203105/Z/16/Z]; Medical Research Council (UK)
   [MR/N025431/1]; European Research Council [309548]; Wellcome Trust
   Pathfinder Scheme [201064/Z/16/Z]; Newton Fund (UK/Turkey)
   [MR/N027302/1]; European Union Seventh Framework Programme [305444
   RD-Connect, 305121 Neuromics]; Wellcome Trust; Medical Research Council
   Mitochondrial Biology Unit [MC_UP_1501/2]; UK NIHR; EU TIRCON; National
   Institute for Health Research (NIHR) Biomedical Research Centre based at
   Cambridge University Hospitals NHS Foundation Trust; University of
   Cambridge; Medical Research Council (UK) Centre for Translational Muscle
   Disease [G0601943]; FONDECYT [1150677]; MRC [G1000848, G0601943,
   MR/N025431/1, MR/N025431/2] Funding Source: UKRI; Newton Fund
   [MR/N027302/1, MR/N027302/2] Funding Source: UKRI
FX Wellcome Trust Investigator (109915/Z/15/Z), Wellcome Centre for
   Mitochondrial Research (203105/Z/16/Z), Medical Research Council (UK)
   (MR/N025431/1), European Research Council (309548) to RH. Wellcome Trust
   Pathfinder Scheme (201064/Z/16/Z), Newton Fund (UK/Turkey,
   MR/N027302/1), European Union Seventh Framework Programme
   (FP7/2007-2013, 305444 RD-Connect and 305121 Neuromics) to HL. Wellcome
   Trust Senior Fellow in Clinical Science (101876/Z/13/Z), UK NIHR Senior
   Investigator, Medical Research Council Mitochondrial Biology Unit
   (MC_UP_1501/2), EU FP7 TIRCON, and the National Institute for Health
   Research (NIHR) Biomedical Research Centre based at Cambridge University
   Hospitals NHS Foundation Trust and the University of Cambridge to PFC.
   Medical Research Council (UK) Centre for Translational Muscle Disease
   (G0601943) to RH, HL and PFC. FONDECYT 1150677 to VE. Funding to pay the
   Open Access publication charges for this article was provided by the
   Wellcome Trust.
CR Calvo J, 2009, ARCH NEUROL-CHICAGO, V66, P1511, DOI 10.1001/archneurol.2009.284
   Chang CR, 2007, J BIOL CHEM, V282, P21583, DOI 10.1074/jbc.C700083200
   Csordás G, 2010, MOL CELL, V39, P121, DOI 10.1016/j.molcel.2010.06.029
   Duchen MR, 2010, ESSAYS BIOCHEM, V47, P115, DOI [10.1042/bse0470115, 10.1042/BSE0470115]
   Eisner V, 2017, P NATL ACAD SCI USA, V114, pE859, DOI 10.1073/pnas.1617288114
   Eisner V, 2014, J CELL BIOL, V205, P179, DOI 10.1083/jcb.201312066
   Eisner V, 2013, J CELL SCI, V126, P2965, DOI 10.1242/jcs.093609
   Fahrner JA, 2016, AM J MED GENET A, V170, P2002, DOI 10.1002/ajmg.a.37721
   Gerber S, 2017, BRAIN, V140, P2586, DOI 10.1093/brain/awx219
   Gilkerson RW, 2003, FEBS LETT, V546, P355, DOI 10.1016/S0014-5793(03)00633-1
   Griparic L, 2004, J BIOL CHEM, V279, P18792, DOI 10.1074/jbc.M400920200
   Ingerman E, 2005, J CELL BIOL, V170, P1021, DOI 10.1083/jcb.200506078
   Invernizzi F, 2012, MITOCHONDRION, V12, P328, DOI 10.1016/j.mito.2012.01.001
   Karbowski M, 2004, J CELL BIOL, V164, P493, DOI 10.1083/jcb.200309082
   Kirby DM, 2007, METHOD CELL BIOL, V80, P93, DOI 10.1016/S0091-679X(06)80004-X
   Koch J, 2016, J MED GENET, V53, P270, DOI 10.1136/jmedgenet-2015-103500
   Liu T, 2013, EXP CELL RES, V319, P2893, DOI 10.1016/j.yexcr.2013.07.010
   Lodi R, 2011, ARCH NEUROL-CHICAGO, V68, P67, DOI 10.1001/archneurol.2010.228
   Losón OC, 2015, PROTEIN SCI, V24, P386, DOI 10.1002/pro.2629
   Losón OC, 2014, STRUCTURE, V22, P367, DOI 10.1016/j.str.2014.01.001
   Losón OC, 2013, MOL BIOL CELL, V24, P659, DOI 10.1091/mbc.E12-10-0721
   Mears JA, 2011, NAT STRUCT MOL BIOL, V18, P20, DOI 10.1038/nsmb.1949
   Mishra P, 2014, NAT REV MOL CELL BIO, V15, P634, DOI 10.1038/nrm3877
   Nasca A, 2016, HUM MUTAT, V37, P898, DOI 10.1002/humu.23033
   Osellame LD, 2016, J CELL SCI, V129, P2170, DOI 10.1242/jcs.185165
   Otera H, 2016, J CELL BIOL, V212, P531, DOI 10.1083/jcb.201508099
   Otera H, 2010, J CELL BIOL, V191, P1141, DOI 10.1083/jcb.201007152
   Palmer CS, 2013, J BIOL CHEM, V288, P27584, DOI 10.1074/jbc.M113.479873
   Palmer CS, 2011, EMBO REP, V12, P565, DOI 10.1038/embor.2011.54
   Pyle A, 2015, BRAIN, V138, P276, DOI 10.1093/brain/awu348
   Richter V, 2014, J CELL BIOL, V204, P477, DOI 10.1083/jcb.201311014
   Shamseldin HE, 2012, J MED GENET, V49, P234, DOI 10.1136/jmedgenet-2012-100836
   Sitarz KS, 2012, BRAIN, V135, DOI 10.1093/brain/aws049
   Smirnova E, 2001, MOL BIOL CELL, V12, P2245, DOI 10.1091/mbc.12.8.2245
   Vanstone JR, 2016, EUR J HUM GENET, V24, P1084, DOI 10.1038/ejhg.2015.243
   Vital A, 2012, J NEUROPATH EXP NEUR, V71, P1036, DOI 10.1097/NEN.0b013e3182764d47
   Waterham HR, 2007, NEW ENGL J MED, V356, P1736, DOI 10.1056/NEJMoa064436
   Westermann B, 2010, NAT REV MOL CELL BIO, V11, P872, DOI 10.1038/nrm3013
   Yu-Wai-Man P, 2010, BRAIN, V133, P771, DOI 10.1093/brain/awq007
   Zhu PP, 2004, J BIOL CHEM, V279, P35967, DOI 10.1074/jbc.M404105200
   Züchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341
NR 41
TC 50
Z9 55
U1 0
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD APR 1
PY 2018
VL 27
IS 7
BP 1186
EP 1195
DI 10.1093/hmg/ddy033
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA GB4CZ
UT WOS:000429009400006
PM 29361167
OA Green Published, hybrid
DA 2024-11-01
ER

PT J
AU Tyynismaa, H
   Carroll, CJ
   Raimundo, N
   Ahola-Erkkilä, S
   Wenz, T
   Ruhanen, H
   Guse, K
   Hemminki, A
   Peltola-Mjosund, KE
   Tulkki, V
   Oresic, M
   Moraes, CT
   Pietiläinen, K
   Hovatta, I
   Suomalainen, A
AF Tyynismaa, Henna
   Carroll, Christopher J.
   Raimundo, Nuno
   Ahola-Erkkila, Sofia
   Wenz, Tina
   Ruhanen, Heini
   Guse, Kilian
   Hemminki, Akseli
   Peltola-Mjosund, Katja E.
   Tulkki, Valtteri
   Oresic, Matej
   Moraes, Carlos T.
   Pietilainen, Kirsi
   Hovatta, Iiris
   Suomalainen, Anu
TI Mitochondrial myopathy induces a starvation-like response
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; FIBROBLAST GROWTH FACTOR-21;
   MULTIPLE DELETIONS; SKELETAL-MUSCLE; GENE-EXPRESSION; MTDNA MAINTENANCE;
   MAMMALIAN-CELLS; PPAR-ALPHA; MICE; DNA
AB Mitochondrial respiratory chain (RC) deficiency is among the most common causes of inherited metabolic disease, but its physiological consequences are poorly characterized. We studied the skeletal muscle gene expression profiles of mice with late-onset mitochondrial myopathy. These animals express a dominant patient mutation in the mitochondrial replicative helicase Twinkle, leading to accumulation of multiple mtDNA deletions and progressive subtle RC deficiency in the skeletal muscle. The global gene expression pattern of the mouse skeletal muscle showed induction of pathways involved in amino acid starvation response and activation of Akt signaling. Furthermore, the muscle showed induction of a fasting-related hormone, fibroblast growth factor 21 (Fgf21). This secreted regulator of lipid metabolism was also elevated in the mouse serum, and the animals showed widespread changes in their lipid metabolism: small adipocyte size, low fat content in the liver and resistance to high-fat diet. We propose that RC deficiency induces a mitochondrial stress response, with local and global changes mimicking starvation, in a normal nutritional state. These results may have important implications for understanding the metabolic consequences of mitochondrial myopathies.
C1 [Tyynismaa, Henna; Carroll, Christopher J.; Raimundo, Nuno; Ahola-Erkkila, Sofia; Ruhanen, Heini; Peltola-Mjosund, Katja E.; Tulkki, Valtteri; Hovatta, Iiris; Suomalainen, Anu] Biomedicum Helsinki, Res Program Mol Neurol, Helsinki 00290, Finland.
   [Wenz, Tina; Moraes, Carlos T.] Univ Miami, Miller Sch Med, Dept Neurol & Cell Biol & Anat, Miami, FL 33136 USA.
   [Guse, Kilian; Hemminki, Akseli] Haartman Inst, Mol Canc Biol Program, Helsinki 00290, Finland.
   [Guse, Kilian; Hemminki, Akseli] Haartman Inst, Transplantat Lab, Helsinki 00290, Finland.
   [Guse, Kilian; Hemminki, Akseli] Finnish Inst Mol Med, Helsinki 00290, Finland.
   [Guse, Kilian; Hemminki, Akseli] HUSLAB, Helsinki 00290, Finland.
   [Guse, Kilian; Hemminki, Akseli] Univ Helsinki, Cent Hosp, Canc Gene Therapy Grp, FIN-00290 Helsinki, Finland.
   [Oresic, Matej; Suomalainen, Anu] Univ Helsinki, Inst Mol Med Finland FIMM, Helsinki 00290, Finland.
   [Oresic, Matej] VTT Tech Res Ctr Finland, Espoo 02044, Vtt, Finland.
   [Pietilainen, Kirsi] Univ Helsinki, Cent Hosp, Dept Psychiat, Obes Res Unit, Helsinki 00290, Finland.
   [Hovatta, Iiris] Univ Helsinki, Natl Inst Hlth & Welf, Dept Mental Hlth & Subst Abuse Serv, Helsinki 00271, Finland.
   [Hovatta, Iiris] Univ Helsinki, Dept Med Genet, Helsinki 00271, Finland.
   [Suomalainen, Anu] Univ Helsinki, Cent Hosp, Dept Neurol, Helsinki 00029, Finland.
C3 University of Helsinki; University of Miami; University of Helsinki;
   Helsinki University Central Hospital; University of Helsinki; VTT
   Technical Research Center Finland; University of Helsinki; Helsinki
   University Central Hospital; Finland National Institute for Health &
   Welfare; University of Helsinki; University of Helsinki; University of
   Helsinki; Helsinki University Central Hospital
RP Suomalainen, A (corresponding author), Biomedicum Helsinki, Res Program Mol Neurol, RC523B,Haartmaninkatu 8, Helsinki 00290, Finland.
EM anu.wartiovaara@helsinki.fi
RI Raimundo, Nuno/AAD-9498-2020; Carroll, Christopher/AAV-8023-2021;
   Pietiläinen, Kirsi/HJA-4960-2022; Oresic, Matej/K-7673-2016; Tyynismaa,
   Henna/F-1428-2011; Ahola, Sofia/JEP-4595-2023; Moraes,
   Carlos/AAT-3818-2021; Hovatta, Iiris/D-6871-2012
OI Oresic, Matej/0000-0002-2856-9165; Hemminki, Akseli/0000-0001-7103-8530;
   Raimundo, Nuno/0000-0002-5988-9129; Ahola, Sofia/0000-0001-7552-4843;
   Pietilainen, Kirsi/0000-0002-8522-1288; Hovatta,
   Iiris/0000-0002-5990-7892; Carroll, Christopher/0000-0002-2814-6955;
   Suomalainen-Wartiovaara, Anu/0000-0003-4833-5195; Tyynismaa,
   Henna/0000-0002-2493-2422
FU Helsinki Biomedical Graduate School; Academy of Finland; Sigrid Juselius
   Foundation; Jane and Aatos Erkko Foundation; University of Helsinki
FX This study was supported by Helsinki Biomedical Graduate School (H. T.,
   N.R. and S. A.-E.), Academy of Finland (A. S. and H. T.), Sigrid
   Juselius Foundation, Jane and Aatos Erkko Foundation and University of
   Helsinki (A. S.).
CR Ahola-Erkkilä S, 2010, HUM MOL GENET, V19, P1974, DOI 10.1093/hmg/ddq076
   Badman MK, 2007, CELL METAB, V5, P426, DOI 10.1016/j.cmet.2007.05.002
   Crimi M, 2005, FASEB J, V19, P866, DOI 10.1096/fj.04-3045fje
   Di Pietro E, 2004, BBA-GEN SUBJECTS, V1674, P78, DOI 10.1016/j.bbagen.2004.06.014
   Diaz F, 2005, HUM MOL GENET, V14, P2737, DOI 10.1093/hmg/ddi307
   Estall JL, 2009, P NATL ACAD SCI USA, V106, P22510, DOI 10.1073/pnas.0912533106
   Fujita Y, 2007, MITOCHONDRION, V7, P80, DOI 10.1016/j.mito.2006.11.003
   Goetz R, 2007, MOL CELL BIOL, V27, P3417, DOI 10.1128/MCB.02249-06
   Hojman P, 2009, DIABETES, V58, P2797, DOI 10.2337/db09-0713
   Inagaki T, 2007, CELL METAB, V5, P415, DOI 10.1016/j.cmet.2007.05.003
   Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015
   Izumiya Y, 2008, CELL METAB, V7, P159, DOI 10.1016/j.cmet.2007.11.003
   Izumiya Y, 2008, FEBS LETT, V582, P3805, DOI 10.1016/j.febslet.2008.10.021
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kharitonenkov A, 2005, J CLIN INVEST, V115, P1627, DOI 10.1172/JCI23606
   Kharitonenkov A, 2008, BIODRUGS, V22, P37, DOI 10.2165/00063030-200822010-00004
   Kharitonenkov A, 2007, ENDOCRINOLOGY, V148, P774, DOI 10.1210/en.2006-1168
   Kilberg MS, 2005, ANNU REV NUTR, V25, P59, DOI 10.1146/annurev.nutr.24.012003.132145
   Lara MC, 2007, BIOSCIENCE REP, V27, P151, DOI 10.1007/s10540-007-9043-2
   Lauritzen HPMM, 2008, DIABETES, V57, P315, DOI 10.2337/db06-1578
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Muise ES, 2008, MOL PHARMACOL, V74, P403, DOI 10.1124/mol.108.044826
   Potthoff MJ, 2009, P NATL ACAD SCI USA, V106, P10853, DOI 10.1073/pnas.0904187106
   Reitman ML, 2007, CELL METAB, V5, P405, DOI 10.1016/j.cmet.2007.05.010
   Schefer V, 1996, EXP GERONTOL, V31, P387, DOI 10.1016/0531-5565(95)02032-2
   Sen P, 2003, MOL CELL BIOCHEM, V253, P241, DOI 10.1023/A:1026020101379
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Stevenson EJ, 2005, J APPL PHYSIOL, V98, P1396, DOI 10.1152/japplphysiol.01055.2004
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
   Tyynismaa H, 2004, HUM MOL GENET, V13, P3219, DOI 10.1093/hmg/ddh342
   Tyynismaa H, 2009, AM J HUM GENET, V85, P290, DOI 10.1016/j.ajhg.2009.07.009
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Wenz T, 2008, CELL METAB, V8, P249, DOI 10.1016/j.cmet.2008.07.006
   Zapala MA, 2005, P NATL ACAD SCI USA, V102, P10357, DOI 10.1073/pnas.0503357102
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
   Zhao Q, 2002, EMBO J, V21, P4411, DOI 10.1093/emboj/cdf445
NR 38
TC 240
Z9 258
U1 0
U2 10
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD OCT 15
PY 2010
VL 19
IS 20
BP 3948
EP 3958
DI 10.1093/hmg/ddq310
PG 11
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 657UF
UT WOS:000282439700005
PM 20656789
DA 2024-11-01
ER

PT J
AU Zierz, CM
   Joshi, PR
   Zierz, S
AF Zierz, Charlotte Maria
   Joshi, Pushpa Raj
   Zierz, Stephan
TI Frequencies of myohistological mitochondrial changes in patients with
   mitochondrial DNA deletions and the common m.3243A&gt;G point mutation
SO NEUROPATHOLOGY
LA English
DT Article
DE COX-deficient; ragged-red fibers; mtDNA; myohistological changes; point
   mutation; single; multiple deletions
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; RAGGED-RED FIBERS;
   SKELETAL-MUSCLE; DISEASES; PATHOLOGY; MYOPATHY; NEUROPATHY; DISORDERS;
   FEATURES; MELAS
AB Frequencies of typical myohistological changes such as ragged red fibers (RRF) and cytochrome c oxidase (COX)-deficient fibers have been suggested to be dependent on underlying mitochondrial DNA (mtDNA) defect. However, there are no systematic studies comparing frequencies of myohistological changes and underlying genotypes. The histopathological changes were analysed in 29 patients with genetically confirmed mitochondrial myopathies. Genotypes included multiple mtDNA deletions due to POLG1 mutations (n=11), single mtDNA deletion (n=10) and mtDNA point mutation m.3243A>G (n=8). Histochemical reactions, including Gomori-trichome, COX/SDH (succinate dehydrogenase) and SDH as well as immunohistological reaction with COX-antibody against subunit I (COI) were carried out in muscle biopsy sections of all patients. The COX-deficient fibers were observed most frequently in all three patient groups. The frequencies of myopathological changes were not significantly different in the different genotypes in all three histochemical stains. However, there was a tendency to lower means and variations in patients with point mutation. Only COI-negative fibers were histochemically negative for COX activity in all patient groups. Frequency of COI-negative fibers was significantly lower in patients with mtDNA point mutation than in patients with deletions. This suggests that impact of point mutation on protein synthesis is less than that of deletions.
C1 [Zierz, Charlotte Maria; Joshi, Pushpa Raj; Zierz, Stephan] Univ Halle Wittenberg, Dept Neurol, D-06120 Halle, Saale, Germany.
C3 Martin Luther University Halle Wittenberg
RP Joshi, PR (corresponding author), Univ Halle Wittenberg, Dept Neurol, Ernst Grube Str 40, D-06120 Halle, Saale, Germany.
EM pushpa.joshi@medizin.uni-halle.de
FU German Federal Ministry of Education and Research (BMBF)
FX PRJ and SZ are members of the German mitoNET, funded by the German
   Federal Ministry of Education and Research (BMBF). The authors thank
   Prof. Marcus Deschauer (Department of Neurology, Halle, Germany) for
   genetic characterization of patients and critical review, Prof. Robert W
   Taylor (Wellcome Trust Centre for Mitochondrial Research,
   Newcastle-upon-Tyne, England) for investigating POLG1 in three patients
   with multiple deletions and Mrs. Brita Mathejczyk (Elisabeth-Gymnasium,
   Halle) for fruitful discussion. The authors gratefully acknowledge the
   technical assistance of Mrs. Thekla Wangemann and Mrs. Kathleen Zietz
   (Neuromuscular Laboratory Halle).
CR Bourgeois JM, 2004, MITOCHONDRION, V4, P441, DOI 10.1016/j.mito.2004.07.036
   CHARIOT P, 1993, ANN NEUROL, V34, P561, DOI 10.1002/ana.410340409
   Choi BO, 2010, EXP MOL MED, V42, P446, DOI 10.3858/emm.2010.42.6.046
   COLLINS S, 1995, ACTA NEUROL SCAND, V91, P287, DOI 10.1111/j.1600-0404.1995.tb07007.x
   DEVIVO DC, 1993, BRAIN DEV-JPN, V15, P1, DOI 10.1016/0387-7604(93)90002-P
   GOTO Y, 1990, J NEUROL SCI, V100, P63, DOI 10.1016/0022-510X(90)90014-E
   GOTO Y, 1992, NEUROLOGY, V42, P545, DOI 10.1212/WNL.42.3.545
   Hudson G, 2006, HUM MOL GENET, V15, pR244, DOI 10.1093/hmg/ddl233
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   KAWAI H, 1995, MUSCLE NERVE, V18, P753, DOI 10.1002/mus.880180712
   Koga Y, 2000, ACTA NEUROPATHOL, V99, P186, DOI 10.1007/PL00007423
   LAFORET P, 1995, NEUROMUSCULAR DISORD, V5, P399, DOI 10.1016/0960-8966(94)00080-S
   Milone M, 2008, NEUROMUSCULAR DISORD, V18, P626, DOI 10.1016/j.nmd.2008.05.009
   Possekel S, 1996, NEUROMUSCULAR DISORD, V6, P215, DOI 10.1016/0960-8966(96)00002-8
   POULTON J, 1995, NEUROMUSCULAR DISORD, V5, P345, DOI 10.1016/0960-8966(95)00073-V
   Reichmann H, 1996, EUR NEUROL, V36, P98, DOI 10.1159/000117217
   RIFAI Z, 1995, ANN NEUROL, V37, P24, DOI 10.1002/ana.410370107
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Tarnopolsky MA, 2004, AM J MED GENET A, V124A, P372, DOI 10.1002/ajmg.a.20449
   Taylor RW, 2003, J CLIN INVEST, V112, P1351, DOI 10.1172/JCI200319435
   YAMAMOTO M, 1989, J NEUROL SCI, V91, P207, DOI 10.1016/0022-510X(89)90088-9
   YAMAMOTO M, 1988, ACTA NEUROPATHOL, V76, P558, DOI 10.1007/BF00689593
   YAMAMOTO M, 1991, NEUROLOGY, V41, P1822, DOI 10.1212/WNL.41.11.1822
NR 23
TC 10
Z9 13
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0919-6544
EI 1440-1789
J9 NEUROPATHOLOGY
JI Neuropathology
PD APR
PY 2015
VL 35
IS 2
BP 130
EP 136
DI 10.1111/neup.12173
PG 7
WC Clinical Neurology; Neurosciences; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pathology
GA CF5WV
UT WOS:000352628900004
PM 25378026
DA 2024-11-01
ER

PT J
AU Milone, M
   Brunetti-Pierri, N
   Tang, LY
   Kumar, N
   Mezei, MM
   Josephs, K
   Powell, S
   Simpson, E
   Wong, LJC
AF Milone, Margherita
   Brunetti-Pierri, Nicola
   Tang, Lin-Ya
   Kumar, Neeraj
   Mezei, Michelle M.
   Josephs, Keith
   Powell, Suzanne
   Simpson, Ericka
   Wong, Lee-Jun C.
TI Sensory ataxic neuropathy with ophthalmoparesis caused by <i>POLG</i>
   mutations
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE DNA polymerase gamma; POLG mutations; SANDO; arPEO; mtDNA multiple
   deletions; sensory ataxia
ID MITOCHONDRIAL-DNA POLYMERASE; PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA;
   DIFFUSE CEREBRAL DEGENERATION; GAMMA; DEPLETION; SPECTRUM; A467T; GENE
AB Mutations in POLG gene are responsible for a wide spectrum of clinical disorders with altered mitochondrial DNA (mtDNA) integrity, including mtDNA multiple deletions and depletion. Sensory ataxic neuropathy with ophthalmoparesis (SANDO) caused by mutations in POLG gene, fulfilling the clinical triad of sensory ataxic neuropathy, dysarthria and/or dysphagia and ophthalmoparesis, has described in a few reports. Here we described five cases of adult onset autosomal recessive sensory ataxic neuropathy with ophthalmoplegia. All patients had ataxia, neuropathy, myopathy, and progressive external ophthalmoplegia (PEO). The muscle pathology revealed ragged-red and cytochrome c oxidase (COX) negative fibers in three patients. However, deficiencies in the activities of mitochondrial respiratory chain enzyme complexes were not detected in any of the patients' muscle samples. Multiple deletions of mtDNA were detected in blood and muscle specimens but mtDNA depletion was not found. Due to these diagnostic difficulties, POLG-related syndromes are definitively diagnosed based on the presence of deleterious mutations in the POLG gene. (C) 2008 Published by Elsevier B.V.
C1 [Brunetti-Pierri, Nicola; Tang, Lin-Ya; Wong, Lee-Jun C.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
   [Milone, Margherita; Kumar, Neeraj; Josephs, Keith] Mayo Clin, Dept Neurol, Rochester, MN USA.
   [Powell, Suzanne; Simpson, Ericka] Methodist Hosp, Dept Neurol, Houston, TX 77030 USA.
   [Mezei, Michelle M.] Univ British Columbia, Div Neurol, Vancouver, BC V5Z 1M9, Canada.
C3 Baylor College of Medicine; Mayo Clinic; Houston Methodist Hospital;
   University of British Columbia
RP Wong, LJC (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza,NAB2015, Houston, TX 77030 USA.
EM ljwong@bcm.edu
RI Kumar, Neeraj/L-3500-2016; Brunetti-Pierri, Nicola/K-8465-2016
OI Brunetti-Pierri, Nicola/0000-0002-6895-8819
CR Bai RK, 2005, J MOL DIAGN, V7, P613, DOI 10.1016/S1525-1578(10)60595-8
   BLACKWOOD W, 1963, ARCH DIS CHILD, V38, P193, DOI 10.1136/adc.38.199.193
   Chan SSL, 2005, J BIOL CHEM, V280, P31341, DOI 10.1074/jbc.M506762200
   Davidzon G, 2006, ANN NEUROL, V59, P859, DOI 10.1002/ana.20831
   Fadic R, 1997, NEUROLOGY, V49, P239, DOI 10.1212/WNL.49.1.239
   Gago MF, 2006, NEUROMUSCULAR DISORD, V16, P507, DOI 10.1016/j.nmd.2006.05.016
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Hudson G, 2005, NEUROLOGY, V64, P371, DOI 10.1212/01.WNL.0000149767.51152.83
   Hudson G, 2007, ARCH NEUROL-CHICAGO, V64, P553, DOI 10.1001/archneur.64.4.553
   Hudson G, 2006, HUM MOL GENET, V15, pR244, DOI 10.1093/hmg/ddl233
   HUTTENLOCHER PR, 1976, ARCH NEUROL-CHICAGO, V33, P186, DOI 10.1001/archneur.1976.00500030042009
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Lecrenier N, 1997, GENE, V185, P147, DOI 10.1016/S0378-1119(96)00663-4
   Liang MH, 1998, AM J MED GENET, V77, P395, DOI 10.1002/(SICI)1096-8628(19980605)77:5<395::AID-AJMG8>3.0.CO;2-M
   Naïmi M, 2006, EUR J HUM GENET, V14, P917, DOI 10.1038/sj.ejhg.5201627
   Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490
   Rovio AT, 2001, NAT GENET, V29, P261, DOI 10.1038/ng759
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   Wong LJC, 2007, HEPATOLOGY, V46, P1218, DOI 10.1002/hep.21799
   Wong LJC, 1997, CLIN CHEM, V43, P1857
   Wong LJC, 2005, CLIN CHIM ACTA, V354, P1, DOI 10.1016/j.cccn.2004.11.003
   Wong LJC, 2003, J MED GENET, V40
NR 27
TC 55
Z9 58
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD AUG
PY 2008
VL 18
IS 8
BP 626
EP 632
DI 10.1016/j.nmd.2008.05.009
PG 7
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 353UM
UT WOS:000259594000005
PM 18585914
DA 2024-11-01
ER

PT J
AU Kollberg, G
   Jansson, M
   Pérez-Bercoff, Å
   Melberg, A
   Lindberg, C
   Holme, E
   Moslemi, AR
   Oldfors, A
AF Kollberg, G
   Jansson, M
   Pérez-Bercoff, Å
   Melberg, A
   Lindberg, C
   Holme, E
   Moslemi, AR
   Oldfors, A
TI Low frequency of mtDNA point mutations in patients with PEO associated
   with <i>POLG1</i> mutations
SO EUROPEAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
DE mtDNA point mutations; multiple deletions; mitochondrial myopathy;
   polymerase gamma; progressive external ophthalmoplegia
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; MITOCHONDRIAL-DNA POLYMERASE;
   AUTOSOMAL-DOMINANT; NEUROGASTROINTESTINAL ENCEPHALOMYOPATHY; MULTIPLE
   DELETIONS; GAMMA-A; TWINKLE; DISORDER; DEFECTS; MUSCLE
AB Mitochondrial myopathy in progressive external ophthalmoplegia (PEO) has been associated with POLG1 mutations. POLG1 encodes the catalytic a subunit of polymerase c and is the only polymerase known to be involved in mtDNA replication. It has two functionally different domains, one polymerase domain and one exonuclease domain with proofreading activity. In this study we have investigated whether mtDNA point mutations are involved, directly or indirectly, in the pathogenesis of PEO. Muscle biopsy specimens from patients with POLG1 mutations, affecting either the exonuclease or the polymerase domain, were investigated. Single cytochrome c oxidase (COX)-deficient muscle fibers were dissected and screened for clonally expanded mtDNA point mutations using a sensitive denaturing gradient gel electrophoresis analysis, in which three different regions of mtDNA, including five different tRNA genes, were investigated. To screen for randomly distributed mtDNA point mutations in muscle, two regions of mtDNA including deletion breakpoints were investigated by high-fidelity PCR, followed by cloning and sequencing. Long-range PCR revealed multiple mtDNA deletions in all the patients but not the controls. No point mutations were identified in single COX-deficient muscle fibers. Cloning and sequencing of muscle homogenate identified randomly distributed point mutations at very low frequency in patients and controls (<1: 50 000). We conclude that mtDNA point mutations do not appear to be directly or indirectly involved in the pathogenesis of mitochondrial disease in patients with different POLG1 mutations.
C1 Sahlgrens Univ Hosp, Dept Pathol, SE-41345 Gothenburg, Sweden.
   Univ Uppsala Hosp, Dept Neurosci, Uppsala, Sweden.
   Sahlgrens Univ Hosp, Dept Neurol, SE-41345 Gothenburg, Sweden.
   Sahlgrens Univ Hosp, Dept Clin Chem, SE-41345 Gothenburg, Sweden.
C3 Sahlgrenska University Hospital; Uppsala University; Uppsala University
   Hospital; Sahlgrenska University Hospital; Sahlgrenska University
   Hospital
RP Sahlgrens Univ Hosp, Dept Pathol, SE-41345 Gothenburg, Sweden.
EM ali-reza.moslemi@pathology.gu.se
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Bell JB, 1997, J BIOL CHEM, V272, P7345, DOI 10.1074/jbc.272.11.7345
   CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6
   Del Bo R, 2003, NEUROLOGY, V61, P903, DOI 10.1212/01.WNL.0000092303.13864.BE
   Domínguez BM, 2002, ARCH LATINOAM NUTR, V52, P219
   Fayet G, 2002, NEUROMUSCULAR DISORD, V12, P484, DOI 10.1016/S0960-8966(01)00332-7
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Moslemi AR, 1996, ANN NEUROL, V40, P707, DOI 10.1002/ana.410400506
   Moslemi AR, 1999, NEUROLOGY, V53, P79, DOI 10.1212/WNL.53.1.79
   Nishigaki Y, 2004, HUM MOL GENET, V13, P91, DOI 10.1093/hmg/ddh010
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   OLDFORS A, 1995, J NEUROPATH EXP NEUR, V54, P581, DOI 10.1097/00005072-199507000-00012
   Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200
   Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spelbrink JN, 2000, J BIOL CHEM, V275, P24818, DOI 10.1074/jbc.M000559200
   Sternberg D, 1998, HUM MOL GENET, V7, P33, DOI 10.1093/hmg/7.1.33
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, EUR J HUM GENET, V11, P547, DOI 10.1038/sj.ejhg.5201002
   Wanrooij S, 2004, NUCLEIC ACIDS RES, V32, P3053, DOI 10.1093/nar/gkh634
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 26
TC 25
Z9 26
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1018-4813
EI 1476-5438
J9 EUR J HUM GENET
JI Eur. J. Hum. Genet.
PD APR
PY 2005
VL 13
IS 4
BP 463
EP 469
DI 10.1038/sj.ejhg.5201341
PG 7
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 909KF
UT WOS:000227858100015
PM 15702133
OA Bronze
DA 2024-11-01
ER

PT J
AU Lehtonen, JM
   Forsström, S
   Bottani, E
   Viscomi, C
   Baris, OR
   Isoniemi, H
   Höckerstedt, K
   Österlund, P
   Hurme, M
   Jylhävä, J
   Leppä, S
   Markkula, R
   Heliö, T
   Mombelli, G
   Uusimaa, J
   Laaksonen, R
   Laaksovirta, H
   Auranen, M
   Zeviani, M
   Smeitink, J
   Wiesner, RJ
   Nakada, K
   Isohanni, P
   Suomalainen, A
AF Lehtonen, Jenni M.
   Forsstrom, Saara
   Bottani, Emanuela
   Viscomi, Carlo
   Baris, Olivier R.
   Isoniemi, Helena
   Hockerstedt, Krister
   Osterlund, Pia
   Hurme, Mikko
   Jylhava, Juulia
   Leppa, Sirpa
   Markkula, Ritva
   Helio, Tiina
   Mombelli, Giuliana
   Uusimaa, Johanna
   Laaksonen, Reijo
   Laaksovirta, Hannu
   Auranen, Mari
   Zeviani, Massimo
   Smeitink, Jan
   Wiesner, Rudolf J.
   Nakada, Kazuto
   Isohanni, Pirjo
   Suomalainen, Anu
TI FGF21 is a biomarker for mitochondrial translation and mtDNA maintenance
   disorders
SO NEUROLOGY
LA English
DT Article
ID GROWTH; MICE; DISEASE; DEFICIENCY; ACTIVATION; MUTATIONS; DELETIONS;
   MYOPATHY; TWINKLE; OBESITY
AB Objective: To validate new mitochondrial myopathy serum biomarkers for diagnostic use.
   Methods: We analyzed serum FGF21 (S-FGF21) and GDF15 from patients with (1) mitochondrial diseases and (2) nonmitochondrial disorders partially overlapping with mitochondrial disorder phenotypes. We (3) did a meta-analysis of S-FGF21 in mitochondrial disease and (4) analyzed S-Fgf21 and skeletal muscle Fgf21 expression in 6 mouse models with different muscle-manifesting mitochondrial dysfunctions.
   Results: We report that S-FGF21 consistently increases in primary mitochondrial myopathy, especially in patients with mitochondrial translation defects or mitochondrial DNA (mtDNA) deletions (675 and 347 pg/mL, respectively; controls: 66 pg/mL, p<0.0001 for both). This is corroborated in mice (mtDNA deletions 1,163 vs 379 pg/mL, p<0.0001). However, patients and mice with structural respiratory chain subunit or assembly factor defects showed low induction (human 335 pg/mL, p<0.05; mice 335 pg/mL, not significant). Overall specificities of FGF21 and GDF15 to find patients with mitochondrial myopathy were 89.3% vs 86.4%, and sensitivities 67.3% and 76.0%, respectively. However, GDF15 was increased also in a wide range of nonmitochondrial conditions.
   Conclusions: S-FGF21 is a specific biomarker for muscle-manifesting defects of mitochondrial translation, including mitochondrial transfer-RNA mutations and primary and secondary mtDNA deletions, the most common causes of mitochondrial disease. However, normal S-FGF21 does not exclude structural respiratory chain complex or assembly factor defects, important to acknowledge in diagnostics. Classification of evidence: This study provides Class III evidence that elevated S-FGF21 accurately distinguishes patients with mitochondrial myopathies from patients with other conditions, and FGF21 and GDF15 mitochondrial myopathy from other myopathies.
C1 [Lehtonen, Jenni M.; Forsstrom, Saara; Isoniemi, Helena; Auranen, Mari; Isohanni, Pirjo] Univ Helsinki, Res Programs Unit, Mol Neurol, Helsinki, Finland.
   [Osterlund, Pia] Univ Helsinki, Fac Med Clinicum, Oncol, Helsinki, Finland.
   [Leppa, Sirpa] Univ Helsinki, Finland Genome Scale Biol Program, Helsinki, Finland.
   [Bottani, Emanuela; Viscomi, Carlo; Zeviani, Massimo] MRC, Mitochondrial Biol Unit, Mitochondrial Med Grp, Cambridge, England.
   [Baris, Olivier R.; Wiesner, Rudolf J.] Univ Cologne, Inst Vegetat Physiol, Ctr Physiol & Pathophysiol, Cologne, Germany.
   [Isoniemi, Helena; Hockerstedt, Krister] Helsinki Univ Hosp, Transplantat & Liver Surg Clin, Helsinki, Finland.
   [Osterlund, Pia; Leppa, Sirpa] Helsinki Univ Hosp, Dept Oncol, Helsinki, Finland.
   [Helio, Tiina] Helsinki Univ Hosp, Dept Cardiol, Heart & Lung Ctr, Helsinki, Finland.
   [Hurme, Mikko; Jylhava, Juulia; Laaksonen, Reijo] Univ Tampere, Sch Med, Tampere, Finland.
   [Markkula, Ritva] Univ Helsinki, Anaesthesiol Intens Care & Pain Med, Helsinki, Finland.
   [Laaksovirta, Hannu; Auranen, Mari; Suomalainen, Anu] Univ Helsinki, Neurol, Clin Neurosci, Helsinki, Finland.
   [Isohanni, Pirjo] Univ Helsinki, Childrens Hosp, Child Neurol, Helsinki, Finland.
   Helsinki Univ Hosp, Helsinki, Finland.
   [Mombelli, Giuliana] Osped Niguarda Ca Granda, Cardiotoracovasc Dept, Dyslipidemia Ctr, Milan, Italy.
   [Uusimaa, Johanna] Univ Oulu, PEDEGO Res Unit, Oulu, Finland.
   [Uusimaa, Johanna] Univ Oulu, Bioctr Oulu, Oulu, Finland.
   [Laaksonen, Reijo] Tampere Univ Hosp, Finnish Clin Biobank Tampere, Tampere, Finland.
   [Smeitink, Jan] Radboud Univ Nijmegen, Med Ctr, Nijmegen Ctr Mitochondrial Disorders, Nijmegen, Netherlands.
   [Wiesner, Rudolf J.] Univ Cologne, Cologne Excellence Cluster Cellular Stress Respon, Cologne, Germany.
   [Wiesner, Rudolf J.] Univ Cologne, Ctr Mol Med, CMMC, Cologne, Germany.
   [Nakada, Kazuto] Univ Tsukuba, Fac Life & Environm Sci, Tsukuba, Ibaraki, Japan.
   [Uusimaa, Johanna] Oulu Univ Hosp, Med Res Ctr Oulu, Oulu, Finland.
   [Uusimaa, Johanna] Univ Oulu, Oulu, Finland.
C3 University of Helsinki; University of Helsinki; University of Helsinki;
   University of Cologne; University of Helsinki; Helsinki University
   Central Hospital; University of Helsinki; Helsinki University Central
   Hospital; University of Helsinki; Helsinki University Central Hospital;
   Tampere University; University of Helsinki; University of Helsinki;
   University of Helsinki; University of Helsinki; Helsinki University
   Central Hospital; Ospedale Niguarda Ca' Granda; IRCCS Ca Granda Ospedale
   Maggiore Policlinico; University of Oulu; University of Oulu; Tampere
   University; Tampere University Hospital; Radboud University Nijmegen;
   University of Cologne; University of Cologne; University of Tsukuba;
   University of Oulu; University of Oulu
RP Suomalainen, A (corresponding author), Univ Helsinki, Neurol, Clin Neurosci, Helsinki, Finland.
EM anu.wartiovaara@helsinki.fi
RI Zeviani, Massimo/AAU-2632-2021; viscomi, Carlo/R-1940-2016; Bottani,
   Emanuela/X-1778-2019; Baris, Olivier/L-3463-2016; Smeitink,
   Jan/C-1351-2013
OI Forsstrom, Saara/0000-0003-1610-6793; Hurme, Mikko/0000-0002-8614-1044;
   Bottani, Emanuela/0000-0003-1217-8722; Baris,
   Olivier/0000-0003-0974-6856; Leppa, Sirpa/0000-0002-8265-511X; Jylhava,
   Juulia/0000-0003-0250-4491; Suomalainen-Wartiovaara,
   Anu/0000-0003-4833-5195; Zeviani, Massimo/0000-0002-9067-5508; Viscomi,
   Carlo/0000-0001-6050-0566; Markkula, Ritva Anneli/0009-0001-8191-5880
FU MRC [MC_UP_1002/1] Funding Source: UKRI; Grants-in-Aid for Scientific
   Research [16H04678, 16K14719] Funding Source: KAKEN; Medical Research
   Council [MC_UP_1002/1] Funding Source: Medline
CR Al Payne B, 2013, AIDS RES THER, V10, DOI 10.1186/1742-6405-10-27
   Baris OR, 2015, CELL METAB, V21, P667, DOI 10.1016/j.cmet.2015.04.005
   Bratic A, 2013, J CLIN INVEST, V123, P951, DOI 10.1172/JCI64125
   Davis RL, 2016, NEUROLOGY, V86, P2010, DOI 10.1212/WNL.0000000000002705
   Davis RL, 2013, NEUROLOGY, V81, P1819, DOI 10.1212/01.wnl.0000436068.43384.ef
   Dell'Agnello C, 2007, HUM MOL GENET, V16, P431, DOI 10.1093/hmg/ddl477
   Dogan SA, 2014, CELL METAB, V19, P458, DOI 10.1016/j.cmet.2014.02.004
   Fried LP, 2001, J GERONTOL A-BIOL, V56, pM146, DOI 10.1093/gerona/56.3.M146
   Fujita Y, 2015, MITOCHONDRION, V20, P34, DOI 10.1016/j.mito.2014.10.006
   Gälman C, 2008, CELL METAB, V8, P169, DOI 10.1016/j.cmet.2008.06.014
   Kalko SG, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-91
   Han SH, 2010, METABOLISM, V59, P1656, DOI 10.1016/j.metabol.2010.03.018
   Hudson G, 2006, HUM MOL GENET, V15, pR244, DOI 10.1093/hmg/ddl233
   Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826
   Koene S, 2014, NEUROLOGY, V83, P125, DOI 10.1212/WNL.0000000000000578
   Kramer F, 2011, BIOMARKERS, V16, pS31, DOI 10.3109/1354750X.2011.561498
   Kruse SE, 2008, CELL METAB, V7, P312, DOI 10.1016/j.cmet.2008.02.004
   LAYFIELD LJ, 1995, ACTA CYTOL, V39, P11
   Lin ZF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018398
   Lin ZF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015534
   Montero R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148709
   Mraz M, 2009, CLIN ENDOCRINOL, V71, P369, DOI 10.1111/j.1365-2265.2008.03502.x
   Nawarskas James J, 2005, Cardiol Rev, V13, P76, DOI 10.1097/01.crd.0000154790.42283.a1
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Rhodes CJ, 2013, HANDB EXP PHARMACOL, V218, P77, DOI 10.1007/978-3-642-38664-0_4
   Salehi MH, 2013, MOL BIOL REP, V40, P6495, DOI 10.1007/s11033-013-2767-0
   Schirris TJJ, 2015, CELL METAB, V22, P399, DOI 10.1016/j.cmet.2015.08.002
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Suomalainen A, 2011, LANCET NEUROL, V10, P806, DOI 10.1016/S1474-4422(11)70155-7
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
   Tyynismaa H, 2011, J CLIN ENDOCR METAB, V96, pE351, DOI 10.1210/jc.2010-1326
   Tyynismaa H, 2010, HUM MOL GENET, V19, P3948, DOI 10.1093/hmg/ddq310
   Viscomi C, 2009, HUM MOL GENET, V18, P12, DOI 10.1093/hmg/ddn309
   Wong LJC, 2010, DEV DISABIL RES REV, V16, P154, DOI 10.1002/ddrr.104
   Yang CF, 2013, BMC GASTROENTEROL, V13, DOI 10.1186/1471-230X-13-67
   Yatsuga S, 2015, ANN NEUROL, V78, P814, DOI 10.1002/ana.24506
   Yilmaz Y, 2010, EUR J CLIN INVEST, V40, P887, DOI 10.1111/j.1365-2362.2010.02338.x
   Zhang X, 2008, DIABETES, V57, P1246, DOI 10.2337/db07-1476
NR 38
TC 157
Z9 167
U1 0
U2 20
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD NOV 29
PY 2016
VL 87
IS 22
BP 2290
EP 2299
DI 10.1212/WNL.0000000000003374
PG 10
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA EI1MA
UT WOS:000392240300010
PM 27794108
OA Green Published, Bronze
DA 2024-11-01
ER

PT J
AU Virgilio, R
   Ronchi, D
   Hadjigeorgiou, GM
   Bordoni, A
   Saladino, F
   Moggio, M
   Adobbati, L
   Kafetsouli, D
   Tsironi, E
   Previtali, S
   Papadimitriou, A
   Bresolin, N
   Comi, GP
AF Virgilio, Roberta
   Ronchi, Dario
   Hadjigeorgiou, Georgios M.
   Bordoni, Andreina
   Saladino, Francesca
   Moggio, Maurizio
   Adobbati, Laura
   Kafetsouli, Demetra
   Tsironi, Evangelia
   Previtali, Stefano
   Papadimitriou, Alexandros
   Bresolin, Nereo
   Comi, Giacomo P.
TI Novel Twinkle (<i>PE01</i>) gene mutations in mendelian progressive
   external ophthalmoplegia
SO JOURNAL OF NEUROLOGY
LA English
DT Article
DE mtDNA deletions; progressive external ophthalmoplegia
ID MITOCHONDRIAL-DNA DEPLETION; POLYMERASE-GAMMA MUTATIONS; MTDNA
   MAINTENANCE; OPTIC ATROPHY; DELETIONS; POLG; OPA1; PARKINSONISM;
   DOMINANT; ATAXIA
AB Multiple deletions of mitochondrial DNA (mtDNA) are associated with different mitochondrial disorders inherited as autosomal dominant and recessive traits. Causative mutations have been found in five genes, mainly involved in mtDNA replication and stability. They include POLG1, the gene encoding the catalytic subunit of mtDNA polymerase (poly), POLG2 encoding its accessory subunit, ANT1 coding the adenine nucleotide translocator and PEO1 which codes for Twinkle, the mitochondrial helicase. Finally OPA1 missense mutations are involved in phenotypes presenting optic atrophy as a major feature. To define the relative contribution of POLG 1, POLG2, ANT1 and PEO1 genes to the mtDNA multiple deletion syndromes, we analysed them in a cohort of 67 probands showing accumulation of multiple mtDNA deletions in muscle. The patients were predominantly affected with a mitochondrial myopathy with or without progressive external ophthalmoplegia (PEO). Genetic analysis revealed that 1) PEO1 has a major role in determining familial PEO, since it accounts for 26.8 % of familial cases, followed by ANT1 (14.6 %) and POLG 1 (9.8 %); 2) no mutations in any of the known genes were found in 53.7 % of probands of this series. Six novel missense mutations contributing to the mutational load of PEO1 gene (p.R334P, p.W315S, p. S426N, p.W474S, p.F478I, p.E479K) were associated with an adult onset PEO phenotype.
C1 [Virgilio, Roberta; Ronchi, Dario; Bordoni, Andreina; Saladino, Francesca; Moggio, Maurizio; Bresolin, Nereo; Comi, Giacomo P.] Univ Milan, Ctr Dino Ferrari, Dipartimento Sci Neurol, Fdn IRCCS Osped Maggiore Policlin Mangiagolli & R, I-20122 Milan, Italy.
   [Hadjigeorgiou, Georgios M.; Papadimitriou, Alexandros] Univ Thessaly, Sch Med, Neurogenet Unit, Larisa, Greece.
   [Adobbati, Laura] Univ Milan, Ctr Dino Ferrari, Dept Neurosci, IRCCS Ist Auxol Italiano, I-20122 Milan, Italy.
   [Kafetsouli, Demetra; Tsironi, Evangelia] Univ Thessaly, Sch Med, Dept Ophthalmol, Larisa, Greece.
   [Previtali, Stefano] Ist Sci San Raffaele, Dept Neurol, Neuropathol Unit, I-20132 Milan, Italy.
   [Bresolin, Nereo] Associaz Nostra Famiglia, IRCCS E Medea, Lecce, Italy.
C3 University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico;
   University of Thessaly; IRCCS Istituto Auxologico Italiano; University
   of Milan; University of Thessaly; Vita-Salute San Raffaele University;
   IRCCS Ospedale San Raffaele; IRCCS Eugenio Medea
RP Comi, GP (corresponding author), Univ Milan, Ctr Dino Ferrari, Dipartimento Sci Neurol, Fdn IRCCS Osped Maggiore Policlin Mangiagolli & R, Via Sforza 35, I-20122 Milan, Italy.
EM giacomo.comi@unimi.it
RI Previtali, Stefano/Z-1962-2019; Comi, Giacomo/K-5702-2016; Ronchi,
   Dario/K-8011-2016
OI Comi, Giacomo/0000-0002-1383-5248; Ronchi, Dario/0000-0002-6093-9816;
   Previtali, Stefano Carlo/0000-0003-2546-4357; Bresolin,
   Nereo/0000-0001-6694-3595
FU Associazione Amici del Centro Dino Ferrari; Italian Ministry of
   University and Research [PRIN 2006]; Bank of DNA, Nerve and Muscle
   Tissues [GTF02008]; Eurobiobank [QLTR2001-02769]; Fondazione Telethon
   Funding Source: Custom
FX We thank the patients and their families for their support and
   collaboration. This research received support by the "Associazione Amici
   del Centro Dino Ferrari" and by a Research Grant from Italian Ministry
   of University and Research "PRIN 2006" entitled "Un approccio integrato
   allo studio della eziopatogenesi delle mitocondriopatie" to G.P.C. The
   Telethon "Bank of DNA, Nerve and Muscle Tissues" (no. GTF02008) was the
   source of the skeletal muscle samples and DNA used in this study. The
   Eurobiobank project QLTR2001-02769 is also gratefully acknowledged.
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   Baloh RH, 2007, ARCH NEUROL-CHICAGO, V64, P998, DOI 10.1001/archneur.64.7.998
   Di Fonzo A, 2003, HUM MUTAT, V22, DOI 10.1002/humu.9203
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Ferraris S, 2008, ARCH NEUROL-CHICAGO, V65, P125, DOI 10.1001/archneurol.2007.9
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   Hudson G, 2008, BRAIN, V131, P329, DOI 10.1093/brain/awm272
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Napoli L, 2001, NEUROLOGY, V57, P2295, DOI 10.1212/WNL.57.12.2295
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nikali K, 2005, HUM MOL GENET, V14, P2981, DOI 10.1093/hmg/ddi328
   Sarzi E, 2007, ANN NEUROL, V62, P579, DOI 10.1002/ana.21207
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2005, GENE, V354, P162, DOI 10.1016/j.gene.2005.03.025
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
NR 22
TC 31
Z9 34
U1 0
U2 9
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-5354
J9 J NEUROL
JI J. Neurol.
PD SEP
PY 2008
VL 255
IS 9
BP 1384
EP 1391
DI 10.1007/s00415-008-0926-3
PG 8
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 359IV
UT WOS:000259980900015
PM 18575922
DA 2024-11-01
ER

PT J
AU Shelton, GD
   Mickelson, JR
   Friedenberg, SG
   Cullen, JN
   Mehra, JM
   Guo, LT
   Minor, KM
AF Shelton, G. Diane
   Mickelson, James R.
   Friedenberg, Steven G.
   Cullen, Jonah N.
   Mehra, Jaya M.
   Guo, Ling T.
   Minor, Katie M.
TI Multi-Allelic Mitochondrial DNA Deletions in an Adult Dog with Chronic
   Weakness, Exercise Intolerance and Lactic Acidemia
SO ANIMALS
LA English
DT Article
DE canine; muscle; myopathy; whole-genome sequencing (WGS); variant
   analysis
ID MUTATION; GENE; IDENTIFICATION; MUSCLE; MYOPATHY; DISEASE
AB Simple Summary Mitochondrial diseases in people are a heterogeneous group of genetically, biochemically, and clinically diverse disorders caused by defects in the metabolic pathways of oxidation phosphorylation (OXPHOS) and ATP production. While infrequently described in dogs, mitochondrial diseases may be more common than is currently known. Both the nuclear and mitochondrial genomes encode components of the enzyme complexes of the OXPHOS system, resulting in the genetic bases of mitochondrial diseases being transmitted in a Mendelian fashion, maternally, or as sporadic diseases. The pathogenicity is further complicated by heteroplasmy, with several different mitochondrial genomes existing within a given cell. A major challenge in the diagnosis of mitochondrial diseases is the clinical heterogeneity, with multi-system diseases affecting three or more organs and characteristically affecting tissues with high energy demands such as the central nervous system, skeletal muscle, eye and heart. Novel clinical syndromes have been reported in association with mitochondrial dysfunction and many patients can be misdiagnosed. The advent of next-generation sequencing has resulted in the discovery of new pathogenetic variants and has become the standard for the diagnosis of mitochondrial disease. Here, we describe an adult dog with a chronic myopathy associated with a mitochondrial deletion disorder.Abstract (1) Background: An adult dog was presented to a board-certified veterinary neurologist for evaluation of chronic weakness, exercise intolerance and lactic acidemia. (2) Methods: A mitochondrial myopathy was diagnosed based on the histological and histochemical phenotype of numerous COX-negative muscle fibers. Whole-genome sequencing established the presence of multiple extended deletions in the mitochondrial DNA (mtDNA), with the highest prevalence between the 1-11 kb positions of the approximately 16 kb mitochondrial chromosome. Such findings are typically suggestive of an underlying nuclear genome variant affecting mitochondrial replication, repair, or metabolism. (3) Results: Numerous variants in the nuclear genome unique to the case were identified in the whole-genome sequence data, and one, the insertion of a DYNLT1 retrogene, whose parent gene is a regulator of the mitochondrial voltage-dependent anion channel (VDAC), was considered a plausible causal variant. (4) Conclusions: Here, we add mitochondrial deletion disorders to the spectrum of myopathies affecting adult dogs.
C1 [Shelton, G. Diane; Guo, Ling T.] Univ Calif San Diego, Sch Med, Dept Pathol, La Jolla, CA 92093 USA.
   [Mickelson, James R.] Univ Minnesota, Coll Vet Med, Dept Vet & Biomed Sci, St Paul, MN 55108 USA.
   [Friedenberg, Steven G.; Cullen, Jonah N.; Minor, Katie M.] Univ Minnesota, Coll Vet Med, Dept Vet Clin Sci, St Paul, MN 55108 USA.
   [Mehra, Jaya M.] VCA Anim Care Ctr Sonoma Cty, Rohnert Pk, CA 94928 USA.
C3 University of California System; University of California San Diego;
   University of Minnesota System; University of Minnesota Twin Cities;
   University of Minnesota System; University of Minnesota Twin Cities
RP Shelton, GD (corresponding author), Univ Calif San Diego, Sch Med, Dept Pathol, La Jolla, CA 92093 USA.
EM gshelton@health.ucsd.edu; micke001@umn.edu; fried255@umn.edu;
   cull0084@umn.edu; jaya.mehra@vca.com; liguo@health.ucsd.edu;
   minork@umn.edu
RI Friedenberg, Steven/L-2681-2019
OI Minor, Katie/0000-0002-5472-5088; Friedenberg,
   Steven/0000-0002-7510-2322
FU NIH Special Emphasis Research Career Award in Pathology and Comparative
   Medicine by the Division of Comparative Medicine, Office of Research
   Infrastructure Programs [1 K01OD027058]
FX S.G.F. is supported in part by an NIH Special Emphasis Research Career
   Award (1 K01OD027058) in Pathology and Comparative Medicine sponsored by
   the Division of Comparative Medicine, Office of Research Infrastructure
   Programs.
CR Ahmed ST, 2018, NEUROTHERAPEUTICS, V15, P943, DOI 10.1007/s13311-018-00674-4
   Baranowska I, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000499
   Bua E, 2006, AM J HUM GENET, V79, P469, DOI 10.1086/507132
   Cameron JM, 2007, MOL GENET METAB, V90, P15, DOI 10.1016/j.ymgme.2006.09.011
   Christen M, 2024, SCI REP-UK, V14, DOI 10.1038/s41598-024-53314-7
   Cullen JN, 2023, G3-GENES GENOM GENET, V13, DOI 10.1093/g3journal/jkad117
   Dickinson PJ, 2002, VET CLIN N AM-SMALL, V32, P63, DOI 10.1016/S0195-5616(03)00080-9
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   DiMauro S, 2013, NAT REV NEUROL, V9, P429, DOI 10.1038/nrneurol.2013.126
   Drögemüller M, 2020, GENES-BASEL, V11, DOI 10.3390/genes11101215
   Dubowitz V., 2007, Muscle Biopsy: A Practical Approach
   El-Hattab AW, 2017, BBA-MOL BASIS DIS, V1863, P1539, DOI 10.1016/j.bbadis.2017.02.017
   Emmanuele V, 2022, MOL GENET METAB, V136, P125, DOI 10.1016/j.ymgme.2022.05.001
   Fang YD, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028052
   Glass EN, 2002, VET CLIN N AM-SMALL, V32, P1, DOI 10.1016/S0195-5616(03)00078-0
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Huang L, 2023, MOL MED, V29, DOI 10.1186/s10020-023-00663-0
   Kirby DM, 2004, J MED GENET, V41, P784, DOI 10.1136/jmg.2004.020537
   Knudsen S, 1999, BIOINFORMATICS, V15, P356, DOI 10.1093/bioinformatics/15.5.356
   Lepori V, 2018, G3-GENES GENOM GENET, V8, P1545, DOI 10.1534/g3.118.200084
   Li FY, 2006, NEUROBIOL DIS, V21, P35, DOI 10.1016/j.nbd.2005.06.009
   Meadows JRS, 2023, GENOME BIOL, V24, DOI 10.1186/s13059-023-03023-7
   Meurs KM, 2019, GENES-BASEL, V10, DOI 10.3390/genes10020168
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Naghdi S, 2016, BBA-MOL CELL RES, V1863, P2503, DOI 10.1016/j.bbamcr.2016.04.020
   Parikh S, 2017, GENET MED, V19, DOI 10.1038/gim.2017.107
   Parker HG, 2009, SCIENCE, V325, P995, DOI 10.1126/science.1173275
   Pinton P, 2008, ONCOGENE, V27, P6407, DOI 10.1038/onc.2008.308
   Rygiel KA, 2016, J PHYSIOL-LONDON, V594, P4499, DOI 10.1113/JP271212
   Santorelli FM, 1997, BIOCHEM BIOPH RES CO, V238, P326, DOI 10.1006/bbrc.1997.7167
   Schwarzer C, 2002, INT J BIOCHEM CELL B, V34, P1059, DOI 10.1016/S1357-2725(02)00026-2
   Shelton GD, 2019, J NEUROMUSCULAR DIS, V6, P485, DOI 10.3233/JND-190421
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   Shoubridge EA, 2001, HUM MOL GENET, V10, P2277, DOI 10.1093/hmg/10.20.2277
   Solovyev VV, 2010, METHODS MOL BIOL, V674, P57, DOI 10.1007/978-1-60761-854-6_5
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Tkaczyk-Wlizlo A, 2022, MITOCHONDRION, V63, P72, DOI 10.1016/j.mito.2022.02.001
   Varughese JT, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10071737
   Vernau KM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057195
   VIJAYASARATHY C, 1994, COMP BIOCHEM PHYS A, V109, P887, DOI 10.1016/0300-9629(94)90236-4
   Volpi L, 2011, Musculoskelet Surg, V95, P59, DOI 10.1007/s12306-011-0096-9
   Wang C, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-01698-x
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
   Zeviani M, 2004, BRAIN, V127, P2153, DOI 10.1093/brain/awh259
NR 45
TC 1
Z9 1
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2076-2615
J9 ANIMALS-BASEL
JI Animals
PD JUL
PY 2024
VL 14
IS 13
AR 1946
DI 10.3390/ani14131946
PG 15
WC Agriculture, Dairy & Animal Science; Veterinary Sciences; Zoology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Agriculture; Veterinary Sciences; Zoology
GA YP6C2
UT WOS:001269717600001
PM 38998058
OA gold, Green Published
DA 2024-11-01
ER

PT J
AU DiMauro, S
AF DiMauro, Salvatore
TI Mitochondrial myopathies
SO CURRENT OPINION IN RHEUMATOLOGY
LA English
DT Review
DE Alpers syndrome; coenzyme Q10 deficiency; mitochondrial DNA;
   mitochondrial DNA depletion; multiple mitochondrial DNA deletions;
   nuclear DNA
ID POLG MUTATIONS; DNA; DEFICIENCY; CARDIOLIPIN; GENE; DISEASE;
   ENCEPHALOMYOPATHY; DIAGNOSIS; SUBUNITS; SPECTRUM
AB Purpose of review Our understanding of mitochondrial diseases (defined restrictively as defects of the mitochondrial respiratory chain) is expanding rapidly. In this review, I will give the latest information on disorders affecting predominantly or exclusively skeletal muscle.
   Recent findings The most recently described mitochondrial myopathies are due to defects in nuclear DNA, including coenzyme Q10 deficiency and mutations in genes controlling mitochondrial DNA abundance and structure, such as POLG, TK2, and MPV17. Barth syndrome, an X-linked recessive mitochondrial myopathy/cardiopathy, is associated with decreased amount and altered structure of cardiolipin, the main phospholipid of the inner mitochondrial membrane, but a secondary impairment of respiratory chain function is plausible. The role of mutations in protein-coding genes of mitochondrial DNA in causing isolated myopathies has been confirmed. Mutations in tRNA genes of mitochondrial DNA can also cause predominantly myopathic syndromes and - contrary to conventional wisdom - these mutations can be homoplasmic.
   Summary Defects in the mitochondrial respiratory chain impair energy production and almost invariably involve skeletal muscle, causing exercise intolerance, cramps, recurrent myoglobinuria, or fixed weakness, which often affects extraocular muscles and results in droopy eyelids (ptosis) and progressive external ophthalmoplegia.
C1 Columbia Univ, Med Ctr, Dept Neurol, New York, NY USA.
C3 Columbia University
RP DiMauro, S (corresponding author), 4 420 Coll Phys & Surg, 630 W 168th St, New York, NY 10032 USA.
EM sd12@columbia.edu
FU NICHD NIH HHS [HD32062] Funding Source: Medline; NINDS NIH HHS [NS11766]
   Funding Source: Medline
CR Auré K, 2006, BRAIN, V129, P1249, DOI 10.1093/brain/awl061
   Barron MJ, 2005, NEUROMUSCULAR DISORD, V15, P768, DOI 10.1016/j.nmd.2005.06.018
   Calvo S, 2006, NAT GENET, V38, P576, DOI 10.1038/ng1776
   Crimi M, 2005, IUBMB LIFE, V57, P811, DOI 10.1080/15216540500460269
   Crimi M, 2005, FASEB J, V19, P866, DOI 10.1096/fj.04-3045fje
   Curbo S, 2006, GENOMICS, V87, P410, DOI 10.1016/j.ygeno.2005.09.017
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   Diaz F, 2005, HUM MOL GENET, V14, P2737, DOI 10.1093/hmg/ddi307
   DiMauro S, 2005, NEUROMUSCULAR DISORD, V15, P276, DOI 10.1016/j.nmd.2004.12.008
   Dimauro S, 2005, ANN MED, V37, P222, DOI 10.1080/07853890510007368
   DIMAURO S, 2006, MITOCHONDRIAL MED
   DiMauro S, 2006, BRAIN, V129, P1637, DOI 10.1093/brain/awl169
   Durham SE, 2005, NEUROLOGY, V65, P453, DOI 10.1212/01.wnl.0000171861.30277.88
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Goios A, 2005, J INHERIT METAB DIS, V28, P769, DOI 10.1007/s10545-005-0023-z
   Hays AP., 2006, Mitochondrial Medicine, P45
   Hirano M., 2006, Mitochondrial Medicine, P27
   Horváth R, 2005, NEUROMUSCULAR DISORD, V15, P851, DOI 10.1016/j.nmd.2005.09.005
   Horvath R, 2006, NEUROLOGY, V66, P253, DOI 10.1212/01.wnl.0000194241.35115.7c
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Hudson G, 2006, NEUROLOGY, V66, P1439, DOI 10.1212/01.wnl.0000210486.32196.24
   Kärppä M, 2005, BRAIN, V128, P1861, DOI 10.1093/brain/awh515
   Kollberg G, 2005, J NEUROPATH EXP NEUR, V64, P123, DOI 10.1093/jnen/64.2.123
   Lalani SR, 2005, ARCH NEUROL-CHICAGO, V62, P317, DOI 10.1001/archneur.62.2.317
   Lamperti C, 2005, ARCH NEUROL-CHICAGO, V62, P1709, DOI 10.1001/archneur.62.11.1709
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   McFarland R, 2004, NEUROMUSCULAR DISORD, V14, P162, DOI 10.1016/j.nmd.2003.10.011
   McPherson E, 2006, AM J MED GENET A, V140A, P184, DOI 10.1002/ajmg.a.31041
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   OGASAHARA S, 1989, P NATL ACAD SCI USA, V86, P2379, DOI 10.1073/pnas.86.7.2379
   Ogilvie I, 2005, J CLIN INVEST, V115, P2784, DOI 10.1172/JCI26020
   Owczarek J, 2005, PHARMACOL REP, V57, P23
   Pulkes T, 2005, NEUROMUSCULAR DISORD, V15, P364, DOI 10.1016/j.nmd.2005.01.006
   Pulkes T, 2005, NEUROLOGY, V64, P1091, DOI 10.1212/01.WNL.0000154471.33156.55
   Quinzii C, 2006, AM J HUM GENET, V78, P345, DOI 10.1086/500092
   Rahman S, 2001, J PEDIATR-US, V139, P456, DOI 10.1067/mpd.2001.117575
   Remes AM, 2005, NEUROLOGY, V64, P976, DOI 10.1212/01.WNL.0000154518.31302.ED
   Rötig A, 2000, LANCET, V356, P391, DOI 10.1016/S0140-6736(00)02531-9
   Salviati L, 2005, NEUROLOGY, V65, P606, DOI 10.1212/01.wnl.0000172859.55579.a7
   Schlame M, 2003, J AM COLL CARDIOL, V42, P1994, DOI 10.1016/j.jacc.2003.06.015
   Schlame M, 2002, ANN NEUROL, V51, P634, DOI 10.1002/ana.10176
   Sedlák E, 2006, BIOCHEMISTRY-US, V45, P746, DOI 10.1021/bi050870z
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Spinazzola A, 2005, GENE, V354, P162, DOI 10.1016/j.gene.2005.03.025
   Tarnopolsky MA, 2005, MED SCI SPORT EXER, V37, P2086, DOI 10.1249/01.mss.0000177341.89478.06
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Vreken P, 2000, BIOCHEM BIOPH RES CO, V279, P378, DOI 10.1006/bbrc.2000.3952
   Wallace DC, 2005, GENE, V354, P169, DOI 10.1016/j.gene.2005.05.001
   Zhang M, 2005, J BIOL CHEM, V280, P29403, DOI 10.1074/jbc.M504955200
NR 51
TC 79
Z9 94
U1 0
U2 16
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8711
EI 1531-6963
J9 CURR OPIN RHEUMATOL
JI Curr. Opin. Rheumatol.
PD NOV
PY 2006
VL 18
IS 6
BP 636
EP 641
DI 10.1097/01.bor.0000245729.17759.f2
PG 6
WC Rheumatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Rheumatology
GA 108VF
UT WOS:000242266600012
PM 17053512
DA 2024-11-01
ER

PT J
AU El-Hattab, A
   Scaglia, F
AF El-Hattab, Ayman W.
   Scaglia, Fernando
TI Mitochondrial DNA Depletion Syndromes: Review and Updates of Genetic
   Basis, Manifestations, and Therapeutic Options
SO NEUROTHERAPEUTICS
LA English
DT Review
DE Mitochondrial myopathy; Mitochondrial encephalomyopathy; Hepatocerebral
   syndrome; Mitochondrial neurogastrointestinal (MNGIE) disease;
   Alpers-Huttenlocher syndrome
ID NEUROGASTROINTESTINAL ENCEPHALOMYOPATHY MNGIE; PROGRESSIVE EXTERNAL
   OPHTHALMOPLEGIA; ONSET SPINOCEREBELLAR ATAXIA; STEM-CELL
   TRANSPLANTATION; CORRECTS BIOCHEMICAL DERANGEMENTS; RESPIRATORY-CHAIN
   DEFICIENCY; DEOXYGUANOSINE KINASE GENE; MULTIPLE MTDNA DELETIONS; POLG
   MUTATIONS; HEPATOCEREBRAL FORM
AB Mitochondrial DNA (mtDNA) depletion syndromes (MDS) are a genetically and clinically heterogeneous group of autosomal recessive disorders that are characterized by a severe reduction in mtDNA content leading to impaired energy production in affected tissues and organs. MDS are due to defects in mtDNA maintenance caused by mutations in nuclear genes that function in either mitochondrial nucleotide synthesis (TK2, SUCLA2, SUCLG1, RRM2B, DGUOK, and TYMP) or mtDNA replication (POLG and C10orf2). MDS are phenotypically heterogeneous and usually classified as myopathic, encephalomyopathic, hepatocerebral or neurogastrointestinal. Myopathic MDS, caused by mutations in TK2, usually present before the age of 2 years with hypotonia and muscle weakness. Encephalomyopathic MDS, caused by mutations in SUCLA2, SUCLG1, or RRM2B, typically present during infancy with hypotonia and pronounced neurological features. Hepatocerebral MDS, caused by mutations in DGUOK, MPV17, POLG, or C10orf2, commonly have an early-onset liver dysfunction and neurological involvement. Finally, TYMP mutations have been associated with mitochondrial neurogastrointestinal encephalopathy (MNGIE) disease that typically presents before the age of 20 years with progressive gastrointestinal dysmotility and peripheral neuropathy. Overall, MDS are severe disorders with poor prognosis in the majority of affected individuals. No efficacious therapy is available for any of these disorders. Affected individuals should have a comprehensive evaluation to assess the degree of involvement of different systems. Treatment is directed mainly toward providing symptomatic management. Nutritional modulation and cofactor supplementation may be beneficial. Liver transplantation remains controversial. Finally, stem cell transplantation in MNGIE disease shows promising results.
C1 [El-Hattab, Ayman W.] King Saud bin Abdulaziz Univ Hlth Sci, King Fahad Med City, Childrens Hosp, Div Med Genet,Dept Pediat, Riyadh, Saudi Arabia.
   [El-Hattab, Ayman W.] King Saud bin Abdulaziz Univ Hlth Sci, Fac Med, Riyadh, Saudi Arabia.
   [Scaglia, Fernando] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
C3 King Saud Bin Abdulaziz University for Health Sciences; King Fahad
   Medical City; King Saud Bin Abdulaziz University for Health Sciences;
   Baylor College of Medicine
RP Scaglia, F (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza,MS BCM225, Houston, TX 77030 USA.
EM fscaglia@bcm.edu
CR Acham-Roschitz B, 2009, MOL GENET METAB, V98, P300, DOI 10.1016/j.ymgme.2009.06.012
   Alberio S, 2007, MITOCHONDRION, V7, P6, DOI 10.1016/j.mito.2006.11.010
   Béhin A, 2012, NEUROLOGY, V78, P644, DOI 10.1212/WNL.0b013e318248df2b
   BICKNESE AR, 1992, ANN NEUROL, V32, P767, DOI 10.1002/ana.410320610
   Blakely E, 2008, NEUROMUSCULAR DISORD, V18, P557, DOI 10.1016/j.nmd.2008.04.014
   Blakely EL, 2012, NEUROMUSCULAR DISORD, V22, P587, DOI 10.1016/j.nmd.2012.03.006
   Blondon H, 2005, GASTROEN CLIN BIOL, V29, P773, DOI 10.1016/S0399-8320(05)86346-8
   Bornstein B, 2008, NEUROMUSCULAR DISORD, V18, P453, DOI 10.1016/j.nmd.2008.04.006
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Bulst S, 2012, MOL GENET METAB, V107, P95, DOI 10.1016/j.ymgme.2012.04.022
   Carrozzo R, 2007, BRAIN, V130, P862, DOI 10.1093/brain/awl389
   Cohen BH, GENEREVIEWS
   Collins J, 2009, NEUROMUSCULAR DISORD, V19, P784, DOI 10.1016/j.nmd.2009.08.002
   Dallabona C, 2010, HUM MOL GENET, V19, P1098, DOI 10.1093/hmg/ddp581
   Darin N, 2001, ANN NEUROL, V49, P377, DOI 10.1002/ana.75
   De Camaret BM, 2007, BIOCHEM J, V402, P377, DOI 10.1042/BJ20060705
   Dimmock DP, 2008, HUM MUTAT, V29, P330, DOI 10.1002/humu.9519
   Dimmock DP, 2008, LIVER TRANSPLANT, V14, P1480, DOI 10.1002/lt.21556
   Ducluzeau PH, 1999, J HEPATOL, V30, P149, DOI 10.1016/S0168-8278(99)80019-1
   El-Hattab AW., GeneReviews Internet
   El-Hattab AW, 2010, MOL GENET METAB, V99, P300, DOI 10.1016/j.ymgme.2009.10.003
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Fadic R, 1997, NEUROLOGY, V49, P239, DOI 10.1212/WNL.49.1.239
   Feranchak AP, 2007, LIVER DISEASE IN CHILDREN, 3RD EDITION, P190, DOI 10.1017/CBO9780511547409.012
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Filosto M, 2004, ACTA NEUROPATHOL, V108, P168, DOI 10.1007/s00401-004-0872-9
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   Filosto M, 2012, J NEUROL, V259, P2699, DOI 10.1007/s00415-012-6572-9
   Finsterer J, 2012, SEIZURE-EUR J EPILEP, V21, P316, DOI 10.1016/j.seizure.2012.03.003
   Finsterer J, 2011, J NEUROL SCI, V304, P9, DOI 10.1016/j.jns.2011.02.012
   Finsterer J, 2009, J NEUROL SCI, V283, P143, DOI 10.1016/j.jns.2009.02.347
   Fratter C, 2011, NEUROLOGY, V76, P2032, DOI 10.1212/WNL.0b013e31821e558b
   Freisinger P, 2006, ARCH NEUROL-CHICAGO, V63, P1129, DOI 10.1001/archneur.63.8.1129
   Galbiati S, 2006, PEDIATR NEUROL, V34, P177, DOI 10.1016/j.pediatrneurol.2005.07.013
   Gauthier-Villars M, 2001, NEUROPEDIATRICS, V32, P150, DOI 10.1055/s-2001-16614
   Giordano C, 2006, GASTROENTEROLOGY, V130, P893, DOI 10.1053/j.gastro.2006.01.004
   Giordano C, 2008, AM J PATHOL, V173, P1120, DOI 10.2353/ajpath.2008.080252
   Gold DR, 2001, SEMIN NEUROL, V21, P309, DOI 10.1055/s-2001-17948
   Götz A, 2008, BRAIN, V131, P2841, DOI 10.1093/brain/awn236
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   Halter J, 2011, BONE MARROW TRANSPL, V46, P330, DOI 10.1038/bmt.2010.100
   Hanchard NA, 2011, MOL GENET METAB, V103, P262, DOI 10.1016/j.ymgme.2011.03.006
   Hartley JN, 2012, CASE REP PEDIAT, V2012, DOI 10.1155/2012/303096
   Hasselmann O, 2010, MOL GENET METAB, V99, P58, DOI 10.1016/j.ymgme.2009.08.005
   Hirano M, 2006, NEUROLOGY, V67, P1458, DOI 10.1212/01.wnl.0000240853.97716.24
   Hirano M, 2004, NEUROLOGIST, V10, P8, DOI 10.1097/01.nrl.0000106919.06469.04
   HIRANO M, 1994, NEUROLOGY, V44, P721, DOI 10.1212/WNL.44.4.721
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Jeppesen TD, 2008, NEUROMUSCULAR DISORD, V18, P306, DOI 10.1016/j.nmd.2007.10.007
   Johansson M, 1997, J BIOL CHEM, V272, P8454, DOI 10.1074/jbc.272.13.8454
   Kaji S, 2009, MOL GENET METAB, V97, P292, DOI 10.1016/j.ymgme.2009.04.014
   Karadimas CL, 2006, AM J HUM GENET, V79, P544, DOI 10.1086/506913
   Kiechl S, 2004, J NEUROL NEUROSUR PS, V75, P1125, DOI 10.1136/jnnp.2003.025890
   Kollberg G, 2009, NEUROMUSCULAR DISORD, V19, P147, DOI 10.1016/j.nmd.2008.11.014
   KOSKINEN T, 1994, J NEUROL SCI, V121, P50, DOI 10.1016/0022-510X(94)90156-2
   KOSKINEN T, 1995, NEUROPEDIATRICS, V26, P263, DOI 10.1055/s-2007-979769
   KOSKINEN T, 1994, MUSCLE NERVE, V17, P509, DOI 10.1002/mus.880170507
   KOSKINEN T, 1995, AM J NEURORADIOL, V16, P1427
   Kowluru A, 2002, ARCH BIOCHEM BIOPHYS, V398, P160, DOI 10.1006/abbi.2001.2710
   Labarthe F, 2005, J HEPATOL, V43, P333, DOI 10.1016/j.jhep.2005.03.023
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Lara MC, 2007, BIOSCIENCE REP, V27, P151, DOI 10.1007/s10540-007-9043-2
   Lara MC, 2006, NEUROLOGY, V67, P1461, DOI 10.1212/01.wnl.0000239824.95411.52
   Lecrenier N, 1997, GENE, V185, P147, DOI 10.1016/S0378-1119(96)00663-4
   Lee NC, 2009, ARCH DIS CHILD, V94, P55, DOI 10.1136/adc.2008.139584
   Lesko N, 2010, NEUROMUSCULAR DISORD, V20, P198, DOI 10.1016/j.nmd.2009.11.013
   Mancuso M, 2005, ARCH NEUROL-CHICAGO, V62, P745, DOI 10.1001/archneur.62.5.745
   Mandel H, 2001, HEPATOLOGY, V34, P776, DOI 10.1053/jhep.2001.27664
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Martí R, 2004, CLIN CHEM, V50, P120, DOI 10.1373/clinchem.2003.026179
   Martí R, 2010, PEDIATR RES, V68, P151, DOI 10.1203/00006450-201011001-00294
   MELAS Scaglia F, GENEREVIEWS
   Merkle A N, 2012, AJNR Am J Neuroradiol, V33, pE34, DOI 10.3174/ajnr.A2455
   Milone M, 2011, NEUROLOGY, V77, P1847, DOI 10.1212/WNL.0b013e318238863a
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Morava E, 2009, MITOCHONDRION, V9, P438, DOI 10.1016/j.mito.2009.08.003
   Navarro-Sastre A, 2008, MOL GENET METAB, V94, P234, DOI 10.1016/j.ymgme.2008.01.012
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Naviaux RK, 1999, ANN NEUROL, V45, P54, DOI 10.1002/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B
   Nguyen KV, 2006, J HEPATOL, V45, P108, DOI 10.1016/j.jhep.2005.12.026
   Nguyen KV, 2005, NEUROLOGY, V65, P1493, DOI 10.1212/01.wnl.0000182814.55361.70
   Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828
   Nishino I, 2000, ANN NEUROL, V47, P792
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Oskoui M, 2006, ARCH NEUROL-CHICAGO, V63, P1122, DOI 10.1001/archneur.63.8.1122
   Ostergaard E, GENEREVIEWS
   Ostergaard E, 2007, AM J HUM GENET, V81, P383, DOI 10.1086/519222
   Ostergaard E, 2007, BRAIN, V130, P853, DOI 10.1093/brain/awl383
   Ostergaard E, 2010, EUR J PEDIATR, V169, P201, DOI 10.1007/s00431-009-1007-z
   Papadimitriou A, 1998, NEUROLOGY, V51, P1086, DOI 10.1212/WNL.51.4.1086
   Parini R, 2009, J HEPATOL, V50, P215, DOI 10.1016/j.jhep.2008.08.019
   Perez-Atayde AR, 1998, AM J SURG PATHOL, V22, P1141, DOI 10.1097/00000478-199809000-00014
   Pons R, 1996, PEDIATR NEUROL, V15, P153, DOI 10.1016/0887-8994(96)00118-X
   Pontarin G, 2008, P NATL ACAD SCI USA, V105, P17801, DOI 10.1073/pnas.0808198105
   Rabinowitz SS, 2004, J PEDIATR GASTR NUTR, V38, P216, DOI 10.1097/00005176-200402000-00022
   Rahman S, 2007, NEUROLOGY, V68, P1872, DOI 10.1212/01.wnl.0000265356.98295.be
   Rahman S, 2012, DEV MED CHILD NEUROL, V54, P397, DOI 10.1111/j.1469-8749.2011.04214.x
   Rodriguez MC, 2007, MUSCLE NERVE, V35, P235, DOI 10.1002/mus.20688
   Ronchi D, 2012, BRAIN, V135, P3404, DOI 10.1093/brain/aws258
   Saito K, 2012, BBA-GEN SUBJECTS, V1820, P632, DOI 10.1016/j.bbagen.2011.08.006
   Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284
   Saneto RP, 2010, SEIZURE-EUR J EPILEP, V19, P140, DOI 10.1016/j.seizure.2010.01.002
   Sarzi E, 2007, ANN NEUROL, V62, P579, DOI 10.1002/ana.21207
   Sarzi E, 2007, J PEDIATR-US, V150, P531, DOI 10.1016/j.jpeds.2007.01.044
   Shaibani A, 2009, ARCH NEUROL-CHICAGO, V66, P1028, DOI 10.1001/archneurol.2009.139
   Shoffner JM, GENEREVIEWS
   Slama A, 2005, MOL GENET METAB, V86, P462, DOI 10.1016/j.ymgme.2005.09.006
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Spinazzola A, 2011, SEMIN FETAL NEONAT M, V16, P190, DOI 10.1016/j.siny.2011.04.011
   Spinazzola A, 2009, J INHERIT METAB DIS, V32, P143, DOI 10.1007/s10545-008-1038-z
   Spinazzola A, 2008, ARCH NEUROL-CHICAGO, V65, P1108, DOI 10.1001/archneur.65.8.1108
   Suomalainen A, 2010, NEUROMUSCULAR DISORD, V20, P429, DOI 10.1016/j.nmd.2010.03.017
   Szigeti K, 2004, J MED GENET, V41, P125, DOI 10.1136/jmg.2003.013789
   Taanman JW, 2002, ANN NEUROL, V52, P237, DOI 10.1002/ana.10247
   Tadiboyina VT, 2005, AM J MED GENET A, V135A, P289, DOI 10.1002/ajmg.a.30748
   Tang S, 2012, J NEUROL, V259, P862, DOI 10.1007/s00415-011-6268-6
   Teitelbaum JE, 2002, J PEDIATR GASTR NUTR, V35, P377, DOI 10.1097/00005176-200209000-00029
   Tyynismaa H, 2012, HUM MOL GENET, V21, P66, DOI 10.1093/hmg/ddr438
   Tyynismaa H, 2009, AM J HUM GENET, V85, P290, DOI 10.1016/j.ajhg.2009.07.009
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Virgilio R, 2008, J NEUROL, V255, P1384, DOI 10.1007/s00415-008-0926-3
   Vissing J, 2002, NEUROLOGY, V59, P926, DOI 10.1212/WNL.59.6.926
   Wang LY, 2005, MOL GENET METAB, V84, P75, DOI 10.1016/j.ymgme.2004.09.005
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   Wong LJC, 2007, HEPATOLOGY, V46, P1218, DOI 10.1002/hep.21799
   Wong LJC, 2012, SEMIN NEUROL, V32, P55, DOI 10.1055/s-0032-1306387
   Wong LJC, 2008, HUM MUTAT, V29, pE150, DOI 10.1002/humu.20824
   Worle H, 1998, CLIN NEUROPATHOL, V17, P63
   Yavuz H, 2007, ARCH NEUROL-CHICAGO, V64, P435, DOI 10.1001/archneur.64.3.435
   Zhang SL, 2010, MOL GENET METAB, V99, P53, DOI 10.1016/j.ymgme.2009.09.003
NR 134
TC 225
Z9 269
U1 0
U2 67
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1933-7213
EI 1878-7479
J9 NEUROTHERAPEUTICS
JI Neurotherapeutics
PD APR
PY 2013
VL 10
IS 2
BP 186
EP 198
DI 10.1007/s13311-013-0177-6
PG 13
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA 127EC
UT WOS:000317677900002
PM 23385875
OA Bronze, Green Published
DA 2024-11-01
ER

PT J
AU Liu, CS
   Cheng, WL
   Lee, CF
   Ma, YS
   Lin, CY
   Huang, CC
   Wei, YH
AF Liu, CS
   Cheng, WL
   Lee, CF
   Ma, YS
   Lin, CY
   Huang, CC
   Wei, YH
TI Alteration in the copy number of mitochondrial DNA in leukocytes of
   patients with mitochondrial encephalomyopathies
SO ACTA NEUROLOGICA SCANDINAVICA
LA English
DT Article
DE MERRF; MELAS; copy number; mitochondrial DNA; heteroplasmy; age
ID RED FIBERS MERRF; OXIDATIVE STRESS; MYOCLONIC EPILEPSY; QUANTITATIVE
   PCR; HUMAN-CELLS; MUTATION; DEPLETION; MTDNA; PHENOTYPE; MELAS
AB Objectives - We investigated whether mutation of mitochondrial DNA (mtDNA) affects the copy number of the mitochondrial genome in patients with mitochondrial myopathy encephalopathy with lactic acidosis and stroke-like episodes (MELAS) and those with myoclonic epilepsy with ragged-red fiber (MERRF) syndromes. Materials and methods - Forty-eight Taiwanese patients with MELAS syndrome and 20 patients with MERRF syndrome were recruited in this study. Results - In relation to controls, the copy numbers of mtDNA in leukocytes of patients with MELAS or MERRF syndrome were significantly higher at a young age but lower at an advanced age. In addition, MELAS patients harboring higher proportions of mtDNA with A3243G transition had lower mtDNA copy numbers. The MELAS or MERRF patients with multi-system disorders had lower mtDNA copy numbers in leukocytes. Furthermore, higher proportions of mtDNA with 4977 bp deletion were found in leukocytes of MERRF patients with multi-system involvement. Conclusion - In leukocytes, alteration in the copy number of mtDNA is related to the proportion of mtDNA with a point mutation or large-scale deletion, which may serve as a biomarker in the pathogenesis and disease progression of MELAS and MERRF syndromes.
C1 Natl Yang Ming Univ, Sch Life Sci, Dept Biochem & Mol Biol, Taipei 112, Taiwan.
   Changhua Christian Hosp, Vasc & Genom Res Ctr, Changhua, Taiwan.
   Chung Shan Med Univ Hosp, Taichung, Taiwan.
   Chung Shan Med Univ, Dept Neurol, Taichung, Taiwan.
   Changhua Christian Hosp, Dept Neurol, Changhua, Taiwan.
   Chang Gung Mem Hosp, Dept Neurol, Taoyuan, Taiwan.
C3 National Yang Ming Chiao Tung University; Changhua Christian Hospital;
   Chung Shan Medical University; Chung Shan Medical University Hospital;
   Chung Shan Medical University; Changhua Christian Hospital; Chang Gung
   Memorial Hospital
RP Natl Yang Ming Univ, Sch Life Sci, Dept Biochem & Mol Biol, Taipei 112, Taiwan.
EM joeman@ym.edu.tw
RI Wei, Yau-Huei/ABA-6841-2021; Chen, yafang/GVS-0304-2022
OI Wei, Yau-Huei/0000-0002-6429-2546
CR Bai RK, 2004, ANN NY ACAD SCI, V1011, P304, DOI 10.1196/annals.1293.029
   Barthélémy C, 2001, ANN NEUROL, V49, P607, DOI 10.1002/ana.1002.abs
   Bentlage HACM, 1996, HUM MOL GENET, V5, P197, DOI 10.1093/hmg/5.2.197
   Chen DX, 2002, J NEUROCHEM, V81, P1273, DOI 10.1046/j.1471-4159.2002.00916.x
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   CHU NS, 1994, MUSCLE NERVE, V17, P1230
   CORRALDEBRINSKI M, 1994, GENOMICS, V23, P471, DOI 10.1006/geno.1994.1525
   Ducluzeau PH, 1999, J HEPATOL, V30, P149, DOI 10.1016/S0168-8278(99)80019-1
   FANG W, 1994, MUSCLE NERVE, V17, P52, DOI 10.1002/mus.880170107
   HAMMANS SR, 1993, BRAIN, V116, P617, DOI 10.1093/brain/116.3.617
   HUANG CC, 1994, J NEUROL NEUROSUR PS, V57, P586, DOI 10.1136/jnnp.57.5.586
   James AM, 2002, J BIOMED SCI, V9, P475, DOI 10.1159/000064721
   Kapsa RMI, 1998, NUCLEIC ACIDS RES, V26, P4365, DOI 10.1093/nar/26.19.4365
   Lee HC, 2001, BIOGERONTOLOGY, V2, P231, DOI 10.1023/A:1013270512172
   Lee HC, 2000, BIOCHEM J, V348, P425, DOI 10.1042/0264-6021:3480425
   Liu CS, 2003, FREE RADICAL RES, V37, P1307, DOI 10.1080/10715760310001621342
   Liu CY, 2004, ANN NY ACAD SCI, V1011, P133, DOI 10.1196/annals.1293.014
   Mancuso M, 2003, ARCH NEUROL-CHICAGO, V60, P1007, DOI 10.1001/archneur.60.7.1007
   Mita S, 1998, MUSCLE NERVE, V21, P490, DOI 10.1002/(SICI)1097-4598(199804)21:4<490::AID-MUS7>3.0.CO;2-4
   MITA S, 1995, MUSCLE NERVE       S, V3, P113
   Mohamed SA, 2004, EXP GERONTOL, V39, P181, DOI 10.1016/j.exger.2003.10.011
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Müller-Höcker J, 2002, HUM PATHOL, V33, P247, DOI 10.1053/hupa.2002.31477
   Oldfors A, 2003, J NEUROPATH EXP NEUR, V62, P217, DOI 10.1093/jnen/62.3.217
   Pang CY, 1999, J FORMOS MED ASSOC, V98, P326
   Pollack M, 2001, J GERONTOL A-BIOL, V56, pB475, DOI 10.1093/gerona/56.11.B475
   SCELSI R, 1992, PATHOL RES PRACT, V188, P607, DOI 10.1016/S0344-0338(11)80065-8
   SHONER JM, 1990, CELL, V61, P931
   Steensberg A, 2001, EUR J APPL PHYSIOL, V84, P155, DOI 10.1007/s004210000351
   Suomalainen A, 2001, AM J MED GENET, V106, P53, DOI 10.1002/ajmg.1379
   Tang YY, 2000, MOL BIOL CELL, V11, P1471, DOI 10.1091/mbc.11.4.1471
   Wei YH, 2001, ANN NY ACAD SCI, V928, P97
   Wei YH, 2003, ADV CLIN CHEM, V37, P83, DOI 10.1016/S0065-2423(03)37007-6
   Wong Alice, 2002, Methods Mol Biol, V197, P129, DOI 10.1385/1-59259-284-8:129
   Yano S, 2003, J INHERIT METAB DIS, V26, P481, DOI 10.1023/A:1025125427868
NR 35
TC 55
Z9 60
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0001-6314
EI 1600-0404
J9 ACTA NEUROL SCAND
JI Acta Neurol. Scand.
PD MAY
PY 2006
VL 113
IS 5
BP 334
EP 341
DI 10.1111/j.1600-0404.2006.00586.x
PG 8
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 028BB
UT WOS:000236459200009
PM 16629770
OA gold
DA 2024-11-01
ER

PT J
AU Alston, CL
   Lowe, J
   Turnbull, DM
   Maddison, P
   Taylor, RW
AF Alston, Charlotte L.
   Lowe, James
   Turnbull, Douglass M.
   Maddison, Paul
   Taylor, Robert W.
TI A novel mitochondrial tRNA<SUP>Glu</SUP> (<i>MTTE</i>) gene mutation
   causing chronic progressive external ophthalmoplegia at low levels of
   heteroplasmy in muscle
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE Mitochondrial DNA; Chronic progressive external ophthalmoplegia;
   tRNA(Glu); Single fibre studies; Pathogenicity
ID GLUTAMIC-ACID GENE; DIABETES-MELLITUS; SKELETAL-MUSCLE; POINT MUTATIONS;
   DNA MUTATIONS; MTDNA; MYOPATHY; CELLS; ENCEPHALOMYOPATHY; POPULATION
AB Mitochondrial respiratory chain defects are associated with diverse clinical phenotypes in both adults and children, and may be caused by mutations in either nuclear or mitochondrial DNA (mtDNA). We report the molecular genetic investigations of a patient with chronic progressive external ophthalmoplegia (CPEO) and myopathy where muscle biopsies taken 11 years apart revealed a progressive increase in the proportion of cytochrome c oxidase (COX)-deficient fibres. Mitochondrial genetic analysis of the early biopsy had seemingly excluded both mtDNA rearrangements and mtDNA point mutations. Sequencing mtDNA from individual COX-deficient muscle fibres in the second biopsy, however, identified an unreported m.14723 T>C substitution within the mitochondrial tRNA(Glu) (MTTE) gene, which fulfilled all canonical criteria for pathogenicity. The m.14723 T>C mutation was absent from several tissues, including muscle, from maternal relatives suggesting a de novo event, whilst quantitative analysis of the first muscle biopsy confirmed a very low level of the mutation (7% mutated mtDNA), highlighting a potential problem whereby pathogenic mtDNA mutations may remain undetected using established screening methodologies. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Alston, Charlotte L.; Turnbull, Douglass M.; Taylor, Robert W.] Newcastle Univ, Sch Med, Inst Ageing & Hlth, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Lowe, James] Univ Nottingham, Sch Mol Med Sci, Nottingham NG7 2RD, England.
   [Maddison, Paul] Nottingham Univ Hosp NHS Trust, Dept Clin Neurol, Nottingham, England.
C3 Newcastle University - UK; University of Nottingham; Nottingham
   University Hospital NHS Trust
RP Taylor, RW (corresponding author), Newcastle Univ, Sch Med, Inst Ageing & Hlth, Mitochondrial Res Grp, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM r.w.taylor@ncl.ac.uk
RI Alston, Charlotte/ABG-9602-2020
OI Lowe, James/0000-0002-9856-1599; Turnbull, Doug/0000-0002-8878-9901;
   Alston, Charlotte/0000-0003-2095-5464
FU Wellcome Trust [074454/Z/04/Z]; UK National Commissioning Group; MRC
   [G0800674, G0601943] Funding Source: UKRI
FX DMT and RWT acknowledge the continuing financial support of a Wellcome
   Trust Programme Grant (074454/Z/04/Z) and the UK National Commissioning
   Group which funds the "Rare Mitochondrial Disorders of Adults and
   Children" Diagnostic Service
   (http://www.mitochondrialncg.nhs.uk/index.html).
CR Al-Dosary M, 2009, NEUROMUSCULAR DISORD, V19, P841, DOI 10.1016/j.nmd.2009.10.001
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Anitori R, 2005, MOL GENET METAB, V84, P176, DOI 10.1016/j.ymgme.2004.10.003
   Blakely EL, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.011296
   Bruno C, 2003, J CHILD NEUROL, V18, P300, DOI 10.1177/08830738030180040401
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   Elson JL, 2009, HUM MUTAT, V30, pE984, DOI 10.1002/humu.21113
   Hancock DK, 2005, GENOMICS, V86, P446, DOI 10.1016/j.ygeno.2005.06.006
   HANNA MG, 1995, AM J HUM GENET, V56, P1026
   HAO HL, 1995, AM J HUM GENET, V56, P1017
   Horvath R, 2009, BRAIN, V132, P3165, DOI 10.1093/brain/awp221
   Ingman M, 2006, NUCLEIC ACIDS RES, V34, pD749, DOI 10.1093/nar/gkj010
   Kondrashov FA, 2005, HUM MOL GENET, V14, P2415, DOI 10.1093/hmg/ddi243
   Mayr JA, 2006, NEUROMUSCULAR DISORD, V16, P874, DOI 10.1016/j.nmd.2006.08.010
   McDonnell MT, 2004, EUR J HUM GENET, V12, P778, DOI 10.1038/sj.ejhg.5201216
   McFarland R, 2004, TRENDS GENET, V20, P591, DOI 10.1016/j.tig.2004.09.014
   OLD SL, 1989, HISTOCHEM J, V21, P545, DOI 10.1007/BF01753355
   Pancrudo J, 2007, J CHILD NEUROL, V22, P858, DOI 10.1177/0883073807304199
   Pereira C, 2007, BIOCHEM BIOPH RES CO, V354, P937, DOI 10.1016/j.bbrc.2007.01.068
   Ruiz-Pesini E, 2007, NUCLEIC ACIDS RES, V35, pD823, DOI 10.1093/nar/gkl927
   Sacconi S, 2008, HUM MOL GENET, V17, P1814, DOI 10.1093/hmg/ddn073
   Taylor RW, 2003, J CLIN INVEST, V112, P1351, DOI 10.1172/JCI200319435
   Taylor RW, 2001, NUCLEIC ACIDS RES, V29, part. no., DOI 10.1093/nar/29.15.e74
   Uusimaa J, 2004, PEDIATRICS, V114, P443, DOI 10.1542/peds.114.2.443
   Weber K, 1997, AM J HUM GENET, V60, P373
   White HE, 2005, GENET TEST, V9, P190, DOI 10.1089/gte.2005.9.190
NR 26
TC 9
Z9 10
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD NOV 15
PY 2010
VL 298
IS 1-2
BP 140
EP 144
DI 10.1016/j.jns.2010.08.014
PG 5
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 682ZJ
UT WOS:000284441200029
PM 20810132
DA 2024-11-01
ER

PT J
AU Milone, M
   Wong, LJ
AF Milone, Margherita
   Wong, Lee-Jun
TI Diagnosis of mitochondrial myopathies
SO MOLECULAR GENETICS AND METABOLISM
LA English
DT Review
DE Mitochondrial DNA; Mitochondrial myopathy; Progressive external
   ophthalmoplegia; Oxidative phosphorylation; NGS diagnosis of
   mitochondrial disorders; Molecular diagnosis
ID CYTOCHROME-C-OXIDASE; PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; COMPARATIVE
   GENOMIC HYBRIDIZATION; DNA DEPLETION; MOLECULAR DIAGNOSIS;
   LEIGH-SYNDROME; EXERCISE INTOLERANCE; LACTIC-ACIDOSIS; SKELETAL-MUSCLE;
   DISEASE GENES
AB Mitochondria are ubiquitous organelles and play crucial roles in vital functions, most importantly, the oxidative phosphorylation and energy metabolism. Therefore, mitochondrial dysfunction can affect multiple tissues, with muscle and nerve preferentially affected. Mitochondrial myopathy is a common clinical phenotype, which is characterized by early fatigue and/or fixed muscle weakness; rhabdomyolysis can seldom occur. Muscle biopsy often identifies signs of diseased mitochondria by morphological studies, while biochemical analysis may identify respiratory chain deficiencies. The clinical, morphological and biochemical data guide molecular analysis. Being the mitochondrial function under the control of both mitochondrial DNA and nuclear DNA, the search for mitochondrial DNA mutations and mitochondrial DNA quantitation, may not be sufficient for the molecular diagnosis of mitochondrial myopathies. Approximately 1500 nuclear genes can affect mitochondrial structure and function and the targeting of such genes may be necessary to reach the diagnosis. The identification of causative molecular defects in nuclear or mitochondrial genome leads to the definite diagnosis of mitochondrial myopathy. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Milone, Margherita] Mayo Clin, Neuromuscular Div, Dept Neurol, Rochester, MN USA.
   [Wong, Lee-Jun] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
C3 Mayo Clinic; Baylor College of Medicine
RP Wong, LJ (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza,NAB 2015, Houston, TX 77030 USA.
EM ljwong@bcm.edu
FU MDA
FX This work is partly supported by an MDA grant to LJW.
CR Andreu AL, 1999, ANN NEUROL, V45, P820, DOI 10.1002/1531-8249(199906)45:6<820::AID-ANA22>3.0.CO;2-W
   Andreu AL, 1999, ANN NEUROL, V45, P127, DOI 10.1002/1531-8249(199901)45:1<127::AID-ART20>3.0.CO;2-Y
   Béhin A, 2012, NEUROLOGY, V78, P644, DOI 10.1212/WNL.0b013e318248df2b
   Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   Calvo S, 2006, NAT GENET, V38, P576, DOI 10.1038/ng1776
   Calvo SE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003310
   Chanprasert S, 2013, MOL GENET METAB, V110, P153, DOI 10.1016/j.ymgme.2013.07.009
   Chen HC, 2010, CELL, V141, P280, DOI 10.1016/j.cell.2010.02.026
   Chinault AC, 2009, GENET MED, V11, P518, DOI 10.1097/GIM.0b013e3181abd83c
   Cui H, 2013, GENET MED, V15, P388, DOI 10.1038/gim.2012.144
   Darras BT, 2000, PEDIATR NEUROL, V22, P87, DOI 10.1016/S0887-8994(99)00133-2
   Debray FG, 2007, CLIN CHEM, V53, P916, DOI 10.1373/clinchem.2006.081166
   Dimmock DP, 2008, HUM MUTAT, V29, P330, DOI 10.1002/humu.9519
   Dimmock D, 2010, CLIN CHEM, V56, P1119, DOI 10.1373/clinchem.2009.141549
   Duchen MR, 2010, ESSAYS BIOCHEM, V47, P115, DOI [10.1042/bse0470115, 10.1042/BSE0470115]
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Emmanuele V, 2012, ARCH NEUROL-CHICAGO, V69, P978, DOI 10.1001/archneurol.2012.206
   Emmanuele V, 2011, J NEUROL SCI, V303, P39, DOI 10.1016/j.jns.2011.01.018
   Engel A.G., 2004, ULTRASTRUCTURAL CHAN
   Enns GM, 2006, MOL GENET METAB, V88, P364, DOI 10.1016/j.ymgme.2006.02.001
   FELIG P, 1975, NEW ENGL J MED, V293, P1078
   Freisinger P, 2006, ARCH NEUROL-CHICAGO, V63, P1129, DOI 10.1001/archneur.63.8.1129
   Giordano C, 2010, ARCH NEUROL-CHICAGO, V67, P1144, DOI 10.1001/archneurol.2010.200
   Haller RG, 2004, NEUROLOGY, V62, P82, DOI 10.1212/WNL.62.1.82
   Hirano M, 2012, BBA-GEN SUBJECTS, V1820, P625, DOI 10.1016/j.bbagen.2012.01.006
   Horváth R, 2005, NEUROMUSCULAR DISORD, V15, P851, DOI 10.1016/j.nmd.2005.09.005
   Horvath R, 2006, NEUROLOGY, V66, P253, DOI 10.1212/01.wnl.0000194241.35115.7c
   Jaksch M, 2000, HUM MOL GENET, V9, P795, DOI 10.1093/hmg/9.5.795
   Jeppesen TD, 2007, J NEUROL, V254, P29, DOI 10.1007/s00415-006-0229-5
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Koopman WJH, 2012, NEW ENGL J MED, V366, P1132, DOI 10.1056/NEJMra1012478
   Kowald A, 2013, AGING CELL, V12, P728, DOI 10.1111/acel.12098
   Larsson NG, 2010, ANNU REV BIOCHEM, V79, P683, DOI 10.1146/annurev-biochem-060408-093701
   Lee IC, 2012, HUM MUTAT, V33, P1192, DOI 10.1002/humu.22095
   Leshinsky-Silver E, 2008, EUR J PAEDIATR NEURO, V12, P309, DOI 10.1016/j.ejpn.2007.09.005
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Massie R, 2012, J NEUROL SCI, V319, P158, DOI 10.1016/j.jns.2012.05.003
   Massie R, 2010, MUSCLE NERVE, V42, P136, DOI 10.1002/mus.21649
   Mastaglia FL, 2012, CURR NEUROL NEUROSCI, V12, P54, DOI 10.1007/s11910-011-0232-9
   McFarland R, 2008, ARCH DIS CHILD, V93, P151, DOI 10.1136/adc.2007.122911
   McFarland R, 2004, NEUROMUSCULAR DISORD, V14, P162, DOI 10.1016/j.nmd.2003.10.011
   Milone M, 2009, MITOCHONDRION, V9, P279, DOI 10.1016/j.mito.2009.03.001
   MITA S, 1995, MUSCLE NERVE, pS113
   Moslemi AR, 2003, NEUROLOGY, V61, P991, DOI 10.1212/01.WNL.0000082391.98672.0A
   Nouws J, 2012, BRAIN, V135, P12, DOI 10.1093/brain/awr261
   Olsen RKJ, 2007, BRAIN, V130, P2045, DOI 10.1093/brain/awm135
   Paradas C, 2013, NEUROLOGY, V80, P504, DOI 10.1212/WNL.0b013e31827f0ff7
   Pecina P, 2003, BBA-MOL BASIS DIS, V1639, P53, DOI 10.1016/S0925-4439(03)00127-3
   Pestronk A, 2011, CURR OPIN RHEUMATOL, V23, P595, DOI 10.1097/BOR.0b013e32834bab42
   PETRUZZELLA V, 1994, HUM MOL GENET, V3, P449, DOI 10.1093/hmg/3.3.449
   Pfeffer G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004426.pub3
   Pitceathly RDS, 2012, BRAIN, V135, P3392, DOI 10.1093/brain/aws231
   Quinzii CM, 2010, DEV DISABIL RES REV, V16, P183, DOI 10.1002/ddrr.108
   Riley LG, 2010, AM J HUM GENET, V87, P52, DOI 10.1016/j.ajhg.2010.06.001
   Ronchi D, 2013, AM J HUM GENET, V92, P293, DOI 10.1016/j.ajhg.2012.12.014
   Saada A, 2009, AM J HUM GENET, V84, P718, DOI 10.1016/j.ajhg.2009.04.020
   Sacconi S, 2003, PEDIATR RES, V53, P224, DOI 10.1203/01.PDR.0000048100.91730.6A
   Salviati L, 2012, J MED GENET, V49, P187, DOI 10.1136/jmedgenet-2011-100394
   Saneto RP, 2010, SEIZURE-EUR J EPILEP, V19, P140, DOI 10.1016/j.seizure.2010.01.002
   Schapira AHV, 2012, LANCET, V379, P1825, DOI 10.1016/S0140-6736(11)61305-6
   Scharfe C, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000374
   Schon EA, 2010, TRENDS MOL MED, V16, P268, DOI 10.1016/j.molmed.2010.04.007
   Shanske S, 2004, MITOCHONDRION, V4, P403, DOI 10.1016/j.mito.2004.07.026
   Shoubridge EA, 2001, AM J MED GENET, V106, P46, DOI 10.1002/ajmg.1378
   Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063
   Smeitink JAM, 2004, CURR NEUROVASC RES, V1, P29, DOI 10.2174/1567202043480224
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2005, GENE, V354, P162, DOI 10.1016/j.gene.2005.03.025
   Talim B, 2013, BRAIN, V136, DOI 10.1093/brain/aws197
   Tang S, 2013, HUM MUTAT, V34, P882, DOI 10.1002/humu.22307
   Tang S, 2011, J MED GENET, V48, P669, DOI 10.1136/jmedgenet-2011-100222
   Tay SKH, 2005, J CHILD NEUROL, V20, P670, DOI 10.1177/08830738050200080701
   Techritz S, 2013, PROTEOMICS, V13, P179, DOI 10.1002/pmic.201100539
   Treff NR, 2012, FERTIL STERIL, V98, P1236, DOI 10.1016/j.fertnstert.2012.07.1119
   Tyynismaa H, 2012, HUM MOL GENET, V21, P66, DOI 10.1093/hmg/ddr438
   Tyynismaa H, 2009, AM J HUM GENET, V85, P290, DOI 10.1016/j.ajhg.2009.07.009
   Uusimaa J, 2014, EUR J HUM GENET, V22, P184, DOI 10.1038/ejhg.2013.112
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Vasta V, 2012, PEDIATR INT, V54, P585, DOI 10.1111/j.1442-200X.2012.03644.x
   Venhoff N, 2007, ANTIVIR THER, V12, P1075
   Von Kleist-Retzow JC, 2001, J MED GENET, V38, P109, DOI 10.1136/jmg.38.2.109
   Wallace D.C., 2001, The Metabolic and Molecular Basis of Inherited Disease, P2425
   Wang J., 2011, Curr. Protoc. Hum. Genet.
   Wang J, 2013, GENET MED, V15, P106, DOI 10.1038/gim.2012.104
   Wong LJC, 2008, CLIN CHEM, V54, P1141, DOI 10.1373/clinchem.2008.103721
   Wong LJC, 2013, MITOCHONDRION, V13, P379, DOI 10.1016/j.mito.2013.02.001
   Wong LJC, 2010, MOL GENET METAB, V100, P111, DOI 10.1016/j.ymgme.2010.02.024
   Wong LJC, 2003, J MED GENET, V40
   Yao JB, 1999, HUM MOL GENET, V8, P2541, DOI 10.1093/hmg/8.13.2541
   Young MJ, 2011, HUM MOL GENET, V20, P3052, DOI 10.1093/hmg/ddr209
   Yu-Wai-Man P, 2010, BRAIN, V133, P771, DOI 10.1093/brain/awq007
   Yu-Wai-Man P, 2011, BRAIN, V134, DOI 10.1093/brain/awq288
   Zhang W, 2012, CLIN CHEM, V58, P1322, DOI 10.1373/clinchem.2011.181438
   Zhang XB, 2010, NUCLEIC ACIDS RES, V38, P7378, DOI 10.1093/nar/gkq618
   Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804
NR 96
TC 55
Z9 65
U1 0
U2 33
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1096-7192
EI 1096-7206
J9 MOL GENET METAB
JI Mol. Genet. Metab.
PD SEP-OCT
PY 2013
VL 110
IS 1-2
BP 35
EP 41
DI 10.1016/j.ymgme.2013.07.007
PG 7
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental
   Medicine
GA 209ZP
UT WOS:000323799400004
PM 23911206
DA 2024-11-01
ER

PT J
AU Mposhi, A
   Liang, L
   Mennega, KP
   Yildiz, D
   Kampert, C
   Hof, IH
   Jellema, PG
   de Koning, TJ
   Faber, KN
   Ruiters, MHJ
   Niezen-Koning, KE
   Rots, MG
AF Mposhi, Archibold
   Liang, Lin
   Mennega, Kevin P.
   Yildiz, Dilemin
   Kampert, Crista
   Hof, Ingrid H.
   Jellema, Pytrick G.
   de Koning, Tom J.
   Faber, Klaas Nico
   Ruiters, Marcel H. J.
   Niezen-Koning, Klary E.
   Rots, Marianne G.
TI The Mitochondrial Epigenome: An Unexplored Avenue to Explain Unexplained
   Myopathies?
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE mitochondrial epigenome; myopathies; mitochondrial DNA methylation;
   cytochrome B
ID DISPLACEMENT LOOP; GENE-EXPRESSION; DNA; METHYLATION; MTDNA; NUMBER;
   MASS; DIAGNOSIS; FEATURES; GENOME
AB Mutations in either mitochondrial DNA (mtDNA) or nuclear genes that encode mitochondrial proteins may lead to dysfunctional mitochondria, giving rise to mitochondrial diseases. Some mitochondrial myopathies, however, present without a known underlying cause. Interestingly, methylation of mtDNA has been associated with various clinical pathologies. The present study set out to assess whether mtDNA methylation could explain impaired mitochondrial function in patients diagnosed with myopathy without known underlying genetic mutations. Enhanced mtDNA methylation was indicated by pyrosequencing for muscle biopsies of 14 myopathy patients compared to four healthy controls, at selected cytosines in the Cytochrome B (CYTB) gene, but not within the displacement loop (D-loop) region. The mtDNA methylation patterns of the four healthy muscle biopsies were highly consistent and showed intriguing tissue-specific differences at particular cytosines with control skin fibroblasts cultured in vitro. Within individual myopathy patients, the overall mtDNA methylation pattern correlated well between muscle and skin fibroblasts. Despite this correlation, a pilot analysis of four myopathy and five healthy fibroblast samples did not reveal a disease-associated difference in mtDNA methylation. We did, however, detect increased expression of solute carrier family 25A26 (SLC25A26), encoding the importer of S-adenosylmethionine, together with enhanced mtDNA copy numbers in myopathy fibroblasts compared to healthy controls. To confirm that pyrosequencing indeed reflected DNA methylation and not bisulfite accessibility, mass spectrometry was employed. Although no myopathy-related differences in total amount of methylated cytosines were detected at this stage, a significant contribution of contaminating nuclear DNA (nDNA) was revealed, and steps to improve enrichment for mtDNA are reported. In conclusion, in this explorative study we show that analyzing the mitochondrial genome beyond its sequence opens novel avenues to identify potential molecular biomarkers assisting in the diagnosis of unexplained myopathies.
C1 [Mposhi, Archibold; Liang, Lin; Mennega, Kevin P.; Jellema, Pytrick G.; Ruiters, Marcel H. J.; Rots, Marianne G.] Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, Hanzepl 1, NL-9713 GZ Groningen, Netherlands.
   [Mposhi, Archibold; Faber, Klaas Nico] Univ Groningen, Univ Med Ctr Groningen, Dept Gastroenterol & Hepatol, Hanzepl 1, NL-9713 GZ Groningen, Netherlands.
   [Mennega, Kevin P.; Yildiz, Dilemin; Kampert, Crista; Hof, Ingrid H.; Niezen-Koning, Klary E.] Univ Groningen, Univ Med Ctr Groningen, Dept Lab Med, Lab Metab Dis, NL-9713 GZ Groningen, Netherlands.
   [de Koning, Tom J.] Univ Groningen, Univ Med Ctr Groningen, Dept Genet, Antonius Deusinglaan 1, NL-9713 AV Groningen, Netherlands.
   [de Koning, Tom J.] Lund Univ, Dept Clin Sci, Lasarettgatan 40, S-22185 Lund, Sweden.
C3 University of Groningen; University of Groningen; University of
   Groningen; University of Groningen; Lund University
RP Rots, MG (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Pathol & Med Biol, Hanzepl 1, NL-9713 GZ Groningen, Netherlands.
EM mposhiarchibold@gmail.com; l.liang@umcg.nl; k.p.mennega@umcg.nl;
   dileminyildiz@gmail.com; crista.kampert@gmail.com; i.h.hof@umcg.nl;
   p.g.jellema@umcg.nl; t.j.de.koning@umcg.nl; k.n.faber@umcg.nl;
   m.h.j.ruiters@umcg.nl; k.e.niezen-koning@umcg.nl; m.g.rots@umcg.nl
RI Yildiz, Dilemin/AAM-4107-2021; De Koning, Tom/AAE-1323-2020; Liang,
   Lin/JVE-0735-2024
OI Yildiz, Dilemin/0000-0002-3176-5159; Liang, Lin/0000-0003-4347-2465;
   Mposhi, Archibold/0000-0002-9481-5045; Rots,
   Marianne/0000-0002-7416-2788; Niezen-Koning, Klary E/0000-0002-9384-4354
FU University Medical Center Groningen; China Scholarship Council (CSC); EU
   H2020 [CM1406]; COST (European Cooperation in Science and Technology)
FX This work was supported by the University Medical Center Groningen (a
   Talent grant to Archibold Mposhi) and funding to the Laboratory of
   Metabolic Diseases (Laboratory Medicine) UMCG. Lin Liang was supported
   by the China Scholarship Council (CSC). The authors also wish to
   acknowledge EU H2020 CM1406 (www.EpiChemBio.eu (accessed on 30 December
   2021)) supported by COST (European Cooperation in Science and
   Technology).
CR Ahuja AS, 2018, PEERJ, V6, DOI 10.7717/peerj.4790
   Baccarelli AA, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0078-0
   Bachmann C, 2019, HUM MUTAT, V40, P962, DOI 10.1002/humu.23745
   Bai RK, 2005, J MOL DIAGN, V7, P613, DOI 10.1016/S1525-1578(10)60595-8
   Bai YD, 2004, ANN NY ACAD SCI, V1011, P272, DOI 10.1196/annals.1293.026
   Barchiesi A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092221
   Barrès R, 2009, CELL METAB, V10, P189, DOI 10.1016/j.cmet.2009.07.011
   Basu U, 2020, J BIOL CHEM, V295, P18406, DOI 10.1074/jbc.REV120.011202
   Bicci I, 2021, NUCLEIC ACIDS RES, V49, P12757, DOI 10.1093/nar/gkab1179
   de Laat P, 2012, J INHERIT METAB DIS, V35, P1059, DOI 10.1007/s10545-012-9465-2
   Devall M, 2017, CLIN EPIGENETICS, V9, DOI 10.1186/s13148-017-0337-3
   Dorman Charles J, 2016, Biophys Rev, V8, P209, DOI 10.1007/s12551-016-0205-y
   Dostal V, 2019, BBA-GENE REGUL MECH, V1862, P598, DOI 10.1016/j.bbagrm.2019.01.006
   Dou XY, 2019, GENOME RES, V29, P1622, DOI 10.1101/gr.234021.117
   Emmanuele V, 2013, J CHILD NEUROL, V28, P236, DOI 10.1177/0883073812445787
   Feng S, 2012, MOL MED REP, V6, P125, DOI 10.3892/mmr.2012.870
   Filograna R, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav9824
   Friedman JR, 2014, NATURE, V505, P335, DOI 10.1038/nature12985
   Gammage PA, 2014, EMBO MOL MED, V6, P458, DOI 10.1002/emmm.201303672
   Gao JH, 2015, MOL MED REP, V12, P7033, DOI 10.3892/mmr.2015.4256
   Goldsmith C, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-87457-8
   Gu F, 2013, TRANSL PSYCHIAT, V3, DOI 10.1038/tp.2013.68
   Hao ZY, 2020, MOL CELL, V78, P382, DOI 10.1016/j.molcel.2020.02.018
   Infantino V, 2011, MOL GENET METAB, V102, P378, DOI 10.1016/j.ymgme.2010.11.166
   Janssen AJM, 2006, CLIN CHEM, V52, P860, DOI 10.1373/clinchem.2005.062414
   Jin CJ, 2007, J NUTR, V137, P339, DOI 10.1093/jn/137.2.339
   Pirola CJ, 2013, GUT, V62, P1356, DOI 10.1136/gutjnl-2012-302962
   Legros F, 2001, EUR J HUM GENET, V9, P510, DOI 10.1038/sj.ejhg.5200678
   Lin XC, 2016, ANAL CHEM, V88, P1083, DOI 10.1021/acs.analchem.5b04247
   Liu BJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep23421
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lueth T, 2021, FRONT AGING NEUROSCI, V13, DOI 10.3389/fnagi.2021.713084
   Lunnon K, 2017, NEUROBIOL AGING, V53, P36, DOI 10.1016/j.neurobiolaging.2016.12.029
   Massie R, 2010, MUSCLE NERVE, V42, P136, DOI 10.1002/mus.21649
   Matsuda S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24251-z
   Mechta M, 2017, FRONT GENET, V8, DOI 10.3389/fgene.2017.00166
   Menga A, 2017, FEBS J, V284, P967, DOI 10.1111/febs.14028
   Montier LLC, 2009, J GENET GENOMICS, V36, P125, DOI 10.1016/S1673-8527(08)60099-5
   Mposhi A, 2017, FRONT BIOSCI-LANDMRK, V22, P1099, DOI 10.2741/4535
   Nakamura M, 2021, NAT CELL BIOL, V23, P11, DOI 10.1038/s41556-020-00620-7
   Ngo HB, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4077
   Nicholls TJ, 2014, EXP GERONTOL, V56, P175, DOI 10.1016/j.exger.2014.03.027
   Niyazov DM, 2016, MOL SYNDROMOL, V7, P122, DOI 10.1159/000446586
   Owa C, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0192722
   Patil V, 2019, NUCLEIC ACIDS RES, V47, P10072, DOI 10.1093/nar/gkz762
   Powell CA, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00079
   Rackham O, 2011, RNA, V17, P2085, DOI 10.1261/rna.029405.111
   Rebelo AP, 2009, NUCLEIC ACIDS RES, V37, P6701, DOI 10.1093/nar/gkp727
   REIS RJS, 1983, J BIOL CHEM, V258, P9078
   Rodenburg RJT, 2011, J INHERIT METAB DIS, V34, P283, DOI 10.1007/s10545-010-9081-y
   Stoccoro A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094594
   Stoccoro A, 2018, EPIGENOMICS-UK, V10, P1431, DOI 10.2217/epi-2018-0072
   van der Wijst MGP, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00263-z
   van der Wijst MGP, 2015, TRENDS GENET, V31, P353, DOI 10.1016/j.tig.2015.03.009
   Vattemi G, 2014, AUTOIMMUN HIGHLIGHTS, V5, P77, DOI 10.1007/s13317-014-0062-2
   Veeranki S, 2015, INT J MOL SCI, V16, P1252, DOI 10.3390/ijms16011252
   Wredenberg A, 2002, P NATL ACAD SCI USA, V99, P15066, DOI 10.1073/pnas.232591499
   Yahata N, 2021, MOL THER-METH CLIN D, V20, P54, DOI 10.1016/j.omtm.2020.10.017
   Zheng LD, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0093-1
   Zhou GS, 2014, FOOD CHEM, V150, P260, DOI 10.1016/j.foodchem.2013.10.143
NR 60
TC 8
Z9 8
U1 0
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD FEB
PY 2022
VL 23
IS 4
AR 2197
DI 10.3390/ijms23042197
PG 19
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA ZN0GP
UT WOS:000764724100001
PM 35216315
OA Green Published, gold
DA 2024-11-01
ER

PT J
AU Mancuso, M
   Orsucci, D
   Angelini, C
   Bertini, E
   Carelli, V
   Comi, GP
   Donati, MA
   Federico, A
   Minetti, C
   Moggio, M
   Mongini, T
   Santorelli, FM
   Servidei, S
   Tonin, P
   Toscano, A
   Bruno, C
   Bello, L
   Ienco, EC
   Cardaioli, E
   Catteruccia, M
   Da Pozzo, P
   Filosto, M
   Lamperti, C
   Moroni, I
   Musumeci, O
   Pegoraro, E
   Ronchi, D
   Sauchelli, D
   Scarpelli, M
   Sciacco, M
   Valentino, ML
   Vercelli, L
   Zeviani, M
   Siciliano, G
AF Mancuso, Michelangelo
   Orsucci, Daniele
   Angelini, Corrado
   Bertini, Enrico
   Carelli, Valerio
   Comi, Giacomo Pietro
   Donati, Maria Alice
   Federico, Antonio
   Minetti, Carlo
   Moggio, Maurizio
   Mongini, Tiziana
   Santorelli, Filippo Maria
   Servidei, Serenella
   Tonin, Paola
   Toscano, Antonio
   Bruno, Claudio
   Bello, Luca
   Ienco, Elena Caldarazzo
   Cardaioli, Elena
   Catteruccia, Michela
   Da Pozzo, Paola
   Filosto, Massimiliano
   Lamperti, Costanza
   Moroni, Isabella
   Musumeci, Olimpia
   Pegoraro, Elena
   Ronchi, Dario
   Sauchelli, Donato
   Scarpelli, Mauro
   Sciacco, Monica
   Valentino, Maria Lucia
   Vercelli, Liliana
   Zeviani, Massimo
   Siciliano, Gabriele
TI Redefining phenotypes associated with mitochondrial DNA single deletion
SO JOURNAL OF NEUROLOGY
LA English
DT Article
DE CPEO; KSS; Mitochondrial disorders; mtDNA; Pearson syndrome; Single
   deletion
ID OCULAR MYOPATHY; DISEASE; OPHTHALMOPLEGIA; NEUROPATHOLOGY; MECHANISMS;
   DISORDERS; MUTATION; PATIENT; ADULTS; MUSCLE
AB Progressive external ophthalmoplegia (PEO), Kearns-Sayre syndrome (KSS) and Pearson syndrome are the three sporadic clinical syndromes classically associated with single large-scale deletions of mitochondrial DNA (mtDNA). PEO plus is a term frequently utilized in the clinical setting to identify patients with PEO and some degree of multisystem involvement, but a precise definition is not available. The purpose of the present study is to better define the clinical phenotypes associated with a single mtDNA deletion, by a retrospective study on a large cohort of 228 patients from the database of the "Nation-wide Italian Collaborative Network of Mitochondrial Diseases". In our database, single deletions account for about a third of all patients with mtDNA-related disease, more than previously recognized. We elaborated new criteria for the definition of PEO and "KSS spectrum" (a category of which classic KSS represents the most severe extreme). The criteria for "KSS spectrum" include the resulting multisystem clinical features associated with the KSS features, and which therefore can predict their presence or subsequent development. With the new criteria, we were able to classify nearly all our single-deletion patients: 64.5 % PEO, 31.6 % KSS spectrum (including classic KSS 6.6 %) and 2.6 % Pearson syndrome. The deletion length was greater in KSS spectrum than in PEO, whereas heteroplasmy was inversely related with age at onset. We believe that the new phenotype definitions implemented here may contribute to a more homogeneous patient categorization, which will be useful in future cohort studies of natural history and clinical trials.
C1 [Mancuso, Michelangelo; Orsucci, Daniele; Ienco, Elena Caldarazzo; Siciliano, Gabriele] Univ Pisa, Neurol Clin, I-56126 Pisa, Italy.
   [Angelini, Corrado; Bello, Luca; Pegoraro, Elena] Univ Padua, Neurol Clin, Padua, Italy.
   [Bertini, Enrico; Catteruccia, Michela] Bambino Gesu Pediat Hosp, IRCCS, Mol Med Lab, Unit Neuromuscular & Neurodegenerat Disorders, Rome, Italy.
   [Carelli, Valerio; Valentino, Maria Lucia] Univ Bologna, IRCCS Ist Sci Neurol Bologna, Dept Biomed & Neuromotor Sci, Bologna, Italy.
   [Comi, Giacomo Pietro; Ronchi, Dario] Univ Milan, IRCCS Fdn Ca Granda Osped Maggiore Policlin, Dept Pathophysiol & Transplantat DEPT, Neurosci Sect,Neurol Unit,Dino Ferrari Ctr, Milan, Italy.
   [Donati, Maria Alice] Univ Florence, Meyer Childrens Hosp, Florence, Italy.
   [Federico, Antonio; Cardaioli, Elena; Da Pozzo, Paola] Univ Siena, Dept Med Surg & Neurosci, I-53100 Siena, Italy.
   [Minetti, Carlo; Bruno, Claudio] Ist Giannina Gaslini, Neuropediat, I-16148 Genoa, Italy.
   [Minetti, Carlo; Bruno, Claudio] Ist Giannina Gaslini, Ctr Myol & Neurodegnerat Disorders, I-16148 Genoa, Italy.
   [Moggio, Maurizio; Sciacco, Monica] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Neuromuscular Unit, Dino Ferrari Ctr, Milan, Italy.
   [Mongini, Tiziana; Vercelli, Liliana] Univ Turin, Dept Neurosci, Turin, Italy.
   [Santorelli, Filippo Maria] IRCCS Stella Maris, Pisa, Italy.
   [Servidei, Serenella; Sauchelli, Donato] Univ Cattolica Sacro Cuore, Inst Neurol, I-00168 Rome, Italy.
   [Tonin, Paola; Scarpelli, Mauro] Univ Verona, Neurol Clin, I-37100 Verona, Italy.
   [Toscano, Antonio; Musumeci, Olimpia] Univ Messina, Dept Neurosci, Messina, Italy.
   [Moroni, Isabella] Fdn Carlo Besta Inst Neurol IRCCS, Child Neurol Unit, Milan, Italy.
   [Lamperti, Costanza; Zeviani, Massimo] Fdn Carlo Besta Inst Neurol IRCCS, Unit Mol Neurogenet, Milan, Italy.
   [Filosto, Massimiliano] Univ Hosp Spedali Civili, Neurol Clin, Brescia, Italy.
C3 University of Pisa; University of Padua; IRCCS Bambino Gesu; IRCCS
   Istituto delle Scienze Neurologiche di Bologna (ISNB); University of
   Bologna; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of
   Milan; University of Florence; Azienda Ospedaliera Universitaria (AOU)
   MEYER; University of Siena; University of Genoa; IRCCS Istituto Giannina
   Gaslini; University of Genoa; IRCCS Istituto Giannina Gaslini;
   University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico;
   University of Turin; IRCCS Fondazione Stella Maris; Catholic University
   of the Sacred Heart; IRCCS Policlinico Gemelli; University of Verona;
   University of Messina; Fondazione IRCCS Istituto Neurologico Carlo
   Besta; Fondazione IRCCS Istituto Neurologico Carlo Besta; Hospital
   Spedali Civili Brescia
RP Mancuso, M (corresponding author), Univ Pisa, Neurol Clin, Via Roma 67, I-56126 Pisa, Italy.
EM mancusomichelangelo@gmail.com
RI Federico, Antonio/H-8871-2017; Orsucci, Daniele/AAA-7576-2019; Ronchi,
   Dario/K-8011-2016; Toscano, Antonio/AHE-4657-2022; Comi,
   Giacomo/K-5702-2016; Catteruccia, Michela/AAB-5714-2020; Servidei,
   Serenella/ABC-4262-2021; Angelini, Corrado/J-3655-2019; Zeviani,
   Massimo/AAU-2632-2021; Bello, Luca/B-6397-2012; Bruno,
   Claudio/A-3148-2015; Ienco, Elena/K-9142-2016; lamperti,
   costanza/J-8801-2016; Sciacco, Monica/AAC-6500-2022; Mancuso,
   Michelangelo/K-4170-2016; Filosto, Massimiliano/S-9446-2019; Tonin,
   Paola/AAC-5052-2022; Musumeci, Olimpia/AHE-3041-2022; Bertini,
   Enrico/A-2284-2014; MINETTI, Carlo/K-4666-2018; Siciliano,
   Gabriele/K-7259-2016; Santorelli, Filippo M/ABE-5124-2020; moroni,
   isabella/AAL-1336-2021
OI Cardaioli, Elena/0000-0003-2850-6698; Filosto,
   Massimiliano/0000-0002-2852-7512; Bertini, Enrico/0000-0001-9276-4590;
   Sauchelli, Donato/0000-0003-0254-0767; MINETTI,
   Carlo/0000-0002-0640-1804; Siciliano, Gabriele/0000-0002-6142-2384;
   federico, antonio/0000-0002-5246-1621; Caldarazzo Ienco,
   Elena/0000-0003-0134-5062; Orsucci, Daniele/0000-0003-4847-7812;
   CARELLI, VALERIO/0000-0003-4923-6404; Angelini,
   Corrado/0000-0002-9554-8794; VALENTINO, MARIA LUCIA/0000-0001-5323-0115;
   Zeviani, Massimo/0000-0002-9067-5508; mancuso,
   michelangelo/0000-0003-2738-8562; Santorelli, Filippo
   M/0000-0002-1359-9062; Ronchi, Dario/0000-0002-6093-9816; Bello,
   Luca/0000-0002-3075-6525; Comi, Giacomo/0000-0002-1383-5248; SERVIDEI,
   Serenella/0000-0001-8478-2799; moroni, isabella/0000-0002-3322-1681;
   Sciacco, Monica/0000-0003-4593-4977; MARIA ALICE,
   DONATI/0000-0003-4769-5025
FU Telethon [GUP09004]; MITOCON
FX This work was supported by Telethon (grant number GUP09004). The
   patients' association MITOCON provided the Web-platform assistance. The
   work of Dr Orsucci was also supported by MITOCON
   (http://www.mitocon.it).
CR Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   Broomfield A, 2015, J INHERIT METAB DIS, V38, P445, DOI 10.1007/s10545-014-9778-4
   Campos Y, 1996, NEUROLOGY, V47, P1012, DOI 10.1212/WNL.47.4.1012
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Filosto M, 2007, ACTA NEUROL SCAND, V115, P211, DOI 10.1111/j.1600-0404.2006.00777.x
   Filosto M, 2007, BIOSCIENCE REP, V27, P23, DOI 10.1007/s10540-007-9034-3
   Grady JP, 2014, BRAIN, V137, P323, DOI 10.1093/brain/awt321
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Horga A, 2014, BRAIN, V137, P3200, DOI 10.1093/brain/awu279
   Kiyomoto BH, 1997, J NEUROL SCI, V152, P160, DOI 10.1016/S0022-510X(97)00158-5
   López-Gallardo E, 2009, MITOCHONDRION, V9, P314, DOI 10.1016/j.mito.2009.04.005
   Magalhaes PJ, 1996, ACTA OPHTHALMOL SCAN, V74, P29
   Mancuso M, 2009, CURR MOL MED, V9, P1095, DOI 10.2174/156652409789839099
   Mancuso M, 2008, MOVEMENT DISORD, V23, P2098, DOI 10.1002/mds.22050
   Mancuso M, 2014, J NEUROL, V261, P504, DOI 10.1007/s00415-013-7225-3
   Mancuso M, 2013, NEUROLOGY, V80, P2049, DOI 10.1212/WNL.0b013e318294b44c
   MORIKAWA Y, 1993, VIRCHOWS ARCH A, V423, P227, DOI 10.1007/BF01614775
   Pitceathly RDS, 2012, NEUROMUSCULAR DISORD, V22, P577, DOI 10.1016/j.nmd.2012.03.009
   Santorelli FM, 1996, NEUROLOGY, V47, P1320, DOI 10.1212/WNL.47.5.1320
   Schaefer AM, 2008, ANN NEUROL, V63, P35, DOI 10.1002/ana.21217
   Schröder R, 2000, J NEUROPATH EXP NEUR, V59, P353, DOI 10.1093/jnen/59.5.353
   Vilarinho L, 1998, EUR NEUROL, V39, P148, DOI 10.1159/000007925
   Yamashita S, 2008, J HUM GENET, V53, P598, DOI 10.1007/s10038-008-0289-8
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
NR 24
TC 65
Z9 65
U1 0
U2 11
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-5354
EI 1432-1459
J9 J NEUROL
JI J. Neurol.
PD MAY
PY 2015
VL 262
IS 5
BP 1301
EP 1309
DI 10.1007/s00415-015-7710-y
PG 9
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA CI7NN
UT WOS:000354950500024
PM 25808502
DA 2024-11-01
ER

PT J
AU Gal, A
   Inczedy-Farkas, G
   Pal, E
   Remenyi, V
   Bereznai, B
   Geller, L
   Szelid, Z
   Merkely, B
   Molnar, MJ
AF Gal, Aniko
   Inczedy-Farkas, Gabriella
   Pal, Endre
   Remenyi, Viktoria
   Bereznai, Benjamin
   Geller, Laszlo
   Szelid, Zsolt
   Merkely, Bela
   Molnar, Maria Judit
TI The coexistence of <i>dynamin 2</i> mutation and multiple mitochondrial
   DNA (mtDNA) deletions in the background of severe cardiomyopathy and
   centronuclear myopathy
SO CLINICAL NEUROPATHOLOGY
LA English
DT Article
DE centronuclear myopathy; repetitive discharge; dynamin 2 mutation;
   cardiomyopathy; mitochondrial DNA (mtDNA) deletion
ID MARIE-TOOTH DISEASE; NEONATAL ONSET; MUSCLE; NEUROPATHY; PHENOTYPE;
   FEATURES; FISSION; PATIENT; GENE
AB Dynamin2 (DNM2) gene mutations may result in Charcot-Marie-Tooth disease and centronuclear myopathy. Here, we present a patient suffering from cardiomyopathy and centronuclear myopathy with repetitive discharges and mild axonal neuropathy due to DNM2 mutation. Detailed cardiological and neurological examinations, electrophysiological tests, muscle biopsy, and molecular genetic analysis were performed. The patient developed left bundle branch block at age 40 and was fitted with a pacemaker at the age of 43. The patient has severe heart failure, ptosis, strabism, facial and proximal muscle weakness. Electrophysiological investigations found myopathy, complex repetitive discharges, and axonal neuropathy. Skeletal muscle biopsy detected centronuclear myopathy and cytochrome C oxidase (COX) negative fibers. Genetic analysis detected a pathogenic c.1105C>T (p.R369W) DNM2 gene mutation and heteroplasmic multiple mitochondrial DNA (mtDNA) deletion. Our data broadens the phenotypic spectrum of DNM2 mutations. The presence of the multiple mtDNA deletions may provide new aspects to understanding the pathogenesis of multisystemic symptoms in patients with DNM2 mutations.
C1 [Gal, Aniko; Inczedy-Farkas, Gabriella; Remenyi, Viktoria; Bereznai, Benjamin; Molnar, Maria Judit] Semmelweis Univ, Inst Genom Med & Rare Disorders, H-1083 Budapest, Hungary.
   [Pal, Endre] Univ Pecs, Dept Neurol, Pecs, Hungary.
   [Geller, Laszlo; Szelid, Zsolt; Merkely, Bela] Semmelweis Univ, Ctr Heart, H-1083 Budapest, Hungary.
C3 Semmelweis University; University of Pecs; Semmelweis University
RP Molnar, MJ (corresponding author), Semmelweis Univ, Inst Genom Med & Rare Disorders, Tomostr 25-29, H-1083 Budapest, Hungary.
EM molnarmj@gmail.com
RI Pal, Endre/I-8962-2019
OI Pal, Endre/0000-0001-6525-0754
FU Hungarian Brain Research Program;  [BIOINF09 TET_10-1-2011-0058]
FX This study was supported by the Hungarian Brain Research Program and
   BIOINF09 TET_10-1-2011-0058 grants. The authors would like to thank to
   Gyorgyi Bathori and Monika Sary for their technical help and David M.
   Booth for language revision.
CR Al-Rinvaishid A, 2003, BRAIN DEV, V25, P62
   Barsoum MJ, 2006, EMBO J, V25, P3900, DOI 10.1038/sj.emboj.7601253
   Bitoun M, 2005, NAT GENET, V37, P1207, DOI 10.1038/ng1657
   Bitoun M, 2009, NEUROLOGY, V72, P93, DOI 10.1212/01.wnl.0000338624.25852.12
   Bitoun M, 2008, NEUROMUSCULAR DISORD, V18, P334, DOI 10.1016/j.nmd.2008.01.005
   Bitoun M, 2007, ANN NEUROL, V62, P666, DOI 10.1002/ana.21235
   Cao H, 1998, MOL BIOL CELL, V9, P2595, DOI 10.1091/mbc.9.9.2595
   Catteruccia M, 2013, NEUROMUSCULAR DISORD, V23, P229, DOI 10.1016/j.nmd.2012.12.009
   Claeys KG, 2009, BRAIN, V132, P1741, DOI 10.1093/brain/awp115
   Durieux AC, 2010, J MOL MED, V88, P339, DOI 10.1007/s00109-009-0587-4
   Fabrizi GM, 2007, NEUROLOGY, V69, P291, DOI 10.1212/01.wnl.0000265820.51075.61
   Hanisch F, 2011, J NEUROL, V258, P1085, DOI 10.1007/s00415-010-5889-5
   Heymann JAW, 2009, J CELL SCI, V122, P3427, DOI 10.1242/jcs.051714
   Jones SM, 1998, SCIENCE, V279, P573, DOI 10.1126/science.279.5350.573
   Jungbluth H, 2008, ORPHANET J RARE DIS, V3, DOI 10.1186/1750-1172-3-26
   Kierdaszuk B, 2013, NEUROMUSCULAR DISORD, V23, P219, DOI 10.1016/j.nmd.2012.12.007
   Koutsopoulos OS, 2013, EUR J HUM GENET, V21, P637, DOI 10.1038/ejhg.2012.226
   Krishnan KJ, 2012, NEUROMUSCULAR DISORD, V22, P839, DOI 10.1016/j.nmd.2012.06.124
   Li J, 2013, INT J CARDIOL, V168, P2109, DOI 10.1016/j.ijcard.2013.01.006
   Liu N, 2011, J CLIN INVEST, V121, P3258, DOI 10.1172/JCI46267
   Melberg A, 2010, NEUROMUSCULAR DISORD, V20, P53, DOI 10.1016/j.nmd.2009.10.006
   Nomura S, 2011, INT J CARDIOL, V150, P213, DOI 10.1016/j.ijcard.2011.05.009
   Park YE, 2014, J CLIN NEUROL, V10, P24
   Praefcke GJK, 2004, NAT REV MOL CELL BIO, V5, P133, DOI 10.1038/nrm1313
   Susman RD, 2010, NEUROMUSCULAR DISORD, V20, P229, DOI 10.1016/j.nmd.2010.02.016
   Tang S, 2011, J MED GENET, V48, P669, DOI 10.1136/jmedgenet-2011-100222
   Tinelli E, 2013, HUM MOL GENET, V22, P4417, DOI 10.1093/hmg/ddt292
   Tosch V, 2006, HUM MOL GENET, V15, P3098, DOI 10.1093/hmg/ddl250
   VERHIEST W, 1976, BRIT HEART J, V38, P504
   Zanoteli E, 2009, ARQ NEURO-PSIQUIAT, V67, P102, DOI 10.1590/S0004-282X2009000100023
   Züchner S, 2005, NAT GENET, V37, P289, DOI 10.1038/ng1514
NR 31
TC 9
Z9 9
U1 0
U2 7
PU DUSTRI-VERLAG DR KARL FEISTLE
PI DEISENHOFEN-MUENCHEN
PA BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY
SN 0722-5091
J9 CLIN NEUROPATHOL
JI Clin. Neuropathol.
PD MAR-APR
PY 2015
VL 34
IS 2
BP 89
EP 95
DI 10.5414/NP300789
PG 7
WC Clinical Neurology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pathology
GA CE0KE
UT WOS:000351492100006
PM 25492887
OA Green Accepted
DA 2024-11-01
ER

PT J
AU Echaniz-Laguna, A
   Chanson, JB
   Wilhelm, JM
   Sellal, F
   Mayençon, M
   Mohr, M
   Tranchant, C
   de Camaret, BM
AF Echaniz-Laguna, Andoni
   Chanson, Jean-Baptiste
   Wilhelm, Jean-Marie
   Sellal, Francois
   Mayencon, Martine
   Mohr, Michel
   Tranchant, Christine
   de Camaret, Benedicte Mousson
TI A novel variation in the Twinkle linker region causing late-onset
   dementia
SO NEUROGENETICS
LA English
DT Article
DE Dementia; Chronic progressive external ophthalmoplegia; Mitochondrial
   disease; Twinkle; PEO1; Myopathy
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; MITOCHONDRIAL-DNA DELETIONS;
   HELICASE TWINKLE; MUTATIONS; DISEASE
AB Variations in the mitochondrial helicase Twinkle (PEO1) gene are usually associated with autosomal dominant chronic progressive external ophthalmoplegia (PEO). We describe five patients from two unrelated Alsatian families with the new R374W variation in the Twinkle linker region who progressively developed an autosomal dominant multisystem disorder with PEO, hearing loss, myopathy, dysphagia, dysphonia, sensory neuropathy, and late-onset dementia resembling Alzheimer's disease. These observations demonstrate that Twinkle variations in the linker domain alter cerebral function and further implicate disrupted mitochondrial DNA integrity in the pathogenesis of dementia.
C1 [Echaniz-Laguna, Andoni; Chanson, Jean-Baptiste; Tranchant, Christine] Hop Civil, Dept Neurol, F-67091 Strasbourg, France.
   [Wilhelm, Jean-Marie] Ctr Hosp Reg, Serv Med Interne, F-68130 Altkirch, France.
   [Sellal, Francois] Ctr Hosp Reg, Serv Neurol, F-68000 Colmar, France.
   [Mayencon, Martine; de Camaret, Benedicte Mousson] CHU Lyon, Ctr Biol & Pathol Est, Serv Malad Hereditaires Metab, F-69677 Bron, France.
   [Mohr, Michel] Hop Hautepierre, Dept Anatomopathol, F-67091 Strasbourg, France.
C3 CHU Strasbourg; Centre Hospitalier Annecy Genevois; Centre Hospitalier
   Annecy Genevois; CHU Lyon; Universites de Strasbourg Etablissements
   Associes; Universite de Strasbourg; CHU Strasbourg
RP Echaniz-Laguna, A (corresponding author), Hop Civil, Dept Neurol, BP 426, F-67091 Strasbourg, France.
EM Echaniz-Laguna@medecine.u-strasbg.fr
RI Christine, Tranchant-Dubreuil/JAC-6513-2023; Echaniz-Laguna,
   Andoni/IUN-5392-2023
OI tranchant, christine/0000-0002-2895-1292; Chanson,
   Jean-Baptiste/0000-0003-4221-3840
CR Baloh RH, 2007, ARCH NEUROL-CHICAGO, V64, P998, DOI 10.1001/archneur.64.7.998
   De Camaret BM, 2007, BIOCHEM J, V402, P377, DOI 10.1042/BJ20060705
   Ferlin T, 1997, MOL CELL BIOCHEM, V174, P221, DOI 10.1023/A:1006860508606
   Goffart S, 2009, HUM MOL GENET, V18, P328, DOI 10.1093/hmg/ddn359
   Hudson G, 2005, NEUROLOGY, V64, P371, DOI 10.1212/01.WNL.0000149767.51152.83
   Jeppesen TD, 2008, NEUROMUSCULAR DISORD, V18, P306, DOI 10.1016/j.nmd.2007.10.007
   Korhonen JA, 2008, J MOL BIOL, V377, P691, DOI 10.1016/j.jmb.2008.01.035
   Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292
   MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
   Van Hove JLK, 2009, AM J MED GENET A, V149A, P861, DOI 10.1002/ajmg.a.32731
   Virgilio R, 2008, J NEUROL, V255, P1384, DOI 10.1007/s00415-008-0926-3
NR 15
TC 15
Z9 18
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1364-6745
J9 NEUROGENETICS
JI Neurogenetics
PD FEB
PY 2010
VL 11
IS 1
BP 21
EP 25
DI 10.1007/s10048-009-0202-4
PG 5
WC Genetics & Heredity; Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Neurosciences & Neurology
GA 544UQ
UT WOS:000273685200003
PM 19513767
DA 2024-11-01
ER

PT S
AU Komulainen, T
   Hautakangas, MR
   Hinttala, R
   Pakanen, S
   Vähäsarja, V
   Lehenkari, P
   Olsen, P
   Vieira, P
   Saarenpää-Heikkilä, O
   Palmio, J
   Tuominen, H
   Kinnunen, P
   Majamaa, K
   Rantala, H
   Uusimaa, J
AF Komulainen, Tuomas
   Hautakangas, Milla-Riikka
   Hinttala, Reetta
   Pakanen, Salla
   Vahasarja, Vesa
   Lehenkari, Petri
   Olsen, Paivi
   Vieira, Paivi
   Saarenpaa-Heikkila, Outi
   Palmio, Johanna
   Tuominen, Hannu
   Kinnunen, Pietari
   Majamaa, Kari
   Rantala, Heikki
   Uusimaa, Johanna
BE Zschocke, J
   Baumgartner, M
   Morava, E
   Patterson, M
   Rahman, S
   Peters, V
TI Mitochondrial DNA Depletion and Deletions in Paediatric Patients with
   Neuromuscular Diseases: Novel Phenotypes
SO JIMD REPORTS, VOL 23
SE JIMD Reports
LA English
DT Article; Book Chapter
ID DEOXYGUANOSINE KINASE; MYOTONIC-DYSTROPHY; SUCLA2 MUTATIONS; MTDNA;
   GENE; ENCEPHALOMYOPATHY; QUANTIFICATION; DUPLICATIONS; POPULATION;
   DEFICIENCY
AB Objective: To study the clinical manifestations and occurrence of mtDNA depletion and deletions in paediatric patients with neuromuscular diseases and to identify novel clinical phenotypes associated with mtDNA depletion or deletions.
   Methods: Muscle DNA samples from patients presenting with undefined encephalomyopathies or myopathies were analysed for mtDNA content by quantitative real-time PCR and for deletions by long-range PCR. Direct sequencing of mtDNA maintenance genes and whole-exome sequencing were used to study the genetic aetiologies of the diseases. Clinical and laboratory findings were collected.
   Results: Muscle samples were obtained from 104 paediatric patients with neuromuscular diseases. mtDNA depletion was found in three patients with severe early-onset encephalomyopathy or myopathy. Two of these patients presented with novel types of mitochondrial DNA depletion syndromes associated with increased serum creatine kinase (CK) and multiorgan disease without mutations in any of the known mtDNA maintenance genes; one patient had pathologic endoplasmic reticulum (ER) membranes in muscle. The third patient with mtDNA depletion was diagnosed with merosine-deficient muscular dystrophy caused by a homozygous mutation in the LAMA2 gene. Two patients with an early-onset Kearns-Sayre/ Pearson-like phenotype harboured a large-scale mtDNA deletion, minor multiple deletions and high mtDNA content.
   Conclusions: Novel encephalomyopathic mtDNA depletion syndrome with structural alterations in muscle ER was identified. mtDNA depletion may also refer to secondary mitochondrial changes related to muscular dystrophy. We suggest that a large-scale mtDNA deletion, minor multiple deletions and high mtDNA content associated with Kearns-Sayre/Pearson syndromes may be secondary changes caused by mutations in an unknown nuclear gene.
C1 [Komulainen, Tuomas; Hautakangas, Milla-Riikka; Hinttala, Reetta; Pakanen, Salla; Olsen, Paivi; Vieira, Paivi; Rantala, Heikki; Uusimaa, Johanna] Univ Oulu, PEDEGO Res Grp, POB 5000, FIN-90014 Oulu, Finland.
   [Komulainen, Tuomas; Hautakangas, Milla-Riikka; Hinttala, Reetta; Pakanen, Salla; Lehenkari, Petri; Olsen, Paivi; Vieira, Paivi; Majamaa, Kari; Rantala, Heikki; Uusimaa, Johanna] Univ Oulu, Med Res Ctr Oulu, FIN-90014 Oulu, Finland.
   [Komulainen, Tuomas; Hautakangas, Milla-Riikka; Hinttala, Reetta; Pakanen, Salla; Olsen, Paivi; Vieira, Paivi; Rantala, Heikki; Uusimaa, Johanna] Oulu Univ Hosp, Dept Children & Adolescents, Div Pediat Neurol, FI-90029 Oys Oulu, Finland.
   [Vahasarja, Vesa] Oulu Univ Hosp, Dept Children & Adolescents, Div Pediat, FI-90029 Oys Oulu, Finland.
   [Komulainen, Tuomas; Hautakangas, Milla-Riikka; Hinttala, Reetta; Pakanen, Salla; Lehenkari, Petri; Majamaa, Kari; Rantala, Heikki; Uusimaa, Johanna] Oulu Univ Hosp, FIN-90014 Oulu, Finland.
   [Lehenkari, Petri; Kinnunen, Pietari] Oulu Univ Hosp, Dept Surg, FI-90029 Oys Oulu, Finland.
   [Saarenpaa-Heikkila, Outi] Tampere Univ Hosp, Dept Pediat, FI-33521 Tampere, Finland.
   [Palmio, Johanna] Tampere Univ Hosp, Dept Neurol, FI-33521 Tampere, Finland.
   [Tuominen, Hannu] Oulu Univ Hosp, Dept Pathol, FI-90029 Oys Oulu, Finland.
   [Majamaa, Kari] Univ Oulu, Clin Neurosci Ctr, FIN-90014 Oulu, Finland.
   [Majamaa, Kari] Oulu Univ Hosp, Dept Neurol, FIN-90029 Oys Oulu, Finland.
C3 University of Oulu; University of Oulu; University of Oulu; University
   of Oulu; University of Oulu; University of Oulu; Tampere University;
   Tampere University Hospital; Tampere University; Tampere University
   Hospital; University of Oulu; University of Oulu; University of Oulu
RP Komulainen, T (corresponding author), Univ Oulu, PEDEGO Res Grp, POB 5000, FIN-90014 Oulu, Finland.
EM mikakomu@student.oulu.fi
RI Majamaa, Kari/A-1344-2012; Lehenkari, Petri/O-3009-2016
OI Majamaa, Kari/0000-0002-9070-3791; Hinttala, Reetta/0000-0002-7642-4008
CR Acham-Roschitz B, 2009, MOL GENET METAB, V98, P300, DOI 10.1016/j.ymgme.2009.06.012
   Alberio S, 2007, MITOCHONDRION, V7, P6, DOI 10.1016/j.mito.2006.11.010
   Bornstein B, 2008, NEUROMUSCULAR DISORD, V18, P453, DOI 10.1016/j.nmd.2008.04.006
   Calvo SE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003310
   Carrozzo R, 2007, BRAIN, V130, P862, DOI 10.1093/brain/awl389
   Chan SSL, 2009, BBA-BIOENERGETICS, V1787, P312, DOI 10.1016/j.bbabio.2008.10.007
   Chinnery PF, 2004, LANCET, V364, P592, DOI 10.1016/S0140-6736(04)16851-7
   Dimmock DP, 2008, HUM MUTAT, V29, P330, DOI 10.1002/humu.9519
   Dimmock D, 2010, CLIN CHEM, V56, P1119, DOI 10.1373/clinchem.2009.141549
   El-Hattab A, 2013, NEUROTHERAPEUTICS, V10, P186, DOI 10.1007/s13311-013-0177-6
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   He LP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf067
   Katsetos CD, 2013, SEMIN PEDIATR NEUROL, V20, P202, DOI 10.1016/j.spen.2013.10.010
   Kollberg G, 2009, NEUROMUSCULAR DISORD, V19, P147, DOI 10.1016/j.nmd.2008.11.014
   Kornmann B, 2013, CURR OPIN CELL BIOL, V25, P443, DOI 10.1016/j.ceb.2013.02.010
   Krishnan KJ, 2008, NAT GENET, V40, P275, DOI 10.1038/ng.f.94
   Krishnan KJ, 2007, ANN NY ACAD SCI, V1100, P227, DOI 10.1196/annals.1395.024
   Lesko N, 2010, NEUROMUSCULAR DISORD, V20, P198, DOI 10.1016/j.nmd.2009.11.013
   Lezza AMS, 1997, FEBS LETT, V418, P167, DOI 10.1016/S0014-5793(97)01374-4
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Morten KJ, 2007, MITOCHONDRION, V7, P386, DOI 10.1016/j.mito.2007.09.001
   Muqit MMK, 2008, J NEUROL NEUROSUR PS, V79, P68, DOI 10.1136/jnnp.2006.112250
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Odoardi F, 2003, AM J MED GENET A, V118A, P247, DOI 10.1002/ajmg.a.20006
   Ostergaard E, 2007, AM J HUM GENET, V81, P383, DOI 10.1086/519222
   Ostergaard E, 2007, BRAIN, V130, P853, DOI 10.1093/brain/awl383
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   POULTON J, 1995, J MED GENET, V32, P732, DOI 10.1136/jmg.32.9.732
   POULTON J, 1992, J INHERIT METAB DIS, V15, P487, DOI 10.1007/BF01799607
   Rahman S, 2009, ARCH DIS CHILD, V94, P3, DOI 10.1136/adc.2008.147983
   Remes AM, 2005, NEUROLOGY, V64, P976, DOI 10.1212/01.WNL.0000154518.31302.ED
   Renaldo F, 2012, BRAIN, V135, DOI 10.1093/brain/aws111
   SAHASHI K, 1992, GERONTOLOGY, V38, P18
   Sulonen AM, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-9-r94
   Suomalainen A, 2010, NEUROMUSCULAR DISORD, V20, P429, DOI 10.1016/j.nmd.2010.03.017
   Uusimaa J, 2000, PEDIATRICS, V105, P598, DOI 10.1542/peds.105.3.598
   Uusimaa J, 2014, EUR J HUM GENET, V22, P184, DOI 10.1038/ejhg.2013.112
   Wong LJC, 2003, J MED GENET, V40
   Yu-Wai-Man P, 2012, BRAIN, V135, P9, DOI 10.1093/brain/awr352
   ZEVIANI M, 1990, AM J HUM GENET, V47, P904
NR 40
TC 7
Z9 8
U1 0
U2 6
PU SPRINGER-VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
SN 2192-8304
BN 978-3-662-47467-9; 978-3-662-47466-2
J9 JIMD REP
PY 2015
VL 23
BP 91
EP 100
DI 10.1007/8904_2015_438
D2 10.1007/978-3-662-47467-9
PG 10
WC Endocrinology & Metabolism; Genetics & Heredity
WE Book Citation Index – Science (BKCI-S)
SC Endocrinology & Metabolism; Genetics & Heredity
GA BE8SP
UT WOS:000376988300012
PM 25940035
OA Green Published
DA 2024-11-01
ER

PT J
AU Park, MH
   Woo, HM
   Hong, YB
   Park, JH
   Yoon, BR
   Park, JM
   Yoo, JH
   Koo, H
   Chae, JH
   Chung, KW
   Choi, BO
   Koo, SK
AF Park, Mi-Hyun
   Woo, Hae-Mi
   Hong, Young Bin
   Park, Ji Hoon
   Yoon, Bo Ram
   Park, Jin-Mo
   Yoo, Jeong Hyun
   Koo, Heasoo
   Chae, Jong-Hee
   Chung, Ki Wha
   Choi, Byung-Ok
   Koo, Soo Kyung
TI Recessive <i>C10orf2</i> mutations in a family with infantile-onset
   spinocerebellar ataxia, sensorimotor polyneuropathy, and myopathy
SO NEUROGENETICS
LA English
DT Article
DE C10orf2; Whole exome sequencing (WES); Infantile-onset spinocerebellar
   ataxia (IOSCA); Neuropathy; Myopathy; Mitochondria
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; MARIE-TOOTH-DISEASE;
   MITOCHONDRIAL-DNA; SENSORY NEUROPATHY; TWINKLE MUTATIONS;
   ENCEPHALOPATHY; DEPLETION; DELETIONS
AB Recessive mutations in chromosome 10 open reading frame 2 (C10orf2) are relevant in infantile-onset spinocerebellar ataxia (IOSCA). In this study, we investigated the causative mutation in a Korean family with combined phenotypes of IOSCA, sensorimotor polyneuropathy, and myopathy. We investigated recessive mutations in a Korean family with two individuals affected by IOSCA. Causative mutations were investigated using whole exome sequencing. Electrophysiological analyses and muscle and nerve biopsies were performed, along with magnetic resonance imaging (MRI) of the brain and lower extremities. Compound heterozygous mutations c.1460C > T and c.1485-1G > A in C10orf2 were identified as causative of IOSCA. Skeletal muscle showed mitochondrial DNA (mtDNA) deletions. Both patients showed a period of normal development until 12-15 months, followed by ataxia, athetosis, hearing loss, and intellectual disability. Electrophysiological findings indicated motor and sensory polyneuropathies. Muscle biopsy revealed variations in the size and shape of myofibers with scattered, small, and angulated degenerating myofibers containing abnormal mitochondria; these observations are consistent with myopathy and may be the result of mtDNA deletions. Sural nerve biopsy revealed an axonal neuropathy. High-signal-intensity lesions in the middle cerebellar peduncles were correlated with clinical severity, and MRI of the lower legs was compatible with the hypothesis of length-dependent axonal degeneration. We identified novel compound heterozygous mutations of the C10orf2 gene as the cause of IOSCA with sensorimotor polyneuropathy and myopathy. Signs of motor neuropathy and myopathy were discovered for the first time in IOSCA patients with C10orf2 mutations. These results suggest that the clinical spectrum of IOSCA caused by C10orf2 mutations may be more variable than previously reported.
C1 [Park, Mi-Hyun; Woo, Hae-Mi; Koo, Soo Kyung] Natl Inst Hlth, Ctr Biomed Sci, Div Intractable Dis, Cheongwon Gun 363951, Chungcheongbuk, South Korea.
   [Hong, Young Bin; Choi, Byung-Ok] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Neurol, Seoul 135710, South Korea.
   [Park, Ji Hoon; Yoon, Bo Ram; Chung, Ki Wha] Kongju Natl Univ, Dept Biol Sci, Gongju, South Korea.
   [Park, Jin-Mo] Ewha Womans Univ, Sch Med, Dept Neurol, Seoul, South Korea.
   [Yoo, Jeong Hyun] Ewha Womans Univ, Sch Med, Dept Radiol, Seoul, South Korea.
   [Koo, Heasoo] Ewha Womans Univ, Sch Med, Dept Pathol, Seoul, South Korea.
   [Chae, Jong-Hee] Seoul Natl Univ, Coll Med, Dept Pediat, Seoul, South Korea.
C3 Korea Disease Control & Prevention Agency (KDCA); Korea National
   Institute of Health (KNIH); Korea CDC Center for Biomedical Science;
   Sungkyunkwan University (SKKU); Samsung Medical Center; Kongju National
   University; Ewha Womans University; Ewha Womans University; Ewha Womans
   University; Seoul National University (SNU)
RP Koo, SK (corresponding author), Natl Inst Hlth, Ctr Biomed Sci, Div Intractable Dis, Osong Hlth Technol Adm Complex 643, Cheongwon Gun 363951, Chungcheongbuk, South Korea.
EM bochoi@skku.edu; skkoo@nih.go.kr
RI Chae, Jong/J-5683-2012
FU Korea National Institute of Health; Korea National Institute of Health
   [4800-4845-302-210-13 (2012-N61001-00), 4800-4861-307-210-13
   (2012-NG61004-00)]; Basic Science Research Program through the National
   Research Foundation (NRF) - Ministry of Education [2011-0021533]; Korean
   Health Technology R&D Project, Ministry of Health and Welfare, Republic
   of Korea [A120182]
FX This work was supported by the Korea National Institute of Health
   intramural research program 4800-4845-302-210-13 (2012-N61001-00) and
   4800-4861-307-210-13 (2012-NG61004-00), the Basic Science Research
   Program through the National Research Foundation (NRF) funded by the
   Ministry of Education (2011-0021533), and the Korean Health Technology
   R&D Project, Ministry of Health and Welfare, Republic of Korea
   (A120182).
CR Birouk N, 1998, NEUROLOGY, V50, P1074, DOI 10.1212/WNL.50.4.1074
   Choi BO, 2013, NEUROGENETICS, V14, P35, DOI 10.1007/s10048-012-0346-5
   Choi BO, 2012, HUM MUTAT, V33, P1610, DOI 10.1002/humu.22143
   Dündar H, 2012, PEDIATR NEUROL, V46, P172, DOI 10.1016/j.pediatrneurol.2011.12.006
   Greaves LC, 2012, J PATHOL, V226, P274, DOI 10.1002/path.3028
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   Hartley JN, 2012, CASE REP PEDIAT, V2012, DOI 10.1155/2012/303096
   Hong D, 2011, NUCLEIC ACIDS RES, V39, pD883, DOI 10.1093/nar/gkq1101
   Hudson G, 2005, NEUROLOGY, V64, P371, DOI 10.1212/01.WNL.0000149767.51152.83
   Korhonen JA, 2008, J MOL BIOL, V377, P691, DOI 10.1016/j.jmb.2008.01.035
   KOSKINEN T, 1994, J NEUROL SCI, V121, P50, DOI 10.1016/0022-510X(94)90156-2
   KOSKINEN T, 1994, MUSCLE NERVE, V17, P509, DOI 10.1002/mus.880170507
   Lönnqvist T, 2009, BRAIN, V132, P1553, DOI 10.1093/brain/awp045
   Nikali K, 2005, HUM MOL GENET, V14, P2981, DOI 10.1093/hmg/ddi328
   Park CB, 2011, J CELL BIOL, V193, P809, DOI 10.1083/jcb.201010024
   Sanchez-Martinez A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043954
   Sarzi E, 2007, ANN NEUROL, V62, P579, DOI 10.1002/ana.21207
   Shy ME, 2005, NEUROLOGY, V64, P1209, DOI 10.1212/01.WNL.0000156517.00615.A3
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   Van Hove JLK, 2009, AM J MED GENET A, V149A, P861, DOI 10.1002/ajmg.a.32731
   Woo HM, 2013, BMC MED GENET, V14, DOI 10.1186/1471-2350-14-72
   Zeviani M, 2004, BRAIN, V127, P2153, DOI 10.1093/brain/awh259
NR 23
TC 8
Z9 9
U1 2
U2 13
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1364-6745
EI 1364-6753
J9 NEUROGENETICS
JI Neurogenetics
PD AUG
PY 2014
VL 15
IS 3
BP 171
EP 182
DI 10.1007/s10048-014-0405-1
PG 12
WC Genetics & Heredity; Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Neurosciences & Neurology
GA AM5JE
UT WOS:000339892700005
PM 24816431
OA Green Published, hybrid
DA 2024-11-01
ER

PT J
AU Ferrari, G
   Lamantea, E
   Donati, A
   Filosto, M
   Briem, E
   Carrara, F
   Parini, R
   Simonati, A
   Santer, R
   Zeviani, M
AF Ferrari, G
   Lamantea, E
   Donati, A
   Filosto, M
   Briem, E
   Carrara, F
   Parini, R
   Simonati, A
   Santer, R
   Zeviani, M
TI Infantile hepatocerebral syndromes associated with mutations in the
   mitochondrial DNA polymerase-γA
SO BRAIN
LA English
DT Article
DE POLG; mitochondrial DNA polymerase; Alpers' hepatopathic poliodystrophy;
   valproate toxicity; mtDNA depletion
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; DIFFUSE CEREBRAL DEGENERATION;
   AUTOSOMAL-DOMINANT; POLG MUTATIONS; MULTIPLE DELETIONS; THYMIDINE
   KINASE; DEPLETION; QUANTIFICATION; DISORDERS; MYOPATHY
AB We studied nine infant patients with a combination of progressive neurological and hepatic failure. Eight children, including two sibling pairs and four singletons, were affected by Alpers' hepatopathic poliodystrophy. A ninth baby patient suffered of a severe floppy infant syndrome associated with liver failure. Analysis of POLG1, the gene encoding the catalytic subunit of mitochondrial DNA polymerase, revealed that all the patients carried different allelic mutations in this gene. POLG1 is a major disease gene in mitochondrial disorders. Mutations in this gene can be associated with multiple deletions, depletion or point mutations of mitochondrial DNA (mtDNA). In turn, these different molecular phenotypes dictate an extremely heterogeneous spectrum of clinical outcomes, ranging from adult-onset progressive ophthalmoplegia to juvenile ataxic syndromes with epilepsy, to rapidly fatal hepatocerebral presentations, including Alpers' syndrome.
C1 Natl Neurol Inst Carlo Besta, Unit Mol Neurogenet, Pierfranco & Luisa Mariani Ctr Study Childrens Mi, I-20126 Milan, Italy.
   Meyer Childrens Hosp, Unit Child Neurol, Florence, Italy.
   Univ Verona, Inst Neurol, I-37100 Verona, Italy.
   Univ Hosp, Pediat Unit, Pierfranco & Luisa Mariani Ctr Study Childrens Me, Monza, Italy.
   Univ Hamburg, Childrens Hosp, Hamburg, Germany.
C3 Fondazione IRCCS Istituto Neurologico Carlo Besta; University of
   Florence; Azienda Ospedaliera Universitaria (AOU) MEYER; University of
   Verona; University of Hamburg; University Medical Center
   Hamburg-Eppendorf
RP Natl Neurol Inst Carlo Besta, Unit Mol Neurogenet, Pierfranco & Luisa Mariani Ctr Study Childrens Mi, Via Temolo 4, I-20126 Milan, Italy.
EM zeviani@istituto-besta.it
RI Parini, Rossella/J-9202-2018; Filosto, Massimiliano/S-9446-2019;
   Zeviani, Massimo/K-2891-2014; Lamantea, Eleonora/J-8339-2016
OI Ferrari, Giovanfrancesco/0000-0001-8864-0771; Filosto,
   Massimiliano/0000-0002-2852-7512; parini, rossella/0000-0003-4505-1306;
   Lamantea, Eleonora/0000-0001-5090-6028; Zeviani,
   Massimo/0000-0002-9067-5508
FU Telethon [GGP030039] Funding Source: Medline
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   BLACKWOOD W, 1963, ARCH DIS CHILD, V38, P193, DOI 10.1136/adc.38.199.193
   Bugiani M, 2004, BBA-BIOENERGETICS, V1659, P136, DOI 10.1016/j.bbabio.2004.09.006
   Di Fonzo A, 2003, HUM MUTAT, V22, DOI 10.1002/humu.9203
   Divi RL, 2004, AIDS, V18, P1013, DOI 10.1097/00002030-200404300-00009
   Filosto M, 2004, ACTA NEUROPATHOL, V108, P168, DOI 10.1007/s00401-004-0872-9
   Flemming K, 2002, AM J NEURORADIOL, V23, P1421
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   He LP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf067
   HUTTENLOCHER PR, 1976, ARCH NEUROL-CHICAGO, V33, P186, DOI 10.1001/archneur.1976.00500030042009
   Janes MS, 2004, J HISTOCHEM CYTOCHEM, V52, P1011, DOI 10.1369/jhc.3a6209.2004
   Jazayeri M, 2003, J BIOL CHEM, V278, P9823, DOI 10.1074/jbc.M211730200
   Lamantea E, 2004, ANN NEUROL, V56, P454, DOI 10.1002/ana.20219
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Moslemi AR, 1999, NEUROLOGY, V53, P79, DOI 10.1212/WNL.53.1.79
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Naviaux RK, 1999, ANN NEUROL, V45, P54, DOI 10.1002/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B
   Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200
   Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490
   Rovio AT, 2001, NAT GENET, V29, P261, DOI 10.1038/ng759
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   SERVIDEI S, 1991, NEUROLOGY, V41, P1053, DOI 10.1212/WNL.41.7.1053
   Simonati A, 2003, ACTA NEUROPATHOL, V106, P57, DOI 10.1007/s00401-003-0698-x
   Simonati A, 2003, J NEUROL, V250, P702, DOI 10.1007/s00415-003-1065-5
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   Tesarova M, 2004, NEUROPEDIATRICS, V35, P217, DOI 10.1055/s-2004-821081
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, HUM MUTAT, V22, P175, DOI 10.1002/humu.10246
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   von Wurmb-Schwark N, 2002, FORENSIC SCI INT, V126, P34, DOI 10.1016/S0379-0738(02)00026-9
   Walker UA, 2004, HEPATOLOGY, V39, P311, DOI 10.1002/hep.20074
   WINTERTHUN S, 2005, IN PRESS NEUROLOGY
   Wright DK., 1990, PCR PROTOCOLS GUIDE, P153
   ZEVIANI M, 1990, AM J HUM GENET, V47, P904
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 40
TC 238
Z9 246
U1 0
U2 11
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 1460-2156
J9 BRAIN
JI Brain
PD APR
PY 2005
VL 128
BP 723
EP 731
DI 10.1093/brain/awh410
PN 4
PG 9
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 911BV
UT WOS:000227977200010
PM 15689359
OA Bronze
DA 2024-11-01
ER

PT J
AU Sun, JY
   Su, WW
   Deng, JW
   Qin, Y
   Wang, ZX
   Liu, YH
AF Sun, Jiayu
   Su, Wenwen
   Deng, Jianwen
   Qin, Yao
   Wang, Zhaoxia
   Liu, Yuhe
TI DNA2 mutation causing multisystemic disorder with impaired mitochondrial
   DNA maintenance
SO JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID REPLICATION; MYOPATHY; REVEALS; DISEASE; VARIANT; REPAIR
AB Purpose To describe a novel DNA2 variant contributing to defects in mtDNA maintenance and mtDNA depletion syndrome (MDS), and the clinical and histological findings associated with this variation. Methods Herein, we describe the case of a patient who presented with hearing loss and myopathy, given the family history of similar findings in the father, was evaluated by sequencing of the deafness gene panel, mitochondrial genome, and the exome. Furthermore, tissue staining, mtDNA copy number detection, mtDNA sequencing, and long-range polymerase chain reaction tests were also conducted on the muscle biopsy specimen. In vitro experiments, including analyses of the mtDNA copy number; levels of ATP, ATPase, and reactive oxygen species (ROS); and the membrane potential, were performed. Results The DNA2 heterozygous truncating variant c. 2368C > T (p.Q790X) was identified and verified as the cause of an mtDNA copy number decrement in both functional experiments and muscle tissue analyses. These changes were accompanied by reductions in ATP, ATPase, and ROS levels. Conclusion The DNA2 variant was a likely cause of MDS in this patient. These findings expand the mutational spectrum of MDS and improve our understanding of the functions of DNA2 by revealing its novel role in mtDNA maintenance.
C1 [Sun, Jiayu; Su, Wenwen; Qin, Yao; Liu, Yuhe] Peking Univ, Dept Otolaryngol Head & Neck Surg, Hosp 1, Beijing, Peoples R China.
   [Sun, Jiayu; Liu, Yuhe] Capital Med Univ, Beijing Friendship Hosp, Dept Otolaryngol Head & Neck Surg, Beijing, Peoples R China.
   [Sun, Jiayu] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Otolaryngol Head & Neck Surg, Sch Med, Shanghai, Peoples R China.
   [Deng, Jianwen; Wang, Zhaoxia] Peking Univ, Dept Neurol, Hosp 1, Beijing, Peoples R China.
C3 Peking University; Capital Medical University; Shanghai Jiao Tong
   University; Peking University
RP Liu, YH (corresponding author), Peking Univ, Dept Otolaryngol Head & Neck Surg, Hosp 1, Beijing, Peoples R China.; Liu, YH (corresponding author), Capital Med Univ, Beijing Friendship Hosp, Dept Otolaryngol Head & Neck Surg, Beijing, Peoples R China.
EM liuyuhefeng@163.com
RI Liu, Yuhe/B-1558-2015; su, wenwen/AGQ-0661-2022; SUN,
   JIAYU/ABD-1772-2020; Zhao, Wensi/JDW-1266-2023; li, fangyu/KCY-0521-2024
OI Deng, Jianwen/0000-0003-1206-1778
FU National Natural Science Foundation of China [82071070]; Beijing
   Municipal Science& Technology Commission [Z191100006619027]
FX This project was supported by the National Natural Science Foundation of
   China (Grant numbers 82071070); Beijing Municipal Science& Technology
   Commission (No. Z191100006619027).
CR Almannai M, 2018, ESSAYS BIOCHEM, V62, P297, DOI 10.1042/EBC20170101
   Bai RK, 2004, ANN NY ACAD SCI, V1011, P304, DOI 10.1196/annals.1293.029
   Chae JH, 2015, J MED GENET, V52, P208, DOI 10.1136/jmedgenet-2014-102819
   Chazotte Brad, 2011, Cold Spring Harb Protoc, V2011, DOI 10.1101/pdb.prot065490
   Copeland WC, 2014, DNA REPAIR, V19, P190, DOI 10.1016/j.dnarep.2014.03.010
   Duxin JP, 2012, J BIOL CHEM, V287, P21980, DOI 10.1074/jbc.M112.359018
   Duxin JP, 2009, MOL CELL BIOL, V29, P4274, DOI 10.1128/MCB.01834-08
   El-Hattab AW, 2017, BBA-MOL BASIS DIS, V1863, P1539, DOI 10.1016/j.bbadis.2017.02.017
   El-Hattab A, 2013, NEUROTHERAPEUTICS, V10, P186, DOI 10.1007/s13311-013-0177-6
   González-del Angel A, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.01049
   Gorman GS, 2016, NAT REV DIS PRIMERS, V2, P1, DOI 10.1038/nrdp.2016.80
   Hu JZ, 2012, CELL, V149, P1221, DOI 10.1016/j.cell.2012.04.030
   Karanja KK, 2012, CELL CYCLE, V11, P3983, DOI 10.4161/cc.22215
   Kumar S, 2013, GENE DEV, V27, P313, DOI 10.1101/gad.204750.112
   Li ZK, 2018, EMBO J, V37, DOI 10.15252/embj.201796729
   Lin WQ, 2013, EMBO J, V32, P1425, DOI 10.1038/emboj.2013.88
   Markiewicz-Potoczny M, 2018, GENETICS, V209, P129, DOI 10.1534/genetics.118.300809
   Ng YS, 2021, LANCET NEUROL, V20, P573, DOI 10.1016/S1474-4422(21)00098-3
   Phowthongkum P, 2017, NEUROMUSCULAR DISORD, V27, P616, DOI 10.1016/j.nmd.2017.03.013
   Pinto M, 2014, BBA-MOL BASIS DIS, V1842, P1198, DOI 10.1016/j.bbadis.2013.11.012
   Ronchi D, 2019, ANN CLIN TRANSL NEUR, V6, P1893, DOI 10.1002/acn3.50888
   Ronchi D, 2013, AM J HUM GENET, V92, P293, DOI 10.1016/j.ajhg.2012.12.014
   Shaheen R, 2014, GENOME RES, V24, P291, DOI 10.1101/gr.160572.113
   Tarnauskaite Z, 2019, HUM MUTAT, V40, P1063, DOI 10.1002/humu.23776
   Uusimaa J, 2004, PEDIATRICS, V114, P443, DOI 10.1542/peds.114.2.443
   van Gisbergen MW, 2015, MUTAT RES-REV MUTAT, V764, P16, DOI 10.1016/j.mrrev.2015.01.001
   Zheng L, 2008, MOL CELL, V32, P325, DOI 10.1016/j.molcel.2008.09.024
   Zhong L, 2014, CURR MOL MED, V14, P1273, DOI 10.2174/1566524014666141202161326
NR 28
TC 3
Z9 3
U1 0
U2 5
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 1434-5161
EI 1435-232X
J9 J HUM GENET
JI J. Hum. Genet.
PD DEC
PY 2022
VL 67
IS 12
BP 691
EP 699
DI 10.1038/s10038-022-01075-4
EA SEP 2022
PG 9
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 6L0YV
UT WOS:000850047900001
PM 36064591
OA hybrid, Green Published
DA 2024-11-01
ER

PT J
AU Muqit, MMK
   Larner, AJ
   Sweeney, MG
   Sewry, C
   Stinton, VJ
   Davis, MB
   Healy, DG
   Payne, SJ
   Chotai, K
   Wood, NW
   Lane, RJM
AF Muqit, M. M. K.
   Larner, A. J.
   Sweeney, M. G.
   Sewry, C.
   Stinton, V. J.
   Davis, M. B.
   Healy, D. G.
   Payne, S. J.
   Chotai, K.
   Wood, N. W.
   Lane, R. J. M.
TI Multiple mitochondrial DNA deletions in monozygotic twins with OPMD
SO JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
LA English
DT Article
ID OCULOPHARYNGEAL MUSCULAR-DYSTROPHY; PROGRESSIVE EXTERNAL
   OPHTHALMOPLEGIA; HUMAN SKELETAL-MUSCLE; NUCLEAR INCLUSIONS;
   ABNORMALITIES; EXPANSIONS; MUTATIONS; DISEASE
AB Background: Oculopharyngeal muscular dystrophy (OPMD) is caused by expansions of the poly (A) binding protein 2 (PABP2) gene. Previous histological analyses have revealed mitochondrial abnormalities in the muscles of OPMD patients but their significance remains uncertain.
   Objective: We had the rare opportunity to study monozygotic twins with identical expansions of the PABP2 gene but with markedly different severities of OPMD. Both had histological features of mitochondrial myopathy. We determined whether mitochondrial DNA abnormalities underlay these changes.
   Methods: Clinical information was obtained by history and examination. Muscle biopsies were obtained from each subject and genetic analysis was performed using long-range PCR and Southern blotting.
   Results: We demonstrate, for the first time, the presence of mitochondrial DNA (mtDNA) deletions by Southern blotting in individuals with OPMD. This correlates with the presence of mitochondrial myopathy in both twins. Moreover, both twins had different mtDNA deletions, which might explain their phenotypic differences.
   Conclusion: We hypothesise that mitochondrial dysfunction may occur as a consequence of PABP2 gene mutations, and that this dysfunction may affect the phenotypic manifestations of OPMD.
C1 [Muqit, M. M. K.; Larner, A. J.; Lane, R. J. M.] Univ London Imperial Coll Sci Technol & Med, Div Clin Neurosci & Psychol Med, London SW7 2AZ, England.
   [Muqit, M. M. K.; Sweeney, M. G.; Stinton, V. J.; Davis, M. B.; Healy, D. G.; Wood, N. W.] Inst Neurol, Dept Mol Neurosci, London WC1N 3BG, England.
   [Larner, A. J.] Walton Ctr Neurol & Neurosurg, Liverpool, Merseyside, England.
   [Sewry, C.] Hammersmith Hosp, Dubowitz Neuromuscular Unit, Dept Paediat, London, England.
   [Payne, S. J.; Chotai, K.] Northwick Pk & St Marks NHS Trust, Kennedy Galton Ctr, London, England.
C3 Imperial College London; University of London; University College
   London; Walton Centre; Imperial College London
RP Lane, RJM (corresponding author), Charing Cross Hosp, Div Clin Neurosci & Psychol Med, Fulham Pl Rd, London W6 8RF, England.
EM r.lane@imperial.ac.uk
RI ; Wood, Nicholas/C-2505-2009
OI Muqit, Miratul/0000-0001-9733-2404; Wood, Nicholas/0000-0002-9500-3348
CR Blumen SC, 1999, ANN NEUROL, V46, P115, DOI 10.1002/1531-8249(199907)46:1<115::AID-ANA17>3.0.CO;2-O
   Brais B, 1998, NAT GENET, V18, P164, DOI 10.1038/ng0298-164
   Bua E, 2006, AM J HUM GENET, V79, P469, DOI 10.1086/507132
   Calado A, 2000, HUM MOL GENET, V9, P2321, DOI 10.1093/oxfordjournals.hmg.a018924
   Dreyfus M, 2002, CELL, V111, P611, DOI 10.1016/S0092-8674(02)01137-6
   Fayet G, 2002, NEUROMUSCULAR DISORD, V12, P484, DOI 10.1016/S0960-8966(01)00332-7
   Jansson M, 2000, ACTA NEUROPATHOL, V100, P23, DOI 10.1007/s004010051188
   JULIEN J, 1974, J NEUROL SCI, V21, P165, DOI 10.1016/0022-510X(74)90067-7
   Lezza AMS, 1997, FEBS LETT, V418, P167, DOI 10.1016/S0014-5793(97)01374-4
   MITSUMOTO H, 1992, MUSCLE NERVE, V15, P1210
   OLDFORS AR, 2005, NEUROLOGY, V66, P49
   PAUZNER R, 1991, MUSCLE NERVE, V14, P947, DOI 10.1002/mus.880141004
   Pesce V, 2001, FREE RADICAL BIO MED, V30, P1223, DOI 10.1016/S0891-5849(01)00517-2
   PRATT MF, 1986, LARYNGOSCOPE, V96, P368
   Rowland LP, 1997, NEUROMUSCULAR DISORD, V7, pS15, DOI 10.1016/S0960-8966(97)00076-X
   SCHRODER JM, 1995, NEUROPATH APPL NEURO, V21, P68, DOI 10.1111/j.1365-2990.1995.tb01030.x
   TOME FMS, 1980, ACTA NEUROPATHOL, V49, P85, DOI 10.1007/BF00692226
   Van Goethem G, 2003, NEUROMOL MED, V3, P129, DOI 10.1385/NMM:3:3:129
   VICTOR M, 1962, NEW ENGL J MED, V267, P1267, DOI 10.1056/NEJM196212202672501
   Wong KT, 1996, NEUROMUSCULAR DISORD, V6, P163, DOI 10.1016/0960-8966(95)00039-9
   YUSAKI M, 1989, BIOCHEM BIOPH RES CO, V164, P1352
NR 21
TC 11
Z9 12
U1 0
U2 0
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-3050
J9 J NEUROL NEUROSUR PS
JI J. Neurol. Neurosurg. Psychiatry
PD JAN
PY 2008
VL 79
IS 1
BP 68
EP 71
DI 10.1136/jnnp.2006.112250
PG 4
WC Clinical Neurology; Psychiatry; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Psychiatry; Surgery
GA 240ZD
UT WOS:000251625800019
PM 17550990
DA 2024-11-01
ER

PT J
AU Melberg, A
   Moslemi, AR
   Palm, O
   Raininko, R
   Stålberg, E
   Oldfors, A
AF Melberg, Atle
   Moslemi, Ali-Reza
   Palm, Oscar
   Raininko, Raili
   Stalberg, Erik
   Oldfors, Anders
TI A patient with two mitochondrial DNA mutations causing PEO and LHON
SO EUROPEAN JOURNAL OF MEDICAL GENETICS
LA English
DT Article
DE Progressive external ophthalmoplegia (PEO); Leber hereditary optic
   neuropathy (LHON); Point mutation; Deletion; Mitochondrial DNA
ID HEREDITARY OPTIC NEUROPATHY; PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA;
   DELETIONS; ATROPHY
AB We report a 22-year-old man with PEO and optic atrophy. PEO developed before the onset of optic atrophy. The patient showed mitochondrial myopathy with cytochrome c oxidase deficient fibers. In skeletal muscle the patient was homoplasmic for the mtDNA G11778A Leber hereditary optic neuropathy (LHON) mutation and heteroplasmic for the mtDNA 5 kb "common" deletion mutation. In blood only the homoplasmic LHON mutation was identified.
   The occurrence of two pathogenic mtDNA mutations is exceedingly rare. The clinical findings in this patient indicate that the combination of the two mtDNA mutations resulted in the expected combined phenotype since the mtDNA deletion mutation accounted for the PEO and the mtDNA G11778A point mutation for the optic atrophy. (C) 2008 Elsevier Masson SAS. All rights reserved.
C1 [Moslemi, Ali-Reza; Oldfors, Anders] Sahlgrens Univ Hosp, Dept Pathol, SE-41345 Gothenburg, Sweden.
   [Melberg, Atle; Stalberg, Erik] Univ Uppsala Hosp, Dept Neurosci, Uppsala, Sweden.
   [Raininko, Raili] Univ Uppsala Hosp, Dept Radiol, Uppsala, Sweden.
   [Palm, Oscar] Karlstad Hosp, Dept Ophthalmol, Karlstad, Sweden.
C3 Sahlgrenska University Hospital; Uppsala University; Uppsala University
   Hospital; Uppsala University; Uppsala University Hospital
RP Oldfors, A (corresponding author), Sahlgrens Univ Hosp, Dept Pathol, SE-41345 Gothenburg, Sweden.
EM anders.oldfors@gu.se
FU Selander Foundation; Swedish Association of the Neurologically Disabled;
   Swedish Medical Research Council [7122]
FX This study was supported by the Selander Foundation, the Swedish
   Association of the Neurologically Disabled, and the Swedish Medical
   Research Council (proj no 7122).
CR Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   Hudson G, 2008, BRAIN, V131, P329, DOI 10.1093/brain/awm272
   Kovács GG, 2005, BRAIN, V128, P35, DOI 10.1093/brain/awh310
   LARSSON NG, 1991, ANN NEUROL, V30, P701, DOI 10.1002/ana.410300511
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Moslemi AR, 2000, CARDIOLOGY, V94, P68, DOI 10.1159/000007049
   Moslemi AR, 1999, NEUROLOGY, V53, P79, DOI 10.1212/WNL.53.1.79
   Ohno K, 1996, ANN NEUROL, V39, P761, DOI 10.1002/ana.410390612
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
NR 9
TC 4
Z9 5
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1769-7212
EI 1878-0849
J9 EUR J MED GENET
JI Eur. J. Med. Genet.
PD JAN-FEB
PY 2009
VL 52
IS 1
BP 47
EP 48
DI 10.1016/j.ejmg.2008.10.004
PG 2
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 403ND
UT WOS:000263088400010
PM 19015050
DA 2024-11-01
ER

PT J
AU Tyynismaa, H
   Sun, R
   Ahola-Erkkilä, S
   Almusa, H
   Pöyhönen, R
   Korpela, M
   Honkaniemi, J
   Isohanni, P
   Paetau, A
   Wang, LY
   Suomalainen, A
AF Tyynismaa, Henna
   Sun, Ren
   Ahola-Erkkila, Sofia
   Almusa, Henrikki
   Poyhonen, Rosanna
   Korpela, Mari
   Honkaniemi, Jari
   Isohanni, Pirjo
   Paetau, Anders
   Wang, Liya
   Suomalainen, Anu
TI Thymidine kinase 2 mutations in autosomal recessive progressive external
   ophthalmoplegia with multiple mitochondrial DNA deletions
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID TWINKLE MUTATIONS; MTDNA DEPLETION; PROTEIN; GENE; ENCEPHALOPATHY;
   SPECIFICITY; DISORDER; MYOPATHY; POLG
AB Autosomal-inherited progressive external ophthalmoplegia (PEO) is an adult-onset disease characterized by the accumulation of multiple mitochondrial DNA (mtDNA) deletions in post-mitotic tissues. Mutations in six different genes have been described to cause the autosomal dominant form of the disease, but only mutations in the DNA polymerase gamma gene are known to cause autosomal recessive PEO (arPEO), leaving the genetic background of arPEO mostly unknown. Here we used whole-exome sequencing and identified compound heterozygous mutations, leading to two amino acid alterations R225W and a novel T230A in thymidine kinase 2 (TK2) in arPEO patients. TK2 is an enzyme of the mitochondrial nucleotide salvage pathway and its loss-of-function mutations have previously been shown to underlie the early-infantile myopathic form of mtDNA depletion syndrome (MDS). Our TK2 activity measurements of patient fibroblasts and mutant recombinant proteins show that the combination of the identified arPEO variants, R225W and T230A, leads to a significant reduction in TK2 activity, consistent with the late-onset phenotype, whereas homozygosity for R225W, previously associated with MDS, leads to near-total loss of activity. Our finding identifies a new genetic cause of arPEO with multiple mtDNA deletions. Furthermore, MDS and multiple mtDNA deletion disorders are manifestations of the same pathogenic pathways affecting mtDNA replication and repair, indicating that MDS-associated genes should be studied when searching for genetic background of PEO disorders.
C1 [Tyynismaa, Henna; Ahola-Erkkila, Sofia; Poyhonen, Rosanna; Isohanni, Pirjo; Suomalainen, Anu] Biomedicum Helsinki, Res Programs Unit, Mol Neurol, Helsinki 00290, Finland.
   [Almusa, Henrikki; Suomalainen, Anu] Univ Helsinki, Inst Mol Med Finland FIMM, Helsinki 00290, Finland.
   [Paetau, Anders] Univ Helsinki, Dept Pathol, Helsinki 00290, Finland.
   [Sun, Ren; Wang, Liya] Biomed Ctr, SLU, Sect Vet Med Biochem, Dept Anat Physiol & Biochem, SE-75123 Uppsala, Sweden.
   [Korpela, Mari; Suomalainen, Anu] Helsinki Univ Cent Hosp, Dept Neurol, Helsinki 00290, Finland.
   [Honkaniemi, Jari] Tampere Univ Hosp, Tampere 33520, Finland.
C3 University of Helsinki; University of Helsinki; University of Helsinki;
   Swedish University of Agricultural Sciences; University of Helsinki;
   Helsinki University Central Hospital; Tampere University; Tampere
   University Hospital
RP Tyynismaa, H (corresponding author), Biomedicum Helsinki, Res Programs Unit, Mol Neurol, Haartmaninkatu 8, Helsinki 00290, Finland.
EM henna.tyynismaa@helsinki.fi
RI Ahola, Sofia/JEP-4595-2023; Tyynismaa, Henna/F-1428-2011; Honkaniemi,
   Jari/JZC-7949-2024
OI Ahola, Sofia/0000-0001-7552-4843; Suomalainen-Wartiovaara,
   Anu/0000-0003-4833-5195; Tyynismaa, Henna/0000-0002-2493-2422
FU Academy of Finland; Helsinki Biomedical Graduate School; Sigrid Juselius
   Foundation; University of Helsinki; Swedish Research Council; Swedish
   Research Council for Environment, Agricultural Sciences and Spatial
   Planning
FX This work was supported by the Academy of Finland (to H. T. and A. S.),
   Helsinki Biomedical Graduate School (to S.A.-E.), Sigrid Juselius
   Foundation and University of Helsinki (to A. S.), the Swedish Research
   Council and partly by a grant from the Swedish Research Council for
   Environment, Agricultural Sciences and Spatial Planning (to L.W.).
CR Barroso JF, 2005, BIOCHEMISTRY-US, V44, P4886, DOI 10.1021/bi047766m
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Goffart S, 2009, HUM MOL GENET, V18, P328, DOI 10.1093/hmg/ddn359
   González-Vioque E, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002035
   Götz A, 2008, BRAIN, V131, P2841, DOI 10.1093/brain/awn236
   Götz A, 2011, AM J HUM GENET, V88, P635, DOI 10.1016/j.ajhg.2011.04.006
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   Hazra S, 2010, J MED CHEM, V53, P5792, DOI 10.1021/jm1005379
   Hudson G, 2008, BRAIN, V131, P329, DOI 10.1093/brain/awm272
   Isohanni P, 2011, NEUROLOGY, V76, P811, DOI 10.1212/WNL.0b013e31820e7b25
   Johansson K, 2001, NAT STRUCT BIOL, V8, P616, DOI 10.1038/89661
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kawamata H, 2011, HUM MOL GENET, V20, P2964, DOI 10.1093/hmg/ddr200
   Knecht W, 2002, EMBO J, V21, P1873, DOI 10.1093/emboj/21.7.1873
   Krishnan KJ, 2008, NAT GENET, V40, P275, DOI 10.1038/ng.f.94
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   López LC, 2009, HUM MOL GENET, V18, P714, DOI 10.1093/hmg/ddn401
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Melberg A, 1996, MUSCLE NERVE, V19, P751
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   MUNCHPETERSEN B, 1991, J BIOL CHEM, V266, P9032
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Oskoui M, 2006, ARCH NEUROL-CHICAGO, V63, P1122, DOI 10.1001/archneur.63.8.1122
   Pagliarini DJ, 2008, CELL, V134, P112, DOI 10.1016/j.cell.2008.06.016
   Palacino JJ, 2004, J BIOL CHEM, V279, P18614, DOI 10.1074/jbc.M401135200
   Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274
   Poulton Joanna, 2009, Neuromuscul Disord, V19, P439, DOI 10.1016/j.nmd.2009.04.009
   Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   SERVIDEI S, 1991, NEUROLOGY, V41, P1053, DOI 10.1212/WNL.41.7.1053
   Shaibani A, 2009, ARCH NEUROL-CHICAGO, V66, P1028, DOI 10.1001/archneurol.2009.139
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   Suomalainen A, 2010, NEUROMUSCULAR DISORD, V20, P429, DOI 10.1016/j.nmd.2010.03.017
   Tulinius M, 2005, NEUROMUSCULAR DISORD, V15, P412, DOI 10.1016/j.nmd.2005.03.010
   Tyynismaa H, 2009, AM J HUM GENET, V85, P290, DOI 10.1016/j.ajhg.2009.07.009
   Tzoulis C, 2009, ACTA NEUROL SCAND, V120, P38, DOI 10.1111/j.1600-0404.2009.01212.x
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Wang LY, 2003, J BIOL CHEM, V278, P6963, DOI 10.1074/jbc.M206143200
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 45
TC 68
Z9 78
U1 0
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD JAN 1
PY 2012
VL 21
IS 1
BP 66
EP 75
DI 10.1093/hmg/ddr438
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 859GO
UT WOS:000297865100007
PM 21937588
OA Bronze
DA 2024-11-01
ER

PT J
AU Zhou, Y
   Yi, JH
   Liu, L
   Wang, XP
   Dong, L
   Du, AL
AF Zhou, Ying
   Yi, Jianhua
   Liu, Li
   Wang, Xiaoping
   Dong, Liang
   Du, Ailian
TI Acute mitochondrial myopathy with respiratory insufficiency and motor
   axonal polyneuropathy
SO INTERNATIONAL JOURNAL OF NEUROSCIENCE
LA English
DT Article
DE Pure mitochondrial myopathy; lactic acidosis; respiratory failure; acute
   motor axonal neuropathy; pyrosequencing
ID MERRF MUTATION; GENE; DIAGNOSIS; DNA; FAILURE
AB Background: Mitochondrial myopathies (MMs) are mainly presented with chronic muscle weakness and accompanied with other syndromes. MM with acute respiratory insufficiency is rare. Aims: To reveal the clinical, pathological and molecular characteristics of a life-threatening MM. Methods: Muscle biopsy and enzyme staining were performed in skeletal muscles. Mitochondrial DNA (mtDNA) sequencing was analyzed and heteroplasmy were quantified by pyrosequencing. Results: All three patients had tachycardia, acute lactic acidosis, dyspnea and sudden severe muscle weakness. Two patients had calf edema and abdominal pain, and one had a heart attack. Electromyography in two patients showed dramatically decreased axonal amplitudes of motor nerves. Muscle biopsies showed ragged red fibers and dramatic mitochondrial abnormality. A mtDNA m.3243A>G mutation was identified in Patient 1 (mutation load: 29% in blood and 73% in muscle) and Patient 3 (79% in blood and 89% in muscle). A mtDNA m.8344A>G mutation was found in Patient 2 (mutation load 80.4% in blood). Conclusion: MM characterized by lactic acidosis, respiratory failure and acute motor axonal neuropathy is life threatening.
C1 [Zhou, Ying; Dong, Liang] Zhejiang Univ, Affiliated Hosp 2, Dept Cardiol, Sch Med, Hangzhou, Zhejiang, Peoples R China.
   [Yi, Jianhua] Zhejiang Univ, Affiliated Hosp 2, Dept Emergency Med, Sch Med, Hangzhou, Zhejiang, Peoples R China.
   [Liu, Li] Zhejiang Univ, Inst Genet, Coll Life Sci, Mitochondrial Dis Res Ctr, Hangzhou, Zhejiang, Peoples R China.
   [Wang, Xiaoping; Du, Ailian] Shanghai Jiao Tong Univ, Tongren Hosp, Dept Neurol, Sch Med, Shanghai, Peoples R China.
C3 Zhejiang University; Zhejiang University; Zhejiang University; Shanghai
   Jiao Tong University
RP Du, AL (corresponding author), Shanghai Jiao Tong Univ, Tongren Hosp, Dept Neurol, Sch Med, Shanghai, Peoples R China.
EM lotusdu@126.com
RI Wang, Xiao-Ping/J-3237-2015; zhang, yuhan/HLH-1222-2023; Yi,
   Jian/IUO-2019-2023
FU National Natural Science Foundation of China [81200967]; Shanghai
   Municipal Health and Family Planning Commission [201540050]
FX National Natural Science Foundation of China [grant number 81200967];
   Shanghai Municipal Health and Family Planning Commission [grant number
   201540050].
CR Amornvit Jakkrit, 2014, Journal of the Medical Association of Thailand, V97, P467
   Blakely EL, 2014, NEUROMUSCULAR DISORD, V24, P533, DOI 10.1016/j.nmd.2014.03.011
   Bruno C, 2003, J CHILD NEUROL, V18, P300, DOI 10.1177/08830738030180040401
   Catteruccia M, 2015, J NEUROL, V262, P701, DOI 10.1007/s00415-014-7632-0
   Houshmand M, 1996, HUM GENET, V97, P269, DOI 10.1007/BF02185750
   Kärppä M, 2003, J NEUROL, V250, P216, DOI 10.1007/s00415-003-0981-8
   Milone M, 2013, MOL GENET METAB, V110, P35, DOI 10.1016/j.ymgme.2013.07.007
   Pfeffer G, 2013, ANN MED, V45, P4, DOI 10.3109/07853890.2011.605389
   Rieder MJ, 1998, NUCLEIC ACIDS RES, V26, P967, DOI 10.1093/nar/26.4.967
   Rivera H, 2010, MITOCHONDRION, V10, P362, DOI 10.1016/j.mito.2010.03.003
   Steele HE, 2016, NEUROLOGY, V87, P1031, DOI 10.1212/WNL.0000000000003064
   Swalwell H, 2006, NEUROLOGY, V66, P447, DOI 10.1212/01.wnl.0000196490.36349.83
   SWEENEY MG, 1993, Q J MED, V86, P709
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   Yan JB, 2014, J MOL DIAGN, V16, P431, DOI 10.1016/j.jmoldx.2014.03.005
NR 15
TC 9
Z9 10
U1 0
U2 9
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0020-7454
EI 1563-5279
J9 INT J NEUROSCI
JI Int. J. Neurosci.
PY 2018
VL 128
IS 3
BP 231
EP 236
DI 10.1080/00207454.2017.1387113
PG 6
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA GA2GQ
UT WOS:000428135600004
PM 28969510
DA 2024-11-01
ER

PT J
AU Kiyomoto, BH
   Tengan, CH
   Costa, CK
   Oliveira, AS
   Schmidt, B
   Gabbai, AA
AF Kiyomoto, BH
   Tengan, CH
   Costa, CK
   Oliveira, AS
   Schmidt, B
   Gabbai, AA
TI Frequency of dystrophic muscle abnormalities in chronic progressive
   external ophthalmoplegia: analysis of 86 patients
SO JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
LA English
DT Article
ID MITOCHONDRIAL MYOPATHY; MUTATION; GENE; COMPLEX
AB Background: There are few reports describing the coexistence of dystrophic features with those typical of mitochondrial myopathies in muscle biopsy. A recent study suggested that dystrophic features are frequent in patients with chronic progressive external ophthalmoplegia ( CPEO) with a high mutation load, but the actual frequency of these abnormalities in CPEO remains undetermined.
   Objective: To review the occurrence of dystrophic abnormalities in a large series of patients with CPEO to assess the frequency of such abnormalities and to verify whether they are correlated with specific mitochondrial DNA ( mtDNA) mutations.
   Methods: Retrospective survey of case series ( 86 patients with CPEO).
   Results: Only three cases with dystrophic abnormalities were found: two with a large scale mtDNA deletion and one with the A3251G mutation. All three patients showed predominantly proximal muscular weakness resembling limb girdle muscular dystrophy.
   Conclusions: Dystrophic abnormalities are rare in CPEO and are not correlated with a specific molecular defect.
C1 Univ Fed Sao Paulo, Escola Paulista Med, Dept Neurol, BR-04039032 Sao Paulo, Brazil.
   Univ Fed Sao Paulo, Dept Pathol, BR-04039032 Sao Paulo, Brazil.
C3 Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Sao
   Paulo (UNIFESP)
RP Univ Fed Sao Paulo, Escola Paulista Med, Dept Neurol, Rua Pedro Toledo 781,Setimo Andar, BR-04039032 Sao Paulo, Brazil.
EM beatriz-neuro@pesquisa.epm.br
RI Tengan, Celia/D-8458-2013
CR BUSHBY KMD, 1995, NEUROMUSCULAR DISORD, V5, P71, DOI 10.1016/0960-8966(93)E0006-G
   COLLINS S, 1995, ACTA NEUROL SCAND, V91, P287, DOI 10.1111/j.1600-0404.1995.tb07007.x
   Horváth R, 2003, J MED GENET, V40, P752, DOI 10.1136/jmg.40.10.752
   Houshmand M, 1996, HUM GENET, V97, P269, DOI 10.1007/BF02185750
   Kiyomoto BH, 1997, J NEUROL SCI, V152, P160, DOI 10.1016/S0022-510X(97)00158-5
   LAFORET P, 1995, NEUROMUSCULAR DISORD, V5, P399, DOI 10.1016/0960-8966(94)00080-S
   Olsen DB, 2003, J NEUROL, V250, P1328, DOI 10.1007/s00415-003-0206-1
   Porter JD, 2001, NEUROMUSCULAR DISORD, V11, P197, DOI 10.1016/S0960-8966(00)00171-1
   REICHMANN H, 1993, ACTA NEUROPATHOL, V85, P679, DOI 10.1007/BF00334681
   SCHON EA, 1994, J BIOENERG BIOMEMBR, V26, P291, DOI 10.1007/BF00763100
   Schröder R, 2000, J NEUROPATH EXP NEUR, V59, P353, DOI 10.1093/jnen/59.5.353
   Shoffner JM, 1999, ANN NY ACAD SCI, V893, P42, DOI 10.1111/j.1749-6632.1999.tb07817.x
   SWEENEY MG, 1993, Q J MED, V86, P709
   Vissing J, 1998, NEUROLOGY, V50, P1875, DOI 10.1212/WNL.50.6.1875
NR 14
TC 7
Z9 8
U1 0
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-3050
EI 1468-330X
J9 J NEUROL NEUROSUR PS
JI J. Neurol. Neurosurg. Psychiatry
PD APR
PY 2006
VL 77
IS 4
BP 541
EP 543
DI 10.1136/jnnp.2005.079954
PG 3
WC Clinical Neurology; Psychiatry; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Psychiatry; Surgery
GA 031JT
UT WOS:000236701400030
PM 16543540
OA Green Published
DA 2024-11-01
ER

PT J
AU Siibak, T
   Clemente, P
   Bratic, A
   Bruhn, H
   Kauppila, TES
   Macao, B
   Schober, FA
   Lesko, N
   Wibom, R
   Naess, K
   Nennesmo, I
   Wedell, A
   Peter, B
   Freyer, C
   Falkenberg, M
   Wredenberg, A
AF Siibak, Triinu
   Clemente, Paula
   Bratic, Ana
   Bruhn, Helene
   Kauppila, Timo E. S.
   Macao, Bertil
   Schober, Florian A.
   Lesko, Nicole
   Wibom, Rolf
   Naess, Karin
   Nennesmo, Inger
   Wedell, Anna
   Peter, Bradley
   Freyer, Christoph
   Falkenberg, Maria
   Wredenberg, Anna
TI A multi-systemic mitochondrial disorder due to a dominant p.Y955H
   disease variant in DNA polymerase gamma
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; KEARNS-SAYRE SYNDROME;
   SACCHAROMYCES-CEREVISIAE; MTDNA DELETIONS; MUTATIONS; REPLICATION;
   FIDELITY; DEFECTS; CELLS; POLG
AB Mutations in the mitochondrial DNA polymerase, POLG, are associated with a variety of clinical presentations, ranging from early onset fatal brain disease in Alpers syndrome to chronic progressive external ophthalmoplegia. The majority of mutations are linked with disturbances of mitochondrial DNA (mtDNA) integrity and maintenance. On a molecular level, depending on their location within the enzyme, mutations either lead to mtDNA depletion or the accumulation of multiple mtDNA deletions, and in some cases these molecular changes can be correlated to the clinical presentation. We identified a patient with a dominant p.Y955H mutation in POLG, presenting with a severe, early-onset multi-systemic mitochondrial disease with bilateral sensorineural hearing loss, cataract, myopathy, and liver failure. Using a combination of disease models of Drosophila melanogaster and in vitro biochemistry analysis, we compare the molecular consequences of the p.Y955H mutation to the well-documented p.Y955C mutation. We demonstrate that both mutations affect mtDNA replication and display a dominant negative effect, with the p.Y955H allele resulting in a more severe polymerase dysfunction.
C1 [Siibak, Triinu; Macao, Bertil; Peter, Bradley; Falkenberg, Maria] Univ Gothenburg, Dept Med Biochem & Cell Biol, Inst Biomed, SE-40530 Gothenburg, Sweden.
   [Clemente, Paula; Schober, Florian A.; Wedell, Anna; Freyer, Christoph; Wredenberg, Anna] Karolinska Inst, Max Planck Inst Biol Ageing Karolinska Inst Lab, Div Metab Dis, Dept Lab Med, SE-17177 Stockholm, Sweden.
   [Clemente, Paula; Bruhn, Helene; Schober, Florian A.; Lesko, Nicole; Wibom, Rolf; Naess, Karin; Freyer, Christoph; Wredenberg, Anna] Karolinska Inst, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden.
   [Bratic, Ana; Kauppila, Timo E. S.] Max Planck Inst Biol Ageing, Dept Mitochondrial Biol, D-50931 Cologne, Germany.
   [Bruhn, Helene; Lesko, Nicole; Wibom, Rolf; Naess, Karin; Wedell, Anna; Freyer, Christoph; Wredenberg, Anna] Karolinska Univ Hosp, Ctr Inherited Metab Dis, SE-17176 Stockholm, Sweden.
   [Nennesmo, Inger] Karolinska Univ Hosp, Dept Pathol, SE-17177 Stockholm, Sweden.
   [Wedell, Anna] Karolinska Inst, Dept Mol Med & Surg, SE-17176 Stockholm, Sweden.
   [Siibak, Triinu] Univ Cologne, Cologne Excellence Cluster Cellular Stress Respon, D-50931 Cologne, Germany.
C3 University of Gothenburg; Karolinska Institutet; Karolinska Institutet;
   Max Planck Society; Karolinska Institutet; Karolinska University
   Hospital; Karolinska Institutet; Karolinska University Hospital;
   Karolinska Institutet; University of Cologne
RP Falkenberg, M (corresponding author), Univ Gothenburg, Dept Med Biochem & Cell Biol, Inst Biomed, SE-40530 Gothenburg, Sweden.; Wredenberg, A (corresponding author), Karolinska Inst, Max Planck Inst Biol Ageing Karolinska Inst Lab, Div Metab Dis, Dept Lab Med, SE-17177 Stockholm, Sweden.; Wredenberg, A (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, SE-17177 Stockholm, Sweden.; Wredenberg, A (corresponding author), Karolinska Univ Hosp, Ctr Inherited Metab Dis, SE-17176 Stockholm, Sweden.
EM maria.falkenberg@medkem.gu.se; anna.wredenberg@ki.se
RI Clemente, Paula/AAA-5768-2021; Rosenberger, Florian/HLX-7402-2023
OI Naess, Karin/0000-0003-4310-7927; Falkenberg, Maria/0000-0001-8713-173X;
   Bruhn, Helene/0009-0007-4449-5382; Rosenberger,
   Florian/0000-0003-4604-6170; Freyer, Christoph/0000-0003-0418-1673;
   Wredenberg, Anna/0000-0002-2500-6121; Clemente,
   Paula/0000-0002-6885-3750
FU Swedish Research Council [VR521-2012-2571, VR521-2013-2341,
   VR521-2013-3621]; Stockholm County Council [K01762012, 20140053];
   Swedish Foundation for Strategic Research [ICA 12-0017]; Knut & Alice
   Wallenberg Foundation [KAW 2013.0026, KAW 2011, KAW 2014]; Swedish
   Cancer Foundation [CAN 2016/816]; European Research Council; Swedish
   Brain Foundation [FO2015-0146]
FX This study was supported by the Swedish Research Council [A.W.
   (VR521-2012-2571), A. We. (VR521-2013-2341) and M.F. (VR521-2013-3621)];
   Stockholm County Council [ A.W. (K01762012) and A. We. (20140053)];
   Swedish Foundation for Strategic Research [A.W. (ICA 12-0017)]; Knut &
   Alice Wallenberg Foundation [A.W. and A. We. (KAW 2013.0026) and M.F.
   (KAW 2011 and KAW 2014]); The Swedish Cancer Foundation [M.F. (CAN
   2016/816]; European Research Council [M.F.]; The Swedish Brain
   Foundation [A. We. (FO2015-0146)]. A.W. is a Ragnar Soderberg fellow in
   Medicine (M77/13). Funding to pay the Open Access publication charges
   for this article was provided by the Swedish Research Council
   (VR521-2012-2571).
CR Atanassova N, 2011, HUM MOL GENET, V20, P1212, DOI 10.1093/hmg/ddq565
   Baruffini E, 2006, HUM MOL GENET, V15, P2846, DOI 10.1093/hmg/ddl219
   BIRKY CW, 1994, J HERED, V85, P355, DOI 10.1093/oxfordjournals.jhered.a111480
   Bratic A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9808
   CLAYTON DA, 1992, INT REV CYTOL, V141, P217, DOI 10.1016/S0074-7696(08)62067-7
   Estep PA, 2011, BIOCHEMISTRY-US, V50, P6376, DOI 10.1021/bi200280r
   Falkenberg M, 2007, ANNU REV BIOCHEM, V76, P679, DOI 10.1146/annurev.biochem.76.060305.152028
   Freyer C, 2015, J MED GENET, V52, P779, DOI 10.1136/jmedgenet-2015-102986
   Gandhi VV, 2011, NUCLEOS NUCLEOT NUCL, V30, P317, DOI 10.1080/15257770.2011.586955
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   Graziewicz MA, 2007, HUM MOL GENET, V16, P2729, DOI 10.1093/hmg/ddm227
   Gustafsson CM, 2016, ANNU REV BIOCHEM, V85, P133, DOI 10.1146/annurev-biochem-060815-014402
   Huang J, 2009, P NATL ACAD SCI USA, V106, P8284, DOI 10.1073/pnas.0900641106
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kool ET, 2002, ANNU REV BIOCHEM, V71, P191, DOI 10.1146/annurev.biochem.71.110601.135453
   Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257
   Kurt B, 2010, ARCH NEUROL-CHICAGO, V67, P239, DOI 10.1001/archneurol.2009.332
   LARSSON NG, 1990, PEDIATR RES, V28, P131, DOI 10.1203/00006450-199028020-00011
   Lee YS, 2009, CELL, V139, P312, DOI 10.1016/j.cell.2009.07.050
   Lewis W, 2007, LAB INVEST, V87, P326, DOI 10.1038/labinvest.3700523
   Lim SE, 2003, J MOL BIOL, V329, P45, DOI 10.1016/S0022-2836(03)00405-4
   Longley MJ, 2001, J BIOL CHEM, V276, P38555, DOI 10.1074/jbc.M105230200
   Luoma PT, 2005, HUM MOL GENET, V14, P1907, DOI 10.1093/hmg/ddi196
   Macao B, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8303
   McClelland C, 2016, CURR NEUROL NEUROSCI, V16, DOI 10.1007/s11910-016-0652-7
   Merski M, 2013, J MED CHEM, V56, P2874, DOI 10.1021/jm301823g
   Merski M, 2012, P NATL ACAD SCI USA, V109, P16179, DOI 10.1073/pnas.1208076109
   Naess K, 2012, JIMD REP, V4, P67, DOI 10.1007/8904_2011_73
   Pagnamenta AT, 2006, HUM REPROD, V21, P2467, DOI 10.1093/humrep/del076
   Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200
   Qian YF, 2014, J BIOL CHEM, V289, P5970, DOI 10.1074/jbc.M113.526418
   SHOICHET BK, 1995, P NATL ACAD SCI USA, V92, P452, DOI 10.1073/pnas.92.2.452
   Song SW, 2005, P NATL ACAD SCI USA, V102, P4990, DOI 10.1073/pnas.0500253102
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Stranneheim H, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-1090
   Stuart GR, 2006, HUM MOL GENET, V15, P363, DOI 10.1093/hmg/ddi454
   Taylor RW, 2001, NUCLEIC ACIDS RES, V29, part. no., DOI 10.1093/nar/29.15.e74
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
   Uusimaa J, 2013, EPILEPSIA, V54, P1002, DOI 10.1111/epi.12115
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   VanGoethem G, 1997, EUR J NEUROL, V4, P476
   Young MJ, 2016, CURR OPIN GENET DEV, V38, P52, DOI 10.1016/j.gde.2016.03.005
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
   Zeviani M, 2004, BRAIN, V127, P2153, DOI 10.1093/brain/awh259
NR 44
TC 9
Z9 9
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD JUL 1
PY 2017
VL 26
IS 13
BP 2515
EP 2525
DI 10.1093/hmg/ddx146
PG 11
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA EX7WS
UT WOS:000403460700013
PM 28430993
OA Green Published, hybrid
DA 2024-11-01
ER

PT J
AU Rahman, S
   Copeland, WC
AF Rahman, Shamima
   Copeland, William C.
TI <i>POLG</i>-related disorders and their neurological manifestations
SO NATURE REVIEWS NEUROLOGY
LA English
DT Review
ID DNA-POLYMERASE-GAMMA; ACUTE LIVER-FAILURE; ENCEPHALOMYOPATHY
   (MNGIE)-LIKE PHENOTYPE; MITOCHONDRIAL POINT MUTATIONS; REFRACTORY STATUS
   EPILEPTICUS; IMPAIR MTDNA REPLICATION; ONSET ALPERS-SYNDROME; DISEASE
   MUTATIONS; W748S MUTATION; DECANOIC ACID
AB The POLG gene encodes the mitochondrial DNA polymerase that is responsible for replication of the mitochondrial genome. Mutations in POLG can cause early childhood mitochondrial DNA (mtDNA) depletion syndromes or later-onset syndromes arising from mtDNA deletions. POLG mutations are the most common cause of inherited mitochondrial disorders, with as many as 2% of the population carrying these mutations. POLG-related disorders comprise a continuum of overlapping phenotypes with onset from infancy to late adulthood. The six leading disorders caused by POLG mutations are Alpers-Huttenlocher syndrome, which is one of the most severe phenotypes; childhood myocerebrohepatopathy spectrum, which presents within the first 3 years of life; myoclonic epilepsy myopathy sensory ataxia; ataxia neuropathy spectrum; autosomal recessive progressive external ophthalmoplegia; and autosomal dominant progressive external ophthalmoplegia. This Review describes the clinical features, pathophysiology, natural history and treatment of POLG-related disorders, focusing particularly on the neurological manifestations of these conditions.
C1 [Rahman, Shamima] UCL Great Ormond St Inst Child Hlth, Mitochondrial Res Grp, London, England.
   [Rahman, Shamima] Great Ormond St Hosp Children NHS Fdn Trust, Metab Unit, London, England.
   [Copeland, William C.] NIEHS, Mitochondrial DNA Replicat Grp, Genome Integr & Struct Biol Lab, NIH, Durham, NC 27709 USA.
C3 University of London; University College London; University of London;
   University College London; Great Ormond Street Hospital for Children NHS
   Foundation Trust; National Institutes of Health (NIH) - USA; NIH
   National Institute of Environmental Health Sciences (NIEHS)
RP Copeland, WC (corresponding author), NIEHS, Mitochondrial DNA Replicat Grp, Genome Integr & Struct Biol Lab, NIH, Durham, NC 27709 USA.
EM copelan1@niehs.nih.gov
RI Rahman, Shamima/C-5232-2008; Copeland, William/C-4242-2019
OI Copeland, William/0000-0002-0359-0953
FU Intramural Research Program of the NIH, National Institute of
   Environmental Health Sciences [ES 065078, ES 065080]; Great Ormond
   Street Hospital Children's Charity Research Leadership Award [V1260];
   Lily Foundation; National Institute for Health Research Biomedical
   Research Centre at Great Ormond Street Hospital for Children NHS
   Foundation Trust; University College London, UK; MRC [G0200335] Funding
   Source: UKRI
FX This work was supported by funding from the Intramural Research Program
   of the NIH, National Institute of Environmental Health Sciences (grants
   ES 065078 and ES 065080) to W.C.C., and from the Great Ormond Street
   Hospital Children's Charity Research Leadership Award (V1260), the Lily
   Foundation, and the National Institute for Health Research Biomedical
   Research Centre at Great Ormond Street Hospital for Children NHS
   Foundation Trust and University College London, UK, to S.R.
CR Ahmed N, 2015, INT J MOL SCI, V16, P18054, DOI 10.3390/ijms160818054
   Ahola-Erkkilä S, 2010, HUM MOL GENET, V19, P1974, DOI 10.1093/hmg/ddq076
   Anagnostou ME, 2016, EPILEPSIA, V57, P1531, DOI 10.1111/epi.13508
   ARNAUDO E, 1991, LANCET, V337, P508, DOI 10.1016/0140-6736(91)91294-5
   Bebenek K, 2004, ADV PROTEIN CHEM, V69, P137
   BELL EA, 1992, ANN PHARMACOTHER, V26, P18, DOI 10.1177/106002809202600104
   Besse A, 2015, CELL METAB, V21, P417, DOI 10.1016/j.cmet.2015.02.008
   BICKNESE AR, 1992, ANN NEUROL, V32, P767, DOI 10.1002/ana.410320610
   Bindoff LA, 2012, EPILEPSIA, V53, P92, DOI 10.1111/j.1528-1167.2012.03618.x
   Bonnen PE, 2013, AM J HUM GENET, V93, P471, DOI 10.1016/j.ajhg.2013.07.017
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Bugiardini E, 2017, NEUROL-GENET, V3, DOI 10.1212/NXG.0000000000000149
   Bulst S, 2009, HUM MOL GENET, V18, P1590, DOI 10.1093/hmg/ddp074
   Chan SSL, 2006, HUM MOL GENET, V15, P3473, DOI 10.1093/hmg/ddl424
   Chan SSL, 2005, J BIOL CHEM, V280, P31341, DOI 10.1074/jbc.M506762200
   Chang P, 2016, BRAIN, V139, P431, DOI 10.1093/brain/awv325
   Cohen BH, GENEREVIEWS
   Copeland WC, 2014, DNA REPAIR, V19, P190, DOI 10.1016/j.dnarep.2014.03.010
   CORTOPASSI GA, 1992, P NATL ACAD SCI USA, V89, P7370, DOI 10.1073/pnas.89.16.7370
   CORTOPASSI GA, 1990, NUCLEIC ACIDS RES, V18, P6927, DOI 10.1093/nar/18.23.6927
   Craig K, 2007, BRAIN, V130, DOI 10.1093/brain/awm009
   Dagan T, 2002, MITOCHONDRION, V1, P397, DOI 10.1016/S1567-7249(02)00003-X
   DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602
   Davidzon G, 2006, ANN NEUROL, V59, P859, DOI 10.1002/ana.20831
   de Vries MC, 2007, EUR J PEDIATR, V166, P229, DOI 10.1007/s00431-006-0234-9
   DeBalsi KL, 2017, J BIOL CHEM, V292, P4198, DOI 10.1074/jbc.M116.773341
   Delarue A, 2000, Pediatr Transplant, V4, P67, DOI 10.1034/j.1399-3046.2000.00090.x
   Deschauer M, 2007, NEUROLOGY, V68, P1741, DOI 10.1212/01.wnl.0000261929.92478.3e
   Dhamija R, 2011, NEUROLOGY, V76, pE22, DOI 10.1212/WNL.0b013e31820a0d39
   Di Bella D, 2010, NAT GENET, V42, P313, DOI 10.1038/ng.544
   Di Fonzo A, 2009, AM J HUM GENET, V84, P594, DOI 10.1016/j.ajhg.2009.04.004
   Di Meo I, 2012, EMBO MOL MED, V4, P1008, DOI 10.1002/emmm.201201433
   Duncan AJ, 2012, HUM REPROD, V27, P2243, DOI 10.1093/humrep/des130
   Echaniz-Laguna A, 2010, ARCH NEUROL-CHICAGO, V67, P1140, DOI 10.1001/archneurol.2010.219
   Elleuch N, 2006, NEUROLOGY, V66, P654, DOI 10.1212/01.wnl.0000201185.91110.15
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Engelsen BA, 2008, BRAIN, V131, P818, DOI 10.1093/brain/awn007
   Euro L, 2011, NUCLEIC ACIDS RES, V39, P9072, DOI 10.1093/nar/gkr618
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   GATTERMANN N, 1995, LEUKEMIA, V9, P1704
   Giordano C, 2009, NEUROLOGY, V72, P1103, DOI 10.1212/01.wnl.0000345002.47396.e1
   Gorman GS, 2015, ANN NEUROL, V77, P753, DOI 10.1002/ana.24362
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   Graziewicz MA, 2006, CHEM REV, V106, P383, DOI 10.1021/cr040463d
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Hakonen AH, 2007, EUR J HUM GENET, V15, P779, DOI 10.1038/sj.ejhg.5201831
   Hanisch F, 2015, J NEUROL NEUROSUR PS, V86, P630, DOI 10.1136/jnnp-2013-306748
   HARDING BN, 1990, J CHILD NEUROL, V5, P273, DOI 10.1177/088307389000500402
   Harris MO, 2010, ARCH NEUROL-CHICAGO, V67, P493, DOI 10.1001/archneurol.2010.36
   Hasselmann O, 2010, MOL GENET METAB, V99, P58, DOI 10.1016/j.ymgme.2009.08.005
   Hikmat O, 2017, GENET MED, V19, P1217, DOI 10.1038/gim.2017.35
   Hikmat O, 2017, J INHERIT METAB DIS, V40, P861, DOI 10.1007/s10545-017-0084-9
   Hinnell C, 2012, MOVEMENT DISORD, V27, P162, DOI 10.1002/mds.23960
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Hughes SD, 2014, J NEUROCHEM, V129, P426, DOI 10.1111/jnc.12646
   Hynynen J, 2014, LIVER TRANSPLANT, V20, P1402, DOI 10.1002/lt.23965
   Isohanni P, 2011, NEUROLOGY, V76, P811, DOI 10.1212/WNL.0b013e31820e7b25
   Johansen KK, 2008, MOVEMENT DISORD, V23, P1624, DOI 10.1002/mds.22178
   Johnson AA, 2000, BIOCHEMISTRY-US, V39, P1702, DOI 10.1021/bi992104w
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   Kanabus M, 2016, J INHERIT METAB DIS, V39, P415, DOI 10.1007/s10545-016-9930-4
   Kasiviswanathan R, 2009, J BIOL CHEM, V284, P19501, DOI 10.1074/jbc.M109.011940
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kayihan N, 2000, Pediatr Transplant, V4, P211, DOI 10.1034/j.1399-3046.2000.00115.x
   Kennedy SR, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003794
   Khan A, 2012, J CHILD NEUROL, V27, P636, DOI 10.1177/0883073811423973
   Kirschenbaum D, 2018, NEUROPATH APPL NEURO, V44, P639, DOI 10.1111/nan.12429
   Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257
   Kornblum C, 2013, NAT GENET, V45, P214, DOI 10.1038/ng.2501
   Kremer LS, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15824
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   Kukat C, 2011, P NATL ACAD SCI USA, V108, P13534, DOI 10.1073/pnas.1109263108
   Larsson NG, 1995, ANNU REV GENET, V29, P151, DOI 10.1146/annurev.ge.29.120195.001055
   Lee YS, 2009, CELL, V139, P312, DOI 10.1016/j.cell.2009.07.050
   Lewis W, 2001, LAB INVEST, V81, P777, DOI 10.1038/labinvest.3780288
   Lewis W, 2003, NAT REV DRUG DISCOV, V2, P812, DOI 10.1038/nrd1201
   Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Longley MJ, 1998, BIOCHEMISTRY-US, V37, P10529, DOI 10.1021/bi980772w
   Longley MJ, 2001, J BIOL CHEM, V276, P38555, DOI 10.1074/jbc.M105230200
   Lopez-Gomez C, 2017, ANN NEUROL, V81, P641, DOI 10.1002/ana.24922
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Luoma PT, 2005, HUM MOL GENET, V14, P1907, DOI 10.1093/hmg/ddi196
   Lupashko S, 2011, CHILD NERV SYST, V27, P1321, DOI 10.1007/s00381-011-1495-9
   Mancuso M, 2016, NEUROMUSCULAR DISORD, V26, P272, DOI 10.1016/j.nmd.2016.02.008
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Martikainen MH, 2016, JAMA NEUROL, V73, P668, DOI 10.1001/jamaneurol.2016.0355
   Martikainen MH, 2012, EPILEPTIC DISORD, V14, P438, DOI 10.1684/epd.2012.0543
   McFarland R, 2008, ARCH DIS CHILD, V93, P151, DOI 10.1136/adc.2007.122911
   McKiernan P, 2016, J PEDIATR GASTR NUTR, V63, P592, DOI 10.1097/MPG.0000000000001345
   McKiernan P, 2014, LIVER TRANSPLANT, V20, P1287, DOI 10.1002/lt.23988
   Menezes MP, 2016, MITOCHONDRION, V30, P162, DOI 10.1016/j.mito.2016.07.014
   Meyer JN, 2013, TOXICOL SCI, V134, P1, DOI 10.1093/toxsci/kft102
   Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774
   Mindikoglu AL, 2011, J PEDIATR-US, V158, P802, DOI 10.1016/j.jpeds.2010.10.033
   Nadanaciva S, 2011, CURR PHARM DESIGN, V17, P2100, DOI 10.2174/138161211796904795
   Naviaux RK, 2005, ANN NEUROL, V58, P491, DOI 10.1002/ana.20544
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Naviaux RK, 1999, ANN NEUROL, V45, P54, DOI 10.1002/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B
   Neeve VCM, 2012, BRAIN, V135, P3614, DOI 10.1093/brain/aws298
   Nguyen KV, 2006, J HEPATOL, V45, P108, DOI 10.1016/j.jhep.2005.12.026
   Nicastro N, 2016, CEREBELLUM, V15, P829, DOI 10.1007/s12311-015-0749-6
   Nicholls TJ, 2018, MOL CELL, V69, P9, DOI 10.1016/j.molcel.2017.11.033
   Nikkanen J, 2018, EMBO MOL MED, V10, P13, DOI 10.15252/emmm.201707993
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Nurminen A, 2017, BBA CLIN, V7, P147, DOI 10.1016/j.bbacli.2017.04.001
   Orsucci D, 2017, J NEUROL, V264, P1777, DOI 10.1007/s00415-017-8567-z
   Ostergaard E, 2007, AM J HUM GENET, V81, P383, DOI 10.1086/519222
   Pagnamenta AT, 2006, HUM REPROD, V21, P2467, DOI 10.1093/humrep/del076
   Palin EJH, 2012, J NEUROL SCI, V315, P160, DOI 10.1016/j.jns.2011.11.028
   Parikh S, 2016, MOL GENET METAB, V118, P178, DOI 10.1016/j.ymgme.2016.04.009
   Pfeffer G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004426.pub3
   Pitayu L, 2016, HUM MOL GENET, V25, P715, DOI 10.1093/hmg/ddv509
   Pitceathly RDS, 2013, J NEUROL NEUROSUR PS, V84, P107, DOI 10.1136/jnnp-2012-303232
   Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200
   Prasun P, 2014, J NEUROL, V261, P1818, DOI 10.1007/s00415-014-7428-2
   Prüss H, 2008, EPILEPSY RES, V82, P219, DOI 10.1016/j.eplepsyres.2008.08.005
   Rahman S, 2013, J INHERIT METAB DIS, V36, P659, DOI 10.1007/s10545-013-9614-2
   Rahman S, 2012, DEV MED CHILD NEUROL, V54, P397, DOI 10.1111/j.1469-8749.2011.04214.x
   Rajakulendran S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0145500
   Reyes A, 2015, AM J HUM GENET, V97, P186, DOI 10.1016/j.ajhg.2015.05.013
   Ronchi D, 2013, AM J HUM GENET, V92, P293, DOI 10.1016/j.ajhg.2012.12.014
   Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490
   Rouzier C, 2012, BRAIN, V135, P23, DOI 10.1093/brain/awr323
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Saneto RP, 2010, DEV DISABIL RES REV, V16, P163, DOI 10.1002/ddrr.105
   Saneto RP, 2010, SEIZURE-EUR J EPILEP, V19, P140, DOI 10.1016/j.seizure.2010.01.002
   Santra S, 2004, ANN NEUROL, V56, P662, DOI 10.1002/ana.20240
   Schicks J, 2010, MOVEMENT DISORD, V25, P2678, DOI 10.1002/mds.23286
   Scuderi C, 2015, NEUROMUSCULAR DISORD, V25, P333, DOI 10.1016/j.nmd.2015.01.004
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spiegler J, 2011, NEUROPEDIATRICS, V42, P194, DOI 10.1055/s-0031-1287812
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Staufner C, 2016, J INHERIT METAB DIS, V39, P3, DOI 10.1007/s10545-015-9896-7
   Stewart JD, 2008, NEUROLOGY, V71, P1829, DOI 10.1212/01.wnl.0000335931.54095.0a
   Stiles AR, 2016, MOL GENET METAB, V119, P91, DOI 10.1016/j.ymgme.2016.07.001
   Suomalainen A, 2011, LANCET NEUROL, V10, P806, DOI 10.1016/S1474-4422(11)70155-7
   Sweasy JB, 2006, RADIAT RES, V166, P693, DOI 10.1667/RR0706.1
   Synofzik M, 2010, MOVEMENT DISORD, V25, P2472, DOI 10.1002/mds.23307
   Szymanski MR, 2015, EMBO J, V34, P1959, DOI 10.15252/embj.201591520
   Taanman JW, 2003, HUM MOL GENET, V12, P1839, DOI 10.1093/hmg/ddg192
   Tang S, 2012, J NEUROL, V259, P862, DOI 10.1007/s00415-011-6268-6
   Thomson MA, 2000, TRANSPLANT P, V32, P200, DOI 10.1016/S0041-1345(99)00936-7
   Torres-Torronteras J, 2011, GENE THER, V18, P795, DOI 10.1038/gt.2011.24
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Tzoulis C, 2016, MITOCHONDRION, V28, P33, DOI 10.1016/j.mito.2016.03.003
   Tzoulis C, 2013, BRAIN, V136, P2393, DOI 10.1093/brain/awt103
   Uusimaa J, 2008, EPILEPSIA, V49, P1038, DOI 10.1111/j.1528-1167.2008.01544.x
   Uusimaa J, 2013, EPILEPSIA, V54, P1002, DOI 10.1111/epi.12115
   van Baalen A, 2017, NEUROPEDIATRICS, V48, P5, DOI 10.1055/s-0036-1597271
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, NEUROLOGY, V61, P1811, DOI 10.1212/01.WNL.0000098997.23471.65
   Van Goethem G, 2003, EUR J HUM GENET, V11, P547, DOI 10.1038/sj.ejhg.5201002
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Vermulst M, 2008, NAT GENET, V40, P392, DOI 10.1038/ng.95
   Vermulst M, 2007, NAT GENET, V39, P540, DOI 10.1038/ng1988
   Viscomi C, 2017, J INHERIT METAB DIS, V40, P587, DOI 10.1007/s10545-017-0027-5
   Visser NA, 2010, NEUROLOGY, V74, P1231, DOI 10.1212/WNL.0b013e3181d90005
   Visser NA, 2011, J NEUROL, V258, P218, DOI 10.1007/s00415-010-5721-2
   Whittaker RG, 2015, ANN NEUROL, V78, P949, DOI 10.1002/ana.24525
   Wiltshire E, 2008, ARCH NEUROL-CHICAGO, V65, P121, DOI 10.1001/archneurol.2007.14
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   Wolf NI, 2009, EPILEPSIA, V50, P1596, DOI 10.1111/j.1528-1167.2008.01877.x
   Wong LJC, 2008, HUM MUTAT, V29, pE150, DOI 10.1002/humu.20824
   Woodbridge P, 2013, INTERN MED J, V43, P150, DOI 10.1111/j.1445-5994.2012.02847.x
   Yatsuga S, 2015, ANN NEUROL, V78, P814, DOI 10.1002/ana.24506
   Young MJ, 2017, FRONT MOL BIOSCI, V4, DOI 10.3389/fmolb.2017.00074
   Young MJ, 2015, HUM MOL GENET, V24, P5184, DOI 10.1093/hmg/ddv240
   Zheng WM, 2006, MUTAT RES-FUND MOL M, V599, P11, DOI 10.1016/j.mrfmmm.2005.12.012
NR 171
TC 210
Z9 220
U1 2
U2 33
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1759-4758
EI 1759-4766
J9 NAT REV NEUROL
JI Nat. Rev. Neurol.
PD JAN
PY 2019
VL 15
IS 1
BP 40
EP 52
DI 10.1038/s41582-018-0101-0
PG 13
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA HG3AJ
UT WOS:000454841000011
PM 30451971
OA Green Accepted
HC Y
HP N
DA 2024-11-01
ER

PT J
AU Ronchi, D
   Garone, C
   Bordoni, A
   Rios, PG
   Calvo, SE
   Ripolone, M
   Ranieri, M
   Rizzuti, M
   Villa, L
   Magri, F
   Corti, S
   Bresolin, N
   Mootha, VK
   Moggio, M
   DiMauro, S
   Comi, GP
   Sciacco, M
AF Ronchi, Dario
   Garone, Caterina
   Bordoni, Andreina
   Rios, Purificacion Gutierrez
   Calvo, Sarah E.
   Ripolone, Michela
   Ranieri, Michela
   Rizzuti, Mafalda
   Villa, Luisa
   Magri, Francesca
   Corti, Stefania
   Bresolin, Nereo
   Mootha, Vamsi K.
   Moggio, Maurizio
   DiMauro, Salvatore
   Comi, Giacomo P.
   Sciacco, Monica
TI Next-generation sequencing reveals <i>DGUOK</i> mutations in adult
   patients with mitochondrial DNA multiple deletions
SO BRAIN
LA English
DT Article
DE DGUOK; mitochondrial DNA instability; autosomal recessive progressive
   external ophthalmoplegia; multiple mitochondrial DNA deletions
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; HUMAN DEOXYGUANOSINE KINASE;
   THYMIDINE KINASE; MTDNA DELETIONS; OPTIC ATROPHY; NEUROGASTROINTESTINAL
   ENCEPHALOMYOPATHY; MOLECULAR-FEATURES; GENE-MUTATIONS; HUMAN-CELLS;
   DEPLETION
AB The molecular diagnosis of mitochondrial disorders still remains elusive in a large proportion of patients, but advances in next generation sequencing are significantly improving our chances to detect mutations even in sporadic patients. Syndromes associated with mitochondrial DNA multiple deletions are caused by different molecular defects resulting in a wide spectrum of predominantly adult-onset clinical presentations, ranging from progressive external ophthalmoplegia to multi-systemic disorders of variable severity. The mutations underlying these conditions remain undisclosed in half of the affected subjects. We applied next-generation sequencing of known mitochondrial targets (MitoExome) to probands presenting with adult-onset mitochondrial myopathy and harbouring mitochondrial DNA multiple deletions in skeletal muscle. We identified autosomal recessive mutations in the DGUOK gene (encoding mitochondrial deoxyguanosine kinase), which has previously been associated with an infantile hepatocerebral form of mitochondrial DNA depletion. Mutations in DGUOK occurred in five independent subjects, representing 5.6% of our cohort of patients with mitochondrial DNA multiple deletions, and impaired both muscle DGUOK activity and protein stability. Clinical presentations were variable, including mitochondrial myopathy with or without progressive external ophthalmoplegia, recurrent rhabdomyolysis in a young female who had received a liver transplant at 9 months of age and adult-onset lower motor neuron syndrome with mild cognitive impairment. These findings reinforce the concept that mutations in genes involved in deoxyribonucleotide metabolism can cause diverse clinical phenotypes and suggest that DGUOK should be screened in patients harbouring mitochondrial DNA deletions in skeletal muscle.
C1 [Ronchi, Dario; Bordoni, Andreina; Ranieri, Michela; Rizzuti, Mafalda; Magri, Francesca; Corti, Stefania; Bresolin, Nereo; Comi, Giacomo P.] Univ Milan, IRCCS Fdn Ca Granda Osped Maggiore Policlin, Dept Pathophysiol & Transplantat DEPT, Dino Ferrari Ctr,Neurosci Sect,Neurol Unit, I-20122 Milan, Italy.
   [Garone, Caterina; Rios, Purificacion Gutierrez; DiMauro, Salvatore] Columbia Univ Med Ctr, Dept Neurol, New York, NY 10032 USA.
   [Garone, Caterina] Univ Turin, Human Genet Joint PhD Programme, I-10125 Turin, Italy.
   [Garone, Caterina] Univ Bologna, I-40125 Bologna, Italy.
   [Calvo, Sarah E.; Mootha, Vamsi K.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
   [Calvo, Sarah E.; Mootha, Vamsi K.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
   [Calvo, Sarah E.; Mootha, Vamsi K.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA.
   [Calvo, Sarah E.; Mootha, Vamsi K.] Broad Inst Harvard & MIT, Seven Cambridge Ctr, Broad Metab Initiat, Cambridge, MA 02142 USA.
   [Ripolone, Michela; Villa, Luisa; Moggio, Maurizio; Sciacco, Monica] Univ Milan, IRCCS Fdn Ca Granda Osped Maggiore Policlin, Dino Ferrari Ctr, Neuromuscular Unit, I-20122 Milan, Italy.
   [Corti, Stefania; Bresolin, Nereo; Comi, Giacomo P.] Univ Milan, Ctr Excellence Neurodegenerat Dis, I-20122 Milan, Italy.
   [Bresolin, Nereo] IRCCS Eugenio Medea, I-23842 Bosisio Parini, Lecco, Italy.
C3 IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan;
   Columbia University; University of Turin; University of Bologna; Harvard
   University; Massachusetts General Hospital; Harvard University;
   Massachusetts General Hospital; Harvard University; Harvard Medical
   School; Harvard University; Massachusetts Institute of Technology (MIT);
   Broad Institute; IRCCS Ca Granda Ospedale Maggiore Policlinico;
   University of Milan; University of Milan; IRCCS Eugenio Medea
RP Ronchi, D (corresponding author), Univ Milan, IRCCS Fdn Ca Granda Osped Maggiore Policlin, Dept Pathophysiol & Transplantat, Neurosci Sect, Via Francesco Sforza 35, I-20122 Milan, Italy.
EM dario.ronchi@unimi.it
RI Ronchi, Dario/K-8011-2016; Garone, Caterina/AAB-8659-2019; Rizzuti,
   Mafalda/AAC-2407-2022; Comi, Giacomo/K-5702-2016; Sciacco,
   Monica/AAC-6500-2022; Ríos, Purificación/I-4234-2015; Magri,
   Francesca/K-5739-2016; corti, stefania/K-6034-2016
OI Comi, Giacomo/0000-0002-1383-5248; Ronchi, Dario/0000-0002-6093-9816;
   Bresolin, Nereo/0000-0001-6694-3595; Ripolone,
   Michela/0000-0001-9293-6823; Sciacco, Monica/0000-0003-4593-4977; Magri,
   Francesca/0000-0001-8974-9453; Garone, Caterina/0000-0003-4928-1037;
   corti, stefania/0000-0001-5425-969X; Rizzuti,
   Mafalda/0000-0001-5734-7476
FU National Institutes of Health [GM077465, GM097136, HD32062]; Marriott
   Mitochondrial Disorder Clinical Research Fund; Italian Telethon
   [GUP09004]; Associazione Amici del Centro Dino Ferrari, University of
   Milan; Telethon project [GTB07001ER]; Eurobiobank project
   [QLTR-2001-02769]; Criobanca Automatizzata di Materiale Biologico
   [02.187]
FX This work was supported by a grant from the National Institutes of
   Health (GM077465 and GM097136 to V.K.M.; HD32062 to S.D.M.), by the
   Marriott Mitochondrial Disorder Clinical Research Fund to S. D. M. and
   by a contribution of the Italian Telethon (grant GUP09004 to G.P.C.)
   'Constructing a database for a nation-wide Italian collaborative network
   of mitochondrial diseases'. The financial support of Associazione Amici
   del Centro Dino Ferrari, University of Milan; the Telethon project
   GTB07001ER; the Eurobiobank project QLTR-2001-02769 and R. F. 02.187
   Criobanca Automatizzata di Materiale Biologico is gratefully
   acknowledged.
CR Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   ARNER ESJ, 1992, BIOCHEM BIOPH RES CO, V188, P712, DOI 10.1016/0006-291X(92)91114-6
   Bentley DR, 2008, NATURE, V456, P53, DOI 10.1038/nature07517
   Bergmeyer H.U., 1974, METHODS ENZYMATIC AN, V1
   Blakely EL, 2012, NEUROMUSCULAR DISORD, V22, P587, DOI 10.1016/j.nmd.2012.03.006
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Buchaklian AH, 2012, MOL GENET METAB
   Calvo SE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003310
   Calvo SE, 2010, NAT GENET, V42, P851, DOI 10.1038/ng.659
   Copeland WC, 2008, ANNU REV MED, V59, P131, DOI 10.1146/annurev.med.59.053006.104646
   De Camaret BM, 2007, BIOCHEM J, V402, P377, DOI 10.1042/BJ20060705
   Dimmock DP, 2008, HUM MUTAT, V29, P330, DOI 10.1002/humu.9519
   Dimmock DP, 2008, LIVER TRANSPLANT, V14, P1480, DOI 10.1002/lt.21556
   Fratter C, 2011, NEUROLOGY, V76, P2032, DOI 10.1212/WNL.0b013e31821e558b
   Galbiati S, 2006, PEDIATR NEUROL, V34, P177, DOI 10.1016/j.pediatrneurol.2005.07.013
   Garone C, 2012, ARCH NEUROL-CHICAGO, V69, P1648, DOI 10.1001/archneurol.2012.405
   Garone C, 2011, BRAIN, V134, P3326, DOI 10.1093/brain/awr245
   Gnirke A, 2009, NAT BIOTECHNOL, V27, P182, DOI 10.1038/nbt.1523
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   Hirano M, 2004, NEUROLOGIST, V10, P8, DOI 10.1097/01.nrl.0000106919.06469.04
   Hirano M, 2008, ARCH NEUROL-CHICAGO, V65, P403, DOI 10.1001/archneurol.2007.65
   Houdayer C, 2011, METHODS MOL BIOL, V760, P269, DOI 10.1007/978-1-61779-176-5_17
   Hudson G, 2008, BRAIN, V131, P329, DOI 10.1093/brain/awm272
   Isohanni P, 2011, NEUROLOGY, V76, P811, DOI 10.1212/WNL.0b013e31820e7b25
   Johansson M, 1996, P NATL ACAD SCI USA, V93, P7258, DOI 10.1073/pnas.93.14.7258
   Jüllig M, 2000, EUR J BIOCHEM, V267, P5466, DOI 10.1046/j.1432-1327.2000.01607.x
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Krishnan KJ, 2008, NAT GENET, V40, P275, DOI 10.1038/ng.f.94
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Ng PC, 2003, NUCLEIC ACIDS RES, V31, P3812, DOI 10.1093/nar/gkg509
   Nikali K, 2005, HUM MOL GENET, V14, P2981, DOI 10.1093/hmg/ddi328
   Pagliarini DJ, 2008, CELL, V134, P112, DOI 10.1016/j.cell.2008.06.016
   Poulton J, 2009, BBA-MOL BASIS DIS, V1792, P1109, DOI 10.1016/j.bbadis.2009.08.016
   Rötig A, 2009, BBA-MOL BASIS DIS, V1792, P1103, DOI 10.1016/j.bbadis.2009.06.009
   Rouzier C, 2012, BRAIN, V135, P23, DOI 10.1093/brain/awr323
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284
   Sarzi E, 2007, ANN NEUROL, V62, P579, DOI 10.1002/ana.21207
   Sciacco M, 2001, J NEUROL, V248, P778, DOI 10.1007/s004150170094
   Slama A, 2005, MOL GENET METAB, V86, P462, DOI 10.1016/j.ymgme.2005.09.006
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Spinazzola A, 2009, J INHERIT METAB DIS, V32, P143, DOI 10.1007/s10545-008-1038-z
   Stewart JD, 2009, J MED GENET, V46, P209, DOI 10.1136/jmg.2008.058180
   Sunyaev S, 2001, HUM MOL GENET, V10, P591, DOI 10.1093/hmg/10.6.591
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   Tyynismaa H, 2012, HUM MOL GENET, V21, P66, DOI 10.1093/hmg/ddr438
   Tyynismaa H, 2009, AM J HUM GENET, V85, P290, DOI 10.1016/j.ajhg.2009.07.009
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Virgilio R, 2008, J NEUROL, V255, P1384, DOI 10.1007/s00415-008-0926-3
   Wanrooij S, 2010, BBA-BIOENERGETICS, V1797, P1378, DOI 10.1016/j.bbabio.2010.04.015
   Yu-Wai-Man P, 2012, BRAIN, V135, P9, DOI 10.1093/brain/awr352
   ZEVIANI M, 1990, ANN NEUROL, V28, P94, DOI 10.1002/ana.410280118
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 57
TC 74
Z9 81
U1 0
U2 10
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
J9 BRAIN
JI Brain
PD NOV
PY 2012
VL 135
BP 3404
EP 3415
DI 10.1093/brain/aws258
PN 11
PG 12
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 044SV
UT WOS:000311644800025
PM 23043144
OA Green Published, Bronze
DA 2024-11-01
ER

PT J
AU Al-Dosary, M
   Whittaker, RG
   Haughton, J
   McFarland, R
   Goodship, J
   Turnbull, DM
   Taylor, RW
AF Al-Dosary, Mazhor
   Whittaker, Roger G.
   Haughton, Joanna
   McFarland, Robert
   Goodship, Judith
   Turnbull, Douglass M.
   Taylor, Robert W.
TI Neuromuscular disease presentation with three genetic defects involving
   two genomes
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE PEO; Mitochondrial DNA; tRNA mutation; Single fibre analysis;
   Segregation
ID MITOCHONDRIAL-DNA MUTATIONS; DEPLETION MYOPATHY; OPHTHALMOPLEGIA;
   DEFICIENCY; CELLS
AB An extensive range of molecular defects have been identified in the human mitochondrial genome (mtDNA), many associated with well-characterised, progressive neurological syndromes. We describe a patient who presented to a mitochondrial clinic with progressive bilateral ptosis, external opthalmoplegia and increasing difficulty with walking. He had previously been diagnosed with a dominant, demyelinating polyneuropathy due to PMP22 gene duplication and had also developed gout, presenting in acute renal failure, due to an X-linked recessive HPRT gene mutation. Muscle biopsy revealed many COX-deficient fibres which we show contain high levels of a third genetic defect - a novel, mitochondrial tRNA(Leu(CUN)) (MTTL2) gene mutation. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Taylor, Robert W.] Univ Newcastle, Mitochondrial Res Grp, Inst Ageing & Hlth, Sch Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Al-Dosary, Mazhor; Whittaker, Roger G.; McFarland, Robert; Turnbull, Douglass M.; Taylor, Robert W.] Univ Newcastle, NCG Rare Mitochondrial Disorders Adults & Childre, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Haughton, Joanna] Newcastle Gen Hosp, Reg Neurosci Ctr, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.
   [Goodship, Judith] Univ Newcastle, Inst Human Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
C3 Newcastle University - UK; Newcastle University - UK; Newcastle General
   Hospital; Newcastle University - UK
RP Taylor, RW (corresponding author), Univ Newcastle, Mitochondrial Res Grp, Inst Ageing & Hlth, Sch Med, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM r.w.taylor@ncl.ac.uk
OI Turnbull, Doug/0000-0002-8878-9901; Whittaker,
   Roger/0000-0002-3403-0182; McFarland, Robert/0000-0002-8833-2688
FU Wellcome Trust; UK National Commissioning Group; MRC [G0800674] Funding
   Source: UKRI
FX We thank Gavin Falkous for excellent technical assistance. D.M.T. and
   R.W.T. acknowledge the continuing financial support of the Wellcome
   Trust and the UK National Commissioning Group for funding the Diagnostic
   Rare Mitochondrial Disorders of Adults and Children Service.
CR Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Battersby BJ, 2003, NAT GENET, V33, P183, DOI 10.1038/ng1073
   Blakely E, 2008, NEUROMUSCULAR DISORD, V18, P557, DOI 10.1016/j.nmd.2008.04.014
   Blakely EL, 2009, ARCH NEUROL-CHICAGO, V66, P399, DOI 10.1001/archneurol.2008.576
   Cardaioli E, 2005, BIOCHEM BIOPH RES CO, V327, P675, DOI 10.1016/j.bbrc.2004.11.170
   Carrozzo R, 2003, HUM MUTAT, V21, DOI 10.1002/humu.9135
   DAVIDSON BL, 1989, J CLIN INVEST, V84, P342, DOI 10.1172/JCI114160
   Deschauer M, 2006, ARCH NEUROL-CHICAGO, V63, P902, DOI 10.1001/archneur.63.6.902
   GIBBS RA, 1989, P NATL ACAD SCI USA, V86, P1919, DOI 10.1073/pnas.86.6.1919
   Ingman M, 2006, NUCLEIC ACIDS RES, V34, pD749, DOI 10.1093/nar/gkj010
   Jacobs HT, 2003, HUM MOL GENET, V12, pR293, DOI 10.1093/hmg/ddg285
   Krishnan KJ, 2007, ANAL BIOCHEM, V370, P127, DOI 10.1016/j.ab.2007.06.024
   McFarland R, 2008, NEUROMUSCULAR DISORD, V18, P63, DOI 10.1016/j.nmd.2007.07.007
   Puig JG, 2001, MEDICINE, V80, P102, DOI 10.1097/00005792-200103000-00003
   Rotig A, 2009, BIOCH BIOPHYS ACTA
   Ruiz-Pesini E, 2007, NUCLEIC ACIDS RES, V35, pD823, DOI 10.1093/nar/gkl927
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Sacconi S, 2008, HUM MOL GENET, V17, P1814, DOI 10.1093/hmg/ddn073
   Schaefer AM, 2005, MUSCLE NERVE, V32, P104, DOI 10.1002/mus.20319
   Schaefer AM, 2008, ANN NEUROL, V63, P35, DOI 10.1002/ana.21217
   Schouten JP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf056
   Taylor RW, 2003, J CLIN INVEST, V112, P1351, DOI 10.1172/JCI200319435
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
NR 23
TC 7
Z9 7
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD DEC
PY 2009
VL 19
IS 12
BP 841
EP 844
DI 10.1016/j.nmd.2009.10.001
PG 4
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 534DB
UT WOS:000272874600009
PM 19853445
DA 2024-11-01
ER

PT J
AU Maghbooli, M
   Ghaffarpour, M
   Ghazizadeh, T
   Shalbaf, NA
   MalekMahmoudi, G
AF Maghbooli, Mehdi
   Ghaffarpour, Majid
   Ghazizadeh, Taher
   Shalbaf, Nazanin Azizi
   MalekMahmoudi, Ghazal
TI Clinicogenetical Variants of Progressive External Ophthalmoplegia - An
   Especial Review of Non-ophthalmic Manifestations
SO NEUROLOGY INDIA
LA English
DT Review
DE Genetic; non-ophthalmic; progressive external ophthalmoplegia plus;
   progressive external ophthalmoplegiaKey Messages: Progressive external
   ophthalmoplegia (PEO) as a genetically heterogeneous entity could be
   accompanied by various non-ophthalmic manifestations such as ataxia;
   skeletal; bulbar or cardiac myopathy; parkinsonism; hearing loss;
   neuropathy; endocrinopathy; depression; hepatopathy and even seizure or
   encephalopathy
ID ONSET SPINOCEREBELLAR ATAXIA; MITOCHONDRIAL-DNA; GENE MUTATION;
   NEUROPATHY; MYOPATHY; TWINKLE; DIAGNOSIS; DELETIONS; PATIENT; ADPEO
AB Progressive external ophthalmoplegia (PEO) is a slowly progressive myopathy characterized by extraocular muscles involvement, leading to frozen eyes without diplopia. The pattern of inheritance may be mitochondrial, autosomal dominant or, rarely, autosomal recessive. Sporadic forms were also reported. Muscular involvement other than extraocular muscles may occur with varying degrees of weakness, but this mostly happens many years after the disease begins. There are also scattered data about systemic signs besides ophthalmoplegia. This article aims to review non-ophthalmic findings of PEO from a clinicogenetical point of view.
C1 [Maghbooli, Mehdi; Ghazizadeh, Taher; Shalbaf, Nazanin Azizi; MalekMahmoudi, Ghazal] Zanjan Univ Med Sci, Dept Neurol, Vali E Asr Hosp, Zanjan, Iran.
   [Ghaffarpour, Majid] Univ Tehran Med Sci, Dept Neurol, Iranian Ctr Neurol Res, Tehran, Iran.
C3 Tehran University of Medical Sciences
RP Maghbooli, M (corresponding author), Zanjan Univ Med Sci, Dept Neurol, Vali E Asr Hosp, Zanjan, Iran.
EM m.maghbooli@zums.ac.ir
RI Maghbooli, Mehdi/I-9321-2016; Azizi, Nazanin/U-3182-2019
OI Azizi, Dr. Nazanin/0000-0001-8872-0093
CR Berardo A, 2010, NEUROMUSCULAR DISORD, V20, P204, DOI 10.1016/j.nmd.2010.01.006
   Born AP, 2015, EUR J PAEDIATR NEURO, V19, P69, DOI 10.1016/j.ejpn.2014.10.006
   Burkett EL, 2005, J AM COLL CARDIOL, V45, P969, DOI 10.1016/j.jacc.2004.11.066
   Casali C, 1999, J AM COLL CARDIOL, V33, P1584, DOI 10.1016/S0735-1097(99)00079-0
   Challa S, 2004, NEUROL INDIA, V52, P353
   Chaussenot A, 2014, REV NEUROL-FRANCE, V170, P323, DOI 10.1016/j.neurol.2014.03.007
   Chen T, 2014, INT J CLIN EXP PATHO, V7, P8887
   Chow J, 2017, NAT REV ENDOCRINOL, V13, P92, DOI 10.1038/nrendo.2016.151
   Cohen B. H., 2018, POLG RELATED DISORDE
   Crippa BL, 2015, AM J MED GENET A, V167, P621, DOI 10.1002/ajmg.a.36939
   Delgado-Alvarado M, 2015, J NEUROL SCI, V350, P93, DOI 10.1016/j.jns.2015.02.011
   Domenis DR, 2011, DIGEST DIS SCI, V56, P2343, DOI 10.1007/s10620-011-1631-0
   El-Hattab AW, 2015, MOL GENET METAB, V116, P4, DOI 10.1016/j.ymgme.2015.06.004
   Emmanuele V, 2011, J NEUROL SCI, V303, P39, DOI 10.1016/j.jns.2011.01.018
   Fadic R, 1997, NEUROLOGY, V49, P239, DOI 10.1212/WNL.49.1.239
   Ferraris S, 2008, ARCH NEUROL-CHICAGO, V65, P125, DOI 10.1001/archneurol.2007.9
   Findlay AR, 2015, MUSCLE NERVE, V51, P638, DOI 10.1002/mus.24566
   Franzoni F, 2011, ACTA MYOL, V30, P164
   Fratter C, 2010, NEUROLOGY, V74, P1619, DOI 10.1212/WNL.0b013e3181df099f
   Garone C, 2012, ARCH NEUROL-CHICAGO, V69, P1648, DOI 10.1001/archneurol.2012.405
   Hakonen AH, 2008, HUM MOL GENET, V17, P3822, DOI 10.1093/hmg/ddn280
   Horváth R, 2003, J MED GENET, V40, P752, DOI 10.1136/jmg.40.10.752
   Houshmand M, 2006, NEUROL INDIA, V54, P182
   Hudson G, 2006, NEUROLOGY, V66, P1439, DOI 10.1212/01.wnl.0000210486.32196.24
   Kato M, 2011, NEUROSCI RES, V69, P331, DOI 10.1016/j.neures.2010.12.013
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kawamata H, 2011, HUM MOL GENET, V20, P2964, DOI 10.1093/hmg/ddr200
   KEARNS TP, 1958, ARCH OPHTHALMOL-CHIC, V60, P280, DOI 10.1001/archopht.1958.00940080296016
   Kiyomoto BH, 2006, J NEUROL NEUROSUR PS, V77, P541, DOI 10.1136/jnnp.2005.079954
   Lam CW, 2015, CLIN CHIM ACTA, V448, P211, DOI 10.1016/j.cca.2015.06.028
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Lax NZ, 2012, ARCH NEUROL-CHICAGO, V69, P490, DOI 10.1001/archneurol.2011.2167
   Lee HF, 2007, EUR J PAEDIATR NEURO, V11, P208, DOI 10.1016/j.ejpn.2006.12.008
   Lewis S, 2002, J NEUROL SCI, V201, P39, DOI 10.1016/S0022-510X(02)00190-9
   Limongelli G, 2012, FUTUR CARDIOL, V8, P71, DOI [10.2217/fca.11.79, 10.2217/FCA.11.79]
   Lönnqvist T, 1998, J NEUROL SCI, V161, P57, DOI 10.1016/S0022-510X(98)00249-4
   LUNDBERG PO, 1962, ACTA NEUROL SCAND, V38, P142
   Mancuso M, 2004, ARCH NEUROL-CHICAGO, V61, P1777, DOI 10.1001/archneur.61.11.1777
   Mancuso M, 2013, NEUROMUSCULAR DISORD, V23, P907, DOI 10.1016/j.nmd.2013.07.011
   Miguel R, 2014, CLIN NEUROL NEUROSUR, V126, P47, DOI 10.1016/j.clineuro.2014.08.020
   Milone M, 2010, NEUROLOGIST, V16, P84, DOI 10.1097/NRL.0b013e3181c78a89
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Naïmi M, 2006, EUR J HUM GENET, V14, P917, DOI 10.1038/sj.ejhg.5201627
   Napoli L, 2001, NEUROLOGY, V57, P2295, DOI 10.1212/WNL.57.12.2295
   Oldfors A, 2003, J NEUROPATH EXP NEUR, V62, P217, DOI 10.1093/jnen/62.3.217
   Olsen DB, 2003, J NEUROL, V250, P1328, DOI 10.1007/s00415-003-0206-1
   Parikh S, 2015, GENET MED, V17, P689, DOI 10.1038/gim.2014.177
   Pierce SB, 2016, CSH MOL CASE STUD, V2, DOI 10.1101/mcs.a001107
   Rai NK, 2010, NEUROL INDIA, V58, P790, DOI 10.4103/0028-3886.72176
   Ronchi D, 2011, J NEUROL SCI, V308, P173, DOI 10.1016/j.jns.2011.05.042
   Sharma NK, 2002, J NEUROL NEUROSUR PS, V73, P95, DOI 10.1136/jnnp.73.1.95
   Tang S, 2012, J NEUROL, V259, P862, DOI 10.1007/s00415-011-6268-6
   Tang S, 2011, J MED GENET, V48, P669, DOI 10.1136/jmedgenet-2011-100222
   Tyynismaa H, 2012, HUM MOL GENET, V21, P66, DOI 10.1093/hmg/ddr438
   Tyynismaa H, 2009, AM J HUM GENET, V85, P290, DOI 10.1016/j.ajhg.2009.07.009
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Wallace DC, 2010, ENVIRON MOL MUTAGEN, V51, P440, DOI 10.1002/em.20586
   Wang YX, 2015, CHINESE MED J-PEKING, V128, P1820, DOI 10.4103/0366-6999.159360
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
NR 59
TC 6
Z9 6
U1 0
U2 0
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0028-3886
EI 1998-4022
J9 NEUROL INDIA
JI Neurol. India
PD JUL-AUG
PY 2020
VL 68
IS 4
BP 760
EP 768
DI 10.4103/0028-3886.293454
PG 9
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA OO6HZ
UT WOS:000587479900006
PM 32859811
DA 2024-11-01
ER

PT J
AU Kato, M
   Nakamura, M
   Ichiba, M
   Tomiyasu, A
   Shimo, H
   Higuchi, I
   Ueno, S
   Sano, A
AF Kato, Maiko
   Nakamura, Masayuki
   Ichiba, Mio
   Tomiyasu, Akiyuki
   Shimo, Hirochika
   Higuchi, Itsuro
   Ueno, Shu-ichi
   Sano, Akira
TI Mitochondrial DNA deletion mutations in patients with neuropsychiatric
   symptoms
SO NEUROSCIENCE RESEARCH
LA English
DT Article
DE Mitochondrial DNA; Deletion mutations; Psychiatric symptoms;
   Schizophrenia; Depression; Dementia
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; MULTIPLE DELETIONS; PEARSON
   MARROW; DISORDER; PROTEIN; MUSCLE; EXPRESSION; OPA1
AB It has been suggested that mitochondrial dysfunction is important in the pathogenesis of psychiatric disorders such as depression, schizophrenia and dementia. We report herein three adult patients exhibiting such psychiatric symptoms as the core manifestation, accompanied by various degrees of myopathic symptoms. Pathological findings in biopsied skeletal muscle were compatible with mitochondrial myopathy in all cases. Maternal inheritance was not apparent in all three cases; however, two patients were born to consanguineous parents. Mutation analysis on the mitochondria! DNA (mtDNA) and seven nuclear genes, in which pathogenic mutations are known to cause mtDNA deletions, was performed. MtDNA deletion mutations were identified in skeletal muscles of all patients. Nether pathogenic mutations nor copy number variation was identified among the nuclear genes. Although further studies are needed, the molecular pathways inducing mitochondrial abnormalities may be implicated in a variety of psychiatric conditions. (c) 2010 Elsevier Ireland Ltd and the Japan Neuroscience Society. All rights reserved.
C1 [Kato, Maiko; Nakamura, Masayuki; Ichiba, Mio; Tomiyasu, Akiyuki; Shimo, Hirochika; Sano, Akira] Kagoshima Univ, Dept Psychiat, Grad Sch Med & Dent Sci, Kagoshima 8908520, Japan.
   [Higuchi, Itsuro] Kagoshima Univ, Dept Neurol, Grad Sch Med & Dent Sci, Kagoshima 8908520, Japan.
   [Higuchi, Itsuro] Kagoshima Univ, Dept Geriatr, Grad Sch Med & Dent Sci, Kagoshima 8908520, Japan.
   [Ueno, Shu-ichi] Ehime Univ, Dept Psychiat, Grad Sch Med, Toon, Ehime 7910295, Japan.
C3 Kagoshima University; Kagoshima University; Kagoshima University; Ehime
   University
RP Sano, A (corresponding author), Kagoshima Univ, Dept Psychiat, Grad Sch Med & Dent Sci, 8-35-1 Sakuragaoka, Kagoshima 8908520, Japan.
EM sano@m3.kufm.kagoshima-u.ac.jp
OI Ueno, Shu-ichi/0000-0002-2611-962X; Sano, Akira/0000-0001-5843-9786;
   Nakamura, Masayuki/0000-0001-5558-0418
FU Ministry of Education, Culture, Sports, Science and Technology, Japan;
   Grants-in-Aid for Scientific Research [23390291, 23659568] Funding
   Source: KAKEN
FX The authors thank all patients and their family members for their
   willingness to participate in this study. We also thank Ms. M. Ishigami
   and Ms. M. Imamura for their excellent technical assistance. This work
   was supported in part by Grants-in-Aid for Research from the Ministry of
   Education, Culture, Sports, Science and Technology, Japan.
CR Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944
   [Anonymous], 2000, DIAGN STAT MAN MENT, DOI [DOI 10.1176/APPI.BOOKS.9780890425787, 10.1176/appi.books.9780890425787]
   Ben-Shachar D, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003676
   Bua E, 2006, AM J HUM GENET, V79, P469, DOI 10.1086/507132
   Chomyn A, 2003, BIOCHEM BIOPH RES CO, V304, P519, DOI 10.1016/S0006-291X(03)00625-9
   Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936
   DEVRIES DD, 1992, NEUROMUSCULAR DISORD, V2, P185, DOI 10.1016/0960-8966(92)90005-Q
   Dror N, 2002, MOL PSYCHIATR, V7, P995, DOI 10.1038/sj.mp.4001116
   Gardner A, 2003, J AFFECT DISORDERS, V76, P55, DOI 10.1016/S0165-0327(02)00067-8
   GOTO Y, 1990, J NEUROL SCI, V100, P63, DOI 10.1016/0022-510X(90)90014-E
   Hirata K, 1999, J HUM GENET, V44, P210, DOI 10.1007/s100380050145
   Houshmand M, 2004, NEUROMUSCULAR DISORD, V14, P195, DOI 10.1016/j.nmd.2003.12.002
   Inoue H, 1998, NAT GENET, V20, P143, DOI 10.1038/2441
   Karry R, 2004, BIOL PSYCHIAT, V55, P676, DOI 10.1016/j.biopsych.2003.12.012
   Kato T, 2001, MOL PSYCHIATR, V6, P625, DOI 10.1038/sj.mp.4000926
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Mancuso M, 2008, J AFFECT DISORDERS, V106, P173, DOI 10.1016/j.jad.2007.05.016
   Maurer I, 2001, SCHIZOPHR RES, V48, P125, DOI 10.1016/S0920-9964(00)00075-X
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Oexle K, 1997, HUM MOL GENET, V6, P905, DOI 10.1093/hmg/6.6.905
   ROTIG A, 1990, J CLIN INVEST, V86, P1601, DOI 10.1172/JCI114881
   Schapira AHV, 2006, LANCET, V368, P70, DOI 10.1016/S0140-6736(06)68970-8
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2006, ACTA NEUROL BELG, V106, P66
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 28
TC 21
Z9 22
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0168-0102
EI 1872-8111
J9 NEUROSCI RES
JI Neurosci. Res.
PD APR
PY 2011
VL 69
IS 4
BP 331
EP 336
DI 10.1016/j.neures.2010.12.013
PG 6
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 741DR
UT WOS:000288843800009
PM 21185889
DA 2024-11-01
ER

PT J
AU Amati-Bonneau, P
   Valentino, ML
   Reynier, P
   Gallardo, ME
   Bornstein, B
   Boissière, A
   Campos, Y
   Rivera, H
   de la Aleja, JG
   Carroccia, R
   Iommarini, L
   Labauge, P
   Figarella-Branger, D
   Marcorelles, P
   Furby, A
   Beauvais, K
   Letournel, F
   Liguori, R
   La Morgia, C
   Montagna, P
   Liguori, M
   Zanna, C
   Rugolo, M
   Cossarizza, A
   Wissinger, B
   Verny, C
   Schwarzenbacher, R
   Martín, MA
   Arenas, J
   Ayuso, C
   Garesse, R
   Lenaers, G
   Bonneau, D
   Carelli, V
AF Amati-Bonneau, Patrizia
   Valentino, Maria Lucia
   Reynier, Pascal
   Gallardo, Maria Esther
   Bornstein, Belen
   Boissiere, Anne
   Campos, Yolanda
   Rivera, Henry
   de la Aleja, Jesus Gonzalez
   Carroccia, Rosanna
   Iommarini, Luisa
   Labauge, Pierre
   Figarella-Branger, Dominique
   Marcorelles, Pascale
   Furby, Alain
   Beauvais, Katell
   Letournel, Franck
   Liguori, Rocco
   La Morgia, Chiara
   Montagna, Pasquale
   Liguori, Maria
   Zanna, Claudia
   Rugolo, Michela
   Cossarizza, Andrea
   Wissinger, Bernd
   Verny, Christophe
   Schwarzenbacher, Robert
   Martin, Miguel Angel
   Arenas, Joaquin
   Ayuso, Carmen
   Garesse, Rafael
   Lenaers, Guy
   Bonneau, Dominique
   Carelli, Valerio
TI <i>OPA1</i> mutations induce mitochondrial DNA instability and optic
   atrophy plus phenotypes
SO BRAIN
LA English
DT Article
DE mitochondria; mtDNA multiple deletions; dominant optic atrophy;
   mitochondrial encephalomyopathy; chronic progressive external
   ophthalmoplegia
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; R445H MUTATION; HEARING-LOSS;
   DELETIONS; GENE; DISEASE; ASSOCIATION; DYNAMICS; DEAFNESS; PROTEIN
AB Mutations in OPA1, a dynamin-related GTPase involved in mitochondrial fusion, cristae organization and control of apoptosis, have been linked to non-syndromic optic neuropathy transmitted as an autosomal-dominant trait (DOA). We here report on eight patients from six independent families showing that mutations in the OPA1 gene can also be responsible for a syndromic form of DOA associated with sensorineural deafness, ataxia, axonal sensory-motor polyneuropathy, chronic progressive external ophthalmoplegia and mitochondrial myopathy with cytochrome c oxidase negative and Ragged Red Fibres. Most remarkably, we demonstrate that these patients all harboured multiple deletions of mitochondrial DNA (mtDNA) in their skeletal muscle, thus revealing an unrecognized role of the OPA1 protein in mtDNA stability. The five OPA1 mutations associated with these DOA plus phenotypes were all mis-sense point mutations affecting highly conserved amino acid positions and the nuclear genes previously known to induce mtDNA multiple deletions such as POLG1, PEO1 (Twinkle) and SLC25A4 (ANT1) were ruled out. Our results show that certain OPA1 mutations exert a dominant negative effect responsible for multi-systemic disease, closely related to classical mitochondrial cytopathies, by a mechanism involving mtDNA instability.
C1 [Valentino, Maria Lucia; Carroccia, Rosanna; Iommarini, Luisa; Liguori, Rocco; La Morgia, Chiara; Montagna, Pasquale; Carelli, Valerio] Univ Bologna, Dipartimento Sci Neurol, Neurogenet Lab, Via Ugo Foscolo 7, I-40123 Bologna, Italy.
   [Amati-Bonneau, Patrizia; Reynier, Pascal] Ctr Hosp Univ Angers, Dept Biochim & Genet, Angers, France.
   [Amati-Bonneau, Patrizia; Reynier, Pascal] INSERM, U694, Angers, France.
   [Gallardo, Maria Esther; Bornstein, Belen] Univ Autonoma Madrid, Fac Med, Inst Investigac Biomed Alberto Sols CSIC UAM, Dept Bioquim,CIBERERISCIII, Madrid, Spain.
   [Boissiere, Anne; Lenaers, Guy] Univ Montpellier I, Inst Neurosci, INSERM, U583, Montpellier, France.
   [Boissiere, Anne; Lenaers, Guy] Univ Montpellier 2, Inst Neurosci, INSERM, U583, Montpellier, France.
   [Campos, Yolanda; Rivera, Henry; de la Aleja, Jesus Gonzalez; Martin, Miguel Angel; Arenas, Joaquin] Hosp Univ 12 Octubre, CIBERER, ISCIII, Ctr Invest, Madrid, Spain.
   [Campos, Yolanda; Rivera, Henry; de la Aleja, Jesus Gonzalez; Martin, Miguel Angel; Arenas, Joaquin] Hosp Univ 12 Octubre, CIBERER, ISCIII, Serv Neurol, Madrid, Spain.
   [Labauge, Pierre] Ctr Hosp Univ Nimes, Serv Neurol, Nimes, France.
   [Figarella-Branger, Dominique] Ctr Hosp Univ, Hop Timone, Serv Anat Pathol & Neuropathol, Marseille, France.
   [Marcorelles, Pascale] Ctr Hosp Univ Brest, Serv Anat Pathol, Brest, France.
   [Furby, Alain; Beauvais, Katell] Ctr Hosp Univ St Brieuc, Serv Neurol, St Brieuc, France.
   [Letournel, Franck] Ctr Hosp Univ Angers, Lab Neurobiol & Neuropathol, Angers, France.
   [Liguori, Maria] Natl Res Ctr Mangone, Inst Neurol Sci, Cosenza, Italy.
   [Zanna, Claudia; Rugolo, Michela] Univ Bologna, Dipartimento Biol Evoluz Sperimentale, Bologna, Italy.
   [Cossarizza, Andrea] Univ Modena, Sezione Patol Gen, Dipartimento Sci Biomed, I-41100 Modena, Italy.
   [Cossarizza, Andrea] Univ Reggio Emilia, Sezione Patol Gen, Dipartimento Sci Biomed, Reggio Emilia, Italy.
   [Wissinger, Bernd] Univ Eye Hosp Tuebingen, Mol Genet Lab, Tubingen, Germany.
   [Verny, Christophe] Ctr Hosp Univ Angers, Dept Neurol, Angers, France.
   [Schwarzenbacher, Robert] Salzburg Univ, A-5020 Salzburg, Austria.
   [Ayuso, Carmen] Fdn Jimenez Diaz, CIBERER, ISCIII, Madrid, Spain.
C3 University of Bologna; Universite d'Angers; Centre Hospitalier
   Universitaire d'Angers; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Universite d'Angers; Consejo Superior de
   Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones
   Biomedicas Alberto Sols (IIBM); Autonomous University of Madrid;
   Universite de Montpellier; Institut National de la Sante et de la
   Recherche Medicale (Inserm); Universite de Montpellier; Institut
   National de la Sante et de la Recherche Medicale (Inserm); Instituto de
   Salud Carlos III; Hospital Universitario 12 de Octubre; CIBER - Centro
   de Investigacion Biomedica en Red; CIBERER; Hospital Universitario 12 de
   Octubre; CIBER - Centro de Investigacion Biomedica en Red; CIBERER;
   Instituto de Salud Carlos III; Universite de Montpellier; CHU de Nimes;
   Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille; CHU
   Brest; Universite d'Angers; Centre Hospitalier Universitaire d'Angers;
   University of Bologna; Universita di Modena e Reggio Emilia; Universita
   di Modena e Reggio Emilia; Eberhard Karls University of Tubingen;
   Eberhard Karls University Hospital; Universite d'Angers; Centre
   Hospitalier Universitaire d'Angers; Salzburg University; Instituto de
   Salud Carlos III; CIBER - Centro de Investigacion Biomedica en Red;
   CIBERER
RP Carelli, V (corresponding author), Univ Bologna, Dipartimento Sci Neurol, Neurogenet Lab, Via Ugo Foscolo 7, I-40123 Bologna, Italy.
EM valerio.carelli@unibo.it
RI La Morgia, Chiara/H-6765-2012; Zanna, Claudia/GVT-1932-2022; Ayuso,
   Carmen/A-4843-2019; Bonneau, Dominique/K-6110-2015; Yolanda,
   Campos/A-8711-2017; Lenaers, guy/X-4727-2019; Gallardo,
   M./AFK-7298-2022; Rugolo, Michela/AAY-8640-2020; Letournel,
   Franck/K-4263-2015; Liguori, Rocco/AAB-7860-2020; Garesse,
   Rafael/F-3836-2012; BOISSIERE, Anne/ABB-5669-2020; Martin,
   Miguel/S-2758-2018; Reynier, Pascal/K-3677-2015; amati-bonneau,
   patrizia/K-6198-2015; lenaers, guy/K-2421-2015; Iommarini,
   Luisa/J-2328-2018; Martin, Miguel Angel/B-6261-2017; Liguori,
   Maria/D-4390-2016
OI CAMPOS, YOLANDA/0000-0003-4785-9659; BOISSIERE,
   Anne/0000-0003-3958-2602; CARELLI, VALERIO/0000-0003-4923-6404; Rugolo,
   Michela/0000-0002-4597-0452; letournel, franck/0000-0003-2925-4453;
   Ayuso, Carmen/0000-0002-9242-7065; lenaers, guy/0000-0003-2736-3349;
   GALLARDO PEREZ, M. ESTHER/0000-0002-8699-8734; Garesse,
   Rafael/0000-0002-0338-2281; Iommarini, Luisa/0000-0002-6804-7302;
   Liguori, Rocco/0000-0002-1815-1013; Martin, Miguel
   Angel/0000-0003-4741-772X; VALENTINO, MARIA LUCIA/0000-0001-5323-0115;
   Reynier, Pascal/0000-0003-0802-4608; Gonzalez de la Aleja Tejera,
   Jesus/0000-0001-8197-1519; Liguori, Maria/0000-0003-4338-0392; Arenas,
   Joaquin/0000-0002-2877-5049; Cossarizza, Andrea/0000-0002-5381-1558; LA
   MORGIA, Chiara/0000-0002-4639-8929
FU Telethon [GGP06233] Funding Source: Medline
CR Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944
   Amati-Bonneau P, 2005, ANN NEUROL, V58, P958, DOI 10.1002/ana.20681
   Amati-Bonneau P, 2003, AM J OPHTHALMOL, V136, P1170, DOI 10.1016/S0002-9394(03)00665-2
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Bua E, 2006, AM J HUM GENET, V79, P469, DOI 10.1086/507132
   Carelli V, 2004, PROG RETIN EYE RES, V23, P53, DOI 10.1016/j.preteyeres.2003.10.003
   Chen HC, 2005, HUM MOL GENET, V14, pR283, DOI 10.1093/hmg/ddi270
   Chen HC, 2007, CELL, V130, P548, DOI 10.1016/j.cell.2007.06.026
   Cohn AC, 2007, AM J OPHTHALMOL, V143, P656, DOI 10.1016/j.ajo.2006.12.038
   Cossarizza A, 2003, ANTIVIR THER, V8, P315
   Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936
   Delettre C, 2002, MOL GENET METAB, V75, P97, DOI 10.1006/mgme.2001.3278
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Ferré M, 2005, HUM MUTAT, V25, P423, DOI 10.1002/humu.20161
   Frezza C, 2006, CELL, V126, P177, DOI 10.1016/j.cell.2006.06.025
   Ghelli A, 2003, J BIOL CHEM, V278, P4145, DOI 10.1074/jbc.M210285200
   González-Vioque E, 2006, ARCH NEUROL-CHICAGO, V63, P107, DOI 10.1001/archneur.63.1.107
   Herlan M, 2003, J BIOL CHEM, V278, P27781, DOI 10.1074/jbc.M211311200
   Hirano M, 2004, NEUROLOGIST, V10, P8, DOI 10.1097/01.nrl.0000106919.06469.04
   HOPPINS S, 2007, ANN REV BIOCH, V776
   HUDSON G, 2007, BRAIN
   Hudson G, 2006, HUM MOL GENET, V15, pR244, DOI 10.1093/hmg/ddl233
   Jaroszewski L, 2002, PROTEIN SCI, V11, P1702, DOI 10.1110/ps.4820102
   JOHNSTON W, 1995, ANN NEUROL, V37, P16, DOI 10.1002/ana.410370106
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kim JY, 2005, NEUROLOGY, V64, P966, DOI 10.1212/01.WNL.0000157282.76715.B1
   KJER P, 1959, ACTA OPHTHALMOL S54, V37, P1
   LIGUORI M, IN PRESS J NEUROL
   Lodi R, 2004, ANN NEUROL, V56, P719, DOI 10.1002/ana.20278
   Low HH, 2006, NATURE, V444, P766, DOI 10.1038/nature05312
   Malka F, 2006, BBA-MOL CELL RES, V1763, P463, DOI 10.1016/j.bbamcr.2006.04.001
   MEIRE F, 1985, OPHTHALMIC PAED GEN, V5, P91, DOI 10.3109/13816818509007861
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Nakamura M, 2006, OPHTHALMOLOGY, V113, P483, DOI 10.1016/j.ophtha.2005.10.054
   Niemann A, 2005, J CELL BIOL, V170, P1067, DOI 10.1083/jcb.200507087
   Nishigaki Y, 2004, HUM MOL GENET, V13, P91, DOI 10.1093/hmg/ddh010
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Olichon A, 2003, J BIOL CHEM, V278, P7743, DOI 10.1074/jbc.C200677200
   Olichon A, 2006, BBA-MOL CELL RES, V1763, P500, DOI 10.1016/j.bbamcr.2006.04.003
   Payne M, 2004, AM J OPHTHALMOL, V138, P749, DOI 10.1016/j.ajo.2004.06.011
   Pesch UEA, 2001, HUM MOL GENET, V10, P1359, DOI 10.1093/hmg/10.13.1359
   Praefcke GJK, 2004, NAT REV MOL CELL BIO, V5, P133, DOI 10.1038/nrm1313
   Shimizu S, 2003, AM J OPHTHALMOL, V135, P256, DOI 10.1016/S0002-9394(02)01929-3
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Staden R, 2000, Methods Mol Biol, V132, P115
   TREFT RL, 1984, OPHTHALMOLOGY, V91, P908
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Waterham HR, 2007, NEW ENGL J MED, V356, P1736, DOI 10.1056/NEJMoa064436
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
   Züchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341
NR 50
TC 399
Z9 430
U1 1
U2 33
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 1460-2156
J9 BRAIN
JI Brain
PD FEB
PY 2008
VL 131
BP 338
EP 351
DI 10.1093/brain/awm298
PN 2
PG 14
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 258XO
UT WOS:000252903900007
PM 18158317
OA Green Published, Green Submitted, hybrid
DA 2024-11-01
ER

PT J
AU Giordano, C
   Sebastiani, M
   De Giorgio, R
   Travaglini, C
   Tancredi, A
   Valentino, ML
   Bellan, M
   Cossarizza, A
   Hirano, M
   d'Amati, G
   Carelli, V
AF Giordano, Carla
   Sebastiani, Mariangela
   De Giorgio, Roberto
   Travaglini, Claudia
   Tancredi, Andrea
   Valentino, Maria Lucia
   Bellan, Marzio
   Cossarizza, Andrea
   Hirano, Michio
   d'Amati, Giulia
   Carelli, Valerio
TI Gastrointestinal dysmotility in mitochondrial neurogastrointestinal
   encephalomyopathy is caused by mitochondrial DNA depletion
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID THYMIDINE; DELETIONS; EXPRESSION; TISSUES; DISEASE; MODEL
AB Chronic intestinal pseudo-obstruction is a life-threatening condition of unknown pathogenic mechanisms. Chronic intestinal pseudo-obstruction can be a feature of mitochondrial disorders, such as mitochondrial neurogastrointestinal encephalomyopathy (MNGIE), a rare autosomal-recessive syndrome, resulting from mutations in the thymidine phosphorylase gene. MNGIE patients show elevated circulating levels of thyrmidine and deoxyuridine, and accumulate somatic mitochondrial DNA (mtDNA) defects. The present study aimed to clarify the molecular basis of chronic intestinal pseudo-obstruction in MNGIE. Using laser capture microdissection, we correlated the histopathological features with mtDNA defects in different tissues from the gastrointestinal wall of five MNGIE and ten control patients. We found mtDNA depletion, mitochondrial proliferation, and smooth cell atrophy in the external layer of the muscularis propria, in the stomach and in the small intestine of MNGIE patients. in controls, the lowest amounts of mtDNA were present at the same sites, as compared with other layers of the gastrointestinal wall. We also observed mitochondrial proliferation and mtDNA depletion in small vessel endothelial and smooth muscle cells. Thus, visceral mitochondrial myopathy likely causes gastrointestinal dysmotility in MNGIE patients. The low baseline abundance of mtDNA molecules may predispose smooth muscle cells of the muscularis propria external layer to the toxic effects of thymidine and deoxyuridine, and exposure to high circulating levels of nucleosides; may account for the mtDNA depletion observed in the small vessel wall.
C1 [Giordano, Carla; Sebastiani, Mariangela; Travaglini, Claudia; d'Amati, Giulia] Univ Roma La Sapienza, Dipartimento Med Sperimentale, I-00161 Rome, Italy.
   Univ Bologna, Dept Internal Med & Gastroentrol, I-40126 Bologna, Italy.
   Univ Bologna, Dipartimento Sci Neurol, I-40126 Bologna, Italy.
   [Tancredi, Andrea] Univ Roma La Sapienza, Dipartimento Studi Geoecon, Rome, Italy.
   [Hirano, Michio] Columbia Univ, Med Ctr, New York, NY USA.
C3 Sapienza University Rome; University of Bologna; University of Bologna;
   Sapienza University Rome; Columbia University
RP d'Amati, G (corresponding author), Univ Roma La Sapienza, Dipartimento Med Sperimentale, Viale Regina Elena 324, I-00161 Rome, Italy.
EM giulia.damati@uniroma1.it
RI d'Amati, Giulia/F-1251-2011; De Giorgio, Roberto/GSD-7139-2022;
   GIORDANO, Carla/L-5657-2015
OI VALENTINO, MARIA LUCIA/0000-0001-5323-0115; CARELLI,
   VALERIO/0000-0003-4923-6404; De Giorgio, Roberto/0000-0003-0867-5873;
   Cossarizza, Andrea/0000-0002-5381-1558; GIORDANO,
   Carla/0000-0002-3716-4303
FU Associazione Serena Tallarico; MIUR; University of Bologna; Sapienza
   University of Rome; Fondazione Del Monte di Bologna e Ravenna;
   Fondazione Gino Galletti
FX Supported by Associazione Serena Tallarico (grant to M.S.), MIUR and
   R.F.O. from University of Bologna (to R. De G.). by Sapienza University
   of Rome grant (to G. d'A.) by Fondazione Del Monte di Bologna e Ravenna
   (to R. De G.), and by Fondazione Gino Galletti (to V.C.).
CR Archer RGE, 2004, BRIT J PHARMACOL, V143, P202, DOI 10.1038/sj.bjp.0705921
   Bindoff L., 2006, Mitochondrial Medicine, P143
   Connor FL, 2006, GASTROENTEROLOGY, V130, pS29, DOI 10.1053/j.gastro.2005.06.081
   De Giorgio R, 2004, GUT, V53, P1549, DOI 10.1136/gut.2004.043968
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Ferraro P, 2005, J BIOL CHEM, V280, P24472, DOI 10.1074/jbc.M502869200
   GERLACH E, 1985, BASIC RES CARDIOL, V80, P459, DOI 10.1007/BF01907911
   Giordano C, 2006, GASTROENTEROLOGY, V130, P893, DOI 10.1053/j.gastro.2006.01.004
   Heddi A, 1999, J BIOL CHEM, V274, P22968, DOI 10.1074/jbc.274.33.22968
   Hirano M, 2006, NEUROLOGY, V67, P1458, DOI 10.1212/01.wnl.0000240853.97716.24
   Jain D, 2003, AM J GASTROENTEROL, V98, P618, DOI 10.1016/S0002-9270(02)06017-3
   Krishnan KJ, 2007, ANAL BIOCHEM, V370, P127, DOI 10.1016/j.ab.2007.06.024
   Löffler M, 2007, ARTERIOSCL THROM VAS, V27, P1004, DOI 10.1161/ATVBAHA.106.126714
   Mussini C, 2005, AIDS, V19, P1627, DOI 10.1097/01.aids.0000186019.47297.0d
   Nishigaki Y, 2004, HUM MOL GENET, V13, P91, DOI 10.1093/hmg/ddh010
   Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828
   Nishino I, 2000, ANN NEUROL, V47, P792
   Pinheiro J.C., 2000, Mixed-Effect. Model. S and S-Plus, P3
   Pontarin G, 2006, J BIOL CHEM, V281, P22720, DOI 10.1074/jbc.M604498200
   Song SW, 2003, J BIOL CHEM, V278, P43893, DOI 10.1074/jbc.C300401200
   Spinazzola A, 2002, J BIOL CHEM, V277, P4128, DOI 10.1074/jbc.M111028200
   Stanghellini V, 2007, NEUROGASTROENT MOTIL, V19, P440, DOI 10.1111/j.1365-2982.2007.00902.x
   Szigeti K, 2004, ANN NEUROL, V56, P881, DOI 10.1002/ana.20302
   Valentino ML, 2007, FEBS LETT, V581, P3410, DOI 10.1016/j.febslet.2007.06.042
NR 24
TC 76
Z9 79
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD OCT
PY 2008
VL 173
IS 4
BP 1120
EP 1128
DI 10.2353/ajpath.2008.080252
PG 9
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 354OD
UT WOS:000259648000020
PM 18787099
OA Bronze, Green Published
DA 2024-11-01
ER

PT J
AU Hong, DJ
   Bi, HY
   Yao, S
   Wang, ZX
   Yuan, Y
AF Hong, Daojun
   Bi, Hongyan
   Yao, Sheng
   Wang, Zhaoxia
   Yuan, Yun
TI CLINICAL PHENOTYPE OF AUTOSOMAL DOMINANT PROGRESSIVE EXTERNAL
   OPHTHALMOPLEGIA IN A FAMILY WITH A NOVEL MUTATION IN THE C10orf2 GENE
SO MUSCLE & NERVE
LA English
DT Article
DE progressive external ophthalmoplegia; mitochondrion; C10orf2 gene;
   autosomal dominant; cardiac abnormality
ID MITOCHONDRIAL-DNA DELETIONS; TWINKLE GENE; MULTIPLE DELETIONS; HELICASE
   TWINKLE; MTDNA DELETIONS; SWISS-MODEL; PROTEIN; REGION; POLG; FEATURES
AB Autosomal dominant progressive external ophthalmoplegia (adPEO) is a mitochondrial disorder caused by mutations in nuclear genes. Here we report the clinical and genetic features of adPEO in a Chinese family. All patients had gradual onset of ptosis, with or without ophthalmoplegia, around age 30. Thirteen patients had limb weakness around age 40. Eight patients developed dysphagia around age 50. Four patients died of cardiac abnormalities around age 60. Muscle biopsy of the proband indicated mitochondrial myopathy characterized by ragged-red fibers, cytochrome c oxidase-negative fibers, and multiple deletions of mitochondrial DNA. A heterozygous missense mutation of c.1342A>G in the C10orf2 gene resulting in the p.448N>D mutation in the protein was found in the proband and four other affected family members. In summary, we identified an adPEO family with a novel C10orf2 gene mutation that manifested an age-dependent phenotype. It suggests that greater attention must be paid to cardiac abnormalities in the late stages of this disease. Muscle Nerve 41: 92-99, 2010
C1 [Hong, Daojun; Yao, Sheng; Wang, Zhaoxia; Yuan, Yun] Peking Univ, Hosp 1, Dept Neurol, Beijing 100034, Peoples R China.
   [Bi, Hongyan] Capital Med Univ, Dept Neurol, Friendship Hosp, Beijing, Peoples R China.
C3 Peking University; Capital Medical University
RP Yuan, Y (corresponding author), Peking Univ, Hosp 1, Dept Neurol, 8 Xishiku St, Beijing 100034, Peoples R China.
EM yuanyun2002@sohu.com
RI Wang, Zilong/IQV-2260-2023
FU National Science Foundation of China [30870864]
FX The authors thank Professor Dingfang Bu for useful suggestions and Ms.
   Qiurong Zhang for technical assistance in muscle biopsy preparations.
   This research was supported by the grant from National Science
   Foundation of China (NO.30870864). The first two authors contributed
   equally to this work.
CR Baloh RH, 2007, ARCH NEUROL-CHICAGO, V64, P998, DOI 10.1001/archneur.64.7.998
   Carrozzo R, 1999, J NEUROL SCI, V170, P24, DOI 10.1016/S0022-510X(99)00193-8
   Crampton DJ, 2006, MOL CELL, V21, P165, DOI 10.1016/j.molcel.2005.11.027
   Deschauer M, 2003, NEUROMUSCULAR DISORD, V13, P568, DOI 10.1016/S0960-8966(03)00071-3
   Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505
   Hirano M, 2001, NEUROLOGY, V57, P2163, DOI 10.1212/WNL.57.12.2163
   Jeppesen TD, 2008, NEUROMUSCULAR DISORD, V18, P306, DOI 10.1016/j.nmd.2007.10.007
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kiechl S, 2004, J NEUROL NEUROSUR PS, V75, P1125, DOI 10.1136/jnnp.2003.025890
   Kopp J, 2004, NUCLEIC ACIDS RES, V32, pD230, DOI 10.1093/nar/gkh008
   Korhonen JA, 2003, J BIOL CHEM, V278, P48627, DOI 10.1074/jbc.M306981200
   Korhonen JA, 2008, J MOL BIOL, V377, P691, DOI 10.1016/j.jmb.2008.01.035
   Lewis S, 2002, J NEUROL SCI, V201, P39, DOI 10.1016/S0022-510X(02)00190-9
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Matsushima Y, 2007, J BIOL CHEM, V282, P9436, DOI 10.1074/jbc.M610550200
   Nikali K, 2005, HUM MOL GENET, V14, P2981, DOI 10.1093/hmg/ddi328
   Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651
   Rivera H, 2007, NEUROMUSCULAR DISORD, V17, P677, DOI 10.1016/j.nmd.2007.05.006
   Sarzi E, 2007, ANN NEUROL, V62, P579, DOI 10.1002/ana.21207
   Shutt TE, 2006, J MOL EVOL, V62, P588, DOI 10.1007/s00239-005-0162-8
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2002, ACTA NEUROL BELG, V102, P39
   Virgilio R, 2008, J NEUROL, V255, P1384, DOI 10.1007/s00415-008-0926-3
   Wanrooij S, 2004, NUCLEIC ACIDS RES, V32, P3053, DOI 10.1093/nar/gkh634
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
   Ziebarth TD, 2007, J MOL BIOL, V367, P1382, DOI 10.1016/j.jmb.2007.01.079
NR 29
TC 7
Z9 7
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0148-639X
EI 1097-4598
J9 MUSCLE NERVE
JI Muscle Nerve
PD JAN
PY 2010
VL 41
IS 1
BP 92
EP 99
DI 10.1002/mus.21439
PG 8
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 540FB
UT WOS:000273315600011
PM 19705478
DA 2024-11-01
ER

PT J
AU Martín-Hernández, E
   García-Silva, MT
   Quijada-Fraile, P
   Rodríguez-García, ME
   Rivera, H
   Hernández-Laín, A
   Coca-Robinot, D
   Fernández-Toral, J
   Arenas, J
   Martín, MA
   Martínez-Azorín, F
AF Martin-Hernandez, Elena
   Teresa Garcia-Silva, Maria
   Quijada-Fraile, Pilar
   Elena Rodriguez-Garcia, Maria
   Rivera, Henry
   Hernandez-Lain, Aurelio
   Coca-Robinot, David
   Fernandez-Toral, Joaquin
   Arenas, Joaquin
   Martin, Miguel A.
   Martinez-Azorin, Francisco
TI Myopathic mtDNA Depletion Syndrome Due to Mutation in <i>TK2</i> Gene
SO PEDIATRIC AND DEVELOPMENTAL PATHOLOGY
LA English
DT Article
DE mitochondria; mitochondrial DNA; whole-exome sequencing; TK2; mtDNA
   depletion syndromes; myopathy
ID MITOCHONDRIAL-DNA DEPLETION
AB Whole-exome sequencing was used to identify the disease gene(s) in a Spanish girl with failure to thrive, muscle weakness, mild facial weakness, elevated creatine kinase, deficiency of mitochondrial complex III and depletion of mtDNA. With wholeexome sequencing data, it was possible to get the whole mtDNA sequencing and discard any pathogenic variant in this genome. The analysis of whole exome uncovered a homozygous pathogenic mutation in thymidine kinase 2 gene (TK2; NM_004614.4:c.323C>T, p.T108M). TK2 mutations have been identified mainly in patients with the myopathic form of mtDNA depletion syndromes. This patient presents an atypical TK2-related myopathic form of mtDNA depletion syndromes, because despite having a very low content of mtDNA (<20%), she presents a slower and less severe evolution of the disease. In conclusion, our data confirm the role of TK2 gene in mtDNA depletion syndromes and expanded the phenotypic spectrum.
C1 [Martin-Hernandez, Elena; Teresa Garcia-Silva, Maria; Quijada-Fraile, Pilar] Hosp Univ 12 Octubre, Unidad Pediat Enfermedades Raras Metab Hereditari, Dept Pediat, Madrid, Spain.
   [Teresa Garcia-Silva, Maria; Rivera, Henry; Arenas, Joaquin; Martin, Miguel A.; Martinez-Azorin, Francisco] CIBERER, Madrid, Spain.
   [Elena Rodriguez-Garcia, Maria; Rivera, Henry; Arenas, Joaquin; Martin, Miguel A.; Martinez-Azorin, Francisco] Hosp Univ 12 Octubre I 12, Lab Enfermedades Mitocondriales, Inst Invest, Madrid, Spain.
   [Hernandez-Lain, Aurelio] Hosp Univ 12 Octubre, Serv Anat Patol Neuropatol, Madrid, Spain.
   [Coca-Robinot, David] Hosp Univ 12 Octubre, Serv Radiol Pediat, Madrid, Spain.
   [Fernandez-Toral, Joaquin] HUCA, Unidad Genet, Oviedo, Asturias, Spain.
C3 Hospital Universitario 12 de Octubre; CIBER - Centro de Investigacion
   Biomedica en Red; CIBERER; Hospital Universitario 12 de Octubre;
   Hospital Universitario 12 de Octubre; Hospital Universitario 12 de
   Octubre; Central University Hospital Asturias
RP Martínez-Azorín, F (corresponding author), Hosp 12 Octubre I 12, Lab Enfermedades Mitocondriales, CAA, 6a Planta,Bloque E,Avda Cordoba S-N, E-28041 Madrid, Spain.
EM fmartinez@h12o.es
RI Lain, Aurelio/S-6172-2018; Martin, Miguel/S-2758-2018; Martínez-Azorín,
   Francisco/HJZ-3939-2023; Martin, Miguel Angel/B-6261-2017
OI Martin-Hernandez, Elena/0000-0002-0656-7660; Martin, Miguel
   Angel/0000-0003-4741-772X; Arenas, Joaquin/0000-0002-2877-5049;
   Martinez-Azorin, Francisco/0000-0001-6250-7745; Rodriguez Garcia, Maria
   Elena/0000-0002-4560-6546
FU Spanish Instituto de Salud Carlos III (ISCIII); European Regional
   Development Fund (ERDF) [PI10/00063, PI14/00790]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This work
   was supported by Spanish Instituto de Salud Carlos III (ISCIII) and
   European Regional Development Fund (ERDF) (grant PI10/00063 and
   PI14/00790 to F.M-A.).
CR Béhin A, 2012, NEUROLOGY, V78, P644, DOI 10.1212/WNL.0b013e318248df2b
   Calvo SE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003310
   Cámara Y, 2015, NEUROLOGY, V84, P2286, DOI 10.1212/WNL.0000000000001644
   Delmiro A, 2013, HUM MUTAT, V34, P1623, DOI 10.1002/humu.22445
   Mancuso M, 2003, ARCH NEUROL-CHICAGO, V60, P1007, DOI 10.1001/archneur.60.7.1007
   Nogueira C, 2014, ITAL J PEDIATR, V40, DOI 10.1186/1824-7288-40-34
   Paradas C, 2013, NEUROLOGY, V80, P504, DOI 10.1212/WNL.0b013e31827f0ff7
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
NR 8
TC 5
Z9 6
U1 0
U2 7
PU ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS
PI LAWRENCE
PA 810 EAST 10TH STREET, LAWRENCE, KS 66044 USA
SN 1093-5266
EI 1615-5742
J9 PEDIATR DEVEL PATHOL
JI Pediatr. Dev. Pathol.
PD SEP-OCT
PY 2017
VL 20
IS 5
BP 416
EP 420
DI 10.1177/1093526616686439
PG 5
WC Pathology; Pediatrics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology; Pediatrics
GA FI9CK
UT WOS:000412301100007
PM 28812460
DA 2024-11-01
ER

PT J
AU Rocha, EBD
   Rodrigues, KD
   Montouro, LAM
   Coelho, EN
   Kouyoumdjian, JA
   Kok, F
   Nóbrega, PR
   Graca, CR
   Morita, MDA
   Estephan, ED
AF Rocha, Emanuelle Bianchi da Silva
   Rodrigues, Ketteny de Lima
   Montouro, Laura Alonso Matheus
   Coelho, erica Nogueira
   Kouyoumdjian, Joao Aris
   Kok, Fernando
   Nobrega, Paulo Ribeiro
   Graca, Carla Renata
   Morita, Maria da Penha Ananias
   Estephan, Eduardo de Paula
TI A case of mitochondrial DNA depletion syndrome type 11-expanding the
   genotype and phenotype
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE Mitochondrial diseases; Chronic progressive external ophthalmoplegia;
   mtDNA depletion syndrome; MGME1
ID MUTATIONS; SEQUENCE; MGME1
AB Mitochondrial DNA depletion syndrome type 11 (MTDPS11) is caused by pathogenic variants in MGME1 gene. We report a woman, 40-year-old, who presented slow progressive drop eyelid at 11-year old with, learning difficulty and frequent falls. Phisical examination revealed: mild scoliosis, elbow hyperextensibility, flat feet, chronic progressive external ophthalmoplegia with upper eyelid ptosis, diffuse hypotonia, and weakness of arm abduction and neck flexion. Investigation evidenced mild serum creatine kinase increase and glucose intolerance; second-degree atrioventricular block; mild mixed type respiratory disorder and atrophy and granular appearance of the retinal pigment epithelium. Brain magnetic resonance showed cerebellar atrophy. Muscle biopsy was compatible with mitochondrial myopathy. Genetic panel revealed a homozygous pathogenic variant in the MGME1 gene, consistent with MTDPS11 (c.862C > T; p.Gln288 *). This case of MTDPS11 can contribute to the phenotypic characterization of this ultra-rare mitochondrial disorder, presenting milder respiratory and nutritional involvement than the previously reported cases, with possible additional features.(c) 2023 Elsevier B.V. All rights reserved.
C1 [Rocha, Emanuelle Bianchi da Silva; Rodrigues, Ketteny de Lima; Montouro, Laura Alonso Matheus; Kouyoumdjian, Joao Aris; Graca, Carla Renata; Morita, Maria da Penha Ananias] Fac Estadual Med Sao Jose Do Rio Preto FAMERP, Dept Neurol Sci Psychiat & Med Psychol, Brigadeiro Faria Lima Ave,5416, BR-15090000 Sao Jose Do Rio Preto, SP, Brazil.
   [Coelho, erica Nogueira] Fdn Fac Reg Med Sao Jose Do Rio Preto FUNFARME, Dept Neurol Sci Psychiat & Med Psychol, Brigadeiro Faria Lima Ave,5416, BR-15090000 Sao Jose Do Rio Preto, SP, Brazil.
   [Kok, Fernando] Univ Sao Paulo FMUSP, Dept Neurol, Fac Med, Ovidio Pires Campos St,225, BR-05403010 Sao Paulo, Brazil.
   [Nobrega, Paulo Ribeiro] Univ Fed Ceara UFC, Dept Neurol, Fac Med, Alexandre Barauna,949, BR-60430160 Fortaleza, CE, Brazil.
   [Estephan, Eduardo de Paula] Hosp Santa Marcelina, Dept Neurol, Sao Paulo, Brazil.
   [Estephan, Eduardo de Paula] Fac Med Santa Marcelina FASM, Dept Med Clin, Sao Paulo, Brazil.
   [Estephan, Eduardo de Paula] Av Dr Eneas Carvalho Aguiar 255,5,Sala 5084, BR-05403900 Sao Paulo, SP, Brazil.
C3 Universidade Federal do Ceara
RP Estephan, ED (corresponding author), Av Dr Eneas Carvalho Aguiar 255,5,Sala 5084, BR-05403900 Sao Paulo, SP, Brazil.
EM eduardo.estephan@santamarcelina.edu.br
RI Estephan, Eduardo/U-7659-2019; Kouyoumdjian, Joao/M-7234-2019
OI Rodrigues, Ketteny/0000-0002-0473-3290; Alonso Matheus Montouro,
   Laura/0000-0001-9856-9921; Estephan, Eduardo/0000-0002-6807-1951
CR Ahmed N, 2015, INT J MOL SCI, V16, P18054, DOI 10.3390/ijms160818054
   Basel D, 2020, CLIN PERINATOL, V47, P123, DOI 10.1016/j.clp.2019.10.008
   DiMauro S, 2004, BBA-BIOENERGETICS, V1658, P80, DOI 10.1016/j.bbabio.2004.03.014
   Gorman GS, 2016, NAT REV DIS PRIMERS, V2, P1, DOI 10.1038/nrdp.2016.80
   Hebbar M, 2017, EUR J MED GENET, V60, P533, DOI 10.1016/j.ejmg.2017.07.010
   Knizewski L, 2007, BMC STRUCT BIOL, V7, DOI 10.1186/1472-6807-7-40
   Kornblum C, 2013, NAT GENET, V45, P214, DOI 10.1038/ng.2501
   Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30
   Steczkiewicz K, 2012, NUCLEIC ACIDS RES, V40, P7016, DOI 10.1093/nar/gks382
   Zhu ZH, 2017, ADV EXP MED BIOL, V1038, P219, DOI 10.1007/978-981-10-6674-0_15
NR 10
TC 4
Z9 4
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD AUG
PY 2023
VL 33
IS 8
BP 692
EP 696
DI 10.1016/j.nmd.2023.06.004
EA AUG 2023
PG 5
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA W9CY5
UT WOS:001094547300001
PM 37429773
DA 2024-11-01
ER

PT J
AU Kiechl, S
   Horváth, R
   Luoma, P
   Kiechl-Kohlendorfer, U
   Wallacher-Scholz, B
   Stucka, R
   Thaler, C
   Wanschitz, J
   Suomalainen, A
   Jaksch, M
   Willeit, J
AF Kiechl, S
   Horváth, R
   Luoma, P
   Kiechl-Kohlendorfer, U
   Wallacher-Scholz, B
   Stucka, R
   Thaler, C
   Wanschitz, J
   Suomalainen, A
   Jaksch, M
   Willeit, J
TI Two families with autosomal dominant progressive external
   ophthalmoplegia
SO JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
LA English
DT Article
ID MITOCHONDRIAL-DNA DELETIONS; MTDNA DELETIONS; MUTATIONS; TWINKLE; GENE;
   FEATURES; DISEASES; POLG; ANT1; ENCEPHALOMYOPATHY
AB Objectives: We report here the clinical and genetic features of two new families with autosomal dominant progressive external ophthalmoplegia (adPEO).
   Patients and methods: The examination of index patients included a detailed clinical characterisation, histological analysis of muscle biopsy specimens, and genetic testing of mitochondrial and nuclear DNA extracted from muscle and leucocytes.
   Results: Index patients in both families presented with PEO and developed other clinical disease manifestations, such as myopathy and cardiomyopathy ( patient 1) and axonal neuropathy, diabetes mellitus, hearing loss, and myopathy ( patient 2), later in the course of illness. Both patients had ragged red fibres on muscle histology. Southern blot of mtDNA from muscle of patient 2 showed multiple deletions. In this case, a novel heterozygous missense mutation F485L was identified in the nuclear encoded putative mitochondrial helicase Twinkle. The mutation co-segregated with the clinical phenotype in the family and was not detected in 150 control chromosomes. In the other index patient, sequencing of ANT1, C10orf2 ( encoding for Twinkle), and POLG1 did not reveal pathogenic mutations.
   Conclusions: Our cases illustrate the clinical variability of adPEO, add a novel pathogenic mutation in Twinkle ( F485L) to the growing list of genetic abnormalities in adPEO, and reinforce the relevance of other yet unidentified genes in mtDNA maintenance and pathogenesis of adPEO.
C1 Univ Innsbruck Hosp, Dept Neurol, A-6020 Innsbruck, Austria.
   Metab Dis Ctr Munich Schwabing, Munich, Germany.
   Acad Hosp Schwabing, Dept Clin Chem, Munich, Germany.
   Univ Helsinki, Biomedicum Helsinki, Program Neurosci, FIN-00014 Helsinki, Finland.
   Univ Helsinki, Dept Neurol, FIN-00014 Helsinki, Finland.
   Univ Innsbruck Hosp, Dept Neonatol, A-6020 Innsbruck, Austria.
   Acad Hosp Schwabing, Dept Pediat, Munich, Germany.
   Univ Munich, Gene Ctr, Munich, Germany.
C3 Medical University of Innsbruck; University of Helsinki; University of
   Helsinki; Medical University of Innsbruck; University of Munich
RP Kiechl, S (corresponding author), Univ Innsbruck, Dept Neurol, Anichstr 35, A-6020 Innsbruck, Austria.
EM stefan.kiechl@uibk.ac.at
RI Horvath, Rita/AAY-7042-2020; Kiechl, Stefan/GQP-0351-2022
OI Suomalainen-Wartiovaara, Anu/0000-0003-4833-5195; Horvath,
   Rita/0000-0002-9841-170X
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Carrozzo R, 1998, NEUROLOGY, V50, P99, DOI 10.1212/WNL.50.1.99
   Chalmers RM, 1996, J NEUROL SCI, V143, P41, DOI 10.1016/S0022-510X(96)00032-9
   FISCHER JC, 1986, EUR J PEDIATR, V144, P441, DOI 10.1007/BF00441735
   Hirano M, 2001, NEUROLOGY, V57, P2163, DOI 10.1212/WNL.57.12.2163
   Hofmann S, 1997, GENOMICS, V39, P8, DOI 10.1006/geno.1996.4474
   JAKSCH M, 1995, CLIN BIOCHEM, V28, P503, DOI 10.1016/0009-9120(95)00035-8
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   KAWAI H, 1995, MUSCLE NERVE, V18, P753, DOI 10.1002/mus.880180712
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Lewis S, 2002, J NEUROL SCI, V201, P39, DOI 10.1016/S0022-510X(02)00190-9
   Moraes CT, 2001, NAT GENET, V28, P200, DOI 10.1038/90020
   Moslemi AR, 1999, NEUROLOGY, V53, P79, DOI 10.1212/WNL.53.1.79
   Napoli L, 2001, NEUROLOGY, V57, P2295, DOI 10.1212/WNL.57.12.2295
   Siciliano G, 2003, NEUROMUSCULAR DISORD, V13, P162, DOI 10.1016/S0960-8966(02)00221-3
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Suomalainen A, 2001, AM J MED GENET, V106, P53, DOI 10.1002/ajmg.1379
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   ZEVIANI M, 1990, AM J HUM GENET, V47, P904
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 21
TC 26
Z9 27
U1 0
U2 1
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-3050
J9 J NEUROL NEUROSUR PS
JI J. Neurol. Neurosurg. Psychiatry
PD AUG
PY 2004
VL 75
IS 8
BP 1125
EP 1128
DI 10.1136/jnnp.2003.025890
PG 4
WC Clinical Neurology; Psychiatry; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Psychiatry; Surgery
GA 838QJ
UT WOS:000222727800010
PM 15258213
OA Green Published, Bronze
DA 2024-11-01
ER

PT J
AU Domínguez-González, C
   Fernández-Torrón, R
   Moore, U
   de la Hoz, CPDF
   Vélez-Gómez, B
   Cabezas, JA
   Alonso-Pérez, J
   González-Mera, L
   Olivé, M
   García-García, J
   Moris, G
   Hernández, JCL
   Muelas, N
   Servian-Morilla, E
   Martin, MA
   Díaz-Manera, J
   Paradas, C
AF Dominguez-Gonzalez, Cristina
   Fernandez-Torron, Roberto
   Moore, Ursula
   de Fuenmayor-Fernandez de la Hoz, Carlos Pablo
   Velez-Gomez, Beatriz
   Antonio Cabezas, Juan
   Alonso-Perez, Jorge
   Gonzalez-Mera, Laura
   Olive, Montse
   Garcia-Garcia, Jorge
   Moris, German
   Leon Hernandez, Juan Carlos
   Muelas, Nuria
   Servian-Morilla, Emilia
   Martin, Miguel A.
   Diaz-Manera, Jordi
   Paradas, Carmen
TI Muscle MRI characteristic pattern for late-onset TK2 deficiency
   diagnosis
SO JOURNAL OF NEUROLOGY
LA English
DT Article
DE TK2; Mitochondrial myopathy; MRI
ID MITOCHONDRIAL-DNA DEPLETION; MAGNETIC-RESONANCE-SPECTROSCOPY; THYMIDINE
   KINASE; IMAGING PATTERNS; INVOLVEMENT
AB Background and objective TK2 deficiency (TK2d) is a rare mitochondrial disorder that manifests predominantly as a progressive myopathy with a broad spectrum of severity and age of onset. The rate of progression is variable, and the prognosis is poor due to early and severe respiratory involvement. Early and accurate diagnosis is particularly important since a specific treatment is under development. This study aims to evaluate the diagnostic value of lower limb muscle MRI in adult patients with TK2d. Methods We studied a cohort of 45 genetically confirmed patients with mitochondrial myopathy (16 with mutations in TK2, 9 with mutations in other nuclear genes involved in mitochondrial DNA [mtDNA] synthesis or maintenance, 10 with single mtDNA deletions, and 10 with point mtDNA mutations) to analyze the imaging pattern of fat replacement in lower limb muscles. We compared the identified pattern in patients with TK2d with the MRI pattern of other non-mitochondrial genetic myopathies that share similar clinical characteristics. Results We found a consistent lower limb muscle MRI pattern in patients with TK2d characterized by involvement of the gluteus maximus, gastrocnemius medialis, and sartorius muscles. The identified pattern in TK2 patients differs from the known radiological involvement of other resembling muscle dystrophies that share clinical features. Conclusions By analyzing the largest cohort of muscle MRI from patients with mitochondrial myopathies studied to date, we identified a characteristic and specific radiological pattern of muscle involvement in patients with TK2d that could be useful to speed up its diagnosis.
C1 [Dominguez-Gonzalez, Cristina; de Fuenmayor-Fernandez de la Hoz, Carlos Pablo] Hosp Univ 12 Octubre, Neurol Dept, Neuromuscular Dis Unit, Madrid, Spain.
   [Dominguez-Gonzalez, Cristina; Martin, Miguel A.] Hosp 12 Octubre Res Inst Imas12, Madrid, Spain.
   [Dominguez-Gonzalez, Cristina; Olive, Montse; Muelas, Nuria; Martin, Miguel A.; Diaz-Manera, Jordi] Inst Salud Carlos III, Biomed Network Res Ctr Rare Dis CIBERER, Madrid, Spain.
   [Fernandez-Torron, Roberto] Hosp Donostia, Biodonostia Hlth Res Inst, Neurol Dept, Basque Hlth Serv,Neuromuscular Area,Doctor Begiri, Donostia San Sebastian, Spain.
   [Moore, Ursula; Diaz-Manera, Jordi] Univ Newcastle, John Walton Muscular Dystrophy Res Ctr, Newcastle Upon Tyne, Tyne & Wear, England.
   [Velez-Gomez, Beatriz; Antonio Cabezas, Juan; Servian-Morilla, Emilia; Paradas, Carmen] Hosp Univ Virgen del Rocio, Neurol Dept, Neuromuscular Dis Unit, Inst Biomed Sevilla, Seville, Spain.
   [Velez-Gomez, Beatriz; Servian-Morilla, Emilia; Paradas, Carmen] Ctr Invest Biomed Red Enfermedades Neurodegenerat, Madrid, Spain.
   [Alonso-Perez, Jorge; Olive, Montse] Univ Autonoma Barcelona, Neurol Dept, Neuromuscular Dis Unit, Hosp Santa Creu & St Pau, Bellaterra, Spain.
   [Gonzalez-Mera, Laura] IDIBELL Hosp Univ Bellvitge, Neurol Dept, Neuromuscular Dis Unit, Barcelona, Spain.
   [Olive, Montse; Diaz-Manera, Jordi] Hosp Santa Creu & Sant Pau, Inst Recerca, Barcelona, Spain.
   [Garcia-Garcia, Jorge] Univ Albacete, Dept Neurol Hosp, Albacete, Spain.
   [Moris, German] Hosp Univ Cent Asturias, Neuromuscular Dis Unit, Neurol Dept, Asturias, Spain.
   [Leon Hernandez, Juan Carlos] Univ Nuestra Senora Candelaria, Neurol Dept Hosp, Tenerife, Spain.
   [Muelas, Nuria] Hosp Univ & Politecn La Fe, Inst Invest Sanitaria La Fe, Neurol Dept, Neuromuscular Dis Unit,Neuromuscular & Ataxias Re, Valencia, Spain.
   [Martin, Miguel A.] Hosp Univ 12 Octubre, Clin Biochem Dept, Mitochondrial Disorders Lab, Madrid, Spain.
   [Paradas, Carmen] Hosp Univ Virgen del Rocio, Unidad Enfermedades Neuromusculares CSUR EURO NMD, Inst Biomed Sevilla, Seville, Spain.
   [Diaz-Manera, Jordi] Newcastle Univ, John Walton Muscular Dystrophy Res Ctr, Clin Res Inst, Cent Pkwy, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.
C3 Hospital Universitario 12 de Octubre; University of Barcelona; Instituto
   de Salud Carlos III; CIBER - Centro de Investigacion Biomedica en Red;
   CIBERER; University Hospital Donostia; Instituto de Investigacion
   Sanitaria Biogipuzkoa; Newcastle University - UK; Consejo Superior de
   Investigaciones Cientificas (CSIC); University of Sevilla; CSIC-JA-USE -
   Instituto de Biomedicina de Sevilla (IBIS); Virgen del Rocio University
   Hospital; CIBERNED; Hospital of Santa Creu i Sant Pau; Autonomous
   University of Barcelona; Institut d'Investigacio Biomedica de Bellvitge
   (IDIBELL); Bellvitge University Hospital; University of Barcelona;
   CIBERNED; Hospital of Santa Creu i Sant Pau; Autonomous University of
   Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut
   de Recerca (VHIR); Central University Hospital Asturias; Hospital
   Universitari i Politecnic La Fe; Hospital Universitario 12 de Octubre;
   Consejo Superior de Investigaciones Cientificas (CSIC); University of
   Sevilla; CSIC-JA-USE - Instituto de Biomedicina de Sevilla (IBIS);
   Virgen del Rocio University Hospital; Newcastle University - UK
RP Díaz-Manera, J (corresponding author), Inst Salud Carlos III, Biomed Network Res Ctr Rare Dis CIBERER, Madrid, Spain.; Díaz-Manera, J (corresponding author), Univ Newcastle, John Walton Muscular Dystrophy Res Ctr, Newcastle Upon Tyne, Tyne & Wear, England.; Paradas, C (corresponding author), Hosp Univ Virgen del Rocio, Neurol Dept, Neuromuscular Dis Unit, Inst Biomed Sevilla, Seville, Spain.; Paradas, C (corresponding author), Ctr Invest Biomed Red Enfermedades Neurodegenerat, Madrid, Spain.; Díaz-Manera, J (corresponding author), Hosp Santa Creu & Sant Pau, Inst Recerca, Barcelona, Spain.; Paradas, C (corresponding author), Hosp Univ Virgen del Rocio, Unidad Enfermedades Neuromusculares CSUR EURO NMD, Inst Biomed Sevilla, Seville, Spain.; Díaz-Manera, J (corresponding author), Newcastle Univ, John Walton Muscular Dystrophy Res Ctr, Clin Res Inst, Cent Pkwy, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.
EM cparadas@us.es
RI Garcia-García, Jorge/AFF-9149-2022; Moris, German/AAT-8916-2021;
   Vélez-Gómez, Beatriz/HTM-1567-2023; Martin, Miguel/S-2758-2018; Martin,
   Miguel Angel/B-6261-2017; Moris, German/M-2920-2018
OI Alonso-Perez, Jorge/0000-0001-8866-5186; Martin, Miguel
   Angel/0000-0003-4741-772X; Velez-Gomez, Beatriz/0000-0001-5796-5872;
   Moris, German/0000-0001-7608-2194; Fernandez-Torron,
   Roberto/0000-0002-2202-8165; de Fuenmayor Fernandez de la Hoz, Carlos
   Pablo/0000-0003-4766-4974; Garcia-Garcia, Jorge/0000-0001-9867-9709;
   Dominguez, Cristina/0000-0001-5151-988X; Gonzalez-Mera,
   Laura/0000-0001-5691-0343
FU Instituto de Salud Carlos III; FEDER [PI18/01374, PMP15/00025]
FX This work was supported in part by the Instituto de Salud Carlos III and
   FEDER (PI18/01374 to MA.M and PMP15/00025 to CP, MO and MAM.). CD-G, CP,
   NM and MO are members of the European Reference Network for
   Neuromuscular Diseases (EURO-NMD) and MO is member of XUECs (Xarxes
   d'Unitats d'Expertesa Clinica en Malalties Minoritaries de Catalunya).
CR Aivazoglou LU, 2021, EUR RADIOL, V31, P8498, DOI 10.1007/s00330-021-07931-9
   Alonso-Jimenez A, 2019, J NEUROL NEUROSUR PS, V90, P576, DOI 10.1136/jnnp-2018-319578
   Alonso-Pérez J, 2020, BRAIN, V143, P2696, DOI 10.1093/brain/awaa228
   Ashley N, 2007, HUM MOL GENET, V16, P1400, DOI 10.1093/hmg/ddm090
   Béhin A, 2012, NEUROLOGY, V78, P644, DOI 10.1212/WNL.0b013e318248df2b
   Carbonell-Corvilloa P, 2018, NEUROMUSCULAR DISORD, V28, P828, DOI 10.1016/j.nmd.2018.07.006
   Castiglioni C, 2014, MUSCLE NERVE, V50, P1011, DOI 10.1002/mus.24353
   Chanprasert S, 2013, MOL GENET METAB, V110, P153, DOI 10.1016/j.ymgme.2013.07.009
   Cohen Bruce H, 2019, Continuum (Minneap Minn), V25, P1732, DOI 10.1212/CON.0000000000000805
   Diaz-Manera J, 2018, J NEUROL NEUROSUR PS, V89, P1071, DOI 10.1136/jnnp-2017-317488
   Dominguez-Gonzalez C, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-66940-8
   Domínguez-González C, 2019, ANN NEUROL, V86, P293, DOI 10.1002/ana.25506
   Domínguez-González C, 2019, ORPHANET J RARE DIS, V14, DOI 10.1186/s13023-019-1071-z
   Donkervoort S, 2019, ACTA NEUROPATHOL, V138, P1013, DOI 10.1007/s00401-019-02059-z
   Fischer D, 2008, NEUROLOGY, V71, P758, DOI 10.1212/01.wnl.0000324927.28817.9b
   Garone C, 2018, J MED GENET, V55, P515, DOI 10.1136/jmedgenet-2017-105012
   Gorman GS, 2016, NAT REV DIS PRIMERS, V2, P1, DOI 10.1038/nrdp.2016.80
   Hankiewicz K, 2015, MUSCLE NERVE, V52, P728, DOI 10.1002/mus.24634
   Hedermann G, 2018, NEUROMUSCULAR DISORD, V28, P408, DOI 10.1016/j.nmd.2018.02.008
   Kemp GJ, 2015, ACTA PHYSIOL, V213, P107, DOI 10.1111/apha.12307
   Kornblum C, 2005, EUR J NEUROL, V12, P300, DOI 10.1111/j.1468-1331.2004.00970.x
   Leung DG, 2017, J NEUROL, V264, P1320, DOI 10.1007/s00415-016-8350-6
   Mancuso M, 2017, NEUROMUSCULAR DISORD, V27, P1126, DOI 10.1016/j.nmd.2017.08.006
   MATTHEWS PM, 1991, ANN NEUROL, V29, P435, DOI 10.1002/ana.410290416
   MATTHEWS PM, 1991, NEUROLOGY, V41, P114, DOI 10.1212/WNL.41.1.114
   Olivé M, 2011, NEUROMUSCULAR DISORD, V21, P533, DOI 10.1016/j.nmd.2011.05.002
   Paradas C, 2013, NEUROLOGY, V80, P504, DOI 10.1212/WNL.0b013e31827f0ff7
   Parikh S, 2017, GENET MED, V19, DOI 10.1038/gim.2017.107
   Peterle E, 2013, J NEUROL, V260, P2033, DOI 10.1007/s00415-013-6931-1
   Rodríguez-López C, 2020, J MED GENET, V57, P643, DOI 10.1136/jmedgenet-2019-106649
   Saada A, 2003, BIOCHEM BIOPH RES CO, V310, P963, DOI 10.1016/j.bbrc.2003.09.104
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Tasca G, 2017, NEUROMUSCULAR DISORD, V27, P500, DOI 10.1016/j.nmd.2017.03.001
   Tasca G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038779
   Tordjman M, 2018, EUR RADIOL, V28, P5293, DOI 10.1007/s00330-018-5472-5
   Verdú-Díaz J, 2020, NEUROLOGY, V94, pE1094, DOI [10.1212/WNL.0000000000008902, 10.1212/WNL.0000000000009068]
   Wang JL, 2018, MOL GENET METAB, V124, P124, DOI 10.1016/j.ymgme.2018.04.012
NR 37
TC 6
Z9 6
U1 1
U2 8
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-5354
EI 1432-1459
J9 J NEUROL
JI J. Neurol.
PD JUL
PY 2022
VL 269
IS 7
BP 3550
EP 3562
DI 10.1007/s00415-021-10957-0
EA MAR 2022
PG 13
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 2I0AS
UT WOS:000768655800001
PM 35286480
OA Green Published, hybrid
DA 2024-11-01
ER

PT J
AU Mancuso, M
   Orsucci, D
   Ienco, EC
   Ricci, G
   Ali, G
   Servadio, A
   Fontanini, G
   Filosto, M
   Vielmi, V
   Rocchi, A
   Petrozzi, L
   LoGerfo, A
   Siciliano, G
AF Mancuso, Michelangelo
   Orsucci, Daniele
   Ienco, Elena Caldarazzo
   Ricci, Giulia
   Ali, Greta
   Servadio, Adele
   Fontanini, Gabriella
   Filosto, Massimiliano
   Vielmi, Valentina
   Rocchi, Anna
   Petrozzi, Lucia
   LoGerfo, Annalisa
   Siciliano, Gabriele
TI An "inflammatory" mitochondrial myopathy. A case report
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE CPEO; Inflammation; IVIg; mtDNA; Respiratory failure
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; MULTIPLE-SCLEROSIS; DNA;
   NEURODEGENERATION; MUTATION; DISEASE; GENE
AB We describe a case of an adult male patient with progressive external ophthalmoplegia and upper limb weakness, who presented with an episode of sudden respiratory failure. Muscle biopsy showed ragged-red and COX-negative fibers associated with discrete inflammatory infiltrates and necrotizing features. Apart from artificial ventilator support, he was treated with intravenous immunoglobulins and carnitine, with excellent clinical outcome. Mitochondrial DNA analysis revealed the 3251A > G mutation, previously reported in association with rapidly progressive mitochondrial myopathy and respiratory failure. Our case expands the spectrum of this mutation and suggests a therapeutib attempt with immunoglobulins in mitochondrial patients with acute respiratory failure, at least when this mutation and/or muscle inflammation is present. Moreover, this case supports the idea of a "pathologic inflammatory response induced by mitochondrial disease; such an abnormal response may be a contributory factor in disease progression or acute exacerbation typical of some mitochondrial diseases, but further studies are needed. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Mancuso, Michelangelo; Orsucci, Daniele; Ienco, Elena Caldarazzo; Ricci, Giulia; Rocchi, Anna; Petrozzi, Lucia; LoGerfo, Annalisa; Siciliano, Gabriele] Univ Pisa, Neurol Clin, I-56126 Pisa, Italy.
   [Ali, Greta; Servadio, Adele; Fontanini, Gabriella] Univ Pisa, Dept Surg, Div Anat Pathol, I-56126 Pisa, Italy.
   [Filosto, Massimiliano; Vielmi, Valentina] Univ Brescia, Neurol Inst, I-25121 Brescia, Italy.
C3 University of Pisa; University of Pisa; University of Brescia
RP Mancuso, M (corresponding author), Univ Pisa, Neurol Clin, Via Roma 67, I-56126 Pisa, Italy.
EM mancusomichelangelo@gmail.com
RI Orsucci, Daniele/AAA-7576-2019; Mancuso, Michelangelo/K-4170-2016;
   Ienco, Elena/K-9142-2016; Filosto, Massimiliano/S-9446-2019; Fontanini,
   Gabriella/O-7636-2015; Ricci, Giulia/K-6731-2016; LoGerfo,
   Annalisa/K-6491-2016; Ali, Greta/J-9642-2016; Siciliano,
   Gabriele/K-7259-2016
OI Fontanini, Gabriella/0000-0003-1957-2052; Caldarazzo Ienco,
   Elena/0000-0003-0134-5062; mancuso, michelangelo/0000-0003-2738-8562;
   Ricci, Giulia/0000-0002-6612-5995; Filosto,
   Massimiliano/0000-0002-2852-7512; Orsucci, Daniele/0000-0003-4847-7812;
   LoGerfo, Annalisa/0000-0001-7825-0649; Ali, Greta/0000-0001-9258-3466;
   Siciliano, Gabriele/0000-0002-6142-2384
FU Telethon Grant [GUP09004]
FX This study was partially supported by Telethon Grant GUP09004.
CR Cohen O, 1998, J NEUROL NEUROSUR PS, V64, P410, DOI 10.1136/jnnp.64.3.410
   Di Filippo M, 2010, J ALZHEIMERS DIS, V20, pS369, DOI 10.3233/JAD-2010-100543
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Echaniz-Laguna A, 2010, ARCH NEUROL-CHICAGO, V67, P1140, DOI 10.1001/archneurol.2010.219
   Escames G, 2012, HUM GENET, V131, P161, DOI 10.1007/s00439-011-1057-y
   Harris MO, 2010, ARCH NEUROL-CHICAGO, V67, P493, DOI 10.1001/archneurol.2010.36
   Houshmand M, 1996, HUM GENET, V97, P269, DOI 10.1007/BF02185750
   Kiyomoto BH, 2006, J NEUROL NEUROSUR PS, V77, P541, DOI 10.1136/jnnp.2005.079954
   Krysko DV, 2011, TRENDS IMMUNOL, V32, P157, DOI 10.1016/j.it.2011.01.005
   Latronico N, 2012, CURR OPIN RHEUMATOL, V24, P616, DOI 10.1097/BOR.0b013e3283588d2f
   Mancuso M, 2010, J NEUROL, V257, P774, DOI 10.1007/s00415-009-5409-7
   Mancuso Michelangelo, 2008, Human Genomics, V3, P71
   Oka T, 2012, NATURE, V485, P251, DOI 10.1038/nature10992
   Satoh M, 2012, CLIN REV ALLERG IMMU, V42, P16, DOI 10.1007/s12016-011-8286-7
   Slee M, 2011, J CLIN NEUROSCI, V18, P1318, DOI 10.1016/j.jocn.2011.02.019
   SWEENEY MG, 1993, Q J MED, V86, P709
   Tidball JG, 2005, CURR OPIN RHEUMATOL, V17, P707, DOI 10.1097/01.bor.0000179948.65895.1a
   Varadhachary AS, 2010, CURR OPIN RHEUMATOL, V22, P651, DOI 10.1097/BOR.0b013e32833f108a
   Yu-Wai-Man P, 2010, BRAIN, V133, P771, DOI 10.1093/brain/awq007
NR 19
TC 11
Z9 12
U1 0
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD NOV
PY 2013
VL 23
IS 11
BP 907
EP 910
DI 10.1016/j.nmd.2013.07.011
PG 4
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 243LN
UT WOS:000326318000008
PM 24011700
DA 2024-11-01
ER

PT J
AU Liu, HM
   Tsai, LP
   Chien, YH
   Wu, JF
   Weng, WC
   Peng, SF
   Wu, ET
   Huang, PH
   Lee, WT
   Tsai, IJ
   Hwu, WL
   Lee, NC
AF Liu, Hsin-Ming
   Tsai, Li-Ping
   Chien, Yin-Hsiu
   Wu, Jia-Feng
   Weng, Wen-Chin
   Peng, Shinn-Forng
   Wu, En-Ting
   Huang, Pei-Hsin
   Lee, Wang-Tso
   Tsai, I-Jun
   Hwu, Wuh-Liang
   Lee, Ni-Chung
TI A Novel 3670-Base Pair Mitochondrial DNA Deletion Resulting in
   Multi-systemic Manifestations in a Child
SO PEDIATRICS AND NEONATOLOGY
LA English
DT Article
DE Fanconi syndrome; mitochondrial DNA deletion; pancreatitis
ID COMPLEX-I-DEFICIENCY; MUTATION
AB Mitochondrial DNA (mtDNA) deletion is a rare occurrence that results in defects to oxidative phosphorylation. The common clinical presentations of mtDNA deletion vary but include mitochondrial myopathy, Pearson syndrome, Kearns-Sayre syndrome, and progressive external ophthalmoplegia. Here, we report the case of a 10-year-old boy who presented with progressive deterioration of his clinical status (which included hypoglycemia, short stature, sensorineural hearing loss, retinitis pigmentosa, and chronic gastrointestinal dysmotility) that progressed to acute deterioration with pancreatitis, Fanconi syndrome, lactic acidosis, and acute encephalopathy. Following treatment, the patient was stabilized and his neurological condition improved. Through a combination of histological examinations and biochemical and molecular analyses, mitochondrial disease was confirmed. A novel 3670-base pair deletion (deletion of mtDNA nt 7,628-11,297) was identified in the muscle tissue. A direct repeat of CTACT at the breakpoints was also detected. Copyright (C) 2012, Taiwan Pediatric Association. Published by Elsevier Taiwan LLC. All rights reserved.
C1 [Liu, Hsin-Ming; Chien, Yin-Hsiu; Wu, Jia-Feng; Weng, Wen-Chin; Wu, En-Ting; Lee, Wang-Tso; Tsai, I-Jun; Hwu, Wuh-Liang; Lee, Ni-Chung] Natl Taiwan Univ Hosp, Dept Pediat, Taipei 10041, Taiwan.
   [Liu, Hsin-Ming; Chien, Yin-Hsiu; Wu, Jia-Feng; Weng, Wen-Chin; Peng, Shinn-Forng; Wu, En-Ting; Huang, Pei-Hsin; Lee, Wang-Tso; Tsai, I-Jun; Hwu, Wuh-Liang; Lee, Ni-Chung] Natl Taiwan Univ, Coll Med, Taipei 10764, Taiwan.
   [Tsai, Li-Ping] Tzu Ji Gen Hosp, Dept Pediat, Taipei, Taiwan.
   [Chien, Yin-Hsiu; Hwu, Wuh-Liang; Lee, Ni-Chung] Natl Taiwan Univ Hosp, Dept Med Genet, Taipei 10041, Taiwan.
   [Peng, Shinn-Forng] Natl Taiwan Univ Hosp, Dept Radiol, Taipei 10041, Taiwan.
   [Huang, Pei-Hsin] Natl Taiwan Univ Hosp, Dept Pathol, Taipei 10041, Taiwan.
C3 National Taiwan University; National Taiwan University Hospital;
   National Taiwan University; National Taiwan University; National Taiwan
   University Hospital; National Taiwan University; National Taiwan
   University Hospital; National Taiwan University; National Taiwan
   University Hospital
RP Lee, NC (corresponding author), Natl Taiwan Univ Hosp, Dept Pediat & Med Genet, Room 19005,19F,Childrens Hosp Bldg,8 Chung Shan S, Taipei 10041, Taiwan.
EM ncleentu@ntu.edu.tw
RI Weng, Wen-Chin/HJZ-0217-2023; Lu, Chun-yi/JXN-8290-2024; Chien,
   Yin-Hsiu/I-2348-2019; WU, JIA-FENG/H-8125-2019
OI Lee, Wang-Tso/0000-0003-3231-9764; CHIEN, YIN-HSIU/0000-0001-8802-5728;
   weng, wen-chin/0000-0002-6923-9138; HUANG, PEI-HSIN/0000-0002-2414-1487;
   LEE, NI-CHUNG/0000-0002-5011-7499; WU, EN-TING/0000-0002-1463-8721;
   PENG, STEVEN SHINN-FORNG/0000-0002-8177-5187; Liu,
   Hsin-Ming/0000-0003-3050-3867; Tsai, I-Jung/0000-0003-3967-9412; HWU,
   WUH-LIANG/0000-0001-6690-4879; WU, JIA-FENG/0000-0001-6343-1658
CR Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   Brautbar A, 2008, MOL GENET METAB, V94, P485, DOI 10.1016/j.ymgme.2008.04.004
   Chinnery P.F., 1993, MITOCHONDRIAL DISORD
   Chol M, 2003, J MED GENET, V40, P188, DOI 10.1136/jmg.40.3.188
   DiMauro S, 2007, MITOCHONDRIAL DNA DE
   Mkaouar-Rebai E, 2010, MITOCHONDRION, V10, P449, DOI 10.1016/j.mito.2010.04.003
   Ruiz-Pesini E, 2010, MITOMAP HUMAN MITOCH
   Sadikovic B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015687
   Wong LJC, 2001, GENET MED, V3, P399, DOI 10.1097/00125817-200111000-00004
NR 9
TC 11
Z9 12
U1 0
U2 2
PU ELSEVIER TAIWAN
PI TAIPEI
PA RM N-412, 4F, CHIA HSIN BUILDING 11, NO 96, ZHONG SHAN N ROAD SEC 2,
   TAIPEI, 10449, TAIWAN
SN 1875-9572
J9 PEDIATR NEONATOL
JI Pediatr. Neonatol.
PD AUG
PY 2012
VL 53
IS 4
BP 264
EP 268
DI 10.1016/j.pedneo.2011.08.013
PG 5
WC Pediatrics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pediatrics
GA 020IP
UT WOS:000309802500009
PM 22964285
OA gold, Green Submitted
DA 2024-11-01
ER

PT J
AU Pitceathly, RDS
   Smith, C
   Fratter, C
   Alston, CL
   He, LP
   Craig, K
   Blakely, EL
   Evans, JC
   Taylor, J
   Shabbir, Z
   Deschauer, M
   Pohl, U
   Roberts, ME
   Jackson, MC
   Halfpenny, CA
   Turnpenny, PD
   Lunt, PW
   Hanna, MG
   Schaefer, AM
   McFarland, R
   Horvath, R
   Chinnery, PF
   Turnbull, DM
   Poulton, J
   Taylor, RW
   Gorman, GS
AF Pitceathly, Robert D. S.
   Smith, Conrad
   Fratter, Carl
   Alston, Charlotte L.
   He, Langping
   Craig, Kate
   Blakely, Emma L.
   Evans, Julie C.
   Taylor, John
   Shabbir, Zarfishan
   Deschauer, Marcus
   Pohl, Ute
   Roberts, Mark E.
   Jackson, Matthew C.
   Halfpenny, Christopher A.
   Turnpenny, Peter D.
   Lunt, Peter W.
   Hanna, Michael G.
   Schaefer, Andrew M.
   McFarland, Robert
   Horvath, Rita
   Chinnery, Patrick F.
   Turnbull, Douglass M.
   Poulton, Joanna
   Taylor, Robert W.
   Gorman, Grainne S.
TI Adults with <i>RRM2B</i>-related mitochondrial disease have distinct
   clinical and molecular characteristics
SO BRAIN
LA English
DT Article
DE mitochondrial DNA; mtDNA maintenance; mtDNA depletion; multiple
   mitochondrial DNA deletions; RRM2B
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; DNA DEPLETION SYNDROMES; REAL-TIME
   PCR; POLYMERASE GAMMA; INDIVIDUAL CELLS; MTDNA DELETIONS; MUTATIONS;
   GENE; RRM2B; DIAGNOSIS
AB Mutations in the nuclear-encoded mitochondrial maintenance gene RRM2B are an important cause of familial mitochondrial disease in both adults and children and represent the third most common cause of multiple mitochondrial DNA deletions in adults, following POLG [polymerase (DNA directed), gamma] and PEO1 (now called C10ORF2, encoding the Twinkle helicase) mutations. However, the clinico-pathological and molecular features of adults with RRM2B-related disease have not been clearly defined. In this multicentre study of 26 adult patients from 22 independent families, including five additional cases published in the literature, we show that extra-ocular neurological complications are common in adults with genetically confirmed RRM2B mutations. We also demonstrate a clear correlation between the clinical phenotype and the underlying genetic defect. Myopathy was a prominent manifestation, followed by bulbar dysfunction and fatigue. Sensorineural hearing loss and gastrointestinal disturbance were also important findings. Severe multisystem neurological disease was associated with recessively inherited compound heterozygous mutations with a mean age of disease onset at 7 years. Dominantly inherited heterozygous mutations were associated with a milder predominantly myopathic phenotype with a later mean age of disease onset at 46 years. Skeletal muscle biopsies revealed subsarcolemmal accumulation of mitochondria and/or cytochrome c oxidase-deficient fibres. Multiple mitochondrial DNA deletions were universally present in patients who underwent a muscle biopsy. We identified 18 different heterozygous RRM2B mutations within our cohort of patients, including five novel mutations that have not previously been reported. Despite marked clinical overlap between the mitochondrial maintenance genes, key clinical features such as bulbar dysfunction, hearing loss and gastrointestinal disturbance should help prioritize genetic testing towards RRM2B analysis, and sequencing of the gene may preclude performance of a muscle biopsy.
C1 [Gorman, Grainne S.] Newcastle Univ, Sch Med, Inst Ageing & Hlth, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Pitceathly, Robert D. S.; Hanna, Michael G.] UCL Inst Neurol, MRC Ctr Neuromuscular Dis, London WC1N 3BG, England.
   [Pitceathly, Robert D. S.; Hanna, Michael G.] Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England.
   [Smith, Conrad; Fratter, Carl; Evans, Julie C.; Taylor, John] Churchill Hosp, Oxford Med Genet Labs, Oxford OX3 7LE, England.
   [Deschauer, Marcus] Univ Halle Wittenberg, Dept Neurol, D-06097 Halle, Germany.
   [Pohl, Ute] Queens Hosp, Dept Cellular Pathol, Romford RM7 0AG, Essex, England.
   [Roberts, Mark E.] Salford Royal NHS Fdn Trust, Dept Neurol, Salford M6 8HD, Lancs, England.
   [Jackson, Matthew C.] Wycombe Gen Hosp, Dept Neurol, High Wycombe HP11 2TT, Bucks, England.
   [Halfpenny, Christopher A.] Queen Alexandra Hosp, Dept Neurol, Portsmouth PO6 3LY, Hants, England.
   [Turnpenny, Peter D.] Royal Devon & Exeter Hosp, Dept Clin Genet, Exeter EX2 5DW, Devon, England.
   [Lunt, Peter W.] Gloucester Royal Hosp, Dept Clin Genet, Gloucester GL1 3NN, England.
   [Horvath, Rita; Chinnery, Patrick F.] Newcastle Univ, Inst Genet Med, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.
   [Poulton, Joanna] Univ Oxford, Nuffield Dept Obstet & Gynaecol, Oxford OX3 9DU, England.
C3 Newcastle University - UK; University of London; University College
   London; University of London; University College London; UCL Medical
   School; University College London Hospitals NHS Foundation Trust;
   University of Oxford; Martin Luther University Halle Wittenberg; Salford
   Royal NHS Foundation Trust; Portsmouth Hospitals NHS Trust; Queen
   Alexandra Hospital; University of Exeter; Newcastle University - UK;
   University of Oxford
RP Gorman, GS (corresponding author), Newcastle Univ, Sch Med, Inst Ageing & Hlth, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM grainne.gorman@ncl.ac.uk
RI Alston, Charlotte/ABG-9602-2020; Poulton, Joanna/AAB-4828-2021; Lunt,
   Peter/AAF-8265-2020; Taylor, John/E-5894-2010; Hanna,
   Michael/B-1995-2009; Horvath, Rita/AAY-7042-2020
OI Schaefer, Andrew/0000-0001-9891-7332; Turnbull,
   Doug/0000-0002-8878-9901; Gorman, Grainne/0000-0002-7585-3409;
   McFarland, Robert/0000-0002-8833-2688; Horvath,
   Rita/0000-0002-9841-170X; Chinnery, Patrick/0000-0002-7065-6617;
   Poulton, Joanna/0000-0002-2460-5587; Pitceathly,
   Robert/0000-0002-6123-4551; Alston, Charlotte/0000-0003-2095-5464;
   Hanna, Michael/0000-0003-0825-4075
FU MRC Centre for Translational Research in Neuromuscular Disease
   Mitochondrial Disease Patient Cohort (UK) [G0800674]; Wellcome Trust
   Centre for Mitochondrial Research [906919]; MRC Centre for Neuromuscular
   Diseases [G0601943]; Newcastle University Centre for Brain Ageing and
   Vitality; BBSRC; EPSRC; ESRC; MRC [G0700718]; Wellcome Trust
   [074454/Z/04/Z]; UK NIHR Biomedical Research Centre for Ageing and
   Age-related disease award; German Federal Ministry of Education and
   Research (BMBF); MRC [G1000848, G0700718, G0800674, G0601943] Funding
   Source: UKRI
FX This work was funded by the following grants: MRC Centre for
   Translational Research in Neuromuscular Disease Mitochondrial Disease
   Patient Cohort (UK) (G0800674); Wellcome Trust Centre for Mitochondrial
   Research (906919); MRC Centre for Neuromuscular Diseases (G0601943);
   Newcastle University Centre for Brain Ageing and Vitality supported by
   BBSRC, EPSRC, ESRC and MRC (G0700718); Wellcome Trust Programme Grant
   (074454/Z/04/Z); UK NIHR Biomedical Research Centre for Ageing and
   Age-related disease award to the Newcastle upon Tyne Foundation
   Hospitals NHS Trust. M. D. is a member of the German network mitoNET
   funded by the German Federal Ministry of Education and Research (BMBF).
CR Acham-Roschitz B, 2009, MOL GENET METAB, V98, P300, DOI 10.1016/j.ymgme.2009.06.012
   Blakely E, 2008, NEUROMUSCULAR DISORD, V18, P557, DOI 10.1016/j.nmd.2008.04.014
   Bornstein B, 2008, NEUROMUSCULAR DISORD, V18, P453, DOI 10.1016/j.nmd.2008.04.006
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Fratter C, 2011, NEUROLOGY, V76, P2032, DOI 10.1212/WNL.0b013e31821e558b
   He LP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf067
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kollberg G, 2009, NEUROMUSCULAR DISORD, V19, P147, DOI 10.1016/j.nmd.2008.11.014
   Krishnan KJ, 2007, ANAL BIOCHEM, V370, P127, DOI 10.1016/j.ab.2007.06.024
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Murphy JL, 2008, BRAIN, V131, P2832, DOI 10.1093/brain/awn252
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Ostergaard E, 2007, AM J HUM GENET, V81, P383, DOI 10.1086/519222
   Pitceathly RDS, 2011, J MED GENET, V48, P610, DOI 10.1136/jmg.2010.088328
   Rahman S, 2009, ARCH DIS CHILD, V94, P3, DOI 10.1136/adc.2008.147983
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Shaibani A, 2009, ARCH NEUROL-CHICAGO, V66, P1028, DOI 10.1001/archneurol.2009.139
   Smith P, 2009, BIOCHEMISTRY-US, V48, P11134, DOI 10.1021/bi9001425
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2009, J INHERIT METAB DIS, V32, P143, DOI 10.1007/s10545-008-1038-z
   Taanman JW, 2009, HUM MUTAT, V30, P248, DOI 10.1002/humu.20852
   Takata A, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-9-r92
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   Tyynismaa H, 2009, AM J HUM GENET, V85, P290, DOI 10.1016/j.ajhg.2009.07.009
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Zhang KQ, 2011, MOL CANCER THER, V10, P269, DOI 10.1158/1535-7163.MCT-10-0728
NR 28
TC 60
Z9 62
U1 0
U2 13
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
J9 BRAIN
JI Brain
PD NOV
PY 2012
VL 135
BP 3392
EP 3403
DI 10.1093/brain/aws231
PN 11
PG 12
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 044SV
UT WOS:000311644800024
PM 23107649
OA Green Published, Green Submitted, hybrid
DA 2024-11-01
ER

PT J
AU da Costa, CK
   Kiyomoto, BH
   Schmidt, B
   Oliveira, ASB
   Gabbai, AA
   Tengan, CH
AF da Costa, Carina K.
   Kiyomoto, Beatriz H.
   Schmidt, Beny
   Oliveira, Acary S. B.
   Gabbai, Alberto A.
   Tengan, Celia H.
TI Age-related mitochondrial DNA point mutations in patients with
   mitochondrial myopathy
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE mitochondrial DNA; aging; mitochondrial diseases; mitochondria
ID MTDNA CONTROL REGION; D-LOOP; SKELETAL-MUSCLE; HEALTHY-SUBJECTS;
   ACCUMULATION; DELETIONS; DUPLICATIONS; REPLICATION; INCREASE; DISEASE
AB Mutations in the control region (D-loop) of mitochondrial DNA (mtDNA) have been described in normal old individuals and it is suggested that they originated from oxidative damage. Respiratory chain defects may lead to increased free radical generation, increased susceptibility to oxidative damage and further increased accumulation of age-related mutations. The objective of this study was to verify whether patients with a mitochondrial disease are more predisposed to accumulate the A189G and T408A mutations in the D-loop and confirm their age-associated nature. We evaluated the presence and levels of heteroplasmy of these two mutations in muscle DNA of 52 individuals with different ages (21 age-matched controls and 31 patients with single or multiple mtDNA deletions). The frequency of both mutations was significantly increased with age, but no differences were observed comparing the group of patients with their age-matched controls. We could not observe correlation of levels of heteroplasmy with age. Our results confirm the age-related nature of the A189G and T408A mutations in the D-loop in controls and patients with mitochondrial disease, but do not suggest that patients are more predisposed to the development of age-related point mutations. (c) 2007 Elsevier B.V. All rights reserved.
C1 [da Costa, Carina K.; Kiyomoto, Beatriz H.; Oliveira, Acary S. B.; Gabbai, Alberto A.; Tengan, Celia H.] Univ Fed Sao Paulo, Escola Paulista Med, Dept Neurol, Sao Paulo, Brazil.
   [Schmidt, Beny] Univ Fed Sao Paulo, Escola Paulista Med, Dept Pathol, Sao Paulo, Brazil.
C3 Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Sao
   Paulo (UNIFESP)
RP Tengan, CH (corresponding author), R Pedro Toledo 781, BR-0403932 Sao Paulo, Brazil.
EM chtengan@neuro.epm.br
RI Tengan, Celia/D-8458-2013
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Bouzidi MF, 1998, HUM MOL GENET, V7, P385, DOI 10.1093/hmg/7.3.385
   Chinnery PF, 2002, LANCET, V360, P1323, DOI 10.1016/S0140-6736(02)11310-9
   COLLINS S, 1995, ACTA NEUROL SCAND, V91, P287, DOI 10.1111/j.1600-0404.1995.tb07007.x
   Cormio A, 2005, NEUROBIOL AGING, V26, P655, DOI 10.1016/j.neurobiolaging.2004.06.014
   CORTOPASSI GA, 1990, NUCLEIC ACIDS RES, V18, P6927, DOI 10.1093/nar/18.23.6927
   Del Bo R, 2003, NEUROBIOL AGING, V24, P829, DOI 10.1016/S0197-4580(02)00233-6
   Del Bo R, 2002, J NEUROL SCI, V202, P85, DOI 10.1016/S0022-510X(02)00247-2
   HARMAN D, 1992, MUTAT RES, V275, P257, DOI 10.1016/0921-8734(92)90030-S
   KATSUMATA K, 1994, BIOCHEM BIOPH RES CO, V202, P102, DOI 10.1006/bbrc.1994.1899
   Kovalenko SA, 1996, BIOCHEM BIOPH RES CO, V222, P201, DOI 10.1006/bbrc.1996.0722
   LEE HC, 1994, FEBS LETT, V354, P79, DOI 10.1016/0014-5793(94)01063-3
   LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4
   MELOV S, 1995, NUCLEIC ACIDS RES, V23, P4122, DOI 10.1093/nar/23.20.4122
   Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774
   RIFAI Z, 1995, ANN NEUROL, V37, P24, DOI 10.1002/ana.410370107
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Tengan CH, 2002, BBA-MOL BASIS DIS, V1588, P65, DOI 10.1016/S0925-4439(02)00140-0
   Tengan CH, 1997, MUTAT RES-FUND MOL M, V379, P1, DOI 10.1016/S0027-5107(97)00076-6
   Trifunovic A, 2005, P NATL ACAD SCI USA, V102, P17993, DOI 10.1073/pnas.0508886102
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Wang Y, 2001, P NATL ACAD SCI USA, V98, P4022, DOI 10.1073/pnas.061013598
   Wiesner RJ, 2006, FREE RADICAL RES, V40, P1284, DOI 10.1080/10715760600913168
   Yowe DL, 1998, GENE, V209, P23, DOI 10.1016/S0378-1119(97)00628-8
NR 24
TC 7
Z9 9
U1 1
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD DEC 15
PY 2007
VL 263
IS 1-2
BP 139
EP 144
DI 10.1016/j.jns.2007.07.006
PG 6
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 269SY
UT WOS:000253671700023
PM 17698085
DA 2024-11-01
ER

PT J
AU Filosto, M
   Lanzi, G
   Nesti, C
   Vielmi, V
   Marchina, E
   Galvagni, A
   Giliani, S
   Santorelli, FM
   Padovani, A
AF Filosto, Massimiliano
   Lanzi, Gaetana
   Nesti, Claudia
   Vielmi, Valentina
   Marchina, Eleonora
   Galvagni, Anna
   Giliani, Silvia
   Santorelli, Filippo M.
   Padovani, Alessandro
TI A novel mitochondrial tRNA<SUP>Ala</SUP> gene variant causes chronic
   progressive external ophthalmoplegia in a patient with Huntington
   disease
SO MOLECULAR GENETICS AND METABOLISM REPORTS
LA English
DT Article
DE Mitochondrial diseases; CPEO; Huntington disease; mtDNA; tRNA
ID DEFECTIVE AXONAL-TRANSPORT; SYNAPTIC DEGENERATION; MUTANT HUNTINGTIN;
   MUTATION; DNA; DYNAMICS; MYOPATHY
AB Chronic progressive external ophthalmoplegia is a mitochondrial disorder usually caused by single or multiple mitochondrial DNA (mtDNA) deletions and, more rarely, by maternally inherited mtDNA point mutations, most frequently in tRNA genes (MTT).
   We report on a patient presenting with a progressive eyelid ptosis with bilateral ophthalmoparesis, dysphagia, dysphonia and mild proximal limb weakness associate with a mild movement disorder characterized by abnormal involuntary movements involving head and limbs, imbalance and gait instability.
   Muscle biopsy demonstrated the presence of ragged red fibers and several cytochrome-C-oxidase negative fibers. Molecular analysis showed the novel m.5613T > C heteroplasmic mutation in the mitochondrial tRNA(Ala) gene (MTTA) which disrupts a conserved site and fulfills the accepted criteria of pathogenicity. Moreover, a 38 CAG trinucleotide repeat expansion was found on the huntingtin gene, thus configuring a singular CPEO/"reduced penetrance" Huntington disease "double trouble".
   With this novel MTTA point mutation, we extend the spectrum of provisional pathogenic changes in this gene, which is a very rare site of pathogenic mutation, and confirm that clinical expression of these mutations is hardly ever heterogeneous, including myopathy and CPEO.
   Mitochondrial involvement is an emerging key determinant in the pathogenesis of Huntington disease and it is well known that mutant huntingtin influences the mitochondrial respiratory complexes II and III. A synergist effect of the HTT and MTTA mutations on respiratory chain function may be hypothesized in our patient and should be regarded as a spur for further studies on the mtDNA/HTT reciprocal interactions. (C) 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
C1 [Filosto, Massimiliano; Vielmi, Valentina; Galvagni, Anna; Padovani, Alessandro] Univ Hosp Spedali Civili, Sect Neuromuscular Dis & Neuropathies, Neurol Clin, Brescia, Italy.
   [Lanzi, Gaetana; Giliani, Silvia] Univ Hosp Spedali Civili, Inst Mol Med A Nocivelli, Brescia, Italy.
   [Nesti, Claudia; Santorelli, Filippo M.] IRCCS Stella Maris, Mol Med Unit, Pisa, Italy.
   [Marchina, Eleonora] Univ Brescia, Dept Biomed Sci & Biotechnol, Div Biol & Genet, I-25121 Brescia, Italy.
C3 Hospital Spedali Civili Brescia; Hospital Spedali Civili Brescia; IRCCS
   Fondazione Stella Maris; University of Brescia
RP Filosto, M (corresponding author), Univ Hosp Spedali Civili, Neurol Clin, Pzle Spedali Civili 1, I-25100 Brescia, Italy.
EM massimiliano.filosto@unibs.it
RI Giliani, Silvia/AAX-8843-2020; Padovani, Alessandro/ABI-7312-2020;
   Filosto, Massimiliano/S-9446-2019; Nesti, Claudia/K-5866-2016;
   Santorelli, Filippo M/ABE-5124-2020
OI Padovani, Alessandro/0000-0002-0119-3639; Filosto,
   Massimiliano/0000-0002-2852-7512; Nesti, Claudia/0000-0001-5769-8655;
   giliani, silvia clara/0000-0001-8137-4642; MARCHINA,
   Eleonora/0000-0002-1672-1908; Santorelli, Filippo M/0000-0002-1359-9062
CR Acevedo-Torres K, 2009, DNA REPAIR, V8, P126, DOI 10.1016/j.dnarep.2008.09.004
   ANDREU AL, 2002, METHODS MOL BIOL NEU, V217, P185
   Bancroft J.D., 1984, MANUAL HISTOLOGICAL
   Chinnery PF, 1997, NEUROLOGY, V49, P1166, DOI 10.1212/WNL.49.4.1166
   Correia SC, 2012, ADV EXP MED BIOL, V724, P205, DOI 10.1007/978-1-4614-0653-2_16
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   Greaves LC, 2012, J PATHOL, V226, P274, DOI 10.1002/path.3028
   Ha AD, 2012, CURR OPIN NEUROL, V25, P491, DOI 10.1097/WCO.0b013e3283550c97
   Han DY, 2007, BIOCHEM BIOPH RES CO, V357, P554, DOI 10.1016/j.bbrc.2007.03.199
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kosinski CM, 2007, MOVEMENT DISORD, V22, P1637, DOI 10.1002/mds.21550
   Lehmann D, 2015, EUR J HUM GENET, V23, P1735, DOI 10.1038/ejhg.2015.73
   Li XM, 2004, NUCLEIC ACIDS RES, V32, P867, DOI 10.1093/nar/gkh226
   Lightowlers RN, 2015, SCIENCE, V349, P1494, DOI 10.1126/science.aac7516
   MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E
   Mancuso Michelangelo, 2008, Human Genomics, V3, P71
   McFarland R, 2008, NEUROMUSCULAR DISORD, V18, P63, DOI 10.1016/j.nmd.2007.07.007
   Pinós T, 2011, MITOCHONDRION, V11, P228, DOI 10.1016/j.mito.2010.08.008
   Reddy PH, 2012, BBA-MOL BASIS DIS, V1822, P101, DOI 10.1016/j.bbadis.2011.10.016
   Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0
   Shirendeb U, 2011, HUM MOL GENET, V20, P1438, DOI 10.1093/hmg/ddr024
   Shirendeb UP, 2012, HUM MOL GENET, V21, P406, DOI 10.1093/hmg/ddr475
   Spagnolo M, 2001, NEUROMUSCULAR DISORD, V11, P481, DOI 10.1016/S0960-8966(01)00195-X
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzi M, 2012, NAT PROTOC, V7, P1235, DOI 10.1038/nprot.2012.058
   Swalwell H, 2006, NEUROLOGY, V66, P447, DOI 10.1212/01.wnl.0000196490.36349.83
   Tang XW, 2010, MOL GENET METAB, V100, P57, DOI 10.1016/j.ymgme.2010.01.008
   Turner C, 2007, MOVEMENT DISORD, V22, P1715, DOI 10.1002/mds.21540
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Yarham JW, 2011, HUM MUTAT, V32, P1319, DOI 10.1002/humu.21575
   Zeviani M, 2004, BRAIN, V127, P2153, DOI 10.1093/brain/awh259
   Zielonka D, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00380
NR 32
TC 5
Z9 8
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
EI 2214-4269
J9 MOL GENET METAB REP
JI Molec. Genet. Metab. Rep.
PD MAR
PY 2016
VL 6
BP 70
EP 73
DI 10.1016/j.ymgmr.2016.02.001
PG 4
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA DZ7CY
UT WOS:000386022900014
PM 27014581
OA Green Published, gold
DA 2024-11-01
ER

PT J
AU Tarnopolsky, MA
   Sundaram, ANE
   Provias, J
   Brady, L
   Sadikovic, B
AF Tarnopolsky, Mark A.
   Sundaram, Arun N. E.
   Provias, John
   Brady, Lauren
   Sadikovic, Bekim
TI CPEO - Like mitochondrial myopathy associated with m.8340G &gt; A
   mutation
SO MITOCHONDRION
LA English
DT Article
ID RAGGED-RED FIBERS; MYOCLONIC EPILEPSY; MUSCLE; MERRF; MTDNA;
   3243A-GREATER-THAN-G; DYSFUNCTION; DEAFNESS; DISEASE
AB Two patients with an m.8340G > A mitochondrial DNA variant have been reported with one patient showing ptosis, ophthalmoparesis and myopathy at 53% heteroplasmy and another with pigmentary retinopathy, cataracts and sensory neural deafness and slightly higher heteroplasmy (65%). Here we report that higher muscle mutant heteroplasmy (93%) for m.8340G > A is associated with ptosis, ophthalmoparesis and mitochondrial myopathy, thus confirming the initial phenotypic association and showing that heteroplasmy per se does not explain the phenotypic spectrum of disease associated with the m.8340G > A mutation.
C1 [Tarnopolsky, Mark A.; Brady, Lauren] McMaster Univ, Dept Pediat, Hamilton, ON, Canada.
   [Sundaram, Arun N. E.] Univ Toronto, Sunnybrook Hlth Sci Ctr, Dept Ophthalmol & Vis Sci, Toronto, ON, Canada.
   [Provias, John] McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada.
   [Sadikovic, Bekim] Childrens Hlth Res Inst, London Hlth Sci Ctr, Mol Genet Lab, Mol Diagnost Div, London, ON, Canada.
C3 McMaster University; University of Toronto; Sunnybrook Research
   Institute; Sunnybrook Health Science Center; McMaster University; London
   Health Sciences Centre
RP Tarnopolsky, MA (corresponding author), McMaster Univ, Med Ctr, Pediat & Med, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.
EM tarnopol@mcmaster.ca
CR Austin SA, 1998, NEUROLOGY, V51, P1447, DOI 10.1212/WNL.51.5.1447
   Crane JD, 2013, J GERONTOL A-BIOL, V68, P631, DOI 10.1093/gerona/gls237
   Devries MC, 2013, J CLIN ENDOCR METAB, V98, P4852, DOI 10.1210/jc.2013-2044
   Gill JS, 2017, BRIT J OPHTHALMOL, V101, P1298, DOI 10.1136/bjophthalmol-2017-310370
   Giordano C, 2011, BRAIN, V134, P220, DOI 10.1093/brain/awq276
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   HOLME E, 1993, AM J HUM GENET, V52, P551
   Howell N, 2003, AM J MED GENET A, V119A, P147, DOI 10.1002/ajmg.a.20135
   Jeppesen TD, 2003, ANN NEUROL, V54, P86, DOI 10.1002/ana.10594
   Jeppesen TD, 2014, NEUROMUSCULAR DISORD, V24, P162, DOI 10.1016/j.nmd.2013.08.004
   Kärppä M, 2005, BRAIN, V128, P1861, DOI 10.1093/brain/awh515
   Kerkhof J, 2017, J MOL DIAGN, V19, P905, DOI 10.1016/j.jmoldx.2017.07.004
   LOMBES A, 1989, ANN NEUROL, V26, P20, DOI 10.1002/ana.410260104
   Lott Marie T, 2013, Curr Protoc Bioinformatics, V44, DOI 10.1002/0471250953.bi0123s44
   Macmillan C, 1998, NEUROLOGY, V50, P417, DOI 10.1212/WNL.50.2.417
   Majamaa-Voltti KAM, 2006, NEUROLOGY, V66, P1470, DOI 10.1212/01.wnl.0000216136.61640.79
   Mancuso M, 2013, NEUROLOGY, V80, P2049, DOI 10.1212/WNL.0b013e318294b44c
   McFarland R, 2004, TRENDS GENET, V20, P591, DOI 10.1016/j.tig.2004.09.014
   MONTAGNA P, 1988, NEUROLOGY, V38, P751, DOI 10.1212/WNL.38.5.751
   Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   Tarnopolsky MA, 2011, MUSCLE NERVE, V43, P717, DOI 10.1002/mus.21945
   van Oven M, 2009, HUM MUTAT, V30, pE386, DOI 10.1002/humu.20921
   VANDENOUWELAND JMW, 1994, DIABETES, V43, P746, DOI 10.2337/diabetes.43.6.746
   2016, J MOL DIAGN, V18, P657, DOI DOI 10.1016/J.JMOLDX.2016.04.002
NR 25
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 1872-8278
J9 MITOCHONDRION
JI Mitochondrion
PD MAY
PY 2019
VL 46
BP 69
EP 72
DI 10.1016/j.mito.2018.02.008
PG 4
WC Cell Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Genetics & Heredity
GA HX8NY
UT WOS:000467663800009
PM 29501485
DA 2024-11-01
ER

PT J
AU Roos, S
   Macao, B
   Fusté, JM
   Lindberg, C
   Jemt, E
   Holme, E
   Moslemi, AR
   Oldfors, A
   Falkenberg, M
AF Roos, Sara
   Macao, Bertil
   Fuste, Javier Miralles
   Lindberg, Christopher
   Jemt, Elisabeth
   Holme, Elisabeth
   Moslemi, Ali-Reza
   Oldfors, Anders
   Falkenberg, Maria
TI Subnormal levels of POLγA cause inefficient initiation of light-strand
   DNA synthesis and lead to mitochondrial DNA deletions and autosomal
   dominant progressive external ophthalmoplegia
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID POLYMERASE-GAMMA; REPLICATION BUBBLE; RNA-POLYMERASE; MUTATIONS; ORIGIN
AB The POLG1 gene encodes the catalytic subunit of mitochondrial DNA (mtDNA) polymerase gamma (POL gamma). We here describe a sibling pair with adult-onset progressive external ophthalmoplegia, cognitive impairment and mitochondrial myopathy characterized by DNA depletion and multiple mtDNA deletions. The phenotype is due to compound heterozygous POLG1 mutations, T914P and the intron mutation c.3104 1 3A > T. The mutant genes produce POL gamma isoforms with heterozygous phenotypes that fail to synthesize longer DNA products in vitro. However, exon skipping in the c.3104 + 3A > T mutant is not complete, and the presence of low levels of wild-type POL gamma explains patient survival. To better understand the underlying pathogenic mechanisms, we characterized the effects of POL gamma depletion in vitro and found that leading-strand DNA synthesis is relatively undisturbed. In contrast, initiation of lagging-strand DNA synthesis is ineffective at lower POL gamma concentrations that uncouples leading strand from lagging-strand DNA synthesis. In vivo, this effect leads to prolonged exposure of the heavy strand in its single-stranded conformation that in turn can cause the mtDNA deletions observed in our patients. Our findings, thus, suggest a molecular mechanism explaining how POL gamma mutations can cause mtDNA deletions in vivo.
C1 [Roos, Sara; Moslemi, Ali-Reza; Oldfors, Anders] Univ Gothenburg, Sahlgrenska Acad, Inst Biomed, Dept Pathol, SE-41345 Gothenburg, Sweden.
   [Macao, Bertil; Fuste, Javier Miralles; Jemt, Elisabeth; Falkenberg, Maria] Univ Gothenburg, Sahlgrenska Acad, Inst Biomed, Dept Med Biochem & Cell Biol, SE-40530 Gothenburg, Sweden.
   [Lindberg, Christopher] Sahlgrens Univ Hosp, Dept Neurol, Neuromuscular Ctr, Gothenburg, Sweden.
   [Holme, Elisabeth] Univ Gothenburg, Sahlgrenska Acad, Inst Biomed, Dept Clin Chem, Gothenburg, Sweden.
C3 University of Gothenburg; University of Gothenburg; Sahlgrenska
   University Hospital; University of Gothenburg
RP Roos, S (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Inst Biomed, Dept Pathol, Gula Straket 8, SE-41345 Gothenburg, Sweden.
EM sara.roos@gu.se
FU Swedish Research Council [2010-3545, 07122]; Swedish Cancer Society
   [2007/1216]; Swedish Strategic Foundation [FFL-3]; European Research
   Council [261248]; European Research Council (ERC) [261248] Funding
   Source: European Research Council (ERC)
FX This work was supported by the Swedish Research Council (grant number
   2010-3545 to M. F. and grant number 07122 to A.O.); the Swedish Cancer
   Society (grant number 2007/1216 to M. F.); the Swedish Strategic
   Foundation (grant number FFL-3 to M. F.); and the European Research
   Council (starting grant number 261248 to M.F.).
CR Ashley N, 2008, HUM MOL GENET, V17, P2496, DOI 10.1093/hmg/ddn150
   Atanassova N, 2011, HUM MOL GENET, V20, P1212, DOI 10.1093/hmg/ddq565
   Bichara M, 2006, MUTAT RES-FUND MOL M, V598, P144, DOI 10.1016/j.mrfmmm.2006.01.020
   Blok MJ, 2009, J MED GENET, V46, P776, DOI 10.1136/jmg.2009.067686
   Bogenhagen DF, 2003, TRENDS BIOCHEM SCI, V28, P357, DOI 10.1016/S0968-0004(03)00132-4
   Bogenhagen DF, 2003, TRENDS BIOCHEM SCI, V28, P404, DOI 10.1016/S0968-0004(03)00165-8
   Brown TA, 2005, GENE DEV, V19, P2466, DOI 10.1101/gad.1352105
   Carrodeguas JA, 2002, J BIOL CHEM, V277, P50008, DOI 10.1074/jbc.M207030200
   CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6
   Falkenberg M, 2007, ANNU REV BIOCHEM, V76, P679, DOI 10.1146/annurev.biochem.76.060305.152028
   Farge G, 2007, NUCLEIC ACIDS RES, V35, P902, DOI 10.1093/nar/gkl1116
   Fusté JM, 2010, MOL CELL, V37, P67, DOI 10.1016/j.molcel.2009.12.021
   Graziewicz MA, 2006, CHEM REV, V106, P383, DOI 10.1021/cr040463d
   Holt IJ, 2003, TRENDS BIOCHEM SCI, V28, P355, DOI 10.1016/S0968-0004(03)00133-6
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Kokoska RJ, 2000, MOL CELL BIOL, V20, P7490, DOI 10.1128/MCB.20.20.7490-7504.2000
   Kollberg G, 2006, J NEUROPATH EXP NEUR, V65, P758, DOI 10.1097/01.jnen.0000229987.17548.6e
   Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257
   Krishnan KJ, 2008, NAT GENET, V40, P275, DOI 10.1038/ng.f.94
   Lee YS, 2009, CELL, V139, P312, DOI 10.1016/j.cell.2009.07.050
   Milone M, 2011, ARCH NEUROL-CHICAGO, V68, P806, DOI 10.1001/archneurol.2011.124
   Moslemi AR, 1999, NEUROLOGY, V53, P79, DOI 10.1212/WNL.53.1.79
   Nguyen KV, 2006, J HEPATOL, V45, P108, DOI 10.1016/j.jhep.2005.12.026
   Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490
   Stumpf JD, 2011, CELL MOL LIFE SCI, V68, P219, DOI 10.1007/s00018-010-0530-4
   Taanman JW, 2009, HUM MUTAT, V30, P248, DOI 10.1002/humu.20852
   Tang S, 2011, J MED GENET, V48, P669, DOI 10.1136/jmedgenet-2011-100222
   TAPPER DP, 1981, J BIOL CHEM, V256, P5109
   Tzoulis C, 2009, ACTA NEUROL SCAND, V120, P38, DOI 10.1111/j.1600-0404.2009.01212.x
   Viguera E, 2001, J MOL BIOL, V312, P323, DOI 10.1006/jmbi.2001.4943
   Wanrooij S, 2008, P NATL ACAD SCI USA, V105, P11122, DOI 10.1073/pnas.0805399105
   Wanrooij S, 2012, EMBO REP, V13, P1130, DOI 10.1038/embor.2012.161
   Wanrooij S, 2010, BBA-BIOENERGETICS, V1797, P1378, DOI 10.1016/j.bbabio.2010.04.015
   Wong LJC, 2008, HUM MUTAT, V29, pE150, DOI 10.1002/humu.20824
   WONG TW, 1986, CELL, V45, P817, DOI 10.1016/0092-8674(86)90556-8
   WONG TW, 1985, CELL, V42, P951, DOI 10.1016/0092-8674(85)90291-0
NR 36
TC 19
Z9 19
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD JUN 15
PY 2013
VL 22
IS 12
BP 2411
EP 2422
DI 10.1093/hmg/ddt094
PG 12
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 151AK
UT WOS:000319432800008
PM 23446635
OA Bronze
DA 2024-11-01
ER

PT J
AU Ronchi, D
   Virgilio, R
   Bordoni, A
   Fassone, E
   Sciacco, M
   Ciscato, P
   Moggio, M
   Govoni, A
   Corti, S
   Bresolin, N
   Comi, GP
AF Ronchi, Dario
   Virgilio, Roberta
   Bordoni, Andreina
   Fassone, Elisa
   Sciacco, Monica
   Ciscato, Patrizia
   Moggio, Maurizio
   Govoni, Alessandra
   Corti, Stefania
   Bresolin, Nereo
   Comi, Giacomo P.
TI The m.12316G&gt;A mutation in the mitochondrial tRNA<SUP>Leu(CUN)</SUP>
   gene is associated with mitochondrial myopathy and respiratory
   impairment
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE mtDNA; tRNA(Leu(CUN)); Late-onset myopathy
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; MTDNA POINT MUTATION;
   SKELETAL-MUSCLE; SPORADIC PATIENT; DNA; ENCEPHALOMYOPATHY; TERMINATION;
   DISORDERS; DISEASE; MELAS
AB Mitochondrial disorders are often associated with mutations in mitochondria! tRNA. Independent observation of the same molecular defect in unrelated subjects is a generally required proof of pathogenicity. A sporadic case of chronic external ophthalmoplegia (cPEO) with ragged red fibres (RRFs) has been previously related to an m.12316G>A substitution in tRNA(Leu(CUN)).
   Sequencing muscle-derived mtDNA, we found the m.12316G>A substitution in an adult woman with mitochondrial myopathy and respiratory impairment. Her muscle biopsy presented several cytochrome c oxidase-negative (COX) fibres, and RRFs as signs of mitochondrial proliferation. Restriction-fragment length polymorphism (RFLP) analysis of the mutation in isolated muscle fibres showed a threshold of at least 60% of mutated mtDNA to determine a COX deficiency phenotype. This second report of the m.12316G>A mutation in a sporadic patient consolidates its pathogenic nature and provides further elements for genetic counselling. (C) 2010 Elsevier B.V. All rights reserved.
C1 [Ronchi, Dario; Virgilio, Roberta; Bordoni, Andreina; Fassone, Elisa; Sciacco, Monica; Ciscato, Patrizia; Moggio, Maurizio; Govoni, Alessandra; Corti, Stefania; Bresolin, Nereo; Comi, Giacomo P.] Univ Milan, Dept Neurol Sci, IRCCS Fdn Osped Maggiore Policlin Mangiagalli & R, Dino Ferrari Ctr, I-20122 Milan, Italy.
   [Corti, Stefania; Bresolin, Nereo; Comi, Giacomo P.] Univ Milan, Ctr Excellence Neurodegenerat Dis, Milan, Italy.
   [Bresolin, Nereo] IRCCS Eugenio Medea, Parini, Lecco, Italy.
C3 University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico;
   University of Milan; IRCCS Eugenio Medea
RP Comi, GP (corresponding author), Univ Milan, Dept Neurol Sci, IRCCS Fdn Osped Maggiore Policlin Mangiagalli & R, Dino Ferrari Ctr, Via Francesco Sforza 35, I-20122 Milan, Italy.
EM giacomo.comi@unimi.it
RI Sciacco, Monica/AAC-6500-2022; Ronchi, Dario/K-8011-2016; Comi,
   Giacomo/K-5702-2016; Govoni, Alessandra/K-7944-2016; corti,
   stefania/K-6034-2016
OI Ronchi, Dario/0000-0002-6093-9816; Sciacco, Monica/0000-0003-4593-4977;
   Govoni, Alessandra/0000-0002-5393-5462; Bresolin,
   Nereo/0000-0001-6694-3595; Comi, Giacomo/0000-0002-1383-5248; corti,
   stefania/0000-0001-5425-969X; simoncini, costanza/0000-0002-6724-5964
FU Associazione Amici del Centro Dino Ferrari; MIUR (Ministry of Education
   University and Research) Italian Ministry [PRIN 2007]; Telethon
   [GTB07001E]; Eurobiobank [QLTR-2001-02769]
FX Gratitude must be expressed to the patient for participating in this
   research. We wish to thank especially the 'Associazione Amici del Centro
   Dino Ferrari' for their support. The financial support of the following
   research grant is gratefully acknowledged: MIUR (Ministry of Education
   University and Research) Italian Ministry PRIN 2007 "An integrated
   approach to the study of molecular etiopathogenesis of mitochondrial
   disorders". Telethon project GTB07001E, and Eurobiobank project
   QLTR-2001-02769.
CR Abu-Amero EK, 2006, J CHILD NEUROL, V21, P971, DOI 10.2310/7010.2006.00208
   Battersby BJ, 2003, NAT GENET, V33, P183, DOI 10.1038/ng1073
   Cardaioli E, 2008, J NEUROL SCI, V272, P106, DOI 10.1016/j.jns.2008.05.005
   Cardaioli E, 2005, BIOCHEM BIOPH RES CO, V327, P675, DOI 10.1016/j.bbrc.2004.11.170
   Crimi M, 2005, FASEB J, V19, P866, DOI 10.1096/fj.04-3045fje
   Filosto M, 2008, NEUROMUSCULAR DISORD, V18, P204, DOI 10.1016/j.nmd.2007.12.005
   Fu K, 1996, HUM MOL GENET, V5, P1835, DOI 10.1093/hmg/5.11.1835
   Gattermann N, 1996, BRIT J HAEMATOL, V93, P845, DOI 10.1046/j.1365-2141.1996.d01-1724.x
   Grasso M, 2001, EUR J HUM GENET, V9, P311, DOI 10.1038/sj.ejhg.5200622
   Jacobs HT, 2003, HUM MOL GENET, V12, pR293, DOI 10.1093/hmg/ddg285
   Karadimas CL, 2002, NEUROMUSCULAR DISORD, V12, P865, DOI 10.1016/S0960-8966(02)00072-X
   KRUSE B, 1989, CELL, V58, P391, DOI 10.1016/0092-8674(89)90853-2
   MITA S, 1995, MUSCLE NERVE, pS113
   Moraes C T, 1996, Methods Enzymol, V264, P522, DOI 10.1016/S0076-6879(96)64046-4
   MORAES CT, 1992, AM J HUM GENET, V50, P934
   Moraes CT, 2003, J MOL DIAGN, V5, P197, DOI 10.1016/S1525-1578(10)60474-6
   Nakamura Y, 2000, NUCLEIC ACIDS RES, V28, P292, DOI 10.1093/nar/28.1.292
   Scaglia F, 2008, MUSCLE NERVE, V37, P150, DOI 10.1002/mus.20917
   Sciacco M, 2001, J NEUROL, V248, P778, DOI 10.1007/s004150170094
   van Eijsden RGE, 2008, J MED GENET, V45, P525, DOI 10.1136/jmg.2008.057497
   Vives-Bauza C, 2001, ANN MED, V33, P493, DOI 10.3109/07853890109002099
   Wittenhagen LM, 2003, TRENDS BIOCHEM SCI, V28, P605, DOI 10.1016/j.tibs.2003.09.006
   ZEVIANI M, 1990, ANN NEUROL, V28, P94, DOI 10.1002/ana.410280118
NR 23
TC 1
Z9 1
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 1878-5883
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD MAY 15
PY 2010
VL 292
IS 1-2
BP 107
EP 110
DI 10.1016/j.jns.2010.01.026
PG 4
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 584WJ
UT WOS:000276784100022
PM 20163808
DA 2024-11-01
ER

PT J
AU Ahmed, ST
   Craven, L
   Russell, OM
   Turnbull, DM
   Vincent, AE
AF Ahmed, Syeda T.
   Craven, Lyndsey
   Russell, Oliver M.
   Turnbull, Doug M.
   Vincent, Amy E.
TI Diagnosis and Treatment of Mitochondrial Myopathies
SO NEUROTHERAPEUTICS
LA English
DT Review
DE Mitochondrial myopathy; diagnosis; treatment; mtDNA; muscle
ID LARGE-SCALE DELETIONS; NICOTINAMIDE RIBOSIDE; SELECTIVE DEGRADATION;
   OXIDATIVE-METABOLISM; PRONUCLEAR TRANSFER; CONTROLLED-TRIAL; COENZYME
   Q(10); DNA-DELETION; MUTANT MTDNA; BIOMARKER
AB Mitochondrial myopathies are progressive muscle conditions caused primarily by the impairment of oxidative phosphorylation (OXPHOS) in the mitochondria. This causes a deficit in energy production in the form of adenosine triphosphate (ATP), particularly in skeletal muscle. The diagnosis of mitochondrial myopathy is reliant on the combination of numerous techniques including traditional histochemical, immunohistochemical, and biochemical testing combined with the fast-emerging molecular genetic techniques, namely next-generation sequencing (NGS). This has allowed for the diagnosis to become more effective in terms of determining causative or novel genes. However, there are currently no effective or disease-modifying treatments available for the vast majority of patients with mitochondrial myopathies. Existing therapeutic options focus on the symptomatic management of disease manifestations. An increasing number of clinical trials have investigated the therapeutic effects of various vitamins, cofactors, and small molecules, though these trials have failed to show definitive outcome measures for clinical practice thus far. In addition, new molecular strategies, specifically mtZFNs and mtTALENs, that cause beneficial heteroplasmic shifts in cell lines harboring varying pathogenic mtDNA mutations offer hope for the future. Moreover, recent developments in the reproductive options for patients with mitochondrial myopathies mean that for some families, the possibility of preventing transmission of the mutation to the next generation is now possible.
C1 [Ahmed, Syeda T.; Craven, Lyndsey; Russell, Oliver M.; Turnbull, Doug M.; Vincent, Amy E.] Newcastle Univ, Inst Neurosci, Wellcome Ctr Mitochondrial Res, Newcastle Upon Tyne, Tyne & Wear, England.
   [Turnbull, Doug M.; Vincent, Amy E.] Newcastle Univ, MRC, Ctr Ageing & Vital, Newcastle Upon Tyne, Tyne & Wear, England.
C3 Newcastle University - UK; Newcastle University - UK
RP Vincent, AE (corresponding author), Newcastle Univ, Inst Neurosci, Wellcome Ctr Mitochondrial Res, Newcastle Upon Tyne, Tyne & Wear, England.; Vincent, AE (corresponding author), Newcastle Univ, MRC, Ctr Ageing & Vital, Newcastle Upon Tyne, Tyne & Wear, England.
EM amy.vincent@ncl.ac.uk
RI Vincent, Amy/J-7284-2019
OI Turnbull, Doug/0000-0002-8878-9901; Vincent, Amy/0000-0002-0360-6644;
   Russell, Oliver/0000-0002-9414-9193; Butterworth,
   Lyndsey/0000-0002-2092-0934
FU MRC [MR/L016354/1] Funding Source: UKRI; Medical Research Council
   [MR/L016354/1] Funding Source: Medline; Wellcome Trust [203105/Z/16/Z]
   Funding Source: Medline
CR Ahmed ST, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-14623-2
   Ahola S, 2016, EMBO MOL MED, V8, P1234, DOI 10.15252/emmm.201606592
   Ahola-Erkkilä S, 2010, HUM MOL GENET, V19, P1974, DOI 10.1093/hmg/ddq076
   Alam NM, 2015, DIS MODEL MECH, V8, P701, DOI 10.1242/dmm.020248
   Alston CL, 2017, J PATHOL, V241, P236, DOI 10.1002/path.4809
   Bacman SR, 2014, METHOD ENZYMOL, V547, P373, DOI 10.1016/B978-0-12-801415-8.00018-7
   Bates MGD, 2013, INT J CARDIOL, V168, P3599, DOI 10.1016/j.ijcard.2013.05.062
   Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   Bieganowski P, 2004, CELL, V117, P495, DOI 10.1016/S0092-8674(04)00416-7
   Bua E, 2006, AM J HUM GENET, V79, P469, DOI 10.1086/507132
   Calvo S, 2006, NAT GENET, V38, P576, DOI 10.1038/ng1776
   Calvo SE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003310
   Campbell G, 2014, HUM MOL GENET, V23, P4612, DOI 10.1093/hmg/ddu176
   Cantó C, 2012, CELL METAB, V15, P838, DOI 10.1016/j.cmet.2012.04.022
   Cejudo P, 2005, MUSCLE NERVE, V32, P342, DOI 10.1002/mus.20368
   Craven L, 2017, ANNU REV GENOM HUM G, V18, P257, DOI 10.1146/annurev-genom-091416-035426
   Craven L, 2016, STEM CELLS, V34, P265, DOI 10.1002/stem.2221
   Craven L, 2010, NATURE, V465, P82, DOI 10.1038/nature08958
   Frazier AE, 2017, J BIOL CHEM
   Fujita Y, 2015, MITOCHONDRION, V20, P34, DOI 10.1016/j.mito.2014.10.006
   Gammage PA, 2016, NUCLEIC ACIDS RES, V44, P7804, DOI 10.1093/nar/gkw676
   Gammage PA, 2014, EMBO MOL MED, V6, P458, DOI 10.1002/emmm.201303672
   Garone C, 2014, EMBO MOL MED, V6, P1016, DOI 10.15252/emmm.201404092
   Giorgio V, 2012, BBA-BIOENERGETICS, V1817, P363, DOI 10.1016/j.bbabio.2011.10.012
   Glover EI, 2010, MUSCLE NERVE, V42, P739, DOI 10.1002/mus.21758
   Gorman GS, 2016, NAT REV DIS PRIMERS, V2, P1, DOI 10.1038/nrdp.2016.80
   Gorman GS, 2015, NEUROMUSCULAR DISORD, V25, P563, DOI 10.1016/j.nmd.2015.03.001
   Gorman GS, 2015, NEW ENGL J MED, V372, P885, DOI 10.1056/NEJMc1500960
   Grady JP, 2014, BRAIN, V137, P323, DOI 10.1093/brain/awt321
   Grady JP, 2018, MTDNA HETEROPLASMY L, V10
   Greenfield A, 2017, NAT BIOTECHNOL, V35, P1059, DOI 10.1038/nbt.3997
   Hashimoto M, 2015, MOL THER, V23, P1592, DOI 10.1038/mt.2015.126
   Hirano M, 2012, STUDY IDEBENONE TREA
   Horvath R, 2012, J NEUROL NEUROSUR PS, V83, P174, DOI 10.1136/jnnp-2011-301258
   Hyslop LA, 2016, NATURE, V534, P383, DOI [10.1038/nature183030, 10.1038/nature18303]
   Jeppesen TD, 2006, BRAIN, V129, P3402, DOI 10.1093/brain/awl149
   Kang EJ, 2016, NATURE, V540, P270, DOI 10.1038/nature20592
   Karaa A, 2018, NEUROLOGY, V90, pE1212, DOI 10.1212/WNL.0000000000005255
   Kaufmann P, 2009, STUDY OF IDEBENONE I
   Khan NA, 2014, EMBO MOL MED, V6, P721, DOI 10.1002/emmm.201403943
   Klopstock T, 2011, BRAIN, V134, P2677, DOI 10.1093/brain/awr170
   Koene S, 2017, ORPHANET J RARE DIS, V12, DOI 10.1186/s13023-017-0715-0
   Lehtonen JM, 2016, NEUROLOGY, V87, P2290, DOI 10.1212/WNL.0000000000003374
   McFarland R, 2010, LANCET NEUROL, V9, P829, DOI 10.1016/S1474-4422(10)70116-2
   Minczuk M, 2008, NUCLEIC ACIDS RES, V36, P3926, DOI 10.1093/nar/gkn313
   MORAES CT, 1992, AM J HUM GENET, V50, P934
   Morovat A, 2017, J CLIN MED, V6, DOI 10.3390/jcm6080080
   Murphy JL, 2008, BRAIN, V131, P2832, DOI 10.1093/brain/awn252
   Nesbitt V, 2014, EUR J HUM GENET, V22, P1255, DOI 10.1038/ejhg.2014.35
   Reddy P, 2015, CELL, V161, P459, DOI 10.1016/j.cell.2015.03.051
   Reisman SA, 2014, RADIAT RES, V181, P512, DOI 10.1667/RR13578.1
   Rocha MC, 2015, SCI REP-UK, V5, DOI 10.1038/srep15037
   Rossignol R, 2003, BIOCHEM J, V370, P751, DOI 10.1042/BJ20021594
   Rygiel KA, 2016, J PHYSIOL-LONDON, V594, P4499, DOI 10.1113/JP271212
   Santra S, 2004, ANN NEUROL, V56, P662, DOI 10.1002/ana.20240
   Shen W, 2008, DIABETOLOGIA, V51, P165, DOI 10.1007/s00125-007-0852-4
   SHOFFNER JM, 1989, P NATL ACAD SCI USA, V86, P7952, DOI 10.1073/pnas.86.20.7952
   Siegel MP, 2013, AGING CELL, V12, P763, DOI 10.1111/acel.12102
   Smeets HJM, 2015, ANN NY ACAD SCI, V1350, P29, DOI 10.1111/nyas.12866
   Smith AC, 2016, NUCLEIC ACIDS RES, V44, pD1258, DOI 10.1093/nar/gkv1001
   Sommerville Ewen W, 2014, J Neuromuscul Dis, V1, P119
   Stacpoole PW, 2012, MITOCHONDRION, V12, P623, DOI 10.1016/j.mito.2012.09.005
   Suomalainen A, 2011, LANCET NEUROL, V10, P806, DOI 10.1016/S1474-4422(11)70155-7
   Szeto HH, 2014, CLIN PHARMACOL THER, V96, P672, DOI 10.1038/clpt.2014.174
   Taivassalo T, 2002, ANN NEUROL, V51, P38, DOI 10.1002/ana.10027
   Taivassalo T, 2001, ANN NEUROL, V50, P133, DOI 10.1002/ana.1050
   Taivassalo T, 2003, BRAIN, V126, P413, DOI 10.1093/brain/awg028
   Taivassalo T, 2006, BRAIN, V129, P3391, DOI 10.1093/brain/awl282
   Tarnopolsky MA, 2004, AM J MED GENET A, V124A, P372, DOI 10.1002/ajmg.a.20449
   Taylor RW, 2014, JAMA-J AM MED ASSOC, V312, P68, DOI 10.1001/jama.2014.7184
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
   van de Weijer T, 2015, DIABETES, V64, P1193, DOI 10.2337/db14-0667
   Viscomi C, 2011, CELL METAB, V14, P80, DOI 10.1016/j.cmet.2011.04.011
   Volpi L, 2011, Musculoskelet Surg, V95, P59, DOI 10.1007/s12306-011-0096-9
   Yamada M, 2016, CELL STEM CELL, V18, P749, DOI 10.1016/j.stem.2016.04.001
   Yatsuga S, 2015, ANN NEUROL, V78, P814, DOI 10.1002/ana.24506
   Yatsuga S, 2012, HUM MOL GENET, V21, P526, DOI 10.1093/hmg/ddr482
   Zeviani M, 2008, BRAIN, V131, P2809, DOI 10.1093/brain/awn264
NR 78
TC 66
Z9 85
U1 0
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1933-7213
EI 1878-7479
J9 NEUROTHERAPEUTICS
JI Neurotherapeutics
PD OCT
PY 2018
VL 15
IS 4
BP 943
EP 953
DI 10.1007/s13311-018-00674-4
PG 11
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pharmacology & Pharmacy
GA HD1QN
UT WOS:000452286500010
PM 30406383
OA hybrid, Green Published
DA 2024-11-01
ER

PT J
AU Santos, C
   Montiel, R
   Arruda, A
   Alvarez, L
   Aluja, MP
   Lima, M
AF Santos, Cristina
   Montiel, Rafael
   Arruda, Adriana
   Alvarez, Luis
   Aluja, Maria Pilar
   Lima, Manuela
TI Mutation patterns of mtDNA: Empirical inferences for the coding region
SO BMC EVOLUTIONARY BIOLOGY
LA English
DT Article
ID MITOCHONDRIAL GENOME VARIATION; MATERNALLY INHERITED MYOPATHY;
   DELETERIOUS MUTATIONS; BACKGROUND SELECTION; SEQUENCE DIVERGENCE;
   ADAPTIVE SELECTION; SUBSTITUTION RATES; TIME DEPENDENCY; DNA; EVOLUTION
AB Background: Human mitochondrial DNA (mtDNA) has been extensively used in population and evolutionary genetics studies. Thus, a valid estimate of human mtDNA evolutionary rate is important in many research fields. The small number of estimations performed for the coding region of the molecule, showed important differences between phylogenetic and empirical approaches. We analyzed a portion of the coding region of mtDNA (tRNA(Leu), NDI and tRNA(Ile) genes), using individuals belonging to extended families from the Azores Islands (Portugal) with the main aim of providing empirical estimations of the mutation rate of the coding region of mtDNA under different assumptions, and hence to better understand the mtDNA evolutionary process.
   Results: Heteroplasmy was detected in 6.5% (3/46) of the families analyzed. In all of the families the presence of mtDNA heteroplasmy resulted from three new point mutations, and no cases of insertions or deletions were identified. Major differences were found in the proportion and type of heteroplasmy found in the genes studied when compared to those obtained in a previous report for the D-loop. Our empirical estimation of mtDNA coding region mutation rate, calculated taking into account the sex of individuals carrying new mutations, the probability of intra-individual fixation of mutations present in heteroplasmy and, to the possible extent, the effect of selection, is similar to that obtained using phylogenetic approaches.
   Conclusion: Based on our results, the discrepancy previously reported between the human mtDNA coding region mutation rates observed along evolutionary timescales and estimations obtained using family pedigrees can be resolved when correcting for the previously cited factors.
C1 [Santos, Cristina; Montiel, Rafael; Arruda, Adriana; Lima, Manuela] Univ Azores, CIRN, Azores, Portugal.
   [Santos, Cristina; Alvarez, Luis; Aluja, Maria Pilar] Autonomous Univ Barcelona, Fac Sci, Dept BABVE, Biol Anthropol Unit, Bellaterra 08193, Spain.
C3 Universidade dos Acores; Autonomous University of Barcelona
RP Santos, C (corresponding author), Univ Azores, CIRN, 9500 Ponta Delgada, Azores, Portugal.
EM cristina.santos@uab.es; montiel@notes.uac.pt; aarruda@linus.uac.pt;
   Luis.Alvarez@uab.es; mariapilar.aluja@uab.es; mlima@notes.uac.pt
RI Alvarez, Luis/J-6022-2013; Santos, Cristina/AAE-7665-2020; Santos,
   Cristina/K-2348-2014; Aluja, Maria Pilar/K-1952-2014; Montiel,
   Rafael/A-6774-2008
OI Santos, Cristina/0000-0002-7014-8014; Lima, Manuela/0000-0002-3357-3273;
   Aluja, Maria Pilar/0000-0002-0407-9356; Montiel,
   Rafael/0000-0001-8052-0679
CR Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Arnason U, 1996, J MOL EVOL, V43, P650, DOI 10.1007/BF02202113
   ATTARDI G, 1986, BIOESSAYS, V5, P34, DOI 10.1002/bies.950050111
   Ballard JWO, 2005, ANNU REV ECOL EVOL S, V36, P621, DOI 10.1146/annurev.ecolsys.36.091704.175513
   Bergstrom CT, 1998, GENETICS, V149, P2135
   BROWN WM, 1980, P NATL ACAD SCI-BIOL, V77, P3605, DOI 10.1073/pnas.77.6.3605
   CANN RL, 1987, NATURE, V325, P31, DOI 10.1038/325031a0
   Cavelier L, 2000, HUM GENET, V107, P45, DOI 10.1007/s004390050009
   CHARLESWORTH B, 1994, GENET RES, V63, P213, DOI 10.1017/S0016672300032365
   CHARLESWORTH B, 1993, GENETICS, V134, P1289
   CHARLESWORTH D, 1995, GENETICS, V141, P1619
   Coskun PE, 2004, P NATL ACAD SCI USA, V101, P10726, DOI 10.1073/pnas.0403649101
   Denver DR, 2000, SCIENCE, V289, P2342, DOI 10.1126/science.289.5488.2342
   Emerson BC, 2007, SYST BIOL, V56, P337, DOI 10.1080/10635150701258795
   Hagelberg E, 2003, TRENDS GENET, V19, P84, DOI 10.1016/S0168-9525(02)00048-3
   Hall T.A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI DOI 10.14344/IOC.ML.11.1
   HASEGAWA M, 1991, J MOL EVOL, V32, P37, DOI 10.1007/BF02099927
   HAUSWIRTH WW, 1985, NUCLEIC ACIDS RES, V13, P8093, DOI 10.1093/nar/13.22.8093
   HAUSWIRTH WW, 1984, CELL, V37, P1001, DOI 10.1016/0092-8674(84)90434-3
   Heyer E, 2001, AM J HUM GENET, V69, P1113, DOI 10.1086/324024
   Ho SYW, 2007, SYST BIOL, V56, P515, DOI 10.1080/10635150701435401
   Ho SYW, 2005, MOL BIOL EVOL, V22, P1561, DOI 10.1093/molbev/msi145
   HORAI S, 1995, P NATL ACAD SCI USA, V92, P532, DOI 10.1073/pnas.92.2.532
   Howell N, 1996, AM J HUM GENET, V59, P501
   Howell N, 2003, AM J HUM GENET, V72, P659, DOI 10.1086/368264
   Ingman M, 2003, GENOME RES, V13, P1600, DOI 10.1101/gr.686603
   Ingman M, 2000, NATURE, V408, P708, DOI 10.1038/35047064
   Kivisild T, 2006, GENETICS, V172, P373, DOI 10.1534/genetics.105.043901
   Lee HY, 2004, ELECTROPHORESIS, V25, P28, DOI 10.1002/elps.200305681
   LUNDSTROM R, 1992, P NATL ACAD SCI USA, V89, P5961, DOI 10.1073/pnas.89.13.5961
   Macaulay VA, 1997, AM J HUM GENET, V61, P983
   MARIOTTI C, 1994, J CLIN INVEST, V93, P1102, DOI 10.1172/JCI117061
   Maynard-Smith J, 1974, GENET RES, V23, P23, DOI [10.1017/S0016672308009579, 10.1017/S0016672300014634]
   MILLER WG, 2003, OPENSTAT2 OS2 VERSIO
   Mishmar D, 2003, P NATL ACAD SCI USA, V100, P171, DOI 10.1073/pnas.0136972100
   Nachman MW, 1998, GENETICA, V102-3, P61, DOI 10.1023/A:1017030708374
   OBAYASHI T, 1992, AM HEART J, V124, P1263, DOI 10.1016/0002-8703(92)90410-W
   OHTA T, 1973, NATURE, V246, P96, DOI 10.1038/246096a0
   OHTA T, 1972, J MOL EVOL, V1, P305, DOI 10.1007/BF01653959
   Paabo S, 1996, AM J HUM GENET, V59, P493
   Parsons TJ, 1997, NAT GENET, V15, P363, DOI 10.1038/ng0497-363
   PESOLE G, 1992, MOL BIOL EVOL, V9, P587
   Rand DM, 1998, GENETICA, V102-3, P393, DOI 10.1023/A:1017006118852
   Rand DM, 2001, ANNU REV ECOL SYST, V32, P415, DOI 10.1146/annurev.ecolsys.32.081501.114109
   Ruiz-Pesini E, 2004, SCIENCE, V303, P223, DOI 10.1126/science.1088434
   Ruiz-Pesini E, 2007, NUCLEIC ACIDS RES, V35, pD823, DOI 10.1093/nar/gkl927
   Ruiz-Pesini E, 2006, HUM MUTAT, V27, P1072, DOI 10.1002/humu.20378
   Santos C, 2005, MOL BIOL EVOL, V22, P1490, DOI 10.1093/molbev/msi141
   Siguroardóttir S, 2000, AM J HUM GENET, V66, P1599, DOI 10.1086/302902
   Soodyall H, 1997, AM J PHYS ANTHROPOL, V104, P157, DOI 10.1002/(SICI)1096-8644(199710)104:2<157::AID-AJPA2>3.0.CO;2-W
   STONEKING M, 1992, PHILOS T ROY SOC B, V337, P167, DOI 10.1098/rstb.1992.0094
   STONEKING M, 1986, COLD SPRING HARB SYM, V51, P433, DOI 10.1101/SQB.1986.051.01.052
   TAMURA K, 1993, MOL BIOL EVOL, V10, P512, DOI 10.1093/oxfordjournals.molbev.a040023
   Tanaka M, 2004, GENOME RES, V14, P1832, DOI 10.1101/gr.2286304
   TORRONI A, 1994, AM J HUM GENET, V54, P303
   Trejaut JA, 2005, PLOS BIOL, V3, P1362, DOI 10.1371/journal.pbio.0030247
   Pellekaan SMV, 2006, AM J PHYS ANTHROPOL, V131, P282, DOI 10.1002/ajpa.20426
   VIGILANT L, 1991, SCIENCE, V253, P1503, DOI 10.1126/science.1840702
   Wallace DC, 2003, COLD SPRING HARB SYM, V68, P479
   ZEVIANI M, 1991, LANCET, V338, P143, DOI 10.1016/0140-6736(91)90136-D
NR 60
TC 21
Z9 22
U1 0
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2148
J9 BMC EVOL BIOL
JI BMC Evol. Biol.
PD JUN 2
PY 2008
VL 8
AR 167
DI 10.1186/1471-2148-8-167
PG 12
WC Evolutionary Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Evolutionary Biology; Genetics & Heredity
GA 323QQ
UT WOS:000257462900001
PM 18518963
OA gold, Green Published
DA 2024-11-01
ER

PT J
AU Buchaklian, AH
   Helbling, D
   Ware, SM
   Dimmock, DP
AF Buchaklian, Adam H.
   Helbling, Daniel
   Ware, Stephanie M.
   Dimmock, David P.
TI Recessive deoxyguanosine kinase deficiency causes juvenile onset
   mitochondrial myopathy
SO MOLECULAR GENETICS AND METABOLISM
LA English
DT Article
DE Mitochondrial DNA depletion; DGUOK deficiency; Hepatocerebral,
   cardiomyopathy
ID DNA DEPLETION SYNDROME; MTDNA DEPLETION; MOLECULAR-FEATURES;
   FIBROBLASTS; MUTATIONS; LIVER; SUPPLEMENTATION; EXPRESSION; GENES
AB Deoxyguanosine kinase (DGUOK) (MIM#601465) deficiency was originally described as the cause of an infantile onset hepatocerebral mitochondrial disease [1]. The classic features of this disorder include significant hepatic failure with nystagmus and hypotonia. Mitochondrial DNA studies reveal significant mitochondrial DNA depletion in the affected tissues. Subsequently it has been shown that the same mutations in this gene may present with isolated acute liver failure without cerebral involvement. In this paper we studied the mitochondrial DNA depletion in cells from a patient presenting with mitochondrial myopathy caused by a novel mutation in DGUOK. Subsequently we developed the method to diagnose this condition using MyoD induced fibroblasts to study the muscle specific phenotype. In addition, supplementation of MyoD induced fibroblasts with dAMP and dGMP resulted in a restoration of mtDNA quantity. (c) 2012 Elsevier Inc. All rights reserved.
C1 [Buchaklian, Adam H.; Helbling, Daniel; Dimmock, David P.] Med Coll Wisconsin, Dept Pediat, Milwaukee, WI 53221 USA.
   [Buchaklian, Adam H.; Helbling, Daniel; Dimmock, David P.] Med Coll Wisconsin, Human & Mol Genet Ctr, Milwaukee, WI 53221 USA.
   [Ware, Stephanie M.] Cincinnati Childrens Hosp, Dept Pediat, Div Human Genet, Cincinnati, OH USA.
   [Ware, Stephanie M.] Cincinnati Childrens Hosp, Dept Pediat, Inst Heart, Cincinnati, OH USA.
C3 Medical College of Wisconsin; Medical College of Wisconsin; Cincinnati
   Children's Hospital Medical Center; Cincinnati Children's Hospital
   Medical Center
RP Dimmock, DP (corresponding author), Med Coll Wisconsin, Dept Pediat, 8701 Watertown Plank Rd, Milwaukee, WI 53221 USA.
EM ddimmock@mcw.edu
RI ; Dimmock, David/I-7913-2015
OI /0000-0002-2693-5598; Dimmock, David/0000-0001-6690-2523
CR Alberio S, 2007, MITOCHONDRION, V7, P6, DOI 10.1016/j.mito.2006.11.010
   AMAYA Y, 1988, J BIOCHEM, V103, P177, DOI 10.1093/oxfordjournals.jbchem.a122227
   Bulst S, 2009, HUM MOL GENET, V18, P1590, DOI 10.1093/hmg/ddp074
   Cameron JM, 2004, MITOCHONDRION, V4, P387, DOI 10.1016/j.mito.2004.07.039
   De Camaret BM, 2007, BIOCHEM J, V402, P377, DOI 10.1042/BJ20060705
   Dimmock DP, 2008, HUM MUTAT, V29, P330, DOI 10.1002/humu.9519
   Dimmock D, 2007, PEDIATRICS, V119, pE773, DOI 10.1542/peds.2006-1950
   Dimmock D, 2010, CLIN CHEM, V56, P1119, DOI 10.1373/clinchem.2009.141549
   Dimmock DP, 2008, LIVER TRANSPLANT, V14, P1480, DOI 10.1002/lt.21556
   Freisinger P, 2006, ARCH NEUROL-CHICAGO, V63, P1129, DOI 10.1001/archneur.63.8.1129
   Labarthe F, 2005, J HEPATOL, V43, P333, DOI 10.1016/j.jhep.2005.03.023
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284
   Spinazzola A, 2005, GENE, V354, P162, DOI 10.1016/j.gene.2005.03.025
   Spinazzola A, 2009, J INHERIT METAB DIS, V32, P143, DOI 10.1007/s10545-008-1038-z
   Taanman JW, 2003, HUM MOL GENET, V12, P1839, DOI 10.1093/hmg/ddg192
   van den Heuvel LP, 2004, MITOCHONDRION, V4, P395, DOI 10.1016/j.mito.2004.07.005
   Viscomi C, 2009, HUM MOL GENET, V18, P12, DOI 10.1093/hmg/ddn309
   WEINTRAUB H, 1989, P NATL ACAD SCI USA, V86, P5434, DOI 10.1073/pnas.86.14.5434
NR 20
TC 20
Z9 24
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1096-7192
J9 MOL GENET METAB
JI Mol. Genet. Metab.
PD SEP-OCT
PY 2012
VL 107
IS 1-2
SI SI
BP 92
EP 94
DI 10.1016/j.ymgme.2012.04.019
PG 3
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental
   Medicine
GA 014KI
UT WOS:000309374200014
PM 22622127
DA 2024-11-01
ER

PT J
AU Kytövuori, L
   Kärppä, M
   Tuominen, H
   Uusimaa, J
   Saari, M
   Hinttala, R
   Majamaa, K
AF Kytovuori, Laura
   Karppa, Mikko
   Tuominen, Hannu
   Uusimaa, Johanna
   Saari, Markku
   Hinttala, Reetta
   Majamaa, Kari
TI Case report: a novel frameshift mutation in the <i>mitochondrial</i>
   <i>cytochrome c oxidase II</i> gene causing mitochondrial disorder
SO BMC NEUROLOGY
LA English
DT Article
DE Neuromuscular disorders; Mitochondrial diseases; Cytochrome c oxidase
   deficiency; Case report
ID SUBUNIT-II; LACTIC-ACIDOSIS; HUMAN MTDNA; COMPLEX IV; ENCEPHALOMYOPATHY;
   DEFICIENCY; DNA; MYOPATHY; DISEASE; COX6B1
AB Background: Mitochondrial cytochrome c oxidase 2, MT-CO2, encodes one of the three subunits, which form the catalytic core of cytochrome c oxidase (COX), complex IV. Mutations in MT-CO2 are rare and the associated phenotypes are variable including nonsyndromic and syndromic forms of mitochondrial diseases.
   Case presentation: We describe a 30-year-old man with cognitive decline, epilepsy, psychosis, exercise intolerance, sensorineural hearing impairment, retinitis pigmentosa, cataract and lactic acidosis. COX-deficient fibers and ragged red fibers were abundant in the muscle. Sequencing of mitochondrial DNA (mtDNA) revealed a novel frameshift mutation m.8156delG that was predicted to cause altered C-terminal amino acid sequence and to lead to truncation of the COX subunit 2. The deletion was heteroplasmic being present in 26% of the mtDNA in blood, 33% in buccal mucosa and 95% in muscle. Deletion heteroplasmy correlated with COX-deficiency in muscle histochemistry. The mother and the siblings of the proband did not harbor the deletion.
   Conclusions: The clinical features and muscle histology of the proband suggested a mitochondrial disorder. The m.8156delG deletion is a new addition to the short list of pathogenic mutations in the mtDNA-encoded subunits of COX. This case illustrates the importance of mtDNA sequence analysis in patients with an evident mitochondrial disorder.
C1 [Kytovuori, Laura; Karppa, Mikko; Majamaa, Kari] Univ Oulu, Res Unit Clin Neurosci, POB 5000, FI-90014 Oulu, Finland.
   [Kytovuori, Laura; Karppa, Mikko; Uusimaa, Johanna; Hinttala, Reetta; Majamaa, Kari] Oulu Univ Hosp, Med Res Ctr Oulu, Oulu, Finland.
   [Kytovuori, Laura; Karppa, Mikko; Uusimaa, Johanna; Hinttala, Reetta; Majamaa, Kari] Univ Oulu, Oulu, Finland.
   [Kytovuori, Laura; Karppa, Mikko; Majamaa, Kari] Oulu Univ Hosp, Dept Neurol, POB 20OYS, FI-90029 Oulu, Finland.
   [Tuominen, Hannu] Univ Oulu, Dept Pathol, Canc & Translat Med Res Unit, Oulu, Finland.
   [Tuominen, Hannu] Oulu Univ Hosp, Dept Pathol, Oulu, Finland.
   [Uusimaa, Johanna; Hinttala, Reetta] Univ Oulu, PEDEGO Res Unit, POB 5000, FI-90014 Oulu, Finland.
   [Uusimaa, Johanna; Hinttala, Reetta] Oulu Univ Hosp, Div Pediat Neurol, Dept Children & Adolescents, Oulu, Finland.
   [Uusimaa, Johanna; Hinttala, Reetta] Univ Oulu, Bioctr Oulu, POB 5000, FI-90014 Oulu, Finland.
   [Saari, Markku] Univ Turku, Turku Ctr Biotechnol, Cell Imaging Core, FI-20520 Turku, Finland.
C3 University of Oulu; University of Oulu; University of Oulu; University
   of Oulu; University of Oulu; University of Oulu; University of Oulu;
   University of Oulu; University of Oulu; University of Turku
RP Kytövuori, L (corresponding author), Univ Oulu, Res Unit Clin Neurosci, POB 5000, FI-90014 Oulu, Finland.; Kytövuori, L (corresponding author), Oulu Univ Hosp, Med Res Ctr Oulu, Oulu, Finland.; Kytövuori, L (corresponding author), Univ Oulu, Oulu, Finland.; Kytövuori, L (corresponding author), Oulu Univ Hosp, Dept Neurol, POB 20OYS, FI-90029 Oulu, Finland.
EM laura.kytovuori@oulu.fi
RI Kytövuori, Laura/AHE-1635-2022; Majamaa, Kari/A-1344-2012
OI Kytovuori, Laura/0000-0003-2790-5646; Hinttala,
   Reetta/0000-0002-7642-4008; Majamaa, Kari/0000-0002-9070-3791
FU Sigrid Juselius Foundation; Medical Research Center; Oulu University
   Hospital and Oulu University Hospital; Academy of Finland [266,498,
   273,790]
FX The study was supported by grants from the Sigrid Juselius Foundation,
   Medical Research Center, University of Oulu and Oulu University
   Hospital, State research funding from Oulu University Hospital, and the
   Academy of Finland (R.H., decision numbers 266,498 and 273,790).
CR Abdulhag UN, 2015, EUR J HUM GENET, V23, P159, DOI 10.1038/ejhg.2014.85
   [Anonymous], A Human Mitochondrial Genome Database
   Bruno C, 1999, AM J HUM GENET, V65, P611, DOI 10.1086/302546
   Campos Y, 2001, ANN NEUROL, V50, P409, DOI 10.1002/ana.1141
   Hallmann K, 2016, BRAIN, V139, P338, DOI 10.1093/brain/awv357
   Hanna MG, 1998, AM J HUM GENET, V63, P29, DOI 10.1086/301910
   Horváth R, 2005, NEUROMUSCULAR DISORD, V15, P851, DOI 10.1016/j.nmd.2005.09.005
   Indrieri A, 2012, AM J HUM GENET, V91, P942, DOI 10.1016/j.ajhg.2012.09.016
   Leary SC, 2013, HUM MUTAT, V34, P1366, DOI 10.1002/humu.22385
   Martikainen MH, 2013, MITOCHONDRION, V13, P83, DOI 10.1016/j.mito.2013.01.012
   Massa V, 2008, AM J HUM GENET, V82, P1281, DOI 10.1016/j.ajhg.2008.05.002
   McFarland R, 2004, NEUROMUSCULAR DISORD, V14, P162, DOI 10.1016/j.nmd.2003.10.011
   Rahman S, 1999, AM J HUM GENET, V65, P1030, DOI 10.1086/302590
   Rossmanith W, 2008, J MED GENET, V45, P117, DOI 10.1136/jmg.2007.052076
   Shoubridge E A, 1996, Methods Enzymol, V264, P465, DOI 10.1016/S0076-6879(96)64042-7
   Shteyer E, 2009, AM J HUM GENET, V84, P412, DOI 10.1016/j.ajhg.2009.02.006
   Spendiff S, 2013, HUM MOL GENET, V22, P4739, DOI 10.1093/hmg/ddt327
   Tamiya G, 2014, AM J HUM GENET, V95, P294, DOI 10.1016/j.ajhg.2014.07.013
   Vissing CR, 2013, NEUROLOGY, V80, P1908, DOI 10.1212/WNL.0b013e3182929fb2
   Wong LJC, 2001, AM J MED GENET, V102, P95, DOI 10.1002/1096-8628(20010722)102:1<95::AID-AJMG1412>3.0.CO;2-U
   Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804
NR 21
TC 8
Z9 8
U1 0
U2 4
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2377
J9 BMC NEUROL
JI BMC Neurol.
PD MAY 18
PY 2017
VL 17
AR 96
DI 10.1186/s12883-017-0883-5
PG 5
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA EV4LF
UT WOS:000401730600001
PM 28521807
OA Green Published, gold
DA 2024-11-01
ER

PT J
AU Chabi, B
   Adhihetty, PJ
   Ljubicic, V
   Hood, DA
AF Chabi, B
   Adhihetty, PJ
   Ljubicic, V
   Hood, DA
TI How is mitochondrial biogenesis affected in mitochondrial disease?
SO MEDICINE AND SCIENCE IN SPORTS AND EXERCISE
LA English
DT Article
DE mitochondrial myopathy; exercise; DNA mutations; skeletal muscle;
   mitochondrial DNA
ID TRANSCRIPTION FACTOR-A; C-OXIDASE DEFICIENCY; PROGRESSIVE EXTERNAL
   OPHTHALMOPLEGIA; GAMMA COACTIVATOR-1-ALPHA EXPRESSION; HEREDITARY OPTIC
   NEUROPATHY; SKELETAL-MUSCLE CELLS; KEARNS-SAYRE SYNDROME; PROTEIN
   IMPORT; CONTRACTILE ACTIVITY; GENE-EXPRESSION
AB Mitochondrial biogenesis occurs when the tissue energy demand is chronically increased to stress the ATP producing capacity of the preexisting mitochondria. In muscle, endurance training is a metabolic stress that is capable of inducing mitochondrial biogenesis, the consequence of which is improved performance during exercise. Expansion of the mitochondrial volume requires the coordinated response of the nuclear and mitochondrial genomes. During acute exercise, the initial signaling events are the perturbations in ATP turnover and calcium (Ca2+) concentrations caused by the contractile process. These alterations activate signal transduction pathways which target transcription factors involved in gene expression. Nuclear gene products are then posttranslationally imported into mitochondria. One of these, Tfam, is important for the regulation of mitochondrial DNA (mtDNA) gene expression. In muscle, a broad range of mitochondrial-specific diseases due to mutations in nuclear DNA or mtDNA exist, termed mitochondrial myopathies. These mutations result in dysfunctional mitochondrial assembly which ultimately leads to reduced ATP production. Mitochondrial myopathy patients exhibit a variety of compensatory responses which attempt to reconcile this energy deficiency, but the extent and the type of compensatory adaptations are disease-specific. Understanding the role of exercise in mediating these compensatory responses leading to mitochondrial biogenesis could help us in prescribing exercise designed to improve mitochondrial function in patients with mitochondrial myopathies. In addition, numerous other diseases (e.g., neurological disorders, cancer, diabetes, and cardiomyopathies), as well as the aging process, have etiologies or consequences attributed, in part, to mitochondrial dysfunction. Thus, insight gained by investigating the steps involved in exercise-induced mitochondrial biogenesis may help us to understand the underlying basis of these other disease states.
C1 York Univ, Sch Kinesiol & Hlth Sci, N York, ON M3J 1P3, Canada.
   York Univ, Dept Biol, N York, ON M3J 1P3, Canada.
C3 York University - Canada; York University - Canada
RP York Univ, Sch Kinesiol & Hlth Sci, N York, ON M3J 1P3, Canada.
EM dhood@yorku.ca
OI CHABI, Beatrice/0000-0002-5604-5668
CR Adhihetty PJ., 2003, BAM PADOVA, V13, P171
   Antonicka H, 2003, AM J HUM GENET, V72, P101, DOI 10.1086/345489
   Baar K, 2002, FASEB J, V16, P1879, DOI 10.1096/fj.02-0367com
   Bengtsson J, 2001, PFLUG ARCH EUR J PHY, V443, P61, DOI 10.1007/s004240100628
   Bergeron R, 2001, AM J PHYSIOL-ENDOC M, V281, pE1340, DOI 10.1152/ajpendo.2001.281.6.E1340
   Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522
   Bohr VA, 2002, GENE, V286, P127, DOI 10.1016/S0378-1119(01)00813-7
   BOURGERON T, 1995, NAT GENET, V11, P144, DOI 10.1038/ng1095-144
   Bua EA, 2002, J APPL PHYSIOL, V92, P2617, DOI 10.1152/japplphysiol.01102.2001
   Butow RA, 2004, MOL CELL, V14, P1, DOI 10.1016/S1097-2765(04)00179-0
   Chin ER, 2004, P NUTR SOC, V63, P279, DOI 10.1079/PNS2004335
   CORTOPASSI GA, 1992, P NATL ACAD SCI USA, V89, P7370, DOI 10.1073/pnas.89.16.7370
   Ekstrand MI, 2004, HUM MOL GENET, V13, P935, DOI 10.1093/hmg/ddh109
   Freyssenet D, 1999, J BIOL CHEM, V274, P9305, DOI 10.1074/jbc.274.14.9305
   Freyssenet D, 2004, AM J PHYSIOL-CELL PH, V286, pC1053, DOI 10.1152/ajpcell.00418.2003
   Ganitkevich VY, 2003, EXP PHYSIOL, V88, P91, DOI 10.1113/eph8802504
   GERBITZ KD, 1995, BBA-MOL BASIS DIS, V1271, P253, DOI 10.1016/0925-4439(95)00036-4
   Gordon JW, 2001, J APPL PHYSIOL, V90, P389, DOI 10.1152/jappl.2001.90.1.389
   Goto M, 2000, BIOCHEM BIOPH RES CO, V274, P350, DOI 10.1006/bbrc.2000.3134
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Grey JY, 2000, AM J PHYSIOL-CELL PH, V279, pC1393, DOI 10.1152/ajpcell.2000.279.5.C1393
   Handschin C, 2003, P NATL ACAD SCI USA, V100, P7111, DOI 10.1073/pnas.1232352100
   Hood DA, 2004, P NUTR SOC, V63, P293, DOI 10.1079/PNS2004342
   Hood DA, 2001, J APPL PHYSIOL, V90, P1137, DOI 10.1152/jappl.2001.90.3.1137
   Irrcher I, 2003, AM J PHYSIOL-CELL PH, V284, pC1669, DOI 10.1152/ajpcell.00409.2002
   JOHNS DR, 1992, BIOCHEM BIOPH RES CO, V187, P1551, DOI 10.1016/0006-291X(92)90479-5
   Joseph AM, 2004, AM J PHYSIOL-CELL PH, V286, pC867, DOI 10.1152/ajpcell.00191.2003
   Kennedy ED, 1998, DIABETES, V47, P374, DOI 10.2337/diabetes.47.3.374
   Khrapko K, 2003, MUTAT RES-FUND MOL M, V522, P13, DOI 10.1016/S0027-5107(02)00306-8
   Koehler CM, 1999, P NATL ACAD SCI USA, V96, P2141, DOI 10.1073/pnas.96.5.2141
   LARSSON NG, 1994, BIOCHEM BIOPH RES CO, V200, P1374, DOI 10.1006/bbrc.1994.1603
   Leonard JV, 2000, LANCET, V355, P389, DOI 10.1016/S0140-6736(99)05226-5
   LESTIENNE P, 1988, LANCET, V1, P885
   LEZZA AMS, 1994, BIOCHEM BIOPH RES CO, V205, P772, DOI 10.1006/bbrc.1994.2732
   LI K, 1995, AM J PHYSIOL-CELL PH, V269, pC1265, DOI 10.1152/ajpcell.1995.269.5.C1265
   Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904
   Loeffen JLCM, 2000, HUM MUTAT, V15, P123, DOI 10.1002/(SICI)1098-1004(200002)15:2<123::AID-HUMU1>3.3.CO;2-G
   LUFT R, 1962, J CLIN INVEST, V41, P1776, DOI 10.1172/JCI104637
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Marusich MF, 1997, BBA-MOL BASIS DIS, V1362, P145, DOI 10.1016/S0925-4439(97)00061-6
   MCSHANE MA, 1991, AM J HUM GENET, V48, P39
   Michael LF, 2001, P NATL ACAD SCI USA, V98, P3820, DOI 10.1073/pnas.061035098
   Miranda S, 1999, BIOCHEM BIOPH RES CO, V258, P44, DOI 10.1006/bbrc.1999.0580
   Miura S, 2003, J BIOL CHEM, V278, P31385, DOI 10.1074/jbc.M304312200
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Nijtmans LGJ, 2001, J BIOL CHEM, V276, P6755, DOI 10.1074/jbc.M008114200
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Nisoli E, 2004, BIOCHEM PHARMACOL, V67, P1, DOI 10.1016/j.bcp.2003.10.015
   Ojuka EO, 2000, J APPL PHYSIOL, V88, P1072, DOI 10.1152/jappl.2000.88.3.1072
   Ojuka EO, 2003, FASEB J, V17, P675, DOI 10.1096/fj.02-0951com
   ORNATSKY OI, 1995, BIOCHEM J, V311, P119, DOI 10.1042/bj3110119
   Papadopoulou LC, 1999, NAT GENET, V23, P333
   Patti ME, 2003, P NATL ACAD SCI USA, V100, P8466, DOI 10.1073/pnas.1032913100
   Petersen KF, 2003, SCIENCE, V300, P1140, DOI 10.1126/science.1082889
   Pfanner N, 2002, BBA-MOL CELL RES, V1592, P15, DOI 10.1016/S0167-4889(02)00260-4
   Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5
   Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012
   Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2
   Rungi AA, 2002, BBA-MOL BASIS DIS, V1586, P146, DOI 10.1016/S0925-4439(01)00072-2
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Scarpulla RC, 2002, BBA-GENE STRUCT EXPR, V1576, P1, DOI 10.1016/S0167-4781(02)00343-3
   Schultz RA, 1998, J BIOL CHEM, V273, P3447, DOI 10.1074/jbc.273.6.3447
   Seidel-Rogol BL, 2002, NUCLEIC ACIDS RES, V30, P1929, DOI 10.1093/nar/30.9.1929
   Shoubridge EA, 2001, AM J MED GENET, V106, P46, DOI 10.1002/ajmg.1378
   Silva JP, 2000, NAT GENET, V26, P336, DOI 10.1038/81649
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Takahashi M, 1998, AM J PHYSIOL-CELL PH, V274, pC1380, DOI 10.1152/ajpcell.1998.274.5.C1380
   Tiranti V, 1998, AM J HUM GENET, V63, P1609, DOI 10.1086/302150
   Valnot I, 2000, AM J HUM GENET, V67, P1104
   Valnot I, 2000, HUM MOL GENET, V9, P1245, DOI 10.1093/hmg/9.8.1245
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   WALLACE DC, 1988, CELL, V55, P601, DOI 10.1016/0092-8674(88)90218-8
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   WICKS KL, 1991, AM J PHYSIOL, V260, pC841, DOI 10.1152/ajpcell.1991.260.4.C841
   Wiedemann N, 2004, J BIOL CHEM, V279, P18188, DOI 10.1074/jbc.M400050200
   WILLIAMS RS, 1986, J BIOL CHEM, V261, P376
   Wu H, 2002, SCIENCE, V296, P349, DOI 10.1126/science.1071163
   Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X
   Zong HH, 2002, P NATL ACAD SCI USA, V99, P15983, DOI 10.1073/pnas.252625599
NR 80
TC 29
Z9 36
U1 0
U2 9
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0195-9131
EI 1530-0315
J9 MED SCI SPORT EXER
JI Med. Sci. Sports Exerc.
PD DEC
PY 2005
VL 37
IS 12
BP 2102
EP 2110
DI 10.1249/01.mss.0000177426.68149.83
PG 9
WC Sport Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Sport Sciences
GA 992DY
UT WOS:000233865800013
PM 16331136
OA Bronze
DA 2024-11-01
ER

PT J
AU Ronchi, D
   Di Fonzo, A
   Lin, WQ
   Bordoni, A
   Liu, CW
   Fassone, E
   Pagliarani, S
   Rizzuti, M
   Zheng, L
   Filosto, M
   Ferrò, MT
   Ranieri, M
   Magri, F
   Peverelli, L
   Li, HZ
   Yuan, YC
   Corti, S
   Sciacco, M
   Moggio, M
   Bresolin, N
   Shen, BH
   Comi, GP
AF Ronchi, Dario
   Di Fonzo, Alessio
   Lin, Weiqiang
   Bordoni, Andreina
   Liu, Changwei
   Fassone, Elisa
   Pagliarani, Serena
   Rizzuti, Mafalda
   Zheng, Li
   Filosto, Massimiliano
   Ferro, Maria Teresa
   Ranieri, Michela
   Magri, Francesca
   Peverelli, Lorenzo
   Li, Hongzhi
   Yuan, Yate-Ching
   Corti, Stefania
   Sciacco, Monica
   Moggio, Maurizio
   Bresolin, Nereo
   Shen, Binghui
   Comi, Giacomo Pietro
TI Mutations in <i>DNA2</i> Link Progressive Myopathy to Mitochondrial DNA
   Instability
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID ENZYMATIC-PROPERTIES; REPLICATION; DISEASE; REPAIR; DELETIONS; PROTEIN;
   TWINKLE; FLAP
AB Syndromes associated with multiple mtDNA deletions are due to different molecular defects that can result in a wide spectrum of predominantly adult-onset clinical presentations, ranging from progressive external ophthalmoplegia (PRO) to multisystemic disorders of variable severity. The autosomal-dominant form of PEO is genetically heterogeneous. Recently, causative mutations have been reported in several nuclear genes that encode proteins of the mtDNA replisome machinery (POLG, POLG2, and C10orf2) or that are involved in pathways for the synthesis of deoxyribonuclotides (ANTI and RRM2B). Despite these findings, putative mutations remain unknown in half of the subjects with PEO. We report the identification, by exome sequencing, of mutations in DNA2 in adult-onset individuals with a form of mitochondrial myopathy featuring instability of muscle mtDNA. DNA2 encodes a helicase/nuclease family member that is most likely involved in mtDNA replication, as well as in the long-patch base-excision repair (LP-BER) pathway. In vitro biochemical analysis of purified mutant proteins revealed a severe impairment of nuclease, helicase, and ATPase activities. These results implicate human DNA2 and the LP-BER pathway in the pathogenesis of adult-onset disorders of mtDNA maintenance.
C1 [Ronchi, Dario; Di Fonzo, Alessio; Bordoni, Andreina; Pagliarani, Serena; Rizzuti, Mafalda; Ranieri, Michela; Magri, Francesca; Corti, Stefania; Bresolin, Nereo; Comi, Giacomo Pietro] Univ Milan, Ist Ricovero & Cura,Neurol Unit, Carattere Sci Fdn Ca Granda Osped Maggiore Policl, Dino Ferrari Ctr,Neurosci Sect,Dept Pathophysiol, I-20122 Milan, Italy.
   [Lin, Weiqiang; Liu, Changwei; Zheng, Li; Shen, Binghui] Beckman Res Inst City Hope, Dept Radiat Biol, Duarte, CA 91010 USA.
   [Fassone, Elisa] UCL, Inst Child Hlth, Mitochondrial Res Grp, London WC1N 3BG, England.
   [Filosto, Massimiliano] Spedali Civil Brescia, Univ Hosp, Sect Neuromuscular Dis & Neuropathies, I-25123 Brescia, Italy.
   [Ferro, Maria Teresa] Osped Maggiore Crema, Neurol Unit, I-26013 Crema, Italy.
   [Corti, Stefania; Bresolin, Nereo; Comi, Giacomo Pietro] Univ Milan, Ctr Excellence Neurodegenerat Dis, I-20122 Milan, Italy.
   [Peverelli, Lorenzo; Sciacco, Monica; Moggio, Maurizio] Univ Milan, Carattere Sci Fdn Ca Granda Osped Maggiore Policl, Ist Ricovero & Cura, Neuromuscular Unit,Dino Ferrari Ctr, I-20122 Milan, Italy.
   [Li, Hongzhi; Yuan, Yate-Ching] City Hope Comprehens Canc Ctr, Beckman Res Inst, Bioinformat Core, Duarte, CA 91010 USA.
   [Bresolin, Nereo] Ist Ricovero & Cura Carattere Sci Eugenio Medea, I-23842 Bosisio Parini, Lecco, Italy.
C3 University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; City
   of Hope; Beckman Research Institute of City of Hope; University of
   London; University College London; Hospital Spedali Civili Brescia;
   University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico;
   University of Milan; City of Hope; Beckman Research Institute of City of
   Hope; IRCCS Eugenio Medea
RP Shen, BH (corresponding author), Beckman Res Inst City Hope, Dept Radiat Biol, Duarte, CA 91010 USA.
EM bshen@coh.org; giacomo.comi@unimi.it
RI Ronchi, Dario/K-8011-2016; Comi, Giacomo/K-5702-2016; Di Fonzo,
   Alessio/A-5702-2013; Sciacco, Monica/AAC-6500-2022; Rizzuti,
   Mafalda/AAC-2407-2022; Filosto, Massimiliano/S-9446-2019; Magri,
   Francesca/K-5739-2016; Pagliarani, Serena/K-8035-2016; corti,
   stefania/K-6034-2016
OI Comi, Giacomo/0000-0002-1383-5248; Lin, Weiqiang/0000-0002-2171-8009; Di
   Fonzo, Alessio/0000-0001-6478-026X; Ronchi, Dario/0000-0002-6093-9816;
   Rizzuti, Mafalda/0000-0001-5734-7476; Magri,
   Francesca/0000-0001-8974-9453; Shen, Binghui/0000-0002-4408-407X;
   Peverelli, Lorenzo/0000-0001-6175-025X; Bresolin,
   Nereo/0000-0001-6694-3595; Pagliarani, Serena/0000-0002-7145-1998;
   Filosto, Massimiliano/0000-0002-2852-7512; Sciacco,
   Monica/0000-0003-4593-4977; corti, stefania/0000-0001-5425-969X
FU Telethon [GTB07001ER, GUP09004]; Eurobiobank project [QLTR-2001-02769];
   National Institutes of Health [R01CA085344]; Associazione Amici del
   Centro Dino Ferrari, University of Milan
FX We wish to thank the patients and their families for their support and
   collaboration. This work was supported by the following grants: Telethon
   project GTB07001ER, Eurobiobank project QLTR-2001-02769, Telethon grant
   GUP09004 to G.P.C., and National Institutes of Health grant R01CA085344
   to B.S. The financial support of Associazione Amici del Centro Dino
   Ferrari, University of Milan is gratefully acknowledged.
CR Bae SH, 2000, J BIOL CHEM, V275, P38022, DOI 10.1074/jbc.M006513200
   Budd ME, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004267
   BUDD ME, 1995, P NATL ACAD SCI USA, V92, P7642, DOI 10.1073/pnas.92.17.7642
   Copeland WC, 2012, CRIT REV BIOCHEM MOL, V47, P64, DOI 10.3109/10409238.2011.632763
   Copeland WC, 2008, MOL CELL, V32, P457, DOI 10.1016/j.molcel.2008.11.007
   Duxin JP, 2009, MOL CELL BIOL, V29, P4274, DOI 10.1128/MCB.01834-08
   Fratter C, 2011, NEUROLOGY, V76, P2032, DOI 10.1212/WNL.0b013e31821e558b
   Gilissen C, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-9-228
   Kim JH, 2006, NUCLEIC ACIDS RES, V34, P1854, DOI 10.1093/nar/gkl102
   Liu Y, 2004, MOL CELL BIOL, V24, P4049, DOI 10.1128/MCB.24.9.4049-4064.2004
   Masuda-Sasa T, 2006, NUCLEIC ACIDS RES, V34, P1865, DOI 10.1093/nar/gkl070
   Robertson AB, 2009, CELL MOL LIFE SCI, V66, P981, DOI 10.1007/s00018-009-8736-z
   Sen D, 2012, J BIOL CHEM, V287, P14545, DOI 10.1074/jbc.M111.309468
   Stumpf JD, 2011, CELL MOL LIFE SCI, V68, P219, DOI 10.1007/s00018-010-0530-4
   Virgilio R, 2008, J NEUROL, V255, P1384, DOI 10.1007/s00415-008-0926-3
   Wanrooij S, 2010, BBA-BIOENERGETICS, V1797, P1378, DOI 10.1016/j.bbabio.2010.04.015
   Ylikallio E, 2010, HUM MOL GENET, V19, P2695, DOI 10.1093/hmg/ddq163
   ZEVIANI M, 1990, ANN NEUROL, V28, P94, DOI 10.1002/ana.410280118
   Zheng L, 2008, MOL CELL, V32, P325, DOI 10.1016/j.molcel.2008.09.024
NR 19
TC 101
Z9 108
U1 0
U2 18
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0002-9297
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD FEB 7
PY 2013
VL 92
IS 2
BP 293
EP 300
DI 10.1016/j.ajhg.2012.12.014
PG 8
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 093GL
UT WOS:000315179600015
PM 23352259
OA Green Published, hybrid
DA 2024-11-01
ER

PT J
AU Vincent, AE
   Grady, JP
   Rocha, MC
   Alston, CL
   Rygiel, KA
   Barresi, R
   Taylor, RW
   Turnbull, DM
AF Vincent, Amy E.
   Grady, John P.
   Rocha, Mariana C.
   Alston, Charlotte L.
   Rygiel, Karolina A.
   Barresi, Rita
   Taylor, Robert W.
   Turnbull, Doug M.
TI Mitochondrial dysfunction in myofibrillar myopathy
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE Myofibrillar myopathy; Mitochondria; Mitochondrial DNA deletion;
   Immunofluorescence; Histochemistry; Cytochrome c oxidase deficiency
ID INCLUSION-BODY MYOSITIS; DNA DELETIONS; MUSCULAR-DYSTROPHY;
   PARKINSON-DISEASE; MUTATIONS; MUSCLE; DESMIN; ABNORMALITIES; CELLS;
   PHOSPHORYLATION
AB Myofibrillar myopathies (MFM) are characterised by focal myofibrillar destruction and accumulation of myofibrillar elements as protein aggregates. They are caused by mutations in the DES, MYOT, CRYAB, FLNC, BAG3, DNAJB6 and ZASP genes as well as other as yet unidentified genes. Previous studies have reported changes in mitochondrial morphology and cellular positioning, as well as clonally-expanded, large-scale mitochondrial DNA (mtDNA) deletions and focal respiratory chain deficiency in muscle of MFM patients. Here we examine skeletal muscle from patients with desmin (n = 6), ZASP (n = 1) and myotilin (n = 2) mutations and MFM protein aggregates, to understand how mitochondrial dysfunction may contribute to the underlying mechanisms causing disease pathology. We have used a validated quantitative immunofluorescent assay to study respiratory chain protein levels, together with oxidative enzyme histochemistry and single cell mitochondrial DNA analysis, to examine mitochondrial changes. Results demonstrate a small number of clonally-expanded mitochondrial DNA deletions, which we conclude are due to both ageing and disease pathology. Further to this we report higher levels of respiratory chain complex I and IV deficiency compared to age matched controls, although overall levels of respiratory deficient muscle fibres in patient biopsies are low. More strikingly, a significantly higher percentage of myofibrillar myopathy patient muscle fibres have a low mitochondrial mass compared to controls. We concluded this is mechanistically unrelated to desmin and myotilin protein aggregates; however, correlation between mitochondrial mass and muscle fibre area is found. We suggest this may be due to reduced mitochondrial biogenesis in combination with muscle fibre hypertrophy. (C) 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
C1 [Vincent, Amy E.; Grady, John P.; Rocha, Mariana C.; Alston, Charlotte L.; Rygiel, Karolina A.; Taylor, Robert W.; Turnbull, Doug M.] Newcastle Univ, Inst Neurosci, Wellcome Trust Ctr Mitochondrial Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Barresi, Rita] Newcastle Upon Tyne Hosp NHS Fdn Trust, Muscle Immunoanal Unit, Rare Dis Advisory Grp, Serv Neuromuscular Dis, Newcastle Upon Tyne NE2 4AZ, Tyne & Wear, England.
C3 Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation
   Trust
RP Turnbull, DM (corresponding author), Newcastle Univ, Sch Med, Inst Neurosci, Wellcome Trust Ctr Mitochondrial Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM doug.turnbull@ncl.ac.uk
RI Vincent, Amy/J-7284-2019; Barresi, Rita/AAB-9569-2022; Alston,
   Charlotte/ABG-9602-2020; Rocha, Mariana/O-4313-2017
OI Alston, Charlotte/0000-0003-2095-5464; Vincent, Amy/0000-0002-0360-6644;
   Turnbull, Doug/0000-0002-8878-9901; Grady, John/0000-0001-9667-3872;
   Rocha, Mariana/0000-0002-0056-9315
FU Medical Research Council [MC_G0802536, MR/L016354/1, MR/K501074/1,
   G0800674, G0700718, MR/K000608/1, G0601943] Funding Source: Medline;
   Wellcome Trust [096919Z/11/Z] Funding Source: Medline; Department of
   Health [NIHR-HCS-D12-03-04] Funding Source: Medline; MRC [G0601943,
   MC_G0802536, G0800674, MR/K000608/1, MR/L016354/1, G0700718] Funding
   Source: UKRI
CR Askanas V, 2006, NEUROLOGY, V66, pS39, DOI 10.1212/01.wnl.0000192128.13875.1e
   Askanas V, 2012, J NEUROPATH EXP NEUR, V71, P680, DOI 10.1097/NEN.0b013e31826183c8
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Chariot P, 1996, ACTA NEUROPATHOL, V91, P530, DOI 10.1007/s004010050462
   Chen HC, 2010, CELL, V141, P280, DOI 10.1016/j.cell.2010.02.026
   Claeys KG, 2008, NEUROMUSCULAR DISORD, V18, P656, DOI 10.1016/j.nmd.2008.06.367
   Dold T, 2012, NEUROMUSCULAR DISORD, V22, P822, DOI 10.1016/j.nmd.2012.06.070
   Goldfarb LG, 1998, NAT GENET, V19, P402, DOI 10.1038/1300
   Greaves LC, 2010, INVEST OPHTH VIS SCI, V51, P3340, DOI 10.1167/iovs.09-4659
   Grünewald A, 2016, ANN NEUROL, V79, P366, DOI 10.1002/ana.24571
   Han XJ, 2008, J CELL BIOL, V182, P573, DOI 10.1083/jcb.200802164
   Henderson M, 2013, ACTA NEUROPATHOL, V125, P917, DOI 10.1007/s00401-013-1113-x
   Joshi PR, 2014, CLIN NEUROPATHOL, V33, P134, DOI 10.5414/NP300693
   McKenzie D, 2002, EUR J BIOCHEM, V269, P2010, DOI 10.1046/j.1432-1033.2002.02867.x
   Moslemi AR, 1997, HUM MUTAT, V10, P381, DOI 10.1002/(SICI)1098-1004(1997)10:5<381::AID-HUMU8>3.0.CO;2-I
   Oldfors A, 2006, NEUROLOGY, V66, pS49, DOI 10.1212/01.wnl.0000192127.63013.8d
   OLDFORS A, 1993, BRAIN, V116, P325, DOI 10.1093/brain/116.2.325
   OLDFORS A, 1995, J NEUROPATH EXP NEUR, V54, P581, DOI 10.1097/00005072-199507000-00012
   Pitceathly RDS, 2012, BRAIN, V135, P3392, DOI 10.1093/brain/aws231
   Rocha MC, 2015, SCI REP-UK, V5, DOI 10.1038/srep15037
   Rygiel KA, 2015, NEUROPATH APPL NEURO, V41, P288, DOI 10.1111/nan.12149
   Rygiel KA, 2016, NUCLEIC ACIDS RES, V44, P5313, DOI 10.1093/nar/gkw382
   Rygiel KA, 2015, SCI REP-UK, V5, DOI 10.1038/srep09906
   Santorelli FM, 1996, ANN NEUROL, V39, P789, DOI 10.1002/ana.410390615
   Schröder R, 2003, HUM MOL GENET, V12, P657, DOI 10.1093/hmg/ddg060
   Selcen D, 2005, ANN NEUROL, V57, P269, DOI 10.1002/ana.20376
   Selcen D, 2004, NEUROLOGY, V62, P1363, DOI 10.1212/01.WNL.0000123576.74801.75
   Selcen D, 2009, ANN NEUROL, V65, P83, DOI 10.1002/ana.21553
   Smolina N, 2014, CELL CALCIUM, V56, P269, DOI 10.1016/j.ceca.2014.08.001
   Taylor RW, 2003, J CLIN INVEST, V112, P1351, DOI 10.1172/JCI200319435
   Vicart P, 1998, NAT GENET, V20, P92, DOI 10.1038/1765
   Vorgerd M, 2005, AM J HUM GENET, V77, P297, DOI 10.1086/431959
NR 32
TC 31
Z9 34
U1 0
U2 18
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD OCT
PY 2016
VL 26
IS 10
BP 691
EP 701
DI 10.1016/j.nmd.2016.08.004
PG 11
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA EA2FL
UT WOS:000386408100010
PM 27618136
OA Green Published
DA 2024-11-01
ER

PT J
AU Gueguen, A
   Jardel, C
   Polivka, M
   Tan, SV
   Gray, F
   Vignal, C
   Lombè, A
   Gout, O
   Bostock, H
AF Gueguen, Antoine
   Jardel, Claude
   Polivka, Marc
   Tan, S. Veronica
   Gray, Francoise
   Vignal, Catherine
   Lombes, Anne
   Gout, Olivier
   Bostock, Hugh
TI Nerve excitability changes related to muscle weakness in chronic
   progressive external ophthalmoplegia
SO CLINICAL NEUROPHYSIOLOGY
LA English
DT Article
DE CPEO; Mitochondrial disease; Nerve excitability; Myelin sheath;
   Barrett-Barrett conductance
ID KEARNS-SAYRE-SYNDROME; MITOCHONDRIAL-DNA DELETIONS; CHANNEL DYSFUNCTION;
   MYELINATED AXONS; MOTOR AXONS; NEUROPATHY; MUTATIONS; DISORDER;
   MYOPATHY; MTDNA
AB Objective: To explore potential spreading to peripheral nerves of the mitochondrial dysfunction in chronic progressive external ophthalmoplegia (CPEO) by assessing axonal excitability.
   Methods: CPEO patients (n = 13) with large size deletion of mitochondrial DNA and matching healthy controls (n = 22) were included in a case-control study. Muscle strength was quantified using MRC sum-score and used to define two groups of patients: CPEO-weak and CPEO-normal (normal strength). Nerve excitability properties of median motor axons were assessed with the TROND protocol and changes interpreted with the aid of a model.
   Results: Alterations of nerve excitability strongly correlated with scores of muscle strength. CPEO-weak displayed abnormal nerve excitability compared to CPEO-normal and healthy controls, with increased superexcitability and responses to hyperpolarizing current. Modeling indicated that the CPEO-weak recordings were best explained by an increase in the 'Barrett-Barrett' conductance across the myelin sheath.
   Conclusion: CPEO patients with skeletal weakness presented sub-clinical nerve excitability changes, which were not consistent with axonal membrane depolarization, but suggested Schwann cell involvement.
   Significance: This study provides new insights into the spreading of large size deletion of mitochondrial DNA to Schwann cells in CPEO patients. (C) 2017 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All rights reserved.
C1 [Gueguen, Antoine; Gout, Olivier] Fdn Ophtalmol A de Rothschild, Dept Neurol, Paris, France.
   [Jardel, Claude; Lombes, Anne] Hop La Pitie Salpetriere, AP HP, Dept Metab Biochem, F-75651 Paris, France.
   [Polivka, Marc; Gray, Francoise] Hop Lariboisiere, AP HP, Dept Anat Pathol, Paris, France.
   [Tan, S. Veronica; Bostock, Hugh] UCL, Inst Neurol, Queen Sq, London WC1N 3BG, England.
   [Vignal, Catherine] Fdn Ophtalmol A de Rothschild, Dept Neuroophthalmol, Paris, France.
   [Jardel, Claude; Lombes, Anne] Inst Cochin, INSERM, U1016, F-75014 Paris, France.
C3 Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital
   Universitaire Pitie-Salpetriere - APHP; Assistance Publique Hopitaux
   Paris (APHP); Universite Paris Cite; Hopital Universitaire
   Lariboisiere-Fernand-Widal - APHP; University of London; University
   College London; Universite Paris Cite; Institut National de la Sante et
   de la Recherche Medicale (Inserm)
RP Bostock, H (corresponding author), UCL, Inst Neurol, Queen Sq, London WC1N 3BG, England.
EM h.bostock@ucl.ac.uk
RI BOSTOCK, HUGH/AAD-8698-2019
CR BARRETT EF, 1982, J PHYSIOL-LONDON, V323, P117, DOI 10.1113/jphysiol.1982.sp014064
   BERENBERG RA, 1977, ANN NEUROL, V1, P37, DOI 10.1002/ana.410010104
   Bostock H, 1998, MUSCLE NERVE, V21, P137, DOI 10.1002/(SICI)1097-4598(199802)21:2<137::AID-MUS1>3.0.CO;2-C
   Chinnery PF, 2004, LANCET, V364, P592, DOI 10.1016/S0140-6736(04)16851-7
   Dey R, 2000, NEUROMUSCULAR DISORD, V10, P488, DOI 10.1016/S0960-8966(00)00125-5
   DRACHMAN DA, 1968, ARCH NEUROL-CHICAGO, V18, P654, DOI 10.1001/archneur.1968.00470360076008
   Farrar MA, 2010, PEDIATRICS, V126, pE734, DOI 10.1542/peds.2009-2930
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   Gellerich FN, 2002, BBA-BIOENERGETICS, V1556, P41, DOI 10.1016/S0005-2728(02)00305-5
   Hirano M, 2001, NEUROLOGY, V57, P2163, DOI 10.1212/WNL.57.12.2163
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Howells J, 2012, J PHYSIOL-LONDON, V590, P1625, DOI 10.1113/jphysiol.2011.225573
   Jen J, 2001, NEUROLOGY, V57, P1843, DOI 10.1212/WNL.57.10.1843
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kiernan MC, 2000, BRAIN, V123, P2542, DOI 10.1093/brain/123.12.2542
   Kiernan MC, 2012, AMINOFFS ELECTRODIAG
   KLEYWEG RP, 1991, MUSCLE NERVE, V14, P1103, DOI 10.1002/mus.880141111
   LIN CSY, 2006, HDB CLIN NEUROPHYSIO, V7, P381
   Merkies ISJ, 2003, MUSCLE NERVE, V28, P93, DOI 10.1002/mus.10410
   Ng K, 2010, J NEUROL NEUROSUR PS, V81, P844, DOI 10.1136/jnnp.2009.178921
   PEYRONNARD JM, 1980, ANN NEUROL, V7, P262, DOI 10.1002/ana.410070310
   SCHRODER JM, 1993, BRAIN PATHOL, V3, P177, DOI 10.1111/j.1750-3639.1993.tb00742.x
   Seneca S, 2001, ARCH NEUROL-CHICAGO, V58, P1113, DOI 10.1001/archneur.58.7.1113
   SHANSKE S, 1990, NEUROLOGY, V40, P24, DOI 10.1212/WNL.40.1.24
   SHY GM, 1967, AM J MED, V42, P163, DOI 10.1016/0002-9343(67)90015-0
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Tomlinson SE, 2016, BRAIN, V139, P380, DOI 10.1093/brain/awv380
   Tomlinson SE, 2010, BRAIN, V133, P3530, DOI 10.1093/brain/awq318
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Wai T, 2008, NAT GENET, V40, P1484, DOI 10.1038/ng.258
   YIANNIKAS C, 1986, ANN NEUROL, V20, P249, DOI 10.1002/ana.410200211
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 32
TC 3
Z9 3
U1 0
U2 5
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 1388-2457
EI 1872-8952
J9 CLIN NEUROPHYSIOL
JI Clin. Neurophysiol.
PD JUL
PY 2017
VL 128
IS 7
BP 1258
EP 1263
DI 10.1016/j.clinph.2017.04.013
PG 6
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA FB2WL
UT WOS:000406003800017
PM 28535487
OA Green Submitted
DA 2024-11-01
ER

PT J
AU Deepha, S
   Govindaraj, P
   Sankaran, BP
   Chiplunkar, S
   Kashinkunti, C
   Nunia, V
   Nagappa, M
   Sinha, S
   Khanna, T
   Thangaraj, K
   Taly, AB
   Gayathri, N
AF Deepha, Sekar
   Govindaraj, Periyasamy
   Sankaran, Bindu Parayil
   Chiplunkar, Shwetha
   Kashinkunti, Chetan
   Nunia, Vandana
   Nagappa, Madhu
   Sinha, Sanjib
   Khanna, Tripti
   Thangaraj, Kumarasamy
   Taly, Arun B.
   Gayathri, Narayanappa
TI Clinico-pathological and Molecular Spectrum of Mitochondrial Polymerase
   γ Mutations in a Cohort from India
SO JOURNAL OF MOLECULAR NEUROSCIENCE
LA English
DT Article
DE POLG; Mitochondrial disease; CPEO; Mutations; mtDNA deletions
ID W748S MUTATION; DNA; POLG; DISORDERS; PCR
AB Polymerase gamma catalytic subunit (POLG), a nuclear gene, encodes the enzyme responsible for mitochondrial DNA (mtDNA) replication. POLG mutations are a major cause of inherited mitochondrial diseases. They present with varied phenotypes, age of onset, and severity. Reports on POLG mutations from India are limited. Hence, this study aimed to describe the clinico-pathological and molecular observations of POLG mutations. A total of 446 patients with clinical diagnosis of mitochondrial disorders were sequenced for all exons and intron-exon boundaries of POLG. Of these, 19 (4.26%) patients (M:F: 10:9) had POLG mutations. The age of onset ranged from 5 to 55 years with an overlapping phenotypic spectrum. Ptosis, peripheral neuropathy, seizures, and ataxia were the common neurological features observed. The most common clinical phenotype was chronic progressive external ophthalmoplegia (CPEO) and CPEO plus (n = 14). Muscle biopsy showed characteristic features of mitochondrial myopathy in fourteen patients (14/19) and respiratory chain enzyme deficiency in eleven patients (11/19). Multiple mtDNA deletions were seen in 47.36% (9/19) patients. Eight pathogenic POLG variations including two novel variations (p.G132R and p.V1106A) were identified. The common pathogenic mutation identified was p.L304R, being present in eight patients (42.1%) predominantly in the younger age group followed by p.W748S in four patients (21%). To the best of our knowledge, this is the first extensive study from India, highlights the clinico-pathological and molecular spectrum of POLG mutations.
C1 [Deepha, Sekar; Govindaraj, Periyasamy; Gayathri, Narayanappa] Natl Inst Mental Hlth & Neurosci NIMHANS, Dept Neuropathol, Bangalore, Karnataka, India.
   [Deepha, Sekar; Govindaraj, Periyasamy; Sankaran, Bindu Parayil; Chiplunkar, Shwetha; Nagappa, Madhu; Taly, Arun B.; Gayathri, Narayanappa] Natl Inst Mental Hlth & Neurosci NIMHANS, Neurobiol Res Ctr NRC, Neuromuscular Lab, Bangalore, Karnataka, India.
   [Govindaraj, Periyasamy] Inst Bioinformat, Int Tech Pk, Bangalore, Karnataka, India.
   [Govindaraj, Periyasamy] Manipal Acad Higher Educ, Manipal, Karnataka, India.
   [Sankaran, Bindu Parayil; Kashinkunti, Chetan; Nagappa, Madhu; Sinha, Sanjib; Taly, Arun B.] Natl Inst Mental Hlth & Neurosci NIMHANS, Dept Neurol, Bangalore, Karnataka, India.
   [Sankaran, Bindu Parayil] Childrens Hosp Westmead, Genet Metab Disorders Serv, Sydney, NSW, Australia.
   [Chiplunkar, Shwetha] Natl Inst Mental Hlth & Neurosci NIMHANS, Dept Clin Neurosci, Bangalore, Karnataka, India.
   [Nunia, Vandana; Thangaraj, Kumarasamy] CSIR, Ctr Cellular & Mol Biol, Hyderabad, India.
   [Nunia, Vandana] Univ Rajasthan, Dept Zool, Radiat & Canc Biol Lab, Jaipur, Rajasthan, India.
   [Khanna, Tripti] Indian Council Med Res ICMR, New Delhi, India.
   [Thangaraj, Kumarasamy] Ctr DNA Fingerprinting & Diagnost, Hyderabad, India.
C3 National Institute of Mental Health & Neurosciences - India; National
   Institute of Mental Health & Neurosciences - India; Manipal Academy of
   Higher Education (MAHE); National Institute of Mental Health &
   Neurosciences - India; NSW Health; The Children's Hospital at Westmead;
   University of Sydney; National Institute of Mental Health &
   Neurosciences - India; Council of Scientific & Industrial Research
   (CSIR) - India; CSIR - Centre for Cellular & Molecular Biology (CCMB);
   University of Rajasthan; Indian Council of Medical Research (ICMR);
   Department of Biotechnology (DBT) India; Centre for DNA Fingerprinting &
   Diagnostics (CDFD)
RP Gayathri, N (corresponding author), Natl Inst Mental Hlth & Neurosci NIMHANS, Dept Neuropathol, Bangalore, Karnataka, India.; Gayathri, N (corresponding author), Natl Inst Mental Hlth & Neurosci NIMHANS, Neurobiol Res Ctr NRC, Neuromuscular Lab, Bangalore, Karnataka, India.
EM gayathri.narayanappa@gmail.com
RI Taly, Arun/AAV-3517-2021; Thangaraj, Kumarasamy/G-5596-2010
OI Nunia, Dr. Vandana/0000-0003-0988-3359; Sinha,
   Sanjib/0000-0002-9736-2985
FU Department of Biotechnology, Government of India
   [BT/PR7470/MED/14/1011/2006]; Indian Council of Medical Research
   [5/4-5/145/Neuro/2014-NCD-I]
FX This study was supported by a grant from the Department of
   Biotechnology, Government of India (Grant No.
   BT/PR7470/MED/14/1011/2006) and Indian Council of Medical Research
   (Grant No. 5/4-5/145/Neuro/2014-NCD-I).
CR Ashley N, 2008, HUM MOL GENET, V17, P2496, DOI 10.1093/hmg/ddn150
   Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   Bindu PS, 2015, MITOCHONDRION, V25, P6, DOI 10.1016/j.mito.2015.08.002
   Blázquez-Bermejo C, 2019, FASEB J, V33, P7168, DOI 10.1096/fj.201801591R
   Blok MJ, 2009, J MED GENET, V46, P776, DOI 10.1136/jmg.2009.067686
   Chan SSL, 2006, HUM MOL GENET, V15, P3473, DOI 10.1093/hmg/ddl424
   Dubowitz V., 2013, MUSCLE BIOPSY PRACTI
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Govindaraj P, 2011, MITOCHONDRION, V11, P504, DOI 10.1016/j.mito.2011.01.009
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Hakonen AH, 2007, EUR J HUM GENET, V15, P779, DOI 10.1038/sj.ejhg.5201831
   Hanisch F, 2015, J NEUROL NEUROSUR PS, V86, P630, DOI 10.1136/jnnp-2013-306748
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Hu M, 2007, NAT PROTOC, V2, P2339, DOI 10.1038/nprot.2007.358
   Kaliszewska M, 2015, HUM GENET, V134, P951, DOI 10.1007/s00439-015-1578-x
   Nagappa Madhu, 2015, Mov Disord Clin Pract, V2, P318, DOI 10.1002/mdc3.12195
   Nurminen A, 2017, BBA CLIN, V7, P147, DOI 10.1016/j.bbacli.2017.04.001
   Paramasiyam A, 2019, MITOCHONDRION, V48, P78, DOI 10.1016/j.mito.2019.08.003
   Piekutowska-Abramczuk D, 2019, MITOCHONDRION, V47, P179, DOI 10.1016/j.mito.2018.11.004
   Rahman S, 2019, NAT REV NEUROL, V15, P40, DOI 10.1038/s41582-018-0101-0
   Rouzier C, 2014, EUR J HUM GENET, V22, P542, DOI 10.1038/ejhg.2013.171
   Sonam K, 2017, MITOCHONDRION, V32, P42, DOI 10.1016/j.mito.2016.11.002
   Stumpf JD, 2011, CELL MOL LIFE SCI, V68, P219, DOI 10.1007/s00018-010-0530-4
   Tang S, 2011, J MED GENET, V48, P669, DOI 10.1136/jmedgenet-2011-100222
   Thangaraj K, 2002, J ANDROL, V23, P815
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Wong LJC, 2008, HUM MUTAT, V29, pE150, DOI 10.1002/humu.20824
NR 28
TC 8
Z9 8
U1 0
U2 4
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0895-8696
EI 1559-1166
J9 J MOL NEUROSCI
JI J. Mol. Neurosci.
PD NOV
PY 2021
VL 71
IS 11
BP 2219
EP 2228
DI 10.1007/s12031-020-01765-8
EA JAN 2021
PG 10
WC Biochemistry & Molecular Biology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA WV9NA
UT WOS:000608943400001
PM 33469851
DA 2024-11-01
ER

PT J
AU Leshinsky-Silver, E
   Michelson, M
   Cohen, S
   Ginsberg, M
   Sadeh, M
   Barash, V
   Lerman-Sagie, T
   Lev, D
AF Leshinsky-Silver, E.
   Michelson, M.
   Cohen, S.
   Ginsberg, M.
   Sadeh, M.
   Barash, V.
   Lerman-Sagie, T.
   Lev, D.
TI A defect in the thymidine kinase 2 gene causing isolated mitochondrial
   myopathy without mtDNA depletion
SO EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY
LA English
DT Article
DE mitochondrial myopathy; thymidine kinase 2; mtDNA depletion; respiratory
   chain
ID DNA COPY NUMBER; TK2 DEFICIENCY; MUTATIONS
AB Isolated mitochondrial myopathies (IMM) are either due to primary defects in mtDNA, in nuclear genes that control mtDNA abundance and structure such as thymidine kinase 2 (TK2), or due to CoQ deficiency. Defects in the TK2 gene have been found to be associated with mtDNA depletion attributed to a depleted mitochondrial dNTP pool in non-dividing cells.
   We report an unusual case of IMM, homozygous for the H90N mutation in the TK2 gene but unlike other cases with the same mutation, does not demonstrate mtDNA depletion. The patient's clinical course is relatively mild and a muscle biopsy showed ragged red muscle fibers with a mild decrease in complexes I and an increase in complexes IV and II activities.
   This report extends the phenotypic expression of TK2 defects and suggests that all patients who present with an IMM even with normal quantities of mtDNA should be screened for TK2 mutations. (C) 2007 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.
C1 [Leshinsky-Silver, E.; Cohen, S.] Wolfson Med Ctr, Mol Genet Lab, Holon, Israel.
   [Leshinsky-Silver, E.; Michelson, M.; Ginsberg, M.; Lerman-Sagie, T.; Lev, D.] Wolfson Med Ctr, Mitochondrial Dis Ctr, Holon, Israel.
   [Michelson, M.; Lev, D.] Wolfson Med Ctr, Genet Inst, Holon, Israel.
   [Ginsberg, M.; Lerman-Sagie, T.] Wolfson Med Ctr, Pediat Neurol Unit, Holon, Israel.
   [Sadeh, M.] Wolfson Med Ctr, Dept Neurol, Holon, Israel.
   [Barash, V.] Hadassah Med Ctr, Metab Unit, IL-91120 Jerusalem, Israel.
C3 Hebrew University of Jerusalem; Hadassah University Medical Center
RP Leshinsky-Silver, E (corresponding author), Wolfson Med Ctr, Mol Genet Lab, Holon, Israel.
EM leshinsky@wolfson.health.gov.il
OI Lerman-Sagie, Tally/0000-0001-6641-6875
CR Brown TA, 2002, NUCLEIC ACIDS RES, V30, P2004, DOI 10.1093/nar/30.9.2004
   Carrozzo R, 2003, HUM MUTAT, V21, DOI 10.1002/humu.9135
   Chiaratti MR, 2006, GENET MOL RES, V5, P55
   DiMauro S, 2005, CURR OPIN NEUROL, V18, P538, DOI 10.1097/01.wco.0000179761.63486.1a
   Durham SE, 2005, NEUROLOGY, V65, P453, DOI 10.1212/01.wnl.0000171861.30277.88
   Galbiati S, 2006, PEDIATR NEUROL, V34, P177, DOI 10.1016/j.pediatrneurol.2005.07.013
   Horváth R, 2005, NEUROMUSCULAR DISORD, V15, P851, DOI 10.1016/j.nmd.2005.09.005
   King M P, 1996, Methods Enzymol, V264, P304, DOI 10.1016/S0076-6879(96)64029-4
   Lalani SR, 2005, ARCH NEUROL-CHICAGO, V62, P317, DOI 10.1001/archneur.62.2.317
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Nevo Y, 2002, J CHILD NEUROL, V17, P499, DOI 10.1177/088307380201700705
   Pyle A, 2007, J MED GENET, V44, P69, DOI 10.1136/jmg.2006.043109
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   Saada A, 2003, BIOCHEM BIOPH RES CO, V310, P963, DOI 10.1016/j.bbrc.2003.09.104
   Saada A, 2003, MOL GENET METAB, V79, P1, DOI 10.1016/S1096-7192(03)00063-5
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Taanman JW, 1997, HUM MOL GENET, V6, P935, DOI 10.1093/hmg/6.6.935
   Tulinius M, 2005, NEUROMUSCULAR DISORD, V15, P412, DOI 10.1016/j.nmd.2005.03.010
   Vilà MR, 2003, NEUROLOGY, V60, P1203, DOI 10.1212/01.WNL.0000055928.58122.47
   Wang LY, 2005, MOL GENET METAB, V84, P75, DOI 10.1016/j.ymgme.2004.09.005
   Wang LY, 2003, J BIOL CHEM, V278, P6963, DOI 10.1074/jbc.M206143200
NR 21
TC 11
Z9 14
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1090-3798
J9 EUR J PAEDIATR NEURO
JI Eur. J. Paediatr. Neurol.
PD JUL
PY 2008
VL 12
IS 4
BP 309
EP 313
DI 10.1016/j.ejpn.2007.09.005
PG 5
WC Clinical Neurology; Pediatrics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pediatrics
GA 320OQ
UT WOS:000257244800006
PM 17951082
DA 2024-11-01
ER

PT J
AU Vincent, AE
   Rosa, HS
   Pabis, K
   Lawless, C
   Chen, C
   Grünewald, A
   Rygiel, KA
   Rocha, MC
   Reeve, AK
   Falkous, G
   Perissi, V
   White, K
   Davey, T
   Petrof, BJ
   Sayer, AA
   Cooper, C
   Deehan, D
   Taylor, RW
   Turnbull, DM
   Picard, M
AF Vincent, Amy E.
   Rosa, Hannah S.
   Pabis, Kamil
   Lawless, Conor
   Chen, Chun
   Gruenewald, Anne
   Rygiel, Karolina A.
   Rocha, Mariana C.
   Reeve, Amy K.
   Falkous, Gavin
   Perissi, Valentina
   White, Kathryn
   Davey, Tracey
   Petrof, Basil J.
   Sayer, Avan A.
   Cooper, Cyrus
   Deehan, David
   Taylor, Robert W.
   Turnbull, Doug M.
   Picard, Martin
TI Subcellular origin of mitochondrial DNA deletions in human skeletal
   muscle
SO ANNALS OF NEUROLOGY
LA English
DT Article
ID DISEASE; CELLS; MUTATIONS; FIBERS; ACCUMULATION; MECHANISMS; MYOPATHY;
   INTERMEDIATE; MAINTENANCE; DYSFUNCTION
AB ObjectiveIn patients with mitochondrial DNA (mtDNA) maintenance disorders and with aging, mtDNA deletions sporadically form and clonally expand within individual muscle fibers, causing respiratory chain deficiency. This study aimed to identify the sub-cellular origin and potential mechanisms underlying this process.
   MethodsSerial skeletal muscle cryosections from patients with multiple mtDNA deletions were subjected to subcellular immunofluorescent, histochemical, and genetic analysis.
   ResultsWe report respiratory chain-deficient perinuclear foci containing mtDNA deletions, which show local elevations of both mitochondrial mass and mtDNA copy number. These subcellular foci of respiratory chain deficiency are associated with a local increase in mitochondrial biogenesis and unfolded protein response signaling pathways. We also find that the commonly reported segmental pattern of mitochondrial deficiency is consistent with the three-dimensional organization of the human skeletal muscle mitochondrial network.
   InterpretationWe propose that mtDNA deletions first exceed the biochemical threshold causing biochemical deficiency in focal regions adjacent to the myonuclei, and induce mitochondrial biogenesis before spreading across the muscle fiber. These subcellular resolution data provide new insights into the possible origin of mitochondrial respiratory chain deficiency in mitochondrial myopathy. Ann Neurol 2018;84:289-301
C1 [Vincent, Amy E.; Rosa, Hannah S.; Pabis, Kamil; Lawless, Conor; Chen, Chun; Gruenewald, Anne; Rygiel, Karolina A.; Rocha, Mariana C.; Reeve, Amy K.; Falkous, Gavin; Taylor, Robert W.; Turnbull, Doug M.] Newcastle Univ, Inst Neurosci, Newcastle Ctr Ageing & Vital, Newcastle Upon Tyne NE4 5PL, Tyne & Wear, England.
   [Picard, Martin] Columbia Univ, Dept Psychiat, Med Ctr, Div Behav Med, New York, NY 10032 USA.
   [Vincent, Amy E.; Rosa, Hannah S.; Pabis, Kamil; Lawless, Conor; Chen, Chun; Gruenewald, Anne; Rygiel, Karolina A.; Rocha, Mariana C.; Reeve, Amy K.; Falkous, Gavin; Taylor, Robert W.; Turnbull, Doug M.] Newcastle Univ, Inst Neurosci, Wellcome Ctr Mitochondrial Res, Newcastle Upon Tyne, Tyne & Wear, England.
   [Gruenewald, Anne] Univ Lubeck, Inst Neurogenet, Lubeck, Germany.
   [Gruenewald, Anne] Univ Luxembourg, Mol & Funct Neurobiol Grp, Luxembourg Ctr Syst Biomed, Esch Sur Alzette, Luxembourg.
   [Perissi, Valentina] Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA.
   [White, Kathryn; Davey, Tracey] Newcastle Univ, Electron Microscopy Res Serv, Newcastle Upon Tyne, Tyne & Wear, England.
   [Petrof, Basil J.] McGill Univ, Hlth Ctr, Dept Med, Meakins Christie Labs, Montreal, PQ, Canada.
   [Sayer, Avan A.] Newcastle Upon Tyne Hosp Natl Hlth Serv Fdn Trust, Natl Inst Hlth Res, Newcastle Biomed Res Ctr, Newcastle Upon Tyne, Tyne & Wear, England.
   [Sayer, Avan A.] Newcastle Univ, Newcastle Upon Tyne, Tyne & Wear, England.
   [Cooper, Cyrus] Univ Southampton, MRC, Lifecourse Epidemiol Unit, Southampton, Hants, England.
   [Deehan, David] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne, Tyne & Wear, England.
   [Picard, Martin] Columbia Univ, Dept Neurol, Med Ctr, H Houston Merritt Ctr, New York, NY 10032 USA.
   [Picard, Martin] Columbia Univ, Med Ctr, H Houston Merritt Ctr, Columbia Translat Neurosci Initiat, New York, NY 10032 USA.
   [Picard, Martin] Columbia Univ, Aging Ctr, New York, NY 10032 USA.
C3 Newcastle University - UK; Columbia University; Newcastle University -
   UK; University of Lubeck; University of Luxembourg; Boston University;
   Newcastle University - UK; McGill University; Newcastle Upon Tyne
   Hospitals NHS Foundation Trust; Newcastle University - UK; University of
   Southampton; Newcastle University - UK; Columbia University; Columbia
   University; Columbia University
RP Turnbull, DM (corresponding author), Newcastle Univ, Inst Neurosci, Newcastle Ctr Ageing & Vital, Newcastle Upon Tyne NE4 5PL, Tyne & Wear, England.; Picard, M (corresponding author), Columbia Univ, Dept Psychiat, Med Ctr, Div Behav Med, New York, NY 10032 USA.
EM doug.turnbull@ncl.ac.uk; martin.picard@columbia.edu
RI Perissi, Valentina/HNO-9945-2023; Grünewald, Anne/ABD-1255-2021; chen,
   chun/AFI-5126-2022; Vincent, Amy/J-7284-2019; Sayer, Avan/A-4359-2012;
   Cooper, Cyrus/ADV-7232-2022; Rocha, Mariana/O-4313-2017; Davey,
   Tracey/JWA-4940-2024
OI Davey, Tracey/0000-0001-9409-7410; Vincent, Amy/0000-0002-0360-6644;
   chen, chun/0000-0002-6162-0284; Rosa, Hannah/0000-0003-4624-752X;
   Perissi, Valentina/0000-0002-3716-0003; Deehan,
   David/0000-0001-5780-8818; Grunewald, Anne/0000-0002-4179-2994; Aihie
   Sayer, Avan/0000-0003-1283-6457; Cooper, Cyrus/0000-0003-3510-0709;
   Reeve, Amy/0000-0002-4474-2204; Picard, Martin/0000-0003-2835-0478;
   Turnbull, Doug/0000-0002-8878-9901
FU Wellcome Centre for Mitochondrial Research [203105/Z/16/Z]; Medical
   Research Council (MRC) Centre for Translational Research in
   Neuromuscular Disease Mitochondrial Disease Patient Cohort [G0800674];
   UK National Institute for Health Research Biomedical Research Centre in
   Age and Age Related Diseases; MRC/Engineering and Physical Sciences
   Research Council Molecular Pathology Node; Lily Foundation; UK NHS
   Specialist Commissioners "Rare Mitochondrial Disorders of Adults and
   Children" Service; MRC as part of the MRC Centre for Neuromuscular
   Disease [MR/K501074/1, MR/K000608/1]; MRC as part of the Centre for
   Ageing and Vitality [MR/L016354/1]; National Research Fund of
   Luxembourg; Barbour Foundation; Wharton Fund; NIH [R35GM119793]; senior
   Parkinson's UK fellowship [F-1401]; BBSRC [BB/M012093/1] Funding Source:
   UKRI; MRC [G0400491, G0800674, MR/K000608/1, MC_U147585827,
   MR/L016354/1, MC_U147585819] Funding Source: UKRI
FX This work was supported by the Wellcome Centre for Mitochondrial
   Research (203105/Z/16/Z), the Medical Research Council (MRC) Centre for
   Translational Research in Neuromuscular Disease Mitochondrial Disease
   Patient Cohort G0800674, the UK National Institute for Health Research
   Biomedical Research Centre in Age and Age Related Diseases award to the
   Newcastle upon Tyne Hospitals National Health Service (NHS) Foundation
   Trust, the MRC/Engineering and Physical Sciences Research Council
   Molecular Pathology Node, the Lily Foundation, and the UK NHS Specialist
   Commissioners "Rare Mitochondrial Disorders of Adults and Children"
   Service. A.E.V. was funded by an MRC studentship (MR/K501074/1) as part
   of the MRC Centre for Neuromuscular Disease (MR/K000608/1) and is now
   funded by the MRC as part of the Centre for Ageing and Vitality
   (MR/L016354/1). A.G. is the recipient of an ATTRACT career development
   grant from the National Research Fund of Luxembourg. H.S.R. was
   supported by the Barbour Foundation. M.P. is supported by the Wharton
   Fund and NIH grant R35GM119793. A.K.R. is supported by a senior
   Parkinson's UK fellowship (F-1401).
CR Bua E, 2006, AM J HUM GENET, V79, P469, DOI 10.1086/507132
   Campbell G, 2014, HUM MOL GENET, V23, P4612, DOI 10.1093/hmg/ddu176
   Cardamone MD, 2017, FASEB J, V31
   Cederquist CT, 2017, MOL METAB, V6, P125, DOI 10.1016/j.molmet.2016.10.007
   Davis AF, 1996, J CELL BIOL, V135, P883, DOI 10.1083/jcb.135.4.883
   deGrey ADNJ, 1997, BIOESSAYS, V19, P161, DOI 10.1002/bies.950190211
   Diaz F, 2002, NUCLEIC ACIDS RES, V30, P4626, DOI 10.1093/nar/gkf602
   Elson JL, 2002, NEUROMUSCULAR DISORD, V12, P858, DOI 10.1016/S0960-8966(02)00047-0
   Elson JL, 2001, AM J HUM GENET, V68, P802, DOI 10.1086/318801
   Fukui H, 2009, HUM MOL GENET, V18, P1028, DOI 10.1093/hmg/ddn437
   Gitschlag BL, 2016, CELL METAB, V24, P91, DOI 10.1016/j.cmet.2016.06.008
   Glancy B, 2015, NATURE, V523, P617, DOI 10.1038/nature14614
   Glancy B, 2014, MICROCIRCULATION, V21, P131, DOI 10.1111/micc.12098
   Gorman GS, 2015, ANN NEUROL, V77, P753, DOI 10.1002/ana.24362
   Grünewald A, 2016, ANN NEUROL, V79, P366, DOI 10.1002/ana.24571
   HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614
   KASAMATSU H, 1971, P NATL ACAD SCI USA, V68, P2252, DOI 10.1073/pnas.68.9.2252
   Kowald A, 2014, P NATL ACAD SCI USA, V111, P2972, DOI 10.1073/pnas.1314970111
   Lin YF, 2016, NATURE, V533, P416, DOI 10.1038/nature17989
   Margariti A, 2013, J BIOL CHEM, V288, P859, DOI 10.1074/jbc.M112.412783
   MATSUOKA T, 1992, MUSCLE NERVE, V15, P209, DOI 10.1002/mus.880150213
   Murphy JL, 2012, NEUROMUSCULAR DISORD, V22, P690, DOI 10.1016/j.nmd.2012.04.003
   Picard M, 2013, J APPL PHYSIOL, V114, P161, DOI 10.1152/japplphysiol.01096.2012
   Picard M, 2012, AM J RESP CRIT CARE, V186, P1140, DOI 10.1164/rccm.201206-0982OC
   Rocha MC, 2015, SCI REP-UK, V5, DOI 10.1038/srep15037
   Rygiel KA, 2016, NUCLEIC ACIDS RES, V44, P5313, DOI 10.1093/nar/gkw382
   Rygiel KA, 2015, SCI REP-UK, V5, DOI 10.1038/srep09906
   SHOUBRIDGE EA, 1990, CELL, V62, P43, DOI 10.1016/0092-8674(90)90238-A
   Syddall HE, 2005, INT J EPIDEMIOL, V34, P1234, DOI 10.1093/ije/dyi127
   Vincent AE, 2016, SCI REP-UK, V6, DOI 10.1038/srep30610
   Viscomi C, 2017, J INHERIT METAB DIS, V40, P587, DOI 10.1007/s10545-017-0027-5
   WALLACE DC, 1989, TRENDS GENET, V5, P9, DOI 10.1016/0168-9525(89)90005-X
NR 32
TC 34
Z9 35
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0364-5134
EI 1531-8249
J9 ANN NEUROL
JI Ann. Neurol.
PD AUG
PY 2018
VL 84
IS 2
BP 289
EP 301
DI 10.1002/ana.25288
PG 13
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA GT5UV
UT WOS:000444576400013
PM 30014514
OA Green Published, Green Accepted, hybrid
DA 2024-11-01
ER

PT J
AU Barron, MJ
   Chinnery, PF
   Howel, D
   Blakely, EL
   Schaefer, AM
   Taylor, RW
   Turnbull, DM
AF Barron, MJ
   Chinnery, PF
   Howel, D
   Blakely, EL
   Schaefer, AM
   Taylor, RW
   Turnbull, DM
TI Cytochrome <i>c</i> oxidase deficient muscle fibres:: Substantial
   variation in their proportions within skeletal muscles from patients
   with mitochondrial myopathy
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
ID KEARNS-SAYRE SYNDROME; TISSUE DISTRIBUTION; DNA DELETIONS; MUTATION;
   ACCUMULATION; DISORDERS
AB Mitochondrial DNA (mtDNA) disease is a common cause of myopathy and the presence of histochemically demonstrated cytochrome c oxidase (COX) deficiency is an extremely useful diagnostic feature. However, there is currently no quantitative information regarding the variability of COX deficiency within or between muscles. This study addresses this issue by studying a number of skeletal muscle samples obtained at post-mortem from three patients with mitochondrial disease due to established mitochondrial DNA defects. COX deficient muscle fibres were enumerated in sections of these muscles and analysed according to patient, individual muscle, position within a particular muscle and sample size. Descriptive statistics were generated followed by an analysis of variance (ANOVA) to assess the effect of these parameters on the mean percentage of COX deficient fibres. We observed statistically significant variation in the percentage of COX deficient fibres within individual muscles from each patient for samples sizes of between 100 and 400 fibres. Our results have implications for the way in which biopsies of skeletal muscle are used for the assessment of disease severity, progression and response to treatment. (C) 2005 Elsevier B.V. All rights reserved.
C1 Univ Newcastle Upon Tyne, Sch Neurol Neurosci & Psychiat, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   Univ Newcastle Upon Tyne, Sch Populat & Hlth Sci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
C3 Newcastle University - UK; Newcastle University - UK
RP Univ Newcastle Upon Tyne, Sch Neurol Neurosci & Psychiat, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM d.m.turnbull@ncl.ac.uk
RI ; Barron, Martin/E-9649-2015
OI Schaefer, Andrew/0000-0001-9891-7332; Chinnery,
   Patrick/0000-0002-7065-6617; Barron, Martin/0000-0002-2047-3513
FU Wellcome Trust [074454] Funding Source: Medline
CR BARRON MJ, 2003, AGING MOL LEVEL, P91
   BOULET L, 1992, AM J HUM GENET, V51, P1187
   Chinnery PF, 2003, J NEUROL SCI, V211, P63, DOI 10.1016/S0022-510X(03)00039-X
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Horváth R, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.015024
   HOWEL D, 1988, STAT MED, V7, P1157, DOI 10.1002/sim.4780071108
   HOWEL D, 1987, J NEUROL SCI, V77, P49, DOI 10.1016/0022-510X(87)90205-X
   JOHNSON MA, 1973, J NEUROL SCI, V18, P111, DOI 10.1016/0022-510X(73)90023-3
   JOHNSON MA, 1993, ANN NEUROL, V33, P28, DOI 10.1002/ana.410330106
   KAWAKAMI Y, 1994, ANN NEUROL, V35, P370, DOI 10.1002/ana.410350322
   Kirches E, 2001, J MED GENET, V38, P312, DOI 10.1136/jmg.38.5.312
   LARSSON NG, 1990, PEDIATR RES, V28, P131, DOI 10.1203/00006450-199028020-00011
   McFarland R, 2004, ANN NEUROL, V55, P478, DOI 10.1002/ana.20004
   Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755
   SELIGMAN AM, 1969, J CELL BIOL, V38, P1
   SHANSKE S, 1990, NEUROLOGY, V40, P24, DOI 10.1212/WNL.40.1.24
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   Weber K, 1997, AM J HUM GENET, V60, P373
   Zeviani M, 2004, BRAIN, V127, P2153, DOI 10.1093/brain/awh259
   ZEVIANI M, 1990, ANN NEUROL, V28, P94, DOI 10.1002/ana.410280118
NR 20
TC 15
Z9 18
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD NOV
PY 2005
VL 15
IS 11
BP 768
EP 774
DI 10.1016/j.nmd.2005.06.018
PG 7
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 983GQ
UT WOS:000233219900004
PM 16198107
DA 2024-11-01
ER

PT J
AU Harihara, S
   Nakamura, K
   Fujiwara, M
   Arai, T
   Sawabe, M
   Takeuchi, F
   Takubo, K
AF Harihara, Shinji
   Nakamura, Kenichi
   Fujiwara, Mutsunori
   Arai, Tomio
   Sawabe, Motoji
   Takeuchi, Fujio
   Takubo, Kaiyo
TI Markedly different clinical features in 2 diabetes mellitus patients
   with extremely high tissue levels of the mitochondrial DNA A3243G
   mutation
SO GERONTOLOGY
LA English
DT Article
DE mitochondrial DNA; mtDNA A3243G mutation; diabetes mellitus
ID STROKE-LIKE EPISODES; LACTIC-ACIDOSIS; GENE MUTATION; ENCEPHALOPATHY;
   HETEROPLASMY; DELETIONS; MYOPATHY; DEAFNESS; FAMILY
AB Background: Mitochondrial DNA (mtDNA) A3243G mutation is one of the major causative factors of mitochondrial diabetes mellitus. We found that tissues from 2 of 142 diabetes mellitus patients showed extremely high levels of the mutation. Objective: To investigate the level of the mutation in each tissue and to find the relationship between the mutation level and clinical features of the patients. Methods: Patient 1 was a 51-year-old woman, diagnosed as having diabetes mellitus at the age of 17, and was admitted to hospital because of cerebral infarction. Patient 2 was an 82-yearold woman who was admitted because of respiratory failure. mtDNA A3243G levels were measured in tissues collected at autopsy. Results: In patient 1, mtDNA A3243G levels were found to vary among the tissues. The patient's highest mtDNA A3243G value was 42% and the lowest value was 9%, whereas the level in most individuals is usually less than 1%. Although patient 2 did not exhibit serious clinical symptoms of diabetes mellitus, the mtDNA A3243G level was extremely high in all of the tissues surveyed (range 32-47%). Conclusion: Although both patients showed high levels of the mtDNA A3243G mutation, their clinical conditions differed greatly. Thus, mitochondrial diabetes mellitus patients may show a wide variety of clinical features and large variations in life span. Copyright (c) 2008 S. Karger AG, Basel.
C1 [Takeuchi, Fujio] Univ Tokyo, Grad Sch Sci, Fac Med, Dept Internal Med, Tokyo 1130033, Japan.
   [Harihara, Shinji] Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Fac Med,Bunkyo Ku, Tokyo 1130033, Japan.
   [Nakamura, Kenichi; Takubo, Kaiyo] Tokyo Metropolitan Inst Gerontol, Res Team Geriatr Dis, Tokyo, Japan.
   [Fujiwara, Mutsunori] Tokyo Red Cross Med Ctr, Dept Lab Med, Tokyo, Japan.
   [Arai, Tomio; Sawabe, Motoji] Tokyo Metropolitan Geriatr Med Ctr, Dept Anat, Tokyo, Japan.
   [Arai, Tomio; Sawabe, Motoji] Tokyo Metropolitan Geriatr Med Ctr, Dept Clin Pathol, Tokyo, Japan.
C3 University of Tokyo; University of Tokyo; Tokyo Metropolitan Institute
   of Gerontology; Tokyo Metropolitan Institute of Gerontology; Tokyo
   Metropolitan Institute of Gerontology
RP Harihara, S (corresponding author), Univ Tokyo, Grad Sch Sci, Dept Biol Sci, Fac Med,Bunkyo Ku, Hongo 7-3-1, Tokyo 1130033, Japan.
EM harihara@biol.s.u-tokyo.ac.jp
RI Sawabe, Motoji/F-4135-2010
CR Asano T, 1999, DIABETOLOGIA, V42, P1439
   Chinnery PF, 1999, AM J MED GENET, V85, P498
   DEVRIES D, 1994, J NEUROL SCI, V124, P77, DOI 10.1016/0022-510X(94)90014-0
   HAMMANS SR, 1995, BRAIN, V118, P721, DOI 10.1093/brain/118.3.721
   Harihara S, 2002, EXP GERONTOL, V37, P917, DOI 10.1016/S0531-5565(02)00020-7
   Harrison TJ, 1997, AM J OPHTHALMOL, V124, P217, DOI 10.1016/S0002-9394(14)70787-1
   HOLME E, 1995, BBA-MOL BASIS DIS, V1271, P249, DOI 10.1016/0925-4439(95)00035-3
   KATAGIRI H, 1994, DIABETOLOGIA, V37, P504, DOI 10.1007/s001250050139
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   LARSSON NG, 1995, ANNU REV GENET, V29, P51
   Maassen JA, 2004, DIABETES, V53, pS103, DOI 10.2337/diabetes.53.2007.S103
   MARIOTTI C, 1995, J NEUROL, V242, P304, DOI 10.1007/BF00878873
   Mawrin C, 2004, NEUROSCI LETT, V357, P111, DOI 10.1016/j.neulet.2003.11.073
   MORAES CT, 1992, NAT GENET, V1, P359, DOI 10.1038/ng0892-359
   OKA Y, 1993, LANCET, V342, P527, DOI 10.1016/0140-6736(93)91649-7
   REARDON W, 1992, LANCET, V340, P1376, DOI 10.1016/0140-6736(92)92560-3
   Takeuchi F, 2003, EXP GERONTOL, V38, P339, DOI 10.1016/S0531-5565(02)002090-7
   Takubo K, 2000, J GERONTOL A-BIOL, V55, pB533, DOI 10.1093/gerona/55.11.B533
   VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368
   Vilarinho L, 1997, J INHERIT METAB DIS, V20, P704, DOI 10.1023/A:1005330611147
   Yasukawa T, 2000, J BIOL CHEM, V275, P4251, DOI 10.1074/jbc.275.6.4251
NR 21
TC 1
Z9 1
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0304-324X
J9 GERONTOLOGY
JI Gerontology
PY 2008
VL 54
IS 3
BP 168
EP 172
DI 10.1159/000127415
PG 5
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA 314GV
UT WOS:000256798800008
PM 18417955
OA Bronze
DA 2024-11-01
ER

PT J
AU Winter, L
   Wittig, I
   Peeva, V
   Eggers, B
   Heidler, J
   Chevessier, F
   Kley, RA
   Barkovits, K
   Strecker, V
   Berwanger, C
   Herrmann, H
   Marcus, K
   Kornblum, C
   Kunz, WS
   Schröder, R
   Clemen, CS
AF Winter, Lilli
   Wittig, Ilka
   Peeva, Viktoriya
   Eggers, Britta
   Heidler, Juliana
   Chevessier, Frederic
   Kley, Rudolf A.
   Barkovits, Katalin
   Strecker, Valentina
   Berwanger, Carolin
   Herrmann, Harald
   Marcus, Katrin
   Kornblum, Cornelia
   Kunz, Wolfram S.
   Schroeder, Rolf
   Clemen, Christoph S.
TI Mutant desmin substantially perturbs mitochondrial morphology, function
   and maintenance in skeletal muscle tissue
SO ACTA NEUROPATHOLOGICA
LA English
DT Article
DE Desminopathy; R350P desmin; R349P desmin knock-in; Desmin knock-out;
   Intermediate filament; Myofibrillar myopathy; Protein aggregate
   myopathy; Mitochondria; Proteome; mtDNA
ID EPIDERMOLYSIS-BULLOSA SIMPLEX; BLUE NATIVE ELECTROPHORESIS; MICE LACKING
   DESMIN; MUSCULAR-DYSTROPHY; COMPLEX-I; NEURODEGENERATIVE DISEASES;
   OXIDATIVE-PHOSPHORYLATION; PROTEIN COMPLEXES; MYOFIBRILLAR MYOPATHIES;
   INTERMEDIATE-FILAMENTS
AB Secondary mitochondrial dysfunction is a feature in a wide variety of human protein aggregate diseases caused by mutations in different proteins, both in the central nervous system and in striated muscle. The functional relationship between the expression of a mutated protein and mitochondrial dysfunction is largely unknown. In particular, the mechanism how this dysfunction drives the disease process is still elusive. To address this issue for protein aggregate myopathies, we performed a comprehensive, multi-level analysis of mitochondrial pathology in skeletal muscles of human patients with mutations in the intermediate filament protein desmin and in muscles of hetero- and homozygous knock-in mice carrying the R349P desmin mutation. We demonstrate that the expression of mutant desmin causes disruption of the extrasarcomeric desmin cytoskeleton and extensive mitochondrial abnormalities regarding subcellular distribution, number and shape. At the molecular level, we uncovered changes in the abundancy and assembly of the respiratory chain complexes and supercomplexes. In addition, we revealed a marked reduction of mtDNA- and nuclear DNA-encoded mitochondrial proteins in parallel with large-scale deletions in mtDNA and reduced mtDNA copy numbers. Hence, our data demonstrate that the expression of mutant desmin causes multi-level damage of mitochondria already in early stages of desminopathies.
C1 [Winter, Lilli; Chevessier, Frederic; Herrmann, Harald; Schroeder, Rolf] Univ Hosp Erlangen, Inst Neuropathol, Schwabachanlage 6, D-91054 Erlangen, Germany.
   [Wittig, Ilka; Heidler, Juliana; Strecker, Valentina] Goethe Univ Frankfurt, Sch Med, Core Unit SFB815, Funct Prote, D-60590 Frankfurt, Germany.
   [Wittig, Ilka] Partner Site RheinMain, German Ctr Cardiovasc Res DZHK, Frankfurt, Germany.
   [Peeva, Viktoriya; Kunz, Wolfram S.] Univ Hosp Bonn, Life & Brain Ctr, D-53127 Bonn, Germany.
   [Peeva, Viktoriya; Kunz, Wolfram S.] Univ Hosp Bonn, Dept Epileptol, D-53105 Bonn, Germany.
   [Eggers, Britta; Barkovits, Katalin; Marcus, Katrin] Ruhr Univ Bochum, Fac Med, Med Proteom Ctr, D-44801 Bochum, Germany.
   [Kley, Rudolf A.] Ruhr Univ Bochum, Univ Hosp Bergmannsheil, Dept Neurol, D-44789 Bochum, Germany.
   [Berwanger, Carolin; Clemen, Christoph S.] Univ Cologne, Inst Biochem 1, Fac Med, Ctr Biochem, Joseph Stelzmann Str 52, D-50931 Cologne, Germany.
   [Kornblum, Cornelia] Univ Hosp Bonn, Dept Neurol, D-53105 Bonn, Germany.
   [Kornblum, Cornelia] Univ Hosp Bonn, Ctr Rare Dis Bonn ZSEB, D-53105 Bonn, Germany.
C3 University of Erlangen Nuremberg; Goethe University Frankfurt; German
   Centre for Cardiovascular Research; University of Bonn; University of
   Bonn; Ruhr University Bochum; Ruhr University Bochum; University of
   Cologne; University of Bonn; University of Bonn
RP Schröder, R (corresponding author), Univ Hosp Erlangen, Inst Neuropathol, Schwabachanlage 6, D-91054 Erlangen, Germany.; Clemen, CS (corresponding author), Univ Cologne, Inst Biochem 1, Fac Med, Ctr Biochem, Joseph Stelzmann Str 52, D-50931 Cologne, Germany.
EM rolf.schroeder@uk-erlangen.de; christoph.clemen@uni-koeln.de
RI Kley, Rudolf/AAT-8094-2020; Herrmann, Hartmut/C-2486-2009; Kornblum,
   Cornelia/IUM-4180-2023; Eggers, Britta/AAO-2904-2021; Schröder,
   Rolf/B-2774-2011; Clemen, Christoph/B-2761-2011; Schroder,
   Katrin/E-6874-2013; Winter, Lilli/R-5949-2017; Kunz, Wolfram/K-1232-2019
OI Eggers, Britta/0000-0002-6553-4631; Schroder,
   Katrin/0000-0002-3099-526X; Winter, Lilli/0000-0002-6368-1160;
   Barkovits, Katalin/0000-0003-2554-8796; Kunz,
   Wolfram/0000-0003-1113-3493; Schroder, Rolf/0000-0002-2772-2615;
   Herrmann, Harald/0000-0002-9959-1781
FU German Research Foundation (DFG) [SFB815, Z01, KU 911/21-1]; BMBF funded
   German Network for Mitochondrial Disorders [01GM1113B]; BONFOR; Faculty
   of Medicine, University of Bonn; P.U.R.E.; Protein Unit for Research in
   Europe, North Rhine-Westphalia; DFG within the framework of the
   multilocation research group [SCHR 562/13-1, FOR1228, CL 381/7-1];
   German muscular dystrophy network [MD-NET2]; Deutsche Gesellschaft fur
   Muskelkranke e.V. (DGM)
FX We thank Prof. Dr. Wolfgang A. Linke and Dr. Andreas Unger for kindly
   providing electron micrographs. We further acknowledge the receipt of
   desmin knock-out mice from Prof. Denise Paulin and Dr. Zhenlin Li. We
   thank Mr. Berthold Gassen, Ms. Jana Meisterknecht, Ms. Frauke de
   Pasquale, Ms. Mariella Kessler, and Ms. Birte Rings for excellent
   technical and Mr. Julian Uszkoreit for bioinformatic support. We thank
   PD Dr. Esther Mahabir-Brenner and her co-workers, Animal Facility at the
   Centre of Molecular Medicine Cologne (CMMC), for support in mice
   husbandry. RS and CSC and jointly conceived the study, reviewed all
   data, prepared the figures, and wrote the manuscript. LW, IW, VP, FC,
   KB, and CSC designed and carried out experiments and analyzed data. BE,
   JH, VS, and CB carried out experiments and analyzed data. RAK, HH, KM,
   CK, and WSK designed experiments and analyzed data. IW was supported by
   the German Research Foundation (DFG) (SFB815, project Z01) and by the
   BMBF funded German Network for Mitochondrial Disorders (mitoNET
   #01GM1113B). VP was supported by the BONFOR Research funding program of
   the Faculty of Medicine, University of Bonn. BE, KB, and KM were
   supported by P.U.R.E., Protein Unit for Research in Europe, North
   Rhine-Westphalia. WSK was supported by the German Research Foundation
   (DFG) (KU 911/21-1). KM, RS and CSC were supported by the DFG within the
   framework of the multilocation research group FOR1228 (Grants (no file
   number) to KM, SCHR 562/13-1 to RS, and CL 381/7-1 to CSC). RS and CSC
   were supported by the German muscular dystrophy network (MD-NET2) funded
   by the German ministry of education and research (BMBF) (project 7), and
   by the Deutsche Gesellschaft fur Muskelkranke e.V. (DGM).
CR Acín-Pérez R, 2004, MOL CELL, V13, P805, DOI 10.1016/S1097-2765(04)00124-8
   [Anonymous], 2013, MUSCLE BIOPSY PRACTI
   Arbustini E, 1998, J AM COLL CARDIOL, V31, P645, DOI 10.1016/S0735-1097(98)00026-6
   Bär H, 2005, HUM MOL GENET, V14, P1251, DOI 10.1093/hmg/ddi136
   Bhat AH, 2015, BIOMED PHARMACOTHER, V74, P101, DOI 10.1016/j.biopha.2015.07.025
   Burté F, 2015, NAT REV NEUROL, V11, P11, DOI 10.1038/nrneurol.2014.228
   Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797
   Carmignac V, 2009, NEUROMUSCULAR DISORD, V19, P600, DOI 10.1016/j.nmd.2009.06.179
   Carrozzo R, 2006, ANN NEUROL, V59, P265, DOI 10.1002/ana.20729
   Cetin N, 2013, J MED GENET, V50, P437, DOI 10.1136/jmedgenet-2012-101487
   Chen J, 2015, SCI REP-UK, V5, DOI 10.1038/srep11438
   Chevessier F, 2015, HUM MOL GENET, V24, P7207, DOI 10.1093/hmg/ddv421
   Chopard A, 2000, ELECTROPHORESIS, V21, P517, DOI 10.1002/(SICI)1522-2683(20000201)21:3<517::AID-ELPS517>3.0.CO;2-9
   Clemen CS, 2015, ACTA NEUROPATHOL, V129, P297, DOI 10.1007/s00401-014-1363-2
   Clemen CS, 2013, ACTA NEUROPATHOL, V125, P47, DOI 10.1007/s00401-012-1057-6
   Clemen CS, 2009, HUM MUTAT, V30, pE490, DOI 10.1002/humu.20941
   Corona JC, 2015, J BIOENERG BIOMEMBR, V47, P89, DOI 10.1007/s10863-014-9576-6
   Cox J, 2014, MOL CELL PROTEOMICS, V13, P2513, DOI 10.1074/mcp.M113.031591
   Cox J, 2008, NAT BIOTECHNOL, V26, P1367, DOI 10.1038/nbt.1511
   Dahl R, 2015, ACTA PHYSIOL, V213, P145, DOI 10.1111/apha.12289
   Diaz F, 2006, MOL CELL BIOL, V26, P4872, DOI 10.1128/MCB.01767-05
   Durmus H, 2016, NEUROLOGY IN PRESS
   Fidzianska A, 2005, NEUROMUSCULAR DISORD, V15, P525, DOI 10.1016/j.nmd.2005.05.006
   Fountoulakis M, 2005, J MOL CELL CARDIOL, V38, P461, DOI 10.1016/j.yjmcc.2004.12.008
   Francis BM, 2014, J ALZHEIMERS DIS, V39, P347, DOI 10.3233/JAD-131499
   Genova ML, 2014, BBA-BIOENERGETICS, V1837, P427, DOI 10.1016/j.bbabio.2013.11.002
   Glancy B, 2015, NATURE, V523, P617, DOI 10.1038/nature14614
   Goldfarb LG, 1998, NAT GENET, V19, P402, DOI 10.1038/1300
   Heidler J, 2013, METHODS MOL BIOL, V1033, P363, DOI 10.1007/978-1-62703-487-6_23
   Henderson M, 2013, ACTA NEUROPATHOL, V125, P917, DOI 10.1007/s00401-013-1113-x
   Hong D, 2011, NEUROPATH APPL NEURO, V37, P257, DOI 10.1111/j.1365-2990.2010.01112.x
   Jackson S, 2015, EUR J NEUROL, V22, P1429, DOI 10.1111/ene.12814
   Joshi PR, 2014, CLIN NEUROPATHOL, V33, P134, DOI 10.5414/NP300693
   Katsetos CD, 2013, SEMIN PEDIATR NEUROL, V20, P202, DOI 10.1016/j.spen.2013.10.010
   Keogh MJ, 2015, BBA-BIOENERGETICS, V1847, P1401, DOI 10.1016/j.bbabio.2015.05.015
   Kley RA, 2007, BRAIN, V130, P3250, DOI 10.1093/brain/awm271
   Kostareva A, 2008, J MUSCLE RES CELL M, V29, P25, DOI 10.1007/s10974-008-9139-8
   KUNZ WS, 1993, BIOCHIM BIOPHYS ACTA, V1144, P46, DOI 10.1016/0005-2728(93)90029-F
   LI ZL, 1989, GENE, V78, P243
   Li ZL, 1996, DEV BIOL, V175, P362, DOI 10.1006/dbio.1996.0122
   Li ZL, 1997, J CELL BIOL, V139, P129, DOI 10.1083/jcb.139.1.129
   Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292
   Lindén M, 2001, J BIOENERG BIOMEMBR, V33, P333, DOI 10.1023/A:1010611408007
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Luan XH, 2010, NEUROMUSCULAR DISORD, V20, P390, DOI 10.1016/j.nmd.2010.03.009
   Maerkens A, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0280-0
   Malfatti E, 2013, J NEUROPATH EXP NEUR, V72, P833, DOI 10.1097/NEN.0b013e3182a23506
   Maranzana E, 2013, ANTIOXID REDOX SIGN, V19, P1469, DOI 10.1089/ars.2012.4845
   McCormick EM, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00199
   McLaughlin HM, 2013, BMC MED GENET, V14, DOI 10.1186/1471-2350-14-68
   Mena NP, 2015, MITOCHONDRION, V21, P92, DOI 10.1016/j.mito.2015.02.001
   Meng FJ, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-34
   Milner DJ, 1996, J CELL BIOL, V134, P1255, DOI 10.1083/jcb.134.5.1255
   Milner DJ, 2000, J CELL BIOL, V150, P1283, DOI 10.1083/jcb.150.6.1283
   Muñoz-Mármol AM, 1998, P NATL ACAD SCI USA, V95, P11312, DOI 10.1073/pnas.95.19.11312
   Nardin RA, 2001, MUSCLE NERVE, V24, P170, DOI 10.1002/1097-4598(200102)24:2<170::AID-MUS30>3.0.CO;2-0
   Nübel E, 2009, PROTEOMICS, V9, P2408, DOI 10.1002/pmic.200800632
   Olivé M, 2005, BRAIN, V128, P2315, DOI 10.1093/brain/awh576
   Piñol-Ripoll G, 2009, NEUROMUSCULAR DISORD, V19, P418, DOI 10.1016/j.nmd.2009.04.004
   Pinto M, 2014, BBA-MOL BASIS DIS, V1842, P1198, DOI 10.1016/j.bbadis.2013.11.012
   Prior KK, 2016, J BIOL CHEM, V291, P7045, DOI 10.1074/jbc.M115.710772
   Reipert S, 1999, EXP CELL RES, V252, P479, DOI 10.1006/excr.1999.4626
   Rezniczek GA, 2007, J CELL BIOL, V176, P965, DOI 10.1083/jcb.200604179
   Schägger H, 2000, EMBO J, V19, P1777, DOI 10.1093/emboj/19.8.1777
   Schröder R, 2003, HUM MOL GENET, V12, P657, DOI 10.1093/hmg/ddg060
   Schröder R, 2002, J NEUROPATH EXP NEUR, V61, P520, DOI 10.1093/jnen/61.6.520
   Schröder R, 2007, HUM MOL GENET, V16, P2989, DOI 10.1093/hmg/ddm269
   Schröder R, 2013, ACTA NEUROPATHOL, V125, P1, DOI 10.1007/s00401-012-1071-8
   Stockburger C, 2014, J ALZHEIMERS DIS, V42, P395, DOI 10.3233/JAD-140381
   Strecker V, 2010, PROTEOMICS, V10, P3379, DOI 10.1002/pmic.201000343
   Su B, 2010, BBA-MOL BASIS DIS, V1802, P135, DOI 10.1016/j.bbadis.2009.09.013
   Thornell LE, 1997, J MOL CELL CARDIOL, V29, P2107, DOI 10.1006/jmcc.1997.0446
   Uszkoreit J, 2015, J PROTEOME RES, V14, P2988, DOI 10.1021/acs.jproteome.5b00121
   Vernengo L, 2010, NEUROMUSCULAR DISORD, V20, P178, DOI 10.1016/j.nmd.2010.01.001
   Winter L, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0314-7
   Winter L, 2015, HUM MOL GENET, V24, P4530, DOI 10.1093/hmg/ddv184
   Wittig I, 2007, MOL CELL PROTEOMICS, V6, P1215, DOI 10.1074/mcp.M700076-MCP200
   Wittig I, 2006, BBA-BIOENERGETICS, V1757, P1066, DOI 10.1016/j.bbabio.2006.05.006
   Wittig I, 2006, NAT PROTOC, V1, P418, DOI 10.1038/nprot.2006.62
   Zerbetto E, 1997, ELECTROPHORESIS, V18, P2059, DOI 10.1002/elps.1150181131
   Zhao S, 2005, J COMPUT BIOL, V12, P1047, DOI 10.1089/cmb.2005.12.1047
   Zsurka G, 2008, J NEUROPATH EXP NEUR, V67, P857, DOI 10.1097/NEN.0b013e3181839b2d
NR 82
TC 53
Z9 56
U1 0
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0001-6322
EI 1432-0533
J9 ACTA NEUROPATHOL
JI Acta Neuropathol.
PD SEP
PY 2016
VL 132
IS 3
BP 453
EP 473
DI 10.1007/s00401-016-1592-7
PG 21
WC Clinical Neurology; Neurosciences; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pathology
GA DU2AA
UT WOS:000382011300008
PM 27393313
OA hybrid, Green Published
DA 2024-11-01
ER

PT J
AU Vincent, AE
   Chen, C
   Gomes, TB
   Di Leo, V
   Laalo, T
   Pabis, K
   Capaldi, R
   Marusich, MF
   McDonald, D
   Filby, A
   Fuller, A
   Urban, DL
   Zierz, S
   Deschauer, M
   Turnbull, D
   Reeve, AK
   Lawless, C
AF Vincent, Amy E.
   Chen, Chun
   Gomes, Tiago Bernardino
   Di Leo, Valeria
   Laalo, Tuomas
   Pabis, Kamil
   Capaldi, Rodrick
   Marusich, Michael F.
   McDonald, David
   Filby, Andrew
   Fuller, Andrew
   Urban, Diana Lehmann
   Zierz, Stephan
   Deschauer, Marcus
   Turnbull, Doug
   Reeve, Amy K.
   Lawless, Conor
TI A stagewise response to mitochondrial dysfunction in mitochondrial DNA
   maintenance disorders
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
LA English
DT Article
DE Myopathy; Cell signalling; OXPHOS; Mitochondrial DNA deletion;
   Mitochondrial disease
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; MUTATIONS; REPLICATION; DELETIONS;
   TWINKLE; FIBERS; GENOME
AB Mitochondrial DNA (mtDNA) deletions which clonally expand in skeletal muscle of patients with mtDNA maintenance disorders, impair mitochondrial oxidative phosphorylation dysfunction. Previously we have shown that these mtDNA deletions arise and accumulate in perinuclear mitochondria causing localised mitochondrial dysfunction before spreading through the muscle fibre. We believe that mito-nuclear signalling is a key contributor in the accumulation and spread of mtDNA deletions, and that knowledge of how muscle fibres respond to mitochondrial dysfunction is key to our understanding of disease mechanisms. To understand the contribution of mito-nuclear signalling to the spread of mitochondrial dysfunction, we use imaging mass cytometry. We characterise the levels of mitochondrial Oxidative Phosphorylation proteins alongside a mitochondrial mass marker, in a cohort of patients with mtDNA maintenance disorders. Our expanded panel included protein markers of key signalling pathways, allowing us to investigate cellular responses to different combinations of oxidative phosphorylation dysfunction and ragged red fibres. We find combined Complex I and IV deficiency to be most common. Interestingly, in fibres deficient for one or more complexes, the remaining complexes are often upregulated beyond the increase of mitochondrial mass typically observed in ragged red fibres. We further find that oxidative phosphorylation deficient fibres exhibit an increase in the abundance of proteins involved in proteostasis, e.g. HSP60 and LONP1, and regulation of mitochondrial metabolism (including oxidative phosphorylation and proteolysis, e.g. PHB1). Our analysis suggests that the cellular response to mitochondrial dysfunction changes depending on the combination of deficient oxidative phosphorylation complexes in each fibre.
C1 [Vincent, Amy E.; Gomes, Tiago Bernardino; Di Leo, Valeria; Pabis, Kamil; Turnbull, Doug; Reeve, Amy K.; Lawless, Conor] Newcastle Univ, Clin & Translat Res Inst, Fac Med Sci, Wellcome Ctr Mitochondrial Res, Newcastle Upon Tyne, England.
   [Vincent, Amy E.; Gomes, Tiago Bernardino; Lawless, Conor] Newcastle Univ, Fac Med Sci, NIHR Biomed Res Ctr, Newcastle Upon Tyne, England.
   [Vincent, Amy E.] Newcastle Univ, Clin & Translat Res Inst, Fac Med Sci, John Walton Muscular Dystrophy Res Ctr, Newcastle Upon Tyne, England.
   [Chen, Chun] Newcastle Univ, Fac Med Sci, Wellcome Ctr Mitochondrial Res, Biosci Inst, Newcastle Upon Tyne, England.
   [Laalo, Tuomas] Univ Helsinki, Fac Med, Stem Cells & Metab Res Program, Helsinki, Finland.
   [Capaldi, Rodrick] Cellstate Biosci, Tucson, AZ USA.
   [Marusich, Michael F.] mAbDx Inc, Eugene, OR USA.
   [McDonald, David; Filby, Andrew; Fuller, Andrew] Newcastle Univ, Biosci Inst, Innovat Methodol & Applicat Res Theme, Newcastle Upon Tyne, England.
   [McDonald, David; Filby, Andrew; Fuller, Andrew] Newcastle Univ, Fac Med Sci, Flow Cytometry Core Facil, Newcastle Upon Tyne, England.
   [Urban, Diana Lehmann] Ulm Univ, Dept Neurol, Ulm, Germany.
   [Zierz, Stephan] Martin Luther Univ Halle Wittenberg, Dept Neurol, Halle, Saale, Germany.
   [Deschauer, Marcus] Tech Univ Munich, Dept Neurol, Munich, Germany.
   [Vincent, Amy E.] Newcastle Univ, Med Sch, 4th Floor Cookson Bldg,Framlington Pl, Newcastle Upon Tyne NE2 4HH, England.
C3 Newcastle University - UK; Newcastle University - UK; Newcastle
   University - UK; Newcastle University - UK; University of Helsinki;
   Newcastle University - UK; Newcastle University - UK; Ulm University;
   Martin Luther University Halle Wittenberg; Technical University of
   Munich; Newcastle University - UK
RP Vincent, AE (corresponding author), Newcastle Univ, Med Sch, 4th Floor Cookson Bldg,Framlington Pl, Newcastle Upon Tyne NE2 4HH, England.
EM amy.vincent@newcastle.ac.uk
RI chen, chun/AFI-5126-2022
OI Di Leo, Valeria/0000-0002-0166-3426; chen, chun/0000-0002-6162-0284
FU Henry Wellcome Postdoctoral Fellowship [215888/Z/19/Z]; NIHR Newcastle
   Biomedical Research Centre; MJFF grant [15707]; PDUK grant [G-2003]
FX This work was funded by a Henry Wellcome Postdoctoral Fellowship to AEV
   (215888/Z/19/Z) and the NIHR Newcastle Biomedical Research Centre
   awarded to the Newcastle upon Tyne Hospitals NHS Foundation Trust and
   Newcastle University. CC was supported by MJFF grant (grant 15707) and
   PDUK grant (G-2003) awarded to AKR. We would like to acknowledge the
   staff of the Newcastle University Flow Cytometry Core Facility for their
   support and technical expertise, Prof Anu Suomalainen advice and helpful
   comments, Dr. Valentina Perissi for the GPS2 anti- body and Dr. Thomas
   Nicholls and Prof Robert Lightowlers for insightful comments.
CR Bankhead P, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-17204-5
   Bourges I, 2004, BIOCHEM J, V383, P491, DOI 10.1042/BJ20040256
   Cardamone MD, 2018, MOL CELL, V69, P757, DOI 10.1016/j.molcel.2018.01.037
   Chen C, 2023, NPJ PARKINSONS DIS, V9, DOI 10.1038/s41531-023-00564-3
   Chen C, 2021, NPJ PARKINSONS DIS, V7, DOI 10.1038/s41531-021-00182-x
   DeBerardinis RJ, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600200
   EGGER J, 1981, ARCH DIS CHILD, V56, P741, DOI 10.1136/adc.56.10.741
   Giesen C, 2014, NAT METHODS, V11, P417, DOI [10.1038/NMETH.2869, 10.1038/nmeth.2869]
   Gitschlag BL, 2016, CELL METAB, V24, P91, DOI 10.1016/j.cmet.2016.06.008
   Khan NA, 2017, CELL METAB, V26, P419, DOI 10.1016/j.cmet.2017.07.007
   Kornblum C, 2013, NAT GENET, V45, P214, DOI 10.1038/ng.2501
   Kruschke JK, 2013, J EXP PSYCHOL GEN, V142, P573, DOI 10.1037/a0029146
   Lehmann D, 2019, NUCLEIC ACIDS RES, V47, P7430, DOI 10.1093/nar/gkz472
   Lin YF, 2016, NATURE, V533, P416, DOI 10.1038/nature17989
   Mito T, 2022, CELL METAB, V34, P197, DOI 10.1016/j.cmet.2021.12.017
   Murgia M, 2019, CELL REP, V29, P3825, DOI 10.1016/j.celrep.2019.11.055
   Murphy JL, 2012, NEUROMUSCULAR DISORD, V22, P690, DOI 10.1016/j.nmd.2012.04.003
   Nargund AM, 2015, MOL CELL, V58, P123, DOI 10.1016/j.molcel.2015.02.008
   Nargund AM, 2012, SCIENCE, V337, P587, DOI 10.1126/science.1223560
   Nijtmans LGJ, 2000, EMBO J, V19, P2444, DOI 10.1093/emboj/19.11.2444
   Nikkanen J, 2016, CELL METAB, V23, P635, DOI 10.1016/j.cmet.2016.01.019
   R Core Team, 2021, R LANG ENV STAT COMP
   Rocha MC, 2018, ANN NEUROL, V83, P115, DOI 10.1002/ana.25127
   Rocha MC, 2015, SCI REP-UK, V5, DOI 10.1038/srep15037
   Rossignol R, 2003, BIOCHEM J, V370, P751, DOI 10.1042/BJ20021594
   Scrucca L, 2016, R J, V8, P289
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
   Tyynismaa H, 2012, HUM MOL GENET, V21, P66, DOI 10.1093/hmg/ddr438
   Tyynismaa H, 2010, HUM MOL GENET, V19, P3948, DOI 10.1093/hmg/ddq310
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Vincent AE, 2018, ANN NEUROL, V84, P289, DOI 10.1002/ana.25288
   Warren C, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-70885-3
   Yaku K, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00622
   YONEDA M, 1992, P NATL ACAD SCI USA, V89, P11164, DOI 10.1073/pnas.89.23.11164
NR 35
TC 0
Z9 0
U1 1
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0925-4439
EI 1879-260X
J9 BBA-MOL BASIS DIS
JI Biochim. Biophys. Acta-Mol. Basis Dis.
PD JUN
PY 2024
VL 1870
IS 5
AR 167131
DI 10.1016/j.bbadis.2024.167131
EA APR 2024
PG 11
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA RG3Q8
UT WOS:001226479000001
PM 38521420
OA Green Submitted, hybrid
DA 2024-11-01
ER

PT J
AU Taivassalo, T
   Gardner, JL
   Taylor, RW
   Schaefer, AM
   Newman, J
   Barron, MJ
   Haller, RG
   Turnbull, DM
AF Taivassalo, Tanja
   Gardner, Julie L.
   Taylor, Robert W.
   Schaefer, Andrew M.
   Newman, Jane
   Barron, Martin J.
   Haller, Ronald G.
   Turnbull, Douglass M.
TI Endurance training and detraining in mitochondrial myopathies due to
   single large-scale mtDNA deletions
SO BRAIN
LA English
DT Article
DE mitochondrial myopathy; deletions; exercise training
ID DNA DELETIONS; EXERCISE; DISEASE; CAPACITY; LACTATE
AB At present there are limited therapeutic interventions for patients with mitochondrial myopathies. Exercise training has been suggested as an approach to improve physical capacity and quality of life but it is uncertain whether it offers a safe and effective treatment for patients with heteroplasmic mitochondrial DNA (mtDNA) mutations. The objectives of this study were to assess the effects of exercise training and detraining in eight patients with single, large-scale mtDNA deletions to determine: (i) the efficacy and safety of endurance training (14 weeks) in this patient population; (ii) to determine the effect of more prolonged (total of 28 weeks) exercise training upon muscle and cardiovascular function and (iii) to evaluate the effect of discontinued training (14 weeks) upon muscle and cardiovascular function. Our results show that: (i) 14 weeks of exercise training significantly improved tolerance of submaximal exercise and peak capacity for work, oxygen utilization and skeletal muscle oxygen extraction with no change in the level of deleted mtDNA; (ii) continued training for an additional 14 weeks maintained these beneficial adaptations; (iii) the cessation of training (detraining) resulted in loss of physiological adaptation to baseline capacity with no overall change in mutation load. Patients' self assessment of quality of life as measured by the SF-36 questionnaire improved with training and declined with detraining. Whilst our findings of beneficial effects of training on physiological outcome and quality of life without increases in the percentage of deleted mtDNA are encouraging, we did not observe changes in mtDNA copy number. Therefore there remains a need for longer term studies to confirm that endurance exercise is a safe and effective treatment for patients with mitochondrial myopathies. The effects of detraining clearly implicate physical inactivity as an important mechanism in reducing exercise capacity and quality of life in patients with mitochondrial myopathy.
C1 McGill Univ, Dept Kinesiol, Montreal, PQ, Canada.
   Univ Newcastle Upon Tyne, Sch Med, Sch Neurol Neurobiol & Psychiat, Mitochondrial Res Grp, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
   Presbyterian Med Ctr, Neuromuscular Ctr, Inst Exercise & Environm Med, Dallas, TX USA.
   Univ Texas, SW Med Ctr, Dallas, TX 75230 USA.
   VA Med Ctr, Dallas, TX USA.
C3 McGill University; Newcastle University - UK; University of Texas
   System; University of Texas Southwestern Medical Center Dallas;
   University of Texas Dallas
RP Turnbull, DM (corresponding author), Univ Newcastle, Mitochondrial Res Grp, Sch Neurol Neurobiol & Psychiat, Sch Med, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM d.m.turnbull@ncl.ac.uk
RI ; Barron, Martin/E-9649-2015
OI Schaefer, Andrew/0000-0001-9891-7332; Barron, Martin/0000-0002-2047-3513
FU Wellcome Trust [074454] Funding Source: Medline
CR Barron MJ, 2005, NEUROMUSCULAR DISORD, V15, P768, DOI 10.1016/j.nmd.2005.06.018
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Blakely EL, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.011296
   BORG G, 1985, EUR J APPL PHYSIOL, V54, P343, DOI 10.1007/BF02337176
   Cejudo P, 2005, MUSCLE NERVE, V32, P342, DOI 10.1002/mus.20368
   Chinnery P F, 2003, Neuromuscul Disord, V13, P757, DOI 10.1016/S0960-8966(03)00097-X
   He LP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf067
   McFarland R, 2002, LANCET NEUROL, V1, P343, DOI 10.1016/S1474-4422(02)00159-X
   Saltin B., 1983, SKELETAL MUSCLE ADAP, P555
   Sciacco M, 1996, Methods Enzymol, V264, P509, DOI 10.1016/S0076-6879(96)64045-2
   Siciliano G, 2000, NEUROMUSCULAR DISORD, V10, P40, DOI 10.1016/S0960-8966(99)00068-1
   Taivassalo T, 1998, NEUROLOGY, V50, P1055, DOI 10.1212/WNL.50.4.1055
   Taivassalo T, 1996, NEUROLOGY, V47, P529, DOI 10.1212/WNL.47.2.529
   Taivassalo T, 2001, ANN NEUROL, V50, P133, DOI 10.1002/ana.1050
   Taivassalo T, 2003, BRAIN, V126, P413, DOI 10.1093/brain/awg028
   Taivassalo T, 2004, BBA-BIOENERGETICS, V1659, P221, DOI 10.1016/j.bbabio.2004.09.007
   Taivassalo Tanja, 1997, Neurology, V48, pA214
   Taylor R.W., 1997, Organelle Diseases : Clinical Features, Diagnosis, Pathogenesis, and Management, P341
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   Wang H, 1999, EUR J APPL PHYSIOL O, V80, P22, DOI 10.1007/s004210050553
   WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002
   Zeviani M, 2004, BRAIN, V127, P2153, DOI 10.1093/brain/awh259
NR 23
TC 145
Z9 153
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
J9 BRAIN
JI Brain
PD DEC
PY 2006
VL 129
BP 3391
EP 3401
DI 10.1093/brain/awl282
PN 12
PG 11
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 111RE
UT WOS:000242471100030
PM 17085458
OA hybrid
DA 2024-11-01
ER

PT J
AU Scuderi, C
   Borgione, E
   Castello, F
   Lo Giudice, M
   Paola, SS
   Giambirtone, M
   Di Blasi, FD
   Elia, M
   Amato, C
   Città, S
   Gagliano, C
   Barbarino, G
   Vitello, GA
   Musumeci, SA
AF Scuderi, Carmela
   Borgione, Eugenia
   Castello, Filippa
   Lo Giudice, Mariangela
   Paola, Sandro Santa
   Giambirtone, Mariaconcetta
   Di Blasi, Francesco Domenico
   Elia, Maurizio
   Amato, Carmelo
   Citta, Santina
   Gagliano, Catalda
   Barbarino, Giuliano
   Vitello, Girolamo Aurelio
   Musumeci, Sebastiano Antonino
TI The in cis T251I and P587L POLG1 base changes: Description of a new
   family and literature review
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE Gene mutation; Mental retardation; Mitochondrial disease; Polymerase
   gamma
ID DNA-POLYMERASE-GAMMA; PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA;
   MITOCHONDRIAL-DNA; MUTATIONS; CONSEQUENCE; PHENOTYPES; FREQUENCY;
   DEPLETION; DELETIONS; TWINKLE
AB Mutations in the polymerase gamma-1 (POLG1) gene, encoding the catalytic subunit of the mtDNA-specific polymerase-gamma, compromise the stability of mitochondrial DNA (mtDNA) and are responsible for numerous clinical presentations as autosomal dominant or recessive progressive external ophthalmoplegia (PEO), sensory ataxia, neuropathy, dysarthria and ophthalmoparesis (SANDO), spinocerebellar ataxia with epilepsy (SCAB) and Alpers syndrome.
   POLG1 mutations result in extremely heterogeneous phenotypes which often have overlapping clinical findings, making it difficult to categorize patients into syndromes, and genotype phenotype correlations are still unclear.
   We describe a new family with a particular spectrum of clinical signs, that carried the c.752C>T mutation in exon 3 (T251I) and the c.1760C>T in exon 10 (P587L) in cis. These mutations were associated in the proband and in her brother with the new probably pathogenic mutation c.347C>A in exon 2 (P116Q).
   The proband presented a progressive cognitive impairment, mild myopathy, dilated cardiac right atrium and posterior white matter mild signal alteration, while her brother had migraine, mild myopathy, palpebral ptosis and posterior white matter mild signal alteration. Their mother and their sister carried the in cis T251I and the P587L mutations. The first presented neurosensorial hypoacusia, fatigue, heart block and a cerebral arteriovenous malformation nidus, while the latter had borderline intellectual functioning and signs of muscular involvement. Their father, with the P116Q mutation, had diabetes and myopathy.
   The complexity of the genotype-phenotype correlations associated with POLG1 mutations is reinforced in this work as evidenced by the presence of different clinic features in patients carrying the same mutations. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Scuderi, Carmela; Borgione, Eugenia; Castello, Filippa; Lo Giudice, Mariangela; Paola, Sandro Santa; Giambirtone, Mariaconcetta; Gagliano, Catalda; Barbarino, Giuliano] IRCCS Oasi Maria SS, Unita Operat Malattie Neuromuscolari, I-94018 Troina, EN, Italy.
   [Di Blasi, Francesco Domenico; Citta, Santina] IRCCS Oasi Maria SS, Unita Operat Psicol, I-94018 Troina, EN, Italy.
   [Elia, Maurizio] IRCCS Oasi Maria SS, Unita Operat Neurol & Neurofisiopatol Clin & Stru, I-94018 Troina, EN, Italy.
   [Amato, Carmelo] IRCCS Oasi Maria SS, Unita Operat Neuroradiol, I-94018 Troina, EN, Italy.
   [Vitello, Girolamo Aurelio; Musumeci, Sebastiano Antonino] IRCCS Oasi Maria SS, Unita Operat Neurol Ritardo Mentale, I-94018 Troina, EN, Italy.
C3 IRCCS Oasi Maria SS; IRCCS Oasi Maria SS; IRCCS Oasi Maria SS; IRCCS
   Oasi Maria SS; IRCCS Oasi Maria SS
RP Scuderi, C (corresponding author), IRCCS Oasi Maria SS, Unita Operat Malattie Neuromuscolari, V Conte Ruggero 73, I-94018 Troina, EN, Italy.
EM cscuderi@oasi.en.it
RI Vitello, Aurelio/E-3208-2017; Castello, Filippa/D-4266-2017; Santa
   Paola, Sandro/D-4174-2017; Giambirtone, Maria Concetta/D-2897-2017;
   Borgione, Eugenia/D-9168-2017; Amato, Carmelo/D-5567-2017; Di Blasi,
   Francesco Domenico/D-8146-2017; Finocchiaro, Maria/E-1288-2017; Scuderi,
   Carmela/D-4734-2017; Citta, Santina/D-8802-2017; Barbarino,
   Giancarlo/L-2559-2015; Lo Giudice, Mariangela/D-4261-2017; Elia,
   Maurizio/K-3285-2016; Vitello, Girolamo Aurelio/HPG-0215-2023; Musumeci,
   Sebastiano Antonino/E-3879-2017; Gagliano, Catalda/E-5420-2017
OI Castello, Filippa/0000-0002-2780-1583; Santa Paola,
   Sandro/0000-0002-3310-782X; Giambirtone, Maria
   Concetta/0000-0002-3717-6400; Borgione, Eugenia/0000-0001-5458-7415;
   Amato, Carmelo/0000-0002-8058-344X; Di Blasi, Francesco
   Domenico/0000-0002-2958-2927; Finocchiaro, Maria/0000-0002-0311-8771;
   Scuderi, Carmela/0000-0001-5901-0041; Citta,
   Santina/0000-0001-7618-3673; Barbarino, Giancarlo/0000-0001-9253-3397;
   Lo Giudice, Mariangela/0000-0001-5961-0362; Elia,
   Maurizio/0000-0002-0414-1359; Vitello, Girolamo
   Aurelio/0000-0002-6285-9692; Musumeci, Sebastiano
   Antonino/0000-0002-6865-5367; Gagliano, Catalda/0000-0002-9413-5306
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Aitken H, 2009, NEUROLOGY, V72, pE86, DOI 10.1212/WNL.0b013e3181a411b8
   Ashley N, 2008, HUM MOL GENET, V17, P2496, DOI 10.1093/hmg/ddn150
   Blok MJ, 2009, J MED GENET, V46, P776, DOI 10.1136/jmg.2009.067686
   Burusnukul P, 2009, J CHILD NEUROL, V24, P482, DOI 10.1177/0883073808324539
   Chan SSL, 2009, BBA-BIOENERGETICS, V1787, P312, DOI 10.1016/j.bbabio.2008.10.007
   Chinnery Patrick F, 2008, Neuromuscul Disord, V18, P259, DOI 10.1016/j.nmd.2007.11.005
   Del Bo R, 2003, NEUROLOGY, V61, P903, DOI 10.1212/01.WNL.0000092303.13864.BE
   Di Fonzo A, 2003, HUM MUTAT, V22, DOI 10.1002/humu.9203
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Ferreira M, 2011, NEUROMUSCULAR DISORD, V21, P483, DOI 10.1016/j.nmd.2011.03.011
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   González-Vioque E, 2006, ARCH NEUROL-CHICAGO, V63, P107, DOI 10.1001/archneur.63.1.107
   Harris MO, 2010, ARCH NEUROL-CHICAGO, V67, P493, DOI 10.1001/archneurol.2010.36
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Hudson G, 2006, HUM MOL GENET, V15, pR244, DOI 10.1093/hmg/ddl233
   Kollberg G, 2005, EUR J HUM GENET, V13, P463, DOI 10.1038/sj.ejhg.5201341
   Lamantea E, 2004, ANN NEUROL, V56, P454, DOI 10.1002/ana.20219
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Ramensky V, 2002, NUCLEIC ACIDS RES, V30, P3894, DOI 10.1093/nar/gkf493
   Rieder MJ, 1998, NUCLEIC ACIDS RES, V26, P967, DOI 10.1093/nar/26.4.967
   Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490
   Saneto RP, 2010, DEV DISABIL RES REV, V16, P163, DOI 10.1002/ddrr.105
   Scuderi C, 2007, NEUROMUSCULAR DISORD, V17, P258, DOI 10.1016/j.nmd.2006.11.006
   Stewart JD, 2009, J MED GENET, V46, P209, DOI 10.1136/jmg.2008.058180
   Taanman JW, 2009, HUM MUTAT, V30, P248, DOI 10.1002/humu.20852
   Tang S, 2011, J MED GENET, V48, P669, DOI 10.1136/jmedgenet-2011-100222
   Tzoulis C, 2009, ACTA NEUROL SCAND, V120, P38, DOI 10.1111/j.1600-0404.2009.01212.x
   Van Goethem G, 2003, EUR J HUM GENET, V11, P547, DOI 10.1038/sj.ejhg.5201002
   Walker RL, 1997, GENOMICS, V40, P376, DOI 10.1006/geno.1996.4580
   Wanrooij S, 2004, NUCLEIC ACIDS RES, V32, P3053, DOI 10.1093/nar/gkh634
   Weiss MD, 2010, MUSCLE NERVE, V41, P882, DOI 10.1002/mus.21636
   Wong LJ, 2008, HUM MUTAT, V29, P150
NR 34
TC 20
Z9 20
U1 0
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD APR
PY 2015
VL 25
IS 4
BP 333
EP 339
DI 10.1016/j.nmd.2015.01.004
PG 7
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA CG2CE
UT WOS:000353081700007
PM 25660390
DA 2024-11-01
ER

PT J
AU Götz, A
   Isohanni, P
   Pihko, H
   Paetau, A
   Herva, R
   Saarenpää-Heikkilä, O
   Valanne, L
   Marjavaara, S
   Suomalainen, A
AF Gotz, Alexandra
   Isohanni, Pirjo
   Pihko, Helena
   Paetau, Anders
   Herva, Riitta
   Saarenpaa-Heikkila, Outi
   Valanne, Leena
   Marjavaara, Sanna
   Suomalainen, Anu
TI Thymidine kinase 2 defects can cause multi-tissue mtDNA depletion
   syndrome
SO BRAIN
LA English
DT Article
ID MITOCHONDRIAL-DNA DEPLETION; RESPIRATORY-CHAIN; POLG MUTATIONS; GENE;
   DEFICIENCY; MYOPATHY; EXPRESSION; PATIENT; PCR
AB Mitochondrial DNA depletion syndrome (MDS) is a severe recessively inherited disease of childhood. It manifests most often in infancy, is rapidly progressive and leads to early death. MDS is caused by an increasing number of nuclear genes leading to multisystemic or tissue-specific decrease in mitochondrial DNA (mtDNA) copy number. Thymidine kinase 2 (TK2) has been reported to cause a myopathic form of MDS. We report here the clinical, autopsy and molecular genetic findings of rapidly progressive fatal infantile mitochondrial syndrome. All of our seven patients had rapidly progressive myopathy/encephalomyopathy, leading to respiratory failure within the first 3 years of life, with high creatine kinase values and dystrophic changes in the muscle with cytochrome c oxidase-negative fibres. In addition, two patients also had terminal-phase seizures, one had epilepsia partialis continua and one had cortical laminar necrosis. We identified two different homozygous or compound heterozygous mutations in the TK2 gene in all the patients: c.739 C s T and c.898 C T, leading to p.R172W and p.R225W changes at conserved protein sites. R172W mutation led to myopathy or encephalomyopathy with the onset during the first months of life, and was associated with severe mtDNA depletion in the muscle, brain and liver. Homozygosity for R225W mutation manifested during the second year of life as a myopathy, and showed muscle-specific mtDNA depletion. Both mutations originated from single ancient founders, with Finnish origin and enrichment for the new R172W mutation, and possibly Scandinavian ancestral origin for the R225W. We conclude that TK2 mutations may manifest as infantile-onset fatal myopathy with dystrophic features, but should be considered also in infantile progressive encephalomyopathy with wide-spread mtDNA depletion.
C1 [Gotz, Alexandra; Isohanni, Pirjo; Marjavaara, Sanna; Suomalainen, Anu] Univ Helsinki, Res Programme Mol Neurol Biomed Helsinki, FIN-00290 Helsinki, Finland.
   [Isohanni, Pirjo; Pihko, Helena; Paetau, Anders] Univ Helsinki, Cent Hosp, Hosp Children & Adolescents, Dept Paediat Neurol, Helsinki, Finland.
   [Paetau, Anders] Univ Helsinki, Dept Pathol, Helsinki, Finland.
   [Herva, Riitta] Oulu Univ Hosp, Dept Pathol, Oulu, Finland.
   [Saarenpaa-Heikkila, Outi] Tampere Univ Hosp, Paediat Clin, Tampere, Finland.
   [Valanne, Leena] Univ Helsinki, Helsinki Med Imaging Ctr, Helsinki, Finland.
   [Suomalainen, Anu] Univ Helsinki, Cent Hosp, Dept Neurol, Helsinki, Finland.
C3 University of Helsinki; University of Helsinki; Helsinki University
   Central Hospital; University of Helsinki; University of Oulu; Tampere
   University; Tampere University Hospital; University of Helsinki;
   University of Helsinki; Helsinki University Central Hospital
RP Suomalainen, A (corresponding author), Univ Helsinki, Res Programme Mol Neurol Biomed Helsinki, Room C523A,Haartmaninkatu 8, FIN-00290 Helsinki, Finland.
EM anu.wartiovaara@helsinki.fi
OI Valanne, Leena/0000-0002-8572-829X; Suomalainen-Wartiovaara,
   Anu/0000-0003-4833-5195; Gotz, Alexandra/0000-0001-9737-6861
FU Academy of Finland; Helsinki University; Sigrid Juselius Foundation;
   Graduate School of Biotechnology and Molecular Biology; Foundation for
   Paediatric Research and Helsinki University Central Hospital EVO; Human
   Frontier Science Program [LT00341/2001-M]
FX Academy of Finland (to A.S. and S.K.M.); Helsinki University; Sigrid
   Juselius Foundation (to A.S. and H.P.); Graduate School of Biotechnology
   and Molecular Biology (to A.G.); Foundation for Paediatric Research and
   Helsinki University Central Hospital EVO grant (to H.P.); Human Frontier
   Science Program (LT00341/2001-M, to S.K.M.).
CR Akman HO, 2008, HUM MOL GENET, V17, P2433, DOI 10.1093/hmg/ddn143
   Alberio S, 2007, MITOCHONDRION, V7, P6, DOI 10.1016/j.mito.2006.11.010
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Carrozzo R, 2003, HUM MUTAT, V21, DOI 10.1002/humu.9135
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Galbiati S, 2006, PEDIATR NEUROL, V34, P177, DOI 10.1016/j.pediatrneurol.2005.07.013
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   MAJANDER A, 1995, J NEUROL SCI, V134, P95, DOI 10.1016/0022-510X(95)00225-5
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   McFarland R, 2002, LANCET NEUROL, V1, P343, DOI 10.1016/S1474-4422(02)00159-X
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Nguyen KV, 2005, NEUROLOGY, V65, P1493, DOI 10.1212/01.wnl.0000182814.55361.70
   Norio R, 2003, HUM GENET, V112, P470, DOI 10.1007/s00439-002-0877-1
   Norio R, 2003, HUM GENET, V112, P441, DOI 10.1007/s00439-002-0875-3
   Oskoui M, 2006, ARCH NEUROL-CHICAGO, V63, P1122, DOI 10.1001/archneur.63.8.1122
   Ostergaard E, 2007, AM J HUM GENET, V81, P383, DOI 10.1086/519222
   Pietiläinen KH, 2008, PLOS MED, V5, DOI 10.1371/journal.pmed.0050051
   PIHKO H, 1992, NEUROPEDIATRICS, V23, P116, DOI 10.1055/s-2008-1071325
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Sarzi E, 2007, ANN NEUROL, V62, P579, DOI 10.1002/ana.21207
   Sarzi E, 2007, J PEDIATR-US, V150, P531, DOI 10.1016/j.jpeds.2007.01.044
   SHIBATA DK, 1988, J EXP MED, V167, P225, DOI 10.1084/jem.167.1.225
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Suomalainen A, 2000, MOL BIOTECHNOL, V15, P123, DOI 10.1385/MB:15:2:123
   Tulinius M, 2005, NEUROMUSCULAR DISORD, V15, P412, DOI 10.1016/j.nmd.2005.03.010
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Vilá MR, 2008, J NEUROL SCI, V267, P137, DOI 10.1016/j.jns.2007.10.019
   Vilà MR, 2003, NEUROLOGY, V60, P1203, DOI 10.1212/01.WNL.0000055928.58122.47
   Vu TH, 1998, NEUROLOGY, V51, P1190, DOI 10.1212/WNL.51.4.1190
NR 31
TC 69
Z9 77
U1 0
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 1460-2156
J9 BRAIN
JI Brain
PD NOV
PY 2008
VL 131
BP 2841
EP 2850
DI 10.1093/brain/awn236
PN 11
PG 10
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 373MQ
UT WOS:000260976400006
PM 18819985
OA Bronze
DA 2024-11-01
ER

PT J
AU Vilá, MR
   Villarroya, J
   Garcia-Arumí, E
   Castellote, A
   Meseguer, A
   Hirano, M
   Roig, M
AF Vila, Maya R.
   Villarroya, Joan
   Garcia-Arumi, Elena
   Castellote, Amparo
   Meseguer, Anna
   Hirano, Michio
   Roig, Manuel
TI Selective muscle fiber loss and molecular compensation in mitochondrial
   myopathy due to TK2 deficiency
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE COX II; mitochondria DNA depletion; muscle; muscle fibers; respiratory
   chain; TK2
ID DNA COPY NUMBER; MTDNA DEPLETION; THYMIDINE KINASE; MUTATIONS; PATIENT;
   GENE
AB A 12-year-old patient with mitochondrial DNA (mtDNA) depletion syndrome due to TK2 gene mutations has been evaluated serially over the last 10 years. We observed progressive muscle atrophy with selective loss of type 2 muscle fibers and, despite severe depletion of mtDNA, normal activities of respiratory chain (RC) complexes and levels of COX It mitochondrial protein in the remaining muscle fibers. These results indicate that compensatory mechanisms account for the slow progression of the disease. Identification of factors that ameliorate mtDNA depletion may reveal new therapeutic targets for these devastating disorders. (C) 2007 Elsevier B.V. All rights reserved.
C1 [Roig, Manuel] Hosp Univ Vall Hebron, Seccio Neurol Pediat, Barcelona 08036, Spain.
   [Vila, Maya R.; Villarroya, Joan; Garcia-Arumi, Elena; Meseguer, Anna] Hosp Univ Vall Hebron, CIBBIM, Barcelona 08036, Spain.
   [Castellote, Amparo] Hosp Univ Vall Hebron, Dept Pediat Radiol, Barcelona 08036, Spain.
   [Roig, Manuel] Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY USA.
C3 Hospital Universitari Vall d'Hebron; Hospital Universitari Vall
   d'Hebron; Hospital Universitari Vall d'Hebron; Columbia University
RP Roig, M (corresponding author), Hosp Univ Vall Hebron, Seccio Neurol Pediat, Pg Vall Hebron 119-129, Barcelona 08036, Spain.
EM manroig@vhebron.net
RI Garcia-Arumi, Elena/ABH-4229-2020; Meseguer, Anna/M-2222-2014;
   Villarroya, Joan/W-4066-2018
OI Garcia-Arumi, Elena/0000-0003-0096-3336; Meseguer,
   Anna/0000-0003-3833-2249; Villarroya, Joan/0000-0002-7859-1109
FU NICHD NIH HHS [P01 HD032062, R01 HD056103] Funding Source: Medline;
   NINDS NIH HHS [P01 NS011766] Funding Source: Medline
CR Barthélémy C, 2001, ANN NEUROL, V49, P607, DOI 10.1002/ana.1002.abs
   Durham SE, 2005, NEUROLOGY, V65, P453, DOI 10.1212/01.wnl.0000171861.30277.88
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Karadimas CL, 2006, AM J HUM GENET, V79, P544, DOI 10.1086/506913
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   MANDERBACKA K, 2001, SCANDINAVIAN J P S55, V29, P41
   Miró O, 2004, JAIDS-J ACQ IMM DEF, V37, P1550, DOI 10.1097/00126334-200412150-00002
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Seidel-Rogol BL, 2002, NUCLEIC ACIDS RES, V30, P1929, DOI 10.1093/nar/30.9.1929
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Vilà MR, 2003, NEUROLOGY, V60, P1203, DOI 10.1212/01.WNL.0000055928.58122.47
   Vu TH, 1998, NEUROLOGY, V51, P1190, DOI 10.1212/WNL.51.4.1190
   Wang LY, 2005, MOL GENET METAB, V84, P75, DOI 10.1016/j.ymgme.2004.09.005
NR 14
TC 17
Z9 18
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD APR 15
PY 2008
VL 267
IS 1-2
BP 137
EP 141
DI 10.1016/j.jns.2007.10.019
PG 5
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 276YW
UT WOS:000254180600022
PM 18021809
OA Green Accepted
DA 2024-11-01
ER

PT J
AU Lim, AZ
   Blakely, EL
   Baty, K
   He, LP
   Hopton, S
   Falkous, G
   McWilliam, K
   Cozens, A
   McFarland, R
   Taylor, RW
AF Lim, Albert Z.
   Blakely, Emma L.
   Baty, Karen
   He, Langping
   Hopton, Sila
   Falkous, Gavin
   McWilliam, Kenneth
   Cozens, Alison
   McFarland, Robert
   Taylor, Robert W.
TI A novel pathogenic m.4412G &gt; A <i>MT</i>-<i>TM</i> mitochondrial DNA
   variant associated with childhood-onset seizures, myopathy and bilateral
   basal ganglia changes
SO MITOCHONDRION
LA English
DT Article
DE Mitochondrial disease; Myopathy; Seizures; mtDNA variant; Basal ganglia
   changes; MTTM
ID MUTATION; FEATURES; MUSCLE
AB Mitochondrial DNA variants in the MT-TM (mt-tRNA(Met)) gene are rare, typically associated with myopathic phenotypes. We identified a novel MT-TM variant resulting in prolonged seizures with childhood-onset myopathy, retinopathy, short stature and elevated CSF lactate associated with bilateral basal ganglia changes on neuroimaging. Muscle biopsy confirmed multiple respiratory chain deficiencies and focal cytochrome c oxidase (COX) histochemical abnormalities. Next-generation sequencing of the mitochondrial genome revealed a novel m.4412G > A variant at high heteroplasmy levels in muscle that fulfils all accepted criteria for pathogenicity including segregation within single muscle fibres, thus broadening the genotypic and phenotypic landscape of mitochondrial tRNA-related disease.
C1 [Lim, Albert Z.; Blakely, Emma L.; Baty, Karen; He, Langping; Hopton, Sila; Falkous, Gavin; McFarland, Robert; Taylor, Robert W.] Newcastle Univ, Inst Neurosci, Wellcome Ctr Mitochondrial Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Blakely, Emma L.; Baty, Karen; He, Langping; Hopton, Sila; Falkous, Gavin; Taylor, Robert W.] Newcastle Tyne Hosp NHS Fdn Trust, NHS Highly Specialised Serv Rare Mitochondrial Di, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [McWilliam, Kenneth] Royal Hosp Sick Children, Dept Paediat Neurol, Edinburgh EH9 1LF, Midlothian, Scotland.
   [Cozens, Alison] NHS Natl Serv Scotland, Inherited Metab Disorders Scotland, Glasgow G2 6QE, Lanark, Scotland.
C3 Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation
   Trust; NHS National Services Scotland
RP Taylor, RW (corresponding author), Newcastle Univ, Inst Neurosci, Wellcome Ctr Mitochondrial Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.; Taylor, RW (corresponding author), Newcastle Tyne Hosp NHS Fdn Trust, NHS Highly Specialised Serv Rare Mitochondrial Di, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM robert.taylor@ncl.ac.uk
OI McFarland, Robert/0000-0002-8833-2688
FU Wellcome Centre for Mitochondrial Research [203105/Z/16/Z]; Medical
   Research Council (MRC) Centre for Translational Research in
   Neuromuscular Disease; MRC Mitochondrial Disease Patient Cohort: A
   Natural History Study and Patient Registry [G0800674]; Lily Foundation;
   UK NIHR Biomedical Research Centre for Ageing; Newcastle upon Tyne
   Foundation Hospitals NHS Trust; MRC/EPSRC Molecular Pathology Node; UK
   NHS Highly Specialised Service for Rare Mitochondrial Disorders of
   Adults and Children
FX Our work are supported by the Wellcome Centre for Mitochondrial Research
   (203105/Z/16/Z), the Medical Research Council (MRC) Centre for
   Translational Research in Neuromuscular Disease, the MRC Mitochondrial
   Disease Patient Cohort: A Natural History Study and Patient Registry
   (G0800674), the Lily Foundation, the UK NIHR Biomedical Research Centre
   for Ageing,the Newcastle upon Tyne Foundation Hospitals NHS Trust, the
   MRC/EPSRC Molecular Pathology Node and the UK NHS Highly Specialised
   Service for Rare Mitochondrial Disorders of Adults and Children.
CR Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Blakely EL, 2013, HUM MUTAT, V34, P1260, DOI 10.1002/humu.22358
   Born AP, 2015, EUR J PAEDIATR NEURO, V19, P69, DOI 10.1016/j.ejpn.2014.10.006
   Darin N, 2001, ANN NEUROL, V49, P377, DOI 10.1002/ana.75
   Gorman GS, 2015, ANN NEUROL, V77, P753, DOI 10.1002/ana.24362
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Kirby DM, 2007, METHOD CELL BIOL, V80, P93, DOI 10.1016/S0091-679X(06)80004-X
   Kuwajima M, 2019, BRAIN DEV-JPN, V41, P465, DOI 10.1016/j.braindev.2019.01.006
   Lombes A, 1998, HUM MUTAT, pS175
   Olsen DB, 2003, J NEUROL, V250, P1328, DOI 10.1007/s00415-003-0206-1
   Peverelli L, 2014, MUSCLE NERVE, V50, P292, DOI 10.1002/mus.24262
   Rocha MC, 2015, SCI REP-UK, V5, DOI 10.1038/srep15037
   Scaglia F, 2004, PEDIATRICS, V114, P925, DOI 10.1542/peds.2004-0718
   Scarpelli M, 2018, NEUROMUSCULAR DISORD, V28, P137, DOI 10.1016/j.nmd.2017.10.006
   Schon EA, 2012, NAT REV GENET, V13, P878, DOI 10.1038/nrg3275
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   Tang S, 2013, HUM MUTAT, V34, P882, DOI 10.1002/humu.22307
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Vissing J, 1998, NEUROLOGY, V50, P1875, DOI 10.1212/WNL.50.6.1875
   Yarham JW, 2011, HUM MUTAT, V32, P1319, DOI 10.1002/humu.21575
   Yarham JW, 2010, WIRES RNA, V1, P304, DOI 10.1002/wrna.27
NR 21
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 1872-8278
J9 MITOCHONDRION
JI Mitochondrion
PD JUL
PY 2019
VL 47
BP 18
EP 23
DI 10.1016/j.mito.2019.04.007
PG 6
WC Cell Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Genetics & Heredity
GA II9VD
UT WOS:000475547200003
PM 31022467
OA Green Published, hybrid
DA 2024-11-01
ER

PT J
AU Ronchi, D
   Sciacco, M
   Bordoni, A
   Raimondi, M
   Ripolone, M
   Fassone, E
   Di Fonzo, A
   Rizzuti, M
   Ciscato, P
   Cosi, A
   Servida, M
   Moggio, M
   Corti, S
   Bresolin, N
   Comi, GP
AF Ronchi, Dario
   Sciacco, Monica
   Bordoni, Andreina
   Raimondi, Monika
   Ripolone, Michela
   Fassone, Elisa
   Di Fonzo, Alessio
   Rizzuti, Mafalda
   Ciscato, Patrizia
   Cosi, Alessandra
   Servida, Maura
   Moggio, Maurizio
   Corti, Stefania
   Bresolin, Nereo
   Comi, Giacomo P.
TI The novel mitochondrial <i>tRNA<SUP>Asn</SUP></i> gene mutation
   m.5709T&gt;C produces ophthalmoparesis and respiratory impairment
SO EUROPEAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
DE progressive external ophthalmoplegia; tRNA(Asn); mitochondrial myopathy
ID TRANSFER-RNA MUTATIONS; DNA MUTATIONS; MYOPATHY; OPHTHALMOPLEGIA;
   DISORDERS; FAILURE; DISEASE; MUSCLE
AB Although mutations in mitochondrial tRNAs constitute the most common mtDNA defect, the presence of pathological variants in mitochondrial tRNA(Asn) is extremely rare. We were able to identify a novel mtDNA tRNA(Asn) gene pathogenic mutation associated with a myopathic phenotype and a previously unreported respiratory impairment. Our proband is an adult woman with ophthalmoparesis and respiratory impairment. Her muscle biopsy presented several cytochrome c oxidase-negative (COX-) fibres and signs of mitochondrial proliferation (ragged red fibres). Sequence analysis of the muscle-derived mtDNA revealed an m.5709T>C substitution, affecting mitochondrial tRNAAsn gene. Restriction-fragment length polymorphism analysis of the mutation in isolated muscle fibres showed that a threshold of at least 91.9% mutated mtDNA results in the COX deficiency phenotype. The new phenotype further increases the clinical spectrum of mitochondrial diseases caused by mutations in the tRNAAsn gene. European Journal of Human Genetics (2012) 20, 357-360; doi:10.1038/ejhg.2011.238; published online 21 December 2011
C1 [Ronchi, Dario; Sciacco, Monica; Bordoni, Andreina; Ripolone, Michela; Fassone, Elisa; Di Fonzo, Alessio; Rizzuti, Mafalda; Ciscato, Patrizia; Cosi, Alessandra; Servida, Maura; Moggio, Maurizio; Corti, Stefania; Bresolin, Nereo; Comi, Giacomo P.] Univ Milan, IRCCS Fdn Ca Granda Osped Maggiore Policlin, Dept Neurol Sci, Dino Ferrari Ctr, I-20122 Milan, Italy.
   [Raimondi, Monika] Neuroctr So Switzerland, Dept Neurol, Lugano, Switzerland.
   [Corti, Stefania; Bresolin, Nereo; Comi, Giacomo P.] Univ Milan, Ctr Excellence Neurodegenerat Dis, I-20122 Milan, Italy.
   [Bresolin, Nereo] IRCCS Eugenio Medea, Bosisio Parini, Lecco, Italy.
C3 IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan;
   University of Milan; IRCCS Eugenio Medea
RP Comi, GP (corresponding author), Univ Milan, IRCCS Fdn Ca Granda Osped Maggiore Policlin, Dept Neurol Sci, Dino Ferrari Ctr, Via Francesco Sforza 35, I-20122 Milan, Italy.
EM giacomo.comi@unimi.it
RI Rizzuti, Mafalda/AAC-2407-2022; Sciacco, Monica/AAC-6500-2022; Comi,
   Giacomo/K-5702-2016; Ronchi, Dario/K-8011-2016; Di Fonzo,
   Alessio/A-5702-2013; corti, stefania/K-6034-2016
OI Ronchi, Dario/0000-0002-6093-9816; Rizzuti, Mafalda/0000-0001-5734-7476;
   corti, stefania/0000-0001-5425-969X; Sciacco,
   Monica/0000-0003-4593-4977; Ripolone, Michela/0000-0001-9293-6823; Comi,
   Giacomo/0000-0002-1383-5248; Bresolin, Nereo/0000-0001-6694-3595; Di
   Fonzo, Alessio/0000-0001-6478-026X
FU Telethon - UILDM [GUP09004]; Associazione Amici del Centro Dino Ferrari;
   University of Milan; Telethon [GTB07001]; Eurobiobank [QLTR-2001-02769,
   RF 02.187]
FX Gratitude has to be expressed to the patient for participating in this
   research. We wish to thank especially the 'Associazione Amici del Centro
   Dino Ferrari' for their support. The financial support of the following
   research grant is gratefully acknowledged: Telethon - UILDM Project
   GUP09004 'Construction of a database for a nation-wide Italian
   collaborative network of mitochondrial diseases', Associazione Amici del
   Centro Dino Ferrari, University of Milan, the Telethon project GTB07001,
   the Eurobiobank project QLTR-2001-02769 and RF 02.187 Criobanca
   Automatizzata di Materiale Biologico.
CR Coulbault L, 2005, BIOCHEM BIOPH RES CO, V329, P1152, DOI 10.1016/j.bbrc.2005.02.083
   CROS D, 1992, CHEST, V101, P824, DOI 10.1378/chest.101.3.824
   Hutchinson David, 2008, Pract Neurol, V8, P229, DOI 10.1136/pn.2008.152611
   McFarland R, 2004, TRENDS GENET, V20, P591, DOI 10.1016/j.tig.2004.09.014
   Meulemans A, 2006, ARCH NEUROL-CHICAGO, V63, P1194, DOI 10.1001/archneur.63.8.1194
   MORAES CT, 1993, J CLIN INVEST, V92, P2906, DOI 10.1172/JCI116913
   MORAES CT, 1992, AM J HUM GENET, V50, P934
   Moraes CT, 2003, J MOL DIAGN, V5, P197, DOI 10.1016/S1525-1578(10)60474-6
   Scaglia F, 2008, MUSCLE NERVE, V37, P150, DOI 10.1002/mus.20917
   Sciacco M, 2001, J NEUROL, V248, P778, DOI 10.1007/s004150170094
   SCIACCO M, 1994, HUM MOL GENET, V3, P13, DOI 10.1093/hmg/3.1.13
   SEIBEL P, 1994, BIOCHEM BIOPH RES CO, V204, P482, DOI 10.1006/bbrc.1994.2485
   Spinazzola A, 2004, NEUROMUSCULAR DISORD, V14, P815, DOI 10.1016/j.nmd.2004.09.002
   Sternberg D, 2001, BRAIN, V124, P984, DOI 10.1093/brain/124.5.984
   Vives-Bauza C, 2003, J INHERIT METAB DIS, V26, P507, DOI 10.1023/A:1025133629685
   ZEVIANI M, 1990, ANN NEUROL, V28, P94, DOI 10.1002/ana.410280118
   Zifa E, 2007, RNA BIOL, V4, P38, DOI 10.4161/rna.4.1.4548
NR 17
TC 5
Z9 5
U1 0
U2 1
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1018-4813
EI 1476-5438
J9 EUR J HUM GENET
JI Eur. J. Hum. Genet.
PD MAR
PY 2012
VL 20
IS 3
BP 357
EP 360
DI 10.1038/ejhg.2011.238
PG 4
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 896XI
UT WOS:000300604300017
PM 22189266
OA Green Published, Bronze
DA 2024-11-01
ER

PT J
AU Peverelli, L
   Gold, CA
   Naini, AB
   Tanji, K
   Akman, HO
   Hirano, M
   DiMauro, S
AF Peverelli, Lorenzo
   Gold, Carl A.
   Naini, Ali B.
   Tanji, Kurenai
   Akman, H. Orhan
   Hirano, Michio
   DiMauro, Salvatore
TI MITOCHONDRIAL MYOPATHY WITH DYSTROPHIC FEATURES DUE TO A NOVEL MUTATION
   IN THE <i>MTTM</i> GENE
SO MUSCLE & NERVE
LA English
DT Article
DE de novo mutation; dystrophic features; late-onset weakness;
   mitochondrial myopathy; mtDNA; tRNAMet
ID TRNA(TRP) GENE; POINT MUTATION; DNA; DISEASE
AB Introduction: A 61-year-old woman with a 5-year history of progressive muscle weakness and atrophy had a muscle biopsy characterized by a combination of dystrophic features (necrotic fibers and endomysial fibrosis) and mitochondrial alterations [ragged-red, cytochrome c oxidase (COX)-negative fibers]. Methods: Sequencing of the whole mtDNA, assessment of the mutation load in muscle and accessible nonmuscle tissues, and single fiber polymerase chain reaction. Results: Muscle mitochondrial DNA (mtDNA) sequencing revealed a novel heteroplasmic mutation (m.4403G>A) in the gene (MTTM) that encodes tRNA(Met). The mutation was not present in accessible nonmuscle tissues from the patient or 2 asymptomatic sisters. Conclusions: The clinical features and muscle morphology in this patient are very similar to those described in a previous patient with a different mutation, also in MTTM, which suggests that mutations in this gene confer a distinctive "dystrophic" quality. This may be a diagnostic clue in patients with isolated mitochondrial myopathy.
C1 [Peverelli, Lorenzo; Gold, Carl A.; Tanji, Kurenai; Akman, H. Orhan; Hirano, Michio; DiMauro, Salvatore] Columbia Univ, Coll Phys & Surg, Dept Neurol, Med Ctr, New York, NY 10027 USA.
   [Naini, Ali B.; Tanji, Kurenai] Columbia Univ, Coll Phys & Surg, Dept Pathol, Med Ctr, New York, NY USA.
C3 Columbia University; Columbia University
RP DiMauro, S (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Neurol, Med Ctr, 630 W 168th St, New York, NY 10027 USA.
EM sd12@columbia.edu
OI Peverelli, Lorenzo/0000-0001-6175-025X
FU NICHD [P01HD032062]; NINDS/NICHD [U54NS078059]; Marriott Mitochondrial
   Disorder Clinical Research Fund (MMDCRF)
FX Supported by grants from NICHD (P01HD032062), NINDS/NICHD (U54NS078059),
   and by the Marriott Mitochondrial Disorder Clinical Research Fund
   (MMDCRF).
CR Baric I, 2013, EUR J HUM GENET, V21, P871, DOI 10.1038/ejhg.2012.272
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   DiMauro S, 2013, NAT REV NEUROL, V9, P429, DOI 10.1038/nrneurol.2013.126
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Greaves LC, 2012, J PATHOL, V226, P274, DOI 10.1002/path.3028
   Jeppesen TD, 2014, NEUROMUSCULAR DISORD, V24, P162, DOI 10.1016/j.nmd.2013.08.004
   Lombes A, 1998, HUM MUTAT, pS175
   Moslemi AR, 2004, NEUROMUSCULAR DISORD, V14, P46, DOI 10.1016/S0960-8966(03)00168-8
   Schon EA, 2012, NAT REV GENET, V13, P878, DOI 10.1038/nrg3275
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   Silvestri G, 1998, NEUROMUSCULAR DISORD, V8, P291, DOI 10.1016/S0960-8966(98)00037-6
   Tanaka M, 2004, GENOME RES, V14, P1832, DOI 10.1101/gr.2286304
   Tanji K, 2001, METHOD CELL BIOL, V65, P311, DOI 10.1016/S0091-679X(01)65019-2
   Vissing J, 1998, NEUROLOGY, V50, P1875, DOI 10.1212/WNL.50.6.1875
NR 14
TC 7
Z9 7
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0148-639X
EI 1097-4598
J9 MUSCLE NERVE
JI Muscle Nerve
PD AUG
PY 2014
VL 50
IS 2
BP 292
EP 295
DI 10.1002/mus.24262
PG 4
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA AM9YN
UT WOS:000340237500022
PM 24711008
OA Green Accepted
DA 2024-11-01
ER

PT J
AU Kwon, MJ
   Ki, CS
   Kim, JY
   Lee, ST
   Kim, JW
   Kang, SY
AF Kwon, Min-Jung
   Ki, Chang-Seok
   Kim, Ji-Youn
   Lee, Seung-Tae
   Kim, Jong-Won
   Kang, Sa-Yoon
TI Multiplex Ligation-Dependent Probe Amplification (MLPA) Assay for the
   Detection of Mitochondrial DNA Deletion in Chronic Progressive External
   Ophthalmoplegia (CPEO)
SO ANNALS OF CLINICAL AND LABORATORY SCIENCE
LA English
DT Article
DE Chronic Progressive External Ophthalmoplegia; CPEO; Mitochondrial DNA;
   deletion; Multiplex ligation-dependent probe amplification; MLPA
AB Chronic progressive external ophthalmoplegia (CPEO) is a mitochondrial myopathy commonly caused by deleterious changes in the mitochondrial DNA (mtDNA). We describe a 45-year-old man who was referred to us for investigation of progressive ptosis. We performed a multiplex ligation-dependent probe amplification (MLPA) assay of mtDNA from muscle tissue and peripheral blood leukocytes, and followed up with gap-polymerase chain reaction (PCR) and direct sequence analysis. Results showed a deletion of a 4,407 bp segment in the mtDNA region, ranging from nucleotide position 8,577 in the MT-ATP6 gene to nucleotide position 12,983 in the MT-ND5 gene. To the best of our knowledge, this is the first report of a CPEO patient with a large novel deletion of mtDNA genetically confirmed by MLPA assay. MLPA can be a feasible platform for clinical laboratories to detect large deletion mutations in the mtDNA for suspected cases.
C1 [Ki, Chang-Seok; Lee, Seung-Tae; Kim, Jong-Won] Sungkyunkwan Univ, Dept Lab Med & Genet, Samsung Med Ctr, Sch Med, Seoul 135710, South Korea.
   [Kwon, Min-Jung] Sungkyunkwan Univ, Dept Lab Med, Kangbuk Samsung Hosp, Sch Med, Seoul 135710, South Korea.
   [Kim, Ji-Youn] Samsung Biomed Res Inst, Clin Res Ctr, Seoul, South Korea.
   [Kang, Sa-Yoon] Jeju Natl Univ, Dept Neurol, Coll Med, Cheju 690756, Jeju Do, South Korea.
C3 Sungkyunkwan University (SKKU); Samsung Medical Center; Sungkyunkwan
   University (SKKU); Samsung Medical Center; Sungkyunkwan University
   (SKKU); Samsung Medical Center; Samsung; Jeju National University
RP Ki, CS (corresponding author), Sungkyunkwan Univ, Dept Lab Med & Genet, Samsung Med Ctr, Sch Med, 50 Irwon Dong, Seoul 135710, South Korea.
EM changski@skku.edu; neurokang@jejunu.ac.k
RI LEE, ST/KPA-8144-2024; Kim, Jong/C-9615-2011; Ki, Chang-Seok/G-7559-2014
OI Ki, Chang-Seok/0000-0001-7679-8731
FU National Research Foundation of Korea (NRF); Korea government (MEST)
   [2010-0004450]
FX This work was supported by the National Research Foundation of Korea
   (NRF) grant funded by the Korea government (MEST) (No. 2010-0004450).
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   DiMauro S., 1993, GENEREVIEWS
   Gellerich FN, 2002, BBA-BIOENERGETICS, V1556, P41, DOI 10.1016/S0005-2728(02)00305-5
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Leonard JV, 2000, LANCET, V355, P299, DOI 10.1016/S0140-6736(99)05225-3
   MITA S, 1990, NUCLEIC ACIDS RES, V18, P561, DOI 10.1093/nar/18.3.561
   ROTIG A, 1989, LANCET, V1, P902
   Schapira AHV, 2006, LANCET, V368, P70, DOI 10.1016/S0140-6736(06)68970-8
   SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184
   Taylor RW, 2003, ANN NEUROL, V54, P521, DOI 10.1002/ana.10673
   Wong LJC, 2005, CLIN CHIM ACTA, V354, P1, DOI 10.1016/j.cccn.2004.11.003
   Yamashita S, 2008, J HUM GENET, V53, P598, DOI 10.1007/s10038-008-0289-8
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
NR 14
TC 6
Z9 6
U1 0
U2 9
PU ASSOC CLINICAL SCIENTISTS
PI MIDDLEBURY
PA PO BOX 1287, MIDDLEBURY, VT 05753 USA
SN 0091-7370
EI 1550-8080
J9 ANN CLIN LAB SCI
JI Ann. Clin. Lab. Sci.
PD FAL
PY 2011
VL 41
IS 4
BP 385
EP 389
PG 5
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology
GA 872PP
UT WOS:000298822100013
PM 22166510
DA 2024-11-01
ER

PT J
AU Urban, DL
   Scholle, LM
   Alt, K
   Ludolph, AC
   Rosenbohm, A
AF Urban, Diana Lehmann
   Scholle, Leila Motlagh
   Alt, Kerstin
   Ludolph, Albert C.
   Rosenbohm, Angela
TI Camptocormia as a Novel Phenotype in a Heterozygous <i>POLG2</i>
   Mutation
SO DIAGNOSTICS
LA English
DT Article
DE mitochondrial myopathy; polymerase gamma 2 (POLG2); camptocormia;
   mutations of nuclear origin
ID MITOCHONDRIAL; MYOPATHY; SPECTRUM; MTDNA
AB Mitochondrial dysfunction is known to play a key role in the pathophysiological pathway of neurodegenerative disorders. Nuclear-encoded proteins are involved in mtDNA replication, including DNA polymerase gamma, which is the only known replicative mtDNA polymerase, encoded by nuclear genes Polymerase gamma 1 (POLG) and Polymerase gamma 2 (POLG2). POLG mutations are well-known as a frequent cause of mitochondrial myopathies of nuclear origin. However, only rare descriptions of POLG2 mutations leading to mitochondriopathies exist. Here we describe a 68-year-old woman presenting with a 20-year history of camptocormia, mild proximal weakness, and moderate CK increase. Muscle histology showed COX-negative fibres. Genetic analysis by next generation sequencing revealed an already reported heterozygous c.1192-8_1207dup24 mutation in the POLG2 gene. This is the first report on a POLG2 mutation leading to camptocormia as the main clinical phenotype, extending the phenotypic spectrum of POLG2 associated diseases. This underlines the broad phenotypic spectrum found in mitochondrial diseases, especially in mitochondrial disorders of nuclear origin.
C1 [Urban, Diana Lehmann; Ludolph, Albert C.; Rosenbohm, Angela] Univ Ulm, Dept Neurol, D-89081 Ulm, Germany.
   [Scholle, Leila Motlagh] Univ Halle S, Dept Neurol, D-06120 Halle, Germany.
   [Alt, Kerstin] Genetikum, D-89231 Neu, Germany.
C3 Ulm University; Martin Luther University Halle Wittenberg
RP Urban, DL (corresponding author), Univ Ulm, Dept Neurol, D-89081 Ulm, Germany.
EM diana.lehmann@rku.de
RI Rosenbohm, Angela/GOJ-9292-2022
OI Motlagh Scholle, Leila/0000-0003-1363-4726
FU Hertha-Nathorff-Programm (HNP) of the Ulm Medical University, Germany -
   German Ministry of Education and Research
FX D.L.U. is funded by the Hertha-Nathorff-Programm (HNP) of the Ulm
   Medical University, Germany. D.L.U. and L.M.S. are members of the German
   mitoNET funded by the German Ministry of Education and Research.
CR Ali F, 2018, NEUROL-CLIN PRACT, V8, P240, DOI 10.1212/CPJ.0000000000000453
   Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393
   Béreau M, 2016, J NEUROL SCI, V368, P70, DOI 10.1016/j.jns.2016.06.062
   Chanson JB, 2016, EUR J NEUROL, V23, P1086, DOI 10.1111/ene.12989
   Cingolani P, 2012, FLY, V6, P80, DOI 10.4161/fly.19695
   Copeland WC, 2014, J CHILD NEUROL, V29, P1216, DOI 10.1177/0883073814537380
   Da Pozzo P, 2017, NEUROL SCI, V38, P563, DOI 10.1007/s10072-016-2734-3
   Delcey V, 2002, REV MED INTERNE, V23, P144, DOI 10.1016/S0248-8663(01)00530-6
   den Dunnen JT, 2016, HUM MUTAT, V37, P564, DOI 10.1002/humu.22981
   El-Hattab A, 2013, NEUROTHERAPEUTICS, V10, P186, DOI 10.1007/s13311-013-0177-6
   Garrison E., 2012, ARXIV12073907
   Gellerich FN, 2002, BBA-BIOENERGETICS, V1556, P41, DOI 10.1016/S0005-2728(02)00305-5
   Gómez-Puerta JA, 2007, CLIN RHEUMATOL, V26, P1017, DOI 10.1007/s10067-006-0259-5
   Jungbluth H, 2007, ORPHANET J RARE DIS, V2, DOI 10.1186/1750-1172-2-25
   Landrum MJ, 2018, NUCLEIC ACIDS RES, V46, pD1062, DOI 10.1093/nar/gkx1153
   Lehmann D, 2015, NEUROMUSCULAR DISORD, V25, P81, DOI 10.1016/j.nmd.2014.09.008
   Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057
   Li Heng, 2013, PREPRINT, DOI DOI 10.48550/ARXIV.1303.3997
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Mose LE, 2014, BIOINFORMATICS, V30, P2813, DOI 10.1093/bioinformatics/btu376
   Paolini C, 2015, SKELET MUSCLE, V5, DOI 10.1186/s13395-015-0035-9
   POULLIN P, 1993, REV RHUM, V60, P159
   Reichmann H, 1996, EUR NEUROL, V36, P98, DOI 10.1159/000117217
   Reimann J, 2017, NEUROL-GENET, V3, DOI 10.1212/NXG.0000000000000147
   Sakiyama Y, 2011, ACTA NEUROPATHOL, V121, P775, DOI 10.1007/s00401-011-0818-y
   Schäbitz WR, 2003, MOVEMENT DISORD, V18, P408, DOI 10.1002/mds.10385
   Serratrice G, 1996, J NEUROL NEUROSUR PS, V60, P51, DOI 10.1136/jnnp.60.1.51
   Sewry CA, 2002, NEUROMUSCULAR DISORD, V12, P930, DOI 10.1016/S0960-8966(02)00135-9
   Stewart JD, 2009, J MED GENET, V46, P209, DOI 10.1136/jmg.2008.058180
   Sturm M, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859-016-1069-7
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Maldergem L, 2017, ANN CLIN TRANSL NEUR, V4, P4, DOI 10.1002/acn3.361
   Varma H, 2016, EUR J MED GENET, V59, P540, DOI 10.1016/j.ejmg.2016.08.012
   Walter MC, 2010, J NEUROL, V257, P1517, DOI 10.1007/s00415-010-5565-9
   Young MJ, 2011, HUM MOL GENET, V20, P3052, DOI 10.1093/hmg/ddr209
   Zierz CM, 2015, NEUROPATHOLOGY, V35, P130, DOI 10.1111/neup.12173
NR 36
TC 3
Z9 3
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2075-4418
J9 DIAGNOSTICS
JI Diagnostics
PD FEB
PY 2020
VL 10
IS 2
AR 68
DI 10.3390/diagnostics10020068
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA KU2LZ
UT WOS:000519541300043
PM 31991853
OA gold, Green Published
DA 2024-11-01
ER

PT J
AU Bacman, SR
   Williams, SL
   Duan, D
   Moraes, CT
AF Bacman, S. R.
   Williams, S. L.
   Duan, D.
   Moraes, C. T.
TI Manipulation of mtDNA heteroplasmy in all striated muscles of newborn
   mice by AAV9-mediated delivery of a mitochondria-targeted restriction
   endonuclease
SO GENE THERAPY
LA English
DT Article
DE mtDNA; heteroplasmy; AAV9; myopathy; mouse model
ID ADENOASSOCIATED VIRUS; DNA HETEROPLASMY; GENE-EXPRESSION; TRANSDUCTION;
   MUTATION; DISEASE; SELECTION; VECTORS; THERAPY; ROUTE
AB Mitochondrial diseases are frequently caused by heteroplasmic mitochondrial DNA (mtDNA) mutations. As these mutations express themselves only at high relative ratios, any approach able to manipulate mtDNA heteroplasmy can potentially be curative. In this study, we developed a system to manipulate mtDNA heteroplasmy in all skeletal muscles from neonate mice. We selected muscle because it is one of the most clinically affected tissues in mitochondrial disorders. A mitochondria-targeted restriction endonuclease (mito-ApaLI) expressed from AAV9 particles was delivered either by intraperitoneal or intravenous injection in neonate mice harboring two mtDNA haplotypes, only one of which was susceptible to ApaLI digestion. A single injection was able to elicit a predictable and marked change in mtDNA heteroplasmy in all striated muscles analyzed, including heart. No health problems or reduction in mtDNA levels were observed in treated mice, suggesting that this approach could have clinical applications for mitochondrial myopathies.
C1 [Bacman, S. R.; Williams, S. L.; Moraes, C. T.] Univ Miami, Sch Med, Dept Neurol, Miami, FL 33136 USA.
   [Duan, D.] Univ Missouri, Sch Med, Dept Mol Biol & Immunol, Columbia, MO USA.
   [Moraes, C. T.] Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33136 USA.
C3 University of Miami; University of Missouri System; University of
   Missouri Columbia; University of Miami
RP Moraes, CT (corresponding author), Univ Miami, Sch Med, Dept Neurol, 1420 NW 9th Ave, Miami, FL 33136 USA.
EM cmoraes@med.miami.edu
RI Moraes, Carlos/AAT-3818-2021
OI Duan, Dongsheng/0000-0003-4109-1132
FU NIH [EY010804, AG036871]; Muscular Dystrophy Association
FX This work was supported by NIH grant EY010804, AG036871 and the Muscular
   Dystrophy Association.
CR Alexeyev MF, 2008, GENE THER, V15, P516, DOI 10.1038/sj.gt.2008.11
   Bacman SR, 2007, GENE THER, V14, P1309, DOI 10.1038/sj.gt.3302981
   Bacman SR, 2010, GENE THER, V17, P713, DOI 10.1038/gt.2010.25
   Bacman SR, 2009, NUCLEIC ACIDS RES, V37, P4218, DOI 10.1093/nar/gkp348
   Battersby BJ, 2003, NAT GENET, V33, P183, DOI 10.1038/ng1073
   Battersby BJ, 2001, HUM MOL GENET, V10, P2469, DOI 10.1093/hmg/10.22.2469
   Bayona-Bafaluy MP, 2005, P NATL ACAD SCI USA, V102, P14392, DOI 10.1073/pnas.0502896102
   Blankinship MJ, 2004, MOL THER, V10, P671, DOI 10.1016/j.ymthe.2004.07.016
   Bostick B, 2007, GENE THER, V14, P1605, DOI 10.1038/sj.gt.3303029
   Chiaratti MR, 2011, MITOCHONDRION, V11, P820, DOI 10.1016/j.mito.2010.11.004
   Cwerman-Thibault H, 2011, J INHERIT METAB DIS, V34, P327, DOI 10.1007/s10545-010-9131-5
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Foust KD, 2009, NAT BIOTECHNOL, V27, P59, DOI 10.1038/nbt.1515
   Ghosh A, 2007, MOL THER, V15, P750, DOI 10.1038/sj.mt.6300081
   Händel EM, 2011, CURR GENE THER, V11, P28, DOI 10.2174/156652311794520120
   Inagaki K, 2006, MOL THER, V14, P45, DOI 10.1016/j.ymthe.2006.03.014
   Jenuth JP, 1997, NAT GENET, V16, P93, DOI 10.1038/ng0597-93
   Kyriakouli DS, 2008, GENE THER, V15, P1017, DOI 10.1038/gt.2008.91
   Lai Y, 2005, NAT BIOTECHNOL, V23, P1435, DOI 10.1038/nbt1153
   Lightowlers RN, 1997, TRENDS GENET, V13, P450, DOI 10.1016/S0168-9525(97)01266-3
   Minczuk M, 2010, METHODS MOL BIOL, V649, P257, DOI 10.1007/978-1-60761-753-2_16
   MORAES CT, 1992, AM J HUM GENET, V50, P934
   Moreno-Loshuertos R, 2006, NAT GENET, V38, P1261, DOI 10.1038/ng1897
   Ogura T, 2006, J GENE MED, V8, P990, DOI 10.1002/jgm.916
   Pacak CA, 2006, CIRC RES, V99, pE3, DOI 10.1161/01.RES.0000237661.18885.f6
   Pettman R, 2007, J Inherit Metab Dis, V30, P404, DOI 10.1007/s10545-007-0460-y
   Poulton J, 2000, Neuromuscul Disord, V10, P460, DOI 10.1016/S0960-8966(00)00101-2
   Pruchnic R, 2000, HUM GENE THER, V11, P521, DOI 10.1089/10430340050015716
   Rossignol R, 2003, BIOCHEM J, V370, P751, DOI 10.1042/BJ20021594
   Srivastava S, 2001, HUM MOL GENET, V10, P3093, DOI 10.1093/hmg/10.26.3093
   Tanaka M, 2002, J BIOMED SCI, V9, P534, DOI 10.1007/BF02254980
   TATUCH Y, 1992, AM J HUM GENET, V50, P852
   Thorburn DR, 2001, AM J MED GENET, V106, P102, DOI 10.1002/ajmg.1380
   Tsao CY, 2001, J CHILD NEUROL, V16, P533, DOI 10.1177/088307380101600716
   Uusimaa J, 2000, PEDIATRICS, V105, P598, DOI 10.1542/peds.105.3.598
   Wenz T, 2010, DEV DISABIL RES REV, V16, P219, DOI 10.1002/ddrr.109
   Zincarelli C, 2008, MOL THER, V16, P1073, DOI 10.1038/mt.2008.76
NR 37
TC 60
Z9 65
U1 0
U2 14
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0969-7128
EI 1476-5462
J9 GENE THER
JI Gene Ther.
PD NOV
PY 2012
VL 19
IS 11
BP 1101
EP 1106
DI 10.1038/gt.2011.196
PG 6
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Research & Experimental Medicine
GA 034AA
UT WOS:000310841300008
PM 22130448
OA Green Accepted, Bronze
DA 2024-11-01
ER

PT J
AU Grady, JP
   Campbell, G
   Ratnaike, T
   Blakely, EL
   Falkous, G
   Nesbitt, V
   Schaefer, AM
   McNally, RJ
   Gorman, GS
   Taylor, RW
   Turnbull, DM
   McFarland, R
AF Grady, John P.
   Campbell, Georgia
   Ratnaike, Thiloka
   Blakely, Emma L.
   Falkous, Gavin
   Nesbitt, Victoria
   Schaefer, Andrew M.
   McNally, Richard J.
   Gorman, Grainne S.
   Taylor, Robert W.
   Turnbull, Doug M.
   McFarland, Robert
TI Disease progression in patients with single, large-scale mitochondrial
   DNA deletions
SO BRAIN
LA English
DT Article
DE mitochondrial diseases; mitochondrial DNA deletion; disease progression
ID REAL-TIME PCR; PARKINSONS-DISEASE; EXTERNAL OPHTHALMOPLEGIA; MTDNA;
   HETEROPLASMY; FEATURES; MUTATIONS; THRESHOLD; COGNITION; DEMENTIA
AB Single, large-scale deletions of mitochondrial DNA are an important cause of mitochondrial disease, with a broad phenotypic spectrum. Grady et al. report that disease severity and progression are correlated with the size of the deletion, its location within the genome, and the deletion heteroplasmy level in skeletal muscle.Single, large-scale deletions of mitochondrial DNA are a common cause of mitochondrial disease and cause a broad phenotypic spectrum ranging from mild myopathy to devastating multi-system syndromes such as Kearns-Sayre syndrome. Studies to date have been inconsistent on the value of putative predictors of clinical phenotype and disease progression such as mutation load and the size or location of the deletion. Using a cohort of 87 patients with single, large-scale mitochondrial DNA deletions we demonstrate that a variety of outcome measures such as COX-deficient fibre density, age-at-onset of symptoms and progression of disease burden, as measured by the Newcastle Mitochondrial Disease Adult Scale, are significantly (P < 0.05) correlated with the size of the deletion, the deletion heteroplasmy level in skeletal muscle, and the location of the deletion within the genome. We validate these findings with re-analysis of 256 cases from published data and clarify the previously conflicting information of the value of these predictors, identifying that multiple regression analysis is necessary to understand the effect of these interrelated predictors. Furthermore, we have used mixed modelling techniques to model the progression of disease according to these predictors, allowing a better understanding of the progression over time of this strikingly variable disease. In this way we have developed a new paradigm in clinical mitochondrial disease assessment and management that sidesteps the perennial difficulty of ascribing a discrete clinical phenotype to a broad multi-dimensional and progressive spectrum of disease, establishing a framework to allow better understanding of disease progression.
C1 [Grady, John P.; Campbell, Georgia; Ratnaike, Thiloka; Blakely, Emma L.; Falkous, Gavin; Nesbitt, Victoria; Schaefer, Andrew M.; Gorman, Grainne S.; Taylor, Robert W.; Turnbull, Doug M.; McFarland, Robert] Newcastle Univ, Inst Ageing & Hlth, Wellcome Trust Ctr Mitochondrial Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [McNally, Richard J.] Newcastle Univ, Inst Hlth & Soc, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
C3 Newcastle University - UK; Newcastle University - UK
RP Turnbull, DM (corresponding author), Newcastle Univ, Inst Ageing & Hlth, Wellcome Trust Ctr Mitochondrial Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM doug.turnbull@newcastle.ac.uk; robert.mcfarland@newcastle.ac.uk
RI Ratnaike, Thiloka/GNM-9569-2022
OI Grady, John/0000-0001-9667-3872; Schaefer, Andrew/0000-0001-9891-7332;
   McNally, Richard/0000-0001-6685-6467; Turnbull,
   Doug/0000-0002-8878-9901; Ratnaike, Thiloka/0000-0001-5400-104X;
   McFarland, Robert/0000-0002-8833-2688; Gorman,
   Grainne/0000-0002-7585-3409
FU Wellcome Trust Centre for Mitochondrial Research [G906919]; Newcastle
   University Centre for Brain Ageing and Vitality; Biotechnology and
   Biological Sciences Research Council; Engineering and Physical Sciences
   Research Council; Economic and Social Research Council; Medical Research
   Council [G0700718]; MRC Centre for Neuromuscular Disease [G000608-1];
   MRC Centre for Translational Research in Neuromuscular Disease
   Mitochondrial Disease Patient Cohort (UK) [G0800674]; Lily Foundation;
   UK NIHR Biomedical Research Centre in Age and Age Related Diseases
   award; UK NHS Specialist Commissioners 'Rare Mitochondrial Disorders of
   Adults and Children' Service; Wellcome Trust [090194/Z/09/Z]; Wellcome
   Trust [090194/Z/09/Z] Funding Source: Wellcome Trust; MRC [G0700718,
   MR/K000608/1, G0800674] Funding Source: UKRI
FX This work was funded by The Wellcome Trust Centre for Mitochondrial
   Research [G906919], Newcastle University Centre for Brain Ageing and
   Vitality (supported by the Biotechnology and Biological Sciences
   Research Council, Engineering and Physical Sciences Research Council,
   Economic and Social Research Council and Medical Research Council
   [G0700718]), MRC Centre for Neuromuscular Disease [G000608-1], The MRC
   Centre for Translational Research in Neuromuscular Disease Mitochondrial
   Disease Patient Cohort (UK) [G0800674], Lily Foundation, the UK NIHR
   Biomedical Research Centre in Age and Age Related Diseases award to the
   Newcastle upon Tyne Hospitals NHS Foundation Trust and UK NHS Specialist
   Commissioners 'Rare Mitochondrial Disorders of Adults and Children'
   Service. JPG was funded by a Wellcome Trust Studentship [090194/Z/09/Z].
CR AKAIKE H, 1974, IEEE T AUTOMAT CONTR, VAC19, P716, DOI 10.1109/TAC.1974.1100705
   Apabhai S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022294
   Auré K, 2007, BRAIN, V130, P1516, DOI 10.1093/brain/awm067
   Bates MGD, 2013, EUR HEART J-CARD IMG, V14, P650, DOI 10.1093/ehjci/jes226
   Blackwood JK, 2010, BIOCHEM BIOPH RES CO, V393, P740, DOI 10.1016/j.bbrc.2010.02.072
   BOX GEP, 1964, J ROY STAT SOC B, V26, P211, DOI 10.1111/j.2517-6161.1964.tb00553.x
   de Laat P, 2012, J INHERIT METAB DIS, V35, P1059, DOI 10.1007/s10545-012-9465-2
   den Heijer T, 2010, BRAIN, V133, P1163, DOI 10.1093/brain/awq048
   Diggle P., 2002, ANAL LONGITUDINAL DA, V2nd ed.
   Dobkin RD, 2011, AM J PSYCHIAT, V168, P1066, DOI 10.1176/appi.ajp.2011.10111669
   Elliott HR, 2008, AM J HUM GENET, V83, P254, DOI 10.1016/j.ajhg.2008.07.004
   Enns GM, 2012, MOL GENET METAB, V105, P91, DOI 10.1016/j.ymgme.2011.10.009
   Galvin JE, 2005, ARCH NEUROL-CHICAGO, V62, P758, DOI 10.1001/archneur.62.5.758
   Gellerich FN, 2002, BBA-BIOENERGETICS, V1556, P41, DOI 10.1016/S0005-2728(02)00305-5
   GOTO Y, 1990, J NEUROL SCI, V100, P63, DOI 10.1016/0022-510X(90)90014-E
   Hassing LB, 2004, J INT NEUROPSYCH SOC, V10, P599, DOI 10.1017/S1355617704104165
   He LP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf067
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   HOLT IJ, 1989, ANN NEUROL, V26, P699, DOI 10.1002/ana.410260603
   Ishikawa Y, 2000, J CHILD NEUROL, V15, P750, DOI 10.1177/088307380001501107
   Jacobs LJAM, 2004, J INHERIT METAB DIS, V27, P47, DOI 10.1023/B:BOLI.0000016601.49372.18
   JOHNS DR, 1989, P NATL ACAD SCI USA, V86, P8059, DOI 10.1073/pnas.86.20.8059
   Johnson DK, 2011, DEMENT GERIATR COGN, V31, P98, DOI 10.1159/000323570
   Johnson DK, 2009, ARCH NEUROL-CHICAGO, V66, P1254, DOI 10.1001/archneurol.2009.158
   KEARNS TP, 1958, ARCH OPHTHALMOL-CHIC, V60, P280, DOI 10.1001/archopht.1958.00940080296016
   Khrapko K, 1999, NUCLEIC ACIDS RES, V27, P2434, DOI 10.1093/nar/27.11.2434
   Knopman DS, 2009, ALZHEIMERS DEMENT, V5, P207, DOI 10.1016/j.jalz.2009.01.027
   Kornblum C, 2013, NAT GENET, V45, P214, DOI 10.1038/ng.2501
   Krishnan KJ, 2007, ANAL BIOCHEM, V370, P127, DOI 10.1016/j.ab.2007.06.024
   Kuha J, 2004, SOCIOL METHOD RES, V33, P188, DOI 10.1177/0049124103262065
   LARSSON NG, 1992, BIOCHIM BIOPHYS ACTA, V1139, P311, DOI 10.1016/0925-4439(92)90106-W
   Lax NZ, 2012, J NEUROPATH EXP NEUR, V71, P148, DOI 10.1097/NEN.0b013e318244477d
   López-Gallardo E, 2009, MITOCHONDRION, V9, P314, DOI 10.1016/j.mito.2009.04.005
   Mancuso M, 2013, NEUROL SCI, V34, P71, DOI 10.1007/s10072-011-0901-0
   McFarland R, 2010, LANCET NEUROL, V9, P829, DOI 10.1016/S1474-4422(10)70116-2
   Meier DS, 2007, NEUROTHERAPEUTICS, V4, P485, DOI 10.1016/j.nurt.2007.05.008
   MITA S, 1989, P NATL ACAD SCI USA, V86, P9509, DOI 10.1073/pnas.86.23.9509
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Moser EB, 2004, P 29 SAS US GROUP IN
   Nandhagopal R, 2009, BRAIN, V132, P2970, DOI 10.1093/brain/awp209
   OLD SL, 1989, HISTOCHEM J, V21, P545, DOI 10.1007/BF01753355
   OLDFORS A, 1992, J NEUROL SCI, V110, P169, DOI 10.1016/0022-510X(92)90025-G
   Orsucci D, 2012, NEUROEPIDEMIOLOGY, V38, P195, DOI 10.1159/000337161
   PEARSON HA, 1979, J PEDIATR-US, V95, P976, DOI 10.1016/S0022-3476(79)80286-3
   Perneger TV, 1998, BRIT MED J, V316, P1236, DOI 10.1136/bmj.316.7139.1236
   Rossignol R, 2003, BIOCHEM J, V370, P751, DOI 10.1042/BJ20021594
   ROTIG A, 1995, HUM MOL GENET, V4, P1327, DOI 10.1093/hmg/4.8.1327
   Sadikovic B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015687
   Schaefer AM, 2006, NEUROLOGY, V66, P1932, DOI 10.1212/01.wnl.0000219759.72195.41
   SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184
   Schon EA, 2012, NAT REV GENET, V13, P878, DOI 10.1038/nrg3275
   Singer JD, 1998, J EDUC BEHAV STAT, V23, P323
   Tornatore JB, 2002, GERONTOLOGIST, V42, P497, DOI 10.1093/geront/42.4.497
   Vu TC, 2012, BRIT J CLIN PHARMACO, V74, P267, DOI 10.1111/j.1365-2125.2012.04192.x
   Whittaker RG, 2009, NEUROLOGY, V72, P568, DOI 10.1212/01.wnl.0000342121.91336.4d
   Yamashita S, 2008, J HUM GENET, V53, P598, DOI 10.1007/s10038-008-0289-8
   Yatsuga S, 2012, BBA-GEN SUBJECTS, V1820, P619, DOI 10.1016/j.bbagen.2011.03.015
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
NR 58
TC 83
Z9 88
U1 1
U2 22
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 1460-2156
J9 BRAIN
JI Brain
PD FEB
PY 2014
VL 137
BP 323
EP 334
DI 10.1093/brain/awt321
PN 2
PG 12
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA AA7QB
UT WOS:000331290900006
PM 24277717
OA hybrid, Green Published, Green Submitted
DA 2024-11-01
ER

PT J
AU Gedikbasi, A
   Toksoy, G
   Karaca, M
   Gulec, C
   Balci, MC
   Gunes, D
   Gunes, S
   Aslanger, AD
   Unverengil, G
   Karaman, B
   Basaran, S
   Demirkol, M
   Gokcay, GF
   Uyguner, ZO
AF Gedikbasi, Asuman
   Toksoy, Guven
   Karaca, Meryem
   Gulec, Cagri
   Balci, Mehmet Cihan
   Gunes, Dilek
   Gunes, Seda
   Aslanger, Ayca Dilruba
   Unverengil, Gokcen
   Karaman, Birsen
   Basaran, Seher
   Demirkol, Mubeccel
   Gokcay, Gulden Fatma
   Uyguner, Zehra Oya
TI Clinical and bi-genomic DNA findings of patients suspected to have
   mitochondrial diseases
SO FRONTIERS IN GENETICS
LA English
DT Article
DE mitochondrial diseases; mtDNA; bi-genomic sequencing; exome sequencing;
   differential diagnosis
ID DEFICIENCY; CLASSIFICATION; MUTATIONS; DIAGNOSIS
AB Background: Mitochondrial diseases are the most common group of inherited metabolic disorders, causing difficulties in definite diagnosis due to clinical and genetic heterogeneity. Clinical components are predominantly associated with pathogenic variants shown in nuclear or mitochondrial genomes that affect vital respiratory chain function. The development of high-throughput sequencing technologies has accelerated the elucidation of the genetic etiology of many genetic diseases that previously remained undiagnosed.
   Methods: Thirty affected patients from 24 unrelated families with clinical, radiological, biochemical, and histopathological evaluations considered for mitochondrial diseases were investigated. DNA isolated from the peripheral blood samples of probands was sequenced for nuclear exome and mitochondrial DNA (mtDNA) analyses. MtDNA sequencing was also performed from the muscle biopsy material in one patient. For segregation, Sanger sequencing is performed for pathogenic alterations in five other affected family members and healthy parents.
   Results: Exome sequencing revealed 14 different pathogenic variants in nine genes encoding mitochondrial function peptides (AARS2, EARS2, ECHS1, FBXL4, MICOS13, NDUFAF6, OXCT1, POLG, and TK2) in 12 patients from nine families and four variants in genes encoding important for muscle structure (CAPN3, DYSF, and TCAP) in six patients from four families. Three probands carried pathogenic mtDNA variations in two genes (MT-ATP6 and MT-TL1). Nine variants in five genes are reported for the first time with disease association: (AARS2: c.277C>T/p.(R93*), c.845C>G/p.(S282C); EARS2: c.319C>T/p.(R107C), c.1283delC/p.(P428Lfs*); ECHS1: c.161G>A/p.(R54His); c.202G>A/p.(E68Lys); NDUFAF6: c.479delA/p.(N162Ifs*27); and OXCT1: c.1370C>T/p.(T457I), c.1173-139G>T/p.(?).
   Conclusion: Bi-genomic DNA sequencing clarified genetic etiology in 67% (16/24) of the families. Diagnostic utility by mtDNA sequencing in 13% (3/24) and exome sequencing in 54% (13/24) of the families prioritized searching for nuclear genome pathologies for the first-tier test. Weakness and muscle wasting observed in 17% (4/24) of the families underlined that limb-girdle muscular dystrophy, similar to mitochondrial myopathy, is an essential point for differential diagnosis. The correct diagnosis is crucial for comprehensive genetic counseling of families. Also, it contributes to making treatment-helpful referrals, such as ensuring early access to medication for patients with mutations in the TK2 gene.
C1 [Gedikbasi, Asuman; Karaman, Birsen] Istanbul Univ, Dept Pediat Basic Sci, Inst Child Hlth, Istanbul, Turkiye.
   [Gedikbasi, Asuman; Karaca, Meryem; Balci, Mehmet Cihan; Gunes, Dilek; Gunes, Seda; Demirkol, Mubeccel; Gokcay, Gulden Fatma] Istanbul Univ, Istanbul Fac Med, Dept Pediat, Div Pediat Nutr & Metab, Istanbul, Turkiye.
   [Toksoy, Guven; Gulec, Cagri; Aslanger, Ayca Dilruba; Karaman, Birsen; Basaran, Seher; Uyguner, Zehra Oya] Istanbul Univ, Istanbul Fac Med, Dept Med Genet, Istanbul, Turkiye.
   [Unverengil, Gokcen] Istanbul Univ, Istanbul Fac Med, Dept Pathol, Istanbul, Turkiye.
C3 Istanbul University; Istanbul University; Istanbul University; Istanbul
   University
RP Uyguner, ZO (corresponding author), Istanbul Univ, Istanbul Fac Med, Dept Med Genet, Istanbul, Turkiye.
EM o.uyguner@istanbul.edu.tr
RI Toksoy, Güven/X-5420-2018; Balci, Mehmet/AAG-7160-2020; Gökçay,
   Gülden/B-2342-2013; Karaman, Birsen/AAB-5941-2020; Karaca,
   Meryem/AAO-5629-2020; Gulec, Cagri/AAG-3939-2020; Gedikbasi,
   Asuman/AAE-3613-2020
OI Toksoy, Guven/0000-0002-8103-9980
FU Scientific Research Projects Coordination Unit of Istanbul University
   [TDK-2018-32544]
FX & nbsp;This study was funded by the Scientific Research Projects
   Coordination Unit of Istanbul University, Project No. TDK-2018-32544.
CR Boczonadi V, 2018, FEBS LETT, V592, P703, DOI 10.1002/1873-3468.12962
   Catania A, 2018, J HUM GENET, V63, P563, DOI 10.1038/s10038-018-0423-1
   Desmet FO, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp215
   Dogan T, 2016, BIOINFORMATICS, V32, P2264, DOI 10.1093/bioinformatics/btw114
   Domínguez-González C, 2022, J NEUROL, V269, P3550, DOI 10.1007/s00415-021-10957-0
   Domínguez-González C, 2019, ANN NEUROL, V86, P293, DOI 10.1002/ana.25506
   Fernandez-Eulate G, 2022, J NEUROL NEUROSUR PS, V93, P413, DOI 10.1136/jnnp-2021-328045
   Ferreira CR, 2021, J INHERIT METAB DIS, V44, P164, DOI 10.1002/jimd.12348
   Fitzsimons PE, 2018, AM J MED GENET A, V176, P1115, DOI 10.1002/ajmg.a.38658
   Gai XW, 2013, AM J HUM GENET, V93, P482, DOI 10.1016/j.ajhg.2013.07.016
   Ganetzky RD, 2019, HUM MUTAT, V40, P499, DOI 10.1002/humu.23723
   Gödiker J, 2018, J HUM GENET, V63, P707, DOI 10.1038/s10038-018-0442-y
   Grünert SC, 2021, BIOCHIMIE, V183, P55, DOI 10.1016/j.biochi.2021.02.003
   Haack TB, 2015, ANN CLIN TRANSL NEUR, V2, P492, DOI 10.1002/acn3.189
   Hamosh A, 2005, NUCLEIC ACIDS RES, V33, pD514
   Itan Y, 2016, NAT METHODS, V13, P109, DOI 10.1038/nmeth.3739
   Kanehisa M, 2023, NUCLEIC ACIDS RES, V51, pD587, DOI 10.1093/nar/gkac963
   Kerr M, 2020, MOL GENET METAB, V131, P66, DOI 10.1016/j.ymgme.2020.08.009
   Kose M, 2021, J PEDIATR ENDOCR MET, V34, P417, DOI 10.1515/jpem-2020-0410
   Landrum MJ, 2018, NUCLEIC ACIDS RES, V46, pD1062, DOI 10.1093/nar/gkx1153
   Lightowlers RN, 2015, SCIENCE, V349, P1494, DOI 10.1126/science.aac7516
   Liu FC, 2016, INT J NEUROSCI, V126, P499, DOI 10.3109/00207454.2015.1034801
   Lott Marie T, 2013, Curr Protoc Bioinformatics, V44, DOI 10.1002/0471250953.bi0123s44
   Nigro Vincenzo, 2014, Acta Myol, V33, P1
   Orsucci D, 2021, J CLIN MED, V10, DOI 10.3390/jcm10061249
   Pronicka E, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0930-9
   Puusepp S, 2018, MOL GENET METAB REP, V15, P80, DOI 10.1016/j.ymgmr.2018.03.004
   Rahman S, 2020, J INTERN MED, V287, P609, DOI 10.1111/joim.13054
   Rahman S, 2019, NAT REV NEUROL, V15, P40, DOI 10.1038/s41582-018-0101-0
   Rahman S, 2009, ARCH DIS CHILD, V94, P3, DOI 10.1136/adc.2008.147983
   Rath S, 2021, NUCLEIC ACIDS RES, V49, pD1541, DOI 10.1093/nar/gkaa1011
   Rentzsch P, 2019, NUCLEIC ACIDS RES, V47, pD886, DOI 10.1093/nar/gky1016
   Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30
   Richter U, 2021, FEBS LETT, V595, P1003, DOI 10.1002/1873-3468.14049
   Roux CJ, 2021, MOL GENET METAB, V133, P222, DOI 10.1016/j.ymgme.2021.04.004
   Sasai H, 2017, J INHERIT METAB DIS, V40, P845, DOI 10.1007/s10545-017-0065-z
   Schlieben LD, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.600079
   Steenweg ME, 2012, BRAIN, V135, P1387, DOI 10.1093/brain/aws070
   Stelzer G., 2016, CURR PROTOC BIOINFOR, V54, p1.30.1, DOI [10.1002 / cpbi.5, DOI 10.1002/CPBI.5, 10.1002/cpbi.5, 10.1002/CPBI.5]
   Stenton SL, 2020, EBIOMEDICINE, V56, DOI 10.1016/j.ebiom.2020.102784
   Taylor RW, 2014, JAMA-J AM MED ASSOC, V312, P68, DOI 10.1001/jama.2014.7184
   Theunissen TEJ, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00400
   Turvey AK, 2022, FRONT PHYSIOL, V13, DOI 10.3389/fphys.2022.1029218
   Wang L, 2018, ORPHANET J RARE DIS, V13, DOI 10.1186/s13023-018-0859-6
   Webb Bryn D, 2020, J Transl Genet Genom, V4, P71, DOI 10.20517/jtgg.2020.11
   Wortmann SB, 2015, J INHERIT METAB DIS, V38, P437, DOI 10.1007/s10545-015-9823-y
NR 46
TC 2
Z9 2
U1 11
U2 15
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1664-8021
J9 FRONT GENET
JI Front. Genet.
PD JUN 12
PY 2023
VL 14
AR 1191159
DI 10.3389/fgene.2023.1191159
PG 14
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA L0II9
UT WOS:001020172900001
PM 37377599
OA gold
DA 2024-11-01
ER

PT J
AU Spinazzola, A
   Carrara, F
   Mora, M
   Zeviani, M
AF Spinazzola, A
   Carrara, F
   Mora, M
   Zeviani, M
TI Mitochondrial myopathy and ophthalmoplegia in a sporadic patient with
   the 5698G→A mitochondrial DNA mutation
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE chronic progressive external ophthalmoplegia; mitochondrial myopathy;
   mtDNA; point mutation; tRNA
AB We describe a second patient carrying the 5698G --> A transition in the mitochondrial DNA gene encoding tRNA(Asn) who has an apparently isolated mitochondrial myopathy with chronic progressive external opthalmoplegia. A muscle biopsy showed the presence of ragged-red and COX-negative fibres. Analysis of the mutation load on single muscle fibres showed significant segregation of the 569SG --> A with COX-depleted fibres. These results indicate that the 5698G --> A is pathogenic. (C) 2004 Elsevier B.V. All rights reserved.
C1 Natl Neurol Inst C Besta, Pierfranco & Luisa Mariani Ctr Study Childrens Mi, Unit Mol Neurogenet, I-21033 Milan, Italy.
   Natl Neurol Inst C Besta, Unit Neuromuscular Disorders, I-21033 Milan, Italy.
C3 Fondazione IRCCS Istituto Neurologico Carlo Besta; Fondazione IRCCS
   Istituto Neurologico Carlo Besta
RP Natl Neurol Inst C Besta, Pierfranco & Luisa Mariani Ctr Study Childrens Mi, Unit Mol Neurogenet, Via Temolo 4, I-21033 Milan, Italy.
EM zeviani@tin.it
RI Zeviani, Massimo/K-2891-2014; Pane, Marika/K-1818-2017; Spinazzola,
   Antonella/P-5298-2017; Mora, Marina/J-2883-2018
OI Zeviani, Massimo/0000-0002-9067-5508; Spinazzola,
   Antonella/0000-0003-4242-8091; Mora, Marina/0000-0002-5765-2320
FU Telethon [GGP030039] Funding Source: Medline
CR DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148
   Sternberg D, 2001, BRAIN, V124, P984, DOI 10.1093/brain/124.5.984
   Torroni A, 2001, AM J HUM GENET, V69, P1348, DOI 10.1086/324511
   2004, MITOMAP HUMAN MITOCH
NR 5
TC 11
Z9 11
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD DEC
PY 2004
VL 14
IS 12
BP 815
EP 817
DI 10.1016/j.nmd.2004.09.002
PG 3
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 881CR
UT WOS:000225841500007
PM 15564038
DA 2024-11-01
ER

PT J
AU Thajeb, P
   Ma, YS
   Tzen, CY
   Chuang, CK
   Wu, TY
   Chen, SC
   Wei, YH
AF Thajeb, P
   Ma, YS
   Tzen, CY
   Chuang, CK
   Wu, TY
   Chen, SC
   Wei, YH
TI Oculopharyngeal somatic myopathy in a patient with a novel large-scale
   3399 bp deletion and a homoplasmic T5814C transition of the
   mitochondrial DNA
SO CLINICAL NEUROLOGY AND NEUROSURGERY
LA English
DT Article
DE oculopharyngeal somatic myopathy; mitochondrial myopathy; large-scale
   deletion; mutation; polymorphism; mitochondrial DNA; tRNA(Cys)
ID MELAS SYNDROME; GENE MUTATION; ENCEPHALOPATHY; SEQUENCE; A3243G; FAMILY;
   MUSCLE
AB We report a 65-year-old woman with a sporadic form of progressive oculopharyngeal somatic myopathy due to a novel large-scale 3399 base pair (bp) deletion of the mitochondrial DNA (mtDNA) and co-occurrence of a homoplasmic T5814C transition. The onset of myopathy began from chronic progressive exteral ophthalmoplegia (CPEO) at age of 20 years. Bulbar weakness, neck and proximal limb paralysis, slowly progressed to eventual respiratory failure. The plasma. levels of private (1.5 mg/dL) and lactate (20.2 mg/dL) were elevated. Muscle biopsy showed decreased enzymatic activity of cytochrome c oxidase, but no ragged-red fibers. Electron microscopy showed "parking-lot" paracrystalline inclusions in the enlarged mitochondria suggestive for mitochondrial myopathy. Sequencing of the whole mitochondrial genome of the patient's muscle and leukocytes showed 3399bp deletion of the mtDNA from nucleotide position 8024 to 11,423 and a homoplasmic thymidine to cytosine transition at nucleotide position 5814 of the tRNA(Cys) gene of mtDNA (T5814C). T5814C was absent in the white blood cells of the patient's daughter and in 205 normal controls. We conclude that a large-scale deletion may coexist with T5814C transition in patients with sporadic form of mitochondrial cytopathy manifested by slowly progressive oculopharyngeal somatic myopathy. (c) 2005 Elsevier B.V. All rights reserved.
C1 Taipei Med Univ, Mackay Mem Hosp, Dept Neurol, Taipei 11499, Taiwan.
   Taipei Med Univ, Mackay Mem Hosp, Dept Med Res, Taipei 11499, Taiwan.
   Taipei Med Univ, Dept Neurol, Taipei 11499, Taiwan.
   Mackay Mem Hosp, Dept Pathol, Taipei 11499, Taiwan.
   Natl Yang Ming Univ, Sch Life Sci, Dept Biochem & Mol Biol, Taipei 112, Taiwan.
C3 Mackay Memorial Hospital; Taipei Medical University; Taipei Medical
   University; Mackay Memorial Hospital; Taipei Medical University; Mackay
   Memorial Hospital; National Yang Ming Chiao Tung University
RP Thajeb, P (corresponding author), Taipei Med Univ, Mackay Mem Hosp, Dept Neurol, POB Nei Hua 6-30, Taipei 11499, Taiwan.
EM thajebp@hotmail.com
RI Wei, Yau-Huei/ABA-6841-2021
OI Wei, Yau-Huei/0000-0002-6429-2546
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   DiMauro S., 1997, MOL GENETIC BASIS NE, P201
   FANG W, 1993, ARCH NEUROL-CHICAGO, V50, P977, DOI 10.1001/archneur.1993.00540090074013
   HILTONJONES D, 2001, BRAINS DIS NERVOUS S, P478
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   HUANG CC, 1994, J NEUROL NEUROSUR PS, V57, P586, DOI 10.1136/jnnp.57.5.586
   Koga Y, 2000, ACTA NEUROPATHOL, V99, P186, DOI 10.1007/PL00007423
   Lee HC, 2001, MUTAT RES-GEN TOX EN, V493, P67, DOI 10.1016/S1383-5718(01)00160-7
   Lim PS, 2000, FREE RADICAL BIO MED, V29, P454, DOI 10.1016/S0891-5849(00)00334-8
   LIOU CW, 1994, ACTA NEUROL SCAND, V90, P354
   Manfredi G, 1996, HUM MUTAT, V7, P158
   Munnich A., 2001, METABOLIC MOL BASES, P2261
   Santorelli FM, 1997, NEUROMUSCULAR DISORD, V7, P156, DOI 10.1016/S0960-8966(97)00444-6
   Schapira AHV, 1998, ARCH NEUROL-CHICAGO, V55, P1293, DOI 10.1001/archneur.55.10.1293
   Shoffner JM, 2001, METABOLIC MOL BASES, P2367
   Sternberg D, 2001, BRAIN, V124, P984, DOI 10.1093/brain/124.5.984
   THAJEB P, 1997, CHIN MED J BEIJING, V110, P726
   THAJEB P, 2000, CHIN MED J TAIPEI, V63, P71
   Tzen CY, 2003, MUSCLE NERVE, V28, P575, DOI 10.1002/mus.10473
   Wallace D.C., 2001, The Metabolic and Molecular Basis of Inherited Disease, P2425
   ZHANG Y, 2001, CHIN MED J BEIJING, V114, P129
NR 21
TC 2
Z9 2
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0303-8467
J9 CLIN NEUROL NEUROSUR
JI Clin. Neurol. Neurosurg.
PD JUN
PY 2006
VL 108
IS 4
BP 407
EP 410
DI 10.1016/j.clineuro.2005.01.004
PG 4
WC Clinical Neurology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Surgery
GA 043GY
UT WOS:000237589600015
PM 16644408
DA 2024-11-01
ER

PT J
AU Cardaioli, E
   Da Pozzo, P
   Radi, E
   Dotti, MT
   Federico, A
AF Cardaioli, E
   Da Pozzo, P
   Radi, E
   Dotti, MT
   Federico, A
TI A novel heteroplasmic tRNA <SUP>Leu(CUN)</SUP> mtDNA point mutation
   associated with chronic progressive external ophthalmoplegia
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE mtDNA; tRNA(Leu(CUN)); CPEO
ID MITOCHONDRIAL-DNA; A3243G MUTATION; DILATED CARDIOMYOPATHY; SPORADIC
   PATIENT; SKELETAL-MUSCLE; TRNA(LEU(CUN)); GENES
AB We have sequenced all mitochondrial tRNA genes from a patient with chronic progressive external ophthalmoplegia (CPEO) and mitochondrial myopathy. who had no detectable large mtDNA deletions. Direct sequencing failed to detect previously reported mutations and showed a heteroplasmic mutation at nucleotide 12,276 in the tRNA(Leu(CUN)) gene, in the dihydrouridine stem, which is highly conserved through the species during evolution. RFLP analyses confirmed that 18% of muscle mtDNA harbored the mutation. while it was absent from DNA of fibroblasts and lymphocytes of the proband and in 110 patients with other encephalomyopathies. To date, besides large and single nucleotide deletions, several point mutations on mitochondrial tRNA genes have been reported in CPEO patients, but only three were in the gene coding for tRNA(Leu(CUN)). (C) 2004 Elsevier Inc. All rights reserved.
C1 Univ Siena, Dept Neurol & Behav Sci, I-53100 Siena, Italy.
C3 University of Siena
RP Univ Siena, Dept Neurol & Behav Sci, Via Laterina 8, I-53100 Siena, Italy.
EM federico@unisi.it
RI Federico, Antonio/H-8871-2017
OI Cardaioli, Elena/0000-0003-2850-6698; federico,
   antonio/0000-0002-5246-1621
CR Chinnery PF, 2000, ANN NEUROL, V47, P381, DOI 10.1002/1531-8249(200003)47:3<381::AID-ANA17>3.0.CO;2-2
   Fu K, 1996, HUM MOL GENET, V5, P1835, DOI 10.1093/hmg/5.11.1835
   Grasso M, 2001, EUR J HUM GENET, V9, P311, DOI 10.1038/sj.ejhg.5200622
   HATTORI Y, 1994, J NEUROL SCI, V125, P50, DOI 10.1016/0022-510X(94)90241-0
   Karadimas CL, 2002, NEUROMUSCULAR DISORD, V12, P865, DOI 10.1016/S0960-8966(02)00072-X
   Koga Y, 2000, ARCH DIS CHILD, V82, P407, DOI 10.1136/adc.82.5.407
   Laforêt P, 2000, REV NEUROL-FRANCE, V156, P1136
   Pulkes T, 2003, NEUROLOGY, V61, P1144, DOI 10.1212/01.WNL.0000090465.27024.3D
   Pulkes T, 2001, ADV DRUG DELIVER REV, V49, P27, DOI 10.1016/S0169-409X(01)00124-7
   Tessa A, 1999, EUR J HUM GENET, V7, P847, DOI 10.1038/sj.ejhg.5200380
   Weber K, 1997, AM J HUM GENET, V60, P373
NR 11
TC 14
Z9 14
U1 0
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD FEB 18
PY 2005
VL 327
IS 3
BP 675
EP 678
DI 10.1016/j.bbrc.2004.11.170
PG 4
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 892UF
UT WOS:000226674800008
PM 15649400
DA 2024-11-01
ER

PT S
AU Rafiq, J
   Duno, M
   Ostergaard, E
   Ravn, K
   Vissing, CR
   Wibrand, F
   Vissing, J
AF Rafiq, Jabin
   Duno, Morten
   Ostergaard, Elsebet
   Ravn, Kirstine
   Vissing, Christoffer R.
   Wibrand, Flemming
   Vissing, John
BE Baumgartner, M
   Patterson, M
   Rahman, S
   Zschocke, J
   Morava, E
TI Exercise Intolerance and Myoglobinuria Associated with a Novel
   Maternally Inherited <i>MT</i>-<i>ND1</i> Mutation
SO JIMD REPORTS, VOL 25
SE JIMD Reports
LA English
DT Article; Book Chapter
ID MITOCHONDRIAL-DNA MUTATIONS; DISEASE; GENE
AB The most common clinical phenotype caused by a mtDNA mutation in complex I of the mitochondrial respiratory chain is Leber hereditary optic neuropathy. We report a family with a novel maternally inherited homoplasmic mtDNA m.4087A>G mutation in the ND1 gene (MT-ND1) associated with isolated myopathy, recurrent episodes of myoglobinuria, and rhabdomyolysis. DNA from blood in seven family members and muscle from four family members were PCR amplified and sequenced directly and assessed for the m.4087A>G variation in MT-ND1. Mitochondrial enzyme activity in all muscle biopsies was measured. PCR and direct sequencing of the MT-ND1 genes from blood showed that all seven family members were homoplasmic for the m.4087A>G mutation (NC_012920.1:c.781A>G). The mutation predicts a threonine to alanine substitution at position 261 (p.T261A). The same mutation was found in muscle of all four family members available for muscle biopsy, and biochemical analyses revealed an isolated complex I defect in muscle of all family members (range 22-52% of normal). Muscle morphology showed severe myopathic changes with internal nuclei in multiple fibers of all family members. Monosymptomatic myopathy with recurrent myoglobinuria is a rare phenotype of mitochondrial myopathies. We report this phenotype in a family affected by a novel homoplasmic mutation in MT-ND1. It is the first time such a phenotype has been associated with complex I gene mutations and a homoplasmic mutation of mtDNA.
C1 [Rafiq, Jabin; Vissing, Christoffer R.; Vissing, John] Copenhagen Neuromuscular Ctr, Dept Neurol, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.
   [Duno, Morten; Ostergaard, Elsebet; Ravn, Kirstine; Wibrand, Flemming] Univ Copenhagen, Dept Clin Genet, Rigshosp, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.
C3 University of Copenhagen; Rigshospitalet
RP Vissing, J (corresponding author), Copenhagen Neuromuscular Ctr, Dept Neurol, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.
EM vissing@rh.dk
RI Ravn, Kirstine/ISS-3001-2023; Østergaard, Elsebet/IZE-6519-2023;
   Vissing, John/IUN-4271-2023; Vissing, Christoffer/AAX-2530-2020
OI Ostergaard, Elsebet/0000-0002-8047-063X; Vissing,
   Christoffer/0000-0002-0834-206X
CR ALLEN RC, 1992, AM J HUM GENET, V51, P1229
   ASTRAND I, 1960, Acta Physiol Scand Suppl, V49, P1
   Jeppesen TD, 2003, J NEUROL, V250, P293, DOI 10.1007/s00415-003-0993-4
   Larsen S, 2012, J PHYSIOL-LONDON, V590, P3349, DOI 10.1113/jphysiol.2012.230185
   Ostergaard E, 2007, BRAIN, V130, P853, DOI 10.1093/brain/awl383
   Schapira AHV, 2006, LANCET, V368, P70, DOI 10.1016/S0140-6736(06)68970-8
   SWAIN DP, 1994, MED SCI SPORT EXER, V26, P112
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Vissing CR, 2013, NEUROLOGY, V80, P1908, DOI 10.1212/WNL.0b013e3182929fb2
   Wong LJC, 2007, MUSCLE NERVE, V36, P279, DOI 10.1002/mus.20807
   Yu-Wai-Man P, 2011, PROG RETIN EYE RES, V30, P81, DOI 10.1016/j.preteyeres.2010.11.002
NR 11
TC 4
Z9 4
U1 0
U2 0
PU SPRINGER-VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
SN 2192-8304
BN 978-3-662-49668-8; 978-3-662-49667-1
J9 JIMD REP
PY 2016
VL 25
BP 65
EP 70
DI 10.1007/8904_2015_459
D2 10.1007/978-3-662-49668-8
PG 6
WC Endocrinology & Metabolism; Genetics & Heredity
WE Book Citation Index – Science (BKCI-S)
SC Endocrinology & Metabolism; Genetics & Heredity
GA BI0RD
UT WOS:000405113700010
PM 26108648
OA Green Published
DA 2024-11-01
ER

PT J
AU Maagaard, A
   Holberg-Petersen, M
   Kollberg, G
   Oldfors, A
   Sandvik, L
   Bruun, JN
AF Maagaard, Anne
   Holberg-Petersen, Mona
   Kollberg, Gittan
   Oldfors, Anders
   Sandvik, Leiv
   Bruun, Johan N.
TI Mitochondrial (mt)DNA changes in tissue may not be reflected by
   depletion of mtDNA in peripheral blood mononuclear cells in HIV-infected
   patients
SO ANTIVIRAL THERAPY
LA English
DT Article
ID REVERSE-TRANSCRIPTASE INHIBITORS; SUBCUTANEOUS ADIPOSE-TISSUE;
   ANTIRETROVIRAL THERAPY; DNA DEPLETION; POSITIVE PATIENTS; ZIDOVUDINE;
   TOXICITY; MYOPATHY; MUTATIONS; FAT
AB Objectives: Most data on mitochondrial toxicity have been derived from peripheral blood mononuclear cells (PBMCs). However, whether mitochondrial DNA (mtDNA) content in PBMCs reflects the mitochondrial state in tissues remains elusive. We report herein on mitochondrial toxicity in skeletal muscle in HIV-infected patients naive to antiretroviral treatment (ART [HIV+ART-naive]; n=10) patients exposed to nucleoside reverse transcriptase inhibitors (NRTIs [HIV+NRTI+]; n=24) and healthy controls (n=11), and compare these tissue data with mtDNA in PBMCs. Methods: Muscle biopsies were examined for (i) mtDNA and nuclear DNA (nDNA) content using TaqMan realtime PCR system, (ii) mtDNA deletions using long expand PCR with subsequent gel electrophoresis, and (iii) mitochondrial myopathy expressed as cytochrome c oxidase (COX)-deficient muscle fibres. Results: The mt/n DNA ratio in muscle from HIV+NRTI+ patients was reduced compared with HIV-negative controls (P=0.028). Moreover, mtDNA deletions were more frequent in HIV+NRTI+ patients than in both HIV-negative controls (P=0.009) and HIV+ART-naive patients (P=0.005). HIV+NRTI+ also tended to have more COX-deficient fibres than HIV-negative controls (P=0.076). COX-deficient fibres were positively correlated with mtDNA deletions in HIV+NRTI+ patients (r=0.83, P<0.001). Patients with current use of didanosine (ddl) had more frequent mtDNA deletions and COX-deficient fibres than HIV+NRTI+ not on current treatment with ddl. It should be noted that mitochondrial alterations were not correlated with mtDNA/cell in PBMCs in any group. Conclusions: In skeletal muscle, HIV+NRTI+ had a reduced mt/n DNA ratio, more frequent mtDNA deletions and possibly more COX-deficient muscle fibres than HIV-negative controls. However, the mtDNA/cell in peripheral blood was decreased in both HIV+NRTI+ and HIV+ART-naive patients. Thus, mtDNA in peripheral blood may not be a relevant marker of mitochondrial toxicity in organ-specific tissue.
C1 Ullevaal Univ Hosp, Dept Infect Dis, Oslo, Norway.
   Univ Oslo, Fac Div, Oslo, Norway.
   Ullevaal Univ Hosp, Dept Microbiol, Oslo, Norway.
   Ullevaal Univ Hosp, Clin Res Ctr, Oslo, Norway.
   Sahlgrens Univ Hosp, Dept Pathol, S-41345 Gothenburg, Sweden.
C3 University of Oslo; University of Oslo; University of Oslo; University
   of Oslo; Sahlgrenska University Hospital
RP Maagaard, A (corresponding author), Ullevaal Univ Hosp, Dept Infect Dis, Oslo, Norway.
EM anne.maagaard@medisin.uio.no
CR Andréasson H, 2002, BIOTECHNIQUES, V33, P402, DOI 10.2144/02332rr07
   ARNAUDO E, 1991, LANCET, V337, P508, DOI 10.1016/0140-6736(91)91294-5
   Bergersen BM, 2004, SCAND J INFECT DIS, V36, P186, DOI 10.1080/00365540410019273
   Brinkman K, 1998, AIDS, V12, P1735, DOI 10.1097/00002030-199814000-00004
   Casula M, 2005, J INFECT DIS, V191, P1468, DOI 10.1086/429412
   Chariot P, 1999, J HEPATOL, V30, P156, DOI 10.1016/S0168-8278(99)80020-8
   Cherry CL, 2002, J ACQ IMMUN DEF SYND, V30, P271, DOI [10.1097/00126334-200207010-00002, 10.1097/01.QAI.0000017962.22053.0E]
   Chiappini F, 2004, LAB INVEST, V84, P908, DOI 10.1038/labinvest.3700113
   Christensen ER, 2004, CLIN INFECT DIS, V39, P1371, DOI 10.1086/424881
   Coté HCF, 2002, NEW ENGL J MED, V346, P811, DOI 10.1056/NEJMoa012035
   DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602
   Goto M, 2003, J MED VIROL, V70, P497, DOI 10.1002/jmv.10423
   Haugaard SB, 2005, J MED VIROL, V77, P29, DOI 10.1002/jmv.20410
   Jacotot E, 2000, J EXP MED, V191, P33, DOI 10.1084/jem.191.1.33
   Johnson AA, 2001, J BIOL CHEM, V276, P40847, DOI 10.1074/jbc.M106743200
   Kollberg G, 2005, EUR J HUM GENET, V13, P463, DOI 10.1038/sj.ejhg.5201341
   López S, 2004, ANTIVIR THER, V9, P47
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Maagaard A, 2006, HIV MED, V7, P53, DOI 10.1111/j.1468-1293.2005.00336.x
   Mallon PWG, 2005, J INFECT DIS, V191, P1686, DOI 10.1086/429697
   Martin AM, 2003, AM J HUM GENET, V72, P549, DOI 10.1086/367849
   McComsey G, 2002, AIDS, V16, P513, DOI 10.1097/00002030-200203080-00001
   McComsey GA, 2005, AIDS, V19, P15, DOI 10.1097/00002030-200501030-00002
   Miró O, 2000, AIDS, V14, P1855, DOI 10.1097/00002030-200008180-00024
   Miró O, 2004, CLIN INFECT DIS, V39, P710, DOI 10.1086/423176
   Montaner JSG, 2004, CLIN INFECT DIS, V38, pS73, DOI 10.1086/381449
   Moslemi AR, 1999, NEUROLOGY, V53, P79, DOI 10.1212/WNL.53.1.79
   Nolan D, 2003, AIDS, V17, P1329, DOI 10.1097/00002030-200306130-00007
   Oldfors A, 2003, J NEUROPATH EXP NEUR, V62, P217, DOI 10.1093/jnen/62.3.217
   Pace CS, 2003, ANTIVIR THER, V8, P323
   POLO R, 2001, J ACQ IMMUN DEF SYND, V34, P32
   Raidel SM, 2002, AM J PHYSIOL-HEART C, V282, pH1672, DOI 10.1152/ajpheart.00955.2001
   SCIACCO M, 1994, HUM MOL GENET, V3, P13, DOI 10.1093/hmg/3.1.13
   Shikuma CM, 2001, AIDS, V15, P1801, DOI 10.1097/00002030-200109280-00009
   Vittecoq D, 2002, JAIDS, V31, P299, DOI 10.1097/00126334-200211010-00005
   Zaera MG, 2001, AIDS, V15, P1643, DOI 10.1097/00002030-200109070-00006
NR 36
TC 48
Z9 49
U1 0
U2 3
PU INT MEDICAL PRESS LTD
PI LONDON
PA 2-4 IDOL LANE, LONDON EC3R 5DD, ENGLAND
SN 1359-6535
J9 ANTIVIR THER
JI Antivir. Ther.
PY 2006
VL 11
IS 5
BP 601
EP 608
PG 8
WC Infectious Diseases; Pharmacology & Pharmacy; Virology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Infectious Diseases; Pharmacology & Pharmacy; Virology
GA 076UY
UT WOS:000239984700008
PM 16964828
DA 2024-11-01
ER

PT J
AU Nakada, K
   Sato, A
   Sone, H
   Kasahara, A
   Ikeda, K
   Kagawa, Y
   Yonekawa, H
   Hayashi, J
AF Nakada, K
   Sato, A
   Sone, H
   Kasahara, A
   Ikeda, K
   Kagawa, Y
   Yonekawa, H
   Hayashi, J
TI Accumulation of pathogenic ΔmtDNA induced deafness but not diabetic
   phenotypes in mito-mice
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE mitochondria; mitochondrial diseases; respiration defects; mitochondrial
   DNA; pathogenic deletion mutant mitochondrial DNA; mitochondrial
   diabetes; deafness; disease model mouse; mito-mice
ID MITOCHONDRIAL-DNA DELETIONS; INSULIN-SECRETION; PROTEIN-SYNTHESIS; POINT
   MUTATION; MOUSE MTDNA; HUMAN BRAIN; HELA-CELLS; MELLITUS; GENE; MYOPATHY
AB Mito-mice carrying various proportions of deletion mutant mtDNA (DeltamtDNA) were generated by introduction of the DeltamtDNA from cultured cells into fertilized eggs of C57BL/6.1 (136) strain mice. Great advantages of mito-mice are that they share exactly the same nuclear-genome background, and that their genetic variations are restricted to proportions of pathogenic DeltamtDNA. Since accumulation of DeltamtDNA to more than 75% induced respiration defects, the disease phenotypes observed exclusively in mito-mice carrying more than 75% DeltamtDNA should be due to accumulated DeltamtDNA. In this study, we focused on the expressions of hearing loss and diabetic phenotypes, since these common age-associated abnormalities have sometimes been reported to be inherited maternally and to be associated with pathogenic mutant mtDNAs. The results showed that accumulation of exogenously introduced DeltamtDNA was responsible for hearing loss, but not for expression of diabetic phenotypes in mito-mice. (C) 2004 Elsevier Inc. All rights reserved.
C1 Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki 3058572, Japan.
   Univ Tsukuba, Ctr Tsukuba Adv Res Alliance, Tsukuba, Ibaraki 3058572, Japan.
   Tokyo Metropolitan Inst Med Sci, Dept Lab Anim Sci, Bunkyo Ku, Tokyo 1138613, Japan.
   Kagawa Nutr Univ, High Technol Res Ctr, Sakado, Saitama 3500288, Japan.
   Juntendo Univ, Sch Med, Dept Otorhinolaryngol, Bunkyo Ku, Tokyo 1138421, Japan.
C3 University of Tsukuba; University of Tsukuba; Tokyo Metropolitan
   Institute of Medical Science; Kagawa Nutrition University; Juntendo
   University
RP Univ Tsukuba, Grad Sch Life & Environm Sci, 1-1-1 Tennoudai, Tsukuba, Ibaraki 3058572, Japan.
EM jih45@sakura.cc.tsukuba.ac.jp
CR BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11
   BALLINGER SW, 1994, NAT GENET, V7, P458, DOI 10.1038/ng0894-458
   CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236
   CIAFALONI E, 1992, ANN NEUROL, V31, P391, DOI 10.1002/ana.410310408
   CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Greeley SAW, 2002, NAT MED, V8, P399, DOI 10.1038/nm0402-399
   HANNA MG, 1995, AM J HUM GENET, V56, P1026
   HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614
   Hirai M, 1996, BIOCHEM BIOPH RES CO, V219, P951, DOI 10.1006/bbrc.1996.0324
   Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826
   Inoue K, 1996, BIOCHEM BIOPH RES CO, V223, P496, DOI 10.1006/bbrc.1996.0923
   JABER L, 1992, J MED GENET, V29, P86, DOI 10.1136/jmg.29.2.86
   Johnson KR, 2001, NAT GENET, V27, P191, DOI 10.1038/84831
   KADOWAKI T, 1994, NEW ENGL J MED, V330, P962, DOI 10.1056/NEJM199404073301403
   KANEDA H, 1995, P NATL ACAD SCI USA, V92, P4542, DOI 10.1073/pnas.92.10.4542
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   Kobayashi T, 1997, DIABETES, V46, P1567, DOI 10.2337/diabetes.46.10.1567
   Larsson NG, 1995, ANNU REV GENET, V29, P151, DOI 10.1146/annurev.ge.29.120195.001055
   LOMBES A, 1989, REV NEUROL-FRANCE, V145, P671
   Maechler P, 2001, NATURE, V414, P807, DOI 10.1038/414807a
   Matsuoka R, 1999, BIOCHEM BIOPH RES CO, V257, P228, DOI 10.1006/bbrc.1999.0443
   MIYABAYASHI S, 1984, BRAIN DEV-JPN, V6, P362, DOI 10.1016/S0387-7604(84)80112-6
   Nakada K, 2001, NAT MED, V7, P934, DOI 10.1038/90976
   Perucca-Lostanlen D, 2002, BBA-MOL BASIS DIS, V1588, P210, DOI 10.1016/S0925-4439(02)00167-9
   PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289
   REARDON W, 1992, LANCET, V340, P1376, DOI 10.1016/0140-6736(92)92560-3
   Shitara H, 1998, GENETICS, V148, P851
   Shoubridge EA, 2000, NAT GENET, V26, P132, DOI 10.1038/79832
   Silva JP, 2000, NAT GENET, V26, P336, DOI 10.1038/81649
   Soejima A, 1996, J BIOL CHEM, V271, P26194, DOI 10.1074/jbc.271.42.26194
   SOONG NW, 1992, NAT GENET, V2, P318
   Tang YY, 2000, MOL BIOL CELL, V11, P1471, DOI 10.1091/mbc.11.4.1471
   TULINIUS MH, 1995, EUR J PEDIATR, V154, P35, DOI 10.1007/BF01972970
   VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   YONEDA M, 1994, MOL CELL BIOL, V14, P2699, DOI 10.1128/MCB.14.4.2699
   Zheng QY, 1999, HEARING RES, V130, P94, DOI 10.1016/S0378-5955(99)00003-9
NR 38
TC 34
Z9 35
U1 1
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD OCT 8
PY 2004
VL 323
IS 1
BP 175
EP 184
DI 10.1016/j.bbrc.2004.08.073
PG 10
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 855HY
UT WOS:000223965300027
PM 15351718
DA 2024-11-01
ER

PT J
AU Ahmed, N
   Ronchi, D
   Comi, GP
AF Ahmed, Naghia
   Ronchi, Dario
   Comi, Giacomo Pietro
TI Genes and Pathways Involved in Adult Onset Disorders Featuring Muscle
   Mitochondrial DNA Instability
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE mtDNA maintenance; multiple mtDNA deletions; adult mitochondrial
   disorders; progressive external ophthalmoplegia; mitochondrial myopathy
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; DOMINANT OPTIC ATROPHY;
   POLYMERASE-GAMMA MUTATION; BASE EXCISION-REPAIR; THYMIDINE KINASE;
   SACCHAROMYCES-CEREVISIAE; FAMILIAL PARKINSONISM; SPASTIC PARAPLEGIA;
   TWINKLE HELICASE; MPV17 ENCODES
AB Replication and maintenance of mtDNA entirely relies on a set of proteins encoded by the nuclear genome, which include members of the core replicative machinery, proteins involved in the homeostasis of mitochondrial dNTPs pools or deputed to the control of mitochondrial dynamics and morphology. Mutations in their coding genes have been observed in familial and sporadic forms of pediatric and adult-onset clinical phenotypes featuring mtDNA instability. The list of defects involved in these disorders has recently expanded, including mutations in the exo-/endo-nuclease flap-processing proteins MGME1 and DNA2, supporting the notion that an enzymatic DNA repair system actively takes place in mitochondria. The results obtained in the last few years acknowledge the contribution of next-generation sequencing methods in the identification of new disease loci in small groups of patients and even single probands. Although heterogeneous, these genes can be conveniently classified according to the pathway to which they belong. The definition of the molecular and biochemical features of these pathways might be helpful for fundamental knowledge of these disorders, to accelerate genetic diagnosis of patients and the development of rational therapies. In this review, we discuss the molecular findings disclosed in adult patients with muscle pathology hallmarked by mtDNA instability.
C1 [Ahmed, Naghia; Ronchi, Dario; Comi, Giacomo Pietro] Univ Milan, IRCCS Fdn Ca Granda Osped Maggiore Policlin, Dino Ferrari Ctr, Dept Pathophysiol & Transplantat,Neurol Unit, I-20122 Milan, Italy.
C3 IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan
RP Ronchi, D (corresponding author), Univ Milan, IRCCS Fdn Ca Granda Osped Maggiore Policlin, Dino Ferrari Ctr, Dept Pathophysiol & Transplantat,Neurol Unit, Via Francesco Sforza 35, I-20122 Milan, Italy.
EM naghia.ahmed89@gmail.com; dario.ronchi@gmail.com; giacomo.comi@unimi.it
RI Ronchi, Dario/K-8011-2016; Comi, Giacomo/K-5702-2016
OI Ronchi, Dario/0000-0002-6093-9816; Comi, Giacomo/0000-0002-1383-5248
FU Fondazione Cariplo [2014-1010]
FX The financial support of Fondazione Cariplo to Dario Ronchi (Project
   number: 2014-1010) is gratefully acknowledged.
CR Ajroud-Driss S, 2015, NEUROGENETICS, V16, P1, DOI 10.1007/s10048-014-0421-1
   Akbari M, 2015, DNA REPAIR, V32, P172, DOI 10.1016/j.dnarep.2015.04.029
   Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944
   Alexeyev M, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a012641
   Alston CL, 2013, NEUROLOGY, V81, P2051, DOI 10.1212/01.wnl.0000436931.94291.e6
   Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   Antonenkov VD, 2015, J BIOL CHEM, V290, P13840, DOI 10.1074/jbc.M114.608083
   Baines CP, 2003, CIRC RES, V92, P873, DOI 10.1161/01.RES.0000069215.36389.8D
   Baloh RH, 2007, ARCH NEUROL-CHICAGO, V64, P998, DOI 10.1001/archneur.64.7.998
   Bannwarth S, 2014, BRAIN, V137, P2329, DOI 10.1093/brain/awu138
   Belenguer P, 2013, BBA-MOL CELL RES, V1833, P176, DOI 10.1016/j.bbamcr.2012.08.004
   Besse A, 2015, CELL METAB, V21, P417, DOI 10.1016/j.cmet.2015.02.008
   Blakely EL, 2012, NEUROMUSCULAR DISORD, V22, P587, DOI 10.1016/j.nmd.2012.03.006
   Bonnen PE, 2013, AM J HUM GENET, V93, P773, DOI 10.1016/j.ajhg.2013.09.003
   Boschetti E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096692
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Budd ME, 2013, J BIOL CHEM, V288, P29414, DOI 10.1074/jbc.M113.472456
   Calvo SE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003310
   Carelli V, 2015, ANN NEUROL, V78, P21, DOI 10.1002/ana.24410
   Casari G, 1998, CELL, V93, P973, DOI 10.1016/S0092-8674(00)81203-9
   Cogliati S, 2013, CELL, V155, P160, DOI 10.1016/j.cell.2013.08.032
   Davidzon G, 2006, ANN NEUROL, V59, P859, DOI 10.1002/ana.20831
   Del Bo R, 2003, NEUROLOGY, V61, P903, DOI 10.1212/01.WNL.0000092303.13864.BE
   Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936
   Delgado-Alvarado M, 2015, J NEUROL SCI, V350, P93, DOI 10.1016/j.jns.2015.02.011
   Delonlay P, 2013, HAND CLINIC, V113, P1651, DOI 10.1016/B978-0-444-59565-2.00033-2
   Di Re M, 2009, NUCLEIC ACIDS RES, V37, P5701, DOI 10.1093/nar/gkp614
   Ding L, 2015, INT J MOL SCI, V16, P10870, DOI 10.3390/ijms160510870
   Dörner A, 2007, TRENDS CARDIOVAS MED, V17, P284, DOI 10.1016/j.tcm.2007.10.001
   Duxin JP, 2009, MOL CELL BIOL, V29, P4274, DOI 10.1128/MCB.01834-08
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Evgrafov OV, 2004, NAT GENET, V36, P602, DOI 10.1038/ng1354
   Finsterer J, 2013, CAN J NEUROL SCI, V40, P635, DOI 10.1017/S0317167100014852
   Fratter C, 2010, NEUROLOGY, V74, P1619, DOI 10.1212/WNL.0b013e3181df099f
   Gai XW, 2013, AM J HUM GENET, V93, P482, DOI 10.1016/j.ajhg.2013.07.016
   Garone C, 2012, ARCH NEUROL-CHICAGO, V69, P1648, DOI 10.1001/archneurol.2012.405
   Garone C, 2011, BRAIN, V134, P3326, DOI 10.1093/brain/awr245
   Gloor JW, 2012, NUCLEIC ACIDS RES, V40, P6774, DOI 10.1093/nar/gks388
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   Hanisch F, 2015, J NEUROL NEUROSUR PS, V86, P630, DOI 10.1136/jnnp-2013-306748
   Holt IJ, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a012971
   Hudson G, 2008, BRAIN, V131, P329, DOI 10.1093/brain/awm272
   IEEE, 2013, 2013 IEEE INT, DOI DOI 10.1155/2013/146860
   Isohanni P, 2011, NEUROLOGY, V76, P811, DOI 10.1212/WNL.0b013e31820e7b25
   Itoh K, 2013, TRENDS CELL BIOL, V23, P64, DOI 10.1016/j.tcb.2012.10.006
   Jahani-Asl A, 2011, J BIOL CHEM, V286, P4772, DOI 10.1074/jbc.M110.167155
   Jenuth JP, 1997, NAT GENET, V16, P93, DOI 10.1038/ng0597-93
   Jordens EZ, 2002, ANN NEUROL, V52, P95, DOI 10.1002/ana.10214
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kazachkova N, 2013, AGING DIS, V4, P337, DOI 10.14336/AD.2013.0400337
   Kiferle L, 2013, NEUROSCI LETT, V556, P1, DOI 10.1016/j.neulet.2013.09.034
   Klebe S, 2012, BRAIN, V135, P2980, DOI 10.1093/brain/aws240
   Kornblum C, 2013, NAT GENET, V45, P214, DOI 10.1038/ng.2501
   Lieber DS, 2013, NEUROLOGY, V80, P1762, DOI 10.1212/WNL.0b013e3182918c40
   Löllgen S, 2015, BIOL CHEM, V396, P13, DOI 10.1515/hsz-2014-0198
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Mancuso M, 2004, ARCH NEUROL-CHICAGO, V61, P1777, DOI 10.1001/archneur.61.11.1777
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Mendelsohn BA, 2014, JIMD REP, V13, P37, DOI 10.1007/8904_2013_267
   Milenkovic D, 2013, HUM MOL GENET, V22, P1983, DOI 10.1093/hmg/ddt051
   Mishra P, 2014, NAT REV MOL CELL BIO, V15, P634, DOI 10.1038/nrm3877
   Neeve VCM, 2012, BRAIN, V135, P3614, DOI 10.1093/brain/aws298
   Nguyen D, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.117
   Nicholls TJ, 2014, HUM MOL GENET, V23, P6147, DOI 10.1093/hmg/ddu336
   Nikali K, 2005, HUM MOL GENET, V14, P2981, DOI 10.1093/hmg/ddi328
   Nishino I, 2000, ANN NEUROL, V47, P792
   Ostergaard E, 2007, AM J HUM GENET, V81, P383, DOI 10.1086/519222
   Pagnamenta AT, 2006, HUM REPROD, V21, P2467, DOI 10.1093/humrep/del076
   Pareyson D, 2015, NEUROSCI LETT, V596, P66, DOI 10.1016/j.neulet.2015.04.001
   Penttilä S, 2015, ANN NEUROL, V77, P163, DOI 10.1002/ana.24319
   Pfeffer G, 2014, BRAIN, V137, P1323, DOI 10.1093/brain/awu060
   Pitceathly RDS, 2012, BRAIN, V135, P3392, DOI 10.1093/brain/aws231
   Pontarin G, 2008, P NATL ACAD SCI USA, V105, P17801, DOI 10.1073/pnas.0808198105
   Prakash A, 2015, J CELL BIOCHEM, V116, P1490, DOI 10.1002/jcb.25103
   Rampazzo C, 2004, J BIOL CHEM, V279, P17019, DOI 10.1074/jbc.M313957200
   Ranieri M, 2013, NEUROL RES INT, V2013, DOI 10.1155/2013/293893
   Ronchi D, 2015, BRAIN, V138, pE372, DOI 10.1093/brain/awu384
   Ronchi D, 2013, AM J HUM GENET, V92, P293, DOI 10.1016/j.ajhg.2012.12.014
   Ronchi D, 2012, BRAIN, V135, P3404, DOI 10.1093/brain/aws258
   Rouzier C, 2012, BRAIN, V135, P23, DOI 10.1093/brain/awr323
   Saada A, 2003, MOL GENET METAB, V79, P1, DOI 10.1016/S1096-7192(03)00063-5
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Sarzi E, 2007, ANN NEUROL, V62, P579, DOI 10.1002/ana.21207
   Scarpelli M, 2013, NEURORADIOL J, V26, P520, DOI 10.1177/197140091302600505
   Schapira AHV, 2012, LANCET, V379, P1825, DOI 10.1016/S0140-6736(11)61305-6
   Shaheen R, 2014, GENOME RES, V24, P291, DOI 10.1101/gr.160572.113
   Shim EY, 2010, EMBO J, V29, P3370, DOI 10.1038/emboj.2010.219
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spelbrink JN, 2000, J BIOL CHEM, V275, P24818, DOI 10.1074/jbc.M000559200
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Spinazzola A, 2009, ADV EXP MED BIOL, V652, P69, DOI 10.1007/978-90-481-2813-6_6
   Steczkiewicz K, 2012, NUCLEIC ACIDS RES, V40, P7016, DOI 10.1093/nar/gks382
   Stuart GR, 2006, HUM MOL GENET, V15, P363, DOI 10.1093/hmg/ddi454
   Stumpf JD, 2010, HUM MOL GENET, V19, P2123, DOI 10.1093/hmg/ddq089
   Sundaram C, 2011, J CLIN NEUROSCI, V18, P535, DOI 10.1016/j.jocn.2010.06.014
   Synofzik M, 2012, NEUROLOGY, V78, DOI 10.1007/s12311-012-0378-2
   Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506
   Tchikviladze M, 2015, J NEUROL NEUROSUR PS, V86, P646, DOI 10.1136/jnnp-2013-306799
   Tyynismaa H, 2004, HUM MOL GENET, V13, P3219, DOI 10.1093/hmg/ddh342
   Tyynismaa H, 2012, HUM MOL GENET, V21, P66, DOI 10.1093/hmg/ddr438
   Tyynismaa H, 2009, AM J HUM GENET, V85, P290, DOI 10.1016/j.ajhg.2009.07.009
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, NEUROMOL MED, V3, P129, DOI 10.1385/NMM:3:3:129
   Vielhaber S, 2013, ACTA NEUROPATHOL, V125, P245, DOI 10.1007/s00401-012-1036-y
   Virgilio R, 2008, J NEUROL, V255, P1384, DOI 10.1007/s00415-008-0926-3
   Walter MC, 2010, J NEUROL, V257, P1517, DOI 10.1007/s00415-010-5565-9
   Wanrooij S, 2010, BBA-BIOENERGETICS, V1797, P1378, DOI 10.1016/j.bbabio.2010.04.015
   Wong LJC, 2005, CLIN CHIM ACTA, V354, P1, DOI 10.1016/j.cccn.2004.11.003
   Wortmann SB, 2015, J INHERIT METAB DIS, V38, P437, DOI 10.1007/s10545-015-9823-y
   Young MJ, 2011, HUM MOL GENET, V20, P3052, DOI 10.1093/hmg/ddr209
   Yu-Wai-Man C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075048
   Zanna C, 2008, BRAIN, V131, P352, DOI 10.1093/brain/awm335
   ZHANG C, 1992, FEBS LETT, V297, P34, DOI 10.1016/0014-5793(92)80321-7
   Zheng L, 2008, MOL CELL, V32, P325, DOI 10.1016/j.molcel.2008.09.024
NR 116
TC 22
Z9 24
U1 1
U2 8
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD AUG
PY 2015
VL 16
IS 8
BP 18054
EP 18076
DI 10.3390/ijms160818054
PG 23
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA CZ0WE
UT WOS:000366826100073
PM 26251896
OA Green Published, Green Submitted, gold
DA 2024-11-01
ER

PT J
AU Spendiff, S
   Reza, M
   Murphy, JL
   Gorman, G
   Blakely, EL
   Taylor, RW
   Horvath, R
   Campbell, G
   Newman, J
   Lochmüller, H
   Turnbull, DM
AF Spendiff, Sally
   Reza, Mojgan
   Murphy, Julie L.
   Gorman, Grainne
   Blakely, Emma L.
   Taylor, Robert W.
   Horvath, Rita
   Campbell, Georgia
   Newman, Jane
   Lochmueller, Hanns
   Turnbull, Doug M.
TI Mitochondrial DNA deletions in muscle satellite cells: implications for
   therapies
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID HUMAN SKELETAL-MUSCLE; KEARNS-SAYRE SYNDROME; REAL-TIME PCR; INDIVIDUAL
   CELLS; POINT MUTATION; SELF-RENEWAL; MTDNA; ENCEPHALOMYOPATHY;
   MYOPATHIES; PATIENT
AB Progressive myopathy is a major clinical feature of patients with mitochondrial DNA (mtDNA) disease. There is limited treatment available for these patients although exercise and other approaches to activate muscle stem cells (satellite cells) have been proposed. The majority of mtDNA defects are heteroplasmic (a mixture of mutated and wild-type mtDNA present within the muscle) with high levels of mutated mtDNA and low levels of wild-type mtDNA associated with more severe disease. The culture of satellite cell-derived myoblasts often reveals no evidence of the original mtDNA mutation although it is not known if this is lost by selection or simply not present in these cells. We have explored if the mtDNA mutation is present in the satellite cells in one of the commonest genotypes associated with mitochondrial myopathies (patients with single, large-scale mtDNA deletions). Analysis of satellite cells from eight patients showed that the level of mtDNA mutation in the satellite cells is the same as in the mature muscle but is most often subsequently lost during culture. We show that there are two periods of selection against the mutated form, one early on possibly during satellite cell activation and the other during the rapid replication phase of myoblast culture. Our data suggest that the mutations are also lost during rapid replication in vivo, implying that strategies to activate satellite cells remain a viable treatment for mitochondrial myopathies in specific patient groups.
C1 [Spendiff, Sally; Murphy, Julie L.; Gorman, Grainne; Blakely, Emma L.; Taylor, Robert W.; Horvath, Rita; Campbell, Georgia; Newman, Jane; Turnbull, Doug M.] Newcastle Univ, Sch Med, Wellcome Trust Ctr Mitochondrial Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Spendiff, Sally] McGill Univ, Dept Kinesiol & Phys Educ, Montreal, PQ H2W 1S4, Canada.
   [Reza, Mojgan; Horvath, Rita; Lochmueller, Hanns] Newcastle Univ, Inst Med Genet, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.
C3 Newcastle University - UK; McGill University; Newcastle University - UK
RP Turnbull, DM (corresponding author), Newcastle Univ, Sch Med, Wellcome Trust Ctr Mitochondrial Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM doug.turnbull@newcastle.ac.uk
RI Spendiff, Sally/K-7464-2019; Horvath, Rita/AAY-7042-2020
OI Lochmuller, Hanns/0000-0003-2324-8001; Turnbull,
   Doug/0000-0002-8878-9901; Gorman, Grainne/0000-0002-7585-3409; Horvath,
   Rita/0000-0002-9841-170X; Spendiff, Sally/0000-0001-9579-3514
FU Medical Research Centre for Neuromuscular Diseases, Newcastle University
   Centre for Brain Ageing and Vitality; Biotechnology and Biological
   Sciences Research Council; Engineering and Physical Sciences Research
   Council; Medical Research Council as part of the cross-council Lifelong
   Health and Wellbeing Initiative [G0700718]; Wellcome Trust Centre for
   Mitochondrial Research [906919]; Newcastle NIHR Biomedical Research
   Centre; RCUK; MRC [G1000848, MR/K000608/1, G0700718] Funding Source:
   UKRI
FX This work was supported by the Medical Research Centre for Neuromuscular
   Diseases, Newcastle University Centre for Brain Ageing and Vitality
   supported by the Biotechnology and Biological Sciences Research Council,
   Engineering and Physical Sciences Research Council and the Medical
   Research Council as part of the cross-council Lifelong Health and
   Wellbeing Initiative (G0700718), The Wellcome Trust Centre for
   Mitochondrial Research (906919) and Newcastle NIHR Biomedical Research
   Centre. Funding to pay the Open Access publication charges for this
   article was provided by RCUK.
CR [Anonymous], 2010, HEALTH TECHNOL ASSES, DOI DOI 10.1369/JHC.2010.956201
   Auré K, 2007, BRAIN, V130, P1516, DOI 10.1093/brain/awm067
   Blackwood JK, 2010, BIOCHEM BIOPH RES CO, V393, P740, DOI 10.1016/j.bbrc.2010.02.072
   Blakely EL, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.011296
   Clark KM, 1997, NAT GENET, V16, P222, DOI 10.1038/ng0797-222
   Fu K, 1996, HUM MOL GENET, V5, P1835, DOI 10.1093/hmg/5.11.1835
   Gros J, 2005, NATURE, V435, P954, DOI 10.1038/nature03572
   Hawke TJ, 2001, J APPL PHYSIOL, V91, P534, DOI 10.1152/jappl.2001.91.2.534
   He LP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf067
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   HOLT IJ, 1989, ANN NEUROL, V26, P699, DOI 10.1002/ana.410260603
   Krishnan KJ, 2007, ANAL BIOCHEM, V370, P127, DOI 10.1016/j.ab.2007.06.024
   Kuang S, 2008, CELL STEM CELL, V2, P22, DOI 10.1016/j.stem.2007.12.012
   Kuang SH, 2007, CELL, V129, P999, DOI 10.1016/j.cell.2007.03.044
   LANIER LL, 1986, J IMMUNOL, V136, P4480
   Larsson NG, 2001, ACTA PHYSIOL SCAND, V171, P385, DOI 10.1046/j.1365-201x.2001.00842.x
   Le Grand F, 2007, CURR OPIN CELL BIOL, V19, P628, DOI 10.1016/j.ceb.2007.09.012
   MAURO A, 1961, J BIOPHYS BIOCHEM CY, V9, P493, DOI 10.1083/jcb.9.2.493
   MCSHANE MA, 1991, AM J HUM GENET, V48, P39
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   MORAES CT, 1989, BIOCHEM BIOPH RES CO, V160, P765, DOI 10.1016/0006-291X(89)92499-6
   Murphy JL, 2008, BRAIN, V131, P2832, DOI 10.1093/brain/awn252
   Murphy JL, 2012, NEUROMUSCULAR DISORD, V22, P690, DOI 10.1016/j.nmd.2012.04.003
   OLD SL, 1989, HISTOCHEM J, V21, P545, DOI 10.1007/BF01753355
   POULTON J, 1993, HUM MOL GENET, V2, P23, DOI 10.1093/hmg/2.1.23
   Reeve AK, 2008, AM J HUM GENET, V82, P228, DOI 10.1016/j.ajhg.2007.09.018
   Rossignol R, 1999, J BIOL CHEM, V274, P33426, DOI 10.1074/jbc.274.47.33426
   Rossignol R, 2003, BIOCHEM J, V370, P751, DOI 10.1042/BJ20021594
   ROTIG A, 1995, HUM MOL GENET, V4, P1327, DOI 10.1093/hmg/4.8.1327
   Rozen S, 2000, Methods Mol Biol, V132, P365
   Shoubridge EA, 1997, HUM MOL GENET, V6, P2239, DOI 10.1093/hmg/6.13.2239
   Taivassalo T, 1999, HUM MOL GENET, V8, P1047, DOI 10.1093/hmg/8.6.1047
   Taivassalo T, 2004, BBA-BIOENERGETICS, V1659, P221, DOI 10.1016/j.bbabio.2004.09.007
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   Weber K, 1997, AM J HUM GENET, V60, P373
NR 36
TC 27
Z9 28
U1 0
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD DEC 1
PY 2013
VL 22
IS 23
BP 4739
EP 4747
DI 10.1093/hmg/ddt327
PG 9
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 251ZD
UT WOS:000326973000008
PM 23847047
OA Green Published, Green Submitted
DA 2024-11-01
ER

PT J
AU Bornstein, B
   Area, E
   Flanigan, KM
   Ganesh, J
   Jayakar, P
   Swoboda, KJ
   Coku, J
   Naini, A
   Shanske, S
   Tanji, K
   Hirano, M
   DiMauro, S
AF Bornstein, Belen
   Area, Estela
   Flanigan, Kevin M.
   Ganesh, Jaya
   Jayakar, Parul
   Swoboda, Kathryn J.
   Coku, Jorida
   Naini, Ali
   Shanske, Sara
   Tanji, Kurenal
   Hirano, Michio
   DiMauro, Salvatore
TI Mitochondrial DNA depletion syndrome due to mutations in the
   <i>RRM2B</i> gene
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE mtDNA depletion; mitochondrial myopathy; RRM2B
ID RIBONUCLEOTIDE REDUCTASE; THYMIDINE KINASE; MTDNA DEPLETION;
   ALPERS-SYNDROME; POLG MUTATIONS; DEFICIENCY
AB Mitochondrial DNA depletion syndrome (MDS) is characterized by a reduction in mtDNA copy number and has been associated with mutations in eight nuclear genes, including enzymes involved in mitochondrial nucleotide metabolism (POLG, TK2, DGUOK, SUCLA2, SUCLG1, PEO1) and MPV17. Recently, mutations in the RRM2B gene, encoding the p53-controlled ribonucleotide reductase subunit, have been described in seven infants from four families, who presented with various combinations of hypotonia, tubulopathy, seizures, respiratory distress, diarrhea, and lactic acidosis. All children died before 4 months of age.
   We sequenced the RRM2B gene in three unrelated cases with unexplained severe mtDNA depletion. The first patient developed intractable diarrhea, profound weakness, respiratory distress, and died at 3 months. The other two unrelated patients had a much milder phenotype and are still alive at ages 27 and 36 months.
   All three patients had lactic acidosis and severe depletion of mtDNA in muscle. Muscle histochemistry showed RRF and COX deficiency. Sequencing the RRM2B gene revealed three missense mutations and two single nucleotide deletions in exons 6, 8, and 9, confirming that RRM2B mutations are important causes of MDS and that the clinical phenotype is heterogeneous and not invariably fatal in infancy. (C) 2008 Elsevier B.V. All rights reserved.
C1 [Area, Estela; Coku, Jorida; Naini, Ali; Shanske, Sara; Hirano, Michio; DiMauro, Salvatore] Columbia Univ, Med Ctr, Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA.
   [Bornstein, Belen] UAM, CSIC, CIBERER,ISCiii,Dept Bioquim, Inst Invest Biomed,Hosp Univ Puerta Hierro, Madrid, Spain.
   [Tanji, Kurenal] Columbia Univ, Med Ctr, Dept Pathol, New York, NY 10032 USA.
   [Flanigan, Kevin M.; Swoboda, Kathryn J.] Univ Utah, Sch Med, Dept Neurol, Salt Lake City, UT USA.
   [Flanigan, Kevin M.; Swoboda, Kathryn J.] Univ Utah, Sch Med, Dept Pathol, Salt Lake City, UT USA.
   [Flanigan, Kevin M.; Swoboda, Kathryn J.] Univ Utah, Sch Med, Dept Human Genet, Salt Lake City, UT 84132 USA.
   [Ganesh, Jaya] Univ Penn, Sch Med, Childrens Hosp Philadelphia, Dept Metab & Genet, Philadelphia, PA 19104 USA.
   [Jayakar, Parul] Miami Childrens Hosp, Dr John T Mcdonald Fdn Ctr Med Genet, Miami, FL USA.
C3 Columbia University; CIBER - Centro de Investigacion Biomedica en Red;
   CIBERER; Hospital Puerta de Hierro-Majadahonda; Autonomous University of
   Madrid; Instituto de Salud Carlos III; Consejo Superior de
   Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones
   Biomedicas Alberto Sols (IIBM); Columbia University; Utah System of
   Higher Education; University of Utah; Utah System of Higher Education;
   University of Utah; Utah System of Higher Education; University of Utah;
   University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of
   Philadelphia
RP DiMauro, S (corresponding author), Columbia Univ, Med Ctr, Coll Phys & Surg, Dept Neurol, 3-313 Russ Berrie Med Sci Pavil,,1150 St Nichola, New York, NY 10032 USA.
EM sd12@columbia.edu
OI Area Gomez, Estela/0000-0002-0962-1570; Swoboda,
   Kathryn/0000-0002-4593-6342; Flanigan, Kevin/0000-0001-6440-3376
FU NICHD NIH HHS [P01 HD032062, HD32062] Funding Source: Medline
CR Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Chinnery PF, 2007, BRAIN, V130, P606, DOI 10.1093/brain/awm023
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   Di Mauro S, 2008, MOL GENETIC BASIS NE, P169
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   Larsson KM, 2004, NAT STRUCT MOL BIOL, V11, P1142, DOI 10.1038/nsmb838
   Mancuso M, 2005, ARCH NEUROL-CHICAGO, V62, P745, DOI 10.1001/archneur.62.5.745
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   MANDERBACKA K, 2001, SCANDINAVIAN J P S55, V29, P41
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Ostergaard E, 2007, AM J HUM GENET, V81, P383, DOI 10.1086/519222
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Sarzi E, 2007, ANN NEUROL, V62, P579, DOI 10.1002/ana.21207
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Tanji K, 2001, METHOD CELL BIOL, V65, P311, DOI 10.1016/S0091-679X(01)65019-2
NR 19
TC 70
Z9 77
U1 0
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD JUN
PY 2008
VL 18
IS 6
BP 453
EP 459
DI 10.1016/j.nmd.2008.04.006
PG 7
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 331PB
UT WOS:000258023000004
PM 18504129
OA Green Accepted
DA 2024-11-01
ER

PT J
AU Van Goethem, G
   Luoma, P
   Rantamäki, M
   Al Memar, A
   Kaakkola, S
   Hackman, P
   Krahe, R
   Löfgren, A
   Martin, JJ
   De Jonghe, P
   Suomalainen, A
   Udd, B
   Van Broeckhoven, C
AF Van Goethem, G
   Luoma, P
   Rantamäki, M
   Al Memar, A
   Kaakkola, S
   Hackman, P
   Krahe, R
   Löfgren, A
   Martin, JJ
   De Jonghe, P
   Suomalainen, A
   Udd, B
   Van Broeckhoven, C
TI <i>POLG</i> mutations in neurodegenerative disorders with ataxia but no
   muscle involvement
SO NEUROLOGY
LA English
DT Article
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; MITOCHONDRIAL-DNA DELETIONS;
   MULTIPLE DELETIONS; NEUROGASTROINTESTINAL ENCEPHALOMYOPATHY;
   AUTOSOMAL-DOMINANT; POLYMERASE-GAMMA; MTDNA DELETIONS; PATIENT;
   CARDIOMYOPATHY; NEUROPATHY
AB Objective: To identify POLG mutations in patients with sensory ataxia and CNS features. Methods: The authors characterized clinical, laboratory, and molecular genetic features in eight patients from five European families. The authors conducted sequencing of coding exons of POLG, C10orf2 ( Twinkle), and ANT1 and analyzed muscle mitochondrial DNA ( mtDNA), including Southern blot analysis and long-range PCR. Results: Ataxia occurred in combination with various CNS features, including myoclonus, epilepsy, cognitive decline, nystagmus, dysarthria, thalamic and cerebellar white matter lesions on MRI, and neuronal loss in discrete gray nuclei on autopsy. Gastrointestinal dysmotility, weight loss, cardiomyopathy, and valproate-induced hepatotoxicity occurred less frequently. Two patients died without preceding signs of progressive external ophthalmoplegia. In muscle, typical findings of mitochondrial disease, such as ragged red fibers and Southern blot mtDNA abnormalities, were absent. POLG mutations were present in eight patients, including two isolated cases, and one Finnish and two unrelated Belgian families contained in total six patients. All POLG mutations were recessive, occurring in a homozygous state in seven patients and in a compound heterozygous state in one patient. The novel W748S mutation was identified in five patients from three unrelated families. Conclusions: The clinical spectrum of recessive POLG mutations is expanded by sensory ataxic neuropathy, combined with variable features of involvement of CNS and other organs. Progressive external ophthalmoplegia, myopathy, ragged red fibers, and Southern blot abnormalities of muscle mitochondrial DNA also are not mandatory features associated with POLG mutations.
C1 Univ Instelling Antwerp, Dept Mol Genet, B-2610 Antwerp, Belgium.
   Univ Antwerp Hosp, Div Neurol, Antwerp, Belgium.
   Univ Antwerp Hosp, Neuromuscular Reference Ctr, Antwerp, Belgium.
   Flanders Interuniv Inst Biotechnol VIB8, Dept Mol Genet, Antwerp, Belgium.
   Born Bunge Fdn, Dept Neuropathol, Antwerp, Belgium.
   Univ Helsinki, Program Neurosci, Helsinki, Finland.
   Univ Helsinki, Dept Neurol, Helsinki, Finland.
   Univ Helsinki, Cent Hosp, Dept Neurol, Helsinki, Finland.
   Seinajoki Cent Hosp, Dept Phys Med, Seinajoki, Finland.
   Seinajoki Cent Hosp, Dept Rehabil & Neurol, Seinajoki, Finland.
   Atkinson Morelys Hosp, Dept Neurol, London, England.
   Univ Helsinki, Dept Med Genet, Folkhalsan Inst Genet, Helsinki, Finland.
   Univ Texas, MD Anderson Canc Ctr, Sect Canc Genet, Dept Mol Genet, Houston, TX 77030 USA.
   Vaasa Cent Hosp, Vaasa, Finland.
   Tampere Univ Hosp, Tampere, Finland.
C3 University of Antwerp; University of Antwerp; University of Antwerp;
   University of Helsinki; University of Helsinki; University of Helsinki;
   Helsinki University Central Hospital; Seinajoki Central Hospital;
   Seinajoki Central Hospital; University of Helsinki; University of Texas
   System; UTMD Anderson Cancer Center; Vaasa Central Hospital; Tampere
   University; Tampere University Hospital
RP Van Goethem, G (corresponding author), Univ Instelling Antwerp, Dept Mol Genet, VIB8 Univ Pl 1, B-2610 Antwerp, Belgium.
EM gert.vangoethem@ua.ac.be
RI Udd, Bjarne/JBE-3483-2023; Van Broeckhoven, Christine/M-7853-2019; Van
   Broeckhoven, Christine/G-8362-2017
OI Suomalainen-Wartiovaara, Anu/0000-0003-4833-5195; Van Broeckhoven,
   Christine/0000-0003-0183-7665; Krahe, Ralf/0000-0002-7810-2539
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Alderborn A, 2000, GENOME RES, V10, P1249, DOI 10.1101/gr.10.8.1249
   Blumenthal DT, 1998, NEUROLOGY, V50, P524, DOI 10.1212/WNL.50.2.524
   Bohlega S, 1996, NEUROLOGY, V46, P1329, DOI 10.1212/WNL.46.5.1329
   CORMIER V, 1991, AM J HUM GENET, V48, P643
   Cottrell DA, 2000, J NEUROPATH EXP NEUR, V59, P621, DOI 10.1093/jnen/59.7.621
   Di Fonzo A, 2003, HUM MUTAT, V22, DOI 10.1002/humu.9203
   Fadic R, 1997, NEUROLOGY, V49, P239, DOI 10.1212/WNL.49.1.239
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   HIRANO M, 1994, NEUROLOGY, V44, P721, DOI 10.1212/WNL.44.4.721
   KAGUNI LS, 1982, P NATL ACAD SCI-BIOL, V79, P983, DOI 10.1073/pnas.79.4.983
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kogelnik AM, 1996, NUCLEIC ACIDS RES, V24, P177, DOI 10.1093/nar/24.1.177
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   MARTIN JJ, 1991, HDB CLIN NEUROLOGY, V1660, P701
   MORAES CT, 1992, NAT GENET, V1, P359, DOI 10.1038/ng0892-359
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Nishino I, 2000, ANN NEUROL, V47, P792
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   OHNO K, 1991, ANN NEUROL, V29, P364, DOI 10.1002/ana.410290406
   Parton MJ, 2002, HUM MUTAT, V20, DOI 10.1002/humu.9081
   Paul R, 2000, EUR J HUM GENET, V8, P331, DOI 10.1038/sj.ejhg.5200463
   Rantamäki M, 2001, NEUROLOGY, V57, P1043, DOI 10.1212/WNL.57.6.1043
   SPARACO M, 1993, J NEUROPATH EXP NEUR, V52, P1, DOI 10.1097/00005072-199301000-00001
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   SUOMALAINEN A, 1992, LANCET, V340, P1319, DOI 10.1016/0140-6736(92)92496-3
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, NEUROLOGY, V61, P1811, DOI 10.1212/01.WNL.0000098997.23471.65
   Van Goethem G, 2003, NEUROMOL MED, V3, P129, DOI 10.1385/NMM:3:3:129
   Van Goethem G, 2003, HUM MUTAT, V22, P175, DOI 10.1002/humu.10246
   Van Goethem G, 2003, EUR J HUM GENET, V11, P547, DOI 10.1038/sj.ejhg.5201002
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   VanGoethem G, 1997, EUR J NEUROL, V4, P476
   Ye F, 1996, NUCLEIC ACIDS RES, V24, P1481, DOI 10.1093/nar/24.8.1481
   YUZAKI M, 1989, BIOCHEM BIOPH RES CO, V164, P1352, DOI 10.1016/0006-291X(89)91818-4
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 37
TC 204
Z9 215
U1 0
U2 11
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD OCT 12
PY 2004
VL 63
IS 7
BP 1251
EP 1257
DI 10.1212/01.WNL.0000140494.58732.83
PG 7
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 861HV
UT WOS:000224408000021
PM 15477547
DA 2024-11-01
ER

PT J
AU Nakada, K
   Sato, A
   Hayashi, JI
AF Nakada, Kazuto
   Sato, Akitsugu
   Hayashi, Jun-Ichi
TI Reverse genetic studies of mitochondrial DNA-based diseases using a
   mouse model
SO PROCEEDINGS OF THE JAPAN ACADEMY SERIES B-PHYSICAL AND BIOLOGICAL
   SCIENCES
LA English
DT Review
DE mouse model; mitochondrial DNA; large-scale deletion mutation;
   mitochondrial complementation; mitochondrial diseases
ID PROTEIN-SYNTHESIS; OXIDATIVE-PHOSPHORYLATION; DILATED CARDIOMYOPATHY;
   FUNCTIONAL INTEGRITY; RESPIRATION DEFECTS; SKELETAL-MUSCLE; MUTANT
   MTDNA; CELL LINES; MUTATIONS; MICE
AB In the situation that it would not be able to produce model animals for mitochondrial diseases caused by mitochondrial DNA (mtDNA) with pathogenic mutations, we succeeded in generating mice with pathogenic deletion mutant mtDNA (Delta mtDNA), named "mito-mice", by direct introduction of mitochondria with Delta mtDNA into mouse zygotes. In the mito-mice, accumulation of Delta mtDNA induced mitochondrial respiration defects in various tissues, resulting in mitochondrial disease phenotypes, such as low body weight, lactic acidosis, ischemia, myopathy, heart block, deafness, male infertility, and renal failure. Thus, mito-mice are the first model animal for mtDNA-based diseases, and the mice could be valuable for understanding precise pathogeneses and testing therapies of mitochondrial diseases. In the present review, we summarized reverse genetic studies using the mito-mice.
C1 [Nakada, Kazuto; Sato, Akitsugu; Hayashi, Jun-Ichi] Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki 3058572, Japan.
C3 University of Tsukuba
RP Hayashi, JI (corresponding author), Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki 3058572, Japan.
EM jih45@sakura.cc.tsukuba.ac.jp
CR Anderson DE, 2002, J CELL BIOL, V156, P419, DOI 10.1083/jcb.200111002
   Barton NR, 1996, P NATL ACAD SCI USA, V93, P1735, DOI 10.1073/pnas.93.5.1735
   CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236
   CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221
   CLAYTON DA, 1984, ANNU REV BIOCHEM, V53, P573
   CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6
   Cobb J, 1998, SEMIN CELL DEV BIOL, V9, P445, DOI 10.1006/scdb.1998.0202
   Cohen J, 1997, LANCET, V350, P186, DOI 10.1016/S0140-6736(05)62353-7
   Cohen J, 1998, MOL HUM REPROD, V4, P269, DOI 10.1093/molehr/4.3.269
   CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324
   Dimmer KS, 2006, PHYSIOLOGY, V21, P233, DOI 10.1152/physiol.00010.2006
   Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226
   Habu T, 1996, NUCLEIC ACIDS RES, V24, P470, DOI 10.1093/nar/24.3.470
   HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614
   HAYASHI JI, 1994, J BIOL CHEM, V269, P6878
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826
   Inoue K, 1997, BIOCHEM BIOPH RES CO, V239, P257, DOI 10.1006/bbrc.1997.7446
   Inoue K, 1997, J BIOL CHEM, V272, P15510, DOI 10.1074/jbc.272.24.15510
   Inoue SI, 2007, FEBS LETT, V581, P1910, DOI 10.1016/j.febslet.2007.03.092
   Isobe K, 1998, J BIOL CHEM, V273, P4601, DOI 10.1074/jbc.273.8.4601
   Ito S, 1998, BIOCHEM BIOPH RES CO, V247, P432, DOI 10.1006/bbrc.1998.8800
   Ito S, 1999, P NATL ACAD SCI USA, V96, P2099, DOI 10.1073/pnas.96.5.2099
   Kasahara A, 2006, HUM MOL GENET, V15, P871, DOI 10.1093/hmg/ddl005
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   Laderman KA, 1996, J BIOL CHEM, V271, P15891, DOI 10.1074/jbc.271.27.15891
   Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231
   LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376
   LINNANE AW, 1989, LANCET, V1, P642, DOI 10.1016/S0140-6736(89)92145-4
   Liu VWS, 1998, NUCLEIC ACIDS RES, V26, P1268, DOI 10.1093/nar/26.5.1268
   Maechler P, 2001, NATURE, V414, P807, DOI 10.1038/414807a
   Marchington DR, 1998, AM J HUM GENET, V63, P769, DOI 10.1086/302009
   Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774
   MORITA T, 1993, P NATL ACAD SCI USA, V90, P6577, DOI 10.1073/pnas.90.14.6577
   Nagley P, 1998, TRENDS GENET, V14, P513, DOI 10.1016/S0168-9525(98)01580-7
   Nakada K, 2004, BIOCHEM BIOPH RES CO, V323, P175, DOI 10.1016/j.bbrc.2004.08.073
   Nakada K, 2001, BIOCHEM BIOPH RES CO, V288, P901, DOI 10.1006/bbrc.2001.5873
   Nakada K, 2001, NAT MED, V7, P934, DOI 10.1038/90976
   Nakada K, 2006, P NATL ACAD SCI USA, V103, P15148, DOI 10.1073/pnas.0604641103
   Ono T, 2001, NAT GENET, V28, P272, DOI 10.1038/90116
   Pospisilik JA, 2007, CELL, V131, P476, DOI 10.1016/j.cell.2007.08.047
   Sato A, 2005, P NATL ACAD SCI USA, V102, P16765, DOI 10.1073/pnas.0506197102
   Sato A, 2005, P NATL ACAD SCI USA, V102, P6057, DOI 10.1073/pnas.0408666102
   Sato A, 2004, GENETICS, V167, P1855, DOI 10.1534/genetics.103.021287
   Sato A, 2007, GENETICS, V177, P2031, DOI 10.1534/genetics.107.081026
   SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   Silva JP, 2000, NAT GENET, V26, P336, DOI 10.1038/81649
   SOONG NW, 1992, NAT GENET, V2, P318
   Sörensen L, 2001, J NEUROSCI, V21, P8082, DOI 10.1523/JNEUROSCI.21-20-08082.2001
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Thorburn DR, 2001, AM J MED GENET, V106, P102, DOI 10.1002/ajmg.1380
   TROUNCE I, 1989, LANCET, V1, P637, DOI 10.1016/S0140-6736(89)92143-0
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953
   Wang JM, 1999, NAT GENET, V21, P133, DOI 10.1038/5089
   Wredenberg A, 2006, BIOCHEM BIOPH RES CO, V350, P202, DOI 10.1016/j.bbrc.2006.09.029
   YONEDA M, 1994, MOL CELL BIOL, V14, P2699, DOI 10.1128/MCB.14.4.2699
NR 58
TC 5
Z9 7
U1 0
U2 12
PU JAPAN ACAD
PI TOKYO
PA 7-32, UENO PARK, TAITO-KU, TOKYO, 110-0007, JAPAN
SN 0386-2208
J9 P JPN ACAD B-PHYS
JI Proc. Jpn. Acad. Ser. B-Phys. Biol. Sci.
PD MAY
PY 2008
VL 84
IS 5
BP 155
EP 165
DI 10.2183/pjab.84.155
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 307KE
UT WOS:000256317000004
PM 18941295
OA Green Published, Bronze, Green Accepted
DA 2024-11-01
ER

PT J
AU Garone, C
   Gurgel-Giannetti, J
   Sanna-Cherchi, S
   Krishna, S
   Naini, A
   Quinzii, CM
   Hirano, M
AF Garone, Caterina
   Gurgel-Giannetti, Juliana
   Sanna-Cherchi, Simone
   Krishna, Sindu
   Naini, Ali
   Quinzii, Catarina M.
   Hirano, Michio
TI A Novel <i>SUCLA2</i> Mutation Presenting as a Complex Childhood
   Movement Disorder
SO JOURNAL OF CHILD NEUROLOGY
LA English
DT Article
DE SUCLA2; coenzyme Q10; movement disorders; brain MRI
ID MITOCHONDRIAL-DNA DEPLETION; ENCEPHALOMYOPATHY; REPLICATION; DEFICIENCY;
   DEFECTS; SUBUNIT; DISEASE
AB SUCLA2 defects have been associated with mitochondrial DNA (mtDNA) depletion and the triad of hypotonia, dystonia/ Leighlike syndrome, and deafness. A 9-year-old Brazilian boy of consanguineous parents presented with psychomotor delay, deafness, myopathy, ataxia, and chorea. Despite the prominent movement disorder, brain magnetic resonance imaging (MRI) was normal while 1 H-magnetic resonance spectroscopy (MRS) showed lactate peaks in the cerebral cortex and lateral ventricles. Decreased biochemical activities of mitochondrial respiratory chain enzymes containing mtDNA-encoded subunits and mtDNA depletion were observed in muscle and fibroblasts. A novel homozygous mutation in SUCLA2, the first one in the ligase coenzyme A (CoA) domain of the protein, was identified. Escalating doses of CoQ10 up to 2000 mg daily were associated with improvement of muscle weakness and stabilization of the disease course. The findings indicate the importance of screening for mitochondrial dysfunction in patients with complex movement disorders without brain MRI lesions and further investigation for potential secondary CoQ10 deficiency in patients with SUCLA2 mutations.
C1 [Garone, Caterina; Krishna, Sindu; Quinzii, Catarina M.; Hirano, Michio] Columbia Univ, Med Ctr, Dept Neurol, New York, NY USA.
   [Garone, Caterina] Univ Turin, Turin, Italy.
   [Garone, Caterina] Univ Bologna, Turin, Italy.
   [Gurgel-Giannetti, Juliana] Univ Fed Minas Gerais, Dept Pediat, Belo Horizonte, MG, Brazil.
   [Sanna-Cherchi, Simone] Columbia Univ, Med Ctr, Dept Med, New York, NY USA.
   [Naini, Ali] Columbia Univ, Med Ctr, Dept Pathol, New York, NY USA.
C3 Columbia University; University of Turin; University of Bologna;
   Universidade Federal de Minas Gerais; Columbia University; Columbia
   University
RP Hirano, M (corresponding author), Columbia Univ, Med Ctr, 630 168th St, New York, NY 10032 USA.
EM mh29@columbia.edu
RI Garone, Caterina/AAB-8659-2019; Gurgel-Giannetti, Juliana/AAK-2172-2021
OI Garone, Caterina/0000-0003-4928-1037; Gurgel-Giannetti,
   Juliana/0000-0003-3335-1491
FU NIH [U54 NS078059, P01 HD080642]; MDA; Marriott Mitochondrial Disease
   Clinical Research Fund (MMDCRF); Eunice Kennedy Shriver National
   Institute of Child Health and Human Development [K23 HD065871]
FX The authors disclosed receipt of the following financial support for the
   research, authorship, and/or publication of this article: MH is
   supported by grants from NIH (U54 NS078059 and P01 HD080642), MDA, and
   the Marriott Mitochondrial Disease Clinical Research Fund (MMDCRF). CMQ
   is supported by grant K23 HD065871 from the Eunice Kennedy Shriver
   National Institute of Child Health and Human Development and MDA.
CR Carrozzo R, 2007, BRAIN, V130, P862, DOI 10.1093/brain/awl389
   Copeland WC, 2012, CRIT REV BIOCHEM MOL, V47, P64, DOI 10.3109/10409238.2011.632763
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279
   Jaberi E, 2013, J HUM GENET, V58, P526, DOI 10.1038/jhg.2013.45
   Kornblum C, 2013, NAT GENET, V45, P214, DOI 10.1038/ng.2501
   Lamperti C, 2012, MOL GENET METAB, V107, P403, DOI 10.1016/j.ymgme.2012.08.020
   Miller C, 2011, BBA-MOL BASIS DIS, V1812, P625, DOI 10.1016/j.bbadis.2011.01.013
   Morava E, 2009, MITOCHONDRION, V9, P438, DOI 10.1016/j.mito.2009.08.003
   Ostergaard E, 2007, AM J HUM GENET, V81, P383, DOI 10.1086/519222
   Ostergaard E, 2007, BRAIN, V130, P853, DOI 10.1093/brain/awl383
   Walker UA, 1996, EUR NEUROL, V36, P260, DOI 10.1159/000117269
NR 12
TC 10
Z9 12
U1 0
U2 1
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0883-0738
EI 1708-8283
J9 J CHILD NEUROL
JI J. Child Neurol.
PD FEB
PY 2017
VL 32
IS 2
BP 246
EP 250
DI 10.1177/0883073816666221
PG 5
WC Clinical Neurology; Pediatrics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pediatrics
GA EP2LC
UT WOS:000397213600015
PM 27651038
OA Green Accepted
DA 2024-11-01
ER

PT J
AU Lehmann, D
   Schubert, K
   Joshi, PR
   Hardy, SA
   Tuppen, HAL
   Baty, K
   Blakely, EL
   Bamberg, C
   Zierz, S
   Deschauer, M
   Taylor, RW
AF Lehmann, Diana
   Schubert, Kathrin
   Joshi, Pushpa R.
   Hardy, Steven A.
   Tuppen, Helen A. L.
   Baty, Karen
   Blakely, Emma L.
   Bamberg, Christian
   Zierz, Stephan
   Deschauer, Marcus
   Taylor, Robert W.
TI Pathogenic mitochondrial mt-tRNA<SUP>Ala</SUP> variants are uniquely
   associated with isolated myopathy
SO EUROPEAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID RNA POINT MUTATIONS; EXTERNAL OPHTHALMOPLEGIA; TRNA(ALA) GENE; PURE
   MYOPATHY; DNA MUTATIONS; HUMAN-DISEASE; PATIENT
AB Pathogenic mitochondrial DNA (mtDNA) point mutations are associated with a wide range of clinical phenotypes, often involving multiple organ systems. We report two patients with isolated myopathy owing to novel mt-tRNA(Ala) variants. Muscle biopsy revealed extensive histopathological findings including cytochrome c oxidase (COX)-deficient fibres. Pyrosequencing confirmed mtDNA heteroplasmy for both mutations (m.5631G>A and m.5610G>A) whilst single-muscle fibre segregation studies (revealing statistically significant higher mutation loads in COX-deficient fibres than in COX-positive fibres), hierarchical mutation segregation within patient tissues and decreased steady-state mt-tRNAAla levels all provide compelling evidence of pathogenicity. Interestingly, both patients showed very high-mutation levels in all tissues, inferring that the threshold for impairment of oxidative phosphorylation, as evidenced by COX deficiency, appears to be extremely high for these mt-tRNAAla variants. Previously described mt-tRNAAla mutations are also associated with a pure myopathic phenotype and demonstrate very high mtDNA heteroplasmy thresholds, inferring at least some genotype: phenotype correlation for mutations within this particular mt-tRNA gene.
C1 [Lehmann, Diana; Schubert, Kathrin; Joshi, Pushpa R.; Zierz, Stephan; Deschauer, Marcus] Univ Halle Wittenberg, Dept Neurol, D-06108 Halle, Saale, Germany.
   [Hardy, Steven A.; Tuppen, Helen A. L.; Baty, Karen; Blakely, Emma L.; Taylor, Robert W.] Newcastle Univ, Sch Med, Inst Neurosci, Wellcome Trust Ctr Mitochondrial Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Bamberg, Christian] Rhein Mosel Fachklin, Dept Neurol, Andernach, Germany.
C3 Martin Luther University Halle Wittenberg; Newcastle University - UK
RP Taylor, RW (corresponding author), Newcastle Univ, Sch Med, Inst Neurosci, Wellcome Trust Ctr Mitochondrial Res, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM robert.taylor@ncl.ac.uk
OI Bamberg, Christian/0000-0002-8135-0453; Tuppen,
   Helen/0000-0001-8762-0824
FU German Ministry of Education and Research; Wellcome Trust
   [096919Z/11/Z]; Medical Research Council (UK) Centre for Translational
   Muscle Disease Research [G0601943]; Lily Foundation; UK NHS Specialist
   Commissioners funds the 'Rare Mitochondrial Disorders of Adults and
   Children' Diagnostic Service in Newcastle upon Tyne; MRC [G0601943,
   MR/K000608/1] Funding Source: UKRI
FX We acknowledge the technical assistance of Kathleen Zietz, Thekla
   Wangemann and Gavin Falkous. DL, PRJ, SZ and MD are members of the
   German mitoNET funded by the German Ministry of Education and Research.
   RWT is supported by a Wellcome Trust Strategic Award (096919Z/11/Z), the
   Medical Research Council (UK) Centre for Translational Muscle Disease
   Research (G0601943), The Lily Foundation and the UK NHS Specialist
   Commissioners which funds the 'Rare Mitochondrial Disorders of Adults
   and Children' Diagnostic Service in Newcastle upon Tyne
   (http://www.mitoresearch.org.uk/).
CR Blakely EL, 2013, HUM MUTAT, V34, P1260, DOI 10.1002/humu.22358
   Deschauer M, 2003, NEUROMUSCULAR DISORD, V13, P568, DOI 10.1016/S0960-8966(03)00071-3
   DIMAURO S, 1993, ARCH NEUROL-CHICAGO, V50, P1197, DOI 10.1001/archneur.1993.00540110075008
   Gellerich FN, 2002, BBA-BIOENERGETICS, V1556, P41, DOI 10.1016/S0005-2728(02)00305-5
   He LP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf067
   McFarland R, 2008, NEUROMUSCULAR DISORD, V18, P63, DOI 10.1016/j.nmd.2007.07.007
   Pinós T, 2011, MITOCHONDRION, V11, P228, DOI 10.1016/j.mito.2010.08.008
   Spagnolo M, 2001, NEUROMUSCULAR DISORD, V11, P481, DOI 10.1016/S0960-8966(01)00195-X
   Swalwell H, 2006, NEUROLOGY, V66, P447, DOI 10.1212/01.wnl.0000196490.36349.83
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Taylor RW, 2003, J AM COLL CARDIOL, V41, P1786, DOI 10.1016/S0735-1097(03)00300-0
   Tuppen HAL, 2010, BRAIN, V133, P2952, DOI 10.1093/brain/awq232
   Tuppen HAL, 2010, BBA-BIOENERGETICS, V1797, P113, DOI 10.1016/j.bbabio.2009.09.005
   White HE, 2005, GENET TEST, V9, P190, DOI 10.1089/gte.2005.9.190
   Wong LJC, 2007, MITOCHONDRION, V7, P45, DOI 10.1016/j.mito.2006.11.025
   Yarham JW, 2012, MITOCHONDRION, V12, P533, DOI 10.1016/j.mito.2012.06.009
   Yarham JW, 2010, WIRES RNA, V1, P304, DOI 10.1002/wrna.27
NR 17
TC 19
Z9 20
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1018-4813
EI 1476-5438
J9 EUR J HUM GENET
JI Eur. J. Hum. Genet.
PD DEC
PY 2015
VL 23
IS 12
BP 1735
EP 1738
DI 10.1038/ejhg.2015.73
PG 4
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA CW6TC
UT WOS:000365129700025
PM 25873012
OA Green Accepted, hybrid
DA 2024-11-01
ER

PT J
AU Darin, N
   Siibak, T
   Peter, B
   Hedberg-Oldfors, C
   Kollberg, G
   Kalbin, V
   Moslemi, AR
   Macao, B
   Oldfors, A
   Falkenberg, M
AF Darin, Niklas
   Siibak, Triinu
   Peter, Bradley
   Hedberg-Oldfors, Carola
   Kollberg, Gittan
   Kalbin, Vassili
   Moslemi, Ali-Reza
   Macao, Bertil
   Oldfors, Anders
   Falkenberg, Maria
TI Functional analysis of a novel POLγ A mutation associated with a severe
   perinatal mitochondrial encephalomyopathy
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE DNA polymerase gamma; Mutation; Mitochondrial replication; Disease;
   Perinatal phenotype
ID DNA-POLYMERASE-GAMMA; CIS T251I; SPECTRUM; REPLICATION; STABILITY;
   DISEASES; MUTANTS
AB Mutations in the mitochondrial DNA polymerase gamma catalytic subunit (POL. A) compromise the stability of mitochondrial DNA (mtDNA) by leading to mutations, deletions and depletions in mtDNA. Patients with mutations in POL gamma A often differ remarkably in disease severity and age of onset. In this work we have studied the functional consequence of POL gamma A mutations in a patient with an uncommon and a very severe disease phenotype characterized by prenatal onset with intrauterine growth restriction, lactic acidosis from birth, encephalopathy, hepatopathy, myopathy, and early death. Muscle biopsy identified scattered COX-deficient muscle fibers, respiratory chain dysfunction and mtDNA depletion. We identified a novel POL.A mutation (p.His1134Tyr) in trans with the previously identified p.Thr251Ile/Pro587Leu double mutant. Biochemical characterization of the purified recombinant POL gamma A variants showed that the p.His1134Tyr mutation caused severe polymerase dysfunction. The p.Thr251Ile/Pro587Leu mutation caused reduced polymerase function in conditions of low dNTP concentration that mimic postmitotic tissues. Critically, when p.His1134Tyr and p.Thr251Ile/Pro587Leu were combined under these conditions, mtDNA replication was severely diminished and featured prominent stalling. Our data provide a molecular explanation for the patients mtDNA depletion and clinical features, particularly in tissues such as brain and muscle that have low dNTP concentration. (c) 2021 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)
C1 [Darin, Niklas] Univ Gothenburg, Dept Pediat, Inst Clin Sci, Gothenburg, Sweden.
   [Siibak, Triinu; Peter, Bradley; Kalbin, Vassili; Macao, Bertil; Falkenberg, Maria] Univ Gothenburg, Inst Biomed, Dept Med Biochem & Cell Biol, Box 440, S-40530 Gothenburg, Sweden.
   [Hedberg-Oldfors, Carola; Kollberg, Gittan; Moslemi, Ali-Reza; Oldfors, Anders] Univ Gothenburg, Inst Biomed, Dept Lab Med, Gothenburg, Sweden.
C3 University of Gothenburg; University of Gothenburg; University of
   Gothenburg
RP Darin, N (corresponding author), Univ Gothenburg, Dept Pediat, Inst Clin Sci, Gothenburg, Sweden.; Falkenberg, M (corresponding author), Univ Gothenburg, Inst Biomed, Dept Med Biochem & Cell Biol, Box 440, S-40530 Gothenburg, Sweden.
EM niklas.darin@vgregion.se; maria.falkenberg@medkem.gu.se
OI Falkenberg, Maria/0000-0001-8713-173X
FU Swedish Research Council; Swedish Cancer Foundation; European Research
   Council; IngaBritt and Arne Lundberg Foundation; Knut and Alice
   Wallenbergs Foundation; AnnMari and Per Ahlqvist Foundation; Vastra
   Gotalands Regionen [ALFGBG-727491, ALFGBG-718681, ALFGBG-716821]
FX We are grateful to Dr. Jay P. Uhler who helped to prepare the
   illustrations and to coordinate the manuscript. This work was supported
   by the Swedish Research Council (MF and AO); Swedish Cancer Foundation
   (MF); European Research Council (MF); the IngaBritt and Arne Lundberg
   Foundation (MF); the Knut and Alice Wallenbergs Foundation (MF); AnnMari
   and Per Ahlqvist Foundation (ND). Vastra Gotalands Regionen to M.F.
   (ALFGBG-727491), N.D. (ALFGBG-718681) and A.O. (ALFGBG-716821).
CR Bratic A, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9808
   Calvo SE, 2016, NUCLEIC ACIDS RES, V44, pD1251, DOI 10.1093/nar/gkv1003
   Chinnery Patrick F, 2008, Neuromuscul Disord, V18, P259, DOI 10.1016/j.nmd.2007.11.005
   CLAYTON DA, 1992, J INHERIT METAB DIS, V15, P439, DOI 10.1007/BF01799602
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   DeBalsi KL, 2017, J BIOL CHEM, V292, P4198, DOI 10.1074/jbc.M116.773341
   Falkenberg M, 2007, ANNU REV BIOCHEM, V76, P679, DOI 10.1146/annurev.biochem.76.060305.152028
   Farge G, 2007, NUCLEIC ACIDS RES, V35, P902, DOI 10.1093/nar/gkl1116
   Farnum GA, 2014, BBA-BIOENERGETICS, V1837, P1113, DOI 10.1016/j.bbabio.2014.01.021
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Ferraro P, 2006, P NATL ACAD SCI USA, V103, P18586, DOI 10.1073/pnas.0609020103
   Giordano C, 2009, NEUROLOGY, V72, P1103, DOI 10.1212/01.wnl.0000345002.47396.e1
   Hedberg-Oldfors C, 2020, NEUROL-GENET, V6, DOI 10.1212/NXG.0000000000000391
   Hikmat O, 2017, GENET MED, V19, P1217, DOI 10.1038/gim.2017.35
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Isohanni P, 2011, NEUROLOGY, V76, P811, DOI 10.1212/WNL.0b013e31820e7b25
   Kollberg G, 2005, EUR J HUM GENET, V13, P463, DOI 10.1038/sj.ejhg.5201341
   Kong ZQ, 2018, NUCLEIC ACIDS RES, V46, DOI 10.1093/nar/gky203
   Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257
   Lee YS, 2009, CELL, V139, P312, DOI 10.1016/j.cell.2009.07.050
   Lopez-Gomez C, 2017, ANN NEUROL, V81, P641, DOI 10.1002/ana.24922
   Lovan Alyson, 2013, BMJ Case Rep, V2013, DOI 10.1136/bcr-2013-010343
   Matulis D, 2005, BIOCHEMISTRY-US, V44, P5258, DOI 10.1021/bi048135v
   Moslemi AR, 1999, NEUROLOGY, V53, P79, DOI 10.1212/WNL.53.1.79
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Roos S, 2013, HUM MOL GENET, V22, P2411, DOI 10.1093/hmg/ddt094
   Scuderi C, 2015, NEUROMUSCULAR DISORD, V25, P333, DOI 10.1016/j.nmd.2015.01.004
   Shahim P, 2013, EUR J PAEDIATR NEURO, V17, P7, DOI 10.1016/j.ejpn.2012.09.005
   Sofou K, 2012, EUR J PAEDIATR NEURO, V16, P379, DOI 10.1016/j.ejpn.2011.12.006
   Szymanski MR, 2015, EMBO J, V34, P1959, DOI 10.15252/embj.201591520
   Taanman JW, 2009, HUM MUTAT, V30, P248, DOI 10.1002/humu.20852
   Tang S, 2011, J MED GENET, V48, P669, DOI 10.1136/jmedgenet-2011-100222
   Topham CM, 1997, PROTEIN ENG, V10, P7, DOI 10.1093/protein/10.1.7
   TULINIUS MH, 1991, J PEDIATR-US, V119, P242, DOI 10.1016/S0022-3476(05)80734-6
   Weiss MD, 2010, MUSCLE NERVE, V41, P882, DOI 10.1002/mus.21636
   Wheeler LJ, 2011, J BIOL CHEM, V286, P16992, DOI 10.1074/jbc.M111.236968
   Young MJ, 2016, CURR OPIN GENET DEV, V38, P52, DOI 10.1016/j.gde.2016.03.005
NR 37
TC 2
Z9 2
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD APR
PY 2021
VL 31
IS 4
BP 348
EP 358
DI 10.1016/j.nmd.2021.01.004
EA APR 2021
PG 11
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA RO6EP
UT WOS:000641136000009
PM 33579567
OA hybrid
DA 2024-11-01
ER

PT J
AU Gambello, MJ
   Bai, RK
   Chen, TJ
   Dimachkie, M
   Wong, LJC
AF Gambello, Michael J.
   Bai, Ren-Kui
   Chen, Tian-Jian
   Dimachkie, Mazen
   Wong, Lee-Jun C.
TI Exercise intolerance associated with a novel 8300T&gt;C mutation in
   mitochondrial transfer RNA<SUP>lys</SUP>
SO MUSCLE & NERVE
LA English
DT Article
DE exercise intolerance; mtDNA mutation; mitochondrial myopathy; transfer
   RNA; tRNA(lys)
ID TRANSFER-RNAS; DNA; DISEASE; DISORDERS; GENE
AB Mutations in the mitochondrial genome contribute to the pathophysiology of many neuromuscular diseases. Recently there has been an increased appreciation of the role of mitochondrial DNA (mtDNA) mutations in the etiology of exercise intolerance. Using TTGE (temporal temperature-gradient gel electrophoresis) and sequence analyses of the entire mitochondrial genome, we identified a novel heteroplasmic mutation (8300T > C) in the tRNA(lys) gene (MTTK) from a patient with unexplained exercise intolerance. The mutation was present in blood, hair, and muscle, with the highest percentage of heteroplasmy found in muscle. The results of muscle respiratory chain enzyme analysis are consistent with tRNA mutation. These data suggest that this novel mutation is yet another mtDNA mutation associated with muscle disease and should be considered in patients with similar symptoms.
C1 Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
   Univ Texas, Hlth Sci Ctr, Div Med Genet, Dept Pediat, Houston, TX USA.
   Univ S Alabama, Dept Med Genet, Mobile, AL USA.
   Univ Texas, Hlth Sci Ctr, Dept Neurol, Houston, TX USA.
C3 Baylor College of Medicine; University of Texas System; University of
   Texas Health Science Center Houston; University of South Alabama;
   University of Texas System; University of Texas Health Science Center
   Houston
RP Wong, LJC (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Pl,NAB 2015, Houston, TX 77030 USA.
EM ljwong@bcm.edu
RI Dimachkie, Mazen/AAH-8300-2021
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   Bai RK, 2004, CLIN CHEM, V50, P996, DOI 10.1373/clinchem.2004.031153
   Brandon MC, 2005, NUCLEIC ACIDS RES, V33, pD611
   Chen TJ, 1999, CLIN CHEM, V45, P1162
   DiMauro S, 2001, ANN MED, V33, P472, DOI 10.3109/07853890109002096
   Florentz C, 2003, CELL MOL LIFE SCI, V60, P1356, DOI 10.1007/s00018-003-2343-1
   Florentz C, 2001, EMBO REP, V2, P481, DOI 10.1093/embo-reports/kve111
   FLORENTZ C, COMPILATION MAMMALIA
   Grafakou O, 2003, J INHERIT METAB DIS, V26, P593, DOI 10.1023/A:1025960300710
   Larsson NG, 1999, FEBS LETT, V455, P199, DOI 10.1016/S0014-5793(99)00854-6
   Liang HM, 1998, CLIN CHEM, V44, P1578
   Liang MH, 1998, AM J MED GENET, V77, P395, DOI 10.1002/(SICI)1096-8628(19980605)77:5<395::AID-AJMG8>3.0.CO;2-M
   LUFT R, 1962, J CLIN INVEST, V41, P1776, DOI 10.1172/JCI104637
   Matsumoto M, 1999, Ophthalmic Genet, V20, P153, DOI 10.1076/opge.20.3.153.2281
   McFarland R, 2004, TRENDS GENET, V20, P591, DOI 10.1016/j.tig.2004.09.014
   McFarland R, 2004, ANN NEUROL, V55, P478, DOI 10.1002/ana.20004
   Odawara M, 1996, BIOCHEM BIOPH RES CO, V227, P147, DOI 10.1006/bbrc.1996.1481
   Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   Wong LJC, 1997, CLIN CHEM, V43, P1241
   Wong LJC, 2005, CLIN CHIM ACTA, V354, P1, DOI 10.1016/j.cccn.2004.11.003
   Wong LJC, 2002, AM J MED GENET, V113, P59, DOI 10.1002/ajmg.10767
   Wong LJC, 2001, AM J MED GENET, V102, P95, DOI 10.1002/1096-8628(20010722)102:1<95::AID-AJMG1412>3.0.CO;2-U
   Zeviani M, 2003, CURR OPIN GENET DEV, V13, P262, DOI 10.1016/S0959-437X(03)00052-2
NR 25
TC 7
Z9 8
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0148-639X
EI 1097-4598
J9 MUSCLE NERVE
JI Muscle Nerve
PD OCT
PY 2006
VL 34
IS 4
BP 437
EP 443
DI 10.1002/mus.20605
PG 7
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 089OR
UT WOS:000240890600007
PM 16810691
OA Bronze
DA 2024-11-01
ER

PT J
AU Heighton, JN
   Brady, LI
   Sadikovic, B
   Bulman, DE
   Tarnopolsky, MA
AF Heighton, Julia N.
   Brady, Lauren I.
   Sadikovic, Bekim
   Bulman, Dennis E.
   Tarnopolsky, Mark A.
TI Genotypes of chronic progressive external ophthalmoplegia in a large
   adult-onset cohort
SO MITOCHONDRION
LA English
DT Article
DE Chronic Progressive External Ophthalmoplegia; mtDNA deletion; POLG;
   WFS1; Sensorineural hearing loss
ID MITOCHONDRIAL-DNA DELETIONS; AUTOSOMAL-DOMINANT; MUTATIONS; DISEASE;
   SINGLE; GENE; WFS1
AB Chronic progressive external ophthalmoplegia (CPEO) is a common presentation of mitochondrial disease. We performed a retrospective evaluation of the molecular genetic testing and genotype-phenotype correlations in a large cohort of adult-onset CPEO patients (N = 111). One hundred percent of patients tested had at least one mitochondrial DNA (mtDNA) deletion. Genetic testing of nuclear genes encoding mitochondrial proteins identified pathogenic/likely pathogenic variants likely to be associated with CPEO in 7.6% of patients. As expected, the nuclear gene most associated with DNA variation was POLG. A single likely pathogenic mitochondrial DNA variant (m.12278T > C) was identified in two unrelated patients. No significant differences were noted in the clinical phenotypes of patients with pathogenic or likely pathogenic nuclear variants in comparison to those with negative nuclear gene testing. Analysis of deletion size and heteroplasmy in muscle-derived mtDNA showed significant correlations with age of symptom onset but not disease severity (number of canonical CPEO features). Results suggest that smaller mtDNA deletions (p = 0.0127, r(2) = 0.1201) and higher heteroplasmy of single mtDNA deletions (p = 0.0112, r(2) = 0.2483) are associated with an earlier age of onset in CPEO patients.
C1 [Heighton, Julia N.; Brady, Lauren I.; Tarnopolsky, Mark A.] McMaster Univ, Dept Pediat, Hamilton, ON, Canada.
   [Sadikovic, Bekim] Western Univ, Dept Pathol & Lab Med, London, ON, Canada.
   [Bulman, Dennis E.] Childrens Hosp Eastern Ontario, Newborn Screening Ontario, Ottawa, ON, Canada.
   [Bulman, Dennis E.] Childrens Hosp Eastern Ontario, CHEO Res Inst, Ottawa, ON, Canada.
   [Sadikovic, Bekim] London Hlth Sci Ctr, Mol Genet Lab, Mol Diagnost Div, London, ON, Canada.
C3 McMaster University; Western University (University of Western Ontario);
   University of Ottawa; Children's Hospital of Eastern Ontario; University
   of Ottawa; Children's Hospital of Eastern Ontario; London Health
   Sciences Centre
RP Tarnopolsky, MA (corresponding author), McMaster Univ, Dept Pediat, Hamilton, ON, Canada.
EM tarnopol@mcmaster.ca
RI Bulman, Dennis/IQW-6645-2023
FU Canadian Institute for Health Research grant [143325]
FX We would like to thank Mr. Dan Wright and family and Warren Lammert and
   Kathy Corkins for the above mentioned donations. We would also like to
   thank Ms. Brigitte Belanger and Bart Hettinga for their contributions to
   the study. Dr. Tarnopolsky was funded from a Canadian Institute for
   Health Research grant that partially supported the current project
   (#143325).
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Barrientos A, 1996, J CLIN INVEST, V97, P1570, DOI 10.1172/JCI118581
   Belmonte FR, 2016, SCI REP-UK, V6, DOI 10.1038/srep25186
   Chinnery PF, 2004, LANCET, V364, P592, DOI 10.1016/S0140-6736(04)16851-7
   Cruz S, 2017, MUSCLE NERVE, V56, P868, DOI 10.1002/mus.25593
   Cryns K, 2003, HUM MUTAT, V22, P275, DOI 10.1002/humu.10258
   GOTO Y, 1990, J NEUROL SCI, V100, P63, DOI 10.1016/0022-510X(90)90014-E
   Grady JP, 2014, BRAIN, V137, P323, DOI 10.1093/brain/awt321
   Heighton JN, 2019, MITOCHONDRION, V44, P15, DOI 10.1016/j.mito.2017.12.006
   Huang Taosheng, 2011, Curr Protoc Hum Genet, VChapter 19, DOI 10.1002/0471142905.hg1908s71
   Kerkhof J, 2017, J MOL DIAGN, V19, P905, DOI 10.1016/j.jmoldx.2017.07.004
   Kraytsberg Y, 2009, METHODS MOL BIOL, V554, P329, DOI 10.1007/978-1-59745-521-3_21
   LAFORET P, 1995, NEUROMUSCULAR DISORD, V5, P399, DOI 10.1016/0960-8966(94)00080-S
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Lee Andrew G, 2002, Curr Neurol Neurosci Rep, V2, P413, DOI 10.1007/s11910-002-0067-5
   López-Gallardo E, 2009, MITOCHONDRION, V9, P314, DOI 10.1016/j.mito.2009.04.005
   Lott M.T., 2013, CURR PROTOC BIOINFOR, V44
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   MORAES CT, 1993, NEUROMUSCULAR DISORD, V3, P43, DOI 10.1016/0960-8966(93)90040-Q
   Moslemi AR, 1996, ANN NEUROL, V40, P707, DOI 10.1002/ana.410400506
   Park KP, 2011, J CLIN NEUROL, V7, P25, DOI 10.3988/jcn.2011.7.1.25
   Pfeffer G, 2014, BRAIN, V137, P1323, DOI 10.1093/brain/awu060
   Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30
   Sadikovic B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015687
   Schenkel LC, 2016, J MOL DIAGN, V18, P657, DOI 10.1016/j.jmoldx.2016.04.002
   Smits BW, 2011, NEUROMUSCULAR DISORD, V21, P272, DOI 10.1016/j.nmd.2010.12.008
   Sonney S, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005867
   Sotiriou E, 2009, NEUROMUSCULAR DISORD, V19, P297, DOI 10.1016/j.nmd.2009.01.014
   Van den Ouweland JMW, 2003, J MOL DIAGN, V5, P88, DOI 10.1016/S1525-1578(10)60457-6
   YAMAMOTO M, 1991, NEUROLOGY, V41, P1822, DOI 10.1212/WNL.41.11.1822
   Yamashita S, 2008, J HUM GENET, V53, P598, DOI 10.1007/s10038-008-0289-8
   Yu-Wai-Man P, 2010, BRAIN, V133, P771, DOI 10.1093/brain/awq007
NR 32
TC 14
Z9 14
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 1872-8278
J9 MITOCHONDRION
JI Mitochondrion
PD NOV
PY 2019
VL 49
BP 227
EP 231
DI 10.1016/j.mito.2019.09.002
PG 5
WC Cell Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Genetics & Heredity
GA JX2AW
UT WOS:000503545000025
PM 31521625
DA 2024-11-01
ER

PT J
AU Yan, NH
   Cai, SP
   Guo, B
   Mou, Y
   Zhu, J
   Chen, J
   Zhang, T
   Li, RH
   Liu, XY
AF Yan, Naihong
   Cai, Shuping
   Guo, Bo
   Mou, Yi
   Zhu, Jing
   Chen, Jun
   Zhang, Ting
   Li, Ronghua
   Liu, Xuyang
TI A novel mitochondrial tRNA<SUP>Val</SUP> T1658C mutation identified in a
   CPEO family
SO MOLECULAR VISION
LA English
DT Article
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; TRANSFER-RNA GENES; POINT
   MUTATION; DNA; DISEASE; SEQUENCE; MELAS; TRNA(ASN); MYOPATHY; PATIENT
AB Purpose: To analyze mitochondrial DNA (mt DNA) gene mutations in a 19-year-old female patient, who presented with chronic progressive external ophthalmoplegia (CPEO), together with her mother and younger sister.
   Methods: The diagnosis of mitochondrial myopathy was made based on clinical and biologic analysis. Histochemical methods were used to detect ragged-red fibers (RRFs) and ragged-blue fibers (RBFs) on a muscle biopsy of the patient. All mitochondrial gene DNA fragments of the patient, her mother, and younger sister were amplified by polymerase chain reaction. The products were sequenced and compared with reference databases.
   Results: A novel T1658C mutation and a known A10006G mutation were identified in the mitochondrial tRNA(Val) gene and the tRNA(Gly) gene, respectively, in the patient, her mother, and younger sister. The T1658C mutation changes the T loop structure of mitochondrial tRNA(Val) and the A10006G mutation disturbs the D loop of mitochondrial tRNA(Gly).
   Conclusions: The T1658C and A10006G mutations of mtDNA may be responsible for the pathogenesis of the patient with CPEO.
C1 [Yan, Naihong; Cai, Shuping; Guo, Bo; Mou, Yi; Zhu, Jing; Chen, Jun; Zhang, Ting; Liu, Xuyang] Sichuan Univ, W China Hosp, Ophthalm Labs, Chengdu 610041, Peoples R China.
   [Yan, Naihong; Cai, Shuping; Guo, Bo; Mou, Yi; Zhu, Jing; Chen, Jun; Zhang, Ting; Liu, Xuyang] Sichuan Univ, W China Hosp, Dept Ophthalmol, Chengdu 610041, Peoples R China.
   [Li, Ronghua] Sichuan Univ, W China Hosp, Dept Med Genet, Chengdu 610064, Sichuan, Peoples R China.
C3 Sichuan University; Sichuan University; Sichuan University
RP Liu, XY (corresponding author), Sichuan Univ, W China Hosp, Ophthalm Labs, Chengdu 610041, Peoples R China.
EM xliu1213@yahoo.com.cn
RI Li, Ronghua/AAP-8236-2021; Zhang, Ting/P-8913-2017; zhu,
   jing/IUM-4558-2023
CR Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Bau V, 2005, STRABISMUS, V13, P133, DOI 10.1080/09273970500216432
   Chinnery PF, 1997, NEUROLOGY, V49, P1166, DOI 10.1212/WNL.49.4.1166
   Franceschina L, 1998, J NEUROL, V245, P755, DOI 10.1007/s004150050283
   GOTO Y, 1992, ANN NEUROL, V31, P672, DOI 10.1002/ana.410310617
   Hao HL, 1997, MOL CELL BIOL, V17, P6831, DOI 10.1128/MCB.17.12.6831
   HATTORI Y, 1994, J NEUROL SCI, V125, P50, DOI 10.1016/0022-510X(94)90241-0
   HOUSHMAND M, 1994, BBA-MOL BASIS DIS, V1226, P49, DOI 10.1016/0925-4439(94)90058-2
   JEANFRANCOIS MJB, 1994, AUST NZ J MED, V24, P188, DOI 10.1111/j.1445-5994.1994.tb00556.x
   Kirino Y, 2005, P NATL ACAD SCI USA, V102, P7127, DOI 10.1073/pnas.0500563102
   LAUBER J, 1991, NUCLEIC ACIDS RES, V19, P1393, DOI 10.1093/nar/19.7.1393
   Levinger L, 2004, NUCLEIC ACIDS RES, V32, P5430, DOI 10.1093/nar/gkh884
   MARZUKI S, 1991, HUM GENET, V88, P139
   MERANTE F, 1994, AM J HUM GENET, V55, P437
   MORAES CT, 1993, J CLIN INVEST, V92, P2906, DOI 10.1172/JCI116913
   MORAES CT, 1993, NEUROMUSCULAR DISORD, V3, P43, DOI 10.1016/0960-8966(93)90040-Q
   MUNSCHER C, 1993, BIOL CHEM H-S, V374, P1099, DOI 10.1515/bchm3.1993.374.7-12.1099
   NOER AS, 1991, AM J HUM GENET, V49, P715
   Park H, 2003, BIOCHEMISTRY-US, V42, P958, DOI 10.1021/bi026882r
   Pulkes T, 2003, NEUROLOGY, V61, P1144, DOI 10.1212/01.WNL.0000090465.27024.3D
   Pulkes T, 2000, LANCET, V356, P2068, DOI 10.1016/S0140-6736(00)03408-5
   Rieder MJ, 1998, NUCLEIC ACIDS RES, V26, P967, DOI 10.1093/nar/26.4.967
   SANDIFER PH, 1946, J NEUROL NEUROSUR PS, V9, P81, DOI 10.1136/jnnp.9.3.81
   SATO W, 1994, BIOCHEM MOL BIOL INT, V33, P1055
   Schaefer AM, 2005, MUSCLE NERVE, V32, P104, DOI 10.1002/mus.20319
   SEIBEL P, 1994, BIOCHEM BIOPH RES CO, V204, P482, DOI 10.1006/bbrc.1994.2485
   Spagnolo M, 2001, NEUROMUSCULAR DISORD, V11, P481, DOI 10.1016/S0960-8966(01)00195-X
   Sternberg D, 2001, BRAIN, V124, P984, DOI 10.1093/brain/124.5.984
   Taylor RW, 1998, BIOCHEM BIOPH RES CO, V243, P47, DOI 10.1006/bbrc.1997.8055
   Tiranti V, 1999, NEUROMUSCULAR DISORD, V9, P66, DOI 10.1016/S0960-8966(98)00103-5
   VANDENOUWELAND JMW, 1992, NUCLEIC ACIDS RES, V20, P679, DOI 10.1093/nar/20.4.679
NR 31
TC 10
Z9 11
U1 0
U2 2
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
   ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD AUG 25
PY 2010
VL 16
IS 187-89
BP 1736
EP 1742
PG 7
WC Biochemistry & Molecular Biology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Ophthalmology
GA 643ZY
UT WOS:000281341400002
PM 20806033
DA 2024-11-01
ER

PT J
AU Wang, S
   Miao, J
   Feng, JC
AF Wang, Shuang
   Miao, Jing
   Feng, Jiachun
TI Case Report: Mitochondrial Encephalomyopathy Presents as Epilepsy,
   Ataxia, and Dystonia With a Rare Mutation in <i>MT-TW</i>
SO FRONTIERS IN NEUROLOGY
LA English
DT Article
DE mitochondrial encephalomyopathy; MT-TW; epilepsy; ataxia; dystonia
ID MTDNA MUTATION; TRNA(TRP)
AB Mitochondrial diseases are a group of common inherited disorders caused by mutations in nuclear DNA or mitochondrial DNA (mtDNA); the clinical phenotype of diseases caused by mutant mtDNA is challenging owing to heteroplasmy of mtDNA and may delay diagnosis and treatment. Herein, we report the case of an adult male who slowly developed epilepsy, ataxia, dystonia, impaired cognition, and hearing impairment over 14 years in the absence of clinical myopathy. His lactate level was normal. Brain computed tomography showed calcifications of the bilateral basal ganglia, thalamus, and cerebellar dentate nuclei. Magnetic resonance imaging revealed multiple lesions in the bilateral internal capsule and periventricular areas, which were hypointense on T1-weighted images and hyperintense on T2-weighted images. The first blood genetic test result was negative. Two years later, a muscle biopsy was performed. Succinate dehydrogenase (SDH) staining showed several ragged blue fibers and atypical strongly SDH-reactive vessels. Cytochrome C oxidase (COX) staining revealed abundant COX-deficient fibers. mtDNA testing of blood and muscle revealed a rare m.5549G>A mutation in the MT-TW gene. It was heteroplasmic, with 5.4% mutant mtDNA in the blood and 61.5% in the muscle. The patient was diagnosed with mitochondrial encephalomyopathy and treated with levetiracetam instead of valproate to reduce possible mitochondrial toxicity. After receiving anti-epileptic drugs and mitochondrial supplements, the patient remained clinically stable. For mitochondrial disease, when mutant mtDNA is not detected in blood, muscle biopsy should be performed in routine analysis, and it should be genetically tested, even if there are no manifestations of myopathy.
C1 [Wang, Shuang; Miao, Jing; Feng, Jiachun] First Hosp Jilin Univ, Dept Neurol, Changchun, Peoples R China.
C3 Jilin University
RP Miao, J; Feng, JC (corresponding author), First Hosp Jilin Univ, Dept Neurol, Changchun, Peoples R China.
EM jdyymiaojing@jlu.edu.cn; fengjc@jlu.edu.cn
RI Feng, Jiachun/F-6480-2011
CR Blakely EL, 2013, HUM MUTAT, V34, P1260, DOI 10.1002/humu.22358
   Cardaioli E, 2018, BIOCHEM BIOPH RES CO, V500, P158, DOI 10.1016/j.bbrc.2018.04.009
   Duff RM, 2015, MITOCHONDRION, V25, P113, DOI 10.1016/j.mito.2015.10.008
   Finsterer J, 2019, J NEUROL SCI, V404, P29, DOI 10.1016/j.jns.2019.07.013
   Finsterer J, 2017, SEIZURE-EUR J EPILEP, V50, P166, DOI 10.1016/j.seizure.2017.06.010
   Finsterer J, 2012, EXPERT OPIN DRUG MET, V8, P71, DOI 10.1517/17425255.2012.644535
   Gorman GS, 2016, NAT REV DIS PRIMERS, V2, P1, DOI 10.1038/nrdp.2016.80
   Gorman GS, 2015, ANN NEUROL, V77, P753, DOI 10.1002/ana.24362
   Liu KM, 2021, CNS NEUROSCI THER, V27, P733, DOI 10.1111/cns.13618
   Maniura-Weber K, 2004, EUR J HUM GENET, V12, P509, DOI 10.1038/sj.ejhg.5201185
   Mascalchi M, 2018, ESSAYS BIOCHEM, V62, P409, DOI 10.1042/EBC20170109
   NELSON I, 1995, ANN NEUROL, V37, P400, DOI 10.1002/ana.410370317
   Rahman S, 2001, AM J HUM GENET, V68, P238, DOI 10.1086/316930
   Silvestri G, 2000, NEUROLOGY, V54, P1693, DOI 10.1212/WNL.54.8.1693
   Smits P, 2010, EUR J HUM GENET, V18, P324, DOI 10.1038/ejhg.2009.169
   Weissig V, 2020, TRENDS MOL MED, V26, P40, DOI 10.1016/j.molmed.2019.09.002
   Witters P, 2018, GENET MED, V20, P444, DOI 10.1038/gim.2017.125
NR 17
TC 1
Z9 1
U1 1
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2295
J9 FRONT NEUROL
JI Front. Neurol.
PD JUL 1
PY 2021
VL 12
AR 679302
DI 10.3389/fneur.2021.679302
PG 8
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA TJ6RV
UT WOS:000673607200001
PM 34276539
OA Green Published, gold
DA 2024-11-01
ER

PT J
AU Shammas, MK
   Nie, Y
   Gilsrud, A
   Huang, XP
   Narendra, DP
   Chinnery, PF
AF Shammas, Mario K.
   Nie, Yu
   Gilsrud, Alexandra
   Huang, Xiaoping
   Narendra, Derek P.
   Chinnery, Patrick F.
TI CHCHD10 mutations induce tissue-specific mitochondrial DNA deletions
   with a distinct signature
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
DE mitochondria; neurodegeneration; mtDNA deletions; mitochondrial DNA;
   CHCHD10
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; MULTIPLE MTDNA DELETIONS;
   ENDONUCLEASE-G; MOTOR NEURONOPATHY; CLONAL EXPANSION; DIRECT REPEATS;
   GENE; REPLICATION; GENERATION; ELECTRON
AB Mutations affecting the mitochondrial intermembrane space protein CHCHD10 cause human disease, but it is not known why different amino acid substitutions cause markedly different clinical phenotypes, including amyotrophic lateral sclerosis-frontotemporal dementia, spinal muscular atrophy Jokela-type, isolated autosomal dominant mitochondrial myopathy and cardiomyopathy. CHCHD10 mutations have been associated with deletions of mitochondrial DNA (mtDNA deletions), raising the possibility that these explain the clinical variability. Here, we sequenced mtDNA obtained from hearts, skeletal muscle, livers and spinal cords of WT and Chchd10 G58R or S59L knockin mice to characterise the mtDNA deletion signatures of the two mutant lines. We found that the deletion levels were higher in G58R and S59L mice than in WT mice in some tissues depending on the Chchd10 genotype, and the deletion burden increased with age. Furthermore, we observed that the spinal cord was less prone to the development of mtDNA deletions than the other tissues examined. Finally, in addition to accelerating the rate of naturally occurring deletions, Chchd10 mutations also led to the accumulation of a novel set of deletions characterised by shorter direct repeats flanking the deletion breakpoints. Our results indicate that Chchd10 mutations in mice induce tissue-specific deletions which may also contribute to the clinical phenotype associated with these mutations in humans.
C1 [Shammas, Mario K.; Nie, Yu; Chinnery, Patrick F.] Univ Cambridge, Sch Clin Med, Dept Clin Neurosci, Cambridge Biomed Campus, Cambridge CB2 0QQ, England.
   [Shammas, Mario K.; Nie, Yu; Chinnery, Patrick F.] Univ Cambridge, Med Res Council Mitochondrial Biol Unit, Cambridge Biomed Campus,Hills Rd, Cambridge CB2 0XY, England.
   [Shammas, Mario K.; Gilsrud, Alexandra; Huang, Xiaoping; Narendra, Derek P.] NINDS, Inherited Movement Disorders Unit, Neurogenet Branch, NIH, 35 Convent Dr, Bethesda, MD 20892 USA.
   [Chinnery, Patrick F.] Keith Peters Bldg Rm 3-28,Hills Rd, Cambridge CB2 0XY, England.
C3 University of Cambridge; UK Research & Innovation (UKRI); Medical
   Research Council UK (MRC); University of Cambridge; National Institutes
   of Health (NIH) - USA; NIH National Institute of Neurological Disorders
   & Stroke (NINDS)
RP Chinnery, PF (corresponding author), Keith Peters Bldg Rm 3-28,Hills Rd, Cambridge CB2 0XY, England.
EM pfc25@cam.ac.uk
RI Narendra, Derek/W-1535-2019
FU MRC [MR/S005021/1] Funding Source: UKRI
CR Ajroud-Driss S, 2015, NEUROGENETICS, V16, P1, DOI 10.1007/s10048-014-0421-1
   Alston CL, 2013, NEUROLOGY, V81, P2051, DOI 10.1212/01.wnl.0000436931.94291.e6
   Anderson CJ, 2019, ACTA NEUROPATHOL, V138, P103, DOI 10.1007/s00401-019-01989-y
   Bannwarth S, 2014, BRAIN, V137, P2329, DOI 10.1093/brain/awu138
   Basu S, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1009242
   Burstein SR, 2018, HUM MOL GENET, V27, P160, DOI 10.1093/hmg/ddx397
   CORTOPASSI GA, 1990, NUCLEIC ACIDS RES, V18, P6927, DOI 10.1093/nar/18.23.6927
   Fayet G, 2002, NEUROMUSCULAR DISORD, V12, P484, DOI 10.1016/S0960-8966(01)00332-7
   Feichtinger RG, 2017, AM J HUM GENET, V101, P525, DOI 10.1016/j.ajhg.2017.08.015
   Fontana GA, 2020, NUCLEIC ACIDS RES, V48, P11244, DOI 10.1093/nar/gkaa804
   Funayama M, 2015, LANCET NEUROL, V14, P274, DOI 10.1016/S1474-4422(14)70266-2
   Genin EC, 2022, BRAIN, V145, P3415, DOI 10.1093/brain/awac197
   Genin EC, 2019, ACTA NEUROPATHOL, V138, P123, DOI 10.1007/s00401-019-01988-z
   Gorman GS, 2015, JAMA NEUROL, V72, P106, DOI 10.1001/jamaneurol.2014.1753
   Guo L, 2021, NEUROMUSCULAR DISORD, V31, P859, DOI 10.1016/j.nmd.2021.06.014
   HeimanPatterson TD, 1997, MUSCLE NERVE, V20, P1219, DOI 10.1002/(SICI)1097-4598(199710)20:10<1219::AID-MUS2>3.0.CO;2-F
   Huang XP, 2018, HUM MOL GENET, V27, P3881, DOI 10.1093/hmg/ddy270
   Iborra FJ, 2004, BMC BIOL, V2, DOI 10.1186/1741-7007-2-9
   Irvine RA, 2005, MOL CELL BIOL, V25, P294, DOI 10.1128/MCB.25.1.294-302.2005
   Ishihara T, 2022, P NATL ACAD SCI USA, V119, DOI 10.1073/pnas.2210730119
   Johnson JO, 2014, BRAIN, V137, DOI 10.1093/brain/awu265
   Jokela M, 2011, NEUROLOGY, V77, P334, DOI 10.1212/WNL.0b013e3182267b71
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Keeney PM, 2010, MOL NEURODEGENER, V5, DOI 10.1186/1750-1326-5-21
   Kornblum C, 2013, NAT GENET, V45, P214, DOI 10.1038/ng.2501
   Kurzwelly D, 2015, BRAIN, V138, DOI 10.1093/brain/awv014
   Liu YT, 2020, HUM MOL GENET, V29, P1547, DOI 10.1093/hmg/ddaa077
   Lujan SA, 2020, GENOME BIOL, V21, DOI 10.1186/s13059-020-02138-5
   Marchet S, 2020, HUM MUTAT, V41, P1745, DOI 10.1002/humu.24081
   MITA S, 1990, NUCLEIC ACIDS RES, V18, P561, DOI 10.1093/nar/18.3.561
   MITCHELL P, 1961, NATURE, V191, P144, DOI 10.1038/191144a0
   Müller K, 2014, BRAIN, V137, DOI 10.1093/brain/awu227
   Nasca A, 2022, CELLS-BASEL, V11, DOI 10.3390/cells11060974
   NASS MMK, 1963, J CELL BIOL, V19, P593, DOI 10.1083/jcb.19.3.593
   Nie Y, 2022, ACTA NEUROPATHOL, V143, P687, DOI 10.1007/s00401-022-02423-6
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Paradas C, 2013, NEUROLOGY, V80, P504, DOI 10.1212/WNL.0b013e31827f0ff7
   Payne BAI, 2011, NAT GENET, V43, P806, DOI 10.1038/ng.863
   Penttilä S, 2015, ANN NEUROL, V77, P163, DOI 10.1002/ana.24319
   Persson Ö, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08673-5
   Pfeffer G, 2014, BRAIN, V137, P1323, DOI 10.1093/brain/awu060
   Phillips AF, 2017, MOL CELL, V65, P527, DOI 10.1016/j.molcel.2016.12.014
   PIKO L, 1988, MECH AGEING DEV, V43, P279, DOI 10.1016/0047-6374(88)90037-1
   Quispe-Tintaya W, 2013, BIOTECHNIQUES, V55, P133, DOI 10.2144/000114077
   Rackham O, 2022, NAT REV GENET, V23, P606, DOI 10.1038/s41576-022-00480-x
   Rath S, 2021, NUCLEIC ACIDS RES, V49, pD1541, DOI 10.1093/nar/gkaa1011
   Rouzier C, 2012, BRAIN, V135, P23, DOI 10.1093/brain/awr323
   Samuels DC, 2004, TRENDS GENET, V20, P393, DOI 10.1016/j.tig.2004.07.003
   SCHATZ G, 1964, BIOCHEM BIOPH RES CO, V15, P127, DOI 10.1016/0006-291X(64)90311-0
   SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184
   Shammas MK, 2023, BIOCHEM SOC T, V51, P797, DOI 10.1042/BST20221365
   Shammas MK, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI157504
   Shi CH, 2016, NEUROBIOL AGING, V38, DOI 10.1016/j.neurobiolaging.2015.10.040
   Southwell N., 2023, BIORXIV
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Srivastava S, 2005, HUM MOL GENET, V14, P893, DOI 10.1093/hmg/ddi082
   Stewart JD, 2008, NEUROLOGY, V71, P1829, DOI 10.1212/01.wnl.0000335931.54095.0a
   Straub IR, 2018, HUM MOL GENET, V27, P178, DOI 10.1093/hmg/ddx393
   TANHAUSER SM, 1995, J BIOL CHEM, V270, P24769, DOI 10.1074/jbc.270.42.24769
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   van Loo G, 2001, CELL DEATH DIFFER, V8, P1136, DOI 10.1038/sj.cdd.4400944
   Vermulst M, 2008, NAT GENET, V40, P392, DOI 10.1038/ng.95
   Viscomi C, 2017, J INHERIT METAB DIS, V40, P587, DOI 10.1007/s10545-017-0027-5
   Zambelli F, 2017, EUR J HUM GENET, V25, P1229, DOI 10.1038/ejhg.2017.129
   Zhou QH, 2016, SCIENCE, V353, P394, DOI 10.1126/science.aaf4777
NR 66
TC 0
Z9 0
U1 1
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD DEC 12
PY 2023
VL 33
IS 1
BP 91
EP 101
DI 10.1093/hmg/ddad161
EA OCT 2023
PG 11
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA CI1N6
UT WOS:001083052700001
PM 37815936
OA hybrid, Green Published
DA 2024-11-01
ER

PT J
AU El-Hattab, AW
   Wang, JL
   Dai, HZ
   Almannai, M
   Staufner, C
   Alfadhel, M
   Gambello, MJ
   Prasun, P
   Raza, S
   Lyons, HJ
   Afqi, M
   Saleh, MAM
   Faqeih, EA
   Alzaidan, HI
   Alshenqiti, A
   Flore, LA
   Hertecant, J
   Sacharow, S
   Barbouth, DS
   Murayama, K
   Shah, AA
   Lin, HC
   Wong, LJC
AF El-Hattab, Ayman W.
   Wang, Julia
   Dai, Hongzheng
   Almannai, Mohammed
   Staufner, Christian
   Alfadhel, Majid
   Gambello, Michael J.
   Prasun, Pankaj
   Raza, Saleem
   Lyons, Hernando J.
   Afqi, Manal
   Saleh, Mohammed A. M.
   Faqeih, Eissa A.
   Alzaidan, Hamad I.
   Alshenqiti, Abduljabbar
   Flore, Leigh Anne
   Hertecant, Jozef
   Sacharow, Stephanie
   Barbouth, Deborah S.
   Murayama, Kei
   Shah, Amit A.
   Lin, Henry C.
   Wong, Lee-Jun C.
TI <i>MPV17</i>-related mitochondrial DNA maintenance defect: New cases and
   review of clinical, biochemical, and molecular aspects
SO HUMAN MUTATION
LA English
DT Review
DE mitochondrial DNA (mtDNA); MPV17; mtDNA depletion; mtDNA maintenance;
   multiple mtDNA deletions
ID DEPLETION SYNDROME; NAVAJO NEUROHEPATOPATHY; HEPATOCEREBRAL FORM; MPV17
   MUTATION; LIVER-FAILURE; PROTEIN; DISEASE; GENE
AB Mitochondrial DNA (mtDNA) maintenance defects are a group of diseases caused by deficiency of proteins involved in mtDNA synthesis, mitochondrial nucleotide supply, or mitochondrial dynamics. One of the mtDNA maintenance proteins is MPV17, which is a mitochondrial inner membrane protein involved in importing deoxynucleotides into the mitochondria. In 2006, pathogenic variants in MPV17 were first reported to cause infantile-onset hepatocerebral mtDNA depletion syndrome and Navajo neurohepatopathy. To date, 75 individuals with MPV17-related mtDNA maintenance defect have been reported with 39 different MPV17 pathogenic variants. In this report, we present an additional 25 affected individuals with nine novel MPV17 pathogenic variants. We summarize the clinical features of all 100 affected individuals and review the total 48 MPV17 pathogenic variants. The vast majority of affected individuals presented with an early-onset encephalohepatopathic disease characterized by hepatic and neurological manifestations, failure to thrive, lactic acidemia, and mtDNA depletion detected mainly in liver tissue. Rarely, MPV17 deficiency can cause a late-onset neuromyopathic disease characterized by myopathy and peripheral neuropathy with no or minimal liver involvement. Approximately half of the MPV17 pathogenic variants are missense. A genotype with biallelic missense variants, in particular homozygous p.R50Q, p.P98L, and p.R41Q, can carry a relatively better prognosis.
C1 [El-Hattab, Ayman W.; Hertecant, Jozef] Tawam Hosp, Pediat Dept, Div Clin Genet & Metab Disorders, Al Ain, U Arab Emirates.
   [Wang, Julia] Baylor Coll Med, Med Scientist Training Program, Houston, TX 77030 USA.
   [Wang, Julia] Baylor Coll Med, Program Dev Biol, Houston, TX 77030 USA.
   [Dai, Hongzheng; Wong, Lee-Jun C.] Baylor Coll Med, Dept Mol & Human Genet, One Baylor Plaza,MS225, Houston, TX 77030 USA.
   [Staufner, Christian] Univ Hosp Heidelberg, Dept Gen Pediat, Div Neuropediat & Metab Med, Heidelberg, Germany.
   [Alfadhel, Majid] King Saud Bin Abdulaziz Univ Hlth Sci, King Abdullah Int Med Res Ctr, King Abdulaziz Med City, Minist Natl Guard Hlth Affairs NGHA,Div Genet,Dep, Riyadh, Saudi Arabia.
   [Gambello, Michael J.] Emory Univ, Sch Med, Dept Human Genet, Div Med Genet, Atlanta, GA USA.
   [Prasun, Pankaj] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA.
   [Raza, Saleem; Lyons, Hernando J.] St John Hosp & Med Ctr, Dept Pediat, Detroit, MI USA.
   [Raza, Saleem; Lyons, Hernando J.] Wayne State Univ, Sch Med, Detroit, MI USA.
   [Afqi, Manal; Saleh, Mohammed A. M.; Faqeih, Eissa A.] Childrens Specialist Hosp, King Fahad Med City, Sect Med Genet, Riyadh, Saudi Arabia.
   [Alzaidan, Hamad I.; Alshenqiti, Abduljabbar] King Faisal Specialist Hosp & Res Ctr, Dept Med Genet, Riyadh, Saudi Arabia.
   [Flore, Leigh Anne] Childrens Hosp Michigan, Div Genet Genom & Metab Disorders, Detroit, MI 48201 USA.
   [Flore, Leigh Anne] Wayne State Univ, Detroit, MI USA.
   [Sacharow, Stephanie] Boston Childrens Hosp, Div Genet & Genom, Boston, MA USA.
   [Barbouth, Deborah S.] Univ Miami, Miller Sch Med, Dept Human Genet, Dr John T Macdonald Fdn,Div Clin & Translat Genet, Miami, FL 33136 USA.
   [Murayama, Kei] Chiba Childrens Hosp, Dept Metab, Chiba, Japan.
   [Shah, Amit A.; Lin, Henry C.] Childrens Hosp Philadelphia, Div Gastroenterol Hepatol & Nutr, Philadelphia, PA 19104 USA.
C3 Baylor College of Medicine; Baylor College of Medicine; Baylor College
   of Medicine; Ruprecht Karls University Heidelberg; King Saud Bin
   Abdulaziz University for Health Sciences; King Abdulaziz Medical City -
   Riyadh; King Abdullah International Medical Research Center (KAIMRC);
   Ministry of National Guard - Health Affairs; National Guard Health
   Affairs - Saudi Arabia; Emory University; Icahn School of Medicine at
   Mount Sinai; St. John Hospital & Medical Center; Wayne State University;
   King Fahad Medical City; King Faisal Specialist Hospital & Research
   Center; Children's Hospital of Michigan; Wayne State University; Harvard
   University; Boston Children's Hospital; University of Miami; Chiba
   Children's Hospital; University of Pennsylvania; Pennsylvania Medicine;
   Childrens Hospital of Philadelphia
RP Wong, LJC (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, One Baylor Plaza,MS225, Houston, TX 77030 USA.
EM ljwong@bcm.edu
RI Wang, Julia/AAZ-7000-2020; Alzaidan, Hamad/LLL-9372-2024; Murayama,
   Kei/JGM-3674-2023
OI Wang, Julia/0000-0002-6984-8283; El-Hattab, Ayman/0000-0002-5737-5271
FU Japan Agency for Medical Research and Development (AMED) [JP17ek0109273]
FX K.M was supported by the Grants-in-Aid of Practical Research Project for
   Rare/Intractable Diseases (No. JP17ek0109273) from the Japan Agency for
   Medical Research and Development (AMED).
CR Al Sarkhy A, 2014, ANN SAUDI MED, V34, P175, DOI 10.5144/0256-4947.2014.175
   Al-Hussaini A., 2014, J PEDIAT, V164, P553
   Al-Jasmi F, 2011, MOL GENET METAB, V104, P529, DOI 10.1016/j.ymgme.2011.09.023
   AlSaman A, 2012, SAUDI J GASTROENTERO, V18, P285, DOI 10.4103/1319-3767.98439
   Bijarnia-Mahay S, 2014, INDIAN PEDIATR, V51, P666, DOI 10.1007/s13312-014-0475-z
   Bitting CP, 2016, ACTA GASTRO-ENT BELG, V79, P463
   Blakely EL, 2012, NEUROMUSCULAR DISORD, V22, P587, DOI 10.1016/j.nmd.2012.03.006
   Calvo SE, 2016, NUCLEIC ACIDS RES, V44, pD1251, DOI 10.1093/nar/gkv1003
   Choi YR, 2015, BMC NEUROL, V15, DOI 10.1186/s12883-015-0430-1
   El-Hattab A.W., 2012, GeneReviews
   El-Hattab AW, 2017, BBA-MOL BASIS DIS, V1863, P1539, DOI 10.1016/j.bbadis.2017.02.017
   El-Hattab A, 2013, NEUROTHERAPEUTICS, V10, P186, DOI 10.1007/s13311-013-0177-6
   El-Hattab AW, 2010, MOL GENET METAB, V99, P300, DOI 10.1016/j.ymgme.2009.10.003
   Garone C, 2012, ARCH NEUROL-CHICAGO, V69, P1648, DOI 10.1001/archneurol.2012.405
   Iida R, 2003, J BIOL CHEM, V278, P6301, DOI 10.1074/jbc.M210886200
   Kaji S, 2009, MOL GENET METAB, V97, P292, DOI 10.1016/j.ymgme.2009.04.014
   Karadimas CL, 2006, AM J HUM GENET, V79, P544, DOI 10.1086/506913
   Kim J, 2016, MOL GENET METAB REP, V8, P74, DOI 10.1016/j.ymgmr.2016.06.006
   Lang BF, 1999, ANNU REV GENET, V33, P351, DOI 10.1146/annurev.genet.33.1.351
   Löllgen S, 2015, BIOL CHEM, V396, P13, DOI 10.1515/hsz-2014-0198
   McKiernan P, 2016, J PEDIATR GASTR NUTR, V63, P592, DOI 10.1097/MPG.0000000000001345
   Mendelsohn BA, 2014, JIMD REP, V13, P37, DOI 10.1007/8904_2013_267
   Merkle A N, 2012, AJNR Am J Neuroradiol, V33, pE34, DOI 10.3174/ajnr.A2455
   Navarro-Sastre A, 2008, MOL GENET METAB, V94, P234, DOI 10.1016/j.ymgme.2008.01.012
   Nogueira C, 2012, MOL GENET METAB, V107, P764, DOI 10.1016/j.ymgme.2012.10.010
   Parikh S, 2016, MOL GENET METAB, V118, P178, DOI 10.1016/j.ymgme.2016.04.009
   Parini R, 2009, J HEPATOL, V50, P215, DOI 10.1016/j.jhep.2008.08.019
   Piekutowska-Abramczuk D, 2014, CLIN GENET, V85, P573, DOI 10.1111/cge.12228
   Rosa ID, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005779
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Spinazzola A, 2011, SEMIN FETAL NEONAT M, V16, P190, DOI 10.1016/j.siny.2011.04.011
   Spinazzola A, 2008, ARCH NEUROL-CHICAGO, V65, P1108, DOI 10.1001/archneur.65.8.1108
   Uusimaa J, 2014, EUR J HUM GENET, V22, P184, DOI 10.1038/ejhg.2013.112
   Vilarinho S, 2014, J HEPATOL, V61, P1056, DOI 10.1016/j.jhep.2014.06.038
   Wong LJC, 2007, HEPATOLOGY, V46, P1218, DOI 10.1002/hep.21799
NR 35
TC 40
Z9 45
U1 1
U2 16
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1059-7794
EI 1098-1004
J9 HUM MUTAT
JI Hum. Mutat.
PD APR
PY 2018
VL 39
IS 4
BP 461
EP 470
DI 10.1002/humu.23387
PG 10
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA FY3NV
UT WOS:000426727800001
PM 29282788
OA Green Published, gold
DA 2024-11-01
ER

PT J
AU Pfeffer, G
   Mezei, MM
AF Pfeffer, Gerald
   Mezei, Michelle M.
TI CARDIAC SCREENING INVESTIGATIONS IN ADULT-ONSET PROGRESSIVE EXTERNAL
   OPHTHALMOPLEGIA PATIENTS
SO MUSCLE & NERVE
LA English
DT Article
DE adult onset; asymptomatic; cardiac conduction; cardiomyopathy;
   echocardiogram; electrocardiogram; mitochondrial myopathy; progressive
   external ophthalmoplegia; screening
ID MITOCHONDRIAL-DNA; MUTATION; INVOLVEMENT; PHENOTYPE
AB Introduction: Patients with mitochondrial myopathies may develop cardiac complications such as cardiomyopathy and/or cardiac conduction defects. To identify these potentially life-threatening and treatable conditions, it is common practice to screen patients intermittently with electrocardiography and echocardiography. The optimal time interval for such screening investigations is unknown. We developed this study to review our screening results in adult-onset patients with progressive external ophthalmoplegia (PEO). Methods: This study was a retrospective review of PEO patients with 5 years or more of cardiac screening investigations who did not have any cardiac symptoms. Results: Fifteen patients were included, and cardiomyopathy was identified on screening echo-cardiogram in 1 patient. Four patients had other abnormalities identified, which were unrelated to their mitochondrial myopathy. Conclusions: Only 1 patient in 15 developed cardiac complications related to mitochondrial disease during 5 years of follow-up. We suggest that a screening interval of 3-5 years is probably appropriate for adult-onset PEO patients who do not have cardiac symptoms. Muscle Nerve 46: 593-596, 2012
C1 [Pfeffer, Gerald; Mezei, Michelle M.] Univ British Columbia, Div Neurol, Vancouver, BC V5Z 1M9, Canada.
   [Pfeffer, Gerald] Univ British Columbia, Clinician Investigator Program, Vancouver, BC V5Z 1M9, Canada.
   [Mezei, Michelle M.] Univ British Columbia, Adult Metab Dis Clin, GLDHCC, Vancouver, BC V5Z 1M9, Canada.
C3 University of British Columbia; University of British Columbia;
   University of British Columbia
RP Mezei, MM (corresponding author), Univ British Columbia, Div Neurol, Vancouver, BC V5Z 1M9, Canada.
EM mezei@mail.ubc.ca
OI Pfeffer, Gerald/0000-0002-7657-7098
FU University of British Columbia; Canadian Institutes of Health Research
FX The authors thank Anna Koochin, Margaret O'Reilly, and the staff of the
   Adult Metabolic Disease Clinic for their assistance. This study was
   funded by the Clinician Investigator Program of the University of
   British Columbia and by a Bisby fellowship from the Canadian Institutes
   of Health Research (to G.P.).
CR ANAN R, 1995, CIRCULATION, V91, P955, DOI 10.1161/01.CIR.91.4.955
   Auré K, 2007, BRAIN, V130, P1516, DOI 10.1093/brain/awm067
   Bau V, 2005, STRABISMUS, V13, P133, DOI 10.1080/09273970500216432
   Bhati RS, 2005, J HEART LUNG TRANSPL, V24, P2286, DOI 10.1016/j.healun.2005.05.012
   LAFORET P, 1995, NEUROMUSCULAR DISORD, V5, P399, DOI 10.1016/0960-8966(94)00080-S
   Pfeffer G, 2011, CAN J NEUROL SCI, V38, P119, DOI 10.1017/S031716710001115X
   POLAK PE, 1989, EUR HEART J, V10, P281, DOI 10.1093/oxfordjournals.eurheartj.a059477
   Stricker S, 2009, J NEUROL NEUROSUR PS, V80, P1181, DOI 10.1136/jnnp.2008.166066
   Wahbi K, 2010, NEUROLOGY, V74, P674, DOI 10.1212/WNL.0b013e3181d0ccf4
   Yamanaka H, 2007, J INFECT DIS, V195, P1419, DOI 10.1086/513872
   Yamashita S, 2008, J HUM GENET, V53, P598, DOI 10.1007/s10038-008-0289-8
NR 11
TC 8
Z9 9
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0148-639X
EI 1097-4598
J9 MUSCLE NERVE
JI Muscle Nerve
PD OCT
PY 2012
VL 46
IS 4
BP 593
EP 596
DI 10.1002/mus.23538
PG 5
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 007FR
UT WOS:000308874700019
PM 22987704
DA 2024-11-01
ER

PT J
AU Ng, YS
   Thompson, K
   Loher, D
   Hopton, S
   Falkous, G
   Hardy, SA
   Schaefer, AM
   Shaunak, S
   Roberts, ME
   Lilleker, JB
   Taylor, RW
AF Ng, Yi Shiau
   Thompson, Kyle
   Loher, Daniela
   Hopton, Sila
   Falkous, Gavin
   Hardy, Steven A.
   Schaefer, Andrew M.
   Shaunak, Sandip
   Roberts, Mark E.
   Lilleker, James B.
   Taylor, Robert W.
TI Novel <i>MT-ND</i> Gene Variants Causing Adult-Onset Mitochondrial
   Disease and Isolated Complex I Deficiency
SO FRONTIERS IN GENETICS
LA English
DT Article
DE mitochondrial DNA; muscle biopsy; myopathy; deafness; tissue segregation
ID EXERCISE INTOLERANCE; MUTATIONS; ASSAY; MTDNA
AB Mitochondrial complex I deficiency is associated with a diverse range of clinical phenotypes and can arise due to either mitochondrial DNA (mtDNA) or nuclear gene defects. We investigated two adult patients who exhibited non-syndromic neurological features and evidence of isolated mitochondrial complex I deficiency in skeletal muscle biopsies. The first presented with indolent myopathy, progressive since age 17, while the second developed deafness around age 20 and other relapsing-remitting neurological symptoms since. A novel, likely de novo, frameshift variant in MT-ND6 (m.14512_14513del) and a novel maternally-inherited transversion mutation in MT-ND1 were identified, respectively. Skewed tissue segregation of mutant heteroplasmy level was observed; the mutant heteroplasmy levels of both variants were greater than 70% in muscle homogenate, however, in blood the MT-ND6 variant was undetectable while the mutant heteroplasmy level of the MT-ND1 variant was low (12%). Assessment of complex I assembly by Blue-Native PAGE demonstrated a decrease in fully assembled complex I in the muscle of both cases. SDS-PAGE and immunoblotting showed decreased levels of mtDNA-encoded ND1 and several nuclear encoded complex I subunits in both cases, consistent with functional pathogenic consequences of the identified variants. Pathogenicity of the m.14512_14513del was further corroborated by single-fiber segregation studies.
C1 [Ng, Yi Shiau; Thompson, Kyle; Loher, Daniela; Hopton, Sila; Falkous, Gavin; Hardy, Steven A.; Schaefer, Andrew M.; Taylor, Robert W.] Newcastle Univ, Fac Med Sci, Wellcome Ctr Mitochondrial Res, Translat & Clin Res Inst, Newcastle Upon Tyne, Tyne & Wear, England.
   [Ng, Yi Shiau; Schaefer, Andrew M.] Newcastle Upon Tyne Hosp NHS Fdn Trust, Royal Victoria Infirm, Directorate Neurosci, Newcastle Upon Tyne, Tyne & Wear, England.
   [Loher, Daniela] Univ Freiburg, Fac Med, Inst Biochem & Mol Biol, ZBMZ, Freiburg, Germany.
   [Hopton, Sila; Falkous, Gavin; Hardy, Steven A.; Taylor, Robert W.] Newcastle Upon Tyne Hosp NHS Fdn Trust, NHS Highly Specialised Serv Rare Mitochondrial Di, Newcastle Upon Tyne, Tyne & Wear, England.
   [Shaunak, Sandip] Royal Preston Hosp, Dept Neurol, Preston, Lancs, England.
   [Roberts, Mark E.; Lilleker, James B.] Salford Royal NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester Ctr Clin Neurosci, Salford, Lancs, England.
   [Lilleker, James B.] Univ Manchester, Ctr Musculoskeletal Res, Sch Biol Sci, Div Musculoskeletal & Dermatol Sci, Manchester, Lancs, England.
C3 Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation
   Trust; Newcastle University - UK; University of Freiburg; Newcastle Upon
   Tyne Hospitals NHS Foundation Trust; Royal Preston Hospital; Salford
   Royal NHS Foundation Trust; University of Manchester
RP Taylor, RW (corresponding author), Newcastle Univ, Fac Med Sci, Wellcome Ctr Mitochondrial Res, Translat & Clin Res Inst, Newcastle Upon Tyne, Tyne & Wear, England.; Taylor, RW (corresponding author), Newcastle Upon Tyne Hosp NHS Fdn Trust, NHS Highly Specialised Serv Rare Mitochondrial Di, Newcastle Upon Tyne, Tyne & Wear, England.
EM robert.taylor@ncl.ac.uk
RI Ng, Yi/AFF-1445-2022; Lilleker, James/U-6121-2019
OI Lilleker, James/0000-0002-9230-4137; Ng, Yi Shiau/0000-0002-7591-2034
FU Wellcome Centre for Mitochondrial Research [203105/Z/16/Z]; Medical
   Research Council (MRC) International Centre for Genomic Medicine in
   Neuromuscular Disease; Mitochondrial Disease Patient Cohort (UK)
   [G0800674]; Newcastle University Centre for Ageing and Vitality
   (Biotechnology and Biological Sciences Research Council); Newcastle
   University Centre for Ageing and Vitality (Medical Research Council)
   [L016354]; UK NIHR Biomedical Research Centre for Ageing and Age-related
   disease award; Lily Foundation; NIHR Clinical Lectureship in Neurology
   [CL-2016-01-003, NWN/006/025/A]; UK NHS
FX RT is supported by the Wellcome Centre for Mitochondrial Research
   (203105/Z/16/Z), the Medical Research Council (MRC) International Centre
   for Genomic Medicine in Neuromuscular Disease, the Mitochondrial Disease
   Patient Cohort (UK) (G0800674), Newcastle University Centre for Ageing
   and Vitality (supported by the Biotechnology and Biological Sciences
   Research Council and Medical Research Council L016354), UK NIHR
   Biomedical Research Centre for Ageing and Age-related disease award to
   the Newcastle upon Tyne Hospitals NHS Foundation Trust, the Lily
   Foundation and the UK NHS Specialist Commissioners which funds the "Rare
   Mitochondrial Disorders of Adults and Children" Diagnostic Service in
   Newcastle upon Tyne YN holds a NIHR Clinical Lectureship in Neurology
   (CL-2016-01-003). JL holds a NIHR Clinical Lectureship in Neurology
   (NWN/006/025/A). The views expressed are those of the authors and not
   necessarily of the NHS, NIHR, or Department of Health.
CR Alston CL, 2017, J PATHOL, V241, P236, DOI 10.1002/path.4809
   Alston CL, 2010, NEUROMUSCULAR DISORD, V20, P131, DOI 10.1016/j.nmd.2009.10.010
   Andreu AL, 1999, ANN NEUROL, V45, P820, DOI 10.1002/1531-8249(199906)45:6<820::AID-ANA22>3.0.CO;2-W
   Distelmaier F, 2009, BRAIN, V132, P833, DOI 10.1093/brain/awp058
   Formosa LE, 2018, SEMIN CELL DEV BIOL, V76, P154, DOI 10.1016/j.semcdb.2017.08.011
   Gorman GS, 2015, NEUROMUSCULAR DISORD, V25, P563, DOI 10.1016/j.nmd.2015.03.001
   Gorman GS, 2015, CLIN SCI, V128, P895, DOI 10.1042/CS20140705
   Grady JP, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708262
   Hardy SA, 2016, NEUROL-GENET, V2, DOI 10.1212/NXG.0000000000000082
   Hoefs SJG, 2012, MITOCHONDRION, V12, P520, DOI 10.1016/j.mito.2012.07.106
   Janssen RJRJ, 2006, J INHERIT METAB DIS, V29, P499, DOI 10.1007/s10545-006-0362-4
   Kirby DM, 1999, NEUROLOGY, V52, P1255, DOI 10.1212/WNL.52.6.1255
   Krishnan KJ, 2007, ANAL BIOCHEM, V370, P127, DOI 10.1016/j.ab.2007.06.024
   Man PYW, 2002, J MED GENET, V39, P162, DOI 10.1136/jmg.39.3.162
   Mimaki M, 2012, BBA-BIOENERGETICS, V1817, P851, DOI 10.1016/j.bbabio.2011.08.010
   Musumeci O, 2000, AM J HUM GENET, V66, P1900, DOI 10.1086/302927
   Ng YS, 2018, EBIOMEDICINE, V30, P86, DOI 10.1016/j.ebiom.2018.02.010
   O'Toole JF, 2014, INT J NEPHROL RENOV, V7, P57, DOI 10.2147/IJNRD.S37887
   Oláhová M, 2015, BRAIN, V138, P3503, DOI 10.1093/brain/awv291
   OLD SL, 1989, HISTOCHEM J, V21, P545, DOI 10.1007/BF01753355
   Rocha MC, 2015, SCI REP-UK, V5, DOI 10.1038/srep15037
   Thompson K, 2020, J INHERIT METAB DIS, V43, P36, DOI 10.1002/jimd.12104
   Thompson K, 2016, AM J HUM GENET, V99, P860, DOI 10.1016/j.ajhg.2016.08.014
   Zierz CM, 2019, J CLIN MED, V8, DOI 10.3390/jcm8060789
NR 24
TC 12
Z9 12
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1664-8021
J9 FRONT GENET
JI Front. Genet.
PD FEB 25
PY 2020
VL 11
AR 24
DI 10.3389/fgene.2020.00024
PG 7
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA LC3DV
UT WOS:000525206400001
PM 32158465
OA Green Published, gold
DA 2024-11-01
ER

PT J
AU Collins, J
   Bove, KE
   Dimmock, D
   Morehart, P
   Wong, LJ
   Wong, B
AF Collins, James
   Bove, Kevin E.
   Dimmock, David
   Morehart, Paula
   Wong, Lee-Jun
   Wong, Brenda
TI Progressive myofiber loss with extensive fibro-fatty replacement in a
   child with mitochondrial DNA depletion syndrome and novel thymidine
   kinase 2 gene mutations
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE Mitochondrial DNA depletion syndrome; Thymidine kinase 2; Myopathy;
   Respiratory chain
ID MTDNA DEPLETION; MYOPATHY
AB The mitochondrial DNA depletion syndromes (MDS) are autosomal recessive disorders with a decreased mitochondrial DNA copy number. Mutations in thymidine kinase 2 (TK2) have been responsible for the myopathic form of MDS. We describe a child with congenital muscle weakness who had a progressive mitochondrial myopathy associated with extensive fibro-fatty replacement of myofibers resembling muscular dystrophy. MDS was suspected based upon findings in the initial muscle biopsy. Sequence analysis of the TK2 gene revealed two novel heterozygous mutations: the frame shift mutation, c.255_c.258delAGAA and the heterozygous missense mutation, c.515G>A, (p.R172Q). This report extends the phenotype and genotype of TK2 defects. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Collins, James; Morehart, Paula; Wong, Brenda] Cincinnati Childrens Hosp, Div Neurol, Med Ctr, Cincinnati, OH 45229 USA.
   [Bove, Kevin E.] Cincinnati Childrens Hosp, Div Pathol & Lab Med, Med Ctr, Cincinnati, OH 45229 USA.
   [Dimmock, David; Wong, Lee-Jun] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
C3 Cincinnati Children's Hospital Medical Center; Cincinnati Children's
   Hospital Medical Center; Baylor College of Medicine
RP Wong, B (corresponding author), Cincinnati Childrens Hosp, Div Neurol, Med Ctr, MLC 2015,3333 Burnet Ave, Cincinnati, OH 45229 USA.
EM brenda.wong@cchmc.org
RI Dimmock, David/I-7913-2015
OI Dimmock, David/0000-0001-6690-2523
FU NCRR NIH HHS [K12 RR017665] Funding Source: Medline
CR Barthélémy C, 2001, ANN NEUROL, V49, P607, DOI 10.1002/ana.1002.abs
   Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   Carrozzo R, 2003, HUM MUTAT, V21, DOI 10.1002/humu.9135
   Dimmock DP, 2008, HUM MUTAT, V29, P330, DOI 10.1002/humu.9519
   Galbiati S, 2006, PEDIATR NEUROL, V34, P177, DOI 10.1016/j.pediatrneurol.2005.07.013
   Saada A, 2003, MOL GENET METAB, V79, P1, DOI 10.1016/S1096-7192(03)00063-5
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Vilá MR, 2008, J NEUROL SCI, V267, P137, DOI 10.1016/j.jns.2007.10.019
   Vilà MR, 2003, NEUROLOGY, V60, P1203, DOI 10.1212/01.WNL.0000055928.58122.47
   Wong LJC, 2003, J MED GENET, V40
NR 10
TC 15
Z9 18
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD NOV
PY 2009
VL 19
IS 11
BP 784
EP 787
DI 10.1016/j.nmd.2009.08.002
PG 4
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 522SZ
UT WOS:000272020400010
PM 19736010
DA 2024-11-01
ER

PT J
AU DiMauro, S
AF DiMauro, Salvatore
TI A history of mitochondrial diseases
SO JOURNAL OF INHERITED METABOLIC DISEASE
LA English
DT Article
ID CYTOCHROME-C-OXIDASE; DOMINANT OPTIC ATROPHY; PROGRESSIVE EXTERNAL
   OPHTHALMOPLEGIA; COENZYME-Q DEFICIENCY; RAGGED-RED FIBERS;
   OXIDATIVE-PHOSPHORYLATION; CEREBELLAR-ATAXIA; LACTIC-ACIDOSIS;
   SKELETAL-MUSCLE; BARTH-SYNDROME
AB This articles reviews the development of mitochondrial medicine from the premolecular era (1962-1988), when mitochondrial diseases were defined on the basis of clinical examination, muscle biopsy, and biochemical criteria, through the molecular era, when the full complexity of these disorders became evident. In a chronological order, I have followed the introduction of new pathogenic concepts that have shaped a rational genetic classification of these clinically heterogeneous disorders. Thus, mitochondrial DNA (mtDNA)-related diseases can be divided into two main groups: those that impair mitochondrial protein synthesis in toto, and those that affect specific respiratory chain proteins. Mutations in nuclear DNA can affect components of respiratory chain complexes (direct hits) or assembly proteins (indirect hits), but they can also impair mtDNA integrity (multiple mtDNA mutations), replication (mtDNA depletion), or mtDNA translation. Besides these disorders that affect the respiratory chain directly, defects in other mitochondrial functions may also affect oxidative phosphorylation, including problems in mitochondrial protein import, alterations of the inner mitochondrial membrane lipid composition, and defects of mitochondrial dynamics. The enormous and still ongoing progress in our understanding of mitochondrial medicine was made possible by the intense collaboration of an international cadre of "mitochondriacs." Having published my first paper on a patient with mitochondrial myopathy 37 years ago (DiMauro et al., 1973), I feel qualified to write a history of the mitochondrial diseases, a fascinating, still evolving, and continuously puzzling area of medicine. In each section, I follow a chronological order of the salient discoveries and I show only the portraits of distinguished deceased mitochondriacs and those whose names became eponyms of mitochondrial diseases.
C1 Columbia Univ, Coll Phys & Surg, Med Ctr, Dept Neurol, New York, NY 10032 USA.
C3 Columbia University
RP DiMauro, S (corresponding author), Columbia Univ, Coll Phys & Surg, Med Ctr, Dept Neurol, Room 4-424B,630 West 168th St, New York, NY 10032 USA.
EM sd12@columbia.edu
FU NIH [HD032062]; Marriott Mitochondrial Clinical Research Fund (MMCRF)
FX This work was supported by NIH grant HD032062 and by the Marriott
   Mitochondrial Clinical Research Fund (MMCRF).
CR Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944
   Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   Antonicka H, 2003, AM J HUM GENET, V72, P101, DOI 10.1086/345489
   Antonicka H, 2006, HUM MOL GENET, V15, P1835, DOI 10.1093/hmg/ddl106
   Area-Gomez E, 2009, AM J PATHOL, V175, P1810, DOI 10.2353/ajpath.2009.090219
   Auré K, 2004, NEUROLOGY, V63, P727, DOI 10.1212/01.WNL.0000134607.76780.B2
   BARTH PG, 1983, J NEUROL SCI, V62, P327, DOI 10.1016/0022-510X(83)90209-5
   Bione S, 1996, NAT GENET, V12, P385, DOI 10.1038/ng0496-385
   BLASS J P, 1970, Journal of Clinical Investigation, V49, P423, DOI 10.1172/JCI106251
   Bolender N, 2008, EMBO REP, V9, P42, DOI 10.1038/sj.embor.7401126
   BONILLA E, 1992, BRAIN PATHOL, V2, P113, DOI 10.1111/j.1750-3639.1992.tb00679.x
   Bossy-Wetzel E, 2003, CURR OPIN CELL BIOL, V15, P706, DOI 10.1016/j.ceb.2003.10.015
   BOURGERON T, 1995, NAT GENET, V11, P144, DOI 10.1038/ng1095-144
   Bykhovskaya Y, 2004, AM J HUM GENET, V74, P1303, DOI 10.1086/421530
   Cao LQ, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000756
   Carelli V., 2006, Mitochondrial Medicine, P105
   Chan DC, 2007, NEW ENGL J MED, V356, P1707, DOI 10.1056/NEJMp078040
   Chan DC, 2006, CELL, V125, P1241, DOI 10.1016/j.cell.2006.06.010
   Chinnery PF, 2000, ANN NEUROL, V47, P381, DOI 10.1002/1531-8249(200003)47:3<381::AID-ANA17>3.0.CO;2-2
   Chomyn A, 2000, J BIOL CHEM, V275, P19198, DOI 10.1074/jbc.M908734199
   CIZKOVA A, 2009, NAT GENET, V40
   Coenen MJH, 2004, NEW ENGL J MED, V351, P2080, DOI 10.1056/NEJMoa041878
   Cree LM, 2008, NAT GENET, V40, P249, DOI 10.1038/ng.2007.63
   Darin N, 2001, ANN NEUROL, V49, P377, DOI 10.1002/ana.75
   Davey KM, 2006, J MED GENET, V43, P385, DOI 10.1136/jmg.2005.036657
   De Meirleir L, 2004, J MED GENET, V41, P120, DOI 10.1136/jmg.2003.012047
   DEFRANCESCO L, 1976, J BIOL CHEM, V251, P4588
   Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936
   DESJARDINS P, 1985, MOL CELL BIOL, V5, P1163, DOI 10.1128/MCB.5.5.1163
   DIMAURO S, 1973, ARCH NEUROL-CHICAGO, V29, P170, DOI 10.1001/archneur.1973.00490270052008
   DIMAURO S, 1973, SCIENCE, V182, P929, DOI 10.1126/science.182.4115.929
   DIMAURO S, 1976, J NEUROL SCI, V27, P217, DOI 10.1016/0022-510X(76)90063-0
   DIMAURO S, 1985, ANN NEUROL, V17, P521, DOI 10.1002/ana.410170602
   DIMAURO S, 2006, MITOCHONDRIAL MED
   DiMauro S, 2008, ANNU REV NEUROSCI, V31, P91, DOI 10.1146/annurev.neuro.30.051606.094302
   Diomedi-Camassei F, 2007, J AM SOC NEPHROL, V18, P2773, DOI 10.1681/ASN.2006080833
   Dubeau F, 2000, ANN NEUROL, V47, P179, DOI 10.1002/1531-8249(200002)47:2<179::AID-ANA7>3.0.CO;2-Z
   Duncan AJ, 2009, AM J HUM GENET, V84, P558, DOI 10.1016/j.ajhg.2009.03.018
   Edvardson S, 2007, AM J HUM GENET, V81, P857, DOI 10.1086/521227
   Elliott HR, 2008, AM J HUM GENET, V83, P254, DOI 10.1016/j.ajhg.2008.07.004
   ENGEL AG, 1973, SCIENCE, V179, P899, DOI 10.1126/science.179.4076.899
   ENGEL WK, 1963, NEUROLOGY, V13, P919, DOI 10.1212/WNL.13.11.919
   FENTON WA, 1995, AM J HUM GENET, V57, P235
   Filosto M, 2003, ANN NEUROL, V54, P524, DOI 10.1002/ana.10709
   FUKUHARA N, 1980, J NEUROL SCI, V47, P117, DOI 10.1016/0022-510X(80)90031-3
   Gempel K, 2007, BRAIN, V130, P2037, DOI 10.1093/brain/awm054
   Ghezzi D, 2009, NAT GENET, V41, P654, DOI 10.1038/ng.378
   Gironi M, 2004, NEUROLOGY, V62, P818, DOI 10.1212/01.WNL.0000113719.67643.B7
   GONATAS NK, 1965, EXCERPTA MED INT C S, V100, P606
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Greaves LC, 2006, P NATL ACAD SCI USA, V103, P714, DOI 10.1073/pnas.0505903103
   Guan MX, 2006, AM J HUM GENET, V79, P291, DOI 10.1086/506389
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Hansen JJ, 2002, AM J HUM GENET, V70, P1328, DOI 10.1086/339935
   Haut S, 2003, HUM GENET, V113, P118, DOI 10.1007/s00439-003-0946-0
   HAYDAR NA, 1971, ANN INTERN MED, V74, P548, DOI 10.7326/0003-4819-74-4-548
   HERS HG, 1965, GASTROENTEROLOGY, V48, P625
   Hinson JT, 2007, NEW ENGL J MED, V356, P809, DOI 10.1056/NEJMoa055262
   Hirano M, 2006, NEUROLOGY, V67, P1458, DOI 10.1212/01.wnl.0000240853.97716.24
   HIRANO M, 1994, NEUROLOGY, V44, P721, DOI 10.1212/WNL.44.4.721
   Hirano M, 1998, AM J HUM GENET, V63, P526, DOI 10.1086/301979
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Horvath R, 2009, BRAIN, V132, P3165, DOI 10.1093/brain/awp221
   Hudson G, 2005, AM J HUM GENET, V77, P1086, DOI 10.1086/498176
   Hudson G, 2008, BRAIN, V131, P329, DOI 10.1093/brain/awm272
   Hudson G, 2007, AM J HUM GENET, V81, P228, DOI 10.1086/519394
   Jacobs HT, 2005, TRENDS GENET, V21, P312, DOI 10.1016/j.tig.2005.04.003
   Jenuth JP, 1996, NAT GENET, V14, P146, DOI 10.1038/ng1096-146
   KADOWAKI T, 1994, NEW ENGL J MED, V330, P962, DOI 10.1056/NEJM199404073301403
   Karadimas CL, 2006, AM J HUM GENET, V79, P544, DOI 10.1086/506913
   KARPATI G, 1975, NEUROLOGY, V25, P16, DOI 10.1212/WNL.25.1.16
   Kaufmann P, 2004, NEUROLOGY, V62, P1297, DOI 10.1212/01.WNL.0000120557.83907.A8
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   Kirby DM, 2004, J CLIN INVEST, V114, P837, DOI 10.1172/JCI200420683
   Kraytsberg Y, 2004, SCIENCE, V304, P981, DOI 10.1126/science.1096342
   Lagier-Tourenne C, 2008, AM J HUM GENET, V82, P661, DOI 10.1016/j.ajhg.2007.12.024
   Lalani SR, 2005, ARCH NEUROL-CHICAGO, V62, P317, DOI 10.1001/archneur.62.2.317
   Lamperti C, 2003, NEUROLOGY, V60, P1206, DOI 10.1212/01.WNL.0000055089.39373.FC
   LEDLEY FD, 1990, P NATL ACAD SCI USA, V87, P3147, DOI 10.1073/pnas.87.8.3147
   LESTIENNE P, 1988, LANCET, V1, P885
   López LC, 2006, AM J HUM GENET, V79, P1125, DOI 10.1086/510023
   LUFT R, 1962, J CLIN INVEST, V41, P1776, DOI 10.1172/JCI104637
   Magen D, 2008, AM J HUM GENET, V83, P30, DOI 10.1016/j.ajhg.2008.05.016
   Mangiullo R, 2008, BBA-BIOENERGETICS, V1777, P1326, DOI 10.1016/j.bbabio.2008.08.003
   Manwaring N, 2007, MITOCHONDRION, V7, P230, DOI 10.1016/j.mito.2006.12.004
   Martí R, 2003, BIOCHEM BIOPH RES CO, V303, P14, DOI 10.1016/S0006-291X(03)00294-8
   Massa V, 2008, AM J HUM GENET, V82, P1281, DOI 10.1016/j.ajhg.2008.05.002
   MASUCCI JP, 1995, MOL CELL BIOL, V15, P2872
   McKenzie M, 2006, J MOL BIOL, V361, P462, DOI 10.1016/j.jmb.2006.06.057
   Miller C, 2004, ANN NEUROL, V56, P734, DOI 10.1002/ana.20282
   Mollet J, 2008, AM J HUM GENET, V82, P623, DOI 10.1016/j.ajhg.2007.12.022
   Mollet J, 2007, J CLIN INVEST, V117, P765, DOI 10.1172/JCI29089
   Mootha VK, 2003, P NATL ACAD SCI USA, V100, P605, DOI 10.1073/pnas.242716699
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   MORAES CT, 1992, AM J HUM GENET, V50, P934
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   MORAIS R, 1988, IN VITRO CELL DEV B, V24, P649, DOI 10.1007/BF02623602
   Musumeci O, 2001, NEUROLOGY, V56, P849, DOI 10.1212/WNL.56.7.849
   NASS MMK, 1963, J CELL BIOL, V19, P593, DOI 10.1083/jcb.19.3.593
   NASS S, 1963, J CELL BIOL, V19, P613, DOI 10.1083/jcb.19.3.613
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Naviaux RK, 1999, ANN NEUROL, V45, P54, DOI 10.1002/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B
   Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   OGASAHARA S, 1989, P NATL ACAD SCI USA, V86, P2379, DOI 10.1073/pnas.86.7.2379
   Ogilvie I, 2005, J CLIN INVEST, V115, P2784, DOI 10.1172/JCI26020
   Papadopoulou LC, 1999, NAT GENET, V23, P333
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   PETTY RKH, 1986, BRAIN, V109, P915, DOI 10.1093/brain/109.5.915
   Poulton J, 2009, BBA-MOL BASIS DIS, V1792, P1109, DOI 10.1016/j.bbadis.2009.08.016
   PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289
   Quinzii C, 2006, AM J HUM GENET, V78, P345, DOI 10.1086/500092
   Quinzii CM, 2005, NEUROLOGY, V64, P539, DOI 10.1212/01.WNL.0000150588.75281.58
   Ravera S, 2009, INT J BIOCHEM CELL B, V41, P1581, DOI 10.1016/j.biocel.2009.01.009
   Rötig A, 2009, BBA-MOL BASIS DIS, V1792, P1103, DOI 10.1016/j.bbadis.2009.06.009
   Rötig A, 2000, LANCET, V356, P391, DOI 10.1016/S0140-6736(00)02531-9
   Rowland LP., 1994, Mitochondrial Disorders in Neurology, P116
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Sacconi S, 2008, HUM MOL GENET, V17, P1814, DOI 10.1093/hmg/ddn073
   Salviati L, 2005, NEUROLOGY, V65, P606, DOI 10.1212/01.wnl.0000172859.55579.a7
   Schaefer AM, 2004, BBA-BIOENERGETICS, V1659, P115, DOI 10.1016/j.bbabio.2004.09.005
   Schaefer AM, 2008, ANN NEUROL, V63, P35, DOI 10.1002/ana.21217
   Scheffler I.E., 1986, Carbohydrate Metabolism in Cultured Cells, P77
   Scheper GC, 2007, NAT GENET, V39, P534, DOI 10.1038/ng2013
   Schlame M, 2002, ANN NEUROL, V51, P634, DOI 10.1002/ana.10176
   Schlame M, 2006, FEBS LETT, V580, P5450, DOI 10.1016/j.febslet.2006.07.022
   Schwartz M, 2004, J NEUROL SCI, V218, P99, DOI 10.1016/j.jns.2003.11.008
   Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350
   Servidei Serenella, 2004, Neuromuscul Disord, V14, P107
   Shankar SP, 2008, OPHTHALMIC GENET, V29, P17, DOI 10.1080/13816810701867607
   SHAPIRA Y, 1977, ISRAEL J MED SCI, V13, P161
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   SHY GM, 1966, BRAIN, V89, P133, DOI 10.1093/brain/89.1.133
   SHY GM, 1964, SCIENCE, V145, P493, DOI 10.1126/science.145.3631.493
   Skladal D, 2003, BRAIN, V126, P1905, DOI 10.1093/brain/awg170
   Smeitink J, 1999, AM J HUM GENET, V64, P1505, DOI 10.1086/302432
   Smeitink JAM, 2006, AM J HUM GENET, V79, P869, DOI 10.1086/508434
   Sobreira C, 1997, NEUROLOGY, V48, P1238, DOI 10.1212/WNL.48.5.1238
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Sperl W, 2006, NEUROMUSCULAR DISORD, V16, P821, DOI 10.1016/j.nmd.2006.08.008
   Spinazzola A, 2005, GENE, V354, P162, DOI 10.1016/j.gene.2005.03.025
   Spinazzola A, 2009, J INHERIT METAB DIS, V32, P143, DOI 10.1007/s10545-008-1038-z
   Spinazzola A, 2002, J BIOL CHEM, V277, P4128, DOI 10.1074/jbc.M111028200
   SPIRO AJ, 1970, ARCH NEUROL-CHICAGO, V23, P103, DOI 10.1001/archneur.1970.00480260009002
   Sue CM, 1999, NEUROLOGY, V52, P1905, DOI 10.1212/WNL.52.9.1905
   TAKAKUBO F, 1995, AM J HUM GENET, V57, P772
   Tanji K, 2001, METHOD CELL BIOL, V65, P311, DOI 10.1016/S0091-679X(01)65019-2
   TATUCH Y, 1992, AM J HUM GENET, V50, P852
   Taylor RW, 2003, ANN NEUROL, V54, P521, DOI 10.1002/ana.10673
   Taylor RW, 2003, J AM COLL CARDIOL, V41, P1786, DOI 10.1016/S0735-1097(03)00300-0
   Tiranti V, 2006, J MED GENET, V43, P340, DOI 10.1136/jmg.2005.036210
   Tiranti V, 2004, AM J HUM GENET, V74, P239, DOI 10.1086/381653
   Tiranti V, 1998, AM J HUM GENET, V63, P1609, DOI 10.1086/302150
   Tiranti V, 2009, NAT MED, V15, P200, DOI 10.1038/nm.1907
   Valente L, 2007, AM J HUM GENET, V80, P44, DOI 10.1086/510559
   Valnot I, 2000, AM J HUM GENET, V67, P1104
   Valnot I, 2000, HUM MOL GENET, V9, P1245, DOI 10.1093/hmg/9.8.1245
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Maldergem L, 2002, ANN NEUROL, V52, P750, DOI 10.1002/ana.10371
   Visapää I, 2002, AM J HUM GENET, V71, P863, DOI 10.1086/342773
   Vreken P, 2000, BIOCHEM BIOPH RES CO, V279, P378, DOI 10.1006/bbrc.2000.3952
   Wai T, 2008, NAT GENET, V40, P1484, DOI 10.1038/ng.258
   Wallace DC, 2005, GENE, V354, P169, DOI 10.1016/j.gene.2005.05.001
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   WILLEMS JL, 1977, PEDIATRICS, V60, P850
   Yu YM, 2006, J BIOL CHEM, V281, P36929, DOI 10.1074/jbc.M607703200
   Zanna C, 2008, BRAIN, V131, P352, DOI 10.1093/brain/awm335
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
   Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804
   Züchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341
NR 175
TC 58
Z9 67
U1 0
U2 11
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0141-8955
EI 1573-2665
J9 J INHERIT METAB DIS
JI J. Inherit. Metab. Dis.
PD APR
PY 2011
VL 34
IS 2
BP 261
EP 276
DI 10.1007/s10545-010-9082-x
PG 16
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental
   Medicine
GA 739YI
UT WOS:000288757700004
PM 20490929
DA 2024-11-01
ER

PT J
AU Olimpio, C
   Tiet, MY
   Horvath, R
AF Olimpio, Catarina
   Tiet, May Yung
   Horvath, Rita
TI Primary mitochondrial myopathies in childhood
SO NEUROMUSCULAR DISORDERS
LA English
DT Review
DE Mitochondria; Mitochondrial myopathy; Treatment; Next-generation
   sequencing; Muscle; Differential diagnosis
ID COMPLEX I DEFICIENCY; EXERCISE INTOLERANCE; LACTIC-ACIDOSIS; MUTATION;
   GENE; DISEASES; ENCEPHALOMYOPATHY; MANIFESTATION; PHENOTYPE; CHILDREN
AB Primary mitochondrial myopathies are genetic metabolic disorders of mitochondrial dysfunction affecting mainly, but not exclusively, skeletal muscle. Although individually rare, they are the most common inherited metabolic disorders in childhood. They can be similar to other childhood muscle diseases such as congenital myopathies, dystrophies, myasthenic syndromes or metabolic myopathies and a muscle biopsy and genetic testing are important in the differential diagnosis. Mitochondrial myopathies can present at any age but typically childhood onset myopathies have more significant muscle involvement and are caused by genes encoded in the nuclear DNA. Mitochondrial myopathy in infants presents with hypotonia, muscle weakness and difficulty feeding. In toddlers and older children delayed motor development, exercise intolerance and premature fatigue are common. A number of nuclear DNA and mitochondrial DNA encoded genes are known to cause isolated myopathy in childhood and they are important in a range of mitochondrial functions such as oxidative phosphorylation, mitochondrial transcription/translation and mitochondrial fusion/fission. A rare cause of isolated myopathy in children, reversible infantile respiratory chain deficiency myopathy, is non-progressive and typically associated with spontaneous full recovery. Promising targeted treatments have been reported for a number or mitochondrial myopathies including riboflavin in ACAD9 and ETFDH-myopathies and deoxynucleoside for TK2- related disease. (c) 2021 Published by Elsevier B.V.
C1 [Olimpio, Catarina] Cambridge Univ Hosp NHS Fdn Trust, East Anglian Med Genet Serv, Cambridge, England.
   [Tiet, May Yung; Horvath, Rita] Univ Cambridge, Dept Clin Neurosci, Cambridge, England.
C3 University of Cambridge; University of Cambridge
RP Horvath, R (corresponding author), Univ Cambridge, Dept Clin Neurosci, Cambridge, England.
EM rh732@medschl.cam.ac.uk
RI Horvath, Rita/AAY-7042-2020
OI Tiet, May Yung/0000-0002-3183-7087; Horvath, Rita/0000-0002-9841-170X
FU Wellcome Trust [109915/Z/15/Z]; Medical Research Council (UK)
   [MR/N025431/1, MR/V009346/1]; European Research Council [309548]; Newton
   Fund (UK/Turkey) [MR/N027302/1]; Addenbrookes Charitable Trust
   [G100142]; Evelyn Trust; Stoneygate Trust; Lily Foundation; MRC
   [MR/S005021/1]; NIHR Cambridge Biomedical Research Centre
   [BRC-1215-20014]; MRC [MR/N025431/2, MR/N025431/1, MR/V009346/1,
   MR/N010035/1, MR/S005021/1] Funding Source: UKRI; Newton Fund
   [MR/N027302/2, MR/N027302/1] Funding Source: UKRI
FX R.H. is a Wellcome Trust Investigator (109915/Z/15/Z), who receives
   support from the Medical Research Council (UK) (MR/N025431/1 and
   MR/V009346/1), the European Research Council (309548), the Newton Fund
   (UK/Turkey, MR/N027302/1), the Addenbrookes Charitable Trust (G100142),
   the Evelyn Trust, the Stoneygate Trust, the Lily Foundation and an MRC
   strategic award to establish an International Centre for Genomic
   Medicine in Neuromuscular Diseases (ICGNMD) MR/S005021/1. This research
   was supported by the NIHR Cambridge Biomedical Research Centre
   (BRC-1215-20014). The views expressed are those of the authors and not
   necessarily those of the NIHR or the Department of Health and Social
   Care.
CR Ahmed ST, 2018, NEUROTHERAPEUTICS, V15, P943, DOI 10.1007/s13311-018-00674-4
   Bartsakoulia M, 2018, HUM MOL GENET, V27, P1186, DOI 10.1093/hmg/ddy033
   Basu S, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1009242
   Berardo A, 2010, CURR NEUROL NEUROSCI, V10, P118, DOI 10.1007/s11910-010-0096-4
   Boczonadi V, 2018, ESSAYS BIOCHEM, V62, P321, DOI 10.1042/EBC20170103
   Boczonadi V, 2018, FEBS LETT, V592, P703, DOI 10.1002/1873-3468.12962
   Boczonadi V, 2015, J INHERIT METAB DIS, V38, P427, DOI 10.1007/s10545-014-9784-6
   Bruno C, 2011, BIOCHEM BIOPH RES CO, V412, P518, DOI 10.1016/j.bbrc.2011.06.155
   Carlile TM, 2019, NAT CHEM BIOL, V15, P966, DOI 10.1038/s41589-019-0353-z
   Chen W, 2019, BMC NEUROL, V19, DOI 10.1186/s12883-019-1562-5
   Darin N, 2017, EUR J NEUROL, V24, P587, DOI 10.1111/ene.13249
   de Barcelos IP, 2019, CURR OPIN NEUROL, V32, P715, DOI 10.1097/WCO.0000000000000743
   Debray FG, 2014, MITOCHONDRION, V17, P101, DOI 10.1016/j.mito.2014.06.003
   Diebold I, 2019, MOL CELL PROBE, V44, P14, DOI 10.1016/j.mcp.2019.01.003
   Domínguez-González C, 2019, ANN NEUROL, V86, P293, DOI 10.1002/ana.25506
   Downham E, 2008, NEUROMUSCULAR DISORD, V18, P310, DOI 10.1016/j.nmd.2008.01.003
   Fassone E, 2012, J MED GENET, V49, P578, DOI 10.1136/jmedgenet-2012-101159
   Garone C, 2018, J MED GENET, V55, P515, DOI 10.1136/jmedgenet-2017-105012
   Garone C, 2013, JAMA NEUROL, V70, P1177, DOI 10.1001/jamaneurol.2013.3197
   Gempel K, 2007, BRAIN, V130, P2037, DOI 10.1093/brain/awm054
   Goldstein A., 2021, GENEREVIEWS
   Gorman GS, 2016, NAT REV DIS PRIMERS, V2, P1, DOI 10.1038/nrdp.2016.80
   Gorman GS, 2015, CLIN SCI, V128, P895, DOI 10.1042/CS20140705
   Hardy SA, 2016, NEUROL-GENET, V2, DOI 10.1212/NXG.0000000000000082
   Hathazi D, 2020, EMBO J, V39, DOI 10.15252/embj.2020105364
   He M, 2007, AM J HUM GENET, V81, P87, DOI 10.1086/519219
   Hebbar M, 2017, EUR J MED GENET, V60, P533, DOI 10.1016/j.ejmg.2017.07.010
   Hedberg-Oldfors C, 2021, BRAIN PATHOL, V31, DOI 10.1111/bpa.12931
   Horváth R, 2003, J MED GENET, V40, P752, DOI 10.1136/jmg.40.10.752
   Horvath R, 2009, BRAIN, V132, P3165, DOI 10.1093/brain/awp221
   Jou C, 2019, J CLIN MED, V8, DOI 10.3390/jcm8010068
   Keshavan N, 2020, GENET MED, V22, P199, DOI 10.1038/s41436-019-0613-z
   Kollberg G, 2009, BRAIN, V132, P2170, DOI 10.1093/brain/awp152
   Kornblum C, 2013, NAT GENET, V45, P214, DOI 10.1038/ng.2501
   Legati A, 2017, J MED GENET, V54, P815, DOI 10.1136/jmedgenet-2017-104822
   Leslie N, 2021, GENEREVIEWS
   Lim AZ, 2020, NEUROMUSCULAR DISORD, V30, P661, DOI 10.1016/j.nmd.2020.06.008
   Lim AZ, 2021, GENEREVIEWS
   Longo N, 2006, AM J MED GENET C, V142C, P77, DOI 10.1002/ajmg.c.30087
   Mancuso M, 2017, NEUROMUSCULAR DISORD, V27, P1126, DOI 10.1016/j.nmd.2017.08.006
   Mayr JA, 2006, NEUROMUSCULAR DISORD, V16, P874, DOI 10.1016/j.nmd.2006.08.010
   McFarland R, 2008, NEUROMUSCULAR DISORD, V18, P63, DOI 10.1016/j.nmd.2007.07.007
   Merritt JL, 2020, REV ENDOCR METAB DIS, V21, P479, DOI 10.1007/s11154-020-09568-3
   MITOMAP, 2021, HUM MIT GEN DAT
   Mori M, 2015, MOLEC GENET METAB RE, V4, P39, DOI 10.1016/j.ymgmr.2015.06.001
   Ng YS, 2021, LANCET NEUROL, V20, P573, DOI 10.1016/S1474-4422(21)00098-3
   Ng YS, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00024
   Nogueira C, 2014, ITAL J PEDIATR, V40, DOI 10.1186/1824-7288-40-34
   Oncul U, 2021, J PEDIAT HEMATOL ONC, V43, pE592, DOI 10.1097/MPH.0000000000001806
   Parikh S, 2019, DIAGNOSIS MANAGEMENT, P183, DOI [10. 1007/978- 3-030-05517-2_12, DOI 10.1007/978-3-030-05517-2_12]
   Pitceathly RDS, 2014, CURR OPIN NEUROL, V27, P576, DOI 10.1097/WCO.0000000000000126
   Pyle A, 2015, NEUROL-GENET, V1, DOI 10.1212/NXG.0000000000000006
   Rahman S, 2020, J INTERN MED, V287, P609, DOI 10.1111/joim.13054
   Raymond FL, 2018, NAT REV GENET, V19, P399, DOI 10.1038/s41576-018-0022-1
   Richter U, 2021, FEBS LETT, V595, P1003, DOI 10.1002/1873-3468.14049
   Riley LG, 2010, AM J HUM GENET, V87, P52, DOI 10.1016/j.ajhg.2010.06.001
   Rocha MC, 2015, SCI REP-UK, V5, DOI 10.1038/srep15037
   Roos S, 2019, EUR J HUM GENET, V27, P331, DOI 10.1038/s41431-018-0286-0
   Russell OM, 2020, CELL, V181, P168, DOI 10.1016/j.cell.2020.02.051
   Sanaker PS, 2010, BBA-MOL BASIS DIS, V1802, P539, DOI 10.1016/j.bbadis.2010.02.010
   Schaefer A., 2019, DIAGNOSIS MANAGEMENT, P63, DOI [DOI 10.1007/978-3-030-05517-2_4, 10.1007/978-3-030-05517-24]
   Schon KR, 2020, TRENDS GENET, V36, P702, DOI 10.1016/j.tig.2020.06.009
   Schrank B, 2017, NEUROMUSCULAR DISORD, V27, P473, DOI 10.1016/j.nmd.2017.02.005
   Spiegel R, 2014, EUR J HUM GENET, V22, P902, DOI 10.1038/ejhg.2013.269
   Suzuki T, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18068-6
   Thompson R, 2020, LANCET NEUROL, V19, P522, DOI 10.1016/S1474-4422(20)30028-4
   Trifunov S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30143-z
   Viscomi C, 2017, J INHERIT METAB DIS, V40, P587, DOI 10.1007/s10545-017-0027-5
   Wanders Ronald J A, 2020, J Lipid Atheroscler, V9, P313, DOI 10.12997/jla.2020.9.3.313
   Wang J, 2021, GENEREVIEWS
   Webb Bryn D, 2020, J Transl Genet Genom, V4, P71, DOI 10.20517/jtgg.2020.11
   Yarham JW, 2010, WIRES RNA, V1, P304, DOI 10.1002/wrna.27
   Zanolini A, 2017, MOL GENET METAB REP, V10, P24, DOI 10.1016/j.ymgmr.2016.11.009
NR 73
TC 4
Z9 4
U1 0
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD OCT
PY 2021
VL 31
IS 10
BP 978
EP 987
DI 10.1016/j.nmd.2021.08.005
EA NOV 2021
PG 10
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA WU1UF
UT WOS:000716336700008
PM 34736635
DA 2024-11-01
ER

PT J
AU Mayorga, L
   Laurito, SR
   Loos, MA
   Eiroa, HD
   de Pinho, S
   Lubieniecki, F
   Arroyo, HA
   Pereyra, MF
   Kauffman, MA
   Roqué, M
AF Mayorga, Lia
   Laurito, Sergio R.
   Loos, Mariana A.
   Eiroa, Hernan D.
   de Pinho, Silvina
   Lubieniecki, Fabiana
   Arroyo, Hugo A.
   Pereyra, Marcela F.
   Kauffman, Marcelo A.
   Roque, Maria
TI Mitochondrial DNA deletions detected by Multiplex Ligation-dependent
   Probe Amplification
SO MITOCHONDRIAL DNA PART A
LA English
DT Article
DE Chronic progressive external ophthalmoplegia; copy number changes;
   diagnosis; Kearns Sayre Syndrome; mitochondrial disease; NUMTs
ID QUANTIFICATION; DISEASE
AB The genetic diagnosis algorithm for mitochondrial (mt) diseases starts looking for deletions and common mutations in mtDNA. MtDNA's special features, such as large and variable genome copies, heteroplasmy, polymorphisms, and its duplication in the nuclear genome as pseudogenes (NUMTs), make it vulnerable to diagnostic misleading interpretations. Multiplex Ligation-dependent Probe Amplification (MLPA) is used to detect copy number variations in nuclear genes and its application on mtDNA has not been widely spread. We report three Kearns Sayre Syndrome patients and one Chronic Progressive External Ophthalmoplegia adult, whose diagnostic mtDNA deletions were detected by MLPA using a very low amount of DNA. This managed to "dilute'' the NUMT interference as well as enhance MLPA's efficiency. By this report, we conclude that when MLPA is performed upon a reduced amount of DNA, it can detect effectively mtDNA deletions. We propose MLPA as a possible first step method in the diagnosis of mt diseases.
C1 [Mayorga, Lia; Laurito, Sergio R.; Roque, Maria] IHEM CCT CONICET, Mendoza, Argentina.
   [Mayorga, Lia; Laurito, Sergio R.; Roque, Maria] Natl Univ Cuyo, Mendoza, Argentina.
   [Loos, Mariana A.; Eiroa, Hernan D.; de Pinho, Silvina; Lubieniecki, Fabiana; Arroyo, Hugo A.] Garrahan Childrens Hosp, Buenos Aires, DF, Argentina.
   [Pereyra, Marcela F.] Notti Childrens Hosp, Mendoza, Argentina.
   [Kauffman, Marcelo A.] JM Ramos Meji Gen Hosp, Buenos Aires, DF, Argentina.
C3 Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET);
   University Nacional Cuyo Mendoza; Hospital de Pediatria Doctor Juan
   Garrahan; Hospital Ramos Mejia
RP Mayorga, L (corresponding author), IHEM CCT CONICET, Mendoza, Argentina.; Mayorga, L (corresponding author), Natl Univ Cuyo, Mendoza, Argentina.
EM liamayorga@fcm.uncu.edu.ar
OI Kauffman, Marcelo/0000-0003-1680-5092
CR Chi CS, 2015, PEDIATR NEONATOL, V56, P7, DOI 10.1016/j.pedneo.2014.03.009
   Cui H, 2013, GENET MED, V15, P388, DOI 10.1038/gim.2012.144
   Haas RH, 2008, MOL GENET METAB, V94, P16, DOI 10.1016/j.ymgme.2007.11.018
   Kwon MJ, 2011, ANN CLIN LAB SCI, V41, P385
   Malik AN, 2011, BIOCHEM BIOPH RES CO, V412, P1, DOI 10.1016/j.bbrc.2011.06.067
   Pagliarini DJ, 2008, CELL, V134, P112, DOI 10.1016/j.cell.2008.06.016
   Schouten JP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf056
   Tonska K, 2012, GENE, V506, P161, DOI 10.1016/j.gene.2012.06.081
   ZEVIANI M, 1990, ANN NEUROL, V28, P94, DOI 10.1002/ana.410280118
NR 9
TC 7
Z9 8
U1 0
U2 4
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 2470-1394
EI 2470-1408
J9 MITOCHONDRIAL DNA A
JI Mitochondrial DNA Part A
PY 2016
VL 27
IS 4
BP 2864
EP 2867
DI 10.3109/19401736.2015.1053132
PG 4
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA DO7IQ
UT WOS:000377956300212
PM 26114318
OA Green Published
DA 2024-11-01
ER

PT J
AU Miyaue, N
   Yamanishi, Y
   Tada, S
   Ando, R
   Nagai, M
   Nomoto, M
AF Miyaue, Noriyuki
   Yamanishi, Yuki
   Tada, Satoshi
   Ando, Rina
   Nagai, Masahiro
   Nomoto, Masahiro
TI Falling After Starting Running in a Case of Myoclonus Epilepsy
   Associated with Ragged-red Fibers with a 8344A&gt;G mtDNA Mutation
SO INTERNAL MEDICINE
LA English
DT Article
DE MERRF; mitochondrial myopathy; paroxysmal exercise-induced dyskinesia;
   paroxysmal kinesigenic dyskinesia
ID MITOCHONDRIAL-DNA MUTATIONS; DISEASE; HETEROGENEITY; PREVALENCE
AB Myoclonus epilepsy associated with ragged-red fibers (MERRF) is traditionally characterized by myoclonus, generalized epilepsy and ragged-red fibers. We herein report a 42-year-old man who complained of falling after starting running, symptoms resembling those of paroxysmal kinesigenic dyskinesia. He showed only slight muscle weakness of the right quadriceps femoris. Muscle pathology and a genetic analysis identified him as having MERRF with a 8344A>G mtDNA mutation. We diagnosed his symptoms as having been caused by slight quadriceps femoris muscle weakness and exercise intolerance. This case suggests that mitochondrial myopathy should be considered in cases with strong muscle symptoms for muscle weakness.
C1 [Miyaue, Noriyuki; Yamanishi, Yuki; Tada, Satoshi; Ando, Rina; Nagai, Masahiro; Nomoto, Masahiro] Ehime Univ, Grad Sch Med, Dept Neurol & Clin Pharmacol, Matsuyama, Ehime, Japan.
C3 Ehime University
RP Miyaue, N (corresponding author), Ehime Univ, Grad Sch Med, Dept Neurol & Clin Pharmacol, Matsuyama, Ehime, Japan.
EM miyaue.noriyuki.ec@ehime-u.ac.jp
CR Altmann J, 2016, J NEUROL, V263, P961, DOI 10.1007/s00415-016-8086-3
   Arnold CM, 2012, PHYSIOTHER CAN, V64, P302, DOI 10.3138/ptc.2011-12BH
   Bhatia KP, 2011, MOVEMENT DISORD, V26, P1157, DOI 10.1002/mds.23765
   Bruno MK, 2004, NEUROLOGY, V63, P2280, DOI 10.1212/01.WNL.0000147298.05983.50
   Burgstaller JP, 2015, MOL HUM REPROD, V21, P11, DOI 10.1093/molehr/gau090
   Erro R, 2014, MOVEMENT DISORD, V29, P1108, DOI 10.1002/mds.25933
   Finsterer J, 2002, CAN J NEUROL SCI, V29, P49, DOI 10.1017/S0317167100001712
   Friedman J, 2017, NEUROLOGY, V89, P2297, DOI 10.1212/WNL.0000000000004689
   FUKUHARA N, 1980, J NEUROL SCI, V47, P117, DOI 10.1016/0022-510X(80)90031-3
   Gámez J, 1998, NEUROLOGY, V51, P258, DOI 10.1212/WNL.51.1.258
   Gardiner AR, 2015, BRAIN, V138, P3567, DOI 10.1093/brain/awv310
   Gorman GS, 2015, ANN NEUROL, V77, P753, DOI 10.1002/ana.24362
   Han JY, 2014, J CLIN NEUROSCI, V21, P2009, DOI 10.1016/j.jocn.2014.03.020
   Lorenzoni PJ, 2014, ARQ NEURO-PSIQUIAT, V72, P803, DOI 10.1590/0004-282X20140124
   Mancuso M, 2012, NEUROMUSCULAR DISORD, V22, pS226, DOI 10.1016/j.nmd.2012.10.012
   Mancuso M, 2013, NEUROLOGY, V80, P2049, DOI 10.1212/WNL.0b013e318294b44c
   Méneret A, 2016, REV NEUROL-FRANCE, V172, P433, DOI 10.1016/j.neurol.2016.07.005
   Schaefer AM, 2008, ANN NEUROL, V63, P35, DOI 10.1002/ana.21217
   Sharma NK, 2002, J NEUROL NEUROSUR PS, V73, P95, DOI 10.1136/jnnp.73.1.95
   SHOFFNER JM, 1992, AM J HUM GENET, V51, P1179
   Tuppen HAL, 2010, BBA-BIOENERGETICS, V1797, P113, DOI 10.1016/j.bbabio.2009.09.005
   van Rootselaar Anne-Fleur, 2009, Pract Neurol, V9, P102, DOI 10.1136/jnnp.2009.172213
NR 22
TC 5
Z9 5
U1 0
U2 1
PU JAPAN SOC INTERNAL MEDICINE
PI TOKYO
PA 34-3 3-CHOME HONGO BUNKYO-KU, TOKYO, 113, JAPAN
SN 0918-2918
EI 1349-7235
J9 INTERNAL MED
JI Intern. Med.
PY 2018
VL 57
IS 23
BP 3439
EP 3443
DI 10.2169/internalmedicine.1210-18
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA HD2QE
UT WOS:000452354400018
PM 29984755
OA Green Published, gold, Green Submitted
DA 2024-11-01
ER

PT J
AU Lindholm, H
   Löfberg, M
   Somer, H
   Näveri, H
   Sovijärvi, A
AF Lindholm, H
   Löfberg, M
   Somer, H
   Näveri, H
   Sovijärvi, A
TI Abnormal blood lactate accumulation after exercise in patients with
   multiple mitochondrial DNA deletions and minor muscular symptoms
SO CLINICAL PHYSIOLOGY AND FUNCTIONAL IMAGING
LA English
DT Article
DE cardiopulmonary exercise test; lactate metabolism; mitochondrial
   myopathy; molecular genetics
ID MAGNETIC-RESONANCE SPECTROSCOPY; MCARDLES-DISEASE; SKELETAL-MUSCLE; WORK
   CAPACITY; MYOPATHIES; RESPONSES; DISORDERS; FEATURES
AB Study objectives: Muscle is one of the most commonly affected organs in mitochondrial disorders, and the symptoms are often exercise related. The cardiopulmonary exercise test with the determination of lactic acid formation could give supplementary information about the exercise-induced metabolic stress and compensatory mechanisms used in these disorders. The aim of this study was to evaluate the exercise capacity and lactate kinetics related to exercise in subjects with two genetically characterized mitochondrial disorders (multiple mitochondrial DNA deletions with PEO, MELAS) compared with lactate kinetics in subjects with metabolic myopathy (McArdle's disease) and in the healthy controls.
   Design: The subjects were consecutive, co-operative patients of Department of Neurology of Helsinki University Hospital. Molecular genetic analyses were used for group classification of the mitochondrial myopathy.
   Study subjects: The study groups consisted of 11 patients with multiple deletions (PEO) and five patients with a point mutation in the mitochondrial DNA (MELAS), four patients with a muscle phosphorylase enzyme deficiency (McArdle's disease) and 13 healthy controls. The clinical disease of the patients was relatively mild.
   Measurements and results: A graded exercise test with ventilatory gas analyses and venous blood lactic acid analyses was performed. The main finding was the prolonged accumulation of blood lactate after the exercise in the PEO and MELAS groups compared with the controls. An overcompensation in ventilation was found in the MELAS and PEO group.
   Conclusions: The blood lactate accumulation after exercise occurs in patients with multiple mitochondrial DNA deletions or MELAS even in patients with only mild exercise intolerance. Cardiopulmonary exercise can be used in the diagnostic process of patients with mitochondrial myopathies.
C1 Univ Helsinki Hosp, Div Clin Physiol, Dept Lab, Helsinki, Finland.
   Univ Helsinki Hosp, Dept Neurol, Helsinki, Finland.
   Univ Helsinki Hosp, Dept Med, Helsinki, Finland.
C3 University of Helsinki; Helsinki University Central Hospital; University
   of Helsinki; Helsinki University Central Hospital; University of
   Helsinki; Helsinki University Central Hospital
RP Finnish Inst Occupat Hlth, Dept Physiol, Topeliuksenkatu 41 A, Helsinki 00250, Finland.
EM harri.lindholm@ttl.fi
CR Argov Z, 1998, EUR NEUROL, V39, P65, DOI 10.1159/000007912
   ARGOV Z, 1987, NEUROLOGY, V37, P257, DOI 10.1212/WNL.37.2.257
   ARNOLD DL, 1985, ANN NEUROL, V18, P189, DOI 10.1002/ana.410180205
   BENDAHAN D, 1992, NEUROLOGY, V42, P1203, DOI 10.1212/WNL.42.6.1203
   CIAFALONI E, 1992, ANN NEUROL, V31, P391, DOI 10.1002/ana.410310408
   DEVIVO DC, 1993, BRAIN DEV-JPN, V15, P1, DOI 10.1016/0387-7604(93)90002-P
   ELLIOT DL, 1989, MEDICINE, V68, P163, DOI 10.1097/00005792-198905000-00004
   Flaherty KR, 2001, AM J RESP CRIT CARE, V164, P425, DOI 10.1164/ajrccm.164.3.2005110
   Griggs RC, 1999, NEW ENGL J MED, V341, P1077, DOI 10.1056/NEJM199909303411411
   Haller RG, 1998, NEUROLOGY, V50, P37, DOI 10.1212/WNL.50.1.37
   HARKONEN M, 1982, ANN CLIN RES, V14, P20
   JEHENSON P, 1995, EUR J NUCL MED, V22, P1256, DOI 10.1007/BF00801609
   Leonard JV, 2000, LANCET, V355, P299, DOI 10.1016/S0140-6736(99)05225-3
   Löfberg M, 2001, NEUROMUSCULAR DISORD, V11, P370, DOI 10.1016/S0960-8966(00)00205-4
   Lofberg M, 1998, ACTA NEUROL SCAND, V98, P268, DOI 10.1111/j.1600-0404.1998.tb07307.x
   LOWRY OH, 1964, J BIOL CHEM, V239, P18
   MCARDLE B, 1951, CLIN SCI, V10, P12
   NASHEF L, 1989, J NEUROL NEUROSUR PS, V52, P1090, DOI 10.1136/jnnp.52.9.1090
   NORDESJO LO, 1975, SCAND J CLIN LAB INV, V35, P64
   PORTE D, 1966, NEW ENGL J MED, V275, P406, DOI 10.1056/NEJM196608252750802
   SELIGER V, 1978, EUR J APPL PHYSIOL, V39, P155, DOI 10.1007/BF00421342
   Siciliano G, 2000, NEUROMUSCULAR DISORD, V10, P40, DOI 10.1016/S0960-8966(99)00068-1
   SUE DY, 1991, CHEST, V99, P981, DOI 10.1378/chest.99.4.981
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   Taivassalo T, 1998, NEUROLOGY, V50, P1055, DOI 10.1212/WNL.50.4.1055
   TAYLOR DJ, 1994, J NEUROL SCI, V127, P198, DOI 10.1016/0022-510X(94)90073-6
   WASSERMAN K, 1975, AM REV RESPIR DIS, V112, P219
NR 27
TC 16
Z9 16
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1475-0961
EI 1475-097X
J9 CLIN PHYSIOL FUNCT I
JI Clin. Physiol. Funct. Imaging
PD MAR
PY 2004
VL 24
IS 2
BP 109
EP 115
DI 10.1111/j.1475-097X.2004.00531.x
PG 7
WC Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology
GA 805QN
UT WOS:000220380900007
PM 15056184
DA 2024-11-01
ER

PT J
AU Rivera, H
   Blázquez, A
   Carretero, J
   Alvarez-Cermeño, JC
   Campos, Y
   Cabello, A
   Gonzalez-Vioque, E
   Borstein, B
   Garesse, R
   Arenas, J
   Martín, MA
AF Rivera, Henry
   Blazquez, Alberto
   Carretero, Julian
   Alvarez-Cermeno, Jose C.
   Campos, Y.
   Cabello, Ana
   Gonzalez-Vioque, Emiliano
   Borstein, Belen
   Garesse, Rafael
   Arenas, Joaquin
   Martin, Miguel A.
TI Mild ocular myopathy associated with a novel mutation in mitochondrial
   twinkle helicase
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE PEO1; twinkle; adPEO; mitochondrial disorders; mtDNA multiple deletions
ID EXTERNAL OPHTHALMOPLEGIA; DNA DELETIONS; POLG; ANT1
AB Autosomal dominant PEO is associated with mutations in a number of nuclear genes affecting the intergenomic communication with mitochondrial DNA. We report a Spanish family showing a mild phenotype characterized by autosomal dominant ocular myopathy and morphological signs of mitochondrial dysfunction, that harboured a novel c.1071G > C (p.R357P) mutation in the hot-spot linker region of the twinkle protein. (C) 2007 Published by Elsevier B.V.
C1 [Rivera, Henry; Blazquez, Alberto; Carretero, Julian; Campos, Y.; Arenas, Joaquin; Martin, Miguel A.] Hosp Univ 12 Octubre, Ctr Invest, Madrid, Spain.
   [Alvarez-Cermeno, Jose C.] Hosp Ramon & Cajal, Serv Neurol, Madrid, Spain.
   [Cabello, Ana] Hosp Univ 12 Octubre, Serv Neurol, Madrid, Spain.
   [Rivera, Henry; Blazquez, Alberto; Campos, Y.; Cabello, Ana; Gonzalez-Vioque, Emiliano; Borstein, Belen; Garesse, Rafael; Arenas, Joaquin; Martin, Miguel A.] Ctr Biomed Res Rare Disorders, Madrid, Spain.
   [Gonzalez-Vioque, Emiliano; Borstein, Belen; Garesse, Rafael] Univ Autonoma Madrid, Biomed Res Ctr Rare Disorder, Fac Med, Inst Invest Biomed Albert Sols,CSIC,UAM, E-28049 Madrid, Spain.
C3 Hospital Universitario 12 de Octubre; Hospital Universitario Ramon y
   Cajal; Hospital Universitario 12 de Octubre; CIBER - Centro de
   Investigacion Biomedica en Red; CIBERER; CIBER - Centro de Investigacion
   Biomedica en Red; CIBERER; Autonomous University of Madrid; Consejo
   Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de
   Investigaciones Biomedicas Alberto Sols (IIBM)
RP Martín, MA (corresponding author), Hosp Univ 12 Octubre, Ctr Invest, Av Cordoba S-N, Madrid, Spain.
EM mamcasanueva@h12o.es
RI Martin, Miguel/S-2758-2018; Alvarez-Cermeño, José/E-6432-2013; Yolanda,
   Campos/A-8711-2017; Garesse, Rafael/F-3836-2012; Martin, Miguel
   Angel/B-6261-2017; Blazquez Encinar, Alberto/S-4425-2018
OI CAMPOS, YOLANDA/0000-0003-4785-9659; Arenas,
   Joaquin/0000-0002-2877-5049; Gonzalez Vioque,
   Emiliano/0000-0001-7279-4311; Martin, Miguel Angel/0000-0003-4741-772X;
   Garesse, Rafael/0000-0002-0338-2281; Blazquez Encinar,
   Alberto/0000-0002-6479-3615
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Brierley EJ, 1998, ANN NEUROL, V43, P217, DOI 10.1002/ana.410430212
   Deschauer M, 2003, NEUROMUSCULAR DISORD, V13, P568, DOI 10.1016/S0960-8966(03)00071-3
   DiMauro S., 1997, MOL GENETIC BASIS NE, P201
   González-Vioque E, 2006, ARCH NEUROL-CHICAGO, V63, P107, DOI 10.1001/archneur.63.1.107
   Hirano M, 2001, NEUROLOGY, V57, P2163, DOI 10.1212/WNL.57.12.2163
   Hudson G, 2005, NEUROLOGY, V64, P371, DOI 10.1212/01.WNL.0000149767.51152.83
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 10
TC 13
Z9 14
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD OCT
PY 2007
VL 17
IS 9-10
BP 677
EP 680
DI 10.1016/j.nmd.2007.05.006
PG 4
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 221WL
UT WOS:000250258000004
PM 17614277
DA 2024-11-01
ER

PT J
AU Yamashita, S
   Nishino, I
   Nonaka, I
   Goto, YI
AF Yamashita, Shintaro
   Nishino, Ichizo
   Nonaka, Ikuya
   Goto, Yu-ichi
TI Genotype and phenotype analyses in 136 patients with single large-scale
   mitochondrial DNA deletions
SO JOURNAL OF HUMAN GENETICS
LA English
DT Article
DE mitochondrial DNA; deletion; CPEO; KSS; direct repeat
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; MULTIPLE DELETIONS; MTDNA; MUSCLE;
   INVOLVEMENT; MUTATIONS; GENETICS; LACKING
AB We examined 136 patients with mitochondrial DNA (mtDNA) deletion. Clinical diagnoses included chronic progressive external ophthalmoplegia (94 patients); Kearns-Sayre syndrome (KSS; 33 patients); Pearson's marrow-pancreas syndrome (six patients); and Leigh syndrome, Reye-like syndrome, and mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (one patient). The length and location of deletion were highly variable. Only one patient had deletion within the so-called shorter arc between the two origins of mtDNA replication. The length of deletion and the number of deleted transfer ribonucleic acid (tRNAs) showed a significant relationship with age at onset. Furthermore, KSS patients had longer and larger numbers of deleted tRNAs, which could be risk factors for the systemic involvement of single mtDNA deletion diseases. We found 81 patterns of deletion. Direct repeats of 4 bp or longer flanking the breakpoints were found in 96 patients (70.5%) and those of 10 bp or longer in 49 patients (36.0%). We found two other common deletions besides the most common deletion (34 patients: 25.0%): the 2,310-bp deletion from nt 12113 to nt 14421 (11 patients: 8.0%) and the 7,664-bp deletion from nt 6330 to nt 13993 (ten patients: 7.3%). These deletions had incomplete direct repeats longer than 13 bp with one base mismatch.
C1 [Yamashita, Shintaro; Goto, Yu-ichi] Natl Ctr Neurol & Psychiat, Dept Mental Retardat & Birth Defect Res, Natl Inst Neurosci, Kodaira, Tokyo 1878502, Japan.
   [Nishino, Ichizo; Nonaka, Ikuya] Natl Ctr Neurol & Psychiat, Dept Neuromuscular Res, Natl Inst Neurosci, Kodaira, Tokyo 1878502, Japan.
   [Yamashita, Shintaro] Juntendo Univ, Sch Med, Dept Pediat & Adolescent Med, Bunkyo Ku, Tokyo 113, Japan.
C3 National Center for Neurology & Psychiatry - Japan; National Center for
   Neurology & Psychiatry - Japan; Juntendo University
RP Goto, YI (corresponding author), Natl Ctr Neurol & Psychiat, Dept Mental Retardat & Birth Defect Res, Natl Inst Neurosci, 4-1-1 Ogawahigashi, Kodaira, Tokyo 1878502, Japan.
EM goto@ncnp.go.jp
RI Nishino, Ichizo/G-2676-2010
OI Nishino, Ichizo/0000-0001-9452-112X
CR Akman CI, 2004, J CHILD NEUROL, V19, P258, DOI 10.1177/088307380401900403
   Auré K, 2007, BRAIN, V130, P1516, DOI 10.1093/brain/awm067
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Campos Y, 2000, NEUROMUSCULAR DISORD, V10, P56, DOI 10.1016/S0960-8966(99)00072-3
   DEUGOL F, 1991, NUCLEIC ACIDS RES, V19, P403
   GOTO Y, 1990, J NEUROL SCI, V100, P63, DOI 10.1016/0022-510X(90)90014-E
   GOTO Y, 1990, J PEDIATR-US, V116, P904, DOI 10.1016/S0022-3476(05)80648-1
   Goto YI, 1996, BIOCHEM BIOPH RES CO, V222, P215, DOI 10.1006/bbrc.1996.0724
   HAMMANS SR, 1992, BRAIN, V115, P343, DOI 10.1093/brain/115.2.343
   HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Horton TM, 1996, GENE CHROMOSOME CANC, V15, P95, DOI 10.1002/(SICI)1098-2264(199602)15:2<95::AID-GCC3>3.0.CO;2-Z
   JOHNS DR, 1991, BIOCHEM BIOPH RES CO, V174, P244, DOI 10.1016/0006-291X(91)90512-6
   KATAYAMA M, 1991, BIOCHEM INT, V25, P47
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778
   LARSSON NG, 1990, PEDIATR RES, V28, P131, DOI 10.1203/00006450-199028020-00011
   Marzuki S, 1997, J NEUROL SCI, V145, P155, DOI 10.1016/S0022-510X(96)00241-9
   MCSHANE MA, 1991, AM J HUM GENET, V48, P39
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   MITA S, 1990, NUCLEIC ACIDS RES, V18, P561, DOI 10.1093/nar/18.3.561
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   MORAES CT, 1991, MOL CELL BIOL, V11, P1631, DOI 10.1128/MCB.11.3.1631
   MORI K, 1991, AM J MED GENET, V38, P583, DOI 10.1002/ajmg.1320380417
   NAKAI A, 1994, LANCET, V343, P1397, DOI 10.1016/S0140-6736(94)92527-5
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   OZAWA T, 1988, BIOCHEM BIOPH RES CO, V154, P1240, DOI 10.1016/0006-291X(88)90272-0
   POULTON J, 1989, LANCET, V1, P236
   ROTIG A, 1989, LANCET, V1, P902
   ROWLAND LP, 1983, NEUROLOGY, V33, P1179, DOI 10.1212/WNL.33.9.1179
   Schapira AHV, 2006, LANCET, V368, P70, DOI 10.1016/S0140-6736(06)68970-8
   SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184
   SERVIDEI S, 1991, NEUROLOGY, V41, P1053, DOI 10.1212/WNL.41.7.1053
   SHOFFNER JM, 1989, P NATL ACAD SCI USA, V86, P7952, DOI 10.1073/pnas.86.20.7952
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Vu TH, 2000, MUSCLE NERVE, V23, P80, DOI 10.1002/(SICI)1097-4598(200001)23:1<80::AID-MUS10>3.0.CO;2-V
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 39
TC 64
Z9 68
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1434-5161
EI 1435-232X
J9 J HUM GENET
JI J. Hum. Genet.
PD JUL
PY 2008
VL 53
IS 7
BP 598
EP 606
DI 10.1007/s10038-008-0289-8
PG 9
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 320BH
UT WOS:000257208200003
PM 18414780
OA Bronze
DA 2024-11-01
ER

PT J
AU Kollberg, G
   Moslemi, AR
   Lindberg, C
   Holme, E
   Oldfors, A
AF Kollberg, G
   Moslemi, AR
   Lindberg, C
   Holme, E
   Oldfors, A
TI Mitochondrial myopathy and rhabdomyolysis associated with a novel
   nonsense mutation in the gene encoding cytochrome <i>c</i> oxidase
   subunit I
SO JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
LA English
DT Article
DE COX; mtDNA; mitochondrial myopathy; mutation; rhabdomyolysis
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; RECURRENT MYOGLOBINURIA; DNA
   DELETIONS; EXERCISE INTOLERANCE; MYOGENIC PROGENITORS; METABOLIC CAUSES;
   SKELETAL-MUSCLE; B GENE; PATIENT; MICRODELETION
AB Mitochondrial DNA (mtDNA) mutations associated with rhabdomyolysis are rare but have been described in sporadic cases with mutations in the cytochrome b and cytochrome c oxidase (COX) genes and in 3 cases with tRNA(Leu) mutation. We report a novel heteroplasmic G6708A nonsense mutation in the mtDNA COI gene encoding COX subunit I in a 30-year-old woman with muscle weakness, pain, fatigue, and one episode of rhabdomyolysis. Histochemical examination of muscle biopsy specimens revealed reduced COX activity in the majority of the muscle fibers (similar to90%) and frequent ragged red fibers. Biochemical analysis showed a marked and isolated COX deficiency. Analysis of DNA extracted from single fibers revealed higher levels of the mutation in COX-deficient fibers (> 95%) compared with COX-positive fibers (1%-80%). The mutation was not detected in a skin biopsy, cultured myoblasts, or blood leukocytes. Nor was it identified in blood leukocytes from the asymptomatic mother, indicating a de novo mutation that arose after germ layer differentiation. Western blot analysis and immunohistochemical staining revealed that reduced levels of COX subunit I were accompanied by reduced levels of other mtDNA encoded subunits, as well as nuclear DNA encoded subunit IV, supporting the concept that COX subunit I is essential for the assembly of complex IV in the respiratory chain.
C1 Sahlgrens Univ Hosp, Dept Pathol, SE-41345 Gothenburg, Sweden.
   Sahlgrens Univ Hosp, Dept Neurol, SE-41345 Gothenburg, Sweden.
   Sahlgrens Univ Hosp, Dept Clin Chem, SE-41345 Gothenburg, Sweden.
C3 Sahlgrenska University Hospital; Sahlgrenska University Hospital;
   Sahlgrenska University Hospital
RP Sahlgrens Univ Hosp, Dept Pathol, SE-41345 Gothenburg, Sweden.
EM ali-reza.moslemi@pathology.gu.se
CR Andreu AL, 1999, ANN NEUROL, V45, P127, DOI 10.1002/1531-8249(199901)45:1<127::AID-ART20>3.0.CO;2-Y
   Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Asakura A, 2002, J CELL BIOL, V159, P123, DOI 10.1083/jcb.200202092
   Bischoff R., 1994, SATELLITE CELL MUSCL, P97
   Bonavaud S, 1997, BIOL CELL, V89, P233, DOI 10.1016/S0248-4900(97)80039-1
   Bruno C, 1999, AM J HUM GENET, V65, P611, DOI 10.1086/302546
   CAPALDI RA, 1990, ANNU REV BIOCHEM, V59, P569, DOI 10.1146/annurev.bi.59.070190.003033
   Clark KM, 1997, NAT GENET, V16, P222, DOI 10.1038/ng0797-222
   Comi GP, 1998, ANN NEUROL, V43, P110, DOI 10.1002/ana.410430119
   De Angelis L, 1999, J CELL BIOL, V147, P869, DOI 10.1083/jcb.147.4.869
   Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528
   Gattermann N, 1997, BLOOD, V90, P4961, DOI 10.1182/blood.V90.12.4961.4961_4961_4972
   HARA H, 1994, J NEUROL NEUROSUR PS, V57, P1545, DOI 10.1136/jnnp.57.12.1545-a
   Karadimas CL, 2000, NEUROLOGY, V55, P644, DOI 10.1212/WNL.55.5.644
   Keightley JA, 1996, NAT GENET, V12, P410, DOI 10.1038/ng0496-410
   Kwon JH, 2003, EUR NEUROL, V50, P123, DOI 10.1159/000072517
   Lofberg M, 1998, ACTA NEUROL SCAND, V98, P268, DOI 10.1111/j.1600-0404.1998.tb07307.x
   McFarland R, 2004, NEUROMUSCULAR DISORD, V14, P162, DOI 10.1016/j.nmd.2003.10.011
   Melberg A, 1998, NEUROLOGY, V50, P299, DOI 10.1212/WNL.50.1.299
   Moslemi AR, 1998, NEUROMUSCULAR DISORD, V8, P345, DOI 10.1016/S0960-8966(98)00029-7
   Moslemi AR, 1999, NEUROLOGY, V53, P79, DOI 10.1212/WNL.53.1.79
   Nijtmans LGJ, 1998, EUR J BIOCHEM, V254, P389, DOI 10.1046/j.1432-1327.1998.2540389.x
   OHNO K, 1991, ANN NEUROL, V29, P364, DOI 10.1002/ana.410290406
   OLDFORS A, 1995, J NEUROPATH EXP NEUR, V54, P581, DOI 10.1097/00005072-199507000-00012
   Taivassalo T, 1999, HUM MOL GENET, V8, P1047, DOI 10.1093/hmg/8.6.1047
   TONIN P, 1990, ANN NEUROL, V27, P181, DOI 10.1002/ana.410270214
   Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136
   TULINIUS MH, 1991, J PEDIATR-US, V119, P242, DOI 10.1016/S0022-3476(05)80734-6
   Varlamov DA, 2002, HUM MOL GENET, V11, P1797, DOI 10.1093/hmg/11.16.1797
   Warren JD, 2002, MUSCLE NERVE, V25, P332, DOI 10.1002/mus.10053
NR 31
TC 35
Z9 37
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-3069
EI 1554-6578
J9 J NEUROPATH EXP NEUR
JI J. Neuropathol. Exp. Neurol.
PD FEB
PY 2005
VL 64
IS 2
BP 123
EP 128
DI 10.1093/jnen/64.2.123
PG 6
WC Clinical Neurology; Neurosciences; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pathology
GA 898WK
UT WOS:000227106700004
PM 15751226
OA Bronze
DA 2024-11-01
ER

PT J
AU Filosto, M
   Piccinelli, SC
   Lamperti, C
   Mongini, T
   Servidei, S
   Musumeci, O
   Tonin, P
   Santorelli, FM
   Simoncini, C
   Primiano, G
   Vercelli, L
   Rubegni, A
   Galvagni, A
   Moggio, M
   Comi, GP
   Carelli, V
   Toscano, A
   Padovani, A
   Siciliano, G
   Mancuso, M
AF Filosto, Massimiliano
   Piccinelli, Stefano Cotti
   Lamperti, Costanza
   Mongini, Tiziana
   Servidei, Serenella
   Musumeci, Olimpia
   Tonin, Paola
   Santorelli, Filippo Maria
   Simoncini, Costanza
   Primiano, Guido
   Vercelli, Liliana
   Rubegni, Anna
   Galvagni, Anna
   Moggio, Maurizio
   Comi, Giacomo Pietro
   Carelli, Valerio
   Toscano, Antonio
   Padovani, Alessandro
   Siciliano, Gabriele
   Mancuso, Michelangelo
TI Muscle pain in mitochondrial diseases: a picture from the Italian
   network
SO JOURNAL OF NEUROLOGY
LA English
DT Article
DE Mitochondrial diseases; Muscle pain; Myalgia; cPEO; Mitochondrial
   myopathy
ID EXERCISE INTOLERANCE; MUTATIONS; COHORT
AB Muscle pain may be part of many neuromuscular disorders including myopathies, peripheral neuropathies and lower motor neuron diseases. Although it has been reported also in mitochondrial diseases (MD), no extensive studies in this group of diseases have been performed so far. We reviewed clinical data from 1398 patients affected with mitochondrial diseases listed in the database of the Nation-wide Italian Collaborative Network of Mitochondrial Diseases, to assess muscle pain and its features. Muscle pain was present in 164 patients (11.7%). It was commonly observed in subjects with chronic progressive external ophthalmoplegia (cPEO) and with primary myopathy without cPEO, but alsoalthough less frequentlyin multisystem phenotypes such as MELAS, MERFF, Kearns Sayre syndrome, NARP, MNGIE and Leigh syndrome. Patients mainly complain of diffuse exercise-related muscle pain, but focal/multifocal and at rest myalgia were often also reported. Muscle pain was more commonly detected in patients with mitochondrial DNA mutations (67.8%) than with nuclear DNA changes (32.2%). Only 34% of the patients showed a good response to drug therapy. Interestingly, patients with nuclear DNA mutations tend to have a better therapeutic response than patients with mtDNA mutations. Muscle pain is present in a significant number of patients with MD, being one of the most common symptoms. Although patients with a myopathic phenotype are more prone to develop muscle pain, this is also observed in patients with a multi system involvement, representing an important and disabling symptom having poor response to current therapy.
C1 [Filosto, Massimiliano; Piccinelli, Stefano Cotti; Galvagni, Anna; Padovani, Alessandro] ASST Spedali Civili, Neurol Unit, Ctr Neuromuscular Dis, Brescia, Italy.
   [Filosto, Massimiliano; Piccinelli, Stefano Cotti; Galvagni, Anna; Padovani, Alessandro] Univ Brescia, Brescia, Italy.
   [Lamperti, Costanza] Fdn IRCCS Ist Neurol Carlo Besta, Unit Med Genet & Neurogenet, Milan, Italy.
   [Mongini, Tiziana; Vercelli, Liliana] Univ Torino, Dept Neurosci Rita Levi Montalcini, Turin, Italy.
   [Servidei, Serenella; Primiano, Guido] Univ Cattolica Sacro Cuore, Ist Neurol, Fdn Policlin Univ A Gemelli IRCCS, UOC Neurofisiopatol, Rome, Italy.
   [Musumeci, Olimpia; Toscano, Antonio] Univ Messina, Dept Clin & Expt Med, UOC Neurol & Malattie Neuromuscolari, Messina, Italy.
   [Tonin, Paola] Univ Verona, Neurol Clin, Verona, Italy.
   [Santorelli, Filippo Maria; Rubegni, Anna] IRCCS Fdn Stella Maris, Mol Med Unit, Pisa, Italy.
   [Simoncini, Costanza; Siciliano, Gabriele; Mancuso, Michelangelo] Univ Pisa, Neurol Clin, Pisa, Italy.
   [Moggio, Maurizio] Osped Maggiore Policlin, Fdn IRCCS Ca Granda, Dept Neurosci, Neuromuscular & Rare Dis Unit, Milan, Italy.
   [Comi, Giacomo Pietro] Univ Milan, IRCCS Fdn Ca Granda Osped Maggiore Policlin, Dept Pathophysiol & Transplantat, Neurol Unit,Neurosci Sect,Dino Ferrari Ctr, Milan, Italy.
   [Carelli, Valerio] Bellaria Hosp, IRCCS Inst Neurol Sci Bologna, Bologna, Italy.
C3 Hospital Spedali Civili Brescia; University of Brescia; Fondazione IRCCS
   Istituto Neurologico Carlo Besta; University of Turin; Catholic
   University of the Sacred Heart; IRCCS Policlinico Gemelli; University of
   Messina; University of Verona; IRCCS Fondazione Stella Maris; University
   of Pisa; IRCCS Ca Granda Ospedale Maggiore Policlinico; IRCCS Ca Granda
   Ospedale Maggiore Policlinico; University of Milan; IRCCS Istituto delle
   Scienze Neurologiche di Bologna (ISNB); AUSL di Bologna
RP Filosto, M (corresponding author), ASST Spedali Civili, Neurol Unit, Ctr Neuromuscular Dis, Brescia, Italy.; Filosto, M (corresponding author), Univ Brescia, Brescia, Italy.
EM massimiliano.filosto@unibs.it
RI Servidei, Serenella/ABC-4262-2021; Primiano, Guido/AAB-7829-2019;
   Toscano, Antonio/AHE-4657-2022; Comi, Giacomo/K-5702-2016; Filosto,
   Massimiliano/S-9446-2019; Simoncini, Costanza/AAB-9724-2019; Musumeci,
   Olimpia/AHE-3041-2022; Padovani, Alessandro/ABI-7312-2020; lamperti,
   costanza/J-8801-2016; Tonin, Paola/AAC-5052-2022; Santorelli, Filippo
   M/ABE-5124-2020; Rubegni, Anna/I-3221-2018
OI Filosto, Massimiliano/0000-0002-2852-7512; simoncini,
   costanza/0000-0002-6724-5964; SERVIDEI, Serenella/0000-0001-8478-2799;
   Santorelli, Filippo M/0000-0002-1359-9062; Primiano,
   Guido/0000-0001-7616-7008; Padovani, Alessandro/0000-0002-0119-3639;
   cotti piccinelli, stefano/0000-0002-2060-0279; Rubegni,
   Anna/0000-0002-0484-3799
FU Telethon [GUP09004, GSP16001]; patients' association MITOCON
FX This work was supported by Telethon (Grant numbers GUP09004 and
   GSP16001) and the patients' association MITOCON, which also provided the
   web-platform assistance.
CR Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   Apostolopoulou M, 2015, EUR J CLIN INVEST, V45, P745, DOI 10.1111/eci.12461
   Camerino GM, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00500
   Czell D., 2012, BMJ Case Rep
   Deschauer M, 1999, NEUROMUSCULAR DISORD, V9, P305, DOI 10.1016/S0960-8966(99)00019-X
   du Souich P, 2017, PHARMACOL THERAPEUT, V175, P1, DOI 10.1016/j.pharmthera.2017.02.029
   Filosto M, 2007, ACTA NEUROL SCAND, V115, P211, DOI 10.1111/j.1600-0404.2006.00777.x
   Filosto M, 2007, NEUROLOGY, V68, P181, DOI 10.1212/01.wnl.0000252252.29532.cc
   Gorman GS, 2016, NAT REV DIS PRIMERS, V2, P1, DOI 10.1038/nrdp.2016.80
   Gorman GS, 2015, ANN NEUROL, V77, P753, DOI 10.1002/ana.24362
   Grafakou O, 2003, J INHERIT METAB DIS, V26, P593, DOI 10.1023/A:1025960300710
   Jensen MP, 2005, ARCH PHYS MED REHAB, V86, P1155, DOI 10.1016/j.apmr.2004.11.028
   Lu YY, 2017, J NEUROL SCI, V379, P137, DOI 10.1016/j.jns.2017.05.056
   Mancuso M, 2016, NEUROMUSCULAR DISORD, V26, P272, DOI 10.1016/j.nmd.2016.02.008
   Mancuso M, 2014, MOVEMENT DISORD, V29, P722, DOI 10.1002/mds.25839
   Orsucci D, 2017, J NEUROL, V264, P1777, DOI 10.1007/s00415-017-8567-z
   Pulkes T, 2005, NEUROLOGY, V64, P1091, DOI 10.1212/01.WNL.0000154471.33156.55
   Schapira AHV, 2006, LANCET, V368, P70, DOI 10.1016/S0140-6736(06)68970-8
   van de Glind G, 2007, EUR J PAEDIATR NEURO, V11, P243, DOI 10.1016/j.ejpn.2007.01.004
NR 19
TC 8
Z9 8
U1 0
U2 5
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-5354
EI 1432-1459
J9 J NEUROL
JI J. Neurol.
PD APR
PY 2019
VL 266
IS 4
BP 953
EP 959
DI 10.1007/s00415-019-09219-x
PG 7
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA HS6GQ
UT WOS:000463969200017
PM 30710167
DA 2024-11-01
ER

PT J
AU Carelli, V
   Musumeci, O
   Caporali, L
   Zanna, C
   La Morgia, C
   Del Dotto, V
   Porcelli, AM
   Rugolo, M
   Valentino, ML
   Iommarini, L
   Maresca, A
   Barboni, P
   Carbonelli, M
   Trombetta, C
   Valente, EM
   Patergnani, S
   Giorgi, C
   Pinton, P
   Rizzo, G
   Tonon, C
   Lodi, R
   Avoni, P
   Liguori, R
   Baruzzi, A
   Toscano, A
   Zeviani, M
AF Carelli, Valerio
   Musumeci, Olimpia
   Caporali, Leonardo
   Zanna, Claudia
   La Morgia, Chiara
   Del Dotto, Valentina
   Porcelli, Anna Maria
   Rugolo, Michela
   Valentino, Maria Lucia
   Iommarini, Luisa
   Maresca, Alessandra
   Barboni, Piero
   Carbonelli, Michele
   Trombetta, Costantino
   Valente, Enza Maria
   Patergnani, Simone
   Giorgi, Carlotta
   Pinton, Paolo
   Rizzo, Giovanni
   Tonon, Caterina
   Lodi, Raffaele
   Avoni, Patrizia
   Liguori, Rocco
   Baruzzi, Agostino
   Toscano, Antonio
   Zeviani, Massimo
TI Syndromic parkinsonism and dementia associated with <i>OPA1</i> missense
   mutations
SO ANNALS OF NEUROLOGY
LA English
DT Article
ID DOMINANT OPTIC ATROPHY; MITOCHONDRIAL-DNA DELETIONS; MULTIPLE DELETIONS;
   EXTERNAL OPHTHALMOPLEGIA; GENE; INSTABILITY; PREVALENCE; DISORDERS;
   VARIANTS; PATIENT
AB ObjectiveMounting evidence links neurodegenerative disorders such as Parkinson disease and Alzheimer disease with mitochondrial dysfunction, and recent emphasis has focused on mitochondrial dynamics and quality control. Mitochondrial dynamics and mtDNA maintenance is another link recently emerged, implicating mutations in the mitochondrial fusion genes OPA1 and MFN2 in the pathogenesis of multisystem syndromes characterized by neurodegeneration and accumulation of mtDNA multiple deletions in postmitotic tissues. Here, we report 2 Italian families affected by dominant chronic progressive external ophthalmoplegia (CPEO) complicated by parkinsonism and dementia.
   MethodsPatients were extensively studied by optical coherence tomography (OCT) to assess retinal nerve fibers, and underwent muscle and brain magnetic resonance spectroscopy (MRS), and muscle biopsy and fibroblasts were analyzed. Candidate genes were sequenced, and mtDNA was analyzed for rearrangements.
   ResultsAffected individuals displayed a slowly progressive syndrome characterized by CPEO, mitochondrial myopathy, sensorineural deafness, peripheral neuropathy, parkinsonism, and/or cognitive impairment, in most cases without visual complains, but with subclinical loss of retinal nerve fibers at OCT. Muscle biopsies showed cytochrome c oxidase-negative fibers and mtDNA multiple deletions, and MRS displayed defective oxidative metabolism in muscle and brain. We found 2 heterozygous OPA1 missense mutations affecting highly conserved amino acid positions (p.G488R, p.A495V) in the guanosine triphosphatase domain, each segregating with affected individuals. Fibroblast studies showed a reduced amount of OPA1 protein with normal mRNA expression, fragmented mitochondria, impaired bioenergetics, increased autophagy and mitophagy.
   InterpretationThe association of CPEO and parkinsonism/dementia with subclinical optic neuropathy widens the phenotypic spectrum of OPA1 mutations, highlighting the association of defective mitochondrial dynamics, mtDNA multiple deletions, and altered mitophagy with parkinsonism. Ann Neurol 2015;78:21-38
C1 [Carelli, Valerio; Caporali, Leonardo; La Morgia, Chiara; Valentino, Maria Lucia; Maresca, Alessandra; Rizzo, Giovanni; Avoni, Patrizia; Liguori, Rocco; Baruzzi, Agostino] Bellaria Hosp, IRCCS Inst Neurol Sci Bologna, Bologna, Italy.
   [Carelli, Valerio; Zanna, Claudia; La Morgia, Chiara; Valentino, Maria Lucia; Maresca, Alessandra; Rizzo, Giovanni; Avoni, Patrizia; Liguori, Rocco; Baruzzi, Agostino] Univ Bologna, Dept Biomed & Neuromotor Sci, Neurol Unit, I-40139 Bologna, Italy.
   [Musumeci, Olimpia; Toscano, Antonio] Univ Messina, Dept Neurosci, Messina, Italy.
   [Del Dotto, Valentina; Porcelli, Anna Maria; Rugolo, Michela; Iommarini, Luisa] Univ Bologna, Dept Pharm & Biotechnol, I-40139 Bologna, Italy.
   [Barboni, Piero; Carbonelli, Michele] Studio Oculist DAzeglio, Bologna, Italy.
   [Trombetta, Costantino] Univ Messina, Ophthalmol Clin, Messina, Italy.
   [Valente, Enza Maria] San Giovanni Rotondo, IRCCS Casa Sollievo Sofferenza, Mendel Lab, Foggia, Italy.
   [Patergnani, Simone; Giorgi, Carlotta; Pinton, Paolo] Univ Ferrara, Dept Morphol Surg & Expt Med, I-44100 Ferrara, Italy.
   [Tonon, Caterina; Lodi, Raffaele] Univ Bologna, Dept Biomed & Neuromotor Sci, St Orsola Malpighi Polyclin, Funct Magnet Resonance Unit, I-40139 Bologna, Italy.
   [Zeviani, Massimo] MRC, Mitochondrial Biol Unit, Cambridge, England.
C3 AUSL di Bologna; IRCCS Istituto delle Scienze Neurologiche di Bologna
   (ISNB); University of Bologna; University of Messina; University of
   Bologna; University of Messina; IRCCS Casa Sollievo Della Sofferenza;
   University of Ferrara; IRCCS Azienda Ospedaliero-Universitaria di
   Bologna; University of Bologna
RP Carelli, V (corresponding author), Univ Bologna, Dept Biomed & NeuroMotor Sci DiBiNeM, Bellaria Hosp, IRCCS Inst Neurol Sci Bologna, Via Altura 3, I-40139 Bologna, Italy.
EM valerio.carelli@unibo.it
RI Porcelli, Anna Maria/AFR-3211-2022; La Morgia, Chiara/H-6765-2012;
   Liguori, Rocco/AAB-7860-2020; Patergnani, Simone/AAC-3969-2021;
   Musumeci, Olimpia/AHE-3041-2022; Avoni, Patrizia/AAC-1879-2020; Rugolo,
   Michela/AAY-8640-2020; Toscano, Antonio/AHE-4657-2022; Valente,
   Enza/G-2942-2017; Giorgi, Carlotta/K-4649-2016; Rizzo,
   Giovanni/AAB-9888-2020; Tonon, Caterina/K-6680-2016; Zanna,
   Claudia/GVT-1932-2022; Lodi, Raffaele/K-4984-2016; Del Dotto,
   Valentina/AAB-7073-2020; Zeviani, Massimo/AAU-2632-2021; Caporali,
   Leonardo/J-7398-2016; Pinton, Paolo/J-8025-2012; Barboni,
   Piero/AAA-9936-2020; Iommarini, Luisa/J-2328-2018; Maresca,
   Alessandra/J-7393-2016
OI Valente, Enza Maria/0000-0002-0600-6820; Rugolo,
   Michela/0000-0002-4597-0452; AVONI, PATRIZIA/0000-0003-0719-6803; Rizzo,
   Giovanni/0000-0002-9718-2044; Caporali, Leonardo/0000-0002-0666-4380;
   Pinton, Paolo/0000-0001-7108-6508; Barboni, Piero/0000-0002-0118-4177;
   LA MORGIA, Chiara/0000-0002-4639-8929; Iommarini,
   Luisa/0000-0002-6804-7302; Porcelli, Anna Maria/0000-0002-6209-0692;
   Zeviani, Massimo/0000-0002-9067-5508; Liguori,
   Rocco/0000-0002-1815-1013; Patergnani, Simone/0000-0001-7951-9267;
   Giorgi, Carlotta/0000-0002-2494-7405; TONON,
   CATERINA/0000-0002-0506-499X; DEL DOTTO, VALENTINA/0000-0002-6053-0893;
   CARELLI, VALERIO/0000-0003-4923-6404; Lodi,
   Raffaele/0000-0003-3878-304X; Maresca, Alessandra/0000-0002-8959-8832;
   VALENTINO, MARIA LUCIA/0000-0001-5323-0115
FU Telethon-Italy [GGP06233, GPP10005, GGP14187]; Programma di ricerca
   Regione-Universita [PRUa1RI-2012-008]; European Research Council ERC-FP7
   advanced grant [322424]; European Research Council (ERC) [322424]
   Funding Source: European Research Council (ERC)
FX This study was supported by Telethon-Italy (GGP06233, V.C.; GPP10005,
   M.Z., V.C.; GGP14187, V.C.), Programma di ricerca Regione-Universita
   2010-2012 (PRUa1RI-2012-008, V.C.), and a European Research Council
   ERC-FP7 advanced grant (322424, M.Z.).
CR Agier V, 2012, BBA-MOL BASIS DIS, V1822, P1570, DOI 10.1016/j.bbadis.2012.07.002
   Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944
   Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   Ashrafi G, 2013, CELL DEATH DIFFER, V20, P31, DOI 10.1038/cdd.2012.81
   Austin SA, 1998, NEUROLOGY, V51, P1447, DOI 10.1212/WNL.51.5.1447
   Baloh RH, 2007, ARCH NEUROL-CHICAGO, V64, P998, DOI 10.1001/archneur.64.7.998
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Corti O, 2013, CURR OPIN NEUROBIOL, V23, P100, DOI 10.1016/j.conb.2012.11.002
   Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936
   Elachouri G, 2011, GENOME RES, V21, P12, DOI 10.1101/gr.108696.110
   Ferré M, 2005, HUM MUTAT, V25, P423, DOI 10.1002/humu.20161
   Garone C, 2012, ARCH NEUROL-CHICAGO, V69, P1648, DOI 10.1001/archneurol.2012.405
   Hannah-Shmouni F, 2014, JIMD REP, V12, P17, DOI 10.1007/8904_2013_239
   Hudson G, 2008, BRAIN, V131, P329, DOI 10.1093/brain/awm272
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416
   Klionsky DJ, 2012, AUTOPHAGY, V8, P445, DOI 10.4161/auto.19496
   La Morgia C, 2008, NEUROLOGY, V70, P762, DOI 10.1212/01.wnl.0000295505.74234.d0
   Lodi R, 2011, ARCH NEUROL-CHICAGO, V68, P67, DOI 10.1001/archneurol.2010.228
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Lutz AK, 2009, J BIOL CHEM, V284, P22938, DOI 10.1074/jbc.M109.035774
   Mancuso M, 2008, J AFFECT DISORDERS, V106, P173, DOI 10.1016/j.jad.2007.05.016
   Maresca A, 2013, MOL CELL NEUROSCI, V55, P62, DOI 10.1016/j.mcn.2012.08.004
   Marongiu R, 2008, HUM MUTAT, V29, P565, DOI 10.1002/humu.20719
   Milone M, 2009, MITOCHONDRION, V9, P279, DOI 10.1016/j.mito.2009.03.001
   Müller-Rischart AK, 2013, MOL CELL, V49, P908, DOI 10.1016/j.molcel.2013.01.036
   Narendra D., 2012, Cold Spring Harb Perspect Biol, V4
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Patergnani S, 2015, METHODS MOL BIOL, V1241, P181, DOI 10.1007/978-1-4939-1875-1_15
   Patergnani S, 2013, AUTOPHAGY, V9, P1367, DOI 10.4161/auto.25239
   Pesch UEA, 2001, HUM MOL GENET, V10, P1359, DOI 10.1093/hmg/10.13.1359
   Porcelli AM, 2009, J BIOL CHEM, V284, P2045, DOI 10.1074/jbc.M807321200
   Ratiney H, 2005, NMR BIOMED, V18, P1, DOI 10.1002/nbm.895
   ROBINSON BH, 1992, BIOCHEM MED METAB B, V48, P122, DOI 10.1016/0885-4505(92)90056-5
   Ronchi D, 2013, AM J HUM GENET, V92, P293, DOI 10.1016/j.ajhg.2012.12.014
   Ronchi D, 2012, BRAIN, V135, P3404, DOI 10.1093/brain/aws258
   Rouzier C, 2012, BRAIN, V135, P23, DOI 10.1093/brain/awr323
   Sarzi E, 2012, BRAIN, V135, P3599, DOI 10.1093/brain/aws303
   Savini G, 2010, J GLAUCOMA, V19, P369, DOI 10.1097/IJG.0b013e3181bdb55d
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2007, BIOSCIENCE REP, V27, P39, DOI 10.1007/s10540-007-9036-1
   Suen DF, 2010, P NATL ACAD SCI USA, V107, P11835, DOI 10.1073/pnas.0914569107
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0
   Tyynismaa H, 2012, HUM MOL GENET, V21, P66, DOI 10.1093/hmg/ddr438
   Tyynismaa H, 2009, AM J HUM GENET, V85, P290, DOI 10.1016/j.ajhg.2009.07.009
   Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   White KE, 2009, INVEST OPHTH VIS SCI, V50, P2567, DOI 10.1167/iovs.08-2913
   Yu-Wai-Man P, 2010, BRAIN, V133, P771, DOI 10.1093/brain/awq007
   Zanna C, 2008, BRAIN, V131, P352, DOI 10.1093/brain/awm335
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 53
TC 143
Z9 148
U1 0
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0364-5134
EI 1531-8249
J9 ANN NEUROL
JI Ann. Neurol.
PD JUL
PY 2015
VL 78
IS 1
BP 21
EP 38
DI 10.1002/ana.24410
PG 18
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA CL3AQ
UT WOS:000356821200003
PM 25820230
OA Green Published, hybrid
DA 2024-11-01
ER

PT J
AU Wang, XW
   Salinas, K
   Zuo, XM
   Kucejova, B
   Chen, XJ
AF Wang, Xiaowen
   Salinas, Kelly
   Zuo, Xiaoming
   Kucejova, Blanka
   Chen, Xin Jie
TI Dominant membrane uncoupling by mutant adenine nucleotide translocase in
   mitochondrial diseases
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; SACCHAROMYCES-CEREVISIAE; ADP/ATP
   CARRIER; PROTON CONDUCTANCE; MTDNA MAINTENANCE; OPTIC ATROPHY; DNA
   DELETIONS; FATTY-ACIDS; ANT1 GENE; MUTATION
AB Adenine nucleotide translocase (Ant) is the most abundant protein on the mitochondrial inner membrane (MIM) primarily involved in ADP/ATP exchange. Ant also possesses a discrete membrane uncoupling activity. Specific mis-sense mutations in the human Ant1 cause autosomal dominant Progressive External Ophthalmoplegia (adPEO), mitochondrial myopathy and cardiomyopathy, which are commonly manifested by fractional mitochondrial DNA (mtDNA) deletions. It is currently thought that the pathogenic mutations alter substrate preference (e.g. ATP versus ADP) thereby dominantly disturbing adenine nucleotide homeostasis in mitochondria. This may interfere with mtDNA replication, consequently affecting mtDNA stability and oxidative phosphorylation. Here, we showed that the adPEO-type A128P, A106D and M114P mutations in the yeast Aac2p share the following common dominant phenotypes: electron transport chain damage, intolerance to moderate over-expression, synthetic lethality with low Delta psi(m) conditions, hypersensitivity to the uncoupler carbonyl cyanide m-chlorophenylhydrazone (CCCP) and mtDNA instability. More interestingly, the aac2(A137D) allele mimicking ant1(A123D) in mitochondrial myopathy and cardiomyopathy exhibits similar dominant phenotypes. Because Aac2(A137D) is known to completely lack transport activity, it is strongly argued that the dominant mitochondrial damages are not caused by aberrant nucleotide transport. The four pathogenic mutations occur in a structurally dynamic gating region on the cytosolic side. We provided direct evidence that the mutant alleles uncouple mitochondrial respiration. The pathogenic mutations likely enhance the intrinsic proton-conducting activity of Ant, which excessively uncouples the MIM thereby affecting energy transduction and mitochondrial biogenesis. mtDNA disintegration is a phenotype co-lateral to mitochondrial damages. These findings provide mechanistic insights into the pathogenesis of the Ant1-induced diseases.
C1 [Wang, Xiaowen; Salinas, Kelly; Chen, Xin Jie] SUNY Upstate Med Univ, Dept Biochem & Mol Biol, Syracuse, NY 13210 USA.
   [Zuo, Xiaoming; Kucejova, Blanka] Univ Texas SW Med Ctr Dallas, Dept Mol Biol, Dallas, TX 75390 USA.
C3 State University of New York (SUNY) System; State University of New York
   (SUNY) Upstate Medical Center; University of Texas System; University of
   Texas Southwestern Medical Center Dallas
RP Chen, XJ (corresponding author), SUNY Upstate Med Univ, Dept Biochem & Mol Biol, 750 E Adams St, Syracuse, NY 13210 USA.
EM chenx@upstate.edu
RI Wang, Xiaowen/A-7236-2018
OI Kucejova, Blanka/0000-0002-5058-330X
FU National Institute of Health [AG023731]; American Heart Association
   [0435047N]; American Heart Association (AHA) [0435047N] Funding Source:
   American Heart Association (AHA)
FX This work was supported by National Institute of Health (AG023731) and
   the American Heart Association (0435047N).
CR Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   BETINA S, 1995, EUR J BIOCHEM, V229, P651, DOI 10.1111/j.1432-1033.1995.tb20510.x
   Brand MD, 2005, BIOCHEM J, V392, P353, DOI 10.1042/BJ20050890
   BRUSTOVETSKY N, 1994, J BIOL CHEM, V269, P27329
   Chen XJ, 1999, MOL GEN GENET, V262, P898, DOI 10.1007/s004380051156
   Chen XJ, 2005, NAT REV GENET, V6, P815, DOI 10.1038/nrg1708
   Chen XJ, 2002, HUM MOL GENET, V11, P1835, DOI 10.1093/hmg/11.16.1835
   Copeland WC, 2008, ANNU REV MED, V59, P131, DOI 10.1146/annurev.med.59.053006.104646
   Crompton M, 2004, AGING CELL, V3, P3, DOI 10.1046/j.1474-9728.2003.00073.x
   Deschauer M, 2005, NEUROMUSCULAR DISORD, V15, P311, DOI 10.1016/j.nmd.2004.12.004
   Esposito LA, 1999, P NATL ACAD SCI USA, V96, P4820, DOI 10.1073/pnas.96.9.4820
   Ferraris S, 2008, ARCH NEUROL-CHICAGO, V65, P125, DOI 10.1001/archneurol.2007.9
   Fontanesi F, 2004, HUM MOL GENET, V13, P923, DOI 10.1093/hmg/ddh108
   Hudson G, 2008, BRAIN, V131, P329, DOI 10.1093/brain/awm272
   Jacotot E, 2001, J EXP MED, V193, P509, DOI 10.1084/jem.193.4.509
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kihira Y, 2004, BIOCHEMISTRY-US, V43, P15204, DOI 10.1021/bi0494222
   Klingenberg M, 2008, BBA-BIOMEMBRANES, V1778, P1978, DOI 10.1016/j.bbamem.2008.04.011
   Komaki H, 2002, ANN NEUROL, V51, P645, DOI 10.1002/ana.10172
   Kominsky DJ, 2002, GENETICS, V162, P1595
   Leonhard K, 1996, EMBO J, V15, P4218, DOI 10.1002/j.1460-2075.1996.tb00796.x
   Napoli L, 2001, NEUROLOGY, V57, P2295, DOI 10.1212/WNL.57.12.2295
   Nicholls DG, 2004, AGING CELL, V3, P35, DOI 10.1111/j.1474-9728.2003.00079.x
   Palmieri L, 2005, HUM MOL GENET, V14, P3079, DOI 10.1093/hmg/ddi341
   PEARCE DA, 1995, J BIOL CHEM, V270, P20879, DOI 10.1074/jbc.270.36.20879
   Pebay-Peyroula E, 2003, NATURE, V426, P39, DOI 10.1038/nature02056
   Polcic P, 1997, FEBS LETT, V412, P207, DOI 10.1016/S0014-5793(97)00778-3
   Siciliano G, 2003, NEUROMUSCULAR DISORD, V13, P162, DOI 10.1016/S0960-8966(02)00221-3
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2005, GENE, V354, P162, DOI 10.1016/j.gene.2005.03.025
   Talbot DA, 2004, J PHYSIOL-LONDON, V558, P123, DOI 10.1113/jphysiol.2004.063768
   THORSNESS PE, 1993, MOL CELL BIOL, V13, P5418, DOI 10.1128/MCB.13.9.5418
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Wang XW, 2008, NAT CELL BIOL, V10, P1090, DOI 10.1038/ncb1769
   Weber ER, 1996, MOL BIOL CELL, V7, P307, DOI 10.1091/mbc.7.2.307
NR 35
TC 29
Z9 33
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD DEC 15
PY 2008
VL 17
IS 24
BP 4036
EP 4044
DI 10.1093/hmg/ddn306
PG 9
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 377VQ
UT WOS:000261280300019
PM 18809618
OA Bronze, Green Published
DA 2024-11-01
ER

PT J
AU Jeppesen, TD
   Duno, M
   Vissing, J
AF Jeppesen, Tina D.
   Duno, Morten
   Vissing, John
TI Mutation Load of Single, Large-Scale Deletions of mtDNA in Mitotic and
   Postmitotic Tissues
SO FRONTIERS IN GENETICS
LA English
DT Article
DE mtDNA mutation; mtDNA deletion; phenotype-genotype; mitochondrial
   myopathy; CPEO; chronic progressive external ophthalmoplegia
AB It is generally accepted that patients with chronic progressive ophthalmoplegia caused by single large-scale deletion (SLD) of mitochondrial DNA (mtDNA) only harbor mutation in skeletal and eye muscles. The aim of this study was to investigate the presence and the level of heteroplasmy of mtDNA deletions in mitotic tissues of patients displaying mtDNA deletion of mitotic tissues in patients with SLDs and pure muscle phenotype. MtDNA mutation load was studied in three mitotic (urine epithelial cells, buccal mucosa, and blood) and one postmitotic (skeletal muscle) tissues in 17 patients with SLDs of mtDNA and pure muscle involvement. All patients had mtDNA deletion in skeletal muscle, and 78% of the patients also displayed the mtDNA deletion in mitotic tissues. The mtDNA mutation load was higher in skeletal muscle versus mitotic tissues. The mtDNA mutation load did not correlate with age of sampling of tissues, but there was a correlation between the mtDNA mutations load in skeletal muscle and (1) the site of 5 ' end breaking point of the SLD, (2) the size of SLD, (3) the number of affected tRNAs, and (4) age at onset (r> 0.58,P< 0.05). The findings indicate that mtDNA mutation in mitotic tissue is common in patients with SLDs of mtDNA. The lack of correlation between age of tissue sampling, age at onset, and mtDNA mutation load in mitotic tissues indicates that there is no extensive post-natal modification of mtDNA mutation load in mitotic tissues of patients with pure muscle phenotype.
C1 [Jeppesen, Tina D.; Vissing, John] Univ Copenhagen, Rigshosp, Copenhagen Neuromuscular Ctr, Copenhagen, Denmark.
   [Duno, Morten] Univ Copenhagen, Rigshosp, Dept Clin Genet, Copenhagen, Denmark.
C3 Rigshospitalet; University of Copenhagen; University of Copenhagen;
   Rigshospitalet
RP Jeppesen, TD (corresponding author), Univ Copenhagen, Rigshosp, Copenhagen Neuromuscular Ctr, Copenhagen, Denmark.
EM tina.dysgaard.jeppesen.03@regionh.dk
RI Jeppesen, Tina/AAV-7195-2020; Vissing, John/IUN-4271-2023
FU Augustinus Fonden; Hartmanns Fond; Lippmann Fonden; Kong Christian den
   Tiendes Fond; Sara and Ludvig Elsass Foundation; Danish Medical Research
   Council; NOVO Nordic Foundation; Vanforefonden; University of Copenhagen
FX This work was supported by the Augustinus Fonden, Hartmanns Fond,
   Lippmann Fonden, Kong Christian den Tiendes Fond, Sara and Ludvig Elsass
   Foundation, The Danish Medical Research Council, The NOVO Nordic
   Foundation, Vanforefonden, and the University of Copenhagen.
CR Akman CI, 2004, J CHILD NEUROL, V19, P258, DOI 10.1177/088307380401900403
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Chinnery PF, 2000, MOL MED TODAY, V6, P425, DOI 10.1016/S1357-4310(00)01805-0
   Grady JP, 2014, BRAIN, V137, P323, DOI 10.1093/brain/awt321
   He LP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf067
   LARSSON NG, 1990, PEDIATR RES, V28, P131, DOI 10.1203/00006450-199028020-00011
   López-Gallardo E, 2009, MITOCHONDRION, V9, P314, DOI 10.1016/j.mito.2009.04.005
   MCSHANE MA, 1991, AM J HUM GENET, V48, P39
   Rocha MC, 2018, ANN NEUROL, V83, P115, DOI 10.1002/ana.25127
   SOLIGNAC M, 1987, GENETICS, V117, P687
   Yamashita S, 2008, J HUM GENET, V53, P598, DOI 10.1007/s10038-008-0289-8
NR 11
TC 6
Z9 7
U1 0
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1664-8021
J9 FRONT GENET
JI Front. Genet.
PD OCT 2
PY 2020
VL 11
AR 547638
DI 10.3389/fgene.2020.547638
PG 6
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA OB3CD
UT WOS:000578349200001
PM 33133144
OA Green Published, gold
DA 2024-11-01
ER

PT J
AU Sotiriou, E
   Çoku, J
   Tanji, K
   Huang, HB
   Hirano, M
   DiMauro, S
AF Sotiriou, Evangelia
   Coku, Jorida
   Tanji, Kurenai
   Huang, Hua-bin
   Hirano, Michio
   DiMauro, Salvatore
TI The m.3244G&gt;A mutation in mtDNA is another cause of progressive
   external ophthalmoplegia
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE mtDNA; CPEO; tRNA(Leu(UUR)); Mutation
ID MITOCHONDRIAL-DNA MUTATIONS; FEATURES; ENCEPHALOMYOPATHY; DISEASE;
   CELLS; MERRF
AB We sequenced all mitochondrial tRNA genes in a 61-year-old man with chronic progressive external ophthalmoplegia and mitochondrial myopathy but Without mtDNA rearrangements, and identified a heteroplasmic m.3244G>A mutation in the tRNA(Leu(UUR)) gene. This mutation had been previously associated with the MELAS phenotype, but not described ill any detail.
   The Mutation load in muscle was 84% and COX-negative fibers harbored greater levels of mutant genomes than COX-positive fibers. The m.3244G>A Mutation affects a highly conserved nucleotide in the dihydrouridine loop and has been associated with a wobble modification deficiency of the mutant tRNA. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Sotiriou, Evangelia; Coku, Jorida; Tanji, Kurenai; Huang, Hua-bin; Hirano, Michio; DiMauro, Salvatore] Columbia Univ, Med Ctr, Dept Neurol, New York, NY 10032 USA.
   [Tanji, Kurenai] Columbia Univ, Med Ctr, Dept Pathol, New York, NY 10032 USA.
C3 Columbia University; Columbia University
RP DiMauro, S (corresponding author), Columbia Univ, Med Ctr, Dept Neurol, New York, NY 10032 USA.
EM sd12@columbia.edu
FU NIH [HD32062]; Marriott Mitochondrial Disorders Clinical Research Fund
   (MMDCRF)
FX This work has been supported by NIH Grant HD32062 and the Marriott
   Mitochondrial Disorders Clinical Research Fund (MMDCRF).
CR Carew JS, 2003, LEUKEMIA, V17, P1437, DOI 10.1038/sj.leu.2403043
   Dimauro S, 2005, ANN MED, V37, P222, DOI 10.1080/07853890510007368
   Hutchison WM, 2005, ARCH NEUROL-CHICAGO, V62, P1920, DOI 10.1001/archneur.62.12.1920
   Kirino Y, 2005, P NATL ACAD SCI USA, V102, P7127, DOI 10.1073/pnas.0500563102
   MORAES CT, 1993, NEUROMUSCULAR DISORD, V3, P43, DOI 10.1016/0960-8966(93)90040-Q
   Nishigaki Y, 2003, NEUROMUSCULAR DISORD, V13, P334, DOI 10.1016/S0960-8966(02)00283-3
   Pulkes T, 2001, ADV DRUG DELIVER REV, V49, P27, DOI 10.1016/S0169-409X(01)00124-7
   Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755
   Yao YG, 2007, BLOOD, V109, P756, DOI 10.1182/blood-2006-01-011007
   Yasukawa T, 2000, FEBS LETT, V467, P175, DOI 10.1016/S0014-5793(00)01145-5
NR 10
TC 7
Z9 7
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD APR
PY 2009
VL 19
IS 4
BP 297
EP 299
DI 10.1016/j.nmd.2009.01.014
PG 3
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 442VK
UT WOS:000265868500011
PM 19285865
OA Green Accepted
DA 2024-11-01
ER

PT J
AU Okamoto, Y
   Higuchi, I
   Sakiyama, Y
   Tokunaga, S
   Watanabe, O
   Arimura, K
   Nakagawa, M
   Takashima, H
AF Okamoto, Yuji
   Higuchi, Itsuro
   Sakiyama, Yusuke
   Tokunaga, Shoko
   Watanabe, Osamu
   Arimura, Kimiyoshi
   Nakagawa, Masanori
   Takashima, Hiroshi
TI A New Mitochondria-Related Disease Showing Myopathy with Episodic
   Hyper-creatine Kinase-emia
SO ANNALS OF NEUROLOGY
LA English
DT Article
ID HEREDITARY OPTIC NEUROPATHY; DNA; MUTATION; MICROARRAY; GENE
AB Objective: To elucidate the relationship between mitochondrial DNA (mtDNA) alterations and a mitochondrial disease with a distinct combination of characteristic symptoms, namely episodic hyper-creatine kinase (CK)-emia and mild myopathy.
   Methods: We selected 9 patients with mtDNA np8291 alteration from 586 patients suspected to have a mitochondrial disease, and assessed them clinically, pathologically, and genetically. These 9 patients had undiagnosed mitochondrial myopathy with episodic hyper-CK-emia, all showing similar symptoms and progression.
   Results: Patients had mild muscle weakness and episodic hyper-CK-emia triggered by infections or drugs. Five of 9 patients were initially diagnosed with other conditions, such as myasthenia gravis, polymyositis, viral myositis, and drug-induced myopathy, because these conditions were acute or subacute, and 9 patients showed the same 16 mtDNA alterations, which have been reported to be nonpathological polymorphisms. Muscle biopsy revealed ragged-red fibers, highly expressed succinate dehydrogenase staining fibers, and cytochrome c oxidase-deficient fibers. Because their mitochondrial sequence data was almost the same, and 9 patients live in widely separated cities in Japan, the alterations may have arisen from a single source.
   Interpretation: These findings suggest that mild myopathy with episodic hyper-CK-emia associated with some of the 16 mtDNA alterations or at least with their mitochondria, could be a novel mitochondrial disease. Therefore, we propose that this disease be named as "mitochondrial myopathy with episodic hyper-CK-emia (MIMECK).'' These alterations could work concomitantly and probably modify the impact of medications or other environmental factors. We believe these findings provide an insight into a novel aspect of mitochondrial disease pathogenesis. ANN NEUROL 2011;70:486-492
C1 [Okamoto, Yuji; Higuchi, Itsuro; Sakiyama, Yusuke; Tokunaga, Shoko; Watanabe, Osamu; Takashima, Hiroshi] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Neurol & Geriatr, Kagoshima 8908520, Japan.
   [Arimura, Kimiyoshi] Okatsu Neurol & Rehabil Hosp, Kagoshima, Japan.
   [Nakagawa, Masanori] Kyoto Prefectural Univ Med, Grad Sch Med Sci, Dept Neurol, Kyoto, Japan.
C3 Kagoshima University; Kyoto Prefectural University of Medicine
RP Takashima, H (corresponding author), Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Neurol & Geriatr, 8-35-1 Sakuragaoka, Kagoshima 8908520, Japan.
EM thiroshi@m3.kufm.kagoshima-u.ac.jp
FU Nervous and Mental Disorders and Research Committee for Ataxic Disease
   of the Japanese Ministry of Health, Welfare and Labor [19A-1]; Ministry
   of Education, Culture, Sports, Science, and Technology of Japan
   [21591095, 21591094]; Nervous and Mental Disorders from the Ministry of
   Health, Labor, and Welfare [20B-13]; Eisai; Pfizer; Sanofi-Aventis;
   Teijin Pharma; Novartis; Tanabe-Mitsubishi Dainippon-Sumitomo; Astellas;
   GlaxoSmithkline; Benesis; Grants-in-Aid for Scientific Research
   [21591095, 22590939, 21591094] Funding Source: KAKEN
FX This research was supported by grants from the Nervous and Mental
   Disorders and Research Committee for Ataxic Disease of the Japanese
   Ministry of Health, Welfare and Labor (19A-1 to H. T.); the Ministry of
   Education, Culture, Sports, Science, and Technology of Japan (21591095
   to H. T.; 21591094 to I. H.); and the Nervous and Mental Disorders from
   the Ministry of Health, Labor, and Welfare (20B-13 to I.H.).I.H.
   received grants from the Ministry of Education, Culture, Sports,
   Science, and Technology of Japan (grant 21591094), and the Nervous and
   Mental Disorders from the Ministry of Health, Labor, and Welfare (grant
   20B-13). H. T. received grants from the Nervous and Mental Disorders and
   Research Committee for Ataxic Disease of the Japanese Ministry of
   Health, Welfare and Labor (grant 19A-1) and the Ministry of Education,
   Culture, Sports, Science, and Technology of Japan (grant 21591095). H.
   T. has received research grants or speaking fees from Eisai, Pfizer,
   Sanofi-Aventis, Teijin Pharma, Novartis, Tanabe-Mitsubishi
   Dainippon-Sumitomo, Astellas, GlaxoSmithkline and Benesis.
CR Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   Baker SK, 2001, CLIN INVEST MED, V24, P258
   Boerkoel CF, 2001, AM J HUM GENET, V68, P325, DOI 10.1086/318208
   Brandon MC, 2005, NUCLEIC ACIDS RES, V33, pD611
   BROWN MD, 1995, HUM MUTAT, V6, P311, DOI 10.1002/humu.1380060405
   Chariot Patrick, 1995, Current Opinion in Rheumatology, V7, P497, DOI 10.1097/00002281-199511000-00006
   Cutler DJ, 2001, GENOME RES, V11, P1913, DOI 10.1101/gr.197201
   Dalakas MC, 2001, J PERIPHER NERV SYST, V6, P14, DOI 10.1046/j.1529-8027.2001.006001014.x
   Dimauro S, 2005, ANN MED, V37, P222, DOI 10.1080/07853890510007368
   Dugué A, 2004, EUR J CLIN PHARMACOL, V60, P285, DOI 10.1007/s00228-004-0760-1
   Evans M, 2002, DRUG SAFETY, V25, P649, DOI 10.2165/00002018-200225090-00004
   HAYS AP, 1994, MYOLOGY, V2, P1399
   Hirata K, 1999, J HUM GENET, V44, P210, DOI 10.1007/s100380050145
   JOY JL, 1989, MUSCLE NERVE, V12, P206, DOI 10.1002/mus.880120308
   Kallianpur AR, 2009, PHARMACOGENOMICS, V10, P623, DOI [10.2217/pgs.09.14, 10.2217/PGS.09.14]
   Karadimas CL, 2000, NEUROLOGY, V55, P644, DOI 10.1212/WNL.55.5.644
   Kong QP, 2006, HUM MOL GENET, V15, P2076, DOI 10.1093/hmg/ddl130
   Liang MH, 1998, AM J MED GENET, V77, P395, DOI 10.1002/(SICI)1096-8628(19980605)77:5<395::AID-AJMG8>3.0.CO;2-M
   Maitra A, 2004, GENOME RES, V14, P812, DOI 10.1101/gr.2228504
   Masanés F, 1998, J NEUROL SCI, V159, P226, DOI 10.1016/S0022-510X(98)00151-8
   Melberg A, 1998, NEUROLOGY, V50, P299, DOI 10.1212/WNL.50.1.299
   Mimaki M, 2003, J HUM GENET, V48, P47, DOI 10.1007/s100380300005
   Mimaki M, 2009, MITOCHONDRION, V9, P115, DOI 10.1016/j.mito.2009.01.005
   MUNSAT TL, 1973, JAMA-J AM MED ASSOC, V226, P1536, DOI 10.1001/jama.226.13.1536
   OHNO K, 1991, ANN NEUROL, V29, P364, DOI 10.1002/ana.410290406
   RIODANEVA P, 1995, BRAIN, V118, P319
   Rowland L.P., 1980, MUSCULAR DYSTROPHY R, P3
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   Thompson PD, 2003, JAMA-J AM MED ASSOC, V289, P1681, DOI 10.1001/jama.289.13.1681
   Zhou SY, 2006, J MOL DIAGN, V8, P476, DOI 10.2353/jmoldx.2006.060008
NR 30
TC 4
Z9 5
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0364-5134
EI 1531-8249
J9 ANN NEUROL
JI Ann. Neurol.
PD SEP
PY 2011
VL 70
IS 3
BP 486
EP 492
DI 10.1002/ana.22498
PG 7
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 819HU
UT WOS:000294816800022
PM 21905081
DA 2024-11-01
ER

PT J
AU Tkaczyk-Wlizlo, A
   Kowal, K
   Slaska, B
AF Tkaczyk-Wlizlo, Angelika
   Kowal, Krzysztof
   Slaska, Brygida
TI Mitochondrial DNA alterations in the domestic dog<i> (Canis</i><i>
   lupus</i><i> familiaris)</i> and their association with development of
   diseases: A review
SO MITOCHONDRION
LA English
DT Review
DE mtDNA; Mutation; Canine disease; Tumour; Myopathy
ID SUBACUTE NECROTIZING ENCEPHALOPATHY; LACTIC-ACIDOSIS; MTDNA MUTATION;
   MYOPATHY; GENE; RNA; ENCEPHALOMYELOPATHY; ENCEPHALOMYOPATHY; EXPRESSION;
   EPILEPSY
AB Currently, the issue of the aetiology of mitochondrial diseases resulting from mitochondrial DNA (mtDNA) defects is underestimated. Genetic research is mostly focused on alterations in the nuclear genome (nDNA), and its impact on disease development as well as further health consequences without considering mtDNA abnormalities. However, in the case of energy-dependent diseases, it is important to understand the bioenergetic pathophysiology and its relation with mtDNA changes.In the current animal research, there is limited data about mtDNA defects and their association with the development of bioenergetic diseases in the domestic dog (Canis lupus familiaris) in contrast to human medicine, where mitochondrial genetics research has recently increased. Molecular findings about mtDNA indicate that improper functioning of mitochondria resulting from genetic defects of mtDNA has a severe impact on cells and tissues, especially those that are heavily dependent on oxidative metabolism such as the brain, skeletal and cardiac muscles and, consequently, the whole organism.The aim of this paper is to highlight the role of defects of mitochondria and mtDNA on the development and course of different diseases in the domestic dog. The field of canine mitochondrial genetics and genomics is definitely inexhaustible and it is worth drawing attention to the importance and consequences of the mitochondrial genome alterations. This review collects scientific data on mitochondrial DNA with special regard to the structure, features of canine mtDNA, and abnormalities in the mitochondrial genome and their association with the course and development of diseases, including mitochondrial myopathies, encephalopathies, and tumours.
C1 [Tkaczyk-Wlizlo, Angelika; Kowal, Krzysztof; Slaska, Brygida] Univ Life Sci Lublin, Inst Biol Bases Anim Prod, Akad 13, PL-20950 Lublin, Poland.
C3 University of Life Sciences in Lublin
RP Slaska, B (corresponding author), Univ Life Sci Lublin, Inst Biol Bases Anim Prod, Akad 13, PL-20950 Lublin, Poland.
EM angelika.tkaczyk@up.lublin.pl; krzysztof.kowal@up.lublin.pl;
   brygida.slaska@up.lublin.pl
RI Kowal, Krzysztof/AAP-5167-2020; Ślaska, Brygida/T-8160-2018;
   Tkaczyk-Wlizło, Angelika/ABC-5263-2021
OI Tkaczyk-Wlizlo, Angelika/0000-0003-2261-6909
FU National Science Centre in Poland [2019/35/B/NZ5/00775]
FX Funding The study was funded by the National Science Centre in Poland,
   grant number 2019/35/B/NZ5/00775.
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Appleyard GD, 2006, INVEST OPHTH VIS SCI, V47, P1810, DOI 10.1167/iovs.05-0819
   Baiker K, 2009, ACTA NEUROPATHOL, V118, P697, DOI 10.1007/s00401-009-0548-6
   Baranowska I, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000499
   Bertagnolli AC, 2009, VET J, V182, P269, DOI 10.1016/j.tvjl.2008.07.005
   Bhatti JS, 2017, BBA-MOL BASIS DIS, V1863, P1066, DOI 10.1016/j.bbadis.2016.11.010
   BREITSCHWERDT EB, 1992, J AM VET MED ASSOC, V201, P731
   Brenner O, 1997, ACTA NEUROPATHOL, V94, P390, DOI 10.1007/s004010050724
   Brenner O, 2000, ACTA NEUROPATHOL, V100, P50, DOI 10.1007/s004010051192
   Brenner O, 1997, ACTA NEUROPATHOL, V94, P54, DOI 10.1007/s004010050672
   Chatterjee A, 2006, ONCOGENE, V25, P4663, DOI 10.1038/sj.onc.1209604
   Collins D, 2013, J COMP PATHOL, V148, P345, DOI 10.1016/j.jcpa.2012.08.008
   Copeland WC, 2002, CANCER INVEST, V20, P557, DOI 10.1081/CNV-120002155
   Corona P, 2001, ANN NEUROL, V49, P106, DOI 10.1002/1531-8249(200101)49:1<106::AID-ANA16>3.0.CO;2-T
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Dobson Jane M, 2013, ISRN Vet Sci, V2013, P941275, DOI 10.1155/2013/941275
   EICHMANN C, 2007, INT J LEGAL MED, V121, P411, DOI DOI 10.1007/S00414-006-0143-5
   Finsterer J, 2004, EUR J NEUROL, V11, P163, DOI 10.1046/j.1351-5101.2003.00728.x
   Gammage PA, 2019, BMC BIOL, V17, DOI 10.1186/s12915-019-0668-y
   Goldschmidt M, 2011, VET PATHOL, V48, P117, DOI 10.1177/0300985810393258
   Gruber AD, 2002, VET PATHOL, V39, P732, DOI 10.1354/vp.39-6-732
   Guo L, 2016, BIOCHEM BIOPH RES CO, V479, P800, DOI 10.1016/j.bbrc.2016.09.129
   Hardy SA, 2016, NEUROL-GENET, V2, DOI 10.1212/NXG.0000000000000082
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Kim KS, 1998, MOL PHYLOGENET EVOL, V10, P210, DOI 10.1006/mpev.1998.0513
   KORNEGAY JN, 1988, MUSCLE NERVE, V11, P1056, DOI 10.1002/mus.880111008
   Kowal K, 2019, ANN ANIM SCI, V19, P619, DOI 10.2478/aoas-2019-0027
   Kozakiewicz P, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22105100
   LARSSON NG, 1992, AM J HUM GENET, V51, P1201
   Li FY, 2006, NEUROBIOL DIS, V21, P35, DOI 10.1016/j.nbd.2005.06.009
   Lopes R, 2006, AM J VET RES, V67, P971, DOI 10.2460/ajvr.67.6.971
   MCKERRELL RE, 1986, VET PATHOL, V23, P411, DOI 10.1177/030098588602300410
   MORAES CT, 1992, AM J HUM GENET, V50, P934
   Nisztuk-Pacek S, 2019, ANN ANIM SCI, V19, P61, DOI 10.2478/aoas-2018-0049
   Olby NJ, 1997, J SMALL ANIM PRACT, V38, P213, DOI 10.1111/j.1748-5827.1997.tb03346.x
   Onishi M, 2021, EMBO J, V40, DOI 10.15252/embj.2020104705
   Orsucci D, 2018, EBIOMEDICINE, V30, P3, DOI 10.1016/j.ebiom.2018.03.007
   Paciello O, 2003, VET PATHOL, V40, P507, DOI 10.1354/vp.40-5-507
   Parrella P, 2001, CANCER RES, V61, P7623
   Perli E, 2012, HUM MOL GENET, V21, P85, DOI 10.1093/hmg/ddr440
   Picard M, 2016, MITOCHONDRION, V30, P105, DOI 10.1016/j.mito.2016.07.003
   Prochaska L.J, 2013, ENCY BIOPHYSICS, DOI [10.1007/978-3-642-16712-6_25, DOI 10.1007/978-3-642-16712-6_25]
   Rowell JL, 2011, TRENDS MOL MED, V17, P380, DOI 10.1016/j.molmed.2011.02.004
   Siegmund SE, 2017, HUM MOL GENET, V26, P4588, DOI 10.1093/hmg/ddx341
   SILVESTRI G, 1992, AM J HUM GENET, V51, P1213
   Slaska B, 2016, POL J VET SCI, V19, P461, DOI 10.1515/pjvs-2016-0058
   Slaska B, 2020, ANN ANIM SCI, V20, P919, DOI 10.2478/aoas-2020-0027
   Slaska B, 2015, MITOCHONDR DNA, V26, P452, DOI 10.3109/19401736.2013.840594
   Slaska B, 2014, B VET I PULAWY, V58, P631, DOI 10.2478/bvip-2014-0096
   Slaska B, 2014, MITOCHONDR DNA, V25, P238, DOI 10.3109/19401736.2013.792054
   Smiech A, 2019, IN VIVO, V33, P57, DOI 10.21873/invivo.11439
   Smiech A, 2016, ACTA VET SCAND, V58, DOI 10.1186/s13028-016-0210-y
   Stewart JB, 2021, J INHERIT METAB DIS, V44, P325, DOI 10.1002/jimd.12324
   Suomalainen A, 2010, NEUROMUSCULAR DISORD, V20, P429, DOI 10.1016/j.nmd.2010.03.017
   Tan AS, 2015, CELL METAB, V21, P81, DOI 10.1016/j.cmet.2014.12.003
   Tauro A., 2008, VET REC, V27
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Verscheure S, 2013, ZOOKEYS, P381, DOI 10.3897/zookeys.365.5859
   VIJAYASARATHY C, 1994, COMP BIOCHEM PHYS A, V109, P887, DOI 10.1016/0300-9629(94)90236-4
   Wakshlag JJ, 1999, J SMALL ANIM PRACT, V40, P585, DOI 10.1111/j.1748-5827.1999.tb03028.x
   WALLACE DC, 1988, CELL, V55, P601, DOI 10.1016/0092-8674(88)90218-8
   Wallace DC, 2013, J CLIN INVEST, V123, P1405, DOI 10.1172/JCI61398
   Zhang AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026511
   Zong WX, 2016, MOL CELL, V61, P667, DOI 10.1016/j.molcel.2016.02.011
NR 64
TC 8
Z9 8
U1 0
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 1872-8278
J9 MITOCHONDRION
JI Mitochondrion
PD MAR
PY 2022
VL 63
BP 72
EP 84
DI 10.1016/j.mito.2022.02.001
EA FEB 2022
PG 13
WC Cell Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Genetics & Heredity
GA 0U8BW
UT WOS:000787873200009
PM 35134592
DA 2024-11-01
ER

PT J
AU Ronchi, D
   Caporali, L
   Manenti, GF
   Meneri, M
   Mohamed, S
   Bordoni, A
   Tagliavini, F
   Contin, M
   Piga, D
   Sciacco, M
   Saetti, C
   Carelli, V
   Comi, GP
AF Ronchi, Dario
   Caporali, Leonardo
   Manenti, Giulia Francesca
   Meneri, Megi
   Mohamed, Susan
   Bordoni, Andreina
   Tagliavini, Francesca
   Contin, Manuela
   Piga, Daniela
   Sciacco, Monica
   Saetti, Cristina
   Carelli, Valerio
   Comi, Giacomo Pietro
TI <i>TYMP</i>Variants Result in Late-Onset Mitochondrial Myopathy With
   Altered Muscle Mitochondrial DNA Homeostasis
SO FRONTIERS IN GENETICS
LA English
DT Article
DE mitochondrial myopathy; mitochondrial DNA instability; TYMP;
   mitochondrial neurogatrointestinal encephalomyopathy; mitochondrial DNA
   replication
ID PHOSPHORYLASE GENE-MUTATIONS; NEUROGASTROINTESTINAL ENCEPHALOMYOPATHY;
   POINT MUTATIONS; THYMIDINE; MNGIE; DEFECTS; MTDNA
AB BiallelicTYMPvariants result in the mitochondrial neurogastrointestinal encephalomyopathy (MNGIE), a juvenile-onset disorder with progressive course and fatal outcome. Milder late-onset (>40 years) form has been rarely described. Gene panel sequencing in a cohort of 60 patients featuring muscle accumulation of mitochondrial DNA (mtDNA) deletions detectedTYMPdefects in three subjects (5%), two of them with symptom onset in the fifth decade. One of the patients only displayed ptosis and ophthalmoparesis. Biochemical and molecular studies supported the diagnosis. Screening ofTYMPis recommended in adult patients with muscle mtDNA instability, even in the absence of cardinal MNGIE features.
C1 [Ronchi, Dario; Meneri, Megi; Bordoni, Andreina; Piga, Daniela; Saetti, Cristina] IRCCS Fdn Ca Granda Osped Maggiore Policlin, Neurol Unit, Milan, Italy.
   [Ronchi, Dario; Manenti, Giulia Francesca; Saetti, Cristina; Comi, Giacomo Pietro] Univ Milan, Dino Ferrari Ctr, Dept Pathophysiol & Transplantat, Milan, Italy.
   [Caporali, Leonardo; Mohamed, Susan; Tagliavini, Francesca; Contin, Manuela; Carelli, Valerio] IRCCS Ist Sci Neurol Bologna, Bologna, Italy.
   [Contin, Manuela; Carelli, Valerio] Univ Bologna, Dipartimento Sci Biomed & Neuromotorie DIBINEM, Bologna, Italy.
   [Sciacco, Monica; Comi, Giacomo Pietro] IRCCS Fdn Ca Granda Osped Maggiore Policlin, Neuromuscular & Rare Dis Unit, Milan, Italy.
C3 IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan;
   IRCCS Istituto delle Scienze Neurologiche di Bologna (ISNB); University
   of Bologna; IRCCS Ca Granda Ospedale Maggiore Policlinico
RP Comi, GP (corresponding author), Univ Milan, Dino Ferrari Ctr, Dept Pathophysiol & Transplantat, Milan, Italy.; Carelli, V (corresponding author), IRCCS Ist Sci Neurol Bologna, Bologna, Italy.; Carelli, V (corresponding author), Univ Bologna, Dipartimento Sci Biomed & Neuromotorie DIBINEM, Bologna, Italy.; Comi, GP (corresponding author), IRCCS Fdn Ca Granda Osped Maggiore Policlin, Neuromuscular & Rare Dis Unit, Milan, Italy.
EM valerio.carelli@unibo.it; giacomo.comi@unimi.it
RI Comi, Giacomo/K-5702-2016; Ronchi, Dario/K-8011-2016; Sciacco,
   Monica/AAC-6500-2022; Mohamed, Susan/AAA-8915-2020; contin,
   manuela/AAB-9567-2020; Tagliavini, Fabrizio/AAO-7891-2021; Caporali,
   Leonardo/J-7398-2016
OI MENERI, MEGI/0000-0002-3429-1809; Tagliavini,
   Fabrizio/0000-0003-1039-7315; Caporali, Leonardo/0000-0002-0666-4380
FU Italian Ministry of Health; Ministero della Salute (Fondazione IRCCS Ca'
   Granda Ospedale Maggiore Policlinico, Ricerca Corrente 2020)
FX This work was supported by the Italian Ministry of Health (Ricerca
   Corrente to VC and LC). This work was partially supported by grants from
   the Ministero della Salute (Fondazione IRCCS Ca' Granda Ospedale
   Maggiore Policlinico, Ricerca Corrente 2020) to GC.
CR Ahmed N, 2015, INT J MOL SCI, V16, P18054, DOI 10.3390/ijms160818054
   Amiot A, 2009, GASTROENTEROLOGY, V137, P101, DOI 10.1053/j.gastro.2009.03.054
   Bakker JA, 2010, J INHERIT METAB DIS, V33, pS139, DOI 10.1007/s10545-010-9049-y
   Bohr VA, 1999, J BIOENERG BIOMEMBR, V31, P391, DOI 10.1023/A:1005484004167
   da Costa CK, 2007, J NEUROL SCI, V263, P139, DOI 10.1016/j.jns.2007.07.006
   Del Bo R, 2003, NEUROLOGY, V61, P903, DOI 10.1212/01.WNL.0000092303.13864.BE
   Del Dotto V, 2020, J CLIN INVEST, V130, P108, DOI 10.1172/JCI128514
   Finkenstedt A, 2013, JIMD REP, V10, P41, DOI 10.1007/8904_2012_199
   Garone C, 2011, BRAIN, V134, P3326, DOI 10.1093/brain/awr245
   HIRANO M, 1994, NEUROLOGY, V44, P721, DOI 10.1212/WNL.44.4.721
   Hirano M., 2016, GENEREVIEWS, P1993
   Hirano M, 2012, BBA-GEN SUBJECTS, V1820, P625, DOI 10.1016/j.bbagen.2012.01.006
   Li S., 2019, DIAGNOSIS MANAGEMENT, P205
   Martí R, 2005, ANN NEUROL, V58, P649, DOI 10.1002/ana.20615
   Martí R, 2004, CLIN CHEM, V50, P120, DOI 10.1373/clinchem.2003.026179
   Massa R, 2009, NEUROMUSCULAR DISORD, V19, P837, DOI 10.1016/j.nmd.2009.08.013
   Mohamed S, 2014, J CHROMATOGR B, V949, P58, DOI 10.1016/j.jchromb.2014.01.003
   Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Papadimitriou A, 1998, NEUROLOGY, V51, P1086, DOI 10.1212/WNL.51.4.1086
   Ronchi D, 2018, BRAIN, V141, DOI 10.1093/brain/awx302
   Ronchi D, 2012, BRAIN, V135, P3404, DOI 10.1093/brain/aws258
   Slama A, 2005, MOL GENET METAB, V84, P326, DOI 10.1016/j.ymgme.2004.12.004
   Spinazzola A, 2002, J BIOL CHEM, V277, P4128, DOI 10.1074/jbc.M111028200
   Viscomi C, 2017, J INHERIT METAB DIS, V40, P587, DOI 10.1007/s10545-017-0027-5
   Wang Y, 2001, P NATL ACAD SCI USA, V98, P4022, DOI 10.1073/pnas.061013598
   Yadak R, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00031
NR 27
TC 5
Z9 5
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1664-8021
J9 FRONT GENET
JI Front. Genet.
PD AUG 5
PY 2020
VL 11
AR 860
DI 10.3389/fgene.2020.00860
PG 7
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA NF3RG
UT WOS:000563215000001
PM 32849836
OA Green Published, gold
DA 2024-11-01
ER

PT J
AU Craig, K
   Young, MJ
   Blakely, EL
   Longley, MJ
   Turnbull, DM
   Copeland, WC
   Taylor, RW
AF Craig, Kate
   Young, Matthew J.
   Blakely, Emma L.
   Longley, Matthew J.
   Turnbull, Douglass M.
   Copeland, William C.
   Taylor, Robert W.
TI A p.R369G <i>POLG2</i> mutation associated with adPEO and multiple mtDNA
   deletions causes decreased affinity between polymerase γ subunits
SO MITOCHONDRION
LA English
DT Article
DE Mitochondrial DNA polymerase; POLG2; adPEO; Multiple mtDNA deletions;
   Recombinant enzyme; Replication stalling
ID MITOCHONDRIAL-DNA DELETIONS; PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA;
   REAL-TIME PCR; INDIVIDUAL CELLS; OPTIC ATROPHY; DISEASE; DISORDER;
   MAINTENANCE; MYOPATHY; PATIENT
AB Human mitochondrial DNA (mtDNA) polymerase gamma (pol gamma) is the sole enzyme required to replicate and maintain the integrity of the mitochondrial genome. It comprises two subunits, a catalytic p140 subunit and a smaller p55 accessory subunit encoded by the POLG2 gene. We describe the molecular characterization of a potential dominant POLG2 mutation (p.R369G) in a patient with adPEO and multiple mtDNA deletions. Biochemical studies of the recombinant mutant p55 protein showed a reduced affinity to the pol gamma p140 subunit, leading to impaired processivity of the holoenzyme complex but did not show sensitivity to N-ethylmalaimide (NEM) inhibition, inferring a novel disease mechanism. (C) 2011 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 [Craig, Kate; Blakely, Emma L.; Turnbull, Douglass M.; Taylor, Robert W.] Newcastle Univ, Sch Med, Inst Ageing & Hlth, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Young, Matthew J.; Longley, Matthew J.; Copeland, William C.] NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA.
C3 Newcastle University - UK; National Institutes of Health (NIH) - USA;
   NIH National Institute of Environmental Health Sciences (NIEHS)
RP Taylor, RW (corresponding author), Newcastle Univ, Sch Med, Inst Ageing & Hlth, Mitochondrial Res Grp, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM robert.taylor@ncl.ac.uk
RI ; Copeland, William/C-4242-2019
OI Young, Matthew/0000-0002-5109-4719; Turnbull, Doug/0000-0002-8878-9901;
   Copeland, William/0000-0002-0359-0953
FU Wellcome Trust [074454/Z/04/Z]; UK NHS; NIH, National Institute of
   Environmental Health Sciences [ES 065078]; MRC [G0700718, MC_G0802536,
   G0800674] Funding Source: UKRI
FX This work was supported by a Wellcome Trust Programme Grant
   [074454/Z/04/Z], the UK NHS Specialist Commissioners which funds the
   "Rare Mitochondrial Disorders of Adults and Children" Diagnostic Service
   in Newcastle upon Tyne (http://www.mitochondrialncg.nhs.uk) and by the
   Intramural Research Program of the NIH, National Institute of
   Environmental Health Sciences [ES 065078].
CR Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   Blakely E, 2008, NEUROMUSCULAR DISORD, V18, P557, DOI 10.1016/j.nmd.2008.04.014
   DiMauro S, 2008, ANNU REV NEUROSCI, V31, P91, DOI 10.1146/annurev.neuro.30.051606.094302
   Fratter C, 2011, NEUROLOGY, V76, P2032, DOI 10.1212/WNL.0b013e31821e558b
   Fratter C, 2010, NEUROLOGY, V74, P1619, DOI 10.1212/WNL.0b013e3181df099f
   He LP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf067
   Hudson G, 2008, BRAIN, V131, P329, DOI 10.1093/brain/awm272
   Kasiviswanathan R, 2010, METHODS, V51, P379, DOI 10.1016/j.ymeth.2010.02.015
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Krishnan KJ, 2008, NAT GENET, V40, P275, DOI 10.1038/ng.f.94
   Krishnan KJ, 2007, ANAL BIOCHEM, V370, P127, DOI 10.1016/j.ab.2007.06.024
   Lee YS, 2009, CELL, V139, P312, DOI 10.1016/j.cell.2009.07.050
   Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Longley MJ, 1998, BIOCHEMISTRY-US, V37, P10529, DOI 10.1021/bi980772w
   McFarland R, 2010, LANCET NEUROL, V9, P829, DOI 10.1016/S1474-4422(10)70116-2
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Stumpf JD, 2011, CELL MOL LIFE SCI, V68, P219, DOI 10.1007/s00018-010-0530-4
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   Taylor RW, 2003, J CLIN INVEST, V112, P1351, DOI 10.1172/JCI200319435
   Tyynismaa H, 2009, AM J HUM GENET, V85, P290, DOI 10.1016/j.ajhg.2009.07.009
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Walter MC, 2010, J NEUROL, V257, P1517, DOI 10.1007/s00415-010-5565-9
   Young MJ, 2011, HUM MOL GENET, V20, P3052, DOI 10.1093/hmg/ddr209
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 26
TC 21
Z9 22
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
J9 MITOCHONDRION
JI Mitochondrion
PD MAR
PY 2012
VL 12
IS 2
BP 313
EP 319
DI 10.1016/j.mito.2011.11.006
PG 7
WC Cell Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Genetics & Heredity
GA 913VX
UT WOS:000301906600018
PM 22155748
OA Green Accepted
DA 2024-11-01
ER

PT J
AU Cai, MC
   Yu, Q
   Bao, JF
AF Cai, Minchao
   Yu, Qing
   Bao, Jinfang
TI A case report of mitochondrial myopathy with membranous nephropathy
SO BMC NEPHROLOGY
LA English
DT Article
DE Mitochondrial myopathy; Membranous nephropathy; mtDNA mutation
ID DISEASE; DNA
AB Background MtDNA 3243 A > G mutation leads to mitochondrial myopathies with predominant hyperlactatemia. Given the ubiquitous nature of mitochondria, cellular dysfunction can also appear in tissues with high metabolic turnover; thus, there can be cardiac, digestive, ophthalmologic, and kidney complications. MtDNA 3243 A > G mutation has been shown to be with renal involvement in the previous cases of which are FSGS and tubularinterstitial nephritis. Case presentation We report a case of patient who had the mitochondrial myopathy with mitochondrial DNA (mtDNA) 3243 A > G mutation diagnosed membranous nephropathy by kidney biopsy, which was never reported before. Our patient was found to have chest tightness and shortness of breath with hyperlactatemia and was diagnosed mitochondrial myopathy with mtDNA 3243 A > G mutation 11 months ago. Acute kidney injury occurred with hyperuricemia (urid acid 1011umol/L) which may be associated with mtDNA mutation. Since then, persistent proteinuria was also found and the 24-h urine protein quantitative was around 2 g. Kidney biopsy was performed and the result was consistent with membranous nephropathy, with abnormal mitochondria seen in renal tubules by electron microscopy. Conclusions Patients with mitochondrial myopathy could also have renal presentation of membranous nephropathy. Patients with mtDNA mutation may have various renal manifestations so that more attention should be paid on their kidneys.
C1 [Cai, Minchao; Yu, Qing; Bao, Jinfang] Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Nephrol, 100 Haining Rd, Shanghai 200080, Peoples R China.
C3 Shanghai Jiao Tong University
RP Bao, JF (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Gen Hosp, Dept Nephrol, 100 Haining Rd, Shanghai 200080, Peoples R China.
EM bamboobao@163.com
RI Yu, Qing/KIG-5023-2024
CR Ahmed ST, 2018, NEUROTHERAPEUTICS, V15, P943, DOI 10.1007/s13311-018-00674-4
   Belostotsky R, 2011, AM J HUM GENET, V88, P193, DOI 10.1016/j.ajhg.2010.12.010
   Di Donato S, 2009, J NEUROL, V256, P693, DOI 10.1007/s00415-009-5028-3
   DICKMAN K G, 1990, American Journal of Physiology, V258, pF1608
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Emma F, 2012, PEDIATR NEPHROL, V27, P539, DOI 10.1007/s00467-011-1926-6
   Finsterer J, 2017, BIOMED REP, V6, P487, DOI 10.3892/br.2017.892
   Guéry B, 2003, J AM SOC NEPHROL, V14, P2099, DOI 10.1097/01.ASN.0000080180.51098.02
   Hirano M, 2002, INTERNAL MED, V41, P113, DOI 10.2169/internalmedicine.41.113
   Hotta O, 2001, KIDNEY INT, V59, P1236, DOI 10.1046/j.1523-1755.2001.0590041236.x
   Kawamoto T, 2011, LIPIDS HEALTH DIS, V10, DOI 10.1186/1476-511X-10-105
   Rudnicki M, 2016, AM J KIDNEY DIS, V68, P949, DOI 10.1053/j.ajkd.2016.06.027
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
NR 13
TC 2
Z9 4
U1 0
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2369
J9 BMC NEPHROL
JI BMC Nephrol.
PD MAR 4
PY 2022
VL 23
IS 1
AR 87
DI 10.1186/s12882-022-02710-0
PG 4
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Urology & Nephrology
GA ZN0OM
UT WOS:000764744700004
PM 35246049
OA Green Published, gold
DA 2024-11-01
ER

PT J
AU Bannwarth, S
   Berg-Alonso, L
   Augé, G
   Fragaki, K
   Kolesar, JE
   Lespinasse, F
   Lacas-Gervais, S
   Burel-Vandenbos, F
   Villa, E
   Belmonte, F
   Michiels, JF
   Ricci, JE
   Gherardi, R
   Harrington, L
   Kaufman, BA
   Paquis-Flucklinger, V
AF Bannwarth, Sylvie
   Berg-Alonso, Laetitia
   Auge, Gaelle
   Fragaki, Konstantina
   Kolesar, Jill E.
   Lespinasse, Francoise
   Lacas-Gervais, Sandra
   Burel-Vandenbos, Fanny
   Villa, Elodie
   Belmonte, Frances
   Michiels, Jean-Francois
   Ricci, Jean-Ehrland
   Gherardi, Romain
   Harrington, Lea
   Kaufman, Brett A.
   Paquis-Flucklinger, Veronique
TI Inactivation of Pill helicase causes a mitochondrial myopathy in mice
SO MITOCHONDRION
LA English
DT Article
DE PIA helicase; mtDNA instability; Mitochondrial myopathy; Mitochondrial
   disease
ID HUMAN PIF1 HELICASE; MTDNA MUTATOR MICE; COMPLEX I DEFECT;
   DNA-REPLICATION; SACCHAROMYCES-CEREVISIAE; OXIDATIVE DAMAGE; TELOMERASE;
   PROTEIN; INSTABILITY; NUCLEAR
AB Mutations in genes coding for mitochondrial helicases such as TWINKLE and DNA2 are involved in mitochondrial myopathies with mtDNA instability in both human and mouse. We show that inactivation of Pti1, a third member of the mitochondrial helicase family, causes a similar phenotype in mouse. pif1 -/- animals develop a mitochondria] myopathy with respiratory chain deficiency. Pif1 inactivation is responsible for a deficiency to repair oxidative stress-induced mtDNA damage in mouse embryonic fibroblasts that is improved by complementation with mitochondrial isoform mPif1(67). These results open new perspectives for the exploration of patients with mtDNA instability disorders. (C) 2016 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 [Bannwarth, Sylvie; Berg-Alonso, Laetitia; Auge, Gaelle; Fragaki, Konstantina; Lespinasse, Francoise; Paquis-Flucklinger, Veronique] UNS, IRCAN, CNRS, UMR 7284,INSERM,U1081,Fac Med, Nice, France.
   [Bannwarth, Sylvie; Auge, Gaelle; Fragaki, Konstantina; Paquis-Flucklinger, Veronique] CHU Nice, Serv Genet Med, Hop Archet 2, Nice, France.
   [Kolesar, Jill E.; Belmonte, Frances; Kaufman, Brett A.] Univ Pittsburgh, Dept Med, Ctr Metab & Mitochondrial Med, Pittsburgh, PA USA.
   [Lacas-Gervais, Sandra] Univ Nice Sophia Antipolis, Ctr Commun Microscopie Elect Appl, Fac Sci, Nice, France.
   [Burel-Vandenbos, Fanny; Michiels, Jean-Francois] CHU Nice, Serv Neuropathol, Hop Pasteur, F-06202 Nice, France.
   [Villa, Elodie; Ricci, Jean-Ehrland] Univ Nice Sophia Antipolis, INSERM, U1065, C3M,Equipe Controle Metabol Morts Cellulaires, Nice, France.
   [Gherardi, Romain] Univ Paris Est, INSERM, U955, E10, Creteil, France.
   [Harrington, Lea] Univ Montreal, Inst Rech Immunol & Cancerol, 2950 Chemin Polytech, Montreal, PQ H3T 1J4, Canada.
C3 Centre National de la Recherche Scientifique (CNRS); CNRS - National
   Institute for Biology (INSB); CHU Nice; Institut National de la Sante et
   de la Recherche Medicale (Inserm); Universite Cote d'Azur; CHU Nice;
   Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Universite Cote d'Azur; CHU Nice; Universite Cote d'Azur;
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Universite de Montreal
RP Paquis-Flucklinger, V (corresponding author), UNS, IRCAN, UMR7284, Sch Med,INSERM, 28 Ave Valombrose, F-06107 Nice, France.
EM paquis@hermes.unice.fr
RI Kolesar, Jill/AAA-9727-2020; RICCI, Jean-Ehrland/I-7117-2016
OI LESPINASSE, francoise/0000-0001-7710-0649; RICCI,
   Jean-Ehrland/0000-0003-1585-8117
FU Fondation pour la Recherche Medicale (FRM) [DPM20121125552]; Association
   Francaise contre les Myopathies [AFM-16248];  [R01GM110424]
FX We thank Charlotte Cochaud and Sandra Foustoul for technical help. We
   thank the Animal Facility of IRCAN and the Pasteur-IRCAN Cellular and
   Molecular Imaging platform (PICMI). V.P-F was supported by the Fondation
   pour la Recherche Medicale (FRM - DPM20121125552) and the Association
   Francaise contre les Myopathies (AFM-16248); BAK and FRB were supported
   by grant R01GM110424.
CR Arenas J, 1998, ANN NEUROL, V43, P397, DOI 10.1002/ana.410430321
   Bannwarth S, 2005, HUM MUTAT, V25, P575, DOI 10.1002/humu.20177
   Bannwarth S, 2012, MITOCHONDRION, V12, P654, DOI 10.1016/j.mito.2012.07.111
   Bochman ML, 2010, DNA REPAIR, V9, P237, DOI 10.1016/j.dnarep.2010.01.008
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Budd ME, 2006, MOL CELL BIOL, V26, P2490, DOI 10.1128/MCB.26.7.2490-2500.2006
   Copeland WC, 2008, ANNU REV MED, V59, P131, DOI 10.1146/annurev.med.59.053006.104646
   De Bono JP, 2006, AM J PHYSIOL-REG I, V290, pR926, DOI 10.1152/ajpregu.00694.2005
   de Souza-Pinto NC, 2010, MECH AGEING DEV, V131, P503, DOI 10.1016/j.mad.2010.04.009
   Ding L, 2015, INT J MOL SCI, V16, P10870, DOI 10.3390/ijms160510870
   Doudican NA, 2005, MOL CELL BIOL, V25, P5196, DOI 10.1128/MCB.25.12.5196-5204.2005
   Duxin JP, 2009, MOL CELL BIOL, V29, P4274, DOI 10.1128/MCB.01834-08
   Edgar D, 2009, CELL METAB, V10, P131, DOI 10.1016/j.cmet.2009.06.010
   FOURY F, 1983, P NATL ACAD SCI-BIOL, V80, P5345, DOI 10.1073/pnas.80.17.5345
   Furda AM, 2012, DNA REPAIR, V11, P684, DOI 10.1016/j.dnarep.2012.06.002
   Futami K, 2007, BIOL PHARM BULL, V30, P1685, DOI 10.1248/bpb.30.1685
   George T, 2009, NUCLEIC ACIDS RES, V37, P6491, DOI 10.1093/nar/gkp671
   Hakonen AH, 2008, HUM MOL GENET, V17, P3822, DOI 10.1093/hmg/ddn280
   Kazak L, 2013, NUCLEIC ACIDS RES, V41, P2354, DOI 10.1093/nar/gks1347
   Kolesar JE, 2014, FREE RADICAL BIO MED, V75, P241, DOI 10.1016/j.freeradbiomed.2014.07.038
   Kolesar JE, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gks1324
   Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257
   LAHAYE A, 1993, J BIOL CHEM, V268, P26155
   LeDoux SP, 1999, MUTAT RES-DNA REPAIR, V434, P149, DOI 10.1016/S0921-8777(99)00026-9
   Li JR, 2014, NUCLEIC ACIDS RES, V42, P8527, DOI 10.1093/nar/gku541
   Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063
   Neyton S, 2004, MOL HUM REPROD, V10, P917, DOI 10.1093/molehr/gah123
   Paeschke K, 2013, NATURE, V497, P458, DOI 10.1038/nature12149
   Ronchi D, 2013, AM J HUM GENET, V92, P293, DOI 10.1016/j.ajhg.2012.12.014
   Rothfuss O, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkp1082
   Rouzier C, 2012, BRAIN, V135, P23, DOI 10.1093/brain/awr323
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   Sahin E, 2011, NATURE, V470, P359, DOI 10.1038/nature09787
   Sanders CM, 2010, BIOCHEM J, V430, P119, DOI 10.1042/BJ20100612
   Sawyer DE, 1999, MUTAT RES-DNA REPAIR, V434, P161, DOI 10.1016/S0921-8777(99)00027-0
   SCHULZ VP, 1994, CELL, V76, P145, DOI 10.1016/0092-8674(94)90179-1
   SHULL S, 1991, J BIOL CHEM, V266, P24398
   Snow BE, 2007, MOL CELL BIOL, V27, P1017, DOI 10.1128/MCB.01866-06
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
   Tyynismaa H, 2004, HUM MOL GENET, V13, P3219, DOI 10.1093/hmg/ddh342
   Wilson MA, 2013, NATURE, V502, P393, DOI 10.1038/nature12585
   Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514
   Zhang DH, 2006, NUCLEIC ACIDS RES, V34, P1393, DOI 10.1093/nar/gkl029
   Zheng L, 2008, MOL CELL, V32, P325, DOI 10.1016/j.molcel.2008.09.024
   Zhou JQ, 2000, SCIENCE, V289, P771, DOI 10.1126/science.289.5480.771
NR 46
TC 27
Z9 31
U1 0
U2 8
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 1872-8278
J9 MITOCHONDRION
JI Mitochondrion
PD SEP
PY 2016
VL 30
BP 126
EP 137
DI 10.1016/j.mito.2016.02.005
PG 12
WC Cell Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Genetics & Heredity
GA DX0FN
UT WOS:000384037300014
PM 26923168
OA Green Accepted
DA 2024-11-01
ER

PT J
AU Wortmann, SB
   Rodenburg, RJ
   Backx, AP
   Schmitt, E
   Smeitink, JAM
   Morava, E
AF Wortmann, S. B.
   Rodenburg, R. J.
   Backx, A. P.
   Schmitt, E.
   Smeitink, J. A. M.
   Morava, E.
TI Early cardiac involvement in children carrying the A3243G mtDNA mutation
SO ACTA PAEDIATRICA
LA English
DT Article
DE mitochondrial cardiomyopathy; mitochondrial diseases; mitochondrial DNA
ID MITOCHONDRIAL-DNA; ENCEPHALOMYOPATHY; CARDIOMYOPATHY
AB The phenotypic spectrum of the mitochondrial A3243G DKA mutation is highly variable, particularly when occuring in childhood. In contrast to the classical presentation in adulthood (MELAS syndrome; mitochondria! myopathy, encephalopathy, lactic acidosis and stroke-like episodes) children show a different pattern of symptoms, often without the typical encephalopathy or psychomotor regression. We present six children carrying the A3243G mtDNA mutation with a heteroplasmy above 50 % in muscle tissue. The age of diagnosis ranged from 2 weeks up to 14.5 years. The clinical presentation was rather non-specific including muscle weakness, developmental delay and epilepsy. In this small pediatric group we detected presymptomatic cardiac involvement in five out of six children already at an early stage of disease. The cardiac pathology included cardiomyopathy and biventricular hypertrophy with rhythm disturbances (for example long QT-syndrome). The observed cardiac changes do not always increase the risk of cardiac deterioration; however, two of our patients died early on.
   Conclusion: We hypothesize that the A3243G mutation might be underdiagnosed, as patients could suffer from an unexplained cardiac death before the diagnosis is made. We advise performing regular repeated ECGs and echocardiography in all children carrying a A3243G mtDNA mutation independently from the presence of cardiac symptoms.
C1 Radboud Univ Nijmegen, Nijmegen Med Ctr, Dept Pediat, Nijmegen Ctr Mitochondrial Disorders, NL-6500 HB Nijmegen, Netherlands.
   Radboud Univ Nijmegen, Nijmegen Med Ctr, Lab Pediat & Neurol, Nijmegen Ctr Mitochondrial Disorders, NL-6500 HB Nijmegen, Netherlands.
   Katholisches Klinikum, Dept Neurol, Koblenz, Germany.
C3 Radboud University Nijmegen; Radboud University Nijmegen
RP Morava, E (corresponding author), Radboud Univ Nijmegen, Nijmegen Med Ctr, Dept Pediat, Nijmegen Ctr Mitochondrial Disorders, POB 9101, NL-6500 HB Nijmegen, Netherlands.
EM E.Morava@cukz.umcn.nl
RI Wortmann, Saskia/E-6125-2010; Morava, E./L-4529-2015; Smeitink,
   Jan/C-1351-2013; Rodenburg, Richard/N-3579-2014
OI Rodenburg, Richard/0000-0001-5227-3527
CR Janssen AJM, 2006, CLIN CHEM, V52, P860, DOI 10.1373/clinchem.2005.062414
   Kärppä M, 2005, BRAIN, V128, P1861, DOI 10.1093/brain/awh515
   Kovalenko SA, 1996, BIOCHEM BIOPH RES CO, V222, P201, DOI 10.1006/bbrc.1996.0722
   Lev D, 2004, PEDIATR CARDIOL, V25, P443, DOI 10.1007/s00246-003-0490-7
   MANOUVRIER S, 1995, J MED GENET, V32, P654, DOI 10.1136/jmg.32.8.654
   Okajima Y, 1998, HEART, V80, P292, DOI 10.1136/hrt.80.3.292
   Okhuijsen-Kroes EJ, 2001, NEUROPEDIATRICS, V32, P183, DOI 10.1055/s-2001-17372
NR 7
TC 18
Z9 18
U1 0
U2 1
PU BLACKWELL PUBLISHING
PI OXFORD
PA 9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND
SN 0803-5253
J9 ACTA PAEDIATR
JI Acta Paediatr.
PD MAR
PY 2007
VL 96
IS 3
BP 450
EP 452
DI 10.1111/j.1651-2227.2006.00158.x
PG 3
WC Pediatrics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pediatrics
GA 143JG
UT WOS:000244716300029
PM 17407476
DA 2024-11-01
ER

PT J
AU Horvath, R
   Hudson, G
   Ferrari, G
   Fütterer, N
   Ahola, S
   Lamantea, E
   Prokisch, H
   Lochmüller, H
   McFarland, R
   Ramesh, V
   Klopstock, T
   Freisinger, P
   Salvi, F
   Mayr, JA
   Santer, R
   Tesarova, M
   Zeman, J
   Udd, B
   Taylor, RW
   Turnbull, D
   Hanna, M
   Fialho, D
   Suomalainen, A
   Zeviani, M
   Chinnery, PF
AF Horvath, Rita
   Hudson, Gavin
   Ferrari, Gianfrancesco
   Fuetterer, Nancy
   Ahola, Sofia
   Lamantea, Eleonora
   Prokisch, Holger
   Lochmueller, Hanns
   McFarland, Robert
   Ramesh, V.
   Klopstock, Thomas
   Freisinger, Peter
   Salvi, Fabrizio
   Mayr, Johannes A.
   Santer, Rene
   Tesarova, Marketa
   Zeman, Jiri
   Udd, Bjarne
   Taylor, Robert W.
   Turnbull, Douglass
   Hanna, Michael
   Fialho, Doreen
   Suomalainen, Anu
   Zeviani, Massimo
   Chinnery, Patrick F.
TI Phenotypic spectrum associated with mutations of the mitochondrial
   polymerase γ gene
SO BRAIN
LA English
DT Article
DE mitochondrial encephalopathy; mitochondrial DNA; polymerase gamma;
   mtDNA; chronic progressive external ophthalmoplegia; Alpers syndrome
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; POLG MUTATIONS; DNA-POLYMERASE;
   ALPERS-SYNDROME; ATAXIC NEUROPATHY; DELETIONS; EXPRESSION; PATIENT;
   FAMILY; MUSCLE
AB Mutations in the gene coding for the catalytic subunit of the mitochondrial DNA (mtDNA) polymerase gamma (POLG1) have recently been described in patients with diverse clinical presentations, revealing a complex relationship between genotype and phenotype in patients and their families. POLG1 was sequenced in patients from different European diagnostic and research centres to define the phenotypic spectrum and advance understanding of the recurrence risks. Mutations were identified in 38 cases, with the majority being sporadic compound heterozygotes. Eighty-nine DNA sequence changes were identified, including 2 predicted to alter a splice site, 1 predicted to cause a premature stop codon and 13 predicted to cause novel amino acid substitutions. The majority of children had a mutation in the linker region, often 1399G -> A (A467T), and a mutation affecting the polymerase domain. Others had mutations throughout the gene, and 11 had 3 or more substitutions. The clinical presentation ranged from the neonatal period to late adult life, with an overlapping phenotypic spectrum from severe encephalopathy and liver failure to late-onset external ophthalmoplegia, ataxia, myopathy and isolated muscle pain or epilepsy. There was a strong gender bias in children, with evidence of an environmental interaction with sodium valproate. POLG1 mutations cause an overlapping clinical spectrum of disease with both dominant and recessive modes of inheritance. 1399G -> A (A467T) is common in children, but complete POLG1 sequencing is required to identify multiple mutations that can have complex implications for genetic counselling.
C1 Acad Hosp Schwabing, Inst Clin CHem Mol Diagnost & Mitochondrial Genet, Metab Dis Ctr, Munich, Germany.
   Childrens Hosp, Matab Dis Ctr, Munich, Germany.
   Tech Univ Munich, Inst Med Genet, D-8000 Munich, Germany.
   Univ Munich, Friedrich Baur Inst, Munich, Germany.
   Univ Munich, Dept Neurol, Munich, Germany.
   GSF, Res Ctr Environm & Hlth, Inst Human Genet, Neuherberg, Germany.
   Univ Hamburg, Med Ctr Eppendorf, Dept Pediat, Hamburg, Germany.
   Newcastle Univ, Mitochondrial Res Grp, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
   Newcastle Univ, Inst Human Genet, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
   Newcastle Gen Hosp, Dept Paediat Neurol, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England.
   UCL, Inst Neurol, Dept Mol Neurosci, London, England.
   Natl Neurol Inst, Pierfranco & Luisa Mariani Ctr Study Childrens Mi, Unit Mol Neurogenet, Milan, Italy.
   Osped Bellaria, Dept Neurosci, Neurol Unit, Bologna, Italy.
   Univ Helsinki, Dept Med Genet, Programme Neurosci, FIN-00014 Helsinki, Finland.
   Vaasa Cent Hosp, Dept Neurol, Vaasa, Finland.
   Paracelsus Med Univ, Pediat Clin, Salzburg, Austria.
   Charles Univ Prague, Fac Med, Dept Pediat, Prague, Czech Republic.
   Charles Univ Prague, Fac Med, Ctr Appl Genom, Prague, Czech Republic.
C3 University of Munich; Technical University of Munich; University of
   Munich; University of Munich; Helmholtz Association; Helmholtz-Center
   Munich - German Research Center for Environmental Health; University of
   Hamburg; Newcastle University - UK; Newcastle University - UK; Newcastle
   General Hospital; University of London; University College London;
   Fondazione IRCCS Istituto Neurologico Carlo Besta; University of
   Helsinki; Vaasa Central Hospital; Paracelsus Private Medical University;
   Charles University Prague; Charles University Prague
RP Chinnery, PF (corresponding author), Sch Med, M4014,Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM P.F.Chinnery@ncl.ac.uk
RI Freisinger, Peter/F-2325-2015; Zeviani, Massimo/K-2891-2014; Salvi,
   Fabrizio/AAC-1956-2020; Horvath, Rita/AAY-7042-2020; Ahola,
   Sofia/JEP-4595-2023; Hanna, Michael/B-1995-2009; Hudson,
   Gavin/E-7117-2017; Udd, Bjarne/JBE-3483-2023; Prokisch,
   Holger/N-8964-2013; Lamantea, Eleonora/J-8339-2016; Tesarova,
   Marketa/I-1531-2016; Zeman, Jiri/K-2691-2017
OI Mayr, Johannes/0000-0001-6970-336X; Horvath, Rita/0000-0002-9841-170X;
   Chinnery, Patrick/0000-0002-7065-6617; Lamantea,
   Eleonora/0000-0001-5090-6028; Tesarova, Marketa/0000-0002-5141-2289;
   Zeman, Jiri/0000-0002-2678-7919; Hudson, Gavin/0000-0001-7210-2733;
   Zeviani, Massimo/0000-0002-9067-5508; Ferrari,
   Giovanfrancesco/0000-0001-8864-0771; McFarland,
   Robert/0000-0002-8833-2688; Ahola, Sofia/0000-0001-7552-4843;
   Suomalainen-Wartiovaara, Anu/0000-0003-4833-5195; Hanna,
   Michael/0000-0003-0825-4075; Prokisch, Holger/0000-0003-2379-6286;
   Lochmuller, Hanns/0000-0003-2324-8001; Fialho,
   Doreen/0000-0001-7161-6185
FU Medical Research Council [G108/539] Funding Source: Medline; Telethon
   [GGP030039] Funding Source: Medline; Wellcome Trust Funding Source:
   Medline; MRC [G108/539] Funding Source: UKRI
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   [Anonymous], 2002, Statistical Methods in Medical Research
   Brierley EJ, 1998, ANN NEUROL, V43, P217, DOI 10.1002/ana.410430212
   Carelli V, 2003, TRENDS GENET, V19, P257, DOI 10.1016/S0168-9525(03)00072-6
   Chan SSL, 2005, DNA REPAIR, V4, P1381, DOI 10.1016/j.dnarep.2005.08.010
   Chan SSL, 2005, J BIOL CHEM, V280, P31341, DOI 10.1074/jbc.M506762200
   CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   Del Bo R, 2003, NEUROLOGY, V61, P903, DOI 10.1212/01.WNL.0000092303.13864.BE
   Di Fonzo A, 2003, HUM MUTAT, V22, DOI 10.1002/humu.9203
   Fadic R, 1997, NEUROLOGY, V49, P239, DOI 10.1212/WNL.49.1.239
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   González-Vioque E, 2006, ARCH NEUROL-CHICAGO, V63, P107, DOI 10.1001/archneur.63.1.107
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   He LP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf067
   Hisama FM, 2005, AM J MED GENET A, V135A, P217, DOI 10.1002/ajmg.a.30672
   Hudson G, 2005, AM J HUM GENET, V77, P1086, DOI 10.1086/498176
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   Lamantea E, 2004, ANN NEUROL, V56, P454, DOI 10.1002/ana.20219
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Luoma PT, 2005, HUM MOL GENET, V14, P1907, DOI 10.1093/hmg/ddi196
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nguyen KV, 2005, NEUROLOGY, V65, P1493, DOI 10.1212/01.wnl.0000182814.55361.70
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, HUM MUTAT, V22, P175, DOI 10.1002/humu.10246
   Van Goethem G, 2003, EUR J HUM GENET, V11, P547, DOI 10.1038/sj.ejhg.5201002
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
NR 31
TC 308
Z9 320
U1 0
U2 33
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
J9 BRAIN
JI Brain
PD JUL
PY 2006
VL 129
BP 1674
EP 1684
DI 10.1093/brain/awl088
PN 7
PG 11
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 059VV
UT WOS:000238761200011
PM 16621917
DA 2024-11-01
ER

PT J
AU Montano, V
   Gruosso, F
   Simoncini, C
   Siciliano, G
   Mancuso, M
AF Montano, V
   Gruosso, F.
   Simoncini, C.
   Siciliano, G.
   Mancuso, M.
TI Clinical features of mtDNA-related syndromes in adulthood
SO ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
LA English
DT Article
DE Mitochondrial disorders; MELAS; MERRF; Primary mitochondrial myopathy
ID HEREDITARY OPTIC NEUROPATHY; MITOCHONDRIAL-DNA MUTATIONS; PROGRESSIVE
   EXTERNAL OPHTHALMOPLEGIA; RESPIRATORY-CHAIN DISORDERS; LARGE-SCALE
   DELETIONS; MOLECULAR DIAGNOSIS; REPLACEMENT THERAPY; CONSENSUS
   STATEMENT; MYOCLONIC EPILEPSY; GENE-THERAPY
AB Mitochondrial diseases are the most common inheritable metabolic diseases, due to defects in oxidative phosphorylation. They are caused by mutations of nuclear or mitochondrial DNA in genes involved in mitochondrial function. The peculiarity of "mitochondrial DNA genetics rules" in part explains the marked phenotypic variability, the complexity of genotype-phenotype correlations and the challenge of genetic counseling. The new massive genetic sequencing technologies have changed the diagnostic approach, enhancing mitochondrial DNA-related syndromes diagnosis and often avoiding the need of a tissue biopsy.
   Here we present the most common phenotypes associated with a mitochondrial DNA mutation with the recent advances in diagnosis and in therapeutic perspectives.
C1 [Montano, V; Gruosso, F.; Simoncini, C.; Siciliano, G.; Mancuso, M.] Univ Pisa, Dept Clin & Expt Med, Neurol Clin, Pisa, Italy.
C3 University of Pisa
RP Mancuso, M (corresponding author), Univ Pisa, Dept Clin & Expt Med, Neurol Inst, Pisa, Italy.
EM michelangelo.mancuso@unipi.it
RI Montano, Vincenzo/AAB-8681-2022
OI Montano, Vincenzo/0000-0002-7548-7699; Gruosso,
   Francesco/0000-0001-5277-3548
FU Telethon Grant [GUP09004]; Telethon-MITOCON grant [GSP16001,
   RF-2016-02361495]; EJPRD2019 project GENOMIT
FX This work was partially supported by Telethon Grant GUP09004,
   Telethon-MITOCON grant GSP16001, RF-2016-02361495 and the EJPRD2019
   project GENOMIT
CR Abbott JA, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00158
   Abicht A, 2018, MOL GENET GENOM MED, V6, P1188, DOI 10.1002/mgg3.500
   Alston CL, 2017, J PATHOL, V241, P236, DOI 10.1002/path.4809
   Altmann J, 2016, J NEUROL, V263, P961, DOI 10.1007/s00415-016-8086-3
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   Bacman SR, 2020, METHOD CELL BIOL, V155, P441, DOI 10.1016/bs.mcb.2019.12.004
   Bannwarth S, 2013, J MED GENET, V50, P704, DOI 10.1136/jmedgenet-2013-101604
   Barros MH, 2020, MITOCHONDRION, V50, P94, DOI 10.1016/j.mito.2019.10.008
   Berardo A, 2020, J NEUROL, V267, P823, DOI 10.1007/s00415-019-09619-z
   Berardo A, 2010, CURR NEUROL NEUROSCI, V10, P118, DOI 10.1007/s11910-010-0096-4
   Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   Blakely EL, 2014, NEUROMUSCULAR DISORD, V24, P533, DOI 10.1016/j.nmd.2014.03.011
   Bosworth CM, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1821-7
   Brailova M, 2020, J CLIN MED, V9, DOI 10.3390/jcm9030694
   Bris C, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00632
   Calabrese C, 2014, BIOINFORMATICS, V30, P3115, DOI 10.1093/bioinformatics/btu483
   Calvo SE, 2016, NUCLEIC ACIDS RES, V44, pD1251, DOI 10.1093/nar/gkv1003
   Carelli V, 2002, ARCH NEUROL-CHICAGO, V59, P264, DOI 10.1001/archneur.59.2.264
   Carelli V, 2017, J NEURO-OPHTHALMOL, V37, P371, DOI 10.1097/WNO.0000000000000570
   Carelli V, 2016, BRAIN, V139, DOI 10.1093/brain/awv339
   Castellana S, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005628
   CHARLES R, 1981, CIRCULATION, V63, P214, DOI 10.1161/01.CIR.63.1.214
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   Chinnery PF, 2004, LANCET, V364, P592, DOI 10.1016/S0140-6736(04)16851-7
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   Ciron J, 2018, J NEUROL SCI, V388, P94, DOI 10.1016/j.jns.2018.03.002
   Craven L, 2017, ANNU REV GENOM HUM G, V18, P257, DOI 10.1146/annurev-genom-091416-035426
   Cui H, 2013, GENET MED, V15, P388, DOI 10.1038/gim.2012.144
   Cummings BB, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal5209
   Davis Ryan L, 2018, Handb Clin Neurol, V147, P125, DOI 10.1016/B978-0-444-63233-3.00010-5
   Davis RL, 2016, NEUROLOGY, V86, P2010, DOI 10.1212/WNL.0000000000002705
   de Laat P, 2016, BBA CLIN, V6, P19, DOI 10.1016/j.bbacli.2016.04.007
   De Vries MC, 2020, J INHERIT METAB DIS, V43, P800, DOI 10.1002/jimd.12196
   Debray FG, 2007, CLIN CHEM, V53, P916, DOI 10.1373/clinchem.2006.081166
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   DiMauro S, 2004, BBA-BIOENERGETICS, V1658, P80, DOI 10.1016/j.bbabio.2004.03.014
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   DiMauro S, 2013, NAT REV NEUROL, V9, P429, DOI 10.1038/nrneurol.2013.126
   DiMauro S, 2011, J INHERIT METAB DIS, V34, P261, DOI 10.1007/s10545-010-9082-x
   El-Hattab AW, 2015, MOL GENET METAB, V116, P4, DOI 10.1016/j.ymgme.2015.06.004
   Esterhuizen K, 2017, MITOCHONDRION, V35, P97, DOI 10.1016/j.mito.2017.05.012
   Filosto M, 2007, ACTA NEUROL SCAND, V115, P211, DOI 10.1111/j.1600-0404.2006.00777.x
   Friedman JR, 2014, NATURE, V505, P335, DOI 10.1038/nature12985
   Gagliardi D, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00038
   Gammage PA, 2018, NAT MED, V24, P1691, DOI 10.1038/s41591-018-0165-9
   Gelfand JM, 2011, J NEUROL, V258, P440, DOI 10.1007/s00415-010-5775-1
   GILES RE, 1980, P NATL ACAD SCI-BIOL, V77, P6715, DOI 10.1073/pnas.77.11.6715
   Giordano C, 2011, BRAIN, V134, P220, DOI 10.1093/brain/awq276
   Goldstein A., 2003, GeneReviews, P1993
   González MD, 2020, MITOCHONDRION, V50, P88, DOI 10.1016/j.mito.2019.10.006
   Gorman GS, 2016, NAT REV DIS PRIMERS, V2, P1, DOI 10.1038/nrdp.2016.80
   Gorman GS, 2015, ANN NEUROL, V77, P753, DOI 10.1002/ana.24362
   Grady JP, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708262
   Grady JP, 2014, BRAIN, V137, P323, DOI 10.1093/brain/awt321
   Gropman AL, 2013, NEUROTHERAPEUTICS, V10, P273, DOI 10.1007/s13311-012-0161-6
   Guy J, 2017, OPHTHALMOLOGY, V124, P1621, DOI 10.1016/j.ophtha.2017.05.016
   HAMMANS SR, 1993, BRAIN, V116, P617, DOI 10.1093/brain/116.3.617
   Hedermann G, 2017, MITOCHONDRION, V32, P27, DOI 10.1016/j.mito.2016.11.007
   Heighton JN, 2019, MITOCHONDRION, V44, P15, DOI 10.1016/j.mito.2017.12.006
   HIRANO M, 1994, J CHILD NEUROL, V9, P4, DOI 10.1177/088307389400900102
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   HOWELL N, 1991, AM J HUM GENET, V48, P935
   Hwang TJ, 2017, OPHTHALMOLOGY, V124, P843, DOI 10.1016/j.ophtha.2017.01.002
   Ikawa M, 2020, CURR OPIN CLIN NUTR, V23, P17, DOI 10.1097/MCO.0000000000000610
   Kawamura E, 2020, MOL THER-NUCL ACIDS, V20, P687, DOI 10.1016/j.omtn.2020.04.004
   Khan NA, 2014, EMBO MOL MED, V6, P721, DOI 10.1002/emmm.201403943
   Klopstock T, 2011, BRAIN, V134, P2677, DOI 10.1093/brain/awr170
   Koga Y, 2018, J NEUROL, V265, P2861, DOI 10.1007/s00415-018-9057-7
   Konovalova S, 2019, JOVE-J VIS EXP, DOI 10.3791/59269
   Kraya T, 2019, MITOCHONDRION, V44, P53, DOI 10.1016/j.mito.2017.12.012
   Kremer LS, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15824
   Kutik S, 2009, BBA-GEN SUBJECTS, V1790, P409, DOI 10.1016/j.bbagen.2009.04.004
   La Morgia C, 2008, NEUROLOGY, V70, P762, DOI 10.1212/01.wnl.0000295505.74234.d0
   Lim A, 2020, EUR J PAEDIATR NEURO, V24, P47, DOI 10.1016/j.ejpn.2019.12.021
   López-Gallardo E, 2009, MITOCHONDRION, V9, P314, DOI 10.1016/j.mito.2009.04.005
   Lott MT., 2013, Curr Protoc Bioinf, V44, P1231, DOI DOI 10.1002/0471250953.BI0123S44
   LUFT R, 1962, J CLIN INVEST, V41, P1776, DOI 10.1172/JCI104637
   Man CYW, 2006, EYE, V20, P564, DOI 10.1038/sj.eye.6701924
   Mancuso M, 2009, CURR MOL MED, V9, P1095, DOI 10.2174/156652409789839099
   Mancuso M, 2017, NEUROMUSCULAR DISORD, V27, P1126, DOI 10.1016/j.nmd.2017.08.006
   Mancuso M, 2015, J NEUROL, V262, P1301, DOI 10.1007/s00415-015-7710-y
   Mancuso M, 2013, NEUROLOGY, V80, P2049, DOI 10.1212/WNL.0b013e318294b44c
   Margolin E., 2020, STATPEARLS
   McClelland C, 2016, CURR NEUROL NEUROSCI, V16, DOI 10.1007/s11910-016-0652-7
   McCormick EM, 2018, CURR OPIN PEDIATR, V30, P714, DOI 10.1097/MOP.0000000000000686
   MEIRE F, 1985, OPHTHALMIC PAED GEN, V5, P91, DOI 10.3109/13816818509007861
   Mejia-Vergara AJ, 2020, CURR NEUROL NEUROSCI, V20, DOI 10.1007/s11910-020-01032-8
   Meyerspeer M, 2021, NMR BIOMED, V34, DOI 10.1002/nbm.4246
   Moggio Maurizio, 2014, Acta Myol, V33, P86
   Mok BY, 2020, NATURE, V583, P631, DOI 10.1038/s41586-020-2477-4
   Scholle LM, 2020, GENES-BASEL, V11, DOI 10.3390/genes11020212
   MULLIE MA, 1985, ARCH OPHTHALMOL-CHIC, V103, P1825, DOI 10.1001/archopht.1985.01050120059020
   Murphy R, 2008, DIABETIC MED, V25, P383, DOI 10.1111/j.1464-5491.2008.02359.x
   Musumeci O, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00160
   Nesbitt V, 2014, EUR J HUM GENET, V22, P1255, DOI 10.1038/ejhg.2014.35
   Ng Yi Shiau, 2019, Wellcome Open Res, V4, P201, DOI 10.12688/wellcomeopenres.15599.1
   Niedermayr K, 2018, CONGENIT HEART DIS, V13, P671, DOI 10.1111/chd.12634
   Niroula A, 2016, NUCLEIC ACIDS RES, V44, P2020, DOI 10.1093/nar/gkw046
   Niu FN, 2017, CNS NEUROSCI THER, V23, P686, DOI 10.1111/cns.12714
   Ohtake A, 2014, BBA-GEN SUBJECTS, V1840, P1355, DOI 10.1016/j.bbagen.2014.01.025
   Oldfors A, 2006, NEUROLOGY, V66, pS49, DOI 10.1212/01.wnl.0000192127.63013.8d
   Orsucci D, 2014, CURR MOL MED, V14, P598, DOI 10.2174/1566524014666140603100131
   Oyama M, 2020, BMC NEUROL, V20, DOI 10.1186/s12883-020-01748-7
   Parikh S, 2019, J MED GENET, V56, P123, DOI 10.1136/jmedgenet-2018-105800
   Parikh S, 2017, GENET MED, V19, DOI 10.1038/gim.2017.107
   Parikh S, 2015, GENET MED, V17, P689, DOI 10.1038/gim.2014.177
   Piccoli GB, 2012, BMC NEPHROL, V13, DOI 10.1186/1471-2369-13-9
   Pirinen E, 2020, CELL METAB, V31, P1078, DOI 10.1016/j.cmet.2020.04.008
   Pitceathly RDS, 2014, CURR OPIN NEUROL, V27, P576, DOI 10.1097/WCO.0000000000000126
   POULTON J, 1989, LANCET, V1, P236
   POULTON J, 1993, HUM MOL GENET, V2, P23, DOI 10.1093/hmg/2.1.23
   Puusepp S, 2018, MOL GENET METAB REP, V15, P80, DOI 10.1016/j.ymgmr.2018.03.004
   Rahman J, 2018, LANCET, V391, P2560, DOI 10.1016/S0140-6736(18)30727-X
   Rawle MJ, 2013, CASE REP NEUROL, V5, P204, DOI 10.1159/000357518
   Reynaud-Dulaurier R, 2020, BRAIN, V143, P1686, DOI 10.1093/brain/awaa105
   Rocha MC, 2015, SCI REP-UK, V5, DOI 10.1038/srep15037
   Rodenburg RJT, 2011, J INHERIT METAB DIS, V34, P283, DOI 10.1007/s10545-010-9081-y
   Roger AJ, 2017, CURR BIOL, V27, pR1177, DOI 10.1016/j.cub.2017.09.015
   Santorelli FM, 1997, ANN NEUROL, V42, P256, DOI 10.1002/ana.410420220
   Schaefer AM, 2008, ANN NEUROL, V63, P35, DOI 10.1002/ana.21217
   Sembrano E, 1997, NEUROLOGY, V49, P1714, DOI 10.1212/WNL.49.6.1714
   Shanske S, 2002, AM J HUM GENET, V71, P679, DOI 10.1086/342482
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   Slone J, 2020, NPJ GENOM MED, V5, DOI 10.1038/s41525-020-0116-5
   Sonney S, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005867
   Stendel C, 2020, NEUROL-GENET, V6, DOI 10.1212/NXG.0000000000000393
   Stenton SL, 2020, EBIOMEDICINE, V56, DOI 10.1016/j.ebiom.2020.102784
   Stewart JB, 2015, NAT REV GENET, V16, P530, DOI 10.1038/nrg3966
   Suomalainen A, 2011, LANCET NEUROL, V10, P806, DOI 10.1016/S1474-4422(11)70155-7
   Tachibana M, 2018, REPROD MED BIOL, V17, P421, DOI 10.1002/rmb2.12230
   Taivassalo T, 2006, BRAIN, V129, P3391, DOI 10.1093/brain/awl282
   Tarnopolsky M, 2003, MUSCLE NERVE, V27, P359, DOI 10.1002/mus.10330
   Tarnopolsky MA, 2014, J CHILD NEUROL, V29, P1225, DOI 10.1177/0883073814538512
   Theunissen TEJ, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00400
   Thompson K, 2020, J INHERIT METAB DIS, V43, P36, DOI 10.1002/jimd.12104
   Ticci C, 2020, NEUROGENETICS, V21, P87, DOI 10.1007/s10048-019-00601-5
   Tinley C, 2010, STRABISMUS, V18, P41, DOI 10.3109/09273971003758388
   Vafai SB, 2012, NATURE, V491, P374, DOI 10.1038/nature11707
   van den Heuvel LP, 2004, MITOCHONDRION, V4, P395, DOI 10.1016/j.mito.2004.07.005
   Varhaug KN, 2020, ANN CLIN TRANSL NEUR, V7, P1318, DOI 10.1002/acn3.51119
   Voet NBM, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003907.pub4
   Vydt TCG, 2007, AM J CARDIOL, V99, P264, DOI 10.1016/j.amjcard.2006.07.089
   Wabbels B, 2008, OPHTHALMOLOGE, V105, P550, DOI 10.1007/s00347-007-1643-5
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   Watanabe Yuka, 2009, Brain and Nerve (Tokyo), V61, P309
   Whittaker RG, 2009, NEUROLOGY, V72, P568, DOI 10.1212/01.wnl.0000342121.91336.4d
   Whittaker RG, 2015, ANN NEUROL, V78, P949, DOI 10.1002/ana.24525
   Wong LJC, 2020, GENET MED, DOI 10.1038/s41436-019-0746-0
   Wong LJC, 2013, MITOCHONDRION, V13, P379, DOI 10.1016/j.mito.2013.02.001
   Yamashita S, 2008, J HUM GENET, V53, P598, DOI 10.1007/s10038-008-0289-8
   Yarham JW, 2011, HUM MUTAT, V32, P1319, DOI 10.1002/humu.21575
   Yu-Wai-Man P, 2010, BRAIN, V133, P771, DOI 10.1093/brain/awq007
   Yu-Wai-Man P., 2000, LEBER HEREDITARY OPT, P1993
   Zekonyte U, 2020, J INTERN MED, V287, P685, DOI 10.1111/joim.13055
   ZEVIANI M, 1990, AM J HUM GENET, V47, P904
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
   Zhao Q, 2020, MICRO NANO TECHNOL, P1, DOI 10.1016/C2017-0-02305-4
NR 159
TC 9
Z9 11
U1 1
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0003-9861
EI 1096-0384
J9 ARCH BIOCHEM BIOPHYS
JI Arch. Biochem. Biophys.
PD JAN 15
PY 2021
VL 697
AR 108689
DI 10.1016/j.abb.2020.108689
PG 13
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA PS0LF
UT WOS:000607619400004
PM 33227288
DA 2024-11-01
ER

PT J
AU Keraite, I
   Becker, P
   Canevazzi, D
   Frias-López, C
   Dabad, M
   Tonda-Hernandez, R
   Paramonov, I
   Ingham, MJ
   Brun-Heath, I
   Leno, J
   Abulí, A
   Garcia-Arumí, E
   Heath, SC
   Gut, M
   Gut, IG
AF Keraite, Ieva
   Becker, Philipp
   Canevazzi, Davide
   Frias-Lopez, Cristina
   Dabad, Marc
   Tonda-Hernandez, Raul
   Paramonov, Ida
   Ingham, Matthew John
   Brun-Heath, Isabelle
   Leno, Jordi
   Abuli, Anna
   Garcia-Arumi, Elena
   Heath, Simon Charles
   Gut, Marta
   Gut, Ivo Glynne
TI A method for multiplexed full-length single-molecule sequencing of the
   human mitochondrial genome
SO NATURE COMMUNICATIONS
LA English
DT Article
ID DROSOPHILA-MELANOGASTER; MYOCLONIC EPILEPSY; DNA MUTATIONS;
   HETEROPLASMY; NUCLEAR; ORGANIZATION; PROGRAM; MUSCLE
AB Accurate analysis of mitochondrial DNA is important for mitochondrial disease clinical research and diagnostics. Here, authors present a method using Cas9 cleavage, nanopore sequencing and a custom pipeline to identify pathogenic variants, deletions and accurately quantify heteroplasmy to below 1%.
   Methods to reconstruct the mitochondrial DNA (mtDNA) sequence using short-read sequencing come with an inherent bias due to amplification and mapping. They can fail to determine the phase of variants, to capture multiple deletions and to cover the mitochondrial genome evenly. Here we describe a method to target, multiplex and sequence at high coverage full-length human mitochondrial genomes as native single-molecules, utilizing the RNA-guided DNA endonuclease Cas9. Combining Cas9 induced breaks, that define the mtDNA beginning and end of the sequencing reads, as barcodes, we achieve high demultiplexing specificity and delineation of the full-length of the mtDNA, regardless of the structural variant pattern. The long-read sequencing data is analysed with a pipeline where our custom-developed software, baldur, efficiently detects single nucleotide heteroplasmy to below 1%, physically determines phase and can accurately disentangle complex deletions. Our workflow is a tool for studying mtDNA variation and will accelerate mitochondrial research.
C1 [Keraite, Ieva; Becker, Philipp; Canevazzi, Davide; Frias-Lopez, Cristina; Dabad, Marc; Tonda-Hernandez, Raul; Paramonov, Ida; Ingham, Matthew John; Heath, Simon Charles; Gut, Marta; Gut, Ivo Glynne] Barcelona Inst Sci & Technol BIST, Ctr Genom Regulat CRG, CNAG CRG, Barcelona, Spain.
   [Brun-Heath, Isabelle] Barcelona Inst Sci & Technol BIST, Inst Res Biomed IRB Barcelona, Barcelona, Spain.
   [Brun-Heath, Isabelle] Joint IRB BSC Program Computat Biol, Barcelona, Spain.
   [Leno, Jordi; Abuli, Anna; Garcia-Arumi, Elena] Hosp Univ Vall Hebron, Dept Clin & Mol Genet & Rare Dis, Barcelona, Spain.
   [Leno, Jordi; Abuli, Anna] Hosp Univ Vall Hebron, Med Genet Grp, VHIR, Barcelona, Spain.
   [Garcia-Arumi, Elena] Hosp Univ Vall Hebron, Res Grp Neuromuscular & Mitochondrial Disorders, VHIR, Barcelona, Spain.
   [Garcia-Arumi, Elena] Inst Salud Carlos III, Ctr Invest Biomed Red Enfermedades Raras CIBERER, Barcelona, Spain.
   [Heath, Simon Charles; Gut, Marta; Gut, Ivo Glynne] Univ Pompeu Fabra, Barcelona, Spain.
   [Becker, Philipp] Qiagen, Hilden, Germany.
C3 Barcelona Institute of Science & Technology; Pompeu Fabra University;
   Centre de Regulacio Genomica (CRG); Barcelona Institute of Science &
   Technology; Institute for Research in Biomedicine - IRB Barcelona;
   Barcelona Institute of Science & Technology; Institute for Research in
   Biomedicine - IRB Barcelona; Hospital Universitari Vall d'Hebron;
   Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron;
   Vall d'Hebron Institut de Recerca (VHIR); Autonomous University of
   Barcelona; Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut
   de Recerca (VHIR); CIBER - Centro de Investigacion Biomedica en Red;
   CIBERER; Instituto de Salud Carlos III; Pompeu Fabra University; QIAGEN
   GmbH
RP Gut, M; Gut, IG (corresponding author), Barcelona Inst Sci & Technol BIST, Ctr Genom Regulat CRG, CNAG CRG, Barcelona, Spain.; Gut, M; Gut, IG (corresponding author), Univ Pompeu Fabra, Barcelona, Spain.
EM marta.gut@cnag.crg.eu; ivo.gut@cnag.crg.eu
RI Gut, Ivo/ABF-3188-2020; Becker, Philipp/JPX-3796-2023; Tonda,
   Raul/I-1606-2015; Leno Colorado, Jordi/K-5401-2015; Brun-Heath,
   Isabelle/G-9844-2013; Dabad, Marc/M-9522-2015
OI Tonda, Raul/0000-0001-7893-2404; Keraite, Ieva/0000-0003-1974-9479; Leno
   Colorado, Jordi/0000-0001-6049-256X; Becker,
   Philipp/0000-0001-6901-6527; Brun-Heath, Isabelle/0000-0002-5828-0020;
   Dabad, Marc/0000-0002-6094-747X; Canevazzi, Davide/0000-0002-7165-1009
FU European Union [824110]; ERC Synergy project BCLL@las [810287]; Spanish
   Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias; ERDF
   funds [PI19/01772]; Spanish Ministry of Science and Innovation through
   the Instituto de Salud Carlos III; European Regional Development Fund
   (MINECO/FEDER) [BIO2015-71792-P]; Centro de Excelencia Severo Ochoa;
   Generalitat de Catalunya through the Departament de Salut, Departament
   d'Empresa i Coneixement; CERCA Programme; European Research Council
   (ERC) [810287] Funding Source: European Research Council (ERC)
FX This research has received funding from the European Union's Horizon
   2020 research and innovation programme under grant agreement No 824110 -
   EASI-Genomics (I.G.G.) and the ERC Synergy project BCLL@las under grant
   agreement No 810287 (I.G.G.). Institutional support was from the Spanish
   Instituto de Salud Carlos III, Fondo de Investigaciones Sanitarias and
   cofunded with ERDF funds (PI19/01772). We acknowledge the institutional
   support of the Spanish Ministry of Science and Innovation through the
   Instituto de Salud Carlos III and the 2014-2020 Smart Growth Operating
   Program, to the EMBL partnership and institutional co-financing with the
   European Regional Development Fund (MINECO/FEDER, BIO2015-71792-P). We
   also acknowledge the support of the Centro de Excelencia Severo Ochoa,
   and the Generalitat de Catalunya through the Departament de Salut,
   Departament d'Empresa i Coneixement and the CERCA Programme to the
   institute.
CR Albayrak L, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-3375-x
   Alkanaq AN, 2019, J HUM GENET, V64, P1107, DOI 10.1038/s10038-019-0654-9
   Allio R, 2017, MOL BIOL EVOL, V34, P2762, DOI 10.1093/molbev/msx197
   Alsemari A, 2016, CLIN CASE REP, V4, P111, DOI 10.1002/ccr3.435
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Auton A., 2015, Nature, V526, P68
   Bolger AM, 2014, BIOINFORMATICS, V30, P2114, DOI 10.1093/bioinformatics/btu170
   Bosworth CM, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1821-7
   BOULET L, 1992, AM J HUM GENET, V51, P1187
   Cingolani P, 2012, FLY, V6, P80, DOI 10.4161/fly.19695
   Cingolani Pablo, 2012, Frontiers in Genetics, V3, P35, DOI 10.3389/fgene.2012.00035
   CORMIERDAIRE V, 1994, J PEDIATR-US, V124, P63, DOI 10.1016/S0022-3476(94)70255-1
   Dayama G, 2014, NUCLEIC ACIDS RES, V42, P12640, DOI 10.1093/nar/gku1038
   Duan MQ, 2019, GENE, V699, P145, DOI 10.1016/j.gene.2019.03.016
   Duan MQ, 2018, MOLECULES, V23, DOI 10.3390/molecules23020323
   Dunn T, 2019, BIOINFORMATICS, V35, P1579, DOI 10.1093/bioinformatics/bty849
   Georgieva D, 2020, NUCLEIC ACIDS RES, V48, DOI 10.1093/nar/gkaa517
   Gilpatrick T, 2020, NAT BIOTECHNOL, V38, P433, DOI 10.1038/s41587-020-0407-5
   Goenka SD, 2022, NAT BIOTECHNOL, V40, P1035, DOI 10.1038/s41587-022-01221-5
   Gorman GS, 2015, ANN NEUROL, V77, P753, DOI 10.1002/ana.24362
   Hafford-Tear NJ, 2019, GENET MED, V21, P2092, DOI 10.1038/s41436-019-0453-x
   He YP, 2010, NATURE, V464, P610, DOI 10.1038/nature08802
   Heath S. C., 2022, GITHUB, DOI [10.5281/zenodo.6961084, DOI 10.5281/ZENODO.6961084]
   Heath S. C., 2022, GITHUB, DOI [10.5281/zenodo.6961078, DOI 10.5281/ZENODO.6961078]
   Heath S. C., 2022, METHOD MULTIPLEXED F, DOI [10.5281/zenodo.6959216, DOI 10.5281/ZENODO.6959216]
   HOLT IJ, 1989, J MED GENET, V26, P739, DOI 10.1136/jmg.26.12.739
   Jeppesen TD, 2003, ANN NEUROL, V54, P86, DOI 10.1002/ana.10594
   Kang EJ, 2016, NATURE, V540, P270, DOI 10.1038/nature20592
   Karczewski KJ, 2020, NATURE, V581, P434, DOI 10.1038/s41586-020-2308-7
   Kenneth L., 1997, STAT BIOL HLTH
   Kloss-Brandstätter A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135643
   Krzywinski M, 2009, GENOME RES, V19, P1639, DOI 10.1101/gr.092759.109
   Lanfear R, 2019, BIOINFORMATICS, V35, P523, DOI 10.1093/bioinformatics/bty654
   Lareau CA, 2021, NAT BIOTECHNOL, V39, P451, DOI 10.1038/s41587-020-0645-6
   Laricchia KM, 2022, GENOME RES, V32, P569, DOI 10.1101/gr.276013.121
   Legros F, 2004, J CELL SCI, V117, P2653, DOI 10.1242/jcs.01134
   Li H, 2011, BIOINFORMATICS, V27, P2987, DOI 10.1093/bioinformatics/btr509
   Li H, 2010, BIOINFORMATICS, V26, P589, DOI 10.1093/bioinformatics/btp698
   Li MK, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks499
   Li MK, 2010, AM J HUM GENET, V87, P237, DOI 10.1016/j.ajhg.2010.07.014
   Lott Marie T, 2013, Curr Protoc Bioinformatics, V44, DOI 10.1002/0471250953.bi0123s44
   Macken WL, 2021, NAT REV NEUROL, V17, P215, DOI 10.1038/s41582-021-00455-2
   Maeda R, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67686-z
   Maude H, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00201
   Molder Felix, 2021, F1000Res, V10, P33, DOI 10.12688/f1000research.29032.1
   Palculict ME, 2016, METHODS MOL BIOL, V1351, P3, DOI 10.1007/978-1-4939-3040-1_1
   Payne BAI, 2013, HUM MOL GENET, V22, P384, DOI 10.1093/hmg/dds435
   POULTON J, 1989, LANCET, V1, P236
   Rong EG, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/1286480
   Salas A, 2020, FORENSIC SCI INT-GEN, V47, DOI 10.1016/j.fsigen.2020.102274
   Santibanez-Koref M, 2019, MITOCHONDRION, V46, P302, DOI 10.1016/j.mito.2018.08.003
   Shafin K, 2021, NAT METHODS, V18, P1322, DOI 10.1038/s41592-021-01299-w
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   Sonney S, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005867
   Stewart JB, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005333
   Taanman JW, 1999, BBA-BIOENERGETICS, V1410, P103, DOI 10.1016/S0005-2728(98)00161-3
   Trifunov S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30143-z
   Tully LA, 2000, AM J HUM GENET, V67, P432, DOI 10.1086/302996
   Van der Verren SE, 2020, NAT BIOTECHNOL, V38, DOI 10.1038/s41587-020-0570-8
   Wei W, 2019, SCIENCE, V364, P749, DOI 10.1126/science.aau6520
   Weissensteiner H, 2021, GENOME RES, V31, P309, DOI 10.1101/gr.256545.119
   Yuan Y, 2020, NAT GENET, V52, P342, DOI 10.1038/s41588-019-0557-x
   Zhang W, 2012, CLIN CHEM, V58, P1322, DOI 10.1373/clinchem.2011.181438
   Zhou KX, 2020, J MOL DIAGN, V22, P1408, DOI 10.1016/j.jmoldx.2020.09.005
NR 64
TC 10
Z9 10
U1 0
U2 22
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD OCT 6
PY 2022
VL 13
IS 1
AR 5902
DI 10.1038/s41467-022-33530-3
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 5D0IC
UT WOS:000864633700005
PM 36202811
OA Green Published, gold, Green Submitted
DA 2024-11-01
ER

PT J
AU Diniz, G
   Yavascan, O
   Sarkis, UB
   Yildirim, Z
   Alparslan, C
   Öztürk, C
   Berdeli, A
AF Diniz, Gulden
   Yavascan, Onder
   Sarkis, Umit Basak
   Yildirim, Zubeyde
   Alparslan, Caner
   Ozturk, Can
   Berdeli, Afig
TI A Childhood Inflammatory Myopathy with Cytochrome Oxidase Deficiency:
   Which Came First, the Chicken or the Egg?
SO JOURNAL OF BEHCET UZ CHILDRENS HOSPITAL
LA English
DT Article
DE Childhood inflammatory myopathy; polymyositis with COX-negative
   myofibers; ATP6 synthase gene; ND4 gene; CytB gene; mitochondrial
   myopathy
ID MUTATIONS
AB Inflammatory myopathies are autoimmune disorders rarely seen in childhood. Normally high-dose corticosteroid is the current treatment for inflammatory myopathies. For a specific subgroup of patients with inflammatory myopathy with cytochrome oxidase (COX)-negative myofibers that do not typically respond to corticosteroid treatment, and methotrexate (MTX) is used for therapy. Herein we present a 10-year-old girl who initially received clinical diagnosis of juvenile inflammatory myopathy which did not respond to corticosteroid treatment. Examination of her muscle biopsy specimen showed the presence of COX-negative muscle fibers which are very rarely seen in childhood inflammatory myopathies, and she was diagnosed as inflammatory myopathy characterized with COX-negative myofibers. The patient, who recovered with MTX therapy underwent genetic examination 3 years after the treatment was terminated. The sequence analyses of mitochondrial DNA (mtDNA) identified 19 variants in the rRNA, ND2, ND4, ND5, COX1, COX3, and CytB genes of the mtDNA of the patient and her mother. These mutations generally induce the production of synonym amino acids. However, four missense mutations on the ND4, ATP6, and CytB genes have caused structural changes in amino acids. None of these mutations have been previously reported as pathogenic variants. We have thought that these variations in such essential genes might destabilize mtDNA and could probably affect the ATP synthesis in our patient. Our final diagnosis was established based on abnormal inflammatory response induced by a hereditary mtDNA defect in a child with mitochondrial myopathy, rather than an inflammatory myopathy with COX deficiency.
C1 [Diniz, Gulden] Izmir Democracy Univ, Buca Seyfi Demirsoy Training & Res Hosp, Dept Pathol, Izmir, Turkiye.
   [Yavascan, Onder] Istanbul Medipol Univ, Dept Pediat, Fac Med, Istanbul, Turkiye.
   [Sarkis, Umit Basak; Ozturk, Can] Univ Hlth Sci Turkey, Izmir Tepecik Training & Res Hosp, Pediat Clin, Izmir, Turkiye.
   [Yildirim, Zubeyde] Izmir Katip Celebi Univ, Ataturk Training & Res Hosp, Clin Pathol, Izmir, Turkiye.
   [Alparslan, Caner] Izmir Democracy Univ, Buca Seyfi Demirsoy Training & Res Hosp, Dept Pediat, Izmir, Turkiye.
   [Berdeli, Afig] Ege Univ, Dept Pediat, Mol Med Lab, Fac Med, Izmir, Turkiye.
C3 Izmir Democracy University; Istanbul Medipol University; Izmir Tepecik
   Training & Research Hospital; Izmir Ataturk Training & Research
   Hospital; Izmir Katip Celebi University; Izmir Democracy University; Ege
   University
RP Diniz, G (corresponding author), Izmir Democracy Univ, Buca Seyfi Demirsoy Training & Res Hosp, Dept Pathol, Izmir, Turkiye.
EM gulden.diniz@idu.edu.tr
RI Diniz, Gulden/HKM-3640-2023
CR Felhi R, 2016, BIOCHEM BIOPH RES CO, V473, P61, DOI 10.1016/j.bbrc.2016.03.050
   Habbane M, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9101364
   Kaphan E, 2018, REV NEUROL-FRANCE, V174, P731, DOI 10.1016/j.neurol.2018.03.014
   Kleefeld F, 2022, NEUROLOGY, V99, pE2212, DOI 10.1212/WNL.0000000000201103
   Papadimas GK, 2019, RHEUMATOL INT, V39, P1459, DOI 10.1007/s00296-019-04314-8
   Rider LG, 2016, J INTERN MED, V280, P24, DOI 10.1111/joim.12444
   Schänzer A, 2022, CELLS-BASEL, V11, DOI 10.3390/cells11010109
   Stenzel W, 2021, NEUROMUSCULAR DISORD, V31, P1051, DOI 10.1016/j.nmd.2021.08.007
   Zhao D, 2011, J HUM GENET, V56, P759, DOI 10.1038/jhg.2011.96
NR 9
TC 0
Z9 0
U1 0
U2 0
PU GALENOS PUBL HOUSE
PI ISTANBUL
PA Kacamak Sokak 21/1, ISTANBUL, Findikzade, TURKIYE
EI 2822-4469
J9 J BEHCET UZ CHILD
JI J Behcet Uz Child. Hosp.
PY 2023
VL 13
IS 3
BP 198
EP 202
DI 10.4274/jbuch.galenos.2023.45556
PG 5
WC Medicine, General & Internal
WE Emerging Sources Citation Index (ESCI)
SC General & Internal Medicine
GA LU0X0
UT WOS:001189207200008
OA gold
DA 2024-11-01
ER

PT J
AU Bisceglia, M
   Crociani, P
   Fogli, D
   Centola, A
   Galliani, CA
   Pasquinelli, G
AF Bisceglia, Michele
   Crociani, Paola
   Fogli, Danilo
   Centola, Antonio
   Galliani, Carlos A.
   Pasquinelli, Gianandrea
TI Selected Case From the Arkadi M. Rywlin International Pathology Slide
   Series Mitochondrial Myopathy Presenting With Chronic Progressive
   External Ophthalmoplegia (CPEO): A Case Report
SO ADVANCES IN ANATOMIC PATHOLOGY
LA English
DT Article
DE mitochondria; myopathy; progressive external ophthalmoplegia; ragged-red
   fiber; intramitochondrial paracrystalline inclusions
ID OCULAR MYOPATHIES; DIAGNOSIS; DISEASE; PTOSIS; ADULTS
AB A 43-year-old female patient diagnosed with chronic progressive external ophthalmoplegia (CPEO) because of mitochondrial myopathy documented by muscle biopsy is presented. The chief complaints were represented by blepharoptosis and ophthalmoplegia. The muscle biopsy was evaluated by histology, using the appropriate histochemical and histoenzimological stains. Ragged red fibers with Gomori trichrome stain were seen, which showed cytochrome c oxydase deficiency and abnormal succinate dehydrogenase staining in around 20% of muscle fibres. Electron microscopy was also performed which demonstrated abnormal, hyperplastic, pleomorphic, and hypertrophic mitochondria, characterized by paracrystalline inclusions arranged in parallel rows (parking-lot inclusions), consisting of rectangular arrays of mitochondrial membranes in a linear or grid-like pattern. In conclusion, mitochondrial myopathy was definitely diagnosed. Although molecular analysis, which was subsequently carried out, failed to reveal mutations in the mitochondrial DNA or in selected nuclear genes, the pathologic diagnosis was not changed. The differential diagnosis of CPEO with other forms of ocular myopathies as well as the possible association of CPEO with systemic syndromes is discussed. Ophtalmologists and medical internists should always suspect CPEO when dealing with patients affected by ocular myopathy, either in its pure form or in association with other myopathic or systemic signs.
C1 [Bisceglia, Michele] Referral Canc Ctr Basilicata, IRCCS, Rionero In Vulture, PZ, Italy.
   [Crociani, Paola; Fogli, Danilo] IRCCS Casa Sollievo Sofferenza, Neurol Unit, San Giovanni Rotondo, FG, Italy.
   [Centola, Antonio] F Lastaria Hosp, Ophthalmol Unit, Lucera, Italy.
   [Pasquinelli, Gianandrea] Univ Bologna, S Orsola Polyclin, Dept Clin Pathol, Bologna, Italy.
   [Galliani, Carlos A.] Childrens Hosp & Clin Minnesota, Dept Pathol, Minneapolis, MN USA.
C3 IRCCS CROB; IRCCS Casa Sollievo Della Sofferenza; IRCCS Azienda
   Ospedaliero-Universitaria di Bologna; University of Bologna; Children's
   Hospitals & Clinics of Minnesota
RP Bisceglia, M (corresponding author), Via Santa Chiara 9, I-71043 Manfredonia, FG, Italy.
EM bismich@alice.it
RI Galliani, Carlos/ADQ-8062-2022; Pasquinelli, Gianandrea/I-7088-2012
OI Galliani, Carlos/0000-0003-4051-5044; Pasquinelli,
   Gianandrea/0000-0003-1506-1829
CR Barton JJS, 2010, J NEURO-OPHTHALMOL, V30, P248, DOI 10.1097/WNO.0b013e3181e014c8
   Ben Yaou R, 2006, REV NEUROL-FRANCE, V162, P339, DOI 10.1016/S0035-3787(06)75020-2
   Clauser L, 2006, J CRANIOFAC SURG, V17, P246, DOI 10.1097/00001665-200603000-00008
   Cohen BH, 2013, NEUROTHERAPEUTICS, V10, P227, DOI 10.1007/s13311-013-0188-3
   DiMauro S, 2005, NEUROMUSCULAR DISORD, V15, P276, DOI 10.1016/j.nmd.2004.12.008
   DiMauro S, 2010, Acta Myol, V29, P333
   DiMauro S, 2013, NAT REV NEUROL, V9, P429, DOI 10.1038/nrneurol.2013.126
   DiMauro S, 2013, NEUROLOGY, V81, P281, DOI 10.1212/WNL.0b013e31829bfe89
   Doherty M, 2013, ORBIT, V32, P12, DOI 10.3109/01676830.2012.736599
   Lucci LMD, 2009, ARQ BRAS OFTALMOL, V72, P159, DOI 10.1590/S0004-27492009000200005
   Farrugia ME, 2011, J ROY COLL PHYS EDIN, V41, P43, DOI 10.4997/JRCPE.2011.111
   Filosto M, 2009, J NEUROL NEUROSUR PS, V80, P448, DOI 10.1136/jnnp.2008.150540
   Finsterer J, 2011, J NEUROL SCI, V304, P9, DOI 10.1016/j.jns.2011.02.012
   Gallagher CL, 2002, J CHILD NEUROL, V17, P453, DOI 10.1177/088307380201700612
   Gautier D, 2012, EUR J NEUROL, V19, pE38, DOI 10.1111/j.1468-1331.2011.03657.x
   Gimenes AC, 2007, EUR RESP J S, V51
   Goldstein AC, 2013, NEUROTHERAPEUTICS, V10, P212, DOI 10.1007/s13311-013-0185-6
   Lee Andrew G, 2002, Curr Neurol Neurosci Rep, V2, P413, DOI 10.1007/s11910-002-0067-5
   Montini G, 2008, NEW ENGL J MED, V358, P2849, DOI 10.1056/NEJMc0800582
   Owens William E, 2005, J Clin Neuromuscul Dis, V6, P188, DOI 10.1097/01.cnd.0000167098.73931.41
   Pénisson-Besnier I, 2008, REV NEUROL-FRANCE, V164, P902, DOI 10.1016/j.neurol.2008.02.036
   Perez-Atayde AR, 2013, HUM PATHOL, V44, P1440, DOI 10.1016/j.humpath.2012.12.005
   Pfeffer G, 2013, ANN MED, V45, P4, DOI 10.3109/07853890.2011.605389
   Scarpelli Mauro, 2010, Recent Pat CNS Drug Discov, V5, P203, DOI 10.2174/157488910793362412
   Schaefer AM, 2008, ANN NEUROL, V63, P35, DOI 10.1002/ana.21217
   Schoser BGH, 2006, STRABISMUS, V14, P107, DOI 10.1080/09273970600701218
   SERRATRICE G, 1987, PRESSE MED, V16, P1969
   SERRATRICE G, 1991, REV NEUROL, V147, P474
   Servidei Serenella, 2004, Neuromuscul Disord, V14, P107
   Soejima K, 2006, ANN PLAS SURG, V56, P439, DOI 10.1097/01.sap.0000202885.98998.0a
   Thiriez C, 2010, REV NEUROL-FRANCE, V166, P538, DOI 10.1016/j.neurol.2009.12.004
NR 31
TC 3
Z9 4
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1072-4109
EI 1533-4031
J9 ADV ANAT PATHOL
JI Adv. Anat. Pathol.
PD NOV
PY 2014
VL 21
IS 6
BP 461
EP 468
DI 10.1097/PAP.0000000000000045
PG 8
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA AS4ND
UT WOS:000344252100008
PM 25299315
DA 2024-11-01
ER

PT J
AU Yu-Wai-Man, C
   Smith, FE
   Firbank, MJ
   Guthrie, G
   Guthrie, S
   Gorman, GS
   Taylor, RW
   Turnbull, DM
   Griffiths, PG
   Blamire, AM
   Chinnery, PF
   Yu-Wai-Man, P
AF Yu-Wai-Man, Cynthia
   Smith, Fiona E.
   Firbank, Michael J.
   Guthrie, Grant
   Guthrie, Stuart
   Gorman, Grainne S.
   Taylor, Robert W.
   Turnbull, Douglass M.
   Griffiths, Philip G.
   Blamire, Andrew M.
   Chinnery, Patrick F.
   Yu-Wai-Man, Patrick
TI Extraocular Muscle Atrophy and Central Nervous System Involvement in
   Chronic Progressive External Ophthalmoplegia
SO PLOS ONE
LA English
DT Article
ID MITOCHONDRIAL DISEASE; MR; MUTATIONS; MYOPATHY; SPECTRUM; BRAIN
AB Background: Chronic progressive external ophthalmoplegia (CPEO) is a classical mitochondrial ocular disorder characterised by bilateral progressive ptosis and ophthalmoplegia. These ocular features can develop either in isolation or in association with other prominent neurological deficits (CPEO+). Molecularly, CPEO can be classified into two distinct genetic subgroups depending on whether patients harbour single, large-scale mitochondrial DNA (mtDNA) deletions or multiple mtDNA deletions secondary to a nuclear mutation disrupting mtDNA replication or repair. The aim of this magnetic resonance imaging (MRI) study was to investigate whether the ophthalmoplegia in CPEO is primarily myopathic in origin or whether there is evidence of contributory supranuclear pathway dysfunction.
   Methods: Ten age-matched normal controls and twenty patients with CPEO were recruited nine patients with single, large-scale mtDNA deletions and eleven patients with multiple mtDNA deletions secondary to mutations in POLG, PEO1, OPA1, and RRM2B. All subjects underwent a standardised brain and orbital MRI protocol, together with proton magnetic resonance spectroscopy in two voxels located within the parietal white matter and the brainstem.
   Results: There was evidence of significant extraocular muscle atrophy in patients with single or multiple mtDNA deletions compared with controls. There was no significant difference in metabolite concentrations between the patient and control groups in both the parietal white matter and brainstem voxels. Volumetric brain measurements revealed marked cortical and cerebellar atrophy among patients with CPEO+ phenotypes.
   Conclusion: The results of this study support a primary myopathic aetiology for the progressive limitation of eye movements that develops in CPEO.
C1 [Yu-Wai-Man, Cynthia; Guthrie, Grant; Guthrie, Stuart; Griffiths, Philip G.; Yu-Wai-Man, Patrick] Royal Victoria Infirm, Dept Ophthalmol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
   [Smith, Fiona E.; Blamire, Andrew M.] Newcastle Univ, Inst Cellular Med, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
   [Smith, Fiona E.; Blamire, Andrew M.] Newcastle Univ, Newcastle Magnet Resonance Ctr, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
   [Firbank, Michael J.] Newcastle Univ, Inst Ageing & Hlth, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
   [Gorman, Grainne S.; Turnbull, Douglass M.; Chinnery, Patrick F.] Royal Victoria Infirm, Dept Neurol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
   [Gorman, Grainne S.; Taylor, Robert W.; Turnbull, Douglass M.] Newcastle Univ, Sch Med, Inst Ageing & Hlth, Wellcome Trust Ctr Mitochondrial Res, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
   [Chinnery, Patrick F.; Yu-Wai-Man, Patrick] Newcastle Univ, Inst Med Genet, Wellcome Trust Ctr Mitochondrial Res, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
C3 Newcastle University - UK; Newcastle University - UK; Newcastle
   University - UK; Newcastle University - UK; Newcastle University - UK;
   Newcastle University - UK; Newcastle University - UK
RP Yu-Wai-Man, P (corresponding author), Royal Victoria Infirm, Dept Ophthalmol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
EM Patrick.Yu-Wai-Man@ncl.ac.uk
RI Blamire, Andrew/AAU-6100-2021; Firbank, Michael/K-3335-2012
OI Gorman, Grainne/0000-0002-7585-3409; Yu-Wai-Man,
   Cynthia/0000-0003-4868-5187; Chinnery, Patrick/0000-0002-7065-6617;
   Turnbull, Doug/0000-0002-8878-9901; Blamire, Andrew/0000-0002-8749-1257
FU Newcastle Joint Research Executive Scientific Committee (JRESC); Medical
   Research Council (MRC, UK); Wellcome Trust; MRC [MR/K000608/1, G0700718,
   G1002570, G0701386] Funding Source: UKRI
FX This work was supported by research grants from the Newcastle Joint
   Research Executive Scientific Committee (JRESC), the Medical Research
   Council (MRC, UK), and the Wellcome Trust. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Carlow TJ, 1998, AM J NEURORADIOL, V19, P95
   DAROFF RB, 1966, NEUROLOGY, V16, P161, DOI 10.1212/WNL.16.2_Part_1.161
   Fraser JA, 2010, SURV OPHTHALMOL, V55, P299, DOI 10.1016/j.survophthal.2009.10.002
   Fratter C, 2011, NEUROLOGY, V76, P2032, DOI 10.1212/WNL.0b013e31821e558b
   Fratter C, 2010, NEUROLOGY, V74, P1619, DOI 10.1212/WNL.0b013e3181df099f
   Greaves LC, 2010, INVEST OPHTH VIS SCI, V51, P3340, DOI 10.1167/iovs.09-4659
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Kapeller P, 1996, J NEUROL SCI, V135, P126, DOI 10.1016/0022-510X(95)00290-I
   Lax NZ, 2012, J NEUROPATH EXP NEUR, V71, P148, DOI 10.1097/NEN.0b013e318244477d
   Man CYW, 2006, EYE, V20, P564, DOI 10.1038/sj.eye.6701924
   MATTHEWS PM, 1993, NEUROLOGY, V43, P2484, DOI 10.1212/WNL.43.12.2484
   McFarland R, 2010, LANCET NEUROL, V9, P829, DOI 10.1016/S1474-4422(10)70116-2
   Ortube MC, 2006, J AAPOS, V10, P414, DOI 10.1016/j.jaapos.2006.04.012
   Palin EJH, 2013, BRAIN, V136, P2379, DOI 10.1093/brain/awt160
   Richardson C, 2005, EYE, V19, P258, DOI 10.1038/sj.eye.6701488
   Taherian K, 2007, EYE, V21, P639, DOI 10.1038/sj.eye.6702296
   VIVIAN AJ, 1993, EYE, V7, P565, DOI 10.1038/eye.1993.123
   WRAY SH, 1995, AM J NEURORADIOL, V16, P1167
   Yu-Wai-Man P, 2010, BRAIN, V133, P771, DOI 10.1093/brain/awq007
   Yu-Wai-Man P, 2012, BRIT J OPHTHALMOL, V96, P1536, DOI 10.1136/bjophthalmol-2012-302566
NR 20
TC 20
Z9 20
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 27
PY 2013
VL 8
IS 9
AR e75048
DI 10.1371/journal.pone.0075048
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 228WY
UT WOS:000325223900035
PM 24086434
OA Green Submitted, Green Published, gold
DA 2024-11-01
ER

PT J
AU Blackwood, JK
   Whittaker, RG
   Blakely, EL
   Alston, CL
   Turnbull, DM
   Taylor, RW
AF Blackwood, John K.
   Whittaker, Roger G.
   Blakely, Emma L.
   Alston, Charlotte L.
   Turnbull, Douglass M.
   Taylor, Robert W.
TI The investigation and diagnosis of pathogenic mitochondrial DNA
   mutations in human urothelial cells
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Mitochondrial DNA (mtDNA); Heteroplasmy; MELAS; Urothelial cells; mtDNA
   rearrangements; Non-invasive diagnosis
ID RAGGED-RED FIBERS; REAL-TIME PCR; GENE MUTATION; MTDNA MUTATION; TISSUE
   DISTRIBUTION; MYOCLONUS EPILEPSY; INDIVIDUAL CELLS; POINT MUTATION; PURE
   MYOPATHY; HUMAN-DISEASE
AB Patients with mitochondrial DNA disease are amongst the most challenging to diagnose and manage given the striking phenotypic and genetic heterogeneity, which characterise these conditions. Recently, we and others have demonstrated the m.3243A>G mutation, one of the most common mitochondrial DNA pathogenic mutations, is present at clinically relevant levels in urinary epithelium, thus providing a practical, non-invasive test for diagnosis and mutation screening. In this study we further evaluate the use of these cells in detecting the m.3243A>G mutation, other mtDNA tRNA gene point mutations including the m.8344A>G mutation and single large-scale mtDNA deletions. We observe a robust relationship between m.3243A>G levels in urothelial cells and clinically affected tissues that does not change with time. Conversely, single large-scale mtDNA deletions can be detected in urothelial cells, with higher levels present in younger patients with more severe disease, but generally mtDNA deletion levels are not representative of those seen in a clinically affected tissue. Our results have implications for the diagnosis, management and counselling of families with mtDNA disease. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Blackwood, John K.; Whittaker, Roger G.; Blakely, Emma L.; Alston, Charlotte L.; Turnbull, Douglass M.; Taylor, Robert W.] Univ Newcastle, Sch Med, Inst Ageing & Hlth, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
C3 Newcastle University - UK
RP Taylor, RW (corresponding author), Univ Newcastle, Sch Med, Inst Ageing & Hlth, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM r.w.taylor@ncl.ac.uk
RI Alston, Charlotte/ABG-9602-2020
OI Blackwood, John/0000-0003-1511-7562; Alston,
   Charlotte/0000-0003-2095-5464; Whittaker, Roger/0000-0002-3403-0182;
   Turnbull, Doug/0000-0002-8878-9901
FU SPARKS; Wellcome Trust; UK National Commissioning Group for Rare
   Mitochondrial Disorders of Adults and Children Service
FX This work was funded by a SPARKS project grant and by Wellcome Trust
   Programme Grant funding to D.M.T. and R.W.T. The Mitochondrial
   Diagnostic Laboratory in Newcastle upon Tyne is funded by the UK
   National Commissioning Group for Rare Mitochondrial Disorders of Adults
   and Children Service (www.mitochondrialncg.nhs.uk).
CR Al-Dosary M, 2009, NEUROMUSCULAR DISORD, V19, P841, DOI 10.1016/j.nmd.2009.10.001
   Auré K, 2007, BRAIN, V130, P1516, DOI 10.1093/brain/awm067
   Blakely EL, 2004, J NEUROL SCI, V225, P99, DOI 10.1016/j.jns.2004.07.007
   Blakely EL, 2007, J NEUROL, V254, P1283, DOI 10.1007/s00415-006-0490-7
   Blakely EL, 2009, ARCH NEUROL-CHICAGO, V66, P399, DOI 10.1001/archneurol.2008.576
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   Deschauer M, 2006, ARCH NEUROL-CHICAGO, V63, P902, DOI 10.1001/archneur.63.6.902
   Elson JL, 2009, HUM MUTAT, V30, pE984, DOI 10.1002/humu.21113
   GOT YI, 1990, NATURE, V348, P651
   Greaves LC, 2006, IUBMB LIFE, V58, P143, DOI 10.1080/15216540600686888
   HAMMANS SR, 1995, BRAIN, V118, P721, DOI 10.1093/brain/118.3.721
   He LP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf067
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Krishnan KJ, 2007, ANAL BIOCHEM, V370, P127, DOI 10.1016/j.ab.2007.06.024
   Lightowlers RN, 1997, TRENDS GENET, V13, P450, DOI 10.1016/S0168-9525(97)01266-3
   McDonnell MT, 2004, EUR J HUM GENET, V12, P778, DOI 10.1038/sj.ejhg.5201216
   McFarland R, 2008, NEUROMUSCULAR DISORD, V18, P63, DOI 10.1016/j.nmd.2007.07.007
   Murphy JL, 2008, BRAIN, V131, P2832, DOI 10.1093/brain/awn252
   OLDFORS A, 1995, ACTA NEUROPATHOL, V90, P328
   Pyle A, 2007, J MED GENET, V44, P69, DOI 10.1136/jmg.2006.043109
   Rahman S, 2001, AM J HUM GENET, V68, P238, DOI 10.1086/316930
   Schaefer AM, 2006, NEUROLOGY, V66, P1932, DOI 10.1212/01.wnl.0000219759.72195.41
   Shanske S, 2004, AM J MED GENET A, V130A, P134, DOI 10.1002/ajmg.a.30220
   Sue CM, 1998, J NEUROL SCI, V161, P36, DOI 10.1016/S0022-510X(98)00179-8
   Swalwell H, 2006, NEUROLOGY, V66, P447, DOI 10.1212/01.wnl.0000196490.36349.83
   Swalwell H, 2008, EUR J HUM GENET, V16, P1265, DOI 10.1038/ejhg.2008.65
   TANNO Y, 1993, NEUROLOGY, V43, P1198, DOI 10.1212/WNL.43.6.1198
   Taylor RW, 1998, BIOCHEM BIOPH RES CO, V243, P47, DOI 10.1006/bbrc.1997.8055
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Taylor RW, 2004, NEUROLOGY, V62, P1420, DOI 10.1212/01.WNL.0000120667.77372.46
   Taylor RW, 2002, NEUROMUSCULAR DISORD, V12, P659, DOI 10.1016/S0960-8966(02)00026-3
   tHart LM, 1996, HUM MUTAT, V7, P193
   Weber K, 1997, AM J HUM GENET, V60, P373
   Whittaker RG, 2009, NEUROLOGY, V72, P568, DOI 10.1212/01.wnl.0000342121.91336.4d
   ZEVIANI M, 1991, AM J HUM GENET, V48, P203
NR 35
TC 21
Z9 21
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAR 19
PY 2010
VL 393
IS 4
BP 740
EP 745
DI 10.1016/j.bbrc.2010.02.072
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 575GB
UT WOS:000276053800033
PM 20171163
DA 2024-11-01
ER

PT J
AU Fratter, C
   Gorman, GS
   Stewart, JD
   Buddles, M
   Smith, C
   Evans, J
   Seller, A
   Poulton, J
   Roberts, M
   Hanna, MG
   Rahman, S
   Omer, SE
   Klopstock, T
   Schoser, B
   Kornblum, C
   Czermin, B
   Lecky, B
   Blakely, EL
   Craig, K
   Chinnery, PF
   Turnbull, DM
   Horvath, R
   Taylor, RW
AF Fratter, C.
   Gorman, G. S.
   Stewart, J. D.
   Buddles, M.
   Smith, C.
   Evans, J.
   Seller, A.
   Poulton, J.
   Roberts, M.
   Hanna, M. G.
   Rahman, S.
   Omer, S. E.
   Klopstock, T.
   Schoser, B.
   Kornblum, C.
   Czermin, B.
   Lecky, B.
   Blakely, E. L.
   Craig, K.
   Chinnery, P. F.
   Turnbull, D. M.
   Horvath, R.
   Taylor, R. W.
TI The clinical, histochemical, and molecular spectrum of <i>PEO1</i>
   (Twinkle)-linked adPEO
SO NEUROLOGY
LA English
DT Article
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; DNA-POLYMERASE-GAMMA; RECESSIVE
   TWINKLE MUTATIONS; MITOCHONDRIAL-DNA; MULTIPLE DELETIONS; GENE MUTATION;
   PHENOTYPIC SPECTRUM; OPTIC ATROPHY; PARKINSONISM; ANT1
AB Background: Mutations in the Twinkle (PEO1) gene are a recognized cause of autosomal dominant progressive external ophthalmoplegia (adPEO), resulting in the accumulation of multiple mitochondrial DNA (mtDNA) deletions and cytochrome c oxidase (COX)-deficient fibers in skeletal muscle secondary to a disorder of mtDNA maintenance. Patients typically present with isolated extraocular muscle involvement, with little apparent evidence of the clinical heterogeneity documented in other mtDNA maintenance disorders, in particular POLG-related disease.
   Methods: We reviewed the clinical, histochemical, and molecular genetics analysis of 33 unreported patients from 26 families together with all previous cases described in the literature to define the clinical phenotype associated with PEO1 mutations.
   Results: Ptosis and ophthalmoparesis were almost universal clinical features among this cohort, with 52%(17/33) reporting fatigue and 33%(11/33) having mild proximal myopathy. Features consistent with CNS involvement were rarely described; however, in 24% (8/33) of the patients, cardiac abnormalities were reported. Mitochondrial histochemical changes observed in muscle showed remarkable variability, as did the secondary mtDNA deletions, which in some patients were only detected by PCR-based assays and not Southern blotting. Moreover, we report 7 novel PEO1 variants.
   Conclusions: Our data suggest a shared clinical phenotype with variable mild multiorgan involvement, and that the contribution of PEO1 mutations as a cause of adPEO may well be underestimated. Direct sequencing of the PEO1 gene should be considered in adPEO patients prior to muscle biopsy. Neurology (R) 2010; 74: 1619-1626
C1 [Taylor, R. W.] Univ Newcastle, Sch Med, Inst Ageing & Hlth, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Fratter, C.; Smith, C.; Evans, J.; Seller, A.] Churchill Hosp, Oxford Med Genet Labs, Oxford OX3 7LJ, England.
   [Roberts, M.] Hope Hosp, Dept Neurol, Salford M6 8HD, Lancs, England.
   [Poulton, J.] Univ Oxford, Nuffield Dept Obstet & Gynaecol, Oxford, England.
   [Hanna, M. G.] Inst Neurol, UCL MRC Ctr Neuromuscular Dis, Dept Mol Neurosci, London WC1N 3BG, England.
   [Rahman, S.] UCL Inst Child Hlth, Mitochondrial Res Grp, London, England.
   [Omer, S. E.] Univ London St Georges Hosp, Dept Neurol, London, England.
   [Klopstock, T.; Schoser, B.] LMU, Dept Neurol, Friedrich Baur Inst, Munich, Germany.
   [Czermin, B.] Ctr Med Genet, Munich, Germany.
   [Kornblum, C.] Univ Hosp Bonn, Dept Neurol, Munich, Germany.
   [Lecky, B.] Walton Ctr Neurol & Neurosurg NHS Trust, Liverpool, Merseyside, England.
C3 Newcastle University - UK; University of Oxford; University of Oxford;
   University of London; University College London; University of London;
   University College London; City St Georges, University of London;
   University of Munich; Walton Centre
RP Taylor, RW (corresponding author), Univ Newcastle, Sch Med, Inst Ageing & Hlth, Mitochondrial Res Grp, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM r.w.taylor@ncl.ac.uk
RI Horvath, Rita/AAY-7042-2020; Kornblum, Cornelia/IUM-4180-2023; Inerbaev,
   Talgat/AAB-7633-2020; Hanna, Michael/B-1995-2009; Rahman,
   Shamima/C-5232-2008; Poulton, Joanna/AAB-4828-2021; Stewart, Joanna
   D/H-1614-2012
OI Horvath, Rita/0000-0002-9841-170X; Chinnery,
   Patrick/0000-0002-7065-6617; Schoser, Benedikt/0000-0002-2757-8131;
   Stewart, Joanna D/0000-0002-2608-1967; Gorman,
   Grainne/0000-0002-7585-3409; Hanna, Michael/0000-0003-0825-4075;
   Poulton, Joanna/0000-0002-2460-5587; Turnbull, Doug/0000-0002-8878-9901
FU National Commissioning Group; UK NIHR Biomedical Research Centre for
   Aging; MRC [G0601943, G0800674, G0200335, G0500695] Funding Source: UKRI
FX The authors thank the referring clinicians, the patients, and their
   families for contributing to this study. The mitochondrial diagnostic
   laboratories in Oxford, Newcastle, and London (UCLH/Institute of
   Neurology) are funded by the National Commissioning Group to provide the
   UK "Rare Mitochondrial Disease of Adults and Children" Service. Dr.
   Fratter reports no disclosures. Dr. Gorman receives research support
   from the UK NIHR Biomedical Research Centre for Aging and Age-related
   Disease awarded to the Newcastle upon Tyne Trust Foundation Hospitals
   NHS Trust. Dr. Stewart, Dr. Buddles, Dr. Smith, Dr. Evans, and Dr.
   Seller report no disclosures. Dr. Poulton receives research support from
   the Wellcome Trust, the MRC, and the Angus Memorial Mitochondrial Fund.
   Dr. Roberts reports no disclosures. Dr. Hanna serves as Deputy Editor of
   the Journal of Neurology, Neurosurgery, and Psychiatry and receives
   research support from the MRC Centre for Neuromuscular Diseases and the
   MRC Centre for Translational Research in Neuromuscular Disease
   Mitochondrial Disease Patient Cohort (UK). Dr. Rahman serves as
   Communicating Editor for the Journal of Inherited Metabolic Diseases and
   has received research support from the Medical Research Council, SPARKS,
   and Jeans 4 Genes. Dr. Omer has received funding for travel from Eisai
   Inc. and GlaxoSmithKline. Dr. Klopstock has received funding for travel
   and speaker honoraria from Dr. Willmar Schwabe GmbH & Co. KG and
   receives research support from Santhera Pharmaceuticals and the German
   Ministry of Education and Research (BMBF). Dr. Schoser reports no
   disclosures. Dr. Kornblum has received funding for travel and speaker
   honoraria from Genzyme Corporation and receives research support from
   the German Ministry of Education and Research (BMBF). Dr. Czermin, Dr.
   Lecky, Dr. Blakely, and Dr. Craig report no disclosures. Dr. Chinnery
   serves as an Associate Editor of Brain and receives research support
   from the Wellcome Trust, the MRC, and the UK Parkinson's Disease
   Society. Dr. Turnbull receives research support from Wellcome Trust, the
   MRC Centre for Neuromuscular Diseases, and the MRC Centre for
   Translational Research in Neuromuscular Disease Mitochondrial Disease
   Patient Cohort (UK). Dr. Horvath receives research support from the
   Deutsche Forschungsgemeinschaft, the Newcastle upon Tyne Hospitals NHS
   Charity, and the Academy of Medical Sciences (UK). Dr. Taylor receives
   research support from the Wellcome Trust and the MRC Centre for
   Translational Research in Neuromuscular Disease Mitochondrial Disease
   Patient Cohort (UK).
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   [Anonymous], 2002, Statistical Methods in Medical Research
   Baloh RH, 2007, ARCH NEUROL-CHICAGO, V64, P998, DOI 10.1001/archneur.64.7.998
   Deschauer M, 2003, NEUROMUSCULAR DISORD, V13, P568, DOI 10.1016/S0960-8966(03)00071-3
   Echaniz-Laguna A, 2010, NEUROGENETICS, V11, P21, DOI 10.1007/s10048-009-0202-4
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Houshmand M, 2006, NEUROL INDIA, V54, P182
   Hudson G, 2006, NEUROLOGY, V66, P1439, DOI 10.1212/01.wnl.0000210486.32196.24
   Hudson G, 2005, NEUROLOGY, V64, P371, DOI 10.1212/01.WNL.0000149767.51152.83
   Hudson G, 2008, BRAIN, V131, P329, DOI 10.1093/brain/awm272
   Jeppesen TD, 2008, NEUROMUSCULAR DISORD, V18, P306, DOI 10.1016/j.nmd.2007.10.007
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kiechl S, 2004, J NEUROL NEUROSUR PS, V75, P1125, DOI 10.1136/jnnp.2003.025890
   Lewis S, 2002, J NEUROL SCI, V201, P39, DOI 10.1016/S0022-510X(02)00190-9
   Li FY, 1999, NEUROLOGY, V53, P1265, DOI 10.1212/WNL.53.6.1265
   Liu ZR, 2008, MOL VIS, V14, P1995
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Lönnqvist T, 2009, BRAIN, V132, P1553, DOI 10.1093/brain/awp045
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Murphy JL, 2008, BRAIN, V131, P2832, DOI 10.1093/brain/awn252
   Naïmi M, 2006, EUR J HUM GENET, V14, P917, DOI 10.1038/sj.ejhg.5201627
   Negro R, 2009, NEUROMUSCULAR DISORD, V19, P423, DOI 10.1016/j.nmd.2009.04.008
   Nikali K, 2005, HUM MOL GENET, V14, P2981, DOI 10.1093/hmg/ddi328
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Rivera H, 2007, NEUROMUSCULAR DISORD, V17, P677, DOI 10.1016/j.nmd.2007.05.006
   Sarzi E, 2007, ANN NEUROL, V62, P579, DOI 10.1002/ana.21207
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   Taanman JW, 2009, HUM MUTAT, V30, P248, DOI 10.1002/humu.20852
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   Tyynismaa H, 2009, AM J HUM GENET, V85, P290, DOI 10.1016/j.ajhg.2009.07.009
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, NEUROMOL MED, V3, P129, DOI 10.1385/NMM:3:3:129
   Van Hove JLK, 2009, AM J MED GENET A, V149A, P861, DOI 10.1002/ajmg.a.32731
   Vandenberghe W, 2009, MOVEMENT DISORD, V24, P308, DOI 10.1002/mds.22198
   Virgilio R, 2008, J NEUROL, V255, P1384, DOI 10.1007/s00415-008-0926-3
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 40
TC 64
Z9 68
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD MAY 18
PY 2010
VL 74
IS 20
BP 1619
EP 1626
DI 10.1212/WNL.0b013e3181df099f
PG 8
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 597OG
UT WOS:000277767000010
PM 20479361
OA Green Published, Green Accepted
DA 2024-11-01
ER

PT J
AU Arpa-Gutiérrez, FJ
   Cruz-Martínez, A
   Campos-González, Y
   Gutiérrez-Molina, M
   Santiago-Pérez, S
   Pérez-Conde, MC
   López-Pajares, MR
   Martín-Casarrubias, MA
   Rubio-Muñoz, JC
   del Hoyo, P
   Arpa-Fernández, A
   Arenas-Barbero, J
AF Arpa-Gutiérrez, FJ
   Cruz-Martínez, A
   Campos-González, Y
   Gutiérrez-Molina, M
   Santiago-Pérez, S
   Pérez-Conde, MC
   López-Pajares, MR
   Martín-Casarrubias, MA
   Rubio-Muñoz, JC
   del Hoyo, P
   Arpa-Fernández, A
   Arenas-Barbero, J
TI Mitochondrial respiratory chain diseases.: Evaluation and variability in
   52 patients
SO REVISTA DE NEUROLOGIA
LA English
DT Article
DE electromyography; encephalopathy; genetics; mitochondrial disease;
   muscle biopsy; myopathy; neuropathy; respiratory chain disease
ID RAGGED-RED FIBERS; MUTATION; DNA; NEUROPATHY; MUSCLE;
   ENCEPHALOMYOPATHIES; EPIDEMIOLOGY; DEFICIENCY; DIAGNOSIS; FAMILY
AB Introduction. Clinical, electrophysiological, genetic and biochemical deficiencies variability were evaluated in 52 patients diagnosed of mitochondrial respiratory chain diseases (MRCD). Patients and methods. 26 men and 26 women, aged 19 to 79 years, were tested by clinical examination, electrophysiological techniques, muscle biopsy and genetic and biochemical studies. Results. The patients were classified into seven phenotypes: myopathy, chronic progressive external ophthalmoplegia, progressive ophthalmoplegia plus ataxia, Kearns-Sayre syndrome, mitochondrial encephalomyopathy with lactic acidosis and stroke episodes (MELAS), myoclonic encephalopathy with ragged-red fibers (MERRF), and encephalopathies. Each phenotype may begin by different ways. The electromiography showed myopathy in 39 cases and various types of neuropathy in 10. Ragged-red COX negative fibers or widespread electron microscopic abnormalities were found in 47 cases. Simple deletions, multiple deletions and three different point mutations were observed. Deficiency of complexes I, II, III and IV were found alone or in different associations. Conclusions. MRCD shows wide variations in clinical, genetic and biochemical studies. Some patients with nonspecific manifestations, mainly of central nervous system, need careful attention and to be on account of diagnostic suspicion.
C1 Hosp Univ La Paz, Serv Neurol, E-28046 Madrid, Spain.
   Hosp Severo Ochoa, Madrid, Spain.
   Hosp 12 Octubre, E-28041 Madrid, Spain.
C3 Hospital Universitario La Paz; Severo Ochoa University Hospital;
   Hospital Universitario 12 de Octubre
RP Hosp Univ La Paz, Serv Neurol, Paseo Castellana,261, E-28046 Madrid, Spain.
EM jarpag@ctv.es
RI Yolanda, Campos/A-8711-2017
OI Arenas, Joaquin/0000-0002-2877-5049; CAMPOS, YOLANDA/0000-0003-4785-9659
CR Andreu AL, 1998, NEUROLOGY, V51, P1444, DOI 10.1212/WNL.51.5.1444
   BERKOVIC SF, 1989, BRAIN, V112, P1231, DOI 10.1093/brain/112.5.1231
   Birch-Machin M., 1993, MITOCHONDRIAL DYSFUN, P51
   Blanco-Barca O, 2004, REV NEUROLOGIA, V39, P618
   CALABRESI PA, 1994, MUSCLE NERVE, V17, P943, DOI 10.1002/mus.880170815
   Campos Y, 1998, NEUROMUSCULAR DISORD, V8, P568, DOI 10.1016/S0960-8966(98)00080-7
   Castro-Gago M, 2000, REV NEUROLOGIA, V31, P263, DOI 10.33588/rn.3103.2000074
   CESEN W, 1972, ARCH NEUROL-CHICAGO, V26, P193
   Chinnery PF, 2001, AM J MED GENET, V106, P94, DOI 10.1002/ajmg.1426
   DiMauro S, 1999, J CHILD NEUROL, V14, pS23, DOI 10.1177/0883073899014001051
   Dimauro S, 2004, ANN NY ACAD SCI, V1011, P217, DOI 10.1196/annals.1293.022
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   DiMauro S, 2001, ANN MED, V33, P472, DOI 10.3109/07853890109002096
   DIMAURO S, 1993, ARCH NEUROL-CHICAGO, V50, P11697
   FAWCETT PRW, 1982, J NEUROL SCI, V53, P397, DOI 10.1016/0022-510X(82)90021-1
   Finsterer J, 2004, EUR J NEUROL, V11, P163, DOI 10.1046/j.1351-5101.2003.00728.x
   GEYER CA, 1988, J COMPUT ASSIST TOMO, V12, P40, DOI 10.1097/00004728-198801000-00006
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   GOTO Y, 1995, MUSCLE NERVE, pS107
   HAMMANS SR, 1991, LANCET, V337, P1311, DOI 10.1016/0140-6736(91)92981-7
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   HUBBARD JI, 1973, PHYSIOL REV, V53, P674, DOI 10.1152/physrev.1973.53.3.674
   JACKSON MJ, 1995, BRAIN, V118, P339, DOI 10.1093/brain/118.2.339
   JOHNSON MA, 1993, ANN NEUROL, V33, P28, DOI 10.1002/ana.410330106
   Keightley JA, 2000, AM J HUM GENET, V67, P1400, DOI 10.1086/316900
   KRENDEL DA, 1987, MUSCLE NERVE, V10, P299, DOI 10.1002/mus.880100404
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   Man PYW, 2003, AM J HUM GENET, V72, P333, DOI 10.1016/j.ajhg.2016.05.015
   MORGANHUGHES JA, 1977, BRAIN, V100, P617, DOI 10.1093/brain/100.4.617
   MULLERHOCKER J, 1990, J NEUROL SCI, V100, P14, DOI 10.1016/0022-510x(90)90006-9
   NAGEL T, 1993, PEDRIATR NEUROL, V9, P151
   Nardin RA, 2001, MUSCLE NERVE, V24, P170, DOI 10.1002/1097-4598(200102)24:2<170::AID-MUS30>3.0.CO;2-0
   PAULAKIS SG, 1984, ANN NEUROL, V16, P481
   PETTY RKH, 1986, BRAIN, V109, P915, DOI 10.1093/brain/109.5.915
   PEYRONNARD JM, 1980, ANN NEUROL, V7, P262, DOI 10.1002/ana.410070310
   Pineda M, 2004, REV NEUROLOGIA, V38, P1023, DOI 10.33588/rn.3811.2004019
   Raspall-Chaure M, 2004, REV NEUROLOGIA, V39, P1129, DOI 10.33588/rn.3912.2004296
   Ricoy-Campo JR, 2003, REV NEUROLOGIA, V37, P775, DOI 10.33588/rn.3708.2002596
   RIFAI Z, 1995, ANN NEUROL, V37, P24, DOI 10.1002/ana.410370107
   ROWLAND LP, 1991, REV NEUROL-FRANCE, V147, P467
   SMITH SJM, 1993, J NEUROL, V240, P367, DOI 10.1007/BF00839969
   Sue CM, 1997, NEUROLOGY, V49, P1013, DOI 10.1212/WNL.49.4.1013
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   TEENER JW, 1994, ANN NEUROL, V36, P508
   TORBERGSEN T, 1991, MUSCLE NERVE, V14, P35
   Valanne L, 1998, AM J NEURORADIOL, V19, P369
   Vladutiu GD, 2002, MUSCLE NERVE, V25, P649, DOI 10.1002/mus.10104
   Walker UA, 1996, EUR NEUROL, V36, P260, DOI 10.1159/000117269
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   YIANNIKAS C, 1986, ANN NEUROL, V20, P249, DOI 10.1002/ana.410200211
NR 50
TC 5
Z9 5
U1 1
U2 2
PU REVISTA DE NEUROLOGIA
PI BARCELONA
PA C/O CESAR VIGUERA, EDITOR, APDO 94121, 08080 BARCELONA, SPAIN
SN 0210-0010
EI 1576-6578
J9 REV NEUROLOGIA
JI Rev. Neurologia
PD OCT 16
PY 2005
VL 41
IS 8
BP 449
EP 454
DI 10.33588/rn.4108.2005206
PG 6
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 979ZQ
UT WOS:000232984100001
PM 16224730
DA 2024-11-01
ER

PT J
AU Challa, S
   Kanikannan, MA
   Jagarlapudi, MMK
   Bhoompally, VR
   Surath, M
AF Challa, S
   Kanikannan, MA
   Jagarlapudi, MMK
   Bhoompally, VR
   Surath, M
TI Diagnosis of mitochondrial diseases: Clinical and histological study of
   sixty patients with ragged red fibers
SO NEUROLOGY INDIA
LA English
DT Article
DE mitochondrial disease; ragged-red fiber; progressive external
   ophthalmoplegia; Kearns-Sayre syndrome; myoclonus epilepsy with
   ragged-red fibers; heart block
ID KEARNS-SAYRE-SYNDROME; ATRIOVENTRICULAR-BLOCK; MYOCLONIC EPILEPSY; DNA;
   MUTATION; MYOPATHY; GENE; INVOLVEMENT; DISORDERS; DELETIONS
AB Background: Mitochondrial diseases are caused by mutations in mitochondrial or nuclear genes, or both and most patients do not present with easily recognizable disorders The characteristic morphologic change in muscle biopsy ragged-red fibers (RRFs) provides an important clue to the diagnosis. Materials and Methods: Demographic data, presenting symptoms, neurological features, and investigative findings in 60 patients with ragged-red fibers (RRFs) on muscle biopsy, seen between January 1990 and December 2002, were analyzed. The authors applied the modified respiratory chain (RC) diagnostic criteria retrospectively to determine the number of cases fulfilling the diagnostic criteria of mitochondrial disease. Results: The most common clinical syndrome associated with RRFs on muscle biopsy was progressive external ophthalmoplegia (PEO) with or without other signs, in 38 (63%) patients. Twenty-six patients (43%) had only external ophthalmoplegia, 5 (8%) patients presented with encephalomyopathy. Specific syndromes were the presenting feature in 8 (13%), Kearns-Sayre syndrome (KSS) in 4 and myoclonus epilepsy with, ragged-red fibers (MERRF) in 4. Myopathy was the presenting feature in 5 (8%) and 4 presented with infantile myopathy. Of the 60 patients, 18 (30%) had proximal muscle weakness. Two patients with KSS and one patient with myopathy had complete heart block necessitating pace making. When the modified RC diagnostic criteria were applied, only 26 (43%) patients had one other major criterion in addition to RRFs for the diagnosis of mitochondrial diseases. The remaining 34 (57%) patients with RRFs on Muscle biopsy had only some clinical features suggestive of RC disorder but did not fulfill the clinical criteria (of the modified diagnostic criteria) for the diagnosis of mitochondrial diseases. Conclusion: In patients with clinical features suggestive of RC disorder, demonstration of RRFs on muscle biopsy helps in confirming the diagnosis of mitochondrial disease in only a subgroup of patients.
C1 Nizams Inst Med Sci, Dept Pathol, Hyderabad 50082, Andhra Pradesh, India.
   Nizams Inst Med Sci, Dept Neurol, Hyderabad 50082, Andhra Pradesh, India.
   Care Hosp, Inst Neurol Sci, Hyderabad, Andhra Pradesh, India.
   LV Prasad Eye Inst, Hyderabad, Andhra Pradesh, India.
C3 Nizam's Institute of Medical Sciences; Nizam's Institute of Medical
   Sciences; L. V. Prasad Eye Institute
RP Challa, S (corresponding author), Nizams Inst Med Sci, Dept Pathol, Hyderabad 50082, Andhra Pradesh, India.
EM challa_sundaram@yahoo.com
RI Challa, Sundaram/JZD-6201-2024
CR ACHARYA JN, 1995, EPILEPSIA, V36, P429, DOI 10.1111/j.1528-1157.1995.tb00482.x
   ANAN R, 1995, CIRCULATION, V91, P955, DOI 10.1161/01.CIR.91.4.955
   ARNAUDO E, 1991, LANCET, V337, P508, DOI 10.1016/0140-6736(91)91294-5
   Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   CHARLES R, 1981, CIRCULATION, V63, P214, DOI 10.1161/01.CIR.63.1.214
   DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602
   DIMAURO S, 1990, PEDIATR RES, V28, P536, DOI 10.1203/00006450-199011000-00025
   DUBOWITZ, 1985, MUSCLE BIOPSY PRACTI, P504
   Isashiki Y, 1998, ACTA OPHTHALMOL SCAN, V76, P6, DOI 10.1034/j.1600-0420.1998.760103.x
   JACKSON MJ, 1995, BRAIN, V118, P339, DOI 10.1093/brain/118.2.339
   Kakura H, 1998, JPN CIRC J, V62, P623, DOI 10.1253/jcj.62.623
   Mehndiratta MM, 2002, NEUROL INDIA, V50, P162
   Melberg A, 1996, MUSCLE NERVE, V19, P751
   MORAES CT, 1992, NAT GENET, V1, P359, DOI 10.1038/ng0892-359
   Nardin RA, 2001, MUSCLE NERVE, V24, P170, DOI 10.1002/1097-4598(200102)24:2<170::AID-MUS30>3.0.CO;2-0
   RADHAKRISHNAN VV, 2000, NEUROSCIENCES TODAY, V4, P145
   RIFAI Z, 1995, ANN NEUROL, V37, P24, DOI 10.1002/ana.410370107
   Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350
   SENGERS RCA, 1987, J INHERIT METAB DIS, V10, P98, DOI 10.1007/BF01812850
   Shaag A, 1997, BIOCHEM BIOPH RES CO, V233, P637, DOI 10.1006/bbrc.1997.6496
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   SILVESTRI G, 1993, NEUROLOGY, V43, P1200, DOI 10.1212/WNL.43.6.1200
   SILVESTRI G, 1992, AM J HUM GENET, V51, P1213
   Silvestri G, 1996, BIOCHEM BIOPH RES CO, V220, P623, DOI 10.1006/bbrc.1996.0453
   SIMON LT, 1990, ANN NEUROL, V28, P349, DOI 10.1002/ana.410280308
   SIMPSON MV, 1989, BIOCHEM PHARMACOL, V38, P1033, DOI 10.1016/0006-2952(89)90245-1
   STANSBIE D, 1986, J INHERIT METAB DIS, V9, P105, DOI 10.1007/BF01799447
   SUOMALAINEN A, 1995, NAT GENET, V9, P146, DOI 10.1038/ng0295-146
   SWEENEY MG, 1993, Q J MED, V86, P709
   Taggart RT, 1999, HUM MUTAT, V13, P210
   Taivassalo T, 1998, NEUROLOGY, V50, P1055, DOI 10.1212/WNL.50.4.1055
   Takeda K, 1989, Rinsho Shinkeigaku, V29, P643
   TANAKA M, 1990, LANCET, V336, P1452, DOI 10.1016/0140-6736(90)93162-I
   TORBERGSEN T, 1991, MUSCLE NERVE, V14, P35
   Walker UA, 1996, EUR NEUROL, V36, P260, DOI 10.1159/000117269
   Wolf NI, 2002, NEUROLOGY, V59, P1402, DOI 10.1212/01.WNL.0000031795.91814.D8
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 37
TC 20
Z9 22
U1 0
U2 3
PU NEUROL SOC INDIA
PI CHANDIGARH
PA C/O J S CHOPRA, PGIMER, DEPT NEUROLOGY, CHANDIGARH 160 012, INDIA
SN 0028-3886
J9 NEUROL INDIA
JI Neurol. India
PD SEP
PY 2004
VL 52
IS 3
BP 353
EP 358
PG 6
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 865QE
UT WOS:000224716800011
PM 15472426
DA 2024-11-01
ER

PT J
AU Müller, T
   Deschauer, M
   Neudecker, S
   Zierz, S
AF Müller, T
   Deschauer, M
   Neudecker, S
   Zierz, S
TI Late-onset mitochondrial myopathy with dystrophic changes due to a
   G7497A mutation in the mitochondrial tRNA<SUP>Ser(UCN)</SUP>supercript
   stop gene
SO ACTA NEUROPATHOLOGICA
LA English
DT Article
DE mitochondrial myopathy; muscular dystrophy; transfer RNA mutations
ID POINT MUTATION; EXERCISE INTOLERANCE; RESPIRATORY-CHAIN; MUSCLE; MTDNA;
   SEQUENCE; FAMILY; SIZE
AB Mutations of mitochondrial tRNA genes are usually associated with multi-systemic disorders with onset of symptoms in childhood or early adulthood. Dystrophic myopathic changes are not typical features of these disorders. We report two siblings with a severe progressive myopathy of late onset without external ophthalmoplegia and without involvement of the central and peripheral nervous system. Muscle biopsy specimens showed severe myopathic changes similar to those found in muscular dystrophies. Molecular analysis revealed a G7497A mutation in the mitochondrial tRNA(Ser(UCN))supercript stop gene. In both patients, the proportion of mutated mitochondrial DNA in muscle was more than 97%. Mitochondrial disorder associated with the G7497A mutation has to be included into the differential diagnosis of severe progressive late-onset myopathy with histopathological dystrophic myopathic changes. Mitochondrial myopathy and high level of mutated mtDNA might be a characteristic of the G7497A tRNA(Ser(UCN)) mutation.
C1 Univ Halle Wittenberg, Univ Klin & Poliklin Neurol, D-06097 Halle Saale, Saale, Germany.
C3 Martin Luther University Halle Wittenberg
RP Müller, T (corresponding author), Univ Halle Wittenberg, Univ Klin & Poliklin Neurol, Ernst Grube Str 40, D-06097 Halle Saale, Saale, Germany.
EM tobias.mueller@medizin.uni-halle.de
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   BEYENBURG S, 1991, NERVENARZT, V62, P506
   Dey R, 2000, NEUROMUSCULAR DISORD, V10, P488, DOI 10.1016/S0960-8966(00)00125-5
   Gellerich FN, 2002, BBA-BIOENERGETICS, V1556, P41, DOI 10.1016/S0005-2728(02)00305-5
   GOTO Y, 1992, ANN NEUROL, V31, P672, DOI 10.1002/ana.410310617
   Grafakou O, 2003, J INHERIT METAB DIS, V26, P593, DOI 10.1023/A:1025960300710
   Jaksch M, 1998, ANN NEUROL, V44, P635, DOI 10.1002/ana.410440409
   *MIT, 2004, HUM MIT GEN DAT
   MORAES CT, 1993, NAT GENET, V4, P284, DOI 10.1038/ng0793-284
   NAKAMURA M, 1995, BIOCHEM BIOPH RES CO, V214, P86, DOI 10.1006/bbrc.1995.2260
   REID FM, 1994, HUM MUTAT, V3, P243, DOI 10.1002/humu.1380030311
   Schuelke M, 1998, ANN NEUROL, V44, P700, DOI 10.1002/ana.410440420
   Silvestri G, 1998, NEUROMUSCULAR DISORD, V8, P291, DOI 10.1016/S0960-8966(98)00037-6
   Sternberg D, 2001, BRAIN, V124, P984, DOI 10.1093/brain/124.5.984
   Sue CM, 1999, NEUROLOGY, V52, P1905, DOI 10.1212/WNL.52.9.1905
   Vissing J, 1998, NEUROLOGY, V50, P1875, DOI 10.1212/WNL.50.6.1875
   Weber K, 1997, AM J HUM GENET, V60, P373
NR 17
TC 7
Z9 8
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0001-6322
J9 ACTA NEUROPATHOL
JI Acta Neuropathol.
PD OCT
PY 2005
VL 110
IS 4
BP 426
EP 430
DI 10.1007/s00401-005-1063-z
PG 5
WC Clinical Neurology; Neurosciences; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pathology
GA 985PV
UT WOS:000233391200009
PM 16133542
DA 2024-11-01
ER

PT J
AU Fragaki, K
   Chaussenot, A
   Boutron, A
   Bannwarth, S
   Cochaud, C
   Richelme, C
   Sacconi, S
   Paquis-Flucklinger, V
AF Fragaki, Konstantina
   Chaussenot, Annabelle
   Boutron, Audrey
   Bannwarth, Sylvie
   Cochaud, Charlotte
   Richelme, Christian
   Sacconi, Sabrina
   Paquis-Flucklinger, Veronique
TI SEVERE DEFECT IN MITOCHONDRIAL COMPLEX I ASSEMBLY WITH MITOCHONDRIAL DNA
   DELETIONS IN <i>ACAD9</i>-DEFICIENT MILD MYOPATHY
SO MUSCLE & NERVE
LA English
DT Article
DE ACAD9 mutation; complex I deficiency; complex I disassembly; exercise
   intolerance; mitochondrial myopathy; mtDNA deletions
ID ACAD9; DEFICIENCY; MUTATION
AB Introduction: Acyl-coenzyme A dehydrogenase 9 (ACAD9) has a role in mitochondrial complex I (CI) assembly. Only a few patients who carry ACAD9 mutations have been reported. They mainly present with severe hypertrophic cardiomyopathy, although a minority have only mild isolated myopathy. Although the secondary factors influencing disease severity have not been elucidated, conservation of CI assembly and residual enzymatic activity have been suggested as explanations for the mild phenotypes associated with ACAD9 mutations. Methods: We report a novel homozygous ACAD9 mutation (c.1240C>T; p.Arg414Cys) in a 34-year-old woman who presented with non-progressive myopathy. Results: We show that this ACAD9 mutation led to a severe defect in CI assembly in the patient's muscle. Furthermore, the impact of CI deficiency is confirmed by accumulation of mitochondrial DNA deletions. Conclusion: Our data suggest that a major defect of CI assembly is not responsible for a severe phenotype.
C1 [Fragaki, Konstantina; Chaussenot, Annabelle; Bannwarth, Sylvie; Paquis-Flucklinger, Veronique] Nice Sophia Antipolis Univ, Inst Res Canc & Aging IRCAN, CNRS, INSERM,UMR 7284, 28 Ave Valombrose, F-06107 Nice 2, France.
   [Fragaki, Konstantina; Chaussenot, Annabelle; Bannwarth, Sylvie; Paquis-Flucklinger, Veronique] Sch Med, U1081, 28 Ave Valombrose, F-06107 Nice 2, France.
   [Fragaki, Konstantina; Chaussenot, Annabelle; Bannwarth, Sylvie; Cochaud, Charlotte; Paquis-Flucklinger, Veronique] Nice Teaching Hosp, Natl Ctr Mitochondrial Dis, Dept Med Genet, Nice, France.
   [Boutron, Audrey] Paris Sud Teaching Hosp, Bicetre Hosp, AP HP, Dept Biochem, Paris, France.
   [Richelme, Christian] Nice Teaching Hosp, Dept Pediat, Nice, France.
   [Sacconi, Sabrina] Nice Teaching Hosp, Natl Ctr Neuromuscular Disorders, Nice, France.
C3 Centre National de la Recherche Scientifique (CNRS); Institut National
   de la Sante et de la Recherche Medicale (Inserm); CHU Nice; Universite
   Cote d'Azur; CHU Nice; Assistance Publique Hopitaux Paris (APHP);
   Hopital Universitaire Bicetre - APHP; CHU Nice; CHU Nice
RP Paquis-Flucklinger, V (corresponding author), Nice Sophia Antipolis Univ, Inst Res Canc & Aging IRCAN, CNRS, INSERM,UMR 7284, 28 Ave Valombrose, F-06107 Nice 2, France.; Paquis-Flucklinger, V (corresponding author), Sch Med, U1081, 28 Ave Valombrose, F-06107 Nice 2, France.; Paquis-Flucklinger, V (corresponding author), Nice Teaching Hosp, Natl Ctr Mitochondrial Dis, Dept Med Genet, Nice, France.
EM paquis@hermes.unice.fr
RI SACCONI, Sabrina/AFT-1096-2022
OI SACCONI, Sabrina/0000-0002-0246-1455
CR Bannwarth S, 2014, BRAIN, V137, P2329, DOI 10.1093/brain/awu138
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Collet M, 2016, EUR J HUM GENET, V24, P1112, DOI 10.1038/ejhg.2015.264
   Garone C, 2013, JAMA NEUROL, V70, P1177, DOI 10.1001/jamaneurol.2013.3197
   Gerards M, 2011, BRAIN, V134, P210, DOI 10.1093/brain/awq273
   Haack TB, 2010, NAT GENET, V42, P1131, DOI 10.1038/ng.706
   Krishnan KJ, 2008, NAT GENET, V40, P275, DOI 10.1038/ng.f.94
   Moraes C, 1989, NEW ENGL J MED, V18, P1293
   Nouws J, 2014, JIMD REP, V12, P37, DOI 10.1007/8904_2013_242
   Paul R, 1996, TRENDS GENET, V12, P131
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   Schiff M, 2015, HUM MOL GENET, V24, P3238, DOI 10.1093/hmg/ddv074
NR 12
TC 4
Z9 4
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0148-639X
EI 1097-4598
J9 MUSCLE NERVE
JI Muscle Nerve
PD JUN
PY 2017
VL 55
IS 6
BP 919
EP 922
DI 10.1002/mus.25262
PG 4
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA EY5TA
UT WOS:000404041600027
PM 27438479
DA 2024-11-01
ER

PT J
AU Akman, HO
   Dorado, B
   López, LC
   García-Cazorla, A
   Vilà, MR
   Tanabe, LM
   Dauer, WT
   Bonilla, E
   Tanji, K
   Hirano, M
AF Akman, Hasan O.
   Dorado, Beatriz
   Lopez, Luis C.
   Garcia-Cazorla, Angeles
   Vila, Maya R.
   Tanabe, Lauren M.
   Dauer, William T.
   Bonilla, Eduardo
   Tanji, Kurenai
   Hirano, Michio
TI Thymidine kinase 2 (H126N) knockin mice show the essential role of
   balanced deoxynucleotide pools for mitochondrial DNA maintenance
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID MTDNA DEPLETION; TK2 DEFICIENCY; NEUROGASTROINTESTINAL
   ENCEPHALOMYOPATHY; INTERGENOMIC COMMUNICATION; MULTIPLE DELETIONS;
   RESPIRATORY-CHAIN; GENE-MUTATIONS; COPY NUMBER; KINASE GENE; MYOPATHY
AB Mitochondrial DNA (mtDNA) depletion syndrome (MDS), an autosomal recessive condition, is characterized by variable organ involvement with decreased mtDNA copy number and activities of respiratory chain enzymes in affected tissues. MtDNA depletion has been associated with mutations in nine autosomal genes, including thymidine kinase (TK2), which encodes a ubiquitous mitochondrial protein. To study the pathogenesis of TK2-deficiency, we generated mice harboring an H126N Tk2 mutation. Homozygous Tk2 mutant (Tk2(-/-)) mice developed rapidly progressive weakness after age 10 days and died between ages 2 and 3 weeks. Tk2(-/-) animals showed Tk2 deficiency, unbalanced dNTP pools, mtDNA depletion and defects of respiratory chain enzymes containing mtDNA-encoded subunits that were most prominent in the central nervous system. Histopathology revealed an encephalomyelopathy with prominent vacuolar changes in the anterior horn of the spinal cord. The H126N TK2 mouse is the first knock-in animal model of human MDS and demonstrates that the severity of TK2 deficiency in tissues may determine the organ-specific phenotype.
C1 [Akman, Hasan O.; Dorado, Beatriz; Lopez, Luis C.; Garcia-Cazorla, Angeles; Dauer, William T.; Bonilla, Eduardo; Hirano, Michio] Columbia Univ, Med Ctr, Dept Neurol, New York, NY 10032 USA.
   [Garcia-Cazorla, Angeles] Columbia Univ, Med Ctr, Dept Pharmacol, New York, NY 10032 USA.
   [Vila, Maya R.] Columbia Univ, Med Ctr, Dept Pathol, New York, NY 10032 USA.
   [Tanabe, Lauren M.; Dauer, William T.] Hosp St Joan Deu, Dept Neurol, Barcelona, Spain.
   [Tanabe, Lauren M.; Dauer, William T.] Inst Salud Carlos III, CIBER ER, Barcelona, Spain.
   [Bonilla, Eduardo; Tanji, Kurenai] Hosp Univ Vall Hebron, Ctr Invest Bioquim & Biol Mol CIBBIM, Barcelona, Spain.
C3 Columbia University; Columbia University; Columbia University;
   University of Barcelona; Instituto de Salud Carlos III; CIBER - Centro
   de Investigacion Biomedica en Red; CIBERER; Hospital Universitari Vall
   d'Hebron
RP Hirano, M (corresponding author), Columbia Univ, Med Ctr, Dept Neurol, 1150 St Nicholas Ave,Russ Berrie Med Pavil,Room 3, New York, NY 10032 USA.
EM mh29@columbia.edu
RI ; Lopez, Luis Carlos/L-5129-2014
OI Dorado, Beatriz/0000-0002-1958-4558; Dauer, William/0000-0003-1775-7504;
   Lopez, Luis Carlos/0000-0003-3355-0298; Tanabe,
   Lauren/0000-0003-1760-3468
FU NICHD NIH HHS [R01 HD057543] Funding Source: Medline; NINDS NIH HHS [P01
   NS011766] Funding Source: Medline
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   ARNER ESJ, 1992, BIOCHEM BIOPH RES CO, V188, P712, DOI 10.1016/0006-291X(92)91114-6
   Barrientos A, 2002, METHODS, V26, P307, DOI 10.1016/S1046-2023(02)00036-1
   Barthélémy C, 2001, ANN NEUROL, V49, P607, DOI 10.1002/ana.1002.abs
   BOGENHAGEN D, 1977, CELL, V11, P719, DOI 10.1016/0092-8674(77)90286-0
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Ferraro P, 2005, J BIOL CHEM, V280, P24472, DOI 10.1074/jbc.M502869200
   Ferraro P, 2006, P NATL ACAD SCI USA, V103, P18586, DOI 10.1073/pnas.0609020103
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   Hirano M, 2004, TOP CURR GENET, V8, P177
   Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279
   Kirby DM, 2007, METHOD CELL BIOL, V80, P93, DOI 10.1016/S0091-679X(06)80004-X
   Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231
   Mancuso M, 2003, ARCH NEUROL-CHICAGO, V60, P1007, DOI 10.1001/archneur.60.7.1007
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Manfredi G, 2002, METHODS, V26, P317, DOI 10.1016/S1046-2023(02)00037-3
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Moraes CT, 2001, TRENDS GENET, V17, P199, DOI 10.1016/S0168-9525(01)02238-7
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nevo Y, 2002, J CHILD NEUROL, V17, P499, DOI 10.1177/088307380201700705
   Nishigaki Y, 2004, HUM MOL GENET, V13, P91, DOI 10.1093/hmg/ddh010
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Oskoui M, 2006, ARCH NEUROL-CHICAGO, V63, P1122, DOI 10.1001/archneur.63.8.1122
   Ostergaard E, 2007, AM J HUM GENET, V81, P383, DOI 10.1086/519222
   Rylova SN, 2007, BIOCHEM PHARMACOL, V74, P169, DOI 10.1016/j.bcp.2007.03.029
   Saada A, 2003, MOL GENET METAB, V79, P1, DOI 10.1016/S1096-7192(03)00063-5
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284
   Sarzi E, 2007, ANN NEUROL, V62, P579, DOI 10.1002/ana.21207
   SHERMAN PA, 1989, ANAL BIOCHEM, V180, P222, DOI 10.1016/0003-2697(89)90420-X
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Spinazzola A, 2007, BIOSCIENCE REP, V27, P39, DOI 10.1007/s10540-007-9036-1
   Tanji K, 1999, ANN NEUROL, V45, P377, DOI 10.1002/1531-8249(199903)45:3<377::AID-ANA14>3.0.CO;2-M
   Vilá MR, 2008, J NEUROL SCI, V267, P137, DOI 10.1016/j.jns.2007.10.019
   Vilà MR, 2003, NEUROLOGY, V60, P1203, DOI 10.1212/01.WNL.0000055928.58122.47
   Wang LY, 2003, J BIOL CHEM, V278, P6963, DOI 10.1074/jbc.M206143200
NR 38
TC 84
Z9 95
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD AUG 15
PY 2008
VL 17
IS 16
BP 2433
EP 2440
DI 10.1093/hmg/ddn143
PG 8
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 330SL
UT WOS:000257963000003
PM 18467430
OA Green Published, Bronze
DA 2024-11-01
ER

PT J
AU Baek, MS
   Kim, SH
   Lee, YM
AF Baek, Min-Seong
   Kim, Se Hoon
   Lee, Young-Mock
TI The Usefulness of Muscle Biopsy in Initial Diagnostic Evaluation of
   Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-Like
   Episodes
SO YONSEI MEDICAL JOURNAL
LA English
DT Article
DE MELAS; muscle biopsy; genetic diagnosis; morphological diagnosis
ID CLINICAL-FEATURES; MELAS; MUTATION; ENCEPHALOPATHY; DISEASE; PREVALENCE;
   MANAGEMENT; PHENOTYPE; MYOPATHY; COHORT
AB Purpose: The disease entity mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) is characterized by an early onset of stroke-like episodes. MELAS is the most dominant subtype of mitochondrial disease. Molecular genetic testing is important in the diagnosis of MELAS. The mitochondrial DNA (mtDNA) 3243A>G mutation is found in 80% of MELAS patients. Nevertheless, molecular analysis alone may be insufficient to diagnose MELAS because of mtDNA heteroplasmy. This study aimed to evaluate whether muscle biopsy is useful in MELAS patients as an initial diagnostic evaluation method.
   Materials and Methods: The medical records of patients who were diagnosed with MELAS at the Department of Pediatrics of Gangnam Severance Hospital between January 2006 and January 2017 were reviewed. The study population included 12 patients. They were divided into two subgroups according to whether the results of muscle pathology were in accordance with mitochondrial diseases. Clinical variables, diagnostic evaluations, and clinical outcomes were compared between the two groups.
   Results: Of the 12 patients, seven were muscle pathology-positive for mitochondrial disease. No statistically significant difference in clinical data was observed between the groups that were muscle pathology-positive and muscle pathology-negative for mtDNA 3243A>G mutation. Additionally, the patients with weakness as the initial symptom were all muscle pathology-positive.
   Conclusion: The usefulness of muscle biopsy appears to be limited to an initial confirmative diagnostic evaluation of MELAS. Muscle biopsy can provide some information in MELAS patients with weakness not confirmed by genetic testing.
C1 [Baek, Min-Seong; Lee, Young-Mock] Yonsei Univ, Coll Med, Dept Pediat, Seoul, South Korea.
   [Kim, Se Hoon] Yonsei Univ, Coll Med, Dept Pathol, Seoul, South Korea.
C3 Yonsei University; Yonsei University Health System; Yonsei University;
   Yonsei University Health System
RP Lee, YM (corresponding author), Yonsei Univ, Coll Med, Gangnam Severance Hosp, Dept Pediat, 211 Eonju Ro, Seoul 06273, South Korea.
EM ymleemd@yuhs.ac
RI Lee, Jun Young/CAI-2335-2022; Kim, Hyoungil/M-7288-2019
OI LEE, YOUNG-MOCK/0000-0002-5838-249X; Kim, Se Hoon/0000-0001-7516-7372
FU Korea Health Technology R&D Project through the Korea Health Industry
   Development Institute (KHIDI) - Ministry of Health & Welfare, Republic
   of Korea [HI16C0673]
FX This research was supported by a grant from the Korea Health Technology
   R&D Project through the Korea Health Industry Development Institute
   (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea
   (grant number: HI16C0673).
CR El-Hattab AW, 2015, MOL GENET METAB, V116, P4, DOI 10.1016/j.ymgme.2015.06.004
   GOTO Y, 1992, NEUROLOGY, V42, P545, DOI 10.1212/WNL.42.3.545
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   GOTO Y, 1995, MUSCLE NERVE, pS107
   Haas RH, 2007, PEDIATRICS, V120, P1326, DOI 10.1542/peds.2007-0391
   HIRANO M, 1992, NEUROMUSCULAR DISORD, V2, P125, DOI 10.1016/0960-8966(92)90045-8
   Joyce NC, 2012, PHYS MED REH CLIN N, V23, P609, DOI 10.1016/j.pmr.2012.06.006
   Kisler JE, 2010, DEV MED CHILD NEUROL, V52, P422, DOI 10.1111/j.1469-8749.2009.03605.x
   Koenig MK, 2008, PEDIATR NEUROL, V38, P305, DOI 10.1016/j.pediatrneurol.2007.12.001
   Lorenzoni PJ, 2009, ARQ NEURO-PSIQUIAT, V67, P668, DOI 10.1590/S0004-282X2009000400018
   Manwaring N, 2007, MITOCHONDRION, V7, P230, DOI 10.1016/j.mito.2006.12.004
   MORAES CT, 1993, NEUROMUSCULAR DISORD, V3, P43, DOI 10.1016/0960-8966(93)90040-Q
   MORTEN KJ, 1993, HUM MOL GENET, V2, P2081, DOI 10.1093/hmg/2.12.2081
   Nesbitt V, 2013, J NEUROL NEUROSUR PS, V84, P936, DOI 10.1136/jnnp-2012-303528
   Parikh S, 2015, GENET MED, V17, P689, DOI 10.1038/gim.2014.177
   Parsons T, 2010, ARCH NEUROL-CHICAGO, V67, P976, DOI 10.1001/archneurol.2010.174
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   Rollins S, 2001, AM J CLIN PATHOL, V116, P326
   Sproule DM, 2008, ANN NY ACAD SCI, V1142, P133, DOI 10.1196/annals.1444.011
   Uusimaa J, 2007, ANN NEUROL, V62, P278, DOI 10.1002/ana.21196
   Yatsuga S, 2012, BBA-GEN SUBJECTS, V1820, P619, DOI 10.1016/j.bbagen.2011.03.015
   Zeviani M, 2004, BRAIN, V127, P2153, DOI 10.1093/brain/awh259
NR 22
TC 5
Z9 6
U1 0
U2 5
PU YONSEI UNIV COLL MEDICINE
PI SEOUL
PA 50-1 YONSEI-RO, SEODAEMUN-GU, SEOUL 120-752, SOUTH KOREA
SN 0513-5796
EI 1976-2437
J9 YONSEI MED J
JI Yonsei Med. J.
PD JAN
PY 2019
VL 60
IS 1
BP 98
EP 105
DI 10.3349/ymj.2019.60.1.98
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA HE3FA
UT WOS:000453236500012
PM 30554496
OA Green Submitted, Green Published, gold
DA 2024-11-01
ER

PT J
AU Durham, SE
   Bonilla, E
   Samuels, DC
   DiMauro, S
   Chinnery, PF
AF Durham, SE
   Bonilla, E
   Samuels, DC
   DiMauro, S
   Chinnery, PF
TI Mitochondrial DNA copy number threshold in mtDNA depletion myopathy
SO NEUROLOGY
LA English
DT Article
ID THYMIDINE KINASE; MUTATIONS; GENE; DEFICIENCY
AB The authors measured the absolute amount of mitochondrial DNA ( mtDNA) within single muscle fibers from two patients with thymidine kinase 2 (TK2) deficiency and two healthy controls. TK2 deficient fibers containing more than 0.01 mtDNA/mu m(3) had residual cytochrome c oxidase ( COX) activity. This defines the minimum amount of wild-type mtDNA molecules required to maintain COX activity in skeletal muscle and provides an explanation for the mosaic histochemical pattern seen in patients with mtDNA depletion syndrome.
C1 Univ Newcastle Upon Tyne, Mitochondrial Res Grp, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
   Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY USA.
   Virginia Polytech Inst & State Univ, Virginia Bioinformat Inst, Blacksburg, VA 24061 USA.
C3 Newcastle University - UK; Columbia University; Virginia Polytechnic
   Institute & State University
RP Sch Med, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM P.F.Chinnery@ncl.ac.uk
RI Samuels, David/A-5393-2008
OI Samuels, David/0000-0003-3529-7791; Chinnery,
   Patrick/0000-0002-7065-6617
FU NICHD NIH HHS [HD32062] Funding Source: Medline; Wellcome Trust Funding
   Source: Medline
CR Barthélémy C, 2001, ANN NEUROL, V49, P607, DOI 10.1002/ana.1002.abs
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Vilà MR, 2003, NEUROLOGY, V60, P1203, DOI 10.1212/01.WNL.0000055928.58122.47
NR 8
TC 40
Z9 43
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0028-3878
EI 1526-632X
J9 NEUROLOGY
JI Neurology
PD AUG 9
PY 2005
VL 65
IS 3
BP 453
EP 455
DI 10.1212/01.wnl.0000171861.30277.88
PG 3
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 953HM
UT WOS:000231067200022
PM 16087914
DA 2024-11-01
ER

PT J
AU Coulbault, L
   Herlicoviez, D
   Chapon, F
   Read, MH
   Penniello, MJ
   Reynier, P
   Fayet, G
   Lombès, A
   Jauzac, P
   Allouche, S
AF Coulbault, L
   Herlicoviez, D
   Chapon, F
   Read, MH
   Penniello, MJ
   Reynier, P
   Fayet, G
   Lombès, A
   Jauzac, P
   Allouche, S
TI A novel mutation in the mitochondrial tRNA<SUP>Asn</SUP> gene associated
   with a lethal disease
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE lethal infantile mitochondrial disease; mtDNA; tRNA(Asn) gene mutation;
   respiratory chain deficiency; cytochrome c oxidase deficiency
ID MYOPATHY; SEQUENCE; RNA
AB We describe a lethal mitochondrial disease in a 10-month-old child who presented with encephalomyopathy. Histochemical and electron microscopy examinations of skeletal muscle biopsy revealed abnormal mitochondria associated with a combined deficiency of complexes I and IV. After excluding mitochondrial DNA deletions and depletion, direct sequencing was used to screen for mutation in all transfer RNA (tRNA) genes. A T-to-C Substitution at position 5693 in the tRNA(Asn) gene was found in blood and muscle. Microdissection of muscle biopsy and its analysis revealed the highest level of this mutation in cytochrome c oxidase (COX)-negative fibres. We suggest that this novel mutation would affect the anticodon loop structure of the tRNA(Asn) and cause a fatal mitochondrial disease. (c) 2005 Elsevier Inc. All rights reserved.
C1 Ctr Hosp, Biochim Lab A, F-14033 Caen, France.
   Univ Caen, F-14033 Caen, France.
   Ctr Hosp, Serv Anat Pathol, F-14033 Caen, France.
   Ctr Hosp, Dept Genet & Reprod, F-14033 Caen, France.
   Ctr Hosp, Dept Pediat, F-14033 Caen, France.
   Ctr Hosp, Lab Biochim & Biol Mol, INSERM, U694, F-14033 Caen, France.
   Ctr Hosp, Inst Myol, INSERM, U582, F-75013 Paris, France.
   Univ Pitie Salpetriere, F-75013 Paris, France.
C3 CHU de Caen NORMANDIE; Universite de Caen Normandie; CHU de Caen
   NORMANDIE; CHU de Caen NORMANDIE; CHU de Caen NORMANDIE; Institut
   National de la Sante et de la Recherche Medicale (Inserm); CHU de Caen
   NORMANDIE; Assistance Publique Hopitaux Paris (APHP); Institut National
   de la Sante et de la Recherche Medicale (Inserm); Sorbonne Universite;
   Sorbonne Universite
RP Ctr Hosp, Biochim Lab A, Ave Cote Nacre, F-14033 Caen, France.
EM allouche-s@chu-caen.fr
RI Reynier, Pascal/K-3677-2015; Allouche, Stephane/AFW-3810-2022; Lombes,
   Anne/G-4684-2014
OI Allouche, stephane/0000-0003-3134-7501; Reynier,
   Pascal/0000-0003-0802-4608
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   BROWN MD, 1992, AM J HUM GENET, V51, P446
   Chomyn A, 2000, J BIOL CHEM, V275, P19198, DOI 10.1074/jbc.M908734199
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Helm M, 2000, RNA, V6, P1356, DOI 10.1017/S1355838200001047
   Malgat M., 1999, Mitochondrial Diseases, P357, DOI [10.1007/978-3-642-59884-5_27, DOI 10.1007/978-3-642-59884-5_27]
   May-Panloup P, 2003, HUM REPROD, V18, P550, DOI 10.1093/humrep/deg096
   Merante F, 1996, HUM MUTAT, V8, P216, DOI 10.1002/(SICI)1098-1004(1996)8:3<216::AID-HUMU4>3.0.CO;2-7
   REYNIER P, 1999, MITOCHONDRIAL DIS, P379
   Romero NB., 1999, Mitochondrial diseases- models and methods, P343
   SEIBEL P, 1994, BIOCHEM BIOPH RES CO, V204, P482, DOI 10.1006/bbrc.1994.2485
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   Sternberg D, 2001, BRAIN, V124, P984, DOI 10.1093/brain/124.5.984
NR 13
TC 13
Z9 13
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD APR 15
PY 2005
VL 329
IS 3
BP 1152
EP 1154
DI 10.1016/j.bbrc.2005.02.083
PG 3
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 909UI
UT WOS:000227885800048
PM 15752774
DA 2024-11-01
ER

PT S
AU Duran, GP
   Martinez-Aguayo, A
   Poggi, H
   Lagos, M
   Gutierrez, D
   Harris, PR
AF Duran, Gloria P.
   Martinez-Aguayo, A.
   Poggi, H.
   Lagos, M.
   Gutierrez, D.
   Harris, P. R.
GP SSIEM
TI Large Mitochondrial DNA Deletion in an Infant with Addison Disease
SO JIMD REPORTS - CASE AND RESEARCH REPORTS, 2011/3
SE JIMD Reports
LA English
DT Article; Book Chapter
ID KEARNS-SAYRE-SYNDROME; GROWTH-HORMONE DEFICIENCY; CHRONIC-PANCREATITIS;
   MANIFESTATION; EVOLUTION; CHILD
AB Background: Mitochondrial diseases are a group of disorders caused by mutations in nuclear DNA or mitochondrial DNA, usually involving multiple organ systems. Primary adrenal insufficiency due to mitochondrial disease is extremely infrequent and has been reported in association with mitochondrial DNA deletion syndromes such as Kearns-Sayre syndrome.
   Aim: To report a 3-year-old boy with Addison disease, congenital glaucoma, chronic pancreatitis, and mitochondrial myopathy due to large mitochondrial DNA deletion.
   Method: Molecular analysis of mitochondrial DNA samples obtained from peripheral blood, oral mucosa, and muscle tissue.
   Results: A novel large mitochondrial DNA deletion of 7,372 bp was identified involving almost all genes on the big arch of mtDNA.
   Conclusions: This case reaffirms the association of adrenal insufficiency and mitochondrial DNA deletions and presents new evidence that glaucoma is another manifestation of mitochondrial diseases. Due to the genetic and clinical heterogeneity of mitochondrial disorders, molecular analysis is crucial to confirm diagnosis and to allow accurate genetic counseling.
C1 [Duran, Gloria P.; Martinez-Aguayo, A.; Harris, P. R.] Pontificia Univ Catolica Chile, Dept Pediat, Sch Med, Santiago 8330074, Chile.
   [Poggi, H.; Lagos, M.; Gutierrez, D.] Pontificia Univ Catolica Chile, Dept Clin Labs, Sch Med, Santiago 8330074, Chile.
C3 Pontificia Universidad Catolica de Chile; Pontificia Universidad
   Catolica de Chile
RP Duran, GP (corresponding author), Pontificia Univ Catolica Chile, Dept Pediat, Sch Med, Lira 85,5 Piso, Santiago 8330074, Chile.
EM gduran@med.puc.cl
RI Harris, Paul/HKF-7359-2023
OI Poggi, Helena/0000-0002-5046-639X; Harris, Paul/0000-0001-6226-0957
CR AMMANN RW, 1988, GASTROENTEROLOGY, V95, P1018, DOI 10.1016/0016-5085(88)90178-3
   Arlt W, 2003, LANCET, V361, P1881, DOI 10.1016/S0140-6736(03)13492-7
   Boles RG, 1998, EUR J PEDIATR, V157, P643, DOI 10.1007/s004310050902
   Cassandrini D, 2006, J CHILD NEUROL, V21, P983, DOI 10.1177/08830738060210111001
   Ferlin T, 1997, MOL CELL BIOCHEM, V174, P221, DOI 10.1023/A:1006860508606
   Finsterer J, 2007, Minerva Gastroenterol Dietol, V53, P285
   Finsterer J, 2007, AM J MED GENET A, V143A, P632, DOI 10.1002/ajmg.a.31629
   Gücüyener K, 1998, J INHERIT METAB DIS, V21, P173, DOI 10.1023/A:1005304015278
   HARVEY JN, 1992, CLIN ENDOCRINOL, V37, P97, DOI 10.1111/j.1365-2265.1992.tb02289.x
   KATO S, 1990, J PEDIATR GASTR NUTR, V11, P549, DOI 10.1097/00005176-199011000-00018
   Kishnani PS, 1996, EUR J PEDIATR, V155, P898
   Kleinle S, 1997, HUM GENET, V100, P643, DOI 10.1007/s004390050567
   ROTIG A, 1993, J INHERIT METAB DIS, V16, P527, DOI 10.1007/BF00711672
   Sanaker PS, 2007, ACTA NEUROL SCAND, V115, P64, DOI 10.1111/j.1600-0404.2007.00850.x
   Schleiffer T, 2000, EXP CLIN ENDOCR DIAB, V108, P81, DOI 10.1055/s-2000-5800
   SCURO LA, 1990, INT J PANCREATOL, V6, P139
   Simaan EM, 1999, PEDIATR NEUROL, V21, P830, DOI 10.1016/S0887-8994(99)00084-3
   Toyono M, 2001, NEUROMUSCULAR DISORD, V11, P300, DOI 10.1016/S0960-8966(00)00176-0
   Tsao CY, 2000, J CHILD NEUROL, V15, P822, DOI 10.1177/088307380001501213
   Wong LJC, 2007, MITOCHONDRION, V7, P45, DOI 10.1016/j.mito.2006.11.025
   Yamashita S, 2008, J HUM GENET, V53, P598, DOI 10.1007/s10038-008-0289-8
NR 21
TC 11
Z9 11
U1 0
U2 5
PU SPRINGER-VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
SN 2192-8304
BN 978-3-642-24936-5
J9 JIMD REP
PY 2012
VL 3
BP 5
EP 9
DI 10.1007/8904_2011_33
D2 10.1007/978-3-642-24936-5
PG 5
WC Genetics & Heredity
WE Book Citation Index – Science (BKCI-S)
SC Genetics & Heredity
GA BEB08
UT WOS:000315963200002
PM 23430867
OA Green Published
DA 2024-11-01
ER

PT J
AU Hedermann, G
   Lokken, N
   Dahlqvist, JR
   Vissing, J
AF Hedermann, Gitte
   Lokken, Nicoline
   Dahlqvist, Julia R.
   Vissing, John
TI Dysphagia is prevalent in patients with CPEO and single, large-scale
   deletions in mtDNA
SO MITOCHONDRION
LA English
DT Article
DE Chronic progressive external ophthalmoplegia; Dysphagia; Mitochondrial
   myopathy; Single large-scale deletion; CPEO
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; DISEASE; COMMON
AB Background: The aim of this study was to assess the frequency of subjective and objective dysphagia in patients with chronic progressive external ophthalmoplegia (CPEO) due to single, large-scale deletions (LSDs) of mitochondrial DNA (mtDNA).
   Methods: Sixteen patients with CPEO and single LSDs of mtDNA were included in the study and compared to a control group of 12 patients with the m.3243A > G mtDNA mutation. Patients had to drink 80 ml of water at 4 degrees C as fast as they could (cold-water test) and fill out a standardized questionnaire about dysphagia.
   Results: Eight patients (50%) with CPEO and single LSDs of mtDNA had a prolonged cold-water test, including one with a PEG-tube, who was unable to perform the test, and nine patients reported subjective swallowing problems (56.3%). All mitochondrial myopathy patients in the control group had a normal duration of the cold-water test.
   Conclusions: The study shows that dysphagia is a common problem in patients with CPEO and LSDs of mtDNA. Dysphagia seems to be progressive with age as abnormal swallowing occurred preferentially in persons >= 45 years. The study shows that increased awareness of this symptom should be given to address appropriate treatment interventions and avoid complications such as social isolation, malnutrition and aspiration pneumonia. (C) 2016 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 [Hedermann, Gitte; Lokken, Nicoline; Dahlqvist, Julia R.; Vissing, John] Univ Copenhagen, Dept Neurol, Copenhagen Neuromuscular Ctr, Rigshosp, Sect 3342,Blegdamsvej 9, DK-2100 Copenhagen, Denmark.
C3 University of Copenhagen; Rigshospitalet
RP Hedermann, G (corresponding author), Univ Copenhagen, Dept Neurol, Copenhagen Neuromuscular Ctr, Rigshosp, Sect 3342,Blegdamsvej 9, DK-2100 Copenhagen, Denmark.
EM hedermann@gmail.com; nicoline.loekken@regionh.dk;
   julia.rebecka.dahlqvist@regionh.dk; vissing@rh.dk
RI Vissing, John/IUN-4271-2023; Christensen, Gitte/GRY-3412-2022; Løkken,
   Nicoline/GZL-0909-2022
OI Hedermann, Gitte/0000-0001-8853-0986; Dahlqvist, Julia
   Rebecka/0000-0002-3149-1661; Lokken, Nicoline/0000-0002-5494-8484
CR Altmann J, 2016, J NEUROL, V263, P961, DOI 10.1007/s00415-016-8086-3
   Auré K, 2007, BRAIN, V130, P1516, DOI 10.1093/brain/awm067
   Cox FM, 2009, J NEUROL, V256, P2009, DOI 10.1007/s00415-009-5229-9
   Knuijt S, 2014, DISABIL REHABIL, V36, P1285, DOI 10.3109/09638288.2013.845255
   Kornblum C, 2001, NEUROLOGY, V56, P1409, DOI 10.1212/WNL.56.10.1409
   Mancuso M, 2015, J NEUROL, V262, P1301, DOI 10.1007/s00415-015-7710-y
   Martin-Negrier ML, 2011, EUR J NEUROL, V18, P436, DOI 10.1111/j.1468-1331.2010.03171.x
   Pfeffer G, 2011, CAN J NEUROL SCI, V38, P119, DOI 10.1017/S031716710001115X
   Read JL, 2012, INT J LANG COMM DIS, V47, P106, DOI 10.1111/j.1460-6984.2011.00072.x
   WINTZEN AR, 1994, CAN J NEUROL SCI, V21, P53, DOI 10.1017/S0317167100048770
   Witting N, 2014, ACTA NEUROL SCAND, V130, P125, DOI 10.1111/ane.12244
NR 11
TC 8
Z9 10
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 1872-8278
J9 MITOCHONDRION
JI Mitochondrion
PD JAN
PY 2017
VL 32
BP 27
EP 30
DI 10.1016/j.mito.2016.11.007
PG 4
WC Cell Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Genetics & Heredity
GA EI0LG
UT WOS:000392165400005
PM 27856367
DA 2024-11-01
ER

PT J
AU Saada-Reisch, A
AF Saada-Reisch, A
TI Deoxyribonucleoside kinases in mitochondrial DNA depletion
SO NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS
LA English
DT Article; Proceedings Paper
CT Joint 11th International and 9th European Symposium on Purines and
   Pyrimidines in Man
CY JUN 09-13, 2003
CL Egmond Aan Zee, NETHERLANDS
DE mitochondrial DNA depletion; thymidine kinase 2; deoxyguanosine kinase;
   respiratory chain; myopathy; hepatocerebral; deoxyribonucleoside;
   deoxyribonucleotide
ID THYMIDINE KINASE; MTDNA DEPLETION; GENE; MUTATIONS; MYOPATHY; CELL;
   REPLICATION; METABOLISM; EXPRESSION; MECHANISM
AB Mitochondrial DNA (mtDNA) depletion syndromes (MDS) are a heterogeneous group of mitochondrial disorders, manifested by a decreased mtDNA copy number and respiratory chain dysfunction. Primary MDS are inherited autosomally and may affect a single organ or multiple tissues. Mutated mitochondrial deoxyribonucleoside kinases; deoxyguanosine kinase (dGK) and thymidine kinase 2 (TK2), were associated with the hepatocerebral and myopathic forms of MDS respectively. dGK and TK2 are key enzymes in the mitochondrial nucleotide salvage pathway, providing the mitochondria with deoxyribonucleotides (dNP) essential for mtDNA synthesis. Although the mitochondrial dNP pool is physically separated from the cytosolic one, dNP's may still be imported through specific transport. Non-replicating tissues, where cytosolic dNP supply is down regulated, are thus particularly vulnerable to dGK and TK2 deficiency. The overlapping substrate specificity of deoxycytidine kinase (dCK) may explain the relative sparing of muscle in dGK deficiency, while low basal TK2 activity render this tissue susceptible to TK2 deficiency. The precise pathophysiological mechanisms of mtDNA depletion due to dGK and TK2 deficiencies remain to be determined, though recent findings confirm that it is attributed to imbalanced dNTP pools.
C1 Shaare Zedek Med Ctr, Metab Dis Unit, IL-91031 Jerusalem, Israel.
C3 Hebrew University of Jerusalem; Shaare Zedek Medical Center
RP Shaare Zedek Med Ctr, Metab Dis Unit, POB Reisch 3235, IL-91031 Jerusalem, Israel.
RI Saada, Ann/J-6864-2017
OI Saada, Ann/0000-0003-2951-0656
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   ARNER ESJ, 1995, PHARMACOL THERAPEUT, V67, P155, DOI 10.1016/0163-7258(95)00015-9
   BESTWICK RK, 1982, J BIOL CHEM, V257, P9305
   Carrozzo R, 2003, HUM MUTAT, V21, DOI 10.1002/humu.9135
   Dolce V, 2001, P NATL ACAD SCI USA, V98, P2284, DOI 10.1073/pnas.031430998
   Elpeleg O, 2003, PEDIATR RES, V54, P153, DOI 10.1203/01.PDR.0000072796.25097.A5
   Elpeleg O, 2002, J MOL MED-JMM, V80, P389, DOI 10.1007/s00109-002-0343-5
   Eriksson S, 2002, CELL MOL LIFE SCI, V59, P1327, DOI 10.1007/s00018-002-8511-x
   Gallinaro L, 2002, J BIOL CHEM, V277, P35080, DOI 10.1074/jbc.M203755200
   Johansson K, 2001, NAT STRUCT BIOL, V8, P616, DOI 10.1038/89661
   KARLSSON A, 2003, JOINT 11 INT 9 EUR S
   Kowluru A, 2002, ARCH BIOCHEM BIOPHYS, V398, P160, DOI 10.1006/abbi.2001.2710
   Lewis W, 2003, AM J PHYSIOL-HEART C, V284, pH1, DOI 10.1152/ajpheart.00814.2002
   Mancuso M, 2003, ARCH NEUROL-CHICAGO, V60, P1007, DOI 10.1001/archneur.60.7.1007
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Martí R, 2003, CLIN CHEM LAB MED, V41, P845, DOI 10.1515/CCLM.2003.128
   Martomo SA, 2002, MUTAT RES-FUND MOL M, V499, P197, DOI 10.1016/S0027-5107(01)00283-4
   Mazzon C, 2003, BIOCHEM PHARMACOL, V66, P471, DOI 10.1016/S0006-2952(03)00290-9
   Nevo Y, 2002, J CHILD NEUROL, V17, P499, DOI 10.1177/088307380201700705
   Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828
   Noma T, 2001, BIOCHEM J, V358, P225, DOI 10.1042/0264-6021:3580225
   Saada A, 2003, BIOCHEM BIOPH RES CO, V310, P963, DOI 10.1016/j.bbrc.2003.09.104
   Saada A, 2003, MOL GENET METAB, V79, P1, DOI 10.1016/S1096-7192(03)00063-5
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284
   Shadel GS, 1997, ANNU REV BIOCHEM, V66, P409, DOI 10.1146/annurev.biochem.66.1.409
   Spinazzola A, 2002, J BIOL CHEM, V277, P4128, DOI 10.1074/jbc.M111028200
   Taanman JW, 2003, HUM MOL GENET, V12, P1839, DOI 10.1093/hmg/ddg192
   Taanman JW, 2002, ANN NEUROL, V52, P237, DOI 10.1002/ana.10247
   van der Wilt CL, 2003, EUR J CANCER, V39, P691, DOI 10.1016/S0959-8049(02)00813-4
   Vilà MR, 2003, NEUROLOGY, V60, P1203, DOI 10.1212/01.WNL.0000055928.58122.47
   Wang LY, 2003, J BIOL CHEM, V278, P6963, DOI 10.1074/jbc.M206143200
   YOUNG P, 1994, BIOCHEM BIOPH RES CO, V203, P46, DOI 10.1006/bbrc.1994.2146
NR 34
TC 15
Z9 18
U1 1
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1525-7770
EI 1532-2335
J9 NUCLEOS NUCLEOT NUCL
JI Nucleosides Nucleotides Nucleic Acids
PD OCT
PY 2004
VL 23
IS 8-9
BP 1205
EP 1215
DI 10.1081/NCN-200027480
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)
SC Biochemistry & Molecular Biology
GA 871EY
UT WOS:000225113700028
PM 15571232
DA 2024-11-01
ER

PT J
AU Cao, M
   Donà, M
   Valentino, L
   Semplicini, C
   Maresca, A
   Cassina, M
   Torraco, A
   Galletta, E
   Manfioli, V
   Sorarù, G
   Carelli, V
   Stramare, R
   Bertini, E
   Carozzo, R
   Salviati, L
   Pegoraro, E
AF Cao, Michelangelo
   Dona, Marta
   Valentino, Lucia
   Semplicini, Claudio
   Maresca, Alessandra
   Cassina, Matteo
   Torraco, Alessandra
   Galletta, Eva
   Manfioli, Valeria
   Soraru, Gianni
   Carelli, Valerio
   Stramare, Roberto
   Bertini, Enrico
   Carozzo, Rosalba
   Salviati, Leonardo
   Pegoraro, Elena
TI Clinical and molecular study in a long-surviving patient with MLASA
   syndrome due to novel <i>PUS1</i> mutations
SO NEUROGENETICS
LA English
DT Article
DE Mitochondrial biogenesis; MLASA; mtDNA copy number; PUS1
ID SIDEROBLASTIC ANEMIA-MLASA; MITOCHONDRIAL MYOPATHY; LACTIC-ACIDOSIS;
   TRANSFER-RNA; MISSENSE MUTATION; GENE; YARS2; DEFICIENCY
AB Myopathy-lactic acidosis-sideroblastic anemia (MLASA) syndrome is a rare autosomal recessive disease. We studied a 43-year-old female presenting since childhood with mild cognitive impairment and sideroblastic anemia. She later developed hepatopathy, cardiomyopathy, and insulin-dependent diabetes. Muscle weakness appeared in adolescence and, at age 43, she was unable to walk. Two novel different mutations in the PUS1 gene were identified: c.487delA (p.I163Lfs*4) and c.884 G > A (p.R295Q). Quantitative analysis of DNA from skeletal muscle biopsies showed a significant increase in mitochondrial DNA (mtDNA) content in the patient compared to controls. Clinical and molecular findings of this patient widen the genotype-phenotype spectrum in MLASA syndrome.
C1 [Cao, Michelangelo; Semplicini, Claudio; Galletta, Eva; Manfioli, Valeria; Soraru, Gianni; Pegoraro, Elena] Univ Padua, Dept Neurosci, Padua, Italy.
   [Dona, Marta; Cassina, Matteo; Salviati, Leonardo] Univ Padua, Dept Womens & Childrens Hlth, Padua, Italy.
   [Valentino, Lucia; Carelli, Valerio] Univ Bologna, Neurol Unit, Dept Biomed & NeuroMotor Sci DIBINEM, Bologna, Italy.
   [Valentino, Lucia; Maresca, Alessandra; Carelli, Valerio] Bellaria Hosp, IRCCS Inst Neurol Sci, Bologna, Italy.
   [Torraco, Alessandra; Bertini, Enrico; Carozzo, Rosalba] IRCCS, Childrens Res Hosp Bambino Gesu, Unit Neuromuscular & Neurodegenerat Disorders, Mol Med Lab, Rome, Italy.
   [Stramare, Roberto] Univ Padua, Dept Med, Sect Radiol, Padua, Italy.
   [Pegoraro, Elena] Univ Padua, Dept Neurosci, I-35128 Padua, Italy.
C3 University of Padua; University of Padua; University of Bologna; AUSL di
   Bologna; IRCCS Istituto delle Scienze Neurologiche di Bologna (ISNB);
   IRCCS Bambino Gesu; University of Padua; University of Padua
RP Pegoraro, E (corresponding author), Univ Padua, Dept Neurosci, Padua, Italy.
EM elena.pegoraro@unipd.it
RI Sorarù, Gianni/AAB-8891-2019; Cassina, Matteo/AAB-2669-2019; Stramare,
   Roberto/ABH-6752-2020; Salviati, Leonardo/L-1007-2016; Torraco,
   Alessandra/AAA-6212-2020; Maresca, Alessandra/J-7393-2016; Bertini,
   Enrico/A-2284-2014; Carrozzo, Rosalba/A-2808-2014
OI Cassina, Matteo/0000-0003-0270-1698; Torraco,
   Alessandra/0000-0002-8148-9295; Maresca, Alessandra/0000-0002-8959-8832;
   Soraru, Gianni/0000-0001-9691-6328; Semplicini,
   Claudio/0000-0003-0870-1349; Bertini, Enrico/0000-0001-9276-4590;
   Stramare, Roberto/0000-0002-1818-2290; Carrozzo,
   Rosalba/0000-0002-3327-4054
FU Telethon Italy [GGP13222]; University of Padova [CPDA123573/12];
   Fondazione CARIPARO; Telethon Network of Genetic BioBank [GTB12001D];
   Eurobiobank network
FX We sincerely thank the patient and her family that kindly agreed to
   participate in the study. This work was supported by grants from
   Telethon Italy (GGP13222), the University of Padova (CPDA123573/12), and
   Fondazione CARIPARO (to L.S.). We also acknowledge support from Telethon
   Network of Genetic BioBank (GTB12001D to E.P.) and the Eurobiobank
   network.
CR Ardissone A, 2015, JIMD REP, V20, P95, DOI 10.1007/8904_2014_397
   Burrage LC, 2014, MOL GENET METAB, V113, P207, DOI 10.1016/j.ymgme.2014.06.004
   Bykhovskaya Y, 2004, AM J HUM GENET, V74, P1303, DOI 10.1086/421530
   Bykhovskaya Y, 2007, MOL GENET METAB, V91, P148, DOI 10.1016/j.ymgme.2007.02.006
   Carelli V, 2015, ANN NEUROL, V78, P21, DOI 10.1002/ana.24410
   Casas K, 2004, AM J MED GENET A, V127A, P44, DOI 10.1002/ajmg.a.20652
   Casas KA, 2004, AM J MED GENET A, V125A, P201, DOI 10.1002/ajmg.a.20368
   Czudnochowski N, 2013, J MOL BIOL, V425, P3875, DOI 10.1016/j.jmb.2013.05.014
   Desbats MA, 2015, EUR J HUM GENET, V23, P1254, DOI 10.1038/ejhg.2014.277
   DiMauro S, 2013, NAT REV NEUROL, V9, P429, DOI 10.1038/nrneurol.2013.126
   Fernandez-Vizarra E, 2007, J MED GENET, V44, P173, DOI 10.1136/jmg.2006.045252
   Giordano C, 2014, BRAIN, V137, P335, DOI 10.1093/brain/awt343
   INBAL A, 1995, AM J MED GENET, V55, P372, DOI 10.1002/ajmg.1320550325
   Malena A, 2013, ACTA NEUROPATHOL, V126, P109, DOI 10.1007/s00401-013-1122-9
   Metodiev MD, 2015, EUR J HUM GENET, V23, P880, DOI 10.1038/ejhg.2014.192
   Nakajima J, 2014, J HUM GENET, V59, P229, DOI 10.1038/jhg.2013.143
   Patton JR, 2005, J BIOL CHEM, V280, P19823, DOI 10.1074/jbc.M500216200
   RAWLES JM, 1974, AM J MED, V56, P891, DOI 10.1016/0002-9343(74)90820-1
   Riley LG, 2010, AM J HUM GENET, V87, P52, DOI 10.1016/j.ajhg.2010.06.001
   Sasarman F, 2012, HUM MUTAT, V33, P1201, DOI 10.1002/humu.22098
   Spinazzi M, 2012, NAT PROTOC, V7, P1235, DOI 10.1038/nprot.2012.058
   Trevisson E, 2007, HUM MUTAT, V28, P694, DOI 10.1002/humu.20498
   Zeharia A, 2005, J CHILD NEUROL, V20, P449, DOI 10.1177/08830738050200051301
NR 23
TC 27
Z9 28
U1 0
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1364-6745
EI 1364-6753
J9 NEUROGENETICS
JI Neurogenetics
PD JAN
PY 2016
VL 17
IS 1
BP 65
EP 70
DI 10.1007/s10048-015-0465-x
PG 6
WC Genetics & Heredity; Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Neurosciences & Neurology
GA DA3KJ
UT WOS:000367695300009
PM 26556812
DA 2024-11-01
ER

PT J
AU Crimi, M
   Bordoni, A
   Menozzi, G
   Riva, L
   Fortunato, F
   Galbiati, S
   Del Bo, R
   Pozzoli, U
   Bresolin, N
   Comi, GP
AF Crimi, M
   Bordoni, A
   Menozzi, G
   Riva, L
   Fortunato, F
   Galbiati, S
   Del Bo, R
   Pozzoli, U
   Bresolin, N
   Comi, GP
TI Skeletal muscle gene expression profiling in mitochondrial disorders
SO FASEB JOURNAL
LA English
DT Article
DE mt DNA; MELAS; PEO; real-time PCR; microarray
ID CLUSTER-ANALYSIS; DNA MUTATIONS; TRANSCRIPTION; NUCLEAR; VARIABILITY;
   BIOGENESIS; METABOLISM; ACTIVATION; MECHANISMS; APOPTOSIS
AB Extremely variable clinic and genetic features characterize mitochondrial encephalomyopathy (ME M). Pathogenic mitochondrial DNA(mtDNA) defects can be divided into large-scale rearrangements and single point mutations. Clinical manifestations become evident when a threshold percentage of the total mtDNA is mutated. In some MEM, the "mutant load" in an affected tissue is directly related to the severity of the phenotype. However, the clinical phenotype is not simply a direct consequence of the relative abundance of mutated mtDNA. Other factors, such as nuclear background, can contribute to the disease process, resulting in a wide range of phenotypes caused by the same mutation. Using Affymetrix oligonucleotide cDNA microarrays(HG-U133A), we studied the gene expression profile of muscle tissue biopsies obtained from 12 MEM patients[4 common 4977 bp deleted mtDNA and 8 A3243G:4 progressive external ophthalmoplegia (PEO) and 4 mitochondrial myopathy,encephalopathy, lactic cidosis, and stroke-like episodes syndrome (MELAS) phenotypes] compared with age matched healthy individuals. We found several differentially expressed genes: 35 were markedly up-regulated in the mtDNA macro-deletion group(vs. the control group) and 4 decreased; 56 genes were dysregulated in A3243G-related disorders(53 down-regulated in PEO and 3 upregulated in MELAS). Finally, 12 genes were similarly regulated in the majority of the MEM patients under study. Amongst these, we identified an increased expression of genes related to the metabolism of the amino groups, as well as of several genes involved in genetic information processing. Moreover, few genes were similarly decreased in MEM patients vs. the control group. Real-time PCR demonstrated excellent reproducibility of the microarray-based findings. The observed expression changes are likely to represent a molecular signature for mitochondrial disorders. Furthermore,the differential expression profile of MELAS(A3243G) vs. PEOA3243G may support a role of nuclear background in contributing to these different clinical phenotypes. MEM microarray data are available from GEO database (http://www.ncbi.nlm.nih.gov/geo/) wit h the access ion number: GSE1462.
C1 Univ Milan, Dept Neurol Sci, I-20122 Milan, Italy.
   IRCCS, Osped Maggiore Policlin, Dino Ferrari Ctr, I-20122 Milan, Italy.
   CEND, I-20122 Milan, Italy.
   IRCCS E Medea La Nostra Famiglia, I-23842 Bosisio Parini, LC, Italy.
   Polytech Univ, Dept Biomed Engn, I-20133 Milan, Italy.
C3 University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico;
   IRCCS Eugenio Medea; Polytechnic University of Milan
RP Univ Milan, Dept Neurol Sci, Pad Ne Ponti,Via F Sforza 35, I-20122 Milan, Italy.
EM marcreamy@tiscali.it
RI Comi, Giacomo/K-5702-2016; Crimi, Marco/A-4032-2008; Pozzoli,
   Uberto/AAH-5492-2019; Galbiati, Sara/AAA-7115-2020; Riva,
   Laura/R-2562-2016
OI Pozzoli, Uberto/0000-0003-0670-7106; Comi, Giacomo/0000-0002-1383-5248;
   Galbiati, Sara/0000-0001-6810-359X; Bresolin, Nereo/0000-0001-6694-3595;
   Riva, Laura/0000-0001-5688-4915; Crimi, Marco/0000-0001-6903-9163
CR ALESSI DR, 1993, ONCOGENE, V8, P2015
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Augenlicht LH, 1999, ANN NY ACAD SCI, V889, P20, DOI 10.1111/j.1749-6632.1999.tb08720.x
   Bakay M, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-4
   Biswas G, 1999, EMBO J, V18, P522, DOI 10.1093/emboj/18.3.522
   Camasamudram V, 2003, EUR J BIOCHEM, V270, P1128, DOI 10.1046/j.1432-1033.2003.03461.x
   Cerri C, 1983, MITOCHONDRIAL PATHOL, P141
   Colleluori DM, 2001, ARCH BIOCHEM BIOPHYS, V389, P135, DOI 10.1006/abbi.2001.2324
   DELSITE R, 2002, MOL CANCER, V12, P6
   Dianov GL, 2001, PROG NUCLEIC ACID RE, V68, P285
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   Distel B, 1996, J CELL BIOL, V135, P1, DOI 10.1083/jcb.135.1.1
   Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863
   Ekstrand MI, 2004, HUM MOL GENET, V13, P935, DOI 10.1093/hmg/ddh109
   Garnier A, 2003, J PHYSIOL-LONDON, V551, P491, DOI 10.1113/jphysiol.2003.045104
   Gommans IMP, 2002, J MUSCLE RES CELL M, V23, P59, DOI 10.1023/A:1019984714528
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   HAMMANS SR, 1995, BRAIN, V118, P721, DOI 10.1093/brain/118.3.721
   Hansson A, 2004, P NATL ACAD SCI USA, V101, P3136, DOI 10.1073/pnas.0308710100
   Hauptmann N, 1996, ARCH BIOCHEM BIOPHYS, V335, P295, DOI 10.1006/abbi.1996.0510
   Heddi A, 1999, J BIOL CHEM, V274, P22968, DOI 10.1074/jbc.274.33.22968
   Hoffmann A, 1996, J BIOL CHEM, V271, P18194, DOI 10.1074/jbc.271.30.18194
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Irmler M, 1997, NATURE, V388, P190, DOI 10.1038/40657
   Jacobs HT, 2000, HUM MOL GENET, V9, P463, DOI 10.1093/hmg/9.4.463
   Jiang DW, 2003, J BIOL CHEM, V278, P4763, DOI 10.1074/jbc.M210410200
   Kaufmann P, 1996, ANN NEUROL, V40, P172, DOI 10.1002/ana.410400208
   KOGA Y, 1988, ACTA NEUROPATHOL, V76, P135, DOI 10.1007/BF00688097
   Koga Y, 2002, NEUROLOGY, V58, P827, DOI 10.1212/WNL.58.5.827
   Li RH, 2003, BBA-GENE STRUCT EXPR, V1629, P53, DOI 10.1016/S0167-4781(03)00160-X
   Li XM, 2002, J BIOL CHEM, V277, P27256, DOI 10.1074/jbc.M203267200
   Löhr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200
   Mirabella M, 2000, BRAIN, V123, P93, DOI 10.1093/brain/123.1.93
   Mootha VK, 2004, P NATL ACAD SCI USA, V101, P6570, DOI 10.1073/pnas.0401401101
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   MORAES CT, 1993, NEUROMUSCULAR DISORD, V3, P43, DOI 10.1016/0960-8966(93)90040-Q
   Morris SM, 1997, GENE, V193, P157, DOI 10.1016/S0378-1119(97)00099-1
   NAKASE H, 1990, AM J HUM GENET, V46, P418
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   Puigserver P, 2003, ENDOCR REV, V24, P78, DOI 10.1210/er.2002-0012
   RAO VLR, 1994, NEUROSCI LETT, V170, P27, DOI 10.1016/0304-3940(94)90230-5
   Raychaudhuri S, 2000, Pac Symp Biocomput, P455
   Rusanen H, 2000, BBA-MOL BASIS DIS, V1500, P10, DOI 10.1016/S0925-4439(99)00081-2
   Sciacco M, 2001, NEUROLOGY, V56, P1070, DOI 10.1212/WNL.56.8.1070
   SCRIVER CR, 1995, METABOLIC BASIS INHE
   SEIDEL U, 1988, GENE, V66, P135, DOI 10.1016/0378-1119(88)90231-4
   Shanske S, 2002, AM J HUM GENET, V71, P679, DOI 10.1086/342482
   Shoubridge EA, 2001, HUM MOL GENET, V10, P2277, DOI 10.1093/hmg/10.20.2277
   Silvestri G, 1997, MUSCLE NERVE, V20, P221
   Sturn A, 2002, BIOINFORMATICS, V18, P207, DOI 10.1093/bioinformatics/18.1.207
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   Wiesinger H, 2001, PROG NEUROBIOL, V64, P365, DOI 10.1016/S0301-0082(00)00056-3
   Yamamoto J, 2004, J BIOL CHEM, V279, P16954, DOI 10.1074/jbc.M312079200
   Yuen T, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.10.e48
NR 55
TC 52
Z9 54
U1 0
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0892-6638
EI 1530-6860
J9 FASEB J
JI Faseb J.
PD FEB
PY 2005
VL 19
IS 2
BP 866
EP +
DI 10.1096/fj.04-3045fje
PG 30
WC Biochemistry & Molecular Biology; Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other
   Topics; Cell Biology
GA 905TE
UT WOS:000227591900009
PM 15728662
DA 2024-11-01
ER

PT J
AU Çoku, J
   Shanske, S
   Mehrazin, M
   Tanji, K
   Naini, A
   Emmanuele, V
   Patterson, M
   Hirano, M
   DiMauro, S
AF Coku, Jorida
   Shanske, Sara
   Mehrazin, Mahsa
   Tanji, Kurenai
   Naini, Ali
   Emmanuele, Valentina
   Patterson, Marc
   Hirano, Michio
   DiMauro, Salvatore
TI Slowly progressive encephalopathy with hearing loss due to a mutation in
   the mtDNA tRNA<SUP>Leu(CUN)</SUP> gene
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE Mitochondrial DNA; tRNALeu(UCN); Ataxia; Dementia; Hearing loss
ID MITOCHONDRIAL-DNA; SPORADIC PATIENT; SKELETAL-MUSCLE; OPHTHALMOPLEGIA
AB Pathogenic mutations in the tRNA(Leu(UCN)) gene of mitochondrial DNA (mtDNA) have been invariably accompanied by skeletal myopathy with or without chronic progressive external ophthalmoplegia (CPEO). We report a young woman with a heteroplasmic m.12276G>A mutation in tRNA(Leu(UCN)), who had childhood-onset and slowly progressive encephalopathy with ataxia, cognitive impairment, and hearing loss. Sequencing of the 22 tRNA mitochondrial genes is indicated in all unusual neurological syndromes, even in the absence of maternal inheritance. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Coku, Jorida; Shanske, Sara; Mehrazin, Mahsa; Naini, Ali; Emmanuele, Valentina; Hirano, Michio; DiMauro, Salvatore] Columbia Univ, Med Ctr, Dept Neurol, New York, NY 10032 USA.
   [Tanji, Kurenai] Columbia Univ, Med Ctr, Dept Pathol, New York, NY 10032 USA.
   [Patterson, Marc] Mayo Clin, Div Child & Adolescent Neurol, Rochester, MN USA.
C3 Columbia University; Columbia University; Mayo Clinic
RP DiMauro, S (corresponding author), Columbia Univ, Med Ctr, Dept Neurol, P&S Bldg,4th Floor,POB 31, New York, NY 10032 USA.
EM sd12@columbia.edu
RI Patterson, Marc/H-5331-2019
OI Patterson, Marc/0000-0002-1116-126X
FU NIH [HD 32062]; Marriott Mitochondrial Disorder Clinical Research Fund
   (MMDCRF)
FX This work has been supported by NIH grant HD 32062 and by the Marriott
   Mitochondrial Disorder Clinical Research Fund (MMDCRF).
CR Cardaioli E, 2008, J NEUROL SCI, V272, P106, DOI 10.1016/j.jns.2008.05.005
   Di Mauro S, 2008, MOL GENETIC BASIS NE, P169
   Filosto M, 2008, NEUROMUSCULAR DISORD, V18, P204, DOI 10.1016/j.nmd.2007.12.005
   Fu K, 1996, HUM MOL GENET, V5, P1835, DOI 10.1093/hmg/5.11.1835
   Hirano M., 2006, Mitochondrial Medicine, P27
   Karadimas CL, 2002, NEUROMUSCULAR DISORD, V12, P865, DOI 10.1016/S0960-8966(02)00072-X
   Shanske S, 2004, AM J MED GENET A, V130A, P134, DOI 10.1002/ajmg.a.30220
   Sue CM, 1999, NEUROLOGY, V52, P1905, DOI 10.1212/WNL.52.9.1905
   Tanji K, 2001, METHOD CELL BIOL, V65, P311, DOI 10.1016/S0091-679X(01)65019-2
   Vives-Bauza C, 2001, ANN MED, V33, P493, DOI 10.3109/07853890109002099
   Weber K, 1997, AM J HUM GENET, V60, P373
   Zsurka G, 2004, J MED GENET, V41, DOI 10.1136/jmg.2004.022566
NR 12
TC 3
Z9 3
U1 1
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD MAR 15
PY 2010
VL 290
IS 1-2
BP 166
EP 168
DI 10.1016/j.jns.2009.12.001
PG 3
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 561OK
UT WOS:000274987200036
PM 20022607
OA Green Accepted
DA 2024-11-01
ER

PT J
AU Morten, KJ
   Ashley, N
   Wijburg, F
   Hadzic, N
   Parr, J
   Jayawant, S
   Adams, S
   Bindoff, L
   Bakker, HD
   Mieli-Vergani, G
   Zeviani, M
   Poulton, J
AF Morten, Karl J.
   Ashley, Neil
   Wijburg, Frits
   Hadzic, Nedim
   Parr, Jeremy
   Jayawant, Sandeep
   Adams, Susan
   Bindoff, Laurence
   Bakker, Henk D.
   Mieli-Vergani, Giorgina
   Zeviani, Massimo
   Poulton, Joanna
TI Liver mtDNA content increases during development: A comparison of
   methods and the importance of age- and tissue-specific controls for the
   diagnosis of mtDNA depletion
SO MITOCHONDRION
LA English
DT Article
DE mtDNA depletion syndrome; mitochondrial DNA; PicoGreen; movement
   disorder; hepatocerebral syndrome
ID MITOCHONDRIAL-DNA DEPLETION; DEOXYGUANOSINE KINASE; ALPERS-SYNDROME;
   GENE-MUTATIONS; HUMAN-CELLS; DEFICIENCY; DISORDERS; REVERSION; MYOPATHY;
   DISEASES
AB Background: The quantitative loss of mitochondrial DNA (mtDNA) known as mtDNA depletion, often gives rise to liver disease. The diagnosis of mtDNA depletion syndrome is frequently imprecise, both for technical reasons and because of the lack of established age-adjusted normal ranges. We aimed to refine quantitative methods for diagnosing the hepatic type of mtDNA depletion syndrome, firstly by establishing an age-matched reference range for mitochondrial to nuclear DNA ratio (henceforth "mtDNA content") and secondly by investigating mtDNA in fibroblasts.
   Methods: By comparing realtime PCR with an established method for quantifying mtDNA content we established a reference range for young children using biopsy and post-mortem material from patients < 15 years. In addition, we investigated the arrangement of mtDNA in nucleoids from fibroblasts using fluorescence microscopy.
   Results: Both methods showed that the mtDNA content of liver increases rapidly over the perinatal period. In a patient whose liver mtDNA content fell, but remained within the reference range, early investigation and age-matched controls were essential, as we found a progressive increase in muscle mtDNA copy number, respiratory chain activity and muscle power with age. In three further patients, fluorescence microscopy of the fibroblasts proved diagnostic. In one case a movement disorder was an important pointer.
   Conclusions: These cases highlight the (i) need for comparing mtDNA copy number data generated from patients to DNA isolated from an age-matched normal range from the tissue of interest and (ii) the utility of mtDNA staining with PicoGreen as a method to detect aberrant nucleoid morphology in mtDNA depletion patient fibroblast lines when affected tissues are not available for measuring mtDNA copy number. (c) 2007 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 [Morten, Karl J.; Ashley, Neil; Adams, Susan; Poulton, Joanna] Univ Oxford, Womens Ctr, John Radcliffe Hosp, Nuffield Dept Obstet & Gynaecol, Oxford OX3 9DU, England.
   [Parr, Jeremy; Jayawant, Sandeep] John Radcliffe Hosp, Dept Paediat, Oxford OX3 9DU, England.
   [Wijburg, Frits; Bakker, Henk D.] Univ Hosp Amsterdam, Dept Paediat, Div Metab Disorders, Acad Med Ctr G8 205, NL-1105 AZ Amsterdam, Netherlands.
   [Hadzic, Nedim; Mieli-Vergani, Giorgina] Kings Coll Hosp London, Univ London Kings Coll, Sch Med, Inst Liver Studies, London SE5 9RJ, England.
   [Bindoff, Laurence] Haukeland Hosp, Dept Neurol, Inst Clin Med, N-5021 Bergen, Norway.
   [Zeviani, Massimo] Natl Neurol Inst C Besta, Div Mol Neurogenet, I-20126 Milan, Italy.
C3 University of Oxford; University of Oxford; University of Amsterdam;
   Academic Medical Center Amsterdam; University of London; King's College
   London; King's College Hospital NHS Foundation Trust; King's College
   Hospital; University of Bergen; Haukeland University Hospital;
   Fondazione IRCCS Istituto Neurologico Carlo Besta
RP Poulton, J (corresponding author), Univ Oxford, Womens Ctr, John Radcliffe Hosp, Nuffield Dept Obstet & Gynaecol, Oxford OX3 9DU, England.
EM Joanna.poulton@obs-gyn.ox.ac.uk
RI Mieli-Vergani, Giorgina/G-5616-2011; adams, susan/I-7423-2016; MORTEN,
   Karl/GXM-6291-2022; Poulton, Joanna/AAB-4828-2021; Hadzic,
   Nedim/H-7574-2019; Zeviani, Massimo/K-2891-2014
OI Wijburg, Frits/0000-0002-0950-1368; Morten, Karl/0000-0001-6926-6550;
   Zeviani, Massimo/0000-0002-9067-5508; Mieli-Vergani,
   Giorgina/0000-0002-8215-4489; Poulton, Joanna/0000-0002-2460-5587;
   Bindoff, Laurence/0000-0003-0988-276X; Parr, Jeremy/0000-0002-2507-7878;
   Ashley, Neil/0000-0002-1655-5137
FU MRC [G0500695] Funding Source: UKRI; Medical Research Council [G0500695]
   Funding Source: Medline
CR ANTI M, 1994, CANCER, V73, P281, DOI 10.1002/1097-0142(19940115)73:2<281::AID-CNCR2820730208>3.0.CO;2-6
   Antonicka H, 2006, HUM MOL GENET, V15, P1835, DOI 10.1093/hmg/ddl106
   Ashley N, 2005, EXP CELL RES, V303, P432, DOI 10.1016/j.yexcr.2004.10.013
   Bai RK, 2004, ANN NY ACAD SCI, V1011, P304, DOI 10.1196/annals.1293.029
   Barthélémy C, 2002, HUM GENET, V110, P479, DOI 10.1007/s00439-002-0708-4
   Barthélémy C, 2001, ANN NEUROL, V49, P607, DOI 10.1002/ana.1002.abs
   Chabi B, 2003, CLIN CHEM, V49, P1309, DOI 10.1373/49.8.1309
   Chinnery PF, 2005, J HEPATOL, V43, P207, DOI 10.1016/j.jhep.2005.05.012
   Chiu RWK, 2003, CLIN CHEM, V49, P719, DOI 10.1373/49.5.719
   DIMAURO S, 1983, ANN NEUROL, V14, P226, DOI 10.1002/ana.410140209
   Ducluzeau PH, 2002, J HEPATOL, V36, P698, DOI 10.1016/S0168-8278(02)00021-1
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   EPSTEIN CJ, 1967, NATURE, V214, P1050, DOI 10.1038/2141050a0
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Guidotti JE, 2003, J BIOL CHEM, V278, P19095, DOI 10.1074/jbc.M300982200
   Hargreaves IP, 2002, J INHERIT METAB DIS, V25, P7, DOI 10.1023/A:1015104910239
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Iborra FJ, 2004, BMC BIOL, V2, DOI 10.1186/1741-7007-2-9
   Labarthe F, 2005, J HEPATOL, V43, P333, DOI 10.1016/j.jhep.2005.03.023
   Legros F, 2004, J CELL SCI, V117, P2653, DOI 10.1242/jcs.01134
   Macmillan CJ, 1996, PEDIATR NEUROL, V14, P203, DOI 10.1016/0887-8994(96)00018-5
   Macsween RNM., 2002, PATHOLOGY LIVER, V4th
   Magnusson J, 2003, EXP CELL RES, V289, P133, DOI 10.1016/S0014-4827(03)00249-0
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   MORITZ C, 1987, P NATL ACAD SCI USA, V84, P7183, DOI 10.1073/pnas.84.20.7183
   Morris AAM, 1998, J HEPATOL, V28, P556, DOI 10.1016/S0168-8278(98)80278-X
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Naviaux RK, 1999, ANN NEUROL, V45, P54, DOI 10.1002/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B
   Nguyen KV, 2006, J HEPATOL, V45, P108, DOI 10.1016/j.jhep.2005.12.026
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   POULTON J, 1995, J INHERIT METAB DIS, V18, P4, DOI 10.1007/BF00711367
   POULTON J, DEV MED CHILD NEUROL
   RICCI E, 1992, BRAIN PATHOL, V2, P141, DOI 10.1111/j.1750-3639.1992.tb00682.x
   Roubertoux PL, 2003, NAT GENET, V35, P65, DOI 10.1038/ng1230
   Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284
   SPERL W, 1992, ANN CLIN BIOCHEM, V29, P638, DOI 10.1177/000456329202900604
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Spinazzola A, 2005, GENE, V354, P162, DOI 10.1016/j.gene.2005.03.025
   Taanman JW, 1997, HUM MOL GENET, V6, P935, DOI 10.1093/hmg/6.6.935
   Vilà MR, 2003, NEUROLOGY, V60, P1203, DOI 10.1212/01.WNL.0000055928.58122.47
   Vilarinho L, 1999, J INHERIT METAB DIS, V22, P90, DOI 10.1023/A:1005471904710
   Vu TH, 1998, NEUROLOGY, V50, P1783, DOI 10.1212/WNL.50.6.1783
   Wang LY, 2005, MOL GENET METAB, V84, P75, DOI 10.1016/j.ymgme.2004.09.005
   WATMOUGH NJ, 1989, BIOCHEM BIOPH RES CO, V160, P623, DOI 10.1016/0006-291X(89)92478-9
NR 45
TC 51
Z9 60
U1 0
U2 6
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
J9 MITOCHONDRION
JI Mitochondrion
PD DEC
PY 2007
VL 7
IS 6
BP 386
EP 395
DI 10.1016/j.mito.2007.09.001
PG 10
WC Cell Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Genetics & Heredity
GA 242TU
UT WOS:000251749900004
PM 17981517
DA 2024-11-01
ER

PT J
AU Rygiel, KA
   Tuppen, HA
   Grady, JP
   Vincent, A
   Blakely, EL
   Reeve, AK
   Taylor, RW
   Picard, M
   Miller, J
   Turnbull, DM
AF Rygiel, Karolina A.
   Tuppen, Helen A.
   Grady, John P.
   Vincent, Amy
   Blakely, Emma L.
   Reeve, Amy K.
   Taylor, Robert W.
   Picard, Martin
   Miller, James
   Turnbull, Doug M.
TI Complex mitochondrial DNA rearrangements in individual cells from
   patients with sporadic inclusion body myositis
SO NUCLEIC ACIDS RESEARCH
LA English
DT Article
ID REAL-TIME PCR; MUSCLE-FIBERS; MTDNA REARRANGEMENTS; AUTOSOMAL-DOMINANT;
   DELETION MUTATIONS; MULTIPLE DELETIONS; DUPLICATED MTDNA; SINGLE;
   QUANTIFICATION; ABNORMALITIES
AB Mitochondrial DNA (mtDNA) rearrangements are an important cause of mitochondrial disease and age related mitochondrial dysfunction in tissues including brain and skeletal muscle. It is known that different mtDNA deletions accumulate in single cells, but the detailed nature of these rearrangements is still unknown. To evaluate this we used a complementary set of sensitive assays to explore the mtDNA rearrangements in individual cells from patients with sporadic inclusion body myositis, a late-onset inflammatory myopathy with prominent mitochondrial changes. We identified large-scale mtDNA deletions in individual muscle fibres with 20% of cytochrome c oxidase-deficient myofibres accumulating two or more mtDNA deletions. The majority of deletions removed only the major arc but similar to 10% of all deletions extended into the minor arc removing the origin of light strand replication (O-L) and a variable number of genes. Some mtDNA molecules contained two deletion sites. Additionally, we found evidence of mitochondrial genome duplications allowing replication and clonal expansion of these complex rearranged molecules. The extended spectrum of mtDNA rearrangements in single cells provides insight into the process of clonal expansion which is fundamental to our understanding of the role of mtDNA mutations in ageing and disease.
C1 [Rygiel, Karolina A.; Tuppen, Helen A.; Grady, John P.; Vincent, Amy; Blakely, Emma L.; Reeve, Amy K.; Taylor, Robert W.; Turnbull, Doug M.] Newcastle Univ, Sch Med, Inst Neurosci, Wellcome Trust Ctr Mitochondrial Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Rygiel, Karolina A.; Vincent, Amy; Reeve, Amy K.; Turnbull, Doug M.] Newcastle Univ, Sch Med, Inst Neurosci, Newcastle Univ Ctr Ageing & Vital, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Picard, Martin] Columbia Univ, Dept Neurol, Dept Psychiat, Coll Phys & Surg,Div Behav Med,Med Ctr, New York, NY 10032 USA.
   [Picard, Martin] Columbia Univ, Med Ctr, CTNI, Coll Phys & Surg, New York, NY 10032 USA.
   [Miller, James] Newcastle Upon Tyne Hosp NHS Fdn Trust, Royal Victoria Infirm, Dept Neurol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
C3 Newcastle University - UK; Newcastle University - UK; Columbia
   University; Columbia University; Newcastle University - UK; Newcastle
   Upon Tyne Hospitals NHS Foundation Trust
RP Rygiel, KA; Turnbull, DM (corresponding author), Newcastle Univ, Sch Med, Inst Neurosci, Wellcome Trust Ctr Mitochondrial Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.; Rygiel, KA; Turnbull, DM (corresponding author), Newcastle Univ, Sch Med, Inst Neurosci, Newcastle Univ Ctr Ageing & Vital, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM karolina.rygiel@ncl.ac.uk; doug.turnbull@newcastle.ac.uk
RI Vincent, Amy/J-7284-2019
OI Vincent, Amy/0000-0002-0360-6644; Grady, John/0000-0001-9667-3872;
   Reeve, Amy/0000-0002-4474-2204; Tuppen, Helen/0000-0001-8762-0824;
   Turnbull, Doug/0000-0002-8878-9901; Picard, Martin/0000-0003-2835-0478
FU Newcastle University Centre for Brain Ageing and Vitality (Biotechnology
   and Biological Sciences Research Council) [G0700718]; Newcastle
   University Centre for Brain Ageing and Vitality (Engineering and
   Physical Sciences Research Council) [G0700718]; Newcastle University
   Centre for Brain Ageing and Vitality (Economic and Social Research
   Council) [G0700718]; Newcastle University Centre for Brain Ageing and
   Vitality (Medical Research Council) [G0700718]; UK NIHR Biomedical
   Research Centre in Age and Age Related Diseases; MRC Centre for
   Neuromuscular Disease [G000608-1]; Wellcome Trust Centre for
   Mitochondrial Research [096919/Z/11/Z]; Lily Foundation; UK NHS
   Specialist Commissioners 'Rare Mitochondrial Disorders of Adults and
   Children' Service; MRC [G0700718, MR/L016354/1] Funding Source: UKRI
FX Newcastle University Centre for Brain Ageing and Vitality (supported by
   the Biotechnology and Biological Sciences Research Council, Engineering
   and Physical Sciences Research Council, Economic and Social Research
   Council and Medical Research Council) [G0700718]; UK NIHR Biomedical
   Research Centre in Age and Age Related Diseases award to the Newcastle
   upon Tyne Hospitals NHS Foundation Trust; MRC Centre for Neuromuscular
   Disease [G000608-1]; Wellcome Trust Centre for Mitochondrial Research
   [096919/Z/11/Z]; The Lily Foundation; UK NHS Specialist Commissioners
   'Rare Mitochondrial Disorders of Adults and Children' Service.
CR [Anonymous], 2015, SCI REP-UK
   [Anonymous], 2013, 13033997QBIOGN ARXIV
   Bank C, 2000, BIOCHEM BIOPH RES CO, V279, P595, DOI 10.1006/bbrc.2000.3951
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Blakely EL, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.011296
   Bodyak ND, 2001, HUM MOL GENET, V10, P17, DOI 10.1093/hmg/10.1.17
   Campbell GR, 2011, ANN NEUROL, V69, P481, DOI 10.1002/ana.22109
   Cao ZJ, 2001, NUCLEIC ACIDS RES, V29, P4502, DOI 10.1093/nar/29.21.4502
   Damas J, 2014, HUM MUTAT, V35, P1, DOI 10.1002/humu.22452
   DUNBAR DR, 1993, HUM MOL GENET, V2, P1619, DOI 10.1093/hmg/2.10.1619
   Fratter C, 2011, NEUROLOGY, V76, P2032, DOI 10.1212/WNL.0b013e31821e558b
   Gokey NG, 2004, AGING CELL, V3, P319, DOI 10.1111/j.1474-9728.2004.00122.x
   He LP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf067
   Hilton-Jones D, 2010, NEUROMUSCULAR DISORD, V20, P622, DOI [10.1016/j.nmd.2010.07.087, 10.1016/j.nmd.2009.11.003]
   Holt IJ, 2000, CELL, V100, P515, DOI 10.1016/S0092-8674(00)80688-1
   Huber W, 2015, NAT METHODS, V12, P115, DOI [10.1038/NMETH.3252, 10.1038/nmeth.3252]
   Jansson M, 2000, ACTA NEUROPATHOL, V100, P23, DOI 10.1007/s004010051188
   Kajander OA, 2000, HUM MOL GENET, V9, P2821, DOI 10.1093/hmg/9.19.2821
   Khrapko K, 1999, NUCLEIC ACIDS RES, V27, P2434, DOI 10.1093/nar/27.11.2434
   Kraytsberg Y, 2005, EXPERT REV MOL DIAGN, V5, P809, DOI 10.1586/14737159.5.5.809
   Krishnan KJ, 2007, ANAL BIOCHEM, V370, P127, DOI 10.1016/j.ab.2007.06.024
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Lee CM, 1998, FREE RADICAL BIO MED, V25, P964, DOI 10.1016/S0891-5849(98)00185-3
   Lindgren U, 2015, NEUROMUSCULAR DISORD, V25, P281, DOI 10.1016/j.nmd.2014.12.010
   Manfredi G, 1997, ANN NEUROL, V42, P180, DOI 10.1002/ana.410420208
   Moslemi AR, 1996, ANN NEUROL, V40, P707, DOI 10.1002/ana.410400506
   Moslemi AR, 1997, HUM MUTAT, V10, P381, DOI 10.1002/(SICI)1098-1004(1997)10:5<381::AID-HUMU8>3.0.CO;2-I
   Muraki K, 2001, AM J MED GENET, V98, P205, DOI 10.1002/1096-8628(20010122)98:3<205::AID-AJMG1077>3.0.CO;2-P
   Murphy JL, 2008, BRAIN, V131, P2832, DOI 10.1093/brain/awn252
   Needham M, 2007, MUSCLE NERVE, V35, P549, DOI 10.1002/mus.20766
   Nicholls TJ, 2014, HUM MOL GENET, V23, P6147, DOI 10.1093/hmg/ddu336
   Odoardi F, 2003, AM J MED GENET A, V118A, P247, DOI 10.1002/ajmg.a.20006
   OLD SL, 1989, HISTOCHEM J, V21, P545, DOI 10.1007/BF01753355
   Oldfors A, 2006, NEUROLOGY, V66, pS49, DOI 10.1212/01.wnl.0000192127.63013.8d
   OLDFORS A, 1993, BRAIN, V116, P325, DOI 10.1093/brain/116.2.325
   POULTON J, 1994, HUM MOL GENET, V3, P947, DOI 10.1093/hmg/3.6.947
   POULTON J, 1993, HUM MOL GENET, V2, P23, DOI 10.1093/hmg/2.1.23
   R Development Core Team, 2016, R: A language and environment for statistical computing
   Rygiel KA, 2015, NEUROPATH APPL NEURO, V41, P288, DOI 10.1111/nan.12149
   Santorelli FM, 1996, ANN NEUROL, V39, P789, DOI 10.1002/ana.410390615
   SCIACCO M, 1994, HUM MOL GENET, V3, P13, DOI 10.1093/hmg/3.1.13
   Tawil R, 2002, CURR OPIN RHEUMATOL, V14, P653, DOI 10.1097/00002281-200211000-00004
   Tengan CH, 1998, BBA-MOL BASIS DIS, V1406, P73, DOI 10.1016/S0925-4439(97)00087-2
   Tuppen HAL, 2010, BRAIN, V133, P2952, DOI 10.1093/brain/awq232
   Wanrooij S, 2012, EMBO REP, V13, P1130, DOI 10.1038/embor.2012.161
NR 45
TC 34
Z9 36
U1 1
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0305-1048
EI 1362-4962
J9 NUCLEIC ACIDS RES
JI Nucleic Acids Res.
PD JUN 20
PY 2016
VL 44
IS 11
BP 5313
EP 5329
DI 10.1093/nar/gkw382
PG 17
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA DR2SB
UT WOS:000379753100037
PM 27131788
OA Green Submitted, gold, Green Published
DA 2024-11-01
ER

PT J
AU Feigenbaum, A
   Bai, RK
   Doherty, ES
   Kwon, H
   Tan, D
   Sloane, A
   Cutz, E
   Robinson, BH
   Wong, LJC
AF Feigenbaum, Annette
   Bai, Ren-Kui
   Doherty, Emily S.
   Kwon, Haeyoung
   Tan, Duanjun
   Sloane, Avril
   Cutz, Ernest
   Robinson, Brian H.
   Wong, Lee-Jun C.
TI Novel mitochondrial DNA mutations associated with myopathy,
   cardiomyopathy, renal failure, and deafness
SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A
LA English
DT Article
DE mtDNA mutation; mitochondrial myopathy; cardiomyopathy; 5783G > A;
   15458T > C; 15519T > C
ID QUANTIFICATION; AMPLIFICATION; SEQUENCE
AB Patients with mitochondrial disease usually manifest multisystemic dysfunction with a broad clinical spectrum. When the tests for common mitochondrial DNA (mtDNA) point mutations are negative and the mtDNA defects are still hypothesized, it is necessary to screen the entire mitochondrial genome for unknown mutations in order to confirm the diagnosis. We report an 8-year-old girl who had a long history of ragged-red fiber myopathy, short statute, and deafness, who ultimately developed renal failure and fatal cardiac dysfunction. Respiratory chain enzyme analysis on muscle biopsy revealed deficiency in complexes I, II/III, and IV. Whole mitochondrial genome sequencing analysis was performed. Three novel changes: homoplasmic 15458T > C and 15519T > C in cytochrome b, and a near homoplasmic 5783G > A in tRNA(cys), were found in the proband in various tissues. Her mother and asymptomatic sibling also carry the two homoplasmic mutations and the heteroplasmic 5783G > A mutation in blood, hair follicles, and buccal cells, at lower percentage. The 5783G > A mutation occurs at the T arm of tRNA(cys), resulting in the disruption of the stem structure, which may reduce the stability of the tRNA. 15458T > C changes an amino acid serine to proline at a conserved alpha-helix, which may force the helix to bend. These two mutations may have pathogenic significance. This case emphasizes the importance of pursuing more extensive mutational analysis of mtDNA in the absence of common mtDNA point mutations or large deletions, when there is a high suspicion of a mitochondrial disorder. (c) 2006 Wiley-Liss, Inc.
C1 Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
   Hosp Sick Children, Div Clin & Metab Genet, Toronto, ON M5G 1X8, Canada.
   NHGRI, NIH, Bethesda, MD 20892 USA.
   Dongduk Womens Univ, Dept Appl Chem, Seoul, South Korea.
   Georgetown Univ, Med Ctr, Inst Mol & Human Genet, Washington, DC 20007 USA.
   Hosp Sick Children, Div Pathol, Dept Pediat Lab Med, Toronto, ON M5G 1X8, Canada.
C3 Baylor College of Medicine; University of Toronto; Hospital for Sick
   Children (SickKids); National Institutes of Health (NIH) - USA; NIH
   National Human Genome Research Institute (NHGRI); Dongduk Women's
   University; Georgetown University; University of Toronto; Hospital for
   Sick Children (SickKids)
RP Wong, LJC (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Pl,NAB 2015, Houston, TX 77030 USA.
EM ljwong@bcm.tmc.edu
RI Robinson, B/LBH-2242-2024
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Bai RK, 2005, J MOL DIAGN, V7, P613, DOI 10.1016/S1525-1578(10)60595-8
   Bai RK, 2004, CLIN CHEM, V50, P996, DOI 10.1373/clinchem.2004.031153
   Brandon MC, 2005, NUCLEIC ACIDS RES, V33, pD611
   Flierl A, 1997, J BIOL CHEM, V272, P27189, DOI 10.1074/jbc.272.43.27189
   Florentz C, 2003, CELL MOL LIFE SCI, V60, P1356, DOI 10.1007/s00018-003-2343-1
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Gropman A, 2004, AM J MED GENET A, V124A, P377, DOI 10.1002/ajmg.a.20456
   Kramer KA, 2005, CLIN CHEM, V51, P2110, DOI 10.1373/clinchem.2005.050146
   LAHIRI DK, 1991, NUCLEIC ACIDS RES, V19, P5444, DOI 10.1093/nar/19.19.5444
   Liang MH, 1998, AM J MED GENET, V77, P395, DOI 10.1002/(SICI)1096-8628(19980605)77:5<395::AID-AJMG8>3.0.CO;2-M
   McFarland R, 2002, NAT GENET, V30, P145, DOI 10.1038/ng819
   MERANTE F, 1995, AM J HUM GENET S, V57
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   ROBINSON BH, 1993, FEBS LETT, V328, P99, DOI 10.1016/0014-5793(93)80973-X
   Santorelli FM, 1997, NEUROMUSCULAR DISORD, V7, P156, DOI 10.1016/S0960-8966(97)00444-6
   Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063
   Tarnopolsky MA, 2004, AM J MED GENET A, V124A, P372, DOI 10.1002/ajmg.a.20449
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Wittenhagen LM, 2003, TRENDS BIOCHEM SCI, V28, P605, DOI 10.1016/j.tibs.2003.09.006
   Wong LJC, 1997, CLIN CHEM, V43, P1857
   Wong LJC, 1997, CLIN CHEM, V43, P1241
   Wong LJC, 2003, J MED GENET, V40
NR 24
TC 20
Z9 22
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1552-4825
EI 1552-4833
J9 AM J MED GENET A
JI Am. J. Med. Genet. A
PD OCT 15
PY 2006
VL 140A
IS 20
BP 2216
EP 2222
DI 10.1002/ajmg.a.31436
PG 7
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 091TJ
UT WOS:000241050900009
PM 16955414
DA 2024-11-01
ER

PT J
AU Wu, GP
   Han, YJ
   Zhao, LF
   Zhang, H
   Fan, XZ
   Li, WQ
   Che, XW
   Zhou, Y
AF Wu, Guiping
   Han, Yijun
   Zhao, Lifeng
   Zhang, Hong
   Fan, Xiuzhao
   Li, Weiqin
   Che, Xiaowen
   Zhou, Yun
TI Reversible cardiac function and left ventricular hypertrophy in a
   Chinese man with mitochondrial myopathy: a case report
SO BMC CARDIOVASCULAR DISORDERS
LA English
DT Article
DE Mitochondrial myopathy; Heart failure; Respiratory failure; Pulmonary
   artery hypertension; Left ventricular hypertrophy
AB Background Mitochondrial myopathies (MMs) are a group of multi-system diseases caused by abnormalities in mitochondrial DNA (mtDNA) or mutations of nuclear DNA (nDNA). The diagnosis of mitochondrial myopathy (MM) is reliant on the combination of history and physical examination, muscle biopsy, histochemical studies, and next-generation sequencing. Patients with MMs have diverse clinical manifestations. In the contemporary literature, there is a paucity of reports on cardiac structure and function in this rare disease. We report a Chinese man with MM accompanied with both acute right heart failure and left ventricular hypertrophy.
   Case presentation A 49-year-old man presented with clinical features suggestive of MM, i.e., ophthalmoparesis, weakness of the pharyngeal and extremity muscles, and respiratory muscles which gradually progressed to respiratory insufficiency. He had a family history of mitochondrial myopathy. He had increased levels of serum creatine kinase and lactate. Muscle biopsy of left lateral thigh revealed 8% ragged red fibers (RRF) and 42% COX-negative fibers. Gene sequencing revealed a novel heterozygote TK2 variant (NM_001172644: c.584T>C, p.Leu195Pro) and another heterozygous variant (NM_004614.4:c.156+958G>A; rs1965661603) in the intron of TK2 gene. Based on these findings, we diagnosed the patient as a case of MM. Echocardiography revealed right heart enlargement, pulmonary hypertension, left ventricular hypertrophy, and thickening of the main pulmonary artery and its branches. The patient received non-invasive ventilation and coenzyme Q10 (CoQ10). The cardiac structure and function were restored at 1-month follow-up.
   Conclusions This is the first report of reversible cardiac function impairment and left ventricular hypertrophy in a case of adult-onset MM, nocturnal hypoxia is a potential mechanism for left ventricular hypertrophy in patients with MM.
C1 [Wu, Guiping; Zhang, Hong] Shanxi Med Univ, Shanxi Prov Peoples Hosp, Dept Cardiol, Hosp 5, Taiyuan 030012, Peoples R China.
   [Han, Yijun] Jining Med Univ, Clin Med Coll, Jining 272000, Peoples R China.
   [Zhao, Lifeng; Che, Xiaowen] Taiyuan Ctr Dis Control & Prevent, Dept Microbiol Test, Taiyuan 030012, Peoples R China.
   [Fan, Xiuzhao; Zhou, Yun] Shanxi Med Univ, Dept Nephrol, Shanxi Prov Peoples Hosp, Hosp 5, Taiyuan 030012, Shanxi, Peoples R China.
   [Li, Weiqin] Shanxi Med Univ, Dept Ultrasound, Hosp 5, Shanxi Prov Peoples Hosp, Taiyuan 030012, Peoples R China.
C3 Shanxi Medical University; Shanxi People's Hospital; Jining Medical
   University; Shanxi Medical University; Shanxi People's Hospital; Shanxi
   Medical University; Shanxi People's Hospital
RP Che, XW (corresponding author), Taiyuan Ctr Dis Control & Prevent, Dept Microbiol Test, Taiyuan 030012, Peoples R China.; Zhou, Y (corresponding author), Shanxi Med Univ, Dept Nephrol, Shanxi Prov Peoples Hosp, Hosp 5, Taiyuan 030012, Shanxi, Peoples R China.
EM 79410554@qq.com; zhouyun_sx@163.com
RI Fan, Xiuzhao/HHZ-3513-2022; Zhao, Lifeng/A-1661-2012
FU Natural Science Foundation of Shanxi Province [YDZJSX2021B014];
   Development and Reform Commission Foundation of Shanxi Province (Shanxi
   Genetic Engineering Center for Experimental Animal Models); Research
   Project of Shanxi Provincial Health Commission [2021111]
FX This work was supported by grants from the Natural Science Foundation of
   Shanxi Province (Grant No: YDZJSX2021B014, YZ) and The Development and
   Reform Commission Foundation of Shanxi Province (Shanxi Genetic
   Engineering Center for Experimental Animal Models to Z.Y). This study
   was also supported by the Research Project of Shanxi Provincial Health
   Commission (Grant No: 2021111, GW). The funding body had no role in the
   design or writing of the study.
CR Ahmed ST, 2018, NEUROTHERAPEUTICS, V15, P943, DOI 10.1007/s13311-018-00674-4
   Beshay S, 2020, RESP MED, V171, DOI 10.1016/j.rmed.2020.106099
   Bychkov IO, 2021, MITOCHONDRION, V57, P205, DOI 10.1016/j.mito.2021.01.004
   Dai L F, 2019, Zhonghua Er Ke Za Zhi, V57, P211, DOI 10.3760/cma.j.issn.0578-1310.2019.03.011
   de Barcelos IP, 2019, CURR OPIN NEUROL, V32, P715, DOI 10.1097/WCO.0000000000000743
   Deng M, 2021, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.608347
   Domínguez-González C, 2019, ORPHANET J RARE DIS, V14, DOI 10.1186/s13023-019-1071-z
   García-Alvarez M, 2019, MINERVA ENDOCRINOL, V44, P159, DOI 10.23736/S0391-1977.18.02930-9
   Gehrig SM, 2016, ORPHANET J RARE DIS, V11, DOI 10.1186/s13023-016-0488-x
   GOMEZ A, 1993, CIRCULATION, V87, P247, DOI 10.1161/01.CIR.87.1.247
   Hernandez-Voth A, 2020, BMJ OPEN RESPIR RES, V7, DOI 10.1136/bmjresp-2020-000774
   Hu CP, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.01000
   Nickel NP, 2020, AM J RESP CRIT CARE, V201, P148, DOI 10.1164/rccm.201903-0656CI
   Prados VO, 2020, J BRAS PNEUMOL, V46, DOI 10.36416/1806-3756/e20190136
   Sharp LJ, 2014, NEUROL CLIN, V32, P777, DOI 10.1016/j.ncl.2014.05.001
   Termglinchan T, 2016, NEUROL-GENET, V2, DOI 10.1212/NXG.0000000000000095
NR 16
TC 0
Z9 0
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2261
J9 BMC CARDIOVASC DISOR
JI BMC Cardiovasc. Disord.
PD SEP 15
PY 2023
VL 23
IS 1
AR 464
DI 10.1186/s12872-023-03444-z
PG 8
WC Cardiac & Cardiovascular Systems
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology
GA S0EP9
UT WOS:001067992500003
PM 37715114
OA Green Published, gold
DA 2024-11-01
ER

PT J
AU Krag, TO
   Hauerslev, S
   Jeppesen, TD
   Duno, M
   Vissing, J
AF Krag, T. O.
   Hauerslev, S.
   Jeppesen, T. D.
   Duno, M.
   Vissing, J.
TI Muscle regeneration in mitochondrial myopathies
SO MITOCHONDRION
LA English
DT Article
DE Mitochondria; Muscle regeneration; Mitochondrial myopathy; mtDNA;
   Neonatal myosin heavy chain
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; DNA DELETIONS; POINT MUTATION;
   LATE-ONSET; GENE; TWINKLE; ALPHA-7-BETA-1; EXPRESSION; PHENOTYPE;
   INTEGRIN
AB Mitochondrial myopathies cover a diverse group of disorders in which ragged red and COX-negative fibers are common findings on muscle morphology. In contrast, muscle degeneration and regeneration, typically found in muscular dystrophies, are not considered characteristic features of mitochondrial myopathies. We investigated regeneration in muscle biopsies from 61 genetically well-defined patients affected by mitochondrial myopathy. Our results show that the perturbed energy metabolism in mitochondrial myopathies causes ongoing muscle regeneration in a majority of patients, and some were even affected by a dystrophic morphology. The results add to the complexity of the pathogenesis underlying mitochondrial myopathies, and expand the knowledge about the impact of energy deficiency on another aspect of muscle structure and function. (C) 2013 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 [Krag, T. O.; Hauerslev, S.; Jeppesen, T. D.; Vissing, J.] Univ Copenhagen, Rigshosp, Dept Neurol, Neuromuscular Res Unit, DK-2100 Copenhagen, Denmark.
   [Duno, M.] Univ Copenhagen, Rigshosp, Dept Clin Genet, DK-2100 Copenhagen, Denmark.
C3 Rigshospitalet; University of Copenhagen; Rigshospitalet; University of
   Copenhagen
RP Krag, TO (corresponding author), Rigshosp, Neuromuscular Res Unit, Sect 3342, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.
EM thomas.krag@rh.dk
RI Krag, Thomas/AAD-3307-2021; Vissing, John/IUN-4271-2023; Jeppesen,
   Tina/AAV-7195-2020
OI Krag, Thomas/0000-0001-9330-668X
FU Danish Medical Research Council; Lundbeck Foundation; Novo Nordisk
   Foundation; AP Moller Foundations
FX This work was supported by grants from the Danish Medical Research
   Council, Lundbeck Foundation, Novo Nordisk Foundation and AP Moller
   Foundations to TK. We thank Danuta Olsen, Eva Rathkens, Thomas Lauridsen
   and Anders Stouge for technical assistance.
CR Allikian MJ, 2004, J CELL SCI, V117, P3821, DOI 10.1242/jcs.01234
   DiMauro S, 2004, BBA-BIOENERGETICS, V1658, P80, DOI 10.1016/j.bbabio.2004.03.014
   Dubec SJ, 2008, REJUV RES, V11, P611, DOI 10.1089/rej.2007.0617
   ENRIQUEZ JA, 1995, NAT GENET, V10, P47, DOI 10.1038/ng0595-47
   Fanin M, 2003, AM J PATHOL, V163, P1929, DOI 10.1016/S0002-9440(10)63551-1
   GOTO Y, 1990, J NEUROL SCI, V100, P63, DOI 10.1016/0022-510X(90)90014-E
   Hauerslev S, 2012, BMC MUSCULOSKEL DIS, V13, DOI 10.1186/1471-2474-13-43
   Hodges BL, 1997, J CELL SCI, V110, P2873
   Jeppesen TD, 2003, J NEUROL SCI, V214, P17, DOI 10.1016/S0022-510X(03)00168-0
   Jeppesen TD, 2003, ANN NEUROL, V54, P86, DOI 10.1002/ana.10594
   Jeppesen TD, 2008, NEUROMUSCULAR DISORD, V18, P306, DOI 10.1016/j.nmd.2007.10.007
   Jeppesen TD, 2006, ARCH NEUROL-CHICAGO, V63, P1701, DOI 10.1001/archneur.63.12.1701
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5
   Krag TO, 2011, SKELET MUSCLE, V1, DOI 10.1186/2044-5040-1-31
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   LAFORET P, 1995, NEUROMUSCULAR DISORD, V5, P399, DOI 10.1016/0960-8966(94)00080-S
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Marsh DR, 1997, J APPL PHYSIOL, V83, P1270, DOI 10.1152/jappl.1997.83.4.1270
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Narciso L, 2007, P NATL ACAD SCI USA, V104, P17010, DOI 10.1073/pnas.0701743104
   Olsen DB, 2003, J NEUROL, V250, P1328, DOI 10.1007/s00415-003-0206-1
   SARTORE S, 1982, NATURE, V298, P294, DOI 10.1038/298294a0
   Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Trifunovic A, 2005, P NATL ACAD SCI USA, V102, P17993, DOI 10.1073/pnas.0508886102
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Vissing J, 1998, NEUROLOGY, V50, P1875, DOI 10.1212/WNL.50.6.1875
NR 30
TC 5
Z9 5
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 1872-8278
J9 MITOCHONDRION
JI Mitochondrion
PD MAR
PY 2013
VL 13
IS 2
BP 63
EP 70
DI 10.1016/j.mito.2013.01.009
PG 8
WC Cell Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Genetics & Heredity
GA 125NW
UT WOS:000317547500001
PM 23376095
DA 2024-11-01
ER

PT J
AU Blakely, E
   He, L
   Gardner, JL
   Hudson, G
   Walter, J
   Hughes, I
   Turnbull, DM
   Taylor, RW
AF Blakely, Emma
   He, Langping
   Gardner, Julie L.
   Hudson, Gavin
   Walter, John
   Hughes, Imelda
   Turnbull, Douglass M.
   Taylor, Robert W.
TI Novel mutations in the <i>TK2</i> gene associated with fatal
   mitochondrial DNA depletion myopathy
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE mitochondrial DNA; myopathy; depletion syndrome; TK2 mutations
ID THYMIDINE KINASE; MTDNA DEPLETION
AB Mitochondrial DNA depletion syndromes are a heterogeneous group of childhood neurological disorders characterised by a quantitative abnormality of mitochondrial DNA. We describe two siblings who presented at 8 months and 14 months with myopathy, which rapidly progressed and resulted in death by respiratory failure at age 14 and 18 months, respectively. Muscle biopsy revealed marked respiratory chain defects, with real-time PCR confirming a dramatic depletion of mitochondrial DNA. Sequencing of the thymidine kinase 2 (TK2) gene revealed two, novel heterozygous mutations (p.Q87X and p.N100S) with parental DNA analysis confirming the transmission of mutated alleles. (c) 2008 Elsevier B.V. All rights reserved.
C1 [Blakely, Emma; He, Langping; Gardner, Julie L.; Hudson, Gavin; Turnbull, Douglass M.; Taylor, Robert W.] Univ Newcastle Upon Tyne, Sch Med, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Walter, John] Royal Manchester Childrens Hosp, Willink Biochem Genet Unit, Manchester M27 1HA, Lancs, England.
   [Hughes, Imelda] Royal Manchester Childrens Hosp, Dept Neurol, Manchester M27 1HA, Lancs, England.
   [Turnbull, Douglass M.; Taylor, Robert W.] Univ Newcastle Upon Tyne, Inst Human Genet & Neurosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
C3 Newcastle University - UK; Royal Manchester Children's Hospital; Royal
   Manchester Children's Hospital; Newcastle University - UK
RP Taylor, RW (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM r.w.taylor@ncl.ac.uk
RI Hudson, Gavin/E-7117-2017
OI Hudson, Gavin/0000-0001-7210-2733
FU Wellcome Trust [074454] Funding Source: Medline
CR Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Elpeleg O, 2003, PEDIATR RES, V54, P153, DOI 10.1203/01.PDR.0000072796.25097.A5
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   He LP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf067
   Johansson K, 2001, NAT STRUCT BIOL, V8, P616, DOI 10.1038/89661
   LESHINSKYSILVER E, 2007, EUR J PEDIAT NEUROL
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Oskoui M, 2006, ARCH NEUROL-CHICAGO, V63, P1122, DOI 10.1001/archneur.63.8.1122
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Vilà MR, 2003, NEUROLOGY, V60, P1203, DOI 10.1212/01.WNL.0000055928.58122.47
NR 10
TC 37
Z9 41
U1 0
U2 7
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD JUL
PY 2008
VL 18
IS 7
BP 557
EP 560
DI 10.1016/j.nmd.2008.04.014
PG 4
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 334AD
UT WOS:000258193800007
PM 18508266
DA 2024-11-01
ER

PT J
AU Jeppesen, TD
   Madsen, KL
   Poulsen, NS
   Lokken, N
   Vissing, J
AF Jeppesen, Tina D.
   Madsen, Karen L.
   Poulsen, Nanna S.
   Lokken, Nicoline
   Vissing, John
TI Exercise Testing, Physical Training and Fatigue in Patients with
   Mitochondrial Myopathy Related to mtDNA Mutations
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Review
DE mitochondrial myopathy; mtDNA mutation; exercise testing; fatigue
AB Mutations in mitochondrial DNA (mtDNA) cause disruption of the oxidative phosphorylation chain and impair energy production in cells throughout the human body. Primary mitochondrial disorders due to mtDNA mutations can present with symptoms from adult-onset mono-organ affection to death in infancy due to multi-organ involvement. The heterogeneous phenotypes that patients with a mutation of mtDNA can present with are thought, at least to some extent, to be a result of differences in mtDNA mutation load among patients and even among tissues in the individual. The most common symptom in patients with mitochondrial myopathy (MM) is exercise intolerance. Since mitochondrial function can be assessed directly in skeletal muscle, exercise studies can be used to elucidate the physiological consequences of defective mitochondria due to mtDNA mutations. Moreover, exercise tests have been developed for diagnostic purposes for mitochondrial myopathy. In this review, we present the rationale for exercise testing of patients with MM due to mutations in mtDNA, evaluate the diagnostic yield of exercise tests for MM and touch upon how exercise tests can be used as tools for follow-up to assess disease course or effects of treatment interventions.
C1 [Jeppesen, Tina D.; Madsen, Karen L.; Poulsen, Nanna S.; Lokken, Nicoline; Vissing, John] Univ Hosp Copenhagen, Rigshosp, Dept Neurol, Copenhagen Neuromuscular Ctr, DK-2100 Copenhagen, Denmark.
C3 Rigshospitalet; University of Copenhagen
RP Jeppesen, TD (corresponding author), Univ Hosp Copenhagen, Rigshosp, Dept Neurol, Copenhagen Neuromuscular Ctr, DK-2100 Copenhagen, Denmark.
EM tina.dysgaard.jeppesen.03@regionh.dk; karen.lindhardt.madsen@regionh.dk;
   nanna.scharff.nielsen.01@regionh.dk; nicoline.loekken@regionh.dk;
   john.vissing@regionh.dk
RI Løkken, Nicoline/GZL-0909-2022; Vissing, John/IUN-4271-2023; Jeppesen,
   Tina/AAV-7195-2020
OI Madsen, Karen Lindhardt/0000-0003-0145-1084; Poulsen, Nanna
   Scharff/0000-0002-3739-8759
CR Adhihetty PJ, 2007, AM J PHYSIOL-ENDOC M, V293, pE672, DOI 10.1152/ajpendo.00043.2007
   ANDERSEN P, 1985, J PHYSIOL-LONDON, V366, P233, DOI 10.1113/jphysiol.1985.sp015794
   [Anonymous], 2010, TRANSLATIONAL PAIN R
   ARNOLD DL, 1985, ANN NEUROL, V18, P189, DOI 10.1002/ana.410180205
   ASTRAND PO, 1976, PROG CARDIOVASC DIS, V19, P51, DOI 10.1016/0033-0620(76)90008-6
   Axelson HW, 2002, MUSCLE NERVE, V26, P520, DOI 10.1002/mus.10249
   Bank William, 1998, Biofactors, V7, P243
   Barcia G, 2020, NEUROMUSCULAR DISORD, V30, P593, DOI 10.1016/j.nmd.2020.06.002
   Bassett DR, 2000, MED SCI SPORT EXER, V32, P70, DOI 10.1097/00005768-200001000-00012
   BERGLUND B, 1991, J INTERN MED, V229, P125, DOI 10.1111/j.1365-2796.1991.tb00319.x
   BOGAARD JM, 1985, ADV EXP MED BIOL, V191, P409
   Boone J, 2014, RESP PHYSIOL NEUROBI, V190, P70, DOI 10.1016/j.resp.2013.09.007
   Boushel R, 2011, MITOCHONDRION, V11, P303, DOI 10.1016/j.mito.2010.12.006
   Bravo DM, 2012, EUR J APPL PHYSIOL, V112, P1763, DOI 10.1007/s00421-011-2136-4
   BROOKE MH, 1979, NEUROLOGY, V29, P636, DOI 10.1212/WNL.29.5.636
   Bruce RM, 2019, EXP PHYSIOL, V104, P1605, DOI 10.1113/EP087649
   Burnstock G, 1999, J ANAT, V194, P335, DOI 10.1046/j.1469-7580.1999.19430335.x
   Cejudo P, 2005, MUSCLE NERVE, V32, P342, DOI 10.1002/mus.20368
   Celie BM, 2015, APPL SPECTROSC, V69, P342, DOI 10.1366/14-07604
   Chan A, 1998, J NEUROL, V245, P681, DOI 10.1007/s004150050267
   Charlton Gerald A., 1997, Cardiology Clinics, V15, P345, DOI 10.1016/S0733-8651(05)70344-1
   Chelimsky TC, 1997, ADV EXP MED BIOL, V411, P445
   Chinnery PF, 1993, GENEREVIEWS
   CONSOLI A, 1990, AM J PHYSIOL, V259, pE677, DOI 10.1152/ajpendo.1990.259.5.E677
   DANDURAND RJ, 1995, CHEST, V108, P182, DOI 10.1378/chest.108.1.182
   DAVIS HA, 1983, EUR J APPL PHYSIOL, V50, P383, DOI 10.1007/BF00423244
   DAVIS JA, 1982, MED SCI SPORT EXER, V14, P339
   Davis RL, 2016, NEUROLOGY, V86, P2010, DOI 10.1212/WNL.0000000000002705
   Delaney NF, 2017, P NATL ACAD SCI USA, V114, P8402, DOI 10.1073/pnas.1703338114
   DEMPSEY JA, 1985, FED PROC, V44, P2260
   Dengler R, 1996, MUSCLE NERVE, V19, P456, DOI 10.1002/(SICI)1097-4598(199604)19:4<456::AID-MUS5>3.0.CO;2-B
   di Prampero PE, 2003, EUR J APPL PHYSIOL, V90, P420, DOI 10.1007/s00421-003-0926-z
   DiMauro S, 2006, CURR OPIN RHEUMATOL, V18, P636, DOI 10.1097/01.bor.0000245729.17759.f2
   ELLIOT DL, 1989, MEDICINE, V68, P163, DOI 10.1097/00005792-198905000-00004
   Ellsworth ML, 2000, ACTA PHYSIOL SCAND, V168, P551, DOI 10.1046/j.1365-201x.2000.00708.x
   Filler K, 2014, BBA CLIN, V1, P12, DOI 10.1016/j.bbacli.2014.04.001
   Finsterer J, 2004, EUR J NEUROL, V11, P811, DOI 10.1111/j.1468-1331.2004.00859.x
   Finsterer J, 1998, J NEUROL SCI, V159, P176, DOI 10.1016/S0022-510X(98)00170-1
   Finsterer J, 2003, METAB BRAIN DIS, V18, P155, DOI 10.1023/A:1023867104002
   Finsterer J, 2001, J NEUROSCI METH, V108, P65, DOI 10.1016/S0165-0270(01)00371-5
   Flaherty KR, 2001, AM J RESP CRIT CARE, V164, P425, DOI 10.1164/ajrccm.164.3.2005110
   Forster H V, 1988, Adv Exp Med Biol, V227, P257
   FORSTER HV, 1994, MED SCI SPORT EXER, V26, P328
   Frederiksen AL, 2006, J MED GENET, V43, DOI 10.1136/jmg.2005.039339
   Fujita Y, 2015, MITOCHONDRION, V20, P34, DOI 10.1016/j.mito.2014.10.006
   Galán F, 2015, J INVEST MED HIGH IM, V3, DOI 10.1177/2324709615607908
   Giannoni A, 2017, EUR J HEART FAIL, V19, P1701, DOI 10.1002/ejhf.782
   Gimenes AC, 2011, BRAZ J MED BIOL RES, V44, P354, DOI 10.1590/S0100-879X2011007500023
   GOLDSTEIN I, 1975, J APPL PHYSIOL, V39, P697, DOI 10.1152/jappl.1975.39.5.697
   González-Alonso J, 2006, J PHYSIOL-LONDON, V572, P295, DOI 10.1113/jphysiol.2005.101121
   González-Alonso J, 2002, CIRC RES, V91, P1046, DOI 10.1161/01.RES.0000044939.73286.E2
   GOODWIN GM, 1972, J PHYSIOL-LONDON, V226, P173, DOI 10.1113/jphysiol.1972.sp009979
   Kalko SG, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-91
   Grassi B, 2019, MED SCI SPORT EXER, V51, P2183, DOI 10.1249/MSS.0000000000002056
   GREGG SG, 1989, J APPL PHYSIOL, V67, P756, DOI 10.1152/jappl.1989.67.2.756
   Haller R G, 1978, Trans Am Neurol Assoc, V103, P6
   HALLER RG, 1989, J CLIN INVEST, V84, P155, DOI 10.1172/JCI114135
   Haller RG, 2002, ARCH NEUROL-CHICAGO, V59, P1395, DOI 10.1001/archneur.59.9.1395
   HALLER RG, 1984, MED SCI SPORT EXER, V16, P456, DOI 10.1249/00005768-198410000-00006
   HALLER RG, 1985, ANN NEUROL, V17, P196, DOI 10.1002/ana.410170216
   Hammarén E, 2004, EUR NEUROL, V51, P38, DOI 10.1159/000074981
   Hanisch F, 2006, J NEUROL, V253, P417, DOI 10.1007/s00415-006-0987-0
   Heinicke K, 2011, AM J PHYSIOL-REG I, V301, pR873, DOI 10.1152/ajpregu.00001.2011
   HOOPER RG, 1995, CHEST, V107, P317, DOI 10.1378/chest.107.2.317
   Hoppeler H, 1998, J EXP BIOL, V201, P1051
   Hunter SK, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a029728
   Ichiwata T, 2010, ADV EXP MED BIOL, V662, P537, DOI 10.1007/978-1-4419-1241-1_78
   Jensen TD, 2002, NEUROLOGY, V58, P1533, DOI 10.1212/WNL.58.10.1533
   Jeppesen TD, 2009, EUR J NEUROL, V16, P1336, DOI 10.1111/j.1468-1331.2009.02660.x
   Jeppesen TD, 2003, J NEUROL, V250, P293, DOI 10.1007/s00415-003-0993-4
   Jeppesen TD, 2003, ANN NEUROL, V54, P86, DOI 10.1002/ana.10594
   Jeppesen TD, 2006, BRAIN, V129, P3402, DOI 10.1093/brain/awl149
   Jeppesen TD, 2013, NEUROMUSCULAR DISORD, V23, P629, DOI 10.1016/j.nmd.2013.05.007
   Jeppesen TD, 2012, MITOCHONDRION, V12, P414, DOI 10.1016/j.mito.2011.11.003
   Jeppesen TD, 2006, ARCH NEUROL-CHICAGO, V63, P1701, DOI 10.1001/archneur.63.12.1701
   Jeppesen TD, 2007, J NEUROL, V254, P29, DOI 10.1007/s00415-006-0229-5
   Jeppesen TD, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00349
   Jeppesen TD, 2009, ARCH NEUROL-CHICAGO, V66, P365, DOI 10.1001/archneurol.2009.24
   Ji XB, 2017, MOL NEUROBIOL, V54, P8110, DOI 10.1007/s12035-016-0283-7
   Johnson BD, 1996, MED SCI SPORT EXER, V28, P1129, DOI 10.1097/00005768-199609000-00008
   Jones AM, 2000, SPORTS MED, V29, P373, DOI 10.2165/00007256-200029060-00001
   KEMP GJ, 1994, MAGN RESON QUART, V10, P43
   Kim JK, 2007, AM J PHYSIOL-HEART C, V292, pH866, DOI 10.1152/ajpheart.00771.2006
   Kindig AE, 2007, AM J PHYSIOL-HEART C, V293, pH2995, DOI 10.1152/ajpheart.00743.2007
   Kindig AE, 2007, J PHYSIOL-LONDON, V578, P301, DOI 10.1113/jphysiol.2006.119271
   Kleinert M, 2018, MOL METAB, V9, P187, DOI 10.1016/j.molmet.2017.12.016
   Klopstock T, 2000, NEUROLOGY, V55, P1748, DOI 10.1212/WNL.55.11.1748
   Koene S, 2015, JIMD REP, V24, P69, DOI 10.1007/8904_2015_436
   Koo P, 2018, CLIN CHEST MED, V39, P401, DOI 10.1016/j.ccm.2018.02.001
   Kornblum C, 2005, EUR J NEUROL, V12, P300, DOI 10.1111/j.1468-1331.2004.00970.x
   Levine BD, 1997, J APPL PHYSIOL, V83, P102, DOI 10.1152/jappl.1997.83.1.102
   LEWIS SF, 1986, J APPL PHYSIOL, V61, P391, DOI 10.1152/jappl.1986.61.2.391
   LINDERHOLM H, 1969, ACTA MED SCAND, V185, P153
   Lindholm H, 2004, CLIN PHYSIOL FUNCT I, V24, P109, DOI 10.1111/j.1475-097X.2004.00531.x
   LINDINGER MI, 1995, J APPL PHYSIOL, V78, P765, DOI 10.1152/jappl.1995.78.3.765
   Little JP, 2011, AM J PHYSIOL-REG I, V300, pR1303, DOI 10.1152/ajpregu.00538.2010
   Löfberg M, 2001, NEUROMUSCULAR DISORD, V11, P370, DOI 10.1016/S0960-8966(00)00205-4
   Madsen KL, 2020, NEUROLOGY, V94, pE687, DOI 10.1212/WNL.0000000000008861
   MANCIA G, 1983, CLIN SCI, V65, P227, DOI 10.1042/cs0650227
   Mancuso M, 2012, NEUROMUSCULAR DISORD, V22, pS226, DOI 10.1016/j.nmd.2012.10.012
   MARTIN BJ, 1979, J APPL PHYSIOL, V46, P322, DOI 10.1152/jappl.1979.46.2.322
   MCARDLE B, 1951, CLIN SCI, V10, P12
   McCoy J, 2017, OPEN HEART, V4, DOI 10.1136/openhrt-2017-000632
   MITCHELL JH, 1958, J CLIN INVEST, V37, P538, DOI 10.1172/JCI103636
   Montero R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148709
   Moosmann P, 2000, J ROY SOC MED, V93, P25, DOI 10.1177/014107680009300108
   Murphy JL, 2008, BRAIN, V131, P2832, DOI 10.1093/brain/awn252
   Nabben M, 2017, AM J PHYSIOL-REG I, V312, pR689, DOI 10.1152/ajpregu.00264.2016
   Nakagawa E, 1996, BRAIN DEV-JPN, V18, P68, DOI 10.1016/0387-7604(95)00096-8
   NASHEF L, 1989, J NEUROL NEUROSUR PS, V52, P1090, DOI 10.1136/jnnp.52.9.1090
   Newman Jane, 2015, J Neuromuscul Dis, V2, P151
   Ng K, 2010, J NEUROL NEUROSUR PS, V81, P844, DOI 10.1136/jnnp.2009.178921
   PARATI G, 1983, EUR HEART J, V4, P19, DOI 10.1093/eurheartj/4.suppl_D.19
   Parikh S, 2019, NEUROMUSCULAR DISORD, V29, P895, DOI 10.1016/j.nmd.2019.09.012
   Park Jane, 1998, Biofactors, V7, P253
   PATERSON DJ, 1992, J APPL PHYSIOL, V72, P811, DOI 10.1152/jappl.1992.72.3.811
   Piepoli M, 1996, CIRCULATION, V93, P940, DOI 10.1161/01.CIR.93.5.940
   Porcelli S, 2016, J APPL PHYSIOL, V121, P699, DOI 10.1152/japplphysiol.00885.2015
   POTTS JT, 1993, AM J PHYSIOL, V265, pH1928, DOI 10.1152/ajpheart.1993.265.6.H1928
   Poulsen NS, 2020, MITOCHONDRION, V50, P35, DOI 10.1016/j.mito.2019.10.005
   Radda George K., 1998, Biofactors, V7, P247
   Rasmussen UF, 2001, AM J PHYSIOL-ENDOC M, V280, pE301, DOI 10.1152/ajpendo.2001.280.2.E301
   Reinöhl J, 2003, NEUROSCI LETT, V338, P25, DOI 10.1016/S0304-3940(02)01360-5
   Rodan LH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127066
   Romer LM, 2008, J APPL PHYSIOL, V104, P879, DOI 10.1152/japplphysiol.01157.2007
   Saltin B, 1993, Am J Clin Nutr, V57, p752S, DOI 10.1093/ajcn/57.5.752S
   SALTIN B, 1992, MED SCI SPORT EXER, V24, P30
   Saltin B, 2007, J PHYSIOL-LONDON, V583, P819, DOI 10.1113/jphysiol.2007.136309
   SCARLATO G, 1991, REV NEUROL, V147, P542
   Sheel AW, 2011, CURR OPIN PHARMACOL, V11, P195, DOI 10.1016/j.coph.2011.04.004
   Shoubridge EA, 1997, HUM MOL GENET, V6, P2239, DOI 10.1093/hmg/6.13.2239
   Siciliano G, 1996, MUSCLE NERVE, V19, P342
   Siciliano G, 2000, NEUROMUSCULAR DISORD, V10, P40, DOI 10.1016/S0960-8966(99)00068-1
   Siciliano G, 1999, NEUROMUSCULAR DISORD, V9, P411, DOI 10.1016/S0960-8966(99)00047-4
   Siciliano G, 2012, NEUROMUSCULAR DISORD, V22, pS172, DOI 10.1016/j.nmd.2012.10.005
   Sprague RS, 2007, TRENDS ENDOCRIN MET, V18, P350, DOI 10.1016/j.tem.2007.08.008
   Steensberg A, 2001, EUR J APPL PHYSIOL, V84, P155, DOI 10.1007/s004210000351
   Stefanetti Renae J, 2020, Wellcome Open Res, V5, P84, DOI 10.12688/wellcomeopenres.15825.1
   Taivassalo T, 1998, NEUROLOGY, V50, P1055, DOI 10.1212/WNL.50.4.1055
   Taivassalo T, 2002, ANN NEUROL, V51, P38, DOI 10.1002/ana.10027
   Taivassalo T, 2001, ANN NEUROL, V50, P133, DOI 10.1002/ana.1050
   Taivassalo T, 2003, BRAIN, V126, P413, DOI 10.1093/brain/awg028
   Taivassalo T, 2006, BRAIN, V129, P3391, DOI 10.1093/brain/awl282
   Tarnopolsky M, 2004, MITOCHONDRION, V4, P529, DOI 10.1016/j.mito.2004.07.011
   Tarnopolsky MA, 2014, J CHILD NEUROL, V29, P1225, DOI 10.1177/0883073814538512
   Trenell MI, 2007, EUR J APPL PHYSIOL, V99, P541, DOI 10.1007/s00421-006-0372-9
   Uchida K, 2011, J MED ULTRASON, V38, P157, DOI 10.1007/s10396-011-0306-y
   van Beekvelt MCP, 1999, ANN NEUROL, V46, P667, DOI 10.1002/1531-8249(199910)46:4<667::AID-ANA19>3.0.CO;2-D
   van Hall G, 2003, AM J PHYSIOL-ENDOC M, V284, pE193, DOI 10.1152/ajpendo.00273.2002
   Vissing J, 1996, ANN NEUROL, V40, P655, DOI 10.1002/ana.410400416
   Vissing J, 2001, ANN NEUROL, V49, P672, DOI 10.1002/ana.1026
   Volpi L, 2011, Musculoskelet Surg, V95, P59, DOI 10.1007/s12306-011-0096-9
   Wang HJ, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00398
   WARD SA, 1994, CAN J APPL PHYSIOL, V19, P305, DOI 10.1139/h94-026
   WEBER KT, 1985, J AM COLL CARDIOL, V6, P717, DOI 10.1016/S0735-1097(85)80472-1
   Whitfield KC, 2018, ANN NY ACAD SCI, V1430, P3, DOI 10.1111/nyas.13919
   Xu S, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008716
   Yatsuga S, 2015, ANN NEUROL, V78, P814, DOI 10.1002/ana.24506
   Zoladz JA, 2013, EXP PHYSIOL, V98, P883, DOI 10.1113/expphysiol.2012.069443
NR 159
TC 5
Z9 5
U1 1
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD APR
PY 2021
VL 10
IS 8
AR 1796
DI 10.3390/jcm10081796
PG 19
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA RT4ZI
UT WOS:000644468900001
PM 33924201
OA gold, Green Published
DA 2024-11-01
ER

PT J
AU Srivastava, S
   Moraes, CT
AF Srivastava, S
   Moraes, CT
TI Double-strand breaks of mouse muscle mtDNA promote large deletions
   similar to multiple mtDNA deletions in humans
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID HUMAN MITOCHONDRIAL-DNA; LARGE-SCALE DELETIONS; SKELETAL ACTIN GENE;
   RESTRICTION-ENDONUCLEASE; HOMOLOGOUS RECOMBINATION; DIRECT REPEATS;
   REPLICATION; DEFICIENCY; INITIATION; MUTATIONS
AB Mitochondrial DNA (mtDNA) deletions are a common cause of mitochondrial disorders and have been found to accumulate during normal aging. Despite the fact that hundreds of deletions have been characterized at the molecular level, their mechanisms of genesis are unknown. We tested the effect of double-strand breaks of muscle mtDNA by developing a mouse model in which a mitochondrially targeted restriction endonuclease (PstI) was expressed in skeletal muscle of mice. Because mouse mtDNA harbors two PstI sites, transgenic founders developed a mitochondrial myopathy associated with mtDNA depletion. The founders showed a chimeric pattern of transgene expression and their residual level of wild-type mtDNA in muscle was similar to 40% of controls. We were able to identify the formation of large mtDNA deletions in muscle of transgenic mice. A family of mtDNA deletions was identified, and most of these rearrangements involved one of the PstI sites and the 3' end of the D-loop region. The deletions had no or small direct repeats at the breakpoint region. These features are essentially identical to the ones observed in humans with multiple mtDNA deletions in muscle, suggesting that double-strand DNA breaks mediate the formation of large mtDNA deletions.
C1 Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33136 USA.
   Univ Miami, Sch Med, Dept Neurol, Miami, FL 33136 USA.
C3 University of Miami; University of Miami
RP Univ Miami, Sch Med, Dept Cell Biol & Anat, 1095 NW 14th Terrace, Miami, FL 33136 USA.
EM cmoraes@med.miami.edu
RI Moraes, Carlos/AAT-3818-2021
OI Srivastava, Sarika/0000-0001-9634-5510
FU NEI NIH HHS [EY 10804, R01 EY010804] Funding Source: Medline; NIGMS NIH
   HHS [GM 55766] Funding Source: Medline; NIMH NIH HHS [R01 MH085801]
   Funding Source: Medline; NINDS NIH HHS [NS 041777, R01 NS041777, R56
   NS041777] Funding Source: Medline
CR Barrientos A, 1998, J BIOL CHEM, V273, P14210, DOI 10.1074/jbc.273.23.14210
   BIBB MJ, 1981, CELL, V26, P167, DOI 10.1016/0092-8674(81)90300-7
   Bowmaker M, 2003, J BIOL CHEM, V278, P50961, DOI 10.1074/jbc.M308028200
   BRENNAN KJ, 1993, J BIOL CHEM, V268, P719
   Crawford GE, 2000, J CELL BIOL, V150, P1399, DOI 10.1083/jcb.150.6.1399
   Dudás A, 2004, MUTAT RES-REV MUTAT, V566, P131, DOI 10.1016/j.mrrev.2003.07.001
   Haber JE, 2000, TRENDS GENET, V16, P259, DOI 10.1016/S0168-9525(00)02022-9
   IMLAY JA, 1988, SCIENCE, V240, P1302, DOI 10.1126/science.3287616
   Lee DY, 1998, J BIOL CHEM, V273, P30614, DOI 10.1074/jbc.273.46.30614
   Michel B, 2001, P NATL ACAD SCI USA, V98, P8181, DOI 10.1073/pnas.111008798
   Miller DL, 2001, ANAT HISTOL EMBRYOL, V30, P253, DOI 10.1046/j.1439-0264.2001.00330.x
   MITA S, 1990, NUCLEIC ACIDS RES, V18, P561, DOI 10.1093/nar/18.3.561
   Moraes C T, 1996, Methods Enzymol, V264, P522, DOI 10.1016/S0076-6879(96)64046-4
   MUSCAT GEO, 1987, MOL CELL BIOL, V7, P4089, DOI 10.1128/MCB.7.11.4089
   Nishigaki Y, 2004, HUM MOL GENET, V13, P91, DOI 10.1093/hmg/ddh010
   Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828
   Oshima J, 2002, CANCER RES, V62, P547
   Ozawa T, 1999, J BIOENERG BIOMEMBR, V31, P377, DOI 10.1023/A:1005479920097
   Samuels DC, 2004, TRENDS GENET, V20, P393, DOI 10.1016/j.tig.2004.07.003
   SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184
   Sciacco M, 1996, Methods Enzymol, V264, P509, DOI 10.1016/S0076-6879(96)64045-2
   Srivastava S, 2001, HUM MOL GENET, V10, P3093, DOI 10.1093/hmg/10.26.3093
   SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8
   Tanaka M, 2002, J BIOMED SCI, V9, P534, DOI 10.1007/BF02254980
   Tyynismaa H, 2004, HUM MOL GENET, V13, P3219, DOI 10.1093/hmg/ddh342
   Wanrooij S, 2004, NUCLEIC ACIDS RES, V32, P3053, DOI 10.1093/nar/gkh634
   ZEVIANI M, 1990, AM J HUM GENET, V47, P904
   Zeviani M, 2003, CURR OPIN NEUROL, V16, P585, DOI 10.1097/00019052-200310000-00004
NR 28
TC 131
Z9 161
U1 0
U2 8
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD APR 1
PY 2005
VL 14
IS 7
BP 893
EP 902
DI 10.1093/hmg/ddi082
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 911BJ
UT WOS:000227975800002
PM 15703189
OA Bronze, Green Accepted
DA 2024-11-01
ER

PT J
AU Tesarova, M
   Hansikova, H
   Kytnarova, J
   Houstkova, H
   Bohm, M
   Cerna, L
   Zeman, J
   Houstek, J
AF Tesarova, M
   Hansikova, H
   Kytnarova, J
   Houstkova, H
   Bohm, M
   Cerna, L
   Zeman, J
   Houstek, J
TI Clinical heterogeneity, tissue distribution, and intergenerational
   segregation of mtDNA mutation A3243G
SO TOXICOLOGY MECHANISMS AND METHODS
LA English
DT Article; Proceedings Paper
CT Workshop on Mitochondria DNA Mutations
CY MAY 09-12, 2003
CL POLISH ACAD SCI, WARSAW, POLAND
HO POLISH ACAD SCI
DE intergenerational transmission; mtDNA mutation A3243G
ID TRANSFER RNALEU(UUR) GENE; MITOCHONDRIAL-DNA; LACTIC-ACIDOSIS; POINT
   MUTATION; TRANSFER-RNA; ENCEPHALOMYOPATHIES; ENCEPHALOPATHY;
   HETEROPLASMY; MYOPATHY; MUSCLE
AB Tissue distribution and segregation and the functional consequences of heteroplasmic mitochondrial DNA mutation A3243G were studied in 30 carriers. The mutation load in hair follicles was higher in 20 patients with a broad spectrum of clinical symptoms than in 10 nonaffected carriers. The onset of the disease negatively correlated with the mutation load in blood and muscle. The activities of respiratory chain complexes in isolated muscle mitochondria did not decrease in all patients and were normal in isolated platelets. Changes in the heteroplasmy level between pairs of mothers and offspring suggest that random genetic drift is the mechanism associated with the intergenerational transmission of the A3243G mutation. In conclusion, detailed clinical investigations and mitochondrial DNA analyses in several tissues are of the highest diagnostic value for the prognosis of the disease in carriers of the A3243G mutation.
C1 Charles Univ, Fac Med, Dept Paediat, Ctr Integrated Genom, Prague 12000 2, Czech Republic.
   Acad Sci Czech Republ, Inst Physiol, Prague, Czech Republic.
C3 Charles University Prague; Czech Academy of Sciences; Institute of
   Physiology of the Czech Academy of Sciences
RP Zeman, J (corresponding author), Charles Univ, Fac Med, Dept Paediat, Ctr Integrated Genom, Ke Karlovu 2, Prague 12000 2, Czech Republic.
RI Houstek, Josef/C-5019-2012; Hansikova, Hana/E-9350-2017; Zeman,
   Jiri/K-2691-2017; Tesarova, Marketa/I-1531-2016; Kytnarova,
   Jitka/K-2879-2017; Houstkova, Hana/J-2439-2017
OI Zeman, Jiri/0000-0002-2678-7919; Tesarova, Marketa/0000-0002-5141-2289;
   Kytnarova, Jitka/0000-0003-1144-3440; Houstkova,
   Hana/0000-0003-1123-4171
CR Brown DT, 2001, AM J HUM GENET, V68, P533, DOI 10.1086/318190
   Chinnery PF, 2000, TRENDS GENET, V16, P500, DOI 10.1016/S0168-9525(00)02120-X
   Chomyn A, 2000, J BIOL CHEM, V275, P19198, DOI 10.1074/jbc.M908734199
   DiMauro S, 2001, SEMIN CELL DEV BIOL, V12, P397, DOI 10.1006/scdb.2001.0277
   El Meziane A, 1998, NAT GENET, V18, P350
   FOX JEB, 1992, METHOD ENZYMOL, V215, P42
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Hansrote S, 2002, J NEUROL SCI, V197, P63, DOI 10.1016/S0022-510X(02)00048-5
   Juvonen V, 1997, HUM MUTAT, V9, P412, DOI 10.1002/(SICI)1098-1004(1997)9:5<412::AID-HUMU6>3.3.CO;2-Q
   Kirkinezos IG, 2001, SEMIN CELL DEV BIOL, V12, P449, DOI 10.1006/scdb.2001.0282
   KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   MAKINE MW, 1968, NEUROLOGY, V18, P299
   MARIOTTI C, 1995, J NEUROL, V242, P304, DOI 10.1007/BF00878873
   Morovvati S, 2002, ACTA NEUROL SCAND, V106, P104, DOI 10.1034/j.1600-0404.2002.01172.x
   Olsson C, 1998, HUM MUTAT, V12, P52, DOI 10.1002/(SICI)1098-1004(1998)12:1<52::AID-HUMU8>3.0.CO;2-K
   Rahman S, 2001, AM J HUM GENET, V68, P238, DOI 10.1086/316930
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   Shoubridge E A, 2000, Hum Reprod, V15 Suppl 2, P229
   Sue CM, 1998, J NEUROL SCI, V161, P36, DOI 10.1016/S0022-510X(98)00179-8
   TATUCH Y, 1992, AM J HUM GENET, V50, P852
   Villani G, 1997, P NATL ACAD SCI USA, V94, P1166, DOI 10.1073/pnas.94.4.1166
   Wittenhagen LM, 2002, NAT STRUCT BIOL, V9, P586, DOI 10.1038/nsb820
NR 23
TC 0
Z9 0
U1 0
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 1537-6524
J9 TOXICOL MECH METHOD
JI Toxicol. Mech. Methods
PD JAN-APR
PY 2004
VL 14
IS 1-2
BP 79
EP 84
DI 10.1080/15376520490257527
PG 6
WC Toxicology
WE Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)
SC Toxicology
GA 757FU
UT WOS:000187551000016
PM 20021128
DA 2024-11-01
ER

PT J
AU Jeppesen, TD
AF Jeppesen, Tina Dysgaard
TI Aerobic Exercise Training in Patients With mtDNA-Related Mitochondrial
   Myopathy
SO FRONTIERS IN PHYSIOLOGY
LA English
DT Review
DE mitochondrial DNA; mitochondrial myopathies; treatment; training;
   oxidative capacity
ID SKELETAL-MUSCLE; OXIDATIVE CAPACITY; INSULIN-RESISTANCE; BLOOD-PRESSURE;
   OXYGEN-UPTAKE; METABOLISM; LACTATE; MUTATION; BIOGENESIS; PERFORMANCE
AB In patients with mitochondrial DNA (mtDNA) mutation, a pathogenic mtDNA mutation is heteroplasmically distributed among tissues. The ratio between wild-type and mutated mtDNA copies determines the mtDNA mutation load of the tissue, which correlates inversively with oxidative capacity of the tissue. In patients with mtDNA mutation, the mutation load is often very high in skeletal muscle compared to other tissues. Additionally, skeletal muscle can increase its oxygen demand up to 100-fold from rest to exercise, which is unmatched by any other tissue. Thus, exercise intolerance is the most common symptom in patients with mtDNA mutation. The impaired oxidative capacity in skeletal muscle in patients with mtDNA mutation results in limitation in physical capacity that interferes with daily activities and impairs quality of life. Additionally, patients with mitochondrial disease due to mtDNA mutation often live a sedentary lifestyle, which further impair oxidative capacity and exercise tolerance. Since aerobic exercise training increase mitochondrial function and volume density in healthy individuals, studies have investigated if aerobic training could be used to counteract the progressive exercise intolerance in patients with mtDNA mutation. Overall studies investigating the effect of aerobic training in patients with mtDNA mutation have shown that aerobic training is an efficient way to improve oxidative capacity in this condition, and aerobic training seems to be safe even for patients with high mtDNA mutation in skeletal muscle.
C1 [Jeppesen, Tina Dysgaard] Univ Copenhagen, Dept Neurol, Copenhagen Neuromuscular Clin, Rigshosp, Copenhagen, Denmark.
C3 University of Copenhagen; Rigshospitalet
RP Jeppesen, TD (corresponding author), Univ Copenhagen, Dept Neurol, Copenhagen Neuromuscular Clin, Rigshosp, Copenhagen, Denmark.
EM tina@dysgaard.dk
RI Jeppesen, Tina/AAV-7195-2020
CR Abe K, 1997, NEUROLOGY, V49, P837, DOI 10.1212/WNL.49.3.837
   Adhihetty PJ, 2007, AM J PHYSIOL-ENDOC M, V293, pE672, DOI 10.1152/ajpendo.00043.2007
   ANDERSEN P, 1985, J PHYSIOL-LONDON, V366, P233, DOI 10.1113/jphysiol.1985.sp015794
   BABIJ P, 1988, NEWS PHYSIOL SCI, V3, P100
   Balakrishnan VS, 2010, CLIN J AM SOC NEPHRO, V5, P996, DOI 10.2215/CJN.09141209
   Bangsbo J, 2000, AM J PHYSIOL-REG I, V279, pR899, DOI 10.1152/ajpregu.2000.279.3.R899
   Bank W, 1997, MOL CELL BIOCHEM, V174, P7, DOI 10.1023/A:1006887319200
   BANK W, 1994, ANN NEUROL, V36, P830, DOI 10.1002/ana.410360606
   BERGLUND B, 1991, J INTERN MED, V229, P125, DOI 10.1111/j.1365-2796.1991.tb00319.x
   BOOTH FW, 1985, FED PROC, V44, P2293
   Bruce CR, 2004, MED SCI SPORT EXER, V36, P1196, DOI 10.1249/01.MSS.0000074670.03001.98
   BYLUND AC, 1977, EUR J APPL PHYSIOL, V36, P151, DOI 10.1007/BF00421747
   Cejudo P, 2005, MUSCLE NERVE, V32, P342, DOI 10.1002/mus.20368
   Chinnery PF, 1999, AM J HUM GENET, V64, P1158, DOI 10.1086/302311
   Civitarese AE, 2007, PLOS MED, V4, P485, DOI 10.1371/journal.pmed.0040076
   Cornelissen VA, 2013, J HYPERTENS, V31, P639, DOI 10.1097/HJH.0b013e32835ca964
   DAVIS HA, 1983, EUR J APPL PHYSIOL, V50, P383, DOI 10.1007/BF00423244
   DAVIS JA, 1982, MED SCI SPORT EXER, V14, P339
   DEMPSEY JA, 1985, FED PROC, V44, P2260
   Dengler R, 1996, MUSCLE NERVE, V19, P456, DOI 10.1002/(SICI)1097-4598(199604)19:4<456::AID-MUS5>3.0.CO;2-B
   Di Meo S, 2017, J ENDOCRINOL, V234, pR159, DOI 10.1530/JOE-17-0186
   di Prampero PE, 2003, EUR J APPL PHYSIOL, V90, P420, DOI 10.1007/s00421-003-0926-z
   Finsterer J, 1998, J NEUROL SCI, V159, P176, DOI 10.1016/S0022-510X(98)00170-1
   Flaherty KR, 2001, AM J RESP CRIT CARE, V164, P425, DOI 10.1164/ajrccm.164.3.2005110
   Forster H V, 1988, Adv Exp Med Biol, V227, P257
   Frederiksen AL, 2006, J MED GENET, V43, DOI 10.1136/jmg.2005.039339
   Fritzen A. M., 2019, CELLS, V12, DOI [10.1021/bk-1986-0294.ch002, DOI 10.1021/BK-1986-0294.CH002]
   Fu K, 1996, HUM MOL GENET, V5, P1835, DOI 10.1093/hmg/5.11.1835
   GOLDSTEIN I, 1975, J APPL PHYSIOL, V39, P697, DOI 10.1152/jappl.1975.39.5.697
   Haller R G, 1978, Trans Am Neurol Assoc, V103, P6
   HALLER RG, 1989, J CLIN INVEST, V84, P155, DOI 10.1172/JCI114135
   HALLER RG, 1984, MED SCI SPORT EXER, V16, P456, DOI 10.1249/00005768-198410000-00006
   Hawley JA, 2011, J APPL PHYSIOL, V110, P834, DOI 10.1152/japplphysiol.00949.2010
   Heinicke K, 2011, AM J PHYSIOL-REG I, V301, pR873, DOI 10.1152/ajpregu.00001.2011
   HOLLOSZY JO, 1967, J BIOL CHEM, V242, P2278
   HOLLOSZY JO, 1975, MED SCI SPORT EXER, V7, P155
   Hoppeler H, 2003, MED SCI SPORT EXER, V35, P95, DOI 10.1097/00005768-200301000-00016
   Hoppeler H, 1998, J EXP BIOL, V201, P1051
   Ikawa M, 2009, MITOCHONDRION, V9, P144, DOI 10.1016/j.mito.2009.01.011
   Jacobs RA, 2013, J APPL PHYSIOL, V115, P785, DOI 10.1152/japplphysiol.00445.2013
   Jeppesen TD, 2009, EUR J NEUROL, V16, P1336, DOI 10.1111/j.1468-1331.2009.02660.x
   Jeppesen TD, 2003, ANN NEUROL, V54, P86, DOI 10.1002/ana.10594
   Jeppesen TD, 2006, BRAIN, V129, P3402, DOI 10.1093/brain/awl149
   Jeppesen TD, 2013, NEUROMUSCULAR DISORD, V23, P629, DOI 10.1016/j.nmd.2013.05.007
   Jeppesen TD, 2012, MITOCHONDRION, V12, P414, DOI 10.1016/j.mito.2011.11.003
   Jeppesen TD, 2006, ARCH NEUROL-CHICAGO, V63, P1701, DOI 10.1001/archneur.63.12.1701
   Jeppesen TD, 2009, ARCH NEUROL-CHICAGO, V66, P365, DOI 10.1001/archneurol.2009.24
   KIENS B, 1993, J PHYSIOL-LONDON, V469, P459, DOI 10.1113/jphysiol.1993.sp019823
   Larsen S, 2012, J PHYSIOL-LONDON, V590, P3349, DOI 10.1113/jphysiol.2012.230185
   LARSSON LE, 1964, J NEUROL NEUROSUR PS, V27, P361, DOI 10.1136/jnnp.27.5.361
   LARSSON NG, 1990, PEDIATR RES, V28, P131, DOI 10.1203/00006450-199028020-00011
   Liu CY, 2009, BBA-MOL BASIS DIS, V1792, P783, DOI 10.1016/j.bbadis.2009.05.005
   Lu CY, 2003, MOL GENET METAB, V80, P321, DOI 10.1016/j.ymgme.2003.08.005
   MARTIN BJ, 1979, J APPL PHYSIOL, V46, P322, DOI 10.1152/jappl.1979.46.2.322
   Menshikova EV, 2006, J GERONTOL A-BIOL, V61, P534, DOI 10.1093/gerona/61.6.534
   MITCHELL JH, 1958, J CLIN INVEST, V37, P538, DOI 10.1172/JCI103636
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   OZAWA T, 1995, BIOCHEM BIOPH RES CO, V213, P432, DOI 10.1006/bbrc.1995.2150
   Perry CGR, 2010, J PHYSIOL-LONDON, V588, P4795, DOI 10.1113/jphysiol.2010.199448
   Pfeiffer K, 2003, J BIOL CHEM, V278, P52873, DOI 10.1074/jbc.M308366200
   Porcelli S, 2016, J APPL PHYSIOL, V121, P699, DOI 10.1152/japplphysiol.00885.2015
   Rasmussen UF, 2001, AM J PHYSIOL-ENDOC M, V280, pE301, DOI 10.1152/ajpendo.2001.280.2.E301
   Saltin B, 1981, Ciba Found Symp, V82, P41
   SALTIN B, 1986, ACTA MED SCAND, P11
   SALTIN B, 1993, AM J CLIN NUTR, V57, P752
   SALTIN B, 1992, MED SCI SPORT EXER, V24, P30
   SCHWERZMANN K, 1989, P NATL ACAD SCI USA, V86, P1583, DOI 10.1073/pnas.86.5.1583
   Siciliano G, 2000, NEUROMUSCULAR DISORD, V10, P40, DOI 10.1016/S0960-8966(99)00068-1
   Siciliano G, 2012, NEUROMUSCULAR DISORD, V22, pS172, DOI 10.1016/j.nmd.2012.10.005
   Sveen ML, 2007, NEUROLOGY, V68, P59, DOI 10.1212/01.wnl.0000250358.32199.24
   Sveen ML, 2008, BRAIN, V131, P2824, DOI 10.1093/brain/awn189
   Taivassalo T, 2005, MED SCI SPORT EXER, V37, P2094, DOI 10.1249/01.mss.0000177446.97671.2a
   Taivassalo T, 1999, MUSCLE NERVE, V22, P1239, DOI 10.1002/(SICI)1097-4598(199909)22:9<1239::AID-MUS11>3.0.CO;2-W
   Taivassalo T, 1998, NEUROLOGY, V50, P1055, DOI 10.1212/WNL.50.4.1055
   Taivassalo T, 1996, NEUROLOGY, V47, P529, DOI 10.1212/WNL.47.2.529
   Taivassalo T, 2002, ANN NEUROL, V51, P38, DOI 10.1002/ana.10027
   Taivassalo T, 2001, ANN NEUROL, V50, P133, DOI 10.1002/ana.1050
   Taivassalo T, 2003, BRAIN, V126, P413, DOI 10.1093/brain/awg028
   Taivassalo T, 2006, BRAIN, V129, P3391, DOI 10.1093/brain/awl282
   Tarnopolsky MA, 2007, AM J PHYSIOL-REG I, V292, pR1271, DOI 10.1152/ajpregu.00472.2006
   TATUCH Y, 1992, AM J HUM GENET, V50, P852
   Turner DL, 1997, ACTA PHYSIOL SCAND, V161, P459, DOI 10.1046/j.1365-201X.1997.00246.x
   van Hall G, 2003, AM J PHYSIOL-ENDOC M, V284, pE193, DOI 10.1152/ajpendo.00273.2002
   van Moorsel D, 2016, MOL METAB, V5, P635, DOI 10.1016/j.molmet.2016.06.012
   Vissing J, 1998, J CLIN INVEST, V101, P1654, DOI 10.1172/JCI555
   Weber K, 1997, AM J HUM GENET, V60, P373
   Wu SB, 2010, MOL NEUROBIOL, V41, P256, DOI 10.1007/s12035-010-8123-7
   Zoladz JA, 2013, EXP PHYSIOL, V98, P883, DOI 10.1113/expphysiol.2012.069443
NR 88
TC 11
Z9 12
U1 0
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-042X
J9 FRONT PHYSIOL
JI Front. Physiol.
PD MAY 21
PY 2020
VL 11
AR 349
DI 10.3389/fphys.2020.00349
PG 12
WC Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology
GA LW9JS
UT WOS:000539458500001
PM 32508662
OA Green Published, gold
DA 2024-11-01
ER

PT J
AU Chen, QY
   Kirk, K
   Shurubor, YI
   Zhao, DZ
   Arreguin, AJ
   Shahi, I
   Valsecchi, F
   Primiano, G
   Calder, EL
   Carelli, V
   Denton, TT
   Beal, MF
   Gross, SS
   Manfredi, G
   D'Aurelio, M
AF Chen, Qiuying
   Kirk, Kathryne
   Shurubor, Yevgeniya I.
   Zhao, Dazhi
   Arreguin, Andrea J.
   Shahi, Ifrah
   Valsecchi, Federica
   Primiano, Guido
   Calder, Elizabeth L.
   Carelli, Valerio
   Denton, Travis T.
   Beal, M. Flint
   Gross, Steven S.
   Manfredi, Giovanni
   D'Aurelio, Marilena
TI Rewiring of Glutamine Metabolism Is a Bioenergetic Adaptation of Human
   Cells with Mitochondrial DNA Mutations
SO CELL METABOLISM
LA English
DT Article
ID AMINO-ACID-METABOLISM; STOP-CODON MUTATION; ALPHA-KETOGLUTARATE;
   OXIDATIVE-PHOSPHORYLATION; REDUCTIVE CARBOXYLATION; MUSCLE; CANCER;
   MTDNA; DISEASE; DEHYDROGENASE
AB Using molecular, biochemical, and untargeted stable isotope tracing approaches, we identify a previously unappreciated glutamine-derived alpha-ketoglutarate (alpha KG ) energy-generating anaplerotic flux to be critical in mitochondrial DNA (mtDNA) mutant cells that harbor human disease-associated oxidative phosphorylation defects. Stimulating this flux with alpha KG supplementation enables the survival of diverse mtDNA mutant cells under otherwise lethal obligatory oxidative conditions. Strikingly, we demonstrate that when residual mitochondrial respiration in mtDNA mutant cells exceeds 45% of control levels, alpha KG oxidative flux prevails over reductive carboxylation. Furthermore, in a mouse model of mitochondrial myopathy, we show that increased oxidative alpha KG flux in muscle arises from enhanced alanine synthesis and release into blood, concomitant with accelerated amino acid catabolism from protein breakdown. Importantly, in this mouse model of mitochondriopathy, muscle amino acid imbalance is normalized by alpha KG supplementation. Taken together, our findings provide a rationale for alpha KG supplementation as a therapeutic strategy for mitochondrial myopathies.
C1 [Kirk, Kathryne; Shurubor, Yevgeniya I.; Zhao, Dazhi; Arreguin, Andrea J.; Shahi, Ifrah; Valsecchi, Federica; Beal, M. Flint; Manfredi, Giovanni; D'Aurelio, Marilena] Weill Cornell Med, Feil Family Brain & Mind Res Inst, New York, NY 10065 USA.
   [Chen, Qiuying; Gross, Steven S.] Weill Cornell Med, Dept Pharmacol, New York, NY 10065 USA.
   [Primiano, Guido] Univ Cattolica Sacro Cuore, Inst Neurol, Rome, Italy.
   [Calder, Elizabeth L.] Sloan Kettering Inst Canc Res, Ctr Stem Cell Biol, New York, NY 10065 USA.
   [Calder, Elizabeth L.] Sloan Kettering Inst Canc Res, Dev Biol Program, New York, NY 10065 USA.
   [Carelli, Valerio] Bellaria Hosp, Inst Neurol Sci Bologna, IRCCS, Bologna, Italy.
   [Carelli, Valerio] Univ Bologna, Dept Biomed & NeuroMotor Sci DIBINEM, Bologna, Italy.
   [Denton, Travis T.] Washington State Univ, Coll Pharm, Dept Pharmaceut Sci, Spokane, WA 99210 USA.
C3 Cornell University; Weill Cornell Medicine; Cornell University; Weill
   Cornell Medicine; Catholic University of the Sacred Heart; IRCCS
   Policlinico Gemelli; Memorial Sloan Kettering Cancer Center; Memorial
   Sloan Kettering Cancer Center; AUSL di Bologna; IRCCS Istituto delle
   Scienze Neurologiche di Bologna (ISNB); University of Bologna;
   Washington State University
RP Manfredi, G; D'Aurelio, M (corresponding author), Weill Cornell Med, Feil Family Brain & Mind Res Inst, New York, NY 10065 USA.
EM gim2004@med.cornell.edu; mad2003@med.cornell.edu
RI Primiano, Guido/AAB-7829-2019; chen, qy/JXM-3217-2024
OI Shahi, Ifrah/0009-0000-9538-1368; Arreguin, Andrea
   J./0000-0003-0378-478X; Primiano, Guido/0000-0001-7616-7008; Denton,
   Travis/0000-0002-1222-2538; Shurubor, Yevgeniya/0000-0003-4060-3087
FU Muscular Dystrophy Association [MDA276237]; NIH [GM088999, NS084524]
FX This work was supported by grants from the Muscular Dystrophy
   Association (MDA276237 to M.D.) and NIH (GM088999 and NS084524 to G.M.).
CR Albrecht J, 2007, FRONT BIOSCI-LANDMRK, V12, P332, DOI 10.2741/2067
   Avissar NE, 2001, AM J PHYSIOL-CELL PH, V281, pC963, DOI 10.1152/ajpcell.2001.281.3.C963
   Baracca A, 2005, ARCH NEUROL-CHICAGO, V62, P730, DOI 10.1001/archneur.62.5.730
   BERGSTROM J, 1974, J APPL PHYSIOL, V36, P693, DOI 10.1152/jappl.1974.36.6.693
   Birsoy K, 2015, CELL, V162, P540, DOI 10.1016/j.cell.2015.07.016
   Brosnan ME, 2004, J NUTR, V134, p2791S, DOI 10.1093/jn/134.10.2791S
   Bruno C, 1999, AM J HUM GENET, V65, P611, DOI 10.1086/302546
   Bunik VI, 2005, BIOCHEMISTRY-US, V44, P10552, DOI 10.1021/bi0503100
   Carrozzo R, 2001, NEUROLOGY, V56, P687, DOI 10.1212/WNL.56.5.687
   CHANG TW, 1978, J BIOL CHEM, V253, P3685
   Chen L, 2015, INT J MOL SCI, V16, P22830, DOI 10.3390/ijms160922830
   Chen QY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037149
   Curis E, 2005, AMINO ACIDS, V29, P177, DOI 10.1007/s00726-005-0235-4
   CURTHOYS NP, 1995, ANNU REV NUTR, V15, P133, DOI 10.1146/annurev.nu.15.070195.001025
   D'Aurelio M, 2001, J BIOL CHEM, V276, P46925, DOI 10.1074/jbc.M106429200
   D'Aurelio M, 2010, HUM MOL GENET, V19, P374, DOI 10.1093/hmg/ddp503
   Dai ZL, 2014, J CHROMATOGR B, V964, P116, DOI 10.1016/j.jchromb.2014.03.025
   Danhauser K, 2015, J INHERIT METAB DIS, V38, P467, DOI 10.1007/s10545-014-9796-2
   Daye D, 2012, SEMIN CELL DEV BIOL, V23, P362, DOI 10.1016/j.semcdb.2012.02.002
   de la Rosa V, 2009, NEUROCHEM INT, V55, P76, DOI 10.1016/j.neuint.2009.02.021
   Debray FG, 2010, J CHILD NEUROL, V25, P1000, DOI 10.1177/0883073809351983
   Diaz F, 2005, HUM MOL GENET, V14, P2737, DOI 10.1093/hmg/ddi307
   Eales KL, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2015.50
   Edmonds JL, 2002, ARCH OTOLARYNGOL, V128, P355, DOI 10.1001/archotol.128.4.355
   El-Hattab AW, 2015, MOL GENET METAB, V116, P4, DOI 10.1016/j.ymgme.2015.06.004
   Elgadi KM, 1999, PHYSIOL GENOMICS, V1, P51, DOI 10.1152/physiolgenomics.1999.1.2.51
   Fendt SM, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3236
   Fuchs BC, 2005, SEMIN CANCER BIOL, V15, P254, DOI 10.1016/j.semcancer.2005.04.005
   Gorman GS, 2016, NAT REV DIS PRIMERS, V2, P1, DOI 10.1038/nrdp.2016.80
   HAUSSINGER D, 1986, ADV ENZYME REGUL, V25, P159, DOI 10.1016/0065-2571(86)90013-0
   He YJ, 2010, J BIOL CHEM, V285, P9516, DOI 10.1074/jbc.M109.092429
   Hofhaus G, 1996, Methods Enzymol, V264, P476, DOI 10.1016/S0076-6879(96)64043-9
   Ismailoglu I, 2014, DEV BIOL, V391, P230, DOI 10.1016/j.ydbio.2014.04.005
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   Kita K, 2007, TOXICOL APPL PHARM, V220, P262, DOI 10.1016/j.taap.2007.01.009
   Kjobsted R, 2018, FASEB J, V32, P1741, DOI 10.1096/fj.201700442R
   KOTLYAR AB, 1984, BIOCHIM BIOPHYS ACTA, V784, P24, DOI 10.1016/0167-4838(84)90168-7
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Longo N, 2003, NEUROL CLIN, V21, P817, DOI 10.1016/S0733-8619(03)00015-X
   Marin M, 2003, J VIROL, V77, P2936, DOI 10.1128/JVI.77.5.2936-2945.2003
   MARLISS EB, 1971, J CLIN INVEST, V50, P814, DOI 10.1172/JCI106552
   McGivan JD, 2007, FRONT BIOSCI, V12, P874, DOI 10.2741/2109
   Metallo CM, 2012, NATURE, V481, P380, DOI 10.1038/nature10602
   Metallo CM, 2010, GENE DEV, V24, P2717, DOI 10.1101/gad.2010510
   Meyer O A, 1979, Neurobehav Toxicol, V1, P233
   Morava E, 2006, NEUROLOGY, V67, P1823, DOI 10.1212/01.wnl.0000244435.27645.54
   Mullen AR, 2014, CELL REP, V7, P1679, DOI 10.1016/j.celrep.2014.04.037
   Mullen AR, 2012, NATURE, V481, P385, DOI 10.1038/nature10642
   Naini A, 2005, J NEUROL SCI, V229, P187, DOI 10.1016/j.jns.2004.11.026
   Neel BA, 2013, TRENDS ENDOCRIN MET, V24, P635, DOI 10.1016/j.tem.2013.09.004
   NEWSHOLME EA, 1988, NUTRITION, V4, P261
   Newsholme P, 2003, CELL BIOCHEM FUNCT, V21, P1, DOI 10.1002/cbf.1003
   Nijtmans LGJ, 2001, J BIOL CHEM, V276, P6755, DOI 10.1074/jbc.M008114200
   Nikkanen J, 2016, CELL METAB, V23, P635, DOI 10.1016/j.cmet.2016.01.019
   Palmada M, 2005, BIOCHEM BIOPH RES CO, V331, P272, DOI 10.1016/j.bbrc.2005.03.159
   Parfait B, 1999, EUR J PEDIATR, V158, P55, DOI 10.1007/s004310051009
   Rabier D, 1998, J INHERIT METAB DIS, V21, P216, DOI 10.1023/A:1005391300203
   Robinson B H, 1996, Methods Enzymol, V264, P454, DOI 10.1016/S0076-6879(96)64041-5
   Sakuma K, 2016, J CACHEXIA SARCOPENI, V7, P204, DOI 10.1002/jcsm.12045
   Santos SS, 2006, J NEUROSCI RES, V83, P450, DOI 10.1002/jnr.20749
   Shaham O, 2010, P NATL ACAD SCI USA, V107, P1571, DOI 10.1073/pnas.0906039107
   Shatla HM, 2014, PEDIATR NEUROL, V51, P820, DOI 10.1016/j.pediatrneurol.2014.08.009
   Shin CS, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15074
   Smeitink JA, 2006, CELL METAB, V3, P9, DOI 10.1016/j.cmet.2005.12.001
   Son J, 2013, NATURE, V496, P101, DOI 10.1038/nature12040
   Sullivan LB, 2015, CELL, V162, P552, DOI 10.1016/j.cell.2015.07.017
   Tan HWS, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00369-y
   Tapiero H, 2002, BIOMED PHARMACOTHER, V56, P446, DOI 10.1016/S0753-3322(02)00285-8
   Taylor L, 2004, BIOCHEM MOL BIOL EDU, V32, P291, DOI 10.1002/bmb.2004.494032050388
   Thellin O, 1999, J BIOTECHNOL, V75, P291, DOI 10.1016/S0168-1656(99)00163-7
   Tong XM, 2009, CURR OPIN GENET DEV, V19, P32, DOI 10.1016/j.gde.2009.01.002
   Tyynismaa H, 2010, HUM MOL GENET, V19, P3948, DOI 10.1093/hmg/ddq310
   UtsunomiyaTate N, 1996, J BIOL CHEM, V271, P14883, DOI 10.1074/jbc.271.25.14883
   Wagenmakers AJM, 1998, EXERCISE SPORT SCI R, V26, P287
   Wagenmakers AJM, 1998, ADV EXP MED BIOL, V441, P307
   Wise DR, 2010, TRENDS BIOCHEM SCI, V35, P427, DOI 10.1016/j.tibs.2010.05.003
   Wu GY, 2008, METHOD ENZYMOL, V440, P177, DOI 10.1016/S0076-6879(07)00810-5
   Wu GY, 2009, AMINO ACIDS, V37, P153, DOI 10.1007/s00726-008-0210-y
   Wu GY, 1998, J NUTR, V128, P1249, DOI 10.1093/jn/128.8.1249
NR 80
TC 123
Z9 136
U1 2
U2 35
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 1550-4131
EI 1932-7420
J9 CELL METAB
JI Cell Metab.
PD MAY 1
PY 2018
VL 27
IS 5
BP 1007
EP +
DI 10.1016/j.cmet.2018.03.002
PG 24
WC Cell Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Endocrinology & Metabolism
GA GG1HN
UT WOS:000432438100009
PM 29657030
OA Green Accepted, Bronze
DA 2024-11-01
ER

PT J
AU Taivassalo, T
   Haller, RG
AF Taivassalo, T
   Haller, RG
TI Implications of exercise training in mtDNA defects - use it or lose it?
SO BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS
LA English
DT Article; Proceedings Paper
CT 6th European Meeting on Mitochondrial Pathology (Euromit 6)
CY JUN 30-JUL 04, 2004
CL Nijmegen, NETHERLANDS
DE mitochondrial myopathy; mtDNA defect; exercise intolerance; treatment;
   endurance and resistance training; satellite cell
ID CYTOCHROME-C-OXIDASE; TRANSCRIPTION FACTOR-A; HUMAN SKELETAL-MUSCLE;
   MITOCHONDRIAL-DNA; CONTRACTILE ACTIVITY; SATELLITE CELLS; POINT
   MUTATION; OXYGEN-UPTAKE; OLDER MEN; ADAPTATIONS
AB Whether regular exercise is beneficial or should be avoided is a question currently unsettled in patients with heteroplasmic mitochondrial DNA (mtDNA) disorders of skeletal muscle. Deleterious effects of habitual physical inactivity superimposed upon impaired mitochondrial oxidative phosphorylation may contribute to varying degrees of exercise intolerance in these patients. Endurance exercise training is widely known to improve exercise capacity in healthy subjects and various chronic-disease patient populations. Although we have shown that beneficial physiological and biochemical responses to training increase exercise tolerance in patients with mtDNA defects, knowledge of the muscle adaptive response to endurance training within the setting of mitochondrial heteroplasmy remains limited. In order to determine advisability of endurance training as therapy, it remains to be established whether potential endurance training-induced increases in mutant mtDNA levels may be offset by increases in absolute wild-type mtDNA levels, and whether chronic inactivity leads to a selective downregulation of wild-type mtDNA. Resistance training utilizes a different adaptive exercise approach to induce the transfer of normal mitochondrial templates from satellite cells to mature muscle fibers of patients with sporadic mtDNA disorders. The efficacy and safety of this approach needs to be further established. Our current inability to clearly advise patients to "use it or lose it'' underscores the immediate urgency of studying the effects of exercise on skeletal muscle of patients with heteroplasmic mtDNA defects. (C) 2004 Elsevier B.V. All rights reserved.
C1 Univ Texas, SW Med Ctr, Inst Exercise & Environm Med, Neuromuscular Ctr, Dallas, TX 75231 USA.
   Univ Texas, SW Med Ctr, Dept Neurol, Dallas, TX 75231 USA.
   Dallas VA Med Ctr, Dallas, TX USA.
C3 University of Texas System; University of Texas Dallas; University of
   Texas Southwestern Medical Center Dallas; University of Texas System;
   University of Texas Dallas; University of Texas Southwestern Medical
   Center Dallas
RP Taivassalo, T (corresponding author), Univ Texas, SW Med Ctr, Inst Exercise & Environm Med, Neuromuscular Ctr, 7232 Greenville Ave,Suite 435, Dallas, TX 75231 USA.
EM tanjataivassalo@texashealth.org
CR Adhihetty PJ, 2003, EXP PHYSIOL, V88, P99, DOI 10.1113/eph8802505
   BISCHOFF R, 1994, MYOGENESIS, V2, P97
   BOOTH FW, 1977, J BIOL CHEM, V252, P416
   CHEEK DB, 1985, EARLY HUM DEV, V12, P211, DOI 10.1016/0378-3782(85)90144-6
   Chinnery PF, 2003, J NEUROL SCI, V211, P63, DOI 10.1016/S0022-510X(03)00039-X
   Clark KM, 1997, NAT GENET, V16, P222, DOI 10.1038/ng0797-222
   COYLE EF, 1984, J APPL PHYSIOL, V57, P1857, DOI 10.1152/jappl.1984.57.6.1857
   Crameri RM, 2004, J PHYSIOL-LONDON, V558, P333, DOI 10.1113/jphysiol.2004.061846
   ELSON JL, RANDOM INTRACELLULAR
   Essig D A, 1996, Exerc Sport Sci Rev, V24, P289
   FAULKNER JA, 1977, MED SCI SPORT EXER, V9, P148
   Flück M, 2003, REV PHYSIOL BIOCH P, V146, P159, DOI 10.1007/s10254-002-0004-7
   Fu K, 1996, HUM MOL GENET, V5, P1835, DOI 10.1093/hmg/5.11.1835
   Goffart S, 2003, EXP PHYSIOL, V88, P33, DOI 10.1113/eph8802500
   Gordon JW, 2001, J APPL PHYSIOL, V90, P389, DOI 10.1152/jappl.2001.90.1.389
   HALLER RG, 1983, NEUROLOGY, V33, P1283, DOI 10.1212/WNL.33.10.1283
   HALLER RG, 1989, J CLIN INVEST, V84, P155, DOI 10.1172/JCI114135
   HALLER RG, 1994, MYOLOGY BASIC CLIN, V2, P807
   Hawke TJ, 2001, J APPL PHYSIOL, V91, P534, DOI 10.1152/jappl.2001.91.2.534
   HENRIKSSON J, 1992, DIABETES CARE, V15, P1701, DOI 10.2337/diacare.15.11.1701
   Heslop L, 2000, J CELL SCI, V113, P2299
   Hikida RS, 2000, J GERONTOL A-BIOL, V55, pB347, DOI 10.1093/gerona/55.7.B347
   Hood D A, 2000, Exerc Sport Sci Rev, V28, P68
   HOUSTON ME, 1986, BIOCH EXERCISE, V4, P63
   Ivey FM, 2000, J GERONTOL A-BIOL, V55, pM641, DOI 10.1093/gerona/55.11.M641
   Jenuth JP, 1996, NAT GENET, V14, P146, DOI 10.1038/ng1096-146
   JOHNSON MA, 1983, J NEUROL SCI, V60, P31, DOI 10.1016/0022-510X(83)90125-9
   Kadi F, 2000, HISTOCHEM CELL BIOL, V113, P99, DOI 10.1007/s004180050012
   Kärppä M, 2004, J NEUROL, V251, P556, DOI 10.1007/s00415-004-0363-x
   Kelly DP, 2004, GENE DEV, V18, P357, DOI 10.1101/gad.1177604
   KLAUSEN K, 1981, ACTA PHYSIOL SCAND, V113, P9, DOI 10.1111/j.1748-1716.1981.tb06854.x
   LARSSON NG, 1994, BIOCHEM BIOPH RES CO, V200, P1374, DOI 10.1006/bbrc.1994.1603
   LARSSON NG, 1990, PEDIATR RES, V28, P131, DOI 10.1203/00006450-199028020-00011
   MCCOMAS AJ, 1994, MED SCI SPORT EXER, V26, P1498
   MITCHELL JH, 1971, NEW ENGL J MED, V284, P1018, DOI 10.1056/NEJM197105062841809
   MOORE RL, 1987, J APPL PHYSIOL, V63, P1719, DOI 10.1152/jappl.1987.63.5.1719
   Mujika I, 2001, MED SCI SPORT EXER, V33, P1297, DOI 10.1097/00005768-200108000-00009
   NEUFER PD, 1989, SPORTS MED, V8, P302, DOI 10.2165/00007256-198908050-00004
   Pollock ML, 1998, MED SCI SPORT EXER, V30, P975, DOI 10.1097/00005768-199806000-00032
   Roth SM, 2001, J GERONTOL A-BIOL, V56, pB240, DOI 10.1093/gerona/56.6.B240
   Sale D.G., 1998, Medicine and Science in Sports and Exercise, V20, P135
   SALTIN B, 1980, FED PROC, V39, P1506
   Saltin B., 1983, Comprehensive Physiology, P555
   Shoubridge EA, 1997, HUM MOL GENET, V6, P2239, DOI 10.1093/hmg/6.13.2239
   Taivassalo T, 1999, HUM MOL GENET, V8, P1047, DOI 10.1093/hmg/8.6.1047
   Taivassalo T, 1998, NEUROLOGY, V50, P1055, DOI 10.1212/WNL.50.4.1055
   Taivassalo T, 1996, NEUROLOGY, V47, P529, DOI 10.1212/WNL.47.2.529
   Taivassalo T, 2001, ANN NEUROL, V50, P133, DOI 10.1002/ana.1050
   Taivassalo T, 2003, BRAIN, V126, P413, DOI 10.1093/brain/awg028
   Taivassalo T, 2002, MED SCI SPORTS EXERC, V34, pA943
   TESCH PA, 1989, J APPL PHYSIOL, V83, P67
   WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523
   Weber K, 1997, AM J HUM GENET, V60, P373
NR 53
TC 36
Z9 37
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0005-2728
J9 BBA-BIOENERGETICS
JI Biochim. Biophys. Acta-Bioenerg.
PD DEC 6
PY 2004
VL 1659
IS 2-3
SI SI
BP 221
EP 231
DI 10.1016/j.bbabio.2004.09.007
PG 11
WC Biochemistry & Molecular Biology; Biophysics
WE Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 882KT
UT WOS:000225938500016
PM 15576055
OA Bronze
DA 2024-11-01
ER

PT J
AU Miyahara, H
   Tamai, C
   Inoue, M
   Sekiguchi, K
   Tahara, D
   Tahara, N
   Takeda, K
   Arafuka, S
   Moriyoshi, H
   Koizumi, R
   Akagi, A
   Riku, Y
   Sone, J
   Yoshida, M
   Ihara, K
   Iwasaki, Y
AF Miyahara, Hiroaki
   Tamai, Chisato
   Inoue, Masanori
   Sekiguchi, Kazuhito
   Tahara, Daisuke
   Tahara, Nao
   Takeda, Kazuhiro
   Arafuka, Shusei
   Moriyoshi, Hideyuki
   Koizumi, Ryuichi
   Akagi, Akio
   Riku, Yuichi
   Sone, Jun
   Yoshida, Mari
   Ihara, Kenji
   Iwasaki, Yasushi
TI Neuropathological hallmarks in autopsied cases with mitochondrial
   diseases caused by the mitochondrial 3243A>G mutation
SO BRAIN PATHOLOGY
LA English
DT Article
DE choroidal epithelial cell swelling; MELAS; mitochondrial 3243A>G
   mutation; mitochondrial vasculopathy; mtDNA heteroplasmy; stroke-like
   episodes
ID STROKE-LIKE EPISODES; GROWTH-FACTOR 21; DNA; MELAS; PATHOGENESIS;
   BIOMARKER; FGF-21; HEALTH
AB The mitochondrial (m.) 3243A>G mutation is known to be associated with various mitochondrial diseases including mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS). Their clinical symptoms have been estimated to occur with an increased mitochondrial DNA (mtDNA) heteroplasmy and reduced activity of oxidative phosphorylation (OXPHOS) complexes, but their trends in the central nervous system remain unknown. Six autopsied mutant cases and three disease control cases without the mutation were enrolled in this study. The mutant cases had a disease duration of 1-27 years. Five of six mutant cases were compatible with MELAS. In the mutant cases, cortical lesions including a laminar necrosis were frequently observed in the parietal, lateral temporal, and occipital lobes; less frequently in the frontal lobe including precentral gyrus; and not at all in the medial temporal lobe. The mtDNA heteroplasmy in brain tissue samples of the mutant cases was strikingly high, ranging from 53.8% to 85.2%. The medial temporal lobe was preserved despite an inhospitable environment having high levels of mtDNA heteroplasmy and lactic acid. OXPHOS complex I was widely decreased in the mutant cases. The swelling of smooth muscle cells in the vessels on the leptomeninges, with immunoreactivity (IR) against mitochondria antibody, and a decreased nuclear/cytoplasmic ratio of choroidal epithelial cells were observed in all mutant cases but in none without the mutation. Common neuropathological findings such as cortical laminar necrosis and basal ganglia calcification were not always observed in the mutant cases. A high level of mtDNA heteroplasmy was observed throughout the brain in spite of heterogeneous cortical lesions. A lack of medial temporal lesion, mitochondrial vasculopathy in vessels on the leptomeninges, and an increased cytoplasmic size of epithelial cells in the choroid plexus could be neuropathological hallmarks helpful in the diagnosis of mitochondrial diseases.
C1 [Miyahara, Hiroaki; Tamai, Chisato; Tahara, Daisuke; Tahara, Nao; Takeda, Kazuhiro; Arafuka, Shusei; Moriyoshi, Hideyuki; Koizumi, Ryuichi; Akagi, Akio; Riku, Yuichi; Sone, Jun; Yoshida, Mari; Iwasaki, Yasushi] Aichi Med Univ, Inst Med Res Aging, Dept Neuropathol, Nagakute, Aichi, Japan.
   [Inoue, Masanori; Sekiguchi, Kazuhito; Ihara, Kenji] Oita Univ, Dept Pediat, Fac Med, Oita, Japan.
   [Miyahara, Hiroaki] Aichi Med Univ, Inst Med Sci Aging, Dept Neuropathol, 1-1 Yazakokarimata, Nagakute, Aichi 4801195, Japan.
C3 Aichi Medical University; Oita University; Aichi Medical University
RP Miyahara, H (corresponding author), Aichi Med Univ, Inst Med Sci Aging, Dept Neuropathol, 1-1 Yazakokarimata, Nagakute, Aichi 4801195, Japan.
EM miyahara.hiroaki.926@mail.aichi-med-u.ac.jp
RI Sone, Jun/M-5027-2014; Riku, Yuichi/AAM-7816-2020; Arafuka,
   Shusei/JZD-6711-2024
OI Arafuka, Shusei/0000-0002-8700-8106; Miyahara,
   HIroaki/0000-0003-0723-0047
CR Almudares F, 2023, PEDIATR PULM, V58, P271, DOI 10.1002/ppul.26197
   BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
   Cheng XB, 2011, ENDOCR RES, V36, P142, DOI 10.3109/07435800.2011.558550
   Clark BJ, 2013, CRIT CARE, V17, DOI 10.1186/cc12737
   Conte M, 2022, AGEING RES REV, V75, DOI 10.1016/j.arr.2022.101569
   Feigenbaum A, 1996, AM J MED GENET, V62, P404, DOI 10.1002/(SICI)1096-8628(19960424)62:4<404::AID-AJMG14>3.0.CO;2-S
   GOTO Y, 1992, NEUROLOGY, V42, P545, DOI 10.1212/WNL.42.3.545
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   HAMMANS SR, 1995, BRAIN, V118, P721, DOI 10.1093/brain/118.3.721
   Hirano M, 2020, NEUROPATHOLOGY, V40, P515, DOI 10.1111/neup.12668
   Iizuka T, 2005, CURR NEUROVASC RES, V2, P29, DOI 10.2174/1567202052773544
   Ikawa M, 2009, MITOCHONDRION, V9, P144, DOI 10.1016/j.mito.2009.01.011
   Kawahara Y, 2020, HELICOBACTER, V25, DOI 10.1111/hel.12732
   KOGA Y, 1988, ANN NEUROL, V24, P749, DOI 10.1002/ana.410240609
   Koga Y, 2021, J INHERIT METAB DIS, V44, P358, DOI 10.1002/jimd.12317
   Koga Y, 2010, ANN NY ACAD SCI, V1201, P104, DOI 10.1111/j.1749-6632.2010.05624.x
   Koga Yasutoshi, 2008, Rinsho Shinkeigaku, V48, P1010
   Kralisch S, 2011, CURR OPIN CLIN NUTR, V14, P354, DOI 10.1097/MCO.0b013e328346a326
   Love Seth, 2014, Am J Neurodegener Dis, V3, P19
   Maresca A, 2020, J MOL MED, V98, P1467, DOI 10.1007/s00109-020-01967-y
   McKeith IG, 2005, NEUROLOGY, V65, P1863, DOI 10.1212/01.wnl.0000187889.17253.b1
   Montero R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148709
   Montine TJ, 2012, ACTA NEUROPATHOL, V123, P1, DOI 10.1007/s00401-011-0910-3
   Nishiuchi M, 2018, BIOSCI BIOTECH BIOCH, V82, P2168, DOI 10.1080/09168451.2018.1516543
   Nishiumi S, 2017, ONCOTARGET, V8, P17115, DOI 10.18632/oncotarget.15081
   OHAMA E, 1987, ACTA NEUROPATHOL, V74, P226, DOI 10.1007/BF00688185
   Pang CY, 2001, DIABETES RES CLIN PR, V54, pS45, DOI 10.1016/S0168-8227(01)00335-7
   Phadwal K, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.611922
   Riley LG, 2022, MOL GENET METAB, V135, P63, DOI 10.1016/j.ymgme.2021.12.001
   Rochette L, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22168889
   Rochette L, 2020, BBA-MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2020.165798
   Saito Y, 2004, J NEUROPATH EXP NEUR, V63, P911, DOI 10.1093/jnen/63.9.911
   Scholle LM, 2018, CURR MED CHEM, V25, P2070, DOI 10.2174/0929867325666180111094336
   Sekiguchi K, 2021, NUTRIENTS, V13, DOI 10.3390/nu13093026
   Tanahashi C, 2000, ACTA NEUROPATHOL, V99, P31, DOI 10.1007/PL00007403
   Thal DR, 2002, NEUROLOGY, V58, P1791, DOI 10.1212/WNL.58.12.1791
   Tranah GJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30255-6
   Tuppen HAL, 2010, BBA-BIOENERGETICS, V1797, P113, DOI 10.1016/j.bbabio.2009.09.005
   Xie T, 2017, AM J PHYSIOL-ENDOC M, V313, pE292, DOI 10.1152/ajpendo.00101.2017
NR 39
TC 0
Z9 0
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1015-6305
EI 1750-3639
J9 BRAIN PATHOL
JI Brain Pathol.
PD NOV
PY 2023
VL 33
IS 6
DI 10.1111/bpa.13199
EA AUG 2023
PG 11
WC Clinical Neurology; Neurosciences; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pathology
GA U7RU1
UT WOS:001039828700001
PM 37534760
OA Green Published, gold
DA 2024-11-01
ER

PT J
AU Yahata, N
   Matsumoto, Y
   Omi, M
   Yamamoto, N
   Hata, R
AF Yahata, Naoki
   Matsumoto, Yuji
   Omi, Minoru
   Yamamoto, Naoki
   Hata, Ryuji
TI TALEN-mediated shift of mitochondrial DNA heteroplasmy in MELAS-iPSCs
   with m.13513G>A mutation
SO SCIENTIFIC REPORTS
LA English
DT Article
ID PLURIPOTENT STEM-CELLS; STROKE-LIKE EPISODES; LACTIC-ACIDOSIS; GENOMES;
   CONSTRUCTION; ELIMINATION; PATIENT; GENE
AB Induced pluripotent stem cells (iPSCs) are suitable for studying mitochondrial diseases caused by mitochondrial DNA (mtDNA) mutations. Here, we generated iPSCs from a patient with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) with the m.13513G>A mutation. The patient's dermal fibroblasts were reprogrammed, and we established two iPSC clones with and without mutant mtDNA. Furthermore, we tried to decrease mutant mtDNA level in iPSCs using transcription activator-like effector nucleases (TALENs). We originally engineered platinum TALENs, which were transported into mitochondria, recognized the mtDNA sequence including the m.13513 position, and preferentially cleaved G13513A mutant mtDNA (G13513A-mpTALEN). The m.13513G>A heteroplasmy level in MELAS-iPSCs was decreased in the short term by transduction of G13513A-mpTALEN. Our data demonstrate that this mtDNA-targeted nuclease would be a powerful tool for changing the heteroplasmy level in heteroplasmic iPSCs, which could contribute to elucidation of the pathological mechanisms of mitochondrial diseases caused by mtDNA mutations.
C1 [Yahata, Naoki; Omi, Minoru; Hata, Ryuji] Fujita Hlth Univ, Sch Med, Dept Anat 1, Toyoake, Aichi, Japan.
   [Matsumoto, Yuji] Fujita Hlth Univ, Sch Med, Dept Pediat, Toyoake, Aichi, Japan.
   [Yamamoto, Naoki] Fujita Hlth Univ, Ctr Res Promot & Support, Div Molecularbiol, Joint Res Support Promot Facil, Toyoake, Aichi, Japan.
   [Hata, Ryuji] Ehime Univ, Grad Sch Med, Dept Anat, To On, Ehime, Japan.
C3 Fujita Health University; Fujita Health University; Fujita Health
   University; Ehime University
RP Hata, R (corresponding author), Fujita Hlth Univ, Sch Med, Dept Anat 1, Toyoake, Aichi, Japan.; Hata, R (corresponding author), Ehime Univ, Grad Sch Med, Dept Anat, To On, Ehime, Japan.
EM hata@fujita-hu.ac.jp
RI Yamamoto, Naoki/L-2603-2019
FU Hori Sciences and Arts Foundation; Fujita Health University; JPSP
   KAKENHI [JP16K19675, JP26860831]
FX We would like to express our sincere gratitude to the patient and his
   family for their participation in our research. We are also grateful to
   all our coworkers, and to Dr. Tomihiko Ide (Fujita Health University)
   for assistance at the Institute of Joint Research. The authors also wish
   to express their thanks to Dr. Shinya Yamanaka for supplying
   reprogramming plasmids (Addgene #27077, #27078, and #27080), and to Dr.
   Takashi Yamamoto for supplying the Platinum Gate TALEN kit (Addgene kit
   #1000000043) and the Yamamoto Lab TALEN Accessory Pack including the
   pGL4-SSA plasmid (Addgene #1000000030). This study was supported in part
   by grants from the Hori Sciences and Arts Foundation (N. Yahata), grants
   from the Fujita Health University Research Fund to N. Yahata and R.H.,
   and JPSP KAKENHI Grant Numbers JP16K19675 (N. Yahata) and JP26860831
   (Y.M.).
CR Bacman SR, 2007, GENE THER, V14, P1309, DOI 10.1038/sj.gt.3302981
   Bacman SR, 2013, NAT MED, V19, P1111, DOI 10.1038/nm.3261
   Folmes CDL, 2013, STEM CELLS, V31, P1298, DOI 10.1002/stem.1389
   Fujikura J, 2012, Diabetologia, V55, P1689, DOI 10.1007/s00125-012-2508-2
   Gaj T, 2013, TRENDS BIOTECHNOL, V31, P397, DOI 10.1016/j.tibtech.2013.04.004
   Gammage PA, 2014, EMBO MOL MED, V6, P458, DOI 10.1002/emmm.201303672
   Hämäläinen RH, 2013, P NATL ACAD SCI USA, V110, pE3622, DOI 10.1073/pnas.1311660110
   Hance N, 2005, HUM MOL GENET, V14, P1775, DOI 10.1093/hmg/ddi184
   Hashimoto M, 2015, MOL THER, V23, P1592, DOI 10.1038/mt.2015.126
   Hatakeyama H, 2015, ACTA NEUROPATHOL COM, V3, DOI 10.1186/s40478-015-0227-x
   Iizuka T, 2005, CURR NEUROVASC RES, V2, P29, DOI 10.2174/1567202052773544
   Kodaira M, 2015, FEBS OPEN BIO, V5, P219, DOI 10.1016/j.fob.2015.03.008
   Ma H, 2015, NATURE, V524, P234, DOI 10.1038/nature14546
   Milenkovic D, 2013, HUM MOL GENET, V22, P1983, DOI 10.1093/hmg/ddt051
   Moraes CT, 2014, EMBO MOL MED, V6, P434, DOI 10.1002/emmm.201303769
   MORAES CT, 1992, AM J HUM GENET, V50, P934
   Nakagawa M, 2014, SCI REP-UK, V4, DOI 10.1038/srep03594
   NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D
   Ochiai H, 2010, GENES CELLS, V15, P875, DOI 10.1111/j.1365-2443.2010.01425.x
   Okita K, 2011, NAT METHODS, V8, P409, DOI [10.1038/NMETH.1591, 10.1038/nmeth.1591]
   Reddy P, 2015, CELL, V161, P459, DOI 10.1016/j.cell.2015.03.051
   Sakuma T, 2017, METHODS MOL BIOL, V1630, P25, DOI 10.1007/978-1-4939-7128-2_2
   Sakuma T, 2013, SCI REP-UK, V3, DOI 10.1038/srep03379
   Sakuma T, 2013, GENES CELLS, V18, P315, DOI 10.1111/gtc.12037
   Shanske S, 2008, ARCH NEUROL-CHICAGO, V65, P368, DOI 10.1001/archneurol.2007.67
   Shigemi R, 2011, BRAIN DEV-JPN, V33, P518, DOI 10.1016/j.braindev.2010.07.013
   Stewart JB, 2015, NAT REV GENET, V16, P530, DOI 10.1038/nrg3966
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takahashi K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008067
   Venegas V, 2012, METHODS MOL BIOL, V837, P327, DOI 10.1007/978-1-61779-504-6_22
   Wahlestedt M, 2014, STEM CELLS, V32, P1173, DOI 10.1002/stem.1630
   Wang YX, 2015, CHINESE MED J-PEKING, V128, P1820, DOI 10.4103/0366-6999.159360
   Yokota M, 2015, HUM MOL GENET, V24, P4698, DOI 10.1093/hmg/ddv201
   Yu H, 2012, P NATL ACAD SCI USA, V109, pE1238, DOI 10.1073/pnas.1119577109
   Zheng XD, 2016, ELIFE, V5, DOI 10.7554/eLife.13378
NR 35
TC 52
Z9 54
U1 0
U2 8
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 14
PY 2017
VL 7
AR 15557
DI 10.1038/s41598-017-15871-y
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FM6MF
UT WOS:000415166000053
PM 29138463
OA gold, Green Published
DA 2024-11-01
ER

PT J
AU Stumpf, JD
   Saneto, RP
   Copeland, WC
AF Stumpf, Jeffrey D.
   Saneto, Russell P.
   Copeland, William C.
TI Clinical and Molecular Features of <i>POLG</i>-Related Mitochondrial
   Disease
SO COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY
LA English
DT Article
ID DNA-POLYMERASE-GAMMA; PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; SENSORY
   ATAXIC NEUROPATHY; SACCHAROMYCES-CEREVISIAE; W748S MUTATION;
   AUTOSOMAL-DOMINANT; OXIDATIVE STRESS; POINT MUTATIONS; ALPERS-SYNDROME;
   MTDNA
AB The inability to replicate mitochondrial genomes (mtDNA) by the mitochondrial DNA polymerase (pol gamma) leads to a subset of mitochondrial diseases. Many mutations in POLG, the gene that encodes pol gamma, have been associated with mitochondrial diseases such as myocerebrohepatopathy spectrum (MCHS) disorders, Alpers-Huttenlocher syndrome, myoclonic epilepsy myopathy sensory ataxia (MEMSA), ataxia neuropathy spectrum (ANS), and progressive external ophthalmoplegia (PEO). This chapter explores five important topics in POLG- related disease: (1) clinical symptoms that identify and distinguish POLGrelated diseases, (2) molecular characterization of defects in polymerase activity by POLG disease variants, (3) the importance of holoenzyme formation in disease presentation, (4) the role of pol gamma exonuclease activity and mutagenesis in disease and aging, and (5) novel approaches to therapy and avoidance of toxicity based on primary research in pol gamma replication.
C1 [Stumpf, Jeffrey D.; Copeland, William C.] NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA.
   [Saneto, Russell P.] Univ Washington, Div Pediat Neurol, Seattle Childrens Hosp, Seattle, WA 98105 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute of
   Environmental Health Sciences (NIEHS); Seattle Children's Hospital;
   University of Washington; University of Washington Seattle
RP Copeland, WC (corresponding author), NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA.
EM copelan1@niehs.nih.gov
RI Copeland, William/C-4242-2019
OI Copeland, William/0000-0002-0359-0953
FU Intramural Research Program of the National Institutes of Health;
   National Institute of Environmental Health Sciences [ES 065078];
   Mitochondrial Research Guild at Seattle Children's Hospital
FX We and the rest of the POLG field are indebted to the hard work of
   Margaret Humble for maintaining and updating the pol gamma mutation
   database (http://tools.niehs.nih.gov/polg). We also thank Drs. Richard
   Gradman and Tammy Collins for comments and suggestions from their
   critical reading of this manuscript. This work is supported by the
   Intramural Research Program of the National Institutes of Health, the
   National Institute of Environmental Health Sciences (ES 065078), and the
   Mitochondrial Research Guild at Seattle Children's Hospital.
CR Aitken H, 2009, NEUROLOGY, V72, pE86, DOI 10.1212/WNL.0b013e3181a411b8
   Ameur A, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002028
   Bailey CM, 2009, ANTIMICROB AGENTS CH, V53, P2610, DOI 10.1128/AAC.01659-08
   Bailey LJ, 2009, NUCLEIC ACIDS RES, V37, P2327, DOI 10.1093/nar/gkp091
   Baruffini E, 2007, BBA-MOL BASIS DIS, V1772, P1225, DOI 10.1016/j.bbadis.2007.10.002
   Baruffini E, 2006, HUM MOL GENET, V15, P2846, DOI 10.1093/hmg/ddl219
   Baruffini E, 2011, MITOCHONDRION, V11, P182, DOI 10.1016/j.mito.2010.09.007
   Baruffini E, 2010, MITOCHONDRION, V10, P183, DOI 10.1016/j.mito.2009.10.002
   BICKNESE AR, 1992, ANN NEUROL, V32, P767, DOI 10.1002/ana.410320610
   Blok MJ, 2009, J MED GENET, V46, P776, DOI 10.1136/jmg.2009.067686
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Chan SSL, 2006, HUM MOL GENET, V15, P3473, DOI 10.1093/hmg/ddl424
   Chan SSL, 2009, BBA-BIOENERGETICS, V1787, P312, DOI 10.1016/j.bbabio.2008.10.007
   Chan SSL, 2005, DNA REPAIR, V4, P1381, DOI 10.1016/j.dnarep.2005.08.010
   Chan SSL, 2005, J BIOL CHEM, V280, P31341, DOI 10.1074/jbc.M506762200
   Chinnery Patrick F, 2008, Neuromuscul Disord, V18, P259, DOI 10.1016/j.nmd.2007.11.005
   Cohen BH, 2010, GENE REV GENE TESTS
   Cohen BH, 2010, METHODS, V51, P364, DOI 10.1016/j.ymeth.2010.05.008
   Copeland WC, 2008, ANNU REV MED, V59, P131, DOI 10.1146/annurev.med.59.053006.104646
   Dai DF, 2010, AGING CELL, V9, P536, DOI 10.1111/j.1474-9726.2010.00581.x
   de Vries MC, 2007, EUR J PEDIATR, V166, P229, DOI 10.1007/s00431-006-0234-9
   Di Fonzo A, 2003, HUM MUTAT, V22, DOI 10.1002/humu.9203
   Dimmock D, 2010, CLIN CHEM, V56, P1119, DOI 10.1373/clinchem.2009.141549
   Edgar D, 2009, CELL METAB, V10, P131, DOI 10.1016/j.cmet.2009.06.010
   Engelsen BA, 2008, BRAIN, V131, P818, DOI 10.1093/brain/awn007
   Fadic R, 1997, NEUROLOGY, V49, P239, DOI 10.1212/WNL.49.1.239
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   González-Vioque E, 2006, ARCH NEUROL-CHICAGO, V63, P107, DOI 10.1001/archneur.63.1.107
   GRAY H, 1992, J BIOL CHEM, V267, P5835
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   Guo XH, 2010, BBA-BIOENERGETICS, V1797, P1159, DOI 10.1016/j.bbabio.2010.04.005
   Haas RH, 2008, MOL GENET METAB, V94, P16, DOI 10.1016/j.ymgme.2007.11.018
   Haas RH, 2007, PEDIATRICS, V120, P1326, DOI 10.1542/peds.2007-0391
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Hance N, 2005, HUM MOL GENET, V14, P1775, DOI 10.1093/hmg/ddi184
   HARDING BN, 1990, J CHILD NEUROL, V5, P273, DOI 10.1177/088307389000500402
   HIRANO M, 1994, NEUROLOGY, V44, P721, DOI 10.1212/WNL.44.4.721
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Kakuda TN, 2000, CLIN THER, V22, P685, DOI 10.1016/S0149-2918(00)90004-3
   Kasiviswanathan R, 2011, MITOCHONDRION, V11, P929, DOI 10.1016/j.mito.2011.08.003
   Kasiviswanathan R, 2009, J BIOL CHEM, V284, P19501, DOI 10.1074/jbc.M109.011940
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   LECRENIER N, 1995, MOL GEN GENET, V249, P1, DOI 10.1007/BF00290229
   Lee YS, 2010, J BIOL CHEM, V285, P28105, DOI 10.1074/jbc.M110.122283
   Lee YS, 2010, J BIOL CHEM, V285, P1490, DOI 10.1074/jbc.M109.062752
   Lee YS, 2009, CELL, V139, P312, DOI 10.1016/j.cell.2009.07.050
   Lewis W, 2007, LAB INVEST, V87, P326, DOI 10.1038/labinvest.3700523
   Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197
   Longley MJ, 2010, J BIOL CHEM, V285, P29690, DOI 10.1074/jbc.M110.151795
   Longley MJ, 2005, GENE, V354, P125, DOI 10.1016/j.gene.2005.03.029
   Longley MJ, 1998, BIOCHEMISTRY-US, V37, P10529, DOI 10.1021/bi980772w
   Longley MJ, 1998, P NATL ACAD SCI USA, V95, P12244, DOI 10.1073/pnas.95.21.12244
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Luoma PT, 2005, HUM MOL GENET, V14, P1907, DOI 10.1093/hmg/ddi196
   McElhinny SAN, 2006, CELL CYCLE, V5, P958, DOI 10.4161/cc.5.9.2736
   Milone M, 2008, NEUROMUSCULAR DISORD, V18, P626, DOI 10.1016/j.nmd.2008.05.009
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Naviaux RK, 1999, ANN NEUROL, V45, P54, DOI 10.1002/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B
   Nguyen KV, 2006, J HEPATOL, V45, P108, DOI 10.1016/j.jhep.2005.12.026
   Pagnamenta AT, 2006, HUM REPROD, V21, P2467, DOI 10.1093/humrep/del076
   Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200
   Safdar A, 2011, P NATL ACAD SCI USA, V108, P4135, DOI 10.1073/pnas.1019581108
   Saneto RP, 2010, DEV DISABIL RES REV, V16, P163, DOI 10.1002/ddrr.105
   Saneto RP, 2010, SEIZURE-EUR J EPILEP, V19, P140, DOI 10.1016/j.seizure.2010.01.002
   Sarzi E, 2007, J PEDIATR-US, V150, P531, DOI 10.1016/j.jpeds.2007.01.044
   Shrader WD, 2011, BIOORG MED CHEM LETT, V21, P3693, DOI 10.1016/j.bmcl.2011.04.085
   Stuart GR, 2006, HUM MOL GENET, V15, P363, DOI 10.1093/hmg/ddi454
   Stumpf JD, 2011, CELL MOL LIFE SCI, V68, P219, DOI 10.1007/s00018-010-0530-4
   Stumpf JD, 2010, HUM MOL GENET, V19, P2123, DOI 10.1093/hmg/ddq089
   Szczepanowska K, 2010, HUM MOL GENET, V19, P3516, DOI 10.1093/hmg/ddq267
   Tang S, 2011, J MED GENET, V48, P669, DOI 10.1136/jmedgenet-2011-100222
   Trifunovic A, 2005, P NATL ACAD SCI USA, V102, P17993, DOI 10.1073/pnas.0508886102
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   TULINIUS MH, 1991, BRAIN DEV-JPN, V13, P167, DOI 10.1016/S0387-7604(12)80024-6
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Uusimaa J, 2008, EPILEPSIA, V49, P1038, DOI 10.1111/j.1528-1167.2008.01544.x
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, NEUROLOGY, V61, P1811, DOI 10.1212/01.WNL.0000098997.23471.65
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Vermulst M, 2008, NAT GENET, V40, P392, DOI 10.1038/ng.95
   Vermulst M, 2007, NAT GENET, V39, P540, DOI 10.1038/ng1988
   Vermulst M, 2009, CELL METAB, V10, P437, DOI 10.1016/j.cmet.2009.11.001
   Walter MC, 2010, J NEUROL, V257, P1517, DOI 10.1007/s00415-010-5565-9
   Williams SL, 2010, CELL METAB, V12, P675, DOI 10.1016/j.cmet.2010.11.012
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   Wolf NI, 2009, EPILEPSIA, V50, P1596, DOI 10.1111/j.1528-1167.2008.01877.x
   Wong LJC, 2008, HUM MUTAT, V29, pE150, DOI 10.1002/humu.20824
   Yamanaka H, 2007, J INFECT DIS, V195, P1419, DOI 10.1086/513872
   Zhang DK, 2000, GENOMICS, V69, P151, DOI 10.1006/geno.2000.6333
NR 91
TC 85
Z9 104
U1 0
U2 23
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 1943-0264
J9 CSH PERSPECT BIOL
JI Cold Spring Harbor Perspect. Biol.
PD APR
PY 2013
VL 5
IS 4
AR a011395
DI 10.1101/cshperspect.a011395
PG 17
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 120MT
UT WOS:000317175200009
PM 23545419
OA Green Published, Bronze
DA 2024-11-01
ER

PT J
AU Whittaker, RG
   Schaefer, AM
   McFarland, R
   Taylor, RW
   Walker, M
   Turnbull, DM
AF Whittaker, R. G.
   Schaefer, A. M.
   McFarland, R.
   Taylor, R. W.
   Walker, M.
   Turnbull, D. M.
TI Prevalence and progression of diabetes in mitochondrial disease
SO DIABETOLOGIA
LA English
DT Article
DE diabetes; genotype; heteroplasmy; mitochondria; mutations; prevalence;
   progression
ID DNA MUTATION; DIAGNOSIS; MYOPATHY; MELAS
AB Aims/Hypothesis The aims of this study were (1) to determine the prevalence and rate of progression in diabetes secondary to mitochondrial DNA (mtDNA) mutations; and (2) to determine whether percentage heteroplasmy predicts clinical outcome in patients carrying the m.3243A > G mutation.
   Methods We prospectively assessed 242 patients attending a specialist neuromuscular clinic using a validated mitochondrial disease rating scale. Retrospective clinical data on these patients from up to 25 years of follow-up were also included. Percentage heteroplasmy in blood, urine and muscle was determined for the m.3243A > G group and correlated against clinical features.
   Results Patients carrying the m.3243A > G mutation formed the largest group of patients with diabetes (31/81 patients). The highest prevalence of diabetes was in the m.12258C > A group (2/2 patients), the lowest in the multiple mtDNA deletions group (3/43 patients). The earliest age of onset was in the m.3243A > G group (37.9 years) with the highest age of presentation in the multiple deletion group (56.3 years). Of patients presenting with m.3243A > G, 12.9% required insulin; an additional 32.3% progressed to insulin requirement over a mean of 4.2 years after presentation. Percentage heteroplasmy in blood, urine or muscle did not predict progression of diabetes or risk of developing complications. Early age of presentation with diabetes did predict poor clinical outcome.
   Conclusion/Interpretation Although patients carrying the m.3243A > G mutation account for the majority of cases of diabetes secondary to mtDNA mutations, several other genotypes are also associated with the development of diabetes, some with high penetrance. All show a gradual progression to insulin requirement. Percentage heteroplasmy is a poor predictor of severity of diabetes in the m.3243A > G group.
C1 Newcastle Univ, Mitochondrial Res Grp, Sch Neurol Neurobiol & Psychiat, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   Newcastle Univ, Diabet Res Grp, Sch Clin Med Sci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
C3 Newcastle University - UK; Newcastle University - UK
RP Whittaker, RG (corresponding author), Newcastle Univ, Mitochondrial Res Grp, Sch Neurol Neurobiol & Psychiat, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM r.whittaker@ncl.ac.uk
OI Schaefer, Andrew/0000-0001-9891-7332; Whittaker,
   Roger/0000-0002-3403-0182; McFarland, Robert/0000-0002-8833-2688
FU MRC [G108/539] Funding Source: UKRI
CR Adler AI, 2003, KIDNEY INT, V63, P225, DOI 10.1046/j.1523-1755.2003.00712.x
   ALBERTI KGM, 1999, DEFINITION DIAGNOS 1
   BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11
   Blakely EL, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.011296
   Chinnery PF, 1999, AM J MED GENET, V85, P498
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   DUNBAR DR, 1993, HUM MOL GENET, V2, P1619, DOI 10.1093/hmg/2.10.1619
   HANNA MG, 1995, AM J HUM GENET, V56, P1026
   Kiechl S, 2004, J NEUROL NEUROSUR PS, V75, P1125, DOI 10.1136/jnnp.2003.025890
   Lynn S, 2003, DIABETOLOGIA, V46, P296, DOI 10.1007/s00125-002-1018-z
   Maassen JA, 2004, DIABETES, V53, pS103, DOI 10.2337/diabetes.53.2007.S103
   McDonnell MT, 2004, EUR J HUM GENET, V12, P778, DOI 10.1038/sj.ejhg.5201216
   McFarland R, 2004, ANN NEUROL, V55, P478, DOI 10.1002/ana.20004
   *NIH, 2005, NAT DIAB STAT FACT S
   Ohkubo K, 2001, CLIN CHEM, V47, P1641
   Rahman S, 2001, AM J HUM GENET, V68, P238, DOI 10.1086/316930
   Schaefer AM, 2006, NEUROLOGY, V66, P1932, DOI 10.1212/01.wnl.0000219759.72195.41
   SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/NEJM199307293290502
   Taylor RW, 2001, NUCLEIC ACIDS RES, V29, part. no., DOI 10.1093/nar/29.15.e74
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   Walker M, 2005, DIABETIC MED, V22, P18, DOI 10.1111/j.1464-5491.2005.1761f.x
NR 21
TC 55
Z9 59
U1 1
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0012-186X
EI 1432-0428
J9 DIABETOLOGIA
JI Diabetologia
PD OCT
PY 2007
VL 50
IS 10
BP 2085
EP 2089
DI 10.1007/s00125-007-0779-9
PG 5
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA 208DI
UT WOS:000249299600009
PM 17653689
OA Bronze
DA 2024-11-01
ER

PT J
AU Schrier, SA
   Wong, LJ
   Place, E
   Ji, JQ
   Pierce, EA
   Golden, J
   Santi, M
   Anninger, W
   Falk, MJ
AF Schrier, Samantha A.
   Wong, Lee-Jun
   Place, Emily
   Ji, Jack Q.
   Pierce, Eric A.
   Golden, Jeffrey
   Santi, Mariarita
   Anninger, William
   Falk, Marni J.
TI Mitochondrial tRNA-Serine (AGY) m. C12264T Mutation Causes Severe
   Multisystem Disease with Cataracts
SO DISCOVERY MEDICINE
LA English
DT Article
ID PEARSON-SYNDROME; LACTIC-ACIDOSIS; HEARING-LOSS; COMPLEX-I; MYOPATHY;
   GENE; DEFICIENCY; EYE
AB Progressive multisystem disease should invoke consideration of potential mitochondrial etiologies. Mitochondrial disease can affect any organ system at any time, particularly involving neurologic, cardiac, muscular, gastroenterologic, and/or ophthalmologic manifestations. We report here a 19-year-old Caucasian man who was followed since birth in multiple pediatric subspecialty clinics for myelomeningocele complications. However, he progressively developed a host of additional problems that were not readily attributable to his neural tube defect involving developmental, ophthalmologic, cardiac, muscular, endocrine, and intermediary metabolic manifestations. Clinical diagnostic testing limited to analysis for common point mutations and deletions in his blood mitochondrial DNA (mtDNA) was not revealing. Skeletal muscle biopsy revealed abnormal mitochondrial morphology and immunostaining, mitochondrial proliferation, and mildly reduced respiratory chain complex I-III activity. Whole mitochondrial genome sequencing analysis in muscle identified an apparently homoplasmic, novel, m. 12264C>T transition in the tRNA serine (AGY) gene. The pathogenicity of this mutation was supported by identification of it being present at low heteroplasmy load in his blood (34%) as well as in blood from his maternal grandmother (1%). The proband developed severe nuclear cataracts that proved to be homoplasmic for the pathogenic mtDNA m. 12264C>T mutation. This case highlights the value of pursuing whole mitochondrial genome sequencing in symptomatic tissues in the diagnostic evaluation of suspected mitochondrial disease. Furthermore, it is the first report to directly implicate a single mtDNA mutation in the pathogenesis of ocular cataracts and clearly illustrates the important contribution of normal metabolic activity to the function of the ocular lens. [Discovery Medicine 13(69):143-150, February 2012]
C1 [Schrier, Samantha A.; Place, Emily; Falk, Marni J.] Childrens Hosp Philadelphia, Div Human Genet, Philadelphia, PA 19104 USA.
   [Schrier, Samantha A.; Place, Emily; Pierce, Eric A.; Golden, Jeffrey; Santi, Mariarita; Anninger, William; Falk, Marni J.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
   [Wong, Lee-Jun; Ji, Jack Q.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
   [Pierce, Eric A.] Massachusetts Eye & Ear Infirm, Ocular Genom Inst, Boston, MA 02114 USA.
   [Pierce, Eric A.; Anninger, William] Childrens Hosp Philadelphia, Dept Ophthalmol, Philadelphia, PA 19104 USA.
   [Golden, Jeffrey; Santi, Mariarita] Childrens Hosp Philadelphia, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
C3 University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of
   Philadelphia; University of Pennsylvania; Baylor College of Medicine;
   Harvard University; Massachusetts Eye & Ear Infirmary; University of
   Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia;
   University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of
   Philadelphia
RP Falk, MJ (corresponding author), Childrens Hosp Philadelphia, Div Human Genet, Philadelphia, PA 19104 USA.
EM falkm@email.chop.edu
RI Falk, Marni/K-1997-2014
OI Falk, Marni/0000-0002-1723-6728; Pierce, Eric/0000-0002-2354-4102
FU National Institutes of Health [R03-DK082446]
FX This work was funded in part by a grant from the National Institutes of
   Health (R03-DK082446) to M.J.F. The content is solely the responsibility
   of the authors and does not necessarily represent the official views of
   the National Institutes of Health.
CR Almousa R, 2009, OPHTHAL PLAST RECONS, V25, P366, DOI 10.1097/IOP.0b013e3181b2fd06
   Babizhayev MA, 2010, AM J THER
   Babizhayev MA, 2011, CELL BIOCHEM FUNCT, V29, P183, DOI 10.1002/cbf.1737
   Brennan LA, 2009, EXP EYE RES, V88, P195, DOI 10.1016/j.exer.2008.05.018
   Cardaioli E, 2011, J NEUROL SCI, V303, P142, DOI 10.1016/j.jns.2010.12.020
   Churchill A, 2011, PHILOS T R SOC B, V366, P1234, DOI 10.1098/rstb.2010.0227
   CIULLA TA, 1995, J PEDIATR OPHTHALMOL, V32, P378
   Cursiefen C, 1998, AM J OPHTHALMOL, V125, P260, DOI 10.1016/S0002-9394(99)80105-6
   Di Rosa G, 2006, J INHERIT METAB DIS, V29, P546, DOI 10.1007/s10545-006-0279-y
   Fernandes J., 2006, INBORN METABOLIC DIS, VFourth
   Fletcher AE, 2010, OPHTHALMIC RES, V44, P191, DOI 10.1159/000316476
   Graw J, 2009, MOL VIS, V15, P1881
   Haas RH, 2008, MOL GENET METAB, V94, P16, DOI 10.1016/j.ymgme.2007.11.018
   Haas RH, 2007, PEDIATRICS, V120, P1326, DOI 10.1542/peds.2007-0391
   Ji Q, 2003, PROSTATE, V54, P275, DOI 10.1002/pros.10192
   Jordens EZ, 2002, ANN NEUROL, V52, P95, DOI 10.1002/ana.10214
   LAUBER J, 1991, NUCLEIC ACIDS RES, V19, P1393, DOI 10.1093/nar/19.7.1393
   Leveque M, 2007, EUR J HUM GENET, V15, P1145, DOI 10.1038/sj.ejhg.5201891
   Lou MF, 2003, PROG RETIN EYE RES, V22, P657, DOI 10.1016/S1350-9462(03)00050-8
   Lynn S, 1998, DIABETES, V47, P1800, DOI 10.2337/diabetes.47.11.1800
   Mansergh FC, 1999, AM J HUM GENET, V64, P971, DOI 10.1086/302344
   Nicklas JA, 2006, J FORENSIC SCI, V51, P1005, DOI 10.1111/j.1556-4029.2006.00211.x
   Reddy MA, 2004, HUM MOL GENET, V13, P945, DOI 10.1093/hmg/ddh110
   RIBES A, 1993, J INHERIT METAB DIS, V16, P537, DOI 10.1007/BF00711675
   Scaglia F, 2008, MUSCLE NERVE, V37, P150, DOI 10.1002/mus.20917
   Schmidt W, 2008, MOL VIS, V14, P851
   Schrier SA, 2011, CURR OPIN OPHTHALMOL, V22, P325, DOI 10.1097/ICU.0b013e328349419d
   SENGERS RCA, 1975, J PEDIATR-US, V86, P873, DOI 10.1016/S0022-3476(75)80217-4
   Shutt TE, 2010, ENVIRON MOL MUTAGEN, V51, P360, DOI 10.1002/em.20571
   Tang XW, 2010, MOL GENET METAB, V100, P57, DOI 10.1016/j.ymgme.2010.01.008
   Vinson Joe A, 2006, Pathophysiology, V13, P151, DOI 10.1016/j.pathophys.2006.05.006
   Wong LJC, 2006, J MED GENET, V43, DOI 10.1136/jmg.2005.040626
   Yarham K, 2010, WILEY INTERDISCIP RE, V1, P304
   Zaragoza MV, 2011, EUR J HUM GENET, V19, P200, DOI 10.1038/ejhg.2010.169
NR 34
TC 4
Z9 4
U1 0
U2 1
PU DISCOVERY MEDICINE
PI TIMONIUM
PA 10 GERARD AVE, STE 201, TIMONIUM, MD 21093 USA
SN 1539-6509
EI 1944-7930
J9 DISCOV MED
JI Discov. Med.
PD FEB
PY 2012
VL 13
IS 69
BP 143
EP 150
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 094PH
UT WOS:000315275800005
PM 22369973
DA 2024-11-01
ER

PT J
AU Yatsuga, S
   Suomalainen, A
AF Yatsuga, Shuichi
   Suomalainen, Anu
TI Effect of bezafibrate treatment on late-onset mitochondrial myopathy in
   mice
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID CYTOCHROME-C-OXIDASE; PPAR-ALPHA; COACTIVATOR-1-ALPHA PGC-1-ALPHA;
   LIPID-METABOLISM; RECEPTOR-ALPHA; COX DEFICIENCY; ACTIVATION; MULTIPLE;
   DISEASE; GAMMA
AB Mitochondrial dysfunction is an important cause of metabolic disorders of children and adults, with no effective therapy options. Recently, induction of mitochondrial biogenesis, by transgenic overexpression of PGC1alpha [peroxisome proliferator-activated receptor (PPAR)-gamma coactivator 1-alpha], was reported to delay progression of early-onset cytochrome-c-oxidase (COX) deficiency in skeletal muscle of two mouse models: a muscle-specific knock-out of COX10 (COX10-mKO) and a constitutive knock-out of Surf1 (Surf1-KO). A panPPAR agonist, bezafibrate, could similarly delay myopathy progression in COX10-mKOs, but not in SURF1KOs. We asked whether bezafibrate affected disease progression in late-onset adult-type mitochondrial myopathy mice. These ` Deletor mice' express a dominant patient mutation in Twinkle-helicase, leading to accumulation of multiple mtDNA deletions and subsequent progressive respiratory chain (RC) deficiency with COX-negative muscle fibers at 12 months of age. The primary and secondary molecular findings in Deletor mice mimic closely those in patients with Twinkle myopathy. We applied 0.5% bezafibrate diet to Deletors for 22 weeks, starting at disease manifestation, mimicking patient treatment after diagnosis. Bezafibrate delayed significantly the accumulation of COX-negative fibers and multiple mtDNA deletions. However, mitochondrial biogenesis was not induced: mitochondrial DNA copy number, transcript and RC protein amounts decreased in both Deletors and wild-type mice. Furthermore, bezafibrate induced severe lipid oxidation effects, with hepatomegaly and loss of adipose tissue, the mechanism involving lipid mobilization by high hepatic expression of FGF21 cytokine. However, as bezafibrate has been tolerated well by humans, the beneficial muscle findings in Deletor mice support consideration of bezafibrate trials on adult patients with mitochondrial myopathy.
C1 [Yatsuga, Shuichi; Suomalainen, Anu] Univ Helsinki, Res Programs Unit, FIN-00290 Helsinki, Finland.
   Univ Helsinki, Cent Hosp, Dept Neurol, FIN-00290 Helsinki, Finland.
   [Suomalainen, Anu] Inst Mol Med Finland, Helsinki 00290, Finland.
C3 University of Helsinki; University of Helsinki; Helsinki University
   Central Hospital
RP Suomalainen, A (corresponding author), Univ Helsinki, Res Programs Unit, Haartmaninkatu 8, FIN-00290 Helsinki, Finland.
EM anu.wartiovaara@helsinki.fi
OI Suomalainen-Wartiovaara, Anu/0000-0003-4833-5195
FU Sigrid Juselius foundation; Jane and Aatos Erkko Foundation; University
   of Helsinki; Academy of Finland's Centre of Excellence program;
   Finland-Japan program; CIMO organization
FX We also wish to thank for funding support from the following sources:
   Sigrid Juselius foundation, Jane and Aatos Erkko Foundation, University
   of Helsinki and Academy of Finland's Centre of Excellence program and
   Finland-Japan program, as well as CIMO organization.
CR Ahola-Erkkilä S, 2010, HUM MOL GENET, V19, P1974, DOI 10.1093/hmg/ddq076
   Antonicka H, 2003, HUM MOL GENET, V12, P2693, DOI 10.1093/hmg/ddg284
   Badman MK, 2007, CELL METAB, V5, P426, DOI 10.1016/j.cmet.2007.05.002
   CHEN F, 1993, BIOCHEM BIOPH RES CO, V196, P671, DOI 10.1006/bbrc.1993.2302
   Dell'Agnello C, 2007, HUM MOL GENET, V16, P431, DOI 10.1093/hmg/ddl477
   Desvergne B, 1999, ENDOCR REV, V20, P649, DOI 10.1210/er.20.5.649
   Diaz F, 2005, HUM MOL GENET, V14, P2737, DOI 10.1093/hmg/ddi307
   DIMAURO S, 1980, NEUROLOGY, V30, P795, DOI 10.1212/WNL.30.8.795
   Domouzoglou EM, 2011, AM J CLIN NUTR, V93, p901S, DOI 10.3945/ajcn.110.001941
   Goldenberg I, 2008, VASC HEALTH RISK MAN, V4, P131, DOI 10.2147/vhrm.2008.04.01.131
   Goto T, 2011, J LIPID RES, V52, P873, DOI 10.1194/jlr.M011320
   Huss JM, 2002, J BIOL CHEM, V277, P40265, DOI 10.1074/jbc.M206324200
   Inagaki T, 2007, CELL METAB, V5, P415, DOI 10.1016/j.cmet.2007.05.003
   ISSEMANN I, 1990, NATURE, V347, P645, DOI 10.1038/347645a0
   MINCHOM PE, 1983, J NEUROL SCI, V60, P453, DOI 10.1016/0022-510X(83)90156-9
   Mori Yutaka, 2004, J Atheroscler Thromb, V11, P224
   Nakajima T, 2009, MOL PHARMACOL, V75, P782, DOI 10.1124/mol.108.052928
   Oishi K, 2008, FEBS LETT, V582, P3639, DOI 10.1016/j.febslet.2008.09.046
   Potthoff MJ, 2009, P NATL ACAD SCI USA, V106, P10853, DOI 10.1073/pnas.0904187106
   Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5
   Pyper Sean R, 2010, Nucl Recept Signal, V8, pe002, DOI 10.1621/nrs.08002
   Siersbæk R, 2010, FEBS LETT, V584, P3242, DOI 10.1016/j.febslet.2010.06.010
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   Suomalainen A, 2011, LANCET NEUROL, V10, P806, DOI 10.1016/S1474-4422(11)70155-7
   Suomalainen A, 2011, SEMIN FETAL NEONAT M, V16, P236, DOI 10.1016/j.siny.2011.05.003
   Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
   Tyynismaa H, 2010, HUM MOL GENET, V19, P3948, DOI 10.1093/hmg/ddq310
   Tyynismaa H, 2009, EMBO REP, V10, P137, DOI 10.1038/embor.2008.242
   Varga T, 2011, BBA-MOL BASIS DIS, V1812, P1007, DOI 10.1016/j.bbadis.2011.02.014
   Viscomi C, 2011, CELL METAB, V14, P80, DOI 10.1016/j.cmet.2011.04.011
   Wagner KD, 2010, PHARMACOL THERAPEUT, V125, P423, DOI 10.1016/j.pharmthera.2009.12.001
   Wenz T, 2008, CELL METAB, V8, P249, DOI 10.1016/j.cmet.2008.07.006
   Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X
   Zhang Y, 2004, J BIOL CHEM, V279, P53963, DOI 10.1074/jbc.M406028200
   Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804
NR 36
TC 103
Z9 112
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD FEB 1
PY 2012
VL 21
IS 3
BP 526
EP 535
DI 10.1093/hmg/ddr482
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 879RX
UT WOS:000299351000005
PM 22012983
OA hybrid
DA 2024-11-01
ER

PT J
AU Loos, MA
   Gomez, G
   Mayorga, L
   Caraballo, RH
   Eiroa, HD
   Obregon, MG
   Rugilo, C
   Lubieniecki, F
   Taratuto, AL
   Saccoliti, M
   Alonso, CN
   Araoz, HV
AF Loos, Mariana Amina
   Gomez, Gimena
   Mayorga, Lia
   Caraballo, Roberto Horacio
   Eiroa, Hernan Diego
   Obregon, Maria Gabriela
   Rugilo, Carlos
   Lubieniecki, Fabiana
   Taratuto, Ana Lia
   Saccoliti, Maria
   Alonso, Cristina Noemi
   Araoz, Hilda Veronica
TI Clinical and molecular characterization of mitochondrial DNA disorders
   in a group of Argentinian pediatric patients
SO MOLECULAR GENETICS AND METABOLISM REPORTS
LA English
DT Article
DE Mitochondrial diseases; MELAS; Leigh syndrome; Molecular diagnosis;
   Pediatrics; Mitochondrial DNA
ID HEREDITARY OPTIC NEUROPATHY; LEIGH-SYNDROME; TRANSFER-RNA; DISEASE
   PHENOTYPES; MUTATION; DELETIONS; ATAXIA; DEFICIENCY; MANAGEMENT;
   DIAGNOSIS
AB Objective: To describe the clinical and molecular features of a group of Argentinian pediatric patients with mitochondrial DNA (mtDNA) disorders, and to evaluate the results of the implementation of a classical approach for the molecular diagnosis of mitochondrial diseases.
   Methods: Clinical data from 27 patients with confirmed mtDNA pathogenic variants were obtained from a database of 89 patients with suspected mitochondrial disease, registered from 2014 to 2020. Clinical data, biochemical analysis, neuroimaging findings, muscle biopsy and molecular studies were analyzed.
   Results: Patients were 18 females and 9 males, with ages at onset ranging from 1 week to 14 years (median = 4 years). The clinical phenotypes were: mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome (n = 11), Leigh syndrome (n = 5), Kearns-Sayre syndrome (n = 3), Chronic Progressive External Ophthalmoplegia (n = 2), Leber hereditary optic neuropathy (n = 2), myoclonic epilepsy associated with ragged-red fibers (n = 1) and reversible infantile myopathy with cytochrome-C oxidase deficiency (n = 3). Most of the patients harbored pathogenic single nucleotide variants, mainly involving mt-tRNA genes, such as MT-TL1, MT-TE and MT-TK. Other point variants were found in complex I subunits, like MT-ND6, MT-ND4, MT-ND5; or in MT-ATP6. The m.13513G > A variant in MT-ND5 and the m.9185 T > C variant in MTATP6 were apparently de novo. The rest of the patients presented large scale-rearrangements, either the "common" deletion or a larger deletion.
   Conclusions: This study highlights the clinical and genetic heterogeneity of pediatric mtDNA disorders. All the cases presented with classical phenotypes, being MELAS the most frequent. Applying classical molecular methods, it was possible to achieve a genetic diagnosis in 30% of the cases, suggesting that this is an effective first approach, especially for those centers from low-middle income countries, leaving NGS studies for those patients with inconclusive results.
C1 [Loos, Mariana Amina; Caraballo, Roberto Horacio] Hosp Pediatr Juan P Garrahan, Dept Neurol, Combate Pozos 1881, RA-1245 Buenos Aires, DF, Argentina.
   [Gomez, Gimena; Alonso, Cristina Noemi] Hosp Pediatr Juan P Garrahan, Genom Lab, Combate Pozos 1881, RA-1245 Buenos Aires, DF, Argentina.
   [Mayorga, Lia] Univ Nacl Cuyo, Ctr Univ UNCuyo, CONICET,IHEM, Inst Histol & Embriol Mendoza, RA-5500 Mendoza, Argentina.
   [Eiroa, Hernan Diego] Hosp Pediat Juan P Garrahan, Dept Inborn Errors Metab, Combate Pozos 1881, RA-1245 Buenos Aires, DF, Argentina.
   [Obregon, Maria Gabriela; Araoz, Hilda Veronica] Hosp Pediatria Juan P Garrahan, Dept Med Genet, Combate Pozos 1881, RA-1245 Buenos Aires, DF, Argentina.
   [Rugilo, Carlos] Hosp Pediatr Juan P Garrahan, Dept Diagnost Imaging, Combate Pozos 1881, RA-1245 Buenos Aires, DF, Argentina.
   [Lubieniecki, Fabiana] Hosp Pediat Juan P Garrahan, Dept Pathol, Combate Los Pozos 1881, RA-1245 Buenos Aires, DF, Argentina.
   [Taratuto, Ana Lia; Saccoliti, Maria] Neuropathol & Neuromusc Dis Lab, Buenos Aires, DF, Argentina.
C3 Hospital de Pediatria Doctor Juan Garrahan; Hospital de Pediatria Doctor
   Juan Garrahan; Consejo Nacional de Investigaciones Cientificas y
   Tecnicas (CONICET); University Nacional Cuyo Mendoza; Hospital de
   Pediatria Doctor Juan Garrahan; Hospital de Pediatria Doctor Juan
   Garrahan; Hospital de Pediatria Doctor Juan Garrahan; Hospital de
   Pediatria Doctor Juan Garrahan
RP Loos, MA (corresponding author), Hosp Pediatr Juan P Garrahan, Dept Neurol, Combate Pozos 1881, RA-1245 Buenos Aires, DF, Argentina.
EM mloos@garrahan.gov.ar
RI Gomez, Graciela/AAA-7313-2022
OI Gomez, Gimena/0009-0006-9000-8605
FU Hospital de Pediatria "J. P. Garrahan"
FX This research was supported by Hospital de Pediatria "J. P. Garrahan".
   We did not receive any specific grant from funding agencies in the
   public, commercial, or notforprofit sectors.
CR Blakely EL, 2013, HUM MUTAT, V34, P1260, DOI 10.1002/humu.22358
   Boczonadi V, 2015, J INHERIT METAB DIS, V38, P427, DOI 10.1007/s10545-014-9784-6
   Brautbar A, 2008, MOL GENET METAB, V94, P485, DOI 10.1016/j.ymgme.2008.04.004
   Castagna AE, 2007, AM J MED GENET A, V143A, P808, DOI 10.1002/ajmg.a.31637
   Childs AM, 2007, NEUROPEDIATRICS, V38, P313, DOI 10.1055/s-2008-1065355
   Chinnery PF, 2013, BRIT MED BULL, V106, P135, DOI 10.1093/bmb/ldt017
   Couser N, 2017, CLIN ASPECTS LAB DET, V2, P167, DOI 10.1016/B978-0-12-802896-4.00008-0
   Craig K, 2007, J MED GENET, V44, P797, DOI 10.1136/jmg.2007.052902
   Davison JE, 2017, ARCH DIS CHILD, V102, P1082, DOI 10.1136/archdischild-2016-311370
   DiMauro S, 2013, NAT REV NEUROL, V9, P429, DOI 10.1038/nrneurol.2013.126
   Diogo L, 2009, PEDIATR NEUROL, V40, P351, DOI 10.1016/j.pediatrneurol.2008.11.012
   Finsterer J, 2006, ACTA NEUROL SCAND, V114, P217, DOI 10.1111/j.1600-0404.2006.00671.x
   Gorman GS, 2016, NAT REV DIS PRIMERS, V2, P1, DOI 10.1038/nrdp.2016.80
   Grady JP, 2014, BRAIN, V137, P323, DOI 10.1093/brain/awt321
   Haas RH, 2008, MOL GENET METAB, V94, P16, DOI 10.1016/j.ymgme.2007.11.018
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Horvath R, 2009, BRAIN, V132, P3165, DOI 10.1093/brain/awp221
   Iizuka T, 2002, NEUROLOGY, V59, P816, DOI 10.1212/WNL.59.6.816
   Jou C, 2019, J CLIN MED, V8, DOI 10.3390/jcm8010068
   JUN AS, 1994, P NATL ACAD SCI USA, V91, P6206, DOI 10.1073/pnas.91.13.6206
   Keshavan N, 2018, ESSAYS BIOCHEM, V62, P423, DOI 10.1042/EBC20170108
   Kirby DM, 2008, TWIN RES HUM GENET, V11, P395, DOI 10.1375/twin.11.4.395
   Kirby DM, 2000, ANN NEUROL, V48, P102, DOI 10.1002/1531-8249(200007)48:1<102::AID-ANA15>3.3.CO;2-D
   Kirby DM, 2003, ANN NEUROL, V54, P473, DOI 10.1002/ana.10687
   Lamont PJ, 1998, ARCH DIS CHILD, V79, P22, DOI 10.1136/adc.79.1.22
   Mayorga L, 2019, CELL MOL LIFE SCI, V76, P1397, DOI 10.1007/s00018-019-03008-5
   Mayorga L, 2019, MITOCHONDRIAL DNA B, V4, P530, DOI 10.1080/23802359.2018.1553510
   Mayorga L, 2016, MITOCHONDRIAL DNA A, V27, P2864, DOI 10.3109/19401736.2015.1053132
   Morava E, 2015, J INHERIT METAB DIS, V38, P387, DOI 10.1007/s10545-015-9852-6
   Muramatsu D, 2019, INTERNAL MED, V58, P1797, DOI 10.2169/internalmedicine.2190-18
   Ng Yi Shiau, 2019, Wellcome Open Res, V4, P201, DOI 10.12688/wellcomeopenres.15599.1
   Nissenkorn A, 2000, J CHILD NEUROL, V15, P44, DOI 10.1177/088307380001500110
   Orsucci D, 2018, EBIOMEDICINE, V30, P3, DOI 10.1016/j.ebiom.2018.03.007
   Oyama M, 2020, BMC NEUROL, V20, DOI 10.1186/s12883-020-01748-7
   Parikh S, 2015, GENET MED, V17, P689, DOI 10.1038/gim.2014.177
   Pitceathly RDS, 2012, NEUROMUSCULAR DISORD, V22, P577, DOI 10.1016/j.nmd.2012.03.009
   Rahman S, 2020, J INTERN MED, V287, P609, DOI 10.1111/joim.13054
   Rahman S., 2014, GENEREVIEWS, P1
   Rantamäki MT, 2005, ANN NEUROL, V58, P337, DOI 10.1002/ana.20555
   Ronchi D, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-85
   ROTIG A, 1995, HUM MOL GENET, V4, P1327, DOI 10.1093/hmg/4.8.1327
   Ruhoy LS, 2014, APPL CLIN GENET, V7, P221, DOI 10.2147/TACG.S46176
   Schon EA, 2012, NAT REV GENET, V13, P878, DOI 10.1038/nrg3275
   SHOFFNER JM, 1995, ANN NEUROL, V38, P163, DOI 10.1002/ana.410380207
   Stendel C, 2020, NEUROL-GENET, V6, DOI 10.1212/NXG.0000000000000393
   Sue CM, 1999, J PEDIATR-US, V134, P696, DOI 10.1016/S0022-3476(99)70283-0
   Takada R, 2020, BRAIN DEV-JPN, V42, P69, DOI 10.1016/j.braindev.2019.08.006
   Thompson K, 2020, J INHERIT METAB DIS, V43, P36, DOI 10.1002/jimd.12104
   Thorburn DR, 2004, J INHERIT METAB DIS, V27, P349, DOI 10.1023/B:BOLI.0000031098.41409.55
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   White SL, 1999, AM J HUM GENET, V65, P474, DOI 10.1086/302488
   Xing GQ, 2007, CELL RES, V17, P227, DOI 10.1038/sj.cr.7310124
   Yu HO, 2019, J NEUROL, V266, P1459, DOI 10.1007/s00415-019-09283-3
   Zheng J, 2012, MITOCHONDRION, V12, P406, DOI 10.1016/j.mito.2012.04.001
NR 54
TC 3
Z9 3
U1 0
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 2214-4269
J9 MOL GENET METAB REP
JI Molec. Genet. Metab. Rep.
PD JUN
PY 2021
VL 27
AR 100733
DI 10.1016/j.ymgmr.2021.100733
EA FEB 2021
PG 7
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA SV0DH
UT WOS:000663497800033
PM 33717984
OA Green Published, gold
DA 2024-11-01
ER

PT J
AU Holt, IJ
AF Holt, Ian J.
TI Zen and the art of mitochondrial DNA maintenance
SO TRENDS IN GENETICS
LA English
DT Review
ID SUBSTANTIA-NIGRA NEURONS; TUMOR-SUPPRESSOR P53; TRANSCRIPTION FACTOR;
   THYMIDINE KINASE; MTDNA DEPLETION; POINT MUTATION; DELETIONS; MUTANT;
   MYOPATHY; CELLS
AB Because mitochondrial genes encode proteins essential for aerobic ATP production, mitochondrial DNA defects can cause an energy crisis. These defects fall into two broad categories: primary mutations in mitochondrial DNA and mutations in nuclear genes, whose protein products are involved in mitochondrial DNA maintenance. Evidence is accumulating that both types of defects can cause mitochondrial DNA loss. Hence, regulatory factors, which determine whether mitochondrial DNA molecules are maintained or lost, potentially play a more important role in these disorders than hitherto recognised. Candidates include reactive oxygen species (ROS) and the tumour suppressor p53. The cell might not always be the best judge of when to dispense with the services of mitochondrial DNA, and so interventions that favour its retention could potentially limit the adverse effects of pathological mitochondrial DNAs.
C1 MRC, Mitochondrial Biol Unit, Cambridge CB2 0XY, England.
RP Holt, IJ (corresponding author), MRC, Mitochondrial Biol Unit, Wellcome Trust MRC Bldg,Hills Rd, Cambridge CB2 0XY, England.
EM holt@mrc-mbu.cam.ac.uk
RI holt, ian/AFT-2565-2022
OI holt, ian/0000-0001-5468-0193
FU MRC [MC_U105663140] Funding Source: UKRI; Medical Research Council
   [MC_U105663140] Funding Source: Medline
CR Achanta G, 2005, EMBO J, V24, P3482, DOI 10.1038/sj.emboj.7600819
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Blok RB, 1997, AM J HUM GENET, V60, P1495, DOI 10.1086/515453
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Brandon M, 2006, ONCOGENE, V25, P4647, DOI 10.1038/sj.onc.1209607
   Brown DT, 2001, AM J HUM GENET, V68, P533, DOI 10.1086/318190
   Carelli V, 2009, BBA-BIOENERGETICS, V1787, P518, DOI 10.1016/j.bbabio.2009.02.024
   Chinnery PF, 1999, AM J HUM GENET, V64, P1158, DOI 10.1086/302311
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236
   Dufour E, 2008, HUM MOL GENET, V17, P1418, DOI 10.1093/hmg/ddn030
   DUNBAR DR, 1993, HUM MOL GENET, V2, P1619, DOI 10.1093/hmg/2.10.1619
   DUNBAR DR, 1995, P NATL ACAD SCI USA, V92, P6562, DOI 10.1073/pnas.92.14.6562
   Durham SE, 2006, NEUROLOGY, V67, P502, DOI 10.1212/01.wnl.0000227961.55640.2f
   Fukui H, 2009, HUM MOL GENET, V18, P1028, DOI 10.1093/hmg/ddn437
   Geromel V, 2001, HUM MOL GENET, V10, P1221, DOI 10.1093/hmg/10.11.1221
   Hakonen AH, 2008, HUM MOL GENET, V17, P3822, DOI 10.1093/hmg/ddn280
   HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Holt IJ, 1997, HUM MOL GENET, V6, P1251, DOI 10.1093/hmg/6.8.1251
   Hori A, 2009, NUCLEIC ACIDS RES, V37, P749, DOI 10.1093/nar/gkn993
   Hyvärinen AK, 2007, NUCLEIC ACIDS RES, V35, P6458, DOI 10.1093/nar/gkm676
   Iacovino M, 2009, HUM MOL GENET, V18, P65, DOI 10.1093/hmg/ddn313
   Ishikawa K, 2008, SCIENCE, V320, P661, DOI 10.1126/science.1156906
   Jacobs HT, 2003, AGING CELL, V2, P11, DOI 10.1046/j.1474-9728.2003.00032.x
   Jenuth JP, 1997, NAT GENET, V16, P93, DOI 10.1038/ng0597-93
   Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778
   Krishnan KJ, 2007, ANN NY ACAD SCI, V1100, P227, DOI 10.1196/annals.1395.024
   Lebedeva MA, 2009, BBA-BIOENERGETICS, V1787, P328, DOI 10.1016/j.bbabio.2009.01.004
   Lynn S, 2003, DIABETOLOGIA, V46, P296, DOI 10.1007/s00125-002-1018-z
   Malena A, 2009, HUM MOL GENET, V18, P3407, DOI 10.1093/hmg/ddp281
   Minczuk M, 2006, P NATL ACAD SCI USA, V103, P19689, DOI 10.1073/pnas.0609502103
   MITA S, 1989, P NATL ACAD SCI USA, V86, P9509, DOI 10.1073/pnas.86.23.9509
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Moreno-Loshuertos R, 2006, NAT GENET, V38, P1261, DOI 10.1038/ng1897
   Nguyen KV, 2006, J HEPATOL, V45, P108, DOI 10.1016/j.jhep.2005.12.026
   Nishigaki Y, 2004, HUM MOL GENET, V13, P91, DOI 10.1093/hmg/ddh010
   Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   PETRUZZELLA V, 1994, HUM MOL GENET, V3, P449, DOI 10.1093/hmg/3.3.449
   Poulton Joanna, 2009, Neuromuscul Disord, V19, P439, DOI 10.1016/j.nmd.2009.04.009
   Pyle A, 2007, J MED GENET, V44, P69, DOI 10.1136/jmg.2006.043109
   Saada A, 2004, DNA CELL BIOL, V23, P797
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Sarzi E, 2007, ANN NEUROL, V62, P579, DOI 10.1002/ana.21207
   Shoubridge EA, 2007, CURR TOP DEV BIOL, V77, P87, DOI 10.1016/S0070-2153(06)77004-1
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Stewart JB, 2008, PLOS BIOL, V6, P63, DOI 10.1371/journal.pbio.0060010
   Turner CJ, 2005, GENETICS, V170, P1879, DOI 10.1534/genetics.105.043653
   Tyynismaa H, 2009, AM J HUM GENET, V85, P290, DOI 10.1016/j.ajhg.2009.07.009
   van den Ouweland JMW, 2000, EUR J HUM GENET, V8, P195, DOI 10.1038/sj.ejhg.5200444
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Vergani L, 2007, BRAIN, V130, P2715, DOI 10.1093/brain/awm151
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   Wang JM, 2001, P NATL ACAD SCI USA, V98, P4038, DOI 10.1073/pnas.061038798
   Wenz T, 2008, CELL METAB, V8, P249, DOI 10.1016/j.cmet.2008.07.006
   White SL, 1999, AM J HUM GENET, V65, P474, DOI 10.1086/302488
   Wong TS, 2009, NUCLEIC ACIDS RES, V37, P6765, DOI 10.1093/nar/gkp750
   Wong TS, 2009, NUCLEIC ACIDS RES, V37, P568, DOI 10.1093/nar/gkn974
   YONEDA M, 1992, P NATL ACAD SCI USA, V89, P11164, DOI 10.1073/pnas.89.23.11164
   Yoshida Y, 2003, CANCER RES, V63, P3729
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
   Zhou XS, 2008, HUM MOL GENET, V17, P2329, DOI 10.1093/hmg/ddn133
NR 64
TC 24
Z9 28
U1 0
U2 11
PU ELSEVIER SCIENCE LONDON
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0168-9525
J9 TRENDS GENET
JI Trends Genet.
PD MAR
PY 2010
VL 26
IS 3
BP 103
EP 109
DI 10.1016/j.tig.2009.12.011
PG 7
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 565ES
UT WOS:000275272600004
PM 20117854
DA 2024-11-01
ER

PT J
AU Yamada, T
   Ivarsson, N
   Hernández, A
   Fahlström, A
   Cheng, AJ
   Zhang, SJ
   Bruton, JD
   Ulfhake, B
   Westerblad, H
AF Yamada, Takashi
   Ivarsson, Niklas
   Hernandez, Andres
   Fahlstrom, Andreas
   Cheng, Arthur J.
   Zhang, Shi-Jin
   Bruton, Joseph D.
   Ulfhake, Brun
   Westerblad, Hakan
TI Impaired mitochondrial respiration and decreased fatigue resistance
   followed by severe muscle weakness in skeletal muscle of mitochondrial
   DNA mutator mice
SO JOURNAL OF PHYSIOLOGY-LONDON
LA English
DT Article
ID ENDURANCE EXERCISE; SARCOPLASMIC-RETICULUM; CALCIUM-CONCENTRATION;
   SUPEROXIDE-DISMUTASE; OXIDATIVE STRESS; MOUSE MUSCLE; FIBERS; MUTATIONS;
   MYOPATHY; DISEASE
AB Key points Defective mitochondrial function has been shown to cause muscle weakness and exercise intolerance. We used a mouse model of premature ageing with defective proofreading of mitochondrial DNA (mtDNA): the mtDNA mutator mouse. Muscles of young (35 months) mtDNA mutator mice showed reduced endurance, which was caused by decreased mitochondrial ATP production accompanied by decreased levels of factors stimulating mitochondrial biogenesis. The dominant defect in muscles of old (11 months) mtDNA mutator mice was severe weakness, which was caused by decreased intracellular Ca2+ stores. These results underline two important aspects of mitochondria-to-nucleus signalling in skeletal muscle: (1) it fails to respond adequately to decreased mitochondrial ATP production in sedentary animals; and (2) it can induce decreased intracellular Ca2+ stores and hence muscle weakness. These results have implication for normal ageing and suggest that the decreased mitochondrial function induced by a sedentary lifestyle may predispose to muscle weakness later in life. Abstract Mitochondrial dysfunction can drastically impair muscle function, with weakness and exercise intolerance as key symptoms. Here we examine the time course of development of muscle dysfunction in a mouse model of premature ageing induced by defective proofreading function of mitochondrial DNA (mtDNA) polymerase (mtDNA mutator mouse). Isolated fast-twitch muscles and single muscle fibres from young (35 months) and end-stage (11 months) mtDNA mutator mice were compared to age-matched control mice. Force and free myoplasmic [Ca2+] ([Ca2+]i) were measured under resting conditions and during fatigue induced by repeated tetani. Muscles of young mtDNA mutator mice displayed no weakness in the rested state, but had lower force and [Ca2+]i than control mice during induction of fatigue. Muscles of young mtDNA mutator mice showed decreased activities of citrate synthase and beta-hydroxyacyl-coenzyme A dehydrogenase, reduced expression of cytochrome c oxidase, and decreased expression of triggers of mitochondrial biogenesis (PGC-1 alpha, PPAR alpha, AMPK). Muscles from end-stage mtDNA mutator mice showed weakness under resting conditions with markedly decreased tetanic [Ca2+]i, force per cross-sectional area and protein expression of the sarcoplasmic reticulum Ca2+ pump (SERCA1). In conclusion, fast-twitch muscles of prematurely ageing mtDNA mutator mice display a sequence of deleterious mitochondrial-to-nucleus signalling with an initial decrease in oxidative capacity, which was not counteracted by activation of signalling to increase mitochondrial biogenesis. This was followed by severe muscle weakness in the end stage. These results have implication for normal ageing and suggest that decreased mitochondrial oxidative capacity due to a sedentary lifestyle may predispose towards muscle weakness developing later in life.
C1 [Yamada, Takashi; Ivarsson, Niklas; Hernandez, Andres; Cheng, Arthur J.; Zhang, Shi-Jin; Bruton, Joseph D.; Westerblad, Hakan] Karolinska Inst, Dept Physiol & Pharmacol, SE-17177 Stockholm, Sweden.
   [Fahlstrom, Andreas; Ulfhake, Brun] Karolinska Inst, Dept Neurosci, SE-17177 Stockholm, Sweden.
C3 Karolinska Institutet; Karolinska Institutet
RP Westerblad, H (corresponding author), Karolinska Inst, Dept Physiol & Pharmacol, SE-17177 Stockholm, Sweden.
EM hakan.westerblad@ki.se
RI Cheng, Arthur/Q-9379-2019; 山田, 崇史/U-8443-2019; Fahlström,
   Andreas/ABA-6675-2021; HERNANDEZ-GARCIA, ANDRES/B-9051-2014; Ulfhake,
   Brun/JVO-9211-2024
OI Yamada, Takashi/0000-0003-1797-3880; Cheng, Arthur/0000-0003-3862-2967;
   Fahlstrom, Andreas/0000-0002-0298-8775; Westerblad,
   Hakan/0000-0002-8180-3029; Bruton, Joseph/0000-0002-6985-099X; Ivarsson,
   Niklas/0000-0002-3830-657X
FU Swedish Research Council; Swedish National Center for Sports Research,
   Association Francaise Contre les Myopathies (AFM); National Institute of
   Arthritis and Musculoskeletal and Skin Diseases (NIAMS) [1F32AR057619];
   Grants-in-Aid for Scientific Research [24700541] Funding Source: KAKEN
FX This work was supported by funds from the Swedish Research Council, the
   Swedish National Center for Sports Research, Association Francaise
   Contre les Myopathies (AFM), and by the National Institute of Arthritis
   and Musculoskeletal and Skin Diseases (NIAMS; Grant 1F32AR057619 to
   A.H.).
CR Allen DG, 2008, PHYSIOL REV, V88, P287, DOI 10.1152/physrev.00015.2007
   Andrade FH, 1998, J PHYSIOL-LONDON, V509, P565, DOI 10.1111/j.1469-7793.1998.565bn.x
   Arany Z, 2008, CURR OPIN GENET DEV, V18, P426, DOI 10.1016/j.gde.2008.07.018
   Aydin J, 2009, HUM MOL GENET, V18, P278, DOI 10.1093/hmg/ddn355
   Barclay CJ, 2005, J MUSCLE RES CELL M, V26, P225, DOI 10.1007/s10974-005-9013-x
   BASS A, 1969, EUR J BIOCHEM, V10, P198, DOI 10.1111/j.1432-1033.1969.tb00674.x
   Berger J, 2002, ANNU REV MED, V53, P409, DOI 10.1146/annurev.med.53.082901.104018
   Brookes PS, 2004, AM J PHYSIOL-CELL PH, V287, pC817, DOI 10.1152/ajpcell.00139.2004
   Bruton JD, 2010, J PHYSIOL-LONDON, V588, P4275, DOI 10.1113/jphysiol.2010.198598
   Drummond GB, 2009, J PHYSIOL-LONDON, V587, P713, DOI 10.1113/jphysiol.2008.167387
   Edgar D, 2009, CELL METAB, V10, P131, DOI 10.1016/j.cmet.2009.06.010
   Esposito LA, 1999, P NATL ACAD SCI USA, V96, P4820, DOI 10.1073/pnas.96.9.4820
   Handschin C, 2006, ENDOCR REV, V27, P728, DOI 10.1210/er.2006-0037
   Hardie DG, 2011, P NUTR SOC, V70, P92, DOI 10.1017/S0029665110003915
   Hearn AS, 1999, J BIOL CHEM, V274, P24457, DOI 10.1074/jbc.274.35.24457
   Hiona A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011468
   HOLLOSZY JO, 1984, J APPL PHYSIOL, V56, P831, DOI 10.1152/jappl.1984.56.4.831
   KLEIN MG, 1991, J PHYSIOL-LONDON, V441, P639, DOI 10.1113/jphysiol.1991.sp018771
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   LANNERGREN J, 1991, J PHYSIOL-LONDON, V434, P307
   LANNERGREN J, 1987, J PHYSIOL-LONDON, V390, P285
   Larsson NG, 2001, ACTA PHYSIOL SCAND, V171, P385, DOI 10.1046/j.1365-201x.2001.00842.x
   LUFT R, 1962, J CLIN INVEST, V41, P1776, DOI 10.1172/JCI104637
   MCADAM ME, 1977, BIOCHEM J, V165, P81, DOI 10.1042/bj1650081
   Reisch AS, 2007, METHOD CELL BIOL, V80, P199, DOI 10.1016/S0091-679X(06)80010-5
   Ríos E, 2010, J PHYSIOL SCI, V60, P81, DOI 10.1007/s12576-009-0069-z
   Ristow M, 2009, P NATL ACAD SCI USA, V106, P8665, DOI 10.1073/pnas.0903485106
   Safdar A, 2011, P NATL ACAD SCI USA, V108, P4135, DOI 10.1073/pnas.1019581108
   Tarnopolsky MA, 2005, MED SCI SPORT EXER, V37, P2086, DOI 10.1249/01.mss.0000177341.89478.06
   Trifunovic A, 2005, P NATL ACAD SCI USA, V102, P17993, DOI 10.1073/pnas.0508886102
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Wallace DC, 2001, AM J MED GENET, V106, P71, DOI 10.1002/ajmg.1393
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Wenz T, 2009, J APPL PHYSIOL, V106, P1712, DOI 10.1152/japplphysiol.91571.2008
   WESTERBLAD H, 1994, J PHYSIOL-LONDON, V474, P291, DOI 10.1113/jphysiol.1994.sp020022
   WESTERBLAD H, 1991, J GEN PHYSIOL, V98, P615, DOI 10.1085/jgp.98.3.615
   Wredenberg A, 2002, P NATL ACAD SCI USA, V99, P15066, DOI 10.1073/pnas.232591499
   Wright DC, 2007, J BIOL CHEM, V282, P18793, DOI 10.1074/jbc.M611252200
   Zhang SJ, 2006, J PHYSIOL-LONDON, V572, P551, DOI 10.1113/jphysiol.2005.104521
NR 39
TC 25
Z9 30
U1 0
U2 20
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-3751
J9 J PHYSIOL-LONDON
JI J. Physiol.-London
PD DEC
PY 2012
VL 590
IS 23
BP 6187
EP 6197
DI 10.1113/jphysiol.2012.240077
PG 11
WC Neurosciences; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Physiology
GA 045LK
UT WOS:000311697100023
PM 22988144
OA Green Published
DA 2024-11-01
ER

PT J
AU Kleefeld, F
   Horvath, R
   Pinal-Fernandez, I
   Mammen, AL
   Casal-Dominguez, M
   Hathazi, D
   Melchert, S
   Hahn, K
   Sickmann, A
   Muselmann-Genschow, C
   Hentschel, A
   Preusse, C
   Roos, A
   Schoser, B
   Stenzel, W
AF Kleefeld, Felix
   Horvath, Rita
   Pinal-Fernandez, Iago
   Mammen, Andrew L.
   Casal-Dominguez, Maria
   Hathazi, Denisa
   Melchert, Sarah
   Hahn, Katrin
   Sickmann, Albert
   Muselmann-Genschow, Claudia
   Hentschel, Andreas
   Preusse, Corinna
   Roos, Andreas
   Schoser, Benedikt
   Stenzel, Werner
TI Multi-level profiling unravels mitochondrial dysfunction in myotonic
   dystrophy type 2
SO ACTA NEUROPATHOLOGICA
LA English
DT Article
DE Myotonic dystrophy type 2; Proximal myotonic myopathy; Mitochondrial
   dysfunction
ID MUTATION; TACO1; DELETIONS; MYOPATHY
AB Myotonic dystrophy type 2 (DM2) is an autosomal-dominant multisystemic disease with a core manifestation of proximal muscle weakness, muscle atrophy, myotonia, and myalgia. The disease-causing CCTG tetranucleotide expansion within the CNBP gene on chromosome 3 leads to an RNA-dominated spliceopathy, which is currently untreatable. Research exploring the pathophysiological mechanisms in myotonic dystrophy type 1 has resulted in new insights into disease mechanisms and identified mitochondrial dysfunction as a promising therapeutic target. It remains unclear whether similar mechanisms underlie DM2 and, if so, whether these might also serve as potential therapeutic targets. In this cross-sectional study, we studied DM2 skeletal muscle biopsy specimens on proteomic, molecular, and morphological, including ultrastructural levels in two separate patient cohorts consisting of 8 (explorative cohort) and 40 (confirmatory cohort) patients. Seven muscle biopsy specimens from four female and three male DM2 patients underwent proteomic analysis and respiratory chain enzymology. We performed bulk RNA sequencing, immunoblotting of respiratory chain complexes, mitochondrial DNA copy number determination, and long-range PCR (LR-PCR) to study mitochondrial DNA deletions on six biopsies. Proteomic and transcriptomic analyses revealed a downregulation of essential mitochondrial proteins and their respective RNA transcripts, namely of subunits of respiratory chain complexes I, III, and IV (e.g., mt-CO1, mt-ND1, mt-CYB, NDUFB6) and associated translation factors (TACO1). Light microscopy showed mitochondrial abnormalities (e.g., an age-inappropriate amount of COX-deficient fibers, subsarcolemmal accumulation) in most biopsy specimens. Electron microscopy revealed widespread ultrastructural mitochondrial abnormalities, including dysmorphic mitochondria with paracrystalline inclusions. Immunofluorescence studies with co-localization of autophagy (p62, LC-3) and mitochondrial marker proteins (TOM20, COX-IV), as well as immunohistochemistry for mitophagy marker BNIP3 indicated impaired mitophagic flux. Immunoblotting and LR-PCR did not reveal significant differences between patients and controls. In contrast, mtDNA copy number measurement showed a reduction of mtDNA copy numbers in the patient group compared to controls. This first multi-level study of DM2 unravels thus far undescribed functional and structural mitochondrial abnormalities. However, the molecular link between the tetranucleotide expansion and mitochondrial dysfunction needs to be further elucidated.
C1 [Kleefeld, Felix; Melchert, Sarah; Hahn, Katrin] Charite Univ Med Berlin, Dept Neurol, Charitepl 1, D-10117 Berlin, Germany.
   [Kleefeld, Felix; Hahn, Katrin; Muselmann-Genschow, Claudia; Preusse, Corinna; Stenzel, Werner] Free Univ Berlin, Humboldt Univ Berlin, BIH, Charitepl 1, D-10117 Berlin, Germany.
   [Horvath, Rita; Hathazi, Denisa] Univ Cambridge, Dept Clin Neurosci, Cambridge, England.
   [Pinal-Fernandez, Iago; Mammen, Andrew L.; Casal-Dominguez, Maria] NIAMSD, Muscle Dis Unit, NIH, Bethesda, MD 20892 USA.
   [Pinal-Fernandez, Iago; Mammen, Andrew L.; Casal-Dominguez, Maria] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA.
   [Melchert, Sarah] Free Univ Berlin, Humboldt Univ Berlin, Charitepl 1, D-10117 Berlin, Germany.
   [Sickmann, Albert; Hentschel, Andreas] Leibniz Inst Analyt Wissensch ISAS eV, D-44139 Dortmund, Germany.
   [Muselmann-Genschow, Claudia; Preusse, Corinna; Stenzel, Werner] Charite Univ Med Berlin, Dept Neuropathol, Charitepl 1, D-10117 Berlin, Germany.
   [Preusse, Corinna] Charite Univ Med Berlin, Dept Neuropediat, Augustenburger Pl 1, D-13353 Berlin, Germany.
   [Preusse, Corinna] Humboldt Univ, Freie Univ Berlin, BIH, Augustenburger Pl 1, D-13353 Berlin, Germany.
   [Roos, Andreas] Univ Duisburg Essen, Univ Childrens Hosp, Pediat Neurol, Fac Med, Essen, Germany.
   [Roos, Andreas] Univ Ottawa, Childrens Hosp Eastern Ontario, Res Inst, Ottawa, ON K1H 8L1, Canada.
   [Schoser, Benedikt] Ludwig Maximilians Univ Munchen, Friedrich Baur Inst, Dept Neurol, Munich, Germany.
C3 Berlin Institute of Health; Berlin Institute of Health; Free University
   of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin
   Berlin; Berlin Institute of Health; Berlin Institute of Health; Free
   University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin; University of Cambridge; National Institutes
   of Health (NIH) - USA; NIH National Institute of Arthritis &
   Musculoskeletal & Skin Diseases (NIAMS); Johns Hopkins University;
   Berlin Institute of Health; Berlin Institute of Health; Free University
   of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin
   Berlin; Dortmund University of Technology; Leibniz Institut fur
   Analytische Wissenschaften (ISAS); Berlin Institute of Health; Berlin
   Institute of Health; Free University of Berlin; Humboldt University of
   Berlin; Charite Universitatsmedizin Berlin; Berlin Institute of Health;
   Berlin Institute of Health; Free University of Berlin; Humboldt
   University of Berlin; Charite Universitatsmedizin Berlin; Humboldt
   University of Berlin; Berlin Institute of Health; Berlin Institute of
   Health; Free University of Berlin; University of Duisburg Essen;
   University of Ottawa; Children's Hospital of Eastern Ontario; University
   of Munich
RP Stenzel, W (corresponding author), Charite Univ Med Berlin, Dept Neuropathol, Charitepl 1, D-10117 Berlin, Germany.
EM Werner.Stenzel@charite.de
RI Inerbaev, Talgat/AAB-7633-2020
OI Stenzel, Werner/0000-0002-1143-2103; Hahn, Katrin/0000-0002-6013-0072;
   Preusse, Corinna/0000-0002-5494-8150; Kleefeld,
   Felix/0000-0002-0643-7313
FU Deutsche Gesellschaft fuer Muskelkranke e.V. [KI 3/2]
FX This study was supported by a research grant from Deutsche Gesellschaft
   fuer Muskelkranke e.V. (grant number KI 3/2).
CR Chartier A, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005092
   Chen T, 2011, J HUM GENET, V56, P689, DOI 10.1038/jhg.2011.97
   FISCHER JC, 1986, EUR J PEDIATR, V144, P441, DOI 10.1007/BF00441735
   García-Puga M, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23052901
   García-Puga M, 2020, AGING-US, V12, P6260, DOI 10.18632/aging.103022
   Gramegna LL, 2018, NEUROMUSCULAR DISORD, V28, P144, DOI 10.1016/j.nmd.2017.10.007
   Gu X, 2021, STAR PROTOC, V2, DOI 10.1016/j.xpro.2020.100245
   Hathazi D, 2020, EMBO J, V39, DOI 10.15252/embj.2020105364
   Horváth R, 2003, J MED GENET, V40, P752, DOI 10.1136/jmg.40.10.752
   Johnson NE, 2021, NEUROLOGY, V96, pE1045, DOI 10.1212/WNL.0000000000011425
   Koehorst E, 2020, J CLIN MED, V9, DOI 10.3390/jcm9123939
   Li Y, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419-021-04469-y
   Meola Giovanni, 2020, Acta Myol, V39, P222, DOI 10.36185/2532-1900-026
   Nguyen CDL, 2023, J NEUROL, V270, P3138, DOI 10.1007/s00415-023-11633-1
   Oktay Y, 2020, J NEUROMUSCULAR DIS, V7, P301, DOI 10.3233/JND-200510
   Ophuis RJAO, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008024
   Pinal-Fernandez I, 2020, ANN RHEUM DIS, V79, P1234, DOI 10.1136/annrheumdis-2019-216599
   Preusse C, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0308-5
   Preusse C, 2012, AM J PATHOL, V181, P2161, DOI 10.1016/j.ajpath.2012.08.033
   Rusconi F, 2010, NEUROBIOL DIS, V38, P273, DOI 10.1016/j.nbd.2010.01.017
   SAHASHI K, 1992, GERONTOLOGY, V38, P18
   Seeger J, 2010, NEUROMUSCULAR DISORD, V20, P720, DOI 10.1016/j.nmd.2010.06.017
   Suominen T, 2011, EUR J HUM GENET, V19, P776, DOI 10.1038/ejhg.2011.23
   Todorow V, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22168607
   Udd B, 2019, NEUROMUSCULAR DISORD, V29, P483, DOI 10.1016/j.nmd.2019.03.002
   Weraarpachai W, 2009, NAT GENET, V41, P833, DOI 10.1038/ng.390
   Wong KT, 1996, NEUROMUSCULAR DISORD, V6, P163, DOI 10.1016/0960-8966(95)00039-9
   Yamada T, 2019, AUTOPHAGY, V15, P2012, DOI 10.1080/15548627.2019.1643185
NR 28
TC 2
Z9 2
U1 4
U2 6
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0001-6322
EI 1432-0533
J9 ACTA NEUROPATHOL
JI Acta Neuropathol.
PD JUN
PY 2024
VL 147
IS 1
AR 19
DI 10.1007/s00401-023-02673-y
PG 12
WC Clinical Neurology; Neurosciences; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pathology
GA FL3Q7
UT WOS:001145910400002
PM 38240888
OA Green Published, hybrid
DA 2024-11-01
ER

PT J
AU Kazakos, K
   Kotsa, K
   Yavropoulou, M
   Dionyssopoulos, A
   Grabs, R
   Yovos, J
   Polychronakos, C
AF Kazakos, Kyriakos
   Kotsa, Kalliopi
   Yavropoulou, Maria
   Dionyssopoulos, Alexander
   Grabs, Rosemary
   Yovos, John
   Polychronakos, Constantin
TI Familial Clustering Strongly Suggests that the Phenotypic Variation of
   the 8344 A&gt;G Lys Mitochondrial tRNA Mutation is Encoded in cis
SO ANNALS OF HUMAN GENETICS
LA English
DT Article
DE Diabetes; lipomatosis; lysine tRNA; mitochondrial; myopathy; MERRF
ID MULTIPLE SYMMETRIC LIPOMATOSIS; DNA MUTATION; REPLICATION; MERRF; MTDNA
AB The maternally inherited 8344 A>G mutation in the mitochondrial Lys tRNA is classically associated with the myoclonic epilepsy, ragged-red muscle fiber (MERRF) syndrome. Multiple lipomatosis (Madelung's disease) is occasionally described. Here we report a large kindred with a statistically significant clustering of very unusual clinical manifestations. We have studied a Greek family that includes seven symptomatic cases of 8344 A>G. Clinical features, glucose tolerance and heteroplasmy in fat, muscle and blood were analyzed. The patients, aged 3476 at the time of assessment, all suffer from progressive proximal limb-girdle myopathy and extensive lipomatosis. Four of the seven have either impaired glucose tolerance or diabetes but none has had epilepsy, a cardinal feature of MERRF. Heteroplasmy was not higher in adipose tissue than that found in the literature. Compared to literature reports, the familial clustering of this unusual combination of manifestations (lipomatosis in all, epilepsy in none) is statistically significant. The clustering of unusual manifestations in this large kindred strongly suggests that much of the phenotypic variability of 8344 A>G is determined by mitochondrially encoded modifiers in cis.
C1 [Grabs, Rosemary; Polychronakos, Constantin] McGill Univ, Ctr Hlth, Endocrine Genet Lab, Dept Pediat, Montreal, PQ H3H 1P3, Canada.
   [Kazakos, Kyriakos; Kotsa, Kalliopi; Yavropoulou, Maria; Yovos, John] Aristotle Univ Thessaloniki, Dept Med 1, Ctr Diabet, AHEPA Hosp, GR-54006 Thessaloniki, Greece.
   [Dionyssopoulos, Alexander] Aristotle Univ Thessaloniki, Fac Med, Papageorgiou Hosp, Dept Plast Surg, GR-54006 Thessaloniki, Greece.
C3 McGill University; Aristotle University of Thessaloniki; Ahepa
   University Hospital; Papageorgiou Hospital; Aristotle University of
   Thessaloniki
RP Polychronakos, C (corresponding author), McGill Univ, Ctr Hlth, Endocrine Genet Lab, Dept Pediat, 2300 Tupper St, Montreal, PQ H3H 1P3, Canada.
EM constantin.polychronakos@mcgill.ca
RI Kotsa, Kalliopi/K-8638-2019; Yavropoulou, Maria/AAW-8768-2020;
   Polychronakos, Constantin/B-8151-2008; Dionyssopoulos,
   Alexandre/B-9033-2009
OI Polychronakos, Constantin/0000-0002-7624-6635
FU McGill Department of Paediatrics
FX We thank the patients and family members for their willingness to
   cooperate with this investigation and permission to publish their
   pictures. CP is supported by a Sessenwein award from the McGill
   Department of Paediatrics.
CR Andreu AL, 2003, J NEUROL, V250, P1403, DOI 10.1007/s00415-003-0281-3
   Auré K, 2003, REV NEUROL-FRANCE, V159, P1163
   Austin SA, 1998, NEUROLOGY, V51, P1447, DOI 10.1212/WNL.51.5.1447
   Battersby BJ, 2003, NAT GENET, V33, P183, DOI 10.1038/ng1073
   Battersby BJ, 2001, HUM MOL GENET, V10, P2469, DOI 10.1093/hmg/10.22.2469
   Campos Y, 1996, NEUROLOGY, V47, P1012, DOI 10.1212/WNL.47.4.1012
   Gámez J, 1998, NEUROLOGY, V51, P258, DOI 10.1212/WNL.51.1.258
   KLOPSTOCK T, 1994, NEUROLOGY, V44, P862, DOI 10.1212/WNL.44.5.862
   VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368
   Wai T, 2008, NAT GENET, V40, P1484, DOI 10.1038/ng.258
   WALLACE DC, 1988, CELL, V55, P601, DOI 10.1016/0092-8674(88)90218-8
   WILSON MR, 1995, INT J LEGAL MED, V108, P68, DOI 10.1007/BF01369907
   ZEVIANI M, 1991, AM J HUM GENET, V48, P203
NR 13
TC 8
Z9 8
U1 0
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0003-4800
J9 ANN HUM GENET
JI Ann. Hum. Genet.
PD JUL
PY 2012
VL 76
BP 296
EP 300
DI 10.1111/j.1469-1809.2012.00711.x
PN 4
PG 5
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 956EH
UT WOS:000305072200004
PM 22681518
DA 2024-11-01
ER

PT J
AU Toncheva, D
   Serbezov, D
   Karachanak-Yankova, S
   Nesheva, D
AF Toncheva, Draga
   Serbezov, Dimitar
   Karachanak-Yankova, Sena
   Nesheva, Desislava
TI Ancient mitochondrial DNA pathogenic variants putatively associated with
   mitochondrial disease
SO PLOS ONE
LA English
DT Article
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; RESPIRATORY-CHAIN DEFICIENCY;
   POINT MUTATION; MYOCLONIC EPILEPSY; SEQUENCE VARIATION;
   DIABETES-MELLITUS; TRNA(ASN) GENE; TRNA(LYS); MYOPATHY; PREVALENCE
AB Mitochondrial DNA variants associated with diseases are widely studied in contemporary populations, but their prevalence has not yet been investigated in ancient populations. The publicly available AmtDB database contains 1443 ancient mtDNA Eurasian genomes from different periods. The objective of this study was to use this data to establish the presence of pathogenic mtDNA variants putatively associated with mitochondrial diseases in ancient populations. The clinical significance, pathogenicity prediction and contemporary frequency of mtDNA variants were determined using online platforms. The analyzed ancient mtDNAs contain six variants designated as being "confirmed pathogenic" in modern patients. The oldest of these, m.7510T>C in theMT-TS1gene, was found in a sample from the Neolithic period, dated 5800-5400 BCE. All six have well established clinical association, and their pathogenic effect is corroborated by very low population frequencies in contemporary populations. Analysis of the geographic location of the ancient samples, contemporary epidemiological trends and probable haplogroup association indicate diverse spatiotemporal dynamics of these variants. The dynamics in the prevalence and distribution is conceivably result ofde novomutations or human migrations and subsequent evolutionary processes. In addition, ten variants designated as possibly or likely pathogenic were found, but the clinical effect of these is not yet well established and further research is warranted. All detected mutations putatively associated with mitochondrial disease in ancient mtDNA samples are in tRNA coding genes. Most of these mutations are in a mt-tRNA type (Model 2) that is characterized by loss of D-loop/T-loop interaction. Exposing pathogenic variants in ancient human populations expands our understanding of their origin and prevalence dynamics.
C1 [Toncheva, Draga; Serbezov, Dimitar; Karachanak-Yankova, Sena; Nesheva, Desislava] Med Univ Sofia, Bulgarian Acad Sci, Dept Med Genet, Sofia, Bulgaria.
   [Toncheva, Draga] Bulgarian Acad Sci BAS, Sofia, Bulgaria.
   [Karachanak-Yankova, Sena] Sofia Univ St Kliment Ohridski, Dept Genet, Fac Biol, Sofia, Bulgaria.
C3 Bulgarian Academy of Sciences; Medical University Sofia; Bulgarian
   Academy of Sciences; University of Sofia
RP Toncheva, D (corresponding author), Med Univ Sofia, Bulgarian Acad Sci, Dept Med Genet, Sofia, Bulgaria.; Toncheva, D (corresponding author), Bulgarian Acad Sci BAS, Sofia, Bulgaria.
EM dragatoncheva@gmail.com
RI Serbezov, Dimitar/LCD-9270-2024; Karachanak-Yankova, Sena/HTT-2442-2023
OI Nesheva, Desislava/0000-0002-8574-8477; Karachanak-Yankova,
   Sena/0000-0001-6441-629X
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   [Anonymous], 2013, J SOC PHILOS, V44, P1
   [Anonymous], 2007, ORAL SURG ORAL MED O
   Behar DM, 2012, AM J HUM GENET, V90, P675, DOI 10.1016/j.ajhg.2012.03.002
   Berens AJ, 2017, HUM BIOL, V89, P7, DOI 10.13110/humanbiology.89.1.01
   Binder M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090924
   Blakely EL, 2007, J NEUROL, V254, P1283, DOI 10.1007/s00415-006-0490-7
   Blakely EL, 2013, HUM MUTAT, V34, P1260, DOI 10.1002/humu.22358
   Brandon MC, 2009, HUM MUTAT, V30, P1, DOI 10.1002/humu.20801
   Broushaki F, 2016, SCIENCE, V353, P499, DOI 10.1126/science.aaf7943
   Caporali L, 2017, MITOCHONDRION, V36, P130, DOI 10.1016/j.mito.2017.07.004
   Clark K, 2016, NUCLEIC ACIDS RES, V44, pD67, DOI 10.1093/nar/gkv1276
   Damgaard PD, 2018, NATURE, V557, P369, DOI 10.1038/s41586-018-0094-2
   de Laat P, 2016, BBA CLIN, V6, P19, DOI 10.1016/j.bbacli.2016.04.007
   del Castillo F J, 2002, J Med Genet, V39, pe82, DOI 10.1136/jmg.39.12.e82
   Derenko M, 2014, BMC EVOL BIOL, V14, DOI 10.1186/s12862-014-0217-9
   Diroma MA, 2016, BMC BIOINFORMATICS, V17, DOI 10.1186/s12859-016-1193-4
   Edward JO, 2016, S AFRICAN J SCI, V112
   Entezami P, 2011, HAND CLIN, V27, P1, DOI 10.1016/j.hcl.2010.09.006
   Finnilä S, 2001, J MOL MED, V79, P641, DOI 10.1007/s001090100268
   Finsterer J, 2019, CHINESE MED J-PEKING, V132, P1752, DOI 10.1097/CM9.0000000000000337
   Fu J, 2019, CHINESE MED J-PEKING, V132, P865, DOI 10.1097/CM9.0000000000000151
   Gamba J, 2012, J NEUROL SCI, V320, P131, DOI 10.1016/j.jns.2012.05.037
   Ghelli A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007922
   Gilbert MTP, 2006, NUCL ACID M, V18, P91
   Gill JS, 2017, BRIT J OPHTHALMOL, V101, P1298, DOI 10.1136/bjophthalmol-2017-310370
   González-Vioque E, 2014, MOL GENET GENOM MED, V2, P107, DOI 10.1002/mgg3.47
   Gorman GS, 2015, ANN NEUROL, V77, P753, DOI 10.1002/ana.24362
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Horváth R, 2003, J MED GENET, V40, P752, DOI 10.1136/jmg.40.10.752
   Horvath R, 2010, NEUROMUSCULAR DISORD, V20, pS25, DOI 10.1016/S0960-8966(10)70090-0
   Horvath R, 2009, BRAIN, V132, P3165, DOI 10.1093/brain/awp221
   Hutchin TP, 2000, J MED GENET, V37, P692, DOI 10.1136/jmg.37.9.692
   Jeppesen TD, 2003, ANN NEUROL, V54, P86, DOI 10.1002/ana.10594
   Jeppesen TD, 2014, NEUROMUSCULAR DISORD, V24, P162, DOI 10.1016/j.nmd.2013.08.004
   Juras A, 2017, SCI REP-UK, V7, DOI 10.1038/srep43950
   Kameoka K, 1998, BIOCHEM BIOPH RES CO, V245, P523, DOI 10.1006/bbrc.1998.8437
   Kaufmann P, 2011, NEUROLOGY, V77, P1965, DOI 10.1212/WNL.0b013e31823a0c7f
   Knipper C., 2017, P NATL ACAD SCI
   Komlosi K, 2012, JIMD REPORTS CASE RE, P105
   Kong QP, 2003, AM J HUM GENET, V73, P671, DOI 10.1086/377718
   Kytövuori L, 2017, BRAIN BEHAV, V7, DOI 10.1002/brb3.859
   Labay V, 2008, CLIN GENET, V73, P50, DOI 10.1111/j.1399-0004.2007.00925.x
   Landrum MJ, 2014, NUCLEIC ACIDS RES, V42, pD980, DOI 10.1093/nar/gkt1113
   Langdahl JH, 2018, CLIN GENET, V93, P925, DOI 10.1111/cge.13201
   Lehmann D, 2015, EUR J HUM GENET, V23, P1735, DOI 10.1038/ejhg.2015.73
   Lehmann D, 2015, NEUROMUSCULAR DISORD, V25, P81, DOI 10.1016/j.nmd.2014.09.008
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   Mancuso M, 2014, J NEUROL, V261, P504, DOI 10.1007/s00415-013-7225-3
   MANOUVRIER S, 1995, J MED GENET, V32, P654, DOI 10.1136/jmg.32.8.654
   Manwaring N, 2007, MITOCHONDRION, V7, P230, DOI 10.1016/j.mito.2006.12.004
   Martín-Jiménez R, 2012, MITOCHONDRION, V12, P288, DOI 10.1016/j.mito.2011.10.004
   Mathieson I, 2018, NATURE, V555, P197, DOI 10.1038/nature25778
   McFarland R, 2008, NEUROMUSCULAR DISORD, V18, P63, DOI 10.1016/j.nmd.2007.07.007
   Mimaki M, 2010, ANN NEUROL, V68, P845, DOI 10.1002/ana.22111
   Mitchell AL, 2006, J MED GENET, V43, P175, DOI 10.1136/jmg.2005.032474
   Modi A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41945-0
   Monge J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064539
   MONTAGNA P, 1988, HEADACHE, V28, P477, DOI 10.1111/j.1526-4610.1988.hed2807477.x
   MORAES CT, 1993, J CLIN INVEST, V92, P2906, DOI 10.1172/JCI116913
   MORAES CT, 1993, NEUROMUSCULAR DISORD, V3, P43, DOI 10.1016/0960-8966(93)90040-Q
   Murphy WA, 2003, RADIOLOGY, V226, P614, DOI 10.1148/radiol.2263020338
   Niedermayr K, 2018, CONGENIT HEART DIS, V13, P671, DOI 10.1111/chd.12634
   Nishino I, 1996, BIOCHEM BIOPH RES CO, V225, P180, DOI 10.1006/bbrc.1996.1150
   Odes EJ, 2016, S AFR J SCI, V112, P100
   Olivieri A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070492
   Pala M, 2012, AM J HUM GENET, V90, P915, DOI 10.1016/j.ajhg.2012.04.003
   Pickett SJ, 2018, ANN CLIN TRANSL NEUR, V5, P333, DOI 10.1002/acn3.532
   Sacconi S, 2008, HUM MOL GENET, V17, P1814, DOI 10.1093/hmg/ddn073
   Sangatsuda Y, 2012, MITOCHONDRION, V12, P617, DOI 10.1016/j.mito.2012.10.002
   Scarpelli M, 2018, NEUROMUSCULAR DISORD, V28, P137, DOI 10.1016/j.nmd.2017.10.006
   Schaefer AM, 2008, ANN NEUROL, V63, P35, DOI 10.1002/ana.21217
   Schroeder H, 2019, P NATL ACAD SCI USA, V116, P10705, DOI 10.1073/pnas.1820210116
   Shtilbans A, 1999, J CHILD NEUROL, V14, P610, DOI 10.1177/088307389901400910
   Sonney S, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005867
   Souilem S, 2011, J NEUROL SCI, V300, P187, DOI 10.1016/j.jns.2010.08.065
   Spagnolo M, 2001, NEUROMUSCULAR DISORD, V11, P481, DOI 10.1016/S0960-8966(01)00195-X
   Stolarek I, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-20705-6
   Suzuki S, 1998, DIABETOLOGIA, V41, P584, DOI 10.1007/s001250050950
   Tarnopolsky MA, 2019, MITOCHONDRION, V46, P69, DOI 10.1016/j.mito.2018.02.008
   The UniProt C, 2018, NUCLEIC ACIDS RES, V47, pD506
   The UniProt C, 2018, NUCLEIC ACIDS RES, V47, pD506
   Tiranti V, 1999, NEUROMUSCULAR DISORD, V9, P66, DOI 10.1016/S0960-8966(98)00103-5
   Tranah GJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30255-6
   Usami S., 1993, GeneReviews
   Uusimaa J, 2011, J MED GENET, V48, P660, DOI 10.1136/jmg.2011.089995
   VANDENOUWELAND JMW, 1994, DIABETES, V43, P746, DOI 10.2337/diabetes.43.6.746
   Vives-Bauza C, 2003, J INHERIT METAB DIS, V26, P507, DOI 10.1023/A:1025133629685
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   Wallace DC, 2010, ENVIRON MOL MUTAGEN, V51, P440, DOI 10.1002/em.20586
   Wei W, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1007126
   Wibrand F, 2010, MUSCLE NERVE, V41, P607, DOI 10.1002/mus.21541
   Wong LJC, 2007, MUSCLE NERVE, V36, P279, DOI 10.1002/mus.20807
   Yarham JW, 2011, HUM MUTAT, V32, P1319, DOI 10.1002/humu.21575
NR 94
TC 5
Z9 6
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 24
PY 2020
VL 15
IS 9
AR e0233666
DI 10.1371/journal.pone.0233666
PG 16
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA NY2ZZ
UT WOS:000576265600050
PM 32970680
OA Green Submitted, Green Published, gold
DA 2024-11-01
ER

PT J
AU Murphy, JL
   Ratnaike, TE
   Shang, ES
   Falkous, G
   Blakely, EL
   Alston, CL
   Taivassalo, T
   Haller, RG
   Taylor, RW
   Turnbull, DM
AF Murphy, Julie L.
   Ratnaike, Thiloka E.
   Shang, Ersong
   Falkous, Gavin
   Blakely, Emma L.
   Alston, Charlotte L.
   Taivassalo, Tanja
   Haller, Ronald G.
   Taylor, Robert W.
   Turnbull, Doug M.
TI Cytochrome <i>c</i> oxidase-intermediate fibres: Importance in
   understanding the pathogenesis and treatment of mitochondrial myopathy
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE Mitochondrial myopathy; mtDNA; cytochrome c oxidase; enzyme
   histochemistry
ID REAL-TIME PCR; DNA MUTATIONS; INDIVIDUAL CELLS; MUSCLE-FIBERS;
   DELETIONS; DISEASE; SINGLE; DEFICIENCY; DIAGNOSIS
AB An important diagnostic muscle biopsy finding in patients with mitochondrial DNA disease is the presence of respiratory-chain deficient fibres. These fibres are detected as cytochrome c oxidase-deficient following a sequential cytochrome c oxidase-succinate dehydrogenase reaction, often in a mosaic pattern within a population of cytochrome c oxidase-normal fibres. Detailed analysis of muscle biopsies from patients with various mitochondrial DNA defects shows that a spectrum of deficiency exists, as there are a large number of fibres which do not correspond to being either completely cytochrome c oxidase-normal (brown staining) or cytochrome c oxidase-deficient (blue staining). We have used a combination of histochemical and immunocytochemical techniques to show that a population of cytochrome c oxidase-intermediate reacting fibres are a gradation between normal and deficient fibres. We show that cytochrome c oxidase-intermediate fibres also have different genetic characteristics in terms of amount of mutated and wild-type mtDNA, and as such, may represent an important transition between respiratory normal and deficient fibres. Assessing changes in intermediate fibres will be crucial to evaluating the responses to treatment and in particular to exercise training regimes in patients with mitochondrial DNA disease. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Turnbull, Doug M.] Newcastle Univ, Mitochondrial Res Grp, Inst Ageing & Hlth, Wellcome Trust Ctr Mitochondrial Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Taivassalo, Tanja] McGill Univ, Dept Kinesiol, Montreal, PQ, Canada.
   [Taivassalo, Tanja] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada.
   [Haller, Ronald G.] Texas Hlth Presbyterian Hosp, Neuromuscular Ctr, Inst Exercise & Environm Med, Dallas, TX USA.
   [Haller, Ronald G.] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA.
C3 Newcastle University - UK; McGill University; McGill University;
   University of Texas System; University of Texas Southwestern Medical
   Center Dallas
RP Turnbull, DM (corresponding author), Newcastle Univ, Mitochondrial Res Grp, Inst Ageing & Hlth, Wellcome Trust Ctr Mitochondrial Res, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM doug.turnbull@newcastle.ac.uk
RI Ratnaike, Thiloka/GNM-9569-2022; Alston, Charlotte/ABG-9602-2020
OI Ratnaike, Thiloka/0000-0001-5400-104X; Turnbull,
   Doug/0000-0002-8878-9901; Alston, Charlotte/0000-0003-2095-5464
FU Muscular Dystrophy Campaign, Newcastle University Centre for Brain
   Ageing and Vitality; BBSRC; EPSRC; ESRC; MRC as part of cross-council
   Lifelong Health; Wellbeing Initiative [G0700718]; MRC Mitochondrial
   Disease Cohort Study; Wellcome Trust Centre for Mitochondrial Research
   [906919]; UK NIHR Biomedical Research Centre for Ageing and Age-related
   disease; UK NHS Highly Specialised Services Commissioners; National
   Institutes of Health (National Institute of Arthritis, Musculoskeletal
   and Skin Diseases, NIAMS), USA [RO1-AR050597]; MRC [MC_G0802536,
   G0800674, G0700718] Funding Source: UKRI
FX This work was supported by the The Muscular Dystrophy Campaign,
   Newcastle University Centre for Brain Ageing and Vitality supported by
   BBSRC, EPSRC, ESRC and MRC as part of the cross-council Lifelong Health
   and Wellbeing Initiative (G0700718), MRC Mitochondrial Disease Cohort
   Study, The Wellcome Trust Centre for Mitochondrial Research (906919), UK
   NIHR Biomedical Research Centre for Ageing and Age-related disease award
   to the Newcastle upon Tyne Hospitals NHS Foundation Trust, the UK NHS
   Highly Specialised Services Commissioners which funds the "Rare
   Mitochondrial Disorders of Adults and Children" Diagnostic Service in
   Newcastle upon Tyne (http://www.mitochondrialncg.nhs.uk) and by the
   National Institutes of Health (National Institute of Arthritis,
   Musculoskeletal and Skin Diseases, NIAMS, RO1-AR050597), USA.
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andrews H, 2006, J NEUROSCI RES, V83, P1533, DOI 10.1002/jnr.20842
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   BROOKE MH, 1970, ARCH NEUROL-CHICAGO, V23, P369, DOI 10.1001/archneur.1970.00480280083010
   Capaldi RA, 2004, MITOCHONDRION, V4, P417, DOI 10.1016/j.mito.2004.07.006
   Durham SE, 2005, NEUROLOGY, V65, P453, DOI 10.1212/01.wnl.0000171861.30277.88
   Durham SE, 2007, AM J HUM GENET, V81, P189, DOI 10.1086/518901
   Elson JL, 2002, NEUROMUSCULAR DISORD, V12, P858, DOI 10.1016/S0960-8966(02)00047-0
   Greaves L.C., 2011, J Pathol
   Greaves LC, 2010, INVEST OPHTH VIS SCI, V51, P3340, DOI 10.1167/iovs.09-4659
   He LP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf067
   JACKSON MJ, 1995, BRAIN, V118, P339, DOI 10.1093/brain/118.2.339
   JOHNSON MA, 1993, ANN NEUROL, V33, P28, DOI 10.1002/ana.410330106
   JOHNSON MA, 1983, J NEUROL SCI, V60, P31, DOI 10.1016/0022-510X(83)90125-9
   Krishnan KJ, 2007, ANAL BIOCHEM, V370, P127, DOI 10.1016/j.ab.2007.06.024
   Murphy JL, 2008, BRAIN, V131, P2832, DOI 10.1093/brain/awn252
   Perales-Clemente E, 2010, MOL CELL BIOL, V30, P3038, DOI 10.1128/MCB.00025-10
   Sciacco M, 1996, Methods Enzymol, V264, P509, DOI 10.1016/S0076-6879(96)64045-2
   Taivassalo T, 2001, ANN NEUROL, V50, P133, DOI 10.1002/ana.1050
   Taivassalo T, 2006, BRAIN, V129, P3391, DOI 10.1093/brain/awl282
   Taylor RW, 2003, J CLIN INVEST, V112, P1351, DOI 10.1172/JCI200319435
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
NR 23
TC 37
Z9 41
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD AUG
PY 2012
VL 22
IS 8
BP 690
EP 698
DI 10.1016/j.nmd.2012.04.003
PG 9
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 990GV
UT WOS:000307619900003
PM 22647770
OA hybrid, Green Published
DA 2024-11-01
ER

PT J
AU Mancuso, M
   Filosto, M
   Choub, A
   Tentorio, M
   Broglio, L
   Padovani, A
   Siciliano, G
AF Mancuso, Michelangelo
   Filosto, Massimiliano
   Choub, Anna
   Tentorio, Marta
   Broglio, Laura
   Padovani, Alessandro
   Siciliano, Gabriele
TI Mitochondrial DNA-related disorders
SO BIOSCIENCE REPORTS
LA English
DT Article; Proceedings Paper
CT Conference on Mitochondrial Medicine
CY OCT 25, 2006
CL Univ Pisa, Dept Neurosci, Pisa, ITALY
HO Univ Pisa, Dept Neurosci
DE mitochondrial disease; mitochondrial DNA; MELAS; MERRF; PEO; Leber
ID EXTERNAL OPHTHALMOPLEGIA; PATERNAL INHERITANCE; MUTATION; GENE;
   DELETIONS
AB Mitochondrial diseases are a group of disorders due to a mitochondrial respiratory chain deficiency. They may depend on mitochondrial genome (mtDNA-related disorders) as well as on a nuclear genome defect (nDNA-related disorders). mtDNA-related disorders encompass an increasing number of clinical pictures associated with more than 250 different provisional or confirmed pathogenic changes in mtDNA. Although some clinical syndromes are nosologically defined, most of the cases present with polymorphous phenotypes ranging from pure myopathy to multi-system involvement. Complexity of mitochondrial genetics is in part responsible for the extreme clinical intra- and inter-familial heterogeneity of this group of diseases. In this review, we briefly report an updated classification and overview the main clinical pictures of this class of diseases.
C1 Univ Pisa, Dept Neurosci, I-56126 Pisa, Italy.
   Univ Hosp, Spedali Civili, Sect Neuromuscular Dis & Neuropathies, Brescia, Italy.
   Univ Verona, Dept Neurol Sci & Vis, Sect Clin Neurol, I-37100 Verona, Italy.
C3 University of Pisa; Hospital Spedali Civili Brescia; University of
   Verona
RP Mancuso, M (corresponding author), Univ Pisa, Dept Neurosci, Via Roma 67, I-56126 Pisa, Italy.
EM mmancuso@inwind.it
RI Padovani, Alessandro/ABI-7312-2020; Mancuso, Michelangelo/K-4170-2016;
   Filosto, Massimiliano/S-9446-2019
OI Filosto, Massimiliano/0000-0002-2852-7512; Padovani,
   Alessandro/0000-0002-0119-3639; mancuso,
   michelangelo/0000-0003-2738-8562
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   Carelli V, 2004, PROG RETIN EYE RES, V23, P53, DOI 10.1016/j.preteyeres.2003.10.003
   Chakrapani A, 1998, J INHERIT METAB DIS, V21, P685, DOI 10.1023/A:1005401121344
   Cock HR, 1998, ANN NEUROL, V44, P187, DOI 10.1002/ana.410440208
   DEVRIES DD, 1993, ANN NEUROL, V34, P410, DOI 10.1002/ana.410340319
   DiMauro S, 1999, J CHILD NEUROL, V14, pS23, DOI 10.1177/0883073899014001051
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   DiMauro S, 2002, ADV NEUROL, V89, P217
   DiMauro S, 2001, SEMIN NEUROL, V21, P251, DOI 10.1055/s-2001-17942
   Filosto M, 2003, ANN NEUROL, V54, P524, DOI 10.1002/ana.10709
   FILOSTO M, 2007, ACTA NEUROLO SCAND
   Gillis L, 2002, PEDIATR CLIN N AM, V49, P203, DOI 10.1016/S0031-3955(03)00115-9
   HIRANO M, 1992, NEUROMUSCULAR DISORD, V2, P125, DOI 10.1016/0960-8966(92)90045-8
   Hirano M., 1996, Handbook of Muscle Disease, P479
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   KEARNS TP, 1958, ARCH OPHTHALMOL-CHIC, V60, P280, DOI 10.1001/archopht.1958.00940080296016
   LYONS G, 1996, NEUROLOGY HEREDITARY, P92
   Mancuso M, 2004, NEUROLOGY, V62, P2119, DOI 10.1212/01.WNL.0000127608.48406.F1
   *MIT, 2006, HUM MIT GEN DAT
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   NAKASE H, 1990, AM J HUM GENET, V46, P418
   ROTIG A, 1992, AM J HUM GENET, V50, P364
   SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184
   SCHON EA, 1991, MOL GENETIC APPROACH, P57
   SCHON EA, 2001, MITOCHONDRIA PATHOGE, P53
   Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350
   Servidei Serenella, 2003, Neuromuscul Disord, V13, P848
   Shanske S, 2002, AM J HUM GENET, V71, P679, DOI 10.1086/342482
   Spagnolo M, 2001, NEUROMUSCULAR DISORD, V11, P481, DOI 10.1016/S0960-8966(01)00195-X
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
NR 31
TC 23
Z9 28
U1 0
U2 2
PU PORTLAND PRESS LTD
PI LONDON
PA 5TH FLR, 90 HIGH HOLBORN, LONDON WC1V 6LJ, ENGLAND
SN 0144-8463
EI 1573-4935
J9 BIOSCIENCE REP
JI Biosci. Rep.
PD JUN
PY 2007
VL 27
IS 1-3
BP 31
EP 37
DI 10.1007/s10540-007-9035-2
PG 7
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)
SC Biochemistry & Molecular Biology; Cell Biology
GA 178YM
UT WOS:000247256300005
PM 17484046
DA 2024-11-01
ER

PT J
AU Tzoulis, C
   Papingji, M
   Fiskestrand, T
   Roste, LS
   Bindoff, LA
AF Tzoulis, C.
   Papingji, M.
   Fiskestrand, T.
   Roste, L. S.
   Bindoff, L. A.
TI Mitochondrial DNA depletion in progressive external ophthalmoplegia
   caused by <i>POLG1</i> mutations
SO ACTA NEUROLOGICA SCANDINAVICA
LA English
DT Article
DE progressive external ophthalmoplegia; POLG; mtDNA; depletion
ID POLYMERASE-GAMMA MUTATIONS; DELETIONS; DISEASE; PARKINSONISM; SPECTRUM
AB Objectives - To investigate two patients with late onset, progressive external ophthalmoplegia (PEO) and sensory peripheral neuropathy. Materials & Methods - The patients aged 86 and 50 years were investigated clinically including magnetic resonance imaging of the brain, electrophysiological studies and, in one, skeletal muscle biopsy. Molecular studies included sequencing of the whole coding region of the POLG1 gene and mitochondrial DNA (mtDNA) analysis for deletions and depletion. Results - Both patients were compound heterozygous for gene encoding the catalytic subunit of the DNA-polymerase gamma (POLG1) mutations. One had the p.737R and p.W748S mutations while the other carried the p.T251I, p.P587L and p.W748S mutations. While these mutations have been previously described, these combinations are novel. mtDNA studies in skeletal muscle showed evidence of multiple deletions and approximately 64% depletion of the mitochondrial genome. Conclusion - Our findings broaden the genotypic spectrum of POLG-associated PEO and show that in addition to multiple deletions, mtDNA depletion occurs and may contribute to the pathogenesis of this disorder.
C1 [Tzoulis, C.; Papingji, M.; Bindoff, L. A.] Haukeland Hosp, Dept Neurol, N-5021 Bergen, Norway.
   [Tzoulis, C.; Bindoff, L. A.] Univ Bergen, Dept Clin Med, Bergen, Norway.
   [Fiskestrand, T.] Haukeland Hosp, Ctr Med Genet & Mol Med, N-5021 Bergen, Norway.
   [Roste, L. S.] Univ Hosp, Dept Neurol, Div Clin Neurosci, Rikshosp, Oslo, Norway.
C3 University of Bergen; Haukeland University Hospital; University of
   Bergen; University of Bergen; Haukeland University Hospital; University
   of Oslo; National Hospital Norway
RP Bindoff, LA (corresponding author), Haukeland Hosp, Dept Neurol, N-5021 Bergen, Norway.
EM laurence.bindoff@nevro.uib.no
RI Tzoulis, Charalampos/AGD-5114-2022
OI Tzoulis, Charalampos/0000-0003-0341-5191; Bindoff,
   Laurence/0000-0003-0988-276X
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Ashley N, 2008, HUM MOL GENET, V17, P2496, DOI 10.1093/hmg/ddn150
   Davidzon G, 2006, ANN NEUROL, V59, P859, DOI 10.1002/ana.20831
   Di Fonzo A, 2003, HUM MUTAT, V22, DOI 10.1002/humu.9203
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   González-Vioque E, 2006, ARCH NEUROL-CHICAGO, V63, P107, DOI 10.1001/archneur.63.1.107
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Hakonen AH, 2007, EUR J HUM GENET, V15, P779, DOI 10.1038/sj.ejhg.5201831
   Harrower T, 2008, ARCH NEUROL-CHICAGO, V65, P133, DOI 10.1001/archneurol.2007.4
   He LP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf067
   Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Kollberg G, 2006, J NEUROPATH EXP NEUR, V65, P758, DOI 10.1097/01.jnen.0000229987.17548.6e
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Pagnamenta AT, 2006, HUM REPROD, V21, P2467, DOI 10.1093/humrep/del076
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   Wong LJC, 2008, HUM MUTAT, V29, pE150, DOI 10.1002/humu.20824
NR 19
TC 13
Z9 13
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0001-6314
J9 ACTA NEUROL SCAND
JI Acta Neurol. Scand.
PD AUG
PY 2009
VL 120
SU 189
BP 38
EP 41
DI 10.1111/j.1600-0404.2009.01212.x
PG 4
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 463IK
UT WOS:000267425400008
PM 19566497
OA Green Submitted
DA 2024-11-01
ER

PT J
AU Panadés-de Oliveira, L
   Montoya, J
   Emperador, S
   Ruiz-Pesini, E
   Jericó, I
   Arenas, J
   Hernández-Lain, A
   Blázquez, A
   Martín, MA
   Domínguez-González, C
AF Panades-de Oliveira, Luisa
   Montoya, Julio
   Emperador, Sonia
   Ruiz-Pesini, Eduardo
   Jerico, Ivonne
   Arenas, Joaquin
   Hernandez-Lain, Aurelio
   Blazquez, Alberto
   Martin, Miguel A.
   Dominguez-Gonzalez, Cristina
TI A novel mutation in the mitochondrial <i>MT</i>-<i>ND5</i> gene in a
   family with MELAS. The relevance of genetic analysis on targeted tissues
SO MITOCHONDRION
LA English
DT Article
DE MELAS syndrome; MTND5 gene; Heteroplasmy; Urine sample; Muscle sample;
   Mitochondrial diseases
ID G13513A MUTATION; LACTIC-ACIDOSIS; LEIGH-SYNDROME; ND5 GENE; DNA;
   MYOPATHY; LOADS
AB We report the case of two members of the same family with a novel mitochondrial DNA (mtDNA) gene variant in the MT-ND5 gene associated with MELAS syndrome and discuss limitations of genetics studies. The m.13045A > G mutation was detected at very low load in the daughter's urine cells (5%) and at different levels in the skeletal muscle of both mother (50%) and daughter (84%), being absent in blood, hair and saliva.
   Our findings suggest that non-invasive genetic assessment in urine cells may not be a sensitive diagnostic method neither a good predictor of disease development in relatives of some families with mtDNA-associated MELAS, particularly if involving MT-ND5 gene.
C1 [Panades-de Oliveira, Luisa; Dominguez-Gonzalez, Cristina] Hosp Univ 12 Octubre, Dept Neurol, Madrid, Spain.
   [Montoya, Julio; Emperador, Sonia; Ruiz-Pesini, Eduardo; Arenas, Joaquin; Blazquez, Alberto; Martin, Miguel A.; Dominguez-Gonzalez, Cristina] Ctr Invest Biomed Red Enfermedades Raras CIBERER, Madrid, Spain.
   [Montoya, Julio; Emperador, Sonia; Ruiz-Pesini, Eduardo] Univ Zaragoza, Dept Biochem, Zaragoza, Spain.
   [Montoya, Julio; Emperador, Sonia; Ruiz-Pesini, Eduardo] IIS Aragon, Zaragoza, Spain.
   [Jerico, Ivonne] Complejo Hosp Navarra, IdisNa Navarra Inst Healthe Res, Dept Neurol, Navarra, Spain.
   [Arenas, Joaquin; Blazquez, Alberto; Martin, Miguel A.] Inst Invest Hosp 12 Octubre i12, Dept Biochem, Lab Mitochondrial Dis, Madrid, Spain.
   [Hernandez-Lain, Aurelio] Hosp Univ 12 Octubre, Dept Pathol Neuropathol, Madrid, Spain.
   [Dominguez-Gonzalez, Cristina] Hosp Univ 12 Octubre, Dept Neurol, Neuromuscular Disorders Unit, Madrid, Spain.
C3 Hospital Universitario 12 de Octubre; CIBER - Centro de Investigacion
   Biomedica en Red; CIBERER; University of Zaragoza; Servicio Navarro de
   Salud - Osasunbidea; Hospital Universitario 12 de Octubre; Hospital
   Universitario 12 de Octubre
RP Martín, MA (corresponding author), Hosp Univ 12 Octubre, Ave Cordoba S-N, Madrid, Spain.
EM jmontoya@unizar.es; seortiz@unizar.es; eduruiz@unizar.es;
   ijericop@cfnavarra.es; joaquin.arenas@salud.madrid.org;
   aurelio.hlain@salud.madrid.org; mamcasanueva.imas12@h12o.es;
   cdgonzalez@salud.madrid.org
RI Martin, Miguel/S-2758-2018; Encinar, Alberto/S-4425-2018; Martin, Miguel
   Angel/B-6261-2017
OI Panades-de Oliveira, Luisa/0000-0001-9736-764X; Dominguez,
   Cristina/0000-0001-5151-988X; Martin, Miguel Angel/0000-0003-4741-772X
FU Instituto de Salud Carlos III, Spain [PI18/01374, PI17/00021]; Comunidad
   de Madrid, Spain [B2017/BMD-3721]; Departamento de Ciencia, Tecnologia y
   Universidad del Gobierno de Aragon [B33_17R]; FEDER; European Union
FX This work was supported by grants from Instituto de Salud Carlos III,
   Spain (PI18/01374, and PI17/00021); and from Comunidad de Madrid, Spain,
   (B2017/BMD-3721). Departamento de Ciencia, Tecnologia y Universidad del
   Gobierno de Aragon (Grupos Consolidados B33_17R) and FEDER, Funding
   Program from the European Union. We thank Laia Jimena Vazquez Guillamet
   for assistance with language editing.
CR Bannwarth S, 2013, J MED GENET, V50, P704, DOI 10.1136/jmedgenet-2013-101604
   Blok MJ, 2007, J MED GENET, V44, DOI 10.1136/jmg.2006.045716
   Crimi M, 2003, NEUROLOGY, V60, P1857, DOI 10.1212/01.WNL.0000066048.72780.69
   Emperador S, 2018, FRONT NEUROSCI-SWITZ, V12, DOI 10.3389/fnins.2018.00061
   Kirby DM, 2003, ANN NEUROL, V54, P473, DOI 10.1002/ana.10687
   LEIGH D, 1951, J NEUROL NEUROSUR PS, V14, P216, DOI 10.1136/jnnp.14.3.216
   Lin J, 2014, MITOCHONDR DNA, V25, P56, DOI 10.3109/19401736.2013.779259
   Liolitsa D, 2003, ANN NEUROL, V53, P128, DOI 10.1002/ana.10435
   Liu AH, 2014, CNS NEUROSCI THER, V20, P509, DOI 10.1111/cns.12257
   Ng YS, 2018, EBIOMEDICINE, V30, P86, DOI 10.1016/j.ebiom.2018.02.010
   O'Callaghan MM, 2015, MITOCHONDRION, V22, P17, DOI 10.1016/j.mito.2015.03.001
   Rahman S, 1996, ANN NEUROL, V39, P343, DOI 10.1002/ana.410390311
   Shanske S, 2004, AM J MED GENET A, V130A, P134, DOI 10.1002/ajmg.a.30220
   Shanske S, 2008, ARCH NEUROL-CHICAGO, V65, P368, DOI 10.1001/archneurol.2007.67
   SWEENEY MG, 1993, Q J MED, V86, P709
   Wang YX, 2015, CHINESE MED J-PEKING, V128, P1820, DOI 10.4103/0366-6999.159360
   Whittaker RG, 2009, NEUROLOGY, V72, P568, DOI 10.1212/01.wnl.0000342121.91336.4d
NR 17
TC 6
Z9 6
U1 0
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 1872-8278
J9 MITOCHONDRION
JI Mitochondrion
PD JAN
PY 2020
VL 50
BP 14
EP 18
DI 10.1016/j.mito.2019.10.001
PG 5
WC Cell Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Genetics & Heredity
GA KE0YP
UT WOS:000508287400002
PM 31639449
DA 2024-11-01
ER

PT J
AU Shimizu, A
   Mito, T
   Hashizume, O
   Yonekawa, H
   Ishikawa, K
   Nakada, K
   Hayashi, J
AF Shimizu, Akinori
   Mito, Takayuki
   Hashizume, Osamu
   Yonekawa, Hiromichi
   Ishikawa, Kaori
   Nakada, Kazuto
   Hayashi, Jun-ichi
TI G7731A mutation in mouse mitochondrial <i>tRNA<SUP>LYs</SUP></i>
   regulates late-onset disorders in transmitochondrial mice
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE G7731A mtDNA mutation; Mitochondrial tRNA(Lys) gene; Transmitochondrial
   mice; Respiration defects; Late-onset disorders; Mitochondrial disease
   models
ID MITO-MICE; PRIMARY PREVENTION; PROTEIN-SYNTHESIS; DNA MUTATIONS; MTDNA;
   CELLS; GENE; DISEASE; GENERATION; MYOPATHY
AB We previously generated mito-mice-tRNA(Lys7731) as a model for primary prevention of mitochondrial diseases. These mice harbour a G7731A mtDNA mutation in the tRNA(Lys) gene, but express only muscle weakness and short body length by four months. Here, we examined the effects of their aging on metabolic and histologic features. Unlike young mito-mice-tRNA(Lys7731), aged mito-mice-tRNA(Lys7731) developed muscle atrophy, renal failures, and various metabolic abnormalities, such as lactic acidosis and anemia, characteristic of patients with mitochondrial diseases. These observations provide convincing evidence that the respiration defects induced by high G7731A mtDNA levels cause these late-onset disorders that are relevant to mitochondrial diseases. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Shimizu, Akinori; Mito, Takayuki; Hashizume, Osamu; Ishikawa, Kaori; Nakada, Kazuto; Hayashi, Jun-ichi] Univ Tsukuba, Fac Life & Environm Sci, Tsukuba, Ibaraki 3058572, Japan.
   [Yonekawa, Hiromichi] Tokyo Metropolitan Inst Med Sci, Dept Lab Anim Sci, Setagaya Ku, Tokyo 1568506, Japan.
   [Nakada, Kazuto; Hayashi, Jun-ichi] Univ Tsukuba, Int Inst Integrat Sleep Med WPI IIIS, Tsukuba, Ibaraki 3058572, Japan.
   [Hayashi, Jun-ichi] Univ Tsukuba, TARA Ctr, Tsukuba, Ibaraki 3058572, Japan.
C3 University of Tsukuba; Tokyo Metropolitan Institute of Medical Science;
   University of Tsukuba; University of Tsukuba
RP Hayashi, J (corresponding author), Univ Tsukuba, TARA Ctr, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058572, Japan.
EM jih45@biol.tsukuba.ac.jp
OI Hashizume, Osamu/0009-0000-2318-3602; Shimizu,
   Akinori/0000-0003-2691-2297; Mito, Takayuki/0000-0002-6796-5478;
   ISHIKAWA, Kaori/0000-0001-9895-5996
FU Japan Society for the Promotion of Science [25250011, 23240058,
   24117503]; World Premier International Research Center Initiative,
   Ministry of Education, Culture, Sports, Science, and Technology Japan;
   Grants-in-Aid for Scientific Research [24117503, 25250011, 23240058]
   Funding Source: KAKEN
FX This work was supported by Grants-in-Aid for Scientific Research A (no.
   25250011, to J.-I.H.), Scientific Research A (no. 23240058, to K.N.),
   and Scientific Research on Innovative Areas (no. 24117503, to J.-I.H.)
   from the Japan Society for the Promotion of Science. In addition, this
   work was supported by the World Premier International Research Center
   Initiative, Ministry of Education, Culture, Sports, Science, and
   Technology Japan (to K.N. and J.-I.H.).
CR Blakely EL, 2007, J NEUROL, V254, P1283, DOI 10.1007/s00415-006-0490-7
   CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236
   Cohen BH, 2013, NEUROTHERAPEUTICS, V10, P227, DOI 10.1007/s13311-013-0188-3
   Freyer C, 2012, NAT GENET, V44, P1282, DOI 10.1038/ng.2427
   Hashizume O, 2012, P NATL ACAD SCI USA, V109, P10528, DOI 10.1073/pnas.1202367109
   HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614
   HAYASHI JI, 1983, EXP CELL RES, V147, P51, DOI 10.1016/0014-4827(83)90270-7
   Houshmand M, 1999, HUM MUTAT, V13, P203, DOI 10.1002/(SICI)1098-1004(1999)13:3<203::AID-HUMU4>3.0.CO;2-3
   Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826
   Jansen JJ, 1997, J AM SOC NEPHROL, V8, P1118
   Jenuth JP, 1996, NAT GENET, V14, P146, DOI 10.1038/ng1096-146
   Kasahara A, 2006, HUM MOL GENET, V15, P871, DOI 10.1093/hmg/ddl005
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   Larsson NG, 1995, ANNU REV GENET, V29, P151, DOI 10.1146/annurev.ge.29.120195.001055
   Mito T, 2015, BIOCHEM BIOPH RES CO, V456, P933, DOI 10.1016/j.bbrc.2014.12.009
   Nakada K, 2004, BIOCHEM BIOPH RES CO, V323, P175, DOI 10.1016/j.bbrc.2004.08.073
   Nakada K, 2001, NAT MED, V7, P934, DOI 10.1038/90976
   Nedergaard A, 2013, BEST PRACT RES CL OB, V27, P673, DOI 10.1016/j.bpobgyn.2013.06.001
   ROTIG A, 1992, AM J HUM GENET, V50, P364
   Shimizu A, 2014, P NATL ACAD SCI USA, V111, P3104, DOI 10.1073/pnas.1318109111
   SZABOLCS MJ, 1994, KIDNEY INT, V45, P1388, DOI 10.1038/ki.1994.181
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Wang JM, 1999, NAT GENET, V21, P133, DOI 10.1038/5089
   Yokota M, 2010, FEBS LETT, V584, P3943, DOI 10.1016/j.febslet.2010.07.048
NR 27
TC 12
Z9 12
U1 1
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAR
PY 2015
VL 459
IS 1
BP 66
EP 70
DI 10.1016/j.bbrc.2015.02.070
PG 5
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA CE8UU
UT WOS:000352120400011
PM 25721669
OA Green Submitted
DA 2024-11-01
ER

PT J
AU Finsterer, J
   Zarrouk-Mahjoub, S
AF Finsterer, Josef
   Zarrouk-Mahjoub, Sinda
TI Phenotypic and Genotypic Heterogeneity of <i>RRM2B</i> Variants
SO NEUROPEDIATRICS
LA English
DT Review
DE mitochondrial; mtDNA; phenotype; genotype; myopathy; muscle biopsy;
   RRM2B
ID MITOCHONDRIAL-DNA DEPLETION; PERIPHERAL NEUROPATHY; GENE DEFECT;
   MUTATIONS
AB Objectives Genotype and phenotype of RRM2B mutation have become increasingly heterogeneous. This review aims at summarizing recent advances concerning the genotypic and phenotypic variability of RRM2B mutations.
   Method The review evaluated clinical and instrumental data of 82 patients carrying a mutation in the RRM2B gene reported in 18 publications with regard to onset, frequency, and type of clinical manifestations and genetic findings.
   Results The review showed marked variety of clinical manifestations and marked variety of age at onset. Organs predominantly affected in RRM2B mutation carriers are the skeletal muscle, the brain, and the kidneys. Additionally affected may be the eyes, ears, endocrine organs, heart, gastro-intestinal tract, bone marrow, or the peripheral nerves. So far 43 mutations in 81 patients have been reported. Diagnosing RRM2B-associated disease requires demonstration of an appropriate phenotype and a RRM2B mutation. Various clinical manifestations are accessible to various invasive or non-invasive therapeutic measures. The outcome of RRM2B-associated mitochondrial disorders is highly variable ranging from early death to survival into adulthood.
   Conclusions Phenotype and genotype in RRM2B mutation carriers are more widespread than anticipated. Particularly in patients with chronic progressive external ophthalmoplegia, ptosis, limb muscle weakness, muscle hypotonia, renal tubulopathy, ataxia, deafness, and lactic acidosis, a RRM2B mutation should be considered.
C1 [Finsterer, Josef] Vet Univ Vienna, Messerli Inst, Krankenanstalt Rudolfstiftung, Vienna, Austria.
   [Zarrouk-Mahjoub, Sinda] Univ Tunis El Manar, Tunis, Tunisia.
   [Zarrouk-Mahjoub, Sinda] Pasteur Inst Tunis, Genom Platform, Tunis, Tunisia.
C3 Rudolfstiftung Hospital; University of Veterinary Medicine Vienna;
   Universite de Tunis-El-Manar; Pasteur Network; Universite de
   Tunis-El-Manar; Institut Pasteur Tunis
RP Finsterer, J (corresponding author), Postfach 20, A-1180 Vienna, Austria.
EM fifigs@yahoo.de
OI ZARROUK-MAHJOUB, SINDA/0000-0002-6763-4644
CR Acham-Roschitz B, 2009, MOL GENET METAB, V98, P300, DOI 10.1016/j.ymgme.2009.06.012
   Bornstein B, 2008, NEUROMUSCULAR DISORD, V18, P453, DOI 10.1016/j.nmd.2008.04.006
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Fratter C, 2011, NEUROLOGY, V76, P2032, DOI 10.1212/WNL.0b013e31821e558b
   Gorman G. S., 1993, GENEREVIEWS
   Hernández-Laín A, 2015, J NEUROL SCI, V358, P481, DOI 10.1016/j.jns.2015.08.1550
   Horga A, 2014, BRAIN, V137, P3200, DOI 10.1093/brain/awu279
   Kollberg G, 2009, NEUROMUSCULAR DISORD, V19, P147, DOI 10.1016/j.nmd.2008.11.014
   Kropach N, 2017, NEUROPEDIATRICS, V48, P456, DOI 10.1055/s-0037-1601867
   PAQUISFLUCKLINGER V, 1995, EUR J PEDIATR, V154, P557, DOI 10.1007/s004310050342
   Pitceathly RDS, 2012, BRAIN, V135, P3392, DOI 10.1093/brain/aws231
   Pitceathly RDS, 2011, J MED GENET, V48, P610, DOI 10.1136/jmg.2010.088328
   Shaibani A, 2009, ARCH NEUROL-CHICAGO, V66, P1028, DOI 10.1001/archneurol.2009.139
   Spinazzola A, 2009, J INHERIT METAB DIS, V32, P143, DOI 10.1007/s10545-008-1038-z
   Stojanovic V, 2013, CROAT MED J, V54, P579, DOI 10.3325/cmj.2013.54.579
   Takata A, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-9-r92
   Tyynismaa H, 2009, AM J HUM GENET, V85, P290, DOI 10.1016/j.ajhg.2009.07.009
   Valencia CA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156738
   Wilichowski EKG, 2014, NEUROMUSCULAR DISORD, V24, P866, DOI 10.1016/j.nmd.2014.06.244
NR 19
TC 11
Z9 13
U1 0
U2 4
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0174-304X
EI 1439-1899
J9 NEUROPEDIATRICS
JI Neuropediatrics
PD AUG
PY 2018
VL 49
IS 4
BP 231
EP 237
DI 10.1055/s-0037-1609039
PG 7
WC Clinical Neurology; Pediatrics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pediatrics
GA GM1UV
UT WOS:000437859300002
PM 29241262
DA 2024-11-01
ER

PT J
AU Müller-Nedebock, AC
   Brennan, RR
   Venter, M
   Pienaar, IS
   van der Westhuizen, FH
   Elson, JL
   Ross, OA
   Bardien, S
AF Mueller-Nedebock, Arnica C.
   Brennan, Rebecca R.
   Venter, Marianne
   Pienaar, Ilse S.
   van der Westhuizen, Francois H.
   Elson, Joanna L.
   Ross, Owen A.
   Bardien, Soraya
TI The unresolved role of mitochondrial DNA in Parkinson's disease: An
   overview of published studies, their limitations, and future prospects
SO NEUROCHEMISTRY INTERNATIONAL
LA English
DT Article
DE Parkinson's disease; Mitochondrial DNA; Mitochondrial haplogroups;
   Somatic mtDNA variation; Homoplasmic mtDNA variation; mtDNA depletion
ID TRANSFER-RNA GENES; COMPLEX-I; SUBSTANTIA-NIGRA; POINT MUTATIONS;
   ALZHEIMERS-DISEASE; COPY NUMBER; SKELETAL-MUSCLE; MTDNA MUTATIONS;
   CELL-LINES; 1-METHYL-4-PHENYLPYRIDINIUM ION
AB Parkinson's disease (PD), a progressive neurodegenerative disorder, has long been associated with mitochondrial dysfunction in both sporadic and familial forms of the disease. Mitochondria are crucial for maintaining cellular homeostasis, and their dysfunction is detrimental to dopaminergic neurons. These neurons are highly dependent on mitochondrial adenosine triphosphate (ATP) and degenerate in PD. Mitochondria contain their own genomes (mtDNA). The role of mtDNA has been investigated in PD on the premise that it encodes vital components of the ATP-generating oxidative phosphorylation (OXPHOS) complexes and accumulates somatic variation with age. However, the association between mtDNA variation and PD remains controversial. Herein, we provide an overview of previously published studies on the role of inherited as well as somatic (acquired) mtDNA changes in PD including point mutations, deletions and depletion. We outline limitations of previous investigations and the difficulties associated with studying mtDNA, which have left its role unresolved in the context of PD. Lastly, we highlight the potential for further research in this field and provide suggestions for future studies. Overall, the mitochondrial genome is indispensable for proper cellular function and its contribution to PD requires further, more extensive investigation.
C1 [Mueller-Nedebock, Arnica C.; Bardien, Soraya] Stellenbosch Univ, Fac Med & Hlth Sci, Dept Biomed Sci, Div Mol Biol & Human Genet, Cape Town, South Africa.
   [Brennan, Rebecca R.; Ross, Owen A.] Mayo Clin, Dept Neurosci, Jacksonville, FL 32224 USA.
   [Venter, Marianne; van der Westhuizen, Francois H.; Elson, Joanna L.] North West Univ, Human Metab, Potchefstroom, South Africa.
   [Pienaar, Ilse S.] Univ Sussex, Sch Life Sci, Falmer BN1 9PH, England.
   [Pienaar, Ilse S.] Imperial Coll London, Ctr Neuroinflammat & Neurodegenerat, London, England.
   [Elson, Joanna L.] Newcastle Univ, Inst Genet Med, Newcastle Upon Tyne, Tyne & Wear, England.
   [Ross, Owen A.] Mayo Clin, Dept Clin Genom, Jacksonville, FL 32224 USA.
   [Ross, Owen A.] Univ Coll Dublin, Sch Med & Med Sci, Dublin, Ireland.
C3 Stellenbosch University; Mayo Clinic; North West University - South
   Africa; University of Sussex; Imperial College London; Newcastle
   University - UK; Mayo Clinic; University College Dublin
RP Bardien, S (corresponding author), Stellenbosch Univ, Div Mol Biol & Human Genet, Dept Biomed Sci, POB 241, ZA-8000 Cape Town, South Africa.
EM sbardien@sun.ac.za
RI Bardien, Soraya/AAJ-9003-2020; Ross, Owen/D-7573-2013; Venter,
   Marianne/AAJ-6642-2021; van der Westhuizen, Francois/E-6959-2011
OI Bardien, Soraya/0000-0002-3508-3438; /0000-0002-3551-5624; Ross,
   Owen/0000-0003-4813-756X; Valentino, Rebecca/0000-0001-7253-961X; van
   der Westhuizen, Francois/0000-0002-7879-1776; Muller-Nedebock,
   Amica/0000-0002-5547-9704; Pretorius, Marianne/0000-0001-9679-6346
FU National Research Foundation of South Africa [106052]; South African
   Medical Research Council; Stellenbosch University; NIH [P50NS072187];
   DOD award [W81XWH-17.1-0249]; Lewy Body Dementia Association (LBDA)
   Research Center of Excellence; American Parkinson Disease Association
   Center for Advanced Research; Michael J. Fox Foundation; NRF-DST Centre
   of Excellence for Biomedical Tuberculosis Research; South African
   Medical Research Council Centre for Tuberculosis Research; Division of
   Molecular Biology and Human Genetics, Faculty of Medicine and Health
   Sciences, Stellenbosch University, Cape Town
FX The authors are supported by the National Research Foundation of South
   Africa (Grant Numbers: 106052), the South African Medical Research
   Council (Self-Initiated Research Grant), and Stellenbosch University.
   This work was also supported by an NIH grant (P50NS072187) and DOD award
   (W81XWH-17.1-0249) to OAR, the Mayo Clinic investigators are supported
   in part by a Lewy Body Dementia Association (LBDA) Research Center of
   Excellence, an American Parkinson Disease Association Center for
   Advanced Research and the Michael J. Fox Foundation. We also acknowledge
   the support of the NRF-DST Centre of Excellence for Biomedical
   Tuberculosis Research; South African Medical Research Council Centre for
   Tuberculosis Research; Division of Molecular Biology and Human Genetics,
   Faculty of Medicine and Health Sciences, Stellenbosch University, Cape
   Town.
CR Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   ARNHEIM N, 1992, MUTAT RES, V275, P157, DOI 10.1016/0921-8734(92)90020-P
   Autere J, 2004, HUM GENET, V115, P29, DOI 10.1007/s00439-004-1123-9
   Bandmann O, 1997, J NEUROL, V244, P262, DOI 10.1007/s004150050082
   BARBEAU A, 1984, CAN J NEUROL SCI, V11, P24, DOI 10.1017/S0317167100045273
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Bender A, 2008, J NEUROL, V255, P1231, DOI 10.1007/s00415-008-0892-9
   BENECKE R, 1993, BRAIN, V116, P1451, DOI 10.1093/brain/116.6.1451
   Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834
   BINDOFF LA, 1991, J NEUROL SCI, V104, P203, DOI 10.1016/0022-510X(91)90311-T
   BLIN O, 1994, J NEUROL SCI, V125, P95, DOI 10.1016/0022-510X(94)90248-8
   Borland MK, 2009, BBA-MOL BASIS DIS, V1792, P68, DOI 10.1016/j.bbadis.2008.09.014
   Brichta L, 2014, FRONT NEUROANAT, V8, DOI 10.3389/fnana.2014.00152
   Brown MD, 1996, AM J MED GENET, V61, P283, DOI 10.1002/(SICI)1096-8628(19960122)61:3<283::AID-AJMG15>3.0.CO;2-P
   Bulua AC, 2011, J EXP MED, V208, P519, DOI 10.1084/jem.20102049
   BURNS RS, 1983, P NATL ACAD SCI-BIOL, V80, P4546, DOI 10.1073/pnas.80.14.4546
   Bury AG, 2017, ANN NEUROL, V82, P1016, DOI 10.1002/ana.25099
   Button KS, 2013, NAT REV NEUROSCI, V14, P365, DOI 10.1038/nrn3475
   Calabrese C, 2014, BIOINFORMATICS, V30, P3115, DOI 10.1093/bioinformatics/btu483
   Cantuti-Castelvetria I, 2005, NEUROBIOL AGING, V26, P1343, DOI 10.1016/j.neurobiolaging.2004.11.008
   CARDELLACH F, 1993, NEUROLOGY, V43, P2258, DOI 10.1212/WNL.43.11.2258
   Castellana S, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005628
   Chen CM, 2007, J NEURAL TRANSM, V114, P1017, DOI 10.1007/s00702-007-0658-z
   Chen YF, 2015, CHINESE MED J-PEKING, V128, P1748, DOI 10.4103/0366-6999.159348
   Chinnery PF, 2013, BRIT MED BULL, V106, P135, DOI 10.1093/bmb/ldt017
   Chinnery PF, 1999, AM J HUM GENET, V64, P1158, DOI 10.1086/302311
   Chu QH, 2015, SCI REP-UK, V5, DOI 10.1038/srep17170
   Collier TJ, 2017, MOVEMENT DISORD, V32, P983, DOI 10.1002/mds.27037
   Coxhead J, 2016, NEUROBIOL AGING, V38, DOI 10.1016/j.neurobiolaging.2015.10.036
   Damier P, 1999, BRAIN, V122, P1437, DOI 10.1093/brain/122.8.1437
   DAVIS GC, 1979, PSYCHIAT RES, V1, P249, DOI 10.1016/0165-1781(79)90006-4
   Dominy J. E., COLD SPRING HARB PER, V5
   Done C., 2016, NAT COMMUN, V7, P13548, DOI [10.1038/ncomms13548, DOI 10.1038/NCOMMS13548]
   Edgar D, 2009, CELL METAB, V10, P131, DOI 10.1016/j.cmet.2009.06.010
   Ekstrand MI, 2007, P NATL ACAD SCI USA, V104, P1325, DOI 10.1073/pnas.0605208103
   El-Hattab A, 2013, NEUROTHERAPEUTICS, V10, P186, DOI 10.1007/s13311-013-0177-6
   Elbaz A, 1999, NEUROLOGY, V52, P1876, DOI 10.1212/WNL.52.9.1876
   Elson JL, 2001, AM J HUM GENET, V68, P802, DOI 10.1086/318801
   Esteves AR, 2010, FRONT AGING NEUROSCI, V1, DOI 10.3389/neuro.24.005.2009
   Esteves AR, 2010, J NEUROCHEM, V113, P674, DOI 10.1111/j.1471-4159.2010.06631.x
   Esteves AR, 2010, NEUROBIOL DIS, V37, P723, DOI 10.1016/j.nbd.2009.12.011
   Esteves AR, 2009, ANTIOXID REDOX SIGN, V11, P439, DOI [10.1089/ars.2008.2247, 10.1089/ARS.2008.2247]
   Esteves ARF, 2008, MITOCHONDRION, V8, P219, DOI 10.1016/j.mito.2008.03.004
   Fachal L, 2015, AM J MED GENET B, V168, P54, DOI 10.1002/ajmg.b.32276
   Gaweda-Walerych K, 2008, J NEURAL TRANSM, V115, P1521, DOI 10.1007/s00702-008-0121-9
   Gelb DJ, 1999, ARCH NEUROL-CHICAGO, V56, P33, DOI 10.1001/archneur.56.1.33
   Ghezzi D, 2005, EUR J HUM GENET, V13, P748, DOI 10.1038/sj.ejhg.5201425
   Ghosh SS, 1999, ANN NY ACAD SCI, V893, P176, DOI 10.1111/j.1749-6632.1999.tb07825.x
   Giannoccaro MP, 2017, MOVEMENT DISORD, V32, P346, DOI 10.1002/mds.26966
   Goudenege D., 1407, GENET MED, V21
   Grasbon-Frodl EM, 1999, NEUROGENETICS, V2, P121, DOI 10.1007/s100480050063
   Greaves LC, 2009, AGING CELL, V8, P566, DOI 10.1111/j.1474-9726.2009.00505.x
   Grünewald A, 2016, ANN NEUROL, V79, P366, DOI 10.1002/ana.24571
   Gu GY, 2002, J NEUROPATH EXP NEUR, V61, P634, DOI 10.1093/jnen/61.7.634
   Gu M, 1998, ANN NEUROL, V44, P177, DOI 10.1002/ana.410440207
   Gui YX, 2015, PARKINSONISM RELAT D, V21, P282, DOI 10.1016/j.parkreldis.2014.12.030
   Guyatt AL, 2019, HUM GENOMICS, V13, DOI 10.1186/s40246-018-0190-2
   HAAS RH, 1995, ANN NEUROL, V37, P714, DOI 10.1002/ana.410370604
   HALLIWELL B, 1984, METHOD ENZYMOL, V105, P47
   HEIKKILA RE, 1984, SCIENCE, V224, P1451, DOI 10.1126/science.6610213
   HEIKKILA RE, 1985, NEUROSCI LETT, V62, P389, DOI 10.1016/0304-3940(85)90580-4
   Hellwege J. N., 2017, CURRENT PROTOCOLS HU, V95, P1
   Herbers E, 2019, MITOCHONDRION, V44, P85, DOI 10.1016/j.mito.2018.01.004
   Herrnstadt C, 2004, MITOCHONDRION, V4, P791, DOI 10.1016/j.mito.2004.07.041
   Howell N, 2005, TRENDS GENET, V21, P583, DOI 10.1016/j.tig.2005.08.012
   Hudson G, 2013, NEUROLOGY, V80, P2042, DOI 10.1212/WNL.0b013e318294b434
   Huerta C, 2005, J NEUROL SCI, V236, P49, DOI 10.1016/j.jns.2005.04.016
   IKEBE S, 1990, BIOCHEM BIOPH RES CO, V170, P1044, DOI 10.1016/0006-291X(90)90497-B
   IKEBE S, 1995, MOL BRAIN RES, V28, P281, DOI 10.1016/0169-328X(94)00209-W
   Jandova J, 2012, EXP CELL RES, V318, P2215, DOI 10.1016/j.yexcr.2012.06.006
   JANETZKY B, 1994, NEUROSCI LETT, V169, P126, DOI 10.1016/0304-3940(94)90372-7
   Keeney PM, 2009, EXP NEUROL, V220, P374, DOI 10.1016/j.expneurol.2009.09.025
   Kenney MC, 2014, BBA-MOL BASIS DIS, V1842, P208, DOI 10.1016/j.bbadis.2013.10.016
   Khrapko K, 1997, P NATL ACAD SCI USA, V94, P13798, DOI 10.1073/pnas.94.25.13798
   Khusnutdinova E, 2008, ANN NY ACAD SCI, V1147, P1, DOI 10.1196/annals.1427.001
   Kim KH, 2018, CELL METAB, V28, P516, DOI 10.1016/j.cmet.2018.06.008
   Kim SJ, 2017, J PHYSIOL-LONDON, V595, P6613, DOI 10.1113/JP274472
   Kirchner SC, 2000, NEUROTOXICOLOGY, V21, P441
   Kosel S, 1998, NEUROGENETICS, V1, P197, DOI 10.1007/s100480050029
   Kosel S, 1997, MOVEMENT DISORD, V12, P639, DOI 10.1002/mds.870120504
   Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778
   KRIGE D, 1992, ANN NEUROL, V32, P782, DOI 10.1002/ana.410320612
   Kumar KR, 2011, SEMIN NEUROL, V31, P433, DOI 10.1055/s-0031-1299782
   LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561
   Latsoudis H, 2008, J HUM GENET, V53, P349, DOI 10.1007/s10038-008-0259-1
   Lee C, 2019, MOL CELL ONCOL, V6, DOI 10.1080/23723556.2018.1549464
   Lee C, 2015, CELL METAB, V21, P443, DOI 10.1016/j.cmet.2015.02.009
   Lee CH, 2013, TRENDS ENDOCRIN MET, V24, P222, DOI [10.1016/j.tem.2013.01.005, 10.1016/j.technovation.2020.102140]
   Li MK, 2010, AM J HUM GENET, V87, P237, DOI 10.1016/j.ajhg.2010.07.014
   Lin MT, 2012, ANN NEUROL, V71, P850, DOI 10.1002/ana.23568
   Lin MT, 2002, HUM MOL GENET, V11, P133, DOI 10.1093/hmg/11.2.133
   Liou CW, 2016, EUR J NEUROL, V23, P1289, DOI 10.1111/ene.13020
   Liu WC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004597
   Lott Marie T, 2013, Curr Protoc Bioinformatics, V44, DOI 10.1002/0471250953.bi0123s44
   Luo SY, 2018, P NATL ACAD SCI USA, V115, P13039, DOI 10.1073/pnas.1810946115
   MANN VM, 1992, FEBS LETT, V299, P218, DOI 10.1016/0014-5793(92)80118-Z
   Mayr-Wohlfart U, 1997, Eur J Med Res, V2, P111
   Mehta P, 2009, MOVEMENT DISORD, V24, P290, DOI 10.1002/mds.22389
   Miller FJ, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng060
   MIZUNO Y, 1987, NEUROSCI LETT, V81, P204, DOI 10.1016/0304-3940(87)90366-1
   Moraes CT, 2003, J MOL DIAGN, V5, P197, DOI 10.1016/S1525-1578(10)60474-6
   NAKAGAWAHATTORI Y, 1992, J NEUROL SCI, V107, P29, DOI 10.1016/0022-510X(92)90205-Y
   Neuhaus JFG, 2014, BRAIN, V137, P354, DOI 10.1093/brain/awt291
   Nido GS, 2018, NEUROBIOL AGING, V63, P120, DOI 10.1016/j.neurobiolaging.2017.10.024
   Nissanka N, 2019, TRENDS GENET, V35, P235, DOI 10.1016/j.tig.2019.01.001
   Onyango IG, 2005, MOL CELL NEUROSCI, V28, P452, DOI 10.1016/j.mcn.2004.10.006
   Onyango IG, 2005, NEUROBIOL DIS, V20, P141, DOI 10.1016/j.nbd.2005.02.009
   Otaegui D, 2004, NEUROSCI LETT, V370, P171, DOI 10.1016/j.neulet.2004.08.012
   OZAWA T, 1991, BIOCHEM BIOPH RES CO, V176, P938, DOI 10.1016/S0006-291X(05)80276-1
   OZAWA T, 1990, BIOCHEM BIOPH RES CO, V172, P483, DOI 10.1016/0006-291X(90)90698-M
   Pardo-Seco J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073567
   Pareek CS, 2011, J APPL GENET, V52, P413, DOI 10.1007/s13353-011-0057-x
   Park JS, 2018, CURR NEUROL NEUROSCI, V18, DOI 10.1007/s11910-018-0829-3
   PARKER WD, 1989, ANN NEUROL, V26, P719, DOI 10.1002/ana.410260606
   Peeva V, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04131-w
   Pienaar IS, 2017, MITOCHONDRION, V34, P141, DOI 10.1016/j.mito.2017.04.002
   Pyle A, 2005, ANN NEUROL, V57, P564, DOI 10.1002/ana.20417
   Pyle A, 2016, NEUROBIOL AGING, V38, DOI 10.1016/j.neurobiolaging.2015.10.033
   Pyle A, 2015, ANN NEUROL, V78, P1000, DOI 10.1002/ana.24515
   Pyle A, 2010, INTENS CARE MED, V36, P956, DOI 10.1007/s00134-010-1823-7
   Quirós PM, 2016, NAT REV MOL CELL BIO, V17, P213, DOI 10.1038/nrm.2016.23
   Raule N, 2007, MITOCHONDRION, V7, P29, DOI 10.1016/j.mito.2006.11.013
   Reeve AK, 2008, AM J HUM GENET, V82, P228, DOI 10.1016/j.ajhg.2007.09.018
   Richter G, 2002, J NEURAL TRANSM, V109, P721, DOI 10.1007/s007020200060
   Ross OA, 2003, EXP GERONTOL, V38, P397, DOI 10.1016/S0531-5565(02)00266-8
   Salas A, 2015, J GENET GENOMICS, V42, P169, DOI 10.1016/j.jgg.2015.03.002
   Salas A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0008347
   Samuels DC, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003929
   Samuels DC, 2006, AM J HUM GENET, V78, P713, DOI 10.1086/502682
   SCHAPIRA AHV, 1989, LANCET, V1, P1269, DOI 10.1016/S0140-6736(89)92366-0
   Sekhar GN, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0173474
   Sheehan JP, 1997, J NEUROCHEM, V68, P1221
   SHOFFNER JM, 1991, ANN NEUROL, V30, P332, DOI 10.1002/ana.410300304
   Shokolenko I, 2009, NUCLEIC ACIDS RES, V37, P2539, DOI 10.1093/nar/gkp100
   Simon DK, 2017, ACTA NEUROPATHOL COM, V5, DOI 10.1186/s40478-017-0433-9
   Simon DK, 2004, NEUROBIOL AGING, V25, P71, DOI 10.1016/S0197-4580(03)00037-X
   Simon DK, 2000, NEUROLOGY, V54, P703, DOI 10.1212/WNL.54.3.703
   Smigrodzki R, 2004, NEUROBIOL AGING, V25, P1273, DOI 10.1016/j.neurobiolaging.2004.02.020
   Song SW, 2005, P NATL ACAD SCI USA, V102, P4990, DOI 10.1073/pnas.0500253102
   Sonney S, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005867
   Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166
   Stoneking M, 2000, AM J HUM GENET, V67, P1029, DOI 10.1086/303092
   Strobbe D, 2018, NEUROBIOL DIS, V114, P129, DOI 10.1016/j.nbd.2018.02.010
   Suomalainen A, 2010, NEUROMUSCULAR DISORD, V20, P429, DOI 10.1016/j.nmd.2010.03.017
   Swerdlow RH, 1998, ANN NEUROL, V44, P873, DOI 10.1002/ana.410440605
   Swerdlow RH, 1996, ANN NEUROL, V40, P663, DOI 10.1002/ana.410400417
   Swerdlow RH, 2012, ANTIOXID REDOX SIGN, V16, P950, DOI 10.1089/ars.2011.3948
   Torroni A, 2006, TRENDS GENET, V22, P339, DOI 10.1016/j.tig.2006.04.001
   Trifunovic A, 2005, P NATL ACAD SCI USA, V102, P17993, DOI 10.1073/pnas.0508886102
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Trimmer PA, 2000, EXP NEUROL, V162, P37, DOI 10.1006/exnr.2000.7333
   Trimmer PA, 2004, J NEUROCHEM, V88, P800, DOI 10.1046/j.1471-4159.2003.02168.x
   Trinh J, 2013, NAT REV NEUROL, V9, P445, DOI 10.1038/nrneurol.2013.132
   van der Walt JM, 2003, AM J HUM GENET, V72, P804, DOI 10.1086/373937
   van Oven M, 2009, HUM MUTAT, V30, pE386, DOI 10.1002/humu.20921
   VELTRI KL, 1990, J CELL PHYSIOL, V143, P160, DOI 10.1002/jcp.1041430122
   Venter M, 2019, MITOCHONDRIAL DNA A, V30, P440, DOI 10.1080/24701394.2018.1544248
   Venter M, 2017, J GENET GENOMICS, V44, P139, DOI 10.1016/j.jgg.2016.12.003
   Vermulst M, 2008, NAT GENET, V40, P392, DOI 10.1038/ng.95
   Vivian CJ, 2017, CANCER RES, V77, P6202, DOI 10.1158/0008-5472.CAN-17-1473
   WALLACE RA, 1984, LIFE SCI, V35, P285
   Wei W, 2017, ACTA NEUROPATHOL COM, V5, DOI 10.1186/s40478-016-0404-6
   Weissensteiner H, 2016, NUCLEIC ACIDS RES, V44, pW64, DOI 10.1093/nar/gkw247
   West AP, 2011, NATURE, V472, P476, DOI 10.1038/nature09973
   Wilkins HM, 2014, REDOX BIOL, V2, P619, DOI 10.1016/j.redox.2014.03.006
   Wu HM, 2018, NEUROBIOL DIS, V114, P17, DOI 10.1016/j.nbd.2018.02.015
   Yasukawa T, 2018, J BIOCHEM, V164, P183, DOI 10.1093/jb/mvy058
   Ye F, 2014, MITOCHONDRION, V17, P157, DOI 10.1016/j.mito.2014.05.004
   Ye KX, 2014, P NATL ACAD SCI USA, V111, P10654, DOI 10.1073/pnas.1403521111
   YOSHINO H, 1992, J NEURAL TRANSM-PARK, V4, P27, DOI 10.1007/BF02257619
   Zhang J, 2002, PARKINSONISM RELAT D, V8, P165, DOI 10.1016/S1353-8020(01)00041-4
   Zhang W, 2012, CLIN CHEM, V58, P1322, DOI 10.1373/clinchem.2011.181438
NR 172
TC 22
Z9 24
U1 1
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0197-0186
EI 1872-9754
J9 NEUROCHEM INT
JI Neurochem. Int.
PD OCT
PY 2019
VL 129
AR 104495
DI 10.1016/j.neuint.2019.104495
PG 14
WC Biochemistry & Molecular Biology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA IU9NS
UT WOS:000483908300014
PM 31233840
OA Bronze, Green Accepted, Green Submitted
DA 2024-11-01
ER

PT J
AU Donkervoort, S
   Sabouny, R
   Yun, P
   Gauquelin, L
   Chao, KR
   Hu, Y
   Al Khatib, I
   Topf, A
   Mohassel, P
   Cummings, BB
   Kaur, R
   Saade, D
   Moore, SA
   Waddell, LB
   Farrar, MA
   Goodrich, JK
   Uapinyoying, P
   Chan, SHS
   Javed, A
   Leach, ME
   Karachunski, P
   Dalton, J
   Medne, L
   Harper, A
   Thompson, C
   Thiffault, I
   Specht, S
   Lamont, RE
   Saunders, C
   Racher, H
   Bernier, FP
   Mowat, D
   Witting, N
   Vissing, J
   Hanson, R
   Coffman, KA
   Hainlen, M
   Parboosingh, JS
   Carnevale, A
   Yoon, G
   Schnur, RE
   Boycott, KM
   Mah, JK
   Straub, V
   Foley, AR
   Innes, AM
   Bonnemann, CG
   Shutt, TE
AF Donkervoort, S.
   Sabouny, R.
   Yun, P.
   Gauquelin, L.
   Chao, K. R.
   Hu, Y.
   Al Khatib, I
   Topf, A.
   Mohassel, P.
   Cummings, B. B.
   Kaur, R.
   Saade, D.
   Moore, S. A.
   Waddell, L. B.
   Farrar, M. A.
   Goodrich, J. K.
   Uapinyoying, P.
   Chan, S. H. S.
   Javed, A.
   Leach, M. E.
   Karachunski, P.
   Dalton, J.
   Medne, L.
   Harper, A.
   Thompson, C.
   Thiffault, I
   Specht, S.
   Lamont, R. E.
   Saunders, C.
   Racher, H.
   Bernier, F. P.
   Mowat, D.
   Witting, N.
   Vissing, J.
   Hanson, R.
   Coffman, K. A.
   Hainlen, M.
   Parboosingh, J. S.
   Carnevale, A.
   Yoon, G.
   Schnur, R. E.
   Boycott, K. M.
   Mah, J. K.
   Straub, V
   Foley, A. Reghan
   Innes, A. M.
   Bonnemann, C. G.
   Shutt, T. E.
CA Care4Rare Canada Consortium
TI <i>MSTO1</i> mutations cause mtDNA depletion, manifesting as muscular
   dystrophy with cerebellar involvement
SO ACTA NEUROPATHOLOGICA
LA English
DT Article
DE MSTO1; Mitochondrial fusion; Cerebellar atrophy; Muscular dystrophy;
   MtDNA depletion
ID MITOCHONDRIAL-DNA DEPLETION; OPTIC ATROPHY; RECESSIVE MUTATIONS;
   PROTEIN; EXPRESSION; FUSION; ATAXIA; DYNAMICS; MYOPATHY; BINDING
AB MSTO1 encodes a cytosolic mitochondrial fusion protein, misato homolog 1 or MSTO1. While the full genotype-phenotype spectrum remains to be explored, pathogenic variants in MSTO1 have recently been reported in a small number of patients presenting with a phenotype of cerebellar ataxia, congenital muscle involvement with histologic findings ranging from myopathic to dystrophic and pigmentary retinopathy. The proposed underlying pathogenic mechanism of MSTO1-related disease is suggestive of impaired mitochondrial fusion secondary to a loss of function of MSTO1. Disorders of mitochondrial fusion and fission have been shown to also lead to mitochondrial DNA (mtDNA) depletion, linking them to the mtDNA depletion syndromes, a clinically and genetically diverse class of mitochondrial diseases characterized by a reduction of cellular mtDNA content. However, the consequences of pathogenic variants in MSTO1 on mtDNA maintenance remain poorly understood. We present extensive phenotypic and genetic data from 12 independent families, including 15 new patients harbouring a broad array of bi-allelic MSTO1 pathogenic variants, and we provide functional characterization from seven MSTO1-related disease patient fibroblasts. Bi-allelic loss-of-function variants in MSTO1 manifest clinically with a remarkably consistent phenotype of childhood-onset muscular dystrophy, corticospinal tract dysfunction and early-onset non-progressive cerebellar atrophy. MSTO1 protein was not detectable in the cultured fibroblasts of all seven patients evaluated, suggesting that pathogenic variants result in a loss of protein expression and/or affect protein stability. Consistent with impaired mitochondrial fusion, mitochondrial networks in fibroblasts were found to be fragmented. Furthermore, all fibroblasts were found to have depletion of mtDNA ranging from 30 to 70% along with alterations to mtDNA nucleoids. Our data corroborate the role of MSTO1 as a mitochondrial fusion protein and highlight a previously unrecognized link to mtDNA regulation. As impaired mitochondrial fusion is a recognized cause of mtDNA depletion syndromes, this novel link to mtDNA depletion in patient fibroblasts suggests that MSTO1-deficiency should also be considered a mtDNA depletion syndrome. Thus, we provide mechanistic insight into the disease pathogenesis associated with MSTO1 mutations and further define the clinical spectrum and the natural history of MSTO1-related disease.
C1 [Donkervoort, S.; Yun, P.; Hu, Y.; Mohassel, P.; Kaur, R.; Saade, D.; Uapinyoying, P.; Leach, M. E.; Foley, A. Reghan; Bonnemann, C. G.] NINDS, Neuromuscular & Neurogenet Disorders Childhood Se, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.
   [Sabouny, R.; Al Khatib, I; Shutt, T. E.] Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB, Canada.
   [Gauquelin, L.; Carnevale, A.; Yoon, G.] Univ Toronto, Hosp Sick Children, Dept Paediat, Div Clin & Metab Genet, Toronto, ON, Canada.
   [Gauquelin, L.; Yoon, G.] Univ Toronto, Hosp Sick Children, Dept Paediat, Div Neurol, Toronto, ON, Canada.
   [Chao, K. R.; Cummings, B. B.; Goodrich, J. K.] Broad Inst MIT & Harvard, Ctr Mendelian Genom, Program Med & Populat Genet, Boston, MA USA.
   [Topf, A.; Specht, S.; Straub, V] Newcastle Univ, John Walton Muscular Dystrophy Res Ctr, Inst Genet Med, Newcastle Upon Tyne, Tyne & Wear, England.
   [Moore, S. A.] Univ Iowa, Dept Pathol, Carver Coll Med, Iowa City, IA 52242 USA.
   [Waddell, L. B.] Childrens Hosp Westmead, Kids Neurosci Ctr, Kids Res, Sydney, NSW 2145, Australia.
   [Waddell, L. B.] Univ Sydney, Fac Med & Hlth, Discipline Child & Adolescent Hlth, Westmead, NSW 2145, Australia.
   [Farrar, M. A.] Sydney Childrens Hosp, Dept Neurol, Sydney, NSW, Australia.
   [Farrar, M. A.; Mowat, D.] UNSW Sydney, Sch Womens & Childrens Hlth, Sydney, NSW, Australia.
   [Chan, S. H. S.] Univ Hong Kong, Queen Mary Hosp, Dept Paediat & Adolescent Med, Hong Kong, Peoples R China.
   [Javed, A.] Univ Hong Kong, Sch Biomed Sci, Hong Kong, Peoples R China.
   [Leach, M. E.] Oregon Hlth & Sci Univ, Doernbecher Childrens Hosp, Neuromuscular Program, Portland, OR 97201 USA.
   [Karachunski, P.; Dalton, J.] Univ Minnesota, Dept Neurol, Minneapolis, MN 55455 USA.
   [Medne, L.] Childrens Hosp Philadelphia, Div Human Genet, Philadelphia, PA 19104 USA.
   [Harper, A.] Virginia Commonwealth Univ, Childrens Hosp Richmond VCU, Dept Neurol, Richmond, VA USA.
   [Thompson, C.] Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA.
   [Thiffault, I; Saunders, C.] Childrens Mercy Hosp, Dept Pathol & Lab Med, Kansas City, MO 64108 USA.
   [Thiffault, I; Saunders, C.] Childrens Mercy Hosp, Ctr Pediat Genom Med, Kansas City, MO 64108 USA.
   [Thiffault, I; Saunders, C.; Hanson, R.] Univ Missouri Kansas City, Sch Med, Kansas City, MO USA.
   [Lamont, R. E.; Racher, H.; Bernier, F. P.; Parboosingh, J. S.; Innes, A. M.] Univ Calgary, Cumming Sch Med, Dept Med Genet, Calgary, AB, Canada.
   [Lamont, R. E.; Racher, H.; Bernier, F. P.; Parboosingh, J. S.; Innes, A. M.] Univ Calgary, Cumming Sch Med, Alberta Childrens Hosp, Res Inst, Calgary, AB, Canada.
   [Mowat, D.] Sydney Childrens Hosp, Dept Med Genet, Sydney, NSW, Australia.
   [Witting, N.; Vissing, J.] Univ Hosp, Dept Neurol, Rigshosp, Copenhagen, Denmark.
   [Hanson, R.; Coffman, K. A.; Hainlen, M.] Childrens Mercy Hosp, Dept Pediat, Kansas City, MO 64108 USA.
   [Coffman, K. A.; Hainlen, M.] Childrens Mercy Hosp, Div Neurol, Kansas City, MO 64108 USA.
   [Schnur, R. E.] GeneDx, Gaithersburg, MD USA.
   [Boycott, K. M.] Univ Ottawa, Childrens Hosp Eastern Ontario, Res Inst, Ottawa, ON, Canada.
   [Boycott, K. M.; Care4Rare Canada Consortium] Care4Rare Res Consortium, Ottawa, ON, Canada.
   [Mah, J. K.] Univ Calgary, Dept Pediat, Sect Neurol, Calgary, AB, Canada.
   [Straub, V] Newcastle Hosp NHS Fdn Trust, Newcastle Upon Tyne, Tyne & Wear, England.
   [Shutt, T. E.] Univ Calgary, Alberta Childrens Hosp, Hotchkiss Brain Inst, Dept Med Genet,Res Inst, Calgary, AB, Canada.
   [Uapinyoying, P.] Childrens Natl Med Ctr, Res Genet Med, Washington, DC 20010 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute of
   Neurological Disorders & Stroke (NINDS); University of Calgary;
   University of Toronto; Hospital for Sick Children (SickKids); University
   of Toronto; Hospital for Sick Children (SickKids); Harvard University;
   Massachusetts Institute of Technology (MIT); Broad Institute; Newcastle
   University - UK; University of Iowa; University of Sydney; NSW Health;
   The Children's Hospital at Westmead; University of Sydney; University of
   Sydney; NSW Health; Sydney Childrens Hospitals Network; University of
   New South Wales Sydney; University of Hong Kong; University of Hong
   Kong; Oregon Health & Science University; University of Minnesota
   System; University of Minnesota Twin Cities; University of Pennsylvania;
   Pennsylvania Medicine; Childrens Hospital of Philadelphia; Virginia
   Commonwealth University; University of California System; University of
   California San Diego; Children's Mercy Hospital; Children's Mercy
   Hospital; University of Missouri System; University of Missouri Kansas
   City; University of Calgary; Alberta Childrens Hospital; University of
   Calgary; NSW Health; Sydney Childrens Hospitals Network; University of
   Sydney; Rigshospitalet; University of Copenhagen; Children's Mercy
   Hospital; Children's Mercy Hospital; University of Ottawa; Children's
   Hospital of Eastern Ontario; University of Calgary; Newcastle University
   - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Alberta
   Childrens Hospital; University of Calgary; Children's National Health
   System
RP Bonnemann, CG (corresponding author), NINDS, Neuromuscular & Neurogenet Disorders Childhood Se, NIH, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA.; Shutt, TE (corresponding author), Univ Calgary, Dept Biochem & Mol Biol, Calgary, AB, Canada.; Shutt, TE (corresponding author), Univ Calgary, Alberta Childrens Hosp, Hotchkiss Brain Inst, Dept Med Genet,Res Inst, Calgary, AB, Canada.
EM Carsten.bonnemann@nih.gov; timothy.shutt@ucalgary.ca
RI Vissing, John/IUN-4271-2023; Mohassel, Payam/IST-3469-2023; innes,
   allan/A-9955-2017; Bernier, Dr. Francois/AAP-2174-2020; Coffman,
   Keith/AAS-1342-2021; Saade, Dimah/AAT-9479-2021; Straub,
   Volko/M-9994-2015; Hu, Ying/GQZ-8100-2022; Shutt, Tim/U-9047-2019;
   Waddell, Leigh/L-3037-2017
OI Al Khatib, Iman/0000-0003-3566-6622; Witting, Nanna/0000-0002-0664-0709;
   Moore, Steven/0000-0002-6353-7900; Straub, Volker/0000-0001-9046-3540;
   Mohassel, Payam/0000-0001-5313-9514; Bernier,
   Francois/0000-0001-7063-4269; Innes, Micheil/0000-0001-9881-5467; Leach,
   Meganne E/0009-0007-5599-3512; Chan, Sophelia HS/0000-0002-2990-0163;
   Saade, Dimah/0000-0003-1938-9952; Gauquelin,
   Laurence/0000-0001-6820-1843; Kaur, Rupleen/0000-0001-9170-3921; Farrar,
   Michelle/0000-0002-4472-0902; Shutt, Timothy/0000-0001-5299-2943;
   Uapinyoying, Prech/0000-0003-1950-4164
FU NHGRI NIH HHS [UM1 HG008900] Funding Source: Medline; NINDS NIH HHS [U54
   NS053672] Funding Source: Medline; Ontario Genomics Institute [OGI-147]
   Funding Source: Medline
CR Adle-Biassette H, 2018, HAND CLINIC, V145, P51, DOI 10.1016/B978-0-12-802395-2.00006-7
   Amati-Bonneau P, 2005, ANN NEUROL, V58, P958, DOI 10.1002/ana.20681
   Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   Amberger JS, 2015, NUCLEIC ACIDS RES, V43, pD789, DOI 10.1093/nar/gku1205
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Ardicli D, 2019, NEUROMUSCULAR DISORD
   Ashley N, 2005, EXP CELL RES, V303, P432, DOI 10.1016/j.yexcr.2004.10.013
   Ban-Ishihara R, 2013, P NATL ACAD SCI USA, V110, P11863, DOI 10.1073/pnas.1301951110
   Carss KJ, 2013, AM J HUM GENET, V93, P29, DOI 10.1016/j.ajhg.2013.05.009
   Chen HC, 2007, CELL, V130, P548, DOI 10.1016/j.cell.2007.06.026
   Cirak S, 2013, BRAIN, V136, P269, DOI 10.1093/brain/aws312
   Demers-Lamarche J, 2016, J BIOL CHEM, V291, P10263, DOI 10.1074/jbc.M115.695825
   Eaton JS, 2007, J CLIN INVEST, V117, P2723, DOI 10.1172/JCI31604
   El-Hattab A, 2013, NEUROTHERAPEUTICS, V10, P186, DOI 10.1007/s13311-013-0177-6
   Foley ARD, 2015, NEXT GENERATION SEQU, V1, P2376
   Gal A, 2017, EMBO MOL MED, V9, P967, DOI 10.15252/emmm.201607058
   Godfrey C, 2011, CURR OPIN GENET DEV, V21, P278, DOI 10.1016/j.gde.2011.02.001
   Gustafsson CM, 2016, ANNU REV BIOCHEM, V85, P133, DOI 10.1146/annurev-biochem-060815-014402
   Harding BN, 2008, GREENFIELDS NEUROPAT, P365
   He JY, 2007, J CELL BIOL, V176, P141, DOI 10.1083/jcb.200609158
   Hermann GJ, 1998, J CELL BIOL, V143, P359, DOI 10.1083/jcb.143.2.359
   Hudson G, 2008, BRAIN, V131, P329, DOI 10.1093/brain/awm272
   Iwama K, 2018, J HUM GENET, V63, P263, DOI 10.1038/s10038-017-0405-8
   Kelly RDW, 2012, NUCLEIC ACIDS RES, V40, P10124, DOI 10.1093/nar/gks770
   Kim JY, 2005, NEUROLOGY, V64, P966, DOI 10.1212/01.WNL.0000157282.76715.B1
   Krieger M, 2013, BRAIN, V136, P3634, DOI 10.1093/brain/awt283
   Kukat C, 2015, P NATL ACAD SCI USA, V112, P11288, DOI 10.1073/pnas.1512131112
   Kuryshev VY, 2006, GENOMICS, V88, P143, DOI 10.1016/j.ygeno.2006.02.002
   Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057
   Lewis SC, 2016, SCIENCE, V353, DOI 10.1126/science.aaf5549
   Li K, 2020, EUR J MED GENET, V63, DOI 10.1016/j.ejmg.2019.01.013
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Nasca A, 2017, HUM MUTAT, V38, P970, DOI 10.1002/humu.23262
   Nasca A, 2016, HUM MUTAT, V37, P898, DOI 10.1002/humu.23033
   Nickolls AR, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.035931
   Nogueira C, 2014, ITAL J PEDIATR, V40, DOI 10.1186/1824-7288-40-34
   Nunnari J, 2012, CELL, V148, P1145, DOI 10.1016/j.cell.2012.02.035
   Potorac I, 2016, J ENDOCRINOL, V231, P197, DOI 10.1530/JOE-16-0384
   Ramos ES, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008085
   Renaldo F, 2012, BRAIN, V135, DOI 10.1093/brain/aws111
   Sabouny R, 2017, ANTIOXID REDOX SIGN, V27, P1447, DOI 10.1089/ars.2016.6855
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/nmeth.2019, 10.1038/NMETH.2019]
   Sobreira Nara, 2015, Hum Mutat, V36, P928, DOI 10.1002/humu.22844
   Spiegel R, 2016, J MED GENET, V53, P127, DOI 10.1136/jmedgenet-2015-103361
   Suarez-Rivero Juan M, 2016, Diseases, V5, DOI 10.3390/diseases5010001
   Suomalainen A, 2010, NEUROMUSCULAR DISORD, V20, P429, DOI 10.1016/j.nmd.2010.03.017
   Vielhaber S, 2013, ACTA NEUROPATHOL, V125, P245, DOI 10.1007/s00401-012-1036-y
NR 48
TC 24
Z9 28
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0001-6322
EI 1432-0533
J9 ACTA NEUROPATHOL
JI Acta Neuropathol.
PD DEC
PY 2019
VL 138
IS 6
BP 1013
EP 1031
DI 10.1007/s00401-019-02059-z
PG 19
WC Clinical Neurology; Neurosciences; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pathology
GA JM3NF
UT WOS:000496124600007
PM 31463572
OA hybrid, Green Published
DA 2024-11-01
ER

PT J
AU Ohwada, W
   Kouzu, H
   Sato, T
   Sazawa, K
   Matsui, A
   Nagano, N
   Koyama, M
   Ogasawara, N
   Takada, A
   Yano, T
   Furuhashi, M
AF Ohwada, Wataru
   Kouzu, Hidemichi
   Sato, Tatsuya
   Sazawa, Kahomi
   Matsui, Azumi
   Nagano, Nobutaka
   Koyama, Masayuki
   Ogasawara, Noriko
   Takada, Akifumi
   Yano, Toshiyuki
   Furuhashi, Masato
TI Case report: Transient lactate elevation by intravenous insulin infusion
   therapy for diabetic ketoacidosis in a patient with mitochondrial DNA
   3243 A &gt; G mutation: A glycolysis rebooting syndrome?
SO FRONTIERS IN CARDIOVASCULAR MEDICINE
LA English
DT Article
DE mitochondrial disease; cardiomyopathy; lactate metabolism; glycolysis;
   diabetic ketoacidosis; case report
AB Mitochondrial disease, most cases of which are caused by mitochondrial DNA (mtDNA) mutation, is present with multiple phenotypes including diabetes mellitus, sensorineural hearing loss, cardiomyopathy, muscle weakness, renal dysfunction, and encephalopathy, depending on the degree of heteroplasmy. While mitochondria play an important role in intracellular glucose and lactate metabolism in insulin-sensitive tissues such as muscles, appropriate strategies for glycemic control have not yet been established in a patient with mitochondrial disease, which is often complicated by myopathy. Here, we describe the history of a 40-year-old man with mtDNA 3243A > G who had sensorineural hearing loss, cardiomyopathy, muscle wasting, and diabetes mellitus with stage 3 chronic kidney disease. He developed mild diabetic ketoacidosis (DKA) in the process of treatment for poor glycemic control with severe latent hypoglycemia. According to the standard therapy for DKA, he was treated with continuous intravenous insulin infusion therapy, which unexpectedly resulted in an abrupt and transient elevation in blood lactate levels without exacerbation of heart failure and kidney function. Since blood lactate levels are determined by the balance between lactate production and consumption, an abrupt and transient lactate elevation following intravenous insulin injection therapy may reflect not only enhanced glycolysis in insulin-sensitive tissues with mitochondrial dysfunction but also decreased lactate consumption in the sarcopenic skeletal muscle and failing heart. Intravenous insulin infusion therapy in patients with mitochondrial disease may unmask derangements of intracellular glucose metabolism in response to insulin signaling.
C1 [Ohwada, Wataru; Kouzu, Hidemichi; Sato, Tatsuya; Sazawa, Kahomi; Matsui, Azumi; Nagano, Nobutaka; Koyama, Masayuki; Yano, Toshiyuki; Furuhashi, Masato] Sapporo Med Univ, Dept Cardiovasc Renal & Metab Med, Sch Med, Sapporo, Japan.
   [Sato, Tatsuya] Sapporo Med Univ, Dept Cellular Physiol & Signal Transduct, Sch Med, Sapporo, Japan.
   [Koyama, Masayuki] Sapporo Med Univ, Dept Publ Hlth, Sch Med, Sapporo, Japan.
   [Ogasawara, Noriko] Sapporo Med Univ, Dept Microbiol, Sch Med, Sapporo, Japan.
   [Ogasawara, Noriko] Sapporo Med Univ, Dept Otolaryngol Head & Neck Surg, Sch Med, Sapporo, Japan.
   [Takada, Akifumi] Steel Mem Muroran Hosp, Dept Cardiol Diabetic Internal Med, Muroran, Japan.
C3 Sapporo Medical University; Sapporo Medical University; Sapporo Medical
   University; Sapporo Medical University; Sapporo Medical University
RP Sato, T (corresponding author), Sapporo Med Univ, Dept Cardiovasc Renal & Metab Med, Sch Med, Sapporo, Japan.; Sato, T (corresponding author), Sapporo Med Univ, Dept Cellular Physiol & Signal Transduct, Sch Med, Sapporo, Japan.
EM sato.tatsuya@sapmed.ac.jp
RI Koyama, Masayuki/GQP-8789-2022; Furuhashi, Masato/AAT-5518-2021;
   Ogasawara, Noriko/K-6453-2019; Kouzu, Hidemichi/AAZ-3810-2020
OI Koyama, Masayuki/0000-0002-8165-5855
FU Sapporo Medical University
FX Funding This work was supported by Education and Research Grants in
   2022-2023 from Sapporo Medical University.
CR Brooks GA, 2018, CELL METAB, V27, P757, DOI 10.1016/j.cmet.2018.03.008
   Chen LK, 2014, J AM MED DIR ASSOC, V15, P95, DOI 10.1016/j.jamda.2013.11.025
   de Boer IH, 2022, KIDNEY INT, V102, pS1, DOI 10.1016/j.kint.2022.06.008
   ElSayed NA, 2023, DIABETES CARE, V46, pS267, DOI 10.2337/dc23-S016
   Hou Y, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219628
   Hue L, 2009, AM J PHYSIOL-ENDOC M, V297, pE578, DOI 10.1152/ajpendo.00093.2009
   Keidai Y, 2019, J DIABETES INVEST, V10, P1116, DOI 10.1111/jdi.12992
   Legouis D, 2020, NAT METAB, V2, P732, DOI 10.1038/s42255-020-0238-1
   Li DY, 2022, FRONT GENET, V13, DOI 10.3389/fgene.2022.951185
   Li XL, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/s41392-022-01151-3
   Murphy R, 2008, DIABETIC MED, V25, P383, DOI 10.1111/j.1464-5491.2008.02359.x
   Rabinowitz JD, 2020, NAT METAB, V2, P566, DOI 10.1038/s42255-020-0243-4
   Richter U, 2021, FEBS LETT, V595, P1003, DOI 10.1002/1873-3468.14049
   Sharma R, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI136055
   Stahn A, 2014, DIABETES CARE, V37, P516, DOI 10.2337/dc13-0600
   Stewart JB, 2015, NAT REV GENET, V16, P530, DOI 10.1038/nrg3966
   Yeung RO, 2018, REV ENDOCR METAB DIS, V19, P35, DOI 10.1007/s11154-018-9446-3
NR 17
TC 0
Z9 0
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2297-055X
J9 FRONT CARDIOVASC MED
JI Front. Cardiovasc. Med.
PD APR 17
PY 2023
VL 10
AR 1144925
DI 10.3389/fcvm.2023.1144925
PG 6
WC Cardiac & Cardiovascular Systems
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology
GA E6BG8
UT WOS:000976368800001
PM 37139126
OA Green Published, gold
DA 2024-11-01
ER

PT J
AU Kollberg, G
   Darin, N
   Benan, K
   Moslemi, AR
   Lindal, S
   Tulinius, M
   Oldfors, A
   Holme, E
AF Kollberg, Gittan
   Darin, Niklas
   Benan, Karin
   Moslemi, Ali-Reza
   Lindal, Sigurd
   Tulinius, Mar
   Oldfors, Anders
   Holme, Elisabeth
TI A novel homozygous <i>RRM2B</i> missense mutation in association with
   severe mtDNA depletion
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE mtDNA depletion; Mitochondrial myopathy; RRM2B; p53R2; Ribonucleotide
   reductase; dNTP synthesis
ID MITOCHONDRIAL-DNA; RIBONUCLEOTIDE REDUCTASE; DAMAGE; P53R2
AB This report describes two brothers, both deceased in infancy, with severe depletion of mitochondrial DNA (mtDNA) in muscle tissue. Both had feeding difficulties, failure to thrive, severe Muscular hypotonia and lactic acidosis. One of the boys developed a renal proximal tubulopathy. A novel homozygous c.686 G -> T missense mutation in the RRM2B gene, encoding the p53-inducible ribonucleotide reductase subunit (p53R2), was identified. This is the third report on mutations in RRM2B associated with severe mtDNA depletion, which further highlights the importance of de novo synthesis of deoxyribonucleotides (dNTPs) for mtDNA maintenance. (C) 2008 Elsevier B.V. All rights reserved.
C1 [Kollberg, Gittan; Holme, Elisabeth] Sahlgrens Univ Hosp, Dept Clin Chem, SE-41345 Gothenburg, Sweden.
   [Darin, Niklas; Tulinius, Mar] Queen Silvia Childrens Hosp, Dept Paediat, Gothenburg, Sweden.
   [Benan, Karin] Ullevaal Univ Hosp, Dept Paediat, Oslo, Norway.
   [Moslemi, Ali-Reza; Oldfors, Anders] Sahlgrens Univ Hosp, Dept Pathol, SE-41345 Gothenburg, Sweden.
   [Lindal, Sigurd] Univ Tromso Hosp, Dept Pathol, N-9012 Tromso, Norway.
C3 Sahlgrenska University Hospital; Queen Silvia Children's Hospital;
   University of Oslo; Sahlgrenska University Hospital; UiT The Arctic
   University of Tromso; University Hospital of North Norway
RP Kollberg, G (corresponding author), Sahlgrens Univ Hosp, Dept Clin Chem, Bruna Straket 16, SE-41345 Gothenburg, Sweden.
EM gittan.kollberg@gu.se
RI Darin, Niklas/AAL-6345-2020
CR Alberio S, 2007, MITOCHONDRION, V7, P6, DOI 10.1016/j.mito.2006.11.010
   Andréasson H, 2002, BIOTECHNIQUES, V33, P402, DOI 10.2144/02332rr07
   Bornstein B, 2008, NEUROMUSCULAR DISORD, V18, P453, DOI 10.1016/j.nmd.2008.04.006
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Guittet O, 2001, J BIOL CHEM, V276, P40647, DOI 10.1074/jbc.M106088200
   Håkansson P, 2006, J BIOL CHEM, V281, P7834, DOI 10.1074/jbc.M512894200
   Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71
   Pronicki M, 2008, J CLIN PATHOL, V61, P460, DOI 10.1136/jcp.2007.051060
   Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506
   Thelander L, 2007, NAT GENET, V39, P703, DOI 10.1038/ng0607-703
   Tulinius M, 2005, NEUROMUSCULAR DISORD, V15, P412, DOI 10.1016/j.nmd.2005.03.010
NR 11
TC 52
Z9 59
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD FEB
PY 2009
VL 19
IS 2
BP 147
EP 150
DI 10.1016/j.nmd.2008.11.014
PG 4
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 414MA
UT WOS:000263866700010
PM 19138848
DA 2024-11-01
ER

PT J
AU DeFoor, N
   Paul, S
   Li, S
   Basso, EKG
   Stevenson, V
   Browning, JL
   Prater, AK
   Brindley, S
   Tao, G
   Pickrell, AM
AF DeFoor, Nicole
   Paul, Swagatika
   Li, Shuang
   Basso, Erwin K. Gudenschwager
   Stevenson, Valentina
   Browning, Jack L.
   Prater, Anna K.
   Brindley, Samantha
   Tao, Ge
   Pickrell, Alicia M.
TI Remdesivir increases mtDNA copy number causing mild alterations to
   oxidative phosphorylation
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MITOCHONDRIAL-DNA DEPLETION; ANTIRETROVIRAL THERAPY; AZT; FIALURIDINE;
   LIVER; ACE2; RAT; EXPRESSION; INFECTION; MYOPATHY
AB SARS-CoV-2 causes the severe respiratory disease COVID-19. Remdesivir (RDV) was the first fast-tracked FDA approved treatment drug for COVID-19. RDV acts as an antiviral ribonucleoside (adenosine) analogue that becomes active once it accumulates intracellularly. It then diffuses into the host cell and terminates viral RNA transcription. Previous studies have shown that certain nucleoside analogues unintentionally inhibit mitochondrial RNA or DNA polymerases or cause mutational changes to mitochondrial DNA (mtDNA). These past findings on the mitochondrial toxicity of ribonucleoside analogues motivated us to investigate what effects RDV may have on mitochondrial function. Using in vitro and in vivo rodent models treated with RDV, we observed increases in mtDNA copy number in Mv1Lu cells (35.26% increase +/- 11.33%) and liver (100.27% increase +/- 32.73%) upon treatment. However, these increases only resulted in mild changes to mitochondrial function. Surprisingly, skeletal muscle and heart were extremely resistant to RDV treatment, tissues that have preferentially been affected by other nucleoside analogues. Although our data suggest that RDV does not greatly impact mitochondrial function, these data are insightful for the treatment of RDV for individuals with mitochondrial disease.
C1 [DeFoor, Nicole; Browning, Jack L.; Prater, Anna K.; Brindley, Samantha; Pickrell, Alicia M.] Virginia Tech, Sch Neurosci, Life Sci Room 217,970 Washington St SW, Blacksburg, VA 24061 USA.
   [Paul, Swagatika] Virginia Maryland Coll Vet Med, Grad Program Biomed & Vet Sci, Blacksburg, VA 24061 USA.
   [Li, Shuang; Tao, Ge] Med Univ South Carolina, Dept Regenerat Med & Cell Biol, Charleston, SC 29425 USA.
   [Basso, Erwin K. Gudenschwager] Virginia Maryland Coll Vet Med, Dept Biomed Sci & Pathobiol, Blacksburg, VA 24061 USA.
   [Stevenson, Valentina] Virginia Maryland Coll Vet Med, Virginia Tech Anim Lab Serv, Blacksburg, VA 24061 USA.
C3 Virginia Polytechnic Institute & State University; Medical University of
   South Carolina
RP Pickrell, AM (corresponding author), Virginia Tech, Sch Neurosci, Life Sci Room 217,970 Washington St SW, Blacksburg, VA 24061 USA.
EM alicia.pickrell@vt.edu
RI Tao, Ge/L-1276-2016; Pickrell, Alicia/B-8494-2018
OI Paul, Swagatika/0000-0001-8770-0672; Li, Shuang/0000-0002-0550-8722;
   Gudenschwager Basso, Erwin Kristobal/0000-0001-7903-9992; DeFoor,
   Nicole/0000-0002-2818-680X; Pickrell, Alicia/0000-0002-8470-6056;
   Browning, Jack/0000-0002-3102-0667; Prater, Anna/0009-0008-9035-4588
FU NIH [R21AI162775]
FX This work is sponsored by NIH grant R21AI162775 (AMP). We also thank
   VT-UMD College of Veterinary Medicine's Histopathology core for
   assistance with histology and serum testing. Sequencing was performed at
   the Genomics Sequencing Center, which is part of the Fralin Life Science
   Institute at Virginia Tech.
CR Afgan E, 2019, FUTURE GENER COMP SY, V94, P802, DOI 10.1016/j.future.2018.04.037
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Barrientos Antoni, 2009, Curr Protoc Hum Genet, VChapter 19, DOI 10.1002/0471142905.hg1903s63
   Beigel JH, 2020, NEW ENGL J MED, V383, P1813, DOI 10.1056/NEJMoa2007764
   Bjork JA, 2021, TOXICOL APPL PHARM, V433, DOI 10.1016/j.taap.2021.115783
   Broder S, 2010, ANTIVIR RES, V85, P1, DOI 10.1016/j.antiviral.2009.10.002
   Cazzalini O, 2001, BIOCHEM PHARMACOL, V62, P893, DOI 10.1016/S0006-2952(01)00713-4
   DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   Eastman RT, 2020, ACS CENTRAL SCI, V6, P672, DOI 10.1021/acscentsci.0c00489
   Filograna R, 2021, FEBS LETT, V595, P976, DOI 10.1002/1873-3468.14021
   FISCHL MA, 1987, NEW ENGL J MED, V317, P185, DOI 10.1056/NEJM198707233170401
   FOUREL I, 1992, J MED VIROL, V37, P122, DOI 10.1002/jmv.1890370209
   Gilead R., Summary on compassionate use
   Goldman JD, 2020, NEW ENGL J MED, V383, P1827, DOI 10.1056/NEJMoa2015301
   Gordon CJ, 2020, J BIOL CHEM, V295, P6785, DOI 10.1074/jbc.RA120.013679
   Gordon CJ, 2020, J BIOL CHEM, V295, P4773, DOI 10.1074/jbc.AC120.013056
   Harvey WT, 2021, NAT REV MICROBIOL, V19, P409, DOI 10.1038/s41579-021-00573-0
   HAYAKAWA M, 1991, BIOCHEM BIOPH RES CO, V176, P87, DOI 10.1016/0006-291X(91)90893-C
   Heallen T, 2013, DEVELOPMENT, V140, P4683, DOI 10.1242/dev.102798
   Herbst A, 2022, PLOS ONE, V17, DOI 10.1371/journal.pone.0271850
   HERSKOWITZ A, 1992, ANN INTERN MED, V116, P311, DOI 10.7326/0003-4819-116-4-311
   Hoffmann M, 2020, CELL, V181, P271, DOI 10.1016/j.cell.2020.02.052
   Humeniuk R, 2021, CLIN PHARMACOKINET, V60, P569, DOI 10.1007/s40262-021-00984-5
   Jia HP, 2005, J VIROL, V79, P14614, DOI 10.1128/JVI.79.23.14614-14621.2005
   Justo R, 2005, AM J PHYSIOL-CELL PH, V289, pC372, DOI 10.1152/ajpcell.00035.2005
   Kang L, 2021, CELL, V184, P4392, DOI 10.1016/j.cell.2021.07.007
   Kwok M, 2022, CARDIOVASC RES, V118, P2652, DOI 10.1093/cvr/cvab311
   Lewis W, 2001, LAB INVEST, V81, P777, DOI 10.1038/labinvest.3780288
   Lewis W, 1996, P NATL ACAD SCI USA, V93, P3592, DOI 10.1073/pnas.93.8.3592
   Lewis W, 1997, LAB INVEST, V76, P77
   Masini A, 1999, J NEUROL SCI, V166, P131, DOI 10.1016/S0022-510X(99)00126-4
   MCKENZIE R, 1995, NEW ENGL J MED, V333, P1099, DOI 10.1056/NEJM199510263331702
   Meyerholz DK, 2018, LAB INVEST, V98, P844, DOI 10.1038/s41374-018-0057-0
   MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096
   MODICANAPOLITANO JS, 1993, BIOCHEM BIOPH RES CO, V194, P170, DOI 10.1006/bbrc.1993.1800
   Mossel EC, 2005, J VIROL, V79, P3846, DOI 10.1128/JVI.79.6.3846-3850.2005
   Mulangu S, 2019, NEW ENGL J MED, V381, P2293, DOI 10.1056/NEJMoa1910993
   Onorati M, 2016, CELL REP, V16, P2576, DOI 10.1016/j.celrep.2016.08.038
   Payne BAI, 2011, NAT GENET, V43, P806, DOI 10.1038/ng.863
   Pickrell AM, 2011, J NEUROSCI, V31, P9895, DOI 10.1523/JNEUROSCI.6223-10.2011
   Poirier MC, 1999, J ACQ IMMUN DEF SYND, V22, P477
   Poirier MC, 2015, CURR OPIN PEDIATR, V27, P233, DOI 10.1097/MOP.0000000000000193
   Pruijssers AJ, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.107940
   Richardson S, 2020, JAMA-J AM MED ASSOC, V323, P2052, DOI 10.1001/jama.2020.6775
   Roger AJ, 2017, CURR BIOL, V27, pR1177, DOI 10.1016/j.cub.2017.09.015
   Ross AC, 2012, HIV MED, V13, P98, DOI 10.1111/j.1468-1293.2011.00945.x
   Saffran HA, 2007, EMBO REP, V8, P188, DOI 10.1038/sj.embor.7400878
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Schon EA, 2012, NAT REV GENET, V13, P878, DOI 10.1038/nrg3275
   Sheahan TP, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb5883
   Sheahan TP, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal3653
   Shi CS, 2014, J IMMUNOL, V193, P3080, DOI 10.4049/jimmunol.1303196
   Silaidos C, 2018, BIOL SEX DIFFER, V9, DOI 10.1186/s13293-018-0193-7
   STASCHKE KA, 1994, J VIROL, V68, P8265, DOI 10.1128/JVI.68.12.8265-8269.1994
   Tao G, 2016, NATURE, V534, P119, DOI 10.1038/nature17959
   Tchesnokov EP, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11040326
   Thoolen B, 2010, TOXICOL PATHOL, V38, p5S, DOI 10.1177/0192623310386499
   U.S.F.D.A. Administration, 2020, Update: FDA Issues Emergency Use of Authorization for Potential COVID-19 Treatment
   van Dorp L, 2020, INFECT GENET EVOL, V83, DOI 10.1016/j.meegid.2020.104351
   Wang X, 2011, MOL ONCOL, V5, P399, DOI 10.1016/j.molonc.2011.07.008
   WEISSMAN JD, 1992, NEUROLOGY, V42, P619, DOI 10.1212/WNL.42.3.619
   West AP, 2015, NATURE, V520, P553, DOI 10.1038/nature14156
   WHO, COR DIS COVID 19
   WHO Solidarity Trial Consortium, 2022, LANCET, V399, P1941, DOI 10.1016/S0140-6736(22)00519-0
   Wu KE, 2020, CELL SYST, V11, P102, DOI 10.1016/j.cels.2020.06.008
   Xu YL, 2021, ANTIMICROB AGENTS CH, V65, DOI 10.1128/AAC.02237-20
   Young MJ, 2017, FRONT MOL BIOSCI, V4, DOI 10.3389/fmolb.2017.00074
NR 68
TC 2
Z9 2
U1 0
U2 0
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD SEP 15
PY 2023
VL 13
IS 1
AR 15339
DI 10.1038/s41598-023-42704-y
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA LC7Y8
UT WOS:001184658500013
PM 37714940
OA Green Published, gold
DA 2024-11-01
ER

PT J
AU Bulduk, BK
   Kilic, HB
   Bekircan-Kurt, CE
   Haliloglu, G
   Ozdamar, SE
   Topaloglu, H
   Kocaefe, YC
AF Bulduk, Bengisu Kevser
   Kilic, Hasan Basri
   Bekircan-Kurt, Can Ebru
   Haliloglu, Goknur
   Ozdamar, Sevim Erdem
   Topaloglu, Haluk
   Kocaefe, Y. Cetin
TI A Novel Amplification-Refractory Mutation System-PCR Strategy to Screen
   <i>MT-TL1</i> Pathogenic Variants in Patient Repositories
SO GENETIC TESTING AND MOLECULAR BIOMARKERS
LA English
DT Article
DE mitochondrial cytopathies; ARMS-PCR; HRM; mtDNA; mt-tRNA mutations
ID TRANSFER RNALEU(UUR) GENE; MITOCHONDRIAL TRANSCRIPTION TERMINATION;
   STROKE-LIKE EPISODES; POINT MUTATION; LACTIC-ACIDOSIS; MELAS SUBGROUP;
   DNA; MYOPATHY; MTDNA; CARDIOMYOPATHY
AB Aim: Pathogenic variants within mitochondrial tRNA and rRNA genes negatively affect protein synthesis function and cause oxidative phosphorylation defects. The majority of mitochondrial cytopathies are caused by pathogenic point variants within the mitochondrial tRNA gene for leucine (MT-TL1). This study was designed to evaluate a novel amplification-refractory mutation system (ARMS)-PCR based assay to screen patient samples with a clinical diagnosis of mitochondrial cytopathies.
   Methods: Tissue DNA samples from 219 affected individuals were screened for the pathogenic variants m.3271T>C, m.3291Ty >C, m.3303C>T, m.3256C>T, and m.3260A>G along with the most frequent m.3243A>G mutation in the MT-TL1 gene. The assay included a "High Resolution Melt curve analysis" to enhance detection limits. The precision of the assay was verified using synthetic controls with variant heteroplasmy ratios.
   Results: The screening identified the second reported m.3303C>T case as well as two patients with m.3243A>G variants and a rare variant exhibiting m.3290T>C.
   Conclusion: ARMS-PCR is superior to Sanger sequencing for the detection of variations exhibiting low heteroplasmy. These results provide "proof of concepts" for the implementation of this application for future screening of rare mtDNA variations in sample repositories.
C1 [Bulduk, Bengisu Kevser; Kilic, Hasan Basri; Kocaefe, Y. Cetin] Hacettepe Univ, Sch Med, Dept Med Biol, TR-06100 Ankara, Turkey.
   [Bekircan-Kurt, Can Ebru; Ozdamar, Sevim Erdem] Hacettepe Univ, Sch Med, Dept Neurol, Ankara, Turkey.
   [Haliloglu, Goknur; Topaloglu, Haluk] Hacettepe Univ, Dept Pediat Neurol, Sch Med, Ankara, Turkey.
C3 Hacettepe University; Hacettepe University; Hacettepe University
RP Kocaefe, YC (corresponding author), Hacettepe Univ, Sch Med, Dept Med Biol, TR-06100 Ankara, Turkey.
EM kocaefe@hacettepe.edu.tr
RI Bulduk, Bengisu/H-7561-2013; kurt, canebru/AAQ-5745-2021; KILIÇ, Hasan
   Basri/AAF-5079-2020; KOCAEFE, CETIN/I-8336-2013
OI KILIC, Hasan Basri/0000-0002-3204-5567; Bulduk, Bengisu
   Kevser/0000-0001-7859-4636; KOCAEFE, CETIN/0000-0003-3216-9399
CR Bates MGD, 2012, EUR HEART J, V33, P3023, DOI 10.1093/eurheartj/ehs275
   Brisca G, 2015, BIOCHEM BIOPH RES CO, V458, P601, DOI 10.1016/j.bbrc.2015.01.157
   CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221
   Collins A., 2012, Open Bioinformat. J., V6, P55, DOI [DOI 10.2174/1875036201206010055, 10.2174/1875036201206010055]
   Druml B, 2014, FOOD CHEM, V158, P245, DOI 10.1016/j.foodchem.2014.02.111
   GOTO Y, 1992, ANN NEUROL, V31, P672, DOI 10.1002/ana.410310617
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   GOTO Y, 1995, MUSCLE NERVE, pS107
   GOTO YI, 1994, BIOCHEM BIOPH RES CO, V202, P1624, DOI 10.1006/bbrc.1994.2119
   HAYASHI JI, 1993, BIOCHEM BIOPH RES CO, V197, P1049, DOI 10.1006/bbrc.1993.2584
   HESS JF, 1991, NATURE, V351, P236, DOI 10.1038/351236a0
   Hyvärinen AK, 2007, NUCLEIC ACIDS RES, V35, P6458, DOI 10.1093/nar/gkm676
   Jeppesen TD, 2003, J NEUROL SCI, V214, P17, DOI 10.1016/S0022-510X(03)00168-0
   Kelland E, 2016, MOL GENET METAB REP, V6, P64, DOI 10.1016/j.ymgmr.2016.02.003
   Kiliç HB, 2019, TURK J BIOCHEM, V44, P769, DOI 10.1515/tjb-2018-0372
   KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5
   Li M, 2014, CLIN CHEM, V60, P864, DOI 10.1373/clinchem.2013.220160
   Palecek T, 2012, INT HEART J, V53, P383, DOI 10.1536/ihj.53.383
   Pyle A, 2007, J MED GENET, V44, P69, DOI 10.1136/jmg.2006.043109
   Ryan SE, 2016, MOL VIS, V22, P1169
   SAKUTA R, 1993, J NEUROL SCI, V115, P158, DOI 10.1016/0022-510X(93)90219-O
   SILVESTRI G, 1994, HUM MUTAT, V3, P37, DOI 10.1002/humu.1380030107
   Skladal D, 2003, BRAIN, V126, P1905, DOI 10.1093/brain/awg170
   Suomalainen A, 2015, EMBO MOL MED, V7, P1245, DOI 10.15252/emmm.201505350
   SWEENEY MG, 1993, Q J MED, V86, P435
   Medrano RFV, 2014, MOL BIOTECHNOL, V56, P599, DOI 10.1007/s12033-014-9734-4
   Wallace DC, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a021220
   Wong LJC, 2010, MOL GENET METAB, V100, P111, DOI 10.1016/j.ymgme.2010.02.024
   ZEVIANI M, 1991, LANCET, V338, P143, DOI 10.1016/0140-6736(91)90136-D
NR 29
TC 2
Z9 2
U1 2
U2 8
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1945-0265
EI 1945-0257
J9 GENET TEST MOL BIOMA
JI Genet. Test. Mol. Biomark.
PD MAR 1
PY 2020
VL 24
IS 3
BP 165
EP 170
DI 10.1089/gtmb.2019.0079
PG 6
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA LB8QP
UT WOS:000524895300008
PM 32167396
DA 2024-11-01
ER

PT J
AU Souren, NYP
   Gerdes, LA
   Kümpfel, T
   Lutsik, P
   Klopstock, T
   Hohlfeld, R
   Walter, J
AF Souren, Nicole Y. P.
   Gerdes, Lisa A.
   Kuempfel, Tania
   Lutsik, Pavlo
   Klopstock, Thomas
   Hohlfeld, Reinhard
   Walter, Joern
TI Mitochondrial DNA Variation and Heteroplasmy in Monozygotic Twins
   Clinically Discordant for Multiple Sclerosis
SO HUMAN MUTATION
LA English
DT Article
DE multiple sclerosis; mtDNA; monozygotic twins; heteroplasmy; LHON
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; HEREDITARY OPTIC NEUROPATHY;
   POLYMERASE-GAMMA; TRANSFER-RNA; OXIDATIVE-PHOSPHORYLATION; POINT
   MUTATIONS; GENE; PATHOGENICITY; GENOME; MS
AB We examined the debated link between mitochondrial DNA (mtDNA) variation and multiple sclerosis (MS) using 49 monozygotic (MZ) twin pairs clinically discordant for MS, which enables to associate de novo mtDNA variants, skewed heteroplasmy, and mtDNA copy number with MS manifestation. Ultra-deep sequencing of blood-derived mtDNA revealed 25 heteroplasmic variants with potentially pathogenic features in 18 pairs. All variants were pair-specific and had low and/or similar heteroplasmy levels in both cotwins. In one pair, a confirmed pathogenic variant (m.11778G>A, heteroplasmy approximate to 50%) associated with Leber hereditary optic neuropathy was detected. Detailed diagnostic investigation revealed subclinical MS signs in the prior nondiseased cotwin. Moreover, neither mtDNA deletions nor copy-number variations were involved. Furthermore, the majority of heteroplasmic variants were shared among MZ twins and exhibited more similar heteroplasmy levels in the same tissue of MZ twins as compared with different tissues of the same individual. Heteroplasmy levels were also more similar within MZ twins compared with nonidentical siblings. Our analysis excludes mtDNA variation as a major driver of the discordant clinical manifestation of MS in MZ twins, and provides valuable insights into the occurrence and distribution of heteroplasmic variants within MZ twins and nonidentical siblings, and across different tissues.
C1 [Souren, Nicole Y. P.; Lutsik, Pavlo; Walter, Joern] Univ Saarland, Dept Genet Epigenet, Saarbrucken, Germany.
   [Gerdes, Lisa A.; Kuempfel, Tania; Hohlfeld, Reinhard] Univ Munich, Inst Clin Neuroimmunol, Med Campus Grosshadern, Munich, Germany.
   [Klopstock, Thomas] Univ Munich, Friedrich Baur Inst, Dept Neurol, Munich, Germany.
   [Klopstock, Thomas; Hohlfeld, Reinhard] Munich Cluster Syst Neurol SyNergy, Munich, Germany.
   [Klopstock, Thomas] DZNE German Ctr Neurodegenerat Dis, Munich, Germany.
C3 Saarland University; University of Munich; University of Munich;
   University of Munich; Helmholtz Association; German Center for
   Neurodegenerative Diseases (DZNE)
RP Souren, NYP (corresponding author), Univ Saarland, FR Biowissensch 8 3, Genet Epigenet, Nat Wissensch Tech Fak 3, Postfach 151150, D-66041 Saarbrucken, Germany.
EM nicole.souren@uni-saarland.de
RI Walter, Jörn/AFN-6428-2022; Kümpfel, Tania/ABH-1780-2021; Lutsik,
   Pavlo/T-8337-2019
OI Lutsik, Pavlo/0000-0001-9383-8555
FU German Multiple Sclerosis Foundation (National German and Regional
   Bavarian Foundation); German Research Council [SFB-TR 128 SyNergy];
   Krankheitsbezogenes Kompetenznetz Multiple Sklerose; Verein zur
   Therapieforschung fur MS Kranke; Gemeinnutzige Hertie Stiftung;
   Deutsches Bundesministerium fur Bildung und Forschung through the German
   Network for Mitochondrial Disorders [mitoNET 01GM1113A]
FX Contract grant sponsors: German Multiple Sclerosis Foundation (National
   German and Regional Bavarian Foundation); German Research Council
   [SFB-TR 128 SyNergy]; Krankheitsbezogenes Kompetenznetz Multiple
   Sklerose; Verein zur Therapieforschung fur MS Kranke; Gemeinnutzige
   Hertie Stiftung; Deutsches Bundesministerium fur Bildung und Forschung
   through the German Network for Mitochondrial Disorders [mitoNET
   01GM1113A].
CR Adzhubei Ivan, 2013, Curr Protoc Hum Genet, VChapter 7, DOI 10.1002/0471142905.hg0720s76
   Andrew T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022332
   Avital G, 2012, HUM MOL GENET, V21, P4214, DOI 10.1093/hmg/dds245
   Bai RK, 2005, J MOL DIAGN, V7, P613, DOI 10.1016/S1525-1578(10)60595-8
   Baranzini SE, 2010, NATURE, V464, P1351, DOI 10.1038/nature08990
   Barnett MH, 2004, ANN NEUROL, V55, P458, DOI 10.1002/ana.20016
   Beecham AH, 2013, NAT GENET, V45, P1353, DOI 10.1038/ng.2770
   Bénit P, 2010, TRENDS MOL MED, V16, P210, DOI 10.1016/j.molmed.2010.03.001
   Blakely EL, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.011296
   Blok MJ, 2009, J MED GENET, V46, P776, DOI 10.1136/jmg.2009.067686
   Blokhin A, 2008, J MOL NEUROSCI, V35, P283, DOI 10.1007/s12031-008-9115-1
   Brown MD, 2001, HUM GENET, V109, P33, DOI 10.1007/s004390100538
   Campbell GR, 2011, ANN NEUROL, V69, P481, DOI 10.1002/ana.22109
   Castellana S, 2015, HUM MUTAT, V36, pE2413, DOI 10.1002/humu.22720
   Chan SSL, 2006, HUM MOL GENET, V15, P3473, DOI 10.1093/hmg/ddl424
   Chan SSL, 2009, BBA-BIOENERGETICS, V1787, P312, DOI 10.1016/j.bbabio.2008.10.007
   Chinnery PF, 2001, AM J MED GENET, V98, P235, DOI 10.1002/1096-8628(20010122)98:3<235::AID-AJMG1086>3.0.CO;2-O
   Compston A, 2008, LANCET, V372, P1502, DOI 10.1016/S0140-6736(08)61620-7
   Dahl H H, 2000, Hum Reprod, V15 Suppl 2, P246
   Degos B, 2014, J CLIN NEUROSCI, V21, P186, DOI 10.1016/j.jocn.2013.03.019
   Dimmock D, 2010, CLIN CHEM, V56, P1119, DOI 10.1373/clinchem.2009.141549
   Ebers GC, 2004, LANCET, V363, P1773, DOI 10.1016/S0140-6736(04)16304-6
   Echaniz-Laguna A, 2010, ARCH NEUROL-CHICAGO, V67, P1140, DOI 10.1001/archneurol.2010.219
   Fischer MT, 2012, BRAIN, V135, P886, DOI 10.1093/brain/aws012
   Frederiksen AL, 2006, J MED GENET, V43, DOI 10.1136/jmg.2005.039339
   Freyer C, 2012, NAT GENET, V44, P1282, DOI 10.1038/ng.2427
   Giardine B, 2005, GENOME RES, V15, P1451, DOI 10.1101/gr.4086505
   Goecks J, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-8-r86
   Hawkes CH, 2009, MULT SCLER J, V15, P661, DOI 10.1177/1352458509104592
   Hellebrekers DMEI, 2012, HUM REPROD UPDATE, V18, P341, DOI 10.1093/humupd/dms008
   Henderson APD, 2009, ANN NEUROL, V66, P739, DOI 10.1002/ana.21800
   Hoppenbrouwers IA, 2008, ARCH NEUROL-CHICAGO, V65, P345, DOI 10.1001/archneurol.2007.63
   Howell N, 2003, AM J HUM GENET, V72, P1460, DOI 10.1086/375537
   Hudson G, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004369
   Jacobs L, 2007, MOL HUM REPROD, V13, P149, DOI 10.1093/molehr/gal112
   JOHNS DR, 1993, BIOCHEM BIOPH RES CO, V196, P810, DOI 10.1006/bbrc.1993.2321
   Jokinen R, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001161
   Knez J, 2016, AM J EPIDEMIOL, V183, P138, DOI 10.1093/aje/kwv175
   Koboldt DC, 2012, GENOME RES, V22, P568, DOI 10.1101/gr.129684.111
   LAMMINEN T, 1995, AM J HUM GENET, V56, P1238
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Liu SY, 2011, ASIAN J ANDROL, V13, P298, DOI 10.1038/aja.2010.91
   Lott Marie T, 2013, Curr Protoc Bioinformatics, V44, DOI 10.1002/0471250953.bi0123s44
   Lutz-Bonengel S, 2008, INT J LEGAL MED, V122, P315, DOI 10.1007/s00414-008-0240-8
   McFarland R, 2010, LANCET NEUROL, V9, P829, DOI 10.1016/S1474-4422(10)70116-2
   Molnar MJ, 2009, J NEUROL, V256, P264, DOI 10.1007/s00415-009-0841-2
   Nakahara J, 2012, CLIN REV ALLERG IMMU, V42, P26, DOI 10.1007/s12016-011-8287-6
   Ng PC, 2003, NUCLEIC ACIDS RES, V31, P3812, DOI 10.1093/nar/gkg509
   Nikic I, 2011, NAT MED, V17, P495, DOI 10.1038/nm.2324
   Orsucci D, 2011, J MOL NEUROSCI, V44, P17, DOI 10.1007/s12031-010-9488-9
   Palace J, 2009, J NEUROL SCI, V286, P24, DOI 10.1016/j.jns.2009.09.009
   Payne BAI, 2013, HUM MOL GENET, V22, P384, DOI 10.1093/hmg/dds435
   Pfeffer G, 2013, NEUROLOGY, V81, P2073, DOI 10.1212/01.wnl.0000437308.22603.43
   Polman CH, 2011, ANN NEUROL, V69, P292, DOI 10.1002/ana.22366
   Pütz J, 2007, RNA, V13, P1184, DOI 10.1261/rna.588407
   Pyle A, 2010, INTENS CARE MED, V36, P956, DOI 10.1007/s00134-010-1823-7
   Rausch T, 2012, BIOINFORMATICS, V28, pI333, DOI 10.1093/bioinformatics/bts378
   Rebolledo-Jaramillo B, 2014, P NATL ACAD SCI USA, V111, P15474, DOI 10.1073/pnas.1409328111
   Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754
   Samuels DC, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003929
   Scott Lynette, 2002, Reprod Biomed Online, V5, P276
   Shtilbans A, 1999, J CHILD NEUROL, V14, P610, DOI 10.1177/088307389901400910
   Slee M, 2011, J CLIN NEUROSCI, V18, P1318, DOI 10.1016/j.jocn.2011.02.019
   Smith C, 2010, NUCLEIC ACIDS RES, V38, pW373, DOI 10.1093/nar/gkq316
   Spyropoulos A, 2013, JAMA NEUROL, V70, P1552, DOI 10.1001/jamaneurol.2013.4111
   Stewart JD, 2010, HEPATOLOGY, V52, P1791, DOI 10.1002/hep.23891
   SWEENEY VP, 1986, CAN J NEUROL SCI, V13, P47, DOI 10.1017/S0317167100035782
   Tang S, 2011, J MED GENET, V48, P669, DOI 10.1136/jmedgenet-2011-100222
   Taylor RW, 1998, BIOCHEM BIOPH RES CO, V243, P47, DOI 10.1006/bbrc.1997.8055
   Thiede C, 2000, BONE MARROW TRANSPL, V25, P575, DOI 10.1038/sj.bmt.1702170
   Tranah GJ, 2015, NEUROLOGY, V85, P325, DOI 10.1212/WNL.0000000000001744
   Tuppen HAL, 2010, BBA-BIOENERGETICS, V1797, P113, DOI 10.1016/j.bbabio.2009.09.005
   Vianello D, 2013, HUM MUTAT, V34, P1189, DOI 10.1002/humu.22356
   Wang J, 2012, GENET MED, V14, P620, DOI 10.1038/gim.2012.4
   Westerlind H, 2014, BRAIN, V137, P770, DOI 10.1093/brain/awt356
   Witte ME, 2014, TRENDS MOL MED, V20, P179, DOI 10.1016/j.molmed.2013.11.007
   Wolf C, 2010, BMC GENET, V11, DOI 10.1186/1471-2156-11-8
   Wong LJC, 2008, HUM MUTAT, V29, pE150, DOI 10.1002/humu.20824
   Yarham JW, 2012, MITOCHONDRION, V12, P533, DOI 10.1016/j.mito.2012.06.009
   Yarham JW, 2011, HUM MUTAT, V32, P1319, DOI 10.1002/humu.21575
   Ye KX, 2014, P NATL ACAD SCI USA, V111, P10654, DOI 10.1073/pnas.1403521111
   Zhang W, 2012, CLIN CHEM, V58, P1322, DOI 10.1373/clinchem.2011.181438
NR 83
TC 12
Z9 12
U1 2
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1059-7794
EI 1098-1004
J9 HUM MUTAT
JI Hum. Mutat.
PD AUG
PY 2016
VL 37
IS 8
BP 765
EP 775
DI 10.1002/humu.23003
PG 11
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA DR5GU
UT WOS:000379932300007
PM 27119776
OA gold
DA 2024-11-01
ER

PT J
AU Chinnery, PF
   DiMauro, S
   Shanske, S
   Schon, EA
   Zeviani, M
   Mariotti, C
   Carrara, F
   Lombes, A
   Laforet, P
   Ogier, H
   Jaksch, M
   Lochmüller, H
   Horvath, R
   Deschauer, M
   Thorburn, DR
   Bindoff, LA
   Poulton, J
   Taylor, RW
   Matthews, JNS
   Turnbull, DM
AF Chinnery, PF
   DiMauro, S
   Shanske, S
   Schon, EA
   Zeviani, M
   Mariotti, C
   Carrara, F
   Lombes, A
   Laforet, P
   Ogier, H
   Jaksch, M
   Lochmüller, H
   Horvath, R
   Deschauer, M
   Thorburn, DR
   Bindoff, LA
   Poulton, J
   Taylor, RW
   Matthews, JNS
   Turnbull, DM
TI Risk of developing a mitochondrial DNA deletion disorder
SO LANCET
LA English
DT Article
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; HUMAN OOCYTES; DUPLICATIONS;
   MUTATIONS; MYOPATHY; SON
AB Background Pathogenic mitochondrial DNA (mtDNA) mutations are found in at least one in 8000 individuals. No effective treatment for mtDNA disorders is available, making disease prevention important. Many patients with mtDNA disease harbour a single pathogenic mtDNA deletion, but the risk factors for new cases and disease recurrence are not known.
   Methods We did a multicentre study of 226 families in which a single mtDNA deletion had been identified in the proband, including patients with chronic progressive external ophthalmoplegia, Kearns Sayre syndrome, or Pearson's syndrome. We studied the relation between maternal age and the risk of unaffected mothers having an affected child, and determined the recurrence risks among the siblings and offspring of affected individuals.
   Findings We noted no relation between maternal age and the risk of unaffected mothers having children with an mtDNA deletion disorder. None of the 251 siblings of the index cases developed clinical features of mtDNA disease. Risk of recurrence among the offspring of affected women was 4.11% (95% CI 0.86-11.54, or one in 117 to one in nine births). Only one of the mothers who had an affected child had a duplication of mtDNA in skeletal muscle.
   Interpretation Unlike nuclear chromosomal rearrangements, incidence of mtDNA deletion disorders does not increase with maternal age, and unaffected mothers are unlikely to have more than one affected child. Affected women were previously thought to have a negligible chance of having clinically affected offspring, but the actual risk is, on average, about one in 24 births.
C1 Newcastle Univ, Sch Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   Newcastle Univ, Sch Math & Stat, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   Columbia Univ Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA.
   Columbia Univ Coll Phys & Surg, Dept Genet, New York, NY 10032 USA.
   Columbia Univ Coll Phys & Surg, Dept Dev, New York, NY 10032 USA.
   Natl Neurol Inst Carlo Besta, Pierfranco & Louisa Mariani Ctr Study Childrens M, Unit Mol Neurogenet, Milan, Italy.
   Hop La Pitie Salpetriere, Paris, France.
   Hop Robert Debre, F-75019 Paris, France.
   Metab Dis Ctr Munich Schwabing, Munich, Germany.
   Univ Munich, Dept Neurol, Friedrich Baur Inst, D-8000 Munich, Germany.
   Univ Halle Wittenberg, Dept Neurol, Halle An Der Saale, Germany.
   Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic, Australia.
   Haukeland Hosp, Dept Neurol, N-5021 Bergen, Norway.
   Univ Oxford, Dept Obstet & Gynaecol, Oxford, England.
C3 Newcastle University - UK; Newcastle University - UK; Columbia
   University; Columbia University; Columbia University; Fondazione IRCCS
   Istituto Neurologico Carlo Besta; Assistance Publique Hopitaux Paris
   (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; Sorbonne
   Universite; Assistance Publique Hopitaux Paris (APHP); Universite Paris
   Cite; Hopital Universitaire Robert-Debre - APHP; University of Munich;
   Martin Luther University Halle Wittenberg; Royal Children's Hospital
   Melbourne; Murdoch Children's Research Institute; University of Bergen;
   Haukeland University Hospital; University of Oxford
RP Newcastle Univ, Sch Med, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM P.F.Chinnery@ncl.ac.uk
RI Mariotti, Caterina/AAP-9425-2021; Bindoff, Nathaniel/C-8050-2011;
   Horvath, Rita/AAY-7042-2020; Zeviani, Massimo/K-2891-2014; Thorburn,
   David/G-6266-2013; Matthews, John/H-7502-2013; Lombes, Anne/G-4684-2014
OI Lochmuller, Hanns/0000-0003-2324-8001; Bindoff,
   Laurence/0000-0003-0988-276X; Mariotti, Caterina/0000-0003-2405-3564;
   Poulton, Joanna/0000-0002-2460-5587; thorburn,
   david/0000-0002-7725-9470; Horvath, Rita/0000-0002-9841-170X; Zeviani,
   Massimo/0000-0002-9067-5508; Chinnery, Patrick/0000-0002-7065-6617
FU Telethon [1180] Funding Source: Medline
CR Barritt JA, 1999, MOL HUM REPROD, V5, P927, DOI 10.1093/molehr/5.10.927
   BERNES SM, 1993, J PEDIATR-US, V123, P598, DOI 10.1016/S0022-3476(05)80962-X
   Blakely EL, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.011296
   Brenner CA, 1998, MOL HUM REPROD, V4, P887, DOI 10.1093/molehr/4.9.887
   CHEN X, 1995, AM J HUM GENET, V57, P239
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   CORMIER V, 1990, J PEDIATR-US, V117, P599, DOI 10.1016/S0022-3476(05)80698-5
   CUCKLE HS, 1987, BRIT J OBSTET GYNAEC, V94, P387, DOI 10.1111/j.1471-0528.1987.tb03115.x
   FERGUSONSMITH MA, 1983, BRIT MED BULL, V39, P355, DOI 10.1093/oxfordjournals.bmb.a071848
   HAUSWIRTH WW, 1982, P NATL ACAD SCI-BIOL, V79, P4686, DOI 10.1073/pnas.79.15.4686
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   LARSSON NG, 1992, AM J HUM GENET, V51, P1201
   MACMILLAN C, 1993, NEUROLOGY, V43, P1586, DOI 10.1212/WNL.43.8.1586
   Manfredi G, 1997, ANN NEUROL, V42, P180, DOI 10.1002/ana.410420208
   Marchington DR, 1998, AM J HUM GENET, V63, P769, DOI 10.1086/302009
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Poulton J, 2000, NEUROMUSCULAR DISORD, V10, P484, DOI 10.1016/S0960-8966(00)00130-9
   POULTON J, 1991, AM J HUM GENET, V48, P649
   POULTON J, 1993, HUM MOL GENET, V2, P23, DOI 10.1093/hmg/2.1.23
   POULTON J, 1994, NAT GENET, V8, P313, DOI 10.1038/ng1294-313
   POULTON J, 1995, MUSCLE NERVE       S, V3, P154
   Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755
   SCHON EA, 1991, MOL GENETIC APPROACH, P57
   Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350
   Shanske S, 2002, AM J HUM GENET, V71, P679, DOI 10.1086/342482
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Thorburn DR, 2001, AM J MED GENET, V106, P102, DOI 10.1002/ajmg.1380
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
   Zeviani M, 1998, NEUROLOGY, V51, P1525, DOI 10.1212/WNL.51.6.1525-a
NR 32
TC 131
Z9 145
U1 0
U2 12
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD AUG 14
PY 2004
VL 364
IS 9434
BP 592
EP 596
DI 10.1016/S0140-6736(04)16851-7
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 845WD
UT WOS:000223275100031
PM 15313359
DA 2024-11-01
ER

PT J
AU Tarnopolsky, M
   Brady, L
   MacNeil, L
AF Tarnopolsky, Mark
   Brady, Lauren
   MacNeil, Lauren
TI Myasthenia graves-like symptoms associated with rare mitochondrial
   mutation (m.5728T &gt; C)
SO MITOCHONDRION
LA English
DT Article
ID EXERCISE; DNA
AB We report here on a patient who presented with myasthenia gravis type symptoms (fatigable ptosis, increased jitter on single fiber EMG, and a thymic mass) who was subsequently diagnosed with a mitochondrial myopathy. Sequencing of the mitochondrial genome (mtDNA) identified a transition variant in the tRNA asparagine gene (MT-TN) (m.5728T > C) at in 41% of mtDNA molecules in muscle tissue. The variant was not detectable in blood. The m.5728T > C variant has been reported previously in a ten year old male with global developmental delays, failure to thrive, ataxia, weakness, cognitive regression, seizures, and glomerulosclerosis. The variant was seen in 97% of mtDNA molecules in muscle and 50% in blood. This case report supports the pathogenicity of the m.5728T > C and helps to establish the phenotypic spectrum of this condition at a lower heteroplasmy.
C1 [Tarnopolsky, Mark; Brady, Lauren] McMaser Univ, Med Ctr, Dept Pediat Neuromuscular & Neurometab Disorders, Hamilton, ON L8N 3Z5, Canada.
   [MacNeil, Lauren] Hosp Sick Children, Dept Pediat Lab Med, Div Clin Biochem, Toronto, ON M5G 2L3, Canada.
C3 University of Toronto; Hospital for Sick Children (SickKids)
RP Tarnopolsky, M (corresponding author), McMaser Univ, Med Ctr, Dept Pediat Neuromuscular & Neurometab Disorders, Hamilton, ON L8N 3Z5, Canada.
EM tarnopol@mcmaster.ca
OI MacNeil, Lauren/0000-0003-3827-7147
CR Bannwarth S, 2013, J MED GENET, V50, P704, DOI 10.1136/jmedgenet-2013-101604
   Cruz-Martinez A, 2004, Electromyogr Clin Neurophysiol, V44, P35
   Girlanda P, 1999, CLIN NEUROPHYSIOL, V110, P1284, DOI 10.1016/S1388-2457(98)00041-8
   Lott Marie T, 2013, Curr Protoc Bioinformatics, V44, DOI 10.1002/0471250953.bi0123s44
   McKenzie S, 2000, AM J PHYSIOL-ENDOC M, V278, pE580, DOI 10.1152/ajpendo.2000.278.4.E580
   Meulemans A, 2006, ARCH NEUROL-CHICAGO, V63, P1194, DOI 10.1001/archneur.63.8.1194
   Parise G, 2005, EXP GERONTOL, V40, P173, DOI 10.1016/j.exger.2004.09.002
   Tarnopolsky MA, 2011, MUSCLE NERVE, V43, P717, DOI 10.1002/mus.21945
   UKACHOKE C, 1994, CAN J NEUROL SCI, V21, P125, DOI 10.1017/S0317167100049040
NR 9
TC 5
Z9 5
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 1872-8278
J9 MITOCHONDRION
JI Mitochondrion
PD JUL
PY 2019
VL 47
BP 139
EP 140
DI 10.1016/j.mito.2019.04.003
PG 2
WC Cell Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Genetics & Heredity
GA II9VD
UT WOS:000475547200016
PM 31026515
DA 2024-11-01
ER

PT J
AU Kauppila, JHK
   Baines, HL
   Bratic, A
   Simard, ML
   Freyer, C
   Mourier, A
   Stamp, C
   Filograna, R
   Larsson, NG
   Greaves, LC
   Stewart, JB
AF Kauppila, Johanna H. K.
   Baines, Holly L.
   Bratic, Ana
   Simard, Marie-Lune
   Freyer, Christoph
   Mourier, Arnaud
   Stamp, Craig
   Filograna, Roberta
   Larsson, Nils-Goeran
   Greaves, Laura C.
   Stewart, James B.
TI A Phenotype-Driven Approach to Generate Mouse Models with Pathogenic
   mtDNA Mutations Causing Mitochondrial Disease
SO CELL REPORTS
LA English
DT Article
ID KEARNS-SAYRE SYNDROME; DNA MUTATIONS; TRANSMITOCHONDRIAL MICE;
   RESPIRATORY-CHAIN; GERMLINE; PATIENT; CELLS; HETEROPLASMY; DELETIONS;
   MYOPATHY
AB Mutations of mtDNA are an important cause of human disease, but few animal models exist. Because mammalian mitochondria cannot be transfected, the development of mice with pathogenic mtDNA mutations has been challenging, and the main strategy has therefore been to introduce mutations found in cell lines into mouse embryos. Here, we describe a phenotype-driven strategy that is based on detecting clonal expansion of pathogenic mtDNA mutations in colonic crypts of founder mice derived from heterozygous mtDNA mutator mice. As proof of concept, we report the generation of a mouse line transmitting a heteroplasmic pathogenic mutation in the alanine tRNA gene of mtDNA displaying typical characteristics of classic mitochondrial disease. In summary, we describe a straightforward and technically simple strategy based on mouse breeding and histology to generate animal models of mtDNA-mutation disease, which will be of great importance for studies of disease pathophysiology and preclinical treatment trials.
C1 [Kauppila, Johanna H. K.; Bratic, Ana; Simard, Marie-Lune; Mourier, Arnaud; Larsson, Nils-Goeran; Stewart, James B.] Max Planck Inst Biol Ageing, Dept Mitochondrial Biol, D-50931 Cologne, Germany.
   [Baines, Holly L.; Simard, Marie-Lune; Greaves, Laura C.] Newcastle Univ, LLHW Ctr Ageing & Vital, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Freyer, Christoph; Filograna, Roberta; Larsson, Nils-Goeran] Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden.
   [Greaves, Laura C.] Newcastle Univ, Inst Neurosci, Wellcome Trust Ctr Mitochondrial Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
C3 Max Planck Society; Newcastle University - UK; Karolinska Institutet;
   Newcastle University - UK
RP Larsson, NG; Stewart, JB (corresponding author), Max Planck Inst Biol Ageing, Dept Mitochondrial Biol, D-50931 Cologne, Germany.; Larsson, NG (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden.
EM larsson@age.mpg.de; jstewart@age.mpg.de
RI MOURIER, Arnaud/F-9657-2019; Filograna, Roberta/KHE-2279-2024; Stewart,
   Jim/C-9633-2011; MOURIER, Arnaud/I-8117-2012
OI Stewart, Jim/0000-0002-2902-4968; Freyer, Christoph/0000-0003-0418-1673;
   Larsson, Nils-Goran/0000-0001-5100-996X; Filograna,
   Roberta/0000-0002-6581-9426; MOURIER, Arnaud/0000-0002-5413-611X;
   Greaves, Laura/0000-0002-8071-5916
FU United Mitochondrial Disease Foundation [13-053R]; Swedish Research
   Council [2015-00418]; Knut and Alice Wallenberg Foundation; Newcastle
   University Centre for Ageing and Vitality (Biotechnology and Biological
   Sciences Research Council, Engineering and Physical Sciences Research
   Council, Economic and Social Research Council, and Medical Research
   Council) [G0700718]; Wellcome Trust Centre for Mitochondrial Research
   [G096919]; Ake-Wiberg foundation [367990950]; MRC [G0700718] Funding
   Source: UKRI; Swedish Research Council [2015-00418] Funding Source:
   Swedish Research Council
FX This study was supported by a grant from the United Mitochondrial
   Disease Foundation (project 13-053R) to J.B.S.N.-G.L. was supported by
   The Swedish Research Council (2015-00418) and Knut and Alice Wallenberg
   Foundation. L.C.G. was supported by Newcastle University Centre for
   Ageing and Vitality (supported by the Biotechnology and Biological
   Sciences Research Council, Engineering and Physical Sciences Research
   Council, Economic and Social Research Council, and Medical Research
   Council [G0700718]) and the Wellcome Trust Centre for Mitochondrial
   Research (G096919). C.F. was supported by the Ake-Wiberg foundation
   (367990950). The authors acknowledge the expert contributions by the
   Phenotyping Core Facility of MPI for Biology of Ageing, as well as the
   FACS and Imaging Core Facility of the MPI for Biology of Ageing and
   CECAD Imaging Facility (University of Cologne) for the use of equipment.
   The tRNA ALA mutant mouse is available for commercial use by licensing
   from the Max Planck Society. The mice are provided free of charge to
   academic investigators.
CR Bacman SR, 2013, NAT MED, V19, P1111, DOI 10.1038/nm.3261
   Bai YD, 1998, EMBO J, V17, P4848, DOI 10.1093/emboj/17.16.4848
   Baines HL, 2014, MECH AGEING DEV, V139, P22, DOI 10.1016/j.mad.2014.06.003
   Bayona-Bafaluy MP, 2005, P NATL ACAD SCI USA, V102, P14392, DOI 10.1073/pnas.0502896102
   CIAFALONI E, 1991, NEUROLOGY, V41, P1663, DOI 10.1212/WNL.41.10.1663
   Davies SMK, 2012, FEBS LETT, V586, P3555, DOI 10.1016/j.febslet.2012.07.043
   Fan WW, 2008, SCIENCE, V319, P958, DOI 10.1126/science.1147786
   Finnilä S, 2001, J MOL MED, V79, P641, DOI 10.1007/s001090100268
   Freyer C, 2012, NAT GENET, V44, P1282, DOI 10.1038/ng.2427
   Gammage PA, 2014, EMBO MOL MED, V6, P458, DOI 10.1002/emmm.201303672
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Greaves LC, 2012, J PATHOL, V226, P274, DOI 10.1002/path.3028
   Greaves LC, 2010, EXP GERONTOL, V45, P573, DOI 10.1016/j.exger.2010.01.013
   HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614
   Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826
   Keogh MJ, 2015, BBA-BIOENERGETICS, V1847, P1401, DOI 10.1016/j.bbabio.2015.05.015
   Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231
   Larsson NG, 1995, ANNU REV GENET, V29, P151, DOI 10.1146/annurev.ge.29.120195.001055
   LARSSON NG, 1992, AM J HUM GENET, V51, P1201
   LARSSON NG, 1990, PEDIATR RES, V28, P131, DOI 10.1203/00006450-199028020-00011
   Larsson NG, 2010, ANNU REV BIOCHEM, V79, P683, DOI 10.1146/annurev-biochem-060408-093701
   Leman G, 2015, INT J BIOCHEM CELL B, V65, P91, DOI 10.1016/j.biocel.2015.05.017
   Leshinsky-Silver E, 2010, MOL GENET METAB, V100, P65, DOI 10.1016/j.ymgme.2010.02.002
   Levy SE, 1999, TRANSGENIC RES, V8, P137, DOI 10.1023/A:1008967412955
   Lim SC, 2016, FASEB J, V30, P2236, DOI 10.1096/fj.201500137R
   Lin CS, 2012, P NATL ACAD SCI USA, V109, P20065, DOI 10.1073/pnas.1217113109
   Marchington DR, 1999, NAT MED, V5, P957, DOI 10.1038/11403
   McFarland R, 2008, NEUROMUSCULAR DISORD, V18, P63, DOI 10.1016/j.nmd.2007.07.007
   Minczuk M, 2006, P NATL ACAD SCI USA, V103, P19689, DOI 10.1073/pnas.0609502103
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   MORAES CT, 1992, AM J HUM GENET, V50, P934
   Mourier A, 2014, CELL METAB, V20, P1069, DOI 10.1016/j.cmet.2014.11.005
   Nakada K, 2004, BIOCHEM BIOPH RES CO, V323, P175, DOI 10.1016/j.bbrc.2004.08.073
   Nesbitt V, 2013, J NEUROL NEUROSUR PS, V84, P936, DOI 10.1136/jnnp-2012-303528
   Reddy P, 2015, CELL, V161, P459, DOI 10.1016/j.cell.2015.03.051
   Rocha MC, 2015, SCI REP-UK, V5, DOI 10.1038/srep15037
   Ross JM, 2013, NATURE, V501, P412, DOI 10.1038/nature12474
   ROTIG A, 1990, J CLIN INVEST, V86, P1601, DOI 10.1172/JCI114881
   Shimizu A, 2015, BIOCHEM BIOPH RES CO, V459, P66, DOI 10.1016/j.bbrc.2015.02.070
   Shimizu A, 2014, P NATL ACAD SCI USA, V111, P3104, DOI 10.1073/pnas.1318109111
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   Stewart JB, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004670
   Stewart JB, 2008, PLOS BIOL, V6, P63, DOI 10.1371/journal.pbio.0060010
   Taylor RW, 2003, J CLIN INVEST, V112, P1351, DOI 10.1172/JCI200319435
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Tyynismaa H, 2009, EMBO REP, V10, P137, DOI 10.1038/embor.2008.242
   WATANABE T, 1978, P NATL ACAD SCI USA, V75, P5113, DOI 10.1073/pnas.75.10.5113
   Wonnapinij P, 2008, AM J HUM GENET, V83, P582, DOI 10.1016/j.ajhg.2008.10.007
NR 48
TC 91
Z9 99
U1 0
U2 19
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD SEP 13
PY 2016
VL 16
IS 11
BP 2980
EP 2990
DI 10.1016/j.celrep.2016.08.037
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA DW8CZ
UT WOS:000383882300018
PM 27626666
OA Green Published, gold
DA 2024-11-01
ER

PT J
AU McFarland, R
   Schaefer, AM
   Gardner, JL
   Lynn, S
   Hayes, CM
   Barron, MJ
   Walker, M
   Chinnery, PF
   Taylor, RW
   Turnbull, DM
AF McFarland, R
   Schaefer, AM
   Gardner, JL
   Lynn, S
   Hayes, CM
   Barron, MJ
   Walker, M
   Chinnery, PF
   Taylor, RW
   Turnbull, DM
TI Familial myopathy: New insights into the T14709C mitochondrial tRNA
   mutation
SO ANNALS OF NEUROLOGY
LA English
DT Article
ID DISORDERED OXIDATIVE-METABOLISM; DIABETES-MELLITUS; TRNA(SER(UCN)) GENE;
   POINT MUTATION; MUSCLE FIBERS; ACID MUTATION; DNA MUTATION; DEAFNESS;
   SEQUENCE; PATIENT
AB We have defined the genetic defect in a large family first described in one of the earliest reports of suspected mitochondrial myopathy, as the mutation T14709C in the mitochondrial transfer RNA(Glu) (mt-tRNA(Glu)) gene. Extraordinarily, this mutation has attained homoplasmy (100% mutated mt-tRNA(Glu)) on at least three independent occasions in this family and has done so in one individual who remains asymptomatic with no clinical evidence of disease. Heteroplasmy (dual populations of mutated and wild-type mtDNA) usually is regarded as one of the primary diagnostic criteria for pathogenicity and previous reports of the T14709C mutation detail heteroplasmy in a variety of tissues. In contrast, homoplasmy of mt-tRNA mutations generally has been regarded as evidence of a benign nature, with rare exceptions that result in organ-specific phenotypes. Discovering that T14709C, a common and severe mt-tRNA mutation, can attain homoplasmy without symptoms or clinical signs of disease has profound implications for the identification and prevalence of other pathogenic mt-tRNA mutations. Furthermore, variation in phenotype between homoplasmic individuals implies a crucial contribution from the nuclear genetic environment in determining the clinical outcome of mt-tRNA mutations.
C1 Univ Newcastle Upon Tyne, Sch Med, Mitochondrial Res Grp, Sch Neurol Neurobiol & Psychiat, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   Stanford Univ, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA.
   Univ Newcastle Upon Tyne, Sch Med, Sch Clin Med Sci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
C3 Newcastle University - UK; Stanford University; Newcastle University -
   UK
RP Univ Newcastle Upon Tyne, Sch Med, Mitochondrial Res Grp, Sch Neurol Neurobiol & Psychiat, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM d.m.turnbull@ncl.ac.uk
RI ; Barron, Martin/E-9649-2015
OI McFarland, Robert/0000-0002-8833-2688; Barron,
   Martin/0000-0002-2047-3513; Chinnery, Patrick/0000-0002-7065-6617;
   Schaefer, Andrew/0000-0001-9891-7332
FU MRC [G108/539] Funding Source: UKRI; Medical Research Council [G108/539]
   Funding Source: Medline
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   Chomyn A, 1996, Methods Enzymol, V264, P197, DOI 10.1016/S0076-6879(96)64020-8
   Damore ME, 1999, J PEDIATR ENDOCR MET, V12, P207
   FAWCETT PRW, 1982, J NEUROL SCI, V53, P397, DOI 10.1016/0022-510X(82)90021-1
   HANNA MG, 1995, AM J HUM GENET, V56, P1026
   HAO HL, 1995, AM J HUM GENET, V56, P1017
   HUDGSON P, 1972, J NEUROL SCI, V16, P343, DOI 10.1016/0022-510X(72)90197-9
   HUOPONEN K, 1991, AM J HUM GENET, V48, P1147
   Jaksch M, 1998, ANN NEUROL, V44, P635, DOI 10.1002/ana.410440409
   Lightowlers RN, 1997, TRENDS GENET, V13, P450, DOI 10.1016/S0168-9525(97)01266-3
   McFarland R, 2002, NAT GENET, V30, P145, DOI 10.1038/ng819
   MECHLER F, 1981, J NEUROL SCI, V50, P191, DOI 10.1016/0022-510X(81)90165-9
   OLD SL, 1989, HISTOCHEM J, V21, P545, DOI 10.1007/BF01753355
   Perucca-Lostanlen D, 2002, BBA-MOL BASIS DIS, V1588, P210, DOI 10.1016/S0925-4439(02)00167-9
   PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289
   Rigoli L, 2001, DIABETIC MED, V18, P334, DOI 10.1046/j.1464-5491.2001.00429-2.x
   Sue CM, 1999, NEUROLOGY, V52, P1905, DOI 10.1212/WNL.52.9.1905
   Taylor RW, 2003, J AM COLL CARDIOL, V41, P1786, DOI 10.1016/S0735-1097(03)00300-0
   Taylor RW, 2001, NUCLEIC ACIDS RES, V29, part. no., DOI 10.1093/nar/29.15.e74
   Taylor RW, 1997, ORGANELLE DIS
   Vialettes BH, 1997, DIABETES CARE, V20, P1731, DOI 10.2337/diacare.20.11.1731
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   WORSFOLD M, 1973, J NEUROL SCI, V19, P261, DOI 10.1016/0022-510X(73)90090-7
NR 25
TC 53
Z9 56
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0364-5134
EI 1531-8249
J9 ANN NEUROL
JI Ann. Neurol.
PD APR
PY 2004
VL 55
IS 4
BP 478
EP 484
DI 10.1002/ana.20004
PG 7
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 806ME
UT WOS:000220437200004
PM 15048886
DA 2024-11-01
ER

PT J
AU Keshavan, N
   Abdenur, J
   Anderson, G
   Assouline, Z
   Barcia, G
   Bouhikbar, L
   Chakrapani, A
   Cleary, M
   Cohen, MC
   Feillet, F
   Fratter, C
   Hauser, N
   Jacques, T
   Lam, A
   McCullagh, H
   Phadke, R
   Rötig, A
   Sharrard, M
   Simon, M
   Smith, C
   Sommerville, EW
   Taylor, RW
   Yue, WW
   Rahman, S
AF Keshavan, Nandaki
   Abdenur, Jose
   Anderson, Glenn
   Assouline, Zahra
   Barcia, Giulia
   Bouhikbar, Lamia
   Chakrapani, Anupam
   Cleary, Maureen
   Cohen, Marta C.
   Feillet, Francois
   Fratter, Carl
   Hauser, Natalie
   Jacques, Tom
   Lam, Amanda
   McCullagh, Helen
   Phadke, Rahul
   Rotig, Agnes
   Sharrard, Mark
   Simon, Mariella
   Smith, Conrad
   Sommerville, Ewen W.
   Taylor, Robert W.
   Yue, Wyatt W.
   Rahman, Shamima
TI The natural history of infantile mitochondrial DNA depletion syndrome
   due to RRM2B deficiency
SO GENETICS IN MEDICINE
LA English
DT Article
DE mitochondrial disease; mtDNA depletion; ribonucleotide reductase;
   treatment; outcomes
ID MUTATIONS; MTDNA; P53R2
AB Purpose Mitochondrial DNA (mtDNA) depletion syndrome (MDDS) encompasses a group of genetic disorders of mtDNA maintenance. Mutation of RRM2B is an uncommon cause of infantile-onset encephalomyopathic MDDS. Here we describe the natural history of this disease. Methods Multinational series of new genetically confirmed cases from six pediatric centers. Results Nine new cases of infantile-onset RRM2B deficiency, and 22 previously published cases comprised a total cohort of 31 patients. Infants presented at a mean of 1.95 months with truncal hypotonia, generalized weakness, and faltering growth. Seizures evolved in 39% at a mean of 3.1 months. Non-neurological manifestations included respiratory distress/failure (58%), renal tubulopathy (55%), sensorineural hearing loss (36%), gastrointestinal disturbance (32%), eye abnormalities (13%), and anemia (13%). Laboratory features included elevated lactate (blood, cerebrospinal fluid (CSF), urine, magnetic resonance (MR), spectroscopy), ragged-red and cytochrome c oxidase-deficient fibers, lipid myopathy, and multiple oxidative phosphorylation enzyme deficiencies in skeletal muscle. Eight new RRM2B variants were identified. Patients with biallelic truncating variants had the worst survival. Overall survival was 29% at 6 months and 16% at 1 year. Conclusions Infantile-onset MDDS due to RRM2B deficiency is a severe disorder with characteristic clinical features and extremely poor prognosis. Presently management is supportive as there is no effective treatment. Novel treatments are urgently needed.
C1 [Keshavan, Nandaki; Chakrapani, Anupam; Cleary, Maureen; Rahman, Shamima] Great Ormond St Hosp Children NHS Fdn Trust, Metab Unit, London, England.
   [Keshavan, Nandaki; Rahman, Shamima] UCL Great Ormond St Inst Child Hlth, Mitochondrial Res Grp, London, England.
   [Abdenur, Jose; Simon, Mariella] Childrens Hosp Orange Cty, Div Metab Disorders, Orange, CA 92668 USA.
   [Anderson, Glenn; Jacques, Tom] Great Ormond St Hosp Children NHS Fdn Trust, Dept Histopathol, London, England.
   [Assouline, Zahra; Barcia, Giulia] Necker Hosp Sick Children, Dept Genet, Paris, France.
   [Bouhikbar, Lamia] UCL Great Ormond St Inst Child Hlth, GOSgene Ctr Translat Omics, London, England.
   [Bouhikbar, Lamia] NIHR GOSH Biomed Res Ctr, London, England.
   [Cohen, Marta C.; Sharrard, Mark] Sheffield Childrens NHS Fdn Trust, Sheffield, S Yorkshire, England.
   [Feillet, Francois] Reference Ctr Inherited Metab Dis, Nancy, France.
   [Fratter, Carl; Smith, Conrad] Oxford Univ Hosp NHS Fdn Trust, Oxford Med Genet Labs, Oxford, England.
   [Hauser, Natalie] Inova Translat Med Inst, Falls Church, VA USA.
   [Lam, Amanda] Natl Hosp Neurol & Neurosurg, Neurometabol Unit, London, England.
   [Lam, Amanda; Phadke, Rahul] UCL Queen Sq Inst Neurol, London, England.
   [McCullagh, Helen] Leeds Childrens Hosp, Dept Paediat Neurol, Leeds, W Yorkshire, England.
   [Rotig, Agnes] Imagine Inst, Paris, France.
   [Sommerville, Ewen W.; Taylor, Robert W.] Newcastle Univ, Inst Neurosci, Wellcome Ctr Mitochondrial Res, Newcastle Upon Tyne, Tyne & Wear, England.
   [Sommerville, Ewen W.] Cardiff Univ, Div Psychol Med & Clin Neurosci, Cardiff, Wales.
   [Yue, Wyatt W.] Univ Oxford, Nuffield Dept Med, Struct Genom Consortium, Oxford, England.
C3 University of London; University College London; Great Ormond Street
   Hospital for Children NHS Foundation Trust; University of London;
   University College London; Childrens Hospital of Orange County;
   University of London; University College London; Great Ormond Street
   Hospital for Children NHS Foundation Trust; Assistance Publique Hopitaux
   Paris (APHP); Universite Paris Cite; Hopital Universitaire
   Necker-Enfants Malades - APHP; University of London; University College
   London; Sheffield Children's NHS Foundation Trust; Oxford University
   Hospitals NHS Foundation Trust; University of London; University College
   London; UCL Medical School; University College London Hospitals NHS
   Foundation Trust; University of London; University College London;
   Universite Paris Cite; Newcastle University - UK; Cardiff University;
   University of Oxford
RP Rahman, S (corresponding author), Great Ormond St Hosp Children NHS Fdn Trust, Metab Unit, London, England.; Rahman, S (corresponding author), UCL Great Ormond St Inst Child Hlth, Mitochondrial Res Grp, London, England.
EM shamima.rahman@ucl.ac.uk
RI Jacques, Thomas/C-2209-2008; Rahman, Shamima/C-5232-2008; Barcia,
   Giulia/H-7907-2017; Feillet, Francois/A-3648-2017; ROTIG,
   AGNES/G-9592-2017; Cohen, Marta/A-9937-2016
OI Simon, Mariella/0000-0002-8200-3277; Yue, Wyatt/0000-0001-6959-6007;
   ROTIG, AGNES/0000-0003-0589-0703; Feillet, Francois/0000-0002-6814-0806;
   Cohen, Marta/0000-0001-5534-444X
FU Great Ormond Street Hospital Children's Charity Research Leadership
   Award [V1260]; National Institute for Health Research (NIHR) Great
   Ormond Street Hospital Biomedical Research Center; Lily Foundation;
   Wellcome Center for Mitochondrial Research [203105/Z/16/Z]; Medical
   Research Council (MRC) Center for Translational Research in
   Neuromuscular Disease, Mitochondrial Disease Patient Cohort (UK)
   [G0800674]; UK NIHR Biomedical Research Center for Ageing and
   Age-related disease award; MRC/Engineering and Physical Sciences
   Research Council (EPSRC) Molecular Pathology Node; UK NHS Highly
   Specialised Service for Rare Mitochondrial Disorders of Adults and
   Children; Medical Research Council (MRC); MRC [G0800674] Funding Source:
   UKRI
FX S.R. is supported by a Great Ormond Street Hospital Children's Charity
   Research Leadership Award (V1260), the National Institute for Health
   Research (NIHR) Great Ormond Street Hospital Biomedical Research Center,
   and the Lily Foundation. R.W.T. is supported by the Wellcome Center for
   Mitochondrial Research (203105/Z/16/Z), the Medical Research Council
   (MRC) Center for Translational Research in Neuromuscular Disease,
   Mitochondrial Disease Patient Cohort (UK) (G0800674), the Lily
   Foundation, the UK NIHR Biomedical Research Center for Ageing and
   Age-related disease award to the Newcastle upon Tyne Foundation
   Hospitals NHS Trust, the MRC/Engineering and Physical Sciences Research
   Council (EPSRC) Molecular Pathology Node, and the UK NHS Highly
   Specialised Service for Rare Mitochondrial Disorders of Adults and
   Children. E.W.S. was funded by an Medical Research Council (MRC) PhD
   studentship. The views expressed are those of the authors(s) and not
   necessarily those of the NHS, the NIHR, or the Department of Health.
CR Acham-Roschitz B, 2009, MOL GENET METAB, V98, P300, DOI 10.1016/j.ymgme.2009.06.012
   Bornstein B, 2008, NEUROMUSCULAR DISORD, V18, P453, DOI 10.1016/j.nmd.2008.04.006
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Bulst S, 2012, MOL GENET METAB, V107, P95, DOI 10.1016/j.ymgme.2012.04.022
   El-Hattab A, 2013, NEUROTHERAPEUTICS, V10, P186, DOI 10.1007/s13311-013-0177-6
   Fratter C, 2011, NEUROLOGY, V76, P2032, DOI 10.1212/WNL.0b013e31821e558b
   Garone C, 2018, J MED GENET, V55, P515, DOI 10.1136/jmedgenet-2017-105012
   Garone C, 2014, EMBO MOL MED, V6, P1016, DOI 10.15252/emmm.201404092
   Gorman G. S., 1993, GENEREVIEWS
   Horvath R, 2009, BRAIN, V132, P3165, DOI 10.1093/brain/awp221
   Keshavan N, 2018, ESSAYS BIOCHEM, V62, P423, DOI 10.1042/EBC20170108
   Kimura T, 2003, NAT GENET, V34, P440, DOI 10.1038/ng1212
   Kollberg G, 2009, NEUROMUSCULAR DISORD, V19, P147, DOI 10.1016/j.nmd.2008.11.014
   Kropach N, 2017, NEUROPEDIATRICS, V48, P456, DOI 10.1055/s-0037-1601867
   Larcher V, 2015, ARCH DIS CHILD, V100, pS3, DOI 10.1136/archdischild-2014-306666
   Lopez-Gomez C, 2017, ANN NEUROL, V81, P641, DOI 10.1002/ana.24922
   McCormack Shana E., 2016, MITOCHONDRIAL CASE S, P187
   Mestek-Boukhibar L, 2018, J MED GENET, V55, P721, DOI 10.1136/jmedgenet-2018-105396
   Nicholls TJ, 2018, MOL CELL, V69, P9, DOI 10.1016/j.molcel.2017.11.033
   Pitceathly RDS, 2012, BRAIN, V135, P3392, DOI 10.1093/brain/aws231
   Pitceathly RDS, 2011, J MED GENET, V48, P610, DOI 10.1136/jmg.2010.088328
   Pontarin G, 2012, CELL CYCLE, V11, P4099, DOI 10.4161/cc.22324
   Pontarin G, 2011, J BIOL CHEM, V286, P11132, DOI 10.1074/jbc.M110.202283
   Pontarin G, 2008, P NATL ACAD SCI USA, V105, P17801, DOI 10.1073/pnas.0808198105
   POULTON J, 1995, J INHERIT METAB DIS, V18, P4, DOI 10.1007/BF00711367
   Pronicka E, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0930-9
   Rahman J, 2018, LANCET, V391, P2560, DOI 10.1016/S0140-6736(18)30727-X
   Rahman S, 2019, NAT REV NEUROL, V15, P40, DOI 10.1038/s41582-018-0101-0
   Rahman S, 2009, ARCH DIS CHILD, V94, P3, DOI 10.1136/adc.2008.147983
   Ray S, 2018, ARCH DIS CHILD, V103, P1080, DOI 10.1136/archdischild-2018-314997
   Schymkowitz J, 2005, NUCLEIC ACIDS RES, V33, pW382, DOI 10.1093/nar/gki387
   Shaibani A, 2009, ARCH NEUROL-CHICAGO, V66, P1028, DOI 10.1001/archneurol.2009.139
   Smith P, 2009, BIOCHEMISTRY-US, V48, P11134, DOI 10.1021/bi9001425
   Spinazzola A, 2009, J INHERIT METAB DIS, V32, P143, DOI 10.1007/s10545-008-1038-z
   Stojanovic V, 2013, CROAT MED J, V54, P579, DOI 10.3325/cmj.2013.54.579
   Takata A, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-9-r92
   Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506
   Tyynismaa H, 2009, AM J HUM GENET, V85, P290, DOI 10.1016/j.ajhg.2009.07.009
   Valencia CA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156738
   Viscomi C, 2017, J INHERIT METAB DIS, V40, P587, DOI 10.1007/s10545-017-0027-5
NR 40
TC 15
Z9 16
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1098-3600
EI 1530-0366
J9 GENET MED
JI Genet. Med.
PD JAN
PY 2020
VL 22
IS 1
BP 199
EP 209
DI 10.1038/s41436-019-0613-z
PG 11
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA KH9BF
UT WOS:000510943400024
PM 31462754
OA Green Submitted, Green Accepted, Bronze
DA 2024-11-01
ER

PT J
AU Sobreira, C
   Marques, W
   Neto, OMP
   Santos, AC
   Neto, JMP
   Barreira, AA
AF Sobreira, Claudia
   Marques, Wilson, Jr.
   Neto, Octavio M. Pontes
   Santos, Antonio Carlos
   Neto, Joao M. Pina
   Barreira, Amilton A.
TI Leigh-like syndrome with the T8993G mutation in the mitochondrial ATPase
   6 gene: long-term follow-up discloses a slowly progressive course
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE Myopathy; Mitochondrial diseases; Muscle pathology; Respiratory chain;
   Mitochondrial DNA; Maternally inherited Leigh syndrome (MILS);
   Neurogenic weakness; Ataxia and retinitis pigmentosa (NARP); T8993G
   mitochondrial DNA mutation; Mitochondrial ATPase; Mitochondria
ID CYTOCHROME-C-OXIDASE; MTDNA MUTATION; MUTANT LOAD; DNA; DISEASE; TISSUE
AB We describe the long-term clinical outcome of a patient with Leigh-like syndrome presenting as an early onset encephalopathy and peripheral neuropathy caused by the T8993G mutation in the mitochondrial DNA (mtDNA). Clinical follow-up for 20 years revealed a peculiar pattern of slow disease progression, characterized by the addition of new minor deficits, while worsening of previous symptoms was mild. Brain MRI revealed cerebellar atrophy, diffuse demyelination of corona radiata and parietal white matter, and bilateral and symmetrical putaminal lesions. The proportion of mutant mtDNAs in blood was 72% (+/- 0.02%) and in skeletal muscle was 81% (+/- 0.4%). Leigh-like syndrome caused by the T8993G mtDNA mutation is a progressive disease, although not necessarily associated with an aggressive clinical course. (C) 2009 Elsevier B.V. All rights reserved.
C1 [Sobreira, Claudia; Marques, Wilson, Jr.; Neto, Octavio M. Pontes; Barreira, Amilton A.] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Neurociencias, Div Neurol, BR-14048900 Ribeirao Preto, Brazil.
   [Santos, Antonio Carlos] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Med, Div Radiol, BR-14048900 Ribeirao Preto, Brazil.
   [Neto, Joao M. Pina] Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Genet, BR-14048900 Ribeirao Preto, Brazil.
C3 Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de
   Sao Paulo
RP Sobreira, C (corresponding author), Univ Sao Paulo, Fac Med Ribeirao Preto, Dept Neurociencias & Ciencias Comportamento, Div Neurol, HC 4O Andar,Ave Bandeirantes 3900,Campus Univ Mon, BR-14048900 Ribeirao Preto, Brazil.
EM csobreira@fmrp.usp.br
RI Barreira, Amilton/A-1159-2008; Marques Junior, Wilson/G-4240-2012; Neto,
   João/F-1946-2014; Santos, Antonio/F-5419-2012; Sobreira,
   Cláudia/D-5785-2012; Marques Pontes-Neto, Octavio/G-4294-2012
OI Marques Pontes-Neto, Octavio/0000-0003-0317-843X; Pina Neto, Joao
   Monteiro de/0000-0003-2465-3527; Barreira, Amilton/0000-0002-4791-223X
FU FAPESP (Fundacao de Amparo a Pesquisa do Estado de Sao Paulo
   [98/14928-3]
FX This study was financially Supported by FAPESP (Fundacao de Amparo a
   Pesquisa do Estado de Sao Paulo - grant 98/14928-3), which did not
   influence: the design and conduct of the study; collection, management,
   analysis, and interpretation of the data; preparation, review, or
   approval of the manuscript.
CR Carrozzo R, 2001, NEUROLOGY, V56, P687, DOI 10.1212/WNL.56.5.687
   Chalmers RM, 1997, NEUROLOGY, V49, P589, DOI 10.1212/WNL.49.2.589
   Debray FG, 2007, AM J MED GENET A, V143A, P2046, DOI 10.1002/ajmg.a.31880
   Enns GM, 2006, MOL GENET METAB, V88, P364, DOI 10.1016/j.ymgme.2006.02.001
   Finsterer J, 2008, PEDIATR NEUROL, V39, P223, DOI 10.1016/j.pediatrneurol.2008.07.013
   Fujii T, 1998, PEDIATR NEUROL, V18, P275, DOI 10.1016/S0887-8994(97)00187-2
   Goldenberg PC, 2003, NEUROLOGY, V60, P865, DOI 10.1212/01.WNL.0000049460.72439.7F
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   MORAES CT, 1992, AM J HUM GENET, V50, P934
   Morava E, 2006, AM J MED GENET A, V140A, P863, DOI 10.1002/ajmg.a.31194
   Nagashima T, 1999, ACTA NEUROPATHOL, V97, P416, DOI 10.1007/s004010051007
   Rahman S, 1996, ANN NEUROL, V39, P343, DOI 10.1002/ana.410390311
   SANTORELLI FM, 1993, ANN NEUROL, V34, P827, DOI 10.1002/ana.410340612
   TATUCH Y, 1992, AM J HUM GENET, V50, P852
   Tiranti V, 2000, HUM MOL GENET, V9, P2733, DOI 10.1093/hmg/9.18.2733
   Uziel G, 1997, J NEUROL NEUROSUR PS, V63, P16, DOI 10.1136/jnnp.63.1.16
   White SL, 1999, J INHERIT METAB DIS, V22, P899, DOI 10.1023/A:1005639407166
NR 17
TC 6
Z9 6
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD MAR 15
PY 2009
VL 278
IS 1-2
BP 132
EP 134
DI 10.1016/j.jns.2008.11.023
PG 3
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 411ZF
UT WOS:000263692300027
PM 19144360
DA 2024-11-01
ER

PT J
AU Saada, A
AF Saada, Ann
TI Mitochondrial deoxyribonucleotide pools in deoxyguanosine kinase
   deficiency
SO MOLECULAR GENETICS AND METABOLISM
LA English
DT Article
DE Deoxyguanosine kinase dGK; mtDNA depletion; Mitochondrial depletion
   syndrome; Hepatocerebral; Respiratory chain; Deoxyribonucleotide; dNTP;
   dGTP
ID DNA DEPLETION SYNDROME; DGK GENE-MUTATIONS; THYMIDINE KINASE;
   REPLICATION; ENCEPHALOMYOPATHY; FIBROBLASTS; MAINTENANCE; MYOPATHY;
   DEFECTS; ASSAYS
AB Mutated deoxyguanosine kinase (dGK), which catalyses the first step of the mitochondrial deoxypurine salvage pathway, accounts for a hepatocerebral variant of mitochondrial DNA (mtDNA) depletion syndromes. In order to elucidate the pathogenic mechanism of dGK deficiency, mitochondrial and cytoplasmic deoxyribonucleoside triphosphate (dNTP) pools in cycling and quiescent fibroblasts from a dGK deficient patient were measured. The mitochondrial dNTP pools were found to be imbalanced, mainly in quiescent cells due to decreased dGTP while mtDNA content and mitochondrial respiratory chain activities were concomitantly decreased. Supplementation of deoxyguanosine and deoxyadenosine normalized mitochondrial dNTP pools, mtDNA content and partially restored the MRC function. It is suggested that the cytoplasmic deoxycytine kinase supplemented with external substrates may compensate for the deficient dGK. (C) 2008 Elsevier Inc. All rights reserved.
C1 Hadassah Med Ctr, Metab Dis Unit, IL-91120 Jerusalem, Israel.
C3 Hebrew University of Jerusalem; Hadassah University Medical Center
RP Saada, A (corresponding author), Hadassah Med Ctr, Metab Dis Unit, POB 12000, IL-91120 Jerusalem, Israel.
EM annsr@hadassah.org.il
RI Saada, Ann/J-6864-2017
OI Saada, Ann/0000-0003-2951-0656
FU Israeli Academy of Sciences and Humanities [406/02-1]; United
   Mitochondrial Disease Foundation (UMDF) [07-44]
FX This work was funded by the Israeli Academy of Sciences and Humanities,
   Grant No.406/02-1 and The United Mitochondrial Disease Foundation (UMDF)
   grant no 07-44. Mrs. Rivka Mannheim is acknowledged for expert technical
   assistance. Prof. Hana Mandel is acknowledged for providing the patient
   sample. The author is thankful for the fruitful discussions with Prof
   Staffan Eriksson, Dr. Liya Wang and Prof. Orly Elpeleg.
CR ARNER ESJ, 1992, BIOCHEM BIOPH RES CO, V188, P712, DOI 10.1016/0006-291X(92)91114-6
   Ashley N, 2007, HUM MOL GENET, V16, P1400, DOI 10.1093/hmg/ddm090
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Copeland WC, 2008, ANNU REV MED, V59, P131, DOI 10.1146/annurev.med.59.053006.104646
   DiMauro S, 2004, BBA-BIOENERGETICS, V1659, P107, DOI 10.1016/j.bbabio.2004.08.003
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Elpeleg O, 2003, PEDIATR RES, V54, P153, DOI 10.1203/01.PDR.0000072796.25097.A5
   Eriksson S, 2002, CELL MOL LIFE SCI, V59, P1327, DOI 10.1007/s00018-002-8511-x
   HURLEY MC, 1985, J BIOL CHEM, V260, P5675
   Labarthe F, 2005, J HEPATOL, V43, P333, DOI 10.1016/j.jhep.2005.03.023
   Leanza L, 2008, J BIOL CHEM, V283, P16437, DOI 10.1074/jbc.M801572200
   Mancuso M, 2005, ARCH NEUROL-CHICAGO, V62, P745, DOI 10.1001/archneur.62.5.745
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Mathews CK, 2007, FASEB J, V21, P2294, DOI 10.1096/fj.06-7977rev
   Pogozelski WK, 2003, MITOCHONDRION, V2, P415, DOI 10.1016/S1567-7249(03)00033-3
   Pontarin G, 2007, J BIOL CHEM, V282, P16820, DOI 10.1074/jbc.M701310200
   Pontarin G, 2006, J BIOL CHEM, V281, P22720, DOI 10.1074/jbc.M604498200
   Reisch AS, 2007, METHOD CELL BIOL, V80, P199, DOI 10.1016/S0091-679X(06)80010-5
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   Rylova SN, 2005, BIOCHEM PHARMACOL, V69, P951, DOI 10.1016/j.bcp.2004.12.010
   Saada A, 2004, DNA CELL BIOL, V23, P797
   Saada A, 2003, BIOCHEM BIOPH RES CO, V310, P963, DOI 10.1016/j.bbrc.2003.09.104
   Saada A, 2003, MOL GENET METAB, V79, P1, DOI 10.1016/S1096-7192(03)00063-5
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284
   Sarzi E, 2007, J PEDIATR-US, V150, P531, DOI 10.1016/j.jpeds.2007.01.044
   SHERMAN PA, 1989, ANAL BIOCHEM, V180, P222, DOI 10.1016/0003-2697(89)90420-X
   Song SW, 2005, P NATL ACAD SCI USA, V102, P4990, DOI 10.1073/pnas.0500253102
   Spinazzola A, 2002, J BIOL CHEM, V277, P4128, DOI 10.1074/jbc.M111028200
   Taanman JW, 2003, HUM MOL GENET, V12, P1839, DOI 10.1093/hmg/ddg192
   Wang LY, 2005, MOL GENET METAB, V84, P75, DOI 10.1016/j.ymgme.2004.09.005
   Wang LY, 1996, FEBS LETT, V390, P39, DOI 10.1016/0014-5793(96)00623-0
NR 32
TC 31
Z9 33
U1 0
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1096-7192
J9 MOL GENET METAB
JI Mol. Genet. Metab.
PD NOV
PY 2008
VL 95
IS 3
BP 169
EP 173
DI 10.1016/j.ymgme.2008.07.007
PG 5
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental
   Medicine
GA 368DQ
UT WOS:000260601900007
PM 18723380
DA 2024-11-01
ER

PT J
AU Strauss, KA
   DuBiner, L
   Simon, M
   Zaragoza, M
   Sengupta, PP
   Li, P
   Narula, N
   Dreike, S
   Platt, J
   Procaccio, V
   Ortiz-González, XR
   Puffenberger, EG
   Kelley, RI
   Morton, DH
   Narula, J
   Wallace, DC
AF Strauss, Kevin A.
   DuBiner, Lauren
   Simon, Mariella
   Zaragoza, Michael
   Sengupta, Partho P.
   Li, Peng
   Narula, Navneet
   Dreike, Sandra
   Platt, Julia
   Procaccio, Vincent
   Ortiz-Gonzalez, Xilma R.
   Puffenberger, Erik G.
   Kelley, Richard I.
   Morton, D. Holmes
   Narula, Jagat
   Wallace, Douglas C.
TI Severity of cardiomyopathy associated with adenine nucleotide
   translocator-1 deficiency correlates with mtDNA haplogroup
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE ANT1; oxidative stress; mitochondrial disease; variable penetrance;
   oxidative phosphorylation
ID MITOCHONDRIAL ADP/ATP CARRIERS; HYPERTROPHIC CARDIOMYOPATHY; DILATED
   CARDIOMYOPATHY; ADAPTIVE SELECTION; RESPIRATORY-CHAIN; SKELETAL-MUSCLE;
   DNA; MUTATIONS; MOUSE; EXPRESSION
AB Mutations of both nuclear and mitochondrial DNA (mtDNA) encoded mitochondrial proteins can cause cardiomyopathy associated with mitochondria! dysfunction. Hence, the cardiac phenotype of nuclear DNA mitochondrial mutations might be modulated by mtDNA variation. We studied a 13-generation Mennonite pedigree with autosomal recessive myopathy and cardiomyopathy due to an SLC25A4 frameshift null mutation (c.523delC, p.Q175Rf5X38), which codes for the heart-muscle isoform of the adenine nucleotide translocator-1. Ten homozygous null (adenine nucleotide translocator-1(-)/(-)) patients monitored over a median of 6 years had a phenotype of progressive myocardial thickening, hyperalaninemia, lactic acidosis, exercise intolerance, and persistent adrenergic activation. Electrocardiography and echocardiography with velocity vector imaging revealed abnormal contractile mechanics, myocardial repolarization abnormalities, and impaired left ventricular relaxation. End-stage heart disease was characterized by massive, symmetric, concentric cardiac hypertrophy; widespread cardiomyocyte degeneration; overabundant and structurally abnormal mitochondria; extensive subendocardial interstitial fibrosis; and marked hypertrophy of arteriolar smooth muscle. Substantial variability in the progression and severity of heart disease segregated with maternal lineage, and sequencing of mtDNA from five maternal lineages revealed two major European haplogroups, U and H. Patients with the haplogroup U mtDNAs had more rapid and severe cardiomyopathy than those with haplogroup H.
C1 [Strauss, Kevin A.; Puffenberger, Erik G.; Morton, D. Holmes] Clin Special Children, Strasburg, PA 17579 USA.
   [Strauss, Kevin A.; DuBiner, Lauren; Puffenberger, Erik G.; Morton, D. Holmes] Franklin & Marshall Coll, Dept Biol, Lancaster, PA 17603 USA.
   [Strauss, Kevin A.; Morton, D. Holmes] Lancaster Gen Hosp, Lancaster, PA 17602 USA.
   [Simon, Mariella; Zaragoza, Michael; Dreike, Sandra; Platt, Julia; Procaccio, Vincent; Wallace, Douglas C.] Univ Calif Irvine, Dept Pediat, Irvine, CA 92697 USA.
   [Simon, Mariella; Zaragoza, Michael; Dreike, Sandra; Platt, Julia; Procaccio, Vincent; Wallace, Douglas C.] Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA.
   [Simon, Mariella; Zaragoza, Michael; Dreike, Sandra; Platt, Julia; Procaccio, Vincent; Wallace, Douglas C.] Univ Calif Irvine, Ctr Mol & Mitochondrial Med & Genet, Irvine, CA 92697 USA.
   [Sengupta, Partho P.; Narula, Jagat] Mt Sinai Med Ctr, New York, NY 10029 USA.
   [Li, Peng] Univ Calif Irvine, Dept Med, Irvine, CA 92697 USA.
   [Narula, Navneet] Weill Cornell Med Coll, Dept Pathol, New York, NY 10019 USA.
   [Dreike, Sandra] Kapiolani Med Ctr Women & Children, Honolulu, HI 96826 USA.
   [Platt, Julia] Stanford Univ, Sch Med, Dept Pediat, Palo Alto, CA 94305 USA.
   [Procaccio, Vincent] CHU Angers, Natl Ctr Neurodegenerat & Mitochondrial Dis, Dept Biochem & Genet, F-49933 Angers, France.
   [Ortiz-Gonzalez, Xilma R.; Wallace, Douglas C.] Univ Penn, Ctr Mitochondrial & Epigenom Med, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
   [Ortiz-Gonzalez, Xilma R.; Wallace, Douglas C.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
   [Kelley, Richard I.] Johns Hopkins Univ, Sch Med, Kennedy Krieger Inst, Baltimore, MD 21205 USA.
C3 Franklin & Marshall College; University of California System; University
   of California Irvine; University of California System; University of
   California Irvine; University of California System; University of
   California Irvine; Icahn School of Medicine at Mount Sinai; University
   of California System; University of California Irvine; Cornell
   University; Weill Cornell Medicine; Stanford University; Universite
   d'Angers; Centre Hospitalier Universitaire d'Angers; University of
   Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia;
   University of Pennsylvania; Kennedy Krieger Institute; Johns Hopkins
   University
RP Wallace, DC (corresponding author), Univ Calif Irvine, Dept Pediat, Irvine, CA 92697 USA.
EM wallaced1@email.chop.edu
RI Ortiz-Gonzalez, Xilma/AAD-2211-2021; Sengupta, Partho/AAG-9508-2020;
   peng, li/AAJ-5708-2021; Procaccio, Vincent/M-2596-2015
OI Simon, Mariella/0000-0002-8200-3277; procaccio,
   Vincent/0000-0002-1537-4684; li, peng/0000-0003-2030-1807;
   Ortiz-Gonzalez, Xilma/0000-0002-1710-4696; Puffenberger,
   Erik/0000-0002-6388-9148
FU Postdoctoral Fellowship [5T32NS007413-14]; National Institutes of Health
   R01 [NS41850, NS21328, DK73691]
FX The authors deeply appreciate the assistance of Ms. Marie Lott for
   preparation of this manuscript. This work was supported by Postdoctoral
   Fellowship 5T32NS007413-14 (to X.R.O.-G.) and National Institutes of
   Health R01 Grants NS41850, NS21328, and DK73691 (to D.C.W.).
CR Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Arbustini E, 1998, AM J PATHOL, V153, P1501, DOI 10.1016/S0002-9440(10)65738-0
   Arbustini E, 1998, HEART, V80, P548, DOI 10.1136/hrt.80.6.548
   BOULENGER J-P, 1982, Encephale, V8, P119
   Cacciapuoti F, 2011, J AM SOC HYPERTENS, V5, P449, DOI 10.1016/j.jash.2011.08.006
   Chen XJ, 2002, HUM MOL GENET, V11, P1835, DOI 10.1093/hmg/11.16.1835
   Echaniz-Laguna A, 2012, J MED GENET, V49, P146, DOI 10.1136/jmedgenet-2011-100504
   Elliott P, 2004, LANCET, V363, P1881, DOI 10.1016/S0140-6736(04)16358-7
   Esposito LA, 1999, P NATL ACAD SCI USA, V96, P4820, DOI 10.1073/pnas.96.9.4820
   Flierl A, 2005, GENE THER, V12, P570, DOI 10.1038/sj.gt.3302443
   Gómez-Durán A, 2010, HUM MOL GENET, V19, P3343, DOI 10.1093/hmg/ddq246
   Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226
   GUENTHARD J, 1995, ARCH DIS CHILD, V72, P223, DOI 10.1136/adc.72.3.223
   Ji FY, 2012, P NATL ACAD SCI USA, V109, P7391, DOI 10.1073/pnas.1202484109
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kuster GM, 2005, CIRCULATION, V111, P1192, DOI 10.1161/01.CIR.0000157148.59308.F5
   Lombardi R, 2009, CIRCULATION, V119, P1398, DOI 10.1161/CIRCULATIONAHA.108.790501
   Lousa CD, 2005, BIOCHEMISTRY-US, V44, P4342, DOI 10.1021/bi0475370
   Lousa CD, 2002, BIOCHEMISTRY-US, V41, P14412, DOI 10.1021/bi02641490
   Maron BJ, 2002, JAMA-J AM MED ASSOC, V287, P1308, DOI 10.1001/jama.287.10.1308
   Mitchell HA, 2010, BIOCHEM PHARMACOL, V79, P801, DOI 10.1016/j.bcp.2009.10.004
   Montiel-Sosa F, 2006, GENE, V368, P21, DOI 10.1016/j.gene.2005.09.015
   Murdock DG, 1999, J BIOL CHEM, V274, P14429, DOI 10.1074/jbc.274.20.14429
   Narula N, 2011, JACC-CARDIOVASC IMAG, V4, P1, DOI 10.1016/j.jcmg.2010.06.018
   NISHIZAWA M, 1987, J NEUROL SCI, V78, P189, DOI 10.1016/0022-510X(87)90060-8
   Oei TPS, 2010, BEHAV COGN PSYCHOTH, V38, P479, DOI 10.1017/S1352465810000093
   Palmieri L, 2005, HUM MOL GENET, V14, P3079, DOI 10.1093/hmg/ddi341
   Pebay-Peyroula E, 2003, NATURE, V426, P39, DOI 10.1038/nature02056
   Pervanidou P, 2010, PROG BRAIN RES, V182, P149, DOI 10.1016/S0079-6123(10)82005-9
   Poole JC, 2010, BIOL CHEM, V391, P1115, DOI 10.1515/BC.2010.125
   Potluri P, 2009, MOL GENET METAB, V96, P189, DOI 10.1016/j.ymgme.2008.12.004
   Pryde KR, 2011, J BIOL CHEM, V286, P18056, DOI 10.1074/jbc.M110.186841
   Puffenberger EG, 2004, P NATL ACAD SCI USA, V101, P11689, DOI 10.1073/pnas.0401194101
   Rollins B, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004913
   Ruiz-Pesini E, 2004, SCIENCE, V303, P223, DOI 10.1126/science.1088434
   Ruiz-Pesini E, 2007, NUCLEIC ACIDS RES, V35, pD823, DOI 10.1093/nar/gkl927
   Ruiz-Pesini E, 2006, HUM MUTAT, V27, P1072, DOI 10.1002/humu.20378
   Sharieff GQ, 2006, EMERG MED CLIN N AM, V24, P195, DOI 10.1016/j.emc.2005.08.014
   STEPIEN G, 1992, J BIOL CHEM, V267, P14592
   Strauss KA, 2009, ANNU REV GENOM HUM G, V10, P513, DOI 10.1146/annurev-genom-082908-150040
   Subrarnaniam V, 2008, BBA-BIOENERGETICS, V1777, P666, DOI 10.1016/j.bbabio.2008.03.015
   Teekakirikul P, 2010, J CLIN INVEST, V120, P3520, DOI 10.1172/JCI42028
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Wallace DC, 2013, EMERY RIMOINS PRINCI, V1
   Wallace DC, 2012, NAT REV CANCER, V12, P685, DOI 10.1038/nrc3365
   Wallace DC, 2010, ANNU REV PATHOL-MECH, V5, P297, DOI 10.1146/annurev.pathol.4.110807.092314
   Yin H, 2005, INVEST OPHTH VIS SCI, V46, P4555, DOI 10.1167/iovs.05-0695
   Zaragoza MV, 2011, EUR J HUM GENET, V19, P200, DOI 10.1038/ejhg.2010.169
NR 48
TC 80
Z9 83
U1 0
U2 9
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD FEB 26
PY 2013
VL 110
IS 9
BP 3453
EP 3458
DI 10.1073/pnas.1300690110
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 102JW
UT WOS:000315841900054
PM 23401503
OA Bronze, Green Published, Green Submitted
DA 2024-11-01
ER

PT J
AU Ng, YS
   Hardy, SA
   Shrier, V
   Quaghebeur, G
   Mole, DR
   Daniels, MJ
   Downes, SM
   Freebody, J
   Fratter, C
   Hofer, M
   Nemeth, AH
   Poulton, J
   Taylor, RW
AF Ng, Yi Shiau
   Hardy, Steven A.
   Shrier, Venice
   Quaghebeur, Gerardine
   Mole, David R.
   Daniels, Matthew J.
   Downes, Susan M.
   Freebody, Jane
   Fratter, Carl
   Hofer, Monika
   Nemeth, Andrea H.
   Poulton, Joanna
   Taylor, Robert W.
TI Clinical features of the pathogenic m.5540G&gt;A mitochondrial transfer
   RNA tryptophan gene mutation
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE Mitochondrial DNA disease; Ataxia; Muscle biopsy; Proteinuria; Stroke
ID DNA MUTATIONS; MTDNA MUTATION; SKELETAL-MUSCLE; DISEASE; PREVALENCE;
   MANAGEMENT; DISORDERS; MELAS
AB Mitochondrial DNA disease is one of the most common groups of inherited neuromuscular disorders and frequently associated with marked phenotypic and genotypic heterogeneity. We describe an adult patient who initially presented with childhood-onset ataxia without a family history and an unremarkable diagnostic muscle biopsy. Subsequent multi-system manifestations included basal ganglia calcification, proteinuria, cataract and retinitis pigmentosa, prompting a repeat muscle biopsy that showed features consistent with mitochondrial myopathy 13 years later. She had a stroke with restricted diffusion change in the basal ganglia and internal capsule at age 44 years. Molecular genetic testing identified a previously-reported pathogenic, heteroplasmic mutation in the mitochondrial-encoded transfer RNA tryptophan (MT-TW) gene which based on family studies was likely to have arisen de novo in our patient. Interestingly, we documented an increase in the mutant mtDNA heteroplasmy level in her second biopsy (72% compared to 56%), reflecting the progression of clinical disease. (C) 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
C1 [Ng, Yi Shiau; Hardy, Steven A.; Taylor, Robert W.] Newcastle Univ, Inst Neurosci, Wellcome Trust Ctr Mitochondrial Res, Newcastle Upon Tyne, Tyne & Wear, England.
   [Shrier, Venice; Poulton, Joanna] Womens Ctr, Nuffield Dept Obstet & Gynaecol, Oxford, England.
   [Quaghebeur, Gerardine] Oxford Univ Hosp NHS Fdn Trust, Dept Neuroradiol, Oxford, England.
   [Mole, David R.] Oxford Univ Hosp NHS Fdn Trust, Oxford Kidney Unit, Oxford, England.
   [Daniels, Matthew J.] Univ Oxford, Div Cardiovasc Med, BHF Oxbridge Ctr Regenerat Med, Oxford, England.
   [Downes, Susan M.] Oxford Eye Hosp, Oxford, England.
   [Freebody, Jane] Oxford Univ Hosp NHS Fdn Trust, John Radcliffe Hosp, Neurosci Off, Level 3 West Wing, Oxford, England.
   [Fratter, Carl] Churchill Hosp, Oxford Med Genet Labs, Oxford Univ Hosp NHS Trust, Oxford, England.
   [Hofer, Monika] John Radcliffe Hosp, Neuropathol & Ocular Pathol Dept, Oxford, England.
   [Nemeth, Andrea H.] Univ Oxford, Nuffield Dept Clin Neurosci, Oxford, England.
   [Nemeth, Andrea H.] Churchill Hosp, Oxford, England.
C3 Newcastle University - UK; Oxford University Hospitals NHS Foundation
   Trust; Oxford University Hospitals NHS Foundation Trust; University of
   Oxford; University of Oxford; Oxford University Hospitals NHS Foundation
   Trust; University of Oxford; Oxford University Hospitals NHS Foundation
   Trust; University of Oxford; University of Oxford; University of Oxford
RP Taylor, RW (corresponding author), Newcastle Univ, Sch Med, Inst Neurosci, Wellcome Trust Ctr Mitochondrial Res, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM robert.taylor@ncl.ac.uk
RI Poulton, Joanna/AAB-4828-2021; Ng, Yi/AFF-1445-2022; Daniels,
   Matthew/AFP-1750-2022; Nemeth, Andrea/AGJ-1121-2022
OI Poulton, Joanna/0000-0002-2460-5587; Daniels,
   Matthew/0000-0002-9250-6214; Mole, David/0000-0002-0984-300X; Ng, Yi
   Shiau/0000-0002-7591-2034; Nemeth, Andrea/0000-0002-2941-7657
FU Medical Research Council [MR/J010448/1, G0800674, G0601943] Funding
   Source: Medline; Wellcome Trust [0948685/Z/10/Z, WT098519MA,
   096919/Z/11/Z] Funding Source: Medline; MRC [G0601943, MR/J010448/1,
   G0800674] Funding Source: UKRI
CR Atale A, 2009, EUR J MED GENET, V52, P23, DOI 10.1016/j.ejmg.2008.10.003
   Bannwarth S, 2013, J MED GENET, V50, P704, DOI 10.1136/jmedgenet-2013-101604
   Che RC, 2014, AM J PHYSIOL-RENAL, V306, pF367, DOI 10.1152/ajprenal.00571.2013
   DiMauro S, 2008, ANNU REV NEUROSCI, V31, P91, DOI 10.1146/annurev.neuro.30.051606.094302
   Elliott HR, 2008, AM J HUM GENET, V83, P254, DOI 10.1016/j.ajhg.2008.07.004
   Elson JL, 2009, HUM MUTAT, V30, pE984, DOI 10.1002/humu.21113
   Gorman GS, 2015, ANN NEUROL, V77, P753, DOI 10.1002/ana.24362
   Granadillo JL, 2014, MOLEC GENET METAB RE, V1, P61, DOI 10.1016/j.ymgmr.2013.12.001
   Greaves LC, 2012, J PATHOL, V226, P274, DOI 10.1002/path.3028
   Marchington D, 2010, J MED GENET, V47, P257, DOI 10.1136/jmg.2009.072900
   MORAES CT, 1992, AM J HUM GENET, V50, P934
   Ng YS, 2016, J NEUROL, V263, P179, DOI 10.1007/s00415-015-7884-3
   POULTON J, 1993, HUM MOL GENET, V2, P23, DOI 10.1093/hmg/2.1.23
   Rahman S, 2001, AM J HUM GENET, V68, P238, DOI 10.1086/316930
   Sallevelt SCEH, 2017, J MED GENET, V54, P114, DOI 10.1136/jmedgenet-2016-103876
   Silvestri G, 2000, NEUROLOGY, V54, P1693, DOI 10.1212/WNL.54.8.1693
   Tuppen HAL, 2010, BBA-BIOENERGETICS, V1797, P113, DOI 10.1016/j.bbabio.2009.09.005
   Weber K, 1997, AM J HUM GENET, V60, P373
   White HE, 2005, GENET TEST, V9, P190, DOI 10.1089/gte.2005.9.190
NR 19
TC 4
Z9 4
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD OCT
PY 2016
VL 26
IS 10
BP 702
EP 705
DI 10.1016/j.nmd.2016.08.009
PG 4
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA EA2FL
UT WOS:000386408100011
PM 27618137
OA Green Published, hybrid
DA 2024-11-01
ER

PT J
AU Felhi, R
   Sfaihi, L
   Charif, M
   Desquiret-Dumas, V
   Bris, C
   Goudenège, D
   Ammar-Keskes, L
   Hachicha, M
   Bonneau, D
   Procaccio, V
   Reynier, P
   Amati-Bonneau, P
   Lenaers, G
   Fakhfakh, F
AF Felhi, Rahma
   Sfaihi, Lamia
   Charif, Majida
   Desquiret-Dumas, Valerie
   Bris, Celine
   Goudenege, David
   Ammar-Keskes, Leila
   Hachicha, Mongia
   Bonneau, Dominique
   Procaccio, Vincent
   Reynier, Pascal
   Amati-Bonneau, Patrizia
   Lenaers, Guy
   Fakhfakh, Faiza
TI Next generation sequencing in family with MNGIE syndrome associated to
   optic atrophy: Novel homozygous POLG mutation in the C-terminal
   sub-domain leading to mtDNA depletion
SO CLINICA CHIMICA ACTA
LA English
DT Article
DE MNGIE; POLG; OPA1; mtDNA depletion; Pathogenic variants
ID NEUROGASTROINTESTINAL ENCEPHALOMYOPATHY MNGIE; MITOCHONDRIAL-DNA;
   DISEASE; VARIANTS; PATIENT; SERVER
AB Introduction: Mitochondrial diseases are a group of disorders caused mainly by the impairment of the mitochondrial oxidative phosphorylation process, due to mutations either in the mitochondrial or nuclear genome. Among them, the mitochondrial neuro-gastrointestinal encephalo-myopathy (MNGIE) syndrome affects adolescents or young adults, and is mostly caused by TYMP mutations encoding a cytosolic thymidine phosphorylase (TP).
   Patients and methods: The present study reports the molecular investigation by next-generation re-sequencing of 281 nuclear genes, encoding mitochondrial proteins, of consanguineous family including two individuals with MNGIE syndrome associated to optic atrophy. Bioinformatic analysis was also performed in addition to mtDNA deletion screening and mtDNA copy number quantification in blood of the two patients which were carried out by solf clipping program and qPCR respectively.
   Results: Next-generation re-sequencing revealed a novel homozygous c.2391G > T POLG mutation (p.M797I) co-occurring with the hypomorphic c.1311A > G OPA1 variant (p.I437M). Analysis of the mitochondrial genome in the two patients disclosed mtDNA depletion in blood, but no deletion. Bio-informatics investigations supported the pathogenicity of the novel POW mutation that is located in the C-terminal subdomain and might change POLG 3D structure, stability and function.
   Conclusion: The novel homozygous p.M797I POLG mutation is responsible for MNGIE combined to optic atrophy and mtDNA depletion in the two patients.
C1 [Felhi, Rahma; Fakhfakh, Faiza] Univ Sfax, Fac Sci Sfax, Mol & Funct Genet Lab, Route Soukra Km 3, Sfax, Tunisia.
   [Charif, Majida; Desquiret-Dumas, Valerie; Bris, Celine; Goudenege, David; Bonneau, Dominique; Procaccio, Vincent; Reynier, Pascal; Amati-Bonneau, Patrizia; Lenaers, Guy] Angers Univ, Inst MitoVasc, MitoLab Team, UMR CNRS 6015,INSERM U1083, Angers, France.
   [Sfaihi, Lamia; Hachicha, Mongia] Univ Hosp Hedi Chaker, Dept Pediat, Sfax, Tunisia.
   [Ammar-Keskes, Leila] Univ Sfax, Fac Med Sfax, Human Mol Genet Lab, Sfax, Tunisia.
   [Desquiret-Dumas, Valerie; Bris, Celine; Goudenege, David; Bonneau, Dominique; Procaccio, Vincent; Reynier, Pascal; Amati-Bonneau, Patrizia] Univ Hosp Angers, Dept Biochem & Genet, Angers, France.
C3 Universite de Sfax; Faculty of Sciences Sfax; Universite d'Angers;
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite de Sfax; Hopital Habib Bourguiba; Hopital Hedi Chaker;
   Universite de Sfax; Universite d'Angers; Centre Hospitalier
   Universitaire d'Angers
RP Felhi, R; Fakhfakh, F (corresponding author), Univ Sfax, Fac Sci Sfax, Mol & Funct Genet Lab, Route Soukra Km 3, Sfax, Tunisia.
EM Rahma.90felhi@gmail.com; Faiza.fakfakh02@gmail.com
RI Procaccio, Vincent/M-2596-2015; Desquiret-Dumas, Valérie/K-2695-2015;
   Reynier, Pascal/K-3677-2015; Lenaers, guy/X-4727-2019
OI Desquiret-Dumas, Valerie/0000-0001-9551-9400; procaccio,
   Vincent/0000-0002-1537-4684; Goudenege, David/0000-0003-0738-2905;
   Reynier, Pascal/0000-0003-0802-4608; Keskes, Leila/0000-0002-8420-139X;
   sfaihi, lamia/0000-0003-4480-5313
FU Ministry of Higher Education and Scientific Research in Tunisia,
   University of Sfax; Institut National de la Sante et de la Recherche
   Medicate (INSERM), France; Centre National de la Recherche Scientifique
   (CNRS), France; Universite d'Angers, France; University Hospital of
   Angers, France; Region Pays de Loire, France; Angers Loire Metropole,
   France
FX We would like to thank all the member of the family for their
   cooperation in the present study. This work was supported by the
   Ministry of Higher Education and Scientific Research in Tunisia,
   University of Sfax. We acknowledge the support from the Institut
   National de la Sante et de la Recherche Medicate (INSERM), France;
   Centre National de la Recherche Scientifique (CNRS), France; the
   Universite d'Angers, the University Hospital of Angers, the Region Pays
   de Loire and Angers Loire Metropole, France.
CR Adzhubei Ivan, 2013, Curr Protoc Hum Genet, VChapter 7, DOI 10.1002/0471142905.hg0720s76
   Bai RK, 2005, J MOL DIAGN, V7, P613, DOI 10.1016/S1525-1578(10)60595-8
   Baris Z, 2010, EUR J PEDIATR, V169, P1375, DOI 10.1007/s00431-010-1237-0
   Blok MJ, 2009, J MED GENET, V46, P776, DOI 10.1136/jmg.2009.067686
   Bonifert T, 2014, BRAIN, V137, P2164, DOI 10.1093/brain/awu165
   Bonneau D, 2014, BRAIN, V137, DOI 10.1093/brain/awu184
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Carugo O, 2001, PROTEIN SCI, V10, P1470, DOI 10.1110/ps.690101
   Chiaratti MR, 2011, MITOCHONDRION, V11, P820, DOI 10.1016/j.mito.2010.11.004
   Choi Y, 2015, BIOINFORMATICS, V31, P2745, DOI 10.1093/bioinformatics/btv195
   De Baets G, 2012, NUCLEIC ACIDS RES, V40, pD935, DOI 10.1093/nar/gkr996
   Del Bo R, 2003, NEUROLOGY, V61, P903, DOI 10.1212/01.WNL.0000092303.13864.BE
   Demaria F, 2016, J ADOLESCENT HEALTH, V59, P729, DOI 10.1016/j.jadohealth.2016.08.012
   Dimmock D, 2010, CLIN CHEM, V56, P1119, DOI 10.1373/clinchem.2009.141549
   El-Hattab A, 2013, NEUROTHERAPEUTICS, V10, P186, DOI 10.1007/s13311-013-0177-6
   Euro L, 2011, NUCLEIC ACIDS RES, V39, P9072, DOI 10.1093/nar/gkr618
   Ferreira M, 2011, NEUROMUSCULAR DISORD, V21, P483, DOI 10.1016/j.nmd.2011.03.011
   Foury F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027847
   Montiel-Sosa JF, 2013, MITOCHONDR DNA, V24, P420, DOI 10.3109/19401736.2012.760550
   Gago MF, 2006, NEUROMUSCULAR DISORD, V16, P507, DOI 10.1016/j.nmd.2006.05.016
   Gorman GS, 2016, NAT REV DIS PRIMERS, V2, P1, DOI 10.1038/nrdp.2016.80
   Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505
   Hirano M, 2004, NEUROLOGIST, V10, P8, DOI 10.1097/01.nrl.0000106919.06469.04
   Källberg M, 2014, METHODS MOL BIOL, V1137, P17, DOI 10.1007/978-1-4939-0366-5_2
   Kasiviswanathan R, 2011, MITOCHONDRION, V11, P929, DOI 10.1016/j.mito.2011.08.003
   Koboldt DC, 2013, CELL, V155, P27, DOI 10.1016/j.cell.2013.09.006
   Landrum MJ, 2014, NUCLEIC ACIDS RES, V42, pD980, DOI 10.1093/nar/gkt1113
   LEWIN HA, 1992, BIOTECHNIQUES, V13, P522
   Li B, 2009, BIOINFORMATICS, V25, P2744, DOI 10.1093/bioinformatics/btp528
   McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110
   Miguel R, 2014, CLIN NEUROL NEUROSUR, V126, P47, DOI 10.1016/j.clineuro.2014.08.020
   Milone M, 2011, ARCH NEUROL-CHICAGO, V68, P806, DOI 10.1001/archneurol.2011.124
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Nishino I, 2001, NEUROMUSCULAR DISORD, V11, P7, DOI 10.1016/S0960-8966(00)00159-0
   Nurminen A, 2017, BBA CLIN, V7, P147, DOI 10.1016/j.bbacli.2017.04.001
   Prasun P, 2014, J NEUROL, V261, P1818, DOI 10.1007/s00415-014-7428-2
   Rimmer A, 2014, NAT GENET, V46, P912, DOI 10.1038/ng.3036
   Schimpf S, 2008, HUM MUTAT, V29, P106, DOI 10.1002/humu.20607
   Schwarz JM, 2010, NAT METHODS, V7, P575, DOI 10.1038/nmeth0810-575
   Shaibani A, 2009, ARCH NEUROL-CHICAGO, V66, P1028, DOI 10.1001/archneurol.2009.139
   Smigielski EM, 2000, NUCLEIC ACIDS RES, V28, P352, DOI 10.1093/nar/28.1.352
   Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506
   Tang S, 2011, J MED GENET, V48, P669, DOI 10.1136/jmedgenet-2011-100222
   Van Goethem G, 2003, EUR J HUM GENET, V11, P547, DOI 10.1038/sj.ejhg.5201002
   Venegas V., 2011, CURR PROTOC HUM GENE, P19
   Wei Z, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr599
   Wilm A, 2012, NUCLEIC ACIDS RES, V40, P11189, DOI 10.1093/nar/gks918
   Yang H, 2015, NAT PROTOC, V10, P1556, DOI 10.1038/nprot.2015.105
NR 48
TC 13
Z9 14
U1 1
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0009-8981
EI 1873-3492
J9 CLIN CHIM ACTA
JI Clin. Chim. Acta
PD JAN
PY 2019
VL 488
BP 104
EP 110
DI 10.1016/j.cca.2018.11.003
PG 7
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology
GA HI9EK
UT WOS:000456757900015
PM 30395865
DA 2024-11-01
ER

PT J
AU Lim, AZ
   McMacken, G
   Rastelli, F
   Olahova, M
   Baty, K
   Hopton, S
   Falkous, G
   Töpf, A
   Lochmüller, H
   Marini-Bettolo, C
   McFarland, R
   Taylor, RW
AF Lim, Albert Z.
   McMacken, Grace
   Rastelli, Francesca
   Olahova, Monika
   Baty, Karen
   Hopton, Sila
   Falkous, Gavin
   Topf, Ana
   Lochmueller, Hanns
   Marini-Bettolo, Chiara
   McFarland, Robert
   Taylor, Robert W.
TI A novel, pathogenic dinucleotide deletion in the mitochondrial
   <i>MT-TY</i> gene causing myasthenia-like features
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE Mitochondrial disease; Congenital myasthenia syndromes (CMS); MTTY gene;
   mtDNA tRNA variant; Muscle biopsy
ID TRANSFER-RNA MUTATIONS; POINT MUTATIONS; DIAGNOSIS; MYOPATHY; ASSAY
AB Mitochondrial DNA (mtDNA)-related diseases often pose a diagnostic challenge and require rigorous clinical and laboratory investigation. Pathogenic variants in the mitochondrial tRNA gene MT-TY, which encodes the tRNATyr, are a rare cause of mitochondrial disease. Here we describe a novel m.5860delTA anticodon variant in the MT-TY gene in a patient who initially presented with features akin to a childhood onset myasthenic syndrome. Using histochemical, immunohistochemical and protein studies we demonstrate that this mutation leads to severe biochemical defects of mitochondrial translation, which is reflected in the early onset and progressive phenotype. This case highlights the clinical overlap between mtDNA-related diseases and other neuromuscular disorders, and demonstrates the potential pitfalls in analysis of next generation sequencing results, given whole exome sequencing of a blood DNA sample failed to make a genetics diagnosis. Muscle biopsy remains an important requirement in the diagnosis of mitochondrial disease and in establishing the pathogenicity of novel mtDNA variants. (c) 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license. (http://creativecommons.org/licenses/by/4.0/)
C1 [Lim, Albert Z.; Rastelli, Francesca; Olahova, Monika; Baty, Karen; Hopton, Sila; Falkous, Gavin; McFarland, Robert; Taylor, Robert W.] Newcastle Univ, Sch Med, Wellcome Ctr Mitochondrial Res, Newcastle Upon Tyne, Tyne & Wear, England.
   [McMacken, Grace; Topf, Ana; Marini-Bettolo, Chiara] Newcastle Univ, John Walton Muscular Dystrophy Res Ctr, Newcastle Upon Tyne, Tyne & Wear, England.
   [Baty, Karen; Hopton, Sila; Falkous, Gavin; Taylor, Robert W.] NHS Highly Specialised Serv Rare Mitochondrial Di, Newcastle Upon Tyne, Tyne & Wear, England.
   [McMacken, Grace] Belfast Hlth & Social Care Trust, Royal Victoria Hosp, Dept Neurosci, Belfast, Antrim, North Ireland.
   [Olahova, Monika] Newcastle Univ, Biosci Inst, Fac Med Sci, Newcastle Upon Tyne, Tyne & Wear, England.
   [Lochmueller, Hanns] Univ Freiburg, Dept Neuropediatr & Muscle Disorders, Med Ctr, Freiburg, Germany.
   [Lochmueller, Hanns] Barcelona Inst Sci & Technol, Ctr Genom Regulat, Ctr Nacl Anal Genom CNAG CRG, Barcelona, Spain.
   [Lochmueller, Hanns] Childrens Hosp Eastern Ontario, Res Inst, Ottawa, ON, Canada.
   [Lochmueller, Hanns] Ottawa Univ, Dept Med, Div Neurol, Ottawa, ON, Canada.
   [McFarland, Robert; Taylor, Robert W.] Newcastle Univ, Translat & Clin Res Inst, Fac Med Sci, Newcastle Upon Tyne, Tyne & Wear, England.
C3 Newcastle University - UK; Newcastle University - UK; Newcastle
   University - UK; University of Freiburg; Barcelona Institute of Science
   & Technology; Pompeu Fabra University; Centre de Regulacio Genomica
   (CRG); University of Ottawa; Children's Hospital of Eastern Ontario;
   University of Ottawa; Newcastle University - UK
RP McFarland, R (corresponding author), Newcastle Univ, Translat & Clin Res Inst, Fac Med Sci, Newcastle Upon Tyne, Tyne & Wear, England.; McFarland, R (corresponding author), Newcastle Univ, Wellcome Ctr Mitochondrial Res, Newcastle, NSW NE2 4HH, Australia.
EM robert.mcfarland@ncl.ac
FU Wellcome Centre for Mitochondrial Research [203105/Z/16/Z]; Medical
   Research Council (MRC) International Centre for Genomic Medicine in
   Neuromuscular Disease; Mitochondrial Disease Patient Cohort (UK)
   [G0800674]; Newcastle University Centre for Ageing and Vitality
   (Biotechnology and Biological Sciences Research Council ); Newcastle
   University Centre for Ageing and Vitality (Medical Research Council)
   [L016354]; UK NIHR Biomedical Research Centre for Ageing and Age-related
   disease award; Lily Foundation; UK NHS Specialist Commissioners - "Rare
   Mitochondrial Disorders of Adults and Children" Diagnostic Service in
   Newcastle upon Tyne; Association of British Neurologists Clinical
   Research Training Fellowship; Biobanking and Biomedical Resources
   Research Infrastructure -large prospective cohorts (BBMRILPC) 2016
   access call for Whole Exome Sequencing (FP7/2007-2013) [313010];
   RD-Connect Genome-Phenome Analysis platform developed under
   FP7/2007-2013 [305444]; UK NHS Highly Specialised Service for Rare
   Neuromuscular Disorders in Newcastle upon Tyne; MRC [G0800674] Funding
   Source: UKRI
FX AL, RM and RWT are supported by the Wellcome Centre for Mitochondrial
   Research (203105/Z/16/Z); RM and RWT also receive support from the
   Medical Research Council (MRC) International Centre for Genomic Medicine
   in Neuromuscular Disease, the Mitochondrial Disease Patient Cohort (UK)
   (G0800674), Newcastle University Centre for Ageing and Vitality
   (supported by the Biotechnology and Biological Sciences Research Council
   and Medical Research Council L016354), UK NIHR Biomedical Research
   Centre for Ageing and Age-related disease award to the Newcastle upon
   Tyne Hospitals NHS Foundation Trust, the Lily Foundation and the UK NHS
   Specialist Commissioners which funds the "Rare Mitochondrial Disorders
   of Adults and Children" Diagnostic Service in Newcastle upon Tyne
   (http://www.newcastle-mitochondria.com/).GM is supported by the
   Association of British Neurologists Clinical Research Training
   Fellowship. Biobanking and Biomedical Resources Research Infrastructure
   -large prospective cohorts (BBMRILPC) 2016 access call for Whole Exome
   Sequencing (FP7/2007-2013), Grant Number: 313010. Data were analyzed
   using the RD-Connect Genome-Phenome Analysis platform developed under
   FP7/2007-2013 funded project, Grant Number: 305444. AT, HL, CMB are
   supported by the UK NHS Highly Specialised Service for Rare
   Neuromuscular Disorders in Newcastle upon Tyne
   https://newcastle-muscle.org/clinical/clinical-services/hss/.The
   antibody against MTND2 was a kind gift from Dr. Michael Marusich, mAbDx,
   Inc., Eugene, Oregon.
CR Alston CL, 2017, J PATHOL, V241, P236, DOI 10.1002/path.4809
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Blakely EL, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.011296
   Blakely EL, 2013, HUM MUTAT, V34, P1260, DOI 10.1002/humu.22358
   Braz L.P., 2019, NEUROMUSCULAR JUNCTI, DOI [10.1212/CPJ.0000000000000795, DOI 10.1212/CPJ.0000000000000795]
   Chaouch Amina, 2014, J Neuromuscul Dis, V1, P75
   Guo YR, 2015, NEUROMUSCULAR DISORD, V25, P257, DOI 10.1016/j.nmd.2014.11.017
   Joshi PR, 2020, NEUROMUSCUL DISORD
   Kirby DM, 2007, METHOD CELL BIOL, V80, P93, DOI 10.1016/S0091-679X(06)80004-X
   Kornblum C, 2008, BIOSCIENCE REP, V28, P89, DOI 10.1042/BSR20080004
   KRENDEL DA, 1987, MUSCLE NERVE, V10, P299, DOI 10.1002/mus.880100404
   Lehtokari VL, 2014, HUM MUTAT, V35, P1418, DOI 10.1002/humu.22693
   McFarland R, 2004, TRENDS GENET, V20, P591, DOI 10.1016/j.tig.2004.09.014
   Oláhová M, 2015, BRAIN, V138, P3503, DOI 10.1093/brain/awv291
   OLD SL, 1989, HISTOCHEM J, V21, P545, DOI 10.1007/BF01753355
   Plewnia K, 1997, J SUBMICR CYTOL PATH, V29, P335
   Pulkes T, 2000, NEUROLOGY, V55, P1210, DOI 10.1212/WNL.55.8.1210
   Raffelsberger T, 2001, NEUROLOGY, V57, P2298, DOI 10.1212/WNL.57.12.2298
   Rocha MC, 2015, SCI REP-UK, V5, DOI 10.1038/srep15037
   Sahashi K, 2001, J MED GENET, V38, P703, DOI 10.1136/jmg.38.10.703
   Scaglia F, 2003, AM J MED GENET A, V123A, P172, DOI 10.1002/ajmg.a.20315
   Schon EA, 2012, NAT REV GENET, V13, P878, DOI 10.1038/nrg3275
   Sewry CA, 2019, J MUSCLE RES CELL M, V40, P111, DOI 10.1007/s10974-019-09519-9
   Simoncini C, 2018, CASE REP NEUROL MED, V2018, DOI 10.1155/2018/8406712
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   UKACHOKE C, 1994, CAN J NEUROL SCI, V21, P125, DOI 10.1017/S0317167100049040
   Yarham JW, 2011, HUM MUTAT, V32, P1319, DOI 10.1002/humu.21575
   Yarham JW, 2010, WIRES RNA, V1, P304, DOI 10.1002/wrna.27
NR 29
TC 7
Z9 7
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD AUG
PY 2020
VL 30
IS 8
BP 661
EP 668
DI 10.1016/j.nmd.2020.06.008
PG 8
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA NI7OZ
UT WOS:000565539700006
PM 32684384
OA Green Published, hybrid
DA 2024-11-01
ER

PT J
AU Cordero, MD
   Alcocer-Gómez, E
   Marín-Aguilar, F
   Rybkina, T
   Cotán, D
   Pérez-Pulido, A
   Alvarez-Suarez, JM
   Battino, M
   Sánchez-Alcazar, JA
   Carrión, AM
   Culic, O
   Navarro-Pando, JM
   Bullón, P
AF Cordero, Mario D.
   Alcocer-Gomez, Elisabet
   Marin-Aguilar, Fabiola
   Rybkina, Tatyana
   Cotan, David
   Perez-Pulido, Antonio
   Miguel Alvarez-Suarez, Jose
   Battino, Maurizio
   Antonio Sanchez-Alcazar, Jose
   Carrion, Angel M.
   Culic, Ognjen
   Navarro-Pando, Jose M.
   Bullon, Pedro
TI Mutation in cytochrome b gene of mitochondrial DNA in a family with
   fibromyalgia is associated with NLRP3-inflammasome activation
SO JOURNAL OF MEDICAL GENETICS
LA English
DT Article
ID BLOOD MONONUCLEAR-CELLS; NLRP3 INFLAMMASOME; COENZYME Q(10); OXIDATIVE
   STRESS; DISEASE; MUSCLE; SUPPLEMENTATION; DYSFUNCTION; FIBROBLASTS;
   DEFICIENCY
AB Background Fibromyalgia (FM) is a worldwide diffuse musculoskeletal chronic pain condition that affects up to 5% of the general population. Many symptoms associated with mitochondrial diseases are reported in patients with FM such as exercise intolerance, fatigue, myopathy and mitochondrial dysfunction. In this study, we report a mutation in cytochrome b gene of mitochondrial DNA (mtDNA) in a family with FM with inflammasome complex activation.
   Methods mtDNA from blood cells of five patients with FM were sequenced. We clinically and genetically characterised a patient with FM and family with a new mutation in mtCYB. Mitochondrial mutation phenotypes were determined in skin fibroblasts and transmitochondrial cybrids.
   Results After mtDNA sequence in patients with FM, we found a mitochondrial homoplasmic mutation m. 15804T>C in the mtCYB gene in a patient and family, which was maternally transmitted. Mutation was observed in several tissues and skin fibroblasts showed a very significant mitochondrial dysfunction and oxidative stress. Increased NLRP3-inflammasome complex activation was observed in blood cells from patient and family.
   Conclusions We propose further studies on mtDNA sequence analysis in patients with FM with evidences for maternal inheritance. The presence of similar symptoms in mitochondrial myopathies could unmask mitochondrial diseases among patients with FM. On the other hand, the inflammasome complex activation by mitochondrial dysfunction could be implicated in the pathophysiology of mitochondrial diseases.
C1 [Cordero, Mario D.; Marin-Aguilar, Fabiola; Bullon, Pedro] Univ Seville, Univ Hosp Virgen Rocio CSIC, IBiS Inst Biomed Seville, Seville, Spain.
   [Cordero, Mario D.; Bullon, Pedro] Univ Seville, Dept Oral Med, Res Lab, Seville, Spain.
   [Alcocer-Gomez, Elisabet; Cotan, David; Perez-Pulido, Antonio; Antonio Sanchez-Alcazar, Jose] Univ Pablo Olavide CSIC Junta Andalucia, CABD, Seville, Spain.
   [Alcocer-Gomez, Elisabet; Cotan, David; Antonio Sanchez-Alcazar, Jose] ISCIII, CIBERER, Seville, Spain.
   [Rybkina, Tatyana; Carrion, Angel M.] Univ Pablo Olavide Sevilla, Div Neurociencias, Seville, Spain.
   [Miguel Alvarez-Suarez, Jose] Univ Las Amer, Fac Ciencias Salud, Escuela Med Vet & Zootecnia, Quito, Ecuador.
   [Battino, Maurizio] Univ Politecn Marche, Dipartimento Sci Clin Specialist & Odontostomatol, Ancona, Italy.
   [Culic, Ognjen] Univ Zagreb, Fac Pharm & Biochem, Zagreb 41000, Croatia.
   [Navarro-Pando, Jose M.] Inst Estudio Biol Reprod Humana INEBIR, Unidad Reprod Humana & Cirugia Endoscopia, Seville, Spain.
C3 Consejo Superior de Investigaciones Cientificas (CSIC); University of
   Sevilla; CSIC-JA-USE - Instituto de Biomedicina de Sevilla (IBIS);
   University of Sevilla; Consejo Superior de Investigaciones Cientificas
   (CSIC); Universidad Pablo de Olavide; CSIC - Andalusian Center for
   Developmental Biology (CABD); Instituto de Salud Carlos III; CIBER -
   Centro de Investigacion Biomedica en Red; CIBERER; Universidad Pablo de
   Olavide; Universidad de Las Americas - Ecuador; Marche Polytechnic
   University; University of Zagreb
RP Cordero, MD (corresponding author), Univ Seville, Univ Hosp Virgen Rocio CSIC, IBiS Inst Biomed Seville, Seville, Spain.; Cordero, MD (corresponding author), Univ Seville, Dept Oral Med, Res Lab, Seville, Spain.; Cordero, MD (corresponding author), Univ Seville, Inst Biomed Seville, C Calle Antonio Maura Montaner S-N, Seville 41013, Spain.
EM mdcormor@us.es
RI Rybkina, Tatyana/S-1147-2019; Perez-Pulido, Antonio/K-3384-2012;
   Battino, Maurizio/E-6103-2012; Sanchéz-Alcázar, José/L-4925-2014;
   Cordero, Mario D./L-8006-2014; Carrion Rodriguez, Angel
   Manuel/K-5875-2014; Alvarez-Suarez, Jose M./M-7160-2014; Bullon,
   Pedro/E-6319-2010
OI Cordero, Mario D./0000-0003-0151-3644; Carrion Rodriguez, Angel
   Manuel/0000-0001-8158-9512; Perez-Pulido, Antonio
   J./0000-0003-3343-2822; Alcocer-Gomez, Elisabet/0000-0001-9799-431X;
   Alvarez-Suarez, Jose M./0000-0001-8509-1498; Bullon,
   Pedro/0000-0003-4873-4196
FU Federacion Andaluza de Fibromialgia y Fatiga Cronica (ALBA Andalucia);
   Federacion Onubense de Fibromialgia y Fatiga Cronica; Fundacion Ramon
   Areces; DGICYT (Departamento Gubernamental de Investigaciones
   Cientificas y Tecnologicas) [BFU2011-27207]; Grupo de Investigacion
   Junta de Andalucia [CTS113]; Consejeria de Salud of the Junta de
   Andalucia [PI-0036-2014]
FX This work has been supported by Federacion Andaluza de Fibromialgia y
   Fatiga Cronica (ALBA Andalucia), Federacion Onubense de Fibromialgia y
   Fatiga Cronica, grants from the Fundacion Ramon Areces and DGICYT
   (Departamento Gubernamental de Investigaciones Cientificas y
   Tecnologicas: BFU2011-27207), Grupo de Investigacion Junta de Andalucia
   CTS113 and Consejeria de Salud of the Junta de Andalucia (PI-0036-2014).
CR Alcocer-Gómez E, 2015, BBA-MOL BASIS DIS, V1852, P1257, DOI 10.1016/j.bbadis.2015.03.005
   [Anonymous], 2013, MEDIAT INFLAMM, DOI DOI 10.1155/2013/678627
   Arnold LM, 2004, ARTHRITIS RHEUM-US, V50, P944, DOI 10.1002/art.20042
   Arpa J, 2003, MUSCLE NERVE, V28, P690, DOI 10.1002/mus.10507
   Bagis S, 2005, RHEUMATOL INT, V25, P188, DOI 10.1007/s00296-003-0427-8
   Bazzichi L, 2007, CLIN EXP RHEUMATOL, V25, P225
   Bazzichi L, 2008, CLIN BIOCHEM, V41, P1084, DOI 10.1016/j.clinbiochem.2008.06.012
   Biasini M, 2014, NUCLEIC ACIDS RES, V42, pW252, DOI 10.1093/nar/gku340
   Bonfield JK, 1998, NUCLEIC ACIDS RES, V26, P3404, DOI 10.1093/nar/26.14.3404
   BOYLE JS, 1995, TRENDS GENET, V11, P8, DOI 10.1016/S0168-9525(00)88977-5
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Buskila D, 1996, SEMIN ARTHRITIS RHEU, V26, P605, DOI 10.1016/S0049-0172(96)80011-4
   Chen ZT, 2015, MOL MED REP, V11, P1956, DOI 10.3892/mmr.2014.2911
   Cordero MD, 2014, ANTIOXID REDOX SIGN, V20, P1169, DOI 10.1089/ars.2013.5198
   Cordero MD, 2013, ANTIOXID REDOX SIGN, V19, P1356, DOI 10.1089/ars.2013.5260
   Cordero MD, 2013, ANTIOXID REDOX SIGN, V18, P800, DOI 10.1089/ars.2012.4892
   Cordero MD, 2012, NUTRITION, V28, P1200, DOI 10.1016/j.nut.2012.03.018
   Cordero MD, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2918
   Cotán D, 2011, FASEB J, V25, P2669, DOI 10.1096/fj.10-165340
   Dashdorj A, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-178
   De la Mata M, 2012, NEUROTHERAPEUTICS, V9, P446, DOI 10.1007/s13311-012-0103-3
   Ding ZF, 2014, BIOCHEM BIOPH RES CO, V451, P637, DOI 10.1016/j.bbrc.2014.08.034
   Gerdle B, 2013, EUR J PAIN, V17, P1205, DOI 10.1002/j.1532-2149.2013.00284.x
   Gómez-Durán A, 2010, HUM MOL GENET, V19, P3343, DOI 10.1093/hmg/ddq246
   Greaves LC, 2012, J PATHOL, V226, P274, DOI 10.1002/path.3028
   Haas RH, 2008, MOL GENET METAB, V94, P16, DOI 10.1016/j.ymgme.2007.11.018
   Hargreaves I P, 2014, Int J Biochem Cell Biol, V49, P105, DOI 10.1016/j.biocel.2014.01.020
   Harijith A, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00352
   KALYANRAMAN UP, 1984, J RHEUMATOL, V11, P808
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   Lanciano P, 2013, BBA-BIOENERGETICS, V1827, P1332, DOI 10.1016/j.bbabio.2013.03.009
   LOWRY OH, 1951, J BIOL CHEM, V193, P265
   Mancuso M, 2013, NEUROMUSCULAR DISORD, V23, P907, DOI 10.1016/j.nmd.2013.07.011
   Marchetti C, 2014, J CARDIOVASC PHARM, V63, P316, DOI 10.1097/FJC.0000000000000053
   Menu P, 2011, CLIN EXP IMMUNOL, V166, P1, DOI 10.1111/j.1365-2249.2011.04440.x
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   Miyamae T, 2013, REDOX REP, V18, P12, DOI 10.1179/1351000212Y.0000000036
   Mkaouar-Rebai E, 2011, J CHILD NEUROL, V26, P12, DOI 10.1177/0883073810371227
   Montini G, 2008, NEW ENGL J MED, V358, P2849, DOI 10.1056/NEJMc0800582
   Ozgocmen S, 2006, RHEUMATOL INT, V26, P585, DOI 10.1007/s00296-005-0078-z
   Pongratz DE, 1998, Z RHEUMATOL, V57, P47
   Quinzii CM, 2010, DEV DISABIL RES REV, V16, P183, DOI 10.1002/ddrr.108
   Roos S, 2014, NEUROMUSCULAR DISORD, V24, P713, DOI 10.1016/j.nmd.2014.05.009
   Ross Rebecca L, 2010, Open Immunol J, V3, P9
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   Scarpelli Mauro, 2010, Recent Pat CNS Drug Discov, V5, P203, DOI 10.2174/157488910793362412
   Shimada K, 2012, IMMUNITY, V36, P401, DOI 10.1016/j.immuni.2012.01.009
   Takahashi M, 2014, INT HEART J, V55, P101, DOI 10.1536/ihj.13-388
   Turrens JF, 2003, J PHYSIOL-LONDON, V552, P335, DOI 10.1113/jphysiol.2003.049478
   van de Glind G, 2007, EUR J PAEDIATR NEURO, V11, P243, DOI 10.1016/j.ejpn.2007.01.004
   Vattemi G, 2013, FREE RADICAL BIO MED, V63, P108, DOI 10.1016/j.freeradbiomed.2013.04.025
   Villanova M, 1999, MUSCLE NERVE, V22, P289, DOI 10.1002/(SICI)1097-4598(199902)22:2<289::AID-MUS26>3.0.CO;2-O
   Watson NF, 2009, ARTHRITIS RHEUM-US, V60, P2839, DOI 10.1002/art.24772
   Wheeler TJ, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-7
   YUNUS MB, 1986, AM J MED, V81, P38, DOI 10.1016/0002-9343(86)90872-7
   Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663
NR 56
TC 24
Z9 27
U1 0
U2 19
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-2593
EI 1468-6244
J9 J MED GENET
JI J. Med. Genet.
PD FEB
PY 2016
VL 53
IS 2
BP 113
EP 122
DI 10.1136/jmedgenet-2015-103392
PG 10
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA DB4SF
UT WOS:000368502700005
PM 26566881
DA 2024-11-01
ER

PT J
AU Betts, J
   Jaros, E
   Perry, RH
   Schaefer, AM
   Taylor, RW
   Abdel-All, Z
   Lightowlers, RN
   Turnbull, DM
AF Betts, J.
   Jaros, E.
   Perry, R. H.
   Schaefer, A. M.
   Taylor, R. W.
   Abdel-All, Z.
   Lightowlers, R. N.
   Turnbull, D. M.
TI Molecular neuropathology of MELAS: level of heteroplasmy in individual
   neurones and evidence of extensive vascular involvement
SO NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY
LA English
DT Article
DE MELAS; mitochondrial myopathy; stroke-like episodes and migraine
ID STROKE-LIKE EPISODES; RAGGED-RED FIBERS; MITOCHONDRIAL ENCEPHALOMYOPATHY
   MELAS; LACTIC-ACIDOSIS; SPREADING DEPRESSION; POINT MUTATION;
   BLOOD-VESSELS; SUCCINATE-DEHYDROGENASE; SKELETAL-MUSCLE; CEREBRAL-CORTEX
AB Mitochondrial DNA (mtDNA) disease is an important genetic cause of neurological disability. A variety of different clinical features are observed and one of the most common phenotypes is MELAS (Mitochondrial Myopathy, Encephalopathy, Lactic Acidosis and Stroke-like episodes). The majority of patients with MELAS have the 3243A > G mtDNA mutation. The neuropathology is dominated by multifocal infarct-like lesions in the posterior cortex, thought to underlie the stroke-like episodes seen in patients. To investigate the relationship between mtDNA mutation load, mitochondrial dysfunction and neuropathological features in MELAS, we studied individual neurones from several brain regions of two individuals with the 3243A > G mutation using dual cytochrome c oxidase (COX) and succinate dehydrogenase (SDH) histochemistry, and Polymerase Chain Reaction Restriction Fragment Lenght Polymorphism (PCR-RFLP) analysis. We found a low number of COX-deficient neurones in all brain regions. There appeared to be no correlation between the threshold level for the 3243A > G mutation to cause COX deficiency within single neurones and the degree of pathology in affected brain regions. The most severe COX deficiency associated with the highest proportion of mutated mtDNA was present in the walls of the leptomeningeal and cortical blood vessels in all brain regions. We conclude that vascular mitochondrial dysfunction is important in the pathogenesis of the stroke-like episodes in MELAS patients. As migraine is a commonly encountered feature in MELAS, we propose that coupling of the vascular mitochondrial dysfunction with cortical spreading depression (CSD) might underlie the selective distribution of ischaemic lesions in the posterior cortex in these patients.
C1 Newcastle Univ, Sch Med, Mitochondrial Res Grp, Dept Neurol,Sch Neurol Neurobiol & Psychiat, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   Newcastle Univ, Sch Med, Dept Neuropathol, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
   Newcastle Univ, Sch Med, Inst Ageing & Hlth, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
C3 Newcastle University - UK; Newcastle University - UK; Newcastle
   University - UK
RP Turnbull, DM (corresponding author), Newcastle Univ, Sch Med, Mitochondrial Res Grp, Dept Neurol,Sch Neurol Neurobiol & Psychiat, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM D.M.Turnbull@ncl.ac.uk
OI Schaefer, Andrew/0000-0001-9891-7332
FU Wellcome Trust [074454] Funding Source: Medline
CR [Anonymous], ISOCORTEX MAN
   Bancroft JD, 1990, THEORY PRACTICE HIST
   Bowyer S, 1999, CEPHALALGIA, V19, P542, DOI 10.1046/j.1468-2982.1999.1906541-5.x
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   Chomyn A, 2000, J BIOL CHEM, V275, P19198, DOI 10.1074/jbc.M908734199
   CIAFALONI E, 1991, NEUROLOGY, V41, P1663, DOI 10.1212/WNL.41.10.1663
   CIAFALONI E, 1992, ANN NEUROL, V31, P391, DOI 10.1002/ana.410310408
   Clark JM, 1996, NEUROLOGY, V46, P223, DOI 10.1212/WNL.46.1.223
   Cottrell DA, 2001, NEUROBIOL AGING, V22, P265, DOI 10.1016/S0197-4580(00)00234-7
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   FRACKOWIAK RSJ, 1988, BRAIN, V111, P1009, DOI 10.1093/brain/111.5.1009
   Gilchrist JM, 1996, STROKE, V27, P1420, DOI 10.1161/01.STR.27.8.1420
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   GOTO Y, 1995, MUSCLE NERVE       S, V3, P107
   Hadjikhani N, 2001, P NATL ACAD SCI USA, V98, P4687, DOI 10.1073/pnas.071582498
   HASEGAWA H, 1991, ANN NEUROL, V29, P601, DOI 10.1002/ana.410290606
   HIRANO M, 1994, J CHILD NEUROL, V9, P4, DOI 10.1177/088307389400900102
   IHARA Y, 1989, J NEUROL SCI, V90, P263, DOI 10.1016/0022-510X(89)90112-3
   Kamada K, 2001, J NEUROL NEUROSUR PS, V70, P675, DOI 10.1136/jnnp.70.5.675
   Kaufmann P, 2004, NEUROLOGY, V62, P1297, DOI 10.1212/01.WNL.0000120557.83907.A8
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   Kirby DM, 2004, J MED GENET, V41, P784, DOI 10.1136/jmg.2004.020537
   Kirby DM, 2003, ANN NEUROL, V54, P473, DOI 10.1002/ana.10687
   KURIYAMA M, 1984, NEUROLOGY, V34, P72, DOI 10.1212/WNL.34.1.72
   LAURITZEN M, 1994, BRAIN, V117, P199, DOI 10.1093/brain/117.1.199
   Leao AAP, 1944, J NEUROPHYSIOL, V7, P359, DOI 10.1152/jn.1944.7.6.359
   Liolitsa D, 2003, ANN NEUROL, V53, P128, DOI 10.1002/ana.10435
   LOVE S, 1993, J PATHOL, V170, P9, DOI 10.1002/path.1711700103
   Lynn S, 2003, DIABETOLOGIA, V46, P296, DOI 10.1007/s00125-002-1018-z
   MACMILLAN C, 1993, NEUROLOGY, V43, P1586, DOI 10.1212/WNL.43.8.1586
   MATTHEWS PM, 1993, NEUROLOGY, V43, P2484, DOI 10.1212/WNL.43.12.2484
   McFarland R, 2002, LANCET NEUROL, V1, P343, DOI 10.1016/S1474-4422(02)00159-X
   McFarland R, 2004, ANN NEUROL, V55, P478, DOI 10.1002/ana.20004
   MIZUKAMI K, 1992, ACTA NEUROPATHOL, V83, P449, DOI 10.1007/BF00713541
   MORAES CT, 1992, AM J HUM GENET, V50, P934
   Mori O, 2000, ACTA NEUROPATHOL, V100, P712, DOI 10.1007/s004010000209
   OHAMA E, 1987, ACTA NEUROPATHOL, V74, P226, DOI 10.1007/BF00688185
   OHAMA E, 1987, ACTA NEUROPATHOL, V75, P1, DOI 10.1007/BF00686785
   OLD SL, 1989, HISTOCHEM J, V21, P545, DOI 10.1007/BF01753355
   OLESEN J, 1981, ANN NEUROL, V9, P344, DOI 10.1002/ana.410090406
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   PERRY RH, 1990, J NEUROL SCI, V95, P119, DOI 10.1016/0022-510X(90)90236-G
   PETRUZZELLA V, 1994, HUM MOL GENET, V3, P449, DOI 10.1093/hmg/3.3.449
   Prayson RA, 1998, ARCH PATHOL LAB MED, V122, P978
   Ravn K, 2001, EUR J HUM GENET, V9, P805, DOI 10.1038/sj.ejhg.5200712
   SAKUTA R, 1989, ANN NEUROL, V25, P594, DOI 10.1002/ana.410250611
   SHAPIRA Y, 1975, NEUROLOGY, V25, P614, DOI 10.1212/WNL.25.7.614
   Silvestri G, 2000, AM J MED GENET, V94, P201, DOI 10.1002/1096-8628(20000918)94:3<201::AID-AJMG5>3.0.CO;2-2
   Sparaco M, 2003, ACTA NEUROPATHOL, V106, P202, DOI 10.1007/s00401-003-0716-z
   SPARACO M, 1993, J NEUROPATH EXP NEUR, V52, P1, DOI 10.1097/00005072-199301000-00001
   Sue CM, 1998, J NEUROL NEUROSUR PS, V65, P233, DOI 10.1136/jnnp.65.2.233
   SUGAYA E, 1975, J NEUROPHYSIOL, V38, P822, DOI 10.1152/jn.1975.38.4.822
   Tanahashi C, 2000, ACTA NEUROPATHOL, V99, P31, DOI 10.1007/PL00007403
   Tanji K, 2001, SEMIN CELL DEV BIOL, V12, P429, DOI 10.1006/scdb.2001.0280
   Taylor RW, 2003, J CLIN INVEST, V112, P1351, DOI 10.1172/JCI200319435
   TOKUNAGA M, 1993, ANN NEUROL, V33, P275, DOI 10.1002/ana.410330308
   Tsuchiya K, 1999, ACTA NEUROPATHOL, V97, P520, DOI 10.1007/s004010051023
   Zhou L, 1997, J NEUROSCI, V17, P7746
NR 58
TC 111
Z9 124
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0305-1846
EI 1365-2990
J9 NEUROPATH APPL NEURO
JI Neuropathol. Appl. Neurobiol.
PD AUG
PY 2006
VL 32
IS 4
BP 359
EP 373
DI 10.1111/j.1365-2990.2006.00731.x
PG 15
WC Clinical Neurology; Neurosciences; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pathology
GA 061RZ
UT WOS:000238891400001
PM 16866982
DA 2024-11-01
ER

PT J
AU Finsterer, J
AF Finsterer, Josef
TI Neuromuscular implications in CADASIL
SO CEREBROVASCULAR DISEASES
LA English
DT Review
DE skeletal muscle; cardiomyopathy; neuromuscular disorder; peripheral
   nervous system; neuropathy; myopathy
ID AUTOSOMAL-DOMINANT ARTERIOPATHY; SUBCORTICAL INFARCTS;
   MITOCHONDRIAL-DNA; SKELETAL-MUSCLE; NOTCH3 GENE; SKIN BIOPSY;
   LEUKOENCEPHALOPATHY; MUTATION; PATIENT
AB Objectives: Recent studies indicate that Notch3 gene mutations not only manifest as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) but also in the peripheral nerves and skeletal muscles. Methods: A MEDLINE search with appropriate terms was carried out. Six articles, dealing with neuromuscular involvement in CADASIL, were selected and reviewed. Results: Several case studies presented CADASIL patients with clinical features of myopathy. Neurological diagnostic workup in these patients revealed weakness, wasting, reduced/ exaggerated tendon reflexes, abnormal nerve conduction and electromyography, muscle biopsy with ragged red muscle fibers, reduced COX staining, decreased complex I respiratory chain activity, abnormally structured mitochondria, or mitochondrial DNA ( mtDNA) mutations, such as G5650A in the tRNAAla gene, or various other mtDNA substitutions. Additionally, fibroblasts in skin biopsy may show reduced complex V respiratory chain activity. Conclusions: These findings suggest Notch3 mutations to be associated with mitochondrial disease, particularly affecting the skeletal muscle. Whether mtDNA mutations were induced by Notch3 mutations, by oxidative stress due to chronic hypoxia, resulting from arteriopathy, or occurred spontaneously remains elusive. Patients carrying Notch3 mutations should be systematically investigated for neuromuscular involvement, which may have therapeutic and prognostic implications for these patients. Copyright (c) 2007 S. Karger AG, Basel.
C1 Krankenanstalt Rudolfstiftung Wien, AT-1180 Vienna, Austria.
C3 Rudolfstiftung Hospital
RP Finsterer, J (corresponding author), Krankenanstalt Rudolfstiftung Wien, Postfach 20, AT-1180 Vienna, Austria.
EM duarte@aonmail.at
CR Annunen-Rasila J, 2007, MITOCHONDRION, V7, P96, DOI 10.1016/j.mito.2006.11.004
   Annunen-Rasila J, 2006, NEUROGENETICS, V7, P185, DOI 10.1007/s10048-006-0049-x
   Cumurciuc R, 2006, STROKE, V37, P1100, DOI 10.1161/01.STR.0000209242.68844.20
   de la Peña P, 2001, NEUROLOGY, V57, P1235, DOI 10.1212/WNL.57.7.1235
   Dichgans M, 2002, CEREBROVASC DIS, V13, P37, DOI 10.1159/000049148
   Dotti MT, 2004, ARCH NEUROL-CHICAGO, V61, P942, DOI 10.1001/archneur.61.6.942
   Finnilä S, 2001, J MOL MED, V79, P641, DOI 10.1007/s001090100268
   Goebel HH, 1997, MUSCLE NERVE, V20, P625, DOI 10.1002/(SICI)1097-4598(199705)20:5<625::AID-MUS17>3.0.CO;2-V
   Guidetti D, 2006, CLIN EXP HYPERTENS, V28, P271, DOI 10.1080/10641960600549223
   Ishiko A, 2006, ACTA NEUROPATHOL, V112, P333, DOI 10.1007/s00401-006-0116-2
   Joutel A, 1997, LANCET, V350, P1511, DOI 10.1016/S0140-6736(97)08083-5
   Kalaria RN, 2004, J NEUROL SCI, V226, P35, DOI 10.1016/j.jns.2004.09.008
   Lewandowska E, 2006, FOLIA NEUROPATHOL, V44, P265
   Luft FC, 2001, J MOL MED-JMM, V79, P613, DOI 10.1007/s00109-001-0285-3
   Malandrini A, 2002, NEUROLOGY, V59, P617, DOI 10.1212/WNL.59.4.617
   Mayer M, 1999, J NEUROL, V246, P526, DOI 10.1007/s004150050398
   Miranda M, 2006, MOVEMENT DISORD, V21, P1008, DOI 10.1002/mds.20879
   Mourad A, 2006, REV NEUROL-FRANCE, V162, P827, DOI 10.1016/S0035-3787(06)75085-8
   Opherk C, 2004, BRAIN, V127, P2533, DOI 10.1093/brain/awh282
   Roine S, 2006, OPHTHALMOLOGY, V113, P1411, DOI 10.1016/j.ophtha.2006.03.030
   RUCHOUX MM, 1995, ACTA NEUROPATHOL, V89, P500
   Schröder JM, 2005, ACTA NEUROPATHOL, V110, P587, DOI 10.1007/s00401-005-1082-9
   Sicurelli F, 2005, J NEUROL, V252, P1206, DOI 10.1007/s00415-005-0837-5
   Singhal S, 2004, BRAIN, V127, P2031, DOI 10.1093/brain/awh223
   Viswanathan A, 2006, STROKE, V37, P2690, DOI 10.1161/01.STR.0000245091.28429.6a
   Walsh JS, 2000, J AM ACAD DERMATOL, V43, P1125, DOI 10.1067/mjd.2000.110895
NR 26
TC 14
Z9 14
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1015-9770
EI 1421-9786
J9 CEREBROVASC DIS
JI Cerebrovasc. Dis.
PY 2007
VL 24
IS 5
BP 401
EP 404
DI 10.1159/000108428
PG 4
WC Clinical Neurology; Peripheral Vascular Disease
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 216VR
UT WOS:000249907600001
PM 17878719
DA 2024-11-01
ER

PT J
AU Alberio, S
   Mineri, R
   Tiranti, V
   Zeviani, M
AF Alberio, Simona
   Mineri, Rossana
   Tiranti, Valeria
   Zeviani, Massimo
TI Depletion of mtDNA: Syndromes and genes
SO MITOCHONDRION
LA English
DT Review
DE mtDNA depletion; OXPHOS; tissue specificity
ID MITOCHONDRIAL-DNA DEPLETION; NUCLEOSIDE-DIPHOSPHATE KINASE; THYMIDINE
   KINASE; POLG MUTATIONS; DEOXYGUANOSINE KINASE; MYOPATHY; LOCALIZATION;
   DISORDERS
AB Maintenance of mitochondrial DNA (mtDNA) requires the concerted activity of several nuclear-encoded factors that participate in its replication, being part of the mitochondrial replisome or ensuring the balanced supply of dNTPs to mitochondria. In the past decade, a growing number of syndromes associated with dysfunction due to tissue-specific depletion of mtDNA (MDS) have been reported. This article reviews the current knowledge of the genes responsible for these disorders, the impact of different mutations in the epidemiology of MDS and their role in the pathogenic mechanisms underlying the different clinical presentations. (c) 2006 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
EM zeviani@fastwebnet.it
RI Zeviani, Massimo/K-2891-2014; Tiranti, Valeria/J-8233-2016; Mineri,
   Rossana/HLH-1440-2023
OI Tiranti, Valeria/0000-0002-3584-7338; Mineri,
   Rossana/0000-0002-6636-8954; Zeviani, Massimo/0000-0002-9067-5508
FU Telethon [GGP030039] Funding Source: Medline
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   BOGENHAGEN D, 1976, J BIOL CHEM, V251, P2938
   Calvo S, 2006, NAT GENET, V38, P576, DOI 10.1038/ng1776
   Carrozzo R, 2003, HUM MUTAT, V21, DOI 10.1002/humu.9135
   Chan SSL, 2005, J BIOL CHEM, V280, P31341, DOI 10.1074/jbc.M506762200
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   Ducluzeau PH, 1999, J HEPATOL, V30, P149, DOI 10.1016/S0168-8278(99)80019-1
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Elpeleg O, 2003, PEDIATR RES, V54, P153, DOI 10.1203/01.PDR.0000072796.25097.A5
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Galbiati S, 2006, PEDIATR NEUROL, V34, P177, DOI 10.1016/j.pediatrneurol.2005.07.013
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Johansson M, 1997, J BIOL CHEM, V272, P8454, DOI 10.1074/jbc.272.13.8454
   KADRMAS EF, 1991, BIOCHIM BIOPHYS ACTA, V1074, P339, DOI 10.1016/0304-4165(91)90083-S
   KAVANAUGHBLACK A, 1994, P NATL ACAD SCI USA, V91, P5883, DOI 10.1073/pnas.91.13.5883
   Kowluru A, 2002, ARCH BIOCHEM BIOPHYS, V398, P160, DOI 10.1006/abbi.2001.2710
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Mancuso M, 2003, ARCH NEUROL-CHICAGO, V60, P1007, DOI 10.1001/archneur.60.7.1007
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   MAZZIOTTA MRM, 1992, J PEDIATR-US, V121, P896, DOI 10.1016/S0022-3476(05)80335-X
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Naviaux RK, 2005, ANN NEUROL, V58, P491, DOI 10.1002/ana.20544
   Nguyen KV, 2005, NEUROLOGY, V65, P1493, DOI 10.1212/01.wnl.0000182814.55361.70
   NGUYEN KV, 2006, J HEPATOL
   PARKS RE, 1973, COMP BIOCHEM PHYSIOL, V45, P355, DOI 10.1016/0305-0491(73)90070-9
   Saada A, 2004, DNA CELL BIOL, V23, P797
   Saada A, 2003, MOL GENET METAB, V79, P1, DOI 10.1016/S1096-7192(03)00063-5
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284
   Slama A, 2005, MOL GENET METAB, V86, P462, DOI 10.1016/j.ymgme.2005.09.006
   Taanman JW, 2002, ANN NEUROL, V52, P237, DOI 10.1002/ana.10247
   Tadiboyina VT, 2005, AM J MED GENET A, V135A, P289, DOI 10.1002/ajmg.a.30748
   TRITSCHLER HJ, 1992, NEUROLOGY, V42, P209, DOI 10.1212/WNL.42.1.209
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Vilà MR, 2003, NEUROLOGY, V60, P1203, DOI 10.1212/01.WNL.0000055928.58122.47
   Vu TH, 1998, NEUROLOGY, V50, P1783, DOI 10.1212/WNL.50.6.1783
   Wang LY, 2005, MOL GENET METAB, V84, P75, DOI 10.1016/j.ymgme.2004.09.005
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   Yang MY, 2002, CELL, V111, P495, DOI 10.1016/S0092-8674(02)01075-9
   ZWACKA RM, 1994, EMBO J, V13, P5129, DOI 10.1002/j.1460-2075.1994.tb06842.x
NR 45
TC 76
Z9 84
U1 1
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 1872-8278
J9 MITOCHONDRION
JI Mitochondrion
PD FEB-APR
PY 2007
VL 7
IS 1-2
BP 6
EP 12
DI 10.1016/j.mito.2006.11.010
PG 7
WC Cell Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Genetics & Heredity
GA 157EM
UT WOS:000245701400002
PM 17280874
DA 2024-11-01
ER

PT J
AU Monnot, S
   Samuels, DC
   Hesters, L
   Frydman, N
   Gigarel, N
   Burlet, P
   Kerbrat, V
   Lamazou, F
   Frydman, R
   Benachi, A
   Feingold, J
   Rotig, A
   Munnich, A
   Bonnefont, JP
   Steffann, J
AF Monnot, Sophie
   Samuels, David C.
   Hesters, Laetitia
   Frydman, Nelly
   Gigarel, Nadine
   Burlet, Philippe
   Kerbrat, Violaine
   Lamazou, Frederic
   Frydman, Rene
   Benachi, Alexandra
   Feingold, Josue
   Rotig, Agnes
   Munnich, Arnold
   Bonnefont, Jean-Paul
   Steffann, Julie
TI Mutation dependance of the mitochondrial DNA copy number in the first
   stages of human embryogenesis
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID RAGGED-RED FIBERS; THRESHOLD EXPRESSION; MOUSE EMBRYOS; POLAR BODIES;
   OOCYTES; MUSCLE; HETEROPLASMY; TRANSCRIPTS; MERRF; MELAS
AB Mitochondrial DNA (mtDNA) content is thought to remain stable over the preimplantation period of human embryogenesis that is, therefore, suggested to be entirely dependent on ooplasm mtDNA capital. We have explored the impact of two disease-causing mutations [m.3243AG myopathy, encephalopathy, lactic acidosis and stroke-like syndrome (MELAS) and m.8344AG myoclonic epilepsy associated with ragged-red fibers (MERRF)] on mtDNA amounts in human oocytes and day 45 preimplantation embryos. The mtDNA amount was stable in MERRF and control materials, whereas gradually increasing from the germinal vesicle of oogenesis to the blastocyst stage of embryogenesis in MELAS cells, MELAS embryos carrying 3-fold higher mtDNA amount than control embryos (P 0.0003). A correlation between mtDNA copy numbers and mutant loads was observed in MELAS embryos (R-2 0.42, P 0.0013), suggestive of a compensation for the respiratory chain defect resulting from high mutation levels. These results suggest that mtDNA can replicate in early embryos and emphasize the need for sufficient amount of wild-type mtDNA to sustain embryonic development in humans.
C1 [Monnot, Sophie; Gigarel, Nadine; Burlet, Philippe; Feingold, Josue; Rotig, Agnes; Munnich, Arnold; Bonnefont, Jean-Paul; Steffann, Julie] Univ Paris 05, Hop Necker Enfants Malad, Inst Imagine, F-75015 Paris 15, France.
   [Monnot, Sophie; Gigarel, Nadine; Burlet, Philippe; Feingold, Josue; Rotig, Agnes; Munnich, Arnold; Bonnefont, Jean-Paul; Steffann, Julie] Univ Paris 05, Hop Necker Enfants Malad, INSERM U781, F-75015 Paris 15, France.
   [Samuels, David C.] Vanderbilt Univ, Med Ctr, Dept Mol Physiol & Biophys, Ctr Human Genet Res, Nashville, TN 37232 USA.
   [Hesters, Laetitia; Frydman, Nelly] Hop Antoine Beclere, Serv Biol & Genet Reprod, F-92141 Clamart, France.
   [Kerbrat, Violaine; Lamazou, Frederic; Frydman, Rene; Benachi, Alexandra] Hop Antoine Beclere, Serv Gynecol Obstet & Med Reprod, Unite INSERM U782, F-92141 Clamart, France.
C3 Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite;
   Hopital Universitaire Necker-Enfants Malades - APHP; Assistance Publique
   Hopitaux Paris (APHP); Universite Paris Cite; Hopital Universitaire
   Necker-Enfants Malades - APHP; Institut National de la Sante et de la
   Recherche Medicale (Inserm); Vanderbilt University; Assistance Publique
   Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP;
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Antoine-Beclere - APHP
RP Monnot, S (corresponding author), Hop Necker Enfants Malad, Genet Lab, Tour Lavoisier 3Eme Etage,149 Rue Sevres, F-75015 Paris, France.
EM sophie.monnot@inserm.fr
RI monnot, sophie/H-6152-2017; ROTIG, AGNES/G-9592-2017; Samuels,
   David/A-5393-2008; Steffann, julie/I-2820-2017
OI monnot, sophie/0000-0002-1872-8089; ROTIG, AGNES/0000-0003-0589-0703;
   Samuels, David/0000-0003-3529-7791; BONNEFONT,
   Jean-Paul/0000-0002-4235-1197; Steffann, julie/0000-0001-9493-3239;
   Achour Frydman, Nelly/0000-0002-9027-0586
FU Association Francaise contre les Myopathies
FX This work was supported by the Association Francaise contre les
   Myopathies
CR Barritt J A, 2002, Reprod Biomed Online, V4, P243
   BOULET L, 1992, AM J HUM GENET, V51, P1187
   Chan CCW, 2005, MOL HUM REPROD, V11, P843, DOI 10.1093/molehr/gah243
   Chiaratti MR, 2010, BIOL REPROD, V82, P76, DOI 10.1095/biolreprod.109.077776
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   Cree LM, 2008, NAT GENET, V40, P249, DOI 10.1038/ng.2007.63
   CUI XF, 1989, P NATL ACAD SCI USA, V86, P9389, DOI 10.1073/pnas.86.23.9389
   Dumollard R, 2007, CURR TOP DEV BIOL, V77, P21, DOI 10.1016/S0070-2153(06)77002-8
   EBERT KM, 1988, J REPROD FERTIL, V82, P145, DOI 10.1530/jrf.0.0820145
   ELMEZIANE A, 1989, EMBO J, V8, P1649, DOI 10.1002/j.1460-2075.1989.tb03555.x
   Gigarel N, 2011, AM J HUM GENET, V88, P494, DOI 10.1016/j.ajhg.2011.03.010
   Lin DPC, 2004, FERTIL STERIL, V81, P73, DOI 10.1016/j.fertnstert.2003.05.005
   May-Panloup P, 2005, REPROD BIOL ENDOCRIN, V3, DOI 10.1186/1477-7827-3-65
   May-Panloup P, 2005, HUM REPROD, V20, P593, DOI 10.1093/humrep/deh667
   McConnell JML, 2004, REPROD BIOMED ONLINE, V9, P418, DOI 10.1016/S1472-6483(10)61277-1
   Monnot S, 2011, HUM MUTAT, V32, P116, DOI 10.1002/humu.21417
   Moslemi AR, 1998, NEUROMUSCULAR DISORD, V8, P345, DOI 10.1016/S0960-8966(98)00029-7
   Parfait B, 1998, BIOCHEM BIOPH RES CO, V247, P57, DOI 10.1006/bbrc.1998.8666
   PETRUZZELLA V, 1994, HUM MOL GENET, V3, P449, DOI 10.1093/hmg/3.3.449
   PIKO L, 1987, DEV BIOL, V123, P364, DOI 10.1016/0012-1606(87)90395-2
   Reynier P, 2001, MOL HUM REPROD, V7, P425, DOI 10.1093/molehr/7.5.425
   Silvestri G, 2000, AM J MED GENET, V94, P201, DOI 10.1002/1096-8628(20000918)94:3<201::AID-AJMG5>3.0.CO;2-2
   Spikings EC, 2007, BIOL REPROD, V76, P327, DOI 10.1095/biolreprod.106.054536
   Steuerwald N, 2000, ZYGOTE, V8, P209, DOI 10.1017/S0967199400001003
   Thundathil J, 2005, MOL REPROD DEV, V71, P405, DOI 10.1002/mrd.20260
   TOKUNAGA M, 1994, ANN NEUROL, V35, P413, DOI 10.1002/ana.410350407
   Wai T, 2010, BIOL REPROD, V83, P52, DOI 10.1095/biolreprod.109.080887
   Wonnapinij P, 2008, AM J HUM GENET, V83, P582, DOI 10.1016/j.ajhg.2008.10.007
NR 28
TC 61
Z9 62
U1 0
U2 27
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD MAY 1
PY 2013
VL 22
IS 9
BP 1867
EP 1872
DI 10.1093/hmg/ddt040
PG 6
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 123ZD
UT WOS:000317431100015
PM 23390135
DA 2024-11-01
ER

PT J
AU Finsterer, J
AF Finsterer, J.
TI Genetic, pathogenetic, and phenotypic implications of the mitochondrial
   A3243G tRNALeu(UUR) mutation
SO ACTA NEUROLOGICA SCANDINAVICA
LA English
DT Review
DE mitochondrial; metabolic myopathy; genotype; phenotype; ribonucleic
   acid; mutation; genetics
ID STROKE-LIKE EPISODES; WOBBLE MODIFICATION DEFICIENCY; PEPTIDE
   NUCLEIC-ACID; MUTANT TRANSFER-RNAS; LACTIC-ACIDOSIS; POINT MUTATION; DNA
   MUTATION; LEIGH-SYNDROME; DIABETES-MELLITUS; MELAS MUTATION
AB Mitochondrial disorders are frequently caused by mutations in mitochondrial genes and usually present as multisystem disease. One of the most frequent mitochondrial mutations is the A3243G transition in the tRNALeu(UUR) gene. The phenotypic expression of the mutation is variable and comprises syndromic or non-syndromic mitochondrial disorders. Among the syndromic manifestations the mitochondrial encephalopathy, lactacidosis, and stroke-like episode (MELAS) syndrome is the most frequent. In single cases the A3243G mutation may be associated with maternally inherited diabetes and deafness syndrome, myoclonic epilepsy and ragged-red fibers (MERRF) syndrome, MELAS/MERRF overlap syndrome, maternally inherited Leigh syndrome, chronic external ophthalmoplegia, or Kearns-Sayre syndrome. The wide phenotypic variability of the mutation is explained by the peculiarities of the mitochondrial DNA, such as heteroplasmy and mitotic segregation, resulting in different mutation loads in different tissues and family members. Moreover, there is some evidence that additional mtDNA sequence variations (polymorphisms, haplotypes) influence the phenotype of the A3243G mutation. This review aims to give an overview on the actual knowledge about the genetic, pathogenetic, and phenotypic implications of the A3243G mtDNA mutation.
C1 Krankenanstalt Rudolfstiftung Wien, Vienna, Austria.
C3 Rudolfstiftung Hospital
RP Finsterer, J (corresponding author), Postfach 20, A-1180 Vienna, Austria.
EM duarte@aonmail.at
CR Abe K, 2004, NEUROLOGY, V63, P2458, DOI 10.1212/WNL.63.12.2458
   Abu-Amero Khaled K, 2005, Ophthalmic Genet, V26, P31, DOI 10.1080/13816810590918235
   AGAFITOS E, 1997, GEN DIAGN PATHOL, V142, P335
   Akbari M, 2004, SCAND J CLIN LAB INV, V64, P86, DOI 10.1080/00365510410004209
   Akman CI, 2004, J CHILD NEUROL, V19, P258, DOI 10.1177/088307380401900403
   ANAN R, 1995, CIRCULATION, V91, P955, DOI 10.1161/01.CIR.91.4.955
   Aoki Y, 2002, ANN INTERN MED, V137, P703, DOI 10.7326/0003-4819-137-8-200210150-00031
   Apostolova LG, 2005, ARCH NEUROL-CHICAGO, V62, P1154, DOI 10.1001/archneur.62.7.1154
   Arii J, 2000, AM J NEURORADIOL, V21, P1502
   Bai RK, 2004, CLIN CHEM, V50, P996, DOI 10.1373/clinchem.2004.031153
   Bellmann C, 2004, INVEST OPHTH VIS SCI, V45, P2355, DOI 10.1167/iovs.03-1090
   Blanco-Barca O, 2004, REV NEUROLOGIA, V39, P618
   Börner GV, 2000, HUM MOL GENET, V9, P467, DOI 10.1093/hmg/9.4.467
   Bosbach S, 2003, BRAIN, V126, P1231, DOI 10.1093/brain/awg101
   Brière JJ, 2004, BIOCHEM BIOPH RES CO, V316, P1138, DOI 10.1016/j.bbrc.2004.03.002
   Brown DT, 2001, AM J HUM GENET, V68, P533, DOI 10.1086/318190
   Bruno C, 2002, J CHILD NEUROL, V17, P233, DOI 10.1177/088307380201700318
   Campos Y, 1996, MUSCLE NERVE, V19, P187, DOI 10.1002/(SICI)1097-4598(199602)19:2<187::AID-MUS10>3.0.CO;2-S
   Carmi E, 2001, ANN DERMATOL VENER, V128, P1031
   Casademont J, 2004, MED SCI MONITOR, V10, pCS49
   Chae JH, 2004, BRAIN DEV-JPN, V26, P459, DOI 10.1016/j.braindev.2004.01.002
   Chalmers RM, 1997, NEUROLOGY, V49, P589, DOI 10.1212/WNL.49.2.589
   Chen Yung-Nien, 2004, Chang Gung Med J, V27, P66
   Chinnery PE, 1998, BRAIN, V121, P1889, DOI 10.1093/brain/121.10.1889
   Chinnery PF, 2001, NEUROLOGY, V56, P1101, DOI 10.1212/WNL.56.8.1101
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   Chol M, 2003, J MED GENET, V40, P188, DOI 10.1136/jmg.40.3.188
   Chomyn A, 2000, J BIOL CHEM, V275, P19198, DOI 10.1074/jbc.M908734199
   CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221
   Cooper JM, 2003, BIOFACTORS, V18, P163, DOI 10.1002/biof.5520180219
   Crimi M, 2005, FASEB J, V19, P866, DOI 10.1096/fj.04-3045fje
   de Andrade PBM, 2006, DIABETOLOGIA, V49, P1816, DOI 10.1007/s00125-006-0301-9
   De Coo IFM, 1999, ANN NEUROL, V45, P130, DOI 10.1002/1531-8249(199901)45:1<130::AID-ART21>3.0.CO;2-Z
   Deschauer M, 2004, J NEUROL NEUROSUR PS, V75, P1204, DOI 10.1136/jnnp.2003.026278
   Deschauer M, 2001, ARCH NEUROL-CHICAGO, V58, P1885, DOI 10.1001/archneur.58.11.1885
   Desguerre I, 2003, NEUROPEDIATRICS, V34, P265
   Doleris LM, 2000, KIDNEY INT, V58, P1851, DOI 10.1046/j.1523-1755.2000.00356.x
   Durand-Dubief F, 2004, REV NEUROL-FRANCE, V160, P824, DOI 10.1016/S0035-3787(04)71038-3
   El Meziane A, 1998, HUM MOL GENET, V7, P2141, DOI 10.1093/hmg/7.13.2141
   Fabrizi GM, 1996, J NEUROL NEUROSUR PS, V61, P47, DOI 10.1136/jnnp.61.1.47
   Farina L, 2002, AM J NEURORADIOL, V23, P1095
   Finsterer J, 2006, ACTA NEUROL SCAND, V114, P217, DOI 10.1111/j.1600-0404.2006.00671.x
   Finsterer J, 2005, CLIN NEUROL NEUROSUR, V107, P181, DOI 10.1016/j.clineuro.2004.07.001
   Finsterer J, 2004, CARDIOLOGY, V102, P228, DOI 10.1159/000081015
   Finsterer J, 2003, EUR NEUROL, V49, P186, DOI 10.1159/000069078
   Flierl A, 1997, J BIOL CHEM, V272, P27189, DOI 10.1074/jbc.272.43.27189
   Florentz C, 2002, BIOSCIENCE REP, V22, P81, DOI 10.1023/A:1016065107165
   Fujii A, 2004, INTERNAL MED, V43, P1126, DOI 10.2169/internalmedicine.43.1126
   GERBITZ KD, 1995, BBA-MOL BASIS DIS, V1271, P253, DOI 10.1016/0925-4439(95)00036-4
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Hancock DK, 2002, CLIN CHEM, V48, P2155
   Hao R, 2004, FEBS LETT, V578, P135, DOI 10.1016/j.febslet.2004.11.004
   Helm M, 1999, NUCLEIC ACIDS RES, V27, P756, DOI 10.1093/nar/27.3.756
   Huang CC, 2002, J BIOMED SCI, V9, P527, DOI 10.1007/BF02254979
   Huntsman RJ, 2005, PEDIATR NEUROL, V32, P334, DOI 10.1016/j.pediatrneurol.2004.12.009
   Iizuka T, 2003, NEUROLOGY, V61, P577, DOI 10.1212/01.WNL.0000078931.87815.B3
   Iizuka T, 2002, NEUROLOGY, V59, P816, DOI 10.1212/WNL.59.6.816
   Jacobs HT, 2000, HUM MOL GENET, V9, P463, DOI 10.1093/hmg/9.4.463
   Janssen GMC, 1999, J BIOL CHEM, V274, P29744, DOI 10.1074/jbc.274.42.29744
   Jeppesen TD, 2003, J NEUROL SCI, V214, P17, DOI 10.1016/S0022-510X(03)00168-0
   Jiang YW, 2002, J CHILD NEUROL, V17, P450, DOI 10.1177/088307380201700611
   Jones M, 2004, AM J OPHTHALMOL, V138, P1051, DOI 10.1016/j.ajo.2004.06.026
   Kanaumi T, 2006, PEDIATR NEUROL, V34, P235, DOI 10.1016/j.pediatrneurol.2005.08.024
   Kang JH, 2005, J NEUROL, V252, P103, DOI 10.1007/s00415-005-0600-y
   Kariya S, 2005, NEUROPEPTIDES, V39, P97, DOI 10.1016/j.npep.2004.11.004
   Kaufmann P, 2004, NEUROLOGY, V62, P1297, DOI 10.1212/01.WNL.0000120557.83907.A8
   Kaufmann P, 2006, ARCH NEUROL-CHICAGO, V63, P746, DOI 10.1001/archneur.63.5.746
   Keng WT, 2003, DEV MED CHILD NEUROL, V45, P704
   Kharasch ED, 2006, ANESTHESIOLOGY, V105, P737, DOI 10.1097/00000542-200610000-00020
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   Kirby DM, 2003, ANN NEUROL, V54, P473, DOI 10.1002/ana.10687
   Kirino Y, 2006, HUM MOL GENET, V15, P897, DOI 10.1093/hmg/ddl007
   Kirino Y, 2004, P NATL ACAD SCI USA, V101, P15070, DOI 10.1073/pnas.0405173101
   Kishnani PS, 1996, EUR J PEDIATR, V155, P898
   Klemm T, 2001, EXP CLIN ENDOCR DIAB, V109, P283, DOI 10.1055/s-2001-16348
   Koga A, 2003, NEUROMUSCULAR DISORD, V13, P259, DOI 10.1016/S0960-8966(02)00267-5
   Koga Y, 2006, NEUROLOGY, V66, P1766, DOI 10.1212/01.wnl.0000220197.36849.1e
   Koga Y, 2005, NEUROLOGY, V64, P710, DOI 10.1212/01.WNL.0000151976.60624.01
   Koga Y, 2000, ARCH DIS CHILD, V82, P407, DOI 10.1136/adc.82.5.407
   Köller H, 2003, J NEUROL, V250, P1501, DOI 10.1007/s00415-003-0260-8
   Leonard JV, 2000, LANCET, V355, P389, DOI 10.1016/S0140-6736(99)05226-5
   Lerman-Sagie T, 2005, MOL GENET METAB, V84, P127, DOI 10.1016/j.ymgme.2004.09.008
   Levinger L, 2004, J MOL BIOL, V337, P535, DOI 10.1016/j.jmb.2004.02.008
   Lien LM, 2001, ACTA NEUROL SCAND, V103, P159, DOI 10.1034/j.1600-0404.2001.103003159.x
   Liou CW, 2001, DIABETES RES CLIN PR, V54, pS39, DOI 10.1016/S0168-8227(01)00334-5
   Liu CS, 2006, ACTA NEUROL SCAND, V113, P334, DOI 10.1111/j.1600-0404.2006.00586.x
   Lodi R, 2004, BBA-BIOENERGETICS, V1657, P146, DOI 10.1016/j.bbabio.2004.05.003
   Lorenc A, 2003, MITOCHONDRION, V3, P119, DOI 10.1016/S1567-7249(03)00106-5
   Löwik MM, 2005, NEPHROL DIAL TRANSPL, V20, P336, DOI 10.1093/ndt/gfh546
   Lynn S, 2003, DIABETOLOGIA, V46, P296, DOI 10.1007/s00125-002-1018-z
   Maassen JA, 2005, ANN MED, V37, P213, DOI 10.1080/07853890510007188
   Maassen JA, 2001, EXP CLIN ENDOCR DIAB, V109, P127, DOI 10.1055/s-2001-14834
   Majamaa-Voltti KAM, 2006, NEUROLOGY, V66, P1470, DOI 10.1212/01.wnl.0000216136.61640.79
   Mancuso M, 2004, NEUROLOGY, V62, P2119, DOI 10.1212/01.WNL.0000127608.48406.F1
   Mancuso M, 2004, ACTA NEUROL SCAND, V110, P72, DOI 10.1111/j.1600-0404.2004.00254.x
   MarinGarcia J, 1996, PEDIATR CARDIOL, V17, P387, DOI 10.1007/s002469900084
   Masucci JP, 1996, MOL BIOL REP, V22, P187, DOI 10.1007/BF00988727
   McFarland R, 2002, LANCET NEUROL, V1, P343, DOI 10.1016/S1474-4422(02)00159-X
   Meierhofer D, 2006, BRIT J CANCER, V94, P268, DOI 10.1038/sj.bjc.6602929
   Mikol J, 2005, ANN PATHOL, V25, P292, DOI 10.1016/S0242-6498(05)80133-6
   Mori M, 2004, BRAIN DEV-JPN, V26, P453, DOI 10.1016/j.braindev.2003.12.009
   Moslemi AR, 2003, NEUROLOGY, V61, P991, DOI 10.1212/01.WNL.0000082391.98672.0A
   Nagata H, 2001, J HUM GENET, V46, P595, DOI 10.1007/s100380170027
   Nakano K, 2005, MITOCHONDRION, V5, P426, DOI 10.1016/j.mito.2005.10.002
   Nan DN, 2002, POSTGRAD MED J, V78, P298, DOI 10.1136/pmj.78.919.298
   Narbonne H, 2004, DIABETES METAB, V30, P61, DOI 10.1016/S1262-3636(07)70090-3
   Narbonne H, 2001, EUR J ENDOCRINOL, V145, P541, DOI 10.1530/eje.0.1450541
   Nomiyama T, 2004, ANN NY ACAD SCI, V1011, P193, DOI 10.1196/annals.1293.020
   Ohkubo K, 2001, CLIN CHEM, V47, P1641
   Oishi Kenichi, 2003, Rinsho Shinkeigaku, V43, P154
   Okhuijsen-Kroes EJ, 2001, NEUROPEDIATRICS, V32, P183, DOI 10.1055/s-2001-17372
   Otsuki T, 2005, ARCH NEUROL-CHICAGO, V62, P485, DOI 10.1001/archneur.62.3.485
   Pang CY, 1999, J FORMOS MED ASSOC, V98, P326
   Park H, 2003, BIOCHEMISTRY-US, V42, P958, DOI 10.1021/bi026882r
   Patel MN, 2002, FREE RADICAL RES, V36, P1139, DOI 10.1080/1071576021000016391
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   Pons R, 2004, J PEDIATR-US, V144, P81, DOI 10.1016/j.jpeds.2003.10.023
   Pronicki Maciej, 2002, Med Sci Monit, V8, pCR767
   Pulkes T, 2000, LANCET, V356, P2068, DOI 10.1016/S0140-6736(00)03408-5
   Rahman S, 2001, AM J HUM GENET, V68, P238, DOI 10.1086/316930
   Rossi A, 2003, AM J NEURORADIOL, V24, P1188
   Rossmanith W, 1998, FEBS LETT, V433, P269, DOI 10.1016/S0014-5793(98)00928-4
   Roy MD, 2005, RNA, V11, P254, DOI 10.1261/rna.7143305
   Rustin P, 2003, EXPERT OPIN INV DRUG, V12, P569, DOI 10.1517/eoid.12.4.569.23756
   Sakuta R, 2002, PEDIATR NEUROL, V27, P397, DOI 10.1016/S0887-8994(02)00456-3
   Saneto RP, 2006, J CHILD NEUROL, V21, P77, DOI 10.1177/08830738060210010601
   Sangkhathat S, 2005, PEDIATR SURG INT, V21, P745, DOI 10.1007/s00383-005-1471-0
   Santorelli FM, 1998, MUSCLE NERVE, V21, P681
   Schapira AHV, 1999, EUR J CLIN INVEST, V29, P886
   Schöls L, 2004, J NEURAL TRANSM-SUPP, P135
   SCHON EA, 1992, BIOCHIM BIOPHYS ACTA, V1101, P206, DOI 10.1016/0005-2728(92)90226-R
   Schulte-Mattler WJ, 2003, ARCH NEUROL-CHICAGO, V60, P50, DOI 10.1001/archneur.60.1.50
   Sciacco M, 2003, J NEUROL, V250, P1498, DOI 10.1007/s00415-003-0246-6
   Seneca S, 2001, ARCH NEUROL-CHICAGO, V58, P1113, DOI 10.1001/archneur.58.7.1113
   Servidei Serenella, 2004, Neuromuscul Disord, V14, P107
   Shanske S, 2004, AM J MED GENET A, V130A, P134, DOI 10.1002/ajmg.a.30220
   SHIMOMURA T, 1994, LANCET, V344, P625, DOI 10.1016/S0140-6736(94)92015-X
   Sohm B, 2003, J MOL BIOL, V328, P995, DOI 10.1016/S0022-2836(03)00373-5
   Sparaco M, 2003, ACTA NEUROPATHOL, V106, P202, DOI 10.1007/s00401-003-0716-z
   Strachan J, 2001, J INHERIT METAB DIS, V24, P409, DOI 10.1023/A:1010573122748
   Sue CM, 1998, J NEUROL SCI, V161, P36, DOI 10.1016/S0022-510X(98)00179-8
   Suzuki Y, 2004, DIABETES RES CLIN PR, V63, P225, DOI 10.1016/j.diabres.2003.10.024
   Tafrechi RSJ, 2005, MUTAT RES-FUND MOL M, V578, P43, DOI 10.1016/j.mrfmmm.2005.02.002
   Tanaka K, 2000, INTERNAL MED, V39, P249, DOI 10.2169/internalmedicine.39.249
   Tay SHK, 2006, ARCH NEUROL-CHICAGO, V63, P281, DOI 10.1001/archneur.63.2.281
   Tay SKH, 2005, J CHILD NEUROL, V20, P142, DOI 10.1177/08830738050200022301
   Thauvin-Robinet C, 2006, EUR J MED GENET, V49, P71, DOI 10.1016/j.ejmg.2005.04.001
   Thorns C, 1998, EXP CLIN ENDOCR DIAB, V106, P384, DOI 10.1055/s-0029-1212003
   Torroni A, 2003, AM J HUM GENET, V72, P1005, DOI 10.1086/373936
   TRA J, 1995, ACTA NEUROL SCAND, V92, P394
   Tsao CY, 2003, J CHILD NEUROL, V18, P62, DOI 10.1177/08830738030180011401
   Tsuji M, 2003, BRAIN DEV-JPN, V25, P245, DOI 10.1016/S0387-7604(02)00220-6
   Tzen CY, 2003, MUSCLE NERVE, V28, P575, DOI 10.1002/mus.10473
   Ueki I, 2006, MITOCHONDRION, V6, P29, DOI 10.1016/j.mito.2005.10.003
   Urata M, 2004, CLIN CHEM, V50, P2045, DOI 10.1373/clinchem.2004.033761
   Van Goethem G, 2003, NEUROLOGY, V61, P1811, DOI 10.1212/01.WNL.0000098997.23471.65
   VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368
   Vielhaber S, 2002, J NEUROPATH EXP NEUR, V61, P885, DOI 10.1093/jnen/61.10.885
   WALLACE DC, 1994, P NATL ACAD SCI USA, V91, P8739, DOI 10.1073/pnas.91.19.8739
   Wang Zhen-Cheng, 2003, Yichuan, V25, P383
   White HE, 2005, GENET TEST, V9, P190, DOI 10.1089/gte.2005.9.190
   Wilichowski E, 1998, J NEUROL SCI, V157, P206, DOI 10.1016/S0022-510X(98)00068-9
   Wilson CJ, 2000, J CHILD NEUROL, V15, P830, DOI 10.1177/088307380001501218
   Wittenhagen LM, 2003, NUCLEIC ACIDS RES, V31, P596, DOI 10.1093/nar/gkg131
   Wittenhagen LM, 2002, NAT STRUCT BIOL, V9, P586, DOI 10.1038/nsb820
   Wong LJC, 2004, MUSCLE NERVE, V30, P118, DOI 10.1002/mus.20045
   Yang YL, 2006, CHINESE MED J-PEKING, V119, P373, DOI 10.1097/00029330-200603010-00004
   Yasukawa T, 2005, FEBS LETT, V579, P2948, DOI 10.1016/j.febslet.2005.04.038
   Yasukawa T, 2000, J BIOL CHEM, V275, P4251, DOI 10.1074/jbc.275.6.4251
   Younes-Mhenni S, 2002, REV MED INTERNE, V23, P1027, DOI 10.1016/S0248-8663(02)00730-0
   Zeviani M, 2003, CURR OPIN NEUROL, V16, P585, DOI 10.1097/00019052-200310000-00004
   Zhang Ying, 2005, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V27, P77
NR 172
TC 88
Z9 113
U1 0
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0001-6314
EI 1600-0404
J9 ACTA NEUROL SCAND
JI Acta Neurol. Scand.
PD JUL
PY 2007
VL 116
IS 1
BP 1
EP 14
DI 10.1111/j.1600-0404.2007.00836.x
PG 14
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 181ZS
UT WOS:000247475500001
PM 17587249
OA gold
DA 2024-11-01
ER

PT J
AU Weiss, MD
   Saneto, RP
AF Weiss, Michael D.
   Saneto, Russell P.
TI SENSORY ATAXIC NEUROPATHY WITH DYSARTHRIA AND OPHTHALMOPARESIS (SANDO)
   IN LATE LIFE DUE TO COMPOUND HETEROZYGOUS <i>POLG</i> MUTATIONS
SO MUSCLE & NERVE
LA English
DT Article
DE dysarthria; polymerase gamma; mitochondrial myopathy; progressive
   external ophthalmoplegia; sensory ataxic neuropathy
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; POLYMERASE-GAMMA;
   MITOCHONDRIAL-DNA; DELETIONS; GENE; DISORDERS; SPECTRUM; TWINKLE;
   DISEASE; ANT1
AB Missense mutations in the gene for polymerase gamma 1 (POLG1) cause a number of phenotypically heterogeneous mitochondrial diseases, most commonly progressive external ophthalmoplegia, and are characterized by the accumulation of multiple, large-scale deletions of mitochondrial DNA. The triad of sensory ataxic neuropathy, dysarthria, and ophthalmoparesis (SANDO) has been demonstrated in a small subset of patients with POLG1 mutations. We report a sporadic case of an 80-year-old compound heterozygote man who presented with SANDO and was found to have three known pathogenic mutations in the POLG1 gene (p.T251I/p.P587L/p.G848S). To our knowledge, none of these mutations have been demonstrated previously in SANDO. This patient's late presentation illustrates that a mitochondrial disorder should be considered regardless of age if the clinical symptoms warrant. Muscle Nerve 41: 882-885,2010
C1 [Weiss, Michael D.] Univ Washington, Med Ctr, Dept Neurol, Seattle, WA 98195 USA.
   [Saneto, Russell P.] Seattle Childrens Hosp, Div Pediat Neurol, Seattle, WA USA.
C3 University of Washington; University of Washington Seattle; Seattle
   Children's Hospital
RP Weiss, MD (corresponding author), Univ Washington, Med Ctr, Dept Neurol, Box 356115,1959 NE Pacific St, Seattle, WA 98195 USA.
EM mdweiss@u.washington.edu
RI Weiss, Michael/P-6333-2019
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   Fadic R, 1997, NEUROLOGY, V49, P239, DOI 10.1212/WNL.49.1.239
   Farrugia ME, 2005, CLIN NEUROPHYSIOL, V116, P2550, DOI 10.1016/j.clinph.2005.07.018
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   Gago MF, 2006, NEUROMUSCULAR DISORD, V16, P507, DOI 10.1016/j.nmd.2006.05.016
   González-Vioque E, 2006, ARCH NEUROL-CHICAGO, V63, P107, DOI 10.1001/archneur.63.1.107
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Hudson G, 2007, ARCH NEUROL-CHICAGO, V64, P553, DOI 10.1001/archneur.64.4.553
   Kollberg G, 2005, EUR J HUM GENET, V13, P463, DOI 10.1038/sj.ejhg.5201341
   Longley MJ, 2005, GENE, V354, P125, DOI 10.1016/j.gene.2005.03.029
   Milone M, 2008, NEUROMUSCULAR DISORD, V18, P626, DOI 10.1016/j.nmd.2008.05.009
   Naïmi M, 2006, EUR J HUM GENET, V14, P917, DOI 10.1038/sj.ejhg.5201627
   RIFAI Z, 1995, ANN NEUROL, V37, P24, DOI 10.1002/ana.410370107
   Rivner MH, 2001, MUSCLE NERVE, V24, P1134, DOI 10.1002/mus.1124
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   Wong LJC, 2008, HUM MUTAT, V29, pE150, DOI 10.1002/humu.20824
NR 21
TC 20
Z9 23
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0148-639X
J9 MUSCLE NERVE
JI Muscle Nerve
PD JUN
PY 2010
VL 41
IS 6
BP 882
EP 885
DI 10.1002/mus.21636
PG 4
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 604NI
UT WOS:000278285300022
PM 20513108
DA 2024-11-01
ER

PT J
AU Reiner, JE
   Kishore, RB
   Levin, BC
   Albanetti, T
   Boire, N
   Knipe, A
   Helmerson, K
   Deckman, KH
AF Reiner, Joseph E.
   Kishore, Rani B.
   Levin, Barbara C.
   Albanetti, Thomas
   Boire, Nicholas
   Knipe, Ashley
   Helmerson, Kristian
   Deckman, Koren Holland
TI Detection of Heteroplasmic Mitochondrial DNA in Single Mitochondria
SO PLOS ONE
LA English
DT Article
ID STANDARD REFERENCE MATERIAL; MTDNA GENOME; CHROMOSOME; DISEASE;
   MANIPULATION; ORGANIZATION; ORGANELLES; MUTATIONS; SEQUENCE
AB Background: Mitochondrial DNA (mtDNA) genome mutations can lead to energy and respiratory-related disorders like myoclonic epilepsy with ragged red fiber disease (MERRF), mitochondrial myopathy, encephalopathy, lactic acidosis and stroke (MELAS) syndrome, and Leber's hereditary optic neuropathy (LHON). It is not well understood what effect the distribution of mutated mtDNA throughout the mitochondrial matrix has on the development of mitochondrial-based disorders. Insight into this complex sub-cellular heterogeneity may further our understanding of the development of mitochondria-related diseases.
   Methodology: This work describes a method for isolating individual mitochondria from single cells and performing molecular analysis on that single mitochondrion's DNA. An optical tweezer extracts a single mitochondrion from a lysed human HL-60 cell. Then a micron-sized femtopipette tip captures the mitochondrion for subsequent analysis. Multiple rounds of conventional DNA amplification and standard sequencing methods enable the detection of a heteroplasmic mixture in the mtDNA from a single mitochondrion.
   Significance: Molecular analysis of mtDNA from the individually extracted mitochondrion demonstrates that a heteroplasmy is present in single mitochondria at various ratios consistent with the 50/50 heteroplasmy ratio found in single cells that contain multiple mitochondria.
C1 [Reiner, Joseph E.; Kishore, Rani B.; Helmerson, Kristian] NIST, Phys Measurement Lab, Gaithersburg, MD 20899 USA.
   [Levin, Barbara C.] NIST, Mat Measurement Lab, Gaithersburg, MD 20899 USA.
   [Albanetti, Thomas; Boire, Nicholas; Knipe, Ashley; Deckman, Koren Holland] Gettysburg Coll, Dept Chem, Gettysburg, PA 17325 USA.
C3 National Institute of Standards & Technology (NIST) - USA; National
   Institute of Standards & Technology (NIST) - USA; Gettysburg College
RP Reiner, JE (corresponding author), NIST, Phys Measurement Lab, Gaithersburg, MD 20899 USA.
EM joseph.reiner@nist.gov
RI Helmerson, Kristian/E-3683-2013; Reiner, Joseph/B-7893-2013
OI Helmerson, Kristian/0000-0002-6387-0949; Reiner,
   Joseph/0000-0002-1056-8703
CR Agarwal A, 2007, ANAL CHEM, V79, P3589, DOI 10.1021/ac062049e
   Agarwal R, 2005, OPT EXPRESS, V13, P8906, DOI 10.1364/OPEX.13.008906
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   ASHKIN A, 1990, NATURE, V348, P346, DOI 10.1038/348346a0
   BERNS MW, 1989, P NATL ACAD SCI USA, V86, P4539, DOI 10.1073/pnas.86.12.4539
   Butler JM, 1998, TRENDS BIOTECHNOL, V16, P158, DOI 10.1016/S0167-7799(98)01173-1
   Cavelier L, 2000, EXP CELL RES, V259, P79, DOI 10.1006/excr.2000.4949
   Chan DC, 2006, CELL, V125, P1241, DOI 10.1016/j.cell.2006.06.010
   Chen Y, 2007, ELECTROPHORESIS, V28, P2406, DOI 10.1002/elps.200600628
   Coble MD, 2004, INT J LEGAL MED, V118, P137, DOI 10.1007/s00414-004-0427-6
   Cree LM, 2008, NAT GENET, V40, P249, DOI 10.1038/ng.2007.63
   Dahl HHM, 2001, AM J MED GENET, V106, P1, DOI 10.1002/ajmg.1427
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Dufresne ER, 2001, REV SCI INSTRUM, V72, P1810, DOI 10.1063/1.1344176
   Fuller KM, 2003, CURR OPIN BIOTECH, V14, P35, DOI 10.1016/S0958-1669(02)00008-3
   Gertz EM., 2005, BLAST scoring parameters
   Greaves LC, 2006, IUBMB LIFE, V58, P143, DOI 10.1080/15216540600686888
   Jeffries GDM, 2007, NANO LETT, V7, P415, DOI 10.1021/nl0626784
   Kuroiwa T, 1996, PROTOPLASMA, V194, P275, DOI 10.1007/BF01882033
   Legros F, 2004, J CELL SCI, V117, P2653, DOI 10.1242/jcs.01134
   Levin BC, 2003, MITOCHONDRION, V2, P387, DOI 10.1016/S1567-7249(03)00010-2
   Levin BC, 1999, GENOMICS, V55, P135, DOI 10.1006/geno.1998.5513
   Nakada K, 2001, NAT MED, V7, P934, DOI 10.1038/90976
   Nambiar R, 2002, OPT LETT, V27, P836, DOI 10.1364/OL.27.000836
   Niu H, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000774
   Pauzauskie PJ, 2006, NAT MATER, V5, P97, DOI 10.1038/nmat1563
   Poe BG, 2010, ANAL BIOANAL CHEM, V397, P3397, DOI 10.1007/s00216-010-3751-3
   Resnick A, 2010, J BIOMED OPT, V15, DOI 10.1117/1.3316378
   Ruiz-Pesini E, 2007, NUCLEIC ACIDS RES, V35, pD823, DOI 10.1093/nar/gkl927
   Shelby JP, 2005, PHOTOCHEM PHOTOBIOL, V81, P994, DOI 10.1562/2005-02-02-RA-431R1.1
   Snijder B, 2009, NATURE, V461, P520, DOI 10.1038/nature08282
   Tang H, 2007, OPT EXPRESS, V15, P12708, DOI 10.1364/OE.15.012708
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   van Oven M, 2009, HUM MUTAT, V30, pE386, DOI 10.1002/humu.20921
   VOROBJEV IA, 1993, BIOPHYS J, V64, P533, DOI 10.1016/S0006-3495(93)81398-5
   Wang HW, 2004, J OPT A-PURE APPL OP, V6, P89, DOI 10.1088/1464-4258/6/1/016
   Westermann B, 2002, EMBO REP, V3, P527, DOI 10.1093/embo-reports/kvf113
NR 38
TC 23
Z9 28
U1 0
U2 30
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 16
PY 2010
VL 5
IS 12
AR e14359
DI 10.1371/journal.pone.0014359
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 695OI
UT WOS:000285381200009
PM 21179558
OA gold, Green Published
DA 2024-11-01
ER

PT J
AU Arena, IG
   Pugliese, A
   Volta, S
   Toscano, A
   Musumeci, O
AF Arena, Ignazio Giuseppe
   Pugliese, Alessia
   Volta, Sara
   Toscano, Antonio
   Musumeci, Olimpia
TI Molecular Genetics Overview of Primary Mitochondrial Myopathies
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Review
DE mitochondrial myopathy; exercise intolerance; ophtalmoplegia; mtDNA;
   nDNA; oxidative phosphorylation
ID COMPLEX I DEFICIENCY; PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; CYTOCHROME-B
   GENE; IMPAIR MTDNA REPLICATION; C-OXIDASE DEFICIENCY; STOP-CODON
   MUTATION; EXERCISE INTOLERANCE; NONSENSE MUTATION; RESPIRATORY-CHAIN;
   III DEFICIENCY
AB Mitochondrial disorders are the most common inherited conditions, characterized by defects in oxidative phosphorylation and caused by mutations in nuclear or mitochondrial genes. Due to its high energy request, skeletal muscle is typically involved. According to the International Workshop of Experts in Mitochondrial Diseases held in Rome in 2016, the term Primary Mitochondrial Myopathy (PMM) should refer to those mitochondrial disorders affecting principally, but not exclusively, the skeletal muscle. The clinical presentation may include general isolated myopathy with muscle weakness, exercise intolerance, chronic ophthalmoplegia/ophthalmoparesis (cPEO) and eyelids ptosis, or multisystem conditions where there is a coexistence with extramuscular signs and symptoms. In recent years, new therapeutic targets have been identified leading to the launch of some promising clinical trials that have mainly focused on treating muscle symptoms and that require populations with defined genotype. Advantages in next-generation sequencing techniques have substantially improved diagnosis. So far, an increasing number of mutations have been identified as responsible for mitochondrial disorders. In this review, we focused on the principal molecular genetic alterations in PMM. Accordingly, we carried out a comprehensive review of the literature and briefly discussed the possible approaches which could guide the clinician to a genetic diagnosis.
C1 [Arena, Ignazio Giuseppe; Pugliese, Alessia; Toscano, Antonio; Musumeci, Olimpia] Univ Messina, Unit Neurol & Neuromuscular Disorders, Dept Clin & Expt Med, I-98125 Messina, Italy.
   [Volta, Sara] Univ Padua, Dept Neurosci, I-35100 Padua, Italy.
C3 University of Messina; University of Padua
RP Musumeci, O (corresponding author), Univ Messina, Unit Neurol & Neuromuscular Disorders, Dept Clin & Expt Med, I-98125 Messina, Italy.
EM igna.arena@live.it; alessiapugliese76@gmail.com;
   sara.volta@studenti.unipd.it; atoscano@unime.it; omusumeci@unime.it
RI Toscano, Antonio/AHE-4657-2022; Musumeci, Olimpia/AHE-3041-2022;
   Pugliese, Alessia/IAQ-7432-2023
OI Musumeci, Olimpia/0000-0002-9208-1527; Arena, Ignazio
   Giuseppe/0000-0003-0882-7865
FU European Reference Network for ERN EURO-NMD [739543]
FX FundingThis research received no external funding.
CR Alston CL, 2017, J PATHOL, V241, P236, DOI 10.1002/path.4809
   Alston CL, 2016, AM J HUM GENET, V99, P217, DOI 10.1016/j.ajhg.2016.05.021
   Alston CL, 2012, J MED GENET, V49, P569, DOI 10.1136/jmedgenet-2012-101146
   Alston CL, 2010, NEUROMUSCULAR DISORD, V20, P131, DOI 10.1016/j.nmd.2009.10.010
   Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   Andreu AL, 1999, ANN NEUROL, V45, P820, DOI 10.1002/1531-8249(199906)45:6<820::AID-ANA22>3.0.CO;2-W
   Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   [Anonymous], 1993, GENEREVIEWS
   Auré K, 2013, NEUROLOGY, V81, P1810, DOI 10.1212/01.wnl.0000436067.43384.0b
   Ballana E, 2008, HUM MUTAT, V29, P248, DOI 10.1002/humu.20639
   Baloh RH, 2007, ARCH NEUROL-CHICAGO, V64, P998, DOI 10.1001/archneur.64.7.998
   Barca E, 2020, NEUROL-GENET, V6, DOI 10.1212/NXG.0000000000000402
   Barca E, 2018, HUM MOL GENET, V27, P3305, DOI 10.1093/hmg/ddy231
   Besse A, 2016, MOL BRAIN, V9, DOI 10.1186/s13041-016-0273-8
   Besse A, 2015, CELL METAB, V21, P417, DOI 10.1016/j.cmet.2015.02.008
   Boczonadi V, 2018, ESSAYS BIOCHEM, V62, P321, DOI 10.1042/EBC20170103
   Bornstein B, 2008, NEUROMUSCULAR DISORD, V18, P453, DOI 10.1016/j.nmd.2008.04.006
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   BOUZIDI MF, 1993, NEUROMUSCULAR DISORD, V3, P599
   Brischigliaro M, 2021, BBA-BIOENERGETICS, V1862, DOI 10.1016/j.bbabio.2020.148335
   Bruno C, 2003, MUSCLE NERVE, V28, P508, DOI 10.1002/mus.10429
   Buchaklian AH, 2012, MOL GENET METAB, V107, P92, DOI 10.1016/j.ymgme.2012.04.019
   Burrage LC, 2014, MOL GENET METAB, V113, P207, DOI 10.1016/j.ymgme.2014.06.004
   Calvo SE, 2010, ANNU REV GENOM HUM G, V11, P25, DOI 10.1146/annurev-genom-082509-141720
   Cardaioli E, 2008, J NEUROL SCI, V272, P106, DOI 10.1016/j.jns.2008.05.005
   Carrozzo R, 2007, BRAIN, V130, P862, DOI 10.1093/brain/awl389
   Carrozzo R, 2016, J INHERIT METAB DIS, V39, P243, DOI 10.1007/s10545-015-9894-9
   Chinnery PF, 2015, EMBO MOL MED, V7, P1503, DOI 10.15252/emmm.201505079
   Chinnery PF, 2004, LANCET, V364, P592, DOI 10.1016/S0140-6736(04)16851-7
   Clark KM, 1999, AM J HUM GENET, V64, P1330, DOI 10.1086/302361
   D'Aurelio M, 2010, HUM MOL GENET, V19, P374, DOI 10.1093/hmg/ddp503
   Darin N, 2017, EUR J NEUROL, V24, P587, DOI 10.1111/ene.13249
   DARLEYUSMAR VM, 1983, P NATL ACAD SCI-BIOL, V80, P5103, DOI 10.1073/pnas.80.16.5103
   De Coo IFM, 1999, ANN NEUROL, V45, P130, DOI 10.1002/1531-8249(199901)45:1<130::AID-ART21>3.0.CO;2-Z
   Deschauer M, 2005, NEUROMUSCULAR DISORD, V15, P311, DOI 10.1016/j.nmd.2004.12.004
   DIMAURO S, 1983, ANN NEUROL, V14, P226, DOI 10.1002/ana.410140209
   Downham E, 2008, NEUROMUSCULAR DISORD, V18, P310, DOI 10.1016/j.nmd.2008.01.003
   Dumoulin R, 1996, MOL CELL PROBE, V10, P389, DOI 10.1006/mcpr.1996.0053
   El-Hattab AW, 2017, GENEREVIEWS
   El-Hattab AW., 2009, GeneReviews
   El-Hattab A, 2013, NEUROTHERAPEUTICS, V10, P186, DOI 10.1007/s13311-013-0177-6
   Fassone E, 2015, HUM MOL GENET, V24, P4183, DOI 10.1093/hmg/ddv164
   Fassone E, 2012, J MED GENET, V49, P578, DOI 10.1136/jmedgenet-2012-101159
   Fernandez-Moreira D, 2007, ANN NEUROL, V61, P73, DOI 10.1002/ana.21036
   Fernandez-Vizarra E, 2007, HUM MOL GENET, V16, P1241, DOI 10.1093/hmg/ddm072
   Fernández-Vizarra E, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00134
   Fiedorczuk K, 2018, TRENDS CELL BIOL, V28, P835, DOI 10.1016/j.tcb.2018.06.006
   Finsterer J, 2018, BIOMED REP, V9, P119, DOI 10.3892/br.2018.1115
   Finsterer J, 2018, PEDIATR NEUROL, V80, P8, DOI 10.1016/j.pediatrneurol.2017.12.005
   Franzolin E, 2015, J BIOL CHEM, V290, P25986, DOI 10.1074/jbc.M115.675082
   Fratter C, 2011, NEUROLOGY, V76, P2032, DOI 10.1212/WNL.0b013e31821e558b
   Frazier AE, 2019, J BIOL CHEM, V294, P5386, DOI 10.1074/jbc.R117.809194
   Gandhi VV, 2011, NUCLEOS NUCLEOT NUCL, V30, P317, DOI 10.1080/15257770.2011.586955
   Ganetzky RD, 2019, HUM MUTAT, V40, P499, DOI 10.1002/humu.23723
   Garcia I, 2017, FRONT BIOSCI-LANDMRK, V22, P710, DOI 10.2741/4511
   Garone C, 2018, J MED GENET, V55, P515, DOI 10.1136/jmedgenet-2017-105012
   Garone C, 2011, BRAIN, V134, P3326, DOI 10.1093/brain/awr245
   Gelfand JM, 2011, J NEUROL, V258, P440, DOI 10.1007/s00415-010-5775-1
   Gempel K, 2007, BRAIN, V130, P2037, DOI 10.1093/brain/awm054
   Ghezzi D, 2018, ESSAYS BIOCHEM, V62, P271, DOI 10.1042/EBC20170099
   Gorman GS, 2015, CLIN SCI, V128, P895, DOI 10.1042/CS20140705
   Grady JP, 2014, BRAIN, V137, P323, DOI 10.1093/brain/awt321
   Haack TB, 2010, NAT GENET, V42, P1131, DOI 10.1038/ng.706
   Halter JP, 2015, BRAIN, V138, P2847, DOI 10.1093/brain/awv226
   Hargreaves IP, 2021, J CLIN MED, V10, DOI 10.3390/jcm10091970
   HAYES DJ, 1984, BRAIN, V107, P1165, DOI 10.1093/brain/107.4.1165
   Hejzlarová K, 2014, PHYSIOL RES, V63, pS57, DOI 10.33549/physiolres.932643
   Hellebrekers DMEI, 2019, NEUROMUSCULAR DISORD, V29, P693, DOI 10.1016/j.nmd.2019.08.005
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   Horváth R, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.015024
   Horvath R, 2006, NEUROLOGY, V66, P253, DOI 10.1212/01.wnl.0000194241.35115.7c
   Horvath R, 2009, BRAIN, V132, P3165, DOI 10.1093/brain/awp221
   Inoue M, 2019, ANN NEUROL, V86, P193, DOI 10.1002/ana.25517
   Jain-Ghai S, 2013, AM J MED GENET A, V161A, P285, DOI 10.1002/ajmg.a.35714
   Kara B, 2012, MOL GENET METAB, V107, P389, DOI 10.1016/j.ymgme.2012.06.013
   Karadimas CL, 2002, NEUROMUSCULAR DISORD, V12, P865, DOI 10.1016/S0960-8966(02)00072-X
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Keightley JA, 2000, AM J HUM GENET, V67, P1400, DOI 10.1086/316900
   Keshavan N, 2020, GENET MED, V22, P199, DOI 10.1038/s41436-019-0613-z
   KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5
   Kollberg G, 2005, J NEUROPATH EXP NEUR, V64, P123, DOI 10.1093/jnen/64.2.123
   Kornblum C, 2013, NAT GENET, V45, P214, DOI 10.1038/ng.2501
   Lake NJ, 2016, ANN NEUROL, V79, P190, DOI 10.1002/ana.24551
   Lalani SR, 2005, ARCH NEUROL-CHICAGO, V62, P317, DOI 10.1001/archneur.62.2.317
   Lamantea E, 2002, NEUROMUSCULAR DISORD, V12, P49, DOI 10.1016/S0960-8966(01)00244-9
   Legros F, 2001, EUR J HUM GENET, V9, P510, DOI 10.1038/sj.ejhg.5200678
   Lehmann D, 2015, EUR J HUM GENET, V23, P1735, DOI 10.1038/ejhg.2015.73
   Lenaers G, 2012, ORPHANET J RARE DIS, V7, DOI 10.1186/1750-1172-7-46
   Lightowlers RN, 2015, SCIENCE, V349, P1494, DOI 10.1126/science.aac7516
   Lopez-Gomez C, 2017, ANN NEUROL, V81, P641, DOI 10.1002/ana.24922
   Lu YY, 2017, J NEUROL SCI, V379, P137, DOI 10.1016/j.jns.2017.05.056
   Mahale RR, 2022, ACTA NEUROL BELG, V122, P1115, DOI 10.1007/s13760-021-01598-1
   Mancuso M, 2004, NEUROLOGY, V62, P2119, DOI 10.1212/01.WNL.0000127608.48406.F1
   Mancuso M, 2003, J NEUROL SCI, V209, P61, DOI 10.1016/S0022-510X(02)00462-8
   Mancuso M, 2017, NEUROMUSCULAR DISORD, V27, P1126, DOI 10.1016/j.nmd.2017.08.006
   Mancuso M, 2015, J NEUROL, V262, P1301, DOI 10.1007/s00415-015-7710-y
   McCormick EM, 2018, CURR OPIN PEDIATR, V30, P714, DOI 10.1097/MOP.0000000000000686
   Meyer JN, 2017, TOXICOLOGY, V391, P42, DOI 10.1016/j.tox.2017.07.019
   Meyerson C, 2015, CLIN OPHTHALMOL, V9, P1165, DOI 10.2147/OPTH.S62021
   Mimaki M, 2010, ANN NEUROL, V68, P845, DOI 10.1002/ana.22111
   Musumeci O, 2000, AM J HUM GENET, V66, P1900, DOI 10.1086/302927
   Ng YS, 2021, LANCET NEUROL, V20, P573, DOI 10.1016/S1474-4422(21)00098-3
   Ng YS, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00024
   Nishino I, 2001, NEUROMUSCULAR DISORD, V11, P7, DOI 10.1016/S0960-8966(00)00159-0
   OGASAHARA S, 1989, P NATL ACAD SCI USA, V86, P2379, DOI 10.1073/pnas.86.7.2379
   Ohlenbusch A, 2012, ORPHANET J RARE DIS, V7, DOI 10.1186/1750-1172-7-69
   Osellame LD, 2012, BEST PRACT RES CL EN, V26, P711, DOI 10.1016/j.beem.2012.05.003
   Pagniez-Mammeri H, 2012, MOL GENET METAB, V105, P163, DOI 10.1016/j.ymgme.2011.11.188
   Papadopoulou LC, 1999, NAT GENET, V23, P333
   Pfeffer G, 2014, BRAIN, V137, P1323, DOI 10.1093/brain/awu060
   Pitceathly RDS, 2013, JAMA NEUROL, V70, P1556, DOI 10.1001/jamaneurol.2013.3242
   Pitceathly RDS, 2013, CELL REP, V3, P1795, DOI 10.1016/j.celrep.2013.05.005
   Pitceathly RDS, 2012, NEUROLOGY, V79, P1145, DOI 10.1212/WNL.0b013e3182698d8d
   Quinzii CM, 2008, BIOFACTORS, V32, P113, DOI 10.1002/biof.5520320113
   Rafiq J, 2016, JIMD REP, V25, P65, DOI 10.1007/8904_2015_459
   Rahman S, 1999, AM J HUM GENET, V65, P1030, DOI 10.1086/302590
   Rahman S, 2020, J INTERN MED, V287, P609, DOI 10.1111/joim.13054
   Rahman S, 2012, DEV MED CHILD NEUROL, V54, P397, DOI 10.1111/j.1469-8749.2011.04214.x
   Renkema GH, 2015, EUR J HUM GENET, V23, P202, DOI 10.1038/ejhg.2014.80
   Repp BM, 2018, ORPHANET J RARE DIS, V13, DOI 10.1186/s13023-018-0784-8
   Reyes A, 2015, AM J HUM GENET, V97, P186, DOI 10.1016/j.ajhg.2015.05.013
   Ronchi D, 2012, BRAIN, V135, P3404, DOI 10.1093/brain/aws258
   Roos S, 2019, EUR J HUM GENET, V27, P331, DOI 10.1038/s41431-018-0286-0
   Rossignol R, 2003, BIOCHEM J, V370, P751, DOI 10.1042/BJ20021594
   Rusecka J, 2018, J APPL GENET, V59, P43, DOI 10.1007/s13353-017-0424-3
   Saada A, 2009, AM J HUM GENET, V84, P718, DOI 10.1016/j.ajhg.2009.04.020
   Salviati L, 2002, ARCH NEUROL-CHICAGO, V59, P862, DOI 10.1001/archneur.59.5.862
   Sánchez-Caballero L, 2016, AM J HUM GENET, V99, P208, DOI 10.1016/j.ajhg.2016.05.022
   Sato M, 2013, BBA-MOL CELL RES, V1833, P1979, DOI 10.1016/j.bbamcr.2013.03.010
   SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184
   Schuelke M, 2002, ANN NEUROL, V51, P388, DOI 10.1002/ana.10151
   Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350
   Shoubridge EA, 2001, AM J MED GENET, V106, P46, DOI 10.1002/ajmg.1378
   Soldath P, 2017, BMC MUSCULOSKEL DIS, V18, DOI 10.1186/s12891-017-1781-0
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   SPIRO AJ, 1970, ARCH NEUROL-CHICAGO, V23, P103, DOI 10.1001/archneur.1970.00480260009002
   Swalwell H, 2011, EUR J HUM GENET, V19, P769, DOI 10.1038/ejhg.2011.18
   Takata A, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-9-r92
   Tang S, 2011, J MED GENET, V48, P669, DOI 10.1136/jmedgenet-2011-100222
   Tarnopolsky M, 2019, MITOCHONDRION, V47, P139, DOI 10.1016/j.mito.2019.04.003
   Tilokani L, 2018, ESSAYS BIOCHEM, V62, P341, DOI 10.1042/EBC20170104
   Torres-Torronteras J, 2018, HUM GENE THER, V29, P708, DOI 10.1089/hum.2017.133
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Maldergem L, 2017, ANN CLIN TRANSL NEUR, V4, P4, DOI 10.1002/acn3.361
   van Rahden VA, 2015, AM J HUM GENET, V96, P640, DOI 10.1016/j.ajhg.2015.02.002
   Viscomi C, 2017, J INHERIT METAB DIS, V40, P587, DOI 10.1007/s10545-017-0027-5
   Visuttijai K, 2021, ACTA NEUROL SCAND, V143, P103, DOI 10.1111/ane.13339
   Walter MC, 2010, J NEUROL, V257, P1517, DOI 10.1007/s00415-010-5565-9
   Wedding IM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086340
   Wibrand F, 2001, ANN NEUROL, V50, P540, DOI 10.1002/ana.1224
   Wild KT, 2020, AM J MED GENET A, V182, P365, DOI 10.1002/ajmg.a.61433
   Xia D, 2013, BBA-BIOENERGETICS, V1827, P1278, DOI 10.1016/j.bbabio.2012.11.008
   Yarham JW, 2011, HUM MUTAT, V32, P1319, DOI 10.1002/humu.21575
   Yatsuga S, 2012, BBA-GEN SUBJECTS, V1820, P619, DOI 10.1016/j.bbagen.2011.03.015
   Yu-Wai-Man P, 2010, BRAIN, V133, P771, DOI 10.1093/brain/awq007
   Zanolini A, 2017, MOL GENET METAB REP, V10, P24, DOI 10.1016/j.ymgmr.2016.11.009
NR 156
TC 12
Z9 12
U1 0
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD FEB
PY 2022
VL 11
IS 3
AR 632
DI 10.3390/jcm11030632
PG 27
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA YY8JN
UT WOS:000755031500001
PM 35160083
OA gold, Green Published
DA 2024-11-01
ER

PT J
AU van Tienen, F
   Zelissen, R
   Timmer, E
   van Gisbergen, M
   Lindsey, P
   Quattrocelli, M
   Sampaolesi, M
   Mulder-den Hartog, E
   de Coo, I
   Smeets, H
AF van Tienen, Florence
   Zelissen, Ruby
   Timmer, Erika
   van Gisbergen, Marike
   Lindsey, Patrick
   Quattrocelli, Mattia
   Sampaolesi, Maurilio
   Mulder-den Hartog, Elvira
   de Coo, Irenaeus
   Smeets, Hubert
TI Healthy, mtDNA-mutation free mesoangioblasts from mtDNA patients qualify
   for autologous therapy
SO STEM CELL RESEARCH & THERAPY
LA English
DT Article
DE mtDNA mutation; Mesoangioblasts; Muscle regeneration
ID RAGGED-RED FIBERS; SKELETAL-MUSCLE; POINT MUTATION; MITOCHONDRIAL
   ENCEPHALOMYOPATHY; SATELLITE CELLS; STEM-CELLS; YOUNG; PREVALENCE;
   DELETIONS; SPECTRUM
AB Background Myopathy and exercise intolerance are prominent clinical features in carriers of a point-mutation or large-scale deletion in the mitochondrial DNA (mtDNA). In the majority of patients, the mtDNA mutation is heteroplasmic with varying mutation loads between tissues of an individual. Exercise-induced muscle regeneration has been shown to be beneficial in some mtDNA mutation carriers, but is often not feasible for this patient group. In this study, we performed in vitro analysis of mesoangioblasts from mtDNA mutation carriers to assess their potential to be used as source for autologous myogenic cell therapy. Methods We assessed the heteroplasmy level of patient-derived mesoangioblasts, isolated from skeletal muscle of multiple carriers of different mtDNA point-mutations (n = 25). Mesoangioblast cultures with < 10% mtDNA mutation were further analyzed with respect to immunophenotype, proliferation capacity, in vitro myogenic differentiation potential, mitochondrial function, and mtDNA quantity. Results This study demonstrated that mesoangioblasts in half of the patients contained no or a very low mutation load (< 10%), despite a much higher mutation load in their skeletal muscle. Moreover, none of the large-scale mtDNA deletion carriers displayed the deletion in mesoangioblasts, despite high percentages in skeletal muscle. The mesoangioblasts with no or a very low mutation load (< 10%) displayed normal mitochondrial function, proliferative capacity, and myogenic differentiation capacity. Conclusions Our data demonstrates that in half of the mtDNA mutation carriers, their mesoangioblasts are (nearly) mutation free and can potentially be used as source for autologous cell therapy for generation of new muscle fibers without mtDNA mutation and normal mitochondrial function.
C1 [van Tienen, Florence] Maastricht Univ, Dept Clin Genet, Med Ctr, Maastricht, Netherlands.
   [van Tienen, Florence; Zelissen, Ruby; Timmer, Erika; van Gisbergen, Marike; Smeets, Hubert] Maastricht Univ, Sch Dev Biol & Oncol GROW, Med Ctr, POB 616, NL-6200 MD Maastricht, Netherlands.
   [van Tienen, Florence; de Coo, Irenaeus; Smeets, Hubert] Maastricht Univ, Sch Mental Hlth & Neurosci MHeNS, Med Ctr, Maastricht, Netherlands.
   [van Tienen, Florence; Zelissen, Ruby; Timmer, Erika; Lindsey, Patrick; de Coo, Irenaeus; Smeets, Hubert] Maastricht Univ, Dept Genet & Cell Biol, Med Ctr, Div Clin Genom, Maastricht, Netherlands.
   [van Gisbergen, Marike] Maastricht Univ, Dept Radiat Oncol, Med Ctr, MaastRO Lab, Maastricht, Netherlands.
   [Quattrocelli, Mattia; Sampaolesi, Maurilio] Katholieke Univ Leuven, Translat Cardiomyol, Dept Dev & Regenerat, Leuven, Belgium.
   [Quattrocelli, Mattia] Northwestern Univ, Ctr Genet Med, Chicago, IL 60611 USA.
   [Sampaolesi, Maurilio] Univ Pavia, Human Anat Unit, Dept Publ Hlth Expt & Forens Med, Pavia, Italy.
   [Mulder-den Hartog, Elvira] Erasmus MC, Dept Pediat Surg, Rotterdam, Netherlands.
   [Mulder-den Hartog, Elvira; de Coo, Irenaeus] Neuromuscular & Mitochondrial Res Ctr NeMo, Rotterdam, Netherlands.
C3 Maastricht University; Maastricht University; Maastricht University;
   Maastricht University; Maastricht University; KU Leuven; Northwestern
   University; University of Pavia; Erasmus University Rotterdam; Erasmus
   MC
RP Smeets, H (corresponding author), Maastricht Univ, Sch Dev Biol & Oncol GROW, Med Ctr, POB 616, NL-6200 MD Maastricht, Netherlands.; Smeets, H (corresponding author), Maastricht Univ, Sch Mental Hlth & Neurosci MHeNS, Med Ctr, Maastricht, Netherlands.
EM Bert.smeets@maastrichtuniversity.nl
RI Quattrocelli, Mattia/AGK-7124-2022; Lindsey, Patrick/AAD-8100-2021; van
   Gisbergen, Marike/N-9751-2018; Sampaolesi, Maurilio/H-6509-2013
OI de Coo, Irenaeus/0000-0003-0533-7422; van Gisbergen,
   Marike/0000-0001-8318-7787; Sampaolesi, Maurilio/0000-0002-2422-3757
FU ZonMw "translational adult stem cell program" [116005007]; Ride4Kids
   Foundation [191213]; Metakids "ING goede doelen fonds" [2014-055];
   Prinses Beatrix Spierfonds [PBS W.0R15 09]
FX The research generating these results was supported by grants from ZonMw
   "translational adult stem cell program" (116005007), Ride4Kids
   Foundation (191213), Metakids "ING goede doelen fonds" (2014-055), and
   the Prinses Beatrix Spierfonds (PBS W.0R15 09).
CR Akaike H., 1973, 2 INT S INFORM THEOR, P267, DOI [10.1007/978-1-4612-1694-0, 10.1007/978-1-4612-0919-5_38]
   BOULET L, 1992, AM J HUM GENET, V51, P1187
   Chen CW, 2009, CYTOKINE GROWTH F R, V20, P429, DOI 10.1016/j.cytogfr.2009.10.014
   Clark KM, 1997, NAT GENET, V16, P222, DOI 10.1038/ng0797-222
   Cossu G, 2015, EMBO MOL MED, V7, P1513, DOI 10.15252/emmm.201505636
   Dellavalle A, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1508
   Dellavalle A, 2007, NAT CELL BIOL, V9, P255, DOI 10.1038/ncb1542
   Dreyer HC, 2006, MUSCLE NERVE, V33, P242, DOI 10.1002/mus.20461
   Farup J, 2015, J APPL PHYSIOL, V119, P1053, DOI 10.1152/japplphysiol.01108.2014
   Fu K, 1996, HUM MOL GENET, V5, P1835, DOI 10.1093/hmg/5.11.1835
   Galvez BG, 2006, J CELL BIOL, V174, P231, DOI 10.1083/jcb.200512085
   Gorman GS, 2015, NEUROMUSCULAR DISORD, V25, P563, DOI 10.1016/j.nmd.2015.03.001
   Gorman GS, 2015, ANN NEUROL, V77, P753, DOI 10.1002/ana.24362
   Ihaka Ross, 1996, Journal of Computational and Graphical Statistics, V5, P3, DOI [10.2307/1390807, 10.1080/10618600.1996.10474713]
   Jeppesen TD, 2006, BRAIN, V129, P3402, DOI 10.1093/brain/awl149
   Kärppä M, 2005, BRAIN, V128, P1861, DOI 10.1093/brain/awh515
   Lindsey J, 1999, MODELS REPEATED MEAS, P536
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   Meng JH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017454
   Morosetti R, 2011, Acta Myol, V30, P24
   Murphy JL, 2008, BRAIN, V131, P2832, DOI 10.1093/brain/awn252
   Nederveen JP, 2018, J PHYSIOL-LONDON, V596, P1063, DOI 10.1113/JP275155
   Nightingale H, 2016, BRAIN, V139, P1633, DOI 10.1093/brain/aww081
   PETRUZZELLA V, 1994, HUM MOL GENET, V3, P449, DOI 10.1093/hmg/3.3.449
   Quattrocelli M, 2012, METHODS MOL BIOL, V798, P65, DOI 10.1007/978-1-61779-343-1_4
   Roobrouck VD, 2011, STEM CELLS, V29, P871, DOI 10.1002/stem.633
   Rotini A, 2018, AGING CELL, V17, DOI 10.1111/acel.12714
   Sallevelt SCEH, 2013, J MED GENET, V50, P125, DOI 10.1136/jmedgenet-2012-101172
   Sampaolesi M, 2003, SCIENCE, V301, P487, DOI 10.1126/science.1082254
   Sampaolesi M, 2006, NATURE, V444, P574, DOI 10.1038/nature05282
   Sancricca Cristina, 2010, World J Stem Cells, V2, P39, DOI 10.4252/wjsc.v2.i3.39
   Shoubridge EA, 1997, HUM MOL GENET, V6, P2239, DOI 10.1093/hmg/6.13.2239
   Spendiff S, 2013, HUM MOL GENET, V22, P4739, DOI 10.1093/hmg/ddt327
   Taivassalo T, 1999, HUM MOL GENET, V8, P1047, DOI 10.1093/hmg/8.6.1047
   Taivassalo T, 2003, BRAIN, V126, P413, DOI 10.1093/brain/awg028
   Tedesco FS, 2012, CURR OPIN NEUROL, V25, P597, DOI 10.1097/WCO.0b013e328357f288
   Tonlorenzi R, 2007, CURR PROTOC STEM CEL, V3, P1, DOI DOI 10.1002/9780470151808.SC02B01S3
   Valero MC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029760
   Walker DK, 2012, MUSCLE NERVE, V46, P51, DOI 10.1002/mus.23266
NR 39
TC 10
Z9 10
U1 2
U2 5
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1757-6512
J9 STEM CELL RES THER
JI Stem Cell Res. Ther.
PD DEC 21
PY 2019
VL 10
IS 1
AR 405
DI 10.1186/s13287-019-1510-8
PG 10
WC Cell & Tissue Engineering; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA JY2YV
UT WOS:000504287000001
PM 31864395
OA Green Published, gold
DA 2024-11-01
ER

PT J
AU Schara, U
   von Kleist-Retzow, JC
   Lainka, E
   Gerner, P
   Pyle, A
   Smith, PM
   Lochmüller, H
   Czermin, B
   Abicht, A
   Holinski-Feder, E
   Horvath, R
AF Schara, Ulrike
   von Kleist-Retzow, Juergen-Christoph
   Lainka, Elke
   Gerner, Patrick
   Pyle, Angela
   Smith, Paul M.
   Lochmueller, Hanns
   Czermin, Birgit
   Abicht, Angela
   Holinski-Feder, Elke
   Horvath, Rita
TI Acute liver failure with subsequent cirrhosis as the primary
   manifestation of <i>TRMU</i> mutations
SO JOURNAL OF INHERITED METABOLIC DISEASE
LA English
DT Article
ID MITOCHONDRIAL-DNA DEPLETION; SIDEROBLASTIC ANEMIA-MLASA; RIBOSOMAL-RNA
   MUTATIONS; PHENOTYPIC-EXPRESSION; MOLECULAR-BASIS; COENZYME Q(10);
   HUMAN-DISEASE; TRANSLATION; DEFICIENCY; MYOPATHY
AB Combined respiratory chain deficiency accounts for about 30% of mitochondrial respiratory chain deficiencies and is frequently associated with mtDNA depletion, deletions or point mutations. However combined respiratory chain deficiency may also be caused by mutations in nuclear genes affecting mitochondrial translation. Here we describe a 2-year-old girl, who developed an acute, isolated, severe liver failure with mitochondrial pathology and decreased respiratory chain enzyme activities both in liver and skeletal muscle at 4 months of age. Her liver function improved significantly within a month, liver function tests returned to normal. Liver cirrhosis remained without any further complications so far. Pathogenic compound heterozygous mutations were identified in the TRMU gene. This condition is one of the few mitochondrial disorders with a life-threatening onset showing recovery later in life, therefore a prompt diagnosis and treatment of these patients has great importance in clinical practice. We suggest that TRMU deficiency should be considered in infants with acute liver disease.
C1 [Pyle, Angela; Lochmueller, Hanns; Horvath, Rita] Newcastle Univ, Inst Human Genet, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.
   [Pyle, Angela; Smith, Paul M.; Horvath, Rita] Newcastle Univ, Mitochondrial Res Grp, Inst Ageing & Hlth, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.
   [Czermin, Birgit; Abicht, Angela; Holinski-Feder, Elke; Horvath, Rita] Ctr Med Genet, Munich, Germany.
   [Schara, Ulrike; Lainka, Elke; Gerner, Patrick] Univ Essen Gesamthsch, Essen, Germany.
   [von Kleist-Retzow, Juergen-Christoph] Univ Cologne, Ctr Mol Med CMMC, Cologne, Germany.
   [von Kleist-Retzow, Juergen-Christoph] Univ Cologne, Dept Pediat, Cologne, Germany.
C3 Newcastle University - UK; Newcastle University - UK; University of
   Duisburg Essen; University of Cologne; University of Cologne
RP Horvath, R (corresponding author), Newcastle Univ, Inst Human Genet, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.
EM Rita.Horvath@ncl.ac.uk
RI Horvath, Rita/AAY-7042-2020
OI Lochmuller, Hanns/0000-0003-2324-8001; Horvath, Rita/0000-0002-9841-170X
FU Newcastle upon Tyne Hospitals NHS Charity [RES0211/7262]; Academy of
   Medical Sciences (UK) [BH090164]; MRC (UK); German ministry of education
   and research (BMBF, Bonn, Germany)
FX RH is supported by the Newcastle upon Tyne Hospitals NHS Charity
   (RES0211/7262) and the Academy of Medical Sciences (UK, BH090164) and by
   the MRC (UK) as part of the MRC Centre for Neuromuscular Diseases. US
   and HL are part of the German network on muscular dystrophies (MD-NET)
   and JCvKR of the German network on mitochondrial disorders (mitoNET),
   respectively, both funded by the German ministry of education and
   research (BMBF, Bonn, Germany).
CR Antonicka H, 2006, HUM MOL GENET, V15, P1835, DOI 10.1093/hmg/ddl106
   Bykhovskaya Y, 2004, AM J HUM GENET, V74, P1303, DOI 10.1086/421530
   Coenen MJH, 2004, NEW ENGL J MED, V351, P2080, DOI 10.1056/NEJMoa041878
   Fernandez-Vizarra E, 2007, J MED GENET, V44, P173, DOI 10.1136/jmg.2006.045252
   Guan MX, 2006, AM J HUM GENET, V79, P291, DOI 10.1086/506389
   Horvath R, 2009, BRAIN, V132, P3165, DOI 10.1093/brain/awp221
   Jacobs HT, 2005, TRENDS GENET, V21, P312, DOI 10.1016/j.tig.2005.04.003
   Levinger L, 2004, NUCLEIC ACIDS RES, V32, P5430, DOI 10.1093/nar/gkh884
   Miller C, 2004, ANN NEUROL, V56, P734, DOI 10.1002/ana.20282
   Montero R, 2009, CLIN BIOCHEM, V42, P742, DOI 10.1016/j.clinbiochem.2008.10.027
   Riley LG, 2010, AM J HUM GENET, V87, P52, DOI 10.1016/j.ajhg.2010.06.001
   Saada A, 2007, J MED GENET, V44, P784, DOI 10.1136/jmg.2007.053116
   Sacconi S, 2010, NEUROMUSCULAR DISORD, V20, P44, DOI 10.1016/j.nmd.2009.10.014
   Sarzi E, 2007, J PEDIATR-US, V150, P531, DOI 10.1016/j.jpeds.2007.01.044
   Smeitink JAM, 2006, AM J HUM GENET, V79, P869, DOI 10.1086/508434
   Smits P, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/737385
   Smits P, 2010, EUR J HUM GENET, V18, P324, DOI 10.1038/ejhg.2009.169
   Spinazzola A, 2009, J INHERIT METAB DIS, V32, P143, DOI 10.1007/s10545-008-1038-z
   Tuppen HAL, 2010, BBA-BIOENERGETICS, V1797, P113, DOI 10.1016/j.bbabio.2009.09.005
   Valente L, 2007, AM J HUM GENET, V80, P44, DOI 10.1086/510559
   Yan QF, 2006, BIOCHEM BIOPH RES CO, V342, P1130, DOI 10.1016/j.bbrc.2006.02.078
   Zeharia A, 2009, AM J HUM GENET, V85, P401, DOI 10.1016/j.ajhg.2009.08.004
NR 22
TC 54
Z9 56
U1 0
U2 3
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0141-8955
EI 1573-2665
J9 J INHERIT METAB DIS
JI J. Inherit. Metab. Dis.
PD FEB
PY 2011
VL 34
IS 1
BP 197
EP 201
DI 10.1007/s10545-010-9250-z
PG 5
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental
   Medicine
GA 711QR
UT WOS:000286607000023
PM 21153446
DA 2024-11-01
ER

PT J
AU Cardaioli, E
   Da Pozzo, P
   Malfatti, E
   Gallus, GN
   Rubegni, A
   Malandrini, A
   Gaudiano, C
   Guidi, L
   Serni, G
   Berti, G
   Dotti, MT
   Federico, A
AF Cardaioli, E.
   Da Pozzo, P.
   Malfatti, E.
   Gallus, G. N.
   Rubegni, A.
   Malandrini, A.
   Gaudiano, C.
   Guidi, L.
   Serni, G.
   Berti, G.
   Dotti, M. T.
   Federico, A.
TI Chronic progressive external ophthalmoplegia:: A new heteroplasmic tRNA
   <SUP>Leu(CUN)</SUP> mutation of mitochondrial DNA
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE chronic progressive external opthalmoplegia; mitochondrial DNA; tRNA
   (Leu(CUN))
ID MTDNA POINT MUTATION; A3243G MUTATION; DILATED CARDIOMYOPATHY; SPORADIC
   PATIENT; SKELETAL-MUSCLE; TRNA(LEU(CUN)); PHENOTYPES; NUCLEOTIDE;
   MYOPATHY; SEQUENCE
AB We sequenced all genes of mitochondrial tRNAs of a patient with chronic progressive external ophthalmoplegia with 5% ragged red fibres and 15% COX-negative fibres but without macrorearrangements of mitochondrial DNA (mtDNA). Direct sequencing showed a novel heteroplasmic G > A substitution in position 12316 of tRNA(Leu(CUN)) gene. This change destroys a highly conserved G-C base coupling in tRNA T psi C branch. By RFLP analysis we could demonstrate different degrees of heteroplasiny in different patient's tissues. This alteration, absent in a population of 110 patients with different encephalomyopathies, can be considered pathogenic: it is the tenth tRNA (Leu(CUN)) pathogenic Mutation described up to date. (C) 2008 Elsevier B.V All rights reserved.
C1 [Cardaioli, E.; Da Pozzo, P.; Malfatti, E.; Gallus, G. N.; Rubegni, A.; Malandrini, A.; Gaudiano, C.; Serni, G.; Berti, G.; Dotti, M. T.; Federico, A.] Univ Siena, Dept Neurol & Behav Sci, I-53100 Siena, Italy.
   [Guidi, L.] S Giuseppe Hosp, Neurol Unit, Florence, Italy.
C3 University of Siena
RP Federico, A (corresponding author), Univ Siena, Dipartimento Sci Neurol & Comportamento, Viale Bracci 2, I-53100 Siena, Italy.
EM federico@unisi.it
RI Malfatti, Edoardo/KEI-9379-2024; Federico, Antonio/H-8871-2017; Rubegni,
   Anna/I-3221-2018; GALLUS, GIAN NICOLA/Q-3489-2016
OI Cardaioli, Elena/0000-0003-2850-6698; Rubegni, Anna/0000-0002-0484-3799;
   federico, antonio/0000-0002-5246-1621; GALLUS, GIAN
   NICOLA/0000-0001-5801-223X
FU University of Siena and Regione Toscana
FX Research partly supported by a grant from University of Siena and
   Regione Toscana to AF.
CR Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Cardaioli E, 2005, BIOCHEM BIOPH RES CO, V327, P675, DOI 10.1016/j.bbrc.2004.11.170
   Cardaioli E, 2007, NEUROMUSCULAR DISORD, V17, P681, DOI 10.1016/j.nmd.2007.05.001
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   Chinnery PF, 2000, ANN NEUROL, V47, P381, DOI 10.1002/1531-8249(200003)47:3<381::AID-ANA17>3.0.CO;2-2
   Fu K, 1996, HUM MOL GENET, V5, P1835, DOI 10.1093/hmg/5.11.1835
   Grasso M, 2001, EUR J HUM GENET, V9, P311, DOI 10.1038/sj.ejhg.5200622
   HATTORI Y, 1994, J NEUROL SCI, V125, P50, DOI 10.1016/0022-510X(94)90241-0
   Karadimas CL, 2002, NEUROMUSCULAR DISORD, V12, P865, DOI 10.1016/S0960-8966(02)00072-X
   Koga Y, 2000, ARCH DIS CHILD, V82, P407, DOI 10.1136/adc.82.5.407
   Laforêt P, 2000, REV NEUROL-FRANCE, V156, P1136
   Pulkes T, 2003, NEUROLOGY, V61, P1144, DOI 10.1212/01.WNL.0000090465.27024.3D
   Pulkes T, 2001, ADV DRUG DELIVER REV, V49, P27, DOI 10.1016/S0169-409X(01)00124-7
   Raffelsberger T, 2001, NEUROLOGY, V57, P2298, DOI 10.1212/WNL.57.12.2298
   Taylor RW, 2002, NEUROMUSCULAR DISORD, V12, P659, DOI 10.1016/S0960-8966(02)00026-3
   Tessa A, 1999, EUR J HUM GENET, V7, P847, DOI 10.1038/sj.ejhg.5200380
   Weber K, 1997, AM J HUM GENET, V60, P373
   Zeviani M, 1998, MEDICINE, V77, P59, DOI 10.1097/00005792-199801000-00006
NR 18
TC 15
Z9 16
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD SEP 15
PY 2008
VL 272
IS 1-2
BP 106
EP 109
DI 10.1016/j.jns.2008.05.005
PG 4
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 347HM
UT WOS:000259131200014
PM 18603265
DA 2024-11-01
ER

PT J
AU Hebbar, M
   Girisha, KM
   Srivastava, A
   Bielas, S
   Shukla, A
AF Hebbar, Malavika
   Girisha, Katta M.
   Srivastava, Anshika
   Bielas, Stephanie
   Shukla, Anju
TI Homozygous c.359del variant in <i>MGME1</i> is associated with early
   onset cerebellar ataxia
SO EUROPEAN JOURNAL OF MEDICAL GENETICS
LA English
DT Article
DE MGME1; Mitochondrial DNA depletion syndrome; Exome sequencing; Ataxia
ID SEQUENCING DATA
AB We ascertained a child with early onset cerebellar ataxia and identified a novel frameshift deletion, c.359del [p. (Pro120Leufs*2), NM_052865.2] in exon 2 of MGME1 (mitochondrial genome maintenance exonuclease 1) by exome sequencing. Variations in MGME1 have been reported to cause mitochondrial DNA (mtDNA) depletion syndrome 11 (MIM # 615084) in an earlier work. The phenotype included progressive external ophthalmoplegia, emaciation, respiratory failure and late onset progressive ataxia. However, the child presented here has early onset progressive ataxia, speech delay, microcephaly, cerebellar atrophy and fundus albipunctatus. This is the second report of a mutation in MGME1 and describes a more severe phenotype. (C) 2017 Elsevier Masson SAS. All rights reserved.
C1 [Hebbar, Malavika; Girisha, Katta M.; Shukla, Anju] Manipal Univ, Dept Med Genet, Kasturba Med Coll, Manipal 576104, Karnataka, India.
   [Srivastava, Anshika; Bielas, Stephanie] Univ Michigan, Dept Human Genet, Ann Arbor, MI 48109 USA.
C3 Manipal Academy of Higher Education (MAHE); Kasturba Medical College,
   Manipal; University of Michigan System; University of Michigan
RP Shukla, A (corresponding author), Manipal Univ, Dept Med Genet, Kasturba Med Coll, Manipal 576104, Karnataka, India.
EM anju.shukla@manipal.edu
RI KM, Girisha/AAK-6867-2020
OI Girisha, Katta/0000-0002-0139-8239; Srivastava,
   Anshika/0000-0003-0699-3704; Bielas, Stephanie/0000-0003-0567-5632
FU National Institutes of Health [1R21NS094047-01]
FX We thank the families who cooperated with the evaluation of the subjects
   and consented for participation in this study. This work was supported
   by National Institutes of Health funded the project titled 'Genetic
   Diagnosis of Heritable Neurodevelopmental Disorders in India:
   Investigating the Use of Whole Exome Sequencing and Genetic Counseling
   to Address the High Burden of Neurodevelopmental
   Disorders'(1R21NS094047-01).
CR Girisha KM, 2016, CLIN GENET, V90, P536, DOI 10.1111/cge.12762
   Guo YF, 2015, SCI REP-UK, V5, DOI 10.1038/srep14283
   Kornblum C, 2013, NAT GENET, V45, P214, DOI 10.1038/ng.2501
   Wang K, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq603
NR 4
TC 6
Z9 6
U1 2
U2 6
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1769-7212
EI 1878-0849
J9 EUR J MED GENET
JI Eur. J. Med. Genet.
PD OCT
PY 2017
VL 60
IS 10
BP 533
EP 535
DI 10.1016/j.ejmg.2017.07.010
PG 3
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA FH1OB
UT WOS:000410908200007
PM 28711739
OA Green Accepted
DA 2024-11-01
ER

PT J
AU Lewis, W
   Day, BJ
   Kohler, JJ
   Hosseini, SH
   Chan, SSL
   Green, EC
   Haase, CP
   Keebaugh, ES
   Long, R
   Ludaway, T
   Russ, R
   Steltzer, J
   Tioleco, N
   Santoianni, R
   Copeland, WC
AF Lewis, William
   Day, Brian J.
   Kohler, James J.
   Hosseini, Seyed H.
   Chan, Sherine S. L.
   Green, Elgin C.
   Haase, Chad P.
   Keebaugh, Erin S.
   Long, Robert
   Ludaway, Tomika
   Russ, Rodney
   Steltzer, Jeffrey
   Tioleco, Nina
   Santoianni, Robert
   Copeland, William C.
TI Decreased mtDNA, oxidative stress, cardiomyopathy, and death from
   transgenic cardiac targeted human mutant polymerase γ
SO LABORATORY INVESTIGATION
LA English
DT Article
DE mitochondria; Pol gamma; oxidative stress; cardiomyopathy; transgenic
ID MITOCHONDRIAL-DNA POLYMERASE; PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA;
   MANGANESE SUPEROXIDE-DISMUTASE; P55 ACCESSORY SUBUNIT;
   AUTOSOMAL-DOMINANT; DEOXYNUCLEOTIDE CARRIER; DILATED CARDIOMYOPATHY;
   MULTIPLE DELETIONS; NUCLEAR-DNA; MOUSE HEART
AB POLG is the human gene that encodes the catalytic subunit of DNA polymerase gamma (Pol gamma), the replicase for human mitochondrial DNA (mtDNA). A POLG Y955C point mutation causes human chronic progressive external ophthalmoplegia (CPEO), a mitochondrial disease with eye muscle weakness and mtDNA defects. Y955C POLG was targeted transgenically (TG) to the murine heart. Survival was determined in four TG (+/-) lines and wild- type (WT) littermates (-/-). Left ventricle (LV) performance (echocardiography and MRI), heart rate (electrocardiography), mtDNA abundance ( real time PCR), oxidation of mtDNA (8-OHdG), histopathology and electron microscopy defined the phenotype. Cardiac targeted Y955C POLG yielded a molecular signature of CPEO in the heart with cardiomyopathy (CM), mitochondrial oxidative stress, and premature death. Increased LV cavity size and LV mass, bradycardia, decreased mtDNA, increased 8- OHdG, and cardiac histopathological and mitochondrial EM defects supported and defined the phenotype. This study underscores the pathogenetic role of human mutant POLG and its gene product in mtDNA depletion, mitochondrial oxidative stress, and CM as it relates to the genetic defect in CPEO. The transgenic model pathophysiologically links human mutant Pol gamma, mtDNA depletion, and mitochondrial oxidative stress to the mtDNA replication apparatus and to CM.
C1 Emory Univ, Sch Med, Dept Pathol, Atlanta, GA USA.
   Natl Jewish Med Ctr, Denver, CO USA.
   Natl Inst Environm Hlth Sci, Lab Mol Genet, NIH, Res Triangle Pk, NC USA.
   Emory Univ, Sch Med, Dept Radiol, Atlanta, GA USA.
C3 Emory University; National Jewish Health; National Institutes of Health
   (NIH) - USA; NIH National Institute of Environmental Health Sciences
   (NIEHS); Emory University
RP Lewis, W (corresponding author), Emory Univ, Sch Med, Dept Pathol, Atlanta, GA USA.
EM wlewis@emory.edu
RI Lewis, William/O-6571-2014; Copeland, William/C-4242-2019
OI Day, Brian/0000-0002-5663-0314; Copeland, William/0000-0002-0359-0953
FU Intramural NIH HHS Funding Source: Medline; NHLBI NIH HHS [HL072707, R01
   HL072707, R01 HL059798] Funding Source: Medline; NIEHS NIH HHS [Z01
   ES065080-11, Z01 ES065078-12] Funding Source: Medline
CR Bohlega S, 1996, NEUROLOGY, V46, P1329, DOI 10.1212/WNL.46.5.1329
   Chan SSL, 2005, DNA REPAIR, V4, P1381, DOI 10.1016/j.dnarep.2005.08.010
   Copeland WC, 2003, ACTA BIOCHIM POL, V50, P155
   Côté HCF, 2003, J INFECT DIS, V187, P1972, DOI 10.1086/375353
   DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602
   Davani EY, 2003, CRIT CARE, V7, pR176, DOI 10.1186/cc2375
   DIVI RL, 2006, IN PRESS ENV MOL MUT
   Elpeleg O, 2003, PEDIATR RES, V54, P153, DOI 10.1203/01.PDR.0000072796.25097.A5
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   Graziewicz MA, 2006, CHEM REV, V106, P383, DOI 10.1021/cr040463d
   Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   Kajander OA, 2002, HUM MOL GENET, V11, P317, DOI 10.1093/hmg/11.3.317
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Lewis W, 2006, AIDS, V20, P675, DOI 10.1097/01.aids.0000216367.23325.58
   Lewis W, 2005, ANTIVIR THER, V10, pM13
   Lewis W, 2005, LAB INVEST, V85, P972, DOI 10.1038/labinvest.3700301
   Lewis W, 2005, LAB INVEST, V85, P182, DOI 10.1038/labinvest.3700222
   Lewis W, 2003, NAT REV DRUG DISCOV, V2, P812, DOI 10.1038/nrd1201
   Lewis W, 2003, AIDS, V17, pS36, DOI 10.1097/00002030-200304001-00006
   Lewis W, 2000, LAB INVEST, V80, P187, DOI 10.1038/labinvest.3780022
   Lewis W, 2001, LAB INVEST, V81, P1527, DOI 10.1038/labinvest.3780366
   LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376
   Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197
   Loeb LA, 2005, P NATL ACAD SCI USA, V102, P18769, DOI 10.1073/pnas.0509776102
   Longley DB, 2006, ONCOGENE, V25, P838, DOI 10.1038/sj.onc.1209122
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Longley MJ, 2001, J BIOL CHEM, V276, P38555, DOI 10.1074/jbc.M105230200
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Mott JL, 2001, MUTAT RES-FUND MOL M, V474, P35, DOI 10.1016/S0027-5107(00)00159-7
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Pagnamenta AT, 2006, HUM REPROD, V21, P2467, DOI 10.1093/humrep/del076
   Ponamarev M. V., 2002, J BIOL CHEM, V15, P15
   Raidel SM, 2002, AM J PHYSIOL-HEART C, V282, pH1672, DOI 10.1152/ajpheart.00955.2001
   Rampazzo C, 2004, J BIOL CHEM, V279, P17019, DOI 10.1074/jbc.M313957200
   RICHTER C, 1988, P NATL ACAD SCI USA, V85, P6465, DOI 10.1073/pnas.85.17.6465
   Robbins J, 2000, ANNU REV PHYSIOL, V62, P261, DOI 10.1146/annurev.physiol.62.1.261
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Velsor LW, 2004, TOXICOL APPL PHARM, V199, P10, DOI 10.1016/j.taap.2004.03.005
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Williams MD, 1998, J BIOL CHEM, V273, P28510, DOI 10.1074/jbc.273.43.28510
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
   Zhang D, 2005, AM J PHYSIOL-HEART C, V288, pH2476, DOI 10.1152/ajpheart.00670.2004
   Zhang D, 2005, CARDIOVASC PATHOL, V14, P61, DOI 10.1016/j.carpath.2005.01.006
NR 50
TC 101
Z9 113
U1 0
U2 10
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK STREET, 9TH FLOOR, NEW YORK, NY 10013-1917 USA
SN 0023-6837
J9 LAB INVEST
JI Lab. Invest.
PD APR
PY 2007
VL 87
IS 4
BP 326
EP 335
DI 10.1038/labinvest.3700523
PG 10
WC Medicine, Research & Experimental; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pathology
GA 148UY
UT WOS:000245103200002
PM 17310215
OA Green Accepted, Bronze
DA 2024-11-01
ER

PT J
AU Jeppesen, TD
   Quistorff, B
   Wibrand, F
   Vissing, J
AF Jeppesen, Tina Dysgaard
   Quistorff, Bjorn
   Wibrand, Flemming
   Vissing, John
TI <SUP>31</SUP>P-MRS of skeletal muscle is not a sensitive diagnostic test
   for mitochondrial myopathy
SO JOURNAL OF NEUROLOGY
LA English
DT Article
DE 31-phosphorous magnetic resonance spectroscopy muscle disorders;
   mitochondrial myopathy; diagnostic procedures; mtDNA mutations
ID MAGNETIC-RESONANCE SPECTROSCOPY; TIBIALIS ANTERIOR MUSCLE;
   ENCEPHALOMYOPATHY MERRF; MR SPECTROSCOPY; HEART-FAILURE; HUMAN CALF;
   EXERCISE; RECOVERY; DISEASE; DNA
AB Clinical phenotypes of persons with mitochondrial DNA (mtDNA) mutations vary considerably. Therefore, diagnosing mitochondrial myopathy (MM) patients can be challenging and warrants diagnostic guidelines. (31)phosphorous magnetic resonance spectroscopy (P-31-MRS) have been included as a minor diagnostic criterion for MM but the diagnostic strength of this test has not been compared with that of other commonly used diagnostic procedures for MM. To investigate this, we studied seven patients with single, large-scale deletions-, nine with point mutations of mtDNA and 14 healthy subjects, who were investigated for the following: 1) P-31-MRS of lower arm and leg muscles before and after exercise, 2) resting and peak-exercise induced increases of plasma lactate, 3) muscle morphology and -mitochondrial enzyme activity, 4) maximal oxygen uptake (VO2max), 5) venous oxygen desaturation during handgrip exercise and 6) a neurological examination. All MM patients had clinical symptoms of MM, > 2% ragged red fibers in muscle, and impaired oxygen desaturation during handgrip. Fourteen of 16 patients had impaired VO2max, 10/16 had elevated resting plasma lactate, and 10/11 that were investigated had impaired citrate synthase-corrected complex I activity. Resting PCr/P-i ratio and leg P-i recovery were lower in MM patients vs. healthy subjects. PCr and ATP production after exercise were similar in patients and healthy subjects. Although the specificity for MM of some P-31-MRS variables was as high as 100%, the sensitivity was low (0-63%) and the diagnostic strength of P-31-MRS was inferior to the other diagnostic tests for MM. Thus, P-31-MRS should not be a routine test for MM, but may be an important research tool.
C1 Natl Univ Hosp, Rigshosp, Neuromuscular Res Unit, Sect 7611, DK-2100 Copenhagen, Denmark.
   Univ Copenhagen, Panum Inst, NMR Ctr, DK-2200 Copenhagen, Denmark.
   John F Kennedy Inst, DK-2600 Glostrup, Denmark.
C3 Rigshospitalet; University of Copenhagen; University of Copenhagen
RP Jeppesen, TD (corresponding author), Natl Univ Hosp, Rigshosp, Neuromuscular Res Unit, Sect 7611, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.
EM dysgaard@rh.dk
RI Vissing, John/IUN-4271-2023; Jeppesen, Tina/AAV-7195-2020
CR ARGOV Z, 1991, ANN NEUROL, V30, P90, DOI 10.1002/ana.410300116
   ARGOV Z, 1987, NEUROLOGY, V37, P257, DOI 10.1212/WNL.37.2.257
   Argov Z, 1996, NMR BIOMED, V9, P165, DOI 10.1002/(SICI)1099-1492(199606)9:4<165::AID-NBM408>3.0.CO;2-X
   ARNOLD DL, 1985, ANN NEUROL, V18, P189, DOI 10.1002/ana.410180205
   BANGSBO J, 1993, J APPL PHYSIOL, V74, P2034, DOI 10.1152/jappl.1993.74.4.2034
   Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   Chen JT, 2001, MAGNET RESON MED, V46, P870, DOI 10.1002/mrm.1271
   CIAFALONI E, 1992, ANN NEUROL, V31, P391, DOI 10.1002/ana.410310408
   Dimauro S, 2004, ANN NY ACAD SCI, V1011, P217, DOI 10.1196/annals.1293.022
   HOCH JC, 1995, NMR DATA PROCESSING
   Janssen AJM, 2003, ANN CLIN BIOCHEM, V40, P3, DOI 10.1258/000456303321016114
   Jensen TD, 2002, NEUROLOGY, V58, P1533, DOI 10.1212/WNL.58.10.1533
   Jeppesen TD, 2003, J NEUROL, V250, P293, DOI 10.1007/s00415-003-0993-4
   JOHNSTON W, 1995, ANN NEUROL, V37, P16, DOI 10.1002/ana.410370106
   KATZ SD, 1993, J APPL PHYSIOL, V75, P1974, DOI 10.1152/jappl.1993.75.5.1974
   KEMP GJ, 1993, NMR BIOMED, V6, P302, DOI 10.1002/nbm.1940060504
   KRAUSE KH, 1985, ANN NY ACAD SCI, V447, P297, DOI 10.1111/j.1749-6632.1985.tb18447.x
   KRENTZ AJ, 1990, METABOLISM, V39, P938, DOI 10.1016/0026-0495(90)90304-U
   KUHL CK, 1994, RADIOLOGY, V192, P223, DOI 10.1148/radiology.192.1.8208943
   Laguno M, 2005, ANTIVIR THER, V10, P423
   Larsen AI, 2001, EUR HEART J, V22, P684, DOI 10.1053/euhj.2000.2286
   Larson-Meyer DE, 2000, NMR BIOMED, V13, P14, DOI 10.1002/(SICI)1099-1492(200002)13:1<14::AID-NBM605>3.0.CO;2-0
   MARIOTTI C, 1995, J NEUROL, V242, P547, DOI 10.1007/BF00868806
   MATTHEWS PM, 1991, ANN NEUROL, V29, P435, DOI 10.1002/ana.410290416
   MATTHEWS PM, 1991, NEUROLOGY, V41, P114, DOI 10.1212/WNL.41.1.114
   MCCULLY KK, 1988, MUSCLE NERVE, V11, P212, DOI 10.1002/mus.880110304
   MIZUNO M, 1994, J APPL PHYSIOL, V76, P531, DOI 10.1152/jappl.1994.76.2.531
   Nakagawa Y, 2005, MED SCI SPORT EXER, V37, P937, DOI 10.1249/01.mss.0000166946.94871.9b
   PARK JH, 1990, RADIOLOGY, V177, P473, DOI 10.1148/radiology.177.2.2217788
   POLAGR J, 1973, J NEUROL SCI, V19, P307
   QUISTORFF B, 1993, BIOCHEM J, V291, P681, DOI 10.1042/bj2910681
   Ratkevicius A, 2002, MUSCLE NERVE, V25, P419, DOI 10.1002/mus.10064
   Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350
   Tarnopolsky MA, 1999, MUSCLE NERVE, V22, P1228, DOI 10.1002/(SICI)1097-4598(199909)22:9<1228::AID-MUS9>3.3.CO;2-Y
   TAYLOR DJ, 1994, J NEUROL SCI, V127, P198, DOI 10.1016/0022-510X(94)90073-6
   Vissing J, 1998, NEUROLOGY, V50, P1875, DOI 10.1212/WNL.50.6.1875
   VISSING J, 2002, SKELETAL MUSCLE PATH, P153
   Walker UA, 1996, EUR NEUROL, V36, P260, DOI 10.1159/000117269
   WALLACE DC, 1988, CELL, V55, P601, DOI 10.1016/0092-8674(88)90218-8
   Wibrand F, 2001, ANN NEUROL, V50, P540, DOI 10.1002/ana.1224
   YOUNKIN DP, 1987, NEUROLOGY, V37, P165, DOI 10.1212/WNL.37.1.165
NR 41
TC 32
Z9 34
U1 0
U2 3
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-5354
EI 1432-1459
J9 J NEUROL
JI J. Neurol.
PD JAN
PY 2007
VL 254
IS 1
BP 29
EP 37
DI 10.1007/s00415-006-0229-5
PG 9
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 137NV
UT WOS:000244300200005
PM 17278044
DA 2024-11-01
ER

PT J
AU Hudson, G
   Amati-Bonneau, P
   Blakely, EL
   Stewart, JD
   He, LP
   Schaefer, AM
   Griffiths, PG
   Ahlqvist, K
   Suomalainen, A
   Reynier, P
   McFarland, R
   Turnbull, DM
   Chinnery, PF
   Taylor, RW
AF Hudson, Gavin
   Amati-Bonneau, Patrizia
   Blakely, Emma L.
   Stewart, Joanna D.
   He, Langping
   Schaefer, Andrew M.
   Griffiths, Philip G.
   Ahlqvist, Kati
   Suomalainen, Anu
   Reynier, Pascal
   McFarland, Robert
   Turnbull, Douglass M.
   Chinnery, Patrick F.
   Taylor, Robert W.
TI Mutation of <i>OPA1</i> causes dominant optic atrophy with external
   ophthalmoplegia, ataxia, deafness and multiple mitochondrial DNA
   deletions:: a novel disorder of mtDNA maintenance
SO BRAIN
LA English
DT Article
DE mitochondria; mitochondrial DNA; mitochondrial encephalomyopathy;
   autosomal dominant progressive external ophthalmoplegia; autosomal
   dominant optic atrophy; multiple mtDNA deletions
ID SENSORINEURAL HEARING-LOSS; DYNAMIN-RELATED PROTEIN; AUTOSOMAL-DOMINANT;
   3-METHYLGLUTACONIC ACIDURIA; FUSION MEDIATORS; GENE; DEPLETION;
   DYSFUNCTION; MORPHOLOGY; APOPTOSIS
AB Mutations in nuclear genes involved in mitochondrial DNA ( mtDNA) maintenance cause a wide range of clinical phenotypes associated with the secondary accumulation of multiple mtDNA deletions in affected tissues. The majority of families with autosomal dominant progressive external ophthalmoplegia ( PEO) harbour mutations in genes encoding one of three well-characterized proteins - pol gamma, Twinkle or Ant 1. Here we show that a heterozygous mis-sense mutation in OPA1 leads to multiple mtDNA deletions in skeletal muscle and a mosaic defect of cytochrome c oxidase ( COX). The disorder presented with visual failure and optic atrophy in childhood, followed by PEO, ataxia, deafness and a sensory-motor neuropathy in adult life. COX-deficient skeletal muscle fibres contained supra-threshold levels of multiple mtDNA deletions, and genetic linkage, sequencing and expression analysis excluded POLG1, PEO1 and SLC25A4, the gene encoding Ant 1, as the cause. This demonstrates the importance of OPA1 in mtDNA maintenance, and implicates OPA1 in diseases associated with secondary defects of mtDNA.
C1 [Hudson, Gavin; Blakely, Emma L.; Stewart, Joanna D.; He, Langping; Schaefer, Andrew M.; McFarland, Robert; Turnbull, Douglass M.; Chinnery, Patrick F.; Taylor, Robert W.] Newcastle Univ, Sch Med, Sch Neurol Neurobiol & Psychiat, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Amati-Bonneau, Patrizia; Reynier, Pascal] Ctr Hosp Univ Angers, Dept Biochim & Genet, Angers, France.
   [Amati-Bonneau, Patrizia; Reynier, Pascal] INSERM, U694, Angers, France.
   [Griffiths, Philip G.] Royal Victoria Infirm, Dept Ophthalmol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
   [Ahlqvist, Kati; Suomalainen, Anu] Univ Helsinki, Ctr Hosp, Dept Neurol, Helsinki, Finland.
   [Ahlqvist, Kati; Suomalainen, Anu] Univ Helsinki, Res Program Mol Neurol, FIN-00014 Helsinki, Finland.
   [Turnbull, Douglass M.; Chinnery, Patrick F.; Taylor, Robert W.] Newcastle Univ, Inst Human Genet, Newcastle Upon Tyne, Tyne & Wear, England.
C3 Newcastle University - UK; Universite d'Angers; Centre Hospitalier
   Universitaire d'Angers; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Universite d'Angers; Newcastle University - UK;
   University of Helsinki; University of Helsinki; Newcastle University -
   UK
RP Chinnery, PF (corresponding author), Newcastle Univ, Sch Med, Sch Neurol Neurobiol & Psychiat, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM p.f.chinnery@ncl.ac.uk
RI Hudson, Gavin/E-7117-2017; Reynier, Pascal/K-3677-2015; amati-bonneau,
   patrizia/K-6198-2015; Stewart, Joanna D/H-1614-2012
OI Schaefer, Andrew/0000-0001-9891-7332; McFarland,
   Robert/0000-0002-8833-2688; Hudson, Gavin/0000-0001-7210-2733;
   Suomalainen-Wartiovaara, Anu/0000-0003-4833-5195; Stewart, Joanna
   D/0000-0002-2608-1967; Chinnery, Patrick/0000-0002-7065-6617; Reynier,
   Pascal/0000-0003-0802-4608
FU Medical Research Council [G0601943, G108/539] Funding Source: Medline;
   Wellcome Trust [074454] Funding Source: Medline; MRC [G0601943,
   G108/539] Funding Source: UKRI
CR Alavi MV, 2007, BRAIN, V130, P1029, DOI 10.1093/brain/awm005
   Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944
   Amati-Bonneau P, 2005, ANN NEUROL, V58, P958, DOI 10.1002/ana.20681
   Andrews RM, 1999, BRIT J OPHTHALMOL, V83, P231, DOI 10.1136/bjo.83.2.231
   Anikster Y, 2001, AM J HUM GENET, V69, P1218, DOI 10.1086/324651
   Barbet F, 2005, J MED GENET, V42, DOI 10.1136/jmg.2004.025502
   Barbet F, 2003, EUR J HUM GENET, V11, P966, DOI 10.1038/sj.ejhg.5201070
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Carelli V, 2004, PROG RETIN EYE RES, V23, P53, DOI 10.1016/j.preteyeres.2003.10.003
   Chen HC, 2005, J BIOL CHEM, V280, P26185, DOI 10.1074/jbc.M503062200
   CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324
   CORTOPASSI GA, 1992, P NATL ACAD SCI USA, V89, P7370, DOI 10.1073/pnas.89.16.7370
   COSTEFF H, 1995, BRAIN DEV-JPN, V17, P226, DOI 10.1016/0387-7604(95)00014-3
   Davies VJ, 2007, HUM MOL GENET, V16, P1307, DOI 10.1093/hmg/ddm079
   Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936
   Duvezin-Caubet S, 2006, J BIOL CHEM, V281, P37972, DOI 10.1074/jbc.M606059200
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Garrido N, 2003, MOL BIOL CELL, V14, P1583, DOI 10.1091/mbc.E02-07-0399
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   He LP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf067
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Hudson G, 2006, NEUROLOGY, V66, P1439, DOI 10.1212/01.wnl.0000210486.32196.24
   Jacobs HT, 2000, BIOESSAYS, V22, P564, DOI 10.1002/(SICI)1521-1878(200006)22:6<564::AID-BIES9>3.0.CO;2-4
   Katz BJ, 2006, AM J MED GENET A, V140A, P2207, DOI 10.1002/ajmg.a.31455
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kerrison JB, 1999, ARCH OPHTHALMOL-CHIC, V117, P805
   Kim JY, 2005, NEUROLOGY, V64, P966, DOI 10.1212/01.WNL.0000157282.76715.B1
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Lee S, 2007, J BIOL CHEM, V282, P22977, DOI 10.1074/jbc.M700679200
   Lee YJ, 2004, MOL BIOL CELL, V15, P5001, DOI 10.1091/mbc.E04-04-0294
   Li CM, 2005, AM J MED GENET A, V138A, P208, DOI 10.1002/ajmg.a.30794
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   MANDERBACKA K, 2001, SCANDINAVIAN J P S55, V29, P41
   Nakamura M, 2006, OPHTHALMOLOGY, V113, P483, DOI 10.1016/j.ophtha.2005.10.054
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Olichon A, 2003, J BIOL CHEM, V278, P7743, DOI 10.1074/jbc.C200677200
   Olichon A, 2002, FEBS LETT, V523, P171, DOI 10.1016/S0014-5793(02)02985-X
   Olichow A, 2007, J CELL PHYSIOL, V211, P423, DOI 10.1002/jcp.20950
   Payne M, 2004, AM J OPHTHALMOL, V138, P749, DOI 10.1016/j.ajo.2004.06.011
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Schapira AHV, 2006, LANCET, V368, P70, DOI 10.1016/S0140-6736(06)68970-8
   Sörensen L, 2001, J NEUROSCI, V21, P8082, DOI 10.1523/JNEUROSCI.21-20-08082.2001
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Taylor R.W., 1997, Organelle Diseases : Clinical Features, Diagnosis, Pathogenesis, and Management, P341
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Verhoeven K, 2006, BRAIN, V129, P2093, DOI 10.1093/brain/awl126
   Waterham HR, 2007, NEW ENGL J MED, V356, P1736, DOI 10.1056/NEJMoa064436
   Zeviani M, 2004, BRAIN, V127, P2153, DOI 10.1093/brain/awh259
   Züchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341
   Züchner S, 2006, ANN NEUROL, V59, P276, DOI 10.1002/ana.20797
NR 52
TC 326
Z9 342
U1 0
U2 25
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 1460-2156
J9 BRAIN
JI Brain
PD FEB
PY 2008
VL 131
BP 329
EP 337
DI 10.1093/brain/awm272
PN 2
PG 9
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 258XO
UT WOS:000252903900006
PM 18065439
OA hybrid, Green Submitted
DA 2024-11-01
ER

PT J
AU Deschauer, M
   Krasnianski, A
   Zierz, S
   Taylor, RW
AF Deschauer, M
   Krasnianski, A
   Zierz, S
   Taylor, RW
TI False-positive diagnosis of a single, large-scale mitochondrial DNA
   deletion by Southern blot analysis: The role of neutral polymorphisms
SO GENETIC TESTING
LA English
DT Article
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; KEARNS-SAYRE SYNDROME; MTDNA
   CONTROL REGION; MUTATIONS; MYOPATHIES; MUSCLE; HETEROPLASMY; NEUROPATHY;
   DISORDER; DISEASE
AB Single, large-scale deletions of mitochondrial DNA ( mtDNA) are a common finding in the molecular investigation of patients with suspected mitochondrial disorders and are typically detected by Southern blot analysis of muscle DNA that has been linearized by a single cutter enzyme ( BamHI or PvuII). We describe our investigations of a 47-year-old woman with exercise intolerance, myalgia, and ptosis who underwent a muscle biopsy for a suspected mitochondrial genetic abnormality. Southern blot analysis after digestion of muscle DNA with BamHI revealed the apparent presence of two mtDNA species, indicative of a heteroplasmic deletion of 2.0 - 2.5 kb in length involving approximately 50% of all molecules. Contrary to this observation, long-range polymerase chain reaction (PCR) amplified only wild-type mtDNA. Sequence analysis revealed that the patient harbored two previously recognized control region polymorphisms, a homoplasmic 16390G > A variant that introduces a new BamHI site and a heteroplasmic 16390G > A change that abolishes this site, thus explaining the initial false-positive testing for a heteroplasmic mtDNA deletion. Our findings highlight the potential problems associated with the diagnosis of mitochondrial genetic disease and emphasize the need to confirm positive cases of mtDNA deletions using more than one enzyme or an independent method such as long-range PCR amplification.
C1 Univ Halle Wittenberg, Neurol Klin & Poliklin, Dept Neurol, D-06097 Halle Saale, Germany.
   Univ Newcastle Upon Tyne, Sch Med, Sch Neurol Neurobiol & Psychiat, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
C3 Martin Luther University Halle Wittenberg; Newcastle University - UK
RP Deschauer, M (corresponding author), Univ Halle Wittenberg, Neurol Klin & Poliklin, Dept Neurol, Ernst Grube Str 40, D-06097 Halle Saale, Germany.
EM marcus.deschauer@medizin.uni-halle.de
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   BENDALL KE, 1995, AM J HUM GENET, V57, P248
   Brierley EJ, 1998, ANN NEUROL, V43, P217, DOI 10.1002/ana.410430212
   CHENG S, 1994, NAT GENET, V7, P350, DOI 10.1038/ng0794-350
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   Chinnery PF, 2004, LANCET, V364, P592, DOI 10.1016/S0140-6736(04)16851-7
   Deschauer M, 2003, NEUROMUSCULAR DISORD, V13, P568, DOI 10.1016/S0960-8966(03)00071-3
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   GERBITZ KD, 1990, J NEUROL, V237, P5, DOI 10.1007/BF00319660
   He LP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf067
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Howell N, 2000, AM J HUM GENET, V66, P1589, DOI 10.1086/302910
   JOHNS DR, 1993, AM J HUM GENET, V53, P916
   Kirby DM, 1998, MOL DIAGN, V3, P211, DOI 10.1016/S1084-8592(98)80042-8
   MITA S, 1990, NUCLEIC ACIDS RES, V18, P561, DOI 10.1093/nar/18.3.561
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   ROTIG A, 1990, J CLIN INVEST, V86, P1601, DOI 10.1172/JCI114881
   Taylor RW, 2001, NUCLEIC ACIDS RES, V29, part. no., DOI 10.1093/nar/29.15.e74
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   White SL, 1998, MOL DIAGN, V3, P113, DOI 10.1016/S1084-8592(98)80059-3
   Yamamoto M, 1996, MUSCLE NERVE, V19, P928
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
   ZEVIANI M, 1990, ANN NEUROL, V28, P94, DOI 10.1002/ana.410280118
NR 24
TC 8
Z9 9
U1 0
U2 1
PU MARY ANN LIEBERT INC
PI LARCHMONT
PA 2 MADISON AVENUE, LARCHMONT, NY 10538 USA
SN 1090-6576
J9 GENET TEST
JI Genet. Test.
PD DEC
PY 2004
VL 8
IS 4
BP 395
EP 399
DI 10.1089/gte.2004.8.395
PG 5
WC Genetics & Heredity; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Research & Experimental Medicine
GA 888ZU
UT WOS:000226413900006
PM 15684869
DA 2024-11-01
ER

PT J
AU Danda, S
   Thomas, BM
   Paramasivam, G
   Thomas, R
   Mathew, J
   Danda, D
AF Danda, Sumita
   Thomas, Blessy Mariam
   Paramasivam, G.
   Thomas, Raji
   Mathew, John
   Danda, Debashish
TI A descriptive pilot study of mitochondrial mutations & clinical
   phenotype in fibromyalgia syndrome
SO INDIAN JOURNAL OF MEDICAL RESEARCH
LA English
DT Article
DE DNA deletions; fibromyalgia; genetic; Indian; long-range polymerise
   chain reaction; mitochondrial mutations; vitamin D
AB Background & objectives: Fibromyalgia syndrome (FMS) is one of the most common chronic pain conditions of unknown aetiology. Mitochondria! dysfunction has been reported in FMS with some studies reporting the presence of mitochondria! mutation namely A3243G, which also causes mitochondria! encephalomyopathy, lactic acidosis and stroke-like episodes. This pilot study was conducted to assess this mutation and also detect large deletions in mitochondrial DNA (mtDNA) in patients with FMS.
   Methods: Thirty female patients with FMS participated and 30 matched controls were included. Genomic DNA was subjected to polymerise chain reaction (PCR) amplification using specific primers followed by restriction digestion with Apal enzyme to detect the specific A3243G mtDNA mutation. Long-range PCR was done in two sets to detect the large deletions in the mtDNA. Biochemical parameters including thyroid-stimulating hormone and vitamin D levels were also looked at.
   Results: None of the patients were found to carry the common mutation or large deletions. Low vitamin D level w as a common finding. Hypothyroidism was found in a few patients.
   Interpretation & conclusions: Although the common mutation or large mtDNA deletions were not detected in blood mtDNA in the FMS patients, mutations in the muscle and sequence variation in mtDNA remained a possibility. Future studies in both blood and muscle tissue including mtDNA sequencing are warranted in such patients to determine if a subset of FMS patients have mitochondrial myopathy.
C1 [Danda, Sumita; Thomas, Blessy Mariam; Paramasivam, G.] Christian Med Coll & Hosp, Dept Med Genet, Vellore, Tamil Nadu, India.
   [Thomas, Raji] Christian Med Coll & Hosp, Dept Phys Med & Rehabil, Vellore, Tamil Nadu, India.
   [Mathew, John; Danda, Debashish] Christian Med Coll & Hosp, Dept Clin Immunol & Rheumatol, Vellore 632004, Tamil Nadu, India.
C3 Christian Medical College & Hospital (CMCH) Vellore; Christian Medical
   College & Hospital (CMCH) Vellore; Christian Medical College & Hospital
   (CMCH) Vellore
RP Danda, D (corresponding author), Christian Med Coll & Hosp, Dept Clin Immunol & Rheumatol, Vellore 632004, Tamil Nadu, India.
EM debashisdandacmc@hotmail.com
RI danda, debashish/K-2650-2013
FU Lady Tata foundation for Research, Mumbai
FX Funding was provided by Lady Tata foundation for Research, Mumbai.
CR Abdullah Mishal, 2012, J Med Case Rep, V6, P55, DOI 10.1186/1752-1947-6-55
   Bandelt HJ, 2014, J HUM GENET, V59, P66, DOI 10.1038/jhg.2013.120
   Bhatty SA, 2010, J PAK MED ASSOC, V60, P949
   Castro-Marrero J, 2015, ANTIOXID REDOX SIGN, V22, P679, DOI 10.1089/ars.2014.6181
   Cordero MD, 2016, J MED GENET, V53, P113, DOI 10.1136/jmedgenet-2015-103392
   Cordero MD, 2013, ANTIOXID REDOX SIGN, V18, P800, DOI 10.1089/ars.2012.4892
   Cordero MD, 2011, REUMATOL CLIN, V7, P281, DOI 10.1016/j.reuma.2010.12.007
   Cordero MD, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar2918
   DeSouza RA, 2004, SOUTH MED J, V97, P528, DOI 10.1097/00007611-200405000-00023
   Dogru A, 2017, EURASIAN J MED, V49, P113, DOI 10.5152/eurasianjmed.2017.16283
   Ohkubo K, 2001, CLIN CHEM, V47, P1641
   Sprott H, 2004, ANN RHEUM DIS, V63, P245, DOI 10.1136/ard.2002.004762
   Wolfe F, 2010, ARTHRIT CARE RES, V62, P600, DOI 10.1002/acr.20140
   Zhang W, 2012, CLIN CHEM, V58, P1322, DOI 10.1373/clinchem.2011.181438
   2011, MITOCHONDRION, V11, P623, DOI DOI 10.1016/J.MITO.2011.03.122
NR 15
TC 3
Z9 3
U1 0
U2 5
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0971-5916
J9 INDIAN J MED RES
JI Indian J. Med. Res.
PD JAN
PY 2019
VL 149
IS 1
BP 47
EP 50
DI 10.4103/ijmr.IJMR_1977_16
PG 4
WC Immunology; Medicine, General & Internal; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; General & Internal Medicine; Research & Experimental
   Medicine
GA HV2MR
UT WOS:000465825200008
PM 31115374
OA gold, Green Published
DA 2024-11-01
ER

PT J
AU Komulainen, T
   Hinttala, R
   Kärppä, M
   Pajunen, L
   Finnilä, S
   Tuominen, H
   Rantala, H
   Hassinen, I
   Majamaa, K
   Uusimaa, J
AF Komulainen, Tuomas
   Hinttala, Reetta
   Karppa, Mikko
   Pajunen, Leila
   Finnila, Saara
   Tuominen, Hannu
   Rantala, Heikki
   Hassinen, Ilmo
   Majamaa, Kari
   Uusimaa, Johanna
TI <i>POLG1</i> p.R722H mutation associated with multiple mtDNA deletions
   and a neurological phenotype
SO BMC NEUROLOGY
LA English
DT Article
ID MITOCHONDRIAL-DNA POLYMERASE; PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA;
   W748S MUTATION; ALPERS-SYNDROME; SPACER-REGION; GAMMA; ATAXIA; SPECTRUM;
   A467T
AB Background: The c.2447G>A (p.R722H) mutation in the gene POLG1 of the catalytic subunit of human mitochondrial polymerase gamma has been previously found in a few occasions but its pathogenicity has remained uncertain. We set out to ascertain its contribution to neuromuscular disease.
   Methods: Probands from two families with probable mitochondrial disease were examined clinically, muscle and buccal epithelial DNA were analyzed for mtDNA deletions, and the POLG1, POLG2, ANT1 and Twinkle genes were sequenced.
   Results: An adult proband presented with progressive external ophthalmoplegia, sensorineural hearing impairment, diabetes mellitus, dysphagia, a limb myopathy and dementia. Brain MRI showed central and cortical atrophy, and F-18-deoxyglucose PET revealed reduced glucose uptake. Histochemical analysis of muscle disclosed ragged red fibers and cytochrome c oxidase-negative fibers. Electron microscopy showed subsarcolemmal aggregates of morphologically normal mitochondria. Multiple mtDNA deletions were found in the muscle, and sequencing of the POLG1 gene revealed a homozygous c.2447G>A (p.R722H) mutation. His two siblings were also homozygous with respect to the p.R722H mutation and presented with dementia and sensorineural hearing impairment. In another family the p.R722H mutation was found as compound heterozygosity with the common p.W748S mutation in two siblings with mental retardation, ptosis, epilepsy and psychiatric symptoms. The estimated carrier frequency of the p.R722H mutation was 1:135 in the Finnish population. No mutations in POLG2, ANT1 and Twinkle genes were found. Analysis of the POLG1 sequence by homology modeling supported the notion that the p.R722H mutation is pathogenic.
   Conclusions: The recessive c.2447G>A (p.R722H) mutation in the linker region of the POLG1 gene is pathogenic for multiple mtDNA deletions in muscle and is associated with a late-onset neurological phenotype as a homozygous state. The onset of the disease can be earlier in compound heterozygotes.
C1 [Hinttala, Reetta; Karppa, Mikko; Finnila, Saara; Majamaa, Kari] Univ Oulu, Dept Neurol, FIN-90014 Oulu, Finland.
   [Komulainen, Tuomas; Rantala, Heikki; Uusimaa, Johanna] Univ Oulu, Dept Pediat, FIN-90014 Oulu, Finland.
   [Pajunen, Leila] Univ Oulu, Oulu Univ Hosp, Dept Clin Genet, FIN-90014 Oulu, Finland.
   [Tuominen, Hannu] Univ Oulu, Dept Pathol, FIN-90014 Oulu, Finland.
   [Hassinen, Ilmo] Univ Oulu, Dept Med Biochem & Mol Biol, FIN-90014 Oulu, Finland.
   [Komulainen, Tuomas; Hinttala, Reetta; Karppa, Mikko; Finnila, Saara; Majamaa, Kari; Uusimaa, Johanna] Univ Oulu, Oulu Univ Hosp, Clin Res Ctr, FIN-90014 Oulu, Finland.
C3 University of Oulu; University of Oulu; University of Oulu; University
   of Oulu; University of Oulu; University of Oulu
RP Majamaa, K (corresponding author), Univ Oulu, Dept Neurol, Box 5000, FIN-90014 Oulu, Finland.
EM kari.majamaa@oulu.fi
RI Majamaa, Kari/A-1344-2012
OI Hinttala, Reetta/0000-0002-7642-4008; Majamaa, Kari/0000-0002-9070-3791
FU Research Council for Health at the Academy of Finland; Sigrid Juselius
   Foundation; Finnish Medical Foundation; Arvo and Lea Ylppo Foundation;
   Finnish Foundation for Pediatric Research; Alma and K.A. Snellman
   Foundation
FX The authors thank Ms. Sirpa Miettinen, Ms. Anja Heikkinen and Ms. Pirjo
   Keranen for their expert assistance. The work was supported by grants
   from the Research Council for Health at the Academy of Finland (K.M.),
   the Sigrid Juselius Foundation (K.M.), the Finnish Medical Foundation
   (J.U), the Arvo and Lea Ylppo Foundation (J.U.), the Finnish Foundation
   for Pediatric Research (J.U.) and the Alma and K.A. Snellman Foundation
   (J.U.).
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987
   Braasch DA, 2001, CHEM BIOL, V8, P1, DOI 10.1016/S1074-5521(00)00058-2
   Chan SSL, 2006, HUM MOL GENET, V15, P3473, DOI 10.1093/hmg/ddl424
   Chan SSL, 2005, J BIOL CHEM, V280, P31341, DOI 10.1074/jbc.M506762200
   Cole C, 2008, NUCLEIC ACIDS RES, V36, pW197, DOI 10.1093/nar/gkn238
   Copeland WC, 2008, ANNU REV MED, V59, P131, DOI 10.1146/annurev.med.59.053006.104646
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   González-Vioque E, 2006, ARCH NEUROL-CHICAGO, V63, P107, DOI 10.1001/archneur.63.1.107
   Graziewicz MA, 2006, CHEM REV, V106, P383, DOI 10.1021/cr040463d
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   HOPKINS SE, 2009, J CHILD NEUROL
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Hudson G, 2006, HUM MOL GENET, V15, pR244, DOI 10.1093/hmg/ddl233
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   Kollberg G, 2006, J NEUROPATH EXP NEUR, V65, P758, DOI 10.1097/01.jnen.0000229987.17548.6e
   Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Longley MJ, 2005, GENE, V354, P125, DOI 10.1016/j.gene.2005.03.029
   Luo NG, 2005, J BIOL CHEM, V280, P2491, DOI 10.1074/jbc.M411447200
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Luoma PT, 2007, NEUROLOGY, V69, P1152, DOI 10.1212/01.wnl.0000276955.23735.eb
   Luoma PT, 2005, HUM MOL GENET, V14, P1907, DOI 10.1093/hmg/ddi196
   Minnick DT, 1999, J BIOL CHEM, V274, P3067, DOI 10.1074/jbc.274.5.3067
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Remes AM, 2005, NEUROLOGY, V64, P976, DOI 10.1212/01.WNL.0000154518.31302.ED
   SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626
   Schapira AHV, 2006, LANCET, V368, P70, DOI 10.1016/S0140-6736(06)68970-8
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Uusimaa J, 2008, EPILEPSIA, V49, P1038, DOI 10.1111/j.1528-1167.2008.01544.x
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Van Goethem G, 2002, ACTA NEUROL BELG, V102, P39
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   Yakubovskaya E, 2007, EMBO J, V26, P4283, DOI 10.1038/sj.emboj.7601843
NR 37
TC 17
Z9 17
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2377
J9 BMC NEUROL
JI BMC Neurol.
PD MAY 3
PY 2010
VL 10
AR 29
DI 10.1186/1471-2377-10-29
PG 10
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 603SF
UT WOS:000278227700001
PM 20438629
OA gold, Green Published
DA 2024-11-01
ER

PT J
AU Tafakhori, A
   Ng, AYJ
   Tohari, S
   Venkatesh, B
   Lee, H
   Eskin, A
   Nelson, SF
   Bonnard, C
   Reversade, B
   Kariminejad, A
AF Tafakhori, Abbas
   Ng, Alvin Yu Jin
   Tohari, Sumanty
   Venkatesh, Byrappa
   Lee, Hane
   Eskin, Ascia
   Nelson, Stanley F.
   Bonnard, Carine
   Reversade, Bruno
   Kariminejad, Ariana
TI Mutation in <i>TWINKLE</i> in a Large Iranian Family with Progressive
   External Ophthalmoplegia, Myopathy, Dysphagia and Dysphonia, and
   Behavior Change
SO ARCHIVES OF IRANIAN MEDICINE
LA English
DT Article
DE Dysphonia; myopathy; ptosis; progressive external ophthalmoplegia;
   TWINKLE
ID OCULOPHARYNGEAL MUSCULAR-DYSTROPHY; PEO1 GENE MUTATION;
   MITOCHONDRIAL-DNA; DISTAL MYOPATHY; CELL-DEATH; DEPLETION; AGGREGATION;
   INCLUSIONS; EXPANSION; DELETIONS
AB BACKGROUND: TWINKLE (c10orf2) gene is responsible for autosomal dominant progressive external ophthalmoplegia (PEO). In rare cases, additional features such as muscle weakness, peripheral neuropathy, ataxia, cardiomyopathy, dysphagia, dysphonia, cataracts, depression, dementia, parkinsonism, and hearing loss have been reported in association with heterozygous mutations of the TWINKLE gene.
   METHODS: We have studied a large Iranian family with myopathy, dysphonia, dysphagia, and behavior change in addition to PEO in affected members.
   RESULTS: We identified a missense mutation c.1121G > A in the c10orf2 gene in all affected members. Early death is a novel feature seen in affected members of this family that has not been reported to date.
   CONCLUSION: The association of PEO, myopathy, dysphonia, dysphagia, behavior change and early death has not been previously reported in the literature or other patients with this mutation.
C1 [Tafakhori, Abbas] Univ Tehran Med Sci, Iranian Ctr Neurol Research, Dept Neurol, Tehran, Iran.
   [Ng, Alvin Yu Jin; Tohari, Sumanty; Venkatesh, Byrappa; Reversade, Bruno] ASTAR, Inst Mol & Cell Biol, Singapore, Singapore.
   [Lee, Hane; Eskin, Ascia; Nelson, Stanley F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Human Genet, Los Angeles, CA 90095 USA.
   [Bonnard, Carine; Reversade, Bruno] ASTAR, Inst Med Biol, Singapore, Singapore.
   [Kariminejad, Ariana] Kariminejad Najmabadi Pathol & Genet Ctr, 2,4th St Hasan Seyf St Sanat Sq, Tehran, Iran.
C3 Tehran University of Medical Sciences; Agency for Science Technology &
   Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology
   (IMCB); University of California System; University of California Los
   Angeles; University of California Los Angeles Medical Center; David
   Geffen School of Medicine at UCLA; Agency for Science Technology &
   Research (A*STAR); A*STAR - Institute of Medical Biology (IMB)
RP Kariminejad, A (corresponding author), Kariminejad Najmabadi Pathol & Genet Ctr, 2,4th St Hasan Seyf St Sanat Sq, Tehran, Iran.
EM arianakariminejad@Yahoo.com
RI Nelson, Stanley/D-4771-2009
OI Kariminejad, Ariana/0000-0002-8467-4728; Venkatesh,
   Byrappa/0000-0003-3620-0277; Ng, Alvin/0000-0002-1744-6063; REVERSADE,
   Bruno/0000-0002-4070-7997
CR Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248
   AMATO AA, 1995, MUSCLE NERVE, V18, P842, DOI 10.1002/mus.880180807
   Baloh RH, 2007, ARCH NEUROL-CHICAGO, V64, P998, DOI 10.1001/archneur.64.7.998
   BRAIS B, 1995, HUM MOL GENET, V4, P429, DOI 10.1093/hmg/4.3.429
   Caburet S, 2004, J MED GENET, V41, P932, DOI 10.1136/jmg.2004.024356
   Cunningham V, 2009, AM J MED GENET A, V149A, P981
   Durmus H, 2011, NEUROLOGY, V76, P227, DOI 10.1212/WNL.0b013e318207b043
   Echaniz-Laguna A, 2010, NEUROGENETICS, V11, P21, DOI 10.1007/s10048-009-0202-4
   Fratter C, 2010, NEUROLOGY, V74, P1619, DOI 10.1212/WNL.0b013e3181df099f
   GRANTHAM R, 1974, SCIENCE, V185, P862, DOI 10.1126/science.185.4154.862
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   Hudson G, 2005, NEUROLOGY, V64, P371, DOI 10.1212/01.WNL.0000149767.51152.83
   Jeppesen TD, 2008, NEUROMUSCULAR DISORD, V18, P306, DOI 10.1016/j.nmd.2007.10.007
   Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86
   Liu ZR, 2008, MOL VIS, V14, P1995
   Lönnqvist T, 2009, BRAIN, V132, P1553, DOI 10.1093/brain/awp045
   Martin-Negrier ML, 2011, EUR J NEUROL, V18, P436, DOI 10.1111/j.1468-1331.2010.03171.x
   Messaed C, 2007, NEUROBIOL DIS, V26, P546, DOI 10.1016/j.nbd.2007.02.004
   Naïmi M, 2006, EUR J HUM GENET, V14, P917, DOI 10.1038/sj.ejhg.5201627
   Nasrallah IM, 2004, J CELL BIOL, V167, P411, DOI 10.1083/jcb.200408091
   Nikali K, 2005, HUM MOL GENET, V14, P2981, DOI 10.1093/hmg/ddi328
   Pollard KS, 2010, GENOME RES, V20, P110, DOI 10.1101/gr.097857.109
   Sarzi E, 2007, ANN NEUROL, V62, P579, DOI 10.1002/ana.21207
   SATOYOSHI E, 1977, ARCH NEUROL-CHICAGO, V34, P89, DOI 10.1001/archneur.1977.00500140043007
   SCRIMGEOUR EM, 1984, AM J MED GENET, V17, P763, DOI 10.1002/ajmg.1320170407
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   TOME FMS, 1980, ACTA NEUROPATHOL, V49, P85, DOI 10.1007/BF00692226
   Uyama E, 1998, NEUROMUSCULAR DISORD, V8, P119, DOI 10.1016/S0960-8966(98)00002-9
   van der Sluijs BM, 2004, J NEUROL NEUROSUR PS, V75, P1499, DOI 10.1136/jnnp.2003.025072
   Virgilio R, 2008, J NEUROL, V255, P1384, DOI 10.1007/s00415-008-0926-3
   Zoghbi HY, 1999, CURR OPIN NEUROBIOL, V9, P566, DOI 10.1016/S0959-4388(99)00013-6
NR 31
TC 5
Z9 5
U1 0
U2 2
PU ACAD MEDICAL SCIENCES I R IRAN
PI TEHRAN
PA PO BOX 19395-5655, TEHRAN, 00000, IRAN
SN 1029-2977
EI 1735-3947
J9 ARCH IRAN MED
JI Arch. Iran. Med.
PD FEB
PY 2016
VL 19
IS 2
BP 87
EP 91
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA DC9LX
UT WOS:000369544200002
PM 26838077
DA 2024-11-01
ER

PT J
AU Forli, F
   Mancuso, M
   Santoro, A
   Dotti, MT
   Siciliano, G
   Berrettini, S
AF Forli, F.
   Mancuso, M.
   Santoro, A.
   Dotti, M. T.
   Siciliano, G.
   Berrettini, S.
TI Auditory neuropathy in a patient with mitochondrial myopathy and
   multiple mtDNA deletions
SO JOURNAL OF LARYNGOLOGY AND OTOLOGY
LA English
DT Article
DE auditory; neuropathy; cochlear nerve; sensorineural deafness;
   mitochondrial myopathy; mtDNA deletions
ID HEARING-LOSS; OTOACOUSTIC EMISSIONS; AUDIOLOGICAL FINDINGS; MUTATIONS;
   DNA; DEAFNESS; OTOF; GENE
AB Auditory neuropathy (AN) is a hearing disorder characterized by the absence or severe distortion of the auditory brainstem responses, in the presence of preserved otoacoustic emissions. This peculiar combination suggests the presence of a defect impinging upon the functional complex formed by inner hair cells, the primary afferents (spiral ganglion neurones) and the first order synapses between hair cells and the cochlear nerve. Typically, AN patients show a severe speech perception impairment, which appears reduced out of proportion to pure tone threshold, but the clinical presentation of AN is quite complex.
   Hearing loss is a common symptom associated with mitochondrial diseases; however, AN has only rarely been reported in these disorders.
   Here we report a rare association, the first case observed in Italy, in a patient with autosomal recessive mitochondrial myopathy and mitochondrial DNA multiple deletions, and a hearing deficit with the audiological and electrophysiological features of AN.
C1 Univ Pisa, Dept Neurosci, ENT Div, I-56126 Pisa, Italy.
   Univ Pisa, Dept Neurosci, Neurol Clin, I-56126 Pisa, Italy.
   Univ Siena, Dept Neurol & Behav Sci, I-53100 Siena, Italy.
C3 University of Pisa; University of Pisa; University of Siena
RP Berrettini, S (corresponding author), Univ Pisa, Dept Neurosci, ENT Div, Via Savi N 10, I-56126 Pisa, Italy.
EM s.berrettini@med.unipi.it
RI Mancuso, Michelangelo/K-4170-2016
OI Santoro, Amelia/0000-0002-9819-9198
CR Berlin CI, 1998, EAR HEARING, V19, P37, DOI 10.1097/00003446-199802000-00002
   Brown DK, 2001, J OTOLARYNGOL, V30, P46
   Chinnery PF, 2000, BRAIN, V123, P82, DOI 10.1093/brain/123.1.82
   Corley V M, 1999, J Am Acad Audiol, V10, P484
   DAVIS H, 1979, AUDIOLOGY, V18, P445
   Deltenre E, 1999, AUDIOLOGY, V38, P187
   Deltenre P, 1997, EVOKED POTENTIAL, V104, P17, DOI 10.1016/S0168-5597(96)96635-6
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   ELVERLAND HH, 1991, AM J OTOL, V12, P459
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   Fischel-Ghodsian N, 2003, EAR HEARING, V24, P303, DOI 10.1097/01.AUD.0000079802.82344.B5
   Harrison RV, 1998, EAR HEARING, V19, P355, DOI 10.1097/00003446-199810000-00002
   Korres S, 2002, ORL-J OTO-RHIN-LARYN, V64, P315, DOI 10.1159/000066078
   Madden C, 2002, ARCH OTOLARYNGOL, V128, P1026, DOI 10.1001/archotol.128.9.1026
   Mancuso M, 2004, ACTA NEUROL SCAND, V110, P72, DOI 10.1111/j.1600-0404.2004.00254.x
   Marco J, 2000, ACTA OTO-LARYNGOL, V120, P201
   Park MS, 1998, ACTA OTO-LARYNGOL, V118, P496, DOI 10.1080/00016489850154612
   Rance G, 1999, EAR HEARING, V20, P238, DOI 10.1097/00003446-199906000-00006
   Rapin I, 2003, INT J PEDIATR OTORHI, V67, P707, DOI 10.1016/S0165-5876(03)00103-4
   Rodríguez-Ballesteros M, 2003, HUM MUTAT, V22, P451, DOI 10.1002/humu.10274
   Salvi RJ, 1999, SCAND AUDIOL, V28, P1
   Santarelli R, 2002, HEARING RES, V170, P32, DOI 10.1016/S0378-5955(02)00450-1
   Sawada S, 1997, AM J OTOL, V18, P332
   Sciacco M, 1996, Methods Enzymol, V264, P509, DOI 10.1016/S0076-6879(96)64045-2
   Seidman MD, 1996, LARYNGOSCOPE, V106, P777, DOI 10.1097/00005537-199606000-00021
   Starr A., 2000, Journal of Basic and Clinical Physiology and Pharmacology, V11, P215
   Starr A, 2001, EAR HEARING, V22, P91, DOI 10.1097/00003446-200104000-00002
   Starr A, 1996, BRAIN, V119, P741, DOI 10.1093/brain/119.3.741
   Sue CM, 1998, ANN NEUROL, V43, P350, DOI 10.1002/ana.410430313
   Varga R, 2003, J MED GENET, V40, P45, DOI 10.1136/jmg.40.1.45
NR 31
TC 10
Z9 10
U1 0
U2 1
PU CAMBRIDGE UNIV PRESS
PI CAMBRIDGE
PA EDINBURGH BLDG, SHAFTESBURY RD, CB2 8RU CAMBRIDGE, ENGLAND
SN 0022-2151
EI 1748-5460
J9 J LARYNGOL OTOL
JI J. Laryngol. Otol.
PD OCT
PY 2006
VL 120
IS 10
BP 888
EP 891
DI 10.1017/S0022215106001472
PG 4
WC Otorhinolaryngology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Otorhinolaryngology
GA 103VA
UT WOS:000241913700023
PM 16719954
DA 2024-11-01
ER

PT J
AU Moslemi, AR
   Lindberg, C
   Toft, J
   Holme, E
   Kollberg, G
   Oldfors, A
AF Moslemi, AR
   Lindberg, C
   Toft, J
   Holme, E
   Kollberg, G
   Oldfors, A
TI A novel mutation in the mitochondrial tRNA<SUP>Phe</SUP> gene associated
   with mitochondrial myopathy
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE myopathy; cytochrome c oxidase deficiency; tRNA; mutation; mtDNA
ID POINT MUTATION; MUSCLE DISEASE; DNA; ENCEPHALOMYOPATHY; SEQUENCE; FIBERS
AB We report a novel heteroplasmic T-->C mutation at nt position 582 within the mitochondrial tRNA(Phe) gene of a 70-year-old woman with mitochondrial myopathy. No other family members were affected, suggesting that our patient was a sporadic case. The muscle showed frequent ragged red fibers and 43% cytochrome c oxidase deficient fibers. The mutation alters a conserved base pairing in the aminoacyl acceptor stem. The mutation load was 70% in muscle homogenate and varied from 0 to 95% in individual muscle fiber segments. Cytochrome c oxidase-negative fibers showed significantly higher levels of mutated mtDNA (>75%) than Cytochrome c oxidase-positive fibers (<55%). This mutation adds to the previously described four pathogenic mutations in the tRNA(Phe) gene. (C) 2003 Elsevier B.V. All rights reserved.
C1 Sahlgrens Univ Hosp, Dept Pathol, S-41345 Gothenburg, Sweden.
   Sahlgrens Univ Hosp, Dept Neurol, S-41345 Gothenburg, Sweden.
   S Elfsborg Hosp, Dept Neurol, S-41345 Gothenburg, Sweden.
   Sahlgrens Univ Hosp, Dept Clin Chem, S-41345 Gothenburg, Sweden.
C3 Sahlgrenska University Hospital; Sahlgrenska University Hospital;
   Sahlgrenska University Hospital
RP Sahlgrens Univ Hosp, Dept Pathol, S-41345 Gothenburg, Sweden.
EM ali-reza.moslemi@path.gu.se
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Chinnery PF, 1997, ANN NEUROL, V41, P408, DOI 10.1002/ana.410410319
   *EM U, 2002, MIT HUM MIT GEN DAT
   Fu K, 1996, HUM MOL GENET, V5, P1835, DOI 10.1093/hmg/5.11.1835
   Hanna MG, 1998, J NEUROL NEUROSUR PS, V65, P512, DOI 10.1136/jnnp.65.4.512
   HOUSHMAND M, 1994, BBA-MOL BASIS DIS, V1226, P49, DOI 10.1016/0925-4439(94)90058-2
   Kleinle S, 1998, BIOCHEM BIOPH RES CO, V247, P112, DOI 10.1006/bbrc.1998.8729
   Larsson NG, 2001, ACTA PHYSIOL SCAND, V171, P385, DOI 10.1046/j.1365-201x.2001.00842.x
   MORAES CT, 1993, NAT GENET, V4, P284, DOI 10.1038/ng0793-284
   MORAES CT, 1993, J CLIN INVEST, V92, P2906, DOI 10.1172/JCI116913
   Moslemi AR, 2000, CARDIOLOGY, V94, P68, DOI 10.1159/000007049
   Moslemi AR, 1998, NEUROMUSCULAR DISORD, V8, P345, DOI 10.1016/S0960-8966(98)00029-7
   NASHEF L, 1989, J NEUROL NEUROSUR PS, V52, P1090, DOI 10.1136/jnnp.52.9.1090
   Nishigaki Y, 2002, NEUROLOGY, V58, P1282, DOI 10.1212/WNL.58.8.1282
   OLDFORS A, 1995, J NEUROPATH EXP NEUR, V54, P581, DOI 10.1097/00005072-199507000-00012
   Tiranti V, 1998, ANN NEUROL, V43, P98, DOI 10.1002/ana.410430116
   TULINIUS MH, 1991, J PEDIATR-US, V119, P242, DOI 10.1016/S0022-3476(05)80734-6
   Tzen CY, 2001, KIDNEY INT, V59, P846, DOI 10.1046/j.1523-1755.2001.00567.x
   Yasukawa T, 2000, NUCLEIC ACIDS RES, V28, P3779, DOI 10.1093/nar/28.19.3779
NR 20
TC 16
Z9 18
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD JAN
PY 2004
VL 14
IS 1
BP 46
EP 50
DI 10.1016/S0960-8966(03)00168-8
PG 5
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 756CL
UT WOS:000187448200007
PM 14659412
DA 2024-11-01
ER

PT J
AU Sunami, Y
   Sugaya, K
   Chihara, N
   Goto, Y
   Matsubara, S
AF Sunami, Yoko
   Sugaya, Keizo
   Chihara, Norio
   Goto, Yu-ichi
   Matsubara, Shiro
TI Variable phenotypes in a family with mitochondrial encephalomyopathy
   harboring a 3291T &gt; C mutation in mitochondrial DNA
SO NEUROLOGICAL SCIENCES
LA English
DT Article
DE Mitochondrial encephalomyopathy; Family case; 3291T > C; mtDNA mutation
ID MELAS
AB We present a Japanese family suffering from mitochondrial encephalomyopathy associated with a T-to-C transition at mitochondrial DNA (mtDNA) nucleotide position 3291. Clinical manifestations of the patients include cerebellar ataxia with myopathy, recurrent headache, and myoclonus and epilepsy. The phenotypic variation among the affected members of a single family and the mutational analysis showing maternal inheritance in a heteroplasmic fashion are consistent with well-recognized phenomena associated with many pathogenic point mutations of mtDNA tRNA genes. The 3291 mutation is a rare mtDNA mutation whose clinical presentation had only been reported in three sporadic cases. This is the first report of a family segregating the 3291 mutation with multigenerational matrilinear recurrence of mitochondrial encephalopathy. Our findings provide conclusive evidence for the pathogenicity of the 3291T > C mutation in mtDNA and its characteristic clinical heterogeneity.
C1 [Sunami, Yoko; Sugaya, Keizo; Matsubara, Shiro] Tokyo Metropolitan Neurol Hosp, Dept Neurol, Fuchu, Tokyo 1830042, Japan.
   [Chihara, Norio] Natl Ctr Hosp Neurol & Psychiat, Dept Neurol, Tokyo, Japan.
   [Goto, Yu-ichi] NCNP, Natl Inst Neurosci, Dept Mental Retardat & Birth Defect Res, Tokyo, Japan.
C3 Tokyo Metropolitan Institute for Neuroscience; National Center for
   Neurology & Psychiatry - Japan; National Center for Neurology &
   Psychiatry - Japan
RP Sunami, Y (corresponding author), Tokyo Metropolitan Neurol Hosp, Dept Neurol, 2-6-1 Musashidai, Fuchu, Tokyo 1830042, Japan.
EM youko_sunami@tmhp.jp
RI chihara, norio/GMX-0691-2022
OI Sugaya, Kiminobu/0000-0002-2788-5457; chihara, norio/0000-0003-4499-0790
CR GOTO Y, 1995, MUSCLE NERVE       S, V3, P107
   GOTO YI, 1994, BIOCHEM BIOPH RES CO, V202, P1624, DOI 10.1006/bbrc.1994.2119
   Jacobs HT, 2003, HUM MOL GENET, V12, pR293, DOI 10.1093/hmg/ddg285
   Salsano E, 2011, J NEUROL SCI, V300, P165, DOI 10.1016/j.jns.2010.09.022
   Thajeb Peterus, 2006, Taiwan J Obstet Gynecol, V45, P201
   Uziel G, 2000, NEUROMUSCULAR DISORD, V10, P415, DOI 10.1016/S0960-8966(99)00115-7
   WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523
   Wallace DC, 2008, GENETICS, V179, P727, DOI 10.1534/genetics.104.91769
NR 8
TC 9
Z9 9
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1590-1874
J9 NEUROL SCI
JI Neurol. Sci.
PD OCT
PY 2011
VL 32
IS 5
BP 861
EP 864
DI 10.1007/s10072-011-0719-9
PG 4
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 855EK
UT WOS:000297546400013
PM 21863273
OA Green Published, hybrid
DA 2024-11-01
ER

PT J
AU Hou, Y
   Zhao, XT
   Xie, ZY
   Yu, M
   Lv, H
   Zhang, W
   Yuan, Y
   Wang, ZX
AF Hou, Yue
   Zhao, Xutong
   Xie, Zhiying
   Yu, Meng
   Lv, He
   Zhang, Wei
   Yuan, Yun
   Wang, Zhaoxia
TI Novel and recurrent nuclear gene variations in a cohort of Chinese
   progressive external ophthalmoplegia patients with multiple mtDNA
   deletions
SO MOLECULAR GENETICS & GENOMIC MEDICINE
LA English
DT Article
DE progressive external ophthalmoplegia; mtDNA maintenance defect; multiple
   mtDNA deletion; POLG; POLG2; RRM2B; TK2; TWNK
ID DNA-POLYMERASE; MITOCHONDRIAL DISORDER; SENSORY NEUROPATHY;
   SPACER-REGION; MUTATIONS; ATAXIA; POLG; DISEASE; SPECTRUM; PEO1
AB Objectives: This study aimed to investigate the clinical and genetic spectrum in Chinese patients with multiple mtDNA deletions presenting with autosomal-inherited mitochondrial progressive external ophthalmoplegia (PEO).
   Methods: Long-range polymerase chain reaction and massively parallel sequencing of the mitochondrial genome were performed to detect deletions in muscle mtDNA of 274 unrelated families. Then, targeted next generation sequencing was used to detect nuclear gene variations in patients with multiple mtDNA deletions.
   Results: A total of 40 Chinese PEO patients (10 males and 30 females) from 20 families were found to have multiple mtDNA deletions in this study, and the median age at onset was 35 (1-70) years. PEO and positive family history were the two prominent features of these patients, and ataxia, neuropathy, and hypogonadism were also present as onset symptoms in some patients. Fifteen of 20 probands with multiple mtDNA deletions were identified to carry nuclear gene variants; eight (40.0%) probands had variants within POLG, two (10.0%) within TWNK, two (10.0%) within RRM2B, two (10.0%) within TK2, and one (5.0%) within POLG2. A total of 24 variants were found in these five nuclear genes, of which 19 were novel. The causal nuclear genetic factors in five pedigrees remain undetermined.
   Conclusions: The POLG gene is the most common disease-causing gene in this group of PEO patients with multiple mtDNA deletions. While inherited PEO is the most prominent symptoms in these patients, genotypic and phenotypic heterogeneity still exist, for example in onset age, initial symptoms, and accompanying manifestations.
C1 [Hou, Yue; Zhao, Xutong; Xie, Zhiying; Yu, Meng; Lv, He; Zhang, Wei; Yuan, Yun; Wang, Zhaoxia] Peking Univ, Dept Neurol, Hosp 1, Beijing 100034, Peoples R China.
   [Hou, Yue] Peking Univ, Dept Geriatr, Hosp 1, Beijing, Peoples R China.
   [Wang, Zhaoxia] Beijing Key Lab Neurovasc Dis Discovery, Beijing, Peoples R China.
C3 Peking University; Peking University
RP Wang, ZX (corresponding author), Peking Univ, Dept Neurol, Hosp 1, Beijing 100034, Peoples R China.
EM drwangzx@163.com
OI Xie, Zhiying/0000-0003-2102-6026
FU Ministry of Science and Technology of China [2011ZX09307-001-07];
   Beijing Municipal Science and Technology Commission [Z151100003915126]
FX This work was financially supported by grants from the Ministry of
   Science and Technology of China (2011ZX09307-001-07) and the Beijing
   Municipal Science and Technology Commission (Z151100003915126)
CR Baloh RH, 2007, ARCH NEUROL-CHICAGO, V64, P998, DOI 10.1001/archneur.64.7.998
   Birtel J, 2022, OPHTHALMOL RETINA, V6, P65, DOI 10.1016/j.oret.2021.02.017
   Bostan A, 2012, AUTON NEUROSCI-BASIC, V170, P70, DOI 10.1016/j.autneu.2012.06.002
   Brandt T, 2020, GENET MED, V22, P336, DOI 10.1038/s41436-019-0655-2
   Bugiardini E, 2017, NEUROL-GENET, V3, DOI 10.1212/NXG.0000000000000149
   El-Hattab AW, 2017, BBA-MOL BASIS DIS, V1863, P1539, DOI 10.1016/j.bbadis.2017.02.017
   Farnum GA, 2014, BBA-BIOENERGETICS, V1837, P1113, DOI 10.1016/j.bbabio.2014.01.021
   Finsterer J, 2018, NEUROPEDIATRICS, V49, P231, DOI 10.1055/s-0037-1609039
   Fratter C, 2011, NEUROLOGY, V76, P2032, DOI 10.1212/WNL.0b013e31821e558b
   Fratter C, 2010, NEUROLOGY, V74, P1619, DOI 10.1212/WNL.0b013e3181df099f
   Garone C, 2018, J MED GENET, V55, P515, DOI 10.1136/jmedgenet-2017-105012
   Grady JP, 2014, BRAIN, V137, P323, DOI 10.1093/brain/awt321
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Leng YL, 2015, MITOCHONDR DNA, V26, P208, DOI 10.3109/19401736.2014.905860
   Li H, 2009, BIOINFORMATICS, V25, P1094, DOI [10.1093/bioinformatics/btp100, 10.1093/bioinformatics/btp324]
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Luoma PT, 2005, HUM MOL GENET, V14, P1907, DOI 10.1093/hmg/ddi196
   Martin-Negrier ML, 2011, EUR J NEUROL, V18, P436, DOI 10.1111/j.1468-1331.2010.03171.x
   Nesbitt V, 2014, EUR J HUM GENET, V22, P1255, DOI 10.1038/ejhg.2014.35
   Pitceathly RDS, 2012, BRAIN, V135, P3392, DOI 10.1093/brain/aws231
   Qian YF, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00135
   Rahman S, 2019, NAT REV NEUROL, V15, P40, DOI 10.1038/s41582-018-0101-0
   Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30
   Saneto RP, 2010, SEIZURE-EUR J EPILEP, V19, P140, DOI 10.1016/j.seizure.2010.01.002
   Sarzi E, 2007, ANN NEUROL, V62, P579, DOI 10.1002/ana.21207
   Savard M, 2013, NEUROLOGY, V81, P770, DOI 10.1212/WNL.0b013e3182a1aa78
   Schicks J, 2010, MOVEMENT DISORD, V25, P2678, DOI 10.1002/mds.23286
   Schulte C, 2009, NEUROLOGY, V73, P898, DOI 10.1212/WNL.0b013e3181b78488
   Siibak T, 2017, HUM MOL GENET, V26, P2515, DOI 10.1093/hmg/ddx146
   Sohl CD, 2013, HUM MOL GENET, V22, P1074, DOI 10.1093/hmg/dds509
   Sommerville Ewen W, 2014, J Neuromuscul Dis, V1, P119
   Stumpf JD, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a011395
   Van Goethem G, 2003, EUR J HUM GENET, V11, P547, DOI 10.1038/sj.ejhg.5201002
   Van Maldergem L, 2017, ANN CLIN TRANSL NEUR, V4, P4, DOI 10.1002/acn3.361
   Varma H, 2016, EUR J MED GENET, V59, P540, DOI 10.1016/j.ejmg.2016.08.012
   Viscomi C, 2017, J INHERIT METAB DIS, V40, P587, DOI 10.1007/s10545-017-0027-5
   Vogel AP, 2017, MITOCHONDRION, V37, P1, DOI 10.1016/j.mito.2017.06.002
   Walter MC, 2010, J NEUROL, V257, P1517, DOI 10.1007/s00415-010-5565-9
   Wang JL, 2018, MOL GENET METAB, V124, P124, DOI 10.1016/j.ymgme.2018.04.012
   Woodbridge P, 2013, INTERN MED J, V43, P150, DOI 10.1111/j.1445-5994.2012.02847.x
   Xie ZY, 2019, ORPHANET J RARE DIS, V14, DOI 10.1186/s13023-019-1021-9
   Zhu CC, 2017, OPHTHALMIC GENET, V38, P67, DOI 10.3109/13816810.2015.1130153
NR 43
TC 5
Z9 6
U1 1
U2 5
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2324-9269
J9 MOL GENET GENOM MED
JI Mol. Genet. Genom. Med.
PD MAY
PY 2022
VL 10
IS 5
AR e1921
DI 10.1002/mgg3.1921
EA MAR 2022
PG 12
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 0R7SW
UT WOS:000768646600001
PM 35289132
OA gold, Green Published
DA 2024-11-01
ER

PT J
AU Li, WW
   Zhang, W
   Li, F
   Wang, CL
AF Li, Weiwei
   Zhang, Wei
   Li, Fang
   Wang, Cailing
TI Mitochondrial genetic analysis in a Chinese family suffering from both
   mitochondrial encephalomyopathy with lactic acidosis and stroke-like
   episodes and diabetes
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE Diabetes; A3243G mutation; MELAS; heteroplasmy; polymorphism;
   mitochondrial myopathy
ID MUTATION; MELAS; PHENOTYPE; A3243G
AB To investigate the mitochondrial mutations in patients suffering from both mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS) and maternally inherited diabetes. MELAS was confirmed by muscle biopsy performed from the biceps muscle of the proband. Mitochondrial DNA (mtDNA) was isolated from peripheral blood mononuclear cells. The significant mtDNA loci of other 14 family members were further detected according to the sequencing results of the proband. Direct sequencing of PCR products was used to identify the mitochondrial mutations. The proband (III 1) and her brother (III 3) both harbored the tRNALeu (UUR) A3243G mutation, with heteroplasmic levels of 50% and 33% respectively. Moreover, another two mitochondrial variants, A8860G and A15326G, were also detected in the samples of all the family members. MELAS and diabetes can coexist in one patient, and the main cause for these diseases is the tRNALeu (UUR) A3243G mutation. However, other gene variants may contribute to its pathogenesis. This case also supports the concept that both syndromes can be regarded as two phenotypes of the same disease.
C1 [Li, Weiwei; Zhang, Wei; Li, Fang; Wang, Cailing] Shandong Univ, Qianfoshan Hosp, Dept Endocrinol, Jinan 250014, Peoples R China.
C3 Shandong First Medical University & Shandong Academy of Medical
   Sciences; Shandong University
RP Wang, CL (corresponding author), Shandong Univ, Qianfoshan Hosp, Dept Endocrinol, 66 Jingshi Rd, Jinan 250014, Peoples R China.
EM sdqy.wcl@163.com
FU Natural Science Foundation [ZR2009CQ023]; Medical Science Development
   Plan of Shandong Province, PR China [2009QZ025]
FX We thank the Neuromuscular Pathology Laboratory of Qilu Hospital
   affiliated to Shandong University for detecting muscle pathology. We are
   also grateful to the professors in the Central Laboratory of Shandong
   Provincial Hospital for excellent technical assistance. This research
   was funded by the Natural Science Foundation (grant No. ZR2009CQ023) and
   Medical Science Development Plan (grant No. 2009QZ025) of Shandong
   Province, PR China.
CR Craven L, 2011, HUM MOL GENET, V20, pR168, DOI 10.1093/hmg/ddr373
   de Wit HM, 2012, NETH J MED, V70, P460
   Joko T, 1997, ENDOCR J, V44, P805, DOI 10.1507/endocrj.44.805
   Kara B, 2012, MOL GENET METAB, V107, P389, DOI 10.1016/j.ymgme.2012.06.013
   Liu CH, 2012, J FORMOS MED ASSOC, V111, P489, DOI 10.1016/j.jfma.2011.06.014
   Mezghani N, 2010, J DIABETES COMPLICAT, V24, P270, DOI 10.1016/j.jdiacomp.2009.11.002
   Ohkubo K, 2001, CLIN CHEM, V47, P1641
   Sproule DM, 2008, ANN NY ACAD SCI, V1142, P133, DOI 10.1196/annals.1444.011
   Spyropoulos A, 2013, JAMA NEUROL, V70, P1552, DOI 10.1001/jamaneurol.2013.4111
   Tzen CY, 2003, MUSCLE NERVE, V28, P575, DOI 10.1002/mus.10473
   Wong LJC, 2007, MITOCHONDRION, V7, P45, DOI 10.1016/j.mito.2006.11.025
   Zhang W, 2009, J CELL MOL MED, V13, P4636, DOI 10.1111/j.1582-4934.2008.00670.x
NR 12
TC 8
Z9 9
U1 0
U2 1
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2015
VL 8
IS 6
BP 7022
EP 7027
PG 6
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA CO6PD
UT WOS:000359277700116
PM 26261593
DA 2024-11-01
ER

PT J
AU Arzuffi, P
   Lamperti, C
   Fernandez-Vizarra, E
   Tonin, P
   Morandi, L
   Zeviani, M
AF Arzuffi, Paola
   Lamperti, Costanza
   Fernandez-Vizarra, Erika
   Tonin, Paola
   Morandi, Lucia
   Zeviani, Massimo
TI Partial tandem duplication of mtDNA-tRNA<SUP>Phe</SUP> impairs mtDNA
   translation in late-onset mitochondrial myopathy
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE Mitochondrial myopathy; Oxidative phosphorylation; mtDNA; Cytochrome c
   oxidase; mtDNA translation; mtDNA mutation
ID INCLUSION-BODY MYOPATHY; MUTATION; TRANSCRIPTION; CELLS; GENE; DNA
AB An 80-year-old woman (PI) has been suffering of late onset progressive weakness and wasting of lower-limb muscles, accompanied by high creatine kinase levels in blood. A muscle biopsy, performed at 63 years, showed myopathic features with partial deficiency of cytochrome c oxidase. A second biopsy taken 7 years later confirmed the presence of a mitochondria' myopathy but also of vacuolar degeneration and other morphological features resembling inclusion body myopathy. Her 46-year-old daughter (PII) and 50-year-old son (PIII) are clinically normal, but the creatine kinase levels were moderately elevated and the EMG was consistently myopathic in both. Analysis of mitochondria' DNA sequence revealed in all three patients a novel, homoplasmic 15 bp tandem duplication adjacent to the 5' end of mitochondrial tRNA(Phe) gene, encompassing the first 11 nucleotides of this gene and the four terminal nucleotides of the adjacent D-loop region. Both mutant fibroblasts and cybrids showed low oxygen consumption rate, reduced mitochondria' protein synthesis, and decreased mitochondrial tRNA(Phe) amount. These findings are consistent with an unconventional pathogenic mechanism causing the tandem duplication to interfere with the maturation of the mitochondrial tRNA(Phe) transcript. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Arzuffi, Paola; Lamperti, Costanza; Zeviani, Massimo] Carlo Besta Neurol Inst Fdn IRCCS, Unit Mol Neurogenet, I-20126 Milan, Italy.
   [Fernandez-Vizarra, Erika] Hosp Univ Miguel Servet, Inst Aragones Ciencias Salud, Unidad Invest Translac, Zaragoza, Spain.
   [Tonin, Paola] Univ Verona, Dipartimento Sci Neurol Neuropsicol Morfol & Moto, I-37100 Verona, Italy.
   [Morandi, Lucia] Carlo Besta Neurol Inst Fdn IRCCS, Unit Neuromuscular & Neuroinflammatory Disorders, I-20126 Milan, Italy.
C3 Fondazione IRCCS Istituto Neurologico Carlo Besta; Miguel Servet
   University Hospital; University of Verona; Fondazione IRCCS Istituto
   Neurologico Carlo Besta
RP Zeviani, M (corresponding author), Carlo Besta Neurol Inst Fdn IRCCS, Unit Mol Neurogenet, Via Temolo 4, I-20126 Milan, Italy.
EM zeviani@istituto-besta.it
RI lamperti, costanza/J-8801-2016; Fernandez-Vizarra, Erika/AAE-5600-2020;
   Zeviani, Massimo/K-2891-2014; Tonin, Paola/AAC-5052-2022
OI Fernandez-Vizarra, Erika/0000-0002-2469-142X; Zeviani,
   Massimo/0000-0002-9067-5508
FU Pierfranco and Luisa Mariani Foundation Italy, Ricerca; Fondazione
   Giuseppe Tomasello ONLUS; Fondazione MitoCon ONLUS; Fondazione
   Telethon-Italy [GGP07019, GPP10005]
FX This work was supported by the Pierfranco and Luisa Mariani Foundation
   Italy, Ricerca 2000; Fondazione Giuseppe Tomasello ONLUS and Fondazione
   MitoCon ONLUS; and Fondazione Telethon-Italy grants number GGP07019 and
   GPP10005, to MZ.
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Bersano A, 2009, NEUROBIOL AGING, V30, P752, DOI 10.1016/j.neurobiolaging.2007.08.009
   Bugiani M, 2004, BBA-BIOENERGETICS, V1659, P136, DOI 10.1016/j.bbabio.2004.09.006
   Chomyn A, 1996, Methods Enzymol, V264, P197, DOI 10.1016/S0076-6879(96)64020-8
   Del Bo R, 2003, MUSCLE NERVE, V28, P113, DOI 10.1002/mus.10391
   Enriquez J A, 1996, Methods Enzymol, V264, P183, DOI 10.1016/S0076-6879(96)64019-1
   Enriquez JA, 1996, P NATL ACAD SCI USA, V93, P8300, DOI 10.1073/pnas.93.16.8300
   Fernández-Vizarra E, 2002, METHODS, V26, P292, DOI 10.1016/S1046-2023(02)00034-8
   HECKMATT JZ, 1984, MUSCLE NERVE, V7, P594
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   MONTOYA J, 1983, CELL, V34, P151, DOI 10.1016/0092-8674(83)90145-9
   MONTOYA J, 1982, P NATL ACAD SCI-BIOL, V79, P7195, DOI 10.1073/pnas.79.23.7195
   OJALA D, 1981, NATURE, V290, P470, DOI 10.1038/290470a0
   OJALA D, 1980, CELL, V22, P393, DOI 10.1016/0092-8674(80)90350-5
   Oldfors A, 2006, NEUROLOGY, V66, pS49, DOI 10.1212/01.wnl.0000192127.63013.8d
   Sciacco M, 1996, Methods Enzymol, V264, P509, DOI 10.1016/S0076-6879(96)64045-2
   Shutt TE, 2010, ENVIRON MOL MUTAGEN, V51, P360, DOI 10.1002/em.20571
   Wu M, 2007, AM J PHYSIOL-CELL PH, V292, pC125, DOI 10.1152/ajpcell.00247.2006
   Yasukawa T, 2000, NUCLEIC ACIDS RES, V28, P3779, DOI 10.1093/nar/28.19.3779
   YOKOBORI S, 1995, P NATL ACAD SCI USA, V92, P10432, DOI 10.1073/pnas.92.22.10432
NR 20
TC 2
Z9 3
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD JAN
PY 2012
VL 22
IS 1
BP 50
EP 55
DI 10.1016/j.nmd.2011.07.009
PG 6
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 901ZW
UT WOS:000301009400007
PM 22227277
OA Green Published, Bronze
DA 2024-11-01
ER

PT J
AU Wang, W
   Zhuang, QQ
   Ji, KQ
   Wen, B
   Lin, PF
   Zhao, YY
   Li, W
   Yan, CZ
AF Wang, Wei
   Zhuang, Qianqian
   Ji, Kunqian
   Wen, Bing
   Lin, Pengfei
   Zhao, Yuying
   Li, Wei
   Yan, Chuanzhu
TI Identification of miRNA, lncRNA and mRNA-associated ceRNA networks and
   potential biomarker for MELAS with mitochondrial DNA A3243G mutation
SO SCIENTIFIC REPORTS
LA English
DT Article
ID LONG NONCODING RNA; MICRORNAS; APOPTOSIS; CARDIOMYOCYTES; ACTIVATION;
   COMPLEXITY; AUTOPHAGY; NUCLEAR; PATHWAY; DISEASE
AB Researchers in the field of mitochondrial biology are increasingly unveiling of the complex mechanisms between mitochondrial dysfunction and noncoding RNAs (ncRNAs). However, roles of ncRNAs underlying mitochondrial myopathy remain unexplored. The aim of this study was to elucidate the regulating networks of dysregulated ncRNAs in Mitochondrial myopathy, Encephalopathy, Lactic Acidosis, and Stroke-like episodes (MELAS) with mitochondrial DNA (mtDNA) A3243G mutation, which might make contributions to the unveiling of the complex mechanisms underlying mitochondrial myopathy and, possibly, new tools applicable to clinical practice. Through high-throughput technology followed by quantitative real-time polymerase chain reaction (qRT-PCR) and bioinformatics analyses, for the first time, we found that the dysregulated muscle miRNAs and lncRNAs between 20 MELAS patients with mtDNA A3243G mutation and 20 controls formed complex regulation networks and participated in immune system, signal transduction, translation, muscle contraction and other pathways in discovery and training phase. Then, selected ncRNAs were validated in muscle and serum in independent validation cohorts by qRT-PCR. Finally, ROC curve analysis indicated reduced serum miR-27b-3p had the better diagnosis value than lactate and might serve as a novel, noninvasive biomarker for MELAS. Follow-up investigation is warranted to better understand roles of ncRNAs in mitochondrial myopathy pathogenesis.
C1 [Wang, Wei; Ji, Kunqian; Wen, Bing; Lin, Pengfei; Zhao, Yuying; Li, Wei; Yan, Chuanzhu] Shandong Univ, Qilu Hosp, Lab Neuromuscular Disorders, Jinan, Peoples R China.
   [Wang, Wei; Ji, Kunqian; Wen, Bing; Lin, Pengfei; Zhao, Yuying; Li, Wei; Yan, Chuanzhu] Shandong Univ, Qilu Hosp, Dept Neurol, Jinan, Peoples R China.
   [Zhuang, Qianqian] Qilu Univ Technol, Sch Bioengn, Jinan, Peoples R China.
   [Yan, Chuanzhu] Shandong Univ, Qilu Hosp, Key Lab Expt Teratol, Minist Educ,Brain Sci Res Inst,Dept Neurol, Jinan, Peoples R China.
C3 Shandong University; Shandong University; Qilu University of Technology;
   Shandong University
RP Yan, CZ (corresponding author), Shandong Univ, Qilu Hosp, Lab Neuromuscular Disorders, Jinan, Peoples R China.; Yan, CZ (corresponding author), Shandong Univ, Qilu Hosp, Dept Neurol, Jinan, Peoples R China.
EM chuanzhuyan@163.com
FU National Natural Science Foundation of China [81300983, 81301071,
   81671235]
FX This work was supported in part by grants from the National Natural
   Science Foundation of China (81300983, 81301071 and 81671235).
CR Aurora AB, 2012, J CLIN INVEST, V122, P1222, DOI 10.1172/JCI59327
   Bi R, 2015, BIOCHEM BIOPH RES CO, V460, P469, DOI 10.1016/j.bbrc.2015.03.057
   Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185
   Bucha S, 2015, BIOCHEM BIOPH RES CO, V465, P797, DOI 10.1016/j.bbrc.2015.08.090
   Cha MJ, 2013, BIOCHEM BIOPH RES CO, V435, P720, DOI 10.1016/j.bbrc.2013.05.050
   Crimi M, 2005, FASEB J, V19, P866, DOI 10.1096/fj.04-3045fje
   Dharap A, 2009, J CEREBR BLOOD F MET, V29, P675, DOI 10.1038/jcbfm.2008.157
   Duarte FV, 2015, ADV EXP MED BIOL, V888, P123, DOI 10.1007/978-3-319-22671-2_8
   Finsterer J, 2007, ACTA NEUROL SCAND, V116, P1, DOI 10.1111/j.1600-0404.2007.00836.x
   Friedländer MR, 2014, GENOME BIOL, V15, DOI 10.1186/gb-2014-15-4-r57
   Gorman GS, 2015, ANN NEUROL, V77, P753, DOI 10.1002/ana.24362
   Kalko SG, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-91
   Hangauer MJ, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003569
   Hu Y, 2015, INT J MOL SCI, V16, P24895, DOI 10.3390/ijms161024895
   Huang SY, 2015, AUTOPHAGY, V11, P2172, DOI 10.1080/15548627.2015.1106663
   Johnson SC, 2017, HUM GENET, V136, P55, DOI 10.1007/s00439-016-1736-9
   Kim J, 2016, MOL NEURODEGENER, V11, DOI 10.1186/s13024-016-0121-4
   Lambertini Luca, 2016, Curr Environ Health Rep, V3, P214, DOI 10.1007/s40572-016-0103-2
   Lang A, 2016, AGING-US, V8, P484, DOI 10.18632/aging.100905
   Lee YE, 2015, INT J BIOL SCI, V11, P246, DOI 10.7150/ijbs.11138
   Li HJ, 2015, JPN J CLIN ONCOL, V45, P1055, DOI 10.1093/jjco/hyv132
   Li RW, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029392
   Lightowlers RN, 2015, SCIENCE, V349, P1494, DOI 10.1126/science.aac7516
   Liu F, 2016, ONCOTARGET, V7, P19666, DOI 10.18632/oncotarget.7531
   Maass PG, 2014, J MOL MED, V92, P337, DOI 10.1007/s00109-014-1131-8
   Morris KV, 2014, NAT REV GENET, V15, P423, DOI 10.1038/nrg3722
   Nie Y., 2016, FASEB J OFFICIAL PUB
   Niyazov D. M., MOL SYNDROMOLOGY, V7, P122
   Noh JH, 2016, GENE DEV, V30, P1224, DOI 10.1101/gad.276022.115
   Picard M, 2016, MITOCHONDRION, V30, P105, DOI 10.1016/j.mito.2016.07.003
   Rastogi N, 2014, FREE RADICAL BIO MED, V68, P288, DOI 10.1016/j.freeradbiomed.2013.12.016
   Smith PG, 2005, BLOOD, V105, P308, DOI 10.1182/blood-2004-01-0240
   Sripada L, 2012, MITOCHONDRION, V12, P593, DOI 10.1016/j.mito.2012.10.009
   Stadler PF, 2014, METHODS MOL BIOL, V1097, P199, DOI 10.1007/978-1-62703-709-9_10
   Tay Y, 2014, NATURE, V505, P344, DOI 10.1038/nature12986
   Tomasetti M, 2014, BBA-GEN SUBJECTS, V1840, P1441, DOI 10.1016/j.bbagen.2013.09.002
   van Rooij E, 2008, P NATL ACAD SCI USA, V105, P13027, DOI 10.1073/pnas.0805038105
   Walker UA, 1996, EUR NEUROL, V36, P260, DOI 10.1159/000117269
   Wang K, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004467
   Wang K, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4596
   Wang WX, 2015, EXP NEUROL, V265, P84, DOI 10.1016/j.expneurol.2014.12.018
   Yao DH, 2016, CELL PROLIFERAT, V49, P541, DOI 10.1111/cpr.12277
   Ye YM, 2011, PHYSIOL GENOMICS, V43, P534, DOI 10.1152/physiolgenomics.00130.2010
   Zeng XC, 2016, MOL MED REP, V14, P129, DOI 10.3892/mmr.2016.5208
   Zhang Z, 2014, METHODS, V69, P315, DOI 10.1016/j.ymeth.2014.06.003
   Zhang Z, 2014, INT J BIOCHEM CELL B, V50, P106, DOI 10.1016/j.biocel.2014.02.012
   Zhang Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069282
   Zhao XM, 2016, PEERJ, V4, DOI 10.7717/peerj.1635
   Zhou XH, 2015, J PHYSIOL BIOCHEM, V71, P753, DOI 10.1007/s13105-015-0439-3
   Zhu Qi, 2007, V382, P287, DOI 10.1007/978-1-59745-304-2_19
NR 50
TC 34
Z9 36
U1 0
U2 19
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JAN 31
PY 2017
VL 7
AR 41639
DI 10.1038/srep41639
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EJ3EL
UT WOS:000393095300002
PM 28139706
OA Green Published, gold
DA 2024-11-01
ER

PT J
AU Kripps, KA
   Friederich, MW
   Chen, T
   Larson, AA
   Mirsky, DM
   Wang, Y
   Tanji, K
   Knight, KM
   Wong, LJ
   Van Hove, JLK
AF Kripps, Kimberly A.
   Friederich, Marisa W.
   Chen, Ting
   Larson, Austin A.
   Mirsky, David M.
   Wang, Yue
   Tanji, Kurenai
   Knight, Kaz M.
   Wong, Lee-Jun
   Van Hove, Johan L. K.
TI A novel acceptor stem variant in mitochondrial tRNA<SUP>Tyr</SUP>
   impairs mitochondrial translation and is associated with a severe
   phenotype
SO MOLECULAR GENETICS AND METABOLISM
LA English
DT Article
DE Mitochondrial tRNA; Mt-tRNA(Tyr); Multisystem mitochondrial disorder;
   Neurodegenerative disorder; Mitochondrial translation disorder;
   Pathogenicity of mtDNA variants
ID TRANSFER-RNA; MUTATION; GENE; FEATURES; DISEASE; MELAS
AB Genetic defects in mitochondrial DNA encoded tRNA genes impair mitochondrial translation with resultant defects in the mitochondrial respiratory chain and oxidative phosphorylation system. The phenotypic spectrum of disease seen in mitochondrial tRNA defects is variable and proving pathogenicity of new variants is challenging. Only three pathogenic variants have been described previously in the mitochondrial tRNA(Tyr) gene MT-TY, with the reported phenotypes consisting largely of adult onset myopathy and ptosis. We report a patient with a novel MT-TY acceptor stem variant m.5889A>G at high heteroplasmy in muscle, low in blood, and absent in the mother's blood. The phenotype consisted of a childhood-onset severe multi-system disorder characterized by a neurodegenerative course including ataxia and seizures, failure-to-thrive, combined myopathy and neuropathy, and hearing and vision loss. Brain imaging showed progressive atrophy and basal ganglia calcifications. Mitochondrial biomarkers lactate and GDF15 were increased. Functional studies showed a deficient activity of the respiratory chain enzyme complexes containing mtDNA-encoded subunits I, III and IV. There were decreased steady state levels of these mitochondrial complex proteins, and presence of incompletely assembled complex V forms in muscle. These changes are typical of a mitochondrial translational defect. These data support the pathogenicity of this novel variant. Careful review of variants in MT-TY additionally identified two other pathogenic variants, one likely pathogenic variant, nine variants of unknown significance, five likely benign and four benign variants. (C) 2020 Elsevier Inc. All rights reserved.
C1 [Kripps, Kimberly A.; Friederich, Marisa W.; Larson, Austin A.; Knight, Kaz M.; Van Hove, Johan L. K.] Univ Colorado, Dept Pediat, Sect Clin Genet & Metab, Educ 2 South,L28-4114 13121 East 17th Ave, Aurora, CO 80045 USA.
   [Friederich, Marisa W.; Van Hove, Johan L. K.] Childrens Hosp Colorado, Dept Pathol & Lab Med, 13121 East 16th Ave, Aurora, CO USA.
   [Chen, Ting; Wang, Yue; Wong, Lee-Jun] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
   [Chen, Ting] Soochow Univ, Dept Endocrinol Genet & Metab, Childrens Hosp, Suzhou, Peoples R China.
   [Mirsky, David M.] Univ Colorado, Dept Radiol, Aurora, CO 80045 USA.
   [Mirsky, David M.] Childrens Hosp Colorado, Aurora, CO USA.
   [Tanji, Kurenai] Columbia Univ, Div Neuropathol, Med Ctr, New York, NY USA.
   [Kripps, Kimberly A.] Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97201 USA.
C3 University of Colorado System; University of Colorado Anschutz Medical
   Campus; Children's Hospital Colorado; Baylor College of Medicine;
   Soochow University - China; University of Colorado System; University of
   Colorado Anschutz Medical Campus; Children's Hospital Colorado; Columbia
   University; Oregon Health & Science University
RP Van Hove, JLK (corresponding author), Univ Colorado, Dept Pediat, Sect Clin Genet & Metab, Educ 2 South,L28-4114 13121 East 17th Ave, Aurora, CO 80045 USA.
EM Johan.Vanhove@childrenscolorado.org
RI Larson, Austin/AAN-8673-2021
FU Children's Hospital Colorado Foundation; National Institutes of Health
   [NIH U54NS078059]; NCATS; NIH/NCATS Colorado CTSA Grant [UL1 TR002535]
FX Financial support for this study was received from Children's Hospital
   Colorado Foundation, Summits for Samantha and Miracles for Mito (JVH,
   MWF, KK). JVH, KK, and MWF are supported by a grant from the National
   Institutes of Health, NIH U54NS078059 for the North
   AmericanMitochondrial Disease Consortium (NAMDC). NAMDC is part of the
   Rare Diseases Clinical Research Network (RDCRN), an initiative of the
   Office of Rare Diseases Research (ORDR), NCATS. This consortium is
   funded through a collaboration with NCATS. The study was also supported
   by NIH/NCATS Colorado CTSA Grant Number UL1 TR002535. Contents are the
   authors' sole responsibility and do not necessarily represent official
   NIH views. Funding sources had no role in the design or execution of the
   study, the interpretation of data, or the writing of the study.
CR Abbott JA, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00158
   Barca E, 2020, NEUROL-GENET, V6, DOI 10.1212/NXG.0000000000000402
   Bohnsack MT, 2018, CELL MOL LIFE SCI, V75, P241, DOI 10.1007/s00018-017-2598-6
   Chatfield KC, 2015, MITOCHONDRION, V21, P1, DOI 10.1016/j.mito.2014.12.005
   Coughlin CR, 2015, J MED GENET, V52, P532, DOI 10.1136/jmedgenet-2015-103049
   Finsterer J, 2005, METAB BRAIN DIS, V20, P219, DOI 10.1007/s11011-005-7209-9
   Friederich MW, 2017, HUM MOL GENET, V26, P702, DOI 10.1093/hmg/ddw431
   Kirino Y, 2004, P NATL ACAD SCI USA, V101, P15070, DOI 10.1073/pnas.0405173101
   Kornblum C, 2008, BIOSCIENCE REP, V28, P89, DOI 10.1042/BSR20080004
   MORAES CT, 1992, AM J HUM GENET, V50, P934
   Ng YS, 2016, NEUROMUSCULAR DISORD, V26, P702, DOI 10.1016/j.nmd.2016.08.009
   Pulkes T, 2000, NEUROLOGY, V55, P1210, DOI 10.1212/WNL.55.8.1210
   Raffelsberger T, 2001, NEUROLOGY, V57, P2298, DOI 10.1212/WNL.57.12.2298
   Rebelo-Guiomar P, 2019, BBA-GENE REGUL MECH, V1862, P429, DOI 10.1016/j.bbagrm.2018.11.005
   Richter U, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06471-z
   Sahashi K, 2001, J MED GENET, V38, P703, DOI 10.1136/jmg.38.10.703
   Scaglia F, 2003, AM J MED GENET A, V123A, P172, DOI 10.1002/ajmg.a.20315
   Scaglia F, 2008, MUSCLE NERVE, V37, P150, DOI 10.1002/mus.20917
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   Simoncini C, 2018, CASE REP NEUROL MED, V2018, DOI 10.1155/2018/8406712
   Smet J, 2009, ELECTROPHORESIS, V30, P3565, DOI 10.1002/elps.200900213
   Sonney S, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005867
   Sue CM, 1998, J NEUROL NEUROSUR PS, V65, P233, DOI 10.1136/jnnp.65.2.233
   Tanji K, 2012, METHODS MOL BIOL, V837, P181, DOI 10.1007/978-1-61779-504-6_12
   Wei FY, 2015, CELL METAB, V21, P428, DOI 10.1016/j.cmet.2015.01.019
   Wong LJC, 2020, GENET MED, DOI 10.1038/s41436-019-0746-0
   Zeviani M, 2004, BRAIN, V127, P2153, DOI 10.1093/brain/awh259
   Zhang W, 2012, CLIN CHEM, V58, P1322, DOI 10.1373/clinchem.2011.181438
NR 28
TC 2
Z9 2
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1096-7192
EI 1096-7206
J9 MOL GENET METAB
JI Mol. Genet. Metab.
PD DEC
PY 2020
VL 131
IS 4
BP 398
EP 404
DI 10.1016/j.ymgme.2020.11.006
PG 7
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental
   Medicine
GA PH7WV
UT WOS:000600618800005
PM 33279411
OA Green Accepted
DA 2024-11-01
ER

PT J
AU Stewart, JB
   Chinnery, PF
AF Stewart, James B.
   Chinnery, Patrick F.
TI Extreme heterogeneity of human mitochondrial DNA from organelles to
   populations
SO NATURE REVIEWS GENETICS
LA English
DT Review
ID MTDNA HETEROPLASMY; NATURAL-SELECTION; POINT MUTATIONS; GENETIC
   BOTTLENECK; RAPID SEGREGATION; SUBSTANTIA-NIGRA; SKELETAL-MUSCLE;
   IN-VIVO; GENOME; EVOLUTION
AB Contrary to the long-held view that most humans harbour only identical mitochondrial genomes, deep resequencing has uncovered unanticipated extreme genetic variation within mitochondrial DNA (mtDNA). Most, if not all, humans contain multiple mtDNA genotypes (heteroplasmy); specific patterns of variants accumulate in different tissues, including cancers, over time; and some variants are preferentially passed down or suppressed in the maternal germ line. These findings cast light on the origin and spread of mtDNA mutations at multiple scales, from the organelle to the human population, and challenge the conventional view that high percentages of a mutation are required before a new variant has functional consequences.
   Deep resequencing has revealed extreme genetic variation in mitochondrial genomes at multiple levels. This heterogeneity has implications for the origins of human mitochondrial DNA mutations as well as their impact on rare and common human diseases, including cancer.
C1 [Stewart, James B.] Max Planck Inst Biol Ageing, Cologne, Germany.
   [Stewart, James B.] Newcastle Univ, Fac Med Sci, Biosci Inst, Wellcome Ctr Mitochondrial Res, Newcastle Upon Tyne, Tyne & Wear, England.
   [Chinnery, Patrick F.] Univ Cambridge, Dept Clin Neurosci, Cambridge, England.
   [Chinnery, Patrick F.] Univ Cambridge, Med Res Council, Mitochondrial Biol Unit, Cambridge, England.
C3 Max Planck Society; Newcastle University - UK; University of Cambridge;
   UK Research & Innovation (UKRI); Medical Research Council UK (MRC);
   University of Cambridge
RP Chinnery, PF (corresponding author), Univ Cambridge, Dept Clin Neurosci, Cambridge, England.; Chinnery, PF (corresponding author), Univ Cambridge, Med Res Council, Mitochondrial Biol Unit, Cambridge, England.
EM pfc25@cam.ac.uk
RI Stewart, Jim/C-9633-2011
OI Stewart, Jim/0000-0002-2902-4968; Chinnery, Patrick/0000-0002-7065-6617
FU Max Planck Society; United Mitochondrial Disease Foundation; UK Medical
   Research Council Mitochondrial Biology Unit [MC_UU_00015/9]; Medical
   Research Council International Centre for Genomic Medicine in
   Neuromuscular Disease; Leverhulme Trust [RPG-2018-408]; NIHR Biomedical
   Research Centre based at Cambridge University Hospitals NHS Foundation
   Trust; NIHR Biomedical Research Centre based at University of Cambridge
FX J.B.S. is supported by the Max Planck Society and a project grant from
   the United Mitochondrial Disease Foundation. P.F.C. is a Wellcome Trust
   Principal Research Fellow (212219/Z/18/Z) and a UK National Institute
   for Health Research (NIHR) Senior Investigator, who receives support
   from the UK Medical Research Council Mitochondrial Biology Unit
   (MC_UU_00015/9), the Medical Research Council International Centre for
   Genomic Medicine in Neuromuscular Disease, the Leverhulme Trust
   (RPG-2018-408) and the NIHR Biomedical Research Centre based at
   Cambridge University Hospitals NHS Foundation Trust and the University
   of Cambridge. The views expressed are those of the author(s) and not
   necessarily those of the NHS, the NIHR or the UK Department of Health
   and Social Care.
CR Albayrak L, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-3375-x
   Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477
   Ameur A, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002028
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Antonicka H, 2020, CELL METAB, V32, P479, DOI 10.1016/j.cmet.2020.07.017
   Bacman SR, 2018, NAT MED, V24, P1696, DOI 10.1038/s41591-018-0166-8
   Barrett A, 2020, PHILOS T R SOC B, V375, DOI 10.1098/rstb.2019.0175
   Battersby BJ, 2003, NAT GENET, V33, P183, DOI 10.1038/ng1073
   Baudouin SV, 2005, LANCET, V366, P2118, DOI 10.1016/S0140-6736(05)67890-7
   Bendall KE, 1996, AM J HUM GENET, V59, P1276
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   BEZIAT F, 1993, NUCLEIC ACIDS RES, V21, P387, DOI 10.1093/nar/21.3.387
   BIRKY CW, 1994, J HERED, V85, P355, DOI 10.1093/oxfordjournals.jhered.a111480
   Blier PU, 2001, TRENDS GENET, V17, P400, DOI 10.1016/S0168-9525(01)02338-1
   Bogenhagen DF, 2012, BBA-GENE REGUL MECH, V1819, P914, DOI 10.1016/j.bbagrm.2011.11.005
   BOULET L, 1992, AM J HUM GENET, V51, P1187
   Burgstaller JP, 2014, CELL REP, V7, P2031, DOI 10.1016/j.celrep.2014.05.020
   Burr SP, 2018, DEV GROWTH DIFFER, V60, P21, DOI 10.1111/dgd.12420
   Cai N, 2015, CURR BIOL, V25, P3170, DOI 10.1016/j.cub.2015.10.065
   Calvignac S, 2011, MITOCHONDRION, V11, P246, DOI 10.1016/j.mito.2010.10.004
   Calvo SE, 2016, NUCLEIC ACIDS RES, V44, pD1251, DOI 10.1093/nar/gkv1003
   Calvo SE, 2010, ANNU REV GENOM HUM G, V11, P25, DOI 10.1146/annurev-genom-082509-141720
   Camus MF, 2012, CURR BIOL, V22, P1717, DOI 10.1016/j.cub.2012.07.018
   CANN RL, 1984, GENETICS, V106, P479
   Chan DC, 2020, ANNU REV PATHOL-MECH, V15, P235, DOI 10.1146/annurev-pathmechdis-012419-032711
   Chandel NS, 2015, CELL METAB, V22, P204, DOI 10.1016/j.cmet.2015.05.013
   Chinnery PF, 2010, LANCET NEUROL, V9, P498, DOI 10.1016/S1474-4422(10)70083-1
   Chinnery PF, 1999, AM J HUM GENET, V64, P1158, DOI 10.1086/302311
   Chinnery PF, 2002, LANCET, V360, P1323, DOI 10.1016/S0140-6736(02)11310-9
   Chinnery PF, 2000, TRENDS GENET, V16, P500, DOI 10.1016/S0168-9525(00)02120-X
   Clark KM, 1997, NAT GENET, V16, P222, DOI 10.1038/ng0797-222
   Cree LM, 2008, NAT GENET, V40, P249, DOI 10.1038/ng.2007.63
   Davis AF, 1996, J CELL BIOL, V135, P883, DOI 10.1083/jcb.135.4.883
   Dayama G, 2014, NUCLEIC ACIDS RES, V42, P12640, DOI 10.1093/nar/gku1038
   De Stordeur E, 1997, HEREDITY, V79, P615, DOI 10.1038/sj.hdy.6882760
   Diaz F, 2002, NUCLEIC ACIDS RES, V30, P4626, DOI 10.1093/nar/gkf602
   Dou XY, 2019, GENOME RES, V29, P1622, DOI 10.1101/gr.234021.117
   Douvlataniotis K, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aay3335
   Ellison CK, 2008, J EVOLUTION BIOL, V21, P1844, DOI 10.1111/j.1420-9101.2008.01608.x
   Faith JJ, 2003, GENETICS, V165, P735
   Fan L., 2019, PREPRINT, DOI [10.1101/715870, DOI 10.1101/715870]
   Fan WW, 2008, SCIENCE, V319, P958, DOI 10.1126/science.1147786
   Floros VI, 2018, NAT CELL BIOL, V20, P144, DOI 10.1038/s41556-017-0017-8
   Fonseca MM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106654
   Freyer C, 2012, NAT GENET, V44, P1282, DOI 10.1038/ng.2427
   Fu K, 1996, HUM MOL GENET, V5, P1835, DOI 10.1093/hmg/5.11.1835
   Gammage PA, 2018, NAT MED, V24, P1691, DOI 10.1038/s41591-018-0165-9
   Giorgi C, 2018, NAT REV MOL CELL BIO, V19, P713, DOI 10.1038/s41580-018-0052-8
   Gitschlag BL, 2016, CELL METAB, V24, P91, DOI 10.1016/j.cmet.2016.06.008
   Giuliani C, 2014, AGING-US, V6, P454, DOI 10.18632/aging.100661
   Gómez-Durán A, 2012, BBA-MOL BASIS DIS, V1822, P1216, DOI 10.1016/j.bbadis.2012.04.014
   Gómez-Durán A, 2010, HUM MOL GENET, V19, P3343, DOI 10.1093/hmg/ddq246
   Gorman GS, 2015, ANN NEUROL, V77, P753, DOI 10.1002/ana.24362
   Grandhi S, 2017, HUM MOL GENET, V26, P2912, DOI 10.1093/hmg/ddx172
   Gray MW, 2015, P NATL ACAD SCI USA, V112, P10133, DOI 10.1073/pnas.1421379112
   GROSS NJ, 1969, J BIOL CHEM, V244, P1552
   Guyatt AL, 2019, HUM GENOMICS, V13, DOI 10.1186/s40246-018-0190-2
   Hao ZY, 2020, MOL CELL, V78, P382, DOI 10.1016/j.molcel.2020.02.018
   HAUSWIRTH WW, 1982, P NATL ACAD SCI-BIOL, V79, P4686, DOI 10.1073/pnas.79.15.4686
   Hauswith W.W., 1985, ACHIEVEMENTS PERSPEC, VII, P49
   Hazkani-Covo E, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000834
   He YP, 2010, NATURE, V464, P610, DOI 10.1038/nature08802
   Hellebrekers DMEI, 2012, HUM REPROD UPDATE, V18, P341, DOI 10.1093/humupd/dms008
   Holt IJ, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a012971
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Howell N, 2003, AM J HUM GENET, V72, P659, DOI 10.1086/368264
   Hudson G, 2019, NATURE, V574, pE8, DOI 10.1038/s41586-019-1623-3
   Hudson G, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004369
   Hudson G, 2013, NEUROLOGY, V80, P2042, DOI 10.1212/WNL.0b013e318294b434
   Hübner A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47570-1
   Hyslop LA, 2016, NATURE, V534, P383, DOI [10.1038/nature183030, 10.1038/nature18303]
   Innocenti P, 2011, SCIENCE, V332, P845, DOI 10.1126/science.1201157
   James AC, 2003, GENETICS, V164, P187
   Jenuth JP, 1996, NAT GENET, V14, P146, DOI 10.1038/ng1096-146
   Ji FY, 2012, P NATL ACAD SCI USA, V109, P7391, DOI 10.1073/pnas.1202484109
   Johnston IG, 2015, ELIFE, V4, DOI 10.7554/eLife.07464
   Jokinen R, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001161
   Ju YS, 2014, ELIFE, V3, DOI 10.7554/eLife.02935
   Just RS, 2014, P NATL ACAD SCI USA, V111, pE4546, DOI 10.1073/pnas.1413478111
   Kang EJ, 2016, NATURE, V540, P270, DOI 10.1038/nature20592
   Kauppila JHK, 2018, NUCLEIC ACIDS RES, V46, P6642, DOI 10.1093/nar/gky456
   Kauppila JHK, 2016, CELL REP, V16, P2980, DOI 10.1016/j.celrep.2016.08.037
   Kennedy SR, 2014, NAT PROTOC, V9, P2586, DOI 10.1038/nprot.2014.170
   Kennedy SR, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003794
   Kivisild T, 2006, GENETICS, V172, P373, DOI 10.1534/genetics.105.043901
   Klucnika A, 2019, OPEN BIOL, V9, DOI 10.1098/rsob.180267
   Kraja AT, 2019, AM J HUM GENET, V104, P112, DOI 10.1016/j.ajhg.2018.12.001
   Krasich R, 2017, FRONT BIOSCI-LANDMRK, V22, P692, DOI 10.2741/4510
   Kühl I, 2014, NATURE, V514, pE7, DOI 10.1038/nature13690
   Kukat C, 2015, P NATL ACAD SCI USA, V112, P11288, DOI 10.1073/pnas.1512131112
   Lahti DC, 2009, TRENDS ECOL EVOL, V24, P487, DOI 10.1016/j.tree.2009.03.010
   Latorre-Pellicer A, 2019, CELL METAB, V30, P1120, DOI 10.1016/j.cmet.2019.09.007
   Latorre-Pellicer A, 2016, NATURE, V535, P561, DOI 10.1038/nature18618
   Lee HS, 2012, CELL REP, V1, P506, DOI 10.1016/j.celrep.2012.03.011
   Li MK, 2016, GENOME RES, V26, P417, DOI 10.1101/gr.203216.115
   Li MK, 2015, P NATL ACAD SCI USA, V112, P2491, DOI 10.1073/pnas.1419651112
   Li MK, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks499
   Li MK, 2010, AM J HUM GENET, V87, P237, DOI 10.1016/j.ajhg.2010.07.014
   Lieber T, 2019, NATURE, V570, P380, DOI 10.1038/s41586-019-1213-4
   Lin YF, 2016, NATURE, V533, P416, DOI 10.1038/nature17989
   Lorente L, 2016, J CRIT CARE, V33, P95, DOI 10.1016/j.jcrc.2016.02.003
   Lorente L, 2012, CRIT CARE, V16, DOI 10.1186/cc11150
   Luo SY, 2018, P NATL ACAD SCI USA, V115, P13039, DOI 10.1073/pnas.1810946115
   Ma HS, 2016, NAT GENET, V48, P798, DOI 10.1038/ng.3587
   Martijn J, 2018, NATURE, V557, P101, DOI 10.1038/s41586-018-0059-5
   Maude H, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00201
   McManus MJ, 2019, CELL METAB, V29, P78, DOI 10.1016/j.cmet.2018.08.002
   Mechta M, 2017, FRONT GENET, V8, DOI 10.3389/fgene.2017.00166
   Meirelles FV, 1997, GENETICS, V145, P445
   Milot E, 2017, NAT ECOL EVOL, V1, P1400, DOI 10.1038/s41559-017-0276-6
   Mishmar D, 2003, P NATL ACAD SCI USA, V100, P171, DOI 10.1073/pnas.0136972100
   Mok BY, 2020, NATURE, V583, P631, DOI 10.1038/s41586-020-2477-4
   Mossman JA, 2019, G3-GENES GENOM GENET, V9, P1175, DOI 10.1534/g3.119.400067
   Nagarajan-Radha V, 2019, J GERONTOL A-BIOL, V74, P1573, DOI 10.1093/gerona/glz104
   Narendra D, 2008, J CELL BIOL, V183, P795, DOI 10.1083/jcb.200809125
   Niehuis O, 2008, GENETICS, V178, P413, DOI 10.1534/genetics.107.080523
   OLIVO PD, 1983, NATURE, V306, P400, DOI 10.1038/306400a0
   Otten ABC, 2016, CELL REP, V16, P622, DOI 10.1016/j.celrep.2016.06.023
   Parsons TJ, 1997, NAT GENET, V15, P363, DOI 10.1038/ng0497-363
   Paull D, 2013, NATURE, V493, P632, DOI 10.1038/nature11800
   Payne BAI, 2013, HUM MOL GENET, V22, P384, DOI 10.1093/hmg/dds435
   Payne BAI, 2011, NAT GENET, V43, P806, DOI 10.1038/ng.863
   Persson Ö, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08673-5
   Pfanner N, 2019, NAT REV MOL CELL BIO, V20, P267, DOI 10.1038/s41580-018-0092-0
   Phillips WS, 2015, GENOME BIOL EVOL, V7, P2023, DOI 10.1093/gbe/evv116
   Pirinen E, 2020, CELL METAB, V31, P1078, DOI 10.1016/j.cmet.2020.04.008
   Purhonen J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14201-2
   Rand DM, 2020, PHILOS T R SOC B, V375, DOI 10.1098/rstb.2019.0188
   Ratel D, 2006, FEBS LETT, V580, P3179, DOI 10.1016/j.febslet.2006.04.074
   Rebelo AP, 2009, NUCLEIC ACIDS RES, V37, P6701, DOI 10.1093/nar/gkp727
   Reyes A, 2005, J BIOL CHEM, V280, P3242, DOI 10.1074/jbc.M411916200
   Reyes A, 2013, NUCLEIC ACIDS RES, V41, P5837, DOI 10.1093/nar/gkt196
   Ross JM, 2013, NATURE, V501, P412, DOI 10.1038/nature12474
   Saini SK, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01743-y
   Salas A, 2020, FORENSIC SCI INT-GEN, V47, DOI 10.1016/j.fsigen.2020.102274
   Salk JJ, 2018, NAT REV GENET, V19, P269, DOI 10.1038/nrg.2017.117
   Samuels DC, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003929
   Samuels DC, 2006, AM J HUM GENET, V78, P713, DOI 10.1086/502682
   Santibanez-Koref M, 2019, MITOCHONDRION, V46, P302, DOI 10.1016/j.mito.2018.08.003
   Schmitt MW, 2012, P NATL ACAD SCI USA, V109, P14508, DOI 10.1073/pnas.1208715109
   Sharpley MS, 2012, CELL, V151, P333, DOI 10.1016/j.cell.2012.09.004
   Simon DK, 2004, NEUROBIOL AGING, V25, P71, DOI 10.1016/S0197-4580(03)00037-X
   Steele H, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.201911589
   Stewart JB, 2015, NAT REV GENET, V16, P530, DOI 10.1038/nrg3966
   Stewart JB, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005333
   Stewart JB, 2008, PLOS BIOL, V6, P63, DOI 10.1371/journal.pbio.0060010
   Tsang WY, 2002, BIOCHEM CELL BIOL, V80, P645, DOI 10.1139/O02-135
   van den Ameele J, 2020, SEMIN CELL DEV BIOL, V97, P156, DOI 10.1016/j.semcdb.2019.10.001
   van der Wijst MGP, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-00263-z
   van Oven M, 2009, HUM MUTAT, V30, pE386, DOI 10.1002/humu.20921
   Vaught RC, 2020, J EVOLUTION BIOL, V33, P694, DOI 10.1111/jeb.13605
   Wai T, 2008, NAT GENET, V40, P1484, DOI 10.1038/ng.258
   Wallace DC, 2016, NATURE, V535, P498, DOI 10.1038/nature18902
   Wallace DC, 2015, CELL, V163, P33, DOI 10.1016/j.cell.2015.08.067
   Wei W, 2020, J INTERN MED, V287, P634, DOI 10.1111/joim.13047
   Wei W, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15336-3
   Wei W, 2019, SCIENCE, V364, P749, DOI 10.1126/science.aau6520
   Wei W, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1007126
   Wilson IJ, 2016, HUM MOL GENET, V25, P1031, DOI 10.1093/hmg/ddv626
   Yamamoto K, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-0812-9
   Yang Y, 2008, GENET MED, V10, P187, DOI 10.1097/GIM.0b013e318163c343
   Yasukawa T, 2018, J BIOCHEM, V164, P183, DOI 10.1093/jb/mvy058
   Yuan Y, 2020, NAT GENET, V52, P342, DOI 10.1038/s41588-019-0557-x
   Zaidi AA, 2019, P NATL ACAD SCI USA, V116, P25172, DOI 10.1073/pnas.1906331116
   Zaidi AA, 2019, NAT ECOL EVOL, V3, P213, DOI 10.1038/s41559-018-0766-1
   Zhang HX, 2018, ESSAYS BIOCHEM, V62, P225, DOI 10.1042/EBC20170096
   Zhang Y, 2019, MOL CELL, V73, P1127, DOI 10.1016/j.molcel.2019.01.013
   Zheng WM, 2006, MUTAT RES-FUND MOL M, V599, P11, DOI 10.1016/j.mrfmmm.2005.12.012
NR 168
TC 130
Z9 145
U1 1
U2 56
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1471-0056
EI 1471-0064
J9 NAT REV GENET
JI Nat. Rev. Genet.
PD FEB
PY 2021
VL 22
IS 2
BP 106
EP 118
DI 10.1038/s41576-020-00284-x
EA SEP 2020
PG 13
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA PU3AH
UT WOS:000573441200001
PM 32989265
DA 2024-11-01
ER

PT J
AU Sadikovic, B
   Wang, J
   El-Hattab, A
   Landsverk, M
   Douglas, G
   Brundage, EK
   Craigen, WJ
   Schmitt, ES
   Wong, LJC
AF Sadikovic, Bekim
   Wang, Jing
   El-Hattab, Ayman
   Landsverk, Megan
   Douglas, Ganka
   Brundage, Ellen K.
   Craigen, William J.
   Schmitt, Eric S.
   Wong, Lee-Jun C.
TI Sequence Homology at the Breakpoint and Clinical Phenotype of
   Mitochondrial DNA Deletion Syndromes
SO PLOS ONE
LA English
DT Article
ID HUMAN SKELETAL-MUSCLE; DOUBLE-STRAND BREAKS; MTDNA DELETIONS;
   SACCHAROMYCES-CEREVISIAE; LAGGING-STRAND; DIRECT REPEATS; CELLS;
   MYOPATHIES; MUTATIONS; DISEASE
AB Mitochondrial DNA (mtDNA) deletions are a common cause of mitochondrial disorders. Large mtDNA deletions can lead to a broad spectrum of clinical features with different age of onset, ranging from mild mitochondrial myopathies (MM), progressive external ophthalmoplegia (PEO), and Kearns-Sayre syndrome (KSS), to severe Pearson syndrome. The aim of this study is to investigate the molecular signatures surrounding the deletion breakpoints and their association with the clinical phenotype and age at onset. MtDNA deletions in 67 patients were characterized using array comparative genomic hybridization (aCGH) followed by PCR-sequencing of the deletion junctions. Sequence homology including both perfect and imperfect short repeats flanking the deletion regions were analyzed and correlated with clinical features and patients' age group. In all age groups, there was a significant increase in sequence homology flanking the deletion compared to mtDNA background. The youngest patient group (<6 years old) showed a diffused pattern of deletion distribution in size and locations, with a significantly lower sequence homology flanking the deletion, and the highest percentage of deletion mutant heteroplasmy. The older age groups showed rather discrete pattern of deletions with 44% of all patients over 6 years old carrying the most common 5 kb mtDNA deletion, which was found mostly in muscle specimens (22/41). Only 15% (3/20) of the young patients (<6 years old) carry the 5 kb common deletion, which is usually present in blood rather than muscle. This group of patients predominantly (16 out of 17) exhibit multisystem disorder and/or Pearson syndrome, while older patients had predominantly neuromuscular manifestations including KSS, PEO, and MM. In conclusion, sequence homology at the deletion flanking regions is a consistent feature of mtDNA deletions. Decreased levels of sequence homology and increased levels of deletion mutant heteroplasmy appear to correlate with earlier onset and more severe disease with multisystem involvement.
C1 [Sadikovic, Bekim; Wang, Jing; El-Hattab, Ayman; Landsverk, Megan; Douglas, Ganka; Brundage, Ellen K.; Craigen, William J.; Schmitt, Eric S.; Wong, Lee-Jun C.] Baylor Coll Med, Houston, TX 77030 USA.
C3 Baylor College of Medicine
RP Sadikovic, B (corresponding author), Baylor Coll Med, Houston, TX 77030 USA.
EM ljwong@bcm.edu
FU Fundacao para a Ciencia e Tecnologia, Portugal [SFRH/BD/35854/2007,
   SFRH/BD/38543/2007, PTDC/SAU-ESA/64888/2006, PIC/IC/83065/2007];
   GlaxoSmithkline; Fundacao Calouste Gulbenkian; Fundação para a Ciência e
   a Tecnologia [PTDC/SAU-ESA/64888/2006, PIC/IC/83065/2007,
   SFRH/BD/38543/2007, SFRH/BD/35854/2007] Funding Source: FCT
FX M. C. and M.J.F. are supported by research grants from Fundacao para a
   Ciencia e Tecnologia, Portugal (SFRH/BD/35854/2007 and
   SFRH/BD/38543/2007 respectively). This work was partly supported by
   Fundacao para a Ciencia e Tecnologia, Portugal (PTDC/SAU-ESA/64888/2006
   and PIC/IC/83065/2007), Fundacao Calouste Gulbenkian and an unrestricted
   grant from GlaxoSmithkline. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Boulton SJ, 1996, NUCLEIC ACIDS RES, V24, P4639, DOI 10.1093/nar/24.23.4639
   Bua E, 2006, AM J HUM GENET, V79, P469, DOI 10.1086/507132
   Chinault AC, 2009, GENET MED, V11, P518, DOI 10.1097/GIM.0b013e3181abd83c
   DEGOUL F, 1991, NUCLEIC ACIDS RES, V19, P493, DOI 10.1093/nar/19.3.493
   Hammans SR, 1994, ESSAYS BIOCHEM, V28, P99
   Hanekamp T, 1999, CURR GENET, V34, P438, DOI 10.1007/s002940050418
   Hastings PJ, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000327
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Holt IJ, 2000, CELL, V100, P515, DOI 10.1016/S0092-8674(00)80688-1
   HOLT IJ, 1989, NUCLEIC ACIDS RES, V17, P4465, DOI 10.1093/nar/17.12.4465
   Hudson G, 2006, HUM MOL GENET, V15, pR244, DOI 10.1093/hmg/ddl233
   Krishnan KJ, 2008, NAT GENET, V40, P275, DOI 10.1038/ng.f.94
   Liang F, 1996, P NATL ACAD SCI USA, V93, P8929, DOI 10.1073/pnas.93.17.8929
   Liang MH, 1998, AM J MED GENET, V77, P395, DOI 10.1002/(SICI)1096-8628(19980605)77:5<395::AID-AJMG8>3.0.CO;2-M
   Marie A, 2010, NUCLEIC ACIDS RES, V38, P5706, DOI 10.1093/nar/gkq379
   McVey M, 2008, TRENDS GENET, V24, P529, DOI 10.1016/j.tig.2008.08.007
   MITA S, 1990, NUCLEIC ACIDS RES, V18, P561, DOI 10.1093/nar/18.3.561
   Nguyen LH, 2000, J BIOL CHEM, V275, P25900, DOI 10.1074/jbc.M002672200
   PEARSON HA, 1979, J PEDIATR-US, V95, P976, DOI 10.1016/S0022-3476(79)80286-3
   Reeve AK, 2008, AM J HUM GENET, V82, P228, DOI 10.1016/j.ajhg.2007.09.018
   Reeve AK, 2008, ANN NY ACAD SCI, V1147, P21, DOI 10.1196/annals.1427.016
   ROBBERSO.DL, 1972, P NATL ACAD SCI USA, V69, P3810, DOI 10.1073/pnas.69.12.3810
   Samuels DC, 2004, TRENDS GENET, V20, P393, DOI 10.1016/j.tig.2004.07.003
   Schröder R, 2000, J NEUROPATH EXP NEUR, V59, P353, DOI 10.1093/jnen/59.5.353
   Srivastava S, 2005, HUM MOL GENET, V14, P893, DOI 10.1093/hmg/ddi082
   Srivastava S, 2007, HUM MOL GENET, V16, P993, DOI 10.1093/hmg/ddm045
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Wong LJC, 2005, CLIN CHIM ACTA, V354, P1, DOI 10.1016/j.cccn.2004.11.003
   Wong LJC, 2001, GENET MED, V3, P399, DOI 10.1097/00125817-200111000-00004
   Yasukawa T, 2006, EMBO J, V25, P5358, DOI 10.1038/sj.emboj.7601392
   Zeviani M, 1998, NEUROLOGY, V51, P1525, DOI 10.1212/WNL.51.6.1525-a
NR 31
TC 45
Z9 48
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 20
PY 2010
VL 5
IS 12
AR e15687
DI 10.1371/journal.pone.0015687
PG 9
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 698EM
UT WOS:000285575200064
PM 21187929
OA gold, Green Published
DA 2024-11-01
ER

PT J
AU Yokota, M
   Hatakeyama, H
   Okabe, S
   Ono, Y
   Goto, YI
AF Yokota, Mutsumi
   Hatakeyama, Hideyuki
   Okabe, Saki
   Ono, Yasuha
   Goto, Yu-ichi
TI Mitochondrial respiratory dysfunction caused by a heteroplasmic
   mitochondrial DNA mutation blocks cellular reprogramming
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID PLURIPOTENT STEM-CELLS; LACTIC-ACIDOSIS; POINT MUTATION; ENCEPHALOPATHY;
   SEGREGATION; MYOPATHY; GENOME; LINES; GENE
AB Mitochondrial dysfunction caused by pathogenic mutations in mitochondrial tRNA genes emerges only when mutant mitochondrial DNA (mtDNA) proportions exceed intrinsic pathogenic thresholds; however, little is known about the actual proportions of mutant mtDNA that can affect particular cellular lineage-determining processes. Here, we mainly focused on the effects of mitochondrial respiratory dysfunction caused by m.3243A>G heteroplasmy in MT-TL1 gene on cellular reprogramming. We found that generation of induced pluripotent stem cells (iPSCs) was drastically depressed only by high proportions of mutant mtDNA (>= 90% m.3243A>G), and these proportions were strongly associated with the degree of induced mitochondrial respiratory dysfunction. Nevertheless, all established iPSCs, even those carrying similar to 100% m.3243A>G, exhibited an embryonic stem cell-like pluripotent state. Therefore, our findings clearly demonstrate that loss of physiological integrity in mitochondria triggered by mutant mtDNA constitute a roadblock to cellular rejuvenation, but do not affect the maintenance of the pluripotent state.
C1 [Yokota, Mutsumi; Hatakeyama, Hideyuki; Okabe, Saki; Ono, Yasuha; Goto, Yu-ichi] NCNP, Natl Inst Neurosci, Dept Mental Retardat & Birth Defect Res, Kodaira, Tokyo 1878502, Japan.
   [Goto, Yu-ichi] Natl Ctr Neurol & Psychiat, Med Genome Ctr, Tokyo 1878551, Japan.
   [Yokota, Mutsumi; Hatakeyama, Hideyuki; Goto, Yu-ichi] Japan Agcy Med Res & Dev, AMED CREST, Tokyo 1000004, Japan.
C3 National Center for Neurology & Psychiatry - Japan; National Center for
   Neurology & Psychiatry - Japan
RP Hatakeyama, H (corresponding author), NCNP, Natl Inst Neurosci, Dept Mental Retardat & Birth Defect Res, 4-1-1 Ogawahigashi, Kodaira, Tokyo 1878502, Japan.
EM hideyuki@ncnp.go.jp; goto@ncnp.go.jp
FU Japan Society for the Promotion of Science [25860732]; Ministry of
   Health, Labour and Welfare, Japan; AMED-CREST from the Japan Agency for
   Medical Research and Development; Grants-in-Aid for Scientific Research
   [25860732] Funding Source: KAKEN
FX This study was financially supported in part by a Grant-in-Aid for Young
   Scientists (B) (Grant No. 25860732 to M.Y.) from the Japan Society for
   the Promotion of Science; a Grant-in-Aid for Research on Intractable
   Diseases (Mitochondrial Disorder) from the Ministry of Health, Labour
   and Welfare, Japan; and AMED-CREST from the Japan Agency for Medical
   Research and Development.
CR Akanuma J, 2000, J HUM GENET, V45, P337, DOI 10.1007/s100380070004
   Armstrong L, 2010, STEM CELLS, V28, P661, DOI 10.1002/stem.307
   ATTARDI G, 1995, BBA-MOL BASIS DIS, V1271, P241, DOI 10.1016/0925-4439(95)00034-2
   Cherry ABC, 2013, STEM CELLS, V31, P1287, DOI 10.1002/stem.1354
   Folmes CDL, 2013, STEM CELLS, V31, P1298, DOI 10.1002/stem.1389
   Folmes CDL, 2012, CELL STEM CELL, V11, P596, DOI 10.1016/j.stem.2012.10.002
   Folmes CDL, 2011, CELL METAB, V14, P264, DOI 10.1016/j.cmet.2011.06.011
   Fujikura J, 2012, DIABETOLOGIA, V55, P1689, DOI 10.1007/s00125-012-2508-2
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Hämäläinen RH, 2013, P NATL ACAD SCI USA, V110, pE3622, DOI 10.1073/pnas.1311660110
   Kaufmann P, 1996, ANN NEUROL, V40, P172, DOI 10.1002/ana.410400208
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   KOBAYASHI Y, 1991, AM J HUM GENET, V49, P590
   Lehtinen SK, 2000, GENETICS, V154, P363
   Okita K, 2011, NAT METHODS, V8, P409, DOI [10.1038/NMETH.1591, 10.1038/nmeth.1591]
   Prigione A, 2010, STEM CELLS, V28, P721, DOI 10.1002/stem.404
   Schon EA, 2012, NAT REV GENET, V13, P878, DOI 10.1038/nrg3275
   Suzuki T, 2011, ANNU REV GENET, V45, P299, DOI 10.1146/annurev-genet-110410-132531
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Tanaka M, 2004, ANN NY ACAD SCI, V1011, P7, DOI 10.1196/annals.1293.002
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Xu XL, 2013, CELL METAB, V18, P325, DOI 10.1016/j.cmet.2013.06.005
   YONEDA M, 1992, P NATL ACAD SCI USA, V89, P11164, DOI 10.1073/pnas.89.23.11164
   Yu JY, 2007, SCIENCE, V318, P1917, DOI 10.1126/science.1151526
NR 25
TC 36
Z9 36
U1 0
U2 15
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD AUG 15
PY 2015
VL 24
IS 16
BP 4698
EP 4709
DI 10.1093/hmg/ddv201
PG 12
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA CR4OU
UT WOS:000361315400018
PM 26025377
OA Bronze
DA 2024-11-01
ER

PT J
AU Isohanni, P
   Carroll, CJ
   Jackson, CB
   Pohjanpelto, M
   Lönnqvist, T
   Suomalainen, A
AF Isohanni, Pirjo
   Carroll, Christopher J.
   Jackson, Christopher B.
   Pohjanpelto, Max
   Lonnqvist, Tuula
   Suomalainen, Anu
TI Defective mitochondrial ATPase due to rare mtDNA m.8969G&gt;A
   mutation-causing lactic acidosis, intellectual disability, and poor
   growth
SO NEUROGENETICS
LA English
DT Article
DE Mitochondrial diseases; Mitochondrial DNA; Intellectual disability;
   Lactic acidosis
ID OXIDATIVE-PHOSPHORYLATION; ATP6 GENE; DEFICIENCY; DISEASE; ATAXIA
AB Mutations in mitochondrial ATP synthase 6 (MT-ATP6) are a frequent cause of NARP (neurogenic muscle weakness, ataxia, and retinitis pigmentosa) or Leigh syndromes, especially a point mutation at nucleotide position 8993. M.8969G > A is a rare MT-ATP6 mutation, previously reported only in three individuals, causing multisystem disorders with mitochondrial myopathy, lactic acidosis, and sideroblastic anemia or IgA nephropathy. We present two siblings with the m.8969G > A mutation and a novel, substantially milder phenotype with lactic acidosis, poor growth, and intellectual disability. Our findings expand the phenotypic spectrum and show that mtDNA mutations should be taken account also with milder, stable phenotypes.
C1 [Isohanni, Pirjo; Lonnqvist, Tuula] Univ Helsinki, Childrens Hosp, Dept Child Neurol, Helsinki, Finland.
   [Isohanni, Pirjo; Lonnqvist, Tuula] Helsinki Univ Hosp, Helsinki, Finland.
   [Isohanni, Pirjo; Carroll, Christopher J.; Jackson, Christopher B.; Pohjanpelto, Max; Suomalainen, Anu] Univ Helsinki, Res Programs Unit, Mol Neurol, Biomedicum Helsinki, Helsinki, Finland.
   [Suomalainen, Anu] Univ Helsinki, Neurosci Ctr, Helsinki, Finland.
C3 University of Helsinki; University of Helsinki; Helsinki University
   Central Hospital; University of Helsinki; University of Helsinki
RP Isohanni, P (corresponding author), Univ Helsinki, Childrens Hosp, Dept Child Neurol, Helsinki, Finland.; Isohanni, P (corresponding author), Helsinki Univ Hosp, Helsinki, Finland.; Isohanni, P (corresponding author), Univ Helsinki, Res Programs Unit, Mol Neurol, Biomedicum Helsinki, Helsinki, Finland.
EM pirjo.isohanni@helsinki.fi
RI Carroll, Christopher/AAV-8023-2021; Jackson, Christopher B./M-3222-2013
OI Jackson, Christopher B./0000-0003-1035-6417; Pohjanpelto,
   Max/0000-0002-9262-2282; Carroll, Christopher/0000-0002-2814-6955;
   Isohanni, Pirjo/0000-0002-0156-1614; Suomalainen-Wartiovaara,
   Anu/0000-0003-4833-5195
FU Foundation for Pediatric Research; Helsinki University Hospital;
   University of Helsinki; Swiss National Foundation; Novartis Foundation;
   Sigrid Juselius Foundation; Academy of Finland; Jane and Aatos Erkko
   Foundation
FX The authors would like to thank the family for participation in the
   study. We acknowledge Brendan Battersby for discussions, and the Finnish
   Institute for Molecular Medicine (FIMM) for DNA sequencing services. We
   wish to thank the following funding sources for support: Foundation for
   Pediatric Research (PI), the special governmental subsidy for health
   sciences research of the Helsinki University Hospital. (PI and TL),
   University of Helsinki (CJC and AS), Swiss National Foundation and
   Novartis Foundation (CJB), Sigrid Juselius Foundation, Academy of
   Finland, Jane and Aatos Erkko Foundation (AS).
CR Burrage LC, 2014, MOL GENET METAB, V113, P207, DOI 10.1016/j.ymgme.2014.06.004
   Courage C, 2017, AM J MED GENET A, V173, P225, DOI 10.1002/ajmg.a.37986
   DEVRIES DD, 1993, ANN NEUROL, V34, P410, DOI 10.1002/ana.410340319
   Götz A, 2012, PEDIATR RES, V72, P90, DOI 10.1038/pr.2012.43
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   Jackson CB, 2017, EUR J MED GENET, V60, P345, DOI 10.1016/j.ejmg.2017.04.006
   LAMMINEN T, 1995, AM J HUM GENET, V56, P1238
   Leary SC, 2009, METHODS MOL BIOL, V554, P143, DOI 10.1007/978-1-59745-521-3_10
   Rantamäki MT, 2005, ANN NEUROL, V58, P337, DOI 10.1002/ana.20555
   Sallevelt SCEH, 2017, J MED GENET, V54, P114, DOI 10.1136/jmedgenet-2016-103876
   Sulonen AM, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-9-r94
   TATUCH Y, 1992, AM J HUM GENET, V50, P852
   THYAGARAJAN D, 1995, ANN NEUROL, V38, P468, DOI 10.1002/ana.410380321
   Ware SM, 2009, J MED GENET, V46, P308, DOI 10.1136/jmg.2008.063149
   Wen SZ, 2016, SCI REP-UK, V6, DOI 10.1038/srep36313
NR 15
TC 9
Z9 9
U1 0
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1364-6745
EI 1364-6753
J9 NEUROGENETICS
JI Neurogenetics
PD JAN
PY 2018
VL 19
IS 1
BP 49
EP 53
DI 10.1007/s10048-018-0537-9
PG 5
WC Genetics & Heredity; Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Neurosciences & Neurology
GA FU2SG
UT WOS:000423699700006
PM 29350304
DA 2024-11-01
ER

PT J
AU AlJabri, MF
   Kamal, NM
   Halabi, A
   Korbi, H
   Alsayyali, MMA
   Alzahrani, YA
AF AlJabri, Mohamed F.
   Kamal, Naglaa M.
   Halabi, Abdulrahman
   Korbi, Haifa
   Alsayyali, Mashhour M. A.
   Alzahrani, Yahea A.
TI Lethal neonatal mitochondrial phenotype caused by a novel polymerase
   subunit gamma mutation A case report
SO MEDICINE
LA English
DT Article
DE mitochondrial; neonatal; novel; polymerase subunit gamma mutation; Saudi
ID CHAIN COMPLEX I; PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; DNA; DEFICIENCY;
   DISEASE; POLG; PREVALENCE; DEPLETION; CHILDHOOD; MYOPATHY
AB Rationale: Polymerase subunit gamma (POLG) is a gene that codes for the catalytic subunit of the mitochondrial DNA polymerase, which is involved in the replication of mitochondrial DNA. Mutations in these genes are associated with a range of clinical syndromes characterized by secondary mtDNA defect including mtDNA mutation and mtDNA depletion which may culminate in complete failure of energy production (respiratory changes complex 1 defect) as in this case.
   Patient concerns: We herein report a full term Saudi female neonate born to consanguineous parents, who was noticed immediately after birth to have severe hypotonia, poor respiratory effort, and dysmorphic features. She had 3 siblings who died with same clinical scenario in neonatal period.
   Diagnoses: Molecular genetic testing revealed a novel compound heterozygous mutation of POLG gene c.680G>A (p.Arg227Gin) and c.3098C>T (p.Ala1033Val).
   Interventions: The patient remained in neonatal intensive care unit with multidisciplinary team management and was ventilator dependent until she passed away.
   Outcomes: The detected mutation had led to complete failure of energy production (respiratory changes complex 1 defect) until she died at the age of 5 months.
   Lessons: Mitochondrial respiratory chain defect should be considered in patients with severe neonatal hypotonia, encephalopathy, and respiratory failure especially in highly consanguineous population.
C1 [AlJabri, Mohamed F.] Cairo Univ, Fac Med, Pediat Neurol, Cairo, Egypt.
   [Kamal, Naglaa M.] Cairo Univ, Fac Med, Pediat Hepatol, Cairo, Egypt.
   [Kamal, Naglaa M.] Alhada Armed Forces Hosp, Pediat Hepatol, At Taif, Saudi Arabia.
   [Halabi, Abdulrahman] Alhada Armed Forces Hosp, Pediat Neonatol, At Taif, Saudi Arabia.
   [Korbi, Haifa; Alsayyali, Mashhour M. A.] Alhada Armed Forces Hosp, Pediat, At Taif, Saudi Arabia.
   [Alzahrani, Yahea A.] Taif Univ, Coll Med, Neuroradiol, At Taif, Saudi Arabia.
C3 Egyptian Knowledge Bank (EKB); Cairo University; Egyptian Knowledge Bank
   (EKB); Cairo University; Al Hada Armed Forces Hospital; Al Hada Armed
   Forces Hospital; Al Hada Armed Forces Hospital; Taif University
RP Kamal, NM (corresponding author), Cairo Univ, Fac Med, Pediat & Pediat Hepatol, Cairo, Egypt.
EM Nagla.kamal@kasralainy.edu.eg
OI Mohamed Kamal, Naglaa/0000-0002-8535-3838
CR Arpa J, 2003, MUSCLE NERVE, V28, P690, DOI 10.1002/mus.10507
   Cohen BH, NON TRADITIONAL REF
   Cohen BH, 2010, METHODS, V51, P364, DOI 10.1016/j.ymeth.2010.05.008
   Darin N, 2001, ANN NEUROL, V49, P377, DOI 10.1002/ana.75
   Emmanuele V, 2011, J NEUROL SCI, V303, P39, DOI 10.1016/j.jns.2011.01.018
   Fadic R, 1997, NEUROLOGY, V49, P239, DOI 10.1212/WNL.49.1.239
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   Finsterer J, 2012, SEIZURE-EUR J EPILEP, V21, P316, DOI 10.1016/j.seizure.2012.03.003
   Giordano C, 2009, NEUROLOGY, V72, P1103, DOI 10.1212/01.wnl.0000345002.47396.e1
   Horváth R, 2005, NEUROMUSCULAR DISORD, V15, P851, DOI 10.1016/j.nmd.2005.09.005
   Kirby DM, 1999, NEUROLOGY, V52, P1255, DOI 10.1212/WNL.52.6.1255
   Kollberg G, 2006, J NEUROPATH EXP NEUR, V65, P758, DOI 10.1097/01.jnen.0000229987.17548.6e
   LEIGH D, 1951, J NEUROL NEUROSUR PS, V14, P216, DOI 10.1136/jnnp.14.3.216
   Loeffen J, 1998, AM J HUM GENET, V63, P1598, DOI 10.1086/302154
   Loeffen JLCM, 2000, HUM MUTAT, V15, P123, DOI 10.1002/(SICI)1098-1004(200002)15:2<123::AID-HUMU1>3.3.CO;2-G
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Morris AAM, 1996, ANN NEUROL, V40, P25, DOI 10.1002/ana.410400107
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Rahman S, 2012, DEV MED CHILD NEUROL, V54, P397, DOI 10.1111/j.1469-8749.2011.04214.x
   Skladal D, 2003, BRAIN, V126, P1905, DOI 10.1093/brain/awg170
   Spinazzola A, 2009, J INHERIT METAB DIS, V32, P143, DOI 10.1007/s10545-008-1038-z
   Tang S, 2012, J NEUROL, V259, P862, DOI 10.1007/s00415-011-6268-6
   Triepels RH, 2001, AM J MED GENET, V106, P37, DOI 10.1002/ajmg.1397
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Uusimaa J, 2013, EPILEPSIA, V54, P1002, DOI 10.1111/epi.12115
   van den Heuvel L, 2001, BIOESSAYS, V23, P518, DOI 10.1002/bies.1071
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Worle H, 1998, CLIN NEUROPATHOL, V17, P63
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
NR 29
TC 3
Z9 3
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0025-7974
EI 1536-5964
J9 MEDICINE
JI Medicine (Baltimore)
PD OCT
PY 2018
VL 97
IS 40
AR e12591
DI 10.1097/MD.0000000000012591
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA HD0WR
UT WOS:000452230500040
PM 30290626
OA Green Published, gold
DA 2024-11-01
ER

PT J
AU Hirano, M
   Nishigaki, Y
   Martí, R
AF Hirano, M
   Nishigaki, Y
   Martí, R
TI Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE):: A
   disease of two genomes
SO NEUROLOGIST
LA English
DT Article
DE mitochondria; mitochondrial DNA; MNGIE; mitochondrial encephalomyopathy
ID CELL GROWTH-FACTOR; CHRONIC INTESTINAL PSEUDOOBSTRUCTION; FAMILIAL
   VISCERAL MYOPATHY; KEARNS-SAYRE SYNDROME; MOUSE L-CELLS; THYMIDINE
   PHOSPHORYLASE; MULTISYSTEM DISORDER; TISSUE DISTRIBUTION; MULTIPLE
   DELETIONS; RECTAL BIOPSY
AB Background: Mitochondrial encephalomyopathies are clinically and genetically heterogeneous because mitochondria are the products of 2 genomes: mitochondrial DNA (mtDNA) and nuclear DNA (nDNA). Among the mendelian-inherited mitochondrial diseases are defects of intergenomic communication, disorders due to nDNA mutations that cause depletion and multiple deletions of mtDNA.
   Review Summary: Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) is an autosomal recessive disorder of intergenomic communication and is defined clinically by 1) severe gastrointestinal dysmotility; 2) cachexia; 3) ptosis, ophthalmoparesis, or both; 4) peripheral neuropathy; and 5) leukoencephalopathy. Skeletal muscle biopsies of patients have revealed abnormalities of mtDNA and mitochondrial respiratory chain enzymes. The disease is caused by mutations in the thymidine phosphorylase (TP) gene. TP protein catalyzes phosphorolysis of thymidine to thymine and deoxyribose 1-phosphate. In MNGIE patients, TP enzyme activity is reduced drastically, and plasma thymidine and deoxyuridine are elevated dramatically. We have hypothesized that alterations of nucleoside metabolism cause an imbalanced mitochondrial nucleotide pool that leads to depletion and deletions of mtDNA.
   Conclusions: MNGIE is a recognizable clinical syndrome caused by mutations in TP. The diagnosis can be confirmed by measuring TP activity in buffy coat or plasma levels of thymidine and deoxyuridine. Reduction of circulating thymidine and deoxyuridine in MNGIE patients may be therapeutic.
C1 Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA.
C3 Columbia University
RP Columbia Univ, Coll Phys & Surg, Dept Neurol, 630 W 168th St,P&S 4-443, New York, NY 10032 USA.
EM mh29@columbia.edu
RI Martí, Ramon/Q-3442-2016
OI Marti, Ramon/0000-0002-8273-9540
CR ANURAS S, 1983, GASTROENTEROLOGY, V84, P346
   ARNAUDO E, 1991, LANCET, V337, P508, DOI 10.1016/0140-6736(91)91294-5
   BAN S, 1992, ACTA PATHOL JAPON, V42, P818
   BARDOSI A, 1987, ACTA NEUROPATHOL, V74, P248, DOI 10.1007/BF00688189
   BERK AJ, 1973, J BIOL CHEM, V248, P2722
   BESTWICK RK, 1982, J BIOL CHEM, V257, P9305
   BESTWICK RK, 1982, J BIOL CHEM, V257, P9300
   BOGENHAGEN D, 1976, J BIOL CHEM, V251, P2938
   BOURGERON T, 1995, NAT GENET, V11, P144, DOI 10.1038/ng1095-144
   BRAHAMS D, 1994, LANCET, V343, P1494, DOI 10.1016/S0140-6736(94)92599-2
   Brown NS, 1998, BIOCHEM J, V334, P1
   Carrozzo R, 1998, NEUROLOGY, V50, P99, DOI 10.1212/WNL.50.1.99
   CERVERA R, 1988, GUT, V29, P544, DOI 10.1136/gut.29.4.544
   COLLIER TG, 1996, ANN NEUROL, V40, P545
   CUI LX, 1995, J CLIN INVEST, V95, P555, DOI 10.1172/JCI117698
   DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602
   Debouverie M, 1997, REV NEUROL, V153, P547
   ECCLESTON PA, 1995, NEUROSCI LETT, V192, P137, DOI 10.1016/0304-3940(95)11622-4
   FOX SB, 1995, J PATHOL, V176, P183, DOI 10.1002/path.1711760212
   Gamez J, 2002, NEUROLOGY, V59, P455, DOI 10.1212/WNL.59.3.455
   HAGIWARA K, 1991, MOL CELL BIOL, V11, P2125, DOI 10.1128/MCB.11.4.2125
   Hamano H, 1997, Rinsho Shinkeigaku, V37, P917
   HIRANO M, 1994, NEUROLOGY, V44, P721, DOI 10.1212/WNL.44.4.721
   Hirano M, 1998, AM J HUM GENET, V63, P526, DOI 10.1086/301979
   HOLT I, 1988, NATURE, V331, P34
   IONASESCU V, 1983, AM J MED GENET, V15, P103, DOI 10.1002/ajmg.1320150114
   Johansson M, 1997, J BIOL CHEM, V272, P8454, DOI 10.1074/jbc.272.13.8454
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kuroiwa T, 1998, ACTA NEUROPATHOL, V96, P86, DOI 10.1007/s004010050863
   LESTIENNE P, 1988, LANCET, V1, P885
   LEWIS W, 1995, NAT MED, V1, P417, DOI 10.1038/nm0595-417
   LI V, 1992, DIGEST DIS SCI, V37, P456, DOI 10.1007/BF01307743
   LOWSKY R, 1993, GUT, V34, P279, DOI 10.1136/gut.34.2.279
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Martí R, 2003, BIOCHEM BIOPH RES CO, V303, P14, DOI 10.1016/S0006-291X(03)00294-8
   Matsukawa K, 1996, BBA-MOL CELL RES, V1314, P71, DOI 10.1016/S0167-4889(96)00078-X
   Mueller LA, 1999, GASTROENTEROLOGY, V116, P959, DOI 10.1016/S0016-5085(99)70080-6
   NICHOLL JA, 1993, CLIN NEUROPATHOL, V12, P38
   Nishino I, 2000, ANN NEUROL, V47, P792
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   OKAMURA K, 1976, J NEUROL SCI, V27, P79, DOI 10.1016/0022-510X(76)90236-7
   Papadimitriou A, 1998, NEUROLOGY, V51, P1086, DOI 10.1212/WNL.51.4.1086
   Perez-Atayde AR, 1998, AM J SURG PATHOL, V22, P1141, DOI 10.1097/00000478-199809000-00014
   Rosenberg MJ, 2002, NAT GENET, V32, P175, DOI 10.1038/ng948
   ROWLAND LP, 1992, HDB CLIN NEUROLOGY, P287
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   SCHON EA, 2001, MITOCHONDRIAL DISORD, V2
   SIMON LT, 1990, ANN NEUROL, V28, P349, DOI 10.1002/ana.410280308
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2002, J BIOL CHEM, V277, P4128, DOI 10.1074/jbc.M111028200
   STEINER I, 1987, NEUROLOGY, V37, P1046, DOI 10.1212/WNL.37.6.1046
   UNCINI A, 1994, MUSCLE NERVE, V17, P667, DOI 10.1002/mus.880170616
   Verma A, 1997, PEDIATR RES, V42, P448, DOI 10.1203/00006450-199710000-00005
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   WALTENBERGER J, 1992, FEBS LETT, V313, P129, DOI 10.1016/0014-5793(92)81428-O
   Washington MT, 1996, J BIOL CHEM, V271, P26825, DOI 10.1074/jbc.271.43.26825
   YOSHIMURA A, 1990, BIOCHIM BIOPHYS ACTA, V1034, P107, DOI 10.1016/0304-4165(90)90160-X
   Zelnik N, 1996, PEDIATR NEUROL, V14, P251, DOI 10.1016/0887-8994(96)00046-X
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
NR 59
TC 130
Z9 142
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1074-7931
J9 NEUROLOGIST
JI Neurologist
PD JAN
PY 2004
VL 10
IS 1
BP 8
EP 17
DI 10.1097/01.nrl.0000106919.06469.04
PG 10
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 768GE
UT WOS:000188534600002
PM 14720311
DA 2024-11-01
ER

PT J
AU Copeland, WC
AF Copeland, William C.
TI Defects in mitochondrial DNA replication and human disease
SO CRITICAL REVIEWS IN BIOCHEMISTRY AND MOLECULAR BIOLOGY
LA English
DT Review
DE DNA polymerase g; mitochondrial DNA replication; nucleotide pools;
   mitochondrial DNA depletion syndrome; progressive external
   ophthalmoplegia; ataxia-neuropathy
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; POLYMERASE-GAMMA MUTATIONS;
   NEUROGASTROINTESTINAL ENCEPHALOMYOPATHY MNGIE; THYMIDINE
   PHOSPHORYLASE-DEFICIENCY; RECESSIVE TWINKLE MUTATIONS; MULTIPLE MTDNA
   DELETIONS; P55 ACCESSORY SUBUNIT; DEOXYGUANOSINE KINASE; POLG MUTATIONS;
   SACCHAROMYCES-CEREVISIAE
AB Mitochondrial DNA (mtDNA) is replicated by the DNA polymerase g in concert with accessory proteins such as the mtDNA helicase, single stranded DNA binding protein, topoisomerase, and initiating factors. Nucleotide precursors for mtDNA replication arise from the mitochondrial salvage pathway originating from transport of nucleosides, or alternatively from cytoplasmic reduction of ribonucleotides. Defects in mtDNA replication or nucleotide metabolism can cause mitochondrial genetic diseases due to mtDNA deletions, point mutations, or depletion which ultimately cause loss of oxidative phosphorylation. These genetic diseases include mtDNA depletion syndromes such as Alpers or early infantile hepatocerebral syndromes, and mtDNA deletion disorders, such as progressive external ophthalmoplegia (PEO), ataxia-neuropathy, or mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). This review focuses on our current knowledge of genetic defects of mtDNA replication (POLG, POLG2, C10orf2) and nucleotide metabolism (TYMP, TK2, DGOUK, and RRM2B) that cause instability of mtDNA and mitochondrial disease.
C1 Natl Inst Environm Hlth Sci, Mol Genet Lab, Durham, NC 27709 USA.
RP Copeland, WC (corresponding author), Natl Inst Environm Hlth Sci, Mol Genet Lab, POB 12233, Durham, NC 27709 USA.
EM copelan1@niehs.nih.gov
RI Copeland, William/C-4242-2019
OI Copeland, William/0000-0002-0359-0953
FU National Institute of Environmental Health Sciences, NIH [ES 065078, ES
   065080]
FX The author reports no declarations of interests. This review was
   supported by intramural funds from the National Institute of
   Environmental Health Sciences, NIH (ES 065078 and ES 065080).
CR Akman HO, 2008, HUM MOL GENET, V17, P2433, DOI 10.1093/hmg/ddn143
   Alberio S, 2007, MITOCHONDRION, V7, P6, DOI 10.1016/j.mito.2006.11.010
   Baruffini E, 2007, BBA-MOL BASIS DIS, V1772, P1225, DOI 10.1016/j.bbadis.2007.10.002
   Baruffini E, 2006, HUM MOL GENET, V15, P2846, DOI 10.1093/hmg/ddl219
   Baruffini E, 2011, MITOCHONDRION, V11, P182, DOI 10.1016/j.mito.2010.09.007
   Blakely E, 2008, NEUROMUSCULAR DISORD, V18, P557, DOI 10.1016/j.nmd.2008.04.014
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Carrozzo R, 2003, HUM MUTAT, V21, DOI 10.1002/humu.9135
   Chan SSL, 2006, HUM MOL GENET, V15, P3473, DOI 10.1093/hmg/ddl424
   Chan SSL, 2009, BBA-BIOENERGETICS, V1787, P312, DOI 10.1016/j.bbabio.2008.10.007
   Chan SSL, 2005, DNA REPAIR, V4, P1381, DOI 10.1016/j.dnarep.2005.08.010
   Chan SSL, 2005, J BIOL CHEM, V280, P31341, DOI 10.1074/jbc.M506762200
   Cohen BH, 2010, POLG RELATED DISORDE
   Cohen BH, 2010, METHODS, V51, P364, DOI 10.1016/j.ymeth.2010.05.008
   Collins J, 2009, NEUROMUSCULAR DISORD, V19, P784, DOI 10.1016/j.nmd.2009.08.002
   Copeland WC, 2008, ANNU REV MED, V59, P131, DOI 10.1146/annurev.med.59.053006.104646
   De Camaret BM, 2007, BIOCHEM J, V402, P377, DOI 10.1042/BJ20060705
   de Vries MC, 2007, EUR J PEDIATR, V166, P229, DOI 10.1007/s00431-006-0234-9
   Dimmock DP, 2008, HUM MUTAT, V29, P330, DOI 10.1002/humu.9519
   Eriksson S, 2008, NUCLEOS NUCLEOT NUCL, V27, P800, DOI 10.1080/15257770802146197
   Falkenberg M, 2007, ANNU REV BIOCHEM, V76, P679, DOI 10.1146/annurev.biochem.76.060305.152028
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Fratter C, 2011, NEUROLOGY, V76, P2032, DOI 10.1212/WNL.0b013e31821e558b
   Fratter C, 2010, NEUROLOGY, V74, P1619, DOI 10.1212/WNL.0b013e3181df099f
   Freisinger P, 2006, ARCH NEUROL-CHICAGO, V63, P1129, DOI 10.1001/archneur.63.8.1129
   Galbiati S, 2006, PEDIATR NEUROL, V34, P177, DOI 10.1016/j.pediatrneurol.2005.07.013
   Gandhi VV, 2011, PLOS COMPUT BIOL, V7, DOI 10.1371/journal.pcbi.1002078
   Garrido N, 2003, MOL BIOL CELL, V14, P1583, DOI 10.1091/mbc.E02-07-0399
   Goffart S, 2009, HUM MOL GENET, V18, P328, DOI 10.1093/hmg/ddn359
   Götz A, 2008, BRAIN, V131, P2841, DOI 10.1093/brain/awn236
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   Graziewicz MA, 2006, CHEM REV, V106, P383, DOI 10.1021/cr040463d
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   Hirano M, 2006, NEUROLOGY, V67, P1458, DOI 10.1212/01.wnl.0000240853.97716.24
   Hirano M, 2005, GENE, V354, P152, DOI 10.1016/j.gene.2005.04.041
   Hirano M, 2004, NEUROLOGIST, V10, P8, DOI 10.1097/01.nrl.0000106919.06469.04
   Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279
   Holmlund T, 2009, BBA-MOL BASIS DIS, V1792, P132, DOI 10.1016/j.bbadis.2008.11.009
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Hudson G, 2006, NEUROLOGY, V66, P1439, DOI 10.1212/01.wnl.0000210486.32196.24
   Hudson G, 2005, NEUROLOGY, V64, P371, DOI 10.1212/01.WNL.0000149767.51152.83
   Hudson G, 2006, HUM MOL GENET, V15, pR244, DOI 10.1093/hmg/ddl233
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   Kasiviswanathan R, 2009, J BIOL CHEM, V284, P19501, DOI 10.1074/jbc.M109.011940
   Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257
   Korhonen JA, 2008, J MOL BIOL, V377, P691, DOI 10.1016/j.jmb.2008.01.035
   Kukat C, 2011, P NATL ACAD SCI USA, V108, P13534, DOI 10.1073/pnas.1109263108
   Lara MC, 2006, NEUROLOGY, V67, P1461, DOI 10.1212/01.wnl.0000239824.95411.52
   Lesko N, 2010, NEUROMUSCULAR DISORD, V20, P198, DOI 10.1016/j.nmd.2009.11.013
   Lewis W, 2007, LAB INVEST, V87, P326, DOI 10.1038/labinvest.3700523
   Lim SE, 2001, J BIOL CHEM, V276, P23616, DOI 10.1074/jbc.M101114200
   Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Longley MJ, 2010, J BIOL CHEM, V285, P29690, DOI 10.1074/jbc.M110.151795
   Longley MJ, 2005, GENE, V354, P125, DOI 10.1016/j.gene.2005.03.029
   Longley MJ, 2001, J BIOL CHEM, V276, P38555, DOI 10.1074/jbc.M105230200
   Lönnqvist T, 2009, BRAIN, V132, P1553, DOI 10.1093/brain/awp045
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Luoma PT, 2005, HUM MOL GENET, V14, P1907, DOI 10.1093/hmg/ddi196
   Mancuso M, 2003, ARCH NEUROL-CHICAGO, V60, P1007, DOI 10.1001/archneur.60.7.1007
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Martí R, 2003, BIOCHEM BIOPH RES CO, V303, P14, DOI 10.1016/S0006-291X(03)00294-8
   Matsushima Y, 2007, J BIOL CHEM, V282, P9436, DOI 10.1074/jbc.M610550200
   Miller FJ, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng060
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Naviaux RK, 1999, ANN NEUROL, V45, P54, DOI 10.1002/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B
   Nguyen KV, 2006, J HEPATOL, V45, P108, DOI 10.1016/j.jhep.2005.12.026
   Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828
   Nishino I, 2000, ANN NEUROL, V47, P792
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Pagnamenta AT, 2006, HUM REPROD, V21, P2467, DOI 10.1093/humrep/del076
   Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200
   Saada A, 2003, MOL GENET METAB, V79, P1, DOI 10.1016/S1096-7192(03)00063-5
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284
   Saneto RP, 2010, DEV DISABIL RES REV, V16, P163, DOI 10.1002/ddrr.105
   Scaglia F, 2009, DGUOK RELATED MITOCH
   Shaibani A, 2009, ARCH NEUROL-CHICAGO, V66, P1028, DOI 10.1001/archneurol.2009.139
   Song SW, 2003, J BIOL CHEM, V278, P43893, DOI 10.1074/jbc.C300401200
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2002, J BIOL CHEM, V277, P4128, DOI 10.1074/jbc.M111028200
   Stuart GR, 2006, HUM MOL GENET, V15, P363, DOI 10.1093/hmg/ddi454
   Stumpf JD, 2010, HUM MOL GENET, V19, P2123, DOI 10.1093/hmg/ddq089
   Szczepanowska K, 2010, HUM MOL GENET, V19, P3516, DOI 10.1093/hmg/ddq267
   Tang S, 2011, J MED GENET, V48, P669, DOI 10.1136/jmedgenet-2011-100222
   Torres-Torronteras J, 2011, GENE THER, V18, P795, DOI 10.1038/gt.2011.24
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
   Tyynismaa H, 2009, AM J HUM GENET, V85, P290, DOI 10.1016/j.ajhg.2009.07.009
   Tyynismaa H, 2009, EMBO REP, V10, P137, DOI 10.1038/embor.2008.242
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Valentino ML, 2007, FEBS LETT, V581, P3410, DOI 10.1016/j.febslet.2007.06.042
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Van Hove JLK, 2009, AM J MED GENET A, V149A, P861, DOI 10.1002/ajmg.a.32731
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Walter MC, 2010, J NEUROL, V257, P1517, DOI 10.1007/s00415-010-5565-9
   Wang LY, 2005, MOL GENET METAB, V84, P75, DOI 10.1016/j.ymgme.2004.09.005
   Wang LY, 2003, FEBS LETT, V554, P319, DOI 10.1016/S0014-5793(03)01181-5
   Wang LY, 2003, J BIOL CHEM, V278, P6963, DOI 10.1074/jbc.M206143200
   Wanrooij S, 2007, NUCLEIC ACIDS RES, V35, P3238, DOI 10.1093/nar/gkm215
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   Wong LJC, 2008, HUM MUTAT, V29, pE150, DOI 10.1002/humu.20824
   Young MJ, 2011, HUM MOL GENET, V20, P3052, DOI 10.1093/hmg/ddr209
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 107
TC 125
Z9 149
U1 0
U2 52
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1040-9238
J9 CRIT REV BIOCHEM MOL
JI Crit. Rev. Biochem. Mol. Biol.
PD JAN
PY 2012
VL 47
IS 1
BP 64
EP 74
DI 10.3109/10409238.2011.632763
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 863TA
UT WOS:000298189700005
PM 22176657
OA Green Accepted
DA 2024-11-01
ER

PT J
AU Chung, CY
   Valdebenito, GE
   Chacko, AR
   Duchen, MR
AF Chung, Chih-Yao
   Valdebenito, Gabriel E.
   Chacko, Anitta R.
   Duchen, Michael R.
TI Rewiring cell signalling pathways in pathogenic mtDNA mutations
SO TRENDS IN CELL BIOLOGY
LA English
DT Review
ID HEREDITARY OPTIC NEUROPATHY; MITOCHONDRIAL-DNA MUTATIONS;
   QUALITY-CONTROL; LEIGH-DISEASE; ATP SYNTHESIS; MELAS; METABOLISM;
   HETEROPLASMY; FIBROBLASTS; MYOPATHY
AB Mitochondria generate the energy to sustain cell viability and serve as a hub for cell signalling. Their own genome (mtDNA) encodes genes critical for oxidative phosphorylation. Mutations of mtDNA cause major disease and disability with a wide range of presentations and severity. We review here an emerging body of data suggesting that changes in cell metabolism and signalling pathways in response to the presence of mtDNA mutations play a key role in shaping disease presentation and progression. Understanding the impact of mtDNA mutations on cellular energy homeostasis and signalling pathways seems fundamental to identify novel therapeutic interventions with the potential to improve the prognosis for patients with primary mitochondrial disease.
C1 [Chung, Chih-Yao; Valdebenito, Gabriel E.; Chacko, Anitta R.; Duchen, Michael R.] UCL, Dept Cell & Dev Biol, Gower St, London WC1E 6BT, England.
   [Chung, Chih-Yao; Valdebenito, Gabriel E.; Chacko, Anitta R.; Duchen, Michael R.] UCL, Consortium Mitochondrial Res, Gower St, London WC1E 6BT, England.
C3 University of London; University College London; University of London;
   University College London
RP Duchen, MR (corresponding author), UCL, Dept Cell & Dev Biol, Gower St, London WC1E 6BT, England.; Duchen, MR (corresponding author), UCL, Consortium Mitochondrial Res, Gower St, London WC1E 6BT, England.
EM m.duchen@ucl.ac.uk
RI ; Duchen, Michael/A-2116-2009
OI Valdebenito, Gabriel E/0000-0002-7169-6653; Duchen,
   Michael/0000-0003-2548-4294; Chacko, Anitta Rose/0000-0002-9833-1507;
   Chung, Chih-Yao/0000-0002-2263-4181
FU National Agency for Research and Development (ANID)/Scholarship
   Program/DOCTORADO BECAS CHILE [72200527]; Ministry of Education, Taiwan;
   Medical Research Council; MRC DTP-iCASE programme [MR/RO15759/1]; Action
   Medical Research [GN2158]
FX G.E.V. is supported by the National Agency for Research and Development
   (ANID)/Scholarship Program/DOCTORADO BECAS CHILE/2019 - 72200527. C-Y.C.
   was supported by the Government Scholarship to Study Abroad, Ministry of
   Education, Taiwan for his PhD. A.R.C. is supported by the Medical
   Research Council, MRC DTP-iCASE programme [MR/RO15759/1]. Early work in
   the lab in this area was funded by Action Medical Research, grant
   GN2158.
CR Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   Baracca A, 2007, BBA-BIOENERGETICS, V1767, P913, DOI 10.1016/j.bbabio.2007.05.005
   Barriocanal-Casado E, 2019, EBIOMEDICINE, V42, P511, DOI 10.1016/j.ebiom.2019.03.025
   Beretta S, 2004, BRAIN, V127, P2183, DOI 10.1093/brain/awh258
   Brown MD, 2000, J BIOL CHEM, V275, P39831, DOI 10.1074/jbc.M006476200
   Buzkova J, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201809091
   Cagin U, 2015, P NATL ACAD SCI USA, V112, pE6000, DOI 10.1073/pnas.1505036112
   Campos Y, 1997, NEUROLOGY, V49, P595, DOI 10.1212/WNL.49.2.595
   Carelli V, 2002, ARCH NEUROL-CHICAGO, V59, P264, DOI 10.1001/archneur.59.2.264
   Chen QY, 2018, CELL METAB, V27, P1007, DOI 10.1016/j.cmet.2018.03.002
   Chen Z, 2020, J CELL BIOL, V219, DOI 10.1083/jcb.201905160
   Chiang ACY, 2019, CURR BIOL, V29, P4330, DOI 10.1016/j.cub.2019.10.060
   Chou SJ, 2016, SCI REP-UK, V6, DOI 10.1038/srep23661
   Chung CY, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-26746-2
   Craven L, 2017, ANNU REV GENOM HUM G, V18, P257, DOI 10.1146/annurev-genom-091416-035426
   Dai Y, 2014, HUM MOL GENET, V23, P637, DOI 10.1093/hmg/ddt450
   de Andrade PBM, 2006, DIABETOLOGIA, V49, P1816, DOI 10.1007/s00125-006-0301-9
   de la Barca JMC, 2016, BRAIN, V139, P2864, DOI 10.1093/brain/aww222
   Dogan SA, 2018, CELL METAB, V28, P764, DOI 10.1016/j.cmet.2018.07.012
   Esterhuizen K, 2021, METABOLOMICS, V17, DOI 10.1007/s11306-020-01769-w
   Filograna R, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav9824
   Filograna R, 2021, FEBS LETT, V595, P976, DOI 10.1002/1873-3468.14021
   Floreani M, 2005, FEBS J, V272, P1124, DOI 10.1111/j.1742-4658.2004.04542.x
   Forsström S, 2019, CELL METAB, V30, P1040, DOI [10.1016/j.cmet.2019.013.019, 10.1016/j.cmet.2019.08.019]
   Friedman JR, 2014, NATURE, V505, P335, DOI 10.1038/nature12985
   Garrido-Maraver J, 2015, BBA-MOL BASIS DIS, V1852, P2535, DOI 10.1016/j.bbadis.2015.08.027
   Gaude E, 2018, MOL CELL, V69, P581, DOI 10.1016/j.molcel.2018.01.034
   Ghelli A, 2003, J BIOL CHEM, V278, P4145, DOI 10.1074/jbc.M210285200
   Gilkerson RW, 2012, HUM MOL GENET, V21, P978, DOI 10.1093/hmg/ddr529
   Gitschlag BL, 2016, CELL METAB, V24, P91, DOI 10.1016/j.cmet.2016.06.008
   Gorman GS, 2015, ANN NEUROL, V77, P753, DOI 10.1002/ana.24362
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Granatiero V, 2016, CELL DEATH DIFFER, V23, P231, DOI 10.1038/cdd.2015.84
   Guo H, 2012, BBA-MOL BASIS DIS, V1822, P1535, DOI 10.1016/j.bbadis.2012.06.010
   Haroon S, 2018, CELL REP, V22, P3115, DOI 10.1016/j.celrep.2018.02.099
   Hathazi D, 2020, EMBO J, V39, DOI 10.15252/embj.2020105364
   Hirose M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24290-6
   HOWELL N, 1995, GENETICS, V140, P285
   Ignatenko O, 2020, LIFE SCI ALLIANCE, V3, DOI 10.26508/lsa.202000797
   Ishikawa K, 2008, SCIENCE, V320, P661, DOI 10.1126/science.1156906
   Jain IH, 2020, CELL, V181, P716, DOI 10.1016/j.cell.2020.03.029
   Jain IH, 2019, CELL METAB, V30, P824, DOI 10.1016/j.cmet.2019.07.006
   Jain IH, 2016, SCIENCE, V352, P54, DOI 10.1126/science.aad9642
   James AM, 1999, EUR J BIOCHEM, V259, P462, DOI 10.1046/j.1432-1327.1999.00066.x
   James AM, 1996, BIOCHEM J, V318, P401, DOI 10.1042/bj3180401
   Jiang M, 2017, CELL METAB, V26, P429, DOI 10.1016/j.cmet.2017.07.003
   Jiang PP, 2016, HUM MOL GENET, V25, P3613, DOI 10.1093/hmg/ddw199
   Johnson SC, 2013, SCIENCE, V342, P1524, DOI 10.1126/science.1244360
   Jornayvaz FR, 2010, ESSAYS BIOCHEM, V47, P69, DOI [10.1042/BSE0470069, 10.1042/bse0470069]
   Kandul NP, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13100
   Kang LL, 2016, SCI REP-UK, V6, DOI 10.1038/srep31083
   Keshavan N, 2018, ESSAYS BIOCHEM, V62, P423, DOI 10.1042/EBC20170108
   Khan NA, 2017, CELL METAB, V26, P419, DOI 10.1016/j.cmet.2017.07.007
   Kobayashi H, 2021, NAT CHEM BIOL, V17, P335, DOI 10.1038/s41589-020-00676-4
   Kokotas H, 2007, CLIN GENET, V71, P379, DOI 10.1111/j.1399-0004.2007.00800.x
   Kopinski PK, 2019, P NATL ACAD SCI USA, V116, P16028, DOI 10.1073/pnas.1906896116
   Korsten A, 2010, BBA-BIOENERGETICS, V1797, P197, DOI 10.1016/j.bbabio.2009.10.003
   Koshikawa N, 2009, J BIOL CHEM, V284, P33185, DOI 10.1074/jbc.M109.054221
   Kotiadis VN, 2014, BBA-GEN SUBJECTS, V1840, P1254, DOI 10.1016/j.bbagen.2013.10.041
   Kovac S, 2019, MOL NEUROBIOL, V56, P321, DOI 10.1007/s12035-018-1078-9
   Latorre-Pellicer A, 2019, CELL METAB, V30, P1120, DOI 10.1016/j.cmet.2019.09.007
   Lee P, 2020, NAT REV MOL CELL BIO, V21, P268, DOI 10.1038/s41580-020-0227-y
   Lieber T, 2019, NATURE, V570, P380, DOI 10.1038/s41586-019-1213-4
   Lightowlers RN, 2015, SCIENCE, V349, P1494, DOI 10.1126/science.aac7516
   Lin DS, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8010065
   Lin YF, 2016, NATURE, V533, P416, DOI 10.1038/nature17989
   Llorente-Folch I, 2015, J PHYSIOL-LONDON, V593, P3447, DOI 10.1113/JP270254
   Lombardi AA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12103-x
   LUFT R, 1994, P NATL ACAD SCI USA, V91, P8731, DOI 10.1073/pnas.91.19.8731
   MAKELABENGS P, 1995, PEDIATR RES, V37, P634
   Malena A, 2016, AUTOPHAGY, V12, P2098, DOI 10.1080/15548627.2016.1226734
   Malena A, 2009, HUM MOL GENET, V18, P3407, DOI 10.1093/hmg/ddp281
   Martínez-Reyes I, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-13668-3
   McMillan RP, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42262-2
   Mick E, 2020, ELIFE, V9, DOI 10.7554/eLife.49178
   Morvan D, 2018, METABOLOMICS, V14, DOI 10.1007/s11306-018-1345-9
   Mottis A, 2014, MAMM GENOME, V25, P424, DOI 10.1007/s00335-014-9525-z
   Mutai H, 2017, BMC MED GENET, V18, DOI 10.1186/s12881-017-0389-4
   Naini AB, 2005, ARCH NEUROL-CHICAGO, V62, P473, DOI 10.1001/archneur.62.3.473
   Ng MYW, 2021, DEV CELL, V56, P881, DOI 10.1016/j.devcel.2021.02.009
   Nikkanen J, 2016, CELL METAB, V23, P635, DOI 10.1016/j.cmet.2016.01.019
   Nishioka T, 2003, J HUM GENET, V48, P385, DOI 10.1007/s10038-003-004-2
   Pallotti F, 2004, BIOCHEM J, V384, P287, DOI 10.1042/BJ20040561
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   Peng TI, 2006, BBA-MOL BASIS DIS, V1762, P241, DOI 10.1016/j.bbadis.2005.10.008
   Perry EA, 2021, NAT METAB, V3, P33, DOI 10.1038/s42255-020-00334-y
   Pezet MG, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-02069-2
   Picard M, 2014, P NATL ACAD SCI USA, V111, pE4033, DOI 10.1073/pnas.1414028111
   Pitceathly RDS, 2021, J INHERIT METAB DIS, V44, P22, DOI 10.1002/jimd.12281
   Rawle MJ, 2013, CASE REP NEUROL, V5, P204, DOI 10.1159/000357518
   REID FM, 1994, HUM MUTAT, V3, P243, DOI 10.1002/humu.1380030311
   Rusanen H, 2000, BBA-MOL BASIS DIS, V1500, P10, DOI 10.1016/S0925-4439(99)00081-2
   Russell OM, 2020, CELL, V181, P168, DOI 10.1016/j.cell.2020.02.051
   SANTORELLI FM, 1993, ANN NEUROL, V34, P827, DOI 10.1002/ana.410340612
   Sgarbi G, 2006, BIOCHEM J, V395, P493, DOI 10.1042/BJ20051748
   Sharma A.K., 2016, BMJ CASE REP, V2016
   Sharma R, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI136055
   Stewart JB, 2015, NAT REV GENET, V16, P530, DOI 10.1038/nrg3966
   Suen DF, 2010, P NATL ACAD SCI USA, V107, P11835, DOI 10.1073/pnas.0914569107
   Suomalainen A, 2018, NAT REV MOL CELL BIO, V19, P77, DOI 10.1038/nrm.2017.66
   SWEENEY MG, 1993, Q J MED, V86, P709
   Szczepanowska J, 2012, BBA-BIOENERGETICS, V1817, P1740, DOI 10.1016/j.bbabio.2012.02.028
   TATUCH Y, 1992, AM J HUM GENET, V50, P852
   Tay SKH, 2005, J CHILD NEUROL, V20, P142, DOI 10.1177/08830738050200022301
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Taylor RW, 2002, EUR J HUM GENET, V10, P141, DOI 10.1038/sj.ejhg.5200773
   Valenci I, 2015, MITOCHONDRION, V20, P64, DOI 10.1016/j.mito.2014.11.001
   Van Bergen NJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140919
   van Gisbergen MW, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00770
   Wallace DC, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a021220
   Wei W, 2020, J INTERN MED, V287, P634, DOI 10.1111/joim.13047
   Wiese M, 2020, MOL METAB, V38, DOI 10.1016/j.molmet.2020.01.006
   Wojewoda M, 2011, INT J BIOCHEM CELL B, V43, P1178, DOI 10.1016/j.biocel.2011.04.011
   Wong A, 2002, HUM MOL GENET, V11, P431, DOI 10.1093/hmg/11.4.431
   Wu SB, 2012, BBA-MOL BASIS DIS, V1822, P233, DOI 10.1016/j.bbadis.2011.09.014
   Xu F, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578-020-00416-0
   Zhao LL, 2019, ENZYMES, V45, P311, DOI 10.1016/bs.enz.2019.08.004
   Zheng XD, 2016, ELIFE, V5, DOI 10.7554/eLife.13378
NR 118
TC 12
Z9 12
U1 1
U2 12
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0962-8924
EI 1879-3088
J9 TRENDS CELL BIOL
JI Trends Cell Biol.
PD MAY
PY 2022
VL 32
IS 5
BP 391
EP 405
DI 10.1016/j.tcb.2021.10.005
EA APR 2022
PG 15
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 1G3TR
UT WOS:000795773900006
PM 34836781
OA Green Published, hybrid
DA 2024-11-01
ER

PT J
AU Smolina, N
   Khudiakov, A
   Knyazeva, A
   Zlotina, A
   Sukhareva, K
   Kondratov, K
   Gogvadze, V
   Zhivotovsky, B
   Sejersen, T
   Kostareva, A
AF Smolina, Natalia
   Khudiakov, Aleksandr
   Knyazeva, Anastasiya
   Zlotina, Anna
   Sukhareva, Kseniya
   Kondratov, Kirill
   Gogvadze, Vladimir
   Zhivotovsky, Boris
   Sejersen, Thomas
   Kostareva, Anna
TI Desmin mutations result in mitochondrial dysfunction regardless of their
   aggregation properties
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
LA English
DT Article
DE Desmin; Extracellular vesicles; Mitochondria; mtDNA; Satellite cells;
   Skeletal myopathy
ID INTERMEDIATE-FILAMENTS; ENERGY-METABOLISM; SKELETAL-MUSCLE;
   CYTOSKELETON; RESPIRATION; MYOPATHY; DESMINOPATHIES; RELEASE; PLECTIN;
   CELLS
AB Desmin, being a major intermediate filament of muscle cells, contributes to stabilization and positioning of mitochondria. Desmin mutations have been reported in conjunction with skeletal myopathies accompanied by mitochondrial dysfunction. Depending on the ability to promote intracellular aggregates formation, mutations can be considered aggregate-prone or non-aggregate-prone. The aim of the present study was to describe how expression of different desmin mutant isoforms effects mitochondria and contributes to the development of myocyte dysfunction. To achieve this goal, two non-aggregate-prone (Des S12F and Des A213V) and four aggregate-prone (Des L345P, Des A357P, Des L370P, Des D399Y) desmin mutations were expressed in skeletal muscle cells. We showed that all evaluated mutations affected the morphology of mitochondrial network, suppressed parameters of mitochondrial respiration, diminished mitochondrial membrane potential, increased ADP/ATP ratio, and enhanced mitochondrial DNA (mtDNA) release. mtDNA was partially secreted through exosomes as demonstrated by GW4869 treatment. Dysfunction of mitochondria was observed regardless the type of mutation: aggregate-prone or non-aggregate-prone. However, expression of aggregate-prone mutations resulted in more prominent phenotype. Thus, in this comparative study of six pathogenic desmin mutations that cause skeletal myopathy development, we confirmed a role of mitochondrial dysfunction and mtDNA release in the pathogenesis of desmin myopathies, regardless of the aggregation capacity of the mutated desmin.
C1 [Smolina, Natalia; Khudiakov, Aleksandr; Knyazeva, Anastasiya; Zlotina, Anna; Sukhareva, Kseniya; Kondratov, Kirill; Kostareva, Anna] Almazov Natl Med Res Ctr, St Petersburg, Russia.
   [Smolina, Natalia; Sejersen, Thomas; Kostareva, Anna] Karolinska Inst, Dept Womens & Childrens Hlth, Stockholm, Sweden.
   [Sukhareva, Kseniya] Univ Verona, Verona, Italy.
   [Gogvadze, Vladimir; Zhivotovsky, Boris] Lomonosov Moscow State Univ, Fac Med, Moscow, Russia.
   [Gogvadze, Vladimir; Zhivotovsky, Boris] Karolinska Inst, Inst Environm Med, Stockholm, Sweden.
C3 Almazov National Medical Research Centre; Karolinska Institutet;
   University of Verona; Lomonosov Moscow State University; Karolinska
   Institutet
RP Smolina, N (corresponding author), Almazov Natl Med Res Ctr, St Petersburg, Russia.
EM natalia.smolina@ki.se
RI Sukhareva, Kseniia/ABI-6059-2020; Smolina, Natalia/D-5840-2014;
   Kostareva, Anna/AAO-5429-2020; Khudiakov, Aleksandr/H-1408-2016;
   Zlotina, Anna/J-2531-2013
OI Sukhareva, Kseniia/0000-0002-8194-2002; Khudiakov,
   Aleksandr/0000-0001-9214-0868; Zlotina, Anna/0000-0002-2029-1197
FU Russian Science Foundation [19-14-00122, 14-16-00745]; Swedish Institute
   [25932/2018]; Swedish Cancer Societies [190345]; Stockholm County
   Council [20170831]; Stiftelsen Frimurare Foundation [190528]; Promobilia
   [19039];  [181301]; Russian Science Foundation [19-14-00122] Funding
   Source: Russian Science Foundation
FX This work was supported by grant from the Russian Science Foundation
   (14-16-00745). Experiments on SeaHorse Analyzer were supported by the
   Russian Science Foundation (19-14-00122). AK was supported by Swedish
   Institute grant 25932/2018. BZ and VG were also supported by the
   Stockholm (181301) and Swedish Cancer Societies (190345). TS was
   supported by Stockholm County Council (20170831), Stiftelsen Frimurare
   Foundation (190528), and Promobilia (19039).
CR Alam S, 2018, J AM HEART ASSOC, V7, DOI 10.1161/JAHA.118.009289
   Appaix F, 2003, EXP PHYSIOL, V88, P175, DOI 10.1113/eph8802511
   Arias M, 2006, NEUROMUSCULAR DISORD, V16, P498, DOI 10.1016/j.nmd.2006.05.011
   Bär H, 2006, J MOL BIOL, V360, P1031, DOI 10.1016/j.jmb.2006.05.068
   Balaban RS, 2009, J MOL CELL CARDIOL, V46, P832, DOI 10.1016/j.yjmcc.2009.02.018
   Balaban RS, 2002, J MOL CELL CARDIOL, V34, P1259, DOI 10.1006/jmcc.2002.2082
   Brodehl Andreas, 2018, Biophys Rev, V10, P983, DOI 10.1007/s12551-018-0429-0
   Cabet E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137009
   Chernoivanenko IS, 2015, FASEB J, V29, P820, DOI 10.1096/fj.14-259903
   Clemen CS, 2013, ACTA NEUROPATHOL, V125, P47, DOI 10.1007/s00401-012-1057-6
   Cudré-Mauroux C, 2003, HUM GENE THER, V14, P1525, DOI 10.1089/104303403322495034
   Dalakas MC, 2003, NEUROMUSCULAR DISORD, V13, P252, DOI 10.1016/S0960-8966(02)00271-7
   Dedkova EN, 2008, CELL CALCIUM, V44, P77, DOI 10.1016/j.ceca.2007.11.002
   Dold T, 2012, NEUROMUSCULAR DISORD, V22, P822, DOI 10.1016/j.nmd.2012.06.070
   Fearon U, 2016, NAT REV RHEUMATOL, V12, P385, DOI 10.1038/nrrheum.2016.69
   Fidzianska A, 2005, NEUROMUSCULAR DISORD, V15, P525, DOI 10.1016/j.nmd.2005.05.006
   Forterre A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084153
   Fountoulakis M, 2005, J MOL CELL CARDIOL, V38, P461, DOI 10.1016/j.yjmcc.2004.12.008
   Goldfarb LG, 2008, ADV EXP MED BIOL, V642, P131
   Gonzalez-Hunt Claudia P, 2016, Curr Protoc Toxicol, V67, DOI 10.1002/0471140856.tx2011s67
   Goudeau B, 2006, HUM MUTAT, V27, P906, DOI 10.1002/humu.20351
   Guescini M, 2010, EXP CELL RES, V316, P1977, DOI 10.1016/j.yexcr.2010.04.006
   Jackson S, 2015, EUR J NEUROL, V22, P1429, DOI 10.1111/ene.12814
   Kay L, 1997, BBA-BIOENERGETICS, V1322, P41, DOI 10.1016/S0005-2728(97)00071-6
   Kostareva A, 2006, Acta Myol, V25, P109
   Kreplak L, 2009, J MOL BIOL, V385, P1043, DOI 10.1016/j.jmb.2008.10.095
   LAZARIDES E, 1976, P NATL ACAD SCI USA, V73, P4344, DOI 10.1073/pnas.73.12.4344
   Lowery J, 2015, J BIOL CHEM, V290, P17145, DOI 10.1074/jbc.R115.640359
   Maloyan A, 2009, CIRC RES, V104, P1021, DOI 10.1161/CIRCRESAHA.108.193516
   MCCORMACK JG, 1990, P NUTR SOC, V49, P57, DOI 10.1079/PNS19900009
   McCormick EM, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00199
   Milner DJ, 2000, J CELL BIOL, V150, P1283, DOI 10.1083/jcb.150.6.1283
   Nakahira K, 2015, ANTIOXID REDOX SIGN, V23, P1329, DOI 10.1089/ars.2015.6407
   Patrushev M, 2004, CELL MOL LIFE SCI, V61, P3100, DOI 10.1007/s00018-004-4424-1
   Petronilli V, 1999, BIOPHYS J, V76, P725, DOI 10.1016/S0006-3495(99)77239-5
   Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143
   Reipert S, 1999, EXP CELL RES, V252, P479, DOI 10.1006/excr.1999.4626
   Schröder R, 2003, HUM MOL GENET, V12, P657, DOI 10.1093/hmg/ddg060
   Segard BD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076361
   Sjöberg G, 1999, HUM MOL GENET, V8, P2191, DOI 10.1093/hmg/8.12.2191
   Smolina N, 2017, METHODS MOL BIOL, V1601, P79, DOI 10.1007/978-1-4939-6960-9_7
   Smolina N, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/594751
   Smolina N, 2014, CELL CALCIUM, V56, P269, DOI 10.1016/j.ceca.2014.08.001
   Svitkina TM, 1996, J CELL BIOL, V135, P991, DOI 10.1083/jcb.135.4.991
   THORNELL LE, 1980, J NEUROL SCI, V47, P153, DOI 10.1016/0022-510X(80)90001-5
   Tsikitis Mary, 2018, Biophys Rev, V10, P1007, DOI 10.1007/s12551-018-0443-2
   Varhaug KN, 2017, MITOCHONDRION, V34, P32, DOI 10.1016/j.mito.2016.12.003
   Varikmaa M, 2014, BBA-BIOENERGETICS, V1837, P232, DOI 10.1016/j.bbabio.2013.10.011
   Vernengo L, 2010, NEUROMUSCULAR DISORD, V20, P178, DOI 10.1016/j.nmd.2010.01.001
   Vincent AE, 2016, NEUROMUSCULAR DISORD, V26, P691, DOI 10.1016/j.nmd.2016.08.004
   Vrabie A, 2005, ACTA NEUROPATHOL, V109, P411, DOI 10.1007/s00401-005-0980-1
   WEBER K, 1985, ANN NY ACAD SCI, V455, P126, DOI 10.1111/j.1749-6632.1985.tb50408.x
   Winter L, 2019, NEUROPATH APPL NEURO, V45, P476, DOI 10.1111/nan.12516
   Winter L, 2016, ACTA NEUROPATHOL, V132, P453, DOI 10.1007/s00401-016-1592-7
NR 54
TC 23
Z9 23
U1 0
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0925-4439
EI 1879-260X
J9 BBA-MOL BASIS DIS
JI Biochim. Biophys. Acta-Mol. Basis Dis.
PD JUN 1
PY 2020
VL 1866
IS 6
AR 165745
DI 10.1016/j.bbadis.2020.165745
PG 10
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA LG2PT
UT WOS:000527950000009
PM 32105824
DA 2024-11-01
ER

PT J
AU Dillon, LM
   Williams, SL
   Hida, A
   Peacock, JD
   Prolla, TA
   Lincoln, J
   Moraes, CT
AF Dillon, Lloye M.
   Williams, Sion L.
   Hida, Aline
   Peacock, Jacqueline D.
   Prolla, Tomas A.
   Lincoln, Joy
   Moraes, Carlos T.
TI Increased mitochondrial biogenesis in muscle improves aging phenotypes
   in the mtDNA mutator mouse
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID OXIDATIVE-PHOSPHORYLATION; SKELETAL-MUSCLE; POINT MUTATIONS; DNA
   MUTATIONS; PGC-1-ALPHA; INDUCTION; STRIATUM; PROTECTS; MYOPATHY; STRESS
AB Aging is an intricate process that increases susceptibility to sarcopenia and cardiovascular diseases. The accumulation of mitochondrial DNA (mtDNA) mutations is believed to contribute to mitochondrial dysfunction, potentially shortening lifespan. The mtDNA mutator mouse, a mouse model with a proofreading-deficient mtDNA polymerase , was shown to develop a premature aging phenotype, including sarcopenia, cardiomyopathy and decreased lifespan. This phenotype was associated with an accumulation of mtDNA mutations and mitochondrial dysfunction. We found that increased expression of peroxisome proliferator-activated receptor coactivator-1 (PGC-1), a crucial regulator of mitochondrial biogenesis and function, in the muscle of mutator mice increased mitochondrial biogenesis and function and also improved the skeletal muscle and heart phenotypes of the mice. Deep sequencing analysis of their mtDNA showed that the increased mitochondrial biogenesis did not reduce the accumulation of mtDNA mutations but rather caused a small increase. These results indicate that increased muscle PGC-1 expression is able to improve some premature aging phenotypes in the mutator mice without reverting the accumulation of mtDNA mutations.
C1 [Dillon, Lloye M.; Moraes, Carlos T.] Univ Miami, Miller Sch Med, Dept Cell Biol & Anat, Miami, FL 33136 USA.
   [Williams, Sion L.; Hida, Aline; Moraes, Carlos T.] Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA.
   [Peacock, Jacqueline D.; Lincoln, Joy] Univ Miami, Miller Sch Med, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA.
   [Prolla, Tomas A.] Univ Wisconsin, Dept Genet, Madison, WI 53706 USA.
C3 University of Miami; University of Miami; University of Miami;
   University of Wisconsin System; University of Wisconsin Madison
RP Moraes, CT (corresponding author), 1420 NW 9th Ave,Rm 229, Miami, FL 33136 USA.
EM cmoraes@med.miami.edu
RI Moraes, Carlos/AAT-3818-2021
OI Lincoln, Joy/0000-0003-1517-6888; Dillon, Lloye/0000-0002-5118-1126
FU National Institutes of Health [EY010804, AG036871]; Muscular Dystrophy
   Association; James & Esther King Biomedical Research Program
FX This work was supported by the National Institutes of Health Grant
   EY010804, AG036871 the Muscular Dystrophy Association and the James &
   Esther King Biomedical Research Program (C.T.M.).
CR Ameur A, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002028
   Arany Z, 2005, CELL METAB, V1, P259, DOI 10.1016/j.cmet.2005.03.002
   Arany Z, 2008, NATURE, V451, P1008, DOI 10.1038/nature06613
   Arnold AS, 2011, GERONTOLOGY, V57, P37, DOI 10.1159/000281883
   Barrientos A, 2002, METHODS, V26, P307, DOI 10.1016/S1046-2023(02)00036-1
   Biernacka A, 2011, AGING DIS, V2, P158
   Brault JJ, 2010, J BIOL CHEM, V285, P19460, DOI 10.1074/jbc.M110.113092
   Cheung MC, 2009, J SURG RES, V153, P326, DOI 10.1016/j.jss.2008.05.002
   Conley KE, 2007, EXERC SPORT SCI REV, V35, P43
   de Souza RR, 2002, BIOGERONTOLOGY, V3, P325, DOI 10.1023/A:1021312027486
   Edgar D, 2009, CELL METAB, V10, P131, DOI 10.1016/j.cmet.2009.06.010
   Figueiredo PA, 2008, BIOGERONTOLOGY, V9, P67, DOI 10.1007/s10522-007-9121-7
   Fukui H, 2008, TRENDS NEUROSCI, V31, P251, DOI 10.1016/j.tins.2008.02.008
   Handschin C, 2007, J BIOL CHEM, V282, P30014, DOI 10.1074/jbc.M704817200
   Hiona A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011468
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268
   Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904
   Lira VA, 2010, AM J PHYSIOL-ENDOC M, V299, pE145, DOI 10.1152/ajpendo.00755.2009
   Loeb LA, 2005, P NATL ACAD SCI USA, V102, P18769, DOI 10.1073/pnas.0509776102
   Martinez B, 2001, J NEUROCHEM, V78, P1054, DOI 10.1046/j.1471-4159.2001.00487.x
   Meissner C, 2007, Z GERONTOL GERIATR, V40, P325, DOI 10.1007/s00391-007-0481-z
   Meissner C, 2006, EXP GERONTOL, V41, P518, DOI 10.1016/j.exger.2006.03.010
   Mohamed SA, 2006, EXP GERONTOL, V41, P508, DOI 10.1016/j.exger.2006.03.014
   Peacock JD, 2010, CIRC RES, V106, P712, DOI 10.1161/CIRCRESAHA.109.213702
   Pickrell AM, 2011, J NEUROSCI, V31, P9895, DOI 10.1523/JNEUROSCI.6223-10.2011
   Polisecki EY, 2004, J FORENSIC SCI, V49, P1335
   Rebelo AP, 2011, J INHERIT METAB DIS, V34, P941, DOI 10.1007/s10545-011-9330-8
   Rowe GC, 2010, CIRC RES, V107, P825, DOI 10.1161/CIRCRESAHA.110.223818
   Russell LK, 2004, CIRC RES, V94, P525, DOI 10.1161/01.RES.0000117088.36577.EB
   Safdar A, 2011, J BIOL CHEM, V286, P10605, DOI 10.1074/jbc.M110.211466
   Safdar A, 2011, P NATL ACAD SCI USA, V108, P4135, DOI 10.1073/pnas.1019581108
   Sandri M, 2006, P NATL ACAD SCI USA, V103, P16260, DOI 10.1073/pnas.0607795103
   Sciacco M, 1996, Methods Enzymol, V264, P509, DOI 10.1016/S0076-6879(96)64045-2
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Trifunovic A, 2006, BBA-BIOENERGETICS, V1757, P611, DOI 10.1016/j.bbabio.2006.03.003
   Vermulst M, 2007, NAT GENET, V39, P540, DOI 10.1038/ng1988
   Viña J, 2009, ADV DRUG DELIVER REV, V61, P1369, DOI 10.1016/j.addr.2009.06.006
   Wenz T, 2008, CELL METAB, V8, P249, DOI 10.1016/j.cmet.2008.07.006
   Wenz T, 2009, P NATL ACAD SCI USA, V106, P20405, DOI 10.1073/pnas.0911570106
   Wiesner RJ, 2006, FREE RADICAL RES, V40, P1284, DOI 10.1080/10715760600913168
   Williams SL, 2010, CELL METAB, V12, P675, DOI 10.1016/j.cmet.2010.11.012
   Zahn JM, 2006, PLOS GENET, V2, P1058, DOI 10.1371/journal.pgen.0020115
NR 44
TC 74
Z9 85
U1 3
U2 15
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD MAY 15
PY 2012
VL 21
IS 10
BP 2288
EP 2297
DI 10.1093/hmg/dds049
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 933BH
UT WOS:000303333700013
PM 22357654
OA Green Published, Bronze
DA 2024-11-01
ER

PT J
AU Baric, I
   Fumic, K
   Ramadza, DP
   Sperl, W
   Zimmermann, FA
   Muacevic-Katanec, D
   Mitrovic, Z
   Pazanin, L
   Sojat, LC
   Kekez, T
   Reiner, Z
   Mayr, JA
AF Baric, Ivo
   Fumic, Ksenija
   Ramadza, Danijela Petkovic
   Sperl, Wolfgang
   Zimmermann, Franz A.
   Muacevic-Katanec, Diana
   Mitrovic, Zoran
   Pazanin, Leo
   Sojat, Ljerka Cvitanovic
   Kekez, Tihomir
   Reiner, Zeljko
   Mayr, Johannes A.
TI Mitochondrial myopathy associated with a novel 5522G&gt;A mutation in
   the mitochondrial tRNA<SUP>Trp</SUP> gene
SO EUROPEAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
DE mitochondrial myopathy; mtDNA mutation; tRNA(Trp)
ID TRANSFER-RNA; POINT MUTATION; DNA; GENOME; ENCEPHALOPATHY;
   PATHOGENICITY; DEFICIENCY; DISORDERS; INSERTION
AB We report a novel pathogenic mutation of the mitochondrial transfer RNA (tRNA) gene for tryptophan in a patient with isolated myopathy and persistently elevated creatine kinase. Muscle studies revealed ragged red fibres and decreased activity of respiratory chain complex I and cytochrome c oxidase (COX). Sequencing of the 22 mitochondrial tRNA genes revealed a mutation m.5522G>A, which alters a conserved base pairing in the D-stem of the tRNA for tryptophan. The mutation was heteroplasmic with a mutational load between 88 and 99% in COX-negative fibres. This case contributes to the genetic heterogeneity of mitochondrial diseases caused by mutations in mitochondrial tRNA genes.
C1 [Baric, Ivo; Ramadza, Danijela Petkovic] Univ Hosp Ctr Zagreb, Dept Paediat, Zagreb 10000, Croatia.
   [Baric, Ivo; Muacevic-Katanec, Diana; Reiner, Zeljko] Univ Zagreb, Sch Med, Zagreb 41001, Croatia.
   [Fumic, Ksenija] Univ Hosp Ctr Zagreb, Dept Paediat, Clin Inst Lab Diag, Zagreb 10000, Croatia.
   [Sperl, Wolfgang; Zimmermann, Franz A.; Mayr, Johannes A.] Paracelsus Med Univ, Dept Paediat, Salzburg, Austria.
   [Muacevic-Katanec, Diana; Reiner, Zeljko] Univ Hosp Ctr Zagreb, Dept Internal Med, Zagreb 10000, Croatia.
   [Mitrovic, Zoran] Univ Hosp Ctr Zagreb, Natl Ctr Neuromuscular Dis, Zagreb 10000, Croatia.
   [Mitrovic, Zoran] Univ Hosp Ctr Zagreb, Dept Neurol, Zagreb 10000, Croatia.
   [Pazanin, Leo] Univ Hosp Ctr Zagreb, Clin Inst Pathol & Cytol, Zagreb 10000, Croatia.
   [Sojat, Ljerka Cvitanovic] Univ Hosp Ctr Sestre Milosrdnice, Dept Paediat, Zagreb, Croatia.
   [Kekez, Tihomir] Univ Hosp Ctr Zagreb, Dept Surg, Zagreb 10000, Croatia.
C3 University of Zagreb; University of Zagreb; University of Zagreb;
   Paracelsus Private Medical University; University of Zagreb; University
   of Zagreb; University of Zagreb; University of Zagreb; University of
   Zagreb
RP Baric, I (corresponding author), Univ Hosp Ctr Zagreb, Dept Paediat, Kispaticeva 12, Zagreb 10000, Croatia.
EM ibaric@kbc-zagreb.hr
RI Petković Ramadža, Danijela/AAQ-7287-2021
OI Mayr, Johannes/0000-0001-6970-336X
FU Ministry of Science, Education and Sport, Republic of Croatia
   [108-1081870-1885]; E-rare 2 (European Research Projects on Rare
   Diseases) 'Mitochondriopathy-Network for diagnostics and therapy
   (GENOMIT)'; FWF [I 920-B13]
FX This work was supported by Ministry of Science, Education and Sport,
   Republic of Croatia (grant no.: 108-1081870-1885) and the E-rare 2
   (European Research Projects on Rare Diseases) 'Mitochondriopathy-Network
   for diagnostics and therapy (GENOMIT)' financed by the FWF project
   number I 920-B13.
CR Anitori R, 2005, MOL GENET METAB, V84, P176, DOI 10.1016/j.ymgme.2004.10.003
   Baird MF, 2012, J NUTR METAB, V2012, DOI 10.1155/2012/960363
   BOULET L, 1992, AM J HUM GENET, V51, P1187
   Chinnery PF, 1999, J MED GENET, V36, P425
   Crimi M, 2008, INT J NANOMED, V3, P51
   Filosto M, 2007, BIOSCIENCE REP, V27, P23, DOI 10.1007/s10540-007-9034-3
   Florentz C, 2003, CELL MOL LIFE SCI, V60, P1356, DOI 10.1007/s00018-003-2343-1
   Ingman M, 2000, NATURE, V408, P708, DOI 10.1038/35047064
   Kaufmann P, 2009, ARCH NEUROL-CHICAGO, V66, P85, DOI 10.1001/archneurol.2008.526
   Kleinle S, 1998, BIOCHEM BIOPH RES CO, V247, P112, DOI 10.1006/bbrc.1998.8729
   Leonard JV, 2000, LANCET, V355, P299, DOI 10.1016/S0140-6736(99)05225-3
   Malfatti E, 2010, J NEUROL SCI, V297, P105, DOI 10.1016/j.jns.2010.06.009
   Maniura-Weber K, 2004, EUR J HUM GENET, V12, P509, DOI 10.1038/sj.ejhg.5201185
   Mayr JA, 2004, PEDIATR RES, V55, P988, DOI 10.1203/01.pdr.0000127016.67809.6b
   Meierhofer D, 2005, MITOCHONDRION, V5, P282, DOI 10.1016/j.mito.2005.06.001
   MITOMAP, 2012, MITOMAP HUM MIT GEN
   Mkaouar-Rebai E, 2009, MOL GENET METAB, V97, P179, DOI 10.1016/j.ymgme.2009.03.003
   Montoya J, 2009, BBA-BIOENERGETICS, V1787, P476, DOI 10.1016/j.bbabio.2008.09.003
   NELSON I, 1995, ANN NEUROL, V37, P400, DOI 10.1002/ana.410370317
   OLDFORS A, 1995, J NEUROPATH EXP NEUR, V54, P581, DOI 10.1097/00005072-199507000-00012
   Sacconi S, 2008, HUM MOL GENET, V17, P1814, DOI 10.1093/hmg/ddn073
   Sanaker PS, 2010, ACTA NEUROL SCAND, V121, P109, DOI 10.1111/j.1600-0404.2009.01243.x
   Santorelli FM, 1997, ANN NEUROL, V42, P256, DOI 10.1002/ana.410420220
   Scaglia F, 2008, MUSCLE NERVE, V37, P150, DOI 10.1002/mus.20917
   Servidei Serenella, 2003, Neuromuscul Disord, V13, P848
   Silvestri G, 1998, NEUROMUSCULAR DISORD, V8, P291, DOI 10.1016/S0960-8966(98)00037-6
   Silvestri G, 2000, NEUROLOGY, V54, P1693, DOI 10.1212/WNL.54.8.1693
   Smits P, 2010, EUR J HUM GENET, V18, P324, DOI 10.1038/ejhg.2009.169
   Taanman JW, 1999, BBA-BIOENERGETICS, V1410, P103, DOI 10.1016/S0005-2728(98)00161-3
   Thorburn DR, 2001, AM J MED GENET, V106, P102, DOI 10.1002/ajmg.1380
   Tulinius M, 2003, NEUROPEDIATRICS, V34, P87
   Tuppen HAL, 2010, BBA-BIOENERGETICS, V1797, P113, DOI 10.1016/j.bbabio.2009.09.005
   Valente L, 2009, BBA-BIOENERGETICS, V1787, P491, DOI 10.1016/j.bbabio.2008.10.001
   Yarham JW, 2011, HUM MUTAT, V32, P1319, DOI 10.1002/humu.21575
NR 34
TC 11
Z9 12
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1018-4813
EI 1476-5438
J9 EUR J HUM GENET
JI Eur. J. Hum. Genet.
PD AUG
PY 2013
VL 21
IS 8
BP 871
EP 875
DI 10.1038/ejhg.2012.272
PG 5
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 185FI
UT WOS:000321951100014
PM 23232693
OA Bronze, Green Published
DA 2024-11-01
ER

PT J
AU Marotta, R
   Chin, J
   Quigley, A
   Katsabanis, S
   Kapsa, R
   Byrne, E
   Collins, S
AF Marotta, R
   Chin, J
   Quigley, A
   Katsabanis, S
   Kapsa, R
   Byrne, E
   Collins, S
TI Diagnostic screening of mitochondrial DNA mutations in Australian adults
   1990-2001
SO INTERNAL MEDICINE JOURNAL
LA English
DT Article
DE mitochondria; genome; mutation; polymerase chain reaction; restriction
   fragment length polymorphism
ID HEREDITARY OPTIC NEUROPATHY; RAGGED-RED FIBERS; MYOCLONIC EPILEPSY;
   INTRAMITOCHONDRIAL FIBERS; GENE; ENCEPHALOMYOPATHIES; MYOPATHY; DISEASE;
   MELAS; MERRF
AB Background: Many diverse pathogenic mitochondrial DNA (mtDNA) mutations have been described since 1988. The Melbourne Neuromuscular Research Institute (MNRI) has undertaken diagnostic detection of selected mtDNA mutations since 1990. MtDNA mutations screened have included point mutations associated with Leber's hereditary optic neuropathy (LHON; G3460A, G11778A and T14484C), mitochondrial encephalopathy lactic acidosis and stroke-like episodes (MELAS; A3243G), myoclonus epilepsy and ragged red fibres (MERRF; A8344G) and Leigh's syndrome/neuropathy ataxia retinitis pigmentosa (LS/NARP; T8993C/G). Samples have also been screened for deletions/ rearrangements associated with Kearns-Sayre syndrome (KSS) and chronic progressive external ophthalmoplegia (CPEO).
   Aims: To present an audit of the MNRI mtDNA diagnostic service between 1990 and 2001, encompassing 1725 referred patients.
   Methods: The detection techniques carried out included polymerase chain reaction amplification of mtDNA combined with restriction fragment length polymorphism analysis for mtDNA point mutation detection, supplemented with selected sequence analysis and Southern blots for the detection of deletions/ rearrangements. Tissues tested included blood, hair and skeletal muscle.
   Results: Of the 1184 patients screened for MELAS A3243G, 6.17% were positive for the mutation, whereas for MERRF A8344G, 2.21% carried the mutation and for LS/NARP T8993C/G, 0.32% carried the mutation. The outcomes for the LHON mutations were G11778A, 6.60%, T14484C, 5.76% and G3460A, 0.29%. Of the patients referred for KSS and CPEO, 17.72% had deletions/rearrangements.
   Conclusions: Overall, the detection rate of mtDNA point mutations was low. The protean clinical features of mitochondrial disorders and the frequency of partial phenotypes lead to requests for tests in many patients with a relatively low likelihood of mtDNA mutations. An improved algorithm could involve mutation screening appropriate to the phenotype using sequencing of selected mtDNA regions in patients with a high likelihood of mtDNA disease. Features increasing the likelihood of mtDNA mutations include the following: (i) a typical phenotype, (ii) a maternal inheritance pattern and (iii) histochemical evidence of mitochondrial abnormality in the muscle biopsy. Efficient laboratory diagnosis of mtDNA disease involves good communication between the physician and laboratory scientists, coupled with screening of the appropriate tissue.
C1 St Vincents Hosp, Dept Clin Neurosci, Melbourne Neuromuscular Res Inst, Mitochondrial DNA Diagnost Lab, Fitzroy, Vic 3065, Australia.
   Peter MacCallum Canc Inst, Melbourne, Vic, Australia.
   Univ Melbourne, Ctr Neurosci Victoria, Melbourne, Vic, Australia.
C3 St Vincent's Health; St Vincent's Hospital Melbourne; NSW Health; St
   Vincents Hospital Sydney; Peter Maccallum Cancer Center; University of
   Melbourne
RP Marotta, R (corresponding author), St Vincents Hosp, Dept Clin Neurosci, Melbourne Neuromuscular Res Inst, Mitochondrial DNA Diagnost Lab, 41 Victoria Parade, Fitzroy, Vic 3065, Australia.
EM marottr@svhm.org.au
RI Kapsa, Robert/H-8916-2013
OI Quigley, Anita/0000-0002-4060-2079; Kapsa, Robert Michail
   Ivan/0000-0002-6113-5174
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Blumenthal DT, 1998, NEUROLOGY, V50, P524, DOI 10.1212/WNL.50.2.524
   Brown MD, 2001, AM J MED GENET, V104, P331, DOI 10.1002/1096-8628(2001)104:4<331::AID-AJMG10054>3.0.CO;2-8
   BYRNE E, 1991, MED J AUSTRALIA, V154, P646, DOI 10.5694/j.1326-5377.1991.tb121246.x
   Chinnery PE, 1998, BRAIN, V121, P1889, DOI 10.1093/brain/121.10.1889
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   Chinnery PF, 2001, BRAIN, V124, P209, DOI 10.1093/brain/124.1.209
   DIMAURO S, 1993, ARCH NEUROL-CHICAGO, V50, P1197, DOI 10.1001/archneur.1993.00540110075008
   DIMAURO S, 1994, CURRENT DIAGNOSIS NE, P340
   FUKUHARA N, 1980, J NEUROL SCI, V47, P117, DOI 10.1016/0022-510X(80)90031-3
   GILES RE, 1980, P NATL ACAD SCI-BIOL, V77, P6715, DOI 10.1073/pnas.77.11.6715
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Howell N, 2002, J NEURO-OPHTHALMOL, V22, P262, DOI 10.1097/00041327-200212000-00002
   Kogelnik AM, 1998, NUCLEIC ACIDS RES, V26, P112, DOI 10.1093/nar/26.1.112
   KOTSIMBOS N, 1994, HUM MUTAT, V4, P132, DOI 10.1002/humu.1380040207
   Lamont PJ, 1998, ARCH DIS CHILD, V79, P22, DOI 10.1136/adc.79.1.22
   LERTRIT P, 1992, HUM GENET, V90, P251
   Lewis S, 2002, J NEUROL SCI, V201, P39, DOI 10.1016/S0022-510X(02)00190-9
   MCKELVIE PA, 1991, J NEUROL SCI, V102, P51, DOI 10.1016/0022-510X(91)90093-M
   NASS MMK, 1966, P NATL ACAD SCI USA, V56, P1215, DOI 10.1073/pnas.56.4.1215
   NASS MMK, 1963, J CELL BIOL, V19, P593, DOI 10.1083/jcb.19.3.593
   NASS S, 1963, J CELL BIOL, V19, P613, DOI 10.1083/jcb.19.3.613
   NAVIAUX RK, 1999, SPECTRUM MITOCHONDRI
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   Quigley A, 2001, J Clin Neuromuscul Dis, V3, P77, DOI 10.1097/00131402-200112000-00006
   ROSING HS, 1985, ANN NEUROL, V17, P228, DOI 10.1002/ana.410170303
   Schmiedel J, 2003, J NEUROL, V250, P267, DOI 10.1007/s00415-003-0978-3
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   SHOFFNER JM, 1995, METABOLIC MOL BASIS, V1, P1535
   Sternberg D, 2001, BRAIN, V124, P984, DOI 10.1093/brain/124.5.984
   STRYER L, 1988, BIOCHEMISTRY-US, P823
   Sue CM, 1998, J NEUROL SCI, V161, P36, DOI 10.1016/S0022-510X(98)00179-8
   VANBRUGGEN EFJ, 1963, BIOCHIM BIOPHYS ACTA, V119, P437
   VIKKI J, 1988, HUM GENET, V80, P317
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
NR 36
TC 28
Z9 30
U1 0
U2 1
PU BLACKWELL PUBLISHING ASIA
PI CARLTON
PA 54 UNIVERSITY ST, P O BOX 378, CARLTON, VICTORIA 3053, AUSTRALIA
SN 1444-0903
J9 INTERN MED J
JI Intern. Med. J.
PD JAN-FEB
PY 2004
VL 34
IS 1-2
BP 10
EP 19
DI 10.1111/j.1444-0903.2004.t01-3-.x
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 768KB
UT WOS:000188541200004
PM 14748908
DA 2024-11-01
ER

PT J
AU Orsucci, D
   Angelini, C
   Bertini, E
   Carelli, V
   Comi, G
   Federico, A
   Minetti, C
   Moggio, M
   Mongini, T
   Santorelli, F
   Servidei, S
   Tonin, P
   Ardissone, A
   Bello, L
   Bruno, C
   Ienco, E
   Diodato, D
   Filosto, M
   Lamperti, C
   Moroni, I
   Musumeci, O
   Pegoraro, E
   Primiano, G
   Ronchi, D
   Rubegni, A
   Salvatore, S
   Sciacco, M
   Valentino, M
   Vercelli, L
   Toscano, A
   Zeviani, M
   Siciliano, G
   Mancuso, M
AF Orsucci, D.
   Angelini, C.
   Bertini, E.
   Carelli, V.
   Comi, G. P.
   Federico, A.
   Minetti, C.
   Moggio, M.
   Mongini, T.
   Santorelli, F. M.
   Servidei, S.
   Tonin, P.
   Ardissone, A.
   Bello, L.
   Bruno, C.
   Ienco, E. Caldarazzo
   Diodato, D.
   Filosto, M.
   Lamperti, C.
   Moroni, I.
   Musumeci, O.
   Pegoraro, E.
   Primiano, G.
   Ronchi, D.
   Rubegni, A.
   Salvatore, S.
   Sciacco, M.
   Valentino, M. L.
   Vercelli, L.
   Toscano, A.
   Zeviani, M.
   Siciliano, G.
   Mancuso, M.
TI Revisiting mitochondrial ocular myopathies: a study from the Italian
   Network
SO JOURNAL OF NEUROLOGY
LA English
DT Article
DE CPEO; Mitochondrial disorders; Mitochondrial myopathy; mtDNA; PEO
ID EXTERNAL OPHTHALMOPLEGIA
AB Ocular myopathy, typically manifesting as progressive external ophthalmoplegia (PEO), is among the most common mitochondrial phenotypes. The purpose of this study is to better define the clinical phenotypes associated with ocular myopathy. This is a retrospective study on a large cohort from the database of the "Nation-wide Italian Collaborative Network of Mitochondrial Diseases". We distinguished patients with ocular myopathy as part of a multisystem mitochondrial encephalomyopathy (PEO-encephalomyopathy), and then PEO with isolated ocular myopathy from PEO-plus when PEO was associated with additional features of multisystemic involvement. Ocular myopathy was the most common feature in our cohort of mitochondrial patients. Among the 722 patients with a definite genetic diagnosis, ocular myopathy was observed in 399 subjects (55.3%) and was positively associated with mtDNA single deletions and POLG mutations. Ocular myopathy as manifestation of a multisystem mitochondrial encephalomyopathy (PEO-encephalomyopathy, n = 131) was linked to the m.3243A > G mutation, whereas the other "PEO" patients (n = 268) were associated with mtDNA single deletion and Twinkle mutations. Increased lactate was associated with central neurological involvement. We then defined, among the PEO group, as "pure PEO" the patients with isolated ocular myopathy and "PEO-plus" those with ocular myopathy and other features of neuromuscular and multisystem involvement, excluding central nervous system. The male proportion was significantly lower in pure PEO than PEO-plus. This study reinforces the need for research on the role of gender in mitochondrial diseases. The phenotype definitions here revisited may contribute to a more homogeneous patient categorization, useful in future studies and clinical trials.
C1 [Orsucci, D.; Ienco, E. Caldarazzo; Siciliano, G.; Mancuso, M.] Univ Pisa, Neurol Clin, Via Roma 67, I-56100 Pisa, Italy.
   [Orsucci, D.] San Luca Hosp, Neurol Unit, Lucca, Italy.
   [Angelini, C.] Osped S Camillo, Fdn IRCCS, Venice, Italy.
   [Bertini, E.; Diodato, D.] Bambino Gesu Hosp IRCCS, Unit Neuromuscular Dis, Mol Med Lab, Rome, Italy.
   [Carelli, V.; Valentino, M. L.] Bellaria Hosp, IRCCS Inst Neurol Sci Bologna, Bologna, Italy.
   [Carelli, V.; Valentino, M. L.] Univ Bologna, Dept Biomed & Neuromotor Sci DIBINEM, Bologna, Italy.
   [Comi, G. P.; Ronchi, D.] Univ Milan, IRCCS Fdn Ca Granda Osped Maggiore Policlin, Dept Pathophysiol & Transplantat DEPT, Dino Ferrari Ctr,Neurosci Sect,Neurol Unit, Milan, Italy.
   [Federico, A.; Salvatore, S.] Univ Siena, UOC Clin Neurol & Malattie Neurometab, Dipartimento Sci Med Chirurg & Neurosci, Siena, Italy.
   [Minetti, C.; Bruno, C.] Univ Genoa, G Gaslini Inst, Neuropediat & Muscle Disorders Unit, Genoa, Italy.
   [Moggio, M.; Sciacco, M.] Univ Milan, Neuromuscular & Rare Dis Unit, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dino Ferrari Ctr, Milan, Italy.
   [Mongini, T.; Vercelli, L.] Univ Turin, Dept Neurosci, Turin, Italy.
   [Santorelli, F. M.; Rubegni, A.] IRCCS Stella Maris, Pisa, Italy.
   [Servidei, S.; Primiano, G.] Catholic Univ, Inst Neurol, Rome, Italy.
   [Tonin, P.] Univ Verona, Neurol Clin, Verona, Italy.
   [Ardissone, A.; Moroni, I.] Fdn Carlo Besta Inst Neurol IRCCS, Child Neurol Unit, Milan, Italy.
   [Filosto, M.] Univ Hosp Spedali Civili, Neurol Clin, Brescia, Italy.
   [Lamperti, C.; Zeviani, M.] Fdn Carlo Besta Inst Neurol IRCCS, Unit Mol Neurogenet, Milan, Italy.
   [Musumeci, O.; Toscano, A.] Univ Messina, Dept Clin & Expt Med, Messina, Italy.
   [Bello, L.; Pegoraro, E.] Univ Padua, Dept Neurosci, Neuromuscular Unit, Padua, Italy.
   [Zeviani, M.] Univ Cambridge, Med Res Council Mitochondrial Biol Unit, Cambridge, England.
C3 University of Pisa; IRCCS Ospedale San Camillo; IRCCS Bambino Gesu; AUSL
   di Bologna; IRCCS Istituto delle Scienze Neurologiche di Bologna (ISNB);
   University of Bologna; University of Milan; IRCCS Ca Granda Ospedale
   Maggiore Policlinico; University of Siena; University of Genoa; IRCCS
   Istituto Giannina Gaslini; IRCCS Ca Granda Ospedale Maggiore
   Policlinico; University of Milan; University of Turin; IRCCS Fondazione
   Stella Maris; Catholic University of the Sacred Heart; IRCCS Policlinico
   Gemelli; University of Verona; Fondazione IRCCS Istituto Neurologico
   Carlo Besta; Hospital Spedali Civili Brescia; Fondazione IRCCS Istituto
   Neurologico Carlo Besta; University of Messina; University of Padua;
   University of Cambridge; UK Research & Innovation (UKRI); Medical
   Research Council UK (MRC)
RP Mancuso, M (corresponding author), Univ Pisa, Neurol Clin, Via Roma 67, I-56100 Pisa, Italy.
EM mancusomichelangelo@gmail.com
RI Toscano, Antonio/AHE-4657-2022; Primiano, Guido/AAB-7829-2019; Sciacco,
   Monica/AAC-6500-2022; Bruno, Claudio/A-3148-2015; lamperti,
   costanza/J-8801-2016; Filosto, Massimiliano/S-9446-2019; Orsucci,
   Daniele/AAA-7576-2019; Musumeci, Olimpia/AHE-3041-2022; Tonin,
   Paola/AAC-5052-2022; Zeviani, Massimo/AAU-2632-2021; Ronchi,
   Dario/K-8011-2016; Servidei, Serenella/ABC-4262-2021; Bello,
   Luca/B-6397-2012; Federico, Antonio/H-8871-2017; Angelini,
   Corrado/J-3655-2019; Mancuso, Michelangelo/K-4170-2016; Santorelli,
   Filippo M/ABE-5124-2020; Ardissone, Anna/K-8495-2016; MINETTI,
   Carlo/K-4666-2018; Bertini, Enrico/A-2284-2014; Rubegni,
   Anna/I-3221-2018; moroni, isabella/AAL-1336-2021
OI Santorelli, Filippo M/0000-0002-1359-9062; Ardissone,
   Anna/0000-0003-1969-0147; MINETTI, Carlo/0000-0002-0640-1804; Angelini,
   Corrado/0000-0002-9554-8794; Filosto, Massimiliano/0000-0002-2852-7512;
   SERVIDEI, Serenella/0000-0001-8478-2799; Orsucci,
   Daniele/0000-0003-4847-7812; Primiano, Guido/0000-0001-7616-7008;
   Bertini, Enrico/0000-0001-9276-4590; Zeviani,
   Massimo/0000-0002-9067-5508; Sciacco, Monica/0000-0003-4593-4977; Bello,
   Luca/0000-0002-3075-6525; Rubegni, Anna/0000-0002-0484-3799; moroni,
   isabella/0000-0002-3322-1681
FU Telethon [GUP09004, GSP16001]; MITOCON
FX This work was supported by Telethon (Grant numbers GUP09004 and
   GSP16001). The patients' association MITOCON provided the web-platform
   assistance, partially supported this work and supports the work of Elena
   Caldarazzo Ienco.
CR DiMauro S, 2013, NAT REV NEUROL, V9, P429, DOI 10.1038/nrneurol.2013.126
   DRACHMAN DA, 1968, ARCH NEUROL-CHICAGO, V18, P654, DOI 10.1001/archneur.1968.00470360076008
   Filosto M, 2007, BIOSCIENCE REP, V27, P23, DOI 10.1007/s10540-007-9034-3
   Giordano C, 2011, BRAIN, V134, P220, DOI 10.1093/brain/awq276
   KEARNS TP, 1958, ARCH OPHTHALMOL-CHIC, V60, P280, DOI 10.1001/archopht.1958.00940080296016
   Mancuso M, 2016, NEUROMUSCULAR DISORD, V26, P272, DOI 10.1016/j.nmd.2016.02.008
   Mancuso M, 2015, J NEUROL, V262, P1301, DOI 10.1007/s00415-015-7710-y
   Mancuso M, 2014, MOVEMENT DISORD, V29, P722, DOI 10.1002/mds.25839
   Mancuso M, 2014, J NEUROL, V261, P504, DOI 10.1007/s00415-013-7225-3
   Mancuso M, 2013, NEUROLOGY, V80, P2049, DOI 10.1212/WNL.0b013e318294b44c
   McClelland C, 2016, CURR NEUROL NEUROSCI, V16, DOI 10.1007/s11910-016-0652-7
   Pitceathly RDS, 2016, EUR RADIOL, V26, P130, DOI 10.1007/s00330-015-3801-5
   Smits BW, 2011, J NEUROL, V258, P2020, DOI 10.1007/s00415-011-6060-7
   Smits BW, 2011, NEUROMUSCULAR DISORD, V21, P272, DOI 10.1016/j.nmd.2010.12.008
   Yu-Wai-Man C, 2013, PLOS ONE, V8
NR 15
TC 22
Z9 23
U1 0
U2 1
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-5354
EI 1432-1459
J9 J NEUROL
JI J. Neurol.
PD AUG
PY 2017
VL 264
IS 8
BP 1777
EP 1784
DI 10.1007/s00415-017-8567-z
PG 8
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA FC2SO
UT WOS:000406688800021
PM 28695364
DA 2024-11-01
ER

PT J
AU Punga, AR
   Ahlqvist, K
   Bartoccioni, E
   Scuderi, F
   Marino, M
   Suomalainen, A
   Kalimo, H
   Stålberg, EV
AF Punga, A. Rostedt
   Ahlqvist, K.
   Bartoccioni, E.
   Scuderi, F.
   Marino, M.
   Suomalainen, A.
   Kalimo, H.
   Stalberg, E. V.
TI Neurophysiological and mitochondrial abnormalities in MuSK antibody
   seropositive myasthenia gravis compared to other immunological subtypes
SO CLINICAL NEUROPHYSIOLOGY
LA English
DT Article
DE myasthenia gravis; quantitative EMG; single-fiber EMG; MuSK; myopathy;
   mtDNA deletions
ID ACETYLCHOLINE-RECEPTOR ANTIBODY; SINGLE-FIBER ELECTROMYOGRAPHY; TYROSINE
   KINASE MUSK; AUTOANTIBODIES; EMG; MG; AB
AB Objective: To compare the electrophysiological and histopathological features of immunological myasthenia gravis (MG) subtypes. Methods: Fifty MG patients underwent clinical examination, MuSK-Ab and AChR-Ab analysis. The majority underwent quantitative and single-fiber electromyography (QEMG, SFEMG), repetitive nerve stimulation and deltoid muscle biopsy. From muscle specimens with histological mitochondrial dysfunction, we amplified mitochondrial DNA (mtDNA). In specimens with mtDNA deletions, the nuclear gene POLG1 was sequenced.
   Results: Five AChR-Ab seropositive [AChR(+)] and 5 seronegative [AChR(-)] patients were MuSK-Ab seropositive [MuSK(+)]. Five of 7 neurophysiologically examined MuSK(+) patients (71%) had proximal myopathic pattern, compared to 7 of 31 MuSK(-)/AChR(+) patients (23%) (P=0.012). SFEMG was abnormal in all examined MuSK(+) patients. All 7 biopsied MuSK(+) and 32 MuSK(-) patients (89%) had cytochrome c oxidase (COX) negative fibers. Three of five MuSK(+) and 13 of 20 MuSK(-) patients analyzed had multiple mtDNA deletions but no POLG1 mutations.
   Conclusions: Similar degree of SFEMG abnormalities was present in proximal muscles among MuSK(+) and AChR(+) patients. Proximal myopathy was over represented in MuSK(+) patients; however, both MuSK(+) and MuSK(-) patients had mild myopathy with frequent mitochondrial abnormalities.
   Significance: The weakness in MuSK(+) patients is most likely due to disturbed neuromuscular transmission. The frequently encountered mitochondrial dysfunction in MG warrants further study. (c) 2006 International Federation of Clinical Neurophysiology. Published by Elsevier Ireland Ltd. All fights reserved.
C1 Univ Uppsala Hosp, Dept Clin Neurophysiol, S-75185 Uppsala, Sweden.
   Univ Cattolica Sacro Cuore, Inst Gen Pathol, Rome, Italy.
   Univ Uppsala Hosp, Dept Pathol, S-75185 Uppsala, Sweden.
   Univ Helsinki Hosp, Dept Pathol, Helsinki, Finland.
   Univ Helsinki, Biomedicum Helsinki, Programme Neurosci, Helsinki, Finland.
   Helsinki Univ Hosp, Dept Neurol, Helsinki, Finland.
C3 Uppsala University; Uppsala University Hospital; Catholic University of
   the Sacred Heart; IRCCS Policlinico Gemelli; Uppsala University; Uppsala
   University Hospital; University of Helsinki; Helsinki University Central
   Hospital; University of Helsinki; University of Helsinki; Helsinki
   University Central Hospital
RP Punga, AR (corresponding author), Univ Uppsala Hosp, Dept Clin Neurophysiol, S-75185 Uppsala, Sweden.
EM anna.rostedt@swipnet.se
OI Suomalainen-Wartiovaara, Anu/0000-0003-4833-5195
CR BROOKE MH, 1969, NEUROLOGY, V19, P221, DOI 10.1212/WNL.19.3.221
   Caress JB, 2005, ARCH NEUROL-CHICAGO, V62, P1002, DOI 10.1001/archneur.62.6.1002
   Dubowitz V., 1985, MUSCLE BIOPSY PRACTI, V2nd
   ENGEL WK, 1966, ANN NY ACAD SCI, V135, P68, DOI 10.1111/j.1749-6632.1966.tb45464.x
   Evoli A, 2003, BRAIN, V126, P2304, DOI 10.1093/brain/awg223
   Farrugia ME, 2006, MUSCLE NERVE, V33, P568, DOI 10.1002/mus.20491
   GILCHRIST JM, 1992, MUSCLE NERVE, V15, P151
   HENRIKSSON KG, 1979, ACTA NEUROL SCAND, V59, P317
   Hoch W, 2001, NAT MED, V7, P365, DOI 10.1038/85520
   Jaretzki A, 2000, NEUROLOGY, V55, P16, DOI 10.1212/WNL.55.1.16
   JOHNSTON W, 1995, ANN NEUROL, V37, P16, DOI 10.1002/ana.410370106
   Kajander OA, 2000, HUM MOL GENET, V9, P2821, DOI 10.1093/hmg/9.19.2821
   KRENDEL DA, 1987, MUSCLE NERVE, V10, P299, DOI 10.1002/mus.880100404
   LEFVERT AK, 1978, J NEUROL NEUROSUR PS, V41, P394, DOI 10.1136/jnnp.41.5.394
   LINDSTROM J, 1977, CLIN IMMUNOL IMMUNOP, V7, P36, DOI 10.1016/0090-1229(77)90027-7
   LINDSTROM JM, 1976, NEUROLOGY, V26, P1054, DOI 10.1212/WNL.26.11.1054
   Luoma PT, 2005, HUM MOL GENET, V14, P1907, DOI 10.1093/hmg/ddi196
   Nemoto Y, 2005, J NEUROL NEUROSUR PS, V76, P714, DOI 10.1136/jnnp.2004.043125
   Ohta K, 2005, NEUROLOGY, V65, P1988, DOI 10.1212/01.wnl.0000188881.46043.44
   Ohta K, 2004, NEUROLOGY, V62, P2132, DOI 10.1212/01.WNL.0000129274.12702.92
   OLDFORS A, 1995, J NEUROPATH EXP NEUR, V54, P581, DOI 10.1097/00005072-199507000-00012
   Pesce V, 2001, FREE RADICAL BIO MED, V30, P1223, DOI 10.1016/S0891-5849(01)00517-2
   PESTRONK A, 1985, MUSCLE NERVE, V8, P245, DOI 10.1002/mus.880080311
   Sanders DB, 2003, NEUROLOGY, V60, P1978, DOI 10.1212/01.WNL.0000065882.63904.53
   Sanders DB, 1996, MUSCLE NERVE, V19, P1069
   Scuderi F, 2002, LAB INVEST, V82, P1139, DOI 10.1097/01.LAB.0000028144.48023.9B
   Selcen D, 2004, NEUROLOGY, V62, P1945, DOI 10.1212/01.WNL.0000128048.23930.1D
   SOLIVEN BC, 1988, NEUROLOGY, V38, P514, DOI 10.1212/WNL.38.4.514
   SONOO M, 1993, ELECTROEN CLIN NEURO, V89, P291, DOI 10.1016/0168-5597(93)90068-Z
   STALBERG E, 1995, ELECTROMYOGR MOTOR C, V97, P145, DOI 10.1016/0924-980X(95)00007-8
   STALBERG E, 1978, ACTA ANAESTH SCAND, P112
   STALBERG E, 1980, J NEUROL NEUROSUR PS, V43, P622, DOI 10.1136/jnnp.43.7.622
   Stalberg E, 1976, MOTOR SYSTEM NEUROPH, P79
   Stickler DE, 2005, CLIN NEUROPHYSIOL, V116, P2065, DOI 10.1016/j.clinph.2005.06.003
   Suomalainen A, 2001, AM J MED GENET, V106, P53, DOI 10.1002/ajmg.1379
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   VINCENT A, 1993, ANN NY ACAD SCI, V681, P529, DOI 10.1111/j.1749-6632.1993.tb22936.x
   Zhou L, 2004, MUSCLE NERVE, V30, P55, DOI 10.1002/mus.20069
NR 38
TC 41
Z9 42
U1 0
U2 14
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 1388-2457
EI 1872-8952
J9 CLIN NEUROPHYSIOL
JI Clin. Neurophysiol.
PD JUL
PY 2006
VL 117
IS 7
BP 1434
EP 1443
DI 10.1016/j.clinph.2006.03.028
PG 10
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 066KB
UT WOS:000239227100004
PM 16737845
DA 2024-11-01
ER

PT J
AU Hirano, M
   Angelini, C
   Montagna, P
   Hays, AP
   Tanji, K
   Mitsumoto, H
   Gordon, PH
   Naini, AB
   DiMauro, S
   Rowland, LP
AF Hirano, Michio
   Angelini, Corrado
   Montagna, Pasquale
   Hays, Arthur P.
   Tanji, Kurenai
   Mitsumoto, Hiroshi
   Gordon, Paul H.
   Naini, Ali B.
   DiMauro, Salvatore
   Rowland, Lewis P.
TI Amyotrophic lateral sclerosis with ragged-red fibers
SO ARCHIVES OF NEUROLOGY
LA English
DT Article
ID SPINAL MUSCULAR-ATROPHY; MITOCHONDRIAL-DNA DEPLETION; C-OXIDASE
   DEFICIENCY; MUTATION; GENE; MYOPATHY; DISEASE
AB Background: Motor neuron diseases (amyotrophic lateral sclerosis [ALS] and spinal muscular atrophy [SMA]) have been rarely associated with mitochondrial respiratory chain defects.
   Objectives: To describe a patient with typical ALS and the finding of ragged-red fibers in muscle biopsy specimens and to review the literature on respiratory chain defects in ALS and SMA.
   Design: Case report and review of the literature.
   Setting: Collaboration between tertiary care academic hospitals.
   Patient: A 65-year-old man with typical ALS.
   Main Outcome Measures: The patient had 10% ragged-red fibers and 3% cytochrome-c oxidase-negative fibers in muscle biopsy specimens but no biochemical defects of respiratory chain enzymes or alterations of mitochondrial DNA (mtDNA).
   Results: Amyotrophic lateral sclerosis with ragged-red fibers has been reported in 5 families and is associated with mtDNA mutations in some subjects. Spinal muscular atrophy without mutations in the survival motor neuron gene (SMN; OMIM 600354) has been associated with mtDNA depletion or with mutations in the cytochrome-c oxidase assembly gene (SCO2; OMIM 604377).
   Conclusion: Respiratory chain defects can mimic ALS or SMA and should be considered in the differential diagnosis.
C1 [Hirano, Michio; Hays, Arthur P.; Tanji, Kurenai; Mitsumoto, Hiroshi; Gordon, Paul H.; Naini, Ali B.; DiMauro, Salvatore; Rowland, Lewis P.] Columbia Univ, Med Ctr, Dept Neurol, New York, NY 10032 USA.
   [Hays, Arthur P.; Tanji, Kurenai] Columbia Univ, Med Ctr, Dept Pathol, New York, NY 10032 USA.
   [Angelini, Corrado] Univ Padua, Dept Neurol, Padua, Italy.
   [Montagna, Pasquale] Univ Bologna, Dept Neurol Sci, Bologna, Italy.
C3 Columbia University; Columbia University; University of Padua;
   University of Bologna
RP Hirano, M (corresponding author), Columbia Univ, Med Ctr, Dept Neurol, 3-317 Russ Berrie Med Sci Pavil,1150 St Nicholas, New York, NY 10032 USA.
EM mh29@columbia.edu
RI Angelini, Corrado/J-3655-2019
OI Angelini, Corrado/0000-0002-9554-8794; Gordon, Paul/0000-0001-5714-9875
FU NICHD NIH HHS [HD32062] Funding Source: Medline; Telethon [GTF05003]
   Funding Source: Medline
CR Beal MF, 2005, ANN NEUROL, V58, P495, DOI 10.1002/ana.20624
   Borthwick Gillian M, 2006, Ann Neurol, V59, P570, DOI 10.1002/ana.20758
   Comi GP, 1998, ANN NEUROL, V43, P110, DOI 10.1002/ana.410430119
   DiMauro S, 2004, BBA-BIOENERGETICS, V1659, P107, DOI 10.1016/j.bbabio.2004.08.003
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   DOBKIN BH, 1976, NEUROLOGY, V26, P754, DOI 10.1212/WNL.26.8.754
   Fetoni V, 2004, NEUROMUSCULAR DISORD, V14, P723, DOI 10.1016/j.nmd.2004.07.002
   Finsterer J, 2003, NEUROLOGIST, V9, P45, DOI 10.1097/01.nrl.0000038589.58012.a8
   Hays AP., 2006, Mitochondrial Medicine, P45
   Mancuso M, 2003, ACTA NEUROPATHOL, V105, P621, DOI 10.1007/s00401-003-0699-9
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Oskoui M, 2006, ARCH NEUROL-CHICAGO, V63, P1122, DOI 10.1001/archneur.63.8.1122
   Pons R, 1996, PEDIATR NEUROL, V15, P153, DOI 10.1016/0887-8994(96)00118-X
   ROWLAND LP, 1991, REV NEUROL-FRANCE, V147, P467
   Rubio-Gozalbo ME, 1999, NEUROLOGY, V52, P383, DOI 10.1212/WNL.52.2.383
   Salviati L, 2002, ARCH NEUROL-CHICAGO, V59, P862, DOI 10.1001/archneur.59.5.862
   Tanji K, 2001, METHOD CELL BIOL, V65, P311, DOI 10.1016/S0091-679X(01)65019-2
   Tarnopolsky MA, 2004, AM J MED GENET A, V125A, P310, DOI 10.1002/ajmg.a.20466
NR 18
TC 25
Z9 28
U1 0
U2 2
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9942
EI 1538-3687
J9 ARCH NEUROL-CHICAGO
JI Arch. Neurol.
PD MAR
PY 2008
VL 65
IS 3
BP 403
EP 406
DI 10.1001/archneurol.2007.65
PG 4
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 272TD
UT WOS:000253881900017
PM 18332255
DA 2024-11-01
ER

PT J
AU Zaragoza, MV
   Brandon, MC
   Diegoli, M
   Arbustini, E
   Wallace, DC
AF Zaragoza, Michael V.
   Brandon, Martin C.
   Diegoli, Marta
   Arbustini, Eloisa
   Wallace, Douglas C.
TI Mitochondrial cardiomyopathies: how to identify candidate pathogenic
   mutations by mitochondrial DNA sequencing, MITOMASTER and phylogeny
SO EUROPEAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
DE mitochondria; cardiomyopathies; genetic variation; phylogeny; genetic
   databases
ID HEREDITARY OPTIC NEUROPATHY; DILATED CARDIOMYOPATHY; HYPERTROPHIC
   CARDIOMYOPATHY; POINT MUTATIONS; TRANSFER RNALEU(UUR); DISEASES; GENOME;
   MTDNA; ABNORMALITIES; SELECTION
AB Pathogenic mitochondrial DNA (mtDNA) mutations leading to mitochondrial dysfunction can cause cardiomyopathy and heart failure. Owing to a high mutation rate, mtDNA defects may occur at any nucleotide in its 16 569 bp sequence. Complete mtDNA sequencing may detect pathogenic mutations, which can be difficult to interpret because of normal ethnic/geographic-associated haplogroup variation. Our goal is to show how to identify candidate mtDNA mutations by sorting out polymorphisms using readily available online tools. The purpose of this approach is to help investigators in prioritizing mtDNA variants for functional analysis to establish pathogenicity. We analyzed complete mtDNA sequences from 29 Italian patients with mitochondrial cardiomyopathy or suspected disease. Using MITOMASTER and PhyloTree, we characterized 593 substitution variants by haplogroup and allele frequencies to identify all novel, non-haplogroup-associated variants. MITOMASTER permitted determination of each variant's location, amino acid change and evolutionary conservation. We found that 98% of variants were common or rare, haplogroup-associated variants, and thus unlikely to be primary cause in 80% of cases. Six variants were novel, non-haplogroup variants and thus possible contributors to disease etiology. Two with the greatest pathogenic potential were heteroplasmic, nonsynonymous variants: m.15132T>C in MT-CYB for a patient with hypertrophic dilated cardiomyopathy and m.6570G>T in MT-CO1 for a patient with myopathy. In summary, we have used our automated information system, MITOMASTER, to make a preliminary distinction between normal mtDNA variation and pathogenic mutations in patient samples; this fast and easy approach allowed us to select the variants for traditional analysis to establish pathogenicity. European Journal of Human Genetics (2011) 19, 200-207; doi:10.1038/ejhg.2010.169; published online 27 October 2010
C1 [Zaragoza, Michael V.; Brandon, Martin C.; Wallace, Douglas C.] Univ Calif Irvine, Ctr Mitochondrial & Mol Med & Genet, Irvine, CA 92697 USA.
   [Zaragoza, Michael V.] Univ Calif Irvine, Dept Biol Chem, Irvine, CA 92697 USA.
   [Diegoli, Marta; Arbustini, Eloisa] Univ Calif Irvine, Dept Pediat, Div Genet & Metab, Irvine, CA 92697 USA.
   [Wallace, Douglas C.] IRCCS Fdn Policlin San Matteo, Ctr Inherited Cardiovasc Dis, Pavia, Italy.
C3 University of California System; University of California Irvine;
   University of California System; University of California Irvine;
   University of California System; University of California Irvine; IRCCS
   Fondazione San Matteo
RP Zaragoza, MV (corresponding author), Univ Calif Irvine, Ctr Mitochondrial & Mol Med & Genet, 2011 Hewitt Hall, Irvine, CA 92697 USA.
EM mzaragoz@uci.edu; dwallace@uci.edu
RI Arbustini, Eloisa/K-8174-2016
OI Arbustini, Eloisa/0000-0003-2948-7994
FU NIH NHLBI [HL081222]; Ministry of Health for Inherited Cardiomyopathies;
   EC [241924, Health-2009-2.4.2-3]; NIH [NS21328, AG13154, AG24373,
   AG16573, DK73691]; CIRM
FX This work was supported by NIH NHLBI K08 award HL081222 to MVZ; grants:
   'Cariplo' and RC from the Ministry of Health for Inherited
   Cardiomyopathies and EC INHERITANCE project 241924, Health-2009-2.4.2-3
   awarded to EA; and NIH grants NS21328, AG13154, AG24373, AG16573,
   DK73691 and a CIRM comprehensive grant awarded to DCW.
CR ANAN R, 1995, CIRCULATION, V91, P955, DOI 10.1161/01.CIR.91.4.955
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Arbustini E, 1998, AM J PATHOL, V153, P1501, DOI 10.1016/S0002-9440(10)65738-0
   Arbustini E, 1998, HEART, V80, P548, DOI 10.1136/hrt.80.6.548
   Brandon MC, 2009, HUM MUTAT, V30, P1, DOI 10.1002/humu.20801
   Brega A, 2001, J NUCL CARDIOL, V8, P89, DOI 10.1067/mnc.2001.112755
   Costa-Guda Jessica, 2007, BMC Endocr Disord, V7, P8, DOI 10.1186/1472-6823-7-8
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Ionita-Laza I, 2009, P NATL ACAD SCI USA, V106, P5008, DOI 10.1073/pnas.0807815106
   JOHNSON MJ, 1983, J MOL EVOL, V19, P255, DOI 10.1007/BF02099973
   Jun AS, 1996, MOL CELL BIOL, V16, P771
   JUN AS, 1994, P NATL ACAD SCI USA, V91, P6206, DOI 10.1073/pnas.91.13.6206
   Li YY, 1997, J MOL CELL CARDIOL, V29, P2699, DOI 10.1006/jmcc.1997.0501
   Manolio TA, 2009, NATURE, V461, P747, DOI 10.1038/nature08494
   MANOUVRIER S, 1995, J MED GENET, V32, P654, DOI 10.1136/jmg.32.8.654
   Marin-Garcia J, 2000, J CARD FAIL, V6, P321, DOI 10.1054/jcaf.2000.19232
   MARINGARCIA J, 1994, CARDIOVASC RES, V28, P456, DOI 10.1093/cvr/28.4.456
   MERRIWETHER DA, 1991, J MOL EVOL, V33, P543, DOI 10.1007/BF02102807
   Mishmar D, 2003, P NATL ACAD SCI USA, V100, P171, DOI 10.1073/pnas.0136972100
   Nan DN, 2002, POSTGRAD MED J, V78, P298, DOI 10.1136/pmj.78.919.298
   OBAYASHI T, 1992, AM HEART J, V124, P1263, DOI 10.1016/0002-8703(92)90410-W
   Parr RL, 2006, J MOL DIAGN, V8, P312, DOI 10.2353/jmoldx.2006.050112
   Pereira L, 2009, AM J HUM GENET, V84, P628, DOI 10.1016/j.ajhg.2009.04.013
   Ruiz-Pesini E, 2004, SCIENCE, V303, P223, DOI 10.1126/science.1088434
   Ruiz-Pesini E, 2007, NUCLEIC ACIDS RES, V35, pD823, DOI 10.1093/nar/gkl927
   Ruppert V, 2004, BIOCHEM BIOPH RES CO, V318, P535, DOI 10.1016/j.bbrc.2004.04.061
   Schrijver I, 2009, GENET MED, V11, P118, DOI 10.1097/GIM.0b013e318190356b
   TORRONI A, 1994, J BIOENERG BIOMEMBR, V26, P261, DOI 10.1007/BF00763098
   van Oven M, 2009, HUM MUTAT, V30, pE386, DOI 10.1002/humu.20921
   Vilarinho L, 1997, J MED GENET, V34, P607, DOI 10.1136/jmg.34.7.607
   Vives-Bauza C, 2002, BIOCHEM BIOPH RES CO, V290, P1593, DOI 10.1006/bbrc.2002.6388
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Wallace DC, 1999, GENE, V238, P211, DOI 10.1016/S0378-1119(99)00295-4
   ZEVIANI M, 1991, LANCET, V338, P143, DOI 10.1016/0140-6736(91)90136-D
NR 35
TC 47
Z9 49
U1 0
U2 9
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1018-4813
J9 EUR J HUM GENET
JI Eur. J. Hum. Genet.
PD FEB
PY 2011
VL 19
IS 2
BP 200
EP 207
DI 10.1038/ejhg.2010.169
PG 8
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 705YK
UT WOS:000286176500015
PM 20978534
OA Green Published, hybrid
DA 2024-11-01
ER

PT J
AU Jacobs, LJAM
   Jongbloed, RJE
   Wijburg, FA
   de Klerk, JBC
   Geraedts, JPM
   Nijland, JG
   Scholte, HR
   de Coo, IFM
   Smeets, HJM
AF Jacobs, LJAM
   Jongbloed, RJE
   Wijburg, FA
   de Klerk, JBC
   Geraedts, JPM
   Nijland, JG
   Scholte, HR
   de Coo, IFM
   Smeets, HJM
TI Pearson syndrome and the role of deletion dimers and duplications in the
   mtDNA
SO JOURNAL OF INHERITED METABOLIC DISEASE
LA English
DT Article
ID MITOCHONDRIAL-DNA DELETION; MARROW-PANCREAS-SYNDROME; DIABETES-MELLITUS;
   REARRANGEMENTS; MYOPATHY
AB Pearson syndrome is an often fatal multisystem disease associated with mitochondrial DNA rearrangements. Here we report a patient with a novel mtDNA deletion of 3.4 kb ranging from nucleotides 6097 to 9541 in combination with deletion dimers. The mutation percentage in different tissues <LF>(blood, muscle and liver) varied between 64% and 95%. After a remission period of about a year, the patient suddenly died at the age of 3 years owing to a severe lactic acidosis. A second patient with a previously reported deletion of 8 kb and a milder phenotype was found to have mitochondrial duplications and died at the age of 10 years. From these data and data from previous reports, we hypothesize that duplications might be beneficial in the clinical course of the disease and in life expectancy.
C1 Univ Maastricht, Dept Genet & Cell Biol, Res Inst Growth & Dev GROW, NL-6200 MD Maastricht, Netherlands.
   Univ Amsterdam, Acad Med Ctr, Dept Paediat, NL-1105 AZ Amsterdam, Netherlands.
   Erasmus Univ, Med Ctr Rotterdam, Dept Paediat, Rotterdam, Netherlands.
   Erasmus Univ, Med Ctr Rotterdam, Dept Biochem, Rotterdam, Netherlands.
   Erasmus Univ, Med Ctr Rotterdam, Dept Neurol, Rotterdam, Netherlands.
C3 Maastricht University; University of Amsterdam; Academic Medical Center
   Amsterdam; Erasmus University Rotterdam; Erasmus MC; Erasmus University
   Rotterdam; Erasmus MC; Erasmus University Rotterdam; Erasmus MC
RP Univ Maastricht, Dept Genet & Cell Biol, Res Inst Growth & Dev GROW, POB 616, NL-6200 MD Maastricht, Netherlands.
EM bert.smeets@molcelb.unimaas.nl
OI Wijburg, Frits/0000-0002-0950-1368; de Coo, Irenaeus/0000-0003-0533-7422
CR BALLINGER SW, 1994, NAT GENET, V7, P458, DOI 10.1038/ng0894-458
   DIMAURO, 1993, MOL GENETIC BASIS NE, P665
   DUNBAR DR, 1993, HUM MOL GENET, V2, P1619, DOI 10.1093/hmg/2.10.1619
   Hsieh RH, 2002, FERTIL STERIL, V77, P1012, DOI 10.1016/S0015-0282(02)02994-1
   KEARNS TP, 1958, ARCH OPHTHALMOL-CHIC, V60, P280, DOI 10.1001/archopht.1958.00940080296016
   Manfredi G, 1997, ANN NEUROL, V42, P180, DOI 10.1002/ana.410420208
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   MITA S, 1990, NUCLEIC ACIDS RES, V18, P561, DOI 10.1093/nar/18.3.561
   *MITOMAP, 2001, MITOMAP HUM MIT GEN
   Muraki K, 2001, AM J MED GENET, V98, P205, DOI 10.1002/1096-8628(20010122)98:3<205::AID-AJMG1077>3.0.CO;2-P
   OTA Y, 1994, RETINA-J RET VIT DIS, V14, P270, DOI 10.1097/00006982-199414030-00015
   PEARSON HA, 1979, J PEDIATR-US, V95, P976, DOI 10.1016/S0022-3476(79)80286-3
   POULTON J, 1994, HUM MOL GENET, V3, P947, DOI 10.1093/hmg/3.6.947
   POULTON J, 1993, HUM MOL GENET, V2, P23, DOI 10.1093/hmg/2.1.23
   POULTON J, 1994, NAT GENET, V8, P313, DOI 10.1038/ng1294-313
   POULTON J, 1995, MUSCLE NERVE       S, V3, P154
   ROTIG A, 1990, J CLIN INVEST, V86, P1601, DOI 10.1172/JCI114881
   ROTIG A, 1992, AM J HUM GENET, V50, P364
   ROTIG A, 1995, HUM MOL GENET, V4, P1327, DOI 10.1093/hmg/4.8.1327
   SAMBROOK J., 1998, MOL CLONING LAB MANU
   Shanske S, 2002, AM J HUM GENET, V71, P679, DOI 10.1086/342482
   TANAKA M, 1989, BIOCHEM BIOPH RES CO, V164, P156, DOI 10.1016/0006-291X(89)91696-3
   Tang YY, 2000, MOL BIOL CELL, V11, P1471, DOI 10.1091/mbc.11.4.1471
   van den Ouweland JMW, 2000, EUR J HUM GENET, V8, P195, DOI 10.1038/sj.ejhg.5200444
NR 24
TC 20
Z9 20
U1 0
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0141-8955
EI 1573-2665
J9 J INHERIT METAB DIS
JI J. Inherit. Metab. Dis.
PY 2004
VL 27
IS 1
BP 47
EP 55
DI 10.1023/B:BOLI.0000016601.49372.18
PG 9
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental
   Medicine
GA 774YG
UT WOS:000189013500005
PM 14970745
OA Bronze
DA 2024-11-01
ER

PT J
AU Fujii, T
   Takase, K
   Honda, H
   Kawamura, N
   Yamasaki, R
   Urata, M
   Uchiumi, T
   Iwaki, T
   Kira, J
AF Fujii, Takayuki
   Takase, Kei-ichiro
   Honda, Hiroyuki
   Kawamura, Nobutoshi
   Yamasaki, Ryo
   Urata, Michiyo
   Uchiumi, Takeshi
   Iwaki, Toru
   Kira, Jun-ichi
TI Toxic myopathy with multiple deletions in mitochondrial DNA associated
   with long-term use of oral anti-viral drugs for hepatitis B: A case
   study
SO NEUROPATHOLOGY
LA English
DT Article
DE anti-hepatitis B drugs; common deletion; mitochondrial DNA;
   mitochondrial myopathy; oxidative damage
ID RAGGED-RED FIBERS; SKELETAL-MUSCLE; CYTOPATHY; THERAPY
AB Oral nucleoside analogs (NAs) reduce hepatitis B virus (HBV) replication by inhibiting HBV DNA polymerase. However, NAs can also affect human mitochondrial DNA (mtDNA) polymerase, which can lead to mtDNA depletion (quantitative abnormality). Indeed, several mitochondrial myopathy cases have been reported in which a reduced mtDNA copy number was induced by oral NAs for hepatitis B. Herein, we report a case of toxic myopathy with multiple mtDNA deletions (qualitative abnormality) associated with long-term use of NAs for hepatitis B. A 68-year-old woman, who underwent long-term treatment with lamivudine and adefovir for chronic hepatitis B, developed proximal muscle weakness in the four extremities. Neurological examination showed mild proximal muscle weakness and atrophy in the four extremities. Upon admission to our hospital, her blood lactate/pyruvate ratio during an aerobic exercise test was elevated. Myogenic patterns were observed in lower limb muscles on electromyographic examination. Muscle magnetic resonance imaging revealed diffuse atrophy of proximal muscles in the four extremities with no signal changes. A biopsy from the biceps brachii muscle showed an abnormally large variation in fiber size, scattered muscle fibers with decreased cytochrome c oxidase activity, and ragged-red fibers. Analysis of mtDNA from skeletal muscle revealed no decrease in copy number but increased incidence of multiple deletions, including a deletion of 4977 base pairs (known as the common deletion) reflecting oxidative stress-induced mtDNA damage. This case study indicates that long-term oral antiviral therapy for hepatitis B can induce chronic oxidative damage to mtDNA resulting in qualitative mtDNA abnormalities and toxic myopathy.
C1 [Fujii, Takayuki; Takase, Kei-ichiro; Kawamura, Nobutoshi; Yamasaki, Ryo; Kira, Jun-ichi] Kyushu Univ, Grad Sch Med Sci, Neurol Inst, Dept Neurol, Fukuoka, Fukuoka, Japan.
   [Honda, Hiroyuki; Iwaki, Toru] Kyushu Univ, Grad Sch Med Sci, Neurol Inst, Dept Neuropathol, Fukuoka, Fukuoka, Japan.
   [Urata, Michiyo; Uchiumi, Takeshi] Kyushu Univ Hosp, Dept Clin Chem & Lab Med, Fukuoka, Fukuoka, Japan.
C3 Kyushu University; Kyushu University; Kyushu University
RP Kira, J (corresponding author), Kyushu Univ, Grad Sch Med Sci, Neurol Inst, Dept Neurol,Higashi Ku, 3-1-1 Maidashi, Fukuoka, Fukuoka 8128582, Japan.
EM kira@neuro.med.kyushu-u.ac.jp
RI Yamasaki, Ryo/AAQ-6245-2021; Honda, Hiroyuki/AGQ-2730-2022; Takase,
   Kei-ichiro/KCK-6304-2024
OI Iwaki, Toru/0000-0001-7826-870X; Yamasaki, Ryo/0000-0003-2071-7861;
   Honda, Hiroyuki/0000-0002-4225-7248
FU Grants-in-Aid for Scientific Research [20K20470] Funding Source: KAKEN
CR Capasso M, 2006, NEUROLOGY, V67, P1467, DOI 10.1212/01.wnl.0000240078.47020.5e
   Chen YR, 2014, CIRC RES, V114, P524, DOI 10.1161/CIRCRESAHA.114.300559
   Cohen BH, 2001, CLEV CLIN J MED, V68, P625, DOI 10.3949/ccjm.68.7.625
   EGGER J, 1981, ARCH DIS CHILD, V56, P741, DOI 10.1136/adc.56.10.741
   Fodale V, 2005, ANAESTHESIA, V60, P806, DOI 10.1111/j.1365-2044.2005.04208.x
   Fung J, 2014, J GASTROEN HEPATOL, V29, P428, DOI 10.1111/jgh.12499
   Kayaaslan B, 2017, WORLD J HEPATOL, V9, P227, DOI 10.4254/wjh.v9.i5.227
   Lal A, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.88150
   LEE HC, 1994, BBA-MOL BASIS DIS, V1226, P37, DOI 10.1016/0925-4439(94)90056-6
   López-Gallardo E, 2009, MITOCHONDRION, V9, P314, DOI 10.1016/j.mito.2009.04.005
   Mannion AF, 1997, J ORTHOPAED RES, V15, P881, DOI 10.1002/jor.1100150614
   Meissner C, 2008, EXP GERONTOL, V43, P645, DOI 10.1016/j.exger.2008.03.004
   Muqit MMK, 2008, J NEUROL NEUROSUR PS, V79, P68, DOI 10.1136/jnnp.2006.112250
   Oldfors A, 2006, NEUROLOGY, V66, pS49, DOI 10.1212/01.wnl.0000192127.63013.8d
   Prithivirajsingh S, 2004, FEBS LETT, V571, P227, DOI 10.1016/j.febslet.2004.06.078
   Scruggs ER, 2008, PHARMACOLOGY, V82, P83, DOI 10.1159/000134943
   Stringer HAJ, 2013, J NEUROL SCI, V325, P142, DOI 10.1016/j.jns.2012.12.023
   SWASH M, 1978, J NEUROL SCI, V38, P347, DOI 10.1016/0022-510X(78)90141-7
   Tanji N, 2001, HUM PATHOL, V32, P734, DOI 10.1053/hupa.2001.25586
   Xu HL, 2014, J CLIN PATHOL, V67, P999, DOI 10.1136/jclinpath-2013-202069
NR 20
TC 4
Z9 4
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0919-6544
EI 1440-1789
J9 NEUROPATHOLOGY
JI Neuropathology
PD APR
PY 2019
VL 39
IS 2
BP 162
EP 167
DI 10.1111/neup.12548
PG 6
WC Clinical Neurology; Neurosciences; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pathology
GA HR3LR
UT WOS:000463039500013
PM 30847961
DA 2024-11-01
ER

PT J
AU Ruiz-Pesini, E
   Bayona-Bafaluy, MP
   Sanclemente, T
   Puzo, J
   Montoya, J
   Pacheu-Grau, D
AF Ruiz-Pesini, Eduardo
   Bayona-Bafaluy, Maria Pilar
   Sanclemente, Teresa
   Puzo, Jose
   Montoya, Julio
   Pacheu-Grau, David
TI Mitochondrial Genetic Background May Impact Statins Side Effects and
   Atherosclerosis Development in Familial Hypercholesterolemia
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE familial hypercholesterolemia; mtDNA; mitochondria; CoQ(10)
ID GENOME-WIDE ASSOCIATION; DNA COPY NUMBER; COENZYME Q(10); SUSCEPTIBILITY
   LOCI; MUSCLE SYMPTOMS; POLYMORPHISMS; MYOPATHY; THERAPY;
   PHARMACOGENOMICS; SUPPLEMENTATION
AB Heredity of familial hypercholesterolemia (FH) can present as a dominant monogenic disorder of polygenic origin or with no known genetic cause. In addition, the variability of the symptoms among individuals or within the same families evidence the potential contribution of additional factors than monogenic mutations that could modulate the development and severity of the disease. In addition, statins, the lipid-lowering drugs which constitute the first-line therapy for the disease, cause associated muscular symptoms in a certain number of individuals. Here, we analyze the evidence of the mitochondrial genetic variation with a special emphasis on the role of CoQ(10) to explain this variability found in both disease symptoms and statins side effects. We propose to use mtDNA variants and copy numbers as markers for the cardiovascular disease development of FH patients and to predict potential statin secondary effects and explore new mechanisms to identify new markers of disease or implement personalized medicine strategies for FH therapy.
C1 [Ruiz-Pesini, Eduardo; Bayona-Bafaluy, Maria Pilar; Montoya, Julio; Pacheu-Grau, David] Univ Zaragoza, Dept Bioquim Biol Mol & Celular, Zaragoza 50009, Spain.
   [Ruiz-Pesini, Eduardo; Bayona-Bafaluy, Maria Pilar; Montoya, Julio; Pacheu-Grau, David] Univ Zaragoza, Dept Bioquim Biol Mol & Celular, Zaragoza 50013, Spain.
   [Ruiz-Pesini, Eduardo; Bayona-Bafaluy, Maria Pilar; Montoya, Julio; Pacheu-Grau, David] Inst Invest Sanitaria IIS Aragon, Zaragoza 50009, Spain.
   [Ruiz-Pesini, Eduardo; Bayona-Bafaluy, Maria Pilar; Montoya, Julio; Pacheu-Grau, David] Ctr Invest Biomed Red Enfermedades Raras CIBERER, Madrid 28029, Spain.
   [Bayona-Bafaluy, Maria Pilar] Univ Zaragoza, Inst Biocomp & Fis Sistemas Complejos BIFI, Zaragoza 50018, Spain.
   [Sanclemente, Teresa] Univ Zaragoza, Fac Ciencias Salud & Deporte, Huesca 22002, Spain.
   [Puzo, Jose] Hosp Gen Univ San Jorge Huesca, Serv Bioquim Clin, Unidad Lipidos, Huesca 22004, Spain.
   [Puzo, Jose] Univ Zaragoza, Dept Med, Zaragoza 50009, Spain.
C3 University of Zaragoza; University of Zaragoza; CIBER - Centro de
   Investigacion Biomedica en Red; CIBERER; University of Zaragoza;
   University of Zaragoza; University of Zaragoza
RP Pacheu-Grau, D (corresponding author), Univ Zaragoza, Dept Bioquim Biol Mol & Celular, Zaragoza 50009, Spain.; Pacheu-Grau, D (corresponding author), Univ Zaragoza, Dept Bioquim Biol Mol & Celular, Zaragoza 50013, Spain.; Pacheu-Grau, D (corresponding author), Inst Invest Sanitaria IIS Aragon, Zaragoza 50009, Spain.; Pacheu-Grau, D (corresponding author), Ctr Invest Biomed Red Enfermedades Raras CIBERER, Madrid 28029, Spain.
EM dpacheu@unizar.es
RI Sanclemente, Teresa/HHS-9772-2022; Pacheu Grau, David/GRO-0956-2022;
   Pacheu-Grau, David/A-9074-2017; Puzo Foncillas, Jose/AAE-5827-2021
OI Ruiz Pesini, Eduardo/0000-0002-0269-7337; Pacheu-Grau,
   David/0000-0003-2645-3983; Puzo Foncillas, Jose/0000-0002-1309-4363;
   Montoya Villarroya, Julio/0000-0003-1770-6299; Bayona Bafaluy, Maria
   Pilar/0000-0002-8585-6371; Sanclemente Hernandez, Teresa
   Maria/0000-0002-5407-3876
FU Instituto de Salud Carlos III [PI21/00229]; European Regional
   Development Fund (FEDER) [PI21/00229]; MCIN/AEI [PID2020-116970GA-I00,
   RYC2020-029544-I]; ESF Investing in your future; Gobierno de Aragon
   (Grupos Consolidados) [B33_20R, LMP22_21]; FEDER 2014-2020 'Construyendo
   Europa desde Aragon'; Asociacion de Enfermos de Patologia Mitocondrial
   (AEPMI)
FX This research was funded by grant (PI21/00229) from Instituto de Salud
   Carlos III and European Regional Development Fund (FEDER); Grant
   PID2020-116970GA-I00 and Grant RYC2020-029544-I funded by
   MCIN/AEI/10.13039/501100011033 and by "ESF Investing in your future";
   Gobierno de Aragon (Grupos Consolidados B33_20R, and Grant LMP22_21) and
   FEDER 2014-2020 'Construyendo Europa desde Aragon'; and Asociacion de
   Enfermos de Patologia Mitocondrial (AEPMI).
CR Akioyamen LE, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-016461
   Al-Furoukh N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103141
   Alcázar-Fabra M, 2018, ESSAYS BIOCHEM, V62, P377, DOI 10.1042/EBC20170107
   Amunts A, 2015, SCIENCE, V348, P95, DOI 10.1126/science.aaa1193
   Antoniazzi L, 2021, NUTR METAB CARDIOVAS, V31, P2014, DOI 10.1016/j.numecd.2021.04.006
   Antons KA, 2006, AM J MED, V119, P400, DOI 10.1016/j.amjmed.2006.02.007
   Arroyo-Olivares R, 2019, PUBLIC HEALTH NUTR, V22, P1433, DOI 10.1017/S1368980018003853
   Ashar FN, 2017, JAMA CARDIOL, V2, P1247, DOI 10.1001/jamacardio.2017.3683
   Beheshti SO, 2020, J AM COLL CARDIOL, V75, P2553, DOI 10.1016/j.jacc.2020.03.057
   Bentinger M, 2010, BIOCHEM BIOPH RES CO, V396, P74, DOI 10.1016/j.bbrc.2010.02.147
   Bhagavan HN, 2006, FREE RADICAL RES, V40, P445, DOI 10.1080/10715760600617843
   Castellani CA, 2020, MITOCHONDRION, V53, P214, DOI 10.1016/j.mito.2020.06.004
   Christopher-Stine L, 2006, CURR OPIN RHEUMATOL, V18, P647
   Crane FL, 2007, MITOCHONDRION, V7, pS2, DOI 10.1016/j.mito.2007.02.011
   Degenhardt F, 2016, HUM MOL GENET, V25, P2881, DOI 10.1093/hmg/ddw134
   Fahed AC, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17374-3
   Fedacko J, 2013, CAN J PHYSIOL PHARM, V91, P165, DOI 10.1139/cjpp-2012-0118
   Fischer Alexandra, 2011, BMC Res Notes, V4, P245, DOI 10.1186/1756-0500-4-245
   Garcia-Garcia AB, 2011, ATHEROSCLEROSIS, V218, P423, DOI 10.1016/j.atherosclerosis.2011.07.106
   Garrabou G, 2017, ANTIMICROB AGENTS CH, V61, DOI [10.1128/AAC.00542-17, 10.1128/aac.00542-17]
   Gaspar IM, 2019, ATHEROSCLEROSIS SUPP, V36, P28, DOI 10.1016/j.atherosclerosissup.2019.01.006
   GOLDSTEIN JL, 1974, J BIOL CHEM, V249, P5153
   GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0
   Gómez-Durán A, 2011, DRUG DISCOV TODAY, V16, P176, DOI 10.1016/j.drudis.2010.11.010
   Gómez-Durán A, 2010, HUM MOL GENET, V19, P3343, DOI 10.1093/hmg/ddq246
   Gutierrez-Mariscal FM, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10060906
   Hughes K, 2002, FREE RADICAL BIO MED, V32, P132, DOI 10.1016/S0891-5849(01)00783-3
   Kajinami K, 2005, AM J CARDIOL, V96, p65K, DOI 10.1016/j.amjcard.2005.08.011
   KANE JP, 1990, JAMA-J AM MED ASSOC, V264, P3007, DOI 10.1001/jama.264.23.3007
   Kastelein JJP, 2020, J AM COLL CARDIOL, V75, P2567, DOI 10.1016/j.jacc.2020.03.058
   Kathiresan S, 2009, NAT GENET, V41, P334, DOI 10.1038/ng.327
   Kennedy C, 2020, ATHEROSCLEROSIS, V299, P1, DOI 10.1016/j.atherosclerosis.2020.03.006
   Klopstock T, 2008, CURR OPIN NEUROL, V21, P590, DOI 10.1097/WCO.0b013e32830e2774
   Kolanczyk M, 2011, MOL BIOL CELL, V22, P1, DOI 10.1091/mbc.E10-07-0643
   Lagos J, 2014, MOL DIAGN THER, V18, P435, DOI 10.1007/s40291-014-0094-3
   Lamhonwah AM, 2006, BIOCHEM BIOPH RES CO, V345, P1315, DOI 10.1016/j.bbrc.2006.05.026
   Liu X, 2021, CELL GENOM, V1, DOI 10.1016/j.xgen.2021.100006
   Lorente L, 2018, ENFERM INFEC MICR CL, V36, P539, DOI 10.1016/j.eimc.2017.08.011
   Lorente L, 2012, CRIT CARE, V16, DOI 10.1186/cc11150
   Luo J, 2021, medRxiv, DOI [10.1101/2021.07.01.21259854, 10.1101/2021.07.01.21259854, DOI 10.1101/2021.07.01.21259854]
   Miles MV, 2003, CLIN CHIM ACTA, V332, P123, DOI 10.1016/S0009-8981(03)00137-2
   Montero R, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37542-2
   Montoya J, 2009, ADV EXP MED BIOL, V652, P47, DOI 10.1007/978-90-481-2813-6_5
   Morotti A, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms231911446
   Neil A, 2008, EUR HEART J, V29, P2625, DOI 10.1093/eurheartj/ehn422
   Nikpay M, 2015, NAT GENET, V47, P1121, DOI 10.1038/ng.3396
   Nordestgaard BG, 2013, EUR HEART J, V34, P3478, DOI 10.1093/eurheartj/eht273
   Okura T, 2003, HUM GENET, V113, P432, DOI 10.1007/s00439-003-0983-8
   Ordovas JM, 2004, ANNU REV GENOM HUM G, V5, P71, DOI 10.1146/annurev.genom.5.061903.180008
   Pacheu-Grau D, 2018, CELL STRESS, V2, P184, DOI 10.15698/cst2018.07.147
   Pacheu-Grau D, 2013, HUM MOL GENET, V22, P1132, DOI 10.1093/hmg/dds517
   Pacheu-Grau D, 2010, DRUG DISCOV TODAY, V15, P33, DOI 10.1016/j.drudis.2009.10.008
   Päivä H, 2005, CLIN PHARMACOL THER, V78, P60, DOI 10.1016/j.clpt.2005.03.006
   Paquette M, 2017, J CLIN LIPIDOL, V11, P725, DOI 10.1016/j.jacl.2017.03.019
   Perez-Calahorra S, 2019, ATHEROSCLEROSIS, V284, P245, DOI 10.1016/j.atherosclerosis.2019.02.003
   PULLMAN ME, 1967, ANNU REV BIOCHEM, V36, P539, DOI 10.1146/annurev.bi.36.070167.002543
   Ruiz-Iruela C, 2020, PHARMACOGENOMICS J, V20, P494, DOI 10.1038/s41397-019-0136-7
   Ruiz-Pesini E, 2000, AM J HUM GENET, V67, P682, DOI 10.1086/303040
   Schirris TJJ, 2015, CELL METAB, V22, P399, DOI 10.1016/j.cmet.2015.08.002
   Schunkert H, 2011, NAT GENET, V43, P333, DOI [10.1038/ng.784, 10.1161/CIRCGENETICS.111.960443]
   Skarlovnik A, 2014, MED SCI MONITOR, V20, P2183, DOI 10.12659/MSM.890777
   STOCKER R, 1991, P NATL ACAD SCI USA, V88, P1646, DOI 10.1073/pnas.88.5.1646
   Stringer HAJ, 2013, J NEUROL SCI, V325, P142, DOI 10.1016/j.jns.2012.12.023
   Stroes ES, 2015, EUR HEART J, V36, P1012, DOI 10.1093/eurheartj/ehv043
   Suárez-Rivero JM, 2018, BBA-MOL BASIS DIS, V1864, P3697, DOI 10.1016/j.bbadis.2018.10.009
   Takahashi M, 2022, NUTRIENTS, V14, DOI 10.3390/nu14132579
   Takahashi M, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10030431
   Taylor BA, 2015, ATHEROSCLEROSIS, V238, P329, DOI 10.1016/j.atherosclerosis.2014.12.016
   Toth Stefan, 2017, Journal of Basic and Clinical Physiology and Pharmacology, V28, P327, DOI 10.1515/jbcpp-2016-0149
   Villalba JM, 2010, EXPERT OPIN INV DRUG, V19, P535, DOI 10.1517/13543781003727495
   Vilne B, 2022, GENES-BASEL, V13, DOI 10.3390/genes13030516
   Wang J, 2016, ARTERIOSCL THROM VAS, V36, P2439, DOI 10.1161/ATVBAHA.116.308027
   Wilemon KA, 2020, JAMA CARDIOL, V5, P217, DOI 10.1001/jamacardio.2019.5173
   WILLIAMS RR, 1986, JAMA-J AM MED ASSOC, V255, P219, DOI 10.1001/jama.255.2.219
   Zhou Xiaohong, 2020, Nan Fang Yi Ke Da Xue Xue Bao, V40, P1747, DOI 10.12122/j.issn.1673-4254.2020.12.08
NR 75
TC 4
Z9 4
U1 0
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JAN
PY 2023
VL 24
IS 1
AR 471
DI 10.3390/ijms24010471
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 7R7DP
UT WOS:000910230200001
PM 36613915
OA Green Published, gold
DA 2024-11-01
ER

PT J
AU Burrage, LC
   Tang, S
   Wang, J
   Donti, TR
   Walkiewicz, M
   Luchak, JM
   Chen, LC
   Schmitt, ES
   Niu, ZY
   Erana, R
   Hunter, JV
   Graham, BH
   Wong, LJ
   Scaglia, F
AF Burrage, Lindsay C.
   Tang, Sha
   Wang, Jing
   Donti, Taraka R.
   Walkiewicz, Magdalena
   Luchak, J. Michael
   Chen, Li-Chieh
   Schmitt, Eric S.
   Niu, Zhiyv
   Erana, Rodrigo
   Hunter, Jill V.
   Graham, Brett H.
   Wong, Lee-Jun
   Scaglia, Fernando
TI Mitochondrial myopathy, lactic acidosis, and sideroblastic anemia
   (MLASA) plus associated with a novel <i>de novo</i> mutation
   (m.8969G&gt;A) in the mitochondrial encoded <i>ATP6</i> gene
SO MOLECULAR GENETICS AND METABOLISM
LA English
DT Article
DE MLASA; Lactic acidosis; Mitochondria; ATP6; Mitochondrial myopathy
ID COMPARATIVE GENOMIC HYBRIDIZATION; MOLECULAR DIAGNOSIS; MISSENSE
   MUTATION; YARS2 MUTATIONS; DNA DISORDERS; PUS1 GENE; DEPLETION
AB Mitochondrial myopathy, lactic acidosis and sideroblastic anemia (MLASA) is a rare mitochondrial disorder that has previously been associated with mutations in PUS1 and YARS2. In the present report, we describe a 6-year old male with an MLASA plus phenotype. This patient had features of MLASA in the setting of developmental delay, sensorineural hearing loss, epilepsy, agenesis of the corpus callosum, failure to thrive, and stroke-like episodes. Sequencing of the mitochondrial genome identified a novel de novo, heteroplasmic mutation in the mitochondrial DNA (mtDNA) encoded ATP6 gene (m.8969G>A, p.S148N). Whole exome sequencing did not identify mutations or variants in PUS1 or YARS2 or any known nuclear genes that could affect mitochondrial function and explain this phenotype. Studies of fibroblasts derived from the patient revealed a decrease in oligomycin-sensitive respiration, a finding which is consistent with a complex V defect. Thus, this mutation in MT-ATP6 may represent the first mtDNA point mutation associated with the MLASA phenotype. (C) 2014 Elsevier Inc All rights reserved.
C1 [Burrage, Lindsay C.; Tang, Sha; Wang, Jing; Donti, Taraka R.; Walkiewicz, Magdalena; Luchak, J. Michael; Chen, Li-Chieh; Schmitt, Eric S.; Niu, Zhiyv; Graham, Brett H.; Wong, Lee-Jun; Scaglia, Fernando] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
   [Erana, Rodrigo] Baylor Coll Med, Div Hematol & Oncol, Dept Pediat, Houston, TX 77030 USA.
   [Hunter, Jill V.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA.
C3 Baylor College of Medicine; Baylor College of Medicine; Baylor College
   of Medicine
RP Scaglia, F (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza, Houston, TX 77030 USA.
EM burrage@bcm.edu; stang@ambrygen.com; jwang7@bcm.edu; donti@bcm.edu;
   Magdalena.Walkiewicz@bcm.edu; jluchak@bcm.edu; ziv28@hotmail.com;
   eschmitt@bcm.edu; zniu@bcm.edu; rxerana@txch.org;
   jvhunter@texaschildrens.org; bgraham@bcm.edu; ljwong@bcm.edu;
   fscaglia@bcm.edu
RI Graham, Brett/R-8685-2018; niu, zhiyv/A-6558-2009; Donti,
   Taraka/K-5648-2013
OI Donti, Taraka/0000-0002-3830-155X; Graham, Brett/0000-0001-8451-8154
FU Genzyme/ACMG Foundation for Genetic and Genomic Medicine Medical
   Genetics Training Award in Clinical Biochemical Genetics; Medical
   Genetics Research Fellowship Program NIH/NIGMS [NIH T32 GM07526];
   NIH/NIGMS [R01 GM098387]; Cytometry and Cell Sorting Core at Baylor
   College of Medicine; NIH [NIAID P30AI036211, NCI P30CA125123, NCRR
   S10RR024574]
FX L.C.B. was supported by the Genzyme/ACMG Foundation for Genetic and
   Genomic Medicine Medical Genetics Training Award in Clinical Biochemical
   Genetics and the Medical Genetics Research Fellowship Program NIH/NIGMS
   NIH T32 GM07526. T.D. and B.H.G. were supported by NIH/NIGMS R01
   GM098387 (B.H.G.). This project was also supported by the Cytometry and
   Cell Sorting Core at Baylor College of Medicine with funding from the
   NIH (NIAID P30AI036211, NCI P30CA125123, and NCRR S10RR024574) and the
   assistance of joel M. Sederstrom.
CR Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248
   Bachmeyer C, 2010, BLOOD, V116, P3681, DOI 10.1182/blood-2010-07-299453
   Bykhovskaya Y, 2004, AM J HUM GENET, V74, P1303, DOI 10.1086/421530
   Casas K, 2004, AM J MED GENET A, V127A, P44, DOI 10.1002/ajmg.a.20652
   Chinault AC, 2009, GENET MED, V11, P518, DOI 10.1097/GIM.0b013e3181abd83c
   Cui H, 2013, GENET MED, V15, P388, DOI 10.1038/gim.2012.144
   Donti TR, 2014, DIS MODEL MECH, V7, P271, DOI 10.1242/dmm.013466
   Fernandez-Vizarra E, 2007, J MED GENET, V44, P173, DOI 10.1136/jmg.2006.045252
   INBAL A, 1995, AM J MED GENET, V55, P372, DOI 10.1002/ajmg.1320550325
   Jonckheere AI, 2012, J INHERIT METAB DIS, V35, P211, DOI 10.1007/s10545-011-9382-9
   Nakajima J, 2014, J HUM GENET, V59, P229, DOI 10.1038/jhg.2013.143
   Ng PC, 2001, GENOME RES, V11, P863, DOI 10.1101/gr.176601
   Patton JR, 2005, J BIOL CHEM, V280, P19823, DOI 10.1074/jbc.M500216200
   RAWLES JM, 1974, AM J MED, V56, P891, DOI 10.1016/0002-9343(74)90820-1
   Riley LG, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-193
   Riley LG, 2010, AM J HUM GENET, V87, P52, DOI 10.1016/j.ajhg.2010.06.001
   Sasarman F, 2002, HUM MOL GENET, V11, P1669, DOI 10.1093/hmg/11.14.1669
   Sasarman F, 2012, HUM MUTAT, V33, P1201, DOI 10.1002/humu.22098
   Shahni R, 2013, AM J MED GENET A, V161, P2334, DOI 10.1002/ajmg.a.36065
   Shanske S, 2004, MITOCHONDRION, V4, P403, DOI 10.1016/j.mito.2004.07.026
   Tang S, 2013, HUM MUTAT, V34, P882, DOI 10.1002/humu.22307
   Wong LJC, 2008, CLIN CHEM, V54, P1141, DOI 10.1373/clinchem.2008.103721
   Yang YP, 2013, NEW ENGL J MED, V369, P1502, DOI 10.1056/NEJMoa1306555
   Zeharia A, 2005, J CHILD NEUROL, V20, P449, DOI 10.1177/08830738050200051301
   Zhang W, 2012, CLIN CHEM, V58, P1322, DOI 10.1373/clinchem.2011.181438
NR 25
TC 58
Z9 63
U1 0
U2 20
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1096-7192
EI 1096-7206
J9 MOL GENET METAB
JI Mol. Genet. Metab.
PD NOV
PY 2014
VL 113
IS 3
BP 207
EP 212
DI 10.1016/j.ymgme.2014.06.004
PG 6
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental
   Medicine
GA AT3ON
UT WOS:000344844000009
PM 25037980
OA Green Accepted
DA 2024-11-01
ER

PT J
AU Nogueira, C
   Almeida, LS
   Nesti, C
   Pezzini, I
   Videira, A
   Vilarinho, L
   Santorelli, FM
AF Nogueira, Celia
   Almeida, Ligia S.
   Nesti, Claudia
   Pezzini, Ilaria
   Videira, Arnaldo
   Vilarinho, Laura
   Santorelli, Filippo M.
TI Syndromes associated with mitochondrial DNA depletion
SO ITALIAN JOURNAL OF PEDIATRICS
LA English
DT Review
DE Mitochondrial DNA depletion syndrome; Mitochondrial myopathy;
   Mitochondrial encephalomyopathy; Hepatocerebral syndrome; mtDNA; OxPhos;
   Alpers-Huttenlocher syndrome
ID NEUROGASTROINTESTINAL ENCEPHALOMYOPATHY MNGIE; STEM-CELL
   TRANSPLANTATION; POLYMERASE-GAMMA; MOLECULAR-FEATURES; CLINICAL
   SPECTRUM; MTDNA DEPLETION; MUTATIONS; DEFICIENCY; DISORDERS; DISEASE
AB Mitochondrial dysfunction accounts for a large group of inherited metabolic disorders most of which are due to a dysfunctional mitochondrial respiratory chain (MRC) and, consequently, deficient energy production. MRC function depends on the coordinated expression of both nuclear (nDNA) and mitochondrial (mtDNA) genomes. Thus, mitochondrial diseases can be caused by genetic defects in either the mitochondrial or the nuclear genome, or in the cross-talk between the two. This impaired cross-talk gives rise to so-called nuclear-mitochondrial intergenomic communication disorders, which result in loss or instability of the mitochondrial genome and, in turn, impaired maintenance of qualitative and quantitative mtDNA integrity. In children, most MRC disorders are associated with nuclear gene defects rather than alterations in the mtDNA itself.
   The mitochondrial DNA depletion syndromes (MDSs) are a clinically heterogeneous group of disorders with an autosomal recessive pattern of transmission that have onset in infancy or early childhood and are characterized by a reduced number of copies of mtDNA in affected tissues and organs. The MDSs can be divided into least four clinical presentations: hepatocerebral, myopathic, encephalomyopathic and neurogastrointestinal. The focus of this review is to offer an overview of these syndromes, listing the clinical phenotypes, together with their relative frequency, mutational spectrum, and possible insights for improving diagnostic strategies.
C1 [Nogueira, Celia; Almeida, Ligia S.; Vilarinho, Laura] Natl Inst Hlth, Dept Genet, Res & Dev Unit, P-4000055 Oporto, Portugal.
   [Nesti, Claudia; Pezzini, Ilaria; Santorelli, Filippo M.] IRCCS Stella Maris, Pisa, Italy.
   [Videira, Arnaldo] Natl Inst Hlth, ICBAS, P-4000055 Oporto, Portugal.
   [Santorelli, Filippo M.] Univ Pisa, Dept Child Neurol & Neurogenet, IRCCS Stella Maris, I-56128 Pisa, Italy.
   [Vilarinho, Laura] Natl Inst Hlth, Dept Genet, Newborn Screening Metab & Genet Unit, P-4000055 Oporto, Portugal.
C3 IRCCS Fondazione Stella Maris; Universidade do Porto; IRCCS Fondazione
   Stella Maris; University of Pisa
RP Vilarinho, L (corresponding author), Natl Inst Hlth, Dept Genet, Res & Dev Unit, P-4000055 Oporto, Portugal.
EM laura.vilarinho@insa.min-saude.pt; filippo3364@gmail.com
RI Videira, Arnaldo/H-8150-2013; Nesti, Claudia/K-5866-2016; Santorelli,
   Filippo M/ABE-5124-2020
OI Videira, Arnaldo/0000-0001-7267-4459; Nesti,
   Claudia/0000-0001-5769-8655; Vilarinho, Laura/0000-0001-6186-779X;
   Santorelli, Filippo M/0000-0002-1359-9062; Almeida,
   Ligia/0000-0003-1370-961X; Nogueira, Celia/0000-0003-3640-8537
FU Portuguese Foundation for Science and Technology [SFRH/BD/45247/2008,
   FCT C2008/INSA/P4]; Fundação para a Ciência e a Tecnologia
   [SFRH/BD/45247/2008] Funding Source: FCT
FX CN was supported by the Portuguese Foundation for Science and Technology
   (SFRH/BD/45247/2008). LSA was supported by the Portuguese Foundation for
   Science and Technology (FCT C2008/INSA/P4). We thank Catherine J. Wrenn
   for her expert language editing.
CR Alberio S, 2007, MITOCHONDRION, V7, P6, DOI 10.1016/j.mito.2006.11.010
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Buchaklian AH, 2012, MOL GENET METAB, V107, P92, DOI 10.1016/j.ymgme.2012.04.019
   Calvo SE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003310
   Chinnery Patrick F, 2008, Neuromuscul Disord, V18, P259, DOI 10.1016/j.nmd.2007.11.005
   Cohen BH, 2010, METHODS, V51, P364, DOI 10.1016/j.ymeth.2010.05.008
   Copeland WC, 2012, CRIT REV BIOCHEM MOL, V47, P64, DOI 10.3109/10409238.2011.632763
   Dallabona C, 2010, HUM MOL GENET, V19, P1098, DOI 10.1093/hmg/ddp581
   Darin N, 2001, ANN NEUROL, V49, P377, DOI 10.1002/ana.75
   Delarue A, 2000, Pediatr Transplant, V4, P67, DOI 10.1034/j.1399-3046.2000.00090.x
   DiMauro S, 2004, BBA-BIOENERGETICS, V1659, P107, DOI 10.1016/j.bbabio.2004.08.003
   DiMauro S, 2013, NAT REV NEUROL, V9, P429, DOI 10.1038/nrneurol.2013.126
   DiMauro S, 2010, DEV DISABIL RES REV, V16, P106, DOI 10.1002/ddrr.102
   Dimmock DP, 2008, HUM MUTAT, V29, P330, DOI 10.1002/humu.9519
   Dündar H, 2012, PEDIATR NEUROL, V46, P172, DOI 10.1016/j.pediatrneurol.2011.12.006
   El-Hattab AW, 2009, MOL GENET METAB S12, V1792, P1109
   El-Hattab A, 2013, NEUROTHERAPEUTICS, V10, P186, DOI 10.1007/s13311-013-0177-6
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Filosto M, 2012, J NEUROL, V259, P2699, DOI 10.1007/s00415-012-6572-9
   Finsterer J, 2013, CAN J NEUROL SCI, V40, P635, DOI 10.1017/S0317167100014852
   Haack TB, 2012, J MED GENET, V49, P277, DOI 10.1136/jmedgenet-2012-100846
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   Hasselmann O, 2010, MOL GENET METAB, V99, P58, DOI 10.1016/j.ymgme.2009.08.005
   Hirano M, 2006, NEUROLOGY, V67, P1458, DOI 10.1212/01.wnl.0000240853.97716.24
   Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279
   HIRANO M, 1994, NEUROLOGY, V44, P721, DOI 10.1212/WNL.44.4.721
   Ji JQ, 2010, MITOCHONDRION, V10, P188, DOI 10.1016/j.mito.2009.11.002
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   Kaji S, 2009, MOL GENET METAB, V97, P292, DOI 10.1016/j.ymgme.2009.04.014
   Kayihan N, 2000, Pediatr Transplant, V4, P211, DOI 10.1034/j.1399-3046.2000.00115.x
   Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257
   Lara MC, 2007, BIOSCIENCE REP, V27, P151, DOI 10.1007/s10540-007-9043-2
   Lara MC, 2006, NEUROLOGY, V67, P1461, DOI 10.1212/01.wnl.0000239824.95411.52
   Lee YS, 2009, CELL, V139, P312, DOI 10.1016/j.cell.2009.07.050
   Lesko N, 2010, NEUROMUSCULAR DISORD, V20, P198, DOI 10.1016/j.nmd.2009.11.013
   Lieber DS, 2013, NEUROLOGY, V80, P1762, DOI 10.1212/WNL.0b013e3182918c40
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Morava E, 2009, MITOCHONDRION, V9, P438, DOI 10.1016/j.mito.2009.08.003
   Morten KJ, 2007, MITOCHONDRION, V7, P386, DOI 10.1016/j.mito.2007.09.001
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Naviaux RK, 1999, ANN NEUROL, V45, P54, DOI 10.1002/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Nogueira C, 2011, J CHILD NEUROL, V26, P866, DOI 10.1177/0883073811402072
   Oskoui M, 2006, ARCH NEUROL-CHICAGO, V63, P1122, DOI 10.1001/archneur.63.8.1122
   Ostergaard E, 2007, AM J HUM GENET, V81, P383, DOI 10.1086/519222
   Pagliarini DJ, 2008, CELL, V134, P112, DOI 10.1016/j.cell.2008.06.016
   Parini R, 2009, J HEPATOL, V50, P215, DOI 10.1016/j.jhep.2008.08.019
   Pfeffer G, 2013, NAT REV NEUROL, V9, P474, DOI 10.1038/nrneurol.2013.129
   Rahman S, 2009, ARCH DIS CHILD, V94, P3, DOI 10.1136/adc.2008.147983
   Rivera H, 2010, MITOCHONDRION, V10, P362, DOI 10.1016/j.mito.2010.03.003
   Rötig A, 2009, BBA-MOL BASIS DIS, V1792, P1103, DOI 10.1016/j.bbadis.2009.06.009
   Rouzier C, 2010, J MED GENET, V47, P670, DOI 10.1136/jmg.2009.073445
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Sarzi E, 2007, J PEDIATR-US, V150, P531, DOI 10.1016/j.jpeds.2007.01.044
   Schaefer AM, 2004, BBA-BIOENERGETICS, V1659, P115, DOI 10.1016/j.bbabio.2004.09.005
   Shaibani A, 2009, ARCH NEUROL-CHICAGO, V66, P1028, DOI 10.1001/archneurol.2009.139
   Shendure J, 2012, NAT BIOTECHNOL, V30, P1084, DOI 10.1038/nbt.2421
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Spinazzola A, 2005, GENE, V354, P162, DOI 10.1016/j.gene.2005.03.025
   Spinazzola A, 2009, J INHERIT METAB DIS, V32, P143, DOI 10.1007/s10545-008-1038-z
   Spinazzola A, 2007, BIOSCIENCE REP, V27, P39, DOI 10.1007/s10540-007-9036-1
   Stewart JD, 2010, HEPATOLOGY, V52, P1791, DOI 10.1002/hep.23891
   Tang S, 2012, J NEUROL, V259, P862, DOI 10.1007/s00415-011-6268-6
   van der Giezen M, 2005, EMBO REP, V6, P525, DOI 10.1038/sj.embor.7400440
   Vasta V, 2009, GENOME MED, V1, DOI 10.1186/gm100
   Wong LJC, 2007, HEPATOLOGY, V46, P1218, DOI 10.1002/hep.21799
   Yavuz H, 2007, ARCH NEUROL-CHICAGO, V64, P435, DOI 10.1001/archneur.64.3.435
   Zhang SL, 2010, MOL GENET METAB, V99, P53, DOI 10.1016/j.ymgme.2009.09.003
NR 71
TC 40
Z9 52
U1 0
U2 18
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1720-8424
EI 1824-7288
J9 ITAL J PEDIATR
JI Ital. J. Pediatr.
PD APR 3
PY 2014
VL 40
AR 34
DI 10.1186/1824-7288-40-34
PG 10
WC Pediatrics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pediatrics
GA AF8JR
UT WOS:000334962500001
PM 24708634
OA Green Published, gold
DA 2024-11-01
ER

PT J
AU Visuttijai, K
   Hedberg-Oldfors, C
   Lindgren, U
   Nordström, S
   Elíasdóttir, O
   Lindberg, C
   Oldfors, A
AF Visuttijai, Kittichate
   Hedberg-Oldfors, Carola
   Lindgren, Ulrika
   Nordstrom, Sara
   Eliasdottir, Olof
   Lindberg, Christopher
   Oldfors, Anders
TI Progressive external ophthalmoplegia associated with
   novel<i>MT</i>-<i>TN</i>mutations
SO ACTA NEUROLOGICA SCANDINAVICA
LA English
DT Article
ID MITOCHONDRIAL TRNA(ASN) GENE; POINT MUTATIONS; DNA MUTATIONS;
   IDENTIFICATION; DELETIONS; MUSCLE
AB Objectives To describe two patients with progressive external ophthalmoplegia (PEO) and mitochondrial myopathy associated with mutations in mitochondrial DNA, encoding the tRNA(Asn)gene (MT-TN), which have not previously been published with clinical descriptions. Materials & Methods Two unrelated patients with PEO were clinically examined. Muscle biopsy was performed and investigated by exome sequencing, enzyme histochemistry, and immunohistochemistry. The level of heteroplasmy was investigated in single muscle fibers and in other tissues. Results Patient 1 was a 52-year-old man with ptosis, PEO, and exercise intolerance since childhood. Muscle biopsy demonstrated mitochondrial myopathy with frequent cytochromecoxidase (COX)-deficient fibers and a heteroplasmic mutation, m.5669G>A in theMT-TNgene, resulting in a substitution of a highly conserved C to T in the T stem of tRNA(Asn). Patient 2 was a 66-year-old woman with ptosis, PEO, and exercise intolerance since many years. Muscle biopsy demonstrated mitochondrial myopathy with frequent COX-deficient fibers. She had a novel m.5702delA mutation inMT-TN, resulting in loss of a highly conserved U in the anticodon stem of tRNA(Asn). Single fiber analysis in both cases showed highly significant differences in mutation load between COX-deficient and COX-normal fibers and a high threshold level for COX deficiency. The mutations were not found in blood, urine sediment or buccal cells. Conclusion We describe twoMT-TNmutations associated with PEO and mitochondrial myopathy, and their pathogenicity was demonstrated. Together with previous reports, the results indicate thatMT-TNis a hot spot for mutations causing sporadic PEO.
C1 [Visuttijai, Kittichate; Hedberg-Oldfors, Carola; Lindgren, Ulrika; Oldfors, Anders] Univ Gothenburg, Sahlgrenska Acad, Dept Lab Med, Gothenburg, Sweden.
   [Nordstrom, Sara; Eliasdottir, Olof; Lindberg, Christopher] Sahlgrens Univ Hosp, Dept Neurol, Gothenburg, Sweden.
C3 University of Gothenburg; Sahlgrenska University Hospital
RP Oldfors, A (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Dept Lab Med, Gothenburg, Sweden.
EM anders.oldfors@gu.se
RI Visuttijai, Kittichate/S-4927-2019; Lindgren, Ulrika/HJH-0146-2022
OI Visuttijai, Kittichate/0000-0002-4800-8533
FU Vetenskapsradet [2018-02821]; Swedish Research Council [2018-02821]
   Funding Source: Swedish Research Council; Vinnova [2018-02821] Funding
   Source: Vinnova
FX Vetenskapsradet, Grant/Award Number: 2018-02821
CR Alston CL, 2017, J PATHOL, P139
   Bannwarth S, 2013, J MED GENET, V50, P704, DOI 10.1136/jmedgenet-2013-101604
   Blakely EL, 2013, HUM MUTAT, V34, P1260, DOI 10.1002/humu.22358
   Calvo SE, 2016, NUCLEIC ACIDS RES, V44, pD1251, DOI 10.1093/nar/gkv1003
   Coulbault L, 2005, BIOCHEM BIOPH RES CO, V329, P1152, DOI 10.1016/j.bbrc.2005.02.083
   Dubowitz V., 2020, Muscle biopsy: A practical approach
   Elson JL, 2009, HUM MUTAT, V30, pE984, DOI 10.1002/humu.21113
   Fayet G, 2002, NEUROMUSCULAR DISORD, V12, P484, DOI 10.1016/S0960-8966(01)00332-7
   Meulemans A, 2006, ARCH NEUROL-CHICAGO, V63, P1194, DOI 10.1001/archneur.63.8.1194
   MITOMAP, 2020, HUM MIT GEN DAT
   MORAES CT, 1993, J CLIN INVEST, V92, P2906, DOI 10.1172/JCI116913
   Nishigaki Y, 2010, MITOCHONDRION, V10, P300, DOI 10.1016/j.mito.2010.01.003
   OLDFORS A, 1995, J NEUROPATH EXP NEUR, V54, P581, DOI 10.1097/00005072-199507000-00012
   Pinós T, 2013, NEUROMUSCULAR DISORD, V23, P330, DOI 10.1016/j.nmd.2013.01.001
   Ronchi D, 2012, EUR J HUM GENET, V20, P357, DOI 10.1038/ejhg.2011.238
   SEIBEL P, 1994, BIOCHEM BIOPH RES CO, V204, P482, DOI 10.1006/bbrc.1994.2485
   Sternberg D, 2001, BRAIN, V124, P984, DOI 10.1093/brain/124.5.984
   Tarnopolsky M, 2019, MITOCHONDRION, V47, P139, DOI 10.1016/j.mito.2019.04.003
   Valente L, 2009, BBA-BIOENERGETICS, V1787, P491, DOI 10.1016/j.bbabio.2008.10.001
   Vives-Bauza C, 2003, J INHERIT METAB DIS, V26, P507, DOI 10.1023/A:1025133629685
NR 20
TC 12
Z9 12
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0001-6314
EI 1600-0404
J9 ACTA NEUROL SCAND
JI Acta Neurol. Scand.
PD JAN
PY 2021
VL 143
IS 1
BP 103
EP 108
DI 10.1111/ane.13339
EA SEP 2020
PG 6
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA OZ9KK
UT WOS:000570735800001
PM 32869280
OA gold, Green Published
DA 2024-11-01
ER

PT J
AU Calderwood, L
   Holm, IA
   Teot, LA
   Anselm, I
AF Calderwood, Laurel
   Holm, Ingrid A.
   Teot, Lisa A.
   Anselm, Irina
TI Adrenal Insufficiency in Mitochondrial Disease: A Rare Case of
   GFER-Related Mitochondrial Encephalomyopathy and Review of the
   Literature
SO JOURNAL OF CHILD NEUROLOGY
LA English
DT Review
DE mitochondrial DNA (mtDNA) deletion; congenital cataracts; lactic
   acidosis; next generation panel
ID KEARNS-SAYRE-SYNDROME; DNA DELETION; LIVER-REGENERATION; PEARSON
   SYNDROME; ADDISON-DISEASE; CHILD; AUGMENTOR; MYOPATHY; MUTATION; ACID
AB GFER-related mitochondrial encephalomyopathy has been previously described only in 3 siblings of a consanguineous Moroccan family. Their phenotype included congenital cataracts, hypotonia, developmental delay, and sensorineural hearing loss. Multiple mitochondrial respiratory chain complex deficiencies were identified on muscle biopsy. We describe a now-19-year-old woman with adrenal insufficiency, lactic acidosis, congenital cataracts, and respiratory insufficiency secondary to mitochondrial disorder, who was reported by North et al (1996) as a toddler. Compound heterozygous GFER mutations c.373C>T (Q125X) and c.581G>A (R194 H) were recently discovered in this patient. The purpose of this report is (1) to expand the phenotype this ultra-rare disorder and (2) to provide a review of the literature describing the unique finding of adrenal insufficiency in patients with molecularly confirmed disorders of mitochondrial metabolism.
C1 [Calderwood, Laurel] Boston Univ, Sch Med, Dept Obstet & Gynecol, Boston, MA 02118 USA.
   [Holm, Ingrid A.] Boston Childrens Hosp, Div Genet & Genom, Div Endocrinol, Dept Med,Manton Ctr Orphan Dis Res, Boston, MA 02115 USA.
   [Holm, Ingrid A.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
   [Teot, Lisa A.] Boston Childrens Hosp, Dept Pathol, Boston, MA 02115 USA.
   [Teot, Lisa A.; Anselm, Irina] Harvard Univ, Sch Med, Boston, MA USA.
   [Anselm, Irina] Boston Childrens Hosp, Dept Neurol, 300 Longwood Ave, Boston, MA 02115 USA.
C3 Boston University; Harvard University; Boston Children's Hospital;
   Harvard University; Harvard Medical School; Harvard University; Boston
   Children's Hospital; Harvard University; Harvard Medical School; Harvard
   University; Boston Children's Hospital
RP Anselm, I (corresponding author), Boston Childrens Hosp, Dept Neurol, 300 Longwood Ave, Boston, MA 02115 USA.
EM irina.anselm@childrens.harvard.edu
OI Holm, Ingrid/0000-0003-4712-8821
CR Afroze B, 2014, BRAIN DEV-JPN, V36, P924, DOI 10.1016/j.braindev.2013.12.009
   Artuch R, 1998, HORM RES, V50, P99, DOI 10.1159/000023243
   Boles RG, 1998, EUR J PEDIATR, V157, P643, DOI 10.1007/s004310050902
   Bruno C, 1998, J INHERIT METAB DIS, V21, P155, DOI 10.1023/A:1005347826664
   Chinnery PF, MITOCHONDRIAL DISORD
   Daithankar VN, 2010, BIOCHEMISTRY-US, V49, P6737, DOI 10.1021/bi100912m
   Di Fonzo A, 2009, AM J HUM GENET, V84, P594, DOI 10.1016/j.ajhg.2009.04.004
   Duran GP, 2012, JIMD REP, V3, P5, DOI 10.1007/8904_2011_33
   Gatzidou E, 2006, WORLD J GASTROENTERO, V12, P4951, DOI 10.3748/wjg.v12.i31.4951
   Hopkins SE, 2010, J CHILD NEUROL, V25, P752, DOI 10.1177/0883073809343313
   Nicolino M, 1997, J CLIN ENDOCR METAB, V82, P3063, DOI 10.1210/jc.82.9.3063
   North K, 1996, J PEDIATR-US, V128, P688, DOI 10.1016/S0022-3476(96)80136-3
   RIBES A, 1993, J INHERIT METAB DIS, V16, P537, DOI 10.1007/BF00711675
   Sanaker PS, 2007, ACTA NEUROL SCAND, V115, P64, DOI 10.1111/j.1600-0404.2007.00850.x
   Schaefer AM, 2013, MOL CELL ENDOCRINOL, V379, P2, DOI 10.1016/j.mce.2013.06.004
   Tzoufi M, 2013, EUR J PEDIATR, V172, P557, DOI 10.1007/s00431-012-1798-1
   Williams TB, 2012, MOL GENET METAB, V106, P104, DOI 10.1016/j.ymgme.2012.01.018
NR 17
TC 18
Z9 19
U1 0
U2 5
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0883-0738
EI 1708-8283
J9 J CHILD NEUROL
JI J. Child Neurol.
PD FEB
PY 2016
VL 31
IS 2
BP 190
EP 194
DI 10.1177/0883073815587327
PG 5
WC Clinical Neurology; Pediatrics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pediatrics
GA DC0VB
UT WOS:000368934800011
PM 26018198
DA 2024-11-01
ER

PT J
AU Oskoui, M
   Davidzon, G
   Pascual, J
   Erazo, R
   Gurgel-Giannetti, J
   Krishna, S
   Bonilla, E
   De Vivo, DC
   Shanske, S
   DiMauro, S
AF Oskoui, Maryam
   Davidzon, Guido
   Pascual, Juan
   Erazo, Ricardo
   Gurgel-Giannetti, Juliana
   Krishna, Sindu
   Bonilla, Eduardo
   De Vivo, Darryl C.
   Shanske, Sara
   DiMauro, Salvatore
TI Clinical spectrum of mitochondrial DNA depletion due to mutations in the
   thymidine kinase 2 gene
SO ARCHIVES OF NEUROLOGY
LA English
DT Article
ID DEOXYGUANOSINE KINASE; MTDNA DEPLETION; POLG MUTATIONS; MYOPATHY;
   DEFICIENCY
AB Background: Mitochondrial DNA depletion syndrome is an autosomal recessive disorder characterized by decreased mitochondrial DNA copy numbers in affected tissues. It has been linked to 4 genes involved in deoxyribonucleotide triphosphate metabolism: thymidine kinase 2 (TK2), deoxyguanosine kinase (DGUOK), polymerase gamma (POLG), and SUCLA2, the gene encoding the beta-subunit of the adenosine diphosphate-forming succinyl coenzyme A synthetase ligase.
   Objective: To highlight the variability in the clinical spectrum of TK2-related mitochondrial DNA depletion syndrome.
   Design: Review of patients and the literature.
   Setting: Tertiary care university.
   Patients: Four patients with mitochondrial DNA depletion syndrome and mutations in the TK2 gene.
   Main Outcome Measures: Definition of clinical variability.
   Results: Patient 1 had evidence of lower motoneuron disease and was initially diagnosed as having spinal muscular atrophy type 3. Patient 2, who is alive and ambulatory at age 9 years, presented at age 2 years with a slowly progressive mitochondrial myopathy. Patient 3 had a more severe myopathy, with onset in infancy and death at age 6 years of respiratory failure. Patient 4 had a rapidly progressive congenital myopathy with rigid spine syndrome and he died at age 19 months.
   Conclusion: The clinical spectrum of TK2 mutations is not limited to severe infantile myopathy with motor regression and early death but includes spinal muscular atrophy type 3-like presentation, rigid spine syndrome, and subacute myopathy without motor regression and with longer survival.
C1 Columbia Univ, Coll Phys & Surg 4420, Dept Neurol, Med Ctr, New York, NY 10032 USA.
   Hosp Ninos Luis Calvo Mackenna, Div Pediat Neurol, Santiago, Chile.
   Univ Fed Minas Gerais, Dept Pediat, Belo Horizonte, MG, Brazil.
C3 Columbia University; Universidad de Chile; Universidade Federal de Minas
   Gerais
RP DiMauro, S (corresponding author), Columbia Univ, Coll Phys & Surg 4420, Dept Neurol, Med Ctr, 630 W 168th St, New York, NY 10032 USA.
EM sd12@columbia.edu
RI Gurgel-Giannetti, Juliana/AAK-2172-2021
OI Gurgel-Giannetti, Juliana/0000-0003-3335-1491; Pascual,
   Juan/0000-0002-0843-8221
CR Carrozzo R, 2003, HUM MUTAT, V21, DOI 10.1002/humu.9135
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Mancuso M, 2005, ARCH NEUROL-CHICAGO, V62, P745, DOI 10.1001/archneur.62.5.745
   Mancuso M, 2003, ARCH NEUROL-CHICAGO, V60, P1007, DOI 10.1001/archneur.60.7.1007
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Naviaux RK, 2005, ANN NEUROL, V58, P491, DOI 10.1002/ana.20544
   Nevo Y, 2002, J CHILD NEUROL, V17, P499, DOI 10.1177/088307380201700705
   Pons R, 1996, PEDIATR NEUROL, V15, P153, DOI 10.1016/0887-8994(96)00118-X
   Saada A, 2003, MOL GENET METAB, V79, P1, DOI 10.1016/S1096-7192(03)00063-5
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Sambrook J, 1990, Cold Spring Harbor Laboratories, V186, P182
   Sciacco M, 1996, Methods Enzymol, V264, P509, DOI 10.1016/S0076-6879(96)64045-2
   Tulinius M, 2005, NEUROMUSCULAR DISORD, V15, P412, DOI 10.1016/j.nmd.2005.03.010
   Vu TH, 1998, NEUROLOGY, V50, P1783, DOI 10.1212/WNL.50.6.1783
   Wang LY, 2005, MOL GENET METAB, V84, P75, DOI 10.1016/j.ymgme.2004.09.005
NR 19
TC 93
Z9 106
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9942
EI 1538-3687
J9 ARCH NEUROL-CHICAGO
JI Arch. Neurol.
PD AUG
PY 2006
VL 63
IS 8
BP 1122
EP 1126
DI 10.1001/archneur.63.8.1122
PG 5
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 072ER
UT WOS:000239656400011
PM 16908738
DA 2024-11-01
ER

PT J
AU Cardaioli, E
   Malfatti, E
   Da Pozzo, P
   Gallus, GN
   Carluccio, MA
   Rufa, A
   Volpi, N
   Dotti, MT
   Federico, A
AF Cardaioli, Elena
   Malfatti, Edoardo
   Da Pozzo, Paola
   Gallus, Gian Nicola
   Carluccio, Maria Alessandra
   Rufa, Alessandra
   Volpi, Nila
   Dotti, Maria Teresa
   Federico, Antonio
TI Progressive mitochondrial myopathy, deafness, and sporadic seizures
   associated with a novel mutation in the mitochondrial
   tRNASer<SUP>(AGY)</SUP> gene
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE Encephalomyopathies; Mitochondrial DNA; tRNASer((AGY)); Heteroplasmy;
   Single fibres studies; Pathogenicity; Muscle biochemical analysis
ID TRANSFER-RNA MUTATIONS; POINT MUTATION; DNA MUTATIONS
AB We sequenced the mitochondrial genome from a patient with progressive mitochondrial myopathy associated with deafness, sporadic seizures, and histological and biochemical features of mitochondrial respiratory chain dysfunction. Direct sequencing showed a heteroplasmic mutation at nucleotide 12262 in the tRNASer((AGY)) gene. RFLP analysis confirmed that 63% of muscle mtDNA harboured the mutation, while it was absent in all the other tissues. The mutation is predicted to influence the functional behaviour of the aminoacyl acceptor stem of the tRNA. Several point mutations on mitochondrial tRNA genes have been reported in patients affected by encephalomyopathies, but between them only four were reported for tRNASer((AGY)). (C) 2011 Elsevier B.V. All rights reserved.
C1 [Cardaioli, Elena; Malfatti, Edoardo; Da Pozzo, Paola; Gallus, Gian Nicola; Carluccio, Maria Alessandra; Rufa, Alessandra; Dotti, Maria Teresa; Federico, Antonio] Univ Siena, Dept Neurol Neurosurg & Behav Sci, I-53100 Siena, Italy.
   [Volpi, Nila] Univ Siena, Dept Biomed Sci, Sect Anat & Histol, I-53100 Siena, Italy.
C3 University of Siena; University of Siena
RP Federico, A (corresponding author), Univ Siena, Dept Neurol Neurosurg & Behav Sci, Viale Bracci 2, I-53100 Siena, Italy.
EM federico@unisi.it
RI Rufa, Alessandra/E-8298-2011; Malfatti, Edoardo/KEI-9379-2024; Federico,
   Antonio/H-8871-2017; Volpi, Nicola/D-4874-2015; GALLUS, GIAN
   NICOLA/Q-3489-2016
OI federico, antonio/0000-0002-5246-1621; Rufa,
   Alessandra/0000-0002-2254-2869; VOLPI, NILA/0000-0002-0837-1864;
   Cardaioli, Elena/0000-0003-2850-6698; GALLUS, GIAN
   NICOLA/0000-0001-5801-223X
FU University of Siena [PAR 2008]
FX Research partially supported by a grant from the University of Siena to
   AF (PAR 2008).
CR Bugiani M, 2004, BBA-BIOENERGETICS, V1659, P136, DOI 10.1016/j.bbabio.2004.09.006
   Dimauro S, 2004, ANN NY ACAD SCI, V1011, P217, DOI 10.1196/annals.1293.022
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   Fu K, 1996, HUM MOL GENET, V5, P1835, DOI 10.1093/hmg/5.11.1835
   HOLME E, 1995, BBA-MOL BASIS DIS, V1271, P249, DOI 10.1016/0925-4439(95)00035-3
   Houshmand M, 1999, HUM MUTAT, V13, P203, DOI 10.1002/(SICI)1098-1004(1999)13:3<203::AID-HUMU4>3.0.CO;2-3
   LARSSON NG, 1992, AM J HUM GENET, V51, P1201
   LAUBER J, 1991, NUCLEIC ACIDS RES, V19, P1393, DOI 10.1093/nar/19.7.1393
   Leveque M, 2007, EUR J HUM GENET, V15, P1145, DOI 10.1038/sj.ejhg.5201891
   Lynn S, 1998, DIABETES, V47, P1800, DOI 10.2337/diabetes.47.11.1800
   Mansergh FC, 1999, AM J HUM GENET, V64, P971, DOI 10.1086/302344
   McFarland R, 2004, TRENDS GENET, V20, P591, DOI 10.1016/j.tig.2004.09.014
   Nishigaki Y, 2002, NEUROLOGY, V58, P1282, DOI 10.1212/WNL.58.8.1282
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Wong LJC, 2006, J MED GENET, V43, DOI 10.1136/jmg.2005.040626
   Zeviani M, 1996, J INHERIT METAB DIS, V19, P504, DOI 10.1007/BF01799111
   Zifa E, 2007, RNA BIOL, V4, P38, DOI 10.4161/rna.4.1.4548
NR 17
TC 4
Z9 4
U1 0
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 1878-5883
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD APR 15
PY 2011
VL 303
IS 1-2
BP 142
EP 145
DI 10.1016/j.jns.2010.12.020
PG 4
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 747SO
UT WOS:000289339900025
PM 21257182
DA 2024-11-01
ER

PT J
AU Martikainen, MH
   Kytövuori, L
   Majamaa, K
AF Martikainen, Mika H.
   Kytovuori, Laura
   Majamaa, Kari
TI Juvenile parkinsonism, hypogonadism and Leigh-like MRI changes in a
   patient with m.4296G&gt;A mutation in mitochondrial DNA
SO MITOCHONDRION
LA English
DT Article
DE Hypogonadism; Leigh syndrome; Mitochondrial disease; Parkinsonism; tRNA
   isoleucine
ID TRANSFER-RNA GENES; PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; DISORDERS;
   DISEASE; MYOPATHY; ENCEPHALOPATHY; ABNORMALITIES; CHILDREN
AB Leigh syndrome is a mitochondrial disease with considerable clinical and genetic variation. We present a 16-year-old boy with Leigh-like syndrome and broad developmental retardation, parkinsonism and hypogonadism. Sequencing of the entire mitochondrial DNA from blood revealed the m.4296G>A mutation in the MT-TI gene. The mutation was heteroplasmic with a 95% proportion of the mutant genome, while the proportion was 58% in the blood of the patient's clinically healthy mother. Our results suggest that m.4296G>A is pathogenic in humans, and that the phenotype related to this change includes Leigh-like syndrome in adolescence with parkinsonism and hypogonadism, in addition to the previously reported early infantile Leigh syndrome. (C) 2013 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 [Martikainen, Mika H.] Univ Turku, Turku, Finland.
   [Martikainen, Mika H.] Turku Univ Hosp, Div Clin Neurosci, FIN-20520 Turku, Finland.
   [Kytovuori, Laura; Majamaa, Kari] Univ Oulu, Dept Clin Med Neurol, FIN-90014 Oulu, Finland.
   [Kytovuori, Laura; Majamaa, Kari] Oulu Univ Hosp, Dept Neurol, Oulu, Finland.
   [Kytovuori, Laura; Majamaa, Kari] Oulu Univ Hosp, Clin Res Ctr, Oulu, Finland.
C3 University of Turku; University of Turku; University of Oulu; University
   of Oulu; University of Oulu
RP Martikainen, MH (corresponding author), Univ Oulu, Dept Clin Med Neurol, FIN-90014 Oulu, Finland.
EM kari.majamaa@oulu.fi
RI Majamaa, Kari/A-1344-2012; Kytövuori, Laura/AHE-1635-2022
OI Kytovuori, Laura/0000-0003-2790-5646; Martikainen,
   Mika/0000-0002-7604-8081; Majamaa, Kari/0000-0002-9070-3791
CR Bidooki S, 2004, NEUROMUSCULAR DISORD, V14, P417, DOI 10.1016/j.nmd.2004.03.004
   BROWN MD, 1992, AM J HUM GENET, V51, P446
   Caeic M, 2001, J CHILD NEUROL, V16, P616, DOI 10.1177/088307380101600818
   Cox R, 2012, MITOCHONDRION, V12, P258, DOI 10.1016/j.mito.2011.09.006
   Dahl HHM, 1998, AM J HUM GENET, V63, P1594, DOI 10.1086/302169
   Finnilä S, 2001, AM J HUM GENET, V68, P1475, DOI 10.1086/320591
   Finsterer J, 2008, PEDIATR NEUROL, V39, P223, DOI 10.1016/j.pediatrneurol.2008.07.013
   Finsterer J, 2011, MOVEMENT DISORD, V26, P784, DOI 10.1002/mds.23651
   Horvath R, 2007, NEUROLOGY, V68, P56, DOI 10.1212/01.wnl.0000250334.48038.7a
   Huntsman RJ, 2005, PEDIATR NEUROL, V32, P334, DOI 10.1016/j.pediatrneurol.2004.12.009
   Kärppä M, 2005, BRAIN, V128, P1861, DOI 10.1093/brain/awh515
   Körkkö J, 1998, P NATL ACAD SCI USA, V95, P1681, DOI 10.1073/pnas.95.4.1681
   Lee HF, 2009, PEDIATR NEUROL, V40, P88, DOI 10.1016/j.pediatrneurol.2008.09.020
   Lee I.C., 2012, HUM MUTAT
   Limongelli A, 2004, J MED GENET, V41, P342, DOI 10.1136/jmg.2003.016048
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Maassen JA, 2005, ANN MED, V37, P213, DOI 10.1080/07853890510007188
   Makino M, 2000, J HUM GENET, V45, P69, DOI 10.1007/s100380050014
   Martikainen M.H., 2012, ACTA DIABETOL
   Martikainen MH, 2012, NEUROEPIDEMIOLOGY, V38, P114, DOI 10.1159/000336112
   MUNSCHER C, 1993, BIOL CHEM H-S, V374, P1099, DOI 10.1515/bchm3.1993.374.7-12.1099
   Orsucci D, 2011, J MOL NEUROSCI, V44, P17, DOI 10.1007/s12031-010-9488-9
   Porcelli AM, 2010, HUM MOL GENET, V19, P1019, DOI 10.1093/hmg/ddp566
   QUADE A, 1992, CLIN INVESTIGATOR, V70, P396
   Rahman S, 1996, ANN NEUROL, V39, P343, DOI 10.1002/ana.410390311
   Remes AM, 2008, PARKINSONISM RELAT D, V14, P652, DOI 10.1016/j.parkreldis.2008.01.009
   Rubino F, 2012, NUCLEIC ACIDS RES, V40, pD1150, DOI 10.1093/nar/gkr1086
   Saneto RP, 2008, MITOCHONDRION, V8, P396, DOI 10.1016/j.mito.2008.05.003
   Scaglia F, 2008, MUSCLE NERVE, V37, P150, DOI 10.1002/mus.20917
   Schapira AHV, 2008, LANCET NEUROL, V7, P97, DOI 10.1016/S1474-4422(07)70327-7
   SEIBEL P, 1994, BIOCHEM BIOPH RES CO, V204, P482, DOI 10.1006/bbrc.1994.2485
   Sprinzl M, 1998, NUCLEIC ACIDS RES, V26, P148, DOI 10.1093/nar/26.1.148
   Sternberg D, 2001, BRAIN, V124, P984, DOI 10.1093/brain/124.5.984
   Tsukuda K, 1997, DIABETIC MED, V14, P1032, DOI 10.1002/(SICI)1096-9136(199712)14:12<1032::AID-DIA504>3.0.CO;2-Y
   Uziel G, 2011, SEMIN FETAL NEONAT M, V16, P205, DOI 10.1016/j.siny.2011.04.003
   Valanne L, 1998, AM J NEURORADIOL, V19, P369
   Vilmi T, 2005, J MOL EVOL, V60, P587, DOI 10.1007/s00239-003-0202-1
   YOON KL, 1993, PEDIATR RES, V33, P433, DOI 10.1203/00006450-199305000-00002
   Zifa E, 2007, RNA BIOL, V4, P38, DOI 10.4161/rna.4.1.4548
NR 39
TC 16
Z9 16
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 1872-8278
J9 MITOCHONDRION
JI Mitochondrion
PD MAR
PY 2013
VL 13
IS 2
BP 83
EP 86
DI 10.1016/j.mito.2013.01.012
PG 4
WC Cell Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Genetics & Heredity
GA 125NW
UT WOS:000317547500003
PM 23395828
DA 2024-11-01
ER

PT J
AU Lu, YY
   Zhao, DH
   Yao, S
   Wu, SW
   Hong, DJ
   Wang, QQ
   Liu, J
   Smeitink, JAM
   Yuan, Y
   Wang, ZX
AF Lu, Yuanyuan
   Zhao, Danhua
   Yao, Sheng
   Wu, Shiwen
   Hong, Daojun
   Wang, Qingqing
   Liu, Jing
   Smeitink, Jan A. M.
   Yuan, Yun
   Wang, Zhaoxia
TI Mitochondrial tRNA genes are hotspots for mutations in a cohort of
   patients with exercise intolerance and mitochondrial myopathy
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE Mitochondrial myopathy; Exercise intolerance; Mitochondrial DNA; tRNA
   gene
ID COMPLEX-I; A3243G MUTATION; LACTIC-ACIDOSIS; ENCEPHALOPATHY; DISEASE;
   DNA; INVOLVEMENT; DIAGNOSIS; DEAFNESS
AB Objective: Mitochondrial myopathy (MM) is a relatively rare type of mitochondrial disorder characterized by predominant skeletal muscle involvement. Both mitochondrial DNA (mtDNA) and nuclear DNA (nDNA) mutations have been reported as the genetic causes of this disease. Here, we described the clinical and genetic features of a cohort of patients with MM.
   Methods: We conducted a retrospective, single center study enrolling 22 patients with clinically and myopathologically diagnosed MM. The clinical records and results of laboratory examinations were collected and analyzed. The follow-up was conducted by telephone interview in 12 patients. Muscle biopsy and gene analysis was performed in all patients. MtDNA mutation load was quantified in all available tissues.
   Results: Muscle biopsy revealed ragged red fibers and/or cytochrome c oxidase deficient fibers in all patients. Mitochondrial DNA analysis identified pathogenic mutations in 11 patients, including four previously reported mutations (mt-tRNA(Leb(UUR)) m.3243A>G in five patients, mt-tRNA(LYs) m.8344A>G in four patients, mt-tRNA(Leu(UUR)) m.3302A>G in one patient, and mt-tRNA(Leu(UUR)) m.3250T>C in one patient) and a novel possible pathogenic variant (MTND1 m.3437G>A) in one patient The mtDNA mutation load was consistently higher in muscles than in blood. In the remaining 10 patients, there was no pathogenic mutation found either by the Sanger sequencing of entire mitochondrial genome or by the targeted next-generation sequencing which included 238 nuclear genes related to mitochondrial diseases. Clinically, the onset age of these 22 MM patients ranged from 1 to 51 years (mean = 21.1 +/- 14.3 years), and the disease duration was between 3 and 44 years (mean = 14.1 +/- 9.4 years). Proximal limb weakness with or without exercise intolerance was present in 21 patients, and one patient showed only exercise intolerance. Out of these 22 patients, dysphagia/dysarthria, neck flexor muscle weakness, dyspnea, cardiomyopathy and exercise induced myalgia were observed in five, two, four, one and four patients, respectively. Neither central nervous system manifestation nor brain MRI abnormality was present in these patients. Notably, three of the four patients carrying the m.8344A>G mutation presented with dysarthria. The follow-up of 12 patients revealed symptom improvements in four cases, stable conditions in two cases, and worsened conditions in five cases. The case with the m.3302A>G mutation died of respiratory failure.
   Conclusions: Mitochondrial tRNA genes, as hotspots for mutations, accounted for 50% of MM in this cohort of patients. Patients associated with the m.8344A>G mutation were prone to laryngopharyngeal muscle involvement. The prognosis in our patients is relatively benign except one patient with the m.3302A>G mutation. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Lu, Yuanyuan; Wang, Qingqing; Liu, Jing; Yuan, Yun; Wang, Zhaoxia] Peking Univ, Dept Neurol, Hosp 1, Beijing, Peoples R China.
   [Zhao, Danhua] China Aerosp Corp, Cent Hosp, Dept Neurol, Beijing, Peoples R China.
   [Yao, Sheng] PLA Navy Gen Hosp, Dept Neurol, Beijing, Peoples R China.
   [Wu, Shiwen] Chinese Armed Police Force, Dept Neurol, Gen Hosp, Beijing, Peoples R China.
   [Hong, Daojun] Nanchang Univ, Dept Neurol, Affiliated Hosp 1, Nanchang, Jiangxi, Peoples R China.
   [Smeitink, Jan A. M.] Radboud Univ Nijmegen, Med Ctr, Radboud Ctr Mitochondrial Med, Dept Pediat, Nijmegen, Netherlands.
C3 Peking University; Sixth Medical Center of Chinese PLA General Hospital;
   Nanchang University; Radboud University Nijmegen
RP Wang, ZX (corresponding author), Peking Univ, Dept Neurol, Hosp 1, Beijing, Peoples R China.
EM drwangzx@163.com
RI Smeitink, Jan/C-1351-2013; Wu, Shiwen/JFA-0469-2023
OI Lu, yuanyuan/0000-0002-4628-3195
FU Ministry of Science and Technology of China [2011ZX09307-001-07];
   Beijing Municipal Science and Technology Commission [Z151100003915126]
FX The authors would like to thank the patients and their parents for
   cooperation. We thank Prof. Yinan Ma and Mrs. Ying Zhang for technical
   assistance in doing PCR-RFLP. This work was financially supported by
   grants from the Ministry of Science and Technology of China (No.
   2011ZX09307-001-07) and Beijing Municipal Science and Technology
   Commission (No. Z151100003915126).
CR Altmann J, 2016, J NEUROL, V263, P961, DOI 10.1007/s00415-016-8086-3
   Andreu AL, 1999, ANN NEUROL, V45, P820, DOI 10.1002/1531-8249(199906)45:6<820::AID-ANA22>3.0.CO;2-W
   Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   Angelini C, 2009, Acta Myol, V28, P16
   Beresford MW, 2006, NEUROMUSCULAR DISORD, V16, P613, DOI 10.1016/j.nmd.2006.07.003
   BINDOFF LA, 1993, J BIOL CHEM, V268, P19559
   Blakely EL, 2005, EUR J HUM GENET, V13, P623, DOI 10.1038/sj.ejhg.5201363
   Blakely EL, 2014, NEUROMUSCULAR DISORD, V24, P533, DOI 10.1016/j.nmd.2014.03.011
   Catteruccia M, 2015, J NEUROL, V262, P701, DOI 10.1007/s00415-014-7632-0
   Delmiro A, 2013, HUM MUTAT, V34, P1623, DOI 10.1002/humu.22445
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   DiMauro S, 1999, ITAL J NEUROL SCI, V20, P387
   Gal Aniko, 2008, Orvosi Hetilap, V149, P1593, DOI 10.1556/OH.2008.28398
   Gorman GS, 2015, CLIN SCI, V128, P895, DOI 10.1042/CS20140705
   HAMMANS SR, 1995, BRAIN, V118, P721, DOI 10.1093/brain/118.3.721
   Hardy SA, 2016, NEUROL-GENET, V2, DOI 10.1212/NXG.0000000000000082
   HARTLEY C, 1994, J LARYNGOL OTOL, V108, P685, DOI 10.1017/S0022215100127835
   Hirata K, 1999, J HUM GENET, V44, P210, DOI 10.1007/s100380050145
   JEANFRANCOIS MJB, 1994, AUST NZ J MED, V24, P188, DOI 10.1111/j.1445-5994.1994.tb00556.x
   Kazakos K, 2012, ANN HUM GENET, V76, P296, DOI 10.1111/j.1469-1809.2012.00711.x
   Kelly EA, 2013, ANN OTO RHINOL LARYN, V122, P177, DOI 10.1177/000348941312200306
   Koga Y, 2000, ARCH DIS CHILD, V82, P407, DOI 10.1136/adc.82.5.407
   Lin J, 2014, MITOCHONDR DNA, V25, P56, DOI 10.3109/19401736.2013.779259
   Lorenzoni PJ, 2015, ARQ NEURO-PSIQUIAT, V73, P959
   Ma YN, 2009, MITOCHONDRION, V9, P139, DOI 10.1016/j.mito.2009.01.004
   Marotta R, 2009, J CLIN NEUROSCI, V16, P1223, DOI 10.1016/j.jocn.2008.11.012
   Massie R, 2010, MUSCLE NERVE, V42, P136, DOI 10.1002/mus.21649
   Miller DK, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104879
   Milone M, 2013, MOL GENET METAB, V110, P35, DOI 10.1016/j.ymgme.2013.07.007
   MITOMAP, 2008, HUM MIT GEN DAT
   MORAES CT, 1993, NEUROMUSCULAR DISORD, V3, P43, DOI 10.1016/0960-8966(93)90040-Q
   Muñoz-Málaga A, 2000, MUSCLE NERVE, V23, P538, DOI 10.1002/(SICI)1097-4598(200004)23:4<538::AID-MUS12>3.3.CO;2-K
   Naing A, 2014, J DIABETES COMPLICAT, V28, P542, DOI 10.1016/j.jdiacomp.2014.03.006
   Pagliarini DJ, 2008, CELL, V134, P112, DOI 10.1016/j.cell.2008.06.016
   Pfeffer G, 2012, COCHRANE DB SYST REV, V18, P4
   Scheffler IE, 2001, ADV DRUG DELIVER REV, V49, P3, DOI 10.1016/S0169-409X(01)00123-5
   SHIBASAKI H, 1973, J NEUROL SCI, V18, P301, DOI 10.1016/0022-510X(73)90078-6
   Tarnopoisky M, 2013, AM J MED GENET A, V161, P2020, DOI 10.1002/ajmg.a.36000
   Valentino ML, 2004, ANN NEUROL, V56, P631, DOI 10.1002/ana.20236
   Wahbi K, 2010, NEUROLOGY, V74, P674, DOI 10.1212/WNL.0b013e3181d0ccf4
   Yang CC, 1998, J FORMOS MED ASSOC, V97, P715
   Zhao D, 2011, J HUM GENET, V56, P759, DOI 10.1038/jhg.2011.96
NR 42
TC 17
Z9 17
U1 0
U2 11
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 1878-5883
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD AUG 15
PY 2017
VL 379
BP 137
EP 143
DI 10.1016/j.jns.2017.05.056
PG 7
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA FC9TR
UT WOS:000407184500033
PM 28716227
DA 2024-11-01
ER

PT J
AU Wong, LJC
   Yim, D
   Bai, RK
   Kwon, H
   Vacek, MM
   Zane, J
   Hoppel, CL
   Kerr, DS
AF Wong, L-J C.
   Yim, D.
   Bai, R-K
   Kwon, H.
   Vacek, M. M.
   Zane, J.
   Hoppel, C. L.
   Kerr, D. S.
TI A novel mutation in the mitochondrial tRNA <SUP>Ser(AGY)</SUP> gene
   associated with mitochondrial myopathy, encephalopathy, and complex I
   deficiency
SO JOURNAL OF MEDICAL GENETICS
LA English
DT Article
ID GRADIENT GEL-ELECTROPHORESIS; QUANTITATIVE PCR ANALYSIS;
   LACTIC-ACIDOSIS; OXIDATIVE-PHOSPHORYLATION; DIAGNOSTIC-CRITERIA; DNA
   MUTATIONS; DISEASE; DISORDERS; ENCEPHALOMYOPATHY; QUANTIFICATION
AB Purpose: To identify molecular defects in a girl with clinical features of MELAS (mitochondrial encephalomyopathy and lactic acidosis) and MERRF (ragged-red fibres) syndromes.
   Methods: The enzyme complex activities of the mitochondrial respiratory chain were assayed. Temporal temperature gradient gel electrophoresis was used to scan the entire mitochondrial genome for unknown mitochondrial DNA (mtDNA) alterations, which were then identified by direct DNA sequencing.
   Results: A novel heteroplasmic mtDNA mutation, G12207A, in the tRNA(Ser(AGY)) gene was identified in the patient who had a history of developmental delay, feeding difficulty, lesions within her basal ganglia, cerebral atrophy, proximal muscle weakness, increased blood lactate, liver dysfunction, and fatty infiltration of her muscle. Muscle biopsy revealed ragged red fibres and pleomorphic mitochondria. Study of skeletal muscle mitochondria revealed complex I deficiency associated with mitochondrial proliferation. Real time quantitative PCR analysis showed elevated mtDNA content, 2.5 times higher than normal. The tRNASer(AGY) mutation was found in heteroplasmic state (92%) in the patient's skeletal muscle. It was not present in her unaffected mother's blood or in 200 healthy controls. This mutation occurs at the first nucleotide of the 59 end of tRNA, which is involved in the formation of the stem region of the amino acid acceptor arm. Mutation at this position may affect processing of the precursor RNA, the stability and amino acid charging efficiency of the tRNA, and overall efficiency of protein translation.
   Conclusion: This case underscores the importance of comprehensive mutational analysis of the entire mitochondrial genome when a mtDNA defect is strongly suggested.
C1 Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
   Georgetown Univ, Med Ctr, Inst Mol & Human Genet, Washington, DC 20007 USA.
   Kaiser Permanente Med Grp, Honolulu, HI USA.
   NHGRI, Genet & Mol Biol Branch, NIH, Bethesda, MD 20892 USA.
   Case Western Reserve Univ, Sch Med, Ctr Inherited Disorders Energy Metab, Cleveland, OH 44106 USA.
C3 Baylor College of Medicine; Georgetown University; Kaiser Permanente;
   National Institutes of Health (NIH) - USA; NIH National Human Genome
   Research Institute (NHGRI); University System of Ohio; Case Western
   Reserve University
RP Wong, LJC (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza,NAB 2015, Houston, TX 77030 USA.
EM ljwong@bcm.edu
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Bai RK, 2005, J MOL DIAGN, V7, P613, DOI 10.1016/S1525-1578(10)60595-8
   Bai RK, 2004, ANN NY ACAD SCI, V1011, P304, DOI 10.1196/annals.1293.029
   Bai RK, 2004, CLIN CHEM, V50, P996, DOI 10.1373/clinchem.2004.031153
   Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   Bertrand E, 1996, FOLIA NEUROPATHOL, V34, P193
   Chen TJ, 1999, CLIN CHEM, V45, P1162
   Flierl A, 1997, J BIOL CHEM, V272, P27189, DOI 10.1074/jbc.272.43.27189
   Florentz C, 2003, CELL MOL LIFE SCI, V60, P1356, DOI 10.1007/s00018-003-2343-1
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   HOPPEL CL, 1987, J CLIN INVEST, V80, P71, DOI 10.1172/JCI113066
   LAHIRI DK, 1991, NUCLEIC ACIDS RES, V19, P5444, DOI 10.1093/nar/19.19.5444
   LAUBER J, 1991, NUCLEIC ACIDS RES, V19, P1393, DOI 10.1093/nar/19.7.1393
   Liang HM, 1998, CLIN CHEM, V44, P1578
   Liang MH, 1998, AM J MED GENET, V77, P395, DOI 10.1002/(SICI)1096-8628(19980605)77:5<395::AID-AJMG8>3.0.CO;2-M
   Lynn S, 1998, DIABETES, V47, P1800, DOI 10.2337/diabetes.47.11.1800
   Melone MAB, 2004, ARCH NEUROL-CHICAGO, V61, P269, DOI 10.1001/archneur.61.2.269
   MITA S, 1995, MUSCLE NERVE, pS113
   OJALA D, 1981, NATURE, V290, P470, DOI 10.1038/290470a0
   OLDFORS A, 1995, ACTA NEUROPATHOL, V90, P328
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   Puchowicz MA, 2004, MITOCHONDRION, V4, P377, DOI 10.1016/j.mito.2004.07.004
   ROSSMANITH W, 1995, J BIOL CHEM, V270, P12885, DOI 10.1074/jbc.270.21.12885
   SERVIDEI S, 2003, NEUROMUSCULAR DISORD, V13, P685
   Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063
   WALLACE DC, 1988, CELL, V55, P601, DOI 10.1016/0092-8674(88)90218-8
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   WALLACE DC, 2005, MITOMAP HUMAN MITOCH
   Wolf NI, 2002, NEUROLOGY, V59, P1402, DOI 10.1212/01.WNL.0000031795.91814.D8
   Wong LJC, 1997, CLIN CHEM, V43, P1241
   Wong LJC, 2004, ELECTROPHORESIS, V25, P2602, DOI 10.1002/elps.200406016
   Wong LJC, 2003, J MED GENET, V40
   Wong LJC, 2002, CLIN CHEM, V48, P1901
   Wong LJC, 2002, AM J MED GENET, V113, P59, DOI 10.1002/ajmg.10767
   Wong LJC, 2001, AM J MED GENET, V102, P95, DOI 10.1002/1096-8628(20010722)102:1<95::AID-AJMG1412>3.0.CO;2-U
NR 35
TC 23
Z9 25
U1 1
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-2593
EI 1468-6244
J9 J MED GENET
JI J. Med. Genet.
PD SEP
PY 2006
VL 43
IS 9
AR e46
DI 10.1136/jmg.2005.040626
PG 7
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 080HV
UT WOS:000240239400011
PM 16950817
OA Green Published
DA 2024-11-01
ER

PT J
AU Tulinius, M
   Moslemi, AR
   Darin, N
   Holme, E
   Oldfors, A
AF Tulinius, M
   Moslemi, AR
   Darin, N
   Holme, E
   Oldfors, A
TI Novel mutations in the thymidine kinase 2 gene (<i>TK2</i>) associated
   with fatal mitochondrial myopathy and mitochondrial DNA depletion
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE mitochondrial DNA depletion; thymidine kinase-2; mitochondrial myopathy;
   infants; children
ID MTDNA DEPLETION; DEFICIENCY
AB We describe the clinical, morphological and genetic findings in two siblings with the myopathic form of mitochondrial DNA depletion syndrome (MIM 251880). Sequencing of the thymidine kinase-2 gene revealed two heterozygous missense mutations, a C -> T mutation at nucleotide 191 resulting in a change of threonine to methionine at residue 64 in exon 3, and a C -> T mutational nucleotide 547 resulting in an arginine to tryptophan amino acid change at residue 183 in exon 8. Both mutations changed highly conserved residues in the gene and neither one has been described previously. This report extends the phenotypic expression of mutations in the thymidine kinase-2 gene. (c) 2005 Elsevier B.V. All rights reserved.
C1 Queen Silvia Childrens Hosp, S-41685 Gothenburg, Sweden.
   Univ Gothenburg, Sahlgrenska Hosp, Dept Clin Chem, Gothenburg, Sweden.
   Univ Gothenburg, Sahlgrenska Hosp, Dept Pathol, Gothenburg, Sweden.
C3 Queen Silvia Children's Hospital; University of Gothenburg; Sahlgrenska
   University Hospital; University of Gothenburg; Sahlgrenska University
   Hospital
RP Tulinius, M (corresponding author), Queen Silvia Childrens Hosp, S-41685 Gothenburg, Sweden.
EM mar.tulinius@vgregion.se
RI Darin, Niklas/AAL-6345-2020
CR Carrozzo R, 2003, HUM MUTAT, V21, DOI 10.1002/humu.9135
   Johansson K, 2001, NAT STRUCT BIOL, V8, P616, DOI 10.1038/89661
   LARSSON NG, 1994, BIOCHEM BIOPH RES CO, V200, P1374, DOI 10.1006/bbrc.1994.1603
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   OLDFORS A, 1989, ACTA NEUROPATHOL, V77, P267, DOI 10.1007/BF00687578
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284
   Vilà MR, 2003, NEUROLOGY, V60, P1203, DOI 10.1212/01.WNL.0000055928.58122.47
   Vu TH, 1998, NEUROLOGY, V50, P1783, DOI 10.1212/WNL.50.6.1783
NR 11
TC 22
Z9 26
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD JUN
PY 2005
VL 15
IS 6
BP 412
EP 415
DI 10.1016/j.nmd.2005.03.010
PG 4
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 934UC
UT WOS:000229733100004
PM 15907288
DA 2024-11-01
ER

PT J
AU Mayr, JA
   Moslemi, AR
   Förster, H
   Kamper, A
   Idriceanu, C
   Muss, W
   Huemer, M
   Oldfors, A
   Sperl, W
AF Mayr, Johannes A.
   Moslemi, Ali-Reza
   Foerster, Holger
   Kamper, Adrian
   Idriceanu, Carmen
   Muss, Wolfgang
   Huemer, Michael
   Oldfors, Anders
   Sperl, Wolfgang
TI A novel sporadic mutation G14739A of the mitochondrial
   tRNA<SUP>Glu</SUP> in a girl with exercise intolerance
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE mitochondria; mtDNA; tRNA; mitochondrial myopathy
ID HETEROPLASMIC MUTATIONS; DNA; ENCEPHALOMYOPATHIES; DELETIONS; MTDNA
AB We describe a 7-year-old girl who presented with loss of appetite, weakness and exercise intolerance. Enzyme investigation of the respiratory chain in muscle tissue revealed a combined complex I, III and IV deficiency. A novel heteroplasmic G -> A exchange at nucleotide position 14739 was found in the MTTE gene of the tRNA glutamic acid. The mutation load in muscle was 72%, urine sediment 38%, blood 31% and fibroblasts 29% and it correlated with COX-negative fibres. Our patient presented with a predominantly myopathic phenotype. The G14739A mutation is the third reported in the mitochondrial tRNA glutamic acid gene, and it occurred in a sporadic case. (C) 2006 Elsevier B.V. All rights reserved.
C1 Paracelsus Private Med Univ, Univ Childrens Hosp, A-5020 Salzburg, Austria.
   Sahlgrens Univ Hosp, Dept Pathol, S-41345 Gothenburg, Sweden.
   Paracelsus Private Med Univ, Dept Pathol, Salzburg, Austria.
   Kardinal Schwarzenberg Hosp, Schwarzach, Austria.
C3 Paracelsus Private Medical University; Sahlgrenska University Hospital;
   Paracelsus Private Medical University
RP Mayr, JA (corresponding author), Paracelsus Private Med Univ, Univ Childrens Hosp, Mullner Hauptstr 48, A-5020 Salzburg, Austria.
EM h.mayr@salk.at
OI Mayr, Johannes/0000-0001-6970-336X; MUSS, Wolfgang/0000-0003-1536-9882
CR DiMauro S, 2005, NEUROMUSCULAR DISORD, V15, P276, DOI 10.1016/j.nmd.2004.12.008
   Helm M, 2000, RNA, V6, P1356, DOI 10.1017/S1355838200001047
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Mancuso M, 2005, J NEUROL SCI, V228, P93, DOI 10.1016/j.jns.2004.10.018
   Mayr JA, 2004, PEDIATR RES, V55, P988, DOI 10.1203/01.pdr.0000127016.67809.6b
   Meierhofer D, 2005, MITOCHONDRION, V5, P282, DOI 10.1016/j.mito.2005.06.001
   OLDFORS A, 1995, J NEUROPATH EXP NEUR, V54, P581, DOI 10.1097/00005072-199507000-00012
   Oldfors A, 2003, J NEUROPATH EXP NEUR, V62, P217, DOI 10.1093/jnen/62.3.217
   Uusimaa J, 2004, PEDIATRICS, V114, P443, DOI 10.1542/peds.114.2.443
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
NR 10
TC 11
Z9 11
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD DEC
PY 2006
VL 16
IS 12
BP 874
EP 877
DI 10.1016/j.nmd.2006.08.010
PG 4
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 124RT
UT WOS:000243388300011
PM 17056256
DA 2024-11-01
ER

PT J
AU Hu, CP
   Li, XH
   Zhao, L
   Shi, YY
   Zhou, SZ
   Wang, Y
AF Hu, Chaoping
   Li, Xihua
   Zhao, Lei
   Shi, Yiyun
   Zhou, Shuizhen
   Wang, Yi
TI Clinical Profile and Outcome of Pediatric Mitochondrial Myopathy in
   China
SO FRONTIERS IN NEUROLOGY
LA English
DT Article
DE mitochondrial myopathy; gene mutation; treatment; cytochrome-c oxidase;
   pathology
ID RESPIRATORY INSUFFICIENCY; TRNA(LEU(UUR)) MUTATION; DIAGNOSIS; DISEASE;
   GENOME; COHORT
AB Introduction: Mitochondrial myopathy in children has notable clinical and genetic heterogeneity, but detailed data is lacking.
   Patients and Methods: In this study, we retrospectively reviewed the clinical presentation, laboratory investigation, genetic and histopathological characteristics, and follow-ups of 21 pediatric mitochondrial myopathy cases from China.
   Results: Twenty-four patients suspected with mitochondrial myopathy were enrolled initially and 21 were genetically identified. Fourteen patients were found to harbor mitochondrial DNA point mutations (14/21, 66.7%), including m.3243A>G (9/15, 60%), m.3303C>T (2/15, 13.3%), m.3302A>G (1/15, 6.7%), m.3250T>C (1/15, 6.7%), m.3251A>G (1/15, 6.7%), of whom 12 patients presented with progressive proximal mitochondrial myopathy (12/14, 85.7%). Three patients revealed large-scale deletion in blood or muscle tissue (3/21, 14.3%), presenting with Kearns-Sayer syndrome (1/3, 33.3%) or chronic progressive external ophthalmoplegia (2/3, 66.7%). Four patients were found to harbor pathogenic nuclear gene variants (4/21, 19.0%), including five variants in TK2 gene and two variants in SURF1 gene. During the follow-ups up to 7 years, 10 patients developed cardiomyopathy (10/21, 47.6%), 13 patients occurred at least once hypercapnic respiratory failure (13/21, 61.9%), six experienced recurrent respiratory failure and intubation (6/21, 28.6%), eight patients failed to survive (8/21, 38.1%). With nocturnal non-invasive ventilation of BiPAP, three patients recovered from respiratory failure, and led a relative stable and functional life (3/21, 14.3%).
   Conclusion: Mitochondrial myopathy in children has great clinical, pathological, and genetical heterogeneity. Progressive proximal myopathy is most prevalent. Mitochondrial DNA point mutations are most common. And respiratory failure is a critical risk factor of poor prognosis.
C1 [Hu, Chaoping; Li, Xihua; Zhao, Lei; Shi, Yiyun; Zhou, Shuizhen; Wang, Yi] Fudan Univ, Childrens Hosp, Neurol Dept, Shanghai, Peoples R China.
C3 Fudan University
RP Li, XH; Wang, Y (corresponding author), Fudan Univ, Childrens Hosp, Neurol Dept, Shanghai, Peoples R China.
EM xihual@vip.sina.com; yiwang@shmu.edu.cn
CR Ahmed ST, 2018, NEUROTHERAPEUTICS, V15, P943, DOI 10.1007/s13311-018-00674-4
   Avula S, 2014, CURR TREAT OPTION NE, V16, DOI 10.1007/s11940-014-0292-7
   Ballhausen D, 2010, J INHERIT METAB DIS, V33, pS219, DOI 10.1007/s10545-010-9098-2
   Broomfield A, 2015, J INHERIT METAB DIS, V38, P445, DOI 10.1007/s10545-014-9778-4
   Bruno C, 2003, J CHILD NEUROL, V18, P300, DOI 10.1177/08830738030180040401
   Catteruccia M, 2015, J NEUROL, V262, P701, DOI 10.1007/s00415-014-7632-0
   Chanprasert S, 2013, MOL GENET METAB, V110, P153, DOI 10.1016/j.ymgme.2013.07.009
   Flaherty KR, 2001, AM J RESP CRIT CARE, V164, P425, DOI 10.1164/ajrccm.164.3.2005110
   Garone C, 2018, BIOCHEM SOC T, V46, P1247, DOI 10.1042/BST20180134
   Hardy SA, 2016, NEUROL-GENET, V2, DOI 10.1212/NXG.0000000000000082
   Houshmand M, 1996, HUM GENET, V97, P269, DOI 10.1007/BF02185750
   Hu CP, 2020, EUR J MED GENET, V63, DOI 10.1016/j.ejmg.2020.103898
   Koo P, 2018, CLIN CHEST MED, V39, P401, DOI 10.1016/j.ccm.2018.02.001
   Lee IC, 2012, HUM MUTAT, V33, P1192, DOI 10.1002/humu.22095
   Lu YY, 2017, J NEUROL SCI, V379, P137, DOI 10.1016/j.jns.2017.05.056
   Naddaf E, 2017, MUSCLE NERVE, V56, P881, DOI 10.1002/mus.25602
   Nesbitt V, 2013, J NEUROL NEUROSUR PS, V84, P936, DOI 10.1136/jnnp-2012-303528
   Ogle RF, 1997, J PEDIATR-US, V130, P138, DOI 10.1016/S0022-3476(97)70323-8
   Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30
   Russell OM, 2020, CELL, V181, P168, DOI 10.1016/j.cell.2020.02.051
   SWEENEY MG, 1993, Q J MED, V86, P709
   Tang S, 2013, HUM MUTAT, V34, P882, DOI 10.1002/humu.22307
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   Thompson K, 2020, J INHERIT METAB DIS, V43, P36, DOI 10.1002/jimd.12104
   Ueki I, 2006, MITOCHONDRION, V6, P29, DOI 10.1016/j.mito.2005.10.003
   Zhang W, 2012, CLIN CHEM, V58, P1322, DOI 10.1373/clinchem.2011.181438
   Zhou Y, 2018, INT J NEUROSCI, V128, P231, DOI 10.1080/00207454.2017.1387113
NR 27
TC 5
Z9 5
U1 0
U2 3
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2295
J9 FRONT NEUROL
JI Front. Neurol.
PD SEP 8
PY 2020
VL 11
AR 1000
DI 10.3389/fneur.2020.01000
PG 8
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA NV7CQ
UT WOS:000574475100001
PM 33013660
OA gold, Green Published
DA 2024-11-01
ER

PT J
AU Honzik, T
   Tesarova, M
   Vinsova, K
   Hansikova, H
   Magner, M
   Kratochvilova, H
   Zamecnik, J
   Zeman, J
   Jesina, P
AF Honzik, Tomas
   Tesarova, Marketa
   Vinsova, Kamila
   Hansikova, Hana
   Magner, Martin
   Kratochvilova, Hana
   Zamecnik, Josef
   Zeman, Jiri
   Jesina, Pavel
TI Different laboratory and muscle biopsy findings in a family with an
   m.8851T&gt;C mutation in the mitochondrial <i>MTATP6</i> gene
SO MOLECULAR GENETICS AND METABOLISM
LA English
DT Article
DE Leigh syndrome; ATP synthase; Mitochondrial DNA m.8851T > C mutation
ID LEIGH-SYNDROME; ATP SYNTHASE; POINT MUTATION; ATPASE-6 GENE; DNA
AB We report the second known family with a very rare, maternally inherited missense m.8851T>C mutation in the mitochondrial MTATP6 gene. A failure to thrive, microcephaly, psychomotor retardation and hypotonia were present in a 3-year-old girl with a high mtDNA mutation load (87-97%). Ataxia and Leigh syndrome were subsequently documented in a neurological examination and brain MRI. A muscle biopsy demonstrated decreased ATP synthase and an accumulation of succinate dehydrogenase products, indicating mitochondrial myopathy. Her 36-year-old mother (68% blood heteroplasmy) developed peripheral neuropathy and muscle weakness at the age of 22 years. Our findings extend the clinical and laboratory phenotype associated with the m.8851T>C mutation. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Honzik, Tomas; Tesarova, Marketa; Vinsova, Kamila; Hansikova, Hana; Magner, Martin; Kratochvilova, Hana; Zeman, Jiri] Charles Univ Prague, Dept Pediat & Adolescent Med, Fac Med 1, Prague 12808 2, Czech Republic.
   [Honzik, Tomas; Tesarova, Marketa; Vinsova, Kamila; Hansikova, Hana; Magner, Martin; Kratochvilova, Hana; Zeman, Jiri; Jesina, Pavel] Gen Univ Hosp Prague, Prague 12808 2, Czech Republic.
   [Jesina, Pavel] Charles Univ Prague, Inst Inherited Metab Dis, Fac Med 1, Prague 12808 2, Czech Republic.
   [Zamecnik, Josef] Charles Univ Prague, Dept Pathol & Mol Med, Fac Med 2, Prague 12808 2, Czech Republic.
   [Zamecnik, Josef] Teaching Hosp Motol Prague, Prague, Czech Republic.
C3 Charles University Prague; General University Hospital Prague; Charles
   University Prague; Motol University Hospital; Charles University Prague
RP Jesina, P (corresponding author), Charles Univ Prague, Inst Inherited Metab Dis, Fac Med 1, Ke Karlovu 2, Prague 12808 2, Czech Republic.
EM pavel.jesina@vfn.cz
RI Hansikova, Hana/E-9350-2017; Tesarova, Marketa/I-1531-2016; Honzik,
   Tomas/N-7509-2017; Jesina, Pavel/A-9913-2012; Stufkova,
   Hana/AAT-1930-2021; Magner, Martin/J-3553-2017; Zeman, Jiri/K-2691-2017
OI Tesarova, Marketa/0000-0002-5141-2289; Honzik,
   Tomas/0000-0003-4300-2519; Jesina, Pavel/0000-0002-8513-0976; Stufkova,
   Hana/0000-0003-0084-7730; Magner, Martin/0000-0002-5883-9509; Zeman,
   Jiri/0000-0002-2678-7919
FU  [PRVOUK-P24/LF1/3];  [RVO-VFN64165/2012]
FX Institutional support was provided by the research program
   PRVOUK-P24/LF1/3 and the institutional research project
   RVO-VFN64165/2012.
CR Akagi M, 2002, NEUROMUSCULAR DISORD, V12, P53, DOI 10.1016/S0960-8966(01)00242-5
   Castagna AE, 2007, AM J MED GENET A, V143A, P808, DOI 10.1002/ajmg.a.31637
   D'Aurelio M, 2010, HUM MOL GENET, V19, P374, DOI 10.1093/hmg/ddp503
   DEMEIRLEIR L, 1995, PEDIATR NEUROL, V13, P242, DOI 10.1016/0887-8994(95)00184-H
   Houstek J, 2006, BBA-BIOENERGETICS, V1757, P1400, DOI 10.1016/j.bbabio.2006.04.006
   Janssen AJM, 2006, CLIN CHEM, V52, P860, DOI 10.1373/clinchem.2005.062414
   Jesina P, 2004, BIOCHEM J, V383, P561, DOI 10.1042/BJ20040407
   Lee HF, 2009, PEDIATR NEUROL, V40, P88, DOI 10.1016/j.pediatrneurol.2008.09.020
   Moslemi AR, 2005, NEUROPEDIATRICS, V36, P314, DOI 10.1055/s-2005-872845
   Ogilvie I, 1999, FEBS LETT, V453, P179, DOI 10.1016/S0014-5793(99)00605-5
   Pitceathly RDS, 2012, NEUROLOGY, V79, P1145, DOI 10.1212/WNL.0b013e3182698d8d
   Rajasimha HK, 2008, AM J HUM GENET, V82, P333, DOI 10.1016/j.ajhg.2007.10.007
   Rossignol R, 2003, BIOCHEM J, V370, P751, DOI 10.1042/BJ20021594
NR 13
TC 8
Z9 9
U1 1
U2 8
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1096-7192
J9 MOL GENET METAB
JI Mol. Genet. Metab.
PD JAN
PY 2013
VL 108
IS 1
BP 102
EP 105
DI 10.1016/j.ymgme.2012.11.002
PG 4
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental
   Medicine
GA 075BW
UT WOS:000313859800017
PM 23206802
DA 2024-11-01
ER

PT J
AU Nogueira, C
   Nunes, J
   Evangelista, T
   Fattori, F
   Tessa, A
   Pereira, C
   Santorelli, FM
   Vilarinho, L
AF Nogueira, Celia
   Nunes, Joao
   Evangelista, Teresinha
   Fattori, Fabiana
   Tessa, Alessandra
   Pereira, Cristina
   Santorelli, Filippo M.
   Vilarinho, Laura
TI A new mtDNA-tRNA<SUP>Glu</SUP> mutation (14728T &gt; C) presenting a
   late-onset mitochondrial encephalomyopathy
SO MITOCHONDRION
LA English
DT Article
DE mtDNA; late-onset myopathy; ataxia
ID TRANSFER-RNAS; DNA; DEFICIENCY; FEATURES; DISEASE
AB We identified a new mutation in the mtDNA-encoded transfer RNA glutamate gene (tRNAGlu) in a patient presenting with late-onset myopathy. The mutation was nearly homoplasmic in muscle but hardly detectable in peripheral blood. Adding to the list of disease-related mtDNA variants, our findings propose to consider screening of tRNAGlu in cases of late-onset neuromuscular disorders. (c) 2007 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 [Nogueira, Celia; Pereira, Cristina; Vilarinho, Laura] Inst Med Genet, P-4099028 Oporto, Portugal.
   [Nunes, Joao] Inst Portugues Oncol Francisco Gentil, P-1099023 Lisbon, Portugal.
   [Evangelista, Teresinha] Neuropathol Unit, P-1649035 Lisbon, Portugal.
   [Fattori, Fabiana; Tessa, Alessandra; Santorelli, Filippo M.] Childrens Hosp Bambino Gesu, IRCCS, I-00165 Rome, Italy.
C3 Portuguese Institute of Oncology; IRCCS Bambino Gesu
RP Vilarinho, L (corresponding author), Inst Med Genet, Praca Pedro Nunes 88, P-4099028 Oporto, Portugal.
EM laura.vilarinho@igm.min-saude.pt
RI de Carvalho, Mamede/I-6295-2019; Fattori, Fabiana/K-1033-2016;
   Santorelli, Filippo M/ABE-5124-2020; tessa, alessandra/AAA-4442-2021
OI Nogueira, Celia/0000-0003-3640-8537; Fattori,
   Fabiana/0000-0002-1820-8489; Santorelli, Filippo M/0000-0002-1359-9062;
   tessa, alessandra/0000-0002-1445-6434
CR CORMIERDAIRE V, 1994, J PEDIATR-US, V124, P63, DOI 10.1016/S0022-3476(94)70255-1
   DiMauro S, 2005, NEUROMUSCULAR DISORD, V15, P276, DOI 10.1016/j.nmd.2004.12.008
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   Helm M, 2000, RNA, V6, P1356, DOI 10.1017/S1355838200001047
   Kirino Y, 2005, P NATL ACAD SCI USA, V102, P7127, DOI 10.1073/pnas.0500563102
   Melone MAB, 2004, ARCH NEUROL-CHICAGO, V61, P269, DOI 10.1001/archneur.61.2.269
   MORAES CT, 1993, MITOCHONDRIAL DNA HU, V8, P7
   Pistilli D, 2003, HUM PATHOL, V34, P1058, DOI 10.1053/S0046-8177(03)00344-7
   Sciacco M, 1996, Methods Enzymol, V264, P509, DOI 10.1016/S0076-6879(96)64045-2
   Taylor RW, 1998, BIOCHEM BIOPH RES CO, V251, P883, DOI 10.1006/bbrc.1998.9553
   Vilarinho L, 1999, J NEUROL SCI, V163, P168, DOI 10.1016/S0022-510X(99)00030-1
NR 11
TC 7
Z9 7
U1 1
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
J9 MITOCHONDRION
JI Mitochondrion
PD DEC
PY 2007
VL 7
IS 6
BP 396
EP 398
DI 10.1016/j.mito.2007.08.002
PG 3
WC Cell Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Genetics & Heredity
GA 242TU
UT WOS:000251749900005
PM 17897888
DA 2024-11-01
ER

PT J
AU Suen, DF
   Narendra, DP
   Tanaka, A
   Manfredi, G
   Youle, RJ
AF Suen, Der-Fen
   Narendra, Derek P.
   Tanaka, Atsushi
   Manfredi, Giovanni
   Youle, Richard J.
TI Parkin overexpression selects against a deleterious mtDNA mutation in
   heteroplasmic cybrid cells
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE autophagy; neurodegeneration; Parkinson disease; PINK1; mitochondria
ID MITOCHONDRIAL-DNA DELETIONS; SUBSTANTIA-NIGRA NEURONS; HELICASE TWINKLE;
   GENE-PRODUCT; DISEASE; MITOPHAGY; MUTANTS; DROSOPHILA-PINK1;
   COMPLEMENTATION; DEGENERATION
AB Mitochondrial genomes with deleterious mutations can replicate in cells along with wild-type genomes in a state of heteroplasmy, and are a cause of severe inherited syndromes, such as mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke (MELAS), neuropathy, ataxia, retinitis pigmentosa-maternally inherited Leigh syndrome (NARP-MILS), and Leber's hereditary optic neuropathy (LHON). The cytosolic E3 ligase, Parkin, commonly mutated in recessive familial parkinsonism, translocates to depolarized mitochondria and induces their autophagic elimination, suggesting that Parkin may signal the selective removal of defective mitochondria within the cell. We report that long-term overexpression of Parkin can eliminate mitochondria with deleterious COXI mutations in heteroplasmic cybrid cells, thereby enriching cells for wild-type mtDNA and restoring cytochrome c oxidase activity. After relieving cybrid cells of Parkin overexpression, a more favorable wild-type to mutant mitochondrial genome ratio is stably maintained. These data support the model that Parkin functions in a mitochondrial quality control pathway. Additionally, they suggest that transiently increasing levels of Parkin expression might ameliorate certain mitochondrial diseases.
C1 [Suen, Der-Fen; Narendra, Derek P.; Tanaka, Atsushi; Youle, Richard J.] NINDS, Biochem Sect, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA.
   [Manfredi, Giovanni] Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, New York, NY 10065 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute of
   Neurological Disorders & Stroke (NINDS); Cornell University; Weill
   Cornell Medicine
RP Youle, RJ (corresponding author), NINDS, Biochem Sect, Surg Neurol Branch, NIH, Bethesda, MD 20892 USA.
EM youler@ninds.nih.gov
RI Narendra, Derek/W-1535-2019; Suen, Der-Fen/ACF-7547-2022
FU National Institute of Neurological Disorders and Stroke at the National
   Institutes of Health
FX We thank H. Spelbrink for Twinkle plamids, I. F. de Coo and C. T. Moraes
   for Cytb3.0 cybrid cells, D. Maric for FACS, and C. Smith for confocal
   microscopy. This work was supported by the National Institute of
   Neurological Disorders and Stroke Intramural Research Program at the
   National Institutes of Health.
CR Appleby RD, 1999, EUR J BIOCHEM, V262, P108, DOI 10.1046/j.1432-1327.1999.00350.x
   Baloh RH, 2007, ARCH NEUROL-CHICAGO, V64, P998, DOI 10.1001/archneur.64.7.998
   Bayona-Bafaluy MP, 2005, P NATL ACAD SCI USA, V102, P14392, DOI 10.1073/pnas.0502896102
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Bruno C, 1999, AM J HUM GENET, V65, P611, DOI 10.1086/302546
   Buchet K, 1998, J BIOL CHEM, V273, P22983, DOI 10.1074/jbc.273.36.22983
   Clark IE, 2006, NATURE, V441, P1162, DOI 10.1038/nature04779
   Geisler S, 2010, NAT CELL BIOL, V12, P119, DOI 10.1038/ncb2012
   Gilkerson RW, 2008, J CELL BIOL, V181, P1117, DOI 10.1083/jcb.200712101
   Greene JC, 2003, P NATL ACAD SCI USA, V100, P4078, DOI 10.1073/pnas.0737556100
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416
   Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778
   Matsuda N, 2010, J CELL BIOL, V189, P211, DOI 10.1083/jcb.200910140
   McCormick AL, 2003, J VIROL, V77, P631, DOI 10.1128/JVI.77.1.631-641.2003
   Narendra D, 2008, J CELL BIOL, V183, P795, DOI 10.1083/jcb.200809125
   Narendra DP, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000298
   Palacino JJ, 2004, J BIOL CHEM, V279, P18614, DOI 10.1074/jbc.M401135200
   Park J, 2006, NATURE, V441, P1157, DOI 10.1038/nature04788
   Pawlyk AC, 2003, J BIOL CHEM, V278, P48120, DOI 10.1074/jbc.M306889200
   Rana M, 2000, ANN NEUROL, V48, P774, DOI 10.1002/1531-8249(200011)48:5<774::AID-ANA11>3.3.CO;2-9
   Scaduto RC, 1999, BIOPHYS J, V76, P469, DOI 10.1016/S0006-3495(99)77214-0
   Schapira AHV, 2008, LANCET NEUROL, V7, P97, DOI 10.1016/S1474-4422(07)70327-7
   Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060
   SHOUBRIDGE EA, 1995, BIOCHEM BIOPH RES CO, V213, P189, DOI 10.1006/bbrc.1995.2115
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Stichel CC, 2007, HUM MOL GENET, V16, P2377, DOI 10.1093/hmg/ddm083
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Twig G, 2008, EMBO J, V27, P433, DOI 10.1038/sj.emboj.7601963
   Van Hove JLK, 2009, AM J MED GENET A, V149A, P861, DOI 10.1002/ajmg.a.32731
   Vives-Bauza C, 2010, P NATL ACAD SCI USA, V107, P378, DOI 10.1073/pnas.0911187107
   Wallace DC, 2009, GENE DEV, V23, P1714, DOI 10.1101/gad.1784909
   Wanrooij S, 2007, NUCLEIC ACIDS RES, V35, P3238, DOI 10.1093/nar/gkm215
   Yang YF, 2006, P NATL ACAD SCI USA, V103, P10793, DOI 10.1073/pnas.0602493103
NR 34
TC 254
Z9 298
U1 2
U2 20
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD JUN 29
PY 2010
VL 107
IS 26
BP 11835
EP 11840
DI 10.1073/pnas.0914569107
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 618DT
UT WOS:000279332300034
PM 20547844
OA Green Published
DA 2024-11-01
ER

PT J
AU Berglund, AK
   Navarrete, C
   Engqvist, MKM
   Hoberg, E
   Szilagyi, Z
   Taylor, RW
   Gustafsson, CM
   Falkenberg, M
   Clausen, AR
AF Berglund, Anna-Karin
   Navarrete, Clara
   Engqvist, Martin K. M.
   Hoberg, Emily
   Szilagyi, Zsolt
   Taylor, Robert W.
   Gustafsson, Claes M.
   Falkenberg, Maria
   Clausen, Anders R.
TI Nucleotide pools dictate the identity and frequency of ribonucleotide
   incorporation in mitochondrial DNA
SO PLOS GENETICS
LA English
DT Article
ID IMPAIR MTDNA REPLICATION; DEPLETION MYOPATHY; THYMIDINE KINASE;
   POLYMERASE GAMMA; TOPOISOMERASE-I; STRAND DNA; 7S DNA; MUTATIONS;
   TRANSCRIPTION; MAINTENANCE
AB Previous work has demonstrated the presence of ribonucleotides in human mitochondrial DNA (mtDNA) and in the present study we use a genome-wide approach to precisely map the location of these. We find that ribonucleotides are distributed evenly between the heavy- and light-strand of mtDNA. The relative levels of incorporated ribonucleotides reflect that DNA polymerase. discriminates the four ribonucleotides differentially during DNA synthesis. The observed pattern is also dependent on the mitochondrial deoxyribonucleotide (dNTP) pools and disease-causing mutations that change these pools alter both the absolute and relative levels of incorporated ribonucleotides. Our analyses strongly suggest that DNA polymerase.-dependent incorporation is the main source of ribonucleotides in mtDNA and argues against the existence of a mitochondrial ribonucleotide excision repair pathway in human cells. Furthermore, we clearly demonstrate that when dNTP pools are limiting, ribonucleotides serve as a source of building blocks to maintain DNA replication. Increased levels of embedded ribonucleotides in patient cells with disturbed nucleotide pools may contribute to a pathogenic mechanism that affects mtDNA stability and impair new rounds of mtDNA replication.
C1 [Berglund, Anna-Karin; Navarrete, Clara; Engqvist, Martin K. M.; Hoberg, Emily; Szilagyi, Zsolt; Gustafsson, Claes M.; Falkenberg, Maria; Clausen, Anders R.] Univ Gothenburg, Inst Biomed, Gothenburg, Sweden.
   [Taylor, Robert W.] Newcastle Univ, Sch Med, Inst Neurosci, Wellcome Trust Ctr Mitochondria! Res, Newcastle Upon Tyne, Tyne & Wear, England.
C3 University of Gothenburg; Newcastle University - UK
RP Falkenberg, M; Clausen, AR (corresponding author), Univ Gothenburg, Inst Biomed, Gothenburg, Sweden.
EM maria.falkenberg@medkem.gu.se; anders.clausen@gu.se
RI Clausen, Anders/I-7229-2012
OI Clausen, Anders Ranegaard/0000-0002-5069-0930; Falkenberg,
   Maria/0000-0001-8713-173X; Engqvist, Martin/0000-0003-2174-2225;
   Gustafsson, Claes/0000-0003-3531-8468; Navarrete Roman,
   Clara/0000-0003-4958-0555
FU Swedish Research Council [2012-2583, 2013-3621, 2014-6466]; Swedish
   Cancer Foundation [CAN 2016/816, CAN 2013/855]; European Research
   Council; Swedish Foundation for Strategic Research [ICA14-0060];
   Wellcome Trust [096919/Z/11/Z]; MRC Centre for Neuromuscular Diseases
   [G0601943]; Lily Foundation; UK NHS Highly Specialised Rare
   Mitochondrial Disorders of Adults and Children Service in Newcastle upon
   Tyne; MRC [G0601943] Funding Source: UKRI; Swedish Foundation for
   Strategic Research (SSF) [ICA14-0060] Funding Source: Swedish Foundation
   for Strategic Research (SSF)
FX This study was supported by Swedish Research Council (www.vr.se) grants
   to CMG (2012-2583), MF (2013-3621) and ARC (2014-6466), the Swedish
   Cancer Foundation (www.cancerfonden.se) to MF (CAN 2016/816) and CMG
   (CAN 2013/855), the European Research Council (erc.europa.eu) Starting
   Independent Investigator grant to MF (DELMIT) and the Swedish Foundation
   for Strategic Research (www.stratresearch.se) to ARC (ICA14-0060). RWT
   is supported by a Wellcome Trust Strategic Award (wellcome.ac.uk)
   (096919/Z/11/Z), the MRC Centre for Neuromuscular Diseases (G0601943),
   the Lily Foundation and the UK NHS Highly Specialised Rare Mitochondrial
   Disorders of Adults and Children Service in Newcastle upon Tyne. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Al-Hussaini A, 2014, J PEDIATR-US, V164, P553, DOI 10.1016/j.jpeds.2013.10.082
   Balakrishnan L, 2013, COLD SPRING HARB PER, P5
   Blakely E, 2008, NEUROMUSCULAR DISORD, V18, P557, DOI 10.1016/j.nmd.2008.04.014
   Blakely EL, 2012, NEUROMUSCULAR DISORD, V22, P587, DOI 10.1016/j.nmd.2012.03.006
   Bowmaker M, 2003, J BIOL CHEM, V278, P50961, DOI 10.1074/jbc.M308028200
   Burgers PMJ, 2009, J BIOL CHEM, V284, P4041, DOI 10.1074/jbc.R800062200
   Cerritelli SM, 2003, MOL CELL, V11, P807, DOI 10.1016/S1097-2765(03)00088-1
   Clausen Anders R, 2015, Methods Mol Biol, V1300, P123, DOI 10.1007/978-1-4939-2596-4_9
   Clausen AR, 2015, NAT STRUCT MOL BIOL, V22, P185, DOI 10.1038/nsmb.2957
   Clausen AR, 2013, DNA REPAIR, V12, P121, DOI 10.1016/j.dnarep.2012.11.006
   CLAYTON DA, 1991, ANNU REV CELL BIOL, V7, P453, DOI 10.1146/annurev.cb.07.110191.002321
   Copeland WC, 2014, DNA REPAIR, V19, P190, DOI 10.1016/j.dnarep.2014.03.010
   Ferraro P, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkp1141
   Fish J, 2004, SCIENCE, V306, P2098, DOI 10.1126/science.1102077
   Fusté JM, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004832
   Fusté JM, 2010, MOL CELL, V37, P67, DOI 10.1016/j.molcel.2009.12.021
   Gandhi VV, 2011, NUCLEOS NUCLEOT NUCL, V30, P317, DOI 10.1080/15257770.2011.586955
   Gorman GS, 2015, ANN NEUROL, V77, P753, DOI 10.1002/ana.24362
   GROSSMAN LI, 1973, P NATL ACAD SCI USA, V70, P3339, DOI 10.1073/pnas.70.12.3339
   Gustafsson CM, 2016, ANNU REV BIOCHEM, V85, P133, DOI 10.1146/annurev-biochem-060815-014402
   Kang DC, 1997, J BIOL CHEM, V272, P15275, DOI 10.1074/jbc.272.24.15275
   Kasiviswanathan R, 2011, J BIOL CHEM, V286, P31490, DOI 10.1074/jbc.M111.252460
   Kim N, 2011, SCIENCE, V332, P1561, DOI 10.1126/science.1205016
   Kornblum C, 2013, NAT GENET, V45, P214, DOI 10.1038/ng.2501
   Larsson NG, 2010, ANNU REV BIOCHEM, V79, P683, DOI 10.1146/annurev-biochem-060408-093701
   Li YF, 1999, J AM CHEM SOC, V121, P5364, DOI 10.1021/ja990592p
   Lujan SA, 2013, MOL CELL, V50, P437, DOI 10.1016/j.molcel.2013.03.017
   Macao B, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8303
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   McElhinny SAN, 2010, P NATL ACAD SCI USA, V107, P4949, DOI 10.1073/pnas.0914857107
   Nicholls TJ, 2014, HUM MOL GENET, V23, P6147, DOI 10.1093/hmg/ddu336
   Nicholls TJ, 2014, EXP GERONTOL, V56, P175, DOI 10.1016/j.exger.2014.03.027
   Pham XH, 2006, J BIOL CHEM, V281, P24647, DOI 10.1074/jbc.M602429200
   Pohjoismäki JLO, 2010, J MOL BIOL, V397, P1144, DOI 10.1016/j.jmb.2010.02.029
   Reijns MAM, 2012, CELL, V149, DOI 10.1016/j.cell.2012.04.011
   Reyes A, 2015, AM J HUM GENET, V97, P186, DOI 10.1016/j.ajhg.2015.05.013
   Reyes A, 2013, NUCLEIC ACIDS RES, V41, P5837, DOI 10.1093/nar/gkt196
   Rosa ID, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005779
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Saada A, 2008, MOL GENET METAB, V95, P169, DOI 10.1016/j.ymgme.2008.07.007
   Sekiguchi J, 1997, MOL CELL, V1, P89, DOI 10.1016/S1097-2765(00)80010-6
   Sparks JL, 2012, MOL CELL, V47, P980, DOI 10.1016/j.molcel.2012.06.035
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Sun R, 2014, BIOCHEMISTRY-US, V53, P6142, DOI 10.1021/bi5006877
   Szczesny RJ, 2013, NUCLEIC ACIDS RES, V41, P3144, DOI 10.1093/nar/gkt029
   Taylor RW, 2014, JAMA-J AM MED ASSOC, V312, P68, DOI 10.1001/jama.2014.7184
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Uhler JP, 2016, NUCLEIC ACIDS RES, V44, P5861, DOI 10.1093/nar/gkw468
   Uhler JP, 2015, DNA REPAIR, V34, P28, DOI 10.1016/j.dnarep.2015.07.003
   Uusimaa J, 2014, EUR J HUM GENET, V22, P184, DOI 10.1038/ejhg.2013.112
   Williams JS, 2016, NAT REV MOL CELL BIO, V17, P350, DOI 10.1038/nrm.2016.37
   Williams JS, 2013, MOL CELL, V49, P1010, DOI 10.1016/j.molcel.2012.12.021
   Williams JS, 2012, DNA REPAIR, V11, P649, DOI 10.1016/j.dnarep.2012.05.004
   WONGSTAAL F, 1973, BIOCHEM BIOPH RES CO, V53, P140, DOI 10.1016/0006-291X(73)91412-5
   Yang MY, 2002, CELL, V111, P495, DOI 10.1016/S0092-8674(02)01075-9
   Yasukawa T, 2006, EMBO J, V25, P5358, DOI 10.1038/sj.emboj.7601392
   Zheng L, 2011, J MOL CELL BIOL, V3, P23, DOI 10.1093/jmcb/mjq048
NR 57
TC 47
Z9 50
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD FEB
PY 2017
VL 13
IS 2
AR e1006628
DI 10.1371/journal.pgen.1006628
PG 18
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA EO0QN
UT WOS:000396403100019
PM 28207748
OA Green Submitted, Green Published, gold
DA 2024-11-01
ER

PT J
AU Florez, I
   Pirrone, I
   Casique, L
   Domínguez, CL
   Mahfoud, A
   Rodríguez, T
   Rodríguez, D
   De Lucca, M
   Ramírez, JL
AF Florez, Ingrid
   Pirrone, Irune
   Casique, Liliana
   Luisa Dominguez, Carmen
   Mahfoud, Antonieta
   Rodriguez, Tania
   Rodriguez, Daniel
   De Lucca, Marisel
   Luis Ramirez, Jose
TI Independent origin for m.3243A&gt;G mitochondrial mutation in three
   Venezuelan cases of MELAS syndrome
SO CLINICAL BIOCHEMISTRY
LA English
DT Article
DE MELAS syndrome; mtDNA; Heteroplasmy; Mitochondrial haplogroup; MT-TL1
   gene; Venezuelan patients
ID A3243G MUTATION; DIFFERENT TISSUES; DNA; MTDNA; PREVALENCE; CHILDREN;
   LOADS; GENE
AB Mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) is a multisystem and progressive neurodegenerative mitochondrial disease, caused by point nucleotide changes in the mtDNA where 80 % of cases have the mutation m.3243A>G in the MT-TL1 gene. In this work, we described the clinical, biochemical and molecular analysis of three Venezuelan patients affected with MELAS syndrome. All cases showed lactic acidosis, cortical cerebral atrophy on magnetic resonance imaging and muscular system deficit, and in two of the cases alteration of urine organic acid levels was also registered. A screening for the mutation m.3243A>G in different patients' body samples confirmed the presence of this mutation with variable degrees of heteroplasmy (blood = 7-41 %, buccal mucosa = 14-53 %, urine = 58-94 %). The mitochondrial haplogroups for the three patients were different (H, C1b, and A2), indicating an independent origin for the mutation.
C1 [Florez, Ingrid; Pirrone, Irune; Casique, Liliana; Luis Ramirez, Jose] Fdn Inst Estudios Avanzados IDEA, Biotechnol Ctr, Caracas, Venezuela.
   [Luisa Dominguez, Carmen; Mahfoud, Antonieta; Rodriguez, Tania; Rodriguez, Daniel; De Lucca, Marisel] Fdn Inst Estudios Avanzados IDEA, Biosci Ctr, Inborn Errors Metab Unit, Caracas, Venezuela.
   [De Lucca, Marisel] Univ Tecn Manabi, Fac Hlth Sci, Dept Biol Sci, Portoviejo, Ecuador.
   [Pirrone, Irune; Casique, Liliana] Univ Simon Bolivar, Dept Cell Biol, Lab Human Metab, Caracas, Venezuela.
C3 Universidad Tecnica de Manabi; Simon Bolivar University
RP De Lucca, M (corresponding author), Univ Tecn Manabi, Fac Hlth Sci, Dept Biol Sci, Portoviejo, Ecuador.; Casique, L (corresponding author), Univ Simon Bolivar, Dept Biol Celular, Lab Metab Humano, Caracas 1081A, Venezuela.
EM lcasique@usb.ve; marisel.delucca@utm.edu.ec
RI Blanco, Tania/D-5563-2016; Ramirez, Jose/AAE-3117-2021
OI Pirrone Berecibar, Irune/0000-0002-2103-1936
FU FONACIT Venezuela grant [2008001053]
FX This work was supported by FONACIT Venezuela grant #2008001053.
CR de Guerra DC, 2012, FORENSIC SCI INT-GEN, V6, pE131, DOI 10.1016/j.fsigen.2011.11.004
   Chinnery PF, 1999, J MED GENET, V36, P425
   Choi BO, 2010, EXP MOL MED, V42, P446, DOI 10.3858/emm.2010.42.6.046
   Delgado-Sánchez R, 2007, REV NEUROLOGIA, V44, P18, DOI 10.33588/rn.4401.2006032
   Dvorakova V, 2016, MOL GENET METAB, V118, P288, DOI 10.1016/j.ymgme.2016.06.003
   El-Hattab AW, 2016, MOL GENET METAB, V117, P407, DOI 10.1016/j.ymgme.2016.01.010
   Firestone Chaz, J DEV ECON, V136, P409, DOI [10.1016/j.foodchem.2012.08.013, DOI 10.1016/J.JDEVECO.2009.07.004, 10.1016/j.cognition.2014.10.014]
   Gorman GS, 2015, ANN NEUROL, V77, P753, DOI 10.1002/ana.24362
   Grady JP, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708262
   Guevara-Campos José, 2007, Invest. clín, V48, P243
   HIRANO M, 1992, NEUROMUSCULAR DISORD, V2, P125, DOI 10.1016/0960-8966(92)90045-8
   Jacobs HT, 2000, HUM MOL GENET, V9, P463, DOI 10.1093/hmg/9.4.463
   Kang EJ, 2016, NATURE, V540, P270, DOI 10.1038/nature20592
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   LAHIRI DK, 1991, NUCLEIC ACIDS RES, V19, P5444, DOI 10.1093/nar/19.19.5444
   Lander N, 2008, FORENS SCI INT-GEN S, V1, P346, DOI 10.1016/j.fsigss.2007.10.113
   Ma YN, 2009, MITOCHONDRION, V9, P139, DOI 10.1016/j.mito.2009.01.004
   Martínez H, 2007, HUM BIOL, V79, P201, DOI 10.1353/hub.2007.0032
   McMillan RP, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42262-2
   Mehrazin M, 2009, AM J MED GENET A, V149A, P584, DOI 10.1002/ajmg.a.32703
   O'Callaghan MM, 2015, MITOCHONDRION, V22, P17, DOI 10.1016/j.mito.2015.03.001
   OZAWA T, 1991, BIOCHEM BIOPH RES CO, V177, P518, DOI 10.1016/0006-291X(91)92014-B
   Pierron D, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-41
   Cataldo LR, 2013, REV MED CHILE, V141, P305, DOI 10.4067/S0034-98872013000300004
   Ruiz-Pesini E, 2004, SCIENCE, V303, P223, DOI 10.1126/science.1088434
   Sallevelt SCEH, 2017, J MED GENET, V54, P114, DOI 10.1136/jmedgenet-2016-103876
   Shanske S, 2004, AM J MED GENET A, V130A, P134, DOI 10.1002/ajmg.a.30220
   Torroni A, 2003, AM J HUM GENET, V72, P1005, DOI 10.1086/373936
   Uusimaa J, 2004, PEDIATRICS, V114, P443, DOI 10.1542/peds.114.2.443
   Uusimaa J, 2007, ANN NEUROL, V62, P278, DOI 10.1002/ana.21196
   Venegas V, 2012, METHODS MOL BIOL, V837, P327, DOI 10.1007/978-1-61779-504-6_22
   Wallace DC, 2015, CELL, V163, P33, DOI 10.1016/j.cell.2015.08.067
   Xia CY, 2016, CHINESE MED J-PEKING, V129, P1945, DOI 10.4103/0366-6999.187845
NR 33
TC 1
Z9 1
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-9120
EI 1873-2933
J9 CLIN BIOCHEM
JI Clin. Biochem.
PD NOV-DEC
PY 2022
VL 109
BP 98
EP 101
DI 10.1016/j.clinbiochem.2022.09.007
EA DEC 2022
PG 4
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology
GA 7B1XG
UT WOS:000898934500016
PM 36130631
DA 2024-11-01
ER

PT J
AU Bortot, B
   Barbi, E
   Biffi, S
   Lunazzi, G
   Bussani, R
   Burlina, A
   Norbedo, S
   Ventura, A
   Carrozzi, M
   Severini, GM
AF Bortot, B.
   Barbi, E.
   Biffi, S.
   Lunazzi, G.
   Bussani, R.
   Burlina, A.
   Norbedo, S.
   Ventura, A.
   Carrozzi, M.
   Severini, G. M.
TI Two novel POLG mutations causing hepatic mitochondrial DNA depletion
   with recurrent hypoketotic hypoglycaemia and fatal liver dysfunction
SO DIGESTIVE AND LIVER DISEASE
LA English
DT Article
DE DNA polymerase gamma; Late onset; Liver failure; mtDNA depletion
   syndrome
ID POLYMERASE-GAMMA; ALPERS-SYNDROME; OXIDATIVE-PHOSPHORYLATION;
   SPACER-REGION; DISORDERS; DISEASE; DEFICIENCIES; CHILDHOOD; DIAGNOSIS;
   MYOPATHY
AB Background. Inherited mtDNA depletion syndromes (MDS) are a group of severe mitochondrial disorders resulting from defects in nucleus-encoded factors and often associated with severe or fatal liver failure.
   Patient. In this article, we describe the case of all 18-month-old patient with recurrent hypoketolic hypoglycaemia and fatal hepatic dysfunction with liver mtDNA depletion.
   Methods. The assessment of mtDNA copy number was performed on leucocytes, liver and muscle biopsy by Quantitative Real Time PCR and total RNA from liver biopsy was used as a template to amplify the cDNA of the POLG I gene.
   Results. Sequence analysis identified two previously undescribed mutations (1868T>G and 2263A>G) located in the gene coding the catalytic subunit of mitochondrial DNA polymerase gamma (POLG), predicting all L623W and K755E amino acid change, respectively. Both mutations were located in the highly conserved linker region of the protein and were absent in more than 200 healthy unrelated control Subjects. The identification of these two mutations allowed us to perform genetic counselling and prenatal diagnosis.
   Conclusion. Our data further expand the spectrum of POLG I gene mutations and the unique phenotype reported (late onset isolated liver disease without lactic acidosis) increase the variability of clinical presentations associated with mutations in this gene. (C) 2008 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
C1 [Bortot, B.; Biffi, S.; Lunazzi, G.; Carrozzi, M.; Severini, G. M.] Inst Child Hlth IRCCS, Child Neurol & Psychiat Unit, Neuromuscular Disorders Lab, Trieste, Italy.
   [Barbi, E.; Norbedo, S.; Ventura, A.] Univ Trieste, Inst Child Hlth IRCCS, Dept Pediat, Trieste, Italy.
   [Severini, G. M.] Inst Child Hlth IRCCS, Med Genet Unit, Trieste, Italy.
   [Biffi, S.] CBM Scrl, Opt Imaging Lab, Trieste, Italy.
   [Bussani, R.] Osped Cattinara, Dept Pathol Anat, Trieste, Italy.
   [Burlina, A.] Univ Hosp, Dept Pediat, Div Metab Disorders, Padua, Italy.
C3 University of Trieste; University of Padua; Azienda Ospedaliera -
   Universita di Padova
RP Severini, GM (corresponding author), Inst Child Hlth IRCCS, Child Neurol & Psychiat Unit, Neuromuscular Disorders Lab, Via Istria, Trieste, Italy.
EM severini@burlo.trieste.it
RI biffi, stefania/C-6652-2015; Barbi, Egidio/K-4016-2018
OI biffi, stefania/0000-0003-2257-2053; Ventura,
   Alessandro/0000-0002-4657-1760; Lunazzi, Giulia/0000-0001-6859-9505;
   Bussani, Rossana/0000-0001-8241-9726; Barbi, Egidio/0000-0002-6343-846X;
   Carrozzi, Marco/0000-0001-6282-4417
CR Alberio S, 2007, MITOCHONDRION, V7, P6, DOI 10.1016/j.mito.2006.11.010
   Bai RK, 2004, CLIN CHEM, V50, P996, DOI 10.1373/clinchem.2004.031153
   Blake JC, 1999, AM J PATHOL, V155, P67, DOI 10.1016/S0002-9440(10)65100-0
   Calvo S, 2006, NAT GENET, V38, P576, DOI 10.1038/ng1776
   CHINNERY PF, 2007, NEUROMUSCULAR DISORD, V18, P259
   CormierDaire V, 1997, J PEDIATR-US, V130, P817, DOI 10.1016/S0022-3476(97)80027-3
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   de Vries MC, 2007, EUR J PEDIATR, V166, P229, DOI 10.1007/s00431-006-0234-9
   Dubern B, 2001, TRANSPLANTATION, V71, P633, DOI 10.1097/00007890-200103150-00009
   Elpeleg O, 2003, PEDIATR RES, V54, P153, DOI 10.1203/01.PDR.0000072796.25097.A5
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Freisinger P, 2006, ARCH NEUROL-CHICAGO, V63, P1129, DOI 10.1001/archneur.63.8.1129
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Hudson G, 2006, HUM MOL GENET, V15, pR244, DOI 10.1093/hmg/ddl233
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   Lee WS, 2007, SEMIN LIVER DIS, V27, P259, DOI 10.1055/s-2007-985071
   Longley MJ, 2005, GENE, V354, P125, DOI 10.1016/j.gene.2005.03.029
   Luo NG, 2005, J BIOL CHEM, V280, P2491, DOI 10.1074/jbc.M411447200
   Luoma PT, 2005, HUM MOL GENET, V14, P1907, DOI 10.1093/hmg/ddi196
   MANDERBACKA K, 2001, SCANDINAVIAN J P S55, V29, P41
   Morten KJ, 2007, MITOCHONDRION, V7, P386, DOI 10.1016/j.mito.2007.09.001
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nguyen KV, 2006, J HEPATOL, V45, P108, DOI 10.1016/j.jhep.2005.12.026
   Nguyen KV, 2005, NEUROLOGY, V65, P1493, DOI 10.1212/01.wnl.0000182814.55361.70
   *NIEHS, 2008, HUM DNA POL GAMM MUT
   Rabinowitz SS, 2004, J PEDIATR GASTR NUTR, V38, P216, DOI 10.1097/00005176-200402000-00022
   Remes AM, 2005, NEUROLOGY, V64, P976, DOI 10.1212/01.WNL.0000154518.31302.ED
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Sambrook J., 1989, Molecular Cloning
   Sarzi E, 2007, J PEDIATR-US, V150, P531, DOI 10.1016/j.jpeds.2007.01.044
   Van Goethem G, 2003, NEUROLOGY, V61, P1811, DOI 10.1212/01.WNL.0000098997.23471.65
NR 32
TC 6
Z9 6
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1590-8658
EI 1878-3562
J9 DIGEST LIVER DIS
JI Dig. Liver Dis.
PD JUL
PY 2009
VL 41
IS 7
BP 494
EP 499
DI 10.1016/j.dld.2008.11.013
PG 6
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA 467YU
UT WOS:000267780600008
PM 19195941
DA 2024-11-01
ER

PT J
AU Scarpelli, M
   Carreño-Gago, L
   Russignan, A
   de Luna, N
   Carnicer-Cáceres, C
   Ariatti, A
   Verriello, L
   Devigili, G
   Tonin, P
   Garcia-Arumi, E
   Pinós, T
AF Scarpelli, Mauro
   Carreno-Gago, Lidia
   Russignan, Anna
   de Luna, Noemi
   Carnicer-Caceres, Clara
   Ariatti, Alessandra
   Verriello, Lorenzo
   Devigili, Grazia
   Tonin, Paola
   Garcia-Arumi, Elena
   Pinos, Tomas
TI Identification and characterization of the novel m.8305C&gt;T
   <i>MTTK</i> and m.4440G&gt;A <i>MTTM</i> gene mutations causing
   mitochondrial myopathies
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE Myopathy; Mitochondrial diseases; PEO; mtDNA
ID EXERCISE INTOLERANCE; MERRF MUTATION; MUSCLE
AB We report on two novel mtDNA mutations in patients affected with mitochondrial myopathy. The first patient, a 44-year-old woman, had bilateral eyelid ptosis and the m.8305C>T mutation in the MTTK gene. The second patient, a 56-year-old man, had four-limb muscle weakness and the MTTM gene m.4440G>A mutation. Muscle biopsies in both patients showed ragged red fibers and numerous COX-negative fibers as well as a combined defect of complex I, III and IV activities. The two mutations were heteroplasmic and detected only in muscle tissue, with a higher mutation load in COX-negative fibers. Additionally, both mutations occurred in highly conserved mt-tRNA sites, and were not found by an in silico search in 30,589 human mtDNA sequences. Our report further expands the mutational and phenotypic spectrum of diseases associated with mutations in mitochondrial tRNA genes and reinforces the notion that mutations in mitochondrial tRNAs represent hot spots for mitochondrial myopathies in adults. (C) 2017 Elsevier B.V. All rights reserved.
C1 [Scarpelli, Mauro; Russignan, Anna; Tonin, Paola] Univ Verona, Dept Neurol Biomed & Movement Sci, Neurol Sect, Verona, Italy.
   [Carreno-Gago, Lidia; Garcia-Arumi, Elena; Pinos, Tomas] Vall Hebron Inst Recerca, Mitochondrial Disorders Unit, Barcelona, Spain.
   [Carreno-Gago, Lidia; de Luna, Noemi; Garcia-Arumi, Elena; Pinos, Tomas] Ctr Invest Biomed Red Enfermedades Raras CIBERER, Madrid, Spain.
   [de Luna, Noemi] Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Inst Recerca, Lab Malalties Neuromusculars, Barcelona, Spain.
   [Carnicer-Caceres, Clara] Hosp Univ Vall dHebron, Serv Bioquim, Unidad Metabolopatias, Barcelona, Spain.
   [Ariatti, Alessandra] Univ Hosp Modena, Dept Neurosci, Modena, Italy.
   [Ariatti, Alessandra] Univ Hosp Modena, Dept Oncohaematol, Modena, Italy.
   [Ariatti, Alessandra] Univ Hosp Reggio Emilia, Dept Neurosci, Reggio Emilia, Italy.
   [Ariatti, Alessandra] Univ Hosp Reggio Emilia, Dept Oncohaematol, Reggio Emilia, Italy.
   [Verriello, Lorenzo; Devigili, Grazia] Azienda Osped Univ, Dept Neurosci, Div Neurol, Udine, Italy.
   [Garcia-Arumi, Elena] Hosp Univ Vall dHebron, Area Genet Clin & Mol, Barcelona, Spain.
   [Scarpelli, Mauro] Azienda Osped Univ Integrata, Dept Neurosci, Div Neurol, Verona, Italy.
C3 University of Verona; Autonomous University of Barcelona; Hospital
   Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR);
   CIBER - Centro de Investigacion Biomedica en Red; CIBERER; Hospital of
   Santa Creu i Sant Pau; Autonomous University of Barcelona; Hospital
   Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR);
   Hospital Universitari Vall d'Hebron; Universita di Modena e Reggio
   Emilia; Universita di Modena e Reggio Emilia Hospital; Universita di
   Modena e Reggio Emilia; Universita di Modena e Reggio Emilia Hospital;
   University of Udine; University Hospital of Udine; Hospital Universitari
   Vall d'Hebron; University of Verona; Azienda Ospedaliera Universitaria
   Integrata Verona
RP Garcia-Arumi, E; Pinós, T (corresponding author), Vall Hebron Inst Recerca, Mitochondrial Disorders Unit, Barcelona, Spain.; Garcia-Arumi, E (corresponding author), Hosp Univ Vall dHebron Inst Recerca VHIR, Dept Patol Mitocondrial & Neuromuscular, Barcelona, Spain.
EM elena.garcia@vhir.org; tomas.pinos@vhir.org
RI Tonin, Paola/AAC-5052-2022; Garcia-Arumi, Elena/ABH-4229-2020; de Luna
   Salva, Noemi/H-8705-2017
OI DEVIGILI, GRAZIA/0000-0001-9688-4231; Garcia-Arumi,
   Elena/0000-0003-0096-3336; de Luna Salva, Noemi/0000-0002-4342-794X
FU Spanish Instituto de Salud Carlos III, Fondo de Investigaciones
   Sanitarias (FIS); FIS [PI12-02149-FEDER, PI15/01428-FEDER]
FX This study was supported by Spanish Instituto de Salud Carlos III, Fondo
   de Investigaciones Sanitarias (FIS); EGA has received two FIS grants:
   PI12-02149-FEDER and PI15/01428-FEDER. We thank Dr. Ramon Marti from the
   Mitochondrial Disorders Unit, Vall d'Hebron Institut de Recerca,
   Barcelona, Spain for his valuable intellectual support.
CR Blakely EL, 2014, NEUROMUSCULAR DISORD, V24, P533, DOI 10.1016/j.nmd.2014.03.011
   Born AP, 2015, EUR J PAEDIATR NEURO, V19, P69, DOI 10.1016/j.ejpn.2014.10.006
   DiMauro S, 2013, NAT REV NEUROL, V9, P429, DOI 10.1038/nrneurol.2013.126
   Dubowitz V., 2007, Muscle Biopsy: A Practical Approach
   Jeppesen TD, 2014, NEUROMUSCULAR DISORD, V24, P162, DOI 10.1016/j.nmd.2013.08.004
   King T.E., 1967, METHODS ENZYMOLOGY, V10, P322, DOI [10.1016/0076-6879(67)10061-X, DOI 10.1016/0076-6879(67)10061-X]
   Mancuso M, 2013, NEUROLOGY, V80, P2049, DOI 10.1212/WNL.0b013e318294b44c
   Marotta M, 2007, NEUROMUSCULAR DISORD, V17, P707, DOI 10.1016/j.nmd.2007.05.007
   Medja F, 2009, MITOCHONDRION, V9, P331, DOI 10.1016/j.mito.2009.05.001
   MORAES CT, 1989, BIOCHEM BIOPH RES CO, V160, P765, DOI 10.1016/0006-291X(89)92499-6
   Olsen DB, 2003, J NEUROL, V250, P1328, DOI 10.1007/s00415-003-0206-1
   Peverelli L, 2014, MUSCLE NERVE, V50, P292, DOI 10.1002/mus.24262
   Ruiz-Pesini E, 2007, NUCLEIC ACIDS RES, V35, pD823, DOI 10.1093/nar/gkl927
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   Sternberg D, 2001, BRAIN, V124, P984, DOI 10.1093/brain/124.5.984
   Vissing J, 1998, NEUROLOGY, V50, P1875, DOI 10.1212/WNL.50.6.1875
NR 16
TC 4
Z9 4
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD FEB
PY 2018
VL 28
IS 2
BP 137
EP 143
DI 10.1016/j.nmd.2017.10.006
PG 7
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA GA7AP
UT WOS:000428487300005
PM 29174468
DA 2024-11-01
ER

PT J
AU Rossmanith, W
   Freilinger, M
   Roka, J
   Raffelsberger, T
   Moser-Thier, K
   Prayer, D
   Bernert, G
   Bittner, RE
AF Rossmanith, W.
   Freilinger, M.
   Roka, J.
   Raffelsberger, T.
   Moser-Thier, K.
   Prayer, D.
   Bernert, G.
   Bittner, R. E.
TI Isolated cytochrome c oxidase deficiency as a cause of MELAS
SO JOURNAL OF MEDICAL GENETICS
LA English
DT Article
ID MITOCHONDRIAL MYOPATHY; LACTIC-ACIDOSIS; EPISODES MELAS; ENCEPHALOPATHY;
   DIAGNOSIS; GENE
AB Background: MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes) is one of the more common mitochondrial encephalomyopathies. About 80% of MELAS cases are caused by transition 3243A -> G in the mitochondrial tRNA(Leu(UUR)) gene (MT-TL1). Other mutations in MT-TL1, other mitochondrial tRNA genes and mitochondrial-encoded subunits of respiratory complex I account for the remainder of cases.
   Objective: To characterise the molecular basis of a MELAS case without a mutation in any recognised MELAS target gene.
   Results and methods: Deletion of a single nucleotide (7630delT) within MT-CO2, the gene of subunit II of cytochrome c oxidase (COX), was identified by mitochondrial DNA (mtDNA) sequencing. The deletion-induced frameshift results in a stop codon close to the 59 end of the reading frame. The lack of subunit II (COII) precludes the assembly of COX and leads to the degradation of unassembled subunits, even those not directly affected by the mutation. Despite mitochondrial proliferation and transcriptional upregulation of nuclear and mtDNA-encoded COX genes (including MT-CO2), a severe COX deficiency was found with all investigations of the muscle biopsy (histochemistry, biochemistry, immunoblotting).
   Conclusions: The 7630delT mutation in MT-CO2 leads to a lack of COII with subsequent misassembly and degradation of respiratory complex IV despite transcriptional upregulation of its subunits. The causal association of the resulting isolated COX deficiency with MELAS is at odds with current concepts of the biochemical deficits underlying this common mitochondrial disease, and indicates that the genetic and pathobiochemical heterogeneity of MELAS is greater than previously appreciated.
C1 [Rossmanith, W.; Roka, J.; Raffelsberger, T.; Moser-Thier, K.; Bittner, R. E.] Med Univ Vienna, Ctr Anat & Cell Biol, A-1090 Vienna, Austria.
   [Freilinger, M.; Bernert, G.] Med Univ Vienna, Dept Pediat, Vienna, Austria.
   [Prayer, D.] Med Univ Vienna, Dept Radiol, Vienna, Austria.
C3 Medical University of Vienna; Medical University of Vienna; Medical
   University of Vienna
RP Rossmanith, W (corresponding author), Med Univ Vienna, Ctr Anat & Cell Biol, Wahringer Str 13, A-1090 Vienna, Austria.
EM walter.rossmanith@meduniwien.ac.at
RI Rossmanith, Walter/F-3662-2010
OI Rossmanith, Walter/0000-0003-2337-2248
CR Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Barisic N, 2002, NEUROPEDIATRICS, V33, P157, DOI 10.1055/s-2002-33679
   Conti E, 2005, CURR OPIN CELL BIOL, V17, P316, DOI 10.1016/j.ceb.2005.04.005
   GOTO Y, 1995, MUSCLE NERVE       S, V3, P107
   HASEGAWA H, 1991, ANN NEUROL, V29, P601, DOI 10.1002/ana.410290606
   HIRANO M, 1994, J CHILD NEUROL, V9, P4, DOI 10.1177/088307389400900102
   Ingman M., mtDB - Human Mitochondrial Genome Database 1/3/2007 [cited 2013 12/4/2013]
   Jacobs HT, 2003, HUM MOL GENET, V12, pR293, DOI 10.1093/hmg/ddg285
   Khalimonchuk E, 2005, MITOCHONDRION, V5, P363, DOI 10.1016/j.mito.2005.08.002
   Kirby DM, 2004, J MED GENET, V41, P784, DOI 10.1136/jmg.2004.020537
   KOEHLER CM, 2003, GENETICS MITOCHONDRI, P47
   Liolitsa D, 2003, ANN NEUROL, V53, P128, DOI 10.1002/ana.10435
   McFarland R, 2007, CURR TOP DEV BIOL, V77, P113, DOI 10.1016/S0070-2153(06)77005-3
   Naini A, 2005, J NEUROL SCI, V229, P187, DOI 10.1016/j.jns.2004.11.026
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Rahman S, 1999, AM J HUM GENET, V65, P1030, DOI 10.1086/302590
   Rossmanith W, 2003, ANN NEUROL, V54, P820, DOI 10.1002/ana.10753
   Sambrook J, 1990, Cold Spring Harbor Laboratories, V186, P182
   Scaglia F, 2006, CNS DRUGS, V20, P443, DOI 10.2165/00023210-200620060-00002
   Shoubridge EA, 2001, AM J MED GENET, V106, P46, DOI 10.1002/ajmg.1378
   Taanman JW, 2001, BIOCHEM SOC T, V29, P446, DOI 10.1042/BST0290446
   Taanman JW., 2003, GENETICS MITOCHONDRI, V1, P27
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   Thambisetty M, 2004, EXPERT REV MOL DIAGN, V4, P631, DOI 10.1586/14737159.4.5.631
   Vandesompele J, 2002, ANAL BIOCHEM, V303, P95, DOI 10.1006/abio.2001.5564
   Wallace D. C, MITOMAP HUMAN MITOCH
   Yoneda M, 1996, Methods Enzymol, V264, P432, DOI 10.1016/S0076-6879(96)64039-7
NR 28
TC 23
Z9 27
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-2593
EI 1468-6244
J9 J MED GENET
JI J. Med. Genet.
PD FEB
PY 2008
VL 45
IS 2
BP 117
EP 121
DI 10.1136/jmg.2007.052076
PG 5
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 258MF
UT WOS:000252871300009
PM 18245391
DA 2024-11-01
ER

PT J
AU Nakada, K
   Hayashi, JI
AF Nakada, Kazuto
   Hayashi, Jun-Ichi
TI Transmitochondrial Mice as Models for Mitochondrial DNA-Based Diseases
SO EXPERIMENTAL ANIMALS
LA English
DT Review
DE mitochondria; mitochondrial diseases; mitochondrial DNA mutation;
   mitochondrial respiration defects; model mice
ID LACTIC-ACIDOSIS; OXIDATIVE-PHOSPHORYLATION; DILATED CARDIOMYOPATHY;
   RESPIRATION DEFECTS; MISSENSE MUTATION; PROTEIN-SYNTHESIS; MUTANT MTDNA;
   MITO-MICE; CELLS; GENERATION
AB Mitochondrial genome (mtDNA) mutations and the resultant mitochondrial respiratory abnormalities are associated with a wide variety of disorders, such as mitochondrial diseases, neurodegenerative diseases, diabetes, and cancer, as well as aging. Generation of model animals carrying mutant nntDNAs is important for understanding the pathophysiological mechanisms of the mtDNA-based diseases. We have succeeded in generating three kinds of mice with pathogenic mutant mtDNAs, named "mito-mice," by the introduction of mitochondria carrying pathogenic mutant mtDNAs into mouse zygotes and mouse embryonic stem (ES) cells. In the case of mito-mice possessing the heteroplasmic state of wild-type mtDNA and pathogenic mtDNA with a large-scale deletion (Delta mtDNA, mito-miceA), a high load of Delta mtDNA induced mitochondrial respiration defects in various tissues, resulting in mitochondrial disease phenotypes, such as low body weight, lactic acidosis, ischemia, myopathy, heart block, deafness, male infertility, long-term memory defects, and renal failure. In this review, we summarize generation and clinical phenotypes of three types of mito-mice and we introduce several treatment trials for mitochondrial diseases using mito-mice Delta.
C1 [Nakada, Kazuto; Hayashi, Jun-Ichi] Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki 3058572, Japan.
C3 University of Tsukuba
RP Hayashi, JI (corresponding author), Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki 3058572, Japan.
CR Austin SA, 1998, NEUROLOGY, V51, P1447, DOI 10.1212/WNL.51.5.1447
   Bayona-Bafaluy MP, 2005, P NATL ACAD SCI USA, V102, P14392, DOI 10.1073/pnas.0502896102
   CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236
   CLAYTON DA, 1984, ANNU REV BIOCHEM, V53, P573
   CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6
   Dubeau F, 2000, ANN NEUROL, V47, P179, DOI 10.1002/1531-8249(200002)47:2<179::AID-ANA7>3.0.CO;2-Z
   Gatenby RA, 2004, NAT REV CANCER, V4, P891, DOI 10.1038/nrc1478
   Gladden LB, 2004, J PHYSIOL-LONDON, V558, P5, DOI 10.1113/jphysiol.2003.058701
   Grad LI, 2005, P NATL ACAD SCI USA, V102, P18367, DOI 10.1073/pnas.0506939102
   Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226
   HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   Howard J, 1997, NATURE, V389, P561, DOI 10.1038/39247
   Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021
   Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826
   Inoue SI, 2007, FEBS LETT, V581, P1910, DOI 10.1016/j.febslet.2007.03.092
   Ishikawa K, 2008, SCIENCE, V320, P661, DOI 10.1126/science.1156906
   Jackson DC, 2004, RESP PHYSIOL NEUROBI, V144, P173, DOI 10.1016/j.resp.2004.06.020
   Kasahara A, 2006, HUM MOL GENET, V15, P871, DOI 10.1093/hmg/ddl005
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231
   LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376
   Melone MAB, 2004, ARCH NEUROL-CHICAGO, V61, P269, DOI 10.1001/archneur.61.2.269
   Minczuk M, 2008, NUCLEIC ACIDS RES, V36, P3926, DOI 10.1093/nar/gkn313
   Nakada K, 2004, BIOCHEM BIOPH RES CO, V323, P175, DOI 10.1016/j.bbrc.2004.08.073
   Nakada K, 2001, BIOCHEM BIOPH RES CO, V288, P901, DOI 10.1006/bbrc.2001.5873
   Nakada K, 2001, NAT MED, V7, P934, DOI 10.1038/90976
   Nakada K, 2006, P NATL ACAD SCI USA, V103, P15148, DOI 10.1073/pnas.0604641103
   NAKAI A, 1994, LANCET, V343, P1397, DOI 10.1016/S0140-6736(94)92527-5
   NELSON I, 1995, ANN NEUROL, V37, P400, DOI 10.1002/ana.410370317
   Ogasawara E, 2010, HUM MOL GENET, V19, P3179, DOI 10.1093/hmg/ddq228
   Roubertoux PL, 2003, NAT GENET, V35, P65, DOI 10.1038/ng1230
   Santra S, 2004, ANN NEUROL, V56, P662, DOI 10.1002/ana.20240
   Sato A, 2005, P NATL ACAD SCI USA, V102, P16765, DOI 10.1073/pnas.0506197102
   Sato A, 2007, GENETICS, V177, P2031, DOI 10.1534/genetics.107.081026
   Silva JP, 2000, NAT GENET, V26, P336, DOI 10.1038/81649
   SKUDER P, 1995, INTELLIGENCE, V21, P1, DOI 10.1016/0160-2896(95)90035-7
   Sörensen L, 2001, J NEUROSCI, V21, P8082, DOI 10.1523/JNEUROSCI.21-20-08082.2001
   STACPOOLE PW, 1989, METABOLISM, V38, P1124, DOI 10.1016/0026-0495(89)90051-6
   Tanaka D, 2008, MOL BRAIN, V1, DOI 10.1186/1756-6606-1-21
   Tysoe C, 1996, J MED GENET, V33, P1002, DOI 10.1136/jmg.33.12.1002
   Uusimaa J, 2007, ANN NEUROL, V62, P278, DOI 10.1002/ana.21196
   Varlamov DA, 2002, HUM MOL GENET, V11, P1797, DOI 10.1093/hmg/11.16.1797
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Wang F, 2000, J BIOL CHEM, V275, P4329, DOI 10.1074/jbc.275.6.4329
   Wang JM, 1999, NAT GENET, V21, P133, DOI 10.1038/5089
   Yokota M, 2010, FEBS LETT, V584, P3943, DOI 10.1016/j.febslet.2010.07.048
   YONEDA M, 1994, MOL CELL BIOL, V14, P2699, DOI 10.1128/MCB.14.4.2699
NR 49
TC 20
Z9 22
U1 0
U2 9
PU INT PRESS EDITING CENTRE INC
PI TOKYO
PA 1-2-3 SUGAMO, TOSHIMA-KU, TOKYO, 170 0002, JAPAN
SN 1341-1357
EI 1881-7122
J9 EXP ANIM TOKYO
JI Exp. Anim.
PD OCT
PY 2011
VL 60
IS 5
BP 421
EP 431
PG 11
WC Veterinary Sciences; Zoology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Veterinary Sciences; Zoology
GA 837EW
UT WOS:000296174900001
PM 22041279
DA 2024-11-01
ER

PT J
AU Annunen-Rasila, J
   Finnilä, S
   Mykkänen, K
   Moilanen, JS
   Veijola, J
   Pöyhönen, M
   Viitanen, M
   Kalimo, H
   Majamaa, K
AF Annunen-Rasila, Johanna
   Finnila, Saara
   Mykkanen, Kati
   Moilanen, Jukka S.
   Veijola, Johanna
   Poyhonen, Minna
   Viitanen, Matti
   Kalimo, Hannu
   Majamaa, Kari
TI Mitochondrial DNA sequence variation and mutation rate in patients with
   CADASIL
SO NEUROGENETICS
LA English
DT Article
DE CADASIL; mtDNA; DNA sequence analysis; genetic variation; NOTCH3
ID AUTOSOMAL-DOMINANT ARTERIOPATHY; SUBCORTICAL INFARCTS; PHYLOGENETIC
   NETWORK; NOTCH3 GENE; LEUKOENCEPHALOPATHY CADASIL; SKELETAL-MUSCLE;
   MTDNA; RECOMBINATION; SPECTRUM; GENOME
AB Mutations in the NOTCH3 gene cause cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), which is clinically characterised by recurrent ischemic strokes, migraine with aura, psychiatric symptoms, cognitive decline and dementia. We have previously described a patient with CADASIL caused by a R133C mutation in the NOTCH3 gene and with a concomitant myopathy caused by a 5650G > A mutation in the MTTA gene in mitochondrial DNA (mtDNA). We assume that the co-occurrence of the two mutations is not coincidental and that mutations in the NOTCH3 gene may predispose the mtDNA to mutations. We therefore examined the nucleotide variation in the mtDNA coding region sequences in 20 CADASIL pedigrees with 77 affected patients by conformation-sensitive gel electrophoresis and sequencing. The sequence variation in mtDNA was then compared with that among 192 healthy Finns. A total of 180 mtDNA coding region sequence differences were found relative to the revised Cambridge reference sequence, including five novel synonymous substitutions, two novel nonsynonymous substitutions and one novel tRNA substitution. We found that maternal relatives in two pedigrees differed from each other in their mtDNA. Furthermore, the average number of pairwise differences in sequences from the 41 unrelated maternal lineages with CADASIL was higher than that expected among haplogroup-matched controls. The numbers of polymorphic sites and polymorphisms that were present in only one sequence were also higher among the CADASIL sequences than among the control sequences. Our results show that mtDNA sequence variation is increased within CADASIL pedigrees. These findings suggest a relationship between NOTCH3 and mtDNA.
C1 Oulu Univ, Dept Neurol, Oulu, Finland.
   Oulu Univ Hosp, Clin Res Ctr, Oulu, Finland.
   Turku Univ, Dept Med Genet, Turku, Finland.
   Oulu Univ Hosp, Dept Clin Genet, Oulu, Finland.
   Tampere Univ, Inst Med Technol, FIN-33101 Tampere, Finland.
   Univ Helsinki, Dept Med Genet, Helsinki, Finland.
   Univ Helsinki, Cent Hosp, Dept Clin Genet, Helsinki, Finland.
   Turku Univ, Dept Geriatr Med, Turku, Finland.
   Karolinska Univ Hosp, Div Clin Geriatr, Karolinska Inst, Stockholm, Sweden.
   Univ Helsinki, Dept Pathol, Helsinki, Finland.
   Univ Helsinki, Cent Hosp, Dept Pathol, Helsinki, Finland.
   Turku Univ, Dept Pathol, Turku, Finland.
C3 University of Oulu; University of Oulu; University of Turku; University
   of Oulu; Tampere University; University of Helsinki; University of
   Helsinki; Helsinki University Central Hospital; University of Turku;
   Karolinska Institutet; Karolinska University Hospital; University of
   Helsinki; University of Helsinki; Helsinki University Central Hospital;
   University of Turku
RP Majamaa, K (corresponding author), Turku Univ, Dept Neurol, Turku 20014, Finland.
EM Kari.Majamaa@utu.fi
RI Majamaa, Kari/A-1344-2012; Viitanen, Matti/AAY-5163-2020; Moilanen,
   Jukka/G-2604-2012; Poyhonen, Minna/K-4866-2018
OI Moilanen, Jukka/0000-0002-8041-3205; Poyhonen,
   Minna/0000-0003-2037-2744; Majamaa, Kari/0000-0002-9070-3791
CR Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Bandelt HJ, 2001, INT J LEGAL MED, V115, P64, DOI 10.1007/s004140100228
   Battersby BJ, 2003, NAT GENET, V33, P183, DOI 10.1038/ng1073
   Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235
   Cavelier L, 2000, HUM GENET, V107, P45, DOI 10.1007/s004390050009
   CHABRIAT H, 1995, LANCET, V346, P934, DOI 10.1016/S0140-6736(95)91557-5
   de la Peña P, 2001, NEUROLOGY, V57, P1235, DOI 10.1212/WNL.57.7.1235
   Dichgans M, 1998, ANN NEUROL, V44, P731, DOI 10.1002/ana.410440506
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Dotti MT, 2004, ARCH NEUROL-CHICAGO, V61, P942, DOI 10.1001/archneur.61.6.942
   Finnilä S, 2001, J MOL MED, V79, P641, DOI 10.1007/s001090100268
   Finnilä S, 2001, AM J HUM GENET, V68, P1475, DOI 10.1086/320591
   Finnilä S, 2000, AM J HUM GENET, V66, P1017, DOI 10.1086/302802
   FU YX, 1993, GENETICS, V133, P693
   Howell N, 1996, AM J HUM GENET, V59, P501
   Howell N, 2003, AM J HUM GENET, V72, P659, DOI 10.1086/368264
   HOWELL N, 1995, GENETICS, V140, P285
   Joutel A, 2004, AM J HUM GENET, V74, P338, DOI 10.1086/381506
   Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0
   Kraytsberg Y, 2004, SCIENCE, V304, P981, DOI 10.1126/science.1096342
   Lehtonen MS, 2003, HUM GENET, V113, P220, DOI 10.1007/s00439-003-0966-9
   Loogväli EL, 2004, MOL BIOL EVOL, V21, P2012, DOI 10.1093/molbev/msh209
   Malandrini A, 2002, NEUROLOGY, V59, P617, DOI 10.1212/WNL.59.4.617
   Martz E, 2002, TRENDS BIOCHEM SCI, V27, P107, DOI 10.1016/S0968-0004(01)02008-4
   Mazzei R, 2004, NEUROLOGY, V63, P561, DOI 10.1212/01.WNL.0000133399.37716.84
   McFarland R, 2004, TRENDS GENET, V20, P591, DOI 10.1016/j.tig.2004.09.014
   Moilanen JS, 2003, MOL BIOL EVOL, V20, P2132, DOI 10.1093/molbev/msg230
   Moilanen JS, 2003, MOL BIOL EVOL, V20, P1195, DOI 10.1093/molbev/msg121
   Mykkänen K, 2004, EUR J HUM GENET, V12, P813, DOI 10.1038/sj.ejhg.5201221
   Niemi AK, 2003, HUM GENET, V112, P29, DOI 10.1007/s00439-002-0843-y
   Ohlmeier S, 2004, J BIOL CHEM, V279, P3956, DOI 10.1074/jbc.M310160200
   Okeda R, 2002, STROKE, V33, P2565, DOI 10.1161/01.STR.0000032620.91848.1C
   Parsons TJ, 1997, NAT GENET, V15, P363, DOI 10.1038/ng0497-363
   Rost B, 1996, METHOD ENZYMOL, V266, P525
   ROUSSET F, 1995, GENETICS, V140, P1413
   Sato A, 2005, P NATL ACAD SCI USA, V102, P6057, DOI 10.1073/pnas.0408666102
   Schneider S., 2000, ARLEQUIN VER 2000 SO
   Schröder JM, 2005, ACTA NEUROPATHOL, V110, P587, DOI 10.1007/s00401-005-1082-9
   Sickmann A, 2003, P NATL ACAD SCI USA, V100, P13207, DOI 10.1073/pnas.2135385100
   Siguroardóttir S, 2000, AM J HUM GENET, V66, P1599, DOI 10.1086/302902
   TAJIMA F, 1983, GENETICS, V105, P437
   TOURNIERLASSERVE E, 1993, NAT GENET, V3, P256, DOI 10.1038/ng0393-256
   Uchino M, 2002, ANN NY ACAD SCI, V977, P273, DOI 10.1111/j.1749-6632.2002.tb04826.x
   Vilmi T, 2005, J MOL EVOL, V60, P587, DOI 10.1007/s00239-003-0202-1
   WATTERSON GA, 1975, THEOR POPUL BIOL, V7, P256, DOI 10.1016/0040-5809(75)90020-9
   Zsurka G, 2005, NAT GENET, V37, P873, DOI 10.1038/ng1606
NR 46
TC 15
Z9 16
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1364-6745
EI 1364-6753
J9 NEUROGENETICS
JI Neurogenetics
PD JUL
PY 2006
VL 7
IS 3
BP 185
EP 194
DI 10.1007/s10048-006-0049-x
PG 10
WC Genetics & Heredity; Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Neurosciences & Neurology
GA 063TQ
UT WOS:000239043000007
PM 16807713
DA 2024-11-01
ER

PT J
AU McDonnell, MT
   Schaefer, AM
   Blakely, EL
   McFarland, R
   Chinnery, PF
   Turnbull, DM
   Taylor, RW
AF McDonnell, MT
   Schaefer, AM
   Blakely, EL
   McFarland, R
   Chinnery, PF
   Turnbull, DM
   Taylor, RW
TI Noninvasive diagnosis of the 3243A&gt;G mitochondrial DNA mutation using
   urinary epithelial cells
SO EUROPEAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
DE mitochondrial DNA; MELAS; 3243A > G mutation; noninvasive diagnosis
ID MTDNA MUTATION; MELAS; GENE; A3243G; BLOOD; DECREASE; ADULT; MERRF; LOAD
AB The 3243A>G mutation is one of the most frequently observed mutations of mitochondrial DNA (mtDNA), and is associated with numerous clinical presentations including mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS), progressive external ophthalmoplegia (PEO) and diabetes and deafness. The routine diagnosis of the 3243A>G mutation in blood is difficult as mutation levels are known to decrease in this tissue over time, while in some patients it may be absent. We have directly compared the levels of the 3243A>G mutation in skeletal muscle, blood and urinary epithelial cells in 18 patients and observed a striking correlation between the mutation load in postmitotic muscle and urinary epithelium, a mitotic tissue. These data strongly support the use of urinary epithelial cells as the tissue of choice in the noninvasive diagnosis of the 3243A>G mutation.
C1 Newcastle Univ, Sch Med, Sch Neurol Neurobiol & Psychiat, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
C3 Newcastle University - UK
RP Newcastle Univ, Sch Med, Sch Neurol Neurobiol & Psychiat, Mitochondrial Res Grp, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM r.w.taylor@ncl.ac.uk
OI McFarland, Robert/0000-0002-8833-2688; Chinnery,
   Patrick/0000-0002-7065-6617; Schaefer, Andrew/0000-0001-9891-7332
CR Chinnery PE, 1998, BRAIN, V121, P1889, DOI 10.1093/brain/121.10.1889
   Chinnery PF, 1997, LANCET, V350, P560, DOI 10.1016/S0140-6736(97)05005-8
   Chinnery PF, 1999, AM J MED GENET, V85, P498
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   Chol M, 2003, J MED GENET, V40, P188, DOI 10.1136/jmg.40.3.188
   CIAFALONI E, 1992, ANN NEUROL, V31, P391, DOI 10.1002/ana.410310408
   Dubeau F, 2000, ANN NEUROL, V47, P179, DOI 10.1002/1531-8249(200002)47:2<179::AID-ANA7>3.0.CO;2-Z
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   HAMMANS SR, 1991, LANCET, V337, P1311, DOI 10.1016/0140-6736(91)92981-7
   KOTSIMBOS N, 1994, HUM MUTAT, V4, P132, DOI 10.1002/humu.1380040207
   MACMILLAN C, 1993, NEUROLOGY, V43, P1586, DOI 10.1212/WNL.43.8.1586
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   MATTHEWS PM, 1994, J MED GENET, V31, P41, DOI 10.1136/jmg.31.1.41
   McFarland R, 2002, LANCET NEUROL, V1, P343, DOI 10.1016/S1474-4422(02)00159-X
   McFarland R, 2004, ANN NEUROL, V55, P478, DOI 10.1002/ana.20004
   McFarland R, 2004, ANN NEUROL, V55, P58, DOI 10.1002/ana.10787
   Rahman S, 2001, AM J HUM GENET, V68, P238, DOI 10.1086/316930
   Sue CM, 1998, J NEUROL SCI, V161, P36, DOI 10.1016/S0022-510X(98)00179-8
   Taylor RW, 2003, J CLIN INVEST, V112, P1351, DOI 10.1172/JCI200319435
   tHart LM, 1996, HUM MUTAT, V7, P193
NR 20
TC 74
Z9 80
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1018-4813
EI 1476-5438
J9 EUR J HUM GENET
JI Eur. J. Hum. Genet.
PD SEP
PY 2004
VL 12
IS 9
BP 778
EP 781
DI 10.1038/sj.ejhg.5201216
PG 4
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 847OD
UT WOS:000223403900014
PM 15199381
OA Bronze
DA 2024-11-01
ER

PT J
AU Yu, WF
   Li, ZX
   Wu, WJ
   Zhao, DD
   Yan, CZ
   Lin, PF
AF Yu, Wenfei
   Li, Zhuxun
   Wu, Wenjing
   Zhao, Dandan
   Yan, Chuanzhu
   Lin, Pengfei
TI Insights into the mechanisms of telbivudine-induced myopathy associated
   with mitochondrial dysfunction
SO CHEMICO-BIOLOGICAL INTERACTIONS
LA English
DT Article
DE Telbivudine; Mitochondrial dysfunction; Myotoxicity; Oxidative stress
ID HEPATITIS-B; COMPLEX-I; NEUROPATHY; EFFICACY; MUTATION; THERAPY; DAMAGE;
   ROS
AB As a nucleotide analogue (NA), telbivudine was widely used in the treatment for chronic hepatitis B (CHB) by interfering with reverse transcriptase of hepatitis B virus. However, the use of NAs for hepatitis B treatment has been accompanied by numerous reports highlighting the occurrence of neuromyopathy, particularly in the case of telbivudine. This study aimed to investigate the underlying mechanisms responsible for telbivudine-induced myopathy. We established animal and cell models of telbivudine-induced myopathy using C57BL/6 mice and C2C12 cells, respectively. Our findings revealed that telbivudine significantly reduced mitochondrial DNA (mtDNA) copy number and caused increase of oxidative stress. Telbivudine treatment significantly inhibited mitochondrial complex I and IV expression, impairing the oxidative phosphorylation function of the respiratory chain. Modified Gomori trichrome (MGT) staining of the muscle sections displayed an increase in ragged red fibers (RRFs), indicating abnormal mitochondrial accumulation. In conclusion, our study provides compelling evidence suggesting that telbivudine-induced myopathy is associated with mitochondrial toxicity and impaired energy metabolism. The observed muscle pathology, depletion of mtDNA, elevation of oxidative stress and altered mitochondrial function support the hypothesis that telbivudine disrupts mitochondrial homeostasis, ultimately leading to muscle damage. This may be also a common mechanism for NAs to cause neuromyopathy.
C1 [Yu, Wenfei; Wu, Wenjing; Zhao, Dandan; Yan, Chuanzhu; Lin, Pengfei] Shandong Univ, Dept Neurol, Qilu Hosp, Jinan 250012, Shandong, Peoples R China.
   [Yu, Wenfei] Univ Hlth & Rehabil Sci, 17, Shandong Rd, Qingdao, Shandong, Peoples R China.
   [Li, Zhuxun] Shandong Univ, Cheeloo Coll Med, Jinan 250012, Shandong, Peoples R China.
   [Lin, Pengfei] Shandong Univ, Dept Neurol, Qilu Hosp, 107 Wenhua West Rd, Jinan 250012, Shandong, Peoples R China.
C3 Shandong University; University of Health & Rehabilitation Sciences;
   Shandong University; Shandong University
RP Lin, PF (corresponding author), Shandong Univ, Dept Neurol, Qilu Hosp, 107 Wenhua West Rd, Jinan 250012, Shandong, Peoples R China.
EM lpfsdu@foxmail.com
RI zhao, dandan/AAP-3407-2021; wu, Wenjing/IAO-2302-2023
OI Lin, Pengfei/0000-0002-0861-5785
FU National Natural Science Foundation of China [82271436]; young Taishan
   Scholars Program of Shandong Province; National Key Ramp;D Program of
   China [2021YFC2700904]
FX <B>Acknowledgement</B> This work was supported by the National Natural
   Science Foundation of China (82271436) , the young Taishan Scholars
   Program of Shandong Province (no grant number) , and National Key R & D
   Program of China (No.2021YFC2700904) .
CR Ambang T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162760
   Bridges EG, 2008, ANTIMICROB AGENTS CH, V52, P2521, DOI 10.1128/AAC.00029-08
   Brody H, 2022, NATURE, V603, pS45, DOI 10.1038/d41586-022-00811-2
   Chen J, 2019, INT IMMUNOPHARMACOL, V74, DOI 10.1016/j.intimp.2019.105683
   Chen J, 2018, INT IMMUNOPHARMACOL, V55, P1, DOI 10.1016/j.intimp.2017.11.043
   Cronin-Furman EN, 2013, MOL NEURODEGENER, V8, DOI 10.1186/1750-1326-8-6
   DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602
   DIMAURO S, 1985, ANN NEUROL, V17, P521, DOI 10.1002/ana.410170602
   Finsterer J, 2010, VIROL J, V7, DOI 10.1186/1743-422X-7-323
   Fleischer RD, 2009, J HEPATOL, V51, P787, DOI 10.1016/j.jhep.2009.06.011
   Fontana RJ, 2009, HEPATOLOGY, V49, pS185, DOI 10.1002/hep.22885
   Fung S, 2022, HEPATOLOGY, V76, P233, DOI 10.1002/hep.32314
   Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226
   Guo CY, 2013, NEURAL REGEN RES, V8, P2003, DOI 10.3969/j.issn.1673-5374.2013.21.009
   Gureev AP, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00435
   Hernández-Laín A, 2015, J NEUROL SCI, V358, P481, DOI 10.1016/j.jns.2015.08.1550
   Hernandez-Santiago B, 2002, ANTIMICROB AGENTS CH, V46, P1728, DOI 10.1128/AAC.46.6.1728-1733.2002
   Izzedine H, 2005, AM J KIDNEY DIS, V45, P804, DOI 10.1053/j.ajkd.2005.02.010
   Kohler JJ, 2009, LAB INVEST, V89, P513, DOI 10.1038/labinvest.2009.14
   Kuroda Y, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67336-4
   Kuznetsov AV, 2008, NAT PROTOC, V3, P965, DOI 10.1038/nprot.2008.61
   Lan MY, 2023, J CLIN NEUROL, V19, P52, DOI 10.3988/jcn.2023.19.1.52
   Liaw YF, 2009, GASTROENTEROLOGY, V136, P486, DOI 10.1053/j.gastro.2008.10.026
   Liochev SI, 2013, FREE RADICAL BIO MED, V65, P232, DOI 10.1016/j.freeradbiomed.2013.06.027
   Long JF, 2017, BIOCHEM PHARMACOL, V146, P224, DOI 10.1016/j.bcp.2017.10.005
   Mak LY, 2019, DIGEST DIS SCI, V64, P3630, DOI 10.1007/s10620-019-05717-0
   Mak LY, 2016, EXPERT OPIN DRUG SAF, V15, P383, DOI 10.1517/14740338.2016.1139573
   MITA S, 1995, MUSCLE NERVE, pS113
   MIZUSAWA H, 1988, J NEUROL SCI, V86, P171, DOI 10.1016/0022-510X(88)90096-2
   Nash K, 2009, ADV THER, V26, P155, DOI 10.1007/s12325-009-0004-y
   Nolan D, 2004, ANTIVIR THER, V9, P849
   OLD SL, 1989, HISTOCHEM J, V21, P545, DOI 10.1007/BF01753355
   Papaconstantinou J, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111383
   Perazella MA, 2010, KIDNEY INT, V78, P1060, DOI 10.1038/ki.2010.344
   Pereira CV, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.201910674
   Schieber M, 2014, CURR BIOL, V24, pR453, DOI 10.1016/j.cub.2014.03.034
   Tanji N, 2001, HUM PATHOL, V32, P734, DOI 10.1053/hupa.2001.25586
   Thelen MP, 2020, ACTA NEUROPATHOL COM, V8, DOI 10.1186/s40478-020-01101-6
   Van Linthout S, 2018, ESC HEART FAIL, V5, P818, DOI 10.1002/ehf2.12341
   Xu HL, 2014, J CLIN PATHOL, V67, P999, DOI 10.1136/jclinpath-2013-202069
   Xu J, 2019, J MED VIROL, V91, P2153, DOI 10.1002/jmv.25566
   Zhang JJ, 2018, HUM MOL GENET, V27, P1999, DOI 10.1093/hmg/ddy107
   Zhang JJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05571-y
   Zorov DB, 2014, PHYSIOL REV, V94, P909, DOI 10.1152/physrev.00026.2013
   Zoulim F, 2006, J HEPATOL, V44, pS95, DOI 10.1016/j.jhep.2005.11.020
NR 45
TC 1
Z9 1
U1 0
U2 3
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0009-2797
EI 1872-7786
J9 CHEM-BIOL INTERACT
JI Chem.-Biol. Interact.
PD SEP 25
PY 2023
VL 383
AR 110692
DI 10.1016/j.cbi.2023.110692
EA SEP 2023
PG 11
WC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Toxicology
GA S3HO8
UT WOS:001070115400001
PM 37659625
DA 2024-11-01
ER

PT J
AU Jou, C
   Ortigoza-Escobar, JD
   Ocallaghan, MM
   Nascimento, A
   Darling, A
   Pias-Peleteiro, L
   Perez-Dueñas, B
   Pineda, M
   Codina, A
   Arjona, C
   Armstrong, J
   Palau, F
   Ribes, A
   Gort, L
   Tort, F
   Navas, P
   Ruiz-Pesini, E
   Emperador, S
   Lopez-Gallardo, E
   Bayona-Bafaluy, P
   Montero, R
   Jimenez-Mallebrera, C
   Garcia-Cazorla, A
   Montoya, J
   Yubero, D
   Artuch, R
AF Jou, Cristina
   Ortigoza-Escobar, Juan D.
   Ocallaghan, Maria M.
   Nascimento, Andres
   Darling, Alejandra
   Pias-Peleteiro, Leticia
   Perez-Duenas, Belen
   Pineda, Mercedes
   Codina, Anna
   Arjona, Cesar
   Armstrong, Judith
   Palau, Francesc
   Ribes, Antonia
   Gort, Laura
   Tort, Frederic
   Navas, Placido
   Ruiz-Pesini, Eduardo
   Emperador, Sonia
   Lopez-Gallardo, Ester
   Bayona-Bafaluy, Pilar
   Montero, Raquel
   Jimenez-Mallebrera, Cecilia
   Garcia-Cazorla, Angels
   Montoya, Julio
   Yubero, Delia
   Artuch, Rafael
TI Muscle Involvement in a Large Cohort of Pediatric Patients with Genetic
   Diagnosis of Mitochondrial Disease
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE mitochondrial diseases; myopathy; pediatric patients; biochemical
   markers; muscle histopathology; next generation sequencing
ID RESPIRATORY-CHAIN DISORDERS; DEFICIENCY; MUTATIONS; GENOME
AB Mitochondrial diseases (MD) are a group of genetic and acquired disorders which present significant diagnostic challenges. Here we report the disease characteristics of a large cohort of pediatric MD patients (n = 95) with a definitive genetic diagnosis, giving special emphasis on clinical muscle involvement, biochemical and histopathological features. Of the whole cohort, 51 patients harbored mutations in nuclear DNA (nDNA) genes and 44 patients had mutations in mitochondrial DNA (mtDNA) genes. The nDNA patients were more likely to have a reduction in muscle fiber succinate dehydrogenase (SDH) stains and in SDH-positive blood vessels, while a higher frequency of mtDNA patients had ragged red (RRF) and blue fibers. The presence of positive histopathological features was associated with ophthalmoplegia, myopathic facies, weakness and exercise intolerance. In 17 patients younger than two years of age, RRF and blue fibers were observed only in one case, six cases presented cytochrome c oxidase (COX) reduction/COX-fibers, SDH reduction was observed in five and all except one presented SDH-positive blood vessels. In conclusion, muscle involvement was a frequent finding in our series of MD patients, especially in those harboring mutations in mtDNA genes.
C1 [Jou, Cristina; Ortigoza-Escobar, Juan D.; Ocallaghan, Maria M.; Nascimento, Andres; Darling, Alejandra; Pias-Peleteiro, Leticia; Perez-Duenas, Belen; Pineda, Mercedes; Codina, Anna; Arjona, Cesar; Armstrong, Judith; Palau, Francesc; Montero, Raquel; Jimenez-Mallebrera, Cecilia; Garcia-Cazorla, Angels; Yubero, Delia; Artuch, Rafael] Inst Recerca St Joan de Deu, Clin Biochem Dept, Esplugues 08950, Spain.
   [Jou, Cristina; Ortigoza-Escobar, Juan D.; Ocallaghan, Maria M.; Nascimento, Andres; Darling, Alejandra; Pias-Peleteiro, Leticia; Perez-Duenas, Belen; Pineda, Mercedes; Codina, Anna; Arjona, Cesar; Armstrong, Judith; Palau, Francesc; Montero, Raquel; Jimenez-Mallebrera, Cecilia; Garcia-Cazorla, Angels; Yubero, Delia; Artuch, Rafael] Inst Recerca St Joan de Deu, Pathol Dept, Esplugues 08950, Spain.
   [Jou, Cristina; Ortigoza-Escobar, Juan D.; Ocallaghan, Maria M.; Nascimento, Andres; Darling, Alejandra; Pias-Peleteiro, Leticia; Perez-Duenas, Belen; Pineda, Mercedes; Codina, Anna; Arjona, Cesar; Armstrong, Judith; Palau, Francesc; Montero, Raquel; Jimenez-Mallebrera, Cecilia; Garcia-Cazorla, Angels; Yubero, Delia; Artuch, Rafael] Inst Recerca St Joan de Deu, Paediat Neurol Dept, Esplugues 08950, Spain.
   [Jou, Cristina; Ortigoza-Escobar, Juan D.; Ocallaghan, Maria M.; Nascimento, Andres; Darling, Alejandra; Pias-Peleteiro, Leticia; Perez-Duenas, Belen; Pineda, Mercedes; Codina, Anna; Arjona, Cesar; Armstrong, Judith; Palau, Francesc; Montero, Raquel; Jimenez-Mallebrera, Cecilia; Garcia-Cazorla, Angels; Yubero, Delia; Artuch, Rafael] Inst Recerca St Joan de Deu, Mol Med Dept, Esplugues 08950, Spain.
   [Jou, Cristina; Ortigoza-Escobar, Juan D.; Ocallaghan, Maria M.; Nascimento, Andres; Darling, Alejandra; Pias-Peleteiro, Leticia; Perez-Duenas, Belen; Pineda, Mercedes; Codina, Anna; Arjona, Cesar; Armstrong, Judith; Palau, Francesc; Montero, Raquel; Jimenez-Mallebrera, Cecilia; Garcia-Cazorla, Angels; Yubero, Delia; Artuch, Rafael] CIBERER ISCIII, Esplugues 08950, Spain.
   [Ribes, Antonia; Gort, Laura; Tort, Frederic] Hosp Clin Barcelona, IDIBAPS, CIBERER ISCIII, Seccio Errors Congenits Metab IBC,Serv Bioquim &, Barcelona 08028, Spain.
   [Navas, Placido] Univ Pablo de Olavide, Ctr Andaluz Biol Desarrollo, Seville 41013, Spain.
   [Navas, Placido] CIBERER ISCIII, Seville 41013, Spain.
   [Ruiz-Pesini, Eduardo; Emperador, Sonia; Lopez-Gallardo, Ester; Bayona-Bafaluy, Pilar; Montoya, Julio] Univ Zaragoza, Dept Bioquim Biol Mol & Celular, Inst Invest Sanitaria Aragon, E-50013 Zaragoza, Spain.
   [Ruiz-Pesini, Eduardo; Emperador, Sonia; Lopez-Gallardo, Ester; Bayona-Bafaluy, Pilar; Montoya, Julio] Univ Zaragoza, CIBERER ISCIII, E-50013 Zaragoza, Spain.
C3 CIBER - Centro de Investigacion Biomedica en Red; CIBERER; University of
   Barcelona; Hospital Clinic de Barcelona; IDIBAPS; CIBER - Centro de
   Investigacion Biomedica en Red; CIBERER; Consejo Superior de
   Investigaciones Cientificas (CSIC); Universidad Pablo de Olavide; CSIC -
   Andalusian Center for Developmental Biology (CABD); CIBER - Centro de
   Investigacion Biomedica en Red; CIBERER; University of Zaragoza; CIBER -
   Centro de Investigacion Biomedica en Red; CIBERER; University of
   Zaragoza
RP Yubero, D (corresponding author), Inst Recerca St Joan de Deu, Clin Biochem Dept, Esplugues 08950, Spain.; Yubero, D (corresponding author), Inst Recerca St Joan de Deu, Pathol Dept, Esplugues 08950, Spain.; Yubero, D (corresponding author), Inst Recerca St Joan de Deu, Paediat Neurol Dept, Esplugues 08950, Spain.; Yubero, D (corresponding author), Inst Recerca St Joan de Deu, Mol Med Dept, Esplugues 08950, Spain.; Yubero, D (corresponding author), CIBERER ISCIII, Esplugues 08950, Spain.
EM cjou@sjdhospitalbarcelona.org; jortigoza@sjdhospitalbarcelona.org;
   mocallaghan@sjdhospitalbarcelona.org;
   anascimento@sjdhospitalbarcelona.org; adarling@sjdhospitalbarcelona.org;
   lpias@sjdhospitalbarcelona.org; belen.perez@vhir.org;
   pineda@sjdhospitalbarcelona.org; acodina@fsjd.org; carjona@fsjd.org;
   jarmstrong@sjdhospitalbarcelona.org; fpalau@sjdhospitalbarcelona.org;
   ARIBES@clinic.cat; LGORT@clinic.cat; FTORT@ciberer.es; pnavas@upo.es;
   eduruiz@unizar.es; seortiz@unizar.es; esterlop@unizar.es;
   pbayona@unizar.es; rmontero@sjdhospitalbarcelona.org;
   cjimenezm@fsjd.org; agarcia@sjdhospitalbarcelona.org;
   jmontoya@unizar.es; dyubero@sjdhospitalbarcelona.org;
   rartuch@sjdhospitalbarcelona.org
RI Ortigoza-Escobar, Juan/AAP-8165-2021; Armstrong, Judith/JSA-1522-2023;
   Perez-Duenas, Belen/AAG-9054-2019; NAVAS, PLACIDO/R-5943-2019; Palau,
   Francesc/A-9391-2014; Jimenez-Mallebrera, Cecilia/F-5030-2016
OI Lopez Gallardo, Ester/0000-0002-3217-1424; Gort Mas,
   Laura/0000-0003-4746-1034; Artuch, Rafael/0000-0002-3422-9685; Tort
   Escale, Frederic/0000-0003-2733-1603; Ortigoza Escobar, Juan
   Dario/0000-0002-6320-2641; Ribes Rubio, Antonia/0000-0002-2249-246X;
   Palau, Francesc/0000-0002-8635-5421; Jimenez-Mallebrera,
   Cecilia/0000-0001-8203-7103
FU Instituto de Salud Carlos III [ISCIII-FIS PI17/00109, PI17/00021,
   PI17/01286, PI15/01082, PI16/01048]; Fundacion Mutua Madrilena
   [MMA17/01]; AEPMI; FEDER Funding Program from the European Union;
   Agencia de Gestio d'Ajuts Universitaris i de Recerca (AGAUR) [2014: SGR
   393]; CERCA Programme/Generalitat de Catalunya; CIBERER-ISCIII
FX This work was supported by grants from the Instituto de Salud Carlos III
   (ISCIII-FIS PI17/00109*, PI17/00021*, PI17/01286, PI15/01082 and
   PI16/01048), Fundacion Mutua Madrilena MMA17/01, AEPMI, the FEDER
   Funding Program from the European Union, the Agencia de Gestio d'Ajuts
   Universitaris i de Recerca (AGAUR) (2014: SGR 393), the CERCA
   Programme/Generalitat de Catalunya and CIBERER-ISCIII. *These grants
   have funds to cover publication costs. The Department of Clinical
   Biochemistry and Molecular Medicine is part of the CIBERER-ISCIII and
   'Centre Daniel Bravo de Diagnostic i Recerca en Malalties Minoritaries.
CR Abicht A, 2018, MOL GENET GENOM MED, V6, P1188, DOI 10.1002/mgg3.500
   Alston CL, 2017, J PATHOL, V241, P236, DOI 10.1002/path.4809
   Asencio C, 2016, EUR J HUM GENET, V24, P367, DOI 10.1038/ejhg.2015.112
   Batllori M, 2018, J INHERIT METAB DIS, V41, P1147, DOI 10.1007/s10545-018-0224-x
   Brito S, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00102
   Calvo SE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003310
   Couser N, 2017, CLIN ASPECTS LAB DET, V2, P167, DOI 10.1016/B978-0-12-802896-4.00008-0
   Cruz S, 2017, MUSCLE NERVE, V56, P868, DOI 10.1002/mus.25593
   DaRe JT, 2013, BMC MED GENET, V14, DOI 10.1186/1471-2350-14-118
   Ortigoza-Escobar JD, 2016, EXPERT REV NEUROTHER, V16, P755, DOI 10.1080/14737175.2016.1187562
   Ortigoza-Escobar JD, 2016, MITOCHONDRION, V28, P73, DOI 10.1016/j.mito.2016.04.001
   Díez H, 2017, MOVEMENT DISORD, V32, P1108, DOI 10.1002/mds.27021
   Ferrer-Cortès X, 2013, J INHERIT METAB DIS, V36, P841, DOI 10.1007/s10545-012-9565-z
   Frazier AE, 2019, J BIOL CHEM, V294, P5386, DOI 10.1074/jbc.R117.809194
   Goldstein AC, 2013, NEUROTHERAPEUTICS, V10, P212, DOI 10.1007/s13311-013-0185-6
   Kalko SG, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-91
   Legati A, 2016, BBA-BIOENERGETICS, V1857, P1326, DOI 10.1016/j.bbabio.2016.02.022
   Lightowlers RN, 2015, SCIENCE, V349, P1494, DOI 10.1126/science.aac7516
   Menezes MJ, 2014, BBA-GEN SUBJECTS, V1840, P1368, DOI 10.1016/j.bbagen.2013.12.025
   Montero R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148709
   Morava E, 2006, NEUROLOGY, V67, P1823, DOI 10.1212/01.wnl.0000244435.27645.54
   Navarro-Sastre A, 2012, MOL GENET METAB, V107, P409, DOI 10.1016/j.ymgme.2012.08.018
   O'Callaghan MM, 2015, MITOCHONDRION, V22, P17, DOI 10.1016/j.mito.2015.03.001
   Ohtake A, 2014, BBA-GEN SUBJECTS, V1840, P1355, DOI 10.1016/j.bbagen.2014.01.025
   Palculict ME, 2016, METHODS MOL BIOL, V1351, P3, DOI 10.1007/978-1-4939-3040-1_1
   Phadke R, 2017, J CLIN MED, V6, DOI 10.3390/jcm6070064
   Plutino M, 2018, BMC MED GENET, V19, DOI 10.1186/s12881-018-0568-y
   Pronicka E, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0930-9
   Rocha MC, 2015, SCI REP-UK, V5, DOI 10.1038/srep15037
   Serrano M, 2010, MITOCHONDRION, V10, P429, DOI 10.1016/j.mito.2010.04.001
   Suomalainen A, 2011, LANCET NEUROL, V10, P806, DOI 10.1016/S1474-4422(11)70155-7
   Tang S, 2013, HUM MUTAT, V34, P882, DOI 10.1002/humu.22307
   Taylor RW, 2014, JAMA-J AM MED ASSOC, V312, P68, DOI 10.1001/jama.2014.7184
   Thompson K, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201809060
   Tulinius M, 2011, SEMIN FETAL NEONAT M, V16, P229, DOI 10.1016/j.siny.2011.04.001
   Vasta V, 2012, PEDIATR INT, V54, P585, DOI 10.1111/j.1442-200X.2012.03644.x
   Witters P, 2018, GENET MED, V20, P444, DOI 10.1038/gim.2017.125
   Wortmann SB, 2015, J INHERIT METAB DIS, V38, P437, DOI 10.1007/s10545-015-9823-y
   Yubero D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0156359
NR 39
TC 13
Z9 13
U1 0
U2 8
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD JAN
PY 2019
VL 8
IS 1
AR 68
DI 10.3390/jcm8010068
PG 12
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA HJ4JU
UT WOS:000457141100067
PM 30634555
OA Green Published, Green Submitted, gold
DA 2024-11-01
ER

PT J
AU Goto, M
   Komaki, H
   Saito, T
   Saito, Y
   Nakagawa, E
   Sugai, K
   Sasaki, M
   Nishino, I
   Goto, Y
AF Goto, Masahide
   Komaki, Hirofumi
   Saito, Takashi
   Saito, Yoshiaki
   Nakagawa, Eiji
   Sugai, Kenji
   Sasaki, Masayuki
   Nishino, Ichizo
   Goto, Yu-ichi
TI MELAS phenotype associated with m.3302A&gt;G mutation in mitochondrial
   tRNA<SUP>Leu(UUR)</SUP> gene
SO BRAIN & DEVELOPMENT
LA English
DT Article
DE MELAS; Myopathy; m.3302A > G mutation
ID A3302G MUTATION; DNA; DISEASE
AB The m.3302A > G mutation in the mitochondrial tRNA(Leu(UUR)) gene has been identified in only 12 patients from 6 families, all manifesting adult-onset slowly progressive myopathy with minor central nervous system involvement. An 11-year-old boy presented with progressive proximal-dominant muscle weakness from age 7 years. At age 10, he developed recurrent stroke-like episodes. Mitochondrial myopathy, encephalopathy, lactic acidosis, plus stroke-like episodes (MELAS) was diagnosed by clinical symptoms and muscle biopsy findings. Mitochondrial gene analysis revealed a heteroplasmic m.3302A > G mutation. Histological examination showed strongly SDH reactive blood vessels (SSVs), not present in previous cases with myopathies due to the m.3302A > G mutation. These findings broaden the phenotypic spectrum of this mutation. (C) 2013 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights reserved.
C1 [Goto, Masahide; Komaki, Hirofumi; Saito, Takashi; Saito, Yoshiaki; Nakagawa, Eiji; Sugai, Kenji; Sasaki, Masayuki] Natl Ctr Neurol & Psychiat, Natl Ctr Hosp, Dept Child Neurol, Tokyo, Japan.
   [Nishino, Ichizo] Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Neuromuscular Res, Tokyo, Japan.
   [Goto, Yu-ichi] Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Mental Retardat & Birth Defect Res, Tokyo, Japan.
C3 National Center for Neurology & Psychiatry - Japan; National Center for
   Neurology & Psychiatry - Japan; National Center for Neurology &
   Psychiatry - Japan
RP Komaki, H (corresponding author), NCNP, Dept Child Neurol, Natl Ctr Hosp, 4-1-1 Ogawahigashi Cho, Kodaira, Tokyo 1878551, Japan.
EM komakih@ncnp.go.jp
RI ; Nishino, Ichizo/G-2676-2010
OI Saito, Yoshiaki/0000-0001-5893-3565; Nishino, Ichizo/0000-0001-9452-112X
FU Ministry of Health, Labour and Welfare of Japan [21A-6]
FX This work was partly supported by Research Grant (21A-6) for Nervous and
   Mental Disorders (YG and EN) and Grants-in-Aid for Research on
   Intractable Diseases (Mitochondrial Disease) (YG and HK) from the
   Ministry of Health, Labour and Welfare of Japan. We thank Dr. Yutaka
   Nonoda, and Dr. Hideyuki Hatakeyama, Dr. Chika Sakai, Ms. Mayuko Kato
   and Ms. Yoshie Sawano for technical assistance.
CR Akanuma J, 2000, J HUM GENET, V45, P337, DOI 10.1007/s100380070004
   BALLHAUSEN D, J INHERIT M IN PRESS, DOI DOI 10.1007/S10545-010-9098-2
   Betts J, 2006, NEUROPATH APPL NEURO, V32, P359, DOI 10.1111/j.1365-2990.2006.00731.x
   BINDOFF LA, 1993, J BIOL CHEM, V268, P19559
   GOTO Y, 1995, MUSCLE NERVE, pS107
   HASEGAWA H, 1991, ANN NEUROL, V29, P601, DOI 10.1002/ana.410290606
   Hutchison WM, 2005, ARCH NEUROL-CHICAGO, V62, P1920, DOI 10.1001/archneur.62.12.1920
   Schaefer AM, 2008, ANN NEUROL, V63, P35, DOI 10.1002/ana.21217
   TROUNCE LA, 1996, METHOD ENZYMOL, V264, P484
   van den Bosch BJC, 2004, NEUROMUSCULAR DISORD, V14, P683, DOI 10.1016/j.nmd.2004.06.004
NR 10
TC 10
Z9 11
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0387-7604
EI 1872-7131
J9 BRAIN DEV-JPN
JI Brain Dev.
PD FEB
PY 2014
VL 36
IS 2
BP 180
EP 182
DI 10.1016/j.braindev.2013.03.001
PG 3
WC Clinical Neurology; Pediatrics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pediatrics
GA 295YD
UT WOS:000330151400016
PM 23582502
DA 2024-11-01
ER

PT J
AU Massie, R
   Wang, J
   Chen, LC
   Zhang, VW
   Collins, MP
   Wong, LJC
   Milone, M
AF Massie, Rami
   Wang, Jing
   Chen, Li-Chieh
   Zhang, Victor W.
   Collins, Michael P.
   Wong, Lee-Jun C.
   Milone, Margherita
TI Mitochondrial myopathy due to novel missense mutation in the
   <i>cytochrome</i> <i>c oxidase 1</i> gene
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE Mitochondrial myopathy; Muscle inflammation; Cytochrome c oxidase; COX;
   MTCO1
ID OXIDASE SUBUNIT-II; C-OXIDASE; NONSENSE MUTATION; LACTIC-ACIDOSIS; HUMAN
   MTDNA; RECURRENT MYOGLOBINURIA; DNA; DEFICIENCY; ENCEPHALOMYOPATHY;
   PATIENT
AB We report a novel heteroplasmic mutation p.Y440C in the mitochondrial DNA-encoded subunit! of the cytochrome c oxidase (COX) gene in a patient with late onset progressive painless weakness. Her muscle biopsy showed scattered COX-negative fibers and several small collections of inflammatory cells. The mutation was detected in the patient's muscle but not in her blood. The low mutant load in muscle could explain the patient's late onset of the myopathy and milder phenotype when compared to the previously published cases with MTCO1 mutations. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Wang, Jing; Chen, Li-Chieh; Zhang, Victor W.; Wong, Lee-Jun C.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
   [Massie, Rami; Milone, Margherita] Mayo Clin, Dept Neurol, Rochester, MN 55905 USA.
   [Collins, Michael P.] Med Coll Wisconsin, Dept Neurol, Milwaukee, WI 53226 USA.
C3 Baylor College of Medicine; Mayo Clinic; Medical College of Wisconsin
RP Wong, LJC (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza,NAB 2015, Houston, TX 77030 USA.
EM ljwong@bcm.edu
FU Mayo Clinic CTSA through NIH/NCRR [UL1 RR024150]
FX This publication was made possible by the Mayo Clinic CTSA through grant
   number UL1 RR024150 from NIH/NCRR.
CR Abu-Amero Khaled K, 2005, Ophthalmic Genet, V26, P31, DOI 10.1080/13816810590918235
   Bai RK, 2004, CLIN CHEM, V50, P996, DOI 10.1373/clinchem.2004.031153
   Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   Brautbar A, 2008, MOL GENET METAB, V94, P485, DOI 10.1016/j.ymgme.2008.04.004
   Bruno C, 1999, AM J HUM GENET, V65, P611, DOI 10.1086/302546
   Brzezinski P, 2008, J BIOENERG BIOMEMBR, V40, P521, DOI 10.1007/s10863-008-9181-7
   Campos Y, 2001, ANN NEUROL, V50, P409, DOI 10.1002/ana.1141
   Clark KM, 1999, AM J HUM GENET, V64, P1330, DOI 10.1086/302361
   Comi GP, 1998, ANN NEUROL, V43, P110, DOI 10.1002/ana.410430119
   DeLano WL, 2002, CURR OPIN STRUC BIOL, V12, P14, DOI 10.1016/S0959-440X(02)00283-X
   DEMARCHI JM, 1994, HUM MUTAT, V4, P281, DOI 10.1002/humu.1380040409
   FITZSIMONS RB, 1994, LANCET, V344, P902, DOI 10.1016/S0140-6736(94)92263-2
   Hanna MG, 1998, AM J HUM GENET, V63, P29, DOI 10.1086/301910
   Herrero-Martin Maria D, 2008, Hum Mutat, V29, pE112, DOI 10.1002/humu.20800
   Horváth R, 2005, NEUROMUSCULAR DISORD, V15, P851, DOI 10.1016/j.nmd.2005.09.005
   Horváth R, 2002, J MED GENET, V39, P812, DOI 10.1136/jmg.39.11.812
   Karadimas CL, 2000, NEUROLOGY, V55, P644, DOI 10.1212/WNL.55.5.644
   Keightley JA, 1996, NAT GENET, V12, P410, DOI 10.1038/ng0496-410
   Kollberg G, 2005, J NEUROPATH EXP NEUR, V64, P123, DOI 10.1093/jnen/64.2.123
   Lucioli S, 2006, NEUROGENETICS, V7, P51, DOI 10.1007/s10048-005-0015-z
   MANFREDI G, 1995, NEUROMUSCULAR DISORD, V5, P391, DOI 10.1016/0960-8966(94)00079-O
   McFarland R, 2004, NEUROMUSCULAR DISORD, V14, P162, DOI 10.1016/j.nmd.2003.10.011
   Rahman S, 1999, AM J HUM GENET, V65, P1030, DOI 10.1086/302590
   Rossmanith W, 2008, J MED GENET, V45, P117, DOI 10.1136/jmg.2007.052076
   Shanske S, 2004, MITOCHONDRION, V4, P403, DOI 10.1016/j.mito.2004.07.026
   Tam EWY, 2008, NEUROPEDIATRICS, V39, P328, DOI 10.1055/s-0029-1202287
   Temiz P, 2009, J NEUROL SCI, V278, P25, DOI 10.1016/j.jns.2008.11.010
   Tiranti V, 2000, HUM MOL GENET, V9, P2733, DOI 10.1093/hmg/9.18.2733
   Tsukihara T, 1996, SCIENCE, V272, P1136, DOI 10.1126/science.272.5265.1136
   Tsukihara T, 2003, P NATL ACAD SCI USA, V100, P15304, DOI 10.1073/pnas.2635097100
   Valente L, 2009, BBA-BIOENERGETICS, V1787, P491, DOI 10.1016/j.bbabio.2008.10.001
   Varlamov DA, 2002, HUM MOL GENET, V11, P1797, DOI 10.1093/hmg/11.16.1797
   Wang J, 2009, MOL GENET METAB, V96, P59, DOI 10.1016/j.ymgme.2008.10.006
   Wong LJC, 2007, MUSCLE NERVE, V36, P279, DOI 10.1002/mus.20807
   Wong LJC, 2005, CLIN CHIM ACTA, V354, P1, DOI 10.1016/j.cccn.2004.11.003
   Wong LJC, 2001, AM J MED GENET, V102, P95, DOI 10.1002/1096-8628(20010722)102:1<95::AID-AJMG1412>3.0.CO;2-U
NR 36
TC 6
Z9 7
U1 0
U2 9
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD AUG 15
PY 2012
VL 319
IS 1-2
BP 158
EP 163
DI 10.1016/j.jns.2012.05.003
PG 6
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 971ZS
UT WOS:000306246900032
PM 22632780
DA 2024-11-01
ER

PT J
AU Chinnery, PF
AF Chinnery, PF
TI New approaches to the treatment of mitochondrial disorders
SO REPRODUCTIVE BIOMEDICINE ONLINE
LA English
DT Article
DE gene therapy; mitochondrial disease; mitochondrial encephalomyopathy;
   mtDNA
ID C-OXIDASE DEFICIENCY; DILATED CARDIOMYOPATHY; CLINICAL-FEATURES; DNA
   REPLICATION; GENE-THERAPY; MUTATIONS; DISEASE; SCO2; MICE;
   ENCEPHALOMYOPATHIES
AB Mitochondrial disorders are among the most common inherited metabolic diseases and the issue of treatment arises on a regular basis. There is no established treatment for mitochondrial disorders and current management is largely supportive, but recent advances in our understanding of the pathophysiology provide hope for novel treatments. Patients with mitochondrial myopathy due to mutations of mitochondrial DNA (mtDNA) may benefit from treatments that move normal mitochondrial genomes from the muscle satellite cells into skeletal muscle, but there are concerns about the long-term effects of this approach. A greater understanding of the pathophysiology of a number of nuclear genetic mitochondrial disorders suggests new avenues for treatment (such as copper-histidine in children with SCO2 gene mutations, and strategies modifying intra-mitochondrial nucleoside pools in the various disorders of mtDNA maintenance). A number of different strategies are also being explored at the molecular level, including the use of antigenomic molecules to mutated mtDNA and the allotropic expression of mutated mtDNA genes within the cell nucleus. Nuclear transfer techniques also provide hope for women at risk of transmitting pathogenic mtDNA mutations.
C1 Newcastle Univ, Sch Med, Dept Neurol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
C3 Newcastle University - UK
RP Newcastle Univ, Sch Med, Dept Neurol, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM P.F.Chinnery@ncl.ac.uk
OI Chinnery, Patrick/0000-0002-7065-6617
CR Agostino A, 2003, HUM MOL GENET, V12, P399, DOI 10.1093/hmg/ddg038
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   Chinnery PF, 2002, MITOCHONDRION, V2, P149, DOI 10.1016/S1567-7249(02)00046-6
   Chinnery PF, 2001, AM J MED GENET, V106, P94, DOI 10.1002/ajmg.1426
   Chinnery PF, 1997, J NEUROL NEUROSUR PS, V63, P559, DOI 10.1136/jnnp.63.5.559
   Chinnery PF, 1999, GENE THER, V6, P1919, DOI 10.1038/sj.gt.3301061
   CHINNERY PF, 2003, IN PRESS NEUROMUSCUL
   Christodoulou J, 1998, AM J MED GENET, V76, P154, DOI 10.1002/(SICI)1096-8628(19980305)76:2<154::AID-AJMG9>3.3.CO;2-C
   Clark KM, 1997, NAT GENET, V16, P222, DOI 10.1038/ng0797-222
   Darin N, 2001, ANN NEUROL, V49, P377, DOI 10.1002/ana.75
   DiMauro S, 2000, NEUROL SCI, V21, pS901
   Eichenlaub-Ritter U, 2004, REPROD BIOMED ONLINE, V8, P45, DOI 10.1016/S1472-6483(10)60497-X
   Fu K, 1996, HUM MOL GENET, V5, P1835, DOI 10.1093/hmg/5.11.1835
   Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226
   Guy J, 2002, ANN NEUROL, V52, P534, DOI 10.1002/ana.10354
   Haraguchi M, 2002, MOL CELL BIOL, V22, P5212, DOI 10.1128/MCB.22.14.5212-5221.2002
   Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826
   Jaksch M, 2001, HUM MOL GENET, V10, P3025, DOI 10.1093/hmg/10.26.3025
   Jenuth JP, 1996, NAT GENET, V14, P146, DOI 10.1038/ng1096-146
   Johnson KR, 2001, NAT GENET, V27, P191, DOI 10.1038/84831
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kolesnikova OA, 2000, SCIENCE, V289, P1931, DOI 10.1126/science.289.5486.1931
   Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231
   Larsson NG, 2001, TRENDS MOL MED, V7, P578, DOI 10.1016/S1471-4914(01)02167-0
   LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Manfredi G, 2002, NAT GENET, V30, P394, DOI 10.1038/ng851
   Muratovska A, 2001, NUCLEIC ACIDS RES, V29, P1852, DOI 10.1093/nar/29.9.1852
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Ojaimi J, 2002, MOL BIOL CELL, V13, P3836, DOI 10.1091/mbc.E02-05-0306
   Papadopoulou LC, 1999, NAT GENET, V23, P333
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Salviati L, 2002, BIOCHEM J, V363, P321, DOI 10.1042/0264-6021:3630321
   Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755
   SEIBEL P, 1995, NUCLEIC ACIDS RES, V23, P10, DOI 10.1093/nar/23.1.10
   Silva JP, 2000, NAT GENET, V26, P336, DOI 10.1038/81649
   Sligh JE, 2000, P NATL ACAD SCI USA, V97, P14461, DOI 10.1073/pnas.250491597
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   St John JC, 2004, REPROD BIOMED ONLINE, V8, P34, DOI 10.1016/S1472-6483(10)60496-8
   SUTHERLAND L, 1994, BIOCHEM SOC T, V22, pS413, DOI 10.1042/bst022413s
   Sutovsky P, 2004, REPROD BIOMED ONLINE, V8, P24, DOI 10.1016/S1472-6483(10)60495-6
   Taivassalo T, 1999, HUM MOL GENET, V8, P1047, DOI 10.1093/hmg/8.6.1047
   Taivassalo T, 2001, ANN NEUROL, V50, P133, DOI 10.1002/ana.1050
   Taivassalo T, 1997, NEUROLOGY, V48, P28003
   Tanaka M, 2002, J BIOMED SCI, V9, P534, DOI 10.1007/BF02254980
   Taylor R W, 2000, Hum Reprod, V15 Suppl 2, P79
   Taylor RW, 1997, NAT GENET, V15, P212, DOI 10.1038/ng0297-212
   Thorburn DR, 2001, AM J MED GENET, V106, P102, DOI 10.1002/ajmg.1380
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Wang JM, 1999, NAT GENET, V21, P133, DOI 10.1038/5089
NR 50
TC 12
Z9 14
U1 0
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1472-6483
EI 1472-6491
J9 REPROD BIOMED ONLINE
JI Reprod. Biomed. Online
PD JAN
PY 2004
VL 8
IS 1
BP 16
EP 23
DI 10.1016/S1472-6483(10)60494-4
PG 8
WC Obstetrics & Gynecology; Reproductive Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Obstetrics & Gynecology; Reproductive Biology
GA 879JN
UT WOS:000225714200003
PM 14759282
OA Bronze
DA 2024-11-01
ER

PT J
AU Riley, LG
   Menezes, MJ
   Rudinger-Thirion, J
   Duff, R
   de Lonlay, P
   Rotig, A
   Tchan, MC
   Davis, M
   Cooper, ST
   Christodoulou, J
AF Riley, Lisa G.
   Menezes, Minal J.
   Rudinger-Thirion, Joelle
   Duff, Rachael
   de Lonlay, Pascale
   Rotig, Agnes
   Tchan, Michel C.
   Davis, Mark
   Cooper, Sandra T.
   Christodoulou, John
TI Phenotypic variability and identification of novel <i>YARS2</i>
   mutations in YARS2 mitochondrial myopathy, lactic acidosis and
   sideroblastic anaemia
SO ORPHANET JOURNAL OF RARE DISEASES
LA English
DT Article
DE Mitochondrial respiratory chain; Myopathy with lactic acidosis and
   sideroblastic anemia; Aminoacyl tRNA-synthetase; Mitochondrial
   myopathies; Muscle diseases; Lactic acidaemia; Inborn error of
   metabolism; Mutation
ID TRANSFER-RNA-SYNTHETASE; RESPIRATORY-CHAIN DISORDERS; PERRAULT SYNDROME;
   DNA HAPLOGROUPS; HEARING-LOSS; TRANSCRIPTION; CARDIOMYOPATHY;
   DEFICIENCIES; INITIATION; DISEASES
AB Background: Mutations in the mitochondrial tyrosyl-tRNA synthetase (YARS2) gene have previously been identified as a cause of the tissue specific mitochondrial respiratory chain (RC) disorder, Myopathy, Lactic Acidosis, Sideroblastic Anaemia (MLASA). In this study, a cohort of patients with a mitochondrial RC disorder for who anaemia was a feature, were screened for mutations in YARS2.
   Methods: Twelve patients were screened for YARS2 mutations by Sanger sequencing. Clinical data were compared. Functional assays were performed to confirm the pathogenicity of the novel mutations and to investigate tissue specific effects.
   Results: PathogenicYARS2 mutations were identified in three of twelve patients screened. Two patients were found to be homozygous for the previously reported p.Phe52Leu mutation, one severely and one mildly affected. These patients had different mtDNA haplogroups which may contribute to the observed phenotypic variability. A mildly affected patient was a compound heterozygote for two novel YARS2 mutations, p.Gly191Asp and p.Arg360X. The p.Gly191Asp mutation resulted in a 38-fold loss in YARS2 catalytic efficiency and the p.Arg360X mutation did not produce a stable protein. The p.Phe52Leu and p.Gly191Asp/p.Arg360X mutations resulted in more severe RC deficiency of complexes I, III and IV in muscle cells compared to fibroblasts, but had relatively normal YARS2 protein levels. The muscle-specific RC deficiency can be related to the increased requirement for RC complexes in muscle. There was also a failure of mtDNA proliferation upon myogenesis in patient cells which may compound the RC defect. Patient muscle had increased levels of PGC1-alpha and TFAM suggesting mitochondrial biogenesis was activated as a potential compensatory mechanism.
   Conclusion: In this study we have identified novel YARS2 mutations and noted marked phenotypic variability among YARS2 MLASA patients, with phenotypes ranging from mild to lethal, and we suggest that the background mtDNA haplotype may be contributing to the phenotypic variability. These findings have implications for diagnosis and prognostication of the MLASA and related phenotypes.
C1 [Riley, Lisa G.; Menezes, Minal J.; Christodoulou, John] Childrens Hosp Westmead, Kids Res Inst, Genet Metab Disorders Res Unit, Sydney, NSW 2145, Australia.
   [Riley, Lisa G.; Menezes, Minal J.; Cooper, Sandra T.; Christodoulou, John] Univ Sydney, Discipline Paediat & Child Hlth, Sydney, NSW 2006, Australia.
   [Tchan, Michel C.; Christodoulou, John] Univ Sydney, Discipline Genet Med, Sydney Med Sch, Sydney, NSW 2006, Australia.
   [Rudinger-Thirion, Joelle] Univ Strasbourg, CNRS, IBMC, Architecture & React ARN, F-67084 Strasbourg, France.
   [Duff, Rachael] Univ Western Australia, Med Res Ctr, Perth, WA 6009, Australia.
   [Duff, Rachael] Western Australian Inst Med Res, Perth, WA 6009, Australia.
   [de Lonlay, Pascale; Rotig, Agnes] Univ Paris 05, F-75015 Paris, France.
   [de Lonlay, Pascale; Rotig, Agnes] Hop Necker Enfants Malad, INSERM U781, F-75015 Paris, France.
   [Tchan, Michel C.] Westmead Hosp, Dept Med Genet, Sydney, NSW, Australia.
   [Davis, Mark] QEII Med Ctr, PathWest Lab Med, Nedlands, WA 6009, Australia.
   [Cooper, Sandra T.] Childrens Hosp Westmead, Kids Res Inst, Inst Neurosci & Muscle Res, Sydney, NSW 2145, Australia.
   [Christodoulou, John] Childrens Hosp Westmead, Western Sydney Genet Program, Westmead, NSW 2145, Australia.
C3 NSW Health; The Children's Hospital at Westmead; University of Sydney;
   University of Sydney; University of Sydney; Centre National de la
   Recherche Scientifique (CNRS); Universites de Strasbourg Etablissements
   Associes; Universite de Strasbourg; University of Western Australia;
   University of Western Australia; Universite Paris Cite; Assistance
   Publique Hopitaux Paris (APHP); Universite Paris Cite; Hopital
   Universitaire Necker-Enfants Malades - APHP; Institut National de la
   Sante et de la Recherche Medicale (Inserm); University of Sydney; NSW
   Health; Westmead Hospital; Pathwest Laboratory Medicine; University of
   Western Australia; Queen Elizabeth II Medical Centre; University of
   Sydney; NSW Health; The Children's Hospital at Westmead; NSW Health;
   Sydney Childrens Hospitals Network; The Children's Hospital at Westmead;
   University of Sydney
RP Christodoulou, J (corresponding author), Childrens Hosp Westmead, Kids Res Inst, Genet Metab Disorders Res Unit, Sydney, NSW 2145, Australia.
EM john.christodoulou@health.nsw.gov.au
RI Davis, Mark/KDM-7073-2024; Christodoulou, John/E-5866-2015;
   Christodoulou, John/M-3628-2019; ROTIG, AGNES/G-9592-2017
OI Christodoulou, John/0000-0002-8431-0641; Cooper,
   Sandra/0000-0002-7314-5097; ROTIG, AGNES/0000-0003-0589-0703
FU March of Dimes Research Grant; National Health and Medical Research
   Council of Australia [1026891]; AMDF; Crane family; Perkins family
FX We thank Liz Barnes for advice on statistical analyses. This research
   was supported by a March of Dimes Research Grant, and National Health
   and Medical Research Council of Australia Project Grant 1026891. M.M. is
   an Australian Mitochondrial Diseases Foundation (AMDF) Postgraduate
   Research Scholar, and the AMDF also provided financial support to RD and
   MD. We are grateful to the Crane and Perkins families for their generous
   financial support.
CR Amiott EA, 2006, MOL CELL, V22, P329, DOI 10.1016/j.molcel.2006.03.031
   Antonellis A, 2008, ANNU REV GENOM HUM G, V9, P87, DOI 10.1146/annurev.genom.9.081307.164204
   Antonicka H, 2006, HUM MOL GENET, V15, P1835, DOI 10.1093/hmg/ddl106
   Bai RK, 2005, J MOL DIAGN, V7, P613, DOI 10.1016/S1525-1578(10)60595-8
   Bayat V, 2012, PLOS BIOL, V10, P1
   Belostotsky R, 2011, AM J HUM GENET, V88, P193, DOI 10.1016/j.ajhg.2010.12.010
   Bonawitz ND, 2006, MOL CELL, V24, P813, DOI 10.1016/j.molcel.2006.11.024
   Bonnefond L, 2005, BIOCHEMISTRY-US, V44, P4805, DOI 10.1021/bi047527z
   Bonnefond L, 2007, STRUCTURE, V15, P1505, DOI 10.1016/j.str.2007.09.018
   Campbell CT, 2012, BBA-GENE REGUL MECH, V1819, P921, DOI 10.1016/j.bbagrm.2012.03.002
   Castro MG, 2007, MITOCHONDRION, V7, P354, DOI 10.1016/j.mito.2007.06.002
   Castro MG, 2006, INT J CARDIOL, V112, P202, DOI 10.1016/j.ijcard.2005.09.008
   Cooper ST, 2007, NEUROMUSCULAR DISORD, V17, P276, DOI 10.1016/j.nmd.2006.12.010
   Edvardson S, 2007, AM J HUM GENET, V81, P857, DOI 10.1086/521227
   Elo JM, 2012, HUM MOL GENET, V21, P4521, DOI 10.1093/hmg/dds294
   Fernández-Vizarra E, 2011, MITOCHONDRION, V11, P207, DOI 10.1016/j.mito.2010.09.011
   Gómez-Durán A, 2012, BBA-MOL BASIS DIS, V1822, P1216, DOI 10.1016/j.bbadis.2012.04.014
   Gómez-Durán A, 2010, HUM MOL GENET, V19, P3343, DOI 10.1093/hmg/ddq246
   Götz A, 2011, AM J HUM GENET, V88, P635, DOI 10.1016/j.ajhg.2011.04.006
   Kirby DM, 2007, METHOD CELL BIOL, V80, P93, DOI 10.1016/S0091-679X(06)80004-X
   Messmer M, 2011, BIOCHEM J, V433, P441, DOI 10.1042/BJ20101902
   Moyes CD, 2003, ANNU REV PHYSIOL, V65, P177, DOI 10.1146/annurev.physiol.65.092101.142705
   Patton JR, 2005, J BIOL CHEM, V280, P19823, DOI 10.1074/jbc.M500216200
   Pierce SB, 2013, AM J HUM GENET, V92, P614, DOI 10.1016/j.ajhg.2013.03.007
   Pierce SB, 2011, P NATL ACAD SCI USA, V108, P6543, DOI 10.1073/pnas.1103471108
   Remels AHV, 2010, MOL CELL ENDOCRINOL, V315, P113, DOI 10.1016/j.mce.2009.09.029
   Riley L, 2010, AM J HUM GENET, V97, P1
   Rötig A, 2011, BBA-BIOENERGETICS, V1807, P1198, DOI 10.1016/j.bbabio.2011.06.010
   Rötig A, 2010, DIABETES METAB, V36, P97, DOI 10.1016/j.diabet.2009.11.002
   Ryan MT, 2007, ANNU REV BIOCHEM, V76, P701, DOI 10.1146/annurev.biochem.76.052305.091720
   Sasarman F, 2012, HUM MUTAT, V33, P1201, DOI 10.1002/humu.22098
   Scarpulla RC, 2011, BBA-MOL CELL RES, V1813, P1269, DOI 10.1016/j.bbamcr.2010.09.019
   Skladal D, 2003, BRAIN, V126, P1905, DOI 10.1093/brain/awg170
   Steenweg ME, 2012, BRAIN, V135, P1387, DOI 10.1093/brain/aws070
   Thorburn D R, 2000, Hum Reprod, V15 Suppl 2, P57
   Vianello D, 2013, HUM MUTAT, V34, P1189, DOI 10.1002/humu.22356
NR 36
TC 48
Z9 49
U1 0
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1750-1172
J9 ORPHANET J RARE DIS
JI Orphanet J. Rare Dis.
PD DEC 17
PY 2013
VL 8
AR 193
DI 10.1186/1750-1172-8-193
PG 11
WC Genetics & Heredity; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Research & Experimental Medicine
GA AB8CH
UT WOS:000332017200003
PM 24344687
OA Green Published, gold
DA 2024-11-01
ER

PT J
AU Janes, MS
   Hanson, BJ
   Hill, DM
   Buller, GM
   Agnew, JY
   Sherwood, SW
   Cox, WG
   Yamagata, K
   Capaldi, RA
AF Janes, MS
   Hanson, BJ
   Hill, DM
   Buller, GM
   Agnew, JY
   Sherwood, SW
   Cox, WG
   Yamagata, K
   Capaldi, RA
TI Rapid analysis of mitochondrial DNA depletion by fluorescence in situ
   hybridization and immunocytochemistry: Potential strategies for HIV
   therapeutic monitoring
SO JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY
LA English
DT Article
DE mitochondria; oxidative phosphorylation; mitochondrial DNA; HIV; AIDS;
   mitochondrial disease; nucleoside reverse transcriptase inhibitor;
   cytochrome c oxidase; immunocytochemistry; FISH
ID REVERSE-TRANSCRIPTASE INHIBITORS; ANTIRETROVIRAL THERAPY; TOXICITY;
   GENOME; REPLICATION; MUTATIONS; MYOPATHY; HUMANS
AB Nucleoside reverse transcriptase inhibitors (NRTIs) have been a mainstay in the treatment of human immunodeficiency virus since the introduction of azidothymidine (AZT) in 1987. However, none of the current therapies can completely eradicate the virus, necessitating long-term use of anti-retroviral drugs to prevent viral re-growth. One of the side effects associated with long-term use of NRTIs is mitochondrial toxicity stemming from inhibition of the mitochondrial DNA (mtDNA) polymerase gamma, which leads to mtDNA depletion and consequently to mitochondrial dysfunction. Here we report the use of fluorescence in situ hybridization (FISH) and immunocytochemistry (ICC) to monitor mtDNA depletion in cultured fibroblasts treated with the NRTI 2',3'-dideoxycytidine (ddC). These techniques are amenable to both microscopy and flow cytometry, allowing analysis of populations of cells on a single-cell basis. We show that, as mtDNA depletion progresses, a mosaic population develops, with some cells being depleted of and others retaining mtDNA. These techniques could be useful as potential therapeutic monitors to indicate when NRTI therapy should be interrupted to prevent mitochondrial toxicity and could aid in the development of less toxic NRTIs by providing an assay suitable for pharmacodynamic evaluation of candidate molecules.
C1 Mol Probes Inc, Eugene, OR 97402 USA.
   Univ Oregon, Inst Mol Biol, Eugene, OR 97403 USA.
C3 Thermo Fisher Scientific; Molecular Probes, Inc.; University of Oregon
RP Mol Probes Inc, 29851 Willow Creek Rd, Eugene, OR 97402 USA.
EM janes@probes.com
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Brinkman K, 2000, CURR OPIN INFECT DIS, V13, P5, DOI 10.1097/00001432-200002000-00002
   Carr A, 2000, LANCET, V356, P1423, DOI 10.1016/S0140-6736(00)02854-3
   Carrozzo R, 2003, HUM MUTAT, V21, DOI 10.1002/humu.9135
   Chariot P, 1999, J HEPATOL, V30, P156, DOI 10.1016/S0168-8278(99)80020-8
   Cossarizza A, 2003, CURR OPIN INFECT DIS, V16, P5, DOI 10.1097/00001432-200302000-00002
   Coté HCF, 2002, NEW ENGL J MED, V346, P811, DOI 10.1056/NEJMoa012035
   Elpeleg O, 2002, J MOL MED-JMM, V80, P389, DOI 10.1007/s00109-002-0343-5
   Feng JY, 2001, J BIOL CHEM, V276, P23832, DOI 10.1074/jbc.M101156200
   Fosslien E, 2001, ANN CLIN LAB SCI, V31, P25
   Gourlain K, 2003, HIV Med, V4, P287, DOI 10.1046/j.1468-1293.2003.00158.x
   HAUGLAND RP, 2000, CURRENT PROTOCOLS CE
   Hellerstein MK, 2003, CLIN INFECT DIS, V37, pS52, DOI 10.1086/375888
   Kukhanova M, 1998, MOL PHARMACOL, V53, P801
   Lewis W, 2003, PROG CARDIOVASC DIS, V45, P305, DOI 10.1053/pcad.2003.3b
   Lim SE, 2001, J BIOL CHEM, V276, P23616, DOI 10.1074/jbc.M101114200
   Marusich MF, 1997, BBA-MOL BASIS DIS, V1362, P145, DOI 10.1016/S0925-4439(97)00061-6
   Moyle G, 2000, CLIN THER, V22, P911, DOI 10.1016/S0149-2918(00)80064-8
   Petit C, 2003, JAIDS-J ACQ IMM DEF, V33, P461, DOI 10.1097/00126334-200308010-00006
   Phillips PS, 2002, ANN INTERN MED, V137, P581, DOI 10.7326/0003-4819-137-7-200210010-00009
   Sastre J, 2003, FREE RADICAL BIO MED, V35, P1, DOI 10.1016/S0891-5849(03)00184-9
   Schapira AHV, 2002, J INHERIT METAB DIS, V25, P207, DOI 10.1023/A:1015629912477
   Scheffler I.E., 1999, MITOCHONDRIA
   Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755
   Taanman JW, 1997, HUM MOL GENET, V6, P935, DOI 10.1093/hmg/6.6.935
   Taanman JW, 1999, BBA-BIOENERGETICS, V1410, P103, DOI 10.1016/S0005-2728(98)00161-3
   Temesgen Z, 2001, Expert Opin Pharmacother, V2, P1239, DOI 10.1517/14656566.2.8.1239
   Walker Ulrich A, 2003, J HIV Ther, V8, P32
   Yamagata K, 2002, J AM SOC NEPHROL, V13, DOI 10.1097/01.ASN.0000019772.17954.F8
NR 29
TC 22
Z9 24
U1 0
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0022-1554
EI 1551-5044
J9 J HISTOCHEM CYTOCHEM
JI J. Histochem. Cytochem.
PD AUG
PY 2004
VL 52
IS 8
BP 1011
EP 1018
DI 10.1369/jhc.3a6209.2004
PG 8
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 841JZ
UT WOS:000222927400003
PM 15258176
OA Bronze
DA 2024-11-01
ER

PT J
AU Nakhro, K
   Chung, KW
   Kim, SM
   Sunwoo, IN
   Cho, EM
   Park, SW
   Hwang, JH
   Choi, BO
AF Nakhro, Khriezhanuo
   Chung, Ki Wha
   Kim, Seung-Min
   Sunwoo, Il-Nam
   Cho, Eun Min
   Park, Sun Wha
   Hwang, Jung Hee
   Choi, Byung-Ok
TI Compound mutations of PEO1 and TYMP in a progressive external
   ophthalmoplegia patient with incomplete mitochondrial
   neurogastrointestinal encephalomyopathy phenotype
SO GENES & GENOMICS
LA English
DT Article
DE Mitochondrial disease; Mitochondrial neurogastrointestinal
   encephalomyopathy (MNGIE); PEO; PEO1; TYMP
ID AUTOSOMAL-DOMINANT; MTDNA MAINTENANCE; HELICASE TWINKLE; DNA; MNGIE;
   GENE; DELETIONS; DEPLETION; SPECTRUM; DISEASE
AB The Mendelian inherited progressive external ophthalmoplegia (PEO) and mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) are genetically heterogeneous mitochondrial diseases caused by nuclear-mitochondrial intergenomic defects. The PEO1 and TYMP nuclear genes are closely related in the machinery of the mitochondrial DNA (mtDNA) replication. Mutations in PEO1 and TYMP genes usually cause autosomal dominant PEO, and autosomal recessive MNGIE. We identified a PEO family of Korean origin with additional phenotype of incomplete MNGIE symptom (Family ID: MT16). The entire mitochondrial genome and all coding exons of PEO1, TYMP, ANT1, POLG1, POLG2, DGUOK, and TK2 nuclear genes were sequenced. Clinical information was obtained through history taking, physical examinations, clinical observations, and electrophysiological investigations. Muscle biopsy of left biceps brachii and shoulder magnetic resonance imaging (MRI) were undertaken. We found two heterozygous mutations, Arg374Gln in PEO1 and Glu106Gln in TYMP from the proband who showed complex phenotypes of a typical PEO and late-onset incomplete MNGIE. The PEO1 Arg374Gln has been reported in several PEO patients, but TYMP Glu106Gln has not been reported. Neither large deletion nor causative point mutations were observed in the mtDNA. We suggest that the heterozygous TYMP mutation might affect complex phenotypes as a secondary genetic cause in the co-presence of PEO1 mutation.
C1 [Choi, Byung-Ok] Ewha Womans Univ, Dept Neurol, Sch Med, Seoul, South Korea.
   [Nakhro, Khriezhanuo; Chung, Ki Wha; Cho, Eun Min; Park, Sun Wha] Kongju Natl Univ, Dept Biol Sci, Gongju, Chungnam, South Korea.
   [Nakhro, Khriezhanuo; Chung, Ki Wha; Cho, Eun Min; Park, Sun Wha] Kongju Natl Univ, Biotechnol Res Ctr, Gongju, Chungnam, South Korea.
   [Kim, Seung-Min; Sunwoo, Il-Nam] Yonsei Univ, Coll Med, Dept Neurol, Seoul, South Korea.
   [Hwang, Jung Hee] Natl Forens Serv, DNA Anal Div, Seoul, South Korea.
C3 Ewha Womans University; Kongju National University; Kongju National
   University; Yonsei University; Yonsei University Health System; National
   Forensic Service
RP Choi, BO (corresponding author), Ewha Womans Univ, Dept Neurol, Sch Med, Seoul, South Korea.
EM bochoi@ewha.ac.kr
FU MEST [KRF-2008-313-C00750]; MEST, Republic of Korea
   [R01-2008-000-20604-0]
FX This work was supported by the NRF grants funded by the MEST
   (KRF-2008-313-C00750), and by Mid-career Researcher Program through NRF
   grant funded by the MEST (R01-2008-000-20604-0), Republic of Korea. The
   authors declare that they have no competing interests.
CR BAKKER JA, 2010, J INHERIT M IN PRESS
   Baloh RH, 2007, ARCH NEUROL-CHICAGO, V64, P998, DOI 10.1001/archneur.64.7.998
   Fratter C, 2010, NEUROLOGY, V74, P1619, DOI 10.1212/WNL.0b013e3181df099f
   Gamez J, 2002, NEUROLOGY, V59, P455, DOI 10.1212/WNL.59.3.455
   Giordano C, 2009, NEUROLOGY, V72, P1103, DOI 10.1212/01.wnl.0000345002.47396.e1
   Goffart S, 2009, HUM MOL GENET, V18, P328, DOI 10.1093/hmg/ddn359
   Hirano M, 2004, NEUROLOGIST, V10, P8, DOI 10.1097/01.nrl.0000106919.06469.04
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Ingman M, 2006, NUCLEIC ACIDS RES, V34, pD749, DOI 10.1093/nar/gkj010
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Korhonen JA, 2008, J MOL BIOL, V377, P691, DOI 10.1016/j.jmb.2008.01.035
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   López LC, 2009, HUM MOL GENET, V18, P714, DOI 10.1093/hmg/ddn401
   Martí R, 2005, ANN NEUROL, V58, P649, DOI 10.1002/ana.20615
   Massa R, 2009, NEUROMUSCULAR DISORD, V19, P837, DOI 10.1016/j.nmd.2009.08.013
   Naïmi M, 2006, EUR J HUM GENET, V14, P917, DOI 10.1038/sj.ejhg.5201627
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Ruiz-Pesini E, 2007, NUCLEIC ACIDS RES, V35, pD823, DOI 10.1093/nar/gkl927
   Sarzi E, 2007, ANN NEUROL, V62, P579, DOI 10.1002/ana.21207
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2005, GENE, V354, P162, DOI 10.1016/j.gene.2005.03.025
   Suomalainen A, 2010, NEUROMUSCULAR DISORD, V20, P429, DOI 10.1016/j.nmd.2010.03.017
   Szigeti K, 2004, J MED GENET, V41, P125, DOI 10.1136/jmg.2003.013789
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
   Tyynismaa H, 2004, HUM MOL GENET, V13, P3219, DOI 10.1093/hmg/ddh342
   Tyynismaa H, 2009, AM J HUM GENET, V85, P290, DOI 10.1016/j.ajhg.2009.07.009
NR 26
TC 3
Z9 3
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1976-9571
J9 GENES GENOM
JI Genes Genom.
PD AUG
PY 2011
VL 33
IS 4
BP 431
EP 437
DI 10.1007/s13258-011-0089-y
PG 7
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity
GA 813EF
UT WOS:000294348900015
DA 2024-11-01
ER

PT J
AU Zhang, SL
   Li, FY
   Bass, HN
   Pursley, A
   Schmitt, ES
   Brown, BL
   Brundage, EK
   Mardach, R
   Wong, LJ
AF Zhang, Shulin
   Li, Fang-yuan
   Bass, Harold N.
   Pursley, Amber
   Schmitt, Eric S.
   Brown, Blaire L.
   Brundage, Ellen K.
   Mardach, Rebecca
   Wong, Lee-Jun
TI Application of oligonucleotide array CGH to the simultaneous detection
   of a deletion in the nuclear <i>TK2</i> gene and mtDNA depletion
SO MOLECULAR GENETICS AND METABOLISM
LA English
DT Article
DE TK2 deletion; Array CGH; mtDNA depletion
ID MITOCHONDRIAL-DNA DEPLETION; COMPARATIVE GENOMIC HYBRIDIZATION;
   THYMIDINE KINASE; MYOPATHY; REPLICATION; DIAGNOSIS
AB Thymidine kinase 2 (TK2), encoded by the TK2 gene on chromosome 16q22, is one of the deoxyribonucleoside kinases responsible for the maintenance of mitochondrial deoxyribonucleotide pools. Defects in TK2 mainly cause a myopathic form of the mitochondrial DNA depletion syndrome (MDDS). Currently, only point mutations and small insertions and deletions have been reported in TK2 gene; gross rearrangements of TK2 gene and possible hepatic involvement in patients with TK2 mutations have not been described. We report a non-consanguineous Jordanian family with three deceased siblings due to mtDNA depletion. Sequence analysis of the father detected a heterozygous c.761T > A (p.1254N) mutation in his TK2 gene; however, point mutations in the mother were not detected. Subsequent gene dosage analysis using oligonucleotide array CGH identified an intragenic approximately 5.8-kb deletion encompassing the 5'UTR to intron 2 of her TK2 gene. Sequence analysis confirmed that the deletion spans c.1-495 to c.283-2899 of the TK2 gene (nucleotide 65,136,256-65,142,086 of chromosome 16). Analysis of liver and muscle specimens from one of the deceased infants in this family revealed compound heterozygosity for the paternal point mutation and maternal intragenic deletion. In addition, a significant reduction of the mtDNA content in liver and muscle was detected (10% and 20% of age- and tissue-matched controls, respectively). Prenatal diagnosis was performed in the third pregnancy. The fetus was found to carry both the point mutation and the deletion. This child died 6 months after birth due to myopathy. A serum specimen demonstrated elevated liver transaminases in two of the infants from whom results were available. This report expands the mutation spectrum associated with TK2 deficiency. While the myopathic form of MDDS appears to be the main phenotype of TK2 mutations, liver dysfunction may also be a part of the mitochondrial depletion syndrome caused by TK2 gene defects. (C) 2009 Elsevier Inc. All rights reserved.
C1 [Zhang, Shulin; Li, Fang-yuan; Pursley, Amber; Schmitt, Eric S.; Brundage, Ellen K.; Wong, Lee-Jun] Baylor Coll Med, Dept Mol & Human Genet, Med Genet Lab, Houston, TX 77030 USA.
   [Bass, Harold N.; Brown, Blaire L.; Mardach, Rebecca] Kaiser Permanente Med Program, Dept Genet, Los Angeles, CA USA.
   [Bass, Harold N.; Brown, Blaire L.; Mardach, Rebecca] Kaiser Permanente Med Program, Dept Genet, Bakersfield, CA USA.
   [Bass, Harold N.; Brown, Blaire L.; Mardach, Rebecca] Kaiser Permanente Med Program, Dept Genet, Panorama City, CA USA.
C3 Baylor College of Medicine; Kaiser Permanente; Kaiser Permanente; Kaiser
   Permanente
RP Wong, LJ (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Mitochondrial Diagnost Lab, 1 Baylor Plaza,NAB 2015, Houston, TX 77030 USA.
EM ljwong@bcm.edu
CR Bai RK, 2005, J MOL DIAGN, V7, P613, DOI 10.1016/S1525-1578(10)60595-8
   Beaudet AL, 2008, ANNU REV MED, V59, P113, DOI 10.1146/annurev.med.59.012907.101800
   Blake JC, 1999, AM J PATHOL, V155, P67, DOI 10.1016/S0002-9440(10)65100-0
   Cheung SW, 2007, AM J MED GENET A, V143A, P1679, DOI 10.1002/ajmg.a.31740
   Chinault AC, 2009, GENET MED, V11, P518, DOI 10.1097/GIM.0b013e3181abd83c
   DIMAURO S, 1991, REV NEUROL, V147, P443
   Ducluzeau PH, 1999, J HEPATOL, V30, P149, DOI 10.1016/S0168-8278(99)80019-1
   Lee NC, 2009, ARCH DIS CHILD, V94, P55, DOI 10.1136/adc.2008.139584
   Lu XY, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000327
   Mathews CK, 2007, FASEB J, V21, P2294, DOI 10.1096/fj.06-7977rev
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Oskoui M, 2006, ARCH NEUROL-CHICAGO, V63, P1122, DOI 10.1001/archneur.63.8.1122
   Rahman S, 2009, ARCH DIS CHILD, V94, P3, DOI 10.1136/adc.2008.147983
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Spinazzola A, 2009, J INHERIT METAB DIS, V32, P143, DOI 10.1007/s10545-008-1038-z
   Stankiewicz P, 2007, CURR OPIN GENET DEV, V17, P182, DOI 10.1016/j.gde.2007.04.009
   Taanman JW, 1997, HUM MOL GENET, V6, P935, DOI 10.1093/hmg/6.6.935
   TRITSCHLER HJ, 1992, NEUROLOGY, V42, P209, DOI 10.1212/WNL.42.1.209
   Vu TH, 1998, NEUROLOGY, V50, P1783, DOI 10.1212/WNL.50.6.1783
   Wang L, 1999, FEBS LETT, V443, P170, DOI 10.1016/S0014-5793(98)01711-6
   Wang LY, 2003, J BIOL CHEM, V278, P6963, DOI 10.1074/jbc.M206143200
   Wong LJC, 2008, CLIN CHEM, V54, P1141, DOI 10.1373/clinchem.2008.103721
NR 22
TC 14
Z9 14
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1096-7192
EI 1096-7206
J9 MOL GENET METAB
JI Mol. Genet. Metab.
PD JAN
PY 2010
VL 99
IS 1
BP 53
EP 57
DI 10.1016/j.ymgme.2009.09.003
PG 5
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental
   Medicine
GA 545SV
UT WOS:000273758000008
PM 19815440
DA 2024-11-01
ER

PT J
AU Ji, KQ
   Liu, KM
   Lin, PF
   Wen, B
   Luo, YB
   Zhao, YY
   Yan, CZ
AF Ji, Kunqian
   Liu, Kaiming
   Lin, Pengfei
   Wen, Bing
   Luo, Yue-Bei
   Zhao, Yuying
   Yan, Chuanzhu
TI <i>Twinkle</i> mutations in two Chinese families with autosomal dominant
   progressive external ophthalmoplegia
SO NEUROLOGICAL SCIENCES
LA English
DT Article
DE Autosomal dominant progressive external ophthalmoplegia; PEO; Twinkle;
   A475P; R354P; Chinese population
ID ONSET SPINOCEREBELLAR ATAXIA; MITOCHONDRIAL-DNA HELICASE;
   STRUCTURE-FUNCTION DEFECTS; PEO1 GENE MUTATION; LINKER REGION; MTDNA;
   ADPEO; POLG; ENCEPHALOPATHY; DEPLETION
AB Autosomal dominant progressive external ophthalmoplegia (adPEO) is a common adult onset mitochondrial disease caused by mutations in nuclear DNA (nDNA). Twinkle is one of the nuclear genes associated with adPEO. Clinical, histochemical, and molecular genetics findings of 6 patients from two Chinese families with adPEO were reported. Two point mutations (c.1423G>C, p.A475P and c.1061G>C, p.R354P) of Twinkle gene have been found. Multiple mtDNA deletions were also detected in patient's muscle and fibroblasts. This study confirms two mutations in Chinese adPEO families, which were first reported in the Chinese population.
C1 [Ji, Kunqian; Liu, Kaiming; Lin, Pengfei; Wen, Bing; Luo, Yue-Bei; Zhao, Yuying; Yan, Chuanzhu] Shandong Univ, Qilu Hosp, Dept Neurol, Lab Neuromuscular Disorders, Jinan 250012, Peoples R China.
   [Yan, Chuanzhu] Shandong Univ, Brain Sci Res Inst, Minist Educ, Key Lab Expt Teratol, Jinan 250012, Peoples R China.
C3 Shandong University; Shandong University
RP Yan, CZ (corresponding author), Shandong Univ, Qilu Hosp, Dept Neurol, Lab Neuromuscular Disorders, Jinan 250012, Peoples R China.
EM chuanzhuyan@163.com
RI L, YB/AAF-9728-2021
OI Luo, Yue-Bei/0000-0002-1056-0154
FU National Nature Science Foundation of China [81171182]; National Nature
   Science Foundation for Young Scholars of China [81101157]; Shandong
   Provincial Natural Science Foundation, China [2009ZRB01893]
FX This study was supported by the following funding sources: the National
   Nature Science Foundation of China (No. 81171182), the National Nature
   Science Foundation for Young Scholars of China (No. 81101157) and the
   Shandong Provincial Natural Science Foundation, China (Grant No.
   2009ZRB01893).
CR Bohlega S, 2009, NEUROMUSCULAR DISORD, V19, P845, DOI 10.1016/j.nmd.2009.10.002
   Deschauer M, 2003, NEUROMUSCULAR DISORD, V13, P568, DOI 10.1016/S0960-8966(03)00071-3
   Dündar H, 2012, PEDIATR NEUROL, V46, P172, DOI 10.1016/j.pediatrneurol.2011.12.006
   Echaniz-Laguna A, 2010, NEUROGENETICS, V11, P21, DOI 10.1007/s10048-009-0202-4
   Fratter C, 2010, NEUROLOGY, V74, P1619, DOI 10.1212/WNL.0b013e3181df099f
   Goh V, 2012, J PEDIATR GASTR NUTR, V54, P291, DOI 10.1097/MPG.0b013e318227e53c
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   Hirano M, 2001, NEUROLOGY, V57, P2163, DOI 10.1212/WNL.57.12.2163
   Holmlund T, 2009, BBA-MOL BASIS DIS, V1792, P132, DOI 10.1016/j.bbadis.2008.11.009
   Houshmand M, 2006, NEUROL INDIA, V54, P182
   Hudson G, 2005, NEUROLOGY, V64, P371, DOI 10.1212/01.WNL.0000149767.51152.83
   Jeppesen TD, 2008, NEUROMUSCULAR DISORD, V18, P306, DOI 10.1016/j.nmd.2007.10.007
   Kiechl S, 2004, J NEUROL NEUROSUR PS, V75, P1125, DOI 10.1136/jnnp.2003.025890
   Korhonen JA, 2008, J MOL BIOL, V377, P691, DOI 10.1016/j.jmb.2008.01.035
   Lamperti C, 2009, Acta Myol, V28, P2
   Lewis S, 2002, J NEUROL SCI, V201, P39, DOI 10.1016/S0022-510X(02)00190-9
   Liu ZR, 2008, MOL VIS, V14, P1995
   Longley MJ, 2010, J BIOL CHEM, V285, P29690, DOI 10.1074/jbc.M110.151795
   Lönnqvist T, 2009, BRAIN, V132, P1553, DOI 10.1093/brain/awp045
   Martin-Negrier ML, 2011, EUR J NEUROL, V18, P436, DOI 10.1111/j.1468-1331.2010.03171.x
   Negro R, 2009, NEUROMUSCULAR DISORD, V19, P423, DOI 10.1016/j.nmd.2009.04.008
   Nikali K, 2005, HUM MOL GENET, V14, P2981, DOI 10.1093/hmg/ddi328
   OLD SL, 1989, HISTOCHEM J, V21, P545, DOI 10.1007/BF01753355
   Rivera H, 2007, NEUROMUSCULAR DISORD, V17, P677, DOI 10.1016/j.nmd.2007.05.006
   Ronchi D, 2011, J NEUROL SCI, V308, P173, DOI 10.1016/j.jns.2011.05.042
   Sarzi E, 2007, ANN NEUROL, V62, P579, DOI 10.1002/ana.21207
   Sen D, 2012, J BIOL CHEM, V287, P14545, DOI 10.1074/jbc.M111.309468
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Van Goethem G, 2003, HUM MUTAT, V22, P175, DOI 10.1002/humu.10246
   Van Hove JLK, 2009, AM J MED GENET A, V149A, P861, DOI 10.1002/ajmg.a.32731
   Virgilio R, 2008, J NEUROL, V255, P1384, DOI 10.1007/s00415-008-0926-3
   Wanrooij S, 2004, NUCLEIC ACIDS RES, V32, P3053, DOI 10.1093/nar/gkh634
NR 32
TC 3
Z9 4
U1 0
U2 4
PU SPRINGER-VERLAG ITALIA SRL
PI MILAN
PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY
SN 1590-1874
EI 1590-3478
J9 NEUROL SCI
JI Neurol. Sci.
PD MAR
PY 2014
VL 35
IS 3
BP 443
EP 448
DI 10.1007/s10072-013-1557-8
PG 6
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA AD3FG
UT WOS:000333123100016
PM 24091712
DA 2024-11-01
ER

PT J
AU Wong, LJC
   Naviaux, RK
   Brunetti-Pierri, N
   Zhang, Q
   Schmitt, ES
   Truong, C
   Milone, M
   Cohen, BH
   Wical, B
   Ganesh, J
   Basinger, AA
   Burton, BK
   Swoboda, K
   Gilbert, DL
   Vanderver, A
   Saneto, RP
   Maranda, B
   Arnold, G
   Abdenur, JE
   Waters, PJ
   Copeland, WC
AF Wong, Lee-Jun C.
   Naviaux, Robert K.
   Brunetti-Pierri, Nicola
   Zhang, Qing
   Schmitt, Eric S.
   Truong, Cavatina
   Milone, Margherita
   Cohen, Bruce H.
   Wical, Beverly
   Ganesh, Jaya
   Basinger, Alice A.
   Burton, Barbara K.
   Swoboda, Kathryn
   Gilbert, Donald L.
   Vanderver, Adeline
   Saneto, Russell P.
   Maranda, Bruno
   Arnold, Georgianne
   Abdenur, Jose E.
   Waters, Paula J.
   Copeland, William C.
TI Molecular and Clinical Genetics of Mitochondrial Diseases Due to
   <i>POLG</i> Mutations
SO HUMAN MUTATION
LA English
DT Article
DE POLG; POLG1; Alpers syndrome; PEO; adPEO; arPEO; SANDO; SCAE; ANS;
   MEMSA; MCHS; mtDNA depletion; liver failure
ID DNA-POLYMERASE-GAMMA; PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA;
   AUTOSOMAL-DOMINANT; ATAXIC NEUROPATHY; ALPERS-SYNDROME; W748S MUTATION;
   DEFECTS; PATIENT; FAMILY; PARKINSONISM
AB Mutations in the POLG gene have emerged as one of the most common causes of inherited mitochondrial disease in children and adults. They are responsible for a heterogeneous group of at least 6 major phenotypes of neurodegenerative disease that include: 1) childhood Myocerebrohepatopathy Spectrum disorders (MCHS), 2) Alpers syndrome, 3) Ataxia Neuropathy Spectrum (ANS) disorders, 4) Myoclonus Epilepsy Myopathy Sensory Ataxia (MEMSA), 5) autosomal recessive Progressive External Ophthalmoplegia (arPEO), and 6) autosomal dominant Progressive External Ophthalmoplegia (adPEO). Due to the clinical heterogeneity, time-dependent evolution of symptoms, overlapping phenotypes, and inconsistencies in muscle pathology findings, definitive diagnosis relies on the molecular finding of deleterious mutations. We sequenced the exons and flanking intron region from approximately 350 patients displaying a phenotype consistent with POLG related mitochondrial disease and found informative mutations in 61 (17%). Two mutant alleles were identified in 31 unrelated index patients with autosomal recessive POLG-related disorders. Among them, 20 (67%) had Alpers syndrome, 4 (13%) had arPEO, and 3 (10%) had ANS. In addition, 30 patients carrying one altered POLG allele were found. A total of 25 novel alterations were identified, including 6 null mutations. We describe the predicted structural/functional and clinical importance of the previously unreported missense variants and discuss their likelihood of being pathogenic. In conclusion, sequence analysis allows the identification of mutations responsible for POLG-related disorders and, in most of the autosomal recessive cases where two mutant alleles are found in trans, finding deleterious mutations can provide an unequivocal diagnosis of the disease. Published 2008 Wiley-Liss, Inc.
C1 [Wong, Lee-Jun C.; Brunetti-Pierri, Nicola; Zhang, Qing; Schmitt, Eric S.; Truong, Cavatina] Baylor Coll Med, Dept Mol & Human Genet, One Baylor Plaza,NAB 2015, Houston, TX 77030 USA.
   [Naviaux, Robert K.] Univ Calif San Diego, Mitochondrial & Metab Dis Ctr, Dept Med, San Diego, CA 92103 USA.
   [Naviaux, Robert K.] Univ Calif San Diego, Mitochondrial & Metab Dis Ctr, Dept Pediat, San Diego, CA 92103 USA.
   [Milone, Margherita] Mayo Clin, Dept Neurol, Rochester, MN USA.
   [Cohen, Bruce H.] Cleveland Clin, Neurol Inst, Cleveland, OH 44106 USA.
   [Wical, Beverly] Gillette Childrens Specialty Healthcare, St Paul, MN USA.
   [Ganesh, Jaya] Childrens Hosp Philadelphia, Sect Biochem Genet, Philadelphia, PA 19104 USA.
   [Ganesh, Jaya] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
   [Basinger, Alice A.] Cook Childrens Phys Network, Div Genet, Ft Worth, TX USA.
   [Burton, Barbara K.] Childrens Mem Hosp, Birth Defects & Metab, Div Genet, Chicago, IL 60614 USA.
   [Swoboda, Kathryn] Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT USA.
   [Gilbert, Donald L.] Cincinnati Childrens Hosp Med Ctr, Dept Neurol, Cincinnati, OH 45229 USA.
   [Vanderver, Adeline] Childrens Natl Med Ctr, Dept Neurol, Washington, DC 20010 USA.
   [Saneto, Russell P.] Univ Washington, Childrens Hosp, Div Pediat Neurol, Seattle, WA 98195 USA.
   [Saneto, Russell P.] Univ Washington, Reg Med Ctr, Seattle, WA 98195 USA.
   [Maranda, Bruno] Univ Laval, CHUL CHUQ, Dept Pediat, Serv Genet Med, Quebec City, PQ, Canada.
   [Arnold, Georgianne] Univ Rochester, Sch Med & Dent, Div Pediat & Genet, Rochester, NY USA.
   [Abdenur, Jose E.] Childrens Hosp Orange Cty, Orange, CA 92668 USA.
   [Waters, Paula J.] Childrens & Womens Hlth Ctr British Columbia, Lab Genet Div, Dept Pathol, Vancouver, BC, Canada.
   [Waters, Paula J.] Univ British Columbia, Vancouver, BC, Canada.
   [Copeland, William C.] NIEHS, Lab Mol Genet, NIH, Res Triangle Pk, NC 27709 USA.
C3 Baylor College of Medicine; University of California System; University
   of California San Diego; University of California System; University of
   California San Diego; Mayo Clinic; Cleveland Clinic Foundation;
   University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of
   Philadelphia; University of Pennsylvania; Cook Children's Medical
   Center; Ann & Robert H. Lurie Children's Hospital of Chicago; Utah
   System of Higher Education; University of Utah; Cincinnati Children's
   Hospital Medical Center; Children's National Health System; University
   of Washington; University of Washington Seattle; Seattle Children's
   Hospital; University of Washington; University of Washington Seattle;
   Laval University; University of Rochester; Childrens Hospital of Orange
   County; BC Women's Hospital & Health Centre; University of British
   Columbia; National Institutes of Health (NIH) - USA; NIH National
   Institute of Environmental Health Sciences (NIEHS)
RP Wong, LJC (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, One Baylor Plaza,NAB 2015, Houston, TX 77030 USA.
EM ljwong@bcm.edu
RI ZHANG, QING/AGY-7972-2022; Arnold, Georgianne/KGK-4064-2024; Vanderver,
   Adeline/CAG-5072-2022; Copeland, William/C-4242-2019; Brunetti-Pierri,
   Nicola/K-8465-2016; Gilbert, Donald/D-6443-2016
OI Swoboda, Kathryn/0000-0002-4593-6342; Waters, Paula/0000-0003-4898-1859;
   Vanderver, Adeline/0000-0002-6290-6751; Copeland,
   William/0000-0002-0359-0953; Brunetti-Pierri,
   Nicola/0000-0002-6895-8819; Gilbert, Donald/0000-0002-9245-6878
FU DHHS, NIH [5R01 CA100023]; NIH intramural research funds; NIH
   [5R21-NS051815]; Lennox Foundation; Hailey's Wish Foundation; UCSD
   Christini Fund
FX The authors would like to thank all referring physicians and patients
   who were included in this study and thank Drs. Sherine Chan and
   Lauranell Burch for critical review of this manuscript. This work was
   supported by DHHS, NIH, 5R01 CA100023 to LJW and by NIH intramural
   research funds to WCC. RKN was supported by grants from NIH
   (5R21-NS051815), the Lennox Foundation, Hailey's Wish Foundation, and
   the UCSD Christini Fund.
CR Bao XH, 2008, BRAIN DEV-JPN, V30, P295, DOI 10.1016/j.braindev.2007.08.009
   Barthélémy C, 2002, HUM GENET, V110, P479, DOI 10.1007/s00439-002-0708-4
   Baruffini E, 2007, BBA-MOL BASIS DIS, V1772, P1225, DOI 10.1016/j.bbadis.2007.10.002
   Chan SSL, 2006, HUM MOL GENET, V15, P3473, DOI 10.1093/hmg/ddl424
   Chan SSL, 2005, DNA REPAIR, V4, P1381, DOI 10.1016/j.dnarep.2005.08.010
   Chan SSL, 2005, J BIOL CHEM, V280, P31341, DOI 10.1074/jbc.M506762200
   Davidzon G, 2006, ANN NEUROL, V59, P859, DOI 10.1002/ana.20831
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   de Vries MC, 2007, EUR J PEDIATR, V166, P229, DOI 10.1007/s00431-006-0234-9
   DeLano WL., 2002, The PyMOL molecular graphics system
   Di Fonzo A, 2003, HUM MUTAT, V22, DOI 10.1002/humu.9203
   DiMauro S, 2006, BRAIN, V129, P1637, DOI 10.1093/brain/awl169
   Dimmock DP, 2008, HUM MUTAT, V29, P330, DOI 10.1002/humu.9519
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   González-Vioque E, 2006, ARCH NEUROL-CHICAGO, V63, P107, DOI 10.1001/archneur.63.1.107
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Hudson G, 2007, ARCH NEUROL-CHICAGO, V64, P553, DOI 10.1001/archneur.64.4.553
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Lecrenier N, 1997, GENE, V185, P147, DOI 10.1016/S0378-1119(96)00663-4
   Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Longley MJ, 2005, GENE, V354, P125, DOI 10.1016/j.gene.2005.03.029
   Longley MJ, 2001, J BIOL CHEM, V276, P38555, DOI 10.1074/jbc.M105230200
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Luoma PT, 2005, HUM MOL GENET, V14, P1907, DOI 10.1093/hmg/ddi196
   Mancuso M, 2004, ARCH NEUROL-CHICAGO, V61, P1777, DOI 10.1001/archneur.61.11.1777
   Milone M, 2008, NEUROMUSCULAR DISORD, V18, P626, DOI 10.1016/j.nmd.2008.05.009
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nguyen KV, 2006, J HEPATOL, V45, P108, DOI 10.1016/j.jhep.2005.12.026
   Nguyen KV, 2005, NEUROLOGY, V65, P1493, DOI 10.1212/01.wnl.0000182814.55361.70
   Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490
   Selby K, 2008, NEUROMUSCUL DISORD
   Stopinska K, 2006, ACTA BIOCHIM POL, V53, P591
   Tiangyou W, 2006, NEUROLOGY, V67, P1698, DOI 10.1212/01.wnl.0000238963.07425.d5
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, NEUROLOGY, V61, P1811, DOI 10.1212/01.WNL.0000098997.23471.65
   Van Goethem G, 2003, HUM MUTAT, V22, P175, DOI 10.1002/humu.10246
   Van Goethem G, 2003, EUR J HUM GENET, V11, P547, DOI 10.1038/sj.ejhg.5201002
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   Yamanaka H, 2007, J INFECT DIS, V195, P1419, DOI 10.1086/513872
NR 45
TC 203
Z9 215
U1 0
U2 12
PU WILEY-HINDAWI
PI LONDON
PA ADAM HOUSE, 3RD FL, 1 FITZROY SQ, LONDON, WIT 5HE, ENGLAND
SN 1059-7794
EI 1098-1004
J9 HUM MUTAT
JI Hum. Mutat.
PD SEP
PY 2008
VL 29
IS 9
BP E150
EP E172
DI 10.1002/humu.20824
PG 23
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA VJ8AP
UT WOS:000629246800002
PM 18546365
OA Green Accepted, gold
DA 2024-11-01
ER

PT J
AU Desler, C
   Munch-Petersen, B
   Rasmussen, LJ
AF Desler, C.
   Munch-Petersen, B.
   Rasmussen, L. J.
TI The role of mitochondrial dNTP levels in cells with reduced TK2 activity
SO NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS
LA English
DT Article; Proceedings Paper
CT 10th Symposium of the
   European-Society-for-the-Study-of-Purine-and-Pyrimidine-Metabolism-in-Ma
   n (ESSPPMM)
CY JUN 08-11, 2005
CL Prague, CZECH REPUBLIC
SP European Soc Study Purine & Pyrimidine Metabolism Man
DE thymidine kinase 2; mitochondrial dNTP imbalance; dNTP transport
ID DEPLETION MYOPATHY; KINASE; DNA; TRIPHOSPHATE
AB Both the nuclear and mitochondrial DNA (mtDNA) depend on separate balanced pools of dNTPs for correct function of DNA replication and repair of DNA damage. Import of dNTPs from the cytosolic compartment to the mitochondria has been suggested to have the potential of rectifying a mitochondrial dNTP imbalance. Reduced TK2 activity has been demonstrated to result in mitochondrial dNTP imbalance and consequently mutations of mtDNA in non-dividing cells. In this study, the consequences of a reduced thymidine kinase 2 (TK2) activity were measured in proliferating HeLa cells, on both whole-cell as well as mitochondrial dNTP levels. With the exception of increased mitochondrial dCTP level no significant difference was found in cells with reduced TK2 activity. Our results suggest that import of cytosolic dNTPs in mitochondria of proliferating cells can compensate a TK2 induced imbalance of the mitochondrial dNTP pool.
C1 Roskilde Univ Ctr, Dept Chem & Life Sci, Roskilde, Denmark.
C3 Roskilde University
RP Munch-Petersen, B (corresponding author), Roskilde Univ Ctr, Dept Life Sci, DK-4000 Roskilde, Denmark.
EM bmp@virgil.ruc.dk
OI Rasmussen, Lene Juel/0000-0001-6864-963X; desler,
   claus/0000-0002-0125-004X
CR ARNER ESJ, 1992, BIOCHEM BIOPH RES CO, V188, P712, DOI 10.1016/0006-291X(92)91114-6
   BEBENEK K, 1990, P NATL ACAD SCI USA, V87, P4946, DOI 10.1073/pnas.87.13.4946
   GAO WY, 1994, J BIOL CHEM, V269, P12633
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   MEUTH M, 1989, EXP CELL RES, V181, P305, DOI 10.1016/0014-4827(89)90090-6
   Pontarin G, 2003, P NATL ACAD SCI USA, V100, P12159, DOI 10.1073/pnas.1635259100
   Saada A, 2003, MOL GENET METAB, V79, P1, DOI 10.1016/S1096-7192(03)00063-5
   SHERMAN PA, 1989, ANAL BIOCHEM, V180, P222, DOI 10.1016/0003-2697(89)90420-X
   Song SW, 2003, J BIOL CHEM, V278, P43893, DOI 10.1074/jbc.C300401200
   Wang LY, 2003, J BIOL CHEM, V278, P6963, DOI 10.1074/jbc.M206143200
   WICKREMASINGHE RG, 1980, J CLIN INVEST, V65, P26, DOI 10.1172/JCI109656
NR 11
TC 8
Z9 10
U1 0
U2 4
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1525-7770
EI 1532-2335
J9 NUCLEOS NUCLEOT NUCL
JI Nucleosides Nucleotides Nucleic Acids
PY 2006
VL 25
IS 9-11
BP 1171
EP 1175
DI 10.1080/15257770600894501
PG 5
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)
SC Biochemistry & Molecular Biology
GA 105GS
UT WOS:000242019000037
PM 17065084
DA 2024-11-01
ER

PT S
AU Copeland, WC
AF Copeland, William C.
TI Inherited mitochondrial diseases of DNA replication
SO ANNUAL REVIEW OF MEDICINE
SE Annual Review of Medicine
LA English
DT Review; Book Chapter
DE DNA polymerase gamma; nucleotide pools; mitochondrial DNA depletion
   syndrome; progressive external ophthalmoplegia; ataxia-neuropathy
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; THYMIDINE
   PHOSPHORYLASE-DEFICIENCY; PROBABLE GERMLINE MOSAICISM; POLYMERASE-GAMMA
   MUTATIONS; ALPERS-SYNDROME; SACCHAROMYCES-CEREVISIAE; DEOXYGUANOSINE
   KINASE; MULTIPLE DELETIONS; DEPLETION SYNDROME; POLG MUTATIONS
AB Mitochondrial genetic diseases can result from defects in mitochondrial DNA (mtDNA) in the form of deletions, point mutations, or depletion, which ultimately cause loss of oxidative phosphorylation. These mutations may be spontaneous, maternally inherited, or a result of inherited nuclear defects in genes that maintain mtDNA. This review focuses on our current understanding of nuclear gene mutations that produce mtDNA alterations and cause mitochondrial depletion syndrome (MDS), progressive external ophthalmoplegia (PEO), ataxia-neuropathy, or mitochondrial neurogastrointestinal encephalomyopathy (MNGIE). To date, all of these etiologic nuclear genes fall into one of two categories: genes whose products function directly at the mtDNA replication fork, such as POLG, POLG2, and TWINKLE, or genes whose products supply the mitochondria with deoxynucleotide triphosphate pools needed for DNA replication, such as TK2, DGUOK, TP, SUCLA2, ANT1, and possibly the newly identified MPV17.
C1 [Copeland, William C.] NIEHS, Mol Genet Lab, Res Triangle Pk, NC 27709 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute of
   Environmental Health Sciences (NIEHS)
RP Copeland, WC (corresponding author), NIEHS, Mol Genet Lab, POB 12233, Res Triangle Pk, NC 27709 USA.
EM copelanl@nichs.nih.gov
RI Copeland, William/C-4242-2019
OI Copeland, William/0000-0002-0359-0953
FU Intramural NIH HHS [Z01 ES065078-14] Funding Source: Medline
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Aknin-Seifer IE, 2005, HUM REPROD, V20, P736, DOI 10.1093/humrep/deh666
   Alberio S, 2007, MITOCHONDRION, V7, P6, DOI 10.1016/j.mito.2006.11.010
   Baruffini E, 2006, HUM MOL GENET, V15, P2846, DOI 10.1093/hmg/ddl219
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Calvo S, 2006, NAT GENET, V38, P576, DOI 10.1038/ng1776
   Carrozzo R, 2003, HUM MUTAT, V21, DOI 10.1002/humu.9135
   Carrozzo R, 2007, BRAIN, V130, P862, DOI 10.1093/brain/awl389
   Chan SSL, 2006, HUM MOL GENET, V15, P3473, DOI 10.1093/hmg/ddl424
   Chan SSL, 2005, DNA REPAIR, V4, P1381, DOI 10.1016/j.dnarep.2005.08.010
   Chan SSL, 2005, J BIOL CHEM, V280, P31341, DOI 10.1074/jbc.M506762200
   Deschauer M, 2005, NEUROMUSCULAR DISORD, V15, P311, DOI 10.1016/j.nmd.2004.12.004
   DiMauro S, 2006, BRAIN, V129, P1637, DOI 10.1093/brain/awl169
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Fontanesi F, 2004, HUM MOL GENET, V13, P923, DOI 10.1093/hmg/ddh108
   Freisinger P, 2006, ARCH NEUROL-CHICAGO, V63, P1129, DOI 10.1001/archneur.63.8.1129
   Galbiati S, 2006, PEDIATR NEUROL, V34, P177, DOI 10.1016/j.pediatrneurol.2005.07.013
   Garrido N, 2003, MOL BIOL CELL, V14, P1583, DOI 10.1091/mbc.E02-07-0399
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   Graziewicz MA, 2006, CHEM REV, V106, P383, DOI 10.1021/cr040463d
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Hirano M, 2006, NEUROLOGY, V67, P1458, DOI 10.1212/01.wnl.0000240853.97716.24
   Hirano M, 2005, GENE, V354, P152, DOI 10.1016/j.gene.2005.04.041
   Hirano M, 2004, NEUROLOGIST, V10, P8, DOI 10.1097/01.nrl.0000106919.06469.04
   Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Hudson G, 2006, NEUROLOGY, V66, P1439, DOI 10.1212/01.wnl.0000210486.32196.24
   Hudson G, 2005, NEUROLOGY, V64, P371, DOI 10.1212/01.WNL.0000149767.51152.83
   Hudson G, 2006, HUM MOL GENET, V15, pR244, DOI 10.1093/hmg/ddl233
   Jensen M, 2004, HUM REPROD, V19, P65, DOI 10.1093/humrep/deh038
   Karadimas CL, 2006, AM J HUM GENET, V79, P544, DOI 10.1086/506913
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kaukonen J, 1999, AM J HUM GENET, V65, P256, DOI 10.1086/302445
   Kelley RI, 2002, AM J MED GENET, V112, P318, DOI 10.1002/ajmg.10529
   Kowluru A, 2002, ARCH BIOCHEM BIOPHYS, V398, P160, DOI 10.1006/abbi.2001.2710
   Krausz C, 2004, J CLIN ENDOCR METAB, V89, P4292, DOI 10.1210/jc.2004-0008
   Lara MC, 2006, NEUROLOGY, V67, P1461, DOI 10.1212/01.wnl.0000239824.95411.52
   Lewis W, 2007, LAB INVEST, V87, P326, DOI 10.1038/labinvest.3700523
   Lim SE, 2001, J BIOL CHEM, V276, P23616, DOI 10.1074/jbc.M101114200
   Lindhurst MJ, 2006, P NATL ACAD SCI USA, V103, P15927, DOI 10.1073/pnas.0607661103
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Longley MJ, 2005, GENE, V354, P125, DOI 10.1016/j.gene.2005.03.029
   Longley MJ, 2001, J BIOL CHEM, V276, P38555, DOI 10.1074/jbc.M105230200
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Luoma PT, 2005, HUM MOL GENET, V14, P1907, DOI 10.1093/hmg/ddi196
   Mancuso M, 2003, ARCH NEUROL-CHICAGO, V60, P1007, DOI 10.1001/archneur.60.7.1007
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   MANDERBACKA K, 2001, SCANDINAVIAN J P S55, V29, P41
   Marobbio CMT, 2002, EMBO J, V21, P5653, DOI 10.1093/emboj/cdf583
   Martí R, 2003, BIOCHEM BIOPH RES CO, V303, P14, DOI 10.1016/S0006-291X(03)00294-8
   Napoli L, 2001, NEUROLOGY, V57, P2295, DOI 10.1212/WNL.57.12.2295
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Naviaux RK, 1999, ANN NEUROL, V45, P54, DOI 10.1002/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B
   Nguyen KV, 2006, J HEPATOL, V45, P108, DOI 10.1016/j.jhep.2005.12.026
   Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828
   Nishino I, 2000, ANN NEUROL, V47, P792
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Ostergaard E, 2007, BRAIN, V130, P853, DOI 10.1093/brain/awl383
   Pagnamenta AT, 2006, HUM REPROD, V21, P2467, DOI 10.1093/humrep/del076
   Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200
   Ropp PA, 1996, GENOMICS, V36, P449, DOI 10.1006/geno.1996.0490
   Rosenberg MJ, 2002, NAT GENET, V32, P175, DOI 10.1038/ng948
   Rovio AT, 2001, NAT GENET, V29, P261, DOI 10.1038/ng759
   Saada A, 2003, MOL GENET METAB, V79, P1, DOI 10.1016/S1096-7192(03)00063-5
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284
   Song SW, 2003, J BIOL CHEM, V278, P43893, DOI 10.1074/jbc.C300401200
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spelbrink JN, 2000, J BIOL CHEM, V275, P24818, DOI 10.1074/jbc.M000559200
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Spinazzola A, 2002, J BIOL CHEM, V277, P4128, DOI 10.1074/jbc.M111028200
   SPINAZZOLA A, 2001, J BIOL CHEM, V3, P3
   Stuart GR, 2006, HUM MOL GENET, V15, P363, DOI 10.1093/hmg/ddi454
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Wang LY, 2005, MOL GENET METAB, V84, P75, DOI 10.1016/j.ymgme.2004.09.005
   Wang LY, 2003, FEBS LETT, V554, P319, DOI 10.1016/S0014-5793(03)01181-5
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
   zumGottesberge AMM, 1996, EUR ARCH OTO-RHINO-L, V253, P470, DOI 10.1007/BF00179952
NR 84
TC 213
Z9 246
U1 3
U2 42
PU ANNUAL REVIEWS
PI PALO ALTO
PA 4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0139 USA
SN 0066-4219
BN 978-0-8243-0559-8
J9 ANNU REV MED
JI Annu. Rev. Med.
PY 2008
VL 59
BP 131
EP 146
DI 10.1146/annurev.med.59.053006.104646
PG 16
WC Medicine, Research & Experimental
WE Book Citation Index – Science (BKCI-S); Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 265YJ
UT WOS:000253397600009
PM 17892433
OA Green Accepted
DA 2024-11-01
ER

PT J
AU De Meirleir, L
AF De Meirleir, Linda
TI THE CLINICAL SPECTRUM OF MITOCHONDRIAL DISEASES IN NEONATES AND YOUNG
   CHILDREN AND APPROACH TO DIAGNOSIS
SO PAEDIATRIA CROATICA
LA English
DT Article
DE DNA, MITOCHONDRIAL; LEIGH DISEASE; MITOCHONDRIAL ENCEPHALOMYOPATHIES;
   LACTIC ACIDOSIS
ID RESPIRATORY-CHAIN DEFICIENCY; MUTATIONS CAUSE; DNA; GENE;
   MANIFESTATIONS; ENCEPHALOPATHY; TRANSLATION; PREVALENCE; DISORDERS;
   PATHOLOGY
AB Mitochondrial diseases are becoming more frequently diagnosed in neonates and small children. Different clinical presentations are possible and specific investigations need to he performed in order to get to the right molecular diagnosis necessary for further genetic counseling. MONA or nuclear genes can be investigated after biochemical work-up in the affected tissue. In the neonate, severe presentation may lead to early death, so taking the possible mitochondrial disease in consideration is essential, especially in case of severe lactic acidosis, encephalopathy, myopathy, cardiomyopathy or hepatopathy. In infancy, there are three syndromes that can occur more frequently: Pearson's syndrome due to deletion of mitochondrial DNA; Leigh's encephalopathy, a progressive neurodegenerative disorder with many different mitochondrial gene mutations; and Alpers' disease, progressive gray matter degeneration due to mutations in the POLG gene. Different organ involvement is seen in mtDNA depletion syndromes and finally one should also consider CoQ10 deficiency in certain clinical presentations.
C1 Univ Brussels, Dept Neuropediat, Brussels, Belgium.
C3 Free University of Brussels
RP De Meirleir, L (corresponding author), Univ Brussels, Dept Neuropediat, Laarbeeklaan 101, Brussels, Belgium.
EM linda.demeirleir@uz-bnissel.be
RI De Meirleir, Linda/D-6591-2016
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Cizková A, 2008, NAT GENET, V40, P1288, DOI 10.1038/ng.246
   De Meirleir L, 2003, AM J MED GENET A, V121A, P126, DOI 10.1002/ajmg.a.20171
   DiMauro S, 2004, BBA-BIOENERGETICS, V1659, P107, DOI 10.1016/j.bbabio.2004.08.003
   Engelsen BA, 2008, BRAIN, V131, P818, DOI 10.1093/brain/awn007
   Fellman V, 2011, SEMIN FETAL NEONAT M, V16, P222, DOI 10.1016/j.siny.2011.05.002
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Isohanni P, 2011, NEUROLOGY, V76, P811, DOI 10.1212/WNL.0b013e31820e7b25
   Jonckheere AI, 2012, J INHERIT METAB DIS, V35, P211, DOI 10.1007/s10545-011-9382-9
   Kemp JP, 2011, BRAIN, V134, P183, DOI 10.1093/brain/awq320
   McFarland R, 2007, CURR TOP DEV BIOL, V77, P113, DOI 10.1016/S0070-2153(06)77005-3
   Ostergaard E, 2007, AM J HUM GENET, V81, P383, DOI 10.1086/519222
   Rahman S, 2012, NEUROMUSCULAR DISORD, V22, P76, DOI 10.1016/j.nmd.2011.05.001
   Rötig A, 2010, DIABETES METAB, V36, P97, DOI 10.1016/j.diabet.2009.11.002
   ROTIG A, 1990, J CLIN INVEST, V86, P1601, DOI 10.1172/JCI114881
   Scalais E, 2012, EUR J PAEDIAT NEUROL, V17
   Schaefer AM, 2008, ANN NEUROL, V63, P35, DOI 10.1002/ana.21217
   Schiff M, 2011, SEMIN FETAL NEONAT M, V16, P216, DOI 10.1016/j.siny.2011.04.002
   Shanske S, 2008, ARCH NEUROL-CHICAGO, V65, P368, DOI 10.1001/archneurol.2007.67
   Skladal D, 2003, BRAIN, V126, P1905, DOI 10.1093/brain/awg170
   Smet J, 2009, ELECTROPHORESIS, V30, P3565, DOI 10.1002/elps.200900213
   Valente L, 2007, AM J HUM GENET, V80, P44, DOI 10.1086/510559
   Van Coster R, 2001, PEDIATR RES, V50, P658, DOI 10.1203/00006450-200111000-00020
   von Kleist-Retzow JC, 2003, J PEDIATR-US, V143, P208, DOI 10.1067/S0022-3476(03)00130-6
   Wolf NI, 2009, EPILEPSIA, V50, P1596, DOI 10.1111/j.1528-1167.2008.01877.x
NR 26
TC 0
Z9 0
U1 0
U2 5
PU CHILDRENS HOSPITAL ZAGREB
PI ZAGREB
PA KLAICEVA 16, ZAGREB, 10000, CROATIA
SN 1330-1403
J9 PAEDIATR CROAT
JI Paediatr. Croat.
PD APR-JUN
PY 2012
VL 56
IS 2
BP 99
EP 103
PG 5
WC Pediatrics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pediatrics
GA 986ET
UT WOS:000307324700002
DA 2024-11-01
ER

PT J
AU Desquiret-Dumas, V
   Gueguen, N
   Barth, M
   Chevrollier, A
   Hancock, S
   Wallace, DC
   Amati-Bonneau, P
   Henrion, D
   Bonneau, D
   Reynier, P
   Procaccio, V
AF Desquiret-Dumas, Valerie
   Gueguen, Naig
   Barth, Magalie
   Chevrollier, Arnaud
   Hancock, Saege
   Wallace, Douglas C.
   Amati-Bonneau, Patrizia
   Henrion, Daniel
   Bonneau, Dominique
   Reynier, Pascal
   Procaccio, Vincent
TI Metabolically induced heteroplasmy shifting and l-arginine treatment
   reduce the energetic defect in a neuronal-like model of MELAS
SO BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE
LA English
DT Article
DE Mitochondria; Mitochondrial disorder; mtDNA; MELAS; Neuronal cell;
   L-arginine
ID STROKE-LIKE EPISODES; MITOCHONDRIAL-DNA MUTATION; A3243G MUTATION;
   LACTIC-ACIDOSIS; PROTEIN-SYNTHESIS; OXIDATIVE STRESS; HUMAN-CELLS;
   MYOPATHY; ENCEPHALOPATHY; DYSFUNCTION
AB The m.3243A>G variant in the mitochondrial tRNA(Leu(UUR)) gene is a common mitochondrial DNA (mtDNA) mutation. Phenotypic manifestations depend mainly on the heteroplasmy, i.e. the ratio of mutant to normal mtDNA copies. A high percentage of mutant mtDNA is associated with a severe, life-threatening neurological syndrome known as MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes). MELAS is described as a neurovascular disorder primarily affecting the brain and blood vessels, but the pathophysiology of the disease is poorly understood.
   We developed a series of cybrid cell lines at two different mutant loads: 70% and 100% in the nuclear background of a neuroblastoma cell line (SH-SY5Y). We investigated the impact of the mutation on the metabolism and mitochondrial respiratory chain activity of the cybrids. The m.3243A>G mitochondrial mutation induced a metabolic switch towards glycolysis in the neuronal cells and produced severe defects in respiratory chain assembly and activity. We used two strategies to compensate for the biochemical defects in the mutant cells: one consisted of lowering the glucose content in the culture medium, and the other involved the addition of L-arginine. The reduction of glucose significantly shifted the 100% mutant cells towards the wild-type, reaching a 90% mutant level and restoring respiratory chain complex assembly. The addition of L-arginine, a nitric oxide (NO) donor, improved complex I activity in the mutant cells in which the defective NO metabolism had led to a relative shortage of NO. Thus, metabolically induced heteroplasmy shifting and L-arginine therapy may constitute promising therapeutic strategies against MELAS. (C) 2012 Elsevier B.V. All rights reserved.
C1 [Desquiret-Dumas, Valerie; Gueguen, Naig; Barth, Magalie; Chevrollier, Arnaud; Amati-Bonneau, Patrizia; Bonneau, Dominique; Reynier, Pascal; Procaccio, Vincent] Angers Univ Hosp, Dept Biochem & Genet, Sch Med, F-49000 Angers, France.
   [Desquiret-Dumas, Valerie; Gueguen, Naig; Chevrollier, Arnaud; Amati-Bonneau, Patrizia; Henrion, Daniel; Bonneau, Dominique; Reynier, Pascal; Procaccio, Vincent] Univ Angers, UMR INSERM U1083 CNRS 6214, F-49000 Angers, France.
   [Hancock, Saege; Wallace, Douglas C.] Univ Penn, Ctr Mitochondrial & Epigen Med, Philadelphia, PA 19104 USA.
C3 Universite d'Angers; Centre Hospitalier Universitaire d'Angers;
   Universite d'Angers; Institut National de la Sante et de la Recherche
   Medicale (Inserm); University of Pennsylvania
RP Procaccio, V (corresponding author), CHU Angers, Biochem & Genet Lab, Natl Ctr Neurodegenerat & Mitochondrial Dis, 4 Rue Larrey, F-49933 Angers, France.
EM ViProcaccio@chu-angers.fr
RI Bonneau, Dominique/K-6110-2015; amati-bonneau, patrizia/K-6198-2015;
   Reynier, Pascal/K-3677-2015; Procaccio, Vincent/M-2596-2015;
   Desquiret-Dumas, Valérie/K-2695-2015; Henrion, Daniel/N-7023-2015;
   CHEVROLLIER, Arnaud/K-2853-2015; Henrion, Daniel/J-8141-2015
OI Reynier, Pascal/0000-0003-0802-4608; procaccio,
   Vincent/0000-0002-1537-4684; Desquiret-Dumas,
   Valerie/0000-0001-9551-9400; Bonneau, Dominique/0000-0002-6886-0969;
   CHEVROLLIER, Arnaud/0000-0002-5135-6643; Henrion,
   Daniel/0000-0003-1094-0285
FU University Hospital of Angers; Association contre les Maladies
   Mitochondriales (AMMi); Union Nationale des Aveugles et Deficients
   Visuels (UNADEV); National Institutes of Health [NS21328, AG24373,
   DK73691]
FX The authors thank Stephanie Chupin for cell culture and Cedric Gadras
   for mass spectrometry analysis. We are grateful to Kanaya Malkani for
   critical reading of the manuscript. This work was supported by grants
   from the University Hospital of Angers; the Association contre les
   Maladies Mitochondriales (AMMi); and the Union Nationale des Aveugles et
   Deficients Visuels (UNADEV); and by National Institutes of Health grants
   [NS21328, AG24373, DK73691] awarded to DCW.
CR Ahola-Erkkilä S, 2010, HUM MOL GENET, V19, P1974, DOI 10.1093/hmg/ddq076
   ATTARDI G, 1995, BBA-MOL BASIS DIS, V1271, P241, DOI 10.1016/0925-4439(95)00034-2
   Chomyn A, 2000, J BIOL CHEM, V275, P19198, DOI 10.1074/jbc.M908734199
   Davidson MM, 2009, MITOCHONDRION, V9, P463, DOI 10.1016/j.mito.2009.08.006
   Desquiret V, 2008, INT J BIOCHEM CELL B, V40, P1629, DOI 10.1016/j.biocel.2007.12.010
   El Meziane A, 1998, NAT GENET, V18, P350
   Fernández-Vizarra E, 2009, BBA-MOL CELL RES, V1793, P200, DOI 10.1016/j.bbamcr.2008.05.028
   Flierl A, 1997, J BIOL CHEM, V272, P27189, DOI 10.1074/jbc.272.43.27189
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Gu Z., MOL NEUROBIOL, V41, P55
   Han D, 2005, BIOCHEMISTRY-US, V44, P11986, DOI 10.1021/bi0509393
   Ishikawa K, 2009, METHOD ENZYMOL, V457, P335, DOI 10.1016/S0076-6879(09)05019-8
   Janssen GMC, 1999, J BIOL CHEM, V274, P29744, DOI 10.1074/jbc.274.42.29744
   Jarrett SG, 2008, J NEUROCHEM, V106, P1044, DOI 10.1111/j.1471-4159.2008.05460.x
   Katayama Y, 2009, MITOCHONDRION, V9, P306, DOI 10.1016/j.mito.2009.04.002
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   Koga Y, 2006, NEUROLOGY, V66, P1766, DOI 10.1212/01.wnl.0000220197.36849.1e
   Koga Y, 2005, NEUROLOGY, V64, P710, DOI 10.1212/01.WNL.0000151976.60624.01
   Koga Y, 2007, MITOCHONDRION, V7, P133, DOI 10.1016/j.mito.2006.11.006
   Koga Y, 2010, ANN NY ACAD SCI, V1201, P104, DOI 10.1111/j.1749-6632.2010.05624.x
   Lazarou M, 2009, BBA-MOL CELL RES, V1793, P78, DOI 10.1016/j.bbamcr.2008.04.015
   Lenaz G, 2010, BBA-BIOENERGETICS, V1797, P633, DOI 10.1016/j.bbabio.2010.01.025
   Li R., 2010, Mol Cell Biol, V30, P2147
   Maassen JA, 2004, DIABETES, V53, pS103, DOI 10.2337/diabetes.53.2007.S103
   Nochez Y, 2009, MOL VIS, V15, P598
   Okhuijsen-Kroes EJ, 2001, NEUROPEDIATRICS, V32, P183, DOI 10.1055/s-2001-17372
   Pang CY, 2001, DIABETES RES CLIN PR, V54, pS45, DOI 10.1016/S0168-8227(01)00335-7
   Park H, 2003, BIOCHEMISTRY-US, V42, P958, DOI 10.1021/bi026882r
   Park JS, 2009, HUM MOL GENET, V18, P1578, DOI 10.1093/hmg/ddp069
   Ruiz-Pesini E, 2007, NUCLEIC ACIDS RES, V35, pD823, DOI 10.1093/nar/gkl927
   SAKUTA R, 1989, ANN NEUROL, V25, P594, DOI 10.1002/ana.410250611
   Santra S, 2004, ANN NEUROL, V56, P662, DOI 10.1002/ana.20240
   Sarzi E, 2007, AM J MED GENET A, V143A, P33, DOI 10.1002/ajmg.a.31565
   Sawada N, 2009, EXPERT REV NEUROTHER, V9, P1171, DOI [10.1586/ern.09.70, 10.1586/ERN.09.70]
   Shanske S, 2004, AM J MED GENET A, V130A, P134, DOI 10.1002/ajmg.a.30220
   Shigemi R., 2010, BRAIN DEV
   Sproule DM, 2008, ANN NY ACAD SCI, V1142, P133, DOI 10.1196/annals.1444.011
   Swerdlow RH, 1996, ANN NEUROL, V40, P663, DOI 10.1002/ana.410400417
   Swerdlow RH, 2011, ANTIOXID REDOX SIGNA
   Uusimaa J, 2007, ANN NEUROL, V62, P278, DOI 10.1002/ana.21196
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Wallace DC, 2010, ANNU REV PATHOL-MECH, V5, P297, DOI 10.1146/annurev.pathol.4.110807.092314
   Wu YT, 2010, ANN NY ACAD SCI, V1201, P147, DOI 10.1111/j.1749-6632.2010.05631.x
NR 43
TC 35
Z9 39
U1 0
U2 8
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0925-4439
J9 BBA-MOL BASIS DIS
JI Biochim. Biophys. Acta-Mol. Basis Dis.
PD JUN
PY 2012
VL 1822
IS 6
BP 1019
EP 1029
DI 10.1016/j.bbadis.2012.01.010
PG 11
WC Biochemistry & Molecular Biology; Biophysics; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Cell Biology
GA 941KE
UT WOS:000303961300020
PM 22306605
OA Green Accepted, Bronze
DA 2024-11-01
ER

PT J
AU Soldath, P
   Madsen, KL
   Buch, AE
   Duno, M
   Wibrand, F
   Vissing, J
AF Soldath, Patrick
   Madsen, Karen Lindhardt
   Buch, Astrid Emilie
   Duno, Morten
   Wibrand, Flemming
   Vissing, John
TI Pure exercise intolerance and ophthalmoplegia associated with the m.
   12,294G > A mutation in the <i>MT</i>-<i>TL2</i> gene: a case report
SO BMC MUSCULOSKELETAL DISORDERS
LA English
DT Article
DE Case report; Mitochondrial DNA; MT-TL2 mutation; Mitochondrial myopathy;
   Exercise intolerance; Exercise physiological study; Maximal oxidative
   capacity
ID TRANSFER-RNA MUTATIONS; MITOCHONDRIAL; DNA; MUSCLE; MYOGLOBINURIA;
   PATHOGENICITY; CAPACITY
AB Background: Pure exercise intolerance associated with exclusive affection of skeletal muscle is a very rare phenotype of patients with mitochondrial myopathy. Moreover, the exercise intolerance in these rare patients is yet not well explored, as most of known cases have not been assessed by objective testing, but only by interview. We report a patient with a mitochondrial DNA (mtDNA) mutation that gives rise to an exclusive myopathy associated with exercise intolerance and ophthalmoplegia. We quantified the patient's exercise intolerance through detailed exercise testing.
   Case presentation: A 39-year-old man presented with exercise intolerance and chronic progressive external ophthalmoplegia. Sequencing of the entire mtDNA identified a m. 12,294G > A mutation in the MT-TL2 gene. The mutation was heteroplasmic in skeletal muscle (75%) while undetectable in blood, urinary sediment, and buccal mucosa as well as in tissues from the patient's mother. The mutation affected a highly conserved site in the anticodon stem of the mitochondrial transfer RNA Leucine (CUN) molecule and lead to a severe combined respiratory chain defect. Exercise physiological studies in the patient demonstrated a significantly reduced maximal oxygen uptake of 20.4 ml O-2 x min(-1) x kg(-1) (about half of normal) as well as threefold elevated lactate/pyruvate ratios.
   Conclusion: The findings of our study support that the m. 12,294G > A mutation is pathogenic. Likely, the mutation arose sporadically in early embryogenesis after differentiation of the mesoderm into muscle progenitor cells, leading to a pure myopathic phenotype.
C1 [Soldath, Patrick; Madsen, Karen Lindhardt; Buch, Astrid Emilie; Vissing, John] Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.
   [Soldath, Patrick; Madsen, Karen Lindhardt; Buch, Astrid Emilie; Vissing, John] Rigshosp, Copenhagen Neuromuscular Ctr, Dept Neurol, Copenhagen, Denmark.
   [Duno, Morten; Wibrand, Flemming] Rigshosp, Dept Clin Genet, Copenhagen, Denmark.
C3 University of Copenhagen; University of Copenhagen; Rigshospitalet;
   University of Copenhagen; Rigshospitalet
RP Soldath, P (corresponding author), Univ Copenhagen, Fac Hlth & Med Sci, Copenhagen, Denmark.; Soldath, P (corresponding author), Rigshosp, Copenhagen Neuromuscular Ctr, Dept Neurol, Copenhagen, Denmark.
EM Patricksoldath@gmail.com
RI Vissing, John/IUN-4271-2023
OI Buch, Astrid Emilie/0000-0002-8571-5480; Madsen, Karen
   Lindhardt/0000-0003-0145-1084; Soldath, Patrick/0000-0002-5275-1661
CR Blakely EL, 2013, HUM MUTAT, V34, P1260, DOI 10.1002/humu.22358
   Born AP, 2015, EUR J PAEDIATR NEURO, V19, P69, DOI 10.1016/j.ejpn.2014.10.006
   Elson JL, 2009, HUM MUTAT, V30, pE984, DOI 10.1002/humu.21113
   Hiniker A, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/s40478-014-0137-3
   JACKSON MJ, 1995, BRAIN, V118, P339, DOI 10.1093/brain/118.2.339
   Jeppesen TD, 2003, ANN NEUROL, V54, P86, DOI 10.1002/ana.10594
   Jeppesen TD, 2006, BRAIN, V129, P3402, DOI 10.1093/brain/awl149
   Jeppesen TD, 2014, NEUROMUSCULAR DISORD, V24, P162, DOI 10.1016/j.nmd.2013.08.004
   Kleinle S, 1997, HUM GENET, V100, P643, DOI 10.1007/s004390050567
   Larsen S, 2012, J PHYSIOL-LONDON, V590, P3349, DOI 10.1113/jphysiol.2012.230185
   Lott Marie T, 2013, Curr Protoc Bioinformatics, V44, DOI 10.1002/0471250953.bi0123s44
   McFarland R, 2004, TRENDS GENET, V20, P591, DOI 10.1016/j.tig.2004.09.014
   MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   OLD SL, 1989, HISTOCHEM J, V21, P545, DOI 10.1007/BF01753355
   Parson W, 2013, FORENSIC SCI INT-GEN, V7, P543, DOI 10.1016/j.fsigen.2013.06.003
   Pulkes T, 2003, NEUROLOGY, V61, P1144, DOI 10.1212/01.WNL.0000090465.27024.3D
   Rafiq J, 2016, JIMD REP, V25, P65, DOI 10.1007/8904_2015_459
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Vissing CR, 2013, NEUROLOGY, V80, P1908, DOI 10.1212/WNL.0b013e3182929fb2
   Vissing J, 1998, NEUROLOGY, V50, P1875, DOI 10.1212/WNL.50.6.1875
   WASSERMAN K, 1985, J APPL PHYSIOL, V59, P935, DOI 10.1152/jappl.1985.59.3.935
   Yarham JW, 2011, HUM MUTAT, V32, P1319, DOI 10.1002/humu.21575
   Yarham JW, 2010, WIRES RNA, V1, P304, DOI 10.1002/wrna.27
NR 24
TC 7
Z9 7
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2474
J9 BMC MUSCULOSKEL DIS
JI BMC Musculoskelet. Disord.
PD OCT 19
PY 2017
VL 18
AR 419
DI 10.1186/s12891-017-1781-0
PG 6
WC Orthopedics; Rheumatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Orthopedics; Rheumatology
GA FK4JT
UT WOS:000413460400001
PM 29052516
OA Green Published, gold
DA 2024-11-01
ER

PT J
AU Tyynismaa, H
   Mjosund, KP
   Wanrooij, S
   Lappalainen, I
   Ylikallio, E
   Jalanko, A
   Spelbrink, JN
   Paetau, A
   Suomalainen, A
AF Tyynismaa, H
   Mjosund, KP
   Wanrooij, S
   Lappalainen, I
   Ylikallio, E
   Jalanko, A
   Spelbrink, JN
   Paetau, A
   Suomalainen, A
TI Mutant mitochondrial helicase Twinkle causes multiple mtDNA deletions
   and a late-onset mitochondrial disease in mice
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE mouse model; progressive external ophthalmoplegia; mitochondrial DNA
   replication
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; DNA POLYMERASE; RESPIRATORY-CHAIN;
   CRYSTAL-STRUCTURE; POLG MUTATIONS; MOUSE; MUSCLE; GENE; T7; CELLS
AB Defects of mitochondrial DNA (mtDNA) maintenance have recently been associated with inherited neurodegenerative and muscle diseases and the aging process. Twinkle is a nuclear-encoded mtDNA helicase, dominant mutations of which cause adult-onset progressive external ophthalmoplegia (PEO) with multiple mtDNA deletions. We have generated transgenic mice expressing mouse Twinkle with PEO patient mutations. Multiple mtDNA deletions accumulate in the tissues of these mice, resulting in progressive respiratory dysfunction and chronic late-onset mitochondrial disease starting at 1 year of age. The muscles of the mice faithfully replicate all of the key histological, genetic, and biochemical features of PEO patients. Furthermore, the mice have progressive deficiency of cytochrome c oxidase in distinct neuronal populations. These "deletor" mice do not, however, show premature aging, indicating that subtle accumulation of mtDNA deletions and progressive respiratory chain dysfunction are not sufficient to accelerate aging. This model is a valuable tool for therapy development and testing for adult-onset mitochondrial disorders.
C1 Univ Helsinki, Dept Neurol, FIN-00290 Helsinki, Finland.
   Univ Helsinki, Neurosci Program, FIN-00290 Helsinki, Finland.
   Inst Med Technol, Tampere 33014, Finland.
   Tampere Univ Hosp, Tampere 33014, Finland.
   Natl Publ Hlth Inst, Dept Mol Med, Helsinki 00290, Finland.
   Univ Helsinki, Haartman Inst, Helsinki 00290, Finland.
   Univ Helsinki, Cent Hosp, Dept Pathol, FIN-00290 Helsinki, Finland.
C3 University of Helsinki; University of Helsinki; Tampere University;
   Tampere University Hospital; Finland National Institute for Health &
   Welfare; University of Helsinki; University of Helsinki; Helsinki
   University Central Hospital
RP Univ Helsinki, Dept Neurol, FIN-00290 Helsinki, Finland.
EM anu.wartiovaara@helsinki.fi
RI Ylikallio, Emil/S-9434-2019; Wanrooij, Sjoerd/J-1367-2019; Tyynismaa,
   Henna/F-1428-2011; Spelbrink, Johannes/L-4661-2015
OI Spelbrink, Johannes/0000-0002-9756-2602; Ylikallio,
   Emil/0000-0001-5178-0703; Suomalainen-Wartiovaara,
   Anu/0000-0003-4833-5195; Wanrooij, Sjoerd/0000-0001-6126-4382;
   Tyynismaa, Henna/0000-0002-2493-2422
CR Allen DL, 2001, J APPL PHYSIOL, V90, P1900, DOI 10.1152/jappl.2001.90.5.1900
   Cottrell DA, 2001, NEUROLOGY, V57, P260, DOI 10.1212/WNL.57.2.260
   Cottrell DA, 2001, NEUROBIOL AGING, V22, P265, DOI 10.1016/S0197-4580(00)00234-7
   Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226
   Huo L, 2001, MOL CELL BIOL, V21, P644, DOI 10.1128/MCB.21.2.644-654.2001
   Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826
   Kajander OA, 2000, HUM MOL GENET, V9, P2821, DOI 10.1093/hmg/9.19.2821
   Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257
   Larsson NG, 2001, TRENDS MOL MED, V7, P578, DOI 10.1016/S1471-4914(01)02167-0
   Lewis S, 2002, J NEUROL SCI, V201, P39, DOI 10.1016/S0022-510X(02)00190-9
   Löfberg M, 2001, NEUROMUSCULAR DISORD, V11, P370, DOI 10.1016/S0960-8966(00)00205-4
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   MAJANDER A, 1995, J NEUROL SCI, V134, P95, DOI 10.1016/0022-510X(95)00225-5
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Sawaya MR, 1999, CELL, V99, P167, DOI 10.1016/S0092-8674(00)81648-7
   Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spelbrink JN, 2000, J BIOL CHEM, V275, P24818, DOI 10.1074/jbc.M000559200
   Srivastava S, 2005, HUM MOL GENET, V14, P893, DOI 10.1093/hmg/ddi082
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Tyynismaa H, 2004, HUM MOL GENET, V13, P3219, DOI 10.1093/hmg/ddh342
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   WALBERG MW, 1981, NUCLEIC ACIDS RES, V9, P5411, DOI 10.1093/nar/9.20.5411
   Wanrooij S, 2004, NUCLEIC ACIDS RES, V32, P3053, DOI 10.1093/nar/gkh634
   Washington MT, 1996, J BIOL CHEM, V271, P26825, DOI 10.1074/jbc.271.43.26825
   Zapala MA, 2005, P NATL ACAD SCI USA, V102, P10357, DOI 10.1073/pnas.0503357102
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 31
TC 259
Z9 296
U1 0
U2 16
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD DEC 6
PY 2005
VL 102
IS 49
BP 17687
EP 17692
DI 10.1073/pnas.0505551102
PG 6
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 991XU
UT WOS:000233849000028
PM 16301523
OA Green Published
DA 2024-11-01
ER

PT J
AU Elstner, M
   Olszewski, K
   Prokisch, H
   Klopstock, T
   Murgia, M
AF Elstner, Matthias
   Olszewski, Konrad
   Prokisch, Holger
   Klopstock, Thomas
   Murgia, Marta
TI Multi-Omics Approach to Mitochondrial DNA Damage in Human Muscle Fibers
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE skeletal muscle; mtDNA deletions; transcriptomics; proteomics; myopathy;
   disease models
ID DELETION MUTATIONS; OXIDATIVE DAMAGE; PROTEOMICS; GENETICS
AB Mitochondrial DNA deletions affect energy metabolism at tissue-specific and cell-specific threshold levels, but the pathophysiological mechanisms determining cell fate remain poorly understood. Chronic progressive external ophthalmoplegia (CPEO) is caused by mtDNA deletions and characterized by a mosaic distribution of muscle fibers with defective cytochrome oxidase (COX) activity, interspersed among fibers with retained functional respiratory chain. We used diagnostic histochemistry to distinguish COX-negative from COX-positive fibers in nine muscle biopsies from CPEO patients and performed laser capture microdissection (LCM) coupled to genome-wide gene expression analysis. To gain molecular insight into the pathogenesis, we applied network and pathway analysis to highlight molecular differences of the COX-positive and COX-negative fiber transcriptome. We then integrated our results with proteomics data that we previously obtained comparing COX-positive and COX-negative fiber sections from three other patients. By virtue of the combination of LCM and a multi-omics approach, we here provide a comprehensive resource to tackle the pathogenic changes leading to progressive respiratory chain deficiency and disease in mitochondrial deletion syndromes. Our data show that COX-negative fibers upregulate transcripts involved in translational elongation and protein synthesis. Furthermore, based on functional annotation analysis, we find that mitochondrial transcripts are the most enriched among those with significantly different expression between COX-positive and COX-negative fibers, indicating that our unbiased large-scale approach resolves the core of the pathogenic changes. Further enrichments include transcripts encoding LIM domain proteins, ubiquitin ligases, proteins involved in RNA turnover, and, interestingly, cell cycle arrest and cell death. These pathways may thus have a functional association to the molecular pathogenesis of the disease. Overall, the transcriptome and proteome show a low degree of correlation in CPEO patients, suggesting a relevant contribution of post-transcriptional mechanisms in shaping this disease phenotype.
C1 [Elstner, Matthias] Tech Univ Munich, Dept Neurol, D-81675 Munich, Germany.
   [Olszewski, Konrad] Univ Zurich, Psychiat Hosp, Ctr Addict Disorders, Dept Psychiat Psychotherapy & Psychosomat, CH-8001 Zurich, Switzerland.
   [Prokisch, Holger] Tech Univ Munich, Inst Human Genet, D-81675 Munich, Germany.
   [Prokisch, Holger] Helmholtz Zentrum Munich, Inst Neurogen, D-85764 Neuherberg, Germany.
   [Klopstock, Thomas] Univ Munich, Friedrich Baur Inst, Dept Neurol, D-80336 Munich, Germany.
   [Klopstock, Thomas] German Ctr Neurodegenerat Dis DZNE, D-81675 Munich, Germany.
   [Klopstock, Thomas] Munich Cluster Syst Neurol SyNergy, D-81675 Munich, Germany.
   [Murgia, Marta] Max Planck Inst Biochem, Dept Prote Signal Transduct, D-82352 Martinsried, Germany.
   [Murgia, Marta] Univ Padua, Dept Biomed Sci, I-35131 Padua, Italy.
C3 Technical University of Munich; University of Zurich; Technical
   University of Munich; Helmholtz Association; Helmholtz-Center Munich -
   German Research Center for Environmental Health; University of Munich;
   Helmholtz Association; German Center for Neurodegenerative Diseases
   (DZNE); University of Munich; Max Planck Society; University of Padua
RP Murgia, M (corresponding author), Max Planck Inst Biochem, Dept Prote Signal Transduct, D-82352 Martinsried, Germany.; Murgia, M (corresponding author), Univ Padua, Dept Biomed Sci, I-35131 Padua, Italy.
EM m.elstner@tum.de; kolsz@gmx.net; prokisch@helmholtz-muenchen.de;
   Thomas.Klopstock@med.uni-muenchen.de; mmurgia@biochem.mpg.de
RI Prokisch, Holger/N-8964-2013
OI Klopstock, Thomas/0000-0003-2805-4652; MURGIA,
   MARTA/0000-0001-6244-3358; Prokisch, Holger/0000-0003-2379-6286
FU German Bundesministerium fur Bildung und Forschung (BMBF) [01GM1906A,
   01GM1920A, 01GM1920B]; Italian Space Agency, grant MARS-PRE
   [DC-VUM-2017-006]
FX This research was funded by the German Bundesministerium fur Bildung und
   Forschung (BMBF) through the project mitoNET (01GM1906A) to T.K. and
   through the E-Rare project GENOMIT (01GM1920A,B)to H.P. and T.K. It was
   also funded by the Italian Space Agency, grant MARS-PRE, Project, n.
   DC-VUM-2017-006 to M.M.
CR Aiken J, 2002, ANN NY ACAD SCI, V959, P412, DOI 10.1111/j.1749-6632.2002.tb02111.x
   Alemi M, 2007, FREE RADICAL BIO MED, V42, P32, DOI 10.1016/j.freeradbiomed.2006.09.014
   Alston CL, 2017, J PATHOL, V241, P236, DOI 10.1002/path.4809
   Auré K, 2006, BRAIN, V129, P1249, DOI 10.1093/brain/awl061
   Bakkar N, 2012, J CELL BIOL, V196, P497, DOI 10.1083/jcb.201108118
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Bratic A, 2013, J CLIN INVEST, V123, P951, DOI 10.1172/JCI64125
   Brini M, 1999, NAT MED, V5, P951, DOI 10.1038/11396
   Cox J, 2014, MOL CELL PROTEOMICS, V13, P2513, DOI 10.1074/mcp.M113.031591
   Cox J, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-S16-S12
   Deshmukh AS, 2015, MOL CELL PROTEOMICS, V14, P841, DOI 10.1074/mcp.M114.044222
   DiMauro S, 2012, ADV EXP MED BIOL, V748, P341, DOI 10.1007/978-1-4614-3573-0_14
   Elstner M, 2012, BRAIN RES BULL, V88, P285, DOI 10.1016/j.brainresbull.2011.07.018
   Elstner M, 2011, ACTA NEUROPATHOL, V122, P75, DOI 10.1007/s00401-011-0828-9
   Gomes LC, 2011, NAT CELL BIOL, V13, P589, DOI 10.1038/ncb2220
   Kalko SG, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-91
   Grady JP, 2014, BRAIN, V137, P323, DOI 10.1093/brain/awt321
   Guglielmi V, 2016, CLIN SCI, V130, P167, DOI 10.1042/CS20150394
   Hathazi D, 2020, EMBO J, V39, DOI 10.15252/embj.2020105364
   Heddi A, 1999, J BIOL CHEM, V274, P22968, DOI 10.1074/jbc.274.33.22968
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Kauppila TES, 2017, CELL METAB, V25, P57, DOI 10.1016/j.cmet.2016.09.017
   Kazachkova N, 2013, NEURODEGENER DIS, V11, P206, DOI 10.1159/000339207
   Krishnan KJ, 2008, NAT GENET, V40, P275, DOI 10.1038/ng.f.94
   Krishnan KJ, 2007, ANAL BIOCHEM, V370, P127, DOI 10.1016/j.ab.2007.06.024
   Lu CY, 1999, MUTAT RES-FUND MOL M, V423, P11, DOI 10.1016/S0027-5107(98)00220-6
   Ma YS, 2009, BBA-GEN SUBJECTS, V1790, P1021, DOI 10.1016/j.bbagen.2009.04.012
   Murgia M, 2019, CELL REP, V29, P3825, DOI 10.1016/j.celrep.2019.11.055
   Ng YS, 2016, J NEUROL, V263, P179, DOI 10.1007/s00415-015-7884-3
   Nissanka N, 2019, TRENDS GENET, V35, P235, DOI 10.1016/j.tig.2019.01.001
   Pereira CV, 2021, CRIT REV BIOCHEM MOL, V56, P510, DOI 10.1080/10409238.2021.1934812
   Porteous WK, 1998, EUR J BIOCHEM, V257, P192, DOI 10.1046/j.1432-1327.1998.2570192.x
   Rossignol R, 2003, BIOCHEM J, V370, P751, DOI 10.1042/BJ20021594
   Santacatterina F, 2018, FREE RADICAL BIO MED, V126, P235, DOI 10.1016/j.freeradbiomed.2018.08.020
   Schapira AHV, 2012, LANCET, V379, P1825, DOI 10.1016/S0140-6736(11)61305-6
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI [10.1093/nar/gky1131, 10.1093/nar/gkac1000]
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   Tyanova S, 2016, NAT METHODS, V13, P731, DOI [10.1038/nmeth.3901, 10.1038/NMETH.3901]
   Viscomi C, 2016, BIOCHEM SOC T, V44, P1483, DOI 10.1042/BST20160085
   Wanagat J, 2001, FASEB J, V15, P322, DOI 10.1096/fj.00-0320com
   Wei W, 2019, SCIENCE, V364, P749, DOI 10.1126/science.aau6520
   Wilson WC, 2014, HUM MOL GENET, V23, P6345, DOI 10.1093/hmg/ddu352
   Xiong SQ, 2015, CELL REP, V12, P1391, DOI 10.1016/j.celrep.2015.07.047
NR 44
TC 2
Z9 2
U1 0
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD OCT
PY 2021
VL 22
IS 20
AR 11080
DI 10.3390/ijms222011080
PG 15
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA WU0TD
UT WOS:000716266100001
PM 34681740
OA Green Published, gold
DA 2024-11-01
ER

PT J
AU Van Driessche, K
   Ducatelle, R
   Chiers, K
   Van Coster, R
   van der Kolk, JH
AF Van Driessche, K.
   Ducatelle, R.
   Chiers, K.
   Van Coster, R.
   van der Kolk, J. H.
TI Ultrastructural mitochondrial alterations in Equine myopathies of
   unknown origin
SO VETERINARY QUARTERLY
LA English
DT Article
DE Musculus quadriceps femoris; myopathy; ultrastructure; mitochondrion;
   equine; horse
ID ATYPICAL MYOPATHY; SKELETAL-MUSCLE; DISEASE; DISORDERS; HORSES; DNA;
   MUTATIONS; DIAGNOSIS; DYNAMICS; FUSION
AB Background: Very few mitochondrial myopathies have been described in horses.
   Objective: To examine the ultrastructure of muscle mitochondria in equine cases of myopathy of unknown origin.
   Materials & methods: Biopsies of vastus lateralis of the Musculus quadriceps femoris were taken predominantly immediately post mortem and processed for transmission electron microscopy. As a result, electron micrographs of 90 horses in total were available for analysis comprising 4 control horses, 16 horses suffering from myopathy and 70 otherwise diseased horses.
   Results: Following a thorough clinical and laboratory work-up, four out of five patients that did not fit into the usual algorithm to detect known causes of myopathy showed ultrastructural mitochondrial alterations. Small mitochondria with zones with complete disruption of cristae associated with lactic acidemia were detected in a 17-year-old pony mare, extremely long and slender mitochondria with longitudinal cristae in a 5-year-old Quarter horse stallion, a mixture of irregular extremely large mitochondria (measuring 2500 by 800nm) next to smaller ones in an 8-year-old Hanoverian mare and round mitochondria with only few cristae in a 11-year-old pony gelding. It remains uncertain whether the subsarcolemmal mitochondrial accumulations observed in the fifth patient have any pathological significance.
   Conclusions: Ultrastructural alterations in mitochondria were detected in at least four horses. To conclude that these are due to mitochondrial dysfuntions, biochemical tests should be performed.
   Practical applications: The possibility of a mitochondrial myopathy should be included in the differential diagnosis of muscle weakness.
C1 [Van Driessche, K.; Ducatelle, R.; Chiers, K.] Univ Ghent, Dept Pathol Bacteriol & Avian Med, Fac Vet Med, Merelbeke, Belgium.
   [Van Coster, R.] Univ Ghent, Div Child Neurol & Metab, Dept Pediat & Genet, Fac Med, B-9000 Ghent, Belgium.
   [Van Coster, R.] Univ Ghent, Neuromuscular Reference Ctr, Fac Med, B-9000 Ghent, Belgium.
   [van der Kolk, J. H.] Univ Bern, Swiss Inst Equine Med ISME, Vetsuisse Fac, Div Clin Vet Med, Bern, Switzerland.
   [van der Kolk, J. H.] Euregio Lab Serv, Sect Equine Metab & Genet Dis, Maastricht, Netherlands.
C3 Ghent University; Ghent University; Ghent University; University of
   Bern; Maastricht University
RP Van Driessche, K (corresponding author), Univ Ghent, Dept Pathol Bacteriol & Avian Med, Fac Vet Med, Merelbeke, Belgium.
EM Karolien.VanDriessche@UGent.be
CR Aleman M, 2008, NEUROMUSCULAR DISORD, V18, P277, DOI 10.1016/j.nmd.2008.01.001
   Aleman M, 2006, NEUROMUSCULAR DISORD, V16, P737, DOI 10.1016/j.nmd.2006.07.019
   Bourgeois JM, 2004, MITOCHONDRION, V4, P441, DOI 10.1016/j.mito.2004.07.036
   BROWN WM, 1979, P NATL ACAD SCI USA, V76, P1967, DOI 10.1073/pnas.76.4.1967
   Cassart D, 2007, EQUINE VET J, V39, P26, DOI 10.2746/042516407X157765
   Chen HC, 2010, CELL, V141, P280, DOI 10.1016/j.cell.2010.02.026
   Cheville FN, 1994, ULTRASTRUCT PATHOL, P51
   Detmer SA, 2007, NAT REV MOL CELL BIO, V8, P870, DOI 10.1038/nrm2275
   DEVIVO DC, 1990, BIOL NEONATE, V58, P54
   Dimauro S, 2005, ANN MED, V37, P222, DOI 10.1080/07853890510007368
   Gomes LC, 2011, NAT CELL BIOL, V13, P589, DOI 10.1038/ncb2220
   Haas RH, 2008, MOL GENET METAB, V94, P16, DOI 10.1016/j.ymgme.2007.11.018
   Harrison SP, 2006, MITOCHONDRION, V6, P53, DOI 10.1016/j.mito.2006.01.002
   Jiang QY, 2011, MOL BIOL REP, V38, P593, DOI 10.1007/s11033-010-0145-8
   Kanzaki Y, 2010, CIRCULATION, V121, P831, DOI 10.1161/CIR.0b013e3181d22e2d
   Koshiba T, 2004, SCIENCE, V305, P858, DOI 10.1126/science.1099793
   Mitsuhashi S, 2013, CURR OPIN NEUROL, V26, P536, DOI 10.1097/WCO.0b013e328364c82d
   Okamoto K, 2005, ANNU REV GENET, V39, P503, DOI 10.1146/annurev.genet.38.072902.093019
   Pfeffer G, 2013, ANN MED, V45, P4, DOI 10.3109/07853890.2011.605389
   RIFAI Z, 1995, ANN NEUROL, V37, P24, DOI 10.1002/ana.410370107
   Schaefer AM, 2004, BBA-BIOENERGETICS, V1659, P115, DOI 10.1016/j.bbabio.2004.09.005
   Son Z, 2009, MOL BIOL CELL, V20, P3525
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   VALBERG SJ, 1994, MUSCLE NERVE, V17, P305, DOI 10.1002/mus.880170308
   van Galen G, 2012, EQUINE VET J, V44, P621, DOI 10.1111/j.2042-3306.2012.00555.x
   Westermann B, 2010, NAT REV MOL CELL BIO, V11, P872, DOI 10.1038/nrm3013
   Westermann CM, 2011, MOL GENET METAB, V104, P273, DOI 10.1016/j.ymgme.2011.07.022
NR 27
TC 2
Z9 2
U1 0
U2 14
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0165-2176
EI 1875-5941
J9 VET QUART
JI Vet. Q.
PD JAN 2
PY 2015
VL 35
IS 1
BP 2
EP 8
DI 10.1080/01652176.2015.983681
PG 7
WC Veterinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Veterinary Sciences
GA CB1PZ
UT WOS:000349401400002
PM 25365353
OA Bronze
DA 2024-11-01
ER

PT J
AU Jeppesen, TD
   Duno, M
   Schwartz, M
   Krag, T
   Rafiq, J
   Wibrand, F
   Vissing, J
AF Jeppesen, T. D.
   Duno, M.
   Schwartz, M.
   Krag, T.
   Rafiq, J.
   Wibrand, F.
   Vissing, J.
TI Short- and long-term effects of endurance training in patients with
   mitochondrial myopathy
SO EUROPEAN JOURNAL OF NEUROLOGY
LA English
DT Article
DE mitochondrial myopathy; mtDNA; training
AB Background and purpose:
   It is unknown whether prolonged training is a safe treatment to alleviate exercise intolerance in patients with mitochondrial DNA (mtDNA) mutations.
   Methods:
   The effect of 3 and 12 months training and 3-12 months deconditioning was studied in four patients carrying different mtDNA mutations.
   Results:
   Three-month moderate-intensity training increased oxidative capacity by 23%, which was sustained after 6-12 months of low-intensity training. Training and deconditioning did not induce adverse effects on clinical symptoms, muscle morphology and mtDNA mutation load in muscle.
   Conclusion:
   Long-term training effectively improves exercise capacity in patients with mitochondrial myopathy, and appears to be safe.
C1 [Jeppesen, T. D.] Univ Copenhagen, Rigshosp, Sect 3342, Neuromuscular Res Unit,Dept Neurol, DK-2100 Copenhagen, Denmark.
   [Jeppesen, T. D.; Krag, T.; Rafiq, J.; Vissing, J.] Univ Copenhagen, Rigshosp, Copenhagen Muscle Res Ctr, DK-2100 Copenhagen, Denmark.
   [Duno, M.; Schwartz, M.; Wibrand, F.] Univ Copenhagen, Rigshosp, Dept Clin Genet, DK-2100 Copenhagen, Denmark.
C3 University of Copenhagen; Rigshospitalet; Rigshospitalet; University of
   Copenhagen; University of Copenhagen; Rigshospitalet
RP Jeppesen, TD (corresponding author), Univ Copenhagen, Rigshosp, Sect 3342, Neuromuscular Res Unit,Dept Neurol, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.
EM dysgaard@rh.dk
RI Krag, Thomas/AAD-3307-2021; Vissing, John/IUN-4271-2023; Jeppesen,
   Tina/AAV-7195-2020
OI Krag, Thomas/0000-0001-9330-668X
CR ADHIHETTY PJ, 2007, AM J PHYSIOL-ENDOC M, V293, P72
   Auré K, 2006, BRAIN, V129, P1249, DOI 10.1093/brain/awl061
   Jeppesen TD, 2006, BRAIN, V129, P3402, DOI 10.1093/brain/awl149
   Siciliano G, 2007, BIOSCIENCE REP, V27, P53, DOI 10.1007/s10540-007-9037-0
   Taivassalo T, 2001, ANN NEUROL, V50, P133, DOI 10.1002/ana.1050
   Taivassalo T, 2006, BRAIN, V129, P3391, DOI 10.1093/brain/awl282
   [No title captured]
NR 7
TC 32
Z9 34
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1351-5101
EI 1468-1331
J9 EUR J NEUROL
JI Eur. J. Neurol.
PD DEC
PY 2009
VL 16
IS 12
BP 1336
EP 1339
DI 10.1111/j.1468-1331.2009.02660.x
PG 4
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 522BT
UT WOS:000271973400014
PM 19486129
DA 2024-11-01
ER

PT J
AU Tarnopolsky, MA
   Simon, DK
   Roy, BD
   Chorneyko, K
   Lowther, SA
   Johns, DR
   Sandhu, JK
   Li, Y
   Sikorska, M
AF Tarnopolsky, MA
   Simon, DK
   Roy, BD
   Chorneyko, K
   Lowther, SA
   Johns, DR
   Sandhu, JK
   Li, Y
   Sikorska, M
TI Attenuation of free radical production and paracrystalline inclusions by
   creatine supplementation in a patient with a novel cytochrome <i>b</i>
   mutation
SO MUSCLE & NERVE
LA English
DT Article
DE creatine kinase; cybrids; exercise; dietary supplements; mitochondrial
   myopathy
ID MAGNETIC-RESONANCE SPECTROSCOPY; HUMAN MITOCHONDRIAL MYOPATHIES;
   SKELETAL-MUSCLE; OXIDATIVE STRESS; EXERCISE INTOLERANCE; DNA; DISEASE;
   KINASE; ENCEPHALOMYOPATHIES; BRAIN
AB Mitochondrial cytopathies are associated with increased free radical generation and paracrystalline inclusions. Paracrystalline inclusions were serendipitously found in a young male athlete with a very high respiratory exchange ratio during steady-state exercise; he also had an unusually low aerobic capacity. Direct sequencing of the mitochondrial DNA (mtDNA) coding regions revealed a novel missense mutation (G15497A) resulting in a glycine-->serine conversion at a highly conserved site in the cytochrome b gene in the subject, his mother, and sister. Cybrids, prepared by fusion of the subject's platelets with either U87MG rhodegrees or SH-SY5Y rhodegrees cells, generated higher basal levels of reactive oxygen species (ROS), had a lower adenosine triphosphate (ATP) content, and were more sensitive to oxygen and glucose deprivation and peroxynitrite generation compared to control cybrids with wild-type mtDNA. Cell survival was significantly enhanced with 50 mmol/L creatine monohydrate (CM) administration. The subject was also treated with CM (10 g/d) for a period of 5 weeks and a repeat muscle biopsy showed no paracrystalline inclusions. The results suggest that the development of exercise-induced paracrystalline inclusions may be influenced by the G15497A mtDNA mutation, and that CM mitigates against the pathological consequences of this mutation.
C1 McMaster Univ, Med Ctr, Dept Med, Hamilton, ON L8N 3Z5, Canada.
   McMaster Univ, Med Ctr, Dept Pathol & Mol Med, Hamilton, ON, Canada.
   Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA.
   Harvard Univ, Sch Med, Boston, MA USA.
   Beth Israel Deaconess Med Ctr, Dept Ophthalmol, Boston, MA USA.
   Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada.
C3 McMaster University; McMaster University; Harvard University; Beth
   Israel Deaconess Medical Center; Harvard University; Harvard Medical
   School; Harvard University; Beth Israel Deaconess Medical Center;
   National Research Council Canada
RP McMaster Univ, Med Ctr, Dept Med, 1200 Main St W, Hamilton, ON L8N 3Z5, Canada.
EM tarnopol@mcmaster.ca
RI Roy, Brian/V-6612-2019
OI Roy, Brian/0000-0003-4638-5586
CR Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   ARNOLD DL, 1985, ANN NEUROL, V18, P189, DOI 10.1002/ana.410180205
   Ashton T, 1999, J APPL PHYSIOL, V87, P2032, DOI 10.1152/jappl.1999.87.6.2032
   Barbiroli B, 1997, CELL MOL BIOL, V43, P741
   Borchert A, 1999, MUSCLE NERVE, V22, P1299
   Brown MD, 2002, HUM GENET, V110, P130, DOI 10.1007/s00439-001-0660-8
   Carter SL, 2001, CAN J PHYSIOL PHARM, V79, P386, DOI 10.1139/cjpp-79-5-386
   Chomyn A, 1996, Methods Enzymol, V264, P334, DOI 10.1016/S0076-6879(96)64031-2
   EPPENBERGEREBERHARDT M, 1991, J CELL BIOL, V113, P289, DOI 10.1083/jcb.113.2.289
   Esposito LA, 1999, P NATL ACAD SCI USA, V96, P4820, DOI 10.1073/pnas.96.9.4820
   GREENHAFF PL, 1994, AM J PHYSIOL, V266, pE725, DOI 10.1152/ajpendo.1994.266.5.E725
   Ha HC, 1997, P NATL ACAD SCI USA, V94, P11557, DOI 10.1073/pnas.94.21.11557
   Heddi A, 1999, J BIOL CHEM, V274, P22968, DOI 10.1074/jbc.274.33.22968
   Herrnstadt C, 2002, AM J HUM GENET, V70, P1152, DOI 10.1086/339933
   Hultman E, 1996, J APPL PHYSIOL, V81, P232
   JOHNS DR, 1995, NEW ENGL J MED, V333, P638, DOI 10.1056/NEJM199509073331007
   Khassaf M, 2001, J APPL PHYSIOL, V90, P1031, DOI 10.1152/jappl.2001.90.3.1031
   Klivenyi P, 1999, NAT MED, V5, P347, DOI 10.1038/6568
   Klopstock T, 2000, NEUROLOGY, V55, P1748, DOI 10.1212/WNL.55.11.1748
   Lawler JM, 2002, BIOCHEM BIOPH RES CO, V290, P47, DOI 10.1006/bbrc.2001.6164
   Mahoney DJ, 2002, CURR OPIN CLIN NUTR, V5, P619, DOI 10.1097/00075197-200211000-00004
   MATTHEWS PM, 1991, NEUROLOGY, V41, P114, DOI 10.1212/WNL.41.1.114
   McKenzie S, 2000, AM J PHYSIOL-ENDOC M, V278, pE580, DOI 10.1152/ajpendo.2000.278.4.E580
   Miller SW, 1996, J NEUROCHEM, V67, P1897
   Mirabella M, 2000, BRAIN, V123, P93, DOI 10.1093/brain/123.1.93
   OGorman E, 1996, BBA-BIOENERGETICS, V1276, P161, DOI 10.1016/0005-2728(96)00074-6
   OGorman E, 1997, J CELL SCI, V110, P1403
   OGorman E, 1997, MOL CELL BIOCHEM, V174, P283, DOI 10.1023/A:1006881113149
   OHKOSHI N, 1995, MUSCLE NERVE, V18, P1265, DOI 10.1002/mus.880181108
   Passaquin AC, 2002, NEUROMUSCULAR DISORD, V12, P174, DOI 10.1016/S0960-8966(01)00273-5
   PETROSKI RE, 1994, J NEUROSCI METH, V52, P23, DOI 10.1016/0165-0270(94)90051-5
   Pitkanen S, 1996, J CLIN INVEST, V98, P345, DOI 10.1172/JCI118798
   Rowbottom DG, 1998, MED SCI SPORT EXER, V30, P1345, DOI 10.1097/00005768-199809000-00001
   Rusanen H, 2000, BBA-MOL BASIS DIS, V1500, P10, DOI 10.1016/S0925-4439(99)00081-2
   Santos-Silva A, 2001, CLIN CHIM ACTA, V306, P119, DOI 10.1016/S0009-8981(01)00406-5
   Simon DK, 1999, NEUROLOGY, V53, P1787, DOI 10.1212/WNL.53.8.1787
   Simon DK, 1999, ANNU REV MED, V50, P111
   SMEITINK J, 1992, NEUROMUSCULAR DISORD, V2, P35, DOI 10.1016/0960-8966(92)90024-Z
   Stachowiak O, 1998, J BIOL CHEM, V273, P16694, DOI 10.1074/jbc.273.27.16694
   Stachowiak O, 1998, MOL CELL BIOCHEM, V184, P141, DOI 10.1023/A:1006803431821
   Sullivan PG, 2000, ANN NEUROL, V48, P723, DOI 10.1002/1531-8249(200011)48:5<723::AID-ANA5>3.0.CO;2-W
   Taivassalo T, 1999, HUM MOL GENET, V8, P1047, DOI 10.1093/hmg/8.6.1047
   Taivassalo T, 1998, NEUROLOGY, V50, P1055, DOI 10.1212/WNL.50.4.1055
   Takao M, 1996, J NEUROL SCI, V139, P111
   Tarnopolsky MA, 1999, MUSCLE NERVE, V22, P1228, DOI 10.1002/(SICI)1097-4598(199909)22:9<1228::AID-MUS9>3.3.CO;2-Y
   Tarnopolsky MA, 1997, MUSCLE NERVE, V20, P1502, DOI 10.1002/(SICI)1097-4598(199712)20:12<1502::AID-MUS4>3.0.CO;2-C
   Tarnopolsky MA, 1998, MUSCLE NERVE, V21, P25, DOI 10.1002/(SICI)1097-4598(199801)21:1<25::AID-MUS4>3.0.CO;2-I
   Tarnopolsky MA, 2001, MUSCLE NERVE, V24, P682, DOI 10.1002/mus.1055
   TAUBE R, 1995, MED SCI SPORTS EXERC, V27, P21
   TAYLOR DJ, 1994, J NEUROL SCI, V127, P198, DOI 10.1016/0022-510X(94)90073-6
   Vissing J, 2001, ANN NEUROL, V49, P672, DOI 10.1002/ana.1026
   Vives-Bauza C, 2001, ANN MED, V33, P493, DOI 10.3109/07853890109002099
NR 53
TC 36
Z9 39
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0148-639X
EI 1097-4598
J9 MUSCLE NERVE
JI Muscle Nerve
PD APR
PY 2004
VL 29
IS 4
BP 537
EP 547
DI 10.1002/mus.20020
PG 11
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 808ZA
UT WOS:000220605800007
PM 15052619
DA 2024-11-01
ER

PT J
AU Li, T
   Lu, ZH
   Wang, JJ
   Chen, JY
   Fu, HD
   Mao, JH
AF Li, Ting
   Lu, Zhihong
   Wang, Jingjing
   Chen, Junyi
   Fu, Haidong
   Mao, Jianhua
TI Growth Retardation in the Course of Fanconi Syndrome Caused by the
   4977-bp Mitochondrial DNA Deletion: A Case Report
SO CHILDREN-BASEL
LA English
DT Article
DE mitochondrial DNA; 4977-bp deletion; Fanconi syndrome; growth
   retardation; children
ID PATIENT; DUPLICATION; MYOPATHY
AB Fanconi syndrome is one of the primary renal manifestations of mitochondrial cytopathies caused by mitochondrial DNA (mtDNA) mutation. The common 4977-bp mtDNA deletion has been reported to be associated with aging and diseases involving multiple extrarenal organs. Cases of Fanconi syndrome caused by the 4977-bp deletion were rarely reported previously. Here, we report a 6-year-old girl with growth retardation in the course of Fanconi syndrome. She had mild ptosis and pigmented retinopathy. Abnormal biochemical findings included low-molecular-weight proteinuria, normoglycemic glycosuria, increased urine phosphorus excretion, metabolic acidosis, and hypophosphatemia. Growth records showed that her body weight and height were normal in the first year and failed to thrive after the age of three. Using a highly sensitive mtDNA analysis methodology, she was identified to possess the common 4977-bp mtDNA deletion. The mutation rate was 84.7% in the urine exfoliated cells, 78.67% in the oral mucosal cells, and 23.99% in the blood sample. After three months of oral coenzyme Q10 and levocarnitine treatment in combination with standard electrolyte supplement, her condition was improved. This is a report of growth retardation as the initial major clinical presentation of Fanconi syndrome caused by the deletion of the 4977-bp fragment. Renal tubular abnormality without any other extrarenal dysfunction may be an initial clinical sign of mitochondrial disorders. Moreover, considering the heterogeneity of the phenotypes associated with mtDNA mutations, the risk of developing Kearns-Sayre syndrome (KSS) with age in this patient should be noted because she had ptosis, retinal involvement, and changes in the brain and skeletal muscle.
C1 [Li, Ting; Lu, Zhihong; Wang, Jingjing; Chen, Junyi; Fu, Haidong; Mao, Jianhua] Zhejiang Univ, Childrens Hosp, Dept Nephrol, Sch Med,Natl Clin Res Ctr Child Hlth,Natl Childre, 3333 Binsheng Rd, Hangzhou 310052, Peoples R China.
C3 Zhejiang University
RP Mao, JH (corresponding author), Zhejiang Univ, Childrens Hosp, Dept Nephrol, Sch Med,Natl Clin Res Ctr Child Hlth,Natl Childre, 3333 Binsheng Rd, Hangzhou 310052, Peoples R China.
EM liting170209@126.com; lzhsjf@zju.edu.cn; 6506027@zju.edu.cn;
   chenjunyi0578@163.com; ch61312@163.com; maojh88@zju.edu.cn
RI Mao, Jianhua/GOK-2713-2022
OI Lu, Zhihong/0000-0003-2897-1792; Li, Ting/0000-0001-7125-0224
FU National Natural Science Foundation of China [81770710]; Key Research
   and Development Plan of Zhejiang Province [2019C03028]; Zhejiang
   Province and National Health Commission [WKJ-ZJ-1908]; Natural Science
   Foundation of Zhejiang Province [LQ18H050001]
FX This study was supported by the National Natural Science Foundation of
   China (81770710), the Key Research and Development Plan of Zhejiang
   Province (2019C03028), the Zhejiang Province and National Health
   Commission (WKJ-ZJ-1908), and the Natural Science Foundation of Zhejiang
   Province (LQ18H050001). The funder J.M. is the corresponding author of
   this article. He helped with clinical diagnosis, supported the
   mitochondrial DNA sequencing, and revised the manuscript.
CR Atale A, 2009, EUR J MED GENET, V52, P23, DOI 10.1016/j.ejmg.2008.10.003
   Au KM, 2007, PEDIATR NEPHROL, V22, P136, DOI 10.1007/s00467-006-0288-y
   CAMPOS Y, 1995, PEDIATR NEUROL, V13, P69, DOI 10.1016/0887-8994(95)00082-Q
   Diba LZ, 2016, MITOCHONDRIAL DNA A, V27, P3008, DOI 10.3109/19401736.2015.1063046
   Foreman JW, 2019, PEDIATR CLIN N AM, V66, P159, DOI 10.1016/j.pcl.2018.09.002
   Goldstein A., 1993, GeneReviews((R))
   Govers LP, 2021, PEDIATR NEPHROL, V36, P9, DOI 10.1007/s00467-019-04404-6
   Han BA, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000016302
   Lee JJ, 2012, PEDIATR NEPHROL, V27, P869, DOI 10.1007/s00467-011-2096-2
   Liu HM, 2012, PEDIATR NEONATOL, V53, P264, DOI 10.1016/j.pedneo.2011.08.013
   LUDER A, 1994, J INHERIT METAB DIS, V17, P298, DOI 10.1007/BF00711812
   MAJANDER A, 1991, PEDIATR RES, V30, P327, DOI 10.1203/00006450-199110000-00007
   Mihai Cristina Maria, 2009, J Med Case Rep, V3, P101, DOI 10.1186/1752-1947-3-101
   MORI K, 1991, AM J MED GENET, V38, P583, DOI 10.1002/ajmg.1320380417
   NIAUDET P, 1994, PEDIATR NEPHROL, V8, P164, DOI 10.1007/BF00865468
   Pitchon EM, 2007, KLIN MONATSBL AUGENH, V224, P340, DOI 10.1055/s-2007-962854
   Porteous WK, 1998, EUR J BIOCHEM, V257, P192, DOI 10.1046/j.1432-1327.1998.2570192.x
   Solano A, 2004, PEDIATR NEPHROL, V19, P790, DOI 10.1007/s00467-004-1473-5
   SUPERTIFURGA A, 1993, EUR J PEDIATR, V152, P44, DOI 10.1007/BF02072515
   SZABOLCS MJ, 1994, KIDNEY INT, V45, P1388, DOI 10.1038/ki.1994.181
   Tzoufi M, 2013, EUR J PEDIATR, V172, P557, DOI 10.1007/s00431-012-1798-1
NR 21
TC 0
Z9 0
U1 1
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2227-9067
J9 CHILDREN-BASEL
JI Children-Basel
PD OCT
PY 2021
VL 8
IS 10
AR 887
DI 10.3390/children8100887
PG 7
WC Pediatrics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pediatrics
GA WO1RH
UT WOS:000712238200001
PM 34682152
OA gold, Green Published
DA 2024-11-01
ER

PT J
AU Chinnery, PF
   Hudson, G
AF Chinnery, Patrick Francis
   Hudson, Gavin
TI Mitochondrial genetics
SO BRITISH MEDICAL BULLETIN
LA English
DT Article
DE mitochondria; genetics; mitochondrial DNA; mitochondrial disease; mtDNA
ID CYTOCHROME-C-OXIDASE; COMPLEX-III DEFICIENCY; RESPIRATORY-CHAIN
   DISORDERS; PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; HEREDITARY OPTIC
   NEUROPATHY; TRANSFER-RNA MUTATIONS; LARGE-SCALE DELETION; DNA COPY
   NUMBER; I DEFICIENCY; LACTIC-ACIDOSIS
AB In the last 10 years the field of mitochondrial genetics has widened, shifting the focus from rare sporadic, metabolic disease to the effects of mitochondrial DNA (mtDNA) variation in a growing spectrum of human disease. The aim of this review is to guide the reader through some key concepts regarding mitochondria before introducing both classic and emerging mitochondrial disorders.
   In this article, a review of the current mitochondrial genetics literature was conducted using PubMed (). In addition, this review makes use of a growing number of publically available databases including MITOMAP, a human mitochondrial genome database (), the Human DNA polymerase Gamma Mutation Database () and PhyloTree.org (), a repository of global mtDNA variation.
   The disruption in cellular energy, resulting from defects in mtDNA or defects in the nuclear-encoded genes responsible for mitochondrial maintenance, manifests in a growing number of human diseases.
   The exact mechanisms which govern the inheritance of mtDNA are hotly debated.
   Although still in the early stages, the development of in vitro genetic manipulation could see an end to the inheritance of the most severe mtDNA disease.
C1 [Chinnery, Patrick Francis; Hudson, Gavin] Newcastle Univ, Inst Med Genet, Int Ctr Life, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.
C3 Newcastle University - UK
RP Hudson, G (corresponding author), Newcastle Univ, Inst Med Genet, Int Ctr Life, Newcastle Upon Tyne NE1 3BZ, Tyne & Wear, England.
EM gavin.hudson@ncl.ac.uk
RI Hudson, Gavin/E-7117-2017
OI Chinnery, Patrick/0000-0002-7065-6617; Hudson, Gavin/0000-0001-7210-2733
FU Wellcome Trust; MRC [MR/K000608/1] Funding Source: UKRI
FX Funding to pay the Open Access publication charges for this article was
   provided by The Wellcome Trust.
CR Abu-Amero K, 2009, BR J OPHTHALMOL
   Achilli A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042242
   Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Angerer H, 2011, BIOCHEM J, V437, P279, DOI 10.1042/BJ20110359
   Antonicka H, 2003, HUM MOL GENET, V12, P2693, DOI 10.1093/hmg/ddg284
   Barel O, 2008, AM J HUM GENET, V82, P1211, DOI 10.1016/j.ajhg.2008.03.020
   BARKOVICH AJ, 1993, AM J NEURORADIOL, V14, P1119
   Baysal BE, 2002, J MED GENET, V39, P617, DOI 10.1136/jmg.39.9.617
   Bénit P, 2004, J MED GENET, V41, P14, DOI 10.1136/jmg.2003.014316
   Bénit P, 2003, HUM MUTAT, V21, P582, DOI 10.1002/humu.10225
   Bénit P, 2001, AM J HUM GENET, V68, P1344, DOI 10.1086/320603
   Berger I, 2008, ANN NEUROL, V63, P405, DOI 10.1002/ana.21332
   Birky CW, 2001, ANNU REV GENET, V35, P125, DOI 10.1146/annurev.genet.35.102401.090231
   Bogenhagen DF, 2012, BBA-GENE REGUL MECH, V1819, P914, DOI 10.1016/j.bbagrm.2011.11.005
   Bonnet C, 2007, REJUV RES, V10, P127, DOI 10.1089/rej.2006.0526
   Calvo S, 2006, NAT GENET, V38, P576, DOI 10.1038/ng1776
   Calvo SE, 2010, NAT GENET, V42, P851, DOI 10.1038/ng.659
   Carelli V, 1997, NEUROLOGY, V48, P1623, DOI 10.1212/WNL.48.6.1623
   Carelli V, 2009, BBA-BIOENERGETICS, V1787, P518, DOI 10.1016/j.bbabio.2009.02.024
   Carling PJ, 2011, MITOCHONDRION, V11, P686, DOI 10.1016/j.mito.2011.05.004
   CARVALHO MRS, 1992, HUM HERED, V42, P316, DOI 10.1159/000154089
   Casey JP, 2012, MOL GENET METAB, V106, P351, DOI 10.1016/j.ymgme.2012.04.017
   CHEN JD, 1989, HUM GENET, V82, P203, DOI 10.1007/BF00291154
   Chinnery PF, 2012, INT J EPIDEMIOL, V41, P177, DOI 10.1093/ije/dyr232
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   Chinnery PF, 2000, TRENDS GENET, V16, P500, DOI 10.1016/S0168-9525(00)02120-X
   Christian B, 2009, MOL CELL, V35, P400, DOI 10.1016/j.molcel.2009.08.003
   Clark MJ, 2011, NAT BIOTECHNOL, V29, P908, DOI 10.1038/nbt.1975
   CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6
   Coenen MJH, 2004, ANN NEUROL, V56, P560, DOI 10.1002/ana.20229
   Copeland WC, 2012, CRIT REV BIOCHEM MOL, V47, P64, DOI 10.3109/10409238.2011.632763
   Craven L, 2010, NATURE, V465, P82, DOI 10.1038/nature08958
   Cree LM, 2008, NAT GENET, V40, P249, DOI 10.1038/ng.2007.63
   Darin N, 2001, ANN NEUROL, V49, P377, DOI 10.1002/ana.75
   de Lonlay P, 2001, NAT GENET, V29, P57, DOI 10.1038/ng706
   De Meirleir L, 2004, J MED GENET, V41, P120, DOI 10.1136/jmg.2003.012047
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   Dunning CJR, 2007, EMBO J, V26, P3227, DOI 10.1038/sj.emboj.7601748
   Galmiche L, 2011, HUM MUTAT, V32, P1225, DOI 10.1002/humu.21562
   Gaspari M, 2004, BBA-BIOENERGETICS, V1659, P148, DOI 10.1016/j.bbabio.2004.10.003
   Gerards M, 2010, J MED GENET, V47, P507, DOI 10.1136/jmg.2009.067553
   Ghezzi D, 2008, AM J HUM GENET, V83, P415, DOI 10.1016/j.ajhg.2008.08.009
   Ghezzi D, 2012, ADV EXP MED BIOL, V748, P65, DOI 10.1007/978-1-4614-3573-0_4
   Ghezzi D, 2011, NAT GENET, V43, P259, DOI 10.1038/ng.761
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Götz A, 2011, AM J HUM GENET, V88, P635, DOI 10.1016/j.ajhg.2011.04.006
   Haack TB, 2012, J MED GENET, V49, P277, DOI 10.1136/jmedgenet-2012-100846
   Haack TB, 2010, NAT GENET, V42, P1131, DOI 10.1038/ng.706
   Halter J, 2011, BONE MARROW TRANSPL, V46, P330, DOI 10.1038/bmt.2010.100
   Hammarsund M, 2001, HUM GENET, V109, P542, DOI 10.1007/s00439-001-0610-5
   HARMAN D, 1972, J AM GERIATR SOC, V20, P145, DOI 10.1111/j.1532-5415.1972.tb00787.x
   Haut S, 2003, HUM GENET, V113, P118, DOI 10.1007/s00439-003-0946-0
   Hegde ML, 2012, MECH AGEING DEV, V133, P157, DOI 10.1016/j.mad.2012.01.005
   Hellebrekers DMEI, 2012, HUM REPROD UPDATE, V18, P341, DOI 10.1093/humupd/dms008
   HIRANO M, 1992, NEUROMUSCULAR DISORD, V2, P125, DOI 10.1016/0960-8966(92)90045-8
   Hirst Judy, 2011, Biochem J, V437, pe1, DOI 10.1042/BJ20110918
   Hoefs SJG, 2008, AM J HUM GENET, V82, P1306, DOI 10.1016/j.ajhg.2008.05.007
   Hoefs SJG, 2011, EUR J HUM GENET, V19, P270, DOI 10.1038/ejhg.2010.204
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   HOWELL N, 1983, SOMAT CELL GENET, V9, P1, DOI 10.1007/BF01544045
   Hudson G, 2005, AM J HUM GENET, V77, P1086, DOI 10.1086/498176
   Hudson G, 2007, AM J HUM GENET, V81, P228, DOI 10.1086/519394
   Huigsloot M, 2011, AM J HUM GENET, V88, P488, DOI 10.1016/j.ajhg.2011.03.002
   Indrieri A, 2012, AM J HUM GENET, V91, P942, DOI 10.1016/j.ajhg.2012.09.016
   Janer A, 2012, AM J HUM GENET, V91, P737, DOI 10.1016/j.ajhg.2012.08.020
   Kirby DM, 2004, J CLIN INVEST, V114, P837, DOI 10.1172/JCI200420683
   Kirkman MA, 2009, BRAIN, V132, P2317, DOI 10.1093/brain/awp158
   Klopstock T, 2011, BRAIN, V134, P2677, DOI 10.1093/brain/awr170
   Koc EC, 2002, J BIOL CHEM, V277, P35541, DOI 10.1074/jbc.M202498200
   Kollberg G, 2006, J NEUROPATH EXP NEUR, V65, P758, DOI 10.1097/01.jnen.0000229987.17548.6e
   Koopman WJH, 2013, EMBO J, V32, P9, DOI 10.1038/emboj.2012.300
   Krishnan KJ, 2008, NAT GENET, V40, P275, DOI 10.1038/ng.f.94
   Kukat C, 2011, P NATL ACAD SCI USA, V108, P13534, DOI 10.1073/pnas.1109263108
   Kyriakouli DS, 2008, GENE THER, V15, P1017, DOI 10.1038/gt.2008.91
   Lebre AS, 2011, J MED GENET, V48, P16, DOI 10.1136/jmg.2010.079624
   Leonard JV, 2000, LANCET, V355, P389, DOI 10.1016/S0140-6736(99)05226-5
   Leonard JV, 2000, LANCET, V355, P299, DOI 10.1016/S0140-6736(99)05225-3
   Lin DDM, 2003, AM J NEURORADIOL, V24, P33
   Ling MF, 1997, GENE, V197, P325, DOI 10.1016/S0378-1119(97)00279-5
   Loeffen J, 2001, ANN NEUROL, V49, P195, DOI 10.1002/1531-8249(20010201)49:2<195::AID-ANA39>3.0.CO;2-M
   Loeffen J, 1998, AM J HUM GENET, V63, P1598, DOI 10.1086/302154
   Loeffen JLCM, 2000, HUM MUTAT, V15, P123, DOI 10.1002/(SICI)1098-1004(200002)15:2<123::AID-HUMU1>3.3.CO;2-G
   MA JH, 1995, BBA-GENE STRUCT EXPR, V1261, P321, DOI 10.1016/0167-4781(95)00041-E
   Magner M, 2011, EUR J PAEDIATR NEURO, V15, P101, DOI 10.1016/j.ejpn.2010.10.001
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   Manwaring N, 2007, MITOCHONDRION, V7, P230, DOI 10.1016/j.mito.2006.12.004
   Massa V, 2008, AM J HUM GENET, V82, P1281, DOI 10.1016/j.ajhg.2008.05.002
   Mayr JA, 2010, HUM MOL GENET, V19, P3430, DOI 10.1093/hmg/ddq254
   McCormick E, 2013, NEUROTHERAPEUTICS, V10, P251, DOI 10.1007/s13311-012-0174-1
   McCulloch V, 2003, MOL CELL BIOL, V23, P5816, DOI 10.1128/MCB.23.16.5816-5824.2003
   McCulloch V, 2002, MOL CELL BIOL, V22, P1116, DOI 10.1128/MCB.22.4.1116-1125.2002
   McFarland R, 2004, TRENDS GENET, V20, P591, DOI 10.1016/j.tig.2004.09.014
   Metodiev MD, 2009, CELL METAB, V9, P386, DOI 10.1016/j.cmet.2009.03.001
   Mick DU, 2011, NAT REV MOL CELL BIO, V12, P14, DOI 10.1038/nrm3029
   Miller FJ, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng060
   MITOMAP, 2000, HUM MIT GEN DAT
   Monnot S, 2011, HUM MUTAT, V32, P116, DOI 10.1002/humu.21417
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   NAGLEY P, 1988, P NATL ACAD SCI USA, V85, P2091, DOI 10.1073/pnas.85.7.2091
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Pagliarini DJ, 2008, CELL, V134, P112, DOI 10.1016/j.cell.2008.06.016
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   Payne BAI, 2013, HUM MOL GENET, V22, P384, DOI 10.1093/hmg/dds435
   Pello R, 2008, HUM MOL GENET, V17, P4001, DOI 10.1093/hmg/ddn303
   Petruzzella V, 1998, GENOMICS, V54, P494, DOI 10.1006/geno.1998.5580
   Pfeffer G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004426.pub3
   Pfeffer G, 2012, BRAIN, V135, P1695, DOI 10.1093/brain/aws102
   Phasukkijwatana N, 2010, HUM GENET
   Pierson TM, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002325
   POULTON J, 1995, DIABETOLOGIA, V38, P868, DOI 10.1007/s001250050366
   Poulton J, 2012, BRIT MED J, V345, DOI 10.1136/bmj.e6651
   PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289
   Prokisch H, 2006, NUCLEIC ACIDS RES, V34, pD705, DOI 10.1093/nar/gkj127
   Pyle A, 2005, ANN NEUROL, V57, P564, DOI 10.1002/ana.20417
   Rahman S, 2001, AM J HUM GENET, V68, P238, DOI 10.1086/316930
   Ridge PG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045134
   Rossignol R, 2003, BIOCHEM J, V370, P751, DOI 10.1042/BJ20021594
   ROTIG A, 1990, J CLIN INVEST, V86, P1601, DOI 10.1172/JCI114881
   Saada A, 2007, J MED GENET, V44, P784, DOI 10.1136/jmg.2007.053116
   Saada A, 2008, AM J HUM GENET, V82, P32, DOI 10.1016/j.ajhg.2007.08.003
   Santorelli FM, 1997, BIOCHEM BIOPH RES CO, V238, P326, DOI 10.1006/bbrc.1997.7167
   Santoro A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012037
   Schaefer AM, 2008, ANN NEUROL, V63, P35, DOI 10.1002/ana.21217
   Schapira AHV, 2012, LANCET, V379, P1825, DOI 10.1016/S0140-6736(11)61305-6
   SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184
   Schon EA, 2012, NAT REV GENET, V13, P878, DOI 10.1038/nrg3275
   Schuelke M, 1999, NAT GENET, V21, P260, DOI 10.1038/6772
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   Shoubridge EA, 2001, HUM MOL GENET, V10, P2277, DOI 10.1093/hmg/10.20.2277
   Shteyer E, 2009, AM J HUM GENET, V84, P412, DOI 10.1016/j.ajhg.2009.02.006
   Skladal D, 2003, BRAIN, V126, P1905, DOI 10.1093/brain/awg170
   Smeitink J, 1999, AM J HUM GENET, V64, P1505, DOI 10.1086/302432
   Smirnova E, 1998, J CELL BIOL, V143, P351, DOI 10.1083/jcb.143.2.351
   Smith PM, 2012, BBA-BIOENERGETICS, V1817, P276, DOI 10.1016/j.bbabio.2011.11.009
   Smits P, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/737385
   Soleimanpour-Lichaei HR, 2007, MOL CELL, V27, P745, DOI 10.1016/j.molcel.2007.06.031
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2007, BIOSCIENCE REP, V27, P39, DOI 10.1007/s10540-007-9036-1
   Sutovsky P, 2003, MICROSC RES TECHNIQ, V61, P88, DOI 10.1002/jemt.10319
   Tachibana M, 2013, NATURE, V493, P627, DOI 10.1038/nature11647
   Taivassalo T, 2006, BRAIN, V129, P3391, DOI 10.1093/brain/awl282
   Temperley R, 2010, SCIENCE, V327, P301, DOI 10.1126/science.1180674
   Thorburn DR, 2009, MOL GENET METAB, V98, P5
   Tiranti V, 1999, ANN NEUROL, V46, P161, DOI 10.1002/1531-8249(199908)46:2<161::AID-ANA4>3.0.CO;2-O
   Torroni A, 1996, GENETICS, V144, P1835
   Udar N, 2009, INVEST OPHTH VIS SCI, V50, P2966, DOI 10.1167/iovs.08-2646
   van den Heuvel L, 1998, AM J HUM GENET, V62, P262, DOI 10.1086/301716
   van der Giezen M, 2005, EMBO REP, V6, P525, DOI 10.1038/sj.embor.7400440
   Vedrenne V, 2012, AM J HUM GENET, V91, P912, DOI 10.1016/j.ajhg.2012.09.001
   Vissing JSaM, 2002, NEW ENGL J MED, P2081
   Vogel RO, 2007, BBA-BIOENERGETICS, V1767, P1215, DOI 10.1016/j.bbabio.2007.07.008
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   Wang ZG, 2001, J BIOL CHEM, V276, P30773, DOI 10.1074/jbc.M104133200
   Waterham HR, 2007, NEW ENGL J MED, V356, P1736, DOI 10.1056/NEJMoa064436
   Weber K, 1997, AM J HUM GENET, V60, P373
   Weraarpachai W, 2012, AM J HUM GENET, V90, P142, DOI 10.1016/j.ajhg.2011.11.027
   White SL, 1999, AM J HUM GENET, V65, P474, DOI 10.1086/302488
   WOLF A, 1954, RES PUBL ASSOC RES N, V34, P199
   Wong LJC, 2007, HEPATOLOGY, V46, P1218, DOI 10.1002/hep.21799
   Youle RJ, 2012, SCIENCE, V337, P1062, DOI 10.1126/science.1219855
   Zeharia A, 2005, J CHILD NEUROL, V20, P449, DOI 10.1177/08830738050200051301
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
   Zhang YL, 1998, BBA-GENE STRUCT EXPR, V1443, P245, DOI 10.1016/S0167-4781(98)00223-1
   Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804
   Zifa E, 2007, RNA BIOL, V4, P38, DOI 10.4161/rna.4.1.4548
   Zvulunov A, 1998, BRIT J DERMATOL, V138, P1046
NR 167
TC 274
Z9 318
U1 1
U2 67
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0007-1420
EI 1471-8391
J9 BRIT MED BULL
JI Br. Med. Bull.
PD JUN
PY 2013
VL 106
IS 1
BP 135
EP 159
DI 10.1093/bmb/ldt017
PG 25
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 160JE
UT WOS:000320114900008
PM 23704099
OA Green Submitted, Green Published, hybrid
DA 2024-11-01
ER

PT J
AU Pan, XL
   Wang, LJ
   Fei, GQ
   Dong, JH
   Zhong, CJ
   Lu, JH
   Jin, LR
AF Pan, Xiaoli
   Wang, Lijun
   Fei, Guoqiang
   Dong, Jihong
   Zhong, Chunjiu
   Lu, Jiahong
   Jin, Lirong
TI Acute Respiratory Failure Is the Initial Manifestation in the
   Adult-Onset A3243G tRNALeu mtDNA Mutation: A Case Report and the
   Literature Review
SO FRONTIERS IN NEUROLOGY
LA English
DT Review
DE mitochondrial myopathy; A3243G mutation; respiratory failure; mtDNA;
   sedative drug
ID ISOLATED MITOCHONDRIAL MYOPATHY; PATIENT; DIAGNOSIS; INSUFFICIENCY;
   PHENOTYPES
AB Isolated mitochondrial myopathy refers to the condition of mitochondria' disorders that primarily affect the skeletal muscle system. Here we report on a case of a patient who presented with acute respiratory failure as the initial and predominant clinical manifestation after using anesthetic drugs. The diagnosis of mitochondrial myopathy was made by histochemical findings of ragged red fibers with a modified Gomori trichrome Stain in the skeletal muscle biopsy and the genetic detection of an A3243G point mutation in the tRNALeu (UUR) gene of mitochondrial DNA (mtDNA) in a peripheral blood specimen. The patient revealed a benign clinical outcome with ventilator assistance and a cocktail treatment. Further, we performed a literature review on patients with respiratory failure as the early and predominant manifestation in adult-onset isolated mitochondrial myopathy. Eleven cases in nine studies (including our case) have been reported, and five of whom underwent DNA analysis all harbored the A3243G mutation in the tRNA(Leu) gene of the mtDNA. Use of sedative drugs tends to induce acute respiratory failure in such cases.
C1 [Pan, Xiaoli; Wang, Lijun; Fei, Guoqiang; Dong, Jihong; Zhong, Chunjiu; Jin, Lirong] Fudan Univ, Zhongshan Hosp, Dept Neurol, Shanghai, Peoples R China.
   [Pan, Xiaoli; Wang, Lijun; Fei, Guoqiang; Dong, Jihong; Zhong, Chunjiu; Jin, Lirong] Fudan Univ, Shanghai Med Coll, Shanghai, Peoples R China.
   [Wang, Lijun] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Neurol, Shanghai, Peoples R China.
   [Wang, Lijun] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Coinnovat Ctr Neurodegenerat, Shanghai, Peoples R China.
   [Lu, Jiahong] Fudan Univ, Huashan Hosp, Dept Neurd, Shanghai, Peoples R China.
C3 Fudan University; Fudan University; Shanghai Jiao Tong University;
   Shanghai Jiao Tong University; Fudan University
RP Jin, LR (corresponding author), Fudan Univ, Zhongshan Hosp, Dept Neurol, Shanghai, Peoples R China.; Jin, LR (corresponding author), Fudan Univ, Shanghai Med Coll, Shanghai, Peoples R China.; Lu, JH (corresponding author), Fudan Univ, Huashan Hosp, Dept Neurd, Shanghai, Peoples R China.
EM lujiahong@yahoo.com; jinlr99@163.com
RI LI, Jing/HNB-5575-2023; Jin, Li/M-5063-2019; Zhong, Chunjiu/K-3636-2012
OI Wang, Lijun/0000-0001-6145-1997
FU National Natural Science Foundation of China [91332201]; National
   Natural Science Foundation for Young Scientists of China [81600930]
FX This study was supported by the National Natural Science Foundation of
   China (grant no. 91332201) and the National Natural Science Foundation
   for Young Scientists of China (grant no. 81600930).
CR Amornvit Jakkrit, 2014, Journal of the Medical Association of Thailand, V97, P467
   Anitori R, 2005, MOL GENET METAB, V84, P176, DOI 10.1016/j.ymgme.2004.10.003
   BAROHN RJ, 1990, NEUROLOGY, V40, P103, DOI 10.1212/WNL.40.1.103
   BENNETT DA, 1988, CLIN NEUROPHARMACOL, V11, P303, DOI 10.1097/00002826-198808000-00002
   CARROLL JE, 1976, NEUROLOGY, V26, P140, DOI 10.1212/WNL.26.2.140
   Chang K. C., 2002, Hong Kong Medical Journal, V8, P137
   CROS D, 1992, CHEST, V101, P824, DOI 10.1378/chest.101.3.824
   DiMauro S, 2005, CURR OPIN NEUROL, V18, P538, DOI 10.1097/01.wco.0000179761.63486.1a
   Elliott HR, 2008, AM J HUM GENET, V83, P254, DOI 10.1016/j.ajhg.2008.07.004
   [郭军 GUO Jun], 2010, [北京医学, Beijing Medical Journal], V32, P86
   KAMAKURA K, 1995, J NEUROL, V242, P253, DOI 10.1007/BF00919602
   KIM G W, 1991, Yonsei Medical Journal, V32, P184
   Kleinle S, 1998, BIOCHEM BIOPH RES CO, V247, P112, DOI 10.1006/bbrc.1998.8729
   Lalani SR, 2005, ARCH NEUROL-CHICAGO, V62, P317, DOI 10.1001/archneur.62.2.317
   Leshinsky-Silver E, 2008, EUR J PAEDIATR NEURO, V12, P309, DOI 10.1016/j.ejpn.2007.09.005
   Manwaring N, 2007, MITOCHONDRION, V7, P230, DOI 10.1016/j.mito.2006.12.004
   Naddaf E, 2017, MUSCLE NERVE, V56, P881, DOI 10.1002/mus.25602
   Nesbitt V, 2013, J NEUROL NEUROSUR PS, V84, P936, DOI 10.1136/jnnp-2012-303528
   O'Brien A, 1998, EUR RESPIR J, V12, P742, DOI 10.1183/09031936.98.12030742
   Pfeffer G, 2013, ANN MED, V45, P4, DOI 10.3109/07853890.2011.605389
   Scheffler IE, 2001, MITOCHONDRION, V1, P3, DOI 10.1016/S1567-7249(00)00002-7
   Seneca S, 2005, AM J MED GENET A, V137A, P170, DOI 10.1002/ajmg.a.30854
   Spinazzola A, 2004, NEUROMUSCULAR DISORD, V14, P815, DOI 10.1016/j.nmd.2004.09.002
   Suomalainen A, 2011, J INHERIT METAB DIS, V34, P277, DOI 10.1007/s10545-010-9222-3
   Yang CC, 1998, J FORMOS MED ASSOC, V97, P715
NR 25
TC 9
Z9 10
U1 0
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2295
J9 FRONT NEUROL
JI Front. Neurol.
PD JUL 18
PY 2019
VL 10
AR 780
DI 10.3389/fneur.2019.00780
PG 6
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA IJ5EJ
UT WOS:000475925300001
PM 31379729
OA Green Published, gold
DA 2024-11-01
ER

PT J
AU Bulst, S
   Abicht, A
   Holinski-Feder, E
   Müller-Ziermann, S
   Koehler, U
   Thirion, C
   Walter, MC
   Stewart, JD
   Chinnery, PF
   Lochmüller, H
   Horvath, R
AF Bulst, Stefanie
   Abicht, Angela
   Holinski-Feder, Elke
   Mueller-Ziermann, Solvig
   Koehler, Udo
   Thirion, Christian
   Walter, Maggie C.
   Stewart, Joanna D.
   Chinnery, Patrick F.
   Lochmueller, Hanns
   Horvath, Rita
TI <i>In vitro</i> supplementation with dAMP/dGMP leads to partial
   restoration of mtDNA levels in mitochondrial depletion syndromes
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID DNA DEPLETION; THYMIDINE KINASE; SUCLA2 MUTATIONS; POOL SIZES;
   ENCEPHALOMYOPATHY; DEFICIENCY; GENE; MYOPATHY; DEFECTS; PHOSPHORYLASE
AB Mitochondrial DNA depletion syndrome, a frequent cause of childhood (hepato)encephalomyopathies, is defined as a reduction of mitochondrial DNA copy number related to nuclear DNA. It was previously shown that mtDNA depletion can be prevented by dAMP/dGMP supplementation in deoxyguanosine kinase-deficient fibroblasts. We investigated myotubes of patients diagnosed with mtDNA depletion carrying pathogenic mutations in DGUOK, POLG1 (Alpers syndrome) and TYMP. Differentiating myotubes of all patients and controls were supplemented with different doses of dAMP/dGMP or dAMP/dGMP/dCMP in TYMP deficiency, and analysed for mtDNA/nDNA ratio and for cytochrome c oxidase (COX) activity. Serum deprivation and myotube formation triggered a decrease in mtDNA copy number in DGUOK or POLG1 deficient myotubes, but not in TYMP deficiency and healthy controls. Supplementation with dAMP/dGMP leads to a significant and reproducible rescue of mtDNA depletion in DGUOK deficiency. POLG1 deficient myotubes also showed a mild, not significant increase in mtDNA copy number. MtDNA depletion did not result in deficient COX staining in DGUOK and POLG1-deficient myotubes. Treatment with ethidium bromide resulted in very severe depletion and absence of COX staining in all cell types, and no recovery was observed after supplementation with dAMP/dGMP. We show that supplementation with dAMP/dGMP increases mtDNA copy number significantly in DGUOK deficient myotubes and, leads to a mild, non-significant improvement of mtDNA depletion in POLG1 deficiency. No adverse effect on mtDNA copy number was observed on high-dose supplementation in vitro. Further studies are needed to determine possible therapeutic implications of dAMP/dGMP supplementation for DGUOK deficiency in vivo.
C1 [Bulst, Stefanie; Abicht, Angela; Thirion, Christian; Walter, Maggie C.; Horvath, Rita] Univ Munich, Friedrich Baur Inst, Dept Neurol, D-80539 Munich, Germany.
   [Abicht, Angela; Holinski-Feder, Elke; Mueller-Ziermann, Solvig; Koehler, Udo; Horvath, Rita] Ctr Med Genet, Munich, Germany.
   [Stewart, Joanna D.; Chinnery, Patrick F.; Horvath, Rita] Newcastle Univ, Mitochondrial Res Grp, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
   [Lochmueller, Hanns] Newcastle Univ, Inst Human Genet, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
C3 University of Munich; Newcastle University - UK; Newcastle University -
   UK
RP Horvath, R (corresponding author), Univ Munich, Friedrich Baur Inst, Dept Neurol, D-80539 Munich, Germany.
EM rita.horvath@ncl.ac.uk
RI Horvath, Rita/AAY-7042-2020; Stewart, Joanna D/H-1614-2012
OI Horvath, Rita/0000-0002-9841-170X; Stewart, Joanna
   D/0000-0002-2608-1967; Lochmuller, Hanns/0000-0003-2324-8001; Chinnery,
   Patrick/0000-0002-7065-6617
FU Deutsche Forschungsgemeinschaft [HO2505/2-1]; German ministry of
   education and research (BMBF, Bonn, Germany) [01GM0601]; TREAT- NMD
   [036825]
FX This work is supported by grants from Deutsche Forschungsgemeinschaft
   HO2505/2-1 (R. H.). The Muscle Tissue Culture Collection is part of the
   German network on muscular dystrophies (MD-NET, service structure S1,
   01GM0601) funded by the German ministry of education and research (BMBF,
   Bonn, Germany). The Muscle Tissue Culture Collection is a partner of
   EuroBioBank (www. eurobiobank. org) and TREAT- NMD (EC, 6th FP, proposal
   # 036825).
CR Alberio S, 2007, MITOCHONDRION, V7, P6, DOI 10.1016/j.mito.2006.11.010
   Ashley N, 2008, HUM MOL GENET, V17, P2496, DOI 10.1093/hmg/ddn150
   Ashley N, 2007, HUM MOL GENET, V16, P1400, DOI 10.1093/hmg/ddm090
   Berridge MV, 2005, BIOTECHNOL ANN REV, V11, P127, DOI 10.1016/S1387-2656(05)11004-7
   Blakely EL, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.011296
   BOGENHAGEN D, 1976, J BIOL CHEM, V251, P2938
   Bornstein B, 2008, NEUROMUSCULAR DISORD, V18, P453, DOI 10.1016/j.nmd.2008.04.006
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Carrozzo R, 2007, BRAIN, V130, P862, DOI 10.1093/brain/awl389
   Desler C, 2007, MUTAT RES-FUND MOL M, V625, P112, DOI 10.1016/j.mrfmmm.2007.06.002
   Diaz F, 2002, NUCLEIC ACIDS RES, V30, P4626, DOI 10.1093/nar/gkf602
   Durham SE, 2005, NEUROLOGY, V65, P453, DOI 10.1212/01.wnl.0000171861.30277.88
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   ENRIQUEZ JA, 1994, NUCLEIC ACIDS RES, V22, P1861, DOI 10.1093/nar/22.10.1861
   Ferraro P, 2006, P NATL ACAD SCI USA, V103, P18586, DOI 10.1073/pnas.0609020103
   FISCHER JC, 1986, EUR J PEDIATR, V144, P441, DOI 10.1007/BF00441735
   Freisinger P, 2006, ARCH NEUROL-CHICAGO, V63, P1129, DOI 10.1001/archneur.63.8.1129
   Gazziola C, 2001, J BIOL CHEM, V276, P6185, DOI 10.1074/jbc.M007623200
   Hirano M, 2000, BRAIN PATHOL, V10, P451
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   KAROL MH, 1968, SCIENCE, V162, P470, DOI 10.1126/science.162.3852.470
   Lascaratos G, 2007, VISION RES, V47, P1191, DOI 10.1016/j.visres.2006.12.014
   Leanza L, 2008, J BIOL CHEM, V283, P16437, DOI 10.1074/jbc.M801572200
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Mathews CK, 2007, FASEB J, V21, P2294, DOI 10.1096/fj.06-7977rev
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Ostergaard E, 2007, AM J HUM GENET, V81, P383, DOI 10.1086/519222
   Ostergaard E, 2007, BRAIN, V130, P853, DOI 10.1093/brain/awl383
   Pontarin G, 2003, P NATL ACAD SCI USA, V100, P12159, DOI 10.1073/pnas.1635259100
   Pontarin G, 2006, J BIOL CHEM, V281, P22720, DOI 10.1074/jbc.M604498200
   Rampazzo C, 2004, J BIOL CHEM, V279, P17019, DOI 10.1074/jbc.M313957200
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Saada A, 2008, MOL GENET METAB, V95, P169, DOI 10.1016/j.ymgme.2008.07.007
   Sandrini MPB, 2005, TRENDS BIOCHEM SCI, V30, P225, DOI 10.1016/j.tibs.2005.03.003
   Sarzi E, 2007, J PEDIATR-US, V150, P531, DOI 10.1016/j.jpeds.2007.01.044
   SELIGMAN AM, 1968, J CELL BIOL, V38, P1, DOI 10.1083/jcb.38.1.1
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Spinazzola A, 2005, GENE, V354, P162, DOI 10.1016/j.gene.2005.03.025
   Spinazzola A, 2002, J BIOL CHEM, V277, P4128, DOI 10.1074/jbc.M111028200
   Sumption ND, 2006, MUTAT RES-FUND MOL M, V594, P30, DOI 10.1016/j.mrfmmm.2005.07.007
   Taanman JW, 2003, HUM MOL GENET, V12, P1839, DOI 10.1093/hmg/ddg192
   Torres SM, 2007, ENVIRON MOL MUTAGEN, V48, P224, DOI 10.1002/em.20264
   Wang JH, 2000, BIOCHEM PHARMACOL, V59, P1583, DOI 10.1016/S0006-2952(00)00285-9
   Wang LY, 2003, J BIOL CHEM, V278, P6963, DOI 10.1074/jbc.M206143200
NR 46
TC 41
Z9 45
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD MAY 1
PY 2009
VL 18
IS 9
BP 1590
EP 1599
DI 10.1093/hmg/ddp074
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 431WS
UT WOS:000265096100005
PM 19221117
OA Bronze
DA 2024-11-01
ER

PT J
AU Galbiati, S
   Bordoni, A
   Papadimitriou, D
   Toscano, A
   Rodolico, C
   Katsarou, E
   Sciacco, M
   Garufi, A
   Prelle, A
   Aquennouz, M
   Bonsignore, M
   Crimi, M
   Martinuzzi, A
   Bresolin, N
   Papadimitriou, A
   Comi, GP
AF Galbiati, S
   Bordoni, A
   Papadimitriou, D
   Toscano, A
   Rodolico, C
   Katsarou, E
   Sciacco, M
   Garufi, A
   Prelle, A
   Aquennouz, M
   Bonsignore, M
   Crimi, M
   Martinuzzi, A
   Bresolin, N
   Papadimitriou, A
   Comi, GP
TI New mutations in <i>TK2</i> gene associated with mitochondrial DNA
   depletion
SO PEDIATRIC NEUROLOGY
LA English
DT Article
ID DEOXYGUANOSINE KINASE GENE; THYMIDINE KINASE; MTDNA DEPLETION; MYOPATHY;
   LOCALIZATION; DEFICIENCY; CHILDHOOD; DELETIONS; INFANT
AB Mitochondrial deoxyribonucleic acid depletion syndromes are autosomal recessive disorders characterized by a reduction of the amount of mitochondrial deoxyribonucleic acid, which impairs the synthesis of respiratory chain complexes. Mutations in the deoxyguanosine kinase and polymerase gamma genes have been identified in hepatocerebral forms, whereas thymidine kinase 2 gene mutations have been found in patients with isolated myopathy, encephalomyopathy, or spinal muscular atrophy. Mutations in the gene encoding the P subunit of the adenosine diphosphate-forming succinyl-coenzyme A synthetase have also been reported in a family. In this report, the clinical, molecular, morphologic, and biochemical features of five children from two independent families with an infantile encephalomyopathy are characterized. The affected children manifested muscle mitochondrial deoxyribonucleic acid depletion and three novel thymidine kinase 2 gene mutations. They consist of a homozygous substitution resulting in Ala to Val change at the highly conserved position 181 of thymidine kinase in the first family, and two heterozygous substitutions in the second family: a Cys to Trp change at residue 108 and a Len to Pro change at residue 257 of the enzyme. Common clinical features associated with these TK2 mutations are a normal early developmental phase followed by psychomotor regression, encephalopathy often with epileptic seizures, and myopathy with features of a progressive dystrophic process. (c) 2006 by Elsevier Inc. All rights reserved.
C1 Univ Milan, Dept Neurol Sci, Ctr Dino Ferrari, IRCCS,Osped Maggiore Policlin, Milan, Italy.
   Univ Larissa, Larisa, Greece.
   Red Cross Hosp, Athens, Greece.
   Univ Athens, Dept Pediat 1, Athens, Greece.
   Univ Messina Policlin, Dept Neurosci Psychiat & Anaesthesiol, Neurol Clin 2, Messina, Italy.
   IRCCS Eugenio Medea, Veneto, Italy.
   IRCCS Eugenio Medea, Parini, Italy.
   Univ Messina Policlin, Dept Pediat & Pediat Surg Sci, Messina, Italy.
C3 University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico;
   National & Kapodistrian University of Athens; AOU Policlinico Gaetano
   Martino; University of Messina; IRCCS Eugenio Medea; IRCCS Eugenio
   Medea; AOU Policlinico Gaetano Martino
RP Univ Milan, Dept Neurol Sci, Ctr Dino Ferrari, IRCCS,Fdn Osped Maggiore Policlin, Milan, Italy.
EM neurogene@policlinico.mi.it
RI Sciacco, Monica/AAC-6500-2022; Comi, Giacomo/K-5702-2016; Crimi,
   Marco/A-4032-2008; Padovani, Alessandro/ABI-7312-2020; Aguennouz,
   M'hammed/U-7420-2017; Martinuzzi, Andrea/K-3887-2016; Galbiati,
   Sara/AAA-7115-2020
OI Bresolin, Nereo/0000-0001-6694-3595; RODOLICO,
   Carmelo/0000-0003-2543-6356; Aguennouz, M'hammed/0000-0003-0440-0354;
   Martinuzzi, Andrea/0000-0002-0319-3579; Comi,
   Giacomo/0000-0002-1383-5248; Galbiati, Sara/0000-0001-6810-359X;
   Sciacco, Monica/0000-0003-4593-4977; Crimi, Marco/0000-0001-6903-9163;
   prelle, alessandro/0000-0002-7019-5291
FU Telethon [GTF02008] Funding Source: Medline
CR ANDREETTA F, 1991, J NEUROL SCI, V105, P88, DOI 10.1016/0022-510X(91)90123-O
   ARNER ESJ, 1992, BIOCHEM BIOPH RES CO, V188, P712, DOI 10.1016/0006-291X(92)91114-6
   BONILLA E, 1975, J ULTRA MOL STRUCT R, V51, P404, DOI 10.1016/S0022-5320(75)80103-1
   Bradshaw PC, 2005, AM J PHYSIOL-CELL PH, V288, pC989, DOI 10.1152/ajpcell.00530.2004
   BRESOLIN N, 1985, NEUROLOGY, V35, P802, DOI 10.1212/WNL.35.6.802
   Carrozzo R, 2003, HUM MUTAT, V21, DOI 10.1002/humu.9135
   Darin N, 2001, ANN NEUROL, V49, P377, DOI 10.1002/ana.75
   DiMauro S, 2004, BBA-BIOENERGETICS, V1658, P80, DOI 10.1016/j.bbabio.2004.03.014
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Elpeleg O, 2003, PEDIATR RES, V54, P153, DOI 10.1203/01.PDR.0000072796.25097.A5
   Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Filosto M, 2004, ACTA NEUROPATHOL, V108, P168, DOI 10.1007/s00401-004-0872-9
   Johansson M, 1997, J BIOL CHEM, V272, P8454, DOI 10.1074/jbc.272.13.8454
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Mancuso M, 2003, ARCH NEUROL-CHICAGO, V60, P1445, DOI 10.1001/archneur.60.10.1445
   Mancuso M, 2003, ARCH NEUROL-CHICAGO, V60, P1007, DOI 10.1001/archneur.60.7.1007
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863
   Nevo Y, 2002, J CHILD NEUROL, V17, P499, DOI 10.1177/088307380201700705
   Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Pons R, 1996, PEDIATR NEUROL, V15, P153, DOI 10.1016/0887-8994(96)00118-X
   PRELLE A, 1994, ACTA NEUROPATHOL, V87, P371
   Saada A, 2004, DNA CELL BIOL, V23, P797
   Saada A, 2003, MOL GENET METAB, V79, P1, DOI 10.1016/S1096-7192(03)00063-5
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284
   Taanman JW, 2002, ANN NEUROL, V52, P237, DOI 10.1002/ana.10247
   Tesarova M, 2004, NEUROPEDIATRICS, V35, P217, DOI 10.1055/s-2004-821081
   Tulinius M, 2005, NEUROMUSCULAR DISORD, V15, P412, DOI 10.1016/j.nmd.2005.03.010
   Vilà MR, 2003, NEUROLOGY, V60, P1203, DOI 10.1212/01.WNL.0000055928.58122.47
   Wang LY, 2005, MOL GENET METAB, V84, P75, DOI 10.1016/j.ymgme.2004.09.005
   Wang LY, 2003, FEBS LETT, V554, P319, DOI 10.1016/S0014-5793(03)01181-5
   Zeviani M, 1998, NEUROLOGY, V51, P1525, DOI 10.1212/WNL.51.6.1525-a
NR 38
TC 53
Z9 56
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0887-8994
EI 1873-5150
J9 PEDIATR NEUROL
JI Pediatr. Neurol.
PD MAR
PY 2006
VL 34
IS 3
BP 177
EP 185
DI 10.1016/j.pediatrneurol.2005.07.013
PG 9
WC Clinical Neurology; Pediatrics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pediatrics
GA 022EO
UT WOS:000236037800002
PM 16504786
DA 2024-11-01
ER

PT J
AU Finsterer, J
AF Finsterer, J
TI Mitochondriopathies
SO EUROPEAN JOURNAL OF NEUROLOGY
LA English
DT Review
DE genetics; hereditary disease; multisystem; mutations; neuromuscular
   disease; skeletal muscle
ID RESPIRATORY-CHAIN DISORDERS; LETHAL METABOLIC-DISORDER; COMPLEX-I
   DEFICIENCY; MULTIPLE DELETIONS; AUTOSOMAL-DOMINANT; EXTERNAL
   OPHTHALMOPLEGIA; MTDNA DEPLETION; DNA DELETIONS; SIDEROBLASTIC ANEMIA;
   DIAGNOSTIC-CRITERIA
AB Mitochondriopathies (MCPs) are either due to sporadic or inherited mutations in nuclear or mitochondrial DNA located genes (primary MCPs), or due to exogenous factors (secondary MCPs). MCPs usually show a chronic, slowly progressive course and present with multiorgan involvement with varying onset between birth and late adulthood. Although several proteins with signalling, assembling, transport, enzymatic function can be impaired in MCP, most frequently the activity of the respiratory chain (RC) protein complexes is primarily or secondarily affected, leading to impaired oxygen utilization and reduced energy production. MCPs represent a diagnostic challenge because of their wide variation in presentation and course. Systems frequently affected in MCP are the peripheral nervous system (myopathy, polyneuropathy, lactacidosis), brain (leucencephalopathy, calcifications, stroke-like episodes, atrophy with dementia, epilepsy, upper motor neuron signs, ataxia, extrapyramidal manifestations, fatigue), endocrinium (short stature, hyperhidrosis, diabetes, hyperlipidaemia, hypogonadism, amenorrhoea, delayed puberty), heart (impulse generation or conduction defects, cardiomyopathy, left ventricular non-compaction heart failure), eyes (cataract, glaucoma, pigmentary retinopathy, optic atrophy), ears (deafness, tinnitus, peripheral vertigo), guts (dysphagia, vomiting, diarrhoea, hepatopathy, pseudo-obstruction, pancreatitis, pancreas insufficiency), kidney (renal failure, cysts) and bone marrow (sideroblastic anaemia). Apart from well-recognized syndromes, MCP should be considered in any patient with unexplained progressive multisystem disorder. Although there is actually no specific therapy and cure for MCP, many secondary problems require specific treatment. The rapidly increasing understanding of the pathophysiological background of MCPs may further facilitate the diagnostic approach and open perspectives to future, possibly causative therapies.
C1 Krankenanstalt Rudolfstiftung Wien, Dept Neurol, Vienna, Austria.
C3 Rudolfstiftung Hospital
RP Postfach 348, A-1180 Vienna, Austria.
EM duarte@aonmail.at
CR Abe K, 1997, NEUROLOGY, V49, P837, DOI 10.1212/WNL.49.3.837
   Ackrell BAC, 2002, MOL ASPECTS MED, V23, P369, DOI 10.1016/S0098-2997(02)00012-2
   Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Antonicka H, 2003, AM J HUM GENET, V72, P101, DOI 10.1086/345489
   Argov Z, 1998, MUSCLE NERVE, V21, P1523, DOI 10.1002/(SICI)1097-4598(199811)21:11<1523::AID-MUS22>3.0.CO;2-#
   Barrientos A, 1996, AM J HUM GENET, V58, P963
   Barrientos A, 1996, J CLIN INVEST, V97, P1570, DOI 10.1172/JCI118581
   Bauer MF, 2001, J INHERIT METAB DIS, V24, P166, DOI 10.1023/A:1010314900814
   Bauer MF, 1999, FEBS LETT, V464, P41, DOI 10.1016/S0014-5793(99)01665-8
   Bénit P, 2003, HUM GENET, V112, P563, DOI 10.1007/s00439-002-0884-2
   Bénit P, 2001, AM J HUM GENET, V68, P1344, DOI 10.1086/320603
   Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   Blumenthal DT, 1998, NEUROLOGY, V50, P524, DOI 10.1212/WNL.50.2.524
   Bohlega S, 1996, NEUROLOGY, V46, P1329, DOI 10.1212/WNL.46.5.1329
   BOURGEOIS M, 1992, BRAIN DEV-JPN, V14, P404, DOI 10.1016/S0387-7604(12)80349-4
   BOURGERON T, 1995, NAT GENET, V11, P144, DOI 10.1038/ng1095-144
   Carrozzo R, 1998, NEUROLOGY, V50, P99, DOI 10.1212/WNL.50.1.99
   CASADEMONT J, 1994, HUM MOL GENET, V3, P1945, DOI 10.1093/hmg/3.11.1945
   Chen XJ, 2002, HUM MOL GENET, V11, P1835, DOI 10.1093/hmg/11.16.1835
   Chinnery PF, 1997, J NEUROL NEUROSUR PS, V63, P559, DOI 10.1136/jnnp.63.5.559
   Chow C W, 2000, Hum Reprod, V15 Suppl 2, P68
   CORMIER V, 1991, AM J HUM GENET, V48, P643
   de Lonlay P, 2001, NAT GENET, V29, P57, DOI 10.1038/ng706
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   DiMauro S, 1996, J INHERIT METAB DIS, V19, P489, DOI 10.1007/BF01799110
   Elpeleg O, 2002, J MOL MED-JMM, V80, P389, DOI 10.1007/s00109-002-0343-5
   ERNSTER L, 1959, NATURE, V184, P1851, DOI 10.1038/1841851a0
   Fadic R, 1997, NEUROLOGY, V49, P239, DOI 10.1212/WNL.49.1.239
   Fadic R, 1996, SEMIN NEUROL, V16, P11, DOI 10.1055/s-2008-1040954
   Fellman V, 2002, BLOOD CELL MOL DIS, V29, P444, DOI 10.1006/bcmd.2002.0582
   Finsterer J, 1999, CLIN NEUROPHYSIOL, V110, P1466, DOI 10.1016/S1388-2457(99)00090-5
   Finsterer J, 1997, AKTUEL NEUROL, V24, P231, DOI 10.1055/s-2007-1017815
   Finsterer J, 2002, CAN J NEUROL SCI, V29, P49, DOI 10.1017/S0317167100001712
   Finsterer J, 2002, AMYOTROPH LATERAL SC, V3, P219, DOI 10.1080/146608202760839008
   Finsterer J, 2002, METAB BRAIN DIS, V17, P41, DOI 10.1023/A:1014052330663
   Finsterer J, 2001, ACTA MED AUST, V28, P152, DOI 10.1046/j.1563-2571.2001.01036.x
   Finsterer J, 2001, J INHERIT METAB DIS, V24, P560, DOI 10.1023/A:1012415810881
   Finsterer J, 1998, CAN J ANAESTH, V45, P781, DOI 10.1007/BF03012149
   Finsterer J, 2000, METAB BRAIN DIS, V15, P163
   Garrido N, 2003, MOL BIOL CELL, V14, P1583, DOI 10.1091/mbc.E02-07-0399
   Gillis L, 2002, PEDIATR CLIN N AM, V49, P203, DOI 10.1016/S0031-3955(03)00115-9
   Hansen JJ, 2003, HUM GENET, V112, P71, DOI 10.1007/s00439-002-0837-9
   HARDING AE, 1992, J INHERIT METAB DIS, V15, P480, DOI 10.1007/BF01799606
   HASEGAWA H, 1991, ANN NEUROL, V29, P601, DOI 10.1002/ana.410290606
   Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279
   HIRANO M, 1994, NEUROLOGY, V44, P721, DOI 10.1212/WNL.44.4.721
   Hofmann S, 2002, J BIOL CHEM, V277, P23287, DOI 10.1074/jbc.M201154200
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   HOLT IJ, 1989, ANN NEUROL, V26, P699, DOI 10.1002/ana.410260603
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   HUCKRIEDE A, 1994, BBA-MOL BASIS DIS, V1227, P200, DOI 10.1016/0925-4439(94)90096-5
   IONASESCU V, 1983, AM J MED GENET, V15, P103, DOI 10.1002/ajmg.1320150114
   JACKSON MJ, 1995, BRAIN, V118, P339, DOI 10.1093/brain/118.2.339
   Jensen TD, 2002, NEUROLOGY, V58, P1533, DOI 10.1212/WNL.58.10.1533
   Kaukonen J, 1999, AM J HUM GENET, V65, P256, DOI 10.1086/302445
   Kaukonen JA, 1996, AM J HUM GENET, V58, P763
   KEARNS TP, 1958, ARCH OPHTHALMOL-CHIC, V60, P280, DOI 10.1001/archopht.1958.00940080296016
   Kirches EJF, 1998, J INHERIT METAB DIS, V21, P400, DOI 10.1023/A:1005306725644
   Kornblum C, 2001, NEUROLOGY, V56, P1409, DOI 10.1212/WNL.56.10.1409
   Leonard JV, 2000, LANCET, V355, P389, DOI 10.1016/S0140-6736(99)05226-5
   Leonard JV, 2000, LANCET, V355, P299, DOI 10.1016/S0140-6736(99)05225-3
   Lev D, 2002, Eur J Paediatr Neurol, V6, P121, DOI 10.1053/ejpn.2001.0558
   Lewis S, 2002, J NEUROL SCI, V201, P39, DOI 10.1016/S0022-510X(02)00190-9
   Lin DDM, 2003, AM J NEURORADIOL, V24, P33
   Lodi R, 2002, FREE RADICAL RES, V36, P461, DOI 10.1080/10715760290021324
   Lodi R, 2002, J NEUROL NEUROSUR PS, V72, P805, DOI 10.1136/jnnp.72.6.805
   Lodi R, 2001, ANN NEUROL, V49, P590
   Loeffen J, 2001, ANN NEUROL, V49, P195, DOI 10.1002/1531-8249(20010201)49:2<195::AID-ANA39>3.0.CO;2-M
   Loeffen J, 1998, AM J HUM GENET, V63, P1598, DOI 10.1086/302154
   LUFT R, 1962, J CLIN INVEST, V41, P1776, DOI 10.1172/JCI104637
   Man PYW, 2002, J MED GENET, V39, P162, DOI 10.1136/jmg.39.3.162
   Martínez-Fernández E, 2001, STROKE, V32, P2507, DOI 10.1161/hs1101.098328
   MAZZIOTTA MRM, 1992, J PEDIATR-US, V121, P896, DOI 10.1016/S0022-3476(05)80335-X
   McFarland R, 2002, LANCET NEUROL, V1, P343, DOI 10.1016/S1474-4422(02)00159-X
   *MIT DIS FDN, 2003, MIT DIS FDN
   *MITOMAP, 2003, HUM MIT GEN DAT
   Mitsui T, 2002, J NEUROL, V249, P1004, DOI 10.1007/s00415-002-0774-5
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   MORGANHUGHES JA, 1994, MYOLOGY, P1610
   Moskowitz MA, 2003, STROKE, V34, P324, DOI 10.1161/01.STR.0000054047.14853.AD
   Musumeci O, 2001, NEUROLOGY, V56, P849, DOI 10.1212/WNL.56.7.849
   Nardin RA, 2001, MUSCLE NERVE, V24, P170, DOI 10.1002/1097-4598(200102)24:2<170::AID-MUS30>3.0.CO;2-0
   Naviaux RK, 1999, ANN NEUROL, V45, P54, DOI 10.1002/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B
   Niemann S, 2003, HUM GENET, V113, P92, DOI 10.1007/s00439-003-0938-0
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Nishino I, 2001, NEUROMUSCULAR DISORD, V11, P7, DOI 10.1016/S0960-8966(00)00159-0
   OHNO K, 1991, ANN NEUROL, V29, P364, DOI 10.1002/ana.410290406
   Papadopoulou LC, 1999, NAT GENET, V23, P333
   Parvari R, 2001, AM J HUM GENET, V69, P869, DOI 10.1086/323624
   Paschen SA, 2000, EMBO J, V19, P6392, DOI 10.1093/emboj/19.23.6392
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   PEARSON HA, 1979, J PEDIATR-US, V95, P976, DOI 10.1016/S0022-3476(79)80286-3
   PESTRONK A, 2003, NEUROMUSCULAR DIS CT
   POULTON J, 1994, HUM MOL GENET, V3, P1763, DOI 10.1093/hmg/3.10.1763
   Roesch K, 2002, HUM MOL GENET, V11, P477, DOI 10.1093/hmg/11.5.477
   Sacconi S, 2003, PEDIATR RES, V53, P224, DOI 10.1203/01.PDR.0000048100.91730.6A
   Schapira AHV, 2002, J NEUROL NEUROSUR PS, V72, P144, DOI 10.1136/jnnp.72.2.144
   Schapira AHV, 1999, EUR J CLIN INVEST, V29, P886
   SCHAPIRO AHV, 1994, MITOCHONDRIAL DISORD, P1
   Schuelke M, 1999, NAT GENET, V21, P260, DOI 10.1038/6772
   Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350
   Sciacco M, 2001, J NEUROL, V248, P778, DOI 10.1007/s004150170094
   Servidei Serenella, 2004, Neuromuscul Disord, V14, P107
   Shoubridge EA, 2001, AM J MED GENET, V106, P46, DOI 10.1002/ajmg.1378
   Siciliano G, 2003, NEUROMUSCULAR DISORD, V13, P162, DOI 10.1016/S0960-8966(02)00221-3
   Siciliano G, 1999, NEUROMUSCULAR DISORD, V9, P411, DOI 10.1016/S0960-8966(99)00047-4
   Sperl W, 1997, WIEN KLIN WOCHENSCHR, V109, P93
   Stryer L., 1996, BIOCHEMIE
   Sue CM, 2000, BRAIN PATHOL, V10, P442
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   SUOMALAINEN A, 1995, NAT GENET, V9, P146, DOI 10.1038/ng0295-146
   Suzuki T, 2002, EMBO J, V21, P6581, DOI 10.1093/emboj/cdf656
   Thorburn DR, 2001, J INHERIT METAB DIS, V24, P312, DOI 10.1023/A:1010347808082
   Tiranti V, 1998, AM J HUM GENET, V63, P1609, DOI 10.1086/302150
   Triepels RH, 2001, J BIOL CHEM, V276, P8892, DOI 10.1074/jbc.M009903200
   Triepels RH, 1999, ANN NEUROL, V45, P787, DOI 10.1002/1531-8249(199906)45:6<787::AID-ANA13>3.0.CO;2-6
   TRITSCHLER HJ, 1992, NEUROLOGY, V42, P209, DOI 10.1212/WNL.42.1.209
   TSAIRIS P, 1973, NEUROLOGY, V23, P408
   Valentine JS, 2002, FREE RADICAL BIO MED, V33, P1314, DOI 10.1016/S0891-5849(02)01080-8
   van den Heuvel L, 1998, AM J HUM GENET, V62, P262, DOI 10.1086/301716
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Visapää I, 2002, AM J HUM GENET, V71, P863, DOI 10.1086/342773
   Vissing J, 2001, ANN NEUROL, V49, P672, DOI 10.1002/ana.1026
   Walker U A, 2002, Praxis (Bern 1994), V91, P2129
   Walker UA, 1996, EUR NEUROL, V36, P260, DOI 10.1159/000117269
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   WILLEMS JL, 1977, PEDIATRICS, V60, P850
   Williams RS, 2002, NEW ENGL J MED, V347, P609, DOI 10.1056/NEJMe020083
   Wolf NI, 2002, NEUROLOGY, V59, P1402, DOI 10.1212/01.WNL.0000031795.91814.D8
   YUZAKI M, 1989, BIOCHEM BIOPH RES CO, V164, P1352, DOI 10.1016/0006-291X(89)91818-4
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
   Zeviani M, 1999, ITAL J NEUROL SCI, V20, P401
NR 133
TC 170
Z9 191
U1 1
U2 21
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1351-5101
EI 1468-1331
J9 EUR J NEUROL
JI Eur. J. Neurol.
PD MAR
PY 2004
VL 11
IS 3
BP 163
EP 186
DI 10.1046/j.1351-5101.2003.00728.x
PG 24
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 801AY
UT WOS:000220070000003
PM 15009163
DA 2024-11-01
ER

PT J
AU Finsterer, J
   Ahting, U
AF Finsterer, Josef
   Ahting, Uwe
TI Mitochondrial Depletion Syndromes in Children and Adults
SO CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
LA English
DT Review
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; PHOSPHORYLASE GENE-MUTATIONS;
   RECESSIVE TWINKLE MUTATIONS; POLYMERASE GAMMA DEFICIENCY; THYMIDINE
   KINASE-2 GENE; DNA DEPLETION; MTDNA DEPLETION; ALPERS-SYNDROME; POLG1
   MUTATIONS; DEOXYGUANOSINE KINASE
AB To highlight differences between early-onset and adult mitochondrial depletion syndromes (MDS) concerning etiology and genetic background, pathogenesis, phenotype, clinical presentation and their outcome. MDSs most frequently occur in neonates, infants, or juveniles and more rarely in adolescents or adults. Mutated genes phenotypically presenting with adult-onset MDS include POLG1, TK2, TYMP, RRM2B, or PEO1/twinkle. Adult MDS manifest similarly to early-onset MDS, as myopathy, encephalomyopathy, hepato-cerebral syndrome, or with chronic progressive external ophthalmoplegia (CPEO), fatigue, or only minimal muscular manifestations. Diagnostic work-up or treatment is not at variance from early-onset cases. Histological examination of muscle may be normal but biochemical investigations may reveal multiple respiratory chain defects. The outcome appears to be more favorable in adult than in early-onset forms. Mitochondrial depletion syndromes is not only a Condition of neonates, infants, or juveniles but rarely also occurs in adults, presenting with minimal manifestations or manifestations like in the early-onset forms. Outcome of adult-onset MDS appears more favorable than early-onset MDS.
C1 [Finsterer, Josef] Krankenanstalt Rudolfstiftung Wien, Vienna, Austria.
   [Ahting, Uwe] Tech Univ Munich, Humangenet Lab, D-80290 Munich, Germany.
C3 Rudolfstiftung Hospital; Technical University of Munich
RP Finsterer, J (corresponding author), Postfach 20, A-1180 Vienna, Austria.
EM fifigs1@yahoo.de
CR Acham-Roschitz B, 2009, MOL GENET METAB, V98, P300, DOI 10.1016/j.ymgme.2009.06.012
   AlSaman A, 2012, SAUDI J GASTROENTERO, V18, P285, DOI 10.4103/1319-3767.98439
   Ashley N, 2008, HUM MOL GENET, V17, P2496, DOI 10.1093/hmg/ddn150
   Bartesaghi S, 2010, HUM MOL GENET, V19, P1669, DOI 10.1093/hmg/ddq043
   Béhin A, 2012, NEUROLOGY, V78, P644, DOI 10.1212/WNL.0b013e318248df2b
   Blakely E, 2008, NEUROMUSCULAR DISORD, V18, P557, DOI 10.1016/j.nmd.2008.04.014
   Bornstein B, 2008, NEUROMUSCULAR DISORD, V18, P453, DOI 10.1016/j.nmd.2008.04.006
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Brahimi N, 2009, MOL GENET METAB, V97, P221, DOI 10.1016/j.ymgme.2009.03.007
   Bulst S, 2009, HUM MOL GENET, V18, P1590, DOI 10.1093/hmg/ddp074
   Cardaioli E, 2010, NEUROL SCI, V31, P491, DOI 10.1007/s10072-010-0225-5
   Carrozzo R, 2007, BRAIN, V130, P862, DOI 10.1093/brain/awl389
   Chan SSL, 2005, DNA REPAIR, V4, P1381, DOI 10.1016/j.dnarep.2005.08.010
   Collins J, 2009, NEUROMUSCULAR DISORD, V19, P784, DOI 10.1016/j.nmd.2009.08.002
   De Camaret BM, 2007, BIOCHEM J, V402, P377, DOI 10.1042/BJ20060705
   de Vries MC, 2007, EUR J PEDIATR, V166, P229, DOI 10.1007/s00431-006-0234-9
   Dimmock D, 2010, CLIN CHEM, V56, P1119, DOI 10.1373/clinchem.2009.141549
   Douglas GV, 2011, J HUM GENET, V56, P834, DOI 10.1038/jhg.2011.112
   Durham SE, 2005, NEUROLOGY, V65, P453, DOI 10.1212/01.wnl.0000171861.30277.88
   El-Hattab AW, 2010, MOL GENET METAB, V99, P300, DOI 10.1016/j.ymgme.2009.10.003
   Elachouri G, 2011, GENOME RES, V21, P12, DOI 10.1101/gr.108696.110
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Fellman V, 2011, SEMIN FETAL NEONAT M, V16, P222, DOI 10.1016/j.siny.2011.05.002
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Freisinger P, 2006, ARCH NEUROL-CHICAGO, V63, P1129, DOI 10.1001/archneur.63.8.1129
   Galbiati S, 2006, PEDIATR NEUROL, V34, P177, DOI 10.1016/j.pediatrneurol.2005.07.013
   Garone C, 2012, ARCH NEUROL-CHICAGO, P1
   Garone C, 2011, BRAIN, V134, P3326, DOI 10.1093/brain/awr245
   Giordano C, 2008, AM J PATHOL, V173, P1120, DOI 10.2353/ajpath.2008.080252
   Götz A, 2008, BRAIN, V131, P2841, DOI 10.1093/brain/awn236
   Hakonen AH, 2008, HUM MOL GENET, V17, P3822, DOI 10.1093/hmg/ddn280
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   Haudry C, 2012, MOL GENET METAB, V107, P700, DOI 10.1016/j.ymgme.2012.10.008
   Hirano M, 2006, NEUROLOGY, V67, P1458, DOI 10.1212/01.wnl.0000240853.97716.24
   Honzik T, 2006, Cas Lek Cesk, V145, P665
   Jones SP, 2005, JAIDS-J ACQ IMM DEF, V40, P565, DOI 10.1097/01.qai.0000187443.30838.3e
   Kaji S, 2009, MOL GENET METAB, V97, P292, DOI 10.1016/j.ymgme.2009.04.014
   Karadimas CL, 2006, AM J HUM GENET, V79, P544, DOI 10.1086/506913
   Kasapkara CS, 2012, J PEDIAT GA IN PRESS
   Kiliç M, 2011, TURKISH J PEDIATR, V53, P79
   Kollberg G, 2006, J NEUROPATH EXP NEUR, V65, P758, DOI 10.1097/01.jnen.0000229987.17548.6e
   Kollberg G, 2009, NEUROMUSCULAR DISORD, V19, P147, DOI 10.1016/j.nmd.2008.11.014
   Laforce R, 2009, CLIN NEUROL NEUROSUR, V111, P691, DOI 10.1016/j.clineuro.2009.05.005
   Lamperti C, 2012, MOL GENET METAB, V107, P403, DOI 10.1016/j.ymgme.2012.08.020
   Leshinsky-Silver E, 2008, EUR J PAEDIATR NEURO, V12, P309, DOI 10.1016/j.ejpn.2007.09.005
   Lesko N, 2010, NEUROMUSCULAR DISORD, V20, P198, DOI 10.1016/j.nmd.2009.11.013
   Lönnqvist T, 2009, BRAIN, V132, P1553, DOI 10.1093/brain/awp045
   Mancuso M, 2003, ARCH NEUROL-CHICAGO, V60, P1007, DOI 10.1001/archneur.60.7.1007
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Martí R, 2010, PEDIATR RES, V68, P151, DOI 10.1203/00006450-201011001-00294
   Massa R, 2009, NEUROMUSCULAR DISORD, V19, P837, DOI 10.1016/j.nmd.2009.08.013
   McComsey GA, 2008, ANTIVIR THER, V13, P715
   Mehta AR, 2011, MOVEMENT DISORD, V26, P753, DOI 10.1002/mds.23510
   Merkle A N, 2012, AJNR Am J Neuroradiol, V33, pE34, DOI 10.3174/ajnr.A2455
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Nasi M, 2011, ANTIVIR THER, V16, P365, DOI 10.3851/IMP1764
   Navarro-Sastre A, 2008, MOL GENET METAB, V94, P234, DOI 10.1016/j.ymgme.2008.01.012
   Navarro-Sastre A, 2012, MOL GENET METAB, V107, P409, DOI 10.1016/j.ymgme.2012.08.018
   Naviaux RK, 2005, ANN NEUROL, V58, P491, DOI 10.1002/ana.20544
   Naviaux RK, 1999, ANN NEUROL, V45, P54, DOI 10.1002/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B
   Nguyen KV, 2006, J HEPATOL, V45, P108, DOI 10.1016/j.jhep.2005.12.026
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Nobre S, 2012, BMJ CASE RE IN PRESS
   OKAMURA K, 1976, J NEUROL SCI, V27, P79, DOI 10.1016/0022-510X(76)90236-7
   Oskoui M, 2006, ARCH NEUROL-CHICAGO, V63, P1122, DOI 10.1001/archneur.63.8.1122
   Ostergaard E, 2009, GENEREVIEWS
   Ostergaard E, 2007, AM J HUM GENET, V81, P383, DOI 10.1086/519222
   Ostergaard E, 2010, EUR J PEDIATR, V169, P201, DOI 10.1007/s00431-009-1007-z
   Parini R, 2009, J HEPATOL, V50, P215, DOI 10.1016/j.jhep.2008.08.019
   Pinti M, 2010, AIDS, V24, P841, DOI 10.1097/QAD.0b013e32833779a3
   Pitceathly RDS, 2012, BRAIN, V135, P3392, DOI 10.1093/brain/aws231
   Pitceathly RDS, 2011, J MED GENET, V48, P610, DOI 10.1136/jmg.2010.088328
   Poulton J, 2009, BBA-MOL BASIS DIS, V1792, P1109, DOI 10.1016/j.bbadis.2009.08.016
   Pronicka E, 2011, J APPL GENET, V52, P61, DOI 10.1007/s13353-010-0008-y
   RICCI E, 1992, BRAIN PATHOL, V2, P141, DOI 10.1111/j.1750-3639.1992.tb00682.x
   Rivera H, 2010, MITOCHONDRION, V10, P362, DOI 10.1016/j.mito.2010.03.003
   Rohrbach M, 2009, FETAL DIAGN THER, V25, P177, DOI 10.1159/000209385
   Ronchi D, 2012, BRAIN, V135, P3404, DOI 10.1093/brain/aws258
   Rouzier C, 2010, J MED GENET, V47, P670, DOI 10.1136/jmg.2009.073445
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Sakamoto O, 2011, PEDIATR INT, V53, P921, DOI 10.1111/j.1442-200X.2011.03412.x
   Saneto RP, 2010, DEV DISABIL RES REV, V16, P163, DOI 10.1002/ddrr.105
   Sarzi E, 2007, ANN NEUROL, V62, P579, DOI 10.1002/ana.21207
   Scaglia F, 1993, GENEREVIEWS
   Scalais E, 2012, EUR J PAEDIATR NEURO, V16, P542, DOI 10.1016/j.ejpn.2012.01.013
   Shaibani A, 2009, ARCH NEUROL-CHICAGO, V66, P1028, DOI 10.1001/archneurol.2009.139
   Slama A, 2005, MOL GENET METAB, V84, P326, DOI 10.1016/j.ymgme.2004.12.004
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Spinazzola A, 2005, GENE, V354, P162, DOI 10.1016/j.gene.2005.03.025
   Spinazzola A, 2008, ARCH NEUROL-CHICAGO, V65
   Stewart JD, 2009, J MED GENET, V46, P209, DOI 10.1136/jmg.2008.058180
   Tyynismaa H, 2012, HUM MOL GENET, V21, P66, DOI 10.1093/hmg/ddr438
   Tzoulis C, 2009, ACTA NEUROL SCAND, V120, P38, DOI 10.1111/j.1600-0404.2009.01212.x
   Uusimaa J, 2008, EPILEPSIA, V49, P1038, DOI 10.1111/j.1528-1167.2008.01544.x
   Valayannopoulos V, 2010, MITOCHONDRION, V10, P335, DOI 10.1016/j.mito.2010.02.006
   Vilá MR, 2008, J NEUROL SCI, V267, P137, DOI 10.1016/j.jns.2007.10.019
   Wang LY, 2005, MOL GENET METAB, V84, P75, DOI 10.1016/j.ymgme.2004.09.005
   Wong LJC, 2007, HEPATOLOGY, V46, P1218, DOI 10.1002/hep.21799
   Zhang SL, 2010, MOL GENET METAB, V99, P53, DOI 10.1016/j.ymgme.2009.09.003
NR 99
TC 21
Z9 22
U1 0
U2 9
PU CANADIAN JOURNAL NEUROLOGICAL SCIENCES INC
PI CALGARY
PA 709-7015 MACLEOD TRAIL SW, CALGARY, AB T2H 2K6, CANADA
SN 0317-1671
J9 CAN J NEUROL SCI
JI Can. J. Neurol. Sci.
PD SEP
PY 2013
VL 40
IS 5
BP 635
EP 644
DI 10.1017/S0317167100014852
PG 10
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 241WW
UT WOS:000326200400005
PM 23968935
OA Bronze
DA 2024-11-01
ER

PT J
AU Fujioka, H
   Tandler, B
   Rosca, M
   McCandless, SE
   Katirji, B
   Cohen, ML
   Rapisuwon, S
   Hoppel, CL
AF Fujioka, Hisashi
   Tandler, Bernard
   Rosca, Mariana
   McCandless, Shawn E.
   Katirji, Bashar
   Cohen, Mark L.
   Rapisuwon, Suthee
   Hoppel, Charles L.
TI Multiple Muscle Cell Alterations in a Case of Encephalomyopathy
SO ULTRASTRUCTURAL PATHOLOGY
LA English
DT Article
DE Encephalomyopathy; mitochondrial DNA; mitochondrial function;
   mitochondrial structure; myopathy
ID SARCOPLASMIC-RETICULUM ORIGIN; SKELETAL-MUSCLE; ELECTRON-MICROSCOPY;
   OXIDATIVE-PHOSPHORYLATION; MITOCHONDRIAL MYOPATHY; CRYSTALLOID
   INCLUSIONS; COMPLEX-III; MUTATION; LIVER; HEART
AB Skeletal muscle from an encephalomyopathy was examined by morphological and biochemical modalities. Mitochondria displayed variability in size, numbers per myocyte, and morphology. Certain organelles had stacks of dense cristae, others contained variable numbers of crystalloids or several lipid droplets. In isolated skeletal muscle mitochondria, oxidative phosphorylation was reduced, but activities of the electron transport chain components were unaffected. This is the second case of adult onset encephalomyopathy with a phenotype overlapping MERRF and Kearns-Sayre syndrome associated with a heteroplasmic mtDNA 3255G>A mutation in the tRNA(UUR(LEU)). This study emphasizes the desirability of a multidisciplinary approach in the diagnosis of complex myopathies.
C1 [Fujioka, Hisashi] Case Western Reserve Univ, Electron Microscopy Facil, Cleveland, OH 44106 USA.
   [Fujioka, Hisashi; Tandler, Bernard; Rosca, Mariana; Rapisuwon, Suthee; Hoppel, Charles L.] Case Western Reserve Univ, Sch Med, Ctr Mitochondrial Dis, Cleveland, OH 44106 USA.
   [Tandler, Bernard] Case Western Reserve Univ, Sch Dent Med, Dept Biol Sci, Cleveland, OH 44106 USA.
   [Rosca, Mariana; Rapisuwon, Suthee; Hoppel, Charles L.] Case Western Reserve Univ, Sch Med, Dept Pharmacol, Cleveland, OH 44106 USA.
   [McCandless, Shawn E.] Case Western Reserve Univ, Case Med Ctr, Univ Hosp, Dept Human Genet, Cleveland, OH 44106 USA.
   [Katirji, Bashar; Cohen, Mark L.; Rapisuwon, Suthee] Case Western Reserve Univ, Sch Med, Cleveland, OH 44106 USA.
   [Katirji, Bashar] Case Western Reserve Univ, Case Med Ctr, Univ Hosp, Dept Neurol, Cleveland, OH 44106 USA.
   [Cohen, Mark L.] Case Western Reserve Univ, Case Med Ctr, Univ Hosp, Dept Pathol, Cleveland, OH 44106 USA.
   [Hoppel, Charles L.] Case Western Reserve Univ, Dept Med, Cleveland, OH 44106 USA.
C3 University System of Ohio; Case Western Reserve University; University
   System of Ohio; Case Western Reserve University; University System of
   Ohio; Case Western Reserve University; University System of Ohio; Case
   Western Reserve University; University System of Ohio; Case Western
   Reserve University; University Hospitals of Cleveland; University System
   of Ohio; Case Western Reserve University; University System of Ohio;
   Case Western Reserve University; University Hospitals of Cleveland;
   University Hospitals of Cleveland; University System of Ohio; Case
   Western Reserve University; University System of Ohio; Case Western
   Reserve University
RP Hoppel, CL (corresponding author), Case Western Reserve Univ, Sch Med, Dept Pharmacol, 10900 Euclid Ave, Cleveland, OH 44106 USA.
EM charles.hoppel@case.edu
RI Katirji, Bashar/AAM-8409-2021; Rapisuwon, Suthee/JJE-5529-2023; Rosca,
   Mariana/ABH-7847-2020
OI Rapisuwon, Suthee/0000-0002-1389-925X; Katirji,
   Bashar/0000-0001-7634-975X; Rosca, Mariana/0000-0003-3605-9787
FU Center for Inherited Diseases of Energy Metabolism (CIDEM), University
   Hospital, Case Medical Center, Cleveland, Ohio, USA; Fraternal Order of
   Eagles 2436, Chagrin Falls, Ohio
FX This work was carried out under the auspices of the Center for Inherited
   Diseases of Energy Metabolism (CIDEM), University Hospital, Case Medical
   Center, Cleveland, Ohio, USA. The Fraternal Order of Eagles 2436,
   Chagrin Falls, Ohio, provided funds that helped defray publication
   charges.
CR Bereiter-Hahn Juergen, 2008, Biotechnology Journal, V3, P765, DOI 10.1002/biot.200800024
   BONILLA E, 1980, ACTA NEUROPATHOL, V52, P35, DOI 10.1007/BF00687226
   BOUDIN G, 1976, J NEUROL SCI, V30, P313, DOI 10.1016/0022-510X(76)90137-4
   Chevessier F, 2005, J PATHOL, V207, P313, DOI 10.1002/path.1832
   Chevessier F, 2004, NEUROMUSCULAR DISORD, V14, P208, DOI 10.1016/j.nmd.2003.11.007
   CHOU SM, 1969, ACTA NEUROPATHOL, V12, P68, DOI 10.1007/BF00685312
   Claeys KG, 2010, NEUROMUSCULAR DISORD, V20, P701, DOI 10.1016/j.nmd.2010.06.006
   DEGLIESPOSTI M, 1993, BIOCHIM BIOPHYS ACTA, V1143, P243, DOI 10.1016/0005-2728(93)90197-N
   ENGEL AG, 1968, MAYO CLIN PROC, V43, P233
   Fackenthal DL, 2005, METH MOL B, V311, P73
   FISHER ER, 1969, AM J CLIN PATHOL, V51, P619
   FRANKE WW, 1971, PROTOPLASMA, V73, P35, DOI 10.1007/BF01286409
   HANAICHI T, 1986, J ELECTRON MICROSC, V35, P304
   HOPPEL CL, 1973, BIOCHEM PHARMACOL, V22, P2311, DOI 10.1016/0006-2952(73)90012-9
   HOPPEL CL, 1987, J CLIN INVEST, V80, P71, DOI 10.1172/JCI113066
   Ingman M, 2006, NUCLEIC ACIDS RES, V34, pD749, DOI 10.1093/nar/gkj010
   KALT MR, 1971, J ULTRA MOL STRUCT R, V36, P633, DOI 10.1016/S0022-5320(71)90020-7
   Karnovsky M.J., 1971, Proc 11th Annu Mtg Am Soc Cell Biol, P146
   KRAHENBUHL S, 1991, J BIOL CHEM, V266, P20998
   KRAHENBUHL S, 1994, CLIN CHIM ACTA, V230, P177, DOI 10.1016/0009-8981(94)90270-4
   Kyriacou K, 2005, ULTRASTRUCT PATHOL, V29, P169, DOI 10.1080/01913120590951158
   Miles L, 2006, HUM PATHOL, V37, P173, DOI 10.1016/j.humpath.2005.10.008
   MORRE DJ, 1971, PROTOPLASMA, V73, P43, DOI 10.1007/BF01286410
   Müller HD, 2001, ACTA NEUROPATHOL, V102, P27
   Murakami K, 2010, CELL, V143, P275, DOI 10.1016/j.cell.2010.09.034
   NIAKAN E, 1985, J NEUROL NEUROSUR PS, V48, P882, DOI 10.1136/jnnp.48.9.882
   Nishigaki Y, 2003, NEUROMUSCULAR DISORD, V13, P334, DOI 10.1016/S0960-8966(02)00283-3
   Oldfors A, 2008, ADV EXP MED BIOL, V642, P78
   Pavlovicová M, 2003, GEN PHYSIOL BIOPHYS, V22, P425
   PRICE HM, 1967, J NEUROPATH EXP NEUR, V26, P475, DOI 10.1097/00005072-196707000-00009
   Prince FP, 2004, ANAT REC PART A, V278A, P454, DOI 10.1002/ar.a.20019
   Puchowicz MA, 2004, MITOCHONDRION, V4, P377, DOI 10.1016/j.mito.2004.07.004
   Rajasimha HK, 2008, AM J HUM GENET, V82, P333, DOI 10.1016/j.ajhg.2007.10.007
   Riva A, 2010, ARCH HISTOL CYTOL, V73, P37, DOI 10.1679/aohc.73.37
   Rosca MG, 2008, CARDIOVASC RES, V80, P30, DOI 10.1093/cvr/cvn184
   ROSENBERG NL, 1985, ARCH NEUROL-CHICAGO, V42, P973, DOI 10.1001/archneur.1985.04060090055014
   SALVIATI G, 1985, MUSCLE NERVE, V8, P299, DOI 10.1002/mus.880080406
   SCHELLENS JP, 1969, VIRCHOWS ARCH B, V4, P21
   Sciacco M, 1996, Methods Enzymol, V264, P509, DOI 10.1016/S0076-6879(96)64045-2
   TANDLER B, 1964, J ULTRA MOL STRUCT R, V11, P292, DOI 10.1016/S0022-5320(64)90034-6
   Tandler B, 2004, ENCY BIOL CHEM, V2, P186
   TASSIN S, 1980, NEUROPATH APPL NEURO, V6, P337, DOI 10.1111/j.1365-2990.1980.tb00670.x
   Tomonaga M, 1974, J CLIN ELECT MICROSC, V6, P107
   Voets AM, 2011, MITOCHONDRION, V11, P964, DOI 10.1016/j.mito.2011.09.003
   Wittig I, 2006, NAT PROTOC, V1, P418, DOI 10.1038/nprot.2006.62
NR 45
TC 7
Z9 7
U1 0
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0191-3123
EI 1521-0758
J9 ULTRASTRUCT PATHOL
JI Ultrastruct. Pathol.
PD FEB
PY 2014
VL 38
IS 1
BP 13
EP 25
DI 10.3109/01913123.2013.831158
PG 13
WC Microscopy; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Microscopy; Pathology
GA AC7TQ
UT WOS:000332735200003
PM 24134831
DA 2024-11-01
ER

PT J
AU Wong, LJC
AF Wong, Lee-Jun C.
TI MOLECULAR GENETICS OF MITOCHONDRIAL DISORDERS
SO DEVELOPMENTAL DISABILITIES RESEARCH REVIEWS
LA English
DT Review
DE mitochondrial disorder; mtDNA mutation; mtDNA depletion; mtDNA deletion
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; COMPARATIVE GENOMIC HYBRIDIZATION;
   CYTOCHROME-C-OXIDASE; SIDEROBLASTIC ANEMIA MLASA; COENZYME Q(10)
   DEFICIENCY; DNA DEPLETION SYNDROME; POLG MUTATIONS; LIVER-FAILURE;
   LEIGH-DISEASE; OXIDATIVE-PHOSPHORYLATION
AB Mitochondrial respiratory chain (RC) disorders (RCDs) are a group of genetically and clinically heterogeneous diseases because of the fact that protein components of the RC are encoded by both mitochondrial and nuclear genomes and are essential in all cells. In addition, the biogenesis, structure, and function of mitochondria, including DNA replication, transcription, and translation, all require nuclear-encoded genes. In this review, primary molecular defects in the mitochondrial genome and major classes of nuclear genes causing mitochondrial RCDs, including genes underlying mitochondrial DNA (mtDNA) depletion syndrome, as well as genes encoding RC subunits, complex assembly genes, and translation factors, are described. Diagnostic methodologies used to detect common point mutations, large deletions, and unknown point mutations in the mtDNA and to quantify mutation heteroplasmy are also discussed. Finally, the selection of nuclear genes for gold standard sequence analysis, application of novel technologies including oligonucleotide array comparative genomic hybridization, and massive parallel sequencing of target genes are reviewed. (C) 2010 Wiley-Liss, Inc. Dev Disabil Res Rev 2010;16:154-162.
C1 Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
C3 Baylor College of Medicine
RP Wong, LJC (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Pl,NAB 2015, Houston, TX 77030 USA.
EM ljwong@bcm.edu
CR Antonicka H, 2003, AM J HUM GENET, V72, P101, DOI 10.1086/345489
   Bai RK, 2004, CLIN CHEM, V50, P996, DOI 10.1373/clinchem.2004.031153
   BIANCHI MS, 1995, CYTOGENET CELL GENET, V71, P99, DOI 10.1159/000134072
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Brautbar A, 2008, MOL GENET METAB, V94, P485, DOI 10.1016/j.ymgme.2008.04.004
   Bykhovskaya Y, 2004, AM J HUM GENET, V74, P1303, DOI 10.1086/421530
   Bykhovskaya Y, 2007, MOL GENET METAB, V91, P148, DOI 10.1016/j.ymgme.2007.02.006
   Calvo S, 2006, NAT GENET, V38, P576, DOI 10.1038/ng1776
   Carrozzo R, 2007, BRAIN, V130, P862, DOI 10.1093/brain/awl389
   Chinault AC, 2009, GENET MED, V11, P518, DOI 10.1097/GIM.0b013e3181abd83c
   CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324
   de Lonlay P, 2001, NAT GENET, V29, P57, DOI 10.1038/ng706
   Dieteren CEJ, 2008, J BIOL CHEM, V283, P34753, DOI 10.1074/jbc.M807323200
   DiMauro S, 2004, MITOCHONDRION, V4, P799, DOI 10.1016/j.mito.2004.07.032
   Dimmock DP, 2008, HUM MUTAT, V29, P330, DOI 10.1002/humu.9519
   Dimmock D, 2010, CLIN CHEM, V56, P1119, DOI 10.1373/clinchem.2009.141549
   Edvardson S, 2007, AM J HUM GENET, V81, P857, DOI 10.1086/521227
   El-Hattab AW, 2010, MOL GENET METAB, V99, P300, DOI 10.1016/j.ymgme.2009.10.003
   Elliott HR, 2008, AM J HUM GENET, V83, P254, DOI 10.1016/j.ajhg.2008.07.004
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Enns GM, 2006, MOL GENET METAB, V88, P364, DOI 10.1016/j.ymgme.2006.02.001
   Fernandez-Vizarra E, 2007, J MED GENET, V44, P173, DOI 10.1136/jmg.2006.045252
   Galbiati S, 2006, PEDIATR NEUROL, V34, P177, DOI 10.1016/j.pediatrneurol.2005.07.013
   Geisler S, 2010, NAT CELL BIOL, V12, P119, DOI 10.1038/ncb2012
   Gempel K, 2007, BRAIN, V130, P2037, DOI 10.1093/brain/awm054
   Gropman A, 2004, AM J MED GENET A, V124A, P377, DOI 10.1002/ajmg.a.20456
   Haas RH, 2008, MOL GENET METAB, V94, P16, DOI 10.1016/j.ymgme.2007.11.018
   Haas RH, 2007, PEDIATRICS, V120, P1326, DOI 10.1542/peds.2007-0391
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   Hoefs SJG, 2008, AM J HUM GENET, V82, P1306, DOI 10.1016/j.ajhg.2008.05.007
   Horton TM, 1996, GENE CHROMOSOME CANC, V15, P95, DOI 10.1002/(SICI)1098-2264(199602)15:2<95::AID-GCC3>3.0.CO;2-Z
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Houstek J, 2009, BBA-BIOENERGETICS, V1787, P529, DOI 10.1016/j.bbabio.2008.11.013
   Jessie BC, 2001, EXP GERONTOL, V37, P169, DOI 10.1016/S0531-5565(01)00153-X
   Kenmochi N, 2000, J HUM GENET, V45, P290, DOI 10.1007/s100380070018
   Koene S, 2009, J INTERN MED, V265, P193, DOI 10.1111/j.1365-2796.2008.02058.x
   Lacbawan F, 2000, AM J MED GENET, V95, P266, DOI 10.1002/1096-8628(20001127)95:3<266::AID-AJMG13>3.3.CO;2-S
   Lagier-Tourenne C, 2008, AM J HUM GENET, V82, P661, DOI 10.1016/j.ajhg.2007.12.024
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Lee NC, 2009, ARCH DIS CHILD, V94, P55, DOI 10.1136/adc.2008.139584
   Liang MH, 1998, AM J MED GENET, V77, P395, DOI 10.1002/(SICI)1096-8628(19980605)77:5<395::AID-AJMG8>3.0.CO;2-M
   Lutz RE, 2009, J PEDIATR GASTR NUTR, V49, P126, DOI 10.1097/MPG.0b013e31817d9cad
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Mardis ER, 2009, GENOME MED, V1, DOI 10.1186/gm40
   Miller C, 2004, ANN NEUROL, V56, P734, DOI 10.1002/ana.20282
   Milone M, 2008, NEUROMUSCULAR DISORD, V18, P626, DOI 10.1016/j.nmd.2008.05.009
   Milone M, 2009, MITOCHONDRION, V9, P279, DOI 10.1016/j.mito.2009.03.001
   Mollet J, 2008, AM J HUM GENET, V82, P623, DOI 10.1016/j.ajhg.2007.12.022
   Mollet J, 2007, J CLIN INVEST, V117, P765, DOI 10.1172/JCI29089
   Naïmi M, 2006, EUR J HUM GENET, V14, P917, DOI 10.1038/sj.ejhg.5201627
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nguyen KV, 2005, NEUROLOGY, V65, P1493, DOI 10.1212/01.wnl.0000182814.55361.70
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Ostergaard E, 2007, AM J HUM GENET, V81, P383, DOI 10.1086/519222
   Ostergaard E, 2007, BRAIN, V130, P853, DOI 10.1093/brain/awl383
   Pagliarini DJ, 2008, CELL, V134, P112, DOI 10.1016/j.cell.2008.06.016
   Patton JR, 2005, J BIOL CHEM, V280, P19823, DOI 10.1074/jbc.M500216200
   Quinzii C, 2006, AM J HUM GENET, V78, P345, DOI 10.1086/500092
   Quinzii CM, 2005, NEUROLOGY, V64, P539, DOI 10.1212/01.WNL.0000150588.75281.58
   Saada A, 2009, AM J HUM GENET, V84, P718, DOI 10.1016/j.ajhg.2009.04.020
   Saneto RP, 2010, SEIZURE-EUR J EPILEP, V19, P140, DOI 10.1016/j.seizure.2010.01.002
   Sarzi E, 2007, ANN NEUROL, V62, P579, DOI 10.1002/ana.21207
   Scheper GC, 2007, NAT GENET, V39, P534, DOI 10.1038/ng2013
   Shaibani A, 2009, ARCH NEUROL-CHICAGO, V66, P1028, DOI 10.1001/archneurol.2009.139
   Shanske S, 2004, MITOCHONDRION, V4, P403, DOI 10.1016/j.mito.2004.07.026
   Shchelochkov OA, 2009, MOL GENET METAB, V96, P97, DOI 10.1016/j.ymgme.2008.11.167
   Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063
   Smeitink JAM, 2006, AM J HUM GENET, V79, P869, DOI 10.1086/508434
   SOONG NW, 1992, NAT GENET, V2, P318
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Spinazzola A, 2005, GENE, V354, P162, DOI 10.1016/j.gene.2005.03.025
   Spinazzola A, 2009, J INTERN MED, V265, P174, DOI 10.1111/j.1365-2796.2008.02059.x
   Spinazzola A, 2009, J INHERIT METAB DIS, V32, P143, DOI 10.1007/s10545-008-1038-z
   Spinazzola A, 2007, BIOSCIENCE REP, V27, P39, DOI 10.1007/s10540-007-9036-1
   Tan DJ, 2002, CANCER RES, V62, P972
   Tay SKH, 2004, ARCH NEUROL-CHICAGO, V61, P950, DOI 10.1001/archneur.61.6.950
   Tiranti V, 1998, AM J HUM GENET, V63, P1609, DOI 10.1086/302150
   Valente L, 2009, BBA-MOL BASIS DIS, V1792, P791, DOI 10.1016/j.bbadis.2009.06.002
   Valnot I, 2000, AM J HUM GENET, V67, P1104
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Van Hove JLK, 2009, AM J MED GENET A, V149A, P861, DOI 10.1002/ajmg.a.32731
   Vasta V, 2009, GENOME MED, V1, DOI 10.1186/gm100
   Wallace D.C., 2001, The Metabolic and Molecular Basis of Inherited Disease, P2425
   WALLACE DC, 1995, BBA-MOL BASIS DIS, V1271, P141, DOI 10.1016/0925-4439(95)00021-U
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Willems PHGM, 2008, CELL CALCIUM, V44, P123, DOI 10.1016/j.ceca.2008.01.002
   Wong LJC, 2008, CLIN CHEM, V54, P1141, DOI 10.1373/clinchem.2008.103721
   Wong LJC, 2007, HEPATOLOGY, V46, P1218, DOI 10.1002/hep.21799
   Wong LJC, 2010, MOL GENET METAB, V100, P111, DOI 10.1016/j.ymgme.2010.02.024
   Wong LJC, 2008, HUM MUTAT, V29, pE150, DOI 10.1002/humu.20824
   Wong LJC, 1997, CLIN CHEM, V43, P1857
   Wong LJC, 2001, GENET MED, V3, P399, DOI 10.1097/00125817-200111000-00004
   Zhang SL, 2010, MOL GENET METAB, V99, P53, DOI 10.1016/j.ymgme.2009.09.003
   Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804
NR 96
TC 49
Z9 55
U1 0
U2 7
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1940-5510
J9 DEV DISABIL RES REV
JI Dev. Disabil. Res. Rev.
PY 2010
VL 16
IS 2
BP 154
EP 162
DI 10.1002/ddrr.104
PG 9
WC Clinical Neurology; Neurosciences; Pediatrics; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pediatrics; Psychiatry
GA 642IB
UT WOS:000281201100008
PM 20818730
DA 2024-11-01
ER

PT J
AU Karadag, A
   Avci, Z
   Catal, F
   Odemis, E
AF Karadag, A
   Avci, Z
   Catal, F
   Odemis, E
TI Cytochrome c oxidase deficiency in a child with isolated myopathy
SO FETAL AND PEDIATRIC PATHOLOGY
LA English
DT Article
DE child; cytochrome c oxidase deficiency; isolated myopathy
ID INFANTILE MITOCHONDRIAL MYOPATHY
AB Cytochrome c oxidase ( COX) deficiency is the most commonly recognized respiratory chain defect in childhood. The disease is clinically heterogeneous with phenotypes including Leigh syndrome, hepatic failure and myopathies. COX deficiency has been associated with mitochondrial DNA mutations in COX I, II, and III with large- scale deletions of the mitochondrial genome and with point mutations in mitochondrial tRNA genes. Here we report on a 3.5- year- old girl with a rare type of isolated myopathy due to COX deficiency.
C1 Fatih Univ, Fac Med, Dept Pediat, Ankara, Turkey.
   Baskent Univ, Fac Med, Dept Pediat, TR-06490 Ankara, Turkey.
C3 Fatih University; Baskent University
RP Karadag, A (corresponding author), Hosdere Caddesi 145, TR-06540 Ankara, Turkey.
EM ahmetkaradag@gmail.com
RI Avci, Zekai/KEJ-4161-2024
CR Darin N, 2003, NEUROPEDIATRICS, V34, P311
   DIMAURO S, 1983, ANN NEUROL, V14, P226, DOI 10.1002/ana.410140209
   DIMAURO S, 1980, NEUROLOGY, V30, P795, DOI 10.1212/WNL.30.8.795
   Komura K, 2003, PEDIATR NEUROL, V28, P53, DOI 10.1016/S0887-8994(02)00469-1
   Liet JM, 2003, J PEDIATR-US, V142, P62, DOI 10.1067/mpd.2003.mpd0333
   Rahman S, 1996, ANN NEUROL, V39, P343, DOI 10.1002/ana.410390311
   Rahman S, 2000, BRAIN, V123, P591, DOI 10.1093/brain/123.3.591
   Saitoh S, 1998, NEUROLOGY, V50, P531, DOI 10.1212/WNL.50.2.531
   SAUNIER P, 1995, NEUROMUSCULAR DISORD, V5, P285, DOI 10.1016/0960-8966(94)00071-G
   Shoubridge EA, 2001, AM J MED GENET, V106, P46, DOI 10.1002/ajmg.1378
   WU CM, 1992, MUSCLE NERVE, V15, P1258, DOI 10.1002/mus.880151107
   ZEVIANI M, 1986, ARCH NEUROL-CHICAGO, V43, P1198, DOI 10.1001/archneur.1986.00520110084025
NR 12
TC 1
Z9 1
U1 0
U2 2
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 1551-3815
J9 FETAL PEDIATR PATHOL
JI Fetal Pediatr. Pathol.
PD MAY-JUN
PY 2005
VL 24
IS 3
BP 149
EP 153
DI 10.1080/15227950500304218
PG 5
WC Pathology; Pediatrics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology; Pediatrics
GA 992TH
UT WOS:000233906400003
PM 16338876
DA 2024-11-01
ER

PT J
AU Lopez-Gomez, C
   Hewan, H
   Sierra, C
   Akman, HO
   Sanchez-Quintero, MJ
   Juanola-Falgarona, M
   Tadesse, S
   Tanji, K
   Konofagou, EE
   Hirano, M
AF Lopez-Gomez, Carlos
   Hewan, Henly
   Sierra, Carlos
   Akman, Hasan O.
   Sanchez-Quintero, Maria J.
   Juanola-Falgarona, Marti
   Tadesse, Saba
   Tanji, Kurenai
   Konofagou, Elisa E.
   Hirano, Michio
TI Bioavailability and cytosolic kinases modulate response to
   deoxynucleoside therapy in TK2 deficiency
SO EBIOMEDICINE
LA English
DT Article
DE Thymidine kinase 2; TK2; mtDNA depletion syndrome; Nucleoside;
   Deoxycytidine; Thymidine
ID MITOCHONDRIAL-DNA DEPLETION; THYMIDINE KINASE;
   FUNCTIONAL-CHARACTERIZATION; FOCUSED ULTRASOUND; MUTATIONS; POOLS;
   DEOXYCYTIDINE; EXPRESSION; MECHANISM; DELIVERY
AB Background: TK2 is a nuclear gene encoding the mitochondrial matrix protein thymidine kinase 2 (TK2), a critical enzyme in the mitochondrial nucleotide salvage pathway. Deficiency of TK2 activity causes mitochondrial DNA (mtDNA) depletion, which in humans manifests predominantly as a mitochondria myopathy with onset typically in infancy and childhood. We previously showed that oral treatment of the Tk2 H126N knock-in mouse model (Tk2(-/-)) with the TK2 substrates, deoxycytidine (dCtd) and thymidine (dThd), delayed disease onset and prolonged median survival by 3-fold. Nevertheless, dCtd + dThd treated Tk2(-/-) mice showed mtDNA depletion in brain as early as postnatal day 13 and in virtually all other tissues at age 29 days.
   Methods: To enhance mechanistic understanding and efficacy of dCtd dThd therapy, we studied the bioavailability of dCtd and dThd in various tissues as well as levels of the cytosolic enzymes, TK1 and dCK that convert the deoxynucleosides into dCMP and dTMP.
   Findings: Parenteral treatment relative to oral treatment produced higher levels of dCtd and dThd and improved mtDNA levels in liver and heart, but did not ameliorate molecular defects in brain or prolong survival. Downregulation of TK1 correlated with temporal- and tissue-specificity of response to dCtd + dThd. Finally, we observed in human infant and adult muscle expression of TK1 and dCK, which account for the long-term efficacy to dCtd + dThd therapy in TK2 defident patients.
   Interpretations: These data indicate that the cytosolic pyrimidine salvage pathway enzymes TK1 and dCK are critical for therapeutic efficacy of deoxynucleoside therapy for Tk2 deficiency. (C) 2019 The Authors. Published by Elsevier B.V.
C1 [Lopez-Gomez, Carlos; Hewan, Henly; Akman, Hasan O.; Sanchez-Quintero, Maria J.; Juanola-Falgarona, Marti; Tadesse, Saba; Hirano, Michio] Columbia Univ, Dept Neurol, H Houston Merritt Neuromuscular Res Ctr, Med Ctr, New York, NY 10032 USA.
   [Sierra, Carlos; Konofagou, Elisa E.] Columbia Univ, Dept Biomed Engn Ultrasound & Elast, Imaging Lab, New York, NY USA.
   [Konofagou, Elisa E.] Columbia Univ, Dept Radiol, New York, NY USA.
   [Tanji, Kurenai] Columbia Univ, Dept Pathol & Cell Biol, New York, NY USA.
C3 Columbia University; Columbia University; Columbia University; Columbia
   University
RP Hirano, M (corresponding author), Columbia Univ, Med Ctr, 630 West 168th St,P&S 4-423, New York, NY 10032 USA.
EM mh29@columbia.edu
RI Juanola-Falgarona, Martí/AFN-4252-2022; SANCHEZ-QUINTERO,
   MARIA/AAS-6771-2020; López-Gómez, Carlos/C-8938-2009
OI Lopez-Gomez, Carlos/0000-0003-2699-451X; SANCHEZ-QUINTERO, MARIA
   J/0000-0002-5638-2920; Juanola-Falgarona, Marti/0000-0002-4566-7154;
   Hewan, Henly/0000-0002-2214-7340; Hirano, Michio/0000-0002-7070-7402
FU NIH [P01 HD32062]; Arturo Estopinan TK2 Research Fund; Nicholas Nunno
   Foundation; JDM Fund for Mitochondrial Research; Shuman Mitochondrial
   Disease Fund; Marriott Mitochondrial Disease Clinic Research Fund
   (MMDCRF) from the J. Willard and Alice S. Marriott Foundation; NIH from
   NICHD [R01 HD057543, R01 HD056103]; Office of Dietary Supplements; NINDS
   [U54 NS078059]; NICHD
FX This work was supported by research grants from the NIH (P01 HD32062)
   (MH). MH is supported by the Arturo Estopinan TK2 Research Fund,
   Nicholas Nunno Foundation, JDM Fund for Mitochondrial Research, Shuman
   Mitochondrial Disease Fund, and the Marriott Mitochondrial Disease
   Clinic Research Fund (MMDCRF) from the J. Willard and Alice S. Marriott
   Foundation. MH also acknowledges support from NIH grants (R01 HD057543,
   and R01 HD056103 from NICHD) and the Office of Dietary Supplements, as
   well as U54 NS078059 from NINDS and NICHD. Funders had no role in study
   design, data collection, data analysis, data interpretation, drafting of
   the manuscript or submission for publication.
CR Akman HO, 2008, HUM MOL GENET, V17, P2433, DOI 10.1093/hmg/ddn143
   Béhin A, 2012, NEUROLOGY, V78, P644, DOI 10.1212/WNL.0b013e318248df2b
   BIRCHMACHIN MA, 1994, BIOCHEM MED METAB B, V51, P35, DOI 10.1006/bmmb.1994.1004
   Blazquez-Bermejo C, 2019, AGE RELATED ME UNPUB
   Cámara Y, 2015, NEUROLOGY, V84, P2286, DOI 10.1212/WNL.0000000000001644
   Choi JJ, 2007, PHYS MED BIOL, V52, P5509, DOI 10.1088/0031-9155/52/18/004
   Choi JJ, 2007, ULTRASOUND MED BIOL, V33, P95, DOI 10.1016/j.ultrasmedbio.2006.07.018
   Choi JJ, 2011, P NATL ACAD SCI USA, V108, P16539, DOI 10.1073/pnas.1105116108
   Choi JJ, 2008, ULTRASONIC IMAGING, V30, P189, DOI 10.1177/016173460803000304
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   Domínguez-González C, 2019, ANN NEUROL, V86, P293, DOI 10.1002/ana.25506
   Domínguez-González C, 2019, ORPHANET J RARE DIS, V14, DOI 10.1186/s13023-019-1071-z
   Dorado B, 2011, HUM MOL GENET, V20, P155, DOI 10.1093/hmg/ddq453
   Ferraro P, 2006, P NATL ACAD SCI USA, V103, P18586, DOI 10.1073/pnas.0609020103
   Feshitan JA, 2009, J COLLOID INTERF SCI, V329, P316, DOI 10.1016/j.jcis.2008.09.066
   Franzolin E, 2012, EXP CELL RES, V318, P2226, DOI 10.1016/j.yexcr.2012.05.028
   Garone C, 2018, J MED GENET, V55, P515, DOI 10.1136/jmedgenet-2017-105012
   Garone C, 2014, EMBO MOL MED, V6, P1016, DOI 10.15252/emmm.201404092
   Hodzic J, 2011, NUCLEOS NUCLEOT NUCL, V30, P1214, DOI 10.1080/15257770.2011.629271
   Huang WY, 2017, PROTEIN CELL, V8, P284, DOI 10.1007/s13238-016-0350-x
   Konofagou EE, 2012, CURR PHARM BIOTECHNO, V13, P1332
   Lesko N, 2010, NEUROMUSCULAR DISORD, V20, P198, DOI 10.1016/j.nmd.2009.11.013
   López LC, 2009, HUM MOL GENET, V18, P714, DOI 10.1093/hmg/ddn401
   Lopez-Gomez C, 2017, ANN NEUROL, V81, P641, DOI 10.1002/ana.24922
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Martí R, 2004, CLIN CHEM, V50, P120, DOI 10.1373/clinchem.2003.026179
   Martí R, 2012, METHODS MOL BIOL, V837, P135, DOI 10.1007/978-1-61779-504-6_9
   Martí R, 2012, METHODS MOL BIOL, V837, P121, DOI 10.1007/978-1-61779-504-6_8
   Munch-Petersen B, 2010, NUCLEOS NUCLEOT NUCL, V29, P363, DOI 10.1080/15257771003729591
   Oskoui M, 2006, ARCH NEUROL-CHICAGO, V63, P1122, DOI 10.1001/archneur.63.8.1122
   Rehan S, 2015, PROTEIN EXPRES PURIF, V114, P99, DOI 10.1016/j.pep.2015.07.003
   Saada A, 2003, BIOCHEM BIOPH RES CO, V310, P963, DOI 10.1016/j.bbrc.2003.09.104
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Sierra C, 2017, J CEREBR BLOOD F MET, V37, P1236, DOI 10.1177/0271678X16652630
   Tung YS, 2011, J ACOUST SOC AM, V130, P3059, DOI 10.1121/1.3646905
   Tyynismaa H, 2012, HUM MOL GENET, V21, P66, DOI 10.1093/hmg/ddr438
   Wang LY, 2016, NUCLEOS NUCLEOT NUCL, V35, P578, DOI 10.1080/15257770.2015.1125001
   Young JD, 2013, MOL ASPECTS MED, V34, P529, DOI 10.1016/j.mam.2012.05.007
NR 38
TC 16
Z9 16
U1 1
U2 5
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 2352-3964
J9 EBIOMEDICINE
JI EBioMedicine
PD AUG
PY 2019
VL 46
BP 356
EP 367
DI 10.1016/j.ebiom.2019.07.037
PG 12
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA IY7RE
UT WOS:000486592000045
PM 31383553
OA Green Published, gold
DA 2024-11-01
ER

PT J
AU Ohnuki, Y
   Takahashi, K
   Iijima, E
   Takahashi, W
   Suzuki, S
   Ozaki, Y
   Kitao, R
   Mihara, M
   Ishihara, T
   Nakamura, M
   Sawano, Y
   Goto, Y
   Izumi, S
   Kulski, JK
   Shiina, T
   Takizawa, S
AF Ohnuki, Yuko
   Takahashi, Kazumi
   Iijima, Eri
   Takahashi, Wakoh
   Suzuki, Shingo
   Ozaki, Yuki
   Kitao, Ruriko
   Mihara, Masatoshi
   Ishihara, Tadayuki
   Nakamura, Michiyo
   Sawano, Yoshie
   Goto, Yu-ichi
   Izumi, Shunichiro
   Kulski, Jerzy K.
   Shiina, Takashi
   Takizawa, Shunya
TI Multiple Deletions in Mitochondrial DNA in a Patient with Progressive
   External Ophthalmoplegia, Leukoencephalopathy and Hypogonadism
SO INTERNAL MEDICINE
LA English
DT Article
DE mitochondrial DNA (mtDNA); multiple deletion; progressive external
   ophthalmoplegia (PEO); hypogonadism; leukoencephalopathy
ID MUTATIONS
AB Progressive external ophthalmoplegia (PEO) is one of a number of major types of mitochondrial disorders. Most sporadic PEO patients have a heteroplasmic large deletion of mitochondrial DNA (mtDNA) in the mitochondria in skeletal muscles. We herein analyzed mtDNA deletions using sub-cloning and Sanger sequencing of PCR products in a 31-year-old Japanese man with multiple symptoms, including PEO, muscle weakness, hearing loss, leukoencephalopathy and hypogonadism. A large number of multiple deletions was detected, as well as four kinds of deletion breakpoints identified in different locations, including m.3347_12322, m.5818_13964, m.5829_13964 and m.5837_13503.
C1 [Ohnuki, Yuko; Suzuki, Shingo; Ozaki, Yuki; Kulski, Jerzy K.; Shiina, Takashi] Tokai Univ, Sch Med, Dept Mol Life Sci Basic Med Sci & Mol Med, Hiratsuka, Kanagawa 25912, Japan.
   [Ohnuki, Yuko; Takahashi, Kazumi; Izumi, Shunichiro] Tokai Univ Hosp, Dept Clin Genet, Hiratsuka, Kanagawa, Japan.
   [Takahashi, Kazumi; Izumi, Shunichiro] Tokai Univ, Sch Med, Dept Obstet & Gynecol, Hiratsuka, Kanagawa 25912, Japan.
   [Iijima, Eri; Takahashi, Wakoh; Takizawa, Shunya] Tokai Univ, Sch Med, Dept Internal Med, Div Neurol, Hiratsuka, Kanagawa 25912, Japan.
   [Mihara, Masatoshi; Ishihara, Tadayuki] Natl Hakone Hosp, Dept Neurol, Odawara, Kanagawa, Japan.
   [Nakamura, Michiyo; Sawano, Yoshie; Goto, Yu-ichi] Natl Ctr Neurol & Psychiat, Dept Mental Retardat & Birth Defect Res, Tokyo, Japan.
   [Kulski, Jerzy K.] Univ Western Australia, Ctr Forens Sci, Nedlands, WA 6009, Australia.
C3 Tokai University; Tokai University; Tokai University; Tokai University;
   National Center for Neurology & Psychiatry - Japan; University of
   Western Australia
RP Ohnuki, Y (corresponding author), Tokai Univ, Sch Med, Dept Mol Life Sci Basic Med Sci & Mol Med, Hiratsuka, Kanagawa 25912, Japan.
EM yukom@is.icc.u-tokai.ac.jp
RI kulski, jerzy/V-2046-2019
OI kulski, jerzy/0000-0002-9789-245X; Shiina, Takashi/0000-0002-2067-6708;
   IZUMI, shunichiro/0000-0003-3096-8066; Ohnuki, Yuko/0000-0002-6449-6485;
   Suzuki, Shingo/0000-0003-1880-582X
CR Bose HS, 2002, NATURE, V417, P87, DOI 10.1038/417087a
   CHEN X, 1995, AM J HUM GENET, V57, P239
   DiMauro S, 2011, GENEREVIEWS GENETEST, P1993
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Melberg A, 1996, MUSCLE NERVE, V19, P1561, DOI 10.1002/(SICI)1097-4598(199612)19:12<1561::AID-MUS5>3.0.CO;2-8
   Ronchi D, 2012, BRAIN, V135, P3404, DOI 10.1093/brain/aws258
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, NEUROMOL MED, V3, P129, DOI 10.1385/NMM:3:3:129
NR 11
TC 6
Z9 7
U1 0
U2 0
PU JAPAN SOC INTERNAL MEDICINE
PI TOKYO
PA 34-3 3-CHOME HONGO BUNKYO-KU, TOKYO, 113, JAPAN
SN 0918-2918
EI 1349-7235
J9 INTERNAL MED
JI Intern. Med.
PY 2014
VL 53
IS 12
BP 1365
EP 1369
DI 10.2169/internalmedicine.53.1320
PG 5
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA AJ7UP
UT WOS:000337904300019
PM 24930659
OA hybrid
DA 2024-11-01
ER

PT J
AU Karri, B
   Sebastian, RT
   Kyle, G
   Hart, IK
   Mountford, RC
AF Karri, B.
   Sebastian, R. T.
   Kyle, G.
   Hart, I. K.
   Mountford, R. C.
TI Ptosis as the Only Presenting Feature of a Mitochondrial Cytopathy
SO NEURO-OPHTHALMOLOGY
LA English
DT Article
DE age-related CPEO; chronic progressive external ophthalmoplegia; isolated
   ptosis; mitochondrial cytopathies; myasthenia gravis
ID EXTERNAL OPHTHALMOPLEGIA; EXTRAOCULAR-MUSCLE; DNA DELETIONS; DISEASE;
   MTDNA; ACCUMULATION; MANAGEMENT; MUTATIONS; DEFECTS; TWINKLE
AB Mitochondrial cytopathies (MCs) result from a genetic defect in cells that leads to reduction in energy production. This can affect any organ, especially those with high-energy consumption. The authors highlight two cases of MCs who presented with isolated ptosis. The characteristics initially suggested myasthenia gravis. Subsequently the ptosis became progressive and the diagnosis was revised to MC because mitochondrial rearrangements were found in skeletal muscle DNA. Limb muscle biopsy was conclusive in one patient, but the other patient required periocular muscle to confirm the diagnosis. MC can present in this manner because heteroplasmy of mitochondrial DNA means that not all organs will exhibit clinical manifestations.
C1 [Karri, B.] Aintree Univ Hosp NHS Fdn Trust, Elect Care Ctr, Dept Ophthalmol, Liverpool L9 7AL, Merseyside, England.
   [Hart, I. K.] Walton Ctr Neurol & Neurosurg, Liverpool, Merseyside, England.
   [Mountford, R. C.] Liverpool Womens NHS Fdn Trust, Cheshire & Merseyside Reg Mol Genet Lab, Liverpool, Merseyside, England.
C3 Aintree University Hospitals NHS Foundation Trust; Walton Centre
RP Karri, B (corresponding author), Aintree Univ Hosp NHS Fdn Trust, Elect Care Ctr, Dept Ophthalmol, Liverpool L9 7AL, Merseyside, England.
EM BHAVANI.KARRI@aintree.nhs.uk
CR [Anonymous], NUEOROMUSCUL DISORD
   Barthélémy C, 2001, ANN NEUROL, V49, P607, DOI 10.1002/ana.1002.abs
   Blok MJ, 2009, J MED GENET, V46, P776, DOI 10.1136/jmg.2009.067686
   Carta A, 2000, ARCH OPHTHALMOL-CHIC, V118, P1441
   CORTOPASSI GA, 1992, P NATL ACAD SCI USA, V89, P7370, DOI 10.1073/pnas.89.16.7370
   Finsterer J, 2009, EUR J NEUROL, V16, P1255, DOI 10.1111/j.1468-1331.2009.02811.x
   Fratter C, 2010, NEUROLOGY, V74, P1619, DOI 10.1212/WNL.0b013e3181df099f
   Ghezzi D, 2010, AM J HUM GENET, V86, P639, DOI 10.1016/j.ajhg.2010.03.002
   GOTO Y, 1990, J NEUROL SCI, V100, P63, DOI 10.1016/0022-510X(90)90014-E
   Greaves LC, 2010, INVEST OPHTH VIS SCI, V51, P3340, DOI 10.1167/iovs.09-4659
   Hirano M, 2001, NEUROLOGY, V57, P2163, DOI 10.1212/WNL.57.12.2163
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Hudson G, 2008, BRAIN, V131, P329, DOI 10.1093/brain/awm272
   Jeppesen TD, 2003, ANN NEUROL, V54, P86, DOI 10.1002/ana.10594
   JOHNSTON W, 1995, ANN NEUROL, V37, P16, DOI 10.1002/ana.410370106
   KRENDEL DA, 1987, MUSCLE NERVE, V10, P299, DOI 10.1002/mus.880100404
   LEFORESTIER N, 1995, MUSCLE NERVE, V18, P1338, DOI 10.1002/mus.880181120
   LI YY, 1995, BIOCHEM BIOPH RES CO, V210, P211, DOI 10.1006/bbrc.1995.1648
   Marchington D, 2010, J MED GENET, V47, P257, DOI 10.1136/jmg.2009.072900
   MILLAY DJ, 1989, ARCH OTOLARYNGOL, V115, P198
   OLSON W, 1972, ARCH NEUROL-CHICAGO, V26, P193, DOI 10.1001/archneur.1972.00490090019001
   Pagliarini DJ, 2008, CELL, V134, P112, DOI 10.1016/j.cell.2008.06.016
   PETTY RKH, 1986, BRAIN, V109, P915, DOI 10.1093/brain/109.5.915
   Richardson C, 2005, EYE, V19, P258, DOI 10.1038/sj.eye.6701488
   RIFAI Z, 1995, ANN NEUROL, V37, P24, DOI 10.1002/ana.410370107
   SHIGENAGA MK, 1994, P NATL ACAD SCI USA, V91, P10771, DOI 10.1073/pnas.91.23.10771
   SRIDHARAN GV, 1995, AGE AGEING, V24, P21, DOI 10.1093/ageing/24.1.21
   Tyynismaa H, 2009, AM J HUM GENET, V85, P290, DOI 10.1016/j.ajhg.2009.07.009
   Virgilio R, 2008, J NEUROL, V255, P1384, DOI 10.1007/s00415-008-0926-3
   WALLACE DC, 1994, EPILEPSIA, V35, pS43, DOI 10.1111/j.1528-1157.1994.tb05928.x
   Wanrooij S, 2004, NUCLEIC ACIDS RES, V32, P3053, DOI 10.1093/nar/gkh634
   Wong VA, 2002, OPHTHALMOLOGY, V109, P1023, DOI 10.1016/S0161-6420(02)01009-6
   Yu-Wai-Man P, 2010, INVEST OPHTH VIS SCI, V51, P3347, DOI 10.1167/iovs.09-4660
NR 33
TC 0
Z9 0
U1 0
U2 1
PU TAYLOR & FRANCIS AS
PI OSLO
PA KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY
SN 0165-8107
EI 1744-506X
J9 NEURO-OPHTHALMOLOGY
JI Neuro-Ophthalmol.
PD OCT-DEC
PY 2011
VL 35
IS 5-6
BP 284
EP 288
DI 10.3109/01658107.2011.615453
PG 5
WC Clinical Neurology; Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Ophthalmology
GA 855VP
UT WOS:000297594300012
DA 2024-11-01
ER

PT J
AU Orsucci, D
   Ienco, EC
   Mancuso, M
   Siciliano, G
AF Orsucci, Daniele
   Ienco, Elena Caldarazzo
   Mancuso, Michelangelo
   Siciliano, Gabriele
TI POLG1-Related and other "Mitochondrial Parkinsonisms": an Overview
SO JOURNAL OF MOLECULAR NEUROSCIENCE
LA English
DT Article
DE Haplogroups; Mitochondria; Mitochondrial diseases; mtDNA; Parkinson's
   disease; POLG
ID DNA-POLYMERASE-GAMMA; PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; FAMILIAL
   PARKINSONISM; POLG1 MUTATIONS; W748S MUTATION; A8344G MERRF;
   COMMON-CAUSE; DISEASE; RISK; POLYMORPHISMS
AB Mitochondrial dysfunction has been implicated in the pathogenesis of sporadic, idiopathic Parkinson disease. In some cases, mitochondrial DNA primary genetic abnormalities, or more commonly, secondary rearrangements due to polymerase gamma (POLG1) gene mutation, can directly cause parkinsonism. The case of a Parkinson disease patient with some signs or symptoms suggestive of mitochondrial disease (i.e., ptosis, myopathy, neuropathy) is a relatively common event in the neurological practice. Mitochondrial parkinsonisms do not have distinctive features allowing an immediate diagnosis, and a negative family history does not rule out a possible diagnosis of mitochondrial disorder. In this article, we do not revise the mitochondrial hypothesis of sporadic, idiopathic Parkinson disease, extensively discussed elsewhere, but we review POLG1-related parkinsonism and other well-defined forms of "mitochondrial parkinsonisms", with mtDNA mutations or rearrangements. Lastly, we try to introduce a possible diagnostic approach for patients with parkinsonism and suspected mitochondrial disorder.
C1 [Orsucci, Daniele; Ienco, Elena Caldarazzo; Mancuso, Michelangelo; Siciliano, Gabriele] Univ Pisa, Dept Neurosci, Neurol Clin, I-56126 Pisa, Italy.
C3 University of Pisa
RP Orsucci, D (corresponding author), Univ Pisa, Dept Neurosci, Neurol Clin, Via Roma 67, I-56126 Pisa, Italy.
EM d.orsucci@sssup.it
RI Mancuso, Michelangelo/K-4170-2016; Orsucci, Daniele/AAA-7576-2019;
   Ienco, Elena/K-9142-2016; Siciliano, Gabriele/K-7259-2016
OI Caldarazzo Ienco, Elena/0000-0003-0134-5062; Orsucci,
   Daniele/0000-0003-4847-7812; Siciliano, Gabriele/0000-0002-6142-2384
FU Telethon [GUP09004]
FX This study was partially supported by Telethon Grant GUP09004.
CR Anvret A, 2010, NEUROSCI LETT, V485, P117, DOI 10.1016/j.neulet.2010.08.082
   Autere J, 2004, HUM GENET, V115, P29, DOI 10.1007/s00439-004-1123-9
   Baloh RH, 2007, ARCH NEUROL-CHICAGO, V64, P998, DOI 10.1001/archneur.64.7.998
   Batabyal D, 2010, J BIOL CHEM, V285, P34191, DOI 10.1074/jbc.M110.156182
   Betts-Henderson J, 2009, NEUROPATH APPL NEURO, V35, P120, DOI 10.1111/j.1365-2990.2008.00981.x
   Blok MJ, 2009, J MED GENET, V46, P776, DOI 10.1136/jmg.2009.067686
   Büeler H, 2009, EXP NEUROL, V218, P235, DOI 10.1016/j.expneurol.2009.03.006
   Chan SSL, 2009, BBA-BIOENERGETICS, V1787, P312, DOI 10.1016/j.bbabio.2008.10.007
   Chan SSL, 2005, J BIOL CHEM, V280, P31341, DOI 10.1074/jbc.M506762200
   Copeland WC, 2010, SUBCELL BIOCHEM, V50, P211, DOI 10.1007/978-90-481-3471-7_11
   Craig K, 2007, BRAIN, V130, DOI 10.1093/brain/awm009
   Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3
   Davidzon G, 2006, ANN NEUROL, V59, P859, DOI 10.1002/ana.20831
   De Coo IFM, 1999, ANN NEUROL, V45, P130, DOI 10.1002/1531-8249(199901)45:1<130::AID-ART21>3.0.CO;2-Z
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Echaniz-Laguna A, 2010, ARCH NEUROL-CHICAGO, V67, P1140, DOI 10.1001/archneurol.2010.219
   Eerola J, 2010, NEUROSCI LETT, V477, P1, DOI 10.1016/j.neulet.2010.04.021
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   Fukae J, 2007, MITOCHONDRION, V7, P58, DOI 10.1016/j.mito.2006.12.002
   Galassi G, 2008, NEUROMUSCULAR DISORD, V18, P465, DOI 10.1016/j.nmd.2008.03.013
   Ghezzi D, 2005, EUR J HUM GENET, V13, P748, DOI 10.1038/sj.ejhg.5201425
   González-Vioque E, 2006, ARCH NEUROL-CHICAGO, V63, P107, DOI 10.1001/archneur.63.1.107
   Graziewicz MA, 2007, HUM MOL GENET, V16, P2729, DOI 10.1093/hmg/ddm227
   Gu M, 1998, ANN NEUROL, V44, P177, DOI 10.1002/ana.410440207
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Harris MO, 2010, ARCH NEUROL-CHICAGO, V67, P493, DOI 10.1001/archneurol.2010.36
   Horvath R, 2007, NEUROLOGY, V68, P56, DOI 10.1212/01.wnl.0000250334.48038.7a
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Hudson G, 2007, ARCH NEUROL-CHICAGO, V64, P553, DOI 10.1001/archneur.64.4.553
   Hudson G, 2006, HUM MOL GENET, V15, pR244, DOI 10.1093/hmg/ddl233
   Huerta C, 2005, J NEUROL SCI, V236, P49, DOI 10.1016/j.jns.2005.04.016
   Invernizzi F, 2008, NEUROMUSCULAR DISORD, V18, P460, DOI 10.1016/j.nmd.2008.04.005
   Latsoudis H, 2008, J HUM GENET, V53, P349, DOI 10.1007/s10038-008-0259-1
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Luoma PT, 2007, NEUROLOGY, V69, P1152, DOI 10.1212/01.wnl.0000276955.23735.eb
   Luoma PT, 2005, HUM MOL GENET, V14, P1907, DOI 10.1093/hmg/ddi196
   Mancuso M, 2004, ARCH NEUROL-CHICAGO, V61, P1777, DOI 10.1001/archneur.61.11.1777
   Mancuso M, 2009, CURR MOL MED, V9, P1095, DOI 10.2174/156652409789839099
   Mancuso M, 2008, MOVEMENT DISORD, V23, P2098, DOI 10.1002/mds.22050
   Mancuso M, 2008, PARKINSONISM RELAT D, V14, P381, DOI 10.1016/j.parkreldis.2007.10.001
   Mancuso Michelangelo, 2008, Human Genomics, V3, P71
   Milone M, 2010, NEUROLOGIST, V16, P84, DOI 10.1097/NRL.0b013e3181c78a89
   NIKOSKELAINEN EK, 1995, J NEUROL NEUROSUR PS, V59, P160, DOI 10.1136/jnnp.59.2.160
   Nishioka K, 2010, PARKINSONISM RELAT D, V16, P686, DOI 10.1016/j.parkreldis.2010.09.007
   Orsucci D, 2009, NUTR REV, V67, P427, DOI 10.1111/j.1753-4887.2009.00221.x
   Pagnamenta AT, 2006, HUM REPROD, V21, P2467, DOI 10.1093/humrep/del076
   PARKER WD, 1989, ANN NEUROL, V26, P719, DOI 10.1002/ana.410260606
   Pyle A, 2005, ANN NEUROL, V57, P564, DOI 10.1002/ana.20417
   Remes AM, 2008, PARKINSONISM RELAT D, V14, P652, DOI 10.1016/j.parkreldis.2008.01.009
   Sarzi E, 2007, AM J MED GENET A, V143A, P33, DOI 10.1002/ajmg.a.31565
   Schaefer AM, 2008, ANN NEUROL, V63, P35, DOI 10.1002/ana.21217
   Schicks J, 2010, MOVEMENT DISORD, V25, P2678, DOI 10.1002/mds.23286
   Siciliano G, 2001, J NEUROL NEUROSUR PS, V71, P685, DOI 10.1136/jnnp.71.5.685
   Simon DK, 2010, BMC MED GENET, V11, DOI 10.1186/1471-2350-11-53
   Simon DK, 2003, NEUROGENETICS, V4, P199, DOI 10.1007/s10048-003-0150-3
   Simon DK, 1999, NEUROLOGY, V53, P1787, DOI 10.1212/WNL.53.8.1787
   Solano A, 2003, ANN NEUROL, V54, P527, DOI 10.1002/ana.10682
   Stewart JD, 2008, NEUROLOGY, V71, P1829, DOI 10.1212/01.wnl.0000335931.54095.0a
   Synofzik M, 2010, MOVEMENT DISORD, V25, P243, DOI 10.1002/mds.22865
   Thyagarajan D, 2000, ANN NEUROL, V48, P730, DOI 10.1002/1531-8249(200011)48:5<730::AID-ANA6>3.0.CO;2-0
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   van der Walt JM, 2003, AM J HUM GENET, V72, P804, DOI 10.1086/373937
   Wang K, 2009, NEUROGENETICS, V10, P337, DOI 10.1007/s10048-009-0194-0
   Wilcox RA, 2007, MOVEMENT DISORD, V22, P1020, DOI 10.1002/mds.21416
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   Wong LJC, 2008, HUM MUTAT, V29, pE150, DOI 10.1002/humu.20824
NR 67
TC 42
Z9 46
U1 0
U2 2
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 0895-8696
EI 1559-1166
J9 J MOL NEUROSCI
JI J. Mol. Neurosci.
PD MAY
PY 2011
VL 44
IS 1
BP 17
EP 24
DI 10.1007/s12031-010-9488-9
PG 8
WC Biochemistry & Molecular Biology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Neurosciences & Neurology
GA 750FL
UT WOS:000289530900004
PM 21221844
DA 2024-11-01
ER

PT J
AU Majamaa, K
   Kärppä, M
   Moilanen, JS
AF Majamaa, Kari
   Karppa, Mikko
   Moilanen, Jukka S.
TI Neurological manifestations in adult patients with the m.3243A>G variant
   in mitochondrial DNA
SO BMJ NEUROLOGY OPEN
LA English
DT Article
DE CLINICAL NEUROLOGY; GENETICS; META-ANALYSIS; MITOCHONDRIAL DISORDERS;
   SYSTEMATIC REVIEWS
ID STROKE-LIKE EPISODES; LACTIC-ACIDOSIS; PERIPHERAL NEUROPATHY; MUTATION;
   MELAS; ENCEPHALOPATHY; PREVALENCE; DISEASE; A3243G; POLYMORPHISMS
AB Background The m.3243A>G variant in mitochondrial DNA (mtDNA) is the most common cause of the MELAS (Mitochondrial encephalopathy, lactic acidosis and stroke-like episodes) syndrome usually commencing in childhood or adolescence. In adults, the variant presents with versatile and mostly neurological phenotypes, but MELAS may not be common. Objective To examine the frequency of phenotypes in adults with m.3243A>G in a population-based cohort and in a meta-analysis of reported case series. Methods We clinically examined 51 adult patients with m.3243A>G to determine the frequency of phenotypes and to analyse the contribution of variant heteroplasmy, age, sex and mtDNA haplogroup to the phenotypes. The frequencies of neurological features were also assessed in a meta-analysis on 25 published case series reporting 1314 patients. Results Sensorineural hearing impairment (HI), cognitive impairment and myopathy were the most common manifestations, whereas stroke-like episodes were infrequent. Variant heteroplasmy and age were only modest predictors of the phenotypes, although heteroplasmy correlated significantly with disability and Kaplan-Meier analysis showed progression of phenotypes with age. Male sex predicted more severe disability, whereas haplogroup UK was associated with no significant disability. Meta-analysis revealed substantial heterogeneity of phenotype frequencies and preferential inclusion of the MELAS phenotype. Discussion In adult patients with m.3243A>G sensorineural HI, cognitive impairment and myopathy are common manifestations with lifetime prevalences approaching unity. Stroke-like episodes are rare. Variant heteroplasmy, age, sex and mtDNA haplogroup contribute to the severity of the disease. Meta-analysis provided a solid estimate of the various neurological symptoms in adults with m.3243A>G.
C1 [Majamaa, Kari; Karppa, Mikko] Univ Oulu, Res Unit Clin Med, Neurol, Oulu, Finland.
   [Majamaa, Kari; Karppa, Mikko] Oulu Univ Hosp, Med Res Ctr Oulu & Neuroctr, Oulu, Finland.
   [Moilanen, Jukka S.] Univ Oulu, Res Unit Clin Med, Clin Genet, Oulu, Finland.
   [Moilanen, Jukka S.] Oulu Univ Hosp, Med Res Ctr Oulu, Oulu, Finland.
C3 University of Oulu; University of Oulu; University of Oulu; University
   of Oulu
RP Majamaa, K (corresponding author), Univ Oulu, Res Unit Clin Med, Neurol, Oulu, Finland.; Majamaa, K (corresponding author), Oulu Univ Hosp, Med Res Ctr Oulu & Neuroctr, Oulu, Finland.
EM kari.majamaa@oulu.fi; mikko.karppa@oulu.fi; jukka.moilanen@oulu.fi
OI Majamaa, Kari/0000-0002-9070-3791
FU Sigrid Juselius Foundation
FX This work was supported in part by grants from the Sigrid Juselius
   Foundation.
CR Autere J, 2004, HUM GENET, V115, P29, DOI 10.1007/s00439-004-1123-9
   Balduzzi S, 2019, EVID-BASED MENT HEAL, V22, P153, DOI 10.1136/ebmental-2019-300117
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Boggan RM, 2019, MOL GENET METAB, V128, P19, DOI 10.1016/j.ymgme.2019.09.003
   El-Hattab AW, 2015, MOL GENET METAB, V116, P4, DOI 10.1016/j.ymgme.2015.06.004
   Elliott HR, 2008, AM J HUM GENET, V83, P254, DOI 10.1016/j.ajhg.2008.07.004
   Finnilä S, 2001, AM J HUM GENET, V68, P1475, DOI 10.1086/320591
   Gorman GS, 2015, ANN NEUROL, V77, P753, DOI 10.1002/ana.24362
   Grady JP, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708262
   Guy W., 1976, NATL I MENTAL HLTH R, P218
   Higgins JPT, 2003, BMJ-BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   HIRANO M, 1994, J CHILD NEUROL, V9, P4, DOI 10.1177/088307389400900102
   Hudson G, 2007, AM J HUM GENET, V81, P228, DOI 10.1086/519394
   Kärppä M, 2003, J NEUROL, V250, P216, DOI 10.1007/s00415-003-0981-8
   Karstens AJ, 2024, J INT NEUROPSYCH SOC, V30, P389, DOI 10.1017/S1355617723000760
   KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5
   Liu GQ, 2023, BRAIN, V146, P42, DOI 10.1093/brain/awac327
   Lu YY, 2020, J NEUROL SCI, V408, DOI 10.1016/j.jns.2019.116499
   Luigetti M, 2016, EUR J NEUROL, V23, P1020, DOI 10.1111/ene.12954
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   Majamaa-Voltti Kirsi, 2002, BMC Cardiovasc Disord, V2, P12
   Mancuso M, 2014, J NEUROL, V261, P504, DOI 10.1007/s00415-013-7225-3
   Manwaring N, 2007, MITOCHONDRION, V7, P230, DOI 10.1016/j.mito.2006.12.004
   Martikainen MH, 2024, BMJ NEUROL OPEN, V6, DOI 10.1136/bmjno-2023-000546
   Montano V, 2021, ARCH BIOCHEM BIOPHYS, V697, DOI 10.1016/j.abb.2020.108689
   MORAES CT, 1993, NEUROMUSCULAR DISORD, V3, P43, DOI 10.1016/0960-8966(93)90040-Q
   Nesbitt V, 2013, J NEUROL NEUROSUR PS, V84, P936, DOI 10.1136/jnnp-2012-303528
   Niemi AK, 2003, HUM GENET, V112, P29, DOI 10.1007/s00439-002-0843-y
   Orsucci D, 2017, J NEUROL, V264, P1777, DOI 10.1007/s00415-017-8567-z
   Pickett SJ, 2018, ANN CLIN TRANSL NEUR, V5, P333, DOI 10.1002/acn3.532
   Pierron D, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-41
   RANKIN J, 1957, Scott Med J, V2, P200
   Sovio U, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000409
   Sproule DM, 2008, ANN NY ACAD SCI, V1142, P133, DOI 10.1196/annals.1444.011
   Torroni A, 2003, AM J HUM GENET, V72, P1005, DOI 10.1086/373936
   Uimonen S, 2001, HUM GENET, V108, P284, DOI 10.1007/s004390100475
   WHO Document Production Services, 2006, Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: report of a WHO/IDF consultation
NR 37
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
EI 2632-6140
J9 BMJ NEUROL OPEN
JI BMJ Neurol Open
PD SEP 24
PY 2024
VL 6
IS 2
AR e000825
DI 10.1136/bmjno-2024-000825
PG 9
WC Clinical Neurology
WE Emerging Sources Citation Index (ESCI)
SC Neurosciences & Neurology
GA H0O0B
UT WOS:001320512900001
PM 39324021
OA gold, Green Accepted
DA 2024-11-01
ER

PT J
AU Zhou, XS
   Kannisto, K
   Curbo, S
   von Döbeln, U
   Hultenby, K
   Isetun, S
   Gåfvels, M
   Karlsson, A
AF Zhou, Xiaoshan
   Kannisto, Kristina
   Curbo, Sophie
   von Dobeln, Ulrika
   Hultenby, Kjell
   Isetun, Sindra
   Gafvels, Mats
   Karlsson, Anna
TI Thymidine Kinase 2 Deficiency-Induced mtDNA Depletion in Mouse Liver
   Leads to Defect β-Oxidation
SO PLOS ONE
LA English
DT Article
ID MITOCHONDRIAL-DNA DEPLETION; TANDEM MASS-SPECTROMETRY; DEOXYGUANOSINE
   KINASE; TK2 DEFICIENCY; MYOPATHY; MUTATIONS; GENE; MICE; COMPENSATION;
   METABOLISM
AB Thymidine kinase 2 (TK2) deficiency in humans causes mitochondrial DNA (mtDNA) depletion syndrome. To study the molecular mechanisms underlying the disease and search for treatment options, we previously generated and described a TK2 deficient mouse strain (TK2(-/-)) that progressively loses its mtDNA. The TK2(-/-) mouse model displays symptoms similar to humans harboring TK2 deficient infantile fatal encephalomyopathy. Here, we have studied the TK2(-/-) mouse model to clarify the pathological role of progressive mtDNA depletion in liver for the severe outcome of TK2 deficiency. We observed that a gradual depletion of mtDNA in the liver of the TK2(-/-) mice was accompanied by increasingly hypertrophic mitochondria and accumulation of fat vesicles in the liver cells. The levels of cholesterol and nonesterified fatty acids were elevated and there was accumulation of long chain acylcarnitines in plasma of the TK2(-/-) mice. In mice with hepatic mtDNA levels below 20%, the blood sugar and the ketone levels dropped. These mice also exhibited reduced mitochondrial beta-oxidation due to decreased transport of long chain acylcarnitines into the mitochondria. The gradual loss of mtDNA in the liver of the TK2(-/-) mice causes impaired mitochondrial function that leads to defect beta-oxidation and, as a result, insufficient production of ketone bodies and glucose. This study provides insight into the mechanism of encephalomyopathy caused by TK2 deficiency-induced mtDNA depletion that may be used to explore novel therapeutic strategies.
C1 [Zhou, Xiaoshan; Curbo, Sophie; Karlsson, Anna] Karolinska Inst, Karolinska Univ Hosp, Dept Lab Med, Div Clin Microbiol F68, Huddinge, Sweden.
   [Kannisto, Kristina; Gafvels, Mats] Karolinska Inst, Karolinska Univ Hosp, Dept Lab Med, Div Clin Chem, Huddinge, Sweden.
   [von Dobeln, Ulrika; Isetun, Sindra] Karolinska Inst, Karolinska Univ Hosp, Dept Lab Med, Div Metab Dis, Huddinge, Sweden.
   [Hultenby, Kjell] Karolinska Inst, Karolinska Univ Hosp, Dept Lab Med, Div Clin Res Ctr, Huddinge, Sweden.
   [Gafvels, Mats] Lund Univ, Dept Lab Med, Div Clin Chem, Lund, Sweden.
C3 Karolinska Institutet; Karolinska University Hospital; Karolinska
   Institutet; Karolinska University Hospital; Karolinska Institutet;
   Karolinska University Hospital; Karolinska Institutet; Karolinska
   University Hospital; Lund University
RP Curbo, S (corresponding author), Karolinska Inst, Karolinska Univ Hosp, Dept Lab Med, Div Clin Microbiol F68, Huddinge, Sweden.
EM Sophie.Curbo@ki.se
RI curbo, sophie/AAA-8614-2020; Karlsson, Anna/E-7945-2018
OI Curbo, Sophie/0000-0002-0964-0712; Karlsson, Anna/0000-0001-6843-6685
FU Swedish Research Council [2010-2828]; Medical Faculty of Karolinska
   Institutet
FX This work was supported by grants from the Swedish Research Council
   [A.K. grant number 2010-2828] and the Medical Faculty of Karolinska
   Institutet [A.K., S.C.]. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Akman HO, 2008, HUM MOL GENET, V17, P2433, DOI 10.1093/hmg/ddn143
   Bartesaghi S, 2010, HUM MOL GENET, V19, P1669, DOI 10.1093/hmg/ddq043
   Boudina S, 2005, CIRCULATION, V112, P2686, DOI 10.1161/CIRCULATIONAHA.105.554360
   Carrozzo R, 2003, HUM MUTAT, V21, DOI 10.1002/humu.9135
   Chace DH, 2003, CLIN CHEM, V49, P1797, DOI 10.1373/clinchem.2003.022178
   Chace DH, 2001, CLIN CHEM, V47, P1166
   DIMAURO S, 1993, ARCH NEUROL-CHICAGO, V50, P1197, DOI 10.1001/archneur.1993.00540110075008
   Dorado B, 2011, HUM MOL GENET, V20, P155, DOI 10.1093/hmg/ddq453
   Durham SE, 2005, NEUROLOGY, V65, P453, DOI 10.1212/01.wnl.0000171861.30277.88
   FOLCH J, 1957, J BIOL CHEM, V226, P497
   Ghoshal AK, 2005, CLIN CHIM ACTA, V358, P104, DOI 10.1016/j.cccn.2005.02.011
   Götz A, 2008, BRAIN, V131, P2841, DOI 10.1093/brain/awn236
   HALESTRAP AP, 1989, BIOCHIM BIOPHYS ACTA, V973, P355, DOI 10.1016/S0005-2728(89)80378-0
   Hirschey MD, 2010, NATURE, V464, P121, DOI 10.1038/nature08778
   Lesko N, 2010, NEUROMUSCULAR DISORD, V20, P198, DOI 10.1016/j.nmd.2009.11.013
   Lim KHH, 2002, J PHYSIOL-LONDON, V545, P961, DOI 10.1113/jphysiol.2002.031484
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   McFarland R, 2002, LANCET NEUROL, V1, P343, DOI 10.1016/S1474-4422(02)00159-X
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Müller-Höcker J, 2002, HUM PATHOL, V33, P247, DOI 10.1053/hupa.2002.31477
   Oskoui M, 2006, ARCH NEUROL-CHICAGO, V63, P1122, DOI 10.1001/archneur.63.8.1122
   Parini P, 2006, EUR J CLIN INVEST, V36, P98, DOI 10.1111/j.1365-2362.2006.01597.x
   Parini R, 2009, J HEPATOL, V50, P215, DOI 10.1016/j.jhep.2008.08.019
   Park CB, 2007, CELL, V130, P273, DOI 10.1016/j.cell.2007.05.046
   Pronicka E, 2011, J APPL GENET, V52, P61, DOI 10.1007/s13353-010-0008-y
   Rao JN, 2011, J BIOL CHEM, V286, P42545, DOI 10.1074/jbc.M111.306951
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Saada Ann, 2009, Biochem J, V422, pe3, DOI 10.1042/BJ20091194
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Vilá MR, 2008, J NEUROL SCI, V267, P137, DOI 10.1016/j.jns.2007.10.019
   Villarroya J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029691
   Wang LY, 2005, MOL GENET METAB, V84, P75, DOI 10.1016/j.ymgme.2004.09.005
   Weibel E, 1979, STEREOLOGICAL METHOD, V1, P91
   Wibom R, 2002, ANAL BIOCHEM, V311, P139, DOI 10.1016/S0003-2697(02)00424-4
   Wredenberg A, 2002, P NATL ACAD SCI USA, V99, P15066, DOI 10.1073/pnas.232591499
   Zhou XS, 2008, HUM MOL GENET, V17, P2329, DOI 10.1093/hmg/ddn133
NR 39
TC 11
Z9 13
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 7
PY 2013
VL 8
IS 3
AR e58843
DI 10.1371/journal.pone.0058843
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 136BN
UT WOS:000318334500129
PM 23505564
OA Green Submitted, gold, Green Published
DA 2024-11-01
ER

PT J
AU Cámara, Y
   González-Vioque, E
   Scarpelli, M
   Torres-Torronteras, J
   Caballero, A
   Hirano, M
   Martí, R
AF Camara, Yolanda
   Gonzalez-Vioque, Emiliano
   Scarpelli, Mauro
   Torres-Torronteras, Javier
   Caballero, Andrea
   Hirano, Michio
   Marti, Ramon
TI Administration of deoxyribonucleosides or inhibition of their catabolism
   as a pharmacological approach for mitochondrial DNA depletion syndrome
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID DEOXYGUANOSINE KINASE-DEFICIENCY; IN-VITRO SUPPLEMENTATION; MUTATIONS;
   MYOPATHY; GENE; P53R2; POOLS
AB Mitochondrial DNA (mtDNA) depletion syndrome (MDS) is characterized by a reduction in mtDNA copy number and consequent mitochondrial dysfunction in affected tissues. A subgroup of MDS is caused by mutations in genes that disrupt deoxyribonucleotide metabolism, which ultimately leads to limited availability of one or several deoxyribonucleoside triphosphates (dNTPs), and subsequent mtDNA depletion. Here, using in vitro experimental approaches (primary cell culture of deoxyguanosine kinase-deficient cells and thymidine-induced mtDNA depletion in culture as a model of mitochondrial neurogastrointestinal encephalomyopathy, MNGIE), we show that supplements of those deoxyribonucleosides (dNs) involved in each biochemical defect (deoxyguanosine or deoxycytidine, dCtd) prevents mtDNA copy number reduction. Similar effects can be obtained by specific inhibition of dN catabolism using tetrahydrouridine (THU; inhibitor of cytidine deaminase) or immucillin H (inhibitor of purine nucleoside phosphorylase). In addition, using an MNGIE animal model, we provide evidence that mitochondrial dNTP content can be modulated in vivo by systemic administration of dCtd or THU. In spite of the severity associated with diseases due to defects in mtDNA replication, there are currently no effective therapeutic options available. Only in the case of MNGIE, allogeneic hematopoietic stem cell transplantation has proven efficient as a long-term therapeutic strategy. We propose increasing cellular availability of the deficient dNTP precursor by direct administration of the dN or inhibition of its catabolism, as a potential treatment for mtDNA depletion syndrome caused by defects in dNTP metabolism.
C1 [Camara, Yolanda; Gonzalez-Vioque, Emiliano; Scarpelli, Mauro; Torres-Torronteras, Javier; Caballero, Andrea; Marti, Ramon] Vall dHebron Inst Recerca, Unitat Patol Mitocondrial, Barcelona 08035, Catalonia, Spain.
   [Camara, Yolanda; Gonzalez-Vioque, Emiliano; Torres-Torronteras, Javier; Marti, Ramon] Ctr Biomed Network Res Rare Dis CIBERER, Barcelona, Catalonia, Spain.
   [Scarpelli, Mauro] Univ Verona, Dept Neurol & Movement Sci, Neurol Sect, I-37100 Verona, Italy.
   [Hirano, Michio] Columbia Univ, Med Ctr, Dept Neurol, New York, NY 10032 USA.
C3 CIBER - Centro de Investigacion Biomedica en Red; CIBERER; University of
   Verona; Columbia University
RP Martí, R (corresponding author), Vall dHebron Inst Recerca, Unitat Patol Mitocondrial, Passeig Vall dHebron 119, Barcelona 08035, Catalonia, Spain.
EM ramon.marti@vhir.org
RI Cámara, Yolanda/P-2540-2019; Martí, Ramon/Q-3442-2016;
   Torres-Torronteras, Javier/K-4974-2014; Camara, Yolanda/K-4597-2014
OI Marti, Ramon/0000-0002-8273-9540; Torres-Torronteras,
   Javier/0000-0002-6092-9458; Gonzalez Vioque,
   Emiliano/0000-0001-7279-4311; CABALLERO, ANDREA/0000-0003-2891-6347;
   Camara, Yolanda/0000-0003-2458-6942
FU Spanish Instituto de Salud Carlos III [PI12/00322]; United Mitochondrial
   Disease Foundation (UMDF) [12-029]; French Muscular Dystrophy
   Association-Telethon (AFMTelethon)
FX This work was supported by the Spanish Instituto de Salud Carlos III
   (grant PI12/00322 to R.M.), and postdoctoral grants from the United
   Mitochondrial Disease Foundation (UMDF) to J.T. (grant 12-029) and the
   French Muscular Dystrophy Association-Telethon (AFMTelethon) to Y.C.
CR Al-Kali A, 2010, FUTURE ONCOL, V6, P1211, DOI 10.2217/FON.10.83
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Buchaklian AH, 2012, MOL GENET METAB, V107, P92, DOI 10.1016/j.ymgme.2012.04.019
   Bulst S, 2012, MOL GENET METAB, V107, P95, DOI 10.1016/j.ymgme.2012.04.022
   Bulst S, 2009, HUM MOL GENET, V18, P1590, DOI 10.1093/hmg/ddp074
   COWAN MJ, 1985, CLIN IMMUNOL IMMUNOP, V37, P30, DOI 10.1016/0090-1229(85)90132-1
   Del Toro M, 2005, J INHERIT METAB DIS, V28, P135
   Dimmock DP, 2008, HUM MUTAT, V29, P330, DOI 10.1002/humu.9519
   El-Hattab A, 2013, NEUROTHERAPEUTICS, V10, P186, DOI 10.1007/s13311-013-0177-6
   González-Vioque E, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1002035
   Hecker SJ, 2008, J MED CHEM, V51, P2328, DOI 10.1021/jm701260b
   López LC, 2009, HUM MOL GENET, V18, P714, DOI 10.1093/hmg/ddn401
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   MARKERT M L, 1991, Immunodeficiency Reviews, V3, P45
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Pontarin G, 2006, J BIOL CHEM, V281, P22720, DOI 10.1074/jbc.M604498200
   Pontarin G, 2012, P NATL ACAD SCI USA, V109, P13302, DOI 10.1073/pnas.1211289109
   Rylova SN, 2007, BIOCHEM PHARMACOL, V74, P169, DOI 10.1016/j.bcp.2007.03.029
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Saada A, 2008, MOL GENET METAB, V95, P169, DOI 10.1016/j.ymgme.2008.07.007
   Taanman JW, 2003, HUM MOL GENET, V12, P1839, DOI 10.1093/hmg/ddg192
   Wang LY, 2005, MOL GENET METAB, V84, P75, DOI 10.1016/j.ymgme.2004.09.005
   Wang LY, 2003, J BIOL CHEM, V278, P6963, DOI 10.1074/jbc.M206143200
   Zimmermann H, 2012, PURINERG SIGNAL, V8, P437, DOI 10.1007/s11302-012-9309-4
NR 24
TC 60
Z9 64
U1 0
U2 10
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD MAY 1
PY 2014
VL 23
IS 9
BP 2459
EP 2467
DI 10.1093/hmg/ddt641
PG 9
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA AE9VL
UT WOS:000334359100019
PM 24362886
OA Green Published, Bronze
DA 2024-11-01
ER

PT J
AU Ignatenko, O
   Chilov, D
   Paetau, I
   de Miguel, E
   Jackson, CB
   Capin, G
   Paetau, A
   Terzioglu, M
   Euro, L
   Suomalainen, A
AF Ignatenko, Olesia
   Chilov, Dmitri
   Paetau, Ilse
   de Miguel, Elena
   Jackson, Christopher B.
   Capin, Gabrielle
   Paetau, Anders
   Terzioglu, Mugen
   Euro, Liliya
   Suomalainen, Anu
TI Loss of mtDNA activates astrocytes and leads to spongiotic
   encephalopathy
SO NATURE COMMUNICATIONS
LA English
DT Article
ID DNA POLYMERASE-GAMMA; MITOCHONDRIAL MYOPATHY; MUTATIONS; TWINKLE;
   DISEASE; MICE; NEUROPATHOLOGY; DEGENERATION; REPRODUCE; DELETIONS
AB Mitochondrial dysfunction manifests as different neurological diseases, but the mechanisms underlying the clinical variability remain poorly understood. To clarify whether different brain cells have differential sensitivity to mitochondrial dysfunction, we induced mitochondrial DNA (mtDNA) depletion in either neurons or astrocytes of mice, by inactivating Twinkle (TwKO), the replicative mtDNA helicase. Here we show that astrocytes, the most abundant cerebral cell type, are chronically activated upon mtDNA loss, leading to early-onset spongiotic degeneration of brain parenchyma, microgliosis and secondary neurodegeneration. Neuronal mtDNA loss does not, however, cause symptoms until 8 months of age. Findings in astrocyte-TwKO mimic neuropathology of Alpers syndrome, infantile-onset mitochondrial spongiotic encephalopathy caused by mtDNA maintenance defects. Our evidence indicates that (1) astrocytes are dependent on mtDNA integrity; (2) mitochondrial metabolism contributes to their activation; (3) chronic astrocyte activation has devastating consequences, underlying spongiotic encephalopathy; and that (4) astrocytes are a potential target for interventions.
C1 [Ignatenko, Olesia; Chilov, Dmitri; Paetau, Ilse; Jackson, Christopher B.; Capin, Gabrielle; Terzioglu, Mugen; Euro, Liliya; Suomalainen, Anu] Univ Helsinki, Biomedicum Helsinki, Mol Neurol, Res Programs Unit, Haartmaninkatu 8, FIN-00014 Helsinki, Finland.
   [de Miguel, Elena] Univ Helsinki, Fac Med, Dept Pharmacol, Haartmaninkatu 8, FIN-00014 Helsinki, Finland.
   [Paetau, Anders] Huslab, Dept Pathol, Haartmaninkatu 3, Helsinki 01051, Finland.
   [Paetau, Anders] Helsinki Univ Hosp, Haartmaninkatu 3, Helsinki 01051, Finland.
   [Paetau, Anders] Univ Helsinki, Medicum, Haartmaninkatu 3, Helsinki 01051, Finland.
   [Suomalainen, Anu] Univ Helsinki, Neurosci Ctr, Viikinkaari 4, FIN-00014 Helsinki, Finland.
   [Suomalainen, Anu] Helsinki Univ Hosp, Dept Neurosci, Haartmaninkatu 4, Helsinki 01051, Finland.
C3 University of Helsinki; University of Helsinki; University of Helsinki;
   Helsinki University Central Hospital; University of Helsinki; University
   of Helsinki; University of Helsinki; Helsinki University Central
   Hospital
RP Suomalainen, A (corresponding author), Univ Helsinki, Biomedicum Helsinki, Mol Neurol, Res Programs Unit, Haartmaninkatu 8, FIN-00014 Helsinki, Finland.; Suomalainen, A (corresponding author), Univ Helsinki, Neurosci Ctr, Viikinkaari 4, FIN-00014 Helsinki, Finland.; Suomalainen, A (corresponding author), Helsinki Univ Hosp, Dept Neurosci, Haartmaninkatu 4, Helsinki 01051, Finland.
EM anu.wartiovaara@helsinki.fi
RI ; Jackson, Christopher B./M-3222-2013; Liliya, Euro/F-3808-2015
OI Terzioglu, Mugen/0000-0003-0872-3046; Jackson, Christopher
   B./0000-0003-1035-6417; Suomalainen-Wartiovaara,
   Anu/0000-0003-4833-5195; Ignatenko, Olesia/0000-0002-1510-6153; Liliya,
   Euro/0000-0001-9705-3886; de Miguel, Elena/0000-0002-4573-7175
FU Academy of Finland; Sigrid Juselius Foundation; University of Helsinki;
   European Research Council Advanced Grants; Swiss National Foundation
   postdoc grant; Novartis Foundation for Medical-Biological Research;
   Helsinki Doctoral Program for Biomedicine
FX We thank Markus Innila, Anu Harju, Babette Hollmann, and Tuula Manninen
   for experimental support; the Electron Microscopy Unit of the Institute
   of Biotechnology, Helsinki University, for expertise in ultrastructural
   analysis; Dr. Fang Zhao, Advanced Microscopy Unit, Medicum, Helsinki
   University for consultation and data discussion. Helena Schmidt for
   artwork, Biomedicum Imaging Unit facility imaging expertise and Helsinki
   University Animal Center for professional care of animals. We wish to
   acknowledge the following funding sources: Academy of Finland, Sigrid
   Juselius Foundation (A.S., E.d.M.), University of Helsinki, European
   Research Council Advanced Grants (A.S.), Swiss National Foundation
   postdoc grant and the Novartis Foundation for Medical-Biological
   Research (C.B.J.), and Helsinki Doctoral Program for Biomedicine (O.I.).
CR Ahola-Erkkilä S, 2010, HUM MOL GENET, V19, P1974, DOI 10.1093/hmg/ddq076
   Alpers BJ, 1931, ARCH NEURO PSYCHIATR, V25, P469, DOI 10.1001/archneurpsyc.1931.02230030027002
   [Anonymous], 2014, GENE REV
   Azevedo FAC, 2009, J COMP NEUROL, V513, P532, DOI 10.1002/cne.21974
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Chilov D, 2011, DEV BIOL, V357, P259, DOI 10.1016/j.ydbio.2011.06.029
   COLUCCIGUYON E, 1994, CELL, V79, P679, DOI 10.1016/0092-8674(94)90553-3
   Denise A, 2004, NAT NEUROSCI, V7, P1233, DOI 10.1038/nn1340
   Ekstrand MI, 2007, P NATL ACAD SCI USA, V104, P1325, DOI 10.1073/pnas.0605208103
   GROSS NJ, 1969, J BIOL CHEM, V244, P1552
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   Hance N, 2005, HUM MOL GENET, V14, P1775, DOI 10.1093/hmg/ddi184
   HARDING BN, 1995, J NEUROL NEUROSUR PS, V58, P320, DOI 10.1136/jnnp.58.3.320
   Herrmann JE, 2008, J NEUROSCI, V28, P7231, DOI 10.1523/JNEUROSCI.1709-08.2008
   Jackson CB, 2014, J MED GENET, V51, P170, DOI 10.1136/jmedgenet-2013-101932
   JELLINGER K, 1970, ACTA NEUROPATHOL, V16, P125, DOI 10.1007/BF00687667
   Khan NA, 2014, EMBO MOL MED, V6, P721, DOI 10.1002/emmm.201403943
   Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257
   Lake NJ, 2015, J NEUROPATH EXP NEUR, V74, P482, DOI 10.1097/NEN.0000000000000195
   Lallemand Y, 1998, TRANSGENIC RES, V7, P105, DOI 10.1023/A:1008868325009
   Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231
   Lax NZ, 2012, J NEUROPATH EXP NEUR, V71, P148, DOI 10.1097/NEN.0b013e318244477d
   LEIGH D, 1951, J NEUROL NEUROSUR PS, V14, P216, DOI 10.1136/jnnp.14.3.216
   Liddelow S, 2015, CELL, V162, P1170, DOI 10.1016/j.cell.2015.08.029
   Liddelow SA, 2017, IMMUNITY, V46, P957, DOI 10.1016/j.immuni.2017.06.006
   Liddelow SA, 2017, NATURE, V541, P481, DOI 10.1038/nature21029
   Luong TN, 2011, JOVE-J VIS EXP, DOI 10.3791/2376
   Matsumura H., 1980, METH ENZYMOL, V69, P465, DOI [10.1016/S0076-6879(80)69045-4, DOI 10.1016/S0076-6879(80)69045-4]
   Milenkovic D, 2013, HUM MOL GENET, V22, P1983, DOI 10.1093/hmg/ddt051
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Naviaux RK, 1999, ANN NEUROL, V45, P54, DOI 10.1002/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B
   Nikkanen J, 2016, CELL METAB, V23, P635, DOI 10.1016/j.cmet.2016.01.019
   Nunnari J, 2012, CELL, V148, P1145, DOI 10.1016/j.cell.2012.02.035
   PAUWELS PJ, 1985, J NEUROCHEM, V44, P143, DOI 10.1111/j.1471-4159.1985.tb07123.x
   PEKNY M, 1995, EMBO J, V14, P1590, DOI 10.1002/j.1460-2075.1995.tb07147.x
   Pickrell AM, 2009, J BIOENERG BIOMEMBR, V41, P453, DOI 10.1007/s10863-009-9245-3
   Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8
   Sörensen L, 2001, J NEUROSCI, V21, P8082, DOI 10.1523/JNEUROSCI.21-20-08082.2001
   SPARACO M, 1993, J NEUROPATH EXP NEUR, V52, P1, DOI 10.1097/00005072-199301000-00001
   Suomalainen A, 2010, NEUROMUSCULAR DISORD, V20, P429, DOI 10.1016/j.nmd.2010.03.017
   Supplie LM, 2017, J NEUROSCI, V37, P4231, DOI 10.1523/JNEUROSCI.0756-16.2017
   Tao JF, 2011, J NEUROSCI, V31, P8306, DOI 10.1523/JNEUROSCI.0567-11.2011
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
   Vashchinkina E, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00256
NR 45
TC 38
Z9 40
U1 1
U2 7
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JAN 4
PY 2018
VL 9
AR 70
DI 10.1038/s41467-017-01859-9
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FR9OY
UT WOS:000419404200020
PM 29302033
OA gold, Green Published
DA 2024-11-01
ER

PT J
AU Rubegni, A
   Cardaioli, E
   Chini, E
   Da Pozzo, P
   Battisti, C
   Malandrini, A
   Federico, A
AF Rubegni, Anna
   Cardaioli, Elena
   Chini, Elena
   Da Pozzo, Paola
   Battisti, Carla
   Malandrini, Alessandro
   Federico, Antonio
TI A case of 3243A&gt;G mutation in mtDNA presenting as apparently
   idiopathic hyperCKemia
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE MELAS syndrome; Mitochondrial myopathy; Idiopathic hyperCKemia; 3243A >
   G mutation; Heteroplasmy; Mutation load
ID MITOCHONDRIAL-DNA; CLINICAL PHENOTYPES; MELAS; POPULATION; HETEROPLASMY;
   DIAGNOSIS; DISEASE; URINE; BLOOD; MERRF
AB The 3243A>G mutation of mtDNA usually is associated with MELAS syndrome. Here we report a patient with the 3243A>G mutation presenting only recurrent muscle fatigue and elevated levels of serum creatine kinase (CK). The mother of the proband was referred to us for type 2 diabetes mellitus, muscle pain and sensorineural hearing loss. The percentage of mutation load in different tissues was similar in both subjects, except in the urinary epithelium. The mutation load in the son's urinary epithelial cells (UEC) was consistently higher (nearly 50%) than in his muscle (nearly 20%). We conclude that a correlation between the proportion of the UEC mutation load and the severity of the disease was lacking in this pedigree. The use of UEC as the tissue of choice in the noninvasive diagnosis of the 3243A>G mutation offers a very attractive alternative to muscle biopsy. Finally, our data expand the clinical spectrum of the 3243A>G mutation. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Rubegni, Anna; Cardaioli, Elena; Chini, Elena; Da Pozzo, Paola; Battisti, Carla; Malandrini, Alessandro; Federico, Antonio] Univ Siena, Dept Med Surg & Neurol Sci, I-53100 Siena, Italy.
C3 University of Siena
RP Malandrini, A (corresponding author), Univ Siena, Dept Med Surg & Neurol Sci, Neurometab Unit, Viale Bracci 2, I-53100 Siena, Italy.
EM alessandro.malandrini@unisi.it
RI Federico, Antonio/H-8871-2017; Rubegni, Anna/I-3221-2018
OI federico, antonio/0000-0002-5246-1621; Cardaioli,
   Elena/0000-0003-2850-6698; Malandrini, Alessandro/0000-0003-1034-0845;
   Rubegni, Anna/0000-0002-0484-3799
CR Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   de Laat P, 2012, J INHERIT METAB DIS, V35, P1059, DOI 10.1007/s10545-012-9465-2
   Elliott HR, 2008, AM J HUM GENET, V83, P254, DOI 10.1016/j.ajhg.2008.07.004
   Fabrizi GM, 1996, J NEUROL NEUROSUR PS, V61, P47, DOI 10.1136/jnnp.61.1.47
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Kärppä M, 2005, BRAIN, V128, P1861, DOI 10.1093/brain/awh515
   Mancuso M, 2012, NEUROMUSCULAR DISORD, V22, pS226, DOI 10.1016/j.nmd.2012.10.012
   Manwaring N, 2007, MITOCHONDRION, V7, P230, DOI 10.1016/j.mito.2006.12.004
   McDonnell MT, 2004, EUR J HUM GENET, V12, P778, DOI 10.1038/sj.ejhg.5201216
   Nesbitt V, 2013, J NEUROL NEUROSUR PS, V84, P936, DOI 10.1136/jnnp-2012-303528
   Schaefer AM, 2006, NEUROLOGY, V66, P1932, DOI 10.1212/01.wnl.0000219759.72195.41
   Sciacco M, 2001, J NEUROL, V248, P778, DOI 10.1007/s004150170094
   Sue CM, 1998, J NEUROL SCI, V161, P36, DOI 10.1016/S0022-510X(98)00179-8
   Whittaker RG, 2009, NEUROLOGY, V72, P568, DOI 10.1212/01.wnl.0000342121.91336.4d
NR 14
TC 4
Z9 4
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 1878-5883
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD MAR 15
PY 2014
VL 338
IS 1-2
BP 232
EP 234
DI 10.1016/j.jns.2014.01.010
PG 3
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA AE3NO
UT WOS:000333883400044
PM 24468540
DA 2024-11-01
ER

PT J
AU Sharer, JD
AF Sharer, JD
TI The adenine nucleotide translocase type 1 (ANT1): A new factor in
   mitochondrial disease
SO IUBMB LIFE
LA English
DT Review
DE adenine nucleotide translocase; mitochondrial disorders; autosomal
   dominant progressive external ophthalmoplegia; Senger's syndrome
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; FACIOSCAPULOHUMERAL
   MUSCULAR-DYSTROPHY; DEFECTIVE OXIDATIVE-PHOSPHORYLATION; PERMEABILITY
   TRANSITION PORE; AUTOSOMAL-DOMINANT; MULTIPLE DELETIONS; HYPERTROPHIC
   CARDIOMYOPATHY; SACCHAROMYCES-CEREVISIAE; CONGENITAL CATARACT; NUCLEAR
   GENES
AB Mitochondrial disorders of oxidative phosphorylation (OXPHOS) comprise a growing list of potentially lethal diseases caused by mutations in either mitochondrial (mtDNA) or nuclear DNA (nDNA). Two such conditions, autosomal dominant progressive external ophthalmoplegia (adPEO) and Senger's Syndrome, are associated with dysfunction of the heart and muscle-specific isoform of the adenine nucleotide translocase (ANT1), a nDNA gene product that facilitates transport of ATP and ADP across the inner mitochondrial membrane. AdPEO is a mtDNA deletion disorder broadly characterized by pathology involving the eyes, skeletal muscle, and central nervous system. In addition to ANT1 , mutations in at least two other nuclear genes, twinkle and POLG , have been shown to cause mtDNA destabilization associated with adPEO. Senger's syndrome is an autosomal recessive condition characterized by congenital heart defects, abnormalities of skeletal muscle mitochondria, cataracts, and elevated circulatory levels of lactic acid. This syndrome is associated with severe depletion of ANT1, which may be the result of an as yet unidentified ANT1-specific transcriptional or translational processing error. ANT1 has also been associated with a third condition, autosomal dominant facioscapulohumeral muscular dystrophy (FSHD), an adult onset disorder characterized by variable muscle weakness in the face, feet, shoulders, and hips. FSHD patients possess specific DNA deletions on chromosome 4, which appear to cause derepression of several nearby genes, including ANT1 . Early development of FSHD may involve mitochondrial dysfunction and increased oxidative stress, possibly associated with overexpression of ANT1.
C1 Univ Alabama, Dept Genet, Birmingham, AL 35294 USA.
C3 University of Alabama System; University of Alabama Birmingham
RP Sharer, JD (corresponding author), Univ Alabama, Dept Genet, Kaul 652A,720 20th St S, Birmingham, AL 35294 USA.
EM dsharer@genetics.uab.edu
CR Bauer MKA, 1999, J CELL BIOL, V147, P1493, DOI 10.1083/jcb.147.7.1493
   Belzacq AS, 2003, CANCER RES, V63, P541
   Beutner G, 1996, FEBS LETT, V396, P189, DOI 10.1016/0014-5793(96)01092-7
   Chen XJ, 2002, HUM MOL GENET, V11, P1835, DOI 10.1093/hmg/11.16.1835
   Chevrollier A, 2005, M S-MED SCI, V21, P156, DOI 10.1051/medsci/2005212156
   Chinnery PF, 2003, J NEUROL NEUROSUR PS, V74, P1188, DOI 10.1136/jnnp.74.9.1188
   CRUYSBERG JRM, 1986, AM J OPHTHALMOL, V102, P740, DOI 10.1016/0002-9394(86)90402-2
   Deschauer M, 2005, NEUROMUSCULAR DISORD, V15, P311, DOI 10.1016/j.nmd.2004.12.004
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   DiMauro S, 2003, BASIC APPL MYOL, V13, P145
   DIMAURO S, 2003, GENETESTS
   Flierl A, 2005, GENE THER, V12, P570, DOI 10.1038/sj.gt.3302443
   Fontanesi F, 2004, HUM MOL GENET, V13, P923, DOI 10.1093/hmg/ddh108
   Gabellini D, 2002, CELL, V110, P339, DOI 10.1016/S0092-8674(02)00826-7
   Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226
   HATEFI Y, 1985, ANNU REV BIOCHEM, V54, P1015, DOI 10.1146/annurev.biochem.54.1.1015
   Hirano M, 2001, NEUROLOGY, V57, P2163, DOI 10.1212/WNL.57.12.2163
   Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279
   Jordens EZ, 2002, ANN NEUROL, V52, P95, DOI 10.1002/ana.10214
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kaukonen J, 1999, AM J HUM GENET, V65, P256, DOI 10.1086/302445
   Komaki H, 2002, ANN NEUROL, V51, P645, DOI 10.1002/ana.10172
   Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Laoudj-Chenivesse D, 2005, J MOL MED, V83, P216, DOI 10.1007/s00109-004-0583-7
   Law AKT, 2004, BMC NEUROSCI, V5, DOI 10.1186/1471-2202-5-1
   Levy SE, 2000, GENE, V254, P57, DOI 10.1016/S0378-1119(00)00252-3
   Lousa CD, 2002, BIOCHEMISTRY-US, V41, P14412, DOI 10.1021/bi02641490
   Mandavilli BS, 2002, MUTAT RES-FUND MOL M, V509, P127, DOI 10.1016/S0027-5107(02)00220-8
   Morava E, 2004, EUR J PEDIATR, V163, P467, DOI 10.1007/s00431-004-1465-2
   MUNNICH A, 1992, J INHERIT METAB DIS, V15, P448, DOI 10.1007/BF01799603
   Muthumani K, 2003, BIOCHEM BIOPH RES CO, V304, P583, DOI 10.1016/S0006-291X(03)00631-4
   Napoli L, 2001, NEUROLOGY, V57, P2295, DOI 10.1212/WNL.57.12.2295
   Padberg G W, 1991, Neuromuscul Disord, V1, P231, DOI 10.1016/0960-8966(91)90094-9
   Pebay-Peyroula E, 2003, NATURE, V426, P39, DOI 10.1038/nature02056
   RICCIO P, 1975, FEBS LETT, V56, P133, DOI 10.1016/0014-5793(75)80127-X
   SENGERS RCA, 1975, J PEDIATR-US, V86, P873, DOI 10.1016/S0022-3476(75)80217-4
   Sharer JD, 2002, MOL BIOL CELL, V13, P71, DOI 10.1091/mbc.01-05-0245
   Sharer JD, 1999, J BIOL CHEM, V274, P27553, DOI 10.1074/jbc.274.39.27553
   Shoffner JM., 1995, METABOLIC MOL BASES, V7th, P1535
   Siciliano G, 2003, NEUROMUSCULAR DISORD, V13, P162, DOI 10.1016/S0960-8966(02)00221-3
   Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063
   Smythe GM, 2000, MOL THER, V1, P304, DOI 10.1006/mthe.2000.0049
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   STEPIEN G, 1992, J BIOL CHEM, V267, P14592
   van den Heuvel L, 2001, BIOESSAYS, V23, P518, DOI 10.1002/bies.1071
   van der Maarel SM, 2005, AM J HUM GENET, V76, P375, DOI 10.1086/428361
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   WIJMENGA C, 1992, NAT GENET, V2, P26, DOI 10.1038/ng0992-26
   Winokur ST, 2003, NEUROMUSCULAR DISORD, V13, P322, DOI 10.1016/S0960-8966(02)00284-5
   Woodfield K, 1998, BIOCHEM J, V336, P287, DOI 10.1042/bj3360287
   Zamora M, 2004, FEBS LETT, V563, P155, DOI 10.1016/S0014-5793(04)00293-5
   Zeviani M, 2003, CURR OPIN GENET DEV, V13, P262, DOI 10.1016/S0959-437X(03)00052-2
NR 54
TC 39
Z9 46
U1 0
U2 3
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA
SN 1521-6543
J9 IUBMB LIFE
JI IUBMB Life
PD SEP
PY 2005
VL 57
IS 9
BP 607
EP 614
DI 10.1080/15216540500217735
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 970WF
UT WOS:000232342400002
PM 16203679
OA Bronze
DA 2024-11-01
ER

PT J
AU Kohler, JJ
   Hosseini, SH
   Green, E
   Hoying-Brandt, A
   Cucoranu, I
   Haase, CP
   Russ, R
   Srivastava, J
   Ivey, K
   Ludaway, T
   Kapoor, V
   Abuin, A
   Shapoval, A
   Santoianni, R
   Saada, A
   Elpeleg, O
   Lewis, W
AF Kohler, James J.
   Hosseini, Seyed H.
   Green, Elgin
   Hoying-Brandt, Amy
   Cucoranu, Ioan
   Haase, Chad P.
   Russ, Rodney
   Srivastava, Jaya
   Ivey, Kristopher
   Ludaway, Tomika
   Kapoor, Victor
   Abuin, Allison
   Shapoval, Alexsey
   Santoianni, Robert
   Saada, Ann
   Elpeleg, Orly
   Lewis, William
TI Cardiac-targeted transgenic mutant mitochondrial enzymes: MtDNA defects,
   antiretroviral toxicity and cardiomyopathy
SO CARDIOVASCULAR TOXICOLOGY
LA English
DT Article
DE cardiomyopathy; murine model; mtDNA; NRTI; toxicity
ID DNA-POLYMERASE-GAMMA; THYMIDINE KINASE; DEOXYNUCLEOTIDE CARRIER;
   DEPLETION MYOPATHY; ANTIVIRAL DRUGS; HEART-FAILURE; LONG-TERM;
   ZIDOVUDINE; MECHANISM; THERAPY
AB Mitochondrial (mt) DNA biogenesis is critical to cardiac contractility. DNA polymerase gamma (Pol gamma) replicates mtDNA, whereas thymidine kinase 2 (TK2) monophosphorylates pyrimidines intramitochondrially. Point mutations in POLG and TK2 result in clinical diseases associated with mtDNA depletion and organ dysfunction. Pyrimidine analogs (NRTIs) inhibit Pol gamma and mtDNA replication. Cardiac "dominant negative" murine transgenes (TGs; Pol gamma Y955C, and TK2 H121N or I212N) defined the role of each in the heart. mtDNA abundance, histopathological features, histochemistry, mitochondrial protein abundance, morphometry, and echocardiography were determined for TGs in "2 x 2" studies with or without pyrimidine analogs. Cardiac mtDNA abundance decreased in Y955C TGs (similar to 50%) but increased in H121N and I212N TGs (20-70%). Succinate dehydrogenase (SDH) increased in hearts of all mutants. Ultrastructural changes occurred in Y955C and H121N TGs. Histopathology demonstrated hypertrophy in H121N, LV dilation in I212N, and both hypertrophy and dilation in Y955C TGs. Antiretrovirals increased LV mass (approximate to 50%) for all three TGs which combined with dilation indicates cardiomyopathy. Taken together, these studies demonstrate three manifestations of cardiac dysfunction that depend on the nature of the specific mutation and antiretroviral treatment. Mutations in genes for mtDNA biogenesis increase risk for defective mtDNA replication, leading to LV hypertrophy.
C1 [Kohler, James J.; Hosseini, Seyed H.; Green, Elgin; Hoying-Brandt, Amy; Cucoranu, Ioan; Haase, Chad P.; Russ, Rodney; Srivastava, Jaya; Ivey, Kristopher; Ludaway, Tomika; Kapoor, Victor; Abuin, Allison; Shapoval, Alexsey; Santoianni, Robert; Lewis, William] Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA.
   [Saada, Ann; Elpeleg, Orly] Hadassah Univ Med Ctr, Metab Dis Unit, Jerusalem, Israel.
C3 Emory University; Hebrew University of Jerusalem
RP Kohler, JJ (corresponding author), Emory Univ, Sch Med, Dept Pathol, 7126 Woodruff Mem Bldg,101 Woodrufff Circle, Atlanta, GA 30322 USA.
EM jjkohle@emory.edu
RI Lewis, William/O-6571-2014; Saada, Ann/J-6864-2017
OI Saada, Ann/0000-0003-2951-0656
FU NHLBI NIH HHS [R01 HL059798, R01 HL079867, R01 HL079867-02, R01
   HL072707, R01 HL059798-09] Funding Source: Medline; NIDDK NIH HHS [K01
   DK078513-01A1, K01 DK078513] Funding Source: Medline
CR Abu-Amero KK, 2006, BRIT J OPHTHALMOL, V90, P823, DOI 10.1136/bjo.2006.090332
   BARTH E, 1992, J MOL CELL CARDIOL, V24, P669, DOI 10.1016/0022-2828(92)93381-S
   Barthélémy C, 2001, ANN NEUROL, V49, P607, DOI 10.1002/ana.1002.abs
   Bishop JB, 2004, ENVIRON MOL MUTAGEN, V43, P3, DOI 10.1002/em.10210
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Côté HCF, 2003, J INFECT DIS, V187, P1972, DOI 10.1086/375353
   DALAKAS MC, 1990, NEW ENGL J MED, V322, P1098, DOI 10.1056/NEJM199004193221602
   DAMATI G, 1994, LAB INVEST, V71, P879
   Divi RL, 2007, ENVIRON MOL MUTAGEN, V48, P179, DOI 10.1002/em.20245
   Eriksson S, 2002, CELL MOL LIFE SCI, V59, P1327, DOI 10.1007/s00018-002-8511-x
   Ferraro P, 2006, P NATL ACAD SCI USA, V103, P18586, DOI 10.1073/pnas.0609020103
   Golden KL, 2004, HORM METAB RES, V36, P197
   Graziewicz MA, 2006, CHEM REV, V106, P383, DOI 10.1021/cr040463d
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Hosseini SH, 2007, AM J PATHOL, V170, P865, DOI 10.2353/ajpath.2007.060655
   Iacobazzi V, 2001, CYTOGENET CELL GENET, V93, P40, DOI 10.1159/000056945
   Jiang WW, 2005, CLIN CANCER RES, V11, P2486, DOI 10.1158/1078-0432.CCR-04-2147
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   Katz AM, 2003, J CELL MOL MED, V7, P1, DOI 10.1111/j.1582-4934.2003.tb00197.x
   Kohler JJ, 2007, ENVIRON MOL MUTAGEN, V48, P166, DOI 10.1002/em.20223
   Lewis W, 2006, AIDS, V20, P675, DOI 10.1097/01.aids.0000216367.23325.58
   Lewis W, 2005, ANTIVIR THER, V10, pM13
   Lewis W, 2005, LAB INVEST, V85, P182, DOI 10.1038/labinvest.3700222
   Lewis W, 2003, NAT REV DRUG DISCOV, V2, P812, DOI 10.1038/nrd1201
   Lewis W, 2000, LAB INVEST, V80, P187, DOI 10.1038/labinvest.3780022
   LEWIS W, 1995, NAT MED, V1, P417, DOI 10.1038/nm0595-417
   Lewis W, 2001, LAB INVEST, V81, P1527, DOI 10.1038/labinvest.3780366
   Lewis W, 2007, LAB INVEST, V87, P326, DOI 10.1038/labinvest.3700523
   Lim SE, 2001, J BIOL CHEM, V276, P23616, DOI 10.1074/jbc.M101114200
   Llamas B, 2007, PHYSIOL GENOMICS, V31, P176, DOI 10.1152/physiolgenomics.00072.2007
   McComsey G, 2004, JAIDS-J ACQ IMM DEF, V37, pS30, DOI 10.1097/01.qai.0000137004.63376.27
   Miró O, 2004, JAIDS-J ACQ IMM DEF, V37, P1550, DOI 10.1097/00126334-200412150-00002
   MITSUYA H, 1985, P NATL ACAD SCI USA, V82, P7096, DOI 10.1073/pnas.82.20.7096
   RAIDEL SM, 2002, HEART CIRCULATORY PH, V282, pH1672
   ROSENKRANZWEISS P, 1994, J MOL CELL CARDIOL, V26, P261, DOI 10.1006/jmcc.1994.1029
   Saada A, 2004, DNA CELL BIOL, V23, P797
   Saada A, 2003, MOL GENET METAB, V79, P1, DOI 10.1016/S1096-7192(03)00063-5
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Sciacco M, 1996, Methods Enzymol, V264, P509, DOI 10.1016/S0076-6879(96)64045-2
   Sebastiani M, 2007, J AM COLL CARDIOL, V50, P1362, DOI 10.1016/j.jacc.2007.06.035
   SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613
   Vivet-Boudou V, 2006, CELL MOL LIFE SCI, V63, P163, DOI 10.1007/s00018-005-5367-x
   Wang LY, 2000, BIOCHEM J, V351, P469, DOI 10.1042/0264-6021:3510469
   Wang LY, 2003, J BIOL CHEM, V278, P6963, DOI 10.1074/jbc.M206143200
NR 44
TC 13
Z9 15
U1 0
U2 0
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1530-7905
EI 1559-0259
J9 CARDIOVASC TOXICOL
JI Cardiovasc. Toxicol.
PD JUN
PY 2008
VL 8
IS 2
BP 57
EP 69
DI 10.1007/s12012-008-9015-1
PG 13
WC Cardiac & Cardiovascular Systems; Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology; Toxicology
GA 322IL
UT WOS:000257368300002
PM 18446447
OA Green Accepted
DA 2024-11-01
ER

PT J
AU Ferreiro-Barros, CC
   Tengan, CH
   Barros, MH
   Palenzuela, L
   Kanki, C
   Quinzii, C
   Lou, J
   El Gharaby, N
   Shokr, A
   De Vivo, DC
   DiMauro, S
   Hirano, M
AF Ferreiro-Barros, Claudia C.
   Tengan, Celia H.
   Barros, Mario H.
   Palenzuela, Lluis
   Kanki, Chisaka
   Quinzii, Catarina
   Lou, Johanna
   El Gharaby, Nader
   Shokr, Aly
   De Vivo, Darryl C.
   DiMauro, Salvatore
   Hirano, Michio
TI Neonatal mitochondrial encephaloneuromyopathy due to a defect of
   mitochondrial protein synthesis
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE Mitochondria; Protein synthesis; Autosomal recessive; Mitochondrial
   disease; Respiratory chain
ID HUMAN-CELLS; TRANSLATION; MUTATION; DISEASE; DEFICIENCY; GENES; EFG1
AB Mitochondrial diseases are clinically and genetically heterogeneous disorders due to primary mutations in mitochondrial DNA (mtDNA) or nuclear DNA (nDNA). We studied a male infant with severe congenital encephalopathy, peripheral neuropathy, and myopathy. The patient's lactic acidosis and biochemical defects of respiratory chain complexes I, III, and IV in muscle indicated that he had a mitochondrial disorder while parental consanguinity suggested autosomal recessive inheritance. Cultured fibroblasts from the patient showed a generalized defect of mitochondrial protein synthesis. Fusion of cells from the patient with 143B206 rho(0) cells devoid of mtDNA restored cytochrome c oxidase activity confirming the nDNA origin of the disease. Our studies indicate that the patient has a novel autosomal recessive defect of mitochondrial protein synthesis. (C) 2008 Elsevier B.V. All rights reserved.
C1 [Hirano, Michio] Columbia Univ, Med Ctr, Dept Neurol, New York, NY 10027 USA.
   [Ferreiro-Barros, Claudia C.; Tengan, Celia H.] Univ Fed Sao Paulo, Dept Neurol, Sao Paulo, Brazil.
   [Barros, Mario H.] Univ Sao Paulo, Dept Microbiol, Sao Paulo, Brazil.
   [El Gharaby, Nader; Shokr, Aly] Bugshan Gen Hosp, Dept Pediat, Jeddah, Saudi Arabia.
C3 Columbia University; Universidade Federal de Sao Paulo (UNIFESP);
   Universidade de Sao Paulo
RP Hirano, M (corresponding author), Columbia Univ, Med Ctr, Dept Neurol, 1150 St Nicholas Ave Russ Berrie Room 317, New York, NY 10027 USA.
EM mh29@columbia.edu
RI Barros, Mario/Q-6358-2019; Tengan, Celia/D-8458-2013; Ferreiro-Barros,
   Claudia/D-5873-2012
OI Barros, Mario/0000-0003-2977-9815
FU National Institutes of Health [NS11766, HD32062]; FAPESP; CNPq; Marriott
   Mitochondrial Disorders Clinical Research Fund
FX This research was supported by National Institutes of Health grants
   NS11766 and HD32062 (M.H), FAPESP (CFB, CHT and MHB), CNPq (CHT), and
   Marriott Mitochondrial Disorders Clinical Research Fund (MMDCRF)(CFB,
   CK, SD, MH). We are in debt to Dr. Alexander Tzagoloff (Columbia
   University) for the in vivo mitochondrial translation labeling
   experiment.
CR Antonicka H, 2006, HUM MOL GENET, V15, P1835, DOI 10.1093/hmg/ddl106
   Barrientos A, 2002, METHODS, V26, P307, DOI 10.1016/S1046-2023(02)00036-1
   Birch-Machin MA, 2001, METHOD CELL BIOL, V65, P97, DOI 10.1016/S0091-679X(01)65006-4
   Bykhovskaya Y, 2004, AM J HUM GENET, V74, P1303, DOI 10.1086/421530
   Chomyn A, 1996, Methods Enzymol, V264, P197, DOI 10.1016/S0076-6879(96)64020-8
   Coenen MJH, 2004, NEW ENGL J MED, V351, P2080, DOI 10.1056/NEJMoa041878
   Davidson R L, 1977, Methods Cell Biol, V15, P325, DOI 10.1016/S0091-679X(08)60223-X
   DiMauro S, 2005, NEUROMUSCULAR DISORD, V15, P276, DOI 10.1016/j.nmd.2004.12.008
   Fernandez-Vizarra E, 2007, J MED GENET, V44, P173, DOI 10.1136/jmg.2006.045252
   Jacobs HT, 2005, TRENDS GENET, V21, P312, DOI 10.1016/j.tig.2005.04.003
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0
   LOMBES A, 1991, NEUROLOGY, V41, P491, DOI 10.1212/WNL.41.4.491
   Miller C, 2004, ANN NEUROL, V56, P734, DOI 10.1002/ana.20282
   Nijtmans LGJ, 2002, METHODS, V26, P327, DOI 10.1016/S1046-2023(02)00038-5
   Rana M, 2000, ANN NEUROL, V48, P774, DOI 10.1002/1531-8249(200011)48:5<774::AID-ANA11>3.3.CO;2-9
   Rodel G, 1997, CURR GENET, V31, P375, DOI 10.1007/s002940050219
   Saada A, 2007, J MED GENET, V44, P784, DOI 10.1136/jmg.2007.053116
   Sambrook J., 1989, Molecular cloning: a laboratory manual
   Smeitink JAM, 2006, AM J HUM GENET, V79, P869, DOI 10.1086/508434
   Sylvester JE, 2004, GENET MED, V6, P73, DOI 10.1097/01.GIM.0000117333.21213.17
   Taylor RW, 1997, J BIOENERG BIOMEMBR, V29, P195, DOI 10.1023/A:1022646215643
   Valente L, 2007, AM J HUM GENET, V80, P44, DOI 10.1086/510559
NR 23
TC 8
Z9 8
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 1878-5883
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD DEC 15
PY 2008
VL 275
IS 1-2
BP 128
EP 132
DI 10.1016/j.jns.2008.08.028
PG 5
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 384MO
UT WOS:000261749100023
PM 18835491
OA Green Accepted
DA 2024-11-01
ER

PT J
AU Lu, JQ
   Tarnopolsky, MA
AF Lu, Jian-Qiang
   Tarnopolsky, Mark A.
TI Mitochondrial neuropathy and neurogenic features in mitochondrial
   myopathy
SO MITOCHONDRION
LA English
DT Review
DE Mitochondrial disease; Mitochondrial myopathy; Mitochondrial neuropathy;
   Neuromuscular junction; Neurogenic features; Nerve and muscle pathology
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; KEARNS-SAYRE SYNDROME; PERIPHERAL
   NEUROPATHY; NEUROMUSCULAR-JUNCTION; SKELETAL-MUSCLE; SPINOCEREBELLAR
   ATAXIA; INFANTILE ONSET; POINT MUTATION; LEIGH-SYNDROME; DNA
AB Mitochondrial diseases (MIDs) involve multiple organs including peripheral nerves and skeletal muscle. Mitochondrial neuropathy (MN) and mitochondrial myopathy (MM) are commonly associated and linked at the neuromuscular junction (NMJ). Herein we review MN in connection with neurogenic features of MM, and pathological evidence for the involvement of the peripheral nerve and NMJ in MID patients traditionally assumed to have predominantly MM. MN is not uncommon, but still likely under-reported, and muscle biopsies of MM commonly exhibit neurogenic features. Pathological examination remains the gold standard to assess the nerve and muscle changes in patients with MIDs. Ultrastructural studies by electron microscopy are often necessary to fully characterize the pathology of mitochondrial cytopathy in MN and MM.
C1 [Lu, Jian-Qiang] McMaster Univ, Dept Pathol & Mol Med Neuropathol, Hamilton, ON, Canada.
   [Tarnopolsky, Mark A.] McMaster Univ, Dept Med Neurol, Hamilton, ON, Canada.
   [Tarnopolsky, Mark A.] McMaster Univ, Dept Pediat, Hamilton, ON, Canada.
C3 McMaster University; McMaster University; McMaster University
RP Lu, JQ (corresponding author), Hamilton Gen Hosp, Dept Pathol & Mol Med Neuropathol, 237 Barton St, Hamilton, ON L8L 2X2, Canada.
EM luj85@mcmaster.ca
RI LU, JIAN-QIANG/AAL-1634-2020
OI Lu, Jian-Qiang/0000-0003-1945-5569
CR Almutawa W, 2019, EBIOMEDICINE, V45, P379, DOI 10.1016/j.ebiom.2019.06.018
   Attwell D, 2001, J CEREBR BLOOD F MET, V21, P1133, DOI 10.1097/00004647-200110000-00001
   Baumann M, 2019, CLIN GENET, V95, P182, DOI 10.1111/cge.13462
   Bindu PS, 2016, MITOCHONDRION, V27, P1, DOI 10.1016/j.mito.2015.12.009
   Blakely EL, 2012, NEUROMUSCULAR DISORD, V22, P587, DOI 10.1016/j.nmd.2012.03.006
   Bouillot S, 2002, J PERIPHER NERV SYST, V7, P213, DOI 10.1046/j.1529-8027.2002.02027.x
   Boyd KU, 2011, CLIN PLAST SURG, V38, P643, DOI 10.1016/j.cps.2011.07.008
   Childs AM, 2007, NEUROPEDIATRICS, V38, P313, DOI 10.1055/s-2008-1065355
   Chu CC, 1997, EUR NEUROL, V37, P110, DOI 10.1159/000117420
   Colomer J, 2000, REV NEUROLOGIA, V30, P1117, DOI 10.33588/rn.3012.2000079
   COQUET M, 1993, NEUROMUSCULAR DISORD, V3, P593, DOI 10.1016/0960-8966(93)90122-Z
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Dubowitz V., 2020, Muscle biopsy: A practical approach
   Dupuis L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005390
   Echaniz-Laguna A, 2013, NEUROLOGY, V81, P1523, DOI 10.1212/WNL.0b013e3182a4a518
   EISENBERG HA, 1994, J APPL PHYSIOL, V76, P859, DOI 10.1152/jappl.1994.76.2.859
   Enns GM, 2005, CLIN GENET, V68, P337, DOI 10.1111/j.1399-0004.2005.00499.x
   Esteitie N, 2005, ANN NEUROL, V58, P544, DOI 10.1002/ana.20570
   Fadic R, 1997, NEUROLOGY, V49, P239, DOI 10.1212/WNL.49.1.239
   Finsterer J, 2005, CLIN NEUROL NEUROSUR, V107, P181, DOI 10.1016/j.clineuro.2004.07.001
   Finsterer J, 2011, J NEUROL SCI, V304, P9, DOI 10.1016/j.jns.2011.02.012
   Flippo KH, 2017, J CELL SCI, V130, P671, DOI 10.1242/jcs.171017
   FUJII T, 1991, J NEUROL SCI, V103, P37, DOI 10.1016/0022-510X(91)90280-K
   Gehrig SM, 2016, ORPHANET J RARE DIS, V11, DOI 10.1186/s13023-016-0488-x
   Gelfand JM, 2011, J NEUROL, V258, P440, DOI 10.1007/s00415-010-5775-1
   Genin EC, 2019, ACTA NEUROPATHOL, V138, P123, DOI 10.1007/s00401-019-01988-z
   Girlanda P, 1999, CLIN NEUROPHYSIOL, V110, P1284, DOI 10.1016/S1388-2457(98)00041-8
   GOEBEL HH, 1986, MUSCLE NERVE, V9, P165, DOI 10.1002/mus.880090210
   Graham LC, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0221-9
   Haas RH, 2014, SEMIN NEUROL, V34, P321, DOI 10.1055/s-0034-1386770
   Heighton JN, 2019, MITOCHONDRION, V44, P15, DOI 10.1016/j.mito.2017.12.006
   Higuchi Y, 2018, BRAIN, V141, P1622, DOI 10.1093/brain/awy104
   Hollenbeck PJ, 2005, NEURON, V47, P331, DOI 10.1016/j.neuron.2005.07.017
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   Isohanni P, 2011, NEUROLOGY, V76, P811, DOI 10.1212/WNL.0b013e31820e7b25
   Ji KQ, 2020, J NEUROL, V267, P3319, DOI 10.1007/s00415-020-10017-z
   JOHNS DR, 1995, NEW ENGL J MED, V333, P638, DOI 10.1056/NEJM199509073331007
   Kablar B, 1999, DEV BIOL, V208, P93, DOI 10.1006/dbio.1998.9184
   Kärppä M, 2003, J NEUROL, V250, P216, DOI 10.1007/s00415-003-0981-8
   KOSKINEN T, 1994, MUSCLE NERVE, V17, P509, DOI 10.1002/mus.880170507
   KRENDEL DA, 1987, MUSCLE NERVE, V10, P299, DOI 10.1002/mus.880100404
   Lax NZ, 2012, BRAIN, V135, P62, DOI 10.1093/brain/awr326
   Lee CW, 2008, MOL BIOL CELL, V19, P150, DOI 10.1091/mbc.E07-05-0515
   Lehmann D, 2016, NEUROL-GENET, V2, DOI 10.1212/NXG.0000000000000113
   Lepore E, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8080906
   Lu JQ, 2020, J NEUROL SCI, V413, DOI 10.1016/j.jns.2020.116816
   Lu JQ, 2019, J NEUROPATH EXP NEUR, V78, P508, DOI 10.1093/jnen/nlz029
   Lu JQ, 2016, J NEUROL SCI, V360, P84, DOI 10.1016/j.jns.2015.11.053
   Luigetti M, 2016, EUR J NEUROL, V23, P1020, DOI 10.1111/ene.12954
   Mancuso M, 2016, NEUROMUSCULAR DISORD, V26, P272, DOI 10.1016/j.nmd.2016.02.008
   Mancuso M, 2012, NEUROL SCI, V33, P449, DOI 10.1007/s10072-011-0703-4
   McFarland R, 2010, LANCET NEUROL, V9, P829, DOI 10.1016/S1474-4422(10)70116-2
   Menezes MP, 2012, DEV MED CHILD NEUROL, V54, P407, DOI 10.1111/j.1469-8749.2012.04271.x
   Mitchell WK, 2012, FRONT PHYSIOL, V3, DOI 10.3389/fphys.2012.00260
   MIZUKAMI K, 1992, ACTA NEUROPATHOL, V83, P449, DOI 10.1007/BF00713541
   MIZUSAWA H, 1991, REV NEUROL, V147, P501
   Mnatsakanyan L, 2011, J NEURO-OPHTHALMOL, V31, P6, DOI 10.1097/WNO.0b013e3181fab1b4
   MOLNAR M, 1995, NEUROPATH APPL NEURO, V21, P432, DOI 10.1111/j.1365-2990.1995.tb01080.x
   Mosole S, 2014, J NEUROPATH EXP NEUR, V73, P284, DOI 10.1097/NEN.0000000000000032
   Naumann M, 1997, MUSCLE NERVE, V20, P833, DOI 10.1002/(SICI)1097-4598(199707)20:7<833::AID-MUS7>3.0.CO;2-8
   Olson EN, 2000, CELL, V101, P689, DOI 10.1016/S0092-8674(00)80880-6
   Pareyson D, 2013, LANCET NEUROL, V12, P1011, DOI 10.1016/S1474-4422(13)70158-3
   Prada V, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.01218
   Rebelo AP, 2018, BRAIN, V141, P662, DOI 10.1093/brain/awx369
   Remtulla S, 2019, PEDIATR NEUROL, V90, P61, DOI 10.1016/j.pediatrneurol.2018.08.007
   Said G, 2005, J NEUROL, V252, P655, DOI 10.1007/s00415-005-0712-4
   SAKUTA R, 1989, ANN NEUROL, V25, P594, DOI 10.1002/ana.410250611
   Santorelli FM, 1997, NEUROLOGY, V49, P270, DOI 10.1212/WNL.49.1.270
   Santoro L, 2000, NEUROMUSCULAR DISORD, V10, P450, DOI 10.1016/S0960-8966(99)00122-4
   Sarnat HB, 2012, NEUROPATHOLOGY, V32, P617, DOI 10.1111/j.1440-1789.2012.01308.x
   Sarnat HB, 2005, CAN J NEUROL SCI, V32, P152, DOI 10.1017/S0317167100003929
   Sarzi E, 2007, ANN NEUROL, V62, P579, DOI 10.1002/ana.21207
   Saxton WM, 2012, J CELL SCI, V125, P2095, DOI 10.1242/jcs.053850
   Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371
   SCHRODER JM, 1993, BRAIN PATHOL, V3, P177, DOI 10.1111/j.1750-3639.1993.tb00742.x
   SCHRODER JM, 1991, ACTA NEUROPATHOL, V82, P471, DOI 10.1007/BF00293381
   Sheng ZH, 2014, J CELL BIOL, V204, P1087, DOI 10.1083/jcb.201312123
   Sheng ZH, 2012, NAT REV NEUROSCI, V13, P77, DOI 10.1038/nrn3156
   SIMON LT, 1990, ANN NEUROL, V28, P349, DOI 10.1002/ana.410280308
   So E, 2018, HUM MOL GENET, V27, P463, DOI 10.1093/hmg/ddx415
   Tamiya G, 2014, AM J HUM GENET, V95, P294, DOI 10.1016/j.ajhg.2014.07.013
   Tanahashi C, 2000, ACTA NEUROPATHOL, V99, P31, DOI 10.1007/PL00007403
   Tang S, 2012, J NEUROL, V259, P862, DOI 10.1007/s00415-011-6268-6
   Tilokani L, 2018, ESSAYS BIOCHEM, V62, P341, DOI 10.1042/EBC20170104
   Tryon LD, 2015, AM J PHYSIOL-CELL PH, V309, pC228, DOI 10.1152/ajpcell.00266.2014
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Vandervoort AA, 2002, MUSCLE NERVE, V25, P17, DOI 10.1002/mus.1215
   Vannucci B, 2019, MUSCLE NERVE, V60, P604, DOI 10.1002/mus.26654
   Venhoff N, 2012, ARTHRITIS RES THER, V14, DOI 10.1186/ar4076
   Verstreken P, 2005, NEURON, V47, P365, DOI 10.1016/j.neuron.2005.06.018
   Vital A, 2012, J NEUROPATH EXP NEUR, V71, P1036, DOI 10.1097/NEN.0b013e3182764d47
   Vu TH, 1998, NEUROLOGY, V51, P1190, DOI 10.1212/WNL.51.4.1190
   Wanagat J, 2001, FASEB J, V15, P322, DOI 10.1096/fj.00-0320com
   Wedatilake Y, 2013, ORPHANET J RARE DIS, V8, DOI 10.1186/1750-1172-8-96
   WICKS KL, 1991, AM J PHYSIOL, V260, pC841, DOI 10.1152/ajpcell.1991.260.4.C841
   Wilson MH, 2005, INT J NEUROSCI, V115, P803, DOI 10.1080/00207450590882172
   Wilson RJ, 2018, FREE RADICAL BIO MED, V117, P180, DOI 10.1016/j.freeradbiomed.2018.02.006
   Yamadera M, 2019, NEUROPATHOLOGY, V39, P404, DOI 10.1111/neup.12593
   Yasuda K, 2019, J CLIN NEUROSCI, V61, P302, DOI 10.1016/j.jocn.2018.10.054
   Yu-Wai-Man P, 2016, ACTA NEUROPATHOL, V132, P789, DOI 10.1007/s00401-016-1625-2
   Zanssen S, 1998, CLIN NEUROPATHOL, V17, P291
NR 101
TC 10
Z9 10
U1 0
U2 7
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 1872-8278
J9 MITOCHONDRION
JI Mitochondrion
PD JAN
PY 2021
VL 56
BP 52
EP 61
DI 10.1016/j.mito.2020.11.005
PG 10
WC Cell Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Genetics & Heredity
GA PQ1TJ
UT WOS:000606333800007
PM 33220502
DA 2024-11-01
ER

PT J
AU Catalán-García, M
   Garrabou, G
   Morén, C
   Guitart-Mampel, M
   Hernando, A
   Díaz-Ramos, A
   González-Casacuberta, I
   Juárez, DL
   Bañó, M
   Enrich-Bengoa, J
   Emperador, S
   Milisenda, JC
   Moreno, P
   Tobías, E
   Zorzano, A
   Montoya, J
   Cardellach, F
   Grau, JM
AF Catalan-Garcia, Marc
   Garrabou, Gloria
   Moren, Constanza
   Guitart-Mampel, Mariona
   Hernando, Adriana
   Diaz-Ramos, Angels
   Gonzalez-Casacuberta, Ingrid
   Juarez, Diana-Luz
   Bano, Maria
   Enrich-Bengoa, Jennifer
   Emperador, Sonia
   Cesar Milisenda, Jose
   Moreno, Pedro
   Tobias, Ester
   Zorzano, Antonio
   Montoya, Julio
   Cardellach, Francesc
   Maria Grau, Josep
TI Mitochondrial DNA disturbances and deregulated expression of oxidative
   phosphorylation and mitochondrial fusion proteins in sporadic inclusion
   body myositis
SO CLINICAL SCIENCE
LA English
DT Article
DE deletions; depletion; mitochondria; mitofusin-2; OPA1; sporadic
   inclusion body myositis
ID INNATE IMMUNE-RESPONSES; KEARNS-SAYRE-SYNDROME; MITOFUSIN 2 MFN2;
   SKELETAL-MUSCLE; QUALITY-CONTROL; DYNAMICS; DISEASE; MUTATIONS;
   DELETIONS; FIBERS
AB Sporadic inclusion body myositis (sIBM) is one of the most common myopathies in elderly people. Mitochondrial abnormalities at the histological level are present in these patients. We hypothesize that mitochondrial dysfunction may play a role in disease aetiology. We took the following measurements of muscle and peripheral blood mononuclear cells (PBMCs) from 30 sIBM patients and 38 age-and gender-paired controls: mitochondrial DNA (mtDNA) deletions, amount of mtDNA and mtRNA, mitochondrial protein synthesis, mitochondrial respiratory chain (MRC) complex I and IV enzymatic activity, mitochondrial mass, oxidative stress and mitochondrial dynamics (mitofusin 2 and optic atrophy 1 levels). Depletion of mtDNA was present in muscle from sIBM patients and PBMCs showed deregulated expression of mitochondrial proteins in oxidative phosphorylation. MRC complex IV/citrate synthase activity was significantly decreased in both tissues and mitochondrial dynamics were affected in muscle. Depletion of mtDNA was significantly more severe in patients with mtDNA deletions, which also presented deregulation of mitochondrial fusion proteins. Imbalance in mitochondrial dynamics in muscle was associated with increased mitochondrial genetic disturbances (both depletion and deletions), demonstrating that proper mitochondrial turnover is essential for mitochondrial homoeostasis and muscle function in these patients.
C1 [Catalan-Garcia, Marc; Garrabou, Gloria; Moren, Constanza; Guitart-Mampel, Mariona; Hernando, Adriana; Gonzalez-Casacuberta, Ingrid; Juarez, Diana-Luz; Bano, Maria; Enrich-Bengoa, Jennifer; Cesar Milisenda, Jose; Moreno, Pedro; Tobias, Ester; Cardellach, Francesc; Maria Grau, Josep] Univ Barcelona, Fac Med, CELLEX IDIBAPS, Muscle Res & Mitochondrial Funct Lab, Barcelona, Spain.
   [Catalan-Garcia, Marc; Garrabou, Gloria; Moren, Constanza; Guitart-Mampel, Mariona; Hernando, Adriana; Gonzalez-Casacuberta, Ingrid; Juarez, Diana-Luz; Bano, Maria; Enrich-Bengoa, Jennifer; Cesar Milisenda, Jose; Moreno, Pedro; Tobias, Ester; Cardellach, Francesc; Maria Grau, Josep] Hosp Clin Barcelona, Dept Internal Med, CIBERER U722, Barcelona, Spain.
   [Diaz-Ramos, Angels; Zorzano, Antonio] Barcelona Inst Sci & Technol, Inst Res Biomed IRB Barcelona, Barcelona, Spain.
   [Diaz-Ramos, Angels; Zorzano, Antonio] Univ Barcelona, Fac Biol, Dept Bioquim & Biomed Mol, E-08028 Barcelona, Spain.
   [Diaz-Ramos, Angels; Zorzano, Antonio] Inst Salud Carlos III, CIBER Diabet Enfermedades Metab Asociadas CIBERDE, Madrid, Spain.
   [Emperador, Sonia; Montoya, Julio] Univ Zaragoza, Dept Bioquim Biol Mol & Celular, Inst Invest Sanitarias Aragon, CIBERER U727, Zaragoza, Spain.
C3 University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS;
   University of Barcelona; Hospital Clinic de Barcelona; CIBER - Centro de
   Investigacion Biomedica en Red; CIBERER; Barcelona Institute of Science
   & Technology; Institute for Research in Biomedicine - IRB Barcelona;
   University of Barcelona; Instituto de Salud Carlos III; CIBER - Centro
   de Investigacion Biomedica en Red; CIBERDEM; University of Zaragoza;
   CIBER - Centro de Investigacion Biomedica en Red; CIBERER
RP Garrabou, G (corresponding author), Univ Barcelona, Fac Med, CELLEX IDIBAPS, Muscle Res & Mitochondrial Funct Lab, Barcelona, Spain.; Garrabou, G (corresponding author), Hosp Clin Barcelona, Dept Internal Med, CIBERER U722, Barcelona, Spain.
EM garrabou@clinic.ub.es
RI Morén, Constanza/AAB-6895-2021; Milisenda, Jose/ISU-0307-2023; Zorzano,
   Antonio/R-5479-2018
OI MOREN, CONSTANZA/0000-0001-6848-7407; Garrabou,
   Gloria/0000-0001-8973-9933; Hernando Comerma,
   Adriana/0000-0001-9394-9343; , Jennifer
   Enrich-Bengoa/0009-0008-8280-2424; Milisenda, Jose
   Cesar/0000-0003-0151-7872; Gonzalez-Casacuberta,
   Ingrid/0000-0003-3217-4569; MORENO LOZANO, PEDRO
   JUAN/0000-0002-5501-5272; Catalan Garcia, Marc/0000-0003-1073-7383
FU Instituto de Salud Carlos III (ISCIII) [PI14/00005, PI15/00903,
   PI15/00817, PIE1400061]; Fondo Europeo de Desarrollo Regional (FEDER)
   [SGR 2014/376]; La Marato [87/C/2015]; Fundacio CELLEX and CIBER of Rare
   Diseases (CIBERER, an initiative of ISCIII)
FX This study has been funded by Instituto de Salud Carlos III (ISCIII)
   [PI14/00005, PI15/00903, PI15/00817 and PIE1400061] and Fondo Europeo de
   Desarrollo Regional (FEDER), Suports a Grups de Recerca de la
   Generalitat de Catalunya [SGR 2014/376], La Marato [87/C/2015), Fundacio
   CELLEX and CIBER of Rare Diseases (CIBERER, an initiative of ISCIII).
CR Ascaso FJ, 2010, CLIN EXP OPHTHALMOL, V38, P812, DOI 10.1111/j.1442-9071.2010.02335.x
   Burté F, 2015, NAT REV NEUROL, V11, P11, DOI 10.1038/nrneurol.2014.228
   Carod-Artal FJ, 2006, NEUROLOGIA, V21, P357
   Catalán M, 2014, AUTOIMMUN REV, V13, P363, DOI 10.1016/j.autrev.2014.01.016
   Challa S, 2004, NEUROL INDIA, V52, P353
   Chen HC, 2010, CELL, V141, P280, DOI 10.1016/j.cell.2010.02.026
   Chen KH, 2014, FASEB J, V28, P382, DOI 10.1096/fj.13-230037
   Detmer SA, 2007, NAT REV MOL CELL BIO, V8, P870, DOI 10.1038/nrm2275
   Dorn GW, 2015, GENE DEV, V29, P1981, DOI 10.1101/gad.269894.115
   Gang Q, 2014, ORPHANET J RARE DIS, V9, DOI 10.1186/1750-1172-9-88
   Garrabou G, 2016, ADDICT BIOL, V21, P159, DOI 10.1111/adb.12183
   Garrabou G, 2012, J INFECT DIS, V205, P392, DOI 10.1093/infdis/jir764
   Gomez L, 2006, AM J TRANSPLANT, V6, P487, DOI 10.1111/j.1600-6143.2005.01219.x
   Guedes-Dias P, 2016, NEUROBIOL DIS, V90, P51, DOI 10.1016/j.nbd.2015.09.008
   Herbst A, 2007, J GERONTOL A-BIOL, V62, P235, DOI 10.1093/gerona/62.3.235
   Houston M.J, 2007, MUSCLE BIOPSY PRACTI, V1
   Hu Jing, 2007, Zhonghua Nei Ke Za Zhi, V46, P658
   Hernández-Alvarez MI, 2010, DIABETES CARE, V33, P645, DOI 10.2337/dc09-1305
   Joshi PR, 2014, J CLIN NEUROSCI, V21, P1959, DOI 10.1016/j.jocn.2014.05.051
   Lartigue L, 2013, INT J BIOCHEM CELL B, V45, P2052, DOI 10.1016/j.biocel.2013.06.014
   Liesa M, 2009, PHYSIOL REV, V89, P799, DOI 10.1152/physrev.00030.2008
   Liu K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057223
   Mastaglia F L, 2009, Acta Myol, V28, P66
   Mishra P, 2014, NAT REV MOL CELL BIO, V15, P634, DOI 10.1038/nrm3877
   Montero R, 2013, MITOCHONDRION, V13, P337, DOI 10.1016/j.mito.2013.04.001
   Morén C, 2015, AIDS, V29, P5, DOI 10.1097/QAD.0000000000000486
   Morén C, 2013, DRUG CHEM TOXICOL, V36, P496, DOI 10.3109/01480545.2013.776578
   Morén C, 2012, JAIDS-J ACQ IMM DEF, V60, P111, DOI 10.1097/QAI.0b013e318250455e
   Moslemi AR, 1997, HUM MUTAT, V10, P381, DOI 10.1002/(SICI)1098-1004(1997)10:5<381::AID-HUMU8>3.0.CO;2-I
   Muller FL, 2007, AM J PHYSIOL-REG I, V293, pR1159, DOI 10.1152/ajpregu.00767.2006
   Needham M, 2008, J CLIN NEUROSCI, V15, P1350, DOI 10.1016/j.jocn.2008.01.011
   Ni HM, 2015, REDOX BIOL, V4, P6, DOI 10.1016/j.redox.2014.11.006
   Nogalska A, 2015, J NEUROPATH EXP NEUR, V74, P538, DOI 10.1097/NEN.0000000000000196
   Nogalska A, 2010, AM J PATHOL, V177, P1377, DOI 10.2353/ajpath.2010.100050
   Oldfors A, 2006, NEUROLOGY, V66, pS49, DOI 10.1212/01.wnl.0000192127.63013.8d
   Rose MR, 2013, NEUROMUSCULAR DISORD, V23, P1044, DOI 10.1016/j.nmd.2013.08.007
   Rygiel KA, 2015, NEUROPATH APPL NEURO, V41, P288, DOI 10.1111/nan.12149
   Santel A, 2006, BBA-MOL CELL RES, V1763, P490, DOI 10.1016/j.bbamcr.2006.02.004
   Sebastián D, 2012, P NATL ACAD SCI USA, V109, P5523, DOI 10.1073/pnas.1108220109
   Sivakumar K, 1996, NEUROLOGY, V46, P1337, DOI 10.1212/WNL.46.5.1337
   Solano A, 2004, PEDIATR NEPHROL, V19, P790, DOI 10.1007/s00467-004-1473-5
   Spinazzi M, 2012, NAT PROTOC, V7, P1235, DOI 10.1038/nprot.2012.058
   Sunitha B, 2016, J NEUROCHEM, V138, P174, DOI 10.1111/jnc.13626
   Tezel G, 2009, INVEST OPHTH VIS SCI, V50, P1001, DOI 10.1167/iovs.08-2717
   Vattemi G, 2014, AUTOIMMUN HIGHLIGHTS, V5, P77, DOI 10.1007/s13317-014-0062-2
   Vielhaber S, 2013, ACTA NEUROPATHOL, V125, P245, DOI 10.1007/s00401-012-1036-y
   Walker MA, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/164309
   West AP, 2011, NAT REV IMMUNOL, V11, P389, DOI 10.1038/nri2975
NR 48
TC 33
Z9 34
U1 0
U2 14
PU PORTLAND PRESS LTD
PI LONDON
PA CHARLES DARWIN HOUSE, 12 ROGER STREET, LONDON WC1N 2JU, ENGLAND
SN 0143-5221
EI 1470-8736
J9 CLIN SCI
JI Clin. Sci.
PD OCT 1
PY 2016
VL 130
IS 19
BP 1741
EP 1751
DI 10.1042/CS20160080
PG 11
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA EK2NQ
UT WOS:000393764400005
PM 27413019
OA Bronze, Green Published
DA 2024-11-01
ER

PT J
AU Lehmann, D
   Schubert, K
   Joshi, PR
   Baty, K
   Blakely, EL
   Zierz, S
   Taylor, RW
   Deschauer, M
AF Lehmann, Diana
   Schubert, Kathrin
   Joshi, Pushpa R.
   Baty, Karen
   Blakely, Emma L.
   Zierz, Stephan
   Taylor, Robert W.
   Deschauer, Marcus
TI A novel m.7539C&gt;T point mutation in the mt-tRNA<SUP>Asp</SUP> gene
   associated with multisystemic mitochondrial disease
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE Mitochondria; Multisystemic disease; tRNA(Asp)
ID TRANSFER-RNA MUTATIONS; DNA MUTATIONS
AB Mitochondrial transfer RNA (mt-tRNA) mutations are the commonest sub-type of mitochondrial (mtDNA) mutations associated with human disease. We report a patient with multisytemic disease characterised by myopathy, spinal ataxia, sensorineural hearing loss, cataract and cognitive impairment in whom a novel m.7539C>T mt-tRNA(Asp) transition was identified. Muscle biopsy revealed extensive histopathological findings including cytochrome c oxidase (COX)-deficient fibres. Pyrosequencing confirmed mtDNA heteroplasmy for the mutation whilst single muscle fibre segregation studies revealed statistically significant higher mutation loads in COX-deficient fibres than in COX-positive fibres. Absence from control databases, hierarchical mt-tRNA mutation segregation within tissues, and occurrence at conserved sequence positions, further confirm this novel mt-tRNA mutation to be pathogenic. To date only three mt-tRNA(Asp) gene mutations have been described with clear evidence of pathogenicity. The novel m.7539C>T mt-tRNA(Asp) gene mutation extends the spectrum of pathogenic mutations in this gene, further supporting the notion that mt-tRNA(Asp) gene mutations are associated with multisystemic disease presentations. (C) 2014 The Authors. Published by Elsevier B.V.
C1 [Lehmann, Diana; Schubert, Kathrin; Joshi, Pushpa R.; Zierz, Stephan; Deschauer, Marcus] Univ Halle Wittenberg, Dept Neurol, D-06097 Halle, Germany.
   [Baty, Karen; Blakely, Emma L.; Taylor, Robert W.] Newcastle Univ, Sch Med, Inst Neurosci, Wellcome Trust Ctr Mitochondrial Res, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
C3 Martin Luther University Halle Wittenberg; Newcastle University - UK
RP Deschauer, M (corresponding author), Univ Halle Wittenberg, Dept Neurol, Ernst Grube Str 40, D-06097 Halle, Germany.
EM marcus.deschauer@uk-halle.de
FU German Ministry of Education and Research; Wellcome Trust Centre for
   Mitochondrial Research [096919Z/11/Z]; Medical Research Council (UK)
   Centre for Translational Muscle Disease research [G0601943]; Lily
   Foundation; UK NHS Highly Specialised "Rare Mitochondrial Disorders of
   Adults and Children" Service; MRC [G0601943] Funding Source: UKRI
FX DL, PRJ, SZ, and MD are members of the German mitoNET funded by the
   German Ministry of Education and Research. RWT receives support from the
   Wellcome Trust Centre for Mitochondrial Research (096919Z/11/Z), the
   Medical Research Council (UK) Centre for Translational Muscle Disease
   research (G0601943), the Lily Foundation and the UK NHS Highly
   Specialised "Rare Mitochondrial Disorders of Adults and Children"
   Service.
CR Blakely EL, 2013, HUM MUTAT, V34, P1260, DOI 10.1002/humu.22358
   Deschauer M, 2003, NEUROMUSCULAR DISORD, V13, P568, DOI 10.1016/S0960-8966(03)00071-3
   DIMAURO S, 1993, ARCH NEUROL-CHICAGO, V50, P1197, DOI 10.1001/archneur.1993.00540110075008
   Elson JL, 2009, HUM MUTAT, V30, pE984, DOI 10.1002/humu.21113
   Gellerich FN, 2002, BBA-BIOENERGETICS, V1556, P41, DOI 10.1016/S0005-2728(02)00305-5
   He LP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf067
   Lax NZ, 2013, J NEUROPATH EXP NEUR, V72, P164, DOI 10.1097/NEN.0b013e31828129c5
   Schon EA, 2012, NAT REV GENET, V13, P878, DOI 10.1038/nrg3275
   Seneca S, 2005, AM J MED GENET A, V137A, P170, DOI 10.1002/ajmg.a.30854
   Shtilbans A, 1999, J CHILD NEUROL, V14, P610, DOI 10.1177/088307389901400910
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Tuppen HAL, 2010, BBA-BIOENERGETICS, V1797, P113, DOI 10.1016/j.bbabio.2009.09.005
   White HE, 2005, GENET TEST, V9, P190, DOI 10.1089/gte.2005.9.190
   Yarham JW, 2012, MITOCHONDRION, V12, P533, DOI 10.1016/j.mito.2012.06.009
   Yarham JW, 2011, HUM MUTAT, V32, P1319, DOI 10.1002/humu.21575
   Yarham JW, 2010, WIRES RNA, V1, P304, DOI 10.1002/wrna.27
   ZIERZ S, 1989, NERVENARZT, V60, P545
NR 17
TC 8
Z9 8
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD JAN
PY 2015
VL 25
IS 1
BP 81
EP 84
DI 10.1016/j.nmd.2014.09.008
PG 4
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA CB4AR
UT WOS:000349571100012
PM 25447692
OA Green Published, hybrid
DA 2024-11-01
ER

PT J
AU McKelvie, P
   Marotta, R
   Thorburn, DR
   Chin, J
   Punchihewa, S
   Collins, S
AF McKelvie, P.
   Marotta, R.
   Thorburn, D. R.
   Chin, J.
   Punchihewa, S.
   Collins, S.
TI A case of myelopathy, myopathy, peripheral neuropathy and subcortical
   grey matter degeneration associated with recessive compound heterozygous
   POLG1 mutations
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE Compound heterozygous polymerase-gamma (POLO) mutations; Spinal cord
   degeneration; Dorsal column and dorsal spinocerebellar tract
   degeneration; Multiple mitochondrial DNA deletions; Peripheral
   neuropathy; Mitochondrial myopathy; COX-negative fibres; Ragged-red
   fibres; Substantia nigra degeneration; Thalamic degeneration; SANDO
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; SENSORY ATAXIC NEUROPATHY;
   DNA-POLYMERASE-GAMMA; MITOCHONDRIAL; SANDO
AB This 54 year old woman presented with symptoms of sensory ataxic neuropathy, with cerebellar features. She developed further weakness, visual disturbances with diplopia, dysarthria and dysphasia. After her death at 66 years, she was found to have compound heterozygous mutations of POLO I gene in muscle, and Southern blot showed low levels of multiple deletions of mitochondrial DNA. Neuropathological examination showed profound dorsal column and dorsal spinocerebellar tract degeneration, degeneration of dorsal root ganglia and Clarke's nucleus in spinal cord and severe predominantly sensory peripheral neuropathy. The brain showed severe neuronal loss and gliosis in substantia nigra, medial posterior thalamus and head of caudate. Excess numbers of COX-negative fibres and "ragged-red" fibres were found in five skeletal muscles sampled. (C) 2011 Elsevier B.V. All rights reserved.
C1 [McKelvie, P.] St Vincents Hosp Melbourne, Dept Anat Pathol, Fitzroy, Vic 3065, Australia.
   [Marotta, R.; Chin, J.; Punchihewa, S.; Collins, S.] St Vincents Hosp, St Vincents Melbourne Neuromuscular Diagnost Lab, Dept Clin Neurosci, Melbourne, Vic, Australia.
   [Thorburn, D. R.] Univ Melbourne, Dept Paediat, Royal Childrens Hosp, Parkville, Vic 3052, Australia.
   [Thorburn, D. R.] Murdoch Childrens Res Inst, Parkville, Vic, Australia.
C3 St Vincent's Health; St Vincent's Hospital Melbourne; NSW Health; St
   Vincents Hospital Sydney; St Vincent's Health; St Vincent's Hospital
   Melbourne; Royal Children's Hospital Melbourne; University of Melbourne;
   Murdoch Children's Research Institute
RP McKelvie, P (corresponding author), St Vincents Hosp Melbourne, Dept Anat Pathol, POB 2900, Fitzroy, Vic 3065, Australia.
EM penny.mckelvie@svhm.org.au
RI Thorburn, David/G-6266-2013
OI thorburn, david/0000-0002-7725-9470
CR Chalmers RM, 1996, J NEUROL SCI, V143, P41, DOI 10.1016/S0022-510X(96)00032-9
   Chan SSL, 2009, BBA-BIOENERGETICS, V1787, P312, DOI 10.1016/j.bbabio.2008.10.007
   Cottrell DA, 2000, J NEUROPATH EXP NEUR, V59, P621, DOI 10.1093/jnen/59.7.621
   Fadic R, 1997, NEUROLOGY, V49, P239, DOI 10.1212/WNL.49.1.239
   Gago MF, 2006, NEUROMUSCULAR DISORD, V16, P507, DOI 10.1016/j.nmd.2006.05.016
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Hopkins SE, 2010, J CHILD NEUROL, V25, P752, DOI 10.1177/0883073809343313
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Hudson G, 2007, ARCH NEUROL-CHICAGO, V64, P553, DOI 10.1001/archneur.64.4.553
   Hudson G, 2006, HUM MOL GENET, V15, pR244, DOI 10.1093/hmg/ddl233
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Milone M, 2008, NEUROMUSCULAR DISORD, V18, P626, DOI 10.1016/j.nmd.2008.05.009
   Milone M, 2010, NEUROLOGIST, V16, P84, DOI 10.1097/NRL.0b013e3181c78a89
   Okun MS, 2004, AM J OPHTHALMOL, V137, P951, DOI 10.1016/j.ajo.2003.10.046
   Sato K, 2011, J NEUROL, V258, P1327, DOI 10.1007/s00415-011-5936-x
   Stewart JD, 2009, J MED GENET, V46, P209, DOI 10.1136/jmg.2008.058180
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   vanDomburg PHMF, 1996, BRAIN, V119, P997, DOI 10.1093/brain/119.3.997
   Weiss MD, 2010, MUSCLE NERVE, V41, P882, DOI 10.1002/mus.21636
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   Wong LJC, 2008, HUM MUTAT, V29, pE150, DOI 10.1002/humu.20824
NR 23
TC 8
Z9 8
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD MAY
PY 2012
VL 22
IS 5
BP 401
EP 405
DI 10.1016/j.nmd.2011.10.017
PG 5
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 941OV
UT WOS:000303973400005
PM 22357363
DA 2024-11-01
ER

PT J
AU Chinnery, PF
AF Chinnery, Patrick F.
TI Mitochondrial disease in adults: what's old and what's new?
SO EMBO MOLECULAR MEDICINE
LA English
DT Review
DE mitochondrial disease; mitochondrial DNA; mitochondrial
   encephalomyopathy; myopathy; neurometabolic
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; DOMINANT OPTIC ATROPHY;
   CYTOCHROME-C-OXIDASE; LACTIC-ACIDOSIS; DNA DELETIONS;
   M.3243A-GREATER-THAN-G MUTATION; SPINOCEREBELLAR ATAXIA; THYMIDINE
   KINASE; GENE-MUTATIONS; COMMON-CAUSE
AB Ten years ago, there was an emerging view that the molecular basis for adult mitochondrial disorders was largely known and that the clinical phenotypes had been well described. Nothing could have been further from the truth. The establishment of large cohorts of patients has revealed new aspects of the clinical presentation that were not previously appreciated. Over time, this approach is starting to provide an accurate understanding of the natural history of mitochondrial disease in adults. Advances in molecular diagnostics, underpinned by next generation sequencing technology, have identified novel molecular mechanisms. Recently described mitochondrial disease phenotypes have disparate causes, and yet share common mechanistic themes. In particular, disorders of mtDNA maintenance have emerged as a major cause of mitochondrial disease in adults. Progressive mtDNA depletion and the accumulation of mtDNA mutations explain some of the clinical features, but the genetic and cellular processes responsible for the mtDNA abnormalities are not entirely clear in each instance. Unfortunately, apart from a few specific examples, treatments for adult mitochondrial disease have not been forthcoming. However, the establishment of international consortia, and the first multinational randomised controlled trial, have paved the way for major progress in the near future, underpinned by growing interest from the pharmaceutical industry. Adult mitochondrial medicine is, therefore, in its infancy, and the challenge is to harness the new understanding of its molecular and cellular basis to develop treatments of real benefit to patients.
C1 [Chinnery, Patrick F.] Univ Cambridge, Sch Clin Med, Dept Clin Neurosci, Cambridge, England.
   [Chinnery, Patrick F.] MRC, Mitochondrial Biol Unit, Cambridge, England.
C3 University of Cambridge
RP Chinnery, PF (corresponding author), Univ Cambridge, Sch Clin Med, Dept Clin Neurosci, Cambridge, England.
EM pfc25@medschl.cam.ac.uk
OI Chinnery, Patrick/0000-0002-7065-6617
FU Medical Research Council (UK) Mitochondrial Biology Unit [MC_UP_1501/2];
   Wellcome Trust Centre for Mitochondrial Research [096919Z/11/Z]; Medical
   Research Council (UK) Centre for Translational Muscle Disease Research
   [G0601943]; EU FP7 TIRCON; National Institute for Health Research (NIHR)
   Newcastle Biomedical Research Centre based at Cambridge University
   Hospitals NHS Foundation Trust; University of Cambridge; MRC
   [MR/K000608/1, G0601943] Funding Source: UKRI
FX PFC is a Wellcome Trust Senior Fellow in Clinical Science
   (101876/Z/13/Z), and a UK NIHR Senior Investigator, who receives support
   from the Medical Research Council (UK) Mitochondrial Biology Unit
   (MC_UP_1501/2). He receives additional support from the Wellcome Trust
   Centre for Mitochondrial Research (096919Z/11/Z), the Medical Research
   Council (UK) Centre for Translational Muscle Disease Research
   (G0601943), EU FP7 TIRCON and the National Institute for Health Research
   (NIHR) Newcastle Biomedical Research Centre based at Cambridge
   University Hospitals NHS Foundation Trust and the University of
   Cambridge. The views expressed are those of the author(s) and not
   necessarily those of the NHS, the NIHR or the Department of Health.
CR Alavi MV, 2009, EXP NEUROL, V220, P404, DOI 10.1016/j.expneurol.2009.09.026
   Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944
   Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   Baruffini E, 2013, HUM MUTAT, V34, P1501, DOI 10.1002/humu.22393
   Bates MGD, 2013, EUR HEART J-CARD IMG, V14, P650, DOI 10.1093/ehjci/jes226
   Bykhovskaya Y, 2004, AM J HUM GENET, V74, P1303, DOI 10.1086/421530
   Carelli V, 2015, ANN NEUROL, V78, P21, DOI 10.1002/ana.24410
   Casari G, 1998, CELL, V93, P973, DOI 10.1016/S0092-8674(00)81203-9
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   Darin N, 2001, ANN NEUROL, V49, P377, DOI 10.1002/ana.75
   Dieteren CEJ, 2012, J BIOL CHEM, V287, P41851, DOI 10.1074/jbc.M112.391151
   Dindyal S, 2014, ANN R COLL SURG ENGL, V96, P101, DOI DOI 10.1308/003588414
   Elguindy MM, 2015, J BIOL CHEM, V290, P20815, DOI 10.1074/jbc.M115.641498
   Elliott HR, 2008, AM J HUM GENET, V83, P254, DOI 10.1016/j.ajhg.2008.07.004
   Fernández-Vizarra E, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00134
   Foley AR, 2014, BRAIN, V137, P44, DOI 10.1093/brain/awt315
   Fujikawa M, 2015, FEBS LETT, V589, P2707, DOI 10.1016/j.febslet.2015.08.006
   García-Velasco A, 2003, J INTERN MED, V253, P381, DOI 10.1046/j.1365-2796.2003.01095.x
   Gardner K, 2015, EUR J HUM GENET, V23, P413, DOI 10.1038/ejhg.2014.96
   Ghezzi D, 2012, ADV EXP MED BIOL, V748, P65, DOI 10.1007/978-1-4614-3573-0_4
   Gorman GS, 2015, NEUROMUSCULAR DISORD, V25, P563, DOI 10.1016/j.nmd.2015.03.001
   Gorman GS, 2015, ANN NEUROL, V77, P753, DOI 10.1002/ana.24362
   Gorman GS, 2015, JAMA NEUROL, V72, P106, DOI 10.1001/jamaneurol.2014.1753
   Götz A, 2011, AM J HUM GENET, V88, P635, DOI 10.1016/j.ajhg.2011.04.006
   Grady JP, 2014, BRAIN, V137, P323, DOI 10.1093/brain/awt321
   Hakonen AH, 2008, HUM MOL GENET, V17, P3822, DOI 10.1093/hmg/ddn280
   Hällberg BM, 2014, CELL METAB, V20, P226, DOI 10.1016/j.cmet.2014.07.001
   Halter JP, 2015, BRAIN, V138, P2847, DOI 10.1093/brain/awv226
   Hollingsworth KG, 2012, NEUROMUSCULAR DISORD, V22, P592, DOI 10.1016/j.nmd.2012.03.001
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Howell N, 1998, AM J HUM GENET, V63, P1220, DOI 10.1086/302049
   Hudson G, 2008, BRAIN, V131, P329, DOI 10.1093/brain/awm272
   JACKSON MJ, 1995, BRAIN, V118, P339, DOI 10.1093/brain/118.2.339
   Janer A, 2012, AM J HUM GENET, V91, P737, DOI 10.1016/j.ajhg.2012.08.020
   Kabunga P, 2015, INT J CARDIOL, V181, P303, DOI 10.1016/j.ijcard.2014.12.038
   Kaufmann P, 2009, ARCH NEUROL-CHICAGO, V66, P85, DOI 10.1001/archneurol.2008.526
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kemp JP, 2011, BRAIN, V134, P183, DOI 10.1093/brain/awq320
   Klopstock T, 2011, BRAIN, V134, P2677, DOI 10.1093/brain/awr170
   Koene S, 2014, NEUROLOGY, V83, P125, DOI 10.1212/WNL.0000000000000578
   Koopman WJH, 2012, NEW ENGL J MED, V366, P1132, DOI 10.1056/NEJMra1012478
   Kornblum C, 2001, NEUROLOGY, V56, P1409, DOI 10.1212/WNL.56.10.1409
   Kornblum C, 2013, NAT GENET, V45, P214, DOI 10.1038/ng.2501
   Leonard JV, 2000, LANCET, V355, P389, DOI 10.1016/S0140-6736(99)05226-5
   Leonard JV, 2000, LANCET, V355, P299, DOI 10.1016/S0140-6736(99)05225-3
   Limongelli A, 2004, J MED GENET, V41, P342, DOI 10.1136/jmg.2003.016048
   Lodi R, 2004, BBA-BIOENERGETICS, V1657, P146, DOI 10.1016/j.bbabio.2004.05.003
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   Man PYW, 2003, AM J HUM GENET, V72, P333, DOI 10.1016/j.ajhg.2016.05.015
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   McFarland R, 2002, NAT GENET, V30, P145, DOI 10.1038/ng819
   Nemes A, 2008, EUR J OPHTHALMOL, V18, P309, DOI 10.1177/112067210801800225
   Nemes A, 2009, SWISS MED WKLY, V139, P117, DOI smw-12390
   Nesbitt V, 2013, J NEUROL NEUROSUR PS, V84, P936, DOI 10.1136/jnnp-2012-303528
   Ng YS, 2016, EUR HEART J, V37, P2552, DOI 10.1093/eurheartj/ehv306
   NIKOSKELAINEN EK, 1994, LANCET, V344, P857, DOI 10.1016/S0140-6736(94)92830-4
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Payne BAI, 2015, BBA-BIOENERGETICS, V1847, P1347, DOI 10.1016/j.bbabio.2015.05.022
   Pfeffer G, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004426.pub3
   Pfeffer G, 2015, NEUROLOGY, V84, P1174, DOI 10.1212/WNL.0000000000001369
   Pfeffer G, 2014, BRAIN, V137, P1323, DOI 10.1093/brain/awu060
   Pfeffer G, 2013, NAT REV NEUROL, V9, P474, DOI 10.1038/nrneurol.2013.129
   Pitceathly RDS, 2012, BRAIN, V135, P3392, DOI 10.1093/brain/aws231
   Poulton J, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1001066
   Quinzii CM, 2007, NEUROCHEM RES, V32, P723, DOI 10.1007/s11064-006-9190-z
   Riley LG, 2010, AM J HUM GENET, V87, P52, DOI 10.1016/j.ajhg.2010.06.001
   Rötig A, 2010, DIABETES METAB, V36, P97, DOI 10.1016/j.diabet.2009.11.002
   Ronchi D, 2013, AM J HUM GENET, V92, P293, DOI 10.1016/j.ajhg.2012.12.014
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Skladal D, 2000, J INHERIT METAB DIS, V23, P513, DOI 10.1023/A:1005620515996
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Steenweg ME, 2012, BRAIN, V135, P1387, DOI 10.1093/brain/aws070
   Suomalainen A, 2011, LANCET NEUROL, V10, P806, DOI 10.1016/S1474-4422(11)70155-7
   Taylor RW, 2014, JAMA-J AM MED ASSOC, V312, P68, DOI 10.1001/jama.2014.7184
   Taylor RW, 2003, J AM COLL CARDIOL, V41, P1786, DOI 10.1016/S0735-1097(03)00300-0
   Tiranti V, 2000, HUM MOL GENET, V9, P2733, DOI 10.1093/hmg/9.18.2733
   Tzoulis C, 2014, ANN NEUROL, V76, P66, DOI 10.1002/ana.24185
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Vydt TCG, 2007, AM J CARDIOL, V99, P264, DOI 10.1016/j.amjcard.2006.07.089
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   Yu-Wai-Man P, 2010, BRAIN, V133, P771, DOI 10.1093/brain/awq007
   Yu-Wai-Man P, 2010, OPHTHALMOLOGY, V117, P1538, DOI 10.1016/j.ophtha.2009.12.038
   Yu-Wai-Man P, 2010, HUM MOL GENET, V19, P3043, DOI 10.1093/hmg/ddq209
NR 85
TC 94
Z9 109
U1 1
U2 24
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1757-4676
EI 1757-4684
J9 EMBO MOL MED
JI EMBO Mol. Med.
PD DEC
PY 2015
VL 7
IS 12
BP 1503
EP 1512
DI 10.15252/emmm.201505079
PG 10
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA DA9NF
UT WOS:000368135400001
PM 26612854
OA gold, Green Published
DA 2024-11-01
ER

PT J
AU Bai, RK
   Wong, LJC
AF Bai, RK
   Wong, LJC
TI Detection and quantification of heteroplasmic mutant mitochondrial DNA
   by real-time amplification refractory mutation system quantitative PCR
   analysis: A single-step approach
SO CLINICAL CHEMISTRY
LA English
DT Article
ID BLOOD; CELLS
AB Background: The A3243G mitochondrial tRNA leu(UUR) point mutation causes mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) syndrome, the most common mitochondrial DNA (mtDNA) disorder, and is also found in patients with maternally inherited diabetes and deafness syndrome (MIDD). To correlate disease manifestation with mutation loads, it is necessary to measure the percentage of the A3243G mtDNA mutation.
   Methods: To reliably quantify low proportions of the mutant mtDNA, we developed a real-time amplification refractory mutation system quantitative PCR (ARMS-qPCR) assay. We validated the method with experimental samples containing known proportions of mutant A3243G mtDNA generated by mixing known amounts of cloned plasmid DNA containing either the wild-type or the mutant sequences.
   Results: A correlation coefficient of 0.9995 between the expected and observed values for the proportions of mutant A3243G in the experimental samples was found. Evaluation of a total of 36 patient DNA samples demonstrated consistent results between PCR-restriction fragment length polymorphism (RFLP) analysis and real-time ARMS-qPCR. However, the latter method was much more sensitive for detecting low percentages of mutant heteroplasmy. Three samples contained allele-specific oligonucleotide-detectable but RFLP-undetectable mutations.
   Conclusions: The real-time ARMS-qPCR method provides rapid, reliable, one-step quantitative detection of heteroplasmic mutant mtDNA. (C) 2004 American Association for Clinical Chemistry.
C1 Georgetown Univ, Med Ctr, Inst Mol & Human Genet, Washington, DC 20007 USA.
C3 Georgetown University
RP Georgetown Univ, Med Ctr, Inst Mol & Human Genet, M4000,3800 Reservoir Rd NW, Washington, DC 20007 USA.
EM wonglj@georgetown.edu
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Coté HCF, 2002, NEW ENGL J MED, V346, P811, DOI 10.1056/NEJMoa012035
   DIMAURO S, 2003, MOL GENETIC BASIS NE, P189
   Hammond EL, 2003, J CLIN VIROL, V27, P97, DOI 10.1016/S1386-6532(02)00134-8
   He LP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf067
   JOHNS DR, 1995, NEW ENGL J MED, V333, P638, DOI 10.1056/NEJM199509073331007
   Kogelnik AM, 1998, NUCLEIC ACIDS RES, V26, P112, DOI 10.1093/nar/26.1.112
   LAHIRI DK, 1991, NUCLEIC ACIDS RES, V19, P5444, DOI 10.1093/nar/19.19.5444
   Liang MH, 1998, AM J MED GENET, V77, P395, DOI 10.1002/(SICI)1096-8628(19980605)77:5<395::AID-AJMG8>3.0.CO;2-M
   MORAES CT, 1992, AM J HUM GENET, V50, P934
   NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503
   Nomiyama T, 2002, DIABETOLOGIA, V45, P1577, DOI 10.1007/s00125-002-0893-7
   Ohkubo K, 2001, CLIN CHEM, V47, P1641
   Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063
   Szuhai K, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.3.e13
   Wallace D. C, MITOMAP HUMAN MITOCH
   WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523
   Wong LJC, 1997, CLIN CHEM, V43, P1857
   Wong LJC, 1997, CLIN CHEM, V43, P1241
   Wong LJC, 2003, J MED GENET, V40
NR 20
TC 127
Z9 156
U1 0
U2 32
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0009-9147
EI 1530-8561
J9 CLIN CHEM
JI Clin. Chem.
PY 2004
VL 50
IS 6
BP 996
EP 1001
DI 10.1373/clinchem.2004.031153
PG 6
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology
GA 827BR
UT WOS:000221873800003
PM 15073091
OA Bronze
DA 2024-11-01
ER

PT J
AU Mezghani, N
   Mnif, M
   Kacem, M
   Mkaouar-Rebai, E
   Salem, IH
   Kallel, N
   Charfi, N
   Abid, M
   Fakhfakh, F
AF Mezghani, Najla
   Mnif, Mouna
   Kacem, Maha
   Mkaouar-Rebai, Emna
   Salem, Ikhlass Hadj
   Kallel, Nozha
   Charfi, Nadia
   Abid, Mohamed
   Fakhfakh, Faiza
TI A whole mitochondrial genome screening in a MELAS patient: A novel
   mitochondrial tRNA<SUP>Val</SUP> mutation
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE MELAS syndrome; Mitochondrial mutations; m.3243A > G; tRNA(Val) gene
ID LACTIC-ACIDOSIS; MTDNA MUTATION; ND5 GENE; DNA; IDENTIFICATION;
   PREVALENCE; MYOPATHY; DISEASE; RNA
AB Mitochondrial encephalopathy, lactic acidosis and strokelike episodes (MELAS) syndrome is a mitochondrial disorder characterized by a wide variety of clinical presentations and a multisystemic organ involvement. In this study, we report a Tunisian girl with clinical features of MELAS syndrome who was negative for the common m.3243A>G mutation, but also for the reported mitochondrial DNA (mtDNA) mutations and deletions. Screening of the entire mtDNA genome showed several known mitochondrial variants besides to a novel transition m.1640A>G affecting a wobble adenine in the anticodon stem region of the tRNA(Val). This nucleotide was conserved and it was absent in 150 controls suggesting its pathogenicity. In addition, no mutations were found in the nuclear polymerase gamma-1 gene (POLG1). These results suggest further investigation nuclear genes encoding proteins responsible for stability and structural components of the mtDNA or to the oxidative phosphorylation machinery to explain the phenotypic variability in the studied family. (C) 2011 Elsevier Inc. All rights reserved.
C1 [Mezghani, Najla; Mkaouar-Rebai, Emna; Salem, Ikhlass Hadj; Fakhfakh, Faiza] Univ Sfax, Fac Med Sfax, Lab Genet Mol Humaine, Sfax 3029, Tunisia.
   [Mnif, Mouna; Kallel, Nozha; Charfi, Nadia; Abid, Mohamed] CHU Habib Bourguiba Sfax, Serv Endocrinol, Sfax, Tunisia.
   [Kacem, Maha] CHU Fattouma Bourguiba Monastir, Serv Med Interne, Monastir, Tunisia.
C3 Universite de Sfax; Universite de Sfax; Hopital Habib Bourguiba; Hopital
   Hedi Chaker; Universite de Monastir; Hopital Fattouma Bourguiba
RP Mkaouar-Rebai, E (corresponding author), Univ Sfax, Fac Med Sfax, Lab Genet Mol Humaine, Ave Magida Boulila, Sfax 3029, Tunisia.
EM emna_mkaouar@mail2world.com
RI MKAOUAR-REBAI, Emna/AAE-6650-2019
OI Mkaouar-Rebai, Emna/0000-0003-3095-510X
FU Ministry of Higher Education and Scientific Research in Tunisia
FX We thank the patient and her family for their cooperation in the present
   study. This work was supported by The Ministry of Higher Education and
   Scientific Research in Tunisia.
CR Abu-Amero EK, 2006, J CHILD NEUROL, V21, P971, DOI 10.2310/7010.2006.00208
   Aharoni S, 2010, J NEUROL SCI, V296, P101, DOI 10.1016/j.jns.2010.06.029
   Chalmers RM, 1997, NEUROLOGY, V49, P589, DOI 10.1212/WNL.49.2.589
   Choi BO, 2010, EXP MOL MED, V42, P446, DOI 10.3858/emm.2010.42.6.046
   Corona P, 2001, ANN NEUROL, V49, P106, DOI 10.1002/1531-8249(200101)49:1<106::AID-ANA16>3.0.CO;2-T
   De Coo IFM, 1999, ANN NEUROL, V45, P130, DOI 10.1002/1531-8249(199901)45:1<130::AID-ART21>3.0.CO;2-Z
   de Coo IFM, 1998, NEUROLOGY, V50, P293, DOI 10.1212/WNL.50.1.293
   Deschauer M, 2007, NEUROLOGY, V68, P1741, DOI 10.1212/01.wnl.0000261929.92478.3e
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Finsterer J, 2007, ACTA NEUROL SCAND, V116, P1, DOI 10.1111/j.1600-0404.2007.00836.x
   Finsterer J, 2009, INT J CARDIOL, V137, P60, DOI 10.1016/j.ijcard.2008.04.089
   Herrnstadt C, 2002, AM J HUM GENET, V70, P1152, DOI 10.1086/339933
   Hofacker IL, 2003, NUCLEIC ACIDS RES, V31, P3429, DOI 10.1093/nar/gkg599
   Kirby DM, 2004, J MED GENET, V41, P784, DOI 10.1136/jmg.2004.020537
   Kivisild T, 2004, AM J HUM GENET, V75, P752, DOI 10.1086/425161
   LEWIN HA, 1992, BIOTECHNIQUES, V13, P522
   Liolitsa D, 2003, ANN NEUROL, V53, P128, DOI 10.1002/ana.10435
   Manwaring N, 2007, MITOCHONDRION, V7, P230, DOI 10.1016/j.mito.2006.12.004
   Matsumoto Joyce, 2005, Rev Neurol Dis, V2, P30
   McFarland R, 2002, NAT GENET, V30, P145, DOI 10.1038/ng819
   Menotti Francesca, 2004, Ital Heart J, V5, P460
   Mkaouar-Rebai E, 2007, BIOCHEM BIOPH RES CO, V355, P1031, DOI 10.1016/j.bbrc.2007.02.083
   Murphy R, 2008, DIABETIC MED, V25, P383, DOI 10.1111/j.1464-5491.2008.02359.x
   Ravn K, 2001, EUR J HUM GENET, V9, P805, DOI 10.1038/sj.ejhg.5200712
   Rieder MJ, 1998, NUCLEIC ACIDS RES, V26, P967, DOI 10.1093/nar/26.4.967
   Ruiz-Pesini E, 2006, HUM MUTAT, V27, P1072, DOI 10.1002/humu.20378
   Santorelli FM, 1997, BIOCHEM BIOPH RES CO, V238, P326, DOI 10.1006/bbrc.1997.7167
   Scaglia F, 2006, CNS DRUGS, V20, P443, DOI 10.2165/00023210-200620060-00002
   Schaefer AM, 2008, ANN NEUROL, V63, P35, DOI 10.1002/ana.21217
   Schmiedel J, 2003, J NEUROL, V250, P267, DOI 10.1007/s00415-003-0978-3
   Shanske S, 2008, ARCH NEUROL-CHICAGO, V65, P368, DOI 10.1001/archneurol.2007.67
   Tiranti V, 1998, ANN NEUROL, V43, P98, DOI 10.1002/ana.410430116
   Wong LJC, 2007, MUSCLE NERVE, V36, P279, DOI 10.1002/mus.20807
NR 33
TC 5
Z9 6
U1 0
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD APR 22
PY 2011
VL 407
IS 4
BP 747
EP 752
DI 10.1016/j.bbrc.2011.03.094
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 759KI
UT WOS:000290240500022
PM 21447323
DA 2024-11-01
ER

PT J
AU Rodrigues, ADS
   Kiyomoto, BH
   Oliveira, ASB
   Gabbai, AA
   Schmidt, B
   Tengan, CH
AF Rodrigues, Andresa De Santi
   Kiyomoto, Beatriz H.
   Oliveira, Acary S. B.
   Gabbai, Alberto A.
   Schmidt, Beny
   Tengan, Celia H.
TI Progressive myopathy with a combined respiratory chain defect including
   Complex II
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE mitochondria; succinate dehydrogenase; mitochondrial myopathies;
   respiratory chain; lipid metabolism; muscle; myopathies
ID SUCCINATE-DEHYDROGENASE DEFICIENCY; MITOCHONDRIAL MYOPATHY;
   SKELETAL-MUSCLE; A DEHYDROGENASE; MUTATION; PATIENT; GENE; ACONITASE
AB Biochemical defects in the respiratory chain are mostly associated with deficiencies in Complexes I, III and IV, caused by nuclear or mitochondrial DNA mutations. Combined defects including Complex II have been reported very rarely and have muscular symptoms as the main manifestation, including muscle weakness, exercise intolerance and myoglobinuria. We report a patient with a fatal progressive myopathy and muscle biopsy showing diffuse reduction in succinate dehydrogenase activity, ragged red fibers and intense lipid accumulation. Cytochrome c oxidase (COX) histochemistry demonstrated 30% of fibers with increased subsarcolemmal staining while 27% were COX negative. Western blotting analysis showed reduction in the expression of the 39 kDa subunit of Complex I, subunit II of Complex IV and the 70 kDa subunit of Complex II. Our findings suggest that the patient had a complex pattern of mitochondrial dysfunction affecting multiple respiratory chain complexes (I, II and IV) and fatty acid metabolism. This report adds a new histological pattern associated to combined deficiencies of respiratory chain with involvement of Complex II and shows that this disease may be fatal with a rapid progression. (c) 2007 Elsevier B.V. All rights reserved.
C1 [Rodrigues, Andresa De Santi; Kiyomoto, Beatriz H.; Oliveira, Acary S. B.; Gabbai, Alberto A.; Tengan, Celia H.] Univ Fed Sao Paulo, Escola Paulista Med, Clin Neurol Div,Lab Neurol Mol, Dept Neurol & Neurosurg, BR-04039032 Sao Paulo, SP, Brazil.
   [Schmidt, Beny] Univ Fed Sao Paulo, Escola Paulista Med, Dept Pathol, BR-04039032 Sao Paulo, SP, Brazil.
C3 Universidade Federal de Sao Paulo (UNIFESP); Universidade Federal de Sao
   Paulo (UNIFESP)
RP Tengan, CH (corresponding author), Univ Fed Sao Paulo, Escola Paulista Med, Clin Neurol Div,Lab Neurol Mol, Dept Neurol & Neurosurg, R Pedro Toledo 781, BR-04039032 Sao Paulo, SP, Brazil.
EM chtengan@neuro.epm.br
RI Tengan, Celia/D-8458-2013
CR Acín-Pérez R, 2004, MOL CELL, V13, P805, DOI 10.1016/S1097-2765(04)00124-8
   ANTOZZI C, 1994, NEUROLOGY, V44, P2153, DOI 10.1212/WNL.44.11.2153
   BENNETT MJ, 1994, J INHERIT METAB DIS, V17, P283, DOI 10.1007/BF00711808
   BOURGERON T, 1995, NAT GENET, V11, P144, DOI 10.1038/ng1095-144
   Brière JJ, 2005, CELL MOL LIFE SCI, V62, P2317, DOI 10.1007/s00018-005-5237-6
   Budde SMS, 2000, BIOCHEM BIOPH RES CO, V275, P63, DOI 10.1006/bbrc.2000.3257
   DESNUELLE C, 1989, BIOCHEM BIOPH RES CO, V163, P695, DOI 10.1016/0006-291X(89)92279-1
   HALL RE, 1993, J CLIN INVEST, V92, P2660, DOI 10.1172/JCI116882
   HALLER RG, 1991, J CLIN INVEST, V88, P1197, DOI 10.1172/JCI115422
   LINDERHOLM H, 1990, J INTERN MED, V228, P43, DOI 10.1111/j.1365-2796.1990.tb00191.x
   Loeffen JLCM, 2000, HUM MUTAT, V15, P123, DOI 10.1002/(SICI)1098-1004(200002)15:2<123::AID-HUMU1>3.3.CO;2-G
   MORAES CT, 1992, AM J HUM GENET, V50, P934
   REICHMANN H, 1994, EUR NEUROL, V34, P95
   RIVNER MH, 1989, NEUROLOGY, V39, P693, DOI 10.1212/WNL.39.5.693
   RubioGozalbo ME, 1997, EUR J PEDIATR, V156, P931, DOI 10.1007/s004310050745
   Russell AP, 2003, J CLIN ENDOCR METAB, V88, P5921, DOI 10.1210/jc.2003-030885
   Rustin P, 2002, BBA-BIOENERGETICS, V1553, P117, DOI 10.1016/S0005-2728(01)00228-6
   Schägger H, 2004, J BIOL CHEM, V279, P36349, DOI 10.1074/jbc.M404033200
   SCHAPIRA AHV, 1990, NEW ENGL J MED, V323, P37, DOI 10.1056/NEJM199007053230107
   Sugimoto J, 2000, BRAIN DEV-JPN, V22, P158, DOI 10.1016/S0387-7604(00)00097-8
   Ugalde C, 2004, HUM MOL GENET, V13, P659, DOI 10.1093/hmg/ddh071
   Ugalde C, 2003, ANN NEUROL, V54, P665, DOI 10.1002/ana.10734
   VEITCH K, 1989, BIOCHIM BIOPHYS ACTA, V1006, P335, DOI 10.1016/0005-2760(89)90021-0
   Vladutiu GD, 2000, ARCH PATHOL LAB MED, V124, P1755
NR 24
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD JAN 15
PY 2008
VL 264
IS 1-2
BP 182
EP 186
DI 10.1016/j.jns.2007.08.002
PG 5
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 255VO
UT WOS:000252686200033
PM 17850823
DA 2024-11-01
ER

PT J
AU Ronchi, D
   Liu, CW
   Caporali, L
   Piga, D
   Li, HZ
   Tagliavini, F
   Valentino, ML
   Ferro, MT
   Bini, P
   Zheng, L
   Carelli, V
   Shen, BH
   Comi, GP
AF Ronchi, Dario
   Liu, Changwei
   Caporali, Leonardo
   Piga, Daniela
   Li, Hongzhi
   Tagliavini, Francesca
   Valentino, Maria Lucia
   Ferro, Maria Teresa
   Bini, Paola
   Zheng, Li
   Carelli, Valerio
   Shen, Binghui
   Comi, Giacomo Pietro
TI Novel mutations in DNA2 associated with myopathy and mtDNA instability
SO ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY
LA English
DT Article
ID MITOCHONDRIAL; REPLICATION; NUCLEASE/HELICASE; MAINTENANCE
AB The maintenance of mitochondrial DNA (mtDNA) relies on proteins encoded by nuclear genes. Mutations in their coding sequences result in heterogenous clinical presentations featuring mtDNA instability in affected tissues. DNA2 is a multi-catalytic protein involved in the removal of single strand DNA during mtDNA replication or Long Patch Base Excision Repair pathway. We have previously described DNA2 mutations in adult patients affected with familial and sporadic forms of mitochondrial myopathy. Here we describe four novel probands presenting with limb weakness associated with novel DNA2 molecular defects. Biochemical assays were established to investigate the functional effects of these variants.
C1 [Ronchi, Dario; Piga, Daniela] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Neurol Unit, Milan, Italy.
   [Ronchi, Dario; Comi, Giacomo Pietro] Univ Milan, Dino Ferrari Ctr, Dept Pathophysiol & Transplantat, Milan, Italy.
   [Liu, Changwei; Li, Hongzhi; Zheng, Li; Shen, Binghui] Beckman Res Inst City Hope, Dept Canc Genet & Epigenet, 1500 East Duarte Rd, Duarte, CA 91010 USA.
   [Caporali, Leonardo; Tagliavini, Francesca; Valentino, Maria Lucia; Carelli, Valerio] UOC Clin Neurol, Ist Sci Neurol Bologna, Bologna, Italy.
   [Valentino, Maria Lucia; Carelli, Valerio] Univ Bologna, Dipartimento Sci Biomed & Neuromotorie DIBINEM, Bologna, Italy.
   [Ferro, Maria Teresa] Osped Maggiore Crema, Neurol Unit, Crema, Italy.
   [Bini, Paola] Natl Neurol Inst, IRCCS C Mondino Fdn, Pavia, Italy.
   [Comi, Giacomo Pietro] Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Neurosci, Neuromuscular & Rare Dis Unit, I-20122 Milan, Italy.
C3 IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; City
   of Hope; Beckman Research Institute of City of Hope; IRCCS Istituto
   delle Scienze Neurologiche di Bologna (ISNB); University of Bologna;
   Fondazione IRCCS Istituto Neurologico Carlo Besta; IRCCS Fondazione
   Casimiro Mondino; IRCCS Ca Granda Ospedale Maggiore Policlinico
RP Shen, BH (corresponding author), Beckman Res Inst City Hope, Dept Canc Genet & Epigenet, 1500 East Duarte Rd, Duarte, CA 91010 USA.; Carelli, V (corresponding author), UOC Clin Neurol, Ist Sci Neurol Bologna, Bologna, Italy.; Carelli, V (corresponding author), Univ Bologna, Dipartimento Sci Biomed & Neuromotorie DIBINEM, Bologna, Italy.; Comi, GP (corresponding author), Univ Milan, Dept Pathophysiol & Transplantat, Neurosci Sect, IRCCS Fdn Ca Granda Osped Maggiore Policlin, Via Francesco Sforza 35, I-20122 Milan, Italy.
EM valerio.carelli@unibo.it; bshen@coh.org; giacomo.comi@unimi.it
RI Ronchi, Dario/K-8011-2016; Comi, Giacomo/K-5702-2016; Caporali,
   Leonardo/J-7398-2016; Tagliavini, Francesca/N-5154-2015
OI Ronchi, Dario/0000-0002-6093-9816; Caporali,
   Leonardo/0000-0002-0666-4380; Tagliavini, Francesca/0000-0001-5679-2156;
   Shen, Binghui/0000-0002-4408-407X
FU Fondazione Cariplo [2014-1010]; Italian Telethon [GSP16001]; Italian
   Ministry of Health;  [R01CA085344]
FX This work was supported by Fondazione Cariplo (Project 2014-1010 to
   D.R.), Italian Telethon (Grant GSP16001 to G.P.C.) and the Italian
   Ministry of Health (Ricerca Corrente to V.C.). The work done in the Shen
   laboratory was supported by R01CA085344 to B.H.S.
CR Ahmed N, 2015, INT J MOL SCI, V16, P18054, DOI 10.3390/ijms160818054
   Akhmedov AT, 2015, MOL CELL BIOCHEM, V409, P283, DOI 10.1007/s11010-015-2532-x
   Chae JH, 2015, J MED GENET, V52, P208, DOI 10.1136/jmedgenet-2014-102819
   Duxin JP, 2009, MOL CELL BIOL, V29, P4274, DOI 10.1128/MCB.01834-08
   Jia PP, 2017, DNA REPAIR, V59, P9, DOI 10.1016/j.dnarep.2017.09.001
   Kornblum C, 2013, NAT GENET, V45, P214, DOI 10.1038/ng.2501
   Li ZK, 2018, EMBO J, V37, DOI 10.15252/embj.201796729
   Miller AS, 2017, GENE DEV, V31, P503, DOI 10.1101/gad.295659.116
   Peng G, 2012, CANCER RES, V72, P2802, DOI 10.1158/0008-5472.CAN-11-3152
   Phowthongkum P, 2017, NEUROMUSCULAR DISORD, V27, P616, DOI 10.1016/j.nmd.2017.03.013
   Reyes A, 2015, AM J HUM GENET, V97, P186, DOI 10.1016/j.ajhg.2015.05.013
   Ronchi D, 2013, AM J HUM GENET, V92, P293, DOI 10.1016/j.ajhg.2012.12.014
   Shaheen R, 2014, GENOME RES, V24, P291, DOI 10.1101/gr.160572.113
   Yu-Wai-Man P, 2010, INVEST OPHTH VIS SCI, V51, P3347, DOI 10.1167/iovs.09-4660
   Zheng L, 2008, MOL CELL, V32, P325, DOI 10.1016/j.molcel.2008.09.024
NR 15
TC 11
Z9 11
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2328-9503
J9 ANN CLIN TRANSL NEUR
JI Ann. Clin. Transl. Neurol.
PD SEP
PY 2019
VL 6
IS 9
BP 1893
EP 1899
DI 10.1002/acn3.50888
EA SEP 2019
PG 7
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA JA5LI
UT WOS:000484834100001
PM 31478350
OA Green Published, gold
DA 2024-11-01
ER

PT J
AU Xu, P
   Jia, ML
   Yan, JM
   Yuan, XS
   Yu, WD
   Zhou, ZH
   Fang, HZ
   Gao, F
   Shen, LJ
AF Xu, Pu
   Jia, Manli
   Yan, Jimei
   Yuan, Xiangshu
   Yu, Weidong
   Zhou, Zhuohua
   Fang, Hezhi
   Gao, Feng
   Shen, Lijun
TI Determining Mitochondrial 3243A>G Heteroplasmy Using an ARMS-ddPCR
   Strategy
SO AMERICAN JOURNAL OF CLINICAL PATHOLOGY
LA English
DT Article
DE ARMS-qPCR; ddPCR; Heteroplasmy; mtDNA copy number; Mitochondrial disease
ID LACTIC-ACIDOSIS; COPY NUMBER; MUTATION; DNA; QUANTIFICATION;
   ENCEPHALOPATHY; ACCURATE; MYOPATHY; COMMON; PCR
AB Objectives Determining mitochondrial DNA (mtDNA) A-to-G substitution at nucleotide 3243 (m.3243A>G) heteroplasmy is essential for both precision diagnosis of m.3243A>G-associated mitochondrial disease and genetic counseling. Precise determination of m.3243A>G heteroplasmy is challenging, however, without appropriate strategies to accommodate heteroplasmic levels ranging from 1% to 100% in samples carrying thousands to millions of mtDNA copies. Methods We used a combined strategy of amplification-refractory mutation system-quantitative polymerase chain reaction (ARMS-qPCR) and droplet digital PCR (ddPCR) to determine m.3243A>G heteroplasmy. Primers were specifically designed and screened for both ARMS-qPCR and ddPCR to determine m.3243A>G heteroplasmy. An optimized ARMS-qPCR-ddPCR-based strategy was established using artificial standards, with different mixtures of m.3243A-containing and m.3243G-containing plasmids and further tested using clinical samples containing the m.3243A>G mutation. Results One of 20 primer pairs designed in the study was omitted for ARMS-qPCR-ddPCR strategy application according to criteria of 85% to 110%, R-2 > 0.98 amplification efficiency, melt curve with a single clear peak, and specificity for m.3243A and m.3243G artificial standards (|Ct(Wt)-Ct(Mut)|(max)). Using plasmid standards with various m.3243A>G heteroplasmy (1%-100%) at low, mid, and high copy numbers (3,000, 10(4), and 10(5)-10(7), respectively) and DNA from the blood of 20 patients carrying m.3243A>G with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes, we found that ARMS-qPCR was reliable for determining m.3243A>G at 3% to 100% for low copy number and 1% to 100% for mid to high copy number samples. Meanwhile, ddPCR was reliable for determining m.3243A>G at 1% to 100% at low to mid copy number samples. Conclusions An ARMS-qPCR-ddPCR-based strategy was successfully established for precise determination of m.3243A>G heteroplasmy in complex clinical samples.
C1 [Xu, Pu] Xian Med Univ, Affiliated Hosp 1, Lab Med, Xian, Peoples R China.
   [Xu, Pu; Jia, Manli; Yan, Jimei; Yuan, Xiangshu; Yu, Weidong; Zhou, Zhuohua; Fang, Hezhi; Shen, Lijun] Wenzhou Med Univ, Sch Lab Med & Life Sci, Wenzhou, Peoples R China.
   [Gao, Feng] Hangzhou Med Coll, Affiliated Peoples Hosp, Zhejiang Prov Peoples Hosp, Hangzhou, Peoples R China.
C3 Xi'an Medical University; Wenzhou Medical University; Hangzhou Medical
   College; Zhejiang Provincial People's Hospital
RP Fang, HZ; Shen, LJ (corresponding author), Wenzhou Med Univ, Sch Lab Med & Life Sci, Wenzhou, Peoples R China.; Gao, F (corresponding author), Hangzhou Med Coll, Affiliated Peoples Hosp, Zhejiang Prov Peoples Hosp, Hangzhou, Peoples R China.
EM fangh@wmu.edu.cn; chinapeakcool10000@163.com; ysslj23@163.com
RI Gao, Feng/X-4385-2019
FU Zhejiang Provincial Natural Science Foundation of China [LR20H200001];
   National Natural Science Foundation of China [81830071]; Wenzhou Science
   and Technology Bureau Project [Y20170029]
FX This work was supported by the Zhejiang Provincial Natural Science
   Foundation of China (LR20H200001), the National Natural Science
   Foundation of China (key program, 81830071), and Wenzhou Science and
   Technology Bureau Project (Y20170029).
CR Annesley SJ, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8070680
   Bai RK, 2004, CLIN CHEM, V50, P996, DOI 10.1373/clinchem.2004.031153
   Carelli V, 2002, ARCH NEUROL-CHICAGO, V59, P264, DOI 10.1001/archneur.59.2.264
   Chomyn A, 2000, J BIOL CHEM, V275, P19198, DOI 10.1074/jbc.M908734199
   Christodoulou C, 2017, FERTIL STERIL, V107, P212, DOI 10.1016/j.fertnstert.2016.09.045
   Elliott HR, 2008, AM J HUM GENET, V83, P254, DOI 10.1016/j.ajhg.2008.07.004
   Fakhrai-Rad H, 2002, HUM MUTAT, V19, P479, DOI 10.1002/humu.10078
   Gorman GS, 2016, NAT REV DIS PRIMERS, V2, P1, DOI 10.1038/nrdp.2016.80
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Green Michael R, 2018, Cold Spring Harb Protoc, V2018, DOI 10.1101/pdb.prot095026
   Hardinge P, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-57473-1
   Hartman P, 2019, MOL GENET METAB REP, V19, DOI 10.1016/j.ymgmr.2019.100464
   Hashimoto S, 2017, J ASSIST REPROD GEN, V34, P573, DOI 10.1007/s10815-017-0886-6
   Kisiel MA, 2019, METHODS MOL BIOL, V1993, P71, DOI 10.1007/978-1-4939-9473-1_6
   Liu J, 2012, PLANT METHODS, V8, DOI 10.1186/1746-4811-8-34
   Lorenzoni PJ, 2015, ARQ NEURO-PSIQUIAT, V73, P959
   Lou YY, 2020, J MOL DIAGN, V22, P699, DOI 10.1016/j.jmoldx.2020.02.007
   Manwaring N, 2007, MITOCHONDRION, V7, P230, DOI 10.1016/j.mito.2006.12.004
   Miller FJ, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng060
   Monnot S, 2011, HUM MUTAT, V32, P116, DOI 10.1002/humu.21417
   NEWTON CR, 1989, NUCLEIC ACIDS RES, V17, P2503, DOI 10.1093/nar/17.7.2503
   O'Hara R, 2019, GENOME RES, V29, P1878, DOI 10.1101/gr.250480.119
   Russell OM, 2020, CELL, V181, P168, DOI 10.1016/j.cell.2020.02.051
   Sallevelt SCEH, 2017, HUM REPROD, V32, P698, DOI 10.1093/humrep/dew356
   SANTORELLI FM, 1993, ANN NEUROL, V34, P827, DOI 10.1002/ana.410340612
   Shen SX, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-56
   Sofronova JK, 2016, BIOCHEMISTRY-MOSCOW+, V81, P1031, DOI 10.1134/S0006297916100011
   Tabebi M, 2015, BIOCHEM BIOPH RES CO, V459, P353, DOI 10.1016/j.bbrc.2015.01.151
   Tatuch Yuriy, 1994, European Journal of Human Genetics, V2, P35
   Tranah GJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30255-6
   Uittenbogaard M, 2018, MOL GENET METAB, V124, P71, DOI 10.1016/j.ymgme.2018.03.011
   Wang Jing, 2011, Curr Protoc Hum Genet, VChapter 19, DOI 10.1002/0471142905.hg1906s68
   Wong LJC, 2010, MOL GENET METAB, V100, P111, DOI 10.1016/j.ymgme.2010.02.024
   Xia CY, 2017, CHINESE MED J-PEKING, V130, P2435, DOI 10.4103/0366-6999.216395
   Yan JB, 2014, J MOL DIAGN, V16, P431, DOI 10.1016/j.jmoldx.2014.03.005
   Ye J, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-134
   You FM, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-253
NR 37
TC 1
Z9 1
U1 0
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9173
EI 1943-7722
J9 AM J CLIN PATHOL
JI Am. J. Clin. Pathol.
PD MAY 4
PY 2022
VL 157
IS 5
BP 664
EP 677
DI 10.1093/ajcp/aqab174
EA OCT 2021
PG 14
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 1A1GC
UT WOS:000789176500001
PM 34698344
DA 2024-11-01
ER

PT J
AU Sudo, A
   Honzawa, S
   Nonaka, I
   Goto, Y
AF Sudo, A
   Honzawa, S
   Nonaka, I
   Goto, Y
TI Leigh syndrome caused by mitochondrial DNA G13513A mutation: frequency
   and clinical features in Japan
SO JOURNAL OF HUMAN GENETICS
LA English
DT Article
DE Leigh syndrome; mitochondrial DNA; ND5 subunit gene; G13513A; WPW
   syndrome
ID MISSENSE MUTATION; OVERLAP-SYNDROME; MTDNA MUTATION; COMPLEX-I; GENE;
   MELAS; DISEASE; ND5
AB The mitochondrial DNA (mtDNA) G13513A mutation in the ND5 subunit gene has been recently reported as a common cause of some phenotypes of mitochondrial myopathy. Until now, the prevalence and characteristics of this mutation in Leigh syndrome (LS) has not been determined. We screened 84 patients with Leigh syndrome (LS) and found the mutation in six (7%) of them. The proportions of mutant mtDNA in muscles were relatively low (42-70%). The onset of symptoms for patients with this mutation was from 9 months to 5 years. It should be noted that five patients had cardiac conduction abnormalities, particularly Wolff-Parkinson-White (WPW) syndrome (three patients). This study suggests that G13513A mutation is a frequent cause of LS and that patients with this mutation may have a characteristic clinical course.
C1 NCNP, Natl Inst Neurosci, Dept Mental Retardat & Birth Defect Res, Tokyo 1878502, Japan.
   Natl Ctr Neurol & Psychiat, Natl Ctr Hosp Mental Nervous & Muscular Disorders, Dept Child Neurol, Tokyo, Japan.
   Dokkyo Univ, Sch Med, Koshigaya Hosp, Dept Pediat, Saitama, Japan.
C3 National Center for Neurology & Psychiatry - Japan; National Center for
   Neurology & Psychiatry - Japan; Dokkyo Medical University
RP NCNP, Natl Inst Neurosci, Dept Mental Retardat & Birth Defect Res, 4-1-1 Ogawahigashi, Tokyo 1878502, Japan.
EM goto@ncnp.go.jp
CR Akanuma J, 2000, J HUM GENET, V45, P337, DOI 10.1007/s100380070004
   Arii J, 2000, AM J NEURORADIOL, V21, P1502
   Bai YD, 2000, MOL CELL BIOL, V20, P805, DOI 10.1128/MCB.20.3.805-815.2000
   BERKOVIC SF, 1991, LANCET, V338, P457, DOI 10.1016/0140-6736(91)91090-H
   Campos Y, 1997, NEUROLOGY, V49, P595, DOI 10.1212/WNL.49.2.595
   Chol M, 2003, J MED GENET, V40, P188, DOI 10.1136/jmg.40.3.188
   Corona P, 2001, ANN NEUROL, V49, P106, DOI 10.1002/1531-8249(200101)49:1<106::AID-ANA16>3.0.CO;2-T
   Crimi M, 2003, NEUROLOGY, V60, P1857, DOI 10.1212/01.WNL.0000066048.72780.69
   DEVRIES DD, 1993, ANN NEUROL, V34, P410, DOI 10.1002/ana.410340319
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   HASEGAWA H, 1991, ANN NEUROL, V29, P601, DOI 10.1002/ana.410290606
   Kirby DM, 2000, ANN NEUROL, V48, P102, DOI 10.1002/1531-8249(200007)48:1<102::AID-ANA15>3.3.CO;2-D
   Kirby DM, 2003, ANN NEUROL, V54, P473, DOI 10.1002/ana.10687
   KOGA Y, 1988, ACTA NEUROPATHOL, V76, P135, DOI 10.1007/BF00688097
   Koga Y, 2000, ARCH DIS CHILD, V82, P407, DOI 10.1136/adc.82.5.407
   Komaki H, 2003, MITOCHONDRION, V2, P293, DOI 10.1016/S1567-7249(03)00003-5
   LEIGH D, 1951, J NEUROL NEUROSUR PS, V14, P216, DOI 10.1136/jnnp.14.3.216
   Liolitsa D, 2003, ANN NEUROL, V53, P128, DOI 10.1002/ana.10435
   Makino M, 1998, NEUROMUSCULAR DISORD, V8, P149, DOI 10.1016/S0960-8966(98)00017-0
   Makino M, 2000, J HUM GENET, V45, P69, DOI 10.1007/s100380050014
   Nakada K, 2001, NAT MED, V7, P934, DOI 10.1038/90976
   Penisson-Besnier I, 2000, NEUROLOGY, V55, P317, DOI 10.1212/WNL.55.2.317
   PETERS NS, 1994, EUR HEART J, V15, P981, DOI 10.1093/oxfordjournals.eurheartj.a060619
   PINCUS JH, 1972, DEV MED CHILD NEUROL, V14, P87
   Pulkes T, 1999, ANN NEUROL, V46, P916, DOI 10.1002/1531-8249(199912)46:6<916::AID-ANA16>3.0.CO;2-R
   Rahman S, 1996, ANN NEUROL, V39, P343, DOI 10.1002/ana.410390311
   Santorelli FM, 1997, BIOCHEM BIOPH RES CO, V238, P326, DOI 10.1006/bbrc.1997.7167
   SANTORELLI FM, 1993, ANN NEUROL, V34, P827, DOI 10.1002/ana.410340612
   TATUCH Y, 1992, AM J HUM GENET, V50, P852
   Taylor RW, 2002, EUR J HUM GENET, V10, P141, DOI 10.1038/sj.ejhg.5200773
   THYAGARAJAN D, 1995, ANN NEUROL, V38, P468, DOI 10.1002/ana.410380321
   Tiranti V, 1998, AM J HUM GENET, V63, P1609, DOI 10.1086/302150
   VANERVEN PMM, 1987, CLIN NEUROL NEUROSUR, V89, P217, DOI 10.1016/S0303-8467(87)80020-3
   Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804
NR 34
TC 58
Z9 69
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1434-5161
EI 1435-232X
J9 J HUM GENET
JI J. Hum. Genet.
PD FEB
PY 2004
VL 49
IS 2
BP 92
EP 96
DI 10.1007/s10038-003-0116-1
PG 5
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 779FP
UT WOS:000189284900005
PM 14730434
OA Bronze
DA 2024-11-01
ER

PT J
AU González-del Angel, A
   Bisciglia, M
   Vargas-Cañas, S
   Fernandez-Valverde, F
   Kazakova, E
   Escobar, RE
   Romero, NB
   Jarder, C
   Rucheton, B
   Stojkovic, T
   Malfatti, E
AF Gonzalez-del Angel, Ariadna
   Bisciglia, Michela
   Vargas-Canas, Steven
   Fernandez-Valverde, Francisca
   Kazakova, Ekaterina
   Elena Escobar, Rosa
   Romero, Norma B.
   Jarder, Claude
   Rucheton, Benoit
   Stojkovic, Tanya
   Malfatti, Edoardo
TI Novel Phenotypes and Cardiac Involvement Associated With DNA2 Genetic
   Variants
SO FRONTIERS IN NEUROLOGY
LA English
DT Article
DE mitochondrial disease; early onset myopathy; DNA2; cardiomyopathy;
   velopharyngeal weakness; rhabdomyolysis
ID MUSCLE MITOCHONDRIAL-DNA; MYOPATHY; SPECTRUM; NUCLEAR
AB Objectives: To report two novel DNA2 gene mutations causing early onset myopathy with cardiac involvement and late onset mitochondriopathy with rhabdomyolysis.
   Methods: We performed detailed clinical, muscle histopathology and molecular studies including mitochondrial gene NGS analysis in two patients (Patient 1 and 2), a mother and her son, belonging to a Mexican family, and a third sporadic French patient.
   Results: Patient 1 and 2 presented with an early onsetmyopathy associated with ptosis, velopharyngeal weakness, and cardiac involvement. Patient 3 presented rhabdomyolysis unmasking amitochondrial disease characterized by a sensorineural hearing loss, ptosis, and lipomas. Muscle biopsies performed in all patients showed variable mitochondrial alterations. Patient 3 hadmultiplemtDNA deletion in hismuscle. Genetic studies revealed a novel heterozygous frameshift mutation in DNA2 gene (c.2346delT p.Phe782Leufs*3) in P1 and P2, and a novel heterozygous missense mutation in DNA2 gene (c.578T>C p.Leu193Ser) in the P3.
   Conclusions: To date only few AD cases presenting either missense or truncating DNA2 variants have been reported. None of them presented with a cardiac involvement or rhabdomyolysis. Here we enlarge the genetic and phenotypic spectrum of DNA2-related mitochondrial disorders.
C1 [Gonzalez-del Angel, Ariadna] Inst Nacl Pediat, Dept Genet Humana, Lab Biol Mol, Mexico City, DF, Mexico.
   [Bisciglia, Michela; Romero, Norma B.; Stojkovic, Tanya] GHU La Pitie Saipetriere, AP HP, Inst Myol, Paris, France.
   [Vargas-Canas, Steven; Fernandez-Valverde, Francisca; Romero, Norma B.] Inst Nacl Neurol & Neurochirurg, Mexico City, DF, Mexico.
   [Vargas-Canas, Steven; Fernandez-Valverde, Francisca; Romero, Norma B.] Inst Nacl Neurol & Neurocirug, Lab Patol Expt, Mexico City, DF, Mexico.
   [Kazakova, Ekaterina; Romero, Norma B.] Cedimemm Ctr Diagnost Metab Energet & Med Mitocon, Mexico City, DF, Mexico.
   [Elena Escobar, Rosa; Romero, Norma B.] INR, Unit Muscle Dystrophies, Mexico City, DF, Mexico.
   [Romero, Norma B.] Sorbonne Univ, Ctr Reference Malad Neuromusculaires Nord Est Ile, Ctr Rech, GHU Pitie Salpetriere,INSERM, Paris, France.
   [Jarder, Claude; Rucheton, Benoit] GHU Pitie Salpetriere, AP HP, UF Cardiogenet & Myogenet, Serv Biochim Metabol, Paris, France.
   [Malfatti, Edoardo] CHU Raymond Poincare, Ctr Reference Malad Neuromusculaire Paris Nord, Serv Neurol Med, Garches, France.
   [Malfatti, Edoardo] Univ Versailles St Quentin En Yvelines, UFR Sci Sante Simone Veil, Handicap Neuromusculaire Physiol Biotherapie & Ph, UVSQ,INSERM,U1179, Versailles, France.
C3 Assistance Publique Hopitaux Paris (APHP); Sorbonne Universite;
   Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Pitie-Salpetriere - APHP; Sorbonne Universite; Institut National de la
   Sante et de la Recherche Medicale (Inserm); Sorbonne Universite;
   Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Pitie-Salpetriere - APHP; Assistance Publique Hopitaux Paris (APHP);
   Hopital Universitaire Raymond-Poincare - APHP; Universite Paris Saclay;
   Universite Paris Cite; Institut National de la Sante et de la Recherche
   Medicale (Inserm)
RP Malfatti, E (corresponding author), CHU Raymond Poincare, Ctr Reference Malad Neuromusculaire Paris Nord, Serv Neurol Med, Garches, France.; Malfatti, E (corresponding author), Univ Versailles St Quentin En Yvelines, UFR Sci Sante Simone Veil, Handicap Neuromusculaire Physiol Biotherapie & Ph, UVSQ,INSERM,U1179, Versailles, France.
EM edoardo.malfatti@gmail.com
RI ESCOBAR, ROSA/AAR-4507-2021; Malfatti, Edoardo/KEI-9379-2024; Angel,
   Ariadna/ABA-5719-2020; STOJKOVIC, Tanya/AAA-3967-2021
CR Ahmed N, 2015, INT J MOL SCI, V16, P18054, DOI 10.3390/ijms160818054
   Andalib S, 2017, EXPERT REV MOL MED, V19, DOI 10.1017/erm.2017.5
   Baker SK, 2008, CAN J NEUROL SCI, V35, P94, DOI 10.1017/S0317167100007630
   Budd ME, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004267
   Buja LM, 2013, TEX HEART I J, V40, P221
   Chae JH, 2015, J MED GENET, V52, P208, DOI 10.1136/jmedgenet-2014-102819
   Ding L, 2015, INT J MOL SCI, V16, P10870, DOI 10.3390/ijms160510870
   Duxin JP, 2009, MOL CELL BIOL, V29, P4274, DOI 10.1128/MCB.01834-08
   Fratter C, 2010, NEUROLOGY, V74, P1619, DOI 10.1212/WNL.0b013e3181df099f
   Hirano M, 2001, CURR OPIN CARDIOL, V16, P201, DOI 10.1097/00001573-200105000-00008
   Khetarpal P, 2016, MOL GENET GENOMICS, V291, P1, DOI 10.1007/s00438-015-1110-y
   Mohassel P, 2013, CURR OPIN RHEUMATOL, V25, P747, DOI 10.1097/01.bor.0000434673.85515.89
   Phowthongkum P, 2017, NEUROMUSCULAR DISORD, V27, P616, DOI 10.1016/j.nmd.2017.03.013
   Ronchi D, 2013, AM J HUM GENET, V92, P293, DOI 10.1016/j.ajhg.2012.12.014
   Spiegel R, 2016, J MED GENET, V53, P127, DOI 10.1136/jmedgenet-2015-103361
   Stöllberger C, 2019, EXPERT REV CARDIOVAS, V17, P95, DOI 10.1080/14779072.2019.1561280
   Stringer HAJ, 2013, J NEUROL SCI, V325, P142, DOI 10.1016/j.jns.2012.12.023
   Ye L, 1997, AM J MED GENET, V68, P494, DOI 10.1002/(SICI)1096-8628(19970211)68:4<494::AID-AJMG30>3.0.CO;2-L
   Zheng L, 2008, MOL CELL, V32, P325, DOI 10.1016/j.molcel.2008.09.024
NR 19
TC 7
Z9 7
U1 0
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-2295
J9 FRONT NEUROL
JI Front. Neurol.
PD OCT 4
PY 2019
VL 10
AR 1049
DI 10.3389/fneur.2019.01049
PG 7
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA JO5ZZ
UT WOS:000497657800001
PM 31636600
OA gold, Green Published
DA 2024-11-01
ER

PT J
AU Cha, JH
   Lee, SH
   Yun, Y
   Choi, WH
   Koo, H
   Jung, SH
   Chae, HB
   Lee, DH
   Lee, SJ
   Jo, DH
   Kim, JH
   Song, JJ
   Chae, JH
   Lee, JH
   Park, J
   Kang, JY
   Bae, S
   Lee, SY
AF Cha, Ju Hyuen
   Lee, Seok-Hoon
   Yun, Yejin
   Choi, Won Hoon
   Koo, Hansol
   Jung, Sung Ho
   Chae, Ho Byung
   Lee, Dae Hee
   Lee, Seok Jae
   Jo, Dong Hyun
   Kim, Jeong Hun
   Song, Jae-Jin
   Chae, Jong-Hee
   Lee, Jun Ho
   Park, Jiho
   Kang, Jin Young
   Bae, Sangsu
   Lee, Sang-Yeon
TI Discovery of novel disease-causing mutation in <i>SSBP1 </i>and its
   correction using adenine base editor to improve mitochondrial function
SO MOLECULAR THERAPY NUCLEIC ACIDS
LA English
DT Article
ID MOBILITY SHIFT ASSAY; GENOMIC DNA; REPLICATION; PROTEIN; MODEL
AB Mutations in nuclear genes regulating mitochondrial DNA (mtDNA) replication are associated with mtDNA depletion syndromes. Using whole-genome sequencing, we identified fi ed a heterozygous mutation (c.272G>A:p.Arg91Gln) in single-stranded DNA-binding protein 1 (SSBP1), a crucial protein involved in mtDNA replisome. The proband manifested symptoms including sensorineural deafness, congenital cataract, optic atrophy, macular dystrophy, and myopathy. This mutation impeded multimer formation and DNA-binding affinity, leading to reduced efficiency of mtDNA replication, altered mitochondria dynamics, and compromised mitochondrial function. To correct this mutation, we tested two adenine base editor (ABE) variants on patient-derived fi broblasts. One variant, NG-Cas9-based ABE8e (NG-ABE8e), showed higher editing efficacy (<= 30%) and enhanced mitochondrial replication and function, despite off-target editing frequencies; however, risks from bystander editing were limited due to silent mutations and off-target sites in non-translated regions. The other variant, NG-Cas9-based ABE8eWQ (NG-ABE8eWQ), had a safer therapeutic profile with very few off-target effects, but this came at the cost of lower editing efficacy (<= 10% editing). Despite this, NG-ABE8eWQedited cells still restored replication and improved mtDNA copy number, which in turn recovery of compromised mitochondrial function. Taken together, base editing-based gene therapies may be a promising treatment for mitochondrial diseases, including those associated with SSBP1 mutations.
C1 [Cha, Ju Hyuen; Lee, Seok-Hoon; Yun, Yejin; Choi, Won Hoon; Jung, Sung Ho; Chae, Ho Byung; Lee, Jun Ho; Park, Jiho; Kang, Jin Young; Bae, Sangsu; Lee, Sang-Yeon] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Dept Otorhinolaryngol, Seoul, South Korea.
   [Lee, Seok-Hoon; Bae, Sangsu; Lee, Sang-Yeon] Seoul Natl Univ, Coll Med, Dept Biomed Sci, Seoul, South Korea.
   [Cha, Ju Hyuen; Lee, Seok-Hoon; Yun, Yejin; Choi, Won Hoon; Koo, Hansol; Bae, Sangsu] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea.
   [Lee, Dae Hee] CTCELLS Inc, Daejeon, South Korea.
   [Lee, Seok Jae; Kim, Jeong Hun] Seoul Natl Univ Hosp, Clin Res Inst, Fight Angiogenesis Related Blindness FARB Lab, Seoul, South Korea.
   [Lee, Seok Jae; Kim, Jeong Hun] Seoul Natl Univ, Coll Med, Dept Ophthalmol, Seoul, South Korea.
   [Jo, Dong Hyun] Seoul Natl Univ, Coll Med, Dept Anat & Cell Biol, Seoul, South Korea.
   [Song, Jae-Jin] Seoul Natl Univ, Bundang Hosp, Coll Med, Dept Otorhinolaryngol, Seongnam, South Korea.
   [Chae, Jong-Hee; Lee, Sang-Yeon] Seoul Natl Univ Hosp, Dept Genom Med, Seoul, South Korea.
   [Park, Jiho; Kang, Jin Young] Korea Adv Inst Sci & Technol, Dept Chem, Daejeon 34141, South Korea.
   [Bae, Sangsu] Seoul Natl Univ, Coll Med, Med Res Ctr, Genom Med Inst, Seoul, South Korea.
   [Lee, Sang-Yeon] Seoul Natl Univ, Med Res Ctr, Sensory Organ Res Inst, Seoul, South Korea.
C3 Seoul National University (SNU); Seoul National University Hospital;
   Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University (SNU); Seoul National University Hospital; Seoul
   National University (SNU); Seoul National University (SNU); Seoul
   National University (SNU); Seoul National University (SNU); Seoul
   National University Hospital; Korea Advanced Institute of Science &
   Technology (KAIST); Seoul National University (SNU); Seoul National
   University (SNU)
RP Bae, S; Lee, SY (corresponding author), Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Dept Otorhinolaryngol, Seoul, South Korea.; Bae, S; Lee, SY (corresponding author), Seoul Natl Univ, Coll Med, Dept Biomed Sci, Seoul, South Korea.
EM sbae7@snu.ac.kr; maru4843@hanmail.net
RI Song, Jae-Jin/E-4633-2017; Lee, Dae/D-4573-2011; Choi, Won
   Hoon/ABE-5678-2021; Lee, Seok Jae/KLE-1491-2024; Jung, Sung
   Ho/ABD-1742-2021; Jo, Dong Hyun/HNP-8820-2023
OI Lee, Seok-Hoon/0000-0002-7923-0030
FU National Research Foundation (NRF) of Korea [2022R1C1C1003147,
   2021M3A9H3015389, SRC-NRF2022R1A5A102641311]; Korean Fund for
   Regenerative Medicine (KFRM) [RS-2024-00332601]; SNUH Kun-hee Lee Child
   Cancer & Rare Disease Project [FP-2022-00001-004]; SNU Medicine grant
   [800-20230428]; KAIST UP Program
FX This work was supported by the National Research Foundation (NRF) of
   Korea [No. 2022R1C1C1003147 to S.-Y.L., No. 2021M3A9H3015389,
   SRC-NRF2022R1A5A102641311 to S.B.] , by the Korean Fund for Regenerative
   Medicine (KFRM) No. RS-2024-00332601 to S.B., and funded by SNUH Kun-hee
   Lee Child Cancer & Rare Disease Project No. FP-2022-00001-004 to S.-Y.L.
   and by an SNU Medicine grant (basic and clinic cooperation research
   grant No. 800-20230428) to S.-Y.L., and funded by the KAIST UP Program
   to J.Y.K.
CR Amorim JA, 2022, NAT REV ENDOCRINOL, V18, P243, DOI 10.1038/s41574-021-00626-7
   Bae S, 2014, BIOINFORMATICS, V30, P1473, DOI 10.1093/bioinformatics/btu048
   Bolender N, 2008, EMBO REP, V9, P42, DOI 10.1038/sj.embor.7401126
   Capps GJ, 2003, J THEOR BIOL, V221, P565, DOI 10.1006/jtbi.2003.3207
   Chaudhry A, 2020, AM J PHYSIOL-ENDOC M, V318, pE87, DOI 10.1152/ajpendo.00457.2019
   DeBalsi KL, 2017, AGEING RES REV, V33, P89, DOI 10.1016/j.arr.2016.04.006
   Del Dotto V, 2020, J CLIN INVEST, V130, P108, DOI 10.1172/JCI128514
   Dunbar CE, 2018, SCIENCE, V359, P175, DOI 10.1126/science.aan4672
   El-Hattab AW, 2017, BBA-MOL BASIS DIS, V1863, P1539, DOI 10.1016/j.bbadis.2017.02.017
   Eustaquio T, 2018, EXP CELL RES, V373, P164, DOI 10.1016/j.yexcr.2018.10.009
   Gaudelli NM, 2017, NATURE, V551, P464, DOI 10.1038/nature24644
   Gupta R, 2023, NATURE, V620, DOI 10.1038/s41586-023-06426-5
   Gustafson MA, 2021, DNA REPAIR, V107, DOI 10.1016/j.dnarep.2021.103212
   Gustafson MA, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221829
   Haapaniemi E, 2018, NAT MED, V24, P927, DOI 10.1038/s41591-018-0049-z
   Han KH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161756
   Hellman LM, 2007, NAT PROTOC, V2, P1849, DOI 10.1038/nprot.2007.249
   Hwang GH, 2021, METHODS MOL BIOL, V2162, P23, DOI 10.1007/978-1-0716-0687-2_2
   Hwang GH, 2018, BMC BIOINFORMATICS, V19, DOI 10.1186/s12859-018-2585-4
   Jeong YK, 2021, NAT BIOTECHNOL, V39, P1426, DOI 10.1038/s41587-021-00943-2
   Jiang LY, 2023, MOL THER, V31, P934, DOI 10.1016/j.ymthe.2023.02.001
   Jiang M, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abf8631
   Jo DH, 2023, MOL THER-NUCL ACIDS, V31, P16, DOI 10.1016/j.omtn.2022.11.021
   Kim HS, 2019, NAT BIOTECHNOL, V37, P1145, DOI 10.1038/s41587-019-0254-4
   Kim N, 2024, NAT BIOTECHNOL, V42, DOI 10.1038/s41587-023-01792-x
   Kingwell K, 2022, NAT REV DRUG DISCOV, V21, P545, DOI 10.1038/d41573-022-00124-z
   Komor AC, 2017, CELL, V168, P20, DOI 10.1016/j.cell.2016.10.044
   Komor AC, 2016, NATURE, V533, P420, DOI 10.1038/nature17946
   Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257
   Kosicki M, 2018, NAT BIOTECHNOL, V36, P765, DOI 10.1038/nbt.4192
   Kullar PJ, 2018, BRAIN, V141, P55, DOI 10.1093/brain/awx295
   Kurt IC, 2021, NAT BIOTECHNOL, V39, P41, DOI 10.1038/s41587-020-0609-x
   Lee SY, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10090672
   Liu HT, 2008, BMC BIOTECHNOL, V8, DOI 10.1186/1472-6750-8-91
   Novotny MV, 2023, bioRxiv, DOI [10.1101/2023.07.28.551015, 10.1101/2023.07.28.551015, DOI 10.1101/2023.07.28.551015]
   O'Sullivan JDB, 2023, HEARING RES, V428, DOI 10.1016/j.heares.2022.108660
   Piro-Mégy C, 2020, J CLIN INVEST, V130, P143, DOI 10.1172/JCI128513
   Pla-Martin D, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008140
   Ream JA, 2016, ANAL BIOCHEM, V511, P36, DOI 10.1016/j.ab.2016.07.027
   Rees HA, 2018, NAT REV GENET, V19, P770, DOI 10.1038/s41576-018-0059-1
   Reyes A, 2015, AM J HUM GENET, V97, P186, DOI 10.1016/j.ajhg.2015.05.013
   Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30
   Richter MF, 2020, NAT BIOTECHNOL, V38, P883, DOI 10.1038/s41587-020-0453-z
   Rusecka J, 2018, J APPL GENET, V59, P43, DOI 10.1007/s13353-017-0424-3
   Russell OM, 2020, CELL, V181, P168, DOI 10.1016/j.cell.2020.02.051
   Sabouny R, 2021, J CELL SCI, V134, DOI 10.1242/jcs.258944
   Scheibye-Knudsen M, 2015, TRENDS CELL BIOL, V25, P158, DOI 10.1016/j.tcb.2014.11.002
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/nmeth.2019, 10.1038/NMETH.2019]
   Shalem O, 2015, NAT REV GENET, V16, P299, DOI 10.1038/nrg3899
   Srivastava S, 2019, METABOLITES, V9, DOI 10.3390/metabo9120301
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Tong HW, 2023, NAT BIOTECHNOL, V41, P1080, DOI 10.1038/s41587-022-01595-6
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
   Vangipuram M, 2013, JOVE-J VIS EXP, DOI 10.3791/3779
   Viscomi C, 2017, J INHERIT METAB DIS, V40, P587, DOI 10.1007/s10545-017-0027-5
   Wanrooij S, 2010, BBA-BIOENERGETICS, V1797, P1378, DOI 10.1016/j.bbabio.2010.04.015
   Wojtaszek JL, 2023, NUCLEIC ACIDS RES, V51, P9716, DOI 10.1093/nar/gkad679
   Yang C, 1997, NAT STRUCT BIOL, V4, P153, DOI 10.1038/nsb0297-153
   Zuccaro MV, 2020, CELL, V183, P1650, DOI 10.1016/j.cell.2020.10.025
NR 59
TC 0
Z9 0
U1 5
U2 5
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2162-2531
J9 MOL THER NUCL ACIDS
JI Mol. Ther. Nucl. Acids
PD SEP 10
PY 2024
VL 35
IS 3
AR 102257
DI 10.1016/j.omtn.2024.102257
EA JUL 2024
PG 15
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA YH4K7
UT WOS:001267582500001
PM 39104869
OA gold, Green Published
DA 2024-11-01
ER

PT S
AU Körver-Keularts, IMLW
   de Visser, M
   Bakker, HD
   Wanders, RJA
   Vansenne, F
   Scholte, HR
   Dorland, L
   Nicolaes, GAF
   Spaapen, LMJ
   Smeets, HJM
   Hendrickx, ATM
   van den Bosch, BJC
AF Korver-Keularts, I. M. L. W.
   de Visser, M.
   Bakker, H. D.
   Wanders, R. J. A.
   Vansenne, F.
   Scholte, H. R.
   Dorland, L.
   Nicolaes, G. A. F.
   Spaapen, L. M. J.
   Smeets, H. J. M.
   Hendrickx, A. T. M.
   van den Bosch, B. J. C.
BE Zschocke, J
   Baumgartner, M
   Morava, E
   Patterson, M
   Rahman, S
   Peters, V
TI Two Novel Mutations in the <i>SLC25A4</i> Gene in a Patient with
   Mitochondrial Myopathy
SO JIMD REPORTS, VOL 22
SE JIMD Reports
LA English
DT Article; Book Chapter
ID ADENINE-NUCLEOTIDE TRANSLOCATOR; PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA;
   ADP/ATP CARRIER; MUSCLE; CARDIOMYOPATHY; DEFICIENCY; EXPRESSION; ATP;
   DNA; SEQUENCES
AB In a 28-year-old male with a mild mitochondrial myopathy manifesting as exercise intolerance and early signs of cardiomyopathy without muscle weakness or ophthalmoplegia, we identified two novel mutations in the SLC25A4 gene: c.707G>C in exon 3 (p.(R236P)) and c.116_137del in exon 2 (p.(Q39Lfs*14)). Serum lactate levels at rest were elevated (12.7 mM). Both the patient's father and brother were heterozygous carriers of the c.707G>C mutation and were asymptomatic. The second mutation causes a 22 bp deletion leading to a frame shift likely giving rise to a premature stop codon and nonwsense-mediated decay (NMD). The segregation of the mutations could not be tested directly as the mother had died before. However, indirect evidence from NMD experiments showed that the two mutations were situated on two different alleles in the patient. This case is unique compared to other previously reported patients with either progressive external ophthalmoplegia (PEO) or clear hypertrophic cardiomyopathy with exercise intolerance and/or muscle weakness carrying recessive mutations leading to a complete absence of the SLC25A4 protein. Most likely in our patient, although severely reduced, SLC25A4 is still partially present and functional.
C1 [Korver-Keularts, I. M. L. W.; Dorland, L.; Spaapen, L. M. J.] Maastricht Univ, Med Ctr, Lab Biochem Genet, Dept Clin Genet, NL-6200 MD Maastricht, Netherlands.
   [de Visser, M.] Univ Amsterdam, Acad Med Ctr, Dept Neurol, NL-1105 AZ Amsterdam, Netherlands.
   [Bakker, H. D.] Univ Amsterdam, Acad Med Ctr, Dept Paediat, NL-1105 AZ Amsterdam, Netherlands.
   [Wanders, R. J. A.] Univ Amsterdam, Acad Med Ctr, Lab Genet Metab Dis, NL-1105 AZ Amsterdam, Netherlands.
   [Vansenne, F.] Univ Amsterdam, Acad Med Ctr, Dept Clin Genet, NL-1105 AZ Amsterdam, Netherlands.
   [Scholte, H. R.] Erasmus MC, Dept Neurosci, Rotterdam, Netherlands.
   [Nicolaes, G. A. F.] Maastricht Univ, Dept Biochem, Cardiovasc Res Inst Maastricht, NL-6200 MD Maastricht, Netherlands.
   [Smeets, H. J. M.; Hendrickx, A. T. M.; van den Bosch, B. J. C.] Maastricht Univ, Med Ctr, Dept Clin Genet, Unit Clin Genom, NL-6200 MD Maastricht, Netherlands.
C3 Maastricht University; University of Amsterdam; Academic Medical Center
   Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam;
   University of Amsterdam; Academic Medical Center Amsterdam; Vrije
   Universiteit Amsterdam; University of Amsterdam; Academic Medical Center
   Amsterdam; Erasmus University Rotterdam; Erasmus MC; Maastricht
   University; Maastricht University
RP Körver-Keularts, IMLW (corresponding author), Maastricht Univ, Med Ctr, Lab Biochem Genet, Dept Clin Genet, NL-6200 MD Maastricht, Netherlands.
EM irene.keularts@mumc.nl
RI Vansenne, Fleur/GRS-5151-2022; Nicolaes, Gerry/A-8421-2016
OI Nicolaes, Gerry/0000-0002-2482-0412; Vansenne, Fleur/0000-0002-0156-3417
CR ADRIAN GS, 1986, MOL CELL BIOL, V6, P626, DOI 10.1128/MCB.6.2.626
   Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534
   BAKKER HD, 1993, J INHERIT METAB DIS, V16, P548, DOI 10.1007/BF00711678
   BAKKER HD, 1993, PEDIATR RES, V33, P412
   COZENS AL, 1989, J MOL BIOL, V206, P261, DOI 10.1016/0022-2836(89)90477-4
   Deschauer M, 2005, NEUROMUSCULAR DISORD, V15, P311, DOI 10.1016/j.nmd.2004.12.004
   Dolce V, 2005, FEBS LETT, V579, P633, DOI 10.1016/j.febslet.2004.12.034
   Echaniz-Laguna A, 2012, J MED GENET, V49, P146, DOI 10.1136/jmedgenet-2011-100504
   Fiore C, 1998, BIOCHIMIE, V80, P137, DOI 10.1016/S0300-9084(98)80020-5
   Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226
   Heidkamper D, 1996, BIOCHEMISTRY-US, V35, P16144, DOI 10.1021/bi960668j
   HOULDSWORTH J, 1988, P NATL ACAD SCI USA, V85, P377, DOI 10.1073/pnas.85.2.377
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   KLINGENBERG M, 1981, NATURE, V290, P449, DOI 10.1038/290449a0
   KLINGENBERG M, 1989, ARCH BIOCHEM BIOPHYS, V270, P1, DOI 10.1016/0003-9861(89)90001-5
   Komaki H, 2002, ANN NEUROL, V51, P645, DOI 10.1002/ana.10172
   KU DH, 1990, J BIOL CHEM, V265, P16060
   LI K, 1989, J BIOL CHEM, V264, P13998
   Napoli L, 2001, NEUROLOGY, V57, P2295, DOI 10.1212/WNL.57.12.2295
   Narula N, 2011, JACC-CARDIOVASC IMAG, V4, P1, DOI 10.1016/j.jcmg.2010.06.018
   NECKELMANN N, 1987, P NATL ACAD SCI USA, V84, P7580, DOI 10.1073/pnas.84.21.7580
   NELSON DR, 1993, J MOL BIOL, V230, P1159, DOI 10.1006/jmbi.1993.1233
   Palmieri L, 2005, HUM MOL GENET, V14, P3079, DOI 10.1093/hmg/ddi341
   Pebay-Peyroula E, 2003, NATURE, V426, P39, DOI 10.1038/nature02056
   STEPIEN G, 1992, J BIOL CHEM, V267, P14592
NR 25
TC 23
Z9 25
U1 0
U2 0
PU SPRINGER-VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
SN 2192-8304
BN 978-3-662-47453-2; 978-3-662-47452-5
J9 JIMD REP
PY 2015
VL 22
BP 39
EP 45
DI 10.1007/8904_2015_409
D2 10.1007/978-3-662-47453-2
PG 7
WC Endocrinology & Metabolism; Genetics & Heredity
WE Book Citation Index – Science (BKCI-S)
SC Endocrinology & Metabolism; Genetics & Heredity
GA BE8SO
UT WOS:000376987200006
PM 25732997
OA Green Published
DA 2024-11-01
ER

PT J
AU Mancuso, M
   Ferraris, S
   Nishigaki, Y
   Azan, G
   Mauro, A
   Sammarco, P
   Krishna, S
   Tay, SKH
   Bonilla, E
   Romansky, SG
   Hirano, M
   DiMauro, S
AF Mancuso, M
   Ferraris, S
   Nishigaki, Y
   Azan, G
   Mauro, A
   Sammarco, P
   Krishna, S
   Tay, SKH
   Bonilla, E
   Romansky, SG
   Hirano, M
   DiMauro, S
TI Congenital or late-onset myopathy in patients with the T14709C mtDNA
   mutation
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE mitochondrial myopathy; diabetes mellitus; maternal inheritance; mtDNA
ID MITOCHONDRIAL-DNA MUTATIONS; DIABETES-MELLITUS
AB Three patients with different clinical phenotypes harbored the same point mutation at nucleotide 14109 (T14709C) in the tRNA(Gto) of mitochondrial DNA (mtDNA). The first patient was a 21-month-old child with severe congenital myopathy. respiratory distress and mild mental retardation. Muscle biopsy showed about 12% cytochrome c oxidase (COX)-negative ragged-red fibers (RRFs), and markedly decreased activities of mitochondrial respiratory chain complexes I, III and IV The other two patients were 51- and 55-year-old siblings with slowly progressive myopathy and diabetes mellitus. Muscle biopsy showed focal COX-negative RRFs and decreased activities of complexes I, III and IV. In all three patients, the T14709C mutation was abundant in muscle but present at lower levels in accessible tissues. Previously described patients with the same mutation also showed congenital or late-onset myopathy Diabetes is frequently associated with both phenotypes and is a clinical clue to the molecular diagnosis. (C) 2004 Elsevier B.V. All rights reserved.
C1 Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY 10003 USA.
   Ist Auxol Italiano, Div Neurol, Verbania, Italy.
   Osped V Cervello, Palermo, Italy.
   Long Beach Mem Med Ctr, Long Beach, CA 90801 USA.
C3 Columbia University; IRCCS Istituto Auxologico Italiano
RP Columbia Univ, Coll Phys & Surg, Dept Neurol, 4-420,630 W 168th St, New York, NY 10003 USA.
EM sd12@columbia.edu
RI ; tay, stacey/E-7029-2015
OI Mauro, Alessandro/0000-0001-9072-7454; tay, stacey/0000-0002-3077-4184
FU NICHD NIH HHS [HD32062] Funding Source: Medline; NINDS NIH HHS [NS11766]
   Funding Source: Medline
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11
   BONILLA E, 1992, BRAIN PATHOL, V2, P113, DOI 10.1111/j.1750-3639.1992.tb00679.x
   Carelli V., 2002, MITOCHONDRIAL DISORD, P115
   Damore ME, 1999, J PEDIATR ENDOCR MET, V12, P207
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   DIMAURO S, 2003, GENEREVIEWS GENE TES
   HANNA MG, 1995, AM J HUM GENET, V56, P1026
   HOA H, 1995, AM J HUM GENET, V56, P1017
   Kameoka K, 1998, BIOCHEM BIOPH RES CO, V245, P523, DOI 10.1006/bbrc.1998.8437
   McFarland R, 2004, ANN NEUROL, V55, P478, DOI 10.1002/ana.20004
   MORAES CT, 1993, J CLIN INVEST, V92, P2906, DOI 10.1172/JCI116913
   Schon E.A., 2002, Mitochondrial Disorders in Neurology, V2, P69
   Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755
   Vialettes BH, 1997, DIABETES CARE, V20, P1731, DOI 10.2337/diacare.20.11.1731
NR 15
TC 13
Z9 13
U1 0
U2 0
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 1878-5883
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD JAN 15
PY 2005
VL 228
IS 1
BP 93
EP 97
DI 10.1016/j.jns.2004.10.018
PG 5
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 889JJ
UT WOS:000226439000016
PM 15607216
DA 2024-11-01
ER

PT J
AU Sarnat, HB
   Flores-Sarnat, L
   Casey, R
   Scott, P
   Khan, A
AF Sarnat, Harvey B.
   Flores-Sarnat, Laura
   Casey, Robin
   Scott, Patrick
   Khan, Aneal
TI Endothelial ultrastructural alterations of intramuscular capillaries in
   infantile mitochondrial cytopathies: "Mitochondrial angiopathy"
SO NEUROPATHOLOGY
LA English
DT Article
DE electron microscopy; endoplasmic reticulum; endothelium; microvilli;
   mitochondrial cytopathy; paracrystallin structures
ID CENTRAL-NERVOUS-SYSTEM; ELECTRON-MICROSCOPY; DISORDERS;
   ENCEPHALOMYOPATHY; MYOPATHY; MUSCLE; BRAIN; ENCEPHALOPATHY; DIAGNOSIS;
   PATHOLOGY
AB Electron microscopy (EM) is a reliable method for diagnosing mitochondrial diseases in striated muscle biopsy in infancy. Ultrastructural alterations in mitochondria of myofibers are well documented, but there are few studies of endothelial involvement in intramuscular capillaries. Quadriceps femoris biopsies of five representative infants and toddlers, ages neonate to 3.5 years, were performed because of clinical and laboratory data consistent with mitochondrial disease without mitochondrial DNA (mtDNA) mutations and likely with nuclear DNA mutations. Pathological studies included histochemistry, EM, respiratory chain enzymatic assay and mtDNA sequencing and deletion/duplication analysis. EM demonstrated frequent and severe alterations of mitochondria in capillary endothelium. The most constant changes included: either too few or fragmented cristae; stacked and whorled cristae; paracrystallin structures that often were large and spheroid with stress fractures; closely apposed membranes of granular endoplasmic reticulum surrounding mitochondria with loss of the normal intervening layer of cytoplasm; long narrow, thin looped microvilli extending into the lumen; and thick microvilli containing large, abnormal mitochondria. We conclude that mitochondrial cytopathies in early life exhibit more severe ultrastructural alterations in the endothelium than in myofibers and that paracrystallin body structure differs, perhaps due to less rigid surrounding structures. This distribution may explain the frequent lack of prominent histochemical and biochemical abnormalities in muscle biopsies of young patients. Endothelial changes do not distinguish the genetic defects. Vascular involvement in brain contributes to cerebral lesions and neuronal death by impairment of molecular and nutrient transport and ischemia; endothelium in muscle may reflect similar changes.
C1 [Sarnat, Harvey B.; Flores-Sarnat, Laura; Khan, Aneal] Univ Calgary, Fac Med, Dept Paediat, Edmonton, AB, Canada.
   [Sarnat, Harvey B.] Univ Calgary, Fac Med, Dept Pathol & Lab Med Neuropathol, Edmonton, AB, Canada.
   [Sarnat, Harvey B.; Flores-Sarnat, Laura] Univ Calgary, Fac Med, Dept Clin Neurosci, Edmonton, AB, Canada.
   [Casey, Robin; Khan, Aneal] Univ Calgary, Fac Med, Dept Med Genet, Edmonton, AB, Canada.
   [Sarnat, Harvey B.] Alberta Childrens Prov Gen Hosp, Edmonton, AB, Canada.
   [Scott, Patrick] Univ Alberta, Dept Med Genet, Edmonton, AB, Canada.
C3 University of Calgary; University of Calgary; University of Calgary;
   University of Calgary; Alberta Childrens Hospital; University of
   Calgary; University of Alberta
RP Sarnat, HB (corresponding author), Alberta Childrens Prov Gen Hosp, Dept Pathol & Lab Med, 2888 Shaganappi Trail NW, Calgary, AB T3B 6A8, Canada.
EM harvey.sarnat@albertahealthservices.ca
RI Khan, Aneal/W-2019-2018
OI scott, patrick/0000-0002-4917-8171
CR Agamanolis DP, 2005, FDN DIAGNOSTIC PATHO, P385
   ASMUSSEN I, 1984, ATHEROSCLEROSIS, V50, P203, DOI 10.1016/0021-9150(84)90023-6
   Bauserman SC, 1984, CONT ISSUES SURG PAT, V3, P109
   Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   Carpenter S, 2001, PATHOLOGY SKELETAL M, P453
   Castejón OJ, 2011, FOLIA NEUROPATHOL, V49, P162
   Chinnery PF, 2008, GREENFIELDS NEUROPAT, P601
   COQUET M, 1990, ANN PATHOL, V10, P181
   DIAS MJM, 1984, NEUROPEDIATRICS, V15, P18, DOI 10.1055/s-2008-1052334
   Dubowitz V, 2007, MUSCLE BIOPSY PRACTI, P169
   HAMMERSEN F, 1982, INT J MICROCIRC, V1, P135
   Hays AP., 2006, Mitochondrial Medicine, P45
   Hilton-Jones D, 1995, MAJOR PROBLEMS NEURO, V29, P136
   Hunter MF, 2011, PEDIATR NEUROL, V45, P311, DOI 10.1016/j.pediatrneurol.2011.07.008
   KARIMU AL, 1995, PLACENTA, V16, P93, DOI 10.1016/0143-4004(95)90085-3
   Kaufman RJ, 2002, NAT REV MOL CELL BIO, V3, P411, DOI 10.1038/nrm829
   Lindl KA, 2007, NEUROPATH APPL NEURO, V33, P658, DOI 10.1111/j.1365-2990.2007.00866.x
   Marín-García J, 2003, PEDIATR NEUROL, V29, P26, DOI 10.1016/S0887-8994(03)00013-4
   Mierau GW, 2004, PEDIATR DEVEL PATHOL, V7, P637, DOI 10.1007/s10024-004-5048-z
   MIZUKAMI K, 1992, ACTA NEUROPATHOL, V83, P449, DOI 10.1007/BF00713541
   MOLNAR M, 1995, NEUROPATH APPL NEURO, V21, P432, DOI 10.1111/j.1365-2990.1995.tb01080.x
   OHAMA E, 1987, ACTA NEUROPATHOL, V74, P226, DOI 10.1007/BF00688185
   OLDENDORF WH, 1975, P SOC EXP BIOL MED, V149, P736
   Rodenburg RJT, 2011, J INHERIT METAB DIS, V34, P283, DOI 10.1007/s10545-010-9081-y
   Sarnat HB, 2005, CAN J NEUROL SCI, V32, P152, DOI 10.1017/S0317167100003929
   Sarnat HB, 1984, MUSCLE PATHOLOGY HIS, P76
   SATO W, 1994, AM HEART J, V128, P733, DOI 10.1016/0002-8703(94)90272-0
   SCHOCHET SS, 1981, INTRO DIAGNOSTIC ELE, P131
   SCHRODER JM, 1993, BRAIN PATHOL, V3, P177, DOI 10.1111/j.1750-3639.1993.tb00742.x
   Selim L.A. M., 2009, Res. J. Med. Med. Sci, V4, P369
   Shoubridge EA., 2002, STRUCTURAL MOL BASIS, P202
   SMITH U, 1971, SCIENCE, V173, P925, DOI 10.1126/science.173.4000.925
   STADHOUDERS AM, 1981, MITOCHONDRIA MUSCULA, P113
   Sulbaran T. A., 2002, Journal of Submicroscopic Cytology and Pathology, V34, P389
   Wada H, 1996, BRAIN DEV-JPN, V18, P263, DOI 10.1016/0387-7604(96)00017-4
NR 35
TC 16
Z9 17
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0919-6544
J9 NEUROPATHOLOGY
JI Neuropathology
PD DEC
PY 2012
VL 32
IS 6
BP 617
EP 627
DI 10.1111/j.1440-1789.2012.01308.x
PG 11
WC Clinical Neurology; Neurosciences; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pathology
GA 041JN
UT WOS:000311398200005
PM 23174091
DA 2024-11-01
ER

PT J
AU Hinttala, R
   Smeets, R
   Moilanen, JS
   Ugalde, C
   Uusimaa, J
   Smeitink, JAM
   Majamaa, K
AF Hinttala, R.
   Smeets, R.
   Moilanen, J. S.
   Ugalde, C.
   Uusimaa, J.
   Smeitink, J. A. M.
   Majamaa, K.
TI Analysis of mitochondrial DNA sequences in patients with isolated or
   combined oxidative phosphorylation system deficiency
SO JOURNAL OF MEDICAL GENETICS
LA English
DT Article
ID PHYLOGENETIC NETWORK; GENOME VARIATION; SELECTION; MUTATION; DISEASE;
   ERRORS
AB Background: Enzyme deficiencies of the oxidative phosphorylation ( OXPHOS) system may be caused by mutations in the mitochondrial DNA ( mtDNA) or in the nuclear DNA.
   Objective: To analyse the sequences of the mtDNA coding region in 25 patients with OXPHOS system deficiency to identify the underlying genetic defect.
   Results: Three novel non-synonymous substitutions in protein-coding genes, 4681T -> C in MT-ND2, 9891T -> C in MT-CO3 and 14122A -> G in MT-ND5, and one novel substitution in the 12S rRNA gene, 686A -> G, were found. The definitely pathogenic mutation 3460G -> A was identified in an 18-year-old woman who had severe isolated complex I deficiency and progressive myopathy.
   Conclusions: Bioinformatic analyses suggest a pathogenic role for the novel 4681T -> C substitution found in a boy with Leigh's disease. These results show that the clinical phenotype caused by the primary Leber's hereditary optic neuropathy mutation 3460G -> A is more variable than has been thought. In the remaining 23 patients, the role of mtDNA mutations as a cause of the OXPHOS system deficiency could be excluded. The deficiency in these children probably originates from mutations in the nuclear genes coding for respiratory enzyme subunits or assembly factors.
C1 Univ Turku, Dept Neurol, FIN-20014 Turku, Finland.
   Univ Oulu, Dept Neurol, Oulu, Finland.
   Univ Oulu, Dept Pediat, Oulu, Finland.
   Univ Nijmegen, Med Ctr, Dept Pediat, Ctr Mitochondrial Disorders, Nijmegen, Netherlands.
   Univ Tampere, Inst Med Technol, FIN-33101 Tampere, Finland.
C3 University of Turku; University of Oulu; University of Oulu; Radboud
   University Nijmegen; Tampere University
RP Majamaa, K (corresponding author), Univ Turku, Dept Neurol, FIN-20014 Turku, Finland.
EM kari.majamaa@utu.fi
RI Smeitink, Jan/C-1351-2013; Majamaa, Kari/A-1344-2012; Moilanen,
   Jukka/G-2604-2012; Ugalde, Cristina/P-7533-2016
OI Majamaa, Kari/0000-0002-9070-3791; Moilanen, Jukka/0000-0002-8041-3205;
   Ugalde, Cristina/0000-0002-9742-1877; Hinttala,
   Reetta/0000-0002-7642-4008
CR Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Bandelt HJ, 2005, BIOCHEM BIOPH RES CO, V333, P122, DOI 10.1016/j.bbrc.2005.04.055
   Bandelt HJ, 2001, INT J LEGAL MED, V115, P64, DOI 10.1007/s004140100228
   Coble MD, 2004, INT J LEGAL MED, V118, P137, DOI 10.1007/s00414-004-0427-6
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Esteitie N, 2005, ANN NEUROL, V58, P544, DOI 10.1002/ana.20570
   Finnilä S, 2001, AM J HUM GENET, V68, P1475, DOI 10.1086/320591
   Finnilä S, 2000, AM J HUM GENET, V66, P1017, DOI 10.1086/302802
   Grafakou O, 2003, J INHERIT METAB DIS, V26, P593, DOI 10.1023/A:1025960300710
   Herrnstadt C, 2003, AM J HUM GENET, V72, P1585, DOI 10.1086/375406
   Herrnstadt C, 2002, AM J HUM GENET, V70, P1152, DOI 10.1086/339933
   Howell N, 2003, AM J HUM GENET, V72, P1460, DOI 10.1086/375537
   Ingman M, 2000, NATURE, V408, P708, DOI 10.1038/35047064
   JOHNS DR, 1992, ARCH OPHTHALMOL-CHIC, V110, P1577, DOI 10.1001/archopht.1992.01080230077025
   Kivisild T, 2006, GENETICS, V172, P373, DOI 10.1534/genetics.105.043901
   Man PYW, 2002, J MED GENET, V39, P162, DOI 10.1136/jmg.39.3.162
   Meulemans A, 2004, EUR J PAEDIATR NEURO, V8, P299, DOI 10.1016/j.ejpn.2004.07.006
   Moilanen JS, 2003, MOL BIOL EVOL, V20, P1195, DOI 10.1093/molbev/msg121
   Ruiz-Pesini E, 2004, SCIENCE, V303, P223, DOI 10.1126/science.1088434
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063
   Tanaka M, 2004, GENOME RES, V14, P1832, DOI 10.1101/gr.2286304
   Ugalde C, 2003, ANN NEUROL, V54, P665, DOI 10.1002/ana.10734
   UGALDE C, 2006, IN PRESS MOL GENET M
   VAN SENUS A. H. C., 1963, DOC OPHTHALMOL, V17, P1
   Wong LJC, 2005, CLIN CHIM ACTA, V354, P1, DOI 10.1016/j.cccn.2004.11.003
   Zeviani M, 2004, BRAIN, V127, P2153, DOI 10.1093/brain/awh259
NR 27
TC 20
Z9 22
U1 0
U2 3
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-2593
EI 1468-6244
J9 J MED GENET
JI J. Med. Genet.
PD NOV
PY 2006
VL 43
IS 11
BP 881
EP 886
DI 10.1136/jmg.2006.042168
PG 6
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 101YW
UT WOS:000241778500008
PM 16738010
OA Green Published
DA 2024-11-01
ER

PT J
AU Thompson, K
   Majd, H
   Dallabona, C
   Reinson, K
   King, MS
   Alston, CL
   He, LP
   Lodi, T
   Jones, SA
   Fattal-Valevski, A
   Fraenkel, ND
   Saada, A
   Haham, A
   Isohanni, P
   Vara, R
   Barbosa, IA
   Simpson, MA
   Deshpande, C
   Puusepp, S
   Bonnen, PE
   Rodenburg, RJ
   Suomalainen, A
   Ounap, K
   Elpeleg, O
   Ferrero, I
   McFarland, R
   Kunji, ERS
   Taylor, RW
AF Thompson, Kyle
   Majd, Homa
   Dallabona, Christina
   Reinson, Karit
   King, Martin S.
   Alston, Charlotte L.
   He, Langping
   Lodi, Tiziana
   Jones, Simon A.
   Fattal-Valevski, Aviva
   Fraenkel, Nitay D.
   Saada, Ann
   Haham, Alon
   Isohanni, Pirjo
   Vara, Roshni
   Barbosa, Ines A.
   Simpson, Michael A.
   Deshpande, Charu
   Puusepp, Sanna
   Bonnen, Penelope E.
   Rodenburg, Richard J.
   Suomalainen, Anu
   Ounap, Katrin
   Elpeleg, Orly
   Ferrero, Ileana
   McFarland, Robert
   Kunji, Edmund R. S.
   Taylor, Robert W.
TI Recurrent De Novo Dominant Mutations in <i>SLC2SA4</i> Cause Severe
   Early-Onset Mitochondrial Disease and Loss of Mitochondrial DNA Copy
   Number
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID ADENINE-NUCLEOTIDE TRANSLOCATOR; ADP/ATP CARRIER; RESPIRATORY-CHAIN;
   FUNCTIONAL-CHARACTERIZATION; EXTERNAL OPHTHALMOPLEGIA;
   SACCHAROMYCES-CEREVISIAE; BACTERIAL EXPRESSION; GENE MUTATION; IN-VIVO;
   TRANSPORT
AB Mutations in SLC25A4 encoding the mitochondrial ADP/ATP carrier AAC1 are well-recognized causes of mitochondrial disease. Several heterozygous SLC25A4 mutations cause adult-onset autosomal-dominant progressive external ophthalmoplegia associated with multiple mitochondrial DNA deletions, whereas recessive SLC25A4 mutations cause childhood-onset mitochondrial myopathy and cardiomyopathy. Here, we describe the identification by whole-exome sequencing of seven probands harboring dominant, de novo SLC25A4 mutations. All affected individuals presented at birth, were ventilator dependent and, where tested, revealed severe combined mitochondria' respiratory chain deficiencies associated with a marked loss of mitochondria' DNA copy number in skeletal muscle. Strikingly, an identical c.239G>A (p.Arg80His) mutation was present in four of the seven subjects, and the other three case subjects harbored the same c.703C>G (p.Arg235Gly) mutation. Analysis of skeletal muscle revealed a marked decrease of AAC1 protein levels and loss of respiratory chain complexes containing mitochondria' DNA-encoded subunits. We show that both recombinant AAC1 mutant proteins are severely impaired in ADP/ATP transport, affecting most likely the substrate binding and mechanics of the carrier, respectively. This highly reduced capacity for transport probably affects mitochondria' DNA maintenance and in turn respiration, causing a severe energy crisis. The confirmation of the pathogenicity of these de novo SLC25A4 mutations highlights a third distinct clinical phenotype associated with mutation of this gene and demonstrates that early-onset mitochondria' disease can be caused by recurrent de novo mutations, which has significant implications for the application and analysis of whole-exome sequencing data in mitochondrial disease.
C1 [Thompson, Kyle; Alston, Charlotte L.; He, Langping; McFarland, Robert; Taylor, Robert W.] Newcastle Univ, Inst Neurosci, Wellcome Trust Ctr Mitochondrial Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Majd, Homa; King, Martin S.; Kunji, Edmund R. S.] MRC, Mitochondrial Biol Unit, Cambridge Biomed Campus,Wellcome Trust MRC Bldg, Cambridge CB2 0XY, England.
   [Dallabona, Christina; Lodi, Tiziana; Ferrero, Ileana] Univ Parma, Dept Life Sci, Parco Area Sci 11A, I-43124 Parma, Italy.
   [Reinson, Karit; Puusepp, Sanna; Ounap, Katrin] Univ Tartu, Dept Pediat, Inst Clin Med, EE-51014 Tartu, Estonia.
   [Reinson, Karit; Puusepp, Sanna; Ounap, Katrin] Tartu Univ Hosp, Dept Genet, United Labs, EE-51014 Tartu, Estonia.
   [Jones, Simon A.] Cent Manchester Univ Hosp NHS Fdn Trust, Manchester Ctr Genom Med, St Marys Hosp, Oxford Rd, Manchester M13 9WL, Lancs, England.
   [Fattal-Valevski, Aviva] Tel Aviv Univ, Sackler Fac Med, Paediat Neurol Unit, Dana Children Hosp,Tel Aviv Sourasky Med Ctr, IL-64239 Tel Aviv, Israel.
   [Fraenkel, Nitay D.] Alyn Hosp, Dept Resp Rehabil, IL-91090 Jerusalem, Israel.
   [Saada, Ann] Hadassah Hebrew Univ, Med Ctr, Metab Lab Dept Genet & Metab Dis, IL-91120 Jerusalem, Israel.
   [Haham, Alon] Lis Matern Hosp, Tel Aviv Sourasky Med Ctr, Neonatal Intens Care Unit, IL-64239 Tel Aviv, Israel.
   [Isohanni, Pirjo; Suomalainen, Anu] Univ Helsinki, Biomedicum Helsinki, Mol Neurol, Res Programs Unit, FIN-00290 Helsinki, Finland.
   [Isohanni, Pirjo] Helsinki Univ Hosp, Childrens Hosp, Dept Pediat Neurol, Helsinki 00290, Finland.
   [Isohanni, Pirjo; Suomalainen, Anu] Univ Helsinki, FIN-00290 Helsinki, Finland.
   [Vara, Roshni] Evelina Childrens Hosp, Dept Paediat Inherited Metab Dis, London SE1 7EH, England.
   [Barbosa, Ines A.; Simpson, Michael A.] Kings Coll London, Sch Med, Div Genet & Mol Med, London SE1 9RY, England.
   [Deshpande, Charu] Guys & St Thomas NHS Fdn Trust, Clin Genet Unit, London SE1 9RT, England.
   [Bonnen, Penelope E.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
   [Rodenburg, Richard J.] Radboud Univ Nijmegen, Med Ctr, Translat Metab Lab, Radboud Ctr Mitochondrial Med,Dept Paediat, NL-6525 GA Nijmegen, Netherlands.
   [Suomalainen, Anu] Helsinki Univ Hosp, Dept Neurosci, Helsinki, Finland.
   [Elpeleg, Orly] Hadassah Hebrew Univ, Med Ctr, Monique & Jacques Roboh Dept Genet Res, IL-91120 Jerusalem, Israel.
C3 Newcastle University - UK; University of Parma; University of Tartu;
   University of Manchester; Tel Aviv University; Tel Aviv Sourasky Medical
   Center; Hebrew University of Jerusalem; ALYN Hospital; Hebrew University
   of Jerusalem; Hadassah University Medical Center; Tel Aviv University;
   Tel Aviv Sourasky Medical Center; University of Helsinki; University of
   Helsinki; Helsinki University Central Hospital; University of Helsinki;
   University of London; King's College London; Guy's & St Thomas' NHS
   Foundation Trust; Baylor College of Medicine; Radboud University
   Nijmegen; University of Helsinki; Helsinki University Central Hospital;
   Hebrew University of Jerusalem; Hadassah University Medical Center
RP Taylor, RW (corresponding author), Newcastle Univ, Inst Neurosci, Wellcome Trust Ctr Mitochondrial Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM robert.taylor@ncl.ac.uk
RI Reinson, Karit/AAJ-3939-2021; King, Martin/B-6361-2012; Jones,
   Simon/G-9975-2012; Alston, Charlotte/ABG-9602-2020; Kunji,
   Edmund/AAH-2362-2020; Rodenburg, Richard/N-3579-2014; Simpson,
   Michael/F-4737-2011; OUNAP, KATRIN/Q-1103-2016; Saada, Ann/J-6864-2017
OI jones, simon/0000-0002-5117-0566; Kunji, Edmund/0000-0002-0610-4500;
   McFarland, Robert/0000-0002-8833-2688; Rodenburg,
   Richard/0000-0001-5227-3527; Majd, Homa/0000-0002-2048-1839;
   Suomalainen-Wartiovaara, Anu/0000-0003-4833-5195; DALLABONA,
   Cristina/0000-0003-4397-9143; Simpson, Michael/0000-0002-8539-8753;
   Alston, Charlotte/0000-0003-2095-5464; OUNAP,
   KATRIN/0000-0002-4594-6364; Saada, Ann/0000-0003-2951-0656; King,
   Martin/0000-0001-6030-5154
FU Wellcome Trust [096919/Z/11/Z]; MRC Centre for Neuromuscular Diseases
   [G0601943]; Lily Foundation; UK NHS Highly Specialised "Rare
   Mitochondrial Disorders of Adults and Children" Service in Newcastle
   upon Tyne; NIHR/CSO Healthcare Science Research Fellowship from the
   National Institute for Health Research [NIHR-HCS-D12-03-04]; Department
   of Health via the NIHR comprehensive Biomedical Research Centre award to
   Guy's and St. Thomas' NHS Foundation Trust in partnership with the
   King's College London; Medical Research Council UK [MC_U105663139];
   Fondazione Telethon (Italy) [GGP15041]; Estonian Science Foundation
   [8175, PUT355]; Jane and Aatos Erkko Foundation; Sigrid Juselius
   Foundation; Academy of Finland; Helsinki University Hospital Funds;
   National Institute of Neurological Disorders and Stroke of the National
   Institutes of Health [R01NS083726]; MRC [MC_U105663139] Funding Source:
   UKRI
FX This work was supported by a Wellcome Trust Strategic Award
   (096919/Z/11/Z), the MRC Centre for Neuromuscular Diseases (G0601943),
   the Lily Foundation, the UK NHS Highly Specialised "Rare Mitochondrial
   Disorders of Adults and Children" Service in Newcastle upon Tyne, an
   NIHR/CSO Healthcare Science Research Fellowship from the National
   Institute for Health Research (NIHR-HCS-D12-03-04 to C.L.A.), the
   Department of Health via the NIHR comprehensive Biomedical Research
   Centre award to Guy's and St. Thomas' NHS Foundation Trust in
   partnership with the King's College London, Medical Research Council UK
   (MC_U105663139) (E.R.S.K., M.S.K., H.M.), Fondazione Telethon (Italy)
   (grant GGP15041) (C. Dallabona, T.L., I.F.), Estonian Science Foundation
   (grants 8175 and PUT355) (K.R., K.O.), Jane and Aatos Erkko Foundation,
   Sigrid Juselius Foundation, Academy of Finland and Helsinki University
   Hospital Funds (P.I., A. Suomalainen), and National Institute of
   Neurological Disorders and Stroke of the National Institutes of Health
   (R01NS083726) (P.E.B.). We would also like to thank the Genome
   Technology Center at the RadboudUMC and BGI Copenhagen (R.J.R.) and
   Institute of Molecular Medicine Finland (A. Suomalainen) for technical
   support of the exome sequencing, together with colleagues at the cell
   culture, muscle, and DNA laboratories of the Translational Metabolic
   Laboratory, RadboudUMC Nijmegen for excellent technical assistance
   (R.J.R.).
CR Adzhubei Ivan, 2013, Curr Protoc Hum Genet, VChapter 7, DOI 10.1002/0471142905.hg0720s76
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Bamber L, 2007, P NATL ACAD SCI USA, V104, P10830, DOI 10.1073/pnas.0703969104
   Barrientos A, 2002, METHODS, V26, P307, DOI 10.1016/S1046-2023(02)00036-1
   Baruffini E, 2010, METHODS, V51, P426, DOI 10.1016/j.ymeth.2010.02.023
   BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609
   Carroll CJ, 2013, J MED GENET, V50, P151, DOI 10.1136/jmedgenet-2012-101375
   Clémençon B, 2013, MOL ASPECTS MED, V34, P485, DOI 10.1016/j.mam.2012.05.006
   COULONDRE C, 1978, NATURE, V274, P775, DOI 10.1038/274775a0
   Crichton PG, 2013, J BIOL CHEM, V288, P22163, DOI 10.1074/jbc.M113.484329
   deRuyter PGGA, 1996, APPL ENVIRON MICROB, V62, P3662, DOI 10.1128/AEM.62.10.3662-3667.1996
   Deschauer M, 2005, NEUROMUSCULAR DISORD, V15, P311, DOI 10.1016/j.nmd.2004.12.004
   Dolce V, 2005, FEBS LETT, V579, P633, DOI 10.1016/j.febslet.2004.12.034
   Echaniz-Laguna A, 2012, J MED GENET, V49, P146, DOI 10.1136/jmedgenet-2011-100504
   Esposito LA, 1999, P NATL ACAD SCI USA, V96, P4820, DOI 10.1073/pnas.96.9.4820
   Fiermonte G, 2004, J BIOL CHEM, V279, P30722, DOI 10.1074/jbc.M400445200
   Fischer-Zirnsak B, 2015, AM J HUM GENET, V97, P483, DOI 10.1016/j.ajhg.2015.08.001
   Fontanesi F, 2004, HUM MOL GENET, V13, P923, DOI 10.1093/hmg/ddh108
   Gietz RD, 2007, NAT PROTOC, V2, P31, DOI 10.1038/nprot.2007.13
   Goffrini P, 2009, HUM MOL GENET, V18, P1860, DOI 10.1093/hmg/ddp102
   Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226
   Hashimoto M, 1999, BBA-BIOENERGETICS, V1409, P113, DOI 10.1016/S0005-2728(98)00155-8
   HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2
   IEEE, 2013, 2013 IEEE INT, DOI DOI 10.1155/2013/146860
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kearney JA, 2006, PEDIATR NEUROL, V34, P116, DOI 10.1016/j.pediatrneurol.2005.07.009
   King MS, 2016, BBA-BIOENERGETICS, V1857, P14, DOI 10.1016/j.bbabio.2015.09.013
   Kirby DM, 2007, METHOD CELL BIOL, V80, P93, DOI 10.1016/S0091-679X(06)80004-X
   Kircher M, 2014, NAT GENET, V46, P310, DOI 10.1038/ng.2892
   Klingenberg M, 2008, BBA-BIOMEMBRANES, V1778, P1978, DOI 10.1016/j.bbamem.2008.04.011
   Komaki H, 2002, ANN NEUROL, V51, P645, DOI 10.1002/ana.10172
   Kong A, 2012, NATURE, V488, P471, DOI 10.1038/nature11396
   Körver-Keularts IMLW, 2015, JIMD REP, V22, P39, DOI 10.1007/8904_2015_409
   Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86
   Kunji ERS, 2006, BBA-BIOENERGETICS, V1757, P1237, DOI 10.1016/j.bbabio.2006.03.021
   Kunji ERS, 2016, BBA-MOL CELL RES, V1863, P2379, DOI 10.1016/j.bbamcr.2016.03.015
   Kunji ERS, 2010, BBA-BIOENERGETICS, V1797, P817, DOI 10.1016/j.bbabio.2010.03.023
   Kunji ERS, 2005, CURR OPIN BIOTECH, V16, P546, DOI 10.1016/j.copbio.2005.08.006
   Kunji ERS, 2004, FEBS LETT, V564, P239, DOI 10.1016/S0014-5793(04)00242-X
   Kunji ERS, 2003, J BIOL CHEM, V278, P36985, DOI 10.1074/jbc.C300304200
   LI K, 1989, J BIOL CHEM, V264, P13998
   Lightowlers RN, 2015, SCIENCE, V349, P1494, DOI 10.1126/science.aac7516
   Liu YX, 2015, MOL BIOL CELL, V26, P1985, DOI 10.1091/mbc.E15-01-0030
   MAJANDER A, 1995, J NEUROL SCI, V134, P95, DOI 10.1016/0022-510X(95)00225-5
   Mandel H., 2016, J MED GENET
   Mifsud J, 2013, MOL MEMBR BIOL, V30, P160, DOI 10.3109/09687688.2012.745175
   Muona M, 2015, NAT GENET, V47, P39, DOI 10.1038/ng.3144
   Napoli L, 2001, NEUROLOGY, V57, P2295, DOI 10.1212/WNL.57.12.2295
   Nelson DR, 1998, J MOL BIOL, V277, P285, DOI 10.1006/jmbi.1997.1594
   Neveling K, 2013, HUM MUTAT, V34, P1721, DOI 10.1002/humu.22450
   Palmieri F, 2014, J INHERIT METAB DIS, V37, P565, DOI 10.1007/s10545-014-9708-5
   Palmieri L, 2005, HUM MOL GENET, V14, P3079, DOI 10.1093/hmg/ddi341
   Pebay-Peyroula E, 2003, NATURE, V426, P39, DOI 10.1038/nature02056
   Robinson AJ, 2006, P NATL ACAD SCI USA, V103, P2617, DOI 10.1073/pnas.0509994103
   Robinson AJ, 2008, P NATL ACAD SCI USA, V105, P17766, DOI 10.1073/pnas.0809580105
   Rodenburg RJT, 2011, J INHERIT METAB DIS, V34, P283, DOI 10.1007/s10545-010-9081-y
   Ruprecht JJ, 2014, P NATL ACAD SCI USA, V111, pE426, DOI 10.1073/pnas.1320692111
   SARASTE M, 1982, FEBS LETT, V144, P250, DOI 10.1016/0014-5793(82)80648-0
   Schuurs-Hoeijmakers JHM, 2012, AM J HUM GENET, V91, P1122, DOI 10.1016/j.ajhg.2012.10.013
   Siciliano G, 2003, NEUROMUSCULAR DISORD, V13, P162, DOI 10.1016/S0960-8966(02)00221-3
   Simpson MA, 2011, NAT GENET, V43, P303, DOI 10.1038/ng.779
   Strauss KA, 2013, P NATL ACAD SCI USA, V110, P3453, DOI 10.1073/pnas.1300690110
   Sulonen AM, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-9-r94
   Suomalainen A, 2010, NEUROMUSCULAR DISORD, V20, P429, DOI 10.1016/j.nmd.2010.03.017
   Tavtigian SV, 2006, J MED GENET, V43, P295, DOI 10.1136/jmg.2005.033878
   Taylor RW, 2014, JAMA-J AM MED ASSOC, V312, P68, DOI 10.1001/jama.2014.7184
   Thangaratnarajah C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6491
   THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9
   Wagnon JL, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00104
   Wortmann SB, 2015, J INHERIT METAB DIS, V38, P437, DOI 10.1007/s10545-015-9823-y
NR 70
TC 88
Z9 91
U1 0
U2 5
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0002-9297
EI 1537-6605
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD OCT 6
PY 2016
VL 99
IS 4
BP 860
EP 876
DI 10.1016/j.ajhg.2016.08.014
PG 17
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA DY7UB
UT WOS:000385333700006
PM 27693233
OA Green Published, hybrid
DA 2024-11-01
ER

PT J
AU Oncul, U
   Kose, E
   Eminoglu, FT
AF Oncul, Ummuhan
   Kose, Engin
   Eminoglu, Fatma Tuba
TI A Mild Phenotype of Mitochondrial DNA Depletion Syndrome Type 13 with a
   Novel <i>FBXL4</i> Variant
SO MOLECULAR SYNDROMOLOGY
LA English
DT Article
DE Encephalopathy; FBXL4; Mitochondrial DNA depletion; mtDNA depletion
   syndrome; Myopathy; MTDPS13
ID MUTATIONS
AB Mitochondrial DNA depletion syndromes (MDDS) are a group of rare genetic disorders caused by defects in multiple genes involved in mitochondrial DNA maintenance. Among these, FBXL4 gene variants result in encephalomyopathic mtDNA depletion syndrome 13 (MTDPS13), which commonly presents as a combination of failure to thrive, neurodevelopmental delays, encephalopathy, hypotonia, a pattern of mild facial dysmorphisms, and persistent lactic acidosis. To date, 53 pathogenic FBXL4 variants and 100 cases have been described in the literature. In the present case report, we report on a 4.5-year-old boy with MTDPS13 and a novel variant. The patient had a history of antenatal hydrocephalus, severe developmental delay and mental motor retardation with psychomotor delay, severe hypotonia, mild left ventricular hypertrophic cardiomyopathy, mild facial dysmorphism, and elevated lactate levels. Symptoms suggested mitochondrial myopathy; subsequently, whole-exome sequencing was performed and a novel homozygous variant FBXL4 (NM_012160.4): c.486T>G (p.Tyr162Ter) was identified. While most of the patients with FBLX4 gene mutation have severe clinical manifestation and die at a very young age, clinical progress of our case was milder than previously reported. MDDS are very rare and can present with many different clinical signs and symptoms. In this report, we identified a novel pathogenic variant in the FBXL4 gene. This report shows that patients with FBLX4 gene mutations may present with a milder clinical phenotype than previously reported.
C1 [Oncul, Ummuhan; Kose, Engin; Eminoglu, Fatma Tuba] Ankara Univ, Fac Med, Dept Pediat Metab, Ankara, Turkey.
C3 Ankara University
RP Oncul, U (corresponding author), Ankara Univ, Fac Med, Dept Pediat Metab, Ankara, Turkey.
EM onculummuhan@gmail.com
RI Eminoglu, Tuba/AAF-8522-2019; Oncul, Ummuhan/AAE-6551-2021; kose,
   engin/W-4903-2017
OI Oncul, Ummuhan/0000-0003-0194-9739; Kose, Engin/0000-0001-7238-2894
CR Almannai M, 2017, FBXL4-Related Encephalomyopathic Mitochondrial DNA Depletion Syndrome
   Baroy T, 2016, EUR J MED GENET, V59, P342, DOI 10.1016/j.ejmg.2016.05.005
   Bonnen PE, 2013, AM J HUM GENET, V93, P471, DOI 10.1016/j.ajhg.2013.07.017
   Dai H, 2017, CLIN GENET, V91, P634, DOI 10.1111/cge.12894
   El-Hattab AW, 2017, MOL GENET METAB, V122, P1, DOI 10.1016/j.ymgme.2017.09.009
   El-Hattab AW, 2017, HUM MUTAT, V38, P1649, DOI 10.1002/humu.23341
   El-Hattab AW, 2017, BBA-MOL BASIS DIS, V1863, P1539, DOI 10.1016/j.bbadis.2017.02.017
   Gai XW, 2013, AM J HUM GENET, V93, P482, DOI 10.1016/j.ajhg.2013.07.016
   Huemer M, 2015, J INHERIT METAB DIS, V38, P905, DOI 10.1007/s10545-015-9836-6
   Köse E, 2020, TURKISH J PEDIATR, V62, P652, DOI 10.24953/turkjped.2020.04.016
   Nardi N, 2020, J PEDIATR INTENSIVE, V9, P54, DOI 10.1055/s-0039-1697620
   Pronicka E, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0930-9
   Suarez-Rivero Juan M, 2016, Diseases, V5, DOI 10.3390/diseases5010001
   van Rij MC, 2016, CLIN CASE REP, V4, P425, DOI 10.1002/ccr3.511
NR 14
TC 1
Z9 1
U1 0
U2 0
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1661-8769
EI 1661-8777
J9 MOL SYNDROMOL
JI Mol. Syndromol.
PD AUG
PY 2021
VL 12
IS 5
BP 294
EP 299
DI 10.1159/000515928
EA JUL 2021
PG 6
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA UK7MU
UT WOS:000675442100001
PM 34602956
OA Bronze, Green Published
DA 2024-11-01
ER

PT J
AU Yu-Wai-Man, P
   Griffiths, PG
   Gorman, GS
   Lourenco, CM
   Wright, AF
   Auer-Grumbach, M
   Toscano, A
   Musumeci, O
   Valentino, ML
   Caporali, L
   Lamperti, C
   Tallaksen, CM
   Duffey, P
   Miller, J
   Whittaker, RG
   Baker, MR
   Jackson, MJ
   Clarke, MP
   Dhillon, B
   Czermin, B
   Stewart, JD
   Hudson, G
   Reynier, P
   Bonneau, D
   Marques, W
   Lenaers, G
   McFarland, R
   Taylor, RW
   Turnbull, DM
   Votruba, M
   Zeviani, M
   Carelli, V
   Bindoff, LA
   Horvath, R
   Amati-Bonneau, P
   Chinnery, PF
AF Yu-Wai-Man, P.
   Griffiths, P. G.
   Gorman, G. S.
   Lourenco, C. M.
   Wright, A. F.
   Auer-Grumbach, M.
   Toscano, A.
   Musumeci, O.
   Valentino, M. L.
   Caporali, L.
   Lamperti, C.
   Tallaksen, C. M.
   Duffey, P.
   Miller, J.
   Whittaker, R. G.
   Baker, M. R.
   Jackson, M. J.
   Clarke, M. P.
   Dhillon, B.
   Czermin, B.
   Stewart, J. D.
   Hudson, G.
   Reynier, P.
   Bonneau, D.
   Marques, W., Jr.
   Lenaers, G.
   McFarland, R.
   Taylor, R. W.
   Turnbull, D. M.
   Votruba, M.
   Zeviani, M.
   Carelli, V.
   Bindoff, L. A.
   Horvath, R.
   Amati-Bonneau, P.
   Chinnery, P. F.
TI Multi-system neurological disease is common in patients with <i>OPA1</i>
   mutations
SO BRAIN
LA English
DT Article
DE deletions; dominant optic atrophy; hereditary spastic paraplegia;
   mitochondrial DNA; multiple sclerosis; OPA1
ID DOMINANT OPTIC ATROPHY; PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA;
   MITOCHONDRIAL-DNA DELETIONS; SENSORINEURAL HEARING-LOSS;
   MULTIPLE-SCLEROSIS; CLINICAL-FEATURES; COUNTING FINGERS; HAND MOTION;
   NEUROPATHY; MTDNA
AB Additional neurological features have recently been described in seven families transmitting pathogenic mutations in OPA1, the most common cause of autosomal dominant optic atrophy. However, the frequency of these syndromal 'dominant optic atrophy plus' variants and the extent of neurological involvement have not been established. In this large multi-centre study of 104 patients from 45 independent families, including 60 new cases, we show that extra-ocular neurological complications are common in OPA1 disease, and affect up to 20% of all mutational carriers. Bilateral sensorineural deafness beginning in late childhood and early adulthood was a prominent manifestation, followed by a combination of ataxia, myopathy, peripheral neuropathy and progressive external ophthalmoplegia from the third decade of life onwards. We also identified novel clinical presentations with spastic paraparesis mimicking hereditary spastic paraplegia, and a multiple sclerosis-like illness. In contrast to initial reports, multi-system neurological disease was associated with all mutational subtypes, although there was an increased risk with missense mutations [odds ratio = 3.06, 95% confidence interval = 1.44-6.49; P = 0.0027], and mutations located within the guanosine triphosphate-ase region (odds ratio = 2.29, 95% confidence interval = 1.08-4.82; P = 0.0271). Histochemical and molecular characterization of skeletal muscle biopsies revealed the presence of cytochrome c oxidase-deficient fibres and multiple mitochondrial DNA deletions in the majority of patients harbouring OPA1 mutations, even in those with isolated optic nerve involvement. However, the cytochrome c oxidase-deficient load was over four times higher in the dominant optic atrophy + group compared to the pure optic neuropathy group, implicating a causal role for these secondary mitochondrial DNA defects in disease pathophysiology. Individuals with dominant optic atrophy plus phenotypes also had significantly worse visual outcomes, and careful surveillance is therefore mandatory to optimize the detection and management of neurological disability in a group of patients who already have significant visual impairment.
C1 [Yu-Wai-Man, P.; Griffiths, P. G.; Gorman, G. S.; Whittaker, R. G.; Stewart, J. D.; Hudson, G.; McFarland, R.; Taylor, R. W.; Turnbull, D. M.; Horvath, R.; Chinnery, P. F.] Newcastle Univ, Sch Med, Mitochondrial Res Grp, Inst Ageing & Hlth, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Yu-Wai-Man, P.; Griffiths, P. G.; Clarke, M. P.] Royal Victoria Infirm, Dept Ophthalmol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
   [Lourenco, C. M.; Marques, W., Jr.] Univ Sao Paulo, Sch Med Ribeirao Preto, Dept Neurosci, BR-05508 Sao Paulo, Brazil.
   [Wright, A. F.] Western Gen Hosp, Inst Genet & Mol Med, MRC, Human Genet Unit, Edinburgh EH4 2XU, Midlothian, Scotland.
   [Auer-Grumbach, M.] Med Univ Graz, Inst Human Genet, Graz, Austria.
   [Auer-Grumbach, M.] Med Univ Graz, Univ Clin Internal Med, Div Endocrinol & Nucl Med, Graz, Austria.
   [Toscano, A.; Musumeci, O.] Univ Messina, Dept Neurosci Psychiat & Anaesthesiol, Messina, Italy.
   [Valentino, M. L.; Caporali, L.; Carelli, V.] Univ Bologna, Dipartimento Sci Neurol, Bologna, Italy.
   [Lamperti, C.; Zeviani, M.] Natl Neurol Inst, Study Childrens Mitochondrial Disorders, Pierfranco & Luisa Mariani Ctr, Unit Mol Neurogenet, Milan, Italy.
   [Tallaksen, C. M.] Oslo Univ Hosp, Ulleval Dept Neurol, Oslo, Norway.
   [Duffey, P.] York Hosp, Dept Neurol, York, N Yorkshire, England.
   [Miller, J.; Baker, M. R.; Jackson, M. J.] Royal Victoria Infirm, Dept Neurol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
   [Baker, M. R.] Newcastle Univ, Sch Med, Inst Neurosci, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
   [Dhillon, B.] Princess Alexandra Eye Pavil, Edinburgh, Midlothian, Scotland.
   [Czermin, B.] Med Genet Ctr MGZ, Munich, Germany.
   [Reynier, P.; Bonneau, D.; Amati-Bonneau, P.] CHU Angers, Dept Biochim & Genet, Angers, France.
   [Reynier, P.; Bonneau, D.; Amati-Bonneau, P.] INSERM, U694, Angers, France.
   [Lenaers, G.] Univ Montpellier I & II, Inst Neurosci Montpellier, INSERM, U583, Montpellier, France.
   [Votruba, M.] Cardiff Univ, Sch Optometry & Vis Sci, Cardiff, S Glam, Wales.
   [Votruba, M.] Univ Wales Hosp, Cardiff Eye Unit, Cardiff CF4 4XW, S Glam, Wales.
   [Bindoff, L. A.] Univ Bergen, Dept Clin Med, Bergen, Norway.
   [Bindoff, L. A.] Haukeland Hosp, Dept Neurol, N-5021 Bergen, Norway.
   [Horvath, R.] Univ Munich, Dept Neurol, Friedrich Baur Inst, D-8000 Munich, Germany.
   [Chinnery, P. F.] Newcastle Univ, Inst Human Genet, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
C3 Newcastle University - UK; Newcastle University - UK; Universidade de
   Sao Paulo; University of Edinburgh; Medical University of Graz; Medical
   University of Graz; University of Messina; University of Bologna;
   Fondazione IRCCS Istituto Neurologico Carlo Besta; University of Oslo;
   Newcastle University - UK; Newcastle University - UK; Universite
   d'Angers; Centre Hospitalier Universitaire d'Angers; Institut National
   de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers;
   Universite de Montpellier; Institut National de la Sante et de la
   Recherche Medicale (Inserm); Cardiff University; Cardiff University;
   University of Bergen; University of Bergen; Haukeland University
   Hospital; University of Munich; Newcastle University - UK
RP Chinnery, PF (corresponding author), Newcastle Univ, Sch Med, Mitochondrial Res Grp, Inst Ageing & Hlth, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM p.f.chinnery@ncl.ac.uk
RI Reynier, Pascal/K-3677-2015; Hudson, Gavin/E-7117-2017; Marques Junior,
   Wilson/G-4240-2012; Wright, Alan/C-7782-2013; Bonneau,
   Dominique/K-6110-2015; Toscano, Antonio/AHE-4657-2022; lamperti,
   costanza/J-8801-2016; Lenaers, guy/X-4727-2019; amati-bonneau,
   patrizia/K-6198-2015; Musumeci, Olimpia/AHE-3041-2022; Votruba,
   Marcela/B-7306-2015; Zeviani, Massimo/K-2891-2014; Horvath,
   Rita/AAY-7042-2020; Votruba, Marcela/A-6182-2011; lenaers,
   guy/K-2421-2015; Caporali, Leonardo/J-7398-2016; Stewart, Joanna
   D/H-1614-2012
OI Chinnery, Patrick/0000-0002-7065-6617; VALENTINO, MARIA
   LUCIA/0000-0001-5323-0115; Bindoff, Laurence/0000-0003-0988-276X;
   Votruba, Marcela/0000-0002-7680-9135; lenaers, guy/0000-0003-2736-3349;
   CARELLI, VALERIO/0000-0003-4923-6404; Reynier,
   Pascal/0000-0003-0802-4608; Turnbull, Doug/0000-0002-8878-9901; Horvath,
   Rita/0000-0002-9841-170X; Caporali, Leonardo/0000-0002-0666-4380;
   Hudson, Gavin/0000-0001-7210-2733; Whittaker, Roger/0000-0002-3403-0182;
   Gorman, Grainne/0000-0002-7585-3409; McFarland,
   Robert/0000-0002-8833-2688; Bonneau, Dominique/0000-0002-6886-0969;
   Baker, Mark/0000-0001-6916-1329; Stewart, Joanna D/0000-0002-2608-1967;
   Zeviani, Massimo/0000-0002-9067-5508
FU Parkinson's Disease Society (UK); Medical Research Council Translational
   Muscle Centre; UK NIHR Biomedical Research Centre in Ageing and Age
   related disease; Deutsche Forschungsgemeinschaft [HO2505/2-1]; Academy
   of Medical Sciences; Wellcome Trust; UK National Commissioning Group for
   Rare Mitochondrial Disorders of Adults and Children; Helse Vest (RHF);
   Norwegian Research Council; NIHR Biomedical research Centre for Ageing
   and Age-related disease; Telethon-Italy [GGP06233]; MRC [G0701386,
   G0800674, MC_U127584475, G0700949] Funding Source: UKRI
FX MRC Clinical Research Fellowship in Neuro-ophthalmology to P. Y. W. M.;
   Wellcome Trust Senior Fellowship in Clinical Science to P. F. C.; P. F.
   C. also receives funding from the Parkinson's Disease Society (UK), the
   Medical Research Council Translational Muscle Centre, and the UK NIHR
   Biomedical Research Centre in Ageing and Age related disease. R. H. is
   supported by the Deutsche Forschungsgemeinschaft (HO2505/2-1) and the
   Academy of Medical Sciences. R. M. and M. V. are MRC Clinician
   Scientists. D. M. T. and R. W. T. are funded by the Wellcome Trust, and
   the UK National Commissioning Group for Rare Mitochondrial Disorders of
   Adults and Children. L. B. receives funding from Helse Vest (RHF) and
   the Norwegian Research Council. G. S. G. is supported by the NIHR
   Biomedical research Centre for Ageing and Age-related disease;
   Telethon-Italy grant (GGP06233) to V. C.
CR Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944
   Amati-Bonneau P, 2005, ANN NEUROL, V58, P958, DOI 10.1002/ana.20681
   Amati-Bonneau P, 2005, CLIN GENET, V67, P102, DOI 10.1111/j.1399-0004.2004.00358.x
   Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   Bigal ME, 2006, NEUROLOGY, V67, P246, DOI 10.1212/01.wnl.0000225186.76323.69
   Bland M., 1995, INTRO MED STAT, V2nd
   Brais B, 2009, CURR NEUROL NEUROSCI, V9, P76, DOI 10.1007/s11910-009-0012-y
   Brierley EJ, 1996, QJM-MON J ASSOC PHYS, V89, P251
   Carelli V, 2008, NEUROLOGY, V70, P1075, DOI 10.1212/01.wnl.0000307668.75233.35
   Chan DC, 2007, NEW ENGL J MED, V356, P1707, DOI 10.1056/NEJMp078040
   Chen SQ, 2007, AM J OPHTHALMOL, V143, P186, DOI 10.1016/j.ajo.2006.06.049
   Chevrollier A, 2008, ANN NEUROL, V63, P794, DOI 10.1002/ana.21385
   Chinnery PF, 1999, AM J HUM GENET, V64, P1158, DOI 10.1086/302311
   Chinnery PF, 2006, MITOCHONDRIAL MED, P161
   CHINNERY PF, 2007, NEUROMUSCULAR DISORD, V18, P259
   Cipolat S, 2006, CELL, V126, P163, DOI 10.1016/j.cell.2006.06.021
   Copeland WC, 2008, ANNU REV MED, V59, P131, DOI 10.1146/annurev.med.59.053006.104646
   Cornille K, 2008, ANN NEUROL, V63, P667, DOI 10.1002/ana.21376
   Corona P, 2002, ANN NEUROL, V51, P118, DOI 10.1002/ana.10059
   Cree LM, 2008, DIABETOLOGIA, V51, P1440, DOI 10.1007/s00125-008-1054-4
   Davies V, 2006, EXP EYE RES, V83, P1003, DOI 10.1016/j.exer.2005.11.021
   Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Ferraris S, 2008, ARCH NEUROL-CHICAGO, V65, P125, DOI 10.1001/archneurol.2007.9
   Ferré M, 2005, HUM MUTAT, V25, P423, DOI 10.1002/humu.20161
   Ferré M, 2009, HUM MUTAT, V30, pE692, DOI 10.1002/humu.21025
   Fox CM, 2004, J NEUROL NEUROSUR PS, V75, P56
   Frezza C, 2006, CELL, V126, P177, DOI 10.1016/j.cell.2006.06.025
   Goadsby PJ, 2002, NEW ENGL J MED, V346, P257, DOI 10.1056/NEJMra010917
   HARDING AE, 1992, BRAIN, V115, P979, DOI 10.1093/brain/115.4.979
   HOYT CS, 1980, OPHTHALMOLOGY, V87, P245
   Hudson G, 2008, BRAIN, V131, P329, DOI 10.1093/brain/awm272
   Hudson G, 2006, HUM MOL GENET, V15, pR244, DOI 10.1093/hmg/ddl233
   JOHNSON MA, 1996, HDB MUSCLE DIS, P61
   Ke Tie, 2006, Zhonghua Yixue Yichuanxue Zazhi, V23, P481
   Khanim F, 2001, HUM MUTAT, V17, P357, DOI 10.1002/humu.1110.abs
   Kovács GG, 2005, BRAIN, V128, P35, DOI 10.1093/brain/awh310
   Krishnan KJ, 2008, NAT GENET, V40, P275, DOI 10.1038/ng.f.94
   Lange C, 2009, GRAEF ARCH CLIN EXP, V247, P137, DOI 10.1007/s00417-008-0926-0
   Li CM, 2005, AM J MED GENET A, V138A, P208, DOI 10.1002/ajmg.a.30794
   Lightowlers RH, 1999, TRENDS GENET, V15, P91, DOI 10.1016/S0168-9525(98)01684-9
   Liguori M, 2008, J NEUROL, V255, P127, DOI 10.1007/s00415-008-0571-x
   Mahad DJ, 2009, BRAIN, V132, P1161, DOI 10.1093/brain/awp046
   Man PYW, 2003, AM J HUM GENET, V72, P333, DOI 10.1016/j.ajhg.2016.05.015
   McDermott CJ, 2003, NEUROREPORT, V14, P485, DOI 10.1097/01.wnr.0000058774.36017.cf
   MEIRE F, 1985, OPHTHALMIC PAED GEN, V5, P91, DOI 10.3109/13816818509007861
   Milone M, 2009, MITOCHONDRION, V9, P279, DOI 10.1016/j.mito.2009.03.001
   Newman NJ, 2004, EYE, V18, P1144, DOI 10.1038/sj.eye.6701591
   *NHS QUAL OUTC FRA, 2008, DIS PREV
   *OFF NAT STAT, 2008, POP HOUS
   Olichon A, 2007, CELL DEATH DIFFER, V14, P682, DOI 10.1038/sj.cdd.4402048
   Payne M, 2004, AM J OPHTHALMOL, V138, P749, DOI 10.1016/j.ajo.2004.06.011
   Pesch UEA, 2001, HUM MOL GENET, V10, P1359, DOI 10.1093/hmg/10.13.1359
   Pich S, 2005, HUM MOL GENET, V14, P1405, DOI 10.1093/hmg/ddi149
   Puomila A, 2005, ACTA OPHTHALMOL SCAN, V83, P337, DOI 10.1111/j.1600-0420.2005.00448.x
   Pyle A, 2007, J MED GENET, V44, P69, DOI 10.1136/jmg.2006.043109
   Reid E, 2003, J MED GENET, V40, P81, DOI 10.1136/jmg.40.2.81
   Salinas S, 2008, LANCET NEUROL, V7, P1127, DOI 10.1016/S1474-4422(08)70258-8
   Schapira AHV, 2006, LANCET, V368, P70, DOI 10.1016/S0140-6736(06)68970-8
   Schulze-Bonsel K, 2006, INVEST OPHTH VIS SCI, V47, P1236, DOI 10.1167/iovs.05-0981
   Sinnathuray AR, 2003, OTOL NEUROTOL, V24, P418, DOI 10.1097/00129492-200305000-00012
   Spinazzi M, 2008, HUM MOL GENET, V17, P3291, DOI 10.1093/hmg/ddn225
   Stewart JD, 2008, NEUROLOGY, V71, P1829, DOI 10.1212/01.wnl.0000335931.54095.0a
   Verny C, 2008, NEUROLOGY, V70, P1152, DOI 10.1212/01.wnl.0000289194.89359.a1
   Wingerchuk DM, 2007, LANCET NEUROL, V6, P805, DOI 10.1016/S1474-4422(07)70216-8
   Yu-Wai-Man P, 2009, J MED GENET, V46, P145, DOI 10.1136/jmg.2007.054270
   Yu-Wai-Man P, 2009, INVEST OPHTH VIS SCI, V50, P4561, DOI 10.1167/iovs.09-3634
   Zanna C, 2008, BRAIN, V131, P352, DOI 10.1093/brain/awm335
   Zeviani M, 2008, BRAIN, V131, P314, DOI 10.1093/brain/awm339
   Züchner S, 2006, ANN NEUROL, V59, P276, DOI 10.1002/ana.20797
NR 70
TC 325
Z9 343
U1 1
U2 26
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 1460-2156
J9 BRAIN
JI Brain
PD MAR
PY 2010
VL 133
BP 771
EP 786
DI 10.1093/brain/awq007
PN 3
PG 16
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 575DI
UT WOS:000276046000013
PM 20157015
OA Green Published, Green Submitted, hybrid, Green Accepted
DA 2024-11-01
ER

PT J
AU Schwartz, M
   Vissing, J
AF Schwartz, M
   Vissing, J
TI No evidence for paternal inheritance of mtDNA in patients with sporadic
   mtDNA mutations
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE mtDNA; paternal inheritance; mitochondria
ID MITOCHONDRIAL-DNA; SEQUENCE
AB With the publication of a patient with severe exercise intolerance, in whom the mutated mtDNA in muscle was shown to be paternally inherited, the strict maternal inheritance of mtDNA was challenged. Paternal mtDNA inheritance may have gone unrecognized in cases of mitochondrial disease with no clear maternal pattern of inheritance because mitochondrial haplotypes are rarely investigated in diagnostic analyses. To find further evidence for a paternal inheritance of mtDNA, we reinvestigated 12 patients with mitochondrial myopathy, in whom the pathogenic mutation was known to be sporadic. We compared the mtDNA haplotypes from the patient's muscle with that of the mtDNA haplotypes in blood from either the mother or the patient. No evidence of Paternal inheritance of mtDNA was found in this small study. Although these findings indicate that the Paternal inheritance of mtDNA is rare, they do not rule out that the phenomenon may occur at a rate that could still affect genetic counselling and anthropological research. (C) 2003 Elsevier B.V. All rights reserved.
C1 Univ Copenhagen, Natl Hosp, Rigshosp, Dept Clin Genet 4062, DK-2100 Copenhagen, Denmark.
   Univ Copenhagen, Natl Hosp, Rigshosp, Dept Neurol, DK-2100 Copenhagen, Denmark.
   Univ Copenhagen, Natl Hosp, Rigshosp, Copenhagen Muscle Res Ctr, DK-2100 Copenhagen, Denmark.
C3 Rigshospitalet; University of Copenhagen; Rigshospitalet; University of
   Copenhagen; University of Copenhagen; Rigshospitalet
RP Schwartz, M (corresponding author), Univ Copenhagen, Natl Hosp, Rigshosp, Dept Clin Genet 4062, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.
EM Schwartz@rh.dk
RI Vissing, John/IUN-4271-2023
CR Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Birky CW, 2001, ANNU REV GENET, V35, P125, DOI 10.1146/annurev.genet.35.102401.090231
   Bromham L, 2003, TRENDS ECOL EVOL, V18, P2, DOI 10.1016/S0169-5347(02)00009-5
   Cummins JM, 1997, ZYGOTE, V5, P301, DOI 10.1017/S0967199400003889
   Eyre-Walker A, 2001, J MOL EVOL, V53, P430, DOI 10.1007/s002390010232
   Howell N, 2003, AM J HUM GENET, V72, P659, DOI 10.1086/368264
   JACOBS H, 2002, TRENDS GENET, V18, P551
   Jacobs HT, 2000, BIOESSAYS, V22, P564, DOI 10.1002/(SICI)1521-1878(200006)22:6<564::AID-BIES9>3.0.CO;2-4
   Macaulay V, 1999, P ROY SOC B-BIOL SCI, V266, P2037, DOI 10.1098/rspb.1999.0883
   Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350
   STONEKING M, 1991, AM J HUM GENET, V48, P370
   Vissing J, 2002, NEW ENGL J MED, V347, P2081
NR 12
TC 25
Z9 30
U1 1
U2 15
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD MAR 15
PY 2004
VL 218
IS 1-2
BP 99
EP 101
DI 10.1016/j.jns.2003.11.008
PG 3
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 775WW
UT WOS:000189084500016
PM 14759640
DA 2024-11-01
ER

PT J
AU Lopez-Gomez, C
   Levy, RJ
   Sanchez-Quintero, MJ
   Juanola-Falgarona, M
   Barca, E
   Garcia-Diaz, B
   Tadesse, S
   Garone, C
   Hirano, M
AF Lopez-Gomez, Carlos
   Levy, Rebecca J.
   Sanchez-Quintero, Maria J.
   Juanola-Falgarona, Marti
   Barca, Emanuele
   Garcia-Diaz, Beatriz
   Tadesse, Saba
   Garone, Caterina
   Hirano, Michio
TI Deoxycytidine and Deoxythymidine Treatment for Thymidine Kinase 2
   Deficiency
SO ANNALS OF NEUROLOGY
LA English
DT Article
ID MITOCHONDRIAL-DNA DEPLETION; DEOXYNUCLEOTIDE POOLS; MYOPATHY; MUTATIONS;
   THERAPY; DISEASE; MICE
AB Objective: Thymidine kinase 2 (TK2), a critical enzyme in the mitochondrial pyrimidine salvage pathway, is essential for mitochondrial DNA (mtDNA) maintenance. Mutations in the nuclear gene, TK2, cause TK2 deficiency, which manifests predominantly in children as myopathy with mtDNA depletion. Molecular bypass therapy with the TK2 products, deoxycytidine monophosphate (dCMP) and deoxythymidine monophosphate (dTMP), prolongs the life span of Tk2-deficient (Tk2(-/-)) mice by 2- to 3-fold. Because we observed rapid catabolism of the deoxynucleoside monophosphates to deoxythymidine (dT) and deoxycytidine (dC), we hypothesized that: (1) deoxynucleosides might be the major active agents and (2) inhibition of deoxycytidine deamination might enhance dTMP+dCMP therapy.
   Methods: To test these hypotheses, we assessed two therapies in Tk2(-/-) mice: (1) dT+dC and (2) coadministration of the deaminase inhibitor, tetrahydrouridine (THU), with dTMP+dCMP.
   Results: We observed that dC+dT delayed disease onset, prolonged life span of Tk2-deficient mice and restored mtDNA copy number as well as respiratory chain enzyme activities and levels. In contrast, dCMP+dTMP+THU therapy decreased life span of Tk2(-/-) animals compared to dCMP+dTMP.
   Interpretation: Our studies demonstrate that deoxynucleoside substrate enhancement is a novel therapy, which may ameliorate TK2 deficiency in patients.
C1 [Lopez-Gomez, Carlos; Levy, Rebecca J.; Sanchez-Quintero, Maria J.; Juanola-Falgarona, Marti; Barca, Emanuele; Garcia-Diaz, Beatriz; Tadesse, Saba; Garone, Caterina; Hirano, Michio] Columbia Univ, Med Ctr, H Houston Merritt Neuromuscular Res Ctr, Dept Neurol, New York, NY USA.
   [Barca, Emanuele] Univ Messina, Dept Clin & Expt Med, Messina, Italy.
   [Garcia-Diaz, Beatriz] Hosp Reg Univ Malaga, Inst Invest Biomed Malaga IBIMA, Unidad Gest Clin Neurociencias, Malaga, Spain.
   [Garone, Caterina] Univ Cambridge, MRC, Mitochondrial Biol Unit, Cambridge, England.
C3 Columbia University; University of Messina; Universidad de Malaga;
   Instituto de Investigacion Biomedica de Malaga y Plataforma en
   Nanomedicina (IBIMA); University of Cambridge
RP Hirano, M (corresponding author), Columbia Univ, Med Ctr, 630 West 168th St,P&S 4-423, New York, NY 10032 USA.
EM mh29@columbia.edu
RI SANCHEZ-QUINTERO, MARIA/AAS-6771-2020; Juanola-Falgarona,
   Martí/AFN-4252-2022; Garone, Caterina/AAB-8659-2019; López-Gómez,
   Carlos/C-8938-2009; Garcia Diaz, Beatriz/HJZ-2823-2023
OI Garcia Diaz, Beatriz/0000-0003-2655-571X; Lopez-Gomez,
   Carlos/0000-0003-2699-451X; Levy, Rebecca/0000-0003-0393-6835;
   SANCHEZ-QUINTERO, MARIA J/0000-0002-5638-2920; Garone,
   Caterina/0000-0003-4928-1037; BARCA, EMANUELE/0009-0007-6672-6524;
   Juanola-Falgarona, Marti/0000-0002-4566-7154
FU NIH [P01 HD32062]; Muscular Dystrophy Association; Associazione Malattie
   Metaboliche Congenite ereditarie (AMMeC); Arturo Estopinan TK2 Research
   Fund; Marriott Mitochondrial Disease Clinic Research Fund (MMDCRF) from
   the J. Willard and Alice S. Marriott Foundation; NIH (from NICHD) [R01
   HD057543, R01 HD056103]; Office of Dietary Supplements; NINDS [U54
   NS078059]; NICHD
FX This work was supported by research grants from the lNIH (P01 HD32062)
   (M.H.), Muscular Dystrophy Association (M.H.), and the Associazione
   Malattie Metaboliche Congenite ereditarie (AMMeC) (C.G.), as well as by
   the Arturo Estopinan TK2 Research Fund (M.H.) and the Marriott
   Mitochondrial Disease Clinic Research Fund (MMDCRF) from the J. Willard
   and Alice S. Marriott Foundation (M.H.). M.H. also acknowledges support
   from NIH grants (R01 HD057543, and R01 HD056103 from NICHD) and the
   Office of Dietary Supplements, as well as U54 NS078059 from NINDS and
   NICHD.
CR Akman HO, 2008, HUM MOL GENET, V17, P2433, DOI 10.1093/hmg/ddn143
   Béhin A, 2012, NEUROLOGY, V78, P644, DOI 10.1212/WNL.0b013e318248df2b
   BIRCHMACHIN MA, 1994, BIOCHEM MED METAB B, V51, P35, DOI 10.1006/bmmb.1994.1004
   Cámara Y, 2015, NEUROLOGY, V84, P2286, DOI 10.1212/WNL.0000000000001644
   Cámara Y, 2014, HUM MOL GENET, V23, P2459, DOI 10.1093/hmg/ddt641
   Copeland WC, 2012, CRIT REV BIOCHEM MOL, V47, P64, DOI 10.3109/10409238.2011.632763
   COWAN MJ, 1985, CLIN IMMUNOL IMMUNOP, V37, P30, DOI 10.1016/0090-1229(85)90132-1
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   Dorado B, 2011, HUM MOL GENET, V20, P155, DOI 10.1093/hmg/ddq453
   Ferraro P, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkp1141
   Garone C, 2014, EMBO MOL MED, V6, P1016, DOI 10.15252/emmm.201404092
   Holleran JL, 2015, CANCER CHEMOTH PHARM, V76, P803, DOI 10.1007/s00280-015-2857-x
   Kamath VG, 2015, J BIOL CHEM, V290, P2034, DOI 10.1074/jbc.M114.624213
   Lesko N, 2010, NEUROMUSCULAR DISORD, V20, P198, DOI 10.1016/j.nmd.2009.11.013
   López LC, 2009, HUM MOL GENET, V18, P714, DOI 10.1093/hmg/ddn401
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Martí R, 2012, METHODS MOL BIOL, V837, P135, DOI 10.1007/978-1-61779-504-6_9
   Martí R, 2012, METHODS MOL BIOL, V837, P121, DOI 10.1007/978-1-61779-504-6_8
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Parkinson FE, 2011, CURR TOP MED CHEM, V11, P948
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Sun R, 2014, BIOCHEMISTRY-US, V53, P6142, DOI 10.1021/bi5006877
   Tyynismaa H, 2012, HUM MOL GENET, V21, P66, DOI 10.1093/hmg/ddr438
   Wang L, 2010, NUCLEOS NUCLEOT NUCL, V29, P370, DOI 10.1080/15257771003729732
   Young JD, 2013, MOL ASPECTS MED, V34, P529, DOI 10.1016/j.mam.2012.05.007
   Zeviani M., 2016, MEDLINK NEUROLOGY
NR 26
TC 71
Z9 76
U1 2
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0364-5134
EI 1531-8249
J9 ANN NEUROL
JI Ann. Neurol.
PD MAY
PY 2017
VL 81
IS 5
BP 641
EP 652
DI 10.1002/ana.24922
PG 12
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA EV6PM
UT WOS:000401891300006
PM 28318037
OA Green Accepted, Green Submitted
DA 2024-11-01
ER

PT J
AU Bartesaghi, S
   Betts-Henderson, J
   Cain, K
   Dinsdale, D
   Zhou, XS
   Karlsson, A
   Salomoni, P
   Nicotera, P
AF Bartesaghi, Stefano
   Betts-Henderson, Joanne
   Cain, Kelvin
   Dinsdale, David
   Zhou, Xiaoshan
   Karlsson, Anna
   Salomoni, Paolo
   Nicotera, Pierluigi
TI Loss of thymidine kinase 2 alters neuronal bioenergetics and leads to
   neurodegeneration
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID MITOCHONDRIAL-DNA DEPLETION; DEOXYGUANOSINE KINASE; MTDNA DEPLETION;
   MUTATIONS; ENCEPHALOMYOPATHY; METABOLISM; EXPRESSION; LEVEL; GENE
AB Mutations of thymidine kinase 2 (TK2), an essential component of the mitochondrial nucleotide salvage pathway, can give rise to mitochondrial DNA (mtDNA) depletion syndromes (MDS). These clinically heterogeneous disorders are characterized by severe reduction in mtDNA copy number in affected tissues and are associated with progressive myopathy, hepatopathy and/or encephalopathy, depending in part on the underlying nuclear genetic defect. Mutations of TK2 have previously been associated with an isolated myopathic form of MDS (OMIM 609560). However, more recently, neurological phenotypes have been demonstrated in patients carrying TK2 mutations, thus suggesting that loss of TK2 results in neuronal dysfunction. Here, we directly address the role of TK2 in neuronal homeostasis using a knockout mouse model. We demonstrate that in vivo loss of TK2 activity leads to a severe ataxic phenotype, accompanied by reduced mtDNA copy number and decreased steady-state levels of electron transport chain proteins in the brain. In TK2-deficient cerebellar neurons, these abnormalities are associated with impaired mitochondrial bioenergetic function, aberrant mitochondrial ultrastructure and degeneration of selected neuronal types. Overall, our findings demonstrate that TK2 deficiency leads to neuronal dysfunction in vivo, and have important implications for understanding the mechanisms of neurological impairment in MDS.
C1 [Bartesaghi, Stefano; Betts-Henderson, Joanne; Cain, Kelvin; Dinsdale, David; Salomoni, Paolo; Nicotera, Pierluigi] Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England.
   [Zhou, Xiaoshan; Karlsson, Anna] Karolinska Inst, Dept Lab Med, S-14186 Huddinge, Sweden.
   [Nicotera, Pierluigi] German Ctr Neurodegenerat Dis, D-53175 Bonn, Germany.
C3 University of Leicester; Karolinska Institutet; Helmholtz Association;
   German Center for Neurodegenerative Diseases (DZNE)
RP Nicotera, P (corresponding author), Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England.
EM pierluigi.nicotera@dzne.de
RI Salomoni, Paolo/LMN-4418-2024; Karlsson, Anna/E-7945-2018; Bartesaghi,
   Stefano/G-1916-2015
OI Karlsson, Anna/0000-0001-6843-6685; Bartesaghi,
   Stefano/0000-0002-2083-7807
FU Medical Research Council (MRC); Samantha Dickson Brain Tumour Trust;
   Wellcome Trust; MRC [MC_U132670601, MC_U132664972] Funding Source: UKRI
FX This work was supported by the Medical Research Council (MRC). P. S. is
   also supported by Samantha Dickson Brain Tumour Trust and by the
   Wellcome Trust.
CR Akman HO, 2008, HUM MOL GENET, V17, P2433, DOI 10.1093/hmg/ddn143
   Alberio S, 2007, MITOCHONDRION, V7, P6, DOI 10.1016/j.mito.2006.11.010
   Betts J, 2006, NEUROPATH APPL NEURO, V32, P359, DOI 10.1111/j.1365-2990.2006.00731.x
   Chen HC, 2007, CELL, V130, P548, DOI 10.1016/j.cell.2007.06.026
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Götz A, 2008, BRAIN, V131, P2841, DOI 10.1093/brain/awn236
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   HATTEN ME, 1985, J CELL BIOL, V100, P384, DOI 10.1083/jcb.100.2.384
   Jekabsons MB, 2004, J BIOL CHEM, V279, P32989, DOI 10.1074/jbc.M401540200
   Kukat A, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn124
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Mandel H, 2001, HEPATOLOGY, V34, P776, DOI 10.1053/jhep.2001.27664
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Mathews CK, 2006, FASEB J, V20, P1300, DOI 10.1096/fj.06-5730rev
   McFarland R, 2002, LANCET NEUROL, V1, P343, DOI 10.1016/S1474-4422(02)00159-X
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Nguyen KV, 2005, NEUROLOGY, V65, P1493, DOI 10.1212/01.wnl.0000182814.55361.70
   Oskoui M, 2006, ARCH NEUROL-CHICAGO, V63, P1122, DOI 10.1001/archneur.63.8.1122
   Ostergaard E, 2007, BRAIN, V130, P853, DOI 10.1093/brain/awl383
   Rocher C, 2008, J BIOENERG BIOMEMBR, V40, P59, DOI 10.1007/s10863-008-9130-5
   Rylova SN, 2007, BIOCHEM PHARMACOL, V74, P169, DOI 10.1016/j.bcp.2007.03.029
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Wang LY, 2005, MOL GENET METAB, V84, P75, DOI 10.1016/j.ymgme.2004.09.005
   Wu M, 2007, AM J PHYSIOL-CELL PH, V292, pC125, DOI 10.1152/ajpcell.00247.2006
   Zhou XS, 2008, HUM MOL GENET, V17, P2329, DOI 10.1093/hmg/ddn133
NR 26
TC 31
Z9 37
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD MAY 1
PY 2010
VL 19
IS 9
BP 1669
EP 1677
DI 10.1093/hmg/ddq043
PG 9
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 581MF
UT WOS:000276526700003
PM 20123860
OA Green Published, Green Accepted
DA 2024-11-01
ER

PT J
AU Stenqvist, L
   Paetau, A
   Valanne, L
   Suomalainen, A
   Pihko, H
AF Stenqvist, L
   Paetau, A
   Valanne, L
   Suomalainen, A
   Pihko, H
TI A juvenile case of MELAS with T3271C mitochondrial DNA mutation
SO PEDIATRIC RESEARCH
LA English
DT Article
ID STROKE-LIKE EPISODES; TRANSFER RNALEU(UUR) GENE; LACTIC-ACIDOSIS;
   TRANSFER RNA(LEU(UUR)); CLINICAL-FEATURES; MTDNA MUTATION; POINT
   MUTATION; ENCEPHALOPATHY; MYOPATHY; ENCEPHALOMYOPATHY
AB We present here a patient with muscle fatigue and poor growth since the age of 6 y. The diagnosis of a mitochondrial disease was based on the presence of ragged red fibers in the muscle biopsy and on a combined defect of mitochondrial DNA-encoded respiratory enzymes. Epilepsia partialis continua with stroke-like episodes appeared 2 mo before death at the age of 18 and prompted a search for mitochondrial DNA mutations associated with mitochondrial encephalopathy, lactic acidosis, and stroke-like episodes. Minisequencing of the patient's DNA samples revealed a heteroplasmic T3271C mutation with a 78-94% mutation load in her fibroblasts or autopsy-derived tissue samples. This is the ninth reported non-Japanese patient with T3271C mutation. Our patient shows that despite very high proportion of mutant mtDNA, the T3271C mutation can give rise to mild symptoms in childhood and to a rapid terminal phase that simulates encephalitis.
C1 Univ Helsinki, Biomedicum Helsinki, Programme Neurosci, Dept Neurol, FIN-00290 Helsinki, Finland.
   Univ Helsinki, Dept Pathol, FIN-00014 Helsinki, Finland.
   Univ Helsinki, Cent Hosp, Dept Radiol, FIN-00029 Helsinki, Finland.
   Univ Helsinki, Cent Hosp, Hosp Children & Adolescents, FIN-00029 Helsinki, Finland.
C3 University of Helsinki; University of Helsinki; University of Helsinki;
   Helsinki University Central Hospital; University of Helsinki; Helsinki
   University Central Hospital
RP Univ Helsinki, Biomedicum Helsinki, Programme Neurosci, Dept Neurol, Haartmaninkatu 8,POB 63, FIN-00290 Helsinki, Finland.
EM laura.stenqvist@hus.fi
OI Valanne, Leena/0000-0002-8572-829X; Suomalainen-Wartiovaara,
   Anu/0000-0003-4833-5195
CR Balestri P, 2000, J CHILD NEUROL, V15, P755, DOI 10.1177/088307380001501108
   CHEN CM, 1995, EUR NEUROL, V35, P281, DOI 10.1159/000117150
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   CIAFALONI E, 1992, ANN NEUROL, V31, P391, DOI 10.1002/ana.410310408
   GOTO Y, 1991, BIOCHIM BIOPHYS ACTA, V1097, P238, DOI 10.1016/0925-4439(91)90042-8
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   HAMMANS SR, 1995, BRAIN, V118, P721, DOI 10.1093/brain/118.3.721
   HUANG CC, 1994, J NEUROL NEUROSUR PS, V57, P586, DOI 10.1136/jnnp.57.5.586
   KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   MAJANDER A, 1995, J NEUROL SCI, V134, P95, DOI 10.1016/0022-510X(95)00225-5
   MAKELABENGS P, 1995, PEDIATR RES, V37, P634
   MORAES CT, 1993, NEUROMUSCULAR DISORD, V3, P43, DOI 10.1016/0960-8966(93)90040-Q
   MORGANHUGHES JA, 1995, BBA-MOL BASIS DIS, V1271, P135, DOI 10.1016/0925-4439(95)00020-5
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   Rahman S, 2001, AM J HUM GENET, V68, P238, DOI 10.1086/316930
   SAKUTA R, 1993, J NEUROL SCI, V115, P158, DOI 10.1016/0022-510X(93)90219-O
   SHIBATA DK, 1988, J EXP MED, V167, P225, DOI 10.1084/jem.167.1.225
   Shinde A, 2000, Rinsho Shinkeigaku, V40, P561
   Silvestri G, 1997, MUSCLE NERVE, V20, P221
   SILVESTRI G, 1993, NEUROLOGY, V43, P1200, DOI 10.1212/WNL.43.6.1200
   SUOMALAINEN A, 1993, HUM MOL GENET, V2, P525, DOI 10.1093/hmg/2.5.525
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   SUZUKI T, 1990, NEURORADIOLOGY, V32, P74, DOI 10.1007/BF00593949
   Taivassalo T, 2001, ANN NEUROL, V50, P133, DOI 10.1002/ana.1050
   Takeda A, 1998, JPN CIRC J, V62, P695, DOI 10.1253/jcj.62.695
   Tarnopolsky MA, 1998, MUSCLE NERVE, V21, P25, DOI 10.1002/(SICI)1097-4598(199801)21:1<25::AID-MUS4>3.0.CO;2-I
   Thomeer EC, 1998, J NEUROL NEUROSUR PS, V64, P692, DOI 10.1136/jnnp.64.5.692
   TOKUNAGA M, 1993, ANN NEUROL, V33, P275, DOI 10.1002/ana.410330308
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   van den Ouweland JMW, 1999, DIABETOLOGIA, V42, P485, DOI 10.1007/s001250051183
   VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368
   VANDENOUWELAND JMW, 1995, MUSCLE NERVE, pS124
   Yanagawa T, 1998, INTERNAL MED, V37, P780, DOI 10.2169/internalmedicine.37.780
NR 36
TC 13
Z9 19
U1 1
U2 2
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0031-3998
EI 1530-0447
J9 PEDIATR RES
JI Pediatr. Res.
PD AUG
PY 2005
VL 58
IS 2
BP 258
EP 262
DI 10.1203/01.PDR.0000169966.82325.1A
PG 5
WC Pediatrics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pediatrics
GA 952HV
UT WOS:000230995500015
PM 16006433
OA Bronze
DA 2024-11-01
ER

PT J
AU Kärppä, M
   Kytövuori, L
   Saari, M
   Majamaa, K
AF Karppa, Mikko
   Kytovuori, Laura
   Saari, Markku
   Majamaa, Kari
TI Mutation m.15923A&gt;G in the <i>MT</i>-<i>TT</i> gene causes mild
   myopathy - case report of an adult-onset phenotype
SO BMC NEUROLOGY
LA English
DT Article
DE Case report; Mitochondrial diseases; Mitochondrial tRNA(Thr);
   Single-fibre analysis; Neuromuscular disorders
ID MITOCHONDRIAL-DNA MUTATIONS; ENCEPHALOMYOPATHY; PREVALENCE; INFANTILE;
   DISEASE
AB Background: Only five patients have previously been reported to harbor mutations in the MT-TT gene encoding mitochondrial tRNA threonine. The m.15923A > G mutation has been found in three severely affected children. One of these patients died within days after birth and two had a phenotype of myoclonic epilepsy with ragged red fibers (MERRF) in early childhood. We have now found the mutation in an adult patient with mild myopathy.
   Case presentation: The patient is a 64-year-old Finnish man, who developed bilateral ptosis, diplopia and exercise intolerance in his fifties. Family history was unremarkable. Muscle histology showed cytochrome c-oxidase (COX) negative and ragged red fibres. The m.15923A > G mutation heteroplasmy was 33% in the skeletal muscle and 2% in buccal epithelial cells. The mutation was undetectable in the blood. Single-fibre analysis was performed and COX-negative fibres had a substantially higher heteroplasmy of 92%, than the normal fibres in which it was 43%.
   Conclusions: We report the fourth patient with m. 15923A > G and with a remarkably milder phenotype than the previous three patients. Our findings and recent biochemical studies suggest that the mutation m.15923A > G is a definite disease-causing mutation. Our results also suggest that heteroplasmy of the m.15923A > G mutation correlates with the severity of the phenotype. This study expands the catalog of the phenotypes caused by mutations in mtDNA.
C1 [Karppa, Mikko; Kytovuori, Laura; Majamaa, Kari] Univ Oulu, Res Unit Clin Neurosci, POB 5000, FI-90014 Oulu, Finland.
   [Karppa, Mikko; Kytovuori, Laura; Majamaa, Kari] Oulu Univ Hosp, Med Res Ctr Oulu, Oulu, Finland.
   [Karppa, Mikko; Kytovuori, Laura; Majamaa, Kari] Univ Oulu, OYS Oulu, Oulu, Finland.
   [Karppa, Mikko; Kytovuori, Laura; Majamaa, Kari] Oulu Univ Hosp, Dept Neurol, POB 20, FI-90029 Oulu, Finland.
   [Saari, Markku] Univ Turku, Turku Ctr Biotechnol Cell Imaging Core, FI-20520 Turku, Finland.
C3 University of Oulu; University of Oulu; University of Oulu; University
   of Oulu; University of Turku
RP Kytövuori, L (corresponding author), Univ Oulu, Res Unit Clin Neurosci, POB 5000, FI-90014 Oulu, Finland.; Kytövuori, L (corresponding author), Oulu Univ Hosp, Med Res Ctr Oulu, Oulu, Finland.; Kytövuori, L (corresponding author), Univ Oulu, OYS Oulu, Oulu, Finland.; Kytövuori, L (corresponding author), Oulu Univ Hosp, Dept Neurol, POB 20, FI-90029 Oulu, Finland.
EM laura.kytovuori@oulu.fi
RI Majamaa, Kari/A-1344-2012; Kytövuori, Laura/AHE-1635-2022
OI Majamaa, Kari/0000-0002-9070-3791; Kytovuori, Laura/0000-0003-2790-5646
FU Sigrid Juselius Foundation; Medical Research Center, University of Oulu;
   Oulu University Hospital
FX The study was supported by grants from the Sigrid Juselius Foundation,
   Medical Research Center, University of Oulu and Oulu University
   Hospital, and State research funding from Oulu University Hospital.
CR O'Callaghan MD, 2012, NEUROGENETICS, V13, P245, DOI 10.1007/s10048-012-0322-0
   Dubowitz V., 2006, MUSCLE BIOPSY PRACTI
   Gorman GS, 2015, ANN NEUROL, V77, P753, DOI 10.1002/ana.24362
   Lin H., 2018, NAT COMMUN, V9
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   MITOMAP, 2018, HUM MIT GEN DAT
   Nishino I, 1996, BIOCHEM BIOPH RES CO, V225, P180, DOI 10.1006/bbrc.1996.1150
   Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75
   Soini HK, 2017, BMC MED GENET, V18, DOI 10.1186/s12881-017-0377-8
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   Wang Y, 2018, NUCLEIC ACIDS RES, V46, P4662, DOI 10.1093/nar/gky243
   Yarham JW, 2011, HUM MUTAT, V32, P1319, DOI 10.1002/humu.21575
   YOON KL, 1991, BIOCHEM BIOPH RES CO, V176, P1112, DOI 10.1016/0006-291X(91)90399-R
   YOON KL, 1993, PEDIATR RES, V33, P433, DOI 10.1203/00006450-199305000-00002
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
NR 15
TC 6
Z9 6
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1471-2377
J9 BMC NEUROL
JI BMC Neurol.
PD SEP 20
PY 2018
VL 18
AR 149
DI 10.1186/s12883-018-1159-4
PG 5
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA GU4MT
UT WOS:000445258700002
PM 30236074
OA gold, Green Published
DA 2024-11-01
ER

PT J
AU DiMauro, S
   Mancuso, M
AF DiMauro, Salvatore
   Mancuso, Michelangelo
TI Mitochondrial diseases: Therapeutic approaches
SO BIOSCIENCE REPORTS
LA English
DT Article; Proceedings Paper
CT Conference on Mitochondrial Medicine
CY OCT 25, 2006
CL Univ Pisa, Dept Neurosci, Pisa, ITALY
HO Univ Pisa, Dept Neurosci
DE mtDNA; mitochondrial diseases; therapy
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; SYSTEMIC CARNITINE DEFICIENCY;
   NADH-QUINONE OXIDOREDUCTASE; COMPLEX-III DEFICIENCY; SKELETAL-MUSCLE;
   COENZYME Q(10); OXIDASE ACTIVITY; LACTIC-ACIDOSIS; POINT MUTATION; DNA
   DEPLETION
AB Therapy of mitochondrial encephalomyopathies (defined restrictively as defects of the mitochondrial respiratory chain) is woefully inadequate, despite great progress in our understanding of the molecular bases of these disorders. In this review, we consider sequentially several different therapeutic approaches. Palliative therapy is dictated by good medical practice and includes anticonvulsant medication, control of endocrine dysfunction, and surgical procedures. Removal of noxious metabolites is centered on combating lactic acidosis, but extends to other metabolites. Attempts to bypass blocks in the respiratory chain by administration of electron acceptors have not been successful, but this may be amenable to genetic engineering. Administration of metabolites and cofactors is the mainstay of real-life therapy and is especially important in disorders due to primary deficiencies of specific compounds, such as carnitine or coenzyme Q10. There is increasing interest in the administration of reactive oxygen species scavengers both in primary mitochondrial diseases and in neurodegenerative diseases directly or indirectly related to mitochondrial dysfunction. Aerobic exercise and physical therapy prevent or correct deconditioning and improve exercise tolerance in patients with mitochondrial myopathies due to mitochondrial DNA (mtDNA) mutations. Gene therapy is a challenge because of polyplasmy and heteroplasmy, but interesting experimental approaches are being pursued and include, for example, decreasing the ratio of mutant to wild-type mitochondrial genomes (gene shifting), converting mutated mtDNA genes into normal nuclear DNA genes (allotopic expression), importing cognate genes from other species, or correcting mtDNA mutations with specific restriction endonucleases. Germline therapy raises ethical problems but is being considered for prevention of maternal transmission of mtDNA mutations. Preventive therapy through genetic counseling and prenatal diagnosis is becoming increasingly important for nuclear DNA-related disorders. Progress in each of these approaches provides some glimmer of hope for the future, although much work remains to be done.
C1 Columbia Univ, Med Ctr, Dept Neurol, New York, NY 10032 USA.
   Univ Pisa, Dept Neurosci, I-56100 Pisa, Italy.
C3 Columbia University; University of Pisa
RP DiMauro, S (corresponding author), Columbia Univ, Med Ctr, Dept Neurol, 4-420 Coll Phys & Surg,630 W 168th St, New York, NY 10032 USA.
EM sd12@columbia.edu
RI Mancuso, Michelangelo/K-4170-2016
OI mancuso, michelangelo/0000-0003-2738-8562
CR ALLEN RJ, 1983, ANN NEUROL, V13, P679, DOI 10.1002/ana.410130620
   Andrews RM, 1999, EYE, V13, P769, DOI 10.1038/eye.1999.225
   ARGOV Z, 1986, ANN NEUROL, V19, P598, DOI 10.1002/ana.410190615
   Bai YD, 2001, J BIOL CHEM, V276, P38808, DOI 10.1074/jbc.M106363200
   Barritt JA, 2001, HUM REPROD, V16, P513, DOI 10.1093/humrep/16.3.513
   BAYONABAFULUY MP, 2002, P NATL ACAD SCI USA, V102, P14392
   Beal MF, 2005, ANN NEUROL, V58, P495, DOI 10.1002/ana.20624
   BERNES SM, 1993, J PEDIATR-US, V123, P598, DOI 10.1016/S0022-3476(05)80962-X
   Bohlega S, 1996, NEUROLOGY, V46, P1329, DOI 10.1212/WNL.46.5.1329
   Chinnery P, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004426.pub2
   Chinnery PF, 1999, GENE THER, V6, P1919, DOI 10.1038/sj.gt.3301061
   Clark KM, 1997, NAT GENET, V16, P222, DOI 10.1038/ng0797-222
   DEVIVO DC, 1999, PEDIAT NEUROLOGY PRI, P494
   Di Giovanni S, 2001, NEUROLOGY, V57, P515, DOI 10.1212/WNL.57.3.515
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   DIMAURO S, 1976, J NEUROL SCI, V27, P217, DOI 10.1016/0022-510X(76)90063-0
   DiMauro S., 2006, Mitochondrial Medicine, P261
   Dubern B, 2001, TRANSPLANTATION, V71, P633, DOI 10.1097/00007890-200103150-00009
   ELEFF S, 1984, P NATL ACAD SCI-BIOL, V81, P3529, DOI 10.1073/pnas.81.11.3529
   Ferrante KL, 2005, NEUROLOGY, V65, P1834, DOI 10.1212/01.wnl.0000187070.35365.d7
   Fu K, 1996, HUM MOL GENET, V5, P1835, DOI 10.1093/hmg/5.11.1835
   Guy J, 2002, ANN NEUROL, V52, P534, DOI 10.1002/ana.10354
   HAYDAR NA, 1971, ANN INTERN MED, V74, P548, DOI 10.7326/0003-4819-74-4-548
   Jaksch M, 2001, HUM MOL GENET, V10, P3025, DOI 10.1093/hmg/10.26.3025
   Karadimas CL, 2000, NEUROLOGY, V55, P644, DOI 10.1212/WNL.55.5.644
   Kaufmann P, 2006, NEUROLOGY, V66, P324, DOI 10.1212/01.wnl.0000196641.05913.27
   Kaufmann P, 2004, NEUROLOGY, V62, P1297, DOI 10.1212/01.WNL.0000120557.83907.A8
   Keightley JA, 2000, AM J HUM GENET, V67, P1400, DOI 10.1086/316900
   KENNAWAY NG, 1984, PEDIATR RES, V18, P991
   Kolesnikova OA, 2000, SCIENCE, V289, P1931, DOI 10.1126/science.289.5486.1931
   Kolesnikova OA, 2004, HUM MOL GENET, V13, P2519, DOI 10.1093/hmg/ddh267
   Mancuso M, 2006, J ALZHEIMERS DIS, V10, P59
   Manfred G, 1999, J BIOL CHEM, V274, P9386, DOI 10.1074/jbc.274.14.9386
   Manfredi G, 2002, NAT GENET, V30, P394, DOI 10.1038/ng851
   MATSUOKA T, 1992, NEUROMUSCULAR DISORD, V1, P443
   Nezu JI, 1999, NAT GENET, V21, P91, DOI 10.1038/5030
   Nishino I, 2000, ANN NEUROL, V47, P792
   Ojaimi J, 2002, MOL BIOL CELL, V13, P3836, DOI 10.1091/mbc.E02-05-0306
   Papadopoulou LC, 1999, NAT GENET, V23, P333
   Puoti G, 2003, J MED GENET, V40, P858, DOI 10.1136/jmg.40.11.858
   Qi XP, 2004, ANN NEUROL, V56, P182, DOI 10.1002/ana.20175
   Qi XP, 2003, INVEST OPHTH VIS SCI, V44, P1088, DOI 10.1167/iovs.02-0864
   Qi XP, 2003, ANN NEUROL, V53, P198, DOI 10.1002/ana.10426
   Quinzii CM, 2007, NEUROCHEM RES, V32, P723, DOI 10.1007/s11064-006-9190-z
   Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284
   Salviati L, 2002, BIOCHEM J, V363, P321, DOI 10.1042/0264-6021:3630321
   Santorelli FM, 2002, NEUROMUSCULAR DISORD, V12, P56, DOI 10.1016/S0960-8966(01)00248-6
   Santra S, 2004, ANN NEUROL, V56, P662, DOI 10.1002/ana.20240
   Seo BB, 1998, P NATL ACAD SCI USA, V95, P9167, DOI 10.1073/pnas.95.16.9167
   Shanske S, 2002, AM J HUM GENET, V71, P679, DOI 10.1086/342482
   Shoubridge EA, 1997, HUM MOL GENET, V6, P2239, DOI 10.1093/hmg/6.13.2239
   Shults CW, 2002, ARCH NEUROL-CHICAGO, V59, P1541, DOI 10.1001/archneur.59.10.1541
   Spinazzola A, 2002, J BIOL CHEM, V277, P4128, DOI 10.1074/jbc.M111028200
   STACPOOLE PW, 1989, METABOLISM, V38, P1124, DOI 10.1016/0026-0495(89)90051-6
   Sue CM, 1998, ANN NEUROL, V43, P350, DOI 10.1002/ana.410430313
   Taanman JW, 2003, HUM MOL GENET, V12, P1839, DOI 10.1093/hmg/ddg192
   Taivassalo T, 1999, HUM MOL GENET, V8, P1047, DOI 10.1093/hmg/8.6.1047
   Taivassalo T, 2005, MED SCI SPORT EXER, V37, P2094, DOI 10.1249/01.mss.0000177446.97671.2a
   Taivassalo T, 2004, BBA-BIOENERGETICS, V1659, P221, DOI 10.1016/j.bbabio.2004.09.007
   Tanaka M, 2002, J BIOMED SCI, V9, P534, DOI 10.1007/BF02254980
   Tarnopolsky MA, 1997, MUSCLE NERVE, V20, P1502, DOI 10.1002/(SICI)1097-4598(199712)20:12<1502::AID-MUS4>3.0.CO;2-C
   Taylor RW, 1997, NAT GENET, V15, P212, DOI 10.1038/ng0297-212
   TEIN I, 1990, PEDIATR RES, V28, P247, DOI 10.1203/00006450-199009000-00020
   TEIN I, 1993, PEDIATR RES, V34, P281, DOI 10.1203/00006450-199309000-00008
NR 64
TC 96
Z9 108
U1 0
U2 16
PU PORTLAND PRESS LTD
PI LONDON
PA 5TH FLR, 90 HIGH HOLBORN, LONDON WC1V 6LJ, ENGLAND
SN 0144-8463
EI 1573-4935
J9 BIOSCIENCE REP
JI Biosci. Rep.
PD JUN
PY 2007
VL 27
IS 1-3
BP 125
EP 137
DI 10.1007/s10540-007-9041-4
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)
SC Biochemistry & Molecular Biology; Cell Biology
GA 178YM
UT WOS:000247256300012
PM 17486439
DA 2024-11-01
ER

PT S
AU DiMauro, S
   Tanji, K
   Schon, EA
AF DiMauro, Salvatore
   Tanji, Kurenai
   Schon, Eric A.
BE Kadenbach, B
TI The Many Clinical Faces of Cytochrome <i>c</i> Oxidase Deficiency
SO MITOCHONDRIAL OXIDATIVE PHOSPHORYLATION: NUCLEAR-ENCODED GENES, ENZYME
   REGULATION, AND PATHOPHYSIOLOGY
SE Advances in Experimental Medicine and Biology
LA English
DT Article; Book Chapter
ID INFANTILE MITOCHONDRIAL MYOPATHY; RESPIRATORY-CHAIN DEFICIENCY;
   COPPER-BINDING PROTEIN; LEIGH-SYNDROME; HYPERTROPHIC CARDIOMYOPATHY;
   NONSENSE MUTATION; LACTIC-ACIDOSIS; RENAL DYSFUNCTION; ASSEMBLY GENES;
   COX DEFICIENCY
AB Cytochrome c oxidase (COX) catalyzes the last step in respiration, transferring electrons from cytochrome c to molecular oxygen and coupling electron transfer with proton translocation from the mitochondrial matrix to the intermembrane space. COX is composed of 13 subunits, three larger catalytic subunits encoded by mitochondrial DNA (mtDNA) and ten subunits encoded by nuclear DNA.
   Clinically heterogeneous human diseases were attributed to COX deficiency since the 1970s, mostly based on histochemical or biochemical data in muscle biopsies. Here, we revisit the COX deficiencies described before the molecular era, assess the value of COX histochemistry in conjunction with succinate dehydrogenase (SDH) stain, and review the clinical presentations of primary COX deficiencies defined at the molecular level.
   In general, mutations in mtDNA COX genes are associated with milder and later onset clinical syndromes, probably due to heteroplasmy. Mutations affecting nuclear-encoded COX subunits ("direct hits") are extremely rare whereas mutations affecting assembly proteins ("indirect hits") account for most COX deficiencies and the list keeps growing. Onset is generally in infancy and survival into adolescence or adult life is infrequent. The most common neurological disorder is Leigh syndrome, either alone or associated with cardiopathy, hepatopathy, or nephropathy.
C1 [DiMauro, Salvatore] Columbia Univ, Coll Phys & Surg, Med Ctr, Dept Neurol, New York, NY 10032 USA.
   [Tanji, Kurenai; Schon, Eric A.] Columbia Univ, Med Ctr, Dept Neurol, New York, NY 10032 USA.
   [Tanji, Kurenai] Columbia Univ, Med Ctr, Dept Pathol & Cell Biol, New York, NY 10032 USA.
   [Schon, Eric A.] Columbia Univ, Med Ctr, Dept Genet & Dev, New York, NY 10032 USA.
C3 Columbia University; Columbia University; Columbia University; Columbia
   University
RP DiMauro, S (corresponding author), Columbia Univ, Coll Phys & Surg, Med Ctr, Dept Neurol, New York, NY 10032 USA.
EM sd12@columbia.edu; kt8@columbia.edu; eas3@columbia.edu
FU PHS HHS [P01-H23062] Funding Source: Medline
CR Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   Antonicka H, 2003, HUM MOL GENET, V12, P2693, DOI 10.1093/hmg/ddg284
   Antonicka H, 2003, AM J HUM GENET, V72, P101, DOI 10.1086/345489
   BARDOSI A, 1987, ACTA NEUROPATHOL, V74, P248, DOI 10.1007/BF00688189
   Betts J, 2008, NEUROLOGY, V70, P1290, DOI 10.1212/01.wnl.0000308940.38092.74
   Betts J, 2006, NEUROPATH APPL NEURO, V32, P359, DOI 10.1111/j.1365-2990.2006.00731.x
   Böhm M, 2006, PEDIATR RES, V59, P21, DOI 10.1203/01.pdr.0000190572.68191.13
   Borthwick Gillian M, 2006, Ann Neurol, V59, P570, DOI 10.1002/ana.20758
   Borthwick GM, 1999, ANN NEUROL, V46, P787, DOI 10.1002/1531-8249(199911)46:5<787::AID-ANA17>3.0.CO;2-8
   BOUSTANY RN, 1983, ANN NEUROL, V14, P462, DOI 10.1002/ana.410140411
   BRESOLIN N, 1985, NEUROLOGY, V35, P802, DOI 10.1212/WNL.35.6.802
   Brosel S, 2010, AM J PATHOL, V177, P2541, DOI 10.2353/ajpath.2010.100229
   Bugiani M, 2005, J MED GENET, V42, DOI 10.1136/jmg.2004.029926
   Chrzanowska-Lightowlers Z M A, 2011, Neuromuscul Disord, V21, P142, DOI 10.1016/j.nmd.2010.10.005
   Coenen MJH, 2006, J CHILD NEUROL, V21, P508, DOI 10.1177/08830738060210062501
   Comi GP, 1998, ANN NEUROL, V43, P110, DOI 10.1002/ana.410430119
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   DIMAURO S, 1983, ANN NEUROL, V14, P226, DOI 10.1002/ana.410140209
   DIMAURO S, 1980, NEUROLOGY, V30, P795, DOI 10.1212/WNL.30.8.795
   DIMAURO S, 1986, ANN NY ACAD SCI, V488, P19
   DIMAURO S, 1990, PEDIATR RES, V28, P536, DOI 10.1203/00006450-199011000-00025
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   Fontanesi F, 2008, IUBMB LIFE, V60, P557, DOI 10.1002/iub.86
   Fontanesi F, 2006, AM J PHYSIOL-CELL PH, V291, pC1129, DOI 10.1152/ajpcell.00233.2006
   Freisinger P, 2004, J INHERIT METAB DIS, V27, P67, DOI 10.1023/B:BOLI.0000016614.47380.2f
   Ghezzi D, 2008, AM J HUM GENET, V83, P415, DOI 10.1016/j.ajhg.2008.08.009
   Greaves LC, 2006, P NATL ACAD SCI USA, V103, P714, DOI 10.1073/pnas.0505903103
   HEIMANPATTERSON TD, 1982, NEUROLOGY, V32, P898, DOI 10.1212/WNL.32.8.898
   Hirano M, 2005, GENE, V354, P152, DOI 10.1016/j.gene.2005.04.041
   Horvath R, 2000, BIOCHEM BIOPH RES CO, V276, P530, DOI 10.1006/bbrc.2000.3495
   Horvath R, 2009, BRAIN, V132, P3165, DOI 10.1093/brain/awp221
   Huigsloot M, 2011, AM J HUM GENET, V88, P488, DOI 10.1016/j.ajhg.2011.03.002
   Hüttemann M, 2003, GENE, V312, P95, DOI 10.1016/S0378-1119(03)00604-8
   Jaksch M, 2000, HUM MOL GENET, V9, P795, DOI 10.1093/hmg/9.5.795
   Jaksch M, 2001, HUM MOL GENET, V10, P3025, DOI 10.1093/hmg/10.26.3025
   Jaksch M, 2001, NEUROLOGY, V57, P1440, DOI 10.1212/WNL.57.8.1440
   Karadimas CL, 2000, NEUROLOGY, V55, P644, DOI 10.1212/WNL.55.5.644
   KENNAWAY NG, 1990, PEDIATR RES, V28, P529
   Knuf M, 2007, ACTA PAEDIATR, V96, P130, DOI 10.1111/j.1651-2227.2007.00008.x
   Kollberg G, 2005, J NEUROPATH EXP NEUR, V64, P123, DOI 10.1093/jnen/64.2.123
   Leary SC, 2006, MOL GENET METAB, V89, P129, DOI 10.1016/j.ymgme.2006.04.016
   MANFREDI G, 1995, NEUROMUSCULAR DISORD, V5, P391, DOI 10.1016/0960-8966(94)00079-O
   Massa V, 2008, AM J HUM GENET, V82, P1281, DOI 10.1016/j.ajhg.2008.05.002
   McFarland R, 2004, NEUROMUSCULAR DISORD, V14, P162, DOI 10.1016/j.nmd.2003.10.011
   Menkes JH, 2008, MOL GENETIC BASIS NE, P721
   Mimaki M, 2010, ANN NEUROL, V68, P845, DOI 10.1002/ana.22111
   MINCHOM PE, 1983, J NEUROL SCI, V60, P453, DOI 10.1016/0022-510X(83)90156-9
   Mkaouar-Rebai E, 2011, J CHILD NEUROL, V26, P12, DOI 10.1177/0883073810371227
   Mootha VK, 2003, P NATL ACAD SCI USA, V100, P605, DOI 10.1073/pnas.242716699
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   MORIN C, 1993, AM J HUM GENET, V53, P488
   Oquendo CE, 2004, J MED GENET, V41, P540, DOI 10.1136/jmg.2003.017426
   Papadopoulou LC, 1999, NAT GENET, V23, P333
   Péquignot MO, 2001, HUM MUTAT, V17, P374, DOI 10.1002/humu.1112.abs
   Rossmanith W, 2008, J MED GENET, V45, P117, DOI 10.1136/jmg.2007.052076
   Sacconi S, 2003, PEDIATR RES, V53, P224, DOI 10.1203/01.PDR.0000048100.91730.6A
   Salviati L, 2002, BIOCHEM J, V363, P321, DOI 10.1042/0264-6021:3630321
   Salviati L, 2001, MITOCHONDRION, V1, pS82
   Schara U, 2011, J INHERIT METAB DIS, V34, P197, DOI 10.1007/s10545-010-9250-z
   Seeger J, 2010, NEUROMUSCULAR DISORD, V20, P720, DOI 10.1016/j.nmd.2010.06.017
   SERVIDEI S, 1987, NEUROLOGY, V37, P58, DOI 10.1212/WNL.37.1.58
   Sue CM, 2000, ANN NEUROL, V47, P589, DOI 10.1002/1531-8249(200005)47:5<589::AID-ANA6>3.3.CO;2-4
   Tarnopolsky MA, 2004, AM J MED GENET A, V125A, P310, DOI 10.1002/ajmg.a.20466
   Tay SKH, 2004, ARCH NEUROL-CHICAGO, V61, P950, DOI 10.1001/archneur.61.6.950
   Tiranti V, 1998, AM J HUM GENET, V63, P1609, DOI 10.1086/302150
   Tiranti V, 2009, NAT MED, V15, P200, DOI 10.1038/nm.1907
   Uusimaa J, 2011, J MED GENET, V48, P660, DOI 10.1136/jmg.2011.089995
   Uusimaa J, 2003, PEDIATRICS, V111, DOI 10.1542/peds.111.3.e262
   Valnot I, 2000, AM J HUM GENET, V67, P1104
   Valnot I, 2000, HUM MOL GENET, V9, P1245, DOI 10.1093/hmg/9.8.1245
   VANBIERVLIET JPGM, 1977, PEDIATR RES, V11, P1088, DOI 10.1203/00006450-197711100-00005
   VANCOSTER R, 1991, J NEUROL SCI, V104, P97, DOI 10.1016/0022-510X(91)90222-S
   Vesela K, 2008, APMIS, V116, P41, DOI 10.1111/j.1600-0463.2008.00772.x
   Weraarpachai W, 2012, AM J HUM GENET, V90, P142, DOI 10.1016/j.ajhg.2011.11.027
   Weraarpachai W, 2009, NAT GENET, V41, P833, DOI 10.1038/ng.390
   WILLEMS JL, 1977, PEDIATRICS, V60, P850
   Williams SL, 2004, J BIOL CHEM, V279, P7462, DOI 10.1074/jbc.M309232200
   Wong LJC, 2001, AM J MED GENET, V102, P95, DOI 10.1002/1096-8628(20010722)102:1<95::AID-AJMG1412>3.0.CO;2-U
   Xu FH, 2004, BIOCHEM J, V382, P331, DOI 10.1042/BJ20040469
   ZEVIANI M, 1985, ANN NEUROL, V17, P414, DOI 10.1002/ana.410170422
   ZEVIANI M, 1986, ARCH NEUROL-CHICAGO, V43, P1198, DOI 10.1001/archneur.1986.00520110084025
   Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804
NR 82
TC 49
Z9 51
U1 1
U2 6
PU SPRINGER-VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
SN 0065-2598
EI 2214-8019
BN 978-1-4614-3572-3; 978-1-4614-3573-0
J9 ADV EXP MED BIOL
JI Adv.Exp.Med.Biol.
PY 2012
VL 748
BP 341
EP 357
DI 10.1007/978-1-4614-3573-0_14
D2 10.1007/978-1-4614-3573-0
PG 17
WC Cell Biology; Genetics & Heredity
WE Book Citation Index – Science (BKCI-S); Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Genetics & Heredity
GA BA2SD
UT WOS:000333845500015
PM 22729865
DA 2024-11-01
ER

PT J
AU Bhatt, PS
   Tzoulis, C
   Balafkan, N
   Miletic, H
   Tran, GTT
   Sanaker, PS
   Bindoff, LA
AF Bhatt, Padmanabh S.
   Tzoulis, Charalampos
   Balafkan, Novin
   Miletic, Hrvoje
   Gia Tuong Thi Tran
   Sanaker, Petter Schandl
   Bindoff, Laurence A.
TI Mitochondrial DNA depletion in sporadic inclusion body myositis
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE Sporadic inclusion body myositis; Mitochondrial DNA depletion;
   Mitochondrial DNA deletion; Necrotising myopathy
ID DELETIONS; ABNORMALITIES; PATHOGENESIS; DIAGNOSIS; MUSCLE
AB Sporadic inclusion body myositis (sIBM) is a late onset disorder of unkown aetiology. Mitochondrial changes such as cytochrome oxidase deficient fibres are a well recognised feature and mitochondrial DNA (mtDNA) deletions have also been reported, but not consistently. Since mtDNA deletions are not present in all cases, we investigated whether other types of mtDNA abnormality were responsible for the mitochondrial changes. We studied 9 patients with sIBM. To control for fibre loss or replacement with inflammatory cells, we compared sIBM patients with necrotising myopathy (n = 4) as well as with healthy controls. Qualitative anlysis for mtDNA deletions and quantitative measurement of mtDNA copy number showed that muscle from patients with sIBM contained on average 67% less mtDNA than healthy controls (P=0.001). The level of mtDNA was also significantly depleted in sIBM when compared to necrotising myopathy. No significant difference in copy number was seen in patients with necrotising myopathy compared to controls. Deletions of mtDNA were present in 4 patients with sIBM, but not all. Our findings suggest that mtDNA depletion is a more consistent finding in sIBM, and one that may be implicated in the pathogenesis of the disease. (C) 2019 Elsevier B.V. All rights reserved.
C1 [Bhatt, Padmanabh S.; Tzoulis, Charalampos; Sanaker, Petter Schandl; Bindoff, Laurence A.] Haukeland Hosp, Dept Neurol, N-5021 Bergen, Norway.
   [Tzoulis, Charalampos; Balafkan, Novin; Gia Tuong Thi Tran; Bindoff, Laurence A.] Univ Bergen, Dept Clin Med K1, Pb 7804, N-5020 Bergen, Norway.
   [Miletic, Hrvoje] Haukeland Hosp, Dept Pathol, N-5021 Bergen, Norway.
   [Miletic, Hrvoje] Univ Bergen, Dept Biomed, Pb 7804, N-5020 Bergen, Norway.
C3 University of Bergen; Haukeland University Hospital; University of
   Bergen; University of Bergen; Haukeland University Hospital; University
   of Bergen
RP Bindoff, LA (corresponding author), Haukeland Hosp, Dept Neurol, N-5021 Bergen, Norway.
EM laurence.bindoff@nevro.uib.no
RI Balafkan, Novin/AAE-9134-2019; Tzoulis, Charalampos/AGD-5114-2022
OI Tzoulis, Charalampos/0000-0003-0341-5191; Balafkan,
   Novin/0000-0001-8868-3800; Bindoff, Laurence/0000-0003-0988-276X; Bhatt,
   Padmanabh/0000-0002-6814-0697
CR Askanas V, 2015, BBA-MOL BASIS DIS, V1852, P633, DOI [10.1016/j.bbadis.201409.005, 10.1016/j.bbadis.2014.09.005]
   Campbell GR, 2013, NEUROPATH APPL NEURO, V39, P377, DOI 10.1111/j.1365-2990.2012.01290.x
   Catalán-García M, 2016, CLIN SCI, V130, P1741, DOI 10.1042/CS20160080
   CORTOPASSI GA, 1992, P NATL ACAD SCI USA, V89, P7370, DOI 10.1073/pnas.89.16.7370
   Dalakas MC, 2006, NAT CLIN PRACT NEURO, V2, P437, DOI 10.1038/ncpneuro0261
   Dobloug C, 2012, CLIN EXP RHEUMATOL, V30, P838
   Dölle C, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19745-9
   Downham E, 2008, NEUROMUSCULAR DISORD, V18, P310, DOI 10.1016/j.nmd.2008.01.003
   Horvath R, 1998, J NEUROPATH EXP NEUR, V57, P396, DOI 10.1097/00005072-199805000-00003
   Johnson Liam G, 2009, J Clin Neuromuscul Dis, V10, P178, DOI 10.1097/CND.0b013e3181a23c86
   Lindgren U, 2015, NEUROMUSCULAR DISORD, V25, P281, DOI 10.1016/j.nmd.2014.12.010
   Molberg O, 2016, CURR OPIN RHEUMATOL, V28, P657, DOI 10.1097/BOR.0000000000000327
   Moslemi AR, 1997, HUM MUTAT, V10, P381, DOI 10.1002/(SICI)1098-1004(1997)10:5<381::AID-HUMU8>3.0.CO;2-I
   Needham M, 2016, CLIN NEUROPHYSIOL, V127, P1764, DOI 10.1016/j.clinph.2015.12.011
   Oldfors A, 2006, NEUROLOGY, V66, pS49, DOI 10.1212/01.wnl.0000192127.63013.8d
   OLDFORS A, 1993, BRAIN, V116, P325, DOI 10.1093/brain/116.2.325
   Rose MR, 2013, NEUROMUSCULAR DISORD, V23, P1044, DOI 10.1016/j.nmd.2013.08.007
   Rygiel KA, 2015, NEUROPATH APPL NEURO, V41, P288, DOI 10.1111/nan.12149
   Rygiel KA, 2016, NUCLEIC ACIDS RES, V44, P5313, DOI 10.1093/nar/gkw382
   Tzoulis C, 2014, ANN NEUROL, V76, P66, DOI 10.1002/ana.24185
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
NR 21
TC 9
Z9 10
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD MAR
PY 2019
VL 29
IS 3
BP 242
EP 246
DI 10.1016/j.nmd.2019.02.001
PG 5
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA HS7ZK
UT WOS:000464087600008
PM 30850168
OA Green Published, hybrid
DA 2024-11-01
ER

PT J
AU Varma, H
   Faust, PL
   Iglesias, AD
   Lagana, SM
   Wou, K
   Hirano, M
   DiMauro, S
   Mansukani, MM
   Hoff, KE
   Nagy, PL
   Copeland, WC
   Naini, AB
AF Varma, Hemant
   Faust, Phyllis L.
   Iglesias, Alejandro D.
   Lagana, Stephen M.
   Wou, Karen
   Hirano, Michio
   DiMauro, Salvatore
   Mansukani, Mahesh M.
   Hoff, Kirsten E.
   Nagy, Peter L.
   Copeland, William C.
   Naini, Ali B.
TI Whole exome sequencing identifies a homozygous <i>POLG2</i> missense
   variant in an infant with fulminant hepatic failure and mitochondrial
   DNA depletion
SO EUROPEAN JOURNAL OF MEDICAL GENETICS
LA English
DT Article
DE Mitochondrial DNA depletion; POLG2; Hepatic failure; Whole-exome
   sequencing; POLG
ID POLYMERASE GAMMA; ACCESSORY SUBUNIT; DISEASE
AB Mitochondrial DNA (mtDNA) depletion syndrome manifests as diverse early-onset diseases that affect skeletal muscle, brain and liver function. Mutations in several nuclear DNA-encoded genes cause mtDNA depletion. We report on a patient, a 3-month-old boy who presented with hepatic failure, and was found to have severe mtDNA depletion in liver and muscle. Whole-exome sequencing identified a homozygous missense variant (c.544C > T, p.R182W) in the accessory subunit of mitochondrial DNA polymerase gamma (POLG2), which is required for mitochondrial DNA replication. This variant is predicted to disrupt a critical region needed for homodimerization of the POLG2 protein and cause loss of processive DNA synthesis. Both parents were phenotypically normal and heterozygous for this variant. Heterozygous mutations in POLG2 were previously associated with progressive external ophthalmoplegia and mtDNA deletions. This is the first report of a patient with a homozygous mutation in POLG2 and with a clinical presentation of severe hepatic failure and mitochondrial depletion. (C) 2016 Elsevier Masson SAS. All rights reserved.
C1 [Varma, Hemant; Faust, Phyllis L.; Lagana, Stephen M.; Mansukani, Mahesh M.; Nagy, Peter L.; Naini, Ali B.] Columbia Univ, Dept Pathol & Cell Biol, 630 W,168th St, New York, NY 10032 USA.
   [Iglesias, Alejandro D.] Columbia Univ, Div Med Genet, New York Presbyterian Hosp, New York, NY 10027 USA.
   [Wou, Karen] New York Presbyterian Hosp, Div Genet, New York, NY USA.
   [Hirano, Michio; DiMauro, Salvatore] Columbia Univ, Med Ctr, Dept Neurol, New York, NY 10027 USA.
   [Mansukani, Mahesh M.; Nagy, Peter L.; Naini, Ali B.] Columbia Univ, Med Ctr, Div Personalized Genom Med, Dept Pathol & Cell Biol, New York, NY 10027 USA.
   [Hoff, Kirsten E.; Copeland, William C.] NIEHS, Genome Integr & Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA.
C3 Columbia University; NewYork-Presbyterian Hospital; Columbia University;
   NewYork-Presbyterian Hospital; Columbia University; Columbia University;
   National Institutes of Health (NIH) - USA; NIH National Institute of
   Environmental Health Sciences (NIEHS)
RP Copeland, WC (corresponding author), NIEHS, Genome Integr & Struct Biol Lab, NIH, Res Triangle Pk, NC 27709 USA.; Naini, AB (corresponding author), 630 W 168th St,P&S 17-401, New York, NY 10032 USA.
EM copelan1@niehs.nih.gov; abn2@cumc.columbia.edu
RI Wou, Karen/K-7453-2019; Nagy, Peter/AAT-6055-2020; Copeland,
   William/C-4242-2019
OI Nagy, Peter Lajos/0000-0002-7461-8415; Copeland,
   William/0000-0002-0359-0953
FU National Institutes of Health [5P01 HD080642-02 NIH/NICHD]; Intramural
   Research Program of the NIH, National Institute of Environmental Health
   Sciences [ES 065078]
FX Part of this research was supported by National Institutes of Health
   grants 5P01 HD080642-02 NIH/NICHD (to ABN) and the Intramural Research
   Program of the NIH, National Institute of Environmental Health Sciences
   (ES 065078 to WCC). We thank the CUMC Neuromuscular Laboratory for
   performing the enzyme histochemistry staining of the muscle biopsy. The
   variant has been submitted to the ClinVar database (Submission number:
   SUB1740227).
CR Bourgeois JM, 2004, MITOCHONDRION, V4, P441, DOI 10.1016/j.mito.2004.07.036
   Carrodeguas JA, 2001, MOL CELL, V7, P43, DOI 10.1016/S1097-2765(01)00153-8
   Copeland WC, 2014, J CHILD NEUROL, V29, P1216, DOI 10.1177/0883073814537380
   Cossarizza A, 2003, ANTIVIR THER, V8, P315
   El-Hattab A, 2013, NEUROTHERAPEUTICS, V10, P186, DOI 10.1007/s13311-013-0177-6
   Fan L, 2006, J MOL BIOL, V358, P1229, DOI 10.1016/j.jmb.2006.02.073
   Finsterer J, 2013, CAN J NEUROL SCI, V40, P635, DOI 10.1017/S0317167100014852
   Humble MM, 2013, HUM MOL GENET, V22, P1017, DOI 10.1093/hmg/dds506
   Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Mandel H, 2001, HEPATOLOGY, V34, P776, DOI 10.1053/jhep.2001.27664
   Oliveira MT, 2015, GENOME BIOL EVOL, V7, P943, DOI 10.1093/gbe/evv042
   Pagliarini DJ, 2008, CELL, V134, P112, DOI 10.1016/j.cell.2008.06.016
   Poulton Joanna, 2009, Neuromuscul Disord, V19, P439, DOI 10.1016/j.nmd.2009.04.009
   Suomalainen A, 2010, NEUROMUSCULAR DISORD, V20, P429, DOI 10.1016/j.nmd.2010.03.017
   Tanji K, 2001, METHOD CELL BIOL, V65, P311, DOI 10.1016/S0091-679X(01)65019-2
   Walter MC, 2010, J NEUROL, V257, P1517, DOI 10.1007/s00415-010-5565-9
   Yakubovskaya E, 2006, J BIOL CHEM, V281, P374, DOI 10.1074/jbc.M509730200
   Young MJ, 2015, HUM MOL GENET, V24, P5184, DOI 10.1093/hmg/ddv240
   Young MJ, 2011, HUM MOL GENET, V20, P3052, DOI 10.1093/hmg/ddr209
   Young MJ., 2013, MITOCHONDRIAL DISORD, P49, DOI [10.1007/978-1-4614-3722-2_3, DOI 10.1007/978-1-4614-3722-2_3]
NR 21
TC 19
Z9 21
U1 0
U2 3
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1769-7212
EI 1878-0849
J9 EUR J MED GENET
JI Eur. J. Med. Genet.
PD OCT
PY 2016
VL 59
IS 10
BP 540
EP 545
DI 10.1016/j.ejmg.2016.08.012
PG 6
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA EC6YS
UT WOS:000388283200011
PM 27592148
OA Green Accepted
DA 2024-11-01
ER

PT J
AU De Block, CEM
   De Leeuw, IH
   Maassen, JA
   Ballaux, D
   Martin, JJ
AF De Block, CEM
   De Leeuw, IH
   Maassen, JA
   Ballaux, D
   Martin, JJ
TI A novel 7301-bp deletion in mitochondrial DNA in a patient with
   Kearns-Dayre syndrome, diabetes mellitus, and primary amenorrhoea
SO EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
LA English
DT Article
DE Kearns-Sayre syndrome; mitochondrial DNA mutations; diabetes mellitus
ID SAYRE SYNDROME; EXTERNAL OPHTHALMOPLEGIA; TRNA(LEU(UUR)) GENE; POINT
   MUTATION; HYPOPARATHYROIDISM; ENCEPHALOMYOPATHY; CYTOPATHY; DEAFNESS;
   MYOPATHY; MUSCLE
AB We report a 27-year-old woman with a form of mitochondrial myopathy including chronic progressive external opthalmoplegia, retinal pigmentary dystrophy, cerebellar ataxia, and cardiac conduction block (Kearns-Sayre syndrome). At age 13 years a cardiac pacemaker was implanted. She also had sensineural hearing loss, delayed puberty, and primary amenorrhoea. She was weelchair-bound since the age of 20 years. At age 27, insulin-dependent diabetes mellitus and osteoporosis were diagnosed. Insulin treatment was started and associated endocrinopathies were investigated. DNA analysis identified a novel 7301-bp deletion in mitochondrial DNA, ranging from position 6530 to 13831 corroborating the diagnosis of Kearns-Sayre syndrome.
C1 Univ Hosp Antwerp, Dept Endocrinol Diabetol, B-2650 Edegem, Belgium.
   Leiden Univ, Ctr Med, Sect Signal Transduct, Dept Mol Cell Biol, Leiden, Netherlands.
   Vrije Univ Amsterdam, Leiden, Netherlands.
   Univ Hosp Antwerp, Dept Neurol, Edegem, Belgium.
C3 University of Antwerp; Leiden University - Excl LUMC; Leiden University;
   Vrije Universiteit Amsterdam; University of Antwerp
RP Univ Hosp Antwerp, Dept Endocrinol Diabetol, Wilrijkstr 10, B-2650 Edegem, Belgium.
EM christophe.deblock@ua.ac.be
RI De+Block, Christophe/ABE-1600-2020
OI De Block, Christophe/0000-0002-0679-3203
CR Abramowicz MJ, 1996, J INHERIT METAB DIS, V19, P109, DOI 10.1007/BF01799405
   BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11
   BERENBERG RA, 1977, ANN NEUROL, V1, P37, DOI 10.1002/ana.410010104
   BURNS EC, 1982, ACTA PAEDIATR SCAND, V71, P693, DOI 10.1111/j.1651-2227.1982.tb09504.x
   COULTER DL, 1981, ARCH NEUROL-CHICAGO, V38, P247, DOI 10.1001/archneur.1981.00510040073013
   EGGER J, 1981, ARCH DIS CHILD, V56, P741, DOI 10.1136/adc.56.10.741
   HARVEY JN, 1992, CLIN ENDOCRINOL, V37, P97, DOI 10.1111/j.1365-2265.1992.tb02289.x
   KADOWAKI T, 1994, NEW ENGL J MED, V330, P962, DOI 10.1056/NEJM199404073301403
   KARPATI G, 1973, J NEUROL SCI, V19, P133, DOI 10.1016/0022-510X(73)90158-5
   KEARNS TP, 1958, ARCH OPHTHALMOL-CHIC, V60, P280, DOI 10.1001/archopht.1958.00940080296016
   KISHIMOTO M, 1995, DIABETOLOGIA, V38, P193, DOI 10.1007/s001250050270
   KURIYAMA M, 1984, NEUROLOGY, V34, P253, DOI 10.1212/WNL.34.2.253
   Maassen JA, 2002, AM J MED GENET, V115, P66, DOI 10.1002/ajmg.10346
   MANDRUPPOULSEN T, 1990, CURR TOP MICROBIOL, V164, P169
   Manolagas SC, 2000, ENDOCR REV, V21, P115, DOI 10.1210/er.21.2.115
   McDonald W I, 1972, Trans Ophthalmol Soc U K, V92, P179
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Oexle K, 1996, EXP CLIN ENDOCR DIAB, V104, P212, DOI 10.1055/s-0029-1211445
   Ohno K, 1996, ANN NEUROL, V39, P761, DOI 10.1002/ana.410390612
   OKA Y, 1993, LANCET, V342, P527, DOI 10.1016/0140-6736(93)91649-7
   PELLOCK JM, 1978, ANN NEUROL, V3, P455, DOI 10.1002/ana.410030519
   QUADE A, 1992, CLIN INVESTIGATOR, V70, P396
   REARDON W, 1992, LANCET, V340, P1376, DOI 10.1016/0140-6736(92)92560-3
   SHANSKE S, 1990, NEUROLOGY, V40, P24, DOI 10.1212/WNL.40.1.24
   Tengan CH, 1998, J CLIN ENDOCR METAB, V83, P125, DOI 10.1210/jc.83.1.125
   van den Ouweland JMW, 2000, EUR J HUM GENET, V8, P195, DOI 10.1038/sj.ejhg.5200444
   vandeCorput MPC, 1997, J HISTOCHEM CYTOCHEM, V45, P55
   VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368
   WALLACE DC, 1995, BIOCHIM BIOPHYS ACTA, V1271, P1411
   YONEDA M, 1992, P NATL ACAD SCI USA, V89, P11164, DOI 10.1073/pnas.89.23.11164
NR 30
TC 14
Z9 14
U1 0
U2 5
PU JOHANN AMBROSIUS BARTH VERLAG MEDIZINVERLAGE HEIDELBERG GMBH
PI STUTTGART
PA RUEDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0947-7349
EI 1439-3646
J9 EXP CLIN ENDOCR DIAB
JI Exp. Clin. Endocrinol. Diabet.
PD FEB
PY 2004
VL 112
IS 2
BP 80
EP 83
DI 10.1055/s-2004-815754
PG 4
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA 807BO
UT WOS:000220477200003
PM 15031771
DA 2024-11-01
ER

PT J
AU Wong, LJC
   Scaglia, F
   Graham, BH
   Craigen, WJ
AF Wong, Lee-Jun C.
   Scaglia, Fernando
   Graham, Brett H.
   Craigen, William J.
TI Current molecular diagnostic algorithm for mitochondrial disorders
SO MOLECULAR GENETICS AND METABOLISM
LA English
DT Review
DE Mitochondrial disorder; mtDNA mutation; mtDNA depletion; mtDNA deletion
ID RESPIRATORY-CHAIN DISORDERS; COENZYME Q(10) DEFICIENCY; C-OXIDASE
   DEFICIENCY; DNA DEPLETION; COMPLEX-I; OXIDATIVE-PHOSPHORYLATION;
   CLINICAL SPECTRUM; SUCLA2 MUTATIONS; LACTIC-ACIDOSIS; MTDNA MUTATION
AB Mitochondrial respiratory chain disorders (RCD) are a group of genetically and clinically heterogeneous diseases, clue in part to the biochemical complexity of mitochondrial respiration and the fact that two genomes, one mitochondrial and one nuclear, encode the components of the respiratory chain. Because of the large number of genes involved, attempts to classify mitochondrial RCD incorporate clinical, biochemical, and histological criteria, in addition to DNA-based molecular diagnostic testing. While molecular testing is widely viewed as definitive, confirmation of the diagnosis by molecular methods often remains a challenge because of the large number of genes, the two genome complexity and the varying proportions of pathogenic mitochondrial DNA (mtDNA) molecules in a patient, a concept termed heteroplasmy. The selection of genes to be analyzed depends on the family history and clinical, biochemical, histopathological, and imaging results, as well as the availability of different tissues for analysis. Screening of common point mutations and large deletions in mtDNA is typically the first step. In cases where tissue-specific, recognizable clinical syndromes or characteristic RC complex deficiencies and histochemical abnormalities are observed, direct sequencing of the specific causative nuclear gene(s) can be performed on white blood cell DNA. Measurement of mtDNA content in affected tissues such as muscle and liver allows screening for mtDNA depletion syndromes. The ever-expanding list of known disease-causing genes will undoubtedly improve diagnostic accuracy and genetic counseling. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Wong, Lee-Jun C.; Scaglia, Fernando; Graham, Brett H.; Craigen, William J.] Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
C3 Baylor College of Medicine
RP Wong, LJC (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, 1 Baylor Plaza,NAB 2015, Houston, TX 77030 USA.
EM ljwong@bcm.edu
RI Graham, Brett/R-8685-2018
OI Graham, Brett/0000-0001-8451-8154
CR Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   Böhm M, 2006, PEDIATR RES, V59, P21, DOI 10.1203/01.pdr.0000190572.68191.13
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Carrozzo R, 2007, BRAIN, V130, P862, DOI 10.1093/brain/awl389
   Chretien D, 2003, J INHERIT METAB DIS, V26, P189, DOI 10.1023/A:1024437201166
   Dimmock DP, 2008, HUM MUTAT, V29, P330, DOI 10.1002/humu.9519
   Duncan AJ, 2009, AM J HUM GENET, V84, P558, DOI 10.1016/j.ajhg.2009.03.018
   Elliott HR, 2008, AM J HUM GENET, V83, P254, DOI 10.1016/j.ajhg.2008.07.004
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Guan MX, 2001, HUM MOL GENET, V10, P573, DOI 10.1093/hmg/10.6.573
   Haas RH, 2008, MOL GENET METAB, V94, P16, DOI 10.1016/j.ymgme.2007.11.018
   Haas RH, 2007, PEDIATRICS, V120, P1326, DOI 10.1542/peds.2007-0391
   Hui J, 2006, DEV MED CHILD NEUROL, V48, P132, DOI 10.1017/S0012162206000284
   Jaksch M, 1998, J MED GENET, V35, P895, DOI 10.1136/jmg.35.11.895
   Jaksch M, 2001, J MED GENET, V38, P665, DOI 10.1136/jmg.38.10.665
   Kirby DM, 1999, NEUROLOGY, V52, P1255, DOI 10.1212/WNL.52.6.1255
   Lagier-Tourenne C, 2008, AM J HUM GENET, V82, P661, DOI 10.1016/j.ajhg.2007.12.024
   Liang MH, 1998, AM J MED GENET, V77, P395, DOI 10.1002/(SICI)1096-8628(19980605)77:5<395::AID-AJMG8>3.0.CO;2-M
   Marotta R, 2004, INTERN MED J, V34, P10, DOI 10.1111/j.1444-0903.2004.t01-3-.x
   McDonnell MT, 2004, EUR J HUM GENET, V12, P778, DOI 10.1038/sj.ejhg.5201216
   Mollet J, 2008, AM J HUM GENET, V82, P623, DOI 10.1016/j.ajhg.2007.12.022
   Naïmi M, 2006, EUR J HUM GENET, V14, P917, DOI 10.1038/sj.ejhg.5201627
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Oskoui M, 2006, ARCH NEUROL-CHICAGO, V63, P1122, DOI 10.1001/archneur.63.8.1122
   Ostergaard E, 2007, AM J HUM GENET, V81, P383, DOI 10.1086/519222
   Ostergaard E, 2007, BRAIN, V130, P853, DOI 10.1093/brain/awl383
   Pagliarini DJ, 2008, CELL, V134, P112, DOI 10.1016/j.cell.2008.06.016
   Papadopoulou LC, 1999, NAT GENET, V23, P333
   PoggiTravert F, 1996, J INHERIT METAB DIS, V19, P478, DOI 10.1007/BF01799109
   Quinzii CM, 2007, NEUROCHEM RES, V32, P723, DOI 10.1007/s11064-006-9190-z
   Rahman S, 2001, AM J HUM GENET, V68, P238, DOI 10.1086/316930
   ROBINSON BH, 1993, BIOCHIM BIOPHYS ACTA, V1182, P231, DOI 10.1016/0925-4439(93)90064-8
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Scaglia F, 2004, PEDIATRICS, V114, P925, DOI 10.1542/peds.2004-0718
   Schaefer AM, 2004, BBA-BIOENERGETICS, V1659, P115, DOI 10.1016/j.bbabio.2004.09.005
   Schaefer AM, 2008, ANN NEUROL, V63, P35, DOI 10.1002/ana.21217
   Shoubridge EA, 2001, AM J MED GENET, V106, P46, DOI 10.1002/ajmg.1378
   Skladal D, 2003, BRAIN, V126, P1905, DOI 10.1093/brain/awg170
   Thorburn DR, 2001, J INHERIT METAB DIS, V24, P312, DOI 10.1023/A:1010347808082
   Triepels RH, 1999, ANN NEUROL, V45, P787, DOI 10.1002/1531-8249(199906)45:6<787::AID-ANA13>3.0.CO;2-6
   van den Heuvel LP, 2004, MITOCHONDRION, V4, P395, DOI 10.1016/j.mito.2004.07.005
   Vogel H, 2001, J NEUROPATH EXP NEUR, V60, P217, DOI 10.1093/jnen/60.3.217
   Wolf NI, 2002, NEUROLOGY, V59, P1402, DOI 10.1212/01.WNL.0000031795.91814.D8
   Wong LJC, 2008, CLIN CHEM, V54, P1141, DOI 10.1373/clinchem.2008.103721
   Wong LJC, 2007, HEPATOLOGY, V46, P1218, DOI 10.1002/hep.21799
   Wong LJC, 2008, HUM MUTAT, V29, pE150, DOI 10.1002/humu.20824
   Wong LJC, 2004, MUSCLE NERVE, V30, P118, DOI 10.1002/mus.20045
   Wong LJC, 2003, J MED GENET, V40
NR 48
TC 50
Z9 54
U1 0
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1096-7192
J9 MOL GENET METAB
JI Mol. Genet. Metab.
PD JUN
PY 2010
VL 100
IS 2
BP 111
EP 117
DI 10.1016/j.ymgme.2010.02.024
PG 7
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental
   Medicine
GA 601SP
UT WOS:000278084600002
PM 20359921
DA 2024-11-01
ER

PT J
AU Cruz, S
   Taipa, R
   Nogueira, C
   Pereira, C
   Almeida, LS
   Neiva, R
   Geraldes, T
   Guimaraes, A
   Melo-Pires, M
   Vilarinho, L
AF Cruz, Simao
   Taipa, Ricardo
   Nogueira, Celia
   Pereira, Cristina
   Almeida, Ligia S.
   Neiva, Raquel
   Geraldes, Tiago
   Guimaraes, Antonio
   Melo-Pires, Manuel
   Vilarinho, Laura
TI CLINICAL, BIOCHEMICAL, MOLECULAR, AND HISTOLOGICAL FEATURES OF 65
   PORTUGUESE PATIENTS WITH MITOCHONDRIAL DISORDERS
SO MUSCLE & NERVE
LA English
DT Article
DE chronic progressive external ophthalmoplegia; mitochondrial disorders;
   muscle biopsy; ragged red fibers; respiratory chain
ID RESPIRATORY-CHAIN DEFICIENCIES; TRANSFER-RNA MUTATIONS; DNA; DISEASE;
   MELAS; ENCEPHALOMYOPATHIES; PHENOTYPES; PATHOLOGY; GENOME; FAMILY
AB IntroductionMitochondrial disorders display remarkable genetic and phenotypic heterogeneity. MethodsWe performed a retrospective analysis of the clinical, histological, biochemical, and genetic features of 65 patients with molecular diagnoses of mitochondrial disorders. ResultsThe most common genetic diagnosis was a single large-scale mitochondrial DNA (mtDNA) deletion (41.5%), and the most frequent clinical phenotype was chronic progressive external ophthalmoplegia (CPEO). It occurred in 41.5% of all patients, primarily in those with mtDNA deletions. Histological signs of mitochondrial dysfunction were found in 73.8% of patients, and respiratory chain enzyme assay (RCEA) abnormalities were detected in 51.9%. ConclusionsThis study confirms the high relative frequency of single large-scale deletions among mitochondrial disorders as well as its particular association with CPEO. Muscle histology seems to be particularly useful in older patients and those with mtDNA deletions, whereas RCEA might be more helpful in young children or individuals with mtDNA depletion.
C1 [Cruz, Simao] Hosp Prof Doutor Fernando Fonseca, Dept Neurol, IC 19, P-2720276 Amadora, Portugal.
   [Taipa, Ricardo; Guimaraes, Antonio; Melo-Pires, Manuel] Ctr Hosp Porto, Neuropathol Unit, Hosp Santo Antonio, Oporto, Portugal.
   [Nogueira, Celia; Pereira, Cristina; Almeida, Ligia S.; Neiva, Raquel; Vilarinho, Laura] Dr Ricardo Jorge Natl Hlth Inst, Dept Human Genet, Newborn Screening Metab & Genet Unit, Oporto, Portugal.
   [Geraldes, Tiago] Hosp Garcia de Orta, Dept Neurol, Almada, Portugal.
C3 Hospital Professor Doutor Fernando Fonseca, EPE; Hospital Garcia de Orta
RP Cruz, S (corresponding author), Hosp Prof Doutor Fernando Fonseca, Dept Neurol, IC 19, P-2720276 Amadora, Portugal.
EM simao_cruz13@hotmail.com
RI ; Taipa, Ricardo/R-7472-2017
OI Pires, Manuel/0000-0002-0046-6455; neiva, raquel/0000-0002-2165-1748;
   Pereira, Cristina/0000-0002-5794-127X; Nogueira,
   Celia/0000-0003-3640-8537; Vilarinho, Laura/0000-0001-6186-779X; Taipa,
   Ricardo/0000-0002-9260-0227
CR Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Bai RK, 2005, J MOL DIAGN, V7, P613, DOI 10.1016/S1525-1578(10)60595-8
   Cao YY, 2010, MITOCHONDRION, V10, P330, DOI 10.1016/j.mito.2010.01.008
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   Choi BO, 2008, EXP MOL MED, V40, P354, DOI 10.3858/emm.2008.40.3.354
   CIAFALONI E, 1992, ANN NEUROL, V31, P391, DOI 10.1002/ana.410310408
   COLLOMBET JM, 1993, PEDIATRIE, V48, P287
   Delonlay P, 2013, HAND CLINIC, V113, P1651, DOI 10.1016/B978-0-444-59565-2.00033-2
   DiMauro S, 2005, NEUROMUSCULAR DISORD, V15, P276, DOI 10.1016/j.nmd.2004.12.008
   Finsterer J, 2001, J INHERIT METAB DIS, V24, P560, DOI 10.1023/A:1012415810881
   GRAF WD, 1993, ANN NEUROL, V33, P640, DOI 10.1002/ana.410330613
   HUTCHIN T, 1993, NUCLEIC ACIDS RES, V21, P4174, DOI 10.1093/nar/21.18.4174
   Jaksch M, 2001, J MED GENET, V38, P665, DOI 10.1136/jmg.38.10.665
   JOHNS DR, 1992, BIOCHEM BIOPH RES CO, V187, P1551, DOI 10.1016/0006-291X(92)90479-5
   Mancuso M, 2015, J NEUROL, V262, P1301, DOI 10.1007/s00415-015-7710-y
   Nogueira C, 2013, NEUROGENETICS, V14, P153, DOI 10.1007/s10048-013-0361-1
   Oldfors A., 2013, MUSCLE DIS PATHOLOGY
   Ronchi D, 2011, BIOCHEM BIOPH RES CO, V412, P245, DOI 10.1016/j.bbrc.2011.07.076
   RUSTIN P, 1991, LANCET, V338, P60, DOI 10.1016/0140-6736(91)90057-V
   Sarnat HB, 2005, CAN J NEUROL SCI, V32, P152, DOI 10.1017/S0317167100003929
   Scaglia F, 2004, PEDIATRICS, V114, P925, DOI 10.1542/peds.2004-0718
   Sundaram C, 2011, J CLIN NEUROSCI, V18, P535, DOI 10.1016/j.jocn.2010.06.014
   Tang S, 2013, HUM MUTAT, V34, P882, DOI 10.1002/humu.22307
   Vilarinho L, 1998, EUR NEUROL, V39, P148, DOI 10.1159/000007925
   Wibrand F, 2010, MUSCLE NERVE, V41, P607, DOI 10.1002/mus.21541
NR 26
TC 6
Z9 7
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0148-639X
EI 1097-4598
J9 MUSCLE NERVE
JI Muscle Nerve
PD NOV
PY 2017
VL 56
IS 5
BP 868
EP 872
DI 10.1002/mus.25593
PG 5
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA FJ8UC
UT WOS:000413043100013
PM 28128857
DA 2024-11-01
ER

PT J
AU Kodaira, M
   Hatakeyama, H
   Yuasa, S
   Seki, T
   Egashira, T
   Tohyama, S
   Kuroda, Y
   Tanaka, A
   Okata, S
   Hashimoto, H
   Kusumoto, D
   Kunitomi, A
   Takei, M
   Kashimura, S
   Suzuki, T
   Yozu, G
   Shimojima, M
   Motoda, C
   Hayashiji, N
   Saito, Y
   Goto, Y
   Fukuda, K
AF Kodaira, Masaki
   Hatakeyama, Hideyuki
   Yuasa, Shinsuke
   Seki, Tomohisa
   Egashira, Toru
   Tohyama, Shugo
   Kuroda, Yusuke
   Tanaka, Atsushi
   Okata, Shinichiro
   Hashimoto, Hisayuki
   Kusumoto, Dai
   Kunitomi, Akira
   Takei, Makoto
   Kashimura, Shin
   Suzuki, Tomoyuki
   Yozu, Gakuto
   Shimojima, Masaya
   Motoda, Chikaaki
   Hayashiji, Nozomi
   Saito, Yuki
   Goto, Yu-ichi
   Fukuda, Keiichi
TI Impaired respiratory function in MELAS-induced pluripotent stem cells
   with high heteroplasmy levels
SO FEBS OPEN BIO
LA English
DT Article
DE MELAS; iPS cell; Mitochondrial disease; Disease modeling
ID MITOCHONDRIAL-DNA MUTATIONS; POINT MUTATION; DISEASE; MTDNA; GENERATION;
   GENE
AB Mitochondrial diseases are heterogeneous disorders, caused by mitochondrial dysfunction. Mitochondria are not regulated solely by nuclear genomic DNA but by mitochondrial DNA. It is difficult to develop effective therapies for mitochondrial disease because of the lack of mitochondrial disease models. Mitochondrial myopathy, encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) is one of the major mitochondrial diseases. The aim of this study was to generate MELAS-specific induced pluripotent stem cells (iPSCs) and to demonstrate that MELAS-iPSCs can be models for mitochondrial disease. We successfully established iPSCs from the primary MELAS-fibroblasts carrying 77.7% of m.3243A>G heteroplasmy. MELAS-iPSC lines ranged from 3.6% to 99.4% of m.3243A>G heteroplasmy levels. The enzymatic activities of mitochondrial respiratory complexes indicated that MELAS-iPSC-derived fibroblasts with high heteroplasmy levels showed a deficiency of complex I activity but MELAS-iPSC-derived fibroblasts with low heteroplasmy levels showed normal complex I activity. Our data indicate that MELAS-iPSCs can be models for MELAS but we should carefully select MELAS-iPSCs with appropriate heteroplasmy levels and respiratory functions for mitochondrial disease modeling. (C) 2015 The Authors. Published by Elsevier B.V. on behalf of the Federation of European Biochemical Societies.
C1 [Kodaira, Masaki; Yuasa, Shinsuke; Seki, Tomohisa; Egashira, Toru; Tohyama, Shugo; Kuroda, Yusuke; Tanaka, Atsushi; Okata, Shinichiro; Hashimoto, Hisayuki; Kusumoto, Dai; Kunitomi, Akira; Takei, Makoto; Kashimura, Shin; Suzuki, Tomoyuki; Yozu, Gakuto; Shimojima, Masaya; Motoda, Chikaaki; Hayashiji, Nozomi; Saito, Yuki; Fukuda, Keiichi] Keio Univ, Sch Med, Dept Cardiol, Tokyo 1608582, Japan.
   [Hatakeyama, Hideyuki; Goto, Yu-ichi] Natl Ctr Neurol & Psychiat, Natl Inst Neurosci, Dept Mental Retardat & Birth Defect Res, Tokyo, Japan.
   [Hatakeyama, Hideyuki; Goto, Yu-ichi] Japan Sci & Technol Agcy JST, Core Res Evolut Sci & Technol CREST, Tokyo, Japan.
C3 Keio University; National Center for Neurology & Psychiatry - Japan;
   Japan Science & Technology Agency (JST)
RP Yuasa, S (corresponding author), Keio Univ, Sch Med, Dept Cardiol, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan.
EM yuasa@keio.jp
RI Hashimoto, Hisayuki/AAS-1938-2020; Saito, Yuki/AFD-5094-2022; Seki,
   Tomohisa/L-3524-2013; Fukuda, Keiichi/L-3777-2013; Tohyama,
   Shugo/AFN-7813-2022; Yuasa, Shinsuke/HMO-8133-2023
OI Hashimoto, Hisayuki/0000-0001-7367-4805; Kodaira,
   Masaki/0000-0002-7293-617X; Saito, Yuki/0000-0003-2686-9604; Yuasa,
   Shinsuke/0000-0001-5593-7552; Seki, Tomohisa/0000-0002-4281-135X
FU Ministry of Education, Culture, Sports, Science, and Technology; Health
   Labour Sciences Research Grant; New Energy and Industrial Technology
   Development Organization, Japan; Program for Promotion of Fundamental
   Studies in Health Science of the National Institute of Biomedical
   Innovation; Japan Science and Technology Agency; Research Center Network
   for Realization of Regenerative Medicine "The Program for Intractable
   Diseases Research utilizing Disease-specific iPS cells"; Nakatomi
   Foundation; Japan Heart Foundation/Novartis Grant for Research Award on
   Molecular and Cellular Cardiology SENSHIN Medical Research Foundation;
   Kimura Memorial Heart Foundation Research Grant; Japan Intractable
   Diseases Research Foundation, Japan; Cell Science Research Foundation;
   Tokyo Biochemical Research Foundation; Suzuken Memorial Foundation; Core
   Research for Evolutional Science and Technology, Japan Science and
   Technology Agency, Japan; Grants-in-Aid for Scientific Research
   [25860623] Funding Source: KAKEN
FX This study was supported in part by research grants from the Ministry of
   Education, Culture, Sports, Science, and Technology, Health Labour
   Sciences Research Grant, the New Energy and Industrial Technology
   Development Organization, Japan, the Program for Promotion of
   Fundamental Studies in Health Science of the National Institute of
   Biomedical Innovation, Japan Science and Technology Agency, Research
   Center Network for Realization of Regenerative Medicine "The Program for
   Intractable Diseases Research utilizing Disease-specific iPS cells", The
   Nakatomi Foundation, Japan Heart Foundation/Novartis Grant for Research
   Award on Molecular and Cellular Cardiology SENSHIN Medical Research
   Foundation, Kimura Memorial Heart Foundation Research Grant, Japan
   Intractable Diseases Research Foundation, Japan, and The Cell Science
   Research Foundation, The Tokyo Biochemical Research Foundation, Suzuken
   Memorial Foundation, and by Core Research for Evolutional Science and
   Technology, Japan Science and Technology Agency, Japan.
CR ATTARDI G, 1995, BBA-MOL BASIS DIS, V1271, P241, DOI 10.1016/0925-4439(95)00034-2
   Cherry ABC, 2013, STEM CELLS, V31, P1287, DOI 10.1002/stem.1354
   Egashira T, 2012, CARDIOVASC RES, V95, P419, DOI 10.1093/cvr/cvs206
   Folmes CDL, 2013, STEM CELLS, V31, P1298, DOI 10.1002/stem.1389
   Fujikura J, 2012, DIABETOLOGIA, V55, P1689, DOI 10.1007/s00125-012-2508-2
   Garrido-Maraver J, 2012, BRIT J PHARMACOL, V167, P1311, DOI 10.1111/j.1476-5381.2012.02086.x
   Gellerich FN, 2002, BBA-BIOENERGETICS, V1556, P41, DOI 10.1016/S0005-2728(02)00305-5
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Gropman A L, 2001, Curr Neurol Neurosci Rep, V1, P185
   Hämäläinen RH, 2013, P NATL ACAD SCI USA, V110, pE3622, DOI 10.1073/pnas.1311660110
   Jeppesen TD, 2003, ANN NEUROL, V54, P86, DOI 10.1002/ana.10594
   KOBAYASHI Y, 1991, AM J HUM GENET, V49, P590
   Lagouge M, 2013, J INTERN MED, V273, P529, DOI 10.1111/joim.12055
   Prigione A, 2010, STEM CELLS, V28, P721, DOI 10.1002/stem.404
   Seki T, 2012, NAT PROTOC, V7, P718, DOI 10.1038/nprot.2012.015
   Seki T, 2010, CELL STEM CELL, V7, P11, DOI 10.1016/j.stem.2010.06.003
   Suzuki T, 2011, ANNU REV GENET, V45, P299, DOI 10.1146/annurev-genet-110410-132531
   Tanaka A, 2014, J AM HEART ASSOC, V3, DOI 10.1161/JAHA.114.001263
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   YONEDA M, 1992, P NATL ACAD SCI USA, V89, P11164, DOI 10.1073/pnas.89.23.11164
NR 22
TC 46
Z9 49
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2211-5463
J9 FEBS OPEN BIO
JI FEBS Open Bio
PY 2015
VL 5
BP 219
EP 225
DI 10.1016/j.fob.2015.03.008
PG 7
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA CZ3JC
UT WOS:000366999300028
PM 25853038
OA Green Published, gold
DA 2024-11-01
ER

PT J
AU Finsterer, J
AF Finsterer, Josef
TI Parkinson's Syndrome and Parkinson's Disease in Mitochondrial Disorders
SO MOVEMENT DISORDERS
LA English
DT Review
DE mitochondrial myopathy; metabolic disease; neurodegenerative disorder;
   extrapyramidal disease; mitochondrial DNA; genetics
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; DNA DELETIONS; FAMILIAL
   PARKINSONISM; OXIDATIVE-STRESS; POLG1 MUTATIONS; POINT MUTATIONS;
   LEIGH-SYNDROME; NIGRA NEURONS; CYBRID CELLS; A8344G MERRF
AB In the majority of cases, mitochondrial disorders are multisystem conditions that most frequently affect the skeletal muscle, followed by the central nervous system. One of the clinical manifestations of central nervous system involvement is Parkinson's syndrome (PS). Evidence for an association of mitochondrial defects with PS comes from mitochondrial disorder patients who have developed Parkinson's syndrome and from Parkinson's syndrome patients who have developed a mitochondrial disorder. In addition, there are a number of patients with Parkinson's syndrome or Parkinson's disease (PD) who later develop subclinical immunohistological or biochemical indications of mitochondrial defects or accumulates mitochondrial DNA mutations within various cerebral regions. There are also Parkinson's syndrome patients who present with elevated cerebrospinal-fluid lactate by magnetic resonance spectroscopy. Furthermore, it has been shown that mutations in genes causing PD, such as PINK1, parkin, DJ1, alpha-synuclein, and LRRK2, also cause mitochondrial dysfunction, which is one of the reasons why they are called mitochondrial nigropathies. Parkinson's syndrome in patients with a mitochondrial disorder may also result from oxidative stress or exogenous toxins. Treatment of mitochondrial Parkinson's syndrome is not at variance with the treatment of Parkinson's syndrome due to other causes, but because of the multisystem nature of mitochondrial disorders, mitochondrial Parkinson's syndrome requires additional therapeutic support. (C) 2011 Movement Disorder Society
C1 [Finsterer, Josef] Danube Univ, Krems, Austria.
   [Finsterer, Josef] Krankenanstalt Rudolfstiftung Wien, Vienna, Austria.
C3 Danube University Krems; Rudolfstiftung Hospital
RP Finsterer, J (corresponding author), Postfach 20, A-1180 Vienna, Austria.
EM fifigs1@yahoo.de
CR Baloh RH, 2007, ARCH NEUROL-CHICAGO, V64, P998, DOI 10.1001/archneur.64.7.998
   Bayir H, 2009, J BIOL CHEM, V284, P15951, DOI 10.1074/jbc.M900418200
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Betts-Henderson J, 2009, NEUROPATH APPL NEURO, V35, P120, DOI 10.1111/j.1365-2990.2008.00981.x
   Bisaglia M, 2010, BBA-MOL BASIS DIS, V1802, P699, DOI 10.1016/j.bbadis.2010.06.006
   Borland MK, 2009, BBA-MOL BASIS DIS, V1792, P68, DOI 10.1016/j.bbadis.2008.09.014
   Cavelier L, 2001, HEREDITAS, V135, P65, DOI 10.1111/j.1601-5223.2001.00065.x
   Chalmers RM, 1996, J NEUROL SCI, V143, P41, DOI 10.1016/S0022-510X(96)00032-9
   Chu CT, 2010, HUM MOL GENET, V19, pR28, DOI 10.1093/hmg/ddq143
   Davidzon G, 2006, ANN NEUROL, V59, P859, DOI 10.1002/ana.20831
   De Coo IFM, 1999, ANN NEUROL, V45, P130, DOI 10.1002/1531-8249(199901)45:1<130::AID-ART21>3.0.CO;2-Z
   de Moura MB, 2010, ENVIRON MOL MUTAGEN, V51, P391, DOI 10.1002/em.20575
   Dermaut B, 2010, J NEUROL NEUROSUR PS, V81, P90, DOI 10.1136/jnnp.2008.157354
   Eerola J, 2010, NEUROSCI LETT, V477, P1, DOI 10.1016/j.neulet.2010.04.021
   Egensperger R, 1997, NEUROPATH APPL NEURO, V23, P315, DOI 10.1046/j.1365-2990.1997.4098040.x
   Finsterer J, 2002, ACTA NEUROL SCAND, V105, P384, DOI 10.1034/j.1600-0404.2002.01221.x
   Finsterer J, 2001, NEURORADIOLOGY, V43, P997, DOI 10.1007/s002340100618
   Finsterer J, 2008, INT J CARDIOL, V123, pE45, DOI 10.1016/j.ijcard.2006.11.120
   Finsterer J, 2009, CAN J NEUROL SCI, V36, P143, DOI 10.1017/S0317167100006508
   Foti R, 2010, J BIOL CHEM, V285, P18565, DOI 10.1074/jbc.M109.088294
   Galassi G, 2008, NEUROMUSCULAR DISORD, V18, P465, DOI 10.1016/j.nmd.2008.03.013
   García-Cazorla A, 2006, ANN NEUROL, V59, P121, DOI 10.1002/ana.20709
   Garcia-Cazorla A, 2008, MITOCHONDRION, V8, P273, DOI 10.1016/j.mito.2008.05.001
   Gdynia HJ, 2009, PARKINSONISM RELAT D, V15, P633, DOI 10.1016/j.parkreldis.2009.06.003
   Gispert S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005777
   Grasbon-Frodl EM, 1999, NEUROGENETICS, V2, P121, DOI 10.1007/s100480050063
   Grünewald A, 2009, EXP NEUROL, V219, P266, DOI 10.1016/j.expneurol.2009.05.027
   Hara K, 1994, Rinsho Shinkeigaku, V34, P361
   Horvath R, 2007, NEUROLOGY, V68, P56, DOI 10.1212/01.wnl.0000250334.48038.7a
   Huang JY, 2010, FREE RADICAL BIO MED, V49, P1099, DOI 10.1016/j.freeradbiomed.2010.06.026
   Hudson G, 2007, ARCH NEUROL-CHICAGO, V64, P553, DOI 10.1001/archneur.64.4.553
   Iaccarino C, 2007, HUM MOL GENET, V16, P1319, DOI 10.1093/hmg/ddm080
   Invernizzi F, 2008, NEUROMUSCULAR DISORD, V18, P460, DOI 10.1016/j.nmd.2008.04.005
   Irrcher I, 2010, HUM MOL GENET, V19, P3734, DOI 10.1093/hmg/ddq288
   Keeney PM, 2009, EXP NEUROL, V220, P374, DOI 10.1016/j.expneurol.2009.09.025
   Kosel S, 1998, NEUROGENETICS, V1, P197, DOI 10.1007/s100480050029
   Kösel S, 2000, NEUROGENETICS, V2, P227
   Lin Tsu-Kung, 2009, Chang Gung Med J, V32, P589
   Liu WC, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004597
   Luoma PT, 2007, NEUROLOGY, V69, P1152, DOI 10.1212/01.wnl.0000276955.23735.eb
   MACAYA A, 1993, NEUROPEDIATRICS, V24, P60, DOI 10.1055/s-2008-1071515
   Mancuso M, 2008, PARKINSONISM RELAT D, V14, P381, DOI 10.1016/j.parkreldis.2007.10.001
   Matsuda N, 2010, J CELL BIOL, V189, P211, DOI 10.1083/jcb.200910140
   McFarland MA, 2008, MOL CELL PROTEOMICS, V7, P2123, DOI 10.1074/mcp.M800116-MCP200
   McFarland R, 2010, LANCET NEUROL, V9, P829, DOI 10.1016/S1474-4422(10)70116-2
   MILONE M, 2010, ACTA MYOL, V29, P235
   Misiak M, 2010, BBA-BIOENERGETICS, V1797, P1178, DOI 10.1016/j.bbabio.2010.04.009
   MIZUNO Y, 1987, BIOCHEM BIOPH RES CO, V143, P971, DOI 10.1016/0006-291X(87)90346-9
   Narendra DP, 2010, PLOS BIOL, V8, DOI 10.1371/journal.pbio.1000298
   NICKLAS WJ, 1985, LIFE SCI, V36, P2503, DOI 10.1016/0024-3205(85)90146-8
   Nuytemans K, 2010, HUM MUTAT, V31, P763, DOI 10.1002/humu.21277
   Okatsu K, 2010, GENES CELLS, V15, P887, DOI 10.1111/j.1365-2443.2010.01426.x
   Pienaar IS, 2010, EXPERT REV PROTEOMIC, V7, P205, DOI [10.1586/epr.10.8, 10.1586/EPR.10.8]
   PRZEDBORSKI S, 1993, ANN NEUROL, V34, P715, DOI 10.1002/ana.410340515
   Rakovic A, 2010, HUM MOL GENET, V19, P3124, DOI 10.1093/hmg/ddq215
   Reeve AK, 2008, AM J HUM GENET, V82, P228, DOI 10.1016/j.ajhg.2007.09.018
   Remes AM, 2008, PARKINSONISM RELAT D, V14, P652, DOI 10.1016/j.parkreldis.2008.01.009
   SCHAPIRA AHV, 1994, MOVEMENT DISORD, V9, P125, DOI 10.1002/mds.870090202
   Schnopp NM, 1996, CLIN NEUROPATHOL, V15, P348
   Siciliano G, 2001, J NEUROL NEUROSUR PS, V71, P685, DOI 10.1136/jnnp.71.5.685
   Simon DK, 2010, BMC MED GENET, V11, DOI 10.1186/1471-2350-11-53
   Snow BJ, 2010, MOVEMENT DISORD, V25, P1670, DOI 10.1002/mds.23148
   Suen DF, 2010, P NATL ACAD SCI USA, V107, P11835, DOI 10.1073/pnas.0914569107
   Tan EK, 2010, EXP NEUROL, V221, P10, DOI 10.1016/j.expneurol.2009.10.018
   Tanaka M, 1996, ANN NY ACAD SCI, V786, P102, DOI 10.1111/j.1749-6632.1996.tb39055.x
   Thobois S, 1997, REV NEUROL, V153, P595
   Thomas B, 2009, ANTIOXID REDOX SIGN, V11, P2077, DOI 10.1089/ars.2009.2697
   Trimmer PA, 2009, EXP NEUROL, V218, P320, DOI 10.1016/j.expneurol.2009.03.016
   Vandenberghe W, 2009, MOVEMENT DISORD, V24, P308, DOI 10.1002/mds.22198
   VANERVEN PMM, 1989, DEV MED CHILD NEUROL, V31, P81
   Vives-Bauza C, 2002, BIOCHEM BIOPH RES CO, V290, P1593, DOI 10.1006/bbrc.2002.6388
   Vives-Bauza C, 2010, P NATL ACAD SCI USA, V107, P378, DOI 10.1073/pnas.0911187107
   Wilcox RA, 2007, MOVEMENT DISORD, V22, P1020, DOI 10.1002/mds.21416
   Winklhofer KF, 2010, BBA-MOL BASIS DIS, V1802, P29, DOI 10.1016/j.bbadis.2009.08.013
   Yamamoto M, 1997, J NEUROL NEUROSUR PS, V62, P290, DOI 10.1136/jnnp.62.3.290
   Zhou C, 2008, ANN NY ACAD SCI, V1147, P93, DOI 10.1196/annals.1427.023
   ZIVIANI E, 2010, AUTOPHAGY, P6
NR 77
TC 22
Z9 26
U1 1
U2 20
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0885-3185
J9 MOVEMENT DISORD
JI Mov. Disord.
PD APR
PY 2011
VL 26
IS 5
BP 784
EP 791
DI 10.1002/mds.23651
PG 8
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 762AT
UT WOS:000290445400030
PM 21384429
OA Bronze
DA 2024-11-01
ER

PT J
AU Jeppesen, TD
   Schwartz, M
   Olsen, DB
   Wibrand, F
   Krag, T
   Duno, M
   Hauerslev, S
   Vissing, J
AF Jeppesen, Tina D.
   Schwartz, Marianne
   Olsen, David B.
   Wibrand, Flemming
   Krag, Thomas
   Duno, Morten
   Hauerslev, Simon
   Vissing, John
TI Aerobic training is safe and improves exercise capacity in patients with
   mitochondrial myopathy
SO BRAIN
LA English
DT Article
DE mitochondrial myopathy; training; mtDNA; mutation load
ID SKELETAL-MUSCLE; OXIDATIVE CAPACITY; MUTATION; MTDNA; EXPRESSION;
   APOPTOSIS; INDEXES; FIBERS
AB Exercise intolerance is a prominent symptom in patients with mitochondrial myopathy (MM), but it is still unsettled whether exercise training is safe and beneficial for patients with MM. To address this, we studied the effect of 12 weeks cycle training on exercise capacity, quality of life and underlying molecular and cellular events in five patients with single large-scale deletions, one with a microdeletion and 14 with point mutations of mitochondrial DNA (mtDNA), and 13 healthy subjects. Each training session lasted 30 min, and was performed at an intensity of 70% of VO2max (maximal oxygen uptake). Each subject performed 50 training sessions in 12 weeks. All subjects were evaluated before and after training, and 13 MM patients were studied after 8 weeks of deconditioning. Evaluation included VO2max and mutation load and mtDNA quantity, mitochondrial enzymatic activity, and number of centrally nucleated, apoptotic, ragged red and cytochrome oxidase (COX)-negative fibres in muscle biopsies from the quadriceps muscle. After 12 weeks of training, VO2max and muscle citrate synthase increased in MM (26 and 67%) and healthy (17 and 65%) subjects, while mtDNA quantity in muscle only increased in the MM patients (81%). In the MM patients, training did not change mtDNA mutation load in muscle, mitochondrial enzyme complex activities, muscle morphology and plasma creatine kinase. After deconditioning, VO2max and citrate synthase activity returned to values before training, while muscle mtDNA mutation load decreased. These findings show that aerobic training efficiently improves oxidative capacity in MM patients. Based on unchanged levels of mutant load in muscle, morphological findings on muscle biopsy and plasma creatine kinase levels during training, the treatment appears to be safe. Regular, supervised aerobic exercise is therefore recommended in MM patients with the studied mutations.
C1 Natl Univ Hosp, Neoromuscular Res Unit, Sect 7611, Rigshosp,Dept Neurol,Copenhagen Muscle Res Ctr, DK-2100 Copenhagen, Denmark.
   Natl Univ Hosp, Dept Clin Genet, Rigshosp, DK-2100 Copenhagen, Denmark.
C3 Rigshospitalet; University of Copenhagen; Rigshospitalet; University of
   Copenhagen
RP Jeppesen, TD (corresponding author), Natl Univ Hosp, Neoromuscular Res Unit, Sect 7611, Rigshosp,Dept Neurol,Copenhagen Muscle Res Ctr, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.
EM dysgaard@rh.dk
RI Vissing, John/IUN-4271-2023; Jeppesen, Tina/AAV-7195-2020; Krag,
   Thomas/AAD-3307-2021
OI Krag, Thomas/0000-0001-9330-668X
CR Ansved T, 2001, ACTA PHYSIOL SCAND, V171, P359, DOI 10.1046/j.1365-201x.2001.00839.x
   Cejudo P, 2005, MUSCLE NERVE, V32, P342, DOI 10.1002/mus.20368
   Chinnery PF, 1999, AM J HUM GENET, V64, P1158, DOI 10.1086/302311
   Di Mauro S., 2004, MYOLOGY PHILADELPHIA, P1623
   Fischer CP, 2004, AM J PHYSIOL-ENDOC M, V287, pE1189, DOI 10.1152/ajpendo.00206.2004
   Frederiksen AL, 2006, J MED GENET, V43, DOI 10.1136/jmg.2005.039339
   GOLLNICK PD, 1982, CLIN PHYSIOL, V2, P1, DOI 10.1111/j.1475-097X.1982.tb00001.x
   HOPPELER H, 1973, PFLUG ARCH EUR J PHY, V344, P217, DOI 10.1007/BF00588462
   Iizuka T, 2005, CURR NEUROVASC RES, V2, P29, DOI 10.2174/1567202052773544
   Jeppesen TD, 2003, ANN NEUROL, V54, P86, DOI 10.1002/ana.10594
   JONES DA, 1986, J PHYSIOL-LONDON, V375, P435, DOI 10.1113/jphysiol.1986.sp016126
   LARSSON NG, 1990, PEDIATR RES, V28, P131, DOI 10.1203/00006450-199028020-00011
   Marcuello A, 2005, J APPL PHYSIOL, V99, P1372, DOI 10.1152/japplphysiol.00289.2005
   Mirabella M, 2000, BRAIN, V123, P93, DOI 10.1093/brain/123.1.93
   Olsen DB, 2005, NEUROLOGY, V64, P1064, DOI 10.1212/01.WNL.0000150584.45055.27
   Olsen DB, 2003, J NEUROL, V250, P1328, DOI 10.1007/s00415-003-0206-1
   Orngreen MC, 2005, ANN NEUROL, V57, P754, DOI 10.1002/ana.20460
   Rodríguez LP, 2002, AM J PHYS MED REHAB, V81, P651, DOI 10.1097/00002060-200209000-00004
   ROWELL LB, 1986, AM J PHYSIOL, V251, P1038
   Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350
   Shoubridge EA, 1997, HUM MOL GENET, V6, P2239, DOI 10.1093/hmg/6.13.2239
   Siciliano G, 2000, NEUROMUSCULAR DISORD, V10, P40, DOI 10.1016/S0960-8966(99)00068-1
   Suomalainen A, 1998, METH MOL B, V86, P121
   Taivassalo T, 1999, HUM MOL GENET, V8, P1047, DOI 10.1093/hmg/8.6.1047
   Taivassalo T, 1999, MUSCLE NERVE, V22, P1239, DOI 10.1002/(SICI)1097-4598(199909)22:9<1239::AID-MUS11>3.0.CO;2-W
   Taivassalo T, 1998, NEUROLOGY, V50, P1055, DOI 10.1212/WNL.50.4.1055
   Taivassalo T, 1996, NEUROLOGY, V47, P529, DOI 10.1212/WNL.47.2.529
   Taivassalo T, 2001, ANN NEUROL, V50, P133, DOI 10.1002/ana.1050
   Turner DL, 1997, ACTA PHYSIOL SCAND, V161, P459, DOI 10.1046/j.1365-201X.1997.00246.x
   Umaki Y, 2002, ACTA NEUROPATHOL, V103, P163
   Weber K, 1997, AM J HUM GENET, V60, P373
   Wibrand F, 2001, ANN NEUROL, V50, P540, DOI 10.1002/ana.1224
   [No title captured]
NR 33
TC 145
Z9 152
U1 0
U2 5
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 1460-2156
J9 BRAIN
JI Brain
PD DEC
PY 2006
VL 129
BP 3402
EP 3412
DI 10.1093/brain/awl149
PN 12
PG 11
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 111RE
UT WOS:000242471100031
PM 16815877
DA 2024-11-01
ER

PT J
AU Giannese, D
   Montano, V
   Lopriore, P
   Nesti, C
   LoGerfo, A
   Caligo, MA
   Dal Canto, F
   Pasquinelli, G
   Bonadio, AG
   Moriconi, D
   Siciliano, G
   Mancuso, M
AF Giannese, Domenico
   Montano, Vincenzo
   Lopriore, Piervito
   Nesti, Claudia
   LoGerfo, Annalisa
   Caligo, Maria Adelaide
   Dal Canto, Flavio
   Pasquinelli, Gianandrea
   Bonadio, Angelo Giovanni
   Moriconi, Diego
   Siciliano, Gabriele
   Mancuso, Michelangelo
TI A Multisystem Mitochondrial Disease Caused by a Novel <i>MT-TL1</i>
   <i>mtDNA</i> Variant: A Case Report
SO JOURNAL OF NEUROMUSCULAR DISEASES
LA English
DT Article
DE mtDNA; mitochondrial diseases; mitochondrial myopathies;
   glomerulosclerosis; kidney disease
ID FOLLOW-UP; MUTATION; KIDNEY; PHENOTYPE; GENE
AB Background: Mitochondrial tRNA (MTT) genes are hotspot for mitochondrial DNA mutation and are responsible of half mitochondrial disease. MTT mutations are associated with a broad spectrum of phenotype often with complex multisystem involvement and complex genotype-phenotype correlations. MT-TL1 mutations, among which the m.3243A>G mutation is the most frequent, are associated with myopathy, maternal inherited diabetes and deafness, MELAS, cardiomyopathy, and focal segmental glomerulosclerosis.
   Case study: Here we report the case of an Italian 49-years old female presenting with encephalomyopathy, chronic proteinuric kidney disease and a new heteroplasmic m.3274 3275delAC MT-TL1 gene mutation.
   Conclusions: Our case demonstrates a systemic mitochondrial disease caused by the heteroplasmic m.3274 3275delAC MT-TL1 gene mutation, not yet described in the literature. A mitochondrial disease should be suspected in case of complex multisystem phenotypes, including steroid-resistant nephrotic syndrome with multisystemic involvement.
C1 [Giannese, Domenico] Univ Hosp Pisa, Dept Clin & Expt Med, Nephrol Transplant & Dialysis Div, Pisa, Italy.
   [Montano, Vincenzo; Lopriore, Piervito; Siciliano, Gabriele; Mancuso, Michelangelo] Univ Pisa, Dept Clin & Expt Med, Neurol Clin, Pisa, Italy.
   [Nesti, Claudia; Dal Canto, Flavio] IRCCS Fdn Stella Maris, Mol Med, Pisa, Italy.
   [LoGerfo, Annalisa; Caligo, Maria Adelaide] Azienda Osped Univ Pisana, Lab Mol Genet, Pisa, Italy.
   [Pasquinelli, Gianandrea] Univ Bologna, Dept Expt Biotechnol & Methods Lab Med Diagnost &, Bologna, Italy.
   [Pasquinelli, Gianandrea] IRCCS Azienda Osped Univ Bologna, Pathol Unit, Subcellular Nephrovasc Diagnost Program, Bologna, Italy.
   [Bonadio, Angelo Giovanni] Univ Pisa, Dept Translat Res New Technol Med & Surg, Pisa, Italy.
   [Moriconi, Diego] Univ Pisa, Dept Surg Med Mol & Crit Area Pathol, Pisa, Italy.
C3 University of Pisa; Azienda Ospedaliero Universitaria Pisana; University
   of Pisa; IRCCS Fondazione Stella Maris; University of Pisa; Azienda
   Ospedaliero Universitaria Pisana; University of Bologna; IRCCS Azienda
   Ospedaliero-Universitaria di Bologna; University of Pisa; University of
   Pisa
RP Mancuso, M (corresponding author), Univ Pisa, Dept Clin & Expt Med, Neurol Inst, Pisa, Italy.
EM michelangelo.mancuso@unipi.it
RI Montano, Vincenzo/AAB-8681-2022; Pasquinelli, Gianandrea/I-7088-2012;
   Lopriore, Piervito/KZU-8091-2024; Giannese, Domenico/AAH-6257-2019;
   Moriconi, Diego/ACW-6397-2022; Siciliano, Gabriele/HTP-1909-2023; Nesti,
   Claudia/K-5866-2016; Dal Canto, Flavio/AES-7542-2022
OI Nesti, Claudia/0000-0001-5769-8655; Dal Canto,
   Flavio/0000-0002-6447-4585; Lopriore, Piervito/0000-0002-9789-3129;
   Moriconi, Diego/0000-0002-1223-0167
FU Telethon [GUP09004, GSP16001]; EJP RD Joint Transnational Call (JTC2019)
   GENOMIT
FX This work was partially supported by Telethon Grants (GUP09004 and
   GSP16001) and by EJP RD Joint Transnational Call (JTC2019) GENOMIT.
CR Atmaca M, 2019, TURKISH J PEDIATR, V61, P657, DOI 10.24953/turkjped.2019.05.003
   Bhargava P, 2017, NAT REV NEPHROL, V13, P629, DOI 10.1038/nrneph.2017.107
   de Laat P, 2019, CLIN KIDNEY J, V12, P840, DOI 10.1093/ckj/sfz020
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   Eirin A, 2015, HYPERTENSION, V65, P264, DOI 10.1161/HYPERTENSIONAHA.114.04598
   Emma F, 2006, PEDIATR NEPHROL, V21, P355, DOI 10.1007/s00467-005-2092-5
   Emma F, 2016, NAT REV NEPHROL, V12, P267, DOI 10.1038/nrneph.2015.214
   Govers LP, 2021, PEDIATR NEPHROL, V36, P9, DOI 10.1007/s00467-019-04404-6
   Guillausseau PJ, 2001, ANN INTERN MED, V134, P721, DOI 10.7326/0003-4819-134-9_Part_1-200105010-00008
   Iwasaki N, 2001, J HUM GENET, V46, P330, DOI 10.1007/s100380170068
   Jaksch M, 2001, NEUROLOGY, V57, P1930, DOI 10.1212/WNL.57.10.1930
   Ng YS, 2021, LANCET NEUROL, V20, P573, DOI 10.1016/S1474-4422(21)00098-3
   Piccoli GB, 2012, BMC NEPHROL, V13, DOI 10.1186/1471-2369-13-9
   Preston R, 2019, PEDIATR NEPHROL, V34, P195, DOI 10.1007/s00467-017-3838-6
   Sadowski CE, 2015, J AM SOC NEPHROL, V26, P1279, DOI 10.1681/ASN.2014050489
   Schijvens AM, 2020, KIDNEY INT REP, V5, P2146, DOI 10.1016/j.ekir.2020.09.044
   Smeitink Jan, 2019, JIMD Rep, V46, P52, DOI 10.1002/jmd2.12017
   Sonney S, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005867
   Yarham JW, 2011, HUM MUTAT, V32, P1319, DOI 10.1002/humu.21575
NR 19
TC 0
Z9 0
U1 0
U2 3
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 2214-3599
EI 2214-3602
J9 J NEUROMUSCULAR DIS
JI J. Neuromusc. Dis.
PY 2023
VL 10
IS 1
BP 119
EP 123
DI 10.3233/JND-221526
PG 5
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 7P0JM
UT WOS:000908400700010
PM 36404555
OA Green Published, hybrid
DA 2024-11-01
ER

PT J
AU Crimi, M
   O'Hearn, SF
   Wallace, DC
   Comi, GP
AF Crimi, M
   O'Hearn, SF
   Wallace, DC
   Comi, GP
TI Molecular research technologies in mitochondrial diseases: The
   microarray approach
SO IUBMB LIFE
LA English
DT Review
DE mtDNA; mitochondrial diseases; heteroplosmy; microarray
ID L-ARGININE IMPROVES; GENE-EXPRESSION; OXIDATIVE-PHOSPHORYLATION;
   SKELETAL-MUSCLE; DNA MUTATIONS; NUCLEAR; DYSFUNCTION; APOPTOSIS;
   DIAGNOSIS; RESPONSES
AB Mitochondria are ubiquitous in eukaryotic cells where they generate much of the cellular energy by the process of oxidative phosphorylation (OXPHOS). The approximately 1500 genes of the mitochondrial genome are distributed between the cytoplasmic, maternally-inherited, mitochondrial DNA ( mtDNA) which encodes 37 genes and the nuclear DNA (nDNA) which encompasses the remaining mitochondrial genes. The interplay between the mtDNA and nDNA encoded mitochondrial genes and their role in mitochondrial disorders is still largely unclear. One approach for elucidating the pathophysiology of mitochondrial diseases has been to look at changes in the expression of mtDNA and nDNA-encoded genes in response to specific mitochondrial genetic defects. Initial studies of gene expression changes in response to mtDNA defect employed blot technologies to analyze changes in the expression of individual genes one at a time. While Southern/Northern blot experiments confirmed the importance of nDNA - mtDNA interactions in the pathophysiology of mitochondrial myopathy, the methodology used limited the number of genes that could be analyzed from each patient. This barrier has been overcome, in part by the advent of DNA microarray technology. In DNA microarrays gene sequences or oligonucleotides homologous to gene sequences are arrayed on a solid support. The RNA from the subject is then isolated, the mRNA converted to cDNA and the cDNA labeled with a fluorescent probe. The labeled cDNA is hybridized on the microarray and the fluorescence bound to each array is then quantified. Recently, these technologies have been applied to mitochondrial disease patient tissues and the presence of coordinate changes in mitochondrial gene expression confirmed.
C1 Univ Calif Irvine, Ctr Mol & Mitochondrial Med & Genet, Dept Biol Chem, Irvine, CA 92697 USA.
   Univ Milan, Dino Ferrari Ctr, Dept Neurol Sci, Milan, Italy.
   IRCCS Osped Maggiore Policlin, Milan, Italy.
C3 University of California System; University of California Irvine;
   University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico
RP Univ Calif Irvine, Ctr Mol & Mitochondrial Med & Genet, Dept Biol Chem, Irvine, CA 92697 USA.
EM marco.crimi@gmail.com
RI Crimi, Marco/A-4032-2008; Comi, Giacomo/K-5702-2016
OI Crimi, Marco/0000-0001-6903-9163; Comi, Giacomo/0000-0002-1383-5248
FU NINDS NIH HHS [NS21328] Funding Source: Medline
CR Arnould T, 2002, EMBO J, V21, P53, DOI 10.1093/emboj/21.1.53
   Bandelt HJ, 2005, SCHIZOPHR RES, V72, P267, DOI 10.1016/j.schres.2004.05.003
   Bannwarth S, 2005, HUM MUTAT, V25, P575, DOI 10.1002/humu.20177
   Barrett T, 2005, NUCLEIC ACIDS RES, V33, pD562
   Behan A, 2005, MITOCHONDRION, V5, P173, DOI 10.1016/j.mito.2005.03.002
   Biswas G, 2005, GENE, V354, P132, DOI 10.1016/j.gene.2005.03.028
   Bossy-Wetzel E, 2003, CURR OPIN CELL BIOL, V15, P706, DOI 10.1016/j.ceb.2003.10.015
   Costa RMA, 2003, BIOCHIMIE, V85, P1083, DOI 10.1016/j.biochi.2003.10.017
   Crimi M, 2005, FASEB J, V19, P866, DOI 10.1096/fj.04-3045fje
   Crimi M, 2003, NEUROLOGY, V60, P1857, DOI 10.1212/01.WNL.0000066048.72780.69
   Crimi Marco, 2002, Hum Mutat, V20, P409, DOI 10.1002/humu.9079
   Danielson SR, 2005, BRAIN, V128, P1026, DOI 10.1093/brain/awh447
   Delsite Robert, 2002, Mol Cancer, V1, P6, DOI 10.1186/1476-4598-1-6
   DiMauro S, 2004, BBA-BIOENERGETICS, V1658, P80, DOI 10.1016/j.bbabio.2004.03.014
   Erdogan F, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.7.e36
   Everts HB, 2002, IUBMB LIFE, V54, P45, DOI 10.1080/15216540214316
   Gu GY, 2003, BIOCHEM BIOPH RES CO, V308, P197, DOI 10.1016/S0006-291X(03)01233-6
   HEDDI A, 1994, BBA-MOL BASIS DIS, V1226, P206, DOI 10.1016/0925-4439(94)90030-2
   HEDDI A, 1993, J BIOL CHEM, V268, P12156
   Heddi A, 1999, J BIOL CHEM, V274, P22968, DOI 10.1074/jbc.274.33.22968
   Koga Y, 2005, NEUROLOGY, V64, P710, DOI 10.1212/01.WNL.0000151976.60624.01
   Larsen NB, 2005, MITOCHONDRION, V5, P89, DOI 10.1016/j.mito.2005.02.002
   Li CH, 2005, J BIOL CHEM, V280, P26193, DOI 10.1074/jbc.M501371200
   Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447
   Lobenhofer EK, 2001, ENVIRON HEALTH PERSP, V109, P881, DOI 10.2307/3454988
   Löhr K, 2003, J BIOL CHEM, V278, P32507, DOI 10.1074/jbc.M212517200
   Maitra A, 2004, GENOME RES, V14, P812, DOI 10.1101/gr.2228504
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   Munakata K, 2005, BIOL PSYCHIAT, V57, P525, DOI 10.1016/j.biopsych.2004.11.041
   Murdock DG, 1999, J BIOL CHEM, V274, P14429, DOI 10.1074/jbc.274.20.14429
   Murray J, 2004, BBA-BIOENERGETICS, V1659, P206, DOI 10.1016/j.bbabio.2004.07.005
   Padfield KE, 2005, P NATL ACAD SCI USA, V102, P5368, DOI 10.1073/pnas.0501211102
   Thorburn DR, 2004, BBA-BIOENERGETICS, V1659, P121, DOI 10.1016/j.bbabio.2004.08.006
   Traven A, 2001, J BIOL CHEM, V276, P4020, DOI 10.1074/jbc.M006807200
   van der Westhuizen FH, 2003, NEUROPEDIATRICS, V34, P14, DOI 10.1055/s-2003-38618
   Voisin V, 2005, NEUROBIOL DIS, V20, P123, DOI 10.1016/j.nbd.2005.02.010
   WALLACE D, 2004, BIOCHIM BIOPHYS ACTA, V1657, P4
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Wong LJC, 2005, CLIN CHIM ACTA, V354, P1, DOI 10.1016/j.cccn.2004.11.003
   Zhang D, 2005, CARDIOVASC PATHOL, V14, P61, DOI 10.1016/j.carpath.2005.01.006
   Zhu LP, 2000, CELL CALCIUM, V28, P107, DOI 10.1054/ceca.2000.0138
NR 41
TC 16
Z9 19
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1521-6543
EI 1521-6551
J9 IUBMB LIFE
JI IUBMB Life
PD DEC
PY 2005
VL 57
IS 12
BP 811
EP 818
DI 10.1080/15216540500460269
PG 8
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 997EV
UT WOS:000234228700006
PM 16393784
OA Bronze
DA 2024-11-01
ER

PT J
AU Yu, XL
   Yan, CZ
   Ji, KQ
   Lin, PF
   Xu, XB
   Dai, TJ
   Li, W
   Zhao, YY
AF Yu, Xiao-Lin
   Yan, Chuan-Zhu
   Ji, Kun-Qian
   Lin, Peng-Fei
   Xu, Xue-Bi
   Dai, Ting-Jun
   Li, Wei
   Zhao, Yu-Ying
TI Clinical, Neuroimaging, and Pathological Analyses of 13 Chinese Leigh
   Syndrome Patients with Mitochondrial DNA Mutations
SO CHINESE MEDICAL JOURNAL
LA English
DT Article
DE Clinical Features; Leigh Syndrome; Mitochondrial DNA; Neuroimaging;
   Pathology
ID COMPLEX-I; CHILDREN; DISEASE; MANIFESTATIONS; IDENTIFICATION; PHENOTYPE;
   GENETICS; BRAIN
AB Background: Leigh syndrome (LS) is a rare disease caused by mitochondrial defects and has high phenotypic and genotypic heterogeneity. We analyzed the clinical symptoms, neuroimaging, muscular histopathology, and genotypes of 13 Chinese LS patients with mitochondrial DNA (mtDNA) mutations. Methods: Mutations in mtDNA were identified by targeted sequencing. The brain imaging features on magnetic resonance imaging (MRI) were analyzed. The levels of lactate in fasting blood and cerebrospinal fluid (CSF) were routinely tested. The levels of urinary organic acids, plasma amino acids, and acylcarnitines were examined with gas chromatographyumass spectrometry and tandem mass spectrometry. The histopathological traits of skeletal muscles were analyzed under microscope. Results: Among 13 patients, mutations of MT-NDs (n = 8) and MT-ATP6 (n = 4) genes were most common. Strabismus (8/13), muscle weakness (8/13), and ataxia (5/13) were also common, especially for the patients with late-onset age after 2 years old. However, respiratory distress was common in patients with early-onset age before 2 years old. The most frequently affected brain area in these patients was the brain stem (12/13), particularly the dorsal part of midbrain, followed by basal ganglia (6/13), thalamus (6/13), cerebellum (5/13), and supratentorial white matter (2/13). Besides, the elevated lactate levels in CSF (6/6) were more common than those in serum (7/13). However, the analysis of abnormal plasma amino acid and urinary organic acid showed limited results (0/3 and 1/4, respectively). Muscular histopathology showed mitochondrial myopathy in the three late-onset patients but not in the early-onset ones. Conclusions: Noninvasive genetic screening is recommended for mtDNA mutations in MT-NDs and MT-ATP6 genes in patients with ophthalmoplegia, muscle weakness, ataxia, and respiratory disorder. Furthermore, the lactate detection in CSF and the brain MRI scanning are suggested as the diagnosis methods for LS patients with mtDNA mutations.
C1 [Yu, Xiao-Lin] Shandong Univ, Qilu Hosp, Dept Geriatr Med, Jinan 250012, Shandong, Peoples R China.
   [Yu, Xiao-Lin; Yan, Chuan-Zhu; Ji, Kun-Qian; Lin, Peng-Fei; Xu, Xue-Bi; Dai, Ting-Jun; Li, Wei; Zhao, Yu-Ying] Shandong Univ, Res Inst Neuromuscular & Neurodegenerat Dis, Qilu Hosp, Dept Neurol, 107 West Wenhua Rd, Jinan 250012, Shandong, Peoples R China.
   [Yu, Xiao-Lin] Shandong Univ, Qilu Hosp, Key Lab Cardiovasc Prote Shandong Prov, Jinan 250012, Shandong, Peoples R China.
   [Yan, Chuan-Zhu] Shandong Univ, Qilu Hosp Qingdao, Mitochondrial Med Lab, Qingdao 266035, Shandong, Peoples R China.
   [Yan, Chuan-Zhu] Shandong Univ, Brain Sci Res Inst, Jinan 250012, Shandong, Peoples R China.
C3 Shandong University; Shandong University; Shandong University; Shandong
   University; Shandong University
RP Zhao, YY (corresponding author), Shandong Univ, Res Inst Neuromuscular & Neurodegenerat Dis, Qilu Hosp, Dept Neurol, 107 West Wenhua Rd, Jinan 250012, Shandong, Peoples R China.
EM zyy72@126.com
RI li, weihao/GWZ-3120-2022
FU National Natural Science Foundation of China [81671235, 81701237];
   Taishan Scholars Program of Shandong Province
FX This study was supported by the grants from the National Natural Science
   Foundation of China (No. 81671235 and 81701237) and the Taishan Scholars
   Program of Shandong Province.
CR Arii J, 2000, AM J NEURORADIOL, V21, P1502
   Baertling F, 2014, J NEUROL NEUROSUR PS, V85, P257, DOI 10.1136/jnnp-2012-304426
   Bannwarth S, 2013, J MED GENET, V50, P704, DOI 10.1136/jmedgenet-2013-101604
   Bonfante E, 2016, PEDIATR RADIOL, V46, P443, DOI 10.1007/s00247-015-3523-5
   Chomyn A, 2001, J BIOENERG BIOMEMBR, V33, P251, DOI 10.1023/A:1010791204961
   Chourasia N, 2017, PEDIATR NEUROL, V74, P97, DOI 10.1016/j.pediatrneurol.2017.05.008
   Fang F, 2017, SCI CHINA LIFE SCI, V60, P746, DOI 10.1007/s11427-017-9080-y
   Finsterer J, 2008, PEDIATR NEUROL, V39, P223, DOI 10.1016/j.pediatrneurol.2008.07.013
   Finsterer J, 2017, BIOMED REP, V6, P487, DOI 10.3892/br.2017.892
   Gerards M, 2016, MOL GENET METAB, V117, P300, DOI 10.1016/j.ymgme.2015.12.004
   Han J, 2015, BRIT J OPHTHALMOL, V99, P528, DOI 10.1136/bjophthalmol-2014-305704
   Janssen RJRJ, 2006, J INHERIT METAB DIS, V29, P499, DOI 10.1007/s10545-006-0362-4
   Ji KQ, 2014, NEUROMOL MED, V16, P119, DOI 10.1007/s12017-013-8264-8
   Lake NJ, 2016, ANN NEUROL, V79, P190, DOI 10.1002/ana.24551
   Lake NJ, 2015, J NEUROPATH EXP NEUR, V74, P482, DOI 10.1097/NEN.0000000000000195
   Lebre AS, 2011, J MED GENET, V48, P16, DOI 10.1136/jmg.2010.079624
   Lee HF, 2009, PEDIATR NEUROL, V40, P88, DOI 10.1016/j.pediatrneurol.2008.09.020
   Lee JS, 2016, J CLIN NEUROL, V12, P181, DOI 10.3988/jcn.2016.12.2.181
   LEIGH D, 1951, J NEUROL NEUROSUR PS, V14, P216, DOI 10.1136/jnnp.14.3.216
   Ma YY, 2013, J CLIN NEUROSCI, V20, P1591, DOI 10.1016/j.jocn.2013.03.034
   McFarland R, 2004, ANN NEUROL, V55, P58, DOI 10.1002/ana.10787
   McKelvie P, 2012, J CLIN NEUROSCI, V19, P195, DOI 10.1016/j.jocn.2011.09.009
   Naess K, 2009, BBA-BIOENERGETICS, V1787, P484, DOI 10.1016/j.bbabio.2008.11.014
   Ogawa E, 2017, J INHERIT METAB DIS, V40, P685, DOI 10.1007/s10545-017-0042-6
   Rahman S, 1996, ANN NEUROL, V39, P343, DOI 10.1002/ana.410390311
   Ruhoy LS, 2014, APPL CLIN GENET, V7, P221, DOI 10.2147/TACG.S46176
   Santorelli FM, 1997, BIOCHEM BIOPH RES CO, V238, P326, DOI 10.1006/bbrc.1997.7167
   Sijens PE, 2008, BRAIN DEV-JPN, V30, P579, DOI 10.1016/j.braindev.2008.01.011
   Sinko G, 2014, PEDIATR NEUROL, V51, P585, DOI 10.1016/j.pediatrneurol.2014.07.015
   Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063
   Sofou K, 2018, J MED GENET, V55, P21, DOI 10.1136/jmedgenet-2017-104891
   Sofou K, 2014, ORPHANET J RARE DIS, V9, DOI 10.1186/1750-1172-9-52
   Taylor RW, 2001, ANN NEUROL, V50, P104, DOI 10.1002/ana.1084
   Valente L, 2009, BBA-BIOENERGETICS, V1787, P491, DOI 10.1016/j.bbabio.2008.10.001
   Zhu CC, 2017, OPHTHALMIC GENET, V38, P67, DOI 10.3109/13816810.2015.1130153
NR 35
TC 13
Z9 15
U1 0
U2 12
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0366-6999
J9 CHINESE MED J-PEKING
JI Chin. Med. J.
PD NOV 20
PY 2018
VL 131
IS 22
BP 2705
EP +
DI 10.4103/0366-6999.245265
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA HA3AJ
UT WOS:000450120700009
PM 30425197
OA gold, Green Published
DA 2024-11-01
ER

PT J
AU Frederiksen, AL
   Jeppesen, TD
   Vissing, J
   Schwartz, M
   Kyvik, KO
   Schmitz, O
   Poulsen, PL
   Andersen, PH
AF Frederiksen, Anja Lisbeth
   Jeppesen, Tina Dysgaard
   Vissing, John
   Schwartz, Marianne
   Kyvik, Kirsten Ohm
   Schmitz, Ole
   Poulsen, Per Logstrup
   Andersen, Per Heden
TI High Prevalence of Impaired Glucose Homeostasis and Myopathy in
   Asymptomatic and Oligosymptomatic 3243A&gt;G Mitochondrial DNA
   Mutation-Positive Subjects
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID STROKE-LIKE EPISODES; DIABETES-MELLITUS; TRNA(LEU(UUR)) MUTATION;
   INSULIN-RESISTANCE; LACTIC-ACIDOSIS; GENE; PHENOTYPE; DEAFNESS; MELAS;
   SPECTRUM
AB Introduction: The point mutation of 3243A>G mtDNA is the most frequent cause of mitochondrial diabetes, often presenting as the syndrome maternally inherited diabetes and deafness (MIDD). The mutation may also cause myopathy, ataxia, strokes, ophthalmoplegia, epilepsy, and cardiomyopathy in various combinations. Consequently, it is difficult to predict the "phenotypic risk profile" of 3243A>G mutation-positive subjects. The 3243A>G mutation coexists in cells with wild-type mtDNA, a phenomenon called heteroplasmy. The marked variability in mutation loads in different tissues is the main explanation for the different phenotypes associated with this mutation.
   Aim: The aim of the study was to screen asymptomatic and oligosymptomatic 3243A>G mtDNA carriers for diabetes and myopathy.
   Methods: The study is a case-control study. Nineteen adult 3243A>G carriers presumed to be normoglycemic and matched healthy controls were subjected to an oral glucose tolerance test. Twenty-six adult 3243A>G carriers with unknown myopathy status and 17 healthy controls had a maximal cycle test and a muscle biopsy performed. The mutation loads were quantified in blood and muscle biopsies and correlated to the clinical manifestations of the mutation.
   Results: In the presumed normoglycemic 3243A>G-positive subjects, one subject had overt diabetes, and 10 subjects had impaired glucose tolerance. Sixteen of the 26 subjects with unknown oxidative capacity fulfilled criteria for myopathy. The mutation load in blood and muscle correlated with the age for diagnosis of impaired glucose homeostasis and hearing impairment (rho = -0.71 to -0.78; P < 0.0001).
   Conclusion: The findings suggest that 3243A>G mutation carriers should be screened for diabetes and myopathy. (J Clin Endocrinol Metab 94: 2872-2879, 2009)
C1 [Frederiksen, Anja Lisbeth; Andersen, Per Heden] Ribe Cty Hosp, Dept Endocrinol, DK-6700 Esbjerg, Denmark.
   [Frederiksen, Anja Lisbeth] Odense Univ Hosp, Dept Endocrinol, DK-5000 Odense, Denmark.
   [Jeppesen, Tina Dysgaard; Vissing, John] Univ Copenhagen, Rigshosp, Neuromuscular Res Unit, Dept Neurol, DK-2100 Copenhagen, Denmark.
   [Schwartz, Marianne] Univ Copenhagen, Rigshosp, Dept Clin Genet, DK-2100 Copenhagen, Denmark.
   [Kyvik, Kirsten Ohm] Univ So Denmark, Inst Publ Hlth, Danish Twin Registry, DK-5230 Odense, Denmark.
   [Schmitz, Ole; Poulsen, Per Logstrup] Aarhus Univ Hosp, Dept Endocrinol M, Res Lab, DK-8200 Aarhus, Denmark.
C3 University of Southern Denmark; Odense University Hospital;
   Rigshospitalet; University of Copenhagen; University of Copenhagen;
   Rigshospitalet; University of Southern Denmark; Aarhus University
RP Frederiksen, AL (corresponding author), Ribe Cty Hosp, Dept Endocrinol, Finsensgade 35, DK-6700 Esbjerg, Denmark.
EM anja.frederiksen@ouh.regionsyddanmark.dk
RI Jeppesen, Tina/AAV-7195-2020; Vissing, John/IUN-4271-2023; Frederiksen,
   Anja/AAF-1983-2019; Kyvik, Kirsten Ohm/K-5680-2016
OI Poulsen, Per Logstrup/0000-0001-6468-2715; Frederiksen, Anja
   Lisbeth/0000-0002-7944-8910; Kyvik, Kirsten Ohm/0000-0003-2981-0245
CR [Anonymous], 2008, MITOMAP: A Human Mitochondrial Genome Database
   Becker R, 2002, EXP CLIN ENDOCR DIAB, V110, P291, DOI 10.1055/s-2002-34592
   Blake DR, 2004, DIABETES, V53, P2095, DOI 10.2337/diabetes.53.8.2095
   Brändle M, 2001, DIABETES CARE, V24, P1253, DOI 10.2337/diacare.24.7.1253
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   Chinnery PF, 2000, BRAIN, V123, P82, DOI 10.1093/brain/123.1.82
   DAMIAN MS, 1995, ACTA NEUROL SCAND, V92, P409
   DeSouza RA, 2004, SOUTH MED J, V97, P528, DOI 10.1097/00007611-200405000-00023
   Frederiksen AL, 2006, J MED GENET, V43, DOI 10.1136/jmg.2005.039339
   Gavin JR, 1997, DIABETES CARE, V20, P1183
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Guéry B, 2003, J AM SOC NEPHROL, V14, P2099, DOI 10.1097/01.ASN.0000080180.51098.02
   Guillausseau PJ, 2004, DIABETES METAB, V30, P181, DOI 10.1016/S1262-3636(07)70105-2
   Hotta O, 2001, KIDNEY INT, V59, P1236, DOI 10.1046/j.1523-1755.2001.0590041236.x
   Jansen JJ, 1997, J AM SOC NEPHROL, V8, P1118
   Jeppesen TD, 2003, ANN NEUROL, V54, P86, DOI 10.1002/ana.10594
   Jeppesen TD, 2006, ARCH NEUROL-CHICAGO, V63, P1701, DOI 10.1001/archneur.63.12.1701
   Jones DL, 2004, INTERN MED J, V34, P517, DOI 10.1111/j.1444-0903.2004.00659.x
   Kärppä M, 2004, J NEUROL, V251, P556, DOI 10.1007/s00415-004-0363-x
   Löwik MM, 2005, NEPHROL DIAL TRANSPL, V20, P336, DOI 10.1093/ndt/gfh546
   Maassen JA, 2004, DIABETES, V53, pS103, DOI 10.2337/diabetes.53.2007.S103
   Maassen JA, 2002, J ENDOCRINOL INVEST, V25, P477, DOI 10.1007/BF03344042
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   MANOUVRIER S, 1995, J MED GENET, V32, P654, DOI 10.1136/jmg.32.8.654
   MARIOTTI C, 1995, J NEUROL, V242, P304, DOI 10.1007/BF00878873
   Olsson C, 1998, HUM MUTAT, V12, P52, DOI 10.1002/(SICI)1098-1004(1998)12:1<52::AID-HUMU8>3.0.CO;2-K
   Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350
   Sparaco M, 2003, ACTA NEUROPATHOL, V106, P202, DOI 10.1007/s00401-003-0716-z
   Suomalainen A, 2000, MOL BIOTECHNOL, V15, P123, DOI 10.1385/MB:15:2:123
   Suzuki S, 2003, DIABETES RES CLIN PR, V59, P207, DOI 10.1016/S0168-8227(02)00246-2
   Szendroedi J, 2009, DIABETES CARE, V32, P677, DOI 10.2337/dc08-2078
   Taivassalo T, 2003, BRAIN, V126, P413, DOI 10.1093/brain/awg028
   Torroni A, 2003, AM J HUM GENET, V72, P1005, DOI 10.1086/373936
   Uimonen S, 2001, HUM GENET, V108, P284, DOI 10.1007/s004390100475
   Unwin N, 2002, DIABETIC MED, V19, P708, DOI 10.1046/j.1464-5491.2002.00835.x
   van den Ouweland JMW, 1999, DIABETOLOGIA, V42, P485, DOI 10.1007/s001250051183
   VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368
   Velho G, 1996, DIABETES, V45, P478, DOI 10.2337/diabetes.45.4.478
NR 39
TC 18
Z9 19
U1 0
U2 1
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0021-972X
EI 1945-7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD AUG
PY 2009
VL 94
IS 8
BP 2872
EP 2879
DI 10.1210/jc.2009-0235
PG 8
WC Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism
GA 479UW
UT WOS:000268687700029
PM 19470628
OA Bronze
DA 2024-11-01
ER

PT J
AU Meulemans, A
   Seneca, S
   Smet, J
   De Paepe, B
   Lissens, W
   Van Coster, R
   Debeer, A
   De Meirleir, L
   Jaeken, J
AF Meulemans, Ann
   Seneca, Sara
   Smet, Joel
   De Paepe, Boel
   Lissens, Willy
   Van Coster, Rudy
   Debeer, Anne
   De Meirleir, Linda
   Jaeken, Jaak
TI A new family with the mitochondrial tRNAGLU gene mutation m.14709T&gt;C
   presenting with hydrops fetalis
SO EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY
LA English
DT Article
DE diabetes; hydrops fetalis; mitochondrial disease; mitochondrial
   tRNA(Glu); myopathy; m.14709T >C
ID T14709C POINT MUTATION; DIABETES-MELLITUS; ONSET MYOPATHY; DNA;
   ENCEPHALOMYOPATHY; PATIENT; DEFECT
AB Background: In the heterogeneous group of mitochondrial disorders, patients with the same genotype can show different phenotypes and the same phenotype can be caused by different genotypes. We describe a family with the m.14709T > C mutation and a clinical presentation of hydrops fetalis, in contrast to previous reports in which patients presented with myopathy and/or diabetes mellitus. Aim: To identify a mutation in the mtDNA of a family with a heterogeneous clinical presentation.
   Methods: Both biochemical and molecular analyses were performed.
   Results: Biochemical results showed a decreased complex I and IV activity in muscle tissue of the patients. A mosaic-staining pattern for complex I in the patients' fibroblasts was revealed using immunocytochemistry. Molecular analyses identified the m. 14709T > C mutation in the mitochondrial encoded tRNA(Glu) gene.
   Conclusion: We report 2 siblings with the m.14709T > C mutation in the mitochondrial tRNA(Glu) gene. The first patient showed hydrops fetalis, a new presentation within the clinical spectrum of this mutation, and the other a known presentation namely mild myopathy. (c) 2006 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights reserved.
C1 Katholieke Univ Leuven, Ctr Metab Dis, Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium.
   Dutch Speaking Free Univ Brussels, Ctr Med Genet, AZVUB, Brussels, Belgium.
   Dutch Speaking Free Univ Brussels, Dept Pediat Neurol, AZVUB, Brussels, Belgium.
   Univ Ghent, B-9000 Ghent, Belgium.
   Katholieke Univ Leuven, Dept Neonatol, Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium.
C3 KU Leuven; University Hospital Leuven; Vrije Universiteit Brussel; Vrije
   Universiteit Brussel; Ghent University; KU Leuven; University Hospital
   Leuven
RP Jaeken, J (corresponding author), Katholieke Univ Leuven, Ctr Metab Dis, Univ Hosp Gasthuisberg, Herestr 49, B-3000 Louvain, Belgium.
EM jaak.jaeken@uz.kuleuven.ac.be
RI Debeer, Anne/ABF-8895-2021; De Meirleir, Linda/D-6591-2016; De Paepe,
   Boel/B-7548-2013; Lissens, Willy/B-2892-2013; Smet, Joel/B-7428-2013
OI De Paepe, Boel/0000-0001-9403-4401; Meulemans, Ann/0000-0003-3938-2408;
   Debeer, Anne/0000-0001-9418-8160; Seneca, Sara/0000-0002-0853-9890;
   Lissens, Willy/0000-0003-3875-9955; Smet, Joel/0000-0002-9551-6282
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   BIRCHMACHIN MA, 1989, PEDIATR RES, V25, P553, DOI 10.1203/00006450-198905000-00025
   Damore ME, 1999, J PEDIATR ENDOCR MET, V12, P207
   De Paepe B, 2006, PEDIATR RES, V59, P2, DOI 10.1203/01.pdr.0000191294.34122.ab
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   FISCHER JC, 1986, EUR J PEDIATR, V144, P441, DOI 10.1007/BF00441735
   HANNA MG, 1995, AM J HUM GENET, V56, P1026
   HAO HL, 1995, AM J HUM GENET, V56, P1017
   Kramer KA, 2005, CLIN CHEM, V51, P2110, DOI 10.1373/clinchem.2005.050146
   Mancuso M, 2005, J NEUROL SCI, V228, P93, DOI 10.1016/j.jns.2004.10.018
   McFarland R, 2004, ANN NEUROL, V55, P478, DOI 10.1002/ana.20004
   Perucca-Lostanlen D, 2002, BBA-MOL BASIS DIS, V1588, P210, DOI 10.1016/S0925-4439(02)00167-9
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   Schapira AHV, 2006, LANCET, V368, P70, DOI 10.1016/S0140-6736(06)68970-8
   SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415
   Srere P.A., 1969, Methods in Enzymology, V13, P3
   Van Coster R, 2001, PEDIATR RES, V50, P658, DOI 10.1203/00006450-200111000-00020
   Vialettes BH, 1997, DIABETES CARE, V20, P1731, DOI 10.2337/diacare.20.11.1731
NR 18
TC 13
Z9 13
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1090-3798
EI 1532-2130
J9 EUR J PAEDIATR NEURO
JI Eur. J. Paediatr. Neurol.
PD JAN
PY 2007
VL 11
IS 1
BP 17
EP 20
DI 10.1016/j.ejpn.2006.10.004
PG 4
WC Clinical Neurology; Pediatrics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pediatrics
GA 135UB
UT WOS:000244178200003
PM 17161635
DA 2024-11-01
ER

PT J
AU Ardissone, A
   Ferrera, G
   Lamperti, C
   Tiranti, V
   Ghezzi, D
   Moroni, I
   Lamantea, E
AF Ardissone, Anna
   Ferrera, Giulia
   Lamperti, Costanza
   Tiranti, Valeria
   Ghezzi, Daniele
   Moroni, Isabella
   Lamantea, Eleonora
TI Phenotyping mitochondrial DNA-related diseases in childhood: A cohort
   study of 150 patients
SO EUROPEAN JOURNAL OF NEUROLOGY
LA English
DT Article
DE mitochondrial disorder; mitochondrial DNA; pediatric; phenotypes
ID CYTOCHROME-C-OXIDASE; CLINICAL SPECTRUM; CAVITATING LEUKOENCEPHALOPATHY;
   PEDIATRIC-PATIENTS; MUTATIONS; CHILDREN; FEATURES; DISORDERS; MORTALITY;
   VARIANT
AB Background and purpose: Mitochondrial diseases (MDs) are heterogeneous disorders caused by mutations in nuclear DNA (nDNA) or mitochondrial DNA (mtDNA) associated with specific syndromes. However, especially in childhood, patients often display heterogeneity. Several reports on the biochemical and molecular profiles in children have been published, but studies tend not to differentiate between mtDNA- and nDNA-associated diseases, and focus is often on a specific phenotype. Thus, large cohort studies specifically focusing on mtDNA defects in the pediatric population are lacking.
   Methods: We reviewed the clinical, metabolic, biochemical, and neuroimaging data of 150 patients with MDs due to mtDNA alterations collected at our neurological institute over the past 20 years.
   Results: mtDNA impairment is less frequent than nDNA impairment in pediatric MDs. Ocular involvement is extremely frequent in our cohort, as is classical Leber hereditary optic neuropathy, especially with onset before 12 years of age. Extraneurological manifestations and isolated myopathy appear to be rare, unlike adult phenotypes. Deep gray matter involvement, early disease onset, and specific phenotypes, such as Pearson syndrome and Leigh syndrome, represent unfavorable prognostic factors. Phenotypes related to single large scale mtDNA deletions appear to be very frequent in the pediatric population. Furthermore, we report for the first time an mtDNA pathogenic variant associated with cavitating leukodystrophy.
   Conclusions: We report on a large cohort of pediatric patients with mtDNA defects, adding new data on the phenotypical characterization of mtDNA defects and suggestions for diagnostic workup and therapeutic approach.
C1 [Ardissone, Anna; Ferrera, Giulia; Moroni, Isabella] Fdn IRCCS Ist Neurol Carlo Besta, Dept Pediat Neurosci, Child Neurol Unit, Milan, Italy.
   [Lamperti, Costanza; Tiranti, Valeria; Ghezzi, Daniele; Lamantea, Eleonora] Fdn IRCCS Ist Neurol Carlo Besta, Unit Med Genet & Neurogenet, Milan, Italy.
   [Ghezzi, Daniele] Univ Milan, Dept Pathophysiol & Transplantat, Milan, Italy.
   [Ardissone, Anna] Fdn IRCCS Ist Neurol Carlo Besta, Dept Pediat Neurosci, Child Neurol Unit, Via Celoria 11, I-20133 Milan, Italy.
C3 Fondazione IRCCS Istituto Neurologico Carlo Besta; Fondazione IRCCS
   Istituto Neurologico Carlo Besta; University of Milan; Fondazione IRCCS
   Istituto Neurologico Carlo Besta
RP Ardissone, A (corresponding author), Fdn IRCCS Ist Neurol Carlo Besta, Dept Pediat Neurosci, Child Neurol Unit, Via Celoria 11, I-20133 Milan, Italy.
EM anna.ardissone@istituto-besta.it
RI Ardissone, Anna/K-8495-2016; Ghezzi, Daniele/J-7873-2016; Tiranti,
   Valeria/AFN-5783-2022; Lamantea, Eleonora/J-8339-2016; Tiranti,
   Valeria/J-8233-2016
OI Tiranti, Valeria/0000-0002-3584-7338
FU Italian Ministry of Health [RF-2016-02361241, RF-2016-02361495];
   (Ricerca Corrente); European Joint Programme on Rare Diseases project
   GENOMIT (Italian Ministry of Health) [ERP-2019-23671045]; ERA PerMed
   project PerMiM (Italian Ministry of Health) [ERP-2019-23671048]; Mariani
   Foundation; BIBLIOSAN
FX We thank all the people who over > 20?years have provided technical
   assistance, particularly Franco Carrara, Manuela Spagnolo, and Nadia
   Zanetti. This work was supported by the Italian Ministry of Health
   (grants RF-2016-02361241, RF-2016-02361495, and Ricerca Corrente), the
   European Joint Programme on Rare Diseases project GENOMIT (Italian
   Ministry of Health ERP-2019-23671045), and the ERA PerMed project PerMiM
   (Italian Ministry of Health ERP-2019-23671048). This project was carried
   out at the Center for the Study of Mitochondrial Pediatric Diseases (),
   funded by the Mariani Foundation. A.A., C.L., D.G., and V.T. are members
   of the European Reference Network for Rare Neuromuscular Diseases. The
   Cell Line and DNA Bank of Genetic Movement Disorders and Mitochondrial
   Diseases of the Telethon Network of Genetic Biobanks (GTB12001J) and the
   Eurobiobank Network supplied biological specimens. Open access funding
   provided by BIBLIOSAN.
CR Al-Hassnan ZN, 2015, J MED GENET, V52, P186, DOI 10.1136/jmedgenet-2014-102592
   Anteneová N, 2020, BRAIN SCI, V10, DOI 10.3390/brainsci10110766
   Ardissone A, 2021, ORPHANET J RARE DIS, V16, DOI 10.1186/s13023-021-02029-3
   Ardissone A, 2018, ORPHANET J RARE DIS, V13, DOI 10.1186/s13023-018-0788-4
   Baker PR, 2014, BRAIN, V137, P366, DOI 10.1093/brain/awt328
   Biancheri R, 2010, AJNR Am J Neuroradiol, V31, pE78, DOI 10.3174/ajnr.A2182
   Broomfield A, 2015, J INHERIT METAB DIS, V38, P445, DOI 10.1007/s10545-014-9778-4
   Bugiani M, 2004, BBA-BIOENERGETICS, V1659, P136, DOI 10.1016/j.bbabio.2004.09.006
   Chinnery PF, 2015, EMBO MOL MED, V7, P1503, DOI 10.15252/emmm.201505079
   Craven L, 2010, NATURE, V465, P82, DOI 10.1038/nature08958
   Cruz S, 2017, MUSCLE NERVE, V56, P868, DOI 10.1002/mus.25593
   Dallabona C, 2016, BRAIN, V139, P782, DOI 10.1093/brain/awv392
   Danhelovska T, 2020, BMC PEDIATR, V20, DOI 10.1186/s12887-020-1912-x
   Darin N, 2001, ANN NEUROL, V49, P377, DOI 10.1002/ana.75
   de Laat P, 2021, J MED GENET, V58, P48, DOI 10.1136/jmedgenet-2019-106800
   Debray FG, 2007, PEDIATRICS, V119, P722, DOI 10.1542/peds.2006-1866
   Diodato Daria, 2014, Int J Cell Biol, V2014, P787956, DOI 10.1155/2014/787956
   El-Hattab AW, 2017, MOL GENET METAB, V122, P1, DOI 10.1016/j.ymgme.2017.09.009
   Fang F, 2017, SCI CHINA LIFE SCI, V60, P746, DOI 10.1007/s11427-017-9080-y
   Fassone E, 2012, J MED GENET, V49, P578, DOI 10.1136/jmedgenet-2012-101159
   García-Cazorla A, 2005, PEDIATRICS, V116, P1170, DOI 10.1542/peds.2004-2407
   Gibson K, 2008, PEDIATRICS, V122, P1003, DOI 10.1542/peds.2007-3502
   Gorman GS, 2015, ANN NEUROL, V77, P753, DOI 10.1002/ana.24362
   Honzik T, 2012, J INHERIT METAB DIS, V35, P749, DOI 10.1007/s10545-011-9440-3
   Hu CP, 2020, EUR J MED GENET, V63, DOI 10.1016/j.ejmg.2020.103898
   Invernizzi F, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00412
   Lee JS, 2020, CLIN GENET, V97, P586, DOI 10.1111/cge.13713
   Legati A, 2021, J MOL DIAGN, V23, P732, DOI 10.1016/j.jmoldx.2021.03.002
   Loos MA, 2021, MOL GENET METAB REP, V27, DOI 10.1016/j.ymgmr.2021.100733
   Lyseng-Williamson KA, 2016, DRUGS, V76, P805, DOI 10.1007/s40265-016-0574-3
   Mancuso M, 2015, J NEUROL, V262, P1301, DOI 10.1007/s00415-015-7710-y
   Mancuso M, 2014, J NEUROL, V261, P504, DOI 10.1007/s00415-013-7225-3
   Mancuso M, 2013, NEUROLOGY, V80, P2049, DOI 10.1212/WNL.0b013e318294b44c
   Marco M, 2022, NEUROL SCI, V43, P2081, DOI 10.1007/s10072-022-05881-8
   Melchionda L, 2014, AM J HUM GENET, V95, P315, DOI 10.1016/j.ajhg.2014.08.003
   Naess K, 2021, J PEDIATR-US, V228, P240, DOI 10.1016/j.jpeds.2020.08.025
   Ogawa E, 2020, J INHERIT METAB DIS, V43, P819, DOI 10.1002/jimd.12218
   Puoti G, 2003, J MED GENET, V40, P858, DOI 10.1136/jmg.40.11.858
   Scaglia F, 2004, PEDIATRICS, V114, P925, DOI 10.1542/peds.2004-0718
   Shinagawa Austin, 2020, Radiol Case Rep, V15, P908, DOI 10.1016/j.radcr.2020.04.042
   Skladal D, 2003, CLIN PEDIATR, V42, P703, DOI 10.1177/000992280304200806
   Sofou K, 2014, ORPHANET J RARE DIS, V9, DOI 10.1186/1750-1172-9-52
   Stendel C, 2020, NEUROL-GENET, V6, DOI 10.1212/NXG.0000000000000393
   Swalwell H, 2011, EUR J HUM GENET, V19, P769, DOI 10.1038/ejhg.2011.18
   Thorburn D.R., 1993, GeneReviews
   Tiranti V, 2000, HUM MOL GENET, V9, P2733, DOI 10.1093/hmg/9.18.2733
   Torraco A, 2017, J NEUROL, V264, P102, DOI 10.1007/s00415-016-8312-z
   Verity CM, 2010, DEV MED CHILD NEUROL, V52, P434, DOI 10.1111/j.1469-8749.2009.03463.x
   Wang W, 2021, NEUROMUSCULAR DISORD, V31, P558, DOI 10.1016/j.nmd.2021.02.020
   Zanolini A, 2017, MOL GENET METAB REP, V10, P24, DOI 10.1016/j.ymgmr.2016.11.009
NR 50
TC 4
Z9 4
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1351-5101
EI 1468-1331
J9 EUR J NEUROL
JI Eur. J. Neurol.
PD JUL
PY 2023
VL 30
IS 7
BP 2079
EP 2091
DI 10.1111/ene.15814
EA APR 2023
PG 13
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA I1CO0
UT WOS:000979070900001
PM 37038312
OA hybrid
DA 2024-11-01
ER

PT J
AU Orsucci, D
   Ienco, EC
   Rossi, A
   Siciliano, G
   Mancuso, M
AF Orsucci, Daniele
   Ienco, Elena Caldarazzo
   Rossi, Andrea
   Siciliano, Gabriele
   Mancuso, Michelangelo
TI Mitochondrial Syndromes Revisited
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Review
DE CPEO; leber; Leigh syndrome; MELAS; MERRF; mitochondrial myopathy;
   MNGIE; mtDNA; NARP; PEO
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; CARDIAC INVOLVEMENT; TWINKLE
   MUTATIONS; CEREBELLAR-ATAXIA; OUTCOME MEASURES; LACTIC-ACIDOSIS; DNA
   POLYMERASE; LARGE COHORT; EARLY-ONSET; ENCEPHALOMYOPATHY
AB In the last ten years, the knowledge of the genetic basis of mitochondrial diseases has significantly advanced. However, the vast phenotypic variability linked to mitochondrial disorders and the peculiar characteristics of their genetics make mitochondrial disorders a complex group of disorders. Although specific genetic alterations have been associated with some syndromic presentations, the genotype-phenotype relationship in mitochondrial disorders is complex (a single mutation can cause several clinical syndromes, while different genetic alterations can cause similar phenotypes). This review will revisit the most common syndromic pictures of mitochondrial disorders, from a clinical rather than a molecular perspective. We believe that the new phenotype definitions implemented by recent large multicenter studies, and revised here, may contribute to a more homogeneous patient categorization, which will be useful in future studies on natural history and clinical trials.
C1 [Orsucci, Daniele; Ienco, Elena Caldarazzo] San Luca Hosp, Unit Neurol, I-55100 Lucca, Italy.
   [Rossi, Andrea] Med Affairs & Sci Commun, CH-1260 Nyon, Switzerland.
   [Siciliano, Gabriele; Mancuso, Michelangelo] Univ Pisa, Dept Clin & Expt Med, Neurol Clin, I-56126 Pisa, Italy.
C3 University of Pisa
RP Orsucci, D (corresponding author), San Luca Hosp, Unit Neurol, I-55100 Lucca, Italy.
EM orsuccid@gmail.com; elenacaldarazzoienco@gmail.com;
   molezzano.1@libero.it; g.siciliano@unipi.it; m.mancuso@unipi.it
RI Orsucci, Daniele/AAA-7576-2019; Ienco, Elena/K-9142-2016; Rossi,
   Andrea/AAT-1759-2021
OI Rossi, Andrea/0000-0003-4019-4412; Orsucci, Daniele/0000-0003-4847-7812
FU Telethon Grant [GUP09004]; Telethon-MITOCON Grant [GSP16001]; GENOMIT
   [RF-2016-02361495]
FX The authors are grateful to Telethon Grant GUP09004 and Telethon-MITOCON
   Grant GSP16001 that partially supported their work. M.M. is also
   supported by RF-2016-02361495 and by GENOMIT.
CR Alves CAPF, 2020, ANN NEUROL, V88, P218, DOI 10.1002/ana.25789
   Barca E, 2020, NEUROL-GENET, V6, DOI 10.1212/NXG.0000000000000402
   Boggan RM, 2019, MOL GENET METAB, V128, P19, DOI 10.1016/j.ymgme.2019.09.003
   Brambilla A, 2020, ORPHANET J RARE DIS, V15, DOI 10.1186/s13023-020-01466-w
   Broomfield A, 2015, J INHERIT METAB DIS, V38, P445, DOI 10.1007/s10545-014-9778-4
   Chang XL, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000018634
   D'Aurelio M, 2010, HUM MOL GENET, V19, P374, DOI 10.1093/hmg/ddp503
   Debray FG, 2007, AM J MED GENET A, V143A, P2046, DOI 10.1002/ajmg.a.31880
   DiMauro S, 2013, NAT REV NEUROL, V9, P429, DOI 10.1038/nrneurol.2013.126
   Dorn GW, 2020, FRONT PHYSIOL, V11, DOI 10.3389/fphys.2020.00782
   El-Hattab AW, 2016, FRONT CARDIOVASC MED, V3, DOI 10.3389/fcvm.2016.00025
   Fayssoil A, 2017, EUR J NEUROL, V24, P255, DOI 10.1111/ene.13176
   Fernandez-Vizarra E, 2021, FEBS LETT, V595, P1062, DOI 10.1002/1873-3468.13995
   Filosto M, 2007, ACTA NEUROL SCAND, V115, P211, DOI 10.1111/j.1600-0404.2006.00777.x
   Filosto M, 2018, J CLIN MED, V7, DOI 10.3390/jcm7110389
   Friederich MW, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06250-w
   Galetta F, 2014, J NEUROL SCI, V345, P189, DOI 10.1016/j.jns.2014.07.044
   Gerards M, 2010, MITOCHONDRION, V10, P510, DOI 10.1016/j.mito.2010.05.008
   Giannoni A, 2017, EUR J HEART FAIL, V19, P1701, DOI 10.1002/ejhf.782
   Goffart S, 2009, HUM MOL GENET, V18, P328, DOI 10.1093/hmg/ddn359
   Gorman GS, 2015, ANN NEUROL, V77, P753, DOI 10.1002/ana.24362
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   Hikmat O, 2020, J INHERIT METAB DIS, V43, P726, DOI 10.1002/jimd.12211
   Hirano M, 2021, J INHERIT METAB DIS, V44, P376, DOI 10.1002/jimd.12300
   Hong CM, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.00267
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Jou C, 2019, J CLIN MED, V8, DOI 10.3390/jcm8010068
   Kantorovich V, 2010, BEST PRACT RES CL EN, V24, P415, DOI 10.1016/j.beem.2010.04.001
   Kerr M, 2020, MOL GENET METAB, V131, P66, DOI 10.1016/j.ymgme.2020.08.009
   Kiferle L, 2013, NEUROSCI LETT, V556, P1, DOI 10.1016/j.neulet.2013.09.034
   Kirkman MA, 2009, BRAIN, V132, P2317, DOI 10.1093/brain/awp158
   Labory J, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.590842
   Liu XT, 2020, INT J OPHTHALMOL-CHI, V13, P766, DOI 10.18240/ijo.2020.05.11
   Lucas CHG, 2019, ACAD PATHOL, V6, DOI 10.1177/2374289519888732
   Luoma PT, 2005, HUM MOL GENET, V14, P1907, DOI 10.1093/hmg/ddi196
   Mancuso M, 2012, NEUROMUSCULAR DISORD, V22, pS226, DOI 10.1016/j.nmd.2012.10.012
   Mancuso M, 2017, NEUROMUSCULAR DISORD, V27, P1126, DOI 10.1016/j.nmd.2017.08.006
   Mancuso M, 2016, NEUROMUSCULAR DISORD, V26, P272, DOI 10.1016/j.nmd.2016.02.008
   Mancuso M, 2015, J NEUROL, V262, P1301, DOI 10.1007/s00415-015-7710-y
   Mancuso M, 2014, MOVEMENT DISORD, V29, P722, DOI 10.1002/mds.25839
   Mancuso M, 2014, J NEUROL, V261, P504, DOI 10.1007/s00415-013-7225-3
   Mancuso M, 2013, NEUROLOGY, V80, P2049, DOI 10.1212/WNL.0b013e318294b44c
   Marotta R, 2020, MITOCHONDRION, V54, P128, DOI 10.1016/j.mito.2020.08.007
   Martikainen MH, 2016, JAMA NEUROL, V73, P668, DOI 10.1001/jamaneurol.2016.0355
   McClelland C, 2016, CURR NEUROL NEUROSCI, V16, DOI 10.1007/s11910-016-0652-7
   Montano V, 2020, NEUROL-GENET, V6, DOI 10.1212/NXG.0000000000000519
   Musumeci O, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00160
   Newman NJ, 2020, J NEURO-OPHTHALMOL, V40, P547, DOI 10.1097/WNO.0000000000001045
   Ng Yi Shiau, 2019, Wellcome Open Res, V4, P201, DOI 10.12688/wellcomeopenres.15599.1
   Ng YS, 2019, ANN NEUROL, V86, P310, DOI 10.1002/ana.25525
   Orsucci D, 2017, J NEUROL, V264, P1777, DOI 10.1007/s00415-017-8567-z
   Orsucci Daniele, 2019, Drugs Context, V8, P212588, DOI 10.7573/dic.212588
   Orsucci D, 2011, J MOL NEUROSCI, V44, P17, DOI 10.1007/s12031-010-9488-9
   Papadopoulos C, 2020, J INHERIT METAB DIS, V43, P459, DOI 10.1002/jimd.12185
   Parikh S, 2019, NEUROMUSCULAR DISORD, V29, P895, DOI 10.1016/j.nmd.2019.09.012
   Pitceathly RDS, 2012, NEUROMUSCULAR DISORD, V22, P577, DOI 10.1016/j.nmd.2012.03.009
   Quadir A, 2019, NEUROL-GENET, V5, DOI 10.1212/NXG.0000000000000339
   Quinzii CM, 2008, BIOFACTORS, V32, P113, DOI 10.1002/biof.5520320113
   Rodríguez-López C, 2020, J MED GENET, V57, P643, DOI 10.1136/jmedgenet-2019-106649
   Saneto RP, 2013, PEDIATR NEUROL, V48, P167, DOI 10.1016/j.pediatrneurol.2012.09.014
   Sanger TD, 2010, MOVEMENT DISORD, V25, P1538, DOI 10.1002/mds.23088
   Schicks J, 2010, MOVEMENT DISORD, V25, P2678, DOI 10.1002/mds.23286
   Shahwan A, 2005, LANCET NEUROL, V4, P239, DOI 10.1016/S1474-4422(05)70043-0
   Smits BW, 2011, J NEUROL, V258, P2020, DOI 10.1007/s00415-011-6060-7
   Smits BW, 2011, NEUROMUSCULAR DISORD, V21, P272, DOI 10.1016/j.nmd.2010.12.008
   Ticci C, 2020, NEUROGENETICS, V21, P87, DOI 10.1007/s10048-019-00601-5
   Wahbi K, 2015, EUR HEART J, V36, P2886, DOI 10.1093/eurheartj/ehv307
   Wang R, 2020, MITOCHONDRION, V54, P49, DOI 10.1016/j.mito.2020.07.002
   Wild KT, 2020, AM J MED GENET A, V182, P365, DOI 10.1002/ajmg.a.61433
   Yu-Wai-Man P, 2010, BRAIN, V133, P771, DOI 10.1093/brain/awq007
   Zereg E, 2020, HUM MUTAT, V41, P1394, DOI 10.1002/humu.24037
NR 72
TC 32
Z9 33
U1 0
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD MAR
PY 2021
VL 10
IS 6
AR 1249
DI 10.3390/jcm10061249
PG 18
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA SE2VR
UT WOS:000651931200001
PM 33802970
OA Green Published, gold
DA 2024-11-01
ER

PT J
AU Gorman, GS
   Schaefer, AM
   Ng, Y
   Gomez, N
   Blakely, EL
   Alston, CL
   Feeney, C
   Horvath, R
   Yu-Wai-Man, P
   Chinnery, PF
   Taylor, RW
   Turnbull, DM
   McFarland, R
AF Gorman, Grainne S.
   Schaefer, Andrew M.
   Ng, Yi
   Gomez, Nicholas
   Blakely, Emma L.
   Alston, Charlotte L.
   Feeney, Catherine
   Horvath, Rita
   Yu-Wai-Man, Patrick
   Chinnery, Patrick F.
   Taylor, Robert W.
   Turnbull, Douglass M.
   McFarland, Robert
TI Prevalence of Nuclear and Mitochondrial DNA Mutations Related to Adult
   Mitochondrial Disease
SO ANNALS OF NEUROLOGY
LA English
DT Article
ID DIABETES-MELLITUS; ENCEPHALOMYOPATHY; EPIDEMIOLOGY; POPULATION;
   DELETIONS; MYOPATHY; ENGLAND
AB ObjectiveThe prevalence of mitochondrial disease has proven difficult to establish, predominantly as a result of clinical and genetic heterogeneity. The phenotypic spectrum of mitochondrial disease has expanded significantly since the original reports that associated classic clinical syndromes with mitochondrial DNA (mtDNA) rearrangements and point mutations. The revolution in genetic technologies has allowed interrogation of the nuclear genome in a manner that has dramatically improved the diagnosis of mitochondrial disorders. We comprehensively assessed the prevalence of all forms of adult mitochondrial disease to include pathogenic mutations in both nuclear and mtDNA.
   MethodsAdults with suspected mitochondrial disease in the North East of England were referred to a single neurology center from 1990 to 2014. For the midyear period of 2011, we evaluated the minimum prevalence of symptomatic nuclear DNA mutations and symptomatic and asymptomatic mtDNA mutations causing mitochondrial diseases.
   ResultsThe minimum prevalence rate for mtDNA mutations was 1 in 5,000 (20 per 100,000), comparable with our previously published prevalence rates. In this population, nuclear mutations were responsible for clinically overt adult mitochondrial disease in 2.9 per 100,000 adults.
   InterpretationCombined, our data confirm that the total prevalence of adult mitochondrial disease, including pathogenic mutations of both the mitochondrial and nuclear genomes (approximate to 1 in 4,300), is among the commonest adult forms of inherited neurological disorders. These figures hold important implications for the evaluation of interventions, provision of evidence-based health policies, and planning of future services. Ann Neurol 2015 Ann Neurol 2015;77:753-759
C1 [Gorman, Grainne S.; Schaefer, Andrew M.; Ng, Yi; Gomez, Nicholas; Blakely, Emma L.; Alston, Charlotte L.; Feeney, Catherine; Horvath, Rita; Yu-Wai-Man, Patrick; Chinnery, Patrick F.; Taylor, Robert W.; Turnbull, Douglass M.; McFarland, Robert] Newcastle Univ, Wellcome Ctr Mitochondrial Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Gorman, Grainne S.; Schaefer, Andrew M.; Ng, Yi; Gomez, Nicholas; Blakely, Emma L.; Alston, Charlotte L.; Feeney, Catherine; Taylor, Robert W.; Turnbull, Douglass M.; McFarland, Robert] Newcastle Univ, Inst Neurosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Horvath, Rita; Yu-Wai-Man, Patrick; Chinnery, Patrick F.] Newcastle Univ, Inst Med Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
C3 Newcastle University - UK; Newcastle University - UK; Newcastle
   University - UK
RP Gorman, GS (corresponding author), Newcastle Univ, Sch Med, Wellcome Trust Ctr Mitochondrial Res, Inst Neurosci, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM grainne.gorman@ncl.ac.uk
RI Alston, Charlotte/ABG-9602-2020; Ng, Yi/AFF-1445-2022; Horvath,
   Rita/AAY-7042-2020
OI Schaefer, Andrew/0000-0001-9891-7332; Ng, Yi Shiau/0000-0002-7591-2034;
   Turnbull, Doug/0000-0002-8878-9901; Chinnery,
   Patrick/0000-0002-7065-6617; Alston, Charlotte/0000-0003-2095-5464;
   Horvath, Rita/0000-0002-9841-170X; McFarland,
   Robert/0000-0002-8833-2688; Feeney, Catherine/0000-0003-3189-3991;
   Gorman, Grainne/0000-0002-7585-3409
FU Wellcome Trust [096919Z/11/Z, 074454/Z/04/Z]; Medical Research Council
   [G0601943, G0800674]; UK National Institute for Health Research (NIHR)
   Biomedical Research Centre for Ageing and Age-Related Diseases; UK NHS
   Specialized Services and Newcastle upon Tyne Hospitals NHS Foundation
   Trust; EU; Fight for Sight (UK); UK NIHR as part of the Rare Diseases
   Translational Research Collaboration; MRC [G0502157, G0400074, G1002570,
   G0601943, G1100540, G0701386, G0800674, G0900652, MR/L016451/1] Funding
   Source: UKRI
FX This work was supported by the Wellcome Trust (096919Z/11/Z,
   074454/Z/04/Z, D.M.T., R.W.T.), the Medical Research Council (G0601943,
   G0800674, D.M.T., R.M., R.W.T.), the UK National Institute for Health
   Research (NIHR) Biomedical Research Centre for Ageing and Age-Related
   Diseases award to Newcastle upon Tyne Hospitals National Health Service
   (NHS) Foundation Trust (D.M.T., G.S.G., P.F.C.), and the UK NHS
   Specialized Services and Newcastle upon Tyne Hospitals NHS Foundation
   Trust supporting the "Rare Mitochondrial Disorders of Adults and
   Children" Diagnostic Service (http://www.newcastle-mitochondria.com/).
   P.F.C. is a Wellcome Trust Senior Fellow in Clinical Science
   (084980/Z/08/Z) and a UK NIHR Senior Investigator and receives
   additional support from EU FP7 TIRCON. P.Y.-W.-M. is a Medical Research
   Council Clinician Scientist. P.Y.-W.-M. also receives funding from Fight
   for Sight (UK) and the UK NIHR as part of the Rare Diseases
   Translational Research Collaboration. This work also received
   infrastructure support from the Newcastle NIHR Biomedical Research
   Centre, Newcastle and North Tyneside Comprehensive Local Research
   Network.
CR Altman D. G., 1990, Practical Statistics for Medical Research
   [Anonymous], 2011, AG ETHN MIN POP ENGL
   Blakely EL, 2013, HUM MUTAT, V34, P1260, DOI 10.1002/humu.22358
   Calvo SE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003310
   Chinnery PF, 2004, LANCET, V364, P592, DOI 10.1016/S0140-6736(04)16851-7
   Department of Health Human Fertilisation and Embryology Authority, INN GEN TREATM PREV
   DiMauro S, 2013, NAT REV NEUROL, V9, P429, DOI 10.1038/nrneurol.2013.126
   Gorman GS, 2015, JAMA NEUROL, V72, P106, DOI 10.1001/jamaneurol.2014.1753
   Grady JP, 2014, BRAIN, V137, P323, DOI 10.1093/brain/awt321
   HANNA MG, 1995, AM J HUM GENET, V56, P1026
   HAO HL, 1995, AM J HUM GENET, V56, P1017
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   Man PYW, 2003, AM J HUM GENET, V72, P333, DOI 10.1016/j.ajhg.2016.05.015
   McFarland R, 2010, LANCET NEUROL, V9, P829, DOI 10.1016/S1474-4422(10)70116-2
   Norwood FLM, 2009, BRAIN, V132, P3175, DOI 10.1093/brain/awp236
   Office for National Statistics (UK Government), 2011, 2011 CENS POP EST UK
   Office of National Statistics, 2011, ETHN NAT ID ENGL WAL
   Pfeffer G, 2014, BRAIN, V137, P1323, DOI 10.1093/brain/awu060
   Schaefer AM, 2008, ANN NEUROL, V63, P35, DOI 10.1002/ana.21217
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   Taylor RW, 2014, JAMA-J AM MED ASSOC, V312, P68, DOI 10.1001/jama.2014.7184
   Whittaker RG, 2009, NEUROLOGY, V72, P568, DOI 10.1212/01.wnl.0000342121.91336.4d
NR 22
TC 624
Z9 701
U1 2
U2 69
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0364-5134
EI 1531-8249
J9 ANN NEUROL
JI Ann. Neurol.
PD MAY
PY 2015
VL 77
IS 5
BP 753
EP 759
DI 10.1002/ana.24362
PG 7
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA CG4EF
UT WOS:000353235400005
PM 25652200
OA Green Published, hybrid
HC Y
HP N
DA 2024-11-01
ER

PT J
AU Boggan, RM
   Lim, A
   Taylor, RW
   McFarland, R
   Pickett, SJ
AF Boggan, Roisin M.
   Lim, Albert
   Taylor, Robert W.
   McFarland, Robert
   Pickett, Sarah J.
TI Resolving complexity in mitochondrial disease: Towards precision
   medicine
SO MOLECULAR GENETICS AND METABOLISM
LA English
DT Review
DE Mitochondrial disease; Complex disease; m.3243A > G; Heterogeneity;
   Precision medicine; MELAS
ID STROKE-LIKE EPISODES; TRANSFER RNALEU(UUR) GENE; GREATER-THAN G;
   LACTIC-ACIDOSIS; POINT MUTATION; DNA MUTATIONS; HEARING-LOSS;
   M.3243A-GREATER-THAN-G MUTATION; A3243G MUTATION; MTDNA MUTATION
AB Mitochondrial diseases, caused by mutations in either the nuclear or mitochondrial genomes (mtDNA), are the most common form of inherited neurometabolic disorders. They are remarkably heterogeneous, both in their clinical presentation and genetic etiology, presenting challenges for diagnosis, clinical management and elucidation of molecular mechanism. The multifaceted nature of these diseases, compounded by the unique characteristics of mitochondrial genetics, cement their space in the field of complex disease. In this review we examine the m.3243A > G variant, one of the most prevalent mitochondrial DNA mutations, using it as an exemplar to demonstrate the challenges presented by these complex disorders. Disease caused by m.3243A > G is one of the most phenotypically diverse of all mitochondrial diseases; we outline known causes of this heterogeneity including mtDNA heteroplasmy, mtDNA copy number and nuclear genetic factors. We consider the impact that this has in the clinic, discussing the personalized management of common manifestations attributed to this pathogenic mtDNA variant, including hearing impairment, diabetes mellitus, myopathy, cardiac disease, stroke-like episodes and gastrointestinal disturbances. Future research into this complex disorder must account for this heterogeneity, benefitting from the use of large patient cohorts to build upon current clinical expertise. Through multi-disciplinary collaboration, the complexities of this mitochondrial disease can be addressed with the variety of diagnostic, prognostic, and treatment approaches that are moulded to best fit the needs of each individual patient.
C1 [Boggan, Roisin M.; Lim, Albert; Taylor, Robert W.; McFarland, Robert; Pickett, Sarah J.] Newcastle Univ, Sch Med, Inst Neurosci, Wellcome Ctr Mitochondrial Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
C3 Newcastle University - UK
RP McFarland, R (corresponding author), Newcastle Univ, Sch Med, Inst Neurosci, Wellcome Ctr Mitochondrial Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM robert.mcfarland@ncl.ac.uk
OI Boggan, Roisin M./0000-0002-6592-3020; Pickett,
   Sarah/0000-0002-1242-2927
FU Wellcome Centre for Mitochondrial Research [203105/Z/16/Z]; Wellcome
   Career Re-entry Fellowship [204709/Z/16/Z]; UK NHS Highly Specialised
   Service for Rare Mitochondrial Disorders of Adults and Children
FX This work was supported by the Wellcome Centre for Mitochondrial
   Research (203105/Z/16/Z), a Wellcome Career Re-entry Fellowship
   (204709/Z/16/Z) to SJP and the UK NHS Highly Specialised Service for
   Rare Mitochondrial Disorders of Adults and Children.
CR Abate M, 2020, SEMIN CELL DEV BIOL, V98, P139, DOI 10.1016/j.semcdb.2019.05.022
   Ahmed ST, 2018, NEUROTHERAPEUTICS, V15, P943, DOI 10.1007/s13311-018-00674-4
   Alston CL, 2017, J PATHOL, V241, P236, DOI 10.1002/path.4809
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Apabhai S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022294
   Aurangzeb Sidra, 2014, Pract Neurol, V14, P432, DOI 10.1136/practneurol-2014-000853
   Bates MGD, 2013, INT J CARDIOL, V168, P3599, DOI 10.1016/j.ijcard.2013.05.062
   Bates MGD, 2013, EUR HEART J-CARD IMG, V14, P650, DOI 10.1093/ehjci/jes226
   Bentlage HACM, 1996, HUM MOL GENET, V5, P197, DOI 10.1093/hmg/5.2.197
   Betts J, 2008, NEUROLOGY, V70, P1290, DOI 10.1212/01.wnl.0000308940.38092.74
   Betts J, 2006, NEUROPATH APPL NEURO, V32, P359, DOI 10.1111/j.1365-2990.2006.00731.x
   Bindoff LA, 2012, EPILEPSIA, V53, P92, DOI 10.1111/j.1528-1167.2012.03618.x
   Boal RL, 2019, J CLIN ENDOCR METAB, V104, P2057, DOI 10.1210/jc.2018-00957
   Calvo SE, 2016, NUCLEIC ACIDS RES, V44, pD1251, DOI 10.1093/nar/gkv1003
   Canafoglia L, 2001, NEUROLOGY, V56, P1340, DOI 10.1212/WNL.56.10.1340
   Cao X, 2012, MOL MED REP, V6, P426, DOI 10.3892/mmr.2012.913
   Chin J, 2014, MITOCHONDRION, V17, P34, DOI 10.1016/j.mito.2014.05.005
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   Chinnery PF, 2000, BRAIN, V123, P82, DOI 10.1093/brain/123.1.82
   Chistiakov D. A, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/238463
   Chomyn A, 2000, J BIOL CHEM, V275, P19198, DOI 10.1074/jbc.M908734199
   Conley KE, 2007, CURR OPIN CLIN NUTR, V10, P688, DOI 10.1097/MCO.0b013e3282f0dbfb
   Craven L, 2017, ANNU REV GENOM HUM G, V18, P257, DOI 10.1146/annurev-genom-091416-035426
   Cree LM, 2008, NAT GENET, V40, P249, DOI 10.1038/ng.2007.63
   de Laat P, 2015, NETH J MED, V73, P30
   de Laat P, 2012, J INHERIT METAB DIS, V35, P1059, DOI 10.1007/s10545-012-9465-2
   Deschauer M, 2001, ARCH NEUROL-CHICAGO, V58, P1885, DOI 10.1001/archneur.58.11.1885
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   Doynova MD, 2016, MITOCHONDRION, V30, P187, DOI 10.1016/j.mito.2016.08.003
   Dubeau F, 2000, ANN NEUROL, V47, P179, DOI 10.1002/1531-8249(200002)47:2<179::AID-ANA7>3.0.CO;2-Z
   Dvorakova V, 2016, MOL GENET METAB, V118, P288, DOI 10.1016/j.ymgme.2016.06.003
   Egeberg M, 2006, PALGRAVE STUD EUR UN, P66
   El-Hattab AW, 2017, BBA-MOL BASIS DIS, V1863, P1539, DOI 10.1016/j.bbadis.2017.02.017
   El-Hattab AW, 2015, MOL GENET METAB, V116, P4, DOI 10.1016/j.ymgme.2015.06.004
   Elliott HR, 2008, AM J HUM GENET, V83, P254, DOI 10.1016/j.ajhg.2008.07.004
   Engelsen BA, 2008, BRAIN, V131, P818, DOI 10.1093/brain/awn007
   Fayssoil A, 2017, EUR J NEUROL, V24, P255, DOI 10.1111/ene.13176
   Flierl A., 1997, PATHOPHYSIOLOGY MELA
   Frederiksen AL, 2009, J CLIN ENDOCR METAB, V94, P2872, DOI 10.1210/jc.2009-0235
   Gagliardi D, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00038
   Gill T, 2013, J BIOL CHEM, V288, P26246, DOI 10.1074/jbc.M113.476895
   Giordano L, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.364
   Gorman GS, 2018, LANCET, V392, P1191, DOI 10.1016/S0140-6736(18)31868-3
   Gorman GS, 2016, NAT REV DIS PRIMERS, V2, P1, DOI 10.1038/nrdp.2016.80
   Gorman GS, 2015, ANN NEUROL, V77, P753, DOI 10.1002/ana.24362
   GOTO Y, 1990, J NEUROL SCI, V100, P63, DOI 10.1016/0022-510X(90)90014-E
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Grady JP, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708262
   Greaves LC, 2010, INVEST OPHTH VIS SCI, V51, P3340, DOI 10.1167/iovs.09-4659
   Guillausseau PJ, 2004, DIABETES METAB, V30, P181, DOI 10.1016/S1262-3636(07)70105-2
   HAMMANS SR, 1995, BRAIN, V118, P721, DOI 10.1093/brain/118.3.721
   Hattersley AT, 2017, DIABETOLOGIA, V60, P769, DOI 10.1007/s00125-017-4226-2
   HESS JF, 1991, NATURE, V351, P236, DOI 10.1038/351236a0
   HIRANO M, 1992, NEUROMUSCULAR DISORD, V2, P125, DOI 10.1016/0960-8966(92)90045-8
   Holmgren D, 2003, EUR HEART J, V24, P280, DOI 10.1016/S0195-668X(02)00387-1
   Horan MP, 2014, HUM GENET, V133, P435, DOI 10.1007/s00439-013-1402-4
   Horan MP, 2013, EUR J HUM GENET, V21, P1335, DOI 10.1038/ejhg.2013.75
   HUTCHISO.CA, 1974, NATURE, V251, P536, DOI 10.1038/251536a0
   Hwang J M, 1996, Korean J Ophthalmol, V10, P122
   Iizuka T, 2002, NEUROLOGY, V59, P816, DOI 10.1212/WNL.59.6.816
   Iwanicka-Pronicka K, 2015, MED SCI MONITOR, V21, P694, DOI 10.12659/MSM.890965
   Janssen GMC, 1999, J BIOL CHEM, V274, P29744, DOI 10.1074/jbc.274.42.29744
   KADOWAKI T, 1994, NEW ENGL J MED, V330, P962, DOI 10.1056/NEJM199404073301403
   Kaipparettu BA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061747
   Karaa A, 2019, MOL GENET METAB, V127, P122, DOI 10.1016/j.ymgme.2019.05.012
   Kärppä M, 2004, J NEUROL, V251, P556, DOI 10.1007/s00415-004-0363-x
   Kärppä M, 2005, BRAIN, V128, P1861, DOI 10.1093/brain/awh515
   Kastaniotis AJ, 2017, BBA-MOL CELL BIOL L, V1862, P39, DOI 10.1016/j.bbalip.2016.08.011
   Kaufmann P, 2011, NEUROLOGY, V77, P1965, DOI 10.1212/WNL.0b013e31823a0c7f
   Kaufmann P., 2011, NATURAL HIST MELAS A, P32062, DOI [10.1212/WNL.0b013e31823a0c7f, DOI 10.1212/WNL.0B013E31823A0C7F]
   Kaufmann P, 2009, ARCH NEUROL-CHICAGO, V66, P85, DOI 10.1001/archneurol.2008.526
   Kerrison JB, 2000, AM J OPHTHALMOL, V130, P803, DOI 10.1016/S0002-9394(00)00603-6
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   Kirkman MA, 2009, BRAIN, V132, P2317, DOI 10.1093/brain/awp158
   KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5
   Koene S, 2018, J INHERIT METAB DIS, V41, P1267, DOI 10.1007/s10545-018-0229-5
   Koga Y, 2000, ARCH DIS CHILD, V82, P407, DOI 10.1136/adc.82.5.407
   Kopinski PK, 2019, P NATL ACAD SCI USA, V116, P16028, DOI 10.1073/pnas.1906896116
   Kullar PJ, 2016, BRAIN, V139, pE33, DOI 10.1093/brain/aww051
   Laloi-Michelin M, 2009, J CLIN ENDOCR METAB, V94, P3025, DOI 10.1210/jc.2008-2680
   Larsson NG, 1995, ANNU REV GENET, V29, P151, DOI 10.1146/annurev.ge.29.120195.001055
   Lax NZ, 2016, NEUROPATH APPL NEURO, V42, P180, DOI 10.1111/nan.12238
   Liu CS, 2006, ACTA NEUROL SCAND, V113, P334, DOI 10.1111/j.1600-0404.2006.00586.x
   Liu H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067146
   Lodi R, 2004, BBA-BIOENERGETICS, V1657, P146, DOI 10.1016/j.bbabio.2004.05.003
   Luo SY, 2018, P NATL ACAD SCI USA, V115, P13039, DOI 10.1073/pnas.1810946115
   Lutz-Bonengel S, 2019, P NATL ACAD SCI USA, V116, P1821, DOI 10.1073/pnas.1820533116
   Maassen JA, 2004, DIABETES, V53, pS103, DOI 10.2337/diabetes.53.2007.S103
   Maeda K., 2016, CLIN PHENOTYPE SEGRE, V73, DOI [10.1001/jamaneurol.2016.0886, DOI 10.1001/JAMANEUROL.2016.0886]
   Majamaa-Voltti K, 2008, J NEUROL NEUROSUR PS, V79, DOI 10.1136/jnnp.2007.122648
   Majamaa-Voltti KAM, 2006, NEUROLOGY, V66, P1470, DOI 10.1212/01.wnl.0000216136.61640.79
   Majamaa-Voltti Kirsi, 2002, BMC Cardiovasc Disord, V2, P12
   Malfatti E, 2013, NEUROLOGY, V80, P100, DOI 10.1212/WNL.0b013e31827b1a2f
   Man PYW, 2002, J MED GENET, V39, P162, DOI 10.1136/jmg.39.3.162
   Mancuso M, 2017, NEUROMUSCULAR DISORD, V27, P1126, DOI 10.1016/j.nmd.2017.08.006
   Mancuso M, 2014, J NEUROL, V261, P504, DOI 10.1007/s00415-013-7225-3
   Manwaring N, 2007, MITOCHONDRION, V7, P230, DOI 10.1016/j.mito.2006.12.004
   MARON BJ, 1979, CIRCULATION, V60, P685, DOI 10.1161/01.CIR.60.3.685
   McBride HM, 2006, CURR BIOL, V16, pR551, DOI 10.1016/j.cub.2006.06.054
   McFarland R, 2010, LANCET NEUROL, V9, P829, DOI 10.1016/S1474-4422(10)70116-2
   Mehrazin M, 2009, AM J MED GENET A, V149A, P584, DOI 10.1002/ajmg.a.32703
   Moggio Maurizio, 2014, Acta Myol, V33, P86
   Montier LLC, 2009, J GENET GENOMICS, V36, P125, DOI 10.1016/S1673-8527(08)60099-5
   MORGANHUGHES JA, 1994, CURR OPIN NEUROL, V7, P457, DOI 10.1097/00019052-199410000-00014
   Nadol JB, 2001, INT J PEDIATR OTORHI, V61, P1, DOI 10.1016/S0165-5876(01)00546-8
   Nesbitt V, 2013, J NEUROL NEUROSUR PS, V84, P936, DOI 10.1136/jnnp-2012-303528
   Newkirk JE, 1997, DIABETIC MED, V14, P457, DOI 10.1002/(SICI)1096-9136(199706)14:6<457::AID-DIA372>3.3.CO;2-N
   Ng YS, 2016, ANN NEUROL, V80, P686, DOI 10.1002/ana.24736
   Nguyen T, 2019, INT J PEDIATR OTORHI, V120, P15, DOI 10.1016/j.ijporl.2019.02.002
   Okajima Y, 1998, HEART, V80, P292, DOI 10.1136/hrt.80.3.292
   OLIVO PD, 1983, NATURE, V306, P400, DOI 10.1038/306400a0
   Ott J, 2015, NAT REV GENET, V16, P275, DOI 10.1038/nrg3908
   Ozawa M, 1998, J NEUROL SCI, V159, P170, DOI 10.1016/S0022-510X(98)00152-X
   Pagliarini DJ, 2008, CELL, V134, P112, DOI 10.1016/j.cell.2008.06.016
   Phoenix C, 2006, NEUROMUSCULAR DISORD, V16, P814, DOI 10.1016/j.nmd.2006.08.006
   Picard M, 2016, MITOCHONDRION, V30, P105, DOI 10.1016/j.mito.2016.07.003
   Picard M, 2014, P NATL ACAD SCI USA, V111, pE4033, DOI 10.1073/pnas.1414028111
   Pickett SJ, 2019, NEW ENGL J MED, V380, P1971, DOI 10.1056/NEJMc1808565
   Pickett SJ, 2018, ANN CLIN TRANSL NEUR, V5, P333, DOI 10.1002/acn3.532
   PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289
   Pyle A, 2007, J MED GENET, V44, P69, DOI 10.1136/jmg.2006.043109
   Rahman S, 2001, AM J HUM GENET, V68, P238, DOI 10.1086/316930
   Rajasimha HK, 2008, AM J HUM GENET, V82, P333, DOI 10.1016/j.ajhg.2007.10.007
   ROBIN ED, 1988, J CELL PHYSIOL, V136, P507, DOI 10.1002/jcp.1041360316
   Rossignol R, 2003, BIOCHEM J, V370, P751, DOI 10.1042/BJ20021594
   Sadun AA, 2013, CLIN EXP OPHTHALMOL, V41, P702, DOI 10.1111/ceo.12086
   Sadun F, 2004, AM J OPHTHALMOL, V137, P271, DOI 10.1016/j.ajo.2003.08.010
   Sasarman F, 2008, HUM MOL GENET, V17, P3697, DOI 10.1093/hmg/ddn265
   Scarpelli M, 2017, APPL CLIN GENET, V10, P21, DOI 10.2147/TACG.S94267
   Schaefer AM, 2008, ANN NEUROL, V63, P35, DOI 10.1002/ana.21217
   Schaefer AM, 2013, MOL CELL ENDOCRINOL, V379, P2, DOI 10.1016/j.mce.2013.06.004
   Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755
   Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350
   SCIACCO M, 1994, HUM MOL GENET, V3, P13, DOI 10.1093/hmg/3.1.13
   Shaikh S, 2001, AM J OPHTHALMOL, V131, P143, DOI 10.1016/S0002-9394(00)00716-9
   Shirani J, 2000, J AM COLL CARDIOL, V35, P36, DOI 10.1016/S0735-1097(99)00492-1
   Stewart JD, 2010, HEPATOLOGY, V52, P1791, DOI 10.1002/hep.23891
   Sue CM, 1998, ANN NEUROL, V43, P350, DOI 10.1002/ana.410430313
   Sue CM, 1998, J NEUROL SCI, V161, P36, DOI 10.1016/S0022-510X(98)00179-8
   Suzuki J, 2018, INTERNAL MED, V57, P771, DOI 10.2169/internalmedicine.9632-17
   Suzuki J, 2017, INTERNAL MED, V56, P1089, DOI 10.2169/internalmedicine.56.7753
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Thompson K, 2020, J INHERIT METAB DIS, V43, P36, DOI 10.1002/jimd.12104
   Tsao K, 1999, BRIT J OPHTHALMOL, V83, P577, DOI 10.1136/bjo.83.5.577
   Tzoulis C, 2010, BRAIN, V133, P1428, DOI 10.1093/brain/awq067
   Uimonen S, 2001, HUM GENET, V108, P284, DOI 10.1007/s004390100475
   VANDENOUWELAND JMW, 1994, DIABETES, V43, P746, DOI 10.2337/diabetes.43.6.746
   Veitia RA, 2018, HUM MOL GENET, V27, P1565, DOI 10.1093/hmg/ddy063
   Viscomi C, 2017, J INHERIT METAB DIS, V40, P587, DOI 10.1007/s10545-017-0027-5
   Visscher PM, 2008, NAT REV GENET, V9, P255, DOI 10.1038/nrg2322
   Vrettou CS, 2013, INTENS CARE MED, V39, P1148, DOI 10.1007/s00134-013-2884-1
   Wahbi K, 2015, EUR HEART J, V36, P2886, DOI 10.1093/eurheartj/ehv307
   Wai T, 2008, NAT GENET, V40, P1484, DOI 10.1038/ng.258
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   Wallace DC, 2018, NAT GENET, V50, P1642, DOI 10.1038/s41588-018-0264-z
   Whittaker RG, 2007, DIABETOLOGIA, V50, P2085, DOI 10.1007/s00125-007-0779-9
   Willems PHGM, 2015, CELL METAB, V22, P207, DOI 10.1016/j.cmet.2015.06.006
   Wilson IJ, 2016, HUM MOL GENET, V25, P1031, DOI 10.1093/hmg/ddv626
   Xia CY, 2016, CHINESE MED J-PEKING, V129, P1945, DOI 10.4103/0366-6999.187845
   Yasukawa T, 2000, J BIOL CHEM, V275, P4251, DOI 10.1074/jbc.275.6.4251
   Zhang Z, 2018, J NEUROL SCI, V385, P151, DOI 10.1016/j.jns.2017.12.033
NR 161
TC 23
Z9 27
U1 0
U2 16
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1096-7192
EI 1096-7206
J9 MOL GENET METAB
JI Mol. Genet. Metab.
PD SEP-OCT
PY 2019
VL 128
IS 1-2
BP 19
EP 29
DI 10.1016/j.ymgme.2019.09.003
PG 11
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental
   Medicine
GA JU0SN
UT WOS:000501389600004
PM 31648942
OA hybrid, Green Published
DA 2024-11-01
ER

PT J
AU Thambisetty, M
   Newman, NJ
AF Thambisetty, M
   Newman, NJ
TI Diagnosis and management of MELAS
SO EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
LA English
DT Review
DE encephalopathy; gene therapy; heteroplasmy; MELAS; ragged red fibers;
   stroke
ID STROKE-LIKE EPISODES; MITOCHONDRIAL TRNA(LEU(UUR)) MUTATION;
   MAGNETIC-RESONANCE-SPECTROSCOPY; A3243G POINT MUTATION; KEARNS-SAYRE
   SYNDROME; RED FIBERS MERRF; LACTIC-ACIDOSIS; PRENATAL-DIAGNOSIS; OVERLAP
   SYNDROME; MTDNA MUTATION
AB Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) Is the most common maternally Inherited mitochondrial disease. An A-->G mutation in the transfer RNA(Leu(UUR)) gene at position 3243 of the mitochondrial DNA accounts for most MELAS cases. The transient nature of the stroke-like episodes is reflected In abnormalities on neuroimaging. The cardinal laboratory abnormalities Include elevated serum lactate during the acute episodes and respiratory enzyme defects in skeletal muscle. Muscle biopsy also helps confirm the diagnosis by Identifying abnormal proliferation of mitochondria. Although current treatment options for MELAS are largely supportive, several therapeutic approaches have been attempted with limited success. Genetic counseling is an Important component of patient management In MELAS. Newer reproductive technologies hold promise for reducing the recurrence of MELAS in subsequent generations. Advances in research Into gene therapy offer hope of treatment for the future.
C1 Emory Univ, Ctr Eye, Neuroopthalmol Unit, Atlanta, GA 30322 USA.
   Kings Coll London, Inst Psychiat, Sect Old Age Psychiat, London SE5 8AF, England.
   Kings Coll London, Inst Psychiat, Dept Neurol, London SE5 8AF, England.
C3 Emory University; University of London; King's College London;
   University of London; King's College London
RP Emory Univ, Ctr Eye, Neuroopthalmol Unit, 1365-B Clifton Rd NE, Atlanta, GA 30322 USA.
EM ophinjn@emory.edu
RI Newman, Nancy/AAB-2532-2021
FU NEI NIH HHS [P30-EYO] Funding Source: Medline
CR Abe K, 1999, J NEUROL SCI, V162, P65, DOI 10.1016/S0022-510X(98)00296-2
   ABE K, 1991, ACTA NEUROL SCAND, V83, P356, DOI 10.1111/j.1600-0404.1991.tb03962.x
   ARGOV Z, 1986, ANN NEUROL, V19, P598, DOI 10.1002/ana.410190615
   Balestri P, 2000, J CHILD NEUROL, V15, P755, DOI 10.1177/088307380001501108
   BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11
   Bataillard M, 2001, NEUROLOGY, V56, P405, DOI 10.1212/WNL.56.3.405
   BERENBERG RA, 1977, ANN NEUROL, V1, P37, DOI 10.1002/ana.410010104
   BERKOVIC SF, 1989, BRAIN, V112, P1231, DOI 10.1093/brain/112.5.1231
   Biousse V, 2001, SEMIN NEUROL, V21, P275, DOI 10.1055/s-2001-17945
   BRESOLIN N, 1990, J NEUROL SCI, V100, P70, DOI 10.1016/0022-510X(90)90015-F
   Briones P, 2001, Eur J Paediatr Neurol, V5, P127, DOI 10.1053/ejpn.2001.0483
   Calvani M., 1993, P173
   CAMPOS Y, 1995, PEDIATR NEUROL, V13, P69, DOI 10.1016/0887-8994(95)00082-Q
   Chen RS, 1997, EUR NEUROL, V37, P212, DOI 10.1159/000117445
   Chinnery PE, 1998, BRAIN, V121, P1889, DOI 10.1093/brain/121.10.1889
   CIAFALONI E, 1992, ANN NEUROL, V31, P391, DOI 10.1002/ana.410310408
   Corona P, 2001, ANN NEUROL, V49, P106, DOI 10.1002/1531-8249(200101)49:1<106::AID-ANA16>3.0.CO;2-T
   de Coo IFM, 1998, NEUROLOGY, V50, P293, DOI 10.1212/WNL.50.1.293
   DESTEFANO N, 1995, NEUROLOGY, V45, P1193, DOI 10.1212/WNL.45.6.1193
   DiMauro S, 1996, J INHERIT METAB DIS, V19, P489, DOI 10.1007/BF01799110
   DiMauro S, 2000, NEUROL SCI, V21, pS901
   FANG W, 1993, ARCH NEUROL-CHICAGO, V50, P977, DOI 10.1001/archneur.1993.00540090074013
   Filippi M, 2003, LANCET NEUROL, V2, P337, DOI 10.1016/S1474-4422(03)00408-3
   GODA S, 1987, J NEUROL, V234, P62, DOI 10.1007/BF00314013
   GOTO Y, 1990, J NEUROL SCI, V100, P63, DOI 10.1016/0022-510X(90)90014-E
   GOTO Y, 1991, BIOCHIM BIOPHYS ACTA, V1097, P238, DOI 10.1016/0925-4439(91)90042-8
   GOTO Y, 1992, NEUROLOGY, V42, P545, DOI 10.1212/WNL.42.3.545
   GOTO Y, 1995, MUSCLE NERVE, pS107
   GOTO YI, 1994, BIOCHEM BIOPH RES CO, V202, P1624, DOI 10.1006/bbrc.1994.2119
   Guy J, 2002, ANN NEUROL, V52, P534, DOI 10.1002/ana.10354
   Hancock DK, 2002, CLIN CHEM, V48, P2155
   HASEGAWA H, 1991, ANN NEUROL, V29, P601, DOI 10.1002/ana.410290606
   HIRANO M, 1994, J CHILD NEUROL, V9, P4, DOI 10.1177/088307389400900102
   HIRANO M, 1991, ANN NEUROL, V30, P299
   HOLT IJ, 1989, ANN NEUROL, V26, P699, DOI 10.1002/ana.410260603
   Iizuka T, 2003, NEUROLOGY, V61, P1238, DOI 10.1212/01.WNL.0000091888.26232.FE
   Iizuka T, 2002, NEUROLOGY, V59, P816, DOI 10.1212/WNL.59.6.816
   Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826
   JOHNS DR, 1995, NEW ENGL J MED, V333, P638, DOI 10.1056/NEJM199509073331007
   KADOWAKI T, 1994, NEW ENGL J MED, V330, P962, DOI 10.1056/NEJM199404073301403
   Kärppä M, 2003, J NEUROL, V250, P216, DOI 10.1007/s00415-003-0981-8
   KEARNS TP, 1958, ARCH OPHTHALMOL-CHIC, V60, P280, DOI 10.1001/archopht.1958.00940080296016
   Kuroda Y, 1997, J PEDIATR-US, V131, P450, DOI 10.1016/S0022-3476(97)80075-3
   Latkany P, 1999, AM J OPHTHALMOL, V128, P112, DOI 10.1016/S0002-9394(99)00057-4
   LERTRIT P, 1992, AM J HUM GENET, V51, P457
   Lescuyer P, 2003, PROTEOMICS, V3, P157, DOI 10.1002/pmic.200390024
   Löfberg M, 2001, NEUROMUSCULAR DISORD, V11, P370, DOI 10.1016/S0960-8966(00)00205-4
   Manfredi G, 2002, NAT GENET, V30, P394, DOI 10.1038/ng851
   MATSUOKA T, 1991, J NEUROL SCI, V106, P193, DOI 10.1016/0022-510X(91)90257-8
   MATTHEWS PM, 1991, NEUROLOGY, V41, P1043, DOI 10.1212/WNL.41.7.1043
   MATTHEWS PM, 1993, NEUROLOGY, V43, P2484, DOI 10.1212/WNL.43.12.2484
   Molnár MJ, 2000, NEUROLOGY, V55, P544, DOI 10.1212/WNL.55.4.544
   MORAES CT, 1992, AM J HUM GENET, V50, P934
   MORTEN KJ, 1993, HUM MOL GENET, V2, P2081, DOI 10.1093/hmg/2.12.2081
   Nakada K, 2001, SEMIN CELL DEV BIOL, V12, P459, DOI 10.1006/scdb.2001.0283
   NAKAMURA M, 1995, BIOCHEM BIOPH RES CO, V214, P86, DOI 10.1006/bbrc.1995.2260
   OHAMA E, 1987, ACTA NEUROPATHOL, V74, P226, DOI 10.1007/BF00688185
   Ohkoshi N, 1998, J MED, V29, P13
   Okajima Y, 1998, HEART, V80, P292, DOI 10.1136/hrt.80.3.292
   Oppenheim C, 2000, J NEUROL NEUROSUR PS, V69, P248, DOI 10.1136/jnnp.69.2.248
   Pavlakis SG, 1998, ARCH NEUROL-CHICAGO, V55, P849, DOI 10.1001/archneur.55.6.849
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   Poulton J, 2000, NEUROMUSCULAR DISORD, V10, P484, DOI 10.1016/S0960-8966(00)00130-9
   Pulkes T, 1999, ANN NEUROL, V46, P916, DOI 10.1002/1531-8249(199912)46:6<916::AID-ANA16>3.0.CO;2-R
   Ravn K, 2001, EUR J HUM GENET, V9, P805, DOI 10.1038/sj.ejhg.5200712
   Ruitenbeek W, 1996, J INHERIT METAB DIS, V19, P581, DOI 10.1007/BF01799118
   SAIJO T, 1991, NEUROPEDIATRICS, V22, P166, DOI 10.1055/s-2008-1071436
   Saitoh S, 1998, NEUROLOGY, V50, P531, DOI 10.1212/WNL.50.2.531
   Santorelli FM, 1997, BIOCHEM BIOPH RES CO, V238, P326, DOI 10.1006/bbrc.1997.7167
   SATO W, 1994, BIOCHEM MOL BIOL INT, V33, P1055
   Schaefer PW, 2001, J NEUROIMAGING, V11, P369, DOI 10.1111/j.1552-6569.2001.tb00065.x
   Schlaug G, 1997, NEUROLOGY, V49, P113, DOI 10.1212/WNL.49.1.113
   SCHOFFNER JM, 1997, CURRENT THERAPY NEUR, P332
   Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755
   Shanske Sara, 1997, Current Opinion in Rheumatology, V9, P496, DOI 10.1097/00002281-199711000-00004
   Sinnathuray AR, 2003, OTOL NEUROTOL, V24, P418, DOI 10.1097/00129492-200305000-00012
   STACPOOLE PW, 1988, ANN INTERN MED, V108, P58, DOI 10.7326/0003-4819-108-1-58
   STACPOOLE PW, 1992, DIABETES CARE, V15, P785, DOI 10.2337/diacare.15.6.785
   Sue CM, 1998, ANN NEUROL, V43, P350, DOI 10.1002/ana.410430313
   Sue CM, 1998, J NEUROL NEUROSUR PS, V65, P233, DOI 10.1136/jnnp.65.2.233
   Sue CM, 1998, J NEUROL SCI, V161, P36, DOI 10.1016/S0022-510X(98)00179-8
   Taivassalo T, 1999, HUM MOL GENET, V8, P1047, DOI 10.1093/hmg/8.6.1047
   Taivassalo T, 1998, NEUROLOGY, V50, P1055, DOI 10.1212/WNL.50.4.1055
   Tanahashi C, 2000, ACTA NEUROPATHOL, V99, P31, DOI 10.1007/PL00007403
   Tarnopolsky MA, 1997, MUSCLE NERVE, V20, P1502, DOI 10.1002/(SICI)1097-4598(199712)20:12<1502::AID-MUS4>3.0.CO;2-C
   Taylor RW, 2000, NEUROL SCI, V21, pS909, DOI 10.1007/s100720070002
   Taylor RW, 1997, NAT GENET, V15, P212, DOI 10.1038/ng0297-212
   Taylor RW, 1996, ANN NEUROL, V40, P459, DOI 10.1002/ana.410400318
   Thambisetty M, 2002, NEUROLOGIST, V8, P302, DOI 10.1097/00127893-200209000-00003
   Thorburn DR, 2001, AM J MED GENET, V106, P102, DOI 10.1002/ajmg.1380
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523
   Wilichowski E, 1999, NEUROPEDIATRICS, V30, P256, DOI 10.1055/s-2007-973500
   YAMAMOTO T, 1984, NEUROLOGY, V34, P1456, DOI 10.1212/WNL.34.11.1456
   YANG CY, 1995, CLIN ENDOCRINOL, V43, P235, DOI 10.1111/j.1365-2265.1995.tb01922.x
   Yoneda M, 1999, NEUROLOGY, V53, P2182, DOI 10.1212/WNL.53.9.2182
   Yorifuji T, 1996, J MED GENET, V33, P621, DOI 10.1136/jmg.33.7.621
   Zeviani M, 1998, NEUROLOGY, V51, P1525, DOI 10.1212/WNL.51.6.1525-a
   Zeviani Massimo, 1993, European Journal of Human Genetics, V1, P80
   ZUPANC ML, 1991, ANN NEUROL, V29, P680, DOI 10.1002/ana.410290619
NR 100
TC 36
Z9 45
U1 0
U2 8
PU TAYLOR & FRANCIS AS
PI OSLO
PA KARL JOHANS GATE 5, NO-0154 OSLO, NORWAY
SN 1473-7159
EI 1744-8352
J9 EXPERT REV MOL DIAGN
JI Expert Rev. Mol. Diagn.
PD SEP
PY 2004
VL 4
IS 5
BP 631
EP 644
DI 10.1586/14737159.4.5.631
PG 14
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 853KD
UT WOS:000223825500008
PM 15347257
DA 2024-11-01
ER

PT J
AU Qi, XL
   Tan, L
   Zhang, X
   Jin, JC
   Kong, WN
   Chen, W
   Wang, JY
   Dong, W
   Gao, LJ
   Luo, LJ
   Lu, D
   Gong, JA
   Guan, FF
   Shu, WJ
   Huang, XX
   Zhang, LF
   Wang, SQ
   Shen, B
   Ma, YW
AF Qi, Xiaolong
   Tan, Lei
   Zhang, Xu
   Jin, Jiachuan
   Kong, Weining
   Chen, Wei
   Wang, Jianying
   Dong, Wei
   Gao, Lijuan
   Luo, Lijun
   Lu, Dan
   Gong, Jianan
   Guan, Feifei
   Shu, Wenjie
   Huang, Xingxu
   Zhang, Lianfeng
   Wang, Shengqi
   Shen, Bin
   Ma, Yuanwu
TI Expanding DdCBE-mediated targeting scope to aC motif preference in rat
SO MOLECULAR THERAPY-NUCLEIC ACIDS
LA English
DT Article
ID MITOCHONDRIAL TRANSFER-RNAS; SPORADIC PATIENT; MUTATION; MYOPATHY;
   DISEASE
AB An animal model harboring pathogenic mitochondrial DNA (mtDNA) mutations is important to understand the biological links between mtDNA variation and mitochondrial diseases. DdCBE, a DddA-derived cytosine base editor, has been utilized in zebrafish, mice, and rats for tC sequence-context targeting and human mitochondrial disease modeling. However, human pathogenic mtDNA mutations other than the tC context cannot be manipulated. Here, we screened the combination of different DdCBE pairs at pathogenic mtDNA mutation sites with nC (n for a, g, or c) context and identified that the left-G1333C (L1333C) + right G1333N (R1333N) pair could mediate C & BULL;G-to-T & BULL;A conversion effectively at aC sites in rat C6 cells. The editing efficiency at disease-associated mtDNA mutation sites within aC context was further confirmed to be up to 67.89% in vivo. Also, the installed disease-associated mtDNA mutations were germline transmittable. Moreover, the edited rats showed impaired cardiac function and mito-chondrial function, resembling human mitochondrial disease symptoms. In summary, for the first time, we expanded the DdCBE targeting scope to an aC motif and installed the path-ogenic mutation in rats to model human mitochondrial dis-eases.
C1 [Qi, Xiaolong; Tan, Lei; Zhang, Xu; Jin, Jiachuan; Kong, Weining; Chen, Wei; Dong, Wei; Gao, Lijuan; Luo, Lijun; Lu, Dan; Gong, Jianan; Guan, Feifei; Zhang, Lianfeng; Ma, Yuanwu] Chinese Acad Med Sci, Inst Lab Anim Sci, Beijing Engn Res Ctr Expt Anim Models Human Crit D, Peking Union Med Coll,Natl Hlth Commiss China NHC,, Beijing 100021, Peoples R China.
   [Tan, Lei; Wang, Jianying; Shen, Bin] Nanjing Med Univ, Womens Hosp, Nanjing Matern & Child Hlth Care Hosp, State Key Lab Reprod Med, Nanjing 211100, Jiangsu, Peoples R China.
   [Jin, Jiachuan] Zhengzhou Univ, Affiliated Hosp 3, Ctr Reprod Med, Zhengzhou 450052, Peoples R China.
   [Shu, Wenjie; Wang, Shengqi] Bioinformat Ctr AMMS, Beijing 100850, Peoples R China.
   [Huang, Xingxu; Shen, Bin] Zhejiang Lab, Hangzhou 311121, Zhejiang, Peoples R China.
   [Zhang, Lianfeng; Ma, Yuanwu] Chinese Acad Med Sci, Neurosci Ctr, Beijing 100730, Peoples R China.
   [Shen, Bin] Nanjing Med Univ, Gusu Sch, Nanjing 215031, Jiangsu, Peoples R China.
   [Shen, Bin] Nanjing Med Univ, Ctr Global Hlth, Sch Publ Hlth, Nanjing 211100, Jiangsu, Peoples R China.
   [Ma, Yuanwu] Chinese Acad Med Sci, Inst Lab Anim Sci, Peking Union Med Coll, Natl Human Dis Anim Model Resource Ctr, Beijing 100021, Peoples R China.
C3 Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College; Nanjing Medical University; Zhengzhou
   University; Zhejiang Laboratory; Chinese Academy of Medical Sciences -
   Peking Union Medical College; Nanjing Medical University; Nanjing
   Medical University; Chinese Academy of Medical Sciences - Peking Union
   Medical College; Peking Union Medical College
RP Ma, YW (corresponding author), Chinese Acad Med Sci, Inst Lab Anim Sci, Beijing Engn Res Ctr Expt Anim Models Human Crit D, Peking Union Med Coll,Natl Hlth Commiss China NHC,, Beijing 100021, Peoples R China.; Shen, B (corresponding author), Nanjing Med Univ, Womens Hosp, Nanjing Matern & Child Hlth Care Hosp, State Key Lab Reprod Med, Nanjing 211100, Jiangsu, Peoples R China.; Wang, SQ (corresponding author), Bioinformat Ctr AMMS, Beijing 100850, Peoples R China.
EM sqwang@bmi.ac.cn; binshen@njmu.edu.cn; mayuanwu@cnilas.org
RI Qi, Xiaolong/HTL-9509-2023; Wang, Hongyang/B-1340-2010; Shen,
   Bin/ABD-5084-2021; jiachuan, jin/JJD-3610-2023; dong, wei/KVA-6898-2024
OI Ma, Yuanwu/0000-0002-1882-1777; LU, Dan/0000-0002-5204-2574; Shu,
   Wenjie/0000-0001-9044-2352
FU National Key Research and Development Program of China [2021YFC2700600];
   Funds for Creative Research Groups of China [82221005]; National Natural
   Science Foundation of China [31970796]; CAMS Innovation Fund for Medical
   Sciences of China (CIFMS) [2021-I2M-1-024, 2021-I2M-1- 034,
   2021-1-I2M-018]; Beijing Municipal Natural Science Foundation [M21004];
   Beijing Nova Program [Z211100002121034]; Leading Talents of Guangdong
   province program [2016LJ06S386]; 111 Project of Ministry of Education
   [B20095]
FX This work was supported by the National Key Research and Development
   Program of China (2021YFC2700600) , the Funds for Creative Research
   Groups of China (82221005) , the National Natural Science Foundation of
   China (31970796) , the CAMS Innovation Fund for Medical Sciences of
   China (CIFMS, 2021-I2M-1-024, 2021-I2M-1- 034, and 2021-1-I2M-018) , the
   Beijing Municipal Natural Science Foundation (Grant No. M21004) , the
   Beijing Nova Program (Z211100002121034) , the Leading Talents of
   Guangdong province program (2016LJ06S386) , and the 111 Project of
   Ministry of Education (B20095) .
CR Campbell T, 2022, CELLS-BASEL, V11, DOI 10.3390/cells11182835
   Chomyn A, 2000, J BIOL CHEM, V275, P19198, DOI 10.1074/jbc.M908734199
   Darin N, 2006, NEUROMUSCULAR DISORD, V16, P504, DOI 10.1016/j.nmd.2006.05.010
   Ding Y, 2020, EUR REV MED PHARMACO, V24, P8502, DOI 10.26355/eurrev_202008_22647
   Florentz C, 2003, CELL MOL LIFE SCI, V60, P1356, DOI 10.1007/s00018-003-2343-1
   Guo JY, 2022, MOL THER-NUCL ACIDS, V27, P73, DOI 10.1016/j.omtn.2021.11.016
   Guo JY, 2021, CELL DISCOV, V7, DOI 10.1038/s41421-021-00307-9
   Hahn A, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8090392
   Hanna MG, 1998, J NEUROL NEUROSUR PS, V65, P512, DOI 10.1136/jnnp.65.4.512
   Karadimas CL, 2002, NEUROMUSCULAR DISORD, V12, P865, DOI 10.1016/S0960-8966(02)00072-X
   Ling JQ, 2007, P NATL ACAD SCI USA, V104, P15299, DOI 10.1073/pnas.0704441104
   Ling YH, 2022, LIFE SCI, V297, DOI 10.1016/j.lfs.2022.120485
   Liu YQ, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.634137
   Ma YW, 2014, CELL RES, V24, P122, DOI 10.1038/cr.2013.157
   Mansour HA, 2022, OSLI RETINA, V53, P116, DOI 10.3928/23258160-20220121-04
   Meng FL, 2022, NUCLEIC ACIDS RES, V50, P9453, DOI 10.1093/nar/gkac720
   Mok BY, 2022, NAT BIOTECHNOL, V40, P1378, DOI 10.1038/s41587-022-01256-8
   Murphy E, 2016, CIRC RES, V118, P1960, DOI 10.1161/RES.0000000000000104
   Bayona-Bafaluy MP, 2020, MUTAT RES-REV MUTAT, V786, DOI 10.1016/j.mrrev.2020.108334
   Qi XL, 2021, CELL DISCOV, V7, DOI 10.1038/s41421-021-00325-7
   Ramos ES, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008085
   Richter U, 2021, FEBS LETT, V595, P1003, DOI 10.1002/1873-3468.14049
   Ronchi D, 2010, J NEUROL SCI, V292, P107, DOI 10.1016/j.jns.2010.01.026
   Sacconi S, 2002, ARCH NEUROL-CHICAGO, V59, P1013, DOI 10.1001/archneur.59.6.1013
   Sazonova MA, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/825468
   Sobenin IA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068070
   Stewart JB, 2021, J INHERIT METAB DIS, V44, P325, DOI 10.1002/jimd.12324
   Suzuki T, 2011, ANNU REV GENET, V45, P299, DOI 10.1146/annurev-genet-110410-132531
   Wei YH, 2022, CELL DISCOV, V8, DOI 10.1038/s41421-022-00391-5
   Yasukawa T, 2001, EMBO J, V20, P4794, DOI 10.1093/emboj/20.17.4794
NR 30
TC 5
Z9 5
U1 6
U2 15
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2162-2531
J9 MOL THER-NUCL ACIDS
JI Mol. Ther.-Nucl. Acids
PD JUN 13
PY 2023
VL 32
BP 1
EP 12
DI 10.1016/j.omtn.2023.02.028
EA MAR 2023
PG 12
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA P4CE7
UT WOS:001050134000001
PM 36942261
OA Green Published, gold
DA 2024-11-01
ER

PT J
AU Meulemans, A
   De Paepe, B
   De Bleecker, J
   Smet, J
   Lissens, W
   Van Coster, R
   De Meirleir, L
   Seneca, S
AF Meulemans, Ann
   De Paepe, Boel
   De Bleecker, Jan
   Smet, Joel
   Lissens, Willy
   Van Coster, Rudy
   De Meirleir, Linda
   Seneca, Sara
TI Two novel mitochondrial DNA mutations in muscle tissue of a patient with
   limb-girdle myopathy
SO ARCHIVES OF NEUROLOGY
LA English
DT Article
ID TRNA(TYR) GENE; COMPLEX-I; SEQUENCE; DELETION
AB Background: Defects in the oxidative phosphorylation system can cause a broad spectrum of clinical symptoms ranging from an isolated myopathy to a multisystemic disorder.
   Objective: To study and identify the underlying molecular defect in a patient with limb-girdle myopathy.
   Design: Biochemical, histochemical, and immunocytochemical analyses were performed in combination with polymerase chain reaction-single-strand conformation polymorphism and restriction fragment length polymorphism-polymerase chain reaction techniques.
   Setting: University hospital.
   Patient: A48-year-old woman with limb-girdle myopathy.
   Main Outcome Measures: The pathogenic characteristics of the identified nucleotide alterations were defined using single-muscle fiber analysis.
   Results: A complex III deficiency was detected using blue native-polyacrylamide gel electrophoresis, while immunocytochemical results showed a mosaic staining pattern for complexes I and IV. After molecular analyses, 2 novel heteroplasmic mitochondrial DNA ( mtDNA) nucleotide aberrations, m. 5888insA and m. 14639A > G, were identified in muscle tissue. Single-muscle fiber analyses demonstrated that cytochrome c oxidase-deficient fibers, compared with cytochrome c oxidase-positive fibers, harbored statistically significantly higher levels of both mtDNA mutations ( P < .001, t test).
   Conclusions: These results, together with previously defined canonical criteria determining the pathogenic characteristics of mtDNA mutations, suggest that both nucleotide changes are pathogenic mutations. To our knowledge, this is only the third report of the coexistence of 2 pathogenic mtDNA mutations present in different genes within individual skeletal muscle fibers of a patient.
C1 Vrije Univ Brussels, Ctr Med Genet, B-1090 Brussels, Belgium.
   Vrije Univ Brussels, Univ Ziekenhous Brussel, Dept Pediat Neurol, B-1090 Brussels, Belgium.
   State Univ Ghent Hosp, Dept Neurol, B-9000 Ghent, Belgium.
   State Univ Ghent Hosp, Dept Pediat Neurol, B-9000 Ghent, Belgium.
   State Univ Ghent Hosp, Metab Serv, B-9000 Ghent, Belgium.
C3 Vrije Universiteit Brussel; University Hospital Brussels; Vrije
   Universiteit Brussel; Ghent University; Ghent University Hospital; Ghent
   University; Ghent University Hospital; Ghent University; Ghent
   University Hospital
RP Seneca, S (corresponding author), Vrije Univ Brussels, Ctr Med Genet, Laarbeeklaan 101, B-1090 Brussels, Belgium.
EM lgensas@az.vub.ac.be
RI Smet, Joél/B-7428-2013; De Meirleir, Linda/D-6591-2016; De Paepe,
   Boel/B-7548-2013; De Bleecker, Jan/B-7785-2013; Lissens,
   Willy/B-2892-2013
OI De Bleecker, Jan/0000-0002-1328-1812; Seneca, Sara/0000-0002-0853-9890;
   Meulemans, Ann/0000-0003-3938-2408; Lissens, Willy/0000-0003-3875-9955
CR Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Cao ZJ, 2001, NUCLEIC ACIDS RES, V29, P4502, DOI 10.1093/nar/29.21.4502
   Carrozzo R, 2006, ANN NEUROL, V59, P265, DOI 10.1002/ana.20729
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   El Meziane A, 1998, NAT GENET, V18, P350
   HOLLAND VR, 1974, TETRAHEDRON, V30, P3299, DOI 10.1016/S0040-4020(01)97504-0
   Janssen RJRJ, 2006, J INHERIT METAB DIS, V29, P499, DOI 10.1007/s10545-006-0362-4
   McFarland R, 2004, TRENDS GENET, V20, P591, DOI 10.1016/j.tig.2004.09.014
   Meulemans A, 2007, EUR J PAEDIATR NEURO, V11, P17, DOI 10.1016/j.ejpn.2006.10.004
   Mitchell AL, 2006, J MED GENET, V43, P175, DOI 10.1136/jmg.2005.032474
   *MITOMAP, 2006, HUM MIT GEN DAT
   Moraes C T, 1996, Methods Enzymol, V264, P522, DOI 10.1016/S0076-6879(96)64046-4
   Ohno K, 1996, ANN NEUROL, V40, P480
   Ohno K, 1996, ANN NEUROL, V39, P761, DOI 10.1002/ana.410390612
   Pulkes T, 2000, NEUROLOGY, V55, P1210, DOI 10.1212/WNL.55.8.1210
   Raffelsberger T, 2001, NEUROLOGY, V57, P2298, DOI 10.1212/WNL.57.12.2298
   Van Coster R, 2001, PEDIATR RES, V50, P658, DOI 10.1203/00006450-200111000-00020
NR 17
TC 11
Z9 12
U1 0
U2 5
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0003-9942
EI 1538-3687
J9 ARCH NEUROL-CHICAGO
JI Arch. Neurol.
PD SEP
PY 2007
VL 64
IS 9
BP 1339
EP 1343
DI 10.1001/archneur.64.9.1339
PG 5
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 208TP
UT WOS:000249342400018
PM 17846276
DA 2024-11-01
ER

PT J
AU Liu, YQ
   Zhao, S
   Chen, XL
   Bian, YH
   Cao, YZ
   Xu, PW
   Zhang, CM
   Zhang, JT
   Zhao, SG
   Zhao, H
AF Liu, Yuqing
   Zhao, Shuai
   Chen, Xiaolei
   Bian, Yuehong
   Cao, Yongzhi
   Xu, Peiwen
   Zhang, Changming
   Zhang, Jiangtao
   Zhao, Shigang
   Zhao, Han
TI Variations in mitochondrial DNA coding and d-loop region are associated
   with early embryonic development defects in infertile women
SO HUMAN GENETICS
LA English
DT Article
ID LACTIC-ACIDOSIS; MUTATION; MTDNA; ENCEPHALOPATHY; AMINOACYLATION;
   COMPETENCE; VARIANTS; MYOPATHY; DEAFNESS; OOCYTES
AB Mitochondrial DNA (mtDNA) plays a critical role in oocyte maturation, fertilization, and early embryonic development. Defects in mtDNA may determine the alteration of the mitochondrial function, affecting cellular oxidative phosphorylation and ATP supply, leading to impaired oocyte maturation, abnormal fertilization, and low embryonic developmental potential, ultimately leading to female infertility. This case-control study was established to investigate the correlation between mtDNA variations and early embryonic development defects. Peripheral blood was collected for next-generation sequencing from women who suffered the repeated failures of in vitro fertilization (IVF) and/or intracytoplasmic sperm injection (ICSI) cycles due to early embryonic development defects as well as in-house healthy controls, and the sequencing results were statistically analyzed for all subjects. This study found that infertile women with early embryonic development defects carried more mtDNA variants, especially in the d-loop region, ATP6 gene, and CYTB gene. By univariate logistic regression analysis, 16 mtDNA variants were associated with an increased risk of early embryonic development defects (OR > 1, p < 0.05). Furthermore, we identified 16 potentially pathogenic mtDNA variants only in infertile cases. The data proved that mtDNA variations were associated with early embryonic development defects in infertile Chinese women.
C1 [Liu, Yuqing; Zhao, Shuai; Chen, Xiaolei; Bian, Yuehong; Cao, Yongzhi; Xu, Peiwen; Zhang, Changming; Zhang, Jiangtao; Zhao, Shigang; Zhao, Han] Shandong Univ, Ctr Reprod Med, 157 Jingliu Rd, Jinan 250021, Shandong, Peoples R China.
   [Liu, Yuqing; Zhao, Shuai; Chen, Xiaolei; Bian, Yuehong; Cao, Yongzhi; Xu, Peiwen; Zhang, Changming; Zhang, Jiangtao; Zhao, Shigang; Zhao, Han] Shandong Univ, Key Lab Reprod Endocrinol, Minist Educ, Jinan 250012, Shandong, Peoples R China.
   [Liu, Yuqing; Zhao, Shuai; Chen, Xiaolei; Bian, Yuehong; Cao, Yongzhi; Xu, Peiwen; Zhang, Changming; Zhang, Jiangtao; Zhao, Shigang; Zhao, Han] Shandong Key Lab Reprod Med, Jinan 250012, Shandong, Peoples R China.
   [Liu, Yuqing; Zhao, Shuai; Chen, Xiaolei; Bian, Yuehong; Cao, Yongzhi; Xu, Peiwen; Zhang, Changming; Zhang, Jiangtao; Zhao, Shigang; Zhao, Han] Shandong Prov Clin Res Ctr Reprod Hlth, Jinan 250012, Shandong, Peoples R China.
   [Liu, Yuqing; Zhao, Shuai; Chen, Xiaolei; Bian, Yuehong; Cao, Yongzhi; Xu, Peiwen; Zhang, Changming; Zhang, Jiangtao; Zhao, Shigang; Zhao, Han] Shandong Technol Innovat Ctr Reprod Hlth, Jinan 250012, Shandong, Peoples R China.
   [Liu, Yuqing; Zhao, Shuai; Chen, Xiaolei; Bian, Yuehong; Cao, Yongzhi; Xu, Peiwen; Zhang, Changming; Zhang, Jiangtao; Zhao, Shigang; Zhao, Han] Shandong Univ, Natl Res Ctr Assisted Reprod Technol & Reprod Gen, Jinan 250012, Shandong, Peoples R China.
C3 Shandong University; Shandong University; Shandong University
RP Zhao, H (corresponding author), Shandong Univ, Ctr Reprod Med, 157 Jingliu Rd, Jinan 250021, Shandong, Peoples R China.; Zhao, H (corresponding author), Shandong Univ, Key Lab Reprod Endocrinol, Minist Educ, Jinan 250012, Shandong, Peoples R China.; Zhao, H (corresponding author), Shandong Key Lab Reprod Med, Jinan 250012, Shandong, Peoples R China.; Zhao, H (corresponding author), Shandong Prov Clin Res Ctr Reprod Hlth, Jinan 250012, Shandong, Peoples R China.; Zhao, H (corresponding author), Shandong Technol Innovat Ctr Reprod Hlth, Jinan 250012, Shandong, Peoples R China.; Zhao, H (corresponding author), Shandong Univ, Natl Res Ctr Assisted Reprod Technol & Reprod Gen, Jinan 250012, Shandong, Peoples R China.
EM hanzh80@sdu.edu.cn
RI Zhao, Shigang/ADG-6247-2022; Zhang, Chaoyang/JPK-5044-2023; Liu,
   LiuYuqing/GWZ-5665-2022; zhao, han/JFS-9633-2023
OI Zhao, Han/0000-0001-9515-7534
FU National Key Research and Development Program of China [2021YFC2700400,
   2018YFC1004303]; Basic Science Center Program of NSFC [31988101];
   National Natural Science Foundation of China [82192874, 31871509,
   82071606]; Shandong Provincial Key Research and Development Program
   [2020ZLYS02]; Research Unit of Gametogenesis and Health of
   ART-Offspring, Chinese Academy of Medical Sciences [2020RU001]; Taishan
   Scholars Program of Shandong Province [ts20190988]; Fundamental Research
   Funds of Shandong University
FX This study was supported by the National Key Research and Development
   Program of China (2021YFC2700400, 2018YFC1004303), the Basic Science
   Center Program of NSFC (31988101), the National Natural Science
   Foundation of China (82192874, 31871509, 82071606), Shandong Provincial
   Key Research and Development Program (2020ZLYS02), Research Unit of
   Gametogenesis and Health of ART-Offspring, Chinese Academy of Medical
   Sciences (2020RU001), the Taishan Scholars Program of Shandong Province
   (ts20190988) and the Fundamental Research Funds of Shandong University.
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Au HK, 2005, ANN NY ACAD SCI, V1042, P177, DOI 10.1196/annals.1338.020
   Brown DT, 2001, AM J HUM GENET, V68, P533, DOI 10.1086/318190
   Chomyn A, 2000, J BIOL CHEM, V275, P19198, DOI 10.1074/jbc.M908734199
   Clayton D A, 2000, Hum Reprod, V15 Suppl 2, P11
   Demain LAM, 2017, CLIN GENET, V91, P199, DOI 10.1111/cge.12896
   Dumollard R, 2007, CURR TOP DEV BIOL, V77, P21, DOI 10.1016/S0070-2153(06)77002-8
   Duranthon V, 2001, THERIOGENOLOGY, V55, P1277, DOI 10.1016/S0093-691X(01)00482-4
   Fan L, 2011, MITOCHONDRION, V11, P351, DOI 10.1016/j.mito.2010.09.013
   Fernández-Silva P, 2003, EXP PHYSIOL, V88, P41, DOI 10.1113/eph8802514
   Gorman GS, 2015, ANN NEUROL, V77, P753, DOI 10.1002/ana.24362
   Jancic J, 2020, MITOCHONDRION, V50, P132, DOI 10.1016/j.mito.2019.10.011
   Ji LC, 2020, J ASSIST REPROD GEN, V37, P2181, DOI 10.1007/s10815-020-01893-5
   Ji YC, 2016, INVEST OPHTH VIS SCI, V57, P2377, DOI 10.1167/iovs.16-19243
   KANEDA H, 1995, P NATL ACAD SCI USA, V92, P4542, DOI 10.1073/pnas.92.10.4542
   Keefe D, 2015, FERTIL STERIL, V103, P317, DOI 10.1016/j.fertnstert.2014.12.115
   Lee LN, 2019, J CLIN MED, V8, DOI 10.3390/jcm8081207
   Li XY, 2020, J ASSIST REPROD GEN, V37, P2171, DOI 10.1007/s10815-020-01853-z
   López-Gallardo E, 2014, HUM MOL GENET, V23, P6191, DOI 10.1093/hmg/ddu339
   Lu JX, 2010, MITOCHONDRION, V10, P380, DOI 10.1016/j.mito.2010.01.007
   Maybury BD, 2013, ANTICANCER RES, V33, P3543
   Poincenot L, 2020, OPHTHALMOLOGY, V127, P679, DOI 10.1016/j.ophtha.2019.11.014
   Ruiz-Pesini E, 2007, NUCLEIC ACIDS RES, V35, pD823, DOI 10.1093/nar/gkl927
   Ruiz-Pesini E, 2006, HUM MUTAT, V27, P1072, DOI 10.1002/humu.20378
   Seyedhassani SM, 2010, J ASSIST REPROD GEN, V27, P641, DOI 10.1007/s10815-010-9435-2
   Shamsi MB, 2013, MITOCHONDRION, V13, P96, DOI 10.1016/j.mito.2013.01.002
   Suzuki T, 2011, ANNU REV GENET, V45, P299, DOI 10.1146/annurev-genet-110410-132531
   TOKUNAGA M, 1993, ANN NEUROL, V33, P275, DOI 10.1002/ana.410330308
   Van Blerkom J, 2004, REPRODUCTION, V128, P269, DOI 10.1530/rep.1.00240
   Van Blerkom J, 2011, MITOCHONDRION, V11, P797, DOI 10.1016/j.mito.2010.09.012
   van Oven M, 2009, HUM MUTAT, V30, pE386, DOI 10.1002/humu.20921
   VANDENOUWELAND JMW, 1994, DIABETES, V43, P746, DOI 10.2337/diabetes.43.6.746
   Wang M, 2016, NUCLEIC ACIDS RES, V44, P10974, DOI 10.1093/nar/gkw726
   YANAGISAWA K, 1995, DIABETOLOGIA, V38, P809, DOI 10.1007/s001250050357
NR 34
TC 0
Z9 1
U1 2
U2 10
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0340-6717
EI 1432-1203
J9 HUM GENET
JI Hum. Genet.
PD FEB
PY 2023
VL 142
IS 2
BP 193
EP 200
DI 10.1007/s00439-022-02505-1
EA NOV 2022
PG 8
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 9C8IY
UT WOS:000880534400001
PM 36352239
DA 2024-11-01
ER

PT J
AU Bacalhau, M
   Simoes, M
   Rocha, MC
   Hardy, SA
   Vincent, AE
   Duraes, J
   Macário, MC
   Santos, MJ
   Rebelo, O
   Lopes, C
   Pratas, J
   Mendes, C
   Zuzarte, M
   Rego, AC
   Girao, H
   Wong, LJC
   Taylor, RW
   Grazina, M
AF Bacalhau, Mafalda
   Simoes, Marta
   Rocha, Mariana C.
   Hardy, Steven A.
   Vincent, Amy E.
   Duraes, Joao
   Macario, Maria C.
   Santos, Maria Joao
   Rebelo, Olinda
   Lopes, Carla
   Pratas, Joao
   Mendes, Candida
   Zuzarte, Monica
   Cristina Rego, A.
   Girao, Henrique
   Wong, Lee-Jun C.
   Taylor, Robert W.
   Grazina, Manuela
TI Disclosing the functional changes of two genetic alterations in a
   patient with Chronic Progressive External Ophthalmoplegia: Report of the
   novel mtDNA m.7486G&gt;A variant
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE CPEO; mtDNA common deletion; mt-tRNA variant (m. 7486G > A);
   Bioenergetic dysfunction; Translation defect
ID MITOCHONDRIAL-DNA DELETIONS; REAL-TIME PCR; TRANSFER-RNA; POINT
   MUTATION; TRNA(ILE) GENE; TRNA(ALA) GENE; MYOPATHY; CELLS; DEFICIENCY;
   DEFECTS
AB Chronic Progressive External Ophthalmoplegia (CPEO) is characterized by ptosis and ophthalmoplegia and is usually caused by mitochondrial DNA (mtDNA) deletions or mt-tRNA mutations. The aim of the present work was to clarify the genetic defect in a patient presenting with CPEO and elucidate the underlying pathogenic mechanism. This 62-year-old female first developed ptosis of the right eye at the age of 12 and subsequently the left eye at 45 years, and was found to have external ophthalmoplegia at the age of 55 years. Histopathological abnormalities were detected in the patient's muscle, including ragged-red fibres, a mosaic pattern of COX-deficient muscle fibres and combined deficiency of respiratory chain complexes I and IV. Genetic investigation revealed the "common deletion" in the patient's muscle and fibroblasts. Moreover, a novel, heteroplasmic mt-tRNA(Ser)( UCN) variant (m.7486G>A) in the anticodon loop was detected in muscle homogenate (50%), fibroblasts (11%) and blood (4%). Single-fibre analysis showed segregation with COX-deficient fibres for both genetic alterations. Assembly defects of mtDNA-encoded complexes were demonstrated in fibroblasts. Functional analyses showed significant bioenergetic dysfunction, reduction in respiration rate and ATP production and mitochondria] depolarization. Multilamellar bodies were detected by electron microscopy, suggesting disturbance in autophagy. In conclusion, we report a CPEO patient with two possible genetic origins, both segregating with biochemical and histochemical defect. The "common mtDNA deletion" is the most likely cause, yet the potential pathogenic effect of a novel mt-tRNA(Ser)(UCN) variant cannot be fully excluded. (C) 2017 The Authors. Published by Elsevier B.V.
C1 [Bacalhau, Mafalda; Santos, Maria Joao; Cristina Rego, A.; Girao, Henrique; Grazina, Manuela] Univ Coimbra, FMUC Fac Med, Coimbra, Portugal.
   [Bacalhau, Mafalda; Simoes, Marta; Santos, Maria Joao; Pratas, Joao; Mendes, Candida; Grazina, Manuela] Univ Coimbra, CNC Ctr Neurosci & Cell Biol, Lab Biochem Genet, Coimbra, Portugal.
   [Rocha, Mariana C.; Hardy, Steven A.; Vincent, Amy E.; Taylor, Robert W.] Newcastle Univ, Inst Neurosci, Sch Med, Wellcome Ctr Mitochondria Res, Newcastle Upon Tyne, Tyne & Wear, England.
   [Duraes, Joao; Macario, Maria C.; Rebelo, Olinda] Coimbra Univ Hosp, CHUC Neurol Dept, Coimbra, Portugal.
   [Lopes, Carla] Univ Coimbra, CNC Ctr Neurosci & Cell Biol, Coimbra, Portugal.
   [Zuzarte, Monica; Girao, Henrique] Univ Coimbra, IBILI Inst Biomed Imaging & Life Sci, Coimbra, Portugal.
   [Wong, Lee-Jun C.] Baylor Coll Med, Mitochondria Diagnost Lab, Houston, TX 77030 USA.
C3 Universidade de Coimbra; Universidade de Coimbra; Newcastle University -
   UK; Universidade de Coimbra; Centro Hospitalar e Universitario de
   Coimbra (CHUC); Universidade de Coimbra; Universidade de Coimbra; Baylor
   College of Medicine
RP Grazina, M (corresponding author), Univ Coimbra, FMUC Fac Med, Coimbra, Portugal.
EM mgrazina.fmuc@gmail.com
RI Rego, Ana/AAH-2606-2020; Girao, Henrique/I-7591-2012; Lopes,
   Carla/V-6557-2018; Vincent, Amy/J-7284-2019; Bacalhau,
   Mafalda/AAB-6402-2022; Zuzarte, Monica/L-1485-2014; Rego, Ana
   Cristina/L-4272-2014; Rocha, Mariana/O-4313-2017; Duraes,
   Joao/L-1603-2019; Grazina, Manuela/W-3759-2017
OI Bacalhau, Mafalda/0000-0001-8857-3329; Rego, Ana
   Cristina/0000-0003-0700-3776; Simoes, Marta/0000-0003-3998-1611; Rocha,
   Mariana/0000-0002-0056-9315; Santos, Maria Joao/0000-0002-4018-8787;
   Girao, Henrique/0000-0002-5786-8447; Lopes, Carla/0000-0002-2543-8821;
   Duraes, Joao/0000-0001-9671-593X; Grazina, Manuela/0000-0002-1173-6481
FU Feder funds through Operational Competitiveness Program - COMPETE2020
   [POCI-01-0145-FEDER-007440, CENTRO-01-0145-FEDER-000012-N2323]; National
   Funds by FCT - Portuguese Science and Technology Foundation
   [UID/NEU/04539/2013]; Wellcome Centre for Mitochondrial Research
   [203105/Z/16/Z]; Medical Research Council (MRC) Centre for Translational
   Research in Neuromuscular Disease, Mitochondrial Disease Patient Cohort
   (UK) [G0800674]; Lily Foundation; UK NIHR Biomedical Research Centre; 
   [Pest-C/SAU/LA0001/2013e2014];  [FCT-SFRH/BD/86622/2012]; MRC [G0700718,
   MR/L016354/1, G0800674] Funding Source: UKRI
FX This work was financed by Feder funds through the Operational
   Competitiveness Program - COMPETE2020 (Strategic project
   POCI-01-0145-FEDER-007440; Healthy Aging2020
   CENTRO-01-0145-FEDER-000012-N2323) and National Funds by FCT -
   Portuguese Science and Technology Foundation through the strategic plan
   UID/NEU/04539/2013, the project Pest-C/SAU/LA0001/2013e2014 and a
   Doctoral grant FCT-SFRH/BD/86622/2012; Portugal. RWT is supported by is
   supported by the Wellcome Centre for Mitochondrial Research
   (203105/Z/16/Z), the Medical Research Council (MRC) Centre for
   Translational Research in Neuromuscular Disease, Mitochondrial Disease
   Patient Cohort (UK) (G0800674), the Lily Foundation, the UK NIHR
   Biomedical Research Centre for Ageing and Age-related disease award to
   the Newcastle upon Tyne Foundation Hospitals NHS Trust and the UK NHS
   Highly Specialised "Rare Mitochondrial Disorders of Adults and Children"
   Service in Newcastle upon Tyne.
CR Alemi M, 2007, FREE RADICAL BIO MED, V42, P32, DOI 10.1016/j.freeradbiomed.2006.09.014
   Alston CL, 2010, J NEUROL SCI, V298, P140, DOI 10.1016/j.jns.2010.08.014
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Berardo A, 2010, NEUROMUSCULAR DISORD, V20, P204, DOI 10.1016/j.nmd.2010.01.006
   Bidooki S, 2004, NEUROMUSCULAR DISORD, V14, P417, DOI 10.1016/j.nmd.2004.03.004
   Blakely EL, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.011296
   Blakely EL, 2013, HUM MUTAT, V34, P1260, DOI 10.1002/humu.22358
   Calvaruso MA, 2008, METHODS, V46, P281, DOI 10.1016/j.ymeth.2008.09.023
   Cardaioli E, 2008, J NEUROL SCI, V272, P106, DOI 10.1016/j.jns.2008.05.005
   Cardaioli E, 2007, NEUROMUSCULAR DISORD, V17, P681, DOI 10.1016/j.nmd.2007.05.001
   Chinnery PF, 1997, NEUROLOGY, V49, P1166, DOI 10.1212/WNL.49.4.1166
   D'Silva S, 2011, RNA, V17, P1100, DOI 10.1261/rna.2652611
   Florentz C, 2003, CELL MOL LIFE SCI, V60, P1356, DOI 10.1007/s00018-003-2343-1
   GOTO Y, 1990, J NEUROL SCI, V100, P63, DOI 10.1016/0022-510X(90)90014-E
   Grazina MM, 2012, METHODS MOL BIOL, V837, P73, DOI 10.1007/978-1-61779-504-6_6
   Greaves LC, 2010, INVEST OPHTH VIS SCI, V51, P3340, DOI 10.1167/iovs.09-4659
   Hanisch F, 2015, J NEUROL NEUROSUR PS, V86, P630, DOI 10.1136/jnnp-2013-306748
   HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614
   He LP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf067
   Herrera Alan, 2015, Front Biosci (Schol Ed), V7, P109
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   HOLT IJ, 1989, ANN NEUROL, V26, P699, DOI 10.1002/ana.410260603
   Jackson CB, 2014, BRIT J OPHTHALMOL, V98, P1453, DOI 10.1136/bjophthalmol-2014-305300
   Caballero PEJ, 2007, NEUROLOGIST, V13, P33, DOI 10.1097/01.nrl.0000252953.49721.f5
   Kirchner S, 2015, NAT REV GENET, V16, P98, DOI 10.1038/nrg3861
   Krishnan KJ, 2007, ANAL BIOCHEM, V370, P127, DOI 10.1016/j.ab.2007.06.024
   LEZZA AMS, 1994, BIOCHEM BIOPH RES CO, V205, P772, DOI 10.1006/bbrc.1994.2732
   López-Gallardo E, 2009, MITOCHONDRION, V9, P314, DOI 10.1016/j.mito.2009.04.005
   Meulemans A, 2007, ARCH NEUROL-CHICAGO, V64, P1339, DOI 10.1001/archneur.64.9.1339
   Moore D, 1997, CURRENT PROTOCOLS IN
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   MORAES CT, 1993, J CLIN INVEST, V92, P2906, DOI 10.1172/JCI116913
   Noma A, 2011, RNA, V17, P1111, DOI 10.1261/rna.2653411
   Ohno K, 1996, ANN NEUROL, V39, P761, DOI 10.1002/ana.410390612
   OLD SL, 1989, HISTOCHEM J, V21, P545, DOI 10.1007/BF01753355
   Pinós T, 2011, MITOCHONDRION, V11, P228, DOI 10.1016/j.mito.2010.08.008
   Porteous WK, 1998, EUR J BIOCHEM, V257, P192, DOI 10.1046/j.1432-1327.1998.2570192.x
   Pütz J, 2007, RNA, V13, P1184, DOI 10.1261/rna.588407
   Rocha MC, 2015, SCI REP-UK, V5, DOI 10.1038/srep15037
   Rygiel KA, 2015, SCI REP-UK, V5, DOI 10.1038/srep09906
   Sambrook J., 1987, Molecular Cloning - A Laboratory Manual, V2nd, p9.14, DOI DOI 10.1101/PDB.PROT3225
   Schaller A, 2011, MITOCHONDRION, V11, P488, DOI 10.1016/j.mito.2011.01.005
   SEIBEL P, 1994, BIOCHEM BIOPH RES CO, V204, P482, DOI 10.1006/bbrc.1994.2485
   SHOFFNER JM, 1989, P NATL ACAD SCI USA, V86, P7952, DOI 10.1073/pnas.86.20.7952
   Sievers F, 2011, MOL SYST BIOL, V7, DOI 10.1038/msb.2011.75
   Signorini C, 2014, OXID MED CELL LONGEV, V2014, DOI 10.1155/2014/195935
   Silvestri G, 1996, BIOCHEM BIOPH RES CO, V220, P623, DOI 10.1006/bbrc.1996.0453
   Smits P, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/737385
   Souilem S, 2011, J NEUROL SCI, V300, P187, DOI 10.1016/j.jns.2010.08.065
   Souilem S, 2010, DIAGN MOL PATHOL, V19, P28, DOI 10.1097/PDM.0b013e3181b00f02
   Spagnolo M, 2001, NEUROMUSCULAR DISORD, V11, P481, DOI 10.1016/S0960-8966(01)00195-X
   Suzuki T, 2011, ANNU REV GENET, V45, P299, DOI 10.1146/annurev-genet-110410-132531
   Taylor RW, 1998, BIOCHEM BIOPH RES CO, V243, P47, DOI 10.1006/bbrc.1997.8055
   Thomas AC, 2014, AM J HUM GENET, V95, P611, DOI 10.1016/j.ajhg.2014.10.007
   Tuppen HAL, 2010, BBA-BIOENERGETICS, V1797, P113, DOI 10.1016/j.bbabio.2009.09.005
   Van Goethem G, 2003, NEUROMOL MED, V3, P129, DOI 10.1385/NMM:3:3:129
   van Oven M, 2009, HUM MUTAT, V30, pE386, DOI 10.1002/humu.20921
   Vincent AE, 2016, SCI REP-UK, V6, DOI 10.1038/srep30610
   White HE, 2005, GENET TEST, V9, P190, DOI 10.1089/gte.2005.9.190
   Wittenhagen LM, 2003, TRENDS BIOCHEM SCI, V28, P605, DOI 10.1016/j.tibs.2003.09.006
   Yarham JW, 2012, MITOCHONDRION, V12, P533, DOI 10.1016/j.mito.2012.06.009
   Yarham JW, 2011, HUM MUTAT, V32, P1319, DOI 10.1002/humu.21575
   Zhang J, 2012, NAT PROTOC, V7, P1068, DOI 10.1038/nprot.2012.048
   Zhang W, 2012, CLIN CHEM, V58, P1322, DOI 10.1373/clinchem.2011.181438
NR 64
TC 7
Z9 9
U1 0
U2 8
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD APR
PY 2018
VL 28
IS 4
BP 350
EP 360
DI 10.1016/j.nmd.2017.11.006
PG 11
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA GG5US
UT WOS:000432761800008
PM 29398297
OA Green Published
DA 2024-11-01
ER

PT J
AU Longley, MJ
   Clark, S
   Man, CYW
   Hudson, G
   Durham, SE
   Taylor, RW
   Nightingale, S
   Turnbull, DM
   Copeland, WC
   Chinnery, PF
AF Longley, Matthew J.
   Clark, Susanna
   Man, Cynthia Yu Wai
   Hudson, Gavin
   Durham, Steve E.
   Taylor, Robert W.
   Nightingale, Simon
   Turnbull, Douglass M.
   Copeland, William C.
   Chinnery, Patrick F.
TI Mutant <i>POLG2</i> disrupts DNA polymerase γ subunits and causes
   progressive external ophthalmoplegia
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID ACCESSORY SUBUNIT; ALPERS-SYNDROME; AUTOSOMAL-DOMINANT; MUTATIONS;
   BINDING; IDENTIFICATION; DEPLETION; DELETIONS; MUSCLE
AB DNA polymerase gamma (pol gamma) is required to maintain the genetic integrity of the 16,569-bp human mitochondrial genome (mtDNA). Mutation of the nuclear gene for the catalytic subunit of pol gamma (POLG) has been linked to a wide range of mitochondrial diseases involving mutation, deletion, and depletion of mtDNA. We describe a heterozygous dominant mutation (c.1352G -> A/p.G451E) in POLG2, the gene encoding the p55 accessory subunit of pol gamma, that causes progressive external ophthalmoplegia with multiple mtDNA deletions and cytochrome c oxidase (COX)-deficient muscle fibers. Biochemical characterization of purified, recombinant G451E-substituted p55 protein in vitro revealed incomplete stimulation of the catalytic subunit due to compromised subunit interaction. Although G451E p55 retains a wild-type ability to bind DNA, it fails to enhance the DNA-binding strength of the p140-p55 complex. In vivo, the disease most likely arises through haplotype insufficiency or heterodimerization of the mutated and wild-type proteins, which promote mtDNA deletions by stalling the DNA replication fork. The progressive accumulation of mtDNA deletions causes COX deficiency in muscle fibers and results in the clinical phenotype.
C1 Univ Newcastle Upon Tyne, Sch Med, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   Natl Inst Environm Hlth Sci, Mol Genet Lab, NIH, Res Triangle Pk, NC USA.
   Univ Newcastle Upon Tyne, Inst Human Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   Royal Shrewsbury Hosp, Shrewsbury, Salop, England.
C3 Newcastle University - UK; National Institutes of Health (NIH) - USA;
   NIH National Institute of Environmental Health Sciences (NIEHS);
   Newcastle University - UK
RP Chinnery, PF (corresponding author), Univ Newcastle Upon Tyne, Sch Med, Mitochondrial Res Grp, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM P.F.Chinnery@ncl.ac.uk
RI Hudson, Gavin/E-7117-2017; Copeland, William/C-4242-2019
OI Yu-Wai-Man, Cynthia/0000-0003-4868-5187; Copeland,
   William/0000-0002-0359-0953; Hudson, Gavin/0000-0001-7210-2733;
   Chinnery, Patrick/0000-0002-7065-6617
FU Intramural NIH HHS Funding Source: Medline; Wellcome Trust [074454]
   Funding Source: Medline
CR Blakely EL, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.011296
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Brierley EJ, 1998, ANN NEUROL, V43, P217, DOI 10.1002/ana.410430212
   Carrodeguas JA, 2000, NUCLEIC ACIDS RES, V28, P1237, DOI 10.1093/nar/28.5.1237
   Carrodeguas JA, 2002, J BIOL CHEM, V277, P50008, DOI 10.1074/jbc.M207030200
   Carrodeguas JA, 2001, MOL CELL, V7, P43, DOI 10.1016/S1097-2765(01)00153-8
   Chan SSL, 2005, DNA REPAIR, V4, P1381, DOI 10.1016/j.dnarep.2005.08.010
   Chan SSL, 2005, J BIOL CHEM, V280, P31341, DOI 10.1074/jbc.M506762200
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Durham SE, 2005, NEUROLOGY, V65, P453, DOI 10.1212/01.wnl.0000171861.30277.88
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   He LP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf067
   HUDSON G, IN PRESS NEUROLOGY
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197
   Longley Matthew J, 2002, Methods Mol Biol, V197, P245, DOI 10.1385/1-59259-284-8:245
   Longley MJ, 2005, GENE, V354, P125, DOI 10.1016/j.gene.2005.03.029
   Longley MJ, 1998, BIOCHEMISTRY-US, V37, P10529, DOI 10.1021/bi980772w
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nguyen KV, 2005, NEUROLOGY, V65, P1493, DOI 10.1212/01.wnl.0000182814.55361.70
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Yakubovskaya E, 2006, J BIOL CHEM, V281, P374, DOI 10.1074/jbc.M509730200
NR 26
TC 181
Z9 200
U1 0
U2 2
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0002-9297
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD JUN
PY 2006
VL 78
IS 6
BP 1026
EP 1034
DI 10.1086/504303
PG 9
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 042TZ
UT WOS:000237553800011
PM 16685652
OA Green Published, Bronze, Green Accepted
DA 2024-11-01
ER

PT J
AU Liu, GL
   Shen, XY
   Sun, YG
   Lv, Q
   Li, YY
   Du, A
AF Liu, Gailing
   Shen, Xiya
   Sun, Yongan
   Lv, Qing
   Li, Yuanyuan
   Du, Ailian
TI Heteroplasmy and phenotype spectrum of the mitochondrial
   tRNA<SUP>Leu</SUP> <SUP>(UUR)</SUP> gene m.3243A > G mutation in seven
   Han Chinese families
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE M.3243A > G mutation; Phenotype spectrum; Life-threatening mitochondrial
   myopathy; Heteroplasmy; Chinese patients
ID A3243G MUTATION; RETINITIS-PIGMENTOSA; DIABETES-MELLITUS; DNA MUTATIONS;
   PREVALENCE; MYOPATHY; DISEASE; NUCLEAR; CARDIOMYOPATHY; MANIFESTATION
AB The m.3243A > G mutation in the mitochondrial tRNA(Leu) ((UUR)) gene is associated with a variety of phenotypic heterogeneity. The clinical spectrum and phenotypic-genotypic correlations in the Chinese patients are poorly understood. In the present study, we reported the clinical and genetic characterization, as well as haplogroups of seven Han Chinese families carrying the m.3243A > G mutation. Of the 39 matrilineal individuals, five suffered from mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS), two had life-threatening mitochondrial myopathy (LTMM), and one patient had neuropathy, ataxia, and retinitis pigmentosa (NARP)-like syndrome. The LTMM and NARP like syndromes enriched the phenotypic profile of the m.3243A > G mutation. The heteroplasmy of the m.3243A > G mutation ranged from 16% to 59% in MELAS, 29% to 79% in LTMM, and 57% in a NARP-like syndrome patient. The levels ranged from 0% to 14% in patients that manifested with pure diabetes and pure hearing loss, and 0% to 5% in 13 normal family members. However, we particularly noticed heteroplasmy in four asymptomatic individuals in one LTMM family carried the heteroplasmy mutation ranged from 22% to 78%, implying that there were other modifying factors in this family. The modulation of the phenotype of mtDNA mutations requires further investigation.
C1 [Liu, Gailing; Shen, Xiya; Lv, Qing; Li, Yuanyuan; Du, Ailian] Shanghai Jiao Tong Univ, Tongren Hosp, Dept Neurol, Sch Med, Shanghai 200336, Peoples R China.
   [Sun, Yongan] Perking Univ, Dept Neurol, Hosp 1, Beijing 100034, Peoples R China.
   [Du, Ailian] Zhejiang Univ, Affiliated Hosp 2, Dept Neurol, Sch Med, Hangzhou 310009, Peoples R China.
C3 Shanghai Jiao Tong University; Zhejiang University
RP Du, A (corresponding author), Shanghai Jiao Tong Univ, Tongren Hosp, Dept Neurol, Sch Med, Shanghai 200336, Peoples R China.
EM ailiandu@sjtu.edu.cn
RI Li, Yuanyuan/ABF-5504-2021
FU National Natural Science Foundation of China [81971181]; Shanghai
   Natural Science Foundation [19ZR1449200]; Medical and Engineering
   Crossover Fund of SJTU [YG2017MS67]; Science and Technology Commission
   Foundation of Shanghai Changning District [CNKW2017Y02, CNKW2018Y01]
FX This work was supported by National Natural Science Foundation of China
   (81971181), Shanghai Natural Science Foundation (19ZR1449200), the
   Medical and Engineering Crossover Fund of SJTU (YG2017MS67) and the
   Science and Technology Commission Foundation of Shanghai Changning
   District (CNKW2017Y02, CNKW2018Y01).
CR Al-Gadi IS, 2018, J ENDOCR SOC, V2, P361, DOI 10.1210/js.2017-00434
   Brandon MC, 2005, NUCLEIC ACIDS RES, V33, pD611
   Bruno C, 2003, J CHILD NEUROL, V18, P300, DOI 10.1177/08830738030180040401
   Campos Y, 1996, MUSCLE NERVE, V19, P187, DOI 10.1002/(SICI)1097-4598(199602)19:2<187::AID-MUS10>3.0.CO;2-S
   Cardenas-Robledo S, 2016, J NEURO-OPHTHALMOL, V36, P134, DOI 10.1097/WNO.0000000000000340
   Catteruccia M, 2015, J NEUROL, V262, P701, DOI 10.1007/s00415-014-7632-0
   Duno M, 2013, GENE, V515, P372, DOI 10.1016/j.gene.2012.12.066
   Gorman GS, 2016, NAT REV DIS PRIMERS, V2, P1, DOI 10.1038/nrdp.2016.80
   Gorman GS, 2015, ANN NEUROL, V77, P753, DOI 10.1002/ana.24362
   Grady JP, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708262
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   Houshmand M, 1996, HUM GENET, V97, P269, DOI 10.1007/BF02185750
   Iizuka T, 2002, NEUROLOGY, V59, P816, DOI 10.1212/WNL.59.6.816
   Jiang PP, 2015, INVEST OPHTH VIS SCI, V56, P4778, DOI 10.1167/iovs.14-16158
   Kerrison JB, 2000, ARCH OPHTHALMOL-CHIC, V118, P298
   Koga Y, 2000, ARCH DIS CHILD, V82, P407, DOI 10.1136/adc.82.5.407
   Kraya T, 2018, HEADACHE, V58, P45, DOI 10.1111/head.13219
   Li RH, 2010, MOL CELL BIOL, V30, P2147, DOI 10.1128/MCB.01614-09
   Liang M, 2014, INVEST OPHTH VIS SCI, V55, P1321, DOI 10.1167/iovs.13-13011
   McFarland R, 2008, NEUROMUSCULAR DISORD, V18, P63, DOI 10.1016/j.nmd.2007.07.007
   Meng FL, 2017, J BIOL CHEM, V292, P2881, DOI 10.1074/jbc.M116.749374
   Mordel P, 2017, BIOCHEM BIOPH RES CO, V494, P133, DOI 10.1016/j.bbrc.2017.10.066
   Ng YS, 2016, EUR HEART J, V37, P2552, DOI 10.1093/eurheartj/ehv306
   Pan XL, 2019, FRONT NEUROL, V10, DOI 10.3389/fneur.2019.00780
   Picard M, 2016, JAMA NEUROL, V73, P923, DOI 10.1001/jamaneurol.2016.1676
   Pickett SJ, 2018, ANN CLIN TRANSL NEUR, V5, P333, DOI 10.1002/acn3.532
   Pierron D, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-41
   Rieder MJ, 1998, NUCLEIC ACIDS RES, V26, P967, DOI 10.1093/nar/26.4.967
   Schaefer AM, 2008, ANN NEUROL, V63, P35, DOI 10.1002/ana.21217
   Wang SJ, 2013, GENE, V531, P472, DOI 10.1016/j.gene.2013.09.019
   Wortmann SB, 2012, EUR J MED GENET, V55, P552, DOI 10.1016/j.ejmg.2012.06.002
   Xia CY, 2016, CHINESE MED J-PEKING, V129, P1945, DOI 10.4103/0366-6999.187845
   Yan JB, 2014, J MOL DIAGN, V16, P431, DOI 10.1016/j.jmoldx.2014.03.005
   Yang CC, 1998, J FORMOS MED ASSOC, V97, P715
   Zhang JJ, 2013, MITOCHONDRION, V13, P772, DOI 10.1016/j.mito.2013.05.002
   Zhou Y, 2018, INT J NEUROSCI, V128, P231, DOI 10.1080/00207454.2017.1387113
NR 36
TC 15
Z9 15
U1 0
U2 10
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 1878-5883
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD JAN 15
PY 2020
VL 408
AR 116562
DI 10.1016/j.jns.2019.116562
PG 8
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA KH9EP
UT WOS:000510952200021
PM 31722256
DA 2024-11-01
ER

PT J
AU Smet, J
   Seneca, S
   De Paepe, B
   Meulemans, A
   Verhelst, H
   Leroy, J
   De Meirleir, L
   Lissens, W
   Van Coster, R
AF Smet, Joel
   Seneca, Sara
   De Paepe, Boel
   Meulemans, Ann
   Verhelst, Helene
   Leroy, Jules
   De Meirleir, Linda
   Lissens, Willy
   Van Coster, Rudy
TI Subcomplexes of mitochondrial complex V reveal mutations in
   mitochondrial DNA
SO ELECTROPHORESIS
LA English
DT Article
DE Blue Native PAGE; Complex V subcomplexes; mtDNA depletion; mtDNA point
   mutation; Oxidative phosphorylation
ID ATP-SYNTHASE; RESPIRATORY-CHAIN; LACTIC-ACIDOSIS; GENE MUTATION;
   TRANSLATION; MUSCLE; DEFICIENCIES; MYOPATHY; PATIENT; DEFECT
AB Complex V, site of the final step in oxidative phosphorylation, uses the proton gradient across the inner mitochondrial membrane for the production of ATP. It is a multi-subunit complex composed of a catalytic domain (F-1) and a membrane domain (F-0) linked by two stalks. Subcomplexes of complex V containing the F, domain have previously been reported in small series of patients. We report the results in tissue samples and/or cultured skin fibroblasts studied by blue native PAGE followed by activity staining in the gel. Catalytically active subcomplexes of complex V were detected in 66 tissues originating from 53 patients. In 29 of the latter (55%), a mitochondrial DNA (mtDNA) defect was identified. Twelve patients had a pathogenic point mutation in a mitochondrial tRNA, one a large mtDNA deletion, 12 showed mtDNA depletion and four had a mutation in the MT-ATP6 gene. We conclude that the presence of subcomplexes of complex V is a valuable indicator in the detection of mtDNA defects.
C1 [Smet, Joel; De Paepe, Boel; Verhelst, Helene; Leroy, Jules; Van Coster, Rudy] Ghent Univ Hosp, Dept Pediat, Div Pediat Neurol & Metab, B-9000 Ghent, Belgium.
   [Seneca, Sara; Meulemans, Ann; De Meirleir, Linda; Lissens, Willy] Free Univ Brussels, Div Paediat Neurol & Metab, Brussels, Belgium.
   [Seneca, Sara; Meulemans, Ann; De Meirleir, Linda; Lissens, Willy] Free Univ Brussels, Ctr Med Genet, UZ Brussel Hosp, Brussels, Belgium.
C3 Ghent University; Ghent University Hospital; Universite Libre de
   Bruxelles; Universite Libre de Bruxelles
RP Van Coster, R (corresponding author), Ghent Univ Hosp, Dept Pediat, Div Pediat Neurol & Metab, Pintelaan 185, B-9000 Ghent, Belgium.
EM rudy.vancoster@ugent.be
RI De Meirleir, Linda/D-6591-2016; Smet, Joél/B-7428-2013; Lissens,
   Willy/B-2892-2013; De Paepe, Boel/B-7548-2013
OI Seneca, Sara/0000-0002-0853-9890; Lissens, Willy/0000-0003-3875-9955;
   Meulemans, Ann/0000-0003-3938-2408; De Paepe, Boel/0000-0001-9403-4401
FU Fund for Scientific Research Belgium (FWO) [G.0666.06]
FX This study was supported by a grant from the Fund for Scientific
   Research Belgium (FWO), contract grant number G.0666.06 (Universiteit
   Gent and Vrije Universiteit Brussel). We thank Mary Phelan for help in
   correcting the English language.
CR BIRCHMACHIN MA, 1989, PEDIATR RES, V25, P553, DOI 10.1203/00006450-198905000-00025
   Bozdogan B, 2004, INT J ANTIMICROB AG, V23, P113, DOI 10.1016/j.ijantimicag.2003.11.003
   Carrozzo R, 2006, ANN NEUROL, V59, P265, DOI 10.1002/ana.20729
   Coenen MJH, 2004, NEW ENGL J MED, V351, P2080, DOI 10.1056/NEJMoa041878
   De Vriese AS, 2006, CLIN INFECT DIS, V42, P1111, DOI 10.1086/501356
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   FISCHER JC, 1986, EUR J PEDIATR, V144, P441, DOI 10.1007/BF00441735
   HOUSTEK J, 1995, BBA-MOL BASIS DIS, V1271, P349, DOI 10.1016/0925-4439(95)00063-A
   Jonckheere AI, 2008, J MED GENET, V45, P129, DOI 10.1136/jmg.2007.052084
   King M P, 1996, Methods Enzymol, V264, P304, DOI 10.1016/S0076-6879(96)64029-4
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Meulemans A, 2007, ARCH NEUROL-CHICAGO, V64, P1339, DOI 10.1001/archneur.64.9.1339
   Meulemans A, 2007, EUR J PAEDIATR NEURO, V11, P17, DOI 10.1016/j.ejpn.2006.10.004
   Meulemans A, 2006, ARCH NEUROL-CHICAGO, V63, P1194, DOI 10.1001/archneur.63.8.1194
   Miller C, 2004, ANN NEUROL, V56, P734, DOI 10.1002/ana.20282
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   Saada A, 2007, J MED GENET, V44, P784, DOI 10.1136/jmg.2007.053116
   Scalais E, 2007, Eur J Neurol, V14, pe3, DOI 10.1111/j.1468-1331.2007.01926.x
   SCHOLTE HR, 1992, J INHERIT METAB DIS, V15, P347, DOI 10.1007/BF02435973
   Seneca S, 2005, AM J MED GENET A, V137A, P170, DOI 10.1002/ajmg.a.30854
   Seneca S, 1996, J INHERIT METAB DIS, V19, P115, DOI 10.1007/BF01799407
   Smeitink JAM, 2006, AM J HUM GENET, V79, P869, DOI 10.1086/508434
   SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415
   Srere P.A., 1969, Methods in Enzymology, V13, P3
   Valente L, 2007, AM J HUM GENET, V80, P44, DOI 10.1086/510559
   Van Coster R, 2001, PEDIATR RES, V50, P658, DOI 10.1203/00006450-200111000-00020
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Walker JE, 2006, BBA-BIOENERGETICS, V1757, P286, DOI 10.1016/j.bbabio.2006.01.001
   Zerbetto E, 1997, ELECTROPHORESIS, V18, P2059, DOI 10.1002/elps.1150181131
NR 29
TC 26
Z9 27
U1 0
U2 17
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0173-0835
EI 1522-2683
J9 ELECTROPHORESIS
JI Electrophoresis
PD OCT
PY 2009
VL 30
IS 20
BP 3565
EP 3572
DI 10.1002/elps.200900213
PG 8
WC Biochemical Research Methods; Chemistry, Analytical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 516WG
UT WOS:000271573400010
PM 19862739
DA 2024-11-01
ER

PT J
AU Bidooki, S
   Jackson, MJ
   Johnson, MA
   Chrzanowska-Lightowlers, ZMA
   Taylor, RW
   Venables, G
   Lightowlers, RN
   Turnbull, DM
   Bindoff, LA
AF Bidooki, S
   Jackson, MJ
   Johnson, MA
   Chrzanowska-Lightowlers, ZMA
   Taylor, RW
   Venables, G
   Lightowlers, RN
   Turnbull, DM
   Bindoff, LA
TI Sporadic mitochondrial myopathy due to a new mutation in the
   mitochondrial tRNA<SUP>Ser(UCN)</SUP> gene
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE mitochondrial myopathy; mtDNA; tRNA Serine
ID INHERITED HEARING-LOSS; POINT MUTATION; SEQUENCE; FAMILY; MERRF
AB We describe a young woman with a progressive mitochondrial myopathy that started with muscle weakness and went on to include deafness, dementia and ataxia. Skeletal muscle showed the histological and biochemical features of mitochondrial respiratory chain dysfunction. Genetic analysis identified a novel, heteroplasmic, A to G transition in tRNA(Ser(UCN)) at position 7480 affecting a highly conserved base in the anticodon loop. Single-fibre PCR showed highest levels of mutation in cytochrome c-oxidase-deficient fibres and quantification in two biopsies taken 5 years apart showed no change in percentage heteroplasmy. The mutation was present at lower levels in the patient's blood, but was not found in either her mother's or sister's blood and skeletal muscle, suggesting a sporadic occurrence. This is the eighth disease-causing mutation in this tRNA gene and confirms serine (UCN) as one of the most common sites for mtDNA mutation. (C) 2004 Elsevier B.V. All rights reserved.
C1 Univ Bergen, Haukeland Univ Hosp, Inst Clin Med & Mol Med, Dept Neurol, N-5021 Bergen, Norway.
   Med Sch Newcastle Upon Tyne, Sch Neurol Neurobiol & Psychiat, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   Sheffield Teaching Hosp NHS Trust, Dept Neurol, Sheffield S10 2JF, S Yorkshire, England.
C3 University of Bergen; Haukeland University Hospital; Newcastle
   University - UK; University of Sheffield
RP Univ Bergen, Haukeland Univ Hosp, Inst Clin Med & Mol Med, Dept Neurol, N-5021 Bergen, Norway.
EM laurence.bindoff@helse-bergen.no
RI Bindoff, Nathaniel/C-8050-2011
OI Bindoff, Laurence/0000-0003-0988-276X; Chrzanowska-Lightowlers,
   Zofia/0000-0002-0045-3152
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Bidooki SK, 1997, AM J HUM GENET, V60, P1430, DOI 10.1086/515460
   BINDOFF LA, 1991, J NEUROL SCI, V102, P17, DOI 10.1016/0022-510X(91)90088-O
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Grafakou O, 2003, J INHERIT METAB DIS, V26, P593, DOI 10.1023/A:1025960300710
   Hutchin TP, 2000, J MED GENET, V37, P692, DOI 10.1136/jmg.37.9.692
   Jaksch M, 1998, J MED GENET, V35, P895, DOI 10.1136/jmg.35.11.895
   JOHNSON MA, 1993, ANN NEUROL, V33, P28, DOI 10.1002/ana.410330106
   NAKAMURA M, 1995, BIOCHEM BIOPH RES CO, V214, P86, DOI 10.1006/bbrc.1995.2260
   REID FM, 1994, HUM MUTAT, V3, P243, DOI 10.1002/humu.1380030311
   Servidei Serenella, 2004, Neuromuscul Disord, V14, P107
   Sue CM, 1999, NEUROLOGY, V52, P1905, DOI 10.1212/WNL.52.9.1905
   TIRANTI V, 1995, HUM MOL GENET, V4, P1421, DOI 10.1093/hmg/4.8.1421
   Weber K, 1997, AM J HUM GENET, V60, P373
   YARUS M, 1982, SCIENCE, V218, P646, DOI 10.1126/science.6753149
   Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595
   2003, MITOMAP HUMAN MITOCH
NR 18
TC 18
Z9 20
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD JUL
PY 2004
VL 14
IS 7
BP 417
EP 420
DI 10.1016/j.nmd.2004.03.004
PG 4
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 838LQ
UT WOS:000222715200003
PM 15210164
DA 2024-11-01
ER

PT J
AU Slama, A
   Glurgea, I
   Debrey, D
   Bridoux, D
   de Lonlay, P
   Levy, P
   Chretien, D
   Brivet, M
   Legrand, A
   Rustin, P
   Munnich, A
   Rötig, A
AF Slama, A
   Glurgea, I
   Debrey, D
   Bridoux, D
   de Lonlay, P
   Levy, P
   Chretien, D
   Brivet, M
   Legrand, A
   Rustin, P
   Munnich, A
   Rötig, A
TI Deoxyguanosine kinase mutations and combined deficiencies of the
   mitochondrial respiratory chain in patients with hepatic involvement
SO MOLECULAR GENETICS AND METABOLISM
LA English
DT Article
DE mitochondrial DNA depletion; deoxyguanosine kinase; respiratory chain
   defect
ID DNA DEPLETION SYNDROME; GENE; MYOPATHY; EXPRESSION; DISEASES
AB The activity of deoxyguanosine kinase (DGUOK), a mitochondrial enzyme involved in the anabolism of mitochondrial (mt) deoxyribo-nucleotides, governs the maintenance of the mtDNA. Deleterious mutations of the DGUOK gene are thus associated with mtDNA depletion and result in combined deficiencies of mtDNA-encoded respiratory chain enzymes. With the aim to estimate the prevalence of DGUOK mutations in a cohort of 30 patients with hepatocerebral disease and combined respiratory chain deficiencies, we studied the DGUOK gene and identified previously unreported mutations in five families. Two patients and their affected sibs, born to non-consanguineous parents, were homozygous for a missense mutation (M1T, and L250S, respectively). One patient presented a homozygous 4 pb insertion (796 insT-GAT) and two other patients, and their affected sibs, were compound heterozygous (E165V/L266R and E211G/L266R, respectively). These findings allowed us to propose prenatal diagnosis in two families. In conclusion, we observed a high prevalence of DGUOK mutations (17%) in patients with hepatic involvement and combined respiratory chain deficiencies with hepatic involvement. (c) 2005 Elsevier Inc. All rights reserved.
C1 Hop Bicetre, Lab Biochim 1, AP HP, Le Kremlin Bicetre, France.
   Hop Bicetre, Serv Hepatol Pediat, AP HP, Le Kremlin Bicetre, France.
   Hop Necker Enfants Malad, Serv Genet Med, AP HP, Paris, France.
   Hop Necker Enfants Malad, INSERM U 393, Paris, France.
   Hop Robert Debre, INSERM, U676, F-75019 Paris, France.
C3 Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Antoine-Beclere - APHP; Universite Paris Saclay; Hopital Universitaire
   Bicetre - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital
   Universitaire Bicetre - APHP; Hopital Universitaire Antoine-Beclere -
   APHP; Universite Paris Saclay; Assistance Publique Hopitaux Paris
   (APHP); Universite Paris Cite; Hopital Universitaire Necker-Enfants
   Malades - APHP; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Universite
   Paris Cite; Hopital Universitaire Necker-Enfants Malades - APHP;
   Universite Paris Cite; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital
   Universitaire Robert-Debre - APHP
RP Slama, A (corresponding author), Hop Bicetre, Lab Biochim 1, AP HP, Le Kremlin Bicetre, France.
EM abdel.slama@bct.aphp.fr
RI ; ROTIG, AGNES/G-9592-2017
OI Giurgea, Irina/0000-0002-5035-2958; Rustin, Pierre/0000-0002-5500-7280;
   ROTIG, AGNES/0000-0003-0589-0703
CR Carrozzo R, 2003, HUM MUTAT, V21, DOI 10.1002/humu.9135
   DiMauro S, 2004, BBA-BIOENERGETICS, V1658, P80, DOI 10.1016/j.bbabio.2004.03.014
   Ducluzeau PH, 1999, J HEPATOL, V30, P149, DOI 10.1016/S0168-8278(99)80019-1
   Johansson M, 1996, P NATL ACAD SCI USA, V93, P7258, DOI 10.1073/pnas.93.14.7258
   Mancuso M, 2003, ARCH NEUROL-CHICAGO, V60, P1007, DOI 10.1001/archneur.60.7.1007
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   MAZZIOTTA MRM, 1992, J PEDIATR-US, V121, P896, DOI 10.1016/S0022-3476(05)80335-X
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284
   Taanman JW, 1997, HUM MOL GENET, V6, P935, DOI 10.1093/hmg/6.6.935
   Taanman JW, 2002, ANN NEUROL, V52, P237, DOI 10.1002/ana.10247
   TRITSCHLER HJ, 1992, NEUROLOGY, V42, P209, DOI 10.1212/WNL.42.1.209
   Wang LY, 2005, MOL GENET METAB, V84, P75, DOI 10.1016/j.ymgme.2004.09.005
NR 15
TC 29
Z9 34
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1096-7192
J9 MOL GENET METAB
JI Mol. Genet. Metab.
PD DEC
PY 2005
VL 86
IS 4
BP 462
EP 465
DI 10.1016/j.ymgme.2005.09.006
PG 4
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental
   Medicine
GA 997XP
UT WOS:000234282500007
PM 16263314
DA 2024-11-01
ER

PT J
AU Darin, N
   Kollberg, G
   Moslemi, AR
   Tulinius, M
   Holme, E
   Gröonlund, MA
   Andersson, S
   Oldfors, A
AF Darin, N.
   Kollberg, G.
   Moslemi, A-R.
   Tulinius, M.
   Holme, E.
   Gronlund, M. Andersson
   Andersson, S.
   Oldfors, A.
TI Mitochondrial myopathy with exercise intolerance and retinal dystrophy
   in a sporadic patient with a G583A mutation in the mt tRNA<SUP>phe</SUP>
   gene
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE mitochondrial; tRNA(phe); mutation; myopathy; mtDNA; retinal dystrophy
ID ENCEPHALOMYOPATHIES; CHILDHOOD
AB We describe a second patient with the 583G > A mutation in the tRNA(phe) gene of mitochondrial DNA (mtDNA). This 17-year-old girl had a mitochondrial myopathy with exercise intolerance and an asymptomatic retinopathy. Muscle investigations showed occasional ragged red fibers, 30% cytochrome c oxidase (COX)-negative fibers, and reduced activities of complex I + IV in the respiratory chain. The mutation was heteroplasmic (79%) in muscle but undetectable in other tissues. Analysis of single muscle fibers revealed a significantly higher level of mutated mtDNA in COX-negative fibers. Our study indicates that the 583G > A mutation is pathogenic and expands the clinical spectrum of this mutation. (C) 2006 Elsevier B.V. All rights reserved.
C1 Sahlgrens Univ Hosp, Dept Pediat, Gothenburg, Sweden.
   Sahlgrens Univ Hosp, Dept Pathol, Gothenburg, Sweden.
   Sahlgrens Univ Hosp, Dept Clin Chem, Gothenburg, Sweden.
   Sahlgrens Univ Hosp, Dept Pediat Ophthalmol, Gothenburg, Sweden.
C3 Sahlgrenska University Hospital; Sahlgrenska University Hospital;
   Sahlgrenska University Hospital; Sahlgrenska University Hospital
RP Darin, N (corresponding author), Queen Silvia Childrens Hosp, Dept Pediat, S-41685 Gothenburg, Sweden.
EM niklas.darin@vgregion.se
RI Darin, Niklas/AAL-6345-2020
CR [Anonymous], 2005, MITOMAP: A Human Mitochondrial Genome Database
   Darin N, 2001, ANN NEUROL, V49, P377, DOI 10.1002/ana.75
   Hanna MG, 1998, J NEUROL NEUROSUR PS, V65, P512, DOI 10.1136/jnnp.65.4.512
   HOUSHMAND M, 1994, BBA-MOL BASIS DIS, V1226, P49, DOI 10.1016/0925-4439(94)90058-2
   Kleinle S, 1998, BIOCHEM BIOPH RES CO, V247, P112, DOI 10.1006/bbrc.1998.8729
   Mancuso M, 2004, NEUROLOGY, V62, P2119, DOI 10.1212/01.WNL.0000127608.48406.F1
   Moslemi AR, 2004, NEUROMUSCULAR DISORD, V14, P46, DOI 10.1016/S0960-8966(03)00168-8
   TULINIUS MH, 1991, J PEDIATR-US, V119, P242, DOI 10.1016/S0022-3476(05)80734-6
   Tzen CY, 2001, KIDNEY INT, V59, P846, DOI 10.1046/j.1523-1755.2001.00567.x
   Yasukawa T, 2000, NUCLEIC ACIDS RES, V28, P3779, DOI 10.1093/nar/28.19.3779
NR 10
TC 16
Z9 19
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD AUG
PY 2006
VL 16
IS 8
BP 504
EP 506
DI 10.1016/j.nmd.2006.05.010
PG 3
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 101RV
UT WOS:000241759100006
PM 16806928
DA 2024-11-01
ER

PT J
AU Hakonen, AH
   Isohanni, P
   Paetau, A
   Herva, R
   Suomalainen, A
   Lönnqvist, T
AF Hakonen, Anna H.
   Isohanni, Pirjo
   Paetau, Anders
   Herva, Riitta
   Suomalainen, Anu
   Loennqvist, Tuula
TI Recessive Twinkle mutations in early onset encephalopathy with mtDNA
   depletion
SO BRAIN
LA English
DT Article
DE twinkle; IOSCA; Alpers; encephalopathy; mtDNA
ID MITOCHONDRIAL-DNA DEPLETION; PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA;
   SPINOCEREBELLAR ATAXIA; MULTIPLE DELETIONS; POLG MUTATIONS; SENSORY
   NEUROPATHY; ALPERS-SYNDROME; GENE; DISEASE; DEGENERATION
AB Twinkle is a mitochondrial replicative helicase, the mutations of which have been associated with autosomal dominant progressive external ophthalmoplegia (adPEO), and recessively inherited infantile onset spinocerebellar ataxia (IOSCA). We report here a new phenotype in two siblings with compound heterozygous Twinkle mutations (A318T and Y508C), characterized by severe early onset encephalopathy and signs of liver involvement. The clinical manifestations included hypotonia, athetosis, sensory neuropathy, ataxia, hearing deficit, ophthalmoplegia, intractable epilepsy and elevation of serum transaminases. The liver showed mtDNA depletion, whereas the muscle mtDNA was only slightly affected. Alpers-Huttenlocher syndrome has previously been associated with mutations of polymerase gamma, a replicative polymerase of mtDNA. We show here that recessive mutations of the close functional partner of the polymerase, the Twinkle helicase, can also manifest as early encephalopathy with liver involvement, a phenotype reminiscent of Alpers syndrome, and are a new genetic cause underlying tissue-specific mtDNA depletion.
C1 Univ Helsinki, Biomed Helsinki, Res Program Mol Neurol, FIN-00290 Helsinki, Finland.
   Univ Helsinki, Cent Hosp, Dept Child Neurol, Hosp Childrens & Adolescents, Helsinki, Finland.
   Univ Helsinki, Dept Pathol, Helsinki, Finland.
   HUSLAB, Helsinki, Finland.
   Oulu Univ Hosp, Oulu, Finland.
   Univ Helsinki, Cent Hosp, Dept Neurol, FIN-00014 Helsinki, Finland.
C3 University of Helsinki; University of Helsinki; Helsinki University
   Central Hospital; University of Helsinki; University of Oulu; University
   of Helsinki; Helsinki University Central Hospital
RP Suomalainen, A (corresponding author), Univ Helsinki, Biomed Helsinki, Res Program Mol Neurol, R C523B,POB 63, FIN-00290 Helsinki, Finland.
EM anu.wartiovaara@helsinki.fi
OI Suomalainen-Wartiovaara, Anu/0000-0003-4833-5195
CR Alpers BJ, 1931, ARCH NEURO PSYCHIATR, V25, P469, DOI 10.1001/archneurpsyc.1931.02230030027002
   Baloh RH, 2007, ARCH NEUROL-CHICAGO, V64, P998, DOI 10.1001/archneur.64.7.998
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   Deschauer M, 2003, NEUROMUSCULAR DISORD, V13, P568, DOI 10.1016/S0960-8966(03)00071-3
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Hudson G, 2005, NEUROLOGY, V64, P371, DOI 10.1212/01.WNL.0000149767.51152.83
   HUTTENLOCHER PR, 1976, ARCH NEUROL-CHICAGO, V33, P186, DOI 10.1001/archneur.1976.00500030042009
   KOSKINEN T, 1994, J NEUROL SCI, V121, P50, DOI 10.1016/0022-510X(94)90156-2
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lönnqvist T, 1998, J NEUROL SCI, V161, P57, DOI 10.1016/S0022-510X(98)00249-4
   MANDERBACKA K, 2001, SCANDINAVIAN J P S55, V29, P41
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nikali K, 2005, HUM MOL GENET, V14, P2981, DOI 10.1093/hmg/ddi328
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   Tyynismaa H, 2004, HUM MOL GENET, V13, P3219, DOI 10.1093/hmg/ddh342
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 27
TC 150
Z9 159
U1 0
U2 13
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
J9 BRAIN
JI Brain
PD NOV
PY 2007
VL 130
BP 3032
EP 3040
DI 10.1093/brain/awm242
PN 11
PG 9
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 227RJ
UT WOS:000250675200028
PM 17921179
OA Bronze
DA 2024-11-01
ER

PT J
AU Young, MJ
   Copeland, WC
AF Young, Matthew J.
   Copeland, William C.
TI Human mitochondrial DNA replication machinery and disease
SO CURRENT OPINION IN GENETICS & DEVELOPMENT
LA English
DT Article
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; STRUCTURE-FUNCTION DEFECTS;
   RECESSIVE TWINKLE MUTATIONS; POLYMERASE GAMMA-SUBUNITS; IMPAIR MTDNA
   REPLICATION; MULTIPLE DELETIONS; ACCESSORY SUBUNIT; HELICASE TWINKLE;
   MAMMALIAN EMBRYOGENESIS; RNA-POLYMERASE
AB The human mitochondrial genome is replicated by DNA polymerase gamma in concert with key components of the mitochondrial DNA (mtDNA) replication machinery. Defects in mtDNA replication or nucleotide metabolism cause deletions, point mutations, or depletion of mtDNA. The resulting loss of cellular respiration ultimately induces mitochondrial genetic diseases, including mtDNA depletion syndromes (MDS) such as Alpers or early infantile hepatocerebral syndromes, and mtDNA deletion disorders such as progressive external ophthalmoplegia, ataxia-neuropathy, or mitochondrial neurogastrointestinal encephalomyopathy. Here we review the current literature regarding human mtDNA replication and heritable disorders caused by genetic changes of the POLG, POLG2, Twinkle, RNASEH1, DNA2, and MGME1 genes.
C1 [Young, Matthew J.; Copeland, William C.] NIEHS, Genome Integr & Struct Biol Lab, POB 12233, Res Triangle Pk, NC 27709 USA.
   [Young, Matthew J.] Southern Illinois Univ, Dept Biochem & Mol Biol, Sch Med, Carbondale, IL 62901 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute of
   Environmental Health Sciences (NIEHS); Southern Illinois University
   System; Southern Illinois University
RP Copeland, WC (corresponding author), NIEHS, Genome Integr & Struct Biol Lab, POB 12233, Res Triangle Pk, NC 27709 USA.
EM copelan1@niehs.nih.gov
RI ; Copeland, William/C-4242-2019
OI Young, Matthew/0000-0002-5109-4719; Copeland,
   William/0000-0002-0359-0953
FU Intramural Research Program of the NIH, National Institute of
   Environmental Health Sciences [ES 065078, ES 065080]; NIH Pathway to
   Independence Award [1K99ES022638-01]
FX This research was supported by the Intramural Research Program of the
   NIH, National Institute of Environmental Health Sciences (ES 065078 and
   ES 065080 to WCC) and by a NIH Pathway to Independence Award to MJY
   (1K99ES022638-01).
CR Besse A, 2015, CELL METAB, V21, P417, DOI 10.1016/j.cmet.2015.02.008
   Carrodeguas JA, 2001, MOL CELL, V7, P43, DOI 10.1016/S1097-2765(01)00153-8
   Cerritelli SM, 2003, MOL CELL, V11, P807, DOI 10.1016/S1097-2765(03)00088-1
   Cerritelli SM, 2009, FEBS J, V276, P1494, DOI 10.1111/j.1742-4658.2009.06908.x
   Chan SSL, 2009, BBA-BIOENERGETICS, V1787, P312, DOI 10.1016/j.bbabio.2008.10.007
   Chan SSL, 2005, J BIOL CHEM, V280, P31341, DOI 10.1074/jbc.M506762200
   CHANG DD, 1985, P NATL ACAD SCI USA, V82, P351, DOI 10.1073/pnas.82.2.351
   CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6
   Cohen B.H., 2010, GENEREVIEWS GENETEST
   Cohen BH, 2010, METHODS, V51, P364, DOI 10.1016/j.ymeth.2010.05.008
   Copeland WC, 2008, ANNU REV MED, V59, P131, DOI 10.1146/annurev.med.59.053006.104646
   Copeland WC, 2014, J CHILD NEUROL, V29, P1216, DOI 10.1177/0883073814537380
   Copeland WC, 2014, DNA REPAIR, V19, P190, DOI 10.1016/j.dnarep.2014.03.010
   Craig K, 2012, MITOCHONDRION, V12, P313, DOI 10.1016/j.mito.2011.11.006
   Duxin JP, 2009, MOL CELL BIOL, V29, P4274, DOI 10.1128/MCB.01834-08
   Euro L, 2011, NUCL ACIDS RES
   Falkenberg M, 2007, ANNU REV BIOCHEM, V76, P679, DOI 10.1146/annurev.biochem.76.060305.152028
   Fan L, 2006, J MOL BIOL, V358, P1229, DOI 10.1016/j.jmb.2006.02.073
   Fernández-Millán P, 2015, NUCLEIC ACIDS RES, V43, P4284, DOI 10.1093/nar/gkv189
   Fratter C, 2010, NEUROLOGY, V74, P1619, DOI 10.1212/WNL.0b013e3181df099f
   Fusté JM, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004832
   Fusté JM, 2010, MOL CELL, V37, P67, DOI 10.1016/j.molcel.2009.12.021
   García-Gómez S, 2013, MOL CELL, V52, P541, DOI 10.1016/j.molcel.2013.09.025
   Goffart S, 2009, HUM MOL GENET, V18, P328, DOI 10.1093/hmg/ddn359
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   Graziewicz MA, 2006, CHEM REV, V106, P383, DOI 10.1021/cr040463d
   Graziewicz MA, 2007, HUM MOL GENET, V16, P2729, DOI 10.1093/hmg/ddm227
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   Hance N, 2005, HUM MOL GENET, V14, P1775, DOI 10.1093/hmg/ddi184
   Hensen F, 2014, BIOCHIMIE, V100, P219, DOI 10.1016/j.biochi.2013.09.017
   Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279
   Holmes JB, 2015, P NATL ACAD SCI USA, V112, P9334, DOI 10.1073/pnas.1503653112
   Holmlund T, 2009, BBA-MOL BASIS DIS, V1792, P132, DOI 10.1016/j.bbadis.2008.11.009
   Holt IJ, 2014, BIOESSAYS, V36, P1024, DOI 10.1002/bies.201400052
   Hudson G, 2005, NEUROLOGY, V64, P371, DOI 10.1212/01.WNL.0000149767.51152.83
   Humble MM, 2013, HUM MOL GENET, V22, P1017, DOI 10.1093/hmg/dds506
   Jemt E, 2015, NUCLEIC ACIDS RES, V43, P9262, DOI 10.1093/nar/gkv804
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   Kalifa L, 2009, DNA REPAIR, V8, P1242, DOI 10.1016/j.dnarep.2009.07.008
   KASAMATSU H, 1974, ANNU REV BIOCHEM, V43, P695, DOI 10.1146/annurev.bi.43.070174.003403
   Kasiviswanathan R, 2011, J BIOL CHEM, V286, P31490, DOI 10.1074/jbc.M111.252460
   Keen BA, 2014, NUCLEIC ACIDS RES, V42, P12102, DOI 10.1093/nar/gku879
   Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257
   Korhonen JA, 2003, J BIOL CHEM, V278, P48627, DOI 10.1074/jbc.M306981200
   Korhonen JA, 2008, J MOL BIOL, V377, P691, DOI 10.1016/j.jmb.2008.01.035
   Kornblum C, 2013, NAT GENET, V45, P214, DOI 10.1038/ng.2501
   Lee YS, 2009, CELL, V139, P312, DOI 10.1016/j.cell.2009.07.050
   Lewis W, 2007, LAB INVEST, V87, P326, DOI 10.1038/labinvest.3700523
   Lim SE, 1999, J BIOL CHEM, V274, P38197, DOI 10.1074/jbc.274.53.38197
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Longley MJ, 2010, J BIOL CHEM, V285, P29690, DOI 10.1074/jbc.M110.151795
   Longley MJ, 2005, GENE, V354, P125, DOI 10.1016/j.gene.2005.03.029
   Lönnqvist T, 2009, BRAIN, V132, P1553, DOI 10.1093/brain/awp045
   Luoma PT, 2005, HUM MOL GENET, V14, P1907, DOI 10.1093/hmg/ddi196
   Matsushima Y, 2007, J BIOL CHEM, V282, P9436, DOI 10.1074/jbc.M610550200
   Miller FJ, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng060
   Ngo HB, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4077
   Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200
   Reyes A, 2015, AM J HUM GENET, V97, P186, DOI 10.1016/j.ajhg.2015.05.013
   ROBBERSON DL, 1972, P NATL ACAD SCI USA, V69, P737, DOI 10.1073/pnas.69.3.737
   Ronchi D, 2013, AM J HUM GENET, V92, P293, DOI 10.1016/j.ajhg.2012.12.014
   Rouzier C, 2012, BRAIN, V135, P23, DOI 10.1093/brain/awr323
   Saneto RP, 2010, DEV DISABIL RES REV, V16, P163, DOI 10.1002/ddrr.105
   Saneto RP, 2010, SEIZURE-EUR J EPILEP, V19, P140, DOI 10.1016/j.seizure.2010.01.002
   SERVIDEI S, 1991, NEUROLOGY, V41, P1053, DOI 10.1212/WNL.41.7.1053
   Shadel GS, 1997, ANNU REV BIOCHEM, V66, P409, DOI 10.1146/annurev.biochem.66.1.409
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spelbrink JN, 2010, IUBMB LIFE, V62, P19, DOI 10.1002/iub.282
   Stumpf JD, 2010, HUM MOL GENET, V19, P2123, DOI 10.1093/hmg/ddq089
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   Szymanski MR, 2015, EMBO J, V34, P1959, DOI 10.15252/embj.201591520
   Tang S, 2011, J MED GENET, V48, P669, DOI 10.1136/jmedgenet-2011-100222
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
   Tyynismaa H, 2009, EMBO REP, V10, P137, DOI 10.1038/embor.2008.242
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Hove JLK, 2009, AM J MED GENET A, V149A, P861, DOI 10.1002/ajmg.a.32731
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523
   Walter MC, 2010, J NEUROL, V257, P1517, DOI 10.1007/s00415-010-5565-9
   Wanrooij S, 2008, P NATL ACAD SCI USA, V105, P11122, DOI 10.1073/pnas.0805399105
   Wanrooij S, 2007, NUCLEIC ACIDS RES, V35, P3238, DOI 10.1093/nar/gkm215
   Wong LJC, 2008, HUM MUTAT, V29, pE150, DOI 10.1002/humu.20824
   Young MJ, 2015, HUM MOL GENET, V24, P5184, DOI 10.1093/hmg/ddv240
   Young MJ, 2011, HUM MOL GENET, V20, P3052, DOI 10.1093/hmg/ddr209
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
   Zhang HL, 2014, NUCLEIC ACIDS RES, V42, P7259, DOI 10.1093/nar/gku384
   Zhao FX, 2013, HUM GENET, V132, P913, DOI 10.1007/s00439-013-1303-6
   Zheng L, 2008, MOL CELL, V32, P325, DOI 10.1016/j.molcel.2008.09.024
NR 88
TC 132
Z9 150
U1 2
U2 24
PU CURRENT BIOLOGY LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0959-437X
EI 1879-0380
J9 CURR OPIN GENET DEV
JI Curr. Opin. Genet. Dev.
PD JUN
PY 2016
VL 38
BP 52
EP 62
DI 10.1016/j.gde.2016.03.005
PG 11
WC Cell Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Genetics & Heredity
GA EA6LH
UT WOS:000386740200009
PM 27065468
OA Green Accepted
DA 2024-11-01
ER

PT J
AU De Vriese, AS
   Van Coster, R
   Smet, J
   Seneca, S
   Lovering, A
   Van Haute, LL
   Vanopdenbosch, LJ
   Martin, JJ
   Ceuterick-de Groote, C
   Vandecasteele, S
   Boelaert, JR
AF De Vriese, AS
   Van Coster, R
   Smet, J
   Seneca, S
   Lovering, A
   Van Haute, LL
   Vanopdenbosch, LJ
   Martin, JJ
   Ceuterick-de Groote, C
   Vandecasteele, S
   Boelaert, JR
TI Linezolid-induced inhibition of mitochondrial protein synthesis
SO CLINICAL INFECTIOUS DISEASES
LA English
DT Article
ID OXIDATIVE-PHOSPHORYLATION; PERIPHERAL NEUROPATHY; LACTIC-ACIDOSIS; LEVEL
AB Background Linezolid is an oxazolidinone antibiotic that is increasingly used to treat drug-resistant, gram-positive pathogens. The mechanism of action is inhibition of bacterial protein synthesis. Optic and/or peripheral neuropathy and lactic acidosis are reported side effects, but the underlying pathophysiological mechanism has not been unravelled.
   Methods. We studied mitochondrial ultrastructure, mitochondrial respiratory chain enzyme activity, and mitochondrial DNA ( mtDNA) in muscle, liver, and kidney samples obtained from a patient who developed optic neuropathy, encephalopathy, skeletal myopathy, lactic acidosis, and renal failure after prolonged use of linezolid. In addition, we evaluated mtDNA, respiratory chain enzyme activity, and protein amount in muscle and liver samples obtained from experimental animals that received linezolid or placebo.
   Results. In the patient, mitochondrial respiratory chain enzyme activity was decreased in affected tissues, without ultrastructural mitochondrial abnormalities and without mutations or depletion of mtDNA. In the experimental animals, linezolid induced a dose-and time-dependent decrease of the activity of respiratory chain complexes containing mtDNA-encoded subunits and a decreased amount of protein of these complexes, whereas the amount of mtDNA was normal.
   Conclusion. These results provide direct evidence that linezolid inhibits mitochondrial protein synthesis with potentially severe clinical consequences. Prolonged courses of linezolid should be avoided if alternative treatment options are available.
C1 AZ St Jan Brugge, Dept Internal Med, B-8000 Brugge, Belgium.
   AZ St Jan Brugge, Dept Neurol, B-8000 Brugge, Belgium.
   State Univ Ghent Hosp, Dept Pediat, Div Pediat Neurol & Metab, B-9000 Ghent, Belgium.
   Dutch Speaking Free Univ Brussels, Ctr Med Genet, Univ Hosp, Brussels, Belgium.
   Univ Antwerp, Lab Neuropathol & Electron Microscopy, Born Bunge Inst, B-2020 Antwerp, Belgium.
   Southmead Gen Hosp, Antimicrobial Reference Lab, Dept Med Microbiol, Bristol, Avon, England.
C3 Ghent University; Ghent University Hospital; Vrije Universiteit Brussel;
   University of Antwerp; Southmead Hospital
RP De Vriese, AS (corresponding author), AZ St Jan Brugge, Dept Internal Med, Ruddershove 10, B-8000 Brugge, Belgium.
EM an.devriese@azbrugge.be
RI Van Haute, Lindsey/GWZ-7600-2022; De Vriese, An/KLY-2825-2024
OI De Vriese, An/0000-0002-9596-8529; Van Haute,
   Lindsey/0000-0001-7809-1473; Seneca, Sara/0000-0002-0853-9890
CR Apodaca AA, 2003, NEW ENGL J MED, V348, P86, DOI 10.1056/NEJM200301023480123
   Birmingham MC, 2003, CLIN INFECT DIS, V36, P159, DOI 10.1086/345744
   Bressler AM, 2004, LANCET INFECT DIS, V4, P528, DOI 10.1016/S1473-3099(04)01109-0
   DENSLOW ND, 1978, EUR J BIOCHEM, V91, P441, DOI 10.1111/j.1432-1033.1978.tb12696.x
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   Ferry T, 2005, INFECTION, V33, P151, DOI 10.1007/s15010-005-4057-9
   FISCHER JC, 1986, EUR J PEDIATR, V144, P441, DOI 10.1007/BF00441735
   Frippiat F, 2004, J ANTIMICROB CHEMOTH, V53, P1114, DOI 10.1093/jac/dkh199
   Hancock MR, 2002, ANN CLIN BIOCHEM, V39, P456, DOI 10.1258/000456302320314467
   Kuter DJ, 2001, PHARMACOTHERAPY, V21, P1010, DOI 10.1592/phco.21.11.1010.34517
   Meierhofer D, 2005, MITOCHONDRION, V5, P282, DOI 10.1016/j.mito.2005.06.001
   Meka VG, 2004, CLIN INFECT DIS, V39, P1010, DOI 10.1086/423841
   Nijtmans LGJ, 1995, BBA-MOL BASIS DIS, V1272, P190, DOI 10.1016/0925-4439(95)00087-9
   Palenzuela L, 2005, CLIN INFECT DIS, V40, pE113, DOI 10.1086/430441
   Rho JP, 2004, MAYO CLIN PROC, V79, P927, DOI 10.4065/79.7.927
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488
   Sharma MR, 2003, CELL, V115, P97, DOI 10.1016/S0092-8674(03)00762-1
   Slatter JG, 2002, XENOBIOTICA, V32, P907, DOI 10.1080/00498250210158249
   SOTTOCASA GL, 1967, J CELL BIOL, V32, P415, DOI 10.1083/jcb.32.2.415
   Srere P.A., 1969, Methods in Enzymology, V13, P3
   Tobin CM, 2001, J ANTIMICROB CHEMOTH, V48, P605, DOI 10.1093/jac/48.5.605
   Van Coster R, 2001, PEDIATR RES, V50, P658, DOI 10.1203/00006450-200111000-00020
   Zivkovic SA, 2005, NEUROLOGY, V64, P926, DOI 10.1212/01.WNL.0000152883.53691.5B
NR 24
TC 200
Z9 205
U1 0
U2 13
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 1058-4838
J9 CLIN INFECT DIS
JI Clin. Infect. Dis.
PD APR 15
PY 2006
VL 42
IS 8
BP 1111
EP 1117
DI 10.1086/501356
PG 7
WC Immunology; Infectious Diseases; Microbiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Infectious Diseases; Microbiology
GA 023CC
UT WOS:000236101800008
PM 16575728
OA Bronze
DA 2024-11-01
ER

PT J
AU Müller-Nedebock, AC
   van der Westhuizen, FH
   Koks, S
   Bardien, S
AF Muller-Nedebock, Amica C.
   van Der Westhuizen, Francois H.
   Koks, Sulev
   Bardien, Soraya
TI Nuclear Genes Associated with Mitochondrial DNA Processes as
   Contributors to Parkinson's Disease Risk
SO MOVEMENT DISORDERS
LA English
DT Review
DE Parkinson&apos; s disease; parkinsonism; mitochondrial DNA; mtDNA
   maintenance; mtDNA transcription and translation
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; POLYMERASE-GAMMA MUTATION;
   EARLY-ONSET PARKINSONISM; TRANSCRIPTION FACTORS B1; GENOME-WIDE
   ASSOCIATION; DOMINANT OPTIC ATROPHY; FACTOR-A TFAM; SUBSTANTIA-NIGRA;
   AUTOSOMAL-DOMINANT; 1-METHYL-4-PHENYLPYRIDINIUM ION
AB Over the past four decades, mitochondrial dysfunction has been a recurring theme in Parkinson's disease (PD) and is hypothesized to play a central role in its disease pathogenesis. Given the instrumental role of mitochondria in cellular energy production, their dysfunction can be detrimental to highly energy-dependent dopaminergic neurons, known to degenerate in PD. Mitochondria harbor multiple copies of their own genomes (mtDNA), encoding critical respiratory chain complexes required for energy production. Consequently, mtDNA has been investigated as a source of mitochondrial dysfunction in PD. As seen in multiple mitochondrial diseases, deleterious mtDNA variation and mtDNA copy number depletion can impede mtDNA protein synthesis, leading to inadequate energy production in affected cells and the onset of a disease phenotype. As such, high burdens of mtDNA defects but also mtDNA depletion, previously identified in the substantia nigra of PD patients, have been suggested to play a role in PD. Genetic variation in nuclear DNA encoding factors required for replicating, transcribing, and translating mtDNA, could underlie these observed mtDNA changes. Herein we examine this possibility and provide an overview of studies that have investigated whether nuclear-encoded genes associated with mtDNA processes may influence PD risk. Overall, pathway-based analysis studies, mice models, and case reports of mitochondrial disease patients manifesting with parkinsonism all implicate genes encoding factors related to mtDNA processes in neurodegeneration and PD. Most notably, cumulative genetic variation in these genes likely contributes to neurodegeneration and PD risk by acting together in common pathways to disrupt mtDNA processes or impair their regulation. (c) 2021 International Parkinson and Movement Disorder Society (c) 2021 International Parkinson and Movement Disorder Society
C1 [Muller-Nedebock, Amica C.; Bardien, Soraya] Stellenbosch Univ, Fac Med & Hlth Sci, Dept Biomed Sci, Div Mol Biol & Human Genet, Cape Town, South Africa.
   [van Der Westhuizen, Francois H.] North West Univ, Human Metabol, Potchefstroom, South Africa.
   [Koks, Sulev] Perron Inst Neurol & Translat Sci, Nedlands, WA, Australia.
   [Koks, Sulev] Murdoch Univ, Ctr Mol Med & Innovat Therapeut, Murdoch, WA, Australia.
C3 Stellenbosch University; North West University - South Africa; Perron
   Institute for Neurological & Translational Science; Murdoch University
RP Müller-Nedebock, AC; Bardien, S (corresponding author), Stellenbosch Univ, Div Mol Biol & Human Genet, Dept Biomed Sci, POB 241, ZA-8000 Cape Town, South Africa.
EM amicamuller@sun.ac.za; sbardien@sun.ac.za
RI Koks, Sulev/HSA-8160-2023; Bardien, Soraya/ABB-3313-2020; van der
   Westhuizen, Francois/E-6959-2011
OI van der Westhuizen, Francois/0000-0002-7879-1776; Bardien,
   Soraya/0000-0002-3508-3438; Muller-Nedebock, Amica/0000-0002-5547-9704
FU National Research Foundation of South Africa
FX This work is based on the research supported in part by the National
   Research Foundation of South Africa (Grant Numbers: DAAD-NRF Doctoral
   Scholarship). The authors declare no conflict of interest.
CR Abahuni N, 2007, NEUROSCI LETT, V414, P126, DOI 10.1016/j.neulet.2006.12.053
   Alvarez V, 2008, NEUROSCI LETT, V432, P79, DOI 10.1016/j.neulet.2007.12.010
   Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   Amunts A, 2015, SCIENCE, V348, P95, DOI 10.1126/science.aaa1193
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Antonenkov VD, 2015, J BIOL CHEM, V290, P13840, DOI 10.1074/jbc.M114.608083
   Anvret A, 2010, NEUROSCI LETT, V485, P117, DOI 10.1016/j.neulet.2010.08.082
   ARNHEIM N, 1992, MUTAT RES, V275, P157, DOI 10.1016/0921-8734(92)90020-P
   Balafkan N, 2012, MITOCHONDRION, V12, P640, DOI 10.1016/j.mito.2012.08.004
   Baloh RH, 2007, ARCH NEUROL-CHICAGO, V64, P998, DOI 10.1001/archneur.64.7.998
   Bandres-Ciga S, 2019, MOVEMENT DISORD, V34, P460, DOI 10.1002/mds.27614
   Barchiesi A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092221
   Behrouz B, 2010, NEUROSCI LETT, V486, P228, DOI 10.1016/j.neulet.2010.09.059
   Belin AC, 2007, NEUROSCI LETT, V420, P257, DOI 10.1016/j.neulet.2007.05.010
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x
   Bentley SR, 2014, MITOCHONDRION, V15, P65, DOI 10.1016/j.mito.2014.01.004
   Betts-Henderson J, 2009, NEUROPATH APPL NEURO, V35, P120, DOI 10.1111/j.1365-2990.2008.00981.x
   Billingsley KJ, 2018, CELL TISSUE RES, V373, P9, DOI 10.1007/s00441-018-2817-y
   Billingsley KJ, 2019, NPJ PARKINSONS DIS, V5, DOI 10.1038/s41531-019-0080-x
   BINDOFF LA, 1991, J NEUROL SCI, V104, P203, DOI 10.1016/0022-510X(91)90311-T
   Blok MJ, 2009, J MED GENET, V46, P776, DOI 10.1136/jmg.2009.067686
   Boczonadi V, 2018, ESSAYS BIOCHEM, V62, P321, DOI 10.1042/EBC20170103
   Borsche M, 2020, BRAIN, V143, P3041, DOI 10.1093/brain/awaa246
   Brandon BR, 2013, J NEUROL, V260, P1931, DOI 10.1007/s00415-013-6975-2
   Calvo SE, 2016, NUCLEIC ACIDS RES, V44, pD1251, DOI 10.1093/nar/gkv1003
   Caporali L, 2018, BRAIN, V141, DOI 10.1093/brain/awx301
   Carelli V, 2015, ANN NEUROL, V78, P21, DOI 10.1002/ana.24410
   Chaudhuri KR, 2009, LANCET NEUROL, V8, P464, DOI 10.1016/S1474-4422(09)70068-7
   Chen C, 2020, NEUROBIOL DIS, V134, DOI 10.1016/j.nbd.2019.104631
   Chinnery PF, 2013, BRIT MED BULL, V106, P135, DOI 10.1093/bmb/ldt017
   Chinnery PF, 1999, AM J HUM GENET, V64, P1158, DOI 10.1086/302311
   Cobb LJ, 2016, AGING-US, V8, P796, DOI 10.18632/aging.100943
   Coxhead J, 2016, NEUROBIOL AGING, V38, DOI 10.1016/j.neurobiolaging.2015.10.036
   Damier P, 1999, BRAIN, V122, P1437, DOI 10.1093/brain/122.8.1437
   Davidzon G, 2006, ANN NEUROL, V59, P859, DOI 10.1002/ana.20831
   DAVIS GC, 1979, PSYCHIAT RES, V1, P249, DOI 10.1016/0165-1781(79)90006-4
   di Poggio MB, 2013, BMC MED GENET, V14, DOI 10.1186/1471-2350-14-105
   Dolhun R, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-92
   Dölle C, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13548
   Edgar D, 2009, CELL METAB, V10, P131, DOI 10.1016/j.cmet.2009.06.010
   Eerola J, 2010, NEUROSCI LETT, V477, P1, DOI 10.1016/j.neulet.2010.04.021
   Ekstrand MI, 2007, P NATL ACAD SCI USA, V104, P1325, DOI 10.1073/pnas.0605208103
   El-Hattab AW, 2017, BBA-MOL BASIS DIS, V1863, P1539, DOI 10.1016/j.bbadis.2017.02.017
   Elachouri G, 2011, GENOME RES, V21, P12, DOI 10.1101/gr.108696.110
   Elson JL, 2001, AM J HUM GENET, V68, P802, DOI 10.1086/318801
   Falkenberg M, 2002, NAT GENET, V31, P289, DOI 10.1038/ng909
   Fasullo M, 2015, INT J MOL SCI, V16, P9431, DOI 10.3390/ijms16059431
   Ferreira M, 2011, NEUROMUSCULAR DISORD, V21, P483, DOI 10.1016/j.nmd.2011.03.011
   Frezza C, 2006, CELL, V126, P177, DOI 10.1016/j.cell.2006.06.025
   Fuke S, 2014, ANN CLIN TRANSL NEUR, V1, P909, DOI 10.1002/acn3.133
   Gaare JJ, 2018, MOVEMENT DISORD, V33, P1591, DOI 10.1002/mds.64
   Galassi G, 2008, NEUROMUSCULAR DISORD, V18, P465, DOI 10.1016/j.nmd.2008.03.013
   Galter D, 2010, GENES BRAIN BEHAV, V9, P173, DOI 10.1111/j.1601-183X.2009.00542.x
   García-Gómez S, 2013, MOL CELL, V52, P541, DOI 10.1016/j.molcel.2013.09.025
   Garone C, 2012, ARCH NEUROL-CHICAGO, V69, P1648, DOI 10.1001/archneurol.2012.405
   Gatt AP, 2013, NEUROSCI LETT, V557, P177, DOI 10.1016/j.neulet.2013.10.045
   Gaweda-Walerych K, 2010, NEUROSCI LETT, V469, P24, DOI 10.1016/j.neulet.2009.11.037
   Gibson G, 2010, NAT GENET, V42, P558, DOI 10.1038/ng0710-558
   Gleyzer N, 2005, MOL CELL BIOL, V25, P1354, DOI 10.1128/MCB.25.4.1354-1366.2005
   Greber BJ, 2015, SCIENCE, V348, P303, DOI 10.1126/science.aaa3872
   Grünewald A, 2016, ANN NEUROL, V79, P366, DOI 10.1002/ana.24571
   Güldner M, 2016, PARKINSONISM RELAT D, V31, P148, DOI 10.1016/j.parkreldis.2016.07.005
   Gui YX, 2015, PARKINSONISM RELAT D, V21, P282, DOI 10.1016/j.parkreldis.2014.12.030
   Gui YX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050086
   Gurgel-Giannetti J, 2012, MUSCLE NERVE, V45, P453, DOI 10.1002/mus.22330
   Gustafsson CM, 2016, ANNU REV BIOCHEM, V85, P133, DOI 10.1146/annurev-biochem-060815-014402
   HAAS RH, 1995, ANN NEUROL, V37, P714, DOI 10.1002/ana.410370604
   HEIKKILA RE, 1985, NEUROSCI LETT, V62, P389, DOI 10.1016/0304-3940(85)90580-4
   Hudson G, 2008, BRAIN, V131, P329, DOI 10.1093/brain/awm272
   Hudson G, 2007, AM J HUM GENET, V81, P228, DOI 10.1086/519394
   Hudson G, 2009, MOVEMENT DISORD, V24, P1092, DOI 10.1002/mds.22310
   Hughes K., 2013, BRENNERS ENCY GENETI, pP352
   Iannielli A, 2018, CELL REP, V22, P2066, DOI 10.1016/j.celrep.2018.01.089
   Invernizzi F, 2008, NEUROMUSCULAR DISORD, V18, P460, DOI 10.1016/j.nmd.2008.04.005
   Jang S, 2020, MITOCHONDRION, V51, P30, DOI 10.1016/j.mito.2019.11.006
   Jankovic J, 2008, J NEUROL NEUROSUR PS, V79, P368, DOI 10.1136/jnnp.2007.131045
   Jornayvaz FR, 2010, ESSAYS BIOCHEM, V47, P69, DOI [10.1042/BSE0470069, 10.1042/bse0470069]
   Kammenga JE, 2017, FEBS J, V284, P3362, DOI 10.1111/febs.14080
   Keener AM, 2016, SEMIN NEUROL, V36, P330, DOI 10.1055/s-0036-1585097
   Kiferle L, 2013, NEUROSCI LETT, V556, P1, DOI 10.1016/j.neulet.2013.09.034
   Kim SJ, 2017, J PHYSIOL-LONDON, V595, P6613, DOI 10.1113/JP274472
   Koc EC, 2002, J BIOL CHEM, V277, P35541, DOI 10.1074/jbc.M202498200
   Kopinski PK, 2019, P NATL ACAD SCI USA, V116, P16028, DOI 10.1073/pnas.1906896116
   Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257
   Krasich R, 2017, FRONT BIOSCI-LANDMRK, V22, P692, DOI 10.2741/4510
   Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778
   Kuroda Y, 2006, HUM MOL GENET, V15, P883, DOI 10.1093/hmg/ddl006
   Lake NJ, 2017, AM J HUM GENET, V101, P239, DOI 10.1016/j.ajhg.2017.07.005
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   LANGSTON JW, 1983, SCIENCE, V219, P979, DOI 10.1126/science.6823561
   Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231
   Lax NZ, 2012, J NEUROPATH EXP NEUR, V71, P148, DOI 10.1097/NEN.0b013e318244477d
   Lee C, 2015, CELL METAB, V21, P443, DOI 10.1016/j.cmet.2015.02.009
   Lee CH, 2013, TRENDS ENDOCRIN MET, V24, P222, DOI [10.1016/j.tem.2013.01.005, 10.1016/j.technovation.2020.102140]
   Lefaivre Shannon C, 2016, Cerebellum Ataxias, V3, P13, DOI 10.1186/s40673-016-0051-5
   Lezza Angela M S, 2012, [Frontiers in Biology, 生物学前沿], V7, P30
   Li X, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0059064, 10.1371/journal.pone.0063227, 10.1371/journal.pone.0067880, 10.1371/journal.pone.0080399]
   Lieberman AP, 2019, ANNU REV PATHOL-MECH, V14, P1, DOI 10.1146/annurev-pathmechdis-012418-012857
   Lin MT, 2012, ANN NEUROL, V71, P850, DOI 10.1002/ana.23568
   Lin MT, 2002, HUM MOL GENET, V11, P133, DOI 10.1093/hmg/11.2.133
   Litonin D, 2010, J BIOL CHEM, V285, P18129, DOI 10.1074/jbc.C110.128918
   Liu ZR, 2008, MOL VIS, V14, P1995
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Luoma PT, 2007, NEUROLOGY, V69, P1152, DOI 10.1212/01.wnl.0000276955.23735.eb
   Lynch DS, 2017, NEUROL-GENET, V3, DOI 10.1212/NXG.0000000000000188
   Ma L, 2018, PARKINSONISM RELAT D, V46, pE29
   Machado A, 2006, MOVEMENT DISORD, V21, pS247, DOI 10.1002/mds.20959
   Mancuso M, 2004, ARCH NEUROL-CHICAGO, V61, P1777, DOI 10.1001/archneur.61.11.1777
   Mehta AR, 2011, MOVEMENT DISORD, V26, P753, DOI 10.1002/mds.23510
   Miguel R, 2014, CLIN NEUROL NEUROSUR, V126, P47, DOI 10.1016/j.clineuro.2014.08.020
   MIZUNO Y, 1987, NEUROSCI LETT, V81, P204, DOI 10.1016/0304-3940(87)90366-1
   Müller-Nedebock AC, 2019, NEUROCHEM INT, V129, DOI 10.1016/j.neuint.2019.104495
   Neeve VCM, 2012, BRAIN, V135, P3614, DOI 10.1093/brain/aws298
   Nicholls TJ, 2014, EXP GERONTOL, V56, P175, DOI 10.1016/j.exger.2014.03.027
   Nissanka N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04895-1
   Nogueira C, 2014, ITAL J PEDIATR, V40, DOI 10.1186/1824-7288-40-34
   Ohnmacht J, 2020, J NEURAL TRANSM, V127, P729, DOI 10.1007/s00702-020-02184-0
   Pagnamenta AT, 2006, HUM REPROD, V21, P2467, DOI 10.1093/humrep/del076
   Palin EJH, 2013, BRAIN, V136, P2379, DOI 10.1093/brain/awt160
   Park JS, 2018, CURR NEUROL NEUROSCI, V18, DOI 10.1007/s11910-018-0829-3
   Park JH, 2010, NAT GENET, V42, P570, DOI 10.1038/ng.610
   Perier C, 2013, BRAIN, V136, P2369, DOI 10.1093/brain/awt196
   Podlesniy P, 2019, EBIOMEDICINE, V48, P554, DOI 10.1016/j.ebiom.2019.09.015
   Poewe W, 2008, EUR J NEUROL, V15, P14, DOI 10.1111/j.1468-1331.2008.02056.x
   Pyle A, 2016, NEUROBIOL AGING, V38, DOI 10.1016/j.neurobiolaging.2015.10.033
   Quirós PM, 2016, NAT REV MOL CELL BIO, V17, P213, DOI 10.1038/nrm.2016.23
   Rackham O, 2011, RNA, V17, P2085, DOI 10.1261/rna.029405.111
   Ramos ES, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008085
   Reeve A, 2013, J NEUROSCI, V33, P10790, DOI 10.1523/JNEUROSCI.3525-12.2013
   Remes AM, 2008, PARKINSONISM RELAT D, V14, P652, DOI 10.1016/j.parkreldis.2008.01.009
   Rempe T, 2016, PARKINSONISM RELAT D, V29, P135, DOI 10.1016/j.parkreldis.2016.04.020
   Ro S, 2013, CELL RES, V23, P759, DOI 10.1038/cr.2013.37
   Robak LA, 2017, BRAIN, V140, P3191, DOI 10.1093/brain/awx285
   Rosa ID, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005779
   Ross JM, 2013, NATURE, V501, P412, DOI 10.1038/nature12474
   Rothfuss O, 2009, HUM MOL GENET, V18, P3832, DOI 10.1093/hmg/ddp327
   Rouzier C, 2014, EUR J HUM GENET, V22, P542, DOI 10.1038/ejhg.2013.171
   Sánchez-Ferrero E, 2009, PARKINSONISM RELAT D, V15, P468, DOI 10.1016/j.parkreldis.2008.09.004
   Sato K, 2011, J NEUROL, V258, P1327, DOI 10.1007/s00415-011-5936-x
   Scarpulla RC, 2002, BBA-GENE STRUCT EXPR, V1576, P1, DOI 10.1016/S0167-4781(02)00343-3
   SCHAPIRA AHV, 1989, LANCET, V1, P1269, DOI 10.1016/S0140-6736(89)92366-0
   Schmidt O, 2010, NAT REV MOL CELL BIO, V11, P655, DOI 10.1038/nrm2959
   Shin JH, 2011, CELL, V144, P689, DOI 10.1016/j.cell.2011.02.010
   SHOFFNER JM, 1991, ANN NEUROL, V30, P332, DOI 10.1002/ana.410300304
   Sliter DA, 2018, NATURE, V561, P258, DOI 10.1038/s41586-018-0448-9
   Smith AC, 2016, NUCLEIC ACIDS RES, V44, pD1258, DOI 10.1093/nar/gkv1001
   Song LY, 2012, HUM MOL GENET, V21, P5147, DOI 10.1093/hmg/dds365
   Song ZY, 2009, MOL BIOL CELL, V20, P3525, DOI 10.1091/mbc.E09-03-0252
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Sterky FH, 2011, P NATL ACAD SCI USA, V108, P12937, DOI 10.1073/pnas.1103295108
   Stiles AR, 2016, MOL GENET METAB, V119, P91, DOI 10.1016/j.ymgme.2016.07.001
   Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100
   Stumpf JD, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a011395
   Synofzik M, 2010, MOVEMENT DISORD, V25, P243, DOI 10.1002/mds.22865
   Taanman JW, 2005, NEUROSCI LETT, V376, P56, DOI 10.1016/j.neulet.2004.11.023
   Tiangyou W, 2006, NEUROLOGY, V67, P1698, DOI 10.1212/01.wnl.0000238963.07425.d5
   Trifunovic A, 2005, P NATL ACAD SCI USA, V102, P17993, DOI 10.1073/pnas.0508886102
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Tyynismaa H, 2004, HUM MOL GENET, V13, P3219, DOI 10.1093/hmg/ddh342
   Tzoulis C, 2013, BRAIN, V136, P2393, DOI 10.1093/brain/awt103
   Van Goethem G, 2003, HUM MUTAT, V22, P175, DOI 10.1002/humu.10246
   Van Maldergem L, 2017, ANN CLIN TRANSL NEUR, V4, P4, DOI 10.1002/acn3.361
   Vandenberghe W, 2009, MOVEMENT DISORD, V24, P308, DOI 10.1002/mds.22198
   VIRBASIUS JV, 1994, P NATL ACAD SCI USA, V91, P1309, DOI 10.1073/pnas.91.4.1309
   Wang LY, 2016, NUCLEOS NUCLEOT NUCL, V35, P578, DOI 10.1080/15257770.2015.1125001
   West AP, 2015, NATURE, V520, P553, DOI 10.1038/nature14156
   Wise AL, 2013, AM J HUM GENET, V92, P643, DOI 10.1016/j.ajhg.2013.03.017
   Yakubovskaya E, 2006, J BIOL CHEM, V281, P374, DOI 10.1074/jbc.M509730200
   Ye KX, 2014, P NATL ACAD SCI USA, V111, P10654, DOI 10.1073/pnas.1403521111
   Zheng L, 2017, HUM MOL GENET, V26, P582, DOI 10.1093/hmg/ddw418
   Zhou XS, 2019, HUM MOL GENET, V28, P2874, DOI 10.1093/hmg/ddz103
NR 172
TC 13
Z9 13
U1 0
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-3185
EI 1531-8257
J9 MOVEMENT DISORD
JI Mov. Disord.
PD APR
PY 2021
VL 36
IS 4
BP 815
EP 831
DI 10.1002/mds.28475
EA JAN 2021
PG 17
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA RM8LT
UT WOS:000612831100001
PM 33513296
DA 2024-11-01
ER

PT J
AU Bouchet, C
   Steffann, J
   Corcos, J
   Monnot, S
   Paquis, V
   Rötig, A
   Lebon, S
   Levy, P
   Royer, G
   Giurgea, I
   Gigarel, N
   Benachi, A
   Dumez, Y
   Munnich, A
   Bonnefont, JP
AF Bouchet, C.
   Steffann, J.
   Corcos, J.
   Monnot, S.
   Paquis, V.
   Rotig, A.
   Lebon, S.
   Levy, P.
   Royer, G.
   Giurgea, I.
   Gigarel, N.
   Benachi, A.
   Dumez, Y.
   Munnich, A.
   Bonnefont, J. P.
TI Prenatal diagnosis of myopathy, encephalopathy, lactic acidosis, and
   stroke-like syndrome:: contribution to understanding mitochondrial DNA
   segregation during human embryofetal development
SO JOURNAL OF MEDICAL GENETICS
LA English
DT Article
ID MTDNA MUTATION; MELAS; HETEROPLASMY; FETUS; LOAD
AB Introduction: Myopathy, encephalopathy, lactic acidosis, and stroke-like (MELAS) syndrome, a maternally inherited disorder that is among the most common mitochondrial DNA ( mtDNA) diseases, is usually associated with the m. 3242A > G mutation of the mitochondrial tRNA(leu) gene. Very few data are available with respect to prenatal diagnosis of this serious disease. The rate of mutant versus wild-type mtDNA (heteroplasmy) in fetal DNA is indeed considered to be a poor indicator of postnatal outcome.
   Materials and methods: Taking advantage of a novel semi-quantitative polymerase chain reaction test for m. 3243A > G mutant load assessment, we carried out nine prenatal diagnoses in five unrelated women, using two different fetal tissues (chorionic villi v amniocytes) sampled at two or three different stages of pregnancy.
   Results: Two of the five women, although not carrying m. 3243A > G in blood or extra-blood tissues, were, however, considered at risk for transmission of the mutation, as they were closely related to MELAS-affected individuals. The absence of 3243A > G in the blood of first degree relatives was associated with no mutated mtDNA in the cardiovascular system (CVS) or amniocytes, and their three children are healthy, with a follow-up of 3 months-3 years. Among the six fetuses from the three carrier women, three were shown to be homoplasmic (0% mutant load), the remaining three being heteroplasmic, with a mutant load ranging from 23% to 63%. The fetal mutant load was fairly stable at two or three different stages of pregnancy in CVS and amniocytes. Although pregnancy was terminated in the case of the fetus with a 63% mutant load, all other children are healthy with a follow-up of 3 months-6 years.
   Conclusion: These data suggest that a prenatal diagnosis for MELAS syndrome might be helpful for at-risk families.
C1 Unite INSERM, U781, F-75015 Paris, France.
   Hop Necker Enfants Malad, Dept Genet, Paris, France.
   Hop Archet 2, Dept Genet, Nice, France.
   Hop Necker Enfants Malad, Dept Obstet, Paris, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite;
   Hopital Universitaire Necker-Enfants Malades - APHP; CHU Nice;
   Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite;
   Hopital Universitaire Necker-Enfants Malades - APHP
RP Bonnefont, JP (corresponding author), Unite INSERM, U781, F-75015 Paris, France.
EM bonnefon@necker.fr
RI Giurgea, Irina/AGX-6879-2022; monnot, sophie/H-6152-2017; Steffann,
   julie/I-2820-2017; ROTIG, AGNES/G-9592-2017
OI Lebon, Sophie/0000-0003-0039-5519; Giurgea, Irina/0000-0002-5035-2958;
   monnot, sophie/0000-0002-1872-8089; Steffann, julie/0000-0001-9493-3239;
   BONNEFONT, Jean-Paul/0000-0002-4235-1197; ROTIG,
   AGNES/0000-0003-0589-0703
CR Cardaioli E, 2000, J NEUROL, V247, P885, DOI 10.1007/s004150070080
   Chinnery PE, 1998, BRAIN, V121, P1889, DOI 10.1093/brain/121.10.1889
   Chou YJ, 2004, PRENATAL DIAG, V24, P367, DOI 10.1002/pd.876
   CIAFALONI E, 1992, ANN NEUROL, V31, P391, DOI 10.1002/ana.410310408
   Frederiksen AL, 2006, J MED GENET, V43, DOI 10.1136/jmg.2005.039339
   Gigarel N, 2005, MOL GENET METAB, V84, P289, DOI 10.1016/j.ymgme.2004.10.008
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   MANOUVRIER S, 1995, J MED GENET, V32, P654, DOI 10.1136/jmg.32.8.654
   MATTHEWS PM, 1994, J MED GENET, V31, P41, DOI 10.1136/jmg.31.1.41
   Meirelles FV, 1998, GENETICS, V148, P877
   Parfait B, 1998, BIOCHEM BIOPH RES CO, V247, P57, DOI 10.1006/bbrc.1998.8666
   Poulton J, 2000, NEUROMUSCULAR DISORD, V10, P484, DOI 10.1016/S0960-8966(00)00130-9
   White SL, 1999, AM J HUM GENET, V65, P474, DOI 10.1086/302488
NR 13
TC 34
Z9 37
U1 0
U2 0
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-2593
J9 J MED GENET
JI J. Med. Genet.
PD OCT
PY 2006
VL 43
IS 10
BP 788
EP 792
DI 10.1136/jmg.2005.034140
PG 5
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 100UD
UT WOS:000241693600002
PM 16690729
OA Green Published
DA 2024-11-01
ER

PT J
AU Hellebrekers, DMEI
   Blakely, EL
   Hendrickx, ATM
   Hardy, SA
   Hopton, S
   Falkous, G
   de Coo, IFM
   Smeets, HJM
   van der Beek, NME
   Taylor, RW
AF Hellebrekers, Debby M. E. I.
   Blakely, Emma L.
   Hendrickx, Alexandra T. M.
   Hardy, Steven A.
   Hopton, Sila
   Falkous, Gavin
   de Coo, Irenaeus F. M.
   Smeets, Hubert J. M.
   van der Beek, Nadine M. E.
   Taylor, Robert W.
TI A novel mitochondrial m.4414T&gt;C <i>MT-TM</i> gene variant causing
   progressive external ophthalmoplegia and myopathy
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE Mitochondrial disease; Chronic progressive external ophthalmoplegia;
   Myopathy; mtDNA variant; m.4414T > C; MTTM
ID MUTATION; ASSAY
AB We report a novel mitochondrial m.4414T>C variant in the mt-tRNA(Met) (MT-TM) gene in an adult patient with chronic progressive external ophthalmoplegia and myopathy whose muscle biopsy revealed focal cytochrome c oxidase (COX)-deficient and ragged red fibres. The m.4414T>C variant occurs at a strongly evolutionary conserved sequence position, disturbing a canonical base pair and disrupting the secondary and tertiary structure of the mt-tRNA(Met). Definitive evidence of pathogenicity is provided by clear segregation of m.4414T>C mutant levels with COX deficiency in single muscle fibres. Interestingly, the variant is present in skeletal muscle at relatively low levels (30%) and undetectable in accessible, non-muscle tissues from the patient and her asymptomatic brother, emphasizing the continuing requirement for a diagnostic muscle biopsy as the preferred tissue for mtDNA genetic investigations of mt-tRNA variants leading to mitochondrial myopathy. (C) 2019 The Author(s). Published by Elsevier B.V.
C1 [Hellebrekers, Debby M. E. I.; Hendrickx, Alexandra T. M.] MUMC, Dept Clin Genet, P Debyelaan 25,POB 5800, NL-6202 AZ Maastricht, Netherlands.
   [Blakely, Emma L.; Hardy, Steven A.; Hopton, Sila; Falkous, Gavin; Taylor, Robert W.] Newcastle Upon Tyne Hosp NHS Fdn Trust, Highly Specialised Mitochondrial Diagnost Lab, Newcastle Upon Tyne, Tyne & Wear, England.
   [Blakely, Emma L.; Hardy, Steven A.; Hopton, Sila; Falkous, Gavin; Taylor, Robert W.] Newcastle Univ, Inst Neurosci, Wellcome Ctr Mitochondrial Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [de Coo, Irenaeus F. M.; van der Beek, Nadine M. E.] Erasmus MC, Dept Neurol, Doctor Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands.
   [de Coo, Irenaeus F. M.; van der Beek, Nadine M. E.] Erasmus MC, Dept Pediat, Doctor Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands.
   [de Coo, Irenaeus F. M.; Smeets, Hubert J. M.] Maastricht Univ, Dept Genet & Cell Biol, POB 616, NL-6200 MD Maastricht, Netherlands.
   [de Coo, Irenaeus F. M.] Med Spectrum Twente, Dept Neurol, Koningspl 1, NL-7512 KZ Enschede, Netherlands.
   [Smeets, Hubert J. M.] Maastricht Univ, MHeNs Sch Mental Hlth & Neurosci, POB 616, NL-6200 MD Maastricht, Netherlands.
C3 Maastricht University; Maastricht University Medical Centre (MUMC);
   Newcastle Upon Tyne Hospitals NHS Foundation Trust; Newcastle University
   - UK; Erasmus University Rotterdam; Erasmus MC; Erasmus University
   Rotterdam; Erasmus MC; Maastricht University; Medical Spectrum Twente;
   Maastricht University
RP Hellebrekers, DMEI (corresponding author), MUMC, Dept Clin Genet, P Debyelaan 25,POB 5800, NL-6202 AZ Maastricht, Netherlands.
EM debby.hellebrekers@mumc.nl
OI de Coo, Irenaeus/0000-0003-0533-7422
FU Wellcome Centre for Mitochondrial Research [203105/Z/16/Z]; Medical
   Research Council (MRC) International Centre for Genomic Medicine in
   Neuromuscular Disease; Mitochondrial Disease Patient Cohort (UK)
   [G0800674]; Lily Foundation; UK NIHR Biomedical Research Centre for
   Ageing and Age-related disease award; MRC/EPSRC Molecular Pathology
   Node; UK NHS Highly Specialised Service for Rare Mitochondrial Disorders
   of Adults and Children; NeMO; MRC [MR/L016354/1, G0800674] Funding
   Source: UKRI
FX RWT is supported by the Wellcome Centre for Mitochondrial Research
   (203105/Z/16/Z), the Medical Research Council (MRC) International Centre
   for Genomic Medicine in Neuromuscular Disease, the Mitochondrial Disease
   Patient Cohort (UK) (G0800674), the Lily Foundation, the UK NIHR
   Biomedical Research Centre for Ageing and Age-related disease award to
   the Newcastle upon Tyne Foundation Hospitals NHS Trust, the MRC/EPSRC
   Molecular Pathology Node and the UK NHS Highly Specialised Service for
   Rare Mitochondrial Disorders of Adults and Children
   (http://www.newcastle-mitochondria.corn!). IdC is funded by NeMO.
CR Alston CL, 2010, J NEUROL SCI, V298, P140, DOI 10.1016/j.jns.2010.08.014
   Blakely EL, 2013, HUM MUTAT, V34, P1260, DOI 10.1002/humu.22358
   Cardaioli E, 2005, BIOCHEM BIOPH RES CO, V327, P675, DOI 10.1016/j.bbrc.2004.11.170
   Cardaioli E, 2007, NEUROMUSCULAR DISORD, V17, P681, DOI 10.1016/j.nmd.2007.05.001
   Elson JL, 2009, HUM MUTAT, V30, pE984, DOI 10.1002/humu.21113
   Grady JP, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708262
   Greaves LC, 2010, INVEST OPHTH VIS SCI, V51, P3340, DOI 10.1167/iovs.09-4659
   Hardy SA, 2016, NEUROL-GENET, V2, DOI 10.1212/NXG.0000000000000082
   Helm M, 2000, RNA, V6, P1356, DOI 10.1017/S1355838200001047
   Jackson CB, 2014, BRIT J OPHTHALMOL, V98, P1453, DOI 10.1136/bjophthalmol-2014-305300
   Lim AZ, 2019, MITOCHONDRION, V47, P18, DOI 10.1016/j.mito.2019.04.007
   Lott Marie T, 2013, Curr Protoc Bioinformatics, V44, DOI 10.1002/0471250953.bi0123s44
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   OLD SL, 1989, HISTOCHEM J, V21, P545, DOI 10.1007/BF01753355
   Pinós T, 2011, MITOCHONDRION, V11, P228, DOI 10.1016/j.mito.2010.08.008
   Rocha MC, 2015, SCI REP-UK, V5, DOI 10.1038/srep15037
   Schon EA, 2012, NAT REV GENET, V13, P878, DOI 10.1038/nrg3275
   Theunissen TEJ, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00400
   Yarham JW, 2012, MITOCHONDRION, V12, P533, DOI 10.1016/j.mito.2012.06.009
   Yarham JW, 2011, HUM MUTAT, V32, P1319, DOI 10.1002/humu.21575
   Yarham JW, 2010, WIRES RNA, V1, P304, DOI 10.1002/wrna.27
NR 21
TC 1
Z9 1
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD SEP
PY 2019
VL 29
IS 9
BP 693
EP 697
DI 10.1016/j.nmd.2019.08.005
PG 5
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA JC5WA
UT WOS:000489352400006
PM 31488384
OA Green Published, hybrid
DA 2024-11-01
ER

PT J
AU Pancrudo, J
   Shanske, S
   Bonilla, E
   Daras, M
   Akman, HO
   Krishna, S
   Malkin, E
   DiMauro, S
AF Pancrudo, Jacklyn
   Shanske, Sara
   Bonilla, Eduardo
   Daras, Mariza
   Akman, Hasan O.
   Krishna, Sindu
   Malkin, Elfrida
   DiMauro, Salvatore
TI Mitochondrial encephalomyopathy due to a novel mutation in the
   tRNA<SUP>Glu</SUP> of mitochondrial DNA
SO JOURNAL OF CHILD NEUROLOGY
LA English
DT Article
DE mtDNA mutation; tRNA glutamic acid; mitochondrial encephalomyopathy
ID GLUTAMIC-ACID GENE; DIABETES-MELLITUS; ONSET MYOPATHY
AB A 14-year-old boy had exercise intolerance, weakness, ataxia, and lactic acidosis. Because his muscle biopsy showed a mosaic pattern of fibers staining intensely with the succinate dehydrogenase reaction but not at all with the cytochrome c oxidase reaction, we sequenced his mitochondrial DNA and found a novel mutation (C14680A) in the gene for tRNA(Glu). The mutation was present in accessible tissues from the asymptomatic mother but not from a brother with Asperger syndrome. These data expand the clinical heterogeneity of mutations in this mitochondrial gene.
C1 Columbia Univ, Med Ctr, Dept Neurol, H Houston Merrit Clin Res Ctr Muscular Dystrophy, New York, NY 10027 USA.
   Columbia Presbyterian Med Ctr, Dept Neurol, Columbia, NY USA.
C3 Columbia University; NewYork-Presbyterian Hospital; Columbia University
RP DiMauro, S (corresponding author), Columbia Univ Coll Phys & Surg, Dept Neurol, 4-420,630 W 168th St, New York, NY 10032 USA.
EM sdl2@columbia.edu
CR Anitori R, 2005, MOL GENET METAB, V84, P176, DOI 10.1016/j.ymgme.2004.10.003
   Bruno C, 2003, J CHILD NEUROL, V18, P300, DOI 10.1177/08830738030180040401
   Damore ME, 1999, J PEDIATR ENDOCR MET, V12, P207
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   Dimauro S, 2005, ANN MED, V37, P222, DOI 10.1080/07853890510007368
   HANNA MG, 1995, AM J HUM GENET, V56, P1026
   HAO HL, 1995, AM J HUM GENET, V56, P1017
   Mancuso M, 2005, J NEUROL SCI, V228, P93, DOI 10.1016/j.jns.2004.10.018
   McFarland R, 2004, ANN NEUROL, V55, P478, DOI 10.1002/ana.20004
   Pons R, 2004, J PEDIATR-US, V144, P81, DOI 10.1016/j.jpeds.2003.10.023
   SCHON EA, 2006, MITOCHONDRIAL MED, P329
   Shanske S, 2004, AM J MED GENET A, V130A, P134, DOI 10.1002/ajmg.a.30220
   Tanji K, 2001, METHOD CELL BIOL, V65, P311, DOI 10.1016/S0091-679X(01)65019-2
   VILARINHO L, 2001, P 5 EUR M MIT PATH V, P297
NR 14
TC 5
Z9 5
U1 1
U2 3
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0883-0738
EI 1708-8283
J9 J CHILD NEUROL
JI J. Child Neurol.
PD JUL
PY 2007
VL 22
IS 7
BP 858
EP 862
DI 10.1177/0883073807304199
PG 5
WC Clinical Neurology; Pediatrics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pediatrics
GA 201LG
UT WOS:000248832300012
PM 17715279
DA 2024-11-01
ER

PT J
AU Yang, Q
   Yu, SY
AF Yang, Qian
   Yu, Shengyuan
TI Clinical features of mitochondrial encephalomyopathies in China: 97 case
   study and literature review
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Review
DE Mitochondrial encephalomyopathy; MELAS; MERRF; leigh syndrome; CPEO;
   LHON
ID CYTOCHROME-C-OXIDASE; STROKE-LIKE EPISODES; LACTIC-ACIDOSIS;
   NEUROGASTROINTESTINAL ENCEPHALOMYOPATHY; PARTIAL DEFICIENCY;
   ENCEPHALOPATHY; MELAS; DNA; MYOPATHY; DELETIONS
AB Objective: To comprehensively investigate the mitochondrial encephalomyopathies in China for better diagnosis and treatment. Methods: A total of 97 cases from the PLA General Hospital between January 1993 and September 2012, and 815 cases reported from Wanfang Database, the Chinese National Knowledge Information database, Chinese Biology and Medicine Library Database up to September 2012, were reviewed and analyzed. The information analyzed included general conditions, the first symptom, the way of onset, clinical manifestations, findings from physical examinations, imaging examinations, muscle biopsy and genetic testing. Results: A total 912 cases were identified with a male-to-female ratio of 1.66:1. The age of patients ranged from 56 days to 78 years with a median age of 19 years. The most common type was mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes (MELAS) (50.3%). They frequently reported headaches (46.3%) and presented with an A3243G mitochondrial DNA (mtDNA) mutation (84.3%). Other mitochondrial encephalomyopathies included Leber's hereditary optic neuroretinopathy with decreased vision (95%) and a G11778A mtDNA mutation (42.6%), chronic progressive external ophthalmoplegia with ptosis (76.2%) and ocular movement disorder (79.2%), Leigh syndrome with delayed development (29.2%) and symmetrical abnormalities in the brainstem and basal ganglia (98.2%), myoclonic epilepsy and ragged red fiber with convulsions (35.7%). Many patients had elevated levels of lactic acid, and most showed myogenic injury in the electromyography signals. In the Kearns-Sayre syndrome patients 76.7% showed heart block in the electrocardiograms. Conclusions: Nearly all types of reported mitochondrial encephalomyopathies are present in Chinese population. If the clinical course, neurological findings and imaging features are suggestive of mitochondrial encephalomyopathies, DNA testing may be used for confirmation. If the results are not conclusive, then a muscle biopsy should be performed.
C1 [Yang, Qian] Tianjin Huanhu Hosp, Dept Neurol, 6 Jizhao Rd, Tianjin 300350, Peoples R China.
   [Yu, Shengyuan] Chinese Peoples Liberat Army Gen Hosp, Dept Neurol, Beijing 100853, Peoples R China.
C3 Chinese People's Liberation Army General Hospital
RP Yang, Q (corresponding author), Tianjin Huanhu Hosp, Dept Neurol, 6 Jizhao Rd, Tianjin 300350, Peoples R China.
EM Bian-zhixing232@126.com
CR Almannai M, 2018, CLIN GENET, V93, P1097, DOI 10.1111/cge.13210
   BARDOSI A, 1987, ACTA NEUROPATHOL, V74, P248, DOI 10.1007/BF00688189
   Bhatia KD, 2020, AM J NEURORADIOL, V41, P167, DOI 10.3174/ajnr.A6325
   Bianco Angelica, 2018, BMC Res Notes, V11, P911, DOI 10.1186/s13104-018-4025-y
   Catic A, 2018, PROG MOL BIOL TRANSL, V155, P85, DOI 10.1016/bs.pmbts.2017.12.003
   Chinnery PF, 2001, AM J MED GENET, V106, P94, DOI 10.1002/ajmg.1426
   D'Angelo R, 2017, MITOCHONDRION, V34, P101, DOI 10.1016/j.mito.2017.02.006
   DIMAURO S, 1993, ARCH NEUROL-CHICAGO, V50, P1197, DOI 10.1001/archneur.1993.00540110075008
   DiMauro S, 2007, BIOSCIENCE REP, V27, P125, DOI 10.1007/s10540-007-9041-4
   El-Hattab AW, 2015, MOL GENET METAB, V116, P4, DOI 10.1016/j.ymgme.2015.06.004
   Felczak P, 2019, POL J PATHOL, V70, P144, DOI [10.5114/PJP.2019.87106, 10.5114/pjp.2019.87106]
   Filosto M, 2018, J CLIN MED, V7, DOI 10.3390/jcm7110389
   Finsterer J, 2018, PEDIATR NEUROL, V80, P8, DOI 10.1016/j.pediatrneurol.2017.12.005
   FUKUHARA N, 1995, MUSCLE NERVE, pS90
   Goodfellow JA, 2012, POSTGRAD MED J, V88, P326, DOI 10.1136/postgradmedj-2011-130326
   Gueguen A, 2017, CLIN NEUROPHYSIOL, V128, P1258, DOI 10.1016/j.clinph.2017.04.013
   HARDING AE, 1992, J INHERIT METAB DIS, V15, P480, DOI 10.1007/BF01799606
   HIRANO M, 1994, J CHILD NEUROL, V9, P4, DOI 10.1177/088307389400900102
   HIRANO M, 1994, NEUROLOGY, V44, P721, DOI 10.1212/WNL.44.4.721
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Horbay R, 2016, APOPTOSIS, V21, P1327, DOI 10.1007/s10495-016-1295-5
   HOWELL N, 1992, AM J HUM GENET, V50, P443
   Jancic J, 2020, MITOCHONDRION, V50, P132, DOI 10.1016/j.mito.2019.10.011
   Johns DR, 1996, NAT MED, V2, P1065, DOI 10.1038/nm1096-1065
   JOHNSON MA, 1983, J NEUROL SCI, V60, P31, DOI 10.1016/0022-510X(83)90125-9
   Klopstock T, 1999, NEUROLOGY, V53, P855, DOI 10.1212/WNL.53.4.855
   Larsson NG, 1995, ANNU REV GENET, V29, P151, DOI 10.1146/annurev.ge.29.120195.001055
   Lee SJ, 2018, YONSEI MED J, V59, P1190
   Li XD, 2018, J CLIN NEUROSCI, V55, P65, DOI 10.1016/j.jocn.2018.06.015
   Liu XQ, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015534
   Longo N, 2003, NEUROL CLIN, V21, P817, DOI 10.1016/S0733-8619(03)00015-X
   Luo SY, 2018, P NATL ACAD SCI USA, V115, P13039, DOI 10.1073/pnas.1810946115
   Malhotra K, 2016, CURR PAIN HEADACHE R, V20, DOI 10.1007/s11916-016-0583-7
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Manickam AH, 2017, INDIAN J OPHTHALMOL, V65, P1087, DOI 10.4103/ijo.IJO_358_17
   Meseguer S, 2019, BBA-MOL CELL RES, V1866, P1433, DOI 10.1016/j.bbamcr.2019.06.004
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   MORAES CT, 1993, NEUROMUSCULAR DISORD, V3, P43, DOI 10.1016/0960-8966(93)90040-Q
   Nagata JM, 2017, J ADOLESCENT HEALTH, V61, P661, DOI 10.1016/j.jadohealth.2017.06.023
   Oldfors Anders, 2007, Handb Clin Neurol, V86, P125, DOI 10.1016/S0072-9752(07)86006-4
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   Pek NMQ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2036-9
   Quintos JB, 2016, J PEDIATR ENDOCR MET, V29, P1319, DOI 10.1515/jpem-2016-0172
   Radelfahr F, 2019, NERVENARZT, V90, P121, DOI 10.1007/s00115-018-0666-2
   Radelfahr F, 2018, FORTSCHR NEUROL PSYC, V86, P584, DOI 10.1055/a-0621-9255
   Ryzhkova AI, 2018, THER CLIN RISK MANAG, V14, P1933, DOI 10.2147/TCRM.S154863
   Schapira AHV, 1999, EUR J CLIN INVEST, V29, P886
   SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184
   SILVESTRI G, 1993, NEUROLOGY, V43, P1200, DOI 10.1212/WNL.43.6.1200
   Simon DK, 1999, ANNU REV MED, V50, P111
   SPARACO M, 1993, J NEUROPATH EXP NEUR, V52, P1, DOI 10.1097/00005072-199301000-00001
   Sproule DM, 2008, ANN NY ACAD SCI, V1142, P133, DOI 10.1196/annals.1444.011
   Su LJ, 2018, CHINESE MED J-PEKING, V131, P2433, DOI 10.4103/0366-6999.243568
   Tsang SH, 2018, ADV EXP MED BIOL, V1085, P163, DOI 10.1007/978-3-319-95046-4_31
   Viscomi C, 2017, J INHERIT METAB DIS, V40, P587, DOI 10.1007/s10545-017-0027-5
   Wallace DC, 2000, AM HEART J, V139, pS70, DOI 10.1067/mhj.2000.103934
   WILLEMS JL, 1977, PEDIATRICS, V60, P850
   Yadak R, 2019, ORPHANET J RARE DIS, V14, DOI 10.1186/s13023-019-1016-6
   Yadak R, 2017, FRONT CELL NEUROSCI, V11, DOI 10.3389/fncel.2017.00031
NR 59
TC 0
Z9 0
U1 0
U2 1
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1940-5901
J9 INT J CLIN EXP MED
JI Int. J. Clin. Exp. Med.
PY 2020
VL 13
IS 9
BP 6448
EP 6461
PG 14
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA NY6WC
UT WOS:000576526000024
DA 2024-11-01
ER

PT J
AU Gupta, R
   Kanai, M
   Durham, TJ
   Tsuo, K
   McCoy, JG
   Kotrys, AV
   Zhou, W
   Chinnery, PF
   Karczewski, KJ
   Calvo, SE
   Neale, BM
   Mootha, VK
AF Gupta, Rahul
   Kanai, Masahiro
   Durham, Timothy J.
   Tsuo, Kristin
   McCoy, Jason G.
   Kotrys, Anna V.
   Zhou, Wei
   Chinnery, Patrick F.
   Karczewski, Konrad J.
   Calvo, Sarah E.
   Neale, Benjamin M.
   Mootha, Vamsi K.
TI Nuclear genetic control of mtDNA copy number and heteroplasmy in humans
SO NATURE
LA English
DT Article
ID MITOCHONDRIAL-DNA; CONTROL REGION; ASSOCIATION; MUTATIONS; SEQUENCE;
   TISSUES; VARIANT; MUSCLE; RNA; HERITABILITY
AB Mitochondrial DNA (mtDNA) is a maternally inherited, high-copy-number genome required for oxidative phosphorylation(1). Heteroplasmy refers to the presence of a mixture of mtDNA alleles in an individual and has been associated with disease and ageing. Mechanisms underlying common variation in human heteroplasmy, and the influence of the nuclear genome on this variation, remain insufficiently explored. Here we quantify mtDNA copy number (mtCN) and heteroplasmy using blood-derived whole-genome sequences from 274,832 individuals and perform genome-wide association studies to identify associated nuclear loci. Following blood cell composition correction, we find that mtCN declines linearly with age and is associated with variants at 92 nuclear loci. We observe that nearly everyone harbours heteroplasmic mtDNA variants obeying two principles: (1) heteroplasmic single nucleotide variants tend to arise somatically and accumulate sharply after the age of 70 years, whereas (2) heteroplasmic indels are maternally inherited as mixtures with relative levels associated with 42 nuclear loci involved in mtDNA replication, maintenance and novel pathways. These loci may act by conferring a replicative advantage to certain mtDNA alleles. As an illustrative example, we identify a length variant carried by more than 50% of humans at position chrM:302 within a G-quadruplex previously proposed to mediate mtDNA transcription/replication switching(2,3). We find that this variant exerts cis-acting genetic control over mtDNA abundance and is itself associated in-trans with nuclear loci encoding machinery for this regulatory switch. Our study suggests that common variation in the nuclear genome can shape variation in mtCN and heteroplasmy dynamics across the human population.
C1 [Gupta, Rahul; Durham, Timothy J.; McCoy, Jason G.; Kotrys, Anna V.; Calvo, Sarah E.; Mootha, Vamsi K.] Massachusetts Gen Hosp, Howard Hughes Med Inst, Boston, MA 02114 USA.
   [Gupta, Rahul; Durham, Timothy J.; McCoy, Jason G.; Kotrys, Anna V.; Calvo, Sarah E.; Mootha, Vamsi K.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
   [Gupta, Rahul; Kanai, Masahiro; Durham, Timothy J.; Tsuo, Kristin; McCoy, Jason G.; Kotrys, Anna V.; Zhou, Wei; Karczewski, Konrad J.; Calvo, Sarah E.; Neale, Benjamin M.; Mootha, Vamsi K.] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
   [Gupta, Rahul; Kanai, Masahiro; Tsuo, Kristin; Zhou, Wei; Karczewski, Konrad J.; Neale, Benjamin M.] Massachusetts Gen Hosp, Ctr Genom Med, Analyt & Translat Genet Unit, Boston, MA 02114 USA.
   [Chinnery, Patrick F.] Univ Cambridge, Dept Clin Neurosci, Cambridge, England.
   [Chinnery, Patrick F.] Univ Cambridge, MRC Mitochondrial Biol Unit, Cambridge, England.
   [Mootha, Vamsi K.] Harvard Med Sch, Dept Syst Biol, Boston, MA 02115 USA.
C3 Harvard University; Massachusetts General Hospital; Howard Hughes
   Medical Institute; Harvard University; Massachusetts General Hospital;
   Harvard University; Massachusetts Institute of Technology (MIT); Broad
   Institute; Harvard University; Massachusetts General Hospital;
   University of Cambridge; University of Cambridge; Harvard University;
   Harvard Medical School
RP Gupta, R; Mootha, VK (corresponding author), Massachusetts Gen Hosp, Howard Hughes Med Inst, Boston, MA 02114 USA.; Gupta, R; Mootha, VK (corresponding author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.; Gupta, R; Neale, BM; Mootha, VK (corresponding author), Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.; Gupta, R; Neale, BM (corresponding author), Massachusetts Gen Hosp, Ctr Genom Med, Analyt & Translat Genet Unit, Boston, MA 02114 USA.; Mootha, VK (corresponding author), Harvard Med Sch, Dept Syst Biol, Boston, MA 02115 USA.
EM rahul_gupta@hms.harvard.edu; bneale@broadinstitute.org;
   vamsi_mootha@hms.harvard.edu
RI Li, Xintong/KHD-6915-2024; Gupta, Rahul/ABF-1099-2021; Kanai,
   Masahiro/AAD-6726-2021; Neale, Benjamin/LFS-2894-2024
OI Kanai, Masahiro/0000-0001-5165-4408; Gupta, Rahul/0000-0001-8263-2455;
   Kotrys, Anna/0000-0003-4983-1414
FU National Institutes of Health; Novo Nordisk Foundation; Jane Coffin
   Childs Memorial Fund for Medical Research fellowship; Wellcome Trust
   [5R35GM122455, 5R37MH107649, 5R01MH101244, 5F30AG074507, K99HG012222];
   UK NIHR [NNF21SA0072102]; Medical Research Council (MRC) Mitochondrial
   Biology Unit; MRC International Centre for Genomic Medicine in
   Neuromuscular Disease [212219/Z/18/Z]; Leverhulme Trust; MRC
   [MC_UU_00028/7]; Alzheimer's Society Project Grant [MR/S005021/1]; NIHR
   Cambridge Biomedical Research Centre [RPG-2018-408]; National Institutes
   of Health, Office of the Director [MR/S035699/1];  [AS-PG-18b-022]; 
   [BRC-1215-20014];  [1 OT2 OD026549];  [1 OT2 OD026554];  [1 OT2
   OD026557];  [1 OT2 OD026556];  [1 OT2 OD026550];  [1 OT2 OD 026552];  [1
   OT2 OD026553];  [1 OT2 OD026548];  [1 OT2 OD026551];  [1 OT2 OD026555]; 
   [AOD 16037];  [HHSN 263201600085U];  [5 U2C OD023196];  [1 U24
   OD023121];  [U24 OD023176];  [1 U24 OD023163];  [3 OT2 OD023205];  [3
   OT2 OD023206];  [1 OT2 OD025277];  [3 OT2 OD025315];  [1 OT2 OD025337]; 
   [1 OT2 OD025276]
FX & nbsp;We thank M. Falkenberg, C. Gustafsson, T. Barton-Owen and C.
   Winter for discussions; M. Walker for facilitating access to published
   data; T.-L. To for technical analyses; and K. Laricchia, K. Chao, G.
   Tiao, S. Chapman and N. Gupta for help with gnomAD data and pipelines.
   This project was supported in part by grants no. 5R35GM122455 (V.K.M.),
   no. 5R37MH107649 (B.M.N.), no. 5R01MH101244 (B.M.N.), no. 5F30AG074507
   (R.G.) and no. K99HG012222 (W.Z.) from the National Institutes of
   Health. This work is & nbsp;supported by the Novo Nordisk Foundation,
   no.& nbsp;NNF21SA0072102 & nbsp;(B.M.N.).& nbsp;A.V.K. is supported by
   The Jane Coffin Childs Memorial Fund for Medical Research fellowship.
   P.F.C. is a Wellcome Trust Principal Research Fellow (grant no.
   212219/Z/18/Z), and a UK NIHR Senior Investigator, who receives support
   from the Medical Research Council (MRC) Mitochondrial Biology Unit
   (grant no. MC_UU_00028/7), the MRC International Centre for Genomic
   Medicine in Neuromuscular Disease (grant no. MR/S005021/1), the
   Leverhulme Trust (grant no. RPG-2018-408), an MRC research grant (no.
   MR/S035699/1) and an Alzheimer's Society Project Grant (no.
   AS-PG-18b-022). V.K.M. is an Investigator of the Howard Hughes Medical
   Institute. This research was supported by the NIHR Cambridge Biomedical
   Research Centre (grant no. BRC-1215-20014). The views expressed are
   those of the authors and not necessarily those of the NIHR or the
   Department of Health and Social Care. This research has been conducted
   using the UK Biobank Resource under Application Number 31063. The
   AllofUs Research Program is supported by the National Institutes of
   Health, Office of the Director: Regional Medical Centers: 1 OT2
   OD026549; 1 OT2 OD026554; 1 OT2 OD026557; 1 OT2 OD026556; 1 OT2
   OD026550; 1 OT2 OD 026552; 1 OT2 OD026553; 1 OT2 OD026548; 1 OT2
   OD026551; 1 OT2 OD026555; IAA no.: AOD 16037; Federally Qualified Health
   Centers: HHSN 263201600085U; Data and Research Center: 5 U2C OD023196;
   Biobank: 1 U24 OD023121; The Participant Center: U24 OD023176;
   Participant Technology Systems Center: 1 U24 OD023163; Communications
   and Engagement: 3 OT2 OD023205; 3 OT2 OD023206; and Community Partners:
   1 OT2 OD025277; 3 OT2 OD025315; 1 OT2 OD025337; 1 OT2 OD025276. In
   addition, the AllofUs Research Program would not be possible without the
   partnership of its participants.
CR Agaronyan K, 2015, SCIENCE, V347, P548, DOI 10.1126/science.aaa0986
   Aguet F, 2020, SCIENCE, V369, P1318, DOI 10.1126/science.aaz1776
   All Us Res Program Investigators, 2019, NEW ENGL J MED, V381, P668, DOI 10.1056/NEJMsr1809937
   Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Ashar FN, 2017, JAMA CARDIOL, V2, P1247, DOI 10.1001/jamacardio.2017.3683
   Battersby BJ, 2003, NAT GENET, V33, P183, DOI 10.1038/ng1073
   Binder JX, 2014, DATABASE-OXFORD, DOI 10.1093/database/bau012
   BROWN WM, 1979, P NATL ACAD SCI USA, V76, P1967, DOI 10.1073/pnas.76.4.1967
   Byrska-Bishop M, 2022, CELL, V185, P3426, DOI 10.1016/j.cell.2022.08.004
   Calabrese FM, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-S4-S15
   CANN RL, 1987, NATURE, V325, P31, DOI 10.1038/325031a0
   Chong MR, 2022, NEUROLOGY, V98, pE470, DOI 10.1212/WNL.0000000000013165
   COCHRAN WG, 1954, BIOMETRICS, V10, P417, DOI 10.2307/3001616
   Cui R., 2022, BIORXIV, DOI [10.1101/2022.10.21.513123, DOI 10.1101/2022.10.21.513123]
   Danecek P, 2021, GIGASCIENCE, V10, DOI 10.1093/gigascience/giab008
   Dayama G, 2014, NUCLEIC ACIDS RES, V42, P12640, DOI 10.1093/nar/gku1038
   de Bakker PIW, 2008, HUM MOL GENET, V17, pR122, DOI 10.1093/hmg/ddn288
   Deming WE., 1943, STAT ADJUSTMENT DATA
   Ding J, 2015, PLOS GENET, V11, DOI [10.1371/journal.pgen.1005306, 10.1371/journal.pgen.1005549]
   Edgar RC, 2004, NUCLEIC ACIDS RES, V32, P1792, DOI 10.1093/nar/gkh340
   Ekstrand MI, 2004, HUM MOL GENET, V13, P935, DOI 10.1093/hmg/ddh109
   Elliott HR, 2008, AM J HUM GENET, V83, P254, DOI 10.1016/j.ajhg.2008.07.004
   Falah M, 2017, CLIN INTERV AGING, V12, P459, DOI 10.2147/CIA.S123278
   Falkenberg M, 2020, CRIT REV BIOCHEM MOL, V55, P509, DOI 10.1080/10409238.2020.1818684
   Fazzini F, 2021, J INTERN MED, V290, P190, DOI 10.1111/joim.13242
   Finucane HK, 2018, NAT GENET, V50, P621, DOI 10.1038/s41588-018-0081-4
   Finucane HK, 2015, NAT GENET, V47, P1228, DOI 10.1038/ng.3404
   Gazal S, 2017, NAT GENET, V49, P1421, DOI 10.1038/ng.3954
   Gopal RK, 2018, P NATL ACAD SCI USA, V115, pE6283, DOI 10.1073/pnas.1711888115
   Gupta R, 2021, ELIFE, V10, DOI [10.7554/eLife.68610, 10.7554/eLife.68610.sa1, 10.7554/eLife.68610.sa2]
   Hägg S, 2021, HUM GENET, V140, P849, DOI 10.1007/s00439-020-02249-w
   Hail Team, HAIL 0 2
   Halldorsson BV, 2022, NATURE, V607, P732, DOI 10.1038/s41586-022-04965-x
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Hormozdiari F, 2016, AM J HUM GENET, V99, P1245, DOI 10.1016/j.ajhg.2016.10.003
   Hurtado-Roca Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163770
   Kanai M., 2021, PREPRINT, DOI DOI 10.1101/2021.09.03.21262975
   Kanai M, 2022, CELL GENOM, V2, DOI 10.1016/j.xgen.2022.100210
   Kang EJ, 2016, NATURE, V540, P270, DOI 10.1038/nature20592
   Karczewski KJ, 2022, CELL GENOM, V2, DOI 10.1016/j.xgen.2022.100168
   Kennedy SR, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003794
   Kerimov N, 2021, NAT GENET, V53, P1290, DOI 10.1038/s41588-021-00924-w
   Laricchia KM, 2022, GENOME RES, V32, P569, DOI 10.1101/gr.276013.121
   Lee S, 2012, AM J HUM GENET, V91, P224, DOI 10.1016/j.ajhg.2012.06.007
   Li MK, 2015, P NATL ACAD SCI USA, V112, P2491, DOI 10.1073/pnas.1419651112
   Li MK, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks499
   Liu YW, 2020, J AM STAT ASSOC, V115, P393, DOI 10.1080/01621459.2018.1554485
   Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071
   Longchamps RJ, 2022, HUM GENET, V141, P127, DOI 10.1007/s00439-021-02394-w
   Luo SY, 2018, P NATL ACAD SCI USA, V115, P13039, DOI 10.1073/pnas.1810946115
   LYNCH M, 1993, J HERED, V84, P339, DOI 10.1093/oxfordjournals.jhered.a111354
   Marchington DR, 1997, AM J HUM GENET, V60, P408
   McLaren W, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-0974-4
   Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Pan-UKB team, 2020, PAN UK BIOB
   Pham XH, 2006, J BIOL CHEM, V281, P24647, DOI 10.1074/jbc.M602429200
   Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795
   Quinlan AR, 2010, BIOINFORMATICS, V26, P841, DOI 10.1093/bioinformatics/btq033
   Rath S, 2021, NUCLEIC ACIDS RES, V49, pD1541, DOI 10.1093/nar/gkaa1011
   Ratnaike TE, 2021, NUCLEIC ACIDS RES, V49, P9686, DOI 10.1093/nar/gkab726
   Ridker PM, 2002, NEW ENGL J MED, V347, P1557, DOI 10.1056/NEJMoa021993
   Sanchez MIGL, 2021, AM J HUM GENET, V108, P2159, DOI 10.1016/j.ajhg.2021.09.015
   Sang Y, 2022, MOL THER, V30, P2844, DOI 10.1016/j.ymthe.2022.04.012
   Sherry ST, 1999, GENOME RES, V9, P677
   Stoneking M, 2000, AM J HUM GENET, V67, P1029, DOI 10.1086/303092
   Sudlow C, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001779
   SUOMALAINEN A, 1995, NAT GENET, V9, P146, DOI 10.1038/ng0295-146
   Tan BG, 2016, NUCLEIC ACIDS RES, V44, P7817, DOI 10.1093/nar/gkw648
   Uhler JP, 2016, NUCLEIC ACIDS RES, V44, P5861, DOI 10.1093/nar/gkw468
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Venables WN., 2002, MODERN APPL STAT S, DOI DOI 10.1007/978-0-387-21706-2
   VIGILANT L, 1991, SCIENCE, V253, P1503, DOI 10.1126/science.1840702
   Walker MA, 2020, NEW ENGL J MED, V383, P1556, DOI 10.1056/NEJMoa2001265
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   Wanagat J, 2001, FASEB J, V15, P322, DOI 10.1096/fj.00-0320com
   Wang G, 2020, J R STAT SOC B, V82, P1273, DOI 10.1111/rssb.12388
   Wanrooij PH, 2012, NUCLEIC ACIDS RES, V40, P10334, DOI 10.1093/nar/gks802
   Wanrooij PH, 2010, P NATL ACAD SCI USA, V107, P16072, DOI 10.1073/pnas.1006026107
   Wei W, 2022, NATURE, V611, P105, DOI 10.1038/s41586-022-05288-7
   Weissensteiner H, 2021, GENOME RES, V31, P309, DOI 10.1101/gr.256545.119
   Weissensteiner H, 2016, NUCLEIC ACIDS RES, V44, pW58, DOI 10.1093/nar/gkw233
   Wu MC, 2011, AM J HUM GENET, V89, P82, DOI 10.1016/j.ajhg.2011.05.029
   Yang SY, 2021, GENOME RES, V31, P349, DOI 10.1101/gr.269381.120
   Zhou W, 2022, CELL GENOM, V2, DOI 10.1016/j.xgen.2022.100192
   Zhou W, 2022, NAT GENET, V54, P1466, DOI 10.1038/s41588-022-01178-w
   Zhou W, 2018, NAT GENET, V50, P1335, DOI 10.1038/s41588-018-0184-y
NR 88
TC 39
Z9 43
U1 5
U2 29
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 0028-0836
EI 1476-4687
J9 NATURE
JI Nature
PD AUG
PY 2023
VL 620
IS 7975
DI 10.1038/s41586-023-06426-5
EA AUG 2023
PG 33
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GO5S6
UT WOS:001049978000003
PM 37587338
OA hybrid, Green Published
DA 2024-11-01
ER

PT J
AU Erdinc, D
   Rodríguez-Luis, A
   Fassad, MR
   Mackenzie, S
   Watson, CM
   Valenzuela, S
   Xie, X
   Menger, KE
   Sergeant, K
   Craig, K
   Hopton, S
   Falkous, G
   Poulton, J
   Garcia-Moreno, H
   Giunti, P
   Aschoff, CAD
   Saute, JAM
   Kirby, AJ
   Toro, C
   Wolfe, L
   Novacic, D
   Greenbaum, L
   Eliyahu, A
   Barel, O
   Anikster, Y
   McFarland, R
   Gorman, GS
   Schaefer, AM
   Gustafsson, CM
   Taylor, RW
   Falkenberg, M
   Nicholls, TJ
AF Erdinc, Direnis
   Rodriguez-Luis, Alejandro
   Fassad, Mahmoud R.
   Mackenzie, Sarah
   Watson, Christopher M.
   Valenzuela, Sebastian
   Xie, Xie
   Menger, Katja E.
   Sergeant, Kate
   Craig, Kate
   Hopton, Sila
   Falkous, Gavin
   Poulton, Joanna
   Garcia-Moreno, Hector
   Giunti, Paola
   Aschoff, Carlos A. de Moura
   Saute, Jonas A. Morales
   Kirby, Amelia J.
   Toro, Camilo
   Wolfe, Lynne
   Novacic, Danica
   Greenbaum, Lior
   Eliyahu, Aviva
   Barel, Ortal
   Anikster, Yair
   McFarland, Robert
   Gorman, Grainne S.
   Schaefer, Andrew M.
   Gustafsson, Claes M.
   Taylor, Robert W.
   Falkenberg, Maria
   Nicholls, Thomas J.
CA Genomics England Res Consortium
TI Pathological variants in <i>TOP3A</i> cause distinct disorders of
   mitochondrial and nuclear genome stability
SO EMBO MOLECULAR MEDICINE
LA English
DT Article
DE Bloom syndrome; mitochondrial disease; mtDNA; TOP3A
ID TOPOISOMERASE-III-ALPHA; IMPAIR MTDNA REPLICATION; SYNDROME
   GENE-PRODUCT; D-LOOP; ESSENTIAL COMPONENT; SYNDROME PROTEIN; DNA;
   MUTATIONS; DUPLICATION; DELETIONS
AB Topoisomerase 3 alpha (TOP3A) is an enzyme that removes torsional strain and interlinks between DNA molecules. TOP3A localises to both the nucleus and mitochondria, with the two isoforms playing specialised roles in DNA recombination and replication respectively. Pathogenic variants in TOP3A can cause a disorder similar to Bloom syndrome, which results from bi-allelic pathogenic variants in BLM, encoding a nuclear-binding partner of TOP3A. In this work, we describe 11 individuals from 9 families with an adult-onset mitochondrial disease resulting from bi-allelic TOP3A gene variants. The majority of patients have a consistent clinical phenotype characterised by bilateral ptosis, ophthalmoplegia, myopathy and axonal sensory-motor neuropathy. We present a comprehensive characterisation of the effect of TOP3A variants, from individuals with mitochondrial disease and Bloom-like syndrome, upon mtDNA maintenance and different aspects of enzyme function. Based on these results, we suggest a model whereby the overall severity of the TOP3A catalytic defect determines the clinical outcome, with milder variants causing adult-onset mitochondrial disease and more severe variants causing a Bloom-like syndrome with mitochondrial dysfunction in childhood.
C1 [Erdinc, Direnis; Valenzuela, Sebastian; Xie, Xie; Gustafsson, Claes M.; Falkenberg, Maria] Univ Gothenburg, Dept Med Biochem & Cell Biol, Gothenburg, Sweden.
   [Rodriguez-Luis, Alejandro; Fassad, Mahmoud R.; Menger, Katja E.; Craig, Kate; Hopton, Sila; Falkous, Gavin; McFarland, Robert; Gorman, Grainne S.; Schaefer, Andrew M.; Taylor, Robert W.; Nicholls, Thomas J.] Newcastle Univ, Fac Med Sci, Wellcome Ctr Mitochondrial Res, Newcastle Upon Tyne, England.
   [Rodriguez-Luis, Alejandro; Menger, Katja E.; Nicholls, Thomas J.] Newcastle Univ, Fac Med Sci, Biosci Inst, Newcastle Upon Tyne, England.
   [Fassad, Mahmoud R.; McFarland, Robert; Gorman, Grainne S.; Taylor, Robert W.] Newcastle Univ, Fac Med Sci, Translat & Clin Res Inst, Newcastle Upon Tyne, England.
   [Mackenzie, Sarah] Newcastle Upon Tyne Hosp NHS Fdn Trust, Newcastle Upon Tyne, England.
   [Watson, Christopher M.] St James Univ Hosp, North East & Yorkshire Genom Lab Hub, Cent Lab, Leeds, England.
   [Watson, Christopher M.] Univ Leeds, St Jamess Univ Hosp, Leeds Inst Med Res, Leeds, England.
   [Sergeant, Kate] Oxford Univ Hosp NHS Fdn Trust, Oxford Genet Labs, Oxford, England.
   [Craig, Kate; Hopton, Sila; Falkous, Gavin; Schaefer, Andrew M.; Taylor, Robert W.] Newcastle Upon Tyne Hosp NHS Fdn Trust, NHS Highly Specialised Serv Rare Mitochondrial Di, Newcastle Upon Tyne, England.
   [Poulton, Joanna] Univ Oxford, Womens Ctr, Nuffield Dept Womens & Reprod Hlth, Oxford, England.
   [Garcia-Moreno, Hector; Giunti, Paola] UCL Queen Sq Inst Neurol, Ataxia Ctr, Dept Clin & Movement Neurosci, London, England.
   [Aschoff, Carlos A. de Moura; Saute, Jonas A. Morales] Hosp Clin Porto Alegre HCPA, Med Genet Serv, Porto Alegre, Brazil.
   [Saute, Jonas A. Morales] Univ Fed Rio Grande do Sul, Dept Internal Med, Porto Alegre, Brazil.
   [Saute, Jonas A. Morales] Univ Fed Rio Grande do Sul, Grad Program Med Med Sci, Porto Alegre, Brazil.
   [Kirby, Amelia J.] Wake Forest Sch Med, Dept Pediat, Winston Salem, NC USA.
   [Toro, Camilo; Wolfe, Lynne; Novacic, Danica] Natl Human Genome Res Inst, Undiagnosed Dis Program, NIH, Bethesda, MD USA.
   [Greenbaum, Lior; Eliyahu, Aviva] Sheba Med Ctr, Danek Gertner Inst Human Genet, Tel Hashomer, Israel.
   [Greenbaum, Lior] Sheba Med Ctr, Joseph Sagol Neurosci Ctr, Tel Hashomer, Israel.
   [Greenbaum, Lior; Eliyahu, Aviva; Anikster, Yair] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel.
   [Barel, Ortal] Sheba Med Ctr, Ctr Canc Res, Genom Unit, Tel Hashomer, Israel.
   [Anikster, Yair] Edmond & Lily Safra Childrens Hosp, Sheba Med Ctr, Metab Dis Unit, Tel Hashomer, Israel.
   [Gustafsson, Claes M.] Sahlgrens Univ Hosp, Dept Clin Chem, Gothenburg, Sweden.
C3 University of Gothenburg; Newcastle University - UK; Newcastle
   University - UK; Newcastle University - UK; Newcastle Upon Tyne
   Hospitals NHS Foundation Trust; Saint James's University Hospital;
   University of Leeds; Saint James's University Hospital; Oxford
   University Hospitals NHS Foundation Trust; Newcastle Upon Tyne Hospitals
   NHS Foundation Trust; University of Oxford; University of London;
   University College London; Universidade Federal do Rio Grande do Sul;
   Universidade Federal do Rio Grande do Sul; Wake Forest University;
   National Institutes of Health (NIH) - USA; NIH National Human Genome
   Research Institute (NHGRI); Chaim Sheba Medical Center; Chaim Sheba
   Medical Center; Tel Aviv University; Chaim Sheba Medical Center; Chaim
   Sheba Medical Center; Sahlgrenska University Hospital
RP Nicholls, TJ (corresponding author), Newcastle Univ, Fac Med Sci, Wellcome Ctr Mitochondrial Res, Newcastle Upon Tyne, England.; Nicholls, TJ (corresponding author), Newcastle Univ, Fac Med Sci, Biosci Inst, Newcastle Upon Tyne, England.
EM thomas.nicholls@newcastle.ac.uk
RI Saute, Jonas/F-6635-2015; Fassad, Mahmoud/J-5769-2019; MacKenzie,
   Sarah/HLX-6591-2023
OI Erdinc, Direnis/0000-0002-5830-9911; Nicholls,
   Thomas/0000-0002-3034-4109; Valenzuela, Sebastian/0000-0001-5153-8431;
   Watson, Christopher Mark/0000-0003-2371-1844; Rodriguez Luis,
   Alejandro/0000-0003-3989-1317; Menger, Katja/0000-0002-6972-7326;
   Fowler, Tom/0000-0002-7258-2279; Aschoff, Carlos/0009-0008-1799-4589;
   Falkenberg, Maria/0000-0001-8713-173X
FU Wellcome Centre for Mitochondrial Research [203105/Z/16/Z];
   Mitochondrial Disease Patient Cohort (UK) [G0800674]; UK National
   Institute for Health Research (NIHR) Biomedical Research Centre for
   Ageing; Newcastle upon Tyne Hospitals National Health Service (NHS)
   Foundation Trust; UK NHS Specialist Commissioners - Wellcome Trust;
   Royal Society [213464/Z/18/Z]; Rosetrees and Stoneygate Trust Research
   Fellowship [M811]; Swedish Research Council; Swedish Cancer Foundation;
   IngaBritt and Arne Lundberg Foundation; Knut and Alice Wallenberg
   Foundation [ALFGBG-965954, ALFGBG-966275]; Medical Research Council
   International Centre for Genomic Medicine in Neuromuscular Disease
   [MR/S005021/1]; Lily Foundation; Medical Research Council; Pathological
   Society - Lily Foundation; Angus Memorial Mitochondrial Fund - National
   Institute for Health Research; NHS England; Wellcome Trust; Cancer
   Research UK; MRC [MR/S005021/1, MR/W019027/1] Funding Source: UKRI
FX This research was supported by the Wellcome Centre for Mitochondrial
   Research (203105/Z/16/Z), the Mitochondrial Disease Patient Cohort (UK)
   (G0800674), the UK National Institute for Health Research (NIHR)
   Biomedical Research Centre for Ageing and Age-Related Disease award to
   the Newcastle upon Tyne Hospitals National Health Service (NHS)
   Foundation Trust and the UK NHS Specialist Commissioners, which funds
   the Rare Mitochondrial Disorders of Adults and Children Diagnostic
   Service in Newcastle upon Tyne. TJN is the recipient of a Sir Henry Dale
   Fellowship jointly funded by the Wellcome Trust and the Royal Society
   (213464/Z/18/Z) and a Rosetrees and Stoneygate Trust Research Fellowship
   (M811). MF is funded by the Swedish Research Council, Swedish Cancer
   Foundation, the IngaBritt and Arne Lundberg Foundation, the Knut and
   Alice Wallenberg Foundation and the Vaestra Goetalands Regionen
   (ALFGBG-965954). CMG is funded by the Vaestra Goetalands Regionen
   (ALFGBG-966275). RM and RWT are funded by the Medical Research Council
   International Centre for Genomic Medicine in Neuromuscular Disease
   (MR/S005021/1) and the Lily Foundation. RWT receives additional support
   from the Medical Research Council (MR/W019027/1) and the Pathological
   Society. JP is funded by the Lily Foundation and the Angus Memorial
   Mitochondrial Fund. We gratefully acknowledge access to the data and
   findings generated by the 100,000 Genomes Project, managed by Genomics
   England Limited (a wholly owned company of the Department of Health and
   Social Care). The 100,000 Genomes Project is funded by the National
   Institute for Health Research and NHS England. The Wellcome Trust,
   Cancer Research UK and the Medical Research Council have also funded
   research infrastructure. The 100,000 Genomes Project uses data provided
   by patients and collected by the National Health Service as part of
   their care and support. The views expressed are those of the author(s)
   and not necessarily those of the NIHR, the NHS or the UK Department of
   Health and Social Care. The authors wish to thank Dr Yael Finezilber for
   her clinical assistance.
CR Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4205, DOI 10.1093/nar/26.18.4205
   Basu S, 2020, PLOS GENET, V16, DOI 10.1371/journal.pgen.1009242
   Bizard AH, 2020, J BIOL CHEM, V295, P7138, DOI 10.1074/jbc.REV120.008286
   Bizard AH, 2019, NAT STRUCT MOL BIOL, V26, P267, DOI 10.1038/s41594-019-0201-6
   Blakely EL, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.011296
   Bocquet N, 2014, NAT STRUCT MOL BIOL, V21, P261, DOI 10.1038/nsmb.2775
   BROCKINGTON M, 1993, NAT GENET, V4, P67, DOI 10.1038/ng0593-67
   Cao N, 2020, NUCLEIC ACIDS RES, V48, P4448, DOI 10.1093/nar/gkaa201
   Cejka P, 2012, MOL CELL, V47, P886, DOI 10.1016/j.molcel.2012.06.032
   Chacinska A, 2009, CELL, V138, P628, DOI 10.1016/j.cell.2009.08.005
   Changela A, 2007, J MOL BIOL, V368, P105, DOI 10.1016/j.jmb.2007.01.065
   Chen CF, 2007, J BIOL CHEM, V282, P28971, DOI 10.1074/jbc.M705427200
   DePristo MA, 2011, NAT GENET, V43, P491, DOI 10.1038/ng.806
   ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1
   Filograna R, 2021, FEBS LETT, V595, P976, DOI 10.1002/1873-3468.14021
   Gorman GS, 2016, NAT REV DIS PRIMERS, V2, P1, DOI 10.1038/nrdp.2016.80
   Gustafsson CM, 2016, ANNU REV BIOCHEM, V85, P133, DOI 10.1146/annurev-biochem-060815-014402
   Hagström E, 2014, NUCLEIC ACIDS RES, V42, P1111, DOI 10.1093/nar/gkt969
   Hanai R, 1996, P NATL ACAD SCI USA, V93, P3653, DOI 10.1073/pnas.93.8.3653
   Hangas A, 2022, NUCLEIC ACIDS RES, V50, P8733, DOI 10.1093/nar/gkac660
   Jiang WJ, 2021, BBA-MOL BASIS DIS, V1867, DOI 10.1016/j.bbadis.2021.166106
   Kielbasa SM, 2011, GENOME RES, V21, P487, DOI 10.1101/gr.113985.110
   Kornblum C, 2013, NAT GENET, V45, P214, DOI 10.1038/ng.2501
   Langmead B, 2012, NAT METHODS, V9, P357, DOI [10.1038/NMETH.1923, 10.1038/nmeth.1923]
   Li MX, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gkr1257
   Li Q, 2018, MOLECULES, V23, DOI 10.3390/molecules23092270
   Li W, 1998, P NATL ACAD SCI USA, V95, P1010, DOI 10.1073/pnas.95.3.1010
   LLAURADO A, 2022, GENES-BASEL, V103, P492
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   MANFREDI G, 1995, NEUROLOGY, V45, P762, DOI 10.1212/WNL.45.4.762
   Martin CA, 2018, AM J HUM GENET, V103, P456, DOI 10.1016/j.ajhg.2018.08.012
   Menger KE, 2022, NUCLEIC ACIDS RES, V50, P11154, DOI 10.1093/nar/gkac857
   Nicholls TJ, 2018, MOL CELL, V69, P9, DOI 10.1016/j.molcel.2017.11.033
   Oláhová M, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21279-0
   OLD SL, 1989, HISTOCHEM J, V21, P545, DOI 10.1007/BF01753355
   Persson Ö, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08673-5
   Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084
   Plank JL, 2005, J BIOL CHEM, V280, P3564, DOI 10.1074/jbc.M411337200
   Primiano G, 2022, NEUROL-GENET, V8, DOI 10.1212/NXG.0000000000200007
   Rath S, 2021, NUCLEIC ACIDS RES, V49, pD1541, DOI 10.1093/nar/gkaa1011
   Raynard S, 2006, J BIOL CHEM, V281, P13861, DOI 10.1074/jbc.C600051200
   Reyes A, 2015, AM J HUM GENET, V97, P186, DOI 10.1016/j.ajhg.2015.05.013
   Rocha MC, 2015, SCI REP-UK, V5, DOI 10.1038/srep15037
   Ronchi D, 2013, AM J HUM GENET, V92, P293, DOI 10.1016/j.ajhg.2012.12.014
   Russell OM, 2020, CELL, V181, P168, DOI 10.1016/j.cell.2020.02.051
   Singh TR, 2008, GENE DEV, V22, P2856, DOI 10.1101/gad.1725108
   Smedley D, 2021, NEW ENGL J MED, V385, P1868, DOI 10.1056/NEJMoa2035790
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Sugrañes TA, 2022, GENET MED, V24, P1476, DOI 10.1016/j.gim.2022.03.008
   Tan KM, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv1073
   TORRONI A, 1994, AM J HUM GENET, V55, P760
   Tsai HZ, 2016, J BIOMED SCI, V23, DOI 10.1186/s12929-016-0255-2
   Turnbull C, 2018, BMJ-BRIT MED J, V361, DOI 10.1136/bmj.k1687
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Vos SM, 2011, NAT REV MOL CELL BIO, V12, P827, DOI 10.1038/nrm3228
   Wang Y, 2002, P NATL ACAD SCI USA, V99, P12114, DOI 10.1073/pnas.192449499
   Wu JH, 2010, P NATL ACAD SCI USA, V107, P6228, DOI 10.1073/pnas.1001855107
   Wu L, 2006, P NATL ACAD SCI USA, V103, P4068, DOI 10.1073/pnas.0508295103
   Wu L, 2000, J BIOL CHEM, V275, P9636, DOI 10.1074/jbc.275.13.9636
   Xu DY, 2008, GENE DEV, V22, P2843, DOI 10.1101/gad.1708608
   Yang J, 2010, J BIOL CHEM, V285, P21426, DOI 10.1074/jbc.M110.123216
   Yin JH, 2005, EMBO J, V24, P1465, DOI 10.1038/sj.emboj.7600622
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
   Zhang HL, 2001, P NATL ACAD SCI USA, V98, P10608, DOI 10.1073/pnas.191321998
   Zhang HL, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09258-2
NR 65
TC 8
Z9 8
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1757-4676
EI 1757-4684
J9 EMBO MOL MED
JI EMBO Mol. Med.
PD MAY 8
PY 2023
VL 15
IS 5
DI 10.15252/emmm.202216775
EA APR 2023
PG 21
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA F1VJ3
UT WOS:000962771600001
PM 37013609
OA Green Published, gold
DA 2024-11-01
ER

PT J
AU Pilch, J
   Asman, M
   Jamroz, E
   Kajor, M
   Kotrys-Puchalska, E
   Goss, M
   Krzak, M
   Witecka, J
   Gminski, J
   Sieron, AL
AF Pilch, Jacek
   Asman, Marek
   Jamroz, Ewa
   Kajor, Maciej
   Kotrys-Puchalska, Elibieta
   Goss, Malgorzata
   Krzak, Maria
   Witecka, Joanna
   Gminski, Jan
   Sieron, Aleksander L.
TI Surveyor Nuclease Detection of Mutations and Polymorphisms of mtDNA in
   Children
SO PEDIATRIC NEUROLOGY
LA English
DT Article
ID MITOCHONDRIAL-DNA POLYMORPHISMS; RESPIRATORY-CHAIN DISORDERS; RAPID
   IDENTIFICATION; HETEROPLASMIC MUTATIONS; EXERCISE INTOLERANCE;
   LACTIC-ACIDOSIS; GENOME; CHILDHOOD; DIAGNOSIS; DISEASE
AB Mitochondrial encephalomyopathies are complex disorders with wide range of clinical manifestations. Particularly time-consuming is the identification of mutations in mitochondria! DNA. A group of 20 children with clinical manifestations of mitochondrial encephalomyopathies was selected for molecular studies. The aims were (a) to identify mutations in mtDNA isolated from muscle and (b) to verify detected mutations in DNA isolated from blood, in order to assess the utility of a Surveyor nuclease assay kit for patient screening. The most common changes found were polymorphisms, including a few missense mutations altering the amino acid sequence of mitochondrial proteins. In two boys with MELAS (i.e., mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes), a mutation A --> G3243 was detected in the tRNALeu gene of mtDNA isolated from muscle and blood. In one boy, the carrier status of his mother was confirmed, based on molecular analysis of DNA isolated from blood. A method using Surveyor nuclease allows systematic screening for small mutations in mtDNA, using as its source blood of the patients and asymptomatic carriers. The method still requires confirmation studying a larger group. In some patients, the use of this method should precede and might limit indications for traumatic muscle and skin biopsy. (C) 2010 by Elsevier Inc. All rights reserved.
C1 [Pilch, Jacek; Jamroz, Ewa] Med Univ Silesia, Dept Child Neurol, PL-40752 Katowice, Poland.
   [Kajor, Maciej] Med Univ Silesia, Dept Anatomopathol, PL-40752 Katowice, Poland.
   [Kotrys-Puchalska, Elibieta; Goss, Malgorzata; Gminski, Jan] Med Univ Silesia, Dept Biochem, PL-40752 Katowice, Poland.
   [Krzak, Maria; Witecka, Joanna; Sieron, Aleksander L.] Med Univ Silesia, Dept Gen & Mol Biol & Genet, PL-40752 Katowice, Poland.
   [Asman, Marek] Med Univ Silesia, Dept Parasitol, Sosnowiec, Poland.
C3 Medical University Silesia; Medical University Silesia; Medical
   University Silesia; Medical University Silesia; Medical University
   Silesia
RP Pilch, J (corresponding author), Med Univ Silesia, Dept Child Neurol, Ul Medykow 16, PL-40752 Katowice, Poland.
EM japilch@poczta.onet.pl
RI Sieron, Aleksander/G-1700-2013
OI Kajor, Maciej/0000-0002-2333-456X; Krzak, Maria/0000-0001-5674-9027;
   Sieron, Aleksander L./0000-0002-3894-9508; Asman,
   Marek/0000-0001-8832-7726; Witecka, Joanna/0000-0002-9733-7632
FU Ministry of Science and Higher Education [2PO5E 087 26]; European Union
   [WKP1/1.4/3/2/2005/103/223/565/2007/U];  [NN-1-014/06]
FX The study was supported in part from grams by the Ministry of Science
   and Higher Education 2PO5E 087 26, European Union Regional Structural
   Funds WKP1/1.4/3/2/2005/103/223/565/2007/U, and institutional funding
   NN-1-014/06.
CR Andreu AL, 1999, ANN NEUROL, V45, P820, DOI 10.1002/1531-8249(199906)45:6<820::AID-ANA22>3.0.CO;2-W
   Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   Bannwarth S, 2008, MITOCHONDRION, V8, P136, DOI 10.1016/j.mito.2007.10.008
   Bannwarth S, 2005, HUM MUTAT, V25, P575, DOI 10.1002/humu.20177
   Bannwarth S, 2006, NAT PROTOC, V1, P2037, DOI 10.1038/nprot.2006.318
   Cesaroni E, 2009, PEDIATR NEUROL, V41, P131, DOI 10.1016/j.pediatrneurol.2009.02.018
   Chinnery P.F., 2006, Pract. Neurol, V6, P90, DOI [DOI 10.1136/JNNP.2006.090050, 10.1136/jnnp.2006.090050]
   Darin N, 2001, ANN NEUROL, V49, P377, DOI 10.1002/ana.75
   Filosto M, 2007, ACTA NEUROL SCAND, V115, P211, DOI 10.1111/j.1600-0404.2006.00777.x
   Finsterer J, 2006, ACTA NEUROL SCAND, V114, P217, DOI 10.1111/j.1600-0404.2006.00671.x
   Finsterer J, 2008, PEDIATR NEUROL, V39, P223, DOI 10.1016/j.pediatrneurol.2008.07.013
   Gropman A L, 2001, Curr Neurol Neurosci Rep, V1, P185
   Guo LJ, 2005, MITOCHONDRION, V5, P15, DOI 10.1016/j.mito.2004.09.001
   Horvath R, 2007, NEUROLOGY, V68, P56, DOI 10.1212/01.wnl.0000250334.48038.7a
   Huang CC, 2002, J BIOMED SCI, V9, P527, DOI 10.1007/BF02254979
   Ingman M, 2006, NUCLEIC ACIDS RES, V34, pD749, DOI 10.1093/nar/gkj010
   KARCZMAREWICZ E, 1994, PEDIATR POL, V5, P311
   Kazuno AA, 2006, PLOS GENET, V2, P1167, DOI 10.1371/journal.pgen.0020128
   Koenig MK, 2008, PEDIATR NEUROL, V38, P305, DOI 10.1016/j.pediatrneurol.2007.12.001
   Lamont PJ, 1998, ARCH DIS CHILD, V79, P22, DOI 10.1136/adc.79.1.22
   McFarland R, 2004, TRENDS GENET, V20, P591, DOI 10.1016/j.tig.2004.09.014
   Meierhofer D, 2005, MITOCHONDRION, V5, P282, DOI 10.1016/j.mito.2005.06.001
   Mitchell AL, 2006, J MED GENET, V43, P175, DOI 10.1136/jmg.2005.032474
   *MITOMAP, MITOMAP HUM MIT GEN
   Moraes CT, 2003, J MOL DIAGN, V5, P197, DOI 10.1016/S1525-1578(10)60474-6
   Morava E, 2006, NEUROLOGY, V67, P1823, DOI 10.1212/01.wnl.0000244435.27645.54
   Moslemi AR, 2007, MITOCHONDRION, V7, P241, DOI 10.1016/j.mito.2007.02.002
   Munnich A, 1996, J INHERIT METAB DIS, V19, P521, DOI 10.1007/BF01799112
   Niemi AK, 2005, EUR J HUM GENET, V13, P166, DOI 10.1038/sj.ejhg.5201308
   Oleykowski CA, 1998, NUCLEIC ACIDS RES, V26, P4597, DOI 10.1093/nar/26.20.4597
   Patterson K, 2004, PEDIATR DEVEL PATHOL, V7, P629, DOI 10.1007/s10024-004-5051-4
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   Qiu P, 2004, BIOTECHNIQUES, V36, P702, DOI 10.2144/04364PF01
   Scaglia F, 2004, PEDIATRICS, V114, P925, DOI 10.1542/peds.2004-0718
   Schaefer AM, 2004, BBA-BIOENERGETICS, V1659, P115, DOI 10.1016/j.bbabio.2004.09.005
   Skladal D, 2003, BRAIN, V126, P1905, DOI 10.1093/brain/awg170
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   Thorburn DR, 2004, BBA-BIOENERGETICS, V1659, P121, DOI 10.1016/j.bbabio.2004.08.006
   Thorburn DR, 2004, INTERN MED J, V34, P3, DOI 10.1111/j.1444-0903.2004.00537.x
   Tsao CY, 2000, J CHILD NEUROL, V15, P445, DOI 10.1177/088307380001500704
   Valente L, 2009, BBA-BIOENERGETICS, V1787, P491, DOI 10.1016/j.bbabio.2008.10.001
   van de Glind G, 2007, EUR J PAEDIATR NEURO, V11, P243, DOI 10.1016/j.ejpn.2007.01.004
   Werner KGE, 2009, PEDIATR NEUROL, V41, P27, DOI 10.1016/j.pediatrneurol.2009.02.010
   Wong LJC, 2007, MITOCHONDRION, V7, P45, DOI 10.1016/j.mito.2006.11.025
   Wong LJC, 2005, CLIN CHIM ACTA, V354, P1, DOI 10.1016/j.cccn.2004.11.003
   Wong LJC, 2002, CLIN CHEM, V48, P1901
   Yang B, 2000, BIOCHEMISTRY-US, V39, P3533, DOI 10.1021/bi992376z
   Yu Q, 2007, MITOCHONDRION, V7, P147, DOI 10.1016/j.mito.2006.11.019
   Zeviani M, 2004, BRAIN, V127, P2153, DOI 10.1093/brain/awh259
NR 49
TC 5
Z9 6
U1 0
U2 18
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0887-8994
EI 1873-5150
J9 PEDIATR NEUROL
JI Pediatr. Neurol.
PD NOV
PY 2010
VL 43
IS 5
BP 325
EP 330
DI 10.1016/j.pediatrneurol.2010.05.023
PG 6
WC Clinical Neurology; Pediatrics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pediatrics
GA 672FB
UT WOS:000283567300004
PM 20933175
DA 2024-11-01
ER

PT J
AU Lesko, N
   Naess, K
   Wibom, R
   Solaroli, N
   Nennesmo, I
   von Döbeln, U
   Karlsson, A
   Larsson, NG
AF Lesko, Nicole
   Naess, Karin
   Wibom, Rolf
   Solaroli, Nicola
   Nennesmo, Inger
   von Doebeln, Ulrika
   Karlsson, Anna
   Larsson, Nils-Goeran
TI Two novel mutations in thymidine kinase-2 cause early onset fatal
   encephalomyopathy and severe mtDNA depletion
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE Mitochondrial DNA; mtDNA depletion; Thymidine kinase-2 mutations
ID MITOCHONDRIAL-DNA DEPLETION
AB Deficiency of thymidine kinase-2 (TK2) has been described in children with early onset fatal skeletal myopathy. TK2 is a mitochondrial deoxyribonucleoside kinase required for the phosphorylation of deoxycytidine and deoxythymidine and hence is vital for the maintenance of a balanced mitochondrial dNTP pool in post-mitotic tissues. We describe a patient with two novel TK2 mutations, which caused disease onset shortly after birth and death at the age of three months. One mutation (219insCG) generated an early stop codon, thus preventing the synthesis of a functional protein. The second mutation (R130W) resulted in an amino acid substitution, which caused a severe reduction (< 3%) of TK2 enzyme activity. These two novel TK2 mutations cause an extremely severe phenotype with overwhelming central nervous system symptoms not commonly seen in patients with TK2-deficiency. We conclude that the severe clinical presentation in this patient was due to a virtual lack of mitochondrial TK2 activity. (c) 2009 Elsevier B.V. All rights reserved.
C1 [Lesko, Nicole; Naess, Karin; Wibom, Rolf; Solaroli, Nicola; Nennesmo, Inger; von Doebeln, Ulrika; Karlsson, Anna; Larsson, Nils-Goeran] Karolinska Inst, Div Metab Dis, Dept Lab Med, S-14186 Stockholm, Sweden.
   [Naess, Karin] Karolinska Inst, Dept Clin Sci, S-14186 Stockholm, Sweden.
   [Larsson, Nils-Goeran] Max Planck Inst Biol Ageing, D-50931 Cologne, Germany.
C3 Karolinska Institutet; Karolinska Institutet; Max Planck Society
RP Lesko, N (corresponding author), Karolinska Inst, Div Metab Dis, Dept Lab Med, S-14186 Stockholm, Sweden.
EM Nicole.Lesko@karolinska.se
RI Karlsson, Anna/E-7945-2018; Larsson, Nils-Göran/GVS-5578-2022
OI Karlsson, Anna/0000-0001-6843-6685; Naess, Karin/0000-0003-4310-7927;
   Larsson, Nils-Goran/0000-0001-5100-996X
FU Swedish Research Council; Swedish Heart and Lung Foundation; Stockholm
   County Council
FX The authors wish to acknowledge the excellent technical assistance of H.
   Bruhn, V. Edrisi and I. Westman. This study was supported by the Swedish
   Research Council, the Swedish Heart and Lung Foundation and Stockholm
   County Council.
CR Götz A, 2008, BRAIN, V131, P2841, DOI 10.1093/brain/awn236
   Larsson NG, 2001, ACTA PHYSIOL SCAND, V171, P385, DOI 10.1046/j.1365-201x.2001.00842.x
   MANDERBACKA K, 2001, SCANDINAVIAN J P S55, V29, P41
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Oskoui M, 2006, ARCH NEUROL-CHICAGO, V63, P1122, DOI 10.1001/archneur.63.8.1122
   Saada A, 2003, MOL GENET METAB, V79, P1, DOI 10.1016/S1096-7192(03)00063-5
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Wibom R, 2002, ANAL BIOCHEM, V311, P139, DOI 10.1016/S0003-2697(02)00424-4
NR 8
TC 31
Z9 37
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD MAR
PY 2010
VL 20
IS 3
BP 198
EP 203
DI 10.1016/j.nmd.2009.11.013
PG 6
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 584NK
UT WOS:000276759100008
PM 20083405
DA 2024-11-01
ER

PT J
AU Tulinius, M
   Oldfors, A
AF Tulinius, Mar
   Oldfors, Anders
TI Neonatal muscular manifestations in mitochondrial disorders
SO SEMINARS IN FETAL & NEONATAL MEDICINE
LA English
DT Article
DE Genetic diseases; Infant; Mitochondrial respiratory chain deficiency;
   Myopathies; Neonate
ID C-OXIDASE DEFICIENCY; THYMIDINE KINASE; LACTIC-ACIDOSIS; IRON-OVERLOAD;
   DNA DEPLETION; MUTATIONS; GENE; ENCEPHALOMYOPATHY; TRANSLATION; SUBUNIT
AB During the last decade rapid development has occurred in defining nuclear gene mutations causing mitochondrial disease. Some of these newly defined gene mutations cause neonatal or early infantile onset of disease, often associated with severe progressive encephalomyopathy combined with other multi-organ involvement such as cardiomyopathy or hepatopathy and with early death. Findings suggesting myopathy in neonates are hypotonia, muscle weakness and wasting, and arthrogryposis. We aim to describe the clinical findings of patients with mitochondrial disease presenting with muscular manifestations in the neonatal period or in early infancy and in whom the genetic defect has been characterized. The majority of patients with neonatal onset of mitochondrial disease have mutations in nuclear genes causing dysfunction of the mitochondrial respiratory chain, leading to defective oxidative phosphorylation. (C) 2011 Elsevier Ltd. All rights reserved.
C1 [Tulinius, Mar] Univ Gothenburg, Dept Pediat, Queen Silvia Childrens Hosp, S-41685 Gothenburg, Sweden.
   [Oldfors, Anders] Univ Gothenburg, Dept Pathol, Sahlgrenska Univ Hosp, S-41685 Gothenburg, Sweden.
C3 University of Gothenburg; Queen Silvia Children's Hospital; Sahlgrenska
   University Hospital; University of Gothenburg
RP Tulinius, M (corresponding author), Univ Gothenburg, Dept Pediat, Queen Silvia Childrens Hosp, S-41685 Gothenburg, Sweden.
EM mar.tulinius@gu.se
CR Bodensteiner JB, 2008, SEMIN PEDIATR NEUROL, V15, P10, DOI 10.1016/j.spen.2008.01.003
   Böhm M, 2006, PEDIATR RES, V59, P21, DOI 10.1203/01.pdr.0000190572.68191.13
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Cameron JM, 2011, MITOCHONDRION, V11, P191, DOI 10.1016/j.mito.2010.09.008
   Cizková A, 2008, NAT GENET, V40, P1288, DOI 10.1038/ng.246
   Coenen MJH, 2004, NEW ENGL J MED, V351, P2080, DOI 10.1056/NEJMoa041878
   Damian MS, 1996, AM J MED GENET, V62, P398, DOI 10.1002/(SICI)1096-8628(19960424)62:4<398::AID-AJMG13>3.0.CO;2-J
   De Meirleir L, 2004, J MED GENET, V41, P120, DOI 10.1136/jmg.2003.012047
   DEMAUGRE F, 1991, J CLIN INVEST, V87, P859, DOI 10.1172/JCI115090
   Di Fonzo A, 2009, AM J HUM GENET, V84, P594, DOI 10.1016/j.ajhg.2009.04.004
   Dimauro Salvatore, 2007, Handb Clin Neurol, V86, P167, DOI 10.1016/S0072-9752(07)86007-6
   Dubowitz V, 1980, FLOPPY INFANT
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Fellman V, 1998, LANCET, V351, P490, DOI 10.1016/S0140-6736(97)09272-6
   Götz A, 2008, BRAIN, V131, P2841, DOI 10.1093/brain/awn236
   Gurgey A, 1996, PEDIATR NEPHROL, V10, P637
   HALL JG, 2007, EMERY RIMOINS PRINCI, P3785
   Horvath R, 2009, BRAIN, V132, P3165, DOI 10.1093/brain/awp221
   Houstek J, 2009, BBA-BIOENERGETICS, V1787, P529, DOI 10.1016/j.bbabio.2008.11.013
   Jaksch M, 2000, HUM MOL GENET, V9, P795, DOI 10.1093/hmg/9.5.795
   Kollberg G, 2009, NEUROMUSCULAR DISORD, V19, P147, DOI 10.1016/j.nmd.2008.11.014
   Lesko N, 2010, NEUROMUSCULAR DISORD, V20, P198, DOI 10.1016/j.nmd.2009.11.013
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Massa V, 2008, AM J HUM GENET, V82, P1281, DOI 10.1016/j.ajhg.2008.05.002
   Miller C, 2004, ANN NEUROL, V56, P734, DOI 10.1002/ana.20282
   Mimaki M, 2010, ANN NEUROL, V68, P845, DOI 10.1002/ana.22111
   Morava E, 2006, AM J MED GENET A, V140A, P863, DOI 10.1002/ajmg.a.31194
   Morava E, 2009, MITOCHONDRION, V9, P438, DOI 10.1016/j.mito.2009.08.003
   Nezu JI, 1999, NAT GENET, V21, P91, DOI 10.1038/5030
   Ostergaard E, 2007, AM J HUM GENET, V81, P383, DOI 10.1086/519222
   Ostergaard E, 2007, BRAIN, V130, P853, DOI 10.1093/brain/awl383
   Ostergaard E, 2010, EUR J PEDIATR, V169, P201, DOI 10.1007/s00431-009-1007-z
   Papadopoulou LC, 1999, NAT GENET, V23, P333
   Poulton J, 2009, BBA-MOL BASIS DIS, V1792, P1109, DOI 10.1016/j.bbadis.2009.08.016
   PRASAD AN, 2011, SEMIN FETAL NEO 1203
   Rivera H, 2010, MITOCHONDRION, V10, P362, DOI 10.1016/j.mito.2010.03.003
   ROTIG A, 1990, J CLIN INVEST, V86, P1601, DOI 10.1172/JCI114881
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Saada A, 2009, AM J HUM GENET, V84, P718, DOI 10.1016/j.ajhg.2009.04.020
   SCHIFF M, 2011, SEMIN FETAL NEONATAL, V16
   Smeitink JAM, 2006, AM J HUM GENET, V79, P869, DOI 10.1086/508434
   SMITS P, 2010, EUR J HUM GENET 1201
   SOKOL R, 2011, SEMIN FETAL NEONATAL, V16
   SPIEGEL R, 2010, J MED GENET     1208
   Sue CM, 2000, ANN NEUROL, V47, P589, DOI 10.1002/1531-8249(200005)47:5<589::AID-ANA6>3.3.CO;2-4
   Suomalainen A, 2010, NEUROMUSCULAR DISORD, V20, P429, DOI 10.1016/j.nmd.2010.03.017
   Tuppen HAL, 2010, MOL GENET METAB, V100, P345, DOI 10.1016/j.ymgme.2010.04.010
   UZIEL G, 2011, SEMIN FETAL NEONATAL, V16
   Valente L, 2007, AM J HUM GENET, V80, P44, DOI 10.1086/510559
   Valnot I, 2000, AM J HUM GENET, V67, P1104
   Visapää I, 2002, AM J HUM GENET, V71, P863, DOI 10.1086/342773
NR 52
TC 11
Z9 12
U1 0
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1744-165X
EI 1878-0946
J9 SEMIN FETAL NEONAT M
JI Semin. Fetal Neonatal Med.
PD AUG
PY 2011
VL 16
IS 4
BP 229
EP 235
DI 10.1016/j.siny.2011.04.001
PG 7
WC Pediatrics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pediatrics
GA 799DI
UT WOS:000293263300009
PM 21596636
DA 2024-11-01
ER

PT J
AU Morovat, A
   Weerasinghe, G
   Nesbitt, V
   Hofer, M
   Agnew, T
   Quaghebeur, G
   Sergeant, K
   Fratter, C
   Guha, N
   Mirzazadeh, M
   Poulton, J
AF Morovat, Alireza
   Weerasinghe, Gayani
   Nesbitt, Victoria
   Hofer, Monika
   Agnew, Thomas
   Quaghebeur, Geralrine
   Sergeant, Kate
   Fratter, Carl
   Guha, Nishan
   Mirzazadeh, Mehdi
   Poulton, Joanna
TI Use of FGF-21 as a Biomarker of Mitochondrial Disease in Clinical
   Practice
SO JOURNAL OF CLINICAL MEDICINE
LA English
DT Article
DE fibroblast growth factor-21; FGF-21; mitochondrial disease; diagnosis
ID GROWTH-FACTOR 21; UNFOLDED PROTEIN RESPONSE; FATTY LIVER-DISEASE; FGF21
   EXPRESSION; SKELETAL-MUSCLE; PPAR-ALPHA; STRESS; PREVALENCE; DISORDERS;
   OBESITY
AB Recent work has suggested that fibroblast growth factor-21 (FGF-21) is a useful biomarker of mitochondrial disease (MD). We routinely measured FGF-21 levels on patients who were investigated at our centre for MD and evaluated its diagnostic performance based on detailed genetic and other laboratory findings. Patients' FGF-21 results were assessed by the use of age-adjusted z-scores based on normalised FGF-21 values from a healthy population. One hundred and fifty five patients were investigated. One hundred and four of these patients had molecular evidence for MD, 27 were deemed to have disorders other than MD (non-MD), and 24 had possible MD. Patients with defects in mitochondrial DNA (mtDNA) maintenance (n = 32) and mtDNA rearrangements (n = 17) had the highest median FGF-21 among the MD group. Other MD patients harbouring mtDNA point mutations (n = 40) or mutations in other autosomal genes (n = 7) and those with partially characterised MD had lower FGF-21 levels. The area under the receiver operating characteristic curve for distinguishing MD from non-MD patients was 0.69. No correlation between FGF-21 and creatinine, creatine kinase, or cardio-skeletal myopathy score was found. FGF-21 was significantly associated with plasma lactate and ocular myopathy. Although FGF-21 was found to have a low sensitivity for detecting MD, at a z-score of 2.8, its specificity was above 90%. We suggest that a high serum concentration of FGF-21 would be clinically useful in MD, especially in adult patients with chronic progressive external ophthalmoplegia, and may enable bypassing muscle biopsy and directly opting for genetic analysis. Availability of its assay has thus modified our diagnostic pathway.
C1 [Morovat, Alireza; Weerasinghe, Gayani; Guha, Nishan; Mirzazadeh, Mehdi] Oxford Univ Hosp, Dept Clin Biochem, Oxford OX3 9DU, England.
   [Nesbitt, Victoria] Childrens Hosp, Dept Paediat, Oxford OX3 9DU, England.
   [Hofer, Monika] Oxford Univ Hosp, Dept Neuropathol & Ocular Pathol, Oxford OX3 9DU, England.
   [Agnew, Thomas] Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England.
   [Quaghebeur, Geralrine] Oxford Univ Hosp, Dept Neuroradiol, Oxford OX3 9DU, England.
   [Sergeant, Kate; Fratter, Carl] Oxford Univ Hosp, Oxford Med Genet Labs, NHS Specialised Serv Rare Mitochondrial Disorders, Oxford OX3 7LE, England.
   [Poulton, Joanna] Univ Oxford, Nuffield Dept Obstet & Gynaecol, Oxford OX3 9DU, England.
C3 University of Oxford; University of Oxford; University of Oxford
RP Poulton, J (corresponding author), Univ Oxford, Nuffield Dept Obstet & Gynaecol, Oxford OX3 9DU, England.
EM reza.morovat@ouh.nhs.uk; gayani.weerasinghe@ouh.nhs.uk;
   victoria.nesbitt@ouh.nhs.uk; monika.hofer@ouh.nhs.uk;
   thomas.agnew@path.ox.ac.uk; gerardine.quaghebeur@ouh.nhs.uk;
   kate.sergeant@ouh.nhs.uk; carl.fratter@ouh.nhs.uk;
   nishan.guha@ouh.nhs.uk; mehdi.mirzazadeh@nhs.net;
   joanna.poulton@obs-gyn.ox.ac.uk
RI Morovat, Alireza/ABG-6825-2020; Poulton, Joanna/AAB-4828-2021
OI Poulton, Joanna/0000-0002-2460-5587; Morovat,
   Alireza/0000-0002-5832-7992
FU UK Rare Mitochondrial Disorders of Adults and Children (NHS Highly
   Specialized Services); Lily Foundation; NewLife [SG/14-15/11]; Medical
   Research Council [MR/J010448/1]; Wellcome Trust [0948685/Z/10/Z]; NHS;
   MRC [MR/J010448/1, G0800674] Funding Source: UKRI
FX We would like to thank the patients and their carers for participating
   in this study and the Neurometabolic Unit at the National Hospital for
   Neurology and Neurosurgery in London for respiratory chain analyses.
   J.P., C.F., K.S., and N.G. receive salary support from the UK Rare
   Mitochondrial Disorders of Adults and Children (NHS Highly Specialized
   Services). J.P. acknowledges grant support from the Lily Foundation,
   NewLife (SG/14-15/11), the Medical Research Council (MR/J010448/1) and
   the Wellcome Trust (0948685/Z/10/Z). The NHS and sponsors had no role in
   the design of study or interpretation of results.
CR Badman MK, 2007, CELL METAB, V5, P426, DOI 10.1016/j.cmet.2007.05.002
   Christodoulides C, 2009, J CLIN ENDOCR METAB, V94, P3594, DOI 10.1210/jc.2009-0111
   Crooks DR, 2014, HUM MOL GENET, V23, P24, DOI 10.1093/hmg/ddt393
   Davis RL, 2016, NEUROLOGY, V86, P2010, DOI 10.1212/WNL.0000000000002705
   Davis RL, 2013, NEUROLOGY, V81, P1819, DOI 10.1212/01.wnl.0000436068.43384.ef
   Dogan SA, 2014, CELL METAB, V19, P458, DOI 10.1016/j.cmet.2014.02.004
   Dushay J, 2010, GASTROENTEROLOGY, V139, P456, DOI 10.1053/j.gastro.2010.04.054
   Dushay JR, 2015, MOL METAB, V4, P51, DOI 10.1016/j.molmet.2014.09.008
   Fisher FM, 2016, ANNU REV PHYSIOL, V78, P223, DOI 10.1146/annurev-physiol-021115-105339
   Gaich G, 2013, CELL METAB, V18, P333, DOI 10.1016/j.cmet.2013.08.005
   Gómez-Ambrosi J, 2017, CLIN NUTR, V36, P861, DOI 10.1016/j.clnu.2016.04.027
   Gorman GS, 2015, ANN NEUROL, V77, P753, DOI 10.1002/ana.24362
   Kalko SG, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-91
   Hojman P, 2009, DIABETES, V58, P2797, DOI 10.2337/db09-0713
   Jeanson Y, 2016, BIOCHEM J, V473, P685, DOI 10.1042/BJ20150808
   Ji KQ, 2015, FREE RADICAL BIO MED, V84, P161, DOI 10.1016/j.freeradbiomed.2015.03.020
   Kim KH, 2013, NAT MED, V19, P83, DOI 10.1038/nm.3014
   Koene S, 2014, NEUROLOGY, V83, P125, DOI 10.1212/WNL.0000000000000578
   Lee DV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111767
   Lehtonen JM, 2016, NEUROLOGY, V87, P2290, DOI 10.1212/WNL.0000000000003374
   Li HT, 2013, J HEPATOL, V58, P557, DOI 10.1016/j.jhep.2012.10.029
   Lundåsen T, 2007, BIOCHEM BIOPH RES CO, V360, P437, DOI 10.1016/j.bbrc.2007.06.068
   Luo Yongde, 2013, Front Endocrinol (Lausanne), V4, P194, DOI 10.3389/fendo.2013.00194
   Manwaring N, 2007, MITOCHONDRION, V7, P230, DOI 10.1016/j.mito.2006.12.004
   Mashili FL, 2011, DIABETES-METAB RES, V27, P286, DOI 10.1002/dmrr.1177
   Michel S, 2015, MITOCHONDRION, V21, P58, DOI 10.1016/j.mito.2015.01.005
   Nishimura T, 2000, BBA-GENE STRUCT EXPR, V1492, P203, DOI 10.1016/S0167-4781(00)00067-1
   Oglesbee D, 2006, PEDIATR NEUROL, V35, P289, DOI 10.1016/j.pediatrneurol.2006.05.007
   Ost M, 2016, MOL METAB, V5, P79, DOI 10.1016/j.molmet.2015.11.002
   Phadke R, 2017, J CLIN MED, V6, DOI 10.3390/jcm6070064
   Planavila A, 2015, FRONT ENDOCRINOL, V6, DOI 10.3389/fendo.2015.00133
   Planavila A, 2015, CARDIOVASC RES, V106, P19, DOI 10.1093/cvr/cvu263
   Qin A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027155
   Rath E, 2012, GUT, V61, P1269, DOI 10.1136/gutjnl-2011-300767
   Ribas F, 2014, BIOCHEM J, V463, P191, DOI 10.1042/BJ20140403
   Skladal D, 2003, BRAIN, V126, P1905, DOI 10.1093/brain/awg170
   Sonoda J, 2017, HORM MOL BIOL CLIN I, V30, DOI 10.1515/hmbci-2017-0002
   Suomalainen Anu, 2013, Expert Opin Med Diagn, V7, P313, DOI 10.1517/17530059.2013.812070
   Suomalainen A, 2011, LANCET NEUROL, V10, P806, DOI 10.1016/S1474-4422(11)70155-7
   Thiessen SE, 2015, J CLIN ENDOCR METAB, V100, pE1319, DOI 10.1210/jc.2015-2700
   Tyynismaa H, 2011, J CLIN ENDOCR METAB, V96, pE351, DOI 10.1210/jc.2010-1326
   Tyynismaa H, 2010, HUM MOL GENET, V19, P3948, DOI 10.1093/hmg/ddq310
   Wolny S, 2009, ACTA PAEDIATR, V98, P553, DOI 10.1111/j.1651-2227.2008.01148.x
   Woo YC, 2013, CLIN ENDOCRINOL, V78, P489, DOI 10.1111/cen.12095
NR 44
TC 55
Z9 55
U1 1
U2 5
PU MDPI AG
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2077-0383
J9 J CLIN MED
JI J. Clin. Med.
PD AUG
PY 2017
VL 6
IS 8
AR 80
DI 10.3390/jcm6080080
PG 14
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA FF4CG
UT WOS:000408875600005
PM 28825656
OA Green Published, Green Submitted, gold
DA 2024-11-01
ER

PT J
AU Procaccio, V
   Neckelmann, N
   Paquis-Flucklinger, V
   Bannwarth, S
   Jimenez, R
   Davila, A
   Poole, JC
   Wallace, DC
AF Procaccio, Vincent
   Neckelmann, Nicolas
   Paquis-Flucklinger, Veronique
   Bannwarth, Sylvic
   Jimenez, Richard
   Davila, Antonio
   Poole, Jason C.
   Wallace, Douglas C.
TI Detection of low levels of the mitochondrial tRNA<SUP>Leu</SUP>(UUR)
   3243A&gt;G mutation in blood derived from patients with diabetes
SO MOLECULAR DIAGNOSIS & THERAPY
LA English
DT Article
ID STROKE-LIKE EPISODES; LACTIC-ACIDOSIS; DNA MUTATIONS; POINT MUTATION;
   DEAFNESS; A3243G; MELAS; GENE; ENCEPHALOMYOPATHY; ELECTROPHORESIS
AB Background: Mutations in the human mitochondrial genome have been suspected to play a significant role in the etiological development of mitochondrial diabetes. Detection of the 3243A>G mutation in the mitochondrial transfer RNA(Leu)(UUR) gene (MTTL1), especially at low heteroplasmy levels, is highly desirable since it facilitates the diagnosis and subsequent management of the disease. The proportions of mutant mitochondrial DNA (mtDNA) can vary between tissues and are usually significantly higher in muscle than in blood, but muscle biopsies from patients with diabetes are rarely available.
   Methods: Here, we describe a technique that can not only determine the presence of MTTL1 3243A>G. but can also estimate the percentage of mutant DNA. The technique is based on the use of the WAVE(R) system for the high-performance liquid chromatography (HPLC)-mediated analysis of mutation-specific restriction fragments derived from mutant PCR amplicons. PCR amplicon restriction fragment analysis by HPLC (PARFAH) can also be used for the detection of other mutations.
   Results: This PARFAH analytical approach led to the discovery of the 3243A>G mutation in blood samples from a series of patients who had initially been reported to lack the mutation, even though matrilineal relatives had been shown to harbor the mutation associated with maternally inherited diabetes and deafness (MIDD) or mitochondrial myopathy encephalopathy lactic acidosis stroke-like episodes (MELAS) phenotypes. We have established that the PARFAH method can reliably detect as little as 1% mutant DNA in a sample, which would normally be missed by commonly used gel electrophoresis or sequencing methods.
   Conclusions: The PARFAH method not only provides a sensitive, high-throughput. and cost-effective strategy for the detection of low levels of mtDNA mutations in peripheral tissues, but also facilitates the estimation of the percentage of mutant DNA in the sample. The fact that samples can be readily obtained from peripheral tissues in many cases will avoid the need for invasive muscle biopsies. Our ability to detect low levels of mtDNA mutations in blood samples of carriers will allow us to reassess the prevalence of the MTTL1 3243A>G mutation in patients with diabetes.
C1 Univ Calif Irvine, Ctr Mol & Mitochondrial Med & Genet, Irvine, CA 92697 USA.
   Univ Calif Irvine, Dept Pediat, Irvine, CA 92717 USA.
   Transgenomic Inc, Omaha, NE USA.
   Archet 2 Hosp, Dept Med Genet, Nice, France.
   Univ Nice, Sch Med, FRE CNRS UNSA 2720, Nice, France.
   Univ Calif Irvine, Dept Ecol & Evolutionary Biol, Irvine, CA 92717 USA.
C3 University of California System; University of California Irvine;
   University of California System; University of California Irvine; CHU
   Nice; Universite Cote d'Azur; University of California System;
   University of California Irvine
RP Procaccio, V (corresponding author), Univ Calif Irvine, Ctr Mol & Mitochondrial Med & Genet, Irvine, CA 92697 USA.
EM vproca@uci.edu
RI Procaccio, Vincent/M-2596-2015
OI DAVILA, ANTONIO/0000-0003-1672-2713; procaccio,
   Vincent/0000-0002-1537-4684
FU NHLBI NIH HHS [HL64017] Funding Source: Medline; NIA NIH HHS [AG13154,
   AG24373] Funding Source: Medline; NIDDK NIH HHS [DK73691] Funding
   Source: Medline; NINDS NIH HHS [NS41850, NS21328] Funding Source:
   Medline
CR BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11
   Bannwarth S, 2005, HUM MUTAT, V25, P575, DOI 10.1002/humu.20177
   Biggin A, 2005, MOL GENET METAB, V84, P61, DOI 10.1016/j.ymgme.2004.09.011
   Brandon MC, 2005, NUCLEIC ACIDS RES, V33, pD611
   Carelli V, 2003, TRENDS GENET, V19, P257, DOI 10.1016/S0168-9525(03)00072-6
   Chen TJ, 1999, CLIN CHEM, V45, P1162
   Chomyn A, 2000, J BIOL CHEM, V275, P19198, DOI 10.1074/jbc.M908734199
   DiMauro S, 2004, BBA-BIOENERGETICS, V1658, P80, DOI 10.1016/j.bbabio.2004.03.014
   Gebhart SSP, 1996, METABOLISM, V45, P526, DOI 10.1016/S0026-0495(96)90231-0
   Girald-Rosa W, 2005, CLIN CHEM, V51, P305, DOI 10.1373/clinchem.2004.040311
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Guigas B, 2004, BIOCHEM J, V382, P877, DOI 10.1042/BJ20040885
   Guillausseau PJ, 2001, ANN INTERN MED, V134, P721, DOI 10.7326/0003-4819-134-9_Part_1-200105010-00008
   King M P, 1996, Methods Enzymol, V264, P339, DOI 10.1016/S0076-6879(96)64032-4
   Lamson Davis W, 2002, Altern Med Rev, V7, P94
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   MORAES CT, 1992, AM J HUM GENET, V50, P934
   Moraes CT, 2003, J MOL DIAGN, V5, P197, DOI 10.1016/S1525-1578(10)60474-6
   Murdock DG, 2000, NUCLEIC ACIDS RES, V28, P4350, DOI 10.1093/nar/28.21.4350
   Olsson C, 2001, EUR J HUM GENET, V9, P917, DOI 10.1038/sj.ejhg.5200742
   Rahman S, 2001, AM J HUM GENET, V68, P238, DOI 10.1086/316930
   Shanske S, 2004, AM J MED GENET A, V130A, P134, DOI 10.1002/ajmg.a.30220
   THART LM, 1994, DIABETOLOGIA, V37, P1169
   Thorburn DR, 2004, BBA-BIOENERGETICS, V1659, P121, DOI 10.1016/j.bbabio.2004.08.006
   TROUNCE I, 1994, P NATL ACAD SCI USA, V91, P8334, DOI 10.1073/pnas.91.18.8334
   Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0
   van den Bosch BJC, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.20.e89
   VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368
   VIALETTES B, 1995, DIABETES CARE, V18, P1023, DOI 10.2337/diacare.18.7.1023
   Wallace D.C., 2002, Emery and Rimoin's Principles and Practice of Medical Genetics, P299
   Wong LJC, 2005, CLIN CHIM ACTA, V354, P1, DOI 10.1016/j.cccn.2004.11.003
NR 31
TC 8
Z9 11
U1 0
U2 1
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1177-1062
EI 1179-2000
J9 MOL DIAGN THER
JI Mol. Diagn. Ther.
PY 2006
VL 10
IS 6
BP 381
EP 389
DI 10.1007/BF03256215
PG 9
WC Genetics & Heredity; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Pharmacology & Pharmacy
GA 127EF
UT WOS:000243567400006
PM 17154655
DA 2024-11-01
ER

PT J
AU Wabbels, B
   Schroeder, JA
   Voll, B
   Siegmund, H
   Lorenz, B
AF Wabbels, Bettina
   Schroeder, Josef A.
   Voll, Beate
   Siegmund, Heiko
   Lorenz, Birgit
TI Electron microscopic findings in levator muscle biopsies of patients
   with isolated congenital or acquired ptosis
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Article
DE mitochondria; electron microscopy; ptosis; congenital; acquired; child;
   CPEO
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; MITOCHONDRIAL-DNA DELETION;
   EXTRAOCULAR-MUSCLES; DIAGNOSTIC-VALUE; OCULAR MYOPATHY; DISEASES;
   EXPRESSION; ENCEPHALOMYOPATHIES; POPULATION; DISORDERS
AB Objective Systemic mitochondriopathies as chronic progressive external ophthalmoplegia (CPEO) are frequently associated with ptosis. We investigated whether mitochondrial abnormalities in the levator muscle are also found in patients with isolated congenital or acquired ptosis showing no other signs of mitochondrial cytopathy.
   Methods Biopsies of levator muscle were taken during surgery from 24 patients with isolated congenital (group 1) or early-onset acquired ptosis (group 2). All patients were given a thorough clinical examination before and after surgery. Ultrathin muscle sections were examined by transmission electron microscopy. The findings were compared with biopsies from five patients with CPEO (positive control) and two patients with traumatic ptosis or pseudoptosis (negative control).
   Results The mean levator function equalled 7.3 mm (range 4-10 mm) in group 1 and 12.8 mm (range 9-15 mm) in group 2. Eight out of 11 patients in group 1 and eight out of 13 patients in group 2 were found to have mitochondrial alterations such as megamitochondria, mitochondrial matrix alterations and abnormal cristae, similar to CPEO. Within group 1 and 2, no significant clinical differences were found between patients with and without mitochondrial abnormalities.
   Conclusion Mitochondrial alterations were found in a surprisingly large proportion of levator biopsies from patients with isolated congenital or early-onset acquired ptosis. There was no statistically significant correlation between mitochondrial alterations and levator function. Our findings suggest that the ultrastructural assessment of mitochondria in the eyelid muscle is a valuable tool, and may guide further biochemical and mutation screening tests that will help to understand the etiopathology of this disease.
C1 Univ Regensburg, Dept Pediat Ophthalmol Strabismol & Opthalmogenet, D-93042 Regensburg, Germany.
   Univ Regensburg, Inst Pathol, Cent EM Lab, D-93053 Regensburg, Germany.
   Univ Bonn, Dept Ophthalmol, D-53127 Bonn, Germany.
C3 University of Regensburg; University of Regensburg; University of Bonn
RP Lorenz, B (corresponding author), Univ Regensburg, Dept Pediat Ophthalmol Strabismol & Opthalmogenet, Franz Josef Str Allee 11, D-93042 Regensburg, Germany.
EM birgit.lorenz@klinik.uni-regensburg.de
RI Wabbels, Bettina/AAT-4804-2021
CR AASLY J, 1990, EUR NEUROL, V30, P314, DOI 10.1159/000117363
   Ben Yaou R, 2006, REV NEUROL-FRANCE, V162, P339, DOI 10.1016/S0035-3787(06)75020-2
   Biousse V, 2003, CURR OPIN NEUROL, V16, P35, DOI 10.1097/00019052-200302000-00005
   BUTLER IJ, 1976, ARCH INTERN MED, V136, P1290
   Carta A, 2005, BRIT J OPHTHALMOL, V89, P825, DOI 10.1136/bjo.2004.060590
   Carta A, 2000, ARCH OPHTHALMOL-CHIC, V118, P1441
   Challa S, 2004, NEUROL INDIA, V52, P353
   Chinnery PF, 2004, LANCET, V364, P592, DOI 10.1016/S0140-6736(04)16851-7
   CHOU SM, 1968, ACTA NEUROPATHOL BER, V12, P68
   Chow C W, 2000, Hum Reprod, V15 Suppl 2, P68
   CULLEN MJ, 1975, J NEUROL SCI, V24, P179, DOI 10.1016/0022-510X(75)90232-4
   Deschauer M, 2004, GENET TEST, V8, P395, DOI 10.1089/gte.2004.8.395
   DEVIVO DC, 1993, BRAIN DEV-JPN, V15, P1, DOI 10.1016/0387-7604(93)90002-P
   Fischer MD, 2005, PHYSIOL GENOMICS, V22, P283, DOI 10.1152/physiolgenomics.00158.2004
   Fischer MD, 2002, PHYSIOL GENOMICS, V9, P71, DOI 10.1152/physiolgenomics.00115.2001
   GHADIALLY FN, 1997, ULTRASTRUCT PATHOL, P195
   Greenamyre JT, 1999, BIOCHEM SOC SYMP, V66, P85, DOI 10.1042/bss0660085
   Caballero PEJ, 2007, NEUROLOGIST, V13, P33, DOI 10.1097/01.nrl.0000252953.49721.f5
   KACZMARSKI F, 1979, FOL HISTOCH CYTOCHEM, V17, P85
   KAMINSKI HJ, 1992, ANN NEUROL, V32, P586, DOI 10.1002/ana.410320418
   Kornblum C, 2004, KLIN MONATSBL AUGENH, V221, P1057, DOI 10.1055/s-2004-813830
   KRETSCHMANN U, 2000, OPHTHALMOLOGE, V97, P115
   Lee Andrew G, 2002, Curr Neurol Neurosci Rep, V2, P413, DOI 10.1007/s11910-002-0067-5
   Lee V, 2002, BRIT J OPHTHALMOL, V86, P1282, DOI 10.1136/bjo.86.11.1282
   LINDAL S, 1992, ULTRASTRUCT PATHOL, V16, P263, DOI 10.3109/01913129209061355
   Lucas CA, 1997, INVEST OPHTH VIS SCI, V38, P2817
   Mierau GW, 2004, PEDIATR DEVEL PATHOL, V7, P637, DOI 10.1007/s10024-004-5048-z
   Miles L, 2006, HUM PATHOL, V37, P173, DOI 10.1016/j.humpath.2005.10.008
   Mojon D, 2001, Ther Umsch, V58, P49, DOI 10.1024/0040-5930.58.1.49
   NORRIS FH, 1966, ARCH NEUROL-CHICAGO, V14, P574, DOI 10.1001/archneur.1966.00470120006002
   Okulla T, 2005, GRAEF ARCH CLIN EXP, V243, P380, DOI 10.1007/s00417-004-1000-1
   Piccolo G, 1982, Schweiz Arch Neurol Neurochir Psychiatr, V131, P161
   SADEH M, 2004, MYOLOGY BASIC CLIN, P119
   Sarnat HB, 2005, CAN J NEUROL SCI, V32, P152, DOI 10.1017/S0317167100003929
   Schoser BGH, 2006, STRABISMUS, V14, P107, DOI 10.1080/09273970600701218
   Sciacco M, 2001, J NEUROL, V248, P778, DOI 10.1007/s004150170094
   Sewry CA, 1985, MUSCLE BIOPSY PRACTI, P129
   SHAFIQ SA, 1967, ARCH NEUROL-CHICAGO, V17, P666, DOI 10.1001/archneur.1967.00470300108018
   SHAPIRA Y, 1975, NEUROLOGY, V25, P614, DOI 10.1212/WNL.25.7.614
   Shoubridge EA., 2002, STRUCTURAL MOL BASIS, P202
   SICILIANO G, 1992, CLIN NEUROL NEUROSUR, V94, P133, DOI 10.1016/0303-8467(92)90070-J
   Speeg-Schatz C, 2001, Binocul Vis Strabismus Q, V16, P187
   Uusimaa J, 2000, PEDIATRICS, V105, P598, DOI 10.1542/peds.105.3.598
   Van Goethem G, 2003, NEUROMOL MED, V3, P129, DOI 10.1385/NMM:3:3:129
   Van Huyen JPD, 2003, AM J CLIN PATHOL, V119, P546, DOI 10.1309/8B8BJ6AP5KGV7C1H
   Vogel H, 2001, J NEUROPATH EXP NEUR, V60, P217, DOI 10.1093/jnen/60.3.217
   Wakabayashi T, 2002, J CELL MOL MED, V6, P497, DOI 10.1111/j.1582-4934.2002.tb00452.x
   Wright RA, 1997, J NEURO-OPHTHALMOL, V17, P39
NR 48
TC 15
Z9 18
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING STREET, NEW YORK, NY 10013 USA
SN 0721-832X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD OCT
PY 2007
VL 245
IS 10
BP 1533
EP 1541
DI 10.1007/s00417-007-0603-8
PG 9
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA 209RJ
UT WOS:000249405400016
PM 17522883
DA 2024-11-01
ER

PT J
AU Campbell, GR
   Reeve, A
   Ziabreva, I
   Polvikoski, TM
   Taylor, RW
   Reynolds, R
   Turnbull, DM
   Mahad, DJ
AF Campbell, G. R.
   Reeve, A.
   Ziabreva, I.
   Polvikoski, T. M.
   Taylor, R. W.
   Reynolds, R.
   Turnbull, D. M.
   Mahad, D. J.
TI Mitochondrial DNA deletions and depletion within paraspinal muscles
SO NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY
LA English
DT Article
DE ageing; mitochondrial DNA deletion; paraspinal muscle
ID REAL-TIME PCR; SKELETAL-MUSCLE; PARAVERTEBRAL MUSCLES; CLONAL EXPANSION;
   INDIVIDUAL CELLS; MUTATIONS; DISEASE; CAMPTOCORMIA; MECHANISMS;
   ACCUMULATE
AB G. R. Campbell, A. Reeve, I. Ziabreva, T. M. Polvikoski, R. W. Taylor, R. Reynolds, D. M. Turnbull and D. J. Mahad (2013) Neuropathology and Applied Neurobiology39, 377389 Mitochondrial DNA deletions and depletion within paraspinal muscles Aims: Although mitochondrial abnormalities have been reported within paraspinal muscles in patients with axial weakness and neuromuscular disease as well as with ageing, the basis of respiratory deficiency in paraspinal muscles is not known. This study aimed to determine the extent and basis of respiratory deficiency in paraspinal muscles from cases undergoing surgery for degenerative spinal disease and post mortem cases without a history of spinal disease, where age-related histopathological changes were previously reported. Methods: Cervical and lumbar paraspinal muscles were obtained peri-operatively from 13 patients and from six post mortem control cases (age range 1882 years) without a neurological disease. Sequential COX/SDH (mitochondrial respiratory chain complex IV/complex II) histochemistry was performed to identify respiratory-deficient muscle fibres (lacking complex IV with intact complex II activity). Real-time polymerase chain reaction, long-range polymerase chain reaction and sequencing were used to identify and characterize mitochondrial DNA (mtDNA) deletions and determine mtDNA copy number status. Mitochondrial respiratory chain complex subunits were detected by immunohistochemistry. Results: The density of respiratory-deficient fibres increased with age. On average, 3.96% of fibres in paraspinal muscles were respiratory-deficient (range 010.26). Respiratory deficiency in 36.8% of paraspinal muscle fibres was due to clonally expanded mtDNA deletions. MtDNA depletion accounted for further 13.5% of respiratory deficiency. The profile of immunohistochemically detected subunits of complexes was similar in respiratory-deficient fibres with and without mtDNA deletions or mtDNA depletion. Conclusions: Paraspinal muscles appeared to be particularly susceptible to age-related mitochondrial respiratory chain defects. Clonally expanded mtDNA deletions and focal mtDNA depletion may contribute towards the development of age-related postural abnormalities.
C1 [Campbell, G. R.; Reeve, A.; Ziabreva, I.; Taylor, R. W.; Turnbull, D. M.; Mahad, D. J.] Newcastle Univ, Wellcome Trust Ctr Mitochondrial Res, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Polvikoski, T. M.] Newcastle Univ, Wolfson Res Ctr, Inst Ageing & Hlth, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Reynolds, R.] Univ London Imperial Coll Sci Technol & Med, Fac Med, Wolfson Neurosci Labs, London, England.
C3 Newcastle University - UK; Newcastle University - UK; Imperial College
   London
RP Mahad, DJ (corresponding author), Newcastle Univ, Mitochondrial Res Grp, Inst Ageing & Hlth, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM mahadd@doctors.org.uk
OI Reynolds, Richard/0000-0003-4622-4694; Turnbull,
   Doug/0000-0002-8878-9901; Campbell, Graham/0000-0003-4828-421X; Reeve,
   Amy/0000-0002-4474-2204
FU Wellcome Trust (Intermediate Clinical Fellowship); Newcastle Healthcare
   Charity; Wellcome Trust Centre for Mitochondrial Research; Newcastle
   University Centre for Brain Ageing and Vitality; Biotechnology and
   Biological Sciences Research Council; Engineering and Physical Sciences
   Research Council; Economic and Social Research Council; Medical Research
   Council as part of the cross-council Lifelong Health and Wellbeing
   Initiative [G0700718]; MRC [G0700718, MR/K000608/1, G0900652, G0502157,
   G0400074, G1100540, MR/L016451/1] Funding Source: UKRI
FX This study was supported by the Wellcome Trust (Intermediate Clinical
   Fellowship to D. M.), Newcastle Healthcare Charity (to D. M.), The
   Wellcome Trust Centre for Mitochondrial Research and the Newcastle
   University Centre for Brain Ageing and Vitality funded by Biotechnology
   and Biological Sciences Research Council, Engineering and Physical
   Sciences Research Council, Economic and Social Research Council and
   Medical Research Council as part of the cross-council Lifelong Health
   and Wellbeing Initiative (G0700718). We are grateful to Dr Laurie
   Bindoff for helpful discussion on mitochondrial abnormalities in
   paraspinal muscles. We thank Dr Djordje Gveric from UK Multiple
   Sclerosis and Parkinson's Tissue Bank for providing post mortem tissue
   and Mr Christopher Gerber from Department of Neurosurgery, Newcastle
   General Hospital for providing the peri-operative samples.
CR Brierley EJ, 1996, QJM-MON J ASSOC PHYS, V89, P251
   Brierley EJ, 1998, ANN NEUROL, V43, P217, DOI 10.1002/ana.410430212
   Bua E, 2006, AM J HUM GENET, V79, P469, DOI 10.1086/507132
   Campbell GR, 2011, ANN NEUROL, V69, P481, DOI 10.1002/ana.22109
   Chen YW, 2007, PHYSIOL GENOMICS, V31, P510, DOI 10.1152/physiolgenomics.00115.2006
   De Paepe B, 2009, J CLIN PATHOL, V62, P172, DOI 10.1136/jcp.2008.061267
   DELISLE MB, 1993, NEUROMUSCULAR DISORD, V3, P579, DOI 10.1016/0960-8966(93)90120-9
   Elson JL, 2001, AM J HUM GENET, V68, P802, DOI 10.1086/318801
   Fayet G, 2002, NEUROMUSCULAR DISORD, V12, P484, DOI 10.1016/S0960-8966(01)00332-7
   Greaves LC, 2010, INVEST OPHTH VIS SCI, V51, P3340, DOI 10.1167/iovs.09-4659
   He LP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf067
   HUND E, 1995, NEUROLOGY, V45, P993, DOI 10.1212/WNL.45.5.993
   JOHNSON MA, 1993, ANN NEUROL, V33, P28, DOI 10.1002/ana.410330106
   KEYNES RJ, 1988, DEVELOPMENT, V103, P413
   Krishnan KJ, 2008, NAT GENET, V40, P275, DOI 10.1038/ng.f.94
   Krishnan KJ, 2007, ANAL BIOCHEM, V370, P127, DOI 10.1016/j.ab.2007.06.024
   Larsson NG, 2010, ANNU REV BIOCHEM, V79, P683, DOI 10.1146/annurev-biochem-060408-093701
   McFarland R, 2010, LANCET NEUROL, V9, P829, DOI 10.1016/S1474-4422(10)70116-2
   Nicholas A, 2009, EXP NEUROL, V218, P316, DOI 10.1016/j.expneurol.2009.04.029
   ORDAHL CP, 1992, DEVELOPMENT, V114, P339
   Rahman S, 2000, BRAIN, V123, P591, DOI 10.1093/brain/123.3.591
   Ramsbacher J, 2001, SPINE, V26, P2180, DOI 10.1097/00007632-200110150-00003
   Reeve AK, 2008, ANN NY ACAD SCI, V1147, P21, DOI 10.1196/annals.1427.016
   Regev GJ, 2010, SPINE, V35, P1265, DOI 10.1097/BRS.0b013e3181bfcd98
   Sakiyama Y, 2011, ACTA NEUROPATHOL, V121, P775, DOI 10.1007/s00401-011-0818-y
   Schäbitz WR, 2003, MOVEMENT DISORD, V18, P408, DOI 10.1002/mds.10385
   Serratrice G, 1996, J NEUROL NEUROSUR PS, V60, P51, DOI 10.1136/jnnp.60.1.51
   Serratrice G, 2007, Acta Myol, V26, P11
   Vielhaber S, 2000, BRAIN, V123, P1339, DOI 10.1093/brain/123.7.1339
   Wakata N, 2007, INTERNAL MED, V46, P747, DOI 10.2169/internalmedicine.46.6400
   Wharton SB, 1996, J NEUROL NEUROSUR PS, V61, P461, DOI 10.1136/jnnp.61.5.461
   Yoshiyama Y, 1999, J NEUROL SCI, V167, P22, DOI 10.1016/S0022-510X(99)00129-X
   Yu-Wai-Man P, 2010, INVEST OPHTH VIS SCI, V51, P3347, DOI 10.1167/iovs.09-4660
NR 33
TC 17
Z9 18
U1 0
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0305-1846
J9 NEUROPATH APPL NEURO
JI Neuropathol. Appl. Neurobiol.
PD JUN
PY 2013
VL 39
IS 4
BP 377
EP 389
DI 10.1111/j.1365-2990.2012.01290.x
PG 13
WC Clinical Neurology; Neurosciences; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pathology
GA 137HI
UT WOS:000318425900005
PM 22762368
OA Green Published
DA 2024-11-01
ER

PT J
AU Phadke, M
   Lokeshwar, MR
   Bhutada, S
   Tampi, C
   Saxena, R
   Kohli, S
   Shah, KN
AF Phadke, Meghana
   Lokeshwar, M. R.
   Bhutada, Shraddha
   Tampi, Chandralekha
   Saxena, Renu
   Kohli, Sudha
   Shah, K. N.
TI RETRACTED: Kearns Sayre Syndrome-Case Report with Review of Literature
   (Retracted article. See vol. 80, pg. 982, 2013)
SO INDIAN JOURNAL OF PEDIATRICS
LA English
DT Article; Retracted Publication
DE Kearns-Sayre's syndrome; CPEO (Chronic progressive external
   ophthalmoplegia with myopathy); Chronic progressive external
   ophthalmoplegia with ragged red fibers; Oculo cranio somatic
   neuromuscular disease with ragged red fibers
ID MITOCHONDRIAL-DNA; HEART BLOCK; OPHTHALMOPLEGIA; DELETION
AB Kearns-Sayre Syndrome is form of rare mitochondrial cytopathy, first described by Thomas P. Kearns and George Pomeroy Sayre in 1958 and is characterized by progressive external opthalmoplegia, cardiac conduction block, pigmentary retinal degeneration, variable number of red ragged fibers on muscle biopsy. It presents before the child reaches the age of twenty. Kearns-Sayre syndrome may affect many organ systems and additional features may include myopathy, dystonia, bulbar symptoms in the form of dysarthria and nasal regurgitation and bilateral facial weakness. Endocrine abnormalities (e.g., diabetes, growth retardation/short stature, and hypoparathyroidism), bilateral sensorineural deafness, dementia, cataracts, and proximal renal tubular acidosis, skeletal muscle weakness (proximal more than distal) and exercise intolerance are additional features. Kearns Sayre Syndrome occurs as a result of large-scale single deletions (or rearrangements) of mitochondrial DNA (mtDNA), which is usually not inherited but occurs spontaneously, probably at the germ-cell level or very early in embryonic development. No disease-modifying therapy is available for Kearns-Sayre syndrome (KSS). Management is supportive vigilance for detection of associated problems. In the future, potential treatment in patients with Kearns-Sayre syndrome may attempt to inhibit mutant mtDNA replication or encourage replication of wild-type mtDNA.
C1 [Phadke, Meghana; Lokeshwar, M. R.; Bhutada, Shraddha; Shah, K. N.] Lilavati Hosp & Res Ctr, Dept Pediat, Mumbai, Maharashtra, India.
   [Saxena, Renu; Kohli, Sudha] Sir Gangaram Hosp, Ctr Med Genet, New Delhi, India.
   [Tampi, Chandralekha] Lilavati Hosp & Res Ctr, Dept Pathol, Mumbai, Maharashtra, India.
RP Lokeshwar, MR (corresponding author), 19A Shree Dattaguru Soc, Mumbai 400088, Maharashtra, India.
EM mrlokeshwar@gmail.com
OI saxena, renu/0000-0002-1344-2831
CR Barragan-Campos Hector Manuel, 1999, Archivos del Instituto de Cardiologia de Mexico, V69, P559
   BERENBERG RA, 1977, ANN NEUROL, V1, P37, DOI 10.1002/ana.410010104
   BERKOVIC SF, 1989, BRAIN, V112, P1231, DOI 10.1093/brain/112.5.1231
   Carod-Artal FJ, 2006, NEUROLOGIA, V21, P357
   Chu BC, 1999, NEURORADIOLOGY, V41, P759, DOI 10.1007/s002340050838
   DIMAURO S, 1993, ARCH NEUROL-CHICAGO, V50, P1197, DOI 10.1001/archneur.1993.00540110075008
   FISCHELGHODSIAN N, 1992, PEDIATR RES, V31, P557, DOI 10.1203/00006450-199206000-00004
   Franco E, 1999, NEUROLOGIA, V9, P463
   Gregoratos Gabriel, 2002, Circulation, V106, P2145, DOI 10.1161/01.CIR.0000035996.46455.09
   HARVEY JN, 1992, CLIN ENDOCRINOL, V37, P97, DOI 10.1111/j.1365-2265.1992.tb02289.x
   JAGER BV, 1960, AM J MED, V29, P888, DOI 10.1016/0002-9343(60)90122-4
   Katsanos KH, 2001, AM J NEPHROL, V21, P150, DOI 10.1159/000046239
   KEARNS THOMAS P., 1965, TRANS AMER OPHTHALMOL SOC, V63, P559
   KEARNS TP, 1958, ARCH OPHTHALMOL-CHIC, V60, P280, DOI 10.1001/archopht.1958.00940080296016
   Lee K T, 2001, Kaohsiung J Med Sci, V17, P336
   Lertrit P, 1999, HUM GENET, V105, P127, DOI 10.1007/s004390051074
   LESTIENNE P, 1988, LANCET, V1, P885
   Mehndiratta MM, 2002, NEUROL INDIA, V50, P162
   OGASAHARA S, 1985, NEUROLOGY, V35, P372, DOI 10.1212/WNL.35.3.372
   Rajakannan, 2000, Indian J Ophthalmol, V48, P54
   Seneca S, 2001, ARCH NEUROL-CHICAGO, V58, P1113, DOI 10.1001/archneur.58.7.1113
   Usui M, 2002, Kyobu Geka, V55, P1112
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
NR 23
TC 15
Z9 15
U1 0
U2 23
PU SPRINGER INDIA
PI NEW DELHI
PA 7TH FLOOR, VIJAYA BUILDING, 17, BARAKHAMBA ROAD, NEW DELHI, 110 001,
   INDIA
SN 0019-5456
EI 0973-7693
J9 INDIAN J PEDIATR
JI Indian J. Pediatr.
PD MAY
PY 2012
VL 79
IS 5
BP 650
EP 654
DI 10.1007/s12098-011-0618-3
PG 5
WC Pediatrics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pediatrics
GA 934XX
UT WOS:000303481200009
PM 22231766
DA 2024-11-01
ER

PT J
AU Picca, A
   Guerra, F
   Calvani, R
   Coelho, HJ
   Leeuwenburgh, C
   Bucci, C
   Marzetti, E
AF Picca, Anna
   Guerra, Flora
   Calvani, Riccardo
   Coelho Jr, Helio Jose
   Leeuwenburgh, Christiaan
   Bucci, Cecilia
   Marzetti, Emanuele
TI The contribution of mitochondrial DNA alterations to aging, cancer, and
   neurodegeneration
SO EXPERIMENTAL GERONTOLOGY
LA English
DT Review
DE Heteroplasmy; Mitochondrial biogenesis; mtDNA deletions; mtDNA
   mutations; Mitochondrial diseases; Mitochondrial quality
ID MTDNA CONTROL-REGION; COPY NUMBER; PATERNAL INHERITANCE; TRANSCRIPTION
   FACTOR; OXIDATIVE STRESS; POINT MUTATIONS; CALORIE RESTRICTION; DISEASE;
   CELLS; BIOGENESIS
AB Mitochondrial DNA (mtDNA) is as a double-stranded molecule existing in hundreds to thousands copies in cells depending on cell metabolism and exposure to endogenous and/or environmental stressors. The coordination of mtDNA replication and transcription regulates the pace of mitochondrial biogenesis to guarantee the minimum number of organelles per cell. mtDNA inheritance follows a maternal lineage, although bi-parental inheritance has been reported in some species and in the case of mitochondrial diseases in humans. mtDNA mutations (e.g., point mutations, deletions, copy number variations) have been identified in the setting of several human diseases. For instance, sporadic and inherited rare disorders involving the nervous system as well higher risk of developing cancer and neurodegenerative conditions, including Parkinson's and Alzheimer's disease, have been associated with polymorphic mtDNA variants. An accrual of mtDNA mutations has also been identified in several tissues and organs, including heart and muscle, of old experimental animals and humans, which may contribute to the development of aging phenotypes. The role played by mtDNA homeostasis and mtDNA quality control pathways in human health is actively investigated for the possibility of developing targeted therapeutics for a wide range of conditions.
C1 [Picca, Anna] LUM Univ, Dept Med & Surg, I-70100 Casamassima, Italy.
   [Picca, Anna; Calvani, Riccardo; Marzetti, Emanuele] Fdn Policlin Univ Agostino Gemelli IRCCS, I-00168 Rome, Italy.
   [Guerra, Flora; Bucci, Cecilia] Univ Salento, Dept Biol & Environm Sci & Technol, I-73100 Lecce, Italy.
   [Calvani, Riccardo; Coelho Jr, Helio Jose; Marzetti, Emanuele] Univ Cattolica Sacro Cuore, Dept Geriatr & Orthoped, I-00168 Rome, Italy.
   [Leeuwenburgh, Christiaan] Univ Florida, Dept Physiol & Aging, Gainesville, FL 32601 USA.
   [Calvani, Riccardo] Univ Cattolica Sacro Cuore, Fdn Policlin Univ Agostino Gemelli IRCCS, Ctr Md Invecchiamento CeMI, Largo F Vito 1, I-00168 Rome, Italy.
C3 Lum Jean Monnet University; Catholic University of the Sacred Heart;
   IRCCS Policlinico Gemelli; University of Salento; Catholic University of
   the Sacred Heart; IRCCS Policlinico Gemelli; State University System of
   Florida; University of Florida; Catholic University of the Sacred Heart;
   IRCCS Policlinico Gemelli
RP Calvani, R (corresponding author), Univ Cattolica Sacro Cuore, Fdn Policlin Univ Agostino Gemelli IRCCS, Ctr Md Invecchiamento CeMI, Largo F Vito 1, I-00168 Rome, Italy.
EM riccardo.calvani@unicatt.it
RI Guerra, Flora/D-1755-2014; Picca, Anna/K-2305-2018; Júnior,
   Hélio/AAC-2358-2019; Bucci, Cecilia/F-6699-2012; Marzetti,
   Emanuele/A-9430-2010; Calvani, Riccardo/K-2011-2018
OI Calvani, Riccardo/0000-0001-5472-2365
FU Ministero della Salute - Ricerca Corrente 2023, Universita Cattolica del
   Sacro Cuore [D1.2020, D1.2022]; National Institutes of Health [1RO1
   AG075136]; nonprofit research foundation "Centro Studi Achille e Linda
   Lorenzon", AIRC [25795]; European Commission - Next Generation EU
   (Age-IT spoke 3)
FX This work was supported by Ministero della Salute - Ricerca Corrente
   2023, Universita Cattolica del Sacro Cuore (D1.2020 and D1.2022),
   National Institutes of Health (1RO1 AG075136), the nonprofit research
   foundation "Centro Studi Achille e Linda Lorenzon", AIRC (IG 2021 - ID.
   25795), European Commission - Next Generation EU (Age-IT spoke 3).
CR Anderson AP, 2020, NUCLEIC ACIDS RES, V48, P817, DOI 10.1093/nar/gkz1018
   Annis S, 2019, P NATL ACAD SCI USA, V116, P14797, DOI 10.1073/pnas.1821436116
   Area-Gomez E, 2019, J CLIN INVEST, V129, P34, DOI 10.1172/JCI120848
   Arnold RS, 2015, BONE, V78, P81, DOI 10.1016/j.bone.2015.04.046
   Arnold RS, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/239257
   ATTARDI G, 1988, ANNU REV CELL BIOL, V4, P289, DOI 10.1146/annurev.cb.04.110188.001445
   Bai RK, 2005, J MOL DIAGN, V7, P613, DOI 10.1016/S1525-1578(10)60595-8
   Balciuniene J, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00518
   Bartoletti-Stella A, 2011, ARCH OPHTHALMOL-CHIC, V129, P664, DOI 10.1001/archophthalmol.2011.95
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Bianco Angelica, 2018, BMC Res Notes, V11, P911, DOI 10.1186/s13104-018-4025-y
   Bianco A, 2017, INVEST OPHTH VIS SCI, V58, P2193, DOI 10.1167/iovs.16-20389
   BioRender, 2021, MTDNA HET
   BioRender, 2021, MIT INH
   Bonawitz ND, 2006, MOL CELL, V24, P813, DOI 10.1016/j.molcel.2006.11.024
   Brandon M, 2006, ONCOGENE, V25, P4647, DOI 10.1038/sj.onc.1209607
   Caino MC, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13730
   Calabrese C, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-11
   Canugovi C, 2010, DNA REPAIR, V9, P1080, DOI 10.1016/j.dnarep.2010.07.009
   Cassarino DS, 1998, BIOCHEM BIOPH RES CO, V248, P168, DOI 10.1006/bbrc.1998.8866
   Chen ZX, 2010, CELL DEATH DIFFER, V17, P408, DOI 10.1038/cdd.2009.132
   Chinnery PF, 2002, LANCET, V360, P1323, DOI 10.1016/S0140-6736(02)11310-9
   Chinnery PF, 2001, AM J HUM GENET, V68, P529, DOI 10.1086/318204
   Copeland WC, 2002, CANCER INVEST, V20, P557, DOI 10.1081/CNV-120002155
   Cormio A, 2009, BIOCHEM BIOPH RES CO, V390, P1182, DOI 10.1016/j.bbrc.2009.10.114
   CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324
   CORTOPASSI GA, 1992, P NATL ACAD SCI USA, V89, P7370, DOI 10.1073/pnas.89.16.7370
   Coskun PE, 2004, P NATL ACAD SCI USA, V101, P10726, DOI 10.1073/pnas.0403649101
   Coskun P, 2012, BBA-GEN SUBJECTS, V1820, P553, DOI 10.1016/j.bbagen.2011.08.008
   Courtney KD, 2018, CELL METAB, V28, P793, DOI 10.1016/j.cmet.2018.07.020
   Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617
   Dasgupta S, 2009, INT J CANCER, V125, P2829, DOI 10.1002/ijc.24701
   DeBerardinis RJ, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600200
   Dimmock D, 2010, CLIN CHEM, V56, P1119, DOI 10.1373/clinchem.2009.141549
   Ding J, 2015, PLOS GENET, V11, DOI [10.1371/journal.pgen.1005306, 10.1371/journal.pgen.1005549]
   Dölle C, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13548
   Ekstrand MI, 2004, HUM MOL GENET, V13, P935, DOI 10.1093/hmg/ddh109
   Fayet G, 2002, NEUROMUSCULAR DISORD, V12, P484, DOI 10.1016/S0960-8966(01)00332-7
   Filograna R, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav9824
   Filosto M, 2003, ANN NEUROL, V54, P524, DOI 10.1002/ana.10709
   FISHER RP, 1992, J BIOL CHEM, V267, P3358
   Frahm T, 2005, MECH AGEING DEV, V126, P1192, DOI 10.1016/j.mad.2005.06.008
   Frezza C, 2017, INTERFACE FOCUS, V7, DOI 10.1098/rsfs.2016.0100
   Gan XQ, 2014, FREE RADICAL BIO MED, V75, P230, DOI 10.1016/j.freeradbiomed.2014.07.021
   Gasparre G, 2008, HUM MOL GENET, V17, P986, DOI 10.1093/hmg/ddm371
   Gasparre G, 2007, P NATL ACAD SCI USA, V104, P9001, DOI 10.1073/pnas.0703056104
   Gasparre G, 2011, CANCER RES, V71, P6220, DOI 10.1158/0008-5472.CAN-11-1042
   Gasparre G, 2009, HUM MUTAT, V30, P391, DOI 10.1002/humu.20870
   Gaude E, 2018, MOL CELL, V69, P581, DOI 10.1016/j.molcel.2018.01.034
   Gaude E, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-10
   Giordano C, 2014, BRAIN, V137, P335, DOI 10.1093/brain/awt343
   Gopa RK, 2018, CANCER CELL, V34, P242, DOI 10.1016/j.ccell.2018.06.013
   Grady JP, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201708262
   Grandhi S, 2017, HUM MOL GENET, V26, P2912, DOI 10.1093/hmg/ddx172
   Guerra F., 2011, HUM
   Guerra F, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00295
   Guerra F, 2017, BBA-BIOENERGETICS, V1858, P686, DOI 10.1016/j.bbabio.2017.01.012
   Guerra F, 2012, J CLIN ONCOL, V30, pE373, DOI 10.1200/JCO.2012.43.5933
   Guha M., 2018, BIOCH BIOPHYS ACTA M
   GYLLENSTEN U, 1991, NATURE, V352, P255, DOI 10.1038/352255a0
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Handschin C, 2006, ENDOCR REV, V27, P728, DOI 10.1210/er.2006-0037
   Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249
   He XL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061677
   He YH, 2014, NEUROBIOL AGING, V35, DOI 10.1016/j.neurobiolaging.2014.01.015
   Herrera-Cruz MS, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00105
   Hopkins JF, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00377-y
   HOWELL AN, 1978, P NATL ACAD SCI USA, V75, P2358, DOI 10.1073/pnas.75.5.2358
   Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140
   Hudson G, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004369
   Hudson G, 2013, NEUROLOGY, V80, P2042, DOI 10.1212/WNL.0b013e318294b434
   Ishikawa K, 2008, SCIENCE, V320, P661, DOI 10.1126/science.1156906
   Jiménez-Morales S, 2018, INT J ONCOL, V53, P923, DOI 10.3892/ijo.2018.4468
   Ju YS, 2014, ELIFE, V3, DOI 10.7554/eLife.02935
   Kalsbeek AMF, 2017, ONCOTARGET, V8, P71342, DOI 10.18632/oncotarget.19926
   Kalsbeek AMF, 2016, AGING-US, V8, P2702, DOI 10.18632/aging.101044
   Kauppila JHK, 2016, CELL REP, V16, P2980, DOI 10.1016/j.celrep.2016.08.037
   Keogh M, 2013, CELL METAB, V18, P463, DOI 10.1016/j.cmet.2013.09.015
   Keogh MJ, 2015, BBA-BIOENERGETICS, V1847, P1401, DOI 10.1016/j.bbabio.2015.05.015
   Kim HR, 2018, BLOOD RES, V53, P240, DOI 10.5045/br.2018.53.3.240
   Kim S., 2021, HUMAN MTDNA SEQUENCE
   Knez J, 2016, AM J EPIDEMIOL, V183, P138, DOI 10.1093/aje/kwv175
   Kopinski PK, 2021, NAT REV CANCER, V21, P431, DOI 10.1038/s41568-021-00358-w
   Kopinski PK, 2019, P NATL ACAD SCI USA, V116, P16028, DOI 10.1073/pnas.1906896116
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   Kvist L, 2003, MOL BIOL EVOL, V20, P243, DOI 10.1093/molbev/msg025
   La Morgia C, 2020, J INTERN MED, V287, P592, DOI 10.1111/joim.13064
   Labuschagne CF, 2019, CELL METAB, V30, P720, DOI 10.1016/j.cmet.2019.07.014
   Larsson NG, 2010, ANNU REV BIOCHEM, V79, P683, DOI 10.1146/annurev-biochem-060408-093701
   Lawless C, 2020, OPEN BIOL, V10, DOI 10.1098/rsob.200061
   LeBleu VS, 2014, NAT CELL BIOL, V16, P992, DOI 10.1038/ncb3039
   Letouzé E, 2013, CANCER CELL, V23, P739, DOI 10.1016/j.ccr.2013.04.018
   Li MK, 2010, AM J HUM GENET, V87, P237, DOI 10.1016/j.ajhg.2010.07.014
   Li N, 2018, ONCOL LETT, V16, P3992, DOI 10.3892/ol.2018.9113
   LIN FH, 1992, BIOCHEM BIOPH RES CO, V182, P238, DOI 10.1016/S0006-291X(05)80136-6
   Lin MT, 2012, ANN NEUROL, V71, P850, DOI 10.1002/ana.23568
   Liou C.W., 2016, EUR J NEUROL
   Liu CS, 2006, ACTA NEUROL SCAND, V113, P334, DOI 10.1111/j.1600-0404.2006.00586.x
   Lu C, 2012, NATURE, V483, P474, DOI 10.1038/nature10860
   Luo S., 2018, P NATL ACAD SCI US
   Lutz-Bonengel S, 2019, P NATL ACAD SCI USA, V116, P1821, DOI 10.1073/pnas.1820533116
   Mai N, 2017, CELL TISSUE RES, V367, P5, DOI 10.1007/s00441-016-2456-0
   Maruszak A, 2009, NEUROBIOL AGING, V30, P1749, DOI 10.1016/j.neurobiolaging.2008.01.004
   McWilliams TG, 2019, NATURE, V565, P296, DOI 10.1038/d41586-019-00093-1
   Mengel-From J, 2014, HUM GENET, V133, P1149, DOI 10.1007/s00439-014-1458-9
   MORAES CT, 1992, NAT GENET, V1, P359, DOI 10.1038/ng0892-359
   MULLERHOCKER J, 1990, J NEUROL SCI, V100, P14, DOI 10.1016/0022-510x(90)90006-9
   MULLERHOCKER J, 1989, AM J PATHOL, V134, P1167
   Musicco C, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19072076
   Muyderman H, 2012, MITOCHONDRION, V12, P465, DOI 10.1016/j.mito.2012.06.006
   NAKASE H, 1990, AM J HUM GENET, V46, P418
   Nieborowska-Skorska M, 2012, BLOOD, V119, P4253, DOI 10.1182/blood-2011-10-385658
   Onyango I, 2006, J ALZHEIMERS DIS, V9, P183
   PARISI MA, 1991, SCIENCE, V252, P965, DOI 10.1126/science.2035027
   PAYAMI H, 1993, GENET EPIDEMIOL, V10, P461, DOI 10.1002/gepi.1370100622
   Payne BAI, 2013, HUM MOL GENET, V22, P384, DOI 10.1093/hmg/dds435
   Pereira L, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-53
   Perrone AM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19072048
   Petros JA, 2005, P NATL ACAD SCI USA, V102, P719, DOI 10.1073/pnas.0408894102
   Picard M, 2014, P NATL ACAD SCI USA, V111, pE4033, DOI 10.1073/pnas.1414028111
   Picca A, 2022, CELLS-BASEL, V11, DOI 10.3390/cells11040675
   Picca A, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9030598
   Picca A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18050933
   Picca A, 2015, MITOCHONDRION, V25, P67, DOI 10.1016/j.mito.2015.10.001
   Picca A, 2014, BBA-GEN SUBJECTS, V1840, P2184, DOI 10.1016/j.bbagen.2014.03.004
   Picca A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074644
   Picca A, 2013, AGE, V35, P1607, DOI 10.1007/s11357-012-9465-z
   Piel RB, 2019, MOL GENET METAB, V128, P198, DOI 10.1016/j.ymgme.2019.01.006
   Pinto M, 2017, CELL DEATH DIFFER, V24, P288, DOI 10.1038/cdd.2016.123
   Piskounova E, 2015, NATURE, V527, P186, DOI 10.1038/nature15726
   Porporato PE, 2014, CELL REP, V8, P754, DOI 10.1016/j.celrep.2014.06.043
   Pyle A, 2016, NEUROBIOL AGING, V38, DOI 10.1016/j.neurobiolaging.2015.10.033
   Pyle A, 2015, ANN NEUROL, V78, P1000, DOI 10.1002/ana.24515
   Rahman S, 2020, J INTERN MED, V287, P609, DOI 10.1111/joim.13054
   Rahman S, 2019, NAT REV NEUROL, V15, P40, DOI 10.1038/s41582-018-0101-0
   Rana M, 2000, ANN NEUROL, V48, P774, DOI 10.1002/1531-8249(200011)48:5<774::AID-ANA11>3.3.CO;2-9
   Rebelo AP, 2011, J INHERIT METAB DIS, V34, P941, DOI 10.1007/s10545-011-9330-8
   Reznik E, 2016, ELIFE, V5, DOI 10.7554/eLife.10769
   Rice AC, 2014, J ALZHEIMERS DIS, V40, P319, DOI 10.3233/JAD-131715
   Rius R, 2019, GENET MED, V21, P2823, DOI 10.1038/s41436-019-0568-0
   Ross JM, 2013, NATURE, V501, P412, DOI 10.1038/nature12474
   Rossignol R, 1999, J BIOL CHEM, V274, P33426, DOI 10.1074/jbc.274.47.33426
   Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320
   Scarpulla RC, 2008, PHYSIOL REV, V88, P611, DOI 10.1152/physrev.00025.2007
   Schafer ZT, 2009, NATURE, V461, P109, DOI 10.1038/nature08268
   Schmauck-Medina T, 2022, AGING-US, V14, P6829, DOI 10.18632/aging.204248
   SCHON EA, 1989, SCIENCE, V244, P346, DOI 10.1126/science.2711184
   Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350
   Sciacovelli M, 2016, NATURE, V537, P544, DOI 10.1038/nature19353
   Shidara Y, 2005, CANCER RES, V65, P1655, DOI 10.1158/0008-5472.CAN-04-2012
   Silva DF, 2013, CURR ALZHEIMER RES, V10, P180
   Silva DF, 2013, HUM MOL GENET, V22, P3931, DOI 10.1093/hmg/ddt247
   Srivastava S, 2017, GENES-BASEL, V8, DOI 10.3390/genes8120398
   St John JC, 2004, GENETICS, V167, P897, DOI 10.1534/genetics.103.025049
   Stewart TA, 2015, BBA-BIOMEMBRANES, V1848, P2502, DOI 10.1016/j.bbamem.2014.08.016
   Strobbe D, 2018, NEUROBIOL DIS, V114, P129, DOI 10.1016/j.nbd.2018.02.010
   Swerdlow RH, 2017, PROG MOL BIOL TRANSL, V146, P259, DOI 10.1016/bs.pmbts.2016.12.017
   Swerdlow RH, 2001, EXP NEUROL, V169, P479, DOI 10.1006/exnr.2001.7674
   Swerdlow RH, 1998, ANN NEUROL, V44, P873, DOI 10.1002/ana.410440605
   Tan EK, 2000, NEUROLOGY, V55, P533, DOI 10.1212/WNL.55.4.533
   Taylor RW, 2003, ANN NEUROL, V54, P521, DOI 10.1002/ana.10673
   Thiffault C, 2005, MITOCHONDRION, V5, P109, DOI 10.1016/j.mito.2004.12.002
   Thyagarajan D, 2000, ANN NEUROL, V48, P730, DOI 10.1002/1531-8249(200011)48:5<730::AID-ANA6>3.0.CO;2-0
   Torroni A, 2000, AM J HUM GENET, V66, P1173, DOI 10.1086/302789
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Tyagi A, 2018, MUTAT RES-FUND MOL M, V810, P13, DOI 10.1016/j.mrfmmm.2018.05.002
   Tzoulis C, 2006, BRAIN, V129, P1685, DOI 10.1093/brain/awl097
   Vakifahmetoglu-Norberg H, 2017, BIOCHEM BIOPH RES CO, V482, P426, DOI 10.1016/j.bbrc.2016.11.088
   van den Ameele J, 2020, SEMIN CELL DEV BIOL, V97, P156, DOI 10.1016/j.semcdb.2019.10.001
   van Leeuwen N, 2014, AGE, V36, P1463, DOI 10.1007/s11357-014-9629-0
   Viscomi C, 2017, J INHERIT METAB DIS, V40, P587, DOI 10.1007/s10545-017-0027-5
   Wallace DC, 2018, NAT GENET, V50, P1642, DOI 10.1038/s41588-018-0264-z
   Wallace DC, 2015, CELL, V163, P33, DOI 10.1016/j.cell.2015.08.067
   Wallace DC, 2012, NAT REV CANCER, V12, P685, DOI 10.1038/nrc3365
   Wallace DC, 2010, ANNU REV PATHOL-MECH, V5, P297, DOI 10.1146/annurev.pathol.4.110807.092314
   Wallace DC, 2010, MITOCHONDRION, V10, P12, DOI 10.1016/j.mito.2009.09.006
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Weerts MJA, 2018, CANCERS, V10, DOI 10.3390/cancers10120500
   Wei W, 2020, J INTERN MED, V287, P634, DOI 10.1111/joim.13047
   Wei W, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15336-3
   Wei W, 2017, ACTA NEUROPATHOL COM, V5, DOI 10.1186/s40478-016-0404-6
   Xiao JL, 2018, CARCINOGENESIS, V39, P1311, DOI 10.1093/carcin/bgy133
   Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514
   YEN TC, 1991, BIOCHEM BIOPH RES CO, V178, P124, DOI 10.1016/0006-291X(91)91788-E
   Yuan Y, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1349-z
   Yuan Y, 2020, NAT GENET, V52, P342, DOI 10.1038/s41588-019-0557-x
   Zhang RY, 2017, BMC GENOMICS, V18, DOI 10.1186/s12864-017-4287-0
   Zhao X, 2004, HEREDITY, V93, P399, DOI 10.1038/sj.hdy.6800516
NR 188
TC 14
Z9 14
U1 2
U2 12
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0531-5565
EI 1873-6815
J9 EXP GERONTOL
JI Exp. Gerontol.
PD JUL
PY 2023
VL 178
AR 112203
DI 10.1016/j.exger.2023.112203
EA MAY 2023
PG 13
WC Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Geriatrics & Gerontology
GA J4QG0
UT WOS:001009468200001
PM 37172915
OA hybrid
DA 2024-11-01
ER

PT J
AU Vergani, L
   Malena, A
   Sabatelli, P
   Loro, E
   Cavallini, L
   Magalhaes, P
   Valente, L
   Bragantini, F
   Carrara, F
   Leger, B
   Poulton, J
   Russell, AP
   Holt, IJ
AF Vergani, Lodovica
   Malena, Adriana
   Sabatelli, Patrizia
   Loro, Emanuele
   Cavallini, Lucia
   Magalhaes, Paolo
   Valente, Lucia
   Bragantini, Federica
   Carrara, Franco
   Leger, Bertrand
   Poulton, Joanna
   Russell, Aaron P.
   Holt, Ian J.
TI Cultured muscle cells display defects of mitochondrial myopathy
   ameliorated by anti-oxidants
SO BRAIN
LA English
DT Article
DE cybrids; MELAS; differentiation; ROS
ID STROKE-LIKE EPISODES; OXIDATIVE STRESS; LACTIC-ACIDOSIS; TRANSCRIPTION
   TERMINATION; TISSUE-SPECIFICITY; SKELETAL-MUSCLE; MELAS SUBGROUP;
   MUTATION; MTDNA; DEFICIENCY
AB The mitochondrial DNA A3243G mutation causes neuromuscular disease. To investigate the muscle-specific pathophysiology of mitochondrial disease, rhabdomyosarcoma transmitochondrial hybrid cells (cybrids) were generated that retain the capacity to differentiate to myotubes. In some cases, striated muscle-like fibres were formed after innervation with rat embryonic spinal cord. Myotubes carrying A3243G mtDNA produced more reactive oxygen species than controls, and had altered glutathione homeostasis. Moreover, A3243G mutant myotubes showed evidence of abnormal mitochondrial distribution, which was associated with down-regulation of three genes involved in mitochondrial morphology, Mfn1, Mfn2 and DRP1. Electron microscopy revealed mitochondria with ultrastructural abnormalities and paracrystalline inclusions. All these features were ameliorated by anti-oxidant treatment, with the exception of the paracrystalline inclusions. These data suggest that rhabdomyosarcoma cybrids are a valid cellular model for studying muscle-specific features of mitochondrial disease and that excess reactive oxygen species production is a significant contributor to mitochondrial dysfunction, which is amenable to anti-oxidant therapy.
C1 Univ Padua, Dept Neurol Sci, I-35129 Padua, Italy.
   CNR, ITOI, IOP, I-40136 Bologna, Italy.
   Univ Padua, Dept Biochem, I-35121 Padua, Italy.
   Univ Padua, Dept Biomed Sci, I-35121 Padua, Italy.
   Natl Neurol Inst C Besta, Dept Mol Neurogenet, I-20126 Milan, Italy.
   Clin Romande Readaptat, CH-1951 Sion, Switzerland.
   John Radcliffe Hosp, Dept Obstet & Gynaecol, Oxford OX3 9DU, England.
   Deakin Univ, Sch Exercise & Nutr Sci, Geelong, Vic 3125, Australia.
   Univ Cambridge, MRC, Dunn Human Nutr Unit, Cambridge CB2 OXY, England.
C3 University of Padua; Consiglio Nazionale delle Ricerche (CNR);
   University of Padua; University of Padua; Fondazione IRCCS Istituto
   Neurologico Carlo Besta; University of Oxford; Deakin University; UK
   Research & Innovation (UKRI); Medical Research Council UK (MRC); MRC
   Human Nutrition Research; University of Cambridge
RP Vergani, L (corresponding author), Venetian Inst Mol Med, Via Orus,2, I-35129 Padua, Italy.
EM lodovica.vergani@unipd.it
RI Loro, Emanuele/J-5212-2019; Léger, Bertrand/AAK-4356-2020; Poulton,
   Joanna/AAB-4828-2021; Loro, Emanuele/L-4999-2017; holt,
   ian/AFT-2565-2022; Sabatelli, Patrizia/C-7479-2019
OI Poulton, Joanna/0000-0002-2460-5587; Russell, Aaron/0000-0002-7323-9501;
   Loro, Emanuele/0000-0002-0822-4514; holt, ian/0000-0001-5468-0193;
   Sabatelli, Patrizia/0000-0003-2345-5094; Leger,
   Bertrand/0000-0003-2782-1442
FU MRC [G0500695, MC_U105663140] Funding Source: UKRI; Medical Research
   Council [G0500695, MC_U105663140] Funding Source: Medline; Telethon
   [1252] Funding Source: Medline
CR Antonicka H, 2006, HUM MOL GENET, V15, P1835, DOI 10.1093/hmg/ddl106
   Bach D, 2003, J BIOL CHEM, V278, P17190, DOI 10.1074/jbc.M212754200
   Brookes PS, 2004, AM J PHYSIOL-CELL PH, V287, pC817, DOI 10.1152/ajpcell.00139.2004
   Chan DC, 2006, CELL, V125, P1241, DOI 10.1016/j.cell.2006.06.010
   Chomyn A, 2000, J BIOL CHEM, V275, P19198, DOI 10.1074/jbc.M908734199
   CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221
   DUNBAR DR, 1995, P NATL ACAD SCI USA, V92, P6562, DOI 10.1073/pnas.92.14.6562
   Dunbar DR, 1996, HUM MOL GENET, V5, P123, DOI 10.1093/hmg/5.1.123
   Filosto M, 2002, ACTA NEUROPATHOL, V103, P215, DOI 10.1007/s004010100455
   Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4
   Frieden M, 2004, J BIOL CHEM, V279, P22704, DOI 10.1074/jbc.M312366200
   Gonzalo R, 2005, FEBS LETT, V579, P6909, DOI 10.1016/j.febslet.2005.11.034
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Halliwell B, 2003, FEBS LETT, V540, P3, DOI 10.1016/S0014-5793(03)00235-7
   HAMMANS SR, 1992, BRAIN, V115, P343, DOI 10.1093/brain/115.2.343
   Hargreaves IP, 2005, J INHERIT METAB DIS, V28, P81, DOI 10.1007/s10545-005-4160-1
   HESS JF, 1991, NATURE, V351, P236, DOI 10.1038/351236a0
   Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826
   Jacobs HT, 2003, AGING CELL, V2, P11, DOI 10.1046/j.1474-9728.2003.00032.x
   Kamei S, 2005, INVEST OPHTH VIS SCI, V46, P4288, DOI 10.1167/iovs.03-1407
   Kelly G S, 1998, Altern Med Rev, V3, P114
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   Kirkinezos IG, 2001, SEMIN CELL DEV BIOL, V12, P449, DOI 10.1006/scdb.2001.0282
   KOBAYASHI T, 1987, J NEUROSCI, V7, P3131
   Kraft CS, 2006, AM J PHYSIOL-CELL PH, V290, pC1119, DOI 10.1152/ajpcell.00463.2005
   Leary SC, 1998, BBA-BIOENERGETICS, V1365, P522, DOI 10.1016/S0005-2728(98)00105-4
   Léger B, 2006, FASEB J, V20, P583, DOI 10.1096/fj.05-5249fje
   Lyons CN, 2004, BIOCHEM CELL BIOL, V82, P391, DOI 10.1139/O04-040
   Mattiazzi M, 2004, HUM MOL GENET, V13, P869, DOI 10.1093/hmg/ddh103
   MORAES CT, 1992, AM J HUM GENET, V50, P934
   MORGANHUGHES JA, 1995, BBA-MOL BASIS DIS, V1271, P135, DOI 10.1016/0925-4439(95)00020-5
   OHKOSHI N, 1995, MUSCLE NERVE, V18, P1265, DOI 10.1002/mus.880181108
   PANG CY, 2001, ENHANCED OXIDATIVE D, pS45
   Pletjushkina OY, 2006, BBA-BIOENERGETICS, V1757, P518, DOI 10.1016/j.bbabio.2006.03.018
   Rojo M, 2002, J CELL SCI, V115, P1663
   Saada A, 2003, MOL GENET METAB, V79, P1, DOI 10.1016/S1096-7192(03)00063-5
   Schafer FQ, 2001, FREE RADICAL BIO MED, V30, P1191, DOI 10.1016/S0891-5849(01)00480-4
   Shin KS, 1996, DEV BIOL, V175, P14, DOI 10.1006/dbio.1996.0091
   Smirnova E, 1998, J CELL BIOL, V143, P351, DOI 10.1083/jcb.143.2.351
   Tanaka Y, 1998, CELL, V93, P1147, DOI 10.1016/S0092-8674(00)81459-2
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   TIRANTI V, 1995, HUM MOL GENET, V4, P2017, DOI 10.1093/hmg/4.11.2017
   Tsatmali M, 2005, BRAIN RES, V1040, P137, DOI 10.1016/j.brainres.2005.01.087
   Tsatmali M, 2006, MOL CELL NEUROSCI, V33, P345, DOI 10.1016/j.mcn.2006.08.005
   Van Heerebeek L, 2002, J CLIN PATHOL, V55, P561, DOI 10.1136/jcp.55.8.561
   VANDENOUWELAND JMW, 1992, NAT GENET, V1, P368, DOI 10.1038/ng0892-368
   Vergani L, 2004, EUR J BIOCHEM, V271, P3646, DOI 10.1111/j.1432-1033.2004.04298.x
   Vergani L, 2000, NEUROMUSCULAR DISORD, V10, P454, DOI 10.1016/S0960-8966(00)00096-1
   Wittenhagen LM, 2002, NAT STRUCT BIOL, V9, P586, DOI 10.1038/nsb820
   Wong A, 2002, HUM MOL GENET, V11, P431, DOI 10.1093/hmg/11.4.431
   Wong A, 1997, BIOCHEM BIOPH RES CO, V239, P139, DOI 10.1006/bbrc.1997.7443
   Yasukawa T, 2005, FEBS LETT, V579, P2948, DOI 10.1016/j.febslet.2005.04.038
   Yasukawa T, 2000, J BIOL CHEM, V275, P4251, DOI 10.1074/jbc.275.6.4251
NR 53
TC 13
Z9 14
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
J9 BRAIN
JI Brain
PD OCT
PY 2007
VL 130
BP 2715
EP 2724
DI 10.1093/brain/awm151
PN 10
PG 10
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 218UC
UT WOS:000250039500022
PM 17626036
OA Green Submitted
DA 2024-11-01
ER

PT J
AU Morel, G
   Bannwarth, S
   Chaussenot, A
   Cano, A
   Fragaki, K
   Ait-El-Mkadem, S
   Rouzier, C
   De Paula, AM
   Chabrol, B
   Paquis-Flucklinger, V
AF Morel, Godelieve
   Bannwarth, Sylvie
   Chaussenot, Annabelle
   Cano, Aline
   Fragaki, Konstantina
   Ait-El-Mkadem, Samira
   Rouzier, Cecile
   De Paula, Andre Maues
   Chabrol, Brigitte
   Paquis-Flucklinger, Veronique
TI A new mutation in the mitochondrial tRNA<SUP>Pro</SUP> gene associated
   with early-onset neuromuscular phenotype and ragged-red fibers
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE Mitochondrial myopathy; mtDNA; MTTP gene; Neuromuscular disease; New
   mutation; NGS
ID TRANSFER-RNAS; DNA
AB An 11-year-old boy with psychomotor delay, exercise intolerance, ptosis and growth delay had a muscle biopsy showing typical mitochondrial alterations (60% of ragged-red fibers and 90% of cytochrome-c oxidase-deficient fibers). Next-generation sequencing revealed a novel heteroplasmic mutation (m.15958A>T) in the MTTP gene that encodes tRNA(Pro). The mutation was not present in the accessible non-muscle tissues of the patient's asymptomatic mother. Mutations in the rarely affected MTTP gene are responsible for different clinical presentations. We report the third early-onset case associated with a mutation in this gene. The severity of myopathy is likely related to the high mutation rate (96%) found in the patient's muscle. The clinical heterogeneity associated with MTTP mutations illustrates the value of the next-generation sequencing in routine diagnosis of mitochondrial diseases. (C) 2016 Published by Elsevier B.V.
C1 [Morel, Godelieve; Bannwarth, Sylvie; Chaussenot, Annabelle; Fragaki, Konstantina; Ait-El-Mkadem, Samira; Rouzier, Cecile; Paquis-Flucklinger, Veronique] Nice Teaching Hosp, Dept Med Genet, Natl Ctr Mitochondrial Dis, Nice, France.
   [Bannwarth, Sylvie; Chaussenot, Annabelle; Fragaki, Konstantina; Ait-El-Mkadem, Samira; Rouzier, Cecile; Paquis-Flucklinger, Veronique] Univ Nice Sophia Antipolis, CNRS, IRCAN, INSERM,UMR 7284, F-06107 Nice, France.
   [Bannwarth, Sylvie; Chaussenot, Annabelle; Fragaki, Konstantina; Ait-El-Mkadem, Samira; Rouzier, Cecile; Paquis-Flucklinger, Veronique] Univ Nice Sophia Antipolis, U1081, F-06107 Nice, France.
   [Cano, Aline; Chabrol, Brigitte] Marseille Teaching Hosp, Timone Hosp, Dept Neuropediat, Marseille, France.
   [De Paula, Andre Maues] Marseille Teaching Hosp, Timone Hosp, Dept Neuropathol, Marseille, France.
C3 CHU Nice; Universite Cote d'Azur; Institut National de la Sante et de la
   Recherche Medicale (Inserm); Centre National de la Recherche
   Scientifique (CNRS); CNRS - National Institute for Biology (INSB); CHU
   Nice; Universite Cote d'Azur; Aix-Marseille Universite; Assistance
   Publique-Hopitaux de Marseille; Aix-Marseille Universite; Assistance
   Publique-Hopitaux de Marseille
RP Paquis-Flucklinger, V (corresponding author), Univ Nice Sophia Antipolis, Sch Med, IRCAN, UMR 7284,INSERM,CNRS,U1081,UNS, 28 Ave Valombrose, F-06107 Nice 2, France.
EM paquis@hermes.unice.fr
RI Rouzier, Cecile/KCY-3619-2024
OI MOREL, Godelieve/0000-0002-4132-6264
CR Blakely EL, 2009, ARCH NEUROL-CHICAGO, V66, P399, DOI 10.1001/archneurol.2008.576
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Da Pozzo P, 2009, EUR J HUM GENET, V17, P1092, DOI 10.1038/ejhg.2009.12
   Grasbon-Frodl EM, 1999, NEUROGENETICS, V2, P121, DOI 10.1007/s100480050063
   IONASESCU VV, 1994, NEUROLOGY, V44, P975, DOI 10.1212/WNL.44.5.975
   MORAES CT, 1993, NAT GENET, V4, P284, DOI 10.1038/ng0793-284
   Paul R, 1996, TRENDS GENET, V12, P131
   Rouzier C, 2010, J MED GENET, V47, P670, DOI 10.1136/jmg.2009.073445
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8
   Scaglia F, 2008, MUSCLE NERVE, V37, P150, DOI 10.1002/mus.20917
   Seneca S, 2000, J INHERIT METAB DIS, V23, P853, DOI 10.1023/A:1026729223050
   Suzuki T, 2011, ANNU REV GENET, V45, P299, DOI 10.1146/annurev-genet-110410-132531
   Wong LJC, 2002, AM J MED GENET, V113, P59, DOI 10.1002/ajmg.10767
NR 13
TC 5
Z9 5
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD DEC
PY 2016
VL 26
IS 12
BP 885
EP 889
DI 10.1016/j.nmd.2016.09.012
PG 5
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA EG5HD
UT WOS:000391074000011
PM 27816331
DA 2024-11-01
ER

PT J
AU Dahal, S
   Siddiqua, H
   Sharma, S
   Babu, RK
   Rathore, D
   Sharma, S
   Raghavan, SC
AF Dahal, Sumedha
   Siddiqua, Humaira
   Sharma, Shivangi
   Babu, Ravi K.
   Rathore, Diksha
   Sharma, Sheetal
   Raghavan, Sathees C.
TI Unleashing a novel function of Endonuclease G in mitochondrial genome
   instability
SO ELIFE
LA English
DT Article
DE tetraplexes; mitochondrial fragility; Endo G; double-strand breaks;
   MMEJ; mitochondrial deletion; G4 DNA; E; coli; Human; Rat
ID NON-B-DNA; MAJOR BREAKPOINT REGION; G-QUADRUPLEX STRUCTURES; BASE
   EXCISION-REPAIR; MTDNA CONTROL-REGION; 9-BP DELETION; EVOLUTIONARY
   HISTORY; PROTEIN-A; END; NUCLEASE
AB Having its genome makes the mitochondrion a unique and semiautonomous organelle within cells. Mammalian mitochondrial DNA (mtDNA) is a double-stranded closed circular molecule of about 16 kb coding for 37 genes. Mutations, including deletions in the mitochondrial genome, can culminate in different human diseases. Mapping the deletion junctions suggests that the breakpoints are generally seen at hotspots. '9 bp deletion' (8271-8281), seen in the intergenic region of cytochrome c oxidase II/tRNA(Lys), is the most common mitochondrial deletion. While it is associated with several diseases like myopathy, dystonia, and hepatocellular carcinoma, it has also been used as an evolutionary marker. However, the mechanism responsible for its fragility is unclear. In the current study, we show that Endonuclease G, a mitochondrial nuclease responsible for nonspecific cleavage of nuclear DNA during apoptosis, can induce breaks at sequences associated with '9 bp deletion' when it is present on a plasmid or in the mitochondrial genome. Through a series of in vitro and intracellular studies, we show that Endonuclease G binds to G-quadruplex structures formed at the hotspot and induces DNA breaks. Therefore, we uncover a new role for Endonuclease G in generating mtDNA deletions, which depends on the formation of G4 DNA within the mitochondrial genome. In summary, we identify a novel property of Endonuclease G, besides its role in apoptosis and the recently described 'elimination of paternal mitochondria during fertilisation.
C1 [Dahal, Sumedha; Siddiqua, Humaira; Sharma, Shivangi; Babu, Ravi K.; Rathore, Diksha; Raghavan, Sathees C.] Indian Inst Sci Bangalore, Dept Biochem, Bangalore, India.
   [Sharma, Sheetal] Post Grad Inst Med Educ & Res, Dept Expt Med & Biotechnol, Chandigarh, India.
C3 Indian Institute of Science (IISC) - Bangalore; Post Graduate Institute
   of Medical Education & Research (PGIMER), Chandigarh
RP Raghavan, SC (corresponding author), Indian Inst Sci Bangalore, Dept Biochem, Bangalore, India.
EM sathees@iisc.ac.in
RI ; Dahal, Sumedha/ABG-8228-2021
OI Raghavan, Sathees/0000-0003-3003-1417; Dahal,
   Sumedha/0000-0003-3682-5656
FU Council of Scientific and Industrial Research, India
   [37(1692)/17/EMR-11]; Department of Atomic Energy, Government of India
   [21/01/2016-BRNS/35074]; Department of Biotechnology, Ministry of
   Science and Technology, India [BT/PR/3458/COE/34/33/2015]; IISc-DBT
   partnership programme [BT/PR27952-INF/22/212/2018]; Indian Institute of
   Science
FX Council of Scientific and Industrial Research, India 37(1692)/17/EMR-11
   Sathees C Raghavan Department of Atomic Energy, Government of India
   21/01/2016-BRNS/35074 Sathees C Raghavan Department of Biotechnology,
   Ministry of Science and Technology, India BT/PR/3458/COE/34/33/2015
   Sathees C Raghavan IISc-DBT partnership programme
   BT/PR27952-INF/22/212/2018 Sathees C Raghavan Indian Institute of
   Science Sumedha Dahal Humaira Siddiqua
CR Akbari M, 2008, DNA REPAIR, V7, P605, DOI 10.1016/j.dnarep.2008.01.002
   Bharti SK, 2014, J BIOL CHEM, V289, P29975, DOI 10.1074/jbc.M114.567073
   Bianchi NO, 2001, MUTAT RES-REV MUTAT, V488, P9, DOI 10.1016/S1383-5742(00)00063-6
   Biffi G, 2013, NAT CHEM, V5, P182, DOI [10.1038/nchem.1548, 10.1038/NCHEM.1548]
   Butler TJ, 2020, HUM MOL GENET, V29, P1292, DOI 10.1093/hmg/ddaa043
   Carew Jennifer S, 2002, Mol Cancer, V1, P9, DOI 10.1186/1476-4598-1-9
   Carey Michael F, 2009, Cold Spring Harb Protoc, V2009, DOI 10.1101/pdb.prot5279
   Cer RZ, 2013, NUCLEIC ACIDS RES, V41, pD94, DOI 10.1093/nar/gks955
   Chambers VS, 2015, NAT BIOTECHNOL, V33, P877, DOI 10.1038/nbt.3295
   Chen T, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-8
   Chen XJ, 2005, NAT REV GENET, V6, P815, DOI 10.1038/nrg1708
   Chiruvella KK, 2012, J MOL BIOL, V417, P197, DOI 10.1016/j.jmb.2012.01.029
   Chiruvella KK, 2008, FEBS LETT, V582, P4066, DOI 10.1016/j.febslet.2008.11.001
   Chu IT, 2019, BBA-GEN SUBJECTS, V1863, P418, DOI 10.1016/j.bbagen.2018.11.009
   CLAYTON DA, 1984, ANNU REV BIOCHEM, V53, P573
   COTE J, 1989, J BIOL CHEM, V264, P3301
   Dahal S, 2022, FEBS J, V289, P163, DOI 10.1111/febs.16113
   Dahal S, 2018, CELL MOL LIFE SCI, V75, P1641, DOI 10.1007/s00018-017-2702-y
   Damas J, 2012, NUCLEIC ACIDS RES, V40, P7606, DOI 10.1093/nar/gks500
   Das K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158794
   de Souza-Pinto NC, 2009, DNA REPAIR, V8, P704, DOI 10.1016/j.dnarep.2009.01.021
   Dillon LW, 2010, CURR GENOMICS, V11, P326, DOI 10.2174/138920210791616699
   Dong DW, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-677
   Dong LF, 2017, ELIFE, V6, DOI 10.7554/eLife.22187
   Dornberger U, 1999, J BIOL CHEM, V274, P6957, DOI 10.1074/jbc.274.11.6957
   Duguay BA, 2013, J VIROL, V87, P11787, DOI 10.1128/JVI.02306-13
   Falabella M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41464-y
   Falabella M, 2019, CURR MED CHEM, V26, P2918, DOI 10.2174/0929867325666180228165527
   Gannavaram S, 2008, J CELL SCI, V121, P99, DOI 10.1242/jcs.014050
   Ghosh D, 2022, J MOL BIOL, V434, DOI 10.1016/j.jmb.2022.167617
   Giri B, 2011, NUCLEIC ACIDS RES, V39, P7161, DOI 10.1093/nar/gkr234
   Greene AL, 1999, HUM MOL GENET, V8, P2263, DOI 10.1093/hmg/8.12.2263
   Holthöfer H, 1999, FASEB J, V13, P523, DOI 10.1096/fasebj.13.3.523
   Hudson EK, 1998, FREE RADICAL RES, V29, P573, DOI 10.1080/10715769800300611
   Javadekar SM, 2020, DNA RES, V27, DOI 10.1093/dnares/dsaa024
   Jin YQ, 2012, GENET TEST MOL BIOMA, V16, P330, DOI 10.1089/gtmb.2011.0208
   Jose D, 2009, P NATL ACAD SCI USA, V106, P4231, DOI 10.1073/pnas.0900803106
   Kalifa L, 2009, DNA REPAIR, V8, P1242, DOI 10.1016/j.dnarep.2009.07.008
   Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341
   Komandur S, 2011, GENET TEST MOL BIOMA, V15, P361, DOI 10.1089/gtmb.2010.0205
   Krishnan KJ, 2010, ESSAYS BIOCHEM, V47, P139, DOI [10.1042/BSE0470139, 10.1042/bse0470139]
   Kumar TS, 2010, J BIOL CHEM, V285, P32657, DOI 10.1074/jbc.M110.140350
   Kumari N, 2019, ISCIENCE, V21, P288, DOI 10.1016/j.isci.2019.10.033
   Kumari R, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109390
   Kumari R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119722
   LEE HC, 1994, BBA-MOL BASIS DIS, V1226, P37, DOI 10.1016/0925-4439(94)90056-6
   Li LY, 2001, NATURE, V412, P95, DOI 10.1038/35083620
   Lin WQ, 2013, EMBO J, V32, P1425, DOI 10.1038/emboj.2013.88
   Liu P, 2008, MOL CELL BIOL, V28, P4975, DOI 10.1128/MCB.00457-08
   Lombardi EP, 2020, NUCLEIC ACIDS RES, V48, P1, DOI 10.1093/nar/gkz1097
   Longo PA, 2013, METHOD ENZYMOL, V529, P227, DOI 10.1016/B978-0-12-418687-3.00018-5
   Marni G, 2003, MITOCHONDRIAL DNA DE
   Masuda-Sasa T, 2008, J BIOL CHEM, V283, P24359, DOI 10.1074/jbc.M802244200
   McDermott-Roe C, 2011, NATURE, V478, P114, DOI 10.1038/nature10490
   Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774
   Misic V, 2016, BIOCHEMISTRY-MOSCOW+, V81, P163, DOI 10.1134/S0006297916020103
   Modica-Napolitano JS, 2007, CURR MOL MED, V7, P121, DOI 10.2174/156652407779940495
   Naik AK, 2010, J BIOL CHEM, V285, P7587, DOI 10.1074/jbc.M109.089631
   Nambiar M, 2013, MOL CELL BIOL, V33, P4266, DOI 10.1128/MCB.00540-13
   Nambiar M, 2012, J BIOL CHEM, V287, P8688, DOI 10.1074/jbc.M111.307363
   Nambiar M, 2011, NUCLEIC ACIDS RES, V39, P936, DOI 10.1093/nar/gkq824
   Nishana M, 2012, BIOCHEM J, V448, P115, DOI 10.1042/BJ20121031
   Ohsato T, 2002, EUR J BIOCHEM, V269, P5765, DOI 10.1046/j.1432-1033.2002.03238.x
   Oliveira PH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059907
   Omar Garcia-lepe U, 2019, Mitochondrial genome maintenance: damage and repair pathways
   Paeschke K, 2013, NATURE, V497, P458, DOI 10.1038/nature12149
   Pakendorf B, 2005, ANNU REV GENOM HUM G, V6, P165, DOI 10.1146/annurev.genom.6.080604.162249
   Parrish J, 2001, NATURE, V412, P90, DOI 10.1038/35083608
   Penta JS, 2001, MUTAT RES-REV MUTAT, V488, P119, DOI 10.1016/S1383-5742(01)00053-9
   Phillips AF, 2017, MOL CELL, V65, P527, DOI 10.1016/j.molcel.2016.12.014
   Raghavan SC, 2006, METHOD ENZYMOL, V409, P301, DOI 10.1016/S0076-6879(05)09017-8
   Raghavan SC, 2005, MOL CELL BIOL, V25, P6475, DOI 10.1128/MCB.25.15.6475-6484.2005
   Raghavan SC, 2005, J BIOL CHEM, V280, P22749, DOI 10.1074/jbc.M502952200
   Raghavan SC, 2005, MOL CELL BIOL, V25, P5904, DOI 10.1128/MCB.25.14.5904-5919.2005
   Raghavan SC, 2004, NATURE, V428, P88, DOI 10.1038/nature02355
   Ray U, 2020, MOL CARCINOGEN, V59, P618, DOI 10.1002/mc.23186
   Raymond C, 2011, METHODS, V55, P44, DOI 10.1016/j.ymeth.2011.04.002
   REDD AJ, 1995, MOL BIOL EVOL, V12, P604
   Richards M, 2001, AM J HUM GENET, V68, P1315, DOI 10.1086/320615
   RUIZCARRILLO A, 1987, EMBO J, V6, P401, DOI 10.1002/j.1460-2075.1987.tb04769.x
   Sambrook J., 1989, Molecular cloning: a laboratory manual
   Samuels DC, 2004, TRENDS GENET, V20, P393, DOI 10.1016/j.tig.2004.07.003
   Sanchez MIGL, 2011, CELL CYCLE, V10, P2904, DOI 10.4161/cc.10.17.17060
   Schäfer P, 2004, J MOL BIOL, V338, P217, DOI 10.1016/j.jmb.2004.02.069
   Sharma S, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.58
   Sharma S, 2011, CELL MOL LIFE SCI, V68, P661, DOI 10.1007/s00018-010-0472-x
   Sinha D, 2010, HUM MOL GENET, V19, P1248, DOI 10.1093/hmg/ddq002
   Soodyall H, 1996, AM J HUM GENET, V58, P595
   Srivastava M, 2012, CELL, V151, P1474, DOI 10.1016/j.cell.2012.11.054
   Srivastava S, 2005, HUM MOL GENET, V14, P893, DOI 10.1093/hmg/ddi082
   Sun H, 2001, P NATL ACAD SCI USA, V98, P12444, DOI 10.1073/pnas.231479198
   Suzuki H, 2002, J CELL SCI, V115, P1895
   Tadi SK, 2016, MOL BIOL CELL, V27, P223, DOI 10.1091/mbc.E15-05-0260
   Tan AS, 2015, CELL METAB, V21, P81, DOI 10.1016/j.cmet.2014.12.003
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Thomas E, 2016, SCI REP-UK, V6, DOI 10.1038/srep34653
   Thomas MG, 1998, PHILOS T R SOC B, V353, P955, DOI 10.1098/rstb.1998.0260
   Totaro A, 2011, NUCLEIC ACIDS RES, V39, P635, DOI 10.1093/nar/gkq797
   Van Goethem G, 2003, NEUROMOL MED, V3, P129, DOI 10.1385/NMM:3:3:129
   van Loo G, 2001, CELL DEATH DIFFER, V8, P1136, DOI 10.1038/sj.cdd.4400944
   Voineagu I, 2008, P NATL ACAD SCI USA, V105, P9936, DOI 10.1073/pnas.0804510105
   Wells RD, 2009, J BIOL CHEM, V284, P8997, DOI 10.1074/jbc.X800010200
   Wiehe Rahel Stefanie, 2018, Oncotarget, V9, P18309, DOI 10.18632/oncotarget.24822
   Wisnovsky S, 2018, ACS CHEM BIOL, V13, P900, DOI 10.1021/acschembio.8b00072
   Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514
   Yang C, 2018, NUCLEIC ACIDS RES, V46, P11075, DOI 10.1093/nar/gky855
   YANG JH, 1994, ARCH DERMATOL RES, V286, P386, DOI 10.1007/BF00371798
   Yao YG, 2000, HUM GENET, V107, P504, DOI 10.1007/s004390000403
   YEN TC, 1991, BIOCHEM BIOPH RES CO, V178, P124, DOI 10.1016/0006-291X(91)91788-E
   Yeretssian G, 2011, NATURE, V474, P96, DOI 10.1038/nature09982
   Yu X, 2000, J BIOL CHEM, V275, P18541, DOI 10.1074/jbc.M909494199
   Yusoff AAM, 2019, ONCOL REV, V13, P54, DOI 10.4081/oncol.2019.409
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
   Zhou QH, 2016, SCIENCE, V353, P394, DOI 10.1126/science.aaf4777
   Zhuo GC, 2010, BIOCHEM GENET, V48, P157, DOI 10.1007/s10528-009-9308-5
NR 115
TC 9
Z9 9
U1 1
U2 14
PU eLIFE SCIENCES PUBL LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050-084X
J9 ELIFE
JI eLife
PD NOV 17
PY 2022
VL 11
AR e69916
DI 10.7554/eLife.69916
PG 35
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA 6S5IB
UT WOS:000893019500001
PM 36394256
OA gold, Green Published, Green Submitted
DA 2024-11-01
ER

PT J
AU Pereira, C
   Nogueira, C
   Barbot, C
   Tessa, A
   Soares, C
   Fattori, F
   Guimaraes, A
   Santorelli, FM
   Vilarinho, L
AF Pereira, Cristina
   Nogueira, Celia
   Barbot, Clara
   Tessa, Alessandra
   Soares, Carla
   Fattori, Fabiana
   Guimaraes, Antonio
   Santorelli, Filippo M.
   Vilarinho, Laura
TI Identification of a new mtDNA mutation (14724G&gt;A) associated with
   mitochondrial leukoencephalopathy
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE mtDNA; mutation; transfer RNA
ID WHITE-MATTER INVOLVEMENT; C-OXIDASE DEFICIENCY; POINT MUTATION;
   LEIGH-SYNDROME; DNA; DIAGNOSIS; DISORDERS; TRNA(GLU); CHILDREN; DISEASES
AB We report a novel 14724G > A mutation in the mitochondrial tRNA glutamic acid gene in a 4-year-old boy with myopathy and leukoencephalopathy. A muscle biopsy showed cytochrome c oxidase-negative ragged-red fibers and biochemical analysis of the respiratory chain enzymes in muscle homogenate revealed partial complex I and complex IV deficiencies. The mutation, which affects the dihydrouridine arm at a conserved site, was nearly homoplasmic in muscle and heteroplasmic in blood DNA of the proband, but it was absent in peripheral leukocytes from the asymptomatic mother, sister, and two maternal aunts, suggesting that it arose de novo. This report proposes to look for variants in the mitochondrial genome when dealing with otherwise undetermined leukodystrophies of childhood. (c) 2007 Elsevier Inc. All rights reserved.
C1 Childrens Hosp Bambino Gesu, IRCCS, I-00165 Rome, Italy.
   Inst Genet Med Jacinto de Magalhaes, P-4099028 Oporto, Portugal.
   Hosp Maria Pia, Neuropediat Dept, Oporto, Portugal.
   Hosp S Sebastiao, Dept Pediat, Oporto, Portugal.
   HGSA, Neuropathol Unit, Oporto, Portugal.
C3 IRCCS Bambino Gesu
RP Vilarinho, L (corresponding author), Childrens Hosp Bambino Gesu, IRCCS, Piazza S Onofrio, I-00165 Rome, Italy.
EM fms3@na.flashnet.it; laura.vilarinho@igm.min-saude.pt
RI Barbot, Clara/K-6378-2013; tessa, alessandra/AAA-4442-2021; Fattori,
   Fabiana/K-1033-2016; Santorelli, Filippo M/ABE-5124-2020
OI Barbot, Clara/0000-0002-5597-107X; Pereira,
   Cristina/0000-0002-5794-127X; tessa, alessandra/0000-0002-1445-6434;
   Fattori, Fabiana/0000-0002-1820-8489; Santorelli, Filippo
   M/0000-0002-1359-9062; Nogueira, Celia/0000-0003-3640-8537
CR Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Bruno C, 2003, J CHILD NEUROL, V18, P300, DOI 10.1177/08830738030180040401
   Di Rocco M, 2004, AM J MED GENET B, V129B, P85, DOI 10.1002/ajmg.b.30029
   DiMauro S, 2005, NEUROMUSCULAR DISORD, V15, P276, DOI 10.1016/j.nmd.2004.12.008
   DiMauro S, 2004, BBA-BIOENERGETICS, V1658, P80, DOI 10.1016/j.bbabio.2004.03.014
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   Hao HL, 1996, J BIOL CHEM, V271, P2347, DOI 10.1074/jbc.271.4.2347
   Harpey JP, 1998, J INHERIT METAB DIS, V21, P748, DOI 10.1023/A:1005497116398
   Helm M, 2000, RNA, V6, P1356, DOI 10.1017/S1355838200001047
   Lerman-Sagie T, 2005, MOL GENET METAB, V84, P127, DOI 10.1016/j.ymgme.2004.09.008
   Mayr JA, 2006, NEUROMUSCULAR DISORD, V16, P874, DOI 10.1016/j.nmd.2006.08.010
   McFarland R, 2004, TRENDS GENET, V20, P591, DOI 10.1016/j.tig.2004.09.014
   Melone MAB, 2004, ARCH NEUROL-CHICAGO, V61, P269, DOI 10.1001/archneur.61.2.269
   Meulemans A, 2006, ARCH NEUROL-CHICAGO, V63, P1194, DOI 10.1001/archneur.63.8.1194
   Moroni I, 2002, NEUROPEDIATRICS, V33, P79, DOI 10.1055/s-2002-32372
   Munnich A, 2001, AM J MED GENET, V106, P4, DOI 10.1002/ajmg.1391
   Perucca-Lostanlen D, 2002, BBA-MOL BASIS DIS, V1588, P210, DOI 10.1016/S0925-4439(02)00167-9
   Pistilli D, 2003, HUM PATHOL, V34, P1058, DOI 10.1053/S0046-8177(03)00344-7
   Rossi A, 2003, AM J NEURORADIOL, V24, P1188
   Schapira AHV, 2006, LANCET, V368, P70, DOI 10.1016/S0140-6736(06)68970-8
   Schiffmann R, 2004, CURR OPIN NEUROL, V17, P187, DOI 10.1097/00019052-200404000-00017
   Sciacco M, 1996, Methods Enzymol, V264, P509, DOI 10.1016/S0076-6879(96)64045-2
   Stewart Victoria C., 1998, Biochemical Society Transactions, V26, pS346
   Taylor RW, 1998, BIOCHEM BIOPH RES CO, V251, P883, DOI 10.1006/bbrc.1998.9553
   Tzen CY, 2003, MUSCLE NERVE, V28, P575, DOI 10.1002/mus.10473
   vanderKnaap MS, 1995, NEURORADIOLOGY, V37, P679, DOI 10.1007/BF00593394
   Vilarinho L, 1999, J NEUROL SCI, V163, P168, DOI 10.1016/S0022-510X(99)00030-1
NR 27
TC 12
Z9 13
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD MAR 23
PY 2007
VL 354
IS 4
BP 937
EP 941
DI 10.1016/j.bbrc.2007.01.068
PG 5
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 139DF
UT WOS:000244411800016
PM 17266923
DA 2024-11-01
ER

PT J
AU Connolly, BS
   Feigenbaum, ASJ
   Robinson, BH
   Dipchand, AI
   Simon, DK
   Tarnopolsky, MA
AF Connolly, Barbara S.
   Feigenbaum, Annette S. J.
   Robinson, Brian H.
   Dipchand, Anne I.
   Simon, David K.
   Tarnopolsky, Mark A.
TI MELAS syndrome, cardiomyopathy, rhabdomyolysis, and autism associated
   with the A3260G mitochondrial DNA mutation
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE MELAS syndrome; Leucine transfer RNA; Mitochondrial myopathy; Ragged red
   fibres
ID SPECTRUM DISORDERS; LACTIC-ACIDOSIS; POINT MUTATION; TRANSFER
   RNALEU(UUR); EPISODES MELAS; MYOPATHY; ENCEPHALOPATHY; DYSFUNCTION;
   ABNORMALITIES; GENOME
AB The A to G transition mutation at position 3260 of the mitochondrial genome is usually associated with cardiomyopathy and myopathy. One Japanese kindred reported the phenotype of mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS syndrome) in association with the A3260G mtDNA mutation. We describe the first Caucasian cases of MELAS syndrome associated with the A3260G mutation. Furthermore, this mutation was associated with exercise-induced rhabdomyolysis, hearing loss, seizures, cardiomyopathy, and autism in the large kindred. We conclude that the A3260G mtDNA mutation is associated with wide phenotypic heterogeneity with MELAS and other "classical" mitochondrial phenotypes being manifestations. (C) 2010 Elsevier Inc. All rights reserved.
C1 [Connolly, Barbara S.; Tarnopolsky, Mark A.] Hamilton Hlth Sci, Dept Med, Hamilton, ON, Canada.
   [Feigenbaum, Annette S. J.] Hosp Sick Children, Div Clin & Metab Genet, Toronto, ON M5G 1X8, Canada.
   [Feigenbaum, Annette S. J.; Robinson, Brian H.; Dipchand, Anne I.] Univ Toronto, Toronto, ON, Canada.
   [Robinson, Brian H.] Hosp Sick Children, Program Genet & Genome Biol, SickKids Res Inst, Toronto, ON M5G 1X8, Canada.
   [Robinson, Brian H.] Hosp Sick Children, Dept Pediat, Toronto, ON M5G 1X8, Canada.
   [Robinson, Brian H.] Hosp Sick Children, Dept Biochem, Toronto, ON M5G 1X8, Canada.
   [Dipchand, Anne I.] Hosp Sick Children, Div Cardiol, Toronto, ON M5G 1X8, Canada.
   [Simon, David K.] Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA.
   [Simon, David K.] Harvard Univ, Sch Med, Boston, MA USA.
   [Tarnopolsky, Mark A.] Hamilton Hlth Sci, Dept Pediat Neuromuscular & Neurometab Disorders, Hamilton, ON, Canada.
C3 McMaster University; University of Toronto; Hospital for Sick Children
   (SickKids); University of Toronto; University of Toronto; Hospital for
   Sick Children (SickKids); University of Toronto; Hospital for Sick
   Children (SickKids); University of Toronto; Hospital for Sick Children
   (SickKids); University of Toronto; Hospital for Sick Children
   (SickKids); Harvard University; Beth Israel Deaconess Medical Center;
   Harvard University; Harvard Medical School; McMaster University
RP Tarnopolsky, MA (corresponding author), McMaster Univ, Med Ctr, Dept Pediat & Med, Rm 2H26,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.
EM tarnopol@mcmaster.ca
RI Robinson, B/LBH-2242-2024
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Bourgeois JM, 2004, MITOCHONDRION, V4, P441, DOI 10.1016/j.mito.2004.07.036
   Carnpos Y, 2003, NEUROMUSCULAR DISORD, V13, P416, DOI 10.1016/S0960-8966(03)00039-7
   Chinnery PF, 2001, AM J MED GENET, V106, P94, DOI 10.1002/ajmg.1426
   Filiano JJ, 2002, J CHILD NEUROL, V17, P435, DOI 10.1177/088307380201700607
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   GOTO YI, 1994, BIOCHEM BIOPH RES CO, V202, P1624, DOI 10.1006/bbrc.1994.2119
   Graf WD, 2000, J CHILD NEUROL, V15, P357, DOI 10.1177/088307380001500601
   Hao HL, 1996, J BIOL CHEM, V271, P2347, DOI 10.1074/jbc.271.4.2347
   HIRANO M, 1992, NEUROMUSCULAR DISORD, V2, P125, DOI 10.1016/0960-8966(92)90045-8
   Lombard J, 1998, MED HYPOTHESES, V50, P497, DOI 10.1016/S0306-9877(98)90270-5
   MARIE SKN, 1994, BIOCHEM MED METAB B, V52, P136, DOI 10.1006/bmmb.1994.1045
   Mimaki M, 2009, MITOCHONDRION, V9, P115, DOI 10.1016/j.mito.2009.01.005
   MORTEN KJ, 1993, HUM MOL GENET, V2, P2081, DOI 10.1093/hmg/2.12.2081
   Nishino I, 1996, MUSCLE NERVE, V19, P1603, DOI 10.1002/(SICI)1097-4598(199612)19:12<1603::AID-MUS10>3.0.CO;2-S
   Nissenkorn A, 2000, J CHILD NEUROL, V15, P44, DOI 10.1177/088307380001500110
   Oliveira G, 2005, DEV MED CHILD NEUROL, V47, P185, DOI 10.1017/S0012162205000332
   Palmieri L, 2010, BBA-BIOENERGETICS, V1797, P1130, DOI 10.1016/j.bbabio.2010.04.018
   Pons R, 2004, J PEDIATR-US, V144, P81, DOI 10.1016/j.jpeds.2003.10.023
   Safdar A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010778
   Sproule DM, 2008, ANN NY ACAD SCI, V1142, P133, DOI 10.1196/annals.1444.011
   SWEENEY MG, 1993, Q J MED, V86, P435
   Tarnopolsky MA, 1998, MUSCLE NERVE, V21, P25, DOI 10.1002/(SICI)1097-4598(199801)21:1<25::AID-MUS4>3.0.CO;2-I
   Tsao CY, 2007, J CHILD NEUROL, V22, P1121, DOI 10.1177/0883073807306266
   Weissman JR, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003815
   ZEVIANI M, 1991, LANCET, V338, P143, DOI 10.1016/0140-6736(91)90136-D
NR 26
TC 24
Z9 26
U1 1
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD NOV 12
PY 2010
VL 402
IS 2
BP 443
EP 447
DI 10.1016/j.bbrc.2010.10.060
PG 5
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 688PA
UT WOS:000284862300050
PM 20965148
DA 2024-11-01
ER

PT J
AU Schaefer, AM
   Blakely, EL
   Griffiths, PG
   Turnbull, DM
   Taylor, RW
AF Schaefer, AM
   Blakely, EL
   Griffiths, PG
   Turnbull, DM
   Taylor, RW
TI Ophthalmoplegia due to mitochondrial DNA disease: The need for genetic
   diagnosis
SO MUSCLE & NERVE
LA English
DT Article
DE chronic progressive external ophthalmoplegia; cytochrome c oxidase;
   deletion; histochemistry; mitochondrial DNA
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; CYTOCHROME-C OXIDASE; MUTATION;
   MTDNA; DELETIONS
AB We describe a patient with chronic progressive external ophthalmoplegia (CPEO) who underwent muscle biopsy for suspected mitochondrial disease. In spite of normal histocytochemical cytochrome c oxidase (COX) activity and respiratory chain enzyme measurements in muscle, subsequent molecular genetic analysis revealed the presence of a single, large-scale deletion of mitochondrial DNA (mtDNA). The case serves to illustrate the importance of pursuing the proposed mitochondrial genetic abnormality, even in patients with normal biopsy findings.
C1 Newcastle Univ, Sch Med, Sch Neurol Neurobiol & Psychiat, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   Royal Victoria Infirm, Dept Ophthalmol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
C3 Newcastle University - UK; Newcastle University - UK
RP Newcastle Univ, Sch Med, Sch Neurol Neurobiol & Psychiat, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM r.w.taylor@ncl.ac.uk
OI Schaefer, Andrew/0000-0001-9891-7332
FU Wellcome Trust [074454] Funding Source: Medline
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Blakely EL, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.011296
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   Chinnery PF, 1997, NEUROLOGY, V49, P1166, DOI 10.1212/WNL.49.4.1166
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   JOHNSON MA, 1983, J NEUROL SCI, V60, P31, DOI 10.1016/0022-510X(83)90125-9
   Leigh R.J., 1999, NEUROLOGY EYE MOVEME, V3rd
   McFarland R, 2002, LANCET NEUROL, V1, P343, DOI 10.1016/S1474-4422(02)00159-X
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   MORAES CT, 1993, NEUROMUSCULAR DISORD, V3, P43, DOI 10.1016/0960-8966(93)90040-Q
   OLD SL, 1989, HISTOCHEM J, V21, P545, DOI 10.1007/BF01753355
   Richardson C, 2005, EYE, V19, P258, DOI 10.1038/sj.eye.6701488
   Samuels DC, 2004, TRENDS GENET, V20, P393, DOI 10.1016/j.tig.2004.07.003
   SCIACCO M, 1994, HUM MOL GENET, V3, P13, DOI 10.1093/hmg/3.1.13
   Suomalainen A, 2001, AM J MED GENET, V106, P53, DOI 10.1002/ajmg.1379
   Taylor R.W., 1997, Organelle Diseases : Clinical Features, Diagnosis, Pathogenesis, and Management, P341
   Taylor RW, 1998, BIOCHEM BIOPH RES CO, V243, P47, DOI 10.1006/bbrc.1997.8055
   Taylor RW, 2001, NUCLEIC ACIDS RES, V29, part. no., DOI 10.1093/nar/29.15.e74
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
NR 21
TC 18
Z9 19
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0148-639X
EI 1097-4598
J9 MUSCLE NERVE
JI Muscle Nerve
PD JUL
PY 2005
VL 32
IS 1
BP 104
EP 107
DI 10.1002/mus.20319
PG 4
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 940BQ
UT WOS:000230119100013
PM 15795893
DA 2024-11-01
ER

PT J
AU Samuels, DC
   Li, C
   Li, BS
   Song, Z
   Torstenson, E
   Clay, HB
   Rokas, A
   Thornton-Wells, TA
   Moore, JH
   Hughes, TM
   Hoffman, RD
   Haines, JL
   Murdock, DG
   Mortlock, DP
   Williams, SM
AF Samuels, David C.
   Li, Chun
   Li, Bingshan
   Song, Zhuo
   Torstenson, Eric
   Clay, Hayley Boyd
   Rokas, Antonis
   Thornton-Wells, Tricia A.
   Moore, Jason H.
   Hughes, Tia M.
   Hoffman, Robert D.
   Haines, Jonathan L.
   Murdock, Deborah G.
   Mortlock, Douglas P.
   Williams, Scott M.
TI Recurrent Tissue-Specific mtDNA Mutations Are Common in Humans
SO PLOS GENETICS
LA English
DT Article
ID HUMAN MITOCHONDRIAL-DNA; CONTROL REGION SEQUENCES; MAJOR NONCODING
   REGION; POINT MUTATIONS; HETEROPLASMIC MICE; HEALTHY-SUBJECTS;
   HIGH-FREQUENCY; DATA SET; AGE; REPLICATION
AB Mitochondrial DNA (mtDNA) variation can affect phenotypic variation; therefore, knowing its distribution within and among individuals is of importance to understanding many human diseases. Intra-individual mtDNA variation (heteroplasmy) has been generally assumed to be random. We used massively parallel sequencing to assess heteroplasmy across ten tissues and demonstrate that in unrelated individuals there are tissue-specific, recurrent mutations. Certain tissues, notably kidney, liver and skeletal muscle, displayed the identical recurrent mutations that were undetectable in other tissues in the same individuals. Using RFLP analyses we validated one of the tissue-specific mutations in the two sequenced individuals and replicated the patterns in two additional individuals. These recurrent mutations all occur within or in very close proximity to sites that regulate mtDNA replication, strongly implying that these variations alter the replication dynamics of the mutated mtDNA genome. These recurrent variants are all independent of each other and do not occur in the mtDNA coding regions. The most parsimonious explanation of the data is that these frequently repeated mutations experience tissue-specific positive selection, probably through replication advantage.
C1 [Samuels, David C.; Li, Bingshan; Clay, Hayley Boyd; Thornton-Wells, Tricia A.; Haines, Jonathan L.; Murdock, Deborah G.; Mortlock, Douglas P.; Williams, Scott M.] Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Ctr Human Genet Res, Nashville, TN 37212 USA.
   [Li, Chun] Vanderbilt Univ, Sch Med, Dept Biostat, Ctr Human Genet Res, Nashville, TN 37212 USA.
   [Song, Zhuo; Torstenson, Eric; Hughes, Tia M.] Vanderbilt Univ, Sch Med, Ctr Human Genet Res, Nashville, TN 37212 USA.
   [Rokas, Antonis] Vanderbilt Univ, Sch Med, Dept Biol Sci, Nashville, TN 37212 USA.
   [Moore, Jason H.; Williams, Scott M.] Dartmouth Med Sch, Dept Genet, Computat Genet Lab, Lebanon, NH USA.
   [Hoffman, Robert D.] Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37212 USA.
C3 Vanderbilt University; Vanderbilt University; Vanderbilt University;
   Vanderbilt University; Dartmouth College; Vanderbilt University
RP Samuels, DC (corresponding author), Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Ctr Human Genet Res, Nashville, TN 37212 USA.
EM scott.williams@dartmouth.edu
RI Murdock, Deborah/C-3483-2012; Haines, Jonathan/C-3374-2012; Moore,
   Jason/AAV-9645-2021; li, bing/HTS-1845-2023; Li, Chun/R-1095-2019;
   Mortlock, Douglas/C-9981-2010; Rokas, Antonis/A-9775-2008; Williams,
   Scott/Q-4812-2019; Samuels, David/A-5393-2008
OI Moore, Jason/0000-0002-5015-1099; Williams, Scott/0000-0002-4835-9544;
   Li, Chun/0000-0002-8819-2443; Samuels, David/0000-0003-3529-7791; Rokas,
   Antonis/0000-0002-7248-6551
FU NIH [R01HG004517, R01GM073744, AG019085, AG027944]; Recruitment for
   Genetic Aging Research [1P30AG036445];  [LM010098];  [GM103534];
   Division Of Environmental Biology; Direct For Biological Sciences
   [0844968] Funding Source: National Science Foundation
FX Part of the sequencing and of the efforts of CL and ET were supported by
   the NIH grant R01HG004517. Part of the sequencing and the effort of TATW
   were supported by Recruitment for Genetic Aging Research (1P30AG036445).
   DCS was funded through the NIH grant R01GM073744. JLH was partially
   supported by NIH grants AG019085 and AG027944. JHM and SMW were
   partially supported by LM010098. SMW was partially supported by
   GM103534. Institutional support for sequencing was also provided by
   Vanderbilt University and Dartmouth College. The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Allard MW, 2006, J FORENSIC SCI, V51, P566, DOI 10.1111/j.1556-4029.2006.00136.x
   Allard MW, 2005, FORENSIC SCI INT, V148, P169, DOI 10.1016/j.forsciint.2004.06.001
   Andrew T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022332
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Avital G, 2012, HUM MOL GENET, V21, P4214, DOI 10.1093/hmg/dds245
   Barthélémy C, 2002, HUM GENET, V110, P479, DOI 10.1007/s00439-002-0708-4
   Battersby BJ, 2003, NAT GENET, V33, P183, DOI 10.1038/ng1073
   Battersby BJ, 2001, HUM MOL GENET, V10, P2469, DOI 10.1093/hmg/10.22.2469
   Beeton Christine, 2007, J Vis Exp, P402, DOI 10.3791/402
   Coller HA, 2001, NAT GENET, V28, P147, DOI 10.1038/88859
   Cormio A, 2005, NEUROBIOL AGING, V26, P655, DOI 10.1016/j.neurobiolaging.2004.06.014
   CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324
   CORTOPASSI GA, 1992, P NATL ACAD SCI USA, V89, P7370, DOI 10.1073/pnas.89.16.7370
   Coskun PE, 2004, P NATL ACAD SCI USA, V101, P10726, DOI 10.1073/pnas.0403649101
   Coskun PE, 2003, P NATL ACAD SCI USA, V100, P2174, DOI 10.1073/pnas.0630589100
   Cree LM, 2009, BBA-MOL BASIS DIS, V1792, P1097, DOI 10.1016/j.bbadis.2009.03.002
   da Costa CK, 2007, J NEUROL SCI, V263, P139, DOI 10.1016/j.jns.2007.07.006
   Del Bo R, 2003, NEUROBIOL AGING, V24, P829, DOI 10.1016/S0197-4580(02)00233-6
   Del Bo R, 2002, J NEUROL SCI, V202, P85, DOI 10.1016/S0022-510X(02)00247-2
   Dimauro S, 2005, ANN MED, V37, P222, DOI 10.1080/07853890510007368
   Duncan AW, 2010, NATURE, V467, P707, DOI 10.1038/nature09414
   Elson JL, 2001, AM J HUM GENET, V68, P802, DOI 10.1086/318801
   Fish J, 2004, SCIENCE, V306, P2098, DOI 10.1126/science.1102077
   He YP, 2010, NATURE, V464, P610, DOI 10.1038/nature08802
   Janssen GMC, 2006, EXP CLIN ENDOCR DIAB, V114, P168, DOI 10.1055/s-2006-924066
   Jenuth JP, 1997, NAT GENET, V16, P93, DOI 10.1038/ng0597-93
   Krishnan KJ, 2008, NAT GENET, V40, P275, DOI 10.1038/ng.f.94
   Larsson NG, 2010, ANNU REV BIOCHEM, V79, P683, DOI 10.1146/annurev-biochem-060408-093701
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Malyarchuk BA, 2001, RUSS J GENET+, V37, P823, DOI 10.1023/A:1016707228425
   McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110
   Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774
   Miller FJ, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng060
   Murdock DG, 2000, NUCLEIC ACIDS RES, V28, P4350, DOI 10.1093/nar/28.21.4350
   Pai CY, 2006, FORENSIC SCI INT, V156, P124, DOI 10.1016/j.forsciint.2004.12.021
   Payne BAI, 2013, HUM MOL GENET, V22, P384, DOI 10.1093/hmg/dds435
   Pereira F, 2008, MOL BIOL EVOL, V25, P2759, DOI 10.1093/molbev/msn225
   Pereira L, 2009, AM J HUM GENET, V84, P628, DOI 10.1016/j.ajhg.2009.04.013
   Picornell A, 2006, INT J LEGAL MED, V120, P271, DOI 10.1007/s00414-006-0083-0
   Sharpley MS, 2012, CELL, V151, P333, DOI 10.1016/j.cell.2012.09.004
   Shu L, 2012, INT J OPHTHALMOL-CHI, V5, P28, DOI 10.3980/j.issn.2222-3959.2012.01.06
   Stewart JB, 2008, PLOS BIOL, V6, P63, DOI 10.1371/journal.pbio.0060010
   Suspène R, 2011, P NATL ACAD SCI USA, V108, P4858, DOI 10.1073/pnas.1009687108
   Tully G, 2004, FORENSIC SCI INT, V140, P1, DOI 10.1016/S0379-0738(03)00181-6
   Tully LA, 2000, AM J HUM GENET, V67, P432, DOI 10.1086/302996
   van Oven M, 2009, HUM MUTAT, V30, pE386, DOI 10.1002/humu.20921
   Wang Y, 2001, P NATL ACAD SCI USA, V98, P4022, DOI 10.1073/pnas.061013598
   Yamasoba T, 2002, NEUROMUSCULAR DISORD, V12, P506, DOI 10.1016/S0960-8966(01)00329-7
   Yasukawa T, 2005, MOL CELL, V18, P651, DOI 10.1016/j.molcel.2005.05.002
NR 49
TC 108
Z9 123
U1 1
U2 26
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD NOV
PY 2013
VL 9
IS 11
AR e1003929
DI 10.1371/journal.pgen.1003929
PG 12
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 299BG
UT WOS:000330369000022
PM 24244193
OA Green Published, gold
DA 2024-11-01
ER

PT J
AU Baty, K
   Farrugia, ME
   Hopton, S
   Falkous, G
   Schaefer, AM
   Stewart, W
   Willison, HJ
   Reilly, MM
   Blakely, EL
   Taylor, RW
   Ng, YS
AF Baty, Karen
   Farrugia, Maria E.
   Hopton, Sila
   Falkous, Gavin
   Schaefer, Andrew M.
   Stewart, William
   Willison, Hugh J.
   Reilly, Mary M.
   Blakely, Emma L.
   Taylor, Robert W.
   Ng, Yi Shiau
TI A novel MT-CO2 variant causing cerebellar ataxia and neuropathy: The
   role of muscle biopsy in diagnosis and defining pathogenicity
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE Mitochondrial DNA; Muscle biopsy; Segregation study
ID MITOCHONDRIAL-DNA MUTATIONS; MYOPATHY; PATIENT
AB Pathogenic variants in mitochondrial DNA (mtDNA) are associated with significant clinical heterogeneity with neuromuscular involvement commonly reported. Non-syndromic presentations of mtDNA disease continue to pose a diagnostic challenge and with genomic testing still necessitating a muscle biopsy in many cases. Here we describe an adult patient who presented with progressive ataxia, neuropathy and exercise intolerance in whom the application of numerous Mendelian gene panels had failed to make a genetic diagnosis. Muscle biopsy revealed characteristic mitochondrial pathology (cytochrome c oxidase deficient, ragged-red fibers) prompting a thorough investigation of the mitochondrial genome. Two heteroplasmic MT-CO2 gene variants (NC_012920.1: m.7887G > A and m.8250G > A) were identified, necessitating single fiber segregation and familial studies - including the biopsy of the patient's clinically-unaffected mother - to demonstrate pathogenicity of the novel m.7887G > A p.(Gly101Asp) variant and establishing this as the cause of the mitochondrial biochemical defects and clinical presentation. In the era of high throughput whole exome and genome sequencing, muscle biopsy remains a key investigation in the diagnosis of patients with non-syndromic presentations of adult-onset mitochondrial disease and fully defining the pathogenicity of novel mtDNA variants. (c) 2021 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license ( http://creativecommons.org/licenses/by/4.0/ )
C1 [Baty, Karen; Hopton, Sila; Falkous, Gavin; Schaefer, Andrew M.; Blakely, Emma L.; Taylor, Robert W.; Ng, Yi Shiau] Newcastle Univ, Fac Med Sci, Wellcome Ctr Mitochondrial Res, Translat & Clin Res Inst, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Baty, Karen; Hopton, Sila; Falkous, Gavin; Schaefer, Andrew M.; Blakely, Emma L.; Taylor, Robert W.; Ng, Yi Shiau] Newcastle Upon Tyne Hosp NHS Fdn Trust, NHS Highly Specialised Serv Rare Mitochondrial Di, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
   [Farrugia, Maria E.] Queen Elizabeth Univ Hosp, Inst Neurol Sci, Dept Neurol, Glasgow G51 4TF, Lanark, Scotland.
   [Schaefer, Andrew M.; Ng, Yi Shiau] Newcastle Upon Tyne Hosp NHS Fdn Trust, Royal Victoria Infirm, Directorate Neurosci, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.
   [Stewart, William] Queen Elizabeth Univ Hosp, Dept Neuropathol, Glasgow G51 4TF, Lanark, Scotland.
   [Stewart, William] Univ Glasgow, Inst Neurosci & Psychol, Glasgow G12 8QQ, Lanark, Scotland.
   [Willison, Hugh J.] Univ Glasgow, Dept Neurol, Glasgow G51 4TF, Lanark, Scotland.
   [Willison, Hugh J.] Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow G51 4TF, Lanark, Scotland.
   [Reilly, Mary M.] UCL Queen Sq Inst Neurol, Dept Neuromuscular Dis, MRC Ctr Neuromuscular Dis, London WC1N 3BG, England.
C3 Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation
   Trust; Queen Elizabeth University Hospital (QEUH); University of
   Glasgow; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Newcastle
   University - UK; Queen Elizabeth University Hospital (QEUH); University
   of Glasgow; University of Glasgow; University of Glasgow; University of
   London; University College London
RP Ng, YS (corresponding author), Newcastle Univ, Fac Med Sci, Wellcome Ctr Mitochondrial Res, Translat & Clin Res Inst, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM yi.ng@ncl.ac.uk
RI Reilly, Mary/C-8482-2013; Ng, Yi/AFF-1445-2022; willison,
   hugh/HCI-7819-2022
OI Ng, Yi Shiau/0000-0002-7591-2034; Stewart, William/0000-0003-2199-2582
FU Wellcome Centre for Mitochondrial Research [203105/Z/16/Z]; UK NHS
   Specialist Commissioners; Medical Research Council (MRC) International
   Centre for Genomic Medicine in Neuromuscular Disease [MR/S005021/1];
   Mitochondrial Disease Patient Cohort (UK) [G0800674]; Lily Foundation;
   MRC/EPSRC Molecular Pathology Node; NIHR Clinical Lectureship in
   Neurology [CL-2016-01-003]; NHS Research Scotland; Medical Research
   Council [MRC MR/S005021/1]; National Institutes of Neurological Diseases
   and Stroke; office of Rare Diseases [U54NS065712];  [MDA510281]; MRC
   [MR/K000608/1, MR/S005021/1] Funding Source: UKRI
FX RWT and YSN are supported by the Wellcome Centre for Mitochondrial
   Research (203105/Z/16/Z) and the UK NHS Specialist Commissioners which
   funds the "Rare Mitochondrial Disorders of Adults and Children"
   Diagnostic Service in Newcastle upon Tyne. RWT also receives financial
   support from the Medical Research Council (MRC) International Centre for
   Genomic Medicine in Neuromuscular Disease (MR/S005021/1) , the
   Mitochondrial Disease Patient Cohort (UK) (G0800674) , the Lily
   Foundation and the MRC/EPSRC Molecular Pathology Node. YSN holds an NIHR
   Clinical Lectureship in Neurology (CL-2016-01-003) . WS is supported by
   Career Researcher Fellowship funding from NHS Research Scotland. MMR is
   grateful to the Medical Research Council (MRC MR/S005021/1) , the
   National Institutes of Neurological Diseases and Stroke and office of
   Rare Diseases (U54NS065712) and to Muscular Dystrophy Association
   (MDA510281) for their support. The INC (U54NS065712) is a part of the
   NCATS Rare Diseases Clinical Research Network (RDCRN) . KB, SH, GF and
   ELB are supported by the UK NHS Specialist Commissioners which funds the
   "Rare Mitochondrial Disorders of Adults and Children" Diagnostic Service
   in Newcastle upon Tyne.
CR Bacalhau M, 2018, NEUROMUSCULAR DISORD, V28, P350, DOI 10.1016/j.nmd.2017.11.006
   Bargiela David, 2015, Cerebellum Ataxias, V2, P16, DOI 10.1186/s40673-015-0035-x
   Beaudin M, 2019, CEREBELLUM, V18, P1098, DOI 10.1007/s12311-019-01052-2
   Bidooki SK, 1997, AM J HUM GENET, V60, P1430, DOI 10.1086/515460
   Bortot B, 2009, MITOCHONDRION, V9, P123, DOI 10.1016/j.mito.2009.01.006
   Clark KM, 1999, AM J HUM GENET, V64, P1330, DOI 10.1086/302361
   de Silva RN, 2019, PRACT NEUROL, V19, P196, DOI 10.1136/practneurol-2018-002096
   Gorman GS, 2015, ANN NEUROL, V77, P753, DOI 10.1002/ana.24362
   Hardy SA, 2016, NEUROL-GENET, V2, DOI 10.1212/NXG.0000000000000082
   Horváth R, 2005, NEUROMUSCULAR DISORD, V15, P851, DOI 10.1016/j.nmd.2005.09.005
   La Morgia C, 2020, J INTERN MED, V287, P592, DOI 10.1111/joim.13064
   Legault JT, 2015, CELL REP, V13, P981, DOI 10.1016/j.celrep.2015.09.054
   Lim AZ, 2020, NEUROMUSCULAR DISORD, V30, P661, DOI 10.1016/j.nmd.2020.06.008
   Melberg A, 2009, EUR J MED GENET, V52, P47, DOI 10.1016/j.ejmg.2008.10.004
   Meulemans A, 2007, ARCH NEUROL-CHICAGO, V64, P1339, DOI 10.1001/archneur.64.9.1339
   Mimaki M, 2003, J HUM GENET, V48, P47, DOI 10.1007/s100380300005
   Ng YS, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00024
   Ohno K, 1996, ANN NEUROL, V39, P761, DOI 10.1002/ana.410390612
   OLD SL, 1989, HISTOCHEM J, V21, P545, DOI 10.1007/BF01753355
   Renaud M, 2017, ANN NEUROL, V82, P892, DOI 10.1002/ana.25084
   Rocha MC, 2015, SCI REP-UK, V5, DOI 10.1038/srep15037
   Rodríguez-López C, 2020, J MED GENET, V57, P643, DOI 10.1136/jmedgenet-2019-106649
   Roos S, 2019, EUR J HUM GENET, V27, P331, DOI 10.1038/s41431-018-0286-0
   Rossi M, 2018, MOVEMENT DISORD, V33, P1056, DOI 10.1002/mds.27415
   Rossmanith W, 2008, J MED GENET, V45, P117, DOI 10.1136/jmg.2007.052076
   Sallevelt SCEH, 2017, J MED GENET, V54, P114, DOI 10.1136/jmedgenet-2016-103876
   Sim KG, 2002, METABOLISM, V51, P366, DOI 10.1053/meta.2002.30521
   Stenton SL, 2020, EBIOMEDICINE, V56, DOI 10.1016/j.ebiom.2020.102784
   Swalwell H, 2008, EUR J HUM GENET, V16, P1265, DOI 10.1038/ejhg.2008.65
   Thompson K, 2020, J INHERIT METAB DIS, V43, P36, DOI 10.1002/jimd.12104
   Vissing CR, 2013, NEUROLOGY, V80, P1908, DOI 10.1212/WNL.0b013e3182929fb2
   Wagner M, 2019, J INHERIT METAB DIS, V42, P909, DOI 10.1002/jimd.12109
   Wei W, 2019, SCIENCE, V364, P749, DOI 10.1126/science.aau6520
   Wong LJC, 2020, GENET MED, DOI 10.1038/s41436-019-0746-0
   Zierz CM, 2019, J CLIN MED, V8, DOI 10.3390/jcm8060789
NR 35
TC 3
Z9 3
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD NOV
PY 2021
VL 31
IS 11
BP 1186
EP 1193
DI 10.1016/j.nmd.2021.05.014
EA DEC 2021
PG 8
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA XQ1EZ
UT WOS:000731297600010
PM 34325999
OA Green Published, hybrid
DA 2024-11-01
ER

PT J
AU Ishikawa, K
   Kasahara, A
   Watanabe, N
   Nakada, K
   Sato, A
   Suda, Y
   Aizawa, S
   Hayashi, JI
AF Ishikawa, K
   Kasahara, A
   Watanabe, N
   Nakada, K
   Sato, A
   Suda, Y
   Aizawa, S
   Hayashi, JI
TI Application of ES cells for generation of respiration-deficient mice
   carrying mtDNA with a large-scale deletion
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE mouse Delta mtDNA; intercellular mtDNA transfer; ES cells; mitochondrial
   diseases; disease model mice
ID INTER-MITOCHONDRIAL COMPLEMENTATION; PROTEIN-SYNTHESIS; MOUSE MTDNA;
   DNA; ELIMINATION; EMBRYOGENESIS; DYSFUNCTION; MYOPATHY; DEFECTS; MUTANT
AB In a previous study, we used mouse zygotes as recipients of mtDNA with a large-scale deletion mutation (Delta mtDNA) and generated respiration-deficient mice (mito-mice) carrying Delta mtDNA. In this study, we used mouse ES cells as recipients of Delta mtDNA, and generated mito-mice with Delta mtDNA only when the ES cells carried 17% Delta mtDNA. No chimera mice or their F, progenies were obtained from ES cells carrying more than 61% Delta mtDNA. These observations suggest that respiratory defects of ES cells inhibit their normal differentiation into chimera mice and mito-mice, and that ES cells are more effective than zygotes for generation of mito-mice carrying mtDNAs without significant pathogenic mutations. (c) 2005 Elsevier Inc. All rights reserved.
C1 Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki 3058572, Japan.
   Univ Tsukuba, Ctr TARA, Tsukuba, Ibaraki 3058572, Japan.
   RIKEN, CDB, Lab Vertebrate Body, Kobe, Hyogo 6500047, Japan.
C3 University of Tsukuba; University of Tsukuba; RIKEN
RP Univ Tsukuba, Grad Sch Life & Environm Sci, Tsukuba, Ibaraki 3058572, Japan.
EM jib45@sakura.cc.tsukuba.ac.jp
OI ISHIKAWA, Kaori/0000-0001-9895-5996
CR Attardi G, 2002, NAT GENET, V30, P360, DOI 10.1038/ng0402-360
   CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236
   Hayashi J, 2002, NAT GENET, V30, P361, DOI 10.1038/ng0402-361
   HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614
   Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826
   KANEDA H, 1995, P NATL ACAD SCI USA, V92, P4542, DOI 10.1073/pnas.92.10.4542
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   Larsson NG, 1995, ANNU REV GENET, V29, P151, DOI 10.1146/annurev.ge.29.120195.001055
   Levy SE, 1999, TRANSGENIC RES, V8, P137, DOI 10.1023/A:1008967412955
   McKenzie M, 2004, P NATL ACAD SCI USA, V101, P1685, DOI 10.1073/pnas.0303184101
   Nakada K, 2001, NAT MED, V7, P934, DOI 10.1038/90976
   Sato A, 2005, P NATL ACAD SCI USA, V102, P6057, DOI 10.1073/pnas.0408666102
   Sato A, 2004, GENETICS, V167, P1855, DOI 10.1534/genetics.103.021287
   SELIGMAN AM, 1968, J CELL BIOL, V38, P1, DOI 10.1083/jcb.38.1.1
   Shitara H, 2000, GENETICS, V156, P1277
   Shitara H, 1998, GENETICS, V148, P851
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   YAGI T, 1993, ANAL BIOCHEM, V214, P70, DOI 10.1006/abio.1993.1458
   YONEDA M, 1994, MOL CELL BIOL, V14, P2699, DOI 10.1128/MCB.14.4.2699
   ZIEGLER ML, 1981, SOMAT CELL GENET, V7, P73, DOI 10.1007/BF01544749
NR 20
TC 7
Z9 7
U1 1
U2 3
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JUL 29
PY 2005
VL 333
IS 2
BP 590
EP 595
DI 10.1016/j.bbrc.2005.05.155
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 944HU
UT WOS:000230418700043
PM 15953585
DA 2024-11-01
ER

PT J
AU Arredondo, JJ
   Gallardo, ME
   García-Pavía, P
   Domingo, V
   Bretón, B
   García-Silva, MT
   Sedano, MJ
   Martín, MA
   Arenas, J
   Cervera, M
   Garesse, R
   Bornstein, B
AF Arredondo, Juan J.
   Esther Gallardo, M.
   Garcia-Pavia, Pablo
   Domingo, Veronica
   Breton, Begona
   Teresa Garcia-Silva, M.
   Jesus Sedano, M.
   Martin, Miguel A.
   Arenas, Joaquin
   Cervera, Margarita
   Garesse, Rafael
   Bornstein, Belen
TI Mitochondrial tRNA valine as a recurrent target for mutations involved
   in mitochondrial cardiomyopathies
SO MITOCHONDRION
LA English
DT Article
DE Mitochondrial DNA; m.1628C > T; m.1644G > A; Mitochondrial tRNA
   quantification; Mitochondrial diseases; Mitochondrial cardiomyopathies
ID LACTIC-ACIDOSIS; DNA; GENE; TRNA(LYS); SEQUENCE; AMINOACYLATION;
   PATHOGENICITY; MYOPATHY; HISTORY
AB The aim of this study was to identify the genetic defect in two patients having cardiac dysfunction accompanied by neurological symptoms, and in one case MRI evidence of cortical and cerebellar atrophy with hyper-intensities in the basal ganglia. Muscle biopsies from each patient revealed single and combined mitochondrial respiratory chain deficiency. The complete mtDNA sequencing of both patients revealed two transitions in the mitochondrial tRNA(Val) gene (MT-TV) (m.1628C>T in Patient 1, and m.1644G>A in Patient 2). The functional and molecular analyses reported here suggest that the MT-TV gene should be routinely considered in the diagnosis of mitochondrial cardiomyopathies. (C) 2011 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 [Arredondo, Juan J.; Esther Gallardo, M.; Domingo, Veronica; Breton, Begona; Cervera, Margarita; Garesse, Rafael; Bornstein, Belen] Univ Autonoma Madrid, Fac Med, CSIC, Dept Bioquim,Inst Invest Biomed Alberto Sols, E-28029 Madrid, Spain.
   [Esther Gallardo, M.; Martin, Miguel A.; Arenas, Joaquin; Garesse, Rafael; Bornstein, Belen] CIBERER, Madrid, Spain.
   [Garcia-Pavia, Pablo] Hosp Univ Puerta de Hierro, Serv Cardiol, Madrid, Spain.
   [Garcia-Pavia, Pablo] Red Invest Clin & Basica Insuficiencia Cardiaca R, Madrid, Spain.
   [Teresa Garcia-Silva, M.] Hosp Univ 12 Octubre, Serv Pediat, Madrid, Spain.
   [Jesus Sedano, M.] Hosp Gen Yague, Serv Neurol, Burgos, Spain.
   [Martin, Miguel A.; Arenas, Joaquin] Hosp Univ 12 Octubre, Ctr Invest, Lab Enfermedades Mitocondriales, Madrid, Spain.
   [Bornstein, Belen] Hosp Univ Puerta de Hierro, Serv Bioquim, Madrid, Spain.
C3 Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto
   de Investigaciones Biomedicas Alberto Sols (IIBM); Autonomous University
   of Madrid; CIBER - Centro de Investigacion Biomedica en Red; CIBERER;
   Hospital Puerta de Hierro-Majadahonda; Hospital Universitario 12 de
   Octubre; Hospital General Yague; Hospital Universitario 12 de Octubre;
   Hospital Puerta de Hierro-Majadahonda
RP Bornstein, B (corresponding author), Univ Autonoma Madrid, Fac Med, CSIC, Dept Bioquim,Inst Invest Biomed Alberto Sols, C Arzobispo Morcillo 4, E-28029 Madrid, Spain.
EM belen.bornstein@uam.es
RI Arredondo, Juan/L-2404-2013; Garcia-Pavia, Pablo/T-9100-2019; Martin,
   Miguel/S-2758-2018; Garesse, Rafael/F-3836-2012; Gallardo,
   M./AFK-7298-2022; Martin, Miguel Angel/B-6261-2017
OI Martin, Miguel Angel/0000-0003-4741-772X; Garesse,
   Rafael/0000-0002-0338-2281; /0000-0003-2897-4918; Garcia-Pavia,
   Pablo/0000-0002-5470-2257; GALLARDO PEREZ, M.
   ESTHER/0000-0002-8699-8734; Arenas, Joaquin/0000-0002-2877-5049
FU Instituto de Salud Carlos III (ISCIII), Ministry of Science and
   Innovation (MICIN) [PI060205, PI070167, PI060547]; Comunidad de Madrid
   (CM) [GEN-0269/2006]; Center for Biomedical Research on Rare Diseases
   (CIBERER); ISCIII-MICIN; Agencia Lain Entralgo (CM)
FX This work was supported by Grants PI060205 (to B.B.), PI070167 (to
   R.G.), and PI060547 (to M.A.M.) from the Instituto de Salud Carlos III
   (ISCIII), Ministry of Science and Innovation (MICIN); and GEN-0269/2006
   from the Comunidad de Madrid (CM) (to M.A.M. and R.G.). M.E.G. is a
   Senior Fellow and receives grant support from the Center for Biomedical
   Research on Rare Diseases (CIBERER). B.B. is supported by the Program
   Intensificacion de la Actividad Investigadora from the ISCIII-MICIN and
   the Agencia Lain Entralgo (CM). Members from CIBERER units U717 and U723
   participated in this work.
CR Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andreu AL, 2009, MITOCHONDRION, V9, P242, DOI 10.1016/j.mito.2009.02.006
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Bacman SR, 2003, BIOCHEM J, V374, P131, DOI 10.1042/BJ20030222
   Bénit P, 2003, HUM MUTAT, V21, P582, DOI 10.1002/humu.10225
   Blakely EL, 2004, J NEUROL SCI, V225, P99, DOI 10.1016/j.jns.2004.07.007
   Bornstein B, 2005, BIOCHEM J, V387, P773, DOI 10.1042/BJ20040949
   Chalmers RM, 1997, NEUROLOGY, V49, P589, DOI 10.1212/WNL.49.2.589
   Da Pozzo P, 2009, EUR J HUM GENET, V17, P1092, DOI 10.1038/ejhg.2009.12
   de Coo IFM, 1998, NEUROLOGY, V50, P293, DOI 10.1212/WNL.50.1.293
   DiMauro S., 2011, ACTA MYOL, V29, P333
   DiMauro S, 2008, ANNU REV NEUROSCI, V31, P91, DOI 10.1146/annurev.neuro.30.051606.094302
   DiMauro S, 2006, CURR OPIN RHEUMATOL, V18, P636, DOI 10.1097/01.bor.0000245729.17759.f2
   ENRIQUEZ JA, 1995, NAT GENET, V10, P47, DOI 10.1038/ng0595-47
   Florentz C, 2003, CELL MOL LIFE SCI, V60, P1356, DOI 10.1007/s00018-003-2343-1
   Gallardo ME, 2006, HUM MUTAT, V27, P575, DOI 10.1002/humu.20338
   García-Velasco A, 2003, J INTERN MED, V253, P381, DOI 10.1046/j.1365-2796.2003.01095.x
   Hirano M, 2001, CURR OPIN CARDIOL, V16, P201, DOI 10.1097/00001573-200105000-00008
   Horvath R, 2009, J NEUROL, V256, P810, DOI 10.1007/s00415-009-5023-8
   Ingman M, 2003, GENOME RES, V13, P1600, DOI 10.1101/gr.686603
   Lev D, 2004, PEDIATR CARDIOL, V25, P443, DOI 10.1007/s00246-003-0490-7
   Limongelli G, 2010, EUR J HEART FAIL, V12, P114, DOI 10.1093/eurjhf/hfp186
   Marín-García J, 2002, PEDIATR NEUROL, V27, P213, DOI 10.1016/S0887-8994(02)00426-5
   Marin-Garcia J, 2000, J CARD FAIL, V6, P321, DOI 10.1054/jcaf.2000.19232
   Martinez B, 2001, J NEUROCHEM, V78, P1054, DOI 10.1046/j.1471-4159.2001.00487.x
   MASUCCI JP, 1995, MOL CELL BIOL, V15, P2872
   McFarland R, 2004, TRENDS GENET, V20, P591, DOI 10.1016/j.tig.2004.09.014
   McFarland R, 2002, NAT GENET, V30, P145, DOI 10.1038/ng819
   MORAES CT, 1993, NEUROMUSCULAR DISORD, V3, P43, DOI 10.1016/0960-8966(93)90040-Q
   Papadopoulou LC, 1999, NAT GENET, V23, P333
   Rorbach J, 2008, NUCLEIC ACIDS RES, V36, P3065, DOI 10.1093/nar/gkn147
   Sacconi S, 2002, ARCH NEUROL-CHICAGO, V59, P1013, DOI 10.1001/archneur.59.6.1013
   Sciacco M, 1996, Methods Enzymol, V264, P509, DOI 10.1016/S0076-6879(96)64045-2
   Shimotake T, 1998, J PEDIATR SURG, V33, P1837, DOI 10.1016/S0022-3468(98)90301-3
   SPRINZL M, 1989, NUCLEIC ACIDS RES, V17, pR1, DOI 10.1093/nar/17.1.1
   Tanji K, 2008, J NEUROL SCI, V270, P23, DOI 10.1016/j.jns.2008.01.016
   Taylor RW, 2003, J AM COLL CARDIOL, V41, P1786, DOI 10.1016/S0735-1097(03)00300-0
   Taylor RW, 1996, ANN NEUROL, V40, P459, DOI 10.1002/ana.410400318
   Tiranti V, 1998, ANN NEUROL, V43, P98, DOI 10.1002/ana.410430116
   Torroni A, 2003, AM J HUM GENET, V72, P1005, DOI 10.1086/373936
   Tucker EJ, 2010, CURR NEUROL NEUROSCI, V10, P277, DOI 10.1007/s11910-010-0112-8
   Wahbi K, 2010, NEUROLOGY, V74, P674, DOI 10.1212/WNL.0b013e3181d0ccf4
   Yan NH, 2010, MOL VIS, V16, P1736
   Yarham JW, 2011, HUM MUTAT, V32, P1319, DOI 10.1002/humu.21575
   ZEVIANI M, 1991, LANCET, V338, P143, DOI 10.1016/0140-6736(91)90136-D
NR 46
TC 13
Z9 13
U1 0
U2 3
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 1872-8278
J9 MITOCHONDRION
JI Mitochondrion
PD MAR
PY 2012
VL 12
IS 2
BP 357
EP 362
DI 10.1016/j.mito.2011.09.010
PG 6
WC Cell Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Genetics & Heredity
GA 913VX
UT WOS:000301906600024
PM 21986556
OA Green Accepted
DA 2024-11-01
ER

PT J
AU Zhao, D
   Hong, DJ
   Zhang, W
   Yao, S
   Qi, XK
   Lv, H
   Zheng, RL
   Feng, LQ
   Huang, YN
   Yuan, Y
   Wang, ZX
AF Zhao, Danhua
   Hong, Daojun
   Zhang, Wei
   Yao, Sheng
   Qi, Xiaokun
   Lv, He
   Zheng, Riliang
   Feng, Liqun
   Huang, Yining
   Yuan, Yun
   Wang, Zhaoxia
TI Mutations in mitochondrially encoded complex I enzyme as the second
   common cause in a cohort of Chinese patients with mitochondrial
   myopathy, encephalopathy, lactic acidosis and stroke-like episodes
SO JOURNAL OF HUMAN GENETICS
LA English
DT Article
DE MELAS; mitochondrial DNA; mitochondrially encoded complex I; MTND;
   mutation
ID MELAS-SYNDROME; DNA MUTATIONS; ND5 GENE; OVERLAP SYNDROME; MTDNA
   MUTATION; FREQUENT CAUSE; DISEASE; DEFICIENCY; SUBUNIT; IDENTIFICATION
AB The mutation pattern of mitochondrial DNA (mtDNA) in mainland Chinese patients with mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) has been rarely reported, though previous data suggested that the mutation pattern of MELAS could be different among geographically localized populations. We presented the results of comprehensive mtDNA mutation analysis in 92 unrelated Chinese patients with MELAS (85 with classic MELAS and 7 with MELAS/Leigh syndrome (LS) overlap syndrome). The mtDNA A3243G mutation was the most common causal genotype in this patient group (79/92 and 85.9%). The second common gene mutation was G13513A (7/92 and 7.6%). Additionally, we identified T10191C (p.S45P) in ND3, A11470C (p. K237N) in ND4, T13046C (p.M237T) in ND5 and a large-scale deletion (13025-13033: 14417-14425) involving partial ND5 and ND6 subunits of complex I in one patient each. Among them, A11470C, T13046C and the single deletion were novel mutations. In summary, patients with mutations affecting mitochondrially encoded complex I (MTND) reached 12.0% (11/92) in this group. It is noteworthy that all seven patients with MELAS/LS overlap syndrome were associated with MTND mutations. Our data emphasize the important role of MTND mutations in the pathogenicity of MELAS, especially MELAS/LS overlap syndrome. Journal of Human Genetics (2011) 56, 759-764; doi: 10.1038/jhg.2011.96; published online 18 August 2011
C1 [Zhao, Danhua; Hong, Daojun; Zhang, Wei; Lv, He; Zheng, Riliang; Huang, Yining; Yuan, Yun; Wang, Zhaoxia] Peking Univ, Hosp 1, Dept Neurol, Beijing 100034, Peoples R China.
   [Yao, Sheng; Qi, Xiaokun] Navy Gen Hosp, Dept Neurol, Beijing, Peoples R China.
   [Feng, Liqun] Anzhen Hosp, Dept Neurol, Beijing, Peoples R China.
C3 Peking University; Sixth Medical Center of Chinese PLA General Hospital
RP Wang, ZX (corresponding author), Peking Univ, Hosp 1, Dept Neurol, Beijing 100034, Peoples R China.
EM drwangzx@yahoo.com.cn
RI Zhao, Wensi/JDW-1266-2023; Li, Chun/KBC-9591-2024
FU National Nature Science Foundation of China [30870864]
FX We thank all the doctors that referred patients to our department, as
   well as all patients and their family members that participated in this
   study. The authors also wish to thank Dr Sue Zhong for editorial
   assistance. This study was supported by the National Nature Science
   Foundation of China (No.30870864).
CR Akanuma J, 2000, J HUM GENET, V45, P337, DOI 10.1007/s100380070004
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Blok MJ, 2007, J MED GENET, V44, DOI 10.1136/jmg.2006.045716
   CAMPOS Y, 1995, PEDIATR NEUROL, V13, P69, DOI 10.1016/0887-8994(95)00082-Q
   Cao YY, 2010, MITOCHONDRION, V10, P330, DOI 10.1016/j.mito.2010.01.008
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   Choi BO, 2010, EXP MOL MED, V42, P446, DOI 10.3858/emm.2010.42.6.046
   Chou HF, 2008, PEDIATR NEUROL, V38, P143, DOI 10.1016/j.pediatrneurol.2007.09.015
   Corona P, 2001, ANN NEUROL, V49, P106, DOI 10.1002/1531-8249(200101)49:1<106::AID-ANA16>3.0.CO;2-T
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   GOTO Y, 1992, NEUROLOGY, V42, P545, DOI 10.1212/WNL.42.3.545
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Hanna MG, 1998, J NEUROL NEUROSUR PS, V65, P512, DOI 10.1136/jnnp.65.4.512
   HASEGAWA H, 1991, ANN NEUROL, V29, P601, DOI 10.1002/ana.410290606
   HIRANO M, 1994, J CHILD NEUROL, V9, P4, DOI 10.1177/088307389400900102
   Jaksch M, 2001, J MED GENET, V38, P665, DOI 10.1136/jmg.38.10.665
   Kirby DM, 2004, J MED GENET, V41, P784, DOI 10.1136/jmg.2004.020537
   Lebon S, 2003, J MED GENET, V40, P896, DOI 10.1136/jmg.40.12.896
   LERTRIT P, 1992, AM J HUM GENET, V51, P457
   Liolitsa D, 2003, ANN NEUROL, V53, P128, DOI 10.1002/ana.10435
   Ma YN, 2009, MITOCHONDRION, V9, P139, DOI 10.1016/j.mito.2009.01.004
   Malfatti E, 2007, BRAIN, V130, P1894, DOI 10.1093/brain/awm114
   McDonnell MT, 2004, EUR J HUM GENET, V12, P778, DOI 10.1038/sj.ejhg.5201216
   McFarland R, 2002, LANCET NEUROL, V1, P343, DOI 10.1016/S1474-4422(02)00159-X
   McFarland R, 2004, ANN NEUROL, V55, P58, DOI 10.1002/ana.10787
   MITOMAP, 2011, HUM MIT GEN DAT
   Penisson-Besnier I, 2000, NEUROLOGY, V55, P317, DOI 10.1212/WNL.55.2.317
   Pulkes T, 1999, ANN NEUROL, V46, P916, DOI 10.1002/1531-8249(199912)46:6<916::AID-ANA16>3.0.CO;2-R
   Ravn K, 2001, EUR J HUM GENET, V9, P805, DOI 10.1038/sj.ejhg.5200712
   Ringelstein EB, 2010, J NEUROL SCI, V299, P81, DOI 10.1016/j.jns.2010.08.037
   Ruiz-Pesini E, 2007, NUCLEIC ACIDS RES, V35, pD823, DOI 10.1093/nar/gkl927
   SAKUTA R, 1993, J NEUROL SCI, V115, P158, DOI 10.1016/0022-510X(93)90219-O
   Santorelli FM, 1997, BIOCHEM BIOPH RES CO, V238, P326, DOI 10.1006/bbrc.1997.7167
   Schaefer AM, 2008, ANN NEUROL, V63, P35, DOI 10.1002/ana.21217
   Shanske S, 2008, ARCH NEUROL-CHICAGO, V65, P368, DOI 10.1001/archneurol.2007.67
   Sproule DM, 2008, ANN NY ACAD SCI, V1142, P133, DOI 10.1196/annals.1444.011
   Taylor RW, 2001, ANN NEUROL, V50, P104, DOI 10.1002/ana.1084
   UJIKE H, 1993, JPN J PSYCHIAT NEUR, V47, P637
   Valente L, 2009, BBA-BIOENERGETICS, V1787, P491, DOI 10.1016/j.bbabio.2008.10.001
   Wang ZX, 2010, NEUROPATHOLOGY, V30, P606, DOI 10.1111/j.1440-1789.2010.01115.x
   Yu Q, 2007, MITOCHONDRION, V7, P147, DOI 10.1016/j.mito.2006.11.019
   Zeviani M, 2003, CURR OPIN NEUROL, V16, P585, DOI 10.1097/00019052-200310000-00004
NR 42
TC 27
Z9 33
U1 0
U2 7
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1434-5161
EI 1435-232X
J9 J HUM GENET
JI J. Hum. Genet.
PD NOV
PY 2011
VL 56
IS 11
BP 759
EP 764
DI 10.1038/jhg.2011.96
PG 6
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 861XN
UT WOS:000298053900002
PM 21850008
OA Bronze
DA 2024-11-01
ER

PT J
AU Joshi, PR
   Baty, K
   Hopton, S
   Cordts, I
   Falkous, G
   Schoser, B
   Blakely, EL
   Taylor, RW
   Deschauer, M
AF Joshi, Pushpa Raj
   Baty, Karen
   Hopton, Sila
   Cordts, Isabell
   Falkous, Gavin
   Schoser, Benedikt
   Blakely, Emma L.
   Taylor, Robert W.
   Deschauer, Marcus
TI Progressive external ophthalmoplegia due to a recurrent <i>de novo</i>
   m.15990C&gt;T <i>MT</i>-<i>TP</i> (mt-tRNA<SUP>Pro</SUP>) gene variant
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE Mitochondria; Progressive external ophthalmoplegia; tRNA Pro;
   Pathogenicity; de novo mutation
ID POINT MUTATIONS; MITOCHONDRIAL
AB Progressive external ophthalmoplegia is typically associated with single or multiple mtDNA deletions but occasionally mtDNA single nucleotide variants within mitochondrial transfer RNAs (mt-tRNAs) are identified. We report a 34-year-old female sporadic patient with progressive external ophthalmoplegia accompanied by exercise intolerance but neither fixed weakness nor multisystemic involvement. Histopathologically, abundant COX-deficient fibres were present in muscle with immunofluorescence analysis confirming the loss of mitochondrial complex I and IV proteins. Molecular genetic analysis identified a rare heteroplasmic m.15990C >T mt-tRNA(Pro) variant reported previously in a single patient with childhood-onset myopathy. The variant in our patient was restricted to muscle. Single muscle fibre analysis identified higher heteroplasmy load in COX-deficient fibres than COX-normal fibres, confirming segregation of high heteroplasmic load with a biochemical defect. Our case highlights the phenotypic variability typically observed with pathogenic mt-tRNA mutations, whilst the identification of a second case with the m.15990C >T mutation not only confirms pathogenicity but shows that de novo mt-tRNA point mutations can arise in multiple, unrelated patients. (C) 2020 The Authors. Published by Elsevier B.V.
C1 [Joshi, Pushpa Raj] Martin Luther Univ Halle Wittenberg, Dept Neurol, Ernst Grube Str 40, D-06120 Halle, Saale, Germany.
   [Baty, Karen; Hopton, Sila; Falkous, Gavin; Blakely, Emma L.; Taylor, Robert W.] Newcastle Univ, Wellcome Ctr Mitochondrial Res, Newcastle Upon Tyne, Tyne & Wear, England.
   [Baty, Karen; Hopton, Sila; Falkous, Gavin; Blakely, Emma L.; Taylor, Robert W.] Newcastle Tyne Hosp NHS Fdn Trust, NHS Highly Specialised Mitochondrial Diagnost Lab, Newcastle Upon Tyne, Tyne & Wear, England.
   [Cordts, Isabell; Deschauer, Marcus] Tech Univ Munich, Sch Med, Dept Neurol, Munich, Germany.
   [Schoser, Benedikt] Univ Munich, Dept Neurol, Friedrich Baur Inst, Munich, Germany.
   [Taylor, Robert W.] Newcastle Univ, Fac Med Sci, Translat & Clin Res Inst, Newcastle Upon Tyne, Tyne & Wear, England.
C3 Martin Luther University Halle Wittenberg; Newcastle University - UK;
   Newcastle Upon Tyne Hospitals NHS Foundation Trust; Technical University
   of Munich; University of Munich; Newcastle University - UK
RP Joshi, PR (corresponding author), Martin Luther Univ Halle Wittenberg, Dept Neurol, Ernst Grube Str 40, D-06120 Halle, Saale, Germany.
EM pushpa.joshi@medizin.uni-halle.de
RI Inerbaev, Talgat/AAB-7633-2020
OI Schoser, Benedikt/0000-0002-2757-8131; Taylor,
   Robert/0000-0002-7768-8873; Baty, Karen/0000-0002-0761-0560
FU German Federal Ministry of Education and Research (BMBF); Wellcome
   Centre for Mitochondrial Research [203105/Z/16/Z]; Medical Research
   Council (MRC) International Centre for Genomic Medicine in Neuromuscular
   Disease; Mitochondrial Disease Patient Cohort (UK) [G0800674]; Newcastle
   University Centre for Ageing and Vitality (Biotechnology and Biological
   Sciences Research Council); Newcastle University Centre for Ageing and
   Vitality (Medical Research Council) [L016354]; UK NIHR Biomedical
   Research Centre for Ageing and Age-related disease award; Lily
   Foundation; UK NHS; MRC [G0800674] Funding Source: UKRI
FX PRJ and MD are members of the German mitoNET, funded by the German
   Federal Ministry of Education and Research (BMBF). RWT is supported by
   the Wellcome Centre for Mitochondrial Research (203105/Z/16/Z), the
   Medical Research Council (MRC) International Centre for Genomic Medicine
   in Neuromuscular Disease, the Mitochondrial Disease Patient Cohort (UK)
   (G0800674), Newcastle University Centre for Ageing and Vitality
   (supported by the Biotechnology and Biological Sciences Research Council
   and Medical Research Council L016354), UK NIHR Biomedical Research
   Centre for Ageing and Age-related disease award to the Newcastle upon
   Tyne Hospitals NHS Foundation Trust, the Lily Foundation and the UK NHS
   Specialist Commissioners which funds the "Rare Mitochondrial Disorders
   of Adults and Children" Diagnostic Service in Newcastle upon Tyne
   (http://www.newcastle-mitochondria.com/).
CR Baines HL, 2014, MECH AGEING DEV, V139, P22, DOI 10.1016/j.mad.2014.06.003
   Blakely EL, 2013, HUM MUTAT, V34, P1260, DOI 10.1002/humu.22358
   Deschauer M, 2003, NEUROMUSCULAR DISORD, V13, P568, DOI 10.1016/S0960-8966(03)00071-3
   Elson JL, 2009, HUM MUTAT, V30, pE984, DOI 10.1002/humu.21113
   Grasbon-Frodl EM, 1999, NEUROGENETICS, V2, P121, DOI 10.1007/s100480050063
   Hardy SA, 2016, NEUROL-GENET, V2, DOI 10.1212/NXG.0000000000000082
   He LP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf067
   LAFORET P, 1995, NEUROMUSCULAR DISORD, V5, P399, DOI 10.1016/0960-8966(94)00080-S
   López-Gallardo E, 2009, MITOCHONDRION, V9, P314, DOI 10.1016/j.mito.2009.04.005
   MORAES CT, 1993, NAT GENET, V4, P284, DOI 10.1038/ng0793-284
   Nesbitt V, 2012, DEV MED CHILD NEUROL, V54, P500, DOI 10.1111/j.1469-8749.2012.04224.x
   OLD SL, 1989, HISTOCHEM J, V21, P545, DOI 10.1007/BF01753355
   Qu J, 2006, INVEST OPHTH VIS SCI, V47, P475, DOI 10.1167/iovs.05-0665
   Rocha MC, 2015, SCI REP, V5, P15
   Sallevelt SCEH, 2017, J MED GENET, V54, P114, DOI 10.1136/jmedgenet-2016-103876
   Schon EA, 2012, NAT REV GENET, V13, P878, DOI 10.1038/nrg3275
   Seneca S, 2000, J INHERIT METAB DIS, V23, P853, DOI 10.1023/A:1026729223050
   Cardena MMSG, 2013, MITOCHONDR DNA, V24, P46, DOI 10.3109/19401736.2012.717933
   Sonney S, 2017, PLOS COMPUT BIOL, V13, DOI 10.1371/journal.pcbi.1005867
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   White HE, 2005, GENET TEST, V9, P190, DOI 10.1089/gte.2005.9.190
   Wong LJC, 2002, CLIN CHEM, V48, P1901
   Yarham JW, 2011, HUM MUTAT, V32, P1319, DOI 10.1002/humu.21575
   Yarham JW, 2010, WIRES RNA, V1, P304, DOI 10.1002/wrna.27
   Zierz CM, 2019, J CLIN MED, V8, DOI 10.3390/jcm8060789
NR 25
TC 2
Z9 3
U1 0
U2 2
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD APR
PY 2020
VL 30
IS 4
BP 346
EP 350
DI 10.1016/j.nmd.2020.02.020
PG 5
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA LO4QN
UT WOS:000533614400013
PM 32305257
OA Green Published, hybrid
DA 2024-11-01
ER

PT S
AU Graham, BH
AF Graham, Brett H.
BE Wong, LJC
TI Diagnostic Challenges of Mitochondrial Disorders: Complexities of Two
   Genomes
SO MITOCHONDRIAL DISORDERS: BIOCHEMICAL AND MOLECULAR ANALYSIS
SE Methods in Molecular Biology
LA English
DT Article; Book Chapter
DE Mitochondria; Respiratory chain disorders; Heteroplasmy; mtDNA; Gene
   testing
ID RESPIRATORY-CHAIN DISORDERS; C-OXIDASE DEFICIENCY; DNA DEPLETION;
   CLINICAL SPECTRUM; SUCLA2 MUTATIONS; GENE-MUTATIONS; DISEASE; CHILDREN;
   ENCEPHALOMYOPATHY; DELETIONS
AB Mitochondrial disorders causing respiratory chain dysfunction comprise a group of genetically and clinically heterogeneous diseases. This heterogeneity reflects both the biochemical complexity of oxidative phosphorylation and the genetic contribution of both the nuclear and mitochondrial genomes to the respiratory chain. Current approaches to diagnose and classify mitochondrial disorders incorporate clinical, biochemical, and histological criteria, as well as DNA-based molecular diagnostic testing. While the identification of pathogenic mutations is generally accepted as definitive, the large number of candidate nuclear genes, the involvement of two genomes, and potential heteroplasmy of pathogenic mitochondrial DNA (mtDNA) frequently complicate successful molecular diagnostic confirmation. The strategy for pursuing a diagnosis derives from the integration of family history, clinical findings, biochemical evaluations, histopathological analyses, neuroradiological results, and the availability of different tissues for analyses. Screening for common point mutations and large deletions in mtDNA is usually the first step. Specific subsets of known nuclear disease genes can be screened by direct sequencing for cases of recognizable patterns of respiratory chain deficiencies or clinically identifiable syndromic presentations. Measurement of mtDNA content in affected tissues such as muscle and liver allows screening for mtDNA depletion syndromes. The growing list of known disease-causing genes and the promise of next generation sequencing technologies will undoubtedly improve diagnostic accuracy and genetic counseling for this challenging group of disorders.
C1 Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
C3 Baylor College of Medicine
RP Graham, BH (corresponding author), Baylor Coll Med, Dept Mol & Human Genet, Houston, TX 77030 USA.
RI Graham, Brett/R-8685-2018
OI Graham, Brett/0000-0001-8451-8154
CR Bernier FP, 2002, NEUROLOGY, V59, P1406, DOI 10.1212/01.WNL.0000033795.17156.00
   Böhm M, 2006, PEDIATR RES, V59, P21, DOI 10.1203/01.pdr.0000190572.68191.13
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Carrozzo R, 2007, BRAIN, V130, P862, DOI 10.1093/brain/awl389
   Dimmock DP, 2008, HUM MUTAT, V29, P330, DOI 10.1002/humu.9519
   Dimmock D, 2010, CLIN CHEM, V56, P1119, DOI 10.1373/clinchem.2009.141549
   Duncan AJ, 2009, AM J HUM GENET, V84, P558, DOI 10.1016/j.ajhg.2009.03.018
   Elliott HR, 2008, AM J HUM GENET, V83, P254, DOI 10.1016/j.ajhg.2008.07.004
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Guan MX, 1996, HUM MOL GENET, V5, P963, DOI 10.1093/hmg/5.7.963
   Haas RH, 2008, MOL GENET METAB, V94, P16, DOI 10.1016/j.ymgme.2007.11.018
   Haas RH, 2007, PEDIATRICS, V120, P1326, DOI 10.1542/peds.2007-0391
   Jaksch M, 1998, J MED GENET, V35, P895, DOI 10.1136/jmg.35.11.895
   Jaksch M, 2001, J MED GENET, V38, P665, DOI 10.1136/jmg.38.10.665
   Lagier-Tourenne C, 2008, AM J HUM GENET, V82, P661, DOI 10.1016/j.ajhg.2007.12.024
   Liang MH, 1998, AM J MED GENET, V77, P395, DOI 10.1002/(SICI)1096-8628(19980605)77:5<395::AID-AJMG8>3.0.CO;2-M
   Marotta R, 2004, INTERN MED J, V34, P10, DOI 10.1111/j.1444-0903.2004.t01-3-.x
   Mollet J, 2008, AM J HUM GENET, V82, P623, DOI 10.1016/j.ajhg.2007.12.022
   Naïmi M, 2006, EUR J HUM GENET, V14, P917, DOI 10.1038/sj.ejhg.5201627
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Oskoui M, 2006, ARCH NEUROL-CHICAGO, V63, P1122, DOI 10.1001/archneur.63.8.1122
   Ostergaard E, 2007, AM J HUM GENET, V81, P383, DOI 10.1086/519222
   Ostergaard E, 2007, BRAIN, V130, P853, DOI 10.1093/brain/awl383
   Pagliarini DJ, 2008, CELL, V134, P112, DOI 10.1016/j.cell.2008.06.016
   Quinzii CM, 2010, DEV DISABIL RES REV, V16, P183, DOI 10.1002/ddrr.108
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Scaglia F, 2004, PEDIATRICS, V114, P925, DOI 10.1542/peds.2004-0718
   Schaefer AM, 2004, BBA-BIOENERGETICS, V1659, P115, DOI 10.1016/j.bbabio.2004.09.005
   Schaefer AM, 2008, ANN NEUROL, V63, P35, DOI 10.1002/ana.21217
   Shoubridge EA, 2001, AM J MED GENET, V106, P46, DOI 10.1002/ajmg.1378
   Skladal D, 2003, BRAIN, V126, P1905, DOI 10.1093/brain/awg170
   Wolf NI, 2002, NEUROLOGY, V59, P1402, DOI 10.1212/01.WNL.0000031795.91814.D8
   Wong LJC, 2008, CLIN CHEM, V54, P1141, DOI 10.1373/clinchem.2008.103721
   Wong LJC, 2007, HEPATOLOGY, V46, P1218, DOI 10.1002/hep.21799
   Wong LJC, 2010, MOL GENET METAB, V100, P111, DOI 10.1016/j.ymgme.2010.02.024
   Wong LJC, 2008, HUM MUTAT, V29, pE150, DOI 10.1002/humu.20824
   Wong LJC, 2004, MUSCLE NERVE, V30, P118, DOI 10.1002/mus.20045
   Wong LJC, 2003, J MED GENET, V40
NR 38
TC 18
Z9 28
U1 0
U2 3
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA
SN 1064-3745
BN 978-1-61779-503-9
J9 METHODS MOL BIOL
JI Methods Mol. Biol.
PY 2012
VL 837
BP 35
EP 46
DI 10.1007/978-1-61779-504-6_3
D2 10.1007/978-1-61779-504-6
PG 12
WC Biochemical Research Methods; Biochemistry & Molecular Biology
WE Book Citation Index – Science (BKCI-S)
SC Biochemistry & Molecular Biology
GA BAG90
UT WOS:000304125100003
PM 22215539
DA 2024-11-01
ER

PT J
AU Spangenberg, L
   Graña, M
   Mansilla, S
   Martinez, J
   Tapié, A
   Greif, G
   Montano, N
   Vaglio, A
   Guecaimburú, R
   Robello, C
   Castro, L
   Quijano, C
   Raggio, V
   Naya, H
AF Spangenberg, Lucia
   Grana, Martin
   Mansilla, Santiago
   Martinez, Jennyfer
   Tapie, Alejandra
   Greif, Gonzalo
   Montano, Nelida
   Vaglio, Alicia
   Guecaimburu, Rosario
   Robello, Carlos
   Castro, Laura
   Quijano, Celia
   Raggio, Victor
   Naya, Hugo
TI Deep sequencing discovery of causal mtDNA mutations in a patient with
   unspecific neurological disease
SO MITOCHONDRION
LA English
DT Article
DE Deep sequencing; Neurological disorders; mitDNA; Causative mutation;
   9017C; 9010A
ID MITOCHONDRIAL-DNA; SKELETAL-MUSCLE; HIGH PENETRANCE; HUMAN BRAIN;
   HETEROPLASMY; VARIANTS; DECLINE; WEB
AB Mitochondrial diseases (MD) are a group of diseases that can be caused by either mutations in the mitochondrial genome or nuclear DNA. MD may be difficult to diagnose since very often they are highly heterogeneous and with overlapping phenotypes. Molecular genomics approaches, especially NGS have helped in this sense. In this study we have sequenced the mitochondrial genome of a girl with an unspecific neurological disorder and her mother. The later, while neurologically unaffected, suffers from a myopathy without clear cause. We were able to detect two non-synonymous mutations in the MT-ATP6 gene, which we propose are strong candidates for causative agents. 9017C as the main candidate present at high heteroplasmy frequency in the patient (83,2%) and moderate in the mother (45,4%) while it has a low frequency in the general population. It might act alone or in conjunction with 9010A as an accessory mutation. Evolutionary analysis showed that both mutations were located in a critical position in the F-0 a subunit, from F-0-F-1 ATPase. Functional studies showed that carriers of those mutations in comparison to an unaffected individual (father) presented a decrease in the basal and ATP dependent oxygen consumption rate and a decrease in the maximum respiration rate.
C1 [Spangenberg, Lucia; Grana, Martin; Naya, Hugo] Inst Pasteur Montevideo, Unidad Bioinformat, Montevideo, Uruguay.
   [Tapie, Alejandra; Guecaimburu, Rosario; Raggio, Victor] UDELAR, Dept Genet, Fac Med, Montevideo, Uruguay.
   [Mansilla, Santiago; Martinez, Jennyfer; Castro, Laura; Quijano, Celia] UDELAR, Dept Bioquim, Fac Med, Montevideo, Uruguay.
   [Montano, Nelida; Vaglio, Alicia] Inst Med Genet, Montevideo, Uruguay.
   [Mansilla, Santiago; Martinez, Jennyfer; Castro, Laura; Quijano, Celia] Ctr Free Rad & Biomed Res CEINBIO, Montevideo, Uruguay.
   [Naya, Hugo] UDELAR, Dept Prod Anim & Pasturas, Fac Agron, Montevideo, Uruguay.
   [Greif, Gonzalo; Robello, Carlos] Inst Pasteur Montevideo, Unidad Biol Mol, Montevideo, Uruguay.
C3 Pasteur Network; Institut Pasteur de Montevideo; Universidad de la
   Republica, Uruguay; Universidad de la Republica, Uruguay; Universidad de
   la Republica, Uruguay; Pasteur Network; Institut Pasteur de Montevideo
RP Naya, H (corresponding author), Inst Pasteur Montevideo, Bioinformat Unit, Mataojo 2020, Montevideo 11400, Uruguay.
EM naya@pasteur.edu.uy
RI Grana, Martin/R-7245-2019; ROBELLO, CARLOS/M-5609-2019
OI ROBELLO, CARLOS/0000-0001-6985-6171; Grana, Martin/0000-0003-1182-8236;
   Naya, Hugo/0000-0001-6982-4399; Greif, Gonzalo/0000-0002-6769-3249;
   raggio, victor/0000-0001-5389-5002; Martinez,
   Jennyfer/0000-0001-8116-5920
FU FOCEM (MERCOSUR Structural Convergence Fund) [COF 03/11]; Inter-American
   Development Bank [ATN/KK-14584]; INNOVA-Uruguay; Espacio
   Interdisciplinario - Centros, UDELAR 2015; CSIC grupos I + D [767]; CSIC
   I + D [280]
FX This work was partially founded by FOCEM (MERCOSUR Structural
   Convergence Fund) COF 03/11, Inter-American Development Bank
   ATN/KK-14584UR (-Strengthening Technical and Human capacities for
   Genomic's Services exports parallel to) and INNOVA-Uruguay. SM, JM, LC
   and CQ were partially founded by grants of the Espacio
   Interdisciplinario - Centros, UDELAR 2015. In addition, SM and LC were
   also supported by CSIC grupos I + D 2014 (767) and CSIC I + D 2016
   (280).
CR Adzhubei I, 2013, CURR PROTOC HUM S76, P76
   Ahn BH, 2008, P NATL ACAD SCI USA, V105, P14447, DOI 10.1073/pnas.0803790105
   Anderson KA, 2012, ESSAYS BIOCHEM, V52, P23, DOI [10.1042/BSE0520023, 10.1042/bse0520023]
   Bandelt HJ, 2007, BIOCHEM BIOPH RES CO, V352, P283, DOI 10.1016/j.bbrc.2006.10.131
   Barrientos A, 1997, MOL BRAIN RES, V52, P284, DOI 10.1016/S0169-328X(97)00278-7
   Blein S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136192
   Brand MD, 2011, BIOCHEM J, V435, P297, DOI 10.1042/BJ20110162
   Brandon MC, 2005, NUCLEIC ACIDS RES, V33, pD611
   Calabrese C, 2014, BIOINFORMATICS, V30, P3115, DOI 10.1093/bioinformatics/btu483
   Chacko BK, 2013, LAB INVEST, V93, P690, DOI 10.1038/labinvest.2013.53
   Chen HC, 2005, J BIOL CHEM, V280, P26185, DOI 10.1074/jbc.M503062200
   Chen N, 2016, SCI REP-UK, V6, DOI 10.1038/srep37404
   Chinnery P, 2000, MITOCHONDRIAL DISORD, P1
   Finn RD, 2015, NUCLEIC ACIDS RES, V43, pW30, DOI 10.1093/nar/gkv397
   Hamosh A, 2000, HUM MUTAT, V15, P57, DOI 10.1002/(SICI)1098-1004(200001)15:1<57::AID-HUMU12>3.0.CO;2-G
   Herzig S, 2018, NAT REV MOL CELL BIO, V19, P121, DOI 10.1038/nrm.2017.95
   Ji YC, 2016, INVEST OPHTH VIS SCI, V57, P2377, DOI 10.1167/iovs.16-19243
   Katoh K, 2014, METHODS MOL BIOL, V1079, P131, DOI 10.1007/978-1-62703-646-7_8
   Kelley LA, 2009, NAT PROTOC, V4, P363, DOI 10.1038/nprot.2009.2
   Kramer PA, 2014, JOVE-J VIS EXP, DOI 10.3791/51301
   Landrum MJ, 2014, NUCLEIC ACIDS RES, V42, pD980, DOI 10.1093/nar/gkt1113
   Larsen S, 2012, J PHYSIOL-LONDON, V590, P3349, DOI 10.1113/jphysiol.2012.230185
   Lee HC, 1998, FEBS LETT, V441, P292, DOI 10.1016/S0014-5793(98)01564-6
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Lott Marie T, 2013, Curr Protoc Bioinformatics, V44, DOI 10.1002/0471250953.bi0123s44
   MACMILLAN C, 1993, NEUROLOGY, V43, P1586, DOI 10.1212/WNL.43.8.1586
   Mattiazzi M, 2004, HUM MOL GENET, V13, P869, DOI 10.1093/hmg/ddh103
   McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110
   Monnot S, 2011, HUM MUTAT, V32, P116, DOI 10.1002/humu.21417
   Ojaimi J, 1999, MECH AGEING DEV, V111, P39, DOI 10.1016/S0047-6374(99)00071-8
   Payne BAI, 2013, HUM MOL GENET, V22, P384, DOI 10.1093/hmg/dds435
   Povalko N, 2005, MITOCHONDRION, V5, P194, DOI 10.1016/j.mito.2005.03.003
   Quijano C, 2016, REDOX BIOL, V8, P28, DOI 10.1016/j.redox.2015.11.010
   Short KR, 2005, P NATL ACAD SCI USA, V102, P5618, DOI 10.1073/pnas.0501559102
   Stavropoulos DJ, 2016, NPJ GENOM MED, V1, DOI 10.1038/npjgenmed.2015.12
   Whittaker RG, 2009, NEUROLOGY, V72, P568, DOI 10.1212/01.wnl.0000342121.91336.4d
   Yang JY, 2015, NAT METHODS, V12, P7, DOI 10.1038/nmeth.3213
   Yang YP, 2014, JAMA-J AM MED ASSOC, V312, P1870, DOI 10.1001/jama.2014.14601
   YEN TC, 1989, BIOCHEM BIOPH RES CO, V165, P994, DOI 10.1016/0006-291X(89)92701-0
   Zhou AN, 2015, ELIFE, V4, DOI 10.7554/eLife.10180
   2013, GENES BRAIN BEHAV, V12, P812, DOI DOI 10.1111/GBB.12089
   2016, MITOCHONDRION, V28, P54, DOI DOI 10.1016/J.MITO.2016.03.006
NR 42
TC 6
Z9 7
U1 0
U2 2
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 1872-8278
J9 MITOCHONDRION
JI Mitochondrion
PD MAY
PY 2019
VL 46
BP 337
EP 344
DI 10.1016/j.mito.2018.09.004
PG 8
WC Cell Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Genetics & Heredity
GA HX8NY
UT WOS:000467663800043
PM 30227252
DA 2024-11-01
ER

PT J
AU Anitori, R
   Manning, K
   Quan, F
   Weleber, RG
   Buist, NRM
   Shoubridge, EA
   Kennaway, NG
AF Anitori, R
   Manning, K
   Quan, F
   Weleber, RG
   Buist, NRM
   Shoubridge, EA
   Kennaway, NG
TI Contrasting phenotypes in three patients with novel mutations in
   mitochondrial tRNA genes
SO MOLECULAR GENETICS AND METABOLISM
LA English
DT Article
DE mitochondrial myopathy; mitochondrial encephalomyopathy; pigmentary
   retinopathy; mitochondrial DNA; mitochondrial tRNA mutation; complex I
   deficiency; complex IV deficiency; cytochrome c oxidase negative fibers;
   hair root analysis; pathogenesis of mitochondrial tRNA mutations
ID MTDNA POINT MUTATION; DNA MUTATIONS; DIABETES-MELLITUS;
   PROTEIN-SYNTHESIS; SKELETAL-MUSCLE; WILD-TYPE; MYOPATHY; EXERCISE;
   DEFICIENCY; MELAS
AB We studied three patients, each harboring a novel mutation at a highly conserved position in a different mitochondrial tRNA gene. The mutation in patient 1 (T5543C) was associated with isolated mitochondrial myopathy, and occurred in the anticodon loop of tRNA(Trp). In patient 2, with mitochondrial myopathy and marked retinopathy, the mutation (G14710A) resulted in an anticodon swap (Glu to Lys) in tRNA. Patient 3, who manifested mitochondrial encephalomyopathy and moderate retinal dysfunction, harbored a mutation (C3287A) in the TpsiC loop of tRNA(Leuf(UUR)). The mutations were heteroplasmic in muscle in all cases, and sporadic in two cases. PCR-RFLP analysis in all patients showed much higher amounts of mutated mtDNA in affected tissue (muscle) than unaffected tissue (blood), and significantly higher levels of mutated mtDNA in cytochrome c oxidase (COX)-negative muscle fibers than in COX-positive fibers, confirming the pathogenicity of these mutations. The mutation was also detected in single hair roots from all three patients, indicating that each mutation must have arisen early in embryonic development or in maternal germ cells. This suggests that individual hair root analyses may reflect a wider tissue distribution of mutated mtDNA than is clinically apparent, and might be useful in predicting prognosis and, perhaps, the risk of transmitting the mutation to offspring. Our data suggest a correlation between clinical phenotype and distribution of mutated mtDNA in muscle versus hair roots. Furthermore, the high threshold for phenotypic expression in single muscle fibers (92-96%) suggests that therapies may only need to increase the percentage of wildtype mtDNA by a small amount to be beneficial. (C) 2004 Elsevier Inc. All rights reserved.
C1 Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97239 USA.
   Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97239 USA.
   Oregon Hlth & Sci Univ, Casey Eye Inst, Portland, OR 97239 USA.
   Oregon Hlth & Sci Univ, Dept Pediat, Portland, OR 97239 USA.
   Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97239 USA.
   McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada.
C3 Oregon Health & Science University; Oregon Health & Science University;
   Oregon Health & Science University; Oregon Health & Science University;
   Oregon Health & Science University; McGill University
RP Oregon Hlth & Sci Univ, Dept Mol & Med Genet, Portland, OR 97239 USA.
EM kennaway@ohsu.edu
RI Quan, Fu-Shi/V-1826-2019
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   ANITORI RP, 1999, P 4 EUR M MIT PATH, P73
   BOULET L, 1992, AM J HUM GENET, V51, P1187
   Bruno C, 2003, J CHILD NEUROL, V18, P300, DOI 10.1177/08830738030180040401
   Chomyn A, 2000, J BIOL CHEM, V275, P19198, DOI 10.1074/jbc.M908734199
   CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221
   Damore ME, 1999, J PEDIATR ENDOCR MET, V12, P207
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   DUNBAR DR, 1995, P NATL ACAD SCI USA, V92, P6562, DOI 10.1073/pnas.92.14.6562
   ELLIOT DL, 1989, MEDICINE, V68, P163, DOI 10.1097/00005792-198905000-00004
   ENRIQUEZ JA, 1995, NAT GENET, V10, P47, DOI 10.1038/ng0595-47
   Fu K, 1996, HUM MOL GENET, V5, P1835, DOI 10.1093/hmg/5.11.1835
   Grasso M, 2001, EUR J HUM GENET, V9, P311, DOI 10.1038/sj.ejhg.5200622
   Griggs RC, 1999, NEW ENGL J MED, V341, P1077, DOI 10.1056/NEJM199909303411411
   HANNA MG, 1995, AM J HUM GENET, V56, P1026
   HAO HL, 1995, AM J HUM GENET, V56, P1017
   Hao HL, 1999, HUM MOL GENET, V8, P1117, DOI 10.1093/hmg/8.6.1117
   Helm M, 2000, RNA, V6, P1356, DOI 10.1017/S1355838200001047
   Helm M, 1999, NUCLEIC ACIDS RES, V27, P756, DOI 10.1093/nar/27.3.756
   Houshmand M, 1999, HUM MUTAT, V13, P203, DOI 10.1002/(SICI)1098-1004(1999)13:3<203::AID-HUMU4>3.0.CO;2-3
   Jacobs HT, 2003, HUM MOL GENET, V12, pR293, DOI 10.1093/hmg/ddg285
   James AM, 1999, EUR J BIOCHEM, V259, P462, DOI 10.1046/j.1432-1327.1999.00066.x
   Jenuth JP, 1997, NAT GENET, V16, P93, DOI 10.1038/ng0597-93
   Keightley JA, 2000, AM J HUM GENET, V67, P1400, DOI 10.1086/316900
   Keightley JA, 1996, NAT GENET, V12, P410, DOI 10.1038/ng0496-410
   LI H, 1991, Methods (Orlando), V2, P49, DOI 10.1016/S1046-2023(05)80125-2
   *MITOMAP, 2004, HUM MIT GEN DAT
   MORAES CT, 1993, NAT GENET, V4, P284, DOI 10.1038/ng0793-284
   MORAES CT, 1993, J CLIN INVEST, V92, P2906, DOI 10.1172/JCI116913
   NELSON I, 1995, ANN NEUROL, V37, P400, DOI 10.1002/ana.410370317
   Nishigaki Y, 2002, NEUROLOGY, V58, P1282, DOI 10.1212/WNL.58.8.1282
   Pallanck Leo, 1995, P371
   PENN AMW, 1992, NEUROLOGY, V42, P2147, DOI 10.1212/WNL.42.11.2147
   Pulkes T, 2001, ADV DRUG DELIVER REV, V49, P27, DOI 10.1016/S0169-409X(01)00124-7
   Raha S, 1999, HUM MUTAT, V13, P245, DOI 10.1002/(SICI)1098-1004(1999)13:3<245::AID-HUMU9>3.0.CO;2-B
   Santorelli FM, 1997, ANN NEUROL, V42, P256, DOI 10.1002/ana.410420220
   Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755
   Servidei Serenella, 2004, Neuromuscul Disord, V14, P107
   SHOFFNER JM, 2001, METABOLIC MOL BASES, V2, P2367
   Silvestri G, 1998, NEUROMUSCULAR DISORD, V8, P291, DOI 10.1016/S0960-8966(98)00037-6
   Silvestri G, 2000, NEUROLOGY, V54, P1693, DOI 10.1212/WNL.54.8.1693
   Suzuki Y, 1997, DIABETES CARE, V20, P1138, DOI 10.2337/diacare.20.7.1138
   Taivassalo T, 2001, ANN NEUROL, V50, P133, DOI 10.1002/ana.1050
   Taivassalo T, 2003, BRAIN, V126, P413, DOI 10.1093/brain/awg028
   Tessa A, 1999, EUR J HUM GENET, V7, P847, DOI 10.1038/sj.ejhg.5200380
   Tulinius M, 2003, NEUROPEDIATRICS, V34, P87
   Tzen CY, 2003, MUSCLE NERVE, V28, P575, DOI 10.1002/mus.10473
   Verma A, 1997, PEDIATR RES, V42, P448, DOI 10.1203/00006450-199710000-00005
   Vialettes BH, 1997, DIABETES CARE, V20, P1731, DOI 10.2337/diacare.20.11.1731
   VILARINHO L, 2001, P 5 EUR M MIT PATH V, P297
   WASSERMAN K, 1985, J APPL PHYSIOL, V59, P935, DOI 10.1152/jappl.1985.59.3.935
   WILICHOWSKI E, 2001, P 5 EUR M MIT PATH V, P307
   YONEDA M, 1992, P NATL ACAD SCI USA, V89, P11164, DOI 10.1073/pnas.89.23.11164
NR 55
TC 36
Z9 37
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1096-7192
EI 1096-7206
J9 MOL GENET METAB
JI Mol. Genet. Metab.
PD FEB
PY 2005
VL 84
IS 2
BP 176
EP 188
DI 10.1016/j.ymgme.2004.10.003
PG 13
WC Endocrinology & Metabolism; Genetics & Heredity; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Genetics & Heredity; Research & Experimental
   Medicine
GA 901RP
UT WOS:000227299900011
PM 15670724
DA 2024-11-01
ER

PT J
AU Al-Hussaini, A
   Faqeih, E
   El-Hattab, AW
   Alfadhel, M
   Asery, A
   Alsaleem, B
   Bakhsh, E
   Ali, A
   Alasmari, A
   Lone, K
   Nahari, A
   Eyaid, W
   Al Balwi, M
   Craig, K
   Butterworth, A
   He, LP
   Taylor, RW
AF Al-Hussaini, Abdulrahman
   Faqeih, Eissa
   El-Hattab, Ayman W.
   Alfadhel, Majid
   Asery, Ali
   Alsaleem, Badr
   Bakhsh, Eman
   Ali, Ashraf
   Alasmari, Ali
   Lone, Khurram
   Nahari, Ahmed
   Eyaid, Wafaa
   Al Balwi, Mohammed
   Craig, Kate
   Butterworth, Anna
   He, Langping
   Taylor, Robert W.
TI Clinical and Molecular Characteristics of Mitochondrial DNA Depletion
   Syndrome Associated with Neonatal Cholestasis and Liver Failure
SO JOURNAL OF PEDIATRICS
LA English
DT Article
ID DEOXYGUANOSINE KINASE; MTDNA DEPLETION; MUTATIONS; FEATURES; GENE;
   MYOPATHY; DISEASE
AB Objective To determine the frequency of mitochondrial DNA depletion syndrome (MDS) in infants with cholestasis and liver failure and to further clarify the clinical, biochemical, radiologic, histopathologic, and molecular features associated with MDS due to deoxyguanosine kinase (DGUOK) and MPV17 gene mutations.
   Study design We studied 20 infants with suspected hepatocerebral MDS referred to our tertiary care center between 2007 and 2013. Genomic DNA was isolated from blood leukocytes, liver, and/or skeletal muscle samples by standard methods. Mitochondrial DNA copy number relative to nuclear DNA levels was determined in muscle and/or liver DNA using real-time quantitative polymerase chain reaction and compared with age-matched controls. Nuclear candidate genes, including polymerase gamma, MPV17, and DGUOK were sequenced using standard analyses.
   Results We identified pathogenic MPV17 and DGUOK mutations in 11 infants (6 females) representing 2.5% of the 450 cases of infantile cholestasis and 22% of the 50 cases of infantile liver failure referred to our center during the study period. All of the 11 patients manifested cholestasis that was followed by a rapidly progressive liver failure and death before 2 years of life. Mitochondrial DNA depletion was demonstrated in liver or muscle for 8 out of the 11 cases where tissue was available. Seven patients had mutations in the MPV17 gene (3 novel mutations), 4 patients had DGUOK mutations (of which 2 were novel mutations).
   Conclusion Mutations in the MPV17 and DGUOK genes are present in a significant percentage of infants with liver failure and are associated with poor prognosis.
C1 [Al-Hussaini, Abdulrahman; Asery, Ali; Alsaleem, Badr; Lone, Khurram; Nahari, Ahmed] King Saud bin Abdulaziz Univ Hlth Sci, Div Pediat Gastroenterol, Childrens Hosp, King Fahad Med City,Coll Med, Riyadh 11525, Saudi Arabia.
   [Faqeih, Eissa; El-Hattab, Ayman W.; Alasmari, Ali] King Saud bin Abdulaziz Univ Hlth Sci, Div Med Genet, Childrens Hosp, King Fahad Med City,Coll Med, Riyadh 11525, Saudi Arabia.
   [Alfadhel, Majid; Eyaid, Wafaa] King Saud bin Abdulaziz Univ Hlth Sci, Div Genet, Dept Pediat, King Abdulaziz Med City, Riyadh 11525, Saudi Arabia.
   [Bakhsh, Eman] King Saud bin Abdulaziz Univ Hlth Sci, Dept Radiol, King Fahad Med City, Riyadh 11525, Saudi Arabia.
   [Ali, Ashraf; Al Balwi, Mohammed] King Saud bin Abdulaziz Univ Hlth Sci, King Abdulaziz Med City, Dept Pathol, Riyadh 11525, Saudi Arabia.
   [Al Balwi, Mohammed] King Saud bin Abdulaziz Univ Hlth Sci, King Abdulaziz Med City, King Abdullah Int Med Res Ctr, Riyadh 11525, Saudi Arabia.
   [Craig, Kate; Butterworth, Anna; He, Langping; Taylor, Robert W.] Newcastle Univ, Wellcome Trust Ctr Mitochondrial Res, Newcastle Mitochondrial Highly Specialized Serv D, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
C3 King Saud Bin Abdulaziz University for Health Sciences; King Fahad
   Medical City; King Saud Bin Abdulaziz University for Health Sciences;
   King Fahad Medical City; King Saud Bin Abdulaziz University for Health
   Sciences; King Saud Bin Abdulaziz University for Health Sciences; King
   Saud Bin Abdulaziz University for Health Sciences; King Saud Bin
   Abdulaziz University for Health Sciences; Newcastle University - UK
RP Al-Hussaini, A (corresponding author), King Saud bin Abdulaziz Univ Hlth Sci, Div Pediat Gastroenterol Hepatol & Nutr, Childrens Hosp, King Fahad Med City,Coll Med, POB 59046, Riyadh 11525, Saudi Arabia.
EM aa_alhussaini@yahoo.com
OI Al Balwi, Mohammed/0000-0003-2910-0390; Nahari, Ahmed
   Ali/0000-0002-7552-5237
FU Medical Research Council [MR/K000608/1] Funding Source: Medline;
   Wellcome Trust [096919] Funding Source: Medline; MRC [MR/K000608/1]
   Funding Source: UKRI
CR Blakely E, 2008, NEUROMUSCULAR DISORD, V18, P557, DOI 10.1016/j.nmd.2008.04.014
   Brahimi N, 2009, MOL GENET METAB, V97, P221, DOI 10.1016/j.ymgme.2009.03.007
   Brunetti-Pierri N, 2008, NEUROPEDIATRICS, V39, P179, DOI 10.1055/s-0028-1093334
   Chinnery PF, 2005, J HEPATOL, V43, P207, DOI 10.1016/j.jhep.2005.05.012
   deBruyn JC, 2007, J PEDIATR GASTR NUTR, V45, P252, DOI 10.1097/MPG.0b013e318048838f
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Dimmock DP, 2008, HUM MUTAT, V29, P330, DOI 10.1002/humu.9519
   El-Hattab AW, 2010, MOL GENET METAB, V99, P300, DOI 10.1016/j.ymgme.2009.10.003
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Freisinger P, 2006, ARCH NEUROL-CHICAGO, V63, P1129, DOI 10.1001/archneur.63.8.1129
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   JOHNS DR, 1995, NEW ENGL J MED, V333, P638, DOI 10.1056/NEJM199509073331007
   Labarthe F, 2005, J HEPATOL, V43, P333, DOI 10.1016/j.jhep.2005.03.023
   Lee WS, J PEDIAT IN PRESS
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Merkle A N, 2012, AJNR Am J Neuroradiol, V33, pE34, DOI 10.3174/ajnr.A2455
   Morten KJ, 2007, MITOCHONDRION, V7, P386, DOI 10.1016/j.mito.2007.09.001
   POULTON J, 1995, J INHERIT METAB DIS, V18, P4, DOI 10.1007/BF00711367
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Spinazzola A, 2009, J INHERIT METAB DIS, V32, P143, DOI 10.1007/s10545-008-1038-z
   Uusimaa J, EUR J HUM G IN PRESS
   Vu TH, 1998, NEUROLOGY, V50, P1783, DOI 10.1212/WNL.50.6.1783
   Wang LY, 2005, MOL GENET METAB, V84, P75, DOI 10.1016/j.ymgme.2004.09.005
   Wang LY, 2003, FEBS LETT, V554, P319, DOI 10.1016/S0014-5793(03)01181-5
   Wong LJC, 2007, HEPATOLOGY, V46, P1218, DOI 10.1002/hep.21799
NR 25
TC 34
Z9 39
U1 0
U2 9
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0022-3476
EI 1097-6833
J9 J PEDIATR-US
JI J. Pediatr.
PD MAR
PY 2014
VL 164
IS 3
BP 553
EP +
DI 10.1016/j.jpeds.2013.10.082
PG 9
WC Pediatrics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pediatrics
GA AB1GI
UT WOS:000331539100025
PM 24321534
DA 2024-11-01
ER

PT J
AU Li, JY
   Hsieh, RH
   Peng, NJ
   Lai, PH
   Lee, CF
   Lo, YK
   Wei, YH
AF Li, Jie-Yuan
   Hsieh, Rong-Hong
   Peng, Nan-Jing
   Lai, Ping-Hong
   Lee, Cheng-Feng
   Lo, Yuk-Keung
   Wei, Yau-Huei
TI A follow-up study in a Taiwanese family with mitochondrial myopathy,
   encephalopathy, lactic acidosis and stroke-like episodes syndrome
SO JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION
LA English
DT Article
DE follow-up study; MELAS; mitochondrial disease; mitochondrial DNA;
   mutation
ID TRANSFER RNALEU(UUR) GENE; MELAS SYNDROME; CLINICAL PRESENTATIONS;
   DIABETES-MELLITUS; MUTATION; DNA; ENCEPHALOMYOPATHY; DISEASES; PATIENT;
   INVOLVEMENT
AB Background/Purpose: MELAS (mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes) syndrome is often associated with A3243G point mutation of mitochondrial DNA (mtDNA). We previously described a MELAS family characterized by harboring an additional similar to 260 bp tandem duplication in the D-loop and a novel C3093G point mutation in the 16S rRNA gene of mtDNA in the proband. We studied the clinical progression and fluctuation of mtDNA mutations in this Taiwanese MELAS family. Methods: We followed up the clinical course in all members of this family (I proband, her mother and 3 sons) for 12 years. Mutations of mtDNA in serial muscle biopsies of the proband and blood samples and hair follicles taken at different time points from the members of this family were analyzed. Results: The proband developed repeated stroke-like episodes, chronic intestinal pseudo-obstruction, polyneuropathy, progressive renal failure and dilated cardiomyopathy with heart failure. During the follow-up period, the mother and one of the siblings of the proband developed stroke-like episodes at age 62 and 12, respectively. There was no significant difference in the proportions of mtDNA with A3243G mutation among five serial muscle biopsies of the proband. In one carrier (1-2), the proportion of A3243G mutated mtDNA in blood cells was slightly increased with disease progression. Conclusion: This study underlines the importance of early detection of extraneuromuscular symptoms in the members of a family with MELAS syndrome by adequate follow-up. The age of onset of stroke-like episode in MELAS syndrome may be as late as 62 years. We suggest that the manifestations of MELAS syndrome in this family might be associated with the additional similar to 260 bp tandem duplication in the D-loop region and the coexistence of C3093G mutation in the 16S rRNA gene with the A3243G mutation of mtDNA.
C1 Natl Yang Ming Univ, Sch Life Sci, Dept Biochem Mol Biol, Taipei 112, Taiwan.
   Kaohsiung & Natl Yang Ming Univ, Div Neurol, Taipei, Taiwan.
   Kaohsiung & Natl Yang Ming Univ, Dept Nucl Med, Taipei, Taiwan.
   Kaohsiung & Natl Yang Ming Univ, Kaohsiung Vet Gen Hosp, Dept Radiol, Taipei, Taiwan.
   Taipei Med Univ, Sch Nutr & Hlth Sci, Taipei, Taiwan.
   Natl Yang Ming Univ, Sch Life Sci, Dept Biochem Mol Biol, Taipei, Taiwan.
C3 National Yang Ming Chiao Tung University; Kaohsiung Veterans General
   Hospital; Taipei Medical University; National Yang Ming Chiao Tung
   University
RP Wei, YH (corresponding author), Natl Yang Ming Univ, Sch Life Sci, Dept Biochem Mol Biol, 155 Li Nong St,Sect 2,Shih-Pai, Taipei 112, Taiwan.
EM joeman@ym.edu.tw
RI Wei, Yau-Huei/ABA-6841-2021
OI Wei, Yau-Huei/0000-0002-6429-2546
CR Arenas J, 1999, NEUROLOGY, V52, P377, DOI 10.1212/WNL.52.2.377
   Bidooki SK, 1997, AM J HUM GENET, V60, P1430, DOI 10.1086/515460
   Chang TM, 2004, PEDIATR NEUROL, V31, P374, DOI 10.1016/j.pediatrneurol.2004.05.009
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   CIAFALONI E, 1992, ANN NEUROL, V31, P391, DOI 10.1002/ana.410310408
   DAMIAN MS, 1995, ACTA NEUROL SCAND, V92, P409
   DiMauro S, 2004, BBA-BIOENERGETICS, V1658, P80, DOI 10.1016/j.bbabio.2004.03.014
   Dimauro S, 2005, ANN MED, V37, P222, DOI 10.1080/07853890510007368
   DiMauro S, 2006, MUSCLE NERVE, V34, P265, DOI 10.1002/mus.20598
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Hiel JAP, 1998, NETH J MED, V53, P27, DOI 10.1016/S0300-2977(98)00018-7
   Hsieh RH, 2001, J BIOMED SCI, V8, P328, DOI 10.1159/000054051
   KADOWAKI T, 1994, NEW ENGL J MED, V330, P962, DOI 10.1056/NEJM199404073301403
   KAWAKAMI Y, 1994, ANN NEUROL, V35, P370, DOI 10.1002/ana.410350322
   KOBAYASHI Y, 1990, BIOCHEM BIOPH RES CO, V173, P816, DOI 10.1016/S0006-291X(05)80860-5
   LARSSON NG, 1990, PEDIATR RES, V28, P131, DOI 10.1203/00006450-199028020-00011
   Lev D, 2004, PEDIATR CARDIOL, V25, P443, DOI 10.1007/s00246-003-0490-7
   Li JY, 1996, ACTA NEUROL SCAND, V93, P450
   Lien LM, 2001, ACTA NEUROL SCAND, V103, P159, DOI 10.1034/j.1600-0404.2001.103003159.x
   Miyamoto A, 1997, NEURORADIOLOGY, V39, P427, DOI 10.1007/s002340050438
   MORAES CT, 1993, NEUROMUSCULAR DISORD, V3, P43, DOI 10.1016/0960-8966(93)90040-Q
   Nardin RA, 2001, MUSCLE NERVE, V24, P170, DOI 10.1002/1097-4598(200102)24:2<170::AID-MUS30>3.0.CO;2-0
   Ohno K, 1996, ANN NEUROL, V39, P761, DOI 10.1002/ana.410390612
   Okajima Y, 1998, HEART, V80, P292, DOI 10.1136/hrt.80.3.292
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   ROSEN L, 1990, NEURORADIOLOGY, V32, P168, DOI 10.1007/BF00588572
   Sano M, 1995, ACTA NEUROL SCAND, V92, P497
   Valanne L, 1998, AM J NEURORADIOL, V19, P369
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Watanabe Y, 1998, J NUCL MED, V39, P961
NR 30
TC 13
Z9 17
U1 0
U2 2
PU ELSEVIER TAIWAN
PI TAIPEI
PA RM N-412, 4F, CHIA HSIN BUILDING 11, NO 96, ZHONG SHAN N ROAD SEC 2,
   TAIPEI, 10449, TAIWAN
SN 0929-6646
EI 1876-0821
J9 J FORMOS MED ASSOC
JI J. Formos. Med. Assoc.
PD JUL
PY 2007
VL 106
IS 7
BP 528
EP 536
DI 10.1016/S0929-6646(07)60003-5
PG 9
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 197UT
UT WOS:000248582700003
PM 17660142
DA 2024-11-01
ER

PT J
AU Mahmud, S
   Biswas, S
   Afrose, S
   Mita, MA
   Hasan, MR
   Shimu, MSS
   Paul, GK
   Chung, S
   Abu Saleh, M
   Alshehri, S
   Ghoneim, MM
   Alruwaily, M
   Kim, B
AF Mahmud, Shafi
   Biswas, Suvro
   Afrose, Shamima
   Mita, Mohasana Akter
   Hasan, Md Robiul
   Shimu, Mst Sharmin Sultana
   Paul, Gobindo Kumar
   Chung, Sanghyun
   Abu Saleh, Md
   Alshehri, Sultan
   Ghoneim, Momammed M.
   Alruwaily, Maha
   Kim, Bonglee
TI Use of Next-Generation Sequencing for Identifying Mitochondrial
   Disorders
SO CURRENT ISSUES IN MOLECULAR BIOLOGY
LA English
DT Article
DE mitochondrial disorder; OXPHOS; mtDNA; nDNA; NGS
ID HEREDITARY OPTIC NEUROPATHY; DNA MUTATIONS; WHOLE-EXOME; LEIGH-SYNDROME;
   MOLECULAR DIAGNOSIS; DISEASE; GENOME; NUCLEAR; PREVALENCE; GENES
AB Mitochondria are major contributors to ATP synthesis, generating more than 90% of the total cellular energy production through oxidative phosphorylation (OXPHOS): metabolite oxidation, such as the beta-oxidation of fatty acids, and the Krebs's cycle. OXPHOS inadequacy due to large genetic lesions in mitochondrial as well as nuclear genes and homo- or heteroplasmic point mutations in mitochondrially encoded genes is a characteristic of heterogeneous, maternally inherited genetic disorders known as mitochondrial disorders that affect multisystemic tissues and organs with high energy requirements, resulting in various signs and symptoms. Several traditional diagnostic approaches, including magnetic resonance imaging of the brain, cardiac testing, biochemical screening, variable heteroplasmy genetic testing, identifying clinical features, and skeletal muscle biopsies, are associated with increased risks, high costs, a high degree of false-positive or false-negative results, or a lack of precision, which limits their diagnostic abilities for mitochondrial disorders. Variable heteroplasmy levels, mtDNA depletion, and the identification of pathogenic variants can be detected through genetic sequencing, including the gold standard Sanger sequencing. However, sequencing can be time consuming, and Sanger sequencing can result in the missed recognition of larger structural variations such as CNVs or copy-number variations. Although each sequencing method has its own limitations, genetic sequencing can be an alternative to traditional diagnostic methods. The ever-growing roster of possible mutations has led to the development of next-generation sequencing (NGS). The enhancement of NGS methods can offer a precise diagnosis of the mitochondrial disorder within a short period at a reasonable expense for both research and clinical applications.
C1 [Mahmud, Shafi; Biswas, Suvro; Afrose, Shamima; Mita, Mohasana Akter; Hasan, Md Robiul; Shimu, Mst Sharmin Sultana; Paul, Gobindo Kumar; Abu Saleh, Md] Univ Rajshahi, Dept Genet Engn & Biotechnol, Rajshahi 6205, Bangladesh.
   [Chung, Sanghyun; Kim, Bonglee] Kyung Hee Univ, Coll Korean Med, Dept Pathol, Seoul 02447, South Korea.
   [Alshehri, Sultan] King Saud Univ, Coll Pharm, Dept Pharmaceut, Riyadh 11451, Saudi Arabia.
   [Ghoneim, Momammed M.; Alruwaily, Maha] AlMaarefa Univ, Coll Pharm, Dept Pharm Practice, Ad Diriyah 13713, Saudi Arabia.
C3 University of Rajshahi; Kyung Hee University; King Saud University;
   Almaarefa University
RP Mahmud, S (corresponding author), Univ Rajshahi, Dept Genet Engn & Biotechnol, Rajshahi 6205, Bangladesh.; Kim, B (corresponding author), Kyung Hee Univ, Coll Korean Med, Dept Pathol, Seoul 02447, South Korea.
EM shafimahmudfz@gmail.com; suvrobiswas0@gmail.com;
   shamimaafrose.ru@gmail.com; mohasanamita26@gmail.com;
   rhonanik7@gmail.com; sharminshimu120@gmail.com;
   gobindokumar38@gmail.com; nukyung2@khu.ac.kr; saleh@ru.ac.bd;
   salshehril@ksu.edu.sa; mghoneim@mcst.edu.sa; mrowaili@mcst.edu.sa;
   bongleekim@khu.ac.kr
RI Kim, Bonglee/AAH-9077-2020; Alanazi, Saleh/HKN-9388-2023; Ghoneim,
   Mohammed/ABE-7965-2021
OI Kim, Bonglee/0000-0002-8678-156X; , Sultan/0000-0002-0922-9819; Chung,
   Sanghyun/0009-0001-7751-1103; Ghoneim, Mohammed/0000-0002-9179-4373;
   Saleh, Md. Abu/0000-0001-5610-4763; Paul, Gobindo
   Kumar/0000-0002-8707-199X
FU Basic Science Research Program through the National Research Foundation
   of Korea (NRF) - Ministry of Education [NRF-2020R1I1A2066868]; National
   Research Foundation of Korea (NRF) - Korea government (MSIT)
   [2020R1A5A201941311]
FX This research was funded by Basic Science Research Program through the
   National Research Foundation of Korea (NRF) funded by the Ministry of
   Education (NRF-2020R1I1A2066868), the National Research Foundation of
   Korea (NRF) grant funded by the Korea government (MSIT)
   (No.2020R1A5A201941311).
CR Ahmad R, 2021, INT J HEALTH SCI-IJH, V15, P1
   Alemi M, 2007, FREE RADICAL BIO MED, V42, P32, DOI 10.1016/j.freeradbiomed.2006.09.014
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Bannwarth S, 2013, J MED GENET, V50, P704, DOI 10.1136/jmedgenet-2013-101604
   Bewicke-Copley F, 2019, COMPUT STRUCT BIOTEC, V17, P1348, DOI 10.1016/j.csbj.2019.10.004
   Bhatti JS, 2017, BBA-MOL BASIS DIS, V1863, P1066, DOI 10.1016/j.bbadis.2016.11.010
   Bick D, 2011, CURR OPIN PEDIATR, V23, P594, DOI 10.1097/MOP.0b013e32834b20ec
   Böhm M, 2006, PEDIATR RES, V59, P21, DOI 10.1203/01.pdr.0000190572.68191.13
   Boycott KM, 2013, NAT REV GENET, V14, P681, DOI 10.1038/nrg3555
   Broomfield A, 2015, J INHERIT METAB DIS, V38, P445, DOI 10.1007/s10545-014-9778-4
   Calvo SE, 2010, ANNU REV GENOM HUM G, V11, P25, DOI 10.1146/annurev-genom-082509-141720
   Carroll CJ, 2014, BRIT J PHARMACOL, V171, P1837, DOI 10.1111/bph.12469
   CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527
   Chen C, 2015, PROTEIN CELL, V6, P862, DOI 10.1007/s13238-015-0175-z
   Chin J, 2014, MITOCHONDRION, V17, P34, DOI 10.1016/j.mito.2014.05.005
   Chinnasamy P, 2021, INT CONF COMP COMMUN, DOI 10.1109/ICCCI50826.2021.9402681
   Chinnery PF, 2001, AM J MED GENET, V106, P94, DOI 10.1002/ajmg.1426
   Chow J, 2017, NAT REV ENDOCRINOL, V13, P92, DOI 10.1038/nrendo.2016.151
   Circu ML, 2009, FREE RADICAL BIO MED, V47, P1190, DOI 10.1016/j.freeradbiomed.2009.07.032
   Clark MM, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aat6177
   Clima R, 2017, NUCLEIC ACIDS RES, V45, pD698, DOI 10.1093/nar/gkw1066
   Crispatzu G, 2017, HUM MUTAT, V38, P1325, DOI 10.1002/humu.23275
   Cui H, 2013, GENET MED, V15, P388, DOI 10.1038/gim.2012.144
   Cummings BB, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal5209
   Dai Y, 2018, BIOMED REP, V8, P51, DOI 10.3892/br.2017.1014
   Dames S, 2013, J MOL DIAGN, V15, P526, DOI 10.1016/j.jmoldx.2013.03.005
   DaRe JT, 2013, BMC MED GENET, V14, DOI 10.1186/1471-2350-14-118
   Davis R.L., 2018, MITOCHONDRIAL DIS, V147
   Davis RE, 1997, P NATL ACAD SCI USA, V94, P4526, DOI 10.1073/pnas.94.9.4526
   Dewey FE, 2014, JAMA-J AM MED ASSOC, V311, P1035, DOI 10.1001/jama.2014.1717
   Dillies MA, 2013, BRIEF BIOINFORM, V14, P671, DOI 10.1093/bib/bbs046
   DiMauro S, 2005, NEUROMUSCULAR DISORD, V15, P276, DOI 10.1016/j.nmd.2004.12.008
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   DiMauro S., 2020, ROSENBERGS MOL GENET
   DiMauro S, 2006, MUSCLE NERVE, V34, P265, DOI 10.1002/mus.20598
   DiMauro S, 2013, NAT REV NEUROL, V9, P429, DOI 10.1038/nrneurol.2013.126
   DiMauro S, 2011, J INHERIT METAB DIS, V34, P261, DOI 10.1007/s10545-010-9082-x
   Dimmock DP, 2017, PEDIATR CLIN N AM, V64, P161, DOI 10.1016/j.pcl.2016.08.011
   Dinwiddie DL, 2013, GENOMICS, V102, P148, DOI 10.1016/j.ygeno.2013.04.013
   Diroma MA, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-S3-S2
   Duchen MR, 2010, ESSAYS BIOCHEM, V47, P115, DOI [10.1042/bse0470115, 10.1042/BSE0470115]
   ElBeheiry AA, 2014, EGYPT J RADIOL NUC M, V45, P523, DOI 10.1016/j.ejrnm.2013.12.012
   Elliott HR, 2008, AM J HUM GENET, V83, P254, DOI 10.1016/j.ajhg.2008.07.004
   Escribano-Lopez I, 2016, FRONT MED CHEM, V8, P96
   Falk MJ, 2015, MOL GENET METAB, V114, P388, DOI 10.1016/j.ymgme.2014.11.016
   Fendt L, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-139
   Fernandez D, 2009, AUTOIMMUN REV, V8, P184, DOI 10.1016/j.autrev.2008.07.041
   Fresard L, 2019, NAT MED, V25, P911, DOI 10.1038/s41591-019-0457-8
   Friedman JR, 2014, NATURE, V505, P335, DOI 10.1038/nature12985
   Gambin T, 2017, NUCLEIC ACIDS RES, V45, P1633, DOI 10.1093/nar/gkw1237
   Genomes Project C., 2012, NATURE, V491, P56, DOI DOI 10.1038/nature11632
   Gilissen C, 2014, NATURE, V511, P344, DOI [10.1038/nature13394, 10.3389/fnhum.2013.00444]
   Giordano C, 2011, BRAIN, V134, P220, DOI 10.1093/brain/awq276
   Gorman GS, 2016, NAT REV DIS PRIMERS, V2, P1, DOI 10.1038/nrdp.2016.80
   Gorman GS, 2015, ANN NEUROL, V77, P753, DOI 10.1002/ana.24362
   Gorski MM, 2016, BLOOD, V127, P2924, DOI 10.1182/blood-2015-12-685735
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Griffin HR, 2014, GENET MED, V16, P962, DOI 10.1038/gim.2014.66
   Hakeem K.R., 2016, Plant omics: trends and applications
   Hamilton A, 2016, MOL GENET GENOM MED, V4, P504, DOI 10.1002/mgg3.223
   Heighton JN, 2019, MITOCHONDRION, V44, P15, DOI 10.1016/j.mito.2017.12.006
   Herbers E, 2019, MITOCHONDRION, V44, P85, DOI 10.1016/j.mito.2018.01.004
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   Horvath R, 2019, DIAGNOSIS MANAG MITO, P281, DOI [10.1007/978-3-030-05517-2, DOI 10.1007/978-3-030-05517-2]
   Huang Taosheng, 2011, Curr Protoc Hum Genet, VChapter 19, DOI 10.1002/0471142905.hg1908s71
   Huoponen K, 2001, NEUROGENETICS, V3, P119, DOI 10.1007/s100480100115
   JOHNS DR, 1995, NEW ENGL J MED, V333, P638, DOI 10.1056/NEJM199509073331007
   Jongbloed Jan Dh, 2011, Expert Opin Med Diagn, V5, P9, DOI 10.1517/17530059.2011.540566
   Kaneko T, 2015, METHODS MOL BIOL, V1239, P307, DOI 10.1007/978-1-4939-1862-1_18
   Karbowski M, 2012, ACTA NEUROPATHOL, V123, P157, DOI 10.1007/s00401-011-0921-0
   Kathiresan N, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-09089-1
   Kaufmann P, 2011, NEUROLOGY, V77, P1965, DOI 10.1212/WNL.0b013e31823a0c7f
   Kendall FD, 2012, J PEDIATR BIOCHEM, V2, P193, DOI 10.3233/JPB-120061
   Kerr M, 2020, MOL GENET METAB, V131, P66, DOI 10.1016/j.ymgme.2020.08.009
   Kim JA, 2008, CIRC RES, V102, P401, DOI 10.1161/CIRCRESAHA.107.165472
   Kisilevsley E, 2020, SURV OPHTHALMOL, V65, P294, DOI 10.1016/j.survophthal.2019.11.001
   Koenig MK, 2008, PEDIATR NEUROL, V38, P305, DOI 10.1016/j.pediatrneurol.2007.12.001
   Koopman WJH, 2012, NEW ENGL J MED, V366, P1132, DOI 10.1056/NEJMra1012478
   Kotrys AV, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9010017
   Kremer LS, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15824
   Kulkarni P, 2017, COMPUT STRUCT BIOTEC, V15, P471, DOI 10.1016/j.csbj.2017.10.001
   Landrum MJ, 2014, NUCLEIC ACIDS RES, V42, pD980, DOI 10.1093/nar/gkt1113
   Lee HN, 2020, GENET MED, V22, P490, DOI 10.1038/s41436-019-0672-1
   Lee HF, 2009, PEDIATR NEUROL, V40, P88, DOI 10.1016/j.pediatrneurol.2008.09.020
   Legati A, 2016, BBA-BIOENERGETICS, V1857, P1326, DOI 10.1016/j.bbabio.2016.02.022
   LEIGH D, 1951, J NEUROL NEUROSUR PS, V14, P216, DOI 10.1136/jnnp.14.3.216
   Li L, 2018, MITOCHONDRIAL DNA B, V3, P1004, DOI 10.1080/23802359.2018.1501287
   Li MK, 2010, AM J HUM GENET, V87, P237, DOI 10.1016/j.ajhg.2010.07.014
   Liang C, 2014, BBA-GEN SUBJECTS, V1840, P1360, DOI 10.1016/j.bbagen.2013.10.040
   Liang P, 2012, J APPL BIOINFORM COM, V1, P1, DOI [10.4172/2329-9533.1000101, DOI 10.4172/2329-9533.1000101]
   Lieber DS, 2013, NEUROLOGY, V80, P1762, DOI 10.1212/WNL.0b013e3182918c40
   Limongelli G, 2012, FUTUR CARDIOL, V8, P71, DOI [10.2217/fca.11.79, 10.2217/FCA.11.79]
   Lohmann K, 2014, NEUROTHERAPEUTICS, V11, P699, DOI 10.1007/s13311-014-0288-8
   Lönnqvist T, 2009, BRAIN, V132, P1553, DOI 10.1093/brain/awp045
   Ma ESK, 2017, CANCER GENET-NY, V218, P15, DOI 10.1016/j.cancergen.2017.09.001
   Ma M, 2015, BMC GENOMICS, V16, DOI 10.1186/1471-2164-16-S8-S3
   Macken WL, 2021, NAT REV NEUROL, V17, P215, DOI 10.1038/s41582-021-00455-2
   Magner Martin, 2015, Dev Period Med, V19, P441
   Malicdan MCV, 2018, HUM MUTAT, V39, P69, DOI 10.1002/humu.23345
   Man PYW, 2003, AM J HUM GENET, V72, P333, DOI 10.1016/j.ajhg.2016.05.015
   Mancuso M, 2007, BIOCHEM BIOPH RES CO, V354, P1058, DOI 10.1016/j.bbrc.2007.01.099
   Mancuso M, 2015, J NEUROL, V262, P1301, DOI 10.1007/s00415-015-7710-y
   Mancuso M, 2014, J NEUROL, V261, P504, DOI 10.1007/s00415-013-7225-3
   Maresca A, 2020, J MOL MED, V98, P1467, DOI 10.1007/s00109-020-01967-y
   McCormick E, 2013, NEUROTHERAPEUTICS, V10, P251, DOI 10.1007/s13311-012-0174-1
   McCormick EM, 2018, CURR OPIN PEDIATR, V30, P714, DOI 10.1097/MOP.0000000000000686
   McDermott JH, 2022, CLIN PHARMACOL THER, V111, P366, DOI 10.1002/cpt.2309
   McMillan HJ, 2014, BMC MED GENET, V15, DOI 10.1186/1471-2350-15-36
   Mejia EM, 2016, J BIOENERG BIOMEMBR, V48, P99, DOI 10.1007/s10863-015-9601-4
   Meyers DE, 2013, TEX HEART I J, V40, P385
   Mishra P, 2014, NAT REV MOL CELL BIO, V15, P634, DOI 10.1038/nrm3877
   Molnar M.J., 2018, MITOCHONDRIAL DIS, V145
   Mori M, 2018, CELL BIOL INT, V42, P643, DOI 10.1002/cbin.10917
   Murphy E, 2009, J MOL CELL CARDIOL, V46, P765, DOI 10.1016/j.yjmcc.2009.03.004
   Neiman M, 2009, P ROY SOC B-BIOL SCI, V276, P1201, DOI 10.1098/rspb.2008.1758
   Neveling K, 2013, HUM MUTAT, V34, P1721, DOI 10.1002/humu.22450
   Ng SB, 2009, NATURE, V461, P272, DOI 10.1038/nature08250
   Ng Y.S., 2019, DIAGNOSIS MANAGEMENT, P1
   Nicolson GL, 2014, INTEGR MED CLIN J, V13, P35
   Nissanka N, 2020, EMBO REP, V21, DOI 10.15252/embr.201949612
   Niyazov DM, 2016, MOL SYNDROMOL, V7, P122, DOI 10.1159/000446586
   Norton N, 2012, CURR OPIN CARDIOL, V27, P214, DOI 10.1097/HCO.0b013e328352207e
   Orrenius S, 2007, ANNU REV PHARMACOL, V47, P143, DOI 10.1146/annurev.pharmtox.47.120505.105122
   Parikh S, 2015, GENET MED, V17, P689, DOI 10.1038/gim.2014.177
   Parikh S, 2014, MITOCHONDRION, V14, P26, DOI 10.1016/j.mito.2013.07.116
   Penta JS, 2001, MUTAT RES-REV MUTAT, V488, P119, DOI 10.1016/S1383-5742(01)00053-9
   Pfundt R, 2017, GENET MED, V19, P667, DOI 10.1038/gim.2016.163
   Phadke R, 2017, J CLIN MED, V6, DOI 10.3390/jcm6070064
   Picardi E, 2012, NAT METHODS, V9, P523, DOI 10.1038/nmeth.2029
   Pincus J.H., 1912, DEV MED CHILD NEUROL, V14, P101, DOI [10.1111/j.1469-8749.1972.tb02563.x, DOI 10.1111/J.1469-8749.1972.TB02563.X]
   Pitceathly RDS, 2012, NEUROMUSCULAR DISORD, V22, P577, DOI 10.1016/j.nmd.2012.03.009
   Pitceathly R.D.S., 2020, HUMAN MITOCHONDRIAL, P353
   Pronicka E, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0930-9
   Puusepp S, 2018, MOL GENET METAB REP, V15, P80, DOI 10.1016/j.ymgmr.2018.03.004
   Rachek LI, 2009, TOXICOL APPL PHARM, V240, P348, DOI 10.1016/j.taap.2009.07.021
   Rahman S, 2020, J INTERN MED, V287, P609, DOI 10.1111/joim.13054
   Rahman S, 2001, AM J HUM GENET, V68, P238, DOI 10.1086/316930
   Reddy PH, 2011, CURR ALZHEIMER RES, V8, P393
   Rius R, 2021, GENES-BASEL, V12, DOI 10.3390/genes12040607
   Rodenburg RJT, 2013, MITOCHONDRION, V13, P36, DOI 10.1016/j.mito.2012.11.004
   ROTIG A, 1989, LANCET, V1, P902
   Ruiz-Pesini E, 2007, NUCLEIC ACIDS RES, V35, pD823, DOI 10.1093/nar/gkl927
   Ryan MT, 2007, ANNU REV BIOCHEM, V76, P701, DOI 10.1146/annurev.biochem.76.052305.091720
   Salomao Karina Bezerra, 2013, Indian J Hum Genet, V19, P54, DOI 10.4103/0971-6866.112888
   Schaefer AM, 2008, ANN NEUROL, V63, P35, DOI 10.1002/ana.21217
   Schlieben LD, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.600079
   Schon EA, 2012, NAT REV GENET, V13, P878, DOI 10.1038/nrg3275
   Schon KR, 2020, TRENDS GENET, V36, P702, DOI 10.1016/j.tig.2020.06.009
   Seneca S, 2015, EUR J HUM GENET, V23, P41, DOI 10.1038/ejhg.2014.49
   Shen L, 2020, CLIN LAB MED, V40, P149, DOI 10.1016/j.cll.2020.02.002
   Shen LS, 2018, HUM MUTAT, V39, P806, DOI 10.1002/humu.23422
   Shen LS, 2016, HUM MUTAT, V37, P540, DOI 10.1002/humu.22974
   Shendure J, 2004, NAT REV GENET, V5, P335, DOI 10.1038/nrg1325
   Shendure J, 2012, NAT BIOTECHNOL, V30, P1084, DOI 10.1038/nbt.2421
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   Sikkema-Raddatz B, 2013, HUM MUTAT, V34, P1035, DOI 10.1002/humu.22332
   Skladal D, 2003, BRAIN, V126, P1905, DOI 10.1093/brain/awg170
   Smith RAJ, 2012, TRENDS PHARMACOL SCI, V33, P341, DOI 10.1016/j.tips.2012.03.010
   Smith RAJ, 2011, ANTIOXID REDOX SIGN, V15, P3021, DOI 10.1089/ars.2011.3969
   Solomon D.A., 2018, PRACTICAL SURG NEURO
   Spinazzola A, 2011, SEMIN FETAL NEONAT M, V16, P190, DOI 10.1016/j.siny.2011.04.011
   Spinazzola A, 2009, J INTERN MED, V265, P174, DOI 10.1111/j.1365-2796.2008.02059.x
   Stark Z, 2019, GENET MED, V21, P173, DOI 10.1038/s41436-018-0006-8
   Stenton SL, 2020, EBIOMEDICINE, V56, DOI 10.1016/j.ebiom.2020.102784
   Sudo A, 2004, J HUM GENET, V49, P92, DOI 10.1007/s10038-003-0116-1
   Tamiya G, 2014, AM J HUM GENET, V95, P294, DOI 10.1016/j.ajhg.2014.07.013
   Tatsuta T, 2005, MOL BIOL CELL, V16, P248, DOI 10.1091/mbc.E04-09-0807
   Theunissen TEJ, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00400
   Thompson K, 2020, J INHERIT METAB DIS, V43, P36, DOI 10.1002/jimd.12104
   Thorburn DR, 2004, BBA-BIOENERGETICS, V1659, P121, DOI 10.1016/j.bbabio.2004.08.006
   Uriho A, 2021, ADV TRADIT MED, V21, P1, DOI 10.1007/s13596-020-00492-0
   Vafai SB, 2012, NATURE, V491, P374, DOI 10.1038/nature11707
   Van Blerkom J, 2009, SEMIN CELL DEV BIOL, V20, P354, DOI 10.1016/j.semcdb.2008.12.005
   VANERVEN PMM, 1987, CLIN NEUROL NEUROSUR, V89, P217, DOI 10.1016/S0303-8467(87)80020-3
   Vasta V, 2012, PEDIATR INT, V54, P585, DOI 10.1111/j.1442-200X.2012.03644.x
   Vasta V, 2009, GENOME MED, V1, DOI 10.1186/gm100
   Viscomi C, 2020, J INTERN MED, V287, P665, DOI 10.1111/joim.13046
   Viscomi C, 2015, BBA-BIOENERGETICS, V1847, P544, DOI 10.1016/j.bbabio.2015.03.001
   Wagner M, 2019, J INHERIT METAB DIS, V42, P909, DOI 10.1002/jimd.12109
   Wallace D.C., 1987, SCIENCE, V729, P27
   Wallace DC, 1997, P NATL ACAD SCI USA, V94, P14900, DOI 10.1073/pnas.94.26.14900
   Wallace DC, 2010, ANNU REV PATHOL-MECH, V5, P297, DOI 10.1146/annurev.pathol.4.110807.092314
   Wang Jing, 2011, Curr Protoc Hum Genet, VChapter 19, DOI 10.1002/0471142905.hg1906s68
   Wang X, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22147525
   Wang Z, 2009, NAT REV GENET, V10, P57, DOI 10.1038/nrg2484
   Watson E., 2020, J. Transl. Genet. Genomics, V4, P188, DOI [DOI 10.20517/JTGG.2020.31, 10.20517/jtgg.2020.31]
   WECHSLER H, 1983, NEW ENGL J MED, V308, P97, DOI 10.1056/NEJM198301133080211
   Weigl S, 2013, CURR GENOMICS, V14, P195, DOI 10.2174/1389202911314030005
   Whitaker RM, 2016, ANNU REV PHARMACOL, V56, P229, DOI 10.1146/annurev-pharmtox-010715-103155
   Wong LJC, 2010, MOL GENET METAB, V100, P111, DOI 10.1016/j.ymgme.2010.02.024
   Wortmann SB, 2017, NEUROPEDIATRICS, V48, P309, DOI 10.1055/s-0037-1603776
   Wortmann SB, 2015, J INHERIT METAB DIS, V38, P437, DOI 10.1007/s10545-015-9823-y
   Wortmann SB, 2013, J INHERIT METAB DIS, V36, P913, DOI 10.1007/s10545-012-9579-6
   Wright CF, 2018, GENET MED, V20, P1216, DOI 10.1038/gim.2017.246
   Xie HBM, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-402
   Xue W, 2011, NATURE, V473, P544, DOI 10.1038/nature09909
   Young LT, 2007, J PSYCHIATR NEUROSCI, V32, P160
   Yu JN, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.e13051
   Zare F, 2017, BMC BIOINFORMATICS, V18, DOI 10.1186/s12859-017-1705-x
   Zhang P, 2016, BRIEF BIOINFORM, V17, P224, DOI 10.1093/bib/bbv057
   Zhu ZH, 2017, ADV EXP MED BIOL, V1038, P219, DOI 10.1007/978-981-10-6674-0_15
   Zsurka G, 2010, NEUROLOGY, V74, P507, DOI 10.1212/WNL.0b013e3181cef7ab
NR 202
TC 9
Z9 11
U1 0
U2 13
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1467-3037
EI 1467-3045
J9 CURR ISSUES MOL BIOL
JI Curr. Issues Mol. Biol.
PD MAR
PY 2022
VL 44
IS 3
BP 1127
EP 1148
DI 10.3390/cimb44030074
PG 22
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 0C8NA
UT WOS:000775562300001
PM 35723297
OA gold, Green Published
DA 2024-11-01
ER

PT J
AU Ajroud-Driss, S
   Fecto, F
   Ajroud, K
   Lalani, I
   Calvo, SE
   Mootha, VK
   Deng, HX
   Siddique, N
   Tahmoush, AJ
   Heiman-Patterson, TD
   Siddique, T
AF Ajroud-Driss, Senda
   Fecto, Faisal
   Ajroud, Kaouther
   Lalani, Irfan
   Calvo, Sarah E.
   Mootha, Vamsi K.
   Deng, Han-Xiang
   Siddique, Nailah
   Tahmoush, Albert J.
   Heiman-Patterson, Terry D.
   Siddique, Teepu
TI Mutation in the novel nuclear-encoded mitochondrial protein CHCHD10 in a
   family with autosomal dominant mitochondrial myopathy
SO NEUROGENETICS
LA English
DT Article
DE Mitochondrial myopathy; Genetics; CHCHD10; Mitochondria
ID DISEASE; GENOME
AB Mitochondrial myopathies belong to a larger group of systemic diseases caused by morphological or biochemical abnormalities of mitochondria. Mitochondrial disorders can be caused by mutations in either the mitochondrial or nuclear genome. Only 5 % of all mitochondrial disorders are autosomal dominant. We analyzed DNA from members of the previously reported Puerto Rican kindred with an autosomal dominant mitochondrial myopathy (Heimann-Patterson et al. 1997). Linkage analysis suggested a putative locus on the pericentric region of the long arm of chromosome 22 (22q11). Using the tools of integrative genomics, we established chromosome 22 open reading frame 16 (C22orf16) (later designated as CHCHD10) as the only high-scoring mitochondrial candidate gene in our minimal candidate region. Sequence analysis revealed a double-missense mutation (R15S and G58R) in cis in CHCHD10 which encodes a coiled coil-helix-coiled coil-helix protein of unknown function. These two mutations completely co-segregated with the disease phenotype and were absent in 1,481 Caucasian and 80 Hispanic (including 32 Puerto Rican) controls. Expression profiling showed that CHCHD10 is enriched in skeletal muscle. Mitochondrial localization of the CHCHD10 protein was confirmed using immunofluorescence in cells expressing either wild-type or mutant CHCHD10. We found that the expression of the G58R, but not the R15S, mutation induced mitochondrial fragmentation. Our findings identify a novel gene causing mitochondrial myopathy, thereby expanding the spectrum of mitochondrial myopathies caused by nuclear genes. Our findings also suggest a role for CHCHD10 in the morphologic remodeling of the mitochondria.
C1 [Ajroud-Driss, Senda; Fecto, Faisal; Ajroud, Kaouther; Lalani, Irfan; Deng, Han-Xiang; Siddique, Nailah; Siddique, Teepu] Northwestern Univ, Feinberg Sch Med, Ken & Ruth Davee Dept Neurol & Clin Neurosci, Div Neuromuscular Med, Chicago, IL 60611 USA.
   [Siddique, Teepu] Northwestern Univ, Interdepartmental Neurosci Program, Chicago, IL 60611 USA.
   [Siddique, Teepu] Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA.
   [Calvo, Sarah E.; Mootha, Vamsi K.] Howard Hughes Med Inst, Chevy Chase, MD USA.
   [Calvo, Sarah E.; Mootha, Vamsi K.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
   [Calvo, Sarah E.; Mootha, Vamsi K.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA USA.
   [Calvo, Sarah E.; Mootha, Vamsi K.] Broad Inst, Cambridge, MA USA.
   [Tahmoush, Albert J.; Heiman-Patterson, Terry D.] Thomas Jefferson Univ, Dept Neurol, Philadelphia, PA 19107 USA.
C3 Northwestern University; Feinberg School of Medicine; Northwestern
   University; Northwestern University; Feinberg School of Medicine; Howard
   Hughes Medical Institute; Harvard University; Massachusetts General
   Hospital; Harvard University; Harvard Medical School; Harvard
   University; Massachusetts Institute of Technology (MIT); Broad
   Institute; Jefferson University
RP Ajroud-Driss, S (corresponding author), Northwestern Univ, Feinberg Sch Med, Ken & Ruth Davee Dept Neurol & Clin Neurosci, Div Neuromuscular Med, Chicago, IL 60611 USA.
EM s-ajroud@northwestern.edu; t-siddique@northwestern.edu
RI Siddique, Teepu/AAT-8166-2021
OI Fecto, Faisal/0000-0002-7587-8024; Siddique, Teepu/0000-0001-7293-9146;
   Deng, Han-Xiang/0000-0002-0030-8465
FU National Institute of Neurological Disorders and Stroke [NS050641]; Les
   Turner ALS Foundation/Herbert C. Wenske Foundation Professorship; David
   C. Asselin MD Memorial Fund; Vena E. Schaff ALS Research Fund; George
   Link, Jr. Foundation; Foglia Family Foundation; National Institutes of
   Health [R01GM097136]; NCI CCSG [P30 CA060553]
FX We thank the patients and their family members for participating in this
   study. We also thank Kreshnik B. Ahmeti, LiJun Cheng, and Yi Yang for
   their technical assistance. This work was supported by the National
   Institute of Neurological Disorders and Stroke (NS050641); the Les
   Turner ALS Foundation/Herbert C. Wenske Foundation Professorship; the
   David C. Asselin MD Memorial Fund; the Vena E. Schaff ALS Research Fund;
   the George Link, Jr. Foundation; and the Foglia Family Foundation. This
   work was supported by a grant (R01GM097136) from the National Institutes
   of Health to VKM. Imaging work was performed at the Northwestern
   University Cell Imaging Facility generously supported by NCI CCSG P30
   CA060553 awarded to the Robert H. Lurie Comprehensive Cancer Center.
CR Ajroud-Driss S, 2012, NEUROLOGY, V78
   Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534
   An J, 2012, J BIOL CHEM, V287, P7411, DOI 10.1074/jbc.M111.277103
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Banci L, 2009, FEBS LETT, V583, P1699, DOI 10.1016/j.febslet.2009.03.061
   Bannwarth S, 2014, BRAIN, V137, P2329, DOI 10.1093/brain/awu138
   Baughman JM, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000590
   Cavallaro G, 2010, MOL BIOSYST, V6, P2459, DOI 10.1039/c0mb00058b
   Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x
   Dagda RK, 2009, J BIOL CHEM, V284, P13843, DOI 10.1074/jbc.M808515200
   Darshi M, 2011, J BIOL CHEM, V286, P2918, DOI 10.1074/jbc.M110.171975
   Debray FG, 2008, CURR OPIN PEDIATR, V20, P471, DOI 10.1097/MOP.0b013e328306ebb6
   Deng HX, 2011, NATURE, V477, P211, DOI 10.1038/nature10353
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   HeimanPatterson TD, 1997, MUSCLE NERVE, V20, P1219, DOI 10.1002/(SICI)1097-4598(199710)20:10<1219::AID-MUS2>3.0.CO;2-F
   Herrmann JM, 2007, J CELL BIOL, V176, P559, DOI 10.1083/jcb.200611060
   Longen S, 2009, J MOL BIOL, V393, P356, DOI 10.1016/j.jmb.2009.08.041
   Lopez MF, 2000, ELECTROPHORESIS, V21, P3427, DOI 10.1002/1522-2683(20001001)21:16<3427::AID-ELPS3427>3.0.CO;2-L
   Marchler-Bauer A, 2011, NUCLEIC ACIDS RES, V39, pD225, DOI 10.1093/nar/gkq1189
   Martherus RSRM, 2010, BIOCHEM BIOPH RES CO, V402, P203, DOI 10.1016/j.bbrc.2010.09.109
   Milone M, 2013, MOL GENET METAB, V110, P35, DOI 10.1016/j.ymgme.2013.07.007
   Milone M, 2012, NEUROLOGY, V78, P1612, DOI 10.1212/WNL.0b013e3182563c46
   Pagliarini DJ, 2008, CELL, V134, P112, DOI 10.1016/j.cell.2008.06.016
   Roth RB, 2006, NEUROGENETICS, V7, P67, DOI 10.1007/s10048-006-0032-6
   Schug J, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-4-r33
NR 25
TC 87
Z9 96
U1 0
U2 11
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1364-6745
EI 1364-6753
J9 NEUROGENETICS
JI Neurogenetics
PD JAN
PY 2015
VL 16
IS 1
BP 1
EP 9
DI 10.1007/s10048-014-0421-1
PG 9
WC Genetics & Heredity; Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Neurosciences & Neurology
GA AY2HE
UT WOS:000347408700001
PM 25193783
OA Green Accepted
DA 2024-11-01
ER

PT J
AU Hagen, CM
   Aidt, FH
   Hedley, PL
   Jensen, MK
   Havndrup, O
   Kanters, JK
   Moolman-Smook, JC
   Larsen, SO
   Bundgaard, H
   Christiansen, M
AF Hagen, Christian M.
   Aidt, Frederik H.
   Hedley, Paula L.
   Jensen, Morten K.
   Havndrup, Ole
   Kanters, Jorgen K.
   Moolman-Smook, Johanna C.
   Larsen, Severin O.
   Bundgaard, Henning
   Christiansen, Michael
TI Mitochondrial Haplogroups Modify the Risk of Developing Hypertrophic
   Cardiomyopathy in a Danish Population
SO PLOS ONE
LA English
DT Article
ID OXIDATIVE STRESS; DNA HAPLOGROUPS; HEART-FAILURE; MUTATIONS; DISEASE;
   SUPEROXIDE; LONGEVITY; ORGANIZATION; RADICALS; GENES
AB Hypertrophic cardiomyopathy (HCM) is a genetic disorder caused by mutations in genes coding for proteins involved in sarcomere function. The disease is associated with mitochondrial dysfunction. Evolutionarily developed variation in mitochondrial DNA (mtDNA), defining mtDNA haplogroups and haplogroup clusters, is associated with functional differences in mitochondrial function and susceptibility to various diseases, including ischemic cardiomyopathy. We hypothesized that mtDNA haplogroups, in particular H, J and K, might modify disease susceptibility to HCM. Mitochondrial DNA, isolated from blood, was sequenced and haplogroups identified in 91 probands with HCM. The association with HCM was ascertained using two Danish control populations. Haplogroup H was more prevalent in HCM patients, 60% versus 46% (p = 0.006) and 41% (p = 0.003), in the two control populations. Haplogroup J was less prevalent, 3% vs. 12.4% (p = 0.017) and 9.1%, (p = 0.06). Likewise, the UK haplogroup cluster was less prevalent in HCM, 11% vs. 22.1% (p = 0.02) and 22.8% (p = 0.04). These results indicate that haplogroup H constitutes a susceptibility factor and that haplogroup J and haplogroup cluster UK are protective factors in the development of HCM. Thus, constitutive differences in mitochondrial function may influence the occurrence and clinical presentation of HCM. This could explain some of the phenotypic variability in HCM. The fact that haplogroup H and J are also modifying factors in ischemic cardiomyopathy suggests that mtDNA haplotypes may be of significance in determining whether a physiological hypertrophy develops into myopathy. mtDNA haplotypes may have the potential of becoming significant biomarkers in cardiomyopathy.
C1 [Hagen, Christian M.; Aidt, Frederik H.; Hedley, Paula L.; Larsen, Severin O.; Christiansen, Michael] Statens Serum Inst, Dept Clin Biochem & Immunol, DK-2300 Copenhagen, Denmark.
   [Hagen, Christian M.; Kanters, Jorgen K.] Univ Copenhagen, Dept Biomed Sci, Copenhagen, Denmark.
   [Hedley, Paula L.; Moolman-Smook, Johanna C.] Univ Stellenbosch, Dept Biomed Sci, Cape Town, South Africa.
   [Jensen, Morten K.; Bundgaard, Henning] Rigshosp, Dept Med B, Ctr Heart, DK-2100 Copenhagen, Denmark.
   [Havndrup, Ole] Roskilde Hosp, Dept Cardiol, Roskilde, Denmark.
   [Kanters, Jorgen K.] Gentofte Univ Hosp, Dept Cardiol, Copenhagen, Denmark.
C3 Statens Serum Institut; University of Copenhagen; Stellenbosch
   University; University of Copenhagen; Rigshospitalet; University of
   Copenhagen; Herlev & Gentofte Hospital
RP Christiansen, M (corresponding author), Statens Serum Inst, Dept Clin Biochem & Immunol, DK-2300 Copenhagen, Denmark.
EM mic@ssi.dk
RI Kanters, Jorgen/A-8276-2008; Bundgaard, Henning/AAA-4381-2020;
   Christiansen, Michael/B-4588-2009; Hedley, Paula/E-6156-2011
OI Hagen, Christian/0000-0002-0513-7722; Bundgaard,
   Henning/0000-0002-0563-7049; Jensen, Morten
   Kvistholm/0000-0003-1144-4603; Hedley, Paula/0000-0001-5801-960X;
   Kanters, Jorgen/0000-0002-3267-4910
FU Statens Serum Institut; LUNDBECKFONDEN [R67-A6552]; Danish Strategic
   Research Council
FX The work was supported by Statens Serum Institut (www.ssi.dk),
   LUNDBECKFONDEN (www.lundbeckfonden.com), (Grant: R67-A6552) and The
   Danish Strategic Research Council (www.fivu.dk),(Grant: HEARTSAFE). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Abel ED, 2011, CARDIOVASC RES, V90, P234, DOI 10.1093/cvr/cvr015
   Andersen PS, 2009, HUM MUTAT, V30, P363, DOI 10.1002/humu.20862
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Beckstead WA, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005836
   Benn M, 2008, CIRCULATION, V117, P2492, DOI 10.1161/CIRCULATIONAHA.107.756809
   Brand MD, 2010, EXP GERONTOL, V45, P466, DOI 10.1016/j.exger.2010.01.003
   Castro MG, 2006, INT J CARDIOL, V112, P202, DOI 10.1016/j.ijcard.2005.09.008
   Chinnery PF, 2010, LANCET NEUROL, V9, P498, DOI 10.1016/S1474-4422(10)70083-1
   Dato S, 2004, EUR J HUM GENET, V12, P1080, DOI 10.1038/sj.ejhg.5201278
   Dröge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001
   Elliott HR, 2008, AM J HUM GENET, V83, P254, DOI 10.1016/j.ajhg.2008.07.004
   Fernández-Caggiano M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044128
   Finkel T, 2003, CURR OPIN CELL BIOL, V15, P247, DOI 10.1016/S0955-0674(03)00002-4
   Garnier A, 2003, J PHYSIOL-LONDON, V551, P491, DOI 10.1113/jphysiol.2003.045104
   Gómez-Durán A, 2010, HUM MOL GENET, V19, P3343, DOI 10.1093/hmg/ddq246
   Grieve DJ, 2003, EUR HEART J, V24, P2161, DOI 10.1016/j.ehj.2003.10.015
   Havndrup O, 2010, EUR J HEART FAIL, V12, P535, DOI 10.1093/eurjhf/hfq073
   Hedley PL, 2011, J NEGAT RESULTS BIOM, V10, DOI 10.1186/1477-5751-10-12
   Ide T, 2000, CIRC RES, V86, P152, DOI 10.1161/01.RES.86.2.152
   Ji YL, 2008, AM J HUM GENET, V83, P760, DOI 10.1016/j.ajhg.2008.11.002
   Kalman B, 1999, ACTA NEUROL SCAND, V99, P16
   Korshunov SS, 1997, FEBS LETT, V416, P15, DOI 10.1016/S0014-5793(97)01159-9
   Mallat Z, 1998, CIRCULATION, V97, P1536, DOI 10.1161/01.CIR.97.16.1536
   Marcuello A, 2009, MITOCHONDRION, V9, P326, DOI 10.1016/j.mito.2009.04.007
   MARON BJ, 1987, NEW ENGL J MED, V316, P780, DOI 10.1056/NEJM198703263161305
   Martínez-Redondo D, 2010, MITOCHONDRION, V10, P102, DOI 10.1016/j.mito.2009.11.005
   Mikkelsen M, 2010, FORENSIC SCI INT-GEN, V4, pE87, DOI 10.1016/j.fsigen.2009.07.007
   Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386
   Ott M, 2007, APOPTOSIS, V12, P913, DOI 10.1007/s10495-007-0756-2
   PINOS T, 2011, AGE DORDR
   Richardson P, 1996, CIRCULATION, V93, P841, DOI 10.1161/01.CIR.93.5.841
   Rosca MG, 2010, CARDIOVASC RES, V88, P40, DOI 10.1093/cvr/cvq240
   Rosca MG, 2009, J BIOENERG BIOMEMBR, V41, P107, DOI 10.1007/s10863-009-9215-9
   Rousset F, 2008, MOL ECOL RESOUR, V8, P103, DOI 10.1111/j.1471-8286.2007.01931.x
   Seelert H, 2009, BBA-BIOENERGETICS, V1787, P657, DOI 10.1016/j.bbabio.2009.02.028
   TENCATE FJ, 1979, AM J CARDIOL, V43, P731, DOI 10.1016/0002-9149(79)90071-7
   Towbin JA, 2009, PACE, V32, pS23, DOI 10.1111/j.1540-8159.2009.02381.x
   Tsutsui H, 2009, CARDIOVASC RES, V81, P449, DOI 10.1093/cvr/cvn280
   Valenti L, 2004, J MED GENET, V41, P946, DOI 10.1136/jmg.2004.019588
   van der Walt JM, 2004, NEUROSCI LETT, V365, P28, DOI 10.1016/j.neulet.2004.04.051
   van der Walt JM, 2003, AM J HUM GENET, V72, P804, DOI 10.1086/373937
   van Oven M, 2009, HUM MUTAT, V30, pE386, DOI 10.1002/humu.20921
   Vonck J, 2009, BBA-MOL CELL RES, V1793, P117, DOI 10.1016/j.bbamcr.2008.05.019
   Xu Q, 2010, J MOL CELL CARDIOL, V48, P899, DOI 10.1016/j.yjmcc.2010.03.005
   Zielonka J, 2008, FREE RADICAL BIO MED, V45, P1217, DOI 10.1016/j.freeradbiomed.2008.07.025
NR 45
TC 28
Z9 31
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 5
PY 2013
VL 8
IS 8
AR e71904
DI 10.1371/journal.pone.0071904
PG 7
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 218XC
UT WOS:000324465000231
PM 23940792
OA gold, Green Submitted, Green Published
DA 2024-11-01
ER

PT J
AU Rocha, MC
   Grady, JP
   Grünewald, A
   Vincent, A
   Dobson, PF
   Taylor, RW
   Turnbull, DM
   Rygiel, KA
AF Rocha, Mariana C.
   Grady, John P.
   Gruenewald, Anne
   Vincent, Amy
   Dobson, Philip F.
   Taylor, Robert W.
   Turnbull, Doug M.
   Rygiel, Karolina A.
TI A novel immunofluorescent assay to investigate oxidative phosphorylation
   deficiency in mitochondrial myopathy: understanding mechanisms and
   improving diagnosis
SO SCIENTIFIC REPORTS
LA English
DT Article
ID CYTOCHROME-C-OXIDASE; COMPLEX I DEFICIENCY; DIGITAL IMAGE-ANALYSIS;
   REAL-TIME PCR; DNA DELETIONS; MUSCLE-FIBERS; MUTATION; SINGLE; GENE;
   MTDNA
AB Oxidative phosphorylation defects in human tissues are often challenging to quantify due to a mosaic pattern of deficiency. Biochemical assays are difficult to interpret due to the varying enzyme deficiency levels found in individual cells. Histochemical analysis allows semi-quantitative assessment of complex II and complex IV activities, but there is no validated histochemical assay to assess complex I activity which is frequently affected in mitochondrial pathology. To help improve the diagnosis of mitochondrial disease and to study the mechanisms underlying mitochondrial abnormalities in disease, we have developed a quadruple immunofluorescent technique enabling the quantification of key respiratory chain subunits of complexes I and IV, together with an indicator of mitochondrial mass and a cell membrane marker. This assay gives precise and objective quantification of protein abundance in large numbers of individual muscle fibres. By assessing muscle biopsies from subjects with a range of different mitochondrial genetic defects we have demonstrated that specific genotypes exhibit distinct biochemical signatures in muscle, providing evidence for the diagnostic use of the technique, as well as insight into the underlying molecular pathology. Stringent testing for reproducibility and sensitivity confirms the potential value of the technique for mechanistic studies of disease and in the evaluation of therapeutic approaches.
C1 [Rocha, Mariana C.; Dobson, Philip F.; Turnbull, Doug M.; Rygiel, Karolina A.] Newcastle Univ, Sch Med, Inst Neurosci, Ctr Ageing & Vital, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
   [Rocha, Mariana C.; Grady, John P.; Gruenewald, Anne; Vincent, Amy; Taylor, Robert W.; Turnbull, Doug M.; Rygiel, Karolina A.] Newcastle Univ, Sch Med, Inst Neurosci, Wellcome Trust Ctr Mitochondrial Res, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
C3 Newcastle University - UK; Newcastle University - UK
RP Turnbull, DM (corresponding author), Newcastle Univ, Sch Med, Inst Neurosci, Ctr Ageing & Vital, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
EM doug.turnbull@ncl.ac.uk; karolina.rygiel@ncl.ac.uk
RI Vincent, Amy/J-7284-2019; Grünewald, Anne/ABD-1255-2021; Rocha,
   Mariana/O-4313-2017
OI Grady, John/0000-0001-9667-3872; Turnbull, Doug/0000-0002-8878-9901;
   Vincent, Amy/0000-0002-0360-6644; Rocha, Mariana/0000-0002-0056-9315;
   Grunewald, Anne/0000-0002-4179-2994
FU Wellcome Trust Centre for Mitochondrial Research [G906919]; Newcastle
   University Centre for Brain Ageing and Vitality - Biotechnology and
   Biological Sciences Research Council; Newcastle University Centre for
   Brain Ageing and Vitality - Engineering and Physical Sciences Research
   Council; Newcastle University Centre for Brain Ageing and Vitality -
   Economic and Social Research Council; Newcastle University Centre for
   Brain Ageing and Vitality - Medical Research Council [G0700718]; MRC
   Centre for Neuromuscular Disease [G0006081]; MRC Centre for
   Translational Research in Neuromuscular Disease Mitochondrial Disease
   Patient Cohort (UK) [G0800674]; Lily Foundation; UK NIHR Biomedical
   Research Centre in Age and Age Related Diseases award; UK NHS Specialist
   Commissioners "Rare Mitochondrial Disorders of Adults and Children"
   Service; Wellcome Trust Studentship [090194/Z/09/Z]; Wellcome Trust
   [090194/Z/09/Z] Funding Source: Wellcome Trust; MRC [MR/L016354/1,
   MR/K000608/1, G0700718, MC_G0802536, G0800674] Funding Source: UKRI
FX This work was funded by The Wellcome Trust Centre for Mitochondrial
   Research [G906919], Newcastle University Centre for Brain Ageing and
   Vitality (supported by the Biotechnology and Biological Sciences
   Research Council, Engineering and Physical Sciences Research Council,
   Economic and Social Research Council and Medical Research Council
   [G0700718]), MRC Centre for Neuromuscular Disease [G0006081], The MRC
   Centre for Translational Research in Neuromuscular Disease Mitochondrial
   Disease Patient Cohort (UK) [G0800674], Lily Foundation, the UK NIHR
   Biomedical Research Centre in Age and Age Related Diseases award to the
   Newcastle upon Tyne Hospitals NHS Foundation Trust and UK NHS Specialist
   Commissioners "Rare Mitochondrial Disorders of Adults and Children"
   Service. JPG was funded by a Wellcome Trust Studentship [090194/Z/09/Z].
   We would like to thank Dr Langping He and Mr Gavin Falkous for their
   help with the diagnostic analysis of patient muscle biopsies.
CR Alvarenga AW, 2013, J HISTOCHEM CYTOCHEM, V61, P272, DOI 10.1369/0022155413477661
   [Anonymous], 2014, A Language and Environment for Statistical Computing
   [Anonymous], GOODNESS OF FIT TECH
   BOX GEP, 1964, J ROY STAT SOC B, V26, P211, DOI 10.1111/j.2517-6161.1964.tb00553.x
   Brey EM, 2003, J HISTOCHEM CYTOCHEM, V51, P575, DOI 10.1177/002215540305100503
   Campbell G, 2014, HUM MOL GENET, V23, P4612, DOI 10.1093/hmg/ddu176
   Campbell GR, 2011, ANN NEUROL, V69, P481, DOI 10.1002/ana.22109
   Chinnery PF, 2003, J NEUROL SCI, V211, P63, DOI 10.1016/S0022-510X(03)00039-X
   Choudhury KR, 2010, J HISTOCHEM CYTOCHEM, V58, P95, DOI 10.1369/jhc.2009.953554
   De Paepe B, 2009, J CLIN PATHOL, V62, P172, DOI 10.1136/jcp.2008.061267
   EGGER J, 1981, ARCH DIS CHILD, V56, P741, DOI 10.1136/adc.56.10.741
   Elson JL, 2002, NEUROMUSCULAR DISORD, V12, P858, DOI 10.1016/S0960-8966(02)00047-0
   Fernández-Vizarra E, 2009, BBA-MOL CELL RES, V1793, P200, DOI 10.1016/j.bbamcr.2008.05.028
   Goedkoop AY, 2005, ARCH DERMATOL RES, V297, P51, DOI 10.1007/s00403-005-0578-4
   Gorman GS, 2015, ANN NEUROL, V77, P753, DOI 10.1002/ana.24362
   Gorman GS, 2015, CLIN SCI, V128, P895, DOI 10.1042/CS20140705
   Grady JP, 2014, BRAIN, V137, P323, DOI 10.1093/brain/awt321
   Greaves LC, 2012, J PATHOL, V226, P274, DOI 10.1002/path.3028
   Grünewald A, 2014, J NEUROSCI METH, V232, P143, DOI 10.1016/j.jneumeth.2014.05.026
   Hanson BJ, 2002, J HISTOCHEM CYTOCHEM, V50, P1281, DOI 10.1177/002215540205001001
   He LP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf067
   Horváth R, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.015024
   HUOPONEN K, 1991, AM J HUM GENET, V48, P1147
   James AM, 1996, BIOCHEM J, V318, P401, DOI 10.1042/bj3180401
   Janssen RJRJ, 2006, J INHERIT METAB DIS, V29, P499, DOI 10.1007/s10545-006-0362-4
   JOHNSON MA, 1983, J NEUROL SCI, V60, P31, DOI 10.1016/0022-510X(83)90125-9
   Kirby DM, 2007, METHOD CELL BIOL, V80, P93, DOI 10.1016/S0091-679X(06)80004-X
   Kirby DM, 2004, J MED GENET, V41, P784, DOI 10.1136/jmg.2004.020537
   Klöppel S, 2008, BRAIN, V131, P2969, DOI 10.1093/brain/awn239
   Lazarou M, 2009, BBA-MOL CELL RES, V1793, P78, DOI 10.1016/j.bbamcr.2008.04.015
   Loeffen JLCM, 2000, HUM MUTAT, V15, P123, DOI 10.1002/(SICI)1098-1004(200002)15:2<123::AID-HUMU1>3.3.CO;2-G
   Mahad DJ, 2009, J NEUROSCI METH, V184, P310, DOI 10.1016/j.jneumeth.2009.08.020
   MATSUOKA T, 1992, MUSCLE NERVE, V15, P209, DOI 10.1002/mus.880150213
   McFarland R, 2010, LANCET NEUROL, V9, P829, DOI 10.1016/S1474-4422(10)70116-2
   MERANTE F, 1993, AM J HUM GENET, V53, P481
   Mootha VK, 2003, P NATL ACAD SCI USA, V100, P605, DOI 10.1073/pnas.242716699
   Mula J, 2013, J APPL PHYSIOL, V114, P148, DOI 10.1152/japplphysiol.01022.2012
   Murphy JL, 2008, BRAIN, V131, P2832, DOI 10.1093/brain/awn252
   Murphy JL, 2012, NEUROMUSCULAR DISORD, V22, P690, DOI 10.1016/j.nmd.2012.04.003
   Nesbitt V, 2013, J NEUROL NEUROSUR PS, V84, P936, DOI 10.1136/jnnp-2012-303528
   OLD SL, 1989, HISTOCHEM J, V21, P545, DOI 10.1007/BF01753355
   OLDFORS A, 1992, J NEUROL SCI, V110, P169, DOI 10.1016/0022-510X(92)90025-G
   OLDFORS A, 1993, BRAIN, V116, P325, DOI 10.1093/brain/116.2.325
   Perales-Clemente E, 2010, MOL CELL BIOL, V30, P3038, DOI 10.1128/MCB.00025-10
   Pitceathly RDS, 2014, CURR OPIN NEUROL, V27, P576, DOI 10.1097/WCO.0000000000000126
   Pitceathly RDS, 2012, BRAIN, V135, P3392, DOI 10.1093/brain/aws231
   Rahman S, 2000, BRAIN, V123, P591, DOI 10.1093/brain/123.3.591
   Reeve AK, 2008, AM J HUM GENET, V82, P228, DOI 10.1016/j.ajhg.2007.09.018
   Rizzardi AE, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-42
   Rygiel KA, 2015, NEUROPATH APPL NEURO, V41, P288, DOI 10.1111/nan.12149
   Rygiel KA, 2015, SCI REP-UK, V5, DOI 10.1038/srep09906
   Sciacco M, 1996, Methods Enzymol, V264, P509, DOI 10.1016/S0076-6879(96)64045-2
   SCIACCO M, 1994, HUM MOL GENET, V3, P13, DOI 10.1093/hmg/3.1.13
   Shaag A, 1997, BIOCHEM BIOPH RES CO, V233, P637, DOI 10.1006/bbrc.1997.6496
   SHAPIRO SS, 1965, BIOMETRIKA, V52, P591, DOI 10.2307/2333709
   Swalwell H, 2011, EUR J HUM GENET, V19, P769, DOI 10.1038/ejhg.2011.18
   Taivassalo T, 2006, BRAIN, V129, P3391, DOI 10.1093/brain/awl282
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   Thomson TA, 2001, MODERN PATHOL, V14, P1079, DOI 10.1038/modpathol.3880440
   TRITSCHLER HJ, 1991, NEUROLOGY, V41, P300, DOI 10.1212/WNL.41.2_Part_1.300
   Xu FH, 2004, BIOCHEM J, V382, P331, DOI 10.1042/BJ20040469
NR 61
TC 90
Z9 96
U1 0
U2 16
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD OCT 15
PY 2015
VL 5
AR 15037
DI 10.1038/srep15037
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CT4XV
UT WOS:000362811700001
PM 26469001
OA gold, Green Published
DA 2024-11-01
ER

PT J
AU Kawamata, H
   Tiranti, V
   Magrané, J
   Chinopoulos, C
   Manfredi, G
AF Kawamata, Hibiki
   Tiranti, Valeria
   Magrane, Jordi
   Chinopoulos, Christos
   Manfredi, Giovanni
TI adPEO mutations in ANT1 impair ADP-ATP translocation in muscle
   mitochondria
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID ADENINE-NUCLEOTIDE TRANSLOCASE; PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA;
   PERMEABILITY TRANSITION PORE; NEUROGASTROINTESTINAL ENCEPHALOMYOPATHY;
   NUCLEAR GENES; DNA; DELETIONS; CARRIER; MODEL; STABILITY
AB Mutations in the heart and muscle isoform of adenine nucleotide translocator 1 (ANT1) are associated with autosomal-dominant progressive external opthalmoplegia (adPEO) clinically characterized by exercise intolerance, ptosis and muscle weakness. The pathogenic mechanisms underlying the mitochondrial myopathy caused by ANT1 mutations remain largely unknown. In yeast, expression of ANT1 carrying mutations corresponding to the human adPEO ones causes a wide range of mitochondrial abnormalities. However, functional studies of ANT1 mutations in mammalian cells are lacking, because they have been hindered by the fact that ANT1 expression leads to apoptotic cell death in commonly utilized replicating cell lines. Here, we successfully express functional ANT1 in differentiated mouse myotubes, which naturally contain high levels of ANT1, without causing cell death. We demonstrate, for the first time in these disease-relevant mammalian cells, that mutant human ANT1 causes dominant mitochondrial defects characterized by decreased ADP-ATP exchange function and abnormal translocator reversal potential. These abnormalities are not due to ANT1 loss of function, because knocking down Ant1 in myotubes causes functional changes different from ANT1 mutants. Under certain physiological conditions, mitochondria consume ATP to maintain membrane potential by reversing the ADP-ATP transport. The modified properties of mutant ANT1 can be responsible for disease pathogenesis in adPEO, because exchange reversal occurring at higher than normal membrane potential can cause excessive energy depletion and nucleotide imbalance in ANT1 mutant muscle cells.
C1 [Kawamata, Hibiki; Magrane, Jordi; Manfredi, Giovanni] Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, New York, NY 10065 USA.
   [Tiranti, Valeria] IRCCS Fdn Neurol Inst C Besta, Milan, Italy.
   [Chinopoulos, Christos] Semmelweis Univ, Dept Med Biochem, H-1094 Budapest, Hungary.
C3 Cornell University; Weill Cornell Medicine; Semmelweis University
RP Manfredi, G (corresponding author), Cornell Univ, Weill Med Coll, Dept Neurol & Neurosci, 525 E 68th St,A-505, New York, NY 10065 USA.
EM gim2004@med.cornell.edu
RI Chinopoulos, Christos/A-5175-2008; Magrané, Jordi/AAJ-2967-2020;
   Tiranti, Valeria/J-8233-2016
OI Chinopoulos, Christos/0000-0003-0183-4149; Tiranti,
   Valeria/0000-0002-3584-7338; Magrane, Jordi/0000-0002-6785-2166
FU NIH/NINDS [F31NS054554]; NIH [R01 GM088999]; Orszagos Tudomanyos
   Kutatasi Alapprogram (OTKA)-Nemzeti Kutatasi es Technologiai Hivatal
   (NKTH) [NF68294]; OTKA [NNF78905, NNF2 85658]; Egeszsegugyi Tudomanyos
   Tanacs (ETT) [55160]
FX This work was supported by NIH/NINDS F31NS054554 to H. K., NIH Grant R01
   GM088999 to G. M. and Orszagos Tudomanyos Kutatasi Alapprogram
   (OTKA)-Nemzeti Kutatasi es Technologiai Hivatal (NKTH) Grant NF68294,
   OTKA Grant NNF78905 and NNF2 85658, and an Egeszsegugyi Tudomanyos
   Tanacs (ETT) grant 55160 to C.C.
CR Bauer MKA, 1999, J CELL BIOL, V147, P1493, DOI 10.1083/jcb.147.7.1493
   BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8
   Bogenhagen DF, 2003, MOL CELL PROTEOMICS, V2, P1205, DOI 10.1074/mcp.M300035-MCP200
   Brand MD, 2005, BIOCHEM J, V392, P353, DOI 10.1042/BJ20050890
   BUCHANAN BB, 1976, P NATL ACAD SCI USA, V73, P2280, DOI 10.1073/pnas.73.7.2280
   Chen XJ, 2002, HUM MOL GENET, V11, P1835, DOI 10.1093/hmg/11.16.1835
   Chinopoulos C, 2010, FASEB J, V24, P2405, DOI 10.1096/fj.09-149898
   Chinopoulos C, 2009, BIOPHYS J, V96, P2490, DOI 10.1016/j.bpj.2008.12.3915
   D'Aurelio M, 2004, HUM MOL GENET, V13, P3171, DOI 10.1093/hmg/ddh326
   Deschauer M, 2005, NEUROMUSCULAR DISORD, V15, P311, DOI 10.1016/j.nmd.2004.12.004
   Doerner A, 1997, FEBS LETT, V414, P258, DOI 10.1016/S0014-5793(97)01000-4
   Dolce V, 2005, FEBS LETT, V579, P633, DOI 10.1016/j.febslet.2004.12.034
   Duchen MR, 1998, J CELL BIOL, V142, P975, DOI 10.1083/jcb.142.4.975
   Endres M, 1999, EMBO J, V18, P3214, DOI 10.1093/emboj/18.12.3214
   Esposito LA, 1999, P NATL ACAD SCI USA, V96, P4820, DOI 10.1073/pnas.96.9.4820
   Faustin B, 2004, J BIOL CHEM, V279, P20411, DOI 10.1074/jbc.M314259200
   Ferraro P, 2005, J BIOL CHEM, V280, P24472, DOI 10.1074/jbc.M502869200
   Fontanesi F, 2004, HUM MOL GENET, V13, P923, DOI 10.1093/hmg/ddh108
   Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226
   He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   KAWAMATA H, ANAL BIOCH, V407, P52
   Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229
   Komaki H, 2002, ANN NEUROL, V51, P645, DOI 10.1002/ana.10172
   Limongelli A, 2002, MITOCHONDRION, V2, P39, DOI 10.1016/S1567-7249(02)00043-0
   Manfredi G, 2002, METHODS, V26, P317, DOI 10.1016/S1046-2023(02)00037-3
   Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027
   Napoli L, 2001, NEUROLOGY, V57, P2295, DOI 10.1212/WNL.57.12.2295
   O'Carroll SJ, 2000, BIOTECHNIQUES, V28, P408, DOI 10.2144/00283bm03
   Pallotti F, 2001, METHOD CELL BIOL, V65, P1, DOI 10.1016/S0091-679X(01)65002-7
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   PFANNER N, 1987, J BIOL CHEM, V262, P14851
   Pohjoismäki JLO, 2010, J MOL BIOL, V397, P1144, DOI 10.1016/j.jmb.2010.02.029
   Pontarin G, 2006, J BIOL CHEM, V281, P22720, DOI 10.1074/jbc.M604498200
   Pouvreau S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013035
   Pownall ME, 2002, ANNU REV CELL DEV BI, V18, P747, DOI 10.1146/annurev.cellbio.18.012502.105758
   Ryan MT, 1999, J BIOL CHEM, V274, P20619, DOI 10.1074/jbc.274.29.20619
   Song SW, 2003, J BIOL CHEM, V278, P43893, DOI 10.1074/jbc.C300401200
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2002, J BIOL CHEM, V277, P4128, DOI 10.1074/jbc.M111028200
   STEPIEN G, 1992, J BIOL CHEM, V267, P14592
   Suomalainen A, 2001, AM J MED GENET, V106, P53, DOI 10.1002/ajmg.1379
   Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Vijayvergiya C, 2005, J NEUROSCI, V25, P2463, DOI 10.1523/JNEUROSCI.4385-04.2005
   Wang XW, 2008, HUM MOL GENET, V17, P4036, DOI 10.1093/hmg/ddn306
   Williams SL, 2010, CELL METAB, V12, P675, DOI 10.1016/j.cmet.2010.11.012
   WITTENBERG BA, 1989, ANNU REV PHYSIOL, V51, P857, DOI 10.1146/annurev.physiol.51.1.857
   ZORATTI M, 1995, BBA-REV BIOMEMBRANES, V1241, P139, DOI 10.1016/0304-4157(95)00003-A
NR 49
TC 33
Z9 34
U1 0
U2 2
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD AUG 1
PY 2011
VL 20
IS 15
BP 2964
EP 2974
DI 10.1093/hmg/ddr200
PG 11
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 790AD
UT WOS:000292560000006
PM 21586654
OA Bronze, Green Published
DA 2024-11-01
ER

PT S
AU Wong, LJC
AF Wong, LJC
BE Lee, HK
   DiMauro, S
   Tanaka, M
   Wei, YH
TI Comprehensive molecular diagnosis of mitochondrial disorders -
   Qualitative and quantitative approach
SO MITOCHONDRIAL PATHOGENESIS: FROM GENES AND APOPTOSIS TO AGING AND
   DISEASE
SE Annals of the New York Academy of Sciences
LA English
DT Article; Proceedings Paper
CT 1st Scientific Meeting of the
   Asian-Society-for-Mitochondrial-Research-and-Medicine
CY FEB 05-06, 2003
CL Seoul, SOUTH KOREA
SP Asian Soc Mitochondrial Res & Med, Bukwang Pharmaceut, Dalim Pharmaceut, Mitocon Inc
DE mtDNA mutations; molecular diagnosis; mitochondrial disorder; mtDNA
   deletion; mitochondria
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; DNA; MUTATIONS; DELETIONS
AB Mitochondrial disorders can be caused by mutations in nuclear or mitochondrial encoded genes. Point mutations and large deletions in mitochondrial DNA (mtDNA) are responsible for a small portion of the molecular defects in the mitochondrial oxidative phosphorylation system. A significant number of molecular defects of respiratory chain disorders are probably due to mutations in nuclear genes. Molecular diagnosis of mitochondrial disorders has been difficult because of broad genetic and clinical heterogeneity. Mutational analysis of common point mutations of mtDNA such as A3243G, A8344G, and T8993G/C is routinely performed. However, many patients who clearly have clinical manifestations and muscle pathology consistent with oxidative phosphorylation deficiency do not have detectable common mtDNA point mutations. A more comprehensive mutation screening method, temporal temperature gradient gel electrophoresis, was used to scan for unknown mutations in the entire mitochondrial genome. Novel mutations have been discovered but only account for a small portion of patients with suspected mitochondrial RC disorders. Real-time quantitative PCR analysis was used to measure cellular mtDNA content. Abnormal levels of mtDNA were found in many patients with respiratory chain disorders. Molecular analysis revealed that mutations in the thymidine phosphorylase gene are not seen in young patients with severe mtDNA depletion who do not demonstrate clinical features of mitochondrial neurogastrointestinal encephalomyopathy. It was also noted that an increase in the size or number of mitochondria was not necessarily associated with an increase in mtDNA content. On the contrary, in some cases the mtDNA was depleted. Respiratory activity in patients with a defective mitochondrial genome due to either point mutations or deletions may be compensated by amplification of mtDNA. Therefore, a comprehensive molecular analysis of mitochondrial respiratory chain disorders should include qualitative identification of the mutation and quantitative measurement of both the degree of mutant heteroplasmy and the total amount of mtDNA.
C1 Georgetown Univ, Med Ctr, Inst Mol & Human Genet, Washington, DC 20007 USA.
C3 Georgetown University
RP Georgetown Univ, Med Ctr, Inst Mol & Human Genet, M4000,3800 Reservoir Rd,NW, Washington, DC 20007 USA.
EM wonglj@georgetown.edu
CR Chen TJ, 1999, CLIN CHEM, V45, P1162
   Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Liang MH, 1998, AM J MED GENET, V77, P395, DOI 10.1002/(SICI)1096-8628(19980605)77:5<395::AID-AJMG8>3.0.CO;2-M
   Moraes CT, 2001, NAT GENET, V28, P200, DOI 10.1038/90020
   Nishino I, 2000, ANN NEUROL, V47, P792
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Nollau P, 1997, J Int Fed Clin Chem, V9, P162
   REARDON W, 1992, LANCET, V340, P1376, DOI 10.1016/0140-6736(92)92560-3
   Shoffner JM., 1995, METABOLIC MOL BASES, V7th, P1535
   Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2002, ACTA NEUROL BELG, V102, P39
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Wong LC, 2002, AM J HUM GENET, V71, P501
   Wong LJC, 1997, CLIN CHEM, V43, P1857
   Wong LJC, 2002, CLIN CHEM, V48, P1901
   Wong LJC, 2001, GENET MED, V3, P399, DOI 10.1097/00125817-200111000-00004
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
NR 20
TC 15
Z9 18
U1 0
U2 4
PU NEW YORK ACAD SCIENCES
PI NEW YORK
PA 2 EAST 63RD ST, NEW YORK, NY 10021 USA
SN 0077-8923
BN 1-57331-491-9; 1-57331-490-0
J9 ANN NY ACAD SCI
JI Ann.NY Acad.Sci.
PY 2004
VL 1011
BP 246
EP 258
DI 10.1196/annals.1293.024
PG 13
WC Biochemistry & Molecular Biology; Multidisciplinary Sciences
WE Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Science & Technology - Other Topics
GA BAE70
UT WOS:000221896100024
PM 15126301
DA 2024-11-01
ER

PT J
AU Kasamo, K
   Nakamura, M
   Daimou, Y
   Sano, A
AF Kasamo, Kei
   Nakamura, Masayuki
   Daimou, Yoko
   Sano, Akira
TI A <i>PRIMPOL</i> mutation and variants in multiple genes may contribute
   to phenotypes in a familial case with chronic progressive external
   ophthalmoplegia symptoms
SO NEUROSCIENCE RESEARCH
LA English
DT Article
DE Progressive external ophthalmoplegia; Multiple mitochondrial DNA
   deletions; Whole-exome sequencing; PRIMPOL
ID MITOCHONDRIAL; DELETIONS; PROTEIN; FEVER; POLG; OPA1
AB Chronic progressive external ophthalmoplegia (CPEO) is one of the most common mitochondrial disorders. It is characterized by bilateral, slowly progressing loss of extraocular muscle mobility, orbicularis oculi weakness, ptosis, and other neuromuscular symptoms, which are caused by the accumulation of multiple mitochondrial DNA (mtDNA) deletions. Many mutations in different nuclear genes, such as POLG1, POLG2, ANT1, and others, have been described as causing autosomal-inherited CPEO with multiple mtDNA deletions. Most causative genes are involved in mtDNA replication impairment. Here, we report a family with CPEO-like symptoms characterized by multiple muscle mtDNA deletions, ptosis, diabetes, hearing loss, mental retardation, and emotional instability. We performed genetic analyses to identify nuclear gene mutations in the family. DNA from the proband was analyzed by whole-exome sequencing. In addition to possible pathogenic mutations, rare variants were prioritized for gene-functional phenotype interpretation. We found possible pathogenetic mutations in the PRIMPOL, BRCA1, CPT2, and GJB2 genes, and functional polymorphisms in the CARD8, and MEFV genes. Multiple functional polymorphisms and possible pathogenic mutations may contribute to mitochondrial-disease-like phenotypes in a composite manner. (C) 2019 Elsevier B.V. and Japan Neuroscience Society. All rights reserved.
C1 [Kasamo, Kei; Nakamura, Masayuki; Daimou, Yoko; Sano, Akira] Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Psychiat, 8-35-1 Sakuragaoka, Kagoshima 8908520, Japan.
C3 Kagoshima University
RP Nakamura, M (corresponding author), Kagoshima Univ, Grad Sch Med & Dent Sci, Dept Psychiat, 8-35-1 Sakuragaoka, Kagoshima 8908520, Japan.
EM nakamu36@m.kufm.kagoshima-u.ac.jp
OI Sano, Akira/0000-0001-5843-9786; Nakamura, Masayuki/0000-0001-5558-0418
CR Abe S, 2000, J MED GENET, V37, P41, DOI 10.1136/jmg.37.1.41
   Abe S, 2001, AM J MED GENET, V103, P334, DOI 10.1002/1096-8628(20011101)103:4<334::AID-AJMG1574>3.0.CO;2-F
   Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944
   Bernot A, 1997, NAT GENET, V17, P25
   Bianchi J, 2013, MOL CELL, V52, P566, DOI 10.1016/j.molcel.2013.10.035
   Biousse V, 2001, SEMIN NEUROL, V21, P275, DOI 10.1055/s-2001-17945
   Bohlega S, 1996, NEUROLOGY, V46, P1329, DOI 10.1212/WNL.46.5.1329
   Bonnefont Jean-Paul, 2004, Molecular Aspects of Medicine, V25, P495, DOI 10.1016/j.mam.2004.06.004
   Cheung MS, 2017, J IMMUNOL, V198, P2063, DOI 10.4049/jimmunol.1600760
   Coene ED, 2005, MOL BIOL CELL, V16, P997, DOI 10.1091/mbc.E04-10-0895
   Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936
   Estivill X, 1998, LANCET, V351, P394, DOI 10.1016/S0140-6736(97)11124-2
   García-Gómez S, 2013, MOL CELL, V52, P541, DOI 10.1016/j.molcel.2013.09.025
   Inoue H, 1998, NAT GENET, V20, P143, DOI 10.1038/2441
   Ito S, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4483
   Kato M, 2011, NEUROSCI RES, V69, P331, DOI 10.1016/j.neures.2010.12.013
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Keen BA, 2014, NUCLEIC ACIDS RES, V42, P12102, DOI 10.1093/nar/gku879
   Kubota M, 2012, BRAIN DEV-JPN, V34, P20, DOI 10.1016/j.braindev.2010.12.012
   Li JL, 2015, INVEST OPHTH VIS SCI, V56, P1181, DOI 10.1167/iovs.14-16072
   Lin D, 2012, THIRD CONFERENCE ON HORTICULTURE SCIENCE AND TECHNOLOGY (CHST 2012), P1
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Migita K, 2016, ARTHRITIS RES THER, V18, DOI 10.1186/s13075-016-1071-5
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Rudd SG, 2014, MOL CELL ONCOL, V1, DOI 10.4161/23723548.2014.960754
   Samuels J, 1998, MEDICINE, V77, P268, DOI 10.1097/00005792-199807000-00005
   SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Takata A., 2011, GENOME BIOL BREAST C, DOI 10.3390/ma11061030
   Thuillier L, 2003, HUM MUTAT, V21, P493, DOI 10.1002/humu.10201
   Tyynismaa H, 2009, AM J HUM GENET, V85, P290, DOI 10.1016/j.ajhg.2009.07.009
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, HUM MUTAT, V22, P175, DOI 10.1002/humu.10246
   Yao DB, 2008, HUM MUTAT, V29, P718, DOI 10.1002/humu.20717
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
   Zhang JF, 2013, COMM COM INF SC, V396, P1
   Zhao FX, 2013, HUM GENET, V132, P913, DOI 10.1007/s00439-013-1303-6
NR 37
TC 11
Z9 11
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0168-0102
EI 1872-8111
J9 NEUROSCI RES
JI Neurosci. Res.
PD AUG
PY 2020
VL 157
BP 58
EP 63
DI 10.1016/j.neures.2019.07.006
PG 6
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA NH3IL
UT WOS:000564567300006
PM 31348995
DA 2024-11-01
ER

PT J
AU Busch, KB
   Kowald, A
   Spelbrink, JN
AF Busch, Karin B.
   Kowald, Axel
   Spelbrink, Johannes N.
TI Quality matters: how does mitochondrial network dynamics and quality
   control impact on mtDNA integrity?
SO PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES
LA English
DT Review
DE mitochondrial dynamics; mtDNA; mitophagy; nucleoids; TFAM; OXPHOS
ID DNA DELETION MUTATIONS; AGED MUSCLE-FIBERS; OXIDATIVE STRESS;
   SKELETAL-MUSCLE; SUPERRESOLUTION FLUORESCENCE; FUNCTIONAL-ORGANIZATION;
   CLONAL EXPANSION; OPTIC ATROPHY; FISSION; FUSION
AB Mammalian mtDNA encodes for 13 core proteins of oxidative phosphorylation. Mitochondrial DNA mutations and deletions cause severe myopathies and neuromuscular diseases. Thus, the integrity of mtDNA is pivotal for cell survival and health of the organism. We here discuss the possible impact of mitochondrial fusion and fission on mtDNA maintenance as well as positive and negative selection processes. Our focus is centred on the important question of how the quality of mtDNA nucleoids can be assured when selection and mitochondrial quality control works on functional and physiological phenotypes constituted by oxidative phosphorylation proteins. The organelle control theory suggests a link between phenotype and nucleoid genotype. This is discussed in the light of new results presented here showing that mitochondrial transcription factor A/nucleoids are restricted in their intramitochondrial mobility and probably have a limited sphere of influence. Together with recent published work on mitochondrial and mtDNA heteroplasmy dynamics, these data suggest first, that single mitochondria might well be internally heterogeneous and second, that nucleoid genotypes might be linked to local phenotypes (although the link might often be leaky). We discuss how random or site-specific mitochondrial fission can isolate dysfunctional parts and enable their elimination by mitophagy, stressing the importance of fission in the process of mtDNA quality control. The role of fusion is more multifaceted and less understood in this context, but the mixing and equilibration of matrix content might be one of its important functions.
C1 [Busch, Karin B.] Univ Osnabruck, Sch Biol & Chem, Div Mitochondrial Dynam, D-49069 Osnabruck, Germany.
   [Kowald, Axel] Newcastle Univ, Inst Ageing & Hlth, Ctr Integrated Syst Biol Ageing & Nutr, Newcastle Upon Tyne NE4 5PL, Tyne & Wear, England.
   [Spelbrink, Johannes N.] Radboud Univ Nijmegen, Nijmegen Ctr Mitochondrial Disorders, Med Ctr, Dept Pediat, NL-6500 HB Nijmegen, Netherlands.
   [Spelbrink, Johannes N.] FinMIT Ctr Excellence, Inst Biomed Technol, Tampere 33014, Finland.
   [Spelbrink, Johannes N.] Tampere Univ Hosp, Pirkanmaa Hosp Dist, Tampere 33014, Finland.
C3 University Osnabruck; Newcastle University - UK; Radboud University
   Nijmegen; Pirkanmaa Hospital District; Tampere University; Tampere
   University Hospital
RP Spelbrink, JN (corresponding author), Radboud Univ Nijmegen, Nijmegen Ctr Mitochondrial Disorders, Med Ctr, Dept Pediat, Geert Grootepl 10,POB 9101, NL-6500 HB Nijmegen, Netherlands.
EM hans.spelbrink@radboudumc.nl
RI Busch, Karin/ABH-8594-2020; Spelbrink, Johannes/L-4661-2015
OI Spelbrink, Johannes/0000-0002-9756-2602; Kowald,
   Axel/0000-0001-6448-4364
FU Academy of Finland; Netherlands Organization for Scientific Research
   (NWO: VICI) [865.10.004]; DFG [Bu2288/1-1];  [SFB 944]
FX J.N.S. is supported by the Academy of Finland (CoE funding) and the
   Netherlands Organization for Scientific Research (NWO: VICI grant no.
   865.10.004). K. B. was supported by a DFG grant to Karin Busch
   (Bu2288/1-1) and the SFB 944.
CR ALBRING M, 1977, P NATL ACAD SCI USA, V74, P1348, DOI 10.1073/pnas.74.4.1348
   Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Appelhans T, 2012, NANO LETT, V12, P610, DOI 10.1021/nl203343a
   Arakaki N, 2006, BIOL PHARM BULL, V29, P1962, DOI 10.1248/bpb.29.1962
   Arimura S, 2004, P NATL ACAD SCI USA, V101, P7805, DOI 10.1073/pnas.0401077101
   ARNHEIM N, 1992, MUTAT RES, V275, P157, DOI 10.1016/0921-8734(92)90020-P
   Ban-Ishihara R, 2013, P NATL ACAD SCI USA, V110, P11863, DOI 10.1073/pnas.1301951110
   BANDY B, 1990, FREE RADICAL BIO MED, V8, P523, DOI 10.1016/0891-5849(90)90152-9
   Bereiter-Hahn J., 1997, Experimental Biology Online, V1, P1
   BEREITERHAHN J, 1994, MICROSC RES TECHNIQ, V27, P198, DOI 10.1002/jemt.1070270303
   BEREITHERHAHN J, 1998, EXP BIOL ONLINE, V3, P12
   Bogenhagen DF, 2008, J BIOL CHEM, V283, P3665, DOI 10.1074/jbc.M708444200
   Brierley EJ, 1998, ANN NEUROL, V43, P217, DOI 10.1002/ana.410430212
   Brown TA, 2011, MOL CELL BIOL, V31, P4994, DOI 10.1128/MCB.05694-11
   Busch KB, 2006, MOL MEMBR BIOL, V23, P509, DOI 10.1080/09687860600877292
   Busch KB, 2013, BIOL CHEM, V394, P163, DOI 10.1515/hsz-2012-0254
   Cao ZJ, 2001, NUCLEIC ACIDS RES, V29, P4502, DOI 10.1093/nar/29.21.4502
   Chen HC, 2005, J BIOL CHEM, V280, P26185, DOI 10.1074/jbc.M503062200
   Chen HC, 2010, CELL, V141, P280, DOI 10.1016/j.cell.2010.02.026
   Chinnery PF, 1999, AM J HUM GENET, V64, P1158, DOI 10.1086/302311
   Collins TJ, 2002, EMBO J, V21, P1616, DOI 10.1093/emboj/21.7.1616
   COMFORT A, 1974, MECH AGEING DEV, V3, P1, DOI 10.1016/0047-6374(74)90002-5
   CORTOPASSI GA, 1992, P NATL ACAD SCI USA, V89, P7370, DOI 10.1073/pnas.89.16.7370
   Dai Y, 2014, HUM MOL GENET, V23, P637, DOI 10.1093/hmg/ddt450
   de Vries RLA, 2012, AUTOPHAGY, V8, P699, DOI 10.4161/auto.19470
   deGrey ADNJ, 1997, BIOESSAYS, V19, P161, DOI 10.1002/bies.950190211
   Desagher S, 2000, TRENDS CELL BIOL, V10, P369, DOI 10.1016/S0962-8924(00)01803-1
   Dieteren CEJ, 2011, P NATL ACAD SCI USA, V108, P8657, DOI 10.1073/pnas.1017581108
   Distelmaier F, 2008, CYTOM PART A, V73A, P129, DOI 10.1002/cyto.a.20503
   Elson JL, 2001, AM J HUM GENET, V68, P802, DOI 10.1086/318801
   Gilkerson RW, 2012, HUM MOL GENET, V21, P978, DOI 10.1093/hmg/ddr529
   Gokey NG, 2004, AGING CELL, V3, P319, DOI 10.1111/j.1474-9728.2004.00122.x
   Greaves LC, 2006, P NATL ACAD SCI USA, V103, P714, DOI 10.1073/pnas.0505903103
   HAYASHI JI, 1994, J CELL BIOL, V125, P43, DOI 10.1083/jcb.125.1.43
   Hensen F, 2014, BIOCHIMIE, V100, P219, DOI 10.1016/j.biochi.2013.09.017
   Herbst A, 2007, J GERONTOL A-BIOL, V62, P235, DOI 10.1093/gerona/62.3.235
   Holt IJ, 2014, PHILOS T R SOC B, V369, DOI 10.1098/rstb.2013.0451
   Hudson G, 2008, BRAIN, V131, P329, DOI 10.1093/brain/awm272
   Iborra FJ, 2004, BMC BIOL, V2, DOI 10.1186/1741-7007-2-9
   Ishihara N, 2003, BIOCHEM BIOPH RES CO, V301, P891, DOI 10.1016/S0006-291X(03)00050-0
   Jensen RE, 2000, MICROSC RES TECHNIQ, V51, P573, DOI 10.1002/1097-0029(20001215)51:6<573::AID-JEMT7>3.0.CO;2-2
   Jin SM, 2012, J CELL SCI, V125, P795, DOI 10.1242/jcs.093849
   Karbowski M, 2003, CELL DEATH DIFFER, V10, P870, DOI 10.1038/sj.cdd.4401260
   Khrapko K, 1999, NUCLEIC ACIDS RES, V27, P2434, DOI 10.1093/nar/27.11.2434
   Kim I, 2011, ANTIOXID REDOX SIGN, V14, P1919, DOI 10.1089/ars.2010.3768
   Knott AB, 2008, ANN NY ACAD SCI, V1147, P283, DOI 10.1196/annals.1427.030
   Kopek BG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077209
   Kopek BG, 2012, P NATL ACAD SCI USA, V109, P6136, DOI 10.1073/pnas.1121558109
   Kowald A, 2014, P NATL ACAD SCI USA, V111, P2972, DOI 10.1073/pnas.1314970111
   Kowald A, 2014, J THEOR BIOL, V340, P111, DOI 10.1016/j.jtbi.2013.09.009
   Kowald A, 2013, AGING CELL, V12, P728, DOI 10.1111/acel.12098
   Kowald A, 2011, P NATL ACAD SCI USA, V108, P10237, DOI 10.1073/pnas.1101604108
   Kukat C, 2011, P NATL ACAD SCI USA, V108, P13534, DOI 10.1073/pnas.1109263108
   Lee CM, 1998, FREE RADICAL BIO MED, V25, P964, DOI 10.1016/S0891-5849(98)00185-3
   LEE HC, 1994, BBA-MOL BASIS DIS, V1226, P37, DOI 10.1016/0925-4439(94)90056-6
   Legros F, 2004, J CELL SCI, V117, P2653, DOI 10.1242/jcs.01134
   Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292
   Mai S, 2010, J CELL SCI, V123, P917, DOI 10.1242/jcs.059246
   Malena A, 2009, HUM MOL GENET, V18, P3407, DOI 10.1093/hmg/ddp281
   Malka F, 2005, EMBO REP, V6, P853, DOI 10.1038/sj.embor.7400488
   Margineantu DH, 2002, MITOCHONDRION, V1, P425, DOI 10.1016/S1567-7249(02)00006-5
   McDonald SAC, 2006, CELL CYCLE, V5, P808, DOI 10.4161/cc.5.8.2641
   Meeusen S, 2004, SCIENCE, V305, P1747, DOI 10.1126/science.1100612
   MITCHELL P, 1966, BIOL REV, V41, P445, DOI 10.1111/j.1469-185X.1966.tb01501.x
   Molina AJA, 2009, METHOD ENZYMOL, V457, P289, DOI 10.1016/S0076-6879(09)05016-2
   Muster B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011910
   Narendra DP, 2011, ANTIOXID REDOX SIGN, V14, P1929, DOI 10.1089/ars.2010.3799
   NASS MMK, 1969, J MOL BIOL, V42, P521, DOI 10.1016/0022-2836(69)90240-X
   Nunnari J, 1997, MOL BIOL CELL, V8, P1233, DOI 10.1091/mbc.8.7.1233
   Oettinghaus B, 2012, ACTA NEUROPATHOL, V123, P189, DOI 10.1007/s00401-011-0930-z
   Okamoto K, 1998, J CELL BIOL, V142, P613, DOI 10.1083/jcb.142.3.613
   Perfettini JL, 2005, TRENDS CELL BIOL, V15, P179, DOI 10.1016/j.tcb.2005.02.005
   Rajala N, 2014, NUCLEIC ACIDS RES, V42, P952, DOI 10.1093/nar/gkt988
   Rube DA, 2004, MOL CELL BIOCHEM, V256, P331, DOI 10.1023/B:MCBI.0000009879.01256.f6
   Rugarli EI, 2012, EMBO J, V31, P1336, DOI 10.1038/emboj.2012.38
   SCHWARTZ RM, 1978, SCIENCE, V199, P395, DOI 10.1126/science.202030
   Scorrano L, 2003, CELL DEATH DIFFER, V10, P1287, DOI 10.1038/sj.cdd.4401310
   Shaw JM, 2002, TRENDS CELL BIOL, V12, P178, DOI 10.1016/S0962-8924(01)02246-2
   Sheahan MB, 2005, PLANT J, V44, P744, DOI 10.1111/j.1365-313X.2005.02561.x
   Skulachev VP, 2001, TRENDS BIOCHEM SCI, V26, P23, DOI 10.1016/S0968-0004(00)01735-7
   Spelbrink JN, 2010, IUBMB LIFE, V62, P19, DOI 10.1002/iub.282
   Suen DF, 2010, P NATL ACAD SCI USA, V107, P11835, DOI 10.1073/pnas.0914569107
   Tatsuta T, 2008, EMBO J, V27, P306, DOI 10.1038/sj.emboj.7601972
   Taylor RW, 2003, J CLIN INVEST, V112, P1351, DOI 10.1172/JCI200319435
   Twig G, 2008, EMBO J, V27, P433, DOI 10.1038/sj.emboj.7601963
   Twig G, 2006, AM J PHYSIOL-CELL PH, V291, pC176, DOI 10.1152/ajpcell.00348.2005
   Vielhaber S, 2013, ACTA NEUROPATHOL, V125, P245, DOI 10.1007/s00401-012-1036-y
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953
   Wallace DC, 2010, ENVIRON MOL MUTAGEN, V51, P440, DOI 10.1002/em.20586
   Wanagat J, 2001, FASEB J, V15, P322, DOI 10.1096/fj.00-0320com
   Wilkens V, 2013, J CELL SCI, V126, P103, DOI 10.1242/jcs.108852
   Woldringh CL, 2002, MOL MICROBIOL, V45, P17, DOI 10.1046/j.1365-2958.2002.02993.x
   Yaffe MP, 1999, NAT CELL BIOL, V1, pE149, DOI 10.1038/14101
   Youle RJ, 2012, SCIENCE, V337, P1062, DOI 10.1126/science.1219855
   Zunino R, 2009, J BIOL CHEM, V284, P17783, DOI 10.1074/jbc.M901902200
NR 97
TC 59
Z9 67
U1 1
U2 30
PU ROYAL SOC
PI LONDON
PA 6-9 CARLTON HOUSE TERRACE, LONDON SW1Y 5AG, ENGLAND
SN 0962-8436
EI 1471-2970
J9 PHILOS T R SOC B
JI Philos. Trans. R. Soc. B-Biol. Sci.
PD JUL 5
PY 2014
VL 369
IS 1646
SI SI
AR 20130442
DI 10.1098/rstb.2013.0442
PG 12
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA AJ0SV
UT WOS:000337367200004
PM 24864312
OA Green Published, Bronze
DA 2024-11-01
ER

PT J
AU Zhou, ZD
   Saw, WT
   Tan, EK
AF Zhou, Zhi-Dong
   Saw, Wuan-Ting
   Tan, Eng-King
TI Mitochondrial CHCHD-Containing Proteins: Physiologic Functions and Link
   with Neurodegenerative Diseases
SO MOLECULAR NEUROBIOLOGY
LA English
DT Review
DE Apoptosis; Coiled-coil-helix-coiled-coil-helix domain proteins;
   Mitochondria; Mitochondrial cristae; Neurodegenerative disease
ID CYTOCHROME-C-OXIDASE; AMYOTROPHIC-LATERAL-SCLEROSIS; FRONTOTEMPORAL
   DEMENTIA; INTERMEMBRANE SPACE; RIBOSOMAL-PROTEINS; OXIDATIVE STRESS;
   SKELETAL-MUSCLE; GENE; IDENTIFICATION; MIA40
AB The coiled-coil-helix-coiled-coil-helix domain (CHCHD)-containing proteins are evolutionarily conserved nucleus-encoded small mitochondrial proteins with important functions. So far, nine members have been identified in this protein family. All CHCHD proteins have at least one functional coiled-coil-helix-coiled-coil-helix (CHCH) domain, which is stabilized by two pairs of disulfide bonds between two helices. CHCHD proteins have various important pathophysiological roles in mitochondria and other key cellular processes. Mutations of CHCHD proteins have been associated with various human neurodegenerative diseases. Mutations of CHCHD10 are associated with amyotrophic lateral sclerosis (ALS) and/or frontotemporal lobe dementia (FTD), motor neuron disease, and late-onset spinal muscular atrophy and autosomal dominant mitochondrial myopathy. CHCHD10 stabilizes mitochondrial crista ultrastructure and maintains its integrity. In patients with CHCHD10 mutations, there are abnormal mitochondrial crista structure, deficiencies of respiratory chain complexes, impaired mitochondrial respiration, and multiple mitochondrial DNA (mtDNA) deletions. Recently, CHCHD2 mutations are linked with autosomal dominant and sporadic Parkinson's disease (PD). The CHCHD2 is a multifunctional protein and plays roles in regulation of mitochondrial metabolism, synthesis of respiratory chain components, and modulation of cell apoptosis. With a better understanding of the pathophysiologic roles of CHCHD proteins, they may be potential novel therapeutic targets for human neurodegenerative diseases.
C1 [Zhou, Zhi-Dong; Saw, Wuan-Ting; Tan, Eng-King] Natl Neurosci Inst Singapore, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.
   [Zhou, Zhi-Dong; Tan, Eng-King] Duke NUS Grad Med Sch Singapore, Signature Res Program Neurosci & Behav Disorders, 8 Coll Rd, Singapore 169857, Singapore.
   [Tan, Eng-King] Singapore Gen Hosp, Dept Neurol, Outram Rd, Singapore 169608, Singapore.
C3 Tan Tock Seng Hospital; National Neuroscience Institute (NNI); National
   University of Singapore; Singapore General Hospital
RP Zhou, ZD; Tan, EK (corresponding author), Natl Neurosci Inst Singapore, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.; Zhou, ZD; Tan, EK (corresponding author), Duke NUS Grad Med Sch Singapore, Signature Res Program Neurosci & Behav Disorders, 8 Coll Rd, Singapore 169857, Singapore.; Tan, EK (corresponding author), Singapore Gen Hosp, Dept Neurol, Outram Rd, Singapore 169608, Singapore.
EM Zhidong_zhou@nni.com.sg; saw.wuan.ting@singhealth.com.sg;
   Tan.eng.king@sgh.com.sg
FU Singapore National Medical Research Council (NMRC); STaR award; clinical
   translational research programme in Parkinson's disease; Transition
   award
FX This study is supported by Singapore National Medical Research Council
   (NMRC) grants including STaR and Transition awards and clinical
   translational research programme in Parkinson's disease.
CR Ajroud-Driss S, 2015, NEUROGENETICS, V16, P1, DOI 10.1007/s10048-014-0421-1
   An J, 2012, J BIOL CHEM, V287, P7411, DOI 10.1074/jbc.M111.277103
   [Anonymous], SUBCELLULAR LOCALIZA
   [Anonymous], NEUROBIOL AGING
   Aras S, 2015, MITOCHONDRION, V20, P43, DOI 10.1016/j.mito.2014.10.003
   Aras S, 2013, NUCLEIC ACIDS RES, V41, P2255, DOI 10.1093/nar/gks1454
   Arnesano F, 2005, STRUCTURE, V13, P713, DOI 10.1016/j.str.2005.02.015
   Auranen M, 2015, NEUROL-GENET, V1, DOI 10.1212/NXG.0000000000000003
   Banci L, 2012, J STRUCT BIOL, V180, P190, DOI 10.1016/j.jsb.2012.07.007
   Banci L, 2010, P NATL ACAD SCI USA, V107, P20190, DOI 10.1073/pnas.1010095107
   Banci L, 2009, NAT STRUCT MOL BIOL, V16, P198, DOI 10.1038/nsmb.1553
   Bannai H, 2002, BIOINFORMATICS, V18, P298, DOI 10.1093/bioinformatics/18.2.298
   Bannwarth S, 2014, BRAIN, V137, P2329, DOI 10.1093/brain/awu138
   Baughman JM, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000590
   Bestwick M, 2010, MOL CELL BIOL, V30, P4480, DOI 10.1128/MCB.00228-10
   Bode M, 2013, ANTIOXID REDOX SIGN, V18, P1597, DOI 10.1089/ars.2012.4685
   Brookes PS, 2004, AM J PHYSIOL-CELL PH, V287, pC817, DOI 10.1152/ajpcell.00139.2004
   Brzóska K, 2006, ACTA BIOCHIM POL, V53, P685
   Cavallaro G, 2010, MOL BIOSYST, V6, P2459, DOI 10.1039/c0mb00058b
   Chacinska A, 2008, J BIOL CHEM, V283, P29723, DOI 10.1074/jbc.M805356200
   Chacinska A, 2009, CELL, V138, P628, DOI 10.1016/j.cell.2009.08.005
   Chaussenot A, 2014, Neurobiol
   Chen HC, 2010, CELL, V141, P280, DOI 10.1016/j.cell.2010.02.026
   Chiò A, 2015, NEUROBIOL AGING, V36, DOI 10.1016/j.neurobiolaging.2015.01.017
   CLAROS MG, 1995, COMPUT APPL BIOSCI, V11, P441
   Cogliati S, 2013, CELL, V155, P160, DOI 10.1016/j.cell.2013.08.032
   Cory S, 2002, NAT REV CANCER, V2, P647, DOI 10.1038/nrc883
   Crugnola V, 2010, ARCH NEUROL-CHICAGO, V67, P849, DOI 10.1001/archneurol.2010.128
   Darshi M, 2010, FASEB J, V24
   Darshi M, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.387696
   Darshi M, 2011, J BIOL CHEM, V286, P2918, DOI 10.1074/jbc.M110.171975
   Davies KM, 2011, P NATL ACAD SCI USA, V108, P14121, DOI 10.1073/pnas.1103621108
   Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753
   Ding CL, 2015, SCI REP-UK, V5, DOI 10.1038/srep16064
   Dolezal P, 2006, SCIENCE, V313, P314, DOI 10.1126/science.1127895
   Dols-Icardo O, 2015, BRAIN, V138, pE400, DOI 10.1093/brain/awv175
   Du CY, 2000, CELL, V102, P33, DOI 10.1016/S0092-8674(00)00008-8
   Dudek J, 2013, BBA-MOL CELL RES, V1833, P274, DOI 10.1016/j.bbamcr.2012.05.028
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Foo JN, 2015, LANCET NEUROL, V14, P681, DOI 10.1016/S1474-4422(15)00098-8
   Frey TG, 2000, TRENDS BIOCHEM SCI, V25, P319, DOI 10.1016/S0968-0004(00)01609-1
   Friedman JR, 2015, ELIFE, V4, DOI 10.7554/eLife.07739
   Funayama M, 2015, LANCET NEUROL, V14, P274, DOI 10.1016/S1474-4422(14)70266-2
   Gallego NE, 2015, BIOPHYS J, V108, p611A
   Genin EC, 2016, EMBO MOL MED, V8, P58, DOI 10.15252/emmm.201505496
   Goldschmidt-Reisin S, 1998, J BIOL CHEM, V273, P34828, DOI 10.1074/jbc.273.52.34828
   Graack HR, 1999, BIOCHEMISTRY-US, V38, P16569, DOI 10.1021/bi991543s
   Hangen E, 2015, MOL CELL, V58, P1001, DOI 10.1016/j.molcel.2015.04.020
   Harner M, 2011, EMBO J, V30, P4356, DOI 10.1038/emboj.2011.379
   Herrmann JM, 2012, J BIOL CHEM, V287, P4426, DOI 10.1074/jbc.R111.270678
   Hirai K, 2001, J NEUROSCI, V21, P3017, DOI 10.1523/JNEUROSCI.21-09-03017.2001
   Hofmann S, 2005, J MOL BIOL, V353, P517, DOI 10.1016/j.jmb.2005.08.064
   Jansen IE, 2015, LANCET NEUROL, V14, P678, DOI 10.1016/S1474-4422(15)00094-0
   Jiao B, 2016, BRAIN, V139, DOI 10.1093/brain/awv367
   Jin C, 1997, CURR GENET, V31, P228, DOI 10.1007/s002940050199
   Johnson DC, 2005, ANNU REV BIOCHEM, V74, P247, DOI 10.1146/annurev.biochem.74.082803.133518
   Johnson JO, 2014, BRAIN, V137, DOI 10.1093/brain/awu265
   Khalimonchuk E, 2005, MITOCHONDRION, V5, P363, DOI 10.1016/j.mito.2005.08.002
   Koc EC, 2000, J BIOL CHEM, V275, P32585, DOI 10.1074/jbc.M003596200
   Koc EC, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00183
   Koehler CM, 2009, BBA-MOL CELL RES, V1793, P139, DOI 10.1016/j.bbamcr.2008.08.002
   Koschmidder E, 2016, NEUROLOGY, V86, P577, DOI 10.1212/WNL.0000000000002361
   Kurosaka Satoshi, 2008, Birth Defects Research, V84, P102, DOI 10.1002/bdrc.20125
   Lin MT, 2006, NATURE, V443, P787, DOI 10.1038/nature05292
   Liu H.-M., 2012, J NANOMATER, V2012, DOI [DOI 10.1155/2012/510478, 10.1155/2012/510478]
   Liu XS, 1996, CELL, V86, P147, DOI 10.1016/S0092-8674(00)80085-9
   Liu Y, 2015, CELL DEATH DIFFER, V22, P1035, DOI 10.1038/cdd.2014.194
   Liu Y, 2015, MOL CELL ONCOL, V2, DOI 10.1080/23723556.2015.1004964
   Martherus RSRM, 2010, BIOCHEM BIOPH RES CO, V402, P203, DOI 10.1016/j.bbrc.2010.09.109
   Modjtahedi N, 2016, TRENDS BIOCHEM SCI, V41, P245, DOI 10.1016/j.tibs.2015.12.004
   Müller K, 2014, BRAIN, V137, DOI 10.1093/brain/awu227
   Murari A, 2015, BIOCHEM J, V471, P231, DOI 10.1042/BJ20150012
   MUTISYA EM, 1994, J NEUROCHEM, V63, P2179
   Neupert W, 2007, ANNU REV BIOCHEM, V76, P723, DOI 10.1146/annurev.biochem.76.052705.163409
   Norbury CJ, 2001, ANNU REV PHARMACOL, V41, P367, DOI 10.1146/annurev.pharmtox.41.1.367
   Ogaki K, 2015, NEUROLOGY, V85, P2016, DOI 10.1212/WNL.0000000000002170
   Osellame LD, 2012, BEST PRACT RES CL EN, V26, P711, DOI 10.1016/j.beem.2012.05.003
   Ott C, 2012, MOL CELL BIOL, V32, P1173, DOI 10.1128/MCB.06388-11
   Penttilä S, 2015, ANN NEUROL, V77, P163, DOI 10.1002/ana.24319
   Puschmann A, 2015, LANCET NEUROL, V14, P679, DOI 10.1016/S1474-4422(15)00095-2
   Rabl R, 2009, J CELL BIOL, V185, P1047, DOI 10.1083/jcb.200811099
   Radad K, 2006, NEUROCHEM INT, V49, P379, DOI 10.1016/j.neuint.2006.02.003
   Ronchi D, 2015, BRAIN, V138, pE372, DOI 10.1093/brain/awu384
   Rouault TA, 2008, TRENDS GENET, V24, P398, DOI 10.1016/j.tig.2008.05.008
   Sattler M, 1997, SCIENCE, V275, P983, DOI 10.1126/science.275.5302.983
   Schmidt O, 2010, NAT REV MOL CELL BIO, V11, P655, DOI 10.1038/nrm2959
   Schulz KL, 2012, MOL NEUROBIOL, V46, P205, DOI 10.1007/s12035-012-8308-3
   Seo M, 2010, FASEB J, V24, P464, DOI 10.1096/fj.09-137562
   Shi CH, 2016, NEUROBIOL AGING, V38, DOI 10.1016/j.neurobiolaging.2015.10.040
   Soto IC, 2012, BBA-BIOENERGETICS, V1817, P883, DOI 10.1016/j.bbabio.2011.09.005
   Spiller MP, 2013, BIOCHEM J, V455, P27, DOI 10.1042/BJ20130442
   Suzuki T, 2001, J BIOL CHEM, V276, P21724, DOI 10.1074/jbc.M100432200
   Sztolsztener ME, 2013, TRAFFIC, V14, P309, DOI 10.1111/tra.12030
   Terziyska N, 2005, FEBS LETT, V579, P179, DOI 10.1016/j.febslet.2004.11.072
   Uhlen M, 2010, NAT BIOTECHNOL, V28, P1248, DOI 10.1038/nbt1210-1248
   Vela L, 2013, J BIOL CHEM, V288, P4935, DOI 10.1074/jbc.M112.422204
   Vielhaber S, 2000, BRAIN, V123, P1339, DOI 10.1093/brain/123.7.1339
   Vogel F, 2006, J CELL BIOL, V175, P237, DOI 10.1083/jcb.200605138
   Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108
   Wei YH, 2015, MOL CANCER RES, V13, P1119, DOI 10.1158/1541-7786.MCR-14-0165-T
   Westerman BA, 2004, GENOMICS, V83, P1094, DOI 10.1016/j.ygeno.2003.12.006
   Wiedemann FR, 2002, J NEUROCHEM, V80, P616, DOI 10.1046/j.0022-3042.2001.00731.x
   Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105
   Xie J, 2007, FEBS LETT, V581, P3545, DOI 10.1016/j.febslet.2007.06.052
   Yang J, 2012, J CLIN INVEST, V122, P600, DOI 10.1172/JCI58780
   Yang XL, 2016, PARKINSONISM RELAT D, V29, P42, DOI 10.1016/j.parkreldis.2016.05.032
   Zerbes RM, 2012, J MOL BIOL, V422, P183, DOI 10.1016/j.jmb.2012.05.004
   Zhang M, 2016, NEUROBIOL AGING, V38, DOI 10.1016/j.neurobiolaging.2015.10.038
   Zhang M, 2015, BRAIN, V138, DOI 10.1093/brain/awv082
   Zhu XW, 2006, J ALZHEIMERS DIS, V9, P147
NR 110
TC 41
Z9 44
U1 1
U2 21
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0893-7648
EI 1559-1182
J9 MOL NEUROBIOL
JI Mol. Neurobiol.
PD SEP
PY 2017
VL 54
IS 7
BP 5534
EP 5546
DI 10.1007/s12035-016-0099-5
PG 13
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA FC0BO
UT WOS:000406503500057
PM 27631878
DA 2024-11-01
ER

PT J
AU Pulkes, T
   Liolitsa, D
   Eunson, LH
   Rose, M
   Nelson, IP
   Rahman, S
   Poulton, J
   Marchington, DR
   Landon, DN
   Debono, AG
   Morgan-Hughes, JA
   Hanna, MG
AF Pulkes, T
   Liolitsa, D
   Eunson, LH
   Rose, M
   Nelson, IP
   Rahman, S
   Poulton, J
   Marchington, DR
   Landon, DN
   Debono, AG
   Morgan-Hughes, JA
   Hanna, MG
TI New phenotypic diversity associated with the mitochondrial tRNA
   <SUP>Ser(UCN)</SUP> gene mutation
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE exercise intolerances; MERRF; respiratory chain disease; mitochondrial
   DNA
ID RESPIRATORY-CHAIN; DNA; MTDNA; PROPORTION; MYOPATHY; GENOTYPE; EPILEPSY;
   OOCYTES; STROKE; MERRF
AB We performed detailed clinical, histopathological, biochemical, in vitro translation and molecular genetic analysis in patients from two unrelated families harbouring the tRNA(Ser(UCN)) 7472C-insertion mutation. Proband I developed a progressive neurodegenerative phenotype characterised by myoclonus, epilepsy, cerebellar ataxia and progressive hearing loss. Proband 2 had a comparatively benign phenotype characterised by isolated myopathy with exercise intolerance. Both patients had the 7472C-insertion mutation in identical proportions and they exhibited a similar muscle biochemical and histopathological phenotype. However, proband 2 also had a previously unreported homoplasmic A to C transition at nucleotide position 7472 in the tRNA(Ser(UCN)) gene. This change lengthens further the homopolymeric C run already expanded by the 7472C-insertion. These data extend the phenotypic range associated with the 7472C-insertion to include isolated skeletal myopathy, as well as a MERRF-like phenotype. (c) 2005 Elsevier B.V. All rights reserved.
C1 UCL, Ctr Neuromuscular Dis, Inst Neurol, London WC1N 3BG, England.
   UCL, Dept Mol Neurosci, Inst Neurol, London WC1N 3BG, England.
   Inst Neurol, Dept Neuropathol, London WC1N 3BG, England.
   Kings Neurosci Ctr, Dept Neurol, Reg Neuromuscular Dis Unit, London, England.
   Inst Child Hlth, Metab Unit, London, England.
   John Radcliffe Hosp, Dept Pediat, Oxford OX3 9DU, England.
   St Lukes Hosp, Dept Med, Guardamangia, Malta.
C3 University of London; University College London; University of London;
   University College London; University of London; University College
   London; University of London; King's College London; University of
   London; University College London; University of Oxford
RP UCL, Ctr Neuromuscular Dis, Inst Neurol, Queen Sq, London WC1N 3BG, England.
EM mhanna@ion.ucl.ac.uk
RI Hanna, Michael/B-1995-2009; Rahman, Shamima/C-5232-2008; Poulton,
   Joanna/AAB-4828-2021
OI Beard, Louise/0000-0003-4828-771X; Pulkes,
   Teeratorn/0000-0003-0175-7438; Poulton, Joanna/0000-0002-2460-5587;
   Hanna, Michael/0000-0003-0825-4075; nelson, isabelle/0000-0001-6390-622X
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   BOLANOS JP, 1994, J NEUROCHEM, V63, P910
   HAMMANS SR, 1995, BRAIN, V118, P721, DOI 10.1093/brain/118.3.721
   HAMMANS SR, 1993, BRAIN, V116, P617, DOI 10.1093/brain/116.3.617
   Hanna MG, 1999, CELL MOL LIFE SCI, V55, P691, DOI 10.1007/s000180050327
   HANNA MG, 1995, J NEUROL SCI, V130, P154, DOI 10.1016/0022-510X(95)00022-T
   Jaksch M, 1998, ANN NEUROL, V44, P635, DOI 10.1002/ana.410440409
   KADENBAC.B, 1967, BIOCHIM BIOPHYS ACTA, V138, P651, DOI 10.1016/0005-2787(67)90574-6
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   Marchington DR, 1998, AM J HUM GENET, V63, P769, DOI 10.1086/302009
   Marchington DR, 1997, AM J HUM GENET, V60, P408
   Morgan-Hughes JA, 1999, BBA-BIOENERGETICS, V1410, P125, DOI 10.1016/S0005-2728(98)00162-5
   MORGANHUGHES JA, 1995, BBA-MOL BASIS DIS, V1271, P135, DOI 10.1016/0925-4439(95)00020-5
   PAYNE CM, 1975, J NEUROL SCI, V25, P99, DOI 10.1016/0022-510X(75)90190-2
   Pulkes T, 2001, ADV DRUG DELIVER REV, V49, P27, DOI 10.1016/S0169-409X(01)00124-7
   Pulkes T, 2000, LANCET, V356, P2068, DOI 10.1016/S0140-6736(00)03408-5
   Rahman S, 2000, BRAIN, V123, P591, DOI 10.1093/brain/123.3.591
   Schuelke M, 1998, ANN NEUROL, V44, P700, DOI 10.1002/ana.410440420
   SJOSTROM M, 1982, MUSCLE NERVE, V5, P538, DOI 10.1002/mus.880050708
   SJOSTROM M, 1982, J HISTOCHEM CYTOCHEM, V30, P1, DOI 10.1177/30.1.7054271
   SWEENEY MG, 1994, J NEUROL SCI, V121, P57, DOI 10.1016/0022-510X(94)90157-0
   TIRANTI V, 1995, HUM MOL GENET, V4, P1421, DOI 10.1093/hmg/4.8.1421
   Toompuu M, 1999, HUM MOL GENET, V8, P2275, DOI 10.1093/hmg/8.12.2275
   Verhoeven K, 1999, EUR J HUM GENET, V7, P45, DOI 10.1038/sj.ejhg.5200247
NR 24
TC 25
Z9 26
U1 0
U2 4
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD MAY
PY 2005
VL 15
IS 5
BP 364
EP 371
DI 10.1016/j.nmd.2005.01.006
PG 8
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 923EW
UT WOS:000228893000008
PM 15833431
DA 2024-11-01
ER

PT J
AU Sanaker, PS
   Bindoff, LA
AF Sanaker, Petter Schandl
   Bindoff, Laurence A.
TI MT-ND5 Mutation Causing Exercise Intolerance Displays Intercellular
   Heteroplasmy and Rapid Shifts Between Generations
SO HUMAN MUTATION
LA English
DT Article
DE mitochondrial DNA; mitochondrial myopathy; inheritance; heteroplasmy
ID RED FIBERS MERRF; MITOCHONDRIAL-DNA; SKELETAL-MUSCLE;
   PRENATAL-DIAGNOSIS; MTDNA; GENE; EXPRESSION; MYOPATHY; SEGREGATION;
   DELETIONS
AB We studied the inheritance and cellular segregation of a maternally inherited, heteroplasmic MT-ND5 mutation, m.13271T>C, previously shown to cause only exercise intolerance despite being present in multiple tissues. The mutation was present at low levels in early passage, bulk muscle culture, but on subcloning, only homoplasmic clones were found. Studies of transmission showed that the mutation expanded from very low levels in the patient's mother to higher levels in the patient, particularly skeletal muscle, but was not found in the placenta and umbilical cord blood of her child. Our study suggests that the m.13271T>C is either already strictly segregated (intercellular heteroplasmy), or moves rapidly to this state in cultured cells. Transmission studies suggest that intercellular heteroplasmy may also be present in the patient's germline. Although rapid shifts in heteroplasmic mitochondrial DNA mutations reflect a bottleneck in the female germline, complete segregation will accentuate the effects of this and further complicate genetic counseling.
C1 [Sanaker, Petter Schandl; Bindoff, Laurence A.] Haukeland Hosp, Dept Neurol, N-5021 Bergen, Norway.
   [Sanaker, Petter Schandl; Bindoff, Laurence A.] Univ Bergen, Dept Clin Med, N-5021 Bergen, Norway.
C3 University of Bergen; Haukeland University Hospital; University of
   Bergen
RP Bindoff, LA (corresponding author), Univ Bergen, Haukeland Univ Hosp, IKM, Dept Neurol, N-5021 Bergen, Norway.
EM laurence.bindoff@helse-bergen.no
OI Bindoff, Laurence/0000-0003-0988-276X
FU Research Council of Norway; Western Norway Regional Health Authority
FX Contract grant sponsors: Research Council of Norway; The Western Norway
   Regional Health Authority.
CR Andreu AL, 1999, ANN NEUROL, V45, P820, DOI 10.1002/1531-8249(199906)45:6<820::AID-ANA22>3.0.CO;2-W
   Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   [Anonymous], 2011, MITOMAP HUM MIT GEN
   Bidooki SK, 1997, AM J HUM GENET, V60, P1430, DOI 10.1086/515460
   BOULET L, 1992, AM J HUM GENET, V51, P1187
   BOUZIDI MF, 1993, NEUROMUSCULAR DISORD, V3, P599
   Chinnery P. F., 2000, GENE REV
   Clark KM, 1997, NAT GENET, V16, P222, DOI 10.1038/ng0797-222
   Downham E, 2008, NEUROMUSCULAR DISORD, V18, P310, DOI 10.1016/j.nmd.2008.01.003
   Horváth R, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.015024
   LARSSON NG, 1992, AM J HUM GENET, V51, P1201
   MATTHEWS PM, 1995, HUM GENET, V96, P261
   MORAES CT, 1989, BIOCHEM BIOPH RES CO, V160, P765, DOI 10.1016/0006-291X(89)92499-6
   Murphy JL, 2008, BRAIN, V131, P2832, DOI 10.1093/brain/awn252
   Poulton J, 2000, NEUROMUSCULAR DISORD, V10, P484, DOI 10.1016/S0960-8966(00)00130-9
   Sanaker PS, 2010, BBA-MOL BASIS DIS, V1802, P539, DOI 10.1016/j.bbadis.2010.02.010
   Seale P, 2000, DEV BIOL, V218, P115, DOI 10.1006/dbio.1999.9565
   Shoubridge EA, 1997, HUM MOL GENET, V6, P2239, DOI 10.1093/hmg/6.13.2239
   Shoubridge EA, 2007, CURR TOP DEV BIOL, V77, P87, DOI 10.1016/S0070-2153(06)77004-1
   Taivassalo T, 2001, ANN NEUROL, V50, P133, DOI 10.1002/ana.1050
   Taivassalo T, 2006, BRAIN, V129, P3391, DOI 10.1093/brain/awl282
   Weber K, 1997, AM J HUM GENET, V60, P373
   White SL, 1999, AM J HUM GENET, V65, P474, DOI 10.1086/302488
NR 23
TC 0
Z9 0
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1059-7794
J9 HUM MUTAT
JI Hum. Mutat.
PD FEB
PY 2013
VL 34
IS 2
BP 292
EP 295
DI 10.1002/humu.22238
PG 4
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 083PP
UT WOS:000314477700005
PM 23065728
DA 2024-11-01
ER

PT J
AU Tanji, K
   Kaufmann, P
   Naini, AB
   Lu, J
   Parsons, TC
   Wang, D
   Willey, JZ
   Shanske, S
   Hirano, M
   Bonilla, E
   Kharldji, A
   DiMauro, S
   Rowland, LP
AF Tanji, Kurenal
   Kaufmann, Petra
   Naini, Ali B.
   Lu, Jiesheng
   Parsons, Timothy C.
   Wang, Dong
   Willey, Joshua Z.
   Shanske, Sara
   Hirano, Michio
   Bonilla, Eduardo
   Kharldji, Alexander
   DiMauro, Salvatore
   Rowland, Lewis P.
TI A novel tRNA<SUP>Val</SUP> mitochondrial DNA mutation causing MELAS
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE tRNAVal; mitochondrial DNA; stroke; MELAS
ID STROKE-LIKE EPISODES; LACTIC-ACIDOSIS; BLOOD-VESSELS; GENE; MYOPATHY;
   ENCEPHALOPATHY; SERIAL
AB Mitochondrial encephalopathy, lactic acidosis and stroke-like episodes (MELAS) is the most common mitochondrial disease due to mitochondrial DNA (mtDNA) mutations. At least 15 distinct mtDNA mutations have been associated with MELAS, and about 80% of the cases are caused by the A3243G tRNA (Leu(UUR)) gene mutation. We report here a novel tRNA(Val) mutation in a 37-year-old woman with manifestations of MELAS, and compare her clinicopathological phenotype with other rare cases associated tRNA(Val) mutations. (c) 2008 Elsevier B.V. All rights reserved.
C1 [Tanji, Kurenal; Bonilla, Eduardo] Columbia Univ, Dept Pathol, Div Neuropathol, Coll Phys & Surg,P&S, New York, NY 10032 USA.
   [Kaufmann, Petra; Naini, Ali B.; Lu, Jiesheng; Parsons, Timothy C.; Wang, Dong; Willey, Joshua Z.; Shanske, Sara; Hirano, Michio; Bonilla, Eduardo; DiMauro, Salvatore; Rowland, Lewis P.] Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA.
   [Kharldji, Alexander] Columbia Univ, Coll Phys & Surg, Dept Radiol, New York, NY 10032 USA.
C3 Columbia University; Columbia University; Columbia University
RP Tanji, K (corresponding author), Columbia Univ, Dept Pathol, Div Neuropathol, Coll Phys & Surg,P&S, 630 W 168th St,PH15Stem 124, New York, NY 10032 USA.
EM kt8@columbia.edu
OI Parsons, Timothy/0000-0001-9088-1929
FU NICHD NIH HHS [P01 HD080642, R01 HD056103] Funding Source: Medline;
   NINDS NIH HHS [U54 NS078059] Funding Source: Medline
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   Betts J, 2006, NEUROPATH APPL NEURO, V32, P359, DOI 10.1111/j.1365-2990.2006.00731.x
   Blakely EL, 2004, J NEUROL SCI, V225, P99, DOI 10.1016/j.jns.2004.07.007
   Chalmers RM, 1997, NEUROLOGY, V49, P589, DOI 10.1212/WNL.49.2.589
   de Coo IFM, 1998, NEUROLOGY, V50, P293, DOI 10.1212/WNL.50.1.293
   DIMAURO S, GENE REV GENE TEST M
   HASEGAWA H, 1991, ANN NEUROL, V29, P601, DOI 10.1002/ana.410290606
   Hays AP., 2006, Mitochondrial Medicine, P45
   HIRANO M, 1994, J CHILD NEUROL, V9, P4, DOI 10.1177/088307389400900102
   HIRANO M, 1992, NEUROMUSCULAR DISORD, V2, P125, DOI 10.1016/0960-8966(92)90045-8
   Hirano M., 2006, Mitochondrial Medicine, P27
   MATSUOKA T, 1992, CLIN NEUROL, V32, P645
   McFarland R, 2002, NAT GENET, V30, P145, DOI 10.1038/ng819
   MIZUKAMI K, 1992, ACTA NEUROPATHOL, V83, P449, DOI 10.1007/BF00713541
   MORAES CT, 1993, NEUROMUSCULAR DISORD, V3, P43, DOI 10.1016/0960-8966(93)90040-Q
   OHAMA E, 1987, ACTA NEUROPATHOL, V74, P226, DOI 10.1007/BF00688185
   Ohshita T, 2000, NEURORADIOLOGY, V42, P651, DOI 10.1007/s002340000335
   Sacconi S, 2002, ARCH NEUROL-CHICAGO, V59, P1013, DOI 10.1001/archneur.59.6.1013
   SPRINZI M, 1989, NUCLEIC ACIDS RES, pR1
   Tanji K, 2003, ACTA NEUROPATHOL, V105, P69, DOI 10.1007/s00401-002-0604-y
   Tanji K, 2001, SEMIN CELL DEV BIOL, V12, P429, DOI 10.1006/scdb.2001.0280
   Taylor RW, 1996, ANN NEUROL, V40, P459, DOI 10.1002/ana.410400318
   Tiranti V, 1998, ANN NEUROL, V43, P98, DOI 10.1002/ana.410430116
   Yoneda M, 1999, NEUROLOGY, V53, P2182, DOI 10.1212/WNL.53.9.2182
NR 25
TC 15
Z9 17
U1 1
U2 2
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 1878-5883
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD JUL 15
PY 2008
VL 270
IS 1-2
BP 23
EP 27
DI 10.1016/j.jns.2008.01.016
PG 5
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 323ZE
UT WOS:000257486500004
PM 18314141
OA Green Accepted
DA 2024-11-01
ER

PT J
AU Gill, JS
   Hardy, SA
   Blakely, EL
   Hopton, S
   Nemeth, AH
   Fratter, C
   Poulton, J
   Taylor, RW
   Downes, SM
AF Gill, Jaidip S.
   Hardy, Steven A.
   Blakely, Emma L.
   Hopton, Sila
   Nemeth, Andrea H.
   Fratter, Carl
   Poulton, Joanna
   Taylor, Robert W.
   Downes, Susan M.
TI Pigmentary retinopathy, rod-cone dysfunction and sensorineural deafness
   associated with a rare mitochondrial tRNA<SUP>Lys</SUP> (m.8340G&gt;A)
   gene variant
SO BRITISH JOURNAL OF OPHTHALMOLOGY
LA English
DT Article
ID TRANSFER-RNA MUTATIONS; DNA MUTATIONS; RETINAL DYSTROPHY; POINT
   MUTATIONS; HUMAN-DISEASE; PATHOGENICITY; PREVALENCE; MYOPATHY
AB Background/Aim The rare mitochondrial DNA (mtDNA) variant m.8340G>A has been previously reported in the literature in a single, sporadic case of mitochondrial myopathy. In this report, we aim to investigate the case of a 39-year-old male patient with sensorineural deafness who presented to the eye clinic with nyctalopia, retinal pigmentary changes and bilateral cortical cataracts.
   Methods The patient was examined clinically and investigated with autofluorescence, full-field electroretinography, electro-oculogram and dark adaptometry. Sequencing of the mitochondrial genome in blood and muscle tissue was followed by histochemical and biochemical analyses together with single fibre studies of a muscle biopsy to confirm a mitochondrial aetiology.
   Results Electrophysiology, colour testing and dark adaptometry showed significant photoreceptor dysfunction with macular involvement. Sequencing the complete mitochondrial genome revealed a rare mitochondrial tRNALys (MTTK) gene variantm. 8340G>A-which was heteroplasmic in blood (11%) and skeletal muscle (65%) and cosegregated with cytochrome c oxidase-deficient fibres in single-fibre studies.
   Conclusion We confirm the pathogenicity of the rare mitochondrial m. 8340G>A variant the basis of single-fibre segregation studies and its association with an expanded clinical phenotype. Our case expands the phenotypic spectrum of diseases associated with mitochondrial tRNA point mutations, highlighting the importance of considering a mitochondrial diagnosis in similar cases presenting to the eye clinic and the importance of further genetic testing if standard mutational analysis does not yield a result.
C1 [Gill, Jaidip S.; Downes, Susan M.] John Radcliffe Hosp, Oxford, England.
   [Hardy, Steven A.; Blakely, Emma L.; Hopton, Sila; Taylor, Robert W.] Newcastle Univ, Inst Neurosci, Wellcome Trust Ctr Mitochondrial Res, Newcastle Upon Tyne, Tyne & Wear, England.
   [Nemeth, Andrea H.; Poulton, Joanna] Churchill Hosp, Dept Clin Genet, Oxford, England.
   [Nemeth, Andrea H.; Downes, Susan M.] John Radcliffe Hosp, Nuffield Dept Clin Neurosci, Oxford, England.
   [Fratter, Carl] Churchill Hosp, Oxford Med Genet Lab, Oxford, England.
C3 University of Oxford; Newcastle University - UK; University of Oxford;
   University of Oxford; University of Oxford
RP Downes, SM (corresponding author), John Radcliffe Hosp, Oxford Eye Hosp, West Wing, Oxford OX3 9DU, England.
EM susan.downes@eye.ox.ac.uk
RI Poulton, Joanna/AAB-4828-2021; Nemeth, Andrea/AGJ-1121-2022
OI Nemeth, Andrea/0000-0002-2941-7657; Poulton, Joanna/0000-0002-2460-5587
FU Medical Research Council [G0601943] Funding Source: Medline; Wellcome
   Trust [096919/Z/11/Z] Funding Source: Medline; MRC [G0601943] Funding
   Source: UKRI
CR Al-Enezi M, 2008, MIDDLE EAST AFR J OP, V15, P81, DOI 10.4103/0974-9233.51998
   Bellmann C, 2004, INVEST OPHTH VIS SCI, V45, P2355, DOI 10.1167/iovs.03-1090
   Blakely EL, 2013, HUM MUTAT, V34, P1260, DOI 10.1002/humu.22358
   Daruich A, 2014, BMC OPHTHALMOL, V14, DOI 10.1186/1471-2415-14-77
   de Laat P, 2013, OPHTHALMOLOGY, V120, P2684, DOI 10.1016/j.ophtha.2013.05.013
   Gorman GS, 2015, ANN NEUROL, V77, P753, DOI 10.1002/ana.24362
   Jarc-Vidmar M, 2015, DOC OPHTHALMOL, V130, P179, DOI 10.1007/s10633-015-9489-7
   Jeppesen TD, 2014, NEUROMUSCULAR DISORD, V24, P162, DOI 10.1016/j.nmd.2013.08.004
   Lott Marie T, 2013, Curr Protoc Bioinformatics, V44, DOI 10.1002/0471250953.bi0123s44
   Massin P, 1999, OPHTHALMOLOGY, V106, P1821, DOI 10.1016/S0161-6420(99)90356-1
   McFarland R, 2004, TRENDS GENET, V20, P591, DOI 10.1016/j.tig.2004.09.014
   Park SB, 2004, YONSEI MED J, V45, P727, DOI 10.3349/ymj.2004.45.4.727
   Rocha MC, 2015, SCI REP-UK, V5, DOI 10.1038/srep15037
   SILVESTRI G, 1992, AM J HUM GENET, V51, P1213
   Smith PR, 1999, OPHTHALMOLOGY, V106, P1101, DOI 10.1016/S0161-6420(99)90244-0
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Tuppen HAL, 2010, BBA-BIOENERGETICS, V1797, P113, DOI 10.1016/j.bbabio.2009.09.005
   van Oven M, 2009, HUM MUTAT, V30, pE386, DOI 10.1002/humu.20921
   Yarham JW, 2012, MITOCHONDRION, V12, P533, DOI 10.1016/j.mito.2012.06.009
   Yarham JW, 2011, HUM MUTAT, V32, P1319, DOI 10.1002/humu.21575
NR 20
TC 6
Z9 6
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0007-1161
EI 1468-2079
J9 BRIT J OPHTHALMOL
JI Br. J. Ophthalmol.
PD SEP
PY 2017
VL 101
IS 9
BP 1298
EP 1302
DI 10.1136/bjophthalmol-2017-310370
PG 5
WC Ophthalmology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Ophthalmology
GA FE5BJ
UT WOS:000408226700026
PM 28729369
OA hybrid, Green Published, Green Submitted
DA 2024-11-01
ER

PT J
AU Swalwell, H
   Blakely, EL
   Sutton, R
   Tonska, K
   Elstner, M
   He, L
   Taivassalo, T
   Burns, DK
   Turnbull, DM
   Haller, RG
   Davidson, MM
   Taylor, RW
AF Swalwell, Helen
   Blakely, Emma L.
   Sutton, Ruth
   Tonska, Kasia
   Elstner, Matthias
   He, Langping
   Taivassalo, Tanja
   Burns, Dennis K.
   Turnbull, Douglass M.
   Haller, Ronald G.
   Davidson, Mercy M.
   Taylor, Robert W.
TI A homoplasmic mtDNA variant can influence the phenotype of the
   pathogenic m.7472Cins <i>MTTS1</i> mutation:: are two mutations better
   than one?
SO EUROPEAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
DE mitochondrial DNA; tRNA mutation; heteroplasmy; cybrid analysis;
   homoplasmic variant
ID MITOCHONDRIAL GENOME DATABASE; INHERITED HEARING-LOSS; 7472INSC
   MUTATION; POINT MUTATION; DNA MUTATIONS; TRNA(SER(UCN)); GENE;
   DEHYDROGENASE; CELLS
AB Mutations in mitochondrial tRNA (mt-tRNA) genes are well recognized as a common cause of human disease, exhibiting a significant degree of clinical heterogeneity. While these differences are explicable, in part, by differences in the innate pathogenicity of the mutation, its distribution and abundance, other factors, including nuclear genetic background, mitochondrial DNA (mtDNA) haplotype and additional mtDNA mutations may influence the expression of mt-tRNA mutations. We describe the clinical, biochemical and molecular findings in a family with progressive myopathy, deafness and diabetes and striking respiratory chain abnormalities due to a well-characterized heteroplasmic mt-tRNA mutation in the mt-tRNA(Ser(UCN)) (MTTS1) gene. In addition to the m.7472Cins mutation, all individuals were homoplasmic for another variant, m.7472>C, affecting the adjacent nucleotide in the mt-tRNA(Ser(UCN)) structure. In addition to available patient tissues, we have analysed transmitochondrial cybrid clones harbouring homoplasmic levels of m.7472>C and varying levels of the m.7472Cins mutation in an attempt to clarify the precise role of the m.7472A>C transversion in the underlying respiratory chain abnormality. Evidence from both in vivo and in vitro studies demonstrate that the m.7472A>C is able to modify the expression of the m.7472Cins mutation and would suggest that it is not a neutral variant but appears to cause a biochemical defect by itself, confirming that homoplasmic mtDNA variants can modulate the phenotypic expression of pathogenic, heteroplasmic mtDNA mutations.
C1 [Swalwell, Helen; Blakely, Emma L.; Tonska, Kasia; Elstner, Matthias; He, Langping; Turnbull, Douglass M.; Taylor, Robert W.] Newcastle Univ, Sch Med, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Sutton, Ruth; Turnbull, Douglass M.; Taylor, Robert W.] Newcastle Univ, Inst Human Genet, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Tonska, Kasia] Univ Warsaw, Dept Genet & Biotechnol, Warsaw, Poland.
   [Elstner, Matthias] Univ Munich, Dept Neurol, D-8000 Munich, Germany.
   [Taivassalo, Tanja] McGill Univ, Dept Kinesiol & Phys Educ, Montreal, PQ, Canada.
   [Burns, Dennis K.] Univ Texas SW Med Ctr Dallas, Dept Pathol, Dallas, TX 75390 USA.
   [Haller, Ronald G.] Presbyterian Med Ctr, Inst Exercise & Environm Med, Neuromuscular Ctr, Dallas, TX USA.
   [Haller, Ronald G.] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA.
   [Haller, Ronald G.] VA Med Ctr, Dallas, TX USA.
   [Davidson, Mercy M.] Columbia Univ, Dept Neurol, Coll Phys & Surg, New York, NY USA.
C3 Newcastle University - UK; Newcastle University - UK; University of
   Warsaw; University of Munich; McGill University; University of Texas
   System; University of Texas Southwestern Medical Center Dallas;
   University of Texas System; University of Texas Southwestern Medical
   Center Dallas; Columbia University
RP Taylor, RW (corresponding author), Newcastle Univ, Sch Med, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM r.w.taylor@ncl.ac.uk
OI Tonska, Katarzyna/0000-0002-1793-6089
FU Muscular Dystrophy Association; United Mitochondrial Disease Foundation;
   US National Institutes of Health; Wellcome Trust, Muscular Dystrophy
   Campaign and Newcastle upon Tyne Hospitals NHS Foundation Trust
FX We thank Christine Hayes, Karen Ayyad, Nadine Romain and Winsome Walker
   for excellent technical assistance. This work was supported by grants
   from the Muscular Dystrophy Association and the United Mitochondrial
   Disease Foundation (to TT and RGH), the US National Institutes of Health
   (to MMD) and The Wellcome Trust, Muscular Dystrophy Campaign and
   Newcastle upon Tyne Hospitals NHS Foundation Trust (to DMT and RWT).
CR Brandon MC, 2005, NUCLEIC ACIDS RES, V33, pD611
   Brown MD, 2002, HUM GENET, V110, P130, DOI 10.1007/s00439-001-0660-8
   Cardaioli E, 2006, NEUROMUSCULAR DISORD, V16, P26, DOI 10.1016/j.nmd.2005.11.001
   Chomyn A, 1996, Methods Enzymol, V264, P197, DOI 10.1016/S0076-6879(96)64020-8
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   El Meziane A, 1998, NAT GENET, V18, P350
   Fetoni V, 2004, NEUROMUSCULAR DISORD, V14, P723, DOI 10.1016/j.nmd.2004.07.002
   Guan MX, 1998, MOL CELL BIOL, V18, P5868, DOI 10.1128/MCB.18.10.5868
   Hutchin TP, 2000, J MED GENET, V37, P692, DOI 10.1136/jmg.37.9.692
   Ingman M, 2006, NUCLEIC ACIDS RES, V34, pD749, DOI 10.1093/nar/gkj010
   Jaksch M, 1998, ANN NEUROL, V44, P635, DOI 10.1002/ana.410440409
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   Kirby DM, 2007, METHOD CELL BIOL, V80, P93, DOI 10.1016/S0091-679X(06)80004-X
   OLD SL, 1989, HISTOCHEM J, V21, P545, DOI 10.1007/BF01753355
   Pulkes T, 2005, NEUROMUSCULAR DISORD, V15, P364, DOI 10.1016/j.nmd.2005.01.006
   Pye D, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl516
   Qu J, 2006, INVEST OPHTH VIS SCI, V47, P475, DOI 10.1167/iovs.05-0665
   REID FM, 1994, HUM MUTAT, V3, P243, DOI 10.1002/humu.1380030311
   Schuelke M, 1998, ANN NEUROL, V44, P700, DOI 10.1002/ana.410440420
   Sue CM, 1999, NEUROLOGY, V52, P1905, DOI 10.1212/WNL.52.9.1905
   Taivassalo T, 2003, BRAIN, V126, P413, DOI 10.1093/brain/awg028
   Taylor RW, 2005, NAT REV GENET, V6, P389, DOI 10.1038/nrg1606
   Taylor RW, 2003, J AM COLL CARDIOL, V41, P1786, DOI 10.1016/S0735-1097(03)00300-0
   Taylor RW, 2001, NUCLEIC ACIDS RES, V29, part. no., DOI 10.1093/nar/29.15.e74
   TIRANTI V, 1995, HUM MOL GENET, V4, P1421, DOI 10.1093/hmg/4.8.1421
   Toompuu M, 1999, HUM MOL GENET, V8, P2275, DOI 10.1093/hmg/8.12.2275
   Toompuu M, 2004, BIOCHEM BIOPH RES CO, V322, P803, DOI 10.1016/j.bbrc.2004.07.181
   Toompuu M, 2002, J BIOL CHEM, V277, P22240, DOI 10.1074/jbc.M200338200
   Verhoeven K, 1999, EUR J HUM GENET, V7, P45, DOI 10.1038/sj.ejhg.5200247
NR 29
TC 25
Z9 27
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1018-4813
EI 1476-5438
J9 EUR J HUM GENET
JI Eur. J. Hum. Genet.
PD OCT
PY 2008
VL 16
IS 10
BP 1265
EP 1274
DI 10.1038/ejhg.2008.65
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 352MV
UT WOS:000259502200018
PM 18398437
OA Bronze
DA 2024-11-01
ER

PT J
AU Palmieri, L
   Alberio, S
   Pisano, I
   Lodi, T
   Meznaric-Petrusa, M
   Zidar, J
   Santoro, A
   Scarcia, P
   Fontanesi, F
   Lamantea, E
   Ferrero, I
   Zeviani, M
AF Palmieri, L
   Alberio, S
   Pisano, I
   Lodi, T
   Meznaric-Petrusa, M
   Zidar, J
   Santoro, A
   Scarcia, P
   Fontanesi, F
   Lamantea, E
   Ferrero, I
   Zeviani, M
TI Complete loss-of-function of the heart/muscle-specific adenine
   nucleotide translocator is associated with mitochondrial myopathy and
   cardiomyopathy
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; POLYMERASE-GAMMA-A; ADP/ATP
   CARRIER; SACCHAROMYCES-CEREVISIAE; AUTOSOMAL-DOMINANT; BACTERIAL
   EXPRESSION; OXIDATIVE-PHOSPHORYLATION; TISSUE DISTRIBUTION; YEAST
   MITOCHONDRIA; GENE MUTATION
AB Multiple mitochondrial DNA deletions are associated with clinically heterogeneous disorders transmitted as mendelian traits. Dominant missense mutations were found in the gene encoding the heart and skeletal muscle-specific isoform of the adenine nucleotide translocator (ANT1) in families with autosomal dominant progressive external opthalmoplegia and in a sporadic patient. We herein report on a sporadic patient who presented with hypertrophic cardiomyopathy, mild myopathy with exercise intolerance and lactic acidosis but no ophthalmoplegia. A muscle biopsy showed the presence of numerous ragged-red fibers, and Southern blot analysis disclosed multiple deletions of muscle mitochondrial DNA. Molecular analysis revealed a C to A homozygous mutation at nucleotide 368 of the ANT1 gene. The mutation converted a highly conserved alanine into an aspartic acid at codon 123 and was absent in 500 control individuals. This is the first report of a recessive mutation in the ANT1 gene. The clinical and biochemical features are different from those found in dominant ANT1 mutations, resembling those described in ANT1 knockout mice. No ATP uptake was measured in proteoliposomes reconstituted with protein extracts from the patient's muscle. The equivalent mutation in AAC2, the yeast ortholog of human ANT1, resulted in a complete loss of transport activity and in the inability to rescue the severe Oxidative Phosphorylation phenotype displayed by WB-12, an AAC1/AAC2 defective strain. Interestingly, exposure to reactive oxygen species (ROS) scavengers dramatically increased the viability of the WB-12 transformant, suggesting that increased redox stress is involved in the pathogenesis of the disease and that anti-ROS therapy may be beneficial to patients.
C1 Ist Nazl Neurol Carlo Besta, Div Neurogenet Mol, I-20126 Milan, Italy.
   Univ Bari, Dept Pharmacobiol, Biochem & Mol Biol Lab, I-70125 Bari, Italy.
   CNR, Inst Biomembranes & Bioenerget, I-70125 Bari, Italy.
   Univ Parma, Dept Genet Anthropol Evolut, I-43100 Parma, Italy.
   Univ Med Ctr, Dept Neurol, Ljubljana, Slovenia.
   Univ Med Ctr, Dept Anat, Ljubljana, Slovenia.
C3 Fondazione IRCCS Istituto Neurologico Carlo Besta; Universita degli
   Studi di Bari Aldo Moro; Consiglio Nazionale delle Ricerche (CNR);
   University of Parma; University Medical Centre Ljubljana; University
   Medical Centre Ljubljana
RP Ist Nazl Neurol Carlo Besta, Div Neurogenet Mol, Via Temolo 4, I-20126 Milan, Italy.
EM zeviani@istituto-besta.it
RI Zeviani, Massimo/K-2891-2014; Scarcia, Pasquale/O-9550-2019; Lamantea,
   Eleonora/J-8339-2016; Lodi, Tiziana/A-5993-2012; Meznaric,
   Marija/A-5112-2016; Scarcia, Pasquale/A-8830-2010
OI Zeviani, Massimo/0000-0002-9067-5508; Lamantea,
   Eleonora/0000-0001-5090-6028; Fontanesi, Flavia/0000-0003-0509-3835;
   Lodi, Tiziana/0000-0002-7294-8971; Santoro,
   Antonella/0000-0002-6193-2050; Meznaric, Marija/0000-0002-5907-6929;
   Scarcia, Pasquale/0000-0001-6216-0411; PISANO,
   Isabella/0000-0003-0728-2226
FU Telethon [GGP030039] Funding Source: Medline
CR [Anonymous], METHOD ENZYMOL
   Bauer MKA, 1999, J CELL BIOL, V147, P1493, DOI 10.1083/jcb.147.7.1493
   BENNETZEN JL, 1982, J BIOL CHEM, V257, P3026
   BONNEAUD N, 1991, YEAST, V7, P609, DOI 10.1002/yea.320070609
   BULDER CJE, 1964, ANTON VAN LEE J M S, V30, P442, DOI 10.1007/BF02046758
   Chen XJ, 2004, GENETICS, V167, P607, DOI 10.1534/genetics.103.023655
   Curran AR, 2003, CURR OPIN STRUC BIOL, V13, P412, DOI 10.1016/S0959-440X(03)00102-7
   Deschauer M, 2005, NEUROMUSCULAR DISORD, V15, P311, DOI 10.1016/j.nmd.2004.12.004
   Dolce V, 2005, FEBS LETT, V579, P633, DOI 10.1016/j.febslet.2004.12.034
   Doudican NA, 2005, MOL CELL BIOL, V25, P5196, DOI 10.1128/MCB.25.12.5196-5204.2005
   Dujon B., 1981, MOL BIOL YEAST SACCH, P505
   Dyall SD, 2003, J BIOL CHEM, V278, P26757, DOI 10.1074/jbc.M302700200
   Esposito LA, 1999, P NATL ACAD SCI USA, V96, P4820, DOI 10.1073/pnas.96.9.4820
   Fagiolari G, 2002, MUSCLE NERVE, V26, P265, DOI 10.1002/mus.10172
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Fiermonte G, 2004, J BIOL CHEM, V279, P30722, DOI 10.1074/jbc.M400445200
   FIERMONTE G, 1993, BIOCHEM J, V294, P293, DOI 10.1042/bj2940293
   Fiore C, 1998, BIOCHIMIE, V80, P137, DOI 10.1016/S0300-9084(98)80020-5
   Fontanesi F, 2004, HUM MOL GENET, V13, P923, DOI 10.1093/hmg/ddh108
   Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226
   Hashimoto M, 1999, BBA-BIOENERGETICS, V1409, P113, DOI 10.1016/S0005-2728(98)00155-8
   Jordens EZ, 2002, ANN NEUROL, V52, P95, DOI 10.1002/ana.10214
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   KLINGENBERG M, 1989, ARCH BIOCHEM BIOPHYS, V270, P1, DOI 10.1016/0003-9861(89)90001-5
   Komaki H, 2002, ANN NEUROL, V51, P645, DOI 10.1002/ana.10172
   KOVACOVA V, 1968, BIOCHIM BIOPHYS ACTA, V162, P157, DOI 10.1016/0005-2728(68)90097-2
   KRAMER R, 1979, BIOCHEMISTRY-US, V18, P4209
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   MacKenzie KR, 1997, SCIENCE, V276, P131, DOI 10.1126/science.276.5309.131
   Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027
   McKenzie M, 2004, NEUROCHEM RES, V29, P589, DOI 10.1023/B:NERE.0000014829.42364.dd
   Napoli L, 2001, NEUROLOGY, V57, P2295, DOI 10.1212/WNL.57.12.2295
   OGUR M, 1957, SCIENCE, V125, P928, DOI 10.1126/science.125.3254.928
   Palmieri F, 1995, METHOD ENZYMOL, V260, P349, DOI 10.1016/0076-6879(95)60150-3
   Pebay-Peyroula E, 2003, NATURE, V426, P39, DOI 10.1038/nature02056
   Schroers A, 1998, J BIOL CHEM, V273, P14269, DOI 10.1074/jbc.273.23.14269
   Siciliano G, 2003, NEUROMUSCULAR DISORD, V13, P162, DOI 10.1016/S0960-8966(02)00221-3
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Tiranti V, 1999, HUM MOL GENET, V8, P2533, DOI 10.1093/hmg/8.13.2533
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
NR 40
TC 139
Z9 147
U1 0
U2 7
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD OCT 15
PY 2005
VL 14
IS 20
BP 3079
EP 3088
DI 10.1093/hmg/ddi341
PG 10
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 972AG
UT WOS:000232425600013
PM 16155110
DA 2024-11-01
ER

PT J
AU Dobrowolski, SF
   Gray, J
   Miller, T
   Sears, M
AF Dobrowolski, Steven F.
   Gray, Jesse
   Miller, Trent
   Sears, Mitch
TI Identifying Sequence Variants in the Human Mitochondrial Genome Using
   High-Resolution Melt (HRM) Profiling
SO HUMAN MUTATION
LA English
DT Article
DE melt profiling; HRM; HRMA; mitochondria; heteroplasmy; MERRF; MELAS
ID SINGLE-NUCLEOTIDE POLYMORPHISMS; POLYMERASE-CHAIN-REACTION; POINT
   MUTATIONS; COLORECTAL-CANCER; RAPID DETECTION; SMALL AMPLICONS; DNA
   MUTATIONS; GENE; DISORDERS; EGFR
AB Identifying mitochondrial DNA (mtDNA) sequence variants in human diseases is complicated. Many pathological mutations are heteroplasmic, with the mutant allele represented at highly variable percentages. High-resolution melt (HRM or HRMA) profiling was applied to comprehensive assessment of the mitochondrial genome and targeted assessment of recognized pathological mutations. The assay panel providing comprehensive coverage of the mitochondrial genome utilizes 36 overlapping fragment (301-658bp) that employ a common PCR protocol. The comprehensive assay identified heteroplasmic mutation in 33 out of 33 patient specimens tested. Allele fraction among the specimens ranged from 1 to 100%. The comprehensive assay panel was also used to assess 125 mtDNA specimens from healthy donors, which identified 431 unique sequence variants. Utilizing the comprehensive mtDNA panel, the mitochondrial genome of a patient specimen may be assessed in less than I day using a single 384-well plate or two 96-well plates. Specific assays were used to identify the myopathy, encephalopathy, lactic acidosis and stroke-like episodes (MELAS) mutation m.3243A>G, myoclonus epilepsy, ragged red fibers (MERRF) mutation m.8344A>G, and m.1555A>G associated with aminoglycoside hearing loss. These assays employ a calibrated, amplicon-based strategy that is exceedingly simple in design, utilization, and interpretation, yet provides sensitivity to detect variants at and below 10% heteroplasmy. Turnaround time for the genotyping tests is about 1 hr. Hum Mutat 30, 891-898, 2009. (C) 2009 Wiley-Liss, Inc.
C1 [Dobrowolski, Steven F.; Gray, Jesse; Miller, Trent] Idaho Technol, Salt Lake City, UT 84108 USA.
   [Sears, Mitch] ARUP Labs, Salt Lake City, UT USA.
C3 Utah System of Higher Education; University of Utah; ARUP Laboratories
RP Dobrowolski, SF (corresponding author), Idaho Technol, 390 Wakara Way, Salt Lake City, UT 84108 USA.
EM steven_dobrowolski@idahotech.com
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andreu AL, 2003, J NEUROL, V250, P1403, DOI 10.1007/s00415-003-0281-3
   Bastien R, 2008, HUM MUTAT, V29, P757, DOI 10.1002/humu.20726
   De Leeneer K, 2008, CLIN CHEM, V54, P982, DOI 10.1373/clinchem.2007.098764
   Do H, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-142
   Dobrowolski SE, 2005, HUM MUTAT, V25, P306, DOI 10.1002/humu.20137
   Dobrowolski SF, 2007, HUM MUTAT, V28, P1133, DOI 10.1002/humu.20558
   Dobrowolski SF, 2007, MOL GENET METAB, V91, P218, DOI 10.1016/j.ymgme.2007.03.010
   Elliott HR, 2008, AM J HUM GENET, V83, P254, DOI 10.1016/j.ajhg.2008.07.004
   Erali M, 2008, EXP MOL PATHOL, V85, P50, DOI 10.1016/j.yexmp.2008.03.012
   Fan AXC, 2008, CLIN CHEM LAB MED, V46, P299, DOI 10.1515/CCLM.2008.071
   Fukui T, 2008, CLIN CANCER RES, V14, P4751, DOI 10.1158/1078-0432.CCR-07-5207
   Gundry CN, 2008, NUCLEIC ACIDS RES, V36, P3401, DOI 10.1093/nar/gkn204
   Hatsch D, 2007, J FORENSIC SCI, V52, P891, DOI 10.1111/j.1556-4029.2007.00473.x
   Laurie AD, 2009, CLIN BIOCHEM, V42, P528, DOI 10.1016/j.clinbiochem.2008.11.015
   Liew M, 2004, CLIN CHEM, V50, P1156, DOI 10.1373/clinchem.2004.032136
   MCKINNEY JT, 2007, ANN M AM SOC HUM GEN, P23
   Mithani SK, 2007, CLIN CANCER RES, V13, P7335, DOI 10.1158/1078-0432.CCR-07-0220
   Montgomery J, 2007, NAT PROTOC, V2, P59, DOI 10.1038/nprot.2007.10
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Palais RA, 2005, ANAL BIOCHEM, V346, P167, DOI 10.1016/j.ab.2005.08.010
   Simi L, 2008, AM J CLIN PATHOL, V130, P247, DOI 10.1309/LWDY1AXHXUULNVHQ
   Sternberg D, 1998, HUM MOL GENET, V7, P33, DOI 10.1093/hmg/7.1.33
   Takano T, 2008, J CLIN ONCOL, V26, P5589, DOI 10.1200/JCO.2008.16.7254
   Tobe SS, 2008, FORENSIC SCI INT-GEN, V2, P249, DOI 10.1016/j.fsigen.2008.03.002
   van den Bosch BJC, 2000, NUCLEIC ACIDS RES, V28, DOI 10.1093/nar/28.20.e89
   van Eijsden RGE, 2006, GENET MED, V8, P620, DOI 10.1097/01.gim.0000237782.94878.05
   Wang JY, 2008, J ZHEJIANG UNIV-SC B, V9, P610, DOI 10.1631/jzus.B0820058
   Wang L, 2008, CANCER EPIDEM BIOMAR, V17, P3558, DOI 10.1158/1055-9965.EPI-08-0434
   Webb E, 2008, BRIT J CANCER, V99, P2088, DOI 10.1038/sj.bjc.6604805
   White HE, 2005, GENET TEST, V9, P190, DOI 10.1089/gte.2005.9.190
   Wittwer CT, 2003, CLIN CHEM, V49, P853, DOI 10.1373/49.6.853
   Wong Lee-Jun C., 2006, V335, P187
   Wong LJC, 2007, MITOCHONDRION, V7, P45, DOI 10.1016/j.mito.2006.11.025
   Wong Lee-Jun C., 2006, V336, P135
   Wong LJC, 1997, CLIN CHEM, V43, P1857
   Wong LJC, 2004, ELECTROPHORESIS, V25, P2602, DOI 10.1002/elps.200406016
   Wong LJC, 2002, CLIN CHEM, V48, P1901
   Zhou LM, 2004, CLIN CHEM, V50, P1328, DOI 10.1373/clinchem.2004.034322
NR 39
TC 60
Z9 65
U1 0
U2 7
PU WILEY-LISS
PI HOBOKEN
PA DIV JOHN WILEY & SONS INC, 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 1059-7794
J9 HUM MUTAT
JI Hum. Mutat.
PD JUN
PY 2009
VL 30
IS 6
BP 891
EP 898
DI 10.1002/humu.21003
PG 8
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 466BJ
UT WOS:000267635100006
PM 19370763
OA gold
DA 2024-11-01
ER

PT J
AU Wallace, DC
   Fan, WW
AF Wallace, Douglas C.
   Fan, WeiWei
TI The pathophysiology of mitochondrial disease as modeled in the mouse
SO GENES & DEVELOPMENT
LA English
DT Review
DE Mitochondrion; mtDNA; OXPHOS dysfunction; mitochondrial disease; mouse
   model
ID CYTOCHROME-C-OXIDASE; HEREDITARY OPTIC NEUROPATHY; PROGRESSIVE EXTERNAL
   OPHTHALMOPLEGIA; ADENINE-NUCLEOTIDE TRANSLOCATOR;
   FOLLICLE-STIMULATING-HORMONE; DYNAMIN-RELATED PROTEIN; BROWN
   ADIPOSE-TISSUE; MTDNA CONTROL-REGION; DNA DELETION LEVELS;
   CHLORAMPHENICOL RESISTANCE
AB It is now clear that mitochondrial defects are associated with a plethora of clinical phenotypes in man and mouse. This is the result of the mitochondria's central role in energy production, reactive oxygen species (ROS) biology, and apoptosis, and because the mitochondrial genome consists of roughly 1500 genes distributed across the maternal mitochondrial DNA (mtDNA) and the Mendelian nuclear DNA (nDNA). While numerous pathogenic mutations in both mtDNA and nDNA mitochondrial genes have been identified in the past 21 years, the causal role of mitochondrial dysfunction in the common metabolic and degenerative diseases, cancer, and aging is still debated. However, the development of mice harboring mitochondrial gene mutations is permitting demonstration of the direct cause-and-effect relationship between mitochondrial dysfunction and disease. Mutations in nDNA-encoded mitochondrial genes involved in energy metabolism, antioxidant defenses, apoptosis via the mitochondrial permeability transition pore (mtPTP), mitochondrial fusion, and mtDNA biogenesis have already demonstrated the phenotypic importance of mitochondrial defects. These studies are being expanded by the recent development of procedures for introducing mtDNA mutations into the mouse. These studies are providing direct proof that mtDNA mutations are sufficient by themselves to generate major clinical phenotypes. As more different mtDNA types and mtDNA gene mutations are introduced into various mouse nDNA backgrounds, the potential functional role of mtDNA variation in permitting humans and mammals to adapt to different environments and in determining their predisposition to a wide array of diseases should be definitively demonstrated.
C1 [Wallace, Douglas C.; Fan, WeiWei] Univ Calif Irvine, Org Res Unit Mol & Mitochondrial Med & Genet, Irvine, CA 92697 USA.
C3 University of California System; University of California Irvine
RP Wallace, DC (corresponding author), Univ Calif Irvine, Org Res Unit Mol & Mitochondrial Med & Genet, Irvine, CA 92697 USA.
EM dwallace@uci.edu
RI Fan, Weiwei/B-3782-2010
FU NIH [NS21328, AG24373, DK73691, AG13154, AG16573]; CIRM Comprehensive
   [RC1-00353-1]; Doris Duke Clinical Interfaces Award 2005
FX This work has been supported by NIH grants NS21328, AG24373, DK73691,
   AG13154, and AG16573; a CIRM Comprehensive Grant RC1-00353-1; a Doris
   Duke Clinical Interfaces Award 2005 awarded to D. C. W.; and a CIRM
   Predoctoral Fellowship awarded to W. F.
CR Acín-Pérez R, 2004, MOL CELL, V13, P805, DOI 10.1016/S1097-2765(04)00124-8
   Acín-Pérez R, 2003, HUM MOL GENET, V12, P329, DOI 10.1093/hmg/ddg021
   Agostino A, 2003, HUM MOL GENET, V12, P399, DOI 10.1093/hmg/ddg038
   Alavi MV, 2007, BRAIN, V130, P1029, DOI 10.1093/brain/awm005
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Anflous K, 2001, J BIOL CHEM, V276, P1954, DOI 10.1074/jbc.M006587200
   Antonicka H, 2003, HUM MOL GENET, V12, P2693, DOI 10.1093/hmg/ddg284
   Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565
   AVISE JC, 1979, GENETICS, V92, P279
   Bai RK, 2007, CANCER RES, V67, P4687, DOI 10.1158/0008-5472.CAN-06-3554
   Bai YD, 1998, EMBO J, V17, P4848, DOI 10.1093/emboj/17.16.4848
   Bai YD, 2000, MOL CELL BIOL, V20, P805, DOI 10.1128/MCB.20.3.805-815.2000
   Baines CP, 2007, NAT CELL BIOL, V9, P550, DOI 10.1038/ncb1575
   Baines CP, 2005, NATURE, V434, P658, DOI 10.1038/nature03434
   BALLINGER SW, 1992, NAT GENET, V1, P11, DOI 10.1038/ng0492-11
   BALLINGER SW, 1994, NAT GENET, V7, P458, DOI 10.1038/ng0894-458
   Basso E, 2005, J BIOL CHEM, V280, P18558, DOI 10.1074/jbc.C500089200
   Baudouin SV, 2005, LANCET, V366, P2118, DOI 10.1016/S0140-6736(05)67890-7
   Bender A, 2006, NAT GENET, V38, P515, DOI 10.1038/ng1769
   BLANC H, 1981, P NATL ACAD SCI-BIOL, V78, P3789, DOI 10.1073/pnas.78.6.3789
   BLANC H, 1981, NUCLEIC ACIDS RES, V9, P5785, DOI 10.1093/nar/9.21.5785
   Booker LM, 2006, J UROLOGY, V175, P468, DOI 10.1016/S0022-5347(05)00163-1
   Brandon M, 2006, ONCOGENE, V25, P4647, DOI 10.1038/sj.onc.1209607
   Brower JV, 2007, J BIOL CHEM, V282, P29658, DOI 10.1074/jbc.M704386200
   Brown MD, 2002, HUM GENET, V110, P130, DOI 10.1007/s00439-001-0660-8
   Brown MD, 1997, AM J HUM GENET, V60, P381
   BROWN MD, 1995, HUM MUTAT, V6, P311, DOI 10.1002/humu.1380060405
   BUNN CL, 1977, SOMAT CELL GENET, V3, P71, DOI 10.1007/BF01550988
   BUNN CL, 1974, P NATL ACAD SCI USA, V71, P1681, DOI 10.1073/pnas.71.5.1681
   Cai JY, 2000, FREE RADICAL BIO MED, V29, P334, DOI 10.1016/S0891-5849(00)00312-9
   Carrieri G, 2001, HUM GENET, V108, P194, DOI 10.1007/s004390100463
   Carrozzo R, 2007, BRAIN, V130, P862, DOI 10.1093/brain/awl389
   Chagnon P, 1999, AM J MED GENET, V85, P20, DOI 10.1002/(SICI)1096-8628(19990702)85:1<20::AID-AJMG6>3.0.CO;2-K
   Chen HC, 2005, J BIOL CHEM, V280, P26185, DOI 10.1074/jbc.M503062200
   Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046
   Chen HC, 2007, CELL, V130, P548, DOI 10.1016/j.cell.2007.06.026
   Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995
   CHOMYN A, 1986, SCIENCE, V234, P614, DOI 10.1126/science.3764430
   CHOMYN A, 1985, NATURE, V314, P592, DOI 10.1038/314592a0
   Cipolat S, 2004, P NATL ACAD SCI USA, V101, P15927, DOI 10.1073/pnas.0407043101
   Clayton DA, 2003, IUBMB LIFE, V55, P213, DOI 10.1080/1521654031000134824
   CORRALDEBRINSKI M, 1991, JAMA-J AM MED ASSOC, V266, P1812, DOI 10.1001/jama.266.13.1812
   CORRALDEBRINSKI M, 1994, GENOMICS, V23, P471, DOI 10.1006/geno.1994.1525
   CORRALDEBRINSKI M, 1992, NAT GENET, V2, P324, DOI 10.1038/ng1292-324
   CORTOPASSI GA, 1990, NUCLEIC ACIDS RES, V18, P6927, DOI 10.1093/nar/18.23.6927
   Coskun PE, 2004, P NATL ACAD SCI USA, V101, P10726, DOI 10.1073/pnas.0403649101
   Crispim D, 2006, ANN HUM GENET, V70, P488, DOI 10.1111/j.1469-1809.2005.00249.x
   DAIRAGHI DJ, 1995, J MOL BIOL, V249, P11, DOI 10.1006/jmbi.1995.9889
   Darvishi K, 2007, CANCER LETT, V249, P249, DOI 10.1016/j.canlet.2006.09.005
   Davies VJ, 2007, HUM MOL GENET, V16, P1307, DOI 10.1093/hmg/ddm079
   De Benedictis G, 1999, FASEB J, V13, P1532, DOI 10.1096/fasebj.13.12.1532
   Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936
   Dell'Agnello C, 2007, HUM MOL GENET, V16, P431, DOI 10.1093/hmg/ddl477
   DENARO M, 1981, P NATL ACAD SCI-BIOL, V78, P5768, DOI 10.1073/pnas.78.9.5768
   Diaz F, 2008, GUT, V57, P232, DOI 10.1136/gut.2006.119180
   Diaz F, 2005, HUM MOL GENET, V14, P2737, DOI 10.1093/hmg/ddi307
   DiMauro S, 1993, MOL GENETIC BASIS NE, P665
   Ekstrand MI, 2007, P NATL ACAD SCI USA, V104, P1325, DOI 10.1073/pnas.0605208103
   Elchuri S, 2005, ONCOGENE, V24, P367, DOI 10.1038/sj.onc.1208207
   Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0
   Esposito LA, 1999, P NATL ACAD SCI USA, V96, P4820, DOI 10.1073/pnas.96.9.4820
   Esposito LA, 2000, FREE RADICAL BIO MED, V28, P754, DOI 10.1016/S0891-5849(00)00161-1
   Evans AR, 2000, MUTAT RES-DNA REPAIR, V461, P83, DOI 10.1016/S0921-8777(00)00046-X
   Falkenberg M, 2002, NAT GENET, V31, P289, DOI 10.1038/ng909
   Falkenberg M, 2007, ANNU REV BIOCHEM, V76, P679, DOI 10.1146/annurev.biochem.76.060305.152028
   Fan WW, 2008, SCIENCE, V319, P958, DOI 10.1126/science.1147786
   FERRIS SD, 1982, NATURE, V295, P163, DOI 10.1038/295163a0
   FISHER RP, 1992, J BIOL CHEM, V267, P3358
   Freeman HC, 2006, DIABETES, V55, P2153, DOI 10.2337/db06-0358
   Fuku N, 2007, AM J HUM GENET, V80, P407, DOI 10.1086/512202
   Fukui H, 2007, P NATL ACAD SCI USA, V104, P14163, DOI 10.1073/pnas.0705738104
   Gandre-Babbe S, 2008, MOL BIOL CELL, V19, P2402, DOI 10.1091/mbc.E07-12-1287
   Ghezzi D, 2005, EUR J HUM GENET, V13, P748, DOI 10.1038/sj.ejhg.5201425
   GILES RE, 1980, P NATL ACAD SCI-BIOL, V77, P6715, DOI 10.1073/pnas.77.11.6715
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Gottlieb E, 2005, NAT REV CANCER, V5, P857, DOI 10.1038/nrc1737
   Graham BH, 1997, NAT GENET, V16, P226, DOI 10.1038/ng0797-226
   Hansen JM, 2006, ANNU REV PHARMACOL, V46, P215, DOI 10.1146/annurev.pharmtox.46.120604.141122
   Hashimoto Y, 2001, P NATL ACAD SCI USA, V98, P6336, DOI 10.1073/pnas.101133498
   Hashizume K, 2008, AM J PATHOL, V172, P1325, DOI 10.2353/ajpath.2008.070730
   Heddi A, 1999, J BIOL CHEM, V274, P22968, DOI 10.1074/jbc.274.33.22968
   Hendrickson SL, 2009, JAIDS-J ACQ IMM DEF, V51, P111, DOI 10.1097/QAI.0b013e3181a324d6
   Hendrickson SL, 2008, AIDS, V22, P2429, DOI 10.1097/QAD.0b013e32831940bb
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   HORTON TM, 1995, NEUROLOGY, V45, P1879, DOI 10.1212/WNL.45.10.1879
   HOWELL N, 1988, J MOL BIOL, V203, P607, DOI 10.1016/0022-2836(88)90195-7
   HOWELL N, 1990, BIOCHEMISTRY-US, V29, P8970, DOI 10.1021/bi00490a013
   HOWELL N, 1987, J BIOL CHEM, V262, P2411
   Huang TT, 2006, HUM MOL GENET, V15, P1187, DOI 10.1093/hmg/ddl034
   Hussein MR, 2005, HUM REPROD UPDATE, V11, P162, DOI 10.1093/humupd/dmi001
   Imamura Y, 2006, P NATL ACAD SCI USA, V103, P11282, DOI 10.1073/pnas.0602131103
   Inoue K, 2000, NAT GENET, V26, P176, DOI 10.1038/82826
   Ishikawa K, 2008, SCIENCE, V320, P661, DOI 10.1126/science.1156906
   Ivanova R, 1998, GERONTOLOGY, V44, P349, DOI 10.1159/000022041
   JACOBSSON A, 1985, J BIOL CHEM, V260, P6250
   James DI, 2003, J BIOL CHEM, V278, P36373, DOI 10.1074/jbc.M303758200
   Jenuth JP, 1996, NAT GENET, V14, P146, DOI 10.1038/ng1096-146
   Jones DP, 2006, CHEM-BIOL INTERACT, V163, P38, DOI 10.1016/j.cbi.2006.07.008
   Jones MM, 2007, ARCH OPHTHALMOL-CHIC, V125, P1235, DOI 10.1001/archopht.125.9.1235
   KAPSA R, 1994, J INHERIT METAB DIS, V17, P521, DOI 10.1007/BF00711584
   Kasahara A, 2006, HUM MOL GENET, V15, P871, DOI 10.1093/hmg/ddl005
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   KAUKONEN J, 1995, AM J HUM GENET, V57, P1246
   Kelley MR, 2001, ANTIOXID REDOX SIGN, V3, P671, DOI 10.1089/15230860152543014
   KHUSNUTDINOVA E, 2008, ANN NY ACAD IN PRESS
   KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477
   Kokoszka JE, 2001, P NATL ACAD SCI USA, V98, P2278, DOI 10.1073/pnas.051627098
   Kokoszka JE, 2004, NATURE, V427, P461, DOI 10.1038/nature02229
   KOZAK LP, 1988, J BIOL CHEM, V263, P12274
   Krauskopf A, 2006, BBA-BIOENERGETICS, V1757, P590, DOI 10.1016/j.bbabio.2006.02.007
   Kraytsberg Y, 2006, NAT GENET, V38, P518, DOI 10.1038/ng1778
   Kruse SE, 2008, CELL METAB, V7, P312, DOI 10.1016/j.cmet.2008.02.004
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   Larsson NG, 1998, NAT GENET, V18, P231, DOI 10.1038/ng0398-231
   Lebovitz RM, 1996, P NATL ACAD SCI USA, V93, P9782, DOI 10.1073/pnas.93.18.9782
   Levy SE, 2000, GENE, V254, P57, DOI 10.1016/S0378-1119(00)00252-3
   Li K, 2000, CELL, V101, P389, DOI 10.1016/S0092-8674(00)80849-1
   LI YB, 1995, NAT GENET, V11, P376, DOI 10.1038/ng1295-376
   Linder T, 2005, CURR GENET, V48, P265, DOI 10.1007/s00294-005-0022-5
   LUFT R, 1962, J CLIN INVEST, V41, P1776, DOI 10.1172/JCI104637
   LUFT R, 1994, P NATL ACAD SCI USA, V91, P8731, DOI 10.1073/pnas.91.19.8731
   MacGregor GR., 2006, EMBRYONIC STEM CELLS, P72
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Martin M, 2005, CELL, V123, P1227, DOI 10.1016/j.cell.2005.09.040
   McCord JM, 2000, AM J MED, V108, P652, DOI 10.1016/S0002-9343(00)00412-5
   McCulloch V, 2003, MOL CELL BIOL, V23, P5816, DOI 10.1128/MCB.23.16.5816-5824.2003
   McKenzie M, 2004, P NATL ACAD SCI USA, V101, P1685, DOI 10.1073/pnas.0303184101
   Melov S, 1999, P NATL ACAD SCI USA, V96, P846, DOI 10.1073/pnas.96.3.846
   Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774
   Mishmar D, 2003, P NATL ACAD SCI USA, V100, P171, DOI 10.1073/pnas.0136972100
   MITA S, 1989, P NATL ACAD SCI USA, V86, P9509, DOI 10.1073/pnas.86.23.9509
   Mohlke KL, 2005, HUM GENET, V118, P245, DOI 10.1007/s00439-005-0046-4
   MONTOYA J, 1981, NATURE, V290, P465, DOI 10.1038/290465a0
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Murdock DG, 2000, NUCLEIC ACIDS RES, V28, P4350, DOI 10.1093/nar/28.21.4350
   Murdock DG, 1999, J BIOL CHEM, V274, P14429, DOI 10.1074/jbc.274.20.14429
   Nachman MW, 1996, GENETICS, V142, P953
   Nakada K, 2006, P NATL ACAD SCI USA, V103, P15148, DOI 10.1073/pnas.0604641103
   Nakagawa T, 2005, NATURE, V434, P652, DOI 10.1038/nature03317
   NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1
   Niemi AK, 2003, HUM GENET, V112, P29, DOI 10.1007/s00439-002-0843-y
   Nishigaki Y, 2007, HUM GENET, V120, P827, DOI 10.1007/s00439-006-0269-z
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   OJALA D, 1981, NATURE, V290, P470, DOI 10.1038/290470a0
   OLIVER NA, 1982, MOL CELL BIOL, V2, P30, DOI 10.1128/MCB.2.1.30
   Palmieri L, 2005, HUM MOL GENET, V14, P3079, DOI 10.1093/hmg/ddi341
   Park CB, 2007, CELL, V130, P273, DOI 10.1016/j.cell.2007.05.046
   Petros JA, 2005, P NATL ACAD SCI USA, V102, P719, DOI 10.1073/pnas.0408894102
   Potluri P, 2009, MOL GENET METAB, V96, P189, DOI 10.1016/j.ymgme.2008.12.004
   Procaccio V, 2004, NEUROLOGY, V62, P1899, DOI 10.1212/01.WNL.0000125251.56131.65
   Raby BA, 2007, J ALLERGY CLIN IMMUN, V120, P351, DOI 10.1016/j.jaci.2007.05.029
   RADI R, 1991, J BIOL CHEM, V266, P22028
   RADI R, 1993, FREE RADICAL BIO MED, V15, P653, DOI 10.1016/0891-5849(93)90169-U
   RADI R, 1993, ARCH BIOCHEM BIOPHYS, V300, P409, DOI 10.1006/abbi.1993.1055
   Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43
   REICHLING S, 1987, BIOCHEM BIOPH RES CO, V142, P696, DOI 10.1016/0006-291X(87)91470-7
   RIDLEY RG, 1986, NUCLEIC ACIDS RES, V14, P4025, DOI 10.1093/nar/14.10.4025
   Rodic N, 2005, STEM CELLS, V23, P1314, DOI 10.1634/stemcells.2005-0119
   Rose G, 2001, EUR J HUM GENET, V9, P701, DOI 10.1038/sj.ejhg.5200703
   ROTIG A, 1995, HUM MOL GENET, V4, P1327, DOI 10.1093/hmg/4.8.1327
   ROTIG A, 1988, LANCET, V2, P567
   Ruiz-Pesini E, 2004, SCIENCE, V303, P223, DOI 10.1126/science.1088434
   Ruiz-Pesini E, 2006, HUM MUTAT, V27, P1072, DOI 10.1002/humu.20378
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Sampson MJ, 2001, J BIOL CHEM, V276, P39206, DOI 10.1074/jbc.M104724200
   Sato A, 2007, GENETICS, V177, P2031, DOI 10.1534/genetics.107.081026
   Saxena R, 2006, AM J HUM GENET, V79, P54, DOI 10.1086/504926
   Schriner SE, 2000, FREE RADICAL BIO MED, V29, P664, DOI 10.1016/S0891-5849(00)00352-X
   Schriner SE, 2005, SCIENCE, V308, P1909, DOI 10.1126/science.1106653
   Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   SHOFFNER JM, 1993, GENOMICS, V17, P171, DOI 10.1006/geno.1993.1299
   Silva JP, 2000, NAT GENET, V26, P336, DOI 10.1038/81649
   Sligh JE, 2000, P NATL ACAD SCI USA, V97, P14461, DOI 10.1073/pnas.250491597
   Smirnova E, 2001, MOL BIOL CELL, V12, P2245, DOI 10.1091/mbc.12.8.2245
   SOONG NW, 1992, NAT GENET, V2, P318
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spiegelman BM, 2004, CELL, V119, P157, DOI 10.1016/j.cell.2004.09.037
   Stewart JB, 2008, PLOS BIOL, V6, P63, DOI 10.1371/journal.pbio.0060010
   Subrarnaniam V, 2008, BBA-BIOENERGETICS, V1777, P666, DOI 10.1016/j.bbabio.2008.03.015
   Tanaka M, 1998, LANCET, V351, P185, DOI 10.1016/S0140-6736(05)78211-8
   Tanaka M, 2000, MECH AGEING DEV, V116, P65, DOI 10.1016/S0047-6374(00)00149-4
   TILLY JL, 1995, ENDOCRINOLOGY, V136, P242, DOI 10.1210/en.136.1.242
   Tiranti V, 1998, AM J HUM GENET, V63, P1609, DOI 10.1086/302150
   Torroni A, 1997, AM J HUM GENET, V60, P1107
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Trounce I, 2000, NUCLEIC ACIDS RES, V28, P2164, DOI 10.1093/nar/28.10.2164
   Tsai-Turton M, 2006, ENDOCRINOLOGY, V147, P1224, DOI 10.1210/en.2005-1281
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
   Udar N, 2009, INVEST OPHTH VIS SCI, V50, P2966, DOI 10.1167/iovs.08-2646
   van der Walt JM, 2004, NEUROSCI LETT, V365, P28, DOI 10.1016/j.neulet.2004.04.051
   van der Walt JM, 2003, AM J HUM GENET, V72, P804, DOI 10.1086/373937
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Vermulst M, 2008, NAT GENET, V40, P392, DOI 10.1038/ng.95
   Vermulst M, 2007, NAT GENET, V39, P540, DOI 10.1038/ng1988
   Vermulst M, 2008, METHODS, V46, P263, DOI 10.1016/j.ymeth.2008.10.008
   Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199
   Wallace DC, 2005, COLD SH Q B, V70, P363, DOI 10.1101/sqb.2005.70.035
   Wallace D.C., 2007, Emery and Rimoin's Principles and Practice of Medical Genetics, V5th, P194
   Wallace D.C., 2002, Emery and Rimoin's Principles and Practice of Medical Genetics, P299
   Wallace D.C., 2001, The Metabolic and Molecular Basis of Inherited Disease, P2425
   WALLACE DC, 1977, SOMAT CELL GENET, V3, P93, DOI 10.1007/BF01550989
   Wallace DC, 2005, GENE, V354, P169, DOI 10.1016/j.gene.2005.05.001
   Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751
   Wallace DC, 2003, COLD SPRING HARB SYM, V68, P479
   WALLACE DC, 1981, MOL CELL BIOL, V1, P697, DOI 10.1128/MCB.1.8.697
   Wallace DC, 1999, GENE, V238, P211, DOI 10.1016/S0378-1119(99)00295-4
   WALLACE DC, 1979, SOMAT CELL GENET, V5, P373, DOI 10.1007/BF01538849
   WALLACE DC, 1988, CELL, V55, P601, DOI 10.1016/0092-8674(88)90218-8
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953
   WALLACE DC, 1975, J CELL BIOL, V67, P174, DOI 10.1083/jcb.67.1.174
   WALLACE DC, 2007, AM J HUM GENET
   Wallace DC, 2008, GENETICS, V179, P727, DOI 10.1534/genetics.104.91769
   Wallace DC, 2007, ANNU REV BIOCHEM, V76, P781, DOI 10.1146/annurev.biochem.76.081205.150955
   Wang JM, 1999, NAT GENET, V21, P133, DOI 10.1038/5089
   Wredenberg A, 2002, P NATL ACAD SCI USA, V99, P15066, DOI 10.1073/pnas.232591499
   Yoon Y, 2003, MOL CELL BIOL, V23, P5409, DOI 10.1128/MCB.23.15.5409-5420.2003
   Zamzami N, 2001, NAT REV MOL CELL BIO, V2, P67, DOI 10.1038/35048073
   Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804
   Züchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341
NR 222
TC 156
Z9 182
U1 0
U2 22
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 0890-9369
EI 1549-5477
J9 GENE DEV
JI Genes Dev.
PD AUG
PY 2009
VL 23
IS 15
BP 1714
EP 1736
DI 10.1101/gad.1784909
PG 23
WC Cell Biology; Developmental Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Developmental Biology; Genetics & Heredity
GA 478OW
UT WOS:000268598600004
PM 19651984
OA Green Published, gold
DA 2024-11-01
ER

PT J
AU Srivastava, S
   Diaz, F
   Iommarini, L
   Aure, K
   Lombes, A
   Moraes, CT
AF Srivastava, Sarika
   Diaz, Francisca
   Iommarini, Luisa
   Aure, Karine
   Lombes, Anne
   Moraes, Carlos T.
TI PGC-1α/β induced expression partially compensates for respiratory chain
   defects in cells from patients with mitochondrial disorders
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID INDUCIBLE COACTIVATOR; MUSCLE-FIBERS; BIOGENESIS; MYOPATHY;
   TRANSCRIPTION; ACTIVATION; PGC-1-BETA; MTDNA
AB Members of the peroxisome proliferator-activated receptor gamma coactivator (PGC) family are potent inducers of mitochondrial biogenesis. We have tested the potential effect of increased mitochondrial biogenesis in cells derived from patients harboring oxidative phosphorylation defects due to either nuclear or mitochondrial DNA mutations. We found that the PGC-1 alpha and/or PGC-1 beta expression improved mitochondrial respiration in cells harboring a complex III or IV deficiency as well as in transmitochondrial cybrids harboring mitochondrial encephalomyopathy lactic acidosis and stroke A3243G tRNA((Leu)UUR) gene mutation. The respiratory function improvement was found to be associated with increased levels of mitochondrial components per cell, although this increase was not homogeneous. These results reinforce the concept that increased mitochondrial biogenesis is a promising venue for the treatment of mitochondrial diseases.
C1 [Srivastava, Sarika; Diaz, Francisca; Iommarini, Luisa; Moraes, Carlos T.] Univ Miami, Sch Med, Dept Neurol, Miami, FL 33136 USA.
   [Moraes, Carlos T.] Univ Miami, Sch Med, Dept Cell Biol & Anat, Miami, FL 33136 USA.
   [Iommarini, Luisa] Univ Bologna, Dipartimento Sci Neurol, Bologna, Italy.
   [Aure, Karine; Lombes, Anne] Univ Paris 06, Inserm 582, AP HP, F-75013 Paris, France.
C3 University of Miami; University of Miami; University of Bologna;
   Assistance Publique Hopitaux Paris (APHP); Institut National de la Sante
   et de la Recherche Medicale (Inserm); Sorbonne Universite
RP Moraes, CT (corresponding author), Univ Miami, Sch Med, Dept Neurol, 1095 NW 14th Terrace, Miami, FL 33136 USA.
EM cmoraes@med.miami.edu
RI Lombes, Anne/G-4684-2014; Moraes, Carlos/AAT-3818-2021; Iommarini,
   Luisa/J-2328-2018
OI Srivastava, Sarika/0000-0001-9634-5510; Iommarini,
   Luisa/0000-0002-6804-7302
FU Muscular Dystrophy Association and PHS [NS041777, CA085700, EY10804];
   James & Esther King Biomedical Research Program
FX This work was supported by Muscular Dystrophy Association and PHS grants
   NS041777, CA085700 and EY10804 ( to C. T. M.). F. D. work was supported
   by the James & Esther King Biomedical Research Program.
CR Andersson U, 2001, MOL CELL BIOL, V21, P3738, DOI 10.1128/MCB.21.11.3738-3749.2001
   Bacman SR, 2007, METHOD CELL BIOL, V80, P503, DOI 10.1016/S0091-679X(06)80025-7
   Barrientos A, 1998, J BIOL CHEM, V273, P14210, DOI 10.1074/jbc.273.23.14210
   Bastin J, 2008, J CLIN ENDOCR METAB, V93, P1433, DOI 10.1210/jc.2007-1701
   DiMauro S, 2008, ANNU REV NEUROSCI, V31, P91, DOI 10.1146/annurev.neuro.30.051606.094302
   Handschin C, 2006, ENDOCR REV, V27, P728, DOI 10.1210/er.2006-0037
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   Krupp G, 2000, Biotechnol Annu Rev, V6, P103, DOI 10.1016/S1387-2656(00)06020-8
   Lehman JJ, 2000, J CLIN INVEST, V106, P847, DOI 10.1172/JCI10268
   Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904
   Lin JD, 2002, J BIOL CHEM, V277, P1645, DOI 10.1074/jbc.C100631200
   MORAES CT, 1992, NAT GENET, V1, P359, DOI 10.1038/ng0892-359
   Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5
   Scarpulla RC, 2008, PHYSIOL REV, V88, P611, DOI 10.1152/physrev.00025.2007
   Scarpulla RC, 2008, ANN NY ACAD SCI, V1147, P321, DOI 10.1196/annals.1427.006
   SCIACCO M, 1994, HUM MOL GENET, V3, P13, DOI 10.1093/hmg/3.1.13
   Spiegelman BM., 2007, NOVARTIS FDN S, V286, P6
   Spiegelman BM., 2007, NOVARTIS FDN S, V286, P196
   Spiegelman BM., 2007, NOVARTIS FDN S, V286, P162
   Spiegelman Bruce M, 2007, Novartis Found Symp, V286, P3
   Srivastava S, 2007, HUM MOL GENET, V16, P993, DOI 10.1093/hmg/ddm045
   St-Pierre J, 2003, J BIOL CHEM, V278, P26597, DOI 10.1074/jbc.M301850200
   Vempati UD, 2009, J BIOL CHEM, V284, P4383, DOI 10.1074/jbc.M805972200
   Villani G, 2007, METHOD CELL BIOL, V80, P121, DOI 10.1016/S0091-679X(06)80005-1
   Wenz T, 2008, CELL METAB, V8, P249, DOI 10.1016/j.cmet.2008.07.006
   Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X
NR 26
TC 91
Z9 102
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD MAY 15
PY 2009
VL 18
IS 10
BP 1805
EP 1812
DI 10.1093/hmg/ddp093
PG 8
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 437ZJ
UT WOS:000265525400007
PM 19297390
OA Green Published, Bronze
DA 2024-11-01
ER

PT J
AU Kiferle, L
   Orsucci, D
   Mancuso, M
   Lo Gerfo, A
   Petrozzi, L
   Siciliano, G
   Ceravolo, R
   Bonuccelli, U
AF Kiferle, Lorenzo
   Orsucci, Daniele
   Mancuso, Michelangelo
   Lo Gerfo, Annalisa
   Petrozzi, Lucia
   Siciliano, Gabriele
   Ceravolo, Roberto
   Bonuccelli, Ubaldo
TI Twinkle mutation in an Italian family with external progressive
   ophthalmoplegia and parkinsonism: A case report and an update on the
   state of art
SO NEUROSCIENCE LETTERS
LA English
DT Article
DE Parkinsonism; PEO1; Twinkle; Ohthalmoplegia
ID MTDNA DELETIONS; DISEASE; POLG
AB The objective is to describe the clinical phenotype and genetic basis of a family with autosomal dominant progressive external ophthalmoplegia and parkinsonism with a Twinkle mutation. The proband, an 82 years old female, reported since childhood bilateral eyelid ptosis, ophthalmoplegia, sensorineural hypoacusis, mild depression since she was 45, with a positive familiar anamnesis of eyelid ptosis (father, two sisters and a son). She developed mild bilateral parkinsonism with a moderate clinical response to levodopa. The I-123-FP-CIT SCAN evidenced a marked bilateral putaminal reduction and moderate caudate uptake reduction. Her 79 years old sister reported eyelid ptosis since she was 45 with ophthalmoplegia and developed a mild bilateral rest and postural tremor with moderate right arm plastic hypertonia when she was 76. The parkinsonism was confirmed with I-123-FP-CIT SCAN. One of the two sons presented eyelid ptosis since he was 30 years old, with peripheral neuropathy with biopsy evidence of myopathy. We identified a G1750A mutation in the c10orf2 gene in the three patients. Mitochondrial dysfunction has been implicated in the pathogenesis of sporadic, idiopathic Parkinson disease (PD). In some cases, mitochondrial DNA primary genetic abnormalities or more commonly secondary rearrangements due to polymerase gamma (POLG) gene mutation can directly cause parkinsonism. Parkinsonism has been reported as a rare symptom associated to Twinkle (c10orf2). Parkinsonism has to be investigated in patients with PEO with analysis of Twinkle mutation. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
C1 [Kiferle, Lorenzo; Orsucci, Daniele; Mancuso, Michelangelo; Lo Gerfo, Annalisa; Petrozzi, Lucia; Siciliano, Gabriele; Ceravolo, Roberto; Bonuccelli, Ubaldo] Univ Pisa, Dept Clin & Pathol Med, Neurol Sect, I-56126 Pisa, Italy.
C3 University of Pisa
RP Kiferle, L (corresponding author), Univ Pisa, Dept Clin & Pathol Med, Neurol Sect, Via Roma 67, I-56126 Pisa, Italy.
EM l.kiferle@virgilio.it
RI Orsucci, Daniele/AAA-7576-2019; ceravolo, roberto/AAB-1293-2019;
   Kiferle, Lorenzo/AAC-6072-2022; Mancuso, Michelangelo/K-4170-2016;
   Bonuccelli, Ubaldo/K-8681-2016; Siciliano, Gabriele/K-7259-2016;
   ceravolo, roberto/K-6831-2016
OI Orsucci, Daniele/0000-0003-4847-7812; Bonuccelli,
   Ubaldo/0000-0001-6218-6312; Siciliano, Gabriele/0000-0002-6142-2384;
   ceravolo, roberto/0000-0003-1412-9406
CR Baloh RH, 2007, ARCH NEUROL-CHICAGO, V64, P998, DOI 10.1001/archneur.64.7.998
   Brandon BR, 2013, J NEUROL, V260, P1931, DOI 10.1007/s00415-013-6975-2
   Greenwood SM, 2010, J NEUROCHEM, V113, P1471, DOI 10.1111/j.1471-4159.2010.06737.x
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Smits BW, 2011, NEUROMUSCULAR DISORD, V21, P272, DOI 10.1016/j.nmd.2010.12.008
   Song LY, 2012, HUM MOL GENET, V21, P5147, DOI 10.1093/hmg/dds365
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
   Um JW, 2010, J NEUROSCI, V30, P11805, DOI 10.1523/JNEUROSCI.2862-09.2010
   Van Goethem G, 2003, HUM MUTAT, V22, P175, DOI 10.1002/humu.10246
   Van Hove JLK, 2009, AM J MED GENET A, V149A, P861, DOI 10.1002/ajmg.a.32731
   Vandenberghe W, 2009, MOVEMENT DISORD, V24, P308, DOI 10.1002/mds.22198
NR 12
TC 29
Z9 29
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3940
EI 1872-7972
J9 NEUROSCI LETT
JI Neurosci. Lett.
PD NOV 27
PY 2013
VL 556
BP 1
EP 4
DI 10.1016/j.neulet.2013.09.034
PG 4
WC Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 273FP
UT WOS:000328520900001
PM 24076137
DA 2024-11-01
ER

PT J
AU Emmanuele, V
   Silvers, DS
   Sotiriou, E
   Tanji, K
   Dimauro, S
   Hirano, M
AF Emmanuele, Valentina
   Silvers, David S.
   Sotiriou, Evangelia
   Tanji, Kurenai
   Dimauro, Salvatore
   Hirano, Michio
TI MERRF AND KEARNS-SAYRE OVERLAP SYNDROME DUE TO THE MITOCHONDRIAL DNA
   M.3291T&gt;C MUTATION
SO MUSCLE & NERVE
LA English
DT Article
DE Kearns-Sayre syndrome; mitochondrial DNA; myoclonus epilepsy; point
   mutation; tRNA(Leu(UUR)); ragged-red fibers
ID DELETIONS; DEFICIENCY; FEATURES; DISEASES; PATIENT; GENOME; MELAS
AB A 48-year-old man presented with a complex phenotype of myoclonus epilepsy with ragged-red fibers (MERRF) syndrome and Kearns Sayre syndrome (KSS), which included progressive myoclonus epilepsy, cerebellar ataxia, hearing loss, myopathic weakness, ophthalmoparesis, pigmentary retinopathy, bifascicular heart block, and ragged-red fibers. The m.3291T>C mutation in the tRNA(Leu(UUR)) gene was found with 92% heteroplasmy in muscle. This mutation has been reported with MELAS, myopathy, and deafness with cognitive impairment. This is the first description with a MERRF/KSS syndrome. Muscle Nerve 44: 448-451, 2011
C1 [Emmanuele, Valentina; Sotiriou, Evangelia; Dimauro, Salvatore; Hirano, Michio] Columbia Univ, Med Ctr, Dept Neurol, New York, NY 10032 USA.
   [Silvers, David S.] Hartford Hosp, Dept Neurol, Hartford, CT 06115 USA.
   [Tanji, Kurenai] Columbia Univ, Med Ctr, Dept Pathol & Cell Biol, New York, NY 10032 USA.
C3 Columbia University; Hartford Hospital; Columbia University
RP Hirano, M (corresponding author), Columbia Univ, Med Ctr, Dept Neurol, 630 W 168th St,P&S 4-423, New York, NY 10032 USA.
EM mh29@columbia.edu
OI Emmanuele, Valentina/0000-0002-4892-2042
FU National Institutes of Health (NIH) [NIH HD32062, R01HD57543,
   R01HD056103, RCNS070232]; Marriott Mitochondrial Disorders Clinical
   Research Fund (MMDCRF); Muscular Dystrophy Association
FX This study was supported by the National Institutes of Health (NIH
   HD32062) and by the Marriott Mitochondrial Disorders Clinical Research
   Fund (MMDCRF). M.H. was supported by NIH grants (R01HD57543,
   R01HD056103, and RCNS070232) and by the Muscular Dystrophy Association.
CR ANAN R, 1995, CIRCULATION, V91, P955, DOI 10.1161/01.CIR.91.4.955
   Brandon MC, 2005, NUCLEIC ACIDS RES, V33, pD611
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   GOTO YI, 1994, BIOCHEM BIOPH RES CO, V202, P1624, DOI 10.1006/bbrc.1994.2119
   Hao R, 2004, FEBS LETT, V578, P135, DOI 10.1016/j.febslet.2004.11.004
   HARDING AE, 1992, J INHERIT METAB DIS, V15, P480, DOI 10.1007/BF01799606
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Kirino Y, 2005, P NATL ACAD SCI USA, V102, P7127, DOI 10.1073/pnas.0500563102
   Naini A, 2007, METHOD CELL BIOL, V80, P437, DOI 10.1016/S0091-679X(06)80022-1
   Nishigaki Y, 2003, NEUROMUSCULAR DISORD, V13, P334, DOI 10.1016/S0960-8966(02)00283-3
   Pulkes T, 2001, ADV DRUG DELIVER REV, V49, P27, DOI 10.1016/S0169-409X(01)00124-7
   Uziel G, 2000, NEUROMUSCULAR DISORD, V10, P415, DOI 10.1016/S0960-8966(99)00115-7
   Valente L, 2009, BBA-BIOENERGETICS, V1787, P491, DOI 10.1016/j.bbabio.2008.10.001
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   YONEDA M, 1990, BIOCHEM INT, V21, P789
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
NR 16
TC 16
Z9 18
U1 0
U2 1
PU WILEY-BLACKWELL
PI MALDEN
PA COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA
SN 0148-639X
J9 MUSCLE NERVE
JI Muscle Nerve
PD SEP
PY 2011
VL 44
IS 3
BP 448
EP 451
DI 10.1002/mus.22149
PG 4
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 814IZ
UT WOS:000294443300022
PM 21996807
OA Green Accepted
DA 2024-11-01
ER

PT J
AU Frangini, M
   Rampazzo, C
   Franzolin, E
   Lara, MC
   Vilà, MR
   Martí, R
   Bianchi, V
AF Frangini, Miriam
   Rampazzo, Chiara
   Franzolin, Elisa
   Lara, Mari-Carmen
   Vila, Maya R.
   Marti, Ramon
   Bianchi, Vera
TI Unchanged thymidine triphosphate pools and thymidine metabolism in two
   lines of thymidine kinase 2-mutated fibroblasts
SO FEBS JOURNAL
LA English
DT Article
DE dTTP pool turnover; mitochondrial DNA depletion syndrome; mitochondrial
   DNA precursors; p53R2; thymidine phosphorylase
ID MITOCHONDRIAL-DNA DEPLETION; NEUROGASTROINTESTINAL ENCEPHALOMYOPATHY;
   TK2 DEFICIENCY; DEOXYNUCLEOTIDE POOLS; DEOXYGUANOSINE KINASE; MTDNA
   DEPLETION; CELL-EXTRACTS; MYOPATHY; 5'-NUCLEOTIDASES; MUTATIONS
AB Mitochondrial thymidine kinase (TK2) catalyzes the phosphorylation of thymidine in mitochondria. Its function becomes essential for dTTP synthesis in noncycling cells, where cytosolic dTTP synthesis via R1/R2 ribonucleotide reductase and thymidine kinase 1 is turned down. Mutations in the nuclear gene for TK2 cause a fatal mtDNA depletion syndrome. Only selected cell types are affected, suggesting that the other cells compensate for the TK2 deficiency by adapting the enzyme network that regulates dTTP synthesis outside S-phase. Here we looked for such metabolic adaptation in quiescent cultures of fibroblasts from two TK2-deficient patients with a slow-progressing syndrome. In cell extracts, we measured the activities of TK2, deoxycytidine kinase, thymidine phosphorylase, deoxynucleotidases and the amounts of the three ribonucleotide reductase subunits. Patient cells contained 40% or 5% TK2 activity and unchanged activities of the other enzymes. However, their mitochondrial and cytosolic dTTP pools were unchanged, and also the overall composition of the dNTP pools was normal. TK2-dependent phosphorylation of [H-3]thymidine in intact cells and the turnover of the dTTP pool showed that even the fibroblasts with 5% residual TK2 activity synthesized dTTP at an almost normal rate. Normal fibroblasts apparently contain more TK2 than needed to maintain dTTP during quiescence, which would explain why TK2-mutated fibroblasts do not manifest mtDNA depletion despite their reduced TK2 activity.
C1 [Frangini, Miriam; Rampazzo, Chiara; Franzolin, Elisa; Bianchi, Vera] Univ Padua, Dept Biol, I-35131 Padua, Italy.
   [Lara, Mari-Carmen; Vila, Maya R.; Marti, Ramon] Univ Vall Hebron, Inst Recerca Hosp, Barcelona, Spain.
C3 University of Padua; Autonomous University of Barcelona; Hospital
   Universitari Vall d'Hebron; Vall d'Hebron Institut de Recerca (VHIR)
RP Bianchi, V (corresponding author), Univ Padua, Dept Biol, Via Ugo Bassi 58B, I-35131 Padua, Italy.
EM vbianchi@bio.unipd.it
RI Frangini, Miriam/I-3532-2013; Martí, Ramon/Q-3442-2016
OI Marti, Ramon/0000-0002-8273-9540
FU Italian Telethon [GGP05001]; AIRC; Spanish Instituto de Salud Carlos III
   [PI 06/0735, CP 04/0240]
FX This work was supported by grants from Italian Telethon (Grant
   GGP05001), AIRC, the Italian Association for Cancer Research, and the
   Cariparo Foundation to V. Bianchi, and from the Spanish Instituto de
   Salud Carlos III (PI 06/0735 and CP 04/0240 to R. Marti and PI 04/0415
   to M. R. Vila).
CR Akman HO, 2008, HUM MOL GENET, V17, P2433, DOI 10.1093/hmg/ddn143
   Barthélémy C, 2001, ANN NEUROL, V49, P607, DOI 10.1002/ana.1002.abs
   Bianchi V, 2003, J BIOL CHEM, V278, P46195, DOI 10.1074/jbc.R300032200
   BIANCHI V, 1987, MOL CELL BIOL, V7, P4218, DOI 10.1128/MCB.7.12.4218
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Chabes AL, 2003, P NATL ACAD SCI USA, V100, P3925, DOI 10.1073/pnas.0330774100
   Copeland WC, 2008, ANNU REV MED, V59, P131, DOI 10.1146/annurev.med.59.053006.104646
   Ferraro P, 2005, J BIOL CHEM, V280, P24472, DOI 10.1074/jbc.M502869200
   Franzolin E, 2006, BIOCHEM BIOPH RES CO, V344, P30, DOI 10.1016/j.bbrc.2006.03.147
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Martí R, 2004, CLIN CHEM, V50, P120, DOI 10.1373/clinchem.2003.026179
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Oskoui M, 2006, ARCH NEUROL-CHICAGO, V63, P1122, DOI 10.1001/archneur.63.8.1122
   Pontarin G, 2003, P NATL ACAD SCI USA, V100, P12159, DOI 10.1073/pnas.1635259100
   Pontarin G, 2007, J BIOL CHEM, V282, P16820, DOI 10.1074/jbc.M701310200
   Pontarin G, 2006, J BIOL CHEM, V281, P22720, DOI 10.1074/jbc.M604498200
   Rampazzo C, 2002, BIOCHEM BIOPH RES CO, V293, P258, DOI 10.1016/S0006-291X(02)00206-1
   Rampazzo C, 2007, J BIOL CHEM, V282, P34758, DOI 10.1074/jbc.M705923200
   REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025
   Rylova SN, 2007, BIOCHEM PHARMACOL, V74, P169, DOI 10.1016/j.bcp.2007.03.029
   Saada A, 2003, BIOCHEM BIOPH RES CO, V310, P963, DOI 10.1016/j.bbrc.2003.09.104
   Saada A, 2003, MOL GENET METAB, V79, P1, DOI 10.1016/S1096-7192(03)00063-5
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   SHERMAN PA, 1989, ANAL BIOCHEM, V180, P222, DOI 10.1016/0003-2697(89)90420-X
   Vilá MR, 2008, J NEUROL SCI, V267, P137, DOI 10.1016/j.jns.2007.10.019
   Vilà MR, 2003, NEUROLOGY, V60, P1203, DOI 10.1212/01.WNL.0000055928.58122.47
   Wang LY, 2005, MOL GENET METAB, V84, P75, DOI 10.1016/j.ymgme.2004.09.005
   Wang LY, 2003, J BIOL CHEM, V278, P6963, DOI 10.1074/jbc.M206143200
   Zhou XS, 2008, HUM MOL GENET, V17, P2329, DOI 10.1093/hmg/ddn133
NR 30
TC 12
Z9 13
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1742-464X
EI 1742-4658
J9 FEBS J
JI FEBS J.
PD FEB
PY 2009
VL 276
IS 4
BP 1104
EP 1113
DI 10.1111/j.1742-4658.2008.06853.x
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 397MN
UT WOS:000262666900019
PM 19154348
DA 2024-11-01
ER

PT J
AU DiMauro, S
AF DiMauro, S
TI Mitochondrial medicine
SO BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS
LA English
DT Article; Proceedings Paper
CT 6th European Meeting on Mitochondrial Pathology (Euromit 6)
CY JUN 30-JUL 04, 2004
CL Nijmegen, NETHERLANDS
ID CYTOCHROME-C-OXIDASE; PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA;
   SKELETAL-MUSCLE; PATERNAL INHERITANCE; COMPLEX-I; SEVERE
   HYPERMETABOLISM; CARNITINE DEFICIENCY; MTDNA DEPLETION; T7511C MUTATION;
   FREQUENT CAUSE
AB After reviewing the history of mitochondrial diseases, I follow a genetic classification to discuss new developments and old conundrums. In the field of mitochondrial DNA (mtDNA) mutations, I argue that we are not yet scraping the bottom of the barrel because: (i) new mtDNA mutations are still being discovered, especially in protein-coding genes; (ii) the pathogenicity of homoplasmic mutations is being revisited; (iii) some genetic dogmas are chipped but not broken; (iv) mtDNA haplotypes are gaining interest in human pathology; (v) pathogenesis is still largely enigmatic.
   In the field of nuclear DNA (nDNA) mutations, there has been good progress in our understanding of disorders due to faulty intergenomic communication. Of the genes responsible for multiple deletions and depletion of mtDNA, mutations in POLG have been associated with a great variety of clinical phenotypes in humans and to precocious aging in mice. Novel pathogenetic mechanisms include alterations in the lipid milieu of the inner mitochondrial membrane and mutations in genes controlling mitochondrial motility, fission, and fusion. (C) 2004 Elsevier B.V. All rights reserved.
C1 Columbia Univ, Coll Phys & Surg 4 420, Dept Neurol, New York, NY 10032 USA.
C3 Columbia University
RP Columbia Univ, Coll Phys & Surg 4 420, Dept Neurol, 630 W 168th St, New York, NY 10032 USA.
EM sd12@columbia.edu
FU NICHD NIH HHS [HD32062] Funding Source: Medline; NINDS NIH HHS [NS11766]
   Funding Source: Medline
CR Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944
   Antonicka H, 2003, AM J HUM GENET, V72, P101, DOI 10.1086/345489
   BARTH PG, 1983, J NEUROL SCI, V62, P327, DOI 10.1016/0022-510X(83)90209-5
   BLASS J P, 1970, Journal of Clinical Investigation, V49, P423, DOI 10.1172/JCI106251
   Bossy-Wetzel E, 2003, CURR OPIN CELL BIOL, V15, P706, DOI 10.1016/j.ceb.2003.10.015
   BOURGERON T, 1995, NAT GENET, V11, P144, DOI 10.1038/ng1095-144
   Carelli V., 2002, MITOCHONDRIAL DISORD, P115
   Chinnery PF, 2000, NEUROLOGY, V55, P302, DOI 10.1212/WNL.55.2.302
   Chol M, 2003, J MED GENET, V40, P188, DOI 10.1136/jmg.40.3.188
   Cock HR, 1998, ANN NEUROL, V44, P187, DOI 10.1002/ana.410440208
   Corona P, 2001, ANN NEUROL, V49, P106, DOI 10.1002/1531-8249(200101)49:1<106::AID-ANA16>3.0.CO;2-T
   Crimi M, 2003, NEUROLOGY, V60, P1857, DOI 10.1212/01.WNL.0000066048.72780.69
   de Lonlay P, 2001, NAT GENET, V29, P57, DOI 10.1038/ng706
   De Meirleir L, 2004, J MED GENET, V41, P120, DOI 10.1136/jmg.2003.012047
   Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936
   DiMauro S, 2000, BRAIN PATHOL, V10, P431
   DIMAURO S, 1973, SCIENCE, V182, P929, DOI 10.1126/science.182.4115.929
   DIMAURO S, 1976, J NEUROL SCI, V27, P217, DOI 10.1016/0022-510X(76)90063-0
   DiMauro S, 2002, MUSCLE NERVE, V26, P597, DOI 10.1002/mus.10194
   DIMAURO S, 1985, ANN NEUROL, V17, P521, DOI 10.1002/ana.410170602
   DIMAURO S, 2003, IN PRESS BASIC APPL, V13
   ENGEL AG, 1973, SCIENCE, V179, P899, DOI 10.1126/science.179.4076.899
   ENGEL WK, 1963, NEUROLOGY, V13, P919, DOI 10.1212/WNL.13.11.919
   Estivill X, 1998, AM J HUM GENET, V62, P27, DOI 10.1086/301676
   Filosto M, 2003, ANN NEUROL, V54, P524, DOI 10.1002/ana.10709
   Fischel-Ghodsian N, 1998, AM J HUM GENET, V62, P15, DOI 10.1086/301695
   GONATAS NK, 1965, P 5 INT C NEUR EXC M, V100, P606
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Guan MX, 1996, HUM MOL GENET, V5, P963, DOI 10.1093/hmg/5.7.963
   HAYDAR NA, 1971, ANN INTERN MED, V74, P548, DOI 10.7326/0003-4819-74-4-548
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Kalman B, 1999, ACTA NEUROL SCAND, V99, P16
   KARPATI G, 1975, NEUROLOGY, V25, P16, DOI 10.1212/WNL.25.1.16
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kirby DM, 2003, ANN NEUROL, V54, P473, DOI 10.1002/ana.10687
   Kraytsberg Y, 2004, SCIENCE, V304, P981, DOI 10.1126/science.1096342
   Li XM, 2004, NUCLEIC ACIDS RES, V32, P867, DOI 10.1093/nar/gkh226
   Liolitsa D, 2003, ANN NEUROL, V53, P128, DOI 10.1002/ana.10435
   LUFT R, 1962, J CLIN INVEST, V41, P1776, DOI 10.1172/JCI104637
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   McFarland R, 2004, ANN NEUROL, V55, P478, DOI 10.1002/ana.20004
   McFarland R, 2002, NAT GENET, V30, P145, DOI 10.1038/ng819
   Mootha VK, 2003, P NATL ACAD SCI USA, V100, P605, DOI 10.1073/pnas.242716699
   Moraes C T, 1996, Methods Enzymol, V264, P522, DOI 10.1016/S0076-6879(96)64046-4
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   NAINI A, 2004, IN PRESS ARCH NEUROL
   NANGAKU M, 1994, CELL, V79, P1209, DOI 10.1016/0092-8674(94)90012-4
   Naviaux RK, 1999, ANN NEUROL, V45, P54, DOI 10.1002/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B
   Neuwald AF, 1997, CURR BIOL, V7, pR465
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Papadopoulou LC, 1999, NAT GENET, V23, P333
   Penisson-Besnier I, 2000, NEUROLOGY, V55, P317, DOI 10.1212/WNL.55.2.317
   PREZANT TR, 1993, NAT GENET, V4, P289, DOI 10.1038/ng0793-289
   Pulkes T, 1999, ANN NEUROL, V46, P916, DOI 10.1002/1531-8249(199912)46:6<916::AID-ANA16>3.0.CO;2-R
   Ruiz-Pesini E, 2004, SCIENCE, V303, P223, DOI 10.1126/science.1088434
   Ruiz-Pesini E, 2000, AM J HUM GENET, V67, P682, DOI 10.1086/303040
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Santorelli FM, 1997, BIOCHEM BIOPH RES CO, V238, P326, DOI 10.1006/bbrc.1997.7167
   Schlame M, 2000, PROG LIPID RES, V39, P257, DOI 10.1016/S0163-7827(00)00005-9
   Schlame M, 2003, J AM COLL CARDIOL, V42, P1994, DOI 10.1016/j.jacc.2003.06.015
   Schlame M, 2002, ANN NEUROL, V51, P634, DOI 10.1002/ana.10176
   Schon EA, 2003, GENETICS MITOCHONDRI, P111
   Schwartz M, 2004, J NEUROL SCI, V218, P99, DOI 10.1016/j.jns.2003.11.008
   Schwartz M, 2002, NEW ENGL J MED, V347, P576, DOI 10.1056/NEJMoa020350
   Servidei Serenella, 2004, Neuromuscul Disord, V14, P107
   Shin WS, 2000, AM J HUM GENET, V67, P1617, DOI 10.1086/316896
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
   SHY GM, 1966, BRAIN, V89, P133, DOI 10.1093/brain/89.1.133
   SHY GM, 1964, SCIENCE, V145, P493, DOI 10.1126/science.145.3631.493
   SKUDER P, 1995, INTELLIGENCE, V21, P1, DOI 10.1016/0160-2896(95)90035-7
   Smeitink J, 1999, AM J HUM GENET, V64, P1505, DOI 10.1086/302432
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Sue CM, 1999, NEUROLOGY, V52, P1905, DOI 10.1212/WNL.52.9.1905
   Suzuki T, 2002, EMBO J, V21, P6581, DOI 10.1093/emboj/cdf656
   Taylor RW, 2003, ANN NEUROL, V54, P521, DOI 10.1002/ana.10673
   Taylor RW, 2003, J AM COLL CARDIOL, V41, P1786, DOI 10.1016/S0735-1097(03)00300-0
   Tiranti V, 2004, AM J HUM GENET, V74, P239, DOI 10.1086/381653
   Tiranti V, 1998, AM J HUM GENET, V63, P1609, DOI 10.1086/302150
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Valnot I, 2000, AM J HUM GENET, V67, P1104
   Valnot I, 2000, HUM MOL GENET, V9, P1245, DOI 10.1093/hmg/9.8.1245
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Visapää I, 2002, AM J HUM GENET, V71, P863, DOI 10.1086/342773
   Vreken P, 2000, BIOCHEM BIOPH RES CO, V279, P378, DOI 10.1006/bbrc.2000.3952
   Wallace DC, 1999, GENE, V238, P211, DOI 10.1016/S0378-1119(99)00295-4
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   WILLEMS JL, 1977, PEDIATRICS, V60, P850
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
   Zhu ZQ, 1998, NAT GENET, V20, P337, DOI 10.1038/3804
   Züchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341
NR 93
TC 41
Z9 49
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0005-2728
EI 1879-2650
J9 BBA-BIOENERGETICS
JI Biochim. Biophys. Acta-Bioenerg.
PD DEC 6
PY 2004
VL 1659
IS 2-3
SI SI
BP 107
EP 114
DI 10.1016/j.bbabio.2004.08.003
PG 8
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)
SC Biochemistry & Molecular Biology; Biophysics
GA 882KT
UT WOS:000225938500002
PM 15576041
OA Bronze
DA 2024-11-01
ER

PT J
AU Nogueira, C
   Pereira, C
   Silva, L
   Laranjeira, M
   Lopes, A
   Neiva, R
   Rodrigues, E
   Campos, T
   Martins, E
   Bandeira, A
   Coelho, M
   Magalhaes, M
   Damásio, J
   Gaspar, A
   Janeiro, P
   Gomes, AL
   Ferreira, AC
   Jacinto, S
   Vieira, JP
   Diogo, L
   Santos, H
   Mendonça, C
   Vilarinho, L
AF Nogueira, C.
   Pereira, C.
   Silva, L.
   Laranjeira, Mateus
   Lopes, A.
   Neiva, R.
   Rodrigues, E.
   Campos, T.
   Martins, E.
   Bandeira, A.
   Coelho, M.
   Magalhaes, M.
   Damasio, J.
   Gaspar, A.
   Janeiro, P.
   Gomes, A. Levy
   Ferreira, A. C.
   Jacinto, S.
   Vieira, J. P.
   Diogo, L.
   Santos, H.
   Mendonca, C.
   Vilarinho, L.
TI The genetic landscape of mitochondrial diseases in the next-generation
   sequencing era: a Portuguese cohort study
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Article
DE mitochondrial diseases; next-generation sequencing; mitochondrial DNA;
   nuclear DNA; nuclear genes; respiratory chain; oxidative phosphorylation
ID A3243G MUTATION; LEIGH-SYNDROME; DNA; SPECTRUM; VARIANTS; MYOPATHY;
   DELETIONS; DEATH
AB Introduction: Rare disorders that are genetically and clinically heterogeneous, such as mitochondrial diseases (MDs), have a challenging diagnosis. Nuclear genes codify most proteins involved in mitochondrial biogenesis, despite all mitochondria having their own DNA. The development of next-generation sequencing (NGS) technologies has revolutionized the understanding of many genes involved in the pathogenesis of MDs. In this new genetic era, using the NGS approach, we aimed to identify the genetic etiology for a suspected MD in a cohort of 450 Portuguese patients.Methods: We examined 450 patients using a combined NGS strategy, starting with the analysis of a targeted mitochondrial panel of 213 nuclear genes, and then proceeding to analyze the whole mitochondrial DNA.Results and Discussion: In this study, we identified disease-related variants in 134 (30%) analyzed patients, 88 with nuclear DNA (nDNA) and 46 with mitochondrial DNA (mtDNA) variants, most of them being pediatric patients (66%), of which 77% were identified in nDNA and 23% in mtDNA. The molecular analysis of this cohort revealed 72 already described pathogenic and 20 novel, probably pathogenic, variants, as well as 62 variants of unknown significance. For this cohort of patients with suspected MDs, the use of a customized gene panel provided a molecular diagnosis in a timely and cost-effective manner. Patients who cannot be diagnosed after this initial approach will be further selected for whole-exome sequencing.Conclusion: As a national laboratory for the study and research of MDs, we demonstrated the power of NGS to achieve a molecular etiology, expanding the mutational spectrum and proposing accurate genetic counseling in this group of heterogeneous diseases without therapeutic options.
C1 [Nogueira, C.; Silva, L.; Laranjeira, Mateus; Vilarinho, L.] Natl Inst Hlth Doutor Ricardo Jorge, Human Genet Dept, Res & Dev Unit, Lisbon, Portugal.
   [Nogueira, C.; Pereira, C.; Silva, L.; Lopes, A.; Neiva, R.; Vilarinho, L.] Natl Inst Hlth Doutor Ricardo Jorge, Human Genet Dept, Newborn Screening Metab & Genet Unit, Lisbon, Portugal.
   [Rodrigues, E.; Campos, T.] Sao Joao Hosp Univ Ctr, Inherited Metab Dis Reference Ctr, Porto, Portugal.
   [Martins, E.; Bandeira, A.; Coelho, M.] Santo Antonio Hosp Univ Ctr, Inherited Metab Dis Reference Ctr, Porto, Portugal.
   [Magalhaes, M.; Damasio, J.] Santo Antonio Hosp Univ Ctr, Neurol Dept, Porto, Portugal.
   [Gaspar, A.; Janeiro, P.] Lisboa Norte Hosp Univ Ctr, Inherited Metab Dis Reference Ctr, Lisbon, Portugal.
   [Gomes, A. Levy] Lisboa Norte Hosp Univ Ctr, Neurol Dept, Lisbon, Portugal.
   [Ferreira, A. C.; Jacinto, S.; Vieira, J. P.] Lisboa Cent Hosp Ctr, Inherited Metab Dis Reference Ctr, Lisbon, Portugal.
   [Diogo, L.] Coimbra Hosp & Univ Ctr, Inherited Metab Dis Reference Ctr, Coimbra, Portugal.
   [Santos, H.] Vila Nova de Gaia Hosp Ctr, Inherited Metab Dis Reference Ctr, Vila Nova De Gaia, Portugal.
   [Mendonca, C.] Faro Hosp & Univ Ctr, Pediat Dept, Faro, Portugal.
C3 Instituto Nacional de Saude Dr. Ricardo Jorge; Instituto Nacional de
   Saude Dr. Ricardo Jorge; Universidade de Coimbra; Centro Hospitalar e
   Universitario de Coimbra (CHUC)
RP Vilarinho, L (corresponding author), Natl Inst Hlth Doutor Ricardo Jorge, Human Genet Dept, Res & Dev Unit, Lisbon, Portugal.; Vilarinho, L (corresponding author), Natl Inst Hlth Doutor Ricardo Jorge, Human Genet Dept, Newborn Screening Metab & Genet Unit, Lisbon, Portugal.
EM laura.vilarinho@insa.min-saude.pt
RI Martins, Elisabete/R-5631-2019; Coelho, Margarida/IVU-6443-2023
OI Laranjeira, Mateus/0009-0000-6299-4010; Paiva Coelho,
   Margarida/0000-0002-6471-4067; Martins, Esmeralda/0000-0002-9247-9391;
   Nogueira, Celia/0000-0003-3640-8537
FU FCT [PTDC/DTP-PIC/2220/2014]; NORTE 2020 [NORTE-01-0246-FEDER-000014]
FX The author(s) declare that financial support was received for the
   research, authorship, and/or publication of this article. This work was
   supported by FCT (PTDC/DTP-PIC/2220/2014) and NORTE 2020
   (NORTE-01-0246-FEDER-000014). The content is solely the responsibility
   of the authors and does not necessarily represent the official views of
   the National Institute of Health.
CR Adzhubei Ivan, 2013, Curr Protoc Hum Genet, VChapter 7, DOI 10.1002/0471142905.hg0720s76
   Alston CL, 2010, NEUROMUSCULAR DISORD, V20, P131, DOI 10.1016/j.nmd.2009.10.010
   Baldo MS, 2023, GENES-BASEL, V14, DOI 10.3390/genes14081536
   Cardaioli E, 2006, NEUROMUSCULAR DISORD, V16, P26, DOI 10.1016/j.nmd.2005.11.001
   Chin J, 2014, MITOCHONDRION, V17, P34, DOI 10.1016/j.mito.2014.05.005
   Chinnery P.F., GeneReviews
   Debray FG, 2007, PEDIATRICS, V119, P722, DOI 10.1542/peds.2006-1866
   DiMauro S, 2013, NAT REV NEUROL, V9, P429, DOI 10.1038/nrneurol.2013.126
   Eom S, 2017, PEDIATR NEUROL, V66, P82, DOI 10.1016/j.pediatrneurol.2016.10.006
   Falk MJ, 2020, Mitochondrial Disease Genes Compendium: From Genes to Clinical Manifestations
   Finsterer J, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000018488
   Frazier AE, 2019, J BIOL CHEM, V294, P5386, DOI 10.1074/jbc.R117.809194
   French CE, 2019, INTENS CARE MED, V45, P627, DOI 10.1007/s00134-019-05552-x
   Friedman JR, 2014, NATURE, V505, P335, DOI 10.1038/nature12985
   Gomez MAR, 2020, RNA, V26, P910, DOI 10.1261/rna.071720.119
   Gorman GS, 2016, NAT REV DIS PRIMERS, V2, P1, DOI 10.1038/nrdp.2016.80
   Gorman GS, 2015, ANN NEUROL, V77, P753, DOI 10.1002/ana.24362
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Houshmand M, 1996, HUM GENET, V97, P269, DOI 10.1007/BF02185750
   Jaksch M, 1998, ANN NEUROL, V44, P635, DOI 10.1002/ana.410440409
   Kircher M, 2014, NAT GENET, V46, P310, DOI 10.1038/ng.2892
   Kotrys AV, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9010017
   Kumar P, 2009, NAT PROTOC, V4, P1073, DOI 10.1038/nprot.2009.86
   Lawless C, 2020, OPEN BIOL, V10, DOI 10.1098/rsob.200061
   Maresca A, 2020, J MOL MED, V98, P1467, DOI 10.1007/s00109-020-01967-y
   McCormick EM, 2020, HUM MUTAT, V41, P2028, DOI 10.1002/humu.24107
   Mishra P, 2014, NAT REV MOL CELL BIO, V15, P634, DOI 10.1038/nrm3877
   Nogueira C, 2019, MITOCHONDRION, V47, P309, DOI 10.1016/j.mito.2019.02.006
   Ogawa E, 2017, J INHERIT METAB DIS, V40, P685, DOI 10.1007/s10545-017-0042-6
   Papadimitriou S, 2019, P NATL ACAD SCI USA, V116, P11878, DOI 10.1073/pnas.1815601116
   Papadopoulos C, 2020, J INHERIT METAB DIS, V43, P459, DOI 10.1002/jimd.12185
   Parikh S, 2015, GENET MED, V17, P689, DOI 10.1038/gim.2014.177
   Pereira Cristina, 2019, J. inborn errors metab. screen., V7, pe20180003, DOI 10.1590/2326-4594-jiems-2018-0003
   Poulton J, 2019, NEUROMUSCULAR DISORD, V29, P725, DOI 10.1016/j.nmd.2019.08.004
   Pronicka E, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0930-9
   Rahman J, 2018, LANCET, V391, P2560, DOI 10.1016/S0140-6736(18)30727-X
   Rahman S, 2020, J INTERN MED, V287, P609, DOI 10.1111/joim.13054
   Richards S, 2015, GENET MED, V17, P405, DOI 10.1038/gim.2015.30
   Riley LG, 2020, GENET MED, V22, P1254, DOI 10.1038/s41436-020-0793-6
   Robinson JC, 2000, J MOL BIOL, V304, P983, DOI 10.1006/jmbi.2000.4242
   Rucheton B, 2020, MITOCHONDRION, V55, P64, DOI 10.1016/j.mito.2020.08.004
   Schlieben LD, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.600079
   Schon KR, 2020, TRENDS GENET, V36, P702, DOI 10.1016/j.tig.2020.06.009
   Schwarz JM, 2010, NAT METHODS, V7, P575, DOI 10.1038/nmeth0810-575
   Sevini F, 2014, EXP GERONTOL, V56, P234, DOI 10.1016/j.exger.2014.03.022
   Shen XY, 2021, NEUROSCIENCES, V26, P128, DOI 10.17712/nsj.2021.2.20200145
   Simon M, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005097
   Sobenin IA, 2013, ATHEROSCLEROSIS, V227, P283, DOI 10.1016/j.atherosclerosis.2013.01.006
   Steenweg ME, 2012, BRAIN, V135, P1387, DOI 10.1093/brain/aws070
   Stenton SL, 2020, EBIOMEDICINE, V56, DOI 10.1016/j.ebiom.2020.102784
   Sterbová K, 2021, NEUROGENETICS, V22, P359, DOI 10.1007/s10048-021-00659-0
   Subathra M, 2016, ANN HUM GENET, V80, P257, DOI 10.1111/ahg.12161
   SWEENEY MG, 1993, Q J MED, V86, P709
   Tiranti V, 1998, AM J HUM GENET, V63, P1609, DOI 10.1086/302150
   Valente L, 2009, BBA-BIOENERGETICS, V1787, P491, DOI 10.1016/j.bbabio.2008.10.001
   Valiente-Pallejà A, 2018, HUM MOL GENET, V27, P891, DOI 10.1093/hmg/ddy009
   Vilarinho L, 1999, J NEUROL SCI, V163, P168, DOI 10.1016/S0022-510X(99)00030-1
   Vilarinho L, 1997, J MED GENET, V34, P607, DOI 10.1136/jmg.34.7.607
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   Wild KT, 2020, AM J MED GENET A, V182, P365, DOI 10.1002/ajmg.a.61433
   Wong TS, 2023, ORPHANET J RARE DIS, V18, DOI 10.1186/s13023-023-02632-6
   Yoshimi A, 2022, ORPHANET J RARE DIS, V17, DOI 10.1186/s13023-022-02538-9
   Zereg E, 2020, HUM MUTAT, V41, P1394, DOI 10.1002/humu.24037
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
   Zhang W, 2012, CLIN CHEM, V58, P1322, DOI 10.1373/clinchem.2011.181438
NR 65
TC 3
Z9 3
U1 0
U2 0
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD FEB 23
PY 2024
VL 12
AR 1331351
DI 10.3389/fcell.2024.1331351
PG 13
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Developmental Biology
GA KB4Q7
UT WOS:001177492100001
PM 38465286
OA gold, Green Published
DA 2024-11-01
ER

PT J
AU Pagnamenta, AT
   Taanman, JW
   Wilson, CJ
   Anderson, NE
   Marotta, R
   Duncan, AJ
   Bitner-Glindzicz, M
   Taylor, RW
   Laskowski, A
   Thorburn, DR
   Rahman, S
AF Pagnamenta, Alistair T.
   Taanman, Jan-Willem
   Wilson, Callum J.
   Anderson, Neil E.
   Marotta, Rosetta
   Duncan, Andrew J.
   Bitner-Glindzicz, Maria
   Taylor, Robert W.
   Laskowski, Adrienne
   Thorburn, David R.
   Rahman, Shamima
TI Dominant inheritance of premature ovarian failure associated with mutant
   mitochondrial DNA polymerase gamma
SO HUMAN REPRODUCTION
LA English
DT Article
DE mitochondrial DNA depletion; parkinsonism; PEO; POLG; premature
   menopause
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; AUTOSOMAL-DOMINANT;
   OXIDATIVE-PHOSPHORYLATION; DEPLETION SYNDROME; MALE-INFERTILITY; POLG
   MUTATIONS; QUANTIFICATION; CELLS; HYPOGONADISM; MENOPAUSE
AB BACKGROUND: Premature ovarian failure (POF) results in menopause before the age of 40. Recently, mutations in the catalytic subunit of mitochondrial DNA polymerase gamma (POLG) were shown to segregate with POF in families with progressive external ophthalmoplegia (PEO) and multiple large-scale rearrangements of mitochondrial DNA (mtDNA). METHODS AND RESULTS: A patient, mother and maternal grandmother are described, all presenting with POF and PEO. The mother developed parkinsonism in her sixth decade. Normal mtDNA sequence excluded mitochondrial inheritance. Sequence analysis of polymerase gamma revealed a dominant Y955C mutation that segregated with disease. Southern blot analysis demonstrated mtDNA depletion in fibroblasts (43% of controls). In contrast, multiple rearrangements of mtDNA were seen in skeletal muscle, consistent with the relative sparing of nuclear-encoded complex II activity compared with other respiratory chain enzymes. Immunoblotting of native gels showed that DNA polymerase gamma stability was not affected, whereas a reverse-transcriptase primer-extension assay suggested a trend towards reduced polymerase activity in fibroblasts. CONCLUSIONS: This study confirms that POLG mutations can segregate with POF and parkinsonism and demonstrates for the first time that the Y955C mutation can lead to mtDNA depletion. Future screening projects will determine the frequency with which POLG is involved in the aetiology of POF and its impact on reproductive counselling.
C1 Inst Child Hlth, Biochem Endocrinol & Metab Unit, London WC1N 1EH, England.
   UCL Royal Free & Univ Coll Med Sch, Univ Dept Clin Neurosci, London NW3 2PF, England.
   Auckland City Hosp, Dept Neurol, Auckland, New Zealand.
   St Vincents Hosp, Ctr Clin Neurosci & Neurol Res, Fitzroy, Vic 3065, Australia.
   Inst Child Hlth, Clin & Mol Genet Unit, London WC1N 1EH, England.
   Newcastle Univ, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   Univ Melbourne, Dept Paediat, Melbourne, Vic 3052, Australia.
   Royal Childrens Hosp, Murdoch Childrens Res Inst, Melbourne, Vic 3052, Australia.
C3 University of London; University College London; University of London;
   University College London; UCL Medical School; Auckland City Hospital;
   NSW Health; St Vincents Hospital Sydney; St Vincent's Health; St
   Vincent's Hospital Melbourne; University of London; University College
   London; Newcastle University - UK; University of Melbourne; Murdoch
   Children's Research Institute; Royal Children's Hospital Melbourne
RP Rahman, S (corresponding author), Inst Child Hlth, Biochem Endocrinol & Metab Unit, London WC1N 1EH, England.
EM s.rahman@ich.ucl.ac.uk
RI Anderson, Neil/HSC-4097-2023; Thorburn, David/G-6266-2013;
   Bitner-Glindzicz, Maria/A-4231-2009; Wilson, Callum/HJI-0213-2023;
   Rahman, Shamima/C-5232-2008; Taanman, Jan-Willem/A-5379-2011
OI Taanman, Jan-Willem/0000-0002-5476-9785; thorburn,
   david/0000-0002-7725-9470
FU Wellcome Trust [074454] Funding Source: Medline
CR Aknin-Seifer IE, 2005, HUM REPROD, V20, P736, DOI 10.1093/humrep/deh666
   Allingham-Hawkins SJ, 1999, AM J MED GENET, V83, P322, DOI 10.1002/(SICI)1096-8628(19990402)83:4<322::AID-AJMG17>3.0.CO;2-B
   Blake JC, 1999, AM J PATHOL, V155, P67, DOI 10.1016/S0002-9440(10)65100-0
   Goswami D, 2005, HUM REPROD UPDATE, V11, P391, DOI 10.1093/humupd/dmi012
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   He LP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf067
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Longley MJ, 1998, BIOCHEMISTRY-US, V37, P10529, DOI 10.1021/bi980772w
   LUNDBERG PO, 1962, ACTA NEUROL SCAND, V38, P142
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Luoma PT, 2005, HUM MOL GENET, V14, P1907, DOI 10.1093/hmg/ddi196
   Magnusson J, 2003, EXP CELL RES, V289, P133, DOI 10.1016/S0014-4827(03)00249-0
   Melberg A, 1996, MUSCLE NERVE, V19, P1561, DOI 10.1002/(SICI)1097-4598(199612)19:12<1561::AID-MUS5>3.0.CO;2-8
   Murabito JM, 2005, J CLIN ENDOCR METAB, V90, P3427, DOI 10.1210/jc.2005-0181
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   POWELL CM, 1994, AM J MED GENET, V52, P19, DOI 10.1002/ajmg.1320520105
   Rahman S, 1996, ANN NEUROL, V39, P343, DOI 10.1002/ana.410390311
   Rovio AT, 2001, NAT GENET, V29, P261, DOI 10.1038/ng759
   Rowe LB, 1996, MAMM GENOME, V7, P886, DOI 10.1007/s003359900262
   Santos TA, 2006, FERTIL STERIL, V85, P584, DOI 10.1016/j.fertnstert.2005.09.017
   SCHAGGER H, 1995, ELECTROPHORESIS, V16, P763, DOI 10.1002/elps.11501601125
   Steuerwald N, 2000, ZYGOTE, V8, P209, DOI 10.1017/S0967199400001003
   Taanman JW, 1997, HUM MOL GENET, V6, P935, DOI 10.1093/hmg/6.6.935
   Taanman JW, 2003, HUM MOL GENET, V12, P1839, DOI 10.1093/hmg/ddg192
   Taylor RW, 2001, NUCLEIC ACIDS RES, V29, part. no., DOI 10.1093/nar/29.15.e74
   THARAPEL AT, 1993, AM J HUM GENET, V52, P463
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Williams SL, 2004, J BIOL CHEM, V279, P7462, DOI 10.1074/jbc.M309232200
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   Wycherley G, 2005, HUM REPROD, V20, P2757, DOI 10.1093/humrep/dei132
NR 32
TC 118
Z9 127
U1 0
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0268-1161
EI 1460-2350
J9 HUM REPROD
JI Hum. Reprod.
PD OCT
PY 2006
VL 21
IS 10
BP 2467
EP 2473
DI 10.1093/humrep/del076
PG 7
WC Obstetrics & Gynecology; Reproductive Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Obstetrics & Gynecology; Reproductive Biology
GA 090CQ
UT WOS:000240928600003
PM 16595552
OA Bronze
DA 2024-11-01
ER

PT J
AU Bacman, SR
   Williams, SL
   Hernandez, D
   Moraes, CT
AF Bacman, S. R.
   Williams, S. L.
   Hernandez, D.
   Moraes, C. T.
TI Modulating mtDNA heteroplasmy by mitochondria-targeted restriction
   endonucleases in a 'differential multiple cleavage-site' model
SO GENE THERAPY
LA English
DT Article
DE mitochondria; mtDNA heteroplasmy; mitochondrial diseases; restriction
   endonuclease; adenovirus
ID GENE-THERAPY; ADENOVIRAL VECTORS; DNA HETEROPLASMY; SKELETAL-MUSCLE;
   TRANSGENE EXPRESSION; POINT MUTATION; RAGGED-RED; IN-VIVO; MICE;
   TRANSDUCTION
AB The ability to manipulate mitochondrial DNA ( mtDNA) heteroplasmy would provide a powerful tool to treat mitochondrial diseases. Recent studies showed that mitochondria-targeted restriction endonucleases can modify mtDNA heteroplasmy in a predictable and efficient manner if it recognizes a single site in the mutant mtDNA. However, the applicability of such model is limited to mutations that create a novel cleavage site, not present in the wild-type mtDNA. We attempted to extend this approach to a 'differential multiple cleavage site' model, where an mtDNA mutation creates an extra restriction site to the ones normally present in the wild-type mtDNA. Taking advantage of a heteroplasmic mouse model harboring two haplotypes of mtDNA (NZB/BALB) and using adenovirus as a gene vector, we delivered a mitochondria-targeted Scal restriction endonuclease to different mouse tissues. Scal recognizes five sites in the NZB mtDNA but only three in BALB mtDNA. Our results showed that changes in mtDNA heteroplasmy were obtained by the expression of mitochondria-targeted ScaI in both liver, after intravenous injection, and in skeletal muscle, after intramuscular injection. Although mtDNA depletion was an undesirable side effect, our data suggest that under a regulated expression system, mtDNA depletion could be minimized and restriction endonucleases recognizing multiple sites could have a potential for therapeutic use.
C1 Univ Miami, Miller Sch Med, Dept Neurol, Miami, FL 33136 USA.
   Univ Miami, Miller Sch Med, Dept Cell Biol & Anat, Miami, FL 33136 USA.
C3 University of Miami; University of Miami
RP Moraes, CT (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol, 1095 NW 14th Terrace, Miami, FL 33136 USA.
EM cmoraes@med.miami.edu
RI Moraes, Carlos/AAT-3818-2021
FU NCI NIH HHS [R01 CA085700-08, R01 CA085700-07, R01 CA085700] Funding
   Source: Medline; NEI NIH HHS [R01 EY010804, R01 EY010804-11S1, R01
   EY010804-13, EY10804, R01 EY010804-14A1] Funding Source: Medline; NINDS
   NIH HHS [R01 NS041777, R56 NS041777, R01 NS041777-07, NS041777, R01
   NS041777-08] Funding Source: Medline
CR Allamand V, 2000, GENE THER, V7, P1385, DOI 10.1038/sj.gt.3301247
   Bangari DS, 2006, CURR GENE THER, V6, P215, DOI 10.2174/156652306776359478
   Barrientos A, 2002, METHODS, V26, P307, DOI 10.1016/S1046-2023(02)00036-1
   Battersby BJ, 2001, HUM MOL GENET, V10, P2469, DOI 10.1093/hmg/10.22.2469
   Bayona-Bafaluy MP, 2005, P NATL ACAD SCI USA, V102, P14392, DOI 10.1073/pnas.0502896102
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Cao HB, 2004, VIRAL IMMUNOL, V17, P327, DOI 10.1089/vim.2004.17.327
   Cazzalini O, 2001, BIOCHEM PHARMACOL, V62, P893, DOI 10.1016/S0006-2952(01)00713-4
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   Chinnery PF, 1999, GENE THER, V6, P1919, DOI 10.1038/sj.gt.3301061
   CHOMYN A, 1992, P NATL ACAD SCI USA, V89, P4221, DOI 10.1073/pnas.89.10.4221
   Clark KM, 1997, NAT GENET, V16, P222, DOI 10.1038/ng0797-222
   D'Souza GGM, 2004, CURR GENE THER, V4, P317
   De Giorgi F, 1999, METHOD CELL BIOL, V58, P75
   Diaz F, 2005, HUM MOL GENET, V14, P2737, DOI 10.1093/hmg/ddi307
   DiMauro S, 2006, CURR OPIN RHEUMATOL, V18, P636, DOI 10.1097/01.bor.0000245729.17759.f2
   Dudley RWR, 2004, HUM GENE THER, V15, P145, DOI 10.1089/104303404772679959
   Everett RS, 2003, HUM GENE THER, V14, P1715, DOI 10.1089/104303403322611737
   Gonzalez-Nicolini V, 2006, J GENE MED, V8, P1208, DOI 10.1002/jgm.960
   Gregorevic P, 2006, NAT MED, V12, P787, DOI 10.1038/nm1439
   HANNA MG, 1995, J NEUROL SCI, V130, P154, DOI 10.1016/0022-510X(95)00022-T
   HUARD J, 1995, GENE THER, V2, P107
   Jazayeri M, 2003, J BIOL CHEM, V278, P9823, DOI 10.1074/jbc.M211730200
   Jenuth JP, 1997, NAT GENET, V16, P93, DOI 10.1038/ng0597-93
   Manfred G, 1999, J BIOL CHEM, V274, P9386, DOI 10.1074/jbc.274.14.9386
   Martin-Touaux E, 2002, HUM MOL GENET, V11, P1637, DOI 10.1093/hmg/11.14.1637
   Menezes KM, 2006, HUM GENE THER, V17, P314, DOI 10.1089/hum.2006.17.314
   Mitsuoka T, 1998, No To Shinkei, V50, P1089
   MORAES CT, 1992, NAT GENET, V1, P359, DOI 10.1038/ng0892-359
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Moreno-Loshuertos R, 2006, NAT GENET, V38, P1261, DOI 10.1038/ng1897
   Nicklin SA, 2005, MOL THER, V12, P384, DOI 10.1016/j.ymthe.2005.05.008
   O'Hara AJ, 2001, MUSCLE NERVE, V24, P488, DOI 10.1002/mus.1031
   PETRUZZELLA V, 1994, HUM MOL GENET, V3, P449, DOI 10.1093/hmg/3.3.449
   Ragot Thierry, 1996, Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales, V190, P13
   REICHMANN H, 1992, HISTOCHEMISTRY, V98, P131, DOI 10.1007/BF00717004
   Schaefer AM, 2004, BBA-BIOENERGETICS, V1659, P115, DOI 10.1016/j.bbabio.2004.09.005
   Shayakhmetov DM, 2004, J VIROL, V78, P5368, DOI 10.1128/JVI.78.10.5368-5381.2004
   Shoubridge EA, 1997, HUM MOL GENET, V6, P2239, DOI 10.1093/hmg/6.13.2239
   SOLIGNAC M, 1983, P NATL ACAD SCI-BIOL, V80, P6942, DOI 10.1073/pnas.80.22.6942
   Srivastava S, 2001, HUM MOL GENET, V10, P3093, DOI 10.1093/hmg/10.26.3093
   Sullivan DE, 1997, HUM GENE THER, V8, P1195, DOI 10.1089/hum.1997.8.10-1195
   Taivassalo T, 1999, HUM MOL GENET, V8, P1047, DOI 10.1093/hmg/8.6.1047
   Tanaka M, 2002, J BIOMED SCI, V9, P534, DOI 10.1007/BF02254980
   Tang YY, 2000, MOL BIOL CELL, V11, P1471, DOI 10.1091/mbc.11.4.1471
   Taylor RW, 1997, NAT GENET, V15, P212, DOI 10.1038/ng0297-212
   Walther W, 2007, MOL CANCER THER, V6, P236, DOI 10.1158/1535-7163.MCT-06-0070
   Xu ZL, 2005, ADV DRUG DELIVER REV, V57, P781, DOI 10.1016/j.addr.2004.12.010
NR 48
TC 72
Z9 86
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0969-7128
EI 1476-5462
J9 GENE THER
JI Gene Ther.
PD SEP
PY 2007
VL 14
IS 18
BP 1309
EP 1318
DI 10.1038/sj.gt.3302981
PG 10
WC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
   Genetics & Heredity; Research & Experimental Medicine
GA 207GP
UT WOS:000249239900001
PM 17597792
OA Green Accepted
DA 2024-11-01
ER

PT J
AU Bugiardini, E
   Poole, OV
   Manole, A
   Pittman, AM
   Horga, A
   Hargreaves, I
   Woodward, CE
   Sweeney, MG
   Holton, JL
   Taanman, JW
   Plant, GT
   Poulton, J
   Zeviani, M
   Ghezzi, D
   Taylor, J
   Smith, C
   Fratter, C
   Kanikannan, MA
   Paramasivam, A
   Thangaraj, K
   Spinazzola, A
   Holt, IJ
   Houlden, H
   Hanna, MG
   Pitceathly, RDS
AF Bugiardini, Enrico
   Poole, Olivia V.
   Manole, Andreea
   Pittman, Alan M.
   Horga, Alejandro
   Hargreaves, Iain
   Woodward, Cathy E.
   Sweeney, Mary G.
   Holton, Janice L.
   Taanman, Jan-Willem
   Plant, Gordon T.
   Poulton, Joanna
   Zeviani, Massimo
   Ghezzi, Daniele
   Taylor, John
   Smith, Conrad
   Fratter, Carl
   Kanikannan, Meena A.
   Paramasivam, Arumugam
   Thangaraj, Kumarasamy
   Spinazzola, Antonella
   Holt, Ian J.
   Houlden, Henry
   Hanna, Michael G.
   Pitceathly, Robert D. S.
TI Clinicopathologic and molecular spectrum of <i>RNASEH1</i>-related
   mitochondrial disease
SO NEUROLOGY-GENETICS
LA English
DT Article
ID H1
AB Objective: Pathologic ribonuclease H1 (RNase H1) causes aberrant mitochondrial DNA (mtDNA) segregation and is associated with multiple mtDNA deletions. We aimed to determine the prevalence of RNase H1 gene (RNASEH1) mutations among patients with mitochondrial disease and establish clinically meaningful genotype-phenotype correlations.
   Methods: RNASEH1 was analyzed in patients with (1) multiple deletions/depletion of muscle mtDNA and (2) mendelian progressive external ophthalmoplegia (PEO) with neuropathologic evidence of mitochondrial dysfunction, but no detectable multiple deletions/depletion of muscle mtDNA. Clinicopathologic and molecular evaluation of the newly identified and previously reported patients harboring RNASEH1 mutations was subsequently undertaken.
   Results: Pathogenic c.424G>A p.Val142Ile RNASEH1 mutations were detected in 3 pedigrees among the 74 probands screened. Given that all 3 families had Indian ancestry, RNASEH1 genetic analysis was undertaken in 50 additional Indian probands with variable clinical presentations associated with multiple mtDNA deletions, but no further RNASEH1 mutations were confirmed. RNASEH1-related mitochondrial disease was characterized by PEO (100%), cerebellar ataxia (57%), and dysphagia (50%). The ataxia neuropathy spectrum phenotype was observed in 1 patient. Although the c.424G>A p.Val142Ile mutation underpins all reported RNASEH1-related mitochondrial disease, haplotype analysis suggested an independent origin, rather than a founder event, for the variant in our families.
   Conclusions: In our cohort, RNASEH1 mutations represent the fourth most common cause of adult mendelian PEO associated with multiple mtDNA deletions, following mutations in POLG, RRM2B, and TWNK. RNASEH1 genetic analysis should also be considered in all patients with POLG-negative ataxia neuropathy spectrum. The pathophysiologic mechanisms by which the c.424G>A p.Val142Ile mutation impairs human RNase H1 warrant further investigation.
C1 [Bugiardini, Enrico; Poole, Olivia V.; Manole, Andreea; Horga, Alejandro; Holton, Janice L.; Houlden, Henry; Hanna, Michael G.; Pitceathly, Robert D. S.] UCL Inst Neurol, MRC Ctr Neuromuscular Dis, London, England.
   Natl Hosp Neurol & Neurosurg, London, England.
   [Manole, Andreea; Pittman, Alan M.; Holton, Janice L.; Houlden, Henry; Hanna, Michael G.] UCL Inst Neurol, Dept Mol Neurosci, London, England.
   [Holton, Janice L.] UCL Inst Neurol, Div Neuropathol, London, England.
   [Taanman, Jan-Willem; Spinazzola, Antonella; Holt, Ian J.] UCL Inst Neurol, Dept Clin Neurosci, London, England.
   [Hargreaves, Iain] Natl Hosp Neurol & Neurosurg, Neurometab Unit, London, England.
   [Woodward, Cathy E.; Sweeney, Mary G.] Natl Hosp Neurol & Neurosurg, Neurogenet Unit, London, England.
   [Plant, Gordon T.] Natl Hosp Neurol & Neurosurg, Dept Neuroophthalmol, London, England.
   [Poulton, Joanna] Univ Oxford, Nuffield Dept Obstet & Gynaecol, Oxford, England.
   [Zeviani, Massimo] MRC Mitochondrial Biol Unit, Cambridge, England.
   [Ghezzi, Daniele] Fdn IRCCS Ist Neurol Carlo Besta, Unit Mol Neurogenet, Milan, Italy.
   [Taylor, John; Smith, Conrad; Fratter, Carl] Churchill Hosp, Oxford Univ Hosp NHS Fdn Trust, Oxford Med Genet Labs, Oxford, England.
   [Kanikannan, Meena A.] Nizams Inst Med Sci, Dept Neurol, Hyderabad, Telangana, India.
   [Paramasivam, Arumugam; Thangaraj, Kumarasamy] CSIR Ctr Cellular & Mol Biol, Hyderabad, Telangana, India.
   [Holt, Ian J.] MRC Mill Hill Lab, London, England.
   [Holt, Ian J.] Biodonostia Res Inst, San Sebastian, Spain.
   [Pitceathly, Robert D. S.] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Basic & Clin Neurosci, London, England.
C3 University of London; University College London; University of London;
   University College London; UCL Medical School; University College London
   Hospitals NHS Foundation Trust; University of London; University College
   London; University of London; University College London; University of
   London; University College London; University of London; University
   College London; UCL Medical School; University College London Hospitals
   NHS Foundation Trust; University of London; University College London;
   UCL Medical School; University College London Hospitals NHS Foundation
   Trust; University of London; University College London; UCL Medical
   School; University College London Hospitals NHS Foundation Trust;
   University of Oxford; Fondazione IRCCS Istituto Neurologico Carlo Besta;
   University of Oxford; Oxford University Hospitals NHS Foundation Trust;
   Nizam's Institute of Medical Sciences; Council of Scientific &
   Industrial Research (CSIR) - India; CSIR - Centre for Cellular &
   Molecular Biology (CCMB); University of London; King's College London
RP Pitceathly, RDS (corresponding author), UCL Inst Neurol, MRC Ctr Neuromuscular Dis, London, England.; Pitceathly, RDS (corresponding author), Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Basic & Clin Neurosci, London, England.
EM r.pitceathly@ucl.ac.uk
RI Holton, Janice/F-6831-2011; Taylor, John/E-5894-2010; Zeviani,
   Massimo/AAU-2632-2021; Arumugam, Paramasivam/JAC-6846-2023; Thangaraj,
   Kumarasamy/G-5596-2010; Horga, Alejandro/AAA-1086-2019; Houlden,
   Henry/C-1532-2008; Poulton, Joanna/AAB-4828-2021; Hargreaves,
   Iain/AAJ-6757-2020; Manole, Andreea/G-5381-2015; Ghezzi,
   Daniele/J-7873-2016; Spinazzola, Antonella/P-5298-2017; holt,
   ian/AFT-2565-2022; Pittman, Alan/D-6231-2012; Taanman,
   Jan-Willem/A-5379-2011; Jayaseelan, Dr. Vijayashree
   Priyadharsini/AAD-4261-2019
OI Horga, Alejandro/0000-0002-2120-2213; Spinazzola,
   Antonella/0000-0003-4242-8091; holt, ian/0000-0001-5468-0193; Manole,
   Andreea/0000-0002-9397-8248; Zeviani, Massimo/0000-0002-9067-5508;
   Houlden, Henry/0000-0002-2866-7777; Pittman, Alan/0000-0002-8112-2987;
   Bugiardini, Enrico/0000-0002-9709-6699; Taanman,
   Jan-Willem/0000-0002-5476-9785; Hanna, Michael/0000-0003-0825-4075;
   Jayaseelan, Dr. Vijayashree Priyadharsini/0000-0001-7884-5466;
   Pitceathly, Robert/0000-0002-6123-4551; Poulton,
   Joanna/0000-0002-2460-5587; Arumugam, Paramasivam/0000-0001-6117-1178
FU European Community's Seventh Framework Programme (FP7) [2012-305121];
   Medical Research Council Centre [G0601943]; Wellcome Trust; Department
   of Health's National Institute for Health Research Biomedical Research
   Centres; National Institute for Health Research; Lily Foundation;
   NewLife [SG/14-15/11]; Medical Research Council [MR/J010448/1]; Wellcome
   Trust [0948685/Z/10/Z]; Department of Biotechnology; Council of
   Scientific and Industrial Research, Government of India [BioAge:
   BSC0118]; Science and Engineering Research Board, Government of India
   [PDF/2016/000881]; Medical Research Council Senior Non-Clinical
   Fellowship [MC_PC_13029]; MRC [MC_UU_00015/5, MR/K000608/1, G0800674,
   G0802760, MC_U105663140, MR/J004758/1, G1001253, MR/J010448/1, G108/638,
   MC_UP_1002/1, MC_PC_13029/2, MC_UP_1202/14] Funding Source: UKRI
FX The research leading to these results has received funding from the
   European Community's Seventh Framework Programme (FP7/2007-2013) under
   grant agreement no. 2012-305121 "Integrated European-omics research
   project for diagnosis and therapy in rare neuromuscular and
   neurodegenerative diseases (NEUROMICS)." This work is also supported by
   a Medical Research Council Centre grant (G0601943) and Wellcome Trust
   grant on Synaptopathies. Part of this work was undertaken in the
   University College London Hospitals/University College London Institute
   of Neurology sequencing facility, which received a proportion of funding
   from the Department of Health's National Institute for Health Research
   Biomedical Research Centres funding scheme. R.D.S.P. is funded by the
   National Institute for Health Research. O.V.P. has received funding from
   the Lily Foundation. J.P. receives support from the Lily Foundation,
   NewLife (SG/14-15/11), the Medical Research Council (MR/J010448/1), and
   the Wellcome Trust (0948685/Z/10/Z). K.T. is supported by the Department
   of Biotechnology and the Council of Scientific and Industrial Research
   (BioAge: BSC0118), Government of India. A.P. is supported by the Science
   and Engineering Research Board (PDF/2016/000881), Government of India.
   A.S. is supported by the Medical Research Council Senior Non-Clinical
   Fellowship, MC_PC_13029.
CR Akman G, 2016, P NATL ACAD SCI USA, V113, pE4276, DOI 10.1073/pnas.1600537113
   Cerritelli SM, 2003, MOL CELL, V11, P807, DOI 10.1016/S1097-2765(03)00088-1
   DiMauro S, 2013, NAT REV NEUROL, V9, P429, DOI 10.1038/nrneurol.2013.126
   Holmes JB, 2015, P NATL ACAD SCI USA, V112, P9334, DOI 10.1073/pnas.1503653112
   KELLER W, 1972, P NATL ACAD SCI USA, V69, P3360, DOI 10.1073/pnas.69.11.3360
   Lax NZ, 2012, BRAIN, V135, P62, DOI 10.1093/brain/awr326
   Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057
   Lieber DS, 2013, NEUROLOGY, V80, P1762, DOI 10.1212/WNL.0b013e3182918c40
   Metspalu M, 2011, AM J HUM GENET, V89, P731, DOI 10.1016/j.ajhg.2011.11.010
   Reyes A, 2015, AM J HUM GENET, V97, P186, DOI 10.1016/j.ajhg.2015.05.013
NR 10
TC 16
Z9 17
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 2376-7839
J9 NEUROL-GENET
JI Neurol.-Genet.
PD JUN
PY 2017
VL 3
IS 3
AR e149
DI 10.1212/NXG.0000000000000149
PG 7
WC Genetics & Heredity; Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Neurosciences & Neurology
GA FW1BM
UT WOS:000425030300003
PM 28508084
OA gold, Green Submitted, Green Accepted, Green Published
DA 2024-11-01
ER

PT J
AU Meira, B
   Roque, R
   Pinto, M
   Caetano, A
AF Meira, Bruna
   Roque, Rafael
   Pinto, Miguel
   Caetano, Andre
TI Late-onset presentation of POLG1-associated mitochondrial disease
SO BMJ CASE REPORTS
LA English
DT Article
DE neuromuscular disease; muscle disease; neuro genetics;
   neuroopthalmology; parkinson's disease
AB Mutations in the nuclear POLG1 gene compromise the integrity of mitochondrial DNA and show great allelic and clinical heterogeneity. Among adult POLG1-associated mitochondrial disease, the main clinical feature is chronic progressive external ophthalmoplegia. Other related clinical manifestations are sensory or cerebellar ataxia, peripheral neuropathy, myopathy or extrapyramidal symptoms. We report the case of a 72-year-old man who presented with a late onset sensory neuronopathy, chronic progressive external ophthalmoplegia, gait ataxia and parkinsonism. Genetic studies showed a compound heterozygosity of known pathogenic mutations in the POLG1 gene (variant T252I/P587L in cis configuration in allele 1 and variant R807C in allele 2). Late life presentation highlights that mitochondrial disorders should be considered regardless of age of onset of symptoms.
C1 [Meira, Bruna; Pinto, Miguel; Caetano, Andre] Ctr Hosp Lisboa Ocidental EPE, Neurol Dept, Lisbon, Portugal.
   [Roque, Rafael] Ctr Hosp Lisboa Norte EPE, Neurol Dept, Neuropathol Unit, Lisbon, Portugal.
C3 Centro Hospitalar de Lisboa Ocidental, EPE; Centro Hospitalar de Lisboa
   Ocidental, EPE
RP Meira, B (corresponding author), Ctr Hosp Lisboa Ocidental EPE, Neurol Dept, Lisbon, Portugal.
EM bmeira.rmm@gmail.com
CR Brais Bernard, 2011, Handb Clin Neurol, V101, P181, DOI 10.1016/B978-0-08-045031-5.00014-1
   Cohen BH, 2010, METHODS, V51, P364, DOI 10.1016/j.ymeth.2010.05.008
   Fadic R, 1997, NEUROLOGY, V49, P239, DOI 10.1212/WNL.49.1.239
   Gago MF, 2006, NEUROMUSCULAR DISORD, V16, P507, DOI 10.1016/j.nmd.2006.05.016
   Hanisch F, 2015, J NEUROL NEUROSUR PS, V86, P630, DOI 10.1136/jnnp-2013-306748
   Lovan Alyson, 2013, BMJ Case Rep, V2013, DOI 10.1136/bcr-2013-010343
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Miguel R, 2014, CLIN NEUROL NEUROSUR, V126, P47, DOI 10.1016/j.clineuro.2014.08.020
   Milone M, 2008, NEUROMUSCULAR DISORD, V18, P626, DOI 10.1016/j.nmd.2008.05.009
   Pesce V, 2001, FREE RADICAL BIO MED, V30, P1223, DOI 10.1016/S0891-5849(01)00517-2
   Scuderi C, 2015, NEUROMUSCULAR DISORD, V25, P333, DOI 10.1016/j.nmd.2015.01.004
   Stumpf JD, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a011395
   Tchikviladze M, 2015, J NEUROL NEUROSUR PS, V86, P646, DOI 10.1136/jnnp-2013-306799
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Weiss MD, 2010, MUSCLE NERVE, V41, P882, DOI 10.1002/mus.21636
NR 15
TC 4
Z9 4
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
EI 1757-790X
J9 BMJ CASE REP
JI BMJ Case Rep.
PD JUN
PY 2019
VL 12
IS 3
AR e228482
DI 10.1136/bcr-2018-228482
PG 4
WC Medicine, General & Internal
WE Emerging Sources Citation Index (ESCI)
SC General & Internal Medicine
GA VK1LQ
UT WOS:000661378700154
PM 30936349
OA Green Published
DA 2024-11-01
ER

PT J
AU Auré, K
   de Baulny, HO
   Laforêt, P
   Jardel, C
   Eymard, B
   Lombès, A
AF Aure, Karine
   de Baulny, Helene Ogier
   Laforet, Pascal
   Jardel, Claude
   Eymard, Bruno
   Lombes, Anne
TI Chronic progressive ophthalmoplegia with large-scale mtDNA
   rearrangement:: can we predict progression?
SO BRAIN
LA English
DT Article
DE mitochondrial disease; deletion; Kearns-Sayre syndrome; CPEO; natural
   history
ID KEARNS-SAYRE SYNDROME; MITOCHONDRIAL-DNA DELETIONS; MARROW-PANCREAS
   SYNDROME; EXTERNAL OPHTHALMOPLEGIA; PEARSON-SYNDROME; TISSUE
   DISTRIBUTION; MUSCLE-FIBERS; MYOPATHIES; DUPLICATIONS; PLUS
AB The prognosis of chronic progressive ophthalmoplegia with large-scale mitochondrial DNA (mtDNA) may strikingly vary from mild slowly progressive myopathy to severe multi-organ involvement. Evaluation of the disease course at the beginning of the disease is reputed impossible. To address the existence of predictive prognostic clues of these diseases, we classified 69 patients with chronic progressive ophthalmoplegia and large size mtDNA deletion into two groups according to the presence of manifestations from brain, inner ear or retina. These manifestations were present in 29 patients (CPEO/+N group) and absent in 40 patients (CPEO/-N group). We retrospectively established the clinical history of the patients and characterized their genetic alteration (amount of residual normal mtDNA molecules, site, size and percentage of the mtDNA deletion in 116 DNA samples from muscle, blood, urinary and buccal cells).
   In both clinical groups, the disease was progressive and heart conduction defects were frequent. We show that the CPEO/+N phenotype segregated with severe prognosis in term of rate of progression, multi-organs involvement and rate of survival. Age at onset appeared a predictive factor. The risk to develop a CPEO/+N phenotype was high when onset was before 9 years of age and low when onset was after 20 years of age. The presence and proportion of the mtDNA deletion in blood was also significantly associated with the CPEO/ +N phenotype.
   This study is the first to establish the natural history of chronic ophthalmoplegia with mtDNA deletion in a large series of patients and to look for parameters potentially predictive of the patients'clinical course.
C1 INSERM, U582, F-75013 Paris, France.
   Univ Paris 06, IFRI4, F-75013 Paris, France.
   Hop Robert Debre, Ctr Reference Maladies Hereditaires Metab, F-75020 Paris, France.
   Hop La Pitie Salpetriere, Inst Myol, F-75013 Paris, France.
   Hop La Pitie Salpetriere, F-75013 Paris, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP);
   Universite Paris Cite; Hopital Universitaire Robert-Debre - APHP;
   Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital
   Universitaire Pitie-Salpetriere - APHP; Sorbonne Universite; Assistance
   Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere
   - APHP
RP Lombes, A (corresponding author), INSERM, U582, Inst Myol, Grp Hosp Pitie Salpetriere, 47-83 Blvd De LHop, F-75013 Paris, France.
EM a.lombes@myologie.chups.jussieu.fr
RI Lombes, Anne/G-4684-2014
CR Auré K, 2006, BRAIN, V129, P1249, DOI 10.1093/brain/awl061
   BASTIAENSEN LAK, 1978, ACTA NEUROL SCAND, V58, P9
   BERENBERG RA, 1977, ANN NEUROL, V1, P37, DOI 10.1002/ana.410010104
   BERNES SM, 1993, J PEDIATR-US, V123, P598, DOI 10.1016/S0022-3476(05)80962-X
   BROCKINGTON M, 1995, J NEUROL SCI, V131, P78, DOI 10.1016/0022-510X(95)00091-F
   BUTLER IJ, 1976, ARCH INTERN MED, V136, P1290
   Cheng G, 1999, DEVELOPMENT, V126, P5041
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   DRACHMAN DA, 1968, ARCH NEUROL-CHICAGO, V18, P654, DOI 10.1001/archneur.1968.00470360076008
   GERBITZ KD, 1990, J NEUROL, V237, P5, DOI 10.1007/BF00319660
   HAMMANS SR, 1992, BRAIN, V115, P343, DOI 10.1093/brain/115.2.343
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   HOLT IJ, 1989, ANN NEUROL, V26, P699, DOI 10.1002/ana.410260603
   HURKO O, 1990, PEDIATR RES, V28, P542, DOI 10.1203/00006450-199011000-00026
   KEARNS TP, 1958, ARCH OPHTHALMOL-CHIC, V60, P280, DOI 10.1001/archopht.1958.00940080296016
   Lacbawan F, 2000, AM J MED GENET, V95, P266, DOI 10.1002/1096-8628(20001127)95:3<266::AID-AJMG13>3.3.CO;2-S
   LARSSON NG, 1990, PEDIATR RES, V28, P131, DOI 10.1203/00006450-199028020-00011
   Manfredi G, 1997, ANN NEUROL, V42, P180, DOI 10.1002/ana.410420208
   MCSHANE MA, 1991, AM J HUM GENET, V48, P39
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Odoardi F, 2003, AM J MED GENET A, V118A, P247, DOI 10.1002/ajmg.a.20006
   OLDFORS A, 1992, J NEUROL SCI, V110, P169, DOI 10.1016/0022-510X(92)90025-G
   PEARSON HA, 1979, J PEDIATR-US, V95, P976, DOI 10.1016/S0022-3476(79)80286-3
   POULTON J, 1991, AM J HUM GENET, V48, P649
   POULTON J, 1994, HUM MOL GENET, V3, P947, DOI 10.1093/hmg/3.6.947
   Remes AM, 2005, NEUROLOGY, V64, P976, DOI 10.1212/01.WNL.0000154518.31302.ED
   ROTIG A, 1995, HUM MOL GENET, V4, P1327, DOI 10.1093/hmg/4.8.1327
   SCIACCO M, 1994, HUM MOL GENET, V3, P13, DOI 10.1093/hmg/3.1.13
   SHANSKE S, 1990, NEUROLOGY, V40, P24, DOI 10.1212/WNL.40.1.24
   Shanske S, 2002, AM J HUM GENET, V71, P679, DOI 10.1086/342482
   SHY GM, 1967, AM J MED, V42, P163, DOI 10.1016/0002-9343(67)90015-0
   YAMAMOTO M, 1991, NEUROLOGY, V41, P1822, DOI 10.1212/WNL.41.11.1822
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
   ZEVIANI M, 1990, ANN NEUROL, V28, P94, DOI 10.1002/ana.410280118
NR 34
TC 48
Z9 52
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
J9 BRAIN
JI Brain
PD JUN
PY 2007
VL 130
BP 1516
EP 1524
DI 10.1093/brain/awm067
PN 6
PG 9
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 183IA
UT WOS:000247565300009
PM 17439982
OA Bronze
DA 2024-11-01
ER

PT J
AU Luoma, PT
   Luo, NG
   Löscher, WN
   Farr, CL
   Horvath, R
   Wanschitz, J
   Kiechl, S
   Kaguni, LS
   Suomalainen, A
AF Luoma, PT
   Luo, NG
   Löscher, WN
   Farr, CL
   Horvath, R
   Wanschitz, J
   Kiechl, S
   Kaguni, LS
   Suomalainen, A
TI Functional defects due to spacer-region mutations of human mitochondrial
   DNA polymerase in a family with an ataxia-myopathy syndrome
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; AUTOSOMAL-DOMINANT; POLG
   MUTATIONS; MULTIPLE DELETIONS; DROSOPHILA-MELANOGASTER; CATALYTIC
   SUBUNIT; STRAND SYNTHESIS; GAMMA-A; MTDNA; NEUROPATHY
AB Defects of mitochondrial polymerase gamma (POLG) underlie neurological diseases ranging from myopathies to parkinsonism and infantile Alpers syndrome. The most severe manifestations have been associated with mutations of the 'spacer' region of POLG, the function of which has remained unstudied in humans. We identified a family, segregating three POLG amino acid variants, A467T, R627Q and Q1236H. The first two affect the spacer region and the third is a polymorphism, allelic with R627Q. Three grades of disease severity appeared to correlate with the genotypes. The patient with the most severe outcome, cerebellar ataxia syndrome, had all three variants, those with R627Q and Q1236H had juvenile-onset ptosis and gait disturbance and those with a single A467T allele had late-onset ptosis. To evaluate the molecular pathogenesis of these spacer defects, we expressed and purified the mutant proteins and studied their catalytic properties in vitro. The A467T substitution resulted in clearly decreased activity, DNA binding and processivity of the polymerase. Our biochemical data, the dominant manifestation of A467T and its previously reported high frequency in the Belgian population (0.6%), emphasize the role of this mutation as a common cause of neurological disease. Further, biochemical evidence that a polymorphic variant may modify the function of a mutant POLG, if occurring in the same polypeptide, is shown here. Finally, and surprisingly, other pathogenic spacer mutants showed DNA-binding affinities and processivities similar to or higher than the controls, suggesting that the disease-causing mechanisms of spacer mutations extend beyond the basic catalytic functions of POLG.
C1 Univ Helsinki, Biomedicum Helsinki, Programme Neurosci, FIN-00290 Helsinki, Finland.
   Univ Helsinki, Cent Hosp, Dept Neurol, Helsinki, Finland.
   Michigan State Univ, Grad Program Genet, E Lansing, MI 48824 USA.
   Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.
   Innsbruck Med Univ, Dept Clin Neurol, Innsbruck, Austria.
   Acad Hosp Schwabing, Metab Dis Ctr, Munich, Germany.
   Acad Hosp Schwabing, Dept Clin Chem, Munich, Germany.
C3 University of Helsinki; University of Helsinki; Helsinki University
   Central Hospital; Michigan State University; Michigan State University;
   Medical University of Innsbruck
RP Univ Helsinki, Biomedicum Helsinki, Programme Neurosci, Room C523B,Haartmaninkatu 8, FIN-00290 Helsinki, Finland.
EM anu.wartiovaara@helsinki.fi
RI Kiechl, Stefan/GQP-0351-2022; Horvath, Rita/AAY-7042-2020
OI Loscher, Wolfgang/0000-0002-7593-3222; Horvath,
   Rita/0000-0002-9841-170X; Suomalainen-Wartiovaara,
   Anu/0000-0003-4833-5195
FU NIGMS NIH HHS [GM45295] Funding Source: Medline
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Bowmaker M, 2003, J BIOL CHEM, V278, P50961, DOI 10.1074/jbc.M308028200
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Brobby GW, 1998, NEW ENGL J MED, V338, P548, DOI 10.1056/NEJM199802193380813
   CLAYTON DA, 1982, CELL, V28, P693, DOI 10.1016/0092-8674(82)90049-6
   Di Fonzo A, 2003, HUM MUTAT, V22, DOI 10.1002/humu.9203
   Farr CL, 1999, J BIOL CHEM, V274, P14779, DOI 10.1074/jbc.274.21.14779
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   FISCHER JC, 1986, EUR J PEDIATR, V144, P441, DOI 10.1007/BF00441735
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   Hofmann S, 1997, GENOMICS, V39, P8, DOI 10.1006/geno.1996.4474
   Holt IJ, 2000, CELL, V100, P515, DOI 10.1016/S0092-8674(00)80688-1
   Iyengar B, 1999, GENETICS, V153, P1809
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   Kajander OA, 1999, NAT MED, V5, P965, DOI 10.1038/12379
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Löffler J, 2001, EUR J HUM GENET, V9, P226, DOI 10.1038/sj.ejhg.5200607
   Longley MJ, 1998, BIOCHEMISTRY-US, V37, P10529, DOI 10.1021/bi980772w
   Luo NG, 2005, J BIOL CHEM, V280, P2491, DOI 10.1074/jbc.M411447200
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Mancuso M, 2004, ARCH NEUROL-CHICAGO, V61, P1777, DOI 10.1001/archneur.61.11.1777
   Moslemi AR, 1999, NEUROLOGY, V53, P79, DOI 10.1212/WNL.53.1.79
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200
   SCHMITT ME, 1993, CURR OPIN GENET DEV, V3, P769, DOI 10.1016/S0959-437X(05)80097-8
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   Suomalainen A, 2000, MOL BIOTECHNOL, V15, P123, DOI 10.1385/MB:15:2:123
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, NEUROLOGY, V61, P1811, DOI 10.1212/01.WNL.0000098997.23471.65
   Van Goethem G, 2003, HUM MUTAT, V22, P175, DOI 10.1002/humu.10246
   Van Goethem G, 2003, EUR J HUM GENET, V11, P547, DOI 10.1038/sj.ejhg.5201002
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Wang YX, 1999, J BIOL CHEM, V274, P28972, DOI 10.1074/jbc.274.41.28972
   Wang YX, 1997, J BIOL CHEM, V272, P13640, DOI 10.1074/jbc.272.21.13640
   Wanrooij S, 2004, NUCLEIC ACIDS RES, V32, P3053, DOI 10.1093/nar/gkh634
   WERNETTE CM, 1986, J BIOL CHEM, V261, P4764
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 42
TC 88
Z9 96
U1 0
U2 4
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD JUL 15
PY 2005
VL 14
IS 14
BP 1907
EP 1920
DI 10.1093/hmg/ddi196
PG 14
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 941HL
UT WOS:000230205800001
PM 15917273
DA 2024-11-01
ER

PT J
AU Ferreira, F
   Bacelar, CG
   Lisboa-Gonçalves, P
   Paulo, N
   Quental, R
   Nunes, AT
   Silva, R
   Tavares, I
AF Ferreira, Filipa
   Bacelar, Clara Goncalves
   Lisboa-Goncalves, Pedro
   Paulo, Nuria
   Quental, Rita
   Nunes, Ana Teresa
   Silva, Roberto
   Tavares, Isabel
TI Renal manifestations in adults with mitochondrial disease from the mtDNA
   m.3243A&gt;G pathogenic variant
SO NEFROLOGIA
LA English
DT Review
DE Focal segmental glomerulosclerosis; mtDNA m.3243A > G; MELAS syndrome;
   Mitochondrial diseases; Renal disease
ID FOCAL SEGMENTAL GLOMERULOSCLEROSIS; LACTIC-ACIDOSIS; EPISODES MELAS;
   ENCEPHALOPATHY; MANAGEMENT; DIAGNOSIS; MYOPATHY; MUTATION; PATIENT;
   TRANSPLANTATION
AB Mitochondrial diseases are a phenotype and genotype heterogeneous group of disorders that typically have a multisystemic involvement. The m.3243A>G pathogenic variant is the most frequent mitochondrial DNA defect, and it causes several different clinical syndromes, such as mitochondrial encephalopathy, lactic acidosis and stroke-like episodes (MELAS), and the maternally inherited diabetes and deafness (MIDD) syndromes. Not frequently reported, renal involvement in these diseases is probably under estimated, yet it increases morbidity. It generally manifests as subnephrotic proteinuria and progressive deterioration of kidney function. Adult presentation of mitochondrial diseases is hard to recognize, especially in oligosymptomatic patients or those with exclusive kidney involvement. However, suspicion should always arise when family history, particularly on the maternal side, and multisystemic symptoms, most often of the central nervous system and skeletal muscles, are present. In this review we discuss the clinical diagnosis and approach of patients with renal manifestations in the context of the mtDNA m.3243A>G pathogenic variant. (c) 2023 Sociedad Espanola de Nefrolog ' ia. Published by Elsevier Espana, S.L.U.
C1 [Ferreira, Filipa; Lisboa-Goncalves, Pedro; Paulo, Nuria; Nunes, Ana Teresa; Tavares, Isabel] Ctr Hosp & Univ Sao Joao, Serv Nefrol, Porto, Portugal.
   [Ferreira, Filipa; Lisboa-Goncalves, Pedro; Paulo, Nuria; Tavares, Isabel] Univ Porto, Dept Med, Fac Med, Porto, Portugal.
   [Bacelar, Clara Goncalves] Univ Porto, Fac Med, Porto, Portugal.
   [Quental, Rita] Ctr Hosp & Univ Sao Joao, Serv Genet Med, Porto, Portugal.
   [Nunes, Ana Teresa; Tavares, Isabel] Univ Porto, I3S Inst Invest Inovacao Saude, Grp Invest & Dev Nefrol & Doencas Infeciosas, Porto, Portugal.
   [Silva, Roberto] Ctr Hosp & Univ Sao Joao, Serv Anat Patol, Porto, Portugal.
C3 Universidade do Porto; Universidade do Porto; Universidade do Porto; i3S
   - Instituto de Investigacao e Inovacao em Saude, Universidade do Porto
RP Ferreira, F (corresponding author), Ctr Hosp & Univ Sao Joao, Serv Nefrol, Porto, Portugal.; Ferreira, F (corresponding author), Univ Porto, Dept Med, Fac Med, Porto, Portugal.
EM filipasilvaf@gmail.com
RI Tavares, Isabel/AAQ-1987-2020
OI Lisboa-Goncalves, Pedro/0000-0001-7918-3601; Tavares,
   Isabel/0000-0002-3497-8416; Ferreira, Filipa/0000-0001-6308-5476
CR Alcubilla-Prats P, 2017, MED CLIN-BARCELONA, V148, P357, DOI [10.1016/j.medcle.2017.04.002, 10.1016/j.medcli.2017.01.029]
   Almannai M, 2018, GeneReviews
   Bell JD, 2017, A A CASE REP, V9, P38, DOI 10.1213/XAA.0000000000000520
   Cavero T, 2015, NEFROLOGIA, V35, P6, DOI 10.3265/Nefrologia.pre2014.Sep.12728
   Che RC, 2014, AM J PHYSIOL-RENAL, V306, pF367, DOI 10.1152/ajprenal.00571.2013
   Chinnery P.F., 2021, GeneReviews, P1
   de Laat P, 2019, CLIN KIDNEY J, V12, P840, DOI 10.1093/ckj/sfz020
   Doleris LM, 2000, KIDNEY INT, V58, P1851, DOI 10.1046/j.1523-1755.2000.00356.x
   Doorenbos CJ, 2001, PERITON DIALYSIS INT, V21, P518
   Eirin A, 2017, HANDB EXP PHARMACOL, V240, P229, DOI 10.1007/164_2016_6
   El-Hattab AW, 2015, MOL GENET METAB, V116, P4, DOI 10.1016/j.ymgme.2015.06.004
   Emma F, 2017, NEPHROL THER, V13, pS23, DOI 10.1016/j.nephro.2017.01.014
   Emma F, 2016, NAT REV NEPHROL, V12, P267, DOI 10.1038/nrneph.2015.214
   Finsterer J, 2017, BIOMED REP, V6, P487, DOI 10.3892/br.2017.892
   Godinho I, 2017, CLIN KIDNEY J, V10, P487, DOI 10.1093/ckj/sfx021
   Hall AM, 2015, KIDNEY INT, V87, P610, DOI 10.1038/ki.2014.297
   Hotta O, 2001, KIDNEY INT, V59, P1236, DOI 10.1046/j.1523-1755.2001.0590041236.x
   Johnson SC, 2019, KIDNEY INT, V95, P455, DOI 10.1016/j.kint.2018.08.038
   Kaufmann P, 2011, NEUROLOGY, V77, P1965, DOI 10.1212/WNL.0b013e31823a0c7f
   Löwik MM, 2005, NEPHROL DIAL TRANSPL, V20, P336, DOI 10.1093/ndt/gfh546
   Martín-Hernández E, 2005, PEDIATR NEPHROL, V20, P1299, DOI 10.1007/s00467-005-1948-z
   Mima A, 2011, RENAL FAILURE, V33, P622, DOI 10.3109/0886022X.2011.585730
   Naing A, 2014, J DIABETES COMPLICAT, V28, P542, DOI 10.1016/j.jdiacomp.2014.03.006
   Narumi K, 2018, NEPHRON, V138, P243, DOI 10.1159/000485109
   Nesbitt V, 2013, J NEUROL NEUROSUR PS, V84, P936, DOI 10.1136/jnnp-2012-303528
   Parikh S, 2016, MOL GENET METAB, V118, P178, DOI 10.1016/j.ymgme.2016.04.009
   Parikh S, 2015, GENET MED, V17, P689, DOI 10.1038/gim.2014.177
   Piccoli GB, 2012, BMC NEPHROL, V13, DOI 10.1186/1471-2369-13-9
   Poulton J, 2017, MOL DIAGN THER, V21, P419, DOI 10.1007/s40291-017-0279-7
   Santa KM, 2010, PHARMACOTHERAPY, V30, P1179, DOI 10.1592/phco.30.11.1179
   Santoro D, 2019, J CLIN MED, V8, DOI 10.3390/jcm8030303
   Sproule DM, 2008, ANN NY ACAD SCI, V1142, P133, DOI 10.1196/annals.1444.011
   Yanagihara C, 2001, INTERNAL MED, V40, P662, DOI 10.2169/internalmedicine.40.662
NR 33
TC 1
Z9 1
U1 1
U2 1
PU SOC ESPANOLA NEFROLOGIA DR RAFAEL MATESANZ
PI SANTANDER
PA C/PASAJE DE PENA 2, 3-C, SANTANDER, SPAIN
SN 0211-6995
EI 1989-2284
J9 NEFROLOGIA
JI Nefrologia
PD DEC
PY 2023
VL 43
SU 1
SI SI
BP 1
EP 7
DI 10.1016/j.nefro.2023.03.004
EA DEC 2023
PG 7
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Urology & Nephrology
GA IN8J8
UT WOS:001167096100001
PM 38355238
OA gold
DA 2024-11-01
ER

PT J
AU Melone, MAB
   Tessa, A
   Petrini, S
   Lus, G
   Sampaolo, S
   di Fede, G
   Santorelli, FM
   Cotrufo, R
AF Melone, MAB
   Tessa, A
   Petrini, S
   Lus, G
   Sampaolo, S
   di Fede, G
   Santorelli, FM
   Cotrufo, R
TI Revelation of a new mitochondrial DNA mutation (G12147A) in a
   MELAS/MERFF phenotype
SO ARCHIVES OF NEUROLOGY
LA English
DT Article
ID LACTIC-ACIDOSIS; STROKELIKE EPISODES; CLINICAL SPECTRUM; MELAS;
   ENCEPHALOPATHY; MERRF; MYOPATHY
AB Background: A 26-year-old man presented at onset with the syndrome of mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes (MELAS) and later with a phenotype for MELAS and myoclonic epilepsy and ragged red fiber disease (MELAS/MERRF).
   Objective: To identify the possible defects in the mitochondrial genome in blood and muscle samples of the patient.
   Design: Case study of a patient clinically exhibiting strokelike episodes and then epilepsy with myoclonic features, ataxia, and dementia.
   Setting: Research unit of a university hospital.
   Main Outcome Measures: Electromyographic, morphologic, and biochemical studies of muscle and molecular analysis of blood and muscle to investigate mitochondrial DNA (mtDNA) size and quantity.
   Results: Morphologically, we found abnormal mitochondrial proliferation with several cytochrome-c oxidase (COX)-negative fibers in muscle biopsy specimens; the analysis of serial sections showed a decreased immunoreactivity for the mtDNA-encoded subunits COXII and, partially, COX1. Biochemically, we found a partial and isolated COX deficiency. The complete mtDNA sequence analysis identified 3 sequence changes, 2 of which were reported polymorphisms. The remaining change, a G12147A transition in the transfer RNA(His) gene, appeared to be the likely pathogenic mutation.
   Conclusions: Our data propose that the G12147A change, the first mutation in the transfer RNA(His) gene associated with an overlapped MELAS/MERFF phenotype, is the cause of the encephalomyopathy in this patient interfering with the overall mitochondrial protein synthesis.
C1 Univ Naples Federico II, Policlin, Div Neurol 1, Dept Neurol Sci,Sch Med, I-80131 Naples, Italy.
   IRCCS, Dept Mol Med, Rome, Italy.
C3 University of Naples Federico II
RP Melone, MAB (corresponding author), Univ Naples Federico II, Policlin, Div Neurol 1, Dept Neurol Sci,Sch Med, Edificio10,Via Sergio Pansini 5, I-80131 Naples, Italy.
EM marina.melone@unina2.it
RI Lus, Giacomo/AHH-5884-2022; Melone, Mariarosa AB/N-6788-2015; Di Fede,
   Giuseppe/A-4471-2019; Petrini, Stefania/I-1464-2018; tessa,
   alessandra/AAA-4442-2021; Santorelli, Filippo M/ABE-5124-2020
OI Melone, Mariarosa AB/0000-0002-7213-9277; Di Fede,
   Giuseppe/0000-0003-3537-6713; Petrini, Stefania/0000-0002-3249-0003;
   tessa, alessandra/0000-0002-1445-6434; Lus, Giacomo/0000-0002-9457-1124;
   Santorelli, Filippo M/0000-0002-1359-9062
CR BERKOVIC SF, 1991, LANCET, V338, P457, DOI 10.1016/0140-6736(91)91090-H
   BYRNE E, 1988, J NEUROL SCI, V88, P327, DOI 10.1016/0022-510X(88)90229-8
   CIAFALONI E, 1992, ANN NEUROL, V31, P391, DOI 10.1002/ana.410310408
   DAMIAN MS, 1995, ACTA NEUROL SCAND, V92, P409
   DANKS RA, 1988, AUST NZ J MED, V18, P69, DOI 10.1111/j.1445-5994.1988.tb02245.x
   Ehrig T, 2001, J MOL DIAGN, V3, P22, DOI 10.1016/S1525-1578(10)60645-9
   FUKUHARA N, 1985, ANN NEUROL, V18, P368, DOI 10.1002/ana.410180323
   Hao HL, 1996, J BIOL CHEM, V271, P2347, DOI 10.1074/jbc.271.4.2347
   HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P1349, DOI 10.1177/29.11.6172466
   KURIYAMA M, 1985, ANN NEUROL, V18, P625, DOI 10.1002/ana.410180525
   Maassen JA, 1996, EXP CLIN ENDOCR DIAB, V104, P205, DOI 10.1055/s-0029-1211444
   MARIOTTI C, 1995, J NEUROL, V242, P304, DOI 10.1007/BF00878873
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   SHOFFNER JM, 1990, CELL, V61, P931, DOI 10.1016/0092-8674(90)90059-N
NR 14
TC 44
Z9 52
U1 1
U2 8
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60610 USA
SN 0003-9942
J9 ARCH NEUROL-CHICAGO
JI Arch. Neurol.
PD FEB
PY 2004
VL 61
IS 2
BP 269
EP 272
DI 10.1001/archneur.61.2.269
PG 4
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 772FW
UT WOS:000188831900016
PM 14967777
DA 2024-11-01
ER

PT J
AU Emmanuele, V
   Sotiriou, E
   Shirazi, M
   Tanji, K
   Haller, RG
   Heinicke, K
   Bosch, PE
   Hirano, M
   Di Mauro, S
AF Emmanuele, Valentina
   Sotiriou, Evangelia
   Shirazi, Maryam
   Tanji, Kurenai
   Haller, Ronald G.
   Heinicke, Katja
   Bosch, Peter E.
   Hirano, Michio
   Di Mauro, Salvatore
TI Recurrent myoglobinuria in a sporadic patient with a novel mitochondrial
   DNA tRNA<SUP>Ile</SUP> mutation
SO JOURNAL OF THE NEUROLOGICAL SCIENCES
LA English
DT Article
DE Mitochondrial myopathy; Myoglobinuria; Mitochondrial DNA; tRNA(Ile);
   Myalgia; Elevated serum CK
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; CYTOCHROME-B GENE; POINT MUTATION;
   TRANSFER-RNA; HYPERTROPHIC CARDIOMYOPATHY; EXERCISE INTOLERANCE;
   NONSENSE MUTATION; LEIGH-SYNDROME; RHABDOMYOLYSIS; DEFICIENCY
AB The differential diagnosis of myoglobinuria includes multiple etiologies, such as infection, inflammation, trauma, endocrinopathies, drugs toxicity, and primary metabolic disorders. Metabolic myopathies can be due to inherited disorders of glycogen metabolism or to defects of fatty acid oxidation. Primary respiratory chain dysfunction is a rare cause of myoglobinuria, but it has been described in sporadic cases with mutations in genes encoding cytochrome b or cytochrome c oxidase (COX) subunits and in four cases with tRNA mutations. We describe a 39-year-old woman with myalgia and exercise-related recurrent myoglobinuria, who harbored a novel mitochondrial DNA mutation at nucleotide 4281 (m.4281A > G) in the tRNA-isoleucine gene. Her muscle biopsy revealed ragged-red and COX-deficient fibers. No deletions or duplication were detected by Southern blot analysis. The m.4281A > G mutation was present in the patient's muscle with a mutation load of 46% and was detected in trace amounts in urine and cheek mucosa. Single-fiber analysis revealed significantly higher levels of the mutation in COX-deficient (65%) than in normal fibers (45%). This novel mutation has to be added to the molecular causes of recurrent myoglobinuria. (C) 2011 Elsevier B.V. All rights reserved.
C1 [Emmanuele, Valentina; Sotiriou, Evangelia; Shirazi, Maryam; Tanji, Kurenai; Hirano, Michio; Di Mauro, Salvatore] Columbia Univ, Dept Neurol, Med Ctr, New York, NY USA.
   [Tanji, Kurenai] Columbia Univ, Dept Pathol, Med Ctr, New York, NY USA.
   [Haller, Ronald G.; Heinicke, Katja] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
   [Haller, Ronald G.; Heinicke, Katja] VA Med Ctr, Dept Neurol, Inst Exercise & Environm Med, Dallas, TX USA.
   [Bosch, Peter E.] Mayo Clin Arizona, Dept Neurol, Scottsdale, AZ USA.
C3 Columbia University; Columbia University; University of Texas System;
   University of Texas Southwestern Medical Center Dallas; Mayo Clinic;
   Mayo Clinic Phoenix
RP Di Mauro, S (corresponding author), Coll Phys & Surg, 4-424 B,630 W 168th St, New York, NY 10032 USA.
EM sd12@columbia.edu
OI Emmanuele, Valentina/0000-0002-4892-2042
FU NIH [HD32062]; Marriott Mitochondrial Disorder Clinical Research Fund
   (MMDCRF)
FX Part of the work described here is supported by NIH grant HD32062 and by
   the Marriott Mitochondrial Disorder Clinical Research Fund (MMDCRF).
CR Andreu AL, 1999, ANN NEUROL, V45, P127, DOI 10.1002/1531-8249(199901)45:1<127::AID-ART20>3.0.CO;2-Y
   Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   Berardo A, 2010, CURR NEUROL NEUROSCI, V10, P118, DOI 10.1007/s11910-010-0096-4
   Borthwick Gillian M, 2006, Ann Neurol, V59, P570, DOI 10.1002/ana.20758
   Borthwick GM, 1999, ANN NEUROL, V46, P787, DOI 10.1002/1531-8249(199911)46:5<787::AID-ANA17>3.0.CO;2-8
   Bosch X, 2009, NEW ENGL J MED, V361, P62, DOI 10.1056/NEJMra0801327
   CASALI C, 1995, BIOCHEM BIOPH RES CO, V213, P588, DOI 10.1006/bbrc.1995.2172
   Chinnery PF, 1997, ANN NEUROL, V41, P408, DOI 10.1002/ana.410410319
   Chinnery PF, 1997, NEUROLOGY, V49, P1166, DOI 10.1212/WNL.49.4.1166
   Corona P, 2002, ANN NEUROL, V51, P118, DOI 10.1002/ana.10059
   Crimi M, 2004, MITOCHONDRION, V3, P279, DOI 10.1016/j.mito.2004.02.004
   Crimi M, 2004, PEDIATR RES, V55, P842, DOI 10.1203/01.PDR.0000117844.73436.68
   DIMAURO S, 1987, ANN NEUROL, V22, P498, DOI 10.1002/ana.410220409
   Finnila Saara, 2001, Mutation Research, V458, P31, DOI 10.1016/S1383-5726(01)00012-7
   Franceschina L, 1998, J NEUROL, V245, P755, DOI 10.1007/s004150050283
   Giannoglou GD, 2007, EUR J INTERN MED, V18, P90, DOI 10.1016/j.ejim.2006.09.020
   HARA H, 1994, J NEUROL NEUROSUR PS, V57, P1545, DOI 10.1136/jnnp.57.12.1545-a
   Karadimas CL, 2000, NEUROLOGY, V55, P644, DOI 10.1212/WNL.55.5.644
   Keightley JA, 1996, NAT GENET, V12, P410, DOI 10.1038/ng0496-410
   Kelley SO, 2001, J BIOL CHEM, V276, P10607, DOI 10.1074/jbc.M008320200
   Kelley SO, 2000, NAT STRUCT BIOL, V7, P862, DOI 10.1038/79612
   Kwon JH, 2003, EUR NEUROL, V50, P123, DOI 10.1159/000072517
   Levinger L, 2003, NUCLEIC ACIDS RES, V31, P1904, DOI 10.1093/nar/gkg282
   Limongelli A, 2004, J MED GENET, V41, P342, DOI 10.1136/jmg.2003.016048
   Lofberg M, 1998, ACTA NEUROL SCAND, V98, P268, DOI 10.1111/j.1600-0404.1998.tb07307.x
   McFarland R, 2004, NEUROMUSCULAR DISORD, V14, P162, DOI 10.1016/j.nmd.2003.10.011
   Merante F, 1996, HUM MUTAT, V8, P216, DOI 10.1002/(SICI)1098-1004(1996)8:3<216::AID-HUMU4>3.0.CO;2-7
   SANTORELLI FM, 1995, BIOCHEM BIOPH RES CO, V216, P835, DOI 10.1006/bbrc.1995.2697
   Schuelke M, 2002, ANN NEUROL, V51, P388, DOI 10.1002/ana.10151
   Smits BW, 2007, J NEUROL, V254, P1614, DOI 10.1007/s00415-007-0608-6
   Taivassalo T, 2003, BRAIN, V126, P413, DOI 10.1093/brain/awg028
   TANAKA M, 1990, LANCET, V336, P1452, DOI 10.1016/0140-6736(90)93162-I
   TANIIKE M, 1992, BIOCHEM BIOPH RES CO, V186, P47, DOI 10.1016/S0006-291X(05)80773-9
   Tanji K, 2001, METHOD CELL BIOL, V65, P311, DOI 10.1016/S0091-679X(01)65019-2
   Taylor RW, 1998, BIOCHEM BIOPH RES CO, V243, P47, DOI 10.1006/bbrc.1997.8055
   Taylor RW, 2003, J AM COLL CARDIOL, V41, P1786, DOI 10.1016/S0735-1097(03)00300-0
   Taylor RW, 2002, NEUROMUSCULAR DISORD, V12, P659, DOI 10.1016/S0960-8966(02)00026-3
   Wilson FH, 2004, SCIENCE, V306, P1190, DOI 10.1126/science.1102521
   WROGEMANN K, 1976, LANCET, V1, P672
NR 39
TC 11
Z9 11
U1 0
U2 0
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-510X
EI 1878-5883
J9 J NEUROL SCI
JI J. Neurol. Sci.
PD APR 15
PY 2011
VL 303
IS 1-2
BP 39
EP 42
DI 10.1016/j.jns.2011.01.018
PG 4
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 747SO
UT WOS:000289339900006
PM 21324494
OA Green Accepted
DA 2024-11-01
ER

PT J
AU Goffart, S
   Cooper, HM
   Tyynismaa, H
   Wanrooij, S
   Suomalainen, A
   Spelbrink, JN
AF Goffart, Steffi
   Cooper, Helen M.
   Tyynismaa, Henna
   Wanrooij, Sjoerd
   Suomalainen, Anu
   Spelbrink, Johannes N.
TI Twinkle mutations associated with autosomal dominant progressive
   external ophthalmoplegia lead to impaired helicase function and <i>in
   vivo</i> mtDNA replication stalling
SO HUMAN MOLECULAR GENETICS
LA English
DT Article
ID HUMAN MITOCHONDRIAL-DNA; CULTURED HUMAN-CELLS; MULTIPLE DELETIONS;
   LINKER REGION; POLG; PROTEIN; DEPLETION; DISEASE; PREVALENCE; EXPRESSION
AB Mutations in the mitochondrial helicase Twinkle underlie autosomal dominant progressive external ophthalmoplegia (PEO), as well as recessively inherited infantile-onset spinocerebellar ataxia and rare forms of mitochondrial DNA (mtDNA) depletion syndrome. Familial PEO is typically associated with the occurrence of multiple mtDNA deletions, but the mechanism by which Twinkle dysfunction induces deletion formation has been under debate. Here we looked at the effects of Twinkle adPEO mutations in human cell culture and studied the mtDNA replication in the Deletor mouse model, which expresses a dominant PEO mutation in Twinkle and accumulates multiple mtDNA deletions during life. We show that expression of dominant Twinkle mutations results in the accumulation of mtDNA replication intermediates in cell culture. This indicated severe replication pausing or stalling and caused mtDNA depletion. A strongly enhanced accumulation of replication intermediates was evident also in six-week-old Deletor mice compared with wild-type littermates, even though mtDNA deletions accumulate in a late-onset fashion in this model. In addition, our results in cell culture pointed to a problem of transcription that preceded the mtDNA depletion phenotype and might be of relevance in adPEO pathophysiology. Finally, in vitro assays showed functional defects in the various Twinkle mutants and broadly agreed with the cell culture phenotypes such as the level of mtDNA depletion and the level of accumulation of replication intermediates. On the basis of our results we suggest that mtDNA replication pausing or stalling is the common consequence of Twinkle PEO mutations that predisposes to multiple deletion formation.
C1 [Goffart, Steffi; Cooper, Helen M.; Wanrooij, Sjoerd; Spelbrink, Johannes N.] Inst Med Technol, Tampere 33014, Finland.
   [Goffart, Steffi; Cooper, Helen M.; Wanrooij, Sjoerd; Spelbrink, Johannes N.] Tampere Univ Hosp, Tampere 33014, Finland.
   [Tyynismaa, Henna; Suomalainen, Anu] Univ Helsinki, Res Program Mol Neurol, Biomedicum, Helsinki, Finland.
   [Tyynismaa, Henna; Suomalainen, Anu] Univ Helsinki, Cent Hosp, Dept Neurol, Helsinki, Finland.
C3 Tampere University; Tampere University Hospital; University of Helsinki;
   University of Helsinki; Helsinki University Central Hospital
RP Spelbrink, JN (corresponding author), Inst Med Technol, Biokatu 6, Tampere 33014, Finland.
EM hans.spelbrink@uta.fi
RI Tyynismaa, Henna/F-1428-2011; COOPER, HOWARD/M-7304-2014; Wanrooij,
   Sjoerd/J-1367-2019; Goffart, Steffi/N-3597-2015; Spelbrink,
   Johannes/L-4661-2015
OI Tyynismaa, Henna/0000-0002-2493-2422; Suomalainen-Wartiovaara,
   Anu/0000-0003-4833-5195; Wanrooij, Sjoerd/0000-0001-6126-4382;
   Spelbrink, Johannes/0000-0002-9756-2602
FU Academy of Finland [110689, 103213]; CoE; Sigrid Juselius Foundation;
   University of Helsinki; EU [LSHM-CT-2004-503116]; Tampere University
   [9G072, 9H079, 9H102]; Academy of Finland (AKA) [103213, 110689] Funding
   Source: Academy of Finland (AKA)
FX This work was supported by the Academy of Finland [110689, 103213 and
   CoE funding to J.N.S.]; Sigrid Juselius Foundation [to A. S. and
   J.N.S.]; the University of Helsinki [to A. S.]; the EU sixth Framework
   Programme for Research, Priority 1 'Life sciences, genomics and
   biotechnology for health [LSHM-CT-2004-503116 to J.N.S. and S. G.]; and
   the Tampere University Hospital Medical Research Fund [9G072, 9H079 to
   J.N.S., 9H102 to H. M. C.]. Funding to Pay the Open Access Charge was
   provided by the Academy of Finland.
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8
   CHINNERY PF, 2007, NEUROMUSCULAR DISORD, V18, P259
   CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991
   Cooper HM, 2008, BIOCHEM J, V411, P279, DOI 10.1042/BJ20071624
   Donmez I, 2006, NUCLEIC ACIDS RES, V34, P4216, DOI 10.1093/nar/gkl508
   Farge G, 2008, NUCLEIC ACIDS RES, V36, P393, DOI 10.1093/nar/gkm1025
   Friedman KL, 1995, METHOD ENZYMOL, V262, P613
   Garrido N, 2003, MOL BIOL CELL, V14, P1583, DOI 10.1091/mbc.E02-07-0399
   Guo SY, 1999, J BIOL CHEM, V274, P30303, DOI 10.1074/jbc.274.42.30303
   Hakonen AH, 2005, AM J HUM GENET, V77, P430, DOI 10.1086/444548
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257
   Korhonen JA, 2003, J BIOL CHEM, V278, P48627, DOI 10.1074/jbc.M306981200
   Korhonen JA, 2008, J MOL BIOL, V377, P691, DOI 10.1016/j.jmb.2008.01.035
   Krishnan KJ, 2008, NAT GENET, V40, P275, DOI 10.1038/ng.f.94
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Leipe DD, 2000, GENOME RES, V10, P5
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   Matsushima Y, 2007, J BIOL CHEM, V282, P9436, DOI 10.1074/jbc.M610550200
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Pohjoismäki JLO, 2006, NUCLEIC ACIDS RES, V34, P5815, DOI 10.1093/nar/gkl703
   Sarzi E, 2007, ANN NEUROL, V62, P579, DOI 10.1002/ana.21207
   Schaefer AM, 2008, ANN NEUROL, V63, P35, DOI 10.1002/ana.21217
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spelbrink JN, 2000, J BIOL CHEM, V275, P24818, DOI 10.1074/jbc.M000559200
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
   Tyynismaa H, 2004, HUM MOL GENET, V13, P3219, DOI 10.1093/hmg/ddh342
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Virgilio R, 2008, J NEUROL, V255, P1384, DOI 10.1007/s00415-008-0926-3
   Wanrooij S, 2007, NUCLEIC ACIDS RES, V35, P3238, DOI 10.1093/nar/gkm215
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   Yakubovskaya E, 2006, J BIOL CHEM, V281, P374, DOI 10.1074/jbc.M509730200
   Yakubovskaya E, 2007, EMBO J, V26, P4283, DOI 10.1038/sj.emboj.7601843
   Yasukawa T, 2005, MOL CELL, V18, P651, DOI 10.1016/j.molcel.2005.05.002
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 40
TC 115
Z9 125
U1 0
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0964-6906
EI 1460-2083
J9 HUM MOL GENET
JI Hum. Mol. Genet.
PD JAN 15
PY 2009
VL 18
IS 2
BP 328
EP 340
DI 10.1093/hmg/ddn359
PG 13
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 386QK
UT WOS:000261897500011
PM 18971204
OA hybrid, Green Published, Green Submitted
DA 2024-11-01
ER

PT J
AU Naue, J
   Hörer, S
   Sänger, T
   Strobl, C
   Hatzer-Grubwieser, P
   Parson, W
   Lutz-Bonengel, S
AF Naue, Jana
   Horer, Steffen
   Sanger, Timo
   Strobl, Christina
   Hatzer-Grubwieser, Petra
   Parson, Walther
   Lutz-Bonengel, Sabine
TI Evidence for frequent and tissue-specific sequence heteroplasmy in human
   mitochondrial DNA
SO MITOCHONDRION
LA English
DT Article
DE Mitochondrial DNA; Point heteroplasmy; Control region; Sanger sequencing
ID MTDNA CONTROL-REGION; SUBSTITUTION RATE VARIATION; HYPERVARIABLE REGION;
   POINT MUTATIONS; NUCLEOTIDE SUBSTITUTION; HEALTHY-SUBJECTS; GENES;
   SITES; AGE; INHERITANCE
AB Mitochondrial point heteroplasmy is a common event observed not only in patients with mitochondrial diseases but also in healthy individuals. We here report a comprehensive investigation of heteroplasmy occurrence in human including the whole mitochondrial control region from nine different tissue types of 100 individuals. Sanger sequencing was used as a standard method and results were supported by cloning, minisequencing, and massively parallel sequencing. Only 12% of all individuals showed no heteroplasmy, whereas 88% showed at least one heteroplasmic position within the investigated tissues. In 66% of individuals up to 8 positions were affected. The highest relative number of heteroplasmies was detected in muscle and liver (79%, 69%), followed by brain, hair, and heart (36.7%-30.2%). Lower percentages were observed in bone, blood, lung, and buccal cells (19.8%-16.2%). Accumulation of position-specific heteroplasmies was found in muscle (positions 64, 72, 73,189, and 408), liver (position 72) and brain (partial deletion at position 71). Deeper analysis of these specific positions in muscle revealed a non-random appearance and position-specific dependency on age. MtDNA heteroplasmy frequency and its potential functional importance have been underestimated in the past and its occurrence is ubiquitous and dependent at least on age, tissue, and position-specific mutation rates. (C) 2014 Elsevier B.V. and Mitochondria Research Society. All rights reserved.
C1 [Naue, Jana; Horer, Steffen; Sanger, Timo; Lutz-Bonengel, Sabine] Univ Freiburg, Med Ctr, Inst Legal Med, D-79104 Freiburg, Germany.
   [Naue, Jana] Univ Freiburg, Fac Biol, D-79104 Freiburg, Germany.
   [Strobl, Christina; Hatzer-Grubwieser, Petra; Parson, Walther] Med Univ Innsbruck, Inst Legal Med, A-6020 Innsbruck, Austria.
   [Parson, Walther] Penn State Eberly Coll Sci, University Pk, PA USA.
C3 University of Freiburg; University of Freiburg; Medical University of
   Innsbruck; Pennsylvania Commonwealth System of Higher Education (PCSHE);
   Pennsylvania State University; Pennsylvania State University -
   University Park
RP Naue, J (corresponding author), Univ Freiburg, Med Ctr, Inst Legal Med, Albertstr 9, D-79104 Freiburg, Germany.
EM jana.naue@uniklinik-freiburg.de; steffen.hoerer@uniklinik-freiburg.de;
   timo.saenger@uniklinik-freiburg.de; christina.strobl@i-med.ac.at;
   petra.hatzer-grubwieser@i-med.ac.at; walther.parson@i-med.ac.at;
   sabinedutz-bonengel@uniklinilc-freiburg.de
RI Lutz-Bonengel, Sabine/HTR-7298-2023; Parson, Walther/AAD-6845-2020
OI Parson, Walther/0000-0002-5692-2392
FU state of Baden-Wurttemberg (Competence Centre "Legal Medicine");
   Wissenschaftliche Gesellschaft Freiburg
FX Grateful thanks go to the former interns and undergraduate students of
   the laboratory in Freiburg for technical assistance and to Daniel
   Entstrasser and Cordula Berger (Innsbruck Medical University). Part of
   this work was supported by the state of Baden-Wurttemberg (Competence
   Centre "Legal Medicine") and by the "Wissenschaftliche Gesellschaft
   Freiburg."
CR Alaeddini R, 2010, FORENSIC SCI INT-GEN, V4, P148, DOI 10.1016/j.fsigen.2009.09.007
   Alonso A, 2002, FORENSIC SCI INT, V125, P1, DOI 10.1016/S0379-0738(01)00602-8
   Andrew T, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022332
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   Avital G, 2012, HUM MOL GENET, V21, P4214, DOI 10.1093/hmg/dds245
   Bandelt HJ, 2008, INT J LEGAL MED, V122, P11, DOI 10.1007/s00414-006-0151-5
   Bandelt HJ, 2002, AM J HUM GENET, V71, P1150, DOI 10.1086/344397
   Bauer CM, 2013, FORENSIC SCI INT-GEN, V7, P313, DOI 10.1016/j.fsigen.2012.10.012
   Birky CW, 2001, ANNU REV GENET, V35, P125, DOI 10.1146/annurev.genet.35.102401.090231
   BIRKY CW, 1995, P NATL ACAD SCI USA, V92, P11331, DOI 10.1073/pnas.92.25.11331
   Brandstätter A, 2007, FORENSIC SCI INT, V166, P164, DOI 10.1016/j.forsciint.2006.05.006
   BROWN WM, 1982, J MOL EVOL, V18, P225, DOI 10.1007/BF01734101
   BROWN WM, 1979, P NATL ACAD SCI USA, V76, P1967, DOI 10.1073/pnas.76.4.1967
   Calloway CD, 2000, AM J HUM GENET, V66, P1384, DOI 10.1086/302844
   Carling PJ, 2011, MITOCHONDRION, V11, P686, DOI 10.1016/j.mito.2011.05.004
   Cormio A, 2005, NEUROBIOL AGING, V26, P655, DOI 10.1016/j.neurobiolaging.2004.06.014
   Coskun PE, 2004, P NATL ACAD SCI USA, V101, P10726, DOI 10.1073/pnas.0403649101
   de Camargo MA, 2011, MOL BIOL REP, V38, P1219, DOI 10.1007/s11033-010-0220-1
   Del Bo R, 2003, NEUROBIOL AGING, V24, P829, DOI 10.1016/S0197-4580(02)00233-6
   Del Bo R, 2002, J NEUROL SCI, V202, P85, DOI 10.1016/S0022-510X(02)00247-2
   Diroma MA, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-S3-S2
   Marinho AND, 2011, GENET MOL BIOL, V34, P31, DOI 10.1590/S1415-47572010005000106
   Duggan AT, 2013, AM J HUM GENET, V92, P279, DOI 10.1016/j.ajhg.2012.12.004
   Excoffier L, 1999, MOL BIOL EVOL, V16, P1357, DOI 10.1093/oxfordjournals.molbev.a026046
   Forster L, 2002, P NATL ACAD SCI USA, V99, P13950, DOI 10.1073/pnas.202400499
   Goto H, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-6-r59
   HASEGAWA M, 1993, J MOL EVOL, V37, P347, DOI 10.1007/BF00178865
   He YP, 2010, NATURE, V464, P610, DOI 10.1038/nature08802
   HUTCHISO.CA, 1974, NATURE, V251, P536, DOI 10.1038/251536a0
   Irwin JA, 2009, J MOL EVOL, V68, P516, DOI 10.1007/s00239-009-9227-4
   Jakupciak JP, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-285
   Jazin E, 1998, NAT GENET, V18, P109, DOI 10.1038/ng0298-109
   Jazin EE, 1996, P NATL ACAD SCI USA, V93, P12382, DOI 10.1073/pnas.93.22.12382
   KRJUTSKOV K, 2013, CURR GENET, P1
   Lacan M, 2009, INT J LEGAL MED, V123, P161, DOI 10.1007/s00414-008-0266-y
   Lagerström-Fermér M, 2001, AM J HUM GENET, V68, P1299, DOI 10.1086/320115
   Lee HY, 2006, ANN HUM GENET, V70, P59, DOI 10.1111/j.1529-8817.2005.00217.x
   Lo MC, 2005, ANN NY ACAD SCI, V1042, P130, DOI 10.1196/annals.1338.013
   Malyarchuk BA, 2002, ANN HUM GENET, V66, P261, DOI 10.1017/S0003480002001161
   Melton T, 2004, Forensic Sci Rev, V16, P1
   Meyer S, 1999, GENETICS, V152, P1103
   Michikawa Y, 1999, SCIENCE, V286, P774, DOI 10.1126/science.286.5440.774
   MIYATA T, 1982, J MOL EVOL, V19, P28, DOI 10.1007/BF02100221
   MONNAT RJ, 1986, GENE, V43, P205, DOI 10.1016/0378-1119(86)90208-8
   MONNAT RJ, 1985, P NATL ACAD SCI USA, V82, P2895, DOI 10.1073/pnas.82.9.2895
   Naue J, 2011, INT J LEGAL MED, V125, P427, DOI 10.1007/s00414-011-0549-6
   Niederstätter H, 2007, FORENSIC SCI INT-GEN, V1, P29, DOI 10.1016/j.fsigen.2006.10.007
   Parson W, 2007, FORENSIC SCI INT-GEN, V1, P88, DOI 10.1016/j.fsigen.2007.01.018
   Parson W, 2013, FORENSIC SCI INT-GEN, V7, P632, DOI 10.1016/j.fsigen.2013.09.007
   Payne BAI, 2013, HUM MOL GENET, V22, P384, DOI 10.1093/hmg/dds435
   Pesole G, 1999, J MOL EVOL, V48, P427, DOI 10.1007/PL00006487
   Ramos A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074636
   Röck AW, 2013, FORENSIC SCI INT-GEN, V7, P601, DOI 10.1016/j.fsigen.2013.07.005
   Rose G, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013395
   Salas A, 2005, BIOCHEM BIOPH RES CO, V335, P891, DOI 10.1016/j.bbrc.2005.07.161
   Salas A, 2001, INT J LEGAL MED, V114, P186, DOI 10.1007/s004140000164
   Samuels DC, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003929
   Sekiguchi K, 2003, MITOCHONDRION, V2, P401, DOI 10.1016/S1567-7249(03)00028-X
   Song SW, 2005, P NATL ACAD SCI USA, V102, P4990, DOI 10.1073/pnas.0500253102
   Stoneking M, 2000, AM J HUM GENET, V67, P1029, DOI 10.1086/303092
   Tan DJ, 2004, ANN NY ACAD SCI, V1011, P310, DOI 10.1196/annals.1293.030
   Thèves C, 2006, J FORENSIC SCI, V51, P865, DOI 10.1111/j.1556-4029.2006.00163.x
   Tully LA, 2000, AM J HUM GENET, V67, P432, DOI 10.1086/302996
   van Oven M, 2009, HUM MUTAT, V30, pE386, DOI 10.1002/humu.20921
   VIGILANT L, 1991, SCIENCE, V253, P1503, DOI 10.1126/science.1840702
   WAKELEY J, 1993, J MOL EVOL, V37, P613
   WALLACE DC, 1987, CURR GENET, V12, P81, DOI 10.1007/BF00434661
   Wang Y, 2001, P NATL ACAD SCI USA, V98, P4022, DOI 10.1073/pnas.061013598
   Wiegand P, 2006, INT J LEGAL MED, V120, P160, DOI 10.1007/s00414-005-0048-8
   Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514
   Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595
NR 71
TC 81
Z9 98
U1 3
U2 32
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1567-7249
EI 1872-8278
J9 MITOCHONDRION
JI Mitochondrion
PD JAN
PY 2015
VL 20
BP 82
EP 94
DI 10.1016/j.mito.2014.12.002
PG 13
WC Cell Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Genetics & Heredity
GA CA0UQ
UT WOS:000348632200011
PM 25526677
DA 2024-11-01
ER

PT J
AU Toscano, A
   Musumeci, O
AF Toscano, A.
   Musumeci, O.
TI Mitochondrial Disorders in Adults
SO CURRENT MOLECULAR MEDICINE
LA English
DT Article
DE Adults; mitochondrial disorders; mtDNA; multisystem; myopathies
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; HEREDITARY OPTIC NEUROPATHY;
   THYMIDINE PHOSPHORYLASE MUTATIONS; COENZYME-Q DEFICIENCY;
   AUTOSOMAL-DOMINANT; CEREBELLAR-ATAXIA; DNA INSTABILITY; MUSCLE; GENE;
   DELETIONS
AB Mitochondrial Disorders (MD) include a heterogeneous group of inherited disorders due to molecular defects mainly affecting the mitochondrial oxidative phosphorylation system. Because the respiratory chain is under control of two different genomes (nuclear DNA-nDNA and mitochondrial DNA-mtDNA), mitochondrial genetics is quite complex and may justify the extreme clinical heterogeneity of these diseases. Clinically, MD usually involve multiple tissues, mainly affecting organs with high energy request as central nervous system and skeletal muscle. They may present at any age, with different onsets, clinical presentation and progression from an isolated involvement of vision or hearing to a multisystemic degenerative disorders with stroke-like episodes, peripheral neuropathy, ophthalmoparesis, seizures, cardiopathy, hepatopathy, endocrinopathies, etc. Over the last 50 years, it became evident that MD represent an important part of the general medicine. The complexity of clinical and genetic spectrum of those disorders is still increasing. The aim of this review is to walk through mitochondrial genetics, highlighting novel clinical entities.
C1 [Toscano, A.; Musumeci, O.] Univ Messina, Dept Neurosci, Messina, Italy.
C3 University of Messina
RP Toscano, A (corresponding author), AOU Policlin, UOC Neurol & Malattie Neuromuscolari, Dept Neurosci, Via C Valeria 1, I-98125 Messina, Italy.
EM atoscano@unime.it
RI Musumeci, Olimpia/AHE-3041-2022; Toscano, Antonio/AHE-4657-2022
CR Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944
   Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andreu AL, 1999, NEW ENGL J MED, V341, P1037, DOI 10.1056/NEJM199909303411404
   Berardo A, 2011, Acta Myol, V30, P9
   Chowers I, 1999, BRIT J OPHTHALMOL, V83, P190, DOI 10.1136/bjo.83.2.190
   de Laat P, 2012, J INHERIT METAB DIS, V35, P1059, DOI 10.1007/s10545-012-9465-2
   DiMauro S, 2003, BASIC APPL MYOL, V13, P145
   DiMauro S, 2013, NAT REV NEUROL, V9, P429, DOI 10.1038/nrneurol.2013.126
   Gempel K, 2007, BRAIN, V130, P2037, DOI 10.1093/brain/awm054
   Giordano C, 2011, BRAIN, V134, P220, DOI 10.1093/brain/awq276
   Hirano M, 2005, GENE, V354, P152, DOI 10.1016/j.gene.2005.04.041
   Hirano M, 2012, BBA-GEN SUBJECTS, V1820, P625, DOI 10.1016/j.bbagen.2012.01.006
   HOLT IJ, 1988, NATURE, V331, P717, DOI 10.1038/331717a0
   Ji YL, 2010, MOL VIS, V16, P416
   Koga Y, 2005, NEUROLOGY, V64, P710, DOI 10.1212/01.WNL.0000151976.60624.01
   Kornblum C, 2013, NAT GENET, V45, P214, DOI 10.1038/ng.2501
   Krähenbühl S, 2000, LIVER, V20, P346, DOI 10.1034/j.1600-0676.2000.020004346.x
   Lagier-Tourenne C, 2008, AM J HUM GENET, V82, P661, DOI 10.1016/j.ajhg.2007.12.024
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Liang WC, 2009, NEUROMUSCULAR DISORD, V19, P212, DOI 10.1016/j.nmd.2009.01.008
   Lin CM, 2007, METAB BRAIN DIS, V22, P105, DOI 10.1007/s11011-006-9039-9
   Mancuso M, 2004, ARCH NEUROL-CHICAGO, V61, P1777, DOI 10.1001/archneur.61.11.1777
   Mancuso M, 2004, NEUROLOGY, V62, P316, DOI 10.1212/WNL.62.2.316
   Mancuso M, 2013, NEUROLOGY, V80, P2049, DOI 10.1212/WNL.0b013e318294b44c
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   McFarland R, 2008, ARCH DIS CHILD, V93, P151, DOI 10.1136/adc.2007.122911
   Montini G, 2008, NEW ENGL J MED, V358, P2849, DOI 10.1056/NEJMc0800582
   Musumeci O, 2001, NEUROLOGY, V56, P849, DOI 10.1212/WNL.56.7.849
   Nishino I, 2000, ANN NEUROL, V47, P792
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   OGASAHARA S, 1989, P NATL ACAD SCI USA, V86, P2379, DOI 10.1073/pnas.86.7.2379
   Pfeffer G, 2011, CAN J NEUROL SCI, V38, P119, DOI 10.1017/S031716710001115X
   Quinzii CM, 2005, NEUROLOGY, V64, P539, DOI 10.1212/01.WNL.0000150588.75281.58
   Ronchi D, 2013, AM J HUM GENET, V92, P293, DOI 10.1016/j.ajhg.2012.12.014
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Sacconi S, 2010, NEUROMUSCULAR DISORD, V20, P44, DOI 10.1016/j.nmd.2009.10.014
   Schaefer AM, 2008, ANN NEUROL, V63, P35, DOI 10.1002/ana.21217
   Schon EA, 2012, NAT REV GENET, V13, P878, DOI 10.1038/nrg3275
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Venhoff N, 2007, ANTIVIR THER, V12, P1075
   WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231
   Züchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341
NR 46
TC 4
Z9 4
U1 0
U2 4
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1566-5240
EI 1875-5666
J9 CURR MOL MED
JI Curr. Mol. Med.
PY 2014
VL 14
IS 8
BP 1001
EP 1008
DI 10.2174/1566524014666141010152340
PG 8
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA AT4RR
UT WOS:000344929400009
PM 28315632
DA 2024-11-01
ER

PT J
AU Rodríguez-López, C
   García-Cárdaba, LM
   Blázquez, A
   Serrano-Lorenzo, P
   Gutiérrez-Gutiérrez, G
   San Millán-Tejado, B
   Muelas, N
   Hernández-Laín, A
   Vílchez, JJ
   Gutiérrez-Rivas, E
   Arenas, J
   Martín, MA
   Domínguez-González, C
AF Rodriguez-Lopez, Claudia
   Garcia-Cardaba, Luis M.
   Blazquez, Alberto
   Serrano-Lorenzo, Pablo
   Gutierrez-Gutierrez, Gerardo
   San Millan-Tejado, Beatriz
   Muelas, Nuria
   Hernandez-Lain, Aurelio
   Vilchez, Juan J.
   Gutierrez-Rivas, Eduardo
   Arenas, Joaquin
   Martin, Miguel A.
   Dominguez-Gonzalez, Cristina
TI Clinical, pathological and genetic spectrum in 89 cases of mitochondrial
   progressive external ophthalmoplegia
SO JOURNAL OF MEDICAL GENETICS
LA English
DT Article
DE clinical genetics; diagnostics; muscle disease; molecular genetics;
   neuromuscular disease
ID MUTATION; POLG
AB Background Mitochondrial progressive external ophthalmoplegia (PEO) encompasses a broad spectrum of clinical and genetic disorders. We describe the phenotypic subtypes of PEO and its correlation with molecular defects and propose a diagnostic algorithm. Methods Retrospective analysis of the clinical, pathological and genetic features of 89 cases. Results Three main phenotypes were found: 'pure PEO' (42%), consisting of isolated palpebral ptosis with ophthalmoparesis; Kearns-Sayre syndrome (10%); and 'PEO plus', which associates extraocular symptoms, distinguishing the following subtypes: : myopathic (33%), bulbar (12%) and others (3%). Muscle biopsy was the most accurate test, showing mitochondrial changes in 95%. Genetic diagnosis was achieved in 96% of the patients. Single large-scale mitochondrial DNA (mtDNA) deletion was the most frequent finding (63%), followed by multiple mtDNA deletions (26%) due to mutations inTWNK(n=8),POLG(n=7),TK2(n=6) orRRM2B(n=2) genes, and point mtDNA mutations (7%). Three new likely pathogenic mutations were identified in theTWNKandMT-TNgenes. Conclusions Phenotype-genotype correlations cannot be brought in mitochondrial PEO. Muscle biopsy should be the first step in the diagnostic flow of PEO when mitochondrial aetiology is suspected since it also enables the study of mtDNA rearrangements. If no mtDNA deletions are identified, whole mtDNA sequencing should be performed.
C1 [Rodriguez-Lopez, Claudia; Garcia-Cardaba, Luis M.; Gutierrez-Rivas, Eduardo] Hosp Univ 12 Octubre, Neurol, Madrid, Comunidad De Ma, Spain.
   [Blazquez, Alberto; Arenas, Joaquin; Martin, Miguel A.] Hosp Univ 12 Octubre, Inst Invest Sanitaria Hosp 12 Octubre Imas12, Clin Biochem Dept, Mitochondrial Disorders Lab, Madrid, Spain.
   [Blazquez, Alberto; Muelas, Nuria; Vilchez, Juan J.; Arenas, Joaquin; Martin, Miguel A.; Dominguez-Gonzalez, Cristina] Ctr Biomed Network Res Rare Dis CIBERER, Madrid, Spain.
   [Serrano-Lorenzo, Pablo; Dominguez-Gonzalez, Cristina] Inst Invest Sanitaria Hosp 12 Octubre Imas12, Mitochondrial Disorders Res Grp, Madrid, Comunidad De Ma, Spain.
   [Gutierrez-Gutierrez, Gerardo] Hosp Univ Infanta Sofia, Neurol, Madrid, Spain.
   [San Millan-Tejado, Beatriz] Complejo Hosp Vigo Hosp Xeral, Pathol, Vigo, Spain.
   [Muelas, Nuria] Hosp Univ & Politecn La Fe, Neurol, Valencia, Valenciana, Spain.
   [Hernandez-Lain, Aurelio] Hosp Univ 12 Octubre, Neuropathol Sect, Pathol, Madrid, Comunidad De Ma, Spain.
   [Vilchez, Juan J.] Hosp Univ & Politecn La Fe, Neurol Dept, Neuromuscular Dis Unit, Valencia, Valenciana, Spain.
   [Vilchez, Juan J.] Inst Invest Sanitaria La Fe, Neuromuscular & Ataxias Res Grp, Valencia, Spain.
   [Dominguez-Gonzalez, Cristina] Hosp Univ 12 Octubre, Neuromuscular Unit, Madrid, Comunidad De Ma, Spain.
C3 Hospital Universitario 12 de Octubre; Hospital Universitario 12 de
   Octubre; CIBER - Centro de Investigacion Biomedica en Red; CIBERER;
   Hospital Universitario Infanta Sofia; Hospital Universitari i Politecnic
   La Fe; Hospital Universitario 12 de Octubre; Hospital Universitari i
   Politecnic La Fe; Hospital Universitario 12 de Octubre
RP Martín, MA (corresponding author), Hosp Univ 12 Octubre, Mitochondrial Disorders Lab, Madrid 28041, Spain.
EM mamcasanueva.imas12@h12o.es
RI Gutiérrez-Gutiérrez, Gerardo/JAX-7259-2023; Vilchez, Juan/JAX-8314-2023;
   Encinar, Alberto/S-4425-2018; Martin, Miguel/S-2758-2018; Martin, Miguel
   Angel/B-6261-2017; Serrano-Lorenzo, Pablo/S-4744-2018
OI Rodriguez-Lopez, Claudia/0000-0001-6150-4702; Martin, Miguel
   Angel/0000-0003-4741-772X; Vilchez, Juan J/0000-0002-0532-2872;
   Gutierrez-Gutierrez, Gerardo/0000-0003-1391-754X; Serrano-Lorenzo,
   Pablo/0000-0002-5661-7574; SAN MILLAN TEJADO,
   BEATRIZ/0000-0002-1620-1283; Dominguez, Cristina/0000-0001-5151-988X
FU Spanish Instituto de Salud Carlos III (ISCIII); European Regional
   Development Fund (ERDF); (FEDER) [PI18/01374, PI15/00431]
FX This work was supported by the Spanish Instituto de Salud Carlos III
   (ISCIII) and the European Regional Development Fund (ERDF; FEDER)
   (grants PI18/01374 and PI15/00431 to MAM).
CR Arredondo JJ, 2012, MITOCHONDRION, V12, P357, DOI 10.1016/j.mito.2011.09.010
   Blázquez-Bermejo C, 2019, FASEB J, V33, P7168, DOI 10.1096/fj.201801591R
   Cámara Y, 2015, NEUROLOGY, V84, P2286, DOI 10.1212/WNL.0000000000001644
   Coelho MP, 2019, EUR J PEDIATR, V178, P21, DOI 10.1007/s00431-018-3292-x
   Domínguez-González C, 2019, ANN NEUROL, V86, P293, DOI 10.1002/ana.25506
   Domínguez-González C, 2019, ORPHANET J RARE DIS, V14, DOI 10.1186/s13023-019-1071-z
   DRACHMAN DA, 1968, ARCH NEUROL-CHICAGO, V18, P654, DOI 10.1001/archneur.1968.00470360076008
   Fratter C, 2010, NEUROLOGY, V74, P1619, DOI 10.1212/WNL.0b013e3181df099f
   Garone C, 2018, J MED GENET, V55, P515, DOI 10.1136/jmedgenet-2017-105012
   Gorman GS, 2014, GENEREVIEWS, P1993
   Martí R, 2010, PEDIATR RES, V68, P151, DOI 10.1203/00006450-201011001-00294
   McClelland C, 2016, CURR NEUROL NEUROSCI, V16, DOI 10.1007/s11910-016-0652-7
   MORAES CT, 1993, NEUROMUSCULAR DISORD, V3, P43, DOI 10.1016/0960-8966(93)90040-Q
   Nurminen A, 2017, BBA CLIN, V7, P147, DOI 10.1016/j.bbacli.2017.04.001
   Orsucci D, 2017, J NEUROL, V264, P1777, DOI 10.1007/s00415-017-8567-z
   Stumpf JD, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a011395
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Wallace DC, 1999, SCIENCE, V283, P1482, DOI 10.1126/science.283.5407.1482
   Zhu JF, 2016, MITOCHONDRIAL DNA A, V27, P1340, DOI 10.3109/19401736.2014.945580
NR 19
TC 17
Z9 18
U1 0
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-2593
EI 1468-6244
J9 J MED GENET
JI J. Med. Genet.
PD SEP
PY 2020
VL 57
IS 9
BP 643
EP 646
DI 10.1136/jmedgenet-2019-106649
PG 4
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA NK8VQ
UT WOS:000567008800009
PM 32161153
DA 2024-11-01
ER

PT J
AU Cardaioli, E
   Da Pozzo, P
   Cerase, A
   Sicurelli, F
   Malandrini, A
   De Stefano, N
   Stromillo, ML
   Battisti, C
   Dotti, MT
   Federico, A
AF Cardaioli, E
   Da Pozzo, P
   Cerase, A
   Sicurelli, F
   Malandrini, A
   De Stefano, N
   Stromillo, ML
   Battisti, C
   Dotti, MT
   Federico, A
TI Rapidly progressive neurodegeneration in a case with the 7472insC
   mutation and the A7472C polymorphism in the mtDNA
   tRNA<SUP>ser(UCN)</SUP> gene
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE mtDNA; tRNASer(UCN); heteroplasmy
ID CREUTZFELDT-JAKOB-DISEASE; HEARING-LOSS; MITOCHONDRIAL MUTATION;
   HERPES-ENCEPHALITIS; CEREBROSPINAL-FLUID; MR; MYOPATHY; BRAIN; TAU
AB The authors report the clinical, neuroimaging, muscle biopsy and mtDNA findings in a patient affected by bilateral hearing loss and mental retardation since infancy, presenting at age 31 years with a rapid deterioration of mental status and ataxia leading to vegetative condition and death at the age of 32 years. Clinical and genetic studies have been also performed in the mother, affected by neurosensorial hearing loss. Muscle biopsy showed severe mitochondrial alterations in the propositus and evidence of mitochondrial alterations in his mother. Direct mtDNA sequencing in all family members revealed the known 7472insC mutation and the recently described A7472C sequence variation in the tRNA(Ser(UCN)) gene. RFLP-PCR confirmed the heteroplasmic nature of the two mutations and failed to find the second transversion in 200 controls. The percentage of mutant genomes harbouring 7472insC ranged from 3 to 7% in asymptomatic family members to 70% in the proband and his mother, whereas the percentage of A7472C mutant genomes was about 90% in all maternal relatives except the proband (56%) and his sister (5%). In conclusion, this is the first report of a rapidly progressive encephalopathy in association with the 7472insC mutation in mtDNA, combined with an A > C variation at the same nucleotide with a possible suppression effect on the pathogenic mutation. (C) 2005 Elsevier B.V. All rights reserved.
C1 Univ Siena, Sch Med, Dept Neurol & Behav Sci, I-53100 Siena, Italy.
   Azienda Osped Univ Senese, Interdept Ctr Nucl Magnet Resonance, Dept Neurosci, Siena, Italy.
   Azienda Osped Univ Senese, Unit Diagnost & Therapeut Neuroradiol, Siena, Italy.
C3 University of Siena; University of Siena; University Hospital of Siena;
   University of Siena; University Hospital of Siena
RP Univ Siena, Sch Med, Dept Neurol & Behav Sci, Viale Bracci 2, I-53100 Siena, Italy.
EM federico@unisi.it
RI Cerase, Alfonso/AFJ-8833-2022; Federico, Antonio/H-8871-2017
OI Cerase, Alfonso/0000-0003-4753-6649; federico,
   antonio/0000-0002-5246-1621; , Maria Laura/0000-0001-6909-623X;
   Cardaioli, Elena/0000-0003-2850-6698
CR Bahn MM, 1999, ARCH NEUROL-CHICAGO, V56, P577, DOI 10.1001/archneur.56.5.577
   Burkhard PR, 2001, NEUROLOGY, V56, P1528, DOI 10.1212/WNL.56.11.1528
   Chinnery PF, 1999, J MED GENET, V36, P505, DOI 10.1136/jmg.36.7.505
   Collie DA, 2003, AM J NEURORADIOL, V24, P1560
   de Toledo M, 2001, REV NEUROLOGIA, V33, P148, DOI 10.33588/rn.3302.2001016
   DiMauro S, 2000, BRAIN PATHOL, V10, P431
   Dubowitz DJ, 1998, AM J NEURORADIOL, V19, P1617
   Dubowitz V., 1985, MUSCLE BIOPSY PRACTI, V2nd
   ELVERLAND HH, 1991, AM J OTOL, V12, P459
   Ensink RJH, 1998, ARCH OTOLARYNGOL, V124, P886, DOI 10.1001/archotol.124.8.886
   Fetoni V, 2004, NEUROMUSCULAR DISORD, V14, P723, DOI 10.1016/j.nmd.2004.07.002
   Finkenstaedt M, 1996, RADIOLOGY, V199, P793, DOI 10.1148/radiology.199.3.8638007
   Fujioka M, 1997, STROKE, V28, P584, DOI 10.1161/01.STR.28.3.584
   Hutchin TP, 2000, CELL MOL LIFE SCI, V57, P1927, DOI 10.1007/PL00000673
   Jaksch M, 1998, ANN NEUROL, V44, P635, DOI 10.1002/ana.410440409
   JOHNS DR, 1993, NEUROLOGY, V43, P2471, DOI 10.1212/WNL.43.12.2471
   Kovalenko SA, 1996, BIOCHEM BIOPH RES CO, V222, P201, DOI 10.1006/bbrc.1996.0722
   Lansberg MG, 1999, NEUROLOGY, V52, P1021, DOI 10.1212/WNL.52.5.1021
   Marchington DR, 1996, HUM MOL GENET, V5, P473, DOI 10.1093/hmg/5.4.473
   Murata T, 2002, AM J NEURORADIOL, V23, P1164
   PETTY RKH, 1986, BRAIN, V109, P915, DOI 10.1093/brain/109.5.915
   Pulkes T, 2005, NEUROMUSCULAR DISORD, V15, P364, DOI 10.1016/j.nmd.2005.01.006
   Schuelke M, 1998, ANN NEUROL, V44, P700, DOI 10.1002/ana.410440420
   Schwaninger M, 1997, J NEUROL NEUROSUR PS, V63, P408, DOI 10.1136/jnnp.63.3.408
   Sharfstein SR, 1999, ARCH NEUROL-CHICAGO, V56, P241, DOI 10.1001/archneur.56.2.241
   TAKAHASHI S, 1993, RADIOLOGY, V189, P449, DOI 10.1148/radiology.189.2.8210374
   TIRANTI V, 1995, HUM MOL GENET, V4, P1421, DOI 10.1093/hmg/4.8.1421
   Toompuu M, 1999, HUM MOL GENET, V8, P2275, DOI 10.1093/hmg/8.12.2275
   Urbach H, 1998, NEURORADIOLOGY, V40, P65, DOI 10.1007/s002340050542
   Van Everbroeck B, 2002, J NEUROL NEUROSUR PS, V73, P79, DOI 10.1136/jnnp.73.1.79
   VANDERMEEREN M, 1993, J NEUROCHEM, V61, P1828, DOI 10.1111/j.1471-4159.1993.tb09823.x
   Verhoeven K, 1999, EUR J HUM GENET, V7, P45, DOI 10.1038/sj.ejhg.5200247
NR 32
TC 15
Z9 16
U1 0
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD JAN
PY 2006
VL 16
IS 1
BP 26
EP 31
DI 10.1016/j.nmd.2005.11.001
PG 6
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 009ZG
UT WOS:000235151700005
PM 16368237
DA 2024-11-01
ER

PT J
AU Garone, C
   Rubio, JC
   Calvo, SE
   Naini, A
   Tanji, K
   DiMauro, S
   Mootha, VK
   Hirano, M
AF Garone, Caterina
   Carlos Rubio, Juan
   Calvo, Sarah E.
   Naini, Ali
   Tanji, Kurenai
   DiMauro, Salvatore
   Mootha, Vamsi K.
   Hirano, Michio
TI <i>MPV17</i> Mutations Causing Adult-Onset Multisystemic Disorder With
   Multiple Mitochondrial DNA Deletions
SO ARCHIVES OF NEUROLOGY
LA English
DT Article
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; DEPLETION SYNDROME; POLG
   MUTATIONS; NAVAJO NEUROHEPATOPATHY; GENE; PROTEIN; PARKINSONISM; DISEASE
AB Objective: To identify the cause of an adult-onset multisystemic disease with multiple deletions of mitochondrial DNA (mtDNA).
   Design: Case report.
   Setting: University hospitals.
   Patient: A 65-year-old man with axonal sensorimotor peripheral neuropathy, ptosis, ophthalmoparesis, diabetes mellitus, exercise intolerance, steatohepatopathy, depression, parkinsonism, and gastrointestinal dysmotility.
   Results: Skeletal muscle biopsy revealed ragged-red and cytochrome-c oxidase-deficient fibers, and Southern blot analysis showed multiple mtDNA deletions. No deletions were detected in fibroblasts, and the results of quantitative polymerase chain reaction showed that the amount of mtDNA was normal in both muscle and fibroblasts. Exome sequencing using a mitochondrial library revealed compound heterozygous MPV17 mutations (p.LysMet88-89MetLeu and p.Leu143*), a novel cause of mtDNA multiple deletions.
   Conclusions: In addition to causing juvenile-onset disorders with mtDNA depletion, MPV17 mutations can cause adult-onset multisystemic disease with multiple mtDNA deletions. Arch Neurol. 2012; 69(12): 1648-1651. Published online September 10, 2012. doi:10.1001/archneurol.2012.405
C1 [Garone, Caterina; Carlos Rubio, Juan; Naini, Ali; DiMauro, Salvatore; Hirano, Michio] Columbia Univ, Med Ctr, Dept Neurol, New York, NY 10032 USA.
   [Tanji, Kurenai] Columbia Univ, Med Ctr, Dept Pathol, New York, NY 10032 USA.
   [Calvo, Sarah E.; Mootha, Vamsi K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Mol Biol, Boston, MA USA.
   [Calvo, Sarah E.; Mootha, Vamsi K.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA USA.
   [Calvo, Sarah E.; Mootha, Vamsi K.] Harvard Univ, Broad Inst, Cambridge, MA 02138 USA.
   [Calvo, Sarah E.; Mootha, Vamsi K.] MIT, Cambridge, MA 02139 USA.
   [Garone, Caterina] Univ Turin, Joint PhD Program, I-10124 Turin, Italy.
   [Garone, Caterina] Univ Bologna, Joint PhD Program, I-40126 Bologna, Italy.
   [Carlos Rubio, Juan] Hosp 12 Octubre, Unidad Genom, Ctr Invest, E-28041 Madrid, Spain.
C3 Columbia University; Columbia University; Harvard University; Harvard
   Medical School; Massachusetts General Hospital; Harvard University;
   Harvard Medical School; Harvard University; Massachusetts Institute of
   Technology (MIT); Broad Institute; Massachusetts Institute of Technology
   (MIT); University of Turin; University of Bologna; Hospital
   Universitario 12 de Octubre
RP Hirano, M (corresponding author), Columbia Univ, Med Ctr, Dept Neurol, 630 W 168th St,P&S 4-423, New York, NY 10032 USA.
EM mh29@columbia.edu
RI Rubio-Romero, Juan/L-9792-2014; Garone, Caterina/AAB-8659-2019
OI Garone, Caterina/0000-0003-4928-1037
FU Associazione Malattie Metaboliche Congenite ereditarie; National
   Institutes of Health [R01HD056103, 1R01HD057543, U54NS078059]; Muscular
   Dystrophy Association; Marriott Mitochondrial Disorder Clinical Research
   Fund
FX Dr Garone is supported by the Associazione Malattie Metaboliche
   Congenite ereditarie. Dr Hirano is supported by National Institutes of
   Health grants R01HD056103, 1R01HD057543, and U54NS078059, by a Muscular
   Dystrophy Association grant, and by the Marriott Mitochondrial Disorder
   Clinical Research Fund.
CR Altshuler D, 2010, NATURE, V467, P1061, DOI 10.1038/nature09534
   Calvo SE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003310
   Davidzon G, 2006, ANN NEUROL, V59, P859, DOI 10.1002/ana.20831
   El-Hattab AW, 2010, MOL GENET METAB, V99, P300, DOI 10.1016/j.ymgme.2009.10.003
   Fratter C, 2011, NEUROLOGY, V76, P2032, DOI 10.1212/WNL.0b013e31821e558b
   Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279
   Holve S, 1999, J PEDIATR-US, V135, P482, DOI 10.1016/S0022-3476(99)70172-1
   Karadimas CL, 2006, AM J HUM GENET, V79, P544, DOI 10.1086/506913
   KARASAWA M, 1993, HUM MOL GENET, V2, P1829, DOI 10.1093/hmg/2.11.1829
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Pagliarini DJ, 2008, CELL, V134, P112, DOI 10.1016/j.cell.2008.06.016
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Spinazzola A, 2008, ARCH NEUROL-CHICAGO, V65, P1108, DOI 10.1001/archneur.65.8.1108
   Spinazzola A, 2009, ADV EXP MED BIOL, V652, P69, DOI 10.1007/978-90-481-2813-6_6
   Tyynismaa H, 2012, HUM MOL GENET, V21, P66, DOI 10.1093/hmg/ddr438
   Van Goethem G, 2003, EUR J HUM GENET, V11, P547, DOI 10.1038/sj.ejhg.5201002
   Vu TH, 2001, HEPATOLOGY, V34, P116, DOI 10.1053/jhep.2001.25921
   Wong LJC, 2007, HEPATOLOGY, V46, P1218, DOI 10.1002/hep.21799
NR 21
TC 59
Z9 61
U1 0
U2 6
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 0003-9942
J9 ARCH NEUROL-CHICAGO
JI Arch. Neurol.
PD DEC
PY 2012
VL 69
IS 12
BP 1648
EP 1651
DI 10.1001/archneurol.2012.405
PG 4
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 052KI
UT WOS:000312196100018
PM 22964873
OA Green Accepted
DA 2024-11-01
ER

PT J
AU Rahman, S
   Poulton, J
AF Rahman, Shamima
   Poulton, Joanna
TI Diagnosis of mitochondrial DNA depletion syndromes
SO ARCHIVES OF DISEASE IN CHILDHOOD
LA English
DT Article
ID COMPARATIVE GENOMIC HYBRIDIZATION; DGK GENE-MUTATIONS; DEOXYGUANOSINE
   KINASE; RESPIRATORY-CHAIN; SUCLA2 MUTATIONS; MTDNA DEPLETION;
   DEFICIENCY; ENCEPHALOMYOPATHY; FEATURES; MYOPATHY
C1 [Rahman, Shamima] UCL Inst Child Hlth, Mitochondrial Res Grp, London, England.
   [Rahman, Shamima] Natl Hosp Neurol, MRC Ctr Neuromuscular Dis, London, England.
   [Rahman, Shamima] Great Ormond St Hosp Sick Children, Metab Unit, London WC1N 3JH, England.
   [Poulton, Joanna] Univ Oxford, Nuffield Dept Obstet & Gynaecol, Oxford, England.
   [Poulton, Joanna] Great Ormond St Hosp Sick Children, Dubowitz Neuromuscular Ctr, London WC1N 3JH, England.
C3 University of London; University College London; University of London;
   University College London; UCL Medical School; University College London
   Hospitals NHS Foundation Trust; University of London; University College
   London; Great Ormond Street Hospital for Children NHS Foundation Trust;
   University of Oxford; University of London; University College London;
   Great Ormond Street Hospital for Children NHS Foundation Trust
RP Poulton, J (corresponding author), John Radcliffe Hosp, Nuffield Dept Obstet & Gynaecol, Womens Ctr, Level 3, Oxford OX3 9DU, England.
EM Joanna.Poulton@obs-gyn.ox.ac.uk
RI Rahman, Shamima/C-5232-2008; Poulton, Joanna/AAB-4828-2021
OI Poulton, Joanna/0000-0002-2460-5587
FU MRC [G0200335, G0500695] Funding Source: UKRI; Medical Research Council
   [G0500695, G0200335] Funding Source: Medline; Wellcome Trust Funding
   Source: Medline
CR Ashley N, 2008, HUM MOL GENET, V17, P2496, DOI 10.1093/hmg/ddn150
   Ashley N, 2007, HUM MOL GENET, V16, P1400, DOI 10.1093/hmg/ddm090
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Carrozzo R, 2007, BRAIN, V130, P862, DOI 10.1093/brain/awl389
   DEMOUSSON CB, 2007, BIOCHEM J, V402, P377
   Dimmock DP, 2008, HUM MUTAT, V29, P330, DOI 10.1002/humu.9519
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Freisinger P, 2006, ARCH NEUROL-CHICAGO, V63, P1129, DOI 10.1001/archneur.63.8.1129
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   Hargreaves IP, 2002, J INHERIT METAB DIS, V25, P7, DOI 10.1023/A:1015104910239
   Labarthe F, 2005, J HEPATOL, V43, P333, DOI 10.1016/j.jhep.2005.03.023
   Lee NC, 2009, ARCH DIS CHILD, V94, P55, DOI 10.1136/adc.2008.139584
   Mancuso M, 2005, ARCH NEUROL-CHICAGO, V62, P745, DOI 10.1001/archneur.62.5.745
   Mancuso M, 2003, ARCH NEUROL-CHICAGO, V60, P1445, DOI 10.1001/archneur.60.10.1445
   MANDERBACKA K, 2001, SCANDINAVIAN J P S55, V29, P41
   Martí R, 2004, CLIN CHEM, V50, P120, DOI 10.1373/clinchem.2003.026179
   Morten KJ, 2007, MITOCHONDRION, V7, P386, DOI 10.1016/j.mito.2007.09.001
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Ostergaard E, 2007, AM J HUM GENET, V81, P383, DOI 10.1086/519222
   Ostergaard E, 2007, BRAIN, V130, P853, DOI 10.1093/brain/awl383
   Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524
   POULTON J, 1995, J INHERIT METAB DIS, V18, P4, DOI 10.1007/BF00711367
   Rabinowitz SS, 2004, J PEDIATR GASTR NUTR, V38, P216, DOI 10.1097/00005176-200402000-00022
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284
   Salviati L, 2002, ARCH NEUROL-CHICAGO, V59, P862, DOI 10.1001/archneur.59.5.862
   Sarzi E, 2007, J PEDIATR-US, V150, P531, DOI 10.1016/j.jpeds.2007.01.044
   Slama A, 2005, MOL GENET METAB, V86, P462, DOI 10.1016/j.ymgme.2005.09.006
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Taanman JW, 2003, HUM MOL GENET, V12, P1839, DOI 10.1093/hmg/ddg192
   Taanman JW, 2002, ANN NEUROL, V52, P237, DOI 10.1002/ana.10247
   Tadiboyina VT, 2005, AM J MED GENET A, V135A, P289, DOI 10.1002/ajmg.a.30748
   Vu TH, 1998, NEUROLOGY, V50, P1783, DOI 10.1212/WNL.50.6.1783
   Wang LY, 2005, MOL GENET METAB, V84, P75, DOI 10.1016/j.ymgme.2004.09.005
NR 36
TC 48
Z9 53
U1 0
U2 3
PU B M J PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-9888
J9 ARCH DIS CHILD
JI Arch. Dis. Child.
PD JAN
PY 2009
VL 94
IS 1
BP 3
EP 5
DI 10.1136/adc.2008.147983
PG 3
WC Pediatrics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pediatrics
GA 387CP
UT WOS:000261929600002
PM 19103785
DA 2024-11-01
ER

PT J
AU Nesbitt, V
   Pitceathly, RDS
   Turnbull, DM
   Taylor, RW
   Sweeney, MG
   Mudanohwo, EE
   Rahman, S
   Hanna, MG
   McFarland, R
AF Nesbitt, Victoria
   Pitceathly, Robert D. S.
   Turnbull, Doug M.
   Taylor, Robert W.
   Sweeney, Mary G.
   Mudanohwo, Ese E.
   Rahman, Shamima
   Hanna, Michael G.
   McFarland, Robert
TI The UK MRC Mitochondrial Disease Patient Cohort Study: clinical
   phenotypes associated with the m.3243A&gt;G mutation-implications for
   diagnosis and management
SO JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
LA English
DT Article
ID DNA MUTATIONS; MELAS; POPULATION; MYOPATHY
AB Background Population-based studies suggest the m.3243A>G mutation in MTTL1 is the most common disease-causing mtDNA mutation, with a carrier rate of 1 in 400 people. The m.3243A>G mutation is associated with several clinical syndromes including mitochondrial encephalopathy lactic acidosis and strokelike episodes (MELAS), maternally inherited deafness and diabetes (MIDD) and progressive external ophthalmoplegia (PEO). Many patients affected by this mutation exhibit a clinical phenotype that does not fall within accepted criteria for the currently recognised classical mitochondria! syndromes.
   Methods We have defined the phenotypic spectrum associated with the m.3243A>G mtDNA mutation in 129 patients, from 83 unrelated families, recruited to the Mitochondria! Disease Patient Cohort Study UK.
   Results 10% of patients exhibited a classical MELAS phenotype, 30% had MIDD, 6% MELAS/MIDD, 2% MELAS/chronic PEO (CPEO) and 5% MIDD/CPEO overlap syndromes. 6% had PEO and other features of mitochondrial disease not consistent with another recognised syndrome. Isolated sensorineural hearing loss occurred in 3%. 28% of patients demonstrated a panoply of clinical features, which were not consistent with any of the classical syndromes associated with the m.3243A>G mutation. 9% of individuals harbouring the mutation were clinically asymptomatic.
   Conclusion Following this study we propose guidelines for screening and for the management of confirmed cases.
C1 [Nesbitt, Victoria; Turnbull, Doug M.; Taylor, Robert W.; McFarland, Robert] Newcastle Univ, Wellcome Trust Ctr Mitochondrial Res Grp, Inst Ageing & Hlth, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Pitceathly, Robert D. S.; Rahman, Shamima; Hanna, Michael G.] UCL Inst Neurol, MRC Ctr Neuromuscular Dis, London, England.
   [Pitceathly, Robert D. S.; Rahman, Shamima; Hanna, Michael G.] Natl Hosp Neurol & Neurosurg, London WC1N 3BG, England.
   [Sweeney, Mary G.; Mudanohwo, Ese E.] Natl Hosp Neurol & Neurosurg, Neurogenet Unit, London WC1N 3BG, England.
C3 Newcastle University - UK; University of London; University College
   London; University of London; University College London; UCL Medical
   School; University College London Hospitals NHS Foundation Trust;
   University of London; University College London; UCL Medical School;
   University College London Hospitals NHS Foundation Trust
RP McFarland, R (corresponding author), Newcastle Univ, Wellcome Trust Ctr Mitochondrial Res Grp, Inst Ageing & Hlth, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM robert.mcfarland@ncl.ac.uk
RI Rahman, Shamima/C-5232-2008
OI Turnbull, Doug/0000-0002-8878-9901; Hanna, Michael/0000-0003-0825-4075;
   McFarland, Robert/0000-0002-8833-2688; Pitceathly,
   Robert/0000-0002-6123-4551
FU Medical Research Council Centre for Translational Research in
   Neuromuscular Diseases [RES/0211/7552]; MRC [MR/K000608/1, G0700718,
   G0800674] Funding Source: UKRI
FX Funding for the establishment and maintenance of the Mitochondrial
   Disease Patient Cohort Study UK was received from the Medical Research
   Council Centre for Translational Research in Neuromuscular Diseases
   (Grant reference number RES/0211/7552).
CR Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   Elliott HR, 2008, AM J HUM GENET, V83, P254, DOI 10.1016/j.ajhg.2008.07.004
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Hanna MG, 1998, J NEUROL NEUROSUR PS, V65, P512, DOI 10.1136/jnnp.65.4.512
   HIRANO M, 1992, NEUROMUSCULAR DISORD, V2, P125, DOI 10.1016/0960-8966(92)90045-8
   Manwaring N, 2007, MITOCHONDRION, V7, P230, DOI 10.1016/j.mito.2006.12.004
   MORAES CT, 1993, NEUROMUSCULAR DISORD, V3, P43, DOI 10.1016/0960-8966(93)90040-Q
   PAVLAKIS SG, 1984, ANN NEUROL, V16, P481, DOI 10.1002/ana.410160409
   SHAPIRA Y, 1975, NEUROLOGY, V25, P614, DOI 10.1212/WNL.25.7.614
   Tuppen HAL, 2010, BBA-BIOENERGETICS, V1797, P113, DOI 10.1016/j.bbabio.2009.09.005
NR 10
TC 156
Z9 166
U1 1
U2 17
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-3050
EI 1468-330X
J9 J NEUROL NEUROSUR PS
JI J. Neurol. Neurosurg. Psychiatry
PD AUG
PY 2013
VL 84
IS 8
BP 936
EP 938
DI 10.1136/jnnp-2012-303528
PG 3
WC Clinical Neurology; Psychiatry; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Psychiatry; Surgery
GA 292NP
UT WOS:000329909200024
PM 23355809
DA 2024-11-01
ER

PT J
AU Rouzier, C
   Bannwarth, S
   Chaussenot, A
   Chevrollier, A
   Verschueren, A
   Bonello-Palot, N
   Fragaki, K
   Cano, A
   Pouget, J
   Pellissier, JF
   Procaccio, V
   Chabrol, B
   Paquis-Flucklinger, V
AF Rouzier, Cecile
   Bannwarth, Sylvie
   Chaussenot, Annabelle
   Chevrollier, Arnaud
   Verschueren, Annie
   Bonello-Palot, Nathalie
   Fragaki, Konstantina
   Cano, Aline
   Pouget, Jean
   Pellissier, Jean-Francois
   Procaccio, Vincent
   Chabrol, Brigitte
   Paquis-Flucklinger, Veronique
TI The <i>MFN2</i> gene is responsible for mitochondrial DNA instability
   and optic atrophy 'plus' phenotype
SO BRAIN
LA English
DT Article
DE MFN2; mitochondrial DNA instability; dominant optic atrophy;
   mitochondrial fusion; Charcot-Marie-Tooth 2A
ID MARIE-TOOTH DISEASE; OPA1 MUTATIONS; EXTERNAL OPHTHALMOPLEGIA; PATIENT
   FIBROBLASTS; COUPLING DEFECT; FUSION; MITOFUSIN-2; DAMAGE; DELETIONS;
   CELLS
AB MFN2 and OPA1 genes encode two dynamin-like GTPase proteins involved in the fusion of the mitochondrial membrane. They have been associated with Charcot-Marie-Tooth disease type 2A and autosomal dominant optic atrophy, respectively. We report a large family with optic atrophy beginning in early childhood, associated with axonal neuropathy and mitochondrial myopathy in adult life. The clinical presentation looks like the autosomal dominant optic atrophy 'plus' phenotype linked to OPA1 mutations but is associated with a novel MFN2 missense mutation (c.629A > T, p.D210V). Multiple mitochondrial DNA deletions were found in skeletal muscle and this observation makes MFN2 a novel gene associated with 'mitochondrial DNA breakage' syndrome. Contrary to previous studies in patients with Charcot-Marie-Tooth disease type 2A, fibroblasts carrying the MFN2 mutation present with a respiratory chain deficiency, a fragmentation of the mitochondrial network and a significant reduction of MFN2 protein expression. Furthermore, we show for the first time that impaired mitochondrial fusion is responsible for a deficiency to repair stress-induced mitochondrial DNA damage. It is likely that defect in mitochondrial DNA repair is due to variability in repair protein content across the mitochondrial population and is at least partially responsible for mitochondrial DNA instability.
C1 [Rouzier, Cecile; Bannwarth, Sylvie; Chaussenot, Annabelle; Fragaki, Konstantina; Paquis-Flucklinger, Veronique] Nice Teaching Hosp, Natl Ctr Mitochondrial Dis, Dept Med Genet, F-06200 Nice, France.
   [Rouzier, Cecile; Bannwarth, Sylvie; Fragaki, Konstantina; Paquis-Flucklinger, Veronique] Nice Sophia Antipolis Univ, Sch Med, INSERM, CNRS,LBPG,UMR 6267,U998,UNS, F-06100 Nice, France.
   [Chevrollier, Arnaud; Procaccio, Vincent] CNRS, INSERM, UMR 6214, U771, F-49000 Angers, France.
   [Chevrollier, Arnaud; Procaccio, Vincent] Angers Teaching Hosp, Dept Biochem & Genet, F-49000 Angers, France.
   [Verschueren, Annie; Pouget, Jean] Marseille Teaching Hosp, Timone Hosp, Dept Neurol, F-13005 Marseille, France.
   [Bonello-Palot, Nathalie] Marseille Teaching Hosp, Timone Hosp, Dept Med Genet, F-13005 Marseille, France.
   [Cano, Aline] Marseille Teaching Hosp, Timone Hosp, Dept Neuropaediat, F-13005 Marseille, France.
   [Pellissier, Jean-Francois] Marseille Teaching Hosp, Timone Hosp, Dept Neuropathol, F-13005 Marseille, France.
C3 CHU Nice; Institut National de la Sante et de la Recherche Medicale
   (Inserm); Centre National de la Recherche Scientifique (CNRS);
   Universite Cote d'Azur; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS);
   Universite d'Angers; Universite d'Angers; Centre Hospitalier
   Universitaire d'Angers; Aix-Marseille Universite; Assistance
   Publique-Hopitaux de Marseille; Aix-Marseille Universite; Assistance
   Publique-Hopitaux de Marseille; Aix-Marseille Universite; Assistance
   Publique-Hopitaux de Marseille; Aix-Marseille Universite; Assistance
   Publique-Hopitaux de Marseille
RP Paquis-Flucklinger, V (corresponding author), Sch Med, INSERM, CNRS, LBPG,UMR 6267,U998,UNS, 28 Av Valombrose, F-06107 Nice 2, France.
EM paquis@hermes.unice.fr
RI Procaccio, Vincent/M-2596-2015; Rouzier, Cecile/KCY-3619-2024;
   CHEVROLLIER, Arnaud/K-2853-2015; Bonello Palot, Nathalie/M-7134-2016;
   Stewart, Joanna D/H-1614-2012
OI CHEVROLLIER, Arnaud/0000-0002-5135-6643; Bonello Palot,
   Nathalie/0000-0002-8657-1271; Stewart, Joanna D/0000-0002-2608-1967;
   procaccio, Vincent/0000-0002-1537-4684
FU Association Francaise contre les Myopathies (AFM)
FX This work was made possible by grants to V.P.-F. from the Association
   Francaise contre les Myopathies (AFM).
CR Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   Amiott EA, 2008, EXP NEUROL, V211, P115, DOI 10.1016/j.expneurol.2008.01.010
   Ballinger SW, 1999, EXP EYE RES, V68, P765, DOI 10.1006/exer.1998.0661
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Cartoni R, 2009, EXP NEUROL, V218, P268, DOI 10.1016/j.expneurol.2009.05.003
   Chen H, 2010, ANN NY ACAD SCI, V1201, P21, DOI 10.1111/j.1749-6632.2010.05615.x
   Chen HC, 2010, CELL, V141, P280, DOI 10.1016/j.cell.2010.02.026
   Chevrollier A, 2008, ANN NEUROL, V63, P794, DOI 10.1002/ana.21385
   Chung KW, 2006, BRAIN, V129, P2103, DOI 10.1093/brain/awl174
   Del Bo R, 2008, NEUROLOGY, V71, P1959, DOI 10.1212/01.wnl.0000327095.32005.a4
   Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936
   Detmer SA, 2007, J CELL BIOL, V176, P405, DOI 10.1083/jcb.200611080
   Griffin EE, 2006, J BIOL CHEM, V281, P16599, DOI 10.1074/jbc.M601847200
   He LP, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/gnf067
   Santos JH, 2006, HUM MOL GENET, V15, P1757, DOI 10.1093/hmg/ddl098
   Hudson G, 2008, BRAIN, V131, P329, DOI 10.1093/brain/awm272
   Hunter SE, 2010, METHODS, V51, P444, DOI 10.1016/j.ymeth.2010.01.033
   Knott AB, 2008, NAT REV NEUROSCI, V9, P505, DOI 10.1038/nrn2417
   Koshiba T, 2004, SCIENCE, V305, P858, DOI 10.1126/science.1099793
   Lawson VH, 2005, NEUROLOGY, V65, P197, DOI 10.1212/01.wnl.0000168898.76071.70
   Liesa M, 2009, PHYSIOL REV, V89, P799, DOI 10.1152/physrev.00030.2008
   Loiseau D, 2007, ANN NEUROL, V61, P315, DOI 10.1002/ana.21086
   Meeusen S, 2004, SCIENCE, V305, P1747, DOI 10.1126/science.1100612
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Naïmi M, 2006, EUR J HUM GENET, V14, P917, DOI 10.1038/sj.ejhg.5201627
   Paul R, 1996, TRENDS GENET, V12, P131
   ROBINSON BH, 1992, BIOCHEM MED METAB B, V48, P122, DOI 10.1016/0885-4505(92)90056-5
   Rouzier C, 2010, J MED GENET, V47, P670, DOI 10.1136/jmg.2009.073445
   RUSTIN P, 1994, CLIN CHIM ACTA, V228, P31
   Santos JH, 2003, J BIOL CHEM, V278, P1728, DOI 10.1074/jbc.M208752200
   SHULL S, 1991, J BIOL CHEM, V266, P24398
   Song ZY, 2009, MOL BIOL CELL, V20, P3525, DOI 10.1091/mbc.E09-03-0252
   Verhoeven K, 2006, BRAIN, V129, P2093, DOI 10.1093/brain/awl126
   Yakes FM, 1997, P NATL ACAD SCI USA, V94, P514, DOI 10.1073/pnas.94.2.514
   Yu-Wai-Man P, 2010, BRAIN, V133, P771, DOI 10.1093/brain/awq007
   Yu-Wai-Man P, 2011, PROG RETIN EYE RES, V30, P81, DOI 10.1016/j.preteyeres.2010.11.002
   Zanna C, 2008, BRAIN, V131, P352, DOI 10.1093/brain/awm335
   Züchner S, 2004, NAT GENET, V36, P449, DOI 10.1038/ng1341
   Züchner S, 2006, ANN NEUROL, V59, P276, DOI 10.1002/ana.20797
NR 39
TC 184
Z9 194
U1 0
U2 22
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0006-8950
EI 1460-2156
J9 BRAIN
JI Brain
PD JAN
PY 2012
VL 135
BP 23
EP 34
DI 10.1093/brain/awr323
PN 1
PG 12
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 888ZX
UT WOS:000300044400012
PM 22189565
OA Bronze, Green Accepted
DA 2024-11-01
ER

PT J
AU Ardissone, A
   Lamantea, E
   Invernizzi, F
   Zeviani, M
   Genitrini, S
   Moroni, I
   Uziel, G
AF Ardissone, A.
   Lamantea, E.
   Invernizzi, F.
   Zeviani, M.
   Genitrini, S.
   Moroni, I.
   Uziel, G.
TI Mitochondrial Diseases in Childhood
SO CURRENT MOLECULAR MEDICINE
LA English
DT Article
DE Encephalomyocardiopathy; leigh disease; leukoencephalopathy;
   mitochondrial depletions syndromes; mitochondrial disorder in childhood;
   respiratory chain defects
ID RECESSIVE TWINKLE MUTATIONS; LEIGH-SYNDROME; DNA DEPLETION; MTDNA
   DEPLETION; ALPERS-SYNDROME; BARTH-SYNDROME; WHITE-MATTER; BRAIN-STEM;
   GENE; ENCEPHALOPATHY
AB Mitochondrial disorders are a group of heterogeneous diseases associated with abnormalities of the oxidative phosphorylation (OXPHOS), the most important source of energy for the cell. The number of mitochondrial syndromes and of identified causative genes is constantly increasing. Taken as a whole they are among the most frequent genetic diseases in humans at any age. The respiratory chain is the only metabolic pathway under double genome control and molecular genetics of these disorders is complicated by the existence of strict interactions between mitochondrial DNA and nuclear DNA. In childhood and infancy, clinical presentation differs from mitochondrial disorders with adult onset. The phenotypes are much more severe, often involving brain, frequently presenting as multisystemic disorders and seldom as isolated myopathy. Mutations in nDNA are more frequent than in adulthood.
   The major phenotypes presenting in infancy are here correlated with genetic defects and biochemical data with the aim to facilitate diagnosis work-up.
C1 [Ardissone, A.; Genitrini, S.; Moroni, I.; Uziel, G.] IRCCS, Fdn Carlo Besta, Unit Child Neurol, Neurol Inst, I-20133 Milan, Italy.
   [Lamantea, E.; Invernizzi, F.; Zeviani, M.] IRCCS, Fdn Carlo Besta, Unit Neurogenet, Neurol Inst, I-20133 Milan, Italy.
C3 Fondazione IRCCS Istituto Neurologico Carlo Besta; Fondazione IRCCS
   Istituto Neurologico Carlo Besta
RP Uziel, G (corresponding author), IRCCS, Fdn Carlo Besta, Unit Child Neurol, Neurol Inst, Via Celoria 11, I-20133 Milan, Italy.
EM uziel53@gmail.com
RI Zeviani, Massimo/AAU-2632-2021; Lamantea, Eleonora/J-8339-2016;
   Invernizzi, Federica/J-9849-2016; Ardissone, Anna/K-8495-2016; moroni,
   isabella/AAL-1336-2021
OI Lamantea, Eleonora/0000-0001-5090-6028; Invernizzi,
   Federica/0000-0001-8072-0152; Zeviani, Massimo/0000-0002-9067-5508;
   Ardissone, Anna/0000-0003-1969-0147; moroni,
   isabella/0000-0002-3322-1681
FU Telethon-Italy [GUP 09004A]; MRC [MC_UP_1002/1] Funding Source: UKRI
FX This work was supported by Telethon-Italy grants number GUP 09004A.
CR ABE K, 1990, NEURORADIOLOGY, V32, P77, DOI 10.1007/BF00593950
   Acham-Roschitz B, 2009, MOL GENET METAB, V98, P300, DOI 10.1016/j.ymgme.2009.06.012
   Alpers BJ, 1931, ARCH NEURO PSYCHIATR, V25, P469, DOI 10.1001/archneurpsyc.1931.02230030027002
   Barth PG, 2004, AM J MED GENET A, V126A, P349, DOI 10.1002/ajmg.a.20660
   Béhin A, 2012, NEUROLOGY, V78, P644, DOI 10.1212/WNL.0b013e318248df2b
   Bornstein B, 2008, NEUROMUSCULAR DISORD, V18, P453, DOI 10.1016/j.nmd.2008.04.006
   Brockmann K, 2002, ANN NEUROL, V52, P38, DOI 10.1002/ana.10232
   Carrozzo R, 2001, NEUROLOGY, V56, P687, DOI 10.1212/WNL.56.5.687
   Carrozzo R, 2007, BRAIN, V130, P862, DOI 10.1093/brain/awl389
   Castagna AE, 2007, AM J MED GENET A, V143A, P808, DOI 10.1002/ajmg.a.31637
   Dallabona C, 2010, HUM MOL GENET, V19, P1098, DOI 10.1093/hmg/ddp581
   Farina L, 2002, AM J NEURORADIOL, V23, P1095
   Finsterer J, 2008, PEDIATR NEUROL, V39, P223, DOI 10.1016/j.pediatrneurol.2008.07.013
   Fujii T, 1998, PEDIATR NEUROL, V18, P275, DOI 10.1016/S0887-8994(97)00187-2
   Galbiati S, 2006, PEDIATR NEUROL, V34, P177, DOI 10.1016/j.pediatrneurol.2005.07.013
   Götz A, 2008, BRAIN, V131, P2841, DOI 10.1093/brain/awn236
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Jaberi E, 2013, J HUM GENET, V58, P526, DOI 10.1038/jhg.2013.45
   Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257
   Lamperti C, 2012, MOL GENET METAB, V107, P403, DOI 10.1016/j.ymgme.2012.08.020
   Lee IC, 2012, HUM MUTAT, V33, P1192, DOI 10.1002/humu.22095
   Lönnqvist T, 2009, BRAIN, V132, P1553, DOI 10.1093/brain/awp045
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Mancuso M, 2013, NEUROLOGY, V80, P2049, DOI 10.1212/WNL.0b013e318294b44c
   MATTHEWS PM, 1993, ANN NEUROL, V33, P652, DOI 10.1002/ana.410330616
   Menezes MP, 2012, DEV MED CHILD NEUROL, V54, P407, DOI 10.1111/j.1469-8749.2012.04271.x
   Milone M, 2010, NEUROLOGIST, V16, P84, DOI 10.1097/NRL.0b013e3181c78a89
   Mineri R, 2008, J MED GENET, V45, P473, DOI 10.1136/jmg.2008.058271
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Moroni I, 2002, NEUROPEDIATRICS, V33, P79, DOI 10.1055/s-2002-32372
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Naviaux RK, 1999, ANN NEUROL, V45, P54, DOI 10.1002/1531-8249(199901)45:1<54::AID-ART10>3.0.CO;2-B
   Oskoui M, 2006, ARCH NEUROL-CHICAGO, V63, P1122, DOI 10.1001/archneur.63.8.1122
   Ostergaard E, 2007, BRAIN, V130, P853, DOI 10.1093/brain/awl383
   Phadke M, 2012, INDIAN J PEDIATR, V79, P650, DOI 10.1007/s12098-011-0618-3
   Piekutowska-Abramczuk D, 2009, CLIN GENET, V76, P195, DOI 10.1111/j.1399-0004.2009.01195.x
   Poulton J, 2009, BBA-MOL BASIS DIS, V1792, P1109, DOI 10.1016/j.bbadis.2009.08.016
   Prasad C, 2013, MOL GENET METAB, V108, P190, DOI 10.1016/j.ymgme.2012.12.007
   Rahman S, 2001, ANN NEUROL, V49, P797, DOI 10.1002/ana.1060
   Rouzier C, 2010, J MED GENET, V47, P670, DOI 10.1136/jmg.2009.073445
   Salviati L, 2004, AM J MED GENET A, V128A, P195, DOI 10.1002/ajmg.a.30073
   SAMSOM JF, 1994, EUR J PEDIATR, V153, P510, DOI 10.1007/BF01957007
   Savoiardo M, 2002, ANN NEUROL, V51, P138, DOI 10.1002/ana.10031
   Schaefer AM, 2004, BBA-BIOENERGETICS, V1659, P115, DOI 10.1016/j.bbabio.2004.09.005
   Scheper GC, 2007, NAT GENET, V39, P534, DOI 10.1038/ng2013
   Shoubridge EA, 2001, HUM MOL GENET, V10, P2277, DOI 10.1093/hmg/10.20.2277
   SILVESTRI G, 1993, NEUROLOGY, V43, P1200, DOI 10.1212/WNL.43.6.1200
   Sofou K, 2013, MITOCHONDRION, V13, P364, DOI 10.1016/j.mito.2013.04.008
   Steenweg ME, 2012, BRAIN, V135, P1387, DOI 10.1093/brain/aws070
   Steward CG, 2010, PRENATAL DIAG, V30, P970, DOI 10.1002/pd.2599
   Suomalainen A, 2010, NEUROMUSCULAR DISORD, V20, P429, DOI 10.1016/j.nmd.2010.03.017
   Tiranti V, 2004, AM J HUM GENET, V74, P239, DOI 10.1086/381653
   Tiranti V, 1999, ANN NEUROL, V46, P161, DOI 10.1002/1531-8249(199908)46:2<161::AID-ANA4>3.0.CO;2-O
   Tiranti V, 2009, NAT MED, V15, P200, DOI 10.1038/nm.1907
   Tumino M, 2011, AM J MED GENET A, V155A, P3063, DOI 10.1002/ajmg.a.34288
   Uusimaa J, 2008, EPILEPSIA, V49, P1038, DOI 10.1111/j.1528-1167.2008.01544.x
   Uziel G, 2011, SEMIN FETAL NEONAT M, V16, P205, DOI 10.1016/j.siny.2011.04.003
   van der Knaap MS, 2002, ANN NEUROL, V53, P252
   vanderKnaap MS, 1996, J INHERIT METAB DIS, V19, P535, DOI 10.1007/BF01799114
   Ware SM, 2009, J MED GENET, V46, P308, DOI 10.1136/jmg.2008.063149
   Wiltshire E, 2008, ARCH NEUROL-CHICAGO, V65, P121, DOI 10.1001/archneurol.2007.14
   Zeviani M, 1999, ITAL J NEUROL SCI, V20, P401
   Zeviani M, 2006, SCI MED, V10, P154
NR 64
TC 4
Z9 5
U1 0
U2 5
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1566-5240
EI 1875-5666
J9 CURR MOL MED
JI Curr. Mol. Med.
PY 2014
VL 14
IS 8
BP 1069
EP 1078
DI 10.2174/1566524014666141010155317
PG 10
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA AT4RR
UT WOS:000344929400014
PM 25323866
DA 2024-11-01
ER

PT J
AU Zhao, Y
   Hou, Y
   Zhao, XT
   Liufu, TL
   Yu, M
   Zhang, W
   Xie, ZY
   Zhang, VW
   Yuan, Y
   Wang, ZX
AF Zhao, Yang
   Hou, Yue
   Zhao, Xutong
   Liufu, Tongling
   Yu, Meng
   Zhang, Wei
   Xie, Zhiying
   Zhang, Victor Wei
   Yuan, Yun
   Wang, Zhaoxia
TI The clinical, myopathological, and genetic analysis of 155 Chinese
   mitochondrial ophthalmoplegia patients with mitochondrial DNA single
   large deletions
SO MOLECULAR GENETICS & GENOMIC MEDICINE
LA English
DT Article
DE chronic progressive external ophthalmoplegia; Kearns-Sayre syndrome;
   mitochondrial DNA; single large-scale deletion
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; MUTATIONS; DIAGNOSIS; GENOME
AB Background: Progressive external ophthalmoplegia (PEO) is a common subtype of mitochondrial encephalomyopathy.Objective: The study aimed to investigate the relationship between mitochondrial DNA (mtDNA) abnormalities, muscle pathology, and clinical manifestations in Chinese patients with single large-scale mtDNA deletion presenting with PEO.Methods: This is a retrospective single-center study. Patients with PEO who had a single large deletion in mitochondrial DNA were included in this study. The associations were analyzed between mtDNA deletion patterns, myopathological changes, and clinical characteristics.Results: In total, 155 patients with mitochondrial PEO carrying single large-scale mtDNA mutations were enrolled, including 137 chronic progressive external ophthalmoplegia (CPEO) and 18 Kearns-Sayre syndrome (KSS) patients. The onset ages were 9.61 +/- 4.12 in KSS and 20.15 +/- 9.06 in CPEO. The mtDNA deletions ranged from 2225 bp to 9131 bp, with m.8470_13446del being the most common. The KSS group showed longer deletions than the CPEO group (p = 0.004). Additionally, a higher number of deleted genes encoding respiratory chain complex subunits (p = 0.001) and tRNA genes (p = 0.009) were also observed in the KSS group. A weak negative correlation between the mtDNA deletion size and ages of onset (p < 0.001, r = -0.369) was observed. The proportion of ragged red fibers, ragged blue fibers, and cytochrome c negative fibers did not correlate significantly with onset ages (p > 0.05). However, a higher percentage of abnormal muscle fibers corresponds to an increased prevalence of exercise intolerance, limb muscle weakness, dysphagia, and cerebellar ataxia.Conclusion: We reported a large Chinese cohort consisting of mitochondrial PEO patients with single large-scale mtDNA deletions. Our results demonstrated that the length and locations of mtDNA deletions may influence onset ages and clinical phenotypes. The severity of muscle pathology could not only indicate diagnosis but also may be associated with clinical manifestations beyond the extraocular muscles.
C1 [Zhao, Yang; Zhao, Xutong; Liufu, Tongling; Yu, Meng; Zhang, Wei; Xie, Zhiying; Yuan, Yun; Wang, Zhaoxia] Peking Univ First Hosp, Dept Neurol, Beijing 100034, Peoples R China.
   [Zhao, Yang; Zhao, Xutong; Liufu, Tongling; Yu, Meng; Zhang, Wei; Xie, Zhiying; Yuan, Yun; Wang, Zhaoxia] Beijing Key Lab Neurovasc Dis Discovery, Beijing, Peoples R China.
   [Hou, Yue] Peking Univ First Hosp, Dept Geriatr, Beijing, Peoples R China.
   [Zhao, Xutong] Beijing Jishuitan Hosp, Dept Neurol, Beijing, Peoples R China.
   [Zhang, Victor Wei] AmCare Genom Lab, Guangzhou, Peoples R China.
C3 Peking University; Peking University
RP Wang, ZX (corresponding author), Peking Univ First Hosp, Dept Neurol, Beijing 100034, Peoples R China.
EM drwangzx@163.com
RI Chen, Zhenghu/ABB-9207-2021
OI Xie, Zhiying/0000-0003-2102-6026; Zhao, Yang/0009-0003-1006-741X
FU Ministry of Science and Technology of China
FX We thank all the patients and families for their participation in this
   study.
CR Ahmed ST, 2018, NEUROTHERAPEUTICS, V15, P943, DOI 10.1007/s13311-018-00674-4
   Anteneová N, 2020, BRAIN SCI, V10, DOI 10.3390/brainsci10110766
   Björkman K, 2023, J MED GENET, V60, P65, DOI 10.1136/jmedgenet-2021-108006
   Bua E, 2006, AM J HUM GENET, V79, P469, DOI 10.1086/507132
   Chinault AC, 2009, GENET MED, V11, P518, DOI 10.1097/GIM.0b013e3181abd83c
   Crimi M, 2005, FASEB J, V19, P866, DOI 10.1096/fj.04-3045fje
   DRACHMAN DA, 1968, ARCH NEUROL-CHICAGO, V18, P654, DOI 10.1001/archneur.1968.00470360076008
   El-Hattab AW, 2017, BBA-MOL BASIS DIS, V1863, P1539, DOI 10.1016/j.bbadis.2017.02.017
   Finsterer J, 2018, PEDIATR NEUROL, V80, P8, DOI 10.1016/j.pediatrneurol.2017.12.005
   Grady JP, 2014, BRAIN, V137, P323, DOI 10.1093/brain/awt321
   Heighton JN, 2019, MITOCHONDRION, V49, P227, DOI 10.1016/j.mito.2019.09.002
   Heighton JN, 2019, MITOCHONDRION, V44, P15, DOI 10.1016/j.mito.2017.12.006
   Hou Y, 2022, MOL GENET GENOM MED, V10, DOI 10.1002/mgg3.1921
   KEARNS TP, 1958, ARCH OPHTHALMOL-CHIC, V60, P280, DOI 10.1001/archopht.1958.00940080296016
   Liu CS, 2006, ACTA NEUROL SCAND, V113, P334, DOI 10.1111/j.1600-0404.2006.00586.x
   López-Gallardo E, 2009, MITOCHONDRION, V9, P314, DOI 10.1016/j.mito.2009.04.005
   Lott MT., 2013, Curr Protoc Bioinf, V44, P1231, DOI DOI 10.1002/0471250953.BI0123S44
   Mancuso M, 2015, J NEUROL, V262, P1301, DOI 10.1007/s00415-015-7710-y
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Nunnari J, 2012, CELL, V148, P1145, DOI 10.1016/j.cell.2012.02.035
   Paramasivam A, 2016, MITOCHONDRION, V26, P81, DOI 10.1016/j.mito.2015.12.006
   Pfeffer G, 2011, CAN J NEUROL SCI, V38, P119, DOI 10.1017/S031716710001115X
   Rahman S, 2019, NAT REV NEUROL, V15, P40, DOI 10.1038/s41582-018-0101-0
   Rak M, 2016, CLIN SCI, V130, P393, DOI 10.1042/CS20150707
   Reichmann H, 1996, EUR NEUROL, V36, P98, DOI 10.1159/000117217
   Rocha MC, 2018, ANN NEUROL, V83, P115, DOI 10.1002/ana.25127
   Rodríguez-López C, 2020, J MED GENET, V57, P643, DOI 10.1136/jmedgenet-2019-106649
   Rygiel KA, 2016, J PHYSIOL-LONDON, V594, P4499, DOI 10.1113/JP271212
   Sadikovic B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015687
   Schon EA, 1997, J BIOENERG BIOMEMBR, V29, P131, DOI 10.1023/A:1022685929755
   Tanji K, 2000, BRAIN PATHOL, V10, P422
   Tetsuka S, 2021, METAB BRAIN DIS, V36, P2181, DOI 10.1007/s11011-021-00772-x
   Yamashita S, 2008, J HUM GENET, V53, P598, DOI 10.1007/s10038-008-0289-8
   Zhang GY, 2020, FRONT NEUROL, V11, DOI 10.3389/fneur.2020.00036
   Zhang W, 2012, CLIN CHEM, V58, P1322, DOI 10.1373/clinchem.2011.181438
NR 35
TC 2
Z9 2
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2324-9269
J9 MOL GENET GENOM MED
JI Mol. Genet. Genom. Med.
PD JAN
PY 2024
VL 12
IS 1
DI 10.1002/mgg3.2328
EA NOV 2023
PG 11
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA MW4Q6
UT WOS:001110381900001
PM 38018320
OA Green Published, gold
DA 2024-11-01
ER

PT J
AU Gammage, PA
   Rorbach, J
   Vincent, AI
   Rebar, EJ
   Minczuk, M
AF Gammage, Payam A.
   Rorbach, Joanna
   Vincent, Anna I.
   Rebar, Edward J.
   Minczuk, Michal
TI Mitochondrially targeted ZFNs for selective degradation of pathogenic
   mitochondrial genomes bearing large-scale deletions or point mutations
SO EMBO MOLECULAR MEDICINE
LA English
DT Article
DE heteroplasmy; zinc finger nuclease; mitochondrial disease; gene therapy
ID ZINC-FINGER NUCLEASES; SEQUENCE-SPECIFIC MODIFICATION;
   RESTRICTION-ENDONUCLEASE; LOCALIZATION SIGNAL; MTDNA HETEROPLASMY; DNA
   HETEROPLASMY; COPY NUMBER; IN-VITRO; DISEASE; CONSTRUCTION
AB We designed and engineered mitochondrially targeted obligate heterodimeric zinc finger nucleases (mtZFNs) for site-specific elimination of pathogenic human mitochondrial DNA (mtDNA). We used mtZFNs to target and cleave mtDNA harbouring the m.8993T>G point mutation associated with neuropathy, ataxia, retinitis pigmentosa (NARP) and the "common deletion" (CD), a 4977-bp repeat-flanked deletion associated with adult-onset chronic progressive external ophthalmoplegia and, less frequently, Kearns-Sayre and Pearson's marrow pancreas syndromes. Expression of mtZFNs led to a reduction in mutant mtDNA haplotype load, and subsequent repopulation of wild-type mtDNA restored mitochondrial respiratory function in a CD cybrid cell model. This study constitutes proof-of-principle that, through heteroplasmy manipulation, delivery of site-specific nuclease activity to mitochondria can alleviate a severe biochemical phenotype in primary mitochondrial disease arising from deleted mtDNA species.
C1 [Gammage, Payam A.; Rorbach, Joanna; Minczuk, Michal] MRC, Mitochondrial Biol Unit, Cambridge, England.
   [Vincent, Anna I.; Rebar, Edward J.] Sangamo BioSci Inc, Richmond, CA USA.
C3 Sangamo Therapeutics, Inc.
RP Minczuk, M (corresponding author), MRC, Mitochondrial Biol Unit, Cambridge, England.
EM michal.minczuk@mrc-mbu.cam.ac.uk
RI rorbach, Joanna/AAM-5683-2021; Minczuk, Michal/G-1638-2014
OI Rorbach, Joanna/0000-0002-2891-2840; Gammage, Payam
   A./0000-0003-1968-1726; Minczuk, Michal/0000-0001-8242-1420
FU Medical Research Council; MRC [MC_U105697135] Funding Source: UKRI
FX This work was supported by the Medical Research Council (P. A. G., J.R.,
   M. M). The authors are grateful to John E. Walker (MRC-MBU) for useful
   insights prior to submission of the manuscript. The authors are also
   grateful to Gabor Zsurka (University of Bonn) for help in preparation of
   Fig 2A and 3A, to Mike Murphy and Andrew James (MRC-MBU) for providing
   the CD H39 HOS cybrid cells and to Eric Schon (Columbia University) for
   providing the m.8993T>G cybrids.
CR Alexeyev MF, 2008, GENE THER, V15, P516, DOI 10.1038/sj.gt.2008.11
   Bacman SR, 2012, GENE THER, V19, P1101, DOI 10.1038/gt.2011.196
   Bacman SR, 2010, GENE THER, V17, P713, DOI 10.1038/gt.2010.25
   Bacman SR, 2013, NAT MED, V19, P1111, DOI 10.1038/nm.3261
   Bacman SR, 2009, NUCLEIC ACIDS RES, V37, P4218, DOI 10.1093/nar/gkp348
   Bayona-Bafaluy MP, 2005, P NATL ACAD SCI USA, V102, P14392, DOI 10.1073/pnas.0502896102
   Carling PJ, 2011, MITOCHONDRION, V11, P686, DOI 10.1016/j.mito.2011.05.004
   Carroll D, 2006, NAT PROTOC, V1, P1329, DOI 10.1038/nprot.2006.231
   Carroll J, 2009, ANAL BIOCHEM, V395, P249, DOI 10.1016/j.ab.2009.08.006
   Chinnery PF, 2000, ANN NEUROL, V48, P188, DOI 10.1002/1531-8249(200008)48:2<188::AID-ANA8>3.3.CO;2-G
   Doyon Y, 2011, NAT METHODS, V8, P74, DOI 10.1038/NMETH.1539
   Ellis BL, 2013, GENE THER, V20, P35, DOI 10.1038/gt.2011.211
   Fernández-Martínez J, 2003, J MOL BIOL, V334, P667, DOI 10.1016/j.jmb.2003.09.072
   Gaj T, 2013, TRENDS BIOTECHNOL, V31, P397, DOI 10.1016/j.tibtech.2013.04.004
   Grady JP, 2014, BRAIN, V137, P323, DOI 10.1093/brain/awt321
   HOLT IJ, 1990, AM J HUM GENET, V46, P428
   Kim S, 2011, NAT METHODS, V8, P7, DOI 10.1038/nmeth0111-7a
   Kim YG, 1996, P NATL ACAD SCI USA, V93, P1156, DOI 10.1073/pnas.93.3.1156
   Lightowlers RN, 2011, EMBO REP, V12, P480, DOI 10.1038/embor.2011.93
   Maeder ML, 2008, MOL CELL, V31, P294, DOI 10.1016/j.molcel.2008.06.016
   Maniura-Weber K, 2004, NUCLEIC ACIDS RES, V32, P6015, DOI 10.1093/nar/gkh921
   MATHENY C, 1994, J BIOL CHEM, V269, P8176
   Miller JC, 2007, NAT BIOTECHNOL, V25, P778, DOI 10.1038/nbt1319
   Minczuk M, 2008, NUCLEIC ACIDS RES, V36, P3926, DOI 10.1093/nar/gkn313
   Minczuk M, 2006, P NATL ACAD SCI USA, V103, P19689, DOI 10.1073/pnas.0609502103
   Minczuk M, 2011, NUCLEIC ACIDS RES, V39, P4284, DOI 10.1093/nar/gkq1224
   Minczuk M, 2010, METHODS MOL BIOL, V649, P257, DOI 10.1007/978-1-60761-753-2_16
   Minczuk M, 2010, NAT PROTOC, V5, P342, DOI 10.1038/nprot.2009.245
   Palpant NJ, 2013, GENE THER, V20, P121, DOI 10.1038/gt.2012.2
   Papworth M, 2006, GENE, V366, P27, DOI 10.1016/j.gene.2005.09.011
   Pearson H, 2008, NATURE, V455, P160, DOI [10.1038/455160a, 10.1038/453150a]
   Pfeffer G, 2013, NAT REV NEUROL, V9, P474, DOI 10.1038/nrneurol.2013.129
   Porteous WK, 1998, EUR J BIOCHEM, V257, P192, DOI 10.1046/j.1432-1327.1998.2570192.x
   Rorbach J, 2012, NUCLEIC ACIDS RES, V40, P4097, DOI 10.1093/nar/gkr1282
   Sander JD, 2011, NAT METHODS, V8, P67, DOI 10.1038/NMETH.1542
   Schaefer AM, 2008, ANN NEUROL, V63, P35, DOI 10.1002/ana.21217
   Smith J, 2000, NUCLEIC ACIDS RES, V28, P3361, DOI 10.1093/nar/28.17.3361
   Suzuki Y, 2010, MOL CELL BIOL, V30, P5123, DOI 10.1128/MCB.00619-10
   Szczepek M, 2007, NAT BIOTECHNOL, V25, P786, DOI 10.1038/nbt1317
   Tanaka M, 2002, J BIOMED SCI, V9, P534, DOI 10.1007/BF02254980
   Taylor RW, 1997, NAT GENET, V15, P212, DOI 10.1038/ng0297-212
   Vafai SB, 2012, NATURE, V491, P374, DOI 10.1038/nature11707
NR 42
TC 216
Z9 245
U1 0
U2 27
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1757-4676
EI 1757-4684
J9 EMBO MOL MED
JI EMBO Mol. Med.
PD APR
PY 2014
VL 6
IS 4
BP 458
EP 466
DI 10.1002/emmm.201303672
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA AE1PR
UT WOS:000333742100006
PM 24567072
OA Green Published, Green Accepted
DA 2024-11-01
ER

PT J
AU Jeppesen, TD
   Schwartz, M
   Colding-Jorgensen, E
   Krag, T
   Hauerslev, S
   Vissing, J
AF Jeppesen, Tina D.
   Schwartz, Marianne
   Colding-Jorgensen, Eskild
   Krag, Thomas
   Hauerslev, Simon
   Vissing, John
TI Phenotype and clinical course in a family with a new <i>de novo</i>
   Twinkle gene mutation
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE mtDNA deletion; mtDNA depletion; Twinkle gene mutation; CPEO; PEO1
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; MITOCHONDRIAL-DNA DELETIONS
AB The Twinkle gene product is important for mtDNA replication. Only a few reports have investigated the clinically effect of mutations in this gene. We describe a new de novo mutation (1110C > A) in the PEO1 gene in a mother and her two sons. The mother had progressive ophthalmoplegia, limb weakness, sensory neuropathy, elevated resting plasma lactate, glucose intolerance and impaired VO2max while her sons only had mild ptosis. In accordance with the clinical presentation, abnormal morphological findings in muscle and multiple deletions and depletion of mtDNA in muscle were more pronounced in the proband than in her sons. (C) 2007 Elsevier B.V. All rights reserved.
C1 [Jeppesen, Tina D.; Krag, Thomas; Hauerslev, Simon; Vissing, John] Univ Copenhagen, Dept Neurol, Neuromuscular Res Unit, Rigshosp,Sect 7611, DK-2100 Copenhagen, Denmark.
   [Jeppesen, Tina D.; Krag, Thomas; Hauerslev, Simon; Vissing, John] Univ Copenhagen, Dept Neurol, Copenhagen Muscle Res Ctr, Rigshosp,Sect 7611, DK-2100 Copenhagen, Denmark.
   [Schwartz, Marianne] Univ Copenhagen, Rigshosp, Dept Clin Genet, DK-2100 Copenhagen, Denmark.
   [Colding-Jorgensen, Eskild] Univ Copenhagen, Glostrup Hosp, Dept Clin Neurophysiol, Glostrup, Denmark.
C3 Rigshospitalet; University of Copenhagen; University of Copenhagen;
   Rigshospitalet; University of Copenhagen; Rigshospitalet; University of
   Copenhagen
RP Jeppesen, TD (corresponding author), Univ Copenhagen, Dept Neurol, Neuromuscular Res Unit, Rigshosp,Sect 7611, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.
EM Dysgaard@rh.dk
RI Krag, Thomas/AAD-3307-2021; Vissing, John/IUN-4271-2023; Jeppesen,
   Tina/AAV-7195-2020
OI Krag, Thomas/0000-0001-9330-668X
CR Carrozzo R, 1999, J NEUROL SCI, V170, P24, DOI 10.1016/S0022-510X(99)00193-8
   Deschauer M, 2003, NEUROMUSCULAR DISORD, V13, P568, DOI 10.1016/S0960-8966(03)00071-3
   Jeppesen TD, 2006, BRAIN, V129, P3402, DOI 10.1093/brain/awl149
   Kiechl S, 2004, J NEUROL NEUROSUR PS, V75, P1125, DOI 10.1136/jnnp.2003.025890
   Lewis S, 2002, J NEUROL SCI, V201, P39, DOI 10.1016/S0022-510X(02)00190-9
   Li FY, 1999, NEUROLOGY, V53, P1265, DOI 10.1212/WNL.53.6.1265
   SARZI E, 2007, ANN NEUROL, P24
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   SUOMALAINEN A, 1995, NAT GENET, V9, P146, DOI 10.1038/ng0295-146
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
NR 10
TC 12
Z9 14
U1 0
U2 0
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD APR
PY 2008
VL 18
IS 4
BP 306
EP 309
DI 10.1016/j.nmd.2007.10.007
PG 4
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 304PS
UT WOS:000256122000005
PM 18396044
DA 2024-11-01
ER

PT J
AU Luoma, P
   Melberg, A
   Rinne, JO
   Kaukonen, JA
   Nupponen, NN
   Chalmers, RM
   Oldfors, A
   Rautakorpi, I
   Peltonen, L
   Majamaa, K
   Somer, H
   Suomalainen, A
AF Luoma, P
   Melberg, A
   Rinne, JO
   Kaukonen, JA
   Nupponen, NN
   Chalmers, RM
   Oldfors, A
   Rautakorpi, I
   Peltonen, L
   Majamaa, K
   Somer, H
   Suomalainen, A
TI Parkinsonism, premature menopause, and mitochondrial DNA polymerase γ
   mutations:: clinical and molecular genetic study
SO LANCET
LA English
DT Article
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; AUTOSOMAL-DOMINANT; MULTIPLE
   DELETIONS; MTDNA DELETIONS; POLG MUTATIONS; DISEASE; FEATURES;
   DISORDERS; ENCEPHALOMYOPATHY; HYPOGONADISM
AB Background Mutations in the gene encoding mitochondrial DNA polymerase gamma (POLG), the enzyme that synthesises mitochondrial DNA (mtDNA), have been associated with a mitochondrial disease-autosomal dominant or recessive progressive external ophthalmoplegia-and multiple deletions of mtDNA. Mitochondrial dysfunction is also suspected to participate in the pathogenesis of Parkinson's disease. However, no primary gene defects affecting mitochondrial proteins causing mendelian transmission of parkinsonism have been characterised. We aimed to analyse the gene sequence of POLG in patients with progressive external ophthalmoplegia and their healthy relatives.
   Methods In seven families of various ethnic origins we assessed patients with progressive external ophthalmoplegia and unaffected individuals by clinical, biochemical, morphological, and molecular genetic characterisation and positron emission tomography (PET).
   Findings We recorded mutations in POLG in members of all seven families. Clinical assessment showed significant cosegregation of parkinsonism with POLG mutations (p<0.0001), and PET findings were consistent with dopaminergic neuron loss. Post-mortem examination in two individuals showed loss of pigmented neurons and pigment phagocytosis in substantia nigra without Lewy bodies. Furthermore, most women with progressive external ophthalmoplegia had early menopause before age 35 years. The POLG gene defect resulted in secondary accumulation of mtDNA deletions in patients' tissues.
   Interpretation Dysfunction of mitochondrial POLG causes a severe progressive multisystem disorder including parkinsonism and premature menopause, which are not typical of mitochondrial disease. Cosegregation of parkinsonism and POLG mutations in our families suggests that when defective, this gene can underlie mendelian transmission of parkinsonism.
   Relevance to practice Awareness that mitochondrial POLG mutations can underlie parkinsonism is important for clinicians working in diagnosis of movement disorders, as well as for studies of the genetics of Parkinson's disease. Further, progressive external ophthalmoplegia with muscle weakness and neuropathy can mask symptoms of parkinsonism, and clinicians should pay special attention to detect and treat parkinsonism in those individuals.
C1 Univ Helsinki, Biomedicum Helsinki, Programme Neurosci, FIN-00290 Helsinki, Finland.
   Univ Helsinki, Biomedicum Helsinki, Dept Neurol, FIN-00290 Helsinki, Finland.
   Univ Helsinki, Biomedicum Helsinki, Dept Oncol, FIN-00290 Helsinki, Finland.
   Univ Helsinki, Cent Hosp, Helsinki, Finland.
   Natl Publ Hlth Inst, Dept Mol Med, Helsinki, Finland.
   Univ Helsinki, Dept Med Genet, Helsinki, Finland.
   Univ Uppsala Hosp, Dept Neurosci & Neurol, Uppsala, Sweden.
   Univ Turku, Turku PET Ctr, Turku, Finland.
   Inst Neurol, Univ Dept Clin Neurol, London WC1N 3BG, England.
   Gothenburg Univ, Sahlgrens Hosp, Dept Pathol, S-41345 Gothenburg, Sweden.
   Cent Hosp Lapland, Dept Neurol, Rovaniemi, Finland.
   Univ Oulu, Bioctr, Oulu, Finland.
   Univ Oulu, Dept Neurol, Oulu, Finland.
C3 University of Helsinki; University of Helsinki; University of Helsinki;
   University of Helsinki; Helsinki University Central Hospital; Finland
   National Institute for Health & Welfare; University of Helsinki; Uppsala
   University; Uppsala University Hospital; University of Turku; University
   of London; University College London; Sahlgrenska University Hospital;
   University of Gothenburg; University of Oulu; University of Oulu
RP Univ Helsinki, Biomedicum Helsinki, Programme Neurosci, Room C522B,Haartmaninkatu 8, FIN-00290 Helsinki, Finland.
EM anu.wartiovaara@helsinki.fi
RI Majamaa, Kari/A-1344-2012
OI Suomalainen-Wartiovaara, Anu/0000-0003-4833-5195; Majamaa,
   Kari/0000-0002-9070-3791
CR Beal MF, 2000, TRENDS NEUROSCI, V23, P298, DOI 10.1016/S0166-2236(00)01584-8
   Betarbet R, 2000, NAT NEUROSCI, V3, P1301, DOI 10.1038/81834
   Bose HS, 2002, NATURE, V417, P87, DOI 10.1038/417087a
   Casali C, 2001, NEUROLOGY, V56, P802, DOI 10.1212/WNL.56.6.802
   Chalmers RM, 1996, J NEUROL SCI, V143, P41, DOI 10.1016/S0022-510X(96)00032-9
   CHECCARELLI N, 1994, J NEUROL SCI, V123, P74, DOI 10.1016/0022-510X(94)90206-2
   de Rijk MC, 2000, NEUROLOGY, V54, pS21
   Dekker MCJ, 2003, BRAIN, V126, P1722, DOI 10.1093/brain/awg172
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   Gu GY, 2002, J NEUROPATH EXP NEUR, V61, P634, DOI 10.1093/jnen/61.7.634
   Guttman M, 2003, MOVEMENT DISORD, V18, P313, DOI 10.1002/mds.10333
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kaukonen J, 1999, AM J HUM GENET, V65, P256, DOI 10.1086/302445
   Klein JA, 2002, NATURE, V419, P367, DOI 10.1038/nature01034
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   LESTIENNE P, 1990, J NEUROCHEM, V55, P1810, DOI 10.1111/j.1471-4159.1990.tb04973.x
   Lewis S, 2002, J NEUROL SCI, V201, P39, DOI 10.1016/S0022-510X(02)00190-9
   LUNDBERG PO, 1962, ACTA NEUROL SCAND, V38, P142
   Melberg A, 1996, MUSCLE NERVE, V19, P1561, DOI 10.1002/(SICI)1097-4598(199612)19:12<1561::AID-MUS5>3.0.CO;2-8
   Moslemi AR, 1999, NEUROLOGY, V53, P79, DOI 10.1212/WNL.53.1.79
   Orth M, 2002, NEUROCHEM INT, V40, P533, DOI 10.1016/S0197-0186(01)00124-3
   Orth M, 2001, AM J MED GENET, V106, P27, DOI 10.1002/ajmg.1425
   OZAWA T, 1990, BIOCHEM BIOPH RES CO, V172, P483, DOI 10.1016/0006-291X(90)90698-M
   Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200
   Rinne JO, 1999, SYNAPSE, V31, P119, DOI 10.1002/(SICI)1098-2396(199902)31:2<119::AID-SYN4>3.0.CO;2-O
   Shults CW, 2002, ARCH NEUROL-CHICAGO, V59, P1541, DOI 10.1001/archneur.59.10.1541
   Siciliano G, 2001, J NEUROL NEUROSUR PS, V71, P685, DOI 10.1136/jnnp.71.5.685
   Speciale SG, 2002, NEUROTOXICOL TERATOL, V24, P607, DOI 10.1016/S0892-0362(02)00222-2
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   *STANF GEN TECHN C, DHPLC MELT PROGR
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   Suomalainen A, 2001, AM J MED GENET, V106, P53, DOI 10.1002/ajmg.1379
   Suomalainen A, 2000, MOL BIOTECHNOL, V15, P123, DOI 10.1385/MB:15:2:123
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, HUM MUTAT, V22, P175, DOI 10.1002/humu.10246
   Van Goethem G, 2003, EUR J HUM GENET, V11, P547, DOI 10.1038/sj.ejhg.5201002
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
   Zhang J, 2002, PARKINSONISM RELAT D, V8, P165, DOI 10.1016/S1353-8020(01)00041-4
NR 40
TC 441
Z9 487
U1 0
U2 27
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
EI 1474-547X
J9 LANCET
JI Lancet
PD SEP 4
PY 2004
VL 364
IS 9437
BP 875
EP 882
DI 10.1016/S0140-6736(04)16983-3
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 851KY
UT WOS:000223685200034
PM 15351195
DA 2024-11-01
ER

PT J
AU Adema, AY
   Janssen, MCH
   van der Heijden, JW
AF Adema, A. Y.
   Janssen, M. C. H.
   van der Heijden, J. W.
TI A novel mutation in mitochondrial DNA in a patient with diabetes,
   deafness and proteinuria
SO NETHERLANDS JOURNAL OF MEDICINE
LA English
DT Article
DE Maternally inherited deafness and diabetes; MIDD; mitochondrial DNA
   mutation; 09155A>G
ID CLINICAL-FEATURES; POINT MUTATION; DIAGNOSIS; MIDD
AB Maternally inherited deafness and diabetes (MIDD) is characterised by a defect in insulin secretion and bilateral hearing impairment. The m.3243A>G mutation is the most reported in mitochondrial DNA (mtDNA) causing MIDD, although other, rare, mtDNA point mutations have also been mentioned. We report on a 28-year-old Caucasian woman with a history of diabetes, kidney disease, deafness, diarrhoea, myopathy and fatigue. The diagnosis of mitochondrial disease was made in this patient, which resulted from a novel 09155A>G mutation in the mtDNA. As far as we know, this mutation has never been described before as causing MIDD.
C1 [Adema, A. Y.; van der Heijden, J. W.] Vrije Univ Amsterdam, Med Ctr, Dept Nephrol, Amsterdam, Netherlands.
   [Janssen, M. C. H.] Radboud Univ Nijmegen, Med Ctr, Dept Internal Med, Nijmegen, Netherlands.
C3 Vrije Universiteit Amsterdam; Radboud University Nijmegen
RP Adema, AY (corresponding author), Vrije Univ Amsterdam, Med Ctr, Dept Nephrol, Amsterdam, Netherlands.
EM a.adema@vumc.nl
RI Janssen, Mirian/D-9777-2016
OI Janssen, Mirian/0000-0003-4668-9977
CR Chinnery PF, 1999, AM J MED GENET, V85, P498
   de Laat P, 2013, JIMD REP, V8, P47, DOI 10.1007/8904_2012_159
   de Laat P, 2012, J INHERIT METAB DIS, V35, P1059, DOI 10.1007/s10545-012-9465-2
   Maassen J. A., 2002, Archives of Physiology and Biochemistry, V110, P186, DOI 10.1076/apab.110.3.186.8294
   Maassen JA, 2005, ANN MED, V37, P213, DOI 10.1080/07853890510007188
   McDonnell MT, 2004, EUR J HUM GENET, V12, P778, DOI 10.1038/sj.ejhg.5201216
   Murphy R, 2008, DIABETIC MED, V25, P383, DOI 10.1111/j.1464-5491.2008.02359.x
   Narbonne H, 2001, EUR J ENDOCRINOL, V145, P541, DOI 10.1530/eje.0.1450541
   REARDON W, 1992, LANCET, V340, P1376, DOI 10.1016/0140-6736(92)92560-3
   Shanske S, 2004, AM J MED GENET A, V130A, P134, DOI 10.1002/ajmg.a.30220
NR 10
TC 8
Z9 10
U1 0
U2 9
PU VAN ZUIDEN COMMUNICATIONS
PI ALPHEN AAN DE RIJN
PA HENRY DUNANTWEG 40A, 2402 NR ALPHEN AAN DE RIJN, NETHERLANDS
SN 0300-2977
EI 1872-9061
J9 NETH J MED
JI Neth. J. Med.
PD DEC
PY 2016
VL 74
IS 10
BP 455
EP 457
PG 3
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA EG7FZ
UT WOS:000391213000008
PM 27966441
DA 2024-11-01
ER

PT J
AU Jeppesen, TD
   Duno, M
   Risom, L
   Wibrand, F
   Rafiq, J
   Krag, T
   Jakobsen, J
   Andersen, H
   Vissing, J
AF Jeppesen, Tina Dysgaard
   Duno, Morten
   Risom, Lotte
   Wibrand, Flemming
   Rafiq, Jabin
   Krag, Thomas
   Jakobsen, Johannes
   Andersen, Henning
   Vissing, John
TI A novel de novo mutation of the mitochondrial tRNA<SUP>lys</SUP> gene
   mt.8340G&gt;A associated with pure myopathy
SO NEUROMUSCULAR DISORDERS
LA English
DT Article
DE Novel mutation; Mitochondrial DNA; MTTK gene; tRNA(lys)
ID TRANSFER-RNA MUTATIONS
AB Most patients with mutations in the tRNA(lys) gene (MTTK) present with symptoms from the central nervous system (CNS). We describe a 41-year-old woman with pure myopathy associated with a novel de novo mtDNA mutation, mt.8340G>A, which was heteroplasmic in muscle (53%), blood, urine and mouth epithelial cells (<7%). No other family members, including her mother, carried the mutation. She presented with exercise intolerance from age 9, and since age 20 she experienced ptosis and reduced ocular motility. A muscle biopsy revealed ragged red fibres (10%), no COX negative fibres, and many fibres with central nuclei (30%), indicating ongoing damage and repair. The present case expands the mutational and phenotypic spectrum of diseases associated with mutations in MTTK. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Jeppesen, Tina Dysgaard; Rafiq, Jabin; Krag, Thomas; Vissing, John] Univ Copenhagen, Rigshosp, Sect 3342, Neuromuscular Res Unit, DK-2100 Copenhagen, Denmark.
   [Jeppesen, Tina Dysgaard; Jakobsen, Johannes; Vissing, John] Univ Copenhagen, Rigshosp, Dept Neurol, DK-2100 Copenhagen, Denmark.
   [Duno, Morten; Risom, Lotte; Wibrand, Flemming; Andersen, Henning] Univ Copenhagen, Rigshosp, Dept Clin Genet, DK-2100 Copenhagen, Denmark.
   [Jeppesen, Tina Dysgaard; Duno, Morten; Risom, Lotte; Wibrand, Flemming; Krag, Thomas; Jakobsen, Johannes; Andersen, Henning; Vissing, John] Univ Aarhus, Aarhus Hosp, Dept Neurol, DK-8000 Aarhus C, Denmark.
C3 University of Copenhagen; Rigshospitalet; University of Copenhagen;
   Rigshospitalet; University of Copenhagen; Rigshospitalet; Aarhus
   University
RP Jeppesen, TD (corresponding author), Univ Copenhagen, Rigshosp, Sect 3342, Neuromuscular Res Unit, Blegdamsvej 9, DK-2100 Copenhagen, Denmark.
EM tina@dysgaard.dk
RI Krag, Thomas/AAD-3307-2021; Jeppesen, Tina/AAV-7195-2020; Vissing,
   John/IUN-4271-2023
OI Krag, Thomas/0000-0001-9330-668X; Andersen, Henning/0000-0002-9082-2694
CR Blakely EL, 2007, J NEUROL, V254, P1283, DOI 10.1007/s00415-006-0490-7
   Finsterer J, 2007, ACTA NEUROL SCAND, V116, P1, DOI 10.1111/j.1600-0404.2007.00836.x
   Greaves LC, 2010, INVEST OPHTH VIS SCI, V51, P3340, DOI 10.1167/iovs.09-4659
   Houshmand M, 1999, HUM MUTAT, V13, P203, DOI 10.1002/(SICI)1098-1004(1999)13:3<203::AID-HUMU4>3.0.CO;2-3
   Jeppesen TD, 2006, BRAIN, V129, P3402, DOI 10.1093/brain/awl149
   MACMILLAN C, 1993, NEUROLOGY, V43, P1586, DOI 10.1212/WNL.43.8.1586
   McFarland R, 2004, TRENDS GENET, V20, P591, DOI 10.1016/j.tig.2004.09.014
   Muñoz-Málaga A, 2000, MUSCLE NERVE, V23, P538, DOI 10.1002/(SICI)1097-4598(200004)23:4<538::AID-MUS12>3.3.CO;2-K
   Schapira AHV, 2006, LANCET, V368, P70, DOI 10.1016/S0140-6736(06)68970-8
   Sternberg D, 2001, BRAIN, V124, P984, DOI 10.1093/brain/124.5.984
   Wibrand F, 2010, MUSCLE NERVE, V41, P607, DOI 10.1002/mus.21541
   2008, MITOMAP HUM MIT GEN
NR 12
TC 12
Z9 12
U1 0
U2 1
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-8966
EI 1873-2364
J9 NEUROMUSCULAR DISORD
JI Neuromusc. Disord.
PD FEB
PY 2014
VL 24
IS 2
BP 162
EP 166
DI 10.1016/j.nmd.2013.08.004
PG 5
WC Clinical Neurology; Neurosciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA AD2NI
UT WOS:000333072000009
PM 24161205
DA 2024-11-01
ER

PT J
AU Priego, EM
   Karlsson, A
   Gago, F
   Camarasa, MJ
   Balzarini, J
   Pérez-Pérez, MJ
AF Priego, Eva-Maria
   Karlsson, Anna
   Gago, Federico
   Camarasa, Maria-Jose
   Balzarini, Jan
   Perez-Perez, Maria-Jesus
TI Recent Advances in Thymidine Kinase 2 (TK2) Inhibitors and New
   Perspectives for Potential Applications
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Review
DE Mitochondrial thymidine kinase 2 (TK2); nucleoside metabolism; enzymatic
   inhibitors; mitochondrial depletion syndrome (MDS); tumorigenesis
ID MITOCHONDRIAL-DNA DEPLETION; ACYCLIC NUCLEOSIDE ANALOGS; SELECTIVE
   INHIBITORS; TRIPHOSPHATE POOLS; MOLECULAR-CLONING; PROGNOSTIC VALUE;
   PHOSPHORYLATION; MUTATIONS; SUBSTRATE; DESIGN
AB Thymidine kinase 2 (TK2), encoded on chromosome 16q22 of the human genome, is a deoxynucleoside kinase (dNK) that catalyzes the phosphorylation of the pyrimidine deoxynucleosides 2'-deoxythymidine (dThd), 2'-deoxyuridine (dUrd) and 2'-deoxycytidine (dCyd) to the corresponding deoxynucleoside 5'-monophosphate derivatives. In contrast to the S-phase-specific thymidine kinase 1 (TK1), TK2 is constitutively expressed in the mitochondria and plays an important role in providing dNTPs for the replication and maintenance of mitochondrial DNA (mtDNA). The severe mitochondrial DNA depletion syndrome (MDS) has been associated with mutations in TK2, resulting in mtDNA depletion, isolated skeletal myopathy, and death of the individual at an early stage of life. Some antiviral nucleoside analogs, such as 3'-azido-dThd (AZT) that is targeting the human immunodeficiency virus (HIV)-encoded reverse transcriptase, are substrates for TK2 and it has been proposed that the mitochondrial toxicity observed after prolonged treatment with such drugs could be due to their interaction with TK2. Therefore, the design of specific TK2 inhibitors may be useful to investigate the role of TK2 in the maintenance and homeostasis of mitochondrial dNTP pools and its contribution to the mitochondrial toxicity of several antiviral and anticancer drugs. Since 2000, several potent and selective TK2 inhibitors have been described. Besides bringing together previously reported inhibitors, special attention will be paid in this review to the new families of TK2 inhibitors more recently described, together with modeling studies and biological assays. Moreover, the last section will be focused on several recent investigations that suggest that depletion of mtDNA can take place both in tumorigenesis and during cancer treatment with certain nucleoside analogues.
C1 [Priego, Eva-Maria; Camarasa, Maria-Jose; Perez-Perez, Maria-Jesus] CSIC, Inst Quim Med, E-28006 Madrid, Spain.
   [Karlsson, Anna] Karolinska Inst, Huddinge Univ Hosp, Dept Lab Med, SE-14186 Stockholm, Sweden.
   [Gago, Federico] Univ Alcala de Henares, Dept Farmacol, E-28871 Alcala De Henares, Madrid, Spain.
   [Balzarini, Jan] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium.
C3 Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto
   de Quimica Organica General (IQOG); CSIC - Instituto de Quimica Medica
   (IQM); Karolinska Institutet; Universidad de Alcala; KU Leuven
RP Priego, EM (corresponding author), CSIC, Inst Quim Med, C Juan de la Cierva 3, E-28006 Madrid, Spain.
EM empriego@iqm.csic.es
RI Karlsson, Anna/E-7945-2018; Priego, Eva-Maria/L-1688-2014; Gago,
   Federico/H-1004-2015; Camarasa, Maria-Jose/B-6340-2015; Perez-Perez,
   Maria-Jesus/O-4580-2014
OI Karlsson, Anna/0000-0001-6843-6685; Priego,
   Eva-Maria/0000-0001-9470-4508; Gago, Federico/0000-0002-3071-4878;
   Camarasa, Maria-Jose/0000-0002-4978-6468; Perez-Perez,
   Maria-Jesus/0000-0003-1336-7760
FU Spanish CICYT [SAF2006-12713-C02, SAF2003-07219-C02, SAF2000-0153-C02];
   European Union [QLRT-2001-01004]; Comunidad de Madrid [S-BIO-0214-2006];
   K.U. Leuven
FX Our research on TK2 inhibitors has been financed by the Spanish CICYT
   (SAF2006-12713-C02; SAF2003-07219-C02 and SAF 2000-0153-C02, to
   M.-J.P.-P., M.-J. C. and F. G.), the European Union (QLRT-2001-01004, to
   M.-J.P.-P., M.-J. C., A. K. and J. B.), and Comunidad de Madrid
   (S-BIO-0214-2006, to M.-J.P.-P., M.-J. C. and F. G.). Part of the
   research data discussed in this paper has been obtained thanks to the
   financial support of the K.U. Leuven to J. B. We would also like to
   thank those collaborators that have been involved in this joint project
   along these years.
CR Apostolova N, 2011, CURR PHARM DESIGN, V17, P2130, DOI 10.2174/138161211796904731
   ARNER ESJ, 1995, PHARMACOL THERAPEUT, V67, P155, DOI 10.1016/0163-7258(95)00015-9
   Balzarini J, 2000, BIOCHEM J, V351, P167, DOI 10.1042/0264-6021:3510167
   Balzarini J, 2003, MOL PHARMACOL, V63, P263, DOI 10.1124/mol.63.2.263
   Balzarini J, 2001, BIOCHEM PHARMACOL, V61, P727, DOI 10.1016/S0006-2952(01)00529-9
   BALZARINI J, 1988, BIOCHEM PHARMACOL, V37, P2847, DOI 10.1016/0006-2952(88)90049-4
   Balzarini J, 2009, MOL PHARMACOL, V75, P1127, DOI 10.1124/mol.108.053785
   Bartesaghi S, 2010, HUM MOL GENET, V19, P1669, DOI 10.1093/hmg/ddq043
   BRADSHAW HD, 1984, MOL CELL BIOL, V4, P2316, DOI 10.1128/MCB.4.11.2316
   Chen ZH, 2008, ANTICANCER RES, V28, P3897
   Ciliberti N, 2007, BIOORGAN MED CHEM, V15, P3065, DOI 10.1016/j.bmc.2007.01.049
   Deville-Bonne D, 2010, ANTIVIR RES, V86, P101, DOI 10.1016/j.antiviral.2010.02.001
   Egeblad-Welin L, 2007, FEBS J, V274, P1542, DOI 10.1111/j.1742-4658.2007.05701.x
   Eriksson S, 2002, CELL MOL LIFE SCI, V59, P1327, DOI 10.1007/s00018-002-8511-x
   FLEMINGTON E, 1987, GENE, V52, P267, DOI 10.1016/0378-1119(87)90053-9
   Frangini M, 2009, FEBS J, V276, P1104, DOI 10.1111/j.1742-4658.2008.06853.x
   Franzolin E, 2006, BIOCHEM BIOPH RES CO, V344, P30, DOI 10.1016/j.bbrc.2006.03.147
   Götz A, 2008, BRAIN, V131, P2841, DOI 10.1093/brain/awn236
   Håkansson P, 2006, J BIOL CHEM, V281, P7834, DOI 10.1074/jbc.M512894200
   HALLEK M, 1992, ANN HEMATOL, V65, P1, DOI 10.1007/BF01715117
   Hernández AI, 2003, BIOORG MED CHEM LETT, V13, P3027, DOI 10.1016/S0960-894X(03)00639-5
   Hernández AI, 2002, J MED CHEM, V45, P4254, DOI 10.1021/jm011128+
   Hernández AI, 2006, J MED CHEM, V49, P7766, DOI 10.1021/jm0610550
   Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279
   Holm L, 2010, NUCLEIC ACIDS RES, V38, pW545, DOI 10.1093/nar/gkq366
   Kelley LA, 2009, NAT PROTOC, V4, P363, DOI 10.1038/nprot.2009.2
   Kierdaszuk B, 1999, NUCLEOS NUCLEOT, V18, P1883, DOI 10.1080/07328319908044850
   Kim EY, 2001, AIDS RES HUM RETROV, V17, P401, DOI 10.1089/088922201750102445
   Lu JX, 2009, CELL RES, V19, P802, DOI 10.1038/cr.2009.69
   Lynx MD, 2006, BIOCHEM PHARMACOL, V72, P239, DOI 10.1016/j.bcp.2006.04.004
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   Manfredini S, 2001, BIOORG MED CHEM LETT, V11, P1329, DOI 10.1016/S0960-894X(01)00207-4
   McGuffin LJ, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-288
   Munch-Petersen B, 2010, NUCLEOS NUCLEOT NUCL, V29, P363, DOI 10.1080/15257771003729591
   Oskoui M, 2006, ARCH NEUROL-CHICAGO, V63, P1122, DOI 10.1001/archneur.63.8.1122
   Payne BAI, 2011, NAT GENET, V43, P806, DOI 10.1038/ng.863
   Pérez-Pérez MJ, 2008, MED RES REV, V28, P797, DOI 10.1002/med.20124
   Pérez-Pérez MJ, 2005, CURR TOP MED CHEM, V5, P1205, DOI 10.2174/156802605774463097
   Pontarin G, 2011, J BIOL CHEM, V286, P11132, DOI 10.1074/jbc.M110.202283
   Priego EM, 2004, BIOORGAN MED CHEM, V12, P5079, DOI 10.1016/j.bmc.2004.07.036
   Rampazzo C, 2004, J BIOL CHEM, V279, P17019, DOI 10.1074/jbc.M313957200
   Rampazzo C, 2007, J BIOL CHEM, V282, P34758, DOI 10.1074/jbc.M705923200
   ROMAIN S, 1995, INT J CANCER, V61, P7, DOI 10.1002/ijc.2910610103
   Saada A, 2004, DNA CELL BIOL, V23, P797
   Samudio I, 2009, CANCER RES, V69, P2163, DOI 10.1158/0008-5472.CAN-08-3722
   Suomalainen A, 2010, NEUROMUSCULAR DISORD, V20, P429, DOI 10.1016/j.nmd.2010.03.017
   Susan-Resiga D, 2007, ANTIMICROB AGENTS CH, V51, P1142, DOI 10.1128/AAC.01227-06
   Van Daele I, 2007, J MED CHEM, V50, P5281, DOI 10.1021/jm0706158
   Van Poecke S, 2011, ORG BIOMOL CHEM, V9, P892, DOI 10.1039/c0ob00591f
   Van Poecke S, 2010, J MED CHEM, V53, P2902, DOI 10.1021/jm901532h
   Van Rompay AR, 2003, PHARMACOL THERAPEUT, V100, P119, DOI 10.1016/j.pharmthera.2003.07.001
   Wang L, 2010, NUCLEOS NUCLEOT NUCL, V29, P370, DOI 10.1080/15257771003729732
   Wang L, 1999, FEBS LETT, V443, P170, DOI 10.1016/S0014-5793(98)01711-6
   Welin M, 2004, P NATL ACAD SCI USA, V101, P17970, DOI 10.1073/pnas.0406332102
   Wettin K, 1999, FEBS LETT, V460, P103, DOI 10.1016/S0014-5793(99)01325-3
   Zhou XS, 2008, HUM MOL GENET, V17, P2329, DOI 10.1093/hmg/ddn133
   Zhou XS, 2010, J INHERIT METAB DIS, V33, P231, DOI 10.1007/s10545-010-9102-x
NR 57
TC 15
Z9 21
U1 1
U2 26
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PD JUL
PY 2012
VL 18
IS 20
BP 2981
EP 2994
DI 10.2174/138161212800672787
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 975YK
UT WOS:000306547500014
PM 22571666
OA Green Published
DA 2024-11-01
ER

PT J
AU Kazuno, AA
   Munakata, K
   Mori, K
   Tanaka, M
   Nanko, S
   Kunugi, H
   Umekage, T
   Tochigi, M
   Kohda, K
   Sasaki, T
   Akiyama, T
   Washizuka, S
   Kato, N
   Kato, T
AF Kazuno, AA
   Munakata, K
   Mori, K
   Tanaka, M
   Nanko, S
   Kunugi, H
   Umekage, T
   Tochigi, M
   Kohda, K
   Sasaki, T
   Akiyama, T
   Washizuka, S
   Kato, N
   Kato, T
TI Mitochondrial DNA sequence analysis of patients with 'atypical
   psychosis'
SO PSYCHIATRY AND CLINICAL NEUROSCIENCES
LA English
DT Article
DE association study; 'atypical psychosis'; genetics; mitochondrial DNA;
   mitochondrial myopathy
ID GENOME DATABASE; TRANSMISSION; DISORDER; MITOMAP; MELAS; POLYMORPHISMS;
   DISEASE; UPDATE; JAPAN; BRAIN
AB Although classical psychopathological studies have shown the presence of an independent diagnostic category, 'atypical psychosis', most psychotic patients are currently classified into two major diagnostic categories, schizophrenia and bipolar disorder, by the Diagnostic and Statistical Manual of Mental Disorders (4th edn; DSM-IV) criteria. 'Atypical psychosis' is characterized by acute confusion without systematic delusion, emotional instability, and psychomotor excitement or stupor. Such clinical features resemble those seen in organic mental syndrome, and differential diagnosis is often difficult. Because patients with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke-like episodes (MELAS) sometimes show organic mental disorder, 'atypical psychosis' may be caused by mutations of mitochondrial DNA (mtDNA) in some patients. In the present study whole mtDNA was sequenced for seven patients with various psychotic disorders, who could be categorized as 'atypical psychosis'. None of them had known mtDNA mutations pathogenic for mitochondrial encephalopathy. Two of seven patients belonged to a subhaplogroup F1b1a with low frequency. These results did not support the hypothesis that clinical presentation of some patients with 'atypical psychosis' is a reflection of subclinical mitochondrial encephalopathy. However, the subhaplogroup F1b1a may be a good target for association study of 'atypical psychosis'.
C1 RIKEN, Lab Mol Dynam Mental Disorders, Brain Sci Inst, Wako, Saitama 3510198, Japan.
   Univ Tokyo, Fac Med, Dept Neuropsychiat, Tokyo 113, Japan.
   Tokyo Metropolitan Inst Gerontol, Tokyo, Japan.
   Teikyo Univ, Sch Med, Dept Psychiat, Tokyo 173, Japan.
   Natl Inst Neurosci, Dept Mental Disorder Res, Tokyo, Japan.
   Univ Tokyo, Dept Psychiat, Hlth Serv Ctr, Tokyo, Japan.
   NTT E Kanto Med Ctr, Dept Psychiat, Tokyo, Japan.
C3 RIKEN; University of Tokyo; Tokyo Metropolitan Institute of Gerontology;
   Teikyo University; National Center for Neurology & Psychiatry - Japan;
   University of Tokyo; Kanto Medical Center NTT EC
RP RIKEN, Lab Mol Dynam Mental Disorders, Brain Sci Inst, Hirosawa 2-1, Wako, Saitama 3510198, Japan.
EM kato@brain.riken.jp
RI Kato, Tadafumi/J-3583-2014; Kunugi, Hiroshi/ABC-5260-2021; Kohda,
   Kazuhisa/L-4731-2013
OI Kato, Tadafumi/0000-0001-7856-3952; Kunugi, Hiroshi/0000-0002-7209-3790
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Andrews RM, 1999, NAT GENET, V23, P147, DOI 10.1038/13779
   CARROLL BT, 1994, J NEUROPSYCH CLIN N, V6, P122
   Chang SW, 2000, BIOCHEM BIOPH RES CO, V273, P203, DOI 10.1006/bbrc.2000.2885
   ELLISON JM, 1984, ANN EMERG MED, V13, P521, DOI 10.1016/S0196-0644(84)80518-1
   Feddersen B, 2003, NEUROLOGY, V61, P1149, DOI 10.1212/01.WNL.0000092497.53706.1B
   Hatotani N, 1996, PSYCHIAT CLIN NEUROS, V50, P1, DOI 10.1111/j.1440-1819.1996.tb01656.x
   Husted J, 1998, AM J MED GENET, V81, P156, DOI 10.1002/(SICI)1096-8628(19980328)81:2<156::AID-AJMG6>3.0.CO;2-U
   JABLENSKY A, 1995, EUR ARCH PSY CLIN N, V245, P202, DOI 10.1007/BF02191798
   KADOWAKI T, 1994, NEW ENGL J MED, V330, P962, DOI 10.1056/NEJM199404073301403
   Kato T, 2001, MOL PSYCHIATR, V6, P625, DOI 10.1038/sj.mp.4000926
   Kogelnik AM, 1998, NUCLEIC ACIDS RES, V26, P112, DOI 10.1093/nar/26.1.112
   Kogelnik AM, 1996, NUCLEIC ACIDS RES, V24, P177, DOI 10.1093/nar/24.1.177
   Kogelnik AM, 1997, NUCLEIC ACIDS RES, V25, P196, DOI 10.1093/nar/25.1.196
   MCMAHON FJ, 1995, AM J HUM GENET, V56, P1277
   MITSUDA H, 1965, ACTA PSYCHIAT SCAND, V41, P372, DOI 10.1111/j.1600-0447.1965.tb04996.x
   MORGANHUGHES JA, 1982, BRAIN, V105, P553, DOI 10.1093/brain/105.3.553
   Ojaimi J, 1998, CEREBROVASC DIS, V8, P102, DOI 10.1159/000015826
   SELTZER B, 1978, AM J PSYCHIAT, V135, P13
   Stöber G, 1998, PSYCHIATR GENET, V8, P213
   SUZUKI T, 1990, NEURORADIOLOGY, V32, P74, DOI 10.1007/BF00593949
   Talbot-Stern JK, 2000, EMERG MED CLIN N AM, V18, P199, DOI 10.1016/S0733-8627(05)70118-8
   Tanaka M, 2004, ANN NY ACAD SCI, V1011, P7, DOI 10.1196/annals.1293.002
   Tanaka M, 2004, GENOME RES, V14, P1832, DOI 10.1101/gr.2286304
   Tanaka M, 1996, Methods Enzymol, V264, P407, DOI 10.1016/S0076-6879(96)64037-3
   Thomeer EC, 1998, J NEUROL NEUROSUR PS, V64, P692, DOI 10.1136/jnnp.64.5.692
   van der Walt JM, 2003, AM J HUM GENET, V72, P804, DOI 10.1086/373937
   Wallace DC, 1999, GENE, V238, P211, DOI 10.1016/S0378-1119(99)00295-4
   Yamazaki M, 1991, Rinsho Shinkeigaku, V31, P1219
NR 29
TC 32
Z9 32
U1 1
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1323-1316
EI 1440-1819
J9 PSYCHIAT CLIN NEUROS
JI Psychiatry Clin. Neurosci.
PD AUG
PY 2005
VL 59
IS 4
BP 497
EP 503
DI 10.1111/j.1440-1819.2005.01404.x
PG 7
WC Clinical Neurology; Neurosciences; Psychiatry
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Psychiatry
GA 946LS
UT WOS:000230574300018
PM 16048457
DA 2024-11-01
ER

PT J
AU Blakely, EL
   de Silva, R
   King, A
   Schwarzer, V
   Harrower, T
   Dawidek, G
   Turnbull, DM
   Taylor, RW
AF Blakely, EL
   de Silva, R
   King, A
   Schwarzer, V
   Harrower, T
   Dawidek, G
   Turnbull, DM
   Taylor, RW
TI LHON/MELAS overlap syndrome associated with a mitochondrial <i>MTND1</i>
   gene mutation
SO EUROPEAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
DE mitochondrial DNA; LHON; MELAS; overlap syndrome; complex I
ID MTDNA MUTATION; ND5; DIAGNOSIS
AB Pathogenic point mutations in the mitochondrial MTND1 gene have previously been described in association with two distinct clinical phenotypes - Leber hereditary optic neuropathy (LHON) and mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes ( MELAS). Here we report the first heteroplasmic mitochondrial DNA ( mtDNA) point mutation (3376G>A) in the MTND1 gene associated with an overlap syndrome comprising the clinical features of both LHON and MELAS. Muscle histochemistry revealed subtle mitochondrial abnormalities, while biochemical analysis showed an isolated complex I deficiency. Our findings serve to highlight the growing importance of mutations in mitochondrial complex I structural genes in MELAS and its associated overlap syndromes.
C1 Newcastle Univ, Sch Med, Sch Neurol Neurobiol & Psychiat, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   Oldchurch Hosp, Dept Neurol, Romford RM7 0BE, Essex, England.
   Oldchurch Hosp, Dept Neuropathol, Romford RM7 0BE, Essex, England.
   Oldchurch Hosp, Dept Ophthalmol, Romford RM7 0BE, Essex, England.
C3 Newcastle University - UK
RP Newcastle Univ, Sch Med, Sch Neurol Neurobiol & Psychiat, Mitochondrial Res Grp, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
EM r.w.taylor@ncl.ac.uk
FU Wellcome Trust [074454] Funding Source: Medline
CR Corona P, 2001, ANN NEUROL, V49, P106, DOI 10.1002/1531-8249(200101)49:1<106::AID-ANA16>3.0.CO;2-T
   Crimi M, 2003, NEUROLOGY, V60, P1857, DOI 10.1212/01.WNL.0000066048.72780.69
   DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567
   Dimauro S, 2001, AM J MED GENET, V106, P18, DOI 10.1002/ajmg.1392
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Kirby DM, 2004, J MED GENET, V41, P784, DOI 10.1136/jmg.2004.020537
   Liolitsa D, 2003, ANN NEUROL, V53, P128, DOI 10.1002/ana.10435
   Man PYW, 2002, J MED GENET, V39, P162, DOI 10.1136/jmg.39.3.162
   McDonnell MT, 2004, EUR J HUM GENET, V12, P778, DOI 10.1038/sj.ejhg.5201216
   McFarland R, 2002, LANCET NEUROL, V1, P343, DOI 10.1016/S1474-4422(02)00159-X
   *MITOMAP, 1907, HUM MIT GEN DAT
   Musumeci O, 2000, AM J HUM GENET, V66, P1900, DOI 10.1086/302927
   Pulkes T, 1999, ANN NEUROL, V46, P916, DOI 10.1002/1531-8249(199912)46:6<916::AID-ANA16>3.0.CO;2-R
   Ravn K, 2001, EUR J HUM GENET, V9, P805, DOI 10.1038/sj.ejhg.5200712
   Santorelli FM, 1997, BIOCHEM BIOPH RES CO, V238, P326, DOI 10.1006/bbrc.1997.7167
   Taylor R.W., 1997, Organelle Diseases : Clinical Features, Diagnosis, Pathogenesis, and Management, P341
   Taylor RW, 2001, NUCLEIC ACIDS RES, V29, part. no., DOI 10.1093/nar/29.15.e74
   Taylor RW, 2004, NEUROMUSCULAR DISORD, V14, P237, DOI 10.1016/j.nmd.2003.12.004
   Wu CH, 2003, NUCLEIC ACIDS RES, V31, P345, DOI 10.1093/nar/gkg040
NR 19
TC 69
Z9 78
U1 0
U2 2
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1018-4813
EI 1476-5438
J9 EUR J HUM GENET
JI Eur. J. Hum. Genet.
PD MAY
PY 2005
VL 13
IS 5
BP 623
EP 627
DI 10.1038/sj.ejhg.5201363
PG 5
WC Biochemistry & Molecular Biology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Genetics & Heredity
GA 920LX
UT WOS:000228692000019
PM 15657614
OA Bronze
DA 2024-11-01
ER

PT J
AU Aniko, G
   Komlosi, K
   Anita, M
   Pentelenyi, K
   Remenyi, V
   Csaba, O
   Valikovics, A
   Peter, D
   Daniel, B
   Melegh, B
   Molnár, MJ
AF Aniko Gal
   Komlosi, Katalin
   Anita Maasz
   Pentelenyi, Klara
   Remenyi, Viktoria
   Csaba Ovary
   Valikovics, Attila
   Peter Dioszeghy
   Daniel Bereczki
   Melegh, Bela
   Molnar, Maria Judit
TI Analysis of mtDNA A3243G mutation frequency in Hungary
SO CENTRAL EUROPEAN JOURNAL OF MEDICINE
LA English
DT Article
DE Mitochondrial encephalomyopathy; Epidemiology; mtDNA; A3243G
ID TYPE-2 DIABETES-MELLITUS; PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA;
   MITOCHONDRIAL-DNA MUTATIONS; CLINICAL-FEATURES; CHINESE PATIENTS; MELAS
   MUTATION; POSITION 3243; GENE; PREVALENCE; POPULATION
AB The A3243G mutation in the mitochondrial tRNA(Leu (UUR)) gene is one of the most common causes of mitochondrial DNA related disorders. Originally it was described in MELAS syndrome (Mitochondrial Encephalomyopathy, Lactic acidosis, Stroke-like episodes), later it had been found to be associated with various phenotypes. In our study the mutation frequency of the A3243G mtDNA mutation was investigated in patients with maternal sensoneural hearing loss, stroke-like episodes, ataxia and myopathy with undetermined etiology. We screened 631 Hungarian patients in North-East, South-West and Central Hungary between 1999 and 2008 for this mutation. The mtDNA analysis was performed from blood and/or muscle tissue. The A3243G substitution was present in 6 patients in heteroplasmic form. The segregation analysis detected 8 further cases. The frequency of the A3243G mutation was 2.22% in the investigated patients. The A3243G mutation frequency in Hungary does not differ significantly from other countries using similar patient selection criteria, however in Finland a higher mutation rate was found. In studies investigated the mutation frequency of this mutation in diabetes mellitus similarly wide variety was detected as well. We conclude that the study design has a huge impact on the result of the genetic epidemiological investigation analyzing the mutation frequency of the A3243G mutation due to the broad clinical phenotype and the different mutation load in different tissues.
C1 [Aniko Gal; Pentelenyi, Klara; Remenyi, Viktoria; Daniel Bereczki; Molnar, Maria Judit] Semmelweis Univ, Dept Neurol, Ctr Mol Neurol, H-1083 Budapest, Hungary.
   [Komlosi, Katalin; Anita Maasz; Melegh, Bela] Univ Pecs, Dept Med Genet, H-7624 Pecs, Hungary.
   [Csaba Ovary] Natl Inst Neurosurg, Natl Stroke Ctr, H-1145 Budapest, Hungary.
   [Valikovics, Attila] Borsod Abauj Zemplen Cty Hosp, Dept Neurol, H-3526 Miskolc, Hungary.
   [Peter Dioszeghy] Josa Andras Cty Hosp, Dept Neurol, H-4400 Nyiregyhaza, Hungary.
C3 Semmelweis University; University of Pecs
RP Molnár, MJ (corresponding author), Semmelweis Univ, Dept Neurol, Ctr Mol Neurol, H-1083 Budapest, Hungary.
EM molnarmj@neur.sote.hu
RI Bereczki, Daniel/AAL-9886-2020
OI Maasz, Anita/0000-0002-5051-7708
FU National Health [ETT 179/2003]
FX The study was supported by a grant from National Health Grant (ETT
   179/2003). The authors would like to thank for all patients
   participating in the study and for Gyorgyi Bathori, Monika Sary, Metta
   Stralendorrf for their technical help.
CR Abad MM, 1997, METABOLISM, V46, P445, DOI 10.1016/S0026-0495(97)90064-0
   Chae JH, 2004, BRAIN DEV-JPN, V26, P459, DOI 10.1016/j.braindev.2004.01.002
   Finsterer J, 2007, ACTA NEUROL SCAND, V116, P1, DOI 10.1111/j.1600-0404.2007.00836.x
   Francisco G, 2005, DIABETES METAB, V31, P621, DOI 10.1016/S1262-3636(07)70240-9
   Gal Aniko, 2008, Orvosi Hetilap, V149, P1593, DOI 10.1556/OH.2008.28398
   GOTO Y, 1990, NATURE, V348, P651, DOI 10.1038/348651a0
   Klemm T, 2001, EXP CLIN ENDOCR DIAB, V109, P283, DOI 10.1055/s-2001-16348
   Komlósi K, 2005, PATHOL ONCOL RES, V11, P82, DOI 10.1007/BF02893371
   Komlosi Katalin, 2004, Orvosi Hetilap, V145, P1805
   Lee YC, 2007, J NEUROL SCI, V254, P65, DOI 10.1016/j.jns.2007.01.005
   Lehto M, 1999, DIABETOLOGIA, V42, P1131, DOI 10.1007/s001250051281
   Leveque M, 2007, EUR J HUM GENET, V15, P1145, DOI 10.1038/sj.ejhg.5201891
   Majamaa K, 1998, AM J HUM GENET, V63, P447, DOI 10.1086/301959
   Majamaa K, 1997, NEUROLOGY, V49, P1331, DOI 10.1212/WNL.49.5.1331
   Malecki M, 2001, MED SCI MONITOR, V7, P246
   Marotta R, 2004, INTERN MED J, V34, P10, DOI 10.1111/j.1444-0903.2004.t01-3-.x
   Martin-Kleiner I, 2004, ACTA DIABETOL, V41, P179, DOI 10.1007/s00592-004-0163-x
   Mkaouar-Rebai E, 2007, BIOCHEM BIOPH RES CO, V355, P1031, DOI 10.1016/j.bbrc.2007.02.083
   MORAES CT, 1993, NEUROMUSCULAR DISORD, V3, P43, DOI 10.1016/0960-8966(93)90040-Q
   Nagata H, 2001, J HUM GENET, V46, P595, DOI 10.1007/s100380170027
   Ng MCY, 2000, CLIN ENDOCRINOL, V52, P557, DOI 10.1046/j.1365-2265.2000.00989.x
   Ohkubo K, 2001, CLIN CHEM, V47, P1641
   Pang CY, 1999, J FORMOS MED ASSOC, V98, P326
   Rodríguez-Hernández M, 2000, REV NEUROLOGIA, V30, P1001, DOI 10.33588/rn.3011.2000037
   Salles JE, 2007, PANCREAS, V34, P133, DOI 10.1097/01.mpa.0000246659.38375.4d
   Salles JEN, 2007, ARQ BRAS ENDOCRINOL, V51, P559, DOI 10.1590/S0004-27302007000400009
   Sternberg D, 2001, BRAIN, V124, P984, DOI 10.1093/brain/124.5.984
   Tang DL, 2006, DIABETES RES CLIN PR, V73, P77, DOI 10.1016/j.diabres.2005.12.001
   Taylor RW, 1998, BIOCHEM BIOPH RES CO, V251, P883, DOI 10.1006/bbrc.1998.9553
   Turner LF, 1998, EUR HEART J, V19, P1725, DOI 10.1053/euhj.1998.1125
   Wang Cai-ling, 2009, Zhonghua Yixue Yichuanxue Zazhi, V26, P74, DOI 10.3760/cma.j.issn.1003-9406.2009.01.017
   Wang Zhao-xia, 2008, Zhonghua Yi Xue Za Zhi, V88, P3254
   Zhang Xiu-ying, 2004, Zhonghua Yi Xue Yi Chuan Xue Za Zhi, V21, P168
   Zhang Y, 2007, J INHERIT METAB DIS, V30, P265, DOI 10.1007/s10545-006-0481-y
   Zhao Jing, 2006, Yichuan, V28, P1206, DOI 10.1360/yc-006-1206
NR 35
TC 3
Z9 3
U1 0
U2 13
PU DE GRUYTER OPEN LTD
PI WARSAW
PA BOGUMILA ZUGA 32A ST, 01-811 WARSAW, POLAND
SN 1895-1058
EI 1644-3640
J9 CENT EUR J MED
JI Cent. Eur. J. Med.
PD JUN
PY 2010
VL 5
IS 3
BP 322
EP 328
DI 10.2478/s11536-009-0118-2
PG 7
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 581GF
UT WOS:000276508900009
OA hybrid
DA 2024-11-01
ER

PT J
AU Stumpf, JD
   Copeland, WC
AF Stumpf, Jeffrey D.
   Copeland, William C.
TI The Exonuclease Activity of the Yeast Mitochondrial DNA Polymerase γ
   Suppresses Mitochondrial DNA Deletions Between Short Direct Repeats in
   <i>Saccharomyces cerevisiae</i>
SO GENETICS
LA English
DT Article
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; OXIDATIVE STRESS; MUTATIONS;
   MTDNA; DISEASE; POLG; QUANTIFICATION; REPLICATION; DEPLETION; FIDELITY
AB The importance of mitochondrial DNA (mtDNA) deletions in the progeroid phenotype of exonuclease-deficient DNA polymerase gamma mice has been intensely debated. We show that disruption of Mip1 exonuclease activity increases mtDNA deletions 160-fold, whereas disease-associated polymerase variants were mostly unaffected, suggesting that exonuclease activity is vital to avoid deletions during mtDNA replication.
C1 [Stumpf, Jeffrey D.; Copeland, William C.] NIEHS, Mol Genet Lab, NIH, Res Triangle Pk, NC 27709 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Institute of
   Environmental Health Sciences (NIEHS)
RP Copeland, WC (corresponding author), NIEHS, Mol Genet Lab, NIH, 111 TW Alexander Dr,Bldg 101,Room E316, Res Triangle Pk, NC 27709 USA.
EM copelan1@niehs.nih.gov
RI Copeland, William/C-4242-2019
OI Copeland, William/0000-0002-0359-0953
FU NIEHS; National Institutes of Health [ES-065078]
FX We thank Elaine Sia for generously providing NPY75; Dmitry Gordenin for
   providing technical assistance; the National Institute of Environmental
   Health Sciences (NIEHS) Sequencing Core Facility for providing
   nucleotide sequences for the plasmids used; and Matthew Young, Matthew
   Longley, and Scott Lujan for critical reading of the manuscript. This
   work was supported by intramural funds from the NIEHS and National
   Institutes of Health (ES-065078).
CR AZPIROZ R, 1993, MOL BIOL CELL, V4, P21, DOI 10.1091/mbc.4.1.21
   Baruffini E, 2007, BBA-MOL BASIS DIS, V1772, P1225, DOI 10.1016/j.bbadis.2007.10.002
   Baruffini E, 2006, HUM MOL GENET, V15, P2846, DOI 10.1093/hmg/ddl219
   Baruffini E, 2011, MITOCHONDRION, V11, P182, DOI 10.1016/j.mito.2010.09.007
   Chomyn A, 2003, BIOCHEM BIOPH RES CO, V304, P519, DOI 10.1016/S0006-291X(03)00625-9
   Cohen BH, 2010, METHODS, V51, P364, DOI 10.1016/j.ymeth.2010.05.008
   CORTOPASSI GA, 1990, NUCLEIC ACIDS RES, V18, P6927, DOI 10.1093/nar/18.23.6927
   FOURY F, 1992, EMBO J, V11, P2717, DOI 10.1002/j.1460-2075.1992.tb05337.x
   Greaves LC, 2009, AGING CELL, V8, P566, DOI 10.1111/j.1474-9726.2009.00505.x
   Johnson AA, 2001, J BIOL CHEM, V276, P38097
   Johnson AA, 2001, J BIOL CHEM, V276, P38090
   JOYCE CM, 1989, J BIOL CHEM, V264, P10858
   Khrapko K, 2007, NAT GENET, V39, P445, DOI 10.1038/ng0407-445
   Kraytsberg Y, 2009, AGING CELL, V8, P502, DOI 10.1111/j.1474-9726.2009.00484.x
   Kujoth GC, 2005, SCIENCE, V309, P481, DOI 10.1126/science.1112125
   LEHMAN IR, 1964, J BIOL CHEM, V239, P2628
   LEWIS W, 1995, NAT MED, V1, P417, DOI 10.1038/nm0595-417
   Lewis W, 2007, LAB INVEST, V87, P326, DOI 10.1038/labinvest.3700523
   Longley MJ, 1998, BIOCHEMISTRY-US, V37, P10529, DOI 10.1021/bi980772w
   Longley MJ, 2001, J BIOL CHEM, V276, P38555, DOI 10.1074/jbc.M105230200
   Pavlov YI, 2006, CURR BIOL, V16, P202, DOI 10.1016/j.cub.2005.12.002
   Phadnis N, 2005, GENETICS, V171, P1549, DOI 10.1534/genetics.105.047092
   Ponamarev MV, 2002, J BIOL CHEM, V277, P15225, DOI 10.1074/jbc.C200100200
   Safdar A, 2011, P NATL ACAD SCI USA, V108, P4135, DOI 10.1073/pnas.1019581108
   SHOFFNER JM, 1989, P NATL ACAD SCI USA, V86, P7952, DOI 10.1073/pnas.86.20.7952
   Spelbrink JN, 2000, J BIOL CHEM, V275, P24818, DOI 10.1074/jbc.M000559200
   Strand MK, 2003, EUKARYOT CELL, V2, P809, DOI 10.1128/EC.2.4.809-820.2003
   Stuart GR, 2006, HUM MOL GENET, V15, P363, DOI 10.1093/hmg/ddi454
   Stumpf JD, 2011, CELL MOL LIFE SCI, V68, P219, DOI 10.1007/s00018-010-0530-4
   Stumpf JD, 2010, HUM MOL GENET, V19, P2123, DOI 10.1093/hmg/ddq089
   Szczepanowska K, 2010, HUM MOL GENET, V19, P3516, DOI 10.1093/hmg/ddq267
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Vermulst M, 2008, NAT GENET, V40, P392, DOI 10.1038/ng.95
   Vermulst M, 2007, NAT GENET, V39, P540, DOI 10.1038/ng1988
   Vermulst M, 2008, METHODS, V46, P263, DOI 10.1016/j.ymeth.2008.10.008
   Zhang DK, 2000, GENOMICS, V69, P151, DOI 10.1006/geno.2000.6333
NR 37
TC 13
Z9 13
U1 0
U2 5
PU GENETICS SOCIETY AMERICA
PI BETHESDA
PA 9650 ROCKVILLE AVE, BETHESDA, MD 20814 USA
SN 0016-6731
EI 1943-2631
J9 GENETICS
JI Genetics
PD JUN
PY 2013
VL 194
IS 2
BP 519
EP 522
DI 10.1534/genetics.113.150920
PG 4
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 156IG
UT WOS:000319814700020
PM 23589460
OA Green Published, Bronze
DA 2024-11-01
ER

PT S
AU Spinazzola, A
   Zeviani, M
AF Spinazzola, Antonella
   Zeviani, Massimo
BE Espinos, C
   Felipo, V
   Palau, F
TI Mitochondrial Diseases: A Cross-Talk Between Mitochondrial and Nuclear
   Genomes
SO INHERITED NEUROMUSCULAR DISEASES: TRANSLATION FROM PATHMECHANISMS TO
   THERAPIES
SE Advances in Experimental Medicine and Biology
LA English
DT Article; Proceedings Paper
CT International Symposium on Rare Diseases - Inherited Neuromuscular
   Diseases, Translation from Pathomechanisms to Therapies
CY NOV 16-18, 2008
CL Valencia, SPAIN
DE Mitochondrial disease; Mitochondrial DNA; mtDNA depletion; mtDNA
   multiple deletions; Nucleus; Mitochondrion cross-talk
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; NUCLEOSIDE-DIPHOSPHATE KINASE;
   ADENINE-NUCLEOTIDE TRANSLOCATOR; DNA DEPLETION SYNDROME;
   AUTOSOMAL-DOMINANT; NEUROGASTROINTESTINAL ENCEPHALOMYOPATHY; MULTIPLE
   DELETIONS; POLG MUTATIONS; NAVAJO NEUROHEPATOPATHY; MTDNA DEPLETION
AB More than one billion years ago, mitochondria were free-living prokaryotic organisms with their own DNA. However, during the evolution, ancestral genes have been transferred from the mitochondrial to the nuclear genome so that mtDNA became dependent on numerous nucleus-encoded factors for its integrity, replication and expression. Mutations in any of these factors may alter the cross-talk between the two genomes and cause Mendelian diseases that affect mtDNA integrity or expression.
C1 [Spinazzola, Antonella; Zeviani, Massimo] Fdn IRCCS Neurol Inst C Besta, Unit Mol Neurogenet, I-20126 Milan, Italy.
RP Zeviani, M (corresponding author), Fdn IRCCS Neurol Inst C Besta, Unit Mol Neurogenet, Via LiberoTemolo 4, I-20126 Milan, Italy.
EM zeviani@istituto-besta.it
RI Zeviani, Massimo/K-2891-2014; Spinazzola, Antonella/P-5298-2017
OI Zeviani, Massimo/0000-0002-9067-5508; Spinazzola,
   Antonella/0000-0003-4242-8091
CR Agostino A, 2003, NEUROLOGY, V60, P1354, DOI 10.1212/01.WNL.0000056088.09408.3C
   Alexander C, 2000, NAT GENET, V26, P211, DOI 10.1038/79944
   Amati-Bonneau P, 2008, BRAIN, V131, P338, DOI 10.1093/brain/awm298
   Bornstein B, 2008, NEUROMUSCULAR DISORD, V18, P453, DOI 10.1016/j.nmd.2008.04.006
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Calvo S, 2006, NAT GENET, V38, P576, DOI 10.1038/ng1776
   Carrozzo R, 2007, BRAIN, V130, P862, DOI 10.1093/brain/awl389
   Clayton DA, 2000, EXP CELL RES, V255, P4, DOI 10.1006/excr.1999.4763
   Contamine V, 2000, MICROBIOL MOL BIOL R, V64, P281, DOI 10.1128/MMBR.64.2.281-315.2000
   Davidzon G, 2005, ANN NEUROL, V57, P921, DOI 10.1002/ana.20498
   Delettre C, 2000, NAT GENET, V26, P207, DOI 10.1038/79936
   Deschauer M, 2003, NEUROMUSCULAR DISORD, V13, P568, DOI 10.1016/S0960-8966(03)00071-3
   Duvezin-Caubet S, 2006, J BIOL CHEM, V281, P37972, DOI 10.1074/jbc.M606059200
   Elpeleg O, 2005, AM J HUM GENET, V76, P1081, DOI 10.1086/430843
   Ferrari G, 2005, BRAIN, V128, P723, DOI 10.1093/brain/awh410
   Ferraro P, 2005, J BIOL CHEM, V280, P24472, DOI 10.1074/jbc.M502869200
   Filosto M, 2003, ARCH NEUROL-CHICAGO, V60, P1279, DOI 10.1001/archneur.60.9.1279
   Galassi G, 2008, NEUROMUSCULAR DISORD, V18, P465, DOI 10.1016/j.nmd.2008.03.013
   Galbiati S, 2006, PEDIATR NEUROL, V34, P177, DOI 10.1016/j.pediatrneurol.2005.07.013
   Graziewicz MA, 2004, NAT STRUCT MOL BIOL, V11, P770, DOI 10.1038/nsmb805
   HAKONEN AH, 2008, HUM MOL GENET   0905
   Hakonen AH, 2007, BRAIN, V130, P3032, DOI 10.1093/brain/awm242
   Hirano M, 2006, NEUROLOGY, V67, P1458, DOI 10.1212/01.wnl.0000240853.97716.24
   Hirano M, 2001, SEMIN CELL DEV BIOL, V12, P417, DOI 10.1006/scdb.2001.0279
   HIRANO M, 1994, NEUROLOGY, V44, P721, DOI 10.1212/WNL.44.4.721
   Holt IJ, 2000, CELL, V100, P515, DOI 10.1016/S0092-8674(00)80688-1
   Horvath R, 2006, BRAIN, V129, P1674, DOI 10.1093/brain/awl088
   Hudson G, 2008, BRAIN, V131, P329, DOI 10.1093/brain/awm272
   Invernizzi F, 2008, NEUROMUSCULAR DISORD, V18, P460, DOI 10.1016/j.nmd.2008.04.005
   KADRMAS EF, 1991, BIOCHIM BIOPHYS ACTA, V1074, P339, DOI 10.1016/0304-4165(91)90083-S
   Kajander OA, 2000, HUM MOL GENET, V9, P2821, DOI 10.1093/hmg/9.19.2821
   Karadimas CL, 2006, AM J HUM GENET, V79, P544, DOI 10.1086/506913
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   KAVANAUGHBLACK A, 1994, P NATL ACAD SCI USA, V91, P5883, DOI 10.1073/pnas.91.13.5883
   KJER P, 1959, ACTA OPHTHALMOL S54, V37, P1
   Kowluru A, 2002, ARCH BIOCHEM BIOPHYS, V398, P160, DOI 10.1006/abbi.2001.2710
   Lamantea E, 2002, ANN NEUROL, V52, P211, DOI 10.1002/ana.10278
   Lara MC, 2006, NEUROLOGY, V67, P1461, DOI 10.1212/01.wnl.0000239824.95411.52
   Lee YJ, 2004, MOL BIOL CELL, V15, P5001, DOI 10.1091/mbc.E04-04-0294
   Longley MJ, 2006, AM J HUM GENET, V78, P1026, DOI 10.1086/504303
   Luoma P, 2004, LANCET, V364, P875, DOI 10.1016/S0140-6736(04)16983-3
   Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746
   Martí R, 2004, CLIN CHEM, V50, P120, DOI 10.1373/clinchem.2003.026179
   MIZUSAWA H, 1988, J NEUROL SCI, V86, P171, DOI 10.1016/0022-510X(88)90096-2
   MORAES CT, 1991, AM J HUM GENET, V48, P492
   Moslemi AR, 1996, ANN NEUROL, V40, P707, DOI 10.1002/ana.410400506
   Naviaux RK, 2004, ANN NEUROL, V55, P706, DOI 10.1002/ana.20079
   Nikali K, 2005, HUM MOL GENET, V14, P2981, DOI 10.1093/hmg/ddi328
   Nishigaki Y, 2003, J CLIN INVEST, V111, P1913, DOI 10.1172/JCI200317828
   Nishino I, 2000, ANN NEUROL, V47, P792
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   Oskoui M, 2006, ARCH NEUROL-CHICAGO, V63, P1122, DOI 10.1001/archneur.63.8.1122
   Ostergaard E, 2007, AM J HUM GENET, V81, P383, DOI 10.1086/519222
   Ostergaard E, 2007, BRAIN, V130, P853, DOI 10.1093/brain/awl383
   Palmieri L, 2005, HUM MOL GENET, V14, P3079, DOI 10.1093/hmg/ddi341
   PARKS RE, 1973, COMP BIOCHEM PHYSIOL, V45, P355, DOI 10.1016/0305-0491(73)90070-9
   Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751
   Salviati L, 2002, ANN NEUROL, V52, P311, DOI 10.1002/ana.10284
   Sarzi E, 2007, ANN NEUROL, V62, P579, DOI 10.1002/ana.21207
   SERVIDEI S, 1991, NEUROLOGY, V41, P1053, DOI 10.1212/WNL.41.7.1053
   Song SW, 2003, J BIOL CHEM, V278, P43893, DOI 10.1074/jbc.C300401200
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765
   Spinazzola A, 2005, GENE, V354, P162, DOI 10.1016/j.gene.2005.03.025
   Spinazzola A, 2002, J BIOL CHEM, V277, P4128, DOI 10.1074/jbc.M111028200
   Spinazzola A, 2008, ARCH NEUROL-CHICAGO, V65, P1108, DOI 10.1001/archneur.65.8.1108
   Spinazzola A, 2008, NEUROMUSCULAR DISORD, V18, P315, DOI 10.1016/j.nmd.2007.12.007
   Tadiboyina VT, 2005, AM J MED GENET A, V135A, P289, DOI 10.1002/ajmg.a.30748
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   TRITSCHLER HJ, 1992, NEUROLOGY, V42, P209, DOI 10.1212/WNL.42.1.209
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2004, NEUROLOGY, V63, P1251, DOI 10.1212/01.WNL.0000140494.58732.83
   Van Goethem G, 2003, NEUROMUSCULAR DISORD, V13, P133, DOI 10.1016/S0960-8966(02)00216-X
   Vu TH, 2001, HEPATOLOGY, V34, P116, DOI 10.1053/jhep.2001.25921
   WANG X, 2008, HUM MOL GENET
   Winterthun S, 2005, NEUROLOGY, V64, P1204, DOI 10.1212/01.WNL.0000156516.77696.5A
   Wong LJC, 2007, HEPATOLOGY, V46, P1218, DOI 10.1002/hep.21799
   Yavuz H, 2007, ARCH NEUROL-CHICAGO, V64, P435, DOI 10.1001/archneur.64.3.435
   YUZAKI M, 1989, BIOCHEM BIOPH RES CO, V164, P1352, DOI 10.1016/0006-291X(89)91818-4
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 80
TC 25
Z9 25
U1 0
U2 3
PU SPRINGER-VERLAG BERLIN
PI BERLIN
PA HEIDELBERGER PLATZ 3, D-14197 BERLIN, GERMANY
SN 0065-2598
EI 2214-8019
BN 978-90-481-2812-9
J9 ADV EXP MED BIOL
JI Adv.Exp.Med.Biol.
PY 2009
VL 652
BP 69
EP 84
DI 10.1007/978-90-481-2813-6_6
PG 16
WC Medicine, Research & Experimental
WE Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA BOT76
UT WOS:000277561400006
PM 20225020
DA 2024-11-01
ER

PT J
AU Coulbault, L
   Deslandes, B
   Herlicoviez, D
   Read, MH
   Leporrier, N
   Schaeffer, S
   Mouadil, A
   Lombès, A
   Chapon, F
   Jauzac, P
   Allouche, S
AF Coulbault, L.
   Deslandes, B.
   Herlicoviez, D.
   Read, M. H.
   Leporrier, N.
   Schaeffer, S.
   Mouadil, A.
   Lombes, A.
   Chapon, F.
   Jauzac, P.
   Allouche, S.
TI A novel mutation 3090 G &gt; A of the mitochondrial 16S ribosomal RNA
   associated with myopathy
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE mitochondrial myopathy; mtDNA; 16S ribosomal RNA gene mutation; combined
   respiratory chain deficiency
ID DNA; SEQUENCE; GENE
AB We describe a young woman who presented with a progressive myopathy since the age of 9. Spectrophotometric analysis of the respiratory chain in muscle tissue revealed combined and profound complex I, III, II + III, and IV deficiency ranging from 60% to 95% associated with morphological and histochemical abnormalities of the muscle. An exhaustive screening of mitochondrial transfer and ribosomal RNAs showed a novel G > A substitution at nucleotide position 3090 which was detected only in urine sediment and muscle of the patient and was not found in her mother's blood cells and urine sample. We suggest that this novel de novo mutation in the 16S ribosomal RNA, a nucleotide which is highly conserved in different species, would impair mitochondrial protein synthesis and would cause a severe myopathy. (c) 2007 Elsevier Inc. All rights reserved.
C1 Ctr Hosp Univ Caen, Biochem Lab, Ave Cote de Nacre, F-14033 Caen, France.
   Ctr Hosp Univ Caen, Serv Anat Pathol, F-14033 Caen, France.
   Ctr Hosp Univ Caen, Dept Genet & Reprod, F-14033 Caen, France.
   Ctr Hosp Univ Caen, Serv Neurol, F-14033 Caen, France.
   Ctr Hosp Univ Caen, Lab Explorat Fonctionnelles, F-14033 Caen, France.
   INSERM, U 582, CHUPS, Inst Myol, F-75013 Paris, France.
C3 CHU de Caen NORMANDIE; Universite de Caen Normandie; CHU de Caen
   NORMANDIE; Universite de Caen Normandie; Universite de Caen Normandie;
   CHU de Caen NORMANDIE; CHU de Caen NORMANDIE; Universite de Caen
   Normandie; Universite de Caen Normandie; CHU de Caen NORMANDIE; Institut
   National de la Sante et de la Recherche Medicale (Inserm); Sorbonne
   Universite
RP Allouche, S (corresponding author), Ctr Hosp Univ Caen, Biochem Lab, Ave Cote de Nacre, F-14033 Caen, France.
EM allouche-s@chu-caen.fr
RI Lombes, Anne/G-4684-2014; Allouche, Stephane/AFW-3810-2022
OI Allouche, stephane/0000-0003-3134-7501
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Bayona-Bafaluy MP, 2003, NUCLEIC ACIDS RES, V31, P5349, DOI 10.1093/nar/gkg739
   Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500
   Di Fonzo A, 2003, HUM MUTAT, V22, DOI 10.1002/humu.9203
   DiMauro S, 2005, CURR OPIN NEUROL, V18, P538, DOI 10.1097/01.wco.0000179761.63486.1a
   Hsieh RH, 2001, J BIOMED SCI, V8, P328, DOI 10.1159/000054051
   Malgat M., 1999, Mitochondrial Diseases, P357, DOI [10.1007/978-3-642-59884-5_27, DOI 10.1007/978-3-642-59884-5_27]
   Mancuso M, 2002, NEUROLOGY, V59, P1197, DOI 10.1212/01.WNL.0000028689.93049.9A
   May-Panloup P, 2003, HUM REPROD, V18, P550, DOI 10.1093/humrep/deg096
   Mollet J, 2007, J CLIN INVEST, V117, P765, DOI 10.1172/JCI29089
   Napoli L, 2001, NEUROLOGY, V57, P2295, DOI 10.1212/WNL.57.12.2295
   Nishibori M, 2005, ANIM GENET, V36, P367, DOI 10.1111/j.1365-2052.2005.01318.x
   REYNIER P, 1999, MITOCHONDRIAL DIS, P379
   Romero NB., 1999, Mitochondrial diseases- models and methods, P343
   Schlick NE, 2006, AM J PHYSIOL-CELL PH, V291, pC1183, DOI 10.1152/ajpcell.00234.2006
   SHAHID SA, SEQUENCE DIVERSITY B
   SHOFFNER JM, 1993, GENOMICS, V17, P171, DOI 10.1006/geno.1993.1299
   Tang J, 1997, PEDIATR NEUROL, V17, P327, DOI 10.1016/S0887-8994(97)00151-3
NR 18
TC 18
Z9 19
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD OCT 26
PY 2007
VL 362
IS 3
BP 601
EP 605
DI 10.1016/j.bbrc.2007.08.040
PG 5
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA 212NG
UT WOS:000249602700011
PM 17761147
DA 2024-11-01
ER

PT J
AU Oldfors, A
   Moslemi, AR
   Jonasson, L
   Ohlsson, M
   Kollberg, G
   Lindberg, C
AF Oldfors, A
   Moslemi, AR
   Jonasson, L
   Ohlsson, M
   Kollberg, G
   Lindberg, C
TI Mitochondrial abnormalities in inclusion-body myositis
SO NEUROLOGY
LA English
DT Article
ID PROGRESSIVE EXTERNAL OPHTHALMOPLEGIA; NEGATIVE MUSCLE-FIBERS; HUMAN
   MTDNA DELETIONS; DNA DELETIONS; INFLAMMATORY MYOPATHIES;
   SKELETAL-MUSCLE; RESONANCE-SPECTROSCOPY; MUTATIONS; ENCEPHALOMYOPATHIES;
   APOPTOSIS
AB Mitochondrial changes are frequently encountered in sporadic inclusion-body myositis (s-IBM). Cytochrome c oxidase (COX)-deficient muscle fibers and large-scale mitochondrial DNA ( mtDNA) deletions are more frequent in s-IBM than in age-matched controls. COX deficient muscle fibers are due to clonal expansion of mtDNA deletions and point mutations in segments of muscle fibers. Such segments range from 75 mu m to more than 1,000 mu m in length. Clonal expansion of the 4977 bp "common deletion" is a frequent cause of COX deficient muscle fiber segments, but many other deletions also occur. The deletion breakpoints cluster in a few regions that are similar to what is found in human mtDNA deletions in general. Analysis in s-IBM patients of three nuclear genes associated with multiple mtDNA deletions, POLG1, ANT1 and C10orf2, failed to demonstrate any mutations. In s-IBM patients with high number of COX-deficient fibers, the impaired mitochondrial function probably contribute to muscle weakness and wasting. Treatment that has positive effects in mitochondrial myopathies may be tried also in s-IBM.
C1 Sahlgrens Univ Hosp, Dept Pathol, S-41345 Gothenburg, Sweden.
   Sahlgrens Univ Hosp, Dept Neurol, S-41345 Gothenburg, Sweden.
C3 Sahlgrenska University Hospital; Sahlgrenska University Hospital
RP Oldfors, A (corresponding author), Sahlgrens Univ Hosp, Dept Pathol, S-41345 Gothenburg, Sweden.
EM anders.oldfors@pathology.gu.se
CR Aiken J, 2002, ANN NY ACAD SCI, V959, P412, DOI 10.1111/j.1749-6632.2002.tb02111.x
   Argov Z, 1998, MUSCLE NERVE, V21, P1523, DOI 10.1002/(SICI)1097-4598(199811)21:11<1523::AID-MUS22>3.0.CO;2-#
   Arnardottir S, 2003, J REHABIL MED, V35, P31, DOI 10.1080/16501970306110
   Askanas V, 1996, P NATL ACAD SCI USA, V93, P1314, DOI 10.1073/pnas.93.3.1314
   ASKANAS V, 1993, ANN NEUROL, V34, P551, DOI 10.1002/ana.410340408
   BAUMER A, 1994, AM J HUM GENET, V54, P618
   Behrens L, 1997, BRAIN, V120, P929, DOI 10.1093/brain/120.6.929
   BENDAHAN D, 1992, NEUROLOGY, V42, P1203, DOI 10.1212/WNL.42.6.1203
   Blume G, 1997, BRAIN, V120, P39, DOI 10.1093/brain/120.1.39
   Brierley EJ, 1998, ANN NEUROL, V43, P217, DOI 10.1002/ana.410430212
   CARPENTER S, 1978, NEUROLOGY, V28, P8, DOI 10.1212/WNL.28.1.8
   Carpenter S., 1975, RECENT ADV MYOLOGY, P374
   Carrozzo R, 2004, J NEUROCHEM, V90, P490, DOI 10.1111/j.1471-4159.2004.02505.x
   Chen RS, 1997, EUR NEUROL, V37, P212, DOI 10.1159/000117445
   Clark KM, 1997, NAT GENET, V16, P222, DOI 10.1038/ng0797-222
   Dahlbom K, 2002, NEUROMUSCULAR DISORD, V12, P853, DOI 10.1016/S0960-8966(02)00098-6
   DESNUELLE C, 1998, INCLUSION BODY MYOSI, P318
   DiMauro S, 2004, BBA-BIOENERGETICS, V1658, P80, DOI 10.1016/j.bbabio.2004.03.014
   DiMauro S, 2004, ANN NY ACAD SCI, V1011, P232, DOI 10.1196/annals.1293.023
   Elpeleg O, 2002, J MOL MED-JMM, V80, P389, DOI 10.1007/s00109-002-0343-5
   Fayet G, 2002, NEUROMUSCULAR DISORD, V12, P484, DOI 10.1016/S0960-8966(01)00332-7
   Fyhr IM, 2002, ACTA NEUROL SCAND, V105, P403, DOI 10.1034/j.1600-0404.2002.01198.x
   Horvath R, 1998, J NEUROPATH EXP NEUR, V57, P396, DOI 10.1097/00005072-199805000-00003
   Ikezoe K, 2002, ACTA NEUROPATHOL, V103, P531, DOI 10.1007/s00401-001-0502-8
   JOHNSTON W, 1995, ANN NEUROL, V37, P16, DOI 10.1002/ana.410370106
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257
   Larsson NG, 2001, ACTA PHYSIOL SCAND, V171, P385, DOI 10.1046/j.1365-201x.2001.00842.x
   Levine TD, 1998, MUSCLE NERVE, V21, P1724, DOI 10.1002/(SICI)1097-4598(199812)21:12<1724::AID-MUS15>3.0.CO;2-2
   Liu VWS, 1998, NUCLEIC ACIDS RES, V26, P1268, DOI 10.1093/nar/26.5.1268
   Lodi R, 1998, BRAIN, V121, P2119, DOI 10.1093/brain/121.11.2119
   Molnar M, 1998, ACTA NEUROPATHOL, V96, P41, DOI 10.1007/s004010050858
   Moslemi AR, 1996, ANN NEUROL, V40, P707, DOI 10.1002/ana.410400506
   Moslemi AR, 1997, HUM MUTAT, V10, P381, DOI 10.1002/(SICI)1098-1004(1997)10:5<381::AID-HUMU8>3.0.CO;2-I
   Moslemi AR, 1999, NEUROLOGY, V53, P79, DOI 10.1212/WNL.53.1.79
   MULLERHOCKER J, 1990, J NEUROL SCI, V100, P14, DOI 10.1016/0022-510x(90)90006-9
   MUNSCHER C, 1993, FEBS LETT, V317, P27, DOI 10.1016/0014-5793(93)81484-H
   Nagaraju K, 2000, J IMMUNOL, V164, P5459, DOI 10.4049/jimmunol.164.10.5459
   Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689
   OLDFORS A, 1993, BRAIN, V116, P325, DOI 10.1093/brain/116.2.325
   OLDFORS A, 1995, J NEUROPATH EXP NEUR, V54, P581, DOI 10.1097/00005072-199507000-00012
   Oldfors A, 2003, J NEUROPATH EXP NEUR, V62, P217, DOI 10.1093/jnen/62.3.217
   OLDFORS A, 1998, INCLUSION BODY MYOSI, P306
   Pak JW, 2003, AGING CELL, V2, P1, DOI 10.1046/j.1474-9728.2003.00034.x
   RIFAI Z, 1995, ANN NEUROL, V37, P24, DOI 10.1002/ana.410370107
   Samuels DC, 2004, TRENDS GENET, V20, P393, DOI 10.1016/j.tig.2004.07.003
   Santorelli FM, 1996, ANN NEUROL, V39, P789, DOI 10.1002/ana.410390615
   SARKOZI E, 1993, NEUROREPORT, V4, P815, DOI 10.1097/00001756-199306000-00055
   Schon EA, 2003, CURR MED CHEM, V10, P2523, DOI 10.2174/0929867033456503
   SCIACCO M, 1994, HUM MOL GENET, V3, P13, DOI 10.1093/hmg/3.1.13
   Smeitink J, 2001, NAT REV GENET, V2, P342, DOI 10.1038/35072063
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Taivassalo T, 1999, HUM MOL GENET, V8, P1047, DOI 10.1093/hmg/8.6.1047
   Taivassalo T, 2001, ANN NEUROL, V50, P133, DOI 10.1002/ana.1050
   Trifunovic A, 2004, NATURE, V429, P417, DOI 10.1038/nature02517
   Tyynismaa H, 2004, HUM MOL GENET, V13, P3219, DOI 10.1093/hmg/ddh342
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Vattemi G, 2000, J NEUROIMMUNOL, V111, P146, DOI 10.1016/S0165-5728(00)00381-7
   WALLACE DC, 1992, SCIENCE, V256, P628, DOI 10.1126/science.1533953
   Wanrooij S, 2004, NUCLEIC ACIDS RES, V32, P3053, DOI 10.1093/nar/gkh634
   Yamanaka T, 2001, NUCL PHYS B-PROC SUP, V99B, P104, DOI 10.1016/S0920-5632(01)01368-8
   YUNIS EJ, 1971, LAB INVEST, V25, P240
   ZHANG C, 1992, FEBS LETT, V297, P34, DOI 10.1016/0014-5793(92)80321-7
NR 63
TC 88
Z9 98
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3261 USA
SN 0028-3878
J9 NEUROLOGY
JI Neurology
PD JAN
PY 2006
VL 66
SU 1
BP S49
EP S55
DI 10.1212/01.wnl.0000192127.63013.8d
PG 7
WC Clinical Neurology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology
GA 005RX
UT WOS:000234842600008
PM 16432145
DA 2024-11-01
ER

PT J
AU Lorenc, A
   Bryk, J
   Bartnik, E
AF Lorenc, A
   Bryk, J
   Bartnik, E
TI Mitochondrial DNA in tumors
SO TOXICOLOGY MECHANISMS AND METHODS
LA English
DT Article; Proceedings Paper
CT Workshop on Mitochondria DNA Mutations
CY MAY 09-12, 2003
CL POLISH ACAD SCI, WARSAW, POLAND
HO POLISH ACAD SCI
DE cancer; mitochondria; mtDNA
ID RED FIBERS MERRF; COMPLEX-II GENE; MTDNA MUTATIONS; COLORECTAL TUMORS;
   PROTEIN-SYNTHESIS; POINT MUTATION; HIGH-FREQUENCY; HUMAN-CELLS; CANCER;
   MYOPATHY
AB Mitochondria, cellular powerhouses, play a central role in apoptosis. In addition, they are suspected to contribute to aging. There is also increasing evidence that abnormalities in mitochondrial function help cancer development. Changes in mitochondrial transcription and oxidative phosphorylation pathways are observed in many types of cancer. Somatic mutations and quantitative changes in mitochondrial DNA were found in tumors, suggesting that alterations in mitochondrial DNA and the resulting respiratory deficiency play a role in carcinogenesis. It was postulated they could be useful as cancer markers. Mitochondria with abnormal functions are suitable targets for anticancer drugs.
C1 Univ Warsaw, Dept Genet, PL-02106 Warsaw, Poland.
   Postgrad Sch Mol Med, Warsaw, Poland.
   Polish Acad Sci, Inst Biochem & Biophys, Warsaw, Poland.
C3 University of Warsaw; Polish Academy of Sciences; Institute of
   Biochemistry & Biophysics - Polish Academy of Sciences
RP Univ Warsaw, Dept Genet, Pawinskiego 5A, PL-02106 Warsaw, Poland.
EM ebartnik@ibb.waw.pl
RI Bryk, Jarosław/C-4883-2009; Lorenc, Anna/AAA-3138-2022
OI Lorenc, Anna/0000-0002-1406-7607; Bryk, Jaroslaw/0000-0002-2791-9709
CR ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0
   Arnuthan G, 2002, ONCOGENE, V21, P7839, DOI 10.1038/sj.onc.1205983
   Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848
   Carelli V, 2003, TRENDS GENET, V19, P257, DOI 10.1016/S0168-9525(03)00072-6
   Carew Jennifer S, 2002, Mol Cancer, V1, P9, DOI 10.1186/1476-4598-1-9
   Cavalli LR, 1997, CELL GROWTH DIFFER, V8, P1189
   CHESTER KA, 1990, J PATHOL, V162, P309, DOI 10.1002/path.1711620406
   Chinnery PF, 1997, BRAIN, V120, P1713, DOI 10.1093/brain/120.10.1713
   Chomyn A, 2003, BIOCHEM BIOPH RES CO, V304, P519, DOI 10.1016/S0006-291X(03)00625-9
   Coller HA, 2001, NAT GENET, V28, P147, DOI 10.1038/88859
   Fliss MS, 2000, SCIENCE, V287, P2017, DOI 10.1126/science.287.5460.2017
   Gimm O, 2000, CANCER RES, V60, P6822
   GOTO Y, 1992, ANN NEUROL, V31, P672, DOI 10.1002/ana.410310617
   Habano W, 1999, INT J CANCER, V83, P625, DOI 10.1002/(SICI)1097-0215(19991126)83:5<625::AID-IJC10>3.0.CO;2-N
   HAYASHI JI, 1992, SOMAT CELL MOLEC GEN, V18, P123, DOI 10.1007/BF01233159
   HOLME E, 1993, AM J HUM GENET, V52, P551
   Jerónimo C, 2001, ONCOGENE, V20, P5195, DOI 10.1038/sj.onc.1204646
   JOHNS DR, 1991, BIOCHEM BIOPH RES CO, V174, P1324, DOI 10.1016/0006-291X(91)91567-V
   Jones JB, 2001, CANCER RES, V61, P1299
   KING MP, 1992, MOL CELL BIOL, V12, P480, DOI 10.1128/MCB.12.2.480
   Kirches E, 2001, INT J CANCER, V93, P534, DOI 10.1002/ijc.1375
   Lightowlers RN, 1997, TRENDS GENET, V13, P450, DOI 10.1016/S0168-9525(97)01266-3
   Liu VWS, 2001, CANCER RES, V61, P5998
   Lorenc A, 2003, MITOCHONDRION, V3, P119, DOI 10.1016/S1567-7249(03)00106-5
   LUCIAKOVA K, 1992, EUR J BIOCHEM, V205, P1187, DOI 10.1111/j.1432-1033.1992.tb16889.x
   MARIOTTI C, 1994, J CLIN INVEST, V93, P1102, DOI 10.1172/JCI117061
   Máximo V, 2000, GASTROENTEROLOGY, V119, P1808, DOI 10.1016/S0016-5085(00)70044-8
   McClintock DS, 2002, MOL CELL BIOL, V22, P94, DOI 10.1128/MCB.22.1.94-104.2002
   Modica-Napolitano JS, 2001, ADV DRUG DELIVER REV, V49, P63, DOI 10.1016/S0169-409X(01)00125-9
   MODICANAPOLITAN.JS, EXP REV MOL MED 0411
   MORAIS R, 1994, CANCER RES, V54, P3889
   Nekhaeva E, 2002, P NATL ACAD SCI USA, V99, P5521, DOI 10.1073/pnas.072670199
   Nomoto S, 2002, CLIN CANCER RES, V8, P481
   Parrella P, 2001, CANCER RES, V61, P7623
   Polyak K, 1998, NAT GENET, V20, P291, DOI 10.1038/3108
   Pulselli R, 1996, ANTICANCER RES, V16, P419
   Sanchez-Cespedes M, 2001, CANCER RES, V61, P7015
   Savagner F, 2001, J CLIN ENDOCR METAB, V86, P4920, DOI 10.1210/jc.86.10.4920
   SHARP MGF, 1992, J PATHOL, V168, P163, DOI 10.1002/path.1711680203
   Silvestri G, 1998, NEUROMUSCULAR DISORD, V8, P291, DOI 10.1016/S0960-8966(98)00037-6
   SILVESTRI G, 1992, AM J HUM GENET, V51, P1213
   Simonnet H, 2002, CARCINOGENESIS, V23, P759, DOI 10.1093/carcin/23.5.759
   Singh KK, 1999, ONCOGENE, V18, P6641, DOI 10.1038/sj.onc.1203056
   Takao M, 1996, J NEUROL SCI, V139, P111
   Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Warburg O., 1930, METABOLISM TUMOURS
   Wei YH, 2001, ANN NY ACAD SCI, V928, P97
   WELTER C, 1989, GENE CHROMOSOME CANC, V1, P79, DOI 10.1002/gcc.2870010112
   Yeh JJ, 2000, ONCOGENE, V19, P2060, DOI 10.1038/sj.onc.1203537
NR 50
TC 2
Z9 2
U1 0
U2 1
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1537-6516
EI 1537-6524
J9 TOXICOL MECH METHOD
JI Toxicol. Mech. Methods
PD JAN-APR
PY 2004
VL 14
IS 1-2
BP 85
EP 90
DI 10.1080/15376520490257563
PG 6
WC Toxicology
WE Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)
SC Toxicology
GA 757FU
UT WOS:000187551000017
PM 20021129
DA 2024-11-01
ER

PT J
AU Feichtinger, RG
   Oláhová, M
   Kishita, Y
   Garone, C
   Kremer, LS
   Yagi, M
   Uchiumi, T
   Jourdain, AA
   Thompson, K
   D'Souza, AR
   Kopajtich, R
   Alston, CL
   Koch, J
   Sperl, W
   Mastantuono, E
   Strom, TM
   Wortmann, SB
   Meitinger, T
   Pierre, G
   Chinnery, PF
   Chrzanowska-Lightowlers, ZM
   Lightowlers, RN
   DiMauro, S
   Calvo, SE
   Mootha, VK
   Moggio, M
   Sciacco, M
   Comi, GP
   Ronchi, D
   Murayama, K
   Ohtake, A
   Rebelo-Guiomar, P
   Kohda, M
   Kang, D
   Mayr, JA
   Taylor, RW
   Okazaki, Y
   Minczuk, M
   Prokisch, H
AF Feichtinger, Rene G.
   Olahova, Monika
   Kishita, Yoshihito
   Garone, Caterina
   Kremer, Laura S.
   Yagi, Mikako
   Uchiumi, Takeshi
   Jourdain, Alexis A.
   Thompson, Kyle
   D'Souza, Aaron R.
   Kopajtich, Robert
   Alston, Charlotte L.
   Koch, Johannes
   Sperl, Wolfgang
   Mastantuono, Elisa
   Strom, Tim M.
   Wortmann, Saskia B.
   Meitinger, Thomas
   Pierre, Germaine
   Chinnery, Patrick F.
   Chrzanowska-Lightowlers, Zofia M.
   Lightowlers, Robert N.
   DiMauro, Salvatore
   Calvo, Sarah E.
   Mootha, Vamsi K.
   Moggio, Maurizio
   Sciacco, Monica
   Comi, Giacomo P.
   Ronchi, Dario
   Murayama, Kei
   Ohtake, Akira
   Rebelo-Guiomar, Pedro
   Kohda, Masakazu
   Kang, Dongchon
   Mayr, Johannes A.
   Taylor, Robert W.
   Okazaki, Yasushi
   Minczuk, Michal
   Prokisch, Holger
TI Biallelic <i>C1QBP</i> Mutations Cause Severe Neonatal-, Childhood-, or
   Later-Onset Cardiomyopathy Associated with Combined Respiratory-Chain
   Deficiencies
SO AMERICAN JOURNAL OF HUMAN GENETICS
LA English
DT Article
ID MITOCHONDRIAL-DNA DELETIONS; P-32 PROTEIN; MATRIX; MAINTENANCE;
   P32/GC1QR; DISORDER; SPECTRUM; RECEPTOR
AB Complement component 1 Q subcomponent-binding protein (C1QBP; also known as p32) is a multi-compartmental protein whose precise function remains unknown. It is an evolutionary conserved multifunctional protein localized primarily in the mitochondrial matrix and has roles in inflammation and infection processes, mitochondrial ribosome biogenesis, and regulation of apoptosis and nuclear transcription. It has an N-terminal mitochondrial targeting peptide that is proteolytically processed after import into the mitochondrial matrix, where it forms a homotrimeric complex organized in a doughnut-shaped structure. Although C1QBP has been reported to exert pleiotropic effects on many cellular processes, we report here four individuals from unrelated families where biallelic mutations in C1QBP cause a defect in mitochondrial energy metabolism. Infants presented with cardiomyopathy accompanied by multisystemic involvement (liver, kidney, and brain), and children and adults presented with myopathy and progressive external ophthalmoplegia. Multiple mitochondrial respiratory-chain defects, associated with the accumulation of multiple deletions of mitochondrial DNA in the later-onset myopathic cases, were identified in all affected individuals. Steady-state C1QBP levels were decreased in all individuals' samples, leading to combined respiratory-chain enzyme deficiency of complexes I, III, and IV. C1qbp(-/-) mouse embryonic fibroblasts (MEFs) resembled the human disease phenotype by showing multiple defects in oxidative phosphorylation (OXPHOS). Complementation with wild-type, but not mutagenized, C1qbp restored OXPHOS protein levels and mitochondrial enzyme activities in C1qbp(-/-) MEFs. C1QBP deficiency represents an important mitochondrial disorder associated with a clinical spectrum ranging from infantile lactic acidosis to childhood (cardio) myopathy and late-onset progressive external ophthalmoplegia.
C1 [Feichtinger, Rene G.; Koch, Johannes; Sperl, Wolfgang; Wortmann, Saskia B.; Mayr, Johannes A.] Paracelsus Med Univ, Univ Hosp Salzburg, Dept Pediat, A-5020 Salzburg, Austria.
   [Olahova, Monika; Thompson, Kyle; Alston, Charlotte L.; Chrzanowska-Lightowlers, Zofia M.; Lightowlers, Robert N.; Taylor, Robert W.] Newcastle Univ, Wellcome Ctr Mitochondrial Res, Inst Neurosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Olahova, Monika; Thompson, Kyle; Alston, Charlotte L.; Chrzanowska-Lightowlers, Zofia M.; Lightowlers, Robert N.; Taylor, Robert W.] Newcastle Univ, Inst Cell & Mol Biosci, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.
   [Kishita, Yoshihito; Kohda, Masakazu; Okazaki, Yasushi] Saitama Med Univ, Res Ctr Genom Med, Saitama 3501241, Japan.
   [Kishita, Yoshihito; Kohda, Masakazu; Okazaki, Yasushi] Juntendo Univ, Grad Sch Med, Diagnost & Therapeut Intractable Dis, Intractable Dis Res Ctr, Tokyo 1138421, Japan.
   [Garone, Caterina; D'Souza, Aaron R.; Chinnery, Patrick F.; Rebelo-Guiomar, Pedro; Minczuk, Michal] Univ Cambridge, Med Res Council, Mitochondrial Biol Unit, Wellcome Trust, MRC Bldg, Cambridge CB2 0XY, England.
   [Kremer, Laura S.; Kopajtich, Robert; Mastantuono, Elisa; Strom, Tim M.; Wortmann, Saskia B.; Meitinger, Thomas; Prokisch, Holger] Tech Univ Munich, Inst Human Genet, D-81675 Munich, Germany.
   [Kremer, Laura S.; Mastantuono, Elisa; Strom, Tim M.; Wortmann, Saskia B.; Meitinger, Thomas; Prokisch, Holger] Helmholtz Zentrum Munchen, Inst Human Genet, D-85764 Neuherberg, Germany.
   [Yagi, Mikako; Uchiumi, Takeshi; Kang, Dongchon] Kyushu Univ, Grad Sch Med Sci, Dept Clin Chem & Lab Med, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.
   [Jourdain, Alexis A.; Calvo, Sarah E.; Mootha, Vamsi K.] Massachusetts Gen Hosp, Ctr Genome Med, Howard Hughes Med Inst, Dept Mol Biol, Boston, MA 02114 USA.
   [Jourdain, Alexis A.; Calvo, Sarah E.; Mootha, Vamsi K.] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
   [Meitinger, Thomas] DZHK German Ctr Cardiovasc Res, Partner Site Munich Heart Alliance, D-80802 Munich, Germany.
   [Pierre, Germaine] Bristol Royal Hosp Children, South West Reg Metab Dept, Bristol BS1 3NU, Avon, England.
   [DiMauro, Salvatore] Columbia Univ, Med Ctr, Dept Neurol, New York, NY 10032 USA.
   [Moggio, Maurizio; Sciacco, Monica] Osped Maggiore Policlin, Fdn IRCCS Ca Granda, Neuromuscular Unit, I-20122 Milan, Italy.
   [Comi, Giacomo P.; Ronchi, Dario] Univ Milan, IRCCS, Fdn Ca Granda,Osped Maggiore Policlin, Neurosci Sect,Dept Pathophysiol & Transplantat,Di, I-20122 Milan, Italy.
   [Murayama, Kei] Chiba Childrens Hosp, Dept Metab, Chiba 2660007, Japan.
   [Ohtake, Akira] Saitama Med Univ, Fac Med, Dept Pediat, Saitama 3500495, Japan.
   [Rebelo-Guiomar, Pedro] Univ Porto, Grad Program Areas Basic & Appl Biol, P-4099002 Oporto, Portugal.
C3 Paracelsus Private Medical University; Newcastle University - UK;
   Newcastle University - UK; Saitama Medical University; Juntendo
   University; University of Cambridge; UK Research & Innovation (UKRI);
   Medical Research Council UK (MRC); Wellcome Trust Sanger Institute;
   Technical University of Munich; Helmholtz Association; Helmholtz-Center
   Munich - German Research Center for Environmental Health; Kyushu
   University; Howard Hughes Medical Institute; Harvard University;
   Massachusetts General Hospital; Harvard University; Massachusetts
   Institute of Technology (MIT); Broad Institute; Munich Heart Alliance;
   German Centre for Cardiovascular Research; Bristol Royal Hospital For
   Children; Columbia University; IRCCS Ca Granda Ospedale Maggiore
   Policlinico; University of Milan; IRCCS Ca Granda Ospedale Maggiore
   Policlinico; Chiba Children's Hospital; Saitama Medical University;
   Universidade do Porto
RP Prokisch, H (corresponding author), Tech Univ Munich, Inst Human Genet, D-81675 Munich, Germany.; Prokisch, H (corresponding author), Helmholtz Zentrum Munchen, Inst Human Genet, D-85764 Neuherberg, Germany.
EM prokisch@helmholtz-muenchen.de
RI Prokisch, Holger/N-8964-2013; Alston, Charlotte/ABG-9602-2020; Ronchi,
   Dario/K-8011-2016; Comi, Giacomo/K-5702-2016; Garone,
   Caterina/AAB-8659-2019; Wortmann, Saskia/E-6125-2010; Murayama,
   Kei/JGM-3674-2023; Jourdain, Alexis/ABF-4838-2020; Meitinger,
   Thomas/O-1318-2015; Sciacco, Monica/AAC-6500-2022; Rebelo-Guiomar,
   Pedro/AAT-3575-2021; Minczuk, Michal/G-1638-2014
OI Rebelo-Guiomar, Pedro/0000-0002-5060-7519; Kremer,
   Laura/0000-0002-1647-7538; Mayr, Johannes/0000-0001-6970-336X; KOHDA,
   Masakazu/0000-0001-5970-2224; Kishita, Yoshihito/0000-0003-4978-1680;
   Ronchi, Dario/0000-0002-6093-9816; Minczuk, Michal/0000-0001-8242-1420;
   Chinnery, Patrick/0000-0002-7065-6617; Garone,
   Caterina/0000-0003-4928-1037; Okazaki, Yasushi/0000-0003-3241-5502;
   Alston, Charlotte/0000-0003-2095-5464; Jourdain, Alexis
   A./0000-0001-5321-6938; Ohtake, Akira/0000-0003-1147-3113; Sciacco,
   Monica/0000-0003-4593-4977; Prokisch, Holger/0000-0003-2379-6286
FU Horizon through E-Rare project GENOMIT [01GM1603, 01GM1207,
   FWF-I2741-B26]; Vereinigung zur Forderung Padiatrischer Forschung
   Salzburg; EU FP7 MEET Project [317433]; Horizon Project SOUND [633974];
   Marie Sklodowska-Curie Actions Reintegration Fellowship
   [Mitobiopath-705560]; UK NHS Highly Specialised Mitochondrial Service;
   Wellcome Centre for Mitochondrial Research [203105/Z/16]; MRC Centre for
   Neuromuscular Diseases [G0601943]; Lily Foundation; UK NIHR fellowship
   [NIHR-HCS-D12-03-04]; Wellcome Senior Fellowship [101876/Z/13/Z]; UK
   NIHR award; MRC Mitochondrial Biology Unit [MC_UP_1501/2]; NIH [R01
   GM0077465, R35 GM122455]; EMBO fellowship [ALTF554-2015]; UK MRC core
   funding for the Mitochondrial Biology Unit of the University of
   Cambridge [MC_U105697135]; Portuguese Fundacao para a Ciencia e a
   Tecnologia [PD/BD/105750/2014]; Italian Telethon [GSP16001]; Fondazione
   Cariplo [2014-1010]; Strategic Research Center in Private Universities
   from MEXT; Practical Research Project for Rare/Intractable Diseases from
   AMED; German BMBF; Fundação para a Ciência e a Tecnologia
   [PD/BD/105750/2014] Funding Source: FCT; MRC [MC_U105697135,
   MC_UU_00015/4] Funding Source: UKRI; Grants-in-Aid for Scientific
   Research [17H01550, 16K09973, 15H04764] Funding Source: KAKEN; Austrian
   Science Fund (FWF) [I2741] Funding Source: Austrian Science Fund (FWF)
FX This study was supported by the German BMBF and Horizon2020 through
   E-Rare project GENOMIT (01GM1603 and 01GM1207 to H.P.; FWF-I2741-B26 to
   J.A.M.); Vereinigung zur Forderung Padiatrischer Forschung Salzburg; EU
   FP7 MEET Project (317433 to H.P. and J.A.M.); Horizon2020 Project SOUND
   (633974 to H.P.); Marie Sklodowska-Curie Actions Reintegration
   Fellowship (Mitobiopath-705560 to C.G.); UK NHS Highly Specialised
   Mitochondrial Service (R.W.T.); Wellcome Centre for Mitochondrial
   Research (203105/Z/16 to Z.M.C.-L.,R.N.L., and R.W.T.); MRC Centre for
   Neuromuscular Diseases (G0601943 to R.W.T. and P.F.C.); Lily Foundation
   (R.W.T. and K.T.); UK NIHR fellowship (NIHR-HCS-D12-03-04 to C.L.A.);
   Wellcome Senior Fellowship (101876/Z/13/Z to P.F.C.); UK NIHR award and
   MRC Mitochondrial Biology Unit (MC_UP_1501/2 to P.F.C.); NIH (R01
   GM0077465 and R35 GM122455 to V.K.M.); EMBO fellowship (ALTF554-2015 to
   A.A.J.); UK MRC core funding for the Mitochondrial Biology Unit of the
   University of Cambridge (MC_U105697135 to A.R.D., P.R.G., and M.
   Minczuk); Portuguese Fundacao para a Ciencia e a Tecnologia
   (PD/BD/105750/2014 to P.R.G.); Italian Telethon (GSP16001 to G.P.C.);
   Fondazione Cariplo (2014-1010 to D.R.); Strategic Research Center in
   Private Universities from MEXT; and Practical Research Project for
   Rare/Intractable Diseases from AMED. We acknowledge Dr. Yosikatsu
   Matsumura for providing clinical information. M. Moggio and M. S. thank
   the Associazione Italiana di Miologia, the Associazione Amici del
   "Centro Dino Ferrari,'' the Biobank for Skeletal Muscle, Peripheral
   Nerve, DNA, and Cell Cultures (Telethon Network of Genetic Biobanks
   GTB12001E), and the Eurobiobank Network.
CR Acham-Roschitz B, 2009, MOL GENET METAB, V98, P300, DOI 10.1016/j.ymgme.2009.06.012
   Bohlega S, 1996, NEUROLOGY, V46, P1329, DOI 10.1212/WNL.46.5.1329
   BRESOLIN N, 1985, NEUROLOGY, V35, P802, DOI 10.1212/WNL.35.6.802
   CALVO SE, 2012, SCI TRANSL MED, V4, DOI DOI 10.1093/BIOINFORMATICS/BTP324
   Craven L, 2017, ANNU REV GENOM HUM G, V18, P257, DOI 10.1146/annurev-genom-091416-035426
   Elstner M, 2009, METHOD ENZYMOL, V457, P3, DOI 10.1016/S0076-6879(09)05001-0
   Feichtinger RG, 2014, GLIA, V62, P514, DOI 10.1002/glia.22621
   FEICHTINGER RG, 2010, BMC CANCER, V10, DOI DOI 10.1002/GLIA.22621
   Floyd BJ, 2016, MOL CELL, V63, P621, DOI 10.1016/j.molcel.2016.06.033
   Fogal V, 2010, MOL CELL BIOL, V30, P1303, DOI 10.1128/MCB.01101-09
   Itahana K, 2008, CANCER CELL, V13, P542, DOI 10.1016/j.ccr.2008.04.002
   Jiang JZ, 1999, P NATL ACAD SCI USA, V96, P3572, DOI 10.1073/pnas.96.7.3572
   Kirby DM, 2007, METHOD CELL BIOL, V80, P93, DOI 10.1016/S0091-679X(06)80004-X
   Kohda M, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1005679
   Kornblum C, 2013, NAT GENET, V45, P214, DOI 10.1038/ng.2501
   Kremer LS, 2016, AM J HUM GENET, V99, P894, DOI 10.1016/j.ajhg.2016.07.018
   Kremer LS, 2016, J HEPATOL, V65, P377, DOI 10.1016/j.jhep.2016.04.017
   Matthews DA, 1998, J GEN VIROL, V79, P1677, DOI 10.1099/0022-1317-79-7-1677
   Mayr JA, 2007, AM J HUM GENET, V80, P478, DOI 10.1086/511788
   Mayr JA, 2015, J INHERIT METAB DIS, V38, P629, DOI 10.1007/s10545-015-9831-y
   Minczuk M, 2010, NAT PROTOC, V5, P342, DOI 10.1038/nprot.2009.245
   Muta T, 1997, J BIOL CHEM, V272, P24363, DOI 10.1074/jbc.272.39.24363
   Oláhová M, 2015, BRAIN, V138, P3503, DOI 10.1093/brain/awv291
   Rahman S, 2016, INBORN METABOLIC DIS, P223
   Rubinstein DB, 2004, INT J CANCER, V110, P741, DOI 10.1002/ijc.20105
   Saito T, 2017, CARDIOVASC RES, V113, P1173, DOI 10.1093/cvr/cvx095
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/nmeth.2019, 10.1038/NMETH.2019]
   Seytter T, 1998, YEAST, V14, P303, DOI 10.1002/(SICI)1097-0061(19980315)14:4<303::AID-YEA217>3.0.CO;2-N
   Soltys BJ, 2000, HISTOCHEM CELL BIOL, V114, P245
   Storz P, 2000, J BIOL CHEM, V275, P24601, DOI 10.1074/jbc.M002964200
   Sunayama J, 2004, CELL DEATH DIFFER, V11, P771, DOI 10.1038/sj.cdd.4401418
   SUOMALAINEN A, 1992, LANCET, V340, P1319, DOI 10.1016/0140-6736(92)92496-3
   Van Haute L, 2015, J INHERIT METAB DIS, V38, P655, DOI 10.1007/s10545-015-9859-z
   Van Hove JLK, 2009, AM J MED GENET A, V149A, P861, DOI 10.1002/ajmg.a.32731
   van Leeuwen HC, 2001, J CELL SCI, V114, P2115
   Viscomi C, 2017, J INHERIT METAB DIS, V40, P587, DOI 10.1007/s10545-017-0027-5
   Wang JT, 2014, CELL REP, V7, P848, DOI 10.1016/j.celrep.2014.03.037
   Wortmann SB, 2015, J INHERIT METAB DIS, V38, P437, DOI 10.1007/s10545-015-9823-y
   Yagi M, 2012, NUCLEIC ACIDS RES, V40, P9717, DOI 10.1093/nar/gks774
   ZEVIANI M, 1990, ANN NEUROL, V28, P94, DOI 10.1002/ana.410280118
NR 40
TC 51
Z9 55
U1 0
U2 6
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 0002-9297
EI 1537-6605
J9 AM J HUM GENET
JI Am. J. Hum. Genet.
PD OCT 5
PY 2017
VL 101
IS 4
BP 525
EP 538
DI 10.1016/j.ajhg.2017.08.015
PG 14
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA FI8UJ
UT WOS:000412277300004
PM 28942965
OA Green Published, hybrid, Green Submitted
DA 2024-11-01
ER

PT J
AU Pitceathly, RDS
   Fassone, E
   Taanman, JW
   Sadowski, M
   Fratter, C
   Mudanohwo, EE
   Woodward, CE
   Sweeney, MG
   Holton, JL
   Hanna, MG
   Rahman, S
AF Pitceathly, Robert D. S.
   Fassone, Elisa
   Taanman, Jan-Willem
   Sadowski, Michael
   Fratter, Carl
   Mudanohwo, Ese E.
   Woodward, Cathy E.
   Sweeney, Mary G.
   Holton, Janice L.
   Hanna, Michael G.
   Rahman, Shamima
TI Kearns-Sayre syndrome caused by defective R1/p53R2 assembly
SO JOURNAL OF MEDICAL GENETICS
LA English
DT Article
ID MITOCHONDRIAL-DNA DELETIONS; RIBONUCLEOTIDE REDUCTION; EXTERNAL
   OPHTHALMOPLEGIA; DEPLETION; MUTATIONS; P53R2; REPLICATION; RRM2B
AB Background Mutations in RRM2B encoding ribonucleotide reductase (RNR) p53R2 subunit usually cause paediatric-onset mitochondrial disease associated with mitochondrial DNA (mtDNA) depletion. The importance of RNR dysfunction in adult mitochondrial disease is unclear.
   Objective To report the RRM2B mutation frequency in adults with multiple mtDNA deletions and examine RNR assembly in a patient with Kearns-Sayre syndrome (KSS) caused by two novel RRM2B mutations.
   Methods 50 adult patients with multiple mtDNA deletions in skeletal muscle were studied. DNA sequencing of RRM2B was performed in patients without mutations in mtDNA maintenance genes POLG and C10orf2. RNR protein was studied using western blot and Blue-native polyacrylamide gel electrophoresis (BN-PAGE).
   Results Four per cent (two unrelated cases) of this adult cohort harboured RRM2B mutations. Patient 1 had KSS and two novel missense mutations: c.122G -> A; p.Arg41Gln and c.391G -> A; p.Glu131Lys. BN-PAGE demonstrated reduced heterotetrameric R1/p53R2 RNR levels compared with controls, despite normal steady-state p53R2 levels on western blot, suggesting failed assembly of functional RNR as a potential disease mechanism. Patient 2 had late-onset progressive external ophthalmoplegia and fatigue. A heterozygous deletion c. 253_255delGAG; p.Glu85del was identified. Muscle histology in both cases showed significant numbers of necrotic muscle fibres, possibly indicating enhanced apoptotic cell death.
   Conclusion These data indicate that 4% of adult mitochondrial disease with multiple deletions is caused by RNR dysfunction. KSS has not previously been linked to a nuclear gene defect. Evidence that disease pathogenesis may be caused by defective RNR assembly is given. RRM2B screening should be considered early in the differential diagnosis of adults with multiple mtDNA deletions.
C1 [Rahman, Shamima] Natl Hosp Neurol & Neurosurg, MRC Ctr Neuromuscular Dis, London WC1N 3BG, England.
   [Pitceathly, Robert D. S.; Holton, Janice L.; Hanna, Michael G.; Rahman, Shamima] UCL Inst Neurol, MRC Ctr Neuromuscular Dis, London, England.
   [Fassone, Elisa; Rahman, Shamima] UCL Inst Child Hlth, Mitochondrial Res Grp, Clin & Mol Genet Unit, London, England.
   [Fassone, Elisa] Univ Milan, Dino Ferrari Ctr, Dept Neurol Sci, Osped Maggiore Policlin,IRCCS Fdn Ca Granda, Milan, Italy.
   [Taanman, Jan-Willem] UCL Inst Neurol, Dept Clin Neurosci, London, England.
   [Sadowski, Michael] Natl Inst Med Res, Div Math Biol, London NW7 1AA, England.
   [Fratter, Carl] Oxford Radcliffe Hosp NHS Trust, Oxford Reg Mol Genet Lab, Oxford, England.
   [Mudanohwo, Ese E.; Woodward, Cathy E.; Sweeney, Mary G.] Natl Hosp Neurol & Neurosurg, Neurogenet Unit, London WC1N 3BG, England.
   [Holton, Janice L.; Hanna, Michael G.] UCL Inst Neurol, Dept Mol Neurosci, London, England.
   [Rahman, Shamima] Great Ormond St Hosp Sick Children, Metab Unit, London WC1N 3JH, England.
C3 University of London; University College London; UCL Medical School;
   University College London Hospitals NHS Foundation Trust; University of
   London; University College London; University of London; University
   College London; IRCCS Ca Granda Ospedale Maggiore Policlinico;
   University of Milan; University of London; University College London;
   MRC National Institute for Medical Research; Oxford University Hospitals
   NHS Foundation Trust; University of Oxford; University of London;
   University College London; UCL Medical School; University College London
   Hospitals NHS Foundation Trust; University of London; University College
   London; University of London; University College London; Great Ormond
   Street Hospital for Children NHS Foundation Trust
RP Rahman, S (corresponding author), Natl Hosp Neurol & Neurosurg, MRC Ctr Neuromuscular Dis, 8-11 Queen Sq, London WC1N 3BG, England.
EM s.rahman@ich.ucl.ac.uk
RI Sadowski, Michael/F-4475-2010; Holton, Janice/F-6831-2011; Rahman,
   Shamima/C-5232-2008; Taanman, Jan-Willem/A-5379-2011
OI Hanna, Michael/0000-0003-0825-4075; Taanman,
   Jan-Willem/0000-0002-5476-9785; Pitceathly, Robert/0000-0002-6123-4551
FU MRC [G0800674]; MRC Centre [G0601943]; Great Ormond Street Hospital
   Children's Charity; Myositis Support Group; Reta Lila Weston Institute
   for Neurological Studies; NIHR UCLH/UCL Comprehensive Biomedical
   Research Centre; Department of Health's National Institute for Health
   Research Biomedical Research Centres; MRC [G0800674, G0200335, G0601943]
   Funding Source: UKRI
FX RDSP is funded by MRC grant number G0800674. MGH is supported by an MRC
   Centre grant G0601943; SR is supported by Great Ormond Street Hospital
   Children's Charity; JH and MGH are supported by the Myositis Support
   Group; and JH is supported by the Reta Lila Weston Institute for
   Neurological Studies. This study was supported by the NIHR UCLH/UCL
   Comprehensive Biomedical Research Centre and undertaken at University
   College London Hospitals/University College London, which received a
   proportion of funding from the Department of Health's National Institute
   for Health Research Biomedical Research Centres funding scheme.
CR Acham-Roschitz B, 2009, MOL GENET METAB, V98, P300, DOI 10.1016/j.ymgme.2009.06.012
   Bai RK, 2005, J MOL DIAGN, V7, P613, DOI 10.1016/S1525-1578(10)60595-8
   Bornstein B, 2008, NEUROMUSCULAR DISORD, V18, P453, DOI 10.1016/j.nmd.2008.04.006
   Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040
   Chang LF, 2008, P NATL ACAD SCI USA, V105, P18519, DOI 10.1073/pnas.0803313105
   DeLano WL., 2002, The PyMOL molecular graphics system
   Håkansson P, 2006, J BIOL CHEM, V281, P7834, DOI 10.1074/jbc.M512894200
   Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71
   Kimura T, 2003, NAT GENET, V34, P440, DOI 10.1038/ng1212
   Kollberg G, 2009, NEUROMUSCULAR DISORD, V19, P147, DOI 10.1016/j.nmd.2008.11.014
   Krishnan KJ, 2008, NAT GENET, V40, P275, DOI 10.1038/ng.f.94
   MORAES CT, 1989, NEW ENGL J MED, V320, P1293, DOI 10.1056/NEJM198905183202001
   Nakano K, 2000, ONCOGENE, V19, P4283, DOI 10.1038/sj.onc.1203774
   Nordlund N, 2006, ANNU REV BIOCHEM, V75, P681, DOI 10.1146/annurev.biochem.75.103004.142443
   Pontarin G, 2008, P NATL ACAD SCI USA, V105, P17801, DOI 10.1073/pnas.0808198105
   Rahman S, 2009, ARCH DIS CHILD, V94, P3, DOI 10.1136/adc.2008.147983
   Shaibani A, 2009, ARCH NEUROL-CHICAGO, V66, P1028, DOI 10.1001/archneurol.2009.139
   SHOFFNER JM, 1989, P NATL ACAD SCI USA, V86, P7952, DOI 10.1073/pnas.86.20.7952
   SHOFFNER JM, 2001, DISORDERS VOLUNTARY, P580
   Smith P, 2009, BIOCHEMISTRY-US, V48, P11134, DOI 10.1021/bi9001425
   Spinazzola A, 2009, J INHERIT METAB DIS, V32, P143, DOI 10.1007/s10545-008-1038-z
   Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506
   Tyynismaa H, 2009, AM J HUM GENET, V85, P290, DOI 10.1016/j.ajhg.2009.07.009
   Williams SL, 2004, J BIOL CHEM, V279, P7462, DOI 10.1074/jbc.M309232200
   Yamaguchi T, 2001, CANCER RES, V61, P8256
   ZEVIANI M, 1988, NEUROLOGY, V38, P1339
NR 26
TC 36
Z9 37
U1 0
U2 6
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0022-2593
EI 1468-6244
J9 J MED GENET
JI J. Med. Genet.
PD SEP
PY 2011
VL 48
IS 9
BP 610
EP 617
DI 10.1136/jmg.2010.088328
PG 8
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 810WQ
UT WOS:000294160000009
PM 21378381
DA 2024-11-01
ER

PT J
AU Matsushima, Y
   Kaguni, LS
AF Matsushima, Yuichi
   Kaguni, Laurie S.
TI Differential phenotypes of active site and human autosomal dominant
   progressive external ophthalmoplegia mutations in <i>Drosophila</i>
   mitochondrial DNA helicase expressed in Schneider cells
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID TRANSCRIPTION FACTOR; COPY NUMBER; MULTIPLE DELETIONS;
   CRYSTAL-STRUCTURE; MTDNA MAINTENANCE; PRIMASE-HELICASE; BACTERIOPHAGE
   T7; BINDING PROTEIN; LINKER REGION; TWINKLE
AB We report the cloning and molecular analysis of Drosophila mitochondrial DNA helicase (d-mtDNA helicase) homologous to human TWINKLE, which encodes one of the genes responsible for autosomal dominant progressive external ophthalmoplegia. An RNA interference construct was designed that reduces expression of d-mtDNA helicase to an undetectable level in Schneider cells. RNA interference knockdown of d-mtDNA helicase decreases the copy number of mitochondrial DNA (mtDNA) similar to 5-fold. In a corollary manner, overexpression of d-mtDNA helicase increases mtDNA levels 1.4-fold. Overexpression of helicase active site mutants K388A and D483A results in a severe depletion of mtDNA and a dominant negative lethal phenotype. Overexpression of mutants analogous to human autosomal dominant progressive external ophthalmoplegia mutations shows differential effects. Overexpression of 1334T and A442P mutants yields a dominant negative effect as for the active site mutants. In contrast, overexpression of A326T, R341Q, and W441C mutants results in increased mtDNA copy number, as observed with wild-type overexpression. Our dominant negative analysis of d-mtDNA helicase in cultured cells provides a tractable model for understanding human autosomal dominant progressive external ophthalmoplegia mutations.
C1 Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.
C3 Michigan State University
RP Kaguni, LS (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.
EM lskaguni@msu.edu
FU NIGMS NIH HHS [GM45295, R01 GM045295] Funding Source: Medline
CR ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2
   Arenas J, 2003, ANN NEUROL, V53, P278, DOI 10.1002/ana.10430
   Baulcombe DC, 1999, CURR BIOL, V9, pR599, DOI 10.1016/S0960-9822(99)80383-2
   BUNCH TA, 1988, NUCLEIC ACIDS RES, V16, P1043, DOI 10.1093/nar/16.3.1043
   Claros MG, 1996, EUR J BIOCHEM, V241, P779, DOI 10.1111/j.1432-1033.1996.00779.x
   Farr CL, 2004, J BIOL CHEM, V279, P17047, DOI 10.1074/jbc.M400283200
   Goto A, 2001, BIOCHEM J, V354, P243, DOI 10.1042/0264-6021:3540243
   Guo SY, 1999, J BIOL CHEM, V274, P30303, DOI 10.1074/jbc.274.42.30303
   Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107
   Horton P, 1997, ISMB-97 - FIFTH INTERNATIONAL CONFERENCE ON INTELLIGENT SYSTEMS FOR MOLECULAR BIOLOGY, PROCEEDINGS, P147
   Kaguni LS, 2004, ANNU REV BIOCHEM, V73, P293, DOI 10.1146/annurev.biochem.72.121801.161455
   Kaukonen J, 2000, SCIENCE, V289, P782, DOI 10.1126/science.289.5480.782
   Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0
   Kiechl S, 2004, J NEUROL NEUROSUR PS, V75, P1125, DOI 10.1136/jnnp.2003.025890
   Korhonen JA, 2004, EMBO J, V23, P2423, DOI 10.1038/sj.emboj.7600257
   Korhonen JA, 2003, J BIOL CHEM, V278, P48627, DOI 10.1074/jbc.M306981200
   Lee SJ, 2004, J BIOL CHEM, V279, P23384, DOI 10.1074/jbc.M400857200
   Lewis S, 2002, J NEUROL SCI, V201, P39, DOI 10.1016/S0022-510X(02)00190-9
   Matsushima Y, 2005, J BIOL CHEM, V280, P16815, DOI 10.1074/jbc.M500569200
   Matsushima Y, 2004, J BIOL CHEM, V279, P26900, DOI 10.1074/jbc.M401643200
   Matsushima Y, 2003, J BIOL CHEM, V278, P31149, DOI 10.1074/jbc.M303842200
   PATEL SS, 1994, BIOCHEMISTRY-US, V33, P7857, DOI 10.1021/bi00191a013
   Patel SS, 2000, ANNU REV BIOCHEM, V69, P651, DOI 10.1146/annurev.biochem.69.1.651
   Sawaya MR, 1999, CELL, V99, P167, DOI 10.1016/S0092-8674(00)81648-7
   Singleton MR, 2000, CELL, V101, P589, DOI 10.1016/S0092-8674(00)80871-5
   Spelbrink JN, 2001, NAT GENET, V28, P223, DOI 10.1038/90058
   Spinazzola A, 2005, GENE, V354, P162, DOI 10.1016/j.gene.2005.03.025
   Suomalainen A, 1997, NEUROLOGY, V48, P1244, DOI 10.1212/WNL.48.5.1244
   SUOMALAINEN A, 1992, J CLIN INVEST, V90, P61, DOI 10.1172/JCI115856
   THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673
   Toth EA, 2003, MOL CELL, V12, P1113, DOI 10.1016/S1097-2765(03)00442-8
   Tyynismaa H, 2005, P NATL ACAD SCI USA, V102, P17687, DOI 10.1073/pnas.0505551102
   Tyynismaa H, 2004, HUM MOL GENET, V13, P3219, DOI 10.1093/hmg/ddh342
   Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034
   Van Goethem G, 2003, HUM MUTAT, V22, P175, DOI 10.1002/humu.10246
   Washington MT, 1996, J BIOL CHEM, V271, P26825, DOI 10.1074/jbc.271.43.26825
   ZEVIANI M, 1989, NATURE, V339, P309, DOI 10.1038/339309a0
NR 37
TC 37
Z9 40
U1 1
U2 2
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
EI 1083-351X
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAR 30
PY 2007
VL 282
IS 13
BP 9436
EP 9444
DI 10.1074/jbc.M610550200
PG 9
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 153HA
UT WOS:000245421700016
PM 17272269
OA hybrid, Green Accepted
DA 2024-11-01
ER

EF